cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
PCPG	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-16.58	9.66e-36	5.74e-30	-1.3	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-16.58	9.66e-36	5.74e-30	-1.3	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-16.58	9.66e-36	5.74e-30	-1.3	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-16.58	9.66e-36	5.74e-30	-1.3	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-16.58	9.66e-36	5.74e-30	-1.3	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	16.46	1.95e-35	1.05e-29	1.2	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	16.45	2.15e-35	1.13e-29	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	16.45	2.15e-35	1.13e-29	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	16.19	1e-34	3.93e-29	1.2	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	16.1	1.7e-34	5.85e-29	1.27	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	16.07	1.96e-34	6.31e-29	1.3	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	16.07	1.96e-34	6.31e-29	1.3	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	16.07	1.96e-34	6.31e-29	1.3	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	16.07	1.96e-34	6.31e-29	1.3	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	16.07	1.96e-34	6.31e-29	1.3	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
PCPG	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	16.04	2.41e-34	7.55e-29	1.06	0.79	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
PCPG	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	15.99	3.15e-34	9.2e-29	1.21	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	15.99	3.15e-34	9.2e-29	1.21	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	15.99	3.15e-34	9.2e-29	1.21	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	15.99	3.15e-34	9.2e-29	1.21	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	15.99	3.15e-34	9.2e-29	1.21	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	15.98	3.4e-34	9.78e-29	1.28	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	15.88	6.03e-34	1.6e-28	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	15.77	1.19e-33	2.92e-28	1.27	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	15.74	1.39e-33	3.35e-28	1.17	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	15.67	2.19e-33	4.94e-28	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
PCPG	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	15.6	3.32e-33	7.2e-28	1.04	0.79	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
PCPG	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	15.59	3.49e-33	7.38e-28	1.25	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	15.59	3.49e-33	7.38e-28	1.28	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	15.55	4.47e-33	9.17e-28	1.28	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	15.53	4.97e-33	1.02e-27	1.27	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	15.49	6.37e-33	1.28e-27	1.19	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	15.49	6.37e-33	1.28e-27	1.19	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-15.46	7.64e-33	1.52e-27	-1.27	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-15.46	7.64e-33	1.52e-27	-1.27	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-15.41	1.01e-32	1.98e-27	-1.26	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-15.32	1.7e-32	3.16e-27	-1.26	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
PCPG	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	15.3	2.01e-32	3.72e-27	1.19	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-15.24	2.79e-32	4.79e-27	-1.27	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-15.24	2.79e-32	4.79e-27	-1.27	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
PCPG	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	15.21	3.38e-32	5.72e-27	0.98	0.78	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	15.19	3.89e-32	6.48e-27	0.89	0.78	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	15.18	3.98e-32	6.6e-27	1.18	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	15.17	4.31e-32	7.01e-27	0.99	0.78	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	15.17	4.31e-32	7.01e-27	0.99	0.78	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	15.16	4.44e-32	7.01e-27	0.92	0.78	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-15.16	4.44e-32	7.01e-27	-0.92	-0.78	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
PCPG	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	15.16	4.47e-32	7.01e-27	0.98	0.78	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	15.16	4.47e-32	7.01e-27	0.98	0.78	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	15.16	4.47e-32	7.01e-27	0.98	0.78	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	15.16	4.47e-32	7.01e-27	0.98	0.78	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	15.16	4.47e-32	7.01e-27	0.98	0.78	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-15.15	4.77e-32	7.41e-27	-1.16	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	15.15	4.89e-32	7.53e-27	0.99	0.78	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	15.15	4.89e-32	7.53e-27	0.99	0.78	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
PCPG	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	15.12	5.62e-32	8.51e-27	1.25	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
PCPG	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	15.1	6.37e-32	9.55e-27	0.91	0.78	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
PCPG	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	15.1	6.65e-32	9.93e-27	1.16	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
PCPG	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	15.1	6.7e-32	9.93e-27	0.98	0.78	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
PCPG	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	15.09	6.95e-32	1.01e-26	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	15.09	6.95e-32	1.01e-26	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	15.09	6.95e-32	1.01e-26	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
PCPG	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
PCPG	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	15.01	1.13e-31	1.25e-26	1.01	0.77	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	15	1.19e-31	1.29e-26	1.01	0.77	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	15	1.19e-31	1.29e-26	1.01	0.77	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-15	1.21e-31	1.3e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	14.98	1.33e-31	1.42e-26	1.01	0.77	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	14.98	1.34e-31	1.43e-26	1.01	0.77	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	14.98	1.35e-31	1.43e-26	1.01	0.77	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	14.98	1.38e-31	1.46e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	14.98	1.38e-31	1.46e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	14.94	1.68e-31	1.69e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	14.94	1.68e-31	1.69e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	14.94	1.68e-31	1.69e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	14.94	1.68e-31	1.69e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	14.94	1.68e-31	1.69e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	14.92	1.88e-31	1.84e-26	1.18	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	14.92	1.88e-31	1.84e-26	1.18	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	14.92	1.88e-31	1.84e-26	1.18	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
PCPG	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	14.92	1.89e-31	1.84e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	14.92	1.89e-31	1.84e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	14.92	1.89e-31	1.84e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
PCPG	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-14.92	1.97e-31	1.91e-26	-0.97	-0.77	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	14.89	2.26e-31	2.17e-26	1	0.77	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	14.89	2.34e-31	2.23e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	14.89	2.36e-31	2.23e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	14.89	2.36e-31	2.23e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	14.89	2.36e-31	2.23e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	14.89	2.36e-31	2.23e-26	1.15	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	14.88	2.47e-31	2.33e-26	0.99	0.77	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	14.88	2.49e-31	2.34e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-14.87	2.67e-31	2.49e-26	-1.18	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	14.82	3.43e-31	3.13e-26	1.16	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
PCPG	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	14.82	3.63e-31	3.28e-26	1	0.77	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	14.81	3.75e-31	3.32e-26	1	0.77	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	14.81	3.75e-31	3.32e-26	1	0.77	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	14.81	3.75e-31	3.32e-26	1	0.77	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	14.81	3.75e-31	3.32e-26	1	0.77	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	14.81	3.75e-31	3.32e-26	1	0.77	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	14.81	3.75e-31	3.32e-26	1	0.77	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	14.8	4.01e-31	3.54e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	14.8	4.1e-31	3.61e-26	1.13	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	14.78	4.46e-31	3.92e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	14.78	4.57e-31	4e-26	1.18	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-14.77	4.7e-31	4.07e-26	-1.15	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-14.77	4.72e-31	4.07e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-14.77	4.72e-31	4.07e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-14.77	4.72e-31	4.07e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-14.77	4.85e-31	4.18e-26	-0.89	-0.77	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	14.77	4.87e-31	4.18e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
PCPG	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	14.76	4.94e-31	4.23e-26	0.97	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
PCPG	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	14.74	5.7e-31	4.86e-26	0.97	0.77	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	14.74	5.7e-31	4.86e-26	0.97	0.77	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	14.72	6.36e-31	5.38e-26	1.16	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	14.72	6.37e-31	5.38e-26	1.18	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-14.71	6.86e-31	5.66e-26	-1.17	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-14.71	6.86e-31	5.66e-26	-1.17	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-14.71	7.04e-31	5.66e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-14.7	7.21e-31	5.78e-26	-1.27	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
PCPG	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-14.69	7.53e-31	6.01e-26	-0.99	-0.77	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	14.68	8.38e-31	6.57e-26	0.91	0.77	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	14.67	8.99e-31	7e-26	0.99	0.77	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	14.67	8.99e-31	7e-26	0.99	0.77	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	14.66	9.14e-31	7.09e-26	1	0.77	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	14.66	9.56e-31	7.39e-26	1	0.77	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-14.64	1.02e-30	7.84e-26	-1.17	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-14.64	1.02e-30	7.84e-26	-1.17	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-14.64	1.02e-30	7.84e-26	-1.17	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-14.64	1.04e-30	7.89e-26	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
PCPG	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	14.64	1.07e-30	8.14e-26	1.01	0.77	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-14.63	1.12e-30	8.48e-26	-1.14	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-14.63	1.12e-30	8.48e-26	-1.14	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-14.62	1.19e-30	8.89e-26	-0.99	-0.77	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	14.59	1.39e-30	1.03e-25	0.9	0.77	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	14.59	1.41e-30	1.03e-25	1.16	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	14.59	1.41e-30	1.03e-25	1.16	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	14.59	1.41e-30	1.03e-25	1.16	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-14.59	1.41e-30	1.03e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-14.59	1.41e-30	1.03e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-14.59	1.41e-30	1.03e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-14.59	1.44e-30	1.05e-25	-0.96	-0.77	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-14.58	1.53e-30	1.07e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-14.58	1.53e-30	1.07e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-14.58	1.53e-30	1.07e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-14.58	1.53e-30	1.07e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-14.58	1.53e-30	1.07e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-14.58	1.53e-30	1.07e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-14.58	1.53e-30	1.07e-25	-1.16	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	14.57	1.56e-30	1.09e-25	0.98	0.77	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	14.57	1.63e-30	1.13e-25	0.99	0.77	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
PCPG	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	14.56	1.72e-30	1.18e-25	0.96	0.77	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-14.55	1.82e-30	1.24e-25	-1.17	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-14.55	1.83e-30	1.24e-25	-1.15	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-14.55	1.83e-30	1.24e-25	-1.15	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-14.55	1.83e-30	1.24e-25	-1.15	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-14.55	1.83e-30	1.24e-25	-1.15	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-14.55	1.83e-30	1.24e-25	-1.15	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
PCPG	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-14.54	1.93e-30	1.31e-25	-1.14	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-14.54	1.93e-30	1.31e-25	-1.14	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-14.53	2.03e-30	1.37e-25	-1.15	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
PCPG	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	14.53	2.1e-30	1.4e-25	1	0.76	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	14.52	2.13e-30	1.42e-25	1	0.76	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-14.52	2.15e-30	1.43e-25	-1.1	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-14.52	2.16e-30	1.43e-25	-1.16	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	14.52	2.16e-30	1.43e-25	1.16	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	14.52	2.22e-30	1.46e-25	1	0.76	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	14.52	2.22e-30	1.46e-25	1	0.76	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
PCPG	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	14.49	2.67e-30	1.74e-25	1.09	0.76	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
PCPG	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	14.45	3.25e-30	2.09e-25	0.97	0.76	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	14.45	3.42e-30	2.15e-25	0.96	0.76	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	14.45	3.42e-30	2.15e-25	0.96	0.76	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	14.45	3.42e-30	2.15e-25	0.96	0.76	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	14.45	3.42e-30	2.15e-25	0.96	0.76	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	14.45	3.42e-30	2.15e-25	0.96	0.76	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	14.44	3.47e-30	2.18e-25	1.13	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	14.44	3.59e-30	2.22e-25	0.89	0.76	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
PCPG	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	14.43	3.8e-30	2.34e-25	0.95	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
PCPG	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-14.41	4.19e-30	2.54e-25	-1.14	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-14.41	4.19e-30	2.54e-25	-1.14	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-14.41	4.19e-30	2.54e-25	-1.14	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-14.41	4.19e-30	2.54e-25	-1.14	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-14.39	4.67e-30	2.83e-25	-1.16	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-14.38	5.23e-30	3.15e-25	-0.99	-0.76	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	14.36	5.69e-30	3.43e-25	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
PCPG	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-14.36	5.84e-30	3.5e-25	-1.2	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
PCPG	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-14.35	6.11e-30	3.65e-25	-1.1	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
PCPG	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	14.34	6.35e-30	3.78e-25	1.11	0.76	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
PCPG	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	14.34	6.55e-30	3.85e-25	0.96	0.76	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	14.33	6.8e-30	3.99e-25	1.1	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
PCPG	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	14.28	9.34e-30	5.34e-25	1	0.76	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	14.28	9.34e-30	5.34e-25	1	0.76	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	14.28	9.34e-30	5.34e-25	1	0.76	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	14.27	9.68e-30	5.48e-25	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	14.27	9.68e-30	5.48e-25	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	14.27	9.68e-30	5.48e-25	0.9	0.76	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
PCPG	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	14.27	9.75e-30	5.48e-25	0.95	0.76	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	14.27	9.75e-30	5.48e-25	0.95	0.76	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	14.27	9.75e-30	5.48e-25	0.95	0.76	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	14.27	9.75e-30	5.48e-25	0.95	0.76	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	14.27	9.75e-30	5.48e-25	0.95	0.76	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	14.27	9.9e-30	5.56e-25	0.89	0.76	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
PCPG	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	14.24	1.21e-29	6.72e-25	0.99	0.76	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-14.23	1.24e-29	6.88e-25	-1.15	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	14.22	1.35e-29	7.44e-25	1	0.76	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-14.22	1.35e-29	7.44e-25	-1	-0.76	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
PCPG	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-14.2	1.49e-29	7.82e-25	-0.99	-0.76	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
PCPG	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-14.19	1.62e-29	8.51e-25	-0.97	-0.76	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
PCPG	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-14.19	1.65e-29	8.59e-25	-0.96	-0.76	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-14.19	1.65e-29	8.59e-25	-0.96	-0.76	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-14.18	1.74e-29	9.05e-25	-0.99	-0.76	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
PCPG	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	14.16	2e-29	1.03e-24	1	0.76	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	14.16	2e-29	1.03e-24	1	0.76	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
PCPG	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-14.15	2.03e-29	1.05e-24	-0.98	-0.76	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
PCPG	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	14.13	2.37e-29	1.21e-24	0.92	0.76	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	14.12	2.43e-29	1.24e-24	0.98	0.76	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	14.12	2.43e-29	1.24e-24	0.98	0.76	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	14.12	2.43e-29	1.24e-24	0.98	0.76	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
PCPG	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	14.11	2.66e-29	1.34e-24	1.04	0.76	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
PCPG	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-14.09	2.91e-29	1.47e-24	-1	-0.75	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-14.08	3.16e-29	1.59e-24	-0.97	-0.75	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
PCPG	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	14.08	3.22e-29	1.62e-24	1.15	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
PCPG	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	14.07	3.33e-29	1.67e-24	0.99	0.75	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	14.07	3.33e-29	1.67e-24	0.99	0.75	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-14.07	3.35e-29	1.68e-24	-0.98	-0.75	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
PCPG	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-14.07	3.43e-29	1.72e-24	-1.01	-0.75	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
PCPG	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	14.06	3.48e-29	1.74e-24	0.98	0.75	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
PCPG	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	14.06	3.63e-29	1.81e-24	0.94	0.75	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-14.05	3.7e-29	1.84e-24	-0.98	-0.75	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-14.04	4.03e-29	1.97e-24	-0.99	-0.75	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-14.04	4.03e-29	1.97e-24	-0.99	-0.75	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-14.04	4.03e-29	1.97e-24	-0.99	-0.75	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-14.04	4.03e-29	1.97e-24	-0.99	-0.75	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-14.04	4.03e-29	1.97e-24	-0.99	-0.75	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-14.04	4.03e-29	1.97e-24	-0.99	-0.75	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-14.04	4.03e-29	1.97e-24	-0.99	-0.75	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
PCPG	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	14.04	4.08e-29	1.99e-24	0.94	0.75	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	14.03	4.32e-29	2.09e-24	1.13	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	14.03	4.32e-29	2.09e-24	1.13	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	14.02	4.49e-29	2.17e-24	0.97	0.75	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	14.02	4.49e-29	2.17e-24	0.97	0.75	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	14.02	4.49e-29	2.17e-24	0.97	0.75	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-14.02	4.57e-29	2.2e-24	-0.97	-0.75	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
PCPG	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-14.02	4.67e-29	2.25e-24	-0.99	-0.75	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	14.01	4.87e-29	2.33e-24	0.94	0.75	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	14.01	4.92e-29	2.35e-24	1.12	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	14.01	4.92e-29	2.35e-24	1.12	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
PCPG	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	13.98	5.94e-29	2.83e-24	0.96	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
PCPG	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	13.97	6.21e-29	2.94e-24	1.13	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	13.94	7.51e-29	3.51e-24	0.95	0.75	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
PCPG	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	13.94	7.57e-29	3.54e-24	1	0.75	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-13.93	7.7e-29	3.59e-24	-1.14	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	13.93	8e-29	3.68e-24	0.94	0.75	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	13.93	8e-29	3.68e-24	0.94	0.75	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	13.93	8e-29	3.68e-24	0.94	0.75	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	13.93	8e-29	3.68e-24	0.94	0.75	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	13.93	8e-29	3.68e-24	0.94	0.75	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	13.93	8e-29	3.68e-24	0.94	0.75	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	13.93	8e-29	3.68e-24	0.94	0.75	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-13.92	8.3e-29	3.76e-24	-0.95	-0.75	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-13.92	8.3e-29	3.76e-24	-0.95	-0.75	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-13.92	8.3e-29	3.76e-24	-0.95	-0.75	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	13.92	8.3e-29	3.76e-24	0.95	0.75	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	13.92	8.3e-29	3.76e-24	0.95	0.75	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	13.92	8.3e-29	3.76e-24	0.95	0.75	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	13.92	8.6e-29	3.89e-24	0.93	0.75	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	13.91	8.85e-29	3.97e-24	0.95	0.75	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	13.91	8.85e-29	3.97e-24	0.95	0.75	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	13.91	8.85e-29	3.97e-24	0.95	0.75	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
PCPG	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	13.91	9.1e-29	4.07e-24	1.04	0.75	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
PCPG	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-13.91	9.13e-29	4.08e-24	-0.97	-0.75	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-13.9	9.29e-29	4.14e-24	-0.99	-0.75	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	13.89	1.02e-28	4.52e-24	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	13.89	1.02e-28	4.52e-24	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	13.89	1.02e-28	4.52e-24	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-13.89	1.02e-28	4.55e-24	-1.16	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-13.88	1.06e-28	4.68e-24	-1.17	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	13.87	1.1e-28	4.89e-24	0.94	0.75	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
PCPG	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-13.87	1.11e-28	4.92e-24	-0.97	-0.75	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
PCPG	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	13.87	1.16e-28	5.13e-24	0.97	0.75	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	13.86	1.17e-28	5.18e-24	1	0.75	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
PCPG	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	13.86	1.22e-28	5.35e-24	1	0.75	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	13.85	1.26e-28	5.52e-24	0.97	0.75	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	13.85	1.29e-28	5.64e-24	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
PCPG	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	13.82	1.53e-28	6.66e-24	0.99	0.75	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	13.81	1.67e-28	7.25e-24	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	13.81	1.67e-28	7.25e-24	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
PCPG	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	13.8	1.7e-28	7.33e-24	1	0.75	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	13.79	1.86e-28	7.99e-24	1.1	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	13.79	1.89e-28	8.09e-24	1.11	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	13.79	1.89e-28	8.09e-24	1.11	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	13.79	1.89e-28	8.09e-24	1.11	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	13.79	1.89e-28	8.09e-24	0.89	0.75	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-13.78	1.94e-28	8.09e-24	-1.16	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-13.78	1.94e-28	8.09e-24	-1.16	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-13.78	1.94e-28	8.09e-24	-1.16	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-13.78	1.94e-28	8.09e-24	-1.16	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	13.78	1.97e-28	8.13e-24	0.85	0.75	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	13.78	1.97e-28	8.13e-24	0.85	0.75	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
PCPG	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-13.75	2.35e-28	9.67e-24	-0.98	-0.75	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	13.74	2.46e-28	1.01e-23	0.98	0.75	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	13.74	2.46e-28	1.01e-23	0.98	0.75	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
PCPG	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	13.74	2.46e-28	1.01e-23	0.98	0.75	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	13.73	2.71e-28	1.11e-23	0.86	0.75	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	13.73	2.71e-28	1.11e-23	0.86	0.75	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	13.72	2.82e-28	1.15e-23	0.86	0.75	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	13.72	2.89e-28	1.18e-23	0.86	0.75	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	13.72	2.91e-28	1.19e-23	0.86	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	13.72	2.91e-28	1.19e-23	0.86	0.75	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	13.7	3.14e-28	1.27e-23	0.86	0.75	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	13.7	3.14e-28	1.27e-23	1.11	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	13.7	3.14e-28	1.27e-23	1.11	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-13.7	3.17e-28	1.28e-23	-0.95	-0.75	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
PCPG	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-13.7	3.28e-28	1.32e-23	-1.13	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-13.7	3.28e-28	1.32e-23	-1.13	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
PCPG	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-13.68	3.57e-28	1.43e-23	-1.11	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	13.68	3.6e-28	1.44e-23	1.14	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-13.68	3.69e-28	1.48e-23	-1.12	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	13.67	3.91e-28	1.56e-23	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	13.67	3.91e-28	1.56e-23	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	13.67	3.92e-28	1.56e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
PCPG	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-13.66	4.07e-28	1.62e-23	-0.98	-0.74	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
PCPG	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	13.65	4.25e-28	1.68e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	13.65	4.25e-28	1.68e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
PCPG	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-13.64	4.55e-28	1.75e-23	-0.96	-0.74	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
PCPG	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	13.64	4.67e-28	1.78e-23	0.96	0.74	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	13.63	4.87e-28	1.84e-23	1.17	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-13.63	4.89e-28	1.84e-23	-1.13	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-13.63	4.89e-28	1.84e-23	-1.13	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
PCPG	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	13.62	5.4e-28	1.93e-23	0.95	0.74	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
PCPG	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-13.61	5.67e-28	2.02e-23	-0.98	-0.74	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
PCPG	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	13.61	5.72e-28	2.03e-23	0.99	0.74	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
PCPG	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	13.6	5.82e-28	2.07e-23	1.17	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
PCPG	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	13.59	6.27e-28	2.22e-23	1.01	0.74	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
PCPG	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	13.59	6.27e-28	2.22e-23	1.01	0.74	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
PCPG	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	13.59	6.27e-28	2.22e-23	1.01	0.74	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
PCPG	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-13.58	6.63e-28	2.32e-23	-0.92	-0.74	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-13.58	6.65e-28	2.32e-23	-1.13	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-13.58	6.65e-28	2.32e-23	-1.13	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	13.58	6.81e-28	2.38e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	13.58	6.9e-28	2.41e-23	0.88	0.74	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
PCPG	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-13.57	7.06e-28	2.46e-23	-1.12	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-13.57	7.06e-28	2.46e-23	-1.12	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
PCPG	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	13.56	7.38e-28	2.57e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	13.56	7.44e-28	2.58e-23	1.14	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	13.56	7.44e-28	2.58e-23	1.14	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	13.56	7.44e-28	2.58e-23	1.14	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
PCPG	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	13.56	7.52e-28	2.61e-23	1.02	0.74	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
PCPG	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	13.56	7.66e-28	2.64e-23	0.98	0.74	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	13.56	7.66e-28	2.64e-23	0.98	0.74	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	13.54	8.8e-28	3.03e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	13.53	8.84e-28	3.03e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	13.53	8.84e-28	3.03e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
PCPG	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	13.53	8.99e-28	3.08e-23	0.92	0.74	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	13.53	9.09e-28	3.11e-23	1.12	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-13.53	9.1e-28	3.11e-23	-0.87	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
PCPG	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-13.52	9.64e-28	3.3e-23	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
PCPG	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-13.5	1.06e-27	3.6e-23	-1.11	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-13.5	1.06e-27	3.6e-23	-1.11	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	13.5	1.1e-27	3.71e-23	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	13.5	1.11e-27	3.76e-23	0.95	0.74	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
PCPG	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-13.49	1.16e-27	3.91e-23	-0.95	-0.74	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	13.48	1.24e-27	4.16e-23	0.96	0.74	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	13.48	1.24e-27	4.16e-23	0.96	0.74	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	13.47	1.32e-27	4.42e-23	1.06	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
PCPG	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	13.47	1.34e-27	4.47e-23	0.97	0.74	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
PCPG	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	13.47	1.34e-27	4.47e-23	1.1	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
PCPG	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-13.46	1.4e-27	4.67e-23	-0.96	-0.74	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
PCPG	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-13.46	1.41e-27	4.69e-23	-1.11	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
PCPG	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-13.45	1.52e-27	5.05e-23	-1.11	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
PCPG	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	13.43	1.65e-27	5.46e-23	1.16	0.74	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-13.43	1.66e-27	5.47e-23	-1.13	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
PCPG	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	13.41	1.88e-27	6.15e-23	1.01	0.74	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
PCPG	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	13.41	1.89e-27	6.18e-23	0.92	0.74	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
PCPG	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	13.41	1.93e-27	6.28e-23	0.98	0.74	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
PCPG	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	13.41	1.94e-27	6.34e-23	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
PCPG	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-13.39	2.12e-27	6.9e-23	-0.99	-0.74	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-13.39	2.18e-27	7.05e-23	-1.13	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	13.34	2.88e-27	9.24e-23	1.07	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	13.34	2.88e-27	9.24e-23	1.07	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	13.34	2.98e-27	9.57e-23	0.95	0.74	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
PCPG	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	13.33	3.14e-27	9.97e-23	1.02	0.74	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
PCPG	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	13.33	3.14e-27	9.97e-23	1.02	0.74	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
PCPG	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-13.32	3.23e-27	1.02e-22	-1.09	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-13.32	3.23e-27	1.02e-22	-1.13	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
PCPG	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-13.32	3.23e-27	1.02e-22	-1.09	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	13.32	3.25e-27	1.02e-22	0.94	0.74	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
PCPG	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	13.31	3.43e-27	1.08e-22	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
PCPG	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-13.31	3.45e-27	1.08e-22	-1.06	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-13.31	3.53e-27	1.11e-22	-1.09	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-13.31	3.53e-27	1.11e-22	-1.09	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-13.31	3.55e-27	1.11e-22	-0.87	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
PCPG	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-13.3	3.68e-27	1.15e-22	-0.92	-0.74	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	13.3	3.77e-27	1.17e-22	0.94	0.74	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	13.3	3.77e-27	1.17e-22	0.94	0.74	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-13.3	3.77e-27	1.17e-22	-0.87	-0.74	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	13.28	4.22e-27	1.3e-22	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	13.28	4.22e-27	1.3e-22	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	13.28	4.22e-27	1.3e-22	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	13.28	4.22e-27	1.3e-22	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	13.28	4.22e-27	1.3e-22	0.87	0.74	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	13.28	4.3e-27	1.32e-22	0.86	0.74	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
PCPG	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	13.27	4.42e-27	1.36e-22	0.98	0.73	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
PCPG	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-13.27	4.46e-27	1.37e-22	-0.93	-0.73	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	13.27	4.47e-27	1.37e-22	1.06	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-13.27	4.52e-27	1.38e-22	-1.08	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
PCPG	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	13.27	4.61e-27	1.4e-22	0.94	0.73	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	13.27	4.61e-27	1.4e-22	0.94	0.73	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	13.27	4.61e-27	1.4e-22	0.94	0.73	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	13.27	4.61e-27	1.4e-22	0.94	0.73	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	13.27	4.61e-27	1.4e-22	0.94	0.73	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
PCPG	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-13.26	4.76e-27	1.45e-22	-0.95	-0.73	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	13.25	4.93e-27	1.49e-22	0.95	0.73	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	13.25	5.08e-27	1.54e-22	1.11	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	13.24	5.27e-27	1.59e-22	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	13.24	5.27e-27	1.59e-22	0.97	0.73	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	13.23	5.62e-27	1.69e-22	1.1	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	13.23	5.89e-27	1.76e-22	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	13.22	6.04e-27	1.8e-22	1.09	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	13.22	6.04e-27	1.8e-22	1.09	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	13.22	6.15e-27	1.83e-22	0.94	0.73	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	13.22	6.15e-27	1.83e-22	0.94	0.73	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	13.22	6.15e-27	1.83e-22	0.94	0.73	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-13.21	6.46e-27	1.9e-22	-1.09	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-13.21	6.46e-27	1.9e-22	-1.09	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-13.21	6.46e-27	1.9e-22	-1.09	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	13.21	6.52e-27	1.92e-22	0.95	0.73	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-13.2	6.71e-27	1.97e-22	-1.11	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	13.2	6.98e-27	2.05e-22	0.96	0.73	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
PCPG	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	13.19	7.18e-27	2.1e-22	0.97	0.73	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
PCPG	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	13.19	7.52e-27	2.2e-22	0.94	0.73	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-13.18	7.63e-27	2.23e-22	-1.08	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	13.18	7.65e-27	2.23e-22	0.94	0.73	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	13.18	7.65e-27	2.23e-22	0.94	0.73	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	13.18	7.65e-27	2.23e-22	0.94	0.73	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
PCPG	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-13.18	7.76e-27	2.26e-22	-0.95	-0.73	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
PCPG	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-13.16	8.65e-27	2.51e-22	-0.97	-0.73	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
PCPG	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-13.16	8.65e-27	2.51e-22	-0.97	-0.73	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
PCPG	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	13.16	8.72e-27	2.52e-22	0.94	0.73	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	13.16	8.72e-27	2.52e-22	0.94	0.73	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	13.16	8.8e-27	2.54e-22	1.09	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	13.16	8.88e-27	2.55e-22	0.87	0.73	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	13.16	8.88e-27	2.55e-22	0.87	0.73	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	13.16	8.88e-27	2.55e-22	0.87	0.73	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	13.16	8.88e-27	2.55e-22	0.87	0.73	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	13.16	8.88e-27	2.55e-22	0.87	0.73	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	13.16	8.9e-27	2.55e-22	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	13.16	8.9e-27	2.55e-22	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
PCPG	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	13.15	9.3e-27	2.65e-22	0.9	0.73	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
PCPG	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-13.14	1.02e-26	2.91e-22	-1	-0.73	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
PCPG	cis	rs9322193	0.923	rs2184370	ENSG00000231760.4	RP11-350J20.5	13.13	1.07e-26	3.03e-22	0.94	0.73	Lung cancer;	chr6:149843242	chr6:149796151~149826294:-
PCPG	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	13.13	1.07e-26	3.05e-22	0.97	0.73	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
PCPG	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-13.13	1.09e-26	3.08e-22	-1.11	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-13.12	1.12e-26	3.17e-22	-1.07	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	13.12	1.14e-26	3.22e-22	0.94	0.73	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	13.1	1.27e-26	3.59e-22	0.94	0.73	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	13.1	1.27e-26	3.59e-22	0.94	0.73	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	13.1	1.29e-26	3.64e-22	1.08	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	13.09	1.32e-26	3.72e-22	1.11	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	13.09	1.36e-26	3.83e-22	0.93	0.73	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	13.09	1.36e-26	3.83e-22	0.93	0.73	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	13.09	1.36e-26	3.83e-22	0.93	0.73	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	13.09	1.36e-26	3.83e-22	0.93	0.73	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
PCPG	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-13.09	1.37e-26	3.84e-22	-0.94	-0.73	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
PCPG	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-13.09	1.39e-26	3.89e-22	-1.1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	13.08	1.41e-26	3.94e-22	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
PCPG	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	13.08	1.47e-26	4.1e-22	0.91	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
PCPG	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	13.08	1.47e-26	4.11e-22	1.15	0.73	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
PCPG	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-13.07	1.52e-26	4.24e-22	-0.96	-0.73	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
PCPG	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	13.07	1.53e-26	4.27e-22	0.94	0.73	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	13.07	1.53e-26	4.27e-22	0.94	0.73	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	13.07	1.55e-26	4.3e-22	0.94	0.73	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
PCPG	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-13.06	1.59e-26	4.41e-22	-1	-0.73	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-13.06	1.59e-26	4.41e-22	-1	-0.73	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
PCPG	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	13.06	1.66e-26	4.57e-22	0.86	0.73	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
PCPG	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	13.01	2.18e-26	5.92e-22	1.14	0.73	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
PCPG	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	13.01	2.18e-26	5.92e-22	1.14	0.73	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
PCPG	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	13.01	2.21e-26	6.01e-22	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-13.01	2.22e-26	6.02e-22	-1.06	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	13.01	2.27e-26	6.13e-22	0.93	0.73	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-13	2.31e-26	6.25e-22	-1.12	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
PCPG	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	13	2.4e-26	6.48e-22	0.95	0.73	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
PCPG	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	12.98	2.6e-26	6.99e-22	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
PCPG	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-12.98	2.62e-26	7.03e-22	-0.94	-0.73	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-12.98	2.62e-26	7.03e-22	-0.94	-0.73	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
PCPG	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	12.98	2.74e-26	7.3e-22	0.93	0.73	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	12.97	2.76e-26	7.34e-22	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	12.94	3.39e-26	8.78e-22	1.08	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
PCPG	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	12.93	3.59e-26	9.28e-22	0.85	0.73	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	12.92	3.89e-26	1.01e-21	0.94	0.73	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	12.9	4.22e-26	1.08e-21	0.85	0.73	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	12.9	4.41e-26	1.13e-21	0.92	0.73	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
PCPG	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	12.89	4.62e-26	1.18e-21	1.18	0.72	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
PCPG	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-12.89	4.73e-26	1.21e-21	-0.95	-0.72	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
PCPG	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	12.88	4.8e-26	1.22e-21	0.93	0.72	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
PCPG	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-12.87	5.15e-26	1.31e-21	-0.94	-0.72	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
PCPG	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-12.87	5.28e-26	1.34e-21	-0.92	-0.72	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
PCPG	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	12.86	5.64e-26	1.43e-21	0.84	0.72	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-12.86	5.69e-26	1.44e-21	-1.04	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	12.85	5.86e-26	1.47e-21	0.92	0.72	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	12.85	5.86e-26	1.47e-21	0.92	0.72	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	12.85	5.86e-26	1.47e-21	0.92	0.72	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	12.85	5.86e-26	1.47e-21	0.92	0.72	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	12.85	5.86e-26	1.47e-21	0.92	0.72	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
PCPG	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	12.84	6.2e-26	1.55e-21	0.94	0.72	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	12.83	6.58e-26	1.64e-21	0.86	0.72	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	12.83	6.61e-26	1.64e-21	0.93	0.72	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	12.82	7e-26	1.73e-21	0.92	0.72	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	12.82	7e-26	1.73e-21	0.92	0.72	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	12.82	7e-26	1.73e-21	0.92	0.72	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	12.82	7.14e-26	1.76e-21	0.93	0.72	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
PCPG	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	12.82	7.14e-26	1.76e-21	0.93	0.72	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
PCPG	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	12.82	7.15e-26	1.76e-21	1.12	0.72	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
PCPG	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	12.81	7.34e-26	1.81e-21	1.11	0.72	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	12.81	7.73e-26	1.9e-21	0.92	0.72	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
PCPG	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-12.8	7.9e-26	1.92e-21	-0.93	-0.72	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
PCPG	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	12.8	7.94e-26	1.93e-21	1.12	0.72	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-12.79	8.4e-26	2.03e-21	-1.05	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
PCPG	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	12.76	1.04e-25	2.46e-21	0.93	0.72	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
PCPG	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-12.76	1.04e-25	2.46e-21	-0.93	-0.72	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	12.75	1.07e-25	2.54e-21	0.92	0.72	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	12.75	1.07e-25	2.54e-21	0.92	0.72	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
PCPG	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	12.75	1.08e-25	2.55e-21	1.1	0.72	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
PCPG	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-12.74	1.19e-25	2.8e-21	-0.97	-0.72	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
PCPG	cis	rs916888	0.821	rs199499	ENSG00000262539.1	RP11-259G18.3	12.73	1.22e-25	2.87e-21	1.25	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46259551~46260606:-
PCPG	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	12.73	1.23e-25	2.87e-21	0.92	0.72	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	12.73	1.23e-25	2.87e-21	0.92	0.72	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	12.73	1.23e-25	2.87e-21	0.92	0.72	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	12.73	1.23e-25	2.87e-21	0.92	0.72	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	12.73	1.23e-25	2.87e-21	0.92	0.72	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	12.73	1.23e-25	2.87e-21	0.92	0.72	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	12.72	1.36e-25	3.18e-21	0.96	0.72	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	12.71	1.39e-25	3.23e-21	0.93	0.72	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	12.71	1.39e-25	3.23e-21	0.93	0.72	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	12.71	1.39e-25	3.23e-21	0.93	0.72	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	12.71	1.39e-25	3.23e-21	0.93	0.72	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	12.71	1.39e-25	3.23e-21	0.93	0.72	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	12.71	1.39e-25	3.23e-21	0.93	0.72	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
PCPG	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	12.71	1.41e-25	3.29e-21	1.17	0.72	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	12.7	1.47e-25	3.4e-21	1.09	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
PCPG	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	12.7	1.47e-25	3.4e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	12.7	1.47e-25	3.4e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	12.7	1.47e-25	3.4e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	12.7	1.47e-25	3.4e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	12.7	1.47e-25	3.4e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	12.7	1.47e-25	3.4e-21	0.93	0.72	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	12.7	1.47e-25	3.4e-21	0.93	0.72	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	12.7	1.51e-25	3.49e-21	0.84	0.72	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
PCPG	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	12.69	1.54e-25	3.54e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
PCPG	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	12.69	1.57e-25	3.62e-21	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
PCPG	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	12.69	1.6e-25	3.69e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
PCPG	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	12.69	1.63e-25	3.75e-21	1.14	0.72	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	12.68	1.64e-25	3.77e-21	0.93	0.72	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	12.68	1.66e-25	3.82e-21	0.93	0.72	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	12.68	1.69e-25	3.86e-21	0.93	0.72	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	12.68	1.69e-25	3.86e-21	0.93	0.72	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	12.68	1.7e-25	3.88e-21	0.84	0.72	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	12.68	1.71e-25	3.9e-21	1.05	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	12.68	1.71e-25	3.9e-21	0.92	0.72	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
PCPG	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	12.68	1.73e-25	3.94e-21	0.92	0.72	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
PCPG	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	12.67	1.75e-25	3.98e-21	0.93	0.72	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	12.67	1.8e-25	4.09e-21	0.93	0.72	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	12.67	1.8e-25	4.09e-21	0.93	0.72	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	12.67	1.82e-25	4.13e-21	1.09	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	12.67	1.83e-25	4.15e-21	0.92	0.72	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
PCPG	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	12.65	1.98e-25	4.48e-21	0.85	0.72	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
PCPG	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	12.65	1.99e-25	4.49e-21	1.13	0.72	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	12.64	2.12e-25	4.77e-21	1.09	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	12.64	2.13e-25	4.78e-21	0.92	0.72	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	12.64	2.13e-25	4.78e-21	0.92	0.72	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	12.64	2.13e-25	4.78e-21	0.92	0.72	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	12.64	2.15e-25	4.82e-21	1.09	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	12.62	2.43e-25	5.39e-21	0.92	0.72	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
PCPG	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	12.62	2.47e-25	5.46e-21	0.86	0.72	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
PCPG	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-12.62	2.48e-25	5.47e-21	-0.96	-0.72	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
PCPG	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	12.61	2.59e-25	5.68e-21	0.86	0.72	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
PCPG	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	12.61	2.61e-25	5.72e-21	0.92	0.72	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
PCPG	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	12.59	3.01e-25	6.55e-21	1.11	0.72	Shingles;	chr7:38346957	chr7:38343894~38350022:-
PCPG	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	12.58	3.14e-25	6.84e-21	0.92	0.72	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	12.58	3.14e-25	6.84e-21	0.92	0.72	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
PCPG	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	12.57	3.38e-25	7.34e-21	1.15	0.72	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
PCPG	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	12.56	3.45e-25	7.47e-21	0.91	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
PCPG	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	12.56	3.5e-25	7.59e-21	0.91	0.72	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	12.55	3.81e-25	8.24e-21	1.05	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	12.55	3.81e-25	8.24e-21	1.05	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	12.52	4.45e-25	9.58e-21	0.92	0.71	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	12.52	4.45e-25	9.58e-21	0.92	0.71	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	12.51	4.77e-25	1.02e-20	0.92	0.71	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	12.5	4.98e-25	1.06e-20	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	12.5	5.04e-25	1.08e-20	0.93	0.71	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	12.5	5.24e-25	1.12e-20	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	12.49	5.43e-25	1.15e-20	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	12.49	5.43e-25	1.15e-20	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	12.48	5.77e-25	1.22e-20	0.91	0.71	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
PCPG	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	12.47	6.09e-25	1.29e-20	0.93	0.71	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
PCPG	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	12.47	6.17e-25	1.31e-20	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
PCPG	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	12.47	6.28e-25	1.33e-20	0.9	0.71	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
PCPG	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-12.45	6.83e-25	1.44e-20	-0.9	-0.71	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
PCPG	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	12.45	7.14e-25	1.51e-20	0.84	0.71	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	12.45	7.14e-25	1.51e-20	0.84	0.71	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	12.45	7.14e-25	1.51e-20	0.84	0.71	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	12.45	7.14e-25	1.51e-20	0.84	0.71	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	12.44	7.19e-25	1.51e-20	0.85	0.71	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
PCPG	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	12.44	7.38e-25	1.55e-20	0.97	0.71	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-12.44	7.38e-25	1.55e-20	-0.9	-0.71	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
PCPG	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	12.44	7.51e-25	1.57e-20	0.84	0.71	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
PCPG	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-12.44	7.53e-25	1.57e-20	-0.9	-0.71	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
PCPG	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-12.44	7.53e-25	1.57e-20	-0.9	-0.71	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
PCPG	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-12.43	7.85e-25	1.64e-20	-0.96	-0.71	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
PCPG	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	12.43	7.99e-25	1.67e-20	1.04	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	12.43	8.04e-25	1.68e-20	1.06	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
PCPG	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	12.43	8.04e-25	1.68e-20	1.1	0.71	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	12.42	8.11e-25	1.69e-20	1.03	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	12.41	8.92e-25	1.85e-20	1.03	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	12.4	9.33e-25	1.93e-20	0.87	0.71	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
PCPG	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	12.4	9.55e-25	1.98e-20	0.89	0.71	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
PCPG	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	12.39	1.02e-24	2.11e-20	0.92	0.71	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	12.39	1.02e-24	2.11e-20	0.92	0.71	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	12.39	1.02e-24	2.11e-20	0.92	0.71	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	12.36	1.23e-24	2.51e-20	0.92	0.71	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	12.36	1.23e-24	2.51e-20	0.92	0.71	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
PCPG	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	12.36	1.24e-24	2.53e-20	1.12	0.71	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
PCPG	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	12.36	1.25e-24	2.54e-20	0.75	0.71	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	12.35	1.26e-24	2.56e-20	0.93	0.71	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
PCPG	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	12.35	1.31e-24	2.67e-20	0.91	0.71	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	12.35	1.32e-24	2.69e-20	0.92	0.71	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	12.34	1.34e-24	2.72e-20	0.9	0.71	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	12.34	1.34e-24	2.72e-20	0.9	0.71	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	12.33	1.41e-24	2.86e-20	0.89	0.71	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	12.33	1.41e-24	2.86e-20	0.89	0.71	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
PCPG	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	12.33	1.45e-24	2.92e-20	0.85	0.71	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	12.33	1.45e-24	2.92e-20	0.85	0.71	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
PCPG	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	12.33	1.46e-24	2.94e-20	0.9	0.71	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	12.28	1.97e-24	3.94e-20	0.93	0.71	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	12.28	1.99e-24	3.97e-20	0.89	0.71	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	12.27	2.08e-24	4.15e-20	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	12.27	2.11e-24	4.19e-20	0.92	0.71	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
PCPG	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	12.27	2.13e-24	4.23e-20	1.11	0.71	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
PCPG	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	12.27	2.13e-24	4.23e-20	1.11	0.71	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
PCPG	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	12.26	2.23e-24	4.42e-20	1.08	0.71	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	12.25	2.38e-24	4.7e-20	0.91	0.71	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
PCPG	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	12.24	2.58e-24	5.06e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	12.24	2.6e-24	5.11e-20	0.81	0.71	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	12.23	2.66e-24	5.22e-20	0.92	0.71	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
PCPG	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	12.23	2.67e-24	5.22e-20	0.89	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
PCPG	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	12.23	2.67e-24	5.22e-20	0.89	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
PCPG	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	12.23	2.75e-24	5.37e-20	0.92	0.71	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
PCPG	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	12.22	2.86e-24	5.54e-20	0.83	0.71	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
PCPG	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	12.2	3.21e-24	6.2e-20	0.82	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	12.19	3.38e-24	6.52e-20	0.91	0.71	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
PCPG	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	12.19	3.42e-24	6.59e-20	0.73	0.71	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
PCPG	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	12.18	3.68e-24	7.06e-20	0.91	0.71	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	12.18	3.68e-24	7.06e-20	0.91	0.71	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	12.18	3.68e-24	7.06e-20	0.91	0.71	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	12.18	3.73e-24	7.14e-20	0.94	0.71	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	12.18	3.73e-24	7.14e-20	0.94	0.71	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	12.18	3.73e-24	7.14e-20	0.94	0.71	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	12.18	3.77e-24	7.14e-20	0.91	0.71	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	12.17	3.97e-24	7.47e-20	0.91	0.7	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	12.17	3.97e-24	7.47e-20	0.91	0.7	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	12.16	4.07e-24	7.65e-20	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	12.15	4.49e-24	8.41e-20	0.91	0.7	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	12.15	4.49e-24	8.41e-20	0.91	0.7	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	12.13	5.1e-24	9.46e-20	1.04	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-12.13	5.13e-24	9.5e-20	-0.91	-0.7	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
PCPG	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-12.12	5.19e-24	9.6e-20	-0.92	-0.7	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	12.11	5.79e-24	1.06e-19	0.82	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	12.11	5.79e-24	1.06e-19	0.9	0.7	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
PCPG	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	12.08	6.78e-24	1.22e-19	0.91	0.7	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-12.08	6.86e-24	1.22e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	12.08	6.86e-24	1.22e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
PCPG	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	12.08	6.94e-24	1.24e-19	0.91	0.7	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
PCPG	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	12.07	7.14e-24	1.27e-19	0.72	0.7	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	12.07	7.14e-24	1.27e-19	0.72	0.7	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	12.07	7.14e-24	1.27e-19	0.72	0.7	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	12.07	7.14e-24	1.27e-19	0.72	0.7	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	12.07	7.14e-24	1.27e-19	0.72	0.7	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	12.07	7.14e-24	1.27e-19	0.72	0.7	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
PCPG	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	12.07	7.21e-24	1.28e-19	0.86	0.7	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	12.07	7.21e-24	1.28e-19	0.86	0.7	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	12.07	7.21e-24	1.28e-19	0.86	0.7	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
PCPG	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-12.07	7.29e-24	1.29e-19	-0.88	-0.7	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
PCPG	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	12.06	7.72e-24	1.36e-19	0.71	0.7	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	12.06	7.72e-24	1.36e-19	0.71	0.7	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	12.06	7.72e-24	1.36e-19	0.71	0.7	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	12.06	7.72e-24	1.36e-19	0.71	0.7	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	12.06	7.72e-24	1.36e-19	0.71	0.7	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
PCPG	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	12.06	7.85e-24	1.38e-19	0.91	0.7	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	12.05	8.19e-24	1.44e-19	0.89	0.7	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
PCPG	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	12.04	8.81e-24	1.54e-19	0.72	0.7	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	12.04	8.81e-24	1.54e-19	0.72	0.7	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	12.04	8.81e-24	1.54e-19	0.72	0.7	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
PCPG	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	12.04	8.93e-24	1.56e-19	0.87	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
PCPG	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-12.03	9.42e-24	1.64e-19	-1.09	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	12.02	9.56e-24	1.66e-19	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	12.02	9.56e-24	1.66e-19	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
PCPG	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	12.02	9.69e-24	1.68e-19	0.72	0.7	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	12.02	9.69e-24	1.68e-19	0.72	0.7	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
PCPG	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	12.01	1.05e-23	1.83e-19	1.11	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	12.01	1.06e-23	1.83e-19	0.94	0.7	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	12.01	1.06e-23	1.83e-19	0.94	0.7	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	12.01	1.06e-23	1.83e-19	0.94	0.7	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	12.01	1.06e-23	1.84e-19	0.8	0.7	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	12	1.09e-23	1.89e-19	1.07	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	12	1.1e-23	1.89e-19	0.94	0.7	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	12	1.1e-23	1.89e-19	0.94	0.7	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
PCPG	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	12	1.1e-23	1.89e-19	0.73	0.7	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
PCPG	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	12	1.11e-23	1.9e-19	0.91	0.7	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	12	1.11e-23	1.9e-19	0.91	0.7	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	12	1.11e-23	1.9e-19	0.94	0.7	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	12	1.11e-23	1.9e-19	0.94	0.7	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	12	1.11e-23	1.9e-19	0.94	0.7	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-12	1.12e-23	1.92e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
PCPG	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	11.99	1.21e-23	2.06e-19	0.93	0.7	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
PCPG	cis	rs916888	0.821	rs199499	ENSG00000214401.4	KANSL1-AS1	11.98	1.23e-23	2.1e-19	1.13	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46193576~46196723:+
PCPG	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	11.98	1.23e-23	2.1e-19	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
PCPG	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-11.96	1.4e-23	2.38e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-11.96	1.4e-23	2.38e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-11.96	1.4e-23	2.38e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-11.96	1.4e-23	2.38e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-11.96	1.4e-23	2.38e-19	-1.05	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
PCPG	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	11.96	1.41e-23	2.39e-19	1.1	0.7	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
PCPG	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	11.95	1.51e-23	2.54e-19	0.86	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
PCPG	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	11.94	1.63e-23	2.74e-19	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	11.94	1.63e-23	2.74e-19	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	11.94	1.63e-23	2.75e-19	1.04	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
PCPG	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-11.92	1.78e-23	3e-19	-0.93	-0.7	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-11.92	1.82e-23	3.06e-19	-0.94	-0.7	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
PCPG	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-11.92	1.86e-23	3.13e-19	-0.89	-0.7	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
PCPG	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	11.92	1.88e-23	3.14e-19	1.05	0.7	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	11.91	1.93e-23	3.23e-19	1.03	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
PCPG	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-11.91	1.94e-23	3.24e-19	-0.82	-0.7	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
PCPG	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	11.91	1.96e-23	3.29e-19	0.89	0.7	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	11.9	2.06e-23	3.45e-19	1.05	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	11.87	2.44e-23	4.07e-19	0.89	0.7	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-11.87	2.47e-23	4.12e-19	-0.79	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
PCPG	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-11.86	2.57e-23	4.26e-19	-0.94	-0.7	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
PCPG	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	11.86	2.66e-23	4.41e-19	0.93	0.7	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	11.84	3.05e-23	5.03e-19	0.93	0.69	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	11.84	3.05e-23	5.03e-19	0.93	0.69	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	11.84	3.05e-23	5.03e-19	0.93	0.69	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-11.83	3.18e-23	5.25e-19	-1.02	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-11.83	3.18e-23	5.25e-19	-0.94	-0.69	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
PCPG	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-11.83	3.23e-23	5.32e-19	-0.98	-0.69	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
PCPG	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-11.81	3.59e-23	5.9e-19	-0.92	-0.69	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-11.8	3.88e-23	6.36e-19	-1.02	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
PCPG	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	11.78	4.29e-23	7.01e-19	1.05	0.69	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
PCPG	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	11.77	4.52e-23	7.37e-19	0.93	0.69	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	11.77	4.69e-23	7.65e-19	0.92	0.69	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
PCPG	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-11.77	4.73e-23	7.71e-19	-0.9	-0.69	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
PCPG	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	11.76	4.85e-23	7.89e-19	1.01	0.69	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
PCPG	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	11.76	4.91e-23	7.98e-19	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
PCPG	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	11.76	4.98e-23	8.08e-19	0.98	0.69	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
PCPG	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	11.75	5.07e-23	8.23e-19	0.69	0.69	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
PCPG	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	11.75	5.17e-23	8.37e-19	0.85	0.69	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
PCPG	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	11.74	5.36e-23	8.65e-19	0.9	0.69	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	11.74	5.46e-23	8.81e-19	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	11.73	5.84e-23	9.39e-19	0.94	0.69	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
PCPG	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	11.72	6.26e-23	1e-18	0.89	0.69	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	11.72	6.26e-23	1e-18	0.89	0.69	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	11.72	6.26e-23	1e-18	0.94	0.69	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
PCPG	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	11.71	6.46e-23	1.03e-18	0.9	0.69	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	11.69	7.32e-23	1.17e-18	0.85	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
PCPG	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	11.68	7.93e-23	1.26e-18	0.71	0.69	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
PCPG	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	11.66	9.16e-23	1.45e-18	0.8	0.69	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	11.65	9.6e-23	1.52e-18	1.06	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-11.65	9.71e-23	1.54e-18	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-11.64	1.04e-22	1.63e-18	-0.82	-0.69	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-11.64	1.04e-22	1.63e-18	-0.82	-0.69	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
PCPG	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-11.64	1.04e-22	1.64e-18	-0.71	-0.69	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
PCPG	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	11.63	1.09e-22	1.7e-18	0.88	0.69	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	11.63	1.09e-22	1.7e-18	0.88	0.69	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	11.63	1.09e-22	1.7e-18	0.88	0.69	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	11.63	1.09e-22	1.7e-18	0.88	0.69	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	11.63	1.09e-22	1.7e-18	0.88	0.69	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	11.63	1.09e-22	1.7e-18	0.88	0.69	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	11.63	1.09e-22	1.7e-18	0.88	0.69	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	11.62	1.17e-22	1.82e-18	0.93	0.69	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	11.62	1.17e-22	1.82e-18	0.93	0.69	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
PCPG	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	11.62	1.17e-22	1.82e-18	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	11.61	1.2e-22	1.86e-18	1.01	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	11.61	1.22e-22	1.89e-18	0.83	0.69	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
PCPG	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	11.6	1.29e-22	1.99e-18	0.72	0.69	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
PCPG	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-11.6	1.34e-22	2.06e-18	-0.86	-0.69	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	11.59	1.36e-22	2.08e-18	0.78	0.69	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	11.59	1.36e-22	2.08e-18	0.78	0.69	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	11.59	1.37e-22	2.09e-18	0.93	0.69	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	11.59	1.39e-22	2.12e-18	0.89	0.69	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-11.58	1.44e-22	2.19e-18	-0.76	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
PCPG	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	11.58	1.49e-22	2.27e-18	0.71	0.69	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
PCPG	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	11.56	1.65e-22	2.49e-18	1.13	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	11.55	1.74e-22	2.63e-18	1.03	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
PCPG	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	11.52	2.1e-22	3.14e-18	1.01	0.69	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
PCPG	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	11.52	2.13e-22	3.18e-18	0.98	0.69	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
PCPG	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	11.52	2.14e-22	3.19e-18	1	0.69	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
PCPG	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	11.52	2.2e-22	3.28e-18	0.89	0.69	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	11.52	2.2e-22	3.28e-18	0.89	0.69	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	11.51	2.25e-22	3.33e-18	0.77	0.68	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	11.51	2.25e-22	3.33e-18	0.77	0.68	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
PCPG	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	11.5	2.46e-22	3.62e-18	0.9	0.68	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
PCPG	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	11.5	2.46e-22	3.62e-18	0.9	0.68	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
PCPG	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	11.5	2.49e-22	3.66e-18	0.85	0.68	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
PCPG	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-11.48	2.71e-22	3.98e-18	-0.94	-0.68	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
PCPG	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	11.47	2.84e-22	4.17e-18	0.7	0.68	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
PCPG	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	11.47	2.95e-22	4.33e-18	0.92	0.68	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
PCPG	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-11.47	2.96e-22	4.33e-18	-0.81	-0.68	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	11.47	2.96e-22	4.33e-18	1.03	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	11.47	2.96e-22	4.33e-18	1.03	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-11.45	3.33e-22	4.84e-18	-1.02	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-11.44	3.6e-22	5.2e-18	-0.83	-0.68	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-11.44	3.6e-22	5.2e-18	-0.83	-0.68	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
PCPG	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	11.43	3.73e-22	5.38e-18	0.9	0.68	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
PCPG	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	11.43	3.73e-22	5.38e-18	0.9	0.68	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
PCPG	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	11.41	4.28e-22	6.15e-18	1	0.68	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
PCPG	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	11.39	4.68e-22	6.69e-18	0.79	0.68	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
PCPG	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	11.39	4.78e-22	6.83e-18	1.05	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	11.38	4.93e-22	7.02e-18	1.06	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	11.38	4.93e-22	7.02e-18	1.06	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
PCPG	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-11.38	5.06e-22	7.2e-18	-0.79	-0.68	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
PCPG	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-11.38	5.15e-22	7.31e-18	-0.93	-0.68	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
PCPG	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	11.35	5.94e-22	8.35e-18	1.04	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	11.34	6.5e-22	9.1e-18	1.01	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	11.34	6.5e-22	9.1e-18	1.01	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-11.33	6.71e-22	9.38e-18	-0.83	-0.68	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
PCPG	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	11.33	6.73e-22	9.39e-18	0.78	0.68	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
PCPG	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-11.33	6.93e-22	9.67e-18	-0.71	-0.68	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	11.32	7.22e-22	1e-17	0.69	0.68	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
PCPG	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	11.32	7.3e-22	1.02e-17	0.77	0.68	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-11.32	7.38e-22	1.03e-17	-1.04	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
PCPG	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-11.32	7.5e-22	1.04e-17	-1.01	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
PCPG	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-11.3	8.42e-22	1.15e-17	-0.84	-0.68	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
PCPG	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	11.3	8.52e-22	1.16e-17	0.83	0.68	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-11.3	8.52e-22	1.16e-17	-0.83	-0.68	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-11.3	8.52e-22	1.16e-17	-0.83	-0.68	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-11.29	8.83e-22	1.2e-17	-0.83	-0.68	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	11.27	9.76e-22	1.32e-17	0.9	0.68	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	11.27	9.76e-22	1.32e-17	0.9	0.68	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
PCPG	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-11.27	1.03e-21	1.38e-17	-0.88	-0.68	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
PCPG	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	11.27	1.03e-21	1.38e-17	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	11.26	1.05e-21	1.42e-17	0.78	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
PCPG	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-11.26	1.09e-21	1.46e-17	-0.83	-0.68	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
PCPG	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	11.26	1.09e-21	1.46e-17	0.87	0.68	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
PCPG	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-11.25	1.1e-21	1.47e-17	-0.68	-0.68	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
PCPG	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	11.25	1.14e-21	1.53e-17	1	0.68	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
PCPG	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-11.24	1.19e-21	1.59e-17	-0.82	-0.68	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	11.24	1.19e-21	1.59e-17	0.82	0.68	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-11.24	1.2e-21	1.6e-17	-0.82	-0.68	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-11.24	1.2e-21	1.6e-17	-0.82	-0.68	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-11.23	1.31e-21	1.74e-17	-0.82	-0.68	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	11.22	1.34e-21	1.77e-17	0.9	0.68	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	11.22	1.35e-21	1.78e-17	0.86	0.68	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
PCPG	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	11.21	1.44e-21	1.88e-17	0.88	0.68	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
PCPG	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	11.21	1.44e-21	1.88e-17	0.88	0.68	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
PCPG	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	11.2	1.54e-21	2e-17	0.88	0.67	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
PCPG	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-11.2	1.54e-21	2.01e-17	-0.81	-0.67	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	11.19	1.65e-21	2.14e-17	0.85	0.67	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
PCPG	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	11.19	1.67e-21	2.17e-17	0.69	0.67	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	11.17	1.8e-21	2.33e-17	0.7	0.67	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	11.17	1.8e-21	2.33e-17	0.7	0.67	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	11.17	1.8e-21	2.33e-17	0.7	0.67	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
PCPG	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	11.17	1.86e-21	2.4e-17	0.88	0.67	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
PCPG	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	11.17	1.9e-21	2.45e-17	0.81	0.67	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
PCPG	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-11.16	1.98e-21	2.55e-17	-0.87	-0.67	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
PCPG	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-11.14	2.15e-21	2.76e-17	-0.86	-0.67	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
PCPG	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	11.14	2.19e-21	2.8e-17	0.7	0.67	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
PCPG	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-11.12	2.56e-21	3.24e-17	-0.84	-0.67	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-11.12	2.56e-21	3.24e-17	-0.84	-0.67	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
PCPG	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	11.1	2.91e-21	3.67e-17	0.87	0.67	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
PCPG	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	11.09	3e-21	3.77e-17	0.69	0.67	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
PCPG	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	11.09	3.02e-21	3.8e-17	0.77	0.67	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
PCPG	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	11.08	3.15e-21	3.95e-17	0.85	0.67	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
PCPG	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	11.08	3.15e-21	3.95e-17	0.89	0.67	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
PCPG	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-11.08	3.23e-21	4.04e-17	-1.02	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-11.08	3.23e-21	4.04e-17	-1.02	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-11.08	3.23e-21	4.04e-17	-1.02	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-11.08	3.23e-21	4.04e-17	-1.02	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
PCPG	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-11.07	3.42e-21	4.27e-17	-0.99	-0.67	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-11.06	3.6e-21	4.48e-17	-1.02	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-11.06	3.6e-21	4.48e-17	-1.02	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-11.05	3.83e-21	4.74e-17	-0.81	-0.67	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	11.05	3.84e-21	4.75e-17	0.92	0.67	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	11.05	3.88e-21	4.8e-17	0.88	0.67	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
PCPG	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-11.05	3.94e-21	4.87e-17	-0.81	-0.67	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	11.04	4.02e-21	4.97e-17	0.77	0.67	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
PCPG	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-11.04	4.16e-21	5.1e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
PCPG	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-11.04	4.16e-21	5.1e-17	-0.81	-0.67	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-11.03	4.36e-21	5.29e-17	-0.81	-0.67	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-11.03	4.36e-21	5.29e-17	-0.81	-0.67	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-11.03	4.36e-21	5.29e-17	-0.81	-0.67	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
PCPG	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-11.02	4.63e-21	5.56e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
PCPG	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-11.02	4.65e-21	5.58e-17	-0.89	-0.67	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
PCPG	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	11.02	4.66e-21	5.59e-17	0.68	0.67	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
PCPG	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	11.02	4.71e-21	5.65e-17	0.78	0.67	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
PCPG	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	11.01	4.86e-21	5.8e-17	0.81	0.67	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
PCPG	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	11.01	4.86e-21	5.8e-17	0.81	0.67	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
PCPG	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	11.01	5.06e-21	6.01e-17	0.78	0.67	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
PCPG	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	11.01	5.08e-21	6.03e-17	0.77	0.67	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	10.99	5.45e-21	6.45e-17	0.92	0.67	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	10.99	5.51e-21	6.51e-17	0.77	0.67	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
PCPG	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-10.99	5.69e-21	6.71e-17	-0.86	-0.67	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
PCPG	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	10.98	5.75e-21	6.78e-17	0.87	0.67	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
PCPG	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	10.98	5.77e-21	6.81e-17	0.77	0.67	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
PCPG	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	10.98	5.8e-21	6.83e-17	0.85	0.67	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
PCPG	cis	rs801193	0.875	rs13227951	ENSG00000226824.5	RP4-756H11.3	10.98	6.01e-21	7.08e-17	0.9	0.67	Aortic root size;	chr7:66748121	chr7:66654538~66669855:+
PCPG	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	10.97	6.21e-21	7.24e-17	0.69	0.67	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
PCPG	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-10.97	6.38e-21	7.42e-17	-0.84	-0.67	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-10.95	7.09e-21	8.19e-17	-0.84	-0.67	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
PCPG	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	10.95	7.2e-21	8.31e-17	0.92	0.67	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
PCPG	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-10.94	7.55e-21	8.63e-17	-0.87	-0.67	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
PCPG	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-10.94	7.63e-21	8.71e-17	-0.87	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
PCPG	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-10.93	7.91e-21	9.02e-17	-0.83	-0.67	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
PCPG	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-10.93	8e-21	9.1e-17	-0.87	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
PCPG	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	10.93	8.06e-21	9.16e-17	0.8	0.67	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
PCPG	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-10.92	8.61e-21	9.75e-17	-0.86	-0.67	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
PCPG	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	10.91	8.97e-21	1.01e-16	0.76	0.67	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
PCPG	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-10.91	8.99e-21	1.01e-16	-0.97	-0.67	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	10.9	9.57e-21	1.07e-16	0.88	0.66	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	10.89	1e-20	1.12e-16	0.76	0.66	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	10.86	1.2e-20	1.27e-16	1	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
PCPG	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-10.84	1.44e-20	1.5e-16	-1.05	-0.66	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
PCPG	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	10.83	1.46e-20	1.53e-16	0.88	0.66	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
PCPG	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	10.83	1.49e-20	1.55e-16	0.79	0.66	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
PCPG	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-10.83	1.51e-20	1.57e-16	-0.85	-0.66	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	10.83	1.52e-20	1.58e-16	0.91	0.66	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	10.83	1.52e-20	1.58e-16	0.91	0.66	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
PCPG	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-10.82	1.56e-20	1.62e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-10.81	1.65e-20	1.71e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-10.81	1.65e-20	1.71e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-10.81	1.65e-20	1.71e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
PCPG	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-10.81	1.68e-20	1.74e-16	-0.79	-0.66	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
PCPG	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	10.81	1.68e-20	1.74e-16	0.68	0.66	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	10.81	1.71e-20	1.76e-16	0.69	0.66	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
PCPG	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-10.81	1.71e-20	1.77e-16	-0.79	-0.66	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
PCPG	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	10.81	1.71e-20	1.77e-16	0.79	0.66	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
PCPG	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-10.8	1.81e-20	1.86e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-10.8	1.81e-20	1.86e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-10.8	1.83e-20	1.88e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-10.8	1.83e-20	1.88e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-10.8	1.83e-20	1.88e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-10.79	1.85e-20	1.9e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-10.79	1.85e-20	1.9e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
PCPG	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	10.79	1.92e-20	1.97e-16	0.78	0.66	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
PCPG	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	10.78	2e-20	2.04e-16	0.98	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
PCPG	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-10.78	2.08e-20	2.11e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-10.78	2.08e-20	2.11e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-10.78	2.08e-20	2.11e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-10.78	2.08e-20	2.11e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-10.78	2.08e-20	2.11e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
PCPG	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	10.77	2.1e-20	2.13e-16	0.69	0.66	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
PCPG	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	10.77	2.11e-20	2.15e-16	0.77	0.66	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
PCPG	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-10.76	2.32e-20	2.35e-16	-0.97	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
PCPG	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	10.76	2.33e-20	2.35e-16	0.77	0.66	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	10.76	2.33e-20	2.35e-16	0.77	0.66	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
PCPG	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	10.75	2.38e-20	2.4e-16	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	10.75	2.38e-20	2.4e-16	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	10.75	2.38e-20	2.4e-16	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	10.75	2.38e-20	2.4e-16	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	10.75	2.38e-20	2.4e-16	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	10.75	2.38e-20	2.4e-16	0.74	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	10.75	2.47e-20	2.48e-16	0.91	0.66	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	10.74	2.56e-20	2.57e-16	0.9	0.66	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
PCPG	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-10.74	2.58e-20	2.59e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
PCPG	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-10.74	2.62e-20	2.62e-16	-0.87	-0.66	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
PCPG	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-10.74	2.65e-20	2.66e-16	-0.9	-0.66	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
PCPG	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	10.73	2.81e-20	2.81e-16	0.9	0.66	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
PCPG	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	10.72	2.9e-20	2.89e-16	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
PCPG	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	10.72	2.97e-20	2.95e-16	0.7	0.66	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	10.72	2.97e-20	2.95e-16	0.7	0.66	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	10.72	2.97e-20	2.95e-16	0.7	0.66	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
PCPG	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	10.71	3.05e-20	3.03e-16	1.22	0.66	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
PCPG	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	10.71	3.15e-20	3.13e-16	0.83	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
PCPG	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-10.71	3.17e-20	3.13e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-10.71	3.17e-20	3.13e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-10.71	3.17e-20	3.13e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-10.71	3.17e-20	3.13e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-10.71	3.17e-20	3.13e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-10.71	3.17e-20	3.13e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-10.7	3.23e-20	3.18e-16	-0.85	-0.66	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-10.7	3.23e-20	3.18e-16	-0.85	-0.66	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-10.7	3.23e-20	3.18e-16	-0.85	-0.66	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-10.7	3.23e-20	3.18e-16	-0.85	-0.66	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
PCPG	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	10.7	3.27e-20	3.22e-16	0.68	0.66	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	10.7	3.27e-20	3.22e-16	0.68	0.66	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	10.7	3.27e-20	3.22e-16	0.68	0.66	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
PCPG	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	10.7	3.33e-20	3.27e-16	0.67	0.66	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
PCPG	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-10.69	3.41e-20	3.34e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-10.69	3.41e-20	3.34e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
PCPG	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	10.69	3.46e-20	3.39e-16	1.04	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
PCPG	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	10.69	3.49e-20	3.42e-16	0.76	0.66	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
PCPG	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-10.69	3.59e-20	3.51e-16	-0.8	-0.66	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-10.69	3.59e-20	3.51e-16	-0.8	-0.66	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-10.69	3.59e-20	3.51e-16	-0.8	-0.66	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	10.69	3.59e-20	3.51e-16	0.76	0.66	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
PCPG	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	10.69	3.6e-20	3.52e-16	0.97	0.66	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
PCPG	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	10.68	3.67e-20	3.58e-16	0.77	0.66	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
PCPG	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-10.68	3.71e-20	3.6e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
PCPG	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	10.68	3.74e-20	3.63e-16	1.07	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	10.67	4.02e-20	3.89e-16	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
PCPG	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-10.66	4.11e-20	3.98e-16	-0.85	-0.66	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
PCPG	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-10.66	4.19e-20	4.05e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-10.66	4.19e-20	4.05e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	10.65	4.51e-20	4.35e-16	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
PCPG	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	10.64	4.65e-20	4.48e-16	0.68	0.66	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
PCPG	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-10.64	4.66e-20	4.49e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-10.64	4.66e-20	4.49e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-10.64	4.66e-20	4.49e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-10.64	4.66e-20	4.49e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-10.64	4.7e-20	4.52e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-10.64	4.7e-20	4.52e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-10.64	4.7e-20	4.52e-16	-0.82	-0.66	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	10.64	4.79e-20	4.6e-16	0.75	0.66	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
PCPG	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-10.64	4.83e-20	4.64e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-10.64	4.83e-20	4.64e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-10.64	4.9e-20	4.69e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-10.64	4.9e-20	4.69e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-10.64	4.9e-20	4.69e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
PCPG	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-10.63	4.94e-20	4.73e-16	-0.85	-0.66	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-10.63	4.94e-20	4.73e-16	-0.85	-0.66	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-10.63	4.94e-20	4.73e-16	-0.85	-0.66	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
PCPG	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-10.63	5.03e-20	4.81e-16	-0.85	-0.66	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-10.63	5.15e-20	4.92e-16	-0.83	-0.66	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
PCPG	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	10.63	5.17e-20	4.93e-16	0.89	0.66	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
PCPG	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-10.62	5.27e-20	5.02e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-10.62	5.27e-20	5.02e-16	-0.84	-0.66	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	10.61	5.67e-20	5.39e-16	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
PCPG	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	10.61	5.7e-20	5.42e-16	0.84	0.65	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	10.61	5.77e-20	5.49e-16	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
PCPG	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	10.6	5.95e-20	5.65e-16	0.66	0.65	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
PCPG	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-10.6	6.16e-20	5.82e-16	-0.84	-0.65	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-10.6	6.16e-20	5.82e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-10.6	6.16e-20	5.82e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
PCPG	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	10.59	6.52e-20	6.15e-16	0.76	0.65	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
PCPG	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	10.58	6.71e-20	6.32e-16	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	10.58	6.71e-20	6.32e-16	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
PCPG	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-10.58	7.05e-20	6.62e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-10.58	7.05e-20	6.62e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-10.58	7.06e-20	6.62e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-10.58	7.06e-20	6.62e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
PCPG	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	10.58	7.06e-20	6.63e-16	0.76	0.65	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
PCPG	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-10.57	7.2e-20	6.75e-16	-0.86	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	10.57	7.41e-20	6.95e-16	0.85	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
PCPG	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	10.56	7.9e-20	7.38e-16	0.97	0.65	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
PCPG	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	10.55	8.47e-20	7.84e-16	0.76	0.65	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
PCPG	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-10.54	8.84e-20	8.16e-16	-0.81	-0.65	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-10.54	8.84e-20	8.16e-16	-0.81	-0.65	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
PCPG	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	10.54	8.99e-20	8.29e-16	0.76	0.65	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	10.54	9.01e-20	8.3e-16	0.74	0.65	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	10.54	9.01e-20	8.3e-16	0.74	0.65	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
PCPG	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	10.53	9.08e-20	8.37e-16	0.66	0.65	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
PCPG	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	10.53	9.32e-20	8.59e-16	1.13	0.65	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
PCPG	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-10.53	9.57e-20	8.81e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-10.53	9.57e-20	8.81e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
PCPG	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	10.53	9.58e-20	8.82e-16	0.76	0.65	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
PCPG	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-10.52	1.02e-19	9.3e-16	-0.83	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
PCPG	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	10.52	1.02e-19	9.3e-16	0.77	0.65	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
PCPG	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	10.52	1.02e-19	9.3e-16	0.77	0.65	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
PCPG	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-10.51	1.03e-19	9.44e-16	-0.83	-0.65	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-10.51	1.04e-19	9.5e-16	-0.82	-0.65	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
PCPG	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	10.51	1.08e-19	9.83e-16	0.77	0.65	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
PCPG	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	10.5	1.12e-19	1.02e-15	0.75	0.65	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
PCPG	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	10.5	1.15e-19	1.04e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
PCPG	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-10.49	1.16e-19	1.05e-15	-0.82	-0.65	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-10.49	1.16e-19	1.05e-15	-0.82	-0.65	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-10.49	1.18e-19	1.07e-15	-0.8	-0.65	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-10.49	1.18e-19	1.07e-15	-0.8	-0.65	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	10.48	1.27e-19	1.15e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
PCPG	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-10.47	1.35e-19	1.22e-15	-0.61	-0.65	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
PCPG	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-10.46	1.42e-19	1.28e-15	-0.84	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	10.46	1.44e-19	1.3e-15	0.83	0.65	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
PCPG	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	10.46	1.45e-19	1.3e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
PCPG	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	10.45	1.49e-19	1.34e-15	0.96	0.65	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-10.45	1.49e-19	1.34e-15	-0.96	-0.65	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
PCPG	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	10.45	1.53e-19	1.38e-15	1.23	0.65	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
PCPG	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-10.42	1.86e-19	1.67e-15	-0.83	-0.65	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	10.41	1.9e-19	1.7e-15	0.78	0.65	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	10.41	1.92e-19	1.71e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
PCPG	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	10.4	2.02e-19	1.8e-15	0.95	0.65	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
PCPG	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	10.4	2.04e-19	1.81e-15	0.7	0.65	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
PCPG	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-10.4	2.08e-19	1.84e-15	-0.82	-0.65	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
PCPG	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-10.39	2.14e-19	1.89e-15	-0.83	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-10.39	2.14e-19	1.89e-15	-0.83	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-10.39	2.14e-19	1.89e-15	-0.83	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-10.39	2.14e-19	1.89e-15	-0.83	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-10.39	2.14e-19	1.89e-15	-0.83	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-10.39	2.14e-19	1.89e-15	-0.83	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
PCPG	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-10.39	2.16e-19	1.91e-15	-0.77	-0.65	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-10.39	2.16e-19	1.91e-15	-0.77	-0.65	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-10.39	2.2e-19	1.94e-15	-0.81	-0.65	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-10.39	2.2e-19	1.94e-15	-0.81	-0.65	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
PCPG	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-10.38	2.27e-19	2e-15	-0.91	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
PCPG	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-10.37	2.45e-19	2.14e-15	-0.61	-0.65	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
PCPG	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-10.37	2.47e-19	2.15e-15	-0.8	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
PCPG	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-10.37	2.5e-19	2.18e-15	-1.19	-0.65	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	10.37	2.5e-19	2.18e-15	1.19	0.65	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
PCPG	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	10.37	2.52e-19	2.19e-15	0.77	0.65	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
PCPG	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-10.36	2.58e-19	2.24e-15	-0.84	-0.65	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
PCPG	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-10.36	2.66e-19	2.31e-15	-0.8	-0.65	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	10.35	2.85e-19	2.47e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
PCPG	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-10.34	2.89e-19	2.5e-15	-0.84	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-10.34	2.89e-19	2.5e-15	-0.84	-0.65	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	10.34	2.9e-19	2.5e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	10.34	2.9e-19	2.5e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	10.34	2.9e-19	2.5e-15	0.74	0.65	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
PCPG	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-10.34	3e-19	2.59e-15	-0.82	-0.65	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-10.34	3e-19	2.59e-15	-0.82	-0.65	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
PCPG	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	10.33	3.16e-19	2.73e-15	0.95	0.64	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	10.31	3.55e-19	3.05e-15	0.73	0.64	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
PCPG	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-10.3	3.7e-19	3.18e-15	-0.8	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
PCPG	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	10.3	3.71e-19	3.19e-15	0.73	0.64	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
PCPG	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	10.3	3.73e-19	3.21e-15	0.77	0.64	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
PCPG	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	10.3	3.75e-19	3.22e-15	0.8	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
PCPG	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	10.3	3.76e-19	3.23e-15	0.8	0.64	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	10.3	3.79e-19	3.26e-15	1.01	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
PCPG	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	10.29	4.05e-19	3.47e-15	0.99	0.64	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
PCPG	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-10.28	4.15e-19	3.55e-15	-0.61	-0.64	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-10.28	4.15e-19	3.55e-15	-0.61	-0.64	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-10.28	4.15e-19	3.55e-15	-0.61	-0.64	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	10.28	4.15e-19	3.55e-15	0.61	0.64	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
PCPG	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	10.28	4.37e-19	3.74e-15	0.76	0.64	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
PCPG	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	10.27	4.44e-19	3.79e-15	0.74	0.64	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
PCPG	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-10.27	4.47e-19	3.82e-15	-0.97	-0.64	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
PCPG	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-10.27	4.55e-19	3.88e-15	-0.84	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
PCPG	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	10.25	4.98e-19	4.24e-15	0.66	0.64	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
PCPG	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	10.25	5.23e-19	4.45e-15	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
PCPG	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	10.24	5.54e-19	4.71e-15	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
PCPG	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	10.24	5.61e-19	4.77e-15	0.83	0.64	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
PCPG	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	10.23	5.93e-19	5.03e-15	0.78	0.64	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
PCPG	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-10.22	6.27e-19	5.31e-15	-0.97	-0.64	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-10.2	6.81e-19	5.76e-15	-0.86	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	10.19	7.18e-19	6.04e-15	1	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
PCPG	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	10.19	7.25e-19	6.1e-15	0.93	0.64	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
PCPG	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	10.19	7.3e-19	6.13e-15	0.92	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
PCPG	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-10.18	7.69e-19	6.43e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-10.18	7.69e-19	6.43e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-10.18	7.69e-19	6.43e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
PCPG	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-10.18	7.78e-19	6.5e-15	-0.82	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-10.18	7.78e-19	6.5e-15	-0.82	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-10.18	7.78e-19	6.5e-15	-0.82	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-10.18	7.78e-19	6.5e-15	-0.82	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
PCPG	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-10.18	8.02e-19	6.7e-15	-0.78	-0.64	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-10.18	8.02e-19	6.7e-15	-0.78	-0.64	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
PCPG	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	10.17	8.11e-19	6.77e-15	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
PCPG	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-10.17	8.29e-19	6.92e-15	-0.82	-0.64	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
PCPG	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-10.17	8.5e-19	7.09e-15	-0.98	-0.64	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	10.17	8.54e-19	7.12e-15	0.87	0.64	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
PCPG	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-10.17	8.57e-19	7.14e-15	-0.83	-0.64	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
PCPG	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	10.16	8.68e-19	7.24e-15	1.24	0.64	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
PCPG	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	10.16	8.85e-19	7.36e-15	0.71	0.64	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
PCPG	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-10.15	9.19e-19	7.64e-15	-0.78	-0.64	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-10.15	9.24e-19	7.67e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-10.15	9.24e-19	7.67e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
PCPG	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-10.14	9.74e-19	8.04e-15	-0.6	-0.64	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
PCPG	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-10.14	9.74e-19	8.04e-15	-0.6	-0.64	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-10.14	9.74e-19	8.04e-15	-0.6	-0.64	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
PCPG	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-10.14	9.74e-19	8.04e-15	-0.6	-0.64	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-10.14	9.74e-19	8.04e-15	-0.6	-0.64	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-10.14	9.74e-19	8.04e-15	-0.6	-0.64	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
PCPG	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-10.14	9.74e-19	8.04e-15	-0.6	-0.64	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
PCPG	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-10.13	1.03e-18	8.52e-15	-0.99	-0.64	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
PCPG	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	10.13	1.06e-18	8.75e-15	0.89	0.64	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
PCPG	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-10.12	1.12e-18	9.17e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-10.12	1.12e-18	9.17e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-10.12	1.14e-18	9.37e-15	-0.77	-0.64	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
PCPG	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-10.11	1.2e-18	9.79e-15	-0.76	-0.64	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
PCPG	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-10.11	1.2e-18	9.81e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-10.11	1.2e-18	9.81e-15	-0.81	-0.64	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-10.11	1.23e-18	1.01e-14	-0.8	-0.64	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-10.1	1.24e-18	1.01e-14	-0.8	-0.64	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-10.1	1.24e-18	1.01e-14	-0.8	-0.64	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-10.1	1.24e-18	1.01e-14	-0.8	-0.64	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-10.1	1.24e-18	1.01e-14	-0.8	-0.64	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-10.1	1.24e-18	1.01e-14	-0.8	-0.64	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	10.1	1.25e-18	1.01e-14	0.8	0.64	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-10.1	1.29e-18	1.05e-14	-0.77	-0.64	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-10.09	1.38e-18	1.12e-14	-0.81	-0.64	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-10.08	1.43e-18	1.16e-14	-0.8	-0.64	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
PCPG	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	10.07	1.5e-18	1.21e-14	0.78	0.64	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
PCPG	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	10.05	1.7e-18	1.36e-14	0.78	0.63	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
PCPG	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	10.05	1.71e-18	1.37e-14	0.74	0.63	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
PCPG	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	10.05	1.78e-18	1.43e-14	0.72	0.63	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
PCPG	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-10.04	1.79e-18	1.44e-14	-0.95	-0.63	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
PCPG	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-10.04	1.87e-18	1.49e-14	-0.81	-0.63	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-10.04	1.87e-18	1.49e-14	-0.81	-0.63	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	10.03	1.91e-18	1.52e-14	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	10.03	1.98e-18	1.57e-14	0.71	0.63	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
PCPG	cis	rs7044106	0.664	rs4837794	ENSG00000226752.6	PSMD5-AS1	-10.03	2.01e-18	1.59e-14	-0.89	-0.63	Hip circumference adjusted for BMI;	chr9:120745577	chr9:120824828~120854385:+
PCPG	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	10.02	2.05e-18	1.63e-14	0.73	0.63	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
PCPG	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-10.02	2.12e-18	1.67e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-10.02	2.12e-18	1.67e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-10.02	2.12e-18	1.67e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
PCPG	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-10.01	2.2e-18	1.74e-14	-0.8	-0.63	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-10.01	2.2e-18	1.74e-14	-0.8	-0.63	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
PCPG	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	10.01	2.25e-18	1.77e-14	0.87	0.63	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
PCPG	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	10.01	2.25e-18	1.77e-14	0.83	0.63	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
PCPG	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-10	2.32e-18	1.82e-14	-0.6	-0.63	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
PCPG	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-10	2.32e-18	1.82e-14	-0.6	-0.63	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
PCPG	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-10	2.32e-18	1.82e-14	-0.6	-0.63	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-10	2.32e-18	1.82e-14	-0.6	-0.63	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-10	2.32e-18	1.82e-14	-0.6	-0.63	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-10	2.32e-18	1.82e-14	-0.6	-0.63	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
PCPG	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-9.99	2.42e-18	1.9e-14	-0.96	-0.63	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	9.99	2.54e-18	1.98e-14	0.76	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
PCPG	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-9.97	2.73e-18	2.11e-14	-0.83	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
PCPG	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	9.97	2.74e-18	2.12e-14	0.88	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
PCPG	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-9.97	2.74e-18	2.12e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-9.97	2.74e-18	2.12e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-9.97	2.74e-18	2.12e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
PCPG	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-9.97	2.74e-18	2.12e-14	-0.98	-0.63	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
PCPG	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-9.97	2.76e-18	2.13e-14	-0.79	-0.63	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
PCPG	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-9.97	2.84e-18	2.19e-14	-0.6	-0.63	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
PCPG	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-9.97	2.84e-18	2.19e-14	-0.6	-0.63	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-9.97	2.84e-18	2.19e-14	-0.6	-0.63	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
PCPG	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-9.97	2.84e-18	2.19e-14	-0.6	-0.63	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-9.97	2.84e-18	2.19e-14	-0.6	-0.63	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-9.97	2.84e-18	2.19e-14	-0.6	-0.63	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-9.97	2.84e-18	2.19e-14	-0.6	-0.63	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
PCPG	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-9.97	2.88e-18	2.22e-14	-0.74	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
PCPG	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	9.96	2.92e-18	2.25e-14	0.93	0.63	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.932	rs2218791	ENSG00000250345.2	RP11-780M14.1	9.96	2.99e-18	2.3e-14	0.77	0.63	Immature fraction of reticulocytes;	chr4:143749300	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-9.96	2.99e-18	2.3e-14	-0.76	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
PCPG	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	9.95	3.1e-18	2.39e-14	0.76	0.63	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
PCPG	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	9.95	3.13e-18	2.41e-14	0.77	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
PCPG	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	9.95	3.19e-18	2.45e-14	0.75	0.63	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	9.94	3.36e-18	2.58e-14	0.85	0.63	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
PCPG	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	9.94	3.37e-18	2.59e-14	0.76	0.63	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
PCPG	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	9.94	3.41e-18	2.61e-14	0.81	0.63	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
PCPG	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-9.93	3.51e-18	2.69e-14	-0.81	-0.63	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
PCPG	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-9.93	3.62e-18	2.77e-14	-0.82	-0.63	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
PCPG	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	9.92	3.69e-18	2.83e-14	0.95	0.63	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
PCPG	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	9.92	3.84e-18	2.93e-14	0.98	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	9.92	3.85e-18	2.93e-14	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
PCPG	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-9.92	3.91e-18	2.98e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
PCPG	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	9.91	4.06e-18	3.09e-14	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
PCPG	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-9.9	4.22e-18	3.21e-14	-0.8	-0.63	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
PCPG	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-9.9	4.22e-18	3.21e-14	-0.83	-0.63	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
PCPG	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	9.9	4.25e-18	3.23e-14	0.78	0.63	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
PCPG	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-9.9	4.31e-18	3.27e-14	-0.6	-0.63	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
PCPG	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-9.9	4.34e-18	3.3e-14	-0.79	-0.63	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
PCPG	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	9.9	4.42e-18	3.35e-14	0.72	0.63	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
PCPG	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-9.89	4.53e-18	3.44e-14	-0.83	-0.63	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-9.89	4.53e-18	3.44e-14	-0.83	-0.63	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
PCPG	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-9.88	4.94e-18	3.72e-14	-0.71	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
PCPG	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-9.88	4.97e-18	3.74e-14	-0.79	-0.63	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	9.87	5.27e-18	3.96e-14	0.75	0.63	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-9.87	5.28e-18	3.97e-14	-0.84	-0.63	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
PCPG	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-9.85	5.75e-18	4.31e-14	-0.72	-0.63	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
PCPG	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	9.85	5.78e-18	4.33e-14	0.75	0.63	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
PCPG	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-9.85	5.82e-18	4.36e-14	-0.99	-0.63	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
PCPG	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-9.84	6.19e-18	4.63e-14	-0.77	-0.63	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
PCPG	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	9.84	6.27e-18	4.69e-14	0.82	0.63	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
PCPG	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-9.83	6.47e-18	4.84e-14	-0.61	-0.63	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
PCPG	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	9.83	6.65e-18	4.97e-14	0.7	0.63	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
PCPG	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	9.83	6.73e-18	5.02e-14	1.21	0.63	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	9.83	6.73e-18	5.02e-14	1.21	0.63	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
PCPG	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-9.82	6.78e-18	5.06e-14	-0.81	-0.63	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
PCPG	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	9.82	7.02e-18	5.22e-14	0.78	0.63	Depression;	chr6:28327262	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.932	rs13135034	ENSG00000250345.2	RP11-780M14.1	-9.81	7.26e-18	5.4e-14	-0.77	-0.63	Immature fraction of reticulocytes;	chr4:143738247	chr4:143760399~143762093:-
PCPG	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	9.81	7.29e-18	5.41e-14	0.9	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
PCPG	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	9.8	7.75e-18	5.74e-14	0.71	0.62	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
PCPG	cis	rs4835473	0.932	rs4835305	ENSG00000250345.2	RP11-780M14.1	9.8	7.79e-18	5.77e-14	0.77	0.62	Immature fraction of reticulocytes;	chr4:143823646	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs11721700	ENSG00000250345.2	RP11-780M14.1	9.8	7.79e-18	5.77e-14	0.77	0.62	Immature fraction of reticulocytes;	chr4:143824264	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs7687976	ENSG00000250345.2	RP11-780M14.1	9.8	8.04e-18	5.94e-14	0.76	0.62	Immature fraction of reticulocytes;	chr4:143749171	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs7683287	ENSG00000250345.2	RP11-780M14.1	9.8	8.04e-18	5.94e-14	0.76	0.62	Immature fraction of reticulocytes;	chr4:143749270	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6853460	ENSG00000250345.2	RP11-780M14.1	9.8	8.04e-18	5.94e-14	0.76	0.62	Immature fraction of reticulocytes;	chr4:143750392	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	9.8	8.08e-18	5.96e-14	0.79	0.62	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
PCPG	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	9.78	8.76e-18	6.45e-14	0.74	0.62	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
PCPG	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	9.78	8.76e-18	6.45e-14	0.74	0.62	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
PCPG	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	9.78	8.97e-18	6.59e-14	0.81	0.62	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	9.78	8.97e-18	6.59e-14	0.81	0.62	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-9.78	8.97e-18	6.59e-14	-0.81	-0.62	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
PCPG	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	9.78	9.1e-18	6.69e-14	0.73	0.62	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
PCPG	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	9.77	9.22e-18	6.77e-14	0.78	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
PCPG	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	9.77	9.23e-18	6.77e-14	0.75	0.62	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
PCPG	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	9.77	9.42e-18	6.89e-14	0.78	0.62	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
PCPG	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-9.77	9.47e-18	6.92e-14	-0.59	-0.62	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
PCPG	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	9.77	9.55e-18	6.97e-14	1.23	0.62	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	9.77	9.55e-18	6.97e-14	1.23	0.62	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
PCPG	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	9.76	1.03e-17	7.49e-14	0.73	0.62	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
PCPG	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-9.75	1.07e-17	7.79e-14	-0.59	-0.62	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
PCPG	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-9.75	1.07e-17	7.79e-14	-0.59	-0.62	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
PCPG	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-9.75	1.07e-17	7.79e-14	-0.59	-0.62	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
PCPG	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-9.73	1.19e-17	8.66e-14	-0.79	-0.62	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
PCPG	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-9.73	1.2e-17	8.71e-14	-0.68	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
PCPG	cis	rs4835473	0.932	rs13147386	ENSG00000250345.2	RP11-780M14.1	-9.73	1.21e-17	8.81e-14	-0.76	-0.62	Immature fraction of reticulocytes;	chr4:143736586	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.778	rs6856553	ENSG00000250345.2	RP11-780M14.1	9.72	1.26e-17	9.12e-14	0.77	0.62	Immature fraction of reticulocytes;	chr4:143825973	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs11737787	ENSG00000250345.2	RP11-780M14.1	9.72	1.26e-17	9.12e-14	0.77	0.62	Immature fraction of reticulocytes;	chr4:143826498	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7683686	ENSG00000250345.2	RP11-780M14.1	9.72	1.3e-17	9.36e-14	0.7	0.62	Immature fraction of reticulocytes;	chr4:143784352	chr4:143760399~143762093:-
PCPG	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	9.72	1.31e-17	9.45e-14	0.6	0.62	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
PCPG	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-9.71	1.32e-17	9.52e-14	-1.02	-0.62	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
PCPG	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	9.71	1.33e-17	9.6e-14	0.74	0.62	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
PCPG	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-9.71	1.34e-17	9.66e-14	-0.69	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
PCPG	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	9.71	1.35e-17	9.69e-14	0.74	0.62	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
PCPG	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-9.71	1.35e-17	9.75e-14	-0.97	-0.62	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
PCPG	cis	rs4835473	0.932	rs6827971	ENSG00000250345.2	RP11-780M14.1	9.71	1.37e-17	9.85e-14	0.77	0.62	Immature fraction of reticulocytes;	chr4:143822126	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs1375982	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143745764	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs4835237	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143746349	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs56084616	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143746697	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.966	rs11722639	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143746884	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.966	rs11722673	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143746946	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6821979	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143748091	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6838887	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143748130	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1982392	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143748604	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1982393	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143748736	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs9683880	ENSG00000250345.2	RP11-780M14.1	9.69	1.49e-17	1.07e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143748787	chr4:143760399~143762093:-
PCPG	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-9.68	1.58e-17	1.13e-13	-0.59	-0.62	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
PCPG	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	9.68	1.63e-17	1.16e-13	0.82	0.62	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	9.68	1.63e-17	1.16e-13	0.82	0.62	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.712	rs2198000	ENSG00000250345.2	RP11-780M14.1	9.68	1.66e-17	1.18e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143750005	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs2198002	ENSG00000250345.2	RP11-780M14.1	9.68	1.66e-17	1.18e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143750028	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.808	rs2060653	ENSG00000250345.2	RP11-780M14.1	9.67	1.7e-17	1.21e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143739132	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-9.67	1.73e-17	1.23e-13	-0.78	-0.62	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-9.67	1.74e-17	1.23e-13	-0.77	-0.62	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
PCPG	cis	rs4835473	0.9	rs4835303	ENSG00000250345.2	RP11-780M14.1	9.67	1.75e-17	1.24e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143821533	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4835034	ENSG00000250345.2	RP11-780M14.1	9.67	1.75e-17	1.24e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143821538	chr4:143760399~143762093:-
PCPG	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	9.66	1.77e-17	1.26e-13	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
PCPG	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-9.66	1.78e-17	1.26e-13	-0.93	-0.62	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
PCPG	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	9.66	1.81e-17	1.28e-13	0.83	0.62	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
PCPG	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-9.65	1.88e-17	1.33e-13	-0.93	-0.62	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
PCPG	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	9.65	1.91e-17	1.34e-13	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	9.65	1.91e-17	1.34e-13	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
PCPG	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-9.65	1.97e-17	1.38e-13	-0.81	-0.62	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
PCPG	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	9.65	1.97e-17	1.38e-13	0.77	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
PCPG	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	9.64	2e-17	1.41e-13	0.81	0.62	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
PCPG	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	9.64	2.06e-17	1.45e-13	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	9.64	2.06e-17	1.45e-13	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	9.64	2.06e-17	1.45e-13	0.76	0.62	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
PCPG	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	9.64	2.1e-17	1.47e-13	0.85	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
PCPG	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-9.63	2.2e-17	1.55e-13	-0.75	-0.62	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
PCPG	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-9.63	2.24e-17	1.57e-13	-0.79	-0.62	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
PCPG	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	9.62	2.31e-17	1.62e-13	1.19	0.62	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
PCPG	cis	rs4835473	0.932	rs34950821	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143738174	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs5016158	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143738472	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs5016157	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143738587	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.808	rs13134564	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143738763	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13139738	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143738828	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs17018165	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143738849	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs2060656	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143739330	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs67749935	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143739852	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs66934100	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143739872	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4325971	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143740167	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4443230	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143740372	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4637344	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143740434	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs56277406	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143740620	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13143879	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143740901	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs36086465	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143742738	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs873430	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143742953	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs873431	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143743035	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs899903	ENSG00000250345.2	RP11-780M14.1	9.62	2.35e-17	1.64e-13	0.74	0.62	Immature fraction of reticulocytes;	chr4:143743551	chr4:143760399~143762093:-
PCPG	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-9.61	2.47e-17	1.72e-13	-0.75	-0.62	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
PCPG	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-9.61	2.48e-17	1.73e-13	-0.87	-0.62	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
PCPG	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-9.61	2.52e-17	1.75e-13	-0.93	-0.62	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-9.61	2.52e-17	1.75e-13	-0.93	-0.62	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-9.61	2.52e-17	1.75e-13	-0.93	-0.62	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
PCPG	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	9.6	2.59e-17	1.8e-13	0.77	0.62	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.868	rs62337291	ENSG00000250345.2	RP11-780M14.1	9.59	2.7e-17	1.87e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143807903	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13121861	ENSG00000250345.2	RP11-780M14.1	9.59	2.7e-17	1.87e-13	0.76	0.62	Immature fraction of reticulocytes;	chr4:143814007	chr4:143760399~143762093:-
PCPG	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	9.59	2.76e-17	1.91e-13	0.77	0.62	Depression;	chr6:28317705	chr6:28176188~28176674:+
PCPG	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-9.59	2.84e-17	1.96e-13	-0.79	-0.62	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
PCPG	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-9.57	3.05e-17	2.1e-13	-0.63	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
PCPG	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	9.57	3.06e-17	2.11e-13	0.99	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
PCPG	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	9.56	3.26e-17	2.24e-13	0.74	0.62	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	9.56	3.42e-17	2.34e-13	0.75	0.62	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	9.56	3.42e-17	2.34e-13	0.75	0.62	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	9.56	3.42e-17	2.34e-13	0.75	0.62	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	9.56	3.42e-17	2.34e-13	0.75	0.62	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs17694797	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143778812	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35947975	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143778969	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.778	rs75562808	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143779065	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1375987	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143779622	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7687151	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143781681	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1450236	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143783069	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs62339580	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143785090	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs62339581	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143785172	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7666368	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143785372	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7690428	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143785400	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34781605	ENSG00000250345.2	RP11-780M14.1	9.55	3.56e-17	2.43e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143785486	chr4:143760399~143762093:-
PCPG	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-9.55	3.6e-17	2.45e-13	-0.75	-0.61	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
PCPG	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-9.55	3.61e-17	2.46e-13	-0.59	-0.61	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
PCPG	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	9.54	3.7e-17	2.52e-13	1.21	0.61	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
PCPG	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-9.54	3.74e-17	2.55e-13	-0.57	-0.61	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
PCPG	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	9.54	3.79e-17	2.58e-13	1.13	0.61	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
PCPG	cis	rs4835473	0.932	rs4615131	ENSG00000250345.2	RP11-780M14.1	9.54	3.81e-17	2.59e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143740295	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4499657	ENSG00000250345.2	RP11-780M14.1	9.54	3.81e-17	2.59e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143740316	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.808	rs2060652	ENSG00000250345.2	RP11-780M14.1	9.53	3.91e-17	2.65e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143739129	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs2060654	ENSG00000250345.2	RP11-780M14.1	9.53	3.91e-17	2.65e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143739155	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs2060655	ENSG00000250345.2	RP11-780M14.1	9.53	3.91e-17	2.65e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143739159	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13152443	ENSG00000250345.2	RP11-780M14.1	9.53	3.92e-17	2.66e-13	0.77	0.61	Immature fraction of reticulocytes;	chr4:143742492	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-9.53	3.99e-17	2.71e-13	-0.74	-0.61	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
PCPG	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	9.53	4.07e-17	2.74e-13	0.7	0.61	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
PCPG	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	9.53	4.08e-17	2.75e-13	0.69	0.61	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
PCPG	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	9.52	4.33e-17	2.91e-13	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
PCPG	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-9.51	4.38e-17	2.94e-13	-0.93	-0.61	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
PCPG	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-9.51	4.42e-17	2.97e-13	-0.95	-0.61	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
PCPG	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	9.51	4.43e-17	2.97e-13	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
PCPG	cis	rs4835473	0.9	rs5015758	ENSG00000250345.2	RP11-780M14.1	9.51	4.45e-17	2.99e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143738052	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs34569841	ENSG00000250345.2	RP11-780M14.1	9.51	4.45e-17	2.99e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143738060	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	9.51	4.49e-17	3.01e-13	0.7	0.61	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
PCPG	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	9.51	4.54e-17	3.03e-13	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
PCPG	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	9.51	4.54e-17	3.03e-13	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
PCPG	cis	rs4835473	0.932	rs9685306	ENSG00000250345.2	RP11-780M14.1	9.5	4.69e-17	3.13e-13	0.78	0.61	Immature fraction of reticulocytes;	chr4:143748843	chr4:143760399~143762093:-
PCPG	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-9.5	4.72e-17	3.14e-13	-0.93	-0.61	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-9.5	4.82e-17	3.21e-13	-0.95	-0.61	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-9.5	4.82e-17	3.21e-13	-0.95	-0.61	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
PCPG	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	9.49	4.96e-17	3.29e-13	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	9.49	4.96e-17	3.29e-13	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	9.49	4.96e-17	3.29e-13	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	9.49	4.96e-17	3.29e-13	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-9.49	4.96e-17	3.29e-13	-0.74	-0.61	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
PCPG	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-9.49	4.99e-17	3.31e-13	-0.76	-0.61	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
PCPG	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-9.49	5.08e-17	3.37e-13	-0.77	-0.61	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
PCPG	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	9.49	5.18e-17	3.44e-13	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
PCPG	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-9.48	5.26e-17	3.49e-13	-0.73	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
PCPG	cis	rs4835473	0.838	rs6832094	ENSG00000250345.2	RP11-780M14.1	9.48	5.39e-17	3.57e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143795388	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	9.48	5.41e-17	3.58e-13	0.77	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
PCPG	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	9.48	5.41e-17	3.58e-13	0.77	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
PCPG	cis	rs4835473	0.932	rs6853676	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143750495	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6848393	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143750537	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs971390	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751264	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs971391	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751324	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs971392	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751384	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.838	rs35978782	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751713	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34060266	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751766	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35300159	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751768	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13139419	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751862	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs13106052	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143751995	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13134401	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752008	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13106287	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752091	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13134679	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752187	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13108134	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752213	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs34406317	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752237	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35863996	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752260	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6836896	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752404	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs2874983	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752589	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs2874984	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752622	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs2323192	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752646	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs2323193	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143752812	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34152627	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143753205	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35670108	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143753280	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs6832005	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143754284	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.838	rs55963933	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143755048	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs35243309	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143755116	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs34790336	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143755284	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35740243	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143755395	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4395452	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143755678	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.741	rs6537180	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143755984	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.741	rs6537181	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143755995	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs6814065	ENSG00000250345.2	RP11-780M14.1	9.47	5.75e-17	3.76e-13	0.75	0.61	Immature fraction of reticulocytes;	chr4:143756233	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-9.47	5.77e-17	3.77e-13	-0.93	-0.61	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.9	rs7689374	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143769567	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6537183	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143770441	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs12512202	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143771248	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6843671	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143772041	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs35395070	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143772283	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs34614750	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143772369	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35002497	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143772952	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13119630	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143773901	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1450233	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143774710	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4308330	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143774761	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs11725708	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143775683	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs17762299	ENSG00000250345.2	RP11-780M14.1	9.46	6.19e-17	4.04e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143777196	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	9.45	6.29e-17	4.09e-13	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
PCPG	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	9.45	6.41e-17	4.17e-13	0.99	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
PCPG	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-9.45	6.43e-17	4.18e-13	-0.97	-0.61	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
PCPG	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	9.44	6.68e-17	4.33e-13	0.8	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
PCPG	cis	rs4835473	0.897	rs7681903	ENSG00000250345.2	RP11-780M14.1	9.44	6.76e-17	4.38e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143759326	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs7656753	ENSG00000250345.2	RP11-780M14.1	9.44	6.76e-17	4.38e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143759414	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs7656786	ENSG00000250345.2	RP11-780M14.1	9.44	6.76e-17	4.38e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143759455	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	9.44	6.79e-17	4.4e-13	0.82	0.61	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
PCPG	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	9.44	6.81e-17	4.41e-13	0.76	0.61	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
PCPG	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	9.44	6.87e-17	4.45e-13	0.79	0.61	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	9.44	6.87e-17	4.45e-13	0.79	0.61	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
PCPG	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-9.44	6.88e-17	4.45e-13	-0.85	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	9.43	7.26e-17	4.69e-13	0.85	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	9.43	7.26e-17	4.69e-13	0.85	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	9.43	7.26e-17	4.69e-13	0.85	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
PCPG	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	9.43	7.34e-17	4.74e-13	0.69	0.61	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
PCPG	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	9.43	7.39e-17	4.77e-13	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
PCPG	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-9.42	7.73e-17	4.99e-13	-0.75	-0.61	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
PCPG	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	9.42	7.81e-17	5.03e-13	0.82	0.61	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
PCPG	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	9.42	7.82e-17	5.04e-13	0.68	0.61	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
PCPG	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	9.41	8.01e-17	5.14e-13	0.68	0.61	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.932	rs12513087	ENSG00000250345.2	RP11-780M14.1	9.41	8.13e-17	5.21e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143758551	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs12513119	ENSG00000250345.2	RP11-780M14.1	9.41	8.13e-17	5.21e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143758619	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs12513130	ENSG00000250345.2	RP11-780M14.1	9.41	8.13e-17	5.21e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143758666	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs935732	ENSG00000250345.2	RP11-780M14.1	9.41	8.13e-17	5.21e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143759164	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs7681891	ENSG00000250345.2	RP11-780M14.1	9.41	8.13e-17	5.21e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143759289	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.771	rs34069296	ENSG00000250345.2	RP11-780M14.1	9.41	8.13e-17	5.21e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143759656	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs5015759	ENSG00000250345.2	RP11-780M14.1	9.41	8.21e-17	5.26e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143738050	chr4:143760399~143762093:-
PCPG	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	9.41	8.35e-17	5.34e-13	0.88	0.61	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
PCPG	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	9.4	8.57e-17	5.47e-13	0.68	0.61	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
PCPG	cis	rs4835473	0.643	rs34680080	ENSG00000250345.2	RP11-780M14.1	9.4	8.63e-17	5.51e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143797290	chr4:143760399~143762093:-
PCPG	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	9.4	8.9e-17	5.67e-13	0.73	0.61	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
PCPG	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	9.39	9.22e-17	5.87e-13	0.79	0.61	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-9.39	9.38e-17	5.97e-13	-0.72	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
PCPG	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	9.39	9.48e-17	6.03e-13	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
PCPG	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	9.38	9.85e-17	6.25e-13	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
PCPG	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	9.38	9.99e-17	6.35e-13	0.74	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
PCPG	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	9.37	1.01e-16	6.42e-13	0.77	0.61	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
PCPG	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	9.37	1.05e-16	6.64e-13	0.75	0.61	Depression;	chr6:28303421	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	9.37	1.05e-16	6.64e-13	0.75	0.61	Depression;	chr6:28323463	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.932	rs1993015	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760202	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs1993016	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760217	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1993017	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760285	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs1375983	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760423	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1375984	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760510	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1375985	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760556	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs17018200	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760866	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs11100805	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143760979	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs56115009	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761073	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs10857406	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761216	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs10857407	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761226	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs10857408	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761333	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs10857409	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761461	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs10857410	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761566	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs10857411	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761599	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1006406	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761710	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1562776	ENSG00000250345.2	RP11-780M14.1	9.36	1.1e-16	6.92e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143761999	chr4:143760399~143762093:-
PCPG	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	9.36	1.1e-16	6.95e-13	0.75	0.61	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs10021860	ENSG00000250345.2	RP11-780M14.1	-9.36	1.1e-16	6.96e-13	-0.75	-0.61	Immature fraction of reticulocytes;	chr4:143754593	chr4:143760399~143762093:-
PCPG	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-9.36	1.11e-16	7e-13	-0.85	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-9.36	1.11e-16	7e-13	-0.85	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
PCPG	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-9.36	1.12e-16	7.02e-13	-0.92	-0.61	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
PCPG	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-9.36	1.12e-16	7.08e-13	-0.73	-0.61	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
PCPG	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-9.36	1.13e-16	7.08e-13	-0.73	-0.61	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
PCPG	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	9.36	1.13e-16	7.08e-13	1.16	0.61	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
PCPG	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	9.36	1.13e-16	7.09e-13	0.68	0.61	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.9	rs4257605	ENSG00000250345.2	RP11-780M14.1	9.36	1.13e-16	7.1e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143740081	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4498094	ENSG00000250345.2	RP11-780M14.1	9.36	1.13e-16	7.1e-13	0.74	0.61	Immature fraction of reticulocytes;	chr4:143740097	chr4:143760399~143762093:-
PCPG	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	9.35	1.16e-16	7.28e-13	0.75	0.61	Depression;	chr6:28301886	chr6:28176188~28176674:+
PCPG	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-9.35	1.17e-16	7.32e-13	-0.68	-0.61	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.932	rs5016160	ENSG00000250345.2	RP11-780M14.1	-9.35	1.17e-16	7.32e-13	-0.75	-0.61	Immature fraction of reticulocytes;	chr4:143738305	chr4:143760399~143762093:-
PCPG	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-9.35	1.17e-16	7.32e-13	-0.91	-0.61	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-9.35	1.17e-16	7.32e-13	-0.91	-0.61	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-9.35	1.17e-16	7.32e-13	-0.91	-0.61	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-9.35	1.17e-16	7.32e-13	-0.91	-0.61	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-9.35	1.17e-16	7.32e-13	-0.91	-0.61	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	9.35	1.19e-16	7.45e-13	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
PCPG	cis	rs17711722	0.583	rs11768292	ENSG00000226824.5	RP4-756H11.3	9.34	1.21e-16	7.56e-13	0.77	0.61	Calcium levels;	chr7:66009814	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.9	rs6816347	ENSG00000250345.2	RP11-780M14.1	9.34	1.21e-16	7.57e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143756674	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.808	rs6847256	ENSG00000250345.2	RP11-780M14.1	9.34	1.21e-16	7.57e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143757032	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs57413073	ENSG00000250345.2	RP11-780M14.1	9.34	1.21e-16	7.57e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143757852	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34732468	ENSG00000250345.2	RP11-780M14.1	9.34	1.21e-16	7.57e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143758009	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs12510395	ENSG00000250345.2	RP11-780M14.1	9.34	1.21e-16	7.57e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143758107	chr4:143760399~143762093:-
PCPG	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	9.34	1.23e-16	7.67e-13	0.78	0.61	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
PCPG	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-9.34	1.26e-16	7.85e-13	-0.74	-0.61	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
PCPG	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-9.33	1.28e-16	8e-13	-0.74	-0.61	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
PCPG	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-9.33	1.32e-16	8.2e-13	-0.91	-0.61	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	9.33	1.34e-16	8.32e-13	0.81	0.61	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
PCPG	cis	rs4835473	0.932	rs17018500	ENSG00000250345.2	RP11-780M14.1	9.33	1.34e-16	8.34e-13	0.76	0.61	Immature fraction of reticulocytes;	chr4:143824849	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-9.32	1.38e-16	8.57e-13	-0.9	-0.61	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-9.32	1.38e-16	8.57e-13	-0.9	-0.61	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	9.32	1.38e-16	8.57e-13	0.82	0.61	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	9.32	1.38e-16	8.57e-13	0.82	0.61	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
PCPG	cis	rs4835473	0.932	rs5015757	ENSG00000250345.2	RP11-780M14.1	-9.32	1.38e-16	8.59e-13	-0.75	-0.61	Immature fraction of reticulocytes;	chr4:143738144	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-9.32	1.41e-16	8.72e-13	-0.76	-0.61	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
PCPG	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-9.32	1.41e-16	8.72e-13	-0.76	-0.61	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
PCPG	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	9.32	1.42e-16	8.81e-13	0.73	0.61	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
PCPG	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-9.32	1.43e-16	8.85e-13	-0.74	-0.61	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
PCPG	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	9.32	1.43e-16	8.86e-13	0.67	0.61	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
PCPG	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	9.31	1.46e-16	9.01e-13	0.77	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
PCPG	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	9.31	1.48e-16	9.12e-13	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
PCPG	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	9.31	1.48e-16	9.17e-13	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
PCPG	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-9.3	1.54e-16	9.51e-13	-0.84	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	9.3	1.55e-16	9.57e-13	0.83	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
PCPG	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	9.3	1.56e-16	9.64e-13	0.78	0.6	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	9.3	1.56e-16	9.64e-13	0.78	0.6	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.897	rs7687915	ENSG00000250345.2	RP11-780M14.1	9.3	1.57e-16	9.66e-13	0.76	0.6	Immature fraction of reticulocytes;	chr4:143759801	chr4:143760399~143762093:-
PCPG	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	9.3	1.57e-16	9.69e-13	0.78	0.6	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
PCPG	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-9.3	1.62e-16	9.96e-13	-0.76	-0.6	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
PCPG	cis	rs4835473	0.932	rs34525847	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143734970	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35277115	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143735001	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34653324	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143735058	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35947648	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143735092	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs66474962	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143735145	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.838	rs35800634	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143735199	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.838	rs34505330	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143735206	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4597770	ENSG00000250345.2	RP11-780M14.1	9.29	1.65e-16	1.01e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143735239	chr4:143760399~143762093:-
PCPG	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	9.29	1.66e-16	1.02e-12	0.67	0.6	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
PCPG	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	9.29	1.69e-16	1.04e-12	0.75	0.6	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.9	rs35230778	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734336	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs34772566	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734355	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35655934	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734697	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs35515006	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734705	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs4629390	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143735302	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.838	rs4583708	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143735610	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs13117932	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143735873	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34257944	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143736443	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs12509642	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737080	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.801	rs76574827	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737303	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.832	rs62337616	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737307	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.832	rs66717029	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737318	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs17750354	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737352	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs17693768	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737503	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.832	rs35398499	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737715	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.832	rs35763177	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737717	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs5015762	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737773	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs5015761	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737791	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-9.29	1.72e-16	1.05e-12	-0.68	-0.6	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.669	rs75704080	ENSG00000250345.2	RP11-780M14.1	9.29	1.72e-16	1.05e-12	0.74	0.6	Immature fraction of reticulocytes;	chr4:143779066	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-9.28	1.73e-16	1.05e-12	-0.76	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
PCPG	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-9.28	1.73e-16	1.05e-12	-0.9	-0.6	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-9.28	1.73e-16	1.05e-12	-0.9	-0.6	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-9.28	1.75e-16	1.07e-12	-0.91	-0.6	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.838	rs13134571	ENSG00000250345.2	RP11-780M14.1	9.28	1.76e-16	1.07e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143738771	chr4:143760399~143762093:-
PCPG	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	9.28	1.76e-16	1.07e-12	0.73	0.6	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
PCPG	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-9.28	1.77e-16	1.08e-12	-0.72	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
PCPG	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-9.28	1.82e-16	1.11e-12	-0.9	-0.6	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.932	rs11734290	ENSG00000250345.2	RP11-780M14.1	9.27	1.83e-16	1.11e-12	0.77	0.6	Immature fraction of reticulocytes;	chr4:143823636	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs11734383	ENSG00000250345.2	RP11-780M14.1	9.27	1.83e-16	1.11e-12	0.77	0.6	Immature fraction of reticulocytes;	chr4:143824093	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs11735295	ENSG00000250345.2	RP11-780M14.1	9.27	1.83e-16	1.11e-12	0.77	0.6	Immature fraction of reticulocytes;	chr4:143824150	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs62337303	ENSG00000250345.2	RP11-780M14.1	9.27	1.83e-16	1.11e-12	0.77	0.6	Immature fraction of reticulocytes;	chr4:143824967	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs5016159	ENSG00000250345.2	RP11-780M14.1	-9.27	1.85e-16	1.13e-12	-0.73	-0.6	Immature fraction of reticulocytes;	chr4:143738362	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-9.27	1.85e-16	1.13e-12	-0.71	-0.6	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
PCPG	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-9.27	1.88e-16	1.14e-12	-0.57	-0.6	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
PCPG	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-9.27	1.89e-16	1.15e-12	-0.78	-0.6	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
PCPG	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	9.26	1.97e-16	1.19e-12	1.23	0.6	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	9.26	1.97e-16	1.19e-12	1.23	0.6	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	9.26	1.97e-16	1.19e-12	1.23	0.6	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
PCPG	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	9.26	2e-16	1.21e-12	0.96	0.6	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
PCPG	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	9.26	2.01e-16	1.22e-12	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
PCPG	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	9.26	2.03e-16	1.23e-12	0.74	0.6	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
PCPG	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	9.26	2.06e-16	1.24e-12	0.79	0.6	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	9.26	2.06e-16	1.24e-12	0.79	0.6	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	9.26	2.06e-16	1.24e-12	0.78	0.6	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	9.26	2.06e-16	1.24e-12	0.78	0.6	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
PCPG	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	9.25	2.13e-16	1.28e-12	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	9.25	2.13e-16	1.28e-12	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
PCPG	cis	rs4835473	0.932	rs13133444	ENSG00000250345.2	RP11-780M14.1	-9.24	2.2e-16	1.32e-12	-0.74	-0.6	Immature fraction of reticulocytes;	chr4:143738191	chr4:143760399~143762093:-
PCPG	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	9.24	2.22e-16	1.33e-12	0.73	0.6	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
PCPG	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-9.24	2.24e-16	1.34e-12	-0.79	-0.6	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
PCPG	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-9.24	2.25e-16	1.35e-12	-0.74	-0.6	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
PCPG	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-9.24	2.3e-16	1.38e-12	-0.9	-0.6	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
PCPG	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	9.24	2.32e-16	1.39e-12	0.78	0.6	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
PCPG	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.33e-16	1.4e-12	-0.9	-0.6	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.33e-16	1.4e-12	-0.9	-0.6	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
PCPG	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	9.23	2.34e-16	1.4e-12	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	9.23	2.38e-16	1.42e-12	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
PCPG	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.38e-16	1.42e-12	-0.91	-0.6	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
PCPG	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	9.23	2.4e-16	1.43e-12	0.74	0.6	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
PCPG	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-9.23	2.43e-16	1.45e-12	-0.83	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
PCPG	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-9.23	2.44e-16	1.45e-12	-0.83	-0.6	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
PCPG	cis	rs4835473	0.932	rs11100806	ENSG00000250345.2	RP11-780M14.1	-9.22	2.47e-16	1.47e-12	-0.77	-0.6	Immature fraction of reticulocytes;	chr4:143761006	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	9.22	2.52e-16	1.5e-12	0.65	0.6	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
PCPG	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	9.22	2.61e-16	1.55e-12	0.78	0.6	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	9.22	2.61e-16	1.55e-12	0.78	0.6	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
PCPG	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-9.21	2.62e-16	1.55e-12	-0.83	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
PCPG	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-9.21	2.62e-16	1.55e-12	-0.83	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
PCPG	cis	rs4835473	0.838	rs6838981	ENSG00000250345.2	RP11-780M14.1	9.21	2.69e-16	1.59e-12	0.77	0.6	Immature fraction of reticulocytes;	chr4:143826484	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-9.21	2.71e-16	1.61e-12	-0.74	-0.6	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
PCPG	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-9.21	2.72e-16	1.61e-12	-0.9	-0.6	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-9.21	2.72e-16	1.61e-12	-0.9	-0.6	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-9.21	2.72e-16	1.61e-12	-0.9	-0.6	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
PCPG	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	9.21	2.77e-16	1.64e-12	0.78	0.6	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
PCPG	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.8e-16	1.65e-12	-0.92	-0.6	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.932	rs13107719	ENSG00000250345.2	RP11-780M14.1	9.2	2.81e-16	1.66e-12	0.77	0.6	Immature fraction of reticulocytes;	chr4:143752034	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs2323194	ENSG00000250345.2	RP11-780M14.1	9.2	2.81e-16	1.66e-12	0.77	0.6	Immature fraction of reticulocytes;	chr4:143752879	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-9.2	2.86e-16	1.69e-12	-0.65	-0.6	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
PCPG	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.87e-16	1.69e-12	-0.9	-0.6	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-9.2	2.91e-16	1.71e-12	-0.9	-0.6	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
PCPG	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-9.2	2.94e-16	1.72e-12	-0.76	-0.6	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
PCPG	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	9.19	3.01e-16	1.76e-12	0.67	0.6	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
PCPG	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	9.19	3.01e-16	1.76e-12	0.67	0.6	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
PCPG	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-9.19	3.02e-16	1.77e-12	-0.88	-0.6	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.9	rs35311036	ENSG00000250345.2	RP11-780M14.1	9.19	3.07e-16	1.79e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734397	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs35906127	ENSG00000250345.2	RP11-780M14.1	9.19	3.07e-16	1.79e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734400	chr4:143760399~143762093:-
PCPG	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	9.18	3.13e-16	1.83e-12	0.79	0.6	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
PCPG	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	9.18	3.14e-16	1.83e-12	0.87	0.6	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.9	rs35419968	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734583	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs66634585	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734608	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs35016507	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734617	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs67600034	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143734670	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs55635947	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143736218	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs56334914	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143736291	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs56324738	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143736297	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs55862664	ENSG00000250345.2	RP11-780M14.1	9.18	3.15e-16	1.83e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143736311	chr4:143760399~143762093:-
PCPG	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	9.18	3.16e-16	1.84e-12	0.67	0.6	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	9.18	3.21e-16	1.87e-12	0.66	0.6	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	9.18	3.25e-16	1.89e-12	0.66	0.6	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
PCPG	cis	rs4835473	0.897	rs17693780	ENSG00000250345.2	RP11-780M14.1	9.17	3.32e-16	1.92e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737563	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs35556180	ENSG00000250345.2	RP11-780M14.1	9.17	3.32e-16	1.92e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737595	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs35377051	ENSG00000250345.2	RP11-780M14.1	9.17	3.32e-16	1.92e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737627	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs17018131	ENSG00000250345.2	RP11-780M14.1	9.17	3.32e-16	1.92e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143737647	chr4:143760399~143762093:-
PCPG	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	9.17	3.34e-16	1.93e-12	0.68	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
PCPG	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	9.17	3.38e-16	1.95e-12	0.78	0.6	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
PCPG	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
PCPG	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-9.17	3.41e-16	1.96e-12	-0.88	-0.6	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
PCPG	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	9.17	3.43e-16	1.97e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
PCPG	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	9.17	3.5e-16	2.02e-12	0.74	0.6	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
PCPG	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-9.16	3.53e-16	2.03e-12	-0.8	-0.6	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
PCPG	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	9.16	3.56e-16	2.05e-12	1.1	0.6	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
PCPG	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	9.16	3.56e-16	2.05e-12	0.77	0.6	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs1839448	ENSG00000250345.2	RP11-780M14.1	-9.16	3.7e-16	2.13e-12	-0.74	-0.6	Immature fraction of reticulocytes;	chr4:143752113	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-9.16	3.71e-16	2.13e-12	-0.88	-0.6	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
PCPG	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	9.15	3.84e-16	2.2e-12	0.82	0.6	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
PCPG	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-9.15	3.85e-16	2.21e-12	-0.77	-0.6	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
PCPG	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	9.15	3.91e-16	2.24e-12	0.74	0.6	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	9.15	3.91e-16	2.24e-12	0.74	0.6	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	9.15	3.95e-16	2.26e-12	0.72	0.6	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
PCPG	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-9.14	3.99e-16	2.28e-12	-0.89	-0.6	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-9.14	3.99e-16	2.28e-12	-0.89	-0.6	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
PCPG	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	9.14	4.01e-16	2.29e-12	0.78	0.6	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
PCPG	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	9.14	4.02e-16	2.3e-12	0.68	0.6	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
PCPG	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	9.14	4.02e-16	2.3e-12	0.68	0.6	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
PCPG	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	9.14	4.02e-16	2.3e-12	0.75	0.6	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	9.14	4.03e-16	2.3e-12	0.73	0.6	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
PCPG	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-9.14	4.07e-16	2.33e-12	-0.77	-0.6	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
PCPG	cis	rs4835473	0.932	rs2323190	ENSG00000250345.2	RP11-780M14.1	9.14	4.15e-16	2.37e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143744282	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-9.14	4.2e-16	2.39e-12	-0.9	-0.6	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-9.14	4.2e-16	2.39e-12	-0.9	-0.6	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-9.14	4.2e-16	2.39e-12	-0.9	-0.6	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-9.14	4.2e-16	2.39e-12	-0.9	-0.6	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-9.14	4.2e-16	2.39e-12	-0.9	-0.6	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-9.14	4.2e-16	2.39e-12	-0.9	-0.6	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-9.14	4.2e-16	2.39e-12	-0.9	-0.6	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	9.13	4.23e-16	2.41e-12	0.71	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
PCPG	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-9.13	4.24e-16	2.41e-12	-0.75	-0.6	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
PCPG	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-9.13	4.32e-16	2.45e-12	-0.84	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
PCPG	cis	rs4835473	0.932	rs34697602	ENSG00000250345.2	RP11-780M14.1	9.13	4.32e-16	2.45e-12	0.75	0.6	Immature fraction of reticulocytes;	chr4:143762499	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34618381	ENSG00000250345.2	RP11-780M14.1	9.13	4.32e-16	2.45e-12	0.75	0.6	Immature fraction of reticulocytes;	chr4:143762612	chr4:143760399~143762093:-
PCPG	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	9.13	4.39e-16	2.49e-12	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
PCPG	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	9.13	4.39e-16	2.49e-12	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
PCPG	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	9.12	4.49e-16	2.54e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	9.12	4.49e-16	2.54e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	9.12	4.49e-16	2.54e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	9.12	4.49e-16	2.54e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	9.12	4.49e-16	2.54e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	9.12	4.49e-16	2.54e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	9.12	4.49e-16	2.54e-12	0.71	0.6	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
PCPG	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-9.12	4.63e-16	2.62e-12	-0.75	-0.6	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-9.12	4.63e-16	2.62e-12	-0.75	-0.6	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
PCPG	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-9.12	4.7e-16	2.66e-12	-0.95	-0.6	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
PCPG	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	9.11	4.82e-16	2.72e-12	0.8	0.6	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
PCPG	cis	rs2075277	1	rs2075279	ENSG00000207575.1	MIR649	9.11	4.88e-16	2.75e-12	1.06	0.6	Eosinophilic esophagitis;	chr22:21029023	chr22:21034176~21034272:-
PCPG	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	9.11	4.96e-16	2.79e-12	0.63	0.6	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
PCPG	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-9.11	4.98e-16	2.81e-12	-0.63	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
PCPG	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	9.1	5.1e-16	2.87e-12	0.89	0.6	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
PCPG	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	9.1	5.14e-16	2.89e-12	0.95	0.6	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
PCPG	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-9.1	5.22e-16	2.93e-12	-0.88	-0.6	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
PCPG	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	9.1	5.23e-16	2.93e-12	0.72	0.6	Depression;	chr6:28240757	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.932	rs11721523	ENSG00000250345.2	RP11-780M14.1	9.1	5.3e-16	2.97e-12	0.75	0.6	Immature fraction of reticulocytes;	chr4:143767301	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs2323191	ENSG00000250345.2	RP11-780M14.1	9.09	5.34e-16	2.99e-12	0.73	0.6	Immature fraction of reticulocytes;	chr4:143744472	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7356157	ENSG00000250345.2	RP11-780M14.1	-9.09	5.39e-16	3.02e-12	-0.73	-0.6	Immature fraction of reticulocytes;	chr4:143739233	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs2127788	ENSG00000250345.2	RP11-780M14.1	-9.09	5.39e-16	3.02e-12	-0.73	-0.6	Immature fraction of reticulocytes;	chr4:143741996	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6852195	ENSG00000250345.2	RP11-780M14.1	-9.09	5.39e-16	3.02e-12	-0.73	-0.6	Immature fraction of reticulocytes;	chr4:143742584	chr4:143760399~143762093:-
PCPG	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	9.09	5.42e-16	3.03e-12	0.75	0.6	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
PCPG	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	9.09	5.47e-16	3.06e-12	0.72	0.6	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs13152209	ENSG00000250345.2	RP11-780M14.1	-9.08	5.68e-16	3.17e-12	-0.72	-0.6	Immature fraction of reticulocytes;	chr4:143776088	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs6834494	ENSG00000250345.2	RP11-780M14.1	9.08	5.69e-16	3.18e-12	0.76	0.6	Immature fraction of reticulocytes;	chr4:143822257	chr4:143760399~143762093:-
PCPG	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	9.08	5.75e-16	3.21e-12	0.93	0.6	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	9.08	5.75e-16	3.21e-12	0.93	0.6	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	9.08	5.75e-16	3.21e-12	0.93	0.6	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	9.08	5.75e-16	3.21e-12	0.93	0.6	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
PCPG	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	9.08	5.81e-16	3.22e-12	0.71	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
PCPG	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	9.08	5.85e-16	3.24e-12	0.91	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
PCPG	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	9.08	5.96e-16	3.3e-12	0.66	0.6	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
PCPG	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-9.08	6e-16	3.32e-12	-0.78	-0.6	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-9.08	6e-16	3.32e-12	-0.78	-0.6	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
PCPG	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-9.07	6.03e-16	3.33e-12	-0.82	-0.6	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
PCPG	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	9.07	6.28e-16	3.47e-12	0.9	0.6	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	9.07	6.36e-16	3.51e-12	0.71	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
PCPG	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	9.06	6.39e-16	3.53e-12	0.78	0.59	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	9.06	6.39e-16	3.53e-12	0.78	0.59	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs62337619	ENSG00000250345.2	RP11-780M14.1	9.06	6.59e-16	3.64e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143742083	chr4:143760399~143762093:-
PCPG	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-9.06	6.62e-16	3.65e-12	-0.77	-0.59	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
PCPG	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	9.05	6.94e-16	3.81e-12	0.72	0.59	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	9.05	6.94e-16	3.81e-12	0.72	0.59	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
PCPG	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-9.05	7.07e-16	3.88e-12	-0.79	-0.59	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
PCPG	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-9.05	7.17e-16	3.93e-12	-0.82	-0.59	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
PCPG	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-9.04	7.18e-16	3.94e-12	-0.77	-0.59	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-9.04	7.18e-16	3.94e-12	-0.77	-0.59	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
PCPG	cis	rs4835473	0.808	rs4054643	ENSG00000250345.2	RP11-780M14.1	9.04	7.28e-16	3.98e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143787329	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs11100810	ENSG00000250345.2	RP11-780M14.1	9.04	7.28e-16	3.98e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143787518	chr4:143760399~143762093:-
PCPG	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	9.04	7.3e-16	3.99e-12	0.77	0.59	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
PCPG	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	9.04	7.46e-16	4.07e-12	0.71	0.59	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.932	rs11730929	ENSG00000250345.2	RP11-780M14.1	9.03	7.64e-16	4.16e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143834795	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs11724752	ENSG00000250345.2	RP11-780M14.1	9.03	7.68e-16	4.18e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143769473	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs5025156	ENSG00000250345.2	RP11-780M14.1	9.03	7.89e-16	4.29e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143738025	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-9.02	8.25e-16	4.47e-12	-0.76	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
PCPG	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	9.02	8.56e-16	4.63e-12	0.71	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
PCPG	cis	rs4835473	0.932	rs17018238	ENSG00000250345.2	RP11-780M14.1	9.01	8.58e-16	4.64e-12	0.73	0.59	Immature fraction of reticulocytes;	chr4:143782737	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	9.01	8.72e-16	4.7e-12	0.71	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
PCPG	cis	rs4835473	0.9	rs13137885	ENSG00000250345.2	RP11-780M14.1	9.01	8.72e-16	4.7e-12	0.72	0.59	Immature fraction of reticulocytes;	chr4:143734212	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13105550	ENSG00000250345.2	RP11-780M14.1	9.01	8.72e-16	4.7e-12	0.72	0.59	Immature fraction of reticulocytes;	chr4:143734220	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13105571	ENSG00000250345.2	RP11-780M14.1	9.01	8.72e-16	4.7e-12	0.72	0.59	Immature fraction of reticulocytes;	chr4:143734241	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs36083417	ENSG00000250345.2	RP11-780M14.1	9.01	8.72e-16	4.7e-12	0.72	0.59	Immature fraction of reticulocytes;	chr4:143734253	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-9.01	8.75e-16	4.72e-12	-0.87	-0.59	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
PCPG	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	9.01	8.8e-16	4.75e-12	0.71	0.59	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
PCPG	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	9.01	8.83e-16	4.76e-12	0.92	0.59	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
PCPG	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	9	9.16e-16	4.93e-12	0.85	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
PCPG	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-9	9.25e-16	4.97e-12	-0.79	-0.59	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
PCPG	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	9	9.47e-16	5.08e-12	0.71	0.59	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.9	rs71612420	ENSG00000250345.2	RP11-780M14.1	8.99	9.79e-16	5.25e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143779107	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13134869	ENSG00000250345.2	RP11-780M14.1	8.99	9.79e-16	5.25e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143782301	chr4:143760399~143762093:-
PCPG	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	8.99	9.92e-16	5.31e-12	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
PCPG	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-8.99	9.96e-16	5.33e-12	-0.74	-0.59	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
PCPG	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-8.99	9.99e-16	5.34e-12	-0.64	-0.59	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.932	rs11100808	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143762728	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7661407	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143762982	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs4285038	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143763637	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1562777	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143763676	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1562778	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143763816	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1562779	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143763999	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1597441	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143764158	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1597442	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143764359	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1597443	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143764406	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1597444	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143764547	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs60038202	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143764662	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34886773	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143764678	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1450230	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143765118	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34683160	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143765227	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs72946226	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143765238	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34230433	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143765253	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7696869	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143765855	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7698287	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143765859	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs11721495	ENSG00000250345.2	RP11-780M14.1	8.99	1.01e-15	5.38e-12	0.74	0.59	Immature fraction of reticulocytes;	chr4:143767216	chr4:143760399~143762093:-
PCPG	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	8.98	1.03e-15	5.46e-12	0.74	0.59	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
PCPG	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	8.98	1.04e-15	5.51e-12	0.75	0.59	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
PCPG	cis	rs4835473	0.897	rs35598237	ENSG00000250345.2	RP11-780M14.1	8.98	1.04e-15	5.51e-12	0.72	0.59	Immature fraction of reticulocytes;	chr4:143735961	chr4:143760399~143762093:-
PCPG	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-8.98	1.05e-15	5.58e-12	-0.72	-0.59	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
PCPG	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	8.98	1.05e-15	5.58e-12	0.76	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
PCPG	cis	rs4835473	0.801	rs35839125	ENSG00000250345.2	RP11-780M14.1	8.98	1.06e-15	5.64e-12	0.73	0.59	Immature fraction of reticulocytes;	chr4:143792351	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.75	rs12498381	ENSG00000250345.2	RP11-780M14.1	8.98	1.06e-15	5.64e-12	0.73	0.59	Immature fraction of reticulocytes;	chr4:143793928	chr4:143760399~143762093:-
PCPG	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-8.98	1.08e-15	5.72e-12	-0.78	-0.59	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
PCPG	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-8.97	1.12e-15	5.93e-12	-0.78	-0.59	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
PCPG	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-8.97	1.12e-15	5.94e-12	-0.99	-0.59	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
PCPG	cis	rs4835473	0.868	rs35809032	ENSG00000250345.2	RP11-780M14.1	8.97	1.12e-15	5.94e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143824797	chr4:143760399~143762093:-
PCPG	cis	rs7044106	0.664	rs7033339	ENSG00000226752.6	PSMD5-AS1	-8.97	1.13e-15	5.99e-12	-0.83	-0.59	Hip circumference adjusted for BMI;	chr9:120741160	chr9:120824828~120854385:+
PCPG	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	8.96	1.17e-15	6.17e-12	0.75	0.59	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
PCPG	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-8.96	1.18e-15	6.23e-12	-0.81	-0.59	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
PCPG	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	8.96	1.18e-15	6.24e-12	0.78	0.59	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	8.96	1.19e-15	6.27e-12	0.76	0.59	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	8.96	1.19e-15	6.27e-12	0.76	0.59	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	8.96	1.19e-15	6.27e-12	0.76	0.59	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	8.96	1.19e-15	6.27e-12	0.76	0.59	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	8.95	1.23e-15	6.47e-12	0.67	0.59	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
PCPG	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-8.95	1.26e-15	6.65e-12	-0.72	-0.59	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
PCPG	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	8.95	1.28e-15	6.7e-12	0.75	0.59	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.9	rs12503074	ENSG00000250345.2	RP11-780M14.1	8.95	1.28e-15	6.73e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143812560	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.808	rs6831401	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143801038	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.778	rs6853798	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143801153	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs12502940	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143812117	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.778	rs2622380	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143814571	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35792820	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143814806	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs62337300	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143815897	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7697498	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143816854	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7656455	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143817005	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13133239	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143818894	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13106488	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143818969	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13105102	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143819046	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.868	rs13105118	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143819077	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35271123	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143819629	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1383443	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143819940	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7669198	ENSG00000250345.2	RP11-780M14.1	8.94	1.3e-15	6.79e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143821229	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13119602	ENSG00000250345.2	RP11-780M14.1	8.93	1.39e-15	7.22e-12	0.71	0.59	Immature fraction of reticulocytes;	chr4:143736621	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	8.93	1.39e-15	7.24e-12	0.73	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
PCPG	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	8.93	1.46e-15	7.58e-12	0.66	0.59	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	8.92	1.52e-15	7.89e-12	0.67	0.59	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-8.91	1.57e-15	8.11e-12	-0.64	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-8.91	1.57e-15	8.11e-12	-0.64	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
PCPG	cis	rs4835473	0.932	rs4835278	ENSG00000250345.2	RP11-780M14.1	8.91	1.58e-15	8.17e-12	0.73	0.59	Immature fraction of reticulocytes;	chr4:143788433	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4835279	ENSG00000250345.2	RP11-780M14.1	8.91	1.61e-15	8.32e-12	0.73	0.59	Immature fraction of reticulocytes;	chr4:143788917	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs17695782	ENSG00000250345.2	RP11-780M14.1	8.91	1.62e-15	8.38e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143830311	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	8.9	1.65e-15	8.49e-12	0.73	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
PCPG	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-8.9	1.68e-15	8.61e-12	-0.87	-0.59	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
PCPG	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-8.9	1.68e-15	8.64e-12	-0.78	-0.59	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
PCPG	cis	rs2075277	1	rs2270384	ENSG00000207575.1	MIR649	8.9	1.69e-15	8.67e-12	1.02	0.59	Eosinophilic esophagitis;	chr22:21030289	chr22:21034176~21034272:-
PCPG	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-8.9	1.69e-15	8.68e-12	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
PCPG	cis	rs4835473	0.932	rs13134327	ENSG00000250345.2	RP11-780M14.1	-8.9	1.69e-15	8.68e-12	-0.7	-0.59	Immature fraction of reticulocytes;	chr4:143738642	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs17750042	ENSG00000250345.2	RP11-780M14.1	8.9	1.7e-15	8.74e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143726691	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1375989	ENSG00000250345.2	RP11-780M14.1	8.9	1.7e-15	8.74e-12	0.75	0.59	Immature fraction of reticulocytes;	chr4:143726893	chr4:143760399~143762093:-
PCPG	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-8.89	1.76e-15	9.03e-12	-0.74	-0.59	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
PCPG	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	8.89	1.79e-15	9.16e-12	0.71	0.59	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
PCPG	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-8.89	1.79e-15	9.17e-12	-0.8	-0.59	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
PCPG	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	8.89	1.8e-15	9.2e-12	0.73	0.59	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
PCPG	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	8.89	1.8e-15	9.2e-12	0.73	0.59	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
PCPG	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	8.89	1.81e-15	9.24e-12	0.76	0.59	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	8.89	1.81e-15	9.24e-12	0.76	0.59	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	8.89	1.83e-15	9.36e-12	0.65	0.59	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
PCPG	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-8.89	1.83e-15	9.36e-12	-0.79	-0.59	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-8.89	1.83e-15	9.36e-12	-0.79	-0.59	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-8.89	1.83e-15	9.36e-12	-0.79	-0.59	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
PCPG	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-8.89	1.84e-15	9.42e-12	-0.7	-0.59	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
PCPG	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	8.88	1.91e-15	9.71e-12	0.6	0.59	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
PCPG	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-8.87	1.98e-15	1e-11	-0.8	-0.59	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
PCPG	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-8.87	2e-15	1.01e-11	-0.76	-0.59	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs35164917	ENSG00000250345.2	RP11-780M14.1	-8.87	2e-15	1.01e-11	-0.73	-0.59	Immature fraction of reticulocytes;	chr4:143748891	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-8.87	2.01e-15	1.02e-11	-0.65	-0.59	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
PCPG	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	8.87	2.02e-15	1.02e-11	0.79	0.59	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	8.87	2.03e-15	1.03e-11	0.79	0.59	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	8.87	2.05e-15	1.04e-11	0.71	0.59	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
PCPG	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-8.87	2.06e-15	1.04e-11	-0.81	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
PCPG	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-8.87	2.08e-15	1.05e-11	-0.69	-0.59	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
PCPG	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-8.86	2.1e-15	1.06e-11	-0.82	-0.59	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
PCPG	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	8.86	2.11e-15	1.06e-11	1.04	0.59	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
PCPG	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	8.86	2.13e-15	1.07e-11	0.71	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
PCPG	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-8.86	2.15e-15	1.08e-11	-0.86	-0.59	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
PCPG	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	8.86	2.17e-15	1.09e-11	0.74	0.59	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
PCPG	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	8.86	2.17e-15	1.09e-11	0.92	0.59	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
PCPG	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	8.86	2.18e-15	1.1e-11	0.69	0.59	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.932	rs7670010	ENSG00000250345.2	RP11-780M14.1	-8.86	2.19e-15	1.1e-11	-0.75	-0.59	Immature fraction of reticulocytes;	chr4:143821679	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7356305	ENSG00000250345.2	RP11-780M14.1	-8.86	2.2e-15	1.11e-11	-0.72	-0.59	Immature fraction of reticulocytes;	chr4:143737850	chr4:143760399~143762093:-
PCPG	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	8.85	2.21e-15	1.11e-11	0.72	0.59	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
PCPG	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-8.85	2.23e-15	1.12e-11	-0.83	-0.59	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
PCPG	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	8.85	2.24e-15	1.12e-11	0.91	0.59	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
PCPG	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	8.85	2.25e-15	1.13e-11	0.75	0.59	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
PCPG	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	8.85	2.31e-15	1.16e-11	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
PCPG	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	8.84	2.38e-15	1.19e-11	0.63	0.59	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
PCPG	cis	rs4835473	0.932	rs35598827	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.74	0.59	Immature fraction of reticulocytes;	chr4:143729605	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34570929	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.74	0.59	Immature fraction of reticulocytes;	chr4:143730766	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs17750172	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.74	0.59	Immature fraction of reticulocytes;	chr4:143731094	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6849896	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.73	0.59	Immature fraction of reticulocytes;	chr4:143794927	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6826665	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.73	0.59	Immature fraction of reticulocytes;	chr4:143795140	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.838	rs35998817	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.73	0.59	Immature fraction of reticulocytes;	chr4:143795355	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13134808	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.73	0.59	Immature fraction of reticulocytes;	chr4:143798339	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4092718	ENSG00000250345.2	RP11-780M14.1	8.84	2.41e-15	1.2e-11	0.73	0.59	Immature fraction of reticulocytes;	chr4:143799637	chr4:143760399~143762093:-
PCPG	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	8.83	2.5e-15	1.25e-11	0.72	0.58	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
PCPG	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-8.83	2.55e-15	1.27e-11	-0.58	-0.58	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
PCPG	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-8.83	2.58e-15	1.28e-11	-0.79	-0.58	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-8.83	2.58e-15	1.28e-11	-0.79	-0.58	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-8.83	2.58e-15	1.28e-11	-0.79	-0.58	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
PCPG	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	8.83	2.63e-15	1.31e-11	0.78	0.58	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
PCPG	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	8.82	2.65e-15	1.31e-11	0.6	0.58	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
PCPG	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	8.82	2.66e-15	1.32e-11	0.75	0.58	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	8.82	2.71e-15	1.35e-11	0.76	0.58	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-8.82	2.72e-15	1.35e-11	-0.77	-0.58	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.838	rs34819068	ENSG00000250345.2	RP11-780M14.1	8.82	2.75e-15	1.36e-11	0.73	0.58	Immature fraction of reticulocytes;	chr4:143787330	chr4:143760399~143762093:-
PCPG	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-8.81	2.81e-15	1.39e-11	-0.95	-0.58	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
PCPG	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	8.81	2.9e-15	1.43e-11	0.91	0.58	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
PCPG	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-8.81	2.9e-15	1.43e-11	-0.76	-0.58	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
PCPG	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
PCPG	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	8.81	2.91e-15	1.44e-11	0.7	0.58	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	8.8	2.96e-15	1.46e-11	0.7	0.58	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs6858195	ENSG00000250345.2	RP11-780M14.1	8.8	2.98e-15	1.47e-11	0.7	0.58	Immature fraction of reticulocytes;	chr4:143768444	chr4:143760399~143762093:-
PCPG	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	8.8	3.06e-15	1.5e-11	0.69	0.58	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
PCPG	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-8.8	3.08e-15	1.51e-11	-0.76	-0.58	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
PCPG	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	8.8	3.09e-15	1.51e-11	0.71	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
PCPG	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	8.79	3.14e-15	1.53e-11	0.9	0.58	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
PCPG	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-8.79	3.2e-15	1.57e-11	-0.81	-0.58	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-8.79	3.2e-15	1.57e-11	-0.81	-0.58	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
PCPG	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	8.79	3.21e-15	1.57e-11	0.96	0.58	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
PCPG	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	8.78	3.36e-15	1.64e-11	0.86	0.58	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
PCPG	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-8.78	3.4e-15	1.65e-11	-0.76	-0.58	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
PCPG	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	8.78	3.43e-15	1.66e-11	0.72	0.58	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
PCPG	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	8.78	3.44e-15	1.67e-11	0.7	0.58	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
PCPG	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	8.78	3.45e-15	1.67e-11	0.95	0.58	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
PCPG	cis	rs4835473	0.932	rs17763107	ENSG00000250345.2	RP11-780M14.1	8.78	3.45e-15	1.67e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143828512	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34917094	ENSG00000250345.2	RP11-780M14.1	8.78	3.45e-15	1.67e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143832003	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs11736609	ENSG00000250345.2	RP11-780M14.1	8.78	3.45e-15	1.67e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143832876	chr4:143760399~143762093:-
PCPG	cis	rs950027	0.815	rs1153835	ENSG00000259520.4	CTD-2651B20.3	-8.78	3.48e-15	1.69e-11	-0.77	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45456409	chr15:45251580~45279251:-
PCPG	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	8.78	3.49e-15	1.69e-11	0.7	0.58	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
PCPG	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-8.77	3.58e-15	1.73e-11	-0.78	-0.58	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
PCPG	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	8.77	3.6e-15	1.74e-11	0.69	0.58	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
PCPG	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	8.77	3.62e-15	1.75e-11	0.57	0.58	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
PCPG	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	8.77	3.74e-15	1.8e-11	0.8	0.58	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
PCPG	cis	rs4835473	0.932	rs13117421	ENSG00000250345.2	RP11-780M14.1	8.76	3.74e-15	1.8e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143769405	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs35055653	ENSG00000250345.2	RP11-780M14.1	8.75	3.98e-15	1.91e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143754836	chr4:143760399~143762093:-
PCPG	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	8.75	4.02e-15	1.93e-11	0.83	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	8.75	4.02e-15	1.93e-11	0.83	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-8.75	4.08e-15	1.95e-11	-0.65	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
PCPG	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	8.75	4.19e-15	2e-11	1.1	0.58	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
PCPG	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-8.74	4.29e-15	2.05e-11	-0.65	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
PCPG	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	8.74	4.3e-15	2.05e-11	0.86	0.58	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
PCPG	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	8.74	4.32e-15	2.06e-11	0.63	0.58	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
PCPG	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	8.74	4.37e-15	2.08e-11	0.75	0.58	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	8.74	4.37e-15	2.08e-11	0.75	0.58	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	8.74	4.37e-15	2.08e-11	0.75	0.58	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs7696106	ENSG00000250345.2	RP11-780M14.1	8.74	4.45e-15	2.12e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143765454	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7680045	ENSG00000250345.2	RP11-780M14.1	8.74	4.45e-15	2.12e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143765470	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-8.74	4.45e-15	2.12e-11	-0.72	-0.58	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
PCPG	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-8.74	4.45e-15	2.12e-11	-0.72	-0.58	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
PCPG	cis	rs4835473	0.932	rs10016223	ENSG00000250345.2	RP11-780M14.1	-8.74	4.46e-15	2.12e-11	-0.71	-0.58	Immature fraction of reticulocytes;	chr4:143777429	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13129702	ENSG00000250345.2	RP11-780M14.1	-8.74	4.46e-15	2.12e-11	-0.71	-0.58	Immature fraction of reticulocytes;	chr4:143785132	chr4:143760399~143762093:-
PCPG	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	8.73	4.48e-15	2.13e-11	0.68	0.58	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
PCPG	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	8.73	4.49e-15	2.14e-11	0.75	0.58	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
PCPG	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	8.73	4.52e-15	2.15e-11	0.64	0.58	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
PCPG	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	8.73	4.52e-15	2.15e-11	0.65	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
PCPG	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	8.73	4.54e-15	2.16e-11	0.75	0.58	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	8.73	4.54e-15	2.16e-11	0.75	0.58	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs35017645	ENSG00000250345.2	RP11-780M14.1	8.73	4.56e-15	2.16e-11	0.75	0.58	Immature fraction of reticulocytes;	chr4:143760196	chr4:143760399~143762093:-
PCPG	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-8.73	4.57e-15	2.17e-11	-0.8	-0.58	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
PCPG	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-8.72	4.88e-15	2.31e-11	-0.74	-0.58	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
PCPG	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-8.72	4.91e-15	2.32e-11	-0.8	-0.58	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
PCPG	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-8.72	4.93e-15	2.33e-11	-0.66	-0.58	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
PCPG	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	8.72	5e-15	2.36e-11	0.74	0.58	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
PCPG	cis	rs4835473	0.868	rs4350958	ENSG00000250345.2	RP11-780M14.1	-8.71	5.09e-15	2.4e-11	-0.73	-0.58	Immature fraction of reticulocytes;	chr4:143744656	chr4:143760399~143762093:-
PCPG	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	8.71	5.15e-15	2.43e-11	0.56	0.58	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
PCPG	cis	rs4835473	0.932	rs12503900	ENSG00000250345.2	RP11-780M14.1	8.71	5.17e-15	2.44e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143812459	chr4:143760399~143762093:-
PCPG	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	8.71	5.18e-15	2.44e-11	1	0.58	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
PCPG	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	8.71	5.18e-15	2.44e-11	1	0.58	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
PCPG	cis	rs4835473	0.808	rs62339607	ENSG00000250345.2	RP11-780M14.1	8.71	5.21e-15	2.45e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143791474	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs13144504	ENSG00000250345.2	RP11-780M14.1	8.71	5.31e-15	2.5e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143707402	chr4:143760399~143762093:-
PCPG	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-8.7	5.33e-15	2.51e-11	-0.76	-0.58	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs6851999	ENSG00000250345.2	RP11-780M14.1	-8.7	5.34e-15	2.52e-11	-0.72	-0.58	Immature fraction of reticulocytes;	chr4:143742567	chr4:143760399~143762093:-
PCPG	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-8.7	5.36e-15	2.52e-11	-0.66	-0.58	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
PCPG	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-8.7	5.41e-15	2.54e-11	-0.68	-0.58	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-8.7	5.41e-15	2.54e-11	-0.68	-0.58	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-8.7	5.41e-15	2.54e-11	-0.68	-0.58	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
PCPG	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-8.7	5.44e-15	2.56e-11	-0.72	-0.58	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
PCPG	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	8.7	5.45e-15	2.56e-11	0.75	0.58	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	8.7	5.47e-15	2.57e-11	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	8.7	5.48e-15	2.57e-11	0.7	0.58	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
PCPG	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	8.7	5.49e-15	2.58e-11	0.9	0.58	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	8.7	5.49e-15	2.58e-11	0.9	0.58	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
PCPG	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	8.69	5.7e-15	2.67e-11	0.92	0.58	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
PCPG	cis	rs4835473	0.932	rs13129993	ENSG00000250345.2	RP11-780M14.1	8.69	5.95e-15	2.77e-11	0.75	0.58	Immature fraction of reticulocytes;	chr4:143763076	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1580002	ENSG00000250345.2	RP11-780M14.1	8.69	5.95e-15	2.77e-11	0.75	0.58	Immature fraction of reticulocytes;	chr4:143766507	chr4:143760399~143762093:-
PCPG	cis	rs12444156	1	rs12444156	ENSG00000260886.1	TAT-AS1	8.69	5.95e-15	2.77e-11	1.22	0.58	Post bronchodilator FEV1;	chr16:71807354	chr16:71565789~71578187:+
PCPG	cis	rs4835473	0.897	rs7676614	ENSG00000250345.2	RP11-780M14.1	8.69	5.97e-15	2.78e-11	0.73	0.58	Immature fraction of reticulocytes;	chr4:143695213	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs7681559	ENSG00000250345.2	RP11-780M14.1	8.69	5.97e-15	2.78e-11	0.73	0.58	Immature fraction of reticulocytes;	chr4:143695248	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.832	rs55935372	ENSG00000250345.2	RP11-780M14.1	8.69	5.97e-15	2.78e-11	0.73	0.58	Immature fraction of reticulocytes;	chr4:143700626	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.838	rs34521499	ENSG00000250345.2	RP11-780M14.1	8.68	5.99e-15	2.78e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143777628	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs34264936	ENSG00000250345.2	RP11-780M14.1	8.68	5.99e-15	2.78e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143780294	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13140028	ENSG00000250345.2	RP11-780M14.1	8.68	5.99e-15	2.78e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143782195	chr4:143760399~143762093:-
PCPG	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	8.68	6.1e-15	2.83e-11	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
PCPG	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	8.68	6.12e-15	2.84e-11	0.75	0.58	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
PCPG	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	8.68	6.33e-15	2.93e-11	0.75	0.58	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
PCPG	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-8.67	6.4e-15	2.96e-11	-0.76	-0.58	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
PCPG	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	8.67	6.42e-15	2.97e-11	1.04	0.58	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
PCPG	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	8.67	6.59e-15	3.04e-11	0.64	0.58	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	8.67	6.65e-15	3.07e-11	0.71	0.58	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
PCPG	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-8.67	6.65e-15	3.07e-11	-0.74	-0.58	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
PCPG	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	8.67	6.68e-15	3.08e-11	0.57	0.58	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
PCPG	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-8.66	6.87e-15	3.17e-11	-0.8	-0.58	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
PCPG	cis	rs4835473	0.9	rs35670120	ENSG00000250345.2	RP11-780M14.1	8.66	7e-15	3.22e-11	0.74	0.58	Immature fraction of reticulocytes;	chr4:143787041	chr4:143760399~143762093:-
PCPG	cis	rs2075277	1	rs2075277	ENSG00000207575.1	MIR649	8.66	7.02e-15	3.23e-11	1	0.58	Eosinophilic esophagitis;	chr22:21028193	chr22:21034176~21034272:-
PCPG	cis	rs2075277	1	rs2072550	ENSG00000207575.1	MIR649	8.66	7.02e-15	3.23e-11	1	0.58	Eosinophilic esophagitis;	chr22:21031730	chr22:21034176~21034272:-
PCPG	cis	rs4835473	0.897	rs1817027	ENSG00000250345.2	RP11-780M14.1	8.66	7.1e-15	3.26e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143713336	chr4:143760399~143762093:-
PCPG	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-8.65	7.15e-15	3.28e-11	-0.75	-0.58	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
PCPG	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	8.65	7.15e-15	3.28e-11	0.67	0.58	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.838	rs56033497	ENSG00000250345.2	RP11-780M14.1	8.65	7.24e-15	3.32e-11	0.71	0.58	Immature fraction of reticulocytes;	chr4:143792341	chr4:143760399~143762093:-
PCPG	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-8.65	7.28e-15	3.34e-11	-0.8	-0.58	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
PCPG	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-8.65	7.42e-15	3.4e-11	-0.67	-0.58	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-8.65	7.42e-15	3.4e-11	-0.67	-0.58	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-8.65	7.42e-15	3.4e-11	-0.67	-0.58	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-8.65	7.42e-15	3.4e-11	-0.67	-0.58	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-8.65	7.42e-15	3.4e-11	-0.67	-0.58	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-8.65	7.42e-15	3.4e-11	-0.67	-0.58	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
PCPG	cis	rs858239	0.676	rs199359	ENSG00000230658.1	KLHL7-AS1	-8.65	7.46e-15	3.42e-11	-0.64	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23298895	chr7:23101228~23105703:-
PCPG	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	8.65	7.49e-15	3.43e-11	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	8.65	7.49e-15	3.43e-11	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	8.65	7.49e-15	3.43e-11	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	8.65	7.49e-15	3.43e-11	0.71	0.58	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
PCPG	cis	rs4835473	0.897	rs34380794	ENSG00000250345.2	RP11-780M14.1	8.65	7.51e-15	3.44e-11	0.69	0.58	Immature fraction of reticulocytes;	chr4:143735800	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.75	rs56372690	ENSG00000250345.2	RP11-780M14.1	8.65	7.51e-15	3.44e-11	0.69	0.58	Immature fraction of reticulocytes;	chr4:143735816	chr4:143760399~143762093:-
PCPG	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-8.64	7.6e-15	3.46e-11	-0.75	-0.58	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.897	rs4054616	ENSG00000250345.2	RP11-780M14.1	-8.64	7.77e-15	3.53e-11	-0.73	-0.58	Immature fraction of reticulocytes;	chr4:143837472	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs2323325	ENSG00000250345.2	RP11-780M14.1	-8.64	7.77e-15	3.53e-11	-0.73	-0.58	Immature fraction of reticulocytes;	chr4:143837561	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.8	rs4835330	ENSG00000250345.2	RP11-780M14.1	-8.64	7.77e-15	3.53e-11	-0.73	-0.58	Immature fraction of reticulocytes;	chr4:143846303	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	8.64	7.83e-15	3.56e-11	0.73	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
PCPG	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-8.64	8.01e-15	3.64e-11	-0.79	-0.58	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
PCPG	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	8.63	8.02e-15	3.64e-11	0.56	0.58	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
PCPG	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	8.63	8.08e-15	3.67e-11	0.67	0.58	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
PCPG	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-8.63	8.08e-15	3.67e-11	-0.8	-0.58	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-8.63	8.08e-15	3.67e-11	-0.8	-0.58	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-8.63	8.08e-15	3.67e-11	-0.8	-0.58	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-8.63	8.08e-15	3.67e-11	-0.8	-0.58	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
PCPG	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-8.63	8.13e-15	3.69e-11	-0.75	-0.58	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
PCPG	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	8.63	8.27e-15	3.75e-11	0.67	0.58	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
PCPG	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	8.63	8.31e-15	3.77e-11	0.77	0.58	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
PCPG	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	8.63	8.38e-15	3.8e-11	0.62	0.58	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
PCPG	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	8.63	8.45e-15	3.83e-11	0.89	0.58	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.808	rs6836630	ENSG00000250345.2	RP11-780M14.1	8.63	8.47e-15	3.83e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143801068	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13101541	ENSG00000250345.2	RP11-780M14.1	8.63	8.47e-15	3.83e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143806590	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs17695238	ENSG00000250345.2	RP11-780M14.1	8.63	8.47e-15	3.83e-11	0.72	0.58	Immature fraction of reticulocytes;	chr4:143820720	chr4:143760399~143762093:-
PCPG	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	8.62	8.62e-15	3.9e-11	0.68	0.58	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
PCPG	cis	rs4835473	0.801	rs999049	ENSG00000250345.2	RP11-780M14.1	8.62	8.63e-15	3.9e-11	0.73	0.58	Immature fraction of reticulocytes;	chr4:143715440	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs11735341	ENSG00000250345.2	RP11-780M14.1	8.62	8.63e-15	3.9e-11	0.73	0.58	Immature fraction of reticulocytes;	chr4:143716030	chr4:143760399~143762093:-
PCPG	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	8.62	8.64e-15	3.9e-11	0.67	0.58	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
PCPG	cis	rs2075277	0.867	rs1477145	ENSG00000207575.1	MIR649	8.62	8.75e-15	3.95e-11	1.02	0.58	Eosinophilic esophagitis;	chr22:21025775	chr22:21034176~21034272:-
PCPG	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-8.62	8.87e-15	4e-11	-0.65	-0.58	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
PCPG	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	8.62	8.92e-15	4.02e-11	0.92	0.58	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
PCPG	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-8.62	8.93e-15	4.02e-11	-0.67	-0.58	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
PCPG	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-8.62	8.93e-15	4.02e-11	-0.67	-0.58	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
PCPG	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-8.62	8.93e-15	4.02e-11	-0.67	-0.58	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
PCPG	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-8.62	8.93e-15	4.02e-11	-0.67	-0.58	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
PCPG	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-8.62	8.93e-15	4.02e-11	-0.67	-0.58	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-8.62	8.93e-15	4.02e-11	-0.67	-0.58	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
PCPG	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	8.62	8.96e-15	4.04e-11	0.7	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
PCPG	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-8.62	8.96e-15	4.04e-11	-0.64	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
PCPG	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-8.62	8.97e-15	4.04e-11	-0.68	-0.58	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.9	rs4054634	ENSG00000250345.2	RP11-780M14.1	8.61	9.05e-15	4.08e-11	0.73	0.58	Immature fraction of reticulocytes;	chr4:143787045	chr4:143760399~143762093:-
PCPG	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-8.61	9.17e-15	4.13e-11	-0.75	-0.58	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
PCPG	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	8.61	9.31e-15	4.17e-11	0.8	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	8.61	9.31e-15	4.17e-11	0.8	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
PCPG	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	8.61	9.34e-15	4.18e-11	0.68	0.58	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
PCPG	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	8.61	9.34e-15	4.18e-11	0.68	0.58	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
PCPG	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	8.61	9.35e-15	4.19e-11	0.65	0.58	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
PCPG	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-8.61	9.37e-15	4.2e-11	-0.87	-0.58	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	8.61	9.39e-15	4.2e-11	0.7	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
PCPG	cis	rs4835473	0.932	rs34324222	ENSG00000250345.2	RP11-780M14.1	8.61	9.42e-15	4.21e-11	0.72	0.57	Immature fraction of reticulocytes;	chr4:143784572	chr4:143760399~143762093:-
PCPG	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	8.61	9.42e-15	4.21e-11	0.68	0.57	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
PCPG	cis	rs4835473	0.897	rs34425128	ENSG00000250345.2	RP11-780M14.1	8.61	9.47e-15	4.24e-11	0.73	0.57	Immature fraction of reticulocytes;	chr4:143725191	chr4:143760399~143762093:-
PCPG	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-8.61	9.53e-15	4.26e-11	-0.75	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
PCPG	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-8.6	9.65e-15	4.31e-11	-0.79	-0.57	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	8.6	9.69e-15	4.33e-11	0.75	0.57	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
PCPG	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-8.6	1e-14	4.47e-11	-0.72	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
PCPG	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-8.59	1.04e-14	4.62e-11	-0.75	-0.57	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-8.59	1.04e-14	4.62e-11	-0.75	-0.57	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.864	rs4835343	ENSG00000250345.2	RP11-780M14.1	-8.59	1.05e-14	4.66e-11	-0.73	-0.57	Immature fraction of reticulocytes;	chr4:143866038	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	8.59	1.06e-14	4.69e-11	0.88	0.57	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-8.59	1.07e-14	4.74e-11	-0.85	-0.57	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-8.59	1.07e-14	4.74e-11	-0.85	-0.57	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-8.59	1.07e-14	4.74e-11	-0.85	-0.57	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	8.58	1.08e-14	4.82e-11	0.63	0.57	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
PCPG	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-8.58	1.08e-14	4.82e-11	-0.68	-0.57	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.897	rs62337587	ENSG00000250345.2	RP11-780M14.1	8.58	1.09e-14	4.82e-11	0.73	0.57	Immature fraction of reticulocytes;	chr4:143725839	chr4:143760399~143762093:-
PCPG	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-8.58	1.1e-14	4.89e-11	-0.66	-0.57	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
PCPG	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	8.58	1.1e-14	4.89e-11	0.69	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
PCPG	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-8.58	1.11e-14	4.9e-11	-0.67	-0.57	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
PCPG	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-8.58	1.11e-14	4.9e-11	-0.67	-0.57	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
PCPG	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	8.58	1.11e-14	4.92e-11	0.73	0.57	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	8.58	1.11e-14	4.92e-11	0.73	0.57	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
PCPG	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	8.58	1.12e-14	4.94e-11	0.6	0.57	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
PCPG	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-8.58	1.13e-14	4.97e-11	-0.75	-0.57	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-8.58	1.13e-14	4.97e-11	-0.75	-0.57	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
PCPG	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	8.58	1.13e-14	4.97e-11	0.67	0.57	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
PCPG	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	8.58	1.13e-14	4.97e-11	0.67	0.57	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
PCPG	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-8.58	1.13e-14	4.97e-11	-0.74	-0.57	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-8.58	1.13e-14	4.97e-11	-0.74	-0.57	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
PCPG	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-8.58	1.13e-14	4.97e-11	-0.66	-0.57	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
PCPG	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	8.58	1.14e-14	5.01e-11	0.69	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
PCPG	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	8.57	1.14e-14	5.04e-11	0.69	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
PCPG	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	8.57	1.15e-14	5.08e-11	0.69	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
PCPG	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-8.57	1.17e-14	5.13e-11	-0.79	-0.57	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
PCPG	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	8.57	1.17e-14	5.13e-11	0.79	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
PCPG	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	8.57	1.18e-14	5.17e-11	0.57	0.57	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	8.57	1.18e-14	5.17e-11	0.57	0.57	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
PCPG	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-8.57	1.18e-14	5.18e-11	-0.63	-0.57	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.932	rs4383567	ENSG00000250345.2	RP11-780M14.1	-8.57	1.19e-14	5.22e-11	-0.71	-0.57	Immature fraction of reticulocytes;	chr4:143788873	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1842484	ENSG00000250345.2	RP11-780M14.1	-8.57	1.19e-14	5.22e-11	-0.71	-0.57	Immature fraction of reticulocytes;	chr4:143793829	chr4:143760399~143762093:-
PCPG	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-8.56	1.21e-14	5.32e-11	-1.04	-0.57	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
PCPG	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-8.56	1.23e-14	5.41e-11	-0.72	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
PCPG	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-8.56	1.23e-14	5.41e-11	-0.66	-0.57	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-8.56	1.23e-14	5.41e-11	-0.66	-0.57	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
PCPG	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-8.56	1.27e-14	5.55e-11	-0.88	-0.57	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
PCPG	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	8.55	1.33e-14	5.79e-11	0.7	0.57	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
PCPG	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-8.55	1.33e-14	5.8e-11	-0.69	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
PCPG	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-8.55	1.33e-14	5.81e-11	-0.77	-0.57	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
PCPG	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	8.54	1.37e-14	5.96e-11	0.88	0.57	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
PCPG	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-8.54	1.38e-14	6e-11	-0.62	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
PCPG	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-8.54	1.38e-14	6e-11	-0.74	-0.57	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.736	rs6851661	ENSG00000250345.2	RP11-780M14.1	-8.54	1.4e-14	6.08e-11	-0.73	-0.57	Immature fraction of reticulocytes;	chr4:143850587	chr4:143760399~143762093:-
PCPG	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	8.54	1.41e-14	6.13e-11	1.05	0.57	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
PCPG	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-8.54	1.41e-14	6.13e-11	-0.66	-0.57	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-8.54	1.41e-14	6.15e-11	-0.74	-0.57	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
PCPG	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	8.54	1.43e-14	6.22e-11	0.94	0.57	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
PCPG	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-8.53	1.44e-14	6.24e-11	-0.86	-0.57	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	8.53	1.46e-14	6.32e-11	0.63	0.57	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
PCPG	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-8.53	1.48e-14	6.4e-11	-0.86	-0.57	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
PCPG	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-8.53	1.48e-14	6.43e-11	-0.65	-0.57	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
PCPG	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	8.53	1.48e-14	6.44e-11	0.49	0.57	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
PCPG	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	8.53	1.49e-14	6.45e-11	0.68	0.57	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
PCPG	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	8.53	1.5e-14	6.48e-11	0.56	0.57	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	8.53	1.5e-14	6.48e-11	0.56	0.57	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	8.53	1.5e-14	6.48e-11	0.56	0.57	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	8.53	1.5e-14	6.48e-11	0.56	0.57	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	8.53	1.5e-14	6.48e-11	0.56	0.57	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
PCPG	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-8.52	1.53e-14	6.62e-11	-0.59	-0.57	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
PCPG	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-8.52	1.53e-14	6.64e-11	-0.73	-0.57	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	8.52	1.55e-14	6.7e-11	0.71	0.57	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	8.52	1.57e-14	6.77e-11	0.77	0.57	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
PCPG	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	8.52	1.58e-14	6.81e-11	0.73	0.57	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.838	rs4271960	ENSG00000250345.2	RP11-780M14.1	8.52	1.59e-14	6.86e-11	0.72	0.57	Immature fraction of reticulocytes;	chr4:143763591	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.808	rs2323198	ENSG00000250345.2	RP11-780M14.1	8.52	1.59e-14	6.86e-11	0.72	0.57	Immature fraction of reticulocytes;	chr4:143763595	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs2323199	ENSG00000250345.2	RP11-780M14.1	8.52	1.59e-14	6.86e-11	0.72	0.57	Immature fraction of reticulocytes;	chr4:143763606	chr4:143760399~143762093:-
PCPG	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-8.52	1.6e-14	6.87e-11	-0.74	-0.57	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
PCPG	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	8.52	1.61e-14	6.89e-11	0.69	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
PCPG	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	8.51	1.63e-14	6.99e-11	0.76	0.57	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	8.51	1.63e-14	6.99e-11	0.76	0.57	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
PCPG	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	8.51	1.64e-14	7.04e-11	0.7	0.57	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
PCPG	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	8.51	1.67e-14	7.13e-11	0.92	0.57	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
PCPG	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-8.5	1.72e-14	7.34e-11	-0.73	-0.57	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
PCPG	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	8.5	1.72e-14	7.35e-11	0.71	0.57	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
PCPG	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-8.5	1.73e-14	7.41e-11	-0.66	-0.57	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
PCPG	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	8.5	1.74e-14	7.43e-11	0.71	0.57	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
PCPG	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	8.5	1.76e-14	7.5e-11	0.86	0.57	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
PCPG	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	8.5	1.76e-14	7.53e-11	0.7	0.57	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
PCPG	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-8.5	1.78e-14	7.58e-11	-0.64	-0.57	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
PCPG	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-8.5	1.8e-14	7.67e-11	-0.71	-0.57	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
PCPG	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-8.5	1.8e-14	7.67e-11	-0.71	-0.57	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
PCPG	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	8.5	1.81e-14	7.69e-11	0.86	0.57	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
PCPG	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	8.49	1.81e-14	7.71e-11	0.71	0.57	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.9	rs58106929	ENSG00000250345.2	RP11-780M14.1	-8.49	1.82e-14	7.73e-11	-0.7	-0.57	Immature fraction of reticulocytes;	chr4:143733166	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs7698963	ENSG00000250345.2	RP11-780M14.1	-8.49	1.82e-14	7.73e-11	-0.7	-0.57	Immature fraction of reticulocytes;	chr4:143733190	chr4:143760399~143762093:-
PCPG	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-8.49	1.85e-14	7.89e-11	-0.74	-0.57	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
PCPG	cis	rs7044106	0.791	rs2900177	ENSG00000226752.6	PSMD5-AS1	-8.49	1.86e-14	7.92e-11	-0.8	-0.57	Hip circumference adjusted for BMI;	chr9:120735367	chr9:120824828~120854385:+
PCPG	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	8.49	1.89e-14	8.01e-11	0.72	0.57	Depression;	chr6:28314871	chr6:28176188~28176674:+
PCPG	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	8.49	1.91e-14	8.11e-11	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
PCPG	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	8.48	1.92e-14	8.13e-11	0.9	0.57	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	8.48	1.92e-14	8.13e-11	0.9	0.57	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	8.48	1.92e-14	8.13e-11	0.9	0.57	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	8.48	1.92e-14	8.13e-11	0.9	0.57	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
PCPG	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	8.48	1.93e-14	8.16e-11	0.74	0.57	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.932	rs12512649	ENSG00000250345.2	RP11-780M14.1	8.48	1.94e-14	8.22e-11	0.71	0.57	Immature fraction of reticulocytes;	chr4:143736745	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs13135627	ENSG00000250345.2	RP11-780M14.1	8.48	1.96e-14	8.29e-11	0.72	0.57	Immature fraction of reticulocytes;	chr4:143691099	chr4:143760399~143762093:-
PCPG	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-8.48	1.96e-14	8.31e-11	-0.67	-0.57	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-8.48	1.96e-14	8.31e-11	-0.67	-0.57	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
PCPG	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-8.48	1.96e-14	8.31e-11	-0.67	-0.57	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
PCPG	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	8.48	2.01e-14	8.48e-11	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
PCPG	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	8.48	2.01e-14	8.49e-11	0.92	0.57	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
PCPG	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	8.48	2.02e-14	8.53e-11	0.71	0.57	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
PCPG	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	8.48	2.03e-14	8.56e-11	0.8	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
PCPG	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	8.48	2.03e-14	8.57e-11	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
PCPG	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-8.47	2.06e-14	8.69e-11	-0.66	-0.57	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.863	rs13146607	ENSG00000250345.2	RP11-780M14.1	8.47	2.09e-14	8.82e-11	0.72	0.57	Immature fraction of reticulocytes;	chr4:143687283	chr4:143760399~143762093:-
PCPG	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	8.47	2.1e-14	8.86e-11	0.93	0.57	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
PCPG	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	8.47	2.13e-14	8.98e-11	0.78	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
PCPG	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	8.47	2.13e-14	8.98e-11	0.78	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
PCPG	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	8.47	2.13e-14	8.98e-11	0.78	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
PCPG	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	8.47	2.13e-14	8.98e-11	0.78	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
PCPG	cis	rs4835473	0.863	rs11735239	ENSG00000250345.2	RP11-780M14.1	8.46	2.16e-14	9.08e-11	0.72	0.57	Immature fraction of reticulocytes;	chr4:143689372	chr4:143760399~143762093:-
PCPG	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	8.46	2.16e-14	9.09e-11	0.67	0.57	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
PCPG	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-8.46	2.21e-14	9.29e-11	-0.76	-0.57	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
PCPG	cis	rs4835473	0.932	rs28796049	ENSG00000250345.2	RP11-780M14.1	-8.46	2.22e-14	9.3e-11	-0.71	-0.57	Immature fraction of reticulocytes;	chr4:143733990	chr4:143760399~143762093:-
PCPG	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-8.46	2.24e-14	9.39e-11	-0.69	-0.57	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
PCPG	cis	rs4835473	0.897	rs13145976	ENSG00000250345.2	RP11-780M14.1	8.46	2.27e-14	9.51e-11	0.69	0.57	Immature fraction of reticulocytes;	chr4:143735710	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs13114071	ENSG00000250345.2	RP11-780M14.1	8.46	2.27e-14	9.51e-11	0.69	0.57	Immature fraction of reticulocytes;	chr4:143735728	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs13140654	ENSG00000250345.2	RP11-780M14.1	8.46	2.27e-14	9.51e-11	0.69	0.57	Immature fraction of reticulocytes;	chr4:143735733	chr4:143760399~143762093:-
PCPG	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-8.46	2.28e-14	9.56e-11	-0.79	-0.57	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
PCPG	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-8.45	2.31e-14	9.67e-11	-0.66	-0.57	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-8.45	2.31e-14	9.67e-11	-0.66	-0.57	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
PCPG	cis	rs4835473	0.932	rs7664248	ENSG00000250345.2	RP11-780M14.1	-8.45	2.31e-14	9.68e-11	-0.72	-0.57	Immature fraction of reticulocytes;	chr4:143732554	chr4:143760399~143762093:-
PCPG	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-8.45	2.35e-14	9.82e-11	-0.64	-0.57	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-8.45	2.35e-14	9.82e-11	-0.64	-0.57	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
PCPG	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	8.45	2.38e-14	9.94e-11	0.66	0.57	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
PCPG	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	8.45	2.39e-14	1e-10	0.62	0.57	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
PCPG	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	8.44	2.42e-14	1.01e-10	0.92	0.57	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
PCPG	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	8.44	2.44e-14	1.02e-10	0.77	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
PCPG	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-8.44	2.5e-14	1.04e-10	-0.67	-0.57	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
PCPG	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-8.44	2.51e-14	1.05e-10	-0.8	-0.57	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
PCPG	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-8.44	2.54e-14	1.06e-10	-0.66	-0.57	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-8.44	2.54e-14	1.06e-10	-0.66	-0.57	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
PCPG	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-8.44	2.54e-14	1.06e-10	-0.66	-0.57	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
PCPG	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	8.43	2.59e-14	1.08e-10	0.67	0.57	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
PCPG	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	8.43	2.61e-14	1.09e-10	0.71	0.57	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
PCPG	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-8.43	2.63e-14	1.09e-10	-0.67	-0.57	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-8.43	2.63e-14	1.09e-10	-0.67	-0.57	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
PCPG	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-8.43	2.64e-14	1.1e-10	-0.83	-0.57	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
PCPG	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-8.43	2.69e-14	1.11e-10	-0.78	-0.57	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-8.43	2.69e-14	1.11e-10	-0.78	-0.57	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
PCPG	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-8.43	2.7e-14	1.12e-10	-0.67	-0.57	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
PCPG	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	8.43	2.71e-14	1.12e-10	0.81	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
PCPG	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	8.42	2.73e-14	1.13e-10	0.66	0.57	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
PCPG	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	8.42	2.75e-14	1.14e-10	0.64	0.57	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
PCPG	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	8.42	2.75e-14	1.14e-10	0.64	0.57	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
PCPG	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	8.42	2.76e-14	1.14e-10	0.57	0.57	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
PCPG	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	8.42	2.81e-14	1.16e-10	0.67	0.57	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
PCPG	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	8.42	2.81e-14	1.16e-10	0.78	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
PCPG	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	8.42	2.81e-14	1.16e-10	0.78	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
PCPG	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	8.42	2.81e-14	1.16e-10	0.78	0.57	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
PCPG	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	8.42	2.84e-14	1.17e-10	0.67	0.57	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
PCPG	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-8.42	2.85e-14	1.18e-10	-0.55	-0.57	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	8.42	2.85e-14	1.18e-10	0.55	0.57	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
PCPG	cis	rs4835473	0.864	rs13145791	ENSG00000250345.2	RP11-780M14.1	8.41	2.9e-14	1.19e-10	0.69	0.57	Immature fraction of reticulocytes;	chr4:143735688	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs5015760	ENSG00000250345.2	RP11-780M14.1	8.41	2.9e-14	1.19e-10	0.69	0.57	Immature fraction of reticulocytes;	chr4:143737955	chr4:143760399~143762093:-
PCPG	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	8.41	2.91e-14	1.2e-10	0.76	0.57	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	8.41	2.91e-14	1.2e-10	0.76	0.57	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	8.41	2.91e-14	1.2e-10	0.76	0.57	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	8.41	2.91e-14	1.2e-10	0.76	0.57	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
PCPG	cis	rs4835473	0.932	rs1597445	ENSG00000250345.2	RP11-780M14.1	8.41	2.93e-14	1.21e-10	0.7	0.57	Immature fraction of reticulocytes;	chr4:143768543	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-8.41	2.95e-14	1.21e-10	-0.63	-0.57	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
PCPG	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	8.41	2.98e-14	1.22e-10	0.93	0.57	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
PCPG	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	8.41	3.01e-14	1.23e-10	0.91	0.57	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
PCPG	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-8.41	3.04e-14	1.25e-10	-0.68	-0.57	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
PCPG	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-8.4	3.09e-14	1.26e-10	-0.55	-0.57	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
PCPG	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	8.4	3.09e-14	1.27e-10	0.66	0.57	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
PCPG	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	8.4	3.12e-14	1.28e-10	1.17	0.57	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
PCPG	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	8.4	3.14e-14	1.29e-10	0.75	0.57	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
PCPG	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-8.4	3.21e-14	1.31e-10	-0.8	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
PCPG	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-8.4	3.22e-14	1.32e-10	-0.86	-0.57	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
PCPG	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-8.4	3.22e-14	1.32e-10	-0.56	-0.57	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
PCPG	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-8.39	3.28e-14	1.34e-10	-0.64	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
PCPG	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	8.39	3.34e-14	1.36e-10	0.78	0.57	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
PCPG	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	8.39	3.37e-14	1.37e-10	0.67	0.57	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	8.38	3.46e-14	1.41e-10	0.7	0.56	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
PCPG	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	8.38	3.49e-14	1.42e-10	0.55	0.56	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
PCPG	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-8.38	3.54e-14	1.44e-10	-0.76	-0.56	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
PCPG	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-8.38	3.55e-14	1.44e-10	-0.8	-0.56	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
PCPG	cis	rs950027	0.967	rs2486280	ENSG00000259520.4	CTD-2651B20.3	-8.38	3.58e-14	1.45e-10	-0.73	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45459691	chr15:45251580~45279251:-
PCPG	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	8.38	3.59e-14	1.45e-10	0.86	0.56	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
PCPG	cis	rs4835473	0.932	rs4835013	ENSG00000250345.2	RP11-780M14.1	-8.37	3.66e-14	1.48e-10	-0.7	-0.56	Immature fraction of reticulocytes;	chr4:143748485	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-8.37	3.66e-14	1.48e-10	-0.81	-0.56	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
PCPG	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-8.37	3.76e-14	1.52e-10	-0.63	-0.56	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
PCPG	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	8.37	3.77e-14	1.53e-10	0.74	0.56	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
PCPG	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	8.37	3.79e-14	1.53e-10	0.66	0.56	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
PCPG	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	8.37	3.83e-14	1.55e-10	0.86	0.56	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	8.37	3.83e-14	1.55e-10	0.86	0.56	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
PCPG	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-8.37	3.84e-14	1.55e-10	-0.66	-0.56	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
PCPG	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-8.36	3.87e-14	1.56e-10	-0.79	-0.56	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
PCPG	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-8.36	3.88e-14	1.57e-10	-0.55	-0.56	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
PCPG	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	8.36	3.89e-14	1.57e-10	0.54	0.56	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
PCPG	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	8.36	3.93e-14	1.58e-10	0.66	0.56	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
PCPG	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-8.36	3.94e-14	1.59e-10	-0.7	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
PCPG	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	8.36	3.96e-14	1.59e-10	0.62	0.56	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
PCPG	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	8.36	4.01e-14	1.61e-10	0.63	0.56	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
PCPG	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-8.35	4.08e-14	1.64e-10	-0.74	-0.56	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
PCPG	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	8.35	4.11e-14	1.65e-10	1.16	0.56	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
PCPG	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	8.35	4.12e-14	1.66e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	8.35	4.14e-14	1.66e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	8.35	4.14e-14	1.66e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	8.35	4.14e-14	1.66e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	8.35	4.14e-14	1.66e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	8.35	4.14e-14	1.66e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	8.35	4.15e-14	1.67e-10	0.66	0.56	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
PCPG	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	8.35	4.2e-14	1.68e-10	0.75	0.56	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
PCPG	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	8.35	4.28e-14	1.72e-10	0.86	0.56	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	8.35	4.28e-14	1.72e-10	0.86	0.56	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
PCPG	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-8.34	4.38e-14	1.75e-10	-0.75	-0.56	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.831	rs1579816	ENSG00000250345.2	RP11-780M14.1	-8.34	4.39e-14	1.76e-10	-0.72	-0.56	Immature fraction of reticulocytes;	chr4:143866772	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4240334	ENSG00000250345.2	RP11-780M14.1	-8.34	4.39e-14	1.76e-10	-0.72	-0.56	Immature fraction of reticulocytes;	chr4:143871352	chr4:143760399~143762093:-
PCPG	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-8.34	4.4e-14	1.76e-10	-0.67	-0.56	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
PCPG	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	8.34	4.4e-14	1.76e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	8.34	4.4e-14	1.76e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	8.34	4.4e-14	1.76e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	8.34	4.4e-14	1.76e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
PCPG	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.34	4.43e-14	1.77e-10	0.54	0.56	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
PCPG	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-8.34	4.44e-14	1.77e-10	-0.67	-0.56	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
PCPG	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	8.34	4.45e-14	1.78e-10	0.59	0.56	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
PCPG	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-8.34	4.48e-14	1.78e-10	-0.63	-0.56	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
PCPG	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-8.34	4.48e-14	1.79e-10	-0.78	-0.56	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
PCPG	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-8.34	4.54e-14	1.81e-10	-0.65	-0.56	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.897	rs11728121	ENSG00000250345.2	RP11-780M14.1	-8.33	4.59e-14	1.83e-10	-0.7	-0.56	Immature fraction of reticulocytes;	chr4:143707079	chr4:143760399~143762093:-
PCPG	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-8.33	4.59e-14	1.83e-10	-0.78	-0.56	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
PCPG	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-8.33	4.6e-14	1.83e-10	-0.63	-0.56	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
PCPG	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	8.33	4.63e-14	1.84e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	8.33	4.63e-14	1.84e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	8.33	4.63e-14	1.84e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	8.33	4.63e-14	1.84e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	8.33	4.63e-14	1.84e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
PCPG	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	8.33	4.63e-14	1.84e-10	0.72	0.56	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	8.33	4.63e-14	1.84e-10	0.72	0.56	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
PCPG	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-8.33	4.63e-14	1.84e-10	-0.63	-0.56	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.897	rs12508285	ENSG00000250345.2	RP11-780M14.1	8.33	4.65e-14	1.84e-10	0.72	0.56	Immature fraction of reticulocytes;	chr4:143792642	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs7667544	ENSG00000250345.2	RP11-780M14.1	8.33	4.65e-14	1.84e-10	0.72	0.56	Immature fraction of reticulocytes;	chr4:143793802	chr4:143760399~143762093:-
PCPG	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	8.33	4.65e-14	1.84e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
PCPG	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-8.33	4.7e-14	1.86e-10	-0.76	-0.56	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
PCPG	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-8.33	4.75e-14	1.87e-10	-0.65	-0.56	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-8.33	4.75e-14	1.87e-10	-0.65	-0.56	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-8.33	4.75e-14	1.87e-10	-0.65	-0.56	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	8.33	4.75e-14	1.87e-10	0.65	0.56	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
PCPG	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	8.33	4.77e-14	1.88e-10	0.67	0.56	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
PCPG	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-8.33	4.8e-14	1.89e-10	-0.63	-0.56	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
PCPG	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	8.33	4.83e-14	1.9e-10	0.75	0.56	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
PCPG	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-8.32	4.85e-14	1.91e-10	-0.75	-0.56	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
PCPG	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-8.32	4.85e-14	1.91e-10	-0.75	-0.56	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
PCPG	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	8.32	4.91e-14	1.93e-10	0.7	0.56	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	8.32	4.91e-14	1.93e-10	0.7	0.56	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	8.32	4.91e-14	1.93e-10	0.7	0.56	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	8.32	4.91e-14	1.93e-10	0.7	0.56	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	8.32	4.91e-14	1.93e-10	0.7	0.56	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	8.32	4.91e-14	1.93e-10	0.7	0.56	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
PCPG	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	8.32	4.92e-14	1.93e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	8.32	4.92e-14	1.93e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	8.32	4.92e-14	1.93e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	8.32	4.92e-14	1.93e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	8.32	4.92e-14	1.93e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	8.32	4.92e-14	1.93e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	8.32	4.92e-14	1.93e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
PCPG	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-8.32	4.95e-14	1.94e-10	-0.67	-0.56	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
PCPG	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	8.32	4.99e-14	1.96e-10	0.54	0.56	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
PCPG	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	8.32	5.04e-14	1.98e-10	0.74	0.56	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	8.32	5.07e-14	1.99e-10	0.7	0.56	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	8.32	5.07e-14	1.99e-10	0.7	0.56	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	8.32	5.07e-14	1.99e-10	0.7	0.56	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.897	rs11723113	ENSG00000250345.2	RP11-780M14.1	-8.32	5.09e-14	2e-10	-0.7	-0.56	Immature fraction of reticulocytes;	chr4:143707283	chr4:143760399~143762093:-
PCPG	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-8.32	5.1e-14	2e-10	-0.78	-0.56	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
PCPG	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-8.31	5.2e-14	2.04e-10	-0.81	-0.56	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-8.31	5.2e-14	2.04e-10	-0.81	-0.56	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
PCPG	cis	rs858239	0.704	rs466240	ENSG00000230658.1	KLHL7-AS1	-8.31	5.21e-14	2.04e-10	-0.62	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23299155	chr7:23101228~23105703:-
PCPG	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-8.31	5.22e-14	2.04e-10	-0.82	-0.56	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
PCPG	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-8.31	5.24e-14	2.05e-10	-0.69	-0.56	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
PCPG	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	8.31	5.34e-14	2.09e-10	0.85	0.56	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
PCPG	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	8.31	5.36e-14	2.09e-10	0.54	0.56	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-8.31	5.36e-14	2.09e-10	-0.54	-0.56	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-8.31	5.36e-14	2.09e-10	-0.54	-0.56	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-8.31	5.36e-14	2.09e-10	-0.54	-0.56	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
PCPG	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	8.3	5.49e-14	2.14e-10	0.61	0.56	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
PCPG	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	8.3	5.59e-14	2.18e-10	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
PCPG	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	8.3	5.61e-14	2.18e-10	0.73	0.56	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	8.3	5.61e-14	2.18e-10	0.73	0.56	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
PCPG	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-8.3	5.64e-14	2.2e-10	-0.77	-0.56	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
PCPG	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-8.3	5.71e-14	2.22e-10	-0.76	-0.56	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
PCPG	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-8.29	5.9e-14	2.29e-10	-0.65	-0.56	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
PCPG	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	8.29	5.91e-14	2.3e-10	0.71	0.56	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
PCPG	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-8.29	6.05e-14	2.35e-10	-0.62	-0.56	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
PCPG	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	8.29	6.09e-14	2.37e-10	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
PCPG	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-8.29	6.1e-14	2.37e-10	-0.64	-0.56	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
PCPG	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	8.28	6.13e-14	2.38e-10	0.75	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
PCPG	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-8.28	6.22e-14	2.41e-10	-0.82	-0.56	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-8.28	6.22e-14	2.41e-10	-0.82	-0.56	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
PCPG	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	8.27	6.52e-14	2.52e-10	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
PCPG	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-8.27	6.53e-14	2.53e-10	-0.63	-0.56	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
PCPG	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	8.27	6.56e-14	2.54e-10	0.72	0.56	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
PCPG	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	8.27	6.56e-14	2.54e-10	0.72	0.56	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
PCPG	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	8.27	6.58e-14	2.55e-10	0.85	0.56	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
PCPG	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-8.27	6.62e-14	2.56e-10	-0.71	-0.56	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
PCPG	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-8.27	6.64e-14	2.56e-10	-0.77	-0.56	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-8.27	6.64e-14	2.56e-10	-0.77	-0.56	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-8.27	6.64e-14	2.56e-10	-0.77	-0.56	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
PCPG	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-8.27	6.68e-14	2.58e-10	-0.74	-0.56	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
PCPG	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-8.27	6.68e-14	2.58e-10	-0.74	-0.56	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
PCPG	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	8.27	6.73e-14	2.6e-10	0.76	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	8.27	6.73e-14	2.6e-10	0.76	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
PCPG	cis	rs4835473	0.9	rs10032963	ENSG00000250345.2	RP11-780M14.1	-8.27	6.74e-14	2.6e-10	-0.7	-0.56	Immature fraction of reticulocytes;	chr4:143733068	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-8.27	6.83e-14	2.63e-10	-0.73	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
PCPG	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	8.26	6.94e-14	2.67e-10	0.66	0.56	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	8.26	6.94e-14	2.67e-10	0.66	0.56	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
PCPG	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	8.26	6.94e-14	2.68e-10	0.77	0.56	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
PCPG	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	8.26	6.97e-14	2.69e-10	0.71	0.56	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
PCPG	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-8.26	6.99e-14	2.7e-10	-0.85	-0.56	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
PCPG	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-8.26	7.08e-14	2.73e-10	-0.66	-0.56	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
PCPG	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-8.26	7.13e-14	2.75e-10	-0.74	-0.56	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
PCPG	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-8.26	7.13e-14	2.75e-10	-0.74	-0.56	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
PCPG	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-8.26	7.15e-14	2.75e-10	-0.54	-0.56	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-8.26	7.15e-14	2.75e-10	-0.54	-0.56	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
PCPG	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	8.26	7.18e-14	2.76e-10	0.85	0.56	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
PCPG	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-8.26	7.21e-14	2.77e-10	-0.8	-0.56	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
PCPG	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-8.26	7.23e-14	2.78e-10	-0.65	-0.56	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-8.26	7.23e-14	2.78e-10	-0.65	-0.56	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-8.25	7.29e-14	2.8e-10	-0.65	-0.56	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
PCPG	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	8.25	7.34e-14	2.82e-10	0.77	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
PCPG	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-8.25	7.38e-14	2.83e-10	-0.65	-0.56	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-8.25	7.38e-14	2.83e-10	-0.65	-0.56	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-8.25	7.38e-14	2.83e-10	-0.65	-0.56	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
PCPG	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	8.25	7.45e-14	2.86e-10	0.85	0.56	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
PCPG	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-8.25	7.45e-14	2.86e-10	-0.65	-0.56	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-8.25	7.45e-14	2.86e-10	-0.65	-0.56	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
PCPG	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-8.25	7.57e-14	2.9e-10	-0.78	-0.56	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
PCPG	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	8.25	7.62e-14	2.92e-10	0.72	0.56	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
PCPG	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	8.25	7.62e-14	2.92e-10	0.72	0.56	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
PCPG	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	8.25	7.62e-14	2.92e-10	0.72	0.56	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
PCPG	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-8.25	7.66e-14	2.93e-10	-0.6	-0.56	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-8.25	7.69e-14	2.94e-10	-0.63	-0.56	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
PCPG	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	8.24	7.72e-14	2.95e-10	0.9	0.56	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
PCPG	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	8.24	7.72e-14	2.95e-10	0.9	0.56	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
PCPG	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	8.24	7.72e-14	2.95e-10	0.9	0.56	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
PCPG	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	8.24	7.72e-14	2.95e-10	0.9	0.56	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
PCPG	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	8.24	7.72e-14	2.95e-10	0.9	0.56	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
PCPG	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	8.24	7.72e-14	2.95e-10	0.9	0.56	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
PCPG	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-8.24	7.86e-14	3e-10	-0.73	-0.56	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
PCPG	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	8.24	7.91e-14	3.02e-10	0.76	0.56	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
PCPG	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	8.24	8.05e-14	3.07e-10	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
PCPG	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-8.24	8.09e-14	3.08e-10	-0.62	-0.56	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-8.24	8.09e-14	3.08e-10	-0.62	-0.56	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.808	rs1984810	ENSG00000250345.2	RP11-780M14.1	-8.24	8.09e-14	3.08e-10	-0.69	-0.56	Immature fraction of reticulocytes;	chr4:143824970	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs1984809	ENSG00000250345.2	RP11-780M14.1	-8.24	8.09e-14	3.08e-10	-0.69	-0.56	Immature fraction of reticulocytes;	chr4:143825018	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs10857413	ENSG00000250345.2	RP11-780M14.1	-8.24	8.09e-14	3.08e-10	-0.69	-0.56	Immature fraction of reticulocytes;	chr4:143827752	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6828935	ENSG00000250345.2	RP11-780M14.1	-8.24	8.09e-14	3.08e-10	-0.69	-0.56	Immature fraction of reticulocytes;	chr4:143829113	chr4:143760399~143762093:-
PCPG	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-8.24	8.11e-14	3.09e-10	-0.65	-0.56	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
PCPG	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-8.24	8.13e-14	3.1e-10	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
PCPG	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	8.23	8.37e-14	3.18e-10	0.73	0.56	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
PCPG	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	8.23	8.4e-14	3.19e-10	0.98	0.56	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
PCPG	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	8.23	8.46e-14	3.22e-10	0.75	0.56	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
PCPG	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	8.23	8.49e-14	3.22e-10	0.69	0.56	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	8.23	8.49e-14	3.22e-10	0.69	0.56	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs12512652	ENSG00000250345.2	RP11-780M14.1	8.23	8.54e-14	3.25e-10	0.68	0.56	Immature fraction of reticulocytes;	chr4:143736787	chr4:143760399~143762093:-
PCPG	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	8.23	8.59e-14	3.26e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
PCPG	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	8.22	8.7e-14	3.3e-10	0.83	0.56	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
PCPG	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-8.22	8.73e-14	3.31e-10	-0.66	-0.56	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
PCPG	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	8.22	8.81e-14	3.34e-10	1.03	0.56	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	8.22	8.81e-14	3.34e-10	1.03	0.56	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
PCPG	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	8.22	8.82e-14	3.35e-10	0.64	0.56	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
PCPG	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-8.22	8.87e-14	3.36e-10	-0.74	-0.56	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
PCPG	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-8.22	8.98e-14	3.4e-10	-0.65	-0.56	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	8.22	9.02e-14	3.42e-10	0.74	0.56	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
PCPG	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	8.22	9.12e-14	3.45e-10	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
PCPG	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.21	9.13e-14	3.45e-10	0.55	0.56	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
PCPG	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-8.21	9.17e-14	3.47e-10	-0.65	-0.56	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.897	rs2036880	ENSG00000250345.2	RP11-780M14.1	-8.21	9.21e-14	3.48e-10	-0.7	-0.56	Immature fraction of reticulocytes;	chr4:143907834	chr4:143760399~143762093:-
PCPG	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	8.21	9.23e-14	3.49e-10	0.76	0.56	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
PCPG	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-8.21	9.25e-14	3.49e-10	-0.65	-0.56	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-8.21	9.25e-14	3.49e-10	-0.65	-0.56	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-8.21	9.25e-14	3.49e-10	-0.65	-0.56	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-8.21	9.25e-14	3.49e-10	-0.65	-0.56	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-8.21	9.25e-14	3.49e-10	-0.65	-0.56	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-8.21	9.25e-14	3.49e-10	-0.65	-0.56	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-8.21	9.25e-14	3.49e-10	-0.65	-0.56	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
PCPG	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-8.21	9.25e-14	3.49e-10	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
PCPG	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	8.21	9.3e-14	3.51e-10	0.58	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
PCPG	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	8.21	9.32e-14	3.51e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
PCPG	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-8.21	9.38e-14	3.53e-10	-0.67	-0.56	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
PCPG	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
PCPG	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-8.21	9.41e-14	3.54e-10	-0.65	-0.56	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.897	rs11100812	ENSG00000250345.2	RP11-780M14.1	-8.21	9.41e-14	3.54e-10	-0.69	-0.56	Immature fraction of reticulocytes;	chr4:143790400	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.545	rs10022856	ENSG00000250345.2	RP11-780M14.1	-8.21	9.41e-14	3.54e-10	-0.69	-0.56	Immature fraction of reticulocytes;	chr4:143793157	chr4:143760399~143762093:-
PCPG	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-8.21	9.49e-14	3.56e-10	-0.65	-0.56	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-8.21	9.49e-14	3.56e-10	-0.65	-0.56	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
PCPG	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-8.21	9.57e-14	3.59e-10	-0.63	-0.56	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
PCPG	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-8.21	9.6e-14	3.6e-10	-0.64	-0.56	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
PCPG	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	8.2	9.84e-14	3.69e-10	1.07	0.56	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
PCPG	cis	rs2075277	1	rs2075278	ENSG00000207575.1	MIR649	8.2	9.86e-14	3.69e-10	0.95	0.56	Eosinophilic esophagitis;	chr22:21028993	chr22:21034176~21034272:-
PCPG	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-8.2	9.89e-14	3.7e-10	-0.77	-0.56	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
PCPG	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	8.2	9.89e-14	3.7e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	8.2	9.89e-14	3.7e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	8.2	9.89e-14	3.7e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	8.2	9.89e-14	3.7e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
PCPG	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-8.2	9.93e-14	3.71e-10	-0.71	-0.56	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
PCPG	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-8.2	1e-13	3.75e-10	-0.65	-0.56	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
PCPG	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	8.2	1.01e-13	3.75e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	8.2	1.01e-13	3.75e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	8.2	1.01e-13	3.75e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	8.2	1.01e-13	3.75e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	8.2	1.01e-13	3.75e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	8.2	1.01e-13	3.75e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	8.2	1.02e-13	3.79e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	8.2	1.02e-13	3.79e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	8.2	1.02e-13	3.79e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	8.2	1.02e-13	3.79e-10	0.67	0.56	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
PCPG	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	8.19	1.04e-13	3.86e-10	0.81	0.56	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-8.19	1.04e-13	3.86e-10	-0.81	-0.56	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-8.19	1.04e-13	3.86e-10	-0.81	-0.56	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-8.19	1.04e-13	3.86e-10	-0.81	-0.56	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
PCPG	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	8.19	1.04e-13	3.88e-10	0.86	0.56	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
PCPG	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-8.19	1.05e-13	3.89e-10	-0.63	-0.56	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
PCPG	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-8.19	1.05e-13	3.9e-10	-0.78	-0.56	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
PCPG	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	8.19	1.05e-13	3.91e-10	0.71	0.56	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
PCPG	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	8.19	1.05e-13	3.91e-10	0.71	0.56	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
PCPG	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-8.19	1.07e-13	3.97e-10	-0.76	-0.56	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
PCPG	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	8.19	1.07e-13	3.98e-10	0.82	0.56	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	8.19	1.07e-13	3.98e-10	0.82	0.56	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	8.19	1.07e-13	3.98e-10	0.82	0.56	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
PCPG	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	8.19	1.07e-13	3.98e-10	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
PCPG	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-8.19	1.08e-13	3.99e-10	-0.77	-0.56	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
PCPG	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	8.18	1.12e-13	4.14e-10	0.65	0.56	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
PCPG	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	8.18	1.12e-13	4.16e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	8.18	1.12e-13	4.16e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	8.18	1.12e-13	4.16e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	8.18	1.12e-13	4.16e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	8.18	1.12e-13	4.16e-10	0.68	0.56	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
PCPG	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	8.18	1.14e-13	4.2e-10	0.63	0.56	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-8.18	1.14e-13	4.21e-10	-0.63	-0.56	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
PCPG	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	8.17	1.17e-13	4.31e-10	0.89	0.56	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	8.17	1.17e-13	4.31e-10	0.73	0.56	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
PCPG	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-8.17	1.17e-13	4.33e-10	-0.63	-0.56	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
PCPG	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	8.17	1.19e-13	4.38e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
PCPG	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	8.17	1.19e-13	4.4e-10	0.74	0.55	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
PCPG	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	8.17	1.2e-13	4.4e-10	0.84	0.55	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
PCPG	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	8.17	1.2e-13	4.43e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	8.17	1.2e-13	4.43e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	8.17	1.2e-13	4.43e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	8.17	1.2e-13	4.43e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	8.17	1.2e-13	4.43e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
PCPG	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-8.17	1.21e-13	4.45e-10	-0.65	-0.55	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
PCPG	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	8.16	1.22e-13	4.47e-10	0.71	0.55	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
PCPG	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	8.16	1.22e-13	4.49e-10	0.82	0.55	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
PCPG	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-8.16	1.25e-13	4.59e-10	-0.64	-0.55	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
PCPG	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	8.16	1.27e-13	4.66e-10	0.87	0.55	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
PCPG	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	8.16	1.28e-13	4.66e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
PCPG	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-8.15	1.29e-13	4.71e-10	-0.81	-0.55	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
PCPG	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	8.15	1.32e-13	4.83e-10	0.57	0.55	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
PCPG	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	8.15	1.34e-13	4.9e-10	0.89	0.55	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
PCPG	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	8.15	1.36e-13	4.97e-10	0.54	0.55	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
PCPG	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-8.15	1.36e-13	4.97e-10	-0.77	-0.55	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
PCPG	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-8.14	1.37e-13	5e-10	-0.72	-0.55	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
PCPG	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	8.14	1.37e-13	5e-10	0.53	0.55	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
PCPG	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-8.14	1.38e-13	5.02e-10	-0.66	-0.55	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
PCPG	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	8.14	1.38e-13	5.03e-10	0.77	0.55	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
PCPG	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	8.14	1.41e-13	5.14e-10	0.88	0.55	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	8.14	1.41e-13	5.14e-10	0.88	0.55	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	8.14	1.41e-13	5.14e-10	0.88	0.55	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	8.14	1.41e-13	5.14e-10	0.88	0.55	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
PCPG	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-8.14	1.42e-13	5.16e-10	-0.63	-0.55	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	8.13	1.45e-13	5.25e-10	0.74	0.55	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
PCPG	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-8.13	1.45e-13	5.26e-10	-0.64	-0.55	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	8.13	1.46e-13	5.31e-10	0.74	0.55	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
PCPG	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-8.13	1.48e-13	5.36e-10	-0.73	-0.55	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
PCPG	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-8.13	1.48e-13	5.37e-10	-0.72	-0.55	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
PCPG	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	8.13	1.49e-13	5.39e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
PCPG	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	8.13	1.5e-13	5.42e-10	0.68	0.55	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
PCPG	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	8.13	1.5e-13	5.44e-10	0.74	0.55	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
PCPG	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	8.13	1.51e-13	5.46e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	8.13	1.51e-13	5.46e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	8.13	1.51e-13	5.46e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	8.13	1.51e-13	5.46e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	8.13	1.51e-13	5.46e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	8.13	1.51e-13	5.46e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
PCPG	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	8.13	1.52e-13	5.47e-10	0.89	0.55	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
PCPG	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-8.12	1.54e-13	5.57e-10	-0.65	-0.55	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-8.12	1.54e-13	5.57e-10	-0.65	-0.55	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
PCPG	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	8.12	1.55e-13	5.58e-10	0.73	0.55	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
PCPG	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-8.12	1.58e-13	5.68e-10	-0.65	-0.55	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
PCPG	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	8.12	1.58e-13	5.69e-10	0.71	0.55	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
PCPG	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	8.12	1.6e-13	5.76e-10	0.55	0.55	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
PCPG	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-8.12	1.61e-13	5.78e-10	-0.73	-0.55	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-8.12	1.61e-13	5.78e-10	-0.73	-0.55	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
PCPG	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	8.12	1.61e-13	5.79e-10	0.64	0.55	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
PCPG	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-8.11	1.63e-13	5.83e-10	-0.76	-0.55	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
PCPG	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	8.11	1.63e-13	5.83e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	8.11	1.63e-13	5.83e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	8.11	1.63e-13	5.83e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	8.11	1.63e-13	5.83e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	8.11	1.63e-13	5.83e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
PCPG	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-8.11	1.63e-13	5.85e-10	-0.77	-0.55	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
PCPG	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	8.11	1.65e-13	5.9e-10	0.7	0.55	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	8.11	1.65e-13	5.9e-10	0.7	0.55	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
PCPG	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	8.11	1.65e-13	5.9e-10	0.74	0.55	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
PCPG	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	8.11	1.71e-13	6.12e-10	0.7	0.55	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
PCPG	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-8.11	1.71e-13	6.13e-10	-0.68	-0.55	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
PCPG	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	8.1	1.73e-13	6.16e-10	0.6	0.55	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
PCPG	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	8.1	1.75e-13	6.23e-10	0.74	0.55	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	8.1	1.75e-13	6.23e-10	0.74	0.55	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	8.1	1.75e-13	6.23e-10	0.74	0.55	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
PCPG	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	8.1	1.75e-13	6.24e-10	0.71	0.55	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
PCPG	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	8.1	1.76e-13	6.27e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	8.1	1.76e-13	6.27e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	8.1	1.76e-13	6.27e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	8.1	1.76e-13	6.27e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	8.1	1.76e-13	6.27e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	8.1	1.76e-13	6.27e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
PCPG	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	8.09	1.83e-13	6.49e-10	1.06	0.55	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
PCPG	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	8.09	1.83e-13	6.5e-10	0.69	0.55	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
PCPG	cis	rs4835473	0.712	rs12509607	ENSG00000250345.2	RP11-780M14.1	8.09	1.83e-13	6.5e-10	0.67	0.55	Immature fraction of reticulocytes;	chr4:143736894	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.712	rs12498218	ENSG00000250345.2	RP11-780M14.1	8.09	1.83e-13	6.5e-10	0.67	0.55	Immature fraction of reticulocytes;	chr4:143736900	chr4:143760399~143762093:-
PCPG	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	8.09	1.84e-13	6.52e-10	0.58	0.55	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
PCPG	cis	rs4835473	0.932	rs10030428	ENSG00000250345.2	RP11-780M14.1	-8.09	1.85e-13	6.57e-10	-0.69	-0.55	Immature fraction of reticulocytes;	chr4:143762699	chr4:143760399~143762093:-
PCPG	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-8.09	1.86e-13	6.58e-10	-0.66	-0.55	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
PCPG	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-8.09	1.86e-13	6.58e-10	-0.62	-0.55	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
PCPG	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	8.09	1.88e-13	6.67e-10	0.74	0.55	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
PCPG	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-8.09	1.92e-13	6.79e-10	-0.62	-0.55	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-8.09	1.92e-13	6.79e-10	-0.62	-0.55	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-8.09	1.92e-13	6.79e-10	-0.62	-0.55	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-8.09	1.92e-13	6.79e-10	-0.62	-0.55	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-8.09	1.92e-13	6.79e-10	-0.62	-0.55	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-8.09	1.92e-13	6.79e-10	-0.62	-0.55	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	8.09	1.92e-13	6.79e-10	0.62	0.55	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
PCPG	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	8.08	1.95e-13	6.88e-10	0.56	0.55	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
PCPG	cis	rs4835473	0.571	rs1992656	ENSG00000250345.2	RP11-780M14.1	-8.08	1.98e-13	6.97e-10	-0.67	-0.55	Immature fraction of reticulocytes;	chr4:143855286	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.571	rs1992655	ENSG00000250345.2	RP11-780M14.1	-8.08	1.98e-13	6.97e-10	-0.67	-0.55	Immature fraction of reticulocytes;	chr4:143855290	chr4:143760399~143762093:-
PCPG	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	8.08	1.99e-13	6.99e-10	0.65	0.55	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
PCPG	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-8.08	1.99e-13	7e-10	-0.63	-0.55	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.838	rs12507468	ENSG00000250345.2	RP11-780M14.1	8.08	1.99e-13	7e-10	0.69	0.55	Immature fraction of reticulocytes;	chr4:143908061	chr4:143760399~143762093:-
PCPG	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	8.08	2.01e-13	7.06e-10	0.56	0.55	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
PCPG	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	8.08	2.01e-13	7.07e-10	0.69	0.55	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	8.08	2.01e-13	7.07e-10	0.69	0.55	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
PCPG	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	8.08	2.01e-13	7.07e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	8.08	2.01e-13	7.07e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	8.08	2.01e-13	7.07e-10	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
PCPG	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	8.08	2.02e-13	7.1e-10	0.85	0.55	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
PCPG	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-8.08	2.03e-13	7.14e-10	-0.7	-0.55	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
PCPG	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	8.07	2.06e-13	7.22e-10	0.69	0.55	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
PCPG	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	8.07	2.08e-13	7.31e-10	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
PCPG	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-8.07	2.1e-13	7.35e-10	-0.63	-0.55	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-8.07	2.1e-13	7.35e-10	-0.63	-0.55	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-8.07	2.1e-13	7.35e-10	-0.63	-0.55	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-8.07	2.1e-13	7.35e-10	-0.63	-0.55	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-8.07	2.1e-13	7.35e-10	-0.63	-0.55	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
PCPG	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-8.07	2.12e-13	7.42e-10	-0.7	-0.55	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
PCPG	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	8.07	2.12e-13	7.42e-10	0.84	0.55	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	8.07	2.12e-13	7.42e-10	0.84	0.55	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
PCPG	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	8.07	2.12e-13	7.42e-10	0.73	0.55	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	8.07	2.12e-13	7.42e-10	0.73	0.55	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	8.07	2.12e-13	7.42e-10	0.73	0.55	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
PCPG	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-8.07	2.13e-13	7.45e-10	-0.66	-0.55	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
PCPG	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-8.07	2.13e-13	7.45e-10	-0.66	-0.55	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-8.07	2.13e-13	7.45e-10	-0.66	-0.55	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
PCPG	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	8.06	2.17e-13	7.61e-10	0.56	0.55	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	8.06	2.17e-13	7.61e-10	0.56	0.55	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
PCPG	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-8.06	2.19e-13	7.67e-10	-0.7	-0.55	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
PCPG	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	8.06	2.2e-13	7.69e-10	0.73	0.55	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	8.06	2.2e-13	7.69e-10	0.73	0.55	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	8.06	2.2e-13	7.69e-10	0.73	0.55	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
PCPG	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.06	2.22e-13	7.75e-10	0.55	0.55	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
PCPG	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-8.06	2.22e-13	7.76e-10	-0.74	-0.55	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	8.06	2.22e-13	7.76e-10	0.74	0.55	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
PCPG	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	8.05	2.31e-13	8.05e-10	0.9	0.55	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	8.05	2.33e-13	8.12e-10	0.71	0.55	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
PCPG	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	8.05	2.33e-13	8.13e-10	0.89	0.55	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
PCPG	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-8.05	2.34e-13	8.16e-10	-0.66	-0.55	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
PCPG	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	8.05	2.37e-13	8.24e-10	0.65	0.55	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
PCPG	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	8.05	2.37e-13	8.24e-10	0.65	0.55	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
PCPG	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	8.05	2.37e-13	8.24e-10	0.65	0.55	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.932	rs2323200	ENSG00000250345.2	RP11-780M14.1	-8.05	2.37e-13	8.25e-10	-0.71	-0.55	Immature fraction of reticulocytes;	chr4:143765448	chr4:143760399~143762093:-
PCPG	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-8.05	2.37e-13	8.25e-10	-0.69	-0.55	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-8.05	2.37e-13	8.25e-10	-0.69	-0.55	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-8.05	2.37e-13	8.25e-10	-0.69	-0.55	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
PCPG	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	8.05	2.4e-13	8.33e-10	1.05	0.55	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
PCPG	cis	rs4835473	0.932	rs7697916	ENSG00000250345.2	RP11-780M14.1	8.05	2.4e-13	8.33e-10	0.72	0.55	Immature fraction of reticulocytes;	chr4:143765628	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	8.05	2.41e-13	8.36e-10	0.69	0.55	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
PCPG	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	8.04	2.43e-13	8.43e-10	0.73	0.55	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	8.04	2.44e-13	8.46e-10	0.69	0.55	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
PCPG	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-8.04	2.45e-13	8.51e-10	-0.71	-0.55	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
PCPG	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	8.04	2.46e-13	8.54e-10	0.75	0.55	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
PCPG	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	8.04	2.51e-13	8.69e-10	0.71	0.55	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
PCPG	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	8.04	2.55e-13	8.81e-10	0.8	0.55	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
PCPG	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	8.04	2.56e-13	8.83e-10	0.69	0.55	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	8.04	2.56e-13	8.83e-10	0.69	0.55	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
PCPG	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	8.03	2.57e-13	8.87e-10	0.84	0.55	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	8.03	2.57e-13	8.87e-10	0.84	0.55	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	8.03	2.57e-13	8.87e-10	0.84	0.55	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
PCPG	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	8.03	2.57e-13	8.89e-10	0.72	0.55	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
PCPG	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	8.03	2.6e-13	8.97e-10	0.48	0.55	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
PCPG	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-8.03	2.6e-13	8.98e-10	-0.63	-0.55	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
PCPG	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	8.03	2.6e-13	8.99e-10	0.69	0.55	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
PCPG	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	8.03	2.62e-13	9.03e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	8.03	2.62e-13	9.03e-10	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
PCPG	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-8.03	2.63e-13	9.06e-10	-0.62	-0.55	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
PCPG	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-8.03	2.65e-13	9.13e-10	-0.73	-0.55	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
PCPG	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	8.03	2.68e-13	9.25e-10	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
PCPG	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-8.02	2.71e-13	9.34e-10	-0.72	-0.55	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
PCPG	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-8.02	2.71e-13	9.34e-10	-0.63	-0.55	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
PCPG	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	8.02	2.72e-13	9.37e-10	0.66	0.55	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	8.02	2.72e-13	9.37e-10	0.66	0.55	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	8.02	2.77e-13	9.53e-10	0.69	0.55	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	8.02	2.77e-13	9.53e-10	0.69	0.55	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
PCPG	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	8.02	2.78e-13	9.57e-10	0.71	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
PCPG	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	8.02	2.8e-13	9.61e-10	0.73	0.55	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	8.02	2.8e-13	9.61e-10	0.73	0.55	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	8.02	2.8e-13	9.61e-10	0.73	0.55	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	8.02	2.8e-13	9.61e-10	0.73	0.55	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	8.02	2.8e-13	9.61e-10	0.73	0.55	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	8.02	2.8e-13	9.61e-10	0.73	0.55	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	8.02	2.8e-13	9.61e-10	0.73	0.55	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
PCPG	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	8.02	2.82e-13	9.7e-10	0.66	0.55	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	8.02	2.82e-13	9.7e-10	0.69	0.55	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
PCPG	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-8.02	2.87e-13	9.85e-10	-0.7	-0.55	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
PCPG	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	8.01	2.91e-13	9.97e-10	0.72	0.55	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	8.01	2.91e-13	9.97e-10	0.72	0.55	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
PCPG	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-8.01	2.96e-13	1.02e-09	-0.81	-0.55	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
PCPG	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	8	3.05e-13	1.04e-09	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	8	3.05e-13	1.04e-09	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	8	3.05e-13	1.04e-09	0.69	0.55	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	8	3.05e-13	1.04e-09	0.69	0.55	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	8	3.05e-13	1.04e-09	0.69	0.55	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
PCPG	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	8	3.1e-13	1.06e-09	0.8	0.55	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
PCPG	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-8	3.1e-13	1.06e-09	-0.72	-0.55	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
PCPG	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-8	3.1e-13	1.06e-09	-0.72	-0.55	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
PCPG	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-8	3.1e-13	1.06e-09	-0.72	-0.55	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
PCPG	cis	rs4835473	0.868	rs1822841	ENSG00000250345.2	RP11-780M14.1	-8	3.1e-13	1.06e-09	-0.67	-0.55	Immature fraction of reticulocytes;	chr4:143921485	chr4:143760399~143762093:-
PCPG	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	8	3.13e-13	1.07e-09	0.68	0.55	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
PCPG	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	8	3.15e-13	1.08e-09	0.73	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
PCPG	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	8	3.16e-13	1.08e-09	0.73	0.55	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
PCPG	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	8	3.19e-13	1.09e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
PCPG	cis	rs4835473	0.932	rs1450235	ENSG00000250345.2	RP11-780M14.1	-7.99	3.24e-13	1.1e-09	-0.68	-0.55	Immature fraction of reticulocytes;	chr4:143782927	chr4:143760399~143762093:-
PCPG	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	7.99	3.25e-13	1.11e-09	0.63	0.55	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.897	rs6537167	ENSG00000250345.2	RP11-780M14.1	-7.99	3.27e-13	1.11e-09	-0.68	-0.55	Immature fraction of reticulocytes;	chr4:143691323	chr4:143760399~143762093:-
PCPG	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	7.99	3.29e-13	1.12e-09	0.75	0.55	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
PCPG	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-7.99	3.3e-13	1.12e-09	-0.58	-0.55	Breast cancer;	chr11:825777	chr11:779617~780755:+
PCPG	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-7.99	3.37e-13	1.14e-09	-0.61	-0.55	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
PCPG	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-7.99	3.37e-13	1.14e-09	-0.76	-0.55	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
PCPG	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-7.98	3.4e-13	1.16e-09	-0.73	-0.55	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
PCPG	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	7.98	3.42e-13	1.16e-09	0.58	0.55	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
PCPG	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-7.98	3.43e-13	1.16e-09	-0.68	-0.55	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
PCPG	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-7.98	3.43e-13	1.16e-09	-0.63	-0.55	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
PCPG	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-7.98	3.45e-13	1.17e-09	-0.65	-0.55	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
PCPG	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	7.98	3.48e-13	1.18e-09	0.74	0.55	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-7.98	3.53e-13	1.2e-09	-0.68	-0.55	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	7.98	3.54e-13	1.2e-09	0.72	0.55	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
PCPG	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	7.98	3.57e-13	1.21e-09	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
PCPG	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	7.98	3.57e-13	1.21e-09	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
PCPG	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-7.97	3.62e-13	1.22e-09	-0.65	-0.55	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
PCPG	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	7.97	3.65e-13	1.24e-09	0.67	0.55	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
PCPG	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	7.97	3.75e-13	1.27e-09	0.9	0.55	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
PCPG	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	7.97	3.76e-13	1.27e-09	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
PCPG	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-7.97	3.78e-13	1.28e-09	-0.75	-0.55	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
PCPG	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-7.96	3.81e-13	1.29e-09	-0.64	-0.55	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-7.96	3.84e-13	1.29e-09	-0.64	-0.55	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
PCPG	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	7.96	3.84e-13	1.29e-09	0.84	0.55	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
PCPG	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	7.96	3.85e-13	1.3e-09	0.73	0.55	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
PCPG	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-7.96	3.87e-13	1.3e-09	-0.56	-0.55	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
PCPG	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	7.96	3.87e-13	1.3e-09	0.87	0.55	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
PCPG	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	7.96	3.9e-13	1.31e-09	0.68	0.54	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
PCPG	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	7.96	3.91e-13	1.31e-09	0.73	0.54	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
PCPG	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	7.96	3.94e-13	1.32e-09	0.56	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	7.96	3.94e-13	1.32e-09	0.56	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
PCPG	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	7.96	3.98e-13	1.33e-09	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
PCPG	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-7.96	3.98e-13	1.33e-09	-0.7	-0.54	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
PCPG	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	7.95	4.07e-13	1.36e-09	0.62	0.54	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
PCPG	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-7.95	4.1e-13	1.37e-09	-0.78	-0.54	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-7.95	4.1e-13	1.37e-09	-0.78	-0.54	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
PCPG	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-7.95	4.1e-13	1.37e-09	-0.78	-0.54	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
PCPG	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	7.95	4.1e-13	1.37e-09	0.64	0.54	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
PCPG	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	7.95	4.11e-13	1.37e-09	0.66	0.54	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	7.95	4.11e-13	1.37e-09	0.71	0.54	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
PCPG	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	7.95	4.12e-13	1.37e-09	0.81	0.54	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
PCPG	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-7.95	4.13e-13	1.38e-09	-0.63	-0.54	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
PCPG	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	7.95	4.2e-13	1.4e-09	0.56	0.54	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
PCPG	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	7.95	4.21e-13	1.4e-09	1.06	0.54	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	7.95	4.21e-13	1.4e-09	1.06	0.54	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
PCPG	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	7.95	4.21e-13	1.4e-09	0.69	0.54	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
PCPG	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.94	4.3e-13	1.43e-09	-0.65	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
PCPG	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-7.94	4.3e-13	1.43e-09	-0.65	-0.54	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
PCPG	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	7.94	4.36e-13	1.45e-09	0.69	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
PCPG	cis	rs4835473	0.863	rs7696828	ENSG00000250345.2	RP11-780M14.1	-7.94	4.38e-13	1.46e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143700846	chr4:143760399~143762093:-
PCPG	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-7.94	4.39e-13	1.46e-09	-0.63	-0.54	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
PCPG	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-7.94	4.43e-13	1.47e-09	-0.79	-0.54	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
PCPG	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-7.94	4.43e-13	1.47e-09	-0.69	-0.54	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
PCPG	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-7.94	4.45e-13	1.48e-09	-0.58	-0.54	Height;	chr3:53070344	chr3:53064283~53065091:-
PCPG	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-7.93	4.56e-13	1.51e-09	-0.6	-0.54	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
PCPG	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-7.93	4.58e-13	1.52e-09	-0.71	-0.54	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
PCPG	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-7.93	4.62e-13	1.53e-09	-0.65	-0.54	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
PCPG	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	7.93	4.63e-13	1.53e-09	0.57	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
PCPG	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-7.93	4.66e-13	1.54e-09	-0.63	-0.54	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-7.93	4.66e-13	1.54e-09	-0.63	-0.54	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-7.93	4.66e-13	1.54e-09	-0.63	-0.54	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
PCPG	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-7.93	4.69e-13	1.55e-09	-0.64	-0.54	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-7.93	4.69e-13	1.55e-09	-0.64	-0.54	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-7.93	4.69e-13	1.55e-09	-0.64	-0.54	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-7.93	4.69e-13	1.55e-09	-0.64	-0.54	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
PCPG	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	7.93	4.75e-13	1.57e-09	1	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
PCPG	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	7.93	4.75e-13	1.57e-09	1	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
PCPG	cis	rs7267979	0.789	rs6083820	ENSG00000125804.12	FAM182A	7.93	4.75e-13	1.57e-09	0.67	0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26054655~26086917:+
PCPG	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-7.92	4.83e-13	1.59e-09	-0.65	-0.54	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	7.92	4.84e-13	1.6e-09	0.68	0.54	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	7.92	4.84e-13	1.6e-09	0.68	0.54	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	7.92	4.85e-13	1.6e-09	0.68	0.54	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	7.92	4.85e-13	1.6e-09	0.68	0.54	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	7.92	4.85e-13	1.6e-09	0.68	0.54	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
PCPG	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	7.92	4.98e-13	1.64e-09	0.66	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
PCPG	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-7.92	4.98e-13	1.64e-09	-0.63	-0.54	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
PCPG	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	7.92	5.05e-13	1.66e-09	0.62	0.54	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
PCPG	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-7.92	5.06e-13	1.66e-09	-0.76	-0.54	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-7.92	5.06e-13	1.66e-09	-0.76	-0.54	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-7.92	5.06e-13	1.66e-09	-0.76	-0.54	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
PCPG	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-7.91	5.07e-13	1.67e-09	-0.6	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
PCPG	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	7.91	5.12e-13	1.68e-09	0.63	0.54	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
PCPG	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	7.91	5.13e-13	1.68e-09	0.66	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
PCPG	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	7.91	5.25e-13	1.72e-09	0.68	0.54	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
PCPG	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	7.91	5.27e-13	1.73e-09	0.79	0.54	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
PCPG	cis	rs4835473	0.797	rs34585546	ENSG00000250345.2	RP11-780M14.1	7.91	5.28e-13	1.73e-09	0.7	0.54	Immature fraction of reticulocytes;	chr4:143680693	chr4:143760399~143762093:-
PCPG	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	7.91	5.33e-13	1.74e-09	0.73	0.54	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
PCPG	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	7.91	5.34e-13	1.74e-09	0.57	0.54	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
PCPG	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	7.91	5.34e-13	1.75e-09	0.73	0.54	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
PCPG	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-7.9	5.43e-13	1.78e-09	-0.75	-0.54	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
PCPG	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	7.9	5.44e-13	1.78e-09	0.57	0.54	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
PCPG	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	7.9	5.44e-13	1.78e-09	0.72	0.54	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	7.9	5.44e-13	1.78e-09	0.72	0.54	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	7.9	5.44e-13	1.78e-09	0.72	0.54	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs13103072	ENSG00000250345.2	RP11-780M14.1	7.9	5.47e-13	1.78e-09	0.66	0.54	Immature fraction of reticulocytes;	chr4:143952116	chr4:143760399~143762093:-
PCPG	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	7.9	5.5e-13	1.79e-09	0.74	0.54	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
PCPG	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	7.9	5.5e-13	1.8e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
PCPG	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.9	5.52e-13	1.8e-09	-0.72	-0.54	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
PCPG	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	7.9	5.53e-13	1.8e-09	0.53	0.54	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
PCPG	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	7.9	5.53e-13	1.81e-09	0.79	0.54	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
PCPG	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	7.89	5.68e-13	1.85e-09	0.76	0.54	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	7.89	5.68e-13	1.85e-09	0.76	0.54	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
PCPG	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	7.89	5.69e-13	1.85e-09	0.57	0.54	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
PCPG	cis	rs4835473	0.932	rs1849135	ENSG00000250345.2	RP11-780M14.1	7.89	5.69e-13	1.85e-09	0.68	0.54	Immature fraction of reticulocytes;	chr4:143912279	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1849136	ENSG00000250345.2	RP11-780M14.1	7.89	5.69e-13	1.85e-09	0.68	0.54	Immature fraction of reticulocytes;	chr4:143912380	chr4:143760399~143762093:-
PCPG	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	7.89	5.7e-13	1.86e-09	0.83	0.54	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
PCPG	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-7.89	5.75e-13	1.87e-09	-0.63	-0.54	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
PCPG	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-7.89	5.76e-13	1.87e-09	-0.78	-0.54	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
PCPG	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-7.89	5.82e-13	1.89e-09	-0.66	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
PCPG	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-7.89	5.82e-13	1.89e-09	-0.63	-0.54	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
PCPG	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-7.89	5.82e-13	1.89e-09	-0.63	-0.54	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
PCPG	cis	rs4835473	0.864	rs1597446	ENSG00000250345.2	RP11-780M14.1	-7.89	5.82e-13	1.89e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143708338	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.835	rs1450247	ENSG00000250345.2	RP11-780M14.1	-7.89	5.82e-13	1.89e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143708529	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs7687317	ENSG00000250345.2	RP11-780M14.1	-7.89	5.82e-13	1.89e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143709010	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs6537171	ENSG00000250345.2	RP11-780M14.1	-7.89	5.82e-13	1.89e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143709222	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs6832722	ENSG00000250345.2	RP11-780M14.1	-7.89	5.82e-13	1.89e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143709430	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	7.89	5.82e-13	1.89e-09	0.67	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
PCPG	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	7.89	5.83e-13	1.89e-09	0.55	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
PCPG	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	7.89	5.87e-13	1.9e-09	0.62	0.54	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
PCPG	cis	rs4835473	0.897	rs28825455	ENSG00000250345.2	RP11-780M14.1	-7.89	5.9e-13	1.91e-09	-0.68	-0.54	Immature fraction of reticulocytes;	chr4:143707593	chr4:143760399~143762093:-
PCPG	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-7.89	5.92e-13	1.91e-09	-0.7	-0.54	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
PCPG	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	7.89	5.93e-13	1.92e-09	0.54	0.54	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
PCPG	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	7.89	5.93e-13	1.92e-09	0.78	0.54	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
PCPG	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	7.88	6.02e-13	1.95e-09	0.62	0.54	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
PCPG	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	7.88	6.03e-13	1.95e-09	0.62	0.54	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
PCPG	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	7.88	6.04e-13	1.95e-09	0.73	0.54	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	7.88	6.04e-13	1.95e-09	0.73	0.54	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	7.88	6.04e-13	1.95e-09	0.73	0.54	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	7.88	6.04e-13	1.95e-09	0.73	0.54	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	7.88	6.06e-13	1.95e-09	0.68	0.54	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	7.88	6.09e-13	1.96e-09	0.62	0.54	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
PCPG	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	7.88	6.17e-13	1.99e-09	0.78	0.54	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
PCPG	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	7.88	6.18e-13	1.99e-09	0.82	0.54	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
PCPG	cis	rs7267979	0.657	rs6107073	ENSG00000125804.12	FAM182A	-7.88	6.18e-13	1.99e-09	-0.67	-0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:26054655~26086917:+
PCPG	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	7.88	6.27e-13	2.02e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	7.88	6.27e-13	2.02e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
PCPG	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-7.88	6.31e-13	2.03e-09	-0.6	-0.54	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-7.88	6.31e-13	2.03e-09	-0.6	-0.54	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-7.88	6.31e-13	2.03e-09	-0.6	-0.54	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-7.88	6.31e-13	2.03e-09	-0.6	-0.54	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-7.88	6.31e-13	2.03e-09	-0.6	-0.54	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
PCPG	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	7.87	6.38e-13	2.05e-09	0.63	0.54	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
PCPG	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	7.87	6.52e-13	2.09e-09	0.74	0.54	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
PCPG	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	7.87	6.59e-13	2.11e-09	0.69	0.54	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
PCPG	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	7.87	6.7e-13	2.15e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	7.87	6.7e-13	2.15e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	7.87	6.7e-13	2.15e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
PCPG	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	7.87	6.71e-13	2.15e-09	0.61	0.54	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
PCPG	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	7.86	6.74e-13	2.16e-09	0.64	0.54	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
PCPG	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-7.86	6.76e-13	2.16e-09	-0.78	-0.54	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	7.86	6.76e-13	2.16e-09	0.78	0.54	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	7.86	6.76e-13	2.16e-09	0.78	0.54	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	7.86	6.76e-13	2.16e-09	0.78	0.54	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	7.86	6.76e-13	2.16e-09	0.78	0.54	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	7.86	6.76e-13	2.16e-09	0.78	0.54	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	7.86	6.76e-13	2.16e-09	0.78	0.54	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	7.86	6.76e-13	2.16e-09	0.78	0.54	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
PCPG	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	7.86	6.77e-13	2.17e-09	0.51	0.54	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
PCPG	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	7.86	6.77e-13	2.17e-09	0.7	0.54	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-7.86	6.87e-13	2.2e-09	-0.74	-0.54	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-7.86	6.87e-13	2.2e-09	-0.74	-0.54	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-7.86	6.87e-13	2.2e-09	-0.74	-0.54	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	7.86	6.88e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
PCPG	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	7.86	6.9e-13	2.2e-09	0.77	0.54	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
PCPG	cis	rs4835473	0.864	rs57648439	ENSG00000250345.2	RP11-780M14.1	7.86	6.91e-13	2.2e-09	0.68	0.54	Immature fraction of reticulocytes;	chr4:143691519	chr4:143760399~143762093:-
PCPG	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	7.86	6.94e-13	2.2e-09	0.56	0.54	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	7.86	6.94e-13	2.2e-09	0.56	0.54	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	7.86	6.94e-13	2.2e-09	0.56	0.54	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
PCPG	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
PCPG	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	7.86	6.94e-13	2.2e-09	0.69	0.54	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	7.86	6.96e-13	2.21e-09	0.72	0.54	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	7.86	6.97e-13	2.21e-09	0.69	0.54	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	7.86	6.99e-13	2.22e-09	0.69	0.54	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	7.86	6.99e-13	2.22e-09	0.69	0.54	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
PCPG	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-7.86	7e-13	2.22e-09	-0.58	-0.54	Height;	chr3:53064759	chr3:53064283~53065091:-
PCPG	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	7.86	7.02e-13	2.22e-09	0.73	0.54	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	7.86	7.04e-13	2.23e-09	0.69	0.54	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.618	rs12499429	ENSG00000250345.2	RP11-780M14.1	7.86	7.09e-13	2.24e-09	0.68	0.54	Immature fraction of reticulocytes;	chr4:143889914	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.801	rs28715976	ENSG00000250345.2	RP11-780M14.1	7.86	7.09e-13	2.24e-09	0.68	0.54	Immature fraction of reticulocytes;	chr4:143891603	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	7.86	7.11e-13	2.25e-09	0.68	0.54	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	7.86	7.11e-13	2.25e-09	0.68	0.54	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
PCPG	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	7.85	7.13e-13	2.26e-09	0.73	0.54	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
PCPG	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	7.85	7.21e-13	2.28e-09	0.56	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
PCPG	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	7.85	7.26e-13	2.29e-09	0.68	0.54	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs2275045	ENSG00000268592.3	RAET1E-AS1	7.85	7.26e-13	2.29e-09	0.68	0.54	Lung cancer;	chr6:149842775	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs9997931	ENSG00000250345.2	RP11-780M14.1	-7.85	7.31e-13	2.31e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143904601	chr4:143760399~143762093:-
PCPG	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-7.85	7.35e-13	2.32e-09	-0.65	-0.54	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
PCPG	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	7.85	7.36e-13	2.32e-09	0.69	0.54	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	7.85	7.38e-13	2.33e-09	0.61	0.54	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
PCPG	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-7.85	7.39e-13	2.33e-09	-0.75	-0.54	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
PCPG	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	7.85	7.4e-13	2.33e-09	0.7	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
PCPG	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	7.85	7.43e-13	2.34e-09	0.56	0.54	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
PCPG	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7.85	7.5e-13	2.36e-09	-0.65	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
PCPG	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	7.84	7.54e-13	2.37e-09	1	0.54	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	7.84	7.54e-13	2.37e-09	1	0.54	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
PCPG	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	7.84	7.56e-13	2.38e-09	0.77	0.54	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	7.84	7.56e-13	2.38e-09	0.77	0.54	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
PCPG	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-7.84	7.58e-13	2.38e-09	-0.69	-0.54	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
PCPG	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	7.84	7.64e-13	2.4e-09	0.75	0.54	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
PCPG	cis	rs7267979	0.789	rs62213729	ENSG00000125804.12	FAM182A	7.84	7.67e-13	2.41e-09	0.66	0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26054655~26086917:+
PCPG	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	7.84	7.67e-13	2.41e-09	0.74	0.54	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	7.84	7.67e-13	2.41e-09	0.74	0.54	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
PCPG	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-7.84	7.68e-13	2.41e-09	-0.66	-0.54	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	7.84	7.76e-13	2.44e-09	0.69	0.54	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	7.84	7.79e-13	2.45e-09	0.68	0.54	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	7.84	7.79e-13	2.45e-09	0.68	0.54	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	7.84	7.79e-13	2.45e-09	0.68	0.54	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	7.84	7.79e-13	2.45e-09	0.62	0.54	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
PCPG	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	7.84	7.83e-13	2.46e-09	0.57	0.54	Height;	chr3:53072864	chr3:53064283~53065091:-
PCPG	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	7.83	7.96e-13	2.5e-09	0.67	0.54	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
PCPG	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-7.83	8.03e-13	2.51e-09	-0.74	-0.54	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-7.83	8.03e-13	2.51e-09	-0.74	-0.54	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-7.83	8.03e-13	2.51e-09	-0.74	-0.54	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-7.83	8.03e-13	2.51e-09	-0.74	-0.54	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-7.83	8.03e-13	2.51e-09	-0.74	-0.54	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-7.83	8.03e-13	2.51e-09	-0.74	-0.54	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
PCPG	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-7.83	8.06e-13	2.52e-09	-0.62	-0.54	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
PCPG	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	7.83	8.07e-13	2.52e-09	0.69	0.54	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	7.83	8.07e-13	2.52e-09	0.69	0.54	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	7.83	8.07e-13	2.52e-09	0.69	0.54	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	7.83	8.07e-13	2.52e-09	0.69	0.54	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	7.83	8.07e-13	2.52e-09	0.69	0.54	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	7.83	8.07e-13	2.52e-09	0.69	0.54	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-7.83	8.08e-13	2.52e-09	-0.62	-0.54	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	7.83	8.08e-13	2.52e-09	0.62	0.54	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
PCPG	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	7.83	8.09e-13	2.52e-09	0.68	0.54	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
PCPG	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-7.83	8.25e-13	2.57e-09	-0.67	-0.54	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
PCPG	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-7.83	8.25e-13	2.57e-09	-0.63	-0.54	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
PCPG	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	7.83	8.28e-13	2.58e-09	0.64	0.54	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
PCPG	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	7.83	8.31e-13	2.59e-09	0.73	0.54	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	7.83	8.31e-13	2.59e-09	0.73	0.54	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	7.83	8.31e-13	2.59e-09	0.73	0.54	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	7.83	8.31e-13	2.59e-09	0.73	0.54	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
PCPG	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	7.83	8.36e-13	2.6e-09	0.77	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
PCPG	cis	rs4835473	0.897	rs7678190	ENSG00000250345.2	RP11-780M14.1	-7.83	8.42e-13	2.62e-09	-0.68	-0.54	Immature fraction of reticulocytes;	chr4:143722421	chr4:143760399~143762093:-
PCPG	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-7.82	8.43e-13	2.62e-09	-0.61	-0.54	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
PCPG	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	7.82	8.44e-13	2.62e-09	0.51	0.54	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
PCPG	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	7.82	8.44e-13	2.62e-09	0.51	0.54	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
PCPG	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-7.82	8.44e-13	2.62e-09	-0.73	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
PCPG	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-7.82	8.47e-13	2.63e-09	-0.69	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
PCPG	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	7.82	8.48e-13	2.63e-09	0.77	0.54	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	7.82	8.48e-13	2.63e-09	0.77	0.54	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	7.82	8.48e-13	2.63e-09	0.77	0.54	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
PCPG	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	7.82	8.49e-13	2.63e-09	0.7	0.54	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	7.82	8.49e-13	2.63e-09	0.7	0.54	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	7.82	8.49e-13	2.63e-09	0.72	0.54	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
PCPG	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	7.82	8.5e-13	2.63e-09	0.66	0.54	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
PCPG	cis	rs748404	0.518	rs2927085	ENSG00000205771.5	CATSPER2P1	-7.82	8.5e-13	2.63e-09	-0.59	-0.54	Lung cancer;	chr15:43697332	chr15:43726918~43747094:-
PCPG	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	7.82	8.58e-13	2.66e-09	0.71	0.54	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	7.82	8.58e-13	2.66e-09	0.71	0.54	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
PCPG	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-7.82	8.71e-13	2.69e-09	-0.67	-0.54	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
PCPG	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-7.82	8.71e-13	2.69e-09	-0.61	-0.54	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	7.82	8.71e-13	2.69e-09	0.61	0.54	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	7.82	8.71e-13	2.69e-09	0.61	0.54	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
PCPG	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	7.82	8.74e-13	2.7e-09	0.62	0.54	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	7.82	8.74e-13	2.7e-09	0.62	0.54	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	7.82	8.76e-13	2.71e-09	0.71	0.54	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
PCPG	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	7.82	8.9e-13	2.75e-09	0.68	0.54	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
PCPG	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	7.81	8.94e-13	2.76e-09	0.75	0.54	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
PCPG	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	7.81	9.08e-13	2.8e-09	0.61	0.54	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
PCPG	cis	rs4835473	0.897	rs7681914	ENSG00000250345.2	RP11-780M14.1	-7.81	9.2e-13	2.83e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143708838	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs7682096	ENSG00000250345.2	RP11-780M14.1	-7.81	9.2e-13	2.83e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143708892	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs7682128	ENSG00000250345.2	RP11-780M14.1	-7.81	9.2e-13	2.83e-09	-0.67	-0.54	Immature fraction of reticulocytes;	chr4:143708950	chr4:143760399~143762093:-
PCPG	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-7.81	9.21e-13	2.84e-09	-0.67	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
PCPG	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-7.81	9.24e-13	2.84e-09	-0.61	-0.54	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
PCPG	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	7.81	9.25e-13	2.85e-09	0.81	0.54	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
PCPG	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	7.81	9.4e-13	2.89e-09	0.67	0.54	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	7.81	9.4e-13	2.89e-09	0.67	0.54	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
PCPG	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	7.81	9.41e-13	2.89e-09	0.67	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
PCPG	cis	rs7267979	0.702	rs449801	ENSG00000125804.12	FAM182A	-7.8	9.44e-13	2.9e-09	-0.65	-0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:26054655~26086917:+
PCPG	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	7.8	9.59e-13	2.94e-09	0.62	0.54	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	7.8	9.59e-13	2.94e-09	0.62	0.54	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	7.8	9.59e-13	2.94e-09	0.62	0.54	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
PCPG	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	7.8	9.6e-13	2.95e-09	0.8	0.54	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
PCPG	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	7.8	9.62e-13	2.95e-09	0.6	0.54	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
PCPG	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	7.8	9.65e-13	2.96e-09	0.78	0.54	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
PCPG	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-7.8	9.65e-13	2.96e-09	-0.72	-0.54	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
PCPG	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	7.8	9.74e-13	2.98e-09	0.75	0.54	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	7.8	9.74e-13	2.98e-09	0.75	0.54	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
PCPG	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	7.8	9.76e-13	2.98e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	7.8	9.76e-13	2.98e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	7.8	9.76e-13	2.98e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	7.8	9.76e-13	2.98e-09	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
PCPG	cis	rs7267979	0.789	rs2260197	ENSG00000125804.12	FAM182A	-7.8	9.81e-13	3e-09	-0.66	-0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26054655~26086917:+
PCPG	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	7.8	9.85e-13	3.01e-09	0.59	0.54	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
PCPG	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	7.8	9.87e-13	3.01e-09	0.68	0.54	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
PCPG	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	7.8	9.93e-13	3.03e-09	0.76	0.54	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	7.8	9.93e-13	3.03e-09	0.76	0.54	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
PCPG	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-7.8	9.97e-13	3.04e-09	-0.83	-0.54	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
PCPG	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	7.79	1e-12	3.05e-09	0.73	0.54	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-7.79	1e-12	3.05e-09	-0.73	-0.54	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-7.79	1e-12	3.05e-09	-0.73	-0.54	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-7.79	1e-12	3.05e-09	-0.73	-0.54	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
PCPG	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	7.79	1e-12	3.06e-09	0.69	0.54	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
PCPG	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	7.79	1.01e-12	3.08e-09	0.64	0.54	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
PCPG	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	7.79	1.01e-12	3.08e-09	0.64	0.54	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
PCPG	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-7.79	1.02e-12	3.1e-09	-0.64	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
PCPG	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-7.79	1.02e-12	3.1e-09	-0.64	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
PCPG	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-7.79	1.02e-12	3.1e-09	-0.64	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
PCPG	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	7.79	1.02e-12	3.1e-09	0.6	0.54	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
PCPG	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-7.79	1.03e-12	3.12e-09	-0.58	-0.54	Height;	chr3:53052712	chr3:53064283~53065091:-
PCPG	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	7.79	1.03e-12	3.13e-09	0.73	0.54	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	7.79	1.03e-12	3.13e-09	0.63	0.54	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
PCPG	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	7.79	1.03e-12	3.15e-09	0.71	0.54	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	7.79	1.03e-12	3.15e-09	0.71	0.54	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	7.79	1.03e-12	3.15e-09	0.71	0.54	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
PCPG	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	7.79	1.05e-12	3.18e-09	0.82	0.54	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	7.79	1.05e-12	3.18e-09	0.82	0.54	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	7.79	1.05e-12	3.18e-09	0.82	0.54	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	7.79	1.05e-12	3.18e-09	0.82	0.54	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
PCPG	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	7.79	1.05e-12	3.18e-09	0.82	0.54	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
PCPG	cis	rs7267979	0.789	rs6076347	ENSG00000125804.12	FAM182A	7.78	1.06e-12	3.21e-09	0.66	0.54	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26054655~26086917:+
PCPG	cis	rs2019137	0.539	rs4849181	ENSG00000274877.1	RP11-65I12.1	-7.78	1.06e-12	3.21e-09	-0.7	-0.54	Lymphocyte counts;	chr2:113234393	chr2:113237595~113240825:+
PCPG	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-7.78	1.06e-12	3.22e-09	-0.71	-0.54	Depression;	chr6:28076704	chr6:28115628~28116551:+
PCPG	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-7.78	1.08e-12	3.26e-09	-0.67	-0.54	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-7.78	1.08e-12	3.26e-09	-0.67	-0.54	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-7.78	1.08e-12	3.26e-09	-0.67	-0.54	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
PCPG	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	7.78	1.09e-12	3.3e-09	0.5	0.54	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
PCPG	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	7.78	1.1e-12	3.33e-09	0.72	0.54	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	7.78	1.1e-12	3.33e-09	0.72	0.54	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	7.78	1.1e-12	3.33e-09	0.72	0.54	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	7.78	1.1e-12	3.33e-09	0.72	0.54	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
PCPG	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	7.78	1.11e-12	3.35e-09	0.6	0.54	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	7.78	1.11e-12	3.36e-09	0.68	0.54	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	7.78	1.11e-12	3.36e-09	0.68	0.54	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	7.78	1.11e-12	3.36e-09	0.68	0.54	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
PCPG	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	7.78	1.11e-12	3.36e-09	1.04	0.54	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
PCPG	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-7.77	1.14e-12	3.44e-09	-0.76	-0.54	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
PCPG	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	7.77	1.15e-12	3.46e-09	0.54	0.54	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
PCPG	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-7.77	1.16e-12	3.5e-09	-0.61	-0.54	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
PCPG	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-7.77	1.16e-12	3.51e-09	-0.63	-0.54	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
PCPG	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	7.77	1.16e-12	3.51e-09	0.61	0.54	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
PCPG	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-7.77	1.17e-12	3.52e-09	-0.7	-0.54	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
PCPG	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	7.76	1.18e-12	3.56e-09	0.74	0.54	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
PCPG	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	7.76	1.19e-12	3.57e-09	0.67	0.54	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	7.76	1.19e-12	3.57e-09	0.71	0.54	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
PCPG	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	7.76	1.19e-12	3.58e-09	0.7	0.54	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	7.76	1.19e-12	3.58e-09	0.7	0.54	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
PCPG	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-7.76	1.19e-12	3.58e-09	-0.63	-0.54	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
PCPG	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	7.76	1.19e-12	3.58e-09	0.68	0.54	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
PCPG	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.76	1.19e-12	3.58e-09	-0.71	-0.54	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
PCPG	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-7.76	1.19e-12	3.58e-09	-0.71	-0.54	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
PCPG	cis	rs4835473	0.9	rs10027246	ENSG00000250345.2	RP11-780M14.1	7.76	1.19e-12	3.58e-09	0.66	0.54	Immature fraction of reticulocytes;	chr4:143935069	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.808	rs11725413	ENSG00000250345.2	RP11-780M14.1	7.76	1.19e-12	3.58e-09	0.66	0.54	Immature fraction of reticulocytes;	chr4:143943366	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	7.76	1.21e-12	3.63e-09	0.68	0.54	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
PCPG	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-7.76	1.21e-12	3.63e-09	-0.74	-0.54	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-7.76	1.21e-12	3.63e-09	-0.74	-0.54	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-7.76	1.21e-12	3.63e-09	-0.74	-0.54	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-7.76	1.21e-12	3.63e-09	-0.74	-0.54	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-7.76	1.21e-12	3.63e-09	-0.74	-0.54	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-7.76	1.21e-12	3.63e-09	-0.74	-0.54	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-7.76	1.21e-12	3.64e-09	-0.68	-0.54	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	7.76	1.21e-12	3.64e-09	0.61	0.54	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
PCPG	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	7.76	1.21e-12	3.64e-09	0.62	0.54	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	7.76	1.22e-12	3.67e-09	0.7	0.54	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	7.76	1.23e-12	3.67e-09	0.68	0.54	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
PCPG	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	7.76	1.25e-12	3.73e-09	0.48	0.53	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
PCPG	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	7.75	1.28e-12	3.82e-09	1.09	0.53	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
PCPG	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	7.75	1.29e-12	3.84e-09	0.68	0.53	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	7.75	1.29e-12	3.86e-09	0.67	0.53	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	7.75	1.29e-12	3.86e-09	0.67	0.53	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
PCPG	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-7.75	1.3e-12	3.88e-09	-0.61	-0.53	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
PCPG	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-7.75	1.31e-12	3.9e-09	-0.72	-0.53	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
PCPG	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	7.75	1.31e-12	3.92e-09	0.62	0.53	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
PCPG	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	7.74	1.32e-12	3.95e-09	0.54	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
PCPG	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	7.74	1.33e-12	3.97e-09	0.6	0.53	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
PCPG	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	7.74	1.34e-12	3.98e-09	0.71	0.53	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-7.74	1.34e-12	3.98e-09	-0.6	-0.53	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
PCPG	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	7.74	1.34e-12	3.99e-09	0.6	0.53	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
PCPG	cis	rs7267979	0.789	rs6083841	ENSG00000125804.12	FAM182A	7.74	1.34e-12	4e-09	0.66	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26054655~26086917:+
PCPG	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	7.74	1.35e-12	4.02e-09	0.67	0.53	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
PCPG	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	7.74	1.36e-12	4.05e-09	0.67	0.53	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
PCPG	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	7.74	1.37e-12	4.07e-09	0.56	0.53	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
PCPG	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	7.74	1.37e-12	4.07e-09	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
PCPG	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.74	1.38e-12	4.1e-09	-0.63	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
PCPG	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.74	1.38e-12	4.1e-09	-0.63	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
PCPG	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	7.74	1.39e-12	4.12e-09	0.71	0.53	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	7.74	1.39e-12	4.12e-09	0.71	0.53	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	7.74	1.39e-12	4.12e-09	0.71	0.53	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	7.74	1.39e-12	4.12e-09	0.71	0.53	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	7.74	1.39e-12	4.12e-09	0.71	0.53	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
PCPG	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-7.73	1.4e-12	4.15e-09	-0.76	-0.53	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
PCPG	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
PCPG	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	7.73	1.4e-12	4.15e-09	0.73	0.53	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
PCPG	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	7.73	1.4e-12	4.16e-09	0.61	0.53	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
PCPG	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	7.73	1.41e-12	4.19e-09	0.67	0.53	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	7.73	1.44e-12	4.27e-09	0.69	0.53	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
PCPG	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	7.73	1.46e-12	4.32e-09	0.68	0.53	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
PCPG	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	7.73	1.46e-12	4.32e-09	0.72	0.53	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-7.73	1.46e-12	4.32e-09	-0.72	-0.53	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	7.73	1.47e-12	4.32e-09	0.68	0.53	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
PCPG	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-7.73	1.47e-12	4.34e-09	-0.68	-0.53	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
PCPG	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.72	1.49e-12	4.39e-09	-0.69	-0.53	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
PCPG	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-7.72	1.49e-12	4.39e-09	-0.72	-0.53	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
PCPG	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	7.72	1.49e-12	4.4e-09	0.56	0.53	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	7.72	1.49e-12	4.4e-09	0.56	0.53	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	7.72	1.49e-12	4.4e-09	0.56	0.53	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	7.72	1.49e-12	4.4e-09	0.56	0.53	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
PCPG	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.72	1.5e-12	4.41e-09	-0.63	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
PCPG	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	7.72	1.5e-12	4.41e-09	0.68	0.53	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	7.72	1.5e-12	4.41e-09	0.68	0.53	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	7.72	1.5e-12	4.41e-09	0.68	0.53	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	7.72	1.5e-12	4.41e-09	0.68	0.53	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	7.72	1.5e-12	4.41e-09	0.68	0.53	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	7.72	1.5e-12	4.41e-09	0.68	0.53	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
PCPG	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	7.72	1.5e-12	4.42e-09	0.81	0.53	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
PCPG	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	7.72	1.5e-12	4.42e-09	0.81	0.53	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
PCPG	cis	rs4835473	0.864	rs28609839	ENSG00000250345.2	RP11-780M14.1	7.72	1.5e-12	4.42e-09	0.65	0.53	Immature fraction of reticulocytes;	chr4:143954160	chr4:143760399~143762093:-
PCPG	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-7.72	1.51e-12	4.43e-09	-0.6	-0.53	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
PCPG	cis	rs7267979	0.789	rs6083810	ENSG00000125804.12	FAM182A	7.72	1.51e-12	4.43e-09	0.65	0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26054655~26086917:+
PCPG	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	7.72	1.51e-12	4.45e-09	0.68	0.53	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	7.72	1.51e-12	4.45e-09	0.68	0.53	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
PCPG	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	7.72	1.52e-12	4.47e-09	0.61	0.53	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	7.72	1.53e-12	4.48e-09	0.68	0.53	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	7.72	1.53e-12	4.48e-09	0.68	0.53	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
PCPG	cis	rs11148252	0.512	rs9526950	ENSG00000198384.8	TPTE2P3	-7.72	1.53e-12	4.49e-09	-0.69	-0.53	Lewy body disease;	chr13:52600328	chr13:52522632~52586906:+
PCPG	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	7.72	1.53e-12	4.5e-09	0.68	0.53	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	7.72	1.53e-12	4.5e-09	0.68	0.53	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	7.72	1.53e-12	4.5e-09	0.68	0.53	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
PCPG	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-7.72	1.53e-12	4.5e-09	-0.6	-0.53	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
PCPG	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	7.72	1.55e-12	4.56e-09	0.55	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	7.72	1.55e-12	4.56e-09	0.55	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	7.72	1.55e-12	4.56e-09	0.55	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	7.72	1.55e-12	4.56e-09	0.55	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
PCPG	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	7.71	1.57e-12	4.6e-09	0.88	0.53	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
PCPG	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	7.71	1.59e-12	4.65e-09	0.73	0.53	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	7.71	1.59e-12	4.65e-09	0.73	0.53	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	7.71	1.6e-12	4.66e-09	0.67	0.53	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	7.71	1.61e-12	4.7e-09	0.67	0.53	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	7.71	1.61e-12	4.7e-09	0.67	0.53	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.9	rs10003922	ENSG00000250345.2	RP11-780M14.1	7.71	1.61e-12	4.71e-09	0.66	0.53	Immature fraction of reticulocytes;	chr4:143921235	chr4:143760399~143762093:-
PCPG	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-7.71	1.63e-12	4.76e-09	-0.72	-0.53	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-7.71	1.63e-12	4.76e-09	-0.72	-0.53	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	7.71	1.64e-12	4.79e-09	0.67	0.53	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	7.71	1.64e-12	4.79e-09	0.67	0.53	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	7.71	1.64e-12	4.79e-09	0.67	0.53	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	7.71	1.64e-12	4.79e-09	0.71	0.53	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	7.71	1.64e-12	4.79e-09	0.71	0.53	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
PCPG	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-7.71	1.64e-12	4.79e-09	-0.71	-0.53	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
PCPG	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	7.7	1.66e-12	4.83e-09	0.61	0.53	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
PCPG	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	7.7	1.66e-12	4.84e-09	0.76	0.53	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
PCPG	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.7	1.67e-12	4.87e-09	-0.64	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
PCPG	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	7.7	1.69e-12	4.93e-09	0.7	0.53	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
PCPG	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-7.7	1.69e-12	4.93e-09	-0.64	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
PCPG	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	7.7	1.69e-12	4.93e-09	0.71	0.53	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
PCPG	cis	rs6452524	0.901	rs12514607	ENSG00000249664.1	CTD-2227C6.2	-7.7	1.7e-12	4.94e-09	-0.64	-0.53	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:83012285~83013109:-
PCPG	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	7.7	1.71e-12	4.98e-09	0.77	0.53	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
PCPG	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	7.7	1.75e-12	5.07e-09	0.71	0.53	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
PCPG	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-7.69	1.77e-12	5.13e-09	-0.59	-0.53	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
PCPG	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	7.69	1.77e-12	5.13e-09	0.67	0.53	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	7.69	1.77e-12	5.13e-09	0.67	0.53	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	7.69	1.77e-12	5.13e-09	0.67	0.53	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	7.69	1.77e-12	5.13e-09	0.67	0.53	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
PCPG	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	7.69	1.78e-12	5.17e-09	0.69	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	7.69	1.78e-12	5.17e-09	0.69	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	7.69	1.78e-12	5.17e-09	0.69	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
PCPG	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	7.69	1.8e-12	5.2e-09	0.82	0.53	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
PCPG	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-7.69	1.81e-12	5.23e-09	-0.6	-0.53	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
PCPG	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	7.69	1.82e-12	5.26e-09	0.45	0.53	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
PCPG	cis	rs2075277	1	rs4822862	ENSG00000207575.1	MIR649	7.69	1.82e-12	5.26e-09	0.95	0.53	Eosinophilic esophagitis;	chr22:21032188	chr22:21034176~21034272:-
PCPG	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-7.69	1.83e-12	5.29e-09	-0.63	-0.53	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
PCPG	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	7.69	1.84e-12	5.3e-09	0.68	0.53	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	7.69	1.84e-12	5.3e-09	0.68	0.53	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
PCPG	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	7.69	1.84e-12	5.3e-09	0.67	0.53	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
PCPG	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-7.68	1.85e-12	5.34e-09	-0.68	-0.53	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
PCPG	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	7.68	1.85e-12	5.34e-09	0.68	0.53	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
PCPG	cis	rs9322193	0.923	rs2184370	ENSG00000268592.3	RAET1E-AS1	7.68	1.86e-12	5.36e-09	0.67	0.53	Lung cancer;	chr6:149843242	chr6:149863494~149919507:+
PCPG	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-7.68	1.86e-12	5.36e-09	-1	-0.53	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
PCPG	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	7.68	1.86e-12	5.36e-09	0.65	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
PCPG	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	7.68	1.88e-12	5.42e-09	0.58	0.53	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
PCPG	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	7.68	1.91e-12	5.49e-09	0.87	0.53	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
PCPG	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	7.68	1.92e-12	5.51e-09	0.7	0.53	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	7.68	1.92e-12	5.51e-09	0.7	0.53	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	7.68	1.92e-12	5.51e-09	0.7	0.53	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	7.68	1.95e-12	5.59e-09	0.67	0.53	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
PCPG	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-7.68	1.95e-12	5.61e-09	-0.66	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
PCPG	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	7.67	1.97e-12	5.64e-09	0.67	0.53	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	7.67	1.97e-12	5.64e-09	0.67	0.53	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
PCPG	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	7.67	1.97e-12	5.65e-09	0.65	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
PCPG	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	7.67	1.97e-12	5.66e-09	0.75	0.53	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
PCPG	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	7.67	1.99e-12	5.71e-09	0.55	0.53	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
PCPG	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	7.67	2e-12	5.74e-09	0.72	0.53	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
PCPG	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	7.67	2.01e-12	5.77e-09	0.74	0.53	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
PCPG	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	7.67	2.02e-12	5.77e-09	0.66	0.53	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	7.67	2.02e-12	5.77e-09	0.66	0.53	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
PCPG	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-7.67	2.02e-12	5.79e-09	-0.68	-0.53	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
PCPG	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-7.67	2.03e-12	5.8e-09	-0.68	-0.53	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
PCPG	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	7.67	2.04e-12	5.83e-09	0.72	0.53	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
PCPG	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	7.67	2.05e-12	5.86e-09	0.76	0.53	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	7.67	2.05e-12	5.86e-09	0.76	0.53	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
PCPG	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-7.67	2.05e-12	5.87e-09	-0.76	-0.53	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-7.67	2.05e-12	5.87e-09	-0.76	-0.53	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
PCPG	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-7.67	2.07e-12	5.91e-09	-0.75	-0.53	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	7.66	2.11e-12	6.03e-09	0.7	0.53	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	7.66	2.11e-12	6.03e-09	0.67	0.53	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
PCPG	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	7.66	2.12e-12	6.06e-09	0.75	0.53	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
PCPG	cis	rs11148252	0.532	rs9536185	ENSG00000198384.8	TPTE2P3	-7.66	2.17e-12	6.19e-09	-0.69	-0.53	Lewy body disease;	chr13:52605666	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.532	rs9536190	ENSG00000198384.8	TPTE2P3	-7.66	2.17e-12	6.19e-09	-0.69	-0.53	Lewy body disease;	chr13:52606909	chr13:52522632~52586906:+
PCPG	cis	rs4835473	0.897	rs11727223	ENSG00000250345.2	RP11-780M14.1	-7.66	2.18e-12	6.2e-09	-0.66	-0.53	Immature fraction of reticulocytes;	chr4:143707090	chr4:143760399~143762093:-
PCPG	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-7.65	2.19e-12	6.25e-09	-0.71	-0.53	Depression;	chr6:28161802	chr6:28115628~28116551:+
PCPG	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	7.65	2.2e-12	6.25e-09	0.65	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
PCPG	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-7.65	2.21e-12	6.3e-09	-0.99	-0.53	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
PCPG	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	7.65	2.21e-12	6.3e-09	0.71	0.53	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
PCPG	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	7.65	2.22e-12	6.31e-09	0.69	0.53	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	7.65	2.22e-12	6.31e-09	0.69	0.53	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-7.65	2.22e-12	6.31e-09	-0.69	-0.53	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
PCPG	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	7.65	2.22e-12	6.32e-09	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
PCPG	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28071237	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28071808	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28074687	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28076559	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28078391	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28079011	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28080757	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28080760	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28082231	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28082261	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28082984	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28083994	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28084025	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-7.65	2.23e-12	6.34e-09	-0.7	-0.53	Depression;	chr6:28085319	chr6:28115628~28116551:+
PCPG	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-7.65	2.23e-12	6.34e-09	-0.61	-0.53	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
PCPG	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-7.65	2.24e-12	6.34e-09	-0.71	-0.53	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-7.65	2.24e-12	6.34e-09	-0.71	-0.53	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-7.65	2.24e-12	6.34e-09	-0.71	-0.53	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-7.65	2.24e-12	6.34e-09	-0.71	-0.53	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	7.65	2.29e-12	6.48e-09	0.66	0.53	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
PCPG	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-7.65	2.29e-12	6.48e-09	-0.52	-0.53	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
PCPG	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	7.65	2.29e-12	6.48e-09	0.67	0.53	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	7.65	2.29e-12	6.48e-09	0.67	0.53	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
PCPG	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-7.65	2.31e-12	6.54e-09	-0.55	-0.53	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
PCPG	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	7.65	2.31e-12	6.54e-09	0.57	0.53	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
PCPG	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	7.64	2.32e-12	6.55e-09	0.73	0.53	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	7.64	2.32e-12	6.55e-09	0.73	0.53	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
PCPG	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	7.64	2.32e-12	6.57e-09	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
PCPG	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	7.64	2.34e-12	6.6e-09	0.58	0.53	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	7.64	2.34e-12	6.63e-09	0.67	0.53	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
PCPG	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	7.64	2.35e-12	6.64e-09	0.76	0.53	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
PCPG	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	7.64	2.36e-12	6.67e-09	0.68	0.53	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
PCPG	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-7.64	2.37e-12	6.69e-09	-0.61	-0.53	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
PCPG	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	7.64	2.4e-12	6.77e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	7.64	2.4e-12	6.77e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
PCPG	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-7.64	2.4e-12	6.77e-09	-0.62	-0.53	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
PCPG	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	7.64	2.42e-12	6.82e-09	0.71	0.53	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	7.64	2.43e-12	6.84e-09	0.73	0.53	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
PCPG	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	7.64	2.43e-12	6.85e-09	0.52	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
PCPG	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	7.64	2.45e-12	6.89e-09	0.67	0.53	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	7.64	2.45e-12	6.89e-09	0.67	0.53	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
PCPG	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-7.63	2.45e-12	6.9e-09	-0.75	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	7.63	2.47e-12	6.95e-09	0.67	0.53	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	7.63	2.47e-12	6.95e-09	0.67	0.53	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
PCPG	cis	rs7267979	0.738	rs2892409	ENSG00000125804.12	FAM182A	-7.63	2.47e-12	6.95e-09	-0.65	-0.53	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:26054655~26086917:+
PCPG	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	7.63	2.48e-12	6.95e-09	0.71	0.53	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-7.63	2.48e-12	6.95e-09	-0.71	-0.53	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
PCPG	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-7.63	2.48e-12	6.95e-09	-0.59	-0.53	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
PCPG	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	7.63	2.5e-12	7e-09	0.52	0.53	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
PCPG	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-7.63	2.51e-12	7.03e-09	-0.59	-0.53	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	7.63	2.51e-12	7.04e-09	0.7	0.53	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
PCPG	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	7.63	2.52e-12	7.06e-09	0.58	0.53	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
PCPG	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-7.63	2.57e-12	7.21e-09	-0.76	-0.53	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
PCPG	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	7.63	2.58e-12	7.23e-09	0.71	0.53	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	7.63	2.59e-12	7.23e-09	0.6	0.53	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	7.63	2.59e-12	7.23e-09	0.6	0.53	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	7.63	2.59e-12	7.23e-09	0.6	0.53	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	7.63	2.59e-12	7.23e-09	0.6	0.53	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
PCPG	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	7.62	2.59e-12	7.25e-09	0.72	0.53	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
PCPG	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-7.62	2.61e-12	7.29e-09	-0.59	-0.53	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-7.62	2.61e-12	7.29e-09	-0.59	-0.53	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-7.62	2.61e-12	7.29e-09	-0.59	-0.53	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-7.62	2.61e-12	7.29e-09	-0.59	-0.53	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-7.62	2.61e-12	7.29e-09	-0.59	-0.53	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-7.62	2.61e-12	7.29e-09	-0.59	-0.53	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
PCPG	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-7.62	2.61e-12	7.3e-09	-0.8	-0.53	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
PCPG	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	7.62	2.62e-12	7.31e-09	0.67	0.53	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs1973608	ENSG00000250345.2	RP11-780M14.1	-7.62	2.64e-12	7.38e-09	-0.67	-0.53	Immature fraction of reticulocytes;	chr4:143913057	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6813011	ENSG00000250345.2	RP11-780M14.1	-7.62	2.64e-12	7.38e-09	-0.67	-0.53	Immature fraction of reticulocytes;	chr4:143914496	chr4:143760399~143762093:-
PCPG	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	7.62	2.65e-12	7.39e-09	0.77	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	7.62	2.65e-12	7.39e-09	0.66	0.53	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	7.62	2.66e-12	7.42e-09	0.67	0.53	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	7.62	2.66e-12	7.42e-09	0.67	0.53	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
PCPG	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	7.62	2.67e-12	7.45e-09	0.8	0.53	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
PCPG	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	7.62	2.71e-12	7.56e-09	0.8	0.53	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
PCPG	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	7.62	2.71e-12	7.56e-09	0.59	0.53	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
PCPG	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	7.62	2.72e-12	7.57e-09	0.74	0.53	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
PCPG	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	7.62	2.73e-12	7.59e-09	0.71	0.53	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
PCPG	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-7.61	2.75e-12	7.66e-09	-0.77	-0.53	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
PCPG	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	7.61	2.76e-12	7.7e-09	0.69	0.53	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
PCPG	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	7.61	2.77e-12	7.7e-09	0.81	0.53	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
PCPG	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-7.61	2.78e-12	7.73e-09	-0.61	-0.53	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
PCPG	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-7.61	2.8e-12	7.79e-09	-0.69	-0.53	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
PCPG	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	7.61	2.81e-12	7.8e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	7.61	2.81e-12	7.8e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	7.61	2.81e-12	7.8e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
PCPG	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-7.61	2.82e-12	7.83e-09	-0.73	-0.53	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
PCPG	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	7.61	2.82e-12	7.84e-09	0.73	0.53	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	7.61	2.82e-12	7.84e-09	0.73	0.53	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
PCPG	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	7.61	2.83e-12	7.86e-09	0.81	0.53	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
PCPG	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-7.6	2.91e-12	8.07e-09	-0.67	-0.53	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
PCPG	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-7.6	2.92e-12	8.09e-09	-0.65	-0.53	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-7.6	2.92e-12	8.09e-09	-0.65	-0.53	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
PCPG	cis	rs4835473	0.714	rs10013005	ENSG00000250345.2	RP11-780M14.1	-7.6	2.93e-12	8.11e-09	-0.64	-0.53	Immature fraction of reticulocytes;	chr4:143711351	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs1553070	ENSG00000250345.2	RP11-780M14.1	-7.6	2.93e-12	8.11e-09	-0.64	-0.53	Immature fraction of reticulocytes;	chr4:143715981	chr4:143760399~143762093:-
PCPG	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	7.6	2.96e-12	8.21e-09	0.67	0.53	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	7.6	2.97e-12	8.21e-09	0.67	0.53	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
PCPG	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	7.6	3.01e-12	8.33e-09	0.66	0.53	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	7.6	3.01e-12	8.33e-09	0.66	0.53	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	7.6	3.01e-12	8.33e-09	0.66	0.53	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	7.6	3.01e-12	8.33e-09	0.66	0.53	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	7.6	3.04e-12	8.39e-09	0.66	0.53	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	7.6	3.04e-12	8.39e-09	0.66	0.53	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	7.6	3.04e-12	8.39e-09	0.66	0.53	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	7.6	3.04e-12	8.39e-09	0.66	0.53	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	7.6	3.04e-12	8.39e-09	0.66	0.53	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
PCPG	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	7.59	3.11e-12	8.58e-09	0.69	0.53	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	7.59	3.11e-12	8.58e-09	0.69	0.53	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	7.59	3.11e-12	8.58e-09	0.69	0.53	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
PCPG	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-7.59	3.14e-12	8.66e-09	-0.77	-0.53	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
PCPG	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	7.59	3.17e-12	8.73e-09	0.59	0.53	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
PCPG	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-7.59	3.17e-12	8.73e-09	-0.68	-0.53	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.932	rs36018946	ENSG00000250345.2	RP11-780M14.1	7.59	3.18e-12	8.77e-09	0.66	0.53	Immature fraction of reticulocytes;	chr4:143980942	chr4:143760399~143762093:-
PCPG	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	7.59	3.2e-12	8.8e-09	0.67	0.53	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
PCPG	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28154567	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28156691	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28158424	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28159056	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28159666	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28159843	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28159925	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28159932	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28162053	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28162598	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28163375	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28163759	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28164580	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28164825	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28164948	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28165025	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28165528	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28168434	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28169019	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28169249	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28169676	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28169755	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28169791	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28170075	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28173770	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28174809	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28175233	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-7.59	3.2e-12	8.8e-09	-0.71	-0.53	Depression;	chr6:28176973	chr6:28115628~28116551:+
PCPG	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	7.59	3.23e-12	8.87e-09	0.74	0.53	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	7.59	3.23e-12	8.87e-09	0.74	0.53	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	7.59	3.23e-12	8.87e-09	0.74	0.53	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
PCPG	cis	rs4835473	0.897	rs2219912	ENSG00000250345.2	RP11-780M14.1	-7.59	3.23e-12	8.87e-09	-0.64	-0.53	Immature fraction of reticulocytes;	chr4:143707909	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs6537172	ENSG00000250345.2	RP11-780M14.1	-7.59	3.23e-12	8.87e-09	-0.64	-0.53	Immature fraction of reticulocytes;	chr4:143710612	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.742	rs7654409	ENSG00000250345.2	RP11-780M14.1	-7.58	3.26e-12	8.93e-09	-0.65	-0.53	Immature fraction of reticulocytes;	chr4:143956842	chr4:143760399~143762093:-
PCPG	cis	rs9326248	0.681	rs641620	ENSG00000254851.1	RP11-109L13.1	7.58	3.26e-12	8.94e-09	0.87	0.53	Blood protein levels;	chr11:117203513	chr11:117135528~117138582:+
PCPG	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-7.58	3.27e-12	8.96e-09	-0.64	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
PCPG	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	7.58	3.27e-12	8.96e-09	0.51	0.53	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	7.58	3.27e-12	8.96e-09	0.51	0.53	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
PCPG	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	7.58	3.27e-12	8.96e-09	0.68	0.53	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
PCPG	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	7.58	3.29e-12	9.01e-09	0.63	0.53	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
PCPG	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	7.58	3.31e-12	9.06e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
PCPG	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-7.58	3.31e-12	9.08e-09	-0.59	-0.53	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
PCPG	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	7.58	3.33e-12	9.12e-09	0.65	0.53	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
PCPG	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	7.58	3.35e-12	9.17e-09	0.74	0.53	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
PCPG	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	7.58	3.35e-12	9.17e-09	0.68	0.53	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
PCPG	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-7.58	3.35e-12	9.18e-09	-0.71	-0.53	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
PCPG	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	7.58	3.35e-12	9.18e-09	0.7	0.53	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
PCPG	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	7.58	3.36e-12	9.19e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	7.58	3.36e-12	9.19e-09	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
PCPG	cis	rs4835473	0.897	rs6537170	ENSG00000250345.2	RP11-780M14.1	-7.58	3.42e-12	9.35e-09	-0.65	-0.53	Immature fraction of reticulocytes;	chr4:143691747	chr4:143760399~143762093:-
PCPG	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-7.57	3.44e-12	9.41e-09	-0.66	-0.53	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
PCPG	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	7.57	3.44e-12	9.41e-09	0.6	0.53	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	7.57	3.44e-12	9.41e-09	0.6	0.53	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	7.57	3.44e-12	9.41e-09	0.6	0.53	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
PCPG	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-7.57	3.5e-12	9.54e-09	-0.68	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
PCPG	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	7.57	3.5e-12	9.55e-09	0.75	0.53	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
PCPG	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	7.57	3.5e-12	9.55e-09	0.75	0.53	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
PCPG	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	7.57	3.5e-12	9.55e-09	0.67	0.53	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
PCPG	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	7.57	3.52e-12	9.61e-09	0.56	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
PCPG	cis	rs4835473	0.897	rs924234	ENSG00000250345.2	RP11-780M14.1	-7.57	3.54e-12	9.65e-09	-0.64	-0.53	Immature fraction of reticulocytes;	chr4:143706799	chr4:143760399~143762093:-
PCPG	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-7.57	3.56e-12	9.72e-09	-0.57	-0.53	Height;	chr3:52949886	chr3:53064283~53065091:-
PCPG	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	7.57	3.57e-12	9.74e-09	0.67	0.53	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
PCPG	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	7.57	3.59e-12	9.78e-09	0.67	0.53	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
PCPG	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	7.57	3.61e-12	9.82e-09	0.59	0.53	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
PCPG	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-7.56	3.63e-12	9.87e-09	-0.76	-0.53	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.897	rs1450246	ENSG00000250345.2	RP11-780M14.1	-7.56	3.64e-12	9.89e-09	-0.65	-0.53	Immature fraction of reticulocytes;	chr4:143702954	chr4:143760399~143762093:-
PCPG	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	7.56	3.67e-12	9.98e-09	0.67	0.53	Height;	chr14:75172868	chr14:75011269~75012851:-
PCPG	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-7.56	3.69e-12	1e-08	-0.65	-0.53	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
PCPG	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-7.56	3.72e-12	1.01e-08	-0.75	-0.53	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
PCPG	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	7.56	3.73e-12	1.01e-08	0.72	0.53	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.897	rs7695328	ENSG00000250345.2	RP11-780M14.1	-7.56	3.73e-12	1.01e-08	-0.65	-0.53	Immature fraction of reticulocytes;	chr4:143703768	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs57137521	ENSG00000250345.2	RP11-780M14.1	7.56	3.73e-12	1.01e-08	0.65	0.53	Immature fraction of reticulocytes;	chr4:143704045	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs55945293	ENSG00000250345.2	RP11-780M14.1	7.56	3.73e-12	1.01e-08	0.65	0.53	Immature fraction of reticulocytes;	chr4:143704766	chr4:143760399~143762093:-
PCPG	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	7.56	3.73e-12	1.01e-08	0.98	0.53	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
PCPG	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-7.56	3.76e-12	1.02e-08	-0.75	-0.53	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
PCPG	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	7.56	3.77e-12	1.02e-08	0.67	0.53	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
PCPG	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	7.56	3.81e-12	1.03e-08	0.66	0.53	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
PCPG	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	7.56	3.82e-12	1.04e-08	0.6	0.53	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
PCPG	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	7.55	3.83e-12	1.04e-08	0.67	0.52	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	7.55	3.83e-12	1.04e-08	0.67	0.52	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	7.55	3.83e-12	1.04e-08	0.67	0.52	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
PCPG	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	7.55	3.84e-12	1.04e-08	0.68	0.52	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
PCPG	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	7.55	3.86e-12	1.05e-08	0.59	0.52	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
PCPG	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	7.55	3.87e-12	1.05e-08	0.62	0.52	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
PCPG	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-7.55	3.89e-12	1.05e-08	-0.61	-0.52	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
PCPG	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	7.55	3.9e-12	1.06e-08	0.75	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
PCPG	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	7.55	3.91e-12	1.06e-08	0.67	0.52	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
PCPG	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	7.55	3.91e-12	1.06e-08	0.67	0.52	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
PCPG	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	7.55	3.94e-12	1.07e-08	0.6	0.52	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
PCPG	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-7.55	3.96e-12	1.07e-08	-0.58	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
PCPG	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	7.55	3.97e-12	1.07e-08	0.58	0.52	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
PCPG	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	7.55	4.01e-12	1.08e-08	0.52	0.52	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
PCPG	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	7.55	4.01e-12	1.08e-08	0.68	0.52	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
PCPG	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-7.55	4.03e-12	1.09e-08	-0.45	-0.52	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
PCPG	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	7.55	4.03e-12	1.09e-08	0.73	0.52	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	7.55	4.03e-12	1.09e-08	0.73	0.52	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	7.55	4.03e-12	1.09e-08	0.73	0.52	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
PCPG	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28089816	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28090857	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28091242	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28091439	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28091659	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28092227	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28093966	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-7.55	4.04e-12	1.09e-08	-0.7	-0.52	Depression;	chr6:28094014	chr6:28115628~28116551:+
PCPG	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	7.54	4.07e-12	1.1e-08	0.74	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
PCPG	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	7.54	4.08e-12	1.1e-08	0.82	0.52	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
PCPG	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	7.54	4.08e-12	1.1e-08	0.55	0.52	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
PCPG	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	7.54	4.09e-12	1.1e-08	0.46	0.52	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
PCPG	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	7.54	4.12e-12	1.11e-08	0.97	0.52	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
PCPG	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	7.54	4.13e-12	1.11e-08	0.68	0.52	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
PCPG	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-7.54	4.16e-12	1.12e-08	-0.74	-0.52	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
PCPG	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	7.54	4.2e-12	1.13e-08	0.78	0.52	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
PCPG	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-7.54	4.2e-12	1.13e-08	-0.65	-0.52	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
PCPG	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-7.54	4.23e-12	1.14e-08	-0.49	-0.52	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
PCPG	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	7.54	4.25e-12	1.14e-08	0.73	0.52	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
PCPG	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	7.54	4.25e-12	1.14e-08	0.73	0.52	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
PCPG	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	7.53	4.28e-12	1.15e-08	0.77	0.52	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	7.53	4.28e-12	1.15e-08	0.77	0.52	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
PCPG	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-7.53	4.3e-12	1.15e-08	-0.64	-0.52	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
PCPG	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-7.53	4.31e-12	1.16e-08	-0.62	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
PCPG	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	7.53	4.32e-12	1.16e-08	0.7	0.52	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	7.53	4.32e-12	1.16e-08	0.7	0.52	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	7.53	4.32e-12	1.16e-08	0.7	0.52	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	7.53	4.32e-12	1.16e-08	0.7	0.52	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
PCPG	cis	rs4835473	0.524	rs4404495	ENSG00000250345.2	RP11-780M14.1	-7.53	4.32e-12	1.16e-08	-0.66	-0.52	Immature fraction of reticulocytes;	chr4:143979791	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	7.53	4.32e-12	1.16e-08	0.66	0.52	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
PCPG	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	7.53	4.34e-12	1.16e-08	0.69	0.52	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	7.53	4.34e-12	1.16e-08	0.69	0.52	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	7.53	4.34e-12	1.16e-08	0.69	0.52	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	7.53	4.34e-12	1.16e-08	0.69	0.52	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
PCPG	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	7.53	4.34e-12	1.16e-08	0.98	0.52	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
PCPG	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	7.53	4.34e-12	1.16e-08	0.57	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	7.53	4.34e-12	1.16e-08	0.57	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
PCPG	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	7.53	4.36e-12	1.17e-08	0.79	0.52	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
PCPG	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	7.53	4.37e-12	1.17e-08	0.71	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
PCPG	cis	rs4835473	0.932	rs28668841	ENSG00000250345.2	RP11-780M14.1	7.53	4.37e-12	1.17e-08	0.66	0.52	Immature fraction of reticulocytes;	chr4:143982530	chr4:143760399~143762093:-
PCPG	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-7.53	4.43e-12	1.18e-08	-0.61	-0.52	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
PCPG	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	7.53	4.43e-12	1.18e-08	0.72	0.52	Depression;	chr6:28251492	chr6:28176188~28176674:+
PCPG	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-7.53	4.49e-12	1.2e-08	-0.63	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
PCPG	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	7.53	4.5e-12	1.2e-08	0.67	0.52	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
PCPG	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	7.53	4.5e-12	1.2e-08	0.5	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
PCPG	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-7.53	4.51e-12	1.2e-08	-0.61	-0.52	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
PCPG	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	7.52	4.53e-12	1.21e-08	0.7	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
PCPG	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-7.52	4.54e-12	1.21e-08	-0.77	-0.52	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
PCPG	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-7.52	4.55e-12	1.21e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
PCPG	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-7.52	4.55e-12	1.21e-08	-0.72	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
PCPG	cis	rs4835473	0.897	rs6832749	ENSG00000250345.2	RP11-780M14.1	-7.52	4.55e-12	1.21e-08	-0.66	-0.52	Immature fraction of reticulocytes;	chr4:143709473	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs6831477	ENSG00000250345.2	RP11-780M14.1	-7.52	4.55e-12	1.21e-08	-0.66	-0.52	Immature fraction of reticulocytes;	chr4:143709487	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	7.52	4.57e-12	1.22e-08	0.65	0.52	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
PCPG	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	7.52	4.57e-12	1.22e-08	0.66	0.52	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
PCPG	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	7.52	4.58e-12	1.22e-08	0.68	0.52	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
PCPG	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	7.52	4.64e-12	1.23e-08	0.69	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	7.52	4.64e-12	1.23e-08	0.69	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
PCPG	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	7.52	4.7e-12	1.25e-08	0.98	0.52	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
PCPG	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	7.52	4.76e-12	1.26e-08	0.69	0.52	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	7.52	4.76e-12	1.26e-08	0.69	0.52	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
PCPG	cis	rs7688540	0.713	rs12511388	ENSG00000275426.1	CH17-262A2.1	7.52	4.77e-12	1.27e-08	0.69	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:149738~150317:+
PCPG	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-7.51	4.84e-12	1.28e-08	-0.73	-0.52	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
PCPG	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	7.51	4.87e-12	1.29e-08	0.67	0.52	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
PCPG	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-7.51	4.9e-12	1.3e-08	-0.74	-0.52	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
PCPG	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-7.51	4.9e-12	1.3e-08	-0.74	-0.52	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-7.51	4.9e-12	1.3e-08	-0.74	-0.52	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
PCPG	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	7.51	4.92e-12	1.3e-08	0.67	0.52	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.897	rs4835333	ENSG00000250345.2	RP11-780M14.1	7.51	4.94e-12	1.31e-08	0.64	0.52	Immature fraction of reticulocytes;	chr4:143703174	chr4:143760399~143762093:-
PCPG	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	7.51	4.95e-12	1.31e-08	0.73	0.52	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
PCPG	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-7.51	4.96e-12	1.31e-08	-0.59	-0.52	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
PCPG	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-7.51	4.98e-12	1.32e-08	-0.55	-0.52	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
PCPG	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-7.51	4.99e-12	1.32e-08	-0.65	-0.52	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
PCPG	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	7.51	4.99e-12	1.32e-08	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
PCPG	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	7.51	5.03e-12	1.33e-08	0.75	0.52	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
PCPG	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	7.51	5.04e-12	1.33e-08	0.81	0.52	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
PCPG	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	7.51	5.04e-12	1.33e-08	0.81	0.52	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
PCPG	cis	rs4835473	0.932	rs10857415	ENSG00000250345.2	RP11-780M14.1	-7.5	5.11e-12	1.35e-08	-0.66	-0.52	Immature fraction of reticulocytes;	chr4:143908753	chr4:143760399~143762093:-
PCPG	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-7.5	5.12e-12	1.35e-08	-0.67	-0.52	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
PCPG	cis	rs7267979	0.753	rs404148	ENSG00000125804.12	FAM182A	-7.5	5.15e-12	1.36e-08	-0.64	-0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:26054655~26086917:+
PCPG	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	7.5	5.15e-12	1.36e-08	0.66	0.52	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
PCPG	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	7.5	5.17e-12	1.36e-08	0.68	0.52	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
PCPG	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-7.5	5.18e-12	1.37e-08	-0.57	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
PCPG	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	7.5	5.18e-12	1.37e-08	0.54	0.52	Height;	chr3:53073584	chr3:53064283~53065091:-
PCPG	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-7.5	5.18e-12	1.37e-08	-0.61	-0.52	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
PCPG	cis	rs4835473	0.897	rs36083752	ENSG00000250345.2	RP11-780M14.1	7.5	5.19e-12	1.37e-08	0.64	0.52	Immature fraction of reticulocytes;	chr4:143693377	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs35162238	ENSG00000250345.2	RP11-780M14.1	7.5	5.19e-12	1.37e-08	0.64	0.52	Immature fraction of reticulocytes;	chr4:143693518	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs1545437	ENSG00000250345.2	RP11-780M14.1	7.5	5.19e-12	1.37e-08	0.64	0.52	Immature fraction of reticulocytes;	chr4:143696689	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs61427459	ENSG00000250345.2	RP11-780M14.1	7.5	5.19e-12	1.37e-08	0.64	0.52	Immature fraction of reticulocytes;	chr4:143699605	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs11100802	ENSG00000250345.2	RP11-780M14.1	7.5	5.19e-12	1.37e-08	0.64	0.52	Immature fraction of reticulocytes;	chr4:143700046	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs7657088	ENSG00000250345.2	RP11-780M14.1	7.5	5.19e-12	1.37e-08	0.64	0.52	Immature fraction of reticulocytes;	chr4:143701877	chr4:143760399~143762093:-
PCPG	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	7.5	5.2e-12	1.37e-08	0.71	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	7.5	5.22e-12	1.38e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	7.5	5.22e-12	1.38e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	7.5	5.22e-12	1.38e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	7.5	5.22e-12	1.38e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
PCPG	cis	rs4835473	0.9	rs13101531	ENSG00000250345.2	RP11-780M14.1	7.5	5.26e-12	1.38e-08	0.65	0.52	Immature fraction of reticulocytes;	chr4:143982197	chr4:143760399~143762093:-
PCPG	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	7.5	5.27e-12	1.39e-08	0.72	0.52	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	7.5	5.28e-12	1.39e-08	0.67	0.52	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	7.5	5.28e-12	1.39e-08	0.67	0.52	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	7.5	5.28e-12	1.39e-08	0.67	0.52	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	7.5	5.28e-12	1.39e-08	0.67	0.52	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
PCPG	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	7.5	5.29e-12	1.39e-08	0.61	0.52	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
PCPG	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	7.5	5.3e-12	1.39e-08	0.78	0.52	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
PCPG	cis	rs7829975	0.511	rs2980512	ENSG00000253893.2	FAM85B	-7.5	5.31e-12	1.4e-08	-0.66	-0.52	Mood instability;	chr8:8283379	chr8:8167819~8226614:-
PCPG	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.5	5.33e-12	1.4e-08	-0.61	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
PCPG	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-7.5	5.33e-12	1.4e-08	-0.61	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
PCPG	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	7.49	5.34e-12	1.4e-08	0.65	0.52	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
PCPG	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-7.49	5.37e-12	1.41e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
PCPG	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	7.49	5.4e-12	1.42e-08	0.65	0.52	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
PCPG	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	7.49	5.41e-12	1.42e-08	0.82	0.52	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
PCPG	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	7.49	5.46e-12	1.43e-08	0.59	0.52	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	7.49	5.46e-12	1.44e-08	0.6	0.52	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-7.49	5.47e-12	1.44e-08	-0.69	-0.52	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
PCPG	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-7.49	5.48e-12	1.44e-08	-0.69	-0.52	Depression;	chr6:28070115	chr6:28115628~28116551:+
PCPG	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-7.49	5.49e-12	1.44e-08	-0.59	-0.52	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
PCPG	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	7.49	5.49e-12	1.44e-08	0.71	0.52	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
PCPG	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	7.49	5.5e-12	1.44e-08	0.59	0.52	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	7.49	5.5e-12	1.44e-08	0.59	0.52	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
PCPG	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	7.49	5.51e-12	1.45e-08	0.7	0.52	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	7.49	5.51e-12	1.45e-08	0.7	0.52	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	7.49	5.51e-12	1.45e-08	0.7	0.52	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	7.49	5.51e-12	1.45e-08	0.7	0.52	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-7.49	5.51e-12	1.45e-08	-0.7	-0.52	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
PCPG	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.49	5.54e-12	1.45e-08	0.62	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
PCPG	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	7.49	5.56e-12	1.46e-08	0.7	0.52	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	7.49	5.56e-12	1.46e-08	0.7	0.52	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	7.49	5.56e-12	1.46e-08	0.7	0.52	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	7.49	5.56e-12	1.46e-08	0.7	0.52	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	7.49	5.56e-12	1.46e-08	0.7	0.52	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
PCPG	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	7.49	5.57e-12	1.46e-08	0.6	0.52	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	7.49	5.57e-12	1.46e-08	0.6	0.52	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
PCPG	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-7.49	5.6e-12	1.47e-08	-0.86	-0.52	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
PCPG	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	7.48	5.65e-12	1.48e-08	0.65	0.52	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	7.48	5.67e-12	1.49e-08	0.66	0.52	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
PCPG	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	7.48	5.71e-12	1.49e-08	0.7	0.52	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
PCPG	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	7.48	5.73e-12	1.5e-08	0.73	0.52	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	7.48	5.73e-12	1.5e-08	0.73	0.52	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	7.48	5.73e-12	1.5e-08	0.73	0.52	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	7.48	5.73e-12	1.5e-08	0.73	0.52	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
PCPG	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	7.48	5.74e-12	1.5e-08	0.72	0.52	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
PCPG	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-7.48	5.74e-12	1.5e-08	-0.59	-0.52	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
PCPG	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	7.48	5.82e-12	1.52e-08	0.69	0.52	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.771	rs4261935	ENSG00000250345.2	RP11-780M14.1	-7.48	5.82e-12	1.52e-08	-0.66	-0.52	Immature fraction of reticulocytes;	chr4:143979751	chr4:143760399~143762093:-
PCPG	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-7.48	5.85e-12	1.53e-08	-0.66	-0.52	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
PCPG	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-7.48	5.85e-12	1.53e-08	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-7.48	5.85e-12	1.53e-08	-0.67	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
PCPG	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	7.48	5.86e-12	1.53e-08	0.56	0.52	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
PCPG	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	7.48	5.87e-12	1.53e-08	0.8	0.52	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
PCPG	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	7.48	5.88e-12	1.53e-08	0.66	0.52	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	7.48	5.95e-12	1.55e-08	0.7	0.52	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
PCPG	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	7.48	5.96e-12	1.55e-08	0.66	0.52	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	7.47	5.96e-12	1.55e-08	0.66	0.52	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
PCPG	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	7.47	6.02e-12	1.57e-08	0.58	0.52	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
PCPG	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	7.47	6.07e-12	1.58e-08	0.73	0.52	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	7.47	6.07e-12	1.58e-08	0.73	0.52	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	7.47	6.07e-12	1.58e-08	0.73	0.52	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
PCPG	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	7.47	6.09e-12	1.58e-08	1.05	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
PCPG	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-7.47	6.13e-12	1.59e-08	-0.7	-0.52	Depression;	chr6:28180209	chr6:28115628~28116551:+
PCPG	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	7.47	6.18e-12	1.61e-08	0.73	0.52	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
PCPG	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	7.47	6.18e-12	1.61e-08	0.73	0.52	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
PCPG	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-7.47	6.19e-12	1.61e-08	-0.69	-0.52	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
PCPG	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	7.47	6.29e-12	1.63e-08	0.7	0.52	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	7.47	6.29e-12	1.63e-08	0.7	0.52	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	7.46	6.33e-12	1.64e-08	0.6	0.52	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
PCPG	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	7.46	6.34e-12	1.65e-08	0.69	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
PCPG	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	7.46	6.42e-12	1.66e-08	0.6	0.52	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
PCPG	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-7.46	6.43e-12	1.67e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
PCPG	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-7.46	6.43e-12	1.67e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
PCPG	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	7.46	6.47e-12	1.68e-08	0.72	0.52	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	7.46	6.47e-12	1.68e-08	0.72	0.52	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.864	rs12507633	ENSG00000250345.2	RP11-780M14.1	-7.46	6.47e-12	1.68e-08	-0.65	-0.52	Immature fraction of reticulocytes;	chr4:143962730	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	7.46	6.48e-12	1.68e-08	0.66	0.52	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
PCPG	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-7.46	6.54e-12	1.7e-08	-0.74	-0.52	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
PCPG	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-7.46	6.61e-12	1.71e-08	-0.68	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
PCPG	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-7.46	6.61e-12	1.71e-08	-0.68	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
PCPG	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.46	6.63e-12	1.72e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
PCPG	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-7.46	6.63e-12	1.72e-08	-0.44	-0.52	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
PCPG	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-7.46	6.64e-12	1.72e-08	-0.59	-0.52	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
PCPG	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	7.45	6.72e-12	1.74e-08	0.66	0.52	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	7.45	6.72e-12	1.74e-08	0.66	0.52	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
PCPG	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	7.45	6.75e-12	1.74e-08	0.56	0.52	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	7.45	6.75e-12	1.74e-08	0.56	0.52	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
PCPG	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	7.45	6.79e-12	1.75e-08	0.66	0.52	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
PCPG	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	7.45	6.83e-12	1.76e-08	0.68	0.52	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
PCPG	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	7.45	6.83e-12	1.76e-08	0.73	0.52	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
PCPG	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	7.45	6.84e-12	1.76e-08	0.7	0.52	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
PCPG	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-7.45	6.86e-12	1.77e-08	-0.71	-0.52	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
PCPG	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-7.45	6.89e-12	1.78e-08	-0.66	-0.52	Height;	chr14:75166305	chr14:75011269~75012851:-
PCPG	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-7.45	6.97e-12	1.8e-08	-0.45	-0.52	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
PCPG	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	7.45	7.02e-12	1.81e-08	0.66	0.52	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
PCPG	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-7.44	7.1e-12	1.83e-08	-0.57	-0.52	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-7.44	7.18e-12	1.85e-08	-0.6	-0.52	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
PCPG	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	7.44	7.19e-12	1.85e-08	0.7	0.52	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
PCPG	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	7.44	7.22e-12	1.86e-08	0.96	0.52	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
PCPG	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	7.44	7.25e-12	1.86e-08	0.66	0.52	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	7.44	7.25e-12	1.86e-08	0.66	0.52	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	7.44	7.29e-12	1.87e-08	0.58	0.52	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
PCPG	cis	rs910316	0.726	rs12882664	ENSG00000279594.1	RP11-950C14.10	7.44	7.32e-12	1.88e-08	0.67	0.52	Height;	chr14:74980075	chr14:75011269~75012851:-
PCPG	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	7.44	7.34e-12	1.88e-08	0.54	0.52	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
PCPG	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	7.44	7.39e-12	1.9e-08	0.6	0.52	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
PCPG	cis	rs4835473	0.708	rs7655939	ENSG00000250345.2	RP11-780M14.1	-7.44	7.4e-12	1.9e-08	-0.65	-0.52	Immature fraction of reticulocytes;	chr4:143956889	chr4:143760399~143762093:-
PCPG	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28145952	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28147378	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28147406	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28148143	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28149979	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28151096	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28152885	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-7.43	7.5e-12	1.92e-08	-0.7	-0.52	Depression;	chr6:28153120	chr6:28115628~28116551:+
PCPG	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-7.43	7.56e-12	1.93e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
PCPG	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-7.43	7.58e-12	1.94e-08	-0.65	-0.52	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
PCPG	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	7.43	7.58e-12	1.94e-08	0.72	0.52	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
PCPG	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-7.43	7.6e-12	1.94e-08	-0.64	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
PCPG	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-7.43	7.6e-12	1.94e-08	-0.64	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
PCPG	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-7.43	7.64e-12	1.95e-08	-0.58	-0.52	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
PCPG	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	7.43	7.7e-12	1.97e-08	0.66	0.52	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	7.43	7.74e-12	1.98e-08	0.67	0.52	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
PCPG	cis	rs4835473	0.932	rs1849112	ENSG00000250345.2	RP11-780M14.1	-7.43	7.82e-12	2e-08	-0.65	-0.52	Immature fraction of reticulocytes;	chr4:143962502	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs4125544	ENSG00000250345.2	RP11-780M14.1	-7.43	7.82e-12	2e-08	-0.65	-0.52	Immature fraction of reticulocytes;	chr4:143962542	chr4:143760399~143762093:-
PCPG	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	7.42	7.87e-12	2.01e-08	0.69	0.52	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
PCPG	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	7.42	7.94e-12	2.02e-08	0.72	0.52	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
PCPG	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-7.42	7.99e-12	2.04e-08	-0.66	-0.52	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
PCPG	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	7.42	8e-12	2.04e-08	0.67	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	7.42	8e-12	2.04e-08	0.67	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	7.42	8e-12	2.04e-08	0.67	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	7.42	8e-12	2.04e-08	0.67	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
PCPG	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	7.42	8.02e-12	2.04e-08	0.75	0.52	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
PCPG	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	7.42	8.04e-12	2.05e-08	0.69	0.52	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	7.42	8.04e-12	2.05e-08	0.69	0.52	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	7.42	8.04e-12	2.05e-08	0.69	0.52	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	7.42	8.04e-12	2.05e-08	0.69	0.52	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
PCPG	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-7.42	8.08e-12	2.06e-08	-0.64	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
PCPG	cis	rs910316	1	rs10146482	ENSG00000279594.1	RP11-950C14.10	7.42	8.17e-12	2.08e-08	0.65	0.52	Height;	chr14:75107384	chr14:75011269~75012851:-
PCPG	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	7.41	8.32e-12	2.11e-08	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
PCPG	cis	rs4835473	0.771	rs4443231	ENSG00000250345.2	RP11-780M14.1	-7.41	8.37e-12	2.13e-08	-0.64	-0.52	Immature fraction of reticulocytes;	chr4:143979501	chr4:143760399~143762093:-
PCPG	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	7.41	8.41e-12	2.14e-08	0.75	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
PCPG	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	7.41	8.44e-12	2.14e-08	0.59	0.52	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
PCPG	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	7.41	8.45e-12	2.15e-08	0.69	0.52	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
PCPG	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-7.41	8.52e-12	2.16e-08	-0.73	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
PCPG	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-7.41	8.58e-12	2.18e-08	-0.71	-0.52	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
PCPG	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	7.41	8.58e-12	2.18e-08	0.61	0.52	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
PCPG	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	7.41	8.58e-12	2.18e-08	0.61	0.52	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
PCPG	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	7.41	8.64e-12	2.19e-08	0.68	0.52	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
PCPG	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-7.41	8.64e-12	2.19e-08	-0.68	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
PCPG	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-7.41	8.67e-12	2.2e-08	-0.6	-0.52	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-7.41	8.67e-12	2.2e-08	-0.6	-0.52	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
PCPG	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-7.41	8.68e-12	2.2e-08	-0.64	-0.52	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
PCPG	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-7.4	8.81e-12	2.23e-08	-0.64	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
PCPG	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	7.4	8.83e-12	2.24e-08	0.73	0.52	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
PCPG	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	7.4	8.83e-12	2.24e-08	0.68	0.52	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
PCPG	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	7.4	8.94e-12	2.26e-08	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
PCPG	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-7.4	8.95e-12	2.26e-08	-0.75	-0.52	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-7.4	8.95e-12	2.26e-08	-0.75	-0.52	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
PCPG	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	7.4	8.95e-12	2.26e-08	0.55	0.52	Height;	chr3:53073764	chr3:53064283~53065091:-
PCPG	cis	rs7267979	1	rs6076339	ENSG00000125804.12	FAM182A	7.4	8.97e-12	2.27e-08	0.6	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6107033	ENSG00000125804.12	FAM182A	7.4	8.97e-12	2.27e-08	0.6	0.52	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:26054655~26086917:+
PCPG	cis	rs4835473	0.8	rs2089839	ENSG00000250345.2	RP11-780M14.1	-7.4	9e-12	2.28e-08	-0.64	-0.52	Immature fraction of reticulocytes;	chr4:143980955	chr4:143760399~143762093:-
PCPG	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	7.4	9.01e-12	2.28e-08	0.72	0.52	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
PCPG	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-7.4	9.09e-12	2.3e-08	-0.62	-0.52	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
PCPG	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	7.4	9.1e-12	2.3e-08	0.7	0.52	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	7.4	9.12e-12	2.3e-08	0.66	0.52	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
PCPG	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	7.4	9.17e-12	2.32e-08	0.5	0.52	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
PCPG	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	7.4	9.21e-12	2.33e-08	0.55	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
PCPG	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-7.39	9.3e-12	2.35e-08	-0.74	-0.52	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
PCPG	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-7.39	9.36e-12	2.36e-08	-0.7	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
PCPG	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	7.39	9.41e-12	2.37e-08	0.7	0.52	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
PCPG	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	7.39	9.42e-12	2.38e-08	0.79	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
PCPG	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-7.39	9.45e-12	2.38e-08	-0.6	-0.52	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
PCPG	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	7.39	9.48e-12	2.39e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	7.39	9.48e-12	2.39e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	7.39	9.48e-12	2.39e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	7.39	9.48e-12	2.39e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
PCPG	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	7.39	9.48e-12	2.39e-08	0.68	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
PCPG	cis	rs4835473	0.932	rs4585249	ENSG00000250345.2	RP11-780M14.1	7.39	9.61e-12	2.42e-08	0.65	0.52	Immature fraction of reticulocytes;	chr4:143981173	chr4:143760399~143762093:-
PCPG	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	7.39	9.66e-12	2.43e-08	0.74	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
PCPG	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-7.39	9.71e-12	2.44e-08	-0.72	-0.52	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
PCPG	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-7.39	9.72e-12	2.44e-08	-0.56	-0.52	Height;	chr3:53027361	chr3:53064283~53065091:-
PCPG	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-7.39	9.74e-12	2.45e-08	-0.64	-0.52	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
PCPG	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	7.38	9.84e-12	2.48e-08	0.59	0.52	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	7.38	9.84e-12	2.48e-08	0.59	0.52	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	7.38	9.84e-12	2.48e-08	0.59	0.52	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	7.38	9.85e-12	2.48e-08	0.57	0.52	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
PCPG	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.38	9.9e-12	2.49e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
PCPG	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	7.38	9.94e-12	2.5e-08	0.64	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
PCPG	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-7.38	9.97e-12	2.51e-08	-0.64	-0.52	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
PCPG	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-7.38	1.01e-11	2.54e-08	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
PCPG	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	7.38	1.02e-11	2.55e-08	1.05	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	7.38	1.02e-11	2.55e-08	1.05	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
PCPG	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-7.38	1.02e-11	2.55e-08	-0.59	-0.52	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-7.38	1.02e-11	2.55e-08	-0.59	-0.52	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-7.38	1.02e-11	2.55e-08	-0.59	-0.52	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-7.38	1.02e-11	2.57e-08	-0.6	-0.52	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-7.38	1.02e-11	2.57e-08	-0.6	-0.52	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-7.38	1.02e-11	2.57e-08	-0.6	-0.52	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-7.38	1.02e-11	2.57e-08	-0.6	-0.52	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
PCPG	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	7.38	1.04e-11	2.6e-08	0.82	0.52	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
PCPG	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Depression;	chr6:28096077	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Depression;	chr6:28096855	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Depression;	chr6:28099759	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Depression;	chr6:28100648	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Depression;	chr6:28104824	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Depression;	chr6:28107222	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-7.37	1.04e-11	2.6e-08	-0.68	-0.52	Depression;	chr6:28108492	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	7.37	1.04e-11	2.6e-08	0.68	0.52	Depression;	chr6:28109824	chr6:28115628~28116551:+
PCPG	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	7.37	1.04e-11	2.6e-08	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	7.37	1.04e-11	2.6e-08	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	7.37	1.04e-11	2.6e-08	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
PCPG	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	7.37	1.04e-11	2.61e-08	0.66	0.52	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
PCPG	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	7.37	1.05e-11	2.62e-08	0.7	0.52	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
PCPG	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	7.37	1.05e-11	2.63e-08	0.73	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
PCPG	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-7.37	1.05e-11	2.64e-08	-0.63	-0.52	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
PCPG	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	7.37	1.06e-11	2.65e-08	0.95	0.52	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
PCPG	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	7.37	1.06e-11	2.65e-08	0.68	0.52	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
PCPG	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-7.37	1.06e-11	2.65e-08	-0.63	-0.52	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
PCPG	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-7.37	1.07e-11	2.67e-08	-0.65	-0.52	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
PCPG	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	7.37	1.07e-11	2.68e-08	0.67	0.52	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	7.37	1.07e-11	2.68e-08	0.67	0.52	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	7.37	1.07e-11	2.68e-08	0.67	0.52	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
PCPG	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-7.37	1.07e-11	2.68e-08	-0.7	-0.52	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
PCPG	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	7.37	1.08e-11	2.69e-08	0.78	0.52	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
PCPG	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-7.37	1.09e-11	2.72e-08	-0.68	-0.52	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
PCPG	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	7.36	1.1e-11	2.74e-08	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	7.36	1.1e-11	2.74e-08	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	7.36	1.1e-11	2.74e-08	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	7.36	1.1e-11	2.74e-08	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
PCPG	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	7.36	1.11e-11	2.76e-08	0.66	0.52	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	7.36	1.11e-11	2.76e-08	0.66	0.52	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	7.36	1.11e-11	2.76e-08	0.66	0.52	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	7.36	1.11e-11	2.76e-08	0.66	0.52	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	7.36	1.11e-11	2.76e-08	0.66	0.52	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
PCPG	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	7.36	1.12e-11	2.8e-08	0.8	0.52	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
PCPG	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-7.36	1.12e-11	2.8e-08	-0.63	-0.52	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
PCPG	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	7.36	1.13e-11	2.82e-08	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
PCPG	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-7.36	1.13e-11	2.82e-08	-0.56	-0.52	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
PCPG	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-7.36	1.14e-11	2.83e-08	-0.58	-0.51	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
PCPG	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-7.36	1.14e-11	2.84e-08	-0.48	-0.51	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
PCPG	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-7.36	1.15e-11	2.87e-08	-0.6	-0.51	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
PCPG	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	7.35	1.16e-11	2.88e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
PCPG	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	7.35	1.17e-11	2.89e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
PCPG	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	7.35	1.18e-11	2.92e-08	0.48	0.51	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	7.35	1.18e-11	2.92e-08	0.48	0.51	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
PCPG	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-7.35	1.18e-11	2.93e-08	-0.57	-0.51	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
PCPG	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-7.35	1.19e-11	2.94e-08	-0.66	-0.51	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
PCPG	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	7.35	1.19e-11	2.94e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
PCPG	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	7.35	1.19e-11	2.94e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	7.35	1.19e-11	2.94e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	7.35	1.19e-11	2.94e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	7.35	1.19e-11	2.94e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	7.35	1.19e-11	2.94e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	7.35	1.19e-11	2.94e-08	0.68	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
PCPG	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	7.35	1.19e-11	2.96e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	7.35	1.19e-11	2.96e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
PCPG	cis	rs910316	0.967	rs4899545	ENSG00000279594.1	RP11-950C14.10	7.35	1.21e-11	2.99e-08	0.65	0.51	Height;	chr14:75101435	chr14:75011269~75012851:-
PCPG	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-7.35	1.21e-11	3e-08	-0.44	-0.51	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
PCPG	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	7.35	1.22e-11	3.01e-08	0.64	0.51	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
PCPG	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-7.35	1.22e-11	3.02e-08	-0.68	-0.51	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-7.35	1.22e-11	3.02e-08	-0.68	-0.51	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
PCPG	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	7.35	1.22e-11	3.02e-08	0.67	0.51	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
PCPG	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	7.34	1.23e-11	3.05e-08	0.71	0.51	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
PCPG	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-7.34	1.25e-11	3.09e-08	-0.61	-0.51	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
PCPG	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	7.34	1.25e-11	3.1e-08	0.54	0.51	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	7.34	1.25e-11	3.1e-08	0.54	0.51	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
PCPG	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-7.34	1.25e-11	3.1e-08	-0.62	-0.51	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
PCPG	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	7.34	1.26e-11	3.12e-08	0.58	0.51	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
PCPG	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	7.34	1.27e-11	3.15e-08	0.69	0.51	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	7.34	1.27e-11	3.15e-08	0.69	0.51	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	7.34	1.27e-11	3.15e-08	0.69	0.51	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	7.34	1.27e-11	3.15e-08	0.69	0.51	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	7.34	1.27e-11	3.15e-08	0.69	0.51	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
PCPG	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-7.34	1.28e-11	3.15e-08	-0.71	-0.51	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
PCPG	cis	rs4835473	0.897	rs35599924	ENSG00000250345.2	RP11-780M14.1	-7.33	1.3e-11	3.2e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143980602	chr4:143760399~143762093:-
PCPG	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	7.33	1.3e-11	3.2e-08	0.5	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
PCPG	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	7.33	1.3e-11	3.21e-08	0.71	0.51	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
PCPG	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	7.33	1.33e-11	3.26e-08	0.79	0.51	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
PCPG	cis	rs4835473	0.864	rs4257604	ENSG00000250345.2	RP11-780M14.1	-7.33	1.33e-11	3.27e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143980261	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4516663	ENSG00000250345.2	RP11-780M14.1	-7.33	1.33e-11	3.27e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143980791	chr4:143760399~143762093:-
PCPG	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-7.33	1.34e-11	3.29e-08	-0.68	-0.51	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-7.33	1.34e-11	3.29e-08	-0.68	-0.51	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
PCPG	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-7.33	1.34e-11	3.29e-08	-0.65	-0.51	Height;	chr14:75170264	chr14:75011269~75012851:-
PCPG	cis	rs4835473	0.932	rs6826862	ENSG00000250345.2	RP11-780M14.1	-7.33	1.35e-11	3.31e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143978180	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.8	rs1849122	ENSG00000250345.2	RP11-780M14.1	-7.33	1.35e-11	3.31e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143978699	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.663	rs4835115	ENSG00000250345.2	RP11-780M14.1	-7.33	1.35e-11	3.31e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143979308	chr4:143760399~143762093:-
PCPG	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-7.33	1.35e-11	3.31e-08	-0.74	-0.51	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
PCPG	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	7.33	1.35e-11	3.33e-08	0.47	0.51	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
PCPG	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	7.33	1.36e-11	3.34e-08	0.62	0.51	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
PCPG	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	7.33	1.36e-11	3.34e-08	0.62	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
PCPG	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	7.32	1.37e-11	3.37e-08	1.01	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
PCPG	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-7.32	1.37e-11	3.37e-08	-0.63	-0.51	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-7.32	1.37e-11	3.37e-08	-0.63	-0.51	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
PCPG	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	7.32	1.38e-11	3.39e-08	0.66	0.51	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
PCPG	cis	rs6452524	0.836	rs4343818	ENSG00000249664.1	CTD-2227C6.2	7.32	1.38e-11	3.39e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83012285~83013109:-
PCPG	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-7.32	1.39e-11	3.41e-08	-0.63	-0.51	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
PCPG	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-7.32	1.4e-11	3.42e-08	-0.61	-0.51	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
PCPG	cis	rs4835473	0.897	rs1391189	ENSG00000250345.2	RP11-780M14.1	7.32	1.4e-11	3.43e-08	0.63	0.51	Immature fraction of reticulocytes;	chr4:143690951	chr4:143760399~143762093:-
PCPG	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-7.32	1.4e-11	3.43e-08	-0.56	-0.51	Height;	chr3:53093751	chr3:53064283~53065091:-
PCPG	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-7.32	1.4e-11	3.43e-08	-0.56	-0.51	Height;	chr3:53094335	chr3:53064283~53065091:-
PCPG	cis	rs4835473	0.897	rs2590034	ENSG00000250345.2	RP11-780M14.1	-7.32	1.41e-11	3.45e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143926778	chr4:143760399~143762093:-
PCPG	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-7.32	1.41e-11	3.46e-08	-0.79	-0.51	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
PCPG	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-7.31	1.44e-11	3.53e-08	-0.63	-0.51	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
PCPG	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-7.31	1.45e-11	3.54e-08	-0.62	-0.51	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
PCPG	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	7.31	1.46e-11	3.57e-08	0.71	0.51	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
PCPG	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	7.31	1.48e-11	3.61e-08	0.5	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
PCPG	cis	rs4835473	0.864	rs2089837	ENSG00000250345.2	RP11-780M14.1	-7.31	1.48e-11	3.62e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143965038	chr4:143760399~143762093:-
PCPG	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	7.31	1.5e-11	3.66e-08	0.66	0.51	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	7.31	1.5e-11	3.66e-08	0.66	0.51	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	7.31	1.5e-11	3.67e-08	0.67	0.51	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
PCPG	cis	rs12220777	1	rs72644211	ENSG00000230091.5	TMEM254-AS1	7.31	1.51e-11	3.68e-08	0.99	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021939	chr10:80046860~80078912:-
PCPG	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	7.3	1.53e-11	3.72e-08	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
PCPG	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	7.3	1.53e-11	3.74e-08	0.65	0.51	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	7.3	1.53e-11	3.74e-08	0.65	0.51	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	7.3	1.53e-11	3.74e-08	0.65	0.51	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	7.3	1.53e-11	3.74e-08	0.65	0.51	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	7.3	1.53e-11	3.74e-08	0.66	0.51	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
PCPG	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-7.3	1.54e-11	3.76e-08	-0.58	-0.51	Breast cancer;	chr11:743813	chr11:779617~780755:+
PCPG	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-7.3	1.56e-11	3.8e-08	-0.64	-0.51	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.897	rs28701142	ENSG00000250345.2	RP11-780M14.1	-7.3	1.56e-11	3.8e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143945730	chr4:143760399~143762093:-
PCPG	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-7.3	1.57e-11	3.82e-08	-0.56	-0.51	Height;	chr3:52941053	chr3:53064283~53065091:-
PCPG	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	7.3	1.57e-11	3.83e-08	0.59	0.51	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
PCPG	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	7.3	1.58e-11	3.83e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	7.3	1.58e-11	3.83e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	7.3	1.58e-11	3.83e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	7.3	1.58e-11	3.83e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	7.3	1.58e-11	3.84e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	7.3	1.58e-11	3.84e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
PCPG	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	7.3	1.58e-11	3.84e-08	0.55	0.51	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	7.3	1.58e-11	3.84e-08	0.55	0.51	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	7.3	1.58e-11	3.84e-08	0.55	0.51	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	7.3	1.58e-11	3.84e-08	0.55	0.51	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
PCPG	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-7.3	1.58e-11	3.85e-08	-0.63	-0.51	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-7.3	1.59e-11	3.86e-08	-0.64	-0.51	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
PCPG	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-7.3	1.6e-11	3.88e-08	-0.73	-0.51	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
PCPG	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	7.3	1.6e-11	3.89e-08	0.72	0.51	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	7.3	1.6e-11	3.89e-08	0.72	0.51	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
PCPG	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-7.3	1.6e-11	3.9e-08	-0.7	-0.51	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
PCPG	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	7.29	1.62e-11	3.93e-08	0.67	0.51	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
PCPG	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	7.29	1.62e-11	3.94e-08	0.59	0.51	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
PCPG	cis	rs7688540	0.723	rs7687112	ENSG00000275426.1	CH17-262A2.1	7.29	1.63e-11	3.96e-08	0.66	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:149738~150317:+
PCPG	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	7.29	1.63e-11	3.96e-08	0.55	0.51	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
PCPG	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	7.29	1.64e-11	3.97e-08	0.64	0.51	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
PCPG	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	7.29	1.64e-11	3.98e-08	0.58	0.51	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
PCPG	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	7.29	1.65e-11	4.01e-08	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	7.29	1.65e-11	4.01e-08	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
PCPG	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	7.29	1.66e-11	4.02e-08	0.63	0.51	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
PCPG	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	7.29	1.66e-11	4.03e-08	0.79	0.51	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
PCPG	cis	rs910316	0.789	rs12894419	ENSG00000279594.1	RP11-950C14.10	7.29	1.66e-11	4.03e-08	0.66	0.51	Height;	chr14:75005099	chr14:75011269~75012851:-
PCPG	cis	rs748404	0.578	rs2244746	ENSG00000205771.5	CATSPER2P1	-7.29	1.67e-11	4.05e-08	-0.58	-0.51	Lung cancer;	chr15:43402885	chr15:43726918~43747094:-
PCPG	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-7.29	1.68e-11	4.07e-08	-0.79	-0.51	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
PCPG	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	7.29	1.68e-11	4.08e-08	0.66	0.51	Height;	chr14:74990535	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.763	rs12588981	ENSG00000279594.1	RP11-950C14.10	7.29	1.68e-11	4.08e-08	0.66	0.51	Height;	chr14:74993858	chr14:75011269~75012851:-
PCPG	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	7.29	1.69e-11	4.08e-08	0.55	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	7.29	1.69e-11	4.08e-08	0.55	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
PCPG	cis	rs12220777	1	rs11201297	ENSG00000230091.5	TMEM254-AS1	7.29	1.69e-11	4.09e-08	0.93	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033993	chr10:80046860~80078912:-
PCPG	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	7.29	1.69e-11	4.09e-08	0.93	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
PCPG	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-7.29	1.69e-11	4.1e-08	-0.55	-0.51	Height;	chr3:52967831	chr3:53064283~53065091:-
PCPG	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	7.28	1.71e-11	4.13e-08	0.69	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
PCPG	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-7.28	1.71e-11	4.14e-08	-0.52	-0.51	Height;	chr3:53085518	chr3:53064283~53065091:-
PCPG	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	7.28	1.71e-11	4.14e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	7.28	1.71e-11	4.14e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	7.28	1.71e-11	4.14e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
PCPG	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-7.28	1.71e-11	4.14e-08	-0.64	-0.51	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
PCPG	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	7.28	1.73e-11	4.17e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
PCPG	cis	rs910316	0.763	rs4556	ENSG00000279594.1	RP11-950C14.10	7.28	1.74e-11	4.2e-08	0.66	0.51	Height;	chr14:75009368	chr14:75011269~75012851:-
PCPG	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-7.28	1.77e-11	4.26e-08	-0.59	-0.51	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
PCPG	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-7.28	1.77e-11	4.26e-08	-0.55	-0.51	Height;	chr3:53027969	chr3:53064283~53065091:-
PCPG	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-7.28	1.77e-11	4.26e-08	-0.55	-0.51	Height;	chr3:53029908	chr3:53064283~53065091:-
PCPG	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-7.28	1.77e-11	4.26e-08	-0.55	-0.51	Height;	chr3:53034139	chr3:53064283~53065091:-
PCPG	cis	rs4835473	0.864	rs2323418	ENSG00000250345.2	RP11-780M14.1	-7.28	1.77e-11	4.28e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143969141	chr4:143760399~143762093:-
PCPG	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	7.28	1.79e-11	4.31e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	7.28	1.79e-11	4.31e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	7.28	1.79e-11	4.31e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	7.28	1.79e-11	4.31e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	7.28	1.79e-11	4.31e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
PCPG	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	7.28	1.79e-11	4.31e-08	0.67	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
PCPG	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	7.28	1.79e-11	4.31e-08	0.68	0.51	Depression;	chr6:28086929	chr6:28115628~28116551:+
PCPG	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	7.28	1.79e-11	4.32e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	7.28	1.79e-11	4.32e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
PCPG	cis	rs4835473	0.932	rs2323417	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143969108	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs11931330	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143970808	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.549	rs11940719	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143970855	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.83	rs7692672	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143971048	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.766	rs6537222	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143971459	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs6537223	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143971541	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.742	rs1838519	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143972242	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs4452380	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143972856	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs7689328	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143973768	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs7694353	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143973787	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.798	rs34353812	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143973949	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs10428468	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143974104	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.75	rs57610804	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143974341	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13148097	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143976238	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs28377887	ENSG00000250345.2	RP11-780M14.1	-7.27	1.8e-11	4.33e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143977075	chr4:143760399~143762093:-
PCPG	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-7.27	1.81e-11	4.34e-08	-0.67	-0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
PCPG	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	7.27	1.82e-11	4.38e-08	0.71	0.51	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	7.27	1.82e-11	4.38e-08	0.71	0.51	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	7.27	1.82e-11	4.38e-08	0.71	0.51	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
PCPG	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-7.27	1.84e-11	4.41e-08	-0.71	-0.51	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
PCPG	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	7.27	1.84e-11	4.43e-08	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
PCPG	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	7.27	1.86e-11	4.45e-08	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
PCPG	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-7.27	1.88e-11	4.5e-08	-0.64	-0.51	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
PCPG	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	7.27	1.88e-11	4.51e-08	0.72	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
PCPG	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	7.26	1.9e-11	4.55e-08	0.71	0.51	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
PCPG	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-7.26	1.91e-11	4.58e-08	-0.54	-0.51	Height;	chr3:53047596	chr3:53064283~53065091:-
PCPG	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	7.26	1.94e-11	4.65e-08	0.68	0.51	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
PCPG	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-7.26	1.94e-11	4.65e-08	-0.62	-0.51	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
PCPG	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	7.26	1.96e-11	4.7e-08	0.69	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
PCPG	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-7.26	1.96e-11	4.7e-08	-0.69	-0.51	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
PCPG	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	7.26	1.98e-11	4.72e-08	0.63	0.51	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
PCPG	cis	rs4835473	0.897	rs7682204	ENSG00000250345.2	RP11-780M14.1	-7.26	1.98e-11	4.73e-08	-0.64	-0.51	Immature fraction of reticulocytes;	chr4:143966306	chr4:143760399~143762093:-
PCPG	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	7.26	1.98e-11	4.74e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	7.26	1.98e-11	4.74e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
PCPG	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-7.26	1.98e-11	4.74e-08	-0.58	-0.51	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
PCPG	cis	rs910316	0.673	rs2012627	ENSG00000279594.1	RP11-950C14.10	7.26	2e-11	4.77e-08	0.64	0.51	Height;	chr14:74976400	chr14:75011269~75012851:-
PCPG	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-7.26	2e-11	4.77e-08	-0.72	-0.51	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
PCPG	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-7.25	2.03e-11	4.83e-08	-0.59	-0.51	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
PCPG	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-7.25	2.04e-11	4.87e-08	-0.77	-0.51	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
PCPG	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	7.25	2.05e-11	4.89e-08	0.6	0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
PCPG	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	7.25	2.06e-11	4.91e-08	0.54	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
PCPG	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	7.25	2.06e-11	4.91e-08	1	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
PCPG	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	7.24	2.12e-11	5.04e-08	0.47	0.51	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
PCPG	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	7.24	2.13e-11	5.06e-08	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
PCPG	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	7.24	2.16e-11	5.12e-08	0.64	0.51	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
PCPG	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-7.24	2.16e-11	5.12e-08	-0.59	-0.51	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
PCPG	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-7.24	2.18e-11	5.18e-08	-0.63	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
PCPG	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	7.24	2.19e-11	5.2e-08	0.58	0.51	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
PCPG	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-7.24	2.2e-11	5.21e-08	-0.5	-0.51	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
PCPG	cis	rs4835473	0.932	rs4835118	ENSG00000250345.2	RP11-780M14.1	-7.24	2.2e-11	5.21e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143981994	chr4:143760399~143762093:-
PCPG	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-7.24	2.21e-11	5.24e-08	-0.77	-0.51	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
PCPG	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	7.24	2.23e-11	5.29e-08	0.5	0.51	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	7.24	2.23e-11	5.29e-08	0.5	0.51	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
PCPG	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-7.23	2.24e-11	5.3e-08	-0.73	-0.51	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
PCPG	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	7.23	2.25e-11	5.32e-08	0.64	0.51	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
PCPG	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	7.23	2.25e-11	5.32e-08	0.64	0.51	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
PCPG	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	7.23	2.26e-11	5.35e-08	0.57	0.51	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
PCPG	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-7.23	2.26e-11	5.36e-08	-0.55	-0.51	Height;	chr3:53029854	chr3:53064283~53065091:-
PCPG	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	7.23	2.28e-11	5.39e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	7.23	2.28e-11	5.39e-08	0.63	0.51	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
PCPG	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-7.23	2.28e-11	5.39e-08	-0.7	-0.51	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
PCPG	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-7.23	2.28e-11	5.39e-08	-0.7	-0.51	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
PCPG	cis	rs916888	0.773	rs199439	ENSG00000232300.1	FAM215B	7.23	2.3e-11	5.44e-08	0.76	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46558830~46562795:-
PCPG	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-7.23	2.31e-11	5.46e-08	-0.65	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
PCPG	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-7.23	2.31e-11	5.46e-08	-0.71	-0.51	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
PCPG	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-7.22	2.36e-11	5.58e-08	-0.61	-0.51	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
PCPG	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-7.22	2.37e-11	5.59e-08	-0.56	-0.51	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
PCPG	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-7.22	2.37e-11	5.59e-08	-0.68	-0.51	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
PCPG	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.22	2.37e-11	5.6e-08	-0.68	-0.51	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
PCPG	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	7.22	2.38e-11	5.61e-08	0.71	0.51	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	7.22	2.38e-11	5.61e-08	0.71	0.51	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	7.22	2.38e-11	5.61e-08	0.71	0.51	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
PCPG	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-7.22	2.38e-11	5.61e-08	-0.74	-0.51	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
PCPG	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-7.22	2.38e-11	5.62e-08	-0.7	-0.51	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
PCPG	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-7.22	2.39e-11	5.63e-08	-0.67	-0.51	Depression;	chr6:28110254	chr6:28115628~28116551:+
PCPG	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	7.22	2.39e-11	5.63e-08	0.48	0.51	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.932	rs10025527	ENSG00000250345.2	RP11-780M14.1	-7.22	2.4e-11	5.67e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143968391	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs3872	ENSG00000250345.2	RP11-780M14.1	-7.22	2.4e-11	5.67e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143968788	chr4:143760399~143762093:-
PCPG	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	7.22	2.42e-11	5.7e-08	0.99	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
PCPG	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	7.22	2.43e-11	5.73e-08	0.7	0.51	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
PCPG	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-7.22	2.45e-11	5.78e-08	-0.74	-0.51	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
PCPG	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	7.22	2.47e-11	5.81e-08	0.61	0.51	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
PCPG	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-7.22	2.49e-11	5.86e-08	-0.5	-0.51	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-7.22	2.49e-11	5.86e-08	-0.5	-0.51	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
PCPG	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	7.21	2.5e-11	5.88e-08	0.64	0.51	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	7.21	2.5e-11	5.88e-08	0.64	0.51	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
PCPG	cis	rs910316	0.763	rs6574205	ENSG00000279594.1	RP11-950C14.10	7.21	2.51e-11	5.91e-08	0.66	0.51	Height;	chr14:74986336	chr14:75011269~75012851:-
PCPG	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-7.21	2.52e-11	5.94e-08	-0.69	-0.51	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
PCPG	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	7.21	2.55e-11	5.99e-08	0.62	0.51	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
PCPG	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-7.21	2.59e-11	6.08e-08	-0.68	-0.51	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
PCPG	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	7.21	2.63e-11	6.17e-08	0.65	0.51	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
PCPG	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-7.2	2.63e-11	6.17e-08	-0.68	-0.51	Depression;	chr6:28140307	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-7.2	2.63e-11	6.17e-08	-0.68	-0.51	Depression;	chr6:28140454	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-7.2	2.63e-11	6.17e-08	-0.68	-0.51	Depression;	chr6:28141189	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-7.2	2.63e-11	6.17e-08	-0.68	-0.51	Depression;	chr6:28141484	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	7.2	2.63e-11	6.17e-08	0.68	0.51	Depression;	chr6:28142370	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-7.2	2.63e-11	6.17e-08	-0.68	-0.51	Depression;	chr6:28143758	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-7.2	2.63e-11	6.17e-08	-0.68	-0.51	Depression;	chr6:28144784	chr6:28115628~28116551:+
PCPG	cis	rs7195287	0.591	rs63744561	ENSG00000276791.1	CTD-2270P14.5	7.2	2.67e-11	6.25e-08	0.58	0.51	Eosinophil counts;	chr16:2778171	chr16:2777319~2780568:+
PCPG	cis	rs2335455	1	rs2335455	ENSG00000276791.1	CTD-2270P14.5	7.2	2.67e-11	6.25e-08	0.58	0.51	Sum eosinophil basophil counts;	chr16:2778172	chr16:2777319~2780568:+
PCPG	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	7.2	2.67e-11	6.26e-08	0.56	0.51	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
PCPG	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	7.2	2.67e-11	6.26e-08	0.62	0.51	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
PCPG	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-7.2	2.68e-11	6.28e-08	-0.5	-0.51	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
PCPG	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-7.2	2.69e-11	6.29e-08	-0.54	-0.51	Height;	chr3:53007328	chr3:53064283~53065091:-
PCPG	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-7.2	2.69e-11	6.29e-08	-0.54	-0.51	Height;	chr3:53009621	chr3:53064283~53065091:-
PCPG	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-7.2	2.69e-11	6.29e-08	-0.54	-0.51	Height;	chr3:53015087	chr3:53064283~53065091:-
PCPG	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	7.2	2.73e-11	6.38e-08	0.71	0.51	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
PCPG	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	7.2	2.73e-11	6.38e-08	0.64	0.51	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
PCPG	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-7.2	2.76e-11	6.45e-08	-0.74	-0.51	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
PCPG	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-7.2	2.78e-11	6.48e-08	-0.71	-0.51	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
PCPG	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	7.19	2.78e-11	6.49e-08	0.55	0.51	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
PCPG	cis	rs910316	1	rs2098297	ENSG00000279594.1	RP11-950C14.10	-7.19	2.8e-11	6.52e-08	-0.64	-0.51	Height;	chr14:75152415	chr14:75011269~75012851:-
PCPG	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-7.19	2.8e-11	6.53e-08	-0.68	-0.51	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
PCPG	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-7.19	2.82e-11	6.57e-08	-0.65	-0.51	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
PCPG	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	7.19	2.84e-11	6.61e-08	0.55	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
PCPG	cis	rs910316	1	rs10142865	ENSG00000279594.1	RP11-950C14.10	7.19	2.84e-11	6.61e-08	0.64	0.51	Height;	chr14:75088921	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs10142626	ENSG00000279594.1	RP11-950C14.10	7.19	2.84e-11	6.61e-08	0.64	0.51	Height;	chr14:75088933	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs7142235	ENSG00000279594.1	RP11-950C14.10	7.19	2.84e-11	6.61e-08	0.64	0.51	Height;	chr14:75093260	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs2010678	ENSG00000279594.1	RP11-950C14.10	7.19	2.84e-11	6.61e-08	0.64	0.51	Height;	chr14:75100475	chr14:75011269~75012851:-
PCPG	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	7.19	2.84e-11	6.62e-08	0.7	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
PCPG	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	7.19	2.84e-11	6.62e-08	0.55	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	7.19	2.85e-11	6.62e-08	0.55	0.51	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
PCPG	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	7.19	2.85e-11	6.63e-08	0.65	0.51	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
PCPG	cis	rs910316	0.967	rs11159116	ENSG00000279594.1	RP11-950C14.10	7.19	2.86e-11	6.66e-08	0.64	0.51	Height;	chr14:75083881	chr14:75011269~75012851:-
PCPG	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-7.19	2.88e-11	6.7e-08	-0.56	-0.51	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
PCPG	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	7.19	2.9e-11	6.74e-08	0.62	0.51	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
PCPG	cis	rs910316	1	rs12590452	ENSG00000279594.1	RP11-950C14.10	7.19	2.9e-11	6.75e-08	0.64	0.51	Height;	chr14:75082053	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs1043674	ENSG00000279594.1	RP11-950C14.10	7.19	2.9e-11	6.75e-08	0.64	0.51	Height;	chr14:75082667	chr14:75011269~75012851:-
PCPG	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-7.19	2.91e-11	6.76e-08	-0.63	-0.51	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
PCPG	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	7.19	2.93e-11	6.8e-08	0.64	0.51	Depression;	chr6:28273214	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	7.19	2.93e-11	6.8e-08	0.64	0.51	Depression;	chr6:28273215	chr6:28176188~28176674:+
PCPG	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	7.18	2.96e-11	6.86e-08	0.71	0.51	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
PCPG	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	7.18	2.96e-11	6.86e-08	0.69	0.51	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	7.18	2.96e-11	6.86e-08	0.69	0.51	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
PCPG	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-7.18	2.97e-11	6.9e-08	-0.63	-0.51	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
PCPG	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-7.18	3.01e-11	6.97e-08	-0.55	-0.51	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
PCPG	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-7.18	3.03e-11	7.02e-08	-0.59	-0.51	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-7.18	3.03e-11	7.02e-08	-0.59	-0.51	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
PCPG	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	7.18	3.05e-11	7.05e-08	0.71	0.51	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	7.18	3.05e-11	7.05e-08	0.71	0.51	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
PCPG	cis	rs4835473	0.932	rs4835471	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143982153	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs4835119	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143982210	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4835120	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143982370	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4835472	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143982398	chr4:143760399~143762093:-
PCPG	cis	rs4835473	1	rs4835473	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143982419	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs4835474	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143982444	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6847869	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143982881	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs6846984	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143983098	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs34617134	ENSG00000250345.2	RP11-780M14.1	-7.18	3.06e-11	7.08e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143983606	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-7.18	3.08e-11	7.13e-08	-0.57	-0.51	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
PCPG	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-7.18	3.08e-11	7.13e-08	-0.64	-0.51	Height;	chr14:75163675	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	7.18	3.08e-11	7.13e-08	0.64	0.51	Height;	chr14:75159339	chr14:75011269~75012851:-
PCPG	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-7.17	3.1e-11	7.16e-08	-0.58	-0.51	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
PCPG	cis	rs4835473	0.639	rs28674022	ENSG00000250345.2	RP11-780M14.1	-7.17	3.1e-11	7.16e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143966409	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs28423022	ENSG00000250345.2	RP11-780M14.1	-7.17	3.1e-11	7.16e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143966416	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs35888177	ENSG00000250345.2	RP11-780M14.1	-7.17	3.1e-11	7.16e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143966863	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs10033382	ENSG00000250345.2	RP11-780M14.1	-7.17	3.1e-11	7.16e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143967103	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7667092	ENSG00000250345.2	RP11-780M14.1	-7.17	3.1e-11	7.16e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143968604	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs3874	ENSG00000250345.2	RP11-780M14.1	-7.17	3.1e-11	7.16e-08	-0.63	-0.51	Immature fraction of reticulocytes;	chr4:143968795	chr4:143760399~143762093:-
PCPG	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	7.17	3.12e-11	7.21e-08	0.5	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
PCPG	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	7.17	3.14e-11	7.24e-08	0.69	0.51	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
PCPG	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-7.17	3.15e-11	7.27e-08	-0.62	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
PCPG	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-7.17	3.15e-11	7.27e-08	-0.71	-0.51	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
PCPG	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	7.17	3.17e-11	7.31e-08	0.7	0.51	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	7.17	3.17e-11	7.31e-08	0.7	0.51	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	7.17	3.17e-11	7.31e-08	0.7	0.51	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
PCPG	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-7.17	3.18e-11	7.33e-08	-0.58	-0.51	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
PCPG	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-7.17	3.2e-11	7.37e-08	-0.69	-0.51	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
PCPG	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-7.17	3.2e-11	7.37e-08	-0.69	-0.51	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
PCPG	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	7.17	3.26e-11	7.5e-08	0.64	0.5	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
PCPG	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	7.17	3.26e-11	7.5e-08	0.63	0.5	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	7.17	3.26e-11	7.5e-08	0.63	0.5	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
PCPG	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	7.16	3.28e-11	7.56e-08	0.48	0.5	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
PCPG	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-7.16	3.29e-11	7.57e-08	-0.64	-0.5	Height;	chr14:74997592	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-7.16	3.29e-11	7.57e-08	-0.64	-0.5	Height;	chr14:74998335	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-7.16	3.29e-11	7.57e-08	-0.64	-0.5	Height;	chr14:75002852	chr14:75011269~75012851:-
PCPG	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	7.16	3.32e-11	7.64e-08	0.65	0.5	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
PCPG	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-7.16	3.33e-11	7.65e-08	-0.68	-0.5	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
PCPG	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-7.16	3.33e-11	7.66e-08	-0.62	-0.5	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
PCPG	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-7.16	3.35e-11	7.7e-08	-0.68	-0.5	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
PCPG	cis	rs4835473	0.897	rs35140014	ENSG00000250345.2	RP11-780M14.1	-7.16	3.37e-11	7.73e-08	-0.63	-0.5	Immature fraction of reticulocytes;	chr4:143964292	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7693772	ENSG00000250345.2	RP11-780M14.1	-7.16	3.38e-11	7.77e-08	-0.62	-0.5	Immature fraction of reticulocytes;	chr4:143965614	chr4:143760399~143762093:-
PCPG	cis	rs910316	0.763	rs175016	ENSG00000279594.1	RP11-950C14.10	-7.16	3.4e-11	7.79e-08	-0.64	-0.5	Height;	chr14:74992930	chr14:75011269~75012851:-
PCPG	cis	rs4835473	0.736	rs11724009	ENSG00000250345.2	RP11-780M14.1	-7.16	3.4e-11	7.8e-08	-0.63	-0.5	Immature fraction of reticulocytes;	chr4:143984291	chr4:143760399~143762093:-
PCPG	cis	rs4323050	0.514	rs28647406	ENSG00000250345.2	RP11-780M14.1	-7.16	3.4e-11	7.8e-08	-0.63	-0.5	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.604	rs11938387	ENSG00000250345.2	RP11-780M14.1	-7.16	3.4e-11	7.8e-08	-0.63	-0.5	Immature fraction of reticulocytes;	chr4:143984476	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.798	rs11100829	ENSG00000250345.2	RP11-780M14.1	-7.16	3.4e-11	7.8e-08	-0.63	-0.5	Immature fraction of reticulocytes;	chr4:143984761	chr4:143760399~143762093:-
PCPG	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-7.16	3.42e-11	7.84e-08	-0.71	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
PCPG	cis	rs910316	1	rs3742773	ENSG00000279594.1	RP11-950C14.10	7.16	3.44e-11	7.9e-08	0.64	0.5	Height;	chr14:75112940	chr14:75011269~75012851:-
PCPG	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-7.15	3.48e-11	7.97e-08	-0.58	-0.5	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
PCPG	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	7.15	3.51e-11	8.03e-08	0.65	0.5	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	7.15	3.51e-11	8.03e-08	0.65	0.5	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
PCPG	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-7.15	3.55e-11	8.14e-08	-0.61	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
PCPG	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-7.15	3.56e-11	8.14e-08	-0.7	-0.5	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
PCPG	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-7.15	3.57e-11	8.16e-08	-0.53	-0.5	Height;	chr3:53074760	chr3:53064283~53065091:-
PCPG	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	7.15	3.6e-11	8.21e-08	0.69	0.5	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
PCPG	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	7.15	3.6e-11	8.22e-08	0.71	0.5	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
PCPG	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-7.15	3.63e-11	8.28e-08	-0.69	-0.5	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
PCPG	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-7.14	3.64e-11	8.32e-08	-0.69	-0.5	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
PCPG	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-7.14	3.65e-11	8.33e-08	-0.58	-0.5	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-7.14	3.65e-11	8.33e-08	-0.58	-0.5	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
PCPG	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	7.14	3.67e-11	8.36e-08	0.68	0.5	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
PCPG	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-7.14	3.68e-11	8.39e-08	-0.56	-0.5	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
PCPG	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-7.14	3.69e-11	8.41e-08	-0.68	-0.5	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
PCPG	cis	rs4835473	0.722	rs7666296	ENSG00000250345.2	RP11-780M14.1	7.14	3.71e-11	8.44e-08	0.64	0.5	Immature fraction of reticulocytes;	chr4:143999004	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.722	rs7662277	ENSG00000250345.2	RP11-780M14.1	7.14	3.71e-11	8.44e-08	0.64	0.5	Immature fraction of reticulocytes;	chr4:143999485	chr4:143760399~143762093:-
PCPG	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	7.14	3.71e-11	8.45e-08	0.7	0.5	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
PCPG	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	7.14	3.76e-11	8.56e-08	0.53	0.5	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
PCPG	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	7.14	3.77e-11	8.57e-08	0.7	0.5	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	7.14	3.77e-11	8.57e-08	0.7	0.5	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
PCPG	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	7.14	3.81e-11	8.66e-08	0.72	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	7.14	3.81e-11	8.66e-08	0.72	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-7.14	3.81e-11	8.66e-08	-0.72	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
PCPG	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	7.14	3.84e-11	8.71e-08	0.55	0.5	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
PCPG	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-7.14	3.84e-11	8.72e-08	-0.67	-0.5	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-7.14	3.84e-11	8.72e-08	-0.67	-0.5	Depression;	chr6:28112175	chr6:28115628~28116551:+
PCPG	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	7.13	3.87e-11	8.78e-08	0.63	0.5	Myopia;	chr6:28302807	chr6:28176188~28176674:+
PCPG	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-7.13	3.89e-11	8.81e-08	-0.64	-0.5	Height;	chr14:75022929	chr14:75011269~75012851:-
PCPG	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-7.13	3.89e-11	8.81e-08	-0.68	-0.5	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
PCPG	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-7.13	3.9e-11	8.84e-08	-0.55	-0.5	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-7.13	3.9e-11	8.84e-08	-0.55	-0.5	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-7.13	3.9e-11	8.84e-08	-0.55	-0.5	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
PCPG	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	7.13	3.91e-11	8.86e-08	0.64	0.5	Height;	chr14:75075251	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-7.13	3.91e-11	8.86e-08	-0.64	-0.5	Height;	chr14:75071514	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.935	rs2268620	ENSG00000279594.1	RP11-950C14.10	-7.13	3.92e-11	8.89e-08	-0.64	-0.5	Height;	chr14:75173700	chr14:75011269~75012851:-
PCPG	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-7.13	3.93e-11	8.89e-08	-0.65	-0.5	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
PCPG	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	7.13	3.93e-11	8.89e-08	0.65	0.5	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
PCPG	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-7.13	3.95e-11	8.93e-08	-0.42	-0.5	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
PCPG	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-7.13	3.95e-11	8.94e-08	-0.67	-0.5	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
PCPG	cis	rs910316	0.904	rs7156089	ENSG00000279594.1	RP11-950C14.10	-7.13	3.96e-11	8.95e-08	-0.64	-0.5	Height;	chr14:75178824	chr14:75011269~75012851:-
PCPG	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	7.13	3.96e-11	8.96e-08	0.72	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	7.13	3.96e-11	8.96e-08	0.72	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
PCPG	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-7.13	3.97e-11	8.96e-08	-0.62	-0.5	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
PCPG	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	7.13	3.97e-11	8.97e-08	0.64	0.5	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
PCPG	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-7.13	4.02e-11	9.07e-08	-0.73	-0.5	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
PCPG	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	7.13	4.03e-11	9.1e-08	0.52	0.5	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
PCPG	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	7.13	4.04e-11	9.1e-08	0.7	0.5	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	7.13	4.04e-11	9.1e-08	0.7	0.5	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
PCPG	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	7.12	4.1e-11	9.25e-08	0.42	0.5	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
PCPG	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-7.12	4.12e-11	9.29e-08	-0.54	-0.5	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
PCPG	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	7.12	4.14e-11	9.32e-08	0.7	0.5	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
PCPG	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	7.12	4.15e-11	9.34e-08	0.62	0.5	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	7.12	4.15e-11	9.34e-08	0.62	0.5	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
PCPG	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	7.12	4.18e-11	9.4e-08	0.63	0.5	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
PCPG	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-7.12	4.18e-11	9.4e-08	-0.62	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
PCPG	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-7.12	4.22e-11	9.47e-08	-0.55	-0.5	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
PCPG	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-7.12	4.23e-11	9.51e-08	-0.54	-0.5	Height;	chr3:52989619	chr3:53064283~53065091:-
PCPG	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-7.12	4.24e-11	9.51e-08	-0.54	-0.5	Height;	chr3:53080524	chr3:53064283~53065091:-
PCPG	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	7.12	4.28e-11	9.59e-08	0.74	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
PCPG	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	7.12	4.28e-11	9.6e-08	0.48	0.5	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	7.12	4.28e-11	9.6e-08	0.48	0.5	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
PCPG	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-7.11	4.32e-11	9.69e-08	-0.67	-0.5	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
PCPG	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	7.11	4.33e-11	9.7e-08	0.63	0.5	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	7.11	4.33e-11	9.7e-08	0.63	0.5	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
PCPG	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-7.11	4.34e-11	9.73e-08	-0.61	-0.5	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
PCPG	cis	rs4835473	0.932	rs11100824	ENSG00000250345.2	RP11-780M14.1	-7.11	4.36e-11	9.78e-08	-0.63	-0.5	Immature fraction of reticulocytes;	chr4:143964845	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.592	rs11100825	ENSG00000250345.2	RP11-780M14.1	-7.11	4.36e-11	9.78e-08	-0.63	-0.5	Immature fraction of reticulocytes;	chr4:143964903	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs2089835	ENSG00000250345.2	RP11-780M14.1	-7.11	4.36e-11	9.78e-08	-0.63	-0.5	Immature fraction of reticulocytes;	chr4:143965127	chr4:143760399~143762093:-
PCPG	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-7.11	4.38e-11	9.81e-08	-0.71	-0.5	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
PCPG	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-7.11	4.4e-11	9.84e-08	-0.52	-0.5	Height;	chr3:53069965	chr3:53064283~53065091:-
PCPG	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-7.11	4.41e-11	9.87e-08	-0.63	-0.5	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
PCPG	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-7.11	4.42e-11	9.89e-08	-0.66	-0.5	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
PCPG	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	7.11	4.42e-11	9.89e-08	0.71	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
PCPG	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-7.11	4.44e-11	9.92e-08	-0.64	-0.5	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
PCPG	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-7.11	4.44e-11	9.92e-08	-0.7	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
PCPG	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-7.11	4.45e-11	9.96e-08	-0.47	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
PCPG	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-7.11	4.46e-11	9.97e-08	-0.61	-0.5	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
PCPG	cis	rs748404	0.578	rs2584701	ENSG00000205771.5	CATSPER2P1	-7.11	4.46e-11	9.97e-08	-0.58	-0.5	Lung cancer;	chr15:43392741	chr15:43726918~43747094:-
PCPG	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	7.11	4.48e-11	1e-07	0.69	0.5	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
PCPG	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	7.11	4.48e-11	1e-07	0.68	0.5	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
PCPG	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-7.1	4.53e-11	1.01e-07	-0.56	-0.5	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
PCPG	cis	rs910316	0.763	rs1548807	ENSG00000279594.1	RP11-950C14.10	7.1	4.57e-11	1.02e-07	0.65	0.5	Height;	chr14:75012879	chr14:75011269~75012851:-
PCPG	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	7.1	4.58e-11	1.02e-07	0.58	0.5	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
PCPG	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	7.1	4.59e-11	1.02e-07	0.68	0.5	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
PCPG	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	7.1	4.59e-11	1.02e-07	0.76	0.5	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
PCPG	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	7.1	4.6e-11	1.02e-07	0.51	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
PCPG	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	7.1	4.6e-11	1.02e-07	0.58	0.5	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
PCPG	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.1	4.6e-11	1.02e-07	0.68	0.5	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
PCPG	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	7.1	4.64e-11	1.03e-07	0.7	0.5	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	7.1	4.64e-11	1.03e-07	0.7	0.5	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	7.1	4.64e-11	1.03e-07	0.7	0.5	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	7.1	4.64e-11	1.03e-07	0.7	0.5	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	7.1	4.64e-11	1.03e-07	0.7	0.5	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
PCPG	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	7.1	4.66e-11	1.04e-07	0.81	0.5	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
PCPG	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	7.1	4.7e-11	1.05e-07	0.75	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	7.1	4.74e-11	1.05e-07	0.71	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
PCPG	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-7.1	4.74e-11	1.05e-07	-0.55	-0.5	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
PCPG	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	7.1	4.74e-11	1.05e-07	0.7	0.5	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
PCPG	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	7.1	4.74e-11	1.05e-07	0.62	0.5	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
PCPG	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	7.1	4.75e-11	1.05e-07	0.5	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
PCPG	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-7.1	4.78e-11	1.06e-07	-0.6	-0.5	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
PCPG	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	7.09	4.83e-11	1.07e-07	0.64	0.5	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	7.09	4.83e-11	1.07e-07	0.64	0.5	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	7.09	4.83e-11	1.07e-07	0.64	0.5	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
PCPG	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-7.09	4.85e-11	1.08e-07	-0.52	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
PCPG	cis	rs910316	1	rs7156328	ENSG00000279594.1	RP11-950C14.10	7.09	4.86e-11	1.08e-07	0.63	0.5	Height;	chr14:75066238	chr14:75011269~75012851:-
PCPG	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-7.09	4.87e-11	1.08e-07	-0.74	-0.5	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
PCPG	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-7.09	4.92e-11	1.09e-07	-0.69	-0.5	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
PCPG	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	7.09	5.04e-11	1.12e-07	0.66	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
PCPG	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	7.09	5.04e-11	1.12e-07	0.7	0.5	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
PCPG	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-7.08	5.06e-11	1.12e-07	-0.6	-0.5	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
PCPG	cis	rs910316	1	rs7303	ENSG00000279594.1	RP11-950C14.10	7.08	5.08e-11	1.13e-07	0.63	0.5	Height;	chr14:75053362	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs10143132	ENSG00000279594.1	RP11-950C14.10	7.08	5.08e-11	1.13e-07	0.63	0.5	Height;	chr14:75059147	chr14:75011269~75012851:-
PCPG	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-7.08	5.1e-11	1.13e-07	-0.66	-0.5	Depression;	chr6:28139876	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-7.08	5.1e-11	1.13e-07	-0.66	-0.5	Depression;	chr6:28139998	chr6:28115628~28116551:+
PCPG	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	7.08	5.11e-11	1.13e-07	0.65	0.5	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
PCPG	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	7.08	5.12e-11	1.13e-07	0.47	0.5	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
PCPG	cis	rs4835473	0.9	rs3856989	ENSG00000250345.2	RP11-780M14.1	-7.08	5.13e-11	1.13e-07	-0.61	-0.5	Immature fraction of reticulocytes;	chr4:143921752	chr4:143760399~143762093:-
PCPG	cis	rs910316	1	rs4903289	ENSG00000279594.1	RP11-950C14.10	-7.08	5.14e-11	1.14e-07	-0.62	-0.5	Height;	chr14:75157285	chr14:75011269~75012851:-
PCPG	cis	rs748404	0.578	rs2012467	ENSG00000205771.5	CATSPER2P1	-7.08	5.19e-11	1.15e-07	-0.58	-0.5	Lung cancer;	chr15:43398367	chr15:43726918~43747094:-
PCPG	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	7.08	5.19e-11	1.15e-07	0.71	0.5	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
PCPG	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-7.08	5.22e-11	1.15e-07	-0.67	-0.5	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
PCPG	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	7.08	5.23e-11	1.15e-07	0.64	0.5	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	7.08	5.23e-11	1.15e-07	0.64	0.5	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	7.08	5.23e-11	1.15e-07	0.64	0.5	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
PCPG	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	7.08	5.24e-11	1.16e-07	0.54	0.5	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
PCPG	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-7.08	5.27e-11	1.16e-07	-0.58	-0.5	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
PCPG	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	7.08	5.27e-11	1.16e-07	0.58	0.5	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
PCPG	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	7.08	5.3e-11	1.17e-07	0.63	0.5	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	7.08	5.3e-11	1.17e-07	0.64	0.5	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
PCPG	cis	rs910316	1	rs175512	ENSG00000279594.1	RP11-950C14.10	-7.08	5.32e-11	1.17e-07	-0.64	-0.5	Height;	chr14:75056679	chr14:75011269~75012851:-
PCPG	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-7.07	5.33e-11	1.18e-07	-0.69	-0.5	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
PCPG	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-7.07	5.38e-11	1.19e-07	-0.68	-0.5	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
PCPG	cis	rs4835473	0.618	rs12499907	ENSG00000250345.2	RP11-780M14.1	7.07	5.42e-11	1.19e-07	0.64	0.5	Immature fraction of reticulocytes;	chr4:143999748	chr4:143760399~143762093:-
PCPG	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	7.07	5.44e-11	1.2e-07	0.65	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
PCPG	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	7.07	5.44e-11	1.2e-07	0.65	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
PCPG	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	7.07	5.44e-11	1.2e-07	0.65	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
PCPG	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-7.07	5.45e-11	1.2e-07	-0.57	-0.5	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
PCPG	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.07	5.54e-11	1.22e-07	-0.68	-0.5	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
PCPG	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-7.07	5.6e-11	1.23e-07	-0.56	-0.5	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
PCPG	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	7.07	5.61e-11	1.23e-07	0.55	0.5	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
PCPG	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-7.06	5.66e-11	1.24e-07	-0.59	-0.5	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-7.06	5.66e-11	1.24e-07	-0.59	-0.5	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
PCPG	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	7.06	5.66e-11	1.24e-07	0.62	0.5	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
PCPG	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-7.06	5.67e-11	1.25e-07	-0.97	-0.5	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
PCPG	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	7.06	5.69e-11	1.25e-07	0.57	0.5	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
PCPG	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	7.06	5.72e-11	1.26e-07	0.64	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
PCPG	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	7.06	5.75e-11	1.26e-07	0.63	0.5	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
PCPG	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-7.06	5.75e-11	1.26e-07	-0.55	-0.5	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
PCPG	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	7.06	5.8e-11	1.27e-07	0.73	0.5	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
PCPG	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-7.06	5.82e-11	1.28e-07	-0.6	-0.5	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-7.06	5.82e-11	1.28e-07	-0.6	-0.5	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
PCPG	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	7.06	5.89e-11	1.29e-07	0.61	0.5	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
PCPG	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-7.06	5.91e-11	1.29e-07	-0.57	-0.5	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
PCPG	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-7.05	6.04e-11	1.32e-07	-0.54	-0.5	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
PCPG	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	7.05	6.09e-11	1.33e-07	0.69	0.5	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	7.05	6.09e-11	1.33e-07	0.69	0.5	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
PCPG	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	7.05	6.1e-11	1.33e-07	0.67	0.5	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.771	rs4835097	ENSG00000250345.2	RP11-780M14.1	-7.05	6.11e-11	1.34e-07	-0.62	-0.5	Immature fraction of reticulocytes;	chr4:143960687	chr4:143760399~143762093:-
PCPG	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	7.05	6.12e-11	1.34e-07	0.57	0.5	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
PCPG	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	7.05	6.13e-11	1.34e-07	0.66	0.5	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
PCPG	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	7.05	6.15e-11	1.34e-07	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
PCPG	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-7.05	6.17e-11	1.35e-07	-0.6	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
PCPG	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	7.05	6.19e-11	1.35e-07	0.65	0.5	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
PCPG	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-7.05	6.25e-11	1.36e-07	-0.66	-0.5	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
PCPG	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	7.04	6.27e-11	1.37e-07	0.61	0.5	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
PCPG	cis	rs7267979	0.816	rs6076358	ENSG00000125804.12	FAM182A	7.04	6.3e-11	1.37e-07	0.59	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26054655~26086917:+
PCPG	cis	rs910316	0.763	rs735452	ENSG00000279594.1	RP11-950C14.10	-7.04	6.31e-11	1.37e-07	-0.64	-0.5	Height;	chr14:75031281	chr14:75011269~75012851:-
PCPG	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	7.04	6.33e-11	1.37e-07	0.63	0.5	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	7.04	6.33e-11	1.37e-07	0.63	0.5	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	7.04	6.33e-11	1.37e-07	0.63	0.5	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	7.04	6.33e-11	1.37e-07	0.63	0.5	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	7.04	6.33e-11	1.37e-07	0.63	0.5	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
PCPG	cis	rs910316	1	rs4899544	ENSG00000279594.1	RP11-950C14.10	7.04	6.38e-11	1.38e-07	0.63	0.5	Height;	chr14:75079853	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs4903279	ENSG00000279594.1	RP11-950C14.10	7.04	6.38e-11	1.38e-07	0.63	0.5	Height;	chr14:75079880	chr14:75011269~75012851:-
PCPG	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-7.04	6.4e-11	1.39e-07	-0.48	-0.5	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
PCPG	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-7.04	6.4e-11	1.39e-07	-0.98	-0.5	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
PCPG	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	7.04	6.42e-11	1.39e-07	0.57	0.5	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
PCPG	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-7.04	6.42e-11	1.39e-07	-0.6	-0.5	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
PCPG	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	7.04	6.46e-11	1.4e-07	0.64	0.5	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
PCPG	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	7.04	6.55e-11	1.42e-07	0.62	0.5	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
PCPG	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	7.04	6.59e-11	1.43e-07	0.68	0.5	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	7.04	6.59e-11	1.43e-07	0.68	0.5	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	7.04	6.59e-11	1.43e-07	0.68	0.5	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	7.04	6.59e-11	1.43e-07	0.68	0.5	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
PCPG	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	7.03	6.64e-11	1.44e-07	0.64	0.5	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
PCPG	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-7.03	6.7e-11	1.45e-07	-0.53	-0.5	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
PCPG	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-7.03	6.72e-11	1.45e-07	-0.58	-0.5	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
PCPG	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	7.03	6.8e-11	1.47e-07	0.62	0.5	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
PCPG	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-7.03	6.8e-11	1.47e-07	-0.59	-0.5	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
PCPG	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-7.03	6.83e-11	1.47e-07	-0.48	-0.5	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
PCPG	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-7.03	6.83e-11	1.47e-07	-0.5	-0.5	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
PCPG	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	7.03	6.88e-11	1.48e-07	0.65	0.5	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
PCPG	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	7.03	6.88e-11	1.48e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
PCPG	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	7.03	6.91e-11	1.49e-07	0.63	0.5	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	7.03	6.91e-11	1.49e-07	0.63	0.5	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
PCPG	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	7.03	6.92e-11	1.49e-07	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
PCPG	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	7.03	6.93e-11	1.49e-07	0.62	0.5	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
PCPG	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	7.02	6.99e-11	1.51e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	7.02	6.99e-11	1.51e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
PCPG	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	7.02	7e-11	1.51e-07	0.71	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
PCPG	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	7.02	7.04e-11	1.52e-07	0.74	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
PCPG	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	7.02	7.05e-11	1.52e-07	0.68	0.5	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
PCPG	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	7.02	7.06e-11	1.52e-07	0.55	0.5	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
PCPG	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-7.02	7.1e-11	1.53e-07	-0.63	-0.5	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-7.02	7.1e-11	1.53e-07	-0.63	-0.5	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-7.02	7.1e-11	1.53e-07	-0.63	-0.5	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
PCPG	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-7.02	7.11e-11	1.53e-07	-0.68	-0.5	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
PCPG	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-7.02	7.16e-11	1.54e-07	-0.56	-0.5	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
PCPG	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	7.02	7.2e-11	1.55e-07	0.64	0.5	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
PCPG	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-7.02	7.33e-11	1.57e-07	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
PCPG	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-7.02	7.33e-11	1.58e-07	-0.97	-0.5	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
PCPG	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-7.01	7.37e-11	1.58e-07	-1	-0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
PCPG	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-7.01	7.38e-11	1.58e-07	-0.62	-0.5	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
PCPG	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-7.01	7.41e-11	1.59e-07	-0.5	-0.5	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-7.01	7.41e-11	1.59e-07	-0.5	-0.5	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-7.01	7.41e-11	1.59e-07	-0.5	-0.5	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
PCPG	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-7.01	7.41e-11	1.59e-07	-0.57	-0.5	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
PCPG	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-7.01	7.42e-11	1.59e-07	-0.57	-0.5	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
PCPG	cis	rs4835473	0.932	rs4305468	ENSG00000250345.2	RP11-780M14.1	7.01	7.43e-11	1.59e-07	0.61	0.5	Immature fraction of reticulocytes;	chr4:143987315	chr4:143760399~143762093:-
PCPG	cis	rs910316	1	rs11845639	ENSG00000279594.1	RP11-950C14.10	7.01	7.43e-11	1.6e-07	0.62	0.5	Height;	chr14:75103590	chr14:75011269~75012851:-
PCPG	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	7.01	7.44e-11	1.6e-07	0.67	0.5	Depression;	chr6:28167882	chr6:28115628~28116551:+
PCPG	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-7.01	7.47e-11	1.6e-07	-0.69	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
PCPG	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	7.01	7.47e-11	1.6e-07	0.62	0.5	Height;	chr14:75044372	chr14:75011269~75012851:-
PCPG	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	7.01	7.52e-11	1.61e-07	0.7	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
PCPG	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-7.01	7.56e-11	1.62e-07	-0.62	-0.5	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-7.01	7.56e-11	1.62e-07	-0.62	-0.5	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
PCPG	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	7.01	7.56e-11	1.62e-07	0.74	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
PCPG	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	7.01	7.61e-11	1.63e-07	0.81	0.5	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
PCPG	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-7.01	7.61e-11	1.63e-07	-0.6	-0.5	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
PCPG	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-7.01	7.61e-11	1.63e-07	-0.54	-0.5	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
PCPG	cis	rs910316	1	rs4899546	ENSG00000279594.1	RP11-950C14.10	7.01	7.64e-11	1.63e-07	0.62	0.5	Height;	chr14:75128243	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs7147118	ENSG00000279594.1	RP11-950C14.10	7.01	7.64e-11	1.63e-07	0.62	0.5	Height;	chr14:75143467	chr14:75011269~75012851:-
PCPG	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	7.01	7.64e-11	1.63e-07	0.66	0.5	Depression;	chr6:28110525	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28111382	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28111650	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28113616	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28113851	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28114487	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28114933	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28115743	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28116411	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28123153	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28124529	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28126588	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28126953	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28127577	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28131566	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28133900	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28136698	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28136856	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28137418	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28138363	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28138981	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28139012	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-7.01	7.64e-11	1.63e-07	-0.66	-0.5	Depression;	chr6:28139049	chr6:28115628~28116551:+
PCPG	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	7.01	7.76e-11	1.66e-07	0.7	0.5	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
PCPG	cis	rs910316	1	rs12897094	ENSG00000279594.1	RP11-950C14.10	7	7.83e-11	1.67e-07	0.63	0.5	Height;	chr14:75112713	chr14:75011269~75012851:-
PCPG	cis	rs9532669	0.89	rs2149570	ENSG00000176268.5	CYCSP34	7	7.84e-11	1.67e-07	0.54	0.5	Cervical cancer;	chr13:40858533	chr13:40863599~40863902:-
PCPG	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	7	7.9e-11	1.68e-07	0.56	0.5	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
PCPG	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	7	7.98e-11	1.7e-07	0.5	0.5	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
PCPG	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-7	8.06e-11	1.72e-07	-0.71	-0.5	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-7	8.06e-11	1.72e-07	-0.71	-0.5	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
PCPG	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	7	8.06e-11	1.72e-07	0.62	0.5	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
PCPG	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	7	8.07e-11	1.72e-07	0.66	0.5	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	7	8.07e-11	1.72e-07	0.66	0.5	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
PCPG	cis	rs916888	0.773	rs199457	ENSG00000232300.1	FAM215B	7	8.08e-11	1.72e-07	0.74	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46558830~46562795:-
PCPG	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	7	8.13e-11	1.73e-07	0.64	0.5	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
PCPG	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	7	8.15e-11	1.73e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	7	8.15e-11	1.73e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	7	8.15e-11	1.73e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	7	8.15e-11	1.73e-07	0.88	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
PCPG	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	7	8.17e-11	1.74e-07	0.55	0.5	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
PCPG	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	7	8.19e-11	1.74e-07	0.49	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
PCPG	cis	rs910316	1	rs4903281	ENSG00000279594.1	RP11-950C14.10	6.99	8.21e-11	1.75e-07	0.63	0.5	Height;	chr14:75087658	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs12589376	ENSG00000279594.1	RP11-950C14.10	6.99	8.21e-11	1.75e-07	0.63	0.5	Height;	chr14:75094449	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs1071989	ENSG00000279594.1	RP11-950C14.10	6.99	8.21e-11	1.75e-07	0.63	0.5	Height;	chr14:75097956	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs9805979	ENSG00000279594.1	RP11-950C14.10	6.99	8.21e-11	1.75e-07	0.63	0.5	Height;	chr14:75099506	chr14:75011269~75012851:-
PCPG	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-6.99	8.29e-11	1.76e-07	-0.67	-0.5	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
PCPG	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-6.99	8.29e-11	1.76e-07	-0.67	-0.5	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
PCPG	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-6.99	8.3e-11	1.76e-07	-0.71	-0.5	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
PCPG	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-6.99	8.31e-11	1.77e-07	-0.68	-0.5	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
PCPG	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-6.99	8.33e-11	1.77e-07	-0.48	-0.5	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
PCPG	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	6.99	8.47e-11	1.8e-07	0.69	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
PCPG	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-6.99	8.47e-11	1.8e-07	-0.69	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
PCPG	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.99	8.47e-11	1.8e-07	-0.67	-0.5	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
PCPG	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-6.99	8.48e-11	1.8e-07	-0.84	-0.5	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
PCPG	cis	rs910316	0.763	rs175047	ENSG00000279594.1	RP11-950C14.10	-6.99	8.48e-11	1.8e-07	-0.63	-0.5	Height;	chr14:75012336	chr14:75011269~75012851:-
PCPG	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-6.99	8.51e-11	1.8e-07	-0.49	-0.5	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	6.99	8.54e-11	1.81e-07	0.48	0.5	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
PCPG	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-6.99	8.58e-11	1.82e-07	-0.43	-0.5	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
PCPG	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-6.99	8.58e-11	1.82e-07	-0.43	-0.5	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
PCPG	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-6.99	8.58e-11	1.82e-07	-0.43	-0.5	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
PCPG	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-6.99	8.58e-11	1.82e-07	-0.43	-0.5	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
PCPG	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	6.98	8.66e-11	1.83e-07	0.67	0.5	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
PCPG	cis	rs4835473	0.663	rs1511423	ENSG00000250345.2	RP11-780M14.1	-6.98	8.68e-11	1.84e-07	-0.61	-0.5	Immature fraction of reticulocytes;	chr4:143990136	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.639	rs5029916	ENSG00000250345.2	RP11-780M14.1	-6.98	8.68e-11	1.84e-07	-0.61	-0.5	Immature fraction of reticulocytes;	chr4:143990684	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1988206	ENSG00000250345.2	RP11-780M14.1	-6.98	8.68e-11	1.84e-07	-0.61	-0.5	Immature fraction of reticulocytes;	chr4:143991344	chr4:143760399~143762093:-
PCPG	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	6.98	8.68e-11	1.84e-07	0.63	0.5	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	6.98	8.68e-11	1.84e-07	0.63	0.5	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
PCPG	cis	rs7267979	0.604	rs242130	ENSG00000125804.12	FAM182A	6.98	8.68e-11	1.84e-07	0.55	0.5	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:26054655~26086917:+
PCPG	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	6.98	8.7e-11	1.84e-07	0.67	0.5	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
PCPG	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	6.98	8.71e-11	1.84e-07	0.68	0.5	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
PCPG	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-6.98	8.75e-11	1.85e-07	-0.61	-0.5	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
PCPG	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	6.98	8.77e-11	1.85e-07	0.86	0.5	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
PCPG	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-6.98	8.89e-11	1.88e-07	-0.68	-0.5	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
PCPG	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	6.98	8.93e-11	1.89e-07	0.67	0.5	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
PCPG	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-6.98	8.97e-11	1.89e-07	-0.59	-0.5	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
PCPG	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-6.98	8.98e-11	1.89e-07	-0.63	-0.5	Height;	chr14:75170656	chr14:75011269~75012851:-
PCPG	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-6.98	8.98e-11	1.89e-07	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-6.98	8.98e-11	1.89e-07	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-6.98	8.98e-11	1.89e-07	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-6.98	8.98e-11	1.89e-07	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-6.98	8.98e-11	1.89e-07	-0.47	-0.5	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
PCPG	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-6.98	9.03e-11	1.9e-07	-0.54	-0.49	Height;	chr3:52975027	chr3:53064283~53065091:-
PCPG	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	6.97	9.13e-11	1.92e-07	0.48	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
PCPG	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	6.97	9.2e-11	1.94e-07	0.67	0.49	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
PCPG	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	6.97	9.22e-11	1.94e-07	0.54	0.49	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
PCPG	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-6.97	9.23e-11	1.94e-07	-0.67	-0.49	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
PCPG	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	6.97	9.26e-11	1.95e-07	0.72	0.49	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
PCPG	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-6.97	9.32e-11	1.96e-07	-0.65	-0.49	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-6.97	9.32e-11	1.96e-07	-0.65	-0.49	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.97	9.32e-11	1.96e-07	-0.65	-0.49	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
PCPG	cis	rs4835473	0.932	rs1511425	ENSG00000250345.2	RP11-780M14.1	-6.97	9.32e-11	1.96e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143985122	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1849120	ENSG00000250345.2	RP11-780M14.1	-6.97	9.32e-11	1.96e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143985337	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4835476	ENSG00000250345.2	RP11-780M14.1	-6.97	9.32e-11	1.96e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143985517	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1828502	ENSG00000250345.2	RP11-780M14.1	-6.97	9.32e-11	1.96e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143985797	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs7668698	ENSG00000250345.2	RP11-780M14.1	-6.97	9.32e-11	1.96e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143986333	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs6537231	ENSG00000250345.2	RP11-780M14.1	-6.97	9.32e-11	1.96e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143986489	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1877234	ENSG00000250345.2	RP11-780M14.1	-6.97	9.32e-11	1.96e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143986774	chr4:143760399~143762093:-
PCPG	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	6.97	9.36e-11	1.97e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
PCPG	cis	rs4835473	0.897	rs4835095	ENSG00000250345.2	RP11-780M14.1	-6.97	9.4e-11	1.97e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143960431	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs2667353	ENSG00000250345.2	RP11-780M14.1	-6.97	9.4e-11	1.97e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143960462	chr4:143760399~143762093:-
PCPG	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	6.97	9.4e-11	1.97e-07	0.62	0.49	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
PCPG	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	6.97	9.4e-11	1.97e-07	0.62	0.49	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
PCPG	cis	rs4835473	0.932	rs6852502	ENSG00000250345.2	RP11-780M14.1	-6.97	9.42e-11	1.98e-07	-0.62	-0.49	Immature fraction of reticulocytes;	chr4:143987174	chr4:143760399~143762093:-
PCPG	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-6.97	9.5e-11	1.99e-07	-0.62	-0.49	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
PCPG	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	6.97	9.54e-11	2e-07	0.67	0.49	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
PCPG	cis	rs9595908	0.931	rs9595595	ENSG00000212293.1	SNORA16	6.96	9.64e-11	2.02e-07	0.6	0.49	Body mass index;	chr13:32473678	chr13:32420390~32420516:-
PCPG	cis	rs916888	0.687	rs199456	ENSG00000232300.1	FAM215B	6.96	9.73e-11	2.04e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46558830~46562795:-
PCPG	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	6.96	9.84e-11	2.06e-07	0.7	0.49	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
PCPG	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-6.96	9.87e-11	2.06e-07	-0.58	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
PCPG	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-6.96	9.88e-11	2.06e-07	-0.55	-0.49	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
PCPG	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-6.96	9.89e-11	2.06e-07	-0.68	-0.49	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
PCPG	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	6.96	9.89e-11	2.06e-07	0.99	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
PCPG	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	6.96	9.96e-11	2.08e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	6.96	9.96e-11	2.08e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	6.96	9.96e-11	2.08e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	6.96	9.96e-11	2.08e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	6.96	9.96e-11	2.08e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	6.96	9.96e-11	2.08e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	6.96	9.96e-11	2.08e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
PCPG	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-6.96	1.01e-10	2.09e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
PCPG	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	6.96	1.01e-10	2.1e-07	0.54	0.49	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	6.96	1.01e-10	2.1e-07	0.54	0.49	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
PCPG	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-6.96	1.01e-10	2.1e-07	-0.61	-0.49	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
PCPG	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	6.96	1.01e-10	2.11e-07	0.67	0.49	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
PCPG	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-6.95	1.02e-10	2.13e-07	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
PCPG	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	6.95	1.02e-10	2.13e-07	0.55	0.49	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
PCPG	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	6.95	1.02e-10	2.13e-07	0.62	0.49	Height;	chr14:75017109	chr14:75011269~75012851:-
PCPG	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	6.95	1.03e-10	2.13e-07	0.61	0.49	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
PCPG	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	6.95	1.03e-10	2.14e-07	0.65	0.49	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
PCPG	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-6.95	1.03e-10	2.14e-07	-0.61	-0.49	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
PCPG	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-6.95	1.03e-10	2.15e-07	-0.55	-0.49	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
PCPG	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-6.95	1.04e-10	2.15e-07	-1.02	-0.49	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
PCPG	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-6.95	1.04e-10	2.16e-07	-0.41	-0.49	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
PCPG	cis	rs910316	0.967	rs10142770	ENSG00000279594.1	RP11-950C14.10	6.95	1.04e-10	2.16e-07	0.63	0.49	Height;	chr14:75058746	chr14:75011269~75012851:-
PCPG	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	6.95	1.04e-10	2.17e-07	0.72	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
PCPG	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	6.95	1.05e-10	2.19e-07	0.48	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
PCPG	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-6.95	1.05e-10	2.19e-07	-0.6	-0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
PCPG	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	6.95	1.06e-10	2.19e-07	0.64	0.49	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
PCPG	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	6.95	1.06e-10	2.2e-07	0.67	0.49	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	6.95	1.06e-10	2.2e-07	0.67	0.49	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
PCPG	cis	rs4835473	0.932	rs4260486	ENSG00000250345.2	RP11-780M14.1	-6.95	1.06e-10	2.2e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143987556	chr4:143760399~143762093:-
PCPG	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	6.95	1.06e-10	2.21e-07	0.61	0.49	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
PCPG	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	6.95	1.07e-10	2.21e-07	0.55	0.49	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
PCPG	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	6.95	1.07e-10	2.22e-07	0.51	0.49	Height;	chr3:53091453	chr3:53064283~53065091:-
PCPG	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-6.95	1.07e-10	2.22e-07	-0.73	-0.49	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
PCPG	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	6.95	1.07e-10	2.22e-07	0.43	0.49	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
PCPG	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-6.95	1.07e-10	2.22e-07	-0.43	-0.49	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
PCPG	cis	rs9481169	0.85	rs4947129	ENSG00000255389.1	C6orf3	-6.95	1.07e-10	2.22e-07	-0.88	-0.49	Inflammatory skin disease;	chr6:111609703	chr6:111599875~111602295:+
PCPG	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-6.95	1.07e-10	2.22e-07	-0.71	-0.49	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
PCPG	cis	rs4835473	0.897	rs6835827	ENSG00000250345.2	RP11-780M14.1	-6.94	1.07e-10	2.23e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143712803	chr4:143760399~143762093:-
PCPG	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-6.94	1.08e-10	2.24e-07	-0.55	-0.49	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-6.94	1.08e-10	2.24e-07	-0.55	-0.49	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-6.94	1.08e-10	2.24e-07	-0.55	-0.49	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
PCPG	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	6.94	1.09e-10	2.25e-07	0.63	0.49	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
PCPG	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-6.94	1.09e-10	2.25e-07	-1	-0.49	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
PCPG	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-6.94	1.09e-10	2.27e-07	-0.74	-0.49	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
PCPG	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-6.94	1.1e-10	2.27e-07	-0.56	-0.49	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
PCPG	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	6.94	1.1e-10	2.28e-07	0.7	0.49	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
PCPG	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-6.94	1.1e-10	2.28e-07	-0.55	-0.49	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
PCPG	cis	rs910316	1	rs12589876	ENSG00000279594.1	RP11-950C14.10	6.94	1.1e-10	2.28e-07	0.62	0.49	Height;	chr14:75077486	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs10246	ENSG00000279594.1	RP11-950C14.10	6.94	1.1e-10	2.28e-07	0.62	0.49	Height;	chr14:75077767	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs12589815	ENSG00000279594.1	RP11-950C14.10	6.94	1.11e-10	2.29e-07	0.62	0.49	Height;	chr14:75077398	chr14:75011269~75012851:-
PCPG	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	6.94	1.11e-10	2.29e-07	0.54	0.49	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
PCPG	cis	rs453301	0.624	rs2915251	ENSG00000253893.2	FAM85B	-6.94	1.11e-10	2.3e-07	-0.61	-0.49	Joint mobility (Beighton score);	chr8:9009901	chr8:8167819~8226614:-
PCPG	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	6.94	1.12e-10	2.31e-07	0.58	0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
PCPG	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-6.94	1.12e-10	2.31e-07	-0.55	-0.49	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
PCPG	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-6.94	1.13e-10	2.33e-07	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
PCPG	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	6.94	1.13e-10	2.33e-07	0.68	0.49	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
PCPG	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	6.93	1.15e-10	2.37e-07	0.55	0.49	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
PCPG	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	6.93	1.16e-10	2.39e-07	1	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
PCPG	cis	rs916888	0.773	rs1378358	ENSG00000232300.1	FAM215B	6.93	1.16e-10	2.39e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.773	rs538628	ENSG00000232300.1	FAM215B	6.93	1.16e-10	2.39e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.773	rs169201	ENSG00000232300.1	FAM215B	6.93	1.16e-10	2.39e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46558830~46562795:-
PCPG	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-6.93	1.16e-10	2.39e-07	-0.61	-0.49	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
PCPG	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	6.93	1.17e-10	2.41e-07	0.66	0.49	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
PCPG	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	6.93	1.18e-10	2.42e-07	0.64	0.49	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
PCPG	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	6.93	1.18e-10	2.42e-07	0.99	0.49	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
PCPG	cis	rs7267979	1	rs6083828	ENSG00000125804.12	FAM182A	6.93	1.18e-10	2.42e-07	0.57	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:26054655~26086917:+
PCPG	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	6.93	1.18e-10	2.43e-07	0.58	0.49	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
PCPG	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-6.93	1.18e-10	2.43e-07	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-6.93	1.18e-10	2.43e-07	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-6.93	1.18e-10	2.43e-07	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-6.93	1.18e-10	2.43e-07	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
PCPG	cis	rs910316	0.783	rs11850751	ENSG00000279594.1	RP11-950C14.10	6.93	1.19e-10	2.44e-07	0.62	0.49	Height;	chr14:75123410	chr14:75011269~75012851:-
PCPG	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	6.92	1.2e-10	2.45e-07	0.64	0.49	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
PCPG	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-6.92	1.2e-10	2.46e-07	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
PCPG	cis	rs910316	1	rs10138183	ENSG00000279594.1	RP11-950C14.10	6.92	1.2e-10	2.46e-07	0.62	0.49	Height;	chr14:75148524	chr14:75011269~75012851:-
PCPG	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-6.92	1.2e-10	2.47e-07	-0.56	-0.49	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
PCPG	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-6.92	1.2e-10	2.47e-07	-0.56	-0.49	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
PCPG	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	6.92	1.21e-10	2.47e-07	0.58	0.49	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
PCPG	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-6.92	1.21e-10	2.47e-07	-0.6	-0.49	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
PCPG	cis	rs6964833	1	rs3846966	ENSG00000277053.3	GTF2IP1	-6.92	1.21e-10	2.47e-07	-0.6	-0.49	Menarche (age at onset);	chr7:74698811	chr7:75185385~75237696:-
PCPG	cis	rs6964833	1	rs2301907	ENSG00000277053.3	GTF2IP1	-6.92	1.21e-10	2.47e-07	-0.6	-0.49	Menarche (age at onset);	chr7:74700517	chr7:75185385~75237696:-
PCPG	cis	rs6964833	0.935	rs7795282	ENSG00000277053.3	GTF2IP1	-6.92	1.21e-10	2.47e-07	-0.6	-0.49	Menarche (age at onset);	chr7:74708526	chr7:75185385~75237696:-
PCPG	cis	rs11148252	0.595	rs4884522	ENSG00000235660.1	LINC00345	-6.92	1.21e-10	2.48e-07	-0.63	-0.49	Lewy body disease;	chr13:52479633	chr13:52484161~52484680:-
PCPG	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	6.92	1.22e-10	2.5e-07	0.68	0.49	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	6.92	1.22e-10	2.5e-07	0.68	0.49	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
PCPG	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	6.92	1.22e-10	2.5e-07	0.66	0.49	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
PCPG	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	6.92	1.22e-10	2.5e-07	0.66	0.49	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
PCPG	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	6.92	1.24e-10	2.53e-07	0.6	0.49	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
PCPG	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	6.92	1.24e-10	2.54e-07	0.49	0.49	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.8	rs1849134	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143958260	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.8	rs1849133	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143958262	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs1849132	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143958309	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs13123407	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143958713	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs61611095	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143958802	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.9	rs4835449	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143958830	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.77	rs4835096	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143960685	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1838516	ENSG00000250345.2	RP11-780M14.1	-6.92	1.25e-10	2.54e-07	-0.61	-0.49	Immature fraction of reticulocytes;	chr4:143962082	chr4:143760399~143762093:-
PCPG	cis	rs910316	1	rs11159117	ENSG00000279594.1	RP11-950C14.10	6.92	1.25e-10	2.55e-07	0.62	0.49	Height;	chr14:75118164	chr14:75011269~75012851:-
PCPG	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-6.92	1.25e-10	2.56e-07	-0.57	-0.49	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
PCPG	cis	rs7267979	0.844	rs2257649	ENSG00000125804.12	FAM182A	-6.92	1.26e-10	2.56e-07	-0.61	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26054655~26086917:+
PCPG	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	6.91	1.26e-10	2.58e-07	0.49	0.49	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
PCPG	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	6.91	1.26e-10	2.58e-07	0.73	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
PCPG	cis	rs4835473	0.932	rs1877235	ENSG00000250345.2	RP11-780M14.1	6.91	1.27e-10	2.58e-07	0.61	0.49	Immature fraction of reticulocytes;	chr4:143986961	chr4:143760399~143762093:-
PCPG	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	6.91	1.27e-10	2.58e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-6.91	1.27e-10	2.58e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-6.91	1.27e-10	2.58e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-6.91	1.27e-10	2.58e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
PCPG	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	6.91	1.28e-10	2.6e-07	0.61	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
PCPG	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	6.91	1.28e-10	2.61e-07	0.68	0.49	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
PCPG	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-6.91	1.28e-10	2.61e-07	-0.63	-0.49	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
PCPG	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	6.91	1.31e-10	2.66e-07	0.69	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
PCPG	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-6.91	1.32e-10	2.69e-07	-0.56	-0.49	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
PCPG	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	6.91	1.33e-10	2.7e-07	0.73	0.49	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
PCPG	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-6.9	1.33e-10	2.71e-07	-0.79	-0.49	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
PCPG	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	6.9	1.34e-10	2.72e-07	0.56	0.49	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
PCPG	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	6.9	1.34e-10	2.73e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	6.9	1.34e-10	2.73e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	6.9	1.34e-10	2.73e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
PCPG	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	6.9	1.35e-10	2.74e-07	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
PCPG	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	6.9	1.35e-10	2.74e-07	0.73	0.49	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
PCPG	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	6.9	1.35e-10	2.74e-07	0.73	0.49	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
PCPG	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	6.9	1.35e-10	2.74e-07	0.73	0.49	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
PCPG	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	6.9	1.35e-10	2.74e-07	0.73	0.49	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
PCPG	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	6.9	1.36e-10	2.76e-07	0.68	0.49	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	6.9	1.36e-10	2.76e-07	0.68	0.49	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	6.9	1.36e-10	2.76e-07	0.68	0.49	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	6.9	1.36e-10	2.76e-07	0.68	0.49	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	6.9	1.36e-10	2.76e-07	0.68	0.49	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
PCPG	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	6.9	1.37e-10	2.76e-07	0.91	0.49	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
PCPG	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	6.9	1.37e-10	2.77e-07	0.6	0.49	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-6.9	1.37e-10	2.78e-07	-0.6	-0.49	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
PCPG	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-6.9	1.38e-10	2.78e-07	-0.57	-0.49	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-6.9	1.38e-10	2.78e-07	-0.57	-0.49	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
PCPG	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	6.9	1.38e-10	2.8e-07	0.67	0.49	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
PCPG	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-6.9	1.39e-10	2.8e-07	-0.55	-0.49	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
PCPG	cis	rs4835473	0.932	rs4287958	ENSG00000250345.2	RP11-780M14.1	-6.9	1.39e-10	2.8e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143987719	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4125545	ENSG00000250345.2	RP11-780M14.1	-6.9	1.39e-10	2.8e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143988650	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs12649594	ENSG00000250345.2	RP11-780M14.1	-6.9	1.39e-10	2.8e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143989307	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs13101482	ENSG00000250345.2	RP11-780M14.1	-6.9	1.39e-10	2.8e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143989463	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.864	rs13135472	ENSG00000250345.2	RP11-780M14.1	-6.9	1.39e-10	2.8e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143989465	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1849118	ENSG00000250345.2	RP11-780M14.1	-6.9	1.39e-10	2.8e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143989822	chr4:143760399~143762093:-
PCPG	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	6.89	1.41e-10	2.83e-07	0.6	0.49	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
PCPG	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	6.89	1.42e-10	2.85e-07	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
PCPG	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-6.89	1.42e-10	2.85e-07	-0.63	-0.49	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-6.89	1.42e-10	2.85e-07	-0.63	-0.49	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
PCPG	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	6.89	1.42e-10	2.85e-07	0.48	0.49	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	6.89	1.42e-10	2.85e-07	0.48	0.49	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
PCPG	cis	rs916888	0.697	rs199516	ENSG00000232300.1	FAM215B	-6.89	1.42e-10	2.85e-07	-0.73	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.821	rs199514	ENSG00000232300.1	FAM215B	-6.89	1.42e-10	2.85e-07	-0.73	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.821	rs199512	ENSG00000232300.1	FAM215B	-6.89	1.42e-10	2.85e-07	-0.73	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.821	rs199509	ENSG00000232300.1	FAM215B	-6.89	1.42e-10	2.85e-07	-0.73	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.821	rs199507	ENSG00000232300.1	FAM215B	-6.89	1.42e-10	2.85e-07	-0.73	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46558830~46562795:-
PCPG	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	6.89	1.42e-10	2.86e-07	0.58	0.49	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-6.89	1.42e-10	2.86e-07	-0.58	-0.49	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
PCPG	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-6.89	1.42e-10	2.86e-07	-0.71	-0.49	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
PCPG	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-6.89	1.43e-10	2.86e-07	-0.51	-0.49	Height;	chr3:52994359	chr3:53064283~53065091:-
PCPG	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	6.89	1.43e-10	2.87e-07	0.59	0.49	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
PCPG	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-6.89	1.43e-10	2.87e-07	-0.53	-0.49	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
PCPG	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.89	1.43e-10	2.88e-07	-0.64	-0.49	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
PCPG	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	6.89	1.44e-10	2.89e-07	0.7	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
PCPG	cis	rs7267979	0.753	rs400357	ENSG00000125804.12	FAM182A	-6.89	1.44e-10	2.9e-07	-0.6	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26054655~26086917:+
PCPG	cis	rs916888	0.773	rs199447	ENSG00000232300.1	FAM215B	6.89	1.44e-10	2.9e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	6.89	1.44e-10	2.9e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	6.89	1.44e-10	2.9e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	6.89	1.44e-10	2.9e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	6.89	1.44e-10	2.9e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
PCPG	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	6.89	1.45e-10	2.91e-07	0.63	0.49	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
PCPG	cis	rs910316	0.935	rs3742771	ENSG00000279594.1	RP11-950C14.10	6.89	1.45e-10	2.91e-07	0.62	0.49	Height;	chr14:75132944	chr14:75011269~75012851:-
PCPG	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-6.89	1.45e-10	2.92e-07	-0.57	-0.49	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
PCPG	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-6.89	1.47e-10	2.94e-07	-0.62	-0.49	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
PCPG	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	6.89	1.47e-10	2.94e-07	0.56	0.49	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
PCPG	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	6.89	1.47e-10	2.94e-07	0.73	0.49	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	6.89	1.47e-10	2.94e-07	0.73	0.49	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
PCPG	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	6.89	1.47e-10	2.94e-07	0.56	0.49	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
PCPG	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	6.89	1.48e-10	2.94e-07	0.74	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
PCPG	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	6.88	1.5e-10	2.97e-07	0.52	0.49	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
PCPG	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-6.88	1.5e-10	2.98e-07	-0.5	-0.49	Height;	chr3:52998472	chr3:53064283~53065091:-
PCPG	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	6.88	1.5e-10	2.98e-07	0.65	0.49	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
PCPG	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	6.88	1.51e-10	3e-07	0.62	0.49	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
PCPG	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	6.88	1.51e-10	3.01e-07	0.52	0.49	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
PCPG	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	6.88	1.52e-10	3.02e-07	0.72	0.49	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
PCPG	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-6.88	1.53e-10	3.03e-07	-0.6	-0.49	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
PCPG	cis	rs7267979	0.816	rs376742	ENSG00000125804.12	FAM182A	-6.88	1.53e-10	3.04e-07	-0.6	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26054655~26086917:+
PCPG	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	6.88	1.54e-10	3.05e-07	0.68	0.49	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	6.88	1.54e-10	3.05e-07	0.68	0.49	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	6.88	1.54e-10	3.05e-07	0.68	0.49	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
PCPG	cis	rs916888	0.821	rs199505	ENSG00000232300.1	FAM215B	-6.88	1.54e-10	3.05e-07	-0.73	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.821	rs70602	ENSG00000232300.1	FAM215B	-6.88	1.54e-10	3.05e-07	-0.73	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46558830~46562795:-
PCPG	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	6.88	1.55e-10	3.07e-07	0.52	0.49	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
PCPG	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-6.88	1.55e-10	3.07e-07	-0.6	-0.49	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-6.88	1.55e-10	3.07e-07	-0.6	-0.49	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
PCPG	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	6.88	1.55e-10	3.08e-07	0.68	0.49	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
PCPG	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	6.88	1.55e-10	3.08e-07	0.72	0.49	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
PCPG	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	6.88	1.56e-10	3.09e-07	0.56	0.49	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
PCPG	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-6.87	1.56e-10	3.09e-07	-0.59	-0.49	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-6.87	1.56e-10	3.09e-07	-0.59	-0.49	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
PCPG	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	6.87	1.57e-10	3.11e-07	0.46	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	6.87	1.57e-10	3.11e-07	0.46	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
PCPG	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	6.87	1.57e-10	3.11e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
PCPG	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-6.87	1.57e-10	3.11e-07	-0.55	-0.49	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-6.87	1.57e-10	3.11e-07	-0.55	-0.49	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-6.87	1.57e-10	3.11e-07	-0.55	-0.49	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-6.87	1.57e-10	3.11e-07	-0.55	-0.49	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-6.87	1.57e-10	3.11e-07	-0.55	-0.49	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
PCPG	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	6.87	1.58e-10	3.12e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	6.87	1.58e-10	3.12e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	6.87	1.58e-10	3.12e-07	0.72	0.49	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
PCPG	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-6.87	1.58e-10	3.12e-07	-0.56	-0.49	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-6.87	1.58e-10	3.12e-07	-0.56	-0.49	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
PCPG	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-6.87	1.58e-10	3.12e-07	-0.68	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
PCPG	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	6.87	1.58e-10	3.12e-07	0.73	0.49	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
PCPG	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	6.87	1.59e-10	3.12e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-6.87	1.59e-10	3.12e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
PCPG	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-6.87	1.59e-10	3.13e-07	-0.72	-0.49	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-6.87	1.59e-10	3.13e-07	-0.72	-0.49	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
PCPG	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	6.87	1.6e-10	3.15e-07	0.57	0.49	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
PCPG	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	6.87	1.6e-10	3.15e-07	0.57	0.49	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
PCPG	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	6.87	1.61e-10	3.16e-07	0.55	0.49	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
PCPG	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	6.87	1.61e-10	3.16e-07	0.62	0.49	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
PCPG	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	6.87	1.61e-10	3.16e-07	0.65	0.49	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
PCPG	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	6.87	1.61e-10	3.16e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
PCPG	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	6.87	1.61e-10	3.16e-07	0.49	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
PCPG	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	6.87	1.63e-10	3.19e-07	0.63	0.49	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
PCPG	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-6.87	1.63e-10	3.19e-07	-0.58	-0.49	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
PCPG	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	6.87	1.63e-10	3.19e-07	0.72	0.49	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
PCPG	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-6.86	1.65e-10	3.22e-07	-0.61	-0.49	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
PCPG	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	6.86	1.66e-10	3.25e-07	0.66	0.49	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	6.86	1.66e-10	3.25e-07	0.66	0.49	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
PCPG	cis	rs4835473	0.9	rs10025455	ENSG00000250345.2	RP11-780M14.1	6.86	1.67e-10	3.26e-07	0.62	0.49	Immature fraction of reticulocytes;	chr4:143998417	chr4:143760399~143762093:-
PCPG	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.86	1.67e-10	3.26e-07	-0.64	-0.49	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
PCPG	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	6.86	1.67e-10	3.26e-07	0.67	0.49	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
PCPG	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	6.86	1.67e-10	3.26e-07	0.67	0.49	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
PCPG	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	6.86	1.67e-10	3.26e-07	0.68	0.49	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
PCPG	cis	rs9595908	0.931	rs11839309	ENSG00000212293.1	SNORA16	6.86	1.67e-10	3.26e-07	0.59	0.49	Body mass index;	chr13:32473853	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	6.86	1.67e-10	3.26e-07	0.59	0.49	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	6.86	1.67e-10	3.26e-07	0.59	0.49	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	6.86	1.67e-10	3.26e-07	0.59	0.49	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	6.86	1.67e-10	3.26e-07	0.59	0.49	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	6.86	1.67e-10	3.26e-07	0.59	0.49	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
PCPG	cis	rs910316	1	rs12879542	ENSG00000279594.1	RP11-950C14.10	6.86	1.67e-10	3.27e-07	0.62	0.49	Height;	chr14:75040822	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs4903275	ENSG00000279594.1	RP11-950C14.10	6.86	1.67e-10	3.27e-07	0.62	0.49	Height;	chr14:75045806	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs10140851	ENSG00000279594.1	RP11-950C14.10	6.86	1.67e-10	3.27e-07	0.62	0.49	Height;	chr14:75045909	chr14:75011269~75012851:-
PCPG	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-6.86	1.68e-10	3.27e-07	-0.65	-0.49	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
PCPG	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	6.86	1.68e-10	3.28e-07	0.67	0.49	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
PCPG	cis	rs910316	1	rs3742780	ENSG00000279594.1	RP11-950C14.10	6.86	1.68e-10	3.28e-07	0.62	0.49	Height;	chr14:75038305	chr14:75011269~75012851:-
PCPG	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	6.86	1.68e-10	3.28e-07	0.61	0.49	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
PCPG	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	6.86	1.68e-10	3.28e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	6.86	1.68e-10	3.28e-07	0.74	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
PCPG	cis	rs71403859	0.57	rs77809998	ENSG00000260886.1	TAT-AS1	6.86	1.7e-10	3.31e-07	1	0.49	Post bronchodilator FEV1;	chr16:71396784	chr16:71565789~71578187:+
PCPG	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-6.86	1.7e-10	3.31e-07	-0.73	-0.49	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
PCPG	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	6.86	1.7e-10	3.31e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
PCPG	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	6.86	1.71e-10	3.33e-07	0.49	0.49	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
PCPG	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-6.86	1.71e-10	3.33e-07	-0.6	-0.49	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-6.86	1.71e-10	3.33e-07	-0.6	-0.49	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
PCPG	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-6.86	1.72e-10	3.34e-07	-0.64	-0.49	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
PCPG	cis	rs910316	1	rs28626045	ENSG00000279594.1	RP11-950C14.10	6.86	1.72e-10	3.34e-07	0.62	0.49	Height;	chr14:75122492	chr14:75011269~75012851:-
PCPG	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-6.86	1.72e-10	3.34e-07	-0.6	-0.49	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
PCPG	cis	rs910316	0.875	rs12588099	ENSG00000279594.1	RP11-950C14.10	6.86	1.72e-10	3.34e-07	0.62	0.49	Height;	chr14:75127759	chr14:75011269~75012851:-
PCPG	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-6.86	1.72e-10	3.35e-07	-0.57	-0.49	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
PCPG	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-6.86	1.73e-10	3.35e-07	-0.66	-0.49	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
PCPG	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	6.86	1.73e-10	3.36e-07	0.68	0.49	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
PCPG	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	6.86	1.73e-10	3.36e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
PCPG	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	6.85	1.75e-10	3.39e-07	0.61	0.49	Height;	chr14:75127136	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	6.85	1.75e-10	3.39e-07	0.61	0.49	Height;	chr14:75127199	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs4322591	ENSG00000279594.1	RP11-950C14.10	6.85	1.75e-10	3.39e-07	0.61	0.49	Height;	chr14:75133994	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs876403	ENSG00000279594.1	RP11-950C14.10	6.85	1.75e-10	3.39e-07	0.61	0.49	Height;	chr14:75136131	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs4903285	ENSG00000279594.1	RP11-950C14.10	6.85	1.75e-10	3.39e-07	0.61	0.49	Height;	chr14:75142565	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs12588240	ENSG00000279594.1	RP11-950C14.10	6.85	1.75e-10	3.39e-07	0.61	0.49	Height;	chr14:75145380	chr14:75011269~75012851:-
PCPG	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-6.85	1.76e-10	3.41e-07	-0.49	-0.49	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
PCPG	cis	rs916888	0.821	rs199506	ENSG00000232300.1	FAM215B	-6.85	1.76e-10	3.41e-07	-0.75	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46558830~46562795:-
PCPG	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-6.85	1.77e-10	3.43e-07	-0.57	-0.49	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-6.85	1.77e-10	3.43e-07	-0.57	-0.49	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
PCPG	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	6.85	1.77e-10	3.43e-07	0.62	0.49	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
PCPG	cis	rs916888	0.773	rs199451	ENSG00000232300.1	FAM215B	6.85	1.78e-10	3.45e-07	0.72	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46558830~46562795:-
PCPG	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	6.85	1.78e-10	3.45e-07	0.72	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
PCPG	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	6.85	1.78e-10	3.45e-07	0.45	0.49	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	6.85	1.78e-10	3.45e-07	0.45	0.49	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
PCPG	cis	rs7267979	1	rs6083813	ENSG00000125804.12	FAM182A	6.85	1.79e-10	3.46e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:26054655~26086917:+
PCPG	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	6.85	1.79e-10	3.46e-07	0.46	0.49	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-6.85	1.79e-10	3.46e-07	-0.46	-0.49	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
PCPG	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-6.85	1.79e-10	3.46e-07	-0.63	-0.49	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
PCPG	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-6.85	1.8e-10	3.47e-07	-0.63	-0.49	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
PCPG	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	6.85	1.8e-10	3.48e-07	0.58	0.49	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
PCPG	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-6.85	1.81e-10	3.49e-07	-0.63	-0.49	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
PCPG	cis	rs4835473	0.932	rs13130345	ENSG00000250345.2	RP11-780M14.1	-6.85	1.82e-10	3.51e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143920939	chr4:143760399~143762093:-
PCPG	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	6.85	1.82e-10	3.51e-07	0.47	0.49	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
PCPG	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-6.85	1.83e-10	3.52e-07	-0.59	-0.49	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
PCPG	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	6.84	1.84e-10	3.54e-07	0.6	0.49	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
PCPG	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-6.84	1.84e-10	3.54e-07	-0.62	-0.49	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
PCPG	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	6.84	1.84e-10	3.54e-07	0.65	0.49	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	6.84	1.84e-10	3.54e-07	0.65	0.49	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
PCPG	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	6.84	1.85e-10	3.55e-07	0.67	0.49	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
PCPG	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-6.84	1.85e-10	3.57e-07	-0.56	-0.49	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-6.84	1.85e-10	3.57e-07	-0.56	-0.49	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
PCPG	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	6.84	1.85e-10	3.57e-07	0.51	0.49	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
PCPG	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	6.84	1.85e-10	3.57e-07	0.72	0.49	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
PCPG	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-6.84	1.86e-10	3.58e-07	-0.48	-0.49	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
PCPG	cis	rs7267979	0.966	rs2261795	ENSG00000125804.12	FAM182A	-6.84	1.86e-10	3.58e-07	-0.56	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:26054655~26086917:+
PCPG	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-6.84	1.86e-10	3.58e-07	-0.62	-0.49	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
PCPG	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-6.84	1.87e-10	3.58e-07	-0.37	-0.49	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
PCPG	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	6.84	1.89e-10	3.61e-07	0.71	0.49	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
PCPG	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	6.84	1.89e-10	3.61e-07	0.71	0.49	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	6.84	1.89e-10	3.61e-07	0.71	0.49	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
PCPG	cis	rs4835473	0.615	rs6857432	ENSG00000250345.2	RP11-780M14.1	-6.84	1.89e-10	3.62e-07	-0.62	-0.49	Immature fraction of reticulocytes;	chr4:143971912	chr4:143760399~143762093:-
PCPG	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	6.84	1.89e-10	3.62e-07	0.48	0.49	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
PCPG	cis	rs4835473	0.8	rs1849117	ENSG00000250345.2	RP11-780M14.1	-6.84	1.89e-10	3.62e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143989791	chr4:143760399~143762093:-
PCPG	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-6.84	1.89e-10	3.62e-07	-0.56	-0.49	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-6.84	1.89e-10	3.62e-07	-0.56	-0.49	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-6.84	1.89e-10	3.62e-07	-0.56	-0.49	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
PCPG	cis	rs4323050	0.546	rs13124157	ENSG00000250345.2	RP11-780M14.1	-6.84	1.9e-10	3.63e-07	-0.62	-0.49	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13147170	ENSG00000250345.2	RP11-780M14.1	-6.84	1.9e-10	3.63e-07	-0.62	-0.49	Immature fraction of reticulocytes;	chr4:143975848	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs13147184	ENSG00000250345.2	RP11-780M14.1	-6.84	1.9e-10	3.63e-07	-0.62	-0.49	Immature fraction of reticulocytes;	chr4:143975873	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.8	rs13124170	ENSG00000250345.2	RP11-780M14.1	-6.84	1.9e-10	3.63e-07	-0.62	-0.49	Immature fraction of reticulocytes;	chr4:143975951	chr4:143760399~143762093:-
PCPG	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	6.84	1.9e-10	3.63e-07	0.69	0.49	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
PCPG	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	6.84	1.9e-10	3.63e-07	0.63	0.49	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
PCPG	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	6.84	1.9e-10	3.64e-07	0.52	0.49	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
PCPG	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-6.84	1.9e-10	3.64e-07	-0.64	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
PCPG	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-6.84	1.92e-10	3.67e-07	-0.59	-0.49	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
PCPG	cis	rs7267979	0.932	rs1985737	ENSG00000125804.12	FAM182A	-6.84	1.92e-10	3.68e-07	-0.56	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:26054655~26086917:+
PCPG	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-6.83	1.94e-10	3.7e-07	-0.61	-0.49	Height;	chr14:75135159	chr14:75011269~75012851:-
PCPG	cis	rs4835473	0.932	rs1849115	ENSG00000250345.2	RP11-780M14.1	-6.83	1.94e-10	3.7e-07	-0.6	-0.49	Immature fraction of reticulocytes;	chr4:143989687	chr4:143760399~143762093:-
PCPG	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	6.83	1.95e-10	3.71e-07	0.54	0.49	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
PCPG	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	6.83	1.96e-10	3.73e-07	0.66	0.49	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
PCPG	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-6.83	1.96e-10	3.74e-07	-0.56	-0.49	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
PCPG	cis	rs7267979	0.844	rs2424703	ENSG00000125804.12	FAM182A	-6.83	1.98e-10	3.77e-07	-0.6	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.74	rs2259961	ENSG00000125804.12	FAM182A	-6.83	1.98e-10	3.77e-07	-0.6	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs2474780	ENSG00000125804.12	FAM182A	-6.83	1.98e-10	3.77e-07	-0.6	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.789	rs4815400	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.6	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs35735333	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.6	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs4815413	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.6	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs6083824	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.6	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs869358	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.6	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs6076343	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.6	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258719	ENSG00000125804.12	FAM182A	-6.83	1.98e-10	3.77e-07	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.933	rs2424708	ENSG00000125804.12	FAM182A	-6.83	1.98e-10	3.77e-07	-0.59	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs884613	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs1888998	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2500433	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2482948	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482919	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6037086	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2482923	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482931	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.934	rs2500399	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2500404	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2500405	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482941	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.903	rs2500423	ENSG00000125804.12	FAM182A	6.83	1.98e-10	3.77e-07	0.59	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:26054655~26086917:+
PCPG	cis	rs916888	0.821	rs70600	ENSG00000232300.1	FAM215B	6.83	1.98e-10	3.77e-07	0.73	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46558830~46562795:-
PCPG	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-6.83	1.99e-10	3.78e-07	-0.69	-0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
PCPG	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	6.83	1.99e-10	3.79e-07	0.68	0.49	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
PCPG	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-6.83	1.99e-10	3.8e-07	-0.6	-0.49	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
PCPG	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-6.83	2.01e-10	3.83e-07	-0.62	-0.49	Height;	chr14:75122121	chr14:75011269~75012851:-
PCPG	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-6.83	2.02e-10	3.84e-07	-0.6	-0.49	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-6.83	2.02e-10	3.84e-07	-0.6	-0.49	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
PCPG	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	6.83	2.02e-10	3.85e-07	0.63	0.49	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
PCPG	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-6.83	2.03e-10	3.85e-07	-0.58	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
PCPG	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-6.83	2.03e-10	3.85e-07	-0.51	-0.49	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
PCPG	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	6.82	2.04e-10	3.88e-07	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
PCPG	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	6.82	2.04e-10	3.88e-07	0.57	0.49	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
PCPG	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	6.82	2.05e-10	3.89e-07	0.67	0.49	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
PCPG	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-6.82	2.05e-10	3.9e-07	-0.72	-0.49	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
PCPG	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-6.82	2.06e-10	3.9e-07	-0.55	-0.49	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-6.82	2.06e-10	3.9e-07	-0.55	-0.49	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
PCPG	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-6.82	2.07e-10	3.92e-07	-0.63	-0.49	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
PCPG	cis	rs748404	0.518	rs2927085	ENSG00000249839.1	AC011330.5	-6.82	2.07e-10	3.94e-07	-0.55	-0.49	Lung cancer;	chr15:43697332	chr15:43663654~43684339:-
PCPG	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	6.82	2.08e-10	3.95e-07	0.54	0.49	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
PCPG	cis	rs910316	1	rs8017642	ENSG00000279594.1	RP11-950C14.10	6.82	2.09e-10	3.96e-07	0.61	0.49	Height;	chr14:75124119	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs1047418	ENSG00000279594.1	RP11-950C14.10	6.82	2.09e-10	3.96e-07	0.61	0.49	Height;	chr14:75139089	chr14:75011269~75012851:-
PCPG	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-6.82	2.09e-10	3.96e-07	-0.56	-0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
PCPG	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-6.82	2.12e-10	4.01e-07	-0.6	-0.49	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
PCPG	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-6.82	2.14e-10	4.06e-07	-0.53	-0.49	Height;	chr3:52971094	chr3:53064283~53065091:-
PCPG	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	6.81	2.15e-10	4.07e-07	0.72	0.49	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
PCPG	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	6.81	2.16e-10	4.07e-07	0.57	0.49	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
PCPG	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-6.81	2.16e-10	4.07e-07	-0.6	-0.49	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
PCPG	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	6.81	2.16e-10	4.08e-07	0.51	0.49	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
PCPG	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	6.81	2.16e-10	4.08e-07	0.71	0.49	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	6.81	2.16e-10	4.08e-07	0.71	0.49	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
PCPG	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
PCPG	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-6.81	2.17e-10	4.09e-07	-0.54	-0.49	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
PCPG	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	6.81	2.17e-10	4.1e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
PCPG	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-6.81	2.17e-10	4.1e-07	-0.63	-0.49	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
PCPG	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	6.81	2.18e-10	4.1e-07	0.56	0.49	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
PCPG	cis	rs7267979	1	rs6050561	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs6083817	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050564	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs6083818	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815409	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs6050567	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6037099	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs4815414	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6083825	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs34645895	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs3827014	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6037105	ENSG00000125804.12	FAM182A	6.81	2.18e-10	4.11e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs10966	ENSG00000125804.12	FAM182A	-6.81	2.18e-10	4.11e-07	-0.56	-0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:26054655~26086917:+
PCPG	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	6.81	2.19e-10	4.12e-07	0.38	0.49	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
PCPG	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-6.81	2.19e-10	4.12e-07	-0.58	-0.49	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-6.81	2.19e-10	4.12e-07	-0.58	-0.49	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-6.81	2.19e-10	4.12e-07	-0.58	-0.49	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
PCPG	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	6.81	2.21e-10	4.15e-07	0.55	0.49	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
PCPG	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-6.81	2.22e-10	4.18e-07	-0.68	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
PCPG	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-6.81	2.23e-10	4.19e-07	-0.62	-0.49	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
PCPG	cis	rs9595908	0.965	rs9595795	ENSG00000212293.1	SNORA16	6.81	2.23e-10	4.19e-07	0.59	0.49	Body mass index;	chr13:32548658	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs4941612	ENSG00000212293.1	SNORA16	6.81	2.23e-10	4.19e-07	0.59	0.49	Body mass index;	chr13:32549791	chr13:32420390~32420516:-
PCPG	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-6.81	2.23e-10	4.19e-07	-0.78	-0.49	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
PCPG	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-6.81	2.23e-10	4.2e-07	-0.58	-0.49	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
PCPG	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	6.81	2.25e-10	4.22e-07	0.51	0.49	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
PCPG	cis	rs7267979	1	rs6115168	ENSG00000125804.12	FAM182A	6.81	2.25e-10	4.23e-07	0.56	0.49	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:26054655~26086917:+
PCPG	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	6.81	2.26e-10	4.23e-07	0.66	0.49	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
PCPG	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	6.8	2.27e-10	4.26e-07	0.72	0.49	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
PCPG	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	6.8	2.27e-10	4.26e-07	0.72	0.49	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
PCPG	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	6.8	2.27e-10	4.26e-07	0.72	0.49	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
PCPG	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	6.8	2.27e-10	4.27e-07	0.57	0.49	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
PCPG	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-6.8	2.28e-10	4.28e-07	-0.66	-0.49	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
PCPG	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	6.8	2.29e-10	4.29e-07	0.63	0.49	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
PCPG	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	6.8	2.29e-10	4.29e-07	0.63	0.49	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
PCPG	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-6.8	2.29e-10	4.3e-07	-0.53	-0.49	Height;	chr3:52977358	chr3:53064283~53065091:-
PCPG	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-6.8	2.3e-10	4.31e-07	-0.71	-0.49	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-6.8	2.3e-10	4.31e-07	-0.71	-0.49	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-6.8	2.3e-10	4.31e-07	-0.71	-0.49	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-6.8	2.3e-10	4.31e-07	-0.71	-0.49	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
PCPG	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	6.8	2.31e-10	4.32e-07	0.81	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
PCPG	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	6.8	2.32e-10	4.35e-07	0.55	0.49	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
PCPG	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-6.8	2.32e-10	4.35e-07	-0.42	-0.49	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
PCPG	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-6.8	2.32e-10	4.35e-07	-0.6	-0.49	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
PCPG	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-6.8	2.35e-10	4.4e-07	-0.54	-0.49	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
PCPG	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-6.8	2.37e-10	4.44e-07	-0.47	-0.49	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
PCPG	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.87	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
PCPG	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-6.8	2.38e-10	4.44e-07	-0.7	-0.49	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
PCPG	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	6.8	2.38e-10	4.44e-07	0.86	0.49	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
PCPG	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	6.8	2.38e-10	4.45e-07	0.37	0.49	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
PCPG	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	6.79	2.39e-10	4.45e-07	0.65	0.49	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
PCPG	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-6.79	2.39e-10	4.46e-07	-0.62	-0.49	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
PCPG	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-6.79	2.39e-10	4.47e-07	-0.51	-0.49	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
PCPG	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-6.79	2.43e-10	4.52e-07	-0.62	-0.48	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
PCPG	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	6.79	2.43e-10	4.53e-07	0.7	0.48	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
PCPG	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	6.79	2.44e-10	4.54e-07	0.51	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
PCPG	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-6.79	2.45e-10	4.55e-07	-0.57	-0.48	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
PCPG	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-6.79	2.45e-10	4.56e-07	-0.51	-0.48	Height;	chr3:52991821	chr3:53064283~53065091:-
PCPG	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-6.79	2.46e-10	4.58e-07	-0.59	-0.48	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
PCPG	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-6.79	2.46e-10	4.58e-07	-0.65	-0.48	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
PCPG	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	6.79	2.46e-10	4.58e-07	0.71	0.48	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	6.79	2.46e-10	4.58e-07	0.71	0.48	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
PCPG	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-6.79	2.46e-10	4.58e-07	-0.57	-0.48	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
PCPG	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	6.79	2.47e-10	4.6e-07	0.53	0.48	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
PCPG	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	6.79	2.47e-10	4.6e-07	0.66	0.48	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	6.79	2.47e-10	4.6e-07	0.66	0.48	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
PCPG	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-6.79	2.48e-10	4.6e-07	-0.7	-0.48	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-6.79	2.48e-10	4.6e-07	-0.7	-0.48	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-6.79	2.48e-10	4.6e-07	-0.7	-0.48	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-6.79	2.48e-10	4.6e-07	-0.7	-0.48	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
PCPG	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-6.79	2.48e-10	4.61e-07	-0.46	-0.48	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-6.79	2.48e-10	4.61e-07	-0.46	-0.48	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
PCPG	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-6.79	2.49e-10	4.62e-07	-0.62	-0.48	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
PCPG	cis	rs9595908	0.827	rs9595885	ENSG00000212293.1	SNORA16	6.79	2.49e-10	4.63e-07	0.59	0.48	Body mass index;	chr13:32593913	chr13:32420390~32420516:-
PCPG	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	6.79	2.5e-10	4.64e-07	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	6.79	2.5e-10	4.64e-07	0.87	0.48	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
PCPG	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	6.78	2.52e-10	4.67e-07	0.6	0.48	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
PCPG	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-6.78	2.53e-10	4.7e-07	-0.57	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
PCPG	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-6.78	2.54e-10	4.71e-07	-0.65	-0.48	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
PCPG	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	6.78	2.55e-10	4.73e-07	0.51	0.48	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
PCPG	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.78	2.56e-10	4.74e-07	0.66	0.48	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
PCPG	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-6.78	2.6e-10	4.81e-07	-0.46	-0.48	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
PCPG	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-6.78	2.6e-10	4.81e-07	-0.56	-0.48	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
PCPG	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-6.78	2.6e-10	4.82e-07	-0.45	-0.48	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
PCPG	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-6.78	2.6e-10	4.82e-07	-0.64	-0.48	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
PCPG	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-6.78	2.6e-10	4.82e-07	-0.64	-0.48	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
PCPG	cis	rs950169	0.881	rs150965	ENSG00000259295.5	CSPG4P12	6.78	2.61e-10	4.82e-07	0.73	0.48	Schizophrenia;	chr15:84537296	chr15:85191438~85213905:+
PCPG	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	6.78	2.61e-10	4.83e-07	0.54	0.48	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
PCPG	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	6.78	2.62e-10	4.84e-07	0.66	0.48	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
PCPG	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-6.78	2.62e-10	4.84e-07	-0.69	-0.48	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
PCPG	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	6.78	2.64e-10	4.88e-07	0.64	0.48	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
PCPG	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	6.78	2.64e-10	4.88e-07	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
PCPG	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-6.78	2.64e-10	4.88e-07	-0.56	-0.48	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
PCPG	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	6.78	2.64e-10	4.89e-07	0.52	0.48	Height;	chr3:53085313	chr3:53064283~53065091:-
PCPG	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-6.78	2.65e-10	4.9e-07	-0.52	-0.48	Height;	chr3:52972039	chr3:53064283~53065091:-
PCPG	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-6.77	2.65e-10	4.91e-07	-0.59	-0.48	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-6.77	2.65e-10	4.91e-07	-0.59	-0.48	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
PCPG	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-6.77	2.66e-10	4.91e-07	-0.66	-0.48	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
PCPG	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-6.77	2.66e-10	4.92e-07	-0.84	-0.48	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
PCPG	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-6.77	2.67e-10	4.93e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
PCPG	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-6.77	2.67e-10	4.94e-07	-0.44	-0.48	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
PCPG	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-6.77	2.68e-10	4.94e-07	-0.48	-0.48	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
PCPG	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	6.77	2.69e-10	4.95e-07	0.96	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
PCPG	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	6.77	2.7e-10	4.97e-07	0.47	0.48	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
PCPG	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-6.77	2.7e-10	4.97e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	6.77	2.71e-10	4.99e-07	0.56	0.48	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
PCPG	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-6.77	2.72e-10	5e-07	-0.66	-0.48	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
PCPG	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-6.77	2.72e-10	5.01e-07	-0.67	-0.48	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
PCPG	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	6.77	2.73e-10	5.02e-07	0.87	0.48	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
PCPG	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-6.77	2.77e-10	5.09e-07	-0.64	-0.48	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
PCPG	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-6.77	2.79e-10	5.13e-07	-0.61	-0.48	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
PCPG	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-6.76	2.8e-10	5.14e-07	-0.57	-0.48	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
PCPG	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	6.76	2.8e-10	5.14e-07	0.63	0.48	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
PCPG	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-6.76	2.82e-10	5.18e-07	-0.6	-0.48	Height;	chr14:75188649	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-6.76	2.82e-10	5.18e-07	-0.6	-0.48	Height;	chr14:75191310	chr14:75011269~75012851:-
PCPG	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-6.76	2.83e-10	5.19e-07	-0.61	-0.48	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
PCPG	cis	rs916888	0.821	rs415430	ENSG00000232300.1	FAM215B	-6.76	2.84e-10	5.21e-07	-0.73	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.779	rs430685	ENSG00000232300.1	FAM215B	-6.76	2.84e-10	5.21e-07	-0.73	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46558830~46562795:-
PCPG	cis	rs910316	0.87	rs7147712	ENSG00000279594.1	RP11-950C14.10	-6.76	2.85e-10	5.22e-07	-0.6	-0.48	Height;	chr14:75204004	chr14:75011269~75012851:-
PCPG	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	6.76	2.85e-10	5.24e-07	0.73	0.48	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
PCPG	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	6.76	2.86e-10	5.24e-07	0.65	0.48	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
PCPG	cis	rs9595908	0.929	rs34916533	ENSG00000212293.1	SNORA16	6.76	2.86e-10	5.25e-07	0.59	0.48	Body mass index;	chr13:32500537	chr13:32420390~32420516:-
PCPG	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-6.76	2.87e-10	5.27e-07	-0.57	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
PCPG	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	6.76	2.88e-10	5.28e-07	0.71	0.48	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	6.76	2.88e-10	5.28e-07	0.71	0.48	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	6.76	2.88e-10	5.28e-07	0.71	0.48	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
PCPG	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	6.76	2.89e-10	5.29e-07	0.66	0.48	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
PCPG	cis	rs6964833	1	rs35203738	ENSG00000277053.3	GTF2IP1	-6.76	2.89e-10	5.29e-07	-0.6	-0.48	Menarche (age at onset);	chr7:74690864	chr7:75185385~75237696:-
PCPG	cis	rs6964833	0.935	rs7795281	ENSG00000277053.3	GTF2IP1	-6.76	2.89e-10	5.29e-07	-0.6	-0.48	Menarche (age at onset);	chr7:74708523	chr7:75185385~75237696:-
PCPG	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	6.76	2.9e-10	5.31e-07	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
PCPG	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-6.76	2.91e-10	5.32e-07	-0.58	-0.48	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
PCPG	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	6.76	2.92e-10	5.34e-07	0.54	0.48	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
PCPG	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	6.76	2.94e-10	5.36e-07	0.72	0.48	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	6.76	2.94e-10	5.36e-07	0.72	0.48	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
PCPG	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	6.75	2.96e-10	5.41e-07	0.65	0.48	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
PCPG	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-6.75	2.96e-10	5.41e-07	-0.64	-0.48	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-6.75	2.96e-10	5.41e-07	-0.64	-0.48	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-6.75	2.96e-10	5.41e-07	-0.64	-0.48	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-6.75	2.96e-10	5.41e-07	-0.64	-0.48	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
PCPG	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	6.75	2.97e-10	5.43e-07	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	6.75	2.97e-10	5.43e-07	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	6.75	2.97e-10	5.43e-07	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	6.75	2.97e-10	5.43e-07	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	6.75	2.97e-10	5.43e-07	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	6.75	2.97e-10	5.43e-07	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
PCPG	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	6.75	2.98e-10	5.43e-07	1.15	0.48	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
PCPG	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	6.75	2.98e-10	5.43e-07	0.59	0.48	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
PCPG	cis	rs4835473	0.897	rs7662736	ENSG00000250345.2	RP11-780M14.1	-6.75	2.99e-10	5.45e-07	-0.59	-0.48	Immature fraction of reticulocytes;	chr4:143958036	chr4:143760399~143762093:-
PCPG	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-6.75	3.01e-10	5.49e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
PCPG	cis	rs4835473	0.932	rs1849113	ENSG00000250345.2	RP11-780M14.1	6.75	3.02e-10	5.51e-07	0.6	0.48	Immature fraction of reticulocytes;	chr4:143962512	chr4:143760399~143762093:-
PCPG	cis	rs7201929	1	rs7201929	ENSG00000251417.2	RP11-1348G14.4	-6.75	3.03e-10	5.52e-07	-0.57	-0.48	QT interval;	chr16:28860645	chr16:28802743~28817828:+
PCPG	cis	rs9595908	0.965	rs9595877	ENSG00000212293.1	SNORA16	6.75	3.04e-10	5.54e-07	0.59	0.48	Body mass index;	chr13:32589512	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs9595903	ENSG00000212293.1	SNORA16	6.75	3.04e-10	5.54e-07	0.59	0.48	Body mass index;	chr13:32608003	chr13:32420390~32420516:-
PCPG	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	6.75	3.04e-10	5.54e-07	0.57	0.48	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-6.75	3.07e-10	5.59e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
PCPG	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-6.75	3.07e-10	5.59e-07	-0.58	-0.48	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
PCPG	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	6.74	3.11e-10	5.66e-07	0.72	0.48	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
PCPG	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-6.74	3.13e-10	5.68e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-6.74	3.13e-10	5.68e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
PCPG	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-6.74	3.14e-10	5.71e-07	-0.59	-0.48	Height;	chr14:75189865	chr14:75011269~75012851:-
PCPG	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	6.74	3.15e-10	5.72e-07	0.52	0.48	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
PCPG	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	6.74	3.15e-10	5.72e-07	0.6	0.48	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
PCPG	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	6.74	3.16e-10	5.74e-07	0.56	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
PCPG	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	6.74	3.16e-10	5.75e-07	0.69	0.48	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
PCPG	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-6.74	3.19e-10	5.8e-07	-0.67	-0.48	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
PCPG	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-6.74	3.2e-10	5.81e-07	-0.45	-0.48	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-6.74	3.2e-10	5.81e-07	-0.45	-0.48	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-6.74	3.2e-10	5.81e-07	-0.45	-0.48	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-6.74	3.2e-10	5.81e-07	-0.45	-0.48	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-6.74	3.2e-10	5.81e-07	-0.45	-0.48	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
PCPG	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	6.74	3.2e-10	5.81e-07	0.67	0.48	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
PCPG	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-6.74	3.22e-10	5.84e-07	-0.57	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
PCPG	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-6.74	3.22e-10	5.85e-07	-0.56	-0.48	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
PCPG	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-6.74	3.22e-10	5.85e-07	-0.57	-0.48	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
PCPG	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-6.74	3.23e-10	5.85e-07	-0.52	-0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
PCPG	cis	rs916888	0.821	rs199504	ENSG00000232300.1	FAM215B	-6.74	3.26e-10	5.91e-07	-0.72	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46558830~46562795:-
PCPG	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	6.73	3.29e-10	5.95e-07	0.64	0.48	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
PCPG	cis	rs910316	1	rs12435391	ENSG00000279594.1	RP11-950C14.10	6.73	3.31e-10	5.98e-07	0.61	0.48	Height;	chr14:75135034	chr14:75011269~75012851:-
PCPG	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	6.73	3.32e-10	5.99e-07	0.64	0.48	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	6.73	3.32e-10	5.99e-07	0.64	0.48	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
PCPG	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-6.73	3.33e-10	6.01e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
PCPG	cis	rs910316	0.967	rs8007539	ENSG00000279594.1	RP11-950C14.10	-6.73	3.34e-10	6.03e-07	-0.6	-0.48	Height;	chr14:75198250	chr14:75011269~75012851:-
PCPG	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	6.73	3.34e-10	6.03e-07	0.37	0.48	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	6.73	3.34e-10	6.03e-07	0.37	0.48	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	6.73	3.34e-10	6.03e-07	0.37	0.48	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
PCPG	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	6.73	3.36e-10	6.06e-07	0.61	0.48	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
PCPG	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	6.73	3.36e-10	6.07e-07	0.65	0.48	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	6.73	3.37e-10	6.08e-07	0.65	0.48	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	6.73	3.37e-10	6.08e-07	0.65	0.48	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
PCPG	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	6.73	3.37e-10	6.08e-07	0.61	0.48	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	6.73	3.37e-10	6.08e-07	0.61	0.48	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
PCPG	cis	rs9595908	0.965	rs12323094	ENSG00000212293.1	SNORA16	6.73	3.37e-10	6.09e-07	0.59	0.48	Body mass index;	chr13:32569227	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs12323101	ENSG00000212293.1	SNORA16	6.73	3.37e-10	6.09e-07	0.59	0.48	Body mass index;	chr13:32569269	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs1123462	ENSG00000212293.1	SNORA16	6.73	3.37e-10	6.09e-07	0.59	0.48	Body mass index;	chr13:32571325	chr13:32420390~32420516:-
PCPG	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-6.73	3.38e-10	6.09e-07	-0.47	-0.48	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
PCPG	cis	rs916888	0.821	rs199513	ENSG00000232300.1	FAM215B	-6.73	3.39e-10	6.12e-07	-0.72	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46558830~46562795:-
PCPG	cis	rs7267979	1	rs4815411	ENSG00000125804.12	FAM182A	6.73	3.41e-10	6.16e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs6107027	ENSG00000125804.12	FAM182A	-6.73	3.42e-10	6.17e-07	-0.6	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26054655~26086917:+
PCPG	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	6.73	3.42e-10	6.17e-07	0.53	0.48	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
PCPG	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	6.73	3.44e-10	6.2e-07	0.62	0.48	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
PCPG	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	6.73	3.44e-10	6.2e-07	0.69	0.48	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
PCPG	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-6.72	3.46e-10	6.23e-07	-0.57	-0.48	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
PCPG	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-6.72	3.46e-10	6.23e-07	-0.57	-0.48	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
PCPG	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-6.72	3.48e-10	6.27e-07	-0.58	-0.48	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
PCPG	cis	rs7267979	1	rs2500418	ENSG00000125804.12	FAM182A	6.72	3.54e-10	6.37e-07	0.58	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2500424	ENSG00000125804.12	FAM182A	6.72	3.54e-10	6.37e-07	0.58	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2500448	ENSG00000125804.12	FAM182A	6.72	3.54e-10	6.37e-07	0.58	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.873	rs6083853	ENSG00000125804.12	FAM182A	6.72	3.54e-10	6.37e-07	0.58	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.934	rs2482913	ENSG00000125804.12	FAM182A	6.72	3.54e-10	6.37e-07	0.58	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050626	ENSG00000125804.12	FAM182A	-6.72	3.56e-10	6.41e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:26054655~26086917:+
PCPG	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	6.72	3.57e-10	6.42e-07	0.52	0.48	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
PCPG	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-6.72	3.58e-10	6.43e-07	-0.57	-0.48	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
PCPG	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-6.72	3.61e-10	6.48e-07	-0.71	-0.48	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
PCPG	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-6.72	3.61e-10	6.48e-07	-0.71	-0.48	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
PCPG	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	6.72	3.61e-10	6.49e-07	0.52	0.48	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
PCPG	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	6.72	3.61e-10	6.49e-07	0.64	0.48	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
PCPG	cis	rs7267979	1	rs2424712	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2424714	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2424715	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050617	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.933	rs2387887	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6037121	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs1047171	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050629	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050630	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050632	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2856	ENSG00000125804.12	FAM182A	-6.72	3.62e-10	6.5e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2387880	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2387882	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2387884	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6076345	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815418	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050590	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4813566	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815421	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs3761117	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs8123949	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2184000	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs4815425	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050599	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050602	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs6083855	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815426	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6115182	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050609	ENSG00000125804.12	FAM182A	6.71	3.65e-10	6.53e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:26054655~26086917:+
PCPG	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-6.71	3.67e-10	6.57e-07	-0.64	-0.48	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
PCPG	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-6.71	3.67e-10	6.57e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
PCPG	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	6.71	3.68e-10	6.59e-07	0.72	0.48	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
PCPG	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	6.71	3.69e-10	6.6e-07	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
PCPG	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	6.71	3.7e-10	6.62e-07	0.51	0.48	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
PCPG	cis	rs7267979	1	rs4815417	ENSG00000125804.12	FAM182A	6.71	3.71e-10	6.63e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050598	ENSG00000125804.12	FAM182A	-6.71	3.71e-10	6.63e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:26054655~26086917:+
PCPG	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	6.71	3.71e-10	6.63e-07	0.55	0.48	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
PCPG	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	6.71	3.72e-10	6.65e-07	0.58	0.48	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
PCPG	cis	rs7267979	0.844	rs6083845	ENSG00000125804.12	FAM182A	6.71	3.72e-10	6.65e-07	0.59	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs6083851	ENSG00000125804.12	FAM182A	6.71	3.72e-10	6.65e-07	0.59	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs4423675	ENSG00000125804.12	FAM182A	6.71	3.72e-10	6.65e-07	0.59	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26054655~26086917:+
PCPG	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	6.71	3.72e-10	6.66e-07	0.56	0.48	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-6.71	3.73e-10	6.66e-07	-0.45	-0.48	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
PCPG	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	6.71	3.73e-10	6.66e-07	0.49	0.48	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
PCPG	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	6.71	3.73e-10	6.67e-07	0.63	0.48	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
PCPG	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	6.71	3.74e-10	6.68e-07	0.61	0.48	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	6.71	3.74e-10	6.68e-07	0.61	0.48	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	6.71	3.74e-10	6.68e-07	0.61	0.48	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
PCPG	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-6.71	3.74e-10	6.68e-07	-0.59	-0.48	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
PCPG	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	6.71	3.78e-10	6.75e-07	0.62	0.48	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
PCPG	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	6.71	3.78e-10	6.75e-07	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	6.71	3.78e-10	6.75e-07	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	6.71	3.78e-10	6.75e-07	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
PCPG	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-6.71	3.79e-10	6.76e-07	-0.5	-0.48	Height;	chr3:52992698	chr3:53064283~53065091:-
PCPG	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	6.71	3.79e-10	6.76e-07	0.51	0.48	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
PCPG	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	6.71	3.8e-10	6.79e-07	0.6	0.48	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
PCPG	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-6.71	3.8e-10	6.79e-07	-0.45	-0.48	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	6.71	3.8e-10	6.79e-07	0.45	0.48	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
PCPG	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	6.71	3.81e-10	6.79e-07	0.71	0.48	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
PCPG	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	6.71	3.82e-10	6.82e-07	0.5	0.48	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
PCPG	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	6.71	3.82e-10	6.82e-07	0.46	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
PCPG	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-6.71	3.83e-10	6.84e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-6.71	3.83e-10	6.84e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
PCPG	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-6.71	3.83e-10	6.84e-07	-0.56	-0.48	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
PCPG	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-6.7	3.86e-10	6.88e-07	-0.64	-0.48	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
PCPG	cis	rs7267979	0.844	rs6115188	ENSG00000125804.12	FAM182A	-6.7	3.87e-10	6.89e-07	-0.59	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26054655~26086917:+
PCPG	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-6.7	3.88e-10	6.92e-07	-0.61	-0.48	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
PCPG	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	6.7	3.89e-10	6.92e-07	0.64	0.48	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
PCPG	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	6.7	3.89e-10	6.92e-07	0.64	0.48	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
PCPG	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-6.7	3.9e-10	6.94e-07	-0.62	-0.48	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
PCPG	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-6.7	3.91e-10	6.95e-07	-0.59	-0.48	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
PCPG	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-6.7	3.91e-10	6.96e-07	-0.61	-0.48	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-6.7	3.91e-10	6.96e-07	-0.61	-0.48	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
PCPG	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	6.7	3.92e-10	6.98e-07	0.69	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
PCPG	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-6.7	3.93e-10	7e-07	-0.56	-0.48	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
PCPG	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-6.7	3.93e-10	7e-07	-0.61	-0.48	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
PCPG	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-6.7	3.94e-10	7.01e-07	-0.62	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-6.7	3.94e-10	7.01e-07	-0.62	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
PCPG	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	6.7	3.95e-10	7.03e-07	0.38	0.48	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	6.7	3.95e-10	7.03e-07	0.38	0.48	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
PCPG	cis	rs7267979	1	rs4815412	ENSG00000125804.12	FAM182A	-6.7	3.95e-10	7.03e-07	-0.55	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6115153	ENSG00000125804.12	FAM182A	6.7	3.95e-10	7.03e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs7268053	ENSG00000125804.12	FAM182A	6.7	3.95e-10	7.03e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6083809	ENSG00000125804.12	FAM182A	6.7	3.95e-10	7.03e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815406	ENSG00000125804.12	FAM182A	6.7	3.95e-10	7.03e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs6107031	ENSG00000125804.12	FAM182A	6.7	3.95e-10	7.03e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6115159	ENSG00000125804.12	FAM182A	6.7	3.95e-10	7.03e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4813562	ENSG00000125804.12	FAM182A	6.7	3.95e-10	7.03e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:26054655~26086917:+
PCPG	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-6.7	3.96e-10	7.04e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-6.7	3.96e-10	7.04e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-6.7	3.96e-10	7.04e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
PCPG	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-6.7	3.96e-10	7.05e-07	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
PCPG	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-6.7	3.97e-10	7.05e-07	-0.64	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-6.7	3.97e-10	7.05e-07	-0.64	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-6.7	3.97e-10	7.05e-07	-0.64	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
PCPG	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-6.7	3.97e-10	7.05e-07	-0.47	-0.48	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
PCPG	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-6.7	3.98e-10	7.06e-07	-0.6	-0.48	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
PCPG	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	6.7	3.98e-10	7.07e-07	0.72	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
PCPG	cis	rs11148252	0.512	rs9526950	ENSG00000235660.1	LINC00345	-6.7	4e-10	7.09e-07	-0.61	-0.48	Lewy body disease;	chr13:52600328	chr13:52484161~52484680:-
PCPG	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-6.7	4.02e-10	7.14e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-6.7	4.02e-10	7.14e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
PCPG	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-6.7	4.03e-10	7.15e-07	-0.64	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-6.7	4.03e-10	7.15e-07	-0.64	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
PCPG	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-6.7	4.03e-10	7.16e-07	-0.6	-0.48	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
PCPG	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-6.7	4.04e-10	7.16e-07	-0.5	-0.48	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
PCPG	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-6.69	4.05e-10	7.18e-07	-0.57	-0.48	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
PCPG	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-6.69	4.05e-10	7.18e-07	-0.57	-0.48	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
PCPG	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	6.69	4.05e-10	7.19e-07	0.57	0.48	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
PCPG	cis	rs916888	0.738	rs199515	ENSG00000232300.1	FAM215B	-6.69	4.05e-10	7.19e-07	-0.7	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46558830~46562795:-
PCPG	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-6.69	4.05e-10	7.19e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
PCPG	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-6.69	4.07e-10	7.21e-07	-0.58	-0.48	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
PCPG	cis	rs7267979	0.844	rs6050477	ENSG00000125804.12	FAM182A	6.69	4.07e-10	7.22e-07	0.56	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs1888999	ENSG00000125804.12	FAM182A	-6.69	4.07e-10	7.22e-07	-0.57	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482927	ENSG00000125804.12	FAM182A	6.69	4.07e-10	7.22e-07	0.57	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482940	ENSG00000125804.12	FAM182A	6.69	4.07e-10	7.22e-07	0.57	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2027003	ENSG00000125804.12	FAM182A	6.69	4.07e-10	7.22e-07	0.57	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2027004	ENSG00000125804.12	FAM182A	6.69	4.07e-10	7.22e-07	0.57	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:26054655~26086917:+
PCPG	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-6.69	4.07e-10	7.22e-07	-0.52	-0.48	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-6.69	4.07e-10	7.22e-07	-0.52	-0.48	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
PCPG	cis	rs7267979	1	rs6050565	ENSG00000125804.12	FAM182A	6.69	4.08e-10	7.23e-07	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:26054655~26086917:+
PCPG	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-6.69	4.08e-10	7.23e-07	-0.67	-0.48	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
PCPG	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-6.69	4.09e-10	7.24e-07	-0.58	-0.48	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
PCPG	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-6.69	4.1e-10	7.25e-07	-0.69	-0.48	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
PCPG	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	6.69	4.1e-10	7.25e-07	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
PCPG	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-6.69	4.1e-10	7.26e-07	-0.58	-0.48	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
PCPG	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	6.69	4.11e-10	7.28e-07	0.85	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
PCPG	cis	rs7267979	1	rs6050573	ENSG00000125804.12	FAM182A	-6.69	4.17e-10	7.37e-07	-0.54	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:26054655~26086917:+
PCPG	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-6.69	4.17e-10	7.38e-07	-0.83	-0.48	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
PCPG	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	6.69	4.18e-10	7.39e-07	0.69	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
PCPG	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-6.69	4.18e-10	7.39e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
PCPG	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	6.69	4.18e-10	7.4e-07	0.89	0.48	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
PCPG	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-6.69	4.19e-10	7.41e-07	-0.52	-0.48	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
PCPG	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-6.69	4.2e-10	7.42e-07	-0.77	-0.48	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
PCPG	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-6.69	4.22e-10	7.46e-07	-0.91	-0.48	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
PCPG	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	6.69	4.23e-10	7.47e-07	0.65	0.48	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
PCPG	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-6.69	4.25e-10	7.51e-07	-0.54	-0.48	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
PCPG	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-6.69	4.26e-10	7.52e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-6.69	4.26e-10	7.52e-07	-0.45	-0.48	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
PCPG	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	6.69	4.26e-10	7.52e-07	0.51	0.48	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	6.69	4.26e-10	7.52e-07	0.51	0.48	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	6.69	4.26e-10	7.52e-07	0.51	0.48	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	6.69	4.26e-10	7.52e-07	0.51	0.48	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
PCPG	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	6.68	4.33e-10	7.62e-07	0.59	0.48	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
PCPG	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	6.68	4.34e-10	7.64e-07	0.51	0.48	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	6.68	4.34e-10	7.64e-07	0.51	0.48	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	6.68	4.34e-10	7.64e-07	0.51	0.48	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	6.68	4.34e-10	7.64e-07	0.51	0.48	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
PCPG	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	6.68	4.37e-10	7.69e-07	0.56	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
PCPG	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	6.68	4.39e-10	7.72e-07	0.65	0.48	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
PCPG	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	6.68	4.39e-10	7.73e-07	0.52	0.48	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
PCPG	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	6.68	4.41e-10	7.75e-07	0.7	0.48	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
PCPG	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-6.68	4.42e-10	7.77e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
PCPG	cis	rs4835473	0.868	rs1828503	ENSG00000250345.2	RP11-780M14.1	6.68	4.42e-10	7.78e-07	0.62	0.48	Immature fraction of reticulocytes;	chr4:143993354	chr4:143760399~143762093:-
PCPG	cis	rs7267979	0.668	rs4815398	ENSG00000125804.12	FAM182A	6.68	4.43e-10	7.78e-07	0.58	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26054655~26086917:+
PCPG	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-6.68	4.43e-10	7.78e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-6.68	4.43e-10	7.78e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-6.68	4.43e-10	7.78e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-6.68	4.43e-10	7.78e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-6.68	4.43e-10	7.78e-07	-0.48	-0.48	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
PCPG	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-6.68	4.43e-10	7.79e-07	-0.62	-0.48	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
PCPG	cis	rs7267979	0.816	rs390123	ENSG00000125804.12	FAM182A	-6.68	4.44e-10	7.79e-07	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.816	rs404775	ENSG00000125804.12	FAM182A	-6.68	4.44e-10	7.79e-07	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.816	rs374701	ENSG00000125804.12	FAM182A	-6.68	4.44e-10	7.79e-07	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.816	rs405822	ENSG00000125804.12	FAM182A	-6.68	4.44e-10	7.79e-07	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.816	rs6138593	ENSG00000125804.12	FAM182A	-6.68	4.44e-10	7.79e-07	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.816	rs409853	ENSG00000125804.12	FAM182A	-6.68	4.44e-10	7.79e-07	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26054655~26086917:+
PCPG	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-6.68	4.46e-10	7.82e-07	-0.86	-0.48	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
PCPG	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	6.68	4.47e-10	7.84e-07	0.59	0.48	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
PCPG	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	6.68	4.47e-10	7.85e-07	0.64	0.48	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
PCPG	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-6.67	4.5e-10	7.89e-07	-0.74	-0.48	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
PCPG	cis	rs56404409	0.911	rs56328670	ENSG00000255414.1	LINC01059	6.67	4.5e-10	7.9e-07	0.69	0.48	Ulcerative colitis;	chr11:123459933	chr11:123454398~123460410:+
PCPG	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-6.67	4.51e-10	7.91e-07	-0.59	-0.48	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-6.67	4.51e-10	7.91e-07	-0.59	-0.48	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-6.67	4.51e-10	7.91e-07	-0.59	-0.48	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
PCPG	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-6.67	4.54e-10	7.96e-07	-0.45	-0.48	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
PCPG	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-6.67	4.54e-10	7.97e-07	-0.37	-0.48	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
PCPG	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	6.67	4.54e-10	7.97e-07	0.45	0.48	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	6.67	4.54e-10	7.97e-07	0.45	0.48	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
PCPG	cis	rs9595908	0.965	rs35193668	ENSG00000212293.1	SNORA16	6.67	4.58e-10	8.02e-07	0.58	0.48	Body mass index;	chr13:32518792	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs2239748	ENSG00000212293.1	SNORA16	6.67	4.58e-10	8.02e-07	0.58	0.48	Body mass index;	chr13:32527680	chr13:32420390~32420516:-
PCPG	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	6.67	4.58e-10	8.03e-07	0.44	0.48	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
PCPG	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	6.67	4.61e-10	8.07e-07	0.6	0.48	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	6.67	4.61e-10	8.07e-07	0.6	0.48	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	6.67	4.61e-10	8.07e-07	0.6	0.48	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	6.67	4.61e-10	8.07e-07	0.6	0.48	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
PCPG	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-6.67	4.63e-10	8.1e-07	-0.61	-0.48	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
PCPG	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	6.67	4.65e-10	8.13e-07	0.53	0.48	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
PCPG	cis	rs11148252	0.532	rs9526975	ENSG00000198384.8	TPTE2P3	-6.67	4.65e-10	8.14e-07	-0.62	-0.48	Lewy body disease;	chr13:52681669	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-6.67	4.67e-10	8.17e-07	-0.61	-0.48	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-6.67	4.67e-10	8.17e-07	-0.61	-0.48	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
PCPG	cis	rs950169	0.84	rs72748702	ENSG00000259295.5	CSPG4P12	6.67	4.68e-10	8.17e-07	0.72	0.48	Schizophrenia;	chr15:84246494	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs4338765	ENSG00000259295.5	CSPG4P12	6.67	4.68e-10	8.17e-07	0.72	0.48	Schizophrenia;	chr15:84248084	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs62028133	ENSG00000259295.5	CSPG4P12	6.67	4.68e-10	8.17e-07	0.72	0.48	Schizophrenia;	chr15:84250623	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.723	rs17589320	ENSG00000259295.5	CSPG4P12	6.67	4.68e-10	8.17e-07	0.72	0.48	Schizophrenia;	chr15:84251244	chr15:85191438~85213905:+
PCPG	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	6.67	4.72e-10	8.24e-07	0.48	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	6.67	4.72e-10	8.24e-07	0.48	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
PCPG	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-6.67	4.73e-10	8.26e-07	-0.54	-0.48	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
PCPG	cis	rs9595908	0.897	rs12429688	ENSG00000212293.1	SNORA16	6.67	4.73e-10	8.26e-07	0.59	0.48	Body mass index;	chr13:32572075	chr13:32420390~32420516:-
PCPG	cis	rs7688540	0.713	rs4624608	ENSG00000275426.1	CH17-262A2.1	6.66	4.74e-10	8.27e-07	0.58	0.48	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:149738~150317:+
PCPG	cis	rs910316	1	rs4903284	ENSG00000279594.1	RP11-950C14.10	6.66	4.74e-10	8.27e-07	0.6	0.48	Height;	chr14:75125780	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs2024653	ENSG00000279594.1	RP11-950C14.10	6.66	4.74e-10	8.27e-07	0.6	0.48	Height;	chr14:75128451	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs2268617	ENSG00000279594.1	RP11-950C14.10	6.66	4.74e-10	8.27e-07	0.6	0.48	Height;	chr14:75142025	chr14:75011269~75012851:-
PCPG	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	6.66	4.76e-10	8.3e-07	0.45	0.48	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
PCPG	cis	rs950169	0.887	rs35986397	ENSG00000259295.5	CSPG4P12	6.66	4.78e-10	8.32e-07	0.74	0.48	Schizophrenia;	chr15:84400409	chr15:85191438~85213905:+
PCPG	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-6.66	4.82e-10	8.4e-07	-0.51	-0.48	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	6.66	4.82e-10	8.4e-07	0.51	0.48	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	6.66	4.82e-10	8.4e-07	0.51	0.48	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	6.66	4.82e-10	8.4e-07	0.51	0.48	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
PCPG	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	6.66	4.83e-10	8.41e-07	0.55	0.48	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
PCPG	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-6.66	4.84e-10	8.43e-07	-0.6	-0.48	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
PCPG	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	6.66	4.84e-10	8.43e-07	0.45	0.48	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	6.66	4.84e-10	8.43e-07	0.45	0.48	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
PCPG	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-6.66	4.85e-10	8.44e-07	-0.66	-0.48	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
PCPG	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-6.66	4.88e-10	8.49e-07	-0.92	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-6.66	4.88e-10	8.49e-07	-0.92	-0.48	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
PCPG	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	6.66	4.88e-10	8.49e-07	0.72	0.48	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
PCPG	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	6.66	4.88e-10	8.5e-07	0.67	0.48	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
PCPG	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-6.66	4.89e-10	8.51e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
PCPG	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-6.66	4.9e-10	8.53e-07	-0.96	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
PCPG	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-6.66	4.95e-10	8.6e-07	-0.64	-0.48	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
PCPG	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	6.65	5.01e-10	8.7e-07	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
PCPG	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	6.65	5.05e-10	8.77e-07	0.67	0.48	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	6.65	5.05e-10	8.77e-07	0.67	0.48	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
PCPG	cis	rs7267979	0.932	rs6115214	ENSG00000125804.12	FAM182A	6.65	5.08e-10	8.82e-07	0.57	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:26054655~26086917:+
PCPG	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-6.65	5.1e-10	8.84e-07	-0.57	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
PCPG	cis	rs1964356	0.967	rs17701675	ENSG00000253893.2	FAM85B	6.65	5.1e-10	8.84e-07	0.59	0.48	Mean corpuscular volume;	chr8:8993123	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	6.65	5.14e-10	8.91e-07	0.59	0.48	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
PCPG	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-6.65	5.17e-10	8.95e-07	-0.4	-0.48	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
PCPG	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-6.65	5.17e-10	8.96e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
PCPG	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	6.65	5.17e-10	8.96e-07	0.48	0.48	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
PCPG	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	6.65	5.18e-10	8.97e-07	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
PCPG	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	6.65	5.19e-10	8.99e-07	0.65	0.48	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
PCPG	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	6.65	5.19e-10	8.99e-07	0.65	0.48	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
PCPG	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	6.65	5.25e-10	9.08e-07	0.51	0.48	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
PCPG	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-6.65	5.25e-10	9.08e-07	-0.55	-0.48	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
PCPG	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	6.64	5.27e-10	9.1e-07	0.37	0.48	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	6.64	5.27e-10	9.1e-07	0.37	0.48	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	6.64	5.27e-10	9.1e-07	0.37	0.48	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	6.64	5.27e-10	9.1e-07	0.37	0.48	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
PCPG	cis	rs910316	1	rs10873275	ENSG00000279594.1	RP11-950C14.10	6.64	5.29e-10	9.14e-07	0.61	0.48	Height;	chr14:75064757	chr14:75011269~75012851:-
PCPG	cis	rs11148252	0.553	rs9536236	ENSG00000235660.1	LINC00345	-6.64	5.32e-10	9.18e-07	-0.61	-0.48	Lewy body disease;	chr13:52680877	chr13:52484161~52484680:-
PCPG	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-6.64	5.32e-10	9.19e-07	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
PCPG	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	6.64	5.38e-10	9.27e-07	0.65	0.48	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
PCPG	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-6.64	5.39e-10	9.3e-07	-0.59	-0.48	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
PCPG	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	6.64	5.41e-10	9.33e-07	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
PCPG	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	6.64	5.42e-10	9.34e-07	0.56	0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
PCPG	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	6.64	5.45e-10	9.38e-07	0.47	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	6.64	5.45e-10	9.38e-07	0.47	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
PCPG	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-6.64	5.45e-10	9.39e-07	-0.58	-0.48	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-6.64	5.45e-10	9.39e-07	-0.58	-0.48	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
PCPG	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-6.64	5.45e-10	9.4e-07	-0.57	-0.48	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-6.64	5.45e-10	9.4e-07	-0.57	-0.48	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
PCPG	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	6.64	5.47e-10	9.42e-07	0.54	0.48	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
PCPG	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-6.64	5.49e-10	9.45e-07	-0.6	-0.48	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
PCPG	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	6.64	5.5e-10	9.47e-07	0.64	0.48	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
PCPG	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	6.64	5.51e-10	9.49e-07	0.73	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
PCPG	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-6.64	5.51e-10	9.49e-07	-0.58	-0.48	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
PCPG	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	6.64	5.51e-10	9.49e-07	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
PCPG	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	6.64	5.53e-10	9.52e-07	0.49	0.48	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
PCPG	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	6.63	5.55e-10	9.54e-07	0.68	0.48	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
PCPG	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-6.63	5.57e-10	9.58e-07	-0.6	-0.48	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
PCPG	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-6.63	5.6e-10	9.63e-07	-0.53	-0.48	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
PCPG	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-6.63	5.63e-10	9.67e-07	-0.51	-0.48	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
PCPG	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	6.63	5.64e-10	9.7e-07	0.45	0.48	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
PCPG	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-6.63	5.67e-10	9.74e-07	-0.58	-0.48	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
PCPG	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-6.63	5.67e-10	9.74e-07	-0.58	-0.48	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
PCPG	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-6.63	5.67e-10	9.74e-07	-0.58	-0.48	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
PCPG	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	6.63	5.69e-10	9.76e-07	0.63	0.48	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
PCPG	cis	rs910316	0.712	rs175015	ENSG00000279594.1	RP11-950C14.10	-6.63	5.69e-10	9.77e-07	-0.62	-0.48	Height;	chr14:74990372	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs8013444	ENSG00000279594.1	RP11-950C14.10	-6.63	5.71e-10	9.8e-07	-0.59	-0.48	Height;	chr14:75195278	chr14:75011269~75012851:-
PCPG	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	6.63	5.77e-10	9.9e-07	0.6	0.48	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
PCPG	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	6.63	5.77e-10	9.9e-07	0.83	0.48	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
PCPG	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-6.63	5.78e-10	9.92e-07	-0.56	-0.48	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-6.63	5.78e-10	9.92e-07	-0.56	-0.48	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-6.63	5.78e-10	9.92e-07	-0.56	-0.48	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
PCPG	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-6.63	5.82e-10	9.97e-07	-0.45	-0.48	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
PCPG	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	6.62	5.85e-10	1e-06	0.62	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
PCPG	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-6.62	5.86e-10	1e-06	-0.57	-0.48	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
PCPG	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	6.62	5.87e-10	1.01e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	6.62	5.87e-10	1.01e-06	0.81	0.48	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	6.62	5.87e-10	1.01e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	6.62	5.87e-10	1.01e-06	0.81	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	6.62	5.87e-10	1.01e-06	0.88	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
PCPG	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-6.62	5.89e-10	1.01e-06	-0.61	-0.48	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
PCPG	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	6.62	5.93e-10	1.01e-06	0.65	0.48	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
PCPG	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-6.62	5.93e-10	1.02e-06	-0.66	-0.48	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
PCPG	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-6.62	5.94e-10	1.02e-06	-0.59	-0.48	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-6.62	5.94e-10	1.02e-06	-0.59	-0.48	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
PCPG	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	6.62	5.96e-10	1.02e-06	0.51	0.48	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
PCPG	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	6.62	5.97e-10	1.02e-06	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	6.62	5.97e-10	1.02e-06	0.5	0.48	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
PCPG	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-6.62	5.99e-10	1.02e-06	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-6.62	5.99e-10	1.02e-06	-0.56	-0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
PCPG	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	6.62	6e-10	1.03e-06	0.44	0.48	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
PCPG	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-6.62	6.04e-10	1.03e-06	-0.55	-0.48	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
PCPG	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	6.62	6.06e-10	1.04e-06	0.62	0.48	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
PCPG	cis	rs7267979	0.932	rs2260997	ENSG00000125804.12	FAM182A	6.62	6.1e-10	1.04e-06	0.55	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:26054655~26086917:+
PCPG	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	6.62	6.1e-10	1.04e-06	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
PCPG	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	6.62	6.13e-10	1.05e-06	0.7	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
PCPG	cis	rs950169	0.8	rs4842847	ENSG00000259295.5	CSPG4P12	6.61	6.16e-10	1.05e-06	0.73	0.48	Schizophrenia;	chr15:84262447	chr15:85191438~85213905:+
PCPG	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-6.61	6.16e-10	1.05e-06	-0.7	-0.48	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
PCPG	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	6.61	6.18e-10	1.05e-06	0.55	0.48	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
PCPG	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-6.61	6.19e-10	1.06e-06	-0.67	-0.48	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
PCPG	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	6.61	6.21e-10	1.06e-06	0.85	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
PCPG	cis	rs7267979	0.718	rs2983489	ENSG00000125804.12	FAM182A	-6.61	6.21e-10	1.06e-06	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.727	rs2474765	ENSG00000125804.12	FAM182A	-6.61	6.21e-10	1.06e-06	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.764	rs2474767	ENSG00000125804.12	FAM182A	-6.61	6.21e-10	1.06e-06	-0.58	-0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26054655~26086917:+
PCPG	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-6.61	6.21e-10	1.06e-06	-0.73	-0.48	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
PCPG	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-6.61	6.22e-10	1.06e-06	-0.5	-0.48	Height;	chr3:52989412	chr3:53064283~53065091:-
PCPG	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	6.61	6.25e-10	1.07e-06	0.51	0.48	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
PCPG	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.61	6.26e-10	1.07e-06	-0.62	-0.48	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
PCPG	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-6.61	6.27e-10	1.07e-06	-0.62	-0.48	Depression;	chr6:28096845	chr6:28115628~28116551:+
PCPG	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-6.61	6.27e-10	1.07e-06	-0.55	-0.48	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
PCPG	cis	rs7267979	0.816	rs443009	ENSG00000125804.12	FAM182A	6.61	6.28e-10	1.07e-06	0.57	0.48	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26054655~26086917:+
PCPG	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-6.61	6.29e-10	1.07e-06	-0.55	-0.48	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
PCPG	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	6.61	6.29e-10	1.07e-06	0.55	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-6.61	6.29e-10	1.07e-06	-0.45	-0.47	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
PCPG	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-6.61	6.32e-10	1.08e-06	-0.5	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
PCPG	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	6.61	6.34e-10	1.08e-06	0.65	0.47	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
PCPG	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-6.61	6.37e-10	1.08e-06	-0.59	-0.47	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
PCPG	cis	rs9595908	0.669	rs4057298	ENSG00000212293.1	SNORA16	6.61	6.41e-10	1.09e-06	0.59	0.47	Body mass index;	chr13:32734227	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs17516382	ENSG00000212293.1	SNORA16	6.61	6.41e-10	1.09e-06	0.59	0.47	Body mass index;	chr13:32735426	chr13:32420390~32420516:-
PCPG	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-6.61	6.42e-10	1.09e-06	-0.59	-0.47	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-6.61	6.42e-10	1.09e-06	-0.59	-0.47	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
PCPG	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	6.61	6.48e-10	1.1e-06	0.51	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	6.6	6.5e-10	1.1e-06	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	6.6	6.51e-10	1.11e-06	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
PCPG	cis	rs853679	0.527	rs9461443	ENSG00000216901.1	AL022393.7	6.6	6.51e-10	1.11e-06	0.65	0.47	Depression;	chr6:28226851	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.55	rs34477097	ENSG00000216901.1	AL022393.7	6.6	6.51e-10	1.11e-06	0.65	0.47	Depression;	chr6:28229408	chr6:28176188~28176674:+
PCPG	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-6.6	6.53e-10	1.11e-06	-0.69	-0.47	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
PCPG	cis	rs7267979	1	rs6083844	ENSG00000125804.12	FAM182A	6.6	6.53e-10	1.11e-06	0.55	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:26054655~26086917:+
PCPG	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-6.6	6.54e-10	1.11e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
PCPG	cis	rs7267979	0.966	rs6037097	ENSG00000125804.12	FAM182A	-6.6	6.56e-10	1.11e-06	-0.54	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:26054655~26086917:+
PCPG	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-6.6	6.57e-10	1.11e-06	-0.52	-0.47	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
PCPG	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-6.6	6.59e-10	1.12e-06	-0.45	-0.47	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-6.6	6.59e-10	1.12e-06	-0.45	-0.47	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-6.6	6.59e-10	1.12e-06	-0.45	-0.47	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-6.6	6.59e-10	1.12e-06	-0.45	-0.47	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	6.6	6.67e-10	1.13e-06	0.44	0.47	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
PCPG	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-6.6	6.67e-10	1.13e-06	-0.41	-0.47	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
PCPG	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	6.6	6.68e-10	1.13e-06	0.82	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
PCPG	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	6.6	6.69e-10	1.13e-06	0.66	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
PCPG	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
PCPG	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	6.6	6.71e-10	1.13e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
PCPG	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-6.6	6.72e-10	1.14e-06	-0.61	-0.47	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
PCPG	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-6.6	6.73e-10	1.14e-06	-0.56	-0.47	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
PCPG	cis	rs9481169	0.557	rs34896684	ENSG00000255389.1	C6orf3	-6.6	6.74e-10	1.14e-06	-0.98	-0.47	Inflammatory skin disease;	chr6:111572034	chr6:111599875~111602295:+
PCPG	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-6.6	6.76e-10	1.14e-06	-0.59	-0.47	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
PCPG	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-6.6	6.82e-10	1.15e-06	-0.55	-0.47	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	6.6	6.83e-10	1.15e-06	0.55	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
PCPG	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	6.59	6.86e-10	1.16e-06	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
PCPG	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	6.59	6.86e-10	1.16e-06	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
PCPG	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-6.59	6.86e-10	1.16e-06	-0.55	-0.47	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
PCPG	cis	rs9595908	0.965	rs9337	ENSG00000212293.1	SNORA16	6.59	6.86e-10	1.16e-06	0.59	0.47	Body mass index;	chr13:32517104	chr13:32420390~32420516:-
PCPG	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-6.59	6.86e-10	1.16e-06	-0.59	-0.47	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
PCPG	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-6.59	6.88e-10	1.16e-06	-0.62	-0.47	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
PCPG	cis	rs34787248	1	rs34787248	ENSG00000216901.1	AL022393.7	6.59	6.88e-10	1.16e-06	0.76	0.47	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28176188~28176674:+
PCPG	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-6.59	6.91e-10	1.16e-06	-0.36	-0.47	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
PCPG	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-6.59	6.91e-10	1.16e-06	-0.57	-0.47	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
PCPG	cis	rs910316	0.81	rs77939209	ENSG00000279594.1	RP11-950C14.10	-6.59	6.94e-10	1.17e-06	-0.6	-0.47	Height;	chr14:75203367	chr14:75011269~75012851:-
PCPG	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	6.59	6.94e-10	1.17e-06	0.69	0.47	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
PCPG	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	6.59	6.95e-10	1.17e-06	0.52	0.47	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
PCPG	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-6.59	6.95e-10	1.17e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
PCPG	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-6.59	6.96e-10	1.17e-06	-0.59	-0.47	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
PCPG	cis	rs7267979	0.816	rs6037158	ENSG00000125804.12	FAM182A	-6.59	7.01e-10	1.18e-06	-0.59	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26054655~26086917:+
PCPG	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-6.59	7.03e-10	1.18e-06	-0.45	-0.47	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-6.59	7.03e-10	1.18e-06	-0.45	-0.47	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
PCPG	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	6.59	7.06e-10	1.18e-06	0.53	0.47	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
PCPG	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-6.59	7.09e-10	1.19e-06	-0.61	-0.47	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
PCPG	cis	rs7267979	1	rs6050555	ENSG00000125804.12	FAM182A	6.59	7.11e-10	1.19e-06	0.54	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:26054655~26086917:+
PCPG	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	6.59	7.16e-10	1.2e-06	0.66	0.47	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	6.59	7.16e-10	1.2e-06	0.66	0.47	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	6.59	7.16e-10	1.2e-06	0.66	0.47	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
PCPG	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	6.59	7.16e-10	1.2e-06	0.65	0.47	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
PCPG	cis	rs910316	0.663	rs175034	ENSG00000279594.1	RP11-950C14.10	-6.59	7.19e-10	1.2e-06	-0.62	-0.47	Height;	chr14:74996984	chr14:75011269~75012851:-
PCPG	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-6.58	7.22e-10	1.21e-06	-0.44	-0.47	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-6.58	7.22e-10	1.21e-06	-0.44	-0.47	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-6.58	7.22e-10	1.21e-06	-0.44	-0.47	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-6.58	7.22e-10	1.21e-06	-0.44	-0.47	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
PCPG	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	6.58	7.22e-10	1.21e-06	0.56	0.47	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
PCPG	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-6.58	7.26e-10	1.21e-06	-0.59	-0.47	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
PCPG	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-6.58	7.28e-10	1.22e-06	-0.54	-0.47	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
PCPG	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-6.58	7.3e-10	1.22e-06	-0.63	-0.47	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
PCPG	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-6.58	7.3e-10	1.22e-06	-0.63	-0.47	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
PCPG	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	6.58	7.3e-10	1.22e-06	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
PCPG	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-6.58	7.33e-10	1.22e-06	-0.58	-0.47	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	6.58	7.38e-10	1.23e-06	0.6	0.47	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
PCPG	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-6.58	7.43e-10	1.24e-06	-0.55	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-6.58	7.43e-10	1.24e-06	-0.55	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-6.58	7.43e-10	1.24e-06	-0.55	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-6.58	7.43e-10	1.24e-06	-0.55	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-6.58	7.43e-10	1.24e-06	-0.55	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
PCPG	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-6.58	7.43e-10	1.24e-06	-0.55	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
PCPG	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	6.58	7.45e-10	1.24e-06	0.36	0.47	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
PCPG	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	6.58	7.46e-10	1.24e-06	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
PCPG	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-6.58	7.46e-10	1.24e-06	-0.69	-0.47	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
PCPG	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-6.58	7.46e-10	1.24e-06	-0.51	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
PCPG	cis	rs7267979	0.816	rs422148	ENSG00000125804.12	FAM182A	-6.58	7.46e-10	1.24e-06	-0.59	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26054655~26086917:+
PCPG	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-6.58	7.49e-10	1.25e-06	-0.51	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
PCPG	cis	rs916888	0.773	rs199448	ENSG00000232300.1	FAM215B	6.58	7.5e-10	1.25e-06	0.7	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46558830~46562795:-
PCPG	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-6.58	7.5e-10	1.25e-06	-0.6	-0.47	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
PCPG	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-6.58	7.52e-10	1.25e-06	-0.61	-0.47	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
PCPG	cis	rs453301	0.522	rs1964356	ENSG00000253893.2	FAM85B	-6.58	7.53e-10	1.25e-06	-0.6	-0.47	Joint mobility (Beighton score);	chr8:8995760	chr8:8167819~8226614:-
PCPG	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	6.58	7.54e-10	1.25e-06	0.6	0.47	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
PCPG	cis	rs1964356	0.967	rs2953802	ENSG00000253893.2	FAM85B	-6.58	7.57e-10	1.26e-06	-0.59	-0.47	Mean corpuscular volume;	chr8:8994371	chr8:8167819~8226614:-
PCPG	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	6.58	7.58e-10	1.26e-06	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	6.58	7.58e-10	1.26e-06	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
PCPG	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	6.57	7.6e-10	1.26e-06	0.68	0.47	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-6.57	7.6e-10	1.26e-06	-0.68	-0.47	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-6.57	7.6e-10	1.26e-06	-0.68	-0.47	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
PCPG	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-6.57	7.62e-10	1.27e-06	-0.54	-0.47	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
PCPG	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-6.57	7.62e-10	1.27e-06	-0.54	-0.47	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
PCPG	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-6.57	7.62e-10	1.27e-06	-0.54	-0.47	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
PCPG	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-6.57	7.62e-10	1.27e-06	-0.54	-0.47	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
PCPG	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	6.57	7.63e-10	1.27e-06	0.68	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
PCPG	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-6.57	7.64e-10	1.27e-06	-0.48	-0.47	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
PCPG	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	6.57	7.64e-10	1.27e-06	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
PCPG	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	6.57	7.66e-10	1.27e-06	0.7	0.47	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
PCPG	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	6.57	7.66e-10	1.27e-06	0.65	0.47	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
PCPG	cis	rs7824557	0.701	rs4568582	ENSG00000255020.1	AF131216.5	6.57	7.68e-10	1.28e-06	0.63	0.47	Retinal vascular caliber;	chr8:11302986	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-6.57	7.68e-10	1.28e-06	-0.59	-0.47	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
PCPG	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	6.57	7.72e-10	1.28e-06	0.61	0.47	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
PCPG	cis	rs950169	0.881	rs72750843	ENSG00000259295.5	CSPG4P12	6.57	7.74e-10	1.28e-06	0.71	0.47	Schizophrenia;	chr15:84592552	chr15:85191438~85213905:+
PCPG	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	6.57	7.74e-10	1.28e-06	0.62	0.47	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
PCPG	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-6.57	7.76e-10	1.29e-06	-0.61	-0.47	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
PCPG	cis	rs950169	0.922	rs2033284	ENSG00000259295.5	CSPG4P12	6.57	7.77e-10	1.29e-06	0.73	0.47	Schizophrenia;	chr15:84391575	chr15:85191438~85213905:+
PCPG	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	6.57	7.77e-10	1.29e-06	0.55	0.47	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
PCPG	cis	rs11148252	0.532	rs9526975	ENSG00000235660.1	LINC00345	-6.57	7.8e-10	1.29e-06	-0.61	-0.47	Lewy body disease;	chr13:52681669	chr13:52484161~52484680:-
PCPG	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-6.57	7.81e-10	1.3e-06	-0.56	-0.47	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
PCPG	cis	rs910316	0.967	rs7146523	ENSG00000279594.1	RP11-950C14.10	-6.57	7.83e-10	1.3e-06	-0.59	-0.47	Height;	chr14:75193177	chr14:75011269~75012851:-
PCPG	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-6.57	7.85e-10	1.3e-06	-0.58	-0.47	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
PCPG	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	6.57	7.86e-10	1.3e-06	0.36	0.47	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	6.57	7.86e-10	1.3e-06	0.36	0.47	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	6.57	7.86e-10	1.3e-06	0.36	0.47	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	6.57	7.86e-10	1.3e-06	0.36	0.47	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	6.57	7.86e-10	1.3e-06	0.36	0.47	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	6.57	7.86e-10	1.3e-06	0.36	0.47	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
PCPG	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	6.57	7.86e-10	1.3e-06	0.36	0.47	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
PCPG	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	6.57	7.92e-10	1.31e-06	0.58	0.47	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
PCPG	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	6.57	7.96e-10	1.32e-06	0.65	0.47	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
PCPG	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-6.57	7.97e-10	1.32e-06	-0.67	-0.47	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
PCPG	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	6.57	7.97e-10	1.32e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
PCPG	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-6.57	7.99e-10	1.32e-06	-0.69	-0.47	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
PCPG	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-6.56	8.01e-10	1.33e-06	-0.47	-0.47	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
PCPG	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	6.56	8.05e-10	1.33e-06	0.57	0.47	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
PCPG	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-6.56	8.06e-10	1.33e-06	-0.36	-0.47	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
PCPG	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	6.56	8.06e-10	1.33e-06	0.45	0.47	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
PCPG	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-6.56	8.07e-10	1.33e-06	-0.5	-0.47	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
PCPG	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-6.56	8.09e-10	1.34e-06	-0.58	-0.47	Height;	chr14:75193543	chr14:75011269~75012851:-
PCPG	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-6.56	8.19e-10	1.35e-06	-0.69	-0.47	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
PCPG	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	6.56	8.22e-10	1.36e-06	0.53	0.47	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
PCPG	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-6.56	8.22e-10	1.36e-06	-0.61	-0.47	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
PCPG	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-6.56	8.22e-10	1.36e-06	-0.47	-0.47	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
PCPG	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	6.56	8.22e-10	1.36e-06	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	6.56	8.22e-10	1.36e-06	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	6.56	8.22e-10	1.36e-06	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
PCPG	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-6.56	8.24e-10	1.36e-06	-0.56	-0.47	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
PCPG	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	6.56	8.28e-10	1.36e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
PCPG	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	6.56	8.28e-10	1.36e-06	0.6	0.47	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
PCPG	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	6.56	8.28e-10	1.36e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	6.56	8.28e-10	1.36e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	6.56	8.28e-10	1.36e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
PCPG	cis	rs6452524	0.837	rs1479569	ENSG00000249664.1	CTD-2227C6.2	6.56	8.29e-10	1.36e-06	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:83012285~83013109:-
PCPG	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-6.56	8.29e-10	1.37e-06	-0.68	-0.47	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
PCPG	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-6.56	8.34e-10	1.37e-06	-0.67	-0.47	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
PCPG	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	6.56	8.36e-10	1.38e-06	0.64	0.47	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
PCPG	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	6.56	8.39e-10	1.38e-06	0.45	0.47	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	6.56	8.39e-10	1.38e-06	0.45	0.47	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	6.56	8.39e-10	1.38e-06	0.45	0.47	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
PCPG	cis	rs910316	0.967	rs4899549	ENSG00000279594.1	RP11-950C14.10	-6.56	8.41e-10	1.38e-06	-0.61	-0.47	Height;	chr14:75180791	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs4899550	ENSG00000279594.1	RP11-950C14.10	-6.56	8.41e-10	1.38e-06	-0.61	-0.47	Height;	chr14:75180963	chr14:75011269~75012851:-
PCPG	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	6.55	8.51e-10	1.39e-06	0.43	0.47	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	6.55	8.51e-10	1.39e-06	0.43	0.47	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
PCPG	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-6.55	8.52e-10	1.39e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-6.55	8.52e-10	1.39e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-6.55	8.52e-10	1.39e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-6.55	8.52e-10	1.39e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-6.55	8.52e-10	1.39e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-6.55	8.52e-10	1.39e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
PCPG	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	6.55	8.53e-10	1.4e-06	0.44	0.47	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	6.55	8.53e-10	1.4e-06	0.44	0.47	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	6.55	8.53e-10	1.4e-06	0.44	0.47	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	6.55	8.53e-10	1.4e-06	0.44	0.47	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
PCPG	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-6.55	8.56e-10	1.4e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
PCPG	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-6.55	8.56e-10	1.4e-06	-0.57	-0.47	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
PCPG	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	6.55	8.57e-10	1.4e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
PCPG	cis	rs950169	0.881	rs4842852	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84387263	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.84	rs4842853	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84387606	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs4842946	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84387633	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.84	rs4842854	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84387641	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.84	rs2896002	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84390423	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.887	rs3860265	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84390487	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.724	rs11632668	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84393989	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.881	rs34591918	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84396135	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.887	rs12903946	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84399732	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.887	rs62029593	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84400482	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.81	rs62029594	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84400554	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.84	rs62029595	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84400603	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.881	rs62029596	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84400736	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.881	rs4081123	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84401537	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.881	rs62029599	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84401867	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.8	rs4099846	ENSG00000259295.5	CSPG4P12	6.55	8.58e-10	1.4e-06	0.73	0.47	Schizophrenia;	chr15:84402196	chr15:85191438~85213905:+
PCPG	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	6.55	8.61e-10	1.41e-06	0.59	0.47	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
PCPG	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-6.55	8.62e-10	1.41e-06	-0.54	-0.47	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
PCPG	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	6.55	8.62e-10	1.41e-06	0.61	0.47	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	6.55	8.62e-10	1.41e-06	0.61	0.47	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
PCPG	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-6.55	8.64e-10	1.41e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
PCPG	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	6.55	8.65e-10	1.41e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
PCPG	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	6.55	8.65e-10	1.41e-06	0.53	0.47	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	6.55	8.65e-10	1.41e-06	0.53	0.47	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	6.55	8.65e-10	1.41e-06	0.53	0.47	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	6.55	8.65e-10	1.41e-06	0.53	0.47	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	6.55	8.65e-10	1.41e-06	0.53	0.47	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	6.55	8.65e-10	1.41e-06	0.53	0.47	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	6.55	8.65e-10	1.41e-06	0.53	0.47	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
PCPG	cis	rs7267979	1	rs2297497	ENSG00000125804.12	FAM182A	6.55	8.66e-10	1.41e-06	0.54	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:26054655~26086917:+
PCPG	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	6.55	8.68e-10	1.41e-06	0.44	0.47	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
PCPG	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-6.55	8.72e-10	1.42e-06	-0.6	-0.47	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
PCPG	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	6.55	8.75e-10	1.42e-06	0.68	0.47	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
PCPG	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	6.55	8.77e-10	1.43e-06	0.66	0.47	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
PCPG	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-6.55	8.77e-10	1.43e-06	-0.65	-0.47	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
PCPG	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	6.55	8.78e-10	1.43e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
PCPG	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-6.55	8.8e-10	1.43e-06	-0.57	-0.47	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
PCPG	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-6.55	8.84e-10	1.44e-06	-0.54	-0.47	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
PCPG	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	6.54	8.89e-10	1.44e-06	0.63	0.47	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
PCPG	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-6.54	8.91e-10	1.45e-06	-0.58	-0.47	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
PCPG	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	6.54	8.91e-10	1.45e-06	0.65	0.47	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	6.54	8.91e-10	1.45e-06	0.65	0.47	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
PCPG	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	6.54	8.91e-10	1.45e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
PCPG	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	6.54	8.94e-10	1.45e-06	0.62	0.47	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
PCPG	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	6.54	8.94e-10	1.45e-06	0.62	0.47	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
PCPG	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	6.54	8.94e-10	1.45e-06	0.62	0.47	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
PCPG	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-6.54	8.95e-10	1.45e-06	-0.6	-0.47	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
PCPG	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	6.54	8.96e-10	1.45e-06	0.44	0.47	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	6.54	8.96e-10	1.45e-06	0.44	0.47	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
PCPG	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-6.54	9e-10	1.46e-06	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-6.54	9e-10	1.46e-06	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
PCPG	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	6.54	9.02e-10	1.46e-06	0.64	0.47	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
PCPG	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-6.54	9.07e-10	1.47e-06	-0.59	-0.47	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
PCPG	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-6.54	9.07e-10	1.47e-06	-0.6	-0.47	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
PCPG	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-6.54	9.09e-10	1.47e-06	-0.55	-0.47	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
PCPG	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-6.54	9.13e-10	1.48e-06	-0.56	-0.47	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
PCPG	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-6.54	9.13e-10	1.48e-06	-0.58	-0.47	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-6.54	9.13e-10	1.48e-06	-0.58	-0.47	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
PCPG	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	6.54	9.14e-10	1.48e-06	0.53	0.47	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	6.54	9.14e-10	1.48e-06	0.53	0.47	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
PCPG	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-6.54	9.15e-10	1.48e-06	-0.62	-0.47	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
PCPG	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	6.54	9.15e-10	1.48e-06	0.83	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
PCPG	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	6.54	9.17e-10	1.48e-06	0.62	0.47	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
PCPG	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-6.54	9.18e-10	1.48e-06	-0.44	-0.47	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-6.54	9.18e-10	1.48e-06	-0.44	-0.47	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-6.54	9.18e-10	1.48e-06	-0.44	-0.47	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-6.54	9.18e-10	1.48e-06	-0.44	-0.47	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
PCPG	cis	rs11148252	0.669	rs61958050	ENSG00000235660.1	LINC00345	-6.54	9.21e-10	1.49e-06	-0.62	-0.47	Lewy body disease;	chr13:52420292	chr13:52484161~52484680:-
PCPG	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-6.54	9.21e-10	1.49e-06	-0.62	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
PCPG	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-6.54	9.22e-10	1.49e-06	-0.36	-0.47	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	6.54	9.22e-10	1.49e-06	0.36	0.47	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	6.54	9.22e-10	1.49e-06	0.36	0.47	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
PCPG	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-6.54	9.27e-10	1.5e-06	-0.68	-0.47	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
PCPG	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-6.54	9.29e-10	1.5e-06	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-6.54	9.29e-10	1.5e-06	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
PCPG	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	6.54	9.29e-10	1.5e-06	0.62	0.47	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
PCPG	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	6.54	9.29e-10	1.5e-06	0.62	0.47	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
PCPG	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	6.53	9.36e-10	1.51e-06	0.49	0.47	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	6.53	9.36e-10	1.51e-06	0.49	0.47	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	6.53	9.36e-10	1.51e-06	0.49	0.47	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-6.53	9.36e-10	1.51e-06	-0.49	-0.47	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-6.53	9.36e-10	1.51e-06	-0.49	-0.47	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-6.53	9.36e-10	1.51e-06	-0.49	-0.47	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
PCPG	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-6.53	9.37e-10	1.51e-06	-0.7	-0.47	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
PCPG	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	6.53	9.37e-10	1.51e-06	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
PCPG	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-6.53	9.39e-10	1.51e-06	-0.45	-0.47	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
PCPG	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-6.53	9.39e-10	1.51e-06	-0.45	-0.47	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
PCPG	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	6.53	9.39e-10	1.51e-06	0.6	0.47	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
PCPG	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-6.53	9.4e-10	1.51e-06	-0.59	-0.47	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
PCPG	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-6.53	9.41e-10	1.51e-06	-0.49	-0.47	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
PCPG	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	6.53	9.52e-10	1.53e-06	0.61	0.47	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
PCPG	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-6.53	9.53e-10	1.53e-06	-0.59	-0.47	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
PCPG	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-6.53	9.54e-10	1.53e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-6.53	9.54e-10	1.53e-06	-0.5	-0.47	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
PCPG	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-6.53	9.56e-10	1.54e-06	-0.61	-0.47	Depression;	chr6:28135913	chr6:28115628~28116551:+
PCPG	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-6.53	9.56e-10	1.54e-06	-0.61	-0.47	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
PCPG	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	6.53	9.66e-10	1.55e-06	0.53	0.47	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	6.53	9.66e-10	1.55e-06	0.53	0.47	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	6.53	9.66e-10	1.55e-06	0.53	0.47	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
PCPG	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	6.53	9.74e-10	1.56e-06	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	6.53	9.74e-10	1.56e-06	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	6.53	9.74e-10	1.56e-06	0.61	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
PCPG	cis	rs4835473	0.838	rs10024263	ENSG00000250345.2	RP11-780M14.1	-6.53	9.75e-10	1.56e-06	-0.6	-0.47	Immature fraction of reticulocytes;	chr4:144038174	chr4:143760399~143762093:-
PCPG	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-6.52	9.88e-10	1.58e-06	-0.68	-0.47	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
PCPG	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-6.52	9.88e-10	1.58e-06	-0.68	-0.47	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
PCPG	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	6.52	9.9e-10	1.59e-06	0.64	0.47	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
PCPG	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	6.52	9.92e-10	1.59e-06	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
PCPG	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	6.52	9.92e-10	1.59e-06	0.5	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
PCPG	cis	rs910316	0.737	rs175510	ENSG00000279594.1	RP11-950C14.10	-6.52	9.94e-10	1.59e-06	-0.61	-0.47	Height;	chr14:75058136	chr14:75011269~75012851:-
PCPG	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-6.52	9.94e-10	1.59e-06	-0.72	-0.47	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
PCPG	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	6.52	9.96e-10	1.59e-06	0.59	0.47	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
PCPG	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-6.52	9.97e-10	1.59e-06	-0.69	-0.47	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
PCPG	cis	rs7201929	1	rs12920514	ENSG00000251417.2	RP11-1348G14.4	6.52	9.98e-10	1.6e-06	0.56	0.47	QT interval;	chr16:28824579	chr16:28802743~28817828:+
PCPG	cis	rs910316	1	rs7145159	ENSG00000279594.1	RP11-950C14.10	6.52	9.99e-10	1.6e-06	0.6	0.47	Height;	chr14:75116565	chr14:75011269~75012851:-
PCPG	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-6.52	1e-09	1.6e-06	-0.6	-0.47	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-6.52	1e-09	1.6e-06	-0.6	-0.47	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
PCPG	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	6.52	1e-09	1.6e-06	0.62	0.47	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
PCPG	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	6.52	1e-09	1.6e-06	0.62	0.47	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
PCPG	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	6.52	1e-09	1.6e-06	0.62	0.47	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
PCPG	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-6.52	1.01e-09	1.61e-06	-0.57	-0.47	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
PCPG	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	6.52	1.02e-09	1.62e-06	0.6	0.47	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	6.52	1.02e-09	1.62e-06	0.6	0.47	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	6.52	1.02e-09	1.62e-06	0.6	0.47	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
PCPG	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	6.52	1.02e-09	1.63e-06	0.57	0.47	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
PCPG	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-6.52	1.03e-09	1.64e-06	-0.58	-0.47	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
PCPG	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-6.52	1.03e-09	1.64e-06	-0.5	-0.47	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
PCPG	cis	rs7267979	0.789	rs1983974	ENSG00000125804.12	FAM182A	6.52	1.03e-09	1.64e-06	0.56	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26054655~26086917:+
PCPG	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-6.52	1.03e-09	1.64e-06	-0.61	-0.47	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
PCPG	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	6.51	1.04e-09	1.65e-06	0.63	0.47	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
PCPG	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	6.51	1.04e-09	1.65e-06	0.72	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	6.51	1.04e-09	1.65e-06	0.72	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
PCPG	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-6.51	1.04e-09	1.65e-06	-0.49	-0.47	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-6.51	1.04e-09	1.65e-06	-0.49	-0.47	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-6.51	1.04e-09	1.65e-06	-0.49	-0.47	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
PCPG	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	6.51	1.04e-09	1.65e-06	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
PCPG	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	6.51	1.05e-09	1.65e-06	0.51	0.47	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	6.51	1.05e-09	1.65e-06	0.51	0.47	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
PCPG	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	6.51	1.05e-09	1.66e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	6.51	1.05e-09	1.66e-06	0.68	0.47	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
PCPG	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	6.51	1.05e-09	1.66e-06	0.63	0.47	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
PCPG	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	6.51	1.05e-09	1.66e-06	0.66	0.47	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
PCPG	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	6.51	1.05e-09	1.66e-06	0.52	0.47	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
PCPG	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	6.51	1.05e-09	1.66e-06	0.69	0.47	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	6.51	1.06e-09	1.67e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
PCPG	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	6.51	1.06e-09	1.67e-06	0.81	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
PCPG	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	6.51	1.06e-09	1.67e-06	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
PCPG	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-6.51	1.06e-09	1.67e-06	-0.59	-0.47	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
PCPG	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	6.51	1.06e-09	1.68e-06	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	6.51	1.06e-09	1.68e-06	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
PCPG	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-6.51	1.07e-09	1.69e-06	-0.62	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
PCPG	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	6.51	1.07e-09	1.69e-06	0.47	0.47	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
PCPG	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-6.51	1.07e-09	1.69e-06	-0.61	-0.47	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
PCPG	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	6.51	1.07e-09	1.69e-06	0.62	0.47	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
PCPG	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-6.51	1.07e-09	1.7e-06	-0.58	-0.47	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
PCPG	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	6.51	1.07e-09	1.7e-06	0.67	0.47	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
PCPG	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-6.51	1.07e-09	1.7e-06	-0.55	-0.47	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
PCPG	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-6.51	1.08e-09	1.7e-06	-0.48	-0.47	Height;	chr3:52994045	chr3:53064283~53065091:-
PCPG	cis	rs9532669	0.889	rs9549302	ENSG00000176268.5	CYCSP34	6.51	1.08e-09	1.7e-06	0.54	0.47	Cervical cancer;	chr13:40843278	chr13:40863599~40863902:-
PCPG	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	6.51	1.08e-09	1.7e-06	0.37	0.47	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-6.51	1.08e-09	1.7e-06	-0.37	-0.47	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-6.51	1.08e-09	1.7e-06	-0.37	-0.47	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
PCPG	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	6.51	1.08e-09	1.71e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	6.51	1.08e-09	1.71e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	6.51	1.08e-09	1.71e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	6.51	1.08e-09	1.71e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	6.51	1.08e-09	1.71e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	6.51	1.08e-09	1.71e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	6.51	1.08e-09	1.71e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
PCPG	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-6.51	1.09e-09	1.71e-06	-0.6	-0.47	Height;	chr14:75119585	chr14:75011269~75012851:-
PCPG	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	6.5	1.1e-09	1.73e-06	0.7	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
PCPG	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-6.5	1.1e-09	1.73e-06	-0.6	-0.47	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
PCPG	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	6.5	1.1e-09	1.73e-06	0.86	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
PCPG	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-6.5	1.1e-09	1.73e-06	-0.46	-0.47	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
PCPG	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-6.5	1.1e-09	1.74e-06	-0.45	-0.47	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
PCPG	cis	rs9481169	0.557	rs2179070	ENSG00000255389.1	C6orf3	-6.5	1.1e-09	1.74e-06	-0.99	-0.47	Inflammatory skin disease;	chr6:111564549	chr6:111599875~111602295:+
PCPG	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-6.5	1.12e-09	1.75e-06	-0.44	-0.47	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	6.5	1.12e-09	1.75e-06	0.44	0.47	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
PCPG	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-6.5	1.12e-09	1.75e-06	-0.49	-0.47	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
PCPG	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	6.5	1.12e-09	1.76e-06	0.64	0.47	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
PCPG	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-6.5	1.12e-09	1.76e-06	-0.52	-0.47	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
PCPG	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	6.5	1.13e-09	1.77e-06	0.37	0.47	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
PCPG	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-6.5	1.13e-09	1.77e-06	-0.5	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-6.5	1.13e-09	1.78e-06	-0.5	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
PCPG	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	6.5	1.14e-09	1.78e-06	0.59	0.47	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	6.5	1.14e-09	1.78e-06	0.59	0.47	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
PCPG	cis	rs7267979	0.932	rs6115215	ENSG00000125804.12	FAM182A	-6.5	1.14e-09	1.78e-06	-0.56	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.866	rs6138609	ENSG00000125804.12	FAM182A	-6.5	1.14e-09	1.78e-06	-0.56	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:26054655~26086917:+
PCPG	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-6.5	1.15e-09	1.79e-06	-0.5	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
PCPG	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	6.49	1.15e-09	1.8e-06	0.59	0.47	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	6.49	1.15e-09	1.8e-06	0.59	0.47	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	6.49	1.15e-09	1.8e-06	0.59	0.47	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-6.49	1.15e-09	1.8e-06	-0.59	-0.47	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	6.49	1.15e-09	1.8e-06	0.59	0.47	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	6.49	1.15e-09	1.8e-06	0.59	0.47	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	6.49	1.15e-09	1.8e-06	0.59	0.47	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	6.49	1.15e-09	1.8e-06	0.59	0.47	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
PCPG	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	6.49	1.15e-09	1.8e-06	0.63	0.47	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	6.49	1.15e-09	1.8e-06	0.63	0.47	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
PCPG	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	6.49	1.16e-09	1.81e-06	0.58	0.47	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
PCPG	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-6.49	1.16e-09	1.81e-06	-0.65	-0.47	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
PCPG	cis	rs950169	0.922	rs12906983	ENSG00000259295.5	CSPG4P12	6.49	1.17e-09	1.82e-06	0.73	0.47	Schizophrenia;	chr15:84262270	chr15:85191438~85213905:+
PCPG	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	6.49	1.17e-09	1.83e-06	0.47	0.47	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
PCPG	cis	rs7267979	0.932	rs6132848	ENSG00000125804.12	FAM182A	-6.49	1.19e-09	1.84e-06	-0.56	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:26054655~26086917:+
PCPG	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	6.49	1.19e-09	1.85e-06	0.6	0.47	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
PCPG	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-6.49	1.2e-09	1.86e-06	-0.69	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
PCPG	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-6.49	1.2e-09	1.86e-06	-0.69	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
PCPG	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-6.49	1.2e-09	1.86e-06	-0.69	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
PCPG	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-6.49	1.2e-09	1.86e-06	-0.69	-0.47	Depression;	chr6:28103220	chr6:28115628~28116551:+
PCPG	cis	rs910316	0.699	rs175039	ENSG00000279594.1	RP11-950C14.10	-6.49	1.21e-09	1.87e-06	-0.62	-0.47	Height;	chr14:75002247	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.763	rs175042	ENSG00000279594.1	RP11-950C14.10	-6.49	1.21e-09	1.87e-06	-0.62	-0.47	Height;	chr14:75004130	chr14:75011269~75012851:-
PCPG	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	6.48	1.21e-09	1.88e-06	0.68	0.47	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
PCPG	cis	rs7824557	0.736	rs35392635	ENSG00000255020.1	AF131216.5	6.48	1.21e-09	1.88e-06	0.62	0.47	Retinal vascular caliber;	chr8:11306840	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.767	rs11775635	ENSG00000255020.1	AF131216.5	6.48	1.21e-09	1.88e-06	0.62	0.47	Retinal vascular caliber;	chr8:11307356	chr8:11345748~11347502:-
PCPG	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-6.48	1.22e-09	1.88e-06	-0.47	-0.47	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
PCPG	cis	rs7267979	0.966	rs910996	ENSG00000125804.12	FAM182A	-6.48	1.22e-09	1.88e-06	-0.54	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:26054655~26086917:+
PCPG	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	6.48	1.22e-09	1.89e-06	0.63	0.47	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
PCPG	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-6.48	1.22e-09	1.89e-06	-0.53	-0.47	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
PCPG	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	6.48	1.23e-09	1.9e-06	0.71	0.47	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
PCPG	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	6.48	1.23e-09	1.91e-06	0.5	0.47	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	6.48	1.23e-09	1.91e-06	0.5	0.47	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
PCPG	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-6.48	1.24e-09	1.92e-06	-0.49	-0.47	Height;	chr3:53084188	chr3:53064283~53065091:-
PCPG	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	6.48	1.24e-09	1.92e-06	0.45	0.47	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
PCPG	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-6.48	1.25e-09	1.93e-06	-0.64	-0.47	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
PCPG	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	6.48	1.25e-09	1.93e-06	0.57	0.47	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
PCPG	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	6.48	1.25e-09	1.93e-06	0.44	0.47	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
PCPG	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-6.48	1.25e-09	1.93e-06	-0.97	-0.47	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
PCPG	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	6.48	1.25e-09	1.93e-06	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
PCPG	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	6.48	1.25e-09	1.94e-06	0.67	0.47	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
PCPG	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-6.48	1.26e-09	1.94e-06	-0.44	-0.47	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-6.48	1.26e-09	1.94e-06	-0.44	-0.47	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-6.48	1.26e-09	1.94e-06	-0.44	-0.47	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-6.48	1.26e-09	1.94e-06	-0.44	-0.47	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
PCPG	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	6.48	1.26e-09	1.94e-06	0.61	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
PCPG	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-6.48	1.26e-09	1.94e-06	-0.6	-0.47	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
PCPG	cis	rs7824557	0.767	rs10104728	ENSG00000255020.1	AF131216.5	6.48	1.26e-09	1.95e-06	0.62	0.47	Retinal vascular caliber;	chr8:11313791	chr8:11345748~11347502:-
PCPG	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-6.48	1.26e-09	1.95e-06	-0.58	-0.47	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
PCPG	cis	rs7201929	0.801	rs9933198	ENSG00000251417.2	RP11-1348G14.4	6.48	1.27e-09	1.95e-06	0.56	0.47	QT interval;	chr16:28877088	chr16:28802743~28817828:+
PCPG	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-6.48	1.27e-09	1.96e-06	-0.6	-0.47	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
PCPG	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	6.48	1.27e-09	1.96e-06	0.79	0.47	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
PCPG	cis	rs910316	0.737	rs175043	ENSG00000279594.1	RP11-950C14.10	-6.48	1.27e-09	1.96e-06	-0.62	-0.47	Height;	chr14:75005100	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.763	rs175044	ENSG00000279594.1	RP11-950C14.10	-6.48	1.27e-09	1.96e-06	-0.62	-0.47	Height;	chr14:75005406	chr14:75011269~75012851:-
PCPG	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-6.48	1.27e-09	1.96e-06	-0.51	-0.47	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
PCPG	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-6.48	1.28e-09	1.96e-06	-0.56	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-6.48	1.28e-09	1.96e-06	-0.56	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
PCPG	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	6.47	1.28e-09	1.97e-06	0.45	0.47	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
PCPG	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-6.47	1.28e-09	1.98e-06	-0.63	-0.47	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-6.47	1.28e-09	1.98e-06	-0.59	-0.47	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-6.47	1.28e-09	1.98e-06	-0.7	-0.47	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
PCPG	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
PCPG	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	6.47	1.29e-09	1.98e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
PCPG	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	6.47	1.29e-09	1.98e-06	0.55	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
PCPG	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	6.47	1.29e-09	1.98e-06	0.36	0.47	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
PCPG	cis	rs7267979	1	rs2424713	ENSG00000125804.12	FAM182A	-6.47	1.3e-09	2e-06	-0.56	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:26054655~26086917:+
PCPG	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	6.47	1.3e-09	2e-06	0.51	0.47	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
PCPG	cis	rs7267979	0.789	rs6050472	ENSG00000125804.12	FAM182A	-6.47	1.3e-09	2e-06	-0.54	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:26054655~26086917:+
PCPG	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-6.47	1.31e-09	2.01e-06	-0.97	-0.47	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
PCPG	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-6.47	1.31e-09	2.01e-06	-0.58	-0.47	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
PCPG	cis	rs910316	0.967	rs175479	ENSG00000279594.1	RP11-950C14.10	-6.47	1.32e-09	2.02e-06	-0.6	-0.47	Height;	chr14:75095168	chr14:75011269~75012851:-
PCPG	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	6.47	1.32e-09	2.03e-06	0.62	0.47	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
PCPG	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	6.47	1.32e-09	2.03e-06	0.62	0.47	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
PCPG	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-6.47	1.33e-09	2.03e-06	-0.55	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
PCPG	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	6.47	1.33e-09	2.04e-06	0.8	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
PCPG	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-6.47	1.34e-09	2.05e-06	-0.36	-0.47	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-6.47	1.34e-09	2.05e-06	-0.36	-0.47	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-6.47	1.34e-09	2.05e-06	-0.36	-0.47	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
PCPG	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	6.47	1.34e-09	2.05e-06	0.57	0.47	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
PCPG	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	6.46	1.36e-09	2.07e-06	0.4	0.47	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
PCPG	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	6.46	1.36e-09	2.08e-06	0.54	0.47	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
PCPG	cis	rs7267979	0.966	rs2387885	ENSG00000125804.12	FAM182A	6.46	1.36e-09	2.08e-06	0.56	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:26054655~26086917:+
PCPG	cis	rs910316	0.763	rs175014	ENSG00000279594.1	RP11-950C14.10	-6.46	1.37e-09	2.09e-06	-0.62	-0.47	Height;	chr14:74990224	chr14:75011269~75012851:-
PCPG	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	6.46	1.37e-09	2.09e-06	0.49	0.47	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
PCPG	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	6.46	1.37e-09	2.1e-06	0.56	0.47	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
PCPG	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	6.46	1.38e-09	2.11e-06	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
PCPG	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-6.46	1.38e-09	2.11e-06	-0.47	-0.47	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
PCPG	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-6.46	1.38e-09	2.11e-06	-0.54	-0.47	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
PCPG	cis	rs950169	0.922	rs11635505	ENSG00000259295.5	CSPG4P12	-6.46	1.38e-09	2.11e-06	-0.68	-0.47	Schizophrenia;	chr15:84553803	chr15:85191438~85213905:+
PCPG	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	6.46	1.39e-09	2.12e-06	0.48	0.47	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
PCPG	cis	rs7267979	1	rs4815420	ENSG00000125804.12	FAM182A	6.46	1.39e-09	2.13e-06	0.54	0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:26054655~26086917:+
PCPG	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	6.46	1.4e-09	2.13e-06	0.65	0.47	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
PCPG	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	6.46	1.4e-09	2.13e-06	0.59	0.47	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	6.46	1.4e-09	2.13e-06	0.59	0.47	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
PCPG	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-6.46	1.4e-09	2.14e-06	-0.54	-0.47	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
PCPG	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	6.46	1.4e-09	2.14e-06	0.59	0.47	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
PCPG	cis	rs916888	0.821	rs199499	ENSG00000232300.1	FAM215B	6.46	1.4e-09	2.14e-06	0.75	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46558830~46562795:-
PCPG	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-6.46	1.41e-09	2.15e-06	-0.71	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
PCPG	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-6.46	1.41e-09	2.15e-06	-0.71	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
PCPG	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	6.46	1.41e-09	2.15e-06	0.57	0.47	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
PCPG	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	6.45	1.42e-09	2.17e-06	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
PCPG	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	6.45	1.42e-09	2.17e-06	0.8	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
PCPG	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	6.45	1.43e-09	2.18e-06	0.62	0.47	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
PCPG	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-6.45	1.43e-09	2.19e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-6.45	1.43e-09	2.19e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-6.45	1.43e-09	2.19e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-6.45	1.43e-09	2.19e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
PCPG	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	6.45	1.44e-09	2.19e-06	0.46	0.47	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
PCPG	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-6.45	1.44e-09	2.19e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
PCPG	cis	rs11148252	0.669	rs4884320	ENSG00000235660.1	LINC00345	-6.45	1.44e-09	2.19e-06	-0.61	-0.47	Lewy body disease;	chr13:52432779	chr13:52484161~52484680:-
PCPG	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	6.45	1.45e-09	2.21e-06	0.46	0.47	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
PCPG	cis	rs910316	0.967	rs11159121	ENSG00000279594.1	RP11-950C14.10	-6.45	1.46e-09	2.22e-06	-0.58	-0.47	Height;	chr14:75199326	chr14:75011269~75012851:-
PCPG	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-6.45	1.46e-09	2.22e-06	-0.54	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
PCPG	cis	rs7824557	0.767	rs2060463	ENSG00000255020.1	AF131216.5	6.45	1.46e-09	2.22e-06	0.62	0.47	Retinal vascular caliber;	chr8:11304101	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.767	rs2164272	ENSG00000255020.1	AF131216.5	6.45	1.46e-09	2.22e-06	0.62	0.47	Retinal vascular caliber;	chr8:11304987	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.701	rs2060465	ENSG00000255020.1	AF131216.5	6.45	1.46e-09	2.22e-06	0.62	0.47	Retinal vascular caliber;	chr8:11305100	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.767	rs3808509	ENSG00000255020.1	AF131216.5	6.45	1.46e-09	2.22e-06	0.62	0.47	Retinal vascular caliber;	chr8:11305747	chr8:11345748~11347502:-
PCPG	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-6.45	1.46e-09	2.22e-06	-0.49	-0.47	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
PCPG	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	6.45	1.46e-09	2.23e-06	0.49	0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
PCPG	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-6.45	1.46e-09	2.23e-06	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-6.45	1.46e-09	2.23e-06	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-6.45	1.46e-09	2.23e-06	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
PCPG	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	6.45	1.47e-09	2.23e-06	0.67	0.47	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	6.45	1.47e-09	2.23e-06	0.67	0.47	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
PCPG	cis	rs7267979	0.899	rs6115213	ENSG00000125804.12	FAM182A	-6.45	1.47e-09	2.24e-06	-0.56	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:26054655~26086917:+
PCPG	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	6.45	1.47e-09	2.24e-06	0.57	0.47	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
PCPG	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-6.45	1.47e-09	2.24e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-6.45	1.47e-09	2.24e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-6.45	1.47e-09	2.24e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-6.45	1.47e-09	2.24e-06	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
PCPG	cis	rs9595908	0.655	rs2213377	ENSG00000212293.1	SNORA16	6.45	1.48e-09	2.24e-06	0.58	0.47	Body mass index;	chr13:32743076	chr13:32420390~32420516:-
PCPG	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	6.45	1.48e-09	2.25e-06	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
PCPG	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-6.45	1.48e-09	2.25e-06	-0.65	-0.47	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
PCPG	cis	rs1075232	1	rs66581165	ENSG00000270055.1	CTD-3092A11.2	-6.44	1.5e-09	2.27e-06	-1.07	-0.47	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30487963~30490313:+
PCPG	cis	rs950169	0.84	rs62019457	ENSG00000259295.5	CSPG4P12	6.44	1.52e-09	2.3e-06	0.68	0.47	Schizophrenia;	chr15:84558911	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	6.44	1.52e-09	2.3e-06	0.68	0.47	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
PCPG	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-6.44	1.53e-09	2.31e-06	-0.49	-0.47	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
PCPG	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	6.44	1.55e-09	2.34e-06	0.81	0.47	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
PCPG	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-6.44	1.55e-09	2.34e-06	-0.51	-0.47	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
PCPG	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	6.44	1.55e-09	2.35e-06	0.49	0.47	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	6.44	1.55e-09	2.35e-06	0.49	0.47	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	6.44	1.55e-09	2.35e-06	0.49	0.47	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	6.44	1.55e-09	2.35e-06	0.49	0.47	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
PCPG	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	6.44	1.57e-09	2.37e-06	0.47	0.47	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
PCPG	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-6.43	1.57e-09	2.37e-06	-0.54	-0.47	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
PCPG	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-6.43	1.58e-09	2.38e-06	-0.61	-0.47	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
PCPG	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-6.43	1.59e-09	2.4e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-6.43	1.59e-09	2.4e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
PCPG	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-6.43	1.59e-09	2.4e-06	-0.45	-0.46	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-6.43	1.59e-09	2.4e-06	-0.45	-0.46	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
PCPG	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	6.43	1.59e-09	2.4e-06	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
PCPG	cis	rs7201929	1	rs7499878	ENSG00000251417.2	RP11-1348G14.4	6.43	1.6e-09	2.41e-06	0.57	0.46	QT interval;	chr16:28857143	chr16:28802743~28817828:+
PCPG	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-6.43	1.62e-09	2.43e-06	-0.43	-0.46	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
PCPG	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-6.43	1.62e-09	2.44e-06	-0.56	-0.46	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
PCPG	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	6.43	1.62e-09	2.44e-06	0.64	0.46	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
PCPG	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-6.43	1.62e-09	2.44e-06	-0.62	-0.46	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
PCPG	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	6.43	1.64e-09	2.46e-06	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
PCPG	cis	rs910316	1	rs13099	ENSG00000279594.1	RP11-950C14.10	-6.43	1.64e-09	2.47e-06	-0.6	-0.46	Height;	chr14:75132452	chr14:75011269~75012851:-
PCPG	cis	rs7267979	0.565	rs6107059	ENSG00000125804.12	FAM182A	6.43	1.65e-09	2.48e-06	0.56	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26054655~26086917:+
PCPG	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	6.42	1.66e-09	2.49e-06	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
PCPG	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	6.42	1.66e-09	2.49e-06	0.59	0.46	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	6.42	1.66e-09	2.49e-06	0.59	0.46	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	6.42	1.66e-09	2.49e-06	0.59	0.46	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	6.42	1.66e-09	2.49e-06	0.59	0.46	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
PCPG	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	6.42	1.66e-09	2.49e-06	0.64	0.46	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-6.42	1.66e-09	2.49e-06	-0.64	-0.46	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
PCPG	cis	rs7824557	0.767	rs28507159	ENSG00000255020.1	AF131216.5	6.42	1.66e-09	2.49e-06	0.61	0.46	Retinal vascular caliber;	chr8:11308567	chr8:11345748~11347502:-
PCPG	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-6.42	1.67e-09	2.5e-06	-0.47	-0.46	Height;	chr3:52994990	chr3:53064283~53065091:-
PCPG	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-6.42	1.67e-09	2.5e-06	-0.55	-0.46	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
PCPG	cis	rs950169	0.922	rs12910334	ENSG00000259295.5	CSPG4P12	6.42	1.67e-09	2.5e-06	0.72	0.46	Schizophrenia;	chr15:84403620	chr15:85191438~85213905:+
PCPG	cis	rs7267979	1	rs1077889	ENSG00000125804.12	FAM182A	-6.42	1.67e-09	2.5e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:26054655~26086917:+
PCPG	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	6.42	1.68e-09	2.51e-06	0.62	0.46	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
PCPG	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-6.42	1.69e-09	2.52e-06	-0.55	-0.46	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
PCPG	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-6.42	1.69e-09	2.52e-06	-0.59	-0.46	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
PCPG	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	6.42	1.69e-09	2.53e-06	0.54	0.46	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
PCPG	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-6.42	1.69e-09	2.53e-06	-0.5	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
PCPG	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-6.42	1.69e-09	2.53e-06	-0.44	-0.46	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
PCPG	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	6.42	1.72e-09	2.56e-06	0.64	0.46	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	6.42	1.72e-09	2.56e-06	0.64	0.46	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
PCPG	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-6.42	1.72e-09	2.56e-06	-0.58	-0.46	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
PCPG	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-6.42	1.72e-09	2.57e-06	-0.6	-0.46	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
PCPG	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	6.42	1.72e-09	2.57e-06	0.65	0.46	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	6.42	1.72e-09	2.57e-06	0.65	0.46	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	6.42	1.72e-09	2.57e-06	0.65	0.46	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
PCPG	cis	rs910316	0.763	rs175490	ENSG00000279594.1	RP11-950C14.10	6.42	1.73e-09	2.58e-06	0.61	0.46	Height;	chr14:75078982	chr14:75011269~75012851:-
PCPG	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-6.41	1.74e-09	2.59e-06	-0.55	-0.46	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
PCPG	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-6.41	1.74e-09	2.59e-06	-0.53	-0.46	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
PCPG	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-6.41	1.74e-09	2.6e-06	-0.68	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
PCPG	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	6.41	1.74e-09	2.6e-06	0.44	0.46	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
PCPG	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-6.41	1.75e-09	2.6e-06	-0.58	-0.46	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
PCPG	cis	rs7267979	0.528	rs34485039	ENSG00000125804.12	FAM182A	6.41	1.75e-09	2.61e-06	0.56	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26054655~26086917:+
PCPG	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.41	1.75e-09	2.61e-06	-0.66	-0.46	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	6.41	1.76e-09	2.61e-06	0.66	0.46	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
PCPG	cis	rs9481169	0.717	rs13191781	ENSG00000255389.1	C6orf3	-6.41	1.76e-09	2.62e-06	-0.84	-0.46	Inflammatory skin disease;	chr6:111620083	chr6:111599875~111602295:+
PCPG	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-6.41	1.76e-09	2.62e-06	-0.68	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
PCPG	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-6.41	1.76e-09	2.62e-06	-0.68	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
PCPG	cis	rs7824557	0.767	rs1897951	ENSG00000255020.1	AF131216.5	6.41	1.76e-09	2.62e-06	0.61	0.46	Retinal vascular caliber;	chr8:11312345	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.767	rs11250127	ENSG00000255020.1	AF131216.5	6.41	1.76e-09	2.62e-06	0.61	0.46	Retinal vascular caliber;	chr8:11312700	chr8:11345748~11347502:-
PCPG	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-6.41	1.76e-09	2.62e-06	-0.6	-0.46	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
PCPG	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-6.41	1.76e-09	2.63e-06	-0.62	-0.46	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
PCPG	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-6.41	1.77e-09	2.63e-06	-0.5	-0.46	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-6.41	1.77e-09	2.63e-06	-0.5	-0.46	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
PCPG	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-6.41	1.77e-09	2.63e-06	-0.55	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
PCPG	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	6.41	1.77e-09	2.64e-06	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
PCPG	cis	rs7826238	0.584	rs1107826	ENSG00000253893.2	FAM85B	-6.41	1.77e-09	2.64e-06	-0.53	-0.46	Systolic blood pressure;	chr8:8453594	chr8:8167819~8226614:-
PCPG	cis	rs910316	0.967	rs175502	ENSG00000279594.1	RP11-950C14.10	-6.41	1.79e-09	2.65e-06	-0.6	-0.46	Height;	chr14:75066976	chr14:75011269~75012851:-
PCPG	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-6.41	1.79e-09	2.66e-06	-0.58	-0.46	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
PCPG	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	6.41	1.81e-09	2.69e-06	0.39	0.46	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
PCPG	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	6.41	1.82e-09	2.69e-06	0.5	0.46	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	6.41	1.82e-09	2.69e-06	0.5	0.46	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
PCPG	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	6.41	1.82e-09	2.7e-06	0.5	0.46	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
PCPG	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-6.41	1.82e-09	2.71e-06	-0.43	-0.46	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
PCPG	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	6.41	1.83e-09	2.71e-06	0.53	0.46	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
PCPG	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	6.41	1.83e-09	2.71e-06	0.53	0.46	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
PCPG	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	6.41	1.83e-09	2.71e-06	0.68	0.46	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
PCPG	cis	rs465969	0.744	rs34659678	ENSG00000255389.1	C6orf3	-6.4	1.83e-09	2.72e-06	-0.98	-0.46	Psoriasis;	chr6:111567337	chr6:111599875~111602295:+
PCPG	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-6.4	1.84e-09	2.72e-06	-0.45	-0.46	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-6.4	1.84e-09	2.72e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-6.4	1.84e-09	2.72e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-6.4	1.84e-09	2.72e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
PCPG	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-6.4	1.85e-09	2.74e-06	-0.36	-0.46	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
PCPG	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-6.4	1.86e-09	2.75e-06	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
PCPG	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	6.4	1.87e-09	2.77e-06	0.49	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	6.4	1.87e-09	2.77e-06	0.49	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
PCPG	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	6.4	1.87e-09	2.77e-06	0.63	0.46	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	6.4	1.87e-09	2.77e-06	0.63	0.46	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
PCPG	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	6.4	1.88e-09	2.78e-06	0.67	0.46	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
PCPG	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-6.4	1.88e-09	2.78e-06	-0.81	-0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
PCPG	cis	rs7267979	1	rs2482943	ENSG00000125804.12	FAM182A	6.4	1.88e-09	2.79e-06	0.56	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:26054655~26086917:+
PCPG	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	6.4	1.89e-09	2.79e-06	0.61	0.46	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
PCPG	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-6.4	1.89e-09	2.8e-06	-0.68	-0.46	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
PCPG	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-6.4	1.9e-09	2.81e-06	-0.55	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
PCPG	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-6.4	1.9e-09	2.81e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-6.4	1.9e-09	2.81e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-6.4	1.9e-09	2.81e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-6.4	1.9e-09	2.81e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-6.4	1.9e-09	2.81e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-6.4	1.9e-09	2.81e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-6.4	1.9e-09	2.81e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
PCPG	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	6.4	1.9e-09	2.81e-06	0.48	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
PCPG	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	6.4	1.92e-09	2.84e-06	0.46	0.46	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
PCPG	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.39	1.93e-09	2.85e-06	-0.59	-0.46	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
PCPG	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	6.39	1.93e-09	2.85e-06	0.63	0.46	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
PCPG	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-6.39	1.94e-09	2.86e-06	-0.65	-0.46	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
PCPG	cis	rs910316	1	rs175443	ENSG00000279594.1	RP11-950C14.10	-6.39	1.94e-09	2.87e-06	-0.59	-0.46	Height;	chr14:75135260	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-6.39	1.94e-09	2.87e-06	-0.59	-0.46	Height;	chr14:75141980	chr14:75011269~75012851:-
PCPG	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-6.39	1.95e-09	2.87e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
PCPG	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	6.39	1.96e-09	2.88e-06	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
PCPG	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-6.39	1.96e-09	2.89e-06	-0.46	-0.46	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
PCPG	cis	rs910316	0.737	rs175072	ENSG00000279594.1	RP11-950C14.10	-6.39	1.96e-09	2.89e-06	-0.61	-0.46	Height;	chr14:75036124	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.712	rs175074	ENSG00000279594.1	RP11-950C14.10	-6.39	1.96e-09	2.89e-06	-0.61	-0.46	Height;	chr14:75037751	chr14:75011269~75012851:-
PCPG	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	6.39	1.97e-09	2.9e-06	0.48	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
PCPG	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-6.39	1.97e-09	2.9e-06	-0.53	-0.46	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-6.39	1.97e-09	2.9e-06	-0.53	-0.46	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
PCPG	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.84	rs12905223	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84571037	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	6.39	1.98e-09	2.91e-06	0.7	0.46	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
PCPG	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-6.39	1.98e-09	2.91e-06	-0.43	-0.46	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
PCPG	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	6.39	1.99e-09	2.92e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	6.39	1.99e-09	2.92e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	6.39	1.99e-09	2.92e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	6.39	1.99e-09	2.92e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	6.39	1.99e-09	2.92e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	6.39	1.99e-09	2.92e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
PCPG	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-6.39	2e-09	2.93e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
PCPG	cis	rs910316	1	rs175425	ENSG00000279594.1	RP11-950C14.10	-6.39	2.01e-09	2.94e-06	-0.6	-0.46	Height;	chr14:75159428	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.935	rs175422	ENSG00000279594.1	RP11-950C14.10	-6.39	2.01e-09	2.94e-06	-0.6	-0.46	Height;	chr14:75160616	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs35446981	ENSG00000279594.1	RP11-950C14.10	-6.39	2.01e-09	2.94e-06	-0.6	-0.46	Height;	chr14:75170648	chr14:75011269~75012851:-
PCPG	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-6.39	2.01e-09	2.94e-06	-0.53	-0.46	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
PCPG	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	6.39	2.01e-09	2.95e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	6.39	2.01e-09	2.95e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
PCPG	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-6.39	2.01e-09	2.95e-06	-0.54	-0.46	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
PCPG	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	6.39	2.01e-09	2.95e-06	0.81	0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
PCPG	cis	rs12220777	0.585	rs75995665	ENSG00000230091.5	TMEM254-AS1	6.39	2.02e-09	2.96e-06	0.79	0.46	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80017462	chr10:80046860~80078912:-
PCPG	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	6.39	2.02e-09	2.96e-06	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
PCPG	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	6.39	2.03e-09	2.97e-06	0.59	0.46	Height;	chr14:75068316	chr14:75011269~75012851:-
PCPG	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-6.38	2.03e-09	2.98e-06	-0.54	-0.46	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
PCPG	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	6.38	2.03e-09	2.98e-06	0.58	0.46	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
PCPG	cis	rs7267979	0.934	rs2261753	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2261790	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2261794	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2145126	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2257705	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2227892	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2257712	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2257461	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.934	rs2257464	ENSG00000125804.12	FAM182A	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:26054655~26086917:+
PCPG	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-6.38	2.04e-09	2.98e-06	-0.53	-0.46	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
PCPG	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-6.38	2.04e-09	2.98e-06	-0.54	-0.46	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-6.38	2.04e-09	2.98e-06	-0.54	-0.46	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
PCPG	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	6.38	2.05e-09	2.99e-06	0.58	0.46	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
PCPG	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-6.38	2.05e-09	3e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-6.38	2.05e-09	3e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-6.38	2.05e-09	3e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-6.38	2.05e-09	3e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
PCPG	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-6.38	2.05e-09	3e-06	-0.51	-0.46	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
PCPG	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	6.38	2.06e-09	3.01e-06	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	6.38	2.06e-09	3.01e-06	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	6.38	2.06e-09	3.01e-06	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	6.38	2.06e-09	3.01e-06	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
PCPG	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	6.38	2.06e-09	3.02e-06	0.65	0.46	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
PCPG	cis	rs7267979	0.932	rs13040655	ENSG00000125804.12	FAM182A	-6.38	2.06e-09	3.02e-06	-0.56	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:26054655~26086917:+
PCPG	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-6.38	2.07e-09	3.02e-06	-0.84	-0.46	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
PCPG	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-6.38	2.07e-09	3.02e-06	-0.5	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
PCPG	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	6.38	2.07e-09	3.02e-06	0.49	0.46	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
PCPG	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	6.38	2.07e-09	3.03e-06	0.65	0.46	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
PCPG	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-6.38	2.07e-09	3.03e-06	-0.55	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
PCPG	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-6.38	2.07e-09	3.03e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-6.38	2.07e-09	3.03e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-6.38	2.07e-09	3.03e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-6.38	2.07e-09	3.03e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-6.38	2.07e-09	3.03e-06	-0.49	-0.46	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
PCPG	cis	rs7267979	0.903	rs6050482	ENSG00000125804.12	FAM182A	-6.38	2.07e-09	3.03e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.706	rs6037069	ENSG00000125804.12	FAM182A	-6.38	2.07e-09	3.03e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:26054655~26086917:+
PCPG	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-6.38	2.08e-09	3.04e-06	-0.56	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
PCPG	cis	rs9595908	0.669	rs56291634	ENSG00000212293.1	SNORA16	6.38	2.08e-09	3.04e-06	0.57	0.46	Body mass index;	chr13:32720404	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs28637641	ENSG00000212293.1	SNORA16	6.38	2.08e-09	3.04e-06	0.57	0.46	Body mass index;	chr13:32726997	chr13:32420390~32420516:-
PCPG	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-6.38	2.09e-09	3.06e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
PCPG	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	6.38	2.1e-09	3.07e-06	0.58	0.46	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	6.38	2.11e-09	3.07e-06	0.56	0.46	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
PCPG	cis	rs7824557	0.767	rs7003241	ENSG00000255020.1	AF131216.5	6.38	2.11e-09	3.07e-06	0.61	0.46	Retinal vascular caliber;	chr8:11311566	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.767	rs1897950	ENSG00000255020.1	AF131216.5	6.38	2.11e-09	3.07e-06	0.61	0.46	Retinal vascular caliber;	chr8:11312042	chr8:11345748~11347502:-
PCPG	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-6.38	2.12e-09	3.09e-06	-0.44	-0.46	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
PCPG	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	6.38	2.12e-09	3.09e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
PCPG	cis	rs910316	0.967	rs175498	ENSG00000279594.1	RP11-950C14.10	-6.38	2.13e-09	3.1e-06	-0.59	-0.46	Height;	chr14:75069666	chr14:75011269~75012851:-
PCPG	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	6.38	2.13e-09	3.1e-06	0.43	0.46	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
PCPG	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-6.38	2.14e-09	3.11e-06	-0.35	-0.46	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-6.38	2.14e-09	3.11e-06	-0.35	-0.46	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
PCPG	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	6.38	2.14e-09	3.11e-06	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
PCPG	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	6.37	2.14e-09	3.11e-06	0.62	0.46	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	6.37	2.14e-09	3.11e-06	0.62	0.46	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	6.37	2.14e-09	3.11e-06	0.62	0.46	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
PCPG	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	6.37	2.14e-09	3.12e-06	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	6.37	2.14e-09	3.12e-06	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
PCPG	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	6.37	2.14e-09	3.13e-06	0.65	0.46	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	6.37	2.14e-09	3.13e-06	0.65	0.46	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
PCPG	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	6.37	2.16e-09	3.15e-06	0.35	0.46	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
PCPG	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	6.37	2.17e-09	3.15e-06	0.57	0.46	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
PCPG	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	6.37	2.2e-09	3.19e-06	0.69	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
PCPG	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	6.37	2.2e-09	3.19e-06	0.63	0.46	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
PCPG	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	6.37	2.2e-09	3.2e-06	0.58	0.46	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
PCPG	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-6.37	2.21e-09	3.21e-06	-0.49	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
PCPG	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-6.37	2.21e-09	3.21e-06	-0.49	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
PCPG	cis	rs7267979	0.745	rs6132845	ENSG00000125804.12	FAM182A	-6.37	2.21e-09	3.21e-06	-0.56	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26054655~26086917:+
PCPG	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	6.37	2.22e-09	3.23e-06	0.58	0.46	Height;	chr14:75077276	chr14:75011269~75012851:-
PCPG	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	6.37	2.22e-09	3.23e-06	0.62	0.46	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
PCPG	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	6.37	2.23e-09	3.24e-06	0.62	0.46	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
PCPG	cis	rs465969	1	rs34530632	ENSG00000255389.1	C6orf3	-6.37	2.24e-09	3.25e-06	-0.96	-0.46	Psoriasis;	chr6:111455132	chr6:111599875~111602295:+
PCPG	cis	rs7824557	0.767	rs17797443	ENSG00000255020.1	AF131216.5	6.37	2.24e-09	3.25e-06	0.61	0.46	Retinal vascular caliber;	chr8:11306503	chr8:11345748~11347502:-
PCPG	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-6.37	2.24e-09	3.25e-06	-0.58	-0.46	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
PCPG	cis	rs7267979	0.932	rs6115200	ENSG00000125804.12	FAM182A	-6.37	2.25e-09	3.26e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs6138588	ENSG00000125804.12	FAM182A	-6.37	2.25e-09	3.26e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:26054655~26086917:+
PCPG	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	6.36	2.26e-09	3.27e-06	0.57	0.46	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
PCPG	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-6.36	2.27e-09	3.28e-06	-0.44	-0.46	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-6.36	2.27e-09	3.28e-06	-0.44	-0.46	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
PCPG	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	6.36	2.27e-09	3.29e-06	0.78	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	6.36	2.27e-09	3.29e-06	0.78	0.46	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
PCPG	cis	rs7267979	0.932	rs449370	ENSG00000125804.12	FAM182A	6.36	2.28e-09	3.3e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:26054655~26086917:+
PCPG	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-6.36	2.28e-09	3.3e-06	-0.66	-0.46	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	6.36	2.28e-09	3.3e-06	0.66	0.46	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	6.36	2.28e-09	3.3e-06	0.66	0.46	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	6.36	2.28e-09	3.31e-06	0.62	0.46	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	6.36	2.28e-09	3.31e-06	0.62	0.46	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
PCPG	cis	rs7267979	1	rs3002702	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2257982	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2257985	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2257988	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2257432	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258066	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258135	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258201	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258563	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2424704	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258617	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.933	rs2258728	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258769	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258879	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2257496	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2258884	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2259837	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2259873	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs11100	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs1046073	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2259926	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2259928	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2259956	ENSG00000125804.12	FAM182A	-6.36	2.29e-09	3.32e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2297496	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs7343481	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6115146	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.934	rs6037085	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs6050532	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6083804	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815405	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050542	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6076336	ENSG00000125804.12	FAM182A	6.36	2.29e-09	3.32e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:26054655~26086917:+
PCPG	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-6.36	2.29e-09	3.32e-06	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
PCPG	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	6.36	2.3e-09	3.32e-06	0.56	0.46	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
PCPG	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-6.36	2.31e-09	3.34e-06	-0.67	-0.46	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
PCPG	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	6.36	2.32e-09	3.35e-06	0.44	0.46	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
PCPG	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	6.36	2.32e-09	3.35e-06	0.61	0.46	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-6.36	2.32e-09	3.35e-06	-0.61	-0.46	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-6.36	2.32e-09	3.35e-06	-0.61	-0.46	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
PCPG	cis	rs7267979	0.966	rs2257233	ENSG00000125804.12	FAM182A	6.36	2.32e-09	3.35e-06	0.53	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:26054655~26086917:+
PCPG	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	6.36	2.32e-09	3.36e-06	0.6	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
PCPG	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	6.36	2.32e-09	3.36e-06	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	6.36	2.32e-09	3.36e-06	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
PCPG	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	6.36	2.33e-09	3.36e-06	0.44	0.46	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	6.36	2.33e-09	3.36e-06	0.44	0.46	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	6.36	2.33e-09	3.36e-06	0.44	0.46	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	6.36	2.33e-09	3.36e-06	0.44	0.46	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	6.36	2.33e-09	3.36e-06	0.44	0.46	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	6.36	2.33e-09	3.36e-06	0.44	0.46	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
PCPG	cis	rs853679	0.76	rs9468317	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28230678	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs2299029	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28231053	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs11967137	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28231986	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs11962305	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28232159	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.723	rs9366718	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28237724	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs9393910	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28240414	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs9368563	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28240780	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs9295768	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28241324	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.699	rs9468318	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28241753	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs9357067	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28242515	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.76	rs967005	ENSG00000216901.1	AL022393.7	6.36	2.33e-09	3.36e-06	0.73	0.46	Depression;	chr6:28242910	chr6:28176188~28176674:+
PCPG	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	6.36	2.33e-09	3.37e-06	0.57	0.46	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
PCPG	cis	rs7267979	1	rs2257420	ENSG00000125804.12	FAM182A	-6.36	2.33e-09	3.37e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2257808	ENSG00000125804.12	FAM182A	-6.36	2.34e-09	3.37e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2257809	ENSG00000125804.12	FAM182A	-6.36	2.34e-09	3.37e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs910997	ENSG00000125804.12	FAM182A	-6.36	2.34e-09	3.37e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:26054655~26086917:+
PCPG	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-6.36	2.34e-09	3.38e-06	-0.57	-0.46	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
PCPG	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-6.36	2.34e-09	3.38e-06	-0.55	-0.46	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
PCPG	cis	rs910316	0.737	rs108621	ENSG00000279594.1	RP11-950C14.10	-6.36	2.34e-09	3.38e-06	-0.6	-0.46	Height;	chr14:75013934	chr14:75011269~75012851:-
PCPG	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-6.36	2.35e-09	3.39e-06	-0.51	-0.46	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-6.36	2.35e-09	3.39e-06	-0.51	-0.46	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
PCPG	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	6.36	2.36e-09	3.41e-06	0.57	0.46	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
PCPG	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-6.35	2.37e-09	3.41e-06	-0.35	-0.46	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-6.35	2.37e-09	3.41e-06	-0.35	-0.46	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
PCPG	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-6.35	2.37e-09	3.42e-06	-0.57	-0.46	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
PCPG	cis	rs8072100	0.905	rs8078686	ENSG00000228782.6	CTD-2026D20.3	-6.35	2.38e-09	3.42e-06	-0.5	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47658340	chr17:47450568~47492492:-
PCPG	cis	rs7267979	1	rs2424700	ENSG00000125804.12	FAM182A	-6.35	2.38e-09	3.42e-06	-0.53	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:26054655~26086917:+
PCPG	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	6.35	2.38e-09	3.42e-06	0.58	0.46	Height;	chr14:75189542	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-6.35	2.38e-09	3.43e-06	-0.59	-0.46	Height;	chr14:75124143	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-6.35	2.38e-09	3.43e-06	-0.59	-0.46	Height;	chr14:75124368	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-6.35	2.38e-09	3.43e-06	-0.59	-0.46	Height;	chr14:75136861	chr14:75011269~75012851:-
PCPG	cis	rs910316	1	rs175426	ENSG00000279594.1	RP11-950C14.10	-6.35	2.38e-09	3.43e-06	-0.59	-0.46	Height;	chr14:75157431	chr14:75011269~75012851:-
PCPG	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	6.35	2.38e-09	3.43e-06	0.49	0.46	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-6.35	2.38e-09	3.43e-06	-0.49	-0.46	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
PCPG	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-6.35	2.38e-09	3.43e-06	-0.55	-0.46	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
PCPG	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-6.35	2.38e-09	3.43e-06	-0.68	-0.46	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
PCPG	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-6.35	2.38e-09	3.43e-06	-0.59	-0.46	Height;	chr14:75123026	chr14:75011269~75012851:-
PCPG	cis	rs9595908	0.669	rs2032508	ENSG00000212293.1	SNORA16	6.35	2.39e-09	3.45e-06	0.57	0.46	Body mass index;	chr13:32779332	chr13:32420390~32420516:-
PCPG	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-6.35	2.4e-09	3.45e-06	-0.56	-0.46	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
PCPG	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-6.35	2.4e-09	3.46e-06	-0.5	-0.46	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
PCPG	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	6.35	2.41e-09	3.47e-06	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
PCPG	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-6.35	2.42e-09	3.47e-06	-0.6	-0.46	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
PCPG	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-6.35	2.42e-09	3.49e-06	-0.46	-0.46	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
PCPG	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	6.35	2.43e-09	3.49e-06	0.49	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	6.35	2.43e-09	3.49e-06	0.49	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
PCPG	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	6.35	2.43e-09	3.49e-06	0.61	0.46	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	6.35	2.43e-09	3.49e-06	0.61	0.46	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
PCPG	cis	rs7044106	0.7	rs1975468	ENSG00000226752.6	PSMD5-AS1	-6.35	2.43e-09	3.49e-06	-0.73	-0.46	Hip circumference adjusted for BMI;	chr9:120734000	chr9:120824828~120854385:+
PCPG	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-6.35	2.43e-09	3.5e-06	-0.43	-0.46	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
PCPG	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	6.35	2.44e-09	3.5e-06	0.49	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
PCPG	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	6.35	2.44e-09	3.51e-06	0.87	0.46	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
PCPG	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	6.35	2.44e-09	3.51e-06	0.81	0.46	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
PCPG	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	6.35	2.45e-09	3.52e-06	0.6	0.46	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
PCPG	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	6.35	2.45e-09	3.53e-06	0.79	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
PCPG	cis	rs910316	0.737	rs398896	ENSG00000279594.1	RP11-950C14.10	-6.35	2.46e-09	3.53e-06	-0.61	-0.46	Height;	chr14:75016124	chr14:75011269~75012851:-
PCPG	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	6.35	2.46e-09	3.53e-06	0.51	0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
PCPG	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	6.35	2.46e-09	3.54e-06	0.5	0.46	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
PCPG	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-6.35	2.47e-09	3.55e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-6.35	2.47e-09	3.55e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
PCPG	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-6.35	2.48e-09	3.56e-06	-0.54	-0.46	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
PCPG	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	6.34	2.49e-09	3.58e-06	0.51	0.46	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
PCPG	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-6.34	2.5e-09	3.58e-06	-0.59	-0.46	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	6.34	2.5e-09	3.58e-06	0.59	0.46	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	6.34	2.5e-09	3.58e-06	0.59	0.46	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	6.34	2.5e-09	3.58e-06	0.59	0.46	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
PCPG	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-6.34	2.51e-09	3.59e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
PCPG	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-6.34	2.52e-09	3.61e-06	-0.49	-0.46	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
PCPG	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-6.34	2.53e-09	3.62e-06	-0.54	-0.46	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-6.34	2.53e-09	3.62e-06	-0.54	-0.46	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-6.34	2.53e-09	3.62e-06	-0.54	-0.46	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-6.34	2.53e-09	3.62e-06	-0.54	-0.46	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-6.34	2.53e-09	3.62e-06	-0.54	-0.46	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-6.34	2.53e-09	3.62e-06	-0.54	-0.46	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
PCPG	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-6.34	2.53e-09	3.62e-06	-0.57	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
PCPG	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	6.34	2.53e-09	3.63e-06	0.67	0.46	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
PCPG	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-6.34	2.54e-09	3.63e-06	-0.49	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
PCPG	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	6.34	2.54e-09	3.63e-06	0.74	0.46	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
PCPG	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-6.34	2.55e-09	3.64e-06	-0.51	-0.46	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
PCPG	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-6.34	2.55e-09	3.64e-06	-0.48	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
PCPG	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	6.34	2.55e-09	3.65e-06	0.51	0.46	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
PCPG	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	6.34	2.56e-09	3.66e-06	0.63	0.46	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
PCPG	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-6.34	2.56e-09	3.66e-06	-0.93	-0.46	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
PCPG	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.34	2.57e-09	3.67e-06	-0.55	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
PCPG	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-6.34	2.58e-09	3.68e-06	-0.58	-0.46	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
PCPG	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	6.34	2.58e-09	3.68e-06	0.64	0.46	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	6.34	2.58e-09	3.68e-06	0.64	0.46	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
PCPG	cis	rs7267979	0.866	rs2424698	ENSG00000125804.12	FAM182A	-6.34	2.58e-09	3.69e-06	-0.55	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:26054655~26086917:+
PCPG	cis	rs7824557	0.767	rs6985460	ENSG00000255020.1	AF131216.5	6.34	2.58e-09	3.69e-06	0.6	0.46	Retinal vascular caliber;	chr8:11313578	chr8:11345748~11347502:-
PCPG	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	6.34	2.59e-09	3.7e-06	0.58	0.46	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
PCPG	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.7e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.7e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.7e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.7e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.7e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.7e-06	-0.52	-0.46	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
PCPG	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	6.34	2.6e-09	3.71e-06	0.43	0.46	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
PCPG	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.71e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.71e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.71e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.71e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-6.34	2.6e-09	3.71e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
PCPG	cis	rs9595908	0.669	rs9596218	ENSG00000212293.1	SNORA16	6.34	2.61e-09	3.72e-06	0.57	0.46	Body mass index;	chr13:32764222	chr13:32420390~32420516:-
PCPG	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-6.34	2.61e-09	3.72e-06	-0.53	-0.46	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
PCPG	cis	rs9326248	0.513	rs1263164	ENSG00000254851.1	RP11-109L13.1	-6.34	2.62e-09	3.73e-06	-0.59	-0.46	Blood protein levels;	chr11:116804575	chr11:117135528~117138582:+
PCPG	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-6.34	2.62e-09	3.73e-06	-0.53	-0.46	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-6.34	2.62e-09	3.73e-06	-0.53	-0.46	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-6.34	2.62e-09	3.73e-06	-0.53	-0.46	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
PCPG	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	6.33	2.64e-09	3.76e-06	0.57	0.46	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
PCPG	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	6.33	2.65e-09	3.78e-06	0.42	0.46	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
PCPG	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	6.33	2.67e-09	3.8e-06	0.49	0.46	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
PCPG	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-6.33	2.68e-09	3.82e-06	-0.5	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
PCPG	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-6.33	2.69e-09	3.83e-06	-0.53	-0.46	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
PCPG	cis	rs7727544	0.788	rs270613	ENSG00000233006.5	AC034220.3	6.33	2.69e-09	3.83e-06	0.36	0.46	Blood metabolite levels;	chr5:132304890	chr5:132311285~132369916:-
PCPG	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	6.33	2.69e-09	3.83e-06	0.55	0.46	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
PCPG	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-6.33	2.7e-09	3.84e-06	-0.51	-0.46	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
PCPG	cis	rs910316	0.967	rs175432	ENSG00000279594.1	RP11-950C14.10	-6.33	2.7e-09	3.84e-06	-0.59	-0.46	Height;	chr14:75148543	chr14:75011269~75012851:-
PCPG	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-6.33	2.7e-09	3.84e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
PCPG	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-6.33	2.71e-09	3.85e-06	-0.6	-0.46	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
PCPG	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	6.33	2.71e-09	3.85e-06	0.81	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
PCPG	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-6.33	2.72e-09	3.87e-06	-0.6	-0.46	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
PCPG	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-6.33	2.74e-09	3.89e-06	-0.58	-0.46	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
PCPG	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-6.33	2.75e-09	3.9e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-6.33	2.75e-09	3.9e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
PCPG	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	6.33	2.75e-09	3.9e-06	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	6.33	2.75e-09	3.9e-06	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
PCPG	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	6.33	2.75e-09	3.91e-06	0.55	0.46	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
PCPG	cis	rs2625529	0.652	rs2415128	ENSG00000260037.4	CTD-2524L6.3	6.33	2.75e-09	3.91e-06	0.65	0.46	Red blood cell count;	chr15:71898732	chr15:71818396~71823384:+
PCPG	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	6.33	2.75e-09	3.91e-06	0.59	0.46	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
PCPG	cis	rs7267979	0.789	rs4815429	ENSG00000125804.12	FAM182A	6.33	2.76e-09	3.91e-06	0.55	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26054655~26086917:+
PCPG	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	6.33	2.76e-09	3.91e-06	0.59	0.46	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
PCPG	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-6.32	2.76e-09	3.92e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
PCPG	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	6.32	2.79e-09	3.95e-06	0.75	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
PCPG	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	6.32	2.79e-09	3.95e-06	0.51	0.46	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
PCPG	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	6.32	2.79e-09	3.95e-06	0.54	0.46	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
PCPG	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	6.32	2.8e-09	3.97e-06	0.6	0.46	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	6.32	2.8e-09	3.97e-06	0.6	0.46	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
PCPG	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-6.32	2.81e-09	3.99e-06	-0.48	-0.46	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
PCPG	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-6.32	2.81e-09	3.99e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-6.32	2.81e-09	3.99e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-6.32	2.81e-09	3.99e-06	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
PCPG	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	6.32	2.82e-09	3.99e-06	0.48	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
PCPG	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	6.32	2.82e-09	3.99e-06	0.48	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
PCPG	cis	rs7824557	0.767	rs2164273	ENSG00000255020.1	AF131216.5	6.32	2.82e-09	3.99e-06	0.6	0.46	Retinal vascular caliber;	chr8:11310990	chr8:11345748~11347502:-
PCPG	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-6.32	2.83e-09	4e-06	-0.44	-0.46	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-6.32	2.83e-09	4e-06	-0.44	-0.46	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
PCPG	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-6.32	2.83e-09	4e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-6.32	2.83e-09	4e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-6.32	2.83e-09	4e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-6.32	2.83e-09	4e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
PCPG	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	6.32	2.83e-09	4.01e-06	0.43	0.46	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
PCPG	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-6.32	2.83e-09	4.01e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
PCPG	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	6.32	2.84e-09	4.02e-06	0.47	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
PCPG	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	6.32	2.85e-09	4.03e-06	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	6.32	2.85e-09	4.04e-06	0.59	0.46	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
PCPG	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-6.32	2.85e-09	4.04e-06	-0.53	-0.46	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
PCPG	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	6.32	2.86e-09	4.05e-06	0.53	0.46	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
PCPG	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-6.32	2.87e-09	4.05e-06	-0.62	-0.46	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
PCPG	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-6.32	2.87e-09	4.05e-06	-0.54	-0.46	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
PCPG	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-6.32	2.88e-09	4.07e-06	-0.48	-0.46	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
PCPG	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-6.32	2.88e-09	4.07e-06	-0.65	-0.46	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-6.32	2.88e-09	4.07e-06	-0.65	-0.46	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
PCPG	cis	rs71403859	0.554	rs12920245	ENSG00000260886.1	TAT-AS1	6.32	2.89e-09	4.08e-06	1.14	0.46	Post bronchodilator FEV1;	chr16:71995170	chr16:71565789~71578187:+
PCPG	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-6.32	2.89e-09	4.08e-06	-0.56	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
PCPG	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	6.32	2.9e-09	4.09e-06	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
PCPG	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-6.31	2.91e-09	4.11e-06	-0.62	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
PCPG	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	6.31	2.91e-09	4.11e-06	0.49	0.46	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
PCPG	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	6.31	2.92e-09	4.12e-06	0.64	0.46	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
PCPG	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	6.31	2.94e-09	4.14e-06	0.5	0.46	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
PCPG	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	6.31	2.95e-09	4.16e-06	0.44	0.46	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	6.31	2.95e-09	4.16e-06	0.44	0.46	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	6.31	2.95e-09	4.16e-06	0.44	0.46	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	6.31	2.95e-09	4.16e-06	0.44	0.46	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	6.31	2.95e-09	4.16e-06	0.44	0.46	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	6.31	2.95e-09	4.16e-06	0.44	0.46	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
PCPG	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-6.31	2.96e-09	4.17e-06	-0.51	-0.46	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
PCPG	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	6.31	2.96e-09	4.17e-06	0.61	0.46	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
PCPG	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-6.31	2.97e-09	4.18e-06	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
PCPG	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	6.31	2.99e-09	4.21e-06	0.51	0.46	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
PCPG	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-6.31	2.99e-09	4.21e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
PCPG	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-6.31	3e-09	4.21e-06	-0.66	-0.46	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
PCPG	cis	rs9309711	0.621	rs11127428	ENSG00000225234.1	TRAPPC12-AS1	-6.31	3.01e-09	4.23e-06	-0.43	-0.46	Neurofibrillary tangles;	chr2:3467375	chr2:3481242~3482409:-
PCPG	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	6.31	3.01e-09	4.24e-06	0.52	0.46	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
PCPG	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	6.31	3.03e-09	4.25e-06	0.61	0.46	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
PCPG	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	6.31	3.03e-09	4.25e-06	0.62	0.46	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
PCPG	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-6.31	3.05e-09	4.28e-06	-0.44	-0.46	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-6.31	3.05e-09	4.28e-06	-0.44	-0.46	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-6.31	3.05e-09	4.28e-06	-0.44	-0.46	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
PCPG	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	6.31	3.05e-09	4.28e-06	0.57	0.46	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	6.31	3.05e-09	4.28e-06	0.57	0.46	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
PCPG	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	6.31	3.05e-09	4.28e-06	0.69	0.46	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	6.31	3.05e-09	4.28e-06	0.69	0.46	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
PCPG	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-6.31	3.05e-09	4.29e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
PCPG	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	6.31	3.06e-09	4.29e-06	0.66	0.46	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
PCPG	cis	rs910316	0.737	rs175049	ENSG00000279594.1	RP11-950C14.10	-6.3	3.06e-09	4.3e-06	-0.6	-0.46	Height;	chr14:75014665	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.737	rs108622	ENSG00000279594.1	RP11-950C14.10	-6.3	3.06e-09	4.3e-06	-0.6	-0.46	Height;	chr14:75015205	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.737	rs424120	ENSG00000279594.1	RP11-950C14.10	-6.3	3.06e-09	4.3e-06	-0.6	-0.46	Height;	chr14:75016125	chr14:75011269~75012851:-
PCPG	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	6.3	3.08e-09	4.31e-06	0.98	0.46	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
PCPG	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-6.3	3.1e-09	4.34e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
PCPG	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	6.3	3.11e-09	4.35e-06	0.67	0.46	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
PCPG	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	6.3	3.11e-09	4.35e-06	0.67	0.46	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
PCPG	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	6.3	3.11e-09	4.36e-06	0.51	0.46	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
PCPG	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-6.3	3.11e-09	4.36e-06	-0.56	-0.46	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-6.3	3.11e-09	4.36e-06	-0.56	-0.46	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
PCPG	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-6.3	3.12e-09	4.37e-06	-0.77	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
PCPG	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	6.3	3.12e-09	4.37e-06	0.77	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
PCPG	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-6.3	3.12e-09	4.37e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
PCPG	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-6.3	3.13e-09	4.38e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-6.3	3.13e-09	4.38e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-6.3	3.14e-09	4.39e-06	-0.48	-0.46	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
PCPG	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	6.3	3.14e-09	4.39e-06	0.49	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
PCPG	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	6.3	3.14e-09	4.39e-06	0.49	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
PCPG	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.3	3.14e-09	4.39e-06	-0.54	-0.46	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
PCPG	cis	rs910316	0.967	rs175505	ENSG00000279594.1	RP11-950C14.10	-6.3	3.14e-09	4.39e-06	-0.59	-0.46	Height;	chr14:75062916	chr14:75011269~75012851:-
PCPG	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-6.3	3.15e-09	4.4e-06	-0.53	-0.46	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
PCPG	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	6.3	3.16e-09	4.42e-06	0.71	0.46	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
PCPG	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-6.3	3.16e-09	4.43e-06	-0.54	-0.46	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
PCPG	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	6.3	3.17e-09	4.44e-06	0.61	0.46	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
PCPG	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-6.3	3.17e-09	4.44e-06	-0.51	-0.46	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
PCPG	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	6.3	3.17e-09	4.44e-06	0.64	0.46	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
PCPG	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-6.3	3.17e-09	4.44e-06	-0.55	-0.46	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
PCPG	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	6.3	3.19e-09	4.46e-06	0.55	0.46	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
PCPG	cis	rs7267979	0.932	rs1541061	ENSG00000125804.12	FAM182A	-6.3	3.19e-09	4.46e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs6138600	ENSG00000125804.12	FAM182A	-6.3	3.19e-09	4.46e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.899	rs2104734	ENSG00000125804.12	FAM182A	-6.3	3.19e-09	4.46e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:26054655~26086917:+
PCPG	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	6.3	3.19e-09	4.47e-06	0.55	0.46	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
PCPG	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-6.3	3.21e-09	4.48e-06	-0.5	-0.46	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
PCPG	cis	rs9595908	0.669	rs9596205	ENSG00000212293.1	SNORA16	-6.29	3.22e-09	4.5e-06	-0.56	-0.46	Body mass index;	chr13:32754487	chr13:32420390~32420516:-
PCPG	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-6.29	3.23e-09	4.51e-06	-0.53	-0.46	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
PCPG	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-6.29	3.23e-09	4.51e-06	-0.58	-0.46	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
PCPG	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-6.29	3.24e-09	4.52e-06	-0.57	-0.46	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
PCPG	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	6.29	3.25e-09	4.54e-06	0.59	0.46	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
PCPG	cis	rs910316	0.967	rs119076	ENSG00000279594.1	RP11-950C14.10	-6.29	3.26e-09	4.55e-06	-0.59	-0.46	Height;	chr14:75105716	chr14:75011269~75012851:-
PCPG	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	6.29	3.26e-09	4.55e-06	0.71	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
PCPG	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-6.29	3.28e-09	4.58e-06	-0.56	-0.46	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
PCPG	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-6.29	3.3e-09	4.61e-06	-0.55	-0.46	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
PCPG	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-6.29	3.35e-09	4.66e-06	-0.6	-0.46	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
PCPG	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-6.29	3.35e-09	4.66e-06	-0.57	-0.46	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
PCPG	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-6.29	3.35e-09	4.66e-06	-0.57	-0.46	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
PCPG	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-6.29	3.37e-09	4.68e-06	-0.85	-0.46	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
PCPG	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-6.29	3.37e-09	4.68e-06	-0.55	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-6.29	3.37e-09	4.68e-06	-0.55	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
PCPG	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	6.29	3.38e-09	4.69e-06	0.58	0.46	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
PCPG	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	6.29	3.38e-09	4.69e-06	0.6	0.46	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
PCPG	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	6.28	3.39e-09	4.7e-06	0.52	0.46	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
PCPG	cis	rs853679	0.55	rs1225598	ENSG00000216901.1	AL022393.7	6.28	3.39e-09	4.71e-06	0.63	0.46	Depression;	chr6:28193021	chr6:28176188~28176674:+
PCPG	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-6.28	3.41e-09	4.73e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
PCPG	cis	rs7267979	0.933	rs2261109	ENSG00000125804.12	FAM182A	-6.28	3.41e-09	4.73e-06	-0.52	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2261698	ENSG00000125804.12	FAM182A	-6.28	3.41e-09	4.73e-06	-0.52	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2261720	ENSG00000125804.12	FAM182A	-6.28	3.41e-09	4.73e-06	-0.52	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2227890	ENSG00000125804.12	FAM182A	-6.28	3.41e-09	4.73e-06	-0.52	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:26054655~26086917:+
PCPG	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	6.28	3.41e-09	4.73e-06	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
PCPG	cis	rs4835473	0.742	rs6537238	ENSG00000250345.2	RP11-780M14.1	-6.28	3.42e-09	4.73e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143996463	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1473055	ENSG00000250345.2	RP11-780M14.1	-6.28	3.42e-09	4.73e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143997714	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs4835126	ENSG00000250345.2	RP11-780M14.1	-6.28	3.42e-09	4.73e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143997740	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.699	rs4835127	ENSG00000250345.2	RP11-780M14.1	-6.28	3.42e-09	4.73e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143997972	chr4:143760399~143762093:-
PCPG	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	6.28	3.42e-09	4.74e-06	0.49	0.46	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
PCPG	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	6.28	3.43e-09	4.75e-06	0.56	0.46	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
PCPG	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	6.28	3.45e-09	4.77e-06	0.44	0.46	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
PCPG	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-6.28	3.46e-09	4.79e-06	-0.61	-0.46	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
PCPG	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-6.28	3.46e-09	4.79e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
PCPG	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	6.28	3.47e-09	4.8e-06	0.64	0.46	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
PCPG	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-6.28	3.47e-09	4.8e-06	-0.55	-0.46	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
PCPG	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	6.28	3.49e-09	4.82e-06	0.45	0.46	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
PCPG	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	6.28	3.5e-09	4.83e-06	0.9	0.46	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	6.28	3.5e-09	4.83e-06	0.9	0.46	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	6.28	3.5e-09	4.83e-06	0.9	0.46	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	6.28	3.5e-09	4.83e-06	0.9	0.46	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
PCPG	cis	rs853679	0.55	rs1150689	ENSG00000216901.1	AL022393.7	6.28	3.5e-09	4.84e-06	0.63	0.46	Depression;	chr6:28197321	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.55	rs1225599	ENSG00000216901.1	AL022393.7	6.28	3.5e-09	4.84e-06	0.63	0.46	Depression;	chr6:28197412	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.574	rs1233705	ENSG00000216901.1	AL022393.7	6.28	3.5e-09	4.84e-06	0.63	0.46	Depression;	chr6:28198669	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.55	rs1233699	ENSG00000216901.1	AL022393.7	6.28	3.5e-09	4.84e-06	0.63	0.46	Depression;	chr6:28201380	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.55	rs1233707	ENSG00000216901.1	AL022393.7	6.28	3.5e-09	4.84e-06	0.63	0.46	Depression;	chr6:28205175	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.55	rs1233704	ENSG00000216901.1	AL022393.7	-6.28	3.5e-09	4.84e-06	-0.63	-0.46	Depression;	chr6:28199145	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.55	rs1233701	ENSG00000216901.1	AL022393.7	-6.28	3.5e-09	4.84e-06	-0.63	-0.46	Depression;	chr6:28200948	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.55	rs1237875	ENSG00000216901.1	AL022393.7	-6.28	3.5e-09	4.84e-06	-0.63	-0.46	Depression;	chr6:28205232	chr6:28176188~28176674:+
PCPG	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-6.28	3.5e-09	4.84e-06	-0.57	-0.46	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-6.28	3.5e-09	4.84e-06	-0.57	-0.46	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
PCPG	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	6.28	3.54e-09	4.89e-06	0.6	0.46	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
PCPG	cis	rs2625529	0.73	rs7403191	ENSG00000260037.4	CTD-2524L6.3	-6.28	3.55e-09	4.89e-06	-0.67	-0.46	Red blood cell count;	chr15:71868623	chr15:71818396~71823384:+
PCPG	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-6.28	3.55e-09	4.89e-06	-0.6	-0.46	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
PCPG	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-6.27	3.56e-09	4.91e-06	-0.44	-0.46	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
PCPG	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	6.27	3.56e-09	4.91e-06	0.64	0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
PCPG	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-6.27	3.57e-09	4.91e-06	-0.6	-0.46	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
PCPG	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	6.27	3.57e-09	4.92e-06	0.43	0.46	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
PCPG	cis	rs11148252	0.846	rs1056335	ENSG00000235660.1	LINC00345	-6.27	3.58e-09	4.92e-06	-0.58	-0.46	Lewy body disease;	chr13:52415728	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.846	rs7985262	ENSG00000235660.1	LINC00345	-6.27	3.58e-09	4.92e-06	-0.58	-0.46	Lewy body disease;	chr13:52423026	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.846	rs4886077	ENSG00000235660.1	LINC00345	-6.27	3.58e-09	4.92e-06	-0.58	-0.46	Lewy body disease;	chr13:52424562	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.846	rs8001624	ENSG00000235660.1	LINC00345	-6.27	3.58e-09	4.92e-06	-0.58	-0.46	Lewy body disease;	chr13:52428860	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.744	rs4884354	ENSG00000235660.1	LINC00345	-6.27	3.58e-09	4.92e-06	-0.58	-0.46	Lewy body disease;	chr13:52443339	chr13:52484161~52484680:-
PCPG	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-6.27	3.58e-09	4.93e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-6.27	3.58e-09	4.93e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
PCPG	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	6.27	3.6e-09	4.95e-06	0.6	0.46	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	6.27	3.6e-09	4.95e-06	0.6	0.46	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
PCPG	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-6.27	3.6e-09	4.96e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
PCPG	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	6.27	3.61e-09	4.96e-06	0.55	0.46	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
PCPG	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-6.27	3.62e-09	4.98e-06	-0.56	-0.46	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
PCPG	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	6.27	3.63e-09	4.99e-06	0.61	0.46	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
PCPG	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	6.27	3.64e-09	5e-06	0.44	0.46	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
PCPG	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-6.27	3.64e-09	5e-06	-0.58	-0.46	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
PCPG	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-6.27	3.69e-09	5.06e-06	-0.46	-0.46	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
PCPG	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	6.27	3.69e-09	5.06e-06	0.51	0.46	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
PCPG	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-6.27	3.69e-09	5.06e-06	-0.5	-0.46	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
PCPG	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-6.27	3.69e-09	5.06e-06	-0.6	-0.46	Height;	chr14:75022243	chr14:75011269~75012851:-
PCPG	cis	rs853679	0.55	rs1150692	ENSG00000216901.1	AL022393.7	6.27	3.7e-09	5.07e-06	0.63	0.46	Depression;	chr6:28206179	chr6:28176188~28176674:+
PCPG	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-6.27	3.7e-09	5.07e-06	-0.49	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
PCPG	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-6.27	3.7e-09	5.07e-06	-0.44	-0.46	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-6.27	3.7e-09	5.07e-06	-0.44	-0.46	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
PCPG	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-6.27	3.71e-09	5.08e-06	-0.49	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
PCPG	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	6.27	3.71e-09	5.08e-06	0.76	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
PCPG	cis	rs950169	0.922	rs11633534	ENSG00000259295.5	CSPG4P12	6.27	3.72e-09	5.09e-06	0.69	0.46	Schizophrenia;	chr15:84581411	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.65	rs12902052	ENSG00000259295.5	CSPG4P12	6.27	3.72e-09	5.09e-06	0.69	0.46	Schizophrenia;	chr15:84582607	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	6.27	3.72e-09	5.09e-06	0.69	0.46	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
PCPG	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	6.27	3.73e-09	5.11e-06	0.65	0.46	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
PCPG	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-6.26	3.75e-09	5.13e-06	-0.59	-0.46	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
PCPG	cis	rs2625529	0.73	rs2957725	ENSG00000260037.4	CTD-2524L6.3	6.26	3.76e-09	5.14e-06	0.63	0.46	Red blood cell count;	chr15:71955864	chr15:71818396~71823384:+
PCPG	cis	rs4835473	0.831	rs4323050	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143992106	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.897	rs4423826	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143992165	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.932	rs1849128	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143992582	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.715	rs4538428	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143992751	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.771	rs2175452	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143992887	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.8	rs2175451	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143992964	chr4:143760399~143762093:-
PCPG	cis	rs4323050	0.51	rs4254715	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143760399~143762093:-
PCPG	cis	rs4323050	0.51	rs4273414	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.831	rs1912743	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143993705	chr4:143760399~143762093:-
PCPG	cis	rs4835473	0.614	rs4487293	ENSG00000250345.2	RP11-780M14.1	-6.26	3.77e-09	5.14e-06	-0.58	-0.46	Immature fraction of reticulocytes;	chr4:143993880	chr4:143760399~143762093:-
PCPG	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	6.26	3.77e-09	5.14e-06	0.51	0.46	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	6.26	3.77e-09	5.14e-06	0.51	0.46	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	6.26	3.77e-09	5.14e-06	0.51	0.46	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
PCPG	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-6.26	3.77e-09	5.15e-06	-0.85	-0.46	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
PCPG	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	6.26	3.77e-09	5.15e-06	0.55	0.46	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
PCPG	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-6.26	3.78e-09	5.16e-06	-0.61	-0.46	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
PCPG	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.26	3.78e-09	5.16e-06	0.54	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
PCPG	cis	rs2625529	0.586	rs2306489	ENSG00000260037.4	CTD-2524L6.3	6.26	3.79e-09	5.17e-06	0.64	0.46	Red blood cell count;	chr15:71935130	chr15:71818396~71823384:+
PCPG	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-6.26	3.8e-09	5.18e-06	-0.48	-0.46	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
PCPG	cis	rs7267979	0.714	rs3787082	ENSG00000125804.12	FAM182A	-6.26	3.8e-09	5.18e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.714	rs6115107	ENSG00000125804.12	FAM182A	-6.26	3.8e-09	5.18e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.78	rs2500413	ENSG00000125804.12	FAM182A	-6.26	3.8e-09	5.18e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.714	rs2474763	ENSG00000125804.12	FAM182A	-6.26	3.8e-09	5.18e-06	-0.54	-0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:26054655~26086917:+
PCPG	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	6.26	3.83e-09	5.22e-06	0.57	0.46	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
PCPG	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-6.26	3.85e-09	5.23e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-6.26	3.85e-09	5.23e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-6.26	3.85e-09	5.23e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-6.26	3.85e-09	5.23e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-6.26	3.85e-09	5.23e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-6.26	3.85e-09	5.23e-06	-0.51	-0.46	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	6.26	3.85e-09	5.23e-06	0.51	0.46	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
PCPG	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	6.26	3.87e-09	5.26e-06	0.58	0.46	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
PCPG	cis	rs7267979	1	rs2257991	ENSG00000125804.12	FAM182A	6.26	3.88e-09	5.27e-06	0.52	0.46	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:26054655~26086917:+
PCPG	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-6.26	3.9e-09	5.29e-06	-0.55	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-6.26	3.9e-09	5.29e-06	-0.55	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
PCPG	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	6.26	3.9e-09	5.29e-06	0.58	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
PCPG	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	6.26	3.9e-09	5.3e-06	0.81	0.45	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
PCPG	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	6.26	3.9e-09	5.3e-06	0.61	0.45	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
PCPG	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-6.26	3.91e-09	5.3e-06	-0.48	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
PCPG	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-6.26	3.91e-09	5.3e-06	-0.71	-0.45	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
PCPG	cis	rs7267979	1	rs6050547	ENSG00000125804.12	FAM182A	6.26	3.92e-09	5.31e-06	0.52	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:26054655~26086917:+
PCPG	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-6.26	3.92e-09	5.32e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-6.26	3.92e-09	5.32e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-6.26	3.92e-09	5.32e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
PCPG	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-6.26	3.93e-09	5.32e-06	-0.6	-0.45	Height;	chr14:75023964	chr14:75011269~75012851:-
PCPG	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	6.26	3.93e-09	5.33e-06	0.59	0.45	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
PCPG	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-6.26	3.94e-09	5.34e-06	-0.57	-0.45	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
PCPG	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-6.25	3.96e-09	5.37e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
PCPG	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	6.25	3.97e-09	5.37e-06	0.62	0.45	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
PCPG	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	6.25	3.97e-09	5.38e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
PCPG	cis	rs7267979	0.966	rs2261784	ENSG00000125804.12	FAM182A	-6.25	3.98e-09	5.39e-06	-0.53	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2261785	ENSG00000125804.12	FAM182A	-6.25	3.98e-09	5.39e-06	-0.53	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:26054655~26086917:+
PCPG	cis	rs853679	0.55	rs6901017	ENSG00000216901.1	AL022393.7	6.25	3.99e-09	5.39e-06	0.63	0.45	Depression;	chr6:28184805	chr6:28176188~28176674:+
PCPG	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-6.25	4.01e-09	5.42e-06	-0.57	-0.45	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
PCPG	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-6.25	4.01e-09	5.42e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
PCPG	cis	rs910316	0.737	rs175084	ENSG00000279594.1	RP11-950C14.10	-6.25	4.04e-09	5.46e-06	-0.6	-0.45	Height;	chr14:75052472	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.737	rs175499	ENSG00000279594.1	RP11-950C14.10	-6.25	4.04e-09	5.46e-06	-0.6	-0.45	Height;	chr14:75069224	chr14:75011269~75012851:-
PCPG	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-6.25	4.05e-09	5.47e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
PCPG	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	6.25	4.07e-09	5.49e-06	0.51	0.45	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
PCPG	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-6.25	4.08e-09	5.5e-06	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
PCPG	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	6.25	4.09e-09	5.52e-06	0.48	0.45	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
PCPG	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	6.25	4.11e-09	5.53e-06	0.55	0.45	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
PCPG	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	6.25	4.13e-09	5.55e-06	0.62	0.45	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
PCPG	cis	rs9595908	0.714	rs1018800	ENSG00000212293.1	SNORA16	6.25	4.14e-09	5.56e-06	0.55	0.45	Body mass index;	chr13:32624039	chr13:32420390~32420516:-
PCPG	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-6.25	4.14e-09	5.56e-06	-0.62	-0.45	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
PCPG	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	6.24	4.16e-09	5.59e-06	0.6	0.45	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	6.24	4.16e-09	5.59e-06	0.6	0.45	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
PCPG	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-6.24	4.17e-09	5.61e-06	-0.74	-0.45	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
PCPG	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	6.24	4.18e-09	5.62e-06	0.59	0.45	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	6.24	4.18e-09	5.62e-06	0.59	0.45	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
PCPG	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-6.24	4.18e-09	5.62e-06	-0.6	-0.45	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
PCPG	cis	rs7824557	0.527	rs2572448	ENSG00000255020.1	AF131216.5	-6.24	4.2e-09	5.65e-06	-0.6	-0.45	Retinal vascular caliber;	chr8:11381843	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs2572447	ENSG00000255020.1	AF131216.5	-6.24	4.2e-09	5.65e-06	-0.6	-0.45	Retinal vascular caliber;	chr8:11382001	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs2572446	ENSG00000255020.1	AF131216.5	-6.24	4.2e-09	5.65e-06	-0.6	-0.45	Retinal vascular caliber;	chr8:11382056	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs10109537	ENSG00000255020.1	AF131216.5	-6.24	4.2e-09	5.65e-06	-0.6	-0.45	Retinal vascular caliber;	chr8:11382131	chr8:11345748~11347502:-
PCPG	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-6.24	4.21e-09	5.65e-06	-0.71	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
PCPG	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	6.24	4.23e-09	5.68e-06	0.59	0.45	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
PCPG	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	6.24	4.24e-09	5.69e-06	0.51	0.45	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-6.24	4.24e-09	5.69e-06	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-6.24	4.24e-09	5.69e-06	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-6.24	4.24e-09	5.69e-06	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-6.24	4.24e-09	5.69e-06	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-6.24	4.24e-09	5.69e-06	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
PCPG	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	6.24	4.24e-09	5.69e-06	0.61	0.45	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
PCPG	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-6.24	4.25e-09	5.7e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
PCPG	cis	rs910316	0.737	rs175077	ENSG00000279594.1	RP11-950C14.10	-6.24	4.25e-09	5.7e-06	-0.6	-0.45	Height;	chr14:75040172	chr14:75011269~75012851:-
PCPG	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	6.24	4.26e-09	5.71e-06	0.59	0.45	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
PCPG	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-6.24	4.26e-09	5.72e-06	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-6.24	4.26e-09	5.72e-06	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-6.24	4.26e-09	5.72e-06	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-6.24	4.26e-09	5.72e-06	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-6.24	4.26e-09	5.72e-06	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
PCPG	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	6.24	4.27e-09	5.72e-06	0.56	0.45	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
PCPG	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-6.24	4.27e-09	5.73e-06	-0.43	-0.45	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-6.24	4.27e-09	5.73e-06	-0.43	-0.45	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
PCPG	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	6.24	4.29e-09	5.75e-06	0.51	0.45	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
PCPG	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-6.24	4.31e-09	5.77e-06	-0.46	-0.45	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-6.24	4.31e-09	5.77e-06	-0.46	-0.45	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-6.24	4.31e-09	5.77e-06	-0.46	-0.45	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
PCPG	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	6.24	4.31e-09	5.77e-06	0.56	0.45	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
PCPG	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	6.24	4.32e-09	5.79e-06	0.6	0.45	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
PCPG	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-6.24	4.33e-09	5.79e-06	-0.65	-0.45	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
PCPG	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-6.24	4.33e-09	5.79e-06	-0.65	-0.45	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
PCPG	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	6.24	4.34e-09	5.81e-06	0.64	0.45	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
PCPG	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-6.24	4.34e-09	5.81e-06	-0.42	-0.45	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
PCPG	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	-6.24	4.35e-09	5.82e-06	-0.52	-0.45	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
PCPG	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	-6.24	4.35e-09	5.82e-06	-0.52	-0.45	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
PCPG	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-6.24	4.36e-09	5.83e-06	-0.44	-0.45	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
PCPG	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	6.23	4.38e-09	5.85e-06	0.65	0.45	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
PCPG	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	6.23	4.38e-09	5.86e-06	0.61	0.45	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	6.23	4.38e-09	5.86e-06	0.61	0.45	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
PCPG	cis	rs2625529	0.73	rs1481860	ENSG00000260037.4	CTD-2524L6.3	6.23	4.38e-09	5.86e-06	0.65	0.45	Red blood cell count;	chr15:71949516	chr15:71818396~71823384:+
PCPG	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-6.23	4.39e-09	5.86e-06	-0.49	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
PCPG	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-6.23	4.4e-09	5.88e-06	-0.53	-0.45	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
PCPG	cis	rs7267979	0.932	rs446649	ENSG00000125804.12	FAM182A	-6.23	4.4e-09	5.88e-06	-0.51	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:26054655~26086917:+
PCPG	cis	rs11951515	0.508	rs10065689	ENSG00000248240.1	RP11-159F24.5	-6.23	4.41e-09	5.89e-06	-0.51	-0.45	Metabolite levels  (X-11787);	chr5:43604156	chr5:43515274~43525310:+
PCPG	cis	rs11951515	0.508	rs67261887	ENSG00000248240.1	RP11-159F24.5	-6.23	4.41e-09	5.89e-06	-0.51	-0.45	Metabolite levels  (X-11787);	chr5:43612339	chr5:43515274~43525310:+
PCPG	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-6.23	4.41e-09	5.9e-06	-0.44	-0.45	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
PCPG	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-6.23	4.42e-09	5.91e-06	-0.46	-0.45	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
PCPG	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	6.23	4.44e-09	5.92e-06	0.56	0.45	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
PCPG	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	6.23	4.46e-09	5.95e-06	0.69	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
PCPG	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	6.23	4.46e-09	5.96e-06	0.57	0.45	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
PCPG	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-6.23	4.47e-09	5.97e-06	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
PCPG	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-6.23	4.48e-09	5.98e-06	-0.61	-0.45	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
PCPG	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	6.23	4.49e-09	5.99e-06	0.58	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
PCPG	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-6.23	4.5e-09	6.01e-06	-0.52	-0.45	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-6.23	4.5e-09	6.01e-06	-0.52	-0.45	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
PCPG	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	6.23	4.51e-09	6.02e-06	0.52	0.45	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
PCPG	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	6.23	4.51e-09	6.02e-06	0.65	0.45	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
PCPG	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-6.23	4.52e-09	6.02e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
PCPG	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-6.23	4.52e-09	6.03e-06	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
PCPG	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-6.23	4.53e-09	6.04e-06	-0.43	-0.45	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
PCPG	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-6.23	4.54e-09	6.05e-06	-0.48	-0.45	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
PCPG	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-6.23	4.55e-09	6.07e-06	-0.43	-0.45	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
PCPG	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	6.23	4.56e-09	6.08e-06	0.58	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
PCPG	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-6.23	4.58e-09	6.11e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-6.22	4.61e-09	6.12e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
PCPG	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	6.22	4.63e-09	6.15e-06	0.59	0.45	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	6.22	4.63e-09	6.15e-06	0.59	0.45	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
PCPG	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-6.22	4.65e-09	6.17e-06	-0.52	-0.45	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
PCPG	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	6.22	4.67e-09	6.19e-06	0.63	0.45	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
PCPG	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	6.22	4.68e-09	6.21e-06	0.69	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
PCPG	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-6.22	4.69e-09	6.23e-06	-0.59	-0.45	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
PCPG	cis	rs7267979	1	rs2424710	ENSG00000125804.12	FAM182A	-6.22	4.71e-09	6.25e-06	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.668	rs2387977	ENSG00000125804.12	FAM182A	6.22	4.71e-09	6.25e-06	0.51	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:26054655~26086917:+
PCPG	cis	rs7824557	0.767	rs6985146	ENSG00000255020.1	AF131216.5	6.22	4.75e-09	6.3e-06	0.6	0.45	Retinal vascular caliber;	chr8:11313212	chr8:11345748~11347502:-
PCPG	cis	rs910316	0.737	rs175065	ENSG00000279594.1	RP11-950C14.10	-6.22	4.77e-09	6.32e-06	-0.59	-0.45	Height;	chr14:75028280	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.737	rs175080	ENSG00000279594.1	RP11-950C14.10	-6.22	4.77e-09	6.32e-06	-0.59	-0.45	Height;	chr14:75047125	chr14:75011269~75012851:-
PCPG	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	6.22	4.79e-09	6.34e-06	0.53	0.45	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
PCPG	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-6.22	4.79e-09	6.34e-06	-0.62	-0.45	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
PCPG	cis	rs7267979	0.714	rs1555329	ENSG00000125804.12	FAM182A	-6.22	4.79e-09	6.35e-06	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:26054655~26086917:+
PCPG	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-6.22	4.8e-09	6.35e-06	-0.61	-0.45	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-6.22	4.8e-09	6.35e-06	-0.61	-0.45	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-6.22	4.8e-09	6.35e-06	-0.61	-0.45	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-6.22	4.8e-09	6.35e-06	-0.61	-0.45	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
PCPG	cis	rs910316	0.737	rs2098251	ENSG00000279594.1	RP11-950C14.10	6.22	4.8e-09	6.35e-06	0.58	0.45	Height;	chr14:75025993	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.664	rs2098252	ENSG00000279594.1	RP11-950C14.10	6.22	4.8e-09	6.35e-06	0.58	0.45	Height;	chr14:75026029	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.737	rs28687415	ENSG00000279594.1	RP11-950C14.10	6.22	4.8e-09	6.35e-06	0.58	0.45	Height;	chr14:75028779	chr14:75011269~75012851:-
PCPG	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-6.22	4.81e-09	6.36e-06	-0.66	-0.45	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
PCPG	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-6.22	4.81e-09	6.37e-06	-0.9	-0.45	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-6.22	4.81e-09	6.37e-06	-0.9	-0.45	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	6.22	4.81e-09	6.37e-06	0.9	0.45	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
PCPG	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-6.21	4.86e-09	6.42e-06	-0.51	-0.45	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
PCPG	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-6.21	4.86e-09	6.42e-06	-0.42	-0.45	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-6.21	4.86e-09	6.42e-06	-0.42	-0.45	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-6.21	4.86e-09	6.42e-06	-0.42	-0.45	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
PCPG	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-6.21	4.86e-09	6.42e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
PCPG	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-6.21	4.86e-09	6.42e-06	-0.57	-0.45	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-6.21	4.87e-09	6.44e-06	-0.65	-0.45	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
PCPG	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-6.21	4.88e-09	6.45e-06	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
PCPG	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	6.21	4.91e-09	6.49e-06	0.69	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	6.21	4.91e-09	6.49e-06	0.69	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	6.21	4.91e-09	6.49e-06	0.69	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	6.21	4.91e-09	6.49e-06	0.69	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	6.21	4.91e-09	6.49e-06	0.69	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
PCPG	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-6.21	4.91e-09	6.49e-06	-0.59	-0.45	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
PCPG	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	6.21	4.94e-09	6.52e-06	0.76	0.45	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
PCPG	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	6.21	4.95e-09	6.53e-06	0.57	0.45	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
PCPG	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	6.21	5e-09	6.6e-06	0.55	0.45	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
PCPG	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-6.21	5.03e-09	6.63e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-6.21	5.03e-09	6.63e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
PCPG	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	6.21	5.03e-09	6.63e-06	0.6	0.45	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
PCPG	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	6.21	5.03e-09	6.63e-06	0.6	0.45	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
PCPG	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	6.21	5.03e-09	6.64e-06	0.58	0.45	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	6.21	5.03e-09	6.64e-06	0.58	0.45	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
PCPG	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-6.21	5.04e-09	6.64e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
PCPG	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-6.21	5.04e-09	6.64e-06	-0.59	-0.45	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-6.21	5.04e-09	6.64e-06	-0.59	-0.45	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-6.21	5.04e-09	6.64e-06	-0.59	-0.45	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-6.21	5.04e-09	6.64e-06	-0.59	-0.45	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-6.21	5.04e-09	6.64e-06	-0.59	-0.45	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-6.21	5.04e-09	6.64e-06	-0.59	-0.45	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-6.21	5.05e-09	6.65e-06	-0.58	-0.45	Depression;	chr6:28206179	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	6.21	5.05e-09	6.65e-06	0.67	0.45	Depression;	chr6:28407125	chr6:28176188~28176674:+
PCPG	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-6.21	5.05e-09	6.65e-06	-0.6	-0.45	Height;	chr14:75031474	chr14:75011269~75012851:-
PCPG	cis	rs10435719	0.902	rs12681142	ENSG00000255020.1	AF131216.5	6.21	5.06e-09	6.66e-06	0.62	0.45	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:11345748~11347502:-
PCPG	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-6.21	5.06e-09	6.66e-06	-0.55	-0.45	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-6.21	5.06e-09	6.66e-06	-0.55	-0.45	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
PCPG	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	6.21	5.06e-09	6.66e-06	0.86	0.45	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
PCPG	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-6.21	5.06e-09	6.67e-06	-0.45	-0.45	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
PCPG	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-6.21	5.07e-09	6.68e-06	-0.63	-0.45	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
PCPG	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-6.21	5.08e-09	6.68e-06	-0.53	-0.45	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
PCPG	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-6.2	5.08e-09	6.69e-06	-0.56	-0.45	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
PCPG	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	6.2	5.09e-09	6.7e-06	0.61	0.45	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	6.2	5.09e-09	6.7e-06	0.61	0.45	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
PCPG	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	6.2	5.1e-09	6.71e-06	0.59	0.45	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
PCPG	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	6.2	5.11e-09	6.72e-06	0.59	0.45	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
PCPG	cis	rs7267979	0.565	rs3752273	ENSG00000125804.12	FAM182A	6.2	5.12e-09	6.74e-06	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26054655~26086917:+
PCPG	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-6.2	5.13e-09	6.74e-06	-0.56	-0.45	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-6.2	5.13e-09	6.74e-06	-0.56	-0.45	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
PCPG	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	6.2	5.16e-09	6.78e-06	0.61	0.45	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	6.2	5.16e-09	6.78e-06	0.61	0.45	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	6.2	5.16e-09	6.78e-06	0.61	0.45	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
PCPG	cis	rs7727544	0.74	rs419291	ENSG00000233006.5	AC034220.3	6.2	5.17e-09	6.79e-06	0.36	0.45	Blood metabolite levels;	chr5:132297662	chr5:132311285~132369916:-
PCPG	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	6.2	5.17e-09	6.79e-06	0.51	0.45	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
PCPG	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-6.2	5.19e-09	6.82e-06	-0.54	-0.45	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-6.2	5.19e-09	6.82e-06	-0.69	-0.45	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
PCPG	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	6.2	5.23e-09	6.87e-06	0.52	0.45	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
PCPG	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-6.2	5.24e-09	6.88e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-6.2	5.24e-09	6.88e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
PCPG	cis	rs7267979	0.899	rs2179459	ENSG00000125804.12	FAM182A	-6.2	5.24e-09	6.89e-06	-0.53	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:26054655~26086917:+
PCPG	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-6.2	5.28e-09	6.93e-06	-0.51	-0.45	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
PCPG	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-6.2	5.3e-09	6.95e-06	-0.56	-0.45	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
PCPG	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-6.2	5.3e-09	6.96e-06	-0.44	-0.45	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
PCPG	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	6.2	5.3e-09	6.96e-06	0.57	0.45	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
PCPG	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	6.19	5.35e-09	7.02e-06	0.56	0.45	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
PCPG	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-6.19	5.37e-09	7.04e-06	-0.53	-0.45	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
PCPG	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-6.19	5.37e-09	7.04e-06	-0.46	-0.45	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
PCPG	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	6.19	5.38e-09	7.05e-06	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
PCPG	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	6.19	5.38e-09	7.05e-06	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
PCPG	cis	rs910316	1	rs175492	ENSG00000279594.1	RP11-950C14.10	6.19	5.38e-09	7.06e-06	0.58	0.45	Height;	chr14:75078517	chr14:75011269~75012851:-
PCPG	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-6.19	5.39e-09	7.06e-06	-0.49	-0.45	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
PCPG	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	6.19	5.4e-09	7.08e-06	0.5	0.45	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
PCPG	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	6.19	5.43e-09	7.11e-06	0.78	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
PCPG	cis	rs7267979	0.528	rs2387976	ENSG00000125804.12	FAM182A	6.19	5.45e-09	7.13e-06	0.55	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs1888997	ENSG00000125804.12	FAM182A	6.19	5.45e-09	7.14e-06	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs3002698	ENSG00000125804.12	FAM182A	6.19	5.45e-09	7.14e-06	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482930	ENSG00000125804.12	FAM182A	6.19	5.45e-09	7.14e-06	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs7019	ENSG00000125804.12	FAM182A	-6.19	5.45e-09	7.14e-06	-0.53	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6115140	ENSG00000125804.12	FAM182A	-6.19	5.45e-09	7.14e-06	-0.53	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:26054655~26086917:+
PCPG	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	6.19	5.45e-09	7.14e-06	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
PCPG	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	6.19	5.47e-09	7.15e-06	0.67	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
PCPG	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	6.19	5.48e-09	7.17e-06	0.52	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
PCPG	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-6.19	5.5e-09	7.19e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-6.19	5.5e-09	7.19e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
PCPG	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	6.19	5.52e-09	7.22e-06	0.58	0.45	Depression;	chr6:28199145	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.19	5.52e-09	7.22e-06	0.58	0.45	Depression;	chr6:28200948	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	6.19	5.52e-09	7.22e-06	0.58	0.45	Depression;	chr6:28205232	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-6.19	5.52e-09	7.22e-06	-0.58	-0.45	Depression;	chr6:28197321	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-6.19	5.52e-09	7.22e-06	-0.58	-0.45	Depression;	chr6:28197412	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-6.19	5.52e-09	7.22e-06	-0.58	-0.45	Depression;	chr6:28198669	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-6.19	5.52e-09	7.22e-06	-0.58	-0.45	Depression;	chr6:28201380	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-6.19	5.52e-09	7.22e-06	-0.58	-0.45	Depression;	chr6:28205175	chr6:28115628~28116551:+
PCPG	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	6.19	5.54e-09	7.23e-06	0.53	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
PCPG	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-6.19	5.54e-09	7.24e-06	-0.48	-0.45	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
PCPG	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-6.19	5.56e-09	7.27e-06	-0.61	-0.45	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
PCPG	cis	rs7267979	1	rs6138572	ENSG00000125804.12	FAM182A	-6.19	5.57e-09	7.27e-06	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6138575	ENSG00000125804.12	FAM182A	-6.19	5.57e-09	7.27e-06	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs11087521	ENSG00000125804.12	FAM182A	-6.19	5.57e-09	7.27e-06	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs13038834	ENSG00000125804.12	FAM182A	-6.19	5.57e-09	7.27e-06	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:26054655~26086917:+
PCPG	cis	rs9595908	0.931	rs7998440	ENSG00000212293.1	SNORA16	6.19	5.58e-09	7.28e-06	0.55	0.45	Body mass index;	chr13:32551069	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs8000071	ENSG00000212293.1	SNORA16	6.19	5.58e-09	7.28e-06	0.55	0.45	Body mass index;	chr13:32551236	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs7991314	ENSG00000212293.1	SNORA16	6.19	5.58e-09	7.28e-06	0.55	0.45	Body mass index;	chr13:32551937	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs7984903	ENSG00000212293.1	SNORA16	6.19	5.58e-09	7.28e-06	0.55	0.45	Body mass index;	chr13:32552002	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs7328733	ENSG00000212293.1	SNORA16	6.19	5.58e-09	7.28e-06	0.55	0.45	Body mass index;	chr13:32552600	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.929	rs7328939	ENSG00000212293.1	SNORA16	6.19	5.58e-09	7.28e-06	0.55	0.45	Body mass index;	chr13:32552711	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.965	rs7318297	ENSG00000212293.1	SNORA16	6.19	5.58e-09	7.28e-06	0.55	0.45	Body mass index;	chr13:32563835	chr13:32420390~32420516:-
PCPG	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-6.19	5.6e-09	7.31e-06	-0.69	-0.45	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
PCPG	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	5.63e-09	7.34e-06	-0.52	-0.45	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
PCPG	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	6.18	5.64e-09	7.35e-06	0.5	0.45	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
PCPG	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	6.18	5.65e-09	7.36e-06	0.63	0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
PCPG	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-6.18	5.67e-09	7.39e-06	-0.46	-0.45	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
PCPG	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-6.18	5.72e-09	7.44e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
PCPG	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	6.18	5.75e-09	7.48e-06	0.42	0.45	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-6.18	5.78e-09	7.51e-06	-0.57	-0.45	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
PCPG	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-6.18	5.79e-09	7.53e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
PCPG	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-6.18	5.8e-09	7.54e-06	-0.59	-0.45	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
PCPG	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-6.18	5.8e-09	7.54e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-6.18	5.8e-09	7.54e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
PCPG	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-6.18	5.82e-09	7.55e-06	-0.59	-0.45	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
PCPG	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-6.18	5.83e-09	7.56e-06	-0.48	-0.45	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-6.18	5.83e-09	7.56e-06	-0.48	-0.45	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-6.18	5.83e-09	7.56e-06	-0.48	-0.45	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-6.18	5.83e-09	7.56e-06	-0.48	-0.45	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-6.18	5.83e-09	7.56e-06	-0.48	-0.45	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
PCPG	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	6.18	5.86e-09	7.6e-06	0.58	0.45	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
PCPG	cis	rs7267979	0.932	rs424487	ENSG00000125804.12	FAM182A	-6.18	5.87e-09	7.61e-06	-0.51	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:26054655~26086917:+
PCPG	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	6.18	5.87e-09	7.61e-06	0.57	0.45	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
PCPG	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-6.18	5.9e-09	7.65e-06	-0.57	-0.45	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
PCPG	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-6.18	5.9e-09	7.65e-06	-0.57	-0.45	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
PCPG	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-6.18	5.9e-09	7.65e-06	-0.57	-0.45	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
PCPG	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-6.18	5.91e-09	7.66e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
PCPG	cis	rs7824557	0.767	rs7837036	ENSG00000255020.1	AF131216.5	6.17	5.91e-09	7.66e-06	0.6	0.45	Retinal vascular caliber;	chr8:11317980	chr8:11345748~11347502:-
PCPG	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-6.17	5.92e-09	7.67e-06	-0.52	-0.45	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
PCPG	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-6.17	5.92e-09	7.67e-06	-0.43	-0.45	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
PCPG	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-6.17	5.93e-09	7.68e-06	-0.52	-0.45	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
PCPG	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-6.17	5.93e-09	7.68e-06	-0.42	-0.45	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
PCPG	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-6.17	5.93e-09	7.69e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
PCPG	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	6.17	5.94e-09	7.7e-06	0.55	0.45	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	6.17	5.94e-09	7.7e-06	0.55	0.45	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	6.17	5.94e-09	7.7e-06	0.55	0.45	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
PCPG	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	6.17	5.94e-09	7.7e-06	0.55	0.45	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
PCPG	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-6.17	5.97e-09	7.73e-06	-0.46	-0.45	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-6.17	5.97e-09	7.73e-06	-0.46	-0.45	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-6.17	5.97e-09	7.73e-06	-0.46	-0.45	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
PCPG	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-6.17	5.97e-09	7.74e-06	-0.42	-0.45	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
PCPG	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-6.17	5.99e-09	7.76e-06	-0.55	-0.45	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
PCPG	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-6.17	6.01e-09	7.78e-06	-0.59	-0.45	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
PCPG	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-6.17	6.02e-09	7.78e-06	-0.43	-0.45	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
PCPG	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-6.17	6.03e-09	7.81e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-6.17	6.03e-09	7.81e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-6.17	6.03e-09	7.81e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-6.17	6.03e-09	7.81e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-6.17	6.03e-09	7.81e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
PCPG	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	6.17	6.06e-09	7.84e-06	0.56	0.45	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
PCPG	cis	rs11148252	0.846	rs13431	ENSG00000235660.1	LINC00345	-6.17	6.06e-09	7.84e-06	-0.59	-0.45	Lewy body disease;	chr13:52413342	chr13:52484161~52484680:-
PCPG	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-6.17	6.1e-09	7.89e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-6.17	6.1e-09	7.89e-06	-0.6	-0.45	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
PCPG	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-6.17	6.12e-09	7.91e-06	-0.46	-0.45	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
PCPG	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-6.17	6.13e-09	7.93e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
PCPG	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-6.17	6.15e-09	7.95e-06	-0.47	-0.45	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-6.17	6.15e-09	7.95e-06	-0.47	-0.45	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
PCPG	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	6.17	6.17e-09	7.97e-06	0.58	0.45	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
PCPG	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-6.17	6.18e-09	7.98e-06	-0.62	-0.45	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-6.17	6.18e-09	7.98e-06	-0.62	-0.45	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
PCPG	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	6.16	6.22e-09	8.01e-06	0.79	0.45	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
PCPG	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	6.16	6.23e-09	8.03e-06	0.59	0.45	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
PCPG	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	6.16	6.23e-09	8.03e-06	0.59	0.45	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
PCPG	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-6.16	6.24e-09	8.05e-06	-0.51	-0.45	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
PCPG	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-6.16	6.29e-09	8.1e-06	-0.62	-0.45	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
PCPG	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	6.16	6.3e-09	8.12e-06	0.61	0.45	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
PCPG	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	6.16	6.31e-09	8.13e-06	0.63	0.45	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
PCPG	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	6.16	6.31e-09	8.13e-06	0.63	0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
PCPG	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	6.16	6.32e-09	8.14e-06	0.68	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
PCPG	cis	rs453301	0.658	rs9650616	ENSG00000173295.6	FAM86B3P	6.16	6.32e-09	8.14e-06	0.52	0.45	Joint mobility (Beighton score);	chr8:9011689	chr8:8228595~8244865:+
PCPG	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-6.16	6.33e-09	8.16e-06	-0.61	-0.45	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
PCPG	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-6.16	6.34e-09	8.17e-06	-0.54	-0.45	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
PCPG	cis	rs9532669	0.926	rs4356344	ENSG00000176268.5	CYCSP34	6.16	6.34e-09	8.17e-06	0.54	0.45	Cervical cancer;	chr13:40874086	chr13:40863599~40863902:-
PCPG	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	6.16	6.36e-09	8.19e-06	0.58	0.45	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
PCPG	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-6.16	6.39e-09	8.22e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
PCPG	cis	rs7688540	0.8	rs28429717	ENSG00000275426.1	CH17-262A2.1	6.16	6.39e-09	8.22e-06	0.55	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:149738~150317:+
PCPG	cis	rs7688540	0.8	rs11731285	ENSG00000275426.1	CH17-262A2.1	6.16	6.39e-09	8.22e-06	0.55	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:149738~150317:+
PCPG	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-6.16	6.44e-09	8.28e-06	-0.58	-0.45	Depression;	chr6:28193021	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	6.16	6.44e-09	8.28e-06	0.64	0.45	Depression;	chr6:28402301	chr6:28176188~28176674:+
PCPG	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	6.16	6.48e-09	8.33e-06	0.8	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	6.16	6.48e-09	8.33e-06	0.8	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	6.16	6.48e-09	8.33e-06	0.8	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
PCPG	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-6.16	6.5e-09	8.35e-06	-0.58	-0.45	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
PCPG	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	6.16	6.51e-09	8.36e-06	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
PCPG	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-6.15	6.56e-09	8.41e-06	-0.5	-0.45	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
PCPG	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-6.15	6.57e-09	8.43e-06	-0.53	-0.45	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
PCPG	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	6.15	6.57e-09	8.43e-06	0.6	0.45	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	6.15	6.57e-09	8.43e-06	0.6	0.45	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
PCPG	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	6.15	6.58e-09	8.44e-06	0.44	0.45	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
PCPG	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	6.15	6.6e-09	8.47e-06	0.6	0.45	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
PCPG	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	6.15	6.64e-09	8.5e-06	0.75	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
PCPG	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-6.15	6.66e-09	8.53e-06	-0.52	-0.45	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
PCPG	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-6.15	6.68e-09	8.55e-06	-0.47	-0.45	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
PCPG	cis	rs5769707	0.904	rs7288869	ENSG00000235111.1	RP1-29C18.8	-6.15	6.7e-09	8.57e-06	-0.5	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49612657~49615716:-
PCPG	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	6.15	6.72e-09	8.6e-06	0.58	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
PCPG	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	6.15	6.73e-09	8.61e-06	0.56	0.45	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
PCPG	cis	rs7267979	0.873	rs6037062	ENSG00000125804.12	FAM182A	-6.15	6.75e-09	8.63e-06	-0.51	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:26054655~26086917:+
PCPG	cis	rs4835473	0.932	rs4835455	ENSG00000250345.2	RP11-780M14.1	-6.15	6.78e-09	8.67e-06	-0.54	-0.45	Immature fraction of reticulocytes;	chr4:143962290	chr4:143760399~143762093:-
PCPG	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-6.15	6.79e-09	8.68e-06	-0.54	-0.45	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
PCPG	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-6.15	6.8e-09	8.69e-06	-0.56	-0.45	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
PCPG	cis	rs910316	0.789	rs175457	ENSG00000279594.1	RP11-950C14.10	-6.15	6.8e-09	8.69e-06	-0.59	-0.45	Height;	chr14:75117804	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.763	rs175450	ENSG00000279594.1	RP11-950C14.10	-6.15	6.8e-09	8.69e-06	-0.59	-0.45	Height;	chr14:75123637	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.789	rs175444	ENSG00000279594.1	RP11-950C14.10	-6.15	6.8e-09	8.69e-06	-0.59	-0.45	Height;	chr14:75135079	chr14:75011269~75012851:-
PCPG	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	6.15	6.8e-09	8.69e-06	0.43	0.45	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	6.15	6.8e-09	8.69e-06	0.43	0.45	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	6.15	6.8e-09	8.69e-06	0.43	0.45	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
PCPG	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	6.15	6.82e-09	8.72e-06	0.55	0.45	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
PCPG	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-6.15	6.83e-09	8.72e-06	-0.44	-0.45	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
PCPG	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-6.15	6.83e-09	8.73e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
PCPG	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-6.15	6.84e-09	8.74e-06	-0.54	-0.45	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
PCPG	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	6.15	6.84e-09	8.74e-06	0.6	0.45	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	6.15	6.84e-09	8.74e-06	0.6	0.45	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
PCPG	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-6.15	6.85e-09	8.74e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-6.15	6.86e-09	8.75e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
PCPG	cis	rs7267979	0.565	rs958075	ENSG00000125804.12	FAM182A	6.14	6.88e-09	8.78e-06	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26054655~26086917:+
PCPG	cis	rs950169	0.922	rs11638445	ENSG00000259295.5	CSPG4P12	6.14	6.89e-09	8.78e-06	0.68	0.45	Schizophrenia;	chr15:84594463	chr15:85191438~85213905:+
PCPG	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-6.14	6.89e-09	8.79e-06	-0.42	-0.45	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-6.14	6.89e-09	8.79e-06	-0.42	-0.45	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-6.14	6.89e-09	8.79e-06	-0.42	-0.45	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-6.14	6.89e-09	8.79e-06	-0.42	-0.45	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
PCPG	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	6.14	6.9e-09	8.8e-06	0.57	0.45	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
PCPG	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-6.14	6.91e-09	8.81e-06	-0.76	-0.45	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
PCPG	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-6.14	6.96e-09	8.86e-06	-0.45	-0.45	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-6.14	6.96e-09	8.86e-06	-0.45	-0.45	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-6.14	6.96e-09	8.86e-06	-0.45	-0.45	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-6.14	6.96e-09	8.86e-06	-0.45	-0.45	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
PCPG	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-6.14	6.99e-09	8.9e-06	-0.6	-0.45	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
PCPG	cis	rs910316	0.935	rs175076	ENSG00000279594.1	RP11-950C14.10	-6.14	6.99e-09	8.9e-06	-0.58	-0.45	Height;	chr14:75038783	chr14:75011269~75012851:-
PCPG	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	6.14	7.02e-09	8.93e-06	0.59	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
PCPG	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-6.14	7.04e-09	8.95e-06	-0.54	-0.45	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
PCPG	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-6.14	7.04e-09	8.96e-06	-0.61	-0.45	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
PCPG	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	6.14	7.1e-09	9.02e-06	0.56	0.45	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
PCPG	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-6.14	7.1e-09	9.02e-06	-0.64	-0.45	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
PCPG	cis	rs11148252	0.846	rs7323666	ENSG00000235660.1	LINC00345	-6.14	7.13e-09	9.05e-06	-0.57	-0.45	Lewy body disease;	chr13:52431923	chr13:52484161~52484680:-
PCPG	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-6.14	7.14e-09	9.07e-06	-0.43	-0.45	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
PCPG	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	6.14	7.15e-09	9.08e-06	0.56	0.45	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
PCPG	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	6.14	7.15e-09	9.08e-06	0.59	0.45	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
PCPG	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-6.14	7.16e-09	9.09e-06	-0.45	-0.45	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
PCPG	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-6.14	7.22e-09	9.14e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
PCPG	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-6.13	7.24e-09	9.15e-06	-0.54	-0.45	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
PCPG	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	6.13	7.24e-09	9.15e-06	0.59	0.45	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
PCPG	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-6.13	7.35e-09	9.28e-06	-0.54	-0.45	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
PCPG	cis	rs7267979	0.866	rs437635	ENSG00000125804.12	FAM182A	-6.13	7.35e-09	9.28e-06	-0.5	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.899	rs442834	ENSG00000125804.12	FAM182A	-6.13	7.35e-09	9.28e-06	-0.5	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs417110	ENSG00000125804.12	FAM182A	-6.13	7.35e-09	9.28e-06	-0.5	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs449703	ENSG00000125804.12	FAM182A	-6.13	7.35e-09	9.28e-06	-0.5	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs433352	ENSG00000125804.12	FAM182A	6.13	7.35e-09	9.28e-06	0.5	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs431579	ENSG00000125804.12	FAM182A	-6.13	7.35e-09	9.28e-06	-0.5	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:26054655~26086917:+
PCPG	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	6.13	7.37e-09	9.3e-06	0.48	0.45	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
PCPG	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	6.13	7.43e-09	9.37e-06	0.61	0.45	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
PCPG	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-6.13	7.44e-09	9.38e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-6.13	7.44e-09	9.38e-06	-0.5	-0.45	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
PCPG	cis	rs7824557	0.767	rs3808513	ENSG00000255020.1	AF131216.5	-6.13	7.45e-09	9.4e-06	-0.58	-0.45	Retinal vascular caliber;	chr8:11299951	chr8:11345748~11347502:-
PCPG	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-6.13	7.46e-09	9.4e-06	-0.62	-0.45	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
PCPG	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	6.13	7.58e-09	9.54e-06	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	6.13	7.58e-09	9.54e-06	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	6.13	7.58e-09	9.54e-06	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
PCPG	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-6.13	7.58e-09	9.54e-06	-0.67	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
PCPG	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-6.12	7.64e-09	9.61e-06	-0.44	-0.45	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
PCPG	cis	rs7267979	0.565	rs6107060	ENSG00000125804.12	FAM182A	-6.12	7.66e-09	9.64e-06	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26054655~26086917:+
PCPG	cis	rs853679	0.628	rs9368560	ENSG00000216901.1	AL022393.7	6.12	7.67e-09	9.65e-06	0.63	0.45	Depression;	chr6:28192182	chr6:28176188~28176674:+
PCPG	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-6.12	7.71e-09	9.68e-06	-0.52	-0.45	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-6.12	7.71e-09	9.68e-06	-0.52	-0.45	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-6.12	7.71e-09	9.68e-06	-0.52	-0.45	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
PCPG	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	6.12	7.72e-09	9.68e-06	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
PCPG	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-6.12	7.73e-09	9.7e-06	-0.48	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
PCPG	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-6.12	7.77e-09	9.74e-06	-0.54	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
PCPG	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-6.12	7.81e-09	9.79e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-6.12	7.81e-09	9.79e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-6.12	7.81e-09	9.79e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-6.12	7.81e-09	9.79e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-6.12	7.81e-09	9.79e-06	-0.59	-0.45	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
PCPG	cis	rs2921073	0.604	rs2979140	ENSG00000253893.2	FAM85B	-6.12	7.82e-09	9.79e-06	-0.55	-0.45	Parkinson's disease;	chr8:8409692	chr8:8167819~8226614:-
PCPG	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-6.12	7.86e-09	9.84e-06	-0.48	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
PCPG	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-6.12	7.87e-09	9.86e-06	-0.61	-0.45	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
PCPG	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-6.12	7.88e-09	9.86e-06	-0.49	-0.45	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
PCPG	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	6.12	7.9e-09	9.89e-06	0.51	0.45	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
PCPG	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-6.12	7.91e-09	9.9e-06	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-6.12	7.91e-09	9.9e-06	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
PCPG	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-6.12	7.91e-09	9.9e-06	-0.53	-0.45	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
PCPG	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	6.12	7.96e-09	9.96e-06	0.55	0.45	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
PCPG	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-6.12	7.99e-09	9.99e-06	-0.55	-0.45	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
PCPG	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	6.12	7.99e-09	9.99e-06	0.59	0.45	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-6.11	8.01e-09	1e-05	-0.59	-0.45	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
PCPG	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-6.11	8.01e-09	1e-05	-0.43	-0.45	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-6.11	8.01e-09	1e-05	-0.43	-0.45	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-6.11	8.01e-09	1e-05	-0.43	-0.45	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-6.11	8.01e-09	1e-05	-0.43	-0.45	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
PCPG	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-6.11	8.01e-09	1e-05	-0.48	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-6.11	8.01e-09	1e-05	-0.48	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-6.11	8.01e-09	1e-05	-0.48	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
PCPG	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-6.11	8.03e-09	1e-05	-0.67	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
PCPG	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-6.11	8.05e-09	1.01e-05	-0.54	-0.45	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-6.11	8.05e-09	1.01e-05	-0.54	-0.45	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
PCPG	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-6.11	8.06e-09	1.01e-05	-0.46	-0.45	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
PCPG	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-6.11	8.06e-09	1.01e-05	-0.5	-0.45	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
PCPG	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-6.11	8.08e-09	1.01e-05	-0.51	-0.45	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
PCPG	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-6.11	8.1e-09	1.01e-05	-0.63	-0.45	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
PCPG	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-6.11	8.11e-09	1.01e-05	-0.49	-0.45	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-6.11	8.11e-09	1.01e-05	-0.49	-0.45	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
PCPG	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-6.11	8.11e-09	1.01e-05	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-6.11	8.11e-09	1.01e-05	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
PCPG	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	6.11	8.14e-09	1.02e-05	0.47	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
PCPG	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-6.11	8.15e-09	1.02e-05	-0.53	-0.45	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	6.11	8.18e-09	1.02e-05	0.52	0.45	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
PCPG	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-6.11	8.21e-09	1.02e-05	-0.41	-0.45	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-6.11	8.21e-09	1.02e-05	-0.41	-0.45	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-6.11	8.21e-09	1.02e-05	-0.41	-0.45	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-6.11	8.21e-09	1.02e-05	-0.41	-0.45	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
PCPG	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-6.11	8.21e-09	1.02e-05	-0.52	-0.45	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
PCPG	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	6.11	8.22e-09	1.02e-05	0.55	0.45	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
PCPG	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-6.11	8.24e-09	1.03e-05	-0.45	-0.45	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
PCPG	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	6.11	8.24e-09	1.03e-05	0.6	0.45	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
PCPG	cis	rs2625529	0.689	rs12161990	ENSG00000260037.4	CTD-2524L6.3	6.11	8.25e-09	1.03e-05	0.64	0.45	Red blood cell count;	chr15:71910099	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.73	rs1481861	ENSG00000260037.4	CTD-2524L6.3	6.11	8.25e-09	1.03e-05	0.64	0.45	Red blood cell count;	chr15:71947788	chr15:71818396~71823384:+
PCPG	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	6.11	8.25e-09	1.03e-05	0.62	0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
PCPG	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-6.11	8.26e-09	1.03e-05	-0.55	-0.45	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
PCPG	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	6.11	8.26e-09	1.03e-05	0.65	0.45	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
PCPG	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-6.11	8.28e-09	1.03e-05	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-6.11	8.28e-09	1.03e-05	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
PCPG	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	6.11	8.28e-09	1.03e-05	0.76	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
PCPG	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-6.11	8.3e-09	1.03e-05	-0.65	-0.45	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
PCPG	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-6.11	8.31e-09	1.04e-05	-0.66	-0.45	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-6.11	8.31e-09	1.04e-05	-0.66	-0.45	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-6.11	8.31e-09	1.04e-05	-0.66	-0.45	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
PCPG	cis	rs910316	0.763	rs175435	ENSG00000279594.1	RP11-950C14.10	6.11	8.32e-09	1.04e-05	0.59	0.45	Height;	chr14:75145322	chr14:75011269~75012851:-
PCPG	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-6.11	8.36e-09	1.04e-05	-0.57	-0.45	Depression;	chr6:28184805	chr6:28115628~28116551:+
PCPG	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-6.11	8.37e-09	1.04e-05	-0.58	-0.45	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
PCPG	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	6.11	8.37e-09	1.04e-05	0.61	0.45	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
PCPG	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	6.11	8.37e-09	1.04e-05	0.61	0.45	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
PCPG	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-6.11	8.37e-09	1.04e-05	-0.45	-0.45	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
PCPG	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	6.11	8.38e-09	1.04e-05	0.78	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
PCPG	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	6.11	8.38e-09	1.04e-05	0.78	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
PCPG	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	6.11	8.38e-09	1.04e-05	0.78	0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
PCPG	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	6.11	8.38e-09	1.04e-05	0.59	0.45	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
PCPG	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-6.11	8.38e-09	1.04e-05	-0.42	-0.45	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-6.11	8.38e-09	1.04e-05	-0.42	-0.45	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-6.11	8.38e-09	1.04e-05	-0.42	-0.45	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-6.11	8.38e-09	1.04e-05	-0.42	-0.45	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-6.11	8.38e-09	1.04e-05	-0.42	-0.45	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
PCPG	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	6.11	8.4e-09	1.04e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	6.11	8.4e-09	1.04e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	6.11	8.4e-09	1.04e-05	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
PCPG	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	6.1	8.42e-09	1.05e-05	0.52	0.45	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
PCPG	cis	rs7267979	1	rs2482911	ENSG00000125804.12	FAM182A	6.1	8.43e-09	1.05e-05	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:26054655~26086917:+
PCPG	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	6.1	8.45e-09	1.05e-05	0.59	0.45	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	6.1	8.45e-09	1.05e-05	0.59	0.45	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	6.1	8.45e-09	1.05e-05	0.59	0.45	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	6.1	8.45e-09	1.05e-05	0.59	0.45	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	6.1	8.45e-09	1.05e-05	0.59	0.45	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
PCPG	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-6.1	8.47e-09	1.05e-05	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
PCPG	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	6.1	8.5e-09	1.05e-05	0.53	0.45	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
PCPG	cis	rs7267979	0.727	rs4815431	ENSG00000125804.12	FAM182A	6.1	8.5e-09	1.06e-05	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.78	rs6050679	ENSG00000125804.12	FAM182A	-6.1	8.52e-09	1.06e-05	-0.54	-0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26054655~26086917:+
PCPG	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-6.1	8.55e-09	1.06e-05	-0.52	-0.45	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
PCPG	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-6.1	8.57e-09	1.06e-05	-0.52	-0.45	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-6.1	8.57e-09	1.06e-05	-0.52	-0.45	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
PCPG	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	6.1	8.58e-09	1.06e-05	0.6	0.45	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
PCPG	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	6.1	8.59e-09	1.07e-05	0.63	0.45	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
PCPG	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-6.1	8.6e-09	1.07e-05	-0.58	-0.45	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
PCPG	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-6.1	8.61e-09	1.07e-05	-0.53	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
PCPG	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-6.1	8.64e-09	1.07e-05	-0.55	-0.45	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
PCPG	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	6.1	8.64e-09	1.07e-05	0.59	0.45	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	6.1	8.64e-09	1.07e-05	0.59	0.45	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
PCPG	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-6.1	8.64e-09	1.07e-05	-0.42	-0.45	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
PCPG	cis	rs11148252	0.574	rs61958118	ENSG00000198384.8	TPTE2P3	-6.1	8.7e-09	1.08e-05	-0.57	-0.45	Lewy body disease;	chr13:52596091	chr13:52522632~52586906:+
PCPG	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-6.1	8.7e-09	1.08e-05	-0.53	-0.45	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
PCPG	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-6.1	8.71e-09	1.08e-05	-0.41	-0.45	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
PCPG	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-6.1	8.74e-09	1.08e-05	-0.43	-0.45	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
PCPG	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-6.1	8.76e-09	1.08e-05	-0.47	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
PCPG	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	6.1	8.79e-09	1.09e-05	0.55	0.45	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
PCPG	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	6.1	8.81e-09	1.09e-05	0.48	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
PCPG	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-6.1	8.82e-09	1.09e-05	-0.55	-0.45	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
PCPG	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-6.1	8.82e-09	1.09e-05	-0.45	-0.45	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
PCPG	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	6.1	8.82e-09	1.09e-05	0.51	0.45	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
PCPG	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.1	8.83e-09	1.09e-05	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.1	8.83e-09	1.09e-05	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
PCPG	cis	rs7824557	0.527	rs2572376	ENSG00000255020.1	AF131216.5	-6.09	8.85e-09	1.09e-05	-0.58	-0.45	Retinal vascular caliber;	chr8:11380247	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs2736305	ENSG00000255020.1	AF131216.5	-6.09	8.85e-09	1.09e-05	-0.58	-0.45	Retinal vascular caliber;	chr8:11380264	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs4634600	ENSG00000255020.1	AF131216.5	-6.09	8.85e-09	1.09e-05	-0.58	-0.45	Retinal vascular caliber;	chr8:11381508	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs4631425	ENSG00000255020.1	AF131216.5	-6.09	8.85e-09	1.09e-05	-0.58	-0.45	Retinal vascular caliber;	chr8:11381545	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.585	rs4549730	ENSG00000255020.1	AF131216.5	-6.09	8.85e-09	1.09e-05	-0.58	-0.45	Neuroticism;	chr8:11381569	chr8:11345748~11347502:-
PCPG	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-6.09	8.91e-09	1.1e-05	-0.57	-0.45	Depression;	chr6:28206812	chr6:28115628~28116551:+
PCPG	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-6.09	8.93e-09	1.1e-05	-0.66	-0.45	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
PCPG	cis	rs7267979	0.966	rs2263204	ENSG00000125804.12	FAM182A	6.09	8.97e-09	1.11e-05	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2500417	ENSG00000125804.12	FAM182A	6.09	8.97e-09	1.11e-05	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:26054655~26086917:+
PCPG	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	6.09	9.04e-09	1.12e-05	0.55	0.45	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	6.09	9.04e-09	1.12e-05	0.55	0.45	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
PCPG	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-6.09	9.05e-09	1.12e-05	-0.55	-0.45	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
PCPG	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-6.09	9.06e-09	1.12e-05	-0.45	-0.45	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-6.09	9.06e-09	1.12e-05	-0.45	-0.45	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-6.09	9.06e-09	1.12e-05	-0.45	-0.45	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-6.09	9.06e-09	1.12e-05	-0.45	-0.45	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
PCPG	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-6.09	9.07e-09	1.12e-05	-0.59	-0.45	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
PCPG	cis	rs910316	0.737	rs175424	ENSG00000279594.1	RP11-950C14.10	-6.09	9.11e-09	1.12e-05	-0.59	-0.45	Height;	chr14:75159554	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.763	rs2080201	ENSG00000279594.1	RP11-950C14.10	-6.09	9.11e-09	1.12e-05	-0.59	-0.45	Height;	chr14:75163269	chr14:75011269~75012851:-
PCPG	cis	rs7267979	0.903	rs2500400	ENSG00000125804.12	FAM182A	6.09	9.12e-09	1.12e-05	0.53	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:26054655~26086917:+
PCPG	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-6.09	9.14e-09	1.13e-05	-0.43	-0.45	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
PCPG	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-6.09	9.16e-09	1.13e-05	-0.61	-0.45	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
PCPG	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	6.09	9.2e-09	1.13e-05	0.87	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
PCPG	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	6.09	9.21e-09	1.13e-05	0.58	0.45	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
PCPG	cis	rs7267979	0.565	rs4815437	ENSG00000125804.12	FAM182A	6.09	9.21e-09	1.13e-05	0.54	0.45	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26054655~26086917:+
PCPG	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-6.09	9.23e-09	1.14e-05	-0.47	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
PCPG	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-6.09	9.24e-09	1.14e-05	-0.59	-0.45	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-6.09	9.24e-09	1.14e-05	-0.59	-0.45	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-6.09	9.24e-09	1.14e-05	-0.59	-0.45	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
PCPG	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-6.09	9.24e-09	1.14e-05	-0.51	-0.45	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
PCPG	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-6.09	9.24e-09	1.14e-05	-0.49	-0.45	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-6.09	9.28e-09	1.14e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
PCPG	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	6.08	9.31e-09	1.14e-05	0.6	0.44	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
PCPG	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	6.08	9.32e-09	1.14e-05	0.64	0.44	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	6.08	9.32e-09	1.14e-05	0.64	0.44	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
PCPG	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-6.08	9.33e-09	1.15e-05	-0.45	-0.44	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
PCPG	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-6.08	9.34e-09	1.15e-05	-0.42	-0.44	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
PCPG	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-6.08	9.34e-09	1.15e-05	-0.43	-0.44	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
PCPG	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-6.08	9.39e-09	1.15e-05	-0.68	-0.44	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
PCPG	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-6.08	9.42e-09	1.15e-05	-0.64	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
PCPG	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	6.08	9.42e-09	1.15e-05	0.55	0.44	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
PCPG	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-6.08	9.48e-09	1.16e-05	-0.52	-0.44	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
PCPG	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-6.08	9.5e-09	1.16e-05	-0.61	-0.44	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-6.08	9.5e-09	1.16e-05	-0.61	-0.44	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-6.08	9.5e-09	1.16e-05	-0.61	-0.44	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-6.08	9.5e-09	1.16e-05	-0.61	-0.44	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-6.08	9.5e-09	1.16e-05	-0.61	-0.44	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
PCPG	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	6.08	9.53e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	6.08	9.53e-09	1.17e-05	0.76	0.44	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	6.08	9.53e-09	1.17e-05	0.76	0.44	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	6.08	9.53e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	6.08	9.54e-09	1.17e-05	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
PCPG	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-6.08	9.54e-09	1.17e-05	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
PCPG	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	6.08	9.55e-09	1.17e-05	0.76	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
PCPG	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	6.08	9.55e-09	1.17e-05	0.56	0.44	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
PCPG	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-6.08	9.55e-09	1.17e-05	-0.45	-0.44	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
PCPG	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-6.08	9.58e-09	1.17e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-6.08	9.58e-09	1.17e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-6.08	9.58e-09	1.17e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-6.08	9.58e-09	1.17e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-6.08	9.58e-09	1.17e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-6.08	9.58e-09	1.17e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-6.08	9.58e-09	1.17e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
PCPG	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	6.08	9.62e-09	1.17e-05	0.6	0.44	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	6.08	9.62e-09	1.17e-05	0.6	0.44	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	6.08	9.62e-09	1.17e-05	0.6	0.44	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
PCPG	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	6.08	9.62e-09	1.18e-05	0.89	0.44	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
PCPG	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-6.08	9.64e-09	1.18e-05	-0.48	-0.44	Height;	chr3:52819385	chr3:53064283~53065091:-
PCPG	cis	rs7267979	1	rs453329	ENSG00000125804.12	FAM182A	-6.08	9.64e-09	1.18e-05	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:26054655~26086917:+
PCPG	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-6.08	9.66e-09	1.18e-05	-0.63	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
PCPG	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-6.08	9.69e-09	1.18e-05	-0.66	-0.44	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
PCPG	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	6.08	9.69e-09	1.18e-05	0.62	0.44	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
PCPG	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-6.08	9.69e-09	1.18e-05	-0.54	-0.44	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
PCPG	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	6.08	9.72e-09	1.19e-05	0.58	0.44	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
PCPG	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-6.08	9.72e-09	1.19e-05	-0.58	-0.44	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
PCPG	cis	rs55665837	0.701	rs11023278	ENSG00000251991.1	RNU7-49P	6.08	9.74e-09	1.19e-05	0.5	0.44	Vitamin D levels;	chr11:14619638	chr11:14478892~14478953:+
PCPG	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-6.08	9.75e-09	1.19e-05	-0.51	-0.44	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
PCPG	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-6.07	9.8e-09	1.2e-05	-0.56	-0.44	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-6.07	9.8e-09	1.2e-05	-0.68	-0.44	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
PCPG	cis	rs7267979	1	rs2500443	ENSG00000125804.12	FAM182A	6.07	9.85e-09	1.2e-05	0.52	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482928	ENSG00000125804.12	FAM182A	6.07	9.85e-09	1.2e-05	0.52	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2500446	ENSG00000125804.12	FAM182A	6.07	9.85e-09	1.2e-05	0.52	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs2482937	ENSG00000125804.12	FAM182A	6.07	9.85e-09	1.2e-05	0.52	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:26054655~26086917:+
PCPG	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	6.07	9.85e-09	1.2e-05	0.58	0.44	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
PCPG	cis	rs7267979	1	rs12428	ENSG00000125804.12	FAM182A	6.07	9.88e-09	1.2e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:26054655~26086917:+
PCPG	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	6.07	9.88e-09	1.2e-05	0.47	0.44	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
PCPG	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-6.07	9.9e-09	1.21e-05	-0.55	-0.44	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
PCPG	cis	rs11951515	0.508	rs11958046	ENSG00000248240.1	RP11-159F24.5	-6.07	9.91e-09	1.21e-05	-0.5	-0.44	Metabolite levels  (X-11787);	chr5:43583287	chr5:43515274~43525310:+
PCPG	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-6.07	9.92e-09	1.21e-05	-0.54	-0.44	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
PCPG	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-6.07	9.93e-09	1.21e-05	-0.41	-0.44	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
PCPG	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-6.07	9.99e-09	1.22e-05	-0.63	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
PCPG	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-6.07	9.99e-09	1.22e-05	-0.63	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
PCPG	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-6.07	9.99e-09	1.22e-05	-0.63	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
PCPG	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-6.07	1e-08	1.22e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
PCPG	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-6.07	1e-08	1.22e-05	-0.51	-0.44	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
PCPG	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-6.07	1e-08	1.22e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
PCPG	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-6.07	1.01e-08	1.23e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-6.07	1.01e-08	1.23e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
PCPG	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-6.07	1.01e-08	1.23e-05	-0.63	-0.44	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
PCPG	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	6.07	1.01e-08	1.23e-05	0.64	0.44	Depression;	chr6:28430971	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	6.07	1.01e-08	1.23e-05	0.64	0.44	Depression;	chr6:28432562	chr6:28176188~28176674:+
PCPG	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	6.07	1.01e-08	1.23e-05	0.43	0.44	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
PCPG	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-6.07	1.01e-08	1.23e-05	-0.45	-0.44	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
PCPG	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-6.07	1.02e-08	1.23e-05	-0.64	-0.44	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-6.07	1.02e-08	1.23e-05	-0.64	-0.44	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-6.07	1.02e-08	1.23e-05	-0.64	-0.44	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
PCPG	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-6.07	1.02e-08	1.24e-05	-0.52	-0.44	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
PCPG	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	6.07	1.02e-08	1.24e-05	0.56	0.44	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
PCPG	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	6.07	1.02e-08	1.24e-05	0.56	0.44	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
PCPG	cis	rs73607972	0.696	rs9931018	ENSG00000275191.1	RP11-36I17.2	-6.07	1.02e-08	1.24e-05	-0.68	-0.44	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53529205	chr16:53628256~53628816:-
PCPG	cis	rs7267979	0.527	rs6083891	ENSG00000125804.12	FAM182A	6.07	1.02e-08	1.24e-05	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26054655~26086917:+
PCPG	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-6.07	1.02e-08	1.24e-05	-0.58	-0.44	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
PCPG	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	6.07	1.02e-08	1.24e-05	0.78	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
PCPG	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	6.07	1.02e-08	1.24e-05	0.55	0.44	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
PCPG	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-6.07	1.02e-08	1.24e-05	-0.6	-0.44	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
PCPG	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	6.07	1.02e-08	1.24e-05	0.61	0.44	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	6.07	1.02e-08	1.24e-05	0.61	0.44	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
PCPG	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-6.07	1.02e-08	1.24e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
PCPG	cis	rs11148252	0.846	rs7333451	ENSG00000235660.1	LINC00345	-6.07	1.03e-08	1.24e-05	-0.56	-0.44	Lewy body disease;	chr13:52473574	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.846	rs9379	ENSG00000235660.1	LINC00345	-6.07	1.03e-08	1.24e-05	-0.56	-0.44	Lewy body disease;	chr13:52476344	chr13:52484161~52484680:-
PCPG	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	6.06	1.03e-08	1.25e-05	0.59	0.44	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
PCPG	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-6.06	1.03e-08	1.25e-05	-0.53	-0.44	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-6.06	1.03e-08	1.25e-05	-0.53	-0.44	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
PCPG	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	6.06	1.03e-08	1.25e-05	0.59	0.44	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	6.06	1.03e-08	1.25e-05	0.59	0.44	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	6.06	1.03e-08	1.25e-05	0.59	0.44	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
PCPG	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	-6.06	1.03e-08	1.25e-05	-0.52	-0.44	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
PCPG	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-6.06	1.04e-08	1.26e-05	-0.47	-0.44	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-6.06	1.04e-08	1.26e-05	-0.47	-0.44	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
PCPG	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-6.06	1.04e-08	1.26e-05	-0.52	-0.44	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
PCPG	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	6.06	1.04e-08	1.26e-05	0.58	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
PCPG	cis	rs10435719	0.902	rs7459545	ENSG00000255020.1	AF131216.5	6.06	1.04e-08	1.26e-05	0.61	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:11345748~11347502:-
PCPG	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	6.06	1.05e-08	1.27e-05	0.5	0.44	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	6.06	1.05e-08	1.27e-05	0.5	0.44	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	6.06	1.05e-08	1.27e-05	0.5	0.44	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
PCPG	cis	rs7267979	1	rs2500432	ENSG00000125804.12	FAM182A	-6.06	1.05e-08	1.27e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:26054655~26086917:+
PCPG	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-6.06	1.05e-08	1.28e-05	-0.9	-0.44	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-6.06	1.05e-08	1.28e-05	-0.9	-0.44	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
PCPG	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-6.06	1.06e-08	1.28e-05	-0.53	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-6.06	1.06e-08	1.28e-05	-0.53	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
PCPG	cis	rs2625529	0.73	rs2929528	ENSG00000260037.4	CTD-2524L6.3	6.06	1.06e-08	1.28e-05	0.62	0.44	Red blood cell count;	chr15:71976996	chr15:71818396~71823384:+
PCPG	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-6.06	1.06e-08	1.28e-05	-0.45	-0.44	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-6.06	1.06e-08	1.28e-05	-0.45	-0.44	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-6.06	1.06e-08	1.28e-05	-0.45	-0.44	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-6.06	1.06e-08	1.28e-05	-0.45	-0.44	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
PCPG	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-6.06	1.06e-08	1.28e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
PCPG	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	6.06	1.06e-08	1.28e-05	0.65	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
PCPG	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	6.06	1.06e-08	1.29e-05	0.56	0.44	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
PCPG	cis	rs2625529	0.73	rs2957368	ENSG00000260037.4	CTD-2524L6.3	-6.06	1.07e-08	1.29e-05	-0.64	-0.44	Red blood cell count;	chr15:72037565	chr15:71818396~71823384:+
PCPG	cis	rs950169	0.922	rs62029585	ENSG00000259295.5	CSPG4P12	6.06	1.07e-08	1.29e-05	0.68	0.44	Schizophrenia;	chr15:84397176	chr15:85191438~85213905:+
PCPG	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-6.06	1.07e-08	1.29e-05	-0.52	-0.44	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
PCPG	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-6.06	1.07e-08	1.29e-05	-0.45	-0.44	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
PCPG	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	6.06	1.07e-08	1.3e-05	0.62	0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
PCPG	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	6.06	1.07e-08	1.3e-05	0.65	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	6.06	1.07e-08	1.3e-05	0.65	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
PCPG	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	6.05	1.09e-08	1.31e-05	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
PCPG	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	6.05	1.09e-08	1.31e-05	0.57	0.44	Depression;	chr6:28187640	chr6:28115628~28116551:+
PCPG	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	6.05	1.09e-08	1.32e-05	0.6	0.44	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
PCPG	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-6.05	1.09e-08	1.32e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-6.05	1.09e-08	1.32e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-6.05	1.09e-08	1.32e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-6.05	1.09e-08	1.32e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-6.05	1.09e-08	1.32e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-6.05	1.09e-08	1.32e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-6.05	1.09e-08	1.32e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
PCPG	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	6.05	1.1e-08	1.32e-05	0.58	0.44	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
PCPG	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-6.05	1.1e-08	1.32e-05	-0.52	-0.44	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
PCPG	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-6.05	1.1e-08	1.33e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-6.05	1.1e-08	1.33e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
PCPG	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-6.05	1.1e-08	1.33e-05	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
PCPG	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	6.05	1.1e-08	1.33e-05	0.47	0.44	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
PCPG	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-6.05	1.1e-08	1.33e-05	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
PCPG	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	6.05	1.1e-08	1.33e-05	0.54	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
PCPG	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-6.05	1.11e-08	1.33e-05	-0.54	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
PCPG	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	6.05	1.11e-08	1.33e-05	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
PCPG	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	6.05	1.11e-08	1.34e-05	0.42	0.44	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
PCPG	cis	rs2625529	0.73	rs2957373	ENSG00000260037.4	CTD-2524L6.3	6.05	1.11e-08	1.34e-05	0.62	0.44	Red blood cell count;	chr15:72048588	chr15:71818396~71823384:+
PCPG	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-6.05	1.12e-08	1.34e-05	-0.66	-0.44	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
PCPG	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	6.05	1.12e-08	1.34e-05	0.65	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	6.05	1.12e-08	1.34e-05	0.65	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
PCPG	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-6.05	1.12e-08	1.34e-05	-0.54	-0.44	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
PCPG	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	6.05	1.12e-08	1.34e-05	0.5	0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
PCPG	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	6.05	1.12e-08	1.35e-05	0.58	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
PCPG	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-6.05	1.12e-08	1.35e-05	-0.48	-0.44	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
PCPG	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-6.05	1.12e-08	1.35e-05	-0.76	-0.44	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
PCPG	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	6.05	1.12e-08	1.35e-05	0.64	0.44	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
PCPG	cis	rs7267979	0.903	rs6132819	ENSG00000125804.12	FAM182A	-6.05	1.13e-08	1.35e-05	-0.53	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:26054655~26086917:+
PCPG	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	6.05	1.13e-08	1.35e-05	0.37	0.44	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
PCPG	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	6.05	1.13e-08	1.35e-05	0.57	0.44	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
PCPG	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	6.05	1.13e-08	1.35e-05	0.57	0.44	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
PCPG	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-6.05	1.13e-08	1.36e-05	-0.45	-0.44	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
PCPG	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-6.05	1.13e-08	1.36e-05	-0.63	-0.44	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
PCPG	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	6.04	1.13e-08	1.36e-05	0.61	0.44	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
PCPG	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	6.04	1.14e-08	1.37e-05	0.6	0.44	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
PCPG	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	-6.04	1.14e-08	1.37e-05	-0.51	-0.44	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
PCPG	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-6.04	1.15e-08	1.38e-05	-0.47	-0.44	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
PCPG	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	6.04	1.15e-08	1.38e-05	0.61	0.44	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
PCPG	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	6.04	1.16e-08	1.38e-05	0.59	0.44	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
PCPG	cis	rs7688540	0.8	rs7694325	ENSG00000275426.1	CH17-262A2.1	6.04	1.16e-08	1.38e-05	0.54	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:149738~150317:+
PCPG	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	6.04	1.16e-08	1.38e-05	0.57	0.44	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
PCPG	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-6.04	1.16e-08	1.38e-05	-0.51	-0.44	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
PCPG	cis	rs7267979	0.932	rs928121	ENSG00000125804.12	FAM182A	-6.04	1.16e-08	1.39e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:26054655~26086917:+
PCPG	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	6.04	1.16e-08	1.39e-05	0.6	0.44	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
PCPG	cis	rs7267979	0.527	rs6076369	ENSG00000125804.12	FAM182A	6.04	1.16e-08	1.39e-05	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26054655~26086917:+
PCPG	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
PCPG	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-6.04	1.17e-08	1.39e-05	-0.45	-0.44	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
PCPG	cis	rs7267979	0.873	rs7453	ENSG00000125804.12	FAM182A	-6.04	1.17e-08	1.4e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:26054655~26086917:+
PCPG	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-6.04	1.17e-08	1.4e-05	-0.51	-0.44	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
PCPG	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-6.04	1.17e-08	1.4e-05	-0.64	-0.44	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
PCPG	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-6.04	1.17e-08	1.4e-05	-0.64	-0.44	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
PCPG	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	6.04	1.17e-08	1.4e-05	0.64	0.44	Depression;	chr6:28364057	chr6:28176188~28176674:+
PCPG	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-6.04	1.18e-08	1.41e-05	-0.53	-0.44	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
PCPG	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	6.04	1.18e-08	1.41e-05	0.57	0.44	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	6.04	1.18e-08	1.41e-05	0.57	0.44	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
PCPG	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-6.04	1.19e-08	1.42e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-6.04	1.19e-08	1.42e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-6.04	1.19e-08	1.42e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
PCPG	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-6.04	1.19e-08	1.42e-05	-0.57	-0.44	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-6.04	1.19e-08	1.42e-05	-0.57	-0.44	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
PCPG	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-6.03	1.2e-08	1.43e-05	-0.63	-0.44	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
PCPG	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-6.03	1.2e-08	1.43e-05	-0.48	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
PCPG	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-6.03	1.2e-08	1.43e-05	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
PCPG	cis	rs2625529	0.775	rs16956273	ENSG00000260037.4	CTD-2524L6.3	-6.03	1.21e-08	1.44e-05	-0.67	-0.44	Red blood cell count;	chr15:71824761	chr15:71818396~71823384:+
PCPG	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-6.03	1.21e-08	1.44e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
PCPG	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	6.03	1.21e-08	1.44e-05	0.59	0.44	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
PCPG	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-6.03	1.21e-08	1.44e-05	-0.54	-0.44	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-6.03	1.21e-08	1.44e-05	-0.54	-0.44	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-6.03	1.21e-08	1.44e-05	-0.54	-0.44	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
PCPG	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	6.03	1.22e-08	1.45e-05	0.6	0.44	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
PCPG	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-6.03	1.22e-08	1.45e-05	-0.57	-0.44	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-6.03	1.22e-08	1.45e-05	-0.57	-0.44	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-6.03	1.22e-08	1.45e-05	-0.57	-0.44	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-6.03	1.22e-08	1.45e-05	-0.57	-0.44	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
PCPG	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-6.03	1.22e-08	1.45e-05	-0.56	-0.44	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
PCPG	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	6.03	1.22e-08	1.45e-05	0.61	0.44	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	6.03	1.22e-08	1.45e-05	0.61	0.44	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
PCPG	cis	rs9595908	0.863	rs11616287	ENSG00000212293.1	SNORA16	6.03	1.22e-08	1.45e-05	0.52	0.44	Body mass index;	chr13:32580139	chr13:32420390~32420516:-
PCPG	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-6.03	1.22e-08	1.45e-05	-0.54	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
PCPG	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-6.03	1.22e-08	1.45e-05	-0.54	-0.44	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
PCPG	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	6.03	1.23e-08	1.46e-05	0.58	0.44	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
PCPG	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-6.03	1.23e-08	1.46e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
PCPG	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-6.03	1.23e-08	1.46e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
PCPG	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	6.03	1.23e-08	1.46e-05	0.54	0.44	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
PCPG	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-6.03	1.24e-08	1.47e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
PCPG	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.03	1.25e-08	1.48e-05	-0.53	-0.44	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
PCPG	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-6.03	1.25e-08	1.48e-05	-0.46	-0.44	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
PCPG	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	6.03	1.25e-08	1.48e-05	0.43	0.44	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
PCPG	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-6.02	1.25e-08	1.49e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-6.02	1.25e-08	1.49e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-6.02	1.25e-08	1.49e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
PCPG	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-6.02	1.25e-08	1.49e-05	-0.51	-0.44	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
PCPG	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	6.02	1.26e-08	1.49e-05	0.62	0.44	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
PCPG	cis	rs9595908	0.746	rs3848087	ENSG00000212293.1	SNORA16	6.02	1.26e-08	1.49e-05	0.55	0.44	Body mass index;	chr13:32697637	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs1029306	ENSG00000212293.1	SNORA16	6.02	1.26e-08	1.49e-05	0.55	0.44	Body mass index;	chr13:32707695	chr13:32420390~32420516:-
PCPG	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-6.02	1.26e-08	1.49e-05	-0.64	-0.44	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
PCPG	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	6.02	1.26e-08	1.49e-05	0.46	0.44	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
PCPG	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-6.02	1.26e-08	1.5e-05	-0.59	-0.44	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
PCPG	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-6.02	1.26e-08	1.5e-05	-0.51	-0.44	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
PCPG	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	6.02	1.27e-08	1.5e-05	0.61	0.44	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
PCPG	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	6.02	1.27e-08	1.51e-05	0.56	0.44	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
PCPG	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	6.02	1.27e-08	1.51e-05	0.44	0.44	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
PCPG	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	6.02	1.27e-08	1.51e-05	0.44	0.44	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
PCPG	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-6.02	1.27e-08	1.51e-05	-0.61	-0.44	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
PCPG	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	6.02	1.28e-08	1.51e-05	0.63	0.44	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	6.02	1.28e-08	1.51e-05	0.63	0.44	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
PCPG	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	6.02	1.28e-08	1.51e-05	0.51	0.44	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
PCPG	cis	rs7267979	0.932	rs4280527	ENSG00000125804.12	FAM182A	-6.02	1.28e-08	1.52e-05	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:26054655~26086917:+
PCPG	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-6.02	1.28e-08	1.52e-05	-0.51	-0.44	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
PCPG	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	6.02	1.29e-08	1.52e-05	0.51	0.44	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
PCPG	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	6.02	1.29e-08	1.52e-05	0.59	0.44	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
PCPG	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	6.02	1.29e-08	1.52e-05	0.43	0.44	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
PCPG	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	6.02	1.29e-08	1.52e-05	0.43	0.44	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
PCPG	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-6.02	1.29e-08	1.53e-05	-0.51	-0.44	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
PCPG	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	6.02	1.29e-08	1.53e-05	0.44	0.44	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
PCPG	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	6.02	1.29e-08	1.53e-05	0.44	0.44	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
PCPG	cis	rs910316	0.503	rs12894709	ENSG00000279594.1	RP11-950C14.10	6.02	1.3e-08	1.53e-05	0.56	0.44	Height;	chr14:74975031	chr14:75011269~75012851:-
PCPG	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-6.02	1.3e-08	1.53e-05	-0.64	-0.44	Depression;	chr6:28422360	chr6:28176188~28176674:+
PCPG	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	-6.02	1.3e-08	1.54e-05	-0.52	-0.44	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
PCPG	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-6.02	1.3e-08	1.54e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-6.02	1.3e-08	1.54e-05	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
PCPG	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-6.02	1.31e-08	1.54e-05	-0.53	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
PCPG	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-6.02	1.31e-08	1.55e-05	-0.6	-0.44	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
PCPG	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-6.02	1.32e-08	1.55e-05	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
PCPG	cis	rs853679	0.506	rs1150693	ENSG00000216901.1	AL022393.7	6.02	1.32e-08	1.55e-05	0.61	0.44	Depression;	chr6:28206812	chr6:28176188~28176674:+
PCPG	cis	rs7267979	0.844	rs8184820	ENSG00000125804.12	FAM182A	6.01	1.32e-08	1.56e-05	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:26054655~26086917:+
PCPG	cis	rs748404	0.578	rs2584701	ENSG00000249839.1	AC011330.5	-6.01	1.32e-08	1.56e-05	-0.52	-0.44	Lung cancer;	chr15:43392741	chr15:43663654~43684339:-
PCPG	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-6.01	1.32e-08	1.56e-05	-0.48	-0.44	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
PCPG	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	6.01	1.34e-08	1.58e-05	0.58	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
PCPG	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	6.01	1.34e-08	1.58e-05	0.39	0.44	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	6.01	1.34e-08	1.58e-05	0.39	0.44	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	6.01	1.34e-08	1.58e-05	0.39	0.44	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
PCPG	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-6.01	1.35e-08	1.59e-05	-0.57	-0.44	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-6.01	1.35e-08	1.59e-05	-0.57	-0.44	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-6.01	1.35e-08	1.59e-05	-0.57	-0.44	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-6.01	1.35e-08	1.59e-05	-0.57	-0.44	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-6.01	1.35e-08	1.59e-05	-0.57	-0.44	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-6.01	1.35e-08	1.59e-05	-0.57	-0.44	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-6.01	1.35e-08	1.59e-05	-0.57	-0.44	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
PCPG	cis	rs910316	0.692	rs7156586	ENSG00000279594.1	RP11-950C14.10	6.01	1.35e-08	1.59e-05	0.69	0.44	Height;	chr14:75039527	chr14:75011269~75012851:-
PCPG	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-6.01	1.35e-08	1.59e-05	-0.49	-0.44	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
PCPG	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	6.01	1.36e-08	1.6e-05	0.71	0.44	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
PCPG	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	6.01	1.36e-08	1.6e-05	0.71	0.44	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
PCPG	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-6.01	1.36e-08	1.6e-05	-0.43	-0.44	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
PCPG	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	6.01	1.36e-08	1.61e-05	0.54	0.44	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
PCPG	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	6.01	1.37e-08	1.61e-05	0.62	0.44	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
PCPG	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-6.01	1.37e-08	1.61e-05	-0.61	-0.44	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
PCPG	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-6.01	1.37e-08	1.61e-05	-0.55	-0.44	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
PCPG	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-6.01	1.37e-08	1.61e-05	-0.52	-0.44	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
PCPG	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-6.01	1.37e-08	1.61e-05	-0.52	-0.44	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
PCPG	cis	rs853679	1	rs6901575	ENSG00000216901.1	AL022393.7	6.01	1.37e-08	1.61e-05	0.75	0.44	Depression;	chr6:28283207	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	6.01	1.37e-08	1.61e-05	0.61	0.44	Depression;	chr6:28363475	chr6:28176188~28176674:+
PCPG	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	6.01	1.37e-08	1.61e-05	0.91	0.44	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
PCPG	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-6.01	1.37e-08	1.62e-05	-0.73	-0.44	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
PCPG	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-6.01	1.37e-08	1.62e-05	-0.41	-0.44	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
PCPG	cis	rs7267979	0.934	rs4815423	ENSG00000125804.12	FAM182A	6.01	1.38e-08	1.62e-05	0.51	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:26054655~26086917:+
PCPG	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-6.01	1.38e-08	1.62e-05	-0.48	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
PCPG	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-6.01	1.38e-08	1.62e-05	-0.41	-0.44	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
PCPG	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-6.01	1.38e-08	1.62e-05	-0.62	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
PCPG	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	6	1.39e-08	1.63e-05	0.55	0.44	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
PCPG	cis	rs2412819	0.545	rs654276	ENSG00000205771.5	CATSPER2P1	6	1.39e-08	1.63e-05	0.57	0.44	Lung cancer;	chr15:43798656	chr15:43726918~43747094:-
PCPG	cis	rs10435719	0.718	rs7813935	ENSG00000255020.1	AF131216.5	6	1.39e-08	1.63e-05	0.6	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.504	rs7830734	ENSG00000255020.1	AF131216.5	6	1.39e-08	1.63e-05	0.6	0.44	Neuroticism;	chr8:11938130	chr8:11345748~11347502:-
PCPG	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	6	1.39e-08	1.64e-05	0.56	0.44	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	6	1.39e-08	1.64e-05	0.56	0.44	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
PCPG	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-6	1.4e-08	1.64e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-6	1.4e-08	1.64e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-6	1.4e-08	1.64e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-6	1.4e-08	1.64e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-6	1.4e-08	1.64e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
PCPG	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	-6	1.4e-08	1.65e-05	-0.51	-0.44	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
PCPG	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	6	1.4e-08	1.65e-05	0.6	0.44	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
PCPG	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	6	1.41e-08	1.65e-05	0.49	0.44	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	6	1.41e-08	1.65e-05	0.49	0.44	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	6	1.41e-08	1.65e-05	0.49	0.44	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	6	1.41e-08	1.65e-05	0.49	0.44	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	6	1.41e-08	1.65e-05	0.49	0.44	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	6	1.41e-08	1.65e-05	0.49	0.44	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
PCPG	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	6	1.41e-08	1.65e-05	0.43	0.44	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
PCPG	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	6	1.41e-08	1.65e-05	0.43	0.44	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
PCPG	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	6	1.41e-08	1.65e-05	0.61	0.44	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
PCPG	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-6	1.41e-08	1.65e-05	-0.44	-0.44	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
PCPG	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-6	1.41e-08	1.65e-05	-0.44	-0.44	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
PCPG	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	6	1.41e-08	1.65e-05	0.58	0.44	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
PCPG	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	6	1.41e-08	1.65e-05	0.48	0.44	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
PCPG	cis	rs7688540	0.771	rs10005733	ENSG00000275426.1	CH17-262A2.1	6	1.41e-08	1.65e-05	0.56	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:149738~150317:+
PCPG	cis	rs7824557	0.527	rs2572449	ENSG00000255020.1	AF131216.5	6	1.42e-08	1.66e-05	0.57	0.44	Retinal vascular caliber;	chr8:11381628	chr8:11345748~11347502:-
PCPG	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-6	1.42e-08	1.66e-05	-0.55	-0.44	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
PCPG	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	6	1.42e-08	1.66e-05	0.49	0.44	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
PCPG	cis	rs9595908	1	rs7999125	ENSG00000212293.1	SNORA16	6	1.42e-08	1.66e-05	0.53	0.44	Body mass index;	chr13:32571858	chr13:32420390~32420516:-
PCPG	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-6	1.42e-08	1.66e-05	-0.49	-0.44	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
PCPG	cis	rs804280	0.509	rs9886639	ENSG00000255020.1	AF131216.5	6	1.42e-08	1.66e-05	0.58	0.44	Myopia (pathological);	chr8:11927020	chr8:11345748~11347502:-
PCPG	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	6	1.42e-08	1.66e-05	0.54	0.44	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	6	1.42e-08	1.66e-05	0.54	0.44	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
PCPG	cis	rs853679	0.55	rs9295762	ENSG00000216901.1	AL022393.7	-6	1.43e-08	1.67e-05	-0.61	-0.44	Depression;	chr6:28187640	chr6:28176188~28176674:+
PCPG	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-6	1.43e-08	1.67e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-6	1.43e-08	1.67e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
PCPG	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	6	1.43e-08	1.67e-05	0.54	0.44	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
PCPG	cis	rs453301	0.686	rs2409120	ENSG00000173295.6	FAM86B3P	6	1.43e-08	1.67e-05	0.51	0.44	Joint mobility (Beighton score);	chr8:9025061	chr8:8228595~8244865:+
PCPG	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-6	1.43e-08	1.68e-05	-0.52	-0.44	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
PCPG	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-6	1.44e-08	1.68e-05	-0.51	-0.44	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
PCPG	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	6	1.44e-08	1.68e-05	0.73	0.44	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
PCPG	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-6	1.44e-08	1.69e-05	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
PCPG	cis	rs2412819	0.571	rs514255	ENSG00000205771.5	CATSPER2P1	-6	1.44e-08	1.69e-05	-0.53	-0.44	Lung cancer;	chr15:43893134	chr15:43726918~43747094:-
PCPG	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	6	1.44e-08	1.69e-05	0.59	0.44	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
PCPG	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-6	1.45e-08	1.69e-05	-0.48	-0.44	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
PCPG	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-6	1.45e-08	1.69e-05	-0.57	-0.44	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
PCPG	cis	rs12291225	0.535	rs11023203	ENSG00000251991.1	RNU7-49P	6	1.45e-08	1.69e-05	0.52	0.44	Sense of smell;	chr11:14388269	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.524	rs2882128	ENSG00000251991.1	RNU7-49P	6	1.45e-08	1.69e-05	0.52	0.44	Vitamin D levels;	chr11:14393088	chr11:14478892~14478953:+
PCPG	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	6	1.45e-08	1.7e-05	0.57	0.44	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
PCPG	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-5.99	1.46e-08	1.71e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
PCPG	cis	rs11951515	0.508	rs6860493	ENSG00000248240.1	RP11-159F24.5	-5.99	1.46e-08	1.71e-05	-0.49	-0.44	Metabolite levels  (X-11787);	chr5:43602611	chr5:43515274~43525310:+
PCPG	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-5.99	1.47e-08	1.71e-05	-0.58	-0.44	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
PCPG	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-5.99	1.48e-08	1.72e-05	-0.5	-0.44	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-5.99	1.48e-08	1.72e-05	-0.5	-0.44	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-5.99	1.48e-08	1.72e-05	-0.5	-0.44	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-5.99	1.48e-08	1.72e-05	-0.5	-0.44	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-5.99	1.48e-08	1.72e-05	-0.5	-0.44	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
PCPG	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-5.99	1.48e-08	1.72e-05	-0.56	-0.44	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
PCPG	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	5.99	1.48e-08	1.72e-05	0.46	0.44	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
PCPG	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-5.99	1.48e-08	1.73e-05	-0.48	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
PCPG	cis	rs7267979	0.966	rs4813557	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815404	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6083805	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050544	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6037095	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050562	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815408	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4813563	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs6037103	ENSG00000125804.12	FAM182A	5.99	1.49e-08	1.74e-05	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.933	rs1130694	ENSG00000125804.12	FAM182A	-5.99	1.49e-08	1.74e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs7018	ENSG00000125804.12	FAM182A	-5.99	1.49e-08	1.74e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:26054655~26086917:+
PCPG	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	5.99	1.5e-08	1.74e-05	0.43	0.44	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
PCPG	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	5.99	1.5e-08	1.74e-05	0.43	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
PCPG	cis	rs11148252	0.716	rs3803262	ENSG00000235660.1	LINC00345	-5.99	1.5e-08	1.75e-05	-0.56	-0.44	Lewy body disease;	chr13:52462263	chr13:52484161~52484680:-
PCPG	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-5.99	1.51e-08	1.75e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
PCPG	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	5.99	1.51e-08	1.75e-05	0.67	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	5.99	1.51e-08	1.75e-05	0.67	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	5.99	1.51e-08	1.75e-05	0.67	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
PCPG	cis	rs7267979	0.868	rs6138553	ENSG00000125804.12	FAM182A	-5.99	1.51e-08	1.76e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.903	rs6115109	ENSG00000125804.12	FAM182A	-5.99	1.51e-08	1.76e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.833	rs4619688	ENSG00000125804.12	FAM182A	-5.99	1.51e-08	1.76e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.903	rs6115118	ENSG00000125804.12	FAM182A	-5.99	1.51e-08	1.76e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.903	rs1118963	ENSG00000125804.12	FAM182A	-5.99	1.51e-08	1.76e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.833	rs6138556	ENSG00000125804.12	FAM182A	-5.99	1.52e-08	1.76e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:26054655~26086917:+
PCPG	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	5.99	1.52e-08	1.76e-05	0.59	0.44	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
PCPG	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-5.99	1.52e-08	1.76e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-5.99	1.52e-08	1.76e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-5.99	1.52e-08	1.76e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
PCPG	cis	rs7688540	0.8	rs12501727	ENSG00000275426.1	CH17-262A2.1	5.99	1.53e-08	1.77e-05	0.53	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:149738~150317:+
PCPG	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	5.99	1.53e-08	1.77e-05	0.6	0.44	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	5.99	1.53e-08	1.77e-05	0.6	0.44	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
PCPG	cis	rs9595908	0.832	rs13378546	ENSG00000212293.1	SNORA16	5.98	1.53e-08	1.78e-05	0.54	0.44	Body mass index;	chr13:32631522	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.832	rs9315172	ENSG00000212293.1	SNORA16	5.98	1.53e-08	1.78e-05	0.54	0.44	Body mass index;	chr13:32634035	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.832	rs9595976	ENSG00000212293.1	SNORA16	5.98	1.53e-08	1.78e-05	0.54	0.44	Body mass index;	chr13:32637910	chr13:32420390~32420516:-
PCPG	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-5.98	1.54e-08	1.78e-05	-0.48	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
PCPG	cis	rs7267979	0.933	rs11699203	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.933	rs6138571	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs416745	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs448396	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs447722	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs422424	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs422844	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs401166	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs404394	ENSG00000125804.12	FAM182A	-5.98	1.54e-08	1.78e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:26054655~26086917:+
PCPG	cis	rs73607972	0.696	rs7201237	ENSG00000275191.1	RP11-36I17.2	-5.98	1.54e-08	1.79e-05	-0.65	-0.44	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53526005	chr16:53628256~53628816:-
PCPG	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	5.98	1.55e-08	1.79e-05	0.61	0.44	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	5.98	1.55e-08	1.79e-05	0.61	0.44	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	5.98	1.55e-08	1.79e-05	0.61	0.44	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
PCPG	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	5.98	1.57e-08	1.82e-05	0.48	0.44	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
PCPG	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	5.98	1.57e-08	1.82e-05	0.6	0.44	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
PCPG	cis	rs7267979	0.528	rs6076366	ENSG00000125804.12	FAM182A	5.98	1.57e-08	1.82e-05	0.53	0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26054655~26086917:+
PCPG	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-5.98	1.58e-08	1.82e-05	-0.63	-0.44	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
PCPG	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-5.98	1.58e-08	1.83e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
PCPG	cis	rs910316	0.737	rs175048	ENSG00000279594.1	RP11-950C14.10	-5.98	1.59e-08	1.83e-05	-0.57	-0.44	Height;	chr14:75013191	chr14:75011269~75012851:-
PCPG	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-5.98	1.59e-08	1.84e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-5.98	1.59e-08	1.84e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-5.98	1.59e-08	1.84e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
PCPG	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-5.98	1.59e-08	1.84e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
PCPG	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-5.98	1.59e-08	1.84e-05	-0.45	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs133381	ENSG00000205702.9	CYP2D7	5.98	1.59e-08	1.84e-05	0.45	0.44	Schizophrenia;	chr22:42074604	chr22:42140203~42144577:-
PCPG	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-5.98	1.59e-08	1.84e-05	-0.54	-0.44	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
PCPG	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	5.98	1.59e-08	1.84e-05	0.4	0.44	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	5.98	1.59e-08	1.84e-05	0.4	0.44	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
PCPG	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	5.98	1.6e-08	1.85e-05	0.56	0.44	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-5.98	1.6e-08	1.85e-05	-0.56	-0.44	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
PCPG	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-5.98	1.6e-08	1.85e-05	-0.56	-0.44	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
PCPG	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	5.98	1.6e-08	1.85e-05	0.59	0.44	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
PCPG	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	5.97	1.61e-08	1.85e-05	0.48	0.44	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
PCPG	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	5.97	1.61e-08	1.85e-05	0.48	0.44	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	5.97	1.61e-08	1.85e-05	0.48	0.44	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	5.97	1.61e-08	1.85e-05	0.48	0.44	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
PCPG	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	5.97	1.62e-08	1.86e-05	0.59	0.44	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
PCPG	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	5.97	1.62e-08	1.86e-05	0.49	0.44	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
PCPG	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	5.97	1.62e-08	1.86e-05	0.53	0.44	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
PCPG	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-5.97	1.62e-08	1.87e-05	-0.43	-0.44	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
PCPG	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	5.97	1.63e-08	1.87e-05	0.72	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
PCPG	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-5.97	1.63e-08	1.88e-05	-0.48	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-5.97	1.63e-08	1.88e-05	-0.48	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
PCPG	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-5.97	1.63e-08	1.88e-05	-0.63	-0.44	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
PCPG	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-5.97	1.63e-08	1.88e-05	-0.42	-0.44	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
PCPG	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	5.97	1.63e-08	1.88e-05	0.6	0.44	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
PCPG	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	5.97	1.64e-08	1.88e-05	0.54	0.44	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
PCPG	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-5.97	1.64e-08	1.89e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
PCPG	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	5.97	1.64e-08	1.89e-05	0.6	0.44	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	5.97	1.64e-08	1.89e-05	0.6	0.44	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
PCPG	cis	rs55665837	0.583	rs78843135	ENSG00000251991.1	RNU7-49P	5.97	1.65e-08	1.89e-05	0.52	0.44	Vitamin D levels;	chr11:14389708	chr11:14478892~14478953:+
PCPG	cis	rs1023500	0.596	rs5751204	ENSG00000205702.9	CYP2D7	5.97	1.65e-08	1.89e-05	0.45	0.44	Schizophrenia;	chr22:42037797	chr22:42140203~42144577:-
PCPG	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	5.97	1.65e-08	1.9e-05	0.63	0.44	Depression;	chr6:28399846	chr6:28176188~28176674:+
PCPG	cis	rs7824557	0.767	rs6991606	ENSG00000255020.1	AF131216.5	5.97	1.65e-08	1.9e-05	0.57	0.44	Retinal vascular caliber;	chr8:11318650	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.737	rs2293855	ENSG00000255020.1	AF131216.5	5.97	1.65e-08	1.9e-05	0.57	0.44	Retinal vascular caliber;	chr8:11319901	chr8:11345748~11347502:-
PCPG	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-5.97	1.65e-08	1.9e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
PCPG	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-5.97	1.66e-08	1.9e-05	-0.48	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
PCPG	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	5.97	1.66e-08	1.9e-05	0.77	0.44	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
PCPG	cis	rs910316	0.934	rs8016330	ENSG00000279594.1	RP11-950C14.10	-5.97	1.66e-08	1.9e-05	-0.55	-0.44	Height;	chr14:75190804	chr14:75011269~75012851:-
PCPG	cis	rs910316	0.967	rs11624893	ENSG00000279594.1	RP11-950C14.10	-5.97	1.66e-08	1.9e-05	-0.55	-0.44	Height;	chr14:75193421	chr14:75011269~75012851:-
PCPG	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-5.97	1.66e-08	1.9e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-5.97	1.66e-08	1.9e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
PCPG	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-5.97	1.66e-08	1.9e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-5.97	1.66e-08	1.9e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-5.97	1.66e-08	1.9e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-5.97	1.66e-08	1.9e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-5.97	1.66e-08	1.9e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
PCPG	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	5.97	1.66e-08	1.9e-05	0.55	0.44	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
PCPG	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-5.97	1.66e-08	1.9e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
PCPG	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	5.97	1.66e-08	1.9e-05	0.6	0.44	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
PCPG	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	5.97	1.66e-08	1.9e-05	0.57	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
PCPG	cis	rs12291225	0.535	rs12806025	ENSG00000251991.1	RNU7-49P	5.97	1.66e-08	1.91e-05	0.5	0.44	Sense of smell;	chr11:14392271	chr11:14478892~14478953:+
PCPG	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	5.97	1.67e-08	1.92e-05	0.44	0.44	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
PCPG	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-5.97	1.68e-08	1.92e-05	-0.63	-0.44	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
PCPG	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-5.97	1.69e-08	1.93e-05	-0.61	-0.44	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
PCPG	cis	rs453301	0.624	rs2979256	ENSG00000173295.6	FAM86B3P	-5.96	1.69e-08	1.93e-05	-0.5	-0.44	Joint mobility (Beighton score);	chr8:9014200	chr8:8228595~8244865:+
PCPG	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	5.96	1.7e-08	1.94e-05	0.47	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
PCPG	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-5.96	1.7e-08	1.94e-05	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-5.96	1.7e-08	1.94e-05	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
PCPG	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	5.96	1.7e-08	1.94e-05	0.45	0.44	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
PCPG	cis	rs7826238	0.584	rs1107826	ENSG00000173295.6	FAM86B3P	-5.96	1.7e-08	1.95e-05	-0.47	-0.44	Systolic blood pressure;	chr8:8453594	chr8:8228595~8244865:+
PCPG	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-5.96	1.71e-08	1.95e-05	-0.59	-0.44	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
PCPG	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-5.96	1.71e-08	1.95e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-5.96	1.71e-08	1.95e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
PCPG	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-5.96	1.71e-08	1.95e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
PCPG	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	5.96	1.71e-08	1.96e-05	0.58	0.44	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs1419183	ENSG00000216901.1	AL022393.7	5.96	1.72e-08	1.96e-05	0.74	0.44	Depression;	chr6:28275017	chr6:28176188~28176674:+
PCPG	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	5.96	1.72e-08	1.97e-05	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
PCPG	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-5.96	1.72e-08	1.97e-05	-0.4	-0.44	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
PCPG	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-5.96	1.72e-08	1.97e-05	-0.49	-0.44	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
PCPG	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-5.96	1.73e-08	1.98e-05	-0.53	-0.44	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
PCPG	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	5.96	1.73e-08	1.98e-05	0.43	0.44	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
PCPG	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	5.96	1.73e-08	1.98e-05	0.57	0.44	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	5.96	1.73e-08	1.98e-05	0.57	0.44	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	5.96	1.73e-08	1.98e-05	0.57	0.44	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	5.96	1.73e-08	1.98e-05	0.57	0.44	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
PCPG	cis	rs10131894	0.611	rs175002	ENSG00000279594.1	RP11-950C14.10	5.96	1.75e-08	1.99e-05	0.55	0.44	Coronary artery disease;	chr14:74969763	chr14:75011269~75012851:-
PCPG	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	5.96	1.75e-08	2e-05	0.71	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
PCPG	cis	rs5769707	1	rs5769707	ENSG00000235111.1	RP1-29C18.8	-5.96	1.75e-08	2e-05	-0.48	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49612657~49615716:-
PCPG	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-5.96	1.75e-08	2e-05	-0.46	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
PCPG	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	5.96	1.76e-08	2e-05	0.62	0.44	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
PCPG	cis	rs440932	1	rs378974	ENSG00000253893.2	FAM85B	-5.96	1.76e-08	2.01e-05	-0.58	-0.44	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8167819~8226614:-
PCPG	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	5.96	1.77e-08	2.01e-05	0.65	0.44	Depression;	chr6:28428413	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	5.96	1.77e-08	2.01e-05	0.65	0.44	Depression;	chr6:28431469	chr6:28176188~28176674:+
PCPG	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-5.95	1.77e-08	2.02e-05	-0.53	-0.44	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-5.95	1.77e-08	2.02e-05	-0.53	-0.44	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
PCPG	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	5.95	1.78e-08	2.02e-05	0.43	0.44	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
PCPG	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-5.95	1.78e-08	2.02e-05	-0.61	-0.44	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
PCPG	cis	rs9595908	0.746	rs2031355	ENSG00000212293.1	SNORA16	5.95	1.78e-08	2.02e-05	0.54	0.44	Body mass index;	chr13:32641495	chr13:32420390~32420516:-
PCPG	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	5.95	1.78e-08	2.02e-05	0.79	0.44	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
PCPG	cis	rs7267979	0.903	rs6115101	ENSG00000125804.12	FAM182A	-5.95	1.78e-08	2.03e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.868	rs6107019	ENSG00000125804.12	FAM182A	-5.95	1.78e-08	2.03e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:26054655~26086917:+
PCPG	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	5.95	1.78e-08	2.03e-05	0.51	0.44	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
PCPG	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	5.95	1.78e-08	2.03e-05	0.43	0.44	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
PCPG	cis	rs453301	0.686	rs7017868	ENSG00000173295.6	FAM86B3P	5.95	1.79e-08	2.03e-05	0.52	0.44	Joint mobility (Beighton score);	chr8:9015783	chr8:8228595~8244865:+
PCPG	cis	rs453301	0.686	rs3895823	ENSG00000173295.6	FAM86B3P	5.95	1.79e-08	2.03e-05	0.52	0.44	Joint mobility (Beighton score);	chr8:9016136	chr8:8228595~8244865:+
PCPG	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	5.95	1.8e-08	2.04e-05	0.63	0.44	Depression;	chr6:28379133	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	5.95	1.8e-08	2.04e-05	0.63	0.44	Depression;	chr6:28379168	chr6:28176188~28176674:+
PCPG	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-5.95	1.8e-08	2.04e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-5.95	1.8e-08	2.04e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-5.95	1.8e-08	2.04e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-5.95	1.8e-08	2.04e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
PCPG	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-5.95	1.81e-08	2.06e-05	-0.42	-0.44	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
PCPG	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	5.95	1.81e-08	2.06e-05	0.56	0.44	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
PCPG	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-5.95	1.82e-08	2.06e-05	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-5.95	1.82e-08	2.06e-05	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
PCPG	cis	rs2625529	0.73	rs2957737	ENSG00000260037.4	CTD-2524L6.3	5.95	1.82e-08	2.07e-05	0.62	0.44	Red blood cell count;	chr15:71973069	chr15:71818396~71823384:+
PCPG	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	5.95	1.83e-08	2.07e-05	0.63	0.44	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
PCPG	cis	rs7267979	0.932	rs6107052	ENSG00000125804.12	FAM182A	-5.95	1.83e-08	2.08e-05	-0.51	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:26054655~26086917:+
PCPG	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-5.95	1.84e-08	2.09e-05	-0.7	-0.44	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
PCPG	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-5.95	1.85e-08	2.09e-05	-0.45	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
PCPG	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-5.94	1.86e-08	2.11e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-5.94	1.86e-08	2.11e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-5.94	1.86e-08	2.11e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-5.94	1.86e-08	2.11e-05	-0.57	-0.44	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-5.94	1.87e-08	2.12e-05	-0.6	-0.44	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
PCPG	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	5.94	1.87e-08	2.12e-05	0.73	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
PCPG	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-5.94	1.87e-08	2.12e-05	-0.53	-0.44	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
PCPG	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	5.94	1.88e-08	2.12e-05	0.59	0.44	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
PCPG	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	5.94	1.88e-08	2.13e-05	0.64	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
PCPG	cis	rs453301	0.686	rs28482034	ENSG00000173295.6	FAM86B3P	5.94	1.88e-08	2.13e-05	0.52	0.44	Joint mobility (Beighton score);	chr8:9012154	chr8:8228595~8244865:+
PCPG	cis	rs453301	0.686	rs11785819	ENSG00000173295.6	FAM86B3P	5.94	1.88e-08	2.13e-05	0.52	0.44	Joint mobility (Beighton score);	chr8:9012868	chr8:8228595~8244865:+
PCPG	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	5.94	1.9e-08	2.14e-05	0.57	0.44	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	5.94	1.9e-08	2.14e-05	0.57	0.44	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
PCPG	cis	rs7267979	1	rs6050631	ENSG00000125804.12	FAM182A	-5.94	1.92e-08	2.17e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:26054655~26086917:+
PCPG	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	5.94	1.92e-08	2.17e-05	0.56	0.44	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
PCPG	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	5.94	1.93e-08	2.18e-05	0.41	0.44	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
PCPG	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-5.94	1.93e-08	2.18e-05	-0.53	-0.44	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
PCPG	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	5.94	1.93e-08	2.18e-05	0.59	0.44	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
PCPG	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	5.94	1.93e-08	2.18e-05	0.59	0.44	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
PCPG	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-5.94	1.93e-08	2.18e-05	-0.56	-0.44	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
PCPG	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-5.94	1.93e-08	2.18e-05	-0.57	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
PCPG	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	5.94	1.94e-08	2.19e-05	0.62	0.44	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
PCPG	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	5.94	1.94e-08	2.19e-05	0.46	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
PCPG	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-5.94	1.94e-08	2.19e-05	-0.87	-0.44	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-5.94	1.94e-08	2.19e-05	-0.87	-0.44	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-5.94	1.94e-08	2.19e-05	-0.87	-0.44	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-5.94	1.94e-08	2.19e-05	-0.87	-0.44	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
PCPG	cis	rs9595908	0.708	rs12429740	ENSG00000212293.1	SNORA16	5.94	1.95e-08	2.2e-05	0.54	0.44	Body mass index;	chr13:32684928	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs9596076	ENSG00000212293.1	SNORA16	5.94	1.95e-08	2.2e-05	0.54	0.44	Body mass index;	chr13:32693515	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs17516171	ENSG00000212293.1	SNORA16	5.94	1.95e-08	2.2e-05	0.54	0.44	Body mass index;	chr13:32694914	chr13:32420390~32420516:-
PCPG	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	5.94	1.95e-08	2.2e-05	0.58	0.44	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs6705977	ENSG00000163016.8	ALMS1P	5.94	1.95e-08	2.2e-05	0.58	0.44	Metabolite levels;	chr2:73622043	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	5.94	1.95e-08	2.2e-05	0.58	0.44	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
PCPG	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-5.94	1.96e-08	2.21e-05	-0.49	-0.44	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
PCPG	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-5.93	1.96e-08	2.21e-05	-0.52	-0.44	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
PCPG	cis	rs11148252	0.819	rs7336679	ENSG00000235660.1	LINC00345	-5.93	1.97e-08	2.22e-05	-0.56	-0.44	Lewy body disease;	chr13:52469198	chr13:52484161~52484680:-
PCPG	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	5.93	1.97e-08	2.22e-05	0.57	0.44	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
PCPG	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-5.93	1.97e-08	2.22e-05	-0.45	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
PCPG	cis	rs7267979	0.903	rs6107015	ENSG00000125804.12	FAM182A	-5.93	1.99e-08	2.24e-05	-0.52	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:26054655~26086917:+
PCPG	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	5.93	1.99e-08	2.24e-05	0.48	0.44	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	5.93	1.99e-08	2.24e-05	0.48	0.44	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
PCPG	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	5.93	1.99e-08	2.24e-05	0.48	0.44	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
PCPG	cis	rs7267979	0.816	rs1044573	ENSG00000125804.12	FAM182A	-5.93	2e-08	2.25e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:26054655~26086917:+
PCPG	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-5.93	2e-08	2.25e-05	-0.43	-0.44	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
PCPG	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-5.93	2e-08	2.25e-05	-0.51	-0.44	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
PCPG	cis	rs7267979	1	rs11087520	ENSG00000125804.12	FAM182A	-5.93	2e-08	2.25e-05	-0.5	-0.44	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:26054655~26086917:+
PCPG	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-5.93	2.01e-08	2.25e-05	-0.53	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
PCPG	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	5.93	2.01e-08	2.26e-05	0.54	0.44	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
PCPG	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	5.93	2.02e-08	2.27e-05	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	5.93	2.02e-08	2.27e-05	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	5.93	2.02e-08	2.27e-05	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	5.93	2.02e-08	2.27e-05	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	5.93	2.02e-08	2.27e-05	0.84	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
PCPG	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	5.93	2.02e-08	2.27e-05	0.65	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
PCPG	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	5.93	2.05e-08	2.3e-05	0.63	0.44	Depression;	chr6:28386473	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	5.93	2.05e-08	2.3e-05	0.63	0.44	Depression;	chr6:28391932	chr6:28176188~28176674:+
PCPG	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-5.93	2.06e-08	2.31e-05	-0.62	-0.44	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
PCPG	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-5.92	2.06e-08	2.31e-05	-0.56	-0.44	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
PCPG	cis	rs804280	0.543	rs13261205	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Myopia (pathological);	chr8:11933707	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.867	rs35778860	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.867	rs34465618	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.867	rs34583868	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:11345748~11347502:-
PCPG	cis	rs804280	0.518	rs34266352	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Myopia (pathological);	chr8:11933953	chr8:11345748~11347502:-
PCPG	cis	rs804280	0.542	rs34117651	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Myopia (pathological);	chr8:11934108	chr8:11345748~11347502:-
PCPG	cis	rs804280	0.542	rs35647515	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Myopia (pathological);	chr8:11934120	chr8:11345748~11347502:-
PCPG	cis	rs804280	0.542	rs36100659	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Myopia (pathological);	chr8:11934144	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.805	rs13269417	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:11345748~11347502:-
PCPG	cis	rs804280	0.517	rs7815179	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Myopia (pathological);	chr8:11934539	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.871	rs7815186	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs7833079	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11934620	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.899	rs7815595	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.744	rs11250175	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.834	rs11250176	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs13252853	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11935465	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs13252854	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11935469	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs13279577	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11935587	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs10112958	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11935631	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs4367597	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11936020	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.899	rs9329251	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.773	rs7842810	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.541	rs7824267	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11936770	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs7825529	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11936935	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs13281077	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11937305	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs13281315	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11937346	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs4840597	ENSG00000255020.1	AF131216.5	5.92	2.06e-08	2.31e-05	0.59	0.44	Neuroticism;	chr8:11938559	chr8:11345748~11347502:-
PCPG	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-5.92	2.07e-08	2.31e-05	-0.44	-0.44	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	5.92	2.07e-08	2.31e-05	0.44	0.44	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	5.92	2.07e-08	2.31e-05	0.44	0.44	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	5.92	2.07e-08	2.31e-05	0.44	0.44	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	5.92	2.07e-08	2.31e-05	0.44	0.44	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	5.92	2.07e-08	2.31e-05	0.44	0.44	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
PCPG	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	5.92	2.07e-08	2.31e-05	0.48	0.44	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
PCPG	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	5.92	2.07e-08	2.31e-05	0.48	0.44	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
PCPG	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	5.92	2.07e-08	2.32e-05	0.58	0.44	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
PCPG	cis	rs561341	0.943	rs508566	ENSG00000265798.5	RP11-271K11.5	5.92	2.09e-08	2.34e-05	0.84	0.44	Hip circumference adjusted for BMI;	chr17:31962842	chr17:31038575~31059121:-
PCPG	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-5.92	2.09e-08	2.34e-05	-0.44	-0.44	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
PCPG	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-5.92	2.1e-08	2.35e-05	-0.75	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
PCPG	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	5.92	2.1e-08	2.35e-05	0.56	0.44	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
PCPG	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-5.92	2.1e-08	2.35e-05	-0.58	-0.44	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
PCPG	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	5.92	2.1e-08	2.35e-05	0.58	0.44	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
PCPG	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	5.92	2.1e-08	2.35e-05	0.57	0.44	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	5.92	2.1e-08	2.35e-05	0.57	0.44	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	5.92	2.1e-08	2.35e-05	0.57	0.44	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
PCPG	cis	rs11951515	0.508	rs10059993	ENSG00000248240.1	RP11-159F24.5	-5.92	2.12e-08	2.37e-05	-0.48	-0.44	Metabolite levels  (X-11787);	chr5:43598250	chr5:43515274~43525310:+
PCPG	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-5.92	2.12e-08	2.37e-05	-0.4	-0.44	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-5.92	2.12e-08	2.37e-05	-0.4	-0.44	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-5.92	2.12e-08	2.37e-05	-0.4	-0.44	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-5.92	2.12e-08	2.37e-05	-0.4	-0.44	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-5.92	2.12e-08	2.37e-05	-0.4	-0.44	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-5.92	2.12e-08	2.37e-05	-0.4	-0.44	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-5.92	2.12e-08	2.37e-05	-0.4	-0.44	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
PCPG	cis	rs2625529	0.73	rs7177242	ENSG00000260037.4	CTD-2524L6.3	5.92	2.12e-08	2.37e-05	0.64	0.44	Red blood cell count;	chr15:71891773	chr15:71818396~71823384:+
PCPG	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	5.92	2.14e-08	2.38e-05	0.65	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
PCPG	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	5.92	2.14e-08	2.38e-05	0.46	0.44	Height;	chr3:53082835	chr3:53064283~53065091:-
PCPG	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-5.92	2.14e-08	2.38e-05	-0.56	-0.44	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-5.92	2.14e-08	2.38e-05	-0.56	-0.44	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-5.92	2.14e-08	2.38e-05	-0.56	-0.44	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
PCPG	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-5.91	2.16e-08	2.41e-05	-0.5	-0.43	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
PCPG	cis	rs7688540	0.8	rs12506277	ENSG00000275426.1	CH17-262A2.1	5.91	2.16e-08	2.41e-05	0.53	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:149738~150317:+
PCPG	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-5.91	2.18e-08	2.42e-05	-0.49	-0.43	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
PCPG	cis	rs12291225	0.535	rs16930126	ENSG00000251991.1	RNU7-49P	-5.91	2.18e-08	2.43e-05	-0.49	-0.43	Sense of smell;	chr11:14383437	chr11:14478892~14478953:+
PCPG	cis	rs11951515	0.508	rs6898866	ENSG00000248240.1	RP11-159F24.5	-5.91	2.18e-08	2.43e-05	-0.49	-0.43	Metabolite levels  (X-11787);	chr5:43586273	chr5:43515274~43525310:+
PCPG	cis	rs2625529	0.689	rs4526973	ENSG00000260037.4	CTD-2524L6.3	-5.91	2.19e-08	2.43e-05	-0.56	-0.43	Red blood cell count;	chr15:71846378	chr15:71818396~71823384:+
PCPG	cis	rs7267979	0.565	rs4815432	ENSG00000125804.12	FAM182A	5.91	2.19e-08	2.43e-05	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.565	rs6076364	ENSG00000125804.12	FAM182A	5.91	2.19e-08	2.43e-05	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.565	rs13040726	ENSG00000125804.12	FAM182A	5.91	2.19e-08	2.43e-05	0.52	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26054655~26086917:+
PCPG	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	5.91	2.19e-08	2.44e-05	0.52	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
PCPG	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-5.91	2.2e-08	2.44e-05	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-5.91	2.2e-08	2.44e-05	-0.51	-0.43	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
PCPG	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	5.91	2.2e-08	2.44e-05	0.61	0.43	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	5.91	2.2e-08	2.44e-05	0.61	0.43	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
PCPG	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-5.91	2.2e-08	2.44e-05	-0.53	-0.43	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
PCPG	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-5.91	2.2e-08	2.45e-05	-0.56	-0.43	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
PCPG	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	5.91	2.21e-08	2.45e-05	0.73	0.43	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
PCPG	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-5.91	2.21e-08	2.46e-05	-0.39	-0.43	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-5.91	2.21e-08	2.46e-05	-0.39	-0.43	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
PCPG	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-5.91	2.21e-08	2.46e-05	-0.55	-0.43	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
PCPG	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	5.91	2.22e-08	2.46e-05	0.51	0.43	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
PCPG	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	5.91	2.22e-08	2.47e-05	0.65	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
PCPG	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-5.91	2.22e-08	2.47e-05	-0.44	-0.43	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.91	2.22e-08	2.47e-05	-0.44	-0.43	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
PCPG	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	5.91	2.22e-08	2.47e-05	0.59	0.43	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	5.91	2.22e-08	2.47e-05	0.59	0.43	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
PCPG	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-5.91	2.22e-08	2.47e-05	-0.48	-0.43	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-5.91	2.22e-08	2.47e-05	-0.48	-0.43	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
PCPG	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-5.91	2.23e-08	2.47e-05	-0.57	-0.43	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
PCPG	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	5.91	2.23e-08	2.48e-05	0.39	0.43	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	5.91	2.23e-08	2.48e-05	0.39	0.43	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
PCPG	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	5.91	2.24e-08	2.48e-05	0.54	0.43	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
PCPG	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-5.91	2.24e-08	2.48e-05	-0.57	-0.43	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
PCPG	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-5.91	2.24e-08	2.49e-05	-0.58	-0.43	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
PCPG	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	5.91	2.24e-08	2.49e-05	0.61	0.43	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
PCPG	cis	rs12291225	0.535	rs10832248	ENSG00000251991.1	RNU7-49P	5.91	2.24e-08	2.49e-05	0.51	0.43	Sense of smell;	chr11:14391541	chr11:14478892~14478953:+
PCPG	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-5.91	2.25e-08	2.5e-05	-0.55	-0.43	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
PCPG	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	5.91	2.25e-08	2.5e-05	0.38	0.43	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	5.91	2.25e-08	2.5e-05	0.38	0.43	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	5.91	2.25e-08	2.5e-05	0.38	0.43	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
PCPG	cis	rs7267979	0.934	rs2261115	ENSG00000125804.12	FAM182A	-5.91	2.26e-08	2.5e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2261747	ENSG00000125804.12	FAM182A	-5.91	2.26e-08	2.5e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs6037125	ENSG00000125804.12	FAM182A	-5.91	2.26e-08	2.5e-05	-0.49	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:26054655~26086917:+
PCPG	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-5.91	2.26e-08	2.51e-05	-0.5	-0.43	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
PCPG	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-5.91	2.27e-08	2.51e-05	-0.5	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
PCPG	cis	rs10435719	0.902	rs7006538	ENSG00000255020.1	AF131216.5	5.9	2.27e-08	2.52e-05	0.59	0.43	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.867	rs6999030	ENSG00000255020.1	AF131216.5	5.9	2.3e-08	2.55e-05	0.59	0.43	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.834	rs6985792	ENSG00000255020.1	AF131216.5	5.9	2.3e-08	2.55e-05	0.59	0.43	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:11345748~11347502:-
PCPG	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	5.9	2.31e-08	2.56e-05	0.75	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
PCPG	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	5.9	2.31e-08	2.56e-05	0.75	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
PCPG	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	5.9	2.31e-08	2.56e-05	0.75	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
PCPG	cis	rs804280	0.509	rs10109241	ENSG00000255020.1	AF131216.5	5.9	2.31e-08	2.56e-05	0.58	0.43	Myopia (pathological);	chr8:11927476	chr8:11345748~11347502:-
PCPG	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-5.9	2.32e-08	2.57e-05	-0.39	-0.43	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-5.9	2.32e-08	2.57e-05	-0.39	-0.43	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
PCPG	cis	rs7267979	1	rs2424716	ENSG00000125804.12	FAM182A	-5.9	2.32e-08	2.57e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs761025	ENSG00000125804.12	FAM182A	-5.9	2.32e-08	2.57e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:26054655~26086917:+
PCPG	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-5.9	2.33e-08	2.57e-05	-0.51	-0.43	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
PCPG	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	5.9	2.33e-08	2.58e-05	0.57	0.43	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	5.9	2.33e-08	2.58e-05	0.57	0.43	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	5.9	2.33e-08	2.58e-05	0.57	0.43	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs11126403	ENSG00000163016.8	ALMS1P	5.9	2.33e-08	2.58e-05	0.57	0.43	Metabolite levels;	chr2:73569796	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.898	rs11126404	ENSG00000163016.8	ALMS1P	5.9	2.33e-08	2.58e-05	0.57	0.43	Metabolite levels;	chr2:73569797	chr2:73644919~73685576:+
PCPG	cis	rs853679	1	rs11965538	ENSG00000216901.1	AL022393.7	5.9	2.34e-08	2.59e-05	0.74	0.43	Depression;	chr6:28272137	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.882	rs2743555	ENSG00000216901.1	AL022393.7	5.9	2.34e-08	2.59e-05	0.74	0.43	Depression;	chr6:28273304	chr6:28176188~28176674:+
PCPG	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-5.9	2.34e-08	2.59e-05	-0.53	-0.43	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
PCPG	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	5.9	2.34e-08	2.59e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
PCPG	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	5.9	2.35e-08	2.6e-05	0.55	0.43	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	5.9	2.35e-08	2.6e-05	0.55	0.43	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	5.9	2.35e-08	2.6e-05	0.55	0.43	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	5.9	2.35e-08	2.6e-05	0.55	0.43	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
PCPG	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-5.9	2.36e-08	2.6e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
PCPG	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-5.9	2.36e-08	2.6e-05	-0.59	-0.43	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
PCPG	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	5.9	2.36e-08	2.6e-05	0.6	0.43	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
PCPG	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-5.9	2.36e-08	2.61e-05	-0.4	-0.43	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-5.9	2.36e-08	2.61e-05	-0.4	-0.43	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-5.9	2.36e-08	2.61e-05	-0.4	-0.43	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
PCPG	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-5.9	2.36e-08	2.61e-05	-0.55	-0.43	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
PCPG	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-5.9	2.36e-08	2.61e-05	-0.53	-0.43	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
PCPG	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-5.9	2.37e-08	2.61e-05	-0.64	-0.43	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
PCPG	cis	rs7267979	1	rs4815424	ENSG00000125804.12	FAM182A	5.9	2.37e-08	2.61e-05	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6515651	ENSG00000125804.12	FAM182A	5.9	2.37e-08	2.61e-05	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2151144	ENSG00000125804.12	FAM182A	5.9	2.37e-08	2.61e-05	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:26054655~26086917:+
PCPG	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	5.9	2.37e-08	2.62e-05	0.6	0.43	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-5.9	2.37e-08	2.62e-05	-0.6	-0.43	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
PCPG	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	5.9	2.37e-08	2.62e-05	0.54	0.43	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
PCPG	cis	rs7267979	0.966	rs6037083	ENSG00000125804.12	FAM182A	5.9	2.38e-08	2.62e-05	0.49	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:26054655~26086917:+
PCPG	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	5.9	2.38e-08	2.63e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
PCPG	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-5.9	2.38e-08	2.63e-05	-0.5	-0.43	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
PCPG	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	5.89	2.39e-08	2.64e-05	0.62	0.43	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
PCPG	cis	rs11951515	0.508	rs7705166	ENSG00000248240.1	RP11-159F24.5	-5.89	2.4e-08	2.64e-05	-0.48	-0.43	Metabolite levels  (X-11787);	chr5:43587346	chr5:43515274~43525310:+
PCPG	cis	rs11951515	0.508	rs1366410	ENSG00000248240.1	RP11-159F24.5	-5.89	2.4e-08	2.64e-05	-0.48	-0.43	Metabolite levels  (X-11787);	chr5:43601508	chr5:43515274~43525310:+
PCPG	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-5.89	2.4e-08	2.64e-05	-0.51	-0.43	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
PCPG	cis	rs9595908	0.746	rs9591222	ENSG00000212293.1	SNORA16	5.89	2.4e-08	2.65e-05	0.54	0.43	Body mass index;	chr13:32653261	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs9591229	ENSG00000212293.1	SNORA16	5.89	2.4e-08	2.65e-05	0.54	0.43	Body mass index;	chr13:32658870	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs4942792	ENSG00000212293.1	SNORA16	5.89	2.4e-08	2.65e-05	0.54	0.43	Body mass index;	chr13:32663326	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs9596048	ENSG00000212293.1	SNORA16	5.89	2.4e-08	2.65e-05	0.54	0.43	Body mass index;	chr13:32664595	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs2301391	ENSG00000212293.1	SNORA16	5.89	2.4e-08	2.65e-05	0.54	0.43	Body mass index;	chr13:32668398	chr13:32420390~32420516:-
PCPG	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-5.89	2.4e-08	2.65e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-5.89	2.4e-08	2.65e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-5.89	2.4e-08	2.65e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-5.89	2.4e-08	2.65e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-5.89	2.4e-08	2.65e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
PCPG	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	5.89	2.41e-08	2.65e-05	0.54	0.43	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
PCPG	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	5.89	2.41e-08	2.65e-05	0.58	0.43	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
PCPG	cis	rs853679	1	rs1936365	ENSG00000216901.1	AL022393.7	-5.89	2.41e-08	2.65e-05	-0.67	-0.43	Depression;	chr6:28300675	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs853694	ENSG00000216901.1	AL022393.7	5.89	2.41e-08	2.65e-05	0.67	0.43	Depression;	chr6:28311323	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs853685	ENSG00000216901.1	AL022393.7	5.89	2.41e-08	2.65e-05	0.67	0.43	Depression;	chr6:28321008	chr6:28176188~28176674:+
PCPG	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	5.89	2.41e-08	2.65e-05	0.58	0.43	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
PCPG	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-5.89	2.41e-08	2.66e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-5.89	2.41e-08	2.66e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-5.89	2.41e-08	2.66e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	5.89	2.41e-08	2.66e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
PCPG	cis	rs853679	1	rs13200462	ENSG00000216901.1	AL022393.7	5.89	2.42e-08	2.66e-05	0.76	0.43	Depression;	chr6:28250421	chr6:28176188~28176674:+
PCPG	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-5.89	2.42e-08	2.66e-05	-0.46	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
PCPG	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	5.89	2.42e-08	2.66e-05	0.49	0.43	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
PCPG	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	5.89	2.43e-08	2.67e-05	0.54	0.43	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
PCPG	cis	rs7267979	1	rs7267979	ENSG00000125804.12	FAM182A	-5.89	2.43e-08	2.67e-05	-0.49	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs8125868	ENSG00000125804.12	FAM182A	5.89	2.43e-08	2.67e-05	0.49	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs4815407	ENSG00000125804.12	FAM182A	5.89	2.43e-08	2.67e-05	0.49	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6050566	ENSG00000125804.12	FAM182A	5.89	2.43e-08	2.67e-05	0.49	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:26054655~26086917:+
PCPG	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-5.89	2.43e-08	2.67e-05	-0.51	-0.43	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-5.89	2.43e-08	2.67e-05	-0.51	-0.43	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-5.89	2.43e-08	2.67e-05	-0.51	-0.43	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-5.89	2.43e-08	2.67e-05	-0.51	-0.43	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-5.89	2.43e-08	2.67e-05	-0.51	-0.43	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-5.89	2.43e-08	2.67e-05	-0.51	-0.43	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	5.89	2.43e-08	2.67e-05	0.51	0.43	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
PCPG	cis	rs11992162	0.591	rs35657308	ENSG00000255020.1	AF131216.5	-5.89	2.43e-08	2.67e-05	-0.59	-0.43	Monocyte count;	chr8:11946893	chr8:11345748~11347502:-
PCPG	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	5.89	2.44e-08	2.68e-05	0.48	0.43	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
PCPG	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	5.89	2.44e-08	2.68e-05	0.5	0.43	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
PCPG	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	5.89	2.44e-08	2.68e-05	0.6	0.43	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
PCPG	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	5.89	2.46e-08	2.7e-05	0.54	0.43	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	5.89	2.46e-08	2.7e-05	0.54	0.43	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-5.89	2.46e-08	2.7e-05	-0.51	-0.43	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
PCPG	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	5.89	2.46e-08	2.7e-05	0.48	0.43	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
PCPG	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-5.89	2.47e-08	2.71e-05	-0.49	-0.43	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
PCPG	cis	rs9532669	0.889	rs7320344	ENSG00000176268.5	CYCSP34	5.89	2.47e-08	2.71e-05	0.53	0.43	Cervical cancer;	chr13:40885502	chr13:40863599~40863902:-
PCPG	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	5.89	2.48e-08	2.73e-05	0.57	0.43	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
PCPG	cis	rs10435719	0.902	rs6601633	ENSG00000255020.1	AF131216.5	-5.89	2.49e-08	2.74e-05	-0.59	-0.43	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11345748~11347502:-
PCPG	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	5.89	2.5e-08	2.74e-05	0.44	0.43	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
PCPG	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-5.89	2.5e-08	2.74e-05	-0.5	-0.43	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-5.89	2.5e-08	2.74e-05	-0.5	-0.43	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-5.89	2.5e-08	2.74e-05	-0.5	-0.43	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-5.89	2.5e-08	2.74e-05	-0.5	-0.43	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-5.89	2.5e-08	2.74e-05	-0.5	-0.43	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-5.89	2.5e-08	2.74e-05	-0.5	-0.43	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
PCPG	cis	rs2625529	0.652	rs2957743	ENSG00000260037.4	CTD-2524L6.3	5.89	2.5e-08	2.74e-05	0.57	0.43	Red blood cell count;	chr15:72009689	chr15:71818396~71823384:+
PCPG	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-5.89	2.5e-08	2.74e-05	-0.45	-0.43	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
PCPG	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	5.89	2.5e-08	2.74e-05	0.59	0.43	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
PCPG	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-5.88	2.51e-08	2.75e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-5.88	2.51e-08	2.75e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
PCPG	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	-5.88	2.51e-08	2.75e-05	-0.49	-0.43	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
PCPG	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	5.88	2.51e-08	2.75e-05	0.86	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
PCPG	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	5.88	2.51e-08	2.75e-05	0.66	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
PCPG	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-5.88	2.52e-08	2.76e-05	-0.63	-0.43	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
PCPG	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-5.88	2.52e-08	2.76e-05	-0.44	-0.43	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-5.88	2.52e-08	2.76e-05	-0.44	-0.43	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
PCPG	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	5.88	2.52e-08	2.76e-05	0.63	0.43	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
PCPG	cis	rs7182621	0.515	rs3803416	ENSG00000182397.13	DNM1P46	5.88	2.52e-08	2.76e-05	0.73	0.43	Colonoscopy-negative controls vs population controls;	chr15:99788855	chr15:99790156~99806927:-
PCPG	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-5.88	2.52e-08	2.76e-05	-0.5	-0.43	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
PCPG	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-5.88	2.52e-08	2.76e-05	-0.6	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
PCPG	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-5.88	2.53e-08	2.76e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	5.88	2.53e-08	2.76e-05	0.59	0.43	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
PCPG	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-5.88	2.53e-08	2.77e-05	-0.5	-0.43	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
PCPG	cis	rs9532669	0.889	rs9525397	ENSG00000176268.5	CYCSP34	5.88	2.54e-08	2.77e-05	0.53	0.43	Cervical cancer;	chr13:40851575	chr13:40863599~40863902:-
PCPG	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	5.88	2.54e-08	2.78e-05	0.56	0.43	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
PCPG	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	5.88	2.55e-08	2.78e-05	0.62	0.43	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
PCPG	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	5.88	2.55e-08	2.78e-05	0.61	0.43	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
PCPG	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	5.88	2.55e-08	2.78e-05	0.6	0.43	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
PCPG	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	5.88	2.55e-08	2.78e-05	0.6	0.43	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
PCPG	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-5.88	2.56e-08	2.79e-05	-0.57	-0.43	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-5.88	2.56e-08	2.79e-05	-0.57	-0.43	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
PCPG	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-5.88	2.56e-08	2.79e-05	-0.47	-0.43	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
PCPG	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.88	2.56e-08	2.79e-05	-0.44	-0.43	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-5.88	2.56e-08	2.79e-05	-0.44	-0.43	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.88	2.56e-08	2.79e-05	-0.44	-0.43	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
PCPG	cis	rs7267979	1	rs6132835	ENSG00000125804.12	FAM182A	-5.88	2.56e-08	2.79e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:26054655~26086917:+
PCPG	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	5.88	2.57e-08	2.8e-05	0.46	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	5.88	2.57e-08	2.8e-05	0.46	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
PCPG	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	5.88	2.57e-08	2.8e-05	0.43	0.43	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
PCPG	cis	rs910316	0.934	rs8006587	ENSG00000279594.1	RP11-950C14.10	5.88	2.59e-08	2.82e-05	0.55	0.43	Height;	chr14:75198236	chr14:75011269~75012851:-
PCPG	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-5.88	2.59e-08	2.82e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-5.88	2.59e-08	2.82e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-5.88	2.59e-08	2.82e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-5.88	2.59e-08	2.82e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-5.88	2.59e-08	2.82e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
PCPG	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-5.88	2.6e-08	2.82e-05	-0.64	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
PCPG	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	5.88	2.6e-08	2.82e-05	0.6	0.43	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	5.88	2.6e-08	2.82e-05	0.6	0.43	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	5.88	2.6e-08	2.83e-05	0.59	0.43	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	5.88	2.6e-08	2.83e-05	0.59	0.43	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
PCPG	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-5.88	2.61e-08	2.84e-05	-0.48	-0.43	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
PCPG	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	5.88	2.61e-08	2.84e-05	0.65	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	5.88	2.61e-08	2.84e-05	0.65	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
PCPG	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	5.88	2.62e-08	2.85e-05	0.44	0.43	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
PCPG	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-5.87	2.64e-08	2.87e-05	-0.42	-0.43	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
PCPG	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-5.87	2.64e-08	2.87e-05	-0.52	-0.43	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
PCPG	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	5.87	2.67e-08	2.9e-05	0.61	0.43	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	5.87	2.67e-08	2.9e-05	0.61	0.43	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
PCPG	cis	rs453301	0.571	rs2929452	ENSG00000173295.6	FAM86B3P	5.87	2.68e-08	2.91e-05	0.51	0.43	Joint mobility (Beighton score);	chr8:9226955	chr8:8228595~8244865:+
PCPG	cis	rs453301	0.507	rs2929306	ENSG00000173295.6	FAM86B3P	5.87	2.68e-08	2.91e-05	0.51	0.43	Joint mobility (Beighton score);	chr8:9227399	chr8:8228595~8244865:+
PCPG	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	5.87	2.69e-08	2.91e-05	0.67	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
PCPG	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	5.87	2.69e-08	2.92e-05	0.57	0.43	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
PCPG	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-5.87	2.7e-08	2.92e-05	-0.59	-0.43	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
PCPG	cis	rs853679	1	rs6905391	ENSG00000216901.1	AL022393.7	5.87	2.71e-08	2.93e-05	0.67	0.43	Depression;	chr6:28294909	chr6:28176188~28176674:+
PCPG	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	5.87	2.71e-08	2.94e-05	0.6	0.43	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
PCPG	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-5.87	2.71e-08	2.94e-05	-0.5	-0.43	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
PCPG	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	5.87	2.72e-08	2.95e-05	0.39	0.43	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
PCPG	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-5.87	2.75e-08	2.97e-05	-0.5	-0.43	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-5.87	2.75e-08	2.97e-05	-0.5	-0.43	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-5.87	2.75e-08	2.97e-05	-0.5	-0.43	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-5.87	2.75e-08	2.97e-05	-0.5	-0.43	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-5.87	2.75e-08	2.97e-05	-0.5	-0.43	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
PCPG	cis	rs7824557	0.767	rs4559208	ENSG00000255020.1	AF131216.5	5.87	2.76e-08	2.98e-05	0.55	0.43	Retinal vascular caliber;	chr8:11296416	chr8:11345748~11347502:-
PCPG	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-5.87	2.76e-08	2.99e-05	-0.63	-0.43	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
PCPG	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-5.86	2.76e-08	2.99e-05	-0.48	-0.43	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
PCPG	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	5.86	2.78e-08	3e-05	0.51	0.43	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
PCPG	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-5.86	2.78e-08	3.01e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
PCPG	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-5.86	2.79e-08	3.01e-05	-0.5	-0.43	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-5.86	2.79e-08	3.01e-05	-0.5	-0.43	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-5.86	2.79e-08	3.01e-05	-0.5	-0.43	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-5.86	2.79e-08	3.01e-05	-0.5	-0.43	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
PCPG	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-5.86	2.8e-08	3.02e-05	-0.43	-0.43	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
PCPG	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-5.86	2.8e-08	3.02e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-5.86	2.8e-08	3.02e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-5.86	2.8e-08	3.02e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
PCPG	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	5.86	2.81e-08	3.03e-05	0.6	0.43	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
PCPG	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-5.86	2.81e-08	3.03e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
PCPG	cis	rs910316	0.726	rs61979167	ENSG00000279594.1	RP11-950C14.10	-5.86	2.81e-08	3.03e-05	-0.56	-0.43	Height;	chr14:75196907	chr14:75011269~75012851:-
PCPG	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	5.86	2.84e-08	3.06e-05	0.62	0.43	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
PCPG	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	5.86	2.84e-08	3.06e-05	0.64	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	5.86	2.84e-08	3.06e-05	0.64	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	5.86	2.85e-08	3.07e-05	0.65	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
PCPG	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	5.86	2.85e-08	3.07e-05	0.56	0.43	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
PCPG	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	5.86	2.85e-08	3.08e-05	0.57	0.43	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
PCPG	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	5.86	2.86e-08	3.08e-05	0.55	0.43	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
PCPG	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	5.86	2.86e-08	3.08e-05	0.55	0.43	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
PCPG	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	5.86	2.87e-08	3.09e-05	0.43	0.43	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-5.86	2.87e-08	3.09e-05	-0.4	-0.43	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
PCPG	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-5.86	2.87e-08	3.1e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
PCPG	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	5.86	2.88e-08	3.1e-05	0.58	0.43	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
PCPG	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-5.86	2.88e-08	3.1e-05	-0.48	-0.43	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
PCPG	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-5.86	2.89e-08	3.11e-05	-0.62	-0.43	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
PCPG	cis	rs1075232	1	rs67634762	ENSG00000270055.1	CTD-3092A11.2	-5.86	2.89e-08	3.11e-05	-0.98	-0.43	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30487963~30490313:+
PCPG	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-5.86	2.89e-08	3.12e-05	-0.66	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
PCPG	cis	rs11951515	0.509	rs12521249	ENSG00000248240.1	RP11-159F24.5	5.86	2.9e-08	3.12e-05	0.47	0.43	Metabolite levels  (X-11787);	chr5:43558527	chr5:43515274~43525310:+
PCPG	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	5.85	2.91e-08	3.13e-05	0.5	0.43	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
PCPG	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-5.85	2.91e-08	3.13e-05	-0.48	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
PCPG	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	5.85	2.92e-08	3.14e-05	0.58	0.43	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
PCPG	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-5.85	2.92e-08	3.14e-05	-0.51	-0.43	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
PCPG	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-5.85	2.92e-08	3.14e-05	-0.47	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-5.85	2.92e-08	3.14e-05	-0.46	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
PCPG	cis	rs440932	0.747	rs330946	ENSG00000253893.2	FAM85B	-5.85	2.93e-08	3.15e-05	-0.53	-0.43	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8167819~8226614:-
PCPG	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	5.85	2.93e-08	3.16e-05	0.43	0.43	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
PCPG	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-5.85	2.93e-08	3.16e-05	-0.57	-0.43	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
PCPG	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-5.85	2.94e-08	3.16e-05	-0.39	-0.43	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
PCPG	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-5.85	2.94e-08	3.16e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
PCPG	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	5.85	2.95e-08	3.17e-05	0.56	0.43	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	5.85	2.95e-08	3.17e-05	0.56	0.43	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
PCPG	cis	rs11723261	0.513	rs2353623	ENSG00000275426.1	CH17-262A2.1	5.85	2.95e-08	3.17e-05	0.53	0.43	Immune response to smallpox vaccine (IL-6);	chr4:95673	chr4:149738~150317:+
PCPG	cis	rs440932	1	rs365309	ENSG00000253893.2	FAM85B	5.85	2.95e-08	3.17e-05	0.55	0.43	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8167819~8226614:-
PCPG	cis	rs916888	0.61	rs199529	ENSG00000232300.1	FAM215B	5.85	2.96e-08	3.18e-05	0.6	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46558830~46562795:-
PCPG	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-5.85	2.97e-08	3.19e-05	-0.53	-0.43	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-5.85	2.97e-08	3.19e-05	-0.53	-0.43	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
PCPG	cis	rs9595908	0.629	rs962454	ENSG00000212293.1	SNORA16	5.85	2.97e-08	3.19e-05	0.52	0.43	Body mass index;	chr13:32719131	chr13:32420390~32420516:-
PCPG	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	5.85	2.97e-08	3.19e-05	0.55	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
PCPG	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	5.85	2.97e-08	3.19e-05	0.47	0.43	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
PCPG	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-5.85	2.98e-08	3.19e-05	-0.69	-0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
PCPG	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-5.85	2.98e-08	3.2e-05	-0.39	-0.43	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-5.85	2.98e-08	3.2e-05	-0.39	-0.43	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
PCPG	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	5.85	2.98e-08	3.2e-05	0.43	0.43	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
PCPG	cis	rs7402982	0.625	rs4966011	ENSG00000278022.1	RP11-35O15.2	-5.85	2.99e-08	3.2e-05	-0.43	-0.43	Birth weight;	chr15:98660777	chr15:98660210~98660668:+
PCPG	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-5.85	2.99e-08	3.2e-05	-0.47	-0.43	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
PCPG	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	5.85	3.01e-08	3.22e-05	0.42	0.43	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
PCPG	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	5.85	3.01e-08	3.23e-05	0.58	0.43	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
PCPG	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	5.85	3.02e-08	3.24e-05	0.5	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
PCPG	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-5.85	3.03e-08	3.25e-05	-0.48	-0.43	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
PCPG	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-5.85	3.04e-08	3.25e-05	-0.46	-0.43	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
PCPG	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	5.85	3.04e-08	3.26e-05	0.58	0.43	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
PCPG	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	5.85	3.04e-08	3.26e-05	0.52	0.43	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
PCPG	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-5.84	3.05e-08	3.27e-05	-0.51	-0.43	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
PCPG	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	5.84	3.05e-08	3.27e-05	0.57	0.43	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
PCPG	cis	rs12291225	0.546	rs11023199	ENSG00000251991.1	RNU7-49P	5.84	3.06e-08	3.27e-05	0.5	0.43	Sense of smell;	chr11:14372712	chr11:14478892~14478953:+
PCPG	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	5.84	3.06e-08	3.28e-05	0.53	0.43	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
PCPG	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-5.84	3.06e-08	3.28e-05	-0.42	-0.43	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-5.84	3.06e-08	3.28e-05	-0.42	-0.43	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
PCPG	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-5.84	3.07e-08	3.29e-05	-0.53	-0.43	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
PCPG	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-5.84	3.07e-08	3.29e-05	-0.55	-0.43	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-5.84	3.07e-08	3.29e-05	-0.55	-0.43	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
PCPG	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	5.84	3.08e-08	3.3e-05	0.54	0.43	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	5.84	3.08e-08	3.3e-05	0.54	0.43	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	5.84	3.08e-08	3.3e-05	0.54	0.43	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	5.84	3.08e-08	3.3e-05	0.54	0.43	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
PCPG	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	5.84	3.08e-08	3.3e-05	0.58	0.43	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	5.84	3.08e-08	3.3e-05	0.58	0.43	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	5.84	3.08e-08	3.3e-05	0.58	0.43	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
PCPG	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-5.84	3.08e-08	3.3e-05	-0.5	-0.43	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
PCPG	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-5.84	3.09e-08	3.31e-05	-0.46	-0.43	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
PCPG	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	5.84	3.09e-08	3.31e-05	0.73	0.43	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
PCPG	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	5.84	3.09e-08	3.31e-05	0.46	0.43	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
PCPG	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	5.84	3.1e-08	3.32e-05	0.57	0.43	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
PCPG	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	5.84	3.1e-08	3.32e-05	0.47	0.43	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
PCPG	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	5.84	3.11e-08	3.33e-05	0.68	0.43	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
PCPG	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	5.84	3.12e-08	3.33e-05	0.58	0.43	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	5.84	3.12e-08	3.33e-05	0.58	0.43	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
PCPG	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	5.84	3.12e-08	3.33e-05	0.56	0.43	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
PCPG	cis	rs453301	0.624	rs4841083	ENSG00000173295.6	FAM86B3P	-5.84	3.12e-08	3.34e-05	-0.5	-0.43	Joint mobility (Beighton score);	chr8:9012918	chr8:8228595~8244865:+
PCPG	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-5.84	3.13e-08	3.34e-05	-0.5	-0.43	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
PCPG	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-5.84	3.14e-08	3.36e-05	-0.57	-0.43	Depression;	chr6:28192182	chr6:28115628~28116551:+
PCPG	cis	rs804280	0.509	rs13276433	ENSG00000255020.1	AF131216.5	5.84	3.14e-08	3.36e-05	0.57	0.43	Myopia (pathological);	chr8:11925527	chr8:11345748~11347502:-
PCPG	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	5.84	3.14e-08	3.36e-05	0.53	0.43	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
PCPG	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-5.84	3.16e-08	3.38e-05	-0.49	-0.43	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
PCPG	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-5.84	3.18e-08	3.39e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
PCPG	cis	rs853679	1	rs7740487	ENSG00000216901.1	AL022393.7	5.84	3.19e-08	3.4e-05	0.75	0.43	Depression;	chr6:28248708	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs68141011	ENSG00000216901.1	AL022393.7	5.84	3.19e-08	3.4e-05	0.75	0.43	Depression;	chr6:28250019	chr6:28176188~28176674:+
PCPG	cis	rs7201929	1	rs8061877	ENSG00000251417.2	RP11-1348G14.4	5.84	3.19e-08	3.41e-05	0.52	0.43	QT interval;	chr16:28845498	chr16:28802743~28817828:+
PCPG	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-5.84	3.19e-08	3.41e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
PCPG	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	5.84	3.2e-08	3.41e-05	0.48	0.43	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	5.84	3.2e-08	3.41e-05	0.48	0.43	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	5.84	3.2e-08	3.41e-05	0.48	0.43	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
PCPG	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	5.83	3.21e-08	3.43e-05	0.56	0.43	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	5.83	3.21e-08	3.43e-05	0.56	0.43	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
PCPG	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-5.83	3.23e-08	3.45e-05	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
PCPG	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-5.83	3.23e-08	3.45e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
PCPG	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	5.83	3.24e-08	3.45e-05	0.78	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
PCPG	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	5.83	3.25e-08	3.47e-05	0.71	0.43	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
PCPG	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	5.83	3.25e-08	3.47e-05	0.71	0.43	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
PCPG	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	5.83	3.25e-08	3.47e-05	0.71	0.43	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
PCPG	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	5.83	3.26e-08	3.47e-05	0.53	0.43	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
PCPG	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-5.83	3.27e-08	3.48e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
PCPG	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	5.83	3.31e-08	3.52e-05	0.58	0.43	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
PCPG	cis	rs7267979	0.873	rs6115093	ENSG00000125804.12	FAM182A	-5.83	3.31e-08	3.53e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:26054655~26086917:+
PCPG	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	5.83	3.32e-08	3.53e-05	0.56	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
PCPG	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-5.83	3.33e-08	3.54e-05	-0.59	-0.43	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
PCPG	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	5.83	3.33e-08	3.54e-05	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
PCPG	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	5.83	3.33e-08	3.54e-05	0.53	0.43	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
PCPG	cis	rs453301	0.686	rs1045527	ENSG00000173295.6	FAM86B3P	5.83	3.33e-08	3.54e-05	0.5	0.43	Joint mobility (Beighton score);	chr8:9032531	chr8:8228595~8244865:+
PCPG	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	5.83	3.34e-08	3.55e-05	0.5	0.43	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
PCPG	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	5.83	3.34e-08	3.55e-05	0.6	0.43	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	5.83	3.34e-08	3.55e-05	0.6	0.43	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	5.83	3.34e-08	3.55e-05	0.6	0.43	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	5.83	3.34e-08	3.55e-05	0.6	0.43	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
PCPG	cis	rs910316	0.967	rs12147532	ENSG00000279594.1	RP11-950C14.10	-5.83	3.35e-08	3.56e-05	-0.55	-0.43	Height;	chr14:75185155	chr14:75011269~75012851:-
PCPG	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-5.82	3.37e-08	3.57e-05	-0.41	-0.43	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
PCPG	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-5.82	3.37e-08	3.58e-05	-0.44	-0.43	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
PCPG	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	5.82	3.37e-08	3.58e-05	0.43	0.43	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
PCPG	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-5.82	3.4e-08	3.6e-05	-0.63	-0.43	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-5.82	3.4e-08	3.6e-05	-0.63	-0.43	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-5.82	3.4e-08	3.6e-05	-0.63	-0.43	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
PCPG	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-5.82	3.4e-08	3.6e-05	-0.84	-0.43	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
PCPG	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-5.82	3.41e-08	3.61e-05	-0.42	-0.43	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
PCPG	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	5.82	3.42e-08	3.62e-05	0.56	0.43	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
PCPG	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	5.82	3.42e-08	3.62e-05	0.43	0.43	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
PCPG	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	5.82	3.42e-08	3.62e-05	0.43	0.43	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
PCPG	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-5.82	3.42e-08	3.62e-05	-0.39	-0.43	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-5.82	3.42e-08	3.62e-05	-0.39	-0.43	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
PCPG	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	5.82	3.45e-08	3.65e-05	0.47	0.43	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
PCPG	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	5.82	3.45e-08	3.65e-05	0.57	0.43	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
PCPG	cis	rs7402982	0.647	rs34038360	ENSG00000278022.1	RP11-35O15.2	-5.82	3.45e-08	3.66e-05	-0.43	-0.43	Birth weight;	chr15:98658344	chr15:98660210~98660668:+
PCPG	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	5.82	3.47e-08	3.67e-05	0.61	0.43	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	5.82	3.47e-08	3.67e-05	0.61	0.43	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
PCPG	cis	rs9595908	1	rs9591143	ENSG00000212293.1	SNORA16	5.82	3.48e-08	3.68e-05	0.51	0.43	Body mass index;	chr13:32585301	chr13:32420390~32420516:-
PCPG	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	5.82	3.49e-08	3.69e-05	0.54	0.43	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
PCPG	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-5.82	3.49e-08	3.69e-05	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-5.82	3.49e-08	3.69e-05	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-5.82	3.49e-08	3.69e-05	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-5.82	3.49e-08	3.69e-05	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
PCPG	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	5.82	3.49e-08	3.69e-05	0.52	0.43	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
PCPG	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-5.82	3.5e-08	3.7e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-5.82	3.5e-08	3.7e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-5.82	3.5e-08	3.7e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-5.82	3.5e-08	3.7e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-5.82	3.5e-08	3.7e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-5.82	3.5e-08	3.7e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
PCPG	cis	rs453301	0.686	rs28665409	ENSG00000173295.6	FAM86B3P	5.82	3.52e-08	3.72e-05	0.5	0.43	Joint mobility (Beighton score);	chr8:9011767	chr8:8228595~8244865:+
PCPG	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-5.82	3.52e-08	3.72e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
PCPG	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	5.82	3.52e-08	3.72e-05	0.56	0.43	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
PCPG	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	5.81	3.54e-08	3.74e-05	0.42	0.43	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
PCPG	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-5.81	3.55e-08	3.75e-05	-0.44	-0.43	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
PCPG	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-5.81	3.55e-08	3.75e-05	-0.51	-0.43	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
PCPG	cis	rs13113518	0.812	rs13116035	ENSG00000272969.1	RP11-528I4.2	5.81	3.56e-08	3.75e-05	0.47	0.43	Height;	chr4:55561218	chr4:55547112~55547889:+
PCPG	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	5.81	3.56e-08	3.75e-05	0.58	0.43	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	5.81	3.56e-08	3.75e-05	0.58	0.43	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	5.81	3.56e-08	3.75e-05	0.58	0.43	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	5.81	3.56e-08	3.75e-05	0.58	0.43	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
PCPG	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	5.81	3.56e-08	3.75e-05	0.58	0.43	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
PCPG	cis	rs453301	0.686	rs11785634	ENSG00000173295.6	FAM86B3P	5.81	3.57e-08	3.77e-05	0.51	0.43	Joint mobility (Beighton score);	chr8:9035087	chr8:8228595~8244865:+
PCPG	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	5.81	3.58e-08	3.78e-05	0.6	0.43	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
PCPG	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-5.81	3.59e-08	3.78e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-5.81	3.59e-08	3.78e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-5.81	3.59e-08	3.78e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-5.81	3.59e-08	3.78e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-5.81	3.59e-08	3.78e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
PCPG	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-5.81	3.59e-08	3.78e-05	-0.54	-0.43	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
PCPG	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	-5.81	3.59e-08	3.79e-05	-0.5	-0.43	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
PCPG	cis	rs910316	0.687	rs11627442	ENSG00000279594.1	RP11-950C14.10	-5.81	3.61e-08	3.8e-05	-0.56	-0.43	Height;	chr14:75202946	chr14:75011269~75012851:-
PCPG	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-5.81	3.62e-08	3.82e-05	-0.42	-0.43	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
PCPG	cis	rs7267979	0.932	rs417130	ENSG00000125804.12	FAM182A	-5.81	3.63e-08	3.82e-05	-0.48	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.932	rs372678	ENSG00000125804.12	FAM182A	-5.81	3.63e-08	3.82e-05	-0.48	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:26054655~26086917:+
PCPG	cis	rs1908814	0.516	rs10113042	ENSG00000255020.1	AF131216.5	5.81	3.65e-08	3.85e-05	0.58	0.43	Neuroticism;	chr8:11935669	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs10113062	ENSG00000255020.1	AF131216.5	5.81	3.65e-08	3.85e-05	0.58	0.43	Neuroticism;	chr8:11935740	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs10113145	ENSG00000255020.1	AF131216.5	5.81	3.65e-08	3.85e-05	0.58	0.43	Neuroticism;	chr8:11935786	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs7812563	ENSG00000255020.1	AF131216.5	5.81	3.65e-08	3.85e-05	0.58	0.43	Neuroticism;	chr8:11936979	chr8:11345748~11347502:-
PCPG	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-5.81	3.67e-08	3.86e-05	-0.46	-0.43	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
PCPG	cis	rs62103177	0.564	rs3930043	ENSG00000261126.6	RP11-795F19.1	5.81	3.67e-08	3.86e-05	0.56	0.43	Opioid sensitivity;	chr18:79963832	chr18:80046900~80095482:+
PCPG	cis	rs62103177	0.564	rs3930042	ENSG00000261126.6	RP11-795F19.1	5.81	3.67e-08	3.86e-05	0.56	0.43	Opioid sensitivity;	chr18:79963843	chr18:80046900~80095482:+
PCPG	cis	rs465969	0.744	rs574056	ENSG00000255389.1	C6orf3	-5.81	3.68e-08	3.87e-05	-0.88	-0.43	Psoriasis;	chr6:111305787	chr6:111599875~111602295:+
PCPG	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-5.81	3.68e-08	3.87e-05	-0.54	-0.43	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
PCPG	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-5.81	3.69e-08	3.88e-05	-0.37	-0.43	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
PCPG	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	5.8	3.73e-08	3.92e-05	0.56	0.43	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
PCPG	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-5.8	3.74e-08	3.93e-05	-0.53	-0.43	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-5.8	3.74e-08	3.93e-05	-0.53	-0.43	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
PCPG	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-5.8	3.74e-08	3.93e-05	-0.57	-0.43	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-5.8	3.74e-08	3.93e-05	-0.57	-0.43	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
PCPG	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	5.8	3.76e-08	3.95e-05	0.44	0.43	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	5.8	3.76e-08	3.95e-05	0.44	0.43	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
PCPG	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	5.8	3.77e-08	3.96e-05	0.38	0.43	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
PCPG	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	5.8	3.79e-08	3.97e-05	0.47	0.43	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
PCPG	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-5.8	3.79e-08	3.97e-05	-0.51	-0.43	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-5.8	3.79e-08	3.97e-05	-0.51	-0.43	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-5.8	3.79e-08	3.97e-05	-0.51	-0.43	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-5.8	3.79e-08	3.97e-05	-0.51	-0.43	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-5.8	3.79e-08	3.97e-05	-0.51	-0.43	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-5.8	3.79e-08	3.97e-05	-0.51	-0.43	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
PCPG	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-5.8	3.79e-08	3.97e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-5.8	3.79e-08	3.97e-05	-0.56	-0.43	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
PCPG	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	5.8	3.8e-08	3.98e-05	0.56	0.43	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
PCPG	cis	rs7267979	1	rs2387881	ENSG00000125804.12	FAM182A	5.8	3.81e-08	3.99e-05	0.49	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:26054655~26086917:+
PCPG	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-5.8	3.81e-08	3.99e-05	-0.51	-0.43	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
PCPG	cis	rs1908814	0.51	rs57655799	ENSG00000255020.1	AF131216.5	5.8	3.81e-08	4e-05	0.58	0.43	Neuroticism;	chr8:11924908	chr8:11345748~11347502:-
PCPG	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-5.8	3.81e-08	4e-05	-0.4	-0.43	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
PCPG	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-5.8	3.82e-08	4e-05	-0.54	-0.43	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
PCPG	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-5.8	3.83e-08	4.01e-05	-0.47	-0.43	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
PCPG	cis	rs6964833	0.554	rs2527366	ENSG00000277053.3	GTF2IP1	5.8	3.83e-08	4.02e-05	0.46	0.43	Menarche (age at onset);	chr7:74684615	chr7:75185385~75237696:-
PCPG	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	5.8	3.83e-08	4.02e-05	0.59	0.43	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-5.8	3.83e-08	4.02e-05	-0.59	-0.43	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-5.8	3.83e-08	4.02e-05	-0.59	-0.43	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-5.8	3.83e-08	4.02e-05	-0.59	-0.43	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
PCPG	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-5.8	3.85e-08	4.03e-05	-0.62	-0.43	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
PCPG	cis	rs2625529	0.73	rs2929527	ENSG00000260037.4	CTD-2524L6.3	5.8	3.85e-08	4.04e-05	0.54	0.43	Red blood cell count;	chr15:71989929	chr15:71818396~71823384:+
PCPG	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-5.8	3.86e-08	4.04e-05	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-5.8	3.86e-08	4.04e-05	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-5.8	3.86e-08	4.04e-05	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
PCPG	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	5.8	3.87e-08	4.05e-05	0.59	0.43	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
PCPG	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-5.8	3.87e-08	4.05e-05	-0.48	-0.43	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
PCPG	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	5.8	3.87e-08	4.05e-05	0.57	0.43	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	5.8	3.87e-08	4.05e-05	0.57	0.43	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
PCPG	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	5.8	3.88e-08	4.07e-05	0.57	0.43	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
PCPG	cis	rs2898290	0.592	rs2736342	ENSG00000255020.1	AF131216.5	-5.8	3.89e-08	4.07e-05	-0.57	-0.43	Systolic blood pressure;	chr8:11489780	chr8:11345748~11347502:-
PCPG	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-5.79	3.92e-08	4.1e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-5.79	3.92e-08	4.1e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
PCPG	cis	rs11148252	0.553	rs9536236	ENSG00000198384.8	TPTE2P3	-5.79	3.92e-08	4.1e-05	-0.56	-0.43	Lewy body disease;	chr13:52680877	chr13:52522632~52586906:+
PCPG	cis	rs7267979	0.744	rs6050463	ENSG00000125804.12	FAM182A	-5.79	3.92e-08	4.1e-05	-0.48	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:26054655~26086917:+
PCPG	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	5.79	3.94e-08	4.12e-05	0.7	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
PCPG	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-5.79	3.95e-08	4.13e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-5.79	3.95e-08	4.13e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-5.79	3.95e-08	4.13e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
PCPG	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	5.79	3.95e-08	4.13e-05	0.6	0.43	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	5.79	3.95e-08	4.13e-05	0.6	0.43	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	5.79	3.95e-08	4.13e-05	0.6	0.43	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	5.79	3.95e-08	4.13e-05	0.6	0.43	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
PCPG	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-5.79	3.96e-08	4.14e-05	-0.55	-0.43	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
PCPG	cis	rs453301	0.686	rs17702602	ENSG00000253893.2	FAM85B	5.79	3.97e-08	4.14e-05	0.54	0.43	Joint mobility (Beighton score);	chr8:9051086	chr8:8167819~8226614:-
PCPG	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	5.79	3.98e-08	4.16e-05	0.59	0.43	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
PCPG	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-5.79	4e-08	4.17e-05	-0.42	-0.43	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
PCPG	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	5.79	4.01e-08	4.18e-05	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	5.79	4.01e-08	4.18e-05	0.79	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
PCPG	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-5.79	4.02e-08	4.2e-05	-0.54	-0.43	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	5.79	4.02e-08	4.2e-05	0.54	0.43	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
PCPG	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-5.79	4.02e-08	4.2e-05	-0.48	-0.43	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-5.79	4.02e-08	4.2e-05	-0.48	-0.43	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
PCPG	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	5.79	4.03e-08	4.2e-05	0.59	0.43	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	5.79	4.03e-08	4.2e-05	0.59	0.43	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
PCPG	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-5.79	4.04e-08	4.21e-05	-0.55	-0.43	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
PCPG	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	5.79	4.05e-08	4.22e-05	0.54	0.43	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
PCPG	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	5.79	4.06e-08	4.23e-05	0.42	0.43	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
PCPG	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	5.79	4.06e-08	4.23e-05	0.61	0.43	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	5.79	4.06e-08	4.23e-05	0.61	0.43	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
PCPG	cis	rs7267979	0.903	rs2474766	ENSG00000125804.12	FAM182A	-5.78	4.11e-08	4.28e-05	-0.49	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.903	rs2474769	ENSG00000125804.12	FAM182A	-5.78	4.11e-08	4.28e-05	-0.49	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:26054655~26086917:+
PCPG	cis	rs13113518	0.812	rs13140590	ENSG00000272969.1	RP11-528I4.2	5.78	4.12e-08	4.29e-05	0.47	0.43	Height;	chr4:55548666	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs12500456	ENSG00000272969.1	RP11-528I4.2	5.78	4.12e-08	4.29e-05	0.47	0.43	Height;	chr4:55561053	chr4:55547112~55547889:+
PCPG	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	5.78	4.12e-08	4.29e-05	0.42	0.43	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
PCPG	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	5.78	4.12e-08	4.29e-05	0.42	0.43	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
PCPG	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-5.78	4.14e-08	4.31e-05	-0.54	-0.43	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
PCPG	cis	rs853679	1	rs853679	ENSG00000216901.1	AL022393.7	5.78	4.15e-08	4.31e-05	0.65	0.43	Depression;	chr6:28329086	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs853678	ENSG00000216901.1	AL022393.7	5.78	4.15e-08	4.31e-05	0.65	0.43	Depression;	chr6:28329536	chr6:28176188~28176674:+
PCPG	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-5.78	4.17e-08	4.34e-05	-0.53	-0.43	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-5.78	4.17e-08	4.34e-05	-0.53	-0.43	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
PCPG	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	5.78	4.18e-08	4.35e-05	0.5	0.43	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
PCPG	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	5.78	4.18e-08	4.35e-05	0.55	0.43	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	5.78	4.19e-08	4.35e-05	0.59	0.43	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
PCPG	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-5.78	4.19e-08	4.36e-05	-0.46	-0.43	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
PCPG	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-5.78	4.21e-08	4.37e-05	-0.52	-0.43	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
PCPG	cis	rs7824557	0.564	rs13260727	ENSG00000255020.1	AF131216.5	5.78	4.21e-08	4.38e-05	0.55	0.43	Retinal vascular caliber;	chr8:11375351	chr8:11345748~11347502:-
PCPG	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	5.78	4.22e-08	4.38e-05	0.55	0.43	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
PCPG	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-5.78	4.23e-08	4.39e-05	-0.49	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
PCPG	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-5.78	4.23e-08	4.39e-05	-0.49	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
PCPG	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-5.78	4.25e-08	4.41e-05	-0.52	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
PCPG	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	5.78	4.26e-08	4.43e-05	0.55	0.43	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
PCPG	cis	rs7267979	0.706	rs6138542	ENSG00000125804.12	FAM182A	-5.78	4.27e-08	4.43e-05	-0.49	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:26054655~26086917:+
PCPG	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-5.78	4.28e-08	4.44e-05	-0.5	-0.43	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
PCPG	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	5.78	4.28e-08	4.44e-05	0.56	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
PCPG	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-5.78	4.28e-08	4.44e-05	-0.56	-0.43	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
PCPG	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	5.77	4.29e-08	4.45e-05	0.59	0.43	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
PCPG	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-5.77	4.29e-08	4.45e-05	-0.51	-0.43	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
PCPG	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-5.77	4.29e-08	4.45e-05	-0.4	-0.43	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
PCPG	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-5.77	4.3e-08	4.46e-05	-0.48	-0.43	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
PCPG	cis	rs7267979	0.816	rs6115094	ENSG00000125804.12	FAM182A	-5.77	4.3e-08	4.46e-05	-0.48	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:26054655~26086917:+
PCPG	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	5.77	4.3e-08	4.46e-05	0.55	0.43	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
PCPG	cis	rs11148252	0.532	rs9536262	ENSG00000235660.1	LINC00345	5.77	4.31e-08	4.47e-05	0.54	0.43	Lewy body disease;	chr13:52728939	chr13:52484161~52484680:-
PCPG	cis	rs9595908	0.965	rs7335710	ENSG00000212293.1	SNORA16	5.77	4.32e-08	4.48e-05	0.51	0.43	Body mass index;	chr13:32561287	chr13:32420390~32420516:-
PCPG	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-5.77	4.35e-08	4.5e-05	-0.38	-0.43	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-5.77	4.35e-08	4.5e-05	-0.38	-0.43	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-5.77	4.35e-08	4.5e-05	-0.38	-0.43	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-5.77	4.35e-08	4.5e-05	-0.38	-0.43	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
PCPG	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	5.77	4.35e-08	4.51e-05	0.58	0.43	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
PCPG	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-5.77	4.37e-08	4.53e-05	-0.41	-0.43	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
PCPG	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	5.77	4.38e-08	4.53e-05	0.39	0.43	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
PCPG	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	5.77	4.4e-08	4.55e-05	0.59	0.43	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	5.77	4.4e-08	4.55e-05	0.59	0.43	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	5.77	4.4e-08	4.55e-05	0.59	0.43	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	5.77	4.4e-08	4.55e-05	0.59	0.43	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
PCPG	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	5.77	4.4e-08	4.55e-05	0.54	0.43	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	5.77	4.4e-08	4.55e-05	0.54	0.43	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-5.77	4.41e-08	4.56e-05	-0.59	-0.43	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
PCPG	cis	rs6964833	0.554	rs2527367	ENSG00000277053.3	GTF2IP1	5.77	4.41e-08	4.56e-05	0.46	0.43	Menarche (age at onset);	chr7:74684804	chr7:75185385~75237696:-
PCPG	cis	rs6964833	0.554	rs2527380	ENSG00000277053.3	GTF2IP1	5.77	4.41e-08	4.56e-05	0.46	0.43	Menarche (age at onset);	chr7:74690372	chr7:75185385~75237696:-
PCPG	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	5.77	4.41e-08	4.56e-05	0.53	0.43	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
PCPG	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-5.77	4.42e-08	4.57e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
PCPG	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	5.77	4.44e-08	4.58e-05	0.59	0.43	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	5.77	4.44e-08	4.58e-05	0.59	0.43	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	5.77	4.44e-08	4.58e-05	0.59	0.43	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
PCPG	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-5.77	4.44e-08	4.58e-05	-0.49	-0.43	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
PCPG	cis	rs6121246	0.529	rs6060142	ENSG00000230613.1	HM13-AS1	5.77	4.45e-08	4.59e-05	0.65	0.43	Mean corpuscular hemoglobin;	chr20:31590225	chr20:31567707~31573263:-
PCPG	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-5.77	4.47e-08	4.61e-05	-0.47	-0.43	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
PCPG	cis	rs2836950	1	rs2836950	ENSG00000255568.3	BRWD1-AS2	-5.77	4.48e-08	4.62e-05	-0.45	-0.43	Menarche (age at onset);	chr21:39232503	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.959	rs4818008	ENSG00000255568.3	BRWD1-AS2	-5.77	4.48e-08	4.62e-05	-0.45	-0.43	Menarche (age at onset);	chr21:39239516	chr21:39313935~39314962:+
PCPG	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	5.77	4.49e-08	4.63e-05	0.55	0.43	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
PCPG	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-5.77	4.49e-08	4.63e-05	-0.62	-0.43	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
PCPG	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-5.77	4.49e-08	4.63e-05	-0.62	-0.43	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
PCPG	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	5.77	4.5e-08	4.64e-05	0.41	0.43	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
PCPG	cis	rs440932	0.887	rs398801	ENSG00000253893.2	FAM85B	5.76	4.5e-08	4.64e-05	0.52	0.43	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8167819~8226614:-
PCPG	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	5.76	4.51e-08	4.65e-05	0.59	0.43	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	5.76	4.51e-08	4.65e-05	0.59	0.43	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
PCPG	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	5.76	4.53e-08	4.67e-05	0.53	0.43	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
PCPG	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	5.76	4.53e-08	4.67e-05	0.53	0.43	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
PCPG	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	5.76	4.53e-08	4.67e-05	0.53	0.43	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
PCPG	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	5.76	4.55e-08	4.68e-05	0.61	0.43	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	5.76	4.55e-08	4.68e-05	0.61	0.43	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
PCPG	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-5.76	4.55e-08	4.68e-05	-0.5	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-5.76	4.55e-08	4.68e-05	-0.5	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
PCPG	cis	rs748404	0.578	rs2244746	ENSG00000249839.1	AC011330.5	-5.76	4.55e-08	4.68e-05	-0.5	-0.43	Lung cancer;	chr15:43402885	chr15:43663654~43684339:-
PCPG	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	5.76	4.56e-08	4.7e-05	0.56	0.43	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
PCPG	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.76	4.57e-08	4.7e-05	0.47	0.43	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
PCPG	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	5.76	4.57e-08	4.7e-05	0.47	0.43	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	5.76	4.57e-08	4.7e-05	0.47	0.43	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	5.76	4.57e-08	4.7e-05	0.47	0.43	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	5.76	4.57e-08	4.7e-05	0.47	0.43	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
PCPG	cis	rs7824557	0.527	rs2572369	ENSG00000255020.1	AF131216.5	-5.76	4.57e-08	4.7e-05	-0.55	-0.43	Retinal vascular caliber;	chr8:11381088	chr8:11345748~11347502:-
PCPG	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	5.76	4.58e-08	4.71e-05	0.53	0.43	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
PCPG	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-5.76	4.58e-08	4.71e-05	-0.52	-0.43	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
PCPG	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	5.76	4.59e-08	4.72e-05	0.57	0.43	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
PCPG	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-5.76	4.59e-08	4.72e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
PCPG	cis	rs2625529	0.617	rs62023343	ENSG00000260037.4	CTD-2524L6.3	5.76	4.61e-08	4.74e-05	0.53	0.43	Red blood cell count;	chr15:71882622	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs2957724	ENSG00000260037.4	CTD-2524L6.3	5.76	4.61e-08	4.74e-05	0.53	0.43	Red blood cell count;	chr15:71956133	chr15:71818396~71823384:+
PCPG	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	5.76	4.61e-08	4.74e-05	0.55	0.43	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	5.76	4.61e-08	4.74e-05	0.55	0.43	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	5.76	4.61e-08	4.74e-05	0.55	0.43	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
PCPG	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	5.76	4.62e-08	4.75e-05	0.67	0.43	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	5.76	4.62e-08	4.75e-05	0.67	0.43	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	5.76	4.62e-08	4.75e-05	0.67	0.43	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
PCPG	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	5.76	4.62e-08	4.75e-05	0.38	0.43	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
PCPG	cis	rs7267979	1	rs2500436	ENSG00000125804.12	FAM182A	5.76	4.62e-08	4.75e-05	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6083856	ENSG00000125804.12	FAM182A	5.76	4.62e-08	4.75e-05	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.966	rs2482918	ENSG00000125804.12	FAM182A	5.76	4.62e-08	4.75e-05	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:26054655~26086917:+
PCPG	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-5.76	4.63e-08	4.75e-05	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-5.76	4.63e-08	4.75e-05	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-5.76	4.63e-08	4.75e-05	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
PCPG	cis	rs7267979	0.844	rs6132824	ENSG00000125804.12	FAM182A	-5.76	4.63e-08	4.75e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.739	rs6138555	ENSG00000125804.12	FAM182A	-5.76	4.63e-08	4.75e-05	-0.5	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:26054655~26086917:+
PCPG	cis	rs10131894	0.611	rs175000	ENSG00000279594.1	RP11-950C14.10	-5.76	4.64e-08	4.76e-05	-0.54	-0.43	Coronary artery disease;	chr14:74969664	chr14:75011269~75012851:-
PCPG	cis	rs7267979	1	rs6050559	ENSG00000125804.12	FAM182A	-5.76	4.65e-08	4.77e-05	-0.48	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:26054655~26086917:+
PCPG	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-5.76	4.66e-08	4.79e-05	-0.47	-0.43	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
PCPG	cis	rs453301	0.658	rs13271797	ENSG00000173295.6	FAM86B3P	5.76	4.66e-08	4.79e-05	0.5	0.43	Joint mobility (Beighton score);	chr8:9028444	chr8:8228595~8244865:+
PCPG	cis	rs55665837	0.701	rs2007361	ENSG00000251991.1	RNU7-49P	5.76	4.67e-08	4.79e-05	0.49	0.43	Vitamin D levels;	chr11:14641176	chr11:14478892~14478953:+
PCPG	cis	rs804280	0.509	rs13268030	ENSG00000255020.1	AF131216.5	5.76	4.67e-08	4.79e-05	0.56	0.43	Myopia (pathological);	chr8:11925564	chr8:11345748~11347502:-
PCPG	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-5.76	4.67e-08	4.79e-05	-0.52	-0.43	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
PCPG	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-5.76	4.68e-08	4.81e-05	-0.83	-0.43	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
PCPG	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	5.76	4.69e-08	4.81e-05	0.48	0.43	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
PCPG	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	5.76	4.71e-08	4.83e-05	0.59	0.43	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
PCPG	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-5.76	4.71e-08	4.83e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-5.76	4.71e-08	4.83e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-5.76	4.71e-08	4.83e-05	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
PCPG	cis	rs6121246	0.567	rs2889488	ENSG00000230613.1	HM13-AS1	5.76	4.71e-08	4.83e-05	0.65	0.43	Mean corpuscular hemoglobin;	chr20:31597955	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs56153385	ENSG00000230613.1	HM13-AS1	5.76	4.71e-08	4.83e-05	0.65	0.43	Mean corpuscular hemoglobin;	chr20:31599806	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6058189	ENSG00000230613.1	HM13-AS1	5.76	4.71e-08	4.83e-05	0.65	0.43	Mean corpuscular hemoglobin;	chr20:31604586	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6060262	ENSG00000230613.1	HM13-AS1	5.76	4.71e-08	4.83e-05	0.65	0.43	Mean corpuscular hemoglobin;	chr20:31605268	chr20:31567707~31573263:-
PCPG	cis	rs6060960	0.502	rs15817	ENSG00000230613.1	HM13-AS1	5.76	4.71e-08	4.83e-05	0.65	0.43	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr20:31605735	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs73235789	ENSG00000230613.1	HM13-AS1	5.76	4.71e-08	4.83e-05	0.65	0.43	Mean corpuscular hemoglobin;	chr20:31608345	chr20:31567707~31573263:-
PCPG	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	5.75	4.72e-08	4.84e-05	0.56	0.43	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
PCPG	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-5.75	4.72e-08	4.84e-05	-0.53	-0.43	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
PCPG	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-5.75	4.73e-08	4.84e-05	-0.51	-0.43	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-5.75	4.73e-08	4.84e-05	-0.51	-0.43	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-5.75	4.73e-08	4.84e-05	-0.51	-0.43	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
PCPG	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	5.75	4.73e-08	4.85e-05	0.47	0.43	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
PCPG	cis	rs2625529	0.689	rs12050794	ENSG00000260037.4	CTD-2524L6.3	5.75	4.74e-08	4.86e-05	0.53	0.43	Red blood cell count;	chr15:71877125	chr15:71818396~71823384:+
PCPG	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	5.75	4.75e-08	4.86e-05	0.44	0.43	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
PCPG	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	5.75	4.75e-08	4.87e-05	0.47	0.43	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
PCPG	cis	rs7267979	0.834	rs6115100	ENSG00000125804.12	FAM182A	-5.75	4.76e-08	4.87e-05	-0.49	-0.43	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:26054655~26086917:+
PCPG	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.77e-08	4.89e-05	-0.38	-0.43	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
PCPG	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-5.75	4.77e-08	4.89e-05	-0.45	-0.43	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
PCPG	cis	rs13113518	0.783	rs2171618	ENSG00000272969.1	RP11-528I4.2	5.75	4.78e-08	4.89e-05	0.46	0.43	Height;	chr4:55564241	chr4:55547112~55547889:+
PCPG	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	5.75	4.78e-08	4.89e-05	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	5.75	4.78e-08	4.89e-05	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	5.75	4.78e-08	4.89e-05	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
PCPG	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-5.75	4.78e-08	4.89e-05	-0.55	-0.43	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
PCPG	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	5.75	4.78e-08	4.89e-05	0.44	0.43	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
PCPG	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	5.75	4.81e-08	4.91e-05	0.38	0.43	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
PCPG	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-5.75	4.82e-08	4.93e-05	-0.46	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-5.75	4.82e-08	4.93e-05	-0.46	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-5.75	4.82e-08	4.93e-05	-0.46	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
PCPG	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-5.75	4.83e-08	4.94e-05	-0.53	-0.42	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
PCPG	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	5.75	4.84e-08	4.95e-05	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
PCPG	cis	rs853679	1	rs2799079	ENSG00000216901.1	AL022393.7	5.75	4.85e-08	4.95e-05	0.69	0.42	Depression;	chr6:28267398	chr6:28176188~28176674:+
PCPG	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-5.75	4.86e-08	4.96e-05	-0.48	-0.42	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
PCPG	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	5.75	4.86e-08	4.96e-05	0.47	0.42	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
PCPG	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	5.75	4.86e-08	4.97e-05	0.72	0.42	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
PCPG	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-5.75	4.87e-08	4.97e-05	-0.61	-0.42	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
PCPG	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	5.75	4.88e-08	4.98e-05	0.52	0.42	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
PCPG	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-5.75	4.89e-08	4.99e-05	-0.55	-0.42	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
PCPG	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-5.75	4.89e-08	4.99e-05	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
PCPG	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	5.75	4.89e-08	4.99e-05	0.48	0.42	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
PCPG	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	5.75	4.89e-08	4.99e-05	0.48	0.42	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
PCPG	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	5.75	4.89e-08	4.99e-05	0.48	0.42	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
PCPG	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	5.75	4.89e-08	4.99e-05	0.48	0.42	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
PCPG	cis	rs7267979	0.966	rs6050611	ENSG00000125804.12	FAM182A	-5.75	4.89e-08	4.99e-05	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:26054655~26086917:+
PCPG	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	5.75	4.92e-08	5.01e-05	0.57	0.42	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
PCPG	cis	rs561341	0.941	rs2428336	ENSG00000265798.5	RP11-271K11.5	5.75	4.92e-08	5.02e-05	0.79	0.42	Hip circumference adjusted for BMI;	chr17:31963558	chr17:31038575~31059121:-
PCPG	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	5.75	4.92e-08	5.02e-05	0.41	0.42	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
PCPG	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-5.75	4.93e-08	5.02e-05	-0.56	-0.42	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
PCPG	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	5.75	4.95e-08	5.05e-05	0.45	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
PCPG	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	5.74	4.96e-08	5.05e-05	0.57	0.42	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
PCPG	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	5.74	4.97e-08	5.07e-05	0.57	0.42	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
PCPG	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	5.74	4.98e-08	5.07e-05	0.62	0.42	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	5.74	4.98e-08	5.07e-05	0.62	0.42	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	5.74	4.98e-08	5.07e-05	0.62	0.42	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	5.74	4.98e-08	5.07e-05	0.62	0.42	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	5.74	4.98e-08	5.07e-05	0.62	0.42	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
PCPG	cis	rs11671005	0.504	rs2305119	ENSG00000269600.1	AC016629.3	-5.74	5e-08	5.09e-05	-0.59	-0.42	Mean platelet volume;	chr19:58556256	chr19:58593896~58599355:-
PCPG	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-5.74	5e-08	5.09e-05	-0.59	-0.42	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
PCPG	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	5.74	5e-08	5.09e-05	0.53	0.42	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
PCPG	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	5.74	5e-08	5.09e-05	0.53	0.42	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
PCPG	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	5.74	5e-08	5.09e-05	0.53	0.42	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
PCPG	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-5.74	5e-08	5.09e-05	-0.6	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
PCPG	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-5.74	5e-08	5.09e-05	-0.6	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
PCPG	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-5.74	5e-08	5.09e-05	-0.6	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
PCPG	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	5.74	5e-08	5.09e-05	0.38	0.42	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
PCPG	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	5.74	5.01e-08	5.1e-05	0.53	0.42	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
PCPG	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	5.74	5.01e-08	5.1e-05	0.53	0.42	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
PCPG	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-5.74	5.02e-08	5.11e-05	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
PCPG	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-5.74	5.02e-08	5.11e-05	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
PCPG	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	5.74	5.03e-08	5.12e-05	0.38	0.42	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	5.74	5.03e-08	5.12e-05	0.38	0.42	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
PCPG	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-5.74	5.05e-08	5.13e-05	-0.47	-0.42	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
PCPG	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-5.74	5.05e-08	5.14e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
PCPG	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-5.74	5.07e-08	5.15e-05	-0.57	-0.42	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
PCPG	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-5.74	5.07e-08	5.15e-05	-0.53	-0.42	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
PCPG	cis	rs10435719	0.647	rs10092605	ENSG00000255020.1	AF131216.5	5.74	5.07e-08	5.16e-05	0.57	0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:11345748~11347502:-
PCPG	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	5.74	5.08e-08	5.17e-05	0.51	0.42	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
PCPG	cis	rs7267979	0.549	rs11698185	ENSG00000125804.12	FAM182A	-5.74	5.12e-08	5.21e-05	-0.49	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.549	rs6138536	ENSG00000125804.12	FAM182A	-5.74	5.12e-08	5.21e-05	-0.49	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.549	rs6138537	ENSG00000125804.12	FAM182A	-5.74	5.13e-08	5.21e-05	-0.49	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25203830	chr20:26054655~26086917:+
PCPG	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	5.74	5.14e-08	5.23e-05	0.81	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
PCPG	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	5.74	5.14e-08	5.23e-05	0.81	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
PCPG	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	5.74	5.18e-08	5.26e-05	0.71	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	5.74	5.18e-08	5.26e-05	0.71	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
PCPG	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-5.74	5.18e-08	5.26e-05	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
PCPG	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-5.74	5.19e-08	5.27e-05	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-5.74	5.19e-08	5.27e-05	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-5.74	5.19e-08	5.27e-05	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
PCPG	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-5.73	5.21e-08	5.29e-05	-0.49	-0.42	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-5.73	5.21e-08	5.29e-05	-0.49	-0.42	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs8030536	ENSG00000249839.1	AC011330.5	-5.73	5.22e-08	5.3e-05	-0.57	-0.42	Lung cancer;	chr15:43627365	chr15:43663654~43684339:-
PCPG	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-5.73	5.22e-08	5.3e-05	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
PCPG	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-5.73	5.22e-08	5.3e-05	-0.53	-0.42	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
PCPG	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-5.73	5.22e-08	5.3e-05	-0.44	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-5.73	5.22e-08	5.3e-05	-0.44	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
PCPG	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-5.73	5.23e-08	5.3e-05	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
PCPG	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-5.73	5.23e-08	5.31e-05	-0.38	-0.42	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-5.73	5.23e-08	5.31e-05	-0.38	-0.42	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-5.73	5.23e-08	5.31e-05	-0.38	-0.42	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-5.73	5.23e-08	5.31e-05	-0.38	-0.42	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-5.73	5.23e-08	5.31e-05	-0.38	-0.42	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-5.73	5.23e-08	5.31e-05	-0.38	-0.42	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-5.73	5.23e-08	5.31e-05	-0.38	-0.42	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
PCPG	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.73	5.24e-08	5.31e-05	0.46	0.42	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
PCPG	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	-5.73	5.26e-08	5.33e-05	-0.49	-0.42	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
PCPG	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	5.73	5.27e-08	5.34e-05	0.71	0.42	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	5.73	5.27e-08	5.34e-05	0.71	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	5.73	5.27e-08	5.34e-05	0.71	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
PCPG	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	5.73	5.27e-08	5.34e-05	0.71	0.42	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
PCPG	cis	rs2625529	0.652	rs2957745	ENSG00000260037.4	CTD-2524L6.3	5.73	5.28e-08	5.35e-05	0.54	0.42	Red blood cell count;	chr15:71995736	chr15:71818396~71823384:+
PCPG	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-5.73	5.29e-08	5.36e-05	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
PCPG	cis	rs2625529	0.652	rs2929525	ENSG00000260037.4	CTD-2524L6.3	5.73	5.29e-08	5.36e-05	0.6	0.42	Red blood cell count;	chr15:71995515	chr15:71818396~71823384:+
PCPG	cis	rs453301	0.658	rs6986044	ENSG00000173295.6	FAM86B3P	5.73	5.29e-08	5.36e-05	0.5	0.42	Joint mobility (Beighton score);	chr8:9017276	chr8:8228595~8244865:+
PCPG	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	5.73	5.3e-08	5.37e-05	0.59	0.42	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
PCPG	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	5.73	5.31e-08	5.37e-05	0.48	0.42	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
PCPG	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	5.73	5.31e-08	5.38e-05	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
PCPG	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	5.73	5.31e-08	5.38e-05	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
PCPG	cis	rs1908814	0.516	rs60176945	ENSG00000255020.1	AF131216.5	5.73	5.31e-08	5.38e-05	0.58	0.42	Neuroticism;	chr8:11939165	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs56102998	ENSG00000255020.1	AF131216.5	5.73	5.31e-08	5.38e-05	0.58	0.42	Neuroticism;	chr8:11939166	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs35391955	ENSG00000255020.1	AF131216.5	5.73	5.31e-08	5.38e-05	0.58	0.42	Neuroticism;	chr8:11939219	chr8:11345748~11347502:-
PCPG	cis	rs1908814	0.516	rs58869268	ENSG00000255020.1	AF131216.5	5.73	5.31e-08	5.38e-05	0.58	0.42	Neuroticism;	chr8:11939586	chr8:11345748~11347502:-
PCPG	cis	rs804280	0.509	rs4841639	ENSG00000255020.1	AF131216.5	5.73	5.32e-08	5.38e-05	0.58	0.42	Myopia (pathological);	chr8:11938584	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.867	rs62493601	ENSG00000255020.1	AF131216.5	5.73	5.34e-08	5.4e-05	0.57	0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:11345748~11347502:-
PCPG	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	5.73	5.35e-08	5.42e-05	0.46	0.42	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
PCPG	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-5.73	5.37e-08	5.44e-05	-0.55	-0.42	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
PCPG	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	5.73	5.38e-08	5.44e-05	0.58	0.42	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
PCPG	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-5.73	5.38e-08	5.44e-05	-0.49	-0.42	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
PCPG	cis	rs7267979	0.714	rs6132825	ENSG00000125804.12	FAM182A	-5.73	5.39e-08	5.45e-05	-0.52	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:26054655~26086917:+
PCPG	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-5.73	5.4e-08	5.45e-05	-0.41	-0.42	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
PCPG	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-5.73	5.43e-08	5.49e-05	-0.48	-0.42	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
PCPG	cis	rs7826238	0.526	rs876955	ENSG00000253893.2	FAM85B	-5.73	5.43e-08	5.49e-05	-0.51	-0.42	Systolic blood pressure;	chr8:8453374	chr8:8167819~8226614:-
PCPG	cis	rs9595908	0.9	rs9591137	ENSG00000212293.1	SNORA16	5.73	5.44e-08	5.5e-05	0.5	0.42	Body mass index;	chr13:32578345	chr13:32420390~32420516:-
PCPG	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	5.73	5.45e-08	5.51e-05	0.38	0.42	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
PCPG	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	5.73	5.46e-08	5.51e-05	0.54	0.42	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
PCPG	cis	rs6964833	0.554	rs2527366	ENSG00000123965.13	PMS2P5	-5.72	5.46e-08	5.52e-05	-0.55	-0.42	Menarche (age at onset);	chr7:74684615	chr7:74894116~74897835:+
PCPG	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-5.72	5.47e-08	5.52e-05	-0.55	-0.42	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
PCPG	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	5.72	5.47e-08	5.52e-05	0.59	0.42	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	5.72	5.47e-08	5.52e-05	0.59	0.42	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
PCPG	cis	rs7267979	0.649	rs2500406	ENSG00000125804.12	FAM182A	5.72	5.48e-08	5.53e-05	0.53	0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:26054655~26086917:+
PCPG	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-5.72	5.48e-08	5.53e-05	-0.53	-0.42	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-5.72	5.48e-08	5.53e-05	-0.53	-0.42	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
PCPG	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	5.72	5.49e-08	5.54e-05	0.54	0.42	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
PCPG	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-5.72	5.5e-08	5.55e-05	-0.53	-0.42	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-5.72	5.5e-08	5.55e-05	-0.53	-0.42	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-5.72	5.5e-08	5.55e-05	-0.53	-0.42	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-5.72	5.5e-08	5.55e-05	-0.53	-0.42	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
PCPG	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-5.72	5.5e-08	5.55e-05	-0.53	-0.42	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
PCPG	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	5.72	5.51e-08	5.56e-05	0.58	0.42	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
PCPG	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	5.72	5.54e-08	5.58e-05	0.59	0.42	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
PCPG	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-5.72	5.55e-08	5.59e-05	-0.54	-0.42	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
PCPG	cis	rs9595908	0.9	rs9595890	ENSG00000212293.1	SNORA16	5.72	5.55e-08	5.59e-05	0.49	0.42	Body mass index;	chr13:32597518	chr13:32420390~32420516:-
PCPG	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-5.72	5.55e-08	5.6e-05	-0.46	-0.42	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-5.72	5.55e-08	5.6e-05	-0.46	-0.42	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-5.72	5.55e-08	5.6e-05	-0.46	-0.42	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-5.72	5.55e-08	5.6e-05	-0.46	-0.42	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
PCPG	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-5.72	5.56e-08	5.6e-05	-0.44	-0.42	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
PCPG	cis	rs10435719	0.764	rs10103485	ENSG00000255020.1	AF131216.5	5.72	5.56e-08	5.61e-05	0.57	0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:11345748~11347502:-
PCPG	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	5.72	5.58e-08	5.62e-05	0.58	0.42	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
PCPG	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	5.72	5.59e-08	5.63e-05	0.43	0.42	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
PCPG	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	5.72	5.6e-08	5.64e-05	0.47	0.42	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
PCPG	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-5.72	5.6e-08	5.64e-05	-0.49	-0.42	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
PCPG	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-5.72	5.6e-08	5.64e-05	-0.56	-0.42	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-5.72	5.6e-08	5.64e-05	-0.56	-0.42	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	5.72	5.6e-08	5.64e-05	0.56	0.42	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
PCPG	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	-5.72	5.6e-08	5.64e-05	-0.49	-0.42	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	-5.72	5.6e-08	5.64e-05	-0.49	-0.42	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
PCPG	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	5.72	5.61e-08	5.65e-05	0.57	0.42	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
PCPG	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-5.72	5.63e-08	5.67e-05	-0.46	-0.42	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-5.72	5.63e-08	5.67e-05	-0.46	-0.42	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-5.72	5.63e-08	5.67e-05	-0.46	-0.42	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-5.72	5.63e-08	5.67e-05	-0.46	-0.42	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-5.72	5.63e-08	5.67e-05	-0.46	-0.42	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-5.72	5.63e-08	5.67e-05	-0.46	-0.42	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-5.72	5.63e-08	5.67e-05	-0.46	-0.42	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
PCPG	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	5.72	5.63e-08	5.67e-05	0.61	0.42	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
PCPG	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-5.72	5.65e-08	5.69e-05	-0.47	-0.42	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
PCPG	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-5.72	5.67e-08	5.71e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
PCPG	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-5.72	5.68e-08	5.71e-05	-0.47	-0.42	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
PCPG	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	5.72	5.68e-08	5.72e-05	0.57	0.42	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
PCPG	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	5.72	5.71e-08	5.74e-05	0.46	0.42	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
PCPG	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-5.72	5.71e-08	5.74e-05	-0.84	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
PCPG	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	5.71	5.73e-08	5.76e-05	0.59	0.42	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
PCPG	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-5.71	5.74e-08	5.76e-05	-0.46	-0.42	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-5.71	5.74e-08	5.76e-05	-0.46	-0.42	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-5.71	5.74e-08	5.76e-05	-0.46	-0.42	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-5.71	5.74e-08	5.76e-05	-0.46	-0.42	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-5.71	5.74e-08	5.76e-05	-0.46	-0.42	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
PCPG	cis	rs9532669	0.819	rs9532652	ENSG00000176268.5	CYCSP34	5.71	5.75e-08	5.78e-05	0.52	0.42	Cervical cancer;	chr13:40903300	chr13:40863599~40863902:-
PCPG	cis	rs2625529	0.689	rs12898868	ENSG00000260037.4	CTD-2524L6.3	5.71	5.79e-08	5.82e-05	0.53	0.42	Red blood cell count;	chr15:71820577	chr15:71818396~71823384:+
PCPG	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-5.71	5.79e-08	5.82e-05	-0.53	-0.42	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-5.71	5.79e-08	5.82e-05	-0.53	-0.42	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
PCPG	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-5.71	5.8e-08	5.83e-05	-0.4	-0.42	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
PCPG	cis	rs6964833	0.554	rs2527367	ENSG00000123965.13	PMS2P5	-5.71	5.81e-08	5.84e-05	-0.56	-0.42	Menarche (age at onset);	chr7:74684804	chr7:74894116~74897835:+
PCPG	cis	rs6964833	0.554	rs2527380	ENSG00000123965.13	PMS2P5	-5.71	5.81e-08	5.84e-05	-0.56	-0.42	Menarche (age at onset);	chr7:74690372	chr7:74894116~74897835:+
PCPG	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-5.71	5.82e-08	5.85e-05	-0.51	-0.42	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
PCPG	cis	rs9595908	0.709	rs3213532	ENSG00000212293.1	SNORA16	5.71	5.83e-08	5.85e-05	0.51	0.42	Body mass index;	chr13:32773550	chr13:32420390~32420516:-
PCPG	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	5.71	5.83e-08	5.85e-05	0.61	0.42	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
PCPG	cis	rs11951515	0.508	rs7706431	ENSG00000248240.1	RP11-159F24.5	-5.71	5.85e-08	5.87e-05	-0.47	-0.42	Metabolite levels  (X-11787);	chr5:43582321	chr5:43515274~43525310:+
PCPG	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	5.71	5.87e-08	5.89e-05	0.47	0.42	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
PCPG	cis	rs7267979	0.773	rs6132821	ENSG00000125804.12	FAM182A	-5.71	5.89e-08	5.91e-05	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.873	rs6132822	ENSG00000125804.12	FAM182A	-5.71	5.89e-08	5.91e-05	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs1555330	ENSG00000125804.12	FAM182A	-5.71	5.89e-08	5.91e-05	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.844	rs6107017	ENSG00000125804.12	FAM182A	-5.71	5.89e-08	5.91e-05	-0.5	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:26054655~26086917:+
PCPG	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-5.71	5.92e-08	5.94e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-5.71	5.93e-08	5.95e-05	-0.61	-0.42	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
PCPG	cis	rs453301	0.624	rs2915251	ENSG00000173295.6	FAM86B3P	-5.71	5.93e-08	5.95e-05	-0.49	-0.42	Joint mobility (Beighton score);	chr8:9009901	chr8:8228595~8244865:+
PCPG	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	5.71	5.95e-08	5.96e-05	0.68	0.42	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	5.71	5.95e-08	5.96e-05	0.68	0.42	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
PCPG	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-5.71	5.95e-08	5.97e-05	-0.42	-0.42	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-5.71	5.95e-08	5.97e-05	-0.42	-0.42	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-5.71	5.95e-08	5.97e-05	-0.42	-0.42	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
PCPG	cis	rs9595908	0.709	rs9591311	ENSG00000212293.1	SNORA16	5.71	5.96e-08	5.97e-05	0.51	0.42	Body mass index;	chr13:32757339	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs4942897	ENSG00000212293.1	SNORA16	5.71	5.96e-08	5.97e-05	0.51	0.42	Body mass index;	chr13:32757615	chr13:32420390~32420516:-
PCPG	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-5.71	5.98e-08	5.99e-05	-0.5	-0.42	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
PCPG	cis	rs2625529	0.652	rs12148078	ENSG00000260037.4	CTD-2524L6.3	5.71	6.01e-08	6.01e-05	0.6	0.42	Red blood cell count;	chr15:72008130	chr15:71818396~71823384:+
PCPG	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-5.7	6.04e-08	6.04e-05	-0.51	-0.42	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
PCPG	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-5.7	6.04e-08	6.05e-05	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-5.7	6.04e-08	6.05e-05	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
PCPG	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-5.7	6.05e-08	6.05e-05	-0.52	-0.42	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
PCPG	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-5.7	6.05e-08	6.05e-05	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
PCPG	cis	rs5769765	0.773	rs9616391	ENSG00000278869.1	CITF22-49E9.3	5.7	6.05e-08	6.06e-05	0.62	0.42	Schizophrenia;	chr22:49920925	chr22:49933198~49934074:-
PCPG	cis	rs9595908	0.709	rs9315179	ENSG00000212293.1	SNORA16	5.7	6.09e-08	6.09e-05	0.51	0.42	Body mass index;	chr13:32773889	chr13:32420390~32420516:-
PCPG	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	5.7	6.09e-08	6.09e-05	0.58	0.42	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	5.7	6.09e-08	6.09e-05	0.58	0.42	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	5.7	6.09e-08	6.09e-05	0.58	0.42	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
PCPG	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	5.7	6.09e-08	6.09e-05	0.38	0.42	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
PCPG	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-5.7	6.09e-08	6.09e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
PCPG	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	5.7	6.1e-08	6.09e-05	0.49	0.42	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.9	rs1324415	ENSG00000212293.1	SNORA16	5.7	6.1e-08	6.09e-05	0.49	0.42	Body mass index;	chr13:32600186	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-5.7	6.1e-08	6.09e-05	-0.49	-0.42	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
PCPG	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-5.7	6.12e-08	6.12e-05	-0.52	-0.42	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
PCPG	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-5.7	6.13e-08	6.13e-05	-0.53	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
PCPG	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-5.7	6.15e-08	6.14e-05	-0.53	-0.42	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
PCPG	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-5.7	6.16e-08	6.15e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
PCPG	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-5.7	6.16e-08	6.15e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
PCPG	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-5.7	6.16e-08	6.15e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
PCPG	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-5.7	6.16e-08	6.15e-05	-0.55	-0.42	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
PCPG	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-5.7	6.17e-08	6.16e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
PCPG	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-5.7	6.2e-08	6.19e-05	-0.59	-0.42	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
PCPG	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	5.7	6.22e-08	6.2e-05	0.53	0.42	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
PCPG	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-5.7	6.22e-08	6.21e-05	-0.51	-0.42	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
PCPG	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-5.7	6.24e-08	6.22e-05	-0.56	-0.42	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
PCPG	cis	rs5769707	0.935	rs5770594	ENSG00000235111.1	RP1-29C18.8	-5.7	6.25e-08	6.24e-05	-0.48	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.967	rs4524218	ENSG00000235111.1	RP1-29C18.8	-5.7	6.25e-08	6.24e-05	-0.48	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49612657~49615716:-
PCPG	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-5.7	6.26e-08	6.24e-05	-0.52	-0.42	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
PCPG	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	5.7	6.27e-08	6.25e-05	0.37	0.42	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
PCPG	cis	rs11148252	0.574	rs73186430	ENSG00000198384.8	TPTE2P3	-5.7	6.28e-08	6.26e-05	-0.54	-0.42	Lewy body disease;	chr13:52658756	chr13:52522632~52586906:+
PCPG	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-5.7	6.28e-08	6.27e-05	-0.37	-0.42	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
PCPG	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-5.7	6.29e-08	6.27e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
PCPG	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-5.7	6.29e-08	6.27e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-5.7	6.29e-08	6.27e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
PCPG	cis	rs853679	1	rs1679732	ENSG00000216901.1	AL022393.7	-5.69	6.32e-08	6.29e-05	-0.71	-0.42	Depression;	chr6:28253486	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs1679709	ENSG00000216901.1	AL022393.7	-5.69	6.32e-08	6.29e-05	-0.71	-0.42	Depression;	chr6:28260564	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs1778511	ENSG00000216901.1	AL022393.7	-5.69	6.32e-08	6.29e-05	-0.71	-0.42	Depression;	chr6:28261633	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs1778508	ENSG00000216901.1	AL022393.7	-5.69	6.32e-08	6.29e-05	-0.71	-0.42	Depression;	chr6:28262103	chr6:28176188~28176674:+
PCPG	cis	rs853679	1	rs2799077	ENSG00000216901.1	AL022393.7	5.69	6.32e-08	6.29e-05	0.71	0.42	Depression;	chr6:28266819	chr6:28176188~28176674:+
PCPG	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-5.69	6.32e-08	6.3e-05	-0.51	-0.42	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
PCPG	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-5.69	6.36e-08	6.34e-05	-0.46	-0.42	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
PCPG	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-5.69	6.38e-08	6.35e-05	-0.54	-0.42	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
PCPG	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	5.69	6.39e-08	6.36e-05	0.54	0.42	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
PCPG	cis	rs2625529	0.689	rs12898728	ENSG00000260037.4	CTD-2524L6.3	-5.69	6.41e-08	6.37e-05	-0.56	-0.42	Red blood cell count;	chr15:71820512	chr15:71818396~71823384:+
PCPG	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-5.69	6.41e-08	6.38e-05	-0.42	-0.42	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
PCPG	cis	rs12681963	0.688	rs12548744	ENSG00000248159.1	HSPA8P11	5.69	6.46e-08	6.42e-05	0.79	0.42	Migraine;	chr8:30184400	chr8:30237382~30240997:+
PCPG	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-5.69	6.48e-08	6.44e-05	-0.46	-0.42	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
PCPG	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-5.69	6.48e-08	6.44e-05	-0.52	-0.42	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
PCPG	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	5.69	6.5e-08	6.46e-05	0.45	0.42	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
PCPG	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-5.69	6.51e-08	6.47e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
PCPG	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-5.69	6.51e-08	6.47e-05	-0.51	-0.42	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
PCPG	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	5.69	6.51e-08	6.47e-05	0.58	0.42	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	5.69	6.51e-08	6.47e-05	0.58	0.42	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
PCPG	cis	rs11148252	0.553	rs2147692	ENSG00000198384.8	TPTE2P3	-5.69	6.53e-08	6.48e-05	-0.54	-0.42	Lewy body disease;	chr13:52712888	chr13:52522632~52586906:+
PCPG	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	5.69	6.54e-08	6.5e-05	0.59	0.42	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	5.69	6.54e-08	6.5e-05	0.59	0.42	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
PCPG	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	5.69	6.55e-08	6.5e-05	0.66	0.42	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
PCPG	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	5.69	6.56e-08	6.51e-05	0.52	0.42	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
PCPG	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-5.69	6.56e-08	6.51e-05	-0.58	-0.42	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
PCPG	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	5.69	6.57e-08	6.52e-05	0.57	0.42	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
PCPG	cis	rs56804039	1	rs17616779	ENSG00000253893.2	FAM85B	-5.69	6.57e-08	6.52e-05	-0.63	-0.42	Cervical cancer;	chr8:8524864	chr8:8167819~8226614:-
PCPG	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-5.69	6.58e-08	6.53e-05	-0.49	-0.42	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
PCPG	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-5.69	6.59e-08	6.53e-05	-0.47	-0.42	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
PCPG	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-5.69	6.59e-08	6.53e-05	-0.47	-0.42	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
PCPG	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-5.69	6.61e-08	6.55e-05	-0.48	-0.42	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
PCPG	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	5.68	6.62e-08	6.57e-05	0.37	0.42	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
PCPG	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	5.68	6.63e-08	6.58e-05	0.58	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
PCPG	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	5.68	6.64e-08	6.58e-05	0.54	0.42	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
PCPG	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-5.68	6.66e-08	6.6e-05	-0.54	-0.42	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
PCPG	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-5.68	6.67e-08	6.61e-05	-0.53	-0.42	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
PCPG	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	5.68	6.68e-08	6.62e-05	0.45	0.42	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
PCPG	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-5.68	6.69e-08	6.63e-05	-0.51	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
PCPG	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	5.68	6.71e-08	6.65e-05	0.53	0.42	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
PCPG	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	5.68	6.74e-08	6.67e-05	0.36	0.42	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	5.68	6.74e-08	6.67e-05	0.36	0.42	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	5.68	6.74e-08	6.67e-05	0.36	0.42	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
PCPG	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	5.68	6.76e-08	6.69e-05	0.5	0.42	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
PCPG	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-5.68	6.77e-08	6.7e-05	-0.49	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
PCPG	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-5.68	6.77e-08	6.7e-05	-0.49	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
PCPG	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	5.68	6.77e-08	6.7e-05	0.59	0.42	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
PCPG	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	5.68	6.79e-08	6.73e-05	0.59	0.42	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	5.68	6.79e-08	6.73e-05	0.59	0.42	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
PCPG	cis	rs9595908	1	rs718444	ENSG00000212293.1	SNORA16	5.68	6.8e-08	6.73e-05	0.5	0.42	Body mass index;	chr13:32572915	chr13:32420390~32420516:-
PCPG	cis	rs9595908	1	rs7332115	ENSG00000212293.1	SNORA16	5.68	6.8e-08	6.73e-05	0.5	0.42	Body mass index;	chr13:32573411	chr13:32420390~32420516:-
PCPG	cis	rs9595908	1	rs7332763	ENSG00000212293.1	SNORA16	5.68	6.8e-08	6.73e-05	0.5	0.42	Body mass index;	chr13:32573751	chr13:32420390~32420516:-
PCPG	cis	rs9595908	1	rs9591134	ENSG00000212293.1	SNORA16	5.68	6.8e-08	6.73e-05	0.5	0.42	Body mass index;	chr13:32574079	chr13:32420390~32420516:-
PCPG	cis	rs4819052	0.655	rs2330103	ENSG00000215447.6	BX322557.10	-5.68	6.82e-08	6.75e-05	-0.38	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45288052~45291738:+
PCPG	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	5.68	6.83e-08	6.75e-05	0.67	0.42	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
PCPG	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-5.68	6.83e-08	6.75e-05	-0.46	-0.42	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
PCPG	cis	rs853679	1	rs9986596	ENSG00000216901.1	AL022393.7	5.68	6.84e-08	6.76e-05	0.73	0.42	Depression;	chr6:28251883	chr6:28176188~28176674:+
PCPG	cis	rs5769765	0.955	rs9616394	ENSG00000278869.1	CITF22-49E9.3	5.68	6.84e-08	6.76e-05	0.6	0.42	Schizophrenia;	chr22:49921279	chr22:49933198~49934074:-
PCPG	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	5.68	6.84e-08	6.76e-05	0.56	0.42	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
PCPG	cis	rs2625529	0.586	rs7173626	ENSG00000260037.4	CTD-2524L6.3	5.68	6.85e-08	6.77e-05	0.52	0.42	Red blood cell count;	chr15:71894585	chr15:71818396~71823384:+
PCPG	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	5.68	6.86e-08	6.78e-05	0.59	0.42	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
PCPG	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-5.68	6.87e-08	6.79e-05	-0.5	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
PCPG	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	5.68	6.88e-08	6.8e-05	0.51	0.42	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
PCPG	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-5.68	6.92e-08	6.84e-05	-0.52	-0.42	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
PCPG	cis	rs5769707	0.967	rs17182154	ENSG00000235111.1	RP1-29C18.8	-5.68	6.92e-08	6.84e-05	-0.46	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49612657~49615716:-
PCPG	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	5.68	6.93e-08	6.84e-05	0.36	0.42	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
PCPG	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-5.67	6.95e-08	6.86e-05	-0.37	-0.42	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
PCPG	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-5.67	6.96e-08	6.87e-05	-0.46	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
PCPG	cis	rs4819052	0.655	rs2330103	ENSG00000223768.1	LINC00205	-5.67	6.97e-08	6.88e-05	-0.51	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45293285~45297354:+
PCPG	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-5.67	6.99e-08	6.89e-05	-0.49	-0.42	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
PCPG	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	5.67	7e-08	6.91e-05	0.59	0.42	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	5.67	7e-08	6.91e-05	0.59	0.42	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
PCPG	cis	rs2412819	0.571	rs66903736	ENSG00000249839.1	AC011330.5	-5.67	7.01e-08	6.92e-05	-0.56	-0.42	Lung cancer;	chr15:43619435	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs66749753	ENSG00000249839.1	AC011330.5	-5.67	7.01e-08	6.92e-05	-0.56	-0.42	Lung cancer;	chr15:43619601	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs8038068	ENSG00000249839.1	AC011330.5	-5.67	7.01e-08	6.92e-05	-0.56	-0.42	Lung cancer;	chr15:43622175	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs56246169	ENSG00000249839.1	AC011330.5	-5.67	7.01e-08	6.92e-05	-0.56	-0.42	Lung cancer;	chr15:43628358	chr15:43663654~43684339:-
PCPG	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	5.67	7.01e-08	6.92e-05	0.52	0.42	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	5.67	7.01e-08	6.92e-05	0.52	0.42	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	5.67	7.01e-08	6.92e-05	0.52	0.42	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	5.67	7.01e-08	6.92e-05	0.52	0.42	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	5.67	7.01e-08	6.92e-05	0.52	0.42	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
PCPG	cis	rs9595908	0.897	rs10083285	ENSG00000212293.1	SNORA16	5.67	7.02e-08	6.92e-05	0.49	0.42	Body mass index;	chr13:32557205	chr13:32420390~32420516:-
PCPG	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	5.67	7.02e-08	6.92e-05	0.45	0.42	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
PCPG	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	5.67	7.04e-08	6.94e-05	0.59	0.42	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
PCPG	cis	rs2625529	0.617	rs2929509	ENSG00000260037.4	CTD-2524L6.3	5.67	7.04e-08	6.94e-05	0.52	0.42	Red blood cell count;	chr15:71946931	chr15:71818396~71823384:+
PCPG	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	5.67	7.05e-08	6.95e-05	0.49	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
PCPG	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	5.67	7.05e-08	6.95e-05	0.6	0.42	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
PCPG	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-5.67	7.08e-08	6.98e-05	-0.55	-0.42	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
PCPG	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-5.67	7.08e-08	6.98e-05	-0.49	-0.42	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
PCPG	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-5.67	7.09e-08	6.99e-05	-0.49	-0.42	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
PCPG	cis	rs7824557	0.734	rs2293856	ENSG00000255020.1	AF131216.5	5.67	7.09e-08	6.99e-05	0.55	0.42	Retinal vascular caliber;	chr8:11319938	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	5.67	7.1e-08	6.99e-05	0.52	0.42	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
PCPG	cis	rs5769707	0.967	rs739248	ENSG00000235111.1	RP1-29C18.8	-5.67	7.1e-08	6.99e-05	-0.48	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.967	rs2071904	ENSG00000235111.1	RP1-29C18.8	-5.67	7.1e-08	6.99e-05	-0.48	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49612657~49615716:-
PCPG	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-5.67	7.1e-08	6.99e-05	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-5.67	7.1e-08	6.99e-05	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
PCPG	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	5.67	7.12e-08	7e-05	0.37	0.42	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
PCPG	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	5.67	7.12e-08	7.01e-05	0.53	0.42	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
PCPG	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-5.67	7.13e-08	7.01e-05	-0.45	-0.42	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
PCPG	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	5.67	7.14e-08	7.02e-05	0.59	0.42	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
PCPG	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	5.67	7.16e-08	7.02e-05	0.44	0.42	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	5.67	7.16e-08	7.02e-05	0.44	0.42	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
PCPG	cis	rs11858159	0.966	rs7172621	ENSG00000259905.4	PWRN1	5.67	7.16e-08	7.03e-05	0.49	0.42	Platelet thrombus formation;	chr15:24555234	chr15:24493137~24652130:+
PCPG	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	5.67	7.16e-08	7.03e-05	0.47	0.42	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
PCPG	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	5.67	7.16e-08	7.03e-05	0.55	0.42	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
PCPG	cis	rs2625529	0.73	rs6494990	ENSG00000260037.4	CTD-2524L6.3	5.67	7.19e-08	7.05e-05	0.58	0.42	Red blood cell count;	chr15:72108733	chr15:71818396~71823384:+
PCPG	cis	rs1023500	0.551	rs2854837	ENSG00000205702.9	CYP2D7	5.67	7.21e-08	7.07e-05	0.44	0.42	Schizophrenia;	chr22:42062477	chr22:42140203~42144577:-
PCPG	cis	rs453301	0.571	rs2929454	ENSG00000173295.6	FAM86B3P	5.67	7.21e-08	7.07e-05	0.49	0.42	Joint mobility (Beighton score);	chr8:9226344	chr8:8228595~8244865:+
PCPG	cis	rs453301	0.571	rs2929453	ENSG00000173295.6	FAM86B3P	5.67	7.21e-08	7.07e-05	0.49	0.42	Joint mobility (Beighton score);	chr8:9226831	chr8:8228595~8244865:+
PCPG	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-5.67	7.22e-08	7.08e-05	-0.46	-0.42	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-5.67	7.22e-08	7.08e-05	-0.46	-0.42	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-5.67	7.22e-08	7.08e-05	-0.46	-0.42	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-5.67	7.22e-08	7.08e-05	-0.46	-0.42	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-5.67	7.22e-08	7.08e-05	-0.46	-0.42	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-5.67	7.22e-08	7.08e-05	-0.46	-0.42	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-5.67	7.22e-08	7.08e-05	-0.46	-0.42	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
PCPG	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	5.67	7.24e-08	7.09e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	5.67	7.24e-08	7.09e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	5.67	7.24e-08	7.09e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	5.67	7.24e-08	7.09e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
PCPG	cis	rs9595908	0.669	rs17594908	ENSG00000212293.1	SNORA16	5.67	7.25e-08	7.1e-05	0.52	0.42	Body mass index;	chr13:32789427	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs2025474	ENSG00000212293.1	SNORA16	5.67	7.25e-08	7.1e-05	0.52	0.42	Body mass index;	chr13:32792319	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.693	rs4942911	ENSG00000212293.1	SNORA16	5.67	7.25e-08	7.1e-05	0.52	0.42	Body mass index;	chr13:32793038	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs4941669	ENSG00000212293.1	SNORA16	5.67	7.25e-08	7.1e-05	0.52	0.42	Body mass index;	chr13:32793045	chr13:32420390~32420516:-
PCPG	cis	rs2625529	0.775	rs4777466	ENSG00000260037.4	CTD-2524L6.3	-5.67	7.26e-08	7.11e-05	-0.56	-0.42	Red blood cell count;	chr15:71844531	chr15:71818396~71823384:+
PCPG	cis	rs7267979	0.586	rs6050445	ENSG00000125804.12	FAM182A	-5.67	7.27e-08	7.12e-05	-0.47	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:26054655~26086917:+
PCPG	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	5.67	7.29e-08	7.13e-05	0.58	0.42	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
PCPG	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	5.67	7.29e-08	7.13e-05	0.53	0.42	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
PCPG	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	5.66	7.3e-08	7.14e-05	0.67	0.42	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	5.66	7.3e-08	7.14e-05	0.67	0.42	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	5.66	7.3e-08	7.14e-05	0.67	0.42	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	5.66	7.3e-08	7.14e-05	0.67	0.42	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	5.66	7.3e-08	7.14e-05	0.67	0.42	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	5.66	7.3e-08	7.14e-05	0.67	0.42	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
PCPG	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	5.66	7.31e-08	7.15e-05	0.52	0.42	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
PCPG	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-5.66	7.31e-08	7.15e-05	-0.38	-0.42	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
PCPG	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	5.66	7.32e-08	7.16e-05	0.45	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
PCPG	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	5.66	7.35e-08	7.19e-05	0.43	0.42	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
PCPG	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-5.66	7.35e-08	7.19e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-5.66	7.35e-08	7.19e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-5.66	7.35e-08	7.19e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-5.66	7.35e-08	7.19e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-5.66	7.35e-08	7.19e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
PCPG	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-5.66	7.37e-08	7.2e-05	-0.54	-0.42	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
PCPG	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	5.66	7.4e-08	7.23e-05	0.58	0.42	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
PCPG	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-5.66	7.4e-08	7.23e-05	-0.47	-0.42	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
PCPG	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	5.66	7.4e-08	7.23e-05	0.5	0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
PCPG	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	5.66	7.44e-08	7.27e-05	0.46	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
PCPG	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-5.66	7.49e-08	7.31e-05	-0.41	-0.42	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
PCPG	cis	rs9595908	0.931	rs55645971	ENSG00000212293.1	SNORA16	5.66	7.5e-08	7.32e-05	0.49	0.42	Body mass index;	chr13:32615452	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.568	rs61945198	ENSG00000212293.1	SNORA16	5.66	7.51e-08	7.33e-05	0.52	0.42	Body mass index;	chr13:32797780	chr13:32420390~32420516:-
PCPG	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-5.66	7.51e-08	7.33e-05	-0.41	-0.42	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
PCPG	cis	rs2625529	0.652	rs2930069	ENSG00000260037.4	CTD-2524L6.3	5.66	7.52e-08	7.34e-05	0.52	0.42	Red blood cell count;	chr15:71934636	chr15:71818396~71823384:+
PCPG	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	5.66	7.52e-08	7.34e-05	0.58	0.42	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	5.66	7.52e-08	7.34e-05	0.58	0.42	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
PCPG	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	5.66	7.52e-08	7.34e-05	0.5	0.42	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
PCPG	cis	rs7402982	0.625	rs4966009	ENSG00000278022.1	RP11-35O15.2	-5.66	7.54e-08	7.36e-05	-0.42	-0.42	Birth weight;	chr15:98660267	chr15:98660210~98660668:+
PCPG	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	5.66	7.54e-08	7.36e-05	0.59	0.42	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
PCPG	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	5.66	7.55e-08	7.37e-05	0.43	0.42	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
PCPG	cis	rs440932	1	rs440932	ENSG00000253893.2	FAM85B	-5.66	7.56e-08	7.37e-05	-0.53	-0.42	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:8167819~8226614:-
PCPG	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	5.66	7.57e-08	7.38e-05	0.76	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
PCPG	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	5.66	7.59e-08	7.4e-05	0.66	0.42	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	5.66	7.59e-08	7.4e-05	0.66	0.42	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
PCPG	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-5.66	7.6e-08	7.41e-05	-0.47	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
PCPG	cis	rs7267979	0.586	rs1007707	ENSG00000125804.12	FAM182A	-5.66	7.61e-08	7.41e-05	-0.47	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.586	rs1007708	ENSG00000125804.12	FAM182A	-5.66	7.61e-08	7.41e-05	-0.47	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.586	rs6050439	ENSG00000125804.12	FAM182A	-5.66	7.61e-08	7.41e-05	-0.47	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:26054655~26086917:+
PCPG	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	5.66	7.61e-08	7.41e-05	0.61	0.42	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
PCPG	cis	rs2412819	0.52	rs17727763	ENSG00000249839.1	AC011330.5	-5.66	7.63e-08	7.43e-05	-0.57	-0.42	Lung cancer;	chr15:43623873	chr15:43663654~43684339:-
PCPG	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-5.66	7.63e-08	7.43e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-5.66	7.63e-08	7.43e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-5.66	7.63e-08	7.43e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
PCPG	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-5.66	7.64e-08	7.44e-05	-0.56	-0.42	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
PCPG	cis	rs6060960	0.502	rs6057968	ENSG00000230613.1	HM13-AS1	5.66	7.65e-08	7.45e-05	0.69	0.42	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr20:31494976	chr20:31567707~31573263:-
PCPG	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-5.65	7.65e-08	7.45e-05	-0.47	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
PCPG	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-5.65	7.65e-08	7.45e-05	-0.47	-0.42	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
PCPG	cis	rs55665837	0.665	rs11023273	ENSG00000251991.1	RNU7-49P	5.65	7.67e-08	7.47e-05	0.47	0.42	Vitamin D levels;	chr11:14609273	chr11:14478892~14478953:+
PCPG	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-5.65	7.68e-08	7.48e-05	-0.47	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
PCPG	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-5.65	7.7e-08	7.5e-05	-0.49	-0.42	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-5.65	7.7e-08	7.5e-05	-0.49	-0.42	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
PCPG	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	5.65	7.72e-08	7.52e-05	0.52	0.42	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
PCPG	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	5.65	7.73e-08	7.52e-05	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	5.65	7.73e-08	7.52e-05	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
PCPG	cis	rs2625529	0.591	rs7172158	ENSG00000260037.4	CTD-2524L6.3	5.65	7.74e-08	7.53e-05	0.57	0.42	Red blood cell count;	chr15:72112972	chr15:71818396~71823384:+
PCPG	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	5.65	7.74e-08	7.53e-05	0.53	0.42	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
PCPG	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	5.65	7.74e-08	7.53e-05	0.53	0.42	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
PCPG	cis	rs6121246	0.542	rs6059761	ENSG00000230613.1	HM13-AS1	5.65	7.75e-08	7.54e-05	0.66	0.42	Mean corpuscular hemoglobin;	chr20:31522719	chr20:31567707~31573263:-
PCPG	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-5.65	7.8e-08	7.59e-05	-0.48	-0.42	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
PCPG	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-5.65	7.85e-08	7.63e-05	-0.51	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
PCPG	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-5.65	7.85e-08	7.63e-05	-0.51	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
PCPG	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-5.65	7.85e-08	7.63e-05	-0.51	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
PCPG	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-5.65	7.88e-08	7.65e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-5.65	7.88e-08	7.65e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
PCPG	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	5.65	7.88e-08	7.65e-05	0.54	0.42	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
PCPG	cis	rs6121246	0.529	rs6060118	ENSG00000230613.1	HM13-AS1	5.65	7.88e-08	7.65e-05	0.67	0.42	Mean corpuscular hemoglobin;	chr20:31583406	chr20:31567707~31573263:-
PCPG	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-5.65	7.89e-08	7.66e-05	-0.55	-0.42	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-5.65	7.89e-08	7.66e-05	-0.55	-0.42	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-5.65	7.89e-08	7.66e-05	-0.55	-0.42	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-5.65	7.89e-08	7.66e-05	-0.55	-0.42	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
PCPG	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-5.65	7.91e-08	7.68e-05	-0.52	-0.42	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
PCPG	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	5.65	7.91e-08	7.68e-05	0.5	0.42	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
PCPG	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-5.65	7.92e-08	7.69e-05	-0.4	-0.42	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
PCPG	cis	rs2898290	0.622	rs1478890	ENSG00000255020.1	AF131216.5	-5.65	7.93e-08	7.7e-05	-0.53	-0.42	Systolic blood pressure;	chr8:11498093	chr8:11345748~11347502:-
PCPG	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	5.65	7.94e-08	7.71e-05	0.56	0.42	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
PCPG	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-5.65	7.95e-08	7.72e-05	-0.49	-0.42	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
PCPG	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-5.65	7.97e-08	7.74e-05	-0.51	-0.42	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
PCPG	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-5.65	8e-08	7.76e-05	-0.49	-0.42	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
PCPG	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	5.65	8.01e-08	7.77e-05	0.58	0.42	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
PCPG	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-5.65	8.01e-08	7.77e-05	-0.75	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
PCPG	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-5.65	8.02e-08	7.78e-05	-0.48	-0.42	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
PCPG	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-5.65	8.02e-08	7.78e-05	-0.48	-0.42	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
PCPG	cis	rs7267979	1	rs7020	ENSG00000125804.12	FAM182A	-5.65	8.02e-08	7.78e-05	-0.48	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:26054655~26086917:+
PCPG	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	5.65	8.02e-08	7.78e-05	0.38	0.42	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
PCPG	cis	rs9595908	0.746	rs12427832	ENSG00000212293.1	SNORA16	-5.64	8.03e-08	7.79e-05	-0.51	-0.42	Body mass index;	chr13:32644896	chr13:32420390~32420516:-
PCPG	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	5.64	8.05e-08	7.8e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	5.64	8.05e-08	7.8e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	5.64	8.05e-08	7.8e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
PCPG	cis	rs2625529	0.689	rs8178	ENSG00000260037.4	CTD-2524L6.3	-5.64	8.12e-08	7.86e-05	-0.56	-0.42	Red blood cell count;	chr15:71822406	chr15:71818396~71823384:+
PCPG	cis	rs804280	0.509	rs12719915	ENSG00000255020.1	AF131216.5	-5.64	8.13e-08	7.87e-05	-0.56	-0.42	Myopia (pathological);	chr8:11928746	chr8:11345748~11347502:-
PCPG	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	5.64	8.16e-08	7.9e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
PCPG	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-5.64	8.18e-08	7.91e-05	-0.49	-0.42	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-5.64	8.18e-08	7.91e-05	-0.49	-0.42	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-5.64	8.18e-08	7.91e-05	-0.49	-0.42	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
PCPG	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-5.64	8.2e-08	7.93e-05	-0.45	-0.42	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
PCPG	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	5.64	8.24e-08	7.98e-05	0.42	0.42	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
PCPG	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	5.64	8.25e-08	7.98e-05	0.6	0.42	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	5.64	8.26e-08	7.99e-05	0.55	0.42	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
PCPG	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	5.64	8.28e-08	8.01e-05	0.48	0.42	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
PCPG	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	5.64	8.28e-08	8.01e-05	0.55	0.42	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
PCPG	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	5.64	8.33e-08	8.05e-05	0.38	0.42	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	5.64	8.33e-08	8.06e-05	0.37	0.42	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
PCPG	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	5.64	8.33e-08	8.06e-05	0.57	0.42	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
PCPG	cis	rs10435719	0.902	rs7459983	ENSG00000255020.1	AF131216.5	5.64	8.35e-08	8.07e-05	0.57	0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:11345748~11347502:-
PCPG	cis	rs9595908	0.965	rs9595893	ENSG00000212293.1	SNORA16	5.64	8.35e-08	8.07e-05	0.49	0.42	Body mass index;	chr13:32601656	chr13:32420390~32420516:-
PCPG	cis	rs9595908	1	rs9595908	ENSG00000212293.1	SNORA16	5.64	8.35e-08	8.07e-05	0.49	0.42	Body mass index;	chr13:32610151	chr13:32420390~32420516:-
PCPG	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	5.64	8.36e-08	8.08e-05	0.55	0.42	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	5.64	8.36e-08	8.08e-05	0.55	0.42	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	5.64	8.36e-08	8.08e-05	0.55	0.42	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	5.64	8.36e-08	8.08e-05	0.55	0.42	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
PCPG	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	5.63	8.42e-08	8.14e-05	0.59	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
PCPG	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-5.63	8.45e-08	8.16e-05	-0.46	-0.42	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-5.63	8.45e-08	8.16e-05	-0.46	-0.42	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
PCPG	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	5.63	8.46e-08	8.17e-05	0.37	0.42	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	5.63	8.47e-08	8.17e-05	0.38	0.42	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
PCPG	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	5.63	8.48e-08	8.18e-05	0.59	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
PCPG	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-5.63	8.49e-08	8.19e-05	-0.42	-0.42	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
PCPG	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	5.63	8.5e-08	8.2e-05	0.45	0.42	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
PCPG	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-5.63	8.51e-08	8.21e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
PCPG	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	5.63	8.52e-08	8.22e-05	0.67	0.42	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
PCPG	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	5.63	8.52e-08	8.22e-05	0.41	0.42	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
PCPG	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-5.63	8.54e-08	8.24e-05	-0.72	-0.42	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
PCPG	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	5.63	8.55e-08	8.25e-05	0.66	0.42	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
PCPG	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	5.63	8.55e-08	8.25e-05	0.55	0.42	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
PCPG	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	5.63	8.55e-08	8.25e-05	0.43	0.42	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
PCPG	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-5.63	8.55e-08	8.25e-05	-0.57	-0.42	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
PCPG	cis	rs55665837	0.701	rs10160597	ENSG00000251991.1	RNU7-49P	5.63	8.57e-08	8.27e-05	0.47	0.42	Vitamin D levels;	chr11:14582446	chr11:14478892~14478953:+
PCPG	cis	rs55665837	0.701	rs11023265	ENSG00000251991.1	RNU7-49P	5.63	8.57e-08	8.27e-05	0.47	0.42	Vitamin D levels;	chr11:14594492	chr11:14478892~14478953:+
PCPG	cis	rs9595908	0.709	rs3752476	ENSG00000212293.1	SNORA16	-5.63	8.59e-08	8.28e-05	-0.51	-0.42	Body mass index;	chr13:32770965	chr13:32420390~32420516:-
PCPG	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	5.63	8.6e-08	8.29e-05	0.59	0.42	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
PCPG	cis	rs10435719	0.753	rs9694940	ENSG00000255020.1	AF131216.5	5.63	8.61e-08	8.3e-05	0.56	0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.78	rs9692662	ENSG00000255020.1	AF131216.5	5.63	8.61e-08	8.3e-05	0.56	0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:11345748~11347502:-
PCPG	cis	rs10435719	0.899	rs9693925	ENSG00000255020.1	AF131216.5	5.63	8.61e-08	8.3e-05	0.56	0.42	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:11345748~11347502:-
PCPG	cis	rs9595908	0.709	rs1924606	ENSG00000212293.1	SNORA16	5.63	8.63e-08	8.32e-05	0.51	0.42	Body mass index;	chr13:32759230	chr13:32420390~32420516:-
PCPG	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-5.63	8.66e-08	8.34e-05	-0.59	-0.42	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
PCPG	cis	rs5769707	0.967	rs9616327	ENSG00000235111.1	RP1-29C18.8	-5.63	8.66e-08	8.35e-05	-0.46	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49612657~49615716:-
PCPG	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	5.63	8.67e-08	8.35e-05	0.51	0.42	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
PCPG	cis	rs13108904	0.65	rs3796618	ENSG00000254094.1	AC078852.1	-5.63	8.68e-08	8.37e-05	-0.49	-0.42	Obesity-related traits;	chr4:1355814	chr4:1356581~1358075:+
PCPG	cis	rs9926296	0.528	rs4785721	ENSG00000260259.1	RP11-368I7.4	-5.63	8.7e-08	8.37e-05	-0.51	-0.42	Vitiligo;	chr16:89773589	chr16:89682620~89686569:-
PCPG	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-5.63	8.74e-08	8.41e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
PCPG	cis	rs910316	0.789	rs4899552	ENSG00000279594.1	RP11-950C14.10	-5.63	8.74e-08	8.41e-05	-0.54	-0.42	Height;	chr14:75201218	chr14:75011269~75012851:-
PCPG	cis	rs2625529	0.652	rs7497104	ENSG00000260037.4	CTD-2524L6.3	-5.63	8.74e-08	8.41e-05	-0.56	-0.42	Red blood cell count;	chr15:71861659	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs28650442	ENSG00000260037.4	CTD-2524L6.3	-5.63	8.74e-08	8.41e-05	-0.56	-0.42	Red blood cell count;	chr15:71863104	chr15:71818396~71823384:+
PCPG	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-5.63	8.75e-08	8.42e-05	-0.5	-0.42	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
PCPG	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-5.63	8.75e-08	8.42e-05	-0.47	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
PCPG	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-5.63	8.75e-08	8.42e-05	-0.55	-0.42	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
PCPG	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-5.63	8.79e-08	8.45e-05	-0.7	-0.42	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
PCPG	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-5.63	8.79e-08	8.45e-05	-0.64	-0.42	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
PCPG	cis	rs12681963	0.614	rs12677295	ENSG00000248159.1	HSPA8P11	5.63	8.79e-08	8.46e-05	0.86	0.42	Migraine;	chr8:30242306	chr8:30237382~30240997:+
PCPG	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-5.63	8.8e-08	8.46e-05	-0.75	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
PCPG	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-5.63	8.81e-08	8.47e-05	-0.49	-0.42	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
PCPG	cis	rs748404	0.578	rs2012467	ENSG00000249839.1	AC011330.5	-5.63	8.82e-08	8.48e-05	-0.5	-0.42	Lung cancer;	chr15:43398367	chr15:43663654~43684339:-
PCPG	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-5.63	8.82e-08	8.48e-05	-0.48	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
PCPG	cis	rs7824557	0.564	rs2043508	ENSG00000255020.1	AF131216.5	-5.63	8.82e-08	8.48e-05	-0.56	-0.42	Retinal vascular caliber;	chr8:11369897	chr8:11345748~11347502:-
PCPG	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	5.63	8.82e-08	8.48e-05	0.48	0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
PCPG	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	5.63	8.83e-08	8.49e-05	0.54	0.42	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
PCPG	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-5.62	8.83e-08	8.49e-05	-0.37	-0.42	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
PCPG	cis	rs2625529	0.652	rs2929517	ENSG00000260037.4	CTD-2524L6.3	5.62	8.85e-08	8.51e-05	0.53	0.42	Red blood cell count;	chr15:72040576	chr15:71818396~71823384:+
PCPG	cis	rs9595908	0.671	rs12428598	ENSG00000212293.1	SNORA16	5.62	8.86e-08	8.51e-05	0.51	0.42	Body mass index;	chr13:32684839	chr13:32420390~32420516:-
PCPG	cis	rs2625529	0.824	rs2415121	ENSG00000260037.4	CTD-2524L6.3	-5.62	8.9e-08	8.55e-05	-0.56	-0.42	Red blood cell count;	chr15:71841677	chr15:71818396~71823384:+
PCPG	cis	rs7824557	0.564	rs2736288	ENSG00000255020.1	AF131216.5	-5.62	8.91e-08	8.56e-05	-0.56	-0.42	Retinal vascular caliber;	chr8:11370591	chr8:11345748~11347502:-
PCPG	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	5.62	8.91e-08	8.56e-05	0.52	0.42	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
PCPG	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-5.62	8.91e-08	8.56e-05	-0.65	-0.42	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
PCPG	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	5.62	8.92e-08	8.57e-05	0.52	0.42	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
PCPG	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	5.62	8.93e-08	8.58e-05	0.38	0.42	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	5.62	8.93e-08	8.58e-05	0.38	0.42	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	5.62	8.94e-08	8.58e-05	0.51	0.42	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
PCPG	cis	rs1908814	0.516	rs4841641	ENSG00000255020.1	AF131216.5	5.62	8.94e-08	8.59e-05	0.57	0.42	Neuroticism;	chr8:11940718	chr8:11345748~11347502:-
PCPG	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	5.62	8.94e-08	8.59e-05	0.35	0.42	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
PCPG	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	5.62	8.95e-08	8.6e-05	0.58	0.42	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	5.62	8.95e-08	8.6e-05	0.58	0.42	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	5.62	8.95e-08	8.6e-05	0.58	0.42	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
PCPG	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	5.62	8.95e-08	8.6e-05	0.41	0.42	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
PCPG	cis	rs7267979	0.932	rs2387891	ENSG00000125804.12	FAM182A	-5.62	8.96e-08	8.6e-05	-0.48	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:26054655~26086917:+
PCPG	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	5.62	8.96e-08	8.61e-05	0.48	0.42	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
PCPG	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-5.62	8.96e-08	8.61e-05	-0.42	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-5.62	8.96e-08	8.61e-05	-0.42	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-5.62	8.96e-08	8.61e-05	-0.42	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
PCPG	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-5.62	8.97e-08	8.62e-05	-0.4	-0.42	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
PCPG	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	5.62	8.99e-08	8.63e-05	0.53	0.42	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
PCPG	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	5.62	9.01e-08	8.65e-05	0.54	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	5.62	9.01e-08	8.65e-05	0.54	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
PCPG	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	5.62	9.02e-08	8.66e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
PCPG	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-5.62	9.04e-08	8.68e-05	-0.75	-0.42	Depression;	chr6:28076050	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-5.62	9.04e-08	8.68e-05	-0.75	-0.42	Depression;	chr6:28085045	chr6:28115628~28116551:+
PCPG	cis	rs13108904	0.901	rs12509700	ENSG00000254094.1	AC078852.1	-5.62	9.04e-08	8.68e-05	-0.47	-0.42	Obesity-related traits;	chr4:1302533	chr4:1356581~1358075:+
PCPG	cis	rs2412819	0.545	rs35822148	ENSG00000249839.1	AC011330.5	-5.62	9.07e-08	8.7e-05	-0.58	-0.42	Lung cancer;	chr15:43808084	chr15:43663654~43684339:-
PCPG	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-5.62	9.12e-08	8.75e-05	-0.47	-0.42	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
PCPG	cis	rs9595908	0.802	rs2010997	ENSG00000212293.1	SNORA16	5.62	9.12e-08	8.75e-05	0.5	0.42	Body mass index;	chr13:32496369	chr13:32420390~32420516:-
PCPG	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-5.62	9.13e-08	8.76e-05	-0.53	-0.42	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-5.62	9.13e-08	8.76e-05	-0.53	-0.42	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
PCPG	cis	rs9926296	0.605	rs12709094	ENSG00000260259.1	RP11-368I7.4	-5.62	9.15e-08	8.77e-05	-0.5	-0.42	Vitiligo;	chr16:89786609	chr16:89682620~89686569:-
PCPG	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-5.62	9.15e-08	8.77e-05	-0.57	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
PCPG	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	5.62	9.17e-08	8.78e-05	0.63	0.42	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
PCPG	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	5.62	9.17e-08	8.79e-05	0.68	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
PCPG	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	5.62	9.18e-08	8.8e-05	0.55	0.42	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
PCPG	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	5.62	9.18e-08	8.8e-05	0.55	0.42	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
PCPG	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-5.62	9.24e-08	8.85e-05	-0.54	-0.42	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
PCPG	cis	rs9595908	1	rs9591165	ENSG00000212293.1	SNORA16	5.62	9.24e-08	8.85e-05	0.49	0.42	Body mass index;	chr13:32611016	chr13:32420390~32420516:-
PCPG	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-5.62	9.26e-08	8.86e-05	-0.58	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
PCPG	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-5.61	9.27e-08	8.87e-05	-0.54	-0.42	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
PCPG	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-5.61	9.28e-08	8.87e-05	-0.52	-0.42	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
PCPG	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-5.61	9.28e-08	8.88e-05	-0.64	-0.42	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
PCPG	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-5.61	9.34e-08	8.93e-05	-0.49	-0.42	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
PCPG	cis	rs2736345	0.502	rs34801597	ENSG00000255020.1	AF131216.5	5.61	9.34e-08	8.93e-05	0.6	0.42	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11468984	chr8:11345748~11347502:-
PCPG	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	5.61	9.34e-08	8.93e-05	0.57	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
PCPG	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	5.61	9.37e-08	8.96e-05	0.52	0.42	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
PCPG	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-5.61	9.39e-08	8.97e-05	-0.46	-0.42	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
PCPG	cis	rs12291225	0.585	rs4757250	ENSG00000251991.1	RNU7-49P	5.61	9.39e-08	8.98e-05	0.49	0.42	Sense of smell;	chr11:14354137	chr11:14478892~14478953:+
PCPG	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	5.61	9.39e-08	8.98e-05	0.38	0.42	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
PCPG	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	5.61	9.4e-08	8.98e-05	0.57	0.42	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
PCPG	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	5.61	9.4e-08	8.98e-05	0.49	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
PCPG	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	5.61	9.4e-08	8.98e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	5.61	9.4e-08	8.98e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	5.61	9.4e-08	8.98e-05	0.57	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
PCPG	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-5.61	9.4e-08	8.98e-05	-0.74	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
PCPG	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-5.61	9.4e-08	8.98e-05	-0.74	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
PCPG	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-5.61	9.41e-08	8.99e-05	-0.74	-0.42	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
PCPG	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	5.61	9.41e-08	8.99e-05	0.59	0.42	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
PCPG	cis	rs453301	0.686	rs7814328	ENSG00000173295.6	FAM86B3P	5.61	9.43e-08	9.01e-05	0.48	0.42	Joint mobility (Beighton score);	chr8:9018719	chr8:8228595~8244865:+
PCPG	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-5.61	9.44e-08	9.02e-05	-0.74	-0.42	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-5.61	9.44e-08	9.02e-05	-0.74	-0.42	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
PCPG	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-5.61	9.44e-08	9.02e-05	-0.74	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-5.61	9.44e-08	9.02e-05	-0.74	-0.42	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
PCPG	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-5.61	9.49e-08	9.06e-05	-0.47	-0.42	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
PCPG	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-5.61	9.49e-08	9.06e-05	-0.55	-0.42	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
PCPG	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	5.61	9.52e-08	9.08e-05	0.42	0.42	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	5.61	9.52e-08	9.08e-05	0.42	0.42	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-5.61	9.52e-08	9.08e-05	-0.42	-0.42	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
PCPG	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-5.61	9.52e-08	9.08e-05	-0.42	-0.42	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-5.61	9.52e-08	9.08e-05	-0.42	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
PCPG	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-5.61	9.52e-08	9.08e-05	-0.42	-0.42	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
PCPG	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	5.61	9.53e-08	9.09e-05	0.56	0.42	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
PCPG	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	5.61	9.55e-08	9.11e-05	0.58	0.42	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
PCPG	cis	rs7267979	1	rs398036	ENSG00000125804.12	FAM182A	-5.61	9.57e-08	9.12e-05	-0.48	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs397119	ENSG00000125804.12	FAM182A	-5.61	9.57e-08	9.12e-05	-0.48	-0.42	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:26054655~26086917:+
PCPG	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	5.61	9.57e-08	9.13e-05	0.56	0.42	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
PCPG	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-5.61	9.58e-08	9.13e-05	-0.5	-0.42	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
PCPG	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	5.61	9.59e-08	9.15e-05	0.61	0.42	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
PCPG	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	5.61	9.61e-08	9.16e-05	0.55	0.42	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	5.61	9.61e-08	9.16e-05	0.55	0.42	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
PCPG	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	5.61	9.63e-08	9.18e-05	0.56	0.42	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
PCPG	cis	rs2625529	0.617	rs8557	ENSG00000260037.4	CTD-2524L6.3	-5.61	9.63e-08	9.18e-05	-0.56	-0.42	Red blood cell count;	chr15:71823392	chr15:71818396~71823384:+
PCPG	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-5.61	9.69e-08	9.23e-05	-0.58	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
PCPG	cis	rs3806843	0.712	rs2530244	ENSG00000202515.1	VTRNA1-3	5.6	9.73e-08	9.26e-05	0.51	0.42	Depressive symptoms (multi-trait analysis);	chr5:140729570	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.801	rs801170	ENSG00000202515.1	VTRNA1-3	5.6	9.73e-08	9.26e-05	0.51	0.42	Depressive symptoms (multi-trait analysis);	chr5:140735758	chr5:140726158~140726246:+
PCPG	cis	rs2625529	0.529	rs1552133	ENSG00000260037.4	CTD-2524L6.3	5.6	9.73e-08	9.27e-05	0.54	0.42	Red blood cell count;	chr15:71940556	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.556	rs1552134	ENSG00000260037.4	CTD-2524L6.3	5.6	9.73e-08	9.27e-05	0.54	0.42	Red blood cell count;	chr15:71940557	chr15:71818396~71823384:+
PCPG	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-5.6	9.74e-08	9.28e-05	-0.49	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
PCPG	cis	rs7819412	0.537	rs2127127	ENSG00000255020.1	AF131216.5	-5.6	9.75e-08	9.28e-05	-0.56	-0.42	Triglycerides;	chr8:11577283	chr8:11345748~11347502:-
PCPG	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-5.6	9.77e-08	9.29e-05	-0.53	-0.42	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
PCPG	cis	rs9926296	0.605	rs6500449	ENSG00000260259.1	RP11-368I7.4	-5.6	9.77e-08	9.29e-05	-0.5	-0.42	Vitiligo;	chr16:89789985	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.605	rs7205053	ENSG00000260259.1	RP11-368I7.4	-5.6	9.77e-08	9.29e-05	-0.5	-0.42	Vitiligo;	chr16:89790355	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.585	rs8045232	ENSG00000260259.1	RP11-368I7.4	-5.6	9.77e-08	9.29e-05	-0.5	-0.42	Vitiligo;	chr16:89791140	chr16:89682620~89686569:-
PCPG	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-5.6	9.78e-08	9.3e-05	-0.61	-0.42	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
PCPG	cis	rs440932	0.757	rs330943	ENSG00000253893.2	FAM85B	-5.6	9.78e-08	9.3e-05	-0.53	-0.42	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:8167819~8226614:-
PCPG	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	5.6	9.79e-08	9.31e-05	0.58	0.42	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
PCPG	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-5.6	9.8e-08	9.32e-05	-0.59	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
PCPG	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-5.6	9.81e-08	9.33e-05	-0.48	-0.42	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
PCPG	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	5.6	9.83e-08	9.35e-05	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
PCPG	cis	rs9595908	0.63	rs4057297	ENSG00000212293.1	SNORA16	5.6	9.84e-08	9.36e-05	0.5	0.42	Body mass index;	chr13:32731612	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.63	rs1929939	ENSG00000212293.1	SNORA16	5.6	9.84e-08	9.36e-05	0.5	0.42	Body mass index;	chr13:32733547	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs17594677	ENSG00000212293.1	SNORA16	5.6	9.84e-08	9.36e-05	0.5	0.42	Body mass index;	chr13:32734875	chr13:32420390~32420516:-
PCPG	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	5.6	9.87e-08	9.38e-05	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
PCPG	cis	rs2625529	0.652	rs2957361	ENSG00000260037.4	CTD-2524L6.3	5.6	9.87e-08	9.38e-05	0.54	0.42	Red blood cell count;	chr15:72052877	chr15:71818396~71823384:+
PCPG	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-5.6	9.89e-08	9.4e-05	-0.5	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-5.6	9.89e-08	9.4e-05	-0.5	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
PCPG	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-5.6	9.89e-08	9.4e-05	-0.4	-0.42	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
PCPG	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	5.6	9.91e-08	9.42e-05	0.36	0.42	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
PCPG	cis	rs4819052	0.634	rs8128636	ENSG00000215447.6	BX322557.10	-5.6	9.92e-08	9.42e-05	-0.37	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.655	rs2330102	ENSG00000215447.6	BX322557.10	-5.6	9.92e-08	9.42e-05	-0.37	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.679	rs8132135	ENSG00000215447.6	BX322557.10	-5.6	9.92e-08	9.42e-05	-0.37	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45288052~45291738:+
PCPG	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	5.6	9.92e-08	9.43e-05	0.6	0.42	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
PCPG	cis	rs453301	0.686	rs6987107	ENSG00000173295.6	FAM86B3P	5.6	9.93e-08	9.43e-05	0.49	0.42	Joint mobility (Beighton score);	chr8:9036071	chr8:8228595~8244865:+
PCPG	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	5.6	9.93e-08	9.43e-05	0.56	0.42	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
PCPG	cis	rs11148252	0.624	rs6561682	ENSG00000235660.1	LINC00345	5.6	9.94e-08	9.43e-05	0.56	0.42	Lewy body disease;	chr13:52692162	chr13:52484161~52484680:-
PCPG	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-5.6	9.94e-08	9.43e-05	-0.49	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
PCPG	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-5.6	9.94e-08	9.44e-05	-0.43	-0.42	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
PCPG	cis	rs5769765	0.908	rs9616390	ENSG00000278869.1	CITF22-49E9.3	5.6	1.01e-07	9.55e-05	0.59	0.42	Schizophrenia;	chr22:49920641	chr22:49933198~49934074:-
PCPG	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	5.6	1.01e-07	9.56e-05	0.46	0.42	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
PCPG	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-5.6	1.01e-07	9.58e-05	-0.5	-0.42	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
PCPG	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-5.6	1.02e-07	9.63e-05	-0.43	-0.42	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
PCPG	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	5.6	1.02e-07	9.64e-05	0.45	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	5.6	1.02e-07	9.64e-05	0.45	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	5.6	1.02e-07	9.64e-05	0.45	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
PCPG	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-5.6	1.02e-07	9.65e-05	-0.48	-0.42	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
PCPG	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-5.59	1.03e-07	9.71e-05	-0.49	-0.42	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
PCPG	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-5.59	1.03e-07	9.72e-05	-0.49	-0.42	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
PCPG	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	5.59	1.03e-07	9.76e-05	0.58	0.42	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	5.59	1.03e-07	9.76e-05	0.58	0.42	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
PCPG	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
PCPG	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	5.59	1.03e-07	9.76e-05	0.56	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
PCPG	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-5.59	1.03e-07	9.77e-05	-0.61	-0.42	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
PCPG	cis	rs11250098	0.547	rs2409764	ENSG00000255020.1	AF131216.5	5.59	1.03e-07	9.77e-05	0.56	0.42	Morning vs. evening chronotype;	chr8:11423764	chr8:11345748~11347502:-
PCPG	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	5.59	1.04e-07	9.78e-05	0.79	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
PCPG	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-5.59	1.04e-07	9.79e-05	-0.49	-0.42	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
PCPG	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-5.59	1.04e-07	9.81e-05	-0.51	-0.42	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
PCPG	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-5.59	1.04e-07	9.83e-05	-0.54	-0.42	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
PCPG	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-5.59	1.04e-07	9.83e-05	-0.49	-0.42	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
PCPG	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-5.59	1.04e-07	9.86e-05	-0.58	-0.42	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
PCPG	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-5.59	1.05e-07	9.89e-05	-0.5	-0.42	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
PCPG	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	5.59	1.05e-07	9.89e-05	0.5	0.42	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	5.59	1.05e-07	9.89e-05	0.5	0.42	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	5.59	1.05e-07	9.89e-05	0.5	0.42	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	5.59	1.05e-07	9.89e-05	0.5	0.42	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	5.59	1.05e-07	9.89e-05	0.5	0.42	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	5.59	1.05e-07	9.89e-05	0.5	0.42	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	5.59	1.05e-07	9.89e-05	0.5	0.42	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
PCPG	cis	rs1609391	0.543	rs2117009	ENSG00000273486.1	RP11-731C17.2	-5.59	1.05e-07	9.92e-05	-0.43	-0.42	Neuroticism;	chr3:136914729	chr3:136837338~136839021:-
PCPG	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-5.59	1.05e-07	9.93e-05	-0.48	-0.42	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
PCPG	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-5.59	1.05e-07	9.93e-05	-0.48	-0.42	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
PCPG	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-5.59	1.05e-07	9.94e-05	-0.49	-0.42	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-5.59	1.05e-07	9.94e-05	-0.49	-0.42	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
PCPG	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	-5.59	1.06e-07	9.96e-05	-0.49	-0.42	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
PCPG	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-5.59	1.06e-07	1e-04	-0.37	-0.42	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
PCPG	cis	rs453301	0.686	rs11787026	ENSG00000173295.6	FAM86B3P	-5.59	1.06e-07	1e-04	-0.5	-0.41	Joint mobility (Beighton score);	chr8:9044861	chr8:8228595~8244865:+
PCPG	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-5.59	1.07e-07	1e-04	-0.82	-0.41	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-5.59	1.07e-07	1e-04	-0.82	-0.41	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-5.59	1.07e-07	1e-04	-0.82	-0.41	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-5.59	1.07e-07	1e-04	-0.82	-0.41	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
PCPG	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-5.58	1.08e-07	0.000101	-0.53	-0.41	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
PCPG	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-5.58	1.08e-07	0.000101	-0.72	-0.41	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
PCPG	cis	rs9926296	0.605	rs8047486	ENSG00000260259.1	RP11-368I7.4	-5.58	1.08e-07	0.000101	-0.5	-0.41	Vitiligo;	chr16:89787617	chr16:89682620~89686569:-
PCPG	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	5.58	1.08e-07	0.000102	0.45	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
PCPG	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-5.58	1.08e-07	0.000102	-0.4	-0.41	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
PCPG	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	5.58	1.09e-07	0.000102	0.5	0.41	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
PCPG	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	5.58	1.09e-07	0.000102	0.6	0.41	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
PCPG	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-5.58	1.09e-07	0.000103	-0.47	-0.41	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-5.58	1.09e-07	0.000103	-0.47	-0.41	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
PCPG	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-5.58	1.09e-07	0.000103	-0.61	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
PCPG	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-5.58	1.09e-07	0.000103	-0.53	-0.41	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
PCPG	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	5.58	1.09e-07	0.000103	0.48	0.41	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
PCPG	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-5.58	1.09e-07	0.000103	-0.54	-0.41	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-5.58	1.09e-07	0.000103	-0.54	-0.41	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
PCPG	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-5.58	1.09e-07	0.000103	-0.48	-0.41	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
PCPG	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-5.58	1.1e-07	0.000103	-0.52	-0.41	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
PCPG	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	5.58	1.1e-07	0.000103	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
PCPG	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	5.58	1.1e-07	0.000103	0.38	0.41	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
PCPG	cis	rs9595908	0.827	rs7321262	ENSG00000212293.1	SNORA16	5.58	1.1e-07	0.000103	0.48	0.41	Body mass index;	chr13:32597942	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.9	rs731414	ENSG00000212293.1	SNORA16	5.58	1.1e-07	0.000103	0.48	0.41	Body mass index;	chr13:32601160	chr13:32420390~32420516:-
PCPG	cis	rs13113518	0.738	rs6849883	ENSG00000272969.1	RP11-528I4.2	5.58	1.1e-07	0.000103	0.47	0.41	Height;	chr4:55387515	chr4:55547112~55547889:+
PCPG	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-5.58	1.1e-07	0.000103	-0.5	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
PCPG	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-5.58	1.1e-07	0.000103	-0.8	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
PCPG	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-5.58	1.1e-07	0.000104	-0.48	-0.41	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-5.58	1.1e-07	0.000104	-0.48	-0.41	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
PCPG	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-5.58	1.1e-07	0.000104	-0.7	-0.41	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
PCPG	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	5.58	1.1e-07	0.000104	0.44	0.41	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
PCPG	cis	rs10131894	0.635	rs174997	ENSG00000279594.1	RP11-950C14.10	-5.58	1.11e-07	0.000104	-0.53	-0.41	Coronary artery disease;	chr14:74968103	chr14:75011269~75012851:-
PCPG	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-5.58	1.11e-07	0.000104	-0.52	-0.41	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
PCPG	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-5.58	1.11e-07	0.000104	-0.4	-0.41	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-5.58	1.11e-07	0.000104	-0.4	-0.41	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
PCPG	cis	rs2274273	0.719	rs17740551	ENSG00000258413.1	RP11-665C16.6	-5.58	1.11e-07	0.000104	-0.55	-0.41	Protein biomarker;	chr14:55284607	chr14:55262767~55272075:-
PCPG	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-5.58	1.11e-07	0.000104	-0.63	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
PCPG	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-5.58	1.11e-07	0.000104	-0.49	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
PCPG	cis	rs10131894	0.611	rs174994	ENSG00000279594.1	RP11-950C14.10	-5.58	1.11e-07	0.000104	-0.53	-0.41	Coronary artery disease;	chr14:74967399	chr14:75011269~75012851:-
PCPG	cis	rs10131894	0.611	rs174995	ENSG00000279594.1	RP11-950C14.10	-5.58	1.11e-07	0.000104	-0.53	-0.41	Coronary artery disease;	chr14:74967480	chr14:75011269~75012851:-
PCPG	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-5.58	1.11e-07	0.000105	-0.53	-0.41	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
PCPG	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-5.58	1.12e-07	0.000105	-0.55	-0.41	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
PCPG	cis	rs55665837	0.701	rs10766188	ENSG00000251991.1	RNU7-49P	5.58	1.12e-07	0.000105	0.47	0.41	Vitamin D levels;	chr11:14639280	chr11:14478892~14478953:+
PCPG	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-5.58	1.12e-07	0.000105	-0.52	-0.41	Temperament;	chr17:14075460	chr17:14024514~14025488:+
PCPG	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	5.58	1.12e-07	0.000105	0.54	0.41	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
PCPG	cis	rs7267979	0.586	rs6083776	ENSG00000125804.12	FAM182A	-5.58	1.12e-07	0.000105	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.586	rs1473695	ENSG00000125804.12	FAM182A	-5.58	1.12e-07	0.000105	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:26054655~26086917:+
PCPG	cis	rs2625529	0.652	rs1481862	ENSG00000260037.4	CTD-2524L6.3	5.57	1.12e-07	0.000105	0.52	0.41	Red blood cell count;	chr15:71953307	chr15:71818396~71823384:+
PCPG	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	5.57	1.12e-07	0.000105	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
PCPG	cis	rs7824557	0.736	rs10107010	ENSG00000255020.1	AF131216.5	-5.57	1.12e-07	0.000105	-0.53	-0.41	Retinal vascular caliber;	chr8:11275203	chr8:11345748~11347502:-
PCPG	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-5.57	1.13e-07	0.000106	-0.53	-0.41	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
PCPG	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-5.57	1.13e-07	0.000106	-0.42	-0.41	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
PCPG	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	5.57	1.13e-07	0.000106	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
PCPG	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-5.57	1.14e-07	0.000106	-0.49	-0.41	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
PCPG	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	5.57	1.14e-07	0.000107	0.63	0.41	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
PCPG	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-5.57	1.14e-07	0.000107	-0.52	-0.41	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
PCPG	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	5.57	1.15e-07	0.000107	0.41	0.41	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	5.57	1.15e-07	0.000107	0.41	0.41	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	5.57	1.15e-07	0.000107	0.41	0.41	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	5.57	1.15e-07	0.000107	0.41	0.41	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
PCPG	cis	rs7267979	0.586	rs6037057	ENSG00000125804.12	FAM182A	-5.57	1.15e-07	0.000107	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.586	rs6050429	ENSG00000125804.12	FAM182A	-5.57	1.15e-07	0.000107	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:26054655~26086917:+
PCPG	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-5.57	1.15e-07	0.000107	-0.58	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
PCPG	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-5.57	1.15e-07	0.000108	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-5.57	1.15e-07	0.000108	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
PCPG	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-5.57	1.15e-07	0.000108	-0.52	-0.41	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
PCPG	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-5.57	1.16e-07	0.000108	-0.52	-0.41	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
PCPG	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	5.57	1.16e-07	0.000108	0.44	0.41	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
PCPG	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	5.57	1.16e-07	0.000108	0.45	0.41	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
PCPG	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	5.57	1.16e-07	0.000108	0.54	0.41	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
PCPG	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	5.57	1.17e-07	0.000109	0.56	0.41	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	5.57	1.17e-07	0.000109	0.56	0.41	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
PCPG	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-5.57	1.17e-07	0.000109	-0.49	-0.41	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
PCPG	cis	rs1044573	0.514	rs2268879	ENSG00000125804.12	FAM182A	5.57	1.17e-07	0.000109	0.47	0.41	Allergic rhinitis;	chr20:25197169	chr20:26054655~26086917:+
PCPG	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	5.57	1.17e-07	0.00011	0.4	0.41	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
PCPG	cis	rs7267979	0.586	rs6050431	ENSG00000125804.12	FAM182A	-5.57	1.17e-07	0.00011	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.586	rs6050432	ENSG00000125804.12	FAM182A	-5.57	1.17e-07	0.00011	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:26054655~26086917:+
PCPG	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-5.56	1.18e-07	0.00011	-0.38	-0.41	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
PCPG	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	5.56	1.18e-07	0.00011	0.57	0.41	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
PCPG	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-5.56	1.18e-07	0.00011	-0.48	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
PCPG	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	5.56	1.19e-07	0.000111	0.35	0.41	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
PCPG	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	5.56	1.19e-07	0.000111	0.61	0.41	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
PCPG	cis	rs453301	0.571	rs2929305	ENSG00000173295.6	FAM86B3P	5.56	1.19e-07	0.000111	0.49	0.41	Joint mobility (Beighton score);	chr8:9227707	chr8:8228595~8244865:+
PCPG	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	5.56	1.19e-07	0.000111	0.52	0.41	Temperament;	chr17:14068990	chr17:14024514~14025488:+
PCPG	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	5.56	1.19e-07	0.000111	0.38	0.41	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	5.56	1.19e-07	0.000111	0.38	0.41	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
PCPG	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-5.56	1.2e-07	0.000111	-0.5	-0.41	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
PCPG	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-5.56	1.2e-07	0.000111	-0.46	-0.41	Migraine;	chr4:56852087	chr4:56960927~56961373:-
PCPG	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	5.56	1.2e-07	0.000112	0.53	0.41	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
PCPG	cis	rs17507216	0.718	rs72751662	ENSG00000228141.5	AC105339.1	-5.56	1.2e-07	0.000112	-0.64	-0.41	Excessive daytime sleepiness;	chr15:82594705	chr15:82710471~82714026:-
PCPG	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	5.56	1.2e-07	0.000112	0.44	0.41	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
PCPG	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-5.56	1.2e-07	0.000112	-0.5	-0.41	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-5.56	1.2e-07	0.000112	-0.5	-0.41	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
PCPG	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-5.56	1.2e-07	0.000112	-0.53	-0.41	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
PCPG	cis	rs2625529	0.652	rs8028115	ENSG00000260037.4	CTD-2524L6.3	5.56	1.21e-07	0.000112	0.53	0.41	Red blood cell count;	chr15:72047162	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs8030815	ENSG00000260037.4	CTD-2524L6.3	5.56	1.21e-07	0.000112	0.53	0.41	Red blood cell count;	chr15:72110660	chr15:71818396~71823384:+
PCPG	cis	rs11148252	0.574	rs3742297	ENSG00000198384.8	TPTE2P3	-5.56	1.21e-07	0.000113	-0.53	-0.41	Lewy body disease;	chr13:52703932	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.574	rs9536247	ENSG00000198384.8	TPTE2P3	-5.56	1.21e-07	0.000113	-0.53	-0.41	Lewy body disease;	chr13:52705407	chr13:52522632~52586906:+
PCPG	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	5.56	1.22e-07	0.000113	0.6	0.41	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
PCPG	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-5.56	1.22e-07	0.000113	-0.47	-0.41	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
PCPG	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-5.56	1.22e-07	0.000113	-0.46	-0.41	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-5.56	1.22e-07	0.000113	-0.46	-0.41	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-5.56	1.22e-07	0.000113	-0.46	-0.41	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	5.56	1.22e-07	0.000113	0.46	0.41	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
PCPG	cis	rs9926296	0.527	rs1800335	ENSG00000260259.1	RP11-368I7.4	-5.56	1.22e-07	0.000114	-0.51	-0.41	Vitiligo;	chr16:89779787	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.605	rs12448860	ENSG00000260259.1	RP11-368I7.4	-5.56	1.22e-07	0.000114	-0.51	-0.41	Vitiligo;	chr16:89783221	chr16:89682620~89686569:-
PCPG	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	5.56	1.22e-07	0.000114	0.69	0.41	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
PCPG	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-5.56	1.22e-07	0.000114	-0.51	-0.41	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.686	rs17702602	ENSG00000173295.6	FAM86B3P	5.56	1.23e-07	0.000114	0.49	0.41	Joint mobility (Beighton score);	chr8:9051086	chr8:8228595~8244865:+
PCPG	cis	rs9595908	0.709	rs7319275	ENSG00000212293.1	SNORA16	5.56	1.23e-07	0.000114	0.5	0.41	Body mass index;	chr13:32733280	chr13:32420390~32420516:-
PCPG	cis	rs73607972	0.696	rs7197014	ENSG00000275191.1	RP11-36I17.2	-5.56	1.23e-07	0.000114	-0.63	-0.41	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525165	chr16:53628256~53628816:-
PCPG	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	5.56	1.23e-07	0.000114	0.54	0.41	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
PCPG	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	5.56	1.23e-07	0.000114	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	5.56	1.23e-07	0.000114	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
PCPG	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	5.56	1.23e-07	0.000114	0.54	0.41	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
PCPG	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-5.55	1.23e-07	0.000115	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-5.55	1.23e-07	0.000115	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
PCPG	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-5.55	1.24e-07	0.000115	-0.53	-0.41	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
PCPG	cis	rs7824557	0.564	rs6601584	ENSG00000255020.1	AF131216.5	-5.55	1.24e-07	0.000115	-0.55	-0.41	Retinal vascular caliber;	chr8:11374834	chr8:11345748~11347502:-
PCPG	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	5.55	1.24e-07	0.000115	0.39	0.41	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
PCPG	cis	rs13113518	0.812	rs1522114	ENSG00000272969.1	RP11-528I4.2	5.55	1.24e-07	0.000115	0.46	0.41	Height;	chr4:55489895	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs7667741	ENSG00000272969.1	RP11-528I4.2	5.55	1.24e-07	0.000115	0.46	0.41	Height;	chr4:55544621	chr4:55547112~55547889:+
PCPG	cis	rs453301	0.686	rs4840389	ENSG00000173295.6	FAM86B3P	5.55	1.24e-07	0.000115	0.49	0.41	Joint mobility (Beighton score);	chr8:9026993	chr8:8228595~8244865:+
PCPG	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	5.55	1.25e-07	0.000116	0.59	0.41	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
PCPG	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	5.55	1.25e-07	0.000116	0.51	0.41	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
PCPG	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-5.55	1.26e-07	0.000117	-0.65	-0.41	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
PCPG	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-5.55	1.26e-07	0.000117	-0.56	-0.41	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-5.55	1.26e-07	0.000117	-0.56	-0.41	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	5.55	1.26e-07	0.000117	0.56	0.41	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	5.55	1.26e-07	0.000117	0.56	0.41	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	5.55	1.26e-07	0.000117	0.56	0.41	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
PCPG	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	5.55	1.26e-07	0.000117	0.56	0.41	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
PCPG	cis	rs7267979	0.966	rs7270835	ENSG00000125804.12	FAM182A	-5.55	1.26e-07	0.000117	-0.48	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6115191	ENSG00000125804.12	FAM182A	-5.55	1.26e-07	0.000117	-0.48	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6107045	ENSG00000125804.12	FAM182A	-5.55	1.26e-07	0.000117	-0.48	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6107046	ENSG00000125804.12	FAM182A	-5.55	1.26e-07	0.000117	-0.48	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:26054655~26086917:+
PCPG	cis	rs7267979	1	rs6107047	ENSG00000125804.12	FAM182A	-5.55	1.26e-07	0.000117	-0.48	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:26054655~26086917:+
PCPG	cis	rs7824557	0.652	rs12677504	ENSG00000255020.1	AF131216.5	-5.55	1.26e-07	0.000117	-0.53	-0.41	Retinal vascular caliber;	chr8:11275666	chr8:11345748~11347502:-
PCPG	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-5.55	1.27e-07	0.000118	-0.37	-0.41	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
PCPG	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-5.55	1.27e-07	0.000118	-0.37	-0.41	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
PCPG	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-5.55	1.27e-07	0.000118	-0.37	-0.41	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
PCPG	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	5.55	1.27e-07	0.000118	0.43	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
PCPG	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	5.55	1.28e-07	0.000119	0.37	0.41	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
PCPG	cis	rs10435719	0.899	rs11250177	ENSG00000255020.1	AF131216.5	5.55	1.28e-07	0.000119	0.56	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11345748~11347502:-
PCPG	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-5.55	1.28e-07	0.000119	-0.53	-0.41	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
PCPG	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-5.55	1.28e-07	0.000119	-0.46	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
PCPG	cis	rs10435719	0.902	rs4840599	ENSG00000255020.1	AF131216.5	-5.55	1.29e-07	0.000119	-0.56	-0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11345748~11347502:-
PCPG	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	5.55	1.29e-07	0.000119	0.45	0.41	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
PCPG	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-5.55	1.29e-07	0.000119	-0.55	-0.41	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
PCPG	cis	rs12291225	0.585	rs10832242	ENSG00000251991.1	RNU7-49P	-5.54	1.29e-07	0.00012	-0.48	-0.41	Sense of smell;	chr11:14318958	chr11:14478892~14478953:+
PCPG	cis	rs9926296	0.546	rs6500442	ENSG00000260259.1	RP11-368I7.4	-5.54	1.29e-07	0.00012	-0.5	-0.41	Vitiligo;	chr16:89762454	chr16:89682620~89686569:-
PCPG	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-5.54	1.3e-07	0.00012	-0.5	-0.41	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
PCPG	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	5.54	1.3e-07	0.00012	0.55	0.41	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	5.54	1.3e-07	0.00012	0.55	0.41	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	5.54	1.3e-07	0.00012	0.55	0.41	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
PCPG	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	5.54	1.3e-07	0.00012	0.59	0.41	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
PCPG	cis	rs56404409	0.823	rs12788072	ENSG00000255414.1	LINC01059	5.54	1.3e-07	0.00012	0.56	0.41	Ulcerative colitis;	chr11:123463590	chr11:123454398~123460410:+
PCPG	cis	rs9926296	0.585	rs6500441	ENSG00000260259.1	RP11-368I7.4	-5.54	1.3e-07	0.00012	-0.5	-0.41	Vitiligo;	chr16:89762261	chr16:89682620~89686569:-
PCPG	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	5.54	1.3e-07	0.00012	0.51	0.41	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
PCPG	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-5.54	1.3e-07	0.00012	-0.53	-0.41	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-5.54	1.3e-07	0.00012	-0.53	-0.41	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-5.54	1.3e-07	0.00012	-0.53	-0.41	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-5.54	1.3e-07	0.00012	-0.53	-0.41	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-5.54	1.3e-07	0.00012	-0.53	-0.41	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
PCPG	cis	rs9595908	0.9	rs7981943	ENSG00000212293.1	SNORA16	5.54	1.3e-07	0.000121	0.48	0.41	Body mass index;	chr13:32593754	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.9	rs7327429	ENSG00000212293.1	SNORA16	5.54	1.3e-07	0.000121	0.48	0.41	Body mass index;	chr13:32595259	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.9	rs731413	ENSG00000212293.1	SNORA16	5.54	1.3e-07	0.000121	0.48	0.41	Body mass index;	chr13:32601519	chr13:32420390~32420516:-
PCPG	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-5.54	1.31e-07	0.000121	-0.45	-0.41	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
PCPG	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	5.54	1.31e-07	0.000121	0.58	0.41	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
PCPG	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-5.54	1.31e-07	0.000121	-0.45	-0.41	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
PCPG	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	5.54	1.31e-07	0.000121	0.37	0.41	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
PCPG	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-5.54	1.31e-07	0.000121	-0.46	-0.41	Migraine;	chr4:56850720	chr4:56960927~56961373:-
PCPG	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-5.54	1.31e-07	0.000121	-0.47	-0.41	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
PCPG	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-5.54	1.32e-07	0.000122	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
PCPG	cis	rs4819052	0.632	rs4819050	ENSG00000215447.6	BX322557.10	-5.54	1.32e-07	0.000122	-0.37	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.632	rs4819050	ENSG00000223768.1	LINC00205	-5.54	1.32e-07	0.000122	-0.5	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45293285~45297354:+
PCPG	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-5.54	1.32e-07	0.000122	-0.54	-0.41	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
PCPG	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-5.54	1.33e-07	0.000122	-0.52	-0.41	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
PCPG	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-5.54	1.33e-07	0.000122	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
PCPG	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-5.54	1.33e-07	0.000123	-0.4	-0.41	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
PCPG	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-5.54	1.34e-07	0.000123	-0.57	-0.41	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
PCPG	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	5.54	1.34e-07	0.000123	0.47	0.41	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
PCPG	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	5.54	1.34e-07	0.000123	0.73	0.41	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
PCPG	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-5.54	1.34e-07	0.000123	-0.54	-0.41	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
PCPG	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-5.54	1.35e-07	0.000124	-0.44	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-5.54	1.35e-07	0.000124	-0.44	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
PCPG	cis	rs1908814	0.516	rs11996277	ENSG00000255020.1	AF131216.5	5.54	1.35e-07	0.000125	0.56	0.41	Neuroticism;	chr8:11942522	chr8:11345748~11347502:-
PCPG	cis	rs7402982	0.625	rs7179841	ENSG00000278022.1	RP11-35O15.2	-5.54	1.35e-07	0.000125	-0.42	-0.41	Birth weight;	chr15:98661423	chr15:98660210~98660668:+
PCPG	cis	rs9595908	0.709	rs7322505	ENSG00000212293.1	SNORA16	5.53	1.36e-07	0.000125	0.5	0.41	Body mass index;	chr13:32756282	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.694	rs3752474	ENSG00000212293.1	SNORA16	5.53	1.36e-07	0.000125	0.5	0.41	Body mass index;	chr13:32758510	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs7988089	ENSG00000212293.1	SNORA16	5.53	1.36e-07	0.000125	0.5	0.41	Body mass index;	chr13:32759738	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.686	rs9591314	ENSG00000212293.1	SNORA16	5.53	1.36e-07	0.000125	0.5	0.41	Body mass index;	chr13:32760248	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.686	rs7988353	ENSG00000212293.1	SNORA16	5.53	1.36e-07	0.000125	0.5	0.41	Body mass index;	chr13:32760250	chr13:32420390~32420516:-
PCPG	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	5.53	1.36e-07	0.000125	0.47	0.41	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
PCPG	cis	rs10435719	0.902	rs11250179	ENSG00000255020.1	AF131216.5	5.53	1.36e-07	0.000125	0.56	0.41	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11345748~11347502:-
PCPG	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-5.53	1.36e-07	0.000125	-0.41	-0.41	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
PCPG	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-5.53	1.36e-07	0.000125	-0.51	-0.41	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
PCPG	cis	rs9595908	0.709	rs4942892	ENSG00000212293.1	SNORA16	-5.53	1.36e-07	0.000125	-0.49	-0.41	Body mass index;	chr13:32754269	chr13:32420390~32420516:-
PCPG	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-5.53	1.37e-07	0.000126	-0.48	-0.41	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
PCPG	cis	rs9926296	0.585	rs1800337	ENSG00000260259.1	RP11-368I7.4	-5.53	1.37e-07	0.000126	-0.5	-0.41	Vitiligo;	chr16:89778786	chr16:89682620~89686569:-
PCPG	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-5.53	1.37e-07	0.000126	-0.52	-0.41	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
PCPG	cis	rs2625529	0.73	rs6494975	ENSG00000260037.4	CTD-2524L6.3	5.53	1.38e-07	0.000127	0.55	0.41	Red blood cell count;	chr15:71885484	chr15:71818396~71823384:+
PCPG	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	5.53	1.38e-07	0.000127	0.55	0.41	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
PCPG	cis	rs62246343	0.786	rs62246267	ENSG00000254485.4	RP11-380O24.1	5.53	1.38e-07	0.000127	0.63	0.41	Fibrinogen levels;	chr3:9361477	chr3:9292588~9363303:-
PCPG	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	5.53	1.38e-07	0.000127	0.59	0.41	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
PCPG	cis	rs9926296	0.546	rs7187436	ENSG00000260259.1	RP11-368I7.4	-5.53	1.38e-07	0.000127	-0.51	-0.41	Vitiligo;	chr16:89778702	chr16:89682620~89686569:-
PCPG	cis	rs7267979	0.808	rs84816	ENSG00000125804.12	FAM182A	-5.53	1.39e-07	0.000128	-0.47	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:26054655~26086917:+
PCPG	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	5.53	1.39e-07	0.000128	0.41	0.41	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
PCPG	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-5.53	1.39e-07	0.000128	-0.43	-0.41	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
PCPG	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-5.53	1.4e-07	0.000129	-0.5	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
PCPG	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-5.53	1.4e-07	0.000129	-0.47	-0.41	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
PCPG	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	5.53	1.41e-07	0.000129	0.53	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
PCPG	cis	rs453301	0.571	rs2929456	ENSG00000173295.6	FAM86B3P	5.53	1.41e-07	0.000129	0.49	0.41	Joint mobility (Beighton score);	chr8:9225906	chr8:8228595~8244865:+
PCPG	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-5.53	1.42e-07	0.00013	-0.5	-0.41	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-5.53	1.42e-07	0.00013	-0.5	-0.41	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
PCPG	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-5.53	1.42e-07	0.00013	-0.46	-0.41	Migraine;	chr4:56852029	chr4:56960927~56961373:-
PCPG	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-5.53	1.42e-07	0.00013	-0.43	-0.41	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
PCPG	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-5.53	1.42e-07	0.00013	-0.4	-0.41	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
PCPG	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-5.53	1.42e-07	0.00013	-0.74	-0.41	Depression;	chr6:28159062	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-5.53	1.42e-07	0.00013	-0.74	-0.41	Depression;	chr6:28173682	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-5.53	1.42e-07	0.00013	-0.74	-0.41	Depression;	chr6:28175340	chr6:28115628~28116551:+
PCPG	cis	rs7824557	0.583	rs2736292	ENSG00000255020.1	AF131216.5	5.52	1.42e-07	0.000131	0.53	0.41	Retinal vascular caliber;	chr8:11376991	chr8:11345748~11347502:-
PCPG	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-5.52	1.42e-07	0.000131	-0.53	-0.41	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
PCPG	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-5.52	1.42e-07	0.000131	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
PCPG	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	5.52	1.43e-07	0.000131	0.53	0.41	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
PCPG	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	5.52	1.43e-07	0.000131	0.67	0.41	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	5.52	1.43e-07	0.000131	0.67	0.41	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
PCPG	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-5.52	1.43e-07	0.000131	-0.74	-0.41	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
PCPG	cis	rs2625529	0.73	rs982752	ENSG00000260037.4	CTD-2524L6.3	-5.52	1.43e-07	0.000131	-0.56	-0.41	Red blood cell count;	chr15:71853596	chr15:71818396~71823384:+
PCPG	cis	rs453301	0.719	rs34004903	ENSG00000173295.6	FAM86B3P	5.52	1.43e-07	0.000131	0.49	0.41	Joint mobility (Beighton score);	chr8:9035094	chr8:8228595~8244865:+
PCPG	cis	rs9595908	0.669	rs9285094	ENSG00000212293.1	SNORA16	5.52	1.43e-07	0.000131	0.5	0.41	Body mass index;	chr13:32761453	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.694	rs2224883	ENSG00000212293.1	SNORA16	5.52	1.43e-07	0.000131	0.5	0.41	Body mass index;	chr13:32763753	chr13:32420390~32420516:-
PCPG	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	5.52	1.43e-07	0.000131	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
PCPG	cis	rs7267979	0.966	rs454723	ENSG00000125804.12	FAM182A	-5.52	1.44e-07	0.000132	-0.47	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:26054655~26086917:+
PCPG	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	5.52	1.45e-07	0.000132	0.42	0.41	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
PCPG	cis	rs9595908	0.709	rs7318563	ENSG00000212293.1	SNORA16	5.52	1.45e-07	0.000133	0.49	0.41	Body mass index;	chr13:32749348	chr13:32420390~32420516:-
PCPG	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	5.52	1.45e-07	0.000133	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
PCPG	cis	rs7188445	0.736	rs4889012	ENSG00000261390.4	RP11-345M22.2	5.52	1.46e-07	0.000133	0.54	0.41	Urate levels;	chr16:79667485	chr16:79715232~79770563:-
PCPG	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-5.52	1.46e-07	0.000133	-0.45	-0.41	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-5.52	1.46e-07	0.000133	-0.45	-0.41	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-5.52	1.46e-07	0.000133	-0.45	-0.41	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
PCPG	cis	rs916888	0.779	rs199498	ENSG00000232300.1	FAM215B	5.52	1.46e-07	0.000133	0.63	0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46558830~46562795:-
PCPG	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-5.52	1.46e-07	0.000134	-0.55	-0.41	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
PCPG	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-5.52	1.46e-07	0.000134	-0.59	-0.41	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
PCPG	cis	rs7208859	0.673	rs9889755	ENSG00000264538.5	SUZ12P1	5.52	1.46e-07	0.000134	0.58	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30709299~30790908:+
PCPG	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	5.52	1.46e-07	0.000134	0.41	0.41	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
PCPG	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	5.52	1.47e-07	0.000134	0.56	0.41	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
PCPG	cis	rs4819052	0.679	rs2838860	ENSG00000215447.6	BX322557.10	-5.52	1.47e-07	0.000134	-0.37	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45288052~45291738:+
PCPG	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	5.52	1.47e-07	0.000135	0.46	0.41	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
PCPG	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-5.52	1.48e-07	0.000135	-0.62	-0.41	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-5.52	1.48e-07	0.000135	-0.62	-0.41	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-5.52	1.48e-07	0.000135	-0.62	-0.41	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
PCPG	cis	rs2625529	0.652	rs8040216	ENSG00000260037.4	CTD-2524L6.3	5.52	1.48e-07	0.000135	0.51	0.41	Red blood cell count;	chr15:71962908	chr15:71818396~71823384:+
PCPG	cis	rs453301	0.522	rs2929309	ENSG00000173295.6	FAM86B3P	5.52	1.48e-07	0.000135	0.5	0.41	Joint mobility (Beighton score);	chr8:9226261	chr8:8228595~8244865:+
PCPG	cis	rs11671005	0.504	rs3794964	ENSG00000269600.1	AC016629.3	-5.52	1.48e-07	0.000135	-0.56	-0.41	Mean platelet volume;	chr19:58559549	chr19:58593896~58599355:-
PCPG	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-5.52	1.48e-07	0.000136	-0.53	-0.41	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
PCPG	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	5.52	1.49e-07	0.000136	0.49	0.41	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	5.52	1.49e-07	0.000136	0.49	0.41	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	5.52	1.49e-07	0.000136	0.49	0.41	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	5.52	1.49e-07	0.000136	0.49	0.41	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	5.52	1.49e-07	0.000136	0.49	0.41	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	5.52	1.49e-07	0.000136	0.49	0.41	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
PCPG	cis	rs561341	1	rs117029332	ENSG00000265798.5	RP11-271K11.5	5.52	1.49e-07	0.000136	0.75	0.41	Hip circumference adjusted for BMI;	chr17:31939066	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs72821971	ENSG00000265798.5	RP11-271K11.5	5.52	1.49e-07	0.000136	0.75	0.41	Hip circumference adjusted for BMI;	chr17:31942324	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs117979353	ENSG00000265798.5	RP11-271K11.5	5.52	1.49e-07	0.000136	0.75	0.41	Hip circumference adjusted for BMI;	chr17:31945847	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs72823785	ENSG00000265798.5	RP11-271K11.5	5.52	1.49e-07	0.000136	0.75	0.41	Hip circumference adjusted for BMI;	chr17:31946765	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs55978022	ENSG00000265798.5	RP11-271K11.5	5.52	1.49e-07	0.000136	0.75	0.41	Hip circumference adjusted for BMI;	chr17:31948918	chr17:31038575~31059121:-
PCPG	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	5.52	1.49e-07	0.000136	0.64	0.41	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
PCPG	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	5.51	1.49e-07	0.000136	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	5.51	1.49e-07	0.000136	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	5.51	1.49e-07	0.000136	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	5.51	1.49e-07	0.000136	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	5.51	1.49e-07	0.000136	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	5.51	1.49e-07	0.000136	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
PCPG	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-5.51	1.5e-07	0.000137	-0.45	-0.41	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
PCPG	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	5.51	1.5e-07	0.000137	0.63	0.41	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
PCPG	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-5.51	1.5e-07	0.000137	-0.5	-0.41	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
PCPG	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-5.51	1.5e-07	0.000137	-0.44	-0.41	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
PCPG	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-5.51	1.5e-07	0.000137	-0.44	-0.41	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
PCPG	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-5.51	1.51e-07	0.000137	-0.5	-0.41	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
PCPG	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-5.51	1.51e-07	0.000137	-0.5	-0.41	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
PCPG	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-5.51	1.51e-07	0.000137	-0.5	-0.41	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
PCPG	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	5.51	1.51e-07	0.000137	0.62	0.41	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
PCPG	cis	rs7267979	1	rs6083862	ENSG00000125804.12	FAM182A	5.51	1.51e-07	0.000138	0.45	0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:26054655~26086917:+
PCPG	cis	rs3806843	0.735	rs2563333	ENSG00000202515.1	VTRNA1-3	5.51	1.51e-07	0.000138	0.5	0.41	Depressive symptoms (multi-trait analysis);	chr5:140672686	chr5:140726158~140726246:+
PCPG	cis	rs9595908	0.965	rs9591180	ENSG00000212293.1	SNORA16	5.51	1.52e-07	0.000138	0.48	0.41	Body mass index;	chr13:32622864	chr13:32420390~32420516:-
PCPG	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-5.51	1.52e-07	0.000138	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
PCPG	cis	rs9595908	1	rs9591145	ENSG00000212293.1	SNORA16	5.51	1.52e-07	0.000139	0.48	0.41	Body mass index;	chr13:32587322	chr13:32420390~32420516:-
PCPG	cis	rs9595908	1	rs3742320	ENSG00000212293.1	SNORA16	5.51	1.52e-07	0.000139	0.48	0.41	Body mass index;	chr13:32590281	chr13:32420390~32420516:-
PCPG	cis	rs9595908	1	rs7992980	ENSG00000212293.1	SNORA16	5.51	1.52e-07	0.000139	0.48	0.41	Body mass index;	chr13:32607005	chr13:32420390~32420516:-
PCPG	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-5.51	1.53e-07	0.000139	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
PCPG	cis	rs11148252	0.904	rs9568732	ENSG00000235660.1	LINC00345	5.51	1.55e-07	0.000141	0.5	0.41	Lewy body disease;	chr13:52419277	chr13:52484161~52484680:-
PCPG	cis	rs910316	0.503	rs4903273	ENSG00000279594.1	RP11-950C14.10	-5.51	1.55e-07	0.000141	-0.52	-0.41	Height;	chr14:74975092	chr14:75011269~75012851:-
PCPG	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-5.51	1.55e-07	0.000141	-0.56	-0.41	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
PCPG	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	5.51	1.56e-07	0.000142	0.5	0.41	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
PCPG	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	5.5	1.56e-07	0.000142	0.56	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
PCPG	cis	rs6762	0.748	rs5030780	ENSG00000279672.1	CMB9-55F22.1	5.5	1.57e-07	0.000142	0.45	0.41	Mean platelet volume;	chr11:838110	chr11:779617~780755:+
PCPG	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	5.5	1.57e-07	0.000142	0.57	0.41	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
PCPG	cis	rs9926296	0.605	rs8046243	ENSG00000260259.1	RP11-368I7.4	-5.5	1.57e-07	0.000142	-0.5	-0.41	Vitiligo;	chr16:89785725	chr16:89682620~89686569:-
PCPG	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-5.5	1.58e-07	0.000143	-0.49	-0.41	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-5.5	1.58e-07	0.000143	-0.49	-0.41	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
PCPG	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	5.5	1.58e-07	0.000144	0.52	0.41	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
PCPG	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-5.5	1.58e-07	0.000144	-0.49	-0.41	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
PCPG	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-5.5	1.59e-07	0.000144	-0.52	-0.41	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
PCPG	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-5.5	1.59e-07	0.000144	-0.52	-0.41	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
PCPG	cis	rs2921073	0.51	rs2976944	ENSG00000253893.2	FAM85B	-5.5	1.59e-07	0.000144	-0.51	-0.41	Parkinson's disease;	chr8:8413404	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-5.5	1.6e-07	0.000145	-0.5	-0.41	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
PCPG	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	5.5	1.6e-07	0.000145	0.4	0.41	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
PCPG	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	5.5	1.6e-07	0.000145	0.4	0.41	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
PCPG	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-5.5	1.6e-07	0.000145	-0.49	-0.41	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
PCPG	cis	rs6762	0.748	rs1130719	ENSG00000279672.1	CMB9-55F22.1	5.5	1.6e-07	0.000145	0.45	0.41	Mean platelet volume;	chr11:838760	chr11:779617~780755:+
PCPG	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-5.5	1.61e-07	0.000145	-0.74	-0.41	Depression;	chr6:28223052	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-5.5	1.61e-07	0.000145	-0.74	-0.41	Depression;	chr6:28223279	chr6:28115628~28116551:+
PCPG	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	5.5	1.61e-07	0.000145	0.72	0.41	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
PCPG	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	5.5	1.61e-07	0.000146	0.56	0.41	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
PCPG	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-5.5	1.61e-07	0.000146	-0.47	-0.41	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
PCPG	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-5.5	1.61e-07	0.000146	-0.71	-0.41	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-5.5	1.61e-07	0.000146	-0.71	-0.41	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
PCPG	cis	rs4819052	0.679	rs2255761	ENSG00000215447.6	BX322557.10	-5.5	1.62e-07	0.000146	-0.37	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.679	rs2838859	ENSG00000215447.6	BX322557.10	-5.5	1.62e-07	0.000146	-0.37	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45288052~45291738:+
PCPG	cis	rs2625529	0.689	rs2957742	ENSG00000260037.4	CTD-2524L6.3	5.5	1.62e-07	0.000146	0.52	0.41	Red blood cell count;	chr15:72010553	chr15:71818396~71823384:+
PCPG	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-5.5	1.62e-07	0.000146	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
PCPG	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-5.5	1.62e-07	0.000146	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
PCPG	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	5.5	1.62e-07	0.000147	0.45	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	5.5	1.62e-07	0.000147	0.45	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
PCPG	cis	rs11671005	0.61	rs4756	ENSG00000269600.1	AC016629.3	-5.5	1.63e-07	0.000147	-0.58	-0.41	Mean platelet volume;	chr19:58563286	chr19:58593896~58599355:-
PCPG	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	5.5	1.63e-07	0.000147	0.55	0.41	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	5.5	1.63e-07	0.000147	0.55	0.41	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
PCPG	cis	rs12291225	0.585	rs10832246	ENSG00000251991.1	RNU7-49P	5.5	1.63e-07	0.000147	0.48	0.41	Sense of smell;	chr11:14359282	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.585	rs11023197	ENSG00000251991.1	RNU7-49P	5.5	1.63e-07	0.000147	0.48	0.41	Sense of smell;	chr11:14359452	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.585	rs4517475	ENSG00000251991.1	RNU7-49P	5.5	1.63e-07	0.000147	0.48	0.41	Sense of smell;	chr11:14364599	chr11:14478892~14478953:+
PCPG	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-5.5	1.63e-07	0.000147	-0.52	-0.41	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
PCPG	cis	rs7811142	1	rs7794485	ENSG00000078319.8	PMS2P1	-5.5	1.63e-07	0.000148	-0.57	-0.41	Platelet count;	chr7:100471313	chr7:100320992~100341908:-
PCPG	cis	rs2625529	0.617	rs2128112	ENSG00000260037.4	CTD-2524L6.3	5.5	1.63e-07	0.000148	0.53	0.41	Red blood cell count;	chr15:71893945	chr15:71818396~71823384:+
PCPG	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-5.49	1.64e-07	0.000148	-0.53	-0.41	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-5.49	1.64e-07	0.000148	-0.53	-0.41	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
PCPG	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	5.49	1.64e-07	0.000148	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
PCPG	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	5.49	1.65e-07	0.000149	0.43	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
PCPG	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-5.49	1.65e-07	0.000149	-0.43	-0.41	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
PCPG	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-5.49	1.65e-07	0.000149	-0.48	-0.41	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
PCPG	cis	rs5769765	0.862	rs9616392	ENSG00000278869.1	CITF22-49E9.3	5.49	1.65e-07	0.000149	0.58	0.41	Schizophrenia;	chr22:49921057	chr22:49933198~49934074:-
PCPG	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-5.49	1.66e-07	0.000149	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
PCPG	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	5.49	1.66e-07	0.00015	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
PCPG	cis	rs957448	0.507	rs1984711	ENSG00000253704.1	RP11-267M23.4	5.49	1.66e-07	0.00015	0.45	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94553722~94569745:+
PCPG	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	5.49	1.66e-07	0.00015	0.47	0.41	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	5.49	1.66e-07	0.00015	0.47	0.41	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	5.49	1.66e-07	0.00015	0.47	0.41	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	5.49	1.66e-07	0.00015	0.47	0.41	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	5.49	1.66e-07	0.00015	0.47	0.41	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	5.49	1.66e-07	0.00015	0.47	0.41	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
PCPG	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	5.49	1.66e-07	0.00015	0.52	0.41	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
PCPG	cis	rs9595908	0.965	rs11840502	ENSG00000212293.1	SNORA16	5.49	1.66e-07	0.00015	0.48	0.41	Body mass index;	chr13:32624572	chr13:32420390~32420516:-
PCPG	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-5.49	1.67e-07	0.00015	-0.44	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
PCPG	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
PCPG	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	5.49	1.67e-07	0.00015	0.5	0.41	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
PCPG	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-5.49	1.68e-07	0.000151	-0.74	-0.41	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
PCPG	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-5.49	1.68e-07	0.000151	-0.74	-0.41	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
PCPG	cis	rs11148252	0.595	rs4885117	ENSG00000198384.8	TPTE2P3	-5.49	1.68e-07	0.000151	-0.53	-0.41	Lewy body disease;	chr13:52578892	chr13:52522632~52586906:+
PCPG	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	5.49	1.68e-07	0.000151	0.5	0.41	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
PCPG	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	5.49	1.68e-07	0.000151	0.54	0.41	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
PCPG	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	5.49	1.68e-07	0.000152	0.66	0.41	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
PCPG	cis	rs10760158	0.51	rs7020643	ENSG00000226752.6	PSMD5-AS1	-5.49	1.68e-07	0.000152	-0.52	-0.41	Pulse pressure;	chr9:121099578	chr9:120824828~120854385:+
PCPG	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	5.49	1.68e-07	0.000152	0.62	0.41	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
PCPG	cis	rs1908814	0.516	rs11250178	ENSG00000255020.1	AF131216.5	5.49	1.69e-07	0.000152	0.56	0.41	Neuroticism;	chr8:11942725	chr8:11345748~11347502:-
PCPG	cis	rs12681963	0.614	rs7013787	ENSG00000248159.1	HSPA8P11	5.49	1.69e-07	0.000152	0.78	0.41	Migraine;	chr8:30203272	chr8:30237382~30240997:+
PCPG	cis	rs853679	0.517	rs9283884	ENSG00000216901.1	AL022393.7	-5.49	1.69e-07	0.000152	-0.59	-0.41	Depression;	chr6:28167882	chr6:28176188~28176674:+
PCPG	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-5.49	1.7e-07	0.000153	-0.51	-0.41	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
PCPG	cis	rs7811142	0.887	rs111972532	ENSG00000078319.8	PMS2P1	-5.49	1.7e-07	0.000153	-0.55	-0.41	Platelet count;	chr7:100471465	chr7:100320992~100341908:-
PCPG	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	5.49	1.7e-07	0.000153	0.49	0.41	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
PCPG	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	5.49	1.71e-07	0.000153	0.38	0.41	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
PCPG	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-5.49	1.71e-07	0.000154	-0.5	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
PCPG	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-5.48	1.73e-07	0.000155	-0.45	-0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
PCPG	cis	rs7208859	0.623	rs7219361	ENSG00000263603.1	CTD-2349P21.5	-5.48	1.74e-07	0.000156	-0.7	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30729469~30731202:+
PCPG	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	5.48	1.74e-07	0.000156	0.54	0.41	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
PCPG	cis	rs73607972	0.696	rs7194983	ENSG00000275191.1	RP11-36I17.2	-5.48	1.74e-07	0.000156	-0.64	-0.41	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525100	chr16:53628256~53628816:-
PCPG	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-5.48	1.74e-07	0.000156	-0.44	-0.41	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
PCPG	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-5.48	1.74e-07	0.000156	-0.54	-0.41	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
PCPG	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	5.48	1.75e-07	0.000157	0.36	0.41	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
PCPG	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	5.48	1.76e-07	0.000158	0.65	0.41	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
PCPG	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-5.48	1.76e-07	0.000158	-0.53	-0.41	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
PCPG	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
PCPG	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	5.48	1.76e-07	0.000158	0.55	0.41	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
PCPG	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-5.48	1.77e-07	0.000158	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
PCPG	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	5.48	1.77e-07	0.000158	0.52	0.41	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
PCPG	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-5.48	1.77e-07	0.000158	-0.54	-0.41	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-5.48	1.77e-07	0.000158	-0.54	-0.41	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-5.48	1.77e-07	0.000158	-0.54	-0.41	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
PCPG	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	5.48	1.77e-07	0.000159	0.38	0.41	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	5.48	1.77e-07	0.000159	0.38	0.41	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	5.48	1.77e-07	0.000159	0.38	0.41	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
PCPG	cis	rs916888	0.779	rs199526	ENSG00000232300.1	FAM215B	-5.48	1.78e-07	0.000159	-0.56	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46558830~46562795:-
PCPG	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-5.48	1.78e-07	0.000159	-0.59	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
PCPG	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-5.48	1.78e-07	0.000159	-0.45	-0.41	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
PCPG	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	5.48	1.78e-07	0.00016	0.64	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
PCPG	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-5.48	1.79e-07	0.00016	-0.53	-0.41	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-5.48	1.79e-07	0.00016	-0.53	-0.41	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
PCPG	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	1.79e-07	0.00016	-0.5	-0.41	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
PCPG	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	5.48	1.79e-07	0.00016	0.37	0.41	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
PCPG	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	5.48	1.79e-07	0.00016	0.55	0.41	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
PCPG	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	5.48	1.79e-07	0.00016	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
PCPG	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-5.47	1.8e-07	0.000161	-0.44	-0.41	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
PCPG	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-5.47	1.8e-07	0.000161	-0.47	-0.41	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
PCPG	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-5.47	1.81e-07	0.000162	-0.46	-0.41	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
PCPG	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	5.47	1.81e-07	0.000162	0.55	0.41	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
PCPG	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-5.47	1.82e-07	0.000162	-0.5	-0.41	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-5.47	1.82e-07	0.000162	-0.5	-0.41	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
PCPG	cis	rs1964356	0.967	rs17701675	ENSG00000173295.6	FAM86B3P	5.47	1.82e-07	0.000163	0.48	0.41	Mean corpuscular volume;	chr8:8993123	chr8:8228595~8244865:+
PCPG	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-5.47	1.82e-07	0.000163	-0.56	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
PCPG	cis	rs300890	0.651	rs300913	ENSG00000250326.1	RP11-284M14.1	5.47	1.83e-07	0.000163	0.36	0.41	Nasopharyngeal carcinoma;	chr4:143355490	chr4:142933195~143184861:-
PCPG	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	5.47	1.83e-07	0.000163	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
PCPG	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-5.47	1.83e-07	0.000163	-0.55	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
PCPG	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	5.47	1.83e-07	0.000164	0.71	0.41	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
PCPG	cis	rs853679	1	rs853676	ENSG00000216901.1	AL022393.7	5.47	1.83e-07	0.000164	0.63	0.41	Depression;	chr6:28331910	chr6:28176188~28176674:+
PCPG	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-5.47	1.85e-07	0.000165	-0.78	-0.41	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
PCPG	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	5.47	1.85e-07	0.000165	0.53	0.41	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
PCPG	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	5.47	1.85e-07	0.000165	0.64	0.41	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
PCPG	cis	rs879620	0.929	rs2238435	ENSG00000262888.1	RP11-462G12.2	-5.47	1.85e-07	0.000165	-0.56	-0.41	Hip circumference;Body mass index;	chr16:3964281	chr16:3931217~3946305:-
PCPG	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-5.47	1.85e-07	0.000165	-0.5	-0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
PCPG	cis	rs9595908	0.9	rs7994229	ENSG00000212293.1	SNORA16	5.47	1.86e-07	0.000165	0.48	0.41	Body mass index;	chr13:32586568	chr13:32420390~32420516:-
PCPG	cis	rs9595908	1	rs9595905	ENSG00000212293.1	SNORA16	5.47	1.86e-07	0.000165	0.48	0.41	Body mass index;	chr13:32609266	chr13:32420390~32420516:-
PCPG	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-5.47	1.86e-07	0.000166	-0.36	-0.41	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
PCPG	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	5.47	1.88e-07	0.000167	0.49	0.41	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-5.47	1.88e-07	0.000167	-0.49	-0.41	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
PCPG	cis	rs2625529	0.73	rs4511483	ENSG00000260037.4	CTD-2524L6.3	-5.47	1.88e-07	0.000167	-0.52	-0.41	Red blood cell count;	chr15:71846249	chr15:71818396~71823384:+
PCPG	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	5.47	1.88e-07	0.000167	0.5	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
PCPG	cis	rs7824557	0.583	rs2736306	ENSG00000255020.1	AF131216.5	5.47	1.88e-07	0.000167	0.54	0.41	Retinal vascular caliber;	chr8:11382253	chr8:11345748~11347502:-
PCPG	cis	rs4835473	0.637	rs1825040	ENSG00000250345.2	RP11-780M14.1	5.47	1.88e-07	0.000167	0.44	0.41	Immature fraction of reticulocytes;	chr4:143794417	chr4:143760399~143762093:-
PCPG	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	-5.47	1.88e-07	0.000168	-0.47	-0.41	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
PCPG	cis	rs7402982	0.625	rs4966008	ENSG00000278022.1	RP11-35O15.2	5.46	1.89e-07	0.000168	0.41	0.41	Birth weight;	chr15:98660216	chr15:98660210~98660668:+
PCPG	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-5.46	1.89e-07	0.000168	-0.41	-0.41	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
PCPG	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	5.46	1.9e-07	0.000169	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	5.46	1.9e-07	0.000169	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
PCPG	cis	rs7688540	0.74	rs28784663	ENSG00000275426.1	CH17-262A2.1	5.46	1.9e-07	0.000169	0.49	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:149738~150317:+
PCPG	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	5.46	1.9e-07	0.000169	0.54	0.41	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
PCPG	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	5.46	1.9e-07	0.000169	0.63	0.41	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
PCPG	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	5.46	1.9e-07	0.000169	0.51	0.41	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
PCPG	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	5.46	1.91e-07	0.000169	0.44	0.41	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
PCPG	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	5.46	1.91e-07	0.00017	0.49	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
PCPG	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	5.46	1.92e-07	0.000171	0.53	0.41	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	5.46	1.92e-07	0.000171	0.53	0.41	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
PCPG	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	5.46	1.92e-07	0.000171	0.44	0.41	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
PCPG	cis	rs7208859	0.623	rs79607958	ENSG00000263603.1	CTD-2349P21.5	-5.46	1.93e-07	0.000171	-0.7	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs75136574	ENSG00000263603.1	CTD-2349P21.5	-5.46	1.93e-07	0.000171	-0.7	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs77544470	ENSG00000263603.1	CTD-2349P21.5	-5.46	1.93e-07	0.000171	-0.7	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30729469~30731202:+
PCPG	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-5.46	1.93e-07	0.000171	-0.54	-0.41	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
PCPG	cis	rs13113518	0.702	rs78829811	ENSG00000272969.1	RP11-528I4.2	5.46	1.94e-07	0.000172	0.46	0.41	Height;	chr4:55558258	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.702	rs75801206	ENSG00000272969.1	RP11-528I4.2	5.46	1.94e-07	0.000172	0.46	0.41	Height;	chr4:55558259	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.702	rs34658078	ENSG00000272969.1	RP11-528I4.2	5.46	1.94e-07	0.000172	0.46	0.41	Height;	chr4:55558261	chr4:55547112~55547889:+
PCPG	cis	rs7688540	0.8	rs10003142	ENSG00000275426.1	CH17-262A2.1	5.46	1.94e-07	0.000172	0.49	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs11723803	ENSG00000275426.1	CH17-262A2.1	5.46	1.94e-07	0.000172	0.49	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:149738~150317:+
PCPG	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-5.46	1.94e-07	0.000172	-0.62	-0.41	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-5.46	1.94e-07	0.000172	-0.62	-0.41	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-5.46	1.94e-07	0.000172	-0.62	-0.41	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-5.46	1.94e-07	0.000172	-0.62	-0.41	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
PCPG	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-5.46	1.95e-07	0.000173	-0.54	-0.41	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
PCPG	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-5.46	1.95e-07	0.000173	-0.56	-0.41	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
PCPG	cis	rs2625529	0.617	rs3784313	ENSG00000260037.4	CTD-2524L6.3	5.46	1.96e-07	0.000173	0.53	0.41	Red blood cell count;	chr15:71895178	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs2957728	ENSG00000260037.4	CTD-2524L6.3	5.46	1.96e-07	0.000173	0.53	0.41	Red blood cell count;	chr15:71944091	chr15:71818396~71823384:+
PCPG	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-5.46	1.96e-07	0.000174	-0.55	-0.41	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
PCPG	cis	rs440932	0.565	rs19334	ENSG00000253893.2	FAM85B	-5.46	1.96e-07	0.000174	-0.51	-0.41	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:8167819~8226614:-
PCPG	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	5.46	1.96e-07	0.000174	0.58	0.41	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	5.46	1.96e-07	0.000174	0.58	0.41	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
PCPG	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-5.46	1.96e-07	0.000174	-0.46	-0.41	Migraine;	chr4:56853383	chr4:56960927~56961373:-
PCPG	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	5.46	1.96e-07	0.000174	0.47	0.41	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
PCPG	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-5.46	1.97e-07	0.000174	-0.5	-0.41	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
PCPG	cis	rs7267979	0.868	rs6138546	ENSG00000125804.12	FAM182A	-5.46	1.97e-07	0.000174	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:26054655~26086917:+
PCPG	cis	rs9595908	0.655	rs56080053	ENSG00000212293.1	SNORA16	5.46	1.97e-07	0.000175	0.49	0.41	Body mass index;	chr13:32720045	chr13:32420390~32420516:-
PCPG	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-5.45	1.99e-07	0.000176	-0.62	-0.41	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-5.45	1.99e-07	0.000176	-0.62	-0.41	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-5.45	1.99e-07	0.000176	-0.62	-0.41	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-5.45	1.99e-07	0.000176	-0.62	-0.41	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
PCPG	cis	rs1045529	0.524	rs34251783	ENSG00000173295.6	FAM86B3P	5.45	1.99e-07	0.000176	0.49	0.41	Myopia (pathological);Myopia;	chr8:9033866	chr8:8228595~8244865:+
PCPG	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-5.45	1.99e-07	0.000176	-0.48	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-5.45	1.99e-07	0.000176	-0.48	-0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
PCPG	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-5.45	1.99e-07	0.000176	-0.52	-0.41	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
PCPG	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	5.45	2e-07	0.000177	0.41	0.41	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
PCPG	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-5.45	2e-07	0.000177	-0.53	-0.41	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
PCPG	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-5.45	2e-07	0.000177	-0.51	-0.41	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
PCPG	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	5.45	2e-07	0.000177	0.55	0.41	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
PCPG	cis	rs453301	0.686	rs10217044	ENSG00000173295.6	FAM86B3P	5.45	2e-07	0.000177	0.48	0.41	Joint mobility (Beighton score);	chr8:9037242	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.508	rs1594437	ENSG00000253893.2	FAM85B	-5.45	2e-07	0.000177	-0.5	-0.41	Mood instability;	chr8:8968365	chr8:8167819~8226614:-
PCPG	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	5.45	2.01e-07	0.000178	0.36	0.41	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
PCPG	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	5.45	2.01e-07	0.000178	0.44	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
PCPG	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	5.45	2.01e-07	0.000178	0.4	0.41	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
PCPG	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-5.45	2.01e-07	0.000178	-0.48	-0.41	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
PCPG	cis	rs1908814	0.503	rs34657250	ENSG00000255020.1	AF131216.5	-5.45	2.02e-07	0.000179	-0.55	-0.41	Neuroticism;	chr8:11937864	chr8:11345748~11347502:-
PCPG	cis	rs9926296	0.548	rs12447465	ENSG00000260259.1	RP11-368I7.4	-5.45	2.02e-07	0.000179	-0.49	-0.41	Vitiligo;	chr16:89763487	chr16:89682620~89686569:-
PCPG	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	5.45	2.02e-07	0.000179	0.4	0.41	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
PCPG	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	5.45	2.03e-07	0.000179	0.38	0.41	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
PCPG	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	5.45	2.03e-07	0.000179	0.38	0.41	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
PCPG	cis	rs9595908	0.9	rs9595850	ENSG00000212293.1	SNORA16	5.45	2.03e-07	0.000179	0.48	0.41	Body mass index;	chr13:32579773	chr13:32420390~32420516:-
PCPG	cis	rs7267979	0.868	rs6138550	ENSG00000125804.12	FAM182A	-5.45	2.03e-07	0.000179	-0.47	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:26054655~26086917:+
PCPG	cis	rs7267979	0.903	rs6050481	ENSG00000125804.12	FAM182A	-5.45	2.03e-07	0.000179	-0.47	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:26054655~26086917:+
PCPG	cis	rs2625529	0.617	rs6494973	ENSG00000260037.4	CTD-2524L6.3	5.45	2.03e-07	0.00018	0.52	0.41	Red blood cell count;	chr15:71853387	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.557	rs7496582	ENSG00000260037.4	CTD-2524L6.3	-5.45	2.03e-07	0.00018	-0.52	-0.41	Red blood cell count;	chr15:71855490	chr15:71818396~71823384:+
PCPG	cis	rs957448	0.561	rs4735302	ENSG00000253704.1	RP11-267M23.4	-5.45	2.04e-07	0.00018	-0.45	-0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94553722~94569745:+
PCPG	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-5.45	2.04e-07	0.00018	-0.47	-0.41	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
PCPG	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	5.45	2.05e-07	0.000181	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	5.45	2.05e-07	0.000181	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	5.45	2.05e-07	0.000181	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	5.45	2.05e-07	0.000181	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	5.45	2.05e-07	0.000181	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	5.45	2.05e-07	0.000181	0.55	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
PCPG	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-5.45	2.05e-07	0.000181	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
PCPG	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-5.45	2.05e-07	0.000181	-0.52	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
PCPG	cis	rs13113518	0.812	rs11945371	ENSG00000272969.1	RP11-528I4.2	5.45	2.05e-07	0.000181	0.44	0.41	Height;	chr4:55409063	chr4:55547112~55547889:+
PCPG	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	5.45	2.05e-07	0.000181	0.53	0.41	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	5.45	2.05e-07	0.000181	0.53	0.41	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
PCPG	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-5.45	2.06e-07	0.000181	-0.51	-0.41	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
PCPG	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	5.45	2.06e-07	0.000182	0.56	0.41	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
PCPG	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-5.45	2.06e-07	0.000182	-0.49	-0.41	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
PCPG	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-5.45	2.06e-07	0.000182	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-5.45	2.06e-07	0.000182	-0.49	-0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
PCPG	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	5.44	2.08e-07	0.000183	0.44	0.41	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
PCPG	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	5.44	2.08e-07	0.000183	0.44	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
PCPG	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-5.44	2.09e-07	0.000184	-0.49	-0.41	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
PCPG	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	5.44	2.09e-07	0.000184	0.67	0.41	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
PCPG	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-5.44	2.09e-07	0.000184	-0.54	-0.41	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
PCPG	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-5.44	2.09e-07	0.000184	-0.53	-0.41	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-5.44	2.09e-07	0.000184	-0.53	-0.41	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-5.44	2.09e-07	0.000184	-0.53	-0.41	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-5.44	2.09e-07	0.000184	-0.53	-0.41	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-5.44	2.09e-07	0.000184	-0.53	-0.41	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
PCPG	cis	rs2625529	0.689	rs10851847	ENSG00000260037.4	CTD-2524L6.3	-5.44	2.09e-07	0.000184	-0.55	-0.41	Red blood cell count;	chr15:71819419	chr15:71818396~71823384:+
PCPG	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-5.44	2.1e-07	0.000184	-0.74	-0.41	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
PCPG	cis	rs7824557	0.564	rs12547100	ENSG00000255020.1	AF131216.5	-5.44	2.1e-07	0.000185	-0.54	-0.41	Retinal vascular caliber;	chr8:11385123	chr8:11345748~11347502:-
PCPG	cis	rs9595908	0.709	rs17516498	ENSG00000212293.1	SNORA16	5.44	2.1e-07	0.000185	0.49	0.41	Body mass index;	chr13:32750477	chr13:32420390~32420516:-
PCPG	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-5.44	2.1e-07	0.000185	-0.47	-0.41	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
PCPG	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	5.44	2.1e-07	0.000185	0.4	0.41	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
PCPG	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-5.44	2.1e-07	0.000185	-0.52	-0.41	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
PCPG	cis	rs910316	0.737	rs175045	ENSG00000279594.1	RP11-950C14.10	-5.44	2.1e-07	0.000185	-0.56	-0.41	Height;	chr14:75008572	chr14:75011269~75012851:-
PCPG	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	5.44	2.11e-07	0.000185	0.56	0.41	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
PCPG	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	5.44	2.11e-07	0.000185	0.64	0.41	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	5.44	2.11e-07	0.000185	0.64	0.41	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	5.44	2.11e-07	0.000185	0.64	0.41	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
PCPG	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-5.44	2.11e-07	0.000186	-0.51	-0.41	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
PCPG	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-5.44	2.11e-07	0.000186	-0.71	-0.41	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
PCPG	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-5.44	2.11e-07	0.000186	-0.59	-0.41	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
PCPG	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	5.44	2.12e-07	0.000186	0.42	0.41	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
PCPG	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-5.44	2.14e-07	0.000188	-0.5	-0.41	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
PCPG	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-5.44	2.14e-07	0.000188	-0.52	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
PCPG	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-5.44	2.14e-07	0.000188	-0.54	-0.41	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
PCPG	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	5.44	2.14e-07	0.000188	0.5	0.41	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
PCPG	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	5.44	2.14e-07	0.000188	0.5	0.41	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
PCPG	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	5.44	2.15e-07	0.000188	0.68	0.41	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
PCPG	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-5.44	2.15e-07	0.000188	-0.54	-0.41	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
PCPG	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-5.44	2.17e-07	0.00019	-0.52	-0.41	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
PCPG	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-5.43	2.17e-07	0.00019	-0.44	-0.41	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
PCPG	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-5.43	2.17e-07	0.00019	-0.39	-0.41	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
PCPG	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-5.43	2.17e-07	0.000191	-0.51	-0.41	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
PCPG	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	5.43	2.18e-07	0.000191	0.45	0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
PCPG	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	5.43	2.18e-07	0.000191	0.45	0.41	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
PCPG	cis	rs9595908	0.669	rs7983309	ENSG00000212293.1	SNORA16	5.43	2.18e-07	0.000191	0.49	0.41	Body mass index;	chr13:32740254	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.609	rs733487	ENSG00000212293.1	SNORA16	5.43	2.18e-07	0.000191	0.49	0.41	Body mass index;	chr13:32741068	chr13:32420390~32420516:-
PCPG	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-5.43	2.18e-07	0.000191	-0.52	-0.41	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
PCPG	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-5.43	2.18e-07	0.000191	-0.52	-0.41	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-5.43	2.18e-07	0.000191	-0.52	-0.41	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-5.43	2.18e-07	0.000191	-0.52	-0.41	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
PCPG	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.51	0.41	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
PCPG	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-5.43	2.18e-07	0.000191	-0.49	-0.41	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-5.43	2.18e-07	0.000191	-0.49	-0.41	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
PCPG	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	5.43	2.18e-07	0.000191	0.53	0.41	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
PCPG	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-5.43	2.2e-07	0.000192	-0.53	-0.41	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-5.43	2.2e-07	0.000192	-0.53	-0.41	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-5.43	2.2e-07	0.000192	-0.53	-0.41	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-5.43	2.2e-07	0.000192	-0.53	-0.41	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
PCPG	cis	rs11148252	0.74	rs9596643	ENSG00000235660.1	LINC00345	5.43	2.2e-07	0.000192	0.51	0.41	Lewy body disease;	chr13:52338245	chr13:52484161~52484680:-
PCPG	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	5.43	2.2e-07	0.000193	0.53	0.41	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
PCPG	cis	rs11148252	0.967	rs11618716	ENSG00000235660.1	LINC00345	5.43	2.2e-07	0.000193	0.52	0.41	Lewy body disease;	chr13:52472701	chr13:52484161~52484680:-
PCPG	cis	rs13113518	1	rs4864548	ENSG00000272969.1	RP11-528I4.2	-5.43	2.21e-07	0.000193	-0.44	-0.41	Height;	chr4:55547636	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs7662966	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55548261	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13115828	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55551447	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13136282	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55551845	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11934897	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55553396	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.934	rs11932293	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55554025	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4864549	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55554380	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4865011	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55554456	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4865013	ENSG00000272969.1	RP11-528I4.2	5.43	2.21e-07	0.000193	0.44	0.41	Height;	chr4:55559957	chr4:55547112~55547889:+
PCPG	cis	rs3806843	0.966	rs2563264	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.52	0.41	Depressive symptoms (multi-trait analysis);	chr5:140757918	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs2563262	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.52	0.41	Depressive symptoms (multi-trait analysis);	chr5:140758127	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.932	rs2563257	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.52	0.41	Depressive symptoms (multi-trait analysis);	chr5:140760944	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.932	rs2563256	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.52	0.41	Depressive symptoms (multi-trait analysis);	chr5:140762194	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs2563255	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.52	0.41	Depressive symptoms (multi-trait analysis);	chr5:140762962	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.9	rs2563254	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.52	0.41	Depressive symptoms (multi-trait analysis);	chr5:140763116	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs7737424	ENSG00000202515.1	VTRNA1-3	-5.43	2.21e-07	0.000193	-0.52	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140766760	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs12659129	ENSG00000202515.1	VTRNA1-3	-5.43	2.21e-07	0.000193	-0.52	-0.41	Depressive symptoms (multi-trait analysis);	chr5:140767663	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.657	rs2563283	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.51	0.41	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.771	rs2563336	ENSG00000202515.1	VTRNA1-3	5.43	2.21e-07	0.000193	0.51	0.41	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr5:140726158~140726246:+
PCPG	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	5.43	2.22e-07	0.000194	0.58	0.41	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
PCPG	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	5.43	2.22e-07	0.000194	0.43	0.41	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
PCPG	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	5.43	2.23e-07	0.000195	0.4	0.41	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
PCPG	cis	rs7267979	0.816	rs8115257	ENSG00000125804.12	FAM182A	-5.43	2.27e-07	0.000198	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:26054655~26086917:+
PCPG	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	5.43	2.27e-07	0.000198	0.39	0.41	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
PCPG	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	5.43	2.27e-07	0.000198	0.69	0.41	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
PCPG	cis	rs9595908	0.709	rs3492	ENSG00000212293.1	SNORA16	5.42	2.27e-07	0.000198	0.49	0.4	Body mass index;	chr13:32775203	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs7326102	ENSG00000212293.1	SNORA16	5.42	2.27e-07	0.000198	0.49	0.4	Body mass index;	chr13:32777857	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs7322668	ENSG00000212293.1	SNORA16	5.42	2.27e-07	0.000198	0.49	0.4	Body mass index;	chr13:32780298	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs7318610	ENSG00000212293.1	SNORA16	5.42	2.27e-07	0.000198	0.49	0.4	Body mass index;	chr13:32781912	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs17516561	ENSG00000212293.1	SNORA16	5.42	2.27e-07	0.000198	0.49	0.4	Body mass index;	chr13:32782063	chr13:32420390~32420516:-
PCPG	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	5.42	2.28e-07	0.000199	0.48	0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-5.42	2.28e-07	0.000199	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-5.42	2.28e-07	0.000199	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
PCPG	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	5.42	2.28e-07	0.000199	0.52	0.4	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
PCPG	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-5.42	2.29e-07	0.000199	-0.47	-0.4	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
PCPG	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	5.42	2.29e-07	0.000199	0.74	0.4	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
PCPG	cis	rs9595908	0.686	rs9596155	ENSG00000212293.1	SNORA16	5.42	2.29e-07	0.000199	0.49	0.4	Body mass index;	chr13:32724002	chr13:32420390~32420516:-
PCPG	cis	rs11148252	0.74	rs9596648	ENSG00000235660.1	LINC00345	5.42	2.29e-07	2e-04	0.51	0.4	Lewy body disease;	chr13:52360434	chr13:52484161~52484680:-
PCPG	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	5.42	2.29e-07	2e-04	0.47	0.4	Height;	chr2:231516534	chr2:231508426~231514339:-
PCPG	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	5.42	2.3e-07	2e-04	0.64	0.4	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
PCPG	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	5.42	2.3e-07	2e-04	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
PCPG	cis	rs11148252	0.74	rs9596642	ENSG00000235660.1	LINC00345	5.42	2.31e-07	0.000201	0.51	0.4	Lewy body disease;	chr13:52326744	chr13:52484161~52484680:-
PCPG	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	5.42	2.31e-07	0.000201	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	5.42	2.31e-07	0.000201	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
PCPG	cis	rs3806843	0.898	rs3756335	ENSG00000202515.1	VTRNA1-3	-5.42	2.31e-07	0.000201	-0.53	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140833925	chr5:140726158~140726246:+
PCPG	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-5.42	2.31e-07	0.000201	-0.53	-0.4	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
PCPG	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-5.42	2.33e-07	0.000202	-0.44	-0.4	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-5.42	2.33e-07	0.000202	-0.44	-0.4	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-5.42	2.33e-07	0.000202	-0.44	-0.4	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-5.42	2.33e-07	0.000202	-0.44	-0.4	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
PCPG	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-5.42	2.33e-07	0.000202	-0.48	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-5.42	2.33e-07	0.000202	-0.48	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
PCPG	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-5.42	2.33e-07	0.000202	-0.53	-0.4	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
PCPG	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-5.42	2.34e-07	0.000203	-0.54	-0.4	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
PCPG	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-5.42	2.34e-07	0.000203	-0.54	-0.4	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
PCPG	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	5.42	2.34e-07	0.000203	0.49	0.4	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
PCPG	cis	rs3806843	1	rs10477033	ENSG00000202515.1	VTRNA1-3	-5.42	2.34e-07	0.000204	-0.52	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140790018	chr5:140726158~140726246:+
PCPG	cis	rs9926296	0.605	rs3743859	ENSG00000260259.1	RP11-368I7.4	5.42	2.35e-07	0.000204	0.5	0.4	Vitiligo;	chr16:89779642	chr16:89682620~89686569:-
PCPG	cis	rs12681963	0.688	rs61621868	ENSG00000248159.1	HSPA8P11	5.42	2.36e-07	0.000205	0.7	0.4	Migraine;	chr8:30182621	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.541	rs56302321	ENSG00000248159.1	HSPA8P11	5.42	2.36e-07	0.000205	0.7	0.4	Migraine;	chr8:30183018	chr8:30237382~30240997:+
PCPG	cis	rs7819412	0.838	rs3021494	ENSG00000255020.1	AF131216.5	-5.42	2.36e-07	0.000205	-0.56	-0.4	Triglycerides;	chr8:11126024	chr8:11345748~11347502:-
PCPG	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-5.42	2.37e-07	0.000205	-0.52	-0.4	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
PCPG	cis	rs7829975	0.511	rs1543238	ENSG00000173295.6	FAM86B3P	-5.42	2.37e-07	0.000205	-0.47	-0.4	Mood instability;	chr8:8277287	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.511	rs1401390	ENSG00000173295.6	FAM86B3P	-5.42	2.37e-07	0.000205	-0.47	-0.4	Mood instability;	chr8:8278888	chr8:8228595~8244865:+
PCPG	cis	rs2625529	0.73	rs8182011	ENSG00000260037.4	CTD-2524L6.3	5.42	2.37e-07	0.000206	0.59	0.4	Red blood cell count;	chr15:72097607	chr15:71818396~71823384:+
PCPG	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-5.42	2.37e-07	0.000206	-0.4	-0.4	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
PCPG	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-5.42	2.37e-07	0.000206	-0.44	-0.4	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
PCPG	cis	rs2736340	0.539	rs9644687	ENSG00000255020.1	AF131216.5	-5.42	2.38e-07	0.000206	-0.55	-0.4	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465516	chr8:11345748~11347502:-
PCPG	cis	rs9309473	1	rs11689392	ENSG00000163016.8	ALMS1P	5.42	2.38e-07	0.000207	0.54	0.4	Metabolite levels;	chr2:73394898	chr2:73644919~73685576:+
PCPG	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	5.42	2.38e-07	0.000207	0.54	0.4	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
PCPG	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-5.41	2.4e-07	0.000207	-0.5	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
PCPG	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	5.41	2.41e-07	0.000208	0.5	0.4	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
PCPG	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	5.41	2.41e-07	0.000208	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
PCPG	cis	rs2625529	0.617	rs11633167	ENSG00000260037.4	CTD-2524L6.3	5.41	2.42e-07	0.000209	0.51	0.4	Red blood cell count;	chr15:71886837	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.617	rs16956369	ENSG00000260037.4	CTD-2524L6.3	5.41	2.42e-07	0.000209	0.51	0.4	Red blood cell count;	chr15:71890472	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs2929513	ENSG00000260037.4	CTD-2524L6.3	5.41	2.42e-07	0.000209	0.51	0.4	Red blood cell count;	chr15:71936839	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs2929508	ENSG00000260037.4	CTD-2524L6.3	5.41	2.42e-07	0.000209	0.51	0.4	Red blood cell count;	chr15:71954623	chr15:71818396~71823384:+
PCPG	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-5.41	2.42e-07	0.000209	-0.8	-0.4	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
PCPG	cis	rs9481169	0.557	rs13190932	ENSG00000255389.1	C6orf3	-5.41	2.42e-07	0.000209	-0.8	-0.4	Inflammatory skin disease;	chr6:111591867	chr6:111599875~111602295:+
PCPG	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	5.41	2.42e-07	0.000209	0.8	0.4	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
PCPG	cis	rs300890	0.662	rs4544668	ENSG00000250326.1	RP11-284M14.1	5.41	2.43e-07	0.00021	0.37	0.4	Nasopharyngeal carcinoma;	chr4:143314650	chr4:142933195~143184861:-
PCPG	cis	rs17507216	0.718	rs4779034	ENSG00000228141.5	AC105339.1	-5.41	2.43e-07	0.00021	-0.63	-0.4	Excessive daytime sleepiness;	chr15:82576799	chr15:82710471~82714026:-
PCPG	cis	rs453301	0.658	rs3855900	ENSG00000173295.6	FAM86B3P	5.41	2.44e-07	0.00021	0.49	0.4	Joint mobility (Beighton score);	chr8:9044411	chr8:8228595~8244865:+
PCPG	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-5.41	2.44e-07	0.00021	-0.46	-0.4	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
PCPG	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-5.41	2.44e-07	0.00021	-0.49	-0.4	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
PCPG	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-5.41	2.45e-07	0.000211	-0.45	-0.4	Migraine;	chr4:56851192	chr4:56960927~56961373:-
PCPG	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	5.41	2.45e-07	0.000211	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
PCPG	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-5.41	2.45e-07	0.000211	-0.51	-0.4	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
PCPG	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-5.41	2.45e-07	0.000211	-0.46	-0.4	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
PCPG	cis	rs2625529	0.878	rs2929511	ENSG00000260037.4	CTD-2524L6.3	5.41	2.45e-07	0.000211	0.52	0.4	Red blood cell count;	chr15:71939341	chr15:71818396~71823384:+
PCPG	cis	rs10131894	0.575	rs2159904	ENSG00000279594.1	RP11-950C14.10	5.41	2.47e-07	0.000213	0.51	0.4	Coronary artery disease;	chr14:74965476	chr14:75011269~75012851:-
PCPG	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	5.41	2.48e-07	0.000213	0.5	0.4	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
PCPG	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-5.41	2.48e-07	0.000213	-0.48	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
PCPG	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-5.41	2.48e-07	0.000213	-0.48	-0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
PCPG	cis	rs7824557	0.707	rs3808518	ENSG00000255020.1	AF131216.5	-5.41	2.48e-07	0.000213	-0.5	-0.4	Retinal vascular caliber;	chr8:11285763	chr8:11345748~11347502:-
PCPG	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	5.41	2.49e-07	0.000214	0.55	0.4	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
PCPG	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	5.41	2.49e-07	0.000214	0.42	0.4	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
PCPG	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	5.41	2.49e-07	0.000214	0.42	0.4	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
PCPG	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	5.41	2.49e-07	0.000214	0.51	0.4	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.624	rs7014430	ENSG00000253893.2	FAM85B	-5.41	2.5e-07	0.000215	-0.5	-0.4	Joint mobility (Beighton score);	chr8:8970227	chr8:8167819~8226614:-
PCPG	cis	rs11992162	0.591	rs4240678	ENSG00000255020.1	AF131216.5	-5.4	2.5e-07	0.000215	-0.53	-0.4	Monocyte count;	chr8:11944917	chr8:11345748~11347502:-
PCPG	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	5.4	2.51e-07	0.000216	0.52	0.4	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
PCPG	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-5.4	2.52e-07	0.000216	-0.51	-0.4	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
PCPG	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-5.4	2.52e-07	0.000217	-0.38	-0.4	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
PCPG	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-5.4	2.52e-07	0.000217	-0.59	-0.4	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
PCPG	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-5.4	2.53e-07	0.000217	-0.5	-0.4	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
PCPG	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-5.4	2.53e-07	0.000217	-0.36	-0.4	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
PCPG	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	5.4	2.53e-07	0.000217	0.64	0.4	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	5.4	2.53e-07	0.000217	0.64	0.4	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
PCPG	cis	rs957448	0.539	rs9643346	ENSG00000253704.1	RP11-267M23.4	5.4	2.53e-07	0.000217	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94553722~94569745:+
PCPG	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-5.4	2.54e-07	0.000218	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
PCPG	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-5.4	2.54e-07	0.000219	-0.53	-0.4	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
PCPG	cis	rs11148252	0.904	rs7321964	ENSG00000235660.1	LINC00345	-5.4	2.55e-07	0.000219	-0.5	-0.4	Lewy body disease;	chr13:52466687	chr13:52484161~52484680:-
PCPG	cis	rs9595908	0.709	rs56347753	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32721685	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs9596149	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32722533	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs4281583	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32722781	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs7322827	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32724396	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.629	rs9596156	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32724977	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.733	rs9591282	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32725844	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs7319787	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32728320	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.669	rs7331529	ENSG00000212293.1	SNORA16	5.4	2.55e-07	0.000219	0.49	0.4	Body mass index;	chr13:32728409	chr13:32420390~32420516:-
PCPG	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	5.4	2.55e-07	0.000219	0.58	0.4	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
PCPG	cis	rs300890	0.662	rs10012713	ENSG00000250326.1	RP11-284M14.1	5.4	2.55e-07	0.000219	0.36	0.4	Nasopharyngeal carcinoma;	chr4:143303957	chr4:142933195~143184861:-
PCPG	cis	rs55665837	0.701	rs11023272	ENSG00000251991.1	RNU7-49P	5.4	2.55e-07	0.000219	0.45	0.4	Vitamin D levels;	chr11:14608824	chr11:14478892~14478953:+
PCPG	cis	rs3806843	0.733	rs801181	ENSG00000202515.1	VTRNA1-3	5.4	2.56e-07	0.000219	0.5	0.4	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr5:140726158~140726246:+
PCPG	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-5.4	2.56e-07	0.00022	-0.45	-0.4	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
PCPG	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-5.4	2.57e-07	0.00022	-0.48	-0.4	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
PCPG	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-5.4	2.57e-07	0.00022	-0.52	-0.4	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
PCPG	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-5.4	2.57e-07	0.00022	-0.52	-0.4	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-5.4	2.57e-07	0.00022	-0.52	-0.4	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-5.4	2.57e-07	0.00022	-0.52	-0.4	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-5.4	2.57e-07	0.00022	-0.52	-0.4	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
PCPG	cis	rs2625529	0.618	rs6494992	ENSG00000260037.4	CTD-2524L6.3	5.4	2.58e-07	0.000221	0.52	0.4	Red blood cell count;	chr15:72128409	chr15:71818396~71823384:+
PCPG	cis	rs12681963	0.688	rs7822756	ENSG00000248159.1	HSPA8P11	-5.4	2.58e-07	0.000221	-0.68	-0.4	Migraine;	chr8:30146743	chr8:30237382~30240997:+
PCPG	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-5.4	2.58e-07	0.000221	-0.4	-0.4	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-5.4	2.58e-07	0.000221	-0.4	-0.4	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
PCPG	cis	rs3806843	0.966	rs11953833	ENSG00000202515.1	VTRNA1-3	-5.4	2.58e-07	0.000221	-0.52	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140775538	chr5:140726158~140726246:+
PCPG	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-5.4	2.59e-07	0.000222	-0.55	-0.4	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
PCPG	cis	rs2625529	0.652	rs2929518	ENSG00000260037.4	CTD-2524L6.3	5.4	2.59e-07	0.000222	0.54	0.4	Red blood cell count;	chr15:72040407	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.617	rs2957365	ENSG00000260037.4	CTD-2524L6.3	5.4	2.59e-07	0.000222	0.54	0.4	Red blood cell count;	chr15:72055765	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs2278987	ENSG00000260037.4	CTD-2524L6.3	5.4	2.59e-07	0.000222	0.54	0.4	Red blood cell count;	chr15:72117428	chr15:71818396~71823384:+
PCPG	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	5.4	2.6e-07	0.000222	0.52	0.4	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
PCPG	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-5.4	2.6e-07	0.000223	-0.52	-0.4	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
PCPG	cis	rs453301	0.522	rs2929455	ENSG00000173295.6	FAM86B3P	5.4	2.6e-07	0.000223	0.49	0.4	Joint mobility (Beighton score);	chr8:9225923	chr8:8228595~8244865:+
PCPG	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-5.4	2.6e-07	0.000223	-0.54	-0.4	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-5.4	2.6e-07	0.000223	-0.54	-0.4	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-5.4	2.6e-07	0.000223	-0.54	-0.4	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
PCPG	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	5.4	2.61e-07	0.000223	0.49	0.4	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
PCPG	cis	rs853679	0.517	rs9393890	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Depression;	chr6:28096077	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9366715	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Depression;	chr6:28096855	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.598	rs9380054	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Depression;	chr6:28099759	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.547	rs2116981	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Parkinson's disease;	chr6:28100173	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368552	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Depression;	chr6:28100648	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs2281588	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Depression;	chr6:28104824	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.542	rs34131763	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Depression;	chr6:28107222	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs35193936	ENSG00000216901.1	AL022393.7	5.4	2.61e-07	0.000224	0.57	0.4	Depression;	chr6:28108492	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs17711344	ENSG00000216901.1	AL022393.7	-5.4	2.61e-07	0.000224	-0.57	-0.4	Depression;	chr6:28109824	chr6:28176188~28176674:+
PCPG	cis	rs12291225	0.546	rs12795545	ENSG00000251991.1	RNU7-49P	5.4	2.62e-07	0.000224	0.47	0.4	Sense of smell;	chr11:14334018	chr11:14478892~14478953:+
PCPG	cis	rs7811142	1	rs11761725	ENSG00000078319.8	PMS2P1	-5.39	2.62e-07	0.000224	-0.56	-0.4	Platelet count;	chr7:100442192	chr7:100320992~100341908:-
PCPG	cis	rs12906542	0.58	rs4509986	ENSG00000259792.1	RP11-114H24.6	5.39	2.62e-07	0.000224	0.45	0.4	Breast cancer;	chr15:77975043	chr15:77993405~77995289:+
PCPG	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-5.39	2.62e-07	0.000224	-0.52	-0.4	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
PCPG	cis	rs300890	0.662	rs300898	ENSG00000250326.1	RP11-284M14.1	5.39	2.62e-07	0.000224	0.36	0.4	Nasopharyngeal carcinoma;	chr4:143311391	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.662	rs592349	ENSG00000250326.1	RP11-284M14.1	-5.39	2.62e-07	0.000224	-0.36	-0.4	Nasopharyngeal carcinoma;	chr4:143299230	chr4:142933195~143184861:-
PCPG	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	5.39	2.63e-07	0.000225	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	5.39	2.63e-07	0.000225	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
PCPG	cis	rs12291225	0.585	rs12270374	ENSG00000251991.1	RNU7-49P	5.39	2.64e-07	0.000226	0.47	0.4	Sense of smell;	chr11:14353533	chr11:14478892~14478953:+
PCPG	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-5.39	2.64e-07	0.000226	-0.41	-0.4	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
PCPG	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	5.39	2.65e-07	0.000227	0.52	0.4	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
PCPG	cis	rs3806843	0.766	rs6848	ENSG00000202515.1	VTRNA1-3	5.39	2.66e-07	0.000227	0.5	0.4	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.766	rs2251860	ENSG00000202515.1	VTRNA1-3	5.39	2.66e-07	0.000227	0.5	0.4	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.766	rs702397	ENSG00000202515.1	VTRNA1-3	5.39	2.66e-07	0.000227	0.5	0.4	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.766	rs2530239	ENSG00000202515.1	VTRNA1-3	5.39	2.66e-07	0.000227	0.5	0.4	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr5:140726158~140726246:+
PCPG	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	5.39	2.66e-07	0.000228	0.51	0.4	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	5.39	2.66e-07	0.000228	0.51	0.4	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	5.39	2.66e-07	0.000228	0.51	0.4	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	5.39	2.66e-07	0.000228	0.51	0.4	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
PCPG	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	5.39	2.66e-07	0.000228	0.51	0.4	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
PCPG	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-5.39	2.67e-07	0.000228	-0.49	-0.4	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
PCPG	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-5.39	2.68e-07	0.000229	-0.36	-0.4	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
PCPG	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	5.39	2.69e-07	0.000229	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	5.39	2.69e-07	0.000229	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	5.39	2.69e-07	0.000229	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	5.39	2.69e-07	0.000229	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	5.39	2.69e-07	0.000229	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
PCPG	cis	rs12681963	0.688	rs4733159	ENSG00000248159.1	HSPA8P11	-5.39	2.69e-07	0.000229	-0.76	-0.4	Migraine;	chr8:30202344	chr8:30237382~30240997:+
PCPG	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-5.39	2.69e-07	0.000229	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-5.39	2.69e-07	0.000229	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-5.39	2.69e-07	0.000229	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
PCPG	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-5.39	2.69e-07	0.000229	-0.49	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-5.39	2.69e-07	0.000229	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
PCPG	cis	rs4819052	0.565	rs35776291	ENSG00000215447.6	BX322557.10	-5.39	2.69e-07	0.00023	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45288052~45291738:+
PCPG	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-5.39	2.69e-07	0.00023	-0.42	-0.4	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
PCPG	cis	rs12681963	0.688	rs6994064	ENSG00000248159.1	HSPA8P11	-5.39	2.7e-07	0.00023	-0.77	-0.4	Migraine;	chr8:30199673	chr8:30237382~30240997:+
PCPG	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	5.39	2.7e-07	0.00023	0.55	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
PCPG	cis	rs7688540	0.771	rs11737268	ENSG00000275426.1	CH17-262A2.1	5.39	2.7e-07	0.00023	0.51	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:149738~150317:+
PCPG	cis	rs7688540	0.771	rs11726829	ENSG00000275426.1	CH17-262A2.1	5.39	2.7e-07	0.00023	0.51	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:149738~150317:+
PCPG	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-5.39	2.7e-07	0.00023	-0.45	-0.4	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
PCPG	cis	rs1023500	0.506	rs6002625	ENSG00000205702.9	CYP2D7	-5.39	2.7e-07	0.00023	-0.42	-0.4	Schizophrenia;	chr22:42121685	chr22:42140203~42144577:-
PCPG	cis	rs17507216	0.718	rs28587782	ENSG00000228141.5	AC105339.1	-5.39	2.72e-07	0.000232	-0.63	-0.4	Excessive daytime sleepiness;	chr15:82576881	chr15:82710471~82714026:-
PCPG	cis	rs453301	0.652	rs2043129	ENSG00000253893.2	FAM85B	-5.39	2.73e-07	0.000232	-0.49	-0.4	Joint mobility (Beighton score);	chr8:8967994	chr8:8167819~8226614:-
PCPG	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	5.39	2.74e-07	0.000233	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
PCPG	cis	rs7688540	0.8	rs10023604	ENSG00000275426.1	CH17-262A2.1	5.38	2.74e-07	0.000234	0.48	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:149738~150317:+
PCPG	cis	rs10131894	0.575	rs1860935	ENSG00000279594.1	RP11-950C14.10	5.38	2.74e-07	0.000234	0.51	0.4	Coronary artery disease;	chr14:74965761	chr14:75011269~75012851:-
PCPG	cis	rs9595908	0.792	rs61947055	ENSG00000212293.1	SNORA16	5.38	2.74e-07	0.000234	0.48	0.4	Body mass index;	chr13:32614414	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.869	rs7998956	ENSG00000212293.1	SNORA16	5.38	2.74e-07	0.000234	0.48	0.4	Body mass index;	chr13:32622239	chr13:32420390~32420516:-
PCPG	cis	rs13108904	0.901	rs6851528	ENSG00000254094.1	AC078852.1	-5.38	2.75e-07	0.000234	-0.46	-0.4	Obesity-related traits;	chr4:1302221	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.901	rs7695691	ENSG00000254094.1	AC078852.1	-5.38	2.75e-07	0.000234	-0.46	-0.4	Obesity-related traits;	chr4:1310844	chr4:1356581~1358075:+
PCPG	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	5.38	2.76e-07	0.000235	0.8	0.4	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	5.38	2.76e-07	0.000235	0.8	0.4	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
PCPG	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-5.38	2.77e-07	0.000235	-0.53	-0.4	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
PCPG	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-5.38	2.78e-07	0.000236	-0.44	-0.4	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
PCPG	cis	rs651907	0.535	rs13085776	ENSG00000244119.1	PDCL3P4	5.38	2.78e-07	0.000236	0.4	0.4	Colorectal cancer;	chr3:101786663	chr3:101712472~101713191:+
PCPG	cis	rs6121246	0.567	rs6060247	ENSG00000230613.1	HM13-AS1	5.38	2.79e-07	0.000237	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31602917	chr20:31567707~31573263:-
PCPG	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-5.38	2.79e-07	0.000237	-0.52	-0.4	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-5.38	2.79e-07	0.000237	-0.52	-0.4	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-5.38	2.79e-07	0.000237	-0.52	-0.4	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-5.38	2.79e-07	0.000237	-0.52	-0.4	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-5.38	2.79e-07	0.000237	-0.52	-0.4	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-5.38	2.79e-07	0.000237	-0.52	-0.4	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-5.38	2.79e-07	0.000237	-0.52	-0.4	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
PCPG	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-5.38	2.8e-07	0.000238	-0.71	-0.4	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
PCPG	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-5.38	2.81e-07	0.000239	-0.4	-0.4	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
PCPG	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-5.38	2.81e-07	0.000239	-0.48	-0.4	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
PCPG	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	5.38	2.82e-07	0.000239	0.44	0.4	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
PCPG	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	5.38	2.82e-07	0.000239	0.36	0.4	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
PCPG	cis	rs561341	0.783	rs512698	ENSG00000265798.5	RP11-271K11.5	5.38	2.82e-07	0.00024	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31965488	chr17:31038575~31059121:-
PCPG	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	5.38	2.83e-07	0.00024	0.53	0.4	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
PCPG	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
PCPG	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.561	rs34471170	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.561	rs9642927	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.529	rs9642928	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.561	rs1808488	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.583	rs754275	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.561	rs1426172	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.561	rs4734282	ENSG00000253704.1	RP11-267M23.4	5.38	2.83e-07	0.00024	0.44	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94553722~94569745:+
PCPG	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-5.38	2.84e-07	0.00024	-0.49	-0.4	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
PCPG	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-5.38	2.84e-07	0.000241	-0.45	-0.4	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-5.38	2.84e-07	0.000241	-0.45	-0.4	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
PCPG	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	5.38	2.84e-07	0.000241	0.52	0.4	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
PCPG	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	5.38	2.84e-07	0.000241	0.52	0.4	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
PCPG	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	5.38	2.84e-07	0.000241	0.38	0.4	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	5.38	2.84e-07	0.000241	0.38	0.4	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	5.38	2.84e-07	0.000241	0.38	0.4	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	5.38	2.84e-07	0.000241	0.38	0.4	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
PCPG	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	5.38	2.84e-07	0.000241	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
PCPG	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	5.38	2.84e-07	0.000241	0.57	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
PCPG	cis	rs11148252	0.904	rs9526927	ENSG00000235660.1	LINC00345	-5.38	2.85e-07	0.000241	-0.5	-0.4	Lewy body disease;	chr13:52477492	chr13:52484161~52484680:-
PCPG	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	5.38	2.85e-07	0.000242	0.69	0.4	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
PCPG	cis	rs11148252	0.583	rs9536048	ENSG00000235660.1	LINC00345	-5.38	2.86e-07	0.000242	-0.53	-0.4	Lewy body disease;	chr13:52384653	chr13:52484161~52484680:-
PCPG	cis	rs9595908	0.709	rs7327412	ENSG00000212293.1	SNORA16	-5.38	2.86e-07	0.000242	-0.48	-0.4	Body mass index;	chr13:32774430	chr13:32420390~32420516:-
PCPG	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	5.38	2.87e-07	0.000243	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
PCPG	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	5.38	2.87e-07	0.000243	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
PCPG	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	5.38	2.87e-07	0.000243	0.37	0.4	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
PCPG	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	5.37	2.89e-07	0.000244	0.75	0.4	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
PCPG	cis	rs561341	1	rs72823787	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31956790	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs72823789	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31957065	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs113115092	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31957145	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs2470243	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31963936	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs483301	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31966379	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs555629	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31967117	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.769	rs559228	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31967508	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs1681718	ENSG00000265798.5	RP11-271K11.5	5.37	2.89e-07	0.000245	0.73	0.4	Hip circumference adjusted for BMI;	chr17:31969426	chr17:31038575~31059121:-
PCPG	cis	rs11148252	0.904	rs9568734	ENSG00000235660.1	LINC00345	-5.37	2.92e-07	0.000246	-0.5	-0.4	Lewy body disease;	chr13:52430087	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.904	rs7990581	ENSG00000235660.1	LINC00345	-5.37	2.92e-07	0.000246	-0.5	-0.4	Lewy body disease;	chr13:52445298	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.904	rs3892337	ENSG00000235660.1	LINC00345	-5.37	2.92e-07	0.000246	-0.5	-0.4	Lewy body disease;	chr13:52455350	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.904	rs9536079	ENSG00000235660.1	LINC00345	-5.37	2.92e-07	0.000246	-0.5	-0.4	Lewy body disease;	chr13:52456430	chr13:52484161~52484680:-
PCPG	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-5.37	2.92e-07	0.000247	-0.49	-0.4	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-5.37	2.92e-07	0.000247	-0.49	-0.4	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
PCPG	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	5.37	2.92e-07	0.000247	0.53	0.4	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
PCPG	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	5.37	2.92e-07	0.000247	0.52	0.4	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
PCPG	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	5.37	2.92e-07	0.000247	0.52	0.4	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
PCPG	cis	rs11148252	0.508	rs11148260	ENSG00000198384.8	TPTE2P3	-5.37	2.93e-07	0.000247	-0.5	-0.4	Lewy body disease;	chr13:52588508	chr13:52522632~52586906:+
PCPG	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-5.37	2.93e-07	0.000248	-0.49	-0.4	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
PCPG	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-5.37	2.94e-07	0.000248	-0.38	-0.4	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
PCPG	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-5.37	2.94e-07	0.000248	-0.36	-0.4	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	-5.37	2.94e-07	0.000248	-0.46	-0.4	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
PCPG	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	5.37	2.94e-07	0.000249	0.42	0.4	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
PCPG	cis	rs9595908	0.709	rs7325016	ENSG00000212293.1	SNORA16	5.37	2.95e-07	0.000249	0.49	0.4	Body mass index;	chr13:32728681	chr13:32420390~32420516:-
PCPG	cis	rs11148252	0.774	rs6561666	ENSG00000198384.8	TPTE2P3	-5.37	2.95e-07	0.000249	-0.47	-0.4	Lewy body disease;	chr13:52355910	chr13:52522632~52586906:+
PCPG	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	5.37	2.95e-07	0.000249	0.44	0.4	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
PCPG	cis	rs12681963	0.688	rs73242322	ENSG00000248159.1	HSPA8P11	5.37	2.95e-07	0.000249	0.72	0.4	Migraine;	chr8:30177573	chr8:30237382~30240997:+
PCPG	cis	rs9595908	0.869	rs9591185	ENSG00000212293.1	SNORA16	5.37	2.97e-07	0.000251	0.47	0.4	Body mass index;	chr13:32627829	chr13:32420390~32420516:-
PCPG	cis	rs853679	0.517	rs2273564	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28089816	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs1853097	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28090857	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393887	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28091242	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393888	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28091439	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs3734573	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28091659	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9357063	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28092227	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs3823180	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28093966	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368551	ENSG00000216901.1	AL022393.7	5.37	2.97e-07	0.000251	0.57	0.4	Depression;	chr6:28094014	chr6:28176188~28176674:+
PCPG	cis	rs2625529	0.938	rs4777464	ENSG00000260037.4	CTD-2524L6.3	-5.37	2.98e-07	0.000251	-0.62	-0.4	Red blood cell count;	chr15:71839422	chr15:71818396~71823384:+
PCPG	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-5.37	2.99e-07	0.000252	-0.52	-0.4	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-5.37	2.99e-07	0.000252	-0.52	-0.4	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
PCPG	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	5.37	2.99e-07	0.000252	0.53	0.4	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
PCPG	cis	rs56804039	1	rs59620654	ENSG00000253893.2	FAM85B	5.37	2.99e-07	0.000252	0.61	0.4	Cervical cancer;	chr8:8525122	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs11780966	ENSG00000253893.2	FAM85B	5.37	2.99e-07	0.000252	0.61	0.4	Cervical cancer;	chr8:8525886	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs34154295	ENSG00000253893.2	FAM85B	5.37	2.99e-07	0.000252	0.61	0.4	Cervical cancer;	chr8:8525967	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs11777086	ENSG00000253893.2	FAM85B	5.37	2.99e-07	0.000252	0.61	0.4	Cervical cancer;	chr8:8526969	chr8:8167819~8226614:-
PCPG	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	5.37	2.99e-07	0.000252	0.39	0.4	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
PCPG	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-5.37	3e-07	0.000253	-0.48	-0.4	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
PCPG	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	5.37	3e-07	0.000253	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	5.37	3e-07	0.000253	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	5.37	3e-07	0.000253	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	5.37	3e-07	0.000253	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	5.37	3e-07	0.000253	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-5.37	3e-07	0.000253	-0.54	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
PCPG	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-5.37	3e-07	0.000253	-0.53	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
PCPG	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	5.37	3e-07	0.000253	0.55	0.4	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
PCPG	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	5.37	3e-07	0.000253	0.63	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
PCPG	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	5.37	3.01e-07	0.000253	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
PCPG	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-5.36	3.01e-07	0.000253	-0.43	-0.4	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
PCPG	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-5.36	3.01e-07	0.000253	-0.35	-0.4	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
PCPG	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-5.36	3.02e-07	0.000254	-0.72	-0.4	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
PCPG	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	5.36	3.02e-07	0.000254	0.5	0.4	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
PCPG	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	5.36	3.02e-07	0.000254	0.49	0.4	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
PCPG	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	5.36	3.03e-07	0.000255	0.65	0.4	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	5.36	3.03e-07	0.000255	0.65	0.4	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	5.36	3.03e-07	0.000255	0.65	0.4	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	5.36	3.03e-07	0.000255	0.65	0.4	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	5.36	3.03e-07	0.000255	0.65	0.4	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	5.36	3.03e-07	0.000255	0.65	0.4	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	5.36	3.03e-07	0.000255	0.65	0.4	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
PCPG	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	5.36	3.03e-07	0.000255	0.53	0.4	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
PCPG	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	5.36	3.04e-07	0.000255	0.54	0.4	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
PCPG	cis	rs12681963	0.925	rs7845133	ENSG00000248159.1	HSPA8P11	5.36	3.06e-07	0.000257	0.6	0.4	Migraine;	chr8:30098071	chr8:30237382~30240997:+
PCPG	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-5.36	3.07e-07	0.000257	-0.5	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
PCPG	cis	rs2625529	0.617	rs2415120	ENSG00000260037.4	CTD-2524L6.3	-5.36	3.07e-07	0.000258	-0.52	-0.4	Red blood cell count;	chr15:71813204	chr15:71818396~71823384:+
PCPG	cis	rs3806843	0.801	rs801171	ENSG00000202515.1	VTRNA1-3	5.36	3.07e-07	0.000258	0.5	0.4	Depressive symptoms (multi-trait analysis);	chr5:140735718	chr5:140726158~140726246:+
PCPG	cis	rs9926296	0.529	rs7195906	ENSG00000260259.1	RP11-368I7.4	-5.36	3.07e-07	0.000258	-0.48	-0.4	Vitiligo;	chr16:89739939	chr16:89682620~89686569:-
PCPG	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	5.36	3.08e-07	0.000258	0.56	0.4	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	5.36	3.08e-07	0.000258	0.56	0.4	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
PCPG	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	5.36	3.08e-07	0.000259	0.47	0.4	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
PCPG	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	5.36	3.09e-07	0.000259	0.44	0.4	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
PCPG	cis	rs11148252	0.595	rs4885325	ENSG00000198384.8	TPTE2P3	-5.36	3.09e-07	0.000259	-0.52	-0.4	Lewy body disease;	chr13:52597182	chr13:52522632~52586906:+
PCPG	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-5.36	3.09e-07	0.000259	-0.49	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
PCPG	cis	rs62246343	0.541	rs17050396	ENSG00000254485.4	RP11-380O24.1	5.36	3.1e-07	0.00026	0.56	0.4	Fibrinogen levels;	chr3:9492652	chr3:9292588~9363303:-
PCPG	cis	rs6121246	0.529	rs750144	ENSG00000230613.1	HM13-AS1	-5.36	3.1e-07	0.00026	-0.62	-0.4	Mean corpuscular hemoglobin;	chr20:31591224	chr20:31567707~31573263:-
PCPG	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-5.36	3.11e-07	0.000261	-0.53	-0.4	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
PCPG	cis	rs7267979	0.816	rs3746337	ENSG00000125804.12	FAM182A	-5.36	3.11e-07	0.000261	-0.47	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:26054655~26086917:+
PCPG	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	5.36	3.11e-07	0.000261	0.53	0.4	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
PCPG	cis	rs853679	0.517	rs56310871	ENSG00000216901.1	AL022393.7	5.36	3.12e-07	0.000261	0.57	0.4	Depression;	chr6:28076704	chr6:28176188~28176674:+
PCPG	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-5.36	3.12e-07	0.000262	-0.43	-0.4	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
PCPG	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	5.36	3.12e-07	0.000262	0.65	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
PCPG	cis	rs2625529	0.73	rs4777485	ENSG00000260037.4	CTD-2524L6.3	-5.36	3.12e-07	0.000262	-0.57	-0.4	Red blood cell count;	chr15:72097043	chr15:71818396~71823384:+
PCPG	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	5.36	3.12e-07	0.000262	0.47	0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
PCPG	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	5.36	3.12e-07	0.000262	0.56	0.4	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
PCPG	cis	rs9595908	0.709	rs1929937	ENSG00000212293.1	SNORA16	5.36	3.13e-07	0.000262	0.49	0.4	Body mass index;	chr13:32722907	chr13:32420390~32420516:-
PCPG	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-5.36	3.13e-07	0.000262	-0.42	-0.4	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
PCPG	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-5.36	3.13e-07	0.000263	-0.36	-0.4	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
PCPG	cis	rs11148252	1	rs11148252	ENSG00000235660.1	LINC00345	-5.36	3.13e-07	0.000263	-0.52	-0.4	Lewy body disease;	chr13:52434913	chr13:52484161~52484680:-
PCPG	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	5.36	3.14e-07	0.000263	0.65	0.4	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	5.36	3.14e-07	0.000263	0.65	0.4	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	5.36	3.14e-07	0.000263	0.65	0.4	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	5.36	3.14e-07	0.000263	0.65	0.4	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	5.36	3.14e-07	0.000263	0.65	0.4	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
PCPG	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	5.36	3.14e-07	0.000263	0.65	0.4	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	5.36	3.14e-07	0.000263	0.65	0.4	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
PCPG	cis	rs9926296	0.605	rs886952	ENSG00000260259.1	RP11-368I7.4	-5.36	3.15e-07	0.000264	-0.49	-0.4	Vitiligo;	chr16:89770373	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.605	rs886951	ENSG00000260259.1	RP11-368I7.4	-5.36	3.15e-07	0.000264	-0.49	-0.4	Vitiligo;	chr16:89770457	chr16:89682620~89686569:-
PCPG	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	5.35	3.16e-07	0.000265	0.64	0.4	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
PCPG	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-5.35	3.16e-07	0.000265	-0.49	-0.4	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
PCPG	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-5.35	3.16e-07	0.000265	-0.44	-0.4	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
PCPG	cis	rs11148252	0.967	rs4286007	ENSG00000235660.1	LINC00345	-5.35	3.17e-07	0.000265	-0.51	-0.4	Lewy body disease;	chr13:52448383	chr13:52484161~52484680:-
PCPG	cis	rs12681963	0.688	rs73242337	ENSG00000248159.1	HSPA8P11	5.35	3.17e-07	0.000265	0.8	0.4	Migraine;	chr8:30200526	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs73242338	ENSG00000248159.1	HSPA8P11	5.35	3.17e-07	0.000265	0.8	0.4	Migraine;	chr8:30200574	chr8:30237382~30240997:+
PCPG	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	5.35	3.18e-07	0.000266	0.56	0.4	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
PCPG	cis	rs11148252	1	rs4886018	ENSG00000235660.1	LINC00345	-5.35	3.18e-07	0.000266	-0.52	-0.4	Lewy body disease;	chr13:52416582	chr13:52484161~52484680:-
PCPG	cis	rs2898290	0.622	rs1382567	ENSG00000255020.1	AF131216.5	-5.35	3.18e-07	0.000266	-0.52	-0.4	Systolic blood pressure;	chr8:11493390	chr8:11345748~11347502:-
PCPG	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	5.35	3.18e-07	0.000266	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	5.35	3.18e-07	0.000266	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	5.35	3.18e-07	0.000266	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-5.35	3.18e-07	0.000266	-0.53	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	5.35	3.18e-07	0.000266	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
PCPG	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-5.35	3.18e-07	0.000266	-0.71	-0.4	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-5.35	3.18e-07	0.000266	-0.71	-0.4	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-5.35	3.18e-07	0.000266	-0.71	-0.4	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-5.35	3.18e-07	0.000266	-0.71	-0.4	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-5.35	3.18e-07	0.000266	-0.71	-0.4	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
PCPG	cis	rs73607972	0.598	rs35726119	ENSG00000275191.1	RP11-36I17.2	-5.35	3.18e-07	0.000266	-0.63	-0.4	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53521927	chr16:53628256~53628816:-
PCPG	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	5.35	3.19e-07	0.000267	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	5.35	3.19e-07	0.000267	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
PCPG	cis	rs2625529	0.652	rs11634608	ENSG00000260037.4	CTD-2524L6.3	5.35	3.19e-07	0.000267	0.52	0.4	Red blood cell count;	chr15:71963377	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs2957734	ENSG00000260037.4	CTD-2524L6.3	5.35	3.19e-07	0.000267	0.52	0.4	Red blood cell count;	chr15:71969044	chr15:71818396~71823384:+
PCPG	cis	rs11148252	0.967	rs11620062	ENSG00000235660.1	LINC00345	-5.35	3.2e-07	0.000267	-0.51	-0.4	Lewy body disease;	chr13:52419891	chr13:52484161~52484680:-
PCPG	cis	rs12906542	0.529	rs2003893	ENSG00000259792.1	RP11-114H24.6	5.35	3.2e-07	0.000267	0.46	0.4	Breast cancer;	chr15:77974619	chr15:77993405~77995289:+
PCPG	cis	rs7811142	0.887	rs35111986	ENSG00000078319.8	PMS2P1	-5.35	3.2e-07	0.000268	-0.56	-0.4	Platelet count;	chr7:100402651	chr7:100320992~100341908:-
PCPG	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	5.35	3.2e-07	0.000268	0.56	0.4	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
PCPG	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	5.35	3.22e-07	0.000269	0.54	0.4	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.544	rs12913702	ENSG00000259728.4	LINC00933	5.35	3.22e-07	0.000269	0.54	0.4	Schizophrenia;	chr15:84609953	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.509	rs71395455	ENSG00000259728.4	LINC00933	5.35	3.22e-07	0.000269	0.54	0.4	Schizophrenia;	chr15:84610573	chr15:84570649~84580175:+
PCPG	cis	rs12681963	0.614	rs59483213	ENSG00000248159.1	HSPA8P11	5.35	3.22e-07	0.000269	0.81	0.4	Migraine;	chr8:30200085	chr8:30237382~30240997:+
PCPG	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-5.35	3.23e-07	0.00027	-0.46	-0.4	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
PCPG	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	5.35	3.23e-07	0.00027	0.49	0.4	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
PCPG	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	5.35	3.24e-07	0.00027	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	5.35	3.24e-07	0.00027	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	5.35	3.24e-07	0.00027	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	5.35	3.24e-07	0.00027	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
PCPG	cis	rs2836950	0.501	rs2070865	ENSG00000255568.3	BRWD1-AS2	-5.35	3.24e-07	0.000271	-0.39	-0.4	Menarche (age at onset);	chr21:39343593	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.501	rs1474490	ENSG00000255568.3	BRWD1-AS2	-5.35	3.24e-07	0.000271	-0.39	-0.4	Menarche (age at onset);	chr21:39344210	chr21:39313935~39314962:+
PCPG	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	5.35	3.25e-07	0.000271	0.84	0.4	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
PCPG	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	5.35	3.25e-07	0.000271	0.84	0.4	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
PCPG	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	5.35	3.25e-07	0.000271	0.53	0.4	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
PCPG	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-5.35	3.25e-07	0.000271	-0.52	-0.4	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
PCPG	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	5.35	3.25e-07	0.000271	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
PCPG	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-5.35	3.25e-07	0.000272	-0.31	-0.4	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
PCPG	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	5.35	3.25e-07	0.000272	0.6	0.4	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
PCPG	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	5.35	3.26e-07	0.000272	0.58	0.4	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	5.35	3.26e-07	0.000272	0.58	0.4	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	5.35	3.26e-07	0.000272	0.58	0.4	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
PCPG	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	5.35	3.26e-07	0.000272	0.58	0.4	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
PCPG	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	5.35	3.26e-07	0.000272	0.55	0.4	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	5.35	3.26e-07	0.000272	0.55	0.4	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
PCPG	cis	rs2625529	0.503	rs7162299	ENSG00000260037.4	CTD-2524L6.3	5.35	3.27e-07	0.000272	0.53	0.4	Red blood cell count;	chr15:72121724	chr15:71818396~71823384:+
PCPG	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-5.35	3.27e-07	0.000272	-0.48	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
PCPG	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-5.35	3.27e-07	0.000272	-0.48	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
PCPG	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-5.35	3.27e-07	0.000273	-0.7	-0.4	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
PCPG	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-5.35	3.28e-07	0.000273	-0.55	-0.4	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
PCPG	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	5.35	3.28e-07	0.000273	0.39	0.4	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
PCPG	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	5.35	3.28e-07	0.000274	0.38	0.4	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
PCPG	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	5.35	3.29e-07	0.000274	0.52	0.4	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
PCPG	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	5.35	3.29e-07	0.000274	0.48	0.4	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
PCPG	cis	rs7811142	1	rs2406255	ENSG00000078319.8	PMS2P1	-5.35	3.29e-07	0.000274	-0.56	-0.4	Platelet count;	chr7:100456067	chr7:100320992~100341908:-
PCPG	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-5.35	3.29e-07	0.000274	-0.39	-0.4	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-5.35	3.29e-07	0.000274	-0.39	-0.4	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-5.35	3.29e-07	0.000274	-0.39	-0.4	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
PCPG	cis	rs13113518	1	rs7660980	ENSG00000272969.1	RP11-528I4.2	-5.35	3.29e-07	0.000275	-0.44	-0.4	Height;	chr4:55542948	chr4:55547112~55547889:+
PCPG	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-5.34	3.3e-07	0.000275	-0.49	-0.4	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
PCPG	cis	rs13113518	1	rs13113518	ENSG00000272969.1	RP11-528I4.2	5.34	3.31e-07	0.000276	0.44	0.4	Height;	chr4:55533481	chr4:55547112~55547889:+
PCPG	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	5.34	3.32e-07	0.000276	0.42	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	5.34	3.32e-07	0.000276	0.42	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	5.34	3.32e-07	0.000276	0.42	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	5.34	3.32e-07	0.000276	0.42	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	5.34	3.32e-07	0.000276	0.42	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
PCPG	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	5.34	3.32e-07	0.000276	0.43	0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
PCPG	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-5.34	3.32e-07	0.000277	-0.4	-0.4	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	5.34	3.36e-07	0.000279	0.48	0.4	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-5.34	3.37e-07	0.00028	-0.49	-0.4	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
PCPG	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	5.34	3.37e-07	0.000281	0.36	0.4	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
PCPG	cis	rs12168402	0.51	rs1076116	ENSG00000235209.1	CTA-150C2.13	5.34	3.37e-07	0.000281	0.43	0.4	Subjective well-being;	chr22:38841832	chr22:38921227~38924708:+
PCPG	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-5.34	3.39e-07	0.000282	-0.41	-0.4	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
PCPG	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	5.34	3.4e-07	0.000282	0.63	0.4	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
PCPG	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-5.34	3.41e-07	0.000283	-0.48	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
PCPG	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-5.34	3.41e-07	0.000283	-0.54	-0.4	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
PCPG	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	5.34	3.41e-07	0.000283	0.45	0.4	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
PCPG	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-5.34	3.41e-07	0.000284	-0.48	-0.4	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
PCPG	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	5.34	3.42e-07	0.000284	0.44	0.4	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	5.34	3.42e-07	0.000284	0.44	0.4	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	5.34	3.42e-07	0.000284	0.44	0.4	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
PCPG	cis	rs11858159	0.9	rs7167211	ENSG00000259905.4	PWRN1	5.34	3.43e-07	0.000285	0.45	0.4	Platelet thrombus formation;	chr15:24555227	chr15:24493137~24652130:+
PCPG	cis	rs55665837	0.701	rs12787709	ENSG00000251991.1	RNU7-49P	5.34	3.43e-07	0.000285	0.47	0.4	Vitamin D levels;	chr11:14617711	chr11:14478892~14478953:+
PCPG	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-5.34	3.44e-07	0.000285	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
PCPG	cis	rs300890	0.513	rs4309787	ENSG00000250326.1	RP11-284M14.1	-5.34	3.44e-07	0.000286	-0.38	-0.4	Nasopharyngeal carcinoma;	chr4:143128069	chr4:142933195~143184861:-
PCPG	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-5.34	3.44e-07	0.000286	-0.5	-0.4	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-5.34	3.44e-07	0.000286	-0.5	-0.4	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
PCPG	cis	rs9595908	0.709	rs9285092	ENSG00000212293.1	SNORA16	5.34	3.45e-07	0.000286	0.48	0.4	Body mass index;	chr13:32745496	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs9285093	ENSG00000212293.1	SNORA16	5.34	3.45e-07	0.000286	0.48	0.4	Body mass index;	chr13:32745500	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs4942867	ENSG00000212293.1	SNORA16	5.34	3.45e-07	0.000286	0.48	0.4	Body mass index;	chr13:32745916	chr13:32420390~32420516:-
PCPG	cis	rs2625529	0.652	rs3759820	ENSG00000260037.4	CTD-2524L6.3	5.34	3.45e-07	0.000286	0.53	0.4	Red blood cell count;	chr15:72007690	chr15:71818396~71823384:+
PCPG	cis	rs6993244	1	rs6993244	ENSG00000173295.6	FAM86B3P	-5.33	3.46e-07	0.000287	-0.46	-0.4	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8228595~8244865:+
PCPG	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-5.33	3.46e-07	0.000287	-0.49	-0.4	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
PCPG	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-5.33	3.47e-07	0.000288	-0.69	-0.4	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
PCPG	cis	rs853679	0.517	rs9380047	ENSG00000216901.1	AL022393.7	5.33	3.49e-07	0.000289	0.57	0.4	Depression;	chr6:28070115	chr6:28176188~28176674:+
PCPG	cis	rs453301	0.686	rs13252797	ENSG00000173295.6	FAM86B3P	-5.33	3.5e-07	0.00029	-0.46	-0.4	Joint mobility (Beighton score);	chr8:9003920	chr8:8228595~8244865:+
PCPG	cis	rs12291225	0.546	rs12291662	ENSG00000251991.1	RNU7-49P	5.33	3.53e-07	0.000292	0.46	0.4	Sense of smell;	chr11:14321403	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.545	rs11023187	ENSG00000251991.1	RNU7-49P	5.33	3.53e-07	0.000292	0.46	0.4	Sense of smell;	chr11:14324013	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.585	rs11023194	ENSG00000251991.1	RNU7-49P	5.33	3.53e-07	0.000292	0.46	0.4	Sense of smell;	chr11:14348223	chr11:14478892~14478953:+
PCPG	cis	rs9595908	0.746	rs9596075	ENSG00000212293.1	SNORA16	5.33	3.53e-07	0.000292	0.5	0.4	Body mass index;	chr13:32692147	chr13:32420390~32420516:-
PCPG	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	5.33	3.55e-07	0.000293	0.9	0.4	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
PCPG	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	5.33	3.55e-07	0.000294	0.49	0.4	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
PCPG	cis	rs3806843	0.966	rs3806842	ENSG00000202515.1	VTRNA1-3	-5.33	3.55e-07	0.000294	-0.52	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140833091	chr5:140726158~140726246:+
PCPG	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	5.33	3.56e-07	0.000294	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
PCPG	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-5.33	3.56e-07	0.000294	-0.5	-0.4	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
PCPG	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	5.33	3.56e-07	0.000294	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
PCPG	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-5.33	3.56e-07	0.000295	-0.36	-0.4	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
PCPG	cis	rs6121246	0.529	rs6060174	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31595735	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6120815	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31597063	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs6060195	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31597835	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs6060210	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31599878	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6058187	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31603120	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6060249	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31603141	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.528	rs6060252	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31603281	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6060260	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31605104	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6060261	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31605145	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6060263	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31605307	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs2811	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31606445	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs6058196	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31606911	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6058197	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31607096	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.522	rs6088736	ENSG00000230613.1	HM13-AS1	5.33	3.57e-07	0.000295	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31607363	chr20:31567707~31573263:-
PCPG	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	5.33	3.58e-07	0.000295	0.65	0.4	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	5.33	3.58e-07	0.000295	0.65	0.4	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	5.33	3.58e-07	0.000295	0.65	0.4	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	5.33	3.58e-07	0.000295	0.65	0.4	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	5.33	3.58e-07	0.000295	0.65	0.4	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
PCPG	cis	rs13113518	0.783	rs1586555	ENSG00000272969.1	RP11-528I4.2	5.33	3.59e-07	0.000296	0.45	0.4	Height;	chr4:55587104	chr4:55547112~55547889:+
PCPG	cis	rs2625529	0.652	rs2957735	ENSG00000260037.4	CTD-2524L6.3	5.33	3.61e-07	0.000298	0.51	0.4	Red blood cell count;	chr15:71972832	chr15:71818396~71823384:+
PCPG	cis	rs561341	0.882	rs2428337	ENSG00000265798.5	RP11-271K11.5	5.33	3.61e-07	0.000298	0.72	0.4	Hip circumference adjusted for BMI;	chr17:31972448	chr17:31038575~31059121:-
PCPG	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	5.33	3.61e-07	0.000298	0.43	0.4	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
PCPG	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-5.33	3.61e-07	0.000298	-0.52	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
PCPG	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	5.33	3.62e-07	0.000298	0.58	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
PCPG	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	5.32	3.62e-07	0.000299	0.58	0.4	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
PCPG	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-5.32	3.63e-07	0.000299	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-5.32	3.63e-07	0.000299	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-5.32	3.63e-07	0.000299	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
PCPG	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-5.32	3.63e-07	0.000299	-0.49	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
PCPG	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	5.32	3.63e-07	0.000299	0.55	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
PCPG	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-5.32	3.63e-07	0.000299	-1.06	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
PCPG	cis	rs2625529	0.761	rs972029	ENSG00000260037.4	CTD-2524L6.3	-5.32	3.64e-07	3e-04	-0.58	-0.4	Red blood cell count;	chr15:71880645	chr15:71818396~71823384:+
PCPG	cis	rs9649213	0.574	rs3816944	ENSG00000272950.1	RP11-307C18.1	5.32	3.64e-07	3e-04	0.52	0.4	Prostate cancer (SNP x SNP interaction);	chr7:98244831	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs34789614	ENSG00000272950.1	RP11-307C18.1	5.32	3.64e-07	3e-04	0.52	0.4	Prostate cancer (SNP x SNP interaction);	chr7:98245313	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.555	rs7796762	ENSG00000272950.1	RP11-307C18.1	5.32	3.64e-07	3e-04	0.52	0.4	Prostate cancer (SNP x SNP interaction);	chr7:98248883	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs13237878	ENSG00000272950.1	RP11-307C18.1	5.32	3.64e-07	3e-04	0.52	0.4	Prostate cancer (SNP x SNP interaction);	chr7:98249192	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs12704977	ENSG00000272950.1	RP11-307C18.1	5.32	3.64e-07	3e-04	0.52	0.4	Prostate cancer (SNP x SNP interaction);	chr7:98249359	chr7:98322853~98323430:+
PCPG	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-5.32	3.65e-07	0.000301	-0.38	-0.4	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
PCPG	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	5.32	3.65e-07	0.000301	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
PCPG	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	5.32	3.65e-07	0.000301	0.63	0.4	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
PCPG	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-5.32	3.65e-07	0.000301	-0.58	-0.4	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
PCPG	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-5.32	3.65e-07	0.000301	-0.58	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
PCPG	cis	rs853679	0.517	rs7755442	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28071237	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713135	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28071808	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs12174753	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28074687	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs55747925	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28076559	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs34716816	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28078391	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393884	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28079011	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380049	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28080757	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380050	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28080760	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393885	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28082231	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393886	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28082261	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.515	rs9368549	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Parkinson's disease;	chr6:28082269	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs56364346	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28082984	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9357061	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28083994	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368550	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28084025	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.542	rs2295594	ENSG00000216901.1	AL022393.7	5.32	3.66e-07	0.000301	0.57	0.4	Depression;	chr6:28085319	chr6:28176188~28176674:+
PCPG	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	5.32	3.66e-07	0.000301	0.54	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
PCPG	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-5.32	3.67e-07	0.000302	-0.72	-0.4	Depression;	chr6:28111963	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-5.32	3.67e-07	0.000302	-0.72	-0.4	Depression;	chr6:28200565	chr6:28115628~28116551:+
PCPG	cis	rs3806843	0.966	rs10036519	ENSG00000202515.1	VTRNA1-3	5.32	3.67e-07	0.000302	0.5	0.4	Depressive symptoms (multi-trait analysis);	chr5:140772116	chr5:140726158~140726246:+
PCPG	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-5.32	3.68e-07	0.000302	-0.4	-0.4	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
PCPG	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-5.32	3.68e-07	0.000303	-0.49	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
PCPG	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-5.32	3.68e-07	0.000303	-0.49	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
PCPG	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-5.32	3.69e-07	0.000304	-0.47	-0.4	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
PCPG	cis	rs1964356	0.967	rs2953802	ENSG00000173295.6	FAM86B3P	-5.32	3.7e-07	0.000304	-0.47	-0.4	Mean corpuscular volume;	chr8:8994371	chr8:8228595~8244865:+
PCPG	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	5.32	3.71e-07	0.000304	0.65	0.4	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
PCPG	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-5.32	3.72e-07	0.000305	-0.71	-0.4	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-5.32	3.72e-07	0.000305	-0.71	-0.4	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-5.32	3.72e-07	0.000305	-0.71	-0.4	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
PCPG	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-5.32	3.72e-07	0.000305	-0.71	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-5.32	3.72e-07	0.000305	-0.71	-0.4	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
PCPG	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	5.32	3.72e-07	0.000305	0.68	0.4	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
PCPG	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-5.32	3.72e-07	0.000306	-0.5	-0.4	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
PCPG	cis	rs7181230	0.885	rs9919974	ENSG00000259584.1	RP11-521C20.2	5.32	3.73e-07	0.000306	0.52	0.4	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40075204~40078704:-
PCPG	cis	rs9926296	0.533	rs12102290	ENSG00000260259.1	RP11-368I7.4	-5.32	3.73e-07	0.000306	-0.48	-0.4	Vitiligo;	chr16:89746209	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.533	rs12102297	ENSG00000260259.1	RP11-368I7.4	-5.32	3.73e-07	0.000306	-0.48	-0.4	Vitiligo;	chr16:89746354	chr16:89682620~89686569:-
PCPG	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-5.32	3.73e-07	0.000307	-0.47	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
PCPG	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-5.32	3.74e-07	0.000307	-0.52	-0.4	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
PCPG	cis	rs12946454	0.521	rs4559944	ENSG00000267288.2	RP13-890H12.2	5.32	3.75e-07	0.000308	0.53	0.4	Systolic blood pressure;	chr17:45183513	chr17:45168800~45171584:-
PCPG	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.32	3.75e-07	0.000308	0.52	0.4	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.32	3.75e-07	0.000308	0.52	0.4	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
PCPG	cis	rs9926296	0.568	rs886950	ENSG00000260259.1	RP11-368I7.4	-5.32	3.75e-07	0.000308	-0.49	-0.4	Vitiligo;	chr16:89770464	chr16:89682620~89686569:-
PCPG	cis	rs11992162	0.56	rs13276386	ENSG00000255020.1	AF131216.5	5.32	3.76e-07	0.000308	0.57	0.4	Monocyte count;	chr8:11939912	chr8:11345748~11347502:-
PCPG	cis	rs11992162	0.621	rs13268810	ENSG00000255020.1	AF131216.5	5.32	3.76e-07	0.000308	0.57	0.4	Monocyte count;	chr8:11939921	chr8:11345748~11347502:-
PCPG	cis	rs11992162	0.636	rs13265816	ENSG00000255020.1	AF131216.5	5.32	3.76e-07	0.000308	0.57	0.4	Monocyte count;	chr8:11939976	chr8:11345748~11347502:-
PCPG	cis	rs2253762	0.54	rs10887051	ENSG00000276742.1	RP11-500G22.4	5.32	3.76e-07	0.000309	0.65	0.4	Breast cancer;	chr10:122026030	chr10:121956782~121957098:+
PCPG	cis	rs9595908	0.709	rs4942880	ENSG00000212293.1	SNORA16	5.32	3.78e-07	0.00031	0.48	0.4	Body mass index;	chr13:32751641	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs7331632	ENSG00000212293.1	SNORA16	5.32	3.78e-07	0.00031	0.48	0.4	Body mass index;	chr13:32753864	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.63	rs79837633	ENSG00000212293.1	SNORA16	5.32	3.78e-07	0.00031	0.48	0.4	Body mass index;	chr13:32754590	chr13:32420390~32420516:-
PCPG	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	5.32	3.78e-07	0.00031	0.45	0.4	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
PCPG	cis	rs561341	1	rs501957	ENSG00000265798.5	RP11-271K11.5	5.32	3.78e-07	0.00031	0.69	0.4	Hip circumference adjusted for BMI;	chr17:31987485	chr17:31038575~31059121:-
PCPG	cis	rs9926296	0.565	rs8055825	ENSG00000260259.1	RP11-368I7.4	-5.31	3.79e-07	0.000311	-0.49	-0.4	Vitiligo;	chr16:89766440	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.568	rs7203907	ENSG00000260259.1	RP11-368I7.4	-5.31	3.79e-07	0.000311	-0.49	-0.4	Vitiligo;	chr16:89767366	chr16:89682620~89686569:-
PCPG	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	5.31	3.8e-07	0.000311	0.43	0.4	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
PCPG	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	5.31	3.81e-07	0.000312	0.62	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
PCPG	cis	rs853679	0.517	rs36078605	ENSG00000216901.1	AL022393.7	5.31	3.82e-07	0.000313	0.56	0.4	Depression;	chr6:28110254	chr6:28176188~28176674:+
PCPG	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.31	3.82e-07	0.000313	0.52	0.4	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
PCPG	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-5.31	3.82e-07	0.000313	-0.39	-0.4	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
PCPG	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-5.31	3.82e-07	0.000313	-0.46	-0.4	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
PCPG	cis	rs2625529	0.652	rs2899775	ENSG00000260037.4	CTD-2524L6.3	5.31	3.83e-07	0.000313	0.52	0.4	Red blood cell count;	chr15:71976013	chr15:71818396~71823384:+
PCPG	cis	rs9595908	0.869	rs55880225	ENSG00000212293.1	SNORA16	5.31	3.83e-07	0.000313	0.47	0.4	Body mass index;	chr13:32616733	chr13:32420390~32420516:-
PCPG	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	5.31	3.83e-07	0.000313	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
PCPG	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	5.31	3.83e-07	0.000313	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
PCPG	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-5.31	3.83e-07	0.000314	-0.51	-0.4	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
PCPG	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	5.31	3.84e-07	0.000314	0.53	0.4	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
PCPG	cis	rs7811142	1	rs67040465	ENSG00000078319.8	PMS2P1	-5.31	3.84e-07	0.000314	-0.55	-0.4	Platelet count;	chr7:100485455	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs73405353	ENSG00000078319.8	PMS2P1	-5.31	3.84e-07	0.000314	-0.55	-0.4	Platelet count;	chr7:100493592	chr7:100320992~100341908:-
PCPG	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	5.31	3.84e-07	0.000314	0.35	0.4	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
PCPG	cis	rs7824557	0.51	rs1435274	ENSG00000255020.1	AF131216.5	-5.31	3.84e-07	0.000314	-0.52	-0.4	Retinal vascular caliber;	chr8:11378401	chr8:11345748~11347502:-
PCPG	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-5.31	3.85e-07	0.000315	-0.53	-0.4	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
PCPG	cis	rs300890	0.586	rs300897	ENSG00000250326.1	RP11-284M14.1	5.31	3.86e-07	0.000315	0.36	0.4	Nasopharyngeal carcinoma;	chr4:143312198	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.662	rs13102116	ENSG00000250326.1	RP11-284M14.1	5.31	3.86e-07	0.000315	0.36	0.4	Nasopharyngeal carcinoma;	chr4:143312502	chr4:142933195~143184861:-
PCPG	cis	rs7824557	0.688	rs2572397	ENSG00000255020.1	AF131216.5	5.31	3.86e-07	0.000315	0.52	0.4	Retinal vascular caliber;	chr8:11318894	chr8:11345748~11347502:-
PCPG	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	5.31	3.86e-07	0.000315	0.37	0.4	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	5.31	3.86e-07	0.000315	0.37	0.4	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	5.31	3.86e-07	0.000315	0.37	0.4	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
PCPG	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-5.31	3.86e-07	0.000315	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
PCPG	cis	rs561341	1	rs55643307	ENSG00000265798.5	RP11-271K11.5	5.31	3.86e-07	0.000315	0.75	0.4	Hip circumference adjusted for BMI;	chr17:31936055	chr17:31038575~31059121:-
PCPG	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-5.31	3.87e-07	0.000316	-0.43	-0.4	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-5.31	3.87e-07	0.000316	-0.43	-0.4	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
PCPG	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	5.31	3.87e-07	0.000316	0.38	0.4	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
PCPG	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-5.31	3.88e-07	0.000317	-0.47	-0.4	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
PCPG	cis	rs9926296	0.508	rs1558184	ENSG00000260259.1	RP11-368I7.4	-5.31	3.9e-07	0.000318	-0.48	-0.4	Vitiligo;	chr16:89775966	chr16:89682620~89686569:-
PCPG	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	5.31	3.91e-07	0.000319	0.65	0.4	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
PCPG	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	5.31	3.91e-07	0.000319	0.48	0.4	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
PCPG	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-5.31	3.91e-07	0.000319	-0.51	-0.4	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
PCPG	cis	rs11148252	0.716	rs1887360	ENSG00000235660.1	LINC00345	-5.31	3.92e-07	0.00032	-0.53	-0.4	Lewy body disease;	chr13:52205031	chr13:52484161~52484680:-
PCPG	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	5.31	3.92e-07	0.00032	0.48	0.4	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
PCPG	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	5.31	3.93e-07	0.00032	0.65	0.4	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
PCPG	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	5.31	3.93e-07	0.00032	0.55	0.4	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
PCPG	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-5.31	3.94e-07	0.000321	-0.52	-0.4	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
PCPG	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	5.31	3.94e-07	0.000321	0.63	0.4	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	5.31	3.94e-07	0.000321	0.63	0.4	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	5.31	3.94e-07	0.000321	0.63	0.4	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
PCPG	cis	rs11148252	0.904	rs9568732	ENSG00000198384.8	TPTE2P3	5.31	3.95e-07	0.000322	0.49	0.4	Lewy body disease;	chr13:52419277	chr13:52522632~52586906:+
PCPG	cis	rs9595908	0.709	rs9596222	ENSG00000212293.1	SNORA16	5.31	3.97e-07	0.000323	0.48	0.4	Body mass index;	chr13:32767679	chr13:32420390~32420516:-
PCPG	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	5.31	3.97e-07	0.000323	0.48	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
PCPG	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	5.3	3.98e-07	0.000324	0.4	0.4	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
PCPG	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.3	3.99e-07	0.000325	0.51	0.4	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
PCPG	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-5.3	4e-07	0.000326	-0.5	-0.4	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
PCPG	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-5.3	4e-07	0.000326	-0.6	-0.4	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
PCPG	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-5.3	4.01e-07	0.000327	-0.47	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
PCPG	cis	rs12681963	0.925	rs13263107	ENSG00000248159.1	HSPA8P11	-5.3	4.02e-07	0.000327	-0.6	-0.4	Migraine;	chr8:30111988	chr8:30237382~30240997:+
PCPG	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	5.3	4.02e-07	0.000327	0.55	0.4	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
PCPG	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	5.3	4.02e-07	0.000327	0.52	0.4	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
PCPG	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	5.3	4.05e-07	0.000329	0.41	0.4	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
PCPG	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	5.3	4.05e-07	0.000329	0.41	0.4	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
PCPG	cis	rs9649213	0.574	rs56229643	ENSG00000272950.1	RP11-307C18.1	5.3	4.05e-07	0.000329	0.52	0.4	Prostate cancer (SNP x SNP interaction);	chr7:98236624	chr7:98322853~98323430:+
PCPG	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-5.3	4.05e-07	0.000329	-0.52	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
PCPG	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-5.3	4.05e-07	0.00033	-0.36	-0.4	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-5.3	4.05e-07	0.00033	-0.36	-0.4	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-5.3	4.05e-07	0.00033	-0.36	-0.4	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
PCPG	cis	rs12681963	0.61	rs2174133	ENSG00000248159.1	HSPA8P11	-5.3	4.05e-07	0.00033	-0.67	-0.4	Migraine;	chr8:30148247	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs10954880	ENSG00000248159.1	HSPA8P11	-5.3	4.05e-07	0.00033	-0.67	-0.4	Migraine;	chr8:30151166	chr8:30237382~30240997:+
PCPG	cis	rs10971721	0.643	rs7040130	ENSG00000260947.1	RP11-384P7.7	5.3	4.06e-07	0.00033	0.58	0.4	Body mass index;	chr9:33785075	chr9:33697459~33700986:+
PCPG	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-5.3	4.09e-07	0.000332	-0.54	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
PCPG	cis	rs3806843	1	rs10053586	ENSG00000202515.1	VTRNA1-3	-5.3	4.1e-07	0.000333	-0.52	-0.4	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr5:140726158~140726246:+
PCPG	cis	rs7811142	1	rs6979335	ENSG00000078319.8	PMS2P1	-5.3	4.12e-07	0.000334	-0.55	-0.4	Platelet count;	chr7:100492237	chr7:100320992~100341908:-
PCPG	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-5.3	4.12e-07	0.000334	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
PCPG	cis	rs11858159	0.967	rs7495965	ENSG00000259905.4	PWRN1	5.3	4.12e-07	0.000335	0.44	0.4	Platelet thrombus formation;	chr15:24594791	chr15:24493137~24652130:+
PCPG	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-5.3	4.13e-07	0.000335	-0.52	-0.4	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
PCPG	cis	rs11671005	0.504	rs7257669	ENSG00000269600.1	AC016629.3	-5.3	4.13e-07	0.000335	-0.54	-0.4	Mean platelet volume;	chr19:58553572	chr19:58593896~58599355:-
PCPG	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	5.3	4.15e-07	0.000336	0.53	0.4	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
PCPG	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	5.3	4.15e-07	0.000336	0.48	0.4	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
PCPG	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-5.3	4.15e-07	0.000337	-0.7	-0.4	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
PCPG	cis	rs56804039	1	rs67180327	ENSG00000253893.2	FAM85B	5.3	4.16e-07	0.000337	0.61	0.4	Cervical cancer;	chr8:8523244	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs67611618	ENSG00000253893.2	FAM85B	5.3	4.16e-07	0.000337	0.61	0.4	Cervical cancer;	chr8:8523429	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs58361948	ENSG00000253893.2	FAM85B	5.3	4.16e-07	0.000337	0.61	0.4	Cervical cancer;	chr8:8523485	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs56804039	ENSG00000253893.2	FAM85B	5.3	4.16e-07	0.000337	0.61	0.4	Cervical cancer;	chr8:8523519	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs6986470	ENSG00000253893.2	FAM85B	5.3	4.16e-07	0.000337	0.61	0.4	Cervical cancer;	chr8:8523920	chr8:8167819~8226614:-
PCPG	cis	rs56804039	1	rs7017341	ENSG00000253893.2	FAM85B	5.3	4.16e-07	0.000337	0.61	0.4	Cervical cancer;	chr8:8524154	chr8:8167819~8226614:-
PCPG	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	5.29	4.16e-07	0.000337	0.43	0.4	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
PCPG	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-5.29	4.17e-07	0.000337	-0.47	-0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
PCPG	cis	rs10899021	1	rs11236211	ENSG00000279353.1	RP11-864N7.4	5.29	4.17e-07	0.000337	0.83	0.4	Response to metformin (IC50);	chr11:74682166	chr11:74698231~74699658:-
PCPG	cis	rs2625529	0.652	rs8036307	ENSG00000260037.4	CTD-2524L6.3	5.29	4.18e-07	0.000339	0.54	0.4	Red blood cell count;	chr15:71882779	chr15:71818396~71823384:+
PCPG	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	5.29	4.19e-07	0.000339	0.55	0.4	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
PCPG	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-5.29	4.2e-07	0.00034	-0.32	-0.4	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
PCPG	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	5.29	4.2e-07	0.00034	0.63	0.4	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	5.29	4.21e-07	0.00034	0.65	0.4	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
PCPG	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-5.29	4.21e-07	0.00034	-0.52	-0.4	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
PCPG	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-5.29	4.21e-07	0.00034	-0.36	-0.4	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-5.29	4.21e-07	0.00034	-0.36	-0.4	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
PCPG	cis	rs2625529	0.617	rs2306576	ENSG00000260037.4	CTD-2524L6.3	5.29	4.21e-07	0.000341	0.52	0.4	Red blood cell count;	chr15:71878345	chr15:71818396~71823384:+
PCPG	cis	rs9926296	0.605	rs12599180	ENSG00000260259.1	RP11-368I7.4	5.29	4.23e-07	0.000342	0.48	0.4	Vitiligo;	chr16:89772898	chr16:89682620~89686569:-
PCPG	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	5.29	4.23e-07	0.000342	0.5	0.4	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
PCPG	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-5.29	4.23e-07	0.000342	-0.47	-0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
PCPG	cis	rs9399135	0.627	rs6930223	ENSG00000232876.1	CTA-212D2.2	-5.29	4.24e-07	0.000343	-0.47	-0.4	Red blood cell count;	chr6:135103065	chr6:135055033~135060550:+
PCPG	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-5.29	4.26e-07	0.000344	-0.37	-0.4	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
PCPG	cis	rs12946454	0.696	rs4792819	ENSG00000267288.2	RP13-890H12.2	-5.29	4.26e-07	0.000344	-0.52	-0.4	Systolic blood pressure;	chr17:45170590	chr17:45168800~45171584:-
PCPG	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-5.29	4.27e-07	0.000345	-0.36	-0.4	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-5.29	4.27e-07	0.000345	-0.36	-0.4	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
PCPG	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-5.29	4.28e-07	0.000345	-0.47	-0.4	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-5.29	4.28e-07	0.000345	-0.47	-0.4	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
PCPG	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-5.29	4.28e-07	0.000346	-0.71	-0.4	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
PCPG	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	5.29	4.29e-07	0.000347	0.43	0.4	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
PCPG	cis	rs17826219	0.5	rs117560728	ENSG00000263531.1	RP13-753N3.1	5.29	4.3e-07	0.000347	0.84	0.4	Body mass index;	chr17:30743920	chr17:30863921~30864940:-
PCPG	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-5.29	4.3e-07	0.000347	-0.45	-0.4	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
PCPG	cis	rs7246657	1	rs7246657	ENSG00000226686.6	LINC01535	5.29	4.31e-07	0.000348	0.61	0.4	Coronary artery calcification;	chr19:37256206	chr19:37251912~37265535:+
PCPG	cis	rs7208859	0.573	rs216443	ENSG00000263603.1	CTD-2349P21.5	-5.29	4.32e-07	0.000348	-0.64	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30729469~30731202:+
PCPG	cis	rs300890	0.516	rs476417	ENSG00000250326.1	RP11-284M14.1	5.29	4.32e-07	0.000348	0.36	0.4	Nasopharyngeal carcinoma;	chr4:143298339	chr4:142933195~143184861:-
PCPG	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	5.29	4.34e-07	0.00035	0.57	0.4	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
PCPG	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	5.28	4.38e-07	0.000353	0.39	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
PCPG	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	5.28	4.38e-07	0.000353	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	5.28	4.38e-07	0.000353	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	5.28	4.38e-07	0.000353	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	5.28	4.38e-07	0.000353	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	5.28	4.38e-07	0.000353	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
PCPG	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	5.28	4.38e-07	0.000353	0.61	0.4	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
PCPG	cis	rs12681963	0.688	rs4733400	ENSG00000248159.1	HSPA8P11	-5.28	4.39e-07	0.000353	-0.67	-0.4	Migraine;	chr8:30154998	chr8:30237382~30240997:+
PCPG	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-5.28	4.39e-07	0.000354	-0.47	-0.4	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
PCPG	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	5.28	4.41e-07	0.000355	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	5.28	4.41e-07	0.000355	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	5.28	4.41e-07	0.000355	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
PCPG	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	5.28	4.41e-07	0.000355	0.52	0.4	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.28	4.41e-07	0.000355	0.52	0.4	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.28	4.41e-07	0.000355	0.52	0.4	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.28	4.41e-07	0.000355	0.52	0.4	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.28	4.41e-07	0.000355	0.52	0.4	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	5.28	4.41e-07	0.000355	0.52	0.4	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
PCPG	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
PCPG	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	5.28	4.41e-07	0.000355	0.45	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
PCPG	cis	rs9926296	0.568	rs4420527	ENSG00000260259.1	RP11-368I7.4	5.28	4.41e-07	0.000355	0.47	0.4	Vitiligo;	chr16:89747780	chr16:89682620~89686569:-
PCPG	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-5.28	4.42e-07	0.000355	-0.39	-0.4	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-5.28	4.42e-07	0.000355	-0.39	-0.4	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-5.28	4.42e-07	0.000355	-0.39	-0.4	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-5.28	4.42e-07	0.000355	-0.39	-0.4	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
PCPG	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-5.28	4.42e-07	0.000355	-0.39	-0.4	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
PCPG	cis	rs73607972	0.597	rs1111487	ENSG00000275191.1	RP11-36I17.2	5.28	4.42e-07	0.000355	0.59	0.4	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53528217	chr16:53628256~53628816:-
PCPG	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-5.28	4.42e-07	0.000356	-0.44	-0.4	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
PCPG	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-5.28	4.42e-07	0.000356	-0.44	-0.4	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
PCPG	cis	rs4789693	0.518	rs6502117	ENSG00000279744.1	RP13-20L14.10	-5.28	4.42e-07	0.000356	-0.34	-0.4	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82462601~82464255:+
PCPG	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	5.28	4.43e-07	0.000356	0.61	0.4	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	5.28	4.43e-07	0.000356	0.61	0.4	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
PCPG	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	5.28	4.43e-07	0.000356	0.63	0.4	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	5.28	4.43e-07	0.000356	0.63	0.4	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	5.28	4.43e-07	0.000356	0.63	0.4	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	5.28	4.43e-07	0.000356	0.63	0.4	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
PCPG	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	5.28	4.44e-07	0.000357	0.43	0.4	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
PCPG	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	5.28	4.45e-07	0.000358	0.56	0.4	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
PCPG	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-5.28	4.45e-07	0.000358	-0.48	-0.4	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
PCPG	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	5.28	4.46e-07	0.000358	0.53	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
PCPG	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	5.28	4.46e-07	0.000358	0.66	0.4	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
PCPG	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	5.28	4.46e-07	0.000358	0.42	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
PCPG	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-5.28	4.47e-07	0.000359	-0.45	-0.4	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
PCPG	cis	rs2898290	0.622	rs7822109	ENSG00000255020.1	AF131216.5	-5.28	4.47e-07	0.000359	-0.51	-0.4	Systolic blood pressure;	chr8:11491638	chr8:11345748~11347502:-
PCPG	cis	rs3806843	0.832	rs2531360	ENSG00000202515.1	VTRNA1-3	5.28	4.47e-07	0.000359	0.49	0.4	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr5:140726158~140726246:+
PCPG	cis	rs13113518	0.783	rs11943206	ENSG00000272969.1	RP11-528I4.2	5.28	4.48e-07	0.00036	0.43	0.4	Height;	chr4:55570843	chr4:55547112~55547889:+
PCPG	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-5.28	4.49e-07	0.00036	-0.73	-0.4	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
PCPG	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-5.28	4.49e-07	0.00036	-0.73	-0.4	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
PCPG	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	5.28	4.49e-07	0.000361	0.36	0.4	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-5.28	4.49e-07	0.000361	-0.39	-0.4	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-5.28	4.49e-07	0.000361	-0.39	-0.4	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-5.28	4.49e-07	0.000361	-0.39	-0.4	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
PCPG	cis	rs561341	0.941	rs112569713	ENSG00000265798.5	RP11-271K11.5	5.28	4.5e-07	0.000361	0.71	0.4	Hip circumference adjusted for BMI;	chr17:31944719	chr17:31038575~31059121:-
PCPG	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	5.28	4.5e-07	0.000361	0.56	0.4	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
PCPG	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	5.28	4.51e-07	0.000362	0.45	0.4	Breast cancer;	chr11:750849	chr11:779617~780755:+
PCPG	cis	rs6121246	0.529	rs6060134	ENSG00000230613.1	HM13-AS1	5.28	4.52e-07	0.000362	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31588991	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs6058152	ENSG00000230613.1	HM13-AS1	5.28	4.52e-07	0.000362	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31590304	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs58757492	ENSG00000230613.1	HM13-AS1	5.28	4.52e-07	0.000362	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31593622	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs6060171	ENSG00000230613.1	HM13-AS1	5.28	4.52e-07	0.000362	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31595466	chr20:31567707~31573263:-
PCPG	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-5.28	4.53e-07	0.000364	-0.42	-0.4	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
PCPG	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	5.28	4.56e-07	0.000365	0.55	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
PCPG	cis	rs11858159	1	rs3924639	ENSG00000259905.4	PWRN1	5.27	4.56e-07	0.000365	0.44	0.4	Platelet thrombus formation;	chr15:24570220	chr15:24493137~24652130:+
PCPG	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	5.27	4.58e-07	0.000366	0.47	0.4	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
PCPG	cis	rs728616	0.558	rs61859793	ENSG00000242600.5	MBL1P	5.27	4.58e-07	0.000367	0.81	0.4	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79904898~79950336:+
PCPG	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-5.27	4.6e-07	0.000368	-0.71	-0.4	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
PCPG	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-5.27	4.6e-07	0.000368	-0.49	-0.4	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
PCPG	cis	rs9926296	0.548	rs6500439	ENSG00000260259.1	RP11-368I7.4	-5.27	4.61e-07	0.000368	-0.47	-0.4	Vitiligo;	chr16:89741867	chr16:89682620~89686569:-
PCPG	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	5.27	4.61e-07	0.000369	0.49	0.4	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
PCPG	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-5.27	4.62e-07	0.000369	-0.49	-0.4	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
PCPG	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-5.27	4.62e-07	0.000369	-0.39	-0.4	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
PCPG	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-5.27	4.64e-07	0.000371	-0.4	-0.4	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
PCPG	cis	rs561341	1	rs55962687	ENSG00000265798.5	RP11-271K11.5	5.27	4.65e-07	0.000371	0.72	0.4	Hip circumference adjusted for BMI;	chr17:31933350	chr17:31038575~31059121:-
PCPG	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-5.27	4.65e-07	0.000372	-0.39	-0.4	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
PCPG	cis	rs6121246	0.567	rs6060295	ENSG00000230613.1	HM13-AS1	5.27	4.68e-07	0.000373	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31610670	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6060297	ENSG00000230613.1	HM13-AS1	5.27	4.68e-07	0.000373	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31610757	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6058203	ENSG00000230613.1	HM13-AS1	5.27	4.68e-07	0.000373	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31611176	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs6120862	ENSG00000230613.1	HM13-AS1	5.27	4.68e-07	0.000373	0.63	0.4	Mean corpuscular hemoglobin;	chr20:31611656	chr20:31567707~31573263:-
PCPG	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	5.27	4.69e-07	0.000374	0.61	0.4	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	5.27	4.69e-07	0.000374	0.61	0.4	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
PCPG	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	5.27	4.69e-07	0.000374	0.62	0.4	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
PCPG	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-5.27	4.69e-07	0.000374	-0.47	-0.4	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
PCPG	cis	rs73607972	0.877	rs66646415	ENSG00000275191.1	RP11-36I17.2	-5.27	4.7e-07	0.000375	-0.61	-0.4	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572317	chr16:53628256~53628816:-
PCPG	cis	rs73607972	0.877	rs67786703	ENSG00000275191.1	RP11-36I17.2	-5.27	4.7e-07	0.000375	-0.61	-0.4	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53572427	chr16:53628256~53628816:-
PCPG	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-5.27	4.71e-07	0.000375	-0.47	-0.4	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
PCPG	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-5.27	4.71e-07	0.000375	-0.52	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
PCPG	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	5.27	4.71e-07	0.000376	0.49	0.4	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
PCPG	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-5.27	4.71e-07	0.000376	-0.43	-0.4	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-5.27	4.71e-07	0.000376	-0.43	-0.4	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-5.27	4.71e-07	0.000376	-0.43	-0.4	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-5.27	4.71e-07	0.000376	-0.43	-0.4	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-5.27	4.71e-07	0.000376	-0.43	-0.4	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-5.27	4.71e-07	0.000376	-0.43	-0.4	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
PCPG	cis	rs7945705	0.875	rs10769947	ENSG00000254860.4	TMEM9B-AS1	-5.27	4.72e-07	0.000376	-0.41	-0.4	Hemoglobin concentration;	chr11:8736567	chr11:8964675~8977527:+
PCPG	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	5.27	4.72e-07	0.000376	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
PCPG	cis	rs13113518	0.783	rs11133389	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55486718	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs4865001	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55490176	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs4864543	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55490228	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs6825774	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55491150	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs3805153	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55493557	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.756	rs7658446	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55495262	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.776	rs13124436	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55502504	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.783	rs6843997	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55508982	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.783	rs12508367	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55509442	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs2272073	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55510177	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs4865003	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55514802	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.756	rs12510275	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55516548	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs12510327	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55516744	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs11939580	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55517185	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs6830409	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55522229	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs13140173	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55527164	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs2035692	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55528801	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs4507426	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55529387	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs2035691	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55529786	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.756	rs11939652	ENSG00000272969.1	RP11-528I4.2	5.27	4.73e-07	0.000376	0.44	0.4	Height;	chr4:55532542	chr4:55547112~55547889:+
PCPG	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-5.27	4.73e-07	0.000377	-0.43	-0.4	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-5.27	4.73e-07	0.000377	-0.43	-0.4	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
PCPG	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	5.27	4.73e-07	0.000377	0.57	0.4	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
PCPG	cis	rs12646107	0.943	rs10025117	ENSG00000261672.1	RP11-475B2.1	-5.27	4.75e-07	0.000378	-0.54	-0.39	Response to amphetamines;	chr4:173594754	chr4:173593672~173594556:+
PCPG	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	5.27	4.76e-07	0.000379	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	5.27	4.76e-07	0.000379	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
PCPG	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-5.27	4.76e-07	0.000379	-0.58	-0.39	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
PCPG	cis	rs7824557	0.67	rs2736381	ENSG00000255020.1	AF131216.5	-5.27	4.77e-07	0.000379	-0.51	-0.39	Retinal vascular caliber;	chr8:11275257	chr8:11345748~11347502:-
PCPG	cis	rs2898290	0.622	rs13272061	ENSG00000255020.1	AF131216.5	-5.27	4.77e-07	0.000379	-0.5	-0.39	Systolic blood pressure;	chr8:11494752	chr8:11345748~11347502:-
PCPG	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-5.27	4.77e-07	0.00038	-0.45	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
PCPG	cis	rs3806843	0.741	rs4912597	ENSG00000202515.1	VTRNA1-3	5.27	4.77e-07	0.00038	0.5	0.39	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.771	rs2563334	ENSG00000202515.1	VTRNA1-3	5.27	4.77e-07	0.00038	0.5	0.39	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr5:140726158~140726246:+
PCPG	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	5.26	4.79e-07	0.000381	0.44	0.39	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
PCPG	cis	rs7079041	1	rs7079041	ENSG00000273038.2	RP11-479G22.8	-5.26	4.81e-07	0.000382	-0.5	-0.39	Suicide in bipolar disorder;	chr10:32704340	chr10:32887255~32889311:-
PCPG	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-5.26	4.81e-07	0.000382	-0.35	-0.39	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
PCPG	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	5.26	4.83e-07	0.000384	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
PCPG	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-5.26	4.84e-07	0.000384	-0.36	-0.39	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
PCPG	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-5.26	4.84e-07	0.000384	-0.36	-0.39	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
PCPG	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-5.26	4.84e-07	0.000384	-0.47	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
PCPG	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-5.26	4.84e-07	0.000384	-0.51	-0.39	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
PCPG	cis	rs13113518	0.812	rs56055342	ENSG00000272969.1	RP11-528I4.2	5.26	4.85e-07	0.000385	0.44	0.39	Height;	chr4:55540928	chr4:55547112~55547889:+
PCPG	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	5.26	4.85e-07	0.000385	0.49	0.39	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
PCPG	cis	rs453301	0.522	rs1964356	ENSG00000173295.6	FAM86B3P	-5.26	4.85e-07	0.000385	-0.47	-0.39	Joint mobility (Beighton score);	chr8:8995760	chr8:8228595~8244865:+
PCPG	cis	rs9926296	0.533	rs9938865	ENSG00000260259.1	RP11-368I7.4	-5.26	4.86e-07	0.000386	-0.48	-0.39	Vitiligo;	chr16:89801389	chr16:89682620~89686569:-
PCPG	cis	rs2736345	0.89	rs4840565	ENSG00000255020.1	AF131216.5	5.26	4.87e-07	0.000387	0.54	0.39	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:11345748~11347502:-
PCPG	cis	rs3736858	1	rs2120060	ENSG00000261105.4	LMO7-AS1	-5.26	4.87e-07	0.000387	-0.61	-0.39	Interleukin-9 levels;	chr13:75838764	chr13:75604700~75635994:-
PCPG	cis	rs453301	0.658	rs6983877	ENSG00000173295.6	FAM86B3P	5.26	4.88e-07	0.000387	0.48	0.39	Joint mobility (Beighton score);	chr8:9047129	chr8:8228595~8244865:+
PCPG	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	5.26	4.89e-07	0.000388	0.63	0.39	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
PCPG	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	5.26	4.9e-07	0.000388	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
PCPG	cis	rs7824557	0.564	rs2736295	ENSG00000255020.1	AF131216.5	5.26	4.9e-07	0.000388	0.52	0.39	Retinal vascular caliber;	chr8:11377271	chr8:11345748~11347502:-
PCPG	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	5.26	4.9e-07	0.000389	0.57	0.39	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
PCPG	cis	rs2412819	0.545	rs35822148	ENSG00000205771.5	CATSPER2P1	-5.26	4.91e-07	0.000389	-0.53	-0.39	Lung cancer;	chr15:43808084	chr15:43726918~43747094:-
PCPG	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	5.26	4.94e-07	0.000391	0.92	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
PCPG	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	5.26	4.94e-07	0.000391	0.92	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
PCPG	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	5.26	4.94e-07	0.000391	0.92	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
PCPG	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	5.26	4.94e-07	0.000391	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	5.26	4.94e-07	0.000391	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	5.26	4.94e-07	0.000391	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
PCPG	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-5.26	4.95e-07	0.000392	-0.37	-0.39	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
PCPG	cis	rs7403037	0.509	rs7180190	ENSG00000259905.4	PWRN1	5.26	4.96e-07	0.000393	0.44	0.39	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24571846	chr15:24493137~24652130:+
PCPG	cis	rs2625529	0.652	rs2899776	ENSG00000260037.4	CTD-2524L6.3	5.26	4.97e-07	0.000393	0.52	0.39	Red blood cell count;	chr15:71976024	chr15:71818396~71823384:+
PCPG	cis	rs6762	0.55	rs8672	ENSG00000279672.1	CMB9-55F22.1	5.26	4.97e-07	0.000394	0.44	0.39	Mean platelet volume;	chr11:838634	chr11:779617~780755:+
PCPG	cis	rs2898290	0.617	rs13273172	ENSG00000255020.1	AF131216.5	-5.26	4.98e-07	0.000394	-0.54	-0.39	Systolic blood pressure;	chr8:11603602	chr8:11345748~11347502:-
PCPG	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	5.26	5e-07	0.000395	0.37	0.39	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
PCPG	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-5.25	5.01e-07	0.000397	-0.39	-0.39	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
PCPG	cis	rs853679	0.517	rs9468298	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28154567	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9295759	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28156691	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9348796	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28158424	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs11552219	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28159056	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380058	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28159666	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393895	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28159843	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393896	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28159925	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393897	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28159932	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9357066	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28162053	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393898	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28162598	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368556	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28163375	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368557	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28163759	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380059	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28164580	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380060	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28164825	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs35227624	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28164948	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380061	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28165025	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368558	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28165528	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.587	rs9393899	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Parkinson's disease;	chr6:28165750	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713150	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28168434	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.527	rs4713151	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Parkinson's disease;	chr6:28168578	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393901	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28169019	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs3173443	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28169249	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713152	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28169676	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9348797	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28169755	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380062	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28169791	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.542	rs9380063	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28170075	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs12332979	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28173770	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs67878650	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28174809	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.569	rs9348798	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28175233	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380065	ENSG00000216901.1	AL022393.7	5.25	5.02e-07	0.000397	0.57	0.39	Depression;	chr6:28176973	chr6:28176188~28176674:+
PCPG	cis	rs9595908	0.694	rs9596233	ENSG00000212293.1	SNORA16	5.25	5.02e-07	0.000397	0.47	0.39	Body mass index;	chr13:32776878	chr13:32420390~32420516:-
PCPG	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-5.25	5.03e-07	0.000397	-0.49	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
PCPG	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	5.25	5.03e-07	0.000397	0.9	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
PCPG	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	5.25	5.03e-07	0.000398	0.51	0.39	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
PCPG	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-5.25	5.05e-07	0.000399	-0.39	-0.39	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
PCPG	cis	rs3806843	0.766	rs801176	ENSG00000202515.1	VTRNA1-3	-5.25	5.05e-07	0.000399	-0.49	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140707425	chr5:140726158~140726246:+
PCPG	cis	rs561341	1	rs8069199	ENSG00000265798.5	RP11-271K11.5	5.25	5.05e-07	0.000399	0.69	0.39	Hip circumference adjusted for BMI;	chr17:31954826	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.882	rs111484028	ENSG00000265798.5	RP11-271K11.5	5.25	5.05e-07	0.000399	0.69	0.39	Hip circumference adjusted for BMI;	chr17:31960682	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.505	rs548298	ENSG00000265798.5	RP11-271K11.5	5.25	5.05e-07	0.000399	0.69	0.39	Hip circumference adjusted for BMI;	chr17:31970475	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.714	rs547473	ENSG00000265798.5	RP11-271K11.5	5.25	5.05e-07	0.000399	0.69	0.39	Hip circumference adjusted for BMI;	chr17:31970541	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs546519	ENSG00000265798.5	RP11-271K11.5	5.25	5.05e-07	0.000399	0.69	0.39	Hip circumference adjusted for BMI;	chr17:31970663	chr17:31038575~31059121:-
PCPG	cis	rs9595908	0.709	rs7318510	ENSG00000212293.1	SNORA16	5.25	5.06e-07	0.000399	0.48	0.39	Body mass index;	chr13:32752122	chr13:32420390~32420516:-
PCPG	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	5.06e-07	0.000399	-0.45	-0.39	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
PCPG	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	5.25	5.06e-07	4e-04	0.55	0.39	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
PCPG	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	5.25	5.07e-07	4e-04	0.47	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
PCPG	cis	rs10899021	0.92	rs76121309	ENSG00000279353.1	RP11-864N7.4	5.25	5.07e-07	4e-04	0.75	0.39	Response to metformin (IC50);	chr11:74632876	chr11:74698231~74699658:-
PCPG	cis	rs7829975	0.511	rs2980512	ENSG00000173295.6	FAM86B3P	-5.25	5.08e-07	0.000401	-0.47	-0.39	Mood instability;	chr8:8283379	chr8:8228595~8244865:+
PCPG	cis	rs7759001	0.69	rs6933354	ENSG00000271755.1	RP1-153G14.4	5.25	5.08e-07	0.000401	0.56	0.39	Glomerular filtration rate (creatinine);	chr6:27496279	chr6:27404010~27406964:-
PCPG	cis	rs6121246	0.523	rs6060286	ENSG00000230613.1	HM13-AS1	5.25	5.08e-07	0.000401	0.63	0.39	Mean corpuscular hemoglobin;	chr20:31609860	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.529	rs6060291	ENSG00000230613.1	HM13-AS1	5.25	5.08e-07	0.000401	0.63	0.39	Mean corpuscular hemoglobin;	chr20:31610240	chr20:31567707~31573263:-
PCPG	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	5.25	5.08e-07	0.000401	0.62	0.39	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	5.25	5.08e-07	0.000401	0.62	0.39	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
PCPG	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-5.25	5.09e-07	0.000401	-0.5	-0.39	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
PCPG	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	5.25	5.1e-07	0.000402	0.58	0.39	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
PCPG	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	5.25	5.1e-07	0.000402	0.6	0.39	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
PCPG	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	5.25	5.11e-07	0.000403	0.48	0.39	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
PCPG	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-5.25	5.13e-07	0.000404	-0.42	-0.39	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-5.25	5.13e-07	0.000404	-0.42	-0.39	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
PCPG	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	5.25	5.13e-07	0.000404	0.42	0.39	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
PCPG	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-5.25	5.14e-07	0.000405	-0.36	-0.39	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
PCPG	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-5.25	5.14e-07	0.000405	-0.38	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
PCPG	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	5.25	5.15e-07	0.000406	0.41	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
PCPG	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-5.25	5.15e-07	0.000406	-0.45	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
PCPG	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	5.25	5.15e-07	0.000406	0.47	0.39	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
PCPG	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	5.25	5.18e-07	0.000408	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
PCPG	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	5.25	5.19e-07	0.000408	0.38	0.39	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
PCPG	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	5.25	5.19e-07	0.000408	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
PCPG	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-5.25	5.19e-07	0.000409	-0.48	-0.39	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
PCPG	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	5.25	5.19e-07	0.000409	0.49	0.39	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
PCPG	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-5.25	5.2e-07	0.000409	-0.49	-0.39	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
PCPG	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-5.25	5.2e-07	0.000409	-0.49	-0.39	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
PCPG	cis	rs17507216	0.718	rs72751657	ENSG00000228141.5	AC105339.1	-5.25	5.2e-07	0.00041	-0.62	-0.39	Excessive daytime sleepiness;	chr15:82581259	chr15:82710471~82714026:-
PCPG	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-5.25	5.21e-07	0.00041	-0.47	-0.39	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-5.25	5.21e-07	0.00041	-0.47	-0.39	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-5.25	5.21e-07	0.00041	-0.47	-0.39	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
PCPG	cis	rs964611	1	rs8037626	ENSG00000259488.2	RP11-154J22.1	-5.25	5.21e-07	0.00041	-0.39	-0.39	Metabolite levels (Pyroglutamine);	chr15:48314149	chr15:48312353~48331856:-
PCPG	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	5.25	5.22e-07	0.00041	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	5.25	5.22e-07	0.00041	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	5.25	5.22e-07	0.00041	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	5.25	5.22e-07	0.00041	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	5.25	5.22e-07	0.00041	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
PCPG	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	5.25	5.22e-07	0.00041	0.52	0.39	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
PCPG	cis	rs9649213	0.593	rs6465673	ENSG00000272950.1	RP11-307C18.1	5.25	5.22e-07	0.000411	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr7:98322853~98323430:+
PCPG	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	5.25	5.22e-07	0.000411	0.44	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
PCPG	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	5.25	5.22e-07	0.000411	0.9	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
PCPG	cis	rs7598759	0.712	rs6735961	ENSG00000181798.2	LINC00471	-5.24	5.25e-07	0.000413	-0.5	-0.39	Noise-induced hearing loss;	chr2:231469703	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.712	rs4972993	ENSG00000181798.2	LINC00471	-5.24	5.25e-07	0.000413	-0.5	-0.39	Noise-induced hearing loss;	chr2:231470324	chr2:231508426~231514339:-
PCPG	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-5.24	5.26e-07	0.000413	-0.53	-0.39	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-5.24	5.26e-07	0.000413	-0.53	-0.39	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-5.24	5.26e-07	0.000413	-0.53	-0.39	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
PCPG	cis	rs453301	0.606	rs7462373	ENSG00000173295.6	FAM86B3P	5.24	5.26e-07	0.000414	0.47	0.39	Joint mobility (Beighton score);	chr8:9041808	chr8:8228595~8244865:+
PCPG	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	5.24	5.27e-07	0.000414	0.56	0.39	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
PCPG	cis	rs11992162	0.507	rs60902764	ENSG00000255020.1	AF131216.5	-5.24	5.28e-07	0.000415	-0.53	-0.39	Monocyte count;	chr8:11927482	chr8:11345748~11347502:-
PCPG	cis	rs2625529	0.652	rs2957736	ENSG00000260037.4	CTD-2524L6.3	5.24	5.3e-07	0.000416	0.51	0.39	Red blood cell count;	chr15:71973003	chr15:71818396~71823384:+
PCPG	cis	rs9595908	0.544	rs7328213	ENSG00000212293.1	SNORA16	5.24	5.3e-07	0.000416	0.49	0.39	Body mass index;	chr13:32803692	chr13:32420390~32420516:-
PCPG	cis	rs11992162	0.613	rs6601634	ENSG00000255020.1	AF131216.5	-5.24	5.31e-07	0.000417	-0.55	-0.39	Monocyte count;	chr8:11948947	chr8:11345748~11347502:-
PCPG	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	5.24	5.31e-07	0.000417	0.6	0.39	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
PCPG	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	5.24	5.31e-07	0.000417	0.67	0.39	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
PCPG	cis	rs4713118	0.587	rs61471148	ENSG00000216901.1	AL022393.7	5.24	5.32e-07	0.000418	0.56	0.39	Parkinson's disease;	chr6:28069254	chr6:28176188~28176674:+
PCPG	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	5.24	5.33e-07	0.000418	0.62	0.39	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
PCPG	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	5.24	5.33e-07	0.000419	0.72	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
PCPG	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-5.24	5.35e-07	0.00042	-0.39	-0.39	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
PCPG	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-5.24	5.37e-07	0.000421	-0.35	-0.39	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
PCPG	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-5.24	5.37e-07	0.000421	-0.36	-0.39	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
PCPG	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	5.24	5.38e-07	0.000422	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
PCPG	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	5.24	5.38e-07	0.000422	0.49	0.39	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
PCPG	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	5.24	5.39e-07	0.000422	0.61	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
PCPG	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-5.24	5.39e-07	0.000423	-0.48	-0.39	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
PCPG	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-5.24	5.4e-07	0.000423	-0.5	-0.39	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
PCPG	cis	rs13113518	0.812	rs12505880	ENSG00000272969.1	RP11-528I4.2	5.24	5.4e-07	0.000423	0.42	0.39	Height;	chr4:55440988	chr4:55547112~55547889:+
PCPG	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	5.24	5.41e-07	0.000424	0.44	0.39	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
PCPG	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-5.24	5.41e-07	0.000424	-0.4	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
PCPG	cis	rs12681963	0.688	rs55725858	ENSG00000248159.1	HSPA8P11	5.24	5.42e-07	0.000425	0.76	0.39	Migraine;	chr8:30194695	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.541	rs56339843	ENSG00000248159.1	HSPA8P11	5.24	5.42e-07	0.000425	0.76	0.39	Migraine;	chr8:30194766	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs7015750	ENSG00000248159.1	HSPA8P11	5.24	5.42e-07	0.000425	0.76	0.39	Migraine;	chr8:30196499	chr8:30237382~30240997:+
PCPG	cis	rs453301	0.624	rs2288671	ENSG00000173295.6	FAM86B3P	-5.24	5.43e-07	0.000425	-0.45	-0.39	Joint mobility (Beighton score);	chr8:9003384	chr8:8228595~8244865:+
PCPG	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	5.24	5.43e-07	0.000426	0.48	0.39	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
PCPG	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	5.24	5.45e-07	0.000427	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	5.24	5.45e-07	0.000427	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
PCPG	cis	rs13113518	0.783	rs12510400	ENSG00000272969.1	RP11-528I4.2	5.24	5.45e-07	0.000427	0.44	0.39	Height;	chr4:55577294	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.783	rs13111128	ENSG00000272969.1	RP11-528I4.2	5.24	5.45e-07	0.000427	0.44	0.39	Height;	chr4:55578154	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs2048564	ENSG00000272969.1	RP11-528I4.2	5.24	5.46e-07	0.000428	0.42	0.39	Height;	chr4:55407965	chr4:55547112~55547889:+
PCPG	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-5.24	5.47e-07	0.000428	-0.43	-0.39	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
PCPG	cis	rs2625529	0.504	rs11072349	ENSG00000260037.4	CTD-2524L6.3	5.24	5.47e-07	0.000428	0.51	0.39	Red blood cell count;	chr15:72172130	chr15:71818396~71823384:+
PCPG	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-5.24	5.48e-07	0.000429	-0.51	-0.39	Depression;	chr6:28226851	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-5.24	5.48e-07	0.000429	-0.51	-0.39	Depression;	chr6:28229408	chr6:28115628~28116551:+
PCPG	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-5.23	5.5e-07	0.00043	-0.5	-0.39	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
PCPG	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	5.23	5.51e-07	0.000431	0.45	0.39	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	5.23	5.51e-07	0.000431	0.45	0.39	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	5.23	5.51e-07	0.000431	0.45	0.39	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
PCPG	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	5.23	5.51e-07	0.000431	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	5.23	5.51e-07	0.000431	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	5.23	5.51e-07	0.000431	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	5.23	5.51e-07	0.000431	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	5.23	5.51e-07	0.000431	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	5.23	5.51e-07	0.000431	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-5.23	5.51e-07	0.000431	-0.52	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
PCPG	cis	rs308097	0.826	rs308089	ENSG00000235944.6	ZNF815P	-5.23	5.52e-07	0.000431	-1.02	-0.39	IgG glycosylation;	chr7:5845529	chr7:5823160~5854435:+
PCPG	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	5.23	5.53e-07	0.000432	0.44	0.39	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
PCPG	cis	rs9595908	0.785	rs9652200	ENSG00000212293.1	SNORA16	5.23	5.55e-07	0.000434	0.47	0.39	Body mass index;	chr13:32715613	chr13:32420390~32420516:-
PCPG	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-5.23	5.56e-07	0.000435	-0.44	-0.39	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-5.23	5.56e-07	0.000435	-0.44	-0.39	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
PCPG	cis	rs9649213	0.511	rs6950994	ENSG00000272950.1	RP11-307C18.1	5.23	5.57e-07	0.000435	0.51	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98258560	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs7794187	ENSG00000272950.1	RP11-307C18.1	5.23	5.57e-07	0.000435	0.51	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98260446	chr7:98322853~98323430:+
PCPG	cis	rs6762	0.748	rs7929032	ENSG00000279672.1	CMB9-55F22.1	5.23	5.57e-07	0.000435	0.44	0.39	Mean platelet volume;	chr11:839078	chr11:779617~780755:+
PCPG	cis	rs6762	0.748	rs7936838	ENSG00000279672.1	CMB9-55F22.1	5.23	5.57e-07	0.000435	0.44	0.39	Mean platelet volume;	chr11:839093	chr11:779617~780755:+
PCPG	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-5.23	5.58e-07	0.000436	-0.42	-0.39	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
PCPG	cis	rs9649213	0.574	rs17436977	ENSG00000272950.1	RP11-307C18.1	5.23	5.59e-07	0.000436	0.51	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98254147	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs34817002	ENSG00000272950.1	RP11-307C18.1	5.23	5.59e-07	0.000436	0.51	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs7789440	ENSG00000272950.1	RP11-307C18.1	5.23	5.59e-07	0.000436	0.51	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.555	rs6955259	ENSG00000272950.1	RP11-307C18.1	5.23	5.59e-07	0.000436	0.51	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98263044	chr7:98322853~98323430:+
PCPG	cis	rs11992162	0.597	rs6996342	ENSG00000255020.1	AF131216.5	-5.23	5.59e-07	0.000436	-0.52	-0.39	Monocyte count;	chr8:11927032	chr8:11345748~11347502:-
PCPG	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-5.23	5.6e-07	0.000437	-0.48	-0.39	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
PCPG	cis	rs9302635	0.515	rs36033103	ENSG00000260886.1	TAT-AS1	5.23	5.6e-07	0.000437	0.85	0.39	Blood protein levels;	chr16:72108139	chr16:71565789~71578187:+
PCPG	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	5.23	5.6e-07	0.000437	0.53	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
PCPG	cis	rs6762	0.748	rs1130663	ENSG00000279672.1	CMB9-55F22.1	5.23	5.61e-07	0.000437	0.43	0.39	Mean platelet volume;	chr11:837582	chr11:779617~780755:+
PCPG	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-5.23	5.61e-07	0.000438	-0.51	-0.39	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
PCPG	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-5.23	5.63e-07	0.000439	-0.52	-0.39	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
PCPG	cis	rs3806843	0.966	rs7710380	ENSG00000202515.1	VTRNA1-3	-5.23	5.64e-07	0.000439	-0.5	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr5:140726158~140726246:+
PCPG	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-5.23	5.64e-07	0.000439	-0.46	-0.39	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
PCPG	cis	rs2898290	0.622	rs11250140	ENSG00000255020.1	AF131216.5	-5.23	5.66e-07	0.000441	-0.51	-0.39	Systolic blood pressure;	chr8:11489083	chr8:11345748~11347502:-
PCPG	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-5.23	5.66e-07	0.000441	-0.89	-0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
PCPG	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-5.23	5.66e-07	0.000441	-0.89	-0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
PCPG	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	5.23	5.66e-07	0.000441	0.89	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
PCPG	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	5.23	5.66e-07	0.000441	0.89	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
PCPG	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	5.23	5.66e-07	0.000441	0.89	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
PCPG	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	5.23	5.66e-07	0.000441	0.89	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
PCPG	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	5.23	5.66e-07	0.000441	0.89	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
PCPG	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	5.23	5.66e-07	0.000441	0.89	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
PCPG	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	5.23	5.68e-07	0.000442	0.43	0.39	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
PCPG	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-5.23	5.68e-07	0.000442	-0.43	-0.39	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
PCPG	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-5.23	5.7e-07	0.000443	-0.52	-0.39	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-5.23	5.7e-07	0.000443	-0.52	-0.39	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
PCPG	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-5.23	5.7e-07	0.000443	-0.38	-0.39	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
PCPG	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	5.23	5.7e-07	0.000443	0.54	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
PCPG	cis	rs7598759	0.712	rs7596227	ENSG00000181798.2	LINC00471	-5.23	5.71e-07	0.000445	-0.5	-0.39	Noise-induced hearing loss;	chr2:231472320	chr2:231508426~231514339:-
PCPG	cis	rs7829975	0.508	rs1594437	ENSG00000173295.6	FAM86B3P	-5.23	5.73e-07	0.000446	-0.45	-0.39	Mood instability;	chr8:8968365	chr8:8228595~8244865:+
PCPG	cis	rs12681963	0.688	rs55810013	ENSG00000248159.1	HSPA8P11	5.22	5.74e-07	0.000447	0.68	0.39	Migraine;	chr8:30181507	chr8:30237382~30240997:+
PCPG	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	5.22	5.75e-07	0.000447	0.49	0.39	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
PCPG	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-5.22	5.75e-07	0.000447	-0.51	-0.39	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-5.22	5.75e-07	0.000447	-0.51	-0.39	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-5.22	5.75e-07	0.000447	-0.51	-0.39	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
PCPG	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-5.22	5.75e-07	0.000447	-0.37	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
PCPG	cis	rs13113518	0.812	rs11932712	ENSG00000272969.1	RP11-528I4.2	5.22	5.76e-07	0.000447	0.43	0.39	Height;	chr4:55436423	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs12501746	ENSG00000272969.1	RP11-528I4.2	5.22	5.76e-07	0.000447	0.43	0.39	Height;	chr4:55437438	chr4:55547112~55547889:+
PCPG	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-5.22	5.77e-07	0.000449	-0.48	-0.39	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-5.22	5.77e-07	0.000449	-0.48	-0.39	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
PCPG	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-5.22	5.77e-07	0.000449	-0.65	-0.39	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
PCPG	cis	rs804280	1	rs804281	ENSG00000255020.1	AF131216.5	5.22	5.79e-07	0.00045	0.57	0.39	Myopia (pathological);	chr8:11754356	chr8:11345748~11347502:-
PCPG	cis	rs853679	1	rs10456362	ENSG00000216901.1	AL022393.7	-5.22	5.82e-07	0.000452	-0.65	-0.39	Depression;	chr6:28254038	chr6:28176188~28176674:+
PCPG	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	5.22	5.84e-07	0.000453	0.51	0.39	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
PCPG	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	5.22	5.84e-07	0.000454	0.51	0.39	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.686	rs6748	ENSG00000173295.6	FAM86B3P	5.22	5.85e-07	0.000454	0.47	0.39	Joint mobility (Beighton score);	chr8:9033292	chr8:8228595~8244865:+
PCPG	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-5.22	5.85e-07	0.000454	-0.39	-0.39	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
PCPG	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	5.22	5.85e-07	0.000454	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	5.22	5.85e-07	0.000454	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	5.22	5.85e-07	0.000454	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
PCPG	cis	rs10435719	0.638	rs67146188	ENSG00000255020.1	AF131216.5	-5.22	5.87e-07	0.000455	-0.53	-0.39	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11345748~11347502:-
PCPG	cis	rs748404	0.706	rs35975365	ENSG00000249839.1	AC011330.5	-5.22	5.87e-07	0.000456	-0.56	-0.39	Lung cancer;	chr15:43379347	chr15:43663654~43684339:-
PCPG	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	5.22	5.87e-07	0.000456	0.57	0.39	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	5.22	5.87e-07	0.000456	0.57	0.39	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
PCPG	cis	rs55665837	0.701	rs12286408	ENSG00000251991.1	RNU7-49P	5.22	5.88e-07	0.000456	0.44	0.39	Vitamin D levels;	chr11:14557830	chr11:14478892~14478953:+
PCPG	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-5.22	5.9e-07	0.000458	-0.41	-0.39	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
PCPG	cis	rs11992162	0.56	rs13256329	ENSG00000255020.1	AF131216.5	-5.22	5.91e-07	0.000458	-0.53	-0.39	Monocyte count;	chr8:11924705	chr8:11345748~11347502:-
PCPG	cis	rs2531992	0.858	rs2230742	ENSG00000262888.1	RP11-462G12.2	5.22	5.93e-07	0.000459	0.65	0.39	Waist circumference;	chr16:3966675	chr16:3931217~3946305:-
PCPG	cis	rs916888	0.779	rs199498	ENSG00000262500.1	RP11-259G18.2	5.22	5.93e-07	0.000459	0.66	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46243606~46245044:+
PCPG	cis	rs3806843	0.735	rs6849	ENSG00000202515.1	VTRNA1-3	5.22	5.93e-07	0.000459	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs702394	ENSG00000202515.1	VTRNA1-3	5.22	5.93e-07	0.000459	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs801180	ENSG00000202515.1	VTRNA1-3	5.22	5.93e-07	0.000459	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr5:140726158~140726246:+
PCPG	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-5.22	5.93e-07	0.000459	-0.48	-0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
PCPG	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-5.22	5.95e-07	0.00046	-0.62	-0.39	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
PCPG	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	5.22	5.95e-07	0.00046	0.6	0.39	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	5.22	5.95e-07	0.00046	0.6	0.39	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	5.22	5.95e-07	0.00046	0.6	0.39	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	5.22	5.95e-07	0.00046	0.6	0.39	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	5.22	5.95e-07	0.00046	0.6	0.39	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
PCPG	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	5.22	5.95e-07	0.000461	0.44	0.39	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
PCPG	cis	rs13113518	0.841	rs7699867	ENSG00000272969.1	RP11-528I4.2	5.22	5.95e-07	0.000461	0.44	0.39	Height;	chr4:55483718	chr4:55547112~55547889:+
PCPG	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	5.22	5.96e-07	0.000461	0.58	0.39	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
PCPG	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	5.22	5.97e-07	0.000462	0.42	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
PCPG	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-5.22	5.98e-07	0.000463	-0.38	-0.39	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
PCPG	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-5.22	5.98e-07	0.000463	-0.8	-0.39	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
PCPG	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-5.22	5.98e-07	0.000463	-0.47	-0.39	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
PCPG	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-5.22	5.99e-07	0.000463	-0.48	-0.39	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
PCPG	cis	rs3806843	0.735	rs801168	ENSG00000202515.1	VTRNA1-3	5.22	6e-07	0.000464	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs801183	ENSG00000202515.1	VTRNA1-3	-5.22	6e-07	0.000464	-0.49	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr5:140726158~140726246:+
PCPG	cis	rs2253762	0.54	rs11200351	ENSG00000276742.1	RP11-500G22.4	5.21	6e-07	0.000464	0.64	0.39	Breast cancer;	chr10:122029957	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs11200353	ENSG00000276742.1	RP11-500G22.4	5.21	6e-07	0.000464	0.64	0.39	Breast cancer;	chr10:122030181	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs10887053	ENSG00000276742.1	RP11-500G22.4	5.21	6e-07	0.000464	0.64	0.39	Breast cancer;	chr10:122030997	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs75670246	ENSG00000276742.1	RP11-500G22.4	5.21	6e-07	0.000464	0.64	0.39	Breast cancer;	chr10:122032687	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs11200357	ENSG00000276742.1	RP11-500G22.4	5.21	6e-07	0.000464	0.64	0.39	Breast cancer;	chr10:122034390	chr10:121956782~121957098:+
PCPG	cis	rs28386778	0.897	rs1062791	ENSG00000240280.5	TCAM1P	-5.21	6.03e-07	0.000466	-0.52	-0.39	Prudent dietary pattern;	chr17:63819127	chr17:63849292~63864379:+
PCPG	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-5.21	6.05e-07	0.000468	-0.38	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
PCPG	cis	rs3806843	0.735	rs2563314	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs2530240	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs801189	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.706	rs1089305	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs801185	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs2563306	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs813897	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.676	rs2563304	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs3776129	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.706	rs2563302	ENSG00000202515.1	VTRNA1-3	5.21	6.06e-07	0.000468	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr5:140726158~140726246:+
PCPG	cis	rs2302464	1	rs58978163	ENSG00000214846.4	RP11-115L11.1	5.21	6.07e-07	0.000469	0.91	0.39	Cerebrospinal fluid biomarker levels;	chr4:15726385	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs16892272	ENSG00000214846.4	RP11-115L11.1	5.21	6.07e-07	0.000469	0.91	0.39	Cerebrospinal fluid biomarker levels;	chr4:15726456	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs73123615	ENSG00000214846.4	RP11-115L11.1	5.21	6.07e-07	0.000469	0.91	0.39	Cerebrospinal fluid biomarker levels;	chr4:15726553	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs16892276	ENSG00000214846.4	RP11-115L11.1	5.21	6.07e-07	0.000469	0.91	0.39	Cerebrospinal fluid biomarker levels;	chr4:15726614	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs60913985	ENSG00000214846.4	RP11-115L11.1	5.21	6.07e-07	0.000469	0.91	0.39	Cerebrospinal fluid biomarker levels;	chr4:15726671	chr4:15730962~15731627:-
PCPG	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	5.21	6.07e-07	0.000469	0.44	0.39	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
PCPG	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	5.21	6.1e-07	0.000471	0.58	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
PCPG	cis	rs453301	0.624	rs2288673	ENSG00000173295.6	FAM86B3P	-5.21	6.13e-07	0.000473	-0.46	-0.39	Joint mobility (Beighton score);	chr8:9002766	chr8:8228595~8244865:+
PCPG	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	5.21	6.13e-07	0.000473	0.44	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
PCPG	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-5.21	6.14e-07	0.000474	-0.5	-0.39	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
PCPG	cis	rs300890	0.717	rs300947	ENSG00000250326.1	RP11-284M14.1	5.21	6.16e-07	0.000475	0.35	0.39	Nasopharyngeal carcinoma;	chr4:143288636	chr4:142933195~143184861:-
PCPG	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-5.21	6.16e-07	0.000475	-0.38	-0.39	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
PCPG	cis	rs2302464	1	rs16892289	ENSG00000214846.4	RP11-115L11.1	-5.21	6.17e-07	0.000476	-0.96	-0.39	Cerebrospinal fluid biomarker levels;	chr4:15730680	chr4:15730962~15731627:-
PCPG	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-5.21	6.19e-07	0.000477	-0.5	-0.39	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
PCPG	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	5.21	6.19e-07	0.000477	0.42	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
PCPG	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
PCPG	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-5.21	6.2e-07	0.000478	-0.49	-0.39	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
PCPG	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-5.21	6.24e-07	0.000481	-0.5	-0.39	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
PCPG	cis	rs7181230	0.885	rs28826672	ENSG00000259584.1	RP11-521C20.2	5.2	6.29e-07	0.000484	0.52	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40075204~40078704:-
PCPG	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	5.2	6.3e-07	0.000485	0.43	0.39	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
PCPG	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	5.2	6.3e-07	0.000485	0.49	0.39	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
PCPG	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-5.2	6.3e-07	0.000485	-0.52	-0.39	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
PCPG	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	5.2	6.31e-07	0.000486	0.46	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
PCPG	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-5.2	6.31e-07	0.000486	-0.56	-0.39	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
PCPG	cis	rs10760158	0.832	rs4837835	ENSG00000226752.6	PSMD5-AS1	5.2	6.32e-07	0.000486	0.5	0.39	Pulse pressure;	chr9:121298711	chr9:120824828~120854385:+
PCPG	cis	rs3806843	0.568	rs2530232	ENSG00000202515.1	VTRNA1-3	5.2	6.33e-07	0.000487	0.49	0.39	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr5:140726158~140726246:+
PCPG	cis	rs12682352	0.605	rs60707155	ENSG00000173295.6	FAM86B3P	-5.2	6.34e-07	0.000487	-0.47	-0.39	Neuroticism;	chr8:8866905	chr8:8228595~8244865:+
PCPG	cis	rs7824557	0.527	rs11785394	ENSG00000255020.1	AF131216.5	-5.2	6.34e-07	0.000487	-0.53	-0.39	Retinal vascular caliber;	chr8:11380520	chr8:11345748~11347502:-
PCPG	cis	rs3806843	0.766	rs801399	ENSG00000202515.1	VTRNA1-3	5.2	6.34e-07	0.000487	0.48	0.39	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr5:140726158~140726246:+
PCPG	cis	rs7598759	0.712	rs7607552	ENSG00000181798.2	LINC00471	-5.2	6.35e-07	0.000488	-0.5	-0.39	Noise-induced hearing loss;	chr2:231475312	chr2:231508426~231514339:-
PCPG	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	5.2	6.36e-07	0.000488	0.6	0.39	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	5.2	6.36e-07	0.000488	0.6	0.39	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	5.2	6.36e-07	0.000488	0.6	0.39	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	5.2	6.36e-07	0.000488	0.6	0.39	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	5.2	6.36e-07	0.000488	0.6	0.39	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-5.2	6.36e-07	0.000488	-0.6	-0.39	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
PCPG	cis	rs7250849	0.79	rs73052830	ENSG00000273837.1	LLNLR-470E3.1	-5.2	6.36e-07	0.000488	-0.74	-0.39	Blood protein levels;	chr19:51657512	chr19:51639478~51639931:-
PCPG	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	5.2	6.36e-07	0.000489	0.62	0.39	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
PCPG	cis	rs13108904	0.967	rs62293658	ENSG00000254094.1	AC078852.1	5.2	6.38e-07	0.000489	0.44	0.39	Obesity-related traits;	chr4:1282628	chr4:1356581~1358075:+
PCPG	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-5.2	6.38e-07	0.000489	-0.36	-0.39	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
PCPG	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-5.2	6.38e-07	0.00049	-0.61	-0.39	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-5.2	6.38e-07	0.00049	-0.61	-0.39	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
PCPG	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-5.2	6.39e-07	0.00049	-0.45	-0.39	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
PCPG	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-5.2	6.39e-07	0.00049	-0.49	-0.39	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
PCPG	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	5.2	6.39e-07	0.00049	0.62	0.39	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
PCPG	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-5.2	6.39e-07	0.00049	-0.49	-0.39	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
PCPG	cis	rs3808502	0.549	rs7831039	ENSG00000255020.1	AF131216.5	-5.2	6.41e-07	0.000492	-0.51	-0.39	Neuroticism;	chr8:11570128	chr8:11345748~11347502:-
PCPG	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-5.2	6.42e-07	0.000492	-0.42	-0.39	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
PCPG	cis	rs12681963	0.688	rs7009988	ENSG00000248159.1	HSPA8P11	5.2	6.43e-07	0.000493	0.73	0.39	Migraine;	chr8:30224947	chr8:30237382~30240997:+
PCPG	cis	rs2625529	0.652	rs11072350	ENSG00000260037.4	CTD-2524L6.3	5.2	6.47e-07	0.000495	0.5	0.39	Red blood cell count;	chr15:72172268	chr15:71818396~71823384:+
PCPG	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-5.2	6.47e-07	0.000495	-0.35	-0.39	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
PCPG	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-5.2	6.48e-07	0.000496	-0.57	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
PCPG	cis	rs453301	0.606	rs6601279	ENSG00000173295.6	FAM86B3P	5.2	6.49e-07	0.000497	0.48	0.39	Joint mobility (Beighton score);	chr8:9050721	chr8:8228595~8244865:+
PCPG	cis	rs453301	0.606	rs6981060	ENSG00000173295.6	FAM86B3P	5.2	6.49e-07	0.000497	0.48	0.39	Joint mobility (Beighton score);	chr8:9050725	chr8:8228595~8244865:+
PCPG	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	5.2	6.5e-07	0.000497	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	5.2	6.5e-07	0.000497	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
PCPG	cis	rs12946454	0.668	rs4792867	ENSG00000267288.2	RP13-890H12.2	-5.2	6.51e-07	0.000498	-0.51	-0.39	Systolic blood pressure;	chr17:45172077	chr17:45168800~45171584:-
PCPG	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	5.2	6.52e-07	0.000499	0.58	0.39	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
PCPG	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-5.2	6.53e-07	5e-04	-0.35	-0.39	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
PCPG	cis	rs4814920	0.818	rs6046387	ENSG00000275142.1	RP5-999L4.2	-5.2	6.54e-07	5e-04	-0.62	-0.39	Bipolar disorder (body mass index interaction);	chr20:19869186	chr20:19871891~19872284:+
PCPG	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-5.2	6.55e-07	0.000501	-0.52	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
PCPG	cis	rs853679	0.517	rs9357065	ENSG00000216901.1	AL022393.7	5.2	6.57e-07	0.000502	0.56	0.39	Depression;	chr6:28161802	chr6:28176188~28176674:+
PCPG	cis	rs748404	0.723	rs512431	ENSG00000205771.5	CATSPER2P1	5.2	6.57e-07	0.000503	0.42	0.39	Lung cancer;	chr15:43249741	chr15:43726918~43747094:-
PCPG	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	-5.19	6.58e-07	0.000503	-0.46	-0.39	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
PCPG	cis	rs17826219	0.706	rs8075357	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Body mass index;	chr17:30730179	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs59447372	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs61643715	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Body mass index;	chr17:30730744	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.636	rs8080829	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Body mass index;	chr17:30731712	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8079891	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73267858	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs56018041	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs56095789	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11656844	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11652533	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11652631	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.58e-07	0.000503	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30729469~30731202:+
PCPG	cis	rs4835473	0.6	rs9997101	ENSG00000250345.2	RP11-780M14.1	-5.19	6.59e-07	0.000503	-0.43	-0.39	Immature fraction of reticulocytes;	chr4:143777892	chr4:143760399~143762093:-
PCPG	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-5.19	6.59e-07	0.000503	-0.48	-0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
PCPG	cis	rs453301	0.598	rs2921383	ENSG00000173295.6	FAM86B3P	-5.19	6.59e-07	0.000503	-0.46	-0.39	Joint mobility (Beighton score);	chr8:9034711	chr8:8228595~8244865:+
PCPG	cis	rs11148252	0.595	rs4884522	ENSG00000198384.8	TPTE2P3	-5.19	6.59e-07	0.000504	-0.51	-0.39	Lewy body disease;	chr13:52479633	chr13:52522632~52586906:+
PCPG	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	5.19	6.6e-07	0.000504	0.63	0.39	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
PCPG	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	5.19	6.6e-07	0.000504	0.4	0.39	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
PCPG	cis	rs3806843	0.735	rs778596	ENSG00000202515.1	VTRNA1-3	5.19	6.6e-07	0.000504	0.48	0.39	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.705	rs35614340	ENSG00000202515.1	VTRNA1-3	5.19	6.6e-07	0.000504	0.48	0.39	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr5:140726158~140726246:+
PCPG	cis	rs13113518	0.783	rs34534635	ENSG00000272969.1	RP11-528I4.2	5.19	6.61e-07	0.000505	0.43	0.39	Height;	chr4:55573424	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.783	rs7690837	ENSG00000272969.1	RP11-528I4.2	5.19	6.61e-07	0.000505	0.43	0.39	Height;	chr4:55575856	chr4:55547112~55547889:+
PCPG	cis	rs2625529	0.652	rs9302260	ENSG00000260037.4	CTD-2524L6.3	5.19	6.61e-07	0.000505	0.53	0.39	Red blood cell count;	chr15:71882270	chr15:71818396~71823384:+
PCPG	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-5.19	6.63e-07	0.000506	-0.51	-0.39	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
PCPG	cis	rs7811142	1	rs7783159	ENSG00000078319.8	PMS2P1	-5.19	6.63e-07	0.000506	-0.55	-0.39	Platelet count;	chr7:100419831	chr7:100320992~100341908:-
PCPG	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	5.19	6.64e-07	0.000507	0.69	0.39	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
PCPG	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	5.19	6.64e-07	0.000507	0.57	0.39	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	5.19	6.64e-07	0.000507	0.57	0.39	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
PCPG	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	5.19	6.64e-07	0.000507	0.34	0.39	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
PCPG	cis	rs853679	0.517	rs6932109	ENSG00000216901.1	AL022393.7	-5.19	6.65e-07	0.000507	-0.55	-0.39	Depression;	chr6:28110525	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393891	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28111382	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9468286	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28111650	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.542	rs9393892	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28113616	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380055	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28113851	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368553	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28114487	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368554	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28114933	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713137	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28115743	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9348793	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28116411	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.586	rs6905516	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Parkinson's disease;	chr6:28118700	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.586	rs6905522	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Parkinson's disease;	chr6:28118701	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.586	rs9468290	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Parkinson's disease;	chr6:28119896	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.542	rs6934769	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28123153	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs17711801	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28124529	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs6922063	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28126588	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs2275508	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28126953	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.527	rs9461433	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Parkinson's disease;	chr6:28127394	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9468292	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28127577	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs1947863	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28131566	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713141	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28133900	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380056	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28136698	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9380057	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28136856	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs1947862	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28137418	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs6941992	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28138363	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.516	rs4713142	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Parkinson's disease;	chr6:28138569	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713143	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28138981	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713144	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28139012	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713145	ENSG00000216901.1	AL022393.7	5.19	6.65e-07	0.000507	0.55	0.39	Depression;	chr6:28139049	chr6:28176188~28176674:+
PCPG	cis	rs9309473	0.66	rs56131703	ENSG00000163016.8	ALMS1P	5.19	6.66e-07	0.000508	0.63	0.39	Metabolite levels;	chr2:73620133	chr2:73644919~73685576:+
PCPG	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	5.19	6.66e-07	0.000508	0.54	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
PCPG	cis	rs11992162	0.573	rs13275808	ENSG00000255020.1	AF131216.5	-5.19	6.68e-07	0.000509	-0.52	-0.39	Monocyte count;	chr8:11925306	chr8:11345748~11347502:-
PCPG	cis	rs17826219	0.636	rs7221463	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.68e-07	0.000509	-0.68	-0.39	Body mass index;	chr17:30753533	chr17:30729469~30731202:+
PCPG	cis	rs7181230	0.885	rs8026641	ENSG00000259584.1	RP11-521C20.2	-5.19	6.68e-07	0.000509	-0.5	-0.39	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40075204~40078704:-
PCPG	cis	rs1155848	0.803	rs61966637	ENSG00000227354.5	RBM26-AS1	5.19	6.68e-07	0.000509	0.83	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79327074	chr13:79406309~79424328:+
PCPG	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	5.19	6.7e-07	0.00051	0.36	0.39	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
PCPG	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-5.19	6.72e-07	0.000512	-0.52	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
PCPG	cis	rs13113518	1	rs11133388	ENSG00000272969.1	RP11-528I4.2	-5.19	6.72e-07	0.000512	-0.43	-0.39	Height;	chr4:55477866	chr4:55547112~55547889:+
PCPG	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	5.19	6.73e-07	0.000512	0.47	0.39	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
PCPG	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-5.19	6.74e-07	0.000513	-0.38	-0.39	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
PCPG	cis	rs7017914	0.69	rs2639942	ENSG00000254031.4	RP11-326E22.1	5.19	6.75e-07	0.000514	0.38	0.39	Bone mineral density;	chr8:71000939	chr8:71155457~71204223:+
PCPG	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	5.19	6.75e-07	0.000514	0.6	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
PCPG	cis	rs62246343	0.719	rs62246308	ENSG00000254485.4	RP11-380O24.1	5.19	6.79e-07	0.000517	0.6	0.39	Fibrinogen levels;	chr3:9427603	chr3:9292588~9363303:-
PCPG	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-5.19	6.79e-07	0.000517	-0.63	-0.39	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
PCPG	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-5.19	6.8e-07	0.000517	-0.49	-0.39	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
PCPG	cis	rs453301	0.624	rs6987558	ENSG00000173295.6	FAM86B3P	-5.19	6.82e-07	0.000519	-0.44	-0.39	Joint mobility (Beighton score);	chr8:9005011	chr8:8228595~8244865:+
PCPG	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	5.19	6.83e-07	0.00052	0.4	0.39	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
PCPG	cis	rs7208859	0.623	rs3794796	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.84e-07	0.00052	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30729469~30731202:+
PCPG	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	5.19	6.84e-07	0.00052	0.54	0.39	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
PCPG	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-5.19	6.85e-07	0.00052	-0.48	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
PCPG	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-5.19	6.85e-07	0.000521	-0.48	-0.39	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
PCPG	cis	rs17507216	0.718	rs72753931	ENSG00000228141.5	AC105339.1	-5.19	6.86e-07	0.000521	-0.61	-0.39	Excessive daytime sleepiness;	chr15:82721485	chr15:82710471~82714026:-
PCPG	cis	rs5769707	0.681	rs9616329	ENSG00000235111.1	RP1-29C18.8	-5.19	6.86e-07	0.000522	-0.46	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49612657~49615716:-
PCPG	cis	rs7208859	0.623	rs7208441	ENSG00000263603.1	CTD-2349P21.5	-5.19	6.87e-07	0.000522	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30729469~30731202:+
PCPG	cis	rs7824557	0.707	rs3808519	ENSG00000255020.1	AF131216.5	5.19	6.88e-07	0.000522	0.48	0.39	Retinal vascular caliber;	chr8:11285461	chr8:11345748~11347502:-
PCPG	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-5.18	6.89e-07	0.000523	-0.55	-0.39	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
PCPG	cis	rs2736345	0.89	rs4840565	ENSG00000154316.13	TDH	5.18	6.9e-07	0.000524	0.51	0.39	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:11339637~11368452:+
PCPG	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	5.18	6.9e-07	0.000524	0.37	0.39	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
PCPG	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	5.18	6.9e-07	0.000524	0.58	0.39	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
PCPG	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-5.18	6.91e-07	0.000525	-0.47	-0.39	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-5.18	6.91e-07	0.000525	-0.47	-0.39	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
PCPG	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-5.18	6.91e-07	0.000525	-0.41	-0.39	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
PCPG	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	5.18	6.92e-07	0.000525	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
PCPG	cis	rs2625529	0.617	rs11630170	ENSG00000260037.4	CTD-2524L6.3	5.18	6.92e-07	0.000526	0.49	0.39	Red blood cell count;	chr15:72156110	chr15:71818396~71823384:+
PCPG	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	5.18	6.92e-07	0.000526	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
PCPG	cis	rs62246343	0.719	rs62246301	ENSG00000254485.4	RP11-380O24.1	5.18	6.92e-07	0.000526	0.6	0.39	Fibrinogen levels;	chr3:9409599	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.719	rs62246302	ENSG00000254485.4	RP11-380O24.1	5.18	6.92e-07	0.000526	0.6	0.39	Fibrinogen levels;	chr3:9411761	chr3:9292588~9363303:-
PCPG	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-5.18	6.93e-07	0.000526	-0.44	-0.39	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
PCPG	cis	rs7945705	0.846	rs11042055	ENSG00000254860.4	TMEM9B-AS1	-5.18	6.94e-07	0.000527	-0.41	-0.39	Hemoglobin concentration;	chr11:8735309	chr11:8964675~8977527:+
PCPG	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-5.18	6.94e-07	0.000527	-0.49	-0.39	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
PCPG	cis	rs12681963	1	rs10954872	ENSG00000248159.1	HSPA8P11	-5.18	6.94e-07	0.000527	-0.61	-0.39	Migraine;	chr8:30121096	chr8:30237382~30240997:+
PCPG	cis	rs12681963	1	rs6468131	ENSG00000248159.1	HSPA8P11	-5.18	6.94e-07	0.000527	-0.61	-0.39	Migraine;	chr8:30123504	chr8:30237382~30240997:+
PCPG	cis	rs12681963	1	rs12547941	ENSG00000248159.1	HSPA8P11	5.18	6.94e-07	0.000527	0.61	0.39	Migraine;	chr8:30122816	chr8:30237382~30240997:+
PCPG	cis	rs71386933	0.509	rs34400689	ENSG00000260886.1	TAT-AS1	5.18	6.96e-07	0.000529	0.79	0.39	Post bronchodilator FEV1;	chr16:71969555	chr16:71565789~71578187:+
PCPG	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-5.18	6.97e-07	0.000529	-0.62	-0.39	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
PCPG	cis	rs12681963	0.925	rs11984896	ENSG00000248159.1	HSPA8P11	5.18	6.98e-07	0.000529	0.59	0.39	Migraine;	chr8:30111513	chr8:30237382~30240997:+
PCPG	cis	rs12449000	1	rs12449000	ENSG00000260259.1	RP11-368I7.4	-5.18	6.98e-07	0.00053	-0.49	-0.39	Schizophrenia;	chr16:89806562	chr16:89682620~89686569:-
PCPG	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	5.18	6.99e-07	0.00053	0.71	0.39	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
PCPG	cis	rs561341	0.941	rs7215147	ENSG00000265798.5	RP11-271K11.5	5.18	6.99e-07	0.000531	0.68	0.39	Hip circumference adjusted for BMI;	chr17:31939692	chr17:31038575~31059121:-
PCPG	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-5.18	6.99e-07	0.000531	-0.43	-0.39	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
PCPG	cis	rs7208859	0.524	rs77498725	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs73267865	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs7223803	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.5	rs2449749	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Body mass index;	chr17:30751280	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9894709	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9896603	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7219712	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs8078656	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8080882	ENSG00000263603.1	CTD-2349P21.5	-5.18	7e-07	0.000531	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30729469~30731202:+
PCPG	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	5.18	7.03e-07	0.000533	0.38	0.39	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
PCPG	cis	rs7208859	0.573	rs73267829	ENSG00000263603.1	CTD-2349P21.5	-5.18	7.04e-07	0.000533	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.562	rs11650923	ENSG00000263603.1	CTD-2349P21.5	-5.18	7.04e-07	0.000533	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs56378576	ENSG00000263603.1	CTD-2349P21.5	-5.18	7.04e-07	0.000533	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs35916850	ENSG00000263603.1	CTD-2349P21.5	-5.18	7.04e-07	0.000533	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30729469~30731202:+
PCPG	cis	rs13113518	0.812	rs12649507	ENSG00000272969.1	RP11-528I4.2	-5.18	7.07e-07	0.000535	-0.43	-0.39	Height;	chr4:55514317	chr4:55547112~55547889:+
PCPG	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	5.18	7.08e-07	0.000535	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	5.18	7.08e-07	0.000535	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
PCPG	cis	rs7246657	0.943	rs6508711	ENSG00000226686.6	LINC01535	-5.18	7.1e-07	0.000537	-0.61	-0.39	Coronary artery calcification;	chr19:37324232	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.882	rs6508716	ENSG00000226686.6	LINC01535	-5.18	7.1e-07	0.000537	-0.61	-0.39	Coronary artery calcification;	chr19:37328108	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7257672	ENSG00000226686.6	LINC01535	-5.18	7.1e-07	0.000537	-0.61	-0.39	Coronary artery calcification;	chr19:37332957	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.891	rs7257495	ENSG00000226686.6	LINC01535	-5.18	7.1e-07	0.000537	-0.61	-0.39	Coronary artery calcification;	chr19:37332974	chr19:37251912~37265535:+
PCPG	cis	rs2921036	0.505	rs35190619	ENSG00000253893.2	FAM85B	5.18	7.1e-07	0.000537	0.51	0.39	Neuroticism;	chr8:8504313	chr8:8167819~8226614:-
PCPG	cis	rs453301	0.652	rs2043129	ENSG00000173295.6	FAM86B3P	-5.18	7.1e-07	0.000537	-0.45	-0.39	Joint mobility (Beighton score);	chr8:8967994	chr8:8228595~8244865:+
PCPG	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-5.18	7.12e-07	0.000539	-0.52	-0.39	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-5.18	7.12e-07	0.000539	-0.52	-0.39	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
PCPG	cis	rs7688540	0.76	rs12506250	ENSG00000275426.1	CH17-262A2.1	5.18	7.13e-07	0.000539	0.47	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:149738~150317:+
PCPG	cis	rs7688540	0.76	rs2883229	ENSG00000275426.1	CH17-262A2.1	5.18	7.13e-07	0.000539	0.47	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:149738~150317:+
PCPG	cis	rs7688540	0.76	rs4510422	ENSG00000275426.1	CH17-262A2.1	5.18	7.13e-07	0.000539	0.47	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:149738~150317:+
PCPG	cis	rs12681963	0.764	rs7838088	ENSG00000248159.1	HSPA8P11	-5.18	7.16e-07	0.000541	-0.77	-0.39	Migraine;	chr8:30139308	chr8:30237382~30240997:+
PCPG	cis	rs853679	0.517	rs3757187	ENSG00000216901.1	AL022393.7	5.18	7.18e-07	0.000542	0.55	0.39	Depression;	chr6:28139876	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs3757185	ENSG00000216901.1	AL022393.7	5.18	7.18e-07	0.000542	0.55	0.39	Depression;	chr6:28139998	chr6:28176188~28176674:+
PCPG	cis	rs9595908	0.785	rs9315174	ENSG00000212293.1	SNORA16	5.18	7.19e-07	0.000543	0.47	0.39	Body mass index;	chr13:32645750	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.758	rs7329120	ENSG00000212293.1	SNORA16	5.18	7.19e-07	0.000543	0.47	0.39	Body mass index;	chr13:32646605	chr13:32420390~32420516:-
PCPG	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-5.18	7.19e-07	0.000543	-0.35	-0.39	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
PCPG	cis	rs13113518	0.812	rs13107810	ENSG00000272969.1	RP11-528I4.2	5.18	7.2e-07	0.000544	0.43	0.39	Height;	chr4:55542243	chr4:55547112~55547889:+
PCPG	cis	rs4713118	0.516	rs7739216	ENSG00000216901.1	AL022393.7	5.17	7.21e-07	0.000544	0.55	0.39	Parkinson's disease;	chr6:28112168	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs35512245	ENSG00000216901.1	AL022393.7	5.17	7.21e-07	0.000544	0.55	0.39	Depression;	chr6:28112175	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.513	rs9468296	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28145952	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4711164	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28147378	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4711165	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28147406	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713148	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28148143	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9348794	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28149979	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9468297	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28151096	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9295758	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28152885	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs17774663	ENSG00000216901.1	AL022393.7	5.17	7.23e-07	0.000546	0.56	0.39	Depression;	chr6:28153120	chr6:28176188~28176674:+
PCPG	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	5.17	7.24e-07	0.000546	0.58	0.39	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
PCPG	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	5.17	7.25e-07	0.000547	0.64	0.39	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	5.17	7.25e-07	0.000547	0.64	0.39	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	5.17	7.25e-07	0.000547	0.64	0.39	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	5.17	7.25e-07	0.000547	0.64	0.39	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
PCPG	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	5.17	7.25e-07	0.000547	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
PCPG	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-5.17	7.25e-07	0.000547	-0.38	-0.39	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
PCPG	cis	rs300890	0.536	rs300938	ENSG00000250326.1	RP11-284M14.1	-5.17	7.27e-07	0.000549	-0.36	-0.39	Nasopharyngeal carcinoma;	chr4:143251638	chr4:142933195~143184861:-
PCPG	cis	rs3002142	0.658	rs2291833	ENSG00000272750.1	RP11-378J18.8	-5.17	7.28e-07	0.000549	-0.58	-0.39	LDL peak particle diameter (total fat intake interaction);	chr1:222653505	chr1:222658867~222661512:-
PCPG	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-5.17	7.28e-07	0.000549	-0.52	-0.39	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
PCPG	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-5.17	7.29e-07	0.000549	-0.5	-0.39	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
PCPG	cis	rs3806843	0.735	rs809635	ENSG00000202515.1	VTRNA1-3	5.17	7.29e-07	0.00055	0.48	0.39	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.648	rs2530233	ENSG00000202515.1	VTRNA1-3	5.17	7.29e-07	0.00055	0.48	0.39	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr5:140726158~140726246:+
PCPG	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	5.17	7.3e-07	0.00055	0.37	0.39	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
PCPG	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	5.17	7.31e-07	0.00055	0.6	0.39	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	5.17	7.31e-07	0.00055	0.6	0.39	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	5.17	7.31e-07	0.00055	0.6	0.39	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	5.17	7.31e-07	0.00055	0.6	0.39	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
PCPG	cis	rs9392556	0.6	rs611500	ENSG00000230648.1	RP3-406P24.3	5.17	7.31e-07	0.000551	0.47	0.39	Blood metabolite levels;	chr6:4126529	chr6:4018843~4021215:-
PCPG	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	5.17	7.32e-07	0.000551	0.39	0.39	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
PCPG	cis	rs7208859	0.623	rs55814012	ENSG00000263603.1	CTD-2349P21.5	-5.17	7.32e-07	0.000552	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30729469~30731202:+
PCPG	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	5.17	7.33e-07	0.000552	0.6	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
PCPG	cis	rs7824557	0.564	rs35009431	ENSG00000255020.1	AF131216.5	-5.17	7.33e-07	0.000552	-0.52	-0.39	Retinal vascular caliber;	chr8:11375279	chr8:11345748~11347502:-
PCPG	cis	rs34381861	0.52	rs74382390	ENSG00000260886.1	TAT-AS1	5.17	7.35e-07	0.000554	0.68	0.39	Post bronchodilator FEV1;	chr16:71424623	chr16:71565789~71578187:+
PCPG	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	5.17	7.36e-07	0.000554	0.6	0.39	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	5.17	7.36e-07	0.000554	0.6	0.39	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
PCPG	cis	rs7017914	0.69	rs4623462	ENSG00000254031.4	RP11-326E22.1	-5.17	7.36e-07	0.000554	-0.37	-0.39	Bone mineral density;	chr8:71034149	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.714	rs3110264	ENSG00000254031.4	RP11-326E22.1	5.17	7.36e-07	0.000554	0.37	0.39	Bone mineral density;	chr8:71032045	chr8:71155457~71204223:+
PCPG	cis	rs7246657	1	rs6508710	ENSG00000226686.6	LINC01535	-5.17	7.4e-07	0.000557	-0.61	-0.39	Coronary artery calcification;	chr19:37258984	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7259968	ENSG00000226686.6	LINC01535	-5.17	7.4e-07	0.000557	-0.61	-0.39	Coronary artery calcification;	chr19:37320952	chr19:37251912~37265535:+
PCPG	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	5.17	7.41e-07	0.000557	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	5.17	7.41e-07	0.000557	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	5.17	7.41e-07	0.000557	0.52	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
PCPG	cis	rs9595908	0.869	rs9595948	ENSG00000212293.1	SNORA16	5.17	7.42e-07	0.000558	0.47	0.39	Body mass index;	chr13:32629519	chr13:32420390~32420516:-
PCPG	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-5.17	7.42e-07	0.000558	-0.47	-0.39	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
PCPG	cis	rs9595908	0.869	rs9595962	ENSG00000212293.1	SNORA16	5.17	7.44e-07	0.000559	0.47	0.39	Body mass index;	chr13:32634429	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.869	rs2320301	ENSG00000212293.1	SNORA16	5.17	7.44e-07	0.000559	0.47	0.39	Body mass index;	chr13:32635067	chr13:32420390~32420516:-
PCPG	cis	rs73607972	0.518	rs8060020	ENSG00000275191.1	RP11-36I17.2	-5.17	7.44e-07	0.00056	-0.54	-0.39	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554152	chr16:53628256~53628816:-
PCPG	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	5.17	7.45e-07	0.00056	0.48	0.39	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
PCPG	cis	rs2302464	1	rs57326588	ENSG00000214846.4	RP11-115L11.1	5.17	7.45e-07	0.00056	0.9	0.39	Cerebrospinal fluid biomarker levels;	chr4:15723813	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs11944132	ENSG00000214846.4	RP11-115L11.1	5.17	7.45e-07	0.00056	0.9	0.39	Cerebrospinal fluid biomarker levels;	chr4:15724291	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs73123607	ENSG00000214846.4	RP11-115L11.1	5.17	7.45e-07	0.00056	0.9	0.39	Cerebrospinal fluid biomarker levels;	chr4:15725058	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs6844968	ENSG00000214846.4	RP11-115L11.1	5.17	7.45e-07	0.00056	0.9	0.39	Cerebrospinal fluid biomarker levels;	chr4:15725641	chr4:15730962~15731627:-
PCPG	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-5.17	7.45e-07	0.00056	-0.39	-0.39	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
PCPG	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	5.17	7.45e-07	0.00056	0.4	0.39	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
PCPG	cis	rs7267979	0.744	rs6050464	ENSG00000125804.12	FAM182A	-5.17	7.45e-07	0.00056	-0.44	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:26054655~26086917:+
PCPG	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	5.17	7.47e-07	0.000562	0.43	0.39	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	5.17	7.47e-07	0.000562	0.43	0.39	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	5.17	7.47e-07	0.000562	0.43	0.39	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
PCPG	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	5.17	7.49e-07	0.000562	0.36	0.39	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
PCPG	cis	rs3806843	1	rs4404730	ENSG00000202515.1	VTRNA1-3	-5.17	7.49e-07	0.000563	-0.5	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr5:140726158~140726246:+
PCPG	cis	rs2625529	0.652	rs2957740	ENSG00000260037.4	CTD-2524L6.3	5.17	7.49e-07	0.000563	0.51	0.39	Red blood cell count;	chr15:72015350	chr15:71818396~71823384:+
PCPG	cis	rs7181230	0.885	rs4497657	ENSG00000259584.1	RP11-521C20.2	5.17	7.5e-07	0.000563	0.51	0.39	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40075204~40078704:-
PCPG	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-5.17	7.5e-07	0.000563	-0.49	-0.39	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
PCPG	cis	rs12908161	0.92	rs35738019	ENSG00000259295.5	CSPG4P12	5.17	7.53e-07	0.000565	0.58	0.39	Schizophrenia;	chr15:84736979	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs34570071	ENSG00000259295.5	CSPG4P12	5.17	7.53e-07	0.000565	0.58	0.39	Schizophrenia;	chr15:84736981	chr15:85191438~85213905:+
PCPG	cis	rs300890	0.513	rs72719159	ENSG00000250326.1	RP11-284M14.1	-5.16	7.54e-07	0.000566	-0.37	-0.39	Nasopharyngeal carcinoma;	chr4:143129943	chr4:142933195~143184861:-
PCPG	cis	rs9595908	0.785	rs9591261	ENSG00000212293.1	SNORA16	5.16	7.55e-07	0.000566	0.47	0.39	Body mass index;	chr13:32710989	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596109	ENSG00000212293.1	SNORA16	5.16	7.55e-07	0.000566	0.47	0.39	Body mass index;	chr13:32712611	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.536	rs73452706	ENSG00000212293.1	SNORA16	5.16	7.55e-07	0.000566	0.47	0.39	Body mass index;	chr13:32718155	chr13:32420390~32420516:-
PCPG	cis	rs300890	0.662	rs300899	ENSG00000250326.1	RP11-284M14.1	5.16	7.55e-07	0.000566	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143323563	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.689	rs624170	ENSG00000250326.1	RP11-284M14.1	5.16	7.55e-07	0.000566	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143324205	chr4:142933195~143184861:-
PCPG	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-5.16	7.56e-07	0.000567	-0.51	-0.39	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-5.16	7.56e-07	0.000567	-0.51	-0.39	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-5.16	7.56e-07	0.000567	-0.51	-0.39	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-5.16	7.56e-07	0.000567	-0.51	-0.39	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
PCPG	cis	rs7819412	0.775	rs4840551	ENSG00000255020.1	AF131216.5	-5.16	7.56e-07	0.000567	-0.53	-0.39	Triglycerides;	chr8:11171530	chr8:11345748~11347502:-
PCPG	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	5.16	7.58e-07	0.000568	0.52	0.39	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	5.16	7.58e-07	0.000568	0.52	0.39	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
PCPG	cis	rs3806843	0.933	rs10069930	ENSG00000202515.1	VTRNA1-3	-5.16	7.6e-07	0.000569	-0.5	-0.39	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr5:140726158~140726246:+
PCPG	cis	rs13113518	1	rs2279458	ENSG00000272969.1	RP11-528I4.2	5.16	7.62e-07	0.000571	0.42	0.39	Height;	chr4:55562653	chr4:55547112~55547889:+
PCPG	cis	rs17772222	0.92	rs61975260	ENSG00000258983.2	RP11-507K2.2	5.16	7.62e-07	0.000571	0.55	0.39	Coronary artery calcification;	chr14:88429597	chr14:88499334~88515502:+
PCPG	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-5.16	7.63e-07	0.000571	-0.5	-0.39	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
PCPG	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	5.16	7.63e-07	0.000572	0.37	0.39	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
PCPG	cis	rs6121246	0.529	rs6060296	ENSG00000230613.1	HM13-AS1	5.16	7.66e-07	0.000574	0.61	0.39	Mean corpuscular hemoglobin;	chr20:31610677	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs7361893	ENSG00000230613.1	HM13-AS1	5.16	7.66e-07	0.000574	0.61	0.39	Mean corpuscular hemoglobin;	chr20:31612948	chr20:31567707~31573263:-
PCPG	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-5.16	7.67e-07	0.000574	-0.47	-0.39	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
PCPG	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-5.16	7.68e-07	0.000575	-0.42	-0.39	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
PCPG	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	5.16	7.68e-07	0.000575	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	5.16	7.68e-07	0.000575	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6465675	ENSG00000272950.1	RP11-307C18.1	-5.16	7.68e-07	0.000575	-0.5	-0.39	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr7:98322853~98323430:+
PCPG	cis	rs7017914	0.967	rs2732087	ENSG00000254031.4	RP11-326E22.1	5.16	7.69e-07	0.000576	0.38	0.39	Bone mineral density;	chr8:70948204	chr8:71155457~71204223:+
PCPG	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	5.16	7.7e-07	0.000576	0.54	0.39	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
PCPG	cis	rs853679	1	rs13200462	ENSG00000219392.1	RP1-265C24.5	-5.16	7.72e-07	0.000577	-0.63	-0.39	Depression;	chr6:28250421	chr6:28115628~28116551:+
PCPG	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	5.16	7.72e-07	0.000577	0.61	0.39	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
PCPG	cis	rs7208859	0.623	rs34756112	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs60724269	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs76633166	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs1061346	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs1061343	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs55938328	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73269988	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs55961983	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs7222803	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9899525	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.568	rs7213925	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Body mass index;	chr17:30794616	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.524	rs11653098	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11658945	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11657990	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9911784	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9911997	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9890862	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs78071511	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11650982	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs2035494	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9915546	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9915566	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs28469200	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Body mass index;	chr17:30806554	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs8064686	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs11654035	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11657369	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8075341	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73271842	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9895815	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs7214313	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs8077116	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.524	rs28760584	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs73271850	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Body mass index;	chr17:30815122	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.636	rs79565452	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Body mass index;	chr17:30815823	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7208088	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7212991	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs28627615	ENSG00000263603.1	CTD-2349P21.5	-5.16	7.72e-07	0.000577	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	5.16	7.73e-07	0.000578	0.65	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
PCPG	cis	rs300890	0.513	rs72719160	ENSG00000250326.1	RP11-284M14.1	-5.16	7.74e-07	0.000578	-0.37	-0.39	Nasopharyngeal carcinoma;	chr4:143130123	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs72719163	ENSG00000250326.1	RP11-284M14.1	-5.16	7.74e-07	0.000578	-0.37	-0.39	Nasopharyngeal carcinoma;	chr4:143130799	chr4:142933195~143184861:-
PCPG	cis	rs3764021	0.933	rs2268146	ENSG00000278635.1	CTD-2318O12.1	-5.16	7.75e-07	0.000579	-0.47	-0.39	Type 1 diabetes;	chr12:9716675	chr12:9415641~9416718:+
PCPG	cis	rs300890	0.513	rs300934	ENSG00000250326.1	RP11-284M14.1	-5.16	7.75e-07	0.000579	-0.36	-0.39	Nasopharyngeal carcinoma;	chr4:143250595	chr4:142933195~143184861:-
PCPG	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	5.16	7.75e-07	0.000579	0.47	0.39	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
PCPG	cis	rs300890	0.662	rs300903	ENSG00000250326.1	RP11-284M14.1	5.16	7.76e-07	0.000579	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143318649	chr4:142933195~143184861:-
PCPG	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	5.16	7.76e-07	0.000579	0.57	0.39	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
PCPG	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	5.16	7.77e-07	0.00058	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
PCPG	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	5.16	7.78e-07	0.000581	0.42	0.39	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
PCPG	cis	rs9392556	0.6	rs661404	ENSG00000230648.1	RP3-406P24.3	5.16	7.78e-07	0.000581	0.47	0.39	Blood metabolite levels;	chr6:4125863	chr6:4018843~4021215:-
PCPG	cis	rs12681963	0.764	rs11778927	ENSG00000248159.1	HSPA8P11	-5.16	7.81e-07	0.000583	-0.79	-0.39	Migraine;	chr8:30139055	chr8:30237382~30240997:+
PCPG	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	5.16	7.83e-07	0.000584	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	5.16	7.83e-07	0.000584	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	5.16	7.83e-07	0.000584	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	5.16	7.83e-07	0.000584	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	5.16	7.83e-07	0.000584	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	5.16	7.83e-07	0.000584	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	5.16	7.83e-07	0.000584	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
PCPG	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	5.16	7.83e-07	0.000584	0.38	0.39	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
PCPG	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-5.16	7.84e-07	0.000585	-0.39	-0.39	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
PCPG	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	5.16	7.85e-07	0.000585	0.43	0.39	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
PCPG	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	5.16	7.85e-07	0.000585	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
PCPG	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	5.16	7.85e-07	0.000585	0.44	0.39	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	5.16	7.85e-07	0.000585	0.44	0.39	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
PCPG	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	5.16	7.86e-07	0.000586	0.52	0.39	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	5.16	7.86e-07	0.000586	0.52	0.39	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	5.16	7.86e-07	0.000586	0.52	0.39	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	5.16	7.86e-07	0.000586	0.52	0.39	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	5.16	7.86e-07	0.000586	0.52	0.39	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	5.16	7.86e-07	0.000586	0.52	0.39	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	5.16	7.86e-07	0.000586	0.52	0.39	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
PCPG	cis	rs12946454	0.521	rs66827053	ENSG00000267288.2	RP13-890H12.2	-5.15	7.91e-07	0.000589	-0.51	-0.39	Systolic blood pressure;	chr17:45173286	chr17:45168800~45171584:-
PCPG	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-5.15	7.93e-07	0.00059	-0.63	-0.39	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
PCPG	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	5.15	7.97e-07	0.000592	0.6	0.39	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
PCPG	cis	rs11148252	0.904	rs7321964	ENSG00000198384.8	TPTE2P3	-5.15	7.98e-07	0.000593	-0.48	-0.39	Lewy body disease;	chr13:52466687	chr13:52522632~52586906:+
PCPG	cis	rs13108904	0.901	rs7673398	ENSG00000254094.1	AC078852.1	-5.15	7.98e-07	0.000593	-0.44	-0.39	Obesity-related traits;	chr4:1306289	chr4:1356581~1358075:+
PCPG	cis	rs7829975	0.714	rs4841040	ENSG00000173295.6	FAM86B3P	-5.15	7.99e-07	0.000594	-0.45	-0.39	Mood instability;	chr8:8797017	chr8:8228595~8244865:+
PCPG	cis	rs17507216	0.718	rs4779033	ENSG00000228141.5	AC105339.1	5.15	8.01e-07	0.000595	0.6	0.39	Excessive daytime sleepiness;	chr15:82576634	chr15:82710471~82714026:-
PCPG	cis	rs62246343	0.719	rs56782786	ENSG00000254485.4	RP11-380O24.1	5.15	8.01e-07	0.000595	0.59	0.39	Fibrinogen levels;	chr3:9425388	chr3:9292588~9363303:-
PCPG	cis	rs17826219	0.568	rs59858012	ENSG00000263603.1	CTD-2349P21.5	-5.15	8.01e-07	0.000595	-0.71	-0.39	Body mass index;	chr17:30751564	chr17:30729469~30731202:+
PCPG	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	5.15	8.03e-07	0.000597	0.49	0.39	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
PCPG	cis	rs9595908	0.686	rs1015364	ENSG00000212293.1	SNORA16	5.15	8.03e-07	0.000597	0.47	0.39	Body mass index;	chr13:32784455	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.709	rs7983889	ENSG00000212293.1	SNORA16	5.15	8.03e-07	0.000597	0.47	0.39	Body mass index;	chr13:32785441	chr13:32420390~32420516:-
PCPG	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-5.15	8.04e-07	0.000597	-0.44	-0.39	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-5.15	8.04e-07	0.000597	-0.44	-0.39	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-5.15	8.04e-07	0.000597	-0.44	-0.39	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
PCPG	cis	rs3808502	0.563	rs10098664	ENSG00000255020.1	AF131216.5	5.15	8.06e-07	0.000598	0.49	0.39	Neuroticism;	chr8:11559984	chr8:11345748~11347502:-
PCPG	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-5.15	8.06e-07	0.000599	-0.46	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
PCPG	cis	rs7945705	0.846	rs905290	ENSG00000254860.4	TMEM9B-AS1	-5.15	8.06e-07	0.000599	-0.41	-0.39	Hemoglobin concentration;	chr11:8732182	chr11:8964675~8977527:+
PCPG	cis	rs453301	0.682	rs2929308	ENSG00000173295.6	FAM86B3P	5.15	8.06e-07	0.000599	0.45	0.39	Joint mobility (Beighton score);	chr8:9226611	chr8:8228595~8244865:+
PCPG	cis	rs7208859	0.573	rs55661352	ENSG00000263603.1	CTD-2349P21.5	-5.15	8.09e-07	6e-04	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30729469~30731202:+
PCPG	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-5.15	8.1e-07	0.000601	-0.37	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
PCPG	cis	rs13108904	0.521	rs4974609	ENSG00000254094.1	AC078852.1	5.15	8.1e-07	0.000601	0.44	0.39	Obesity-related traits;	chr4:1363136	chr4:1356581~1358075:+
PCPG	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	5.15	8.12e-07	0.000602	0.35	0.39	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	5.15	8.16e-07	0.000605	0.47	0.39	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
PCPG	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
PCPG	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
PCPG	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
PCPG	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	5.15	8.16e-07	0.000605	0.54	0.39	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
PCPG	cis	rs7759001	0.744	rs7774613	ENSG00000271755.1	RP1-153G14.4	5.15	8.18e-07	0.000606	0.56	0.39	Glomerular filtration rate (creatinine);	chr6:27518854	chr6:27404010~27406964:-
PCPG	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-5.15	8.18e-07	0.000606	-0.49	-0.39	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-5.15	8.18e-07	0.000606	-0.49	-0.39	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-5.15	8.18e-07	0.000606	-0.49	-0.39	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-5.15	8.18e-07	0.000606	-0.49	-0.39	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-5.15	8.18e-07	0.000606	-0.49	-0.39	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
PCPG	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	5.15	8.19e-07	0.000607	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
PCPG	cis	rs7246657	0.943	rs34603719	ENSG00000226686.6	LINC01535	-5.15	8.19e-07	0.000607	-0.63	-0.39	Coronary artery calcification;	chr19:37303626	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.941	rs67293224	ENSG00000226686.6	LINC01535	-5.15	8.19e-07	0.000607	-0.63	-0.39	Coronary artery calcification;	chr19:37312346	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-5.15	8.19e-07	0.000607	-0.63	-0.39	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-5.15	8.19e-07	0.000607	-0.63	-0.39	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
PCPG	cis	rs2736345	0.747	rs1478901	ENSG00000255020.1	AF131216.5	5.15	8.19e-07	0.000607	0.55	0.39	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11490324	chr8:11345748~11347502:-
PCPG	cis	rs2736345	0.788	rs9693589	ENSG00000255020.1	AF131216.5	5.15	8.19e-07	0.000607	0.55	0.39	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491452	chr8:11345748~11347502:-
PCPG	cis	rs2736345	0.788	rs13277113	ENSG00000255020.1	AF131216.5	5.15	8.19e-07	0.000607	0.55	0.39	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491677	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.934	rs68126063	ENSG00000259905.4	PWRN1	5.15	8.2e-07	0.000607	0.44	0.39	Platelet thrombus formation;	chr15:24541113	chr15:24493137~24652130:+
PCPG	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-5.15	8.2e-07	0.000607	-0.4	-0.39	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
PCPG	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	5.15	8.2e-07	0.000607	0.44	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
PCPG	cis	rs17826219	0.636	rs4055314	ENSG00000263603.1	CTD-2349P21.5	-5.15	8.23e-07	0.000609	-0.67	-0.39	Body mass index;	chr17:30752751	chr17:30729469~30731202:+
PCPG	cis	rs910316	0.967	rs2268619	ENSG00000279594.1	RP11-950C14.10	-5.14	8.26e-07	0.000612	-0.52	-0.39	Height;	chr14:75173651	chr14:75011269~75012851:-
PCPG	cis	rs9595908	0.869	rs9595946	ENSG00000212293.1	SNORA16	5.14	8.27e-07	0.000612	0.47	0.39	Body mass index;	chr13:32628998	chr13:32420390~32420516:-
PCPG	cis	rs13108904	0.901	rs7668661	ENSG00000254094.1	AC078852.1	-5.14	8.29e-07	0.000613	-0.44	-0.39	Obesity-related traits;	chr4:1306384	chr4:1356581~1358075:+
PCPG	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	5.14	8.29e-07	0.000613	0.47	0.39	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
PCPG	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-5.14	8.29e-07	0.000614	-0.53	-0.39	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
PCPG	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	5.14	8.3e-07	0.000614	0.47	0.39	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
PCPG	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-5.14	8.3e-07	0.000614	-0.57	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
PCPG	cis	rs7246657	0.943	rs7253091	ENSG00000226686.6	LINC01535	-5.14	8.33e-07	0.000616	-0.59	-0.39	Coronary artery calcification;	chr19:37476312	chr19:37251912~37265535:+
PCPG	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	5.14	8.33e-07	0.000616	0.61	0.39	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
PCPG	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-5.14	8.33e-07	0.000616	-0.49	-0.39	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
PCPG	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	5.14	8.34e-07	0.000617	0.9	0.39	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
PCPG	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-5.14	8.34e-07	0.000617	-0.49	-0.39	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
PCPG	cis	rs2898290	0.622	rs4840567	ENSG00000255020.1	AF131216.5	-5.14	8.35e-07	0.000618	-0.48	-0.39	Systolic blood pressure;	chr8:11490116	chr8:11345748~11347502:-
PCPG	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	5.14	8.37e-07	0.000619	0.52	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
PCPG	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-5.14	8.39e-07	0.00062	-0.61	-0.39	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
PCPG	cis	rs17507216	0.718	rs17158403	ENSG00000228141.5	AC105339.1	-5.14	8.39e-07	0.00062	-0.61	-0.39	Excessive daytime sleepiness;	chr15:82572478	chr15:82710471~82714026:-
PCPG	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	5.14	8.39e-07	0.00062	0.47	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
PCPG	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-5.14	8.4e-07	0.000621	-0.36	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
PCPG	cis	rs2531992	0.8	rs2601782	ENSG00000262888.1	RP11-462G12.2	-5.14	8.42e-07	0.000622	-0.65	-0.39	Waist circumference;	chr16:3971050	chr16:3931217~3946305:-
PCPG	cis	rs12681963	0.764	rs7824731	ENSG00000248159.1	HSPA8P11	-5.14	8.43e-07	0.000622	-0.78	-0.39	Migraine;	chr8:30139509	chr8:30237382~30240997:+
PCPG	cis	rs7824557	0.751	rs2099456	ENSG00000255020.1	AF131216.5	5.14	8.43e-07	0.000622	0.48	0.39	Retinal vascular caliber;	chr8:11269492	chr8:11345748~11347502:-
PCPG	cis	rs9595908	0.758	rs2031354	ENSG00000212293.1	SNORA16	5.14	8.43e-07	0.000622	0.46	0.39	Body mass index;	chr13:32641454	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7332884	ENSG00000212293.1	SNORA16	5.14	8.43e-07	0.000622	0.46	0.39	Body mass index;	chr13:32642412	chr13:32420390~32420516:-
PCPG	cis	rs2898290	0.622	rs978803	ENSG00000255020.1	AF131216.5	5.14	8.46e-07	0.000624	0.48	0.39	Systolic blood pressure;	chr8:11485966	chr8:11345748~11347502:-
PCPG	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	5.14	8.47e-07	0.000625	0.43	0.39	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
PCPG	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-5.14	8.48e-07	0.000626	-0.39	-0.39	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
PCPG	cis	rs300890	0.513	rs1440419	ENSG00000250326.1	RP11-284M14.1	5.14	8.49e-07	0.000626	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143242187	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs11732484	ENSG00000250326.1	RP11-284M14.1	5.14	8.49e-07	0.000626	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143242330	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs587254	ENSG00000250326.1	RP11-284M14.1	5.14	8.49e-07	0.000626	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143245068	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs534750	ENSG00000250326.1	RP11-284M14.1	5.14	8.49e-07	0.000626	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143245103	chr4:142933195~143184861:-
PCPG	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	5.14	8.5e-07	0.000627	0.47	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	5.14	8.5e-07	0.000627	0.47	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
PCPG	cis	rs13108904	0.901	rs2293634	ENSG00000254094.1	AC078852.1	-5.14	8.51e-07	0.000628	-0.44	-0.39	Obesity-related traits;	chr4:1297923	chr4:1356581~1358075:+
PCPG	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	5.14	8.54e-07	0.000629	0.55	0.39	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
PCPG	cis	rs62246343	0.719	rs62246303	ENSG00000254485.4	RP11-380O24.1	5.14	8.54e-07	0.000629	0.59	0.39	Fibrinogen levels;	chr3:9413078	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.719	rs6767213	ENSG00000254485.4	RP11-380O24.1	5.14	8.54e-07	0.000629	0.59	0.39	Fibrinogen levels;	chr3:9415588	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.719	rs62246305	ENSG00000254485.4	RP11-380O24.1	5.14	8.54e-07	0.000629	0.59	0.39	Fibrinogen levels;	chr3:9416565	chr3:9292588~9363303:-
PCPG	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-5.14	8.55e-07	0.00063	-0.39	-0.39	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
PCPG	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	5.14	8.55e-07	0.00063	0.39	0.39	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
PCPG	cis	rs11148252	0.74	rs9536046	ENSG00000235660.1	LINC00345	-5.14	8.6e-07	0.000633	-0.5	-0.39	Lewy body disease;	chr13:52381764	chr13:52484161~52484680:-
PCPG	cis	rs7208859	0.623	rs1061342	ENSG00000263603.1	CTD-2349P21.5	-5.14	8.63e-07	0.000635	-0.67	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30729469~30731202:+
PCPG	cis	rs7811142	1	rs73161762	ENSG00000078319.8	PMS2P1	-5.13	8.67e-07	0.000637	-0.54	-0.39	Platelet count;	chr7:100417223	chr7:100320992~100341908:-
PCPG	cis	rs9595908	0.785	rs9315173	ENSG00000212293.1	SNORA16	5.13	8.68e-07	0.000638	0.47	0.39	Body mass index;	chr13:32645674	chr13:32420390~32420516:-
PCPG	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-5.13	8.69e-07	0.000639	-0.49	-0.39	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
PCPG	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-5.13	8.69e-07	0.000639	-0.49	-0.39	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
PCPG	cis	rs7246657	0.882	rs13345148	ENSG00000226686.6	LINC01535	-5.13	8.69e-07	0.000639	-0.61	-0.39	Coronary artery calcification;	chr19:37328729	chr19:37251912~37265535:+
PCPG	cis	rs9595908	0.9	rs61947058	ENSG00000212293.1	SNORA16	5.13	8.7e-07	0.000639	0.47	0.39	Body mass index;	chr13:32617419	chr13:32420390~32420516:-
PCPG	cis	rs7208859	0.623	rs60890550	ENSG00000263603.1	CTD-2349P21.5	-5.13	8.7e-07	0.000639	-0.66	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11653955	ENSG00000263603.1	CTD-2349P21.5	-5.13	8.7e-07	0.000639	-0.66	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30729469~30731202:+
PCPG	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-5.13	8.7e-07	0.000639	-0.48	-0.39	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
PCPG	cis	rs7246657	1	rs12709812	ENSG00000226686.6	LINC01535	5.13	8.72e-07	0.000641	0.62	0.39	Coronary artery calcification;	chr19:37303948	chr19:37251912~37265535:+
PCPG	cis	rs9392556	0.6	rs2326408	ENSG00000230648.1	RP3-406P24.3	5.13	8.74e-07	0.000642	0.47	0.39	Blood metabolite levels;	chr6:4119282	chr6:4018843~4021215:-
PCPG	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	5.13	8.75e-07	0.000642	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
PCPG	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	5.13	8.75e-07	0.000642	0.46	0.39	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	5.13	8.75e-07	0.000642	0.46	0.39	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
PCPG	cis	rs13113518	0.902	rs12505266	ENSG00000272969.1	RP11-528I4.2	5.13	8.75e-07	0.000642	0.43	0.39	Height;	chr4:55546002	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs56154935	ENSG00000272969.1	RP11-528I4.2	5.13	8.75e-07	0.000642	0.43	0.39	Height;	chr4:55546378	chr4:55547112~55547889:+
PCPG	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	5.13	8.75e-07	0.000643	0.44	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
PCPG	cis	rs3736858	1	rs60560195	ENSG00000261105.4	LMO7-AS1	-5.13	8.77e-07	0.000644	-0.74	-0.39	Interleukin-9 levels;	chr13:75853715	chr13:75604700~75635994:-
PCPG	cis	rs2898290	0.622	rs7829381	ENSG00000255020.1	AF131216.5	-5.13	8.77e-07	0.000644	-0.51	-0.39	Systolic blood pressure;	chr8:11487064	chr8:11345748~11347502:-
PCPG	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	5.13	8.78e-07	0.000645	0.56	0.39	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
PCPG	cis	rs11992162	0.551	rs35010200	ENSG00000255020.1	AF131216.5	-5.13	8.78e-07	0.000645	-0.52	-0.39	Monocyte count;	chr8:11928146	chr8:11345748~11347502:-
PCPG	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	5.13	8.78e-07	0.000645	0.34	0.39	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	5.13	8.78e-07	0.000645	0.34	0.39	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	5.13	8.78e-07	0.000645	0.34	0.39	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-5.13	8.78e-07	0.000645	-0.34	-0.39	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-5.13	8.78e-07	0.000645	-0.34	-0.39	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-5.13	8.78e-07	0.000645	-0.34	-0.39	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
PCPG	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-5.13	8.79e-07	0.000645	-0.44	-0.39	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
PCPG	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	5.13	8.8e-07	0.000646	0.45	0.39	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
PCPG	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-5.13	8.82e-07	0.000647	-0.6	-0.39	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
PCPG	cis	rs7945705	0.875	rs4929914	ENSG00000254860.4	TMEM9B-AS1	5.13	8.83e-07	0.000648	0.4	0.39	Hemoglobin concentration;	chr11:8802841	chr11:8964675~8977527:+
PCPG	cis	rs11858159	1	rs7402670	ENSG00000259905.4	PWRN1	5.13	8.83e-07	0.000648	0.44	0.39	Platelet thrombus formation;	chr15:24561224	chr15:24493137~24652130:+
PCPG	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs9917081	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37385714	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-5.13	8.83e-07	0.000648	-0.63	-0.39	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
PCPG	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-5.13	8.84e-07	0.000648	-0.46	-0.39	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
PCPG	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-5.13	8.86e-07	0.000649	-0.53	-0.39	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
PCPG	cis	rs11148252	0.711	rs61957304	ENSG00000198384.8	TPTE2P3	-5.13	8.86e-07	0.00065	-0.46	-0.39	Lewy body disease;	chr13:52224288	chr13:52522632~52586906:+
PCPG	cis	rs300890	0.513	rs1440418	ENSG00000250326.1	RP11-284M14.1	5.13	8.89e-07	0.000651	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143241790	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs11100784	ENSG00000250326.1	RP11-284M14.1	5.13	8.89e-07	0.000651	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143242199	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs6848475	ENSG00000250326.1	RP11-284M14.1	5.13	8.89e-07	0.000651	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143242889	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.536	rs632359	ENSG00000250326.1	RP11-284M14.1	5.13	8.89e-07	0.000651	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143246830	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs10002888	ENSG00000250326.1	RP11-284M14.1	5.13	8.89e-07	0.000651	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143248559	chr4:142933195~143184861:-
PCPG	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-5.13	8.9e-07	0.000652	-0.5	-0.39	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
PCPG	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-5.13	8.9e-07	0.000652	-0.45	-0.39	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
PCPG	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	5.13	8.92e-07	0.000653	0.47	0.39	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
PCPG	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	5.13	8.94e-07	0.000655	0.5	0.39	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
PCPG	cis	rs2736340	0.539	rs11250138	ENSG00000255020.1	AF131216.5	-5.13	8.94e-07	0.000655	-0.53	-0.39	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465803	chr8:11345748~11347502:-
PCPG	cis	rs12681963	0.925	rs7357468	ENSG00000248159.1	HSPA8P11	-5.13	8.97e-07	0.000657	-0.6	-0.39	Migraine;	chr8:30109188	chr8:30237382~30240997:+
PCPG	cis	rs300890	0.689	rs11947952	ENSG00000250326.1	RP11-284M14.1	5.13	8.97e-07	0.000657	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143331811	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.708	rs300894	ENSG00000250326.1	RP11-284M14.1	5.13	8.97e-07	0.000657	0.36	0.39	Nasopharyngeal carcinoma;	chr4:143334845	chr4:142933195~143184861:-
PCPG	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-5.13	8.99e-07	0.000658	-0.42	-0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
PCPG	cis	rs11168351	0.926	rs10875719	ENSG00000240399.1	RP1-228P16.1	5.13	8.99e-07	0.000658	0.39	0.39	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48054813~48055591:-
PCPG	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	5.13	9.01e-07	0.000659	0.46	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
PCPG	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-5.13	9.01e-07	0.000659	-0.41	-0.39	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
PCPG	cis	rs2253762	0.54	rs12249581	ENSG00000276742.1	RP11-500G22.4	5.13	9.02e-07	0.00066	0.63	0.39	Breast cancer;	chr10:122013486	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs79586669	ENSG00000276742.1	RP11-500G22.4	5.13	9.02e-07	0.00066	0.63	0.39	Breast cancer;	chr10:122015153	chr10:121956782~121957098:+
PCPG	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-5.13	9.03e-07	0.00066	-0.46	-0.39	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-5.13	9.03e-07	0.00066	-0.46	-0.39	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-5.13	9.03e-07	0.00066	-0.46	-0.39	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-5.13	9.03e-07	0.00066	-0.46	-0.39	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
PCPG	cis	rs4819052	0.679	rs2236450	ENSG00000215447.6	BX322557.10	-5.12	9.05e-07	0.000661	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45288052~45291738:+
PCPG	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	5.12	9.05e-07	0.000662	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
PCPG	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	5.12	9.07e-07	0.000663	0.51	0.39	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
PCPG	cis	rs13113518	0.812	rs6849474	ENSG00000272969.1	RP11-528I4.2	5.12	9.07e-07	0.000663	0.42	0.39	Height;	chr4:55452295	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs4864996	ENSG00000272969.1	RP11-528I4.2	5.12	9.07e-07	0.000663	0.42	0.39	Height;	chr4:55452921	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs2412648	ENSG00000272969.1	RP11-528I4.2	5.12	9.07e-07	0.000663	0.42	0.39	Height;	chr4:55454900	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs12512737	ENSG00000272969.1	RP11-528I4.2	5.12	9.07e-07	0.000663	0.42	0.39	Height;	chr4:55454938	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.812	rs13125984	ENSG00000272969.1	RP11-528I4.2	5.12	9.07e-07	0.000663	0.42	0.39	Height;	chr4:55455102	chr4:55547112~55547889:+
PCPG	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	5.12	9.13e-07	0.000667	0.5	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
PCPG	cis	rs11148252	0.774	rs7334583	ENSG00000198384.8	TPTE2P3	5.12	9.14e-07	0.000667	0.46	0.39	Lewy body disease;	chr13:52356217	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.774	rs9596649	ENSG00000198384.8	TPTE2P3	5.12	9.14e-07	0.000667	0.46	0.39	Lewy body disease;	chr13:52360475	chr13:52522632~52586906:+
PCPG	cis	rs853679	0.517	rs16893666	ENSG00000216901.1	AL022393.7	-5.12	9.14e-07	0.000667	-0.55	-0.39	Depression;	chr6:28086929	chr6:28176188~28176674:+
PCPG	cis	rs1155848	0.892	rs9574421	ENSG00000227354.5	RBM26-AS1	5.12	9.14e-07	0.000667	0.8	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79406205	chr13:79406309~79424328:+
PCPG	cis	rs1155848	0.892	rs2296286	ENSG00000227354.5	RBM26-AS1	5.12	9.14e-07	0.000667	0.8	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79406474	chr13:79406309~79424328:+
PCPG	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	-5.12	9.15e-07	0.000668	-0.44	-0.39	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
PCPG	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-5.12	9.16e-07	0.000668	-0.37	-0.39	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
PCPG	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	5.12	9.22e-07	0.000672	0.5	0.39	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
PCPG	cis	rs13113518	0.966	rs13144598	ENSG00000272969.1	RP11-528I4.2	5.12	9.22e-07	0.000672	0.42	0.39	Height;	chr4:55570311	chr4:55547112~55547889:+
PCPG	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.63	0.39	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	5.12	9.23e-07	0.000673	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
PCPG	cis	rs300890	0.689	rs668011	ENSG00000250326.1	RP11-284M14.1	5.12	9.25e-07	0.000674	0.35	0.39	Nasopharyngeal carcinoma;	chr4:143293747	chr4:142933195~143184861:-
PCPG	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-5.12	9.26e-07	0.000675	-0.48	-0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
PCPG	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-5.12	9.26e-07	0.000675	-0.42	-0.39	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
PCPG	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-5.12	9.26e-07	0.000675	-0.37	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
PCPG	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-5.12	9.28e-07	0.000676	-0.47	-0.39	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
PCPG	cis	rs73607972	0.799	rs112105499	ENSG00000275191.1	RP11-36I17.2	-5.12	9.28e-07	0.000676	-0.66	-0.39	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577948	chr16:53628256~53628816:-
PCPG	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-5.12	9.3e-07	0.000677	-0.35	-0.39	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
PCPG	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	5.12	9.3e-07	0.000677	0.37	0.39	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
PCPG	cis	rs7759001	0.744	rs1014227	ENSG00000271755.1	RP1-153G14.4	5.12	9.3e-07	0.000677	0.54	0.39	Glomerular filtration rate (creatinine);	chr6:27476178	chr6:27404010~27406964:-
PCPG	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	5.12	9.32e-07	0.000679	0.59	0.39	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
PCPG	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-5.12	9.34e-07	0.00068	-0.4	-0.39	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
PCPG	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	5.12	9.34e-07	0.00068	0.64	0.39	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
PCPG	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	5.12	9.34e-07	0.00068	0.64	0.39	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
PCPG	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	5.12	9.35e-07	0.00068	0.37	0.39	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	5.12	9.35e-07	0.00068	0.37	0.39	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
PCPG	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	5.12	9.36e-07	0.000681	0.38	0.39	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
PCPG	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-5.12	9.36e-07	0.000681	-0.58	-0.39	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
PCPG	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-5.12	9.36e-07	0.000681	-0.38	-0.39	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
PCPG	cis	rs9303029	0.611	rs12449726	ENSG00000279744.1	RP13-20L14.10	-5.12	9.38e-07	0.000682	-0.57	-0.39	Protein quantitative trait loci;	chr17:82450007	chr17:82462601~82464255:+
PCPG	cis	rs9649213	0.613	rs6961129	ENSG00000272950.1	RP11-307C18.1	5.12	9.4e-07	0.000683	0.49	0.39	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr7:98322853~98323430:+
PCPG	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	5.12	9.41e-07	0.000684	0.53	0.39	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	5.12	9.41e-07	0.000684	0.53	0.39	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
PCPG	cis	rs12681963	0.688	rs4733429	ENSG00000248159.1	HSPA8P11	5.12	9.41e-07	0.000684	0.73	0.39	Migraine;	chr8:30203643	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs4733431	ENSG00000248159.1	HSPA8P11	5.12	9.41e-07	0.000684	0.73	0.39	Migraine;	chr8:30203919	chr8:30237382~30240997:+
PCPG	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-5.12	9.43e-07	0.000685	-0.49	-0.39	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
PCPG	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-5.12	9.43e-07	0.000685	-0.49	-0.39	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
PCPG	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-5.12	9.43e-07	0.000685	-0.49	-0.39	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
PCPG	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-5.12	9.43e-07	0.000685	-0.48	-0.39	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
PCPG	cis	rs853679	1	rs1419183	ENSG00000219392.1	RP1-265C24.5	-5.12	9.44e-07	0.000686	-0.61	-0.39	Depression;	chr6:28275017	chr6:28115628~28116551:+
PCPG	cis	rs1609391	0.543	rs6800690	ENSG00000273486.1	RP11-731C17.2	5.12	9.44e-07	0.000686	0.4	0.39	Neuroticism;	chr3:136904184	chr3:136837338~136839021:-
PCPG	cis	rs1609391	0.543	rs7651085	ENSG00000273486.1	RP11-731C17.2	5.12	9.44e-07	0.000686	0.4	0.39	Neuroticism;	chr3:136906497	chr3:136837338~136839021:-
PCPG	cis	rs1609391	0.561	rs6439675	ENSG00000273486.1	RP11-731C17.2	5.12	9.44e-07	0.000686	0.4	0.39	Neuroticism;	chr3:136906594	chr3:136837338~136839021:-
PCPG	cis	rs1609391	0.543	rs6761993	ENSG00000273486.1	RP11-731C17.2	5.12	9.44e-07	0.000686	0.4	0.39	Neuroticism;	chr3:136907060	chr3:136837338~136839021:-
PCPG	cis	rs1609391	0.543	rs1347209	ENSG00000273486.1	RP11-731C17.2	5.12	9.44e-07	0.000686	0.4	0.39	Neuroticism;	chr3:136907855	chr3:136837338~136839021:-
PCPG	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	5.11	9.47e-07	0.000688	0.43	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
PCPG	cis	rs7819412	0.538	rs4523214	ENSG00000255020.1	AF131216.5	-5.11	9.47e-07	0.000688	-0.53	-0.39	Triglycerides;	chr8:11113263	chr8:11345748~11347502:-
PCPG	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	5.11	9.48e-07	0.000688	0.48	0.39	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
PCPG	cis	rs11992162	0.551	rs13268217	ENSG00000255020.1	AF131216.5	-5.11	9.49e-07	0.00069	-0.52	-0.39	Monocyte count;	chr8:11925100	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2572394	ENSG00000255020.1	AF131216.5	-5.11	9.5e-07	0.00069	-0.5	-0.39	Retinal vascular caliber;	chr8:11377884	chr8:11345748~11347502:-
PCPG	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-5.11	9.54e-07	0.000693	-0.38	-0.39	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
PCPG	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	5.11	9.54e-07	0.000693	0.48	0.39	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
PCPG	cis	rs9926296	0.533	rs10852623	ENSG00000260259.1	RP11-368I7.4	-5.11	9.55e-07	0.000693	-0.47	-0.39	Vitiligo;	chr16:89798834	chr16:89682620~89686569:-
PCPG	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-5.11	9.55e-07	0.000693	-0.53	-0.39	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
PCPG	cis	rs7598759	0.679	rs4398264	ENSG00000181798.2	LINC00471	-5.11	9.57e-07	0.000695	-0.5	-0.39	Noise-induced hearing loss;	chr2:231473642	chr2:231508426~231514339:-
PCPG	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	5.11	9.58e-07	0.000695	0.38	0.39	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
PCPG	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-5.11	9.58e-07	0.000695	-0.49	-0.39	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-5.11	9.58e-07	0.000695	-0.49	-0.39	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
PCPG	cis	rs7824557	0.564	rs2736290	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11376789	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2572399	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377011	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2736293	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377104	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2736294	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377117	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs2736296	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377335	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.51	rs2736297	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377376	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs2736298	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377627	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs57629785	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377641	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2437152	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11377988	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2736300	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11378070	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2572392	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11378096	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs1435275	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11378226	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2572389	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11378883	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2736301	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11378904	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2736302	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11378910	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.647	rs7821302	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Neuroticism;	chr8:11379063	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs7821459	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11379172	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs7834572	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11379176	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs4631424	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11379300	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs2572386	ENSG00000255020.1	AF131216.5	-5.11	9.59e-07	0.000696	-0.5	-0.39	Retinal vascular caliber;	chr8:11379466	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	5.11	9.61e-07	0.000697	0.48	0.39	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
PCPG	cis	rs12908161	0.96	rs34452033	ENSG00000259295.5	CSPG4P12	5.11	9.61e-07	0.000697	0.57	0.39	Schizophrenia;	chr15:84678762	chr15:85191438~85213905:+
PCPG	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	5.11	9.63e-07	0.000698	0.38	0.39	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
PCPG	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-5.11	9.63e-07	0.000698	-0.53	-0.39	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
PCPG	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	5.11	9.63e-07	0.000698	0.46	0.39	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
PCPG	cis	rs2531992	1	rs710893	ENSG00000262888.1	RP11-462G12.2	-5.11	9.63e-07	0.000698	-0.64	-0.39	Waist circumference;	chr16:3964963	chr16:3931217~3946305:-
PCPG	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-5.11	9.63e-07	0.000698	-0.35	-0.39	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
PCPG	cis	rs7824557	0.564	rs2572379	ENSG00000255020.1	AF131216.5	-5.11	9.66e-07	7e-04	-0.51	-0.39	Retinal vascular caliber;	chr8:11379971	chr8:11345748~11347502:-
PCPG	cis	rs13113518	0.678	rs13149568	ENSG00000272969.1	RP11-528I4.2	5.11	9.66e-07	7e-04	0.44	0.39	Height;	chr4:55370412	chr4:55547112~55547889:+
PCPG	cis	rs7824557	0.564	rs2572395	ENSG00000255020.1	AF131216.5	-5.11	9.67e-07	7e-04	-0.51	-0.39	Retinal vascular caliber;	chr8:11377851	chr8:11345748~11347502:-
PCPG	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	5.11	9.69e-07	0.000701	0.35	0.39	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
PCPG	cis	rs9595908	0.785	rs4942791	ENSG00000212293.1	SNORA16	5.11	9.69e-07	0.000702	0.46	0.39	Body mass index;	chr13:32663085	chr13:32420390~32420516:-
PCPG	cis	rs11148252	0.74	rs7981050	ENSG00000235660.1	LINC00345	-5.11	9.7e-07	0.000702	-0.49	-0.39	Lewy body disease;	chr13:52181014	chr13:52484161~52484680:-
PCPG	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-5.11	9.7e-07	0.000703	-0.5	-0.39	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
PCPG	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-5.11	9.75e-07	0.000706	-0.45	-0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
PCPG	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-5.11	9.76e-07	0.000706	-0.49	-0.38	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
PCPG	cis	rs6762	0.719	rs28655651	ENSG00000279672.1	CMB9-55F22.1	5.11	9.77e-07	0.000707	0.43	0.38	Mean platelet volume;	chr11:837121	chr11:779617~780755:+
PCPG	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	5.11	9.78e-07	0.000707	0.33	0.38	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
PCPG	cis	rs2736345	0.788	rs998683	ENSG00000255020.1	AF131216.5	-5.11	9.79e-07	0.000708	-0.52	-0.38	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:11345748~11347502:-
PCPG	cis	rs17507216	0.667	rs13379724	ENSG00000228141.5	AC105339.1	-5.11	9.79e-07	0.000708	-0.57	-0.38	Excessive daytime sleepiness;	chr15:82619892	chr15:82710471~82714026:-
PCPG	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	5.11	9.8e-07	0.000709	0.42	0.38	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
PCPG	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	5.11	9.81e-07	0.000709	0.59	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
PCPG	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	5.11	9.81e-07	0.00071	0.48	0.38	Height;	chr6:109407238	chr6:109382795~109383666:+
PCPG	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-5.11	9.82e-07	0.00071	-0.51	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
PCPG	cis	rs4835473	0.637	rs9993457	ENSG00000250345.2	RP11-780M14.1	-5.11	9.82e-07	0.00071	-0.43	-0.38	Immature fraction of reticulocytes;	chr4:143752364	chr4:143760399~143762093:-
PCPG	cis	rs9595908	0.581	rs2032507	ENSG00000212293.1	SNORA16	5.11	9.84e-07	0.000711	0.46	0.38	Body mass index;	chr13:32779298	chr13:32420390~32420516:-
PCPG	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-5.11	9.85e-07	0.000712	-0.45	-0.38	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
PCPG	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-5.11	9.85e-07	0.000712	-0.48	-0.38	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
PCPG	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	5.11	9.87e-07	0.000713	0.52	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	5.11	9.87e-07	0.000713	0.52	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
PCPG	cis	rs11992162	0.573	rs61468577	ENSG00000255020.1	AF131216.5	-5.1	9.89e-07	0.000714	-0.52	-0.38	Monocyte count;	chr8:11927416	chr8:11345748~11347502:-
PCPG	cis	rs12908161	1	rs12905057	ENSG00000259295.5	CSPG4P12	5.1	9.92e-07	0.000716	0.58	0.38	Schizophrenia;	chr15:84667534	chr15:85191438~85213905:+
PCPG	cis	rs4835473	0.637	rs1020497	ENSG00000250345.2	RP11-780M14.1	-5.1	9.92e-07	0.000717	-0.43	-0.38	Immature fraction of reticulocytes;	chr4:143741029	chr4:143760399~143762093:-
PCPG	cis	rs11858159	1	rs7402794	ENSG00000259905.4	PWRN1	5.1	9.92e-07	0.000717	0.44	0.38	Platelet thrombus formation;	chr15:24561199	chr15:24493137~24652130:+
PCPG	cis	rs440932	0.798	rs330942	ENSG00000253893.2	FAM85B	-5.1	9.93e-07	0.000717	-0.47	-0.38	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8167819~8226614:-
PCPG	cis	rs440932	0.717	rs330944	ENSG00000253893.2	FAM85B	-5.1	9.93e-07	0.000717	-0.46	-0.38	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:8167819~8226614:-
PCPG	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-5.1	9.94e-07	0.000718	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
PCPG	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-5.1	9.97e-07	0.00072	-0.41	-0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
PCPG	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	5.1	9.99e-07	0.000721	0.46	0.38	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
PCPG	cis	rs6121246	0.52	rs6060425	ENSG00000230613.1	HM13-AS1	5.1	9.99e-07	0.000721	0.57	0.38	Mean corpuscular hemoglobin;	chr20:31636552	chr20:31567707~31573263:-
PCPG	cis	rs853679	0.517	rs1340004	ENSG00000216901.1	AL022393.7	5.1	1e-06	0.000722	0.54	0.38	Depression;	chr6:28135913	chr6:28176188~28176674:+
PCPG	cis	rs7688540	0.515	rs28415975	ENSG00000275426.1	CH17-262A2.1	5.1	1e-06	0.000722	0.47	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:149738~150317:+
PCPG	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-5.1	1e-06	0.000723	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-5.1	1e-06	0.000723	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-5.1	1e-06	0.000723	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
PCPG	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-5.1	1e-06	0.000723	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
PCPG	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	5.1	1e-06	0.000723	0.42	0.38	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
PCPG	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	5.1	1e-06	0.000724	0.42	0.38	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
PCPG	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-5.1	1e-06	0.000724	-0.39	-0.38	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
PCPG	cis	rs1075232	0.579	rs58156651	ENSG00000270055.1	CTD-3092A11.2	-5.1	1.01e-06	0.000725	-0.82	-0.38	Survival in colorectal cancer (non-distant metastatic);	chr15:31456864	chr15:30487963~30490313:+
PCPG	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7795176	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs62478200	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs1859482	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs13246868	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs12672092	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs1468340	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6969234	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs3801257	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs3801256	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7803372	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7776638	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.555	rs6956686	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs36099592	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs13246843	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6465677	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6465678	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.502	rs6465680	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6961438	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	5.1	1.01e-06	0.000726	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
PCPG	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-5.1	1.01e-06	0.000726	-0.38	-0.38	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
PCPG	cis	rs9926296	0.512	rs11076626	ENSG00000260259.1	RP11-368I7.4	-5.1	1.01e-06	0.000726	-0.47	-0.38	Vitiligo;	chr16:89798695	chr16:89682620~89686569:-
PCPG	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	5.1	1.01e-06	0.000727	0.48	0.38	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
PCPG	cis	rs7181230	0.885	rs2412478	ENSG00000259584.1	RP11-521C20.2	5.1	1.01e-06	0.000727	0.5	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40075204~40078704:-
PCPG	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	5.1	1.01e-06	0.000727	0.48	0.38	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
PCPG	cis	rs55665837	0.701	rs1522633	ENSG00000251991.1	RNU7-49P	5.1	1.01e-06	0.000728	0.45	0.38	Vitamin D levels;	chr11:14623692	chr11:14478892~14478953:+
PCPG	cis	rs12908161	1	rs60957376	ENSG00000259295.5	CSPG4P12	5.1	1.01e-06	0.000728	0.57	0.38	Schizophrenia;	chr15:84737561	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs11632465	ENSG00000259295.5	CSPG4P12	5.1	1.01e-06	0.000728	0.57	0.38	Schizophrenia;	chr15:84738814	chr15:85191438~85213905:+
PCPG	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	5.1	1.01e-06	0.00073	0.61	0.38	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
PCPG	cis	rs3806843	0.897	rs2531338	ENSG00000202515.1	VTRNA1-3	5.1	1.02e-06	0.000731	0.48	0.38	Depressive symptoms (multi-trait analysis);	chr5:140757372	chr5:140726158~140726246:+
PCPG	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	5.1	1.02e-06	0.000733	0.41	0.38	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
PCPG	cis	rs300890	0.513	rs11100769	ENSG00000250326.1	RP11-284M14.1	5.1	1.02e-06	0.000734	0.34	0.38	Nasopharyngeal carcinoma;	chr4:143122313	chr4:142933195~143184861:-
PCPG	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-5.1	1.02e-06	0.000735	-0.47	-0.38	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
PCPG	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-5.1	1.02e-06	0.000736	-0.5	-0.38	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
PCPG	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	5.1	1.02e-06	0.000736	0.43	0.38	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	5.1	1.02e-06	0.000736	0.43	0.38	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
PCPG	cis	rs11858159	1	rs7172329	ENSG00000259905.4	PWRN1	5.1	1.02e-06	0.000736	0.44	0.38	Platelet thrombus formation;	chr15:24538386	chr15:24493137~24652130:+
PCPG	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-5.1	1.03e-06	0.000737	-0.64	-0.38	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
PCPG	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	5.1	1.03e-06	0.000738	0.42	0.38	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
PCPG	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	5.1	1.03e-06	0.000738	0.6	0.38	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
PCPG	cis	rs11148252	0.716	rs2760772	ENSG00000235660.1	LINC00345	-5.1	1.03e-06	0.000738	-0.48	-0.38	Lewy body disease;	chr13:52206238	chr13:52484161~52484680:-
PCPG	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	5.1	1.03e-06	0.000739	0.59	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
PCPG	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	5.1	1.03e-06	0.000739	0.57	0.38	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
PCPG	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-5.1	1.03e-06	0.000739	-0.51	-0.38	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
PCPG	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-5.1	1.03e-06	0.000739	-0.58	-0.38	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
PCPG	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-5.1	1.03e-06	0.00074	-0.38	-0.38	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
PCPG	cis	rs3806843	1	rs10477034	ENSG00000202515.1	VTRNA1-3	-5.1	1.03e-06	0.000741	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr5:140726158~140726246:+
PCPG	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-5.1	1.03e-06	0.000741	-0.38	-0.38	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
PCPG	cis	rs3806843	0.868	rs2262574	ENSG00000202515.1	VTRNA1-3	5.1	1.03e-06	0.000742	0.48	0.38	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr5:140726158~140726246:+
PCPG	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	5.1	1.03e-06	0.000743	0.59	0.38	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
PCPG	cis	rs300890	0.513	rs72719173	ENSG00000250326.1	RP11-284M14.1	-5.09	1.04e-06	0.000745	-0.36	-0.38	Nasopharyngeal carcinoma;	chr4:143134728	chr4:142933195~143184861:-
PCPG	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-5.09	1.04e-06	0.000745	-0.44	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
PCPG	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-5.09	1.04e-06	0.000745	-0.43	-0.38	Height;	chr2:231516587	chr2:231508426~231514339:-
PCPG	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	5.09	1.04e-06	0.000746	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	5.09	1.04e-06	0.000746	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	5.09	1.04e-06	0.000746	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
PCPG	cis	rs7824557	0.724	rs2572398	ENSG00000255020.1	AF131216.5	5.09	1.04e-06	0.000747	0.5	0.38	Retinal vascular caliber;	chr8:11320584	chr8:11345748~11347502:-
PCPG	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-5.09	1.04e-06	0.00075	-0.46	-0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
PCPG	cis	rs73607972	0.74	rs66961852	ENSG00000275191.1	RP11-36I17.2	-5.09	1.05e-06	0.000754	-0.6	-0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53587476	chr16:53628256~53628816:-
PCPG	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	5.09	1.05e-06	0.000754	0.46	0.38	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	5.09	1.05e-06	0.000754	0.46	0.38	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
PCPG	cis	rs7688540	0.8	rs9328737	ENSG00000275426.1	CH17-262A2.1	5.09	1.05e-06	0.000754	0.46	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:149738~150317:+
PCPG	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-5.09	1.05e-06	0.000754	-0.37	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
PCPG	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	5.09	1.05e-06	0.000754	0.7	0.38	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	5.09	1.05e-06	0.000754	0.7	0.38	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
PCPG	cis	rs6121246	0.647	rs6088855	ENSG00000230613.1	HM13-AS1	5.09	1.05e-06	0.000755	0.55	0.38	Mean corpuscular hemoglobin;	chr20:31637989	chr20:31567707~31573263:-
PCPG	cis	rs13108904	0.901	rs12641735	ENSG00000254094.1	AC078852.1	-5.09	1.05e-06	0.000755	-0.44	-0.38	Obesity-related traits;	chr4:1310646	chr4:1356581~1358075:+
PCPG	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	5.09	1.05e-06	0.000756	0.49	0.38	Height;	chr6:109407148	chr6:109382795~109383666:+
PCPG	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	5.09	1.05e-06	0.000756	0.4	0.38	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
PCPG	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-5.09	1.05e-06	0.000756	-0.51	-0.38	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
PCPG	cis	rs3808502	0.549	rs1382563	ENSG00000255020.1	AF131216.5	5.09	1.05e-06	0.000756	0.5	0.38	Neuroticism;	chr8:11569281	chr8:11345748~11347502:-
PCPG	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-5.09	1.06e-06	0.000758	-0.35	-0.38	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
PCPG	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	5.09	1.06e-06	0.000759	0.46	0.38	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	5.09	1.06e-06	0.000759	0.46	0.38	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
PCPG	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	5.09	1.06e-06	0.000761	0.53	0.38	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
PCPG	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	5.09	1.06e-06	0.000762	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	5.09	1.06e-06	0.000762	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	5.09	1.06e-06	0.000762	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
PCPG	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	5.09	1.06e-06	0.000762	0.45	0.38	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
PCPG	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-5.09	1.07e-06	0.000762	-0.42	-0.38	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
PCPG	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	5.09	1.07e-06	0.000763	0.47	0.38	Height;	chr6:109391084	chr6:109382795~109383666:+
PCPG	cis	rs853679	0.517	rs9295761	ENSG00000216901.1	AL022393.7	5.09	1.07e-06	0.000763	0.56	0.38	Depression;	chr6:28180209	chr6:28176188~28176674:+
PCPG	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-5.09	1.07e-06	0.000763	-0.34	-0.38	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-5.09	1.07e-06	0.000763	-0.34	-0.38	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
PCPG	cis	rs12908161	1	rs58416181	ENSG00000259295.5	CSPG4P12	5.09	1.07e-06	0.000763	0.57	0.38	Schizophrenia;	chr15:84721230	chr15:85191438~85213905:+
PCPG	cis	rs9595908	0.785	rs17515873	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32647711	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.84	rs2301388	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32648478	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.758	rs2301389	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32648694	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs2301390	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32649307	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.758	rs9591219	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32653020	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.758	rs9591220	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32653059	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs12428283	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32653775	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596032	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32654708	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596035	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32654803	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9591226	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32655322	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7335546	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32658197	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs2301393	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32658298	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9591228	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32658632	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7326809	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32662135	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9591230	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32663944	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7985656	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32664414	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs2874282	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32665876	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596051	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32666528	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596056	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32669402	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596057	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32669831	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596059	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32670145	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596060	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32670467	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs3783267	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32670719	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7317147	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32670838	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs60088097	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32678043	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs6561499	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32681075	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7328827	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32686650	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs3858846	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32687408	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7981925	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32693706	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9315177	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32696214	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.746	rs7985640	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32698228	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9591252	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32698297	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs9596081	ENSG00000212293.1	SNORA16	5.09	1.07e-06	0.000763	0.46	0.38	Body mass index;	chr13:32698405	chr13:32420390~32420516:-
PCPG	cis	rs300890	0.61	rs4690783	ENSG00000250326.1	RP11-284M14.1	5.09	1.07e-06	0.000765	0.33	0.38	Nasopharyngeal carcinoma;	chr4:143270801	chr4:142933195~143184861:-
PCPG	cis	rs7246657	0.882	rs59224125	ENSG00000226686.6	LINC01535	-5.09	1.07e-06	0.000766	-0.59	-0.38	Coronary artery calcification;	chr19:37472303	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs2081096	ENSG00000226686.6	LINC01535	-5.09	1.07e-06	0.000766	-0.59	-0.38	Coronary artery calcification;	chr19:37473798	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7255785	ENSG00000226686.6	LINC01535	-5.09	1.07e-06	0.000766	-0.59	-0.38	Coronary artery calcification;	chr19:37480781	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7255996	ENSG00000226686.6	LINC01535	-5.09	1.07e-06	0.000766	-0.59	-0.38	Coronary artery calcification;	chr19:37480797	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs28373708	ENSG00000226686.6	LINC01535	-5.09	1.07e-06	0.000766	-0.59	-0.38	Coronary artery calcification;	chr19:37485757	chr19:37251912~37265535:+
PCPG	cis	rs7824557	0.872	rs2572417	ENSG00000255020.1	AF131216.5	-5.09	1.07e-06	0.000766	-0.5	-0.38	Retinal vascular caliber;	chr8:11253953	chr8:11345748~11347502:-
PCPG	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	5.09	1.07e-06	0.000767	0.64	0.38	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
PCPG	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	5.09	1.07e-06	0.000767	0.64	0.38	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
PCPG	cis	rs1155848	0.892	rs1977354	ENSG00000227354.5	RBM26-AS1	5.09	1.08e-06	0.000769	0.8	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79383273	chr13:79406309~79424328:+
PCPG	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	5.09	1.08e-06	0.00077	0.53	0.38	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
PCPG	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-5.09	1.08e-06	0.00077	-0.49	-0.38	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
PCPG	cis	rs12681963	0.925	rs7821959	ENSG00000248159.1	HSPA8P11	-5.08	1.08e-06	0.000772	-0.6	-0.38	Migraine;	chr8:30101699	chr8:30237382~30240997:+
PCPG	cis	rs17264034	0.8	rs75882443	ENSG00000250786.1	SNHG18	5.08	1.08e-06	0.000772	0.74	0.38	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555985	chr5:9546200~9550609:+
PCPG	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	5.08	1.08e-06	0.000772	0.55	0.38	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
PCPG	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	5.08	1.08e-06	0.000773	0.46	0.38	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
PCPG	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	5.08	1.08e-06	0.000773	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	5.08	1.08e-06	0.000773	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
PCPG	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	5.08	1.08e-06	0.000773	0.61	0.38	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	5.08	1.08e-06	0.000773	0.61	0.38	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	5.08	1.08e-06	0.000773	0.61	0.38	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
PCPG	cis	rs12946454	0.621	rs11651809	ENSG00000267288.2	RP13-890H12.2	-5.08	1.08e-06	0.000774	-0.5	-0.38	Systolic blood pressure;	chr17:45178314	chr17:45168800~45171584:-
PCPG	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-5.08	1.09e-06	0.000774	-0.48	-0.38	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
PCPG	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-5.08	1.09e-06	0.000774	-0.45	-0.38	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
PCPG	cis	rs12681963	0.541	rs7010163	ENSG00000248159.1	HSPA8P11	5.08	1.09e-06	0.000776	0.74	0.38	Migraine;	chr8:30225049	chr8:30237382~30240997:+
PCPG	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	5.08	1.09e-06	0.000777	0.64	0.38	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
PCPG	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-5.08	1.09e-06	0.000777	-0.34	-0.38	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-5.08	1.09e-06	0.000777	-0.34	-0.38	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
PCPG	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-5.08	1.09e-06	0.000778	-0.58	-0.38	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
PCPG	cis	rs1609391	0.561	rs9817967	ENSG00000273486.1	RP11-731C17.2	5.08	1.09e-06	0.000778	0.4	0.38	Neuroticism;	chr3:136910648	chr3:136837338~136839021:-
PCPG	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	5.08	1.09e-06	0.000778	0.58	0.38	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	5.08	1.09e-06	0.000778	0.58	0.38	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
PCPG	cis	rs7824557	0.545	rs2572380	ENSG00000255020.1	AF131216.5	-5.08	1.09e-06	0.000778	-0.51	-0.38	Retinal vascular caliber;	chr8:11379968	chr8:11345748~11347502:-
PCPG	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-5.08	1.09e-06	0.000779	-0.69	-0.38	Depression;	chr6:28119105	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-5.08	1.09e-06	0.000779	-0.69	-0.38	Depression;	chr6:28124907	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-5.08	1.09e-06	0.000779	-0.69	-0.38	Depression;	chr6:28139579	chr6:28115628~28116551:+
PCPG	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	5.08	1.1e-06	0.00078	0.34	0.38	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
PCPG	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-5.08	1.1e-06	0.000781	-0.39	-0.38	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
PCPG	cis	rs453301	0.658	rs12114954	ENSG00000173295.6	FAM86B3P	5.08	1.1e-06	0.000781	0.46	0.38	Joint mobility (Beighton score);	chr8:9047352	chr8:8228595~8244865:+
PCPG	cis	rs7181230	0.885	rs28444847	ENSG00000259584.1	RP11-521C20.2	5.08	1.1e-06	0.000781	0.5	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40075204~40078704:-
PCPG	cis	rs12908161	0.96	rs62019463	ENSG00000259295.5	CSPG4P12	5.08	1.1e-06	0.000781	0.57	0.38	Schizophrenia;	chr15:84744856	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs62019464	ENSG00000259295.5	CSPG4P12	5.08	1.1e-06	0.000781	0.57	0.38	Schizophrenia;	chr15:84751238	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs11637142	ENSG00000259295.5	CSPG4P12	5.08	1.1e-06	0.000781	0.57	0.38	Schizophrenia;	chr15:84752696	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs12910012	ENSG00000259295.5	CSPG4P12	5.08	1.1e-06	0.000781	0.57	0.38	Schizophrenia;	chr15:84755431	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs12899981	ENSG00000259295.5	CSPG4P12	5.08	1.1e-06	0.000781	0.57	0.38	Schizophrenia;	chr15:84759142	chr15:85191438~85213905:+
PCPG	cis	rs7017914	0.905	rs10091471	ENSG00000254031.4	RP11-326E22.1	5.08	1.1e-06	0.000782	0.38	0.38	Bone mineral density;	chr8:71041520	chr8:71155457~71204223:+
PCPG	cis	rs7246657	0.943	rs4452075	ENSG00000226686.6	LINC01535	-5.08	1.1e-06	0.000782	-0.6	-0.38	Coronary artery calcification;	chr19:37388687	chr19:37251912~37265535:+
PCPG	cis	rs71403859	0.57	rs76231867	ENSG00000260886.1	TAT-AS1	5.08	1.1e-06	0.000782	0.67	0.38	Post bronchodilator FEV1;	chr16:71416023	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.57	rs78972826	ENSG00000260886.1	TAT-AS1	5.08	1.1e-06	0.000782	0.67	0.38	Post bronchodilator FEV1;	chr16:71420361	chr16:71565789~71578187:+
PCPG	cis	rs71403859	0.502	rs8053720	ENSG00000260886.1	TAT-AS1	5.08	1.1e-06	0.000782	0.67	0.38	Post bronchodilator FEV1;	chr16:71422239	chr16:71565789~71578187:+
PCPG	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	5.08	1.1e-06	0.000782	0.68	0.38	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
PCPG	cis	rs300890	0.689	rs300953	ENSG00000250326.1	RP11-284M14.1	5.08	1.1e-06	0.000783	0.35	0.38	Nasopharyngeal carcinoma;	chr4:143280506	chr4:142933195~143184861:-
PCPG	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	5.08	1.1e-06	0.000784	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
PCPG	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	5.08	1.1e-06	0.000786	0.46	0.38	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
PCPG	cis	rs12908161	0.959	rs3748376	ENSG00000259295.5	CSPG4P12	5.08	1.1e-06	0.000786	0.57	0.38	Schizophrenia;	chr15:84785121	chr15:85191438~85213905:+
PCPG	cis	rs17507216	0.671	rs28582623	ENSG00000228141.5	AC105339.1	-5.08	1.11e-06	0.000787	-0.59	-0.38	Excessive daytime sleepiness;	chr15:82577381	chr15:82710471~82714026:-
PCPG	cis	rs4671400	0.571	rs28480287	ENSG00000270820.4	RP11-355B11.2	-5.08	1.11e-06	0.000788	-0.54	-0.38	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61262154	chr2:61471188~61484130:+
PCPG	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	5.08	1.11e-06	0.000788	0.6	0.38	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	5.08	1.11e-06	0.000788	0.6	0.38	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	5.08	1.11e-06	0.000788	0.6	0.38	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	5.08	1.11e-06	0.000788	0.6	0.38	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
PCPG	cis	rs2836950	0.805	rs62223042	ENSG00000255568.3	BRWD1-AS2	-5.08	1.11e-06	0.000788	-0.4	-0.38	Menarche (age at onset);	chr21:39311814	chr21:39313935~39314962:+
PCPG	cis	rs56804039	0.895	rs11776995	ENSG00000253893.2	FAM85B	5.08	1.11e-06	0.000789	0.6	0.38	Cervical cancer;	chr8:8528037	chr8:8167819~8226614:-
PCPG	cis	rs8044188	0.526	rs12926455	ENSG00000261090.1	RP11-20G6.2	5.08	1.11e-06	0.000789	0.55	0.38	Multiple system atrophy;	chr16:23021878	chr16:23020337~23023611:+
PCPG	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	5.08	1.11e-06	0.00079	0.47	0.38	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
PCPG	cis	rs3808502	0.549	rs11991139	ENSG00000255020.1	AF131216.5	-5.08	1.12e-06	0.000794	-0.5	-0.38	Neuroticism;	chr8:11570886	chr8:11345748~11347502:-
PCPG	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-5.08	1.12e-06	0.000795	-0.39	-0.38	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
PCPG	cis	rs13108904	0.901	rs4974594	ENSG00000254094.1	AC078852.1	5.08	1.12e-06	0.000795	0.43	0.38	Obesity-related traits;	chr4:1306692	chr4:1356581~1358075:+
PCPG	cis	rs9595908	0.733	rs9315175	ENSG00000212293.1	SNORA16	5.08	1.12e-06	0.000795	0.46	0.38	Body mass index;	chr13:32649581	chr13:32420390~32420516:-
PCPG	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	5.08	1.12e-06	0.000796	0.5	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
PCPG	cis	rs7246657	1	rs35398388	ENSG00000226686.6	LINC01535	-5.08	1.12e-06	0.000796	-0.63	-0.38	Coronary artery calcification;	chr19:37249456	chr19:37251912~37265535:+
PCPG	cis	rs7246657	1	rs7247672	ENSG00000226686.6	LINC01535	-5.08	1.12e-06	0.000796	-0.63	-0.38	Coronary artery calcification;	chr19:37253026	chr19:37251912~37265535:+
PCPG	cis	rs7246657	1	rs8110011	ENSG00000226686.6	LINC01535	-5.08	1.12e-06	0.000796	-0.63	-0.38	Coronary artery calcification;	chr19:37254911	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.941	rs7259618	ENSG00000226686.6	LINC01535	-5.08	1.12e-06	0.000796	-0.63	-0.38	Coronary artery calcification;	chr19:37259817	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	5.08	1.12e-06	0.000799	0.47	0.38	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
PCPG	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	5.08	1.12e-06	0.000799	0.38	0.38	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
PCPG	cis	rs7017914	0.69	rs3098872	ENSG00000254031.4	RP11-326E22.1	-5.08	1.13e-06	8e-04	-0.37	-0.38	Bone mineral density;	chr8:71019969	chr8:71155457~71204223:+
PCPG	cis	rs34421088	0.56	rs1478898	ENSG00000255020.1	AF131216.5	-5.08	1.13e-06	8e-04	-0.49	-0.38	Neuroticism;	chr8:11537570	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.777	rs560544	ENSG00000173295.6	FAM86B3P	5.08	1.13e-06	0.000801	0.44	0.38	Mood instability;	chr8:8779919	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	5.08	1.13e-06	0.000802	0.47	0.38	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
PCPG	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	5.08	1.13e-06	0.000803	0.34	0.38	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
PCPG	cis	rs7017914	0.967	rs1493198	ENSG00000254031.4	RP11-326E22.1	5.08	1.13e-06	0.000803	0.38	0.38	Bone mineral density;	chr8:70939722	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs13255152	ENSG00000254031.4	RP11-326E22.1	5.08	1.13e-06	0.000803	0.38	0.38	Bone mineral density;	chr8:70947384	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs2639919	ENSG00000254031.4	RP11-326E22.1	5.08	1.13e-06	0.000803	0.38	0.38	Bone mineral density;	chr8:70962893	chr8:71155457~71204223:+
PCPG	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-5.08	1.13e-06	0.000803	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-5.08	1.13e-06	0.000803	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-5.08	1.13e-06	0.000803	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-5.08	1.13e-06	0.000803	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-5.08	1.13e-06	0.000803	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-5.08	1.13e-06	0.000803	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-5.08	1.13e-06	0.000803	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
PCPG	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	5.07	1.14e-06	0.000808	0.42	0.38	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
PCPG	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	5.07	1.14e-06	0.000809	0.56	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
PCPG	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	5.07	1.14e-06	0.00081	0.69	0.38	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
PCPG	cis	rs12908161	0.959	rs62019472	ENSG00000259295.5	CSPG4P12	5.07	1.14e-06	0.00081	0.57	0.38	Schizophrenia;	chr15:84788262	chr15:85191438~85213905:+
PCPG	cis	rs12681963	0.688	rs16876672	ENSG00000248159.1	HSPA8P11	5.07	1.14e-06	0.00081	0.73	0.38	Migraine;	chr8:30207450	chr8:30237382~30240997:+
PCPG	cis	rs9649213	0.531	rs35216698	ENSG00000272950.1	RP11-307C18.1	5.07	1.14e-06	0.000812	0.5	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs34830366	ENSG00000272950.1	RP11-307C18.1	5.07	1.14e-06	0.000812	0.5	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs34776142	ENSG00000272950.1	RP11-307C18.1	5.07	1.14e-06	0.000812	0.5	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98322853~98323430:+
PCPG	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	5.07	1.15e-06	0.000812	0.46	0.38	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
PCPG	cis	rs7824557	0.614	rs2736286	ENSG00000255020.1	AF131216.5	-5.07	1.15e-06	0.000813	-0.51	-0.38	Retinal vascular caliber;	chr8:11369595	chr8:11345748~11347502:-
PCPG	cis	rs7181230	0.813	rs4924417	ENSG00000259584.1	RP11-521C20.2	5.07	1.15e-06	0.000813	0.5	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40075204~40078704:-
PCPG	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	5.07	1.15e-06	0.000813	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
PCPG	cis	rs11858159	1	rs8032894	ENSG00000259905.4	PWRN1	5.07	1.15e-06	0.000815	0.44	0.38	Platelet thrombus formation;	chr15:24540625	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs9920583	ENSG00000259905.4	PWRN1	5.07	1.15e-06	0.000815	0.44	0.38	Platelet thrombus formation;	chr15:24544540	chr15:24493137~24652130:+
PCPG	cis	rs4986172	0.69	rs11657325	ENSG00000267288.2	RP13-890H12.2	-5.07	1.15e-06	0.000815	-0.52	-0.38	Height;	chr17:45165327	chr17:45168800~45171584:-
PCPG	cis	rs300890	0.56	rs9308170	ENSG00000250326.1	RP11-284M14.1	5.07	1.15e-06	0.000816	0.33	0.38	Nasopharyngeal carcinoma;	chr4:143263660	chr4:142933195~143184861:-
PCPG	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-5.07	1.15e-06	0.000817	-0.47	-0.38	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
PCPG	cis	rs7246657	0.941	rs12982333	ENSG00000226686.6	LINC01535	-5.07	1.15e-06	0.000818	-0.62	-0.38	Coronary artery calcification;	chr19:37303822	chr19:37251912~37265535:+
PCPG	cis	rs7246657	1	rs10426297	ENSG00000226686.6	LINC01535	-5.07	1.15e-06	0.000818	-0.62	-0.38	Coronary artery calcification;	chr19:37307471	chr19:37251912~37265535:+
PCPG	cis	rs7246657	1	rs1823061	ENSG00000226686.6	LINC01535	-5.07	1.15e-06	0.000818	-0.62	-0.38	Coronary artery calcification;	chr19:37309724	chr19:37251912~37265535:+
PCPG	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	5.07	1.16e-06	0.000818	0.52	0.38	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	5.07	1.16e-06	0.000818	0.52	0.38	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
PCPG	cis	rs7829975	0.606	rs11776838	ENSG00000173295.6	FAM86B3P	5.07	1.16e-06	0.000818	0.44	0.38	Mood instability;	chr8:8937291	chr8:8228595~8244865:+
PCPG	cis	rs7246657	0.882	rs10412043	ENSG00000226686.6	LINC01535	-5.07	1.16e-06	0.000819	-0.59	-0.38	Coronary artery calcification;	chr19:37335724	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs4803229	ENSG00000226686.6	LINC01535	-5.07	1.16e-06	0.000819	-0.59	-0.38	Coronary artery calcification;	chr19:37373780	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs1559229	ENSG00000226686.6	LINC01535	-5.07	1.16e-06	0.000819	-0.59	-0.38	Coronary artery calcification;	chr19:37385295	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.882	rs6508719	ENSG00000226686.6	LINC01535	-5.07	1.16e-06	0.000819	-0.59	-0.38	Coronary artery calcification;	chr19:37386517	chr19:37251912~37265535:+
PCPG	cis	rs7181230	0.922	rs4924410	ENSG00000259584.1	RP11-521C20.2	-5.07	1.16e-06	0.000821	-0.5	-0.38	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40075204~40078704:-
PCPG	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	5.07	1.16e-06	0.000821	0.32	0.38	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
PCPG	cis	rs1440410	0.798	rs10031363	ENSG00000250326.1	RP11-284M14.1	5.07	1.16e-06	0.000821	0.34	0.38	Ischemic stroke;	chr4:143243045	chr4:142933195~143184861:-
PCPG	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-5.07	1.16e-06	0.000821	-0.38	-0.38	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
PCPG	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	5.07	1.16e-06	0.000823	0.35	0.38	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
PCPG	cis	rs2625529	0.526	rs8032222	ENSG00000260037.4	CTD-2524L6.3	5.07	1.16e-06	0.000824	0.49	0.38	Red blood cell count;	chr15:72186837	chr15:71818396~71823384:+
PCPG	cis	rs7017914	0.69	rs3098875	ENSG00000254031.4	RP11-326E22.1	5.07	1.17e-06	0.000825	0.37	0.38	Bone mineral density;	chr8:71022453	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs3098878	ENSG00000254031.4	RP11-326E22.1	5.07	1.17e-06	0.000825	0.37	0.38	Bone mineral density;	chr8:71025234	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.653	rs3098882	ENSG00000254031.4	RP11-326E22.1	5.07	1.17e-06	0.000825	0.37	0.38	Bone mineral density;	chr8:71027859	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.653	rs3110260	ENSG00000254031.4	RP11-326E22.1	5.07	1.17e-06	0.000825	0.37	0.38	Bone mineral density;	chr8:71028253	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs3110261	ENSG00000254031.4	RP11-326E22.1	5.07	1.17e-06	0.000825	0.37	0.38	Bone mineral density;	chr8:71029216	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs3110262	ENSG00000254031.4	RP11-326E22.1	5.07	1.17e-06	0.000825	0.37	0.38	Bone mineral density;	chr8:71029395	chr8:71155457~71204223:+
PCPG	cis	rs1949733	0.628	rs2688231	ENSG00000205959.3	RP11-689P11.2	-5.07	1.17e-06	0.000825	-0.43	-0.38	Response to antineoplastic agents;	chr4:8489254	chr4:8482270~8512610:+
PCPG	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	5.07	1.17e-06	0.000826	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
PCPG	cis	rs9595908	0.785	rs9596083	ENSG00000212293.1	SNORA16	5.07	1.17e-06	0.000826	0.46	0.38	Body mass index;	chr13:32700494	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs7326314	ENSG00000212293.1	SNORA16	5.07	1.17e-06	0.000826	0.46	0.38	Body mass index;	chr13:32706422	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs4942829	ENSG00000212293.1	SNORA16	5.07	1.17e-06	0.000826	0.46	0.38	Body mass index;	chr13:32708994	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs2183873	ENSG00000212293.1	SNORA16	5.07	1.17e-06	0.000826	0.46	0.38	Body mass index;	chr13:32710508	chr13:32420390~32420516:-
PCPG	cis	rs7246657	0.714	rs12972195	ENSG00000226686.6	LINC01535	-5.07	1.17e-06	0.000826	-0.61	-0.38	Coronary artery calcification;	chr19:37261603	chr19:37251912~37265535:+
PCPG	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	5.07	1.17e-06	0.000827	0.51	0.38	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
PCPG	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	5.07	1.17e-06	0.000827	0.34	0.38	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	5.07	1.17e-06	0.000827	0.34	0.38	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	5.07	1.17e-06	0.000827	0.34	0.38	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
PCPG	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	5.07	1.17e-06	0.000827	0.34	0.38	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
PCPG	cis	rs11148252	0.74	rs9536052	ENSG00000235660.1	LINC00345	5.07	1.17e-06	0.000827	0.49	0.38	Lewy body disease;	chr13:52386574	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.74	rs3803264	ENSG00000235660.1	LINC00345	5.07	1.17e-06	0.000827	0.49	0.38	Lewy body disease;	chr13:52397758	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.74	rs9526914	ENSG00000235660.1	LINC00345	-5.07	1.17e-06	0.000827	-0.49	-0.38	Lewy body disease;	chr13:52402165	chr13:52484161~52484680:-
PCPG	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	5.07	1.17e-06	0.000827	0.66	0.38	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
PCPG	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	5.07	1.17e-06	0.00083	0.43	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
PCPG	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-5.07	1.17e-06	0.00083	-0.42	-0.38	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
PCPG	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-5.07	1.17e-06	0.00083	-0.42	-0.38	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
PCPG	cis	rs853679	0.517	rs9380052	ENSG00000216901.1	AL022393.7	5.07	1.18e-06	0.000831	0.53	0.38	Depression;	chr6:28096845	chr6:28176188~28176674:+
PCPG	cis	rs62246343	0.719	rs1152314	ENSG00000254485.4	RP11-380O24.1	5.07	1.18e-06	0.000832	0.59	0.38	Fibrinogen levels;	chr3:9450656	chr3:9292588~9363303:-
PCPG	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	5.07	1.18e-06	0.000832	0.46	0.38	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
PCPG	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	5.07	1.18e-06	0.000834	0.53	0.38	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
PCPG	cis	rs1488515	0.512	rs2188507	ENSG00000279067.1	GS1-25M2.1	-5.07	1.18e-06	0.000834	-0.56	-0.38	Obesity-related traits;	chr7:96030439	chr7:96118647~96119995:+
PCPG	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	5.07	1.18e-06	0.000835	0.41	0.38	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
PCPG	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	5.06	1.18e-06	0.000836	0.5	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
PCPG	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	5.06	1.18e-06	0.000836	0.44	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
PCPG	cis	rs1044573	0.526	rs6050422	ENSG00000125804.12	FAM182A	-5.06	1.19e-06	0.000837	-0.43	-0.38	Allergic rhinitis;	chr20:25197284	chr20:26054655~26086917:+
PCPG	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-5.06	1.19e-06	0.000837	-0.51	-0.38	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
PCPG	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	1.19e-06	0.000838	-0.45	-0.38	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
PCPG	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	5.06	1.19e-06	0.000838	0.51	0.38	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
PCPG	cis	rs2288884	0.537	rs12151270	ENSG00000275055.1	CTC-471J1.11	-5.06	1.19e-06	0.000838	-0.35	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:52049007~52049754:+
PCPG	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	5.06	1.19e-06	0.000838	0.38	0.38	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	5.06	1.19e-06	0.000838	0.38	0.38	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	5.06	1.19e-06	0.000838	0.38	0.38	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
PCPG	cis	rs9650657	0.515	rs6601560	ENSG00000255020.1	AF131216.5	-5.06	1.19e-06	0.000839	-0.55	-0.38	Neuroticism;	chr8:11093356	chr8:11345748~11347502:-
PCPG	cis	rs9649213	0.593	rs13232181	ENSG00000272950.1	RP11-307C18.1	5.06	1.19e-06	0.00084	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr7:98322853~98323430:+
PCPG	cis	rs7824557	0.836	rs765731	ENSG00000255020.1	AF131216.5	-5.06	1.19e-06	0.000841	-0.48	-0.38	Retinal vascular caliber;	chr8:11263989	chr8:11345748~11347502:-
PCPG	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	5.06	1.19e-06	0.000842	0.39	0.38	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	5.06	1.19e-06	0.000842	0.39	0.38	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
PCPG	cis	rs2625529	0.652	rs2929532	ENSG00000260037.4	CTD-2524L6.3	5.06	1.19e-06	0.000842	0.51	0.38	Red blood cell count;	chr15:72052769	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.529	rs7183055	ENSG00000260037.4	CTD-2524L6.3	5.06	1.19e-06	0.000842	0.51	0.38	Red blood cell count;	chr15:72084707	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.652	rs8027164	ENSG00000260037.4	CTD-2524L6.3	5.06	1.19e-06	0.000842	0.51	0.38	Red blood cell count;	chr15:72115392	chr15:71818396~71823384:+
PCPG	cis	rs7945705	0.902	rs11042088	ENSG00000254860.4	TMEM9B-AS1	-5.06	1.19e-06	0.000843	-0.38	-0.38	Hemoglobin concentration;	chr11:8821968	chr11:8964675~8977527:+
PCPG	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-5.06	1.2e-06	0.000845	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-5.06	1.2e-06	0.000845	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-5.06	1.2e-06	0.000845	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-5.06	1.2e-06	0.000845	-0.42	-0.38	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
PCPG	cis	rs7208859	0.623	rs3752019	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73271869	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73271872	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs55724095	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs56146117	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.568	rs9903854	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Body mass index;	chr17:30826980	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.568	rs9907834	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Body mass index;	chr17:30826995	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs80355557	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9911173	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73271887	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9898858	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs55658077	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9899692	ENSG00000263603.1	CTD-2349P21.5	-5.06	1.2e-06	0.000845	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30729469~30731202:+
PCPG	cis	rs2625529	0.761	rs11853268	ENSG00000260037.4	CTD-2524L6.3	-5.06	1.2e-06	0.000846	-0.61	-0.38	Red blood cell count;	chr15:71946632	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs11072338	ENSG00000260037.4	CTD-2524L6.3	-5.06	1.2e-06	0.000846	-0.61	-0.38	Red blood cell count;	chr15:71953106	chr15:71818396~71823384:+
PCPG	cis	rs62246343	0.719	rs73130116	ENSG00000254485.4	RP11-380O24.1	5.06	1.2e-06	0.000846	0.59	0.38	Fibrinogen levels;	chr3:9452827	chr3:9292588~9363303:-
PCPG	cis	rs11992162	0.636	rs11250182	ENSG00000255020.1	AF131216.5	-5.06	1.21e-06	0.000849	-0.52	-0.38	Monocyte count;	chr8:11950067	chr8:11345748~11347502:-
PCPG	cis	rs2898290	0.622	rs978802	ENSG00000255020.1	AF131216.5	-5.06	1.21e-06	0.000849	-0.48	-0.38	Systolic blood pressure;	chr8:11485769	chr8:11345748~11347502:-
PCPG	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	5.06	1.21e-06	0.000849	0.52	0.38	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	5.06	1.21e-06	0.000849	0.52	0.38	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	5.06	1.21e-06	0.000849	0.52	0.38	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
PCPG	cis	rs73607972	0.575	rs12926468	ENSG00000275191.1	RP11-36I17.2	-5.06	1.21e-06	0.00085	-0.55	-0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53555488	chr16:53628256~53628816:-
PCPG	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-5.06	1.21e-06	0.000851	-0.46	-0.38	Height;	chr2:231539118	chr2:231508426~231514339:-
PCPG	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-5.06	1.21e-06	0.000853	-0.47	-0.38	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
PCPG	cis	rs879620	1	rs879620	ENSG00000262888.1	RP11-462G12.2	5.06	1.21e-06	0.000853	0.53	0.38	Hip circumference;Body mass index;	chr16:3965728	chr16:3931217~3946305:-
PCPG	cis	rs2164273	0.565	rs2736387	ENSG00000255020.1	AF131216.5	5.06	1.22e-06	0.000856	0.47	0.38	Extraversion;	chr8:11299862	chr8:11345748~11347502:-
PCPG	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	5.06	1.22e-06	0.000856	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
PCPG	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	5.06	1.22e-06	0.000856	0.62	0.38	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
PCPG	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	5.06	1.22e-06	0.000856	0.62	0.38	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
PCPG	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	5.06	1.22e-06	0.000856	0.62	0.38	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
PCPG	cis	rs9595908	0.785	rs9591236	ENSG00000212293.1	SNORA16	5.06	1.22e-06	0.000856	0.46	0.38	Body mass index;	chr13:32671667	chr13:32420390~32420516:-
PCPG	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	5.06	1.22e-06	0.000857	0.46	0.38	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
PCPG	cis	rs12646107	1	rs12646107	ENSG00000261672.1	RP11-475B2.1	-5.06	1.22e-06	0.000858	-0.58	-0.38	Response to amphetamines;	chr4:173594531	chr4:173593672~173594556:+
PCPG	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-5.06	1.22e-06	0.000858	-0.63	-0.38	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
PCPG	cis	rs11992162	0.573	rs13264994	ENSG00000255020.1	AF131216.5	-5.06	1.22e-06	0.000859	-0.51	-0.38	Monocyte count;	chr8:11925250	chr8:11345748~11347502:-
PCPG	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-5.06	1.22e-06	0.00086	-0.49	-0.38	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
PCPG	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	5.06	1.23e-06	0.000861	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
PCPG	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	5.06	1.23e-06	0.000862	0.41	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
PCPG	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-5.06	1.23e-06	0.000862	-0.61	-0.38	Depression;	chr6:28283207	chr6:28115628~28116551:+
PCPG	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	5.06	1.23e-06	0.000863	0.42	0.38	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
PCPG	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-5.06	1.23e-06	0.000863	-0.45	-0.38	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
PCPG	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	5.06	1.23e-06	0.000864	0.58	0.38	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
PCPG	cis	rs1440410	0.83	rs2165301	ENSG00000250326.1	RP11-284M14.1	5.06	1.23e-06	0.000864	0.34	0.38	Ischemic stroke;	chr4:143247497	chr4:142933195~143184861:-
PCPG	cis	rs2898290	0.622	rs978804	ENSG00000255020.1	AF131216.5	-5.06	1.23e-06	0.000865	-0.48	-0.38	Systolic blood pressure;	chr8:11486164	chr8:11345748~11347502:-
PCPG	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	5.06	1.23e-06	0.000865	0.59	0.38	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
PCPG	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-5.06	1.23e-06	0.000865	-0.59	-0.38	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
PCPG	cis	rs11148252	0.904	rs9526927	ENSG00000198384.8	TPTE2P3	-5.06	1.23e-06	0.000866	-0.48	-0.38	Lewy body disease;	chr13:52477492	chr13:52522632~52586906:+
PCPG	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-5.06	1.23e-06	0.000866	-0.48	-0.38	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
PCPG	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	5.06	1.23e-06	0.000866	0.37	0.38	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
PCPG	cis	rs6991838	0.548	rs11783633	ENSG00000272010.1	CTD-3025N20.3	5.06	1.23e-06	0.000867	0.35	0.38	Intelligence (multi-trait analysis);	chr8:65556593	chr8:65591850~65592472:-
PCPG	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	5.06	1.23e-06	0.000867	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
PCPG	cis	rs196889	0.536	rs406637	ENSG00000253535.4	RP11-624C23.1	5.06	1.24e-06	0.000867	0.37	0.38	Seasonality;	chr8:24867942	chr8:24295814~24912073:-
PCPG	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-5.06	1.24e-06	0.000868	-0.46	-0.38	Height;	chr2:231541633	chr2:231508426~231514339:-
PCPG	cis	rs3806843	0.868	rs2531352	ENSG00000202515.1	VTRNA1-3	5.06	1.24e-06	0.000868	0.48	0.38	Depressive symptoms (multi-trait analysis);	chr5:140739949	chr5:140726158~140726246:+
PCPG	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-5.06	1.24e-06	0.000868	-0.5	-0.38	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
PCPG	cis	rs1440410	0.83	rs10519678	ENSG00000250326.1	RP11-284M14.1	5.06	1.24e-06	0.000868	0.34	0.38	Ischemic stroke;	chr4:143260920	chr4:142933195~143184861:-
PCPG	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	5.06	1.24e-06	0.000868	0.46	0.38	Height;	chr6:109357369	chr6:109382795~109383666:+
PCPG	cis	rs5758511	0.68	rs5758662	ENSG00000205702.9	CYP2D7	5.05	1.24e-06	0.000869	0.52	0.38	Birth weight;	chr22:42232082	chr22:42140203~42144577:-
PCPG	cis	rs561341	0.941	rs8066558	ENSG00000265798.5	RP11-271K11.5	5.05	1.24e-06	0.000869	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31945860	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs2470267	ENSG00000265798.5	RP11-271K11.5	5.05	1.24e-06	0.000869	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31947113	chr17:31038575~31059121:-
PCPG	cis	rs2302464	1	rs73123625	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Cerebrospinal fluid biomarker levels;	chr4:15727550	chr4:15730962~15731627:-
PCPG	cis	rs7657257	1	rs12643722	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Blood protein levels;	chr4:15728480	chr4:15730962~15731627:-
PCPG	cis	rs7657257	1	rs12640554	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Blood protein levels;	chr4:15728484	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs111541714	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Cerebrospinal fluid biomarker levels;	chr4:15728782	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs73125993	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Cerebrospinal fluid biomarker levels;	chr4:15728890	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs16892287	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Cerebrospinal fluid biomarker levels;	chr4:15730570	chr4:15730962~15731627:-
PCPG	cis	rs7657257	1	rs4321629	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Blood protein levels;	chr4:15730757	chr4:15730962~15731627:-
PCPG	cis	rs7657257	1	rs10516290	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Blood protein levels;	chr4:15730833	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs10516291	ENSG00000214846.4	RP11-115L11.1	5.05	1.24e-06	0.000869	1	0.38	Cerebrospinal fluid biomarker levels;	chr4:15731168	chr4:15730962~15731627:-
PCPG	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	5.05	1.24e-06	0.000869	0.52	0.38	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
PCPG	cis	rs9649213	0.593	rs62478177	ENSG00000272950.1	RP11-307C18.1	5.05	1.24e-06	0.000869	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.555	rs12667634	ENSG00000272950.1	RP11-307C18.1	5.05	1.24e-06	0.000869	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	5.05	1.24e-06	0.000869	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
PCPG	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	5.05	1.24e-06	0.00087	0.46	0.38	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	5.05	1.24e-06	0.00087	0.46	0.38	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
PCPG	cis	rs561341	0.714	rs111760509	ENSG00000265798.5	RP11-271K11.5	5.05	1.24e-06	0.00087	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31977301	chr17:31038575~31059121:-
PCPG	cis	rs2625529	0.712	rs2054601	ENSG00000260037.4	CTD-2524L6.3	-5.05	1.24e-06	0.00087	-0.61	-0.38	Red blood cell count;	chr15:71892627	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs4777475	ENSG00000260037.4	CTD-2524L6.3	-5.05	1.24e-06	0.00087	-0.61	-0.38	Red blood cell count;	chr15:71925865	chr15:71818396~71823384:+
PCPG	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-5.05	1.24e-06	0.000871	-0.4	-0.38	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
PCPG	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	5.05	1.25e-06	0.000872	0.44	0.38	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
PCPG	cis	rs300890	0.689	rs300946	ENSG00000250326.1	RP11-284M14.1	5.05	1.25e-06	0.000873	0.35	0.38	Nasopharyngeal carcinoma;	chr4:143288265	chr4:142933195~143184861:-
PCPG	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	5.05	1.25e-06	0.000873	0.47	0.38	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	5.05	1.25e-06	0.000873	0.47	0.38	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
PCPG	cis	rs7246657	0.943	rs4802136	ENSG00000226686.6	LINC01535	-5.05	1.25e-06	0.000874	-0.62	-0.38	Coronary artery calcification;	chr19:37358909	chr19:37251912~37265535:+
PCPG	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	5.05	1.25e-06	0.000876	0.78	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
PCPG	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	5.05	1.25e-06	0.000876	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	5.05	1.25e-06	0.000876	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
PCPG	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-5.05	1.26e-06	0.000879	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
PCPG	cis	rs7017914	0.967	rs2639903	ENSG00000254031.4	RP11-326E22.1	5.05	1.26e-06	0.00088	0.38	0.38	Bone mineral density;	chr8:71005209	chr8:71155457~71204223:+
PCPG	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	5.05	1.26e-06	0.000882	0.46	0.38	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	5.05	1.26e-06	0.000882	0.46	0.38	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
PCPG	cis	rs2625529	0.938	rs4776579	ENSG00000260037.4	CTD-2524L6.3	-5.05	1.26e-06	0.000882	-0.6	-0.38	Red blood cell count;	chr15:71840267	chr15:71818396~71823384:+
PCPG	cis	rs11148252	0.904	rs9568734	ENSG00000198384.8	TPTE2P3	-5.05	1.26e-06	0.000882	-0.48	-0.38	Lewy body disease;	chr13:52430087	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.904	rs7990581	ENSG00000198384.8	TPTE2P3	-5.05	1.26e-06	0.000882	-0.48	-0.38	Lewy body disease;	chr13:52445298	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.904	rs3892337	ENSG00000198384.8	TPTE2P3	-5.05	1.26e-06	0.000882	-0.48	-0.38	Lewy body disease;	chr13:52455350	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.904	rs9536079	ENSG00000198384.8	TPTE2P3	-5.05	1.26e-06	0.000882	-0.48	-0.38	Lewy body disease;	chr13:52456430	chr13:52522632~52586906:+
PCPG	cis	rs853679	0.517	rs1904841	ENSG00000216901.1	AL022393.7	5.05	1.26e-06	0.000882	0.55	0.38	Depression;	chr6:28140307	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs1904840	ENSG00000216901.1	AL022393.7	5.05	1.26e-06	0.000882	0.55	0.38	Depression;	chr6:28140454	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9368555	ENSG00000216901.1	AL022393.7	5.05	1.26e-06	0.000882	0.55	0.38	Depression;	chr6:28141189	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393893	ENSG00000216901.1	AL022393.7	5.05	1.26e-06	0.000882	0.55	0.38	Depression;	chr6:28141484	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs4713146	ENSG00000216901.1	AL022393.7	5.05	1.26e-06	0.000882	0.55	0.38	Depression;	chr6:28143758	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs9393894	ENSG00000216901.1	AL022393.7	5.05	1.26e-06	0.000882	0.55	0.38	Depression;	chr6:28144784	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.517	rs868987	ENSG00000216901.1	AL022393.7	-5.05	1.26e-06	0.000882	-0.55	-0.38	Depression;	chr6:28142370	chr6:28176188~28176674:+
PCPG	cis	rs11673344	0.523	rs7248948	ENSG00000226686.6	LINC01535	5.05	1.26e-06	0.000883	0.48	0.38	Obesity-related traits;	chr19:37056317	chr19:37251912~37265535:+
PCPG	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	5.05	1.26e-06	0.000883	0.6	0.38	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
PCPG	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	5.05	1.26e-06	0.000884	0.48	0.38	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
PCPG	cis	rs1600249	0.562	rs17153419	ENSG00000255020.1	AF131216.5	-5.05	1.27e-06	0.000884	-0.53	-0.38	Rheumatoid arthritis;	chr8:11536724	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.738	rs7402143	ENSG00000259905.4	PWRN1	5.05	1.27e-06	0.000884	0.41	0.38	Platelet thrombus formation;	chr15:24508163	chr15:24493137~24652130:+
PCPG	cis	rs561341	0.882	rs2521594	ENSG00000265798.5	RP11-271K11.5	5.05	1.27e-06	0.000884	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31975068	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs548957	ENSG00000265798.5	RP11-271K11.5	5.05	1.27e-06	0.000884	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31975392	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs542132	ENSG00000265798.5	RP11-271K11.5	5.05	1.27e-06	0.000884	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31980174	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs484175	ENSG00000265798.5	RP11-271K11.5	5.05	1.27e-06	0.000884	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31982022	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.941	rs4525554	ENSG00000265798.5	RP11-271K11.5	5.05	1.27e-06	0.000884	0.68	0.38	Hip circumference adjusted for BMI;	chr17:31985800	chr17:31038575~31059121:-
PCPG	cis	rs3806843	1	rs10057161	ENSG00000202515.1	VTRNA1-3	-5.05	1.27e-06	0.000888	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr5:140726158~140726246:+
PCPG	cis	rs6121246	0.697	rs6088857	ENSG00000230613.1	HM13-AS1	5.05	1.27e-06	0.000888	0.55	0.38	Mean corpuscular hemoglobin;	chr20:31638961	chr20:31567707~31573263:-
PCPG	cis	rs3806843	1	rs3733710	ENSG00000202515.1	VTRNA1-3	-5.05	1.27e-06	0.000888	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.933	rs2240696	ENSG00000202515.1	VTRNA1-3	-5.05	1.27e-06	0.000888	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs2240695	ENSG00000202515.1	VTRNA1-3	-5.05	1.27e-06	0.000888	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs6579965	ENSG00000202515.1	VTRNA1-3	-5.05	1.27e-06	0.000888	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs6898906	ENSG00000202515.1	VTRNA1-3	-5.05	1.27e-06	0.000888	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr5:140726158~140726246:+
PCPG	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-5.05	1.27e-06	0.000889	-0.42	-0.38	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
PCPG	cis	rs11148252	0.774	rs56033750	ENSG00000198384.8	TPTE2P3	-5.05	1.27e-06	0.000889	-0.46	-0.38	Lewy body disease;	chr13:52173143	chr13:52522632~52586906:+
PCPG	cis	rs13113518	1	rs13114841	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55485974	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs939823	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55487368	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs6838882	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55489310	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13146987	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55491628	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs7677085	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55495801	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs12510681	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55496737	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs12500162	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55496933	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.934	rs3805155	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55497842	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs7686261	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55500224	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11729220	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55501629	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11133390	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55501726	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11133391	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55501788	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs13133484	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55504176	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.934	rs13127906	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55504201	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs6849433	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55506498	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs12501327	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55507248	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11133392	ENSG00000272969.1	RP11-528I4.2	5.05	1.28e-06	0.00089	0.42	0.38	Height;	chr4:55507729	chr4:55547112~55547889:+
PCPG	cis	rs12681963	0.688	rs7012749	ENSG00000248159.1	HSPA8P11	-5.05	1.28e-06	0.000892	-0.65	-0.38	Migraine;	chr8:30156243	chr8:30237382~30240997:+
PCPG	cis	rs11858159	1	rs11858320	ENSG00000259905.4	PWRN1	5.05	1.28e-06	0.000892	0.44	0.38	Platelet thrombus formation;	chr15:24536215	chr15:24493137~24652130:+
PCPG	cis	rs7403037	0.56	rs11161102	ENSG00000259905.4	PWRN1	5.05	1.28e-06	0.000892	0.44	0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24536668	chr15:24493137~24652130:+
PCPG	cis	rs3806843	1	rs2337985	ENSG00000202515.1	VTRNA1-3	-5.05	1.28e-06	0.000892	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs2337986	ENSG00000202515.1	VTRNA1-3	-5.05	1.28e-06	0.000892	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs1548701	ENSG00000202515.1	VTRNA1-3	-5.05	1.28e-06	0.000892	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs10073974	ENSG00000202515.1	VTRNA1-3	-5.05	1.28e-06	0.000892	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs3756342	ENSG00000202515.1	VTRNA1-3	-5.05	1.28e-06	0.000892	-0.49	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr5:140726158~140726246:+
PCPG	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	5.05	1.28e-06	0.000892	0.41	0.38	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	5.05	1.28e-06	0.000892	0.41	0.38	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	5.05	1.28e-06	0.000892	0.41	0.38	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	5.05	1.28e-06	0.000892	0.41	0.38	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	5.05	1.28e-06	0.000892	0.41	0.38	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
PCPG	cis	rs9595908	0.669	rs9591303	ENSG00000212293.1	SNORA16	5.05	1.28e-06	0.000892	0.47	0.38	Body mass index;	chr13:32748278	chr13:32420390~32420516:-
PCPG	cis	rs35538253	0.522	rs10492823	ENSG00000260886.1	TAT-AS1	5.05	1.28e-06	0.000893	0.75	0.38	Post bronchodilator FEV1;	chr16:71984961	chr16:71565789~71578187:+
PCPG	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	5.05	1.28e-06	0.000893	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
PCPG	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-5.05	1.28e-06	0.000894	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
PCPG	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	5.05	1.28e-06	0.000894	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
PCPG	cis	rs7733403	1	rs7733403	ENSG00000202515.1	VTRNA1-3	-5.05	1.28e-06	0.000895	-0.49	-0.38	Schizophrenia;	chr5:140774630	chr5:140726158~140726246:+
PCPG	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-5.05	1.29e-06	0.000896	-0.44	-0.38	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
PCPG	cis	rs1155848	0.892	rs3742121	ENSG00000227354.5	RBM26-AS1	5.05	1.29e-06	0.000897	0.79	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79387009	chr13:79406309~79424328:+
PCPG	cis	rs10131894	0.611	rs175001	ENSG00000279594.1	RP11-950C14.10	5.05	1.29e-06	0.000897	0.49	0.38	Coronary artery disease;	chr14:74969749	chr14:75011269~75012851:-
PCPG	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	5.05	1.29e-06	0.000897	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-5.05	1.29e-06	0.000897	-0.5	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
PCPG	cis	rs561341	0.882	rs504887	ENSG00000265798.5	RP11-271K11.5	5.05	1.29e-06	0.000898	0.67	0.38	Hip circumference adjusted for BMI;	chr17:31995862	chr17:31038575~31059121:-
PCPG	cis	rs1023500	0.573	rs133380	ENSG00000205702.9	CYP2D7	5.05	1.29e-06	0.000898	0.39	0.38	Schizophrenia;	chr22:42072906	chr22:42140203~42144577:-
PCPG	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	5.05	1.29e-06	0.000899	0.56	0.38	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
PCPG	cis	rs7824557	0.564	rs2736304	ENSG00000255020.1	AF131216.5	-5.05	1.29e-06	0.000899	-0.5	-0.38	Retinal vascular caliber;	chr8:11379455	chr8:11345748~11347502:-
PCPG	cis	rs6121246	0.529	rs7261354	ENSG00000230613.1	HM13-AS1	5.05	1.29e-06	9e-04	0.6	0.38	Mean corpuscular hemoglobin;	chr20:31614611	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.567	rs6120890	ENSG00000230613.1	HM13-AS1	5.05	1.29e-06	9e-04	0.6	0.38	Mean corpuscular hemoglobin;	chr20:31619856	chr20:31567707~31573263:-
PCPG	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	5.04	1.3e-06	0.000902	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
PCPG	cis	rs7819412	0.775	rs2001329	ENSG00000255020.1	AF131216.5	-5.04	1.3e-06	0.000904	-0.51	-0.38	Triglycerides;	chr8:11129349	chr8:11345748~11347502:-
PCPG	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	5.04	1.3e-06	0.000905	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
PCPG	cis	rs12681963	0.614	rs7837611	ENSG00000248159.1	HSPA8P11	5.04	1.3e-06	0.000905	0.73	0.38	Migraine;	chr8:30210013	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs7014016	ENSG00000248159.1	HSPA8P11	5.04	1.3e-06	0.000905	0.73	0.38	Migraine;	chr8:30211271	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs73234786	ENSG00000248159.1	HSPA8P11	5.04	1.3e-06	0.000905	0.73	0.38	Migraine;	chr8:30212836	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs12680753	ENSG00000248159.1	HSPA8P11	5.04	1.3e-06	0.000905	0.73	0.38	Migraine;	chr8:30212963	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs55991127	ENSG00000248159.1	HSPA8P11	5.04	1.3e-06	0.000905	0.73	0.38	Migraine;	chr8:30213510	chr8:30237382~30240997:+
PCPG	cis	rs3806843	0.735	rs801167	ENSG00000202515.1	VTRNA1-3	-5.04	1.3e-06	0.000906	-0.47	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr5:140726158~140726246:+
PCPG	cis	rs12908161	0.92	rs35758837	ENSG00000259295.5	CSPG4P12	5.04	1.3e-06	0.000906	0.57	0.38	Schizophrenia;	chr15:84768151	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs17600551	ENSG00000259295.5	CSPG4P12	5.04	1.3e-06	0.000906	0.57	0.38	Schizophrenia;	chr15:84776027	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs36033486	ENSG00000259295.5	CSPG4P12	5.04	1.3e-06	0.000906	0.57	0.38	Schizophrenia;	chr15:84776461	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs62019469	ENSG00000259295.5	CSPG4P12	5.04	1.3e-06	0.000906	0.57	0.38	Schizophrenia;	chr15:84777989	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs12908549	ENSG00000259295.5	CSPG4P12	5.04	1.3e-06	0.000906	0.57	0.38	Schizophrenia;	chr15:84779120	chr15:85191438~85213905:+
PCPG	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	5.04	1.3e-06	0.000907	0.41	0.38	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
PCPG	cis	rs7208859	0.673	rs9915139	ENSG00000263603.1	CTD-2349P21.5	-5.04	1.31e-06	0.000908	-0.61	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30729469~30731202:+
PCPG	cis	rs7017914	0.667	rs2732124	ENSG00000254031.4	RP11-326E22.1	5.04	1.31e-06	0.000908	0.36	0.38	Bone mineral density;	chr8:70986447	chr8:71155457~71204223:+
PCPG	cis	rs12908161	1	rs11638290	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84684405	chr15:85191438~85213905:+
PCPG	cis	rs12908161	0.959	rs34028043	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84688354	chr15:85191438~85213905:+
PCPG	cis	rs12908161	0.959	rs34784022	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84688675	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs12911736	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84696777	chr15:85191438~85213905:+
PCPG	cis	rs12908161	0.959	rs12908699	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84697172	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs35316992	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84704902	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs4643294	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84707022	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs34900908	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84714368	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs35524990	ENSG00000259295.5	CSPG4P12	5.04	1.31e-06	0.000909	0.57	0.38	Schizophrenia;	chr15:84714972	chr15:85191438~85213905:+
PCPG	cis	rs7208859	0.623	rs9906957	ENSG00000263603.1	CTD-2349P21.5	-5.04	1.31e-06	0.00091	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30729469~30731202:+
PCPG	cis	rs9926296	0.533	rs7190823	ENSG00000260259.1	RP11-368I7.4	-5.04	1.31e-06	0.00091	-0.45	-0.38	Vitiligo;	chr16:89799635	chr16:89682620~89686569:-
PCPG	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	5.04	1.31e-06	0.00091	0.33	0.38	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
PCPG	cis	rs9649213	0.593	rs3801263	ENSG00000272950.1	RP11-307C18.1	5.04	1.31e-06	0.000912	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr7:98322853~98323430:+
PCPG	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	5.04	1.31e-06	0.000912	0.39	0.38	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
PCPG	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Depression;	chr6:28399886	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	5.04	1.31e-06	0.000912	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
PCPG	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	5.04	1.32e-06	0.000912	0.43	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
PCPG	cis	rs9392556	0.6	rs664299	ENSG00000230648.1	RP3-406P24.3	5.04	1.32e-06	0.000912	0.46	0.38	Blood metabolite levels;	chr6:4112007	chr6:4018843~4021215:-
PCPG	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	5.04	1.32e-06	0.000913	0.42	0.38	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
PCPG	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-5.04	1.32e-06	0.000913	-0.61	-0.38	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
PCPG	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-5.04	1.32e-06	0.000913	-0.48	-0.38	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
PCPG	cis	rs853679	1	rs7740487	ENSG00000219392.1	RP1-265C24.5	-5.04	1.32e-06	0.000914	-0.62	-0.38	Depression;	chr6:28248708	chr6:28115628~28116551:+
PCPG	cis	rs853679	1	rs68141011	ENSG00000219392.1	RP1-265C24.5	-5.04	1.32e-06	0.000914	-0.62	-0.38	Depression;	chr6:28250019	chr6:28115628~28116551:+
PCPG	cis	rs3806843	0.735	rs801188	ENSG00000202515.1	VTRNA1-3	5.04	1.32e-06	0.000916	0.47	0.38	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr5:140726158~140726246:+
PCPG	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	5.04	1.33e-06	0.000917	0.47	0.38	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
PCPG	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-5.04	1.33e-06	0.000917	-0.35	-0.38	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
PCPG	cis	rs7824557	0.564	rs2572400	ENSG00000255020.1	AF131216.5	-5.04	1.33e-06	0.000917	-0.5	-0.38	Retinal vascular caliber;	chr8:11376858	chr8:11345748~11347502:-
PCPG	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-5.04	1.33e-06	0.000917	-0.42	-0.38	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
PCPG	cis	rs9595908	0.869	rs9591189	ENSG00000212293.1	SNORA16	5.04	1.33e-06	0.000919	0.46	0.38	Body mass index;	chr13:32632514	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.869	rs9591191	ENSG00000212293.1	SNORA16	5.04	1.33e-06	0.000919	0.46	0.38	Body mass index;	chr13:32633397	chr13:32420390~32420516:-
PCPG	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-5.04	1.33e-06	0.000919	-0.61	-0.38	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
PCPG	cis	rs13113518	1	rs13122619	ENSG00000272969.1	RP11-528I4.2	5.04	1.33e-06	0.000919	0.42	0.38	Height;	chr4:55479339	chr4:55547112~55547889:+
PCPG	cis	rs453301	0.624	rs7014430	ENSG00000173295.6	FAM86B3P	-5.04	1.33e-06	0.00092	-0.45	-0.38	Joint mobility (Beighton score);	chr8:8970227	chr8:8228595~8244865:+
PCPG	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-5.04	1.33e-06	0.00092	-0.35	-0.38	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
PCPG	cis	rs7824557	0.778	rs3808502	ENSG00000255020.1	AF131216.5	5.04	1.33e-06	0.000921	0.51	0.38	Retinal vascular caliber;	chr8:11321949	chr8:11345748~11347502:-
PCPG	cis	rs7208859	0.623	rs9912440	ENSG00000263603.1	CTD-2349P21.5	-5.04	1.33e-06	0.000922	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30729469~30731202:+
PCPG	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	-5.04	1.33e-06	0.000922	-0.45	-0.38	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
PCPG	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	5.04	1.34e-06	0.000923	0.56	0.38	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	5.04	1.34e-06	0.000923	0.56	0.38	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
PCPG	cis	rs9595908	0.785	rs6561500	ENSG00000212293.1	SNORA16	5.04	1.34e-06	0.000923	0.46	0.38	Body mass index;	chr13:32681234	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs3912038	ENSG00000212293.1	SNORA16	5.04	1.34e-06	0.000923	0.46	0.38	Body mass index;	chr13:32682061	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.785	rs3848085	ENSG00000212293.1	SNORA16	5.04	1.34e-06	0.000923	0.46	0.38	Body mass index;	chr13:32687527	chr13:32420390~32420516:-
PCPG	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	5.04	1.34e-06	0.000924	0.39	0.38	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	5.04	1.34e-06	0.000924	0.39	0.38	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	5.04	1.34e-06	0.000924	0.39	0.38	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	5.04	1.34e-06	0.000924	0.39	0.38	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	5.04	1.34e-06	0.000924	0.39	0.38	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	5.04	1.34e-06	0.000924	0.39	0.38	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
PCPG	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	5.04	1.34e-06	0.000924	0.47	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
PCPG	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	5.04	1.34e-06	0.000926	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
PCPG	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	5.04	1.34e-06	0.000927	0.5	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
PCPG	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-5.04	1.34e-06	0.000928	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
PCPG	cis	rs561341	1	rs521919	ENSG00000265798.5	RP11-271K11.5	5.04	1.35e-06	0.000929	0.67	0.38	Hip circumference adjusted for BMI;	chr17:31971020	chr17:31038575~31059121:-
PCPG	cis	rs12908161	1	rs62021219	ENSG00000259295.5	CSPG4P12	5.04	1.35e-06	0.000929	0.57	0.38	Schizophrenia;	chr15:84712928	chr15:85191438~85213905:+
PCPG	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-5.04	1.35e-06	0.00093	-0.57	-0.38	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
PCPG	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-5.04	1.35e-06	0.000931	-0.44	-0.38	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
PCPG	cis	rs7474896	0.806	rs1779150	ENSG00000226578.1	RP11-258F22.1	-5.04	1.35e-06	0.000931	-0.82	-0.38	Obesity (extreme);	chr10:37749759	chr10:37775371~37784131:-
PCPG	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	5.04	1.35e-06	0.000933	0.4	0.38	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
PCPG	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	5.04	1.35e-06	0.000933	0.4	0.38	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
PCPG	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	5.04	1.35e-06	0.000933	0.4	0.38	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
PCPG	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	5.04	1.35e-06	0.000933	0.4	0.38	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
PCPG	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	5.04	1.35e-06	0.000933	0.4	0.38	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
PCPG	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	5.03	1.35e-06	0.000934	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
PCPG	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-5.03	1.36e-06	0.000937	-0.49	-0.38	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
PCPG	cis	rs957448	0.561	rs58663902	ENSG00000253704.1	RP11-267M23.4	5.03	1.36e-06	0.000939	0.41	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94553722~94569745:+
PCPG	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	5.03	1.36e-06	0.00094	0.64	0.38	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
PCPG	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	5.03	1.36e-06	0.00094	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
PCPG	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	5.03	1.36e-06	0.000941	0.42	0.38	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
PCPG	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	5.03	1.36e-06	0.000941	0.39	0.38	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
PCPG	cis	rs12908161	0.959	rs12906348	ENSG00000259295.5	CSPG4P12	5.03	1.37e-06	0.000941	0.56	0.38	Schizophrenia;	chr15:84786190	chr15:85191438~85213905:+
PCPG	cis	rs12908161	0.959	rs34342559	ENSG00000259295.5	CSPG4P12	5.03	1.37e-06	0.000941	0.56	0.38	Schizophrenia;	chr15:84788040	chr15:85191438~85213905:+
PCPG	cis	rs12908161	0.959	rs35557864	ENSG00000259295.5	CSPG4P12	5.03	1.37e-06	0.000941	0.56	0.38	Schizophrenia;	chr15:84788398	chr15:85191438~85213905:+
PCPG	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.03	1.37e-06	0.000942	0.6	0.38	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
PCPG	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	5.03	1.37e-06	0.000942	0.42	0.38	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
PCPG	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-5.03	1.37e-06	0.000943	-0.38	-0.38	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
PCPG	cis	rs17507216	0.591	rs7163848	ENSG00000228141.5	AC105339.1	-5.03	1.37e-06	0.000943	-0.59	-0.38	Excessive daytime sleepiness;	chr15:82729563	chr15:82710471~82714026:-
PCPG	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	5.03	1.37e-06	0.000944	0.6	0.38	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
PCPG	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	5.03	1.37e-06	0.000945	0.37	0.38	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	5.03	1.37e-06	0.000945	0.37	0.38	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
PCPG	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-5.03	1.37e-06	0.000946	-0.44	-0.38	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
PCPG	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	5.03	1.38e-06	0.000948	0.62	0.38	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
PCPG	cis	rs7829975	0.511	rs2955578	ENSG00000173295.6	FAM86B3P	-5.03	1.38e-06	0.000949	-0.45	-0.38	Mood instability;	chr8:8279561	chr8:8228595~8244865:+
PCPG	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	5.03	1.38e-06	0.000949	0.47	0.38	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
PCPG	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	5.03	1.38e-06	0.000949	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.613	rs7777415	ENSG00000272950.1	RP11-307C18.1	5.03	1.38e-06	0.000949	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr7:98322853~98323430:+
PCPG	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-5.03	1.38e-06	0.00095	-0.43	-0.38	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
PCPG	cis	rs7208859	0.623	rs7214570	ENSG00000263603.1	CTD-2349P21.5	-5.03	1.38e-06	0.00095	-0.6	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30729469~30731202:+
PCPG	cis	rs11148252	0.514	rs1886539	ENSG00000235660.1	LINC00345	-5.03	1.38e-06	0.000951	-0.48	-0.38	Lewy body disease;	chr13:52151955	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.514	rs9526843	ENSG00000235660.1	LINC00345	-5.03	1.38e-06	0.000951	-0.48	-0.38	Lewy body disease;	chr13:52155921	chr13:52484161~52484680:-
PCPG	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-5.03	1.39e-06	0.000952	-0.48	-0.38	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
PCPG	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	5.03	1.39e-06	0.000952	0.41	0.38	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
PCPG	cis	rs9303029	0.551	rs72859131	ENSG00000279744.1	RP13-20L14.10	-5.03	1.39e-06	0.000954	-0.59	-0.38	Protein quantitative trait loci;	chr17:82471977	chr17:82462601~82464255:+
PCPG	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-5.03	1.39e-06	0.000954	-0.36	-0.38	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-5.03	1.39e-06	0.000954	-0.36	-0.38	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-5.03	1.39e-06	0.000954	-0.36	-0.38	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-5.03	1.39e-06	0.000954	-0.36	-0.38	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-5.03	1.39e-06	0.000954	-0.36	-0.38	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-5.03	1.39e-06	0.000954	-0.36	-0.38	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-5.03	1.39e-06	0.000954	-0.36	-0.38	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	5.03	1.39e-06	0.000954	0.36	0.38	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
PCPG	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	5.03	1.39e-06	0.000955	0.41	0.38	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
PCPG	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	5.03	1.4e-06	0.000958	0.43	0.38	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
PCPG	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	5.03	1.4e-06	0.00096	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
PCPG	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-5.03	1.4e-06	0.000961	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-5.03	1.4e-06	0.000961	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
PCPG	cis	rs300890	0.513	rs11100781	ENSG00000250326.1	RP11-284M14.1	5.03	1.4e-06	0.000962	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143211469	chr4:142933195~143184861:-
PCPG	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	5.03	1.4e-06	0.000962	0.58	0.38	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	5.03	1.4e-06	0.000962	0.58	0.38	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
PCPG	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-5.03	1.4e-06	0.000962	-0.51	-0.38	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
PCPG	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-5.03	1.41e-06	0.000963	-0.47	-0.38	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
PCPG	cis	rs748404	0.589	rs62020616	ENSG00000249839.1	AC011330.5	-5.03	1.41e-06	0.000963	-0.51	-0.38	Lung cancer;	chr15:43558554	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.626	rs60367691	ENSG00000249839.1	AC011330.5	-5.03	1.41e-06	0.000963	-0.51	-0.38	Lung cancer;	chr15:43559201	chr15:43663654~43684339:-
PCPG	cis	rs300890	0.513	rs7673827	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143222187	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs10434185	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143225242	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs2323076	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143230758	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs13138084	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143233086	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs10015751	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143235665	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.56	rs12649219	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143235932	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.536	rs6845478	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Ischemic stroke;	chr4:143239491	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.56	rs1440414	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Ischemic stroke;	chr4:143240837	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs10015412	ENSG00000250326.1	RP11-284M14.1	5.03	1.41e-06	0.000964	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143241429	chr4:142933195~143184861:-
PCPG	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-5.03	1.41e-06	0.000966	-0.4	-0.38	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
PCPG	cis	rs2736345	0.788	rs2618476	ENSG00000255020.1	AF131216.5	5.03	1.41e-06	0.000967	0.51	0.38	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11345748~11347502:-
PCPG	cis	rs7688540	0.8	rs10028482	ENSG00000275426.1	CH17-262A2.1	5.03	1.41e-06	0.000968	0.45	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:149738~150317:+
PCPG	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-5.02	1.42e-06	0.000969	-0.41	-0.38	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
PCPG	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-5.02	1.42e-06	0.00097	-0.41	-0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
PCPG	cis	rs561341	1	rs550264	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31990521	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs564714	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31991385	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs111454793	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31992248	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs527256	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31994274	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs473356	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31994743	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs576985	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31996304	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs510264	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31996395	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs15654	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31999341	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs550923	ENSG00000265798.5	RP11-271K11.5	5.02	1.42e-06	0.000971	0.69	0.38	Hip circumference adjusted for BMI;	chr17:31999994	chr17:31038575~31059121:-
PCPG	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-5.02	1.42e-06	0.000971	-0.46	-0.38	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-5.02	1.42e-06	0.000971	-0.46	-0.38	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-5.02	1.42e-06	0.000971	-0.46	-0.38	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-5.02	1.42e-06	0.000971	-0.46	-0.38	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
PCPG	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-5.02	1.42e-06	0.000972	-0.44	-0.38	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
PCPG	cis	rs12681963	1	rs1355412	ENSG00000248159.1	HSPA8P11	5.02	1.42e-06	0.000972	0.59	0.38	Migraine;	chr8:30128167	chr8:30237382~30240997:+
PCPG	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	5.02	1.42e-06	0.000973	0.43	0.38	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
PCPG	cis	rs5769765	0.773	rs9616382	ENSG00000278869.1	CITF22-49E9.3	5.02	1.42e-06	0.000973	0.53	0.38	Schizophrenia;	chr22:49919331	chr22:49933198~49934074:-
PCPG	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	5.02	1.42e-06	0.000973	0.5	0.38	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
PCPG	cis	rs8072100	0.72	rs4794057	ENSG00000228782.6	CTD-2026D20.3	5.02	1.42e-06	0.000973	0.41	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47709086	chr17:47450568~47492492:-
PCPG	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	5.02	1.42e-06	0.000973	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
PCPG	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	5.02	1.43e-06	0.000975	0.51	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
PCPG	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	5.02	1.43e-06	0.000975	0.43	0.38	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
PCPG	cis	rs9595908	0.785	rs969703	ENSG00000212293.1	SNORA16	5.02	1.43e-06	0.000976	0.46	0.38	Body mass index;	chr13:32708264	chr13:32420390~32420516:-
PCPG	cis	rs853679	1	rs11965538	ENSG00000219392.1	RP1-265C24.5	-5.02	1.43e-06	0.000976	-0.6	-0.38	Depression;	chr6:28272137	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.882	rs2743555	ENSG00000219392.1	RP1-265C24.5	-5.02	1.43e-06	0.000976	-0.6	-0.38	Depression;	chr6:28273304	chr6:28115628~28116551:+
PCPG	cis	rs2830585	0.651	rs229052	ENSG00000197934.7	CYYR1-AS1	5.02	1.43e-06	0.000977	0.5	0.38	Blood protein levels;	chr21:26943889	chr21:26393635~26569252:+
PCPG	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	5.02	1.43e-06	0.000978	0.52	0.38	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
PCPG	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	5.02	1.44e-06	0.000981	0.47	0.38	Height;	chr6:109405536	chr6:109382795~109383666:+
PCPG	cis	rs10435719	0.718	rs7813935	ENSG00000255495.1	AC145124.2	5.02	1.44e-06	0.000982	0.39	0.38	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.504	rs7830734	ENSG00000255495.1	AC145124.2	5.02	1.44e-06	0.000982	0.39	0.38	Neuroticism;	chr8:11938130	chr8:12194467~12196280:+
PCPG	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	5.02	1.44e-06	0.000983	0.39	0.38	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	5.02	1.44e-06	0.000983	0.39	0.38	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
PCPG	cis	rs9595908	0.869	rs7983457	ENSG00000212293.1	SNORA16	-5.02	1.44e-06	0.000983	-0.46	-0.38	Body mass index;	chr13:32631797	chr13:32420390~32420516:-
PCPG	cis	rs17826219	0.706	rs57698184	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Body mass index;	chr17:30737900	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.524	rs59923796	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.5	rs57005940	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Body mass index;	chr17:30739311	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs73267872	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs9893922	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Body mass index;	chr17:30741407	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs56812022	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.524	rs57670615	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.5	rs2874724	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Body mass index;	chr17:30745415	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.568	rs9898097	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Body mass index;	chr17:30745654	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.5	rs9891256	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Body mass index;	chr17:30745674	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9911490	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7503542	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7503335	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs11656278	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs6505207	ENSG00000263603.1	CTD-2349P21.5	-5.02	1.44e-06	0.000983	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30729469~30731202:+
PCPG	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-5.02	1.44e-06	0.000984	-0.5	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
PCPG	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	5.02	1.44e-06	0.000985	0.5	0.38	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
PCPG	cis	rs7181230	0.885	rs749748	ENSG00000259584.1	RP11-521C20.2	5.02	1.44e-06	0.000985	0.5	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40075204~40078704:-
PCPG	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-5.02	1.45e-06	0.000985	-0.47	-0.38	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
PCPG	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-5.02	1.45e-06	0.000985	-0.57	-0.38	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
PCPG	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-5.02	1.45e-06	0.000985	-0.57	-0.38	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
PCPG	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-5.02	1.45e-06	0.000985	-0.57	-0.38	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
PCPG	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	5.02	1.45e-06	0.000986	0.46	0.38	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
PCPG	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	5.02	1.45e-06	0.000986	0.46	0.38	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
PCPG	cis	rs13113518	0.812	rs11133385	ENSG00000272969.1	RP11-528I4.2	5.02	1.45e-06	0.000986	0.42	0.38	Height;	chr4:55460485	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.783	rs6843722	ENSG00000272969.1	RP11-528I4.2	5.02	1.45e-06	0.000986	0.42	0.38	Height;	chr4:55465165	chr4:55547112~55547889:+
PCPG	cis	rs453301	0.624	rs2979265	ENSG00000173295.6	FAM86B3P	-5.02	1.45e-06	0.000986	-0.44	-0.38	Joint mobility (Beighton score);	chr8:9001207	chr8:8228595~8244865:+
PCPG	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-5.02	1.45e-06	0.000989	-0.5	-0.38	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
PCPG	cis	rs2898290	0.506	rs2736311	ENSG00000255556.2	RP11-351I21.6	-5.02	1.45e-06	0.000989	-0.38	-0.38	Systolic blood pressure;	chr8:11394661	chr8:12378679~12380265:-
PCPG	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	5.02	1.46e-06	0.000991	0.43	0.38	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
PCPG	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-5.02	1.46e-06	0.000992	-0.52	-0.38	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
PCPG	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.823	rs4802236	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37428344	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.882	rs10422667	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37446974	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-5.02	1.46e-06	0.000992	-0.61	-0.38	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs4801803	ENSG00000226686.6	LINC01535	5.02	1.46e-06	0.000992	0.61	0.38	Coronary artery calcification;	chr19:37476021	chr19:37251912~37265535:+
PCPG	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	5.02	1.46e-06	0.000994	0.45	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
PCPG	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	5.02	1.46e-06	0.000995	0.43	0.38	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
PCPG	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-5.02	1.46e-06	0.000995	-0.53	-0.38	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
PCPG	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-5.02	1.47e-06	0.000998	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
PCPG	cis	rs11992162	0.636	rs4841644	ENSG00000255020.1	AF131216.5	5.02	1.47e-06	0.000999	0.52	0.38	Monocyte count;	chr8:11940924	chr8:11345748~11347502:-
PCPG	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	5.02	1.47e-06	0.000999	0.38	0.38	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.606	rs10112585	ENSG00000173295.6	FAM86B3P	5.02	1.48e-06	0.001	0.44	0.38	Mood instability;	chr8:8937520	chr8:8228595~8244865:+
PCPG	cis	rs6121246	0.697	rs6088856	ENSG00000230613.1	HM13-AS1	5.01	1.48e-06	0.00101	0.55	0.38	Mean corpuscular hemoglobin;	chr20:31638740	chr20:31567707~31573263:-
PCPG	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	5.01	1.48e-06	0.00101	0.49	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
PCPG	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	5.01	1.48e-06	0.00101	0.46	0.38	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
PCPG	cis	rs300890	0.689	rs300951	ENSG00000250326.1	RP11-284M14.1	5.01	1.49e-06	0.00101	0.34	0.38	Nasopharyngeal carcinoma;	chr4:143280230	chr4:142933195~143184861:-
PCPG	cis	rs9649213	0.555	rs67132564	ENSG00000272950.1	RP11-307C18.1	5.01	1.49e-06	0.00101	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr7:98322853~98323430:+
PCPG	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	5.01	1.49e-06	0.00101	0.38	0.38	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	5.01	1.49e-06	0.00101	0.38	0.38	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	5.01	1.49e-06	0.00101	0.38	0.38	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	5.01	1.49e-06	0.00101	0.38	0.38	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	5.01	1.49e-06	0.00101	0.38	0.38	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	5.01	1.49e-06	0.00101	0.38	0.38	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	5.01	1.49e-06	0.00101	0.38	0.38	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-5.01	1.49e-06	0.00101	-0.38	-0.38	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-5.01	1.49e-06	0.00101	-0.38	-0.38	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-5.01	1.49e-06	0.00101	-0.38	-0.38	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-5.01	1.49e-06	0.00101	-0.38	-0.38	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
PCPG	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-5.01	1.49e-06	0.00101	-0.37	-0.38	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
PCPG	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-5.01	1.49e-06	0.00101	-0.41	-0.38	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
PCPG	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-5.01	1.49e-06	0.00101	-0.42	-0.38	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
PCPG	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	5.01	1.5e-06	0.00102	0.59	0.38	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
PCPG	cis	rs12681963	0.764	rs4733391	ENSG00000248159.1	HSPA8P11	-5.01	1.5e-06	0.00102	-0.77	-0.38	Migraine;	chr8:30140084	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.565	rs4733393	ENSG00000248159.1	HSPA8P11	-5.01	1.5e-06	0.00102	-0.77	-0.38	Migraine;	chr8:30140438	chr8:30237382~30240997:+
PCPG	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	5.01	1.5e-06	0.00102	0.45	0.38	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
PCPG	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	5.01	1.5e-06	0.00102	0.41	0.38	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
PCPG	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	5.01	1.5e-06	0.00102	0.46	0.38	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
PCPG	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-5.01	1.5e-06	0.00102	-0.64	-0.38	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
PCPG	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-5.01	1.5e-06	0.00102	-0.49	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
PCPG	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-5.01	1.5e-06	0.00102	-0.5	-0.38	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-5.01	1.5e-06	0.00102	-0.5	-0.38	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
PCPG	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-5.01	1.51e-06	0.00102	-0.51	-0.38	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
PCPG	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	5.01	1.51e-06	0.00102	0.58	0.38	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
PCPG	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	5.01	1.51e-06	0.00102	0.41	0.38	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
PCPG	cis	rs1440410	0.83	rs12499485	ENSG00000250326.1	RP11-284M14.1	5.01	1.51e-06	0.00102	0.35	0.38	Ischemic stroke;	chr4:143253707	chr4:142933195~143184861:-
PCPG	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-5.01	1.51e-06	0.00103	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
PCPG	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	5.01	1.52e-06	0.00103	0.55	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
PCPG	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-5.01	1.52e-06	0.00103	-0.61	-0.38	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
PCPG	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-5.01	1.52e-06	0.00103	-0.49	-0.38	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
PCPG	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-5.01	1.52e-06	0.00103	-0.43	-0.38	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
PCPG	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-5.01	1.52e-06	0.00103	-0.41	-0.38	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
PCPG	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	5.01	1.52e-06	0.00103	0.45	0.38	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
PCPG	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-5.01	1.52e-06	0.00103	-0.34	-0.38	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
PCPG	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	5.01	1.53e-06	0.00103	0.39	0.38	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
PCPG	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	5.01	1.53e-06	0.00103	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	5.01	1.53e-06	0.00103	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
PCPG	cis	rs7829975	0.606	rs891570	ENSG00000173295.6	FAM86B3P	5.01	1.53e-06	0.00103	0.44	0.38	Mood instability;	chr8:8936944	chr8:8228595~8244865:+
PCPG	cis	rs9595908	0.785	rs9596058	ENSG00000212293.1	SNORA16	5.01	1.53e-06	0.00103	0.45	0.38	Body mass index;	chr13:32669938	chr13:32420390~32420516:-
PCPG	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	5.01	1.53e-06	0.00104	0.43	0.38	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
PCPG	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	5.01	1.53e-06	0.00104	0.34	0.38	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
PCPG	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-5.01	1.54e-06	0.00104	-0.59	-0.38	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
PCPG	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	5.01	1.54e-06	0.00104	0.5	0.38	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
PCPG	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	5.01	1.54e-06	0.00104	0.56	0.38	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
PCPG	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	5.01	1.54e-06	0.00104	0.38	0.38	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	5.01	1.54e-06	0.00104	0.38	0.38	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
PCPG	cis	rs7829975	0.606	rs6422352	ENSG00000173295.6	FAM86B3P	5.01	1.54e-06	0.00104	0.44	0.38	Mood instability;	chr8:8936683	chr8:8228595~8244865:+
PCPG	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	5.01	1.54e-06	0.00104	0.42	0.38	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.01	1.54e-06	0.00104	-0.42	-0.38	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
PCPG	cis	rs2028414	0.512	rs2247712	ENSG00000258701.1	LINC00638	5.01	1.54e-06	0.00104	0.5	0.38	IgG glycosylation;	chr14:104893490	chr14:104821201~104823718:+
PCPG	cis	rs3806843	0.705	rs2530230	ENSG00000202515.1	VTRNA1-3	5.01	1.55e-06	0.00105	0.47	0.38	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr5:140726158~140726246:+
PCPG	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	5	1.55e-06	0.00105	0.54	0.38	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
PCPG	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	-5	1.55e-06	0.00105	-0.43	-0.38	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
PCPG	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	5	1.55e-06	0.00105	0.52	0.38	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
PCPG	cis	rs300890	0.513	rs10000911	ENSG00000250326.1	RP11-284M14.1	5	1.55e-06	0.00105	0.36	0.38	Nasopharyngeal carcinoma;	chr4:143215040	chr4:142933195~143184861:-
PCPG	cis	rs7824557	0.564	rs34389419	ENSG00000255020.1	AF131216.5	-5	1.55e-06	0.00105	-0.49	-0.38	Retinal vascular caliber;	chr8:11371810	chr8:11345748~11347502:-
PCPG	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	5	1.56e-06	0.00105	0.55	0.38	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
PCPG	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	5	1.56e-06	0.00105	0.56	0.38	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
PCPG	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	5	1.56e-06	0.00105	0.5	0.38	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
PCPG	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	5	1.56e-06	0.00105	0.5	0.38	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
PCPG	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	5	1.56e-06	0.00106	0.48	0.38	Height;	chr6:109395761	chr6:109382795~109383666:+
PCPG	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-5	1.57e-06	0.00106	-0.5	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
PCPG	cis	rs453301	0.686	rs3989373	ENSG00000173295.6	FAM86B3P	5	1.57e-06	0.00106	0.44	0.38	Joint mobility (Beighton score);	chr8:9053798	chr8:8228595~8244865:+
PCPG	cis	rs1440410	0.795	rs6822299	ENSG00000250326.1	RP11-284M14.1	5	1.57e-06	0.00106	0.34	0.38	Ischemic stroke;	chr4:143261210	chr4:142933195~143184861:-
PCPG	cis	rs561341	1	rs7210970	ENSG00000265798.5	RP11-271K11.5	5	1.57e-06	0.00106	0.67	0.38	Hip circumference adjusted for BMI;	chr17:31935150	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs8070262	ENSG00000265798.5	RP11-271K11.5	5	1.57e-06	0.00106	0.67	0.38	Hip circumference adjusted for BMI;	chr17:31935448	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.714	rs7218466	ENSG00000265798.5	RP11-271K11.5	5	1.57e-06	0.00106	0.67	0.38	Hip circumference adjusted for BMI;	chr17:31936295	chr17:31038575~31059121:-
PCPG	cis	rs3806843	0.741	rs2563293	ENSG00000202515.1	VTRNA1-3	5	1.57e-06	0.00106	0.48	0.38	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.771	rs801174	ENSG00000202515.1	VTRNA1-3	5	1.57e-06	0.00106	0.48	0.38	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr5:140726158~140726246:+
PCPG	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	5	1.57e-06	0.00106	0.41	0.38	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	5	1.57e-06	0.00106	0.41	0.38	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
PCPG	cis	rs12682352	0.605	rs60707155	ENSG00000253893.2	FAM85B	-5	1.57e-06	0.00106	-0.48	-0.38	Neuroticism;	chr8:8866905	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.572	rs7005000	ENSG00000173295.6	FAM86B3P	5	1.57e-06	0.00106	0.44	0.38	Mood instability;	chr8:8939092	chr8:8228595~8244865:+
PCPG	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	5	1.58e-06	0.00106	0.49	0.38	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
PCPG	cis	rs1440410	0.83	rs985619	ENSG00000250326.1	RP11-284M14.1	5	1.58e-06	0.00107	0.35	0.38	Ischemic stroke;	chr4:143253423	chr4:142933195~143184861:-
PCPG	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	5	1.58e-06	0.00107	0.51	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
PCPG	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	5	1.58e-06	0.00107	0.51	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
PCPG	cis	rs7402982	0.934	rs6598539	ENSG00000278022.1	RP11-35O15.2	-5	1.58e-06	0.00107	-0.38	-0.38	Birth weight;	chr15:98661254	chr15:98660210~98660668:+
PCPG	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	5	1.59e-06	0.00107	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
PCPG	cis	rs7811142	1	rs7803454	ENSG00000078319.8	PMS2P1	-5	1.59e-06	0.00107	-0.5	-0.38	Platelet count;	chr7:100393925	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.943	rs11769886	ENSG00000078319.8	PMS2P1	-5	1.59e-06	0.00107	-0.5	-0.38	Platelet count;	chr7:100400984	chr7:100320992~100341908:-
PCPG	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-5	1.59e-06	0.00107	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
PCPG	cis	rs9649213	0.593	rs6465672	ENSG00000272950.1	RP11-307C18.1	-5	1.59e-06	0.00107	-0.49	-0.38	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr7:98322853~98323430:+
PCPG	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-5	1.59e-06	0.00107	-0.47	-0.38	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
PCPG	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-5	1.59e-06	0.00107	-0.4	-0.38	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
PCPG	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	5	1.6e-06	0.00108	0.41	0.38	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
PCPG	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	-5	1.6e-06	0.00108	-0.54	-0.38	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
PCPG	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	5	1.6e-06	0.00108	0.43	0.38	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
PCPG	cis	rs67383717	0.643	rs72756397	ENSG00000175611.10	LINC00476	-5	1.6e-06	0.00108	-0.4	-0.38	Parkinson's disease (pesticide exposure interaction);	chr9:95790861	chr9:95759231~95875977:-
PCPG	cis	rs2625529	0.526	rs55763892	ENSG00000260037.4	CTD-2524L6.3	5	1.6e-06	0.00108	0.47	0.38	Red blood cell count;	chr15:72247839	chr15:71818396~71823384:+
PCPG	cis	rs9303029	0.611	rs72857493	ENSG00000279744.1	RP13-20L14.10	-5	1.6e-06	0.00108	-0.58	-0.38	Protein quantitative trait loci;	chr17:82454416	chr17:82462601~82464255:+
PCPG	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	5	1.61e-06	0.00108	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
PCPG	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	5	1.61e-06	0.00108	0.38	0.38	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
PCPG	cis	rs9649213	0.593	rs6465682	ENSG00000272950.1	RP11-307C18.1	5	1.61e-06	0.00108	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr7:98322853~98323430:+
PCPG	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-5	1.61e-06	0.00109	-0.39	-0.38	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
PCPG	cis	rs7824557	0.713	rs6601575	ENSG00000255020.1	AF131216.5	4.99	1.62e-06	0.00109	0.51	0.38	Retinal vascular caliber;	chr8:11240295	chr8:11345748~11347502:-
PCPG	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-4.99	1.62e-06	0.00109	-0.57	-0.38	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
PCPG	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-4.99	1.62e-06	0.00109	-0.57	-0.38	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
PCPG	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	4.99	1.62e-06	0.00109	0.34	0.38	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
PCPG	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-4.99	1.62e-06	0.00109	-0.51	-0.38	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
PCPG	cis	rs7826238	0.526	rs876955	ENSG00000173295.6	FAM86B3P	-4.99	1.62e-06	0.00109	-0.43	-0.38	Systolic blood pressure;	chr8:8453374	chr8:8228595~8244865:+
PCPG	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-4.99	1.62e-06	0.00109	-0.41	-0.38	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
PCPG	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-4.99	1.62e-06	0.00109	-0.41	-0.38	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
PCPG	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	4.99	1.63e-06	0.00109	0.45	0.38	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
PCPG	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	4.99	1.63e-06	0.0011	0.46	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
PCPG	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-4.99	1.63e-06	0.0011	-0.36	-0.38	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
PCPG	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-4.99	1.63e-06	0.0011	-0.36	-0.38	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
PCPG	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-4.99	1.63e-06	0.0011	-0.36	-0.38	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
PCPG	cis	rs7688540	0.8	rs2353599	ENSG00000275426.1	CH17-262A2.1	4.99	1.63e-06	0.0011	0.45	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:149738~150317:+
PCPG	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	4.99	1.63e-06	0.0011	0.57	0.38	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
PCPG	cis	rs7208859	0.623	rs609063	ENSG00000263603.1	CTD-2349P21.5	-4.99	1.63e-06	0.0011	-0.63	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs56031503	ENSG00000263603.1	CTD-2349P21.5	-4.99	1.64e-06	0.0011	-0.64	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30729469~30731202:+
PCPG	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	4.99	1.64e-06	0.0011	0.47	0.38	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
PCPG	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	4.99	1.64e-06	0.0011	0.42	0.38	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
PCPG	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	4.99	1.64e-06	0.0011	0.66	0.38	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
PCPG	cis	rs13113518	1	rs11724094	ENSG00000272969.1	RP11-528I4.2	4.99	1.64e-06	0.00111	0.42	0.38	Height;	chr4:55501479	chr4:55547112~55547889:+
PCPG	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-4.99	1.65e-06	0.00111	-0.46	-0.38	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
PCPG	cis	rs591584	0.73	rs11020847	ENSG00000255893.1	RP11-685N10.1	4.99	1.65e-06	0.00111	0.46	0.38	Macrophage Migration Inhibitory Factor levels;	chr11:94590746	chr11:94472908~94473570:-
PCPG	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-4.99	1.65e-06	0.00111	-0.33	-0.38	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-4.99	1.65e-06	0.00111	-0.33	-0.38	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-4.99	1.65e-06	0.00111	-0.33	-0.38	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-4.99	1.65e-06	0.00111	-0.33	-0.38	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-4.99	1.65e-06	0.00111	-0.33	-0.38	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-4.99	1.65e-06	0.00111	-0.33	-0.38	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-4.99	1.65e-06	0.00111	-0.33	-0.38	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
PCPG	cis	rs73607972	0.778	rs55662133	ENSG00000275191.1	RP11-36I17.2	-4.99	1.65e-06	0.00111	-0.59	-0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612761	chr16:53628256~53628816:-
PCPG	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-4.99	1.66e-06	0.00111	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
PCPG	cis	rs9928842	0.882	rs6564241	ENSG00000280152.1	RP11-331F4.5	4.99	1.66e-06	0.00111	0.67	0.38	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75245994~75250077:-
PCPG	cis	rs9650657	0.515	rs7820860	ENSG00000255020.1	AF131216.5	-4.99	1.66e-06	0.00111	-0.54	-0.38	Neuroticism;	chr8:11092886	chr8:11345748~11347502:-
PCPG	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-4.99	1.66e-06	0.00112	-0.32	-0.38	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-4.99	1.66e-06	0.00112	-0.32	-0.38	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-4.99	1.66e-06	0.00112	-0.32	-0.38	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
PCPG	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	4.99	1.66e-06	0.00112	0.5	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
PCPG	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	4.99	1.67e-06	0.00112	0.52	0.38	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
PCPG	cis	rs12906542	0.544	rs35472584	ENSG00000259792.1	RP11-114H24.6	-4.99	1.67e-06	0.00112	-0.44	-0.38	Breast cancer;	chr15:77974385	chr15:77993405~77995289:+
PCPG	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-4.99	1.67e-06	0.00112	-0.38	-0.38	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
PCPG	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	4.99	1.67e-06	0.00112	0.53	0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
PCPG	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	4.99	1.67e-06	0.00112	0.52	0.38	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
PCPG	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	4.99	1.67e-06	0.00112	0.52	0.38	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
PCPG	cis	rs7657257	1	rs11931532	ENSG00000214846.4	RP11-115L11.1	4.99	1.67e-06	0.00112	0.86	0.38	Blood protein levels;	chr4:15724143	chr4:15730962~15731627:-
PCPG	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-4.99	1.67e-06	0.00112	-0.49	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
PCPG	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	4.99	1.68e-06	0.00112	0.45	0.38	Height;	chr6:109358652	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	4.99	1.68e-06	0.00112	0.45	0.38	Height;	chr6:109367528	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	4.99	1.68e-06	0.00112	0.45	0.38	Height;	chr6:109368704	chr6:109382795~109383666:+
PCPG	cis	rs11148252	0.774	rs7993748	ENSG00000198384.8	TPTE2P3	-4.99	1.68e-06	0.00112	-0.46	-0.38	Lewy body disease;	chr13:52367496	chr13:52522632~52586906:+
PCPG	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	4.99	1.68e-06	0.00112	0.55	0.38	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
PCPG	cis	rs13113518	1	rs4864542	ENSG00000272969.1	RP11-528I4.2	-4.99	1.68e-06	0.00112	-0.41	-0.38	Height;	chr4:55487920	chr4:55547112~55547889:+
PCPG	cis	rs1609391	0.543	rs9859810	ENSG00000273486.1	RP11-731C17.2	4.99	1.68e-06	0.00112	0.39	0.38	Neuroticism;	chr3:136911144	chr3:136837338~136839021:-
PCPG	cis	rs1609391	0.543	rs9828009	ENSG00000273486.1	RP11-731C17.2	4.99	1.68e-06	0.00112	0.39	0.38	Neuroticism;	chr3:136912433	chr3:136837338~136839021:-
PCPG	cis	rs2115630	0.653	rs61394864	ENSG00000275120.1	RP11-182J1.17	-4.99	1.68e-06	0.00113	-0.38	-0.38	P wave terminal force;	chr15:84626943	chr15:84599434~84606463:-
PCPG	cis	rs5758511	0.68	rs5758667	ENSG00000205702.9	CYP2D7	4.99	1.68e-06	0.00113	0.51	0.38	Birth weight;	chr22:42237198	chr22:42140203~42144577:-
PCPG	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-4.99	1.68e-06	0.00113	-0.48	-0.38	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-4.99	1.68e-06	0.00113	-0.48	-0.38	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-4.99	1.68e-06	0.00113	-0.48	-0.38	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
PCPG	cis	rs9595908	0.785	rs4120131	ENSG00000212293.1	SNORA16	-4.99	1.68e-06	0.00113	-0.45	-0.38	Body mass index;	chr13:32702949	chr13:32420390~32420516:-
PCPG	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	4.99	1.68e-06	0.00113	0.51	0.38	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
PCPG	cis	rs7246657	1	rs1529957	ENSG00000226686.6	LINC01535	-4.99	1.68e-06	0.00113	-0.6	-0.38	Coronary artery calcification;	chr19:37248899	chr19:37251912~37265535:+
PCPG	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	4.99	1.68e-06	0.00113	0.47	0.38	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	4.99	1.68e-06	0.00113	0.47	0.38	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
PCPG	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-4.99	1.68e-06	0.00113	-0.48	-0.38	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-4.99	1.68e-06	0.00113	-0.48	-0.38	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
PCPG	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	4.99	1.69e-06	0.00113	0.4	0.38	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
PCPG	cis	rs7759001	0.744	rs6650992	ENSG00000271755.1	RP1-153G14.4	4.99	1.69e-06	0.00113	0.53	0.38	Glomerular filtration rate (creatinine);	chr6:27494606	chr6:27404010~27406964:-
PCPG	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	4.98	1.69e-06	0.00113	0.5	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
PCPG	cis	rs12908161	1	rs35726233	ENSG00000259295.5	CSPG4P12	4.98	1.69e-06	0.00113	0.56	0.38	Schizophrenia;	chr15:84794569	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs35960805	ENSG00000259295.5	CSPG4P12	4.98	1.69e-06	0.00113	0.56	0.38	Schizophrenia;	chr15:84800749	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs12912388	ENSG00000259295.5	CSPG4P12	4.98	1.69e-06	0.00113	0.56	0.38	Schizophrenia;	chr15:84801319	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs17601029	ENSG00000259295.5	CSPG4P12	4.98	1.69e-06	0.00113	0.56	0.38	Schizophrenia;	chr15:84804478	chr15:85191438~85213905:+
PCPG	cis	rs300890	0.513	rs72719180	ENSG00000250326.1	RP11-284M14.1	-4.98	1.69e-06	0.00113	-0.35	-0.38	Nasopharyngeal carcinoma;	chr4:143140520	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs4566607	ENSG00000250326.1	RP11-284M14.1	-4.98	1.69e-06	0.00113	-0.35	-0.38	Nasopharyngeal carcinoma;	chr4:143141089	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs6820340	ENSG00000250326.1	RP11-284M14.1	4.98	1.69e-06	0.00113	0.35	0.38	Nasopharyngeal carcinoma;	chr4:143199051	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs4690780	ENSG00000250326.1	RP11-284M14.1	4.98	1.69e-06	0.00113	0.35	0.38	Nasopharyngeal carcinoma;	chr4:143202414	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs7435424	ENSG00000250326.1	RP11-284M14.1	4.98	1.69e-06	0.00113	0.35	0.38	Nasopharyngeal carcinoma;	chr4:143203125	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.536	rs9996072	ENSG00000250326.1	RP11-284M14.1	4.98	1.69e-06	0.00113	0.35	0.38	Nasopharyngeal carcinoma;	chr4:143208808	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.536	rs10009906	ENSG00000250326.1	RP11-284M14.1	4.98	1.69e-06	0.00113	0.35	0.38	Ischemic stroke;	chr4:143210204	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs13151561	ENSG00000250326.1	RP11-284M14.1	4.98	1.69e-06	0.00113	0.35	0.38	Nasopharyngeal carcinoma;	chr4:143215833	chr4:142933195~143184861:-
PCPG	cis	rs9303029	0.611	rs2306753	ENSG00000279744.1	RP13-20L14.10	-4.98	1.69e-06	0.00113	-0.55	-0.38	Protein quantitative trait loci;	chr17:82469114	chr17:82462601~82464255:+
PCPG	cis	rs1440410	0.83	rs12505142	ENSG00000250326.1	RP11-284M14.1	4.98	1.69e-06	0.00113	0.34	0.38	Ischemic stroke;	chr4:143259754	chr4:142933195~143184861:-
PCPG	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-4.98	1.7e-06	0.00113	-0.45	-0.38	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
PCPG	cis	rs2732480	0.538	rs2468943	ENSG00000240399.1	RP1-228P16.1	-4.98	1.7e-06	0.00113	-0.4	-0.38	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48054813~48055591:-
PCPG	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-4.98	1.7e-06	0.00113	-0.5	-0.38	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
PCPG	cis	rs9926296	0.585	rs4785595	ENSG00000260259.1	RP11-368I7.4	4.98	1.7e-06	0.00113	0.46	0.38	Vitiligo;	chr16:89769113	chr16:89682620~89686569:-
PCPG	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	4.98	1.7e-06	0.00114	0.49	0.38	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
PCPG	cis	rs2736345	0.755	rs2736340	ENSG00000255020.1	AF131216.5	4.98	1.7e-06	0.00114	0.53	0.38	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:11345748~11347502:-
PCPG	cis	rs3736858	0.866	rs41287008	ENSG00000261105.4	LMO7-AS1	-4.98	1.7e-06	0.00114	-0.71	-0.38	Interleukin-9 levels;	chr13:75821948	chr13:75604700~75635994:-
PCPG	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-4.98	1.7e-06	0.00114	-0.48	-0.38	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
PCPG	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-4.98	1.71e-06	0.00114	-0.46	-0.38	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
PCPG	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-4.98	1.71e-06	0.00114	-0.57	-0.38	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
PCPG	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-4.98	1.71e-06	0.00114	-0.48	-0.38	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
PCPG	cis	rs5769765	0.819	rs9616379	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49918387	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.862	rs9616380	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49918577	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.862	rs9616381	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49918734	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.773	rs58375955	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49918982	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.773	rs9616383	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49919366	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.862	rs9616384	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49919434	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.862	rs9616385	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49919476	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.862	rs9616386	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49919531	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.773	rs9616208	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49919711	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs9616388	ENSG00000278869.1	CITF22-49E9.3	4.98	1.71e-06	0.00114	0.53	0.38	Schizophrenia;	chr22:49919790	chr22:49933198~49934074:-
PCPG	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	4.98	1.71e-06	0.00114	0.37	0.38	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	4.98	1.71e-06	0.00114	0.37	0.38	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
PCPG	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-4.98	1.71e-06	0.00114	-0.61	-0.38	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
PCPG	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	4.98	1.71e-06	0.00114	0.38	0.38	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
PCPG	cis	rs9595908	0.709	rs916289	ENSG00000212293.1	SNORA16	4.98	1.72e-06	0.00114	0.45	0.38	Body mass index;	chr13:32792110	chr13:32420390~32420516:-
PCPG	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	4.98	1.72e-06	0.00114	0.46	0.38	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
PCPG	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	4.98	1.72e-06	0.00115	0.42	0.38	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
PCPG	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	4.98	1.72e-06	0.00115	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	4.98	1.72e-06	0.00115	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	4.98	1.72e-06	0.00115	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	4.98	1.72e-06	0.00115	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
PCPG	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-4.98	1.72e-06	0.00115	-0.42	-0.38	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
PCPG	cis	rs10435719	0.58	rs13260712	ENSG00000255020.1	AF131216.5	-4.98	1.73e-06	0.00115	-0.5	-0.38	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11345748~11347502:-
PCPG	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	4.98	1.73e-06	0.00115	0.48	0.38	Height;	chr6:109430398	chr6:109382795~109383666:+
PCPG	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-4.98	1.73e-06	0.00115	-0.49	-0.38	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
PCPG	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-4.98	1.73e-06	0.00115	-0.46	-0.38	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
PCPG	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-4.98	1.73e-06	0.00115	-0.46	-0.38	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
PCPG	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	-4.98	1.73e-06	0.00115	-0.42	-0.38	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
PCPG	cis	rs4671400	0.571	rs4672429	ENSG00000270820.4	RP11-355B11.2	-4.98	1.74e-06	0.00116	-0.53	-0.38	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61268334	chr2:61471188~61484130:+
PCPG	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	4.98	1.74e-06	0.00116	0.47	0.38	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	4.98	1.74e-06	0.00116	0.47	0.38	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
PCPG	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	4.98	1.74e-06	0.00116	0.58	0.38	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
PCPG	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-4.98	1.74e-06	0.00116	-0.57	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
PCPG	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-4.98	1.74e-06	0.00116	-0.5	-0.38	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
PCPG	cis	rs7208859	0.623	rs7220999	ENSG00000263603.1	CTD-2349P21.5	-4.98	1.75e-06	0.00116	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs55638872	ENSG00000263603.1	CTD-2349P21.5	-4.98	1.75e-06	0.00116	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9899268	ENSG00000263603.1	CTD-2349P21.5	-4.98	1.75e-06	0.00116	-0.65	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30729469~30731202:+
PCPG	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	4.98	1.75e-06	0.00116	0.38	0.38	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.617	rs4841072	ENSG00000173295.6	FAM86B3P	4.98	1.75e-06	0.00116	0.44	0.38	Mood instability;	chr8:8933743	chr8:8228595~8244865:+
PCPG	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-4.98	1.76e-06	0.00117	-0.37	-0.38	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
PCPG	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	4.98	1.76e-06	0.00117	0.47	0.38	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	4.98	1.76e-06	0.00117	0.47	0.38	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	4.98	1.76e-06	0.00117	0.47	0.38	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
PCPG	cis	rs575908	0.708	rs1571349	ENSG00000254154.7	RP4-798P15.3	4.98	1.76e-06	0.00117	0.37	0.38	Breast cancer;	chr1:177897657	chr1:177928788~178038007:-
PCPG	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	4.98	1.76e-06	0.00117	0.43	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	4.98	1.76e-06	0.00117	0.43	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	4.98	1.76e-06	0.00117	0.43	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
PCPG	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-4.98	1.76e-06	0.00117	-0.41	-0.38	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	4.98	1.76e-06	0.00117	0.41	0.38	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	4.98	1.76e-06	0.00117	0.41	0.38	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
PCPG	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-4.98	1.76e-06	0.00117	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
PCPG	cis	rs561341	0.941	rs2428338	ENSG00000265798.5	RP11-271K11.5	4.97	1.77e-06	0.00117	0.67	0.38	Hip circumference adjusted for BMI;	chr17:31972610	chr17:31038575~31059121:-
PCPG	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	4.97	1.77e-06	0.00118	0.49	0.38	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
PCPG	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-4.97	1.77e-06	0.00118	-0.34	-0.38	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
PCPG	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-4.97	1.77e-06	0.00118	-0.34	-0.38	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
PCPG	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	4.97	1.77e-06	0.00118	0.46	0.38	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
PCPG	cis	rs2531992	0.925	rs2531993	ENSG00000262888.1	RP11-462G12.2	-4.97	1.77e-06	0.00118	-0.62	-0.38	Waist circumference;	chr16:3964244	chr16:3931217~3946305:-
PCPG	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	4.97	1.78e-06	0.00118	0.42	0.38	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
PCPG	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	4.97	1.78e-06	0.00118	0.67	0.38	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
PCPG	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-4.97	1.78e-06	0.00118	-0.39	-0.38	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
PCPG	cis	rs433852	0.718	rs447802	ENSG00000232871.7	SEC1P	-4.97	1.78e-06	0.00118	-0.47	-0.38	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613102	chr19:48638071~48682245:+
PCPG	cis	rs433852	0.718	rs443527	ENSG00000232871.7	SEC1P	-4.97	1.78e-06	0.00118	-0.47	-0.38	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613503	chr19:48638071~48682245:+
PCPG	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-4.97	1.79e-06	0.00119	-0.41	-0.38	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-4.97	1.79e-06	0.00119	-0.41	-0.38	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-4.97	1.79e-06	0.00119	-0.41	-0.38	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-4.97	1.79e-06	0.00119	-0.41	-0.38	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-4.97	1.79e-06	0.00119	-0.41	-0.38	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
PCPG	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	4.97	1.79e-06	0.00119	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	4.97	1.79e-06	0.00119	0.48	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
PCPG	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-4.97	1.79e-06	0.00119	-0.45	-0.38	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
PCPG	cis	rs2284219	0.565	rs2284217	ENSG00000244480.1	AC005154.7	-4.97	1.8e-06	0.00119	-0.41	-0.38	Type 2 diabetes;	chr7:30673992	chr7:30523143~30524535:-
PCPG	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	4.97	1.8e-06	0.00119	0.55	0.38	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
PCPG	cis	rs11992162	0.636	rs4841642	ENSG00000255020.1	AF131216.5	4.97	1.8e-06	0.00119	0.53	0.38	Monocyte count;	chr8:11940825	chr8:11345748~11347502:-
PCPG	cis	rs11992162	0.636	rs4841646	ENSG00000255020.1	AF131216.5	4.97	1.8e-06	0.00119	0.53	0.38	Monocyte count;	chr8:11941198	chr8:11345748~11347502:-
PCPG	cis	rs11992162	0.613	rs6998690	ENSG00000255020.1	AF131216.5	4.97	1.8e-06	0.00119	0.53	0.38	Monocyte count;	chr8:11941287	chr8:11345748~11347502:-
PCPG	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-4.97	1.8e-06	0.00119	-0.48	-0.38	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
PCPG	cis	rs7181230	0.885	rs4924413	ENSG00000259584.1	RP11-521C20.2	4.97	1.8e-06	0.00119	0.49	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40075204~40078704:-
PCPG	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-4.97	1.8e-06	0.00119	-0.48	-0.38	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-4.97	1.8e-06	0.00119	-0.48	-0.38	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-4.97	1.8e-06	0.00119	-0.48	-0.38	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-4.97	1.8e-06	0.00119	-0.48	-0.38	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-4.97	1.8e-06	0.00119	-0.48	-0.38	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
PCPG	cis	rs300890	0.56	rs763918	ENSG00000250326.1	RP11-284M14.1	4.97	1.8e-06	0.00119	0.33	0.38	Nasopharyngeal carcinoma;	chr4:143271964	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.56	rs13114280	ENSG00000250326.1	RP11-284M14.1	4.97	1.8e-06	0.00119	0.33	0.38	Nasopharyngeal carcinoma;	chr4:143272542	chr4:142933195~143184861:-
PCPG	cis	rs7017914	0.667	rs2732098	ENSG00000254031.4	RP11-326E22.1	4.97	1.81e-06	0.0012	0.36	0.38	Bone mineral density;	chr8:71008762	chr8:71155457~71204223:+
PCPG	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	4.97	1.81e-06	0.0012	0.44	0.38	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
PCPG	cis	rs7017914	0.934	rs2639921	ENSG00000254031.4	RP11-326E22.1	4.97	1.81e-06	0.0012	0.37	0.38	Bone mineral density;	chr8:70962599	chr8:71155457~71204223:+
PCPG	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-4.97	1.81e-06	0.0012	-0.5	-0.38	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
PCPG	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-4.97	1.82e-06	0.0012	-0.43	-0.38	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
PCPG	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-4.97	1.82e-06	0.0012	-0.34	-0.38	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
PCPG	cis	rs34375054	0.672	rs2291248	ENSG00000279233.1	RP11-158L12.4	4.97	1.82e-06	0.0012	0.41	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125134762	chr12:125138245~125141711:+
PCPG	cis	rs300890	0.56	rs6844866	ENSG00000250326.1	RP11-284M14.1	-4.97	1.82e-06	0.0012	-0.32	-0.38	Nasopharyngeal carcinoma;	chr4:143265304	chr4:142933195~143184861:-
PCPG	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	4.97	1.82e-06	0.0012	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
PCPG	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-4.97	1.82e-06	0.00121	-0.46	-0.38	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
PCPG	cis	rs1023500	0.505	rs134888	ENSG00000205702.9	CYP2D7	4.97	1.82e-06	0.00121	0.36	0.38	Schizophrenia;	chr22:42278275	chr22:42140203~42144577:-
PCPG	cis	rs916888	0.779	rs199526	ENSG00000262500.1	RP11-259G18.2	-4.97	1.83e-06	0.00121	-0.58	-0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46243606~46245044:+
PCPG	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	4.97	1.83e-06	0.00121	0.49	0.38	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	4.97	1.83e-06	0.00121	0.49	0.38	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
PCPG	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	4.97	1.83e-06	0.00121	0.49	0.38	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
PCPG	cis	rs12908161	1	rs12903134	ENSG00000259295.5	CSPG4P12	4.97	1.83e-06	0.00121	0.56	0.38	Schizophrenia;	chr15:84794468	chr15:85191438~85213905:+
PCPG	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	4.97	1.83e-06	0.00121	0.55	0.38	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
PCPG	cis	rs10131894	0.575	rs6574203	ENSG00000279594.1	RP11-950C14.10	4.97	1.83e-06	0.00121	0.48	0.38	Coronary artery disease;	chr14:74963143	chr14:75011269~75012851:-
PCPG	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-4.97	1.84e-06	0.00121	-0.53	-0.38	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
PCPG	cis	rs964611	0.786	rs10519169	ENSG00000259488.2	RP11-154J22.1	-4.97	1.84e-06	0.00121	-0.34	-0.38	Metabolite levels (Pyroglutamine);	chr15:48372829	chr15:48312353~48331856:-
PCPG	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	4.97	1.84e-06	0.00122	0.57	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
PCPG	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	4.97	1.84e-06	0.00122	0.36	0.38	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
PCPG	cis	rs13113518	0.902	rs12642716	ENSG00000272969.1	RP11-528I4.2	4.97	1.84e-06	0.00122	0.42	0.38	Height;	chr4:55479996	chr4:55547112~55547889:+
PCPG	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-4.97	1.85e-06	0.00122	-0.43	-0.38	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
PCPG	cis	rs7181230	0.885	rs35781999	ENSG00000259584.1	RP11-521C20.2	4.96	1.85e-06	0.00122	0.49	0.38	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40075204~40078704:-
PCPG	cis	rs7789940	0.857	rs12532935	ENSG00000186704.9	DTX2P1	4.96	1.85e-06	0.00122	0.47	0.38	Multiple sclerosis;	chr7:76310381	chr7:76978617~77004308:+
PCPG	cis	rs7824557	0.933	rs6601576	ENSG00000255020.1	AF131216.5	-4.96	1.85e-06	0.00122	-0.48	-0.38	Retinal vascular caliber;	chr8:11242766	chr8:11345748~11347502:-
PCPG	cis	rs62246343	0.719	rs62246276	ENSG00000254485.4	RP11-380O24.1	4.96	1.85e-06	0.00122	0.58	0.38	Fibrinogen levels;	chr3:9403489	chr3:9292588~9363303:-
PCPG	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	-4.96	1.85e-06	0.00122	-0.43	-0.38	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
PCPG	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-4.96	1.85e-06	0.00122	-0.47	-0.38	Height;	chr6:109444615	chr6:109382795~109383666:+
PCPG	cis	rs12681963	0.688	rs4733396	ENSG00000248159.1	HSPA8P11	-4.96	1.85e-06	0.00122	-0.66	-0.38	Migraine;	chr8:30145889	chr8:30237382~30240997:+
PCPG	cis	rs73607972	0.866	rs17803830	ENSG00000275191.1	RP11-36I17.2	4.96	1.86e-06	0.00122	0.64	0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53608948	chr16:53628256~53628816:-
PCPG	cis	rs7247513	1	rs7247513	ENSG00000213290.4	PGK1P2	-4.96	1.86e-06	0.00122	-0.51	-0.38	Bipolar disorder;	chr19:12580371	chr19:12559571~12561105:+
PCPG	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	4.96	1.86e-06	0.00122	0.73	0.38	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
PCPG	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-4.96	1.86e-06	0.00123	-0.48	-0.38	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-4.96	1.86e-06	0.00123	-0.48	-0.38	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs118119933	ENSG00000078319.8	PMS2P1	-4.96	1.86e-06	0.00123	-0.51	-0.38	Platelet count;	chr7:100341427	chr7:100320992~100341908:-
PCPG	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	4.96	1.86e-06	0.00123	0.62	0.38	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	4.96	1.86e-06	0.00123	0.62	0.38	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	4.96	1.86e-06	0.00123	0.62	0.38	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	4.96	1.86e-06	0.00123	0.62	0.38	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	4.96	1.86e-06	0.00123	0.62	0.38	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	4.96	1.86e-06	0.00123	0.62	0.38	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
PCPG	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-4.96	1.87e-06	0.00123	-0.48	-0.38	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
PCPG	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-4.96	1.87e-06	0.00123	-0.41	-0.38	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
PCPG	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-4.96	1.88e-06	0.00124	-0.39	-0.38	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-4.96	1.88e-06	0.00124	-0.39	-0.38	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-4.96	1.88e-06	0.00124	-0.39	-0.38	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-4.96	1.88e-06	0.00124	-0.39	-0.38	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
PCPG	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-4.96	1.88e-06	0.00124	-0.42	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
PCPG	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-4.96	1.88e-06	0.00124	-0.49	-0.38	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
PCPG	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	4.96	1.88e-06	0.00124	0.57	0.38	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
PCPG	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-4.96	1.88e-06	0.00124	-0.59	-0.38	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-4.96	1.88e-06	0.00124	-0.59	-0.38	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-4.96	1.88e-06	0.00124	-0.59	-0.38	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-4.96	1.88e-06	0.00124	-0.59	-0.38	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
PCPG	cis	rs11148252	0.553	rs9536219	ENSG00000198384.8	TPTE2P3	-4.96	1.89e-06	0.00124	-0.49	-0.38	Lewy body disease;	chr13:52653166	chr13:52522632~52586906:+
PCPG	cis	rs13113518	1	rs3805149	ENSG00000272969.1	RP11-528I4.2	4.96	1.89e-06	0.00124	0.41	0.38	Height;	chr4:55442184	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11945370	ENSG00000272969.1	RP11-528I4.2	4.96	1.89e-06	0.00124	0.41	0.38	Height;	chr4:55442875	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs12647677	ENSG00000272969.1	RP11-528I4.2	4.96	1.89e-06	0.00124	0.41	0.38	Height;	chr4:55444253	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.902	rs3805150	ENSG00000272969.1	RP11-528I4.2	4.96	1.89e-06	0.00124	0.41	0.38	Height;	chr4:55446869	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4864990	ENSG00000272969.1	RP11-528I4.2	4.96	1.89e-06	0.00124	0.41	0.38	Height;	chr4:55447523	chr4:55547112~55547889:+
PCPG	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-4.96	1.89e-06	0.00124	-0.43	-0.38	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
PCPG	cis	rs8044188	1	rs8047304	ENSG00000261090.1	RP11-20G6.2	-4.96	1.89e-06	0.00124	-0.58	-0.38	Multiple system atrophy;	chr16:23029284	chr16:23020337~23023611:+
PCPG	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	4.96	1.89e-06	0.00124	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	4.96	1.89e-06	0.00124	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
PCPG	cis	rs11858159	0.651	rs7168626	ENSG00000259905.4	PWRN1	4.96	1.9e-06	0.00125	0.43	0.38	Platelet thrombus formation;	chr15:24555586	chr15:24493137~24652130:+
PCPG	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-4.96	1.9e-06	0.00125	-0.33	-0.38	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-4.96	1.9e-06	0.00125	-0.33	-0.38	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-4.96	1.9e-06	0.00125	-0.33	-0.38	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-4.96	1.9e-06	0.00125	-0.33	-0.38	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-4.96	1.9e-06	0.00125	-0.33	-0.38	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
PCPG	cis	rs7811142	1	rs2897358	ENSG00000078319.8	PMS2P1	-4.96	1.9e-06	0.00125	-0.48	-0.38	Platelet count;	chr7:100491017	chr7:100320992~100341908:-
PCPG	cis	rs7819412	0.745	rs2898260	ENSG00000255020.1	AF131216.5	-4.96	1.9e-06	0.00125	-0.55	-0.38	Triglycerides;	chr8:11081980	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.525	rs13280813	ENSG00000255020.1	AF131216.5	-4.96	1.91e-06	0.00125	-0.49	-0.38	Neuroticism;	chr8:11567596	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.549	rs4841564	ENSG00000255020.1	AF131216.5	-4.96	1.91e-06	0.00125	-0.49	-0.38	Neuroticism;	chr8:11568300	chr8:11345748~11347502:-
PCPG	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	4.96	1.91e-06	0.00125	0.59	0.38	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
PCPG	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-4.96	1.91e-06	0.00125	-0.47	-0.38	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
PCPG	cis	rs3808502	0.525	rs9650661	ENSG00000255020.1	AF131216.5	-4.96	1.91e-06	0.00125	-0.49	-0.38	Neuroticism;	chr8:11569624	chr8:11345748~11347502:-
PCPG	cis	rs7246657	0.943	rs7252325	ENSG00000226686.6	LINC01535	-4.96	1.91e-06	0.00125	-0.6	-0.38	Coronary artery calcification;	chr19:37439743	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	4.96	1.91e-06	0.00126	0.48	0.38	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
PCPG	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-4.96	1.92e-06	0.00126	-0.46	-0.38	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
PCPG	cis	rs7688540	0.8	rs73793597	ENSG00000275426.1	CH17-262A2.1	4.96	1.92e-06	0.00126	0.45	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:149738~150317:+
PCPG	cis	rs7017914	0.875	rs2732107	ENSG00000254031.4	RP11-326E22.1	4.96	1.92e-06	0.00126	0.37	0.38	Bone mineral density;	chr8:71013073	chr8:71155457~71204223:+
PCPG	cis	rs7829975	0.742	rs7832968	ENSG00000173295.6	FAM86B3P	-4.96	1.92e-06	0.00126	-0.44	-0.38	Mood instability;	chr8:8795379	chr8:8228595~8244865:+
PCPG	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-4.96	1.92e-06	0.00126	-0.52	-0.38	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
PCPG	cis	rs3806843	0.966	rs3756341	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs12717860	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs6870764	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs6891995	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs13184940	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs1476768	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs9686540	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs3756339	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs3733708	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs2240694	ENSG00000202515.1	VTRNA1-3	-4.96	1.93e-06	0.00126	-0.48	-0.38	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr5:140726158~140726246:+
PCPG	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	4.96	1.93e-06	0.00126	0.35	0.38	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
PCPG	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	4.96	1.93e-06	0.00127	0.47	0.38	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
PCPG	cis	rs7811142	1	rs11773661	ENSG00000078319.8	PMS2P1	-4.95	1.93e-06	0.00127	-0.48	-0.38	Platelet count;	chr7:100475446	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.943	rs66958101	ENSG00000078319.8	PMS2P1	-4.95	1.93e-06	0.00127	-0.48	-0.38	Platelet count;	chr7:100476397	chr7:100320992~100341908:-
PCPG	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	4.95	1.93e-06	0.00127	0.52	0.38	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
PCPG	cis	rs3806843	0.676	rs2569159	ENSG00000202515.1	VTRNA1-3	4.95	1.94e-06	0.00127	0.48	0.37	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr5:140726158~140726246:+
PCPG	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	4.95	1.94e-06	0.00127	0.37	0.37	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
PCPG	cis	rs7759001	0.779	rs12212293	ENSG00000271755.1	RP1-153G14.4	4.95	1.94e-06	0.00127	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27425410	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.711	rs7747283	ENSG00000271755.1	RP1-153G14.4	4.95	1.94e-06	0.00127	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27425826	chr6:27404010~27406964:-
PCPG	cis	rs10760158	0.8	rs10739595	ENSG00000226752.6	PSMD5-AS1	-4.95	1.95e-06	0.00128	-0.49	-0.37	Pulse pressure;	chr9:121293743	chr9:120824828~120854385:+
PCPG	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-4.95	1.95e-06	0.00128	-0.46	-0.37	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
PCPG	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	4.95	1.95e-06	0.00128	0.44	0.37	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
PCPG	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	4.95	1.95e-06	0.00128	0.56	0.37	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
PCPG	cis	rs4972806	0.849	rs2857535	ENSG00000226363.3	HAGLROS	-4.95	1.95e-06	0.00128	-0.37	-0.37	IgG glycosylation;	chr2:176171483	chr2:176177717~176179008:+
PCPG	cis	rs4713118	0.662	rs9380046	ENSG00000216901.1	AL022393.7	4.95	1.95e-06	0.00128	0.52	0.37	Parkinson's disease;	chr6:28062721	chr6:28176188~28176674:+
PCPG	cis	rs7208859	0.623	rs11651857	ENSG00000263603.1	CTD-2349P21.5	-4.95	1.96e-06	0.00128	-0.62	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs216445	ENSG00000263603.1	CTD-2349P21.5	-4.95	1.96e-06	0.00128	-0.62	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs216446	ENSG00000263603.1	CTD-2349P21.5	-4.95	1.96e-06	0.00128	-0.62	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30729469~30731202:+
PCPG	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-4.95	1.96e-06	0.00128	-0.62	-0.37	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
PCPG	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	4.95	1.97e-06	0.00128	0.38	0.37	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	4.95	1.97e-06	0.00128	0.38	0.37	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
PCPG	cis	rs7824557	0.545	rs2572450	ENSG00000255020.1	AF131216.5	-4.95	1.97e-06	0.00129	-0.5	-0.37	Retinal vascular caliber;	chr8:11372129	chr8:11345748~11347502:-
PCPG	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	4.95	1.97e-06	0.00129	0.6	0.37	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
PCPG	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	4.95	1.97e-06	0.00129	0.6	0.37	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
PCPG	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	4.95	1.97e-06	0.00129	0.6	0.37	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
PCPG	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	4.95	1.97e-06	0.00129	0.42	0.37	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
PCPG	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	4.95	1.97e-06	0.00129	0.47	0.37	Height;	chr6:109388256	chr6:109382795~109383666:+
PCPG	cis	rs7017914	0.87	rs3098883	ENSG00000254031.4	RP11-326E22.1	4.95	1.97e-06	0.00129	0.36	0.37	Bone mineral density;	chr8:71031332	chr8:71155457~71204223:+
PCPG	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	4.95	1.97e-06	0.00129	0.62	0.37	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
PCPG	cis	rs7819412	0.745	rs4841498	ENSG00000255020.1	AF131216.5	-4.95	1.97e-06	0.00129	-0.5	-0.37	Triglycerides;	chr8:11127922	chr8:11345748~11347502:-
PCPG	cis	rs879620	1	rs2531995	ENSG00000262888.1	RP11-462G12.2	-4.95	1.98e-06	0.00129	-0.5	-0.37	Hip circumference;Body mass index;	chr16:3963466	chr16:3931217~3946305:-
PCPG	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-4.95	1.98e-06	0.00129	-0.47	-0.37	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
PCPG	cis	rs300890	0.689	rs7697838	ENSG00000250326.1	RP11-284M14.1	4.95	1.98e-06	0.00129	0.33	0.37	Nasopharyngeal carcinoma;	chr4:143326195	chr4:142933195~143184861:-
PCPG	cis	rs7017914	0.905	rs12542300	ENSG00000254031.4	RP11-326E22.1	-4.95	1.98e-06	0.00129	-0.37	-0.37	Bone mineral density;	chr8:71039160	chr8:71155457~71204223:+
PCPG	cis	rs7246657	0.943	rs1035479	ENSG00000226686.6	LINC01535	4.95	1.98e-06	0.00129	0.59	0.37	Coronary artery calcification;	chr19:37402398	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10415937	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37339162	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10414904	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37339186	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10417844	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37346685	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs1373991	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37348009	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs10405407	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37348262	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs12709813	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37354081	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs13345116	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37356196	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.765	rs7247259	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37360188	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs3745765	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37363333	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs4803460	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37394326	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.882	rs4803539	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37406620	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs3803895	ENSG00000226686.6	LINC01535	-4.95	1.98e-06	0.00129	-0.59	-0.37	Coronary artery calcification;	chr19:37407767	chr19:37251912~37265535:+
PCPG	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	4.95	1.98e-06	0.00129	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
PCPG	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-4.95	1.98e-06	0.00129	-0.44	-0.37	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
PCPG	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-4.95	1.99e-06	0.00129	-0.5	-0.37	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
PCPG	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	4.95	1.99e-06	0.0013	0.67	0.37	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
PCPG	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	4.95	1.99e-06	0.0013	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
PCPG	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	4.95	1.99e-06	0.0013	0.51	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
PCPG	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	4.95	1.99e-06	0.0013	0.42	0.37	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	4.95	1.99e-06	0.0013	0.42	0.37	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-4.95	1.99e-06	0.0013	-0.42	-0.37	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
PCPG	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-4.95	1.99e-06	0.0013	-0.38	-0.37	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
PCPG	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	4.95	2e-06	0.0013	0.5	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
PCPG	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-4.95	2e-06	0.0013	-0.37	-0.37	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
PCPG	cis	rs7759001	0.779	rs10946916	ENSG00000271755.1	RP1-153G14.4	4.95	2e-06	0.0013	0.5	0.37	Glomerular filtration rate (creatinine);	chr6:27410064	chr6:27404010~27406964:-
PCPG	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-4.95	2e-06	0.0013	-0.48	-0.37	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
PCPG	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-4.95	2e-06	0.0013	-0.47	-0.37	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
PCPG	cis	rs4713118	0.662	rs149946	ENSG00000216901.1	AL022393.7	-4.95	2e-06	0.0013	-0.52	-0.37	Parkinson's disease;	chr6:28002253	chr6:28176188~28176674:+
PCPG	cis	rs300890	0.513	rs6812522	ENSG00000250326.1	RP11-284M14.1	4.95	2e-06	0.0013	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143176918	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs7692813	ENSG00000250326.1	RP11-284M14.1	4.95	2e-06	0.0013	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143177940	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs12640698	ENSG00000250326.1	RP11-284M14.1	4.95	2e-06	0.0013	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143182941	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.536	rs11100779	ENSG00000250326.1	RP11-284M14.1	4.95	2e-06	0.0013	0.35	0.37	Ischemic stroke;	chr4:143183611	chr4:142933195~143184861:-
PCPG	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	4.95	2e-06	0.0013	0.47	0.37	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
PCPG	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-4.95	2.01e-06	0.00131	-0.45	-0.37	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
PCPG	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	4.95	2.01e-06	0.00131	0.37	0.37	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	4.95	2.01e-06	0.00131	0.37	0.37	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
PCPG	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	4.95	2.01e-06	0.00131	0.37	0.37	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
PCPG	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	4.95	2.01e-06	0.00131	0.37	0.37	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
PCPG	cis	rs7824557	0.679	rs7004362	ENSG00000255020.1	AF131216.5	-4.95	2.01e-06	0.00131	-0.47	-0.37	Retinal vascular caliber;	chr8:11278465	chr8:11345748~11347502:-
PCPG	cis	rs3806843	1	rs13157397	ENSG00000202515.1	VTRNA1-3	-4.95	2.01e-06	0.00131	-0.48	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr5:140726158~140726246:+
PCPG	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-4.95	2.02e-06	0.00131	-0.38	-0.37	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
PCPG	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	4.95	2.02e-06	0.00131	0.37	0.37	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
PCPG	cis	rs11148252	0.557	rs9536223	ENSG00000198384.8	TPTE2P3	-4.94	2.02e-06	0.00131	-0.48	-0.37	Lewy body disease;	chr13:52659059	chr13:52522632~52586906:+
PCPG	cis	rs3736858	1	rs9544049	ENSG00000261105.4	LMO7-AS1	-4.94	2.02e-06	0.00131	-0.7	-0.37	Interleukin-9 levels;	chr13:75826906	chr13:75604700~75635994:-
PCPG	cis	rs3736858	0.932	rs12430940	ENSG00000261105.4	LMO7-AS1	-4.94	2.02e-06	0.00131	-0.7	-0.37	Interleukin-9 levels;	chr13:75827479	chr13:75604700~75635994:-
PCPG	cis	rs3736858	0.932	rs3783025	ENSG00000261105.4	LMO7-AS1	-4.94	2.02e-06	0.00131	-0.7	-0.37	Interleukin-9 levels;	chr13:75830174	chr13:75604700~75635994:-
PCPG	cis	rs3736858	1	rs9544050	ENSG00000261105.4	LMO7-AS1	-4.94	2.02e-06	0.00131	-0.7	-0.37	Interleukin-9 levels;	chr13:75831254	chr13:75604700~75635994:-
PCPG	cis	rs12908161	0.959	rs17534709	ENSG00000259295.5	CSPG4P12	4.94	2.02e-06	0.00131	0.56	0.37	Schizophrenia;	chr15:84771166	chr15:85191438~85213905:+
PCPG	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-4.94	2.02e-06	0.00131	-0.48	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
PCPG	cis	rs11992162	0.569	rs11786149	ENSG00000255020.1	AF131216.5	-4.94	2.02e-06	0.00131	-0.54	-0.37	Monocyte count;	chr8:11943309	chr8:11345748~11347502:-
PCPG	cis	rs526231	0.584	rs246914	ENSG00000175749.11	EIF3KP1	4.94	2.02e-06	0.00131	0.58	0.37	Primary biliary cholangitis;	chr5:103223706	chr5:103032376~103033031:+
PCPG	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-4.94	2.02e-06	0.00131	-0.41	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
PCPG	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-4.94	2.02e-06	0.00131	-0.42	-0.37	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-4.94	2.02e-06	0.00131	-0.42	-0.37	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
PCPG	cis	rs7017914	0.69	rs2639929	ENSG00000254031.4	RP11-326E22.1	4.94	2.02e-06	0.00131	0.36	0.37	Bone mineral density;	chr8:70972413	chr8:71155457~71204223:+
PCPG	cis	rs2288884	0.559	rs9636139	ENSG00000275055.1	CTC-471J1.11	-4.94	2.02e-06	0.00131	-0.35	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018043	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.559	rs12610953	ENSG00000275055.1	CTC-471J1.11	-4.94	2.02e-06	0.00131	-0.35	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018675	chr19:52049007~52049754:+
PCPG	cis	rs7819412	0.668	rs920047	ENSG00000255020.1	AF131216.5	-4.94	2.02e-06	0.00131	-0.51	-0.37	Triglycerides;	chr8:11229966	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.902	rs28688952	ENSG00000259905.4	PWRN1	4.94	2.02e-06	0.00132	0.43	0.37	Platelet thrombus formation;	chr15:24576460	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs12900960	ENSG00000259905.4	PWRN1	4.94	2.02e-06	0.00132	0.43	0.37	Platelet thrombus formation;	chr15:24576461	chr15:24493137~24652130:+
PCPG	cis	rs10760158	0.832	rs10760169	ENSG00000226752.6	PSMD5-AS1	-4.94	2.02e-06	0.00132	-0.49	-0.37	Pulse pressure;	chr9:121295404	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10760171	ENSG00000226752.6	PSMD5-AS1	-4.94	2.02e-06	0.00132	-0.49	-0.37	Pulse pressure;	chr9:121296081	chr9:120824828~120854385:+
PCPG	cis	rs73607972	0.866	rs111763946	ENSG00000275191.1	RP11-36I17.2	-4.94	2.03e-06	0.00132	-0.64	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602740	chr16:53628256~53628816:-
PCPG	cis	rs300890	0.651	rs300915	ENSG00000250326.1	RP11-284M14.1	4.94	2.03e-06	0.00132	0.33	0.37	Nasopharyngeal carcinoma;	chr4:143353003	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.651	rs300914	ENSG00000250326.1	RP11-284M14.1	4.94	2.03e-06	0.00132	0.33	0.37	Nasopharyngeal carcinoma;	chr4:143353195	chr4:142933195~143184861:-
PCPG	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	4.94	2.03e-06	0.00132	0.5	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
PCPG	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-4.94	2.03e-06	0.00132	-0.37	-0.37	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	4.94	2.03e-06	0.00132	0.48	0.37	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
PCPG	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	4.94	2.03e-06	0.00132	0.69	0.37	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	4.94	2.03e-06	0.00132	0.69	0.37	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	4.94	2.03e-06	0.00132	0.69	0.37	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
PCPG	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	4.94	2.03e-06	0.00132	0.38	0.37	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
PCPG	cis	rs172166	0.543	rs1150691	ENSG00000219392.1	RP1-265C24.5	-4.94	2.04e-06	0.00132	-0.42	-0.37	Cardiac Troponin-T levels;	chr6:28200255	chr6:28115628~28116551:+
PCPG	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	4.94	2.04e-06	0.00132	0.6	0.37	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
PCPG	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	4.94	2.04e-06	0.00132	0.62	0.37	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
PCPG	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-4.94	2.04e-06	0.00133	-0.45	-0.37	Height;	chr2:231490121	chr2:231508426~231514339:-
PCPG	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	4.94	2.05e-06	0.00133	0.63	0.37	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
PCPG	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-4.94	2.05e-06	0.00133	-0.44	-0.37	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-4.94	2.05e-06	0.00133	-0.41	-0.37	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-4.94	2.05e-06	0.00133	-0.41	-0.37	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
PCPG	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	4.94	2.05e-06	0.00133	0.48	0.37	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
PCPG	cis	rs1440410	0.83	rs4690781	ENSG00000250326.1	RP11-284M14.1	4.94	2.05e-06	0.00133	0.34	0.37	Ischemic stroke;	chr4:143259053	chr4:142933195~143184861:-
PCPG	cis	rs7824557	0.569	rs2409718	ENSG00000255020.1	AF131216.5	-4.94	2.06e-06	0.00133	-0.52	-0.37	Retinal vascular caliber;	chr8:11155467	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.872	rs6601577	ENSG00000255020.1	AF131216.5	4.94	2.06e-06	0.00134	0.5	0.37	Retinal vascular caliber;	chr8:11245173	chr8:11345748~11347502:-
PCPG	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-4.94	2.06e-06	0.00134	-0.32	-0.37	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
PCPG	cis	rs7688540	0.8	rs12510827	ENSG00000275426.1	CH17-262A2.1	4.94	2.07e-06	0.00134	0.46	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:149738~150317:+
PCPG	cis	rs1440410	0.83	rs2010767	ENSG00000250326.1	RP11-284M14.1	4.94	2.07e-06	0.00134	0.35	0.37	Ischemic stroke;	chr4:143255393	chr4:142933195~143184861:-
PCPG	cis	rs561341	0.714	rs473535	ENSG00000265798.5	RP11-271K11.5	4.94	2.07e-06	0.00134	0.67	0.37	Hip circumference adjusted for BMI;	chr17:31985346	chr17:31038575~31059121:-
PCPG	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-4.94	2.07e-06	0.00134	-0.48	-0.37	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
PCPG	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	4.94	2.08e-06	0.00135	0.45	0.37	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
PCPG	cis	rs11992162	0.55	rs61426048	ENSG00000255020.1	AF131216.5	-4.94	2.08e-06	0.00135	-0.51	-0.37	Monocyte count;	chr8:11927447	chr8:11345748~11347502:-
PCPG	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	4.94	2.08e-06	0.00135	0.4	0.37	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
PCPG	cis	rs28386778	0.897	rs2727290	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63817368	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs1062787	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63818644	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs1062788	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63818767	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs1062790	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63819095	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs894408	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63819454	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.799	rs2665836	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63820775	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs2727288	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63823837	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584627	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63824079	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs894407	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63824281	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs894406	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63824297	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs716880	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63825462	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584626	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63825819	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.83	rs2584625	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63826085	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584624	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63827186	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs2665834	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63827364	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2727287	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63827368	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2665833	ENSG00000240280.5	TCAM1P	-4.94	2.08e-06	0.00135	-0.5	-0.37	Prudent dietary pattern;	chr17:63829486	chr17:63849292~63864379:+
PCPG	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	4.94	2.08e-06	0.00135	0.48	0.37	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	4.94	2.08e-06	0.00135	0.48	0.37	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
PCPG	cis	rs7246657	0.943	rs10420754	ENSG00000226686.6	LINC01535	-4.94	2.08e-06	0.00135	-0.58	-0.37	Coronary artery calcification;	chr19:37468470	chr19:37251912~37265535:+
PCPG	cis	rs2531992	1	rs2531992	ENSG00000262888.1	RP11-462G12.2	-4.94	2.08e-06	0.00135	-0.61	-0.37	Waist circumference;	chr16:3971733	chr16:3931217~3946305:-
PCPG	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-4.94	2.09e-06	0.00135	-0.47	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
PCPG	cis	rs12646107	0.891	rs11132998	ENSG00000261672.1	RP11-475B2.1	-4.94	2.09e-06	0.00135	-0.59	-0.37	Response to amphetamines;	chr4:173595439	chr4:173593672~173594556:+
PCPG	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	4.94	2.09e-06	0.00135	0.49	0.37	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
PCPG	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-4.94	2.09e-06	0.00135	-0.41	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
PCPG	cis	rs300890	0.56	rs13118943	ENSG00000250326.1	RP11-284M14.1	4.94	2.09e-06	0.00135	0.32	0.37	Nasopharyngeal carcinoma;	chr4:143264276	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.56	rs6857078	ENSG00000250326.1	RP11-284M14.1	4.94	2.09e-06	0.00135	0.32	0.37	Nasopharyngeal carcinoma;	chr4:143266435	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.56	rs4461474	ENSG00000250326.1	RP11-284M14.1	4.94	2.09e-06	0.00135	0.32	0.37	Nasopharyngeal carcinoma;	chr4:143266726	chr4:142933195~143184861:-
PCPG	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-4.94	2.09e-06	0.00136	-0.62	-0.37	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
PCPG	cis	rs7267979	0.545	rs6050426	ENSG00000125804.12	FAM182A	-4.94	2.09e-06	0.00136	-0.42	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25197629	chr20:26054655~26086917:+
PCPG	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	4.94	2.09e-06	0.00136	0.48	0.37	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	4.94	2.09e-06	0.00136	0.48	0.37	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	4.94	2.09e-06	0.00136	0.48	0.37	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	4.94	2.09e-06	0.00136	0.48	0.37	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	4.94	2.09e-06	0.00136	0.48	0.37	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	4.94	2.09e-06	0.00136	0.48	0.37	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
PCPG	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-4.94	2.1e-06	0.00136	-0.38	-0.37	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
PCPG	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	4.94	2.1e-06	0.00136	0.6	0.37	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
PCPG	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	4.94	2.1e-06	0.00136	0.49	0.37	Height;	chr6:109486036	chr6:109382795~109383666:+
PCPG	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-4.94	2.1e-06	0.00136	-0.41	-0.37	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
PCPG	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	4.94	2.1e-06	0.00136	0.36	0.37	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	4.94	2.1e-06	0.00136	0.37	0.37	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
PCPG	cis	rs12681963	0.688	rs7820490	ENSG00000248159.1	HSPA8P11	4.94	2.1e-06	0.00136	0.71	0.37	Migraine;	chr8:30213634	chr8:30237382~30240997:+
PCPG	cis	rs73607972	0.935	rs6499628	ENSG00000275191.1	RP11-36I17.2	-4.94	2.1e-06	0.00136	-0.62	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53570265	chr16:53628256~53628816:-
PCPG	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-4.93	2.11e-06	0.00137	-0.37	-0.37	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
PCPG	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-4.93	2.11e-06	0.00137	-0.41	-0.37	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
PCPG	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-4.93	2.11e-06	0.00137	-0.4	-0.37	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
PCPG	cis	rs11168351	0.927	rs7971880	ENSG00000240399.1	RP1-228P16.1	4.93	2.12e-06	0.00137	0.38	0.37	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48054813~48055591:-
PCPG	cis	rs3806843	0.9	rs2563287	ENSG00000202515.1	VTRNA1-3	-4.93	2.12e-06	0.00137	-0.47	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.9	rs2563286	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140745614	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.808	rs6893708	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140746337	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.75	rs2563285	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.778	rs2531346	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140746554	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.868	rs2531345	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140747196	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.864	rs2531343	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.9	rs2531341	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140751309	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.9	rs2531340	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140751461	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.868	rs2563281	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140751634	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.9	rs2563280	ENSG00000202515.1	VTRNA1-3	4.93	2.12e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140751945	chr5:140726158~140726246:+
PCPG	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	4.93	2.12e-06	0.00137	0.52	0.37	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
PCPG	cis	rs3806843	0.838	rs2563289	ENSG00000202515.1	VTRNA1-3	4.93	2.13e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140743181	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.868	rs2262573	ENSG00000202515.1	VTRNA1-3	4.93	2.13e-06	0.00137	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr5:140726158~140726246:+
PCPG	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	4.93	2.13e-06	0.00137	0.5	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
PCPG	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	4.93	2.13e-06	0.00137	0.37	0.37	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	4.93	2.13e-06	0.00137	0.37	0.37	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	4.93	2.13e-06	0.00137	0.37	0.37	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
PCPG	cis	rs7829975	0.617	rs4841071	ENSG00000173295.6	FAM86B3P	-4.93	2.13e-06	0.00138	-0.43	-0.37	Mood instability;	chr8:8933634	chr8:8228595~8244865:+
PCPG	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-4.93	2.13e-06	0.00138	-0.42	-0.37	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
PCPG	cis	rs561341	0.714	rs75861674	ENSG00000265798.5	RP11-271K11.5	4.93	2.13e-06	0.00138	0.65	0.37	Hip circumference adjusted for BMI;	chr17:31977298	chr17:31038575~31059121:-
PCPG	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	4.93	2.13e-06	0.00138	0.57	0.37	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
PCPG	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	4.93	2.14e-06	0.00138	0.32	0.37	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
PCPG	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-4.93	2.14e-06	0.00138	-0.56	-0.37	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
PCPG	cis	rs561341	1	rs497479	ENSG00000265798.5	RP11-271K11.5	4.93	2.14e-06	0.00138	0.66	0.37	Hip circumference adjusted for BMI;	chr17:32001586	chr17:31038575~31059121:-
PCPG	cis	rs3806843	0.676	rs1583005	ENSG00000202515.1	VTRNA1-3	4.93	2.14e-06	0.00138	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr5:140726158~140726246:+
PCPG	cis	rs7208859	0.623	rs56325146	ENSG00000263603.1	CTD-2349P21.5	-4.93	2.14e-06	0.00138	-0.64	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30729469~30731202:+
PCPG	cis	rs7824557	0.569	rs10106207	ENSG00000255020.1	AF131216.5	-4.93	2.14e-06	0.00138	-0.52	-0.37	Retinal vascular caliber;	chr8:11157828	chr8:11345748~11347502:-
PCPG	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	4.93	2.14e-06	0.00138	0.62	0.37	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
PCPG	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	4.93	2.14e-06	0.00138	0.62	0.37	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
PCPG	cis	rs28386778	0.897	rs2584608	ENSG00000240280.5	TCAM1P	-4.93	2.14e-06	0.00138	-0.5	-0.37	Prudent dietary pattern;	chr17:63859350	chr17:63849292~63864379:+
PCPG	cis	rs7759001	0.744	rs4478400	ENSG00000271755.1	RP1-153G14.4	4.93	2.14e-06	0.00138	0.54	0.37	Glomerular filtration rate (creatinine);	chr6:27518524	chr6:27404010~27406964:-
PCPG	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	4.93	2.14e-06	0.00138	0.36	0.37	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	4.93	2.15e-06	0.00139	0.32	0.37	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	4.93	2.15e-06	0.00139	0.32	0.37	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
PCPG	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs67471932	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100412362	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs73161759	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100412371	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs67315960	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100417501	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs11763414	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100419221	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs66632384	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100421281	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs67163493	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100426215	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.943	rs73403312	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100426530	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs74460138	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100429716	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs6975729	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100430564	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs1073	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100433989	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs4989959	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100434665	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.887	rs4074838	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100435042	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.945	rs6955362	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100458543	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs6975514	ENSG00000078319.8	PMS2P1	-4.93	2.15e-06	0.00139	-0.48	-0.37	Platelet count;	chr7:100458597	chr7:100320992~100341908:-
PCPG	cis	rs453301	0.686	rs6601281	ENSG00000173295.6	FAM86B3P	4.93	2.15e-06	0.00139	0.44	0.37	Joint mobility (Beighton score);	chr8:9053494	chr8:8228595~8244865:+
PCPG	cis	rs5769765	0.908	rs56351880	ENSG00000278869.1	CITF22-49E9.3	4.93	2.15e-06	0.00139	0.53	0.37	Schizophrenia;	chr22:49922949	chr22:49933198~49934074:-
PCPG	cis	rs7246657	0.943	rs2126977	ENSG00000226686.6	LINC01535	4.93	2.16e-06	0.00139	0.55	0.37	Coronary artery calcification;	chr19:37504845	chr19:37251912~37265535:+
PCPG	cis	rs4972806	0.814	rs2113560	ENSG00000226363.3	HAGLROS	-4.93	2.16e-06	0.00139	-0.37	-0.37	IgG glycosylation;	chr2:176166258	chr2:176177717~176179008:+
PCPG	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	4.93	2.16e-06	0.00139	0.32	0.37	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-4.93	2.16e-06	0.00139	-0.32	-0.37	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
PCPG	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	4.93	2.17e-06	0.0014	0.41	0.37	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
PCPG	cis	rs3806843	0.966	rs4141841	ENSG00000202515.1	VTRNA1-3	-4.93	2.17e-06	0.0014	-0.49	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs10050455	ENSG00000202515.1	VTRNA1-3	-4.93	2.17e-06	0.0014	-0.49	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr5:140726158~140726246:+
PCPG	cis	rs8014204	0.604	rs2159906	ENSG00000279594.1	RP11-950C14.10	4.93	2.17e-06	0.0014	0.51	0.37	Caffeine consumption;	chr14:74924209	chr14:75011269~75012851:-
PCPG	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-4.93	2.17e-06	0.0014	-0.51	-0.37	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
PCPG	cis	rs300890	0.513	rs72719182	ENSG00000250326.1	RP11-284M14.1	-4.93	2.17e-06	0.0014	-0.35	-0.37	Nasopharyngeal carcinoma;	chr4:143147652	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs7685464	ENSG00000250326.1	RP11-284M14.1	-4.93	2.17e-06	0.0014	-0.35	-0.37	Nasopharyngeal carcinoma;	chr4:143151285	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs12500240	ENSG00000250326.1	RP11-284M14.1	-4.93	2.17e-06	0.0014	-0.35	-0.37	Nasopharyngeal carcinoma;	chr4:143151507	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs11100775	ENSG00000250326.1	RP11-284M14.1	-4.93	2.17e-06	0.0014	-0.35	-0.37	Nasopharyngeal carcinoma;	chr4:143152759	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.56	rs4395451	ENSG00000250326.1	RP11-284M14.1	4.93	2.17e-06	0.0014	0.35	0.37	Ischemic stroke;	chr4:143155872	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs7680365	ENSG00000250326.1	RP11-284M14.1	4.93	2.17e-06	0.0014	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143157603	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs9998017	ENSG00000250326.1	RP11-284M14.1	4.93	2.17e-06	0.0014	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143184229	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.56	rs4413361	ENSG00000250326.1	RP11-284M14.1	4.93	2.17e-06	0.0014	0.35	0.37	Ischemic stroke;	chr4:143190802	chr4:142933195~143184861:-
PCPG	cis	rs5758511	0.508	rs58099562	ENSG00000205702.9	CYP2D7	4.93	2.17e-06	0.0014	0.51	0.37	Birth weight;	chr22:42057768	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.508	rs2413667	ENSG00000205702.9	CYP2D7	4.93	2.17e-06	0.0014	0.51	0.37	Birth weight;	chr22:42076233	chr22:42140203~42144577:-
PCPG	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-4.93	2.18e-06	0.0014	-0.48	-0.37	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
PCPG	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	4.93	2.18e-06	0.0014	0.31	0.37	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	4.93	2.18e-06	0.0014	0.31	0.37	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	4.93	2.18e-06	0.0014	0.31	0.37	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
PCPG	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	4.93	2.18e-06	0.0014	0.38	0.37	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
PCPG	cis	rs2830585	0.651	rs182774	ENSG00000197934.7	CYYR1-AS1	4.93	2.18e-06	0.0014	0.5	0.37	Blood protein levels;	chr21:26942277	chr21:26393635~26569252:+
PCPG	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	4.93	2.18e-06	0.0014	0.57	0.37	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
PCPG	cis	rs4713118	0.662	rs9468274	ENSG00000216901.1	AL022393.7	4.93	2.19e-06	0.00141	0.52	0.37	Parkinson's disease;	chr6:28058299	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs9468275	ENSG00000216901.1	AL022393.7	4.93	2.19e-06	0.00141	0.52	0.37	Parkinson's disease;	chr6:28058358	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs9468276	ENSG00000216901.1	AL022393.7	4.93	2.19e-06	0.00141	0.52	0.37	Parkinson's disease;	chr6:28059910	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs9468277	ENSG00000216901.1	AL022393.7	4.93	2.19e-06	0.00141	0.52	0.37	Parkinson's disease;	chr6:28060612	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs9468278	ENSG00000216901.1	AL022393.7	4.93	2.19e-06	0.00141	0.52	0.37	Parkinson's disease;	chr6:28060704	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs13218430	ENSG00000216901.1	AL022393.7	4.93	2.19e-06	0.00141	0.52	0.37	Parkinson's disease;	chr6:28062059	chr6:28176188~28176674:+
PCPG	cis	rs7301826	0.627	rs7315707	ENSG00000256299.1	RP11-989F5.3	4.93	2.19e-06	0.00141	0.37	0.37	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810821~130812622:-
PCPG	cis	rs6762	0.719	rs28620453	ENSG00000279672.1	CMB9-55F22.1	4.93	2.19e-06	0.00141	0.41	0.37	Mean platelet volume;	chr11:836971	chr11:779617~780755:+
PCPG	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-4.93	2.19e-06	0.00141	-0.49	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
PCPG	cis	rs3808502	0.526	rs11985709	ENSG00000255020.1	AF131216.5	-4.93	2.19e-06	0.00141	-0.49	-0.37	Neuroticism;	chr8:11565574	chr8:11345748~11347502:-
PCPG	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	4.93	2.2e-06	0.00141	0.42	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	4.93	2.2e-06	0.00141	0.42	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
PCPG	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	4.93	2.2e-06	0.00141	0.54	0.37	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	4.93	2.2e-06	0.00141	0.54	0.37	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	4.93	2.2e-06	0.00141	0.54	0.37	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	4.93	2.2e-06	0.00141	0.54	0.37	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	4.93	2.2e-06	0.00141	0.54	0.37	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	4.93	2.2e-06	0.00141	0.54	0.37	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	4.93	2.2e-06	0.00141	0.54	0.37	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
PCPG	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	4.93	2.2e-06	0.00141	0.54	0.37	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
PCPG	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	4.93	2.2e-06	0.00142	0.36	0.37	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
PCPG	cis	rs11671005	0.568	rs73068329	ENSG00000269600.1	AC016629.3	-4.92	2.2e-06	0.00142	-0.6	-0.37	Mean platelet volume;	chr19:58568958	chr19:58593896~58599355:-
PCPG	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	4.92	2.2e-06	0.00142	0.45	0.37	Height;	chr6:109374782	chr6:109382795~109383666:+
PCPG	cis	rs7688540	0.8	rs6837796	ENSG00000275426.1	CH17-262A2.1	4.92	2.2e-06	0.00142	0.44	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:149738~150317:+
PCPG	cis	rs7688540	0.8	rs9328738	ENSG00000275426.1	CH17-262A2.1	-4.92	2.2e-06	0.00142	-0.44	-0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:149738~150317:+
PCPG	cis	rs950027	0.516	rs12916762	ENSG00000259520.4	CTD-2651B20.3	-4.92	2.21e-06	0.00142	-0.49	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45656104	chr15:45251580~45279251:-
PCPG	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-4.92	2.21e-06	0.00142	-0.47	-0.37	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
PCPG	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	4.92	2.21e-06	0.00142	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
PCPG	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	4.92	2.21e-06	0.00142	0.57	0.37	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	4.92	2.21e-06	0.00142	0.57	0.37	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	4.92	2.21e-06	0.00142	0.57	0.37	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	4.92	2.21e-06	0.00142	0.57	0.37	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	4.92	2.21e-06	0.00142	0.57	0.37	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	4.92	2.21e-06	0.00142	0.57	0.37	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
PCPG	cis	rs2736337	0.53	rs11782375	ENSG00000255020.1	AF131216.5	4.92	2.21e-06	0.00142	0.58	0.37	Rheumatoid arthritis;	chr8:11437425	chr8:11345748~11347502:-
PCPG	cis	rs1440410	0.83	rs4690715	ENSG00000250326.1	RP11-284M14.1	4.92	2.21e-06	0.00142	0.34	0.37	Ischemic stroke;	chr4:143259186	chr4:142933195~143184861:-
PCPG	cis	rs2281603	0.694	rs12385910	ENSG00000259116.1	RP11-973N13.4	-4.92	2.21e-06	0.00142	-0.34	-0.37	Lymphocyte counts;	chr14:64533252	chr14:64514154~64540368:-
PCPG	cis	rs10760158	0.832	rs4837832	ENSG00000226752.6	PSMD5-AS1	4.92	2.21e-06	0.00142	0.49	0.37	Pulse pressure;	chr9:121294150	chr9:120824828~120854385:+
PCPG	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-4.92	2.21e-06	0.00142	-0.4	-0.37	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
PCPG	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-4.92	2.22e-06	0.00142	-0.38	-0.37	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
PCPG	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-4.92	2.22e-06	0.00142	-0.38	-0.37	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
PCPG	cis	rs7182621	0.883	rs10468181	ENSG00000259363.4	CTD-2054N24.2	-4.92	2.22e-06	0.00142	-0.5	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99885244	chr15:99807023~99877148:+
PCPG	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	4.92	2.22e-06	0.00143	0.32	0.37	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
PCPG	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-4.92	2.22e-06	0.00143	-0.39	-0.37	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
PCPG	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-4.92	2.23e-06	0.00143	-0.37	-0.37	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
PCPG	cis	rs6991838	0.548	rs11783633	ENSG00000200714.1	Y_RNA	4.92	2.23e-06	0.00143	0.49	0.37	Intelligence (multi-trait analysis);	chr8:65556593	chr8:65592731~65592820:+
PCPG	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-4.92	2.23e-06	0.00143	-0.48	-0.37	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-4.92	2.23e-06	0.00143	-0.48	-0.37	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-4.92	2.23e-06	0.00143	-0.48	-0.37	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
PCPG	cis	rs11148252	0.574	rs2038826	ENSG00000198384.8	TPTE2P3	-4.92	2.23e-06	0.00143	-0.48	-0.37	Lewy body disease;	chr13:52705878	chr13:52522632~52586906:+
PCPG	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	4.92	2.23e-06	0.00143	0.57	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
PCPG	cis	rs7017914	0.653	rs2732130	ENSG00000254031.4	RP11-326E22.1	4.92	2.24e-06	0.00143	0.35	0.37	Bone mineral density;	chr8:70981238	chr8:71155457~71204223:+
PCPG	cis	rs7824557	0.836	rs2736378	ENSG00000255020.1	AF131216.5	-4.92	2.24e-06	0.00144	-0.47	-0.37	Retinal vascular caliber;	chr8:11262251	chr8:11345748~11347502:-
PCPG	cis	rs6121246	0.954	rs6060978	ENSG00000230613.1	HM13-AS1	4.92	2.24e-06	0.00144	0.53	0.37	Mean corpuscular hemoglobin;	chr20:31829090	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6060979	ENSG00000230613.1	HM13-AS1	4.92	2.24e-06	0.00144	0.53	0.37	Mean corpuscular hemoglobin;	chr20:31829719	chr20:31567707~31573263:-
PCPG	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	4.92	2.24e-06	0.00144	0.45	0.37	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
PCPG	cis	rs1440410	0.83	rs6816223	ENSG00000250326.1	RP11-284M14.1	4.92	2.24e-06	0.00144	0.34	0.37	Ischemic stroke;	chr4:143260558	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.83	rs6832943	ENSG00000250326.1	RP11-284M14.1	4.92	2.24e-06	0.00144	0.34	0.37	Ischemic stroke;	chr4:143260564	chr4:142933195~143184861:-
PCPG	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	4.92	2.24e-06	0.00144	0.47	0.37	Height;	chr6:109414295	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	4.92	2.24e-06	0.00144	0.47	0.37	Height;	chr6:109416225	chr6:109382795~109383666:+
PCPG	cis	rs3806843	1	rs4451093	ENSG00000202515.1	VTRNA1-3	4.92	2.24e-06	0.00144	0.48	0.37	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr5:140726158~140726246:+
PCPG	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-4.92	2.25e-06	0.00144	-0.41	-0.37	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-4.92	2.25e-06	0.00144	-0.41	-0.37	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-4.92	2.25e-06	0.00144	-0.41	-0.37	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	4.92	2.25e-06	0.00144	0.41	0.37	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-4.92	2.25e-06	0.00144	-0.41	-0.37	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
PCPG	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	4.92	2.25e-06	0.00144	0.46	0.37	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
PCPG	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	4.92	2.25e-06	0.00144	0.57	0.37	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
PCPG	cis	rs657075	0.697	rs13179900	ENSG00000233006.5	AC034220.3	4.92	2.25e-06	0.00144	0.53	0.37	Rheumatoid arthritis;	chr5:132311897	chr5:132311285~132369916:-
PCPG	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	4.92	2.25e-06	0.00144	0.42	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
PCPG	cis	rs12681963	0.614	rs4409367	ENSG00000248159.1	HSPA8P11	4.92	2.25e-06	0.00144	0.81	0.37	Migraine;	chr8:30243112	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.614	rs4626556	ENSG00000248159.1	HSPA8P11	4.92	2.25e-06	0.00144	0.81	0.37	Migraine;	chr8:30243325	chr8:30237382~30240997:+
PCPG	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-4.92	2.25e-06	0.00144	-0.62	-0.37	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
PCPG	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	4.92	2.25e-06	0.00144	0.34	0.37	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
PCPG	cis	rs300890	0.689	rs300943	ENSG00000250326.1	RP11-284M14.1	4.92	2.26e-06	0.00144	0.34	0.37	Nasopharyngeal carcinoma;	chr4:143285000	chr4:142933195~143184861:-
PCPG	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	4.92	2.26e-06	0.00145	0.45	0.37	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	4.92	2.26e-06	0.00145	0.45	0.37	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	4.92	2.26e-06	0.00145	0.45	0.37	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
PCPG	cis	rs7181230	0.848	rs1010879	ENSG00000259584.1	RP11-521C20.2	4.92	2.26e-06	0.00145	0.49	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40041714	chr15:40075204~40078704:-
PCPG	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-4.92	2.26e-06	0.00145	-0.53	-0.37	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
PCPG	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	4.92	2.26e-06	0.00145	0.46	0.37	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
PCPG	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-4.92	2.27e-06	0.00145	-0.41	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
PCPG	cis	rs11858159	0.966	rs7163557	ENSG00000259905.4	PWRN1	4.92	2.27e-06	0.00145	0.43	0.37	Platelet thrombus formation;	chr15:24550313	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7180453	ENSG00000259905.4	PWRN1	4.92	2.27e-06	0.00145	0.43	0.37	Platelet thrombus formation;	chr15:24550318	chr15:24493137~24652130:+
PCPG	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	4.92	2.27e-06	0.00145	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	4.92	2.27e-06	0.00145	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	4.92	2.27e-06	0.00145	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	4.92	2.27e-06	0.00145	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	4.92	2.27e-06	0.00145	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
PCPG	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	4.92	2.27e-06	0.00145	0.46	0.37	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
PCPG	cis	rs308097	0.826	rs6969131	ENSG00000235944.6	ZNF815P	4.92	2.27e-06	0.00145	0.89	0.37	IgG glycosylation;	chr7:5814372	chr7:5823160~5854435:+
PCPG	cis	rs308097	0.826	rs7808239	ENSG00000235944.6	ZNF815P	4.92	2.27e-06	0.00145	0.89	0.37	IgG glycosylation;	chr7:5817151	chr7:5823160~5854435:+
PCPG	cis	rs308097	0.51	rs7806927	ENSG00000235944.6	ZNF815P	4.92	2.27e-06	0.00145	0.89	0.37	IgG glycosylation;	chr7:5823343	chr7:5823160~5854435:+
PCPG	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-4.92	2.27e-06	0.00145	-0.41	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-4.92	2.27e-06	0.00145	-0.41	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
PCPG	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-4.92	2.28e-06	0.00146	-0.33	-0.37	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
PCPG	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	4.92	2.28e-06	0.00146	0.55	0.37	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
PCPG	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	4.92	2.28e-06	0.00146	0.47	0.37	Height;	chr6:109375003	chr6:109382795~109383666:+
PCPG	cis	rs3808502	0.503	rs2061830	ENSG00000255020.1	AF131216.5	4.92	2.29e-06	0.00146	0.49	0.37	Neuroticism;	chr8:11539948	chr8:11345748~11347502:-
PCPG	cis	rs7811142	1	rs11764818	ENSG00000078319.8	PMS2P1	-4.92	2.29e-06	0.00146	-0.48	-0.37	Platelet count;	chr7:100445432	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs7811142	ENSG00000078319.8	PMS2P1	-4.92	2.29e-06	0.00146	-0.48	-0.37	Platelet count;	chr7:100467820	chr7:100320992~100341908:-
PCPG	cis	rs11148252	0.74	rs7983971	ENSG00000235660.1	LINC00345	-4.92	2.29e-06	0.00147	-0.47	-0.37	Lewy body disease;	chr13:52216565	chr13:52484161~52484680:-
PCPG	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	4.92	2.3e-06	0.00147	0.43	0.37	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
PCPG	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	4.92	2.3e-06	0.00147	0.34	0.37	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	4.92	2.3e-06	0.00147	0.34	0.37	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	4.92	2.3e-06	0.00147	0.34	0.37	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	4.92	2.3e-06	0.00147	0.34	0.37	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	4.92	2.3e-06	0.00147	0.34	0.37	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	4.92	2.3e-06	0.00147	0.34	0.37	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	4.92	2.3e-06	0.00147	0.34	0.37	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
PCPG	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-4.92	2.3e-06	0.00147	-0.57	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
PCPG	cis	rs73607972	0.877	rs4290466	ENSG00000275191.1	RP11-36I17.2	4.92	2.3e-06	0.00147	0.63	0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53658122	chr16:53628256~53628816:-
PCPG	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	4.92	2.3e-06	0.00147	0.46	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
PCPG	cis	rs9595908	0.869	rs9595949	ENSG00000212293.1	SNORA16	4.91	2.3e-06	0.00147	0.45	0.37	Body mass index;	chr13:32629939	chr13:32420390~32420516:-
PCPG	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-4.91	2.3e-06	0.00147	-0.53	-0.37	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
PCPG	cis	rs7181230	0.885	rs28736699	ENSG00000259584.1	RP11-521C20.2	4.91	2.3e-06	0.00147	0.49	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40075204~40078704:-
PCPG	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	4.91	2.3e-06	0.00147	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	4.91	2.3e-06	0.00147	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	4.91	2.3e-06	0.00147	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	4.91	2.3e-06	0.00147	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	4.91	2.3e-06	0.00147	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	4.91	2.3e-06	0.00147	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
PCPG	cis	rs7017914	0.69	rs11779364	ENSG00000254031.4	RP11-326E22.1	-4.91	2.31e-06	0.00147	-0.35	-0.37	Bone mineral density;	chr8:71042361	chr8:71155457~71204223:+
PCPG	cis	rs11992162	0.551	rs59191504	ENSG00000255020.1	AF131216.5	-4.91	2.31e-06	0.00147	-0.5	-0.37	Monocyte count;	chr8:11927572	chr8:11345748~11347502:-
PCPG	cis	rs3813579	0.517	rs9928324	ENSG00000261390.4	RP11-345M22.2	4.91	2.31e-06	0.00147	0.52	0.37	Thyroid volume;	chr16:79711089	chr16:79715232~79770563:-
PCPG	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-4.91	2.31e-06	0.00148	-0.44	-0.37	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
PCPG	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	4.91	2.31e-06	0.00148	0.51	0.37	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
PCPG	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-4.91	2.32e-06	0.00148	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-4.91	2.32e-06	0.00148	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-4.91	2.32e-06	0.00148	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
PCPG	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	4.91	2.32e-06	0.00148	0.45	0.37	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
PCPG	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-4.91	2.32e-06	0.00148	-0.34	-0.37	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-4.91	2.32e-06	0.00148	-0.34	-0.37	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
PCPG	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-4.91	2.32e-06	0.00148	-0.5	-0.37	Temperament;	chr17:14013482	chr17:14024514~14025488:+
PCPG	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-4.91	2.33e-06	0.00148	-0.34	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
PCPG	cis	rs12220777	0.748	rs12259239	ENSG00000230091.5	TMEM254-AS1	4.91	2.33e-06	0.00148	0.56	0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103265	chr10:80046860~80078912:-
PCPG	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-4.91	2.33e-06	0.00149	-0.38	-0.37	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
PCPG	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-4.91	2.34e-06	0.00149	-0.47	-0.37	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
PCPG	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	4.91	2.34e-06	0.00149	0.49	0.37	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
PCPG	cis	rs17772222	0.916	rs77306894	ENSG00000222990.1	RNU4-22P	4.91	2.34e-06	0.00149	0.5	0.37	Coronary artery calcification;	chr14:88494507	chr14:88513498~88513663:+
PCPG	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	4.91	2.35e-06	0.00149	0.46	0.37	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
PCPG	cis	rs7759001	0.744	rs10452601	ENSG00000271755.1	RP1-153G14.4	4.91	2.35e-06	0.00149	0.53	0.37	Glomerular filtration rate (creatinine);	chr6:27494437	chr6:27404010~27406964:-
PCPG	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	4.91	2.35e-06	0.0015	0.41	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
PCPG	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-4.91	2.35e-06	0.0015	-0.64	-0.37	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
PCPG	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-4.91	2.35e-06	0.0015	-0.46	-0.37	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
PCPG	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-4.91	2.35e-06	0.0015	-0.67	-0.37	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
PCPG	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-4.91	2.36e-06	0.0015	-0.53	-0.37	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
PCPG	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-4.91	2.36e-06	0.0015	-0.42	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
PCPG	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-4.91	2.36e-06	0.0015	-0.63	-0.37	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
PCPG	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	4.91	2.37e-06	0.00151	0.55	0.37	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
PCPG	cis	rs13113518	1	rs10462032	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55479069	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs12501636	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55482317	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs13108409	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55520278	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11726198	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55523835	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs11133396	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55524246	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs7675109	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55525589	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4865005	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55525781	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13108499	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55526514	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13116194	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55531150	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13117836	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55531218	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs7668429	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55531811	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13152173	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55534788	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13141049	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55535489	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.967	rs12507722	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55536421	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.967	rs7696832	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55537080	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4864547	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55538228	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs7691799	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.41	0.37	Height;	chr4:55545574	chr4:55547112~55547889:+
PCPG	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	4.91	2.37e-06	0.00151	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
PCPG	cis	rs13113518	0.966	rs7677952	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55425312	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs1047354	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55429416	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs1056547	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55430596	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs1056545	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55430730	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs5863	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55430740	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs6828570	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55431595	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs3749474	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55434518	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs1474271	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55435912	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11937487	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55436576	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs3805146	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55436985	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11133378	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55439472	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11942279	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55439652	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs3805148	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55440643	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11133380	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55441110	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs12510110	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55441567	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs12510990	ENSG00000272969.1	RP11-528I4.2	4.91	2.37e-06	0.00151	0.4	0.37	Height;	chr4:55441907	chr4:55547112~55547889:+
PCPG	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	4.91	2.37e-06	0.00151	0.45	0.37	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
PCPG	cis	rs17826219	0.568	rs2626985	ENSG00000263603.1	CTD-2349P21.5	-4.91	2.37e-06	0.00151	-0.62	-0.37	Body mass index;	chr17:30750419	chr17:30729469~30731202:+
PCPG	cis	rs13108904	0.935	rs1732102	ENSG00000254094.1	AC078852.1	4.91	2.37e-06	0.00151	0.42	0.37	Obesity-related traits;	chr4:1284136	chr4:1356581~1358075:+
PCPG	cis	rs73607972	0.877	rs8055188	ENSG00000275191.1	RP11-36I17.2	4.91	2.37e-06	0.00151	0.63	0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53655975	chr16:53628256~53628816:-
PCPG	cis	rs9959145	0.543	rs11664013	ENSG00000267199.1	RP11-861E21.2	-4.91	2.37e-06	0.00151	-0.47	-0.37	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12438890~12448205:+
PCPG	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	4.91	2.38e-06	0.00151	0.52	0.37	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
PCPG	cis	rs300890	0.513	rs2323077	ENSG00000250326.1	RP11-284M14.1	4.91	2.38e-06	0.00151	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143231032	chr4:142933195~143184861:-
PCPG	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-4.91	2.38e-06	0.00151	-0.41	-0.37	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
PCPG	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-4.91	2.38e-06	0.00151	-0.45	-0.37	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-4.91	2.38e-06	0.00151	-0.45	-0.37	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.567	rs6601273	ENSG00000173295.6	FAM86B3P	4.91	2.38e-06	0.00152	0.44	0.37	Mood instability;	chr8:8939009	chr8:8228595~8244865:+
PCPG	cis	rs2625529	0.526	rs11637611	ENSG00000260037.4	CTD-2524L6.3	4.91	2.39e-06	0.00152	0.47	0.37	Red blood cell count;	chr15:72259371	chr15:71818396~71823384:+
PCPG	cis	rs7246657	0.943	rs4803347	ENSG00000226686.6	LINC01535	-4.91	2.39e-06	0.00152	-0.58	-0.37	Coronary artery calcification;	chr19:37357115	chr19:37251912~37265535:+
PCPG	cis	rs2625529	0.556	rs35603965	ENSG00000260037.4	CTD-2524L6.3	4.91	2.39e-06	0.00152	0.48	0.37	Red blood cell count;	chr15:72230702	chr15:71818396~71823384:+
PCPG	cis	rs2302464	1	rs12651052	ENSG00000214846.4	RP11-115L11.1	4.91	2.39e-06	0.00152	0.99	0.37	Cerebrospinal fluid biomarker levels;	chr4:15726813	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs56381553	ENSG00000214846.4	RP11-115L11.1	4.91	2.39e-06	0.00152	0.99	0.37	Cerebrospinal fluid biomarker levels;	chr4:15726824	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs12645513	ENSG00000214846.4	RP11-115L11.1	4.91	2.39e-06	0.00152	0.99	0.37	Cerebrospinal fluid biomarker levels;	chr4:15727155	chr4:15730962~15731627:-
PCPG	cis	rs2302464	1	rs58335439	ENSG00000214846.4	RP11-115L11.1	4.91	2.39e-06	0.00152	0.99	0.37	Cerebrospinal fluid biomarker levels;	chr4:15727183	chr4:15730962~15731627:-
PCPG	cis	rs11148252	0.508	rs6561671	ENSG00000198384.8	TPTE2P3	-4.91	2.39e-06	0.00152	-0.46	-0.37	Lewy body disease;	chr13:52608179	chr13:52522632~52586906:+
PCPG	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-4.91	2.39e-06	0.00152	-0.31	-0.37	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-4.91	2.39e-06	0.00152	-0.31	-0.37	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
PCPG	cis	rs7208859	0.623	rs216439	ENSG00000263603.1	CTD-2349P21.5	-4.91	2.4e-06	0.00152	-0.62	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs216442	ENSG00000263603.1	CTD-2349P21.5	-4.91	2.4e-06	0.00152	-0.62	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30729469~30731202:+
PCPG	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	4.91	2.4e-06	0.00152	0.61	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
PCPG	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	4.91	2.4e-06	0.00152	0.42	0.37	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
PCPG	cis	rs9595908	0.686	rs8001047	ENSG00000212293.1	SNORA16	-4.91	2.4e-06	0.00152	-0.44	-0.37	Body mass index;	chr13:32802746	chr13:32420390~32420516:-
PCPG	cis	rs28386778	0.897	rs968719	ENSG00000240280.5	TCAM1P	-4.91	2.4e-06	0.00152	-0.49	-0.37	Prudent dietary pattern;	chr17:63830911	chr17:63849292~63864379:+
PCPG	cis	rs300890	0.536	rs300940	ENSG00000250326.1	RP11-284M14.1	4.91	2.4e-06	0.00153	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143252152	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.56	rs300941	ENSG00000250326.1	RP11-284M14.1	4.91	2.4e-06	0.00153	0.35	0.37	Ischemic stroke;	chr4:143252387	chr4:142933195~143184861:-
PCPG	cis	rs12908161	1	rs35808647	ENSG00000259295.5	CSPG4P12	4.91	2.4e-06	0.00153	0.55	0.37	Schizophrenia;	chr15:84834210	chr15:85191438~85213905:+
PCPG	cis	rs561341	1	rs530209	ENSG00000265798.5	RP11-271K11.5	4.91	2.41e-06	0.00153	0.66	0.37	Hip circumference adjusted for BMI;	chr17:31988268	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs72825712	ENSG00000265798.5	RP11-271K11.5	4.91	2.41e-06	0.00153	0.66	0.37	Hip circumference adjusted for BMI;	chr17:31989100	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs561341	ENSG00000265798.5	RP11-271K11.5	4.91	2.41e-06	0.00153	0.66	0.37	Hip circumference adjusted for BMI;	chr17:31989366	chr17:31038575~31059121:-
PCPG	cis	rs17772222	0.876	rs12587528	ENSG00000222990.1	RNU4-22P	4.9	2.41e-06	0.00153	0.5	0.37	Coronary artery calcification;	chr14:88487652	chr14:88513498~88513663:+
PCPG	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-4.9	2.41e-06	0.00153	-0.49	-0.37	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
PCPG	cis	rs11992162	0.56	rs7846248	ENSG00000255020.1	AF131216.5	4.9	2.41e-06	0.00153	0.52	0.37	Monocyte count;	chr8:11936540	chr8:11345748~11347502:-
PCPG	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	4.9	2.41e-06	0.00153	0.46	0.37	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
PCPG	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-4.9	2.41e-06	0.00153	-0.56	-0.37	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
PCPG	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	4.9	2.41e-06	0.00153	0.62	0.37	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	4.9	2.41e-06	0.00153	0.62	0.37	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
PCPG	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-4.9	2.42e-06	0.00153	-0.34	-0.37	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
PCPG	cis	rs17507216	0.667	rs72753916	ENSG00000228141.5	AC105339.1	-4.9	2.42e-06	0.00153	-0.55	-0.37	Excessive daytime sleepiness;	chr15:82684001	chr15:82710471~82714026:-
PCPG	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-4.9	2.43e-06	0.00154	-0.46	-0.37	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
PCPG	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
PCPG	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-4.9	2.43e-06	0.00154	-0.41	-0.37	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
PCPG	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	4.9	2.43e-06	0.00154	0.38	0.37	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
PCPG	cis	rs7246657	0.943	rs1382357	ENSG00000226686.6	LINC01535	-4.9	2.43e-06	0.00154	-0.58	-0.37	Coronary artery calcification;	chr19:37486707	chr19:37251912~37265535:+
PCPG	cis	rs9650657	0.504	rs10093053	ENSG00000255020.1	AF131216.5	-4.9	2.43e-06	0.00154	-0.49	-0.37	Neuroticism;	chr8:11179678	chr8:11345748~11347502:-
PCPG	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	4.9	2.44e-06	0.00154	0.51	0.37	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
PCPG	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-4.9	2.44e-06	0.00155	-0.42	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
PCPG	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	4.9	2.45e-06	0.00155	0.37	0.37	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
PCPG	cis	rs2302464	1	rs4342183	ENSG00000214846.4	RP11-115L11.1	4.9	2.45e-06	0.00155	0.98	0.37	Cerebrospinal fluid biomarker levels;	chr4:15733817	chr4:15730962~15731627:-
PCPG	cis	rs2898290	0.622	rs1600250	ENSG00000255020.1	AF131216.5	-4.9	2.45e-06	0.00155	-0.49	-0.37	Systolic blood pressure;	chr8:11487916	chr8:11345748~11347502:-
PCPG	cis	rs2898290	0.593	rs1600252	ENSG00000255020.1	AF131216.5	-4.9	2.45e-06	0.00155	-0.49	-0.37	Systolic blood pressure;	chr8:11488135	chr8:11345748~11347502:-
PCPG	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-4.9	2.45e-06	0.00155	-0.45	-0.37	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-4.9	2.45e-06	0.00155	-0.45	-0.37	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-4.9	2.45e-06	0.00155	-0.45	-0.37	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
PCPG	cis	rs748404	0.666	rs12906017	ENSG00000249839.1	AC011330.5	-4.9	2.45e-06	0.00155	-0.5	-0.37	Lung cancer;	chr15:43504710	chr15:43663654~43684339:-
PCPG	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-4.9	2.45e-06	0.00155	-0.57	-0.37	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
PCPG	cis	rs12681963	0.614	rs2341179	ENSG00000248159.1	HSPA8P11	4.9	2.46e-06	0.00155	0.77	0.37	Migraine;	chr8:30243250	chr8:30237382~30240997:+
PCPG	cis	rs7246657	0.943	rs10406177	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37417045	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.882	rs28623164	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37422551	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7252346	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37423780	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs2891699	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37429335	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.882	rs8112610	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37437828	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs8109632	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37440223	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs7255407	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37443034	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.941	rs7256130	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37443079	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs2112923	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37449425	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs3760825	ENSG00000226686.6	LINC01535	-4.9	2.46e-06	0.00155	-0.58	-0.37	Coronary artery calcification;	chr19:37454699	chr19:37251912~37265535:+
PCPG	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-4.9	2.46e-06	0.00155	-0.49	-0.37	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
PCPG	cis	rs2625529	0.526	rs10851850	ENSG00000260037.4	CTD-2524L6.3	4.9	2.46e-06	0.00156	0.47	0.37	Red blood cell count;	chr15:72194168	chr15:71818396~71823384:+
PCPG	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-4.9	2.46e-06	0.00156	-0.45	-0.37	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
PCPG	cis	rs13113518	1	rs55699500	ENSG00000272969.1	RP11-528I4.2	4.9	2.47e-06	0.00156	0.41	0.37	Height;	chr4:55540912	chr4:55547112~55547889:+
PCPG	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	4.9	2.47e-06	0.00156	0.31	0.37	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
PCPG	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-4.9	2.47e-06	0.00156	-0.45	-0.37	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
PCPG	cis	rs5758511	0.68	rs5758687	ENSG00000227370.1	RP4-669P10.19	4.9	2.47e-06	0.00156	0.57	0.37	Birth weight;	chr22:42260582	chr22:42132543~42132998:+
PCPG	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-4.9	2.47e-06	0.00156	-0.46	-0.37	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
PCPG	cis	rs58904263	1	rs58904263	ENSG00000230613.1	HM13-AS1	4.9	2.48e-06	0.00157	0.53	0.37	Monocyte count;	chr20:31813603	chr20:31567707~31573263:-
PCPG	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	4.9	2.48e-06	0.00157	0.5	0.37	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
PCPG	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	4.9	2.48e-06	0.00157	0.5	0.37	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
PCPG	cis	rs7819412	0.775	rs11773990	ENSG00000255020.1	AF131216.5	-4.9	2.48e-06	0.00157	-0.54	-0.37	Triglycerides;	chr8:11077572	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.775	rs4545055	ENSG00000255020.1	AF131216.5	-4.9	2.48e-06	0.00157	-0.54	-0.37	Triglycerides;	chr8:11077856	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.775	rs2898257	ENSG00000255020.1	AF131216.5	-4.9	2.48e-06	0.00157	-0.54	-0.37	Triglycerides;	chr8:11077858	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.775	rs34094119	ENSG00000255020.1	AF131216.5	-4.9	2.48e-06	0.00157	-0.54	-0.37	Triglycerides;	chr8:11078388	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.775	rs4841489	ENSG00000255020.1	AF131216.5	-4.9	2.48e-06	0.00157	-0.54	-0.37	Triglycerides;	chr8:11079301	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.775	rs4841490	ENSG00000255020.1	AF131216.5	-4.9	2.48e-06	0.00157	-0.54	-0.37	Triglycerides;	chr8:11079381	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.871	rs7181390	ENSG00000259905.4	PWRN1	4.9	2.49e-06	0.00157	0.42	0.37	Platelet thrombus formation;	chr15:24566498	chr15:24493137~24652130:+
PCPG	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	4.9	2.49e-06	0.00157	0.41	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
PCPG	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-4.9	2.49e-06	0.00157	-0.47	-0.37	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
PCPG	cis	rs7829975	0.582	rs6982832	ENSG00000173295.6	FAM86B3P	4.9	2.49e-06	0.00158	0.43	0.37	Mood instability;	chr8:8934707	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.582	rs6983150	ENSG00000173295.6	FAM86B3P	4.9	2.49e-06	0.00158	0.43	0.37	Mood instability;	chr8:8934916	chr8:8228595~8244865:+
PCPG	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	4.9	2.5e-06	0.00158	0.39	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
PCPG	cis	rs1600249	0.594	rs12674768	ENSG00000255020.1	AF131216.5	4.9	2.5e-06	0.00158	0.53	0.37	Rheumatoid arthritis;	chr8:11514038	chr8:11345748~11347502:-
PCPG	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	4.9	2.5e-06	0.00158	0.47	0.37	Height;	chr6:109357908	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	4.9	2.5e-06	0.00158	0.47	0.37	Height;	chr6:109359747	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	4.9	2.5e-06	0.00158	0.47	0.37	Height;	chr6:109361318	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	4.9	2.5e-06	0.00158	0.47	0.37	Height;	chr6:109366911	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	4.9	2.5e-06	0.00158	0.47	0.37	Height;	chr6:109371573	chr6:109382795~109383666:+
PCPG	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-4.9	2.5e-06	0.00158	-0.56	-0.37	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
PCPG	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	4.9	2.5e-06	0.00158	0.38	0.37	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	4.9	2.5e-06	0.00158	0.38	0.37	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	4.9	2.5e-06	0.00158	0.38	0.37	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	4.9	2.5e-06	0.00158	0.38	0.37	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
PCPG	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-4.9	2.51e-06	0.00158	-0.44	-0.37	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
PCPG	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-4.9	2.51e-06	0.00158	-0.46	-0.37	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
PCPG	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-4.9	2.51e-06	0.00158	-0.38	-0.37	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
PCPG	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	4.9	2.51e-06	0.00158	0.31	0.37	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
PCPG	cis	rs7017914	0.69	rs3098869	ENSG00000254031.4	RP11-326E22.1	4.9	2.51e-06	0.00159	0.35	0.37	Bone mineral density;	chr8:71017597	chr8:71155457~71204223:+
PCPG	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-4.89	2.52e-06	0.00159	-0.44	-0.37	Height;	chr5:36861889	chr5:36666214~36725195:-
PCPG	cis	rs12050794	0.671	rs62022788	ENSG00000260037.4	CTD-2524L6.3	4.89	2.52e-06	0.00159	0.46	0.37	Metabolite levels (HVA/MHPG ratio);	chr15:72266985	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.526	rs6494997	ENSG00000260037.4	CTD-2524L6.3	4.89	2.52e-06	0.00159	0.46	0.37	Red blood cell count;	chr15:72268301	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.526	rs11634622	ENSG00000260037.4	CTD-2524L6.3	4.89	2.52e-06	0.00159	0.46	0.37	Red blood cell count;	chr15:72269986	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.526	rs7179942	ENSG00000260037.4	CTD-2524L6.3	4.89	2.52e-06	0.00159	0.46	0.37	Red blood cell count;	chr15:72270733	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.526	rs62022789	ENSG00000260037.4	CTD-2524L6.3	4.89	2.52e-06	0.00159	0.46	0.37	Red blood cell count;	chr15:72272151	chr15:71818396~71823384:+
PCPG	cis	rs11671005	0.652	rs56225452	ENSG00000269600.1	AC016629.3	-4.89	2.52e-06	0.00159	-0.6	-0.37	Mean platelet volume;	chr19:58513279	chr19:58593896~58599355:-
PCPG	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-4.89	2.52e-06	0.00159	-0.49	-0.37	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
PCPG	cis	rs12681963	0.688	rs7010839	ENSG00000248159.1	HSPA8P11	-4.89	2.52e-06	0.00159	-0.71	-0.37	Migraine;	chr8:30223451	chr8:30237382~30240997:+
PCPG	cis	rs300890	0.583	rs2012599	ENSG00000250326.1	RP11-284M14.1	4.89	2.52e-06	0.00159	0.33	0.37	Nasopharyngeal carcinoma;	chr4:143275707	chr4:142933195~143184861:-
PCPG	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-4.89	2.52e-06	0.00159	-0.44	-0.37	Height;	chr2:231549981	chr2:231508426~231514339:-
PCPG	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	4.89	2.53e-06	0.00159	0.45	0.37	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
PCPG	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	4.89	2.54e-06	0.0016	0.56	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
PCPG	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	4.89	2.54e-06	0.0016	0.57	0.37	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	4.89	2.54e-06	0.0016	0.57	0.37	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
PCPG	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	4.89	2.54e-06	0.0016	0.61	0.37	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
PCPG	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-4.89	2.54e-06	0.0016	-0.39	-0.37	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
PCPG	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	4.89	2.54e-06	0.0016	0.5	0.37	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
PCPG	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	4.89	2.54e-06	0.0016	0.37	0.37	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
PCPG	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-4.89	2.55e-06	0.0016	-0.41	-0.37	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
PCPG	cis	rs300890	0.513	rs72719151	ENSG00000250326.1	RP11-284M14.1	-4.89	2.55e-06	0.0016	-0.35	-0.37	Nasopharyngeal carcinoma;	chr4:143122417	chr4:142933195~143184861:-
PCPG	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	4.89	2.55e-06	0.0016	0.45	0.37	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	4.89	2.55e-06	0.0016	0.45	0.37	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
PCPG	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	4.89	2.55e-06	0.00161	0.41	0.37	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	4.89	2.55e-06	0.00161	0.41	0.37	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
PCPG	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	4.89	2.56e-06	0.00161	0.5	0.37	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
PCPG	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	4.89	2.56e-06	0.00161	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
PCPG	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	4.89	2.56e-06	0.00161	0.43	0.37	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
PCPG	cis	rs11671005	0.61	rs3816329	ENSG00000269600.1	AC016629.3	-4.89	2.56e-06	0.00161	-0.59	-0.37	Mean platelet volume;	chr19:58547326	chr19:58593896~58599355:-
PCPG	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-4.89	2.57e-06	0.00161	-0.47	-0.37	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
PCPG	cis	rs11148252	0.774	rs9536066	ENSG00000198384.8	TPTE2P3	-4.89	2.57e-06	0.00161	-0.45	-0.37	Lewy body disease;	chr13:52409846	chr13:52522632~52586906:+
PCPG	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	4.89	2.57e-06	0.00162	0.47	0.37	Height;	chr6:109380990	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	4.89	2.57e-06	0.00162	0.47	0.37	Height;	chr6:109382524	chr6:109382795~109383666:+
PCPG	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-4.89	2.58e-06	0.00162	-0.55	-0.37	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
PCPG	cis	rs1440410	0.795	rs10461280	ENSG00000250326.1	RP11-284M14.1	4.89	2.58e-06	0.00162	0.34	0.37	Ischemic stroke;	chr4:143263750	chr4:142933195~143184861:-
PCPG	cis	rs5769765	0.955	rs9616367	ENSG00000278869.1	CITF22-49E9.3	4.89	2.58e-06	0.00162	0.49	0.37	Schizophrenia;	chr22:49909867	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.955	rs9616204	ENSG00000278869.1	CITF22-49E9.3	4.89	2.58e-06	0.00162	0.49	0.37	Schizophrenia;	chr22:49909882	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.955	rs9616368	ENSG00000278869.1	CITF22-49E9.3	4.89	2.58e-06	0.00162	0.49	0.37	Schizophrenia;	chr22:49909885	chr22:49933198~49934074:-
PCPG	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-4.89	2.58e-06	0.00162	-0.44	-0.37	Height;	chr2:231543307	chr2:231508426~231514339:-
PCPG	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	4.89	2.58e-06	0.00162	0.49	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
PCPG	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-4.89	2.59e-06	0.00163	-0.37	-0.37	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
PCPG	cis	rs34421088	0.56	rs2248699	ENSG00000255020.1	AF131216.5	-4.89	2.59e-06	0.00163	-0.48	-0.37	Neuroticism;	chr8:11536255	chr8:11345748~11347502:-
PCPG	cis	rs73607972	0.736	rs73614566	ENSG00000275191.1	RP11-36I17.2	-4.89	2.59e-06	0.00163	-0.68	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53529415	chr16:53628256~53628816:-
PCPG	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-4.89	2.59e-06	0.00163	-0.38	-0.37	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
PCPG	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-4.89	2.6e-06	0.00163	-0.46	-0.37	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
PCPG	cis	rs73607972	0.935	rs73603987	ENSG00000275191.1	RP11-36I17.2	-4.89	2.6e-06	0.00163	-0.63	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53577714	chr16:53628256~53628816:-
PCPG	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	4.89	2.6e-06	0.00163	0.47	0.37	Height;	chr6:109384228	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	4.89	2.6e-06	0.00163	0.47	0.37	Height;	chr6:109385087	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	4.89	2.6e-06	0.00163	0.47	0.37	Height;	chr6:109387685	chr6:109382795~109383666:+
PCPG	cis	rs13113518	1	rs56362210	ENSG00000272969.1	RP11-528I4.2	4.89	2.6e-06	0.00163	0.41	0.37	Height;	chr4:55540972	chr4:55547112~55547889:+
PCPG	cis	rs7181230	0.848	rs62004114	ENSG00000259584.1	RP11-521C20.2	4.89	2.61e-06	0.00164	0.49	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40041154	chr15:40075204~40078704:-
PCPG	cis	rs7181230	0.848	rs75509561	ENSG00000259584.1	RP11-521C20.2	4.89	2.61e-06	0.00164	0.49	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40041268	chr15:40075204~40078704:-
PCPG	cis	rs7181230	0.848	rs7497289	ENSG00000259584.1	RP11-521C20.2	4.89	2.61e-06	0.00164	0.49	0.37	Dehydroepiandrosterone sulphate levels;	chr15:40041456	chr15:40075204~40078704:-
PCPG	cis	rs2625529	0.824	rs12916951	ENSG00000260037.4	CTD-2524L6.3	-4.89	2.61e-06	0.00164	-0.55	-0.37	Red blood cell count;	chr15:71960157	chr15:71818396~71823384:+
PCPG	cis	rs5742933	0.857	rs1437891	ENSG00000273240.1	RP11-455J20.3	-4.89	2.61e-06	0.00164	-0.39	-0.37	Ferritin levels;	chr2:189697982	chr2:189763859~189764456:-
PCPG	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	4.89	2.61e-06	0.00164	0.4	0.37	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
PCPG	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	4.89	2.61e-06	0.00164	0.4	0.37	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
PCPG	cis	rs2281558	0.583	rs11087526	ENSG00000125804.12	FAM182A	-4.89	2.61e-06	0.00164	-0.55	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25667380	chr20:26054655~26086917:+
PCPG	cis	rs561341	0.941	rs2470236	ENSG00000265798.5	RP11-271K11.5	4.89	2.62e-06	0.00164	0.64	0.37	Hip circumference adjusted for BMI;	chr17:31977921	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.714	rs474455	ENSG00000265798.5	RP11-271K11.5	4.89	2.62e-06	0.00164	0.64	0.37	Hip circumference adjusted for BMI;	chr17:31985446	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.941	rs501773	ENSG00000265798.5	RP11-271K11.5	4.89	2.62e-06	0.00164	0.64	0.37	Hip circumference adjusted for BMI;	chr17:31987416	chr17:31038575~31059121:-
PCPG	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	4.89	2.62e-06	0.00164	0.46	0.37	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
PCPG	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	4.89	2.62e-06	0.00164	0.4	0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
PCPG	cis	rs4512344	0.509	rs2409784	ENSG00000255020.1	AF131216.5	-4.89	2.62e-06	0.00164	-0.48	-0.37	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11345748~11347502:-
PCPG	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-4.89	2.62e-06	0.00164	-0.36	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
PCPG	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-4.89	2.63e-06	0.00165	-0.38	-0.37	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
PCPG	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-4.89	2.63e-06	0.00165	-0.38	-0.37	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
PCPG	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-4.89	2.63e-06	0.00165	-0.38	-0.37	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
PCPG	cis	rs12681963	0.614	rs11994173	ENSG00000248159.1	HSPA8P11	4.88	2.63e-06	0.00165	0.7	0.37	Migraine;	chr8:30222047	chr8:30237382~30240997:+
PCPG	cis	rs8098244	0.58	rs1711452	ENSG00000265752.2	RP11-403A21.1	4.88	2.63e-06	0.00165	0.45	0.37	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692607	chr18:23957754~23982556:-
PCPG	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	4.88	2.63e-06	0.00165	0.38	0.37	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
PCPG	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-4.88	2.63e-06	0.00165	-0.44	-0.37	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
PCPG	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	4.88	2.63e-06	0.00165	0.31	0.37	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
PCPG	cis	rs1075232	0.677	rs72714666	ENSG00000270055.1	CTD-3092A11.2	-4.88	2.63e-06	0.00165	-0.84	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31200023	chr15:30487963~30490313:+
PCPG	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	4.88	2.63e-06	0.00165	0.96	0.37	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
PCPG	cis	rs8098244	0.603	rs3017550	ENSG00000265752.2	RP11-403A21.1	4.88	2.63e-06	0.00165	0.45	0.37	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696510	chr18:23957754~23982556:-
PCPG	cis	rs34421088	0.532	rs11782742	ENSG00000255020.1	AF131216.5	4.88	2.63e-06	0.00165	0.47	0.37	Neuroticism;	chr8:11307500	chr8:11345748~11347502:-
PCPG	cis	rs5769765	0.773	rs7410304	ENSG00000278869.1	CITF22-49E9.3	4.88	2.63e-06	0.00165	0.5	0.37	Schizophrenia;	chr22:49923187	chr22:49933198~49934074:-
PCPG	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-4.88	2.64e-06	0.00165	-0.59	-0.37	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
PCPG	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-4.88	2.64e-06	0.00165	-0.59	-0.37	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
PCPG	cis	rs11671005	0.568	rs73068325	ENSG00000269600.1	AC016629.3	-4.88	2.64e-06	0.00165	-0.59	-0.37	Mean platelet volume;	chr19:58567729	chr19:58593896~58599355:-
PCPG	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-4.88	2.64e-06	0.00165	-0.47	-0.37	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
PCPG	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-4.88	2.64e-06	0.00166	-0.47	-0.37	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
PCPG	cis	rs7017914	0.902	rs3098866	ENSG00000254031.4	RP11-326E22.1	4.88	2.65e-06	0.00166	0.36	0.37	Bone mineral density;	chr8:71004339	chr8:71155457~71204223:+
PCPG	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-4.88	2.65e-06	0.00166	-0.47	-0.37	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
PCPG	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-4.88	2.65e-06	0.00166	-0.36	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
PCPG	cis	rs7819412	0.806	rs6980856	ENSG00000255020.1	AF131216.5	4.88	2.65e-06	0.00166	0.53	0.37	Triglycerides;	chr8:11080750	chr8:11345748~11347502:-
PCPG	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	4.88	2.65e-06	0.00166	0.41	0.37	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
PCPG	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-4.88	2.66e-06	0.00167	-0.37	-0.37	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
PCPG	cis	rs5769765	0.955	rs4075330	ENSG00000278869.1	CITF22-49E9.3	4.88	2.66e-06	0.00167	0.48	0.37	Schizophrenia;	chr22:49909601	chr22:49933198~49934074:-
PCPG	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	4.88	2.66e-06	0.00167	0.46	0.37	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
PCPG	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-4.88	2.67e-06	0.00167	-0.62	-0.37	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
PCPG	cis	rs28386778	0.897	rs9915552	ENSG00000240280.5	TCAM1P	-4.88	2.67e-06	0.00167	-0.5	-0.37	Prudent dietary pattern;	chr17:63791735	chr17:63849292~63864379:+
PCPG	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-4.88	2.67e-06	0.00167	-0.34	-0.37	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
PCPG	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-4.88	2.68e-06	0.00168	-0.39	-0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
PCPG	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	4.88	2.68e-06	0.00168	0.42	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
PCPG	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-4.88	2.68e-06	0.00168	-0.5	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
PCPG	cis	rs7759001	0.779	rs4711153	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.5	0.37	Glomerular filtration rate (creatinine);	chr6:27467130	chr6:27404010~27406964:-
PCPG	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	4.88	2.68e-06	0.00168	0.48	0.37	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	4.88	2.68e-06	0.00168	0.48	0.37	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
PCPG	cis	rs3764021	0.87	rs2401391	ENSG00000278635.1	CTD-2318O12.1	-4.88	2.68e-06	0.00168	-0.45	-0.37	Type 1 diabetes;	chr12:9725987	chr12:9415641~9416718:+
PCPG	cis	rs7759001	0.744	rs2893917	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27462962	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.711	rs10807025	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27464049	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.711	rs10946921	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27464076	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs4358616	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27465069	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs13201443	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27465634	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs13201965	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27465816	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.652	rs6920010	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27466057	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs6920408	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27466441	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs6920733	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27466608	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs6921071	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27466663	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs4713104	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27467000	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs2272814	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27467928	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs11970336	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27469245	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs2049944	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27470852	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs2049945	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27470869	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.652	rs7741031	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27470962	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.652	rs7745380	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27471142	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs2179154	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27471152	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs2142705	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27471346	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs7750795	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27472225	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.652	rs2272815	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27472763	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.6	rs2272816	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27472766	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.652	rs7756216	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27473153	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs62401365	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27473751	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.779	rs12215117	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27479517	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs13220155	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27483331	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.711	rs10946929	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27488027	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.744	rs10946931	ENSG00000271755.1	RP1-153G14.4	4.88	2.68e-06	0.00168	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27494167	chr6:27404010~27406964:-
PCPG	cis	rs7017914	0.967	rs3098867	ENSG00000254031.4	RP11-326E22.1	4.88	2.69e-06	0.00168	0.36	0.37	Bone mineral density;	chr8:71004636	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs2639904	ENSG00000254031.4	RP11-326E22.1	4.88	2.69e-06	0.00168	0.36	0.37	Bone mineral density;	chr8:71004895	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs2639901	ENSG00000254031.4	RP11-326E22.1	4.88	2.69e-06	0.00168	0.36	0.37	Bone mineral density;	chr8:71005516	chr8:71155457~71204223:+
PCPG	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-4.88	2.69e-06	0.00168	-0.53	-0.37	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
PCPG	cis	rs7824557	0.524	rs7835318	ENSG00000255020.1	AF131216.5	-4.88	2.69e-06	0.00168	-0.54	-0.37	Retinal vascular caliber;	chr8:11096364	chr8:11345748~11347502:-
PCPG	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	4.88	2.69e-06	0.00168	0.34	0.37	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
PCPG	cis	rs2625529	0.526	rs7183810	ENSG00000260037.4	CTD-2524L6.3	4.88	2.7e-06	0.00169	0.46	0.37	Red blood cell count;	chr15:72268117	chr15:71818396~71823384:+
PCPG	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-4.88	2.7e-06	0.00169	-0.34	-0.37	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-4.88	2.7e-06	0.00169	-0.34	-0.37	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
PCPG	cis	rs7824557	0.679	rs10110008	ENSG00000255020.1	AF131216.5	-4.88	2.7e-06	0.00169	-0.46	-0.37	Retinal vascular caliber;	chr8:11276227	chr8:11345748~11347502:-
PCPG	cis	rs11671005	0.504	rs3794963	ENSG00000269600.1	AC016629.3	4.88	2.7e-06	0.00169	0.5	0.37	Mean platelet volume;	chr19:58559684	chr19:58593896~58599355:-
PCPG	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	4.88	2.7e-06	0.00169	0.41	0.37	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
PCPG	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	4.88	2.7e-06	0.00169	0.57	0.37	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	4.88	2.7e-06	0.00169	0.57	0.37	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	4.88	2.7e-06	0.00169	0.57	0.37	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
PCPG	cis	rs2115630	0.645	rs3825877	ENSG00000275120.1	RP11-182J1.17	-4.88	2.7e-06	0.00169	-0.38	-0.37	P wave terminal force;	chr15:84631400	chr15:84599434~84606463:-
PCPG	cis	rs2115630	0.645	rs3825878	ENSG00000275120.1	RP11-182J1.17	-4.88	2.7e-06	0.00169	-0.38	-0.37	P wave terminal force;	chr15:84631524	chr15:84599434~84606463:-
PCPG	cis	rs7824557	0.592	rs2736280	ENSG00000255020.1	AF131216.5	4.88	2.71e-06	0.00169	0.48	0.37	Retinal vascular caliber;	chr8:11365513	chr8:11345748~11347502:-
PCPG	cis	rs62246343	0.719	rs62246275	ENSG00000254485.4	RP11-380O24.1	4.88	2.71e-06	0.00169	0.58	0.37	Fibrinogen levels;	chr3:9399496	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.719	rs73115804	ENSG00000254485.4	RP11-380O24.1	4.88	2.71e-06	0.00169	0.58	0.37	Fibrinogen levels;	chr3:9399858	chr3:9292588~9363303:-
PCPG	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-4.88	2.71e-06	0.00169	-0.34	-0.37	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
PCPG	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	4.88	2.71e-06	0.00169	0.45	0.37	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
PCPG	cis	rs853679	1	rs9986596	ENSG00000219392.1	RP1-265C24.5	-4.88	2.71e-06	0.00169	-0.6	-0.37	Depression;	chr6:28251883	chr6:28115628~28116551:+
PCPG	cis	rs10419113	0.628	rs9304795	ENSG00000268545.1	VN1R107P	4.88	2.72e-06	0.0017	0.4	0.37	Pediatric bone mineral density (spine);	chr19:57666177	chr19:57459912~57460120:+
PCPG	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	4.88	2.73e-06	0.0017	0.6	0.37	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
PCPG	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	4.88	2.73e-06	0.0017	0.65	0.37	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
PCPG	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	4.88	2.73e-06	0.0017	0.41	0.37	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
PCPG	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-4.88	2.73e-06	0.0017	-0.39	-0.37	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
PCPG	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	4.88	2.73e-06	0.0017	0.51	0.37	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	4.88	2.73e-06	0.0017	0.51	0.37	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
PCPG	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	4.88	2.74e-06	0.00171	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
PCPG	cis	rs7017914	0.905	rs3110255	ENSG00000254031.4	RP11-326E22.1	4.88	2.74e-06	0.00171	0.36	0.37	Bone mineral density;	chr8:71025815	chr8:71155457~71204223:+
PCPG	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	4.87	2.75e-06	0.00171	0.58	0.37	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	4.87	2.75e-06	0.00171	0.57	0.37	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
PCPG	cis	rs6991838	0.702	rs10106749	ENSG00000272010.1	CTD-3025N20.3	4.87	2.76e-06	0.00172	0.33	0.37	Intelligence (multi-trait analysis);	chr8:65692355	chr8:65591850~65592472:-
PCPG	cis	rs1949733	0.656	rs2688224	ENSG00000205959.3	RP11-689P11.2	-4.87	2.76e-06	0.00172	-0.41	-0.37	Response to antineoplastic agents;	chr4:8402973	chr4:8482270~8512610:+
PCPG	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	4.87	2.76e-06	0.00172	0.56	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
PCPG	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-4.87	2.76e-06	0.00172	-0.4	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
PCPG	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-4.87	2.76e-06	0.00172	-0.4	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
PCPG	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	4.87	2.76e-06	0.00172	0.4	0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
PCPG	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	4.87	2.76e-06	0.00172	0.4	0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
PCPG	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-4.87	2.76e-06	0.00172	-0.31	-0.37	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
PCPG	cis	rs4713118	0.621	rs10484403	ENSG00000216901.1	AL022393.7	4.87	2.76e-06	0.00172	0.52	0.37	Parkinson's disease;	chr6:28065745	chr6:28176188~28176674:+
PCPG	cis	rs748404	0.626	rs57938858	ENSG00000249839.1	AC011330.5	-4.87	2.77e-06	0.00172	-0.48	-0.37	Lung cancer;	chr15:43520259	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.589	rs3862138	ENSG00000249839.1	AC011330.5	-4.87	2.77e-06	0.00172	-0.48	-0.37	Lung cancer;	chr15:43523801	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.589	rs62020612	ENSG00000249839.1	AC011330.5	-4.87	2.77e-06	0.00172	-0.48	-0.37	Lung cancer;	chr15:43525881	chr15:43663654~43684339:-
PCPG	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	4.87	2.77e-06	0.00172	0.51	0.37	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
PCPG	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-4.87	2.77e-06	0.00172	-0.52	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
PCPG	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	4.87	2.77e-06	0.00172	0.51	0.37	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
PCPG	cis	rs7849270	1	rs3124499	ENSG00000268707.1	RP11-247A12.7	4.87	2.77e-06	0.00173	0.41	0.37	Blood metabolite ratios;	chr9:129106712	chr9:129170434~129170940:+
PCPG	cis	rs2412819	0.571	rs6493090	ENSG00000249839.1	AC011330.5	4.87	2.78e-06	0.00173	0.48	0.37	Lung cancer;	chr15:43792084	chr15:43663654~43684339:-
PCPG	cis	rs7824557	0.591	rs2572452	ENSG00000255020.1	AF131216.5	-4.87	2.78e-06	0.00173	-0.49	-0.37	Retinal vascular caliber;	chr8:11370745	chr8:11345748~11347502:-
PCPG	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-4.87	2.78e-06	0.00173	-0.4	-0.37	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
PCPG	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	-4.87	2.78e-06	0.00173	-0.44	-0.37	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
PCPG	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	4.87	2.79e-06	0.00173	0.52	0.37	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
PCPG	cis	rs4819052	0.851	rs2838857	ENSG00000215447.6	BX322557.10	-4.87	2.79e-06	0.00174	-0.36	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-4.87	2.79e-06	0.00174	-0.36	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
PCPG	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-4.87	2.79e-06	0.00174	-0.55	-0.37	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
PCPG	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-4.87	2.79e-06	0.00174	-0.46	-0.37	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
PCPG	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-4.87	2.79e-06	0.00174	-0.47	-0.37	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
PCPG	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-4.87	2.79e-06	0.00174	-0.42	-0.37	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
PCPG	cis	rs748404	0.666	rs62021180	ENSG00000249839.1	AC011330.5	-4.87	2.8e-06	0.00174	-0.5	-0.37	Lung cancer;	chr15:43420139	chr15:43663654~43684339:-
PCPG	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	4.87	2.8e-06	0.00174	0.42	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
PCPG	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-4.87	2.8e-06	0.00174	-0.37	-0.37	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
PCPG	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	4.87	2.81e-06	0.00174	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
PCPG	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-4.87	2.81e-06	0.00175	-0.39	-0.37	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
PCPG	cis	rs13113518	1	rs4864999	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55476736	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs12506788	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55477426	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs10517344	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55477545	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs6858803	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55484534	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs6838305	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55508587	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.902	rs12503578	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55509367	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs3828480	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55510352	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs3762837	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55511198	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.966	rs4864544	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55515292	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs6847529	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55518776	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs6822740	ENSG00000272969.1	RP11-528I4.2	4.87	2.81e-06	0.00175	0.41	0.37	Height;	chr4:55518922	chr4:55547112~55547889:+
PCPG	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-4.87	2.81e-06	0.00175	-0.4	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
PCPG	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-4.87	2.81e-06	0.00175	-0.4	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
PCPG	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-4.87	2.81e-06	0.00175	-0.4	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
PCPG	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-4.87	2.81e-06	0.00175	-0.66	-0.37	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	4.87	2.81e-06	0.00175	0.66	0.37	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
PCPG	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	4.87	2.82e-06	0.00175	0.5	0.37	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
PCPG	cis	rs34421088	0.56	rs2467520	ENSG00000255020.1	AF131216.5	-4.87	2.82e-06	0.00175	-0.49	-0.37	Neuroticism;	chr8:11541444	chr8:11345748~11347502:-
PCPG	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-4.87	2.82e-06	0.00175	-0.47	-0.37	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
PCPG	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	4.87	2.82e-06	0.00175	0.62	0.37	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
PCPG	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	4.87	2.82e-06	0.00175	0.62	0.37	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
PCPG	cis	rs11858159	1	rs12913638	ENSG00000259905.4	PWRN1	4.87	2.82e-06	0.00175	0.42	0.37	Platelet thrombus formation;	chr15:24566200	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.783	rs12915660	ENSG00000259905.4	PWRN1	4.87	2.82e-06	0.00175	0.42	0.37	Platelet thrombus formation;	chr15:24566371	chr15:24493137~24652130:+
PCPG	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	4.87	2.83e-06	0.00176	0.79	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
PCPG	cis	rs12681963	0.688	rs2341177	ENSG00000248159.1	HSPA8P11	-4.87	2.83e-06	0.00176	-0.69	-0.37	Migraine;	chr8:30146977	chr8:30237382~30240997:+
PCPG	cis	rs10435719	0.867	rs6999030	ENSG00000255495.1	AC145124.2	4.87	2.83e-06	0.00176	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.834	rs6985792	ENSG00000255495.1	AC145124.2	4.87	2.83e-06	0.00176	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:12194467~12196280:+
PCPG	cis	rs7403037	0.526	rs28545658	ENSG00000259905.4	PWRN1	4.87	2.83e-06	0.00176	0.42	0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24553856	chr15:24493137~24652130:+
PCPG	cis	rs12681963	0.858	rs62499790	ENSG00000248159.1	HSPA8P11	-4.87	2.83e-06	0.00176	-0.57	-0.37	Migraine;	chr8:30094955	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.764	rs56969689	ENSG00000248159.1	HSPA8P11	-4.87	2.83e-06	0.00176	-0.57	-0.37	Migraine;	chr8:30095740	chr8:30237382~30240997:+
PCPG	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-4.87	2.83e-06	0.00176	-0.34	-0.37	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
PCPG	cis	rs2028414	0.512	rs2582545	ENSG00000258701.1	LINC00638	4.87	2.84e-06	0.00176	0.47	0.37	IgG glycosylation;	chr14:104888208	chr14:104821201~104823718:+
PCPG	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-4.87	2.84e-06	0.00176	-0.45	-0.37	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
PCPG	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	4.87	2.84e-06	0.00176	0.56	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
PCPG	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-4.87	2.85e-06	0.00177	-0.37	-0.37	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
PCPG	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	4.87	2.85e-06	0.00177	0.41	0.37	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	4.87	2.85e-06	0.00177	0.41	0.37	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
PCPG	cis	rs7017914	0.69	rs4074908	ENSG00000254031.4	RP11-326E22.1	-4.87	2.85e-06	0.00177	-0.35	-0.37	Bone mineral density;	chr8:71043097	chr8:71155457~71204223:+
PCPG	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	4.87	2.85e-06	0.00177	0.38	0.37	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
PCPG	cis	rs34421088	0.56	rs2618434	ENSG00000255020.1	AF131216.5	-4.87	2.85e-06	0.00177	-0.49	-0.37	Neuroticism;	chr8:11541356	chr8:11345748~11347502:-
PCPG	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	4.87	2.85e-06	0.00177	0.79	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
PCPG	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	4.87	2.85e-06	0.00177	0.79	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
PCPG	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	4.87	2.85e-06	0.00177	0.79	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
PCPG	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	4.87	2.86e-06	0.00177	0.32	0.37	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	4.87	2.86e-06	0.00177	0.32	0.37	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
PCPG	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	4.87	2.86e-06	0.00177	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
PCPG	cis	rs12681963	0.614	rs73234779	ENSG00000248159.1	HSPA8P11	4.86	2.87e-06	0.00177	0.84	0.37	Migraine;	chr8:30200997	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.614	rs16876663	ENSG00000248159.1	HSPA8P11	4.86	2.87e-06	0.00177	0.84	0.37	Migraine;	chr8:30202182	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs73234780	ENSG00000248159.1	HSPA8P11	4.86	2.87e-06	0.00177	0.84	0.37	Migraine;	chr8:30202239	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.614	rs73234781	ENSG00000248159.1	HSPA8P11	4.86	2.87e-06	0.00177	0.84	0.37	Migraine;	chr8:30202242	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.614	rs7001629	ENSG00000248159.1	HSPA8P11	4.86	2.87e-06	0.00177	0.84	0.37	Migraine;	chr8:30203273	chr8:30237382~30240997:+
PCPG	cis	rs3736858	0.825	rs2120061	ENSG00000261105.4	LMO7-AS1	-4.86	2.87e-06	0.00178	-0.68	-0.37	Interleukin-9 levels;	chr13:75813370	chr13:75604700~75635994:-
PCPG	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	4.86	2.87e-06	0.00178	0.31	0.37	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
PCPG	cis	rs853679	1	rs735765	ENSG00000216901.1	AL022393.7	4.86	2.87e-06	0.00178	0.67	0.37	Depression;	chr6:28202519	chr6:28176188~28176674:+
PCPG	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	4.86	2.88e-06	0.00178	0.52	0.37	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
PCPG	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	4.86	2.88e-06	0.00178	0.34	0.37	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
PCPG	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	4.86	2.88e-06	0.00178	0.42	0.37	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
PCPG	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	4.86	2.88e-06	0.00178	0.51	0.37	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
PCPG	cis	rs804280	0.543	rs13261205	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Myopia (pathological);	chr8:11933707	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.867	rs35778860	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933829	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.867	rs34465618	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933847	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.867	rs34583868	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11933874	chr8:12194467~12196280:+
PCPG	cis	rs804280	0.518	rs34266352	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Myopia (pathological);	chr8:11933953	chr8:12194467~12196280:+
PCPG	cis	rs804280	0.542	rs34117651	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Myopia (pathological);	chr8:11934108	chr8:12194467~12196280:+
PCPG	cis	rs804280	0.542	rs35647515	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Myopia (pathological);	chr8:11934120	chr8:12194467~12196280:+
PCPG	cis	rs804280	0.542	rs36100659	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Myopia (pathological);	chr8:11934144	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.805	rs13269417	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:12194467~12196280:+
PCPG	cis	rs804280	0.517	rs7815179	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Myopia (pathological);	chr8:11934539	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.871	rs7815186	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs7833079	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11934620	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.899	rs7815595	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.744	rs11250175	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.834	rs11250176	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs13252853	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11935465	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs13252854	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11935469	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs13279577	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11935587	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs10112958	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11935631	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs4367597	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11936020	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.899	rs9329251	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.773	rs7842810	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.541	rs7824267	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11936770	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs7825529	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11936935	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs13281077	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11937305	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs13281315	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11937346	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs4840597	ENSG00000255495.1	AC145124.2	4.86	2.88e-06	0.00178	0.37	0.37	Neuroticism;	chr8:11938559	chr8:12194467~12196280:+
PCPG	cis	rs3806843	0.966	rs3806844	ENSG00000202515.1	VTRNA1-3	-4.86	2.88e-06	0.00178	-0.48	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr5:140726158~140726246:+
PCPG	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	4.86	2.88e-06	0.00178	0.4	0.37	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
PCPG	cis	rs11671005	0.61	rs2305122	ENSG00000269600.1	AC016629.3	-4.86	2.89e-06	0.00179	-0.59	-0.37	Mean platelet volume;	chr19:58545385	chr19:58593896~58599355:-
PCPG	cis	rs11671005	0.61	rs11669345	ENSG00000269600.1	AC016629.3	-4.86	2.89e-06	0.00179	-0.59	-0.37	Mean platelet volume;	chr19:58550892	chr19:58593896~58599355:-
PCPG	cis	rs11858159	0.902	rs8033788	ENSG00000259905.4	PWRN1	4.86	2.9e-06	0.00179	0.42	0.37	Platelet thrombus formation;	chr15:24540436	chr15:24493137~24652130:+
PCPG	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-4.86	2.9e-06	0.00179	-0.44	-0.37	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
PCPG	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-4.86	2.9e-06	0.00179	-0.45	-0.37	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
PCPG	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	4.86	2.91e-06	0.00179	0.37	0.37	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
PCPG	cis	rs3808502	0.574	rs4841559	ENSG00000255020.1	AF131216.5	-4.86	2.91e-06	0.0018	-0.47	-0.37	Neuroticism;	chr8:11559376	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.526	rs36048422	ENSG00000255020.1	AF131216.5	-4.86	2.91e-06	0.0018	-0.47	-0.37	Neuroticism;	chr8:11559635	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.503	rs34190028	ENSG00000255020.1	AF131216.5	-4.86	2.91e-06	0.0018	-0.47	-0.37	Neuroticism;	chr8:11559641	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.526	rs11783065	ENSG00000255020.1	AF131216.5	-4.86	2.91e-06	0.0018	-0.47	-0.37	Neuroticism;	chr8:11559748	chr8:11345748~11347502:-
PCPG	cis	rs300890	0.56	rs300921	ENSG00000250326.1	RP11-284M14.1	4.86	2.92e-06	0.0018	0.34	0.37	Nasopharyngeal carcinoma;	chr4:143259922	chr4:142933195~143184861:-
PCPG	cis	rs13108904	0.901	rs2293634	ENSG00000253399.1	AC078852.2	-4.86	2.92e-06	0.0018	-0.38	-0.37	Obesity-related traits;	chr4:1297923	chr4:1358479~1359461:+
PCPG	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-4.86	2.92e-06	0.0018	-0.46	-0.37	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
PCPG	cis	rs2898290	0.592	rs2736342	ENSG00000269954.1	RP11-148O21.6	-4.86	2.93e-06	0.00181	-0.43	-0.37	Systolic blood pressure;	chr8:11489780	chr8:11552488~11552991:-
PCPG	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-4.86	2.93e-06	0.00181	-0.39	-0.37	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
PCPG	cis	rs3736858	1	rs9318380	ENSG00000261105.4	LMO7-AS1	-4.86	2.93e-06	0.00181	-0.71	-0.37	Interleukin-9 levels;	chr13:75860990	chr13:75604700~75635994:-
PCPG	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-4.86	2.93e-06	0.00181	-0.46	-0.37	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
PCPG	cis	rs7017914	0.905	rs2732104	ENSG00000254031.4	RP11-326E22.1	4.86	2.94e-06	0.00181	0.36	0.37	Bone mineral density;	chr8:71011284	chr8:71155457~71204223:+
PCPG	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	4.86	2.95e-06	0.00182	0.51	0.37	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
PCPG	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-4.86	2.95e-06	0.00182	-0.46	-0.37	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
PCPG	cis	rs561341	0.556	rs542244	ENSG00000265798.5	RP11-271K11.5	4.86	2.95e-06	0.00182	0.66	0.37	Hip circumference adjusted for BMI;	chr17:31980223	chr17:31038575~31059121:-
PCPG	cis	rs9595908	0.709	rs2025473	ENSG00000212293.1	SNORA16	4.86	2.95e-06	0.00182	0.45	0.37	Body mass index;	chr13:32791632	chr13:32420390~32420516:-
PCPG	cis	rs13108904	0.935	rs6853002	ENSG00000254094.1	AC078852.1	-4.86	2.96e-06	0.00182	-0.41	-0.37	Obesity-related traits;	chr4:1302203	chr4:1356581~1358075:+
PCPG	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	4.86	2.96e-06	0.00182	0.6	0.37	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	4.86	2.96e-06	0.00182	0.6	0.37	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	4.86	2.96e-06	0.00182	0.6	0.37	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	4.86	2.96e-06	0.00182	0.6	0.37	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	4.86	2.96e-06	0.00182	0.6	0.37	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	4.86	2.96e-06	0.00182	0.6	0.37	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	4.86	2.96e-06	0.00182	0.6	0.37	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
PCPG	cis	rs10760158	0.8	rs4836847	ENSG00000226752.6	PSMD5-AS1	-4.86	2.96e-06	0.00182	-0.48	-0.37	Pulse pressure;	chr9:121296665	chr9:120824828~120854385:+
PCPG	cis	rs7250849	0.565	rs73052857	ENSG00000273837.1	LLNLR-470E3.1	-4.86	2.96e-06	0.00183	-0.58	-0.37	Blood protein levels;	chr19:51661182	chr19:51639478~51639931:-
PCPG	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-4.86	2.96e-06	0.00183	-0.58	-0.37	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
PCPG	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-4.86	2.96e-06	0.00183	-0.58	-0.37	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
PCPG	cis	rs300890	0.585	rs542555	ENSG00000250326.1	RP11-284M14.1	-4.86	2.96e-06	0.00183	-0.36	-0.37	Nasopharyngeal carcinoma;	chr4:143264803	chr4:142933195~143184861:-
PCPG	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	4.86	2.97e-06	0.00183	0.41	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	4.86	2.97e-06	0.00183	0.41	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
PCPG	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	4.86	2.97e-06	0.00183	0.58	0.37	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
PCPG	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-4.86	2.98e-06	0.00183	-0.49	-0.37	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
PCPG	cis	rs7829975	0.533	rs13274028	ENSG00000173295.6	FAM86B3P	-4.86	2.98e-06	0.00183	-0.42	-0.37	Mood instability;	chr8:8871683	chr8:8228595~8244865:+
PCPG	cis	rs73607972	0.935	rs17214955	ENSG00000275191.1	RP11-36I17.2	-4.86	2.98e-06	0.00184	-0.63	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53612064	chr16:53628256~53628816:-
PCPG	cis	rs62246343	0.605	rs17746498	ENSG00000254485.4	RP11-380O24.1	4.86	2.98e-06	0.00184	0.55	0.37	Fibrinogen levels;	chr3:9411976	chr3:9292588~9363303:-
PCPG	cis	rs3806843	1	rs10223116	ENSG00000202515.1	VTRNA1-3	-4.86	2.99e-06	0.00184	-0.48	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140813058	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs10037757	ENSG00000202515.1	VTRNA1-3	-4.86	2.99e-06	0.00184	-0.48	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140817637	chr5:140726158~140726246:+
PCPG	cis	rs7246657	0.943	rs2045908	ENSG00000226686.6	LINC01535	-4.85	2.99e-06	0.00184	-0.57	-0.37	Coronary artery calcification;	chr19:37488866	chr19:37251912~37265535:+
PCPG	cis	rs2028414	0.512	rs2919629	ENSG00000258701.1	LINC00638	4.85	3e-06	0.00184	0.47	0.37	IgG glycosylation;	chr14:104889800	chr14:104821201~104823718:+
PCPG	cis	rs28386778	0.897	rs2727320	ENSG00000240280.5	TCAM1P	-4.85	3e-06	0.00184	-0.49	-0.37	Prudent dietary pattern;	chr17:63787965	chr17:63849292~63864379:+
PCPG	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	4.85	3e-06	0.00184	0.41	0.37	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	4.85	3e-06	0.00184	0.41	0.37	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	4.85	3e-06	0.00184	0.41	0.37	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
PCPG	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	4.85	3e-06	0.00184	0.47	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
PCPG	cis	rs28386778	0.897	rs2584635	ENSG00000240280.5	TCAM1P	-4.85	3e-06	0.00184	-0.49	-0.37	Prudent dietary pattern;	chr17:63788574	chr17:63849292~63864379:+
PCPG	cis	rs3808502	0.526	rs1042701	ENSG00000255020.1	AF131216.5	-4.85	3e-06	0.00184	-0.48	-0.37	Neuroticism;	chr8:11564536	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.526	rs7843987	ENSG00000255020.1	AF131216.5	-4.85	3e-06	0.00184	-0.48	-0.37	Neuroticism;	chr8:11564621	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.526	rs7823100	ENSG00000255020.1	AF131216.5	-4.85	3e-06	0.00184	-0.48	-0.37	Neuroticism;	chr8:11564982	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.526	rs7823101	ENSG00000255020.1	AF131216.5	-4.85	3e-06	0.00184	-0.48	-0.37	Neuroticism;	chr8:11564983	chr8:11345748~11347502:-
PCPG	cis	rs12908161	0.959	rs61074241	ENSG00000259295.5	CSPG4P12	4.85	3e-06	0.00184	0.56	0.37	Schizophrenia;	chr15:84790165	chr15:85191438~85213905:+
PCPG	cis	rs7759001	0.744	rs13217798	ENSG00000271755.1	RP1-153G14.4	4.85	3e-06	0.00184	0.51	0.37	Glomerular filtration rate (creatinine);	chr6:27414801	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.779	rs7754977	ENSG00000271755.1	RP1-153G14.4	4.85	3e-06	0.00184	0.51	0.37	Glomerular filtration rate (creatinine);	chr6:27417991	chr6:27404010~27406964:-
PCPG	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-4.85	3e-06	0.00184	-0.45	-0.37	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
PCPG	cis	rs6762	0.642	rs28692469	ENSG00000279672.1	CMB9-55F22.1	4.85	3e-06	0.00185	0.41	0.37	Mean platelet volume;	chr11:839675	chr11:779617~780755:+
PCPG	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	4.85	3e-06	0.00185	0.64	0.37	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
PCPG	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-4.85	3.01e-06	0.00185	-0.31	-0.37	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
PCPG	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-4.85	3.01e-06	0.00185	-0.52	-0.37	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
PCPG	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-4.85	3.01e-06	0.00185	-0.36	-0.37	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
PCPG	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	4.85	3.01e-06	0.00185	0.38	0.37	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
PCPG	cis	rs4713118	0.621	rs9368548	ENSG00000216901.1	AL022393.7	4.85	3.01e-06	0.00185	0.53	0.37	Parkinson's disease;	chr6:28066959	chr6:28176188~28176674:+
PCPG	cis	rs34421088	0.559	rs12386974	ENSG00000255020.1	AF131216.5	4.85	3.02e-06	0.00185	0.48	0.37	Neuroticism;	chr8:11543119	chr8:11345748~11347502:-
PCPG	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-4.85	3.02e-06	0.00185	-0.47	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
PCPG	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-4.85	3.02e-06	0.00185	-0.39	-0.37	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
PCPG	cis	rs1949733	0.656	rs2688243	ENSG00000205959.3	RP11-689P11.2	-4.85	3.02e-06	0.00186	-0.42	-0.37	Response to antineoplastic agents;	chr4:8434559	chr4:8482270~8512610:+
PCPG	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	4.85	3.02e-06	0.00186	0.41	0.37	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
PCPG	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-4.85	3.02e-06	0.00186	-0.44	-0.37	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
PCPG	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-4.85	3.02e-06	0.00186	-0.32	-0.37	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
PCPG	cis	rs561341	0.941	rs550213	ENSG00000265798.5	RP11-271K11.5	4.85	3.03e-06	0.00186	0.64	0.37	Hip circumference adjusted for BMI;	chr17:31990499	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs530715	ENSG00000265798.5	RP11-271K11.5	4.85	3.03e-06	0.00186	0.64	0.37	Hip circumference adjusted for BMI;	chr17:31993525	chr17:31038575~31059121:-
PCPG	cis	rs7759001	0.744	rs12529839	ENSG00000271755.1	RP1-153G14.4	4.85	3.04e-06	0.00186	0.53	0.37	Glomerular filtration rate (creatinine);	chr6:27456187	chr6:27404010~27406964:-
PCPG	cis	rs7811142	1	rs60844404	ENSG00000078319.8	PMS2P1	-4.85	3.04e-06	0.00186	-0.47	-0.37	Platelet count;	chr7:100482851	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs113738841	ENSG00000078319.8	PMS2P1	-4.85	3.04e-06	0.00186	-0.47	-0.37	Platelet count;	chr7:100483683	chr7:100320992~100341908:-
PCPG	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-4.85	3.04e-06	0.00186	-0.53	-0.37	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
PCPG	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	4.85	3.04e-06	0.00186	0.48	0.37	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	4.85	3.04e-06	0.00186	0.48	0.37	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	4.85	3.04e-06	0.00186	0.48	0.37	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	4.85	3.04e-06	0.00186	0.48	0.37	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	4.85	3.04e-06	0.00186	0.48	0.37	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	4.85	3.04e-06	0.00186	0.48	0.37	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	4.85	3.04e-06	0.00186	0.48	0.37	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
PCPG	cis	rs13108904	0.935	rs1620928	ENSG00000254094.1	AC078852.1	4.85	3.04e-06	0.00187	0.42	0.37	Obesity-related traits;	chr4:1285336	chr4:1356581~1358075:+
PCPG	cis	rs7811142	1	rs60257855	ENSG00000078319.8	PMS2P1	-4.85	3.04e-06	0.00187	-0.48	-0.37	Platelet count;	chr7:100429157	chr7:100320992~100341908:-
PCPG	cis	rs3808502	0.526	rs7822958	ENSG00000255020.1	AF131216.5	-4.85	3.04e-06	0.00187	-0.48	-0.37	Neuroticism;	chr8:11564933	chr8:11345748~11347502:-
PCPG	cis	rs5742933	0.857	rs13021611	ENSG00000273240.1	RP11-455J20.3	4.85	3.04e-06	0.00187	0.39	0.37	Ferritin levels;	chr2:189700038	chr2:189763859~189764456:-
PCPG	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	4.85	3.05e-06	0.00187	0.48	0.37	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	4.85	3.05e-06	0.00187	0.48	0.37	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
PCPG	cis	rs17036023	1	rs17036023	ENSG00000203865.8	ATP1A1-AS1	4.85	3.05e-06	0.00187	0.48	0.37	Asthma (childhood onset);	chr1:116587089	chr1:116392247~116418622:-
PCPG	cis	rs17772222	0.958	rs76559451	ENSG00000222990.1	RNU4-22P	4.85	3.05e-06	0.00187	0.47	0.37	Coronary artery calcification;	chr14:88523193	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.958	rs12436326	ENSG00000222990.1	RNU4-22P	4.85	3.05e-06	0.00187	0.47	0.37	Coronary artery calcification;	chr14:88533632	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.958	rs17203789	ENSG00000222990.1	RNU4-22P	4.85	3.05e-06	0.00187	0.47	0.37	Coronary artery calcification;	chr14:88541362	chr14:88513498~88513663:+
PCPG	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-4.85	3.05e-06	0.00187	-0.38	-0.37	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-4.85	3.05e-06	0.00187	-0.38	-0.37	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-4.85	3.05e-06	0.00187	-0.38	-0.37	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
PCPG	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-4.85	3.05e-06	0.00187	-0.52	-0.37	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
PCPG	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-4.85	3.05e-06	0.00187	-0.52	-0.37	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
PCPG	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	4.85	3.05e-06	0.00187	0.48	0.37	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
PCPG	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-4.85	3.06e-06	0.00187	-0.41	-0.37	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
PCPG	cis	rs2625529	0.526	rs16956623	ENSG00000260037.4	CTD-2524L6.3	4.85	3.06e-06	0.00188	0.46	0.37	Red blood cell count;	chr15:72244354	chr15:71818396~71823384:+
PCPG	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	4.85	3.06e-06	0.00188	0.78	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
PCPG	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	4.85	3.06e-06	0.00188	0.51	0.37	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
PCPG	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-4.85	3.06e-06	0.00188	-0.36	-0.37	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
PCPG	cis	rs62246343	0.605	rs7650141	ENSG00000254485.4	RP11-380O24.1	4.85	3.07e-06	0.00188	0.49	0.37	Fibrinogen levels;	chr3:9407726	chr3:9292588~9363303:-
PCPG	cis	rs7208859	0.573	rs8070182	ENSG00000263603.1	CTD-2349P21.5	-4.85	3.07e-06	0.00188	-0.63	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30729469~30731202:+
PCPG	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	4.85	3.08e-06	0.00188	0.38	0.37	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
PCPG	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	4.85	3.08e-06	0.00188	0.38	0.37	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
PCPG	cis	rs9649213	0.593	rs56286037	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs62478233	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6465683	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs3801251	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs3779193	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs12704989	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs62478236	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	4.85	3.08e-06	0.00188	0.48	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
PCPG	cis	rs4713118	0.662	rs149901	ENSG00000216901.1	AL022393.7	4.85	3.08e-06	0.00188	0.5	0.37	Parkinson's disease;	chr6:27997725	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs464312	ENSG00000216901.1	AL022393.7	4.85	3.08e-06	0.00188	0.5	0.37	Parkinson's disease;	chr6:27999813	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs469228	ENSG00000216901.1	AL022393.7	4.85	3.08e-06	0.00188	0.5	0.37	Parkinson's disease;	chr6:28002926	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.54	rs469227	ENSG00000216901.1	AL022393.7	4.85	3.08e-06	0.00188	0.5	0.37	Parkinson's disease;	chr6:28002927	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs149948	ENSG00000216901.1	AL022393.7	4.85	3.08e-06	0.00188	0.5	0.37	Parkinson's disease;	chr6:28007039	chr6:28176188~28176674:+
PCPG	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-4.85	3.08e-06	0.00188	-0.36	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-4.85	3.08e-06	0.00188	-0.36	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
PCPG	cis	rs1440410	0.536	rs13137565	ENSG00000250326.1	RP11-284M14.1	4.85	3.08e-06	0.00189	0.36	0.37	Ischemic stroke;	chr4:143184545	chr4:142933195~143184861:-
PCPG	cis	rs11671005	0.652	rs11670864	ENSG00000269600.1	AC016629.3	-4.85	3.08e-06	0.00189	-0.6	-0.37	Mean platelet volume;	chr19:58519213	chr19:58593896~58599355:-
PCPG	cis	rs7017914	0.934	rs3110239	ENSG00000254031.4	RP11-326E22.1	4.85	3.09e-06	0.00189	0.36	0.37	Bone mineral density;	chr8:71004510	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs2732092	ENSG00000254031.4	RP11-326E22.1	4.85	3.09e-06	0.00189	0.36	0.37	Bone mineral density;	chr8:71006364	chr8:71155457~71204223:+
PCPG	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-4.85	3.09e-06	0.00189	-0.34	-0.37	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
PCPG	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	4.85	3.09e-06	0.00189	0.31	0.37	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
PCPG	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	4.85	3.09e-06	0.00189	0.47	0.37	Height;	chr6:109354040	chr6:109382795~109383666:+
PCPG	cis	rs28386778	0.863	rs2597633	ENSG00000240280.5	TCAM1P	-4.85	3.09e-06	0.00189	-0.49	-0.37	Prudent dietary pattern;	chr17:63795511	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2665844	ENSG00000240280.5	TCAM1P	-4.85	3.09e-06	0.00189	-0.49	-0.37	Prudent dietary pattern;	chr17:63797095	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.83	rs2597637	ENSG00000240280.5	TCAM1P	-4.85	3.09e-06	0.00189	-0.49	-0.37	Prudent dietary pattern;	chr17:63797706	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.83	rs2597636	ENSG00000240280.5	TCAM1P	-4.85	3.09e-06	0.00189	-0.49	-0.37	Prudent dietary pattern;	chr17:63798650	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2727333	ENSG00000240280.5	TCAM1P	-4.85	3.09e-06	0.00189	-0.49	-0.37	Prudent dietary pattern;	chr17:63798663	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2597634	ENSG00000240280.5	TCAM1P	-4.85	3.09e-06	0.00189	-0.49	-0.37	Prudent dietary pattern;	chr17:63800784	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs2251164	ENSG00000240280.5	TCAM1P	-4.85	3.09e-06	0.00189	-0.49	-0.37	Prudent dietary pattern;	chr17:63806760	chr17:63849292~63864379:+
PCPG	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-4.85	3.09e-06	0.00189	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-4.85	3.09e-06	0.00189	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-4.85	3.09e-06	0.00189	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-4.85	3.09e-06	0.00189	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-4.85	3.09e-06	0.00189	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
PCPG	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-4.85	3.1e-06	0.00189	-0.36	-0.37	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
PCPG	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-4.85	3.1e-06	0.00189	-0.35	-0.37	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
PCPG	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	4.85	3.1e-06	0.00189	0.35	0.37	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
PCPG	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-4.85	3.1e-06	0.0019	-0.39	-0.37	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
PCPG	cis	rs561341	1	rs560132	ENSG00000265798.5	RP11-271K11.5	4.85	3.11e-06	0.0019	0.67	0.37	Hip circumference adjusted for BMI;	chr17:31993000	chr17:31038575~31059121:-
PCPG	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	4.85	3.11e-06	0.0019	0.44	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	4.85	3.11e-06	0.0019	0.44	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
PCPG	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-4.85	3.11e-06	0.0019	-0.38	-0.37	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
PCPG	cis	rs13113518	1	rs4864546	ENSG00000272969.1	RP11-528I4.2	4.85	3.11e-06	0.0019	0.4	0.37	Height;	chr4:55537960	chr4:55547112~55547889:+
PCPG	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	4.85	3.11e-06	0.0019	0.45	0.37	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	4.85	3.11e-06	0.0019	0.45	0.37	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
PCPG	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-4.85	3.11e-06	0.0019	-0.44	-0.37	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
PCPG	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-4.85	3.11e-06	0.0019	-0.51	-0.37	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
PCPG	cis	rs4713118	0.615	rs57252182	ENSG00000216901.1	AL022393.7	4.85	3.11e-06	0.0019	0.47	0.37	Parkinson's disease;	chr6:27752470	chr6:28176188~28176674:+
PCPG	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	4.85	3.12e-06	0.0019	0.47	0.37	Height;	chr6:109380457	chr6:109382795~109383666:+
PCPG	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	4.85	3.12e-06	0.0019	0.6	0.37	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	4.85	3.12e-06	0.0019	0.6	0.37	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
PCPG	cis	rs7017914	0.69	rs2008517	ENSG00000254031.4	RP11-326E22.1	4.85	3.12e-06	0.0019	0.35	0.37	Bone mineral density;	chr8:70944285	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.642	rs2732143	ENSG00000254031.4	RP11-326E22.1	4.85	3.12e-06	0.0019	0.35	0.37	Bone mineral density;	chr8:70963007	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs2732133	ENSG00000254031.4	RP11-326E22.1	4.85	3.12e-06	0.0019	0.35	0.37	Bone mineral density;	chr8:70978741	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.629	rs2732120	ENSG00000254031.4	RP11-326E22.1	4.85	3.12e-06	0.0019	0.35	0.37	Bone mineral density;	chr8:70992758	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.714	rs2732119	ENSG00000254031.4	RP11-326E22.1	4.85	3.12e-06	0.0019	0.35	0.37	Bone mineral density;	chr8:70996142	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs2732117	ENSG00000254031.4	RP11-326E22.1	4.85	3.12e-06	0.0019	0.35	0.37	Bone mineral density;	chr8:70996843	chr8:71155457~71204223:+
PCPG	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-4.85	3.12e-06	0.00191	-0.32	-0.37	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-4.85	3.12e-06	0.00191	-0.32	-0.37	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-4.85	3.12e-06	0.00191	-0.32	-0.37	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
PCPG	cis	rs10899021	1	rs11236193	ENSG00000279353.1	RP11-864N7.4	4.85	3.12e-06	0.00191	0.76	0.37	Response to metformin (IC50);	chr11:74657262	chr11:74698231~74699658:-
PCPG	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	4.85	3.13e-06	0.00191	0.37	0.37	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
PCPG	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	4.85	3.13e-06	0.00191	0.47	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
PCPG	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-4.85	3.13e-06	0.00191	-0.39	-0.37	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
PCPG	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-4.84	3.13e-06	0.00191	-0.44	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
PCPG	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-4.84	3.13e-06	0.00191	-0.48	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
PCPG	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	4.84	3.13e-06	0.00191	0.51	0.37	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	4.84	3.13e-06	0.00191	0.51	0.37	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
PCPG	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	4.84	3.14e-06	0.00191	0.54	0.37	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	4.84	3.14e-06	0.00191	0.54	0.37	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	4.84	3.14e-06	0.00191	0.54	0.37	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
PCPG	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-4.84	3.14e-06	0.00191	-0.36	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
PCPG	cis	rs7017914	0.934	rs13255886	ENSG00000254031.4	RP11-326E22.1	4.84	3.14e-06	0.00192	0.36	0.37	Bone mineral density;	chr8:70653719	chr8:71155457~71204223:+
PCPG	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	4.84	3.15e-06	0.00192	0.51	0.37	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
PCPG	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	4.84	3.15e-06	0.00192	0.51	0.37	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
PCPG	cis	rs2734839	0.929	rs11608185	ENSG00000270179.1	RP11-159N11.4	-4.84	3.15e-06	0.00192	-0.38	-0.37	Information processing speed;	chr11:113424254	chr11:113368478~113369117:+
PCPG	cis	rs13113518	0.966	rs11942472	ENSG00000272969.1	RP11-528I4.2	4.84	3.15e-06	0.00192	0.41	0.37	Height;	chr4:55574959	chr4:55547112~55547889:+
PCPG	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-4.84	3.16e-06	0.00192	-0.49	-0.37	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-4.84	3.16e-06	0.00192	-0.49	-0.37	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-4.84	3.16e-06	0.00192	-0.49	-0.37	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
PCPG	cis	rs7246657	0.943	rs7255952	ENSG00000226686.6	LINC01535	-4.84	3.17e-06	0.00193	-0.59	-0.37	Coronary artery calcification;	chr19:37497895	chr19:37251912~37265535:+
PCPG	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-4.84	3.17e-06	0.00193	-0.5	-0.37	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
PCPG	cis	rs804280	0.509	rs9886639	ENSG00000255495.1	AC145124.2	4.84	3.17e-06	0.00193	0.37	0.37	Myopia (pathological);	chr8:11927020	chr8:12194467~12196280:+
PCPG	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	4.84	3.17e-06	0.00193	0.48	0.37	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
PCPG	cis	rs13113518	1	rs4865004	ENSG00000272969.1	RP11-528I4.2	4.84	3.18e-06	0.00193	0.41	0.37	Height;	chr4:55515118	chr4:55547112~55547889:+
PCPG	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	4.84	3.19e-06	0.00194	0.51	0.37	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
PCPG	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	4.84	3.19e-06	0.00194	0.5	0.37	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
PCPG	cis	rs13113518	1	rs34648901	ENSG00000272969.1	RP11-528I4.2	4.84	3.19e-06	0.00194	0.41	0.37	Height;	chr4:55541259	chr4:55547112~55547889:+
PCPG	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	4.84	3.19e-06	0.00194	0.5	0.37	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
PCPG	cis	rs2911132	0.62	rs1065407	ENSG00000248734.2	CTD-2260A17.1	4.84	3.19e-06	0.00194	0.39	0.37	Urate levels (BMI interaction);	chr5:96776379	chr5:96784777~96785999:+
PCPG	cis	rs7181230	0.885	rs17723133	ENSG00000259584.1	RP11-521C20.2	-4.84	3.19e-06	0.00194	-0.46	-0.37	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40075204~40078704:-
PCPG	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	4.84	3.2e-06	0.00194	0.46	0.37	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
PCPG	cis	rs7017914	0.967	rs12679261	ENSG00000254031.4	RP11-326E22.1	4.84	3.2e-06	0.00195	0.36	0.37	Bone mineral density;	chr8:70932414	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs10089583	ENSG00000254031.4	RP11-326E22.1	4.84	3.2e-06	0.00195	0.36	0.37	Bone mineral density;	chr8:70937249	chr8:71155457~71204223:+
PCPG	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-4.84	3.2e-06	0.00195	-0.56	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
PCPG	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	4.84	3.2e-06	0.00195	0.3	0.37	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
PCPG	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-4.84	3.21e-06	0.00195	-0.48	-0.37	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
PCPG	cis	rs3806843	0.838	rs2262567	ENSG00000202515.1	VTRNA1-3	4.84	3.21e-06	0.00195	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr5:140726158~140726246:+
PCPG	cis	rs34421088	0.56	rs2248325	ENSG00000255020.1	AF131216.5	-4.84	3.21e-06	0.00195	-0.48	-0.37	Neuroticism;	chr8:11539365	chr8:11345748~11347502:-
PCPG	cis	rs34421088	0.56	rs2248316	ENSG00000255020.1	AF131216.5	-4.84	3.21e-06	0.00195	-0.48	-0.37	Neuroticism;	chr8:11539564	chr8:11345748~11347502:-
PCPG	cis	rs34421088	0.56	rs2248315	ENSG00000255020.1	AF131216.5	-4.84	3.21e-06	0.00195	-0.48	-0.37	Neuroticism;	chr8:11539577	chr8:11345748~11347502:-
PCPG	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-4.84	3.21e-06	0.00195	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-4.84	3.21e-06	0.00195	-0.41	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
PCPG	cis	rs13113518	1	rs1464490	ENSG00000272969.1	RP11-528I4.2	4.84	3.21e-06	0.00195	0.4	0.37	Height;	chr4:55456620	chr4:55547112~55547889:+
PCPG	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	4.84	3.21e-06	0.00195	0.37	0.37	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
PCPG	cis	rs412050	0.895	rs240065	ENSG00000224086.5	LL22NC03-86G7.1	-4.84	3.21e-06	0.00195	-0.52	-0.37	Attention deficit hyperactivity disorder;	chr22:21941747	chr22:21938293~21977632:+
PCPG	cis	rs412050	0.895	rs6000236	ENSG00000224086.5	LL22NC03-86G7.1	-4.84	3.21e-06	0.00195	-0.52	-0.37	Attention deficit hyperactivity disorder;	chr22:21942087	chr22:21938293~21977632:+
PCPG	cis	rs10419113	0.668	rs10403851	ENSG00000268545.1	VN1R107P	-4.84	3.21e-06	0.00195	-0.39	-0.37	Pediatric bone mineral density (spine);	chr19:57667866	chr19:57459912~57460120:+
PCPG	cis	rs10419113	0.668	rs2360535	ENSG00000268545.1	VN1R107P	4.84	3.21e-06	0.00195	0.39	0.37	Pediatric bone mineral density (spine);	chr19:57668813	chr19:57459912~57460120:+
PCPG	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	4.84	3.22e-06	0.00195	0.51	0.37	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
PCPG	cis	rs12681963	1	rs12681963	ENSG00000248159.1	HSPA8P11	-4.84	3.23e-06	0.00196	-0.63	-0.37	Migraine;	chr8:30125002	chr8:30237382~30240997:+
PCPG	cis	rs4489787	0.892	rs2705161	ENSG00000240399.1	RP1-228P16.1	4.84	3.23e-06	0.00196	0.44	0.37	Prostate cancer (SNP x SNP interaction);	chr12:48506683	chr12:48054813~48055591:-
PCPG	cis	rs7824557	0.564	rs12550129	ENSG00000255020.1	AF131216.5	-4.84	3.23e-06	0.00196	-0.49	-0.37	Retinal vascular caliber;	chr8:11376408	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs13274106	ENSG00000255020.1	AF131216.5	-4.84	3.23e-06	0.00196	-0.49	-0.37	Retinal vascular caliber;	chr8:11376449	chr8:11345748~11347502:-
PCPG	cis	rs6957923	0.818	rs12538407	ENSG00000230658.1	KLHL7-AS1	4.84	3.24e-06	0.00197	0.42	0.37	Height;	chr7:23481697	chr7:23101228~23105703:-
PCPG	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-4.84	3.24e-06	0.00197	-0.52	-0.37	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
PCPG	cis	rs3736858	0.932	rs17065145	ENSG00000261105.4	LMO7-AS1	-4.84	3.25e-06	0.00197	-0.68	-0.37	Interleukin-9 levels;	chr13:75854052	chr13:75604700~75635994:-
PCPG	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-4.84	3.25e-06	0.00197	-0.49	-0.37	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-4.84	3.25e-06	0.00197	-0.49	-0.37	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-4.84	3.25e-06	0.00197	-0.49	-0.37	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
PCPG	cis	rs7811142	1	rs11559117	ENSG00000078319.8	PMS2P1	-4.84	3.25e-06	0.00197	-0.47	-0.37	Platelet count;	chr7:100478991	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs4463351	ENSG00000078319.8	PMS2P1	-4.84	3.25e-06	0.00197	-0.47	-0.37	Platelet count;	chr7:100480603	chr7:100320992~100341908:-
PCPG	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	4.84	3.26e-06	0.00198	0.47	0.37	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
PCPG	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-4.84	3.26e-06	0.00198	-0.49	-0.37	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
PCPG	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-4.84	3.26e-06	0.00198	-0.49	-0.37	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
PCPG	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-4.84	3.26e-06	0.00198	-0.52	-0.37	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
PCPG	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-4.84	3.26e-06	0.00198	-0.52	-0.37	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
PCPG	cis	rs899997	0.862	rs8043123	ENSG00000261143.1	ADAMTS7P3	-4.83	3.27e-06	0.00198	-0.45	-0.37	Coronary artery disease or large artery stroke;	chr15:78681051	chr15:77976042~77993057:+
PCPG	cis	rs7819412	0.811	rs2409691	ENSG00000255020.1	AF131216.5	-4.83	3.27e-06	0.00198	-0.53	-0.37	Triglycerides;	chr8:11085766	chr8:11345748~11347502:-
PCPG	cis	rs964611	0.882	rs11629707	ENSG00000259488.2	RP11-154J22.1	4.83	3.27e-06	0.00198	0.37	0.37	Metabolite levels (Pyroglutamine);	chr15:48348148	chr15:48312353~48331856:-
PCPG	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-4.83	3.27e-06	0.00199	-0.32	-0.37	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
PCPG	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	4.83	3.27e-06	0.00199	0.47	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	4.83	3.27e-06	0.00199	0.47	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
PCPG	cis	rs62103177	0.564	rs55867755	ENSG00000261126.6	RP11-795F19.1	4.83	3.28e-06	0.00199	0.46	0.37	Opioid sensitivity;	chr18:79963434	chr18:80046900~80095482:+
PCPG	cis	rs62103177	0.564	rs59188178	ENSG00000261126.6	RP11-795F19.1	4.83	3.28e-06	0.00199	0.46	0.37	Opioid sensitivity;	chr18:79963435	chr18:80046900~80095482:+
PCPG	cis	rs7824557	0.724	rs2251473	ENSG00000255020.1	AF131216.5	4.83	3.28e-06	0.00199	0.48	0.37	Retinal vascular caliber;	chr8:11319617	chr8:11345748~11347502:-
PCPG	cis	rs12681963	0.764	rs1877184	ENSG00000248159.1	HSPA8P11	-4.83	3.28e-06	0.00199	-0.65	-0.37	Migraine;	chr8:30142424	chr8:30237382~30240997:+
PCPG	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	4.83	3.28e-06	0.00199	0.51	0.37	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
PCPG	cis	rs7621025	0.5	rs4678275	ENSG00000273486.1	RP11-731C17.2	4.83	3.28e-06	0.00199	0.41	0.37	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136837338~136839021:-
PCPG	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-4.83	3.29e-06	0.00199	-0.31	-0.37	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	4.83	3.29e-06	0.00199	0.31	0.37	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	4.83	3.29e-06	0.00199	0.31	0.37	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
PCPG	cis	rs1440410	0.83	rs4290853	ENSG00000250326.1	RP11-284M14.1	4.83	3.29e-06	0.00199	0.33	0.37	Ischemic stroke;	chr4:143262016	chr4:142933195~143184861:-
PCPG	cis	rs3806843	1	rs7732179	ENSG00000202515.1	VTRNA1-3	-4.83	3.29e-06	0.00199	-0.48	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140819454	chr5:140726158~140726246:+
PCPG	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	4.83	3.29e-06	0.00199	0.47	0.37	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
PCPG	cis	rs2115630	0.875	rs8039472	ENSG00000275120.1	RP11-182J1.17	-4.83	3.29e-06	0.00199	-0.36	-0.37	P wave terminal force;	chr15:84818413	chr15:84599434~84606463:-
PCPG	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-4.83	3.29e-06	0.00199	-0.37	-0.37	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
PCPG	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	4.83	3.29e-06	0.002	0.66	0.37	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
PCPG	cis	rs7017914	0.905	rs2639957	ENSG00000254031.4	RP11-326E22.1	4.83	3.29e-06	0.002	0.35	0.37	Bone mineral density;	chr8:71010967	chr8:71155457~71204223:+
PCPG	cis	rs17772222	0.917	rs2004329	ENSG00000222990.1	RNU4-22P	4.83	3.29e-06	0.002	0.48	0.37	Coronary artery calcification;	chr14:88532965	chr14:88513498~88513663:+
PCPG	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	4.83	3.3e-06	0.002	0.47	0.37	Height;	chr6:109634847	chr6:109382795~109383666:+
PCPG	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	4.83	3.3e-06	0.002	0.39	0.37	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
PCPG	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	-4.83	3.3e-06	0.002	-0.43	-0.37	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
PCPG	cis	rs6991838	0.725	rs6995134	ENSG00000200714.1	Y_RNA	4.83	3.31e-06	0.002	0.48	0.37	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65592731~65592820:+
PCPG	cis	rs4713118	0.621	rs9295756	ENSG00000216901.1	AL022393.7	4.83	3.31e-06	0.00201	0.52	0.37	Parkinson's disease;	chr6:28065618	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.621	rs4713132	ENSG00000216901.1	AL022393.7	4.83	3.31e-06	0.00201	0.52	0.37	Parkinson's disease;	chr6:28066257	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.621	rs4713133	ENSG00000216901.1	AL022393.7	4.83	3.31e-06	0.00201	0.52	0.37	Parkinson's disease;	chr6:28066263	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.621	rs4713134	ENSG00000216901.1	AL022393.7	4.83	3.31e-06	0.00201	0.52	0.37	Parkinson's disease;	chr6:28066343	chr6:28176188~28176674:+
PCPG	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-4.83	3.33e-06	0.00201	-0.35	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
PCPG	cis	rs10419113	0.668	rs3746208	ENSG00000268545.1	VN1R107P	4.83	3.33e-06	0.00201	0.39	0.37	Pediatric bone mineral density (spine);	chr19:57688731	chr19:57459912~57460120:+
PCPG	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	4.83	3.33e-06	0.00201	0.49	0.37	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
PCPG	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	4.83	3.33e-06	0.00201	0.45	0.37	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
PCPG	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-4.83	3.33e-06	0.00202	-0.56	-0.37	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
PCPG	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-4.83	3.33e-06	0.00202	-0.57	-0.37	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
PCPG	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-4.83	3.33e-06	0.00202	-0.43	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
PCPG	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	4.83	3.33e-06	0.00202	0.5	0.37	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
PCPG	cis	rs2060793	0.506	rs10741658	ENSG00000251991.1	RNU7-49P	4.83	3.34e-06	0.00202	0.4	0.37	Vitamin D levels;	chr11:14903190	chr11:14478892~14478953:+
PCPG	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	4.83	3.34e-06	0.00202	0.45	0.37	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
PCPG	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	4.83	3.34e-06	0.00202	0.45	0.37	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
PCPG	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	4.83	3.34e-06	0.00202	0.45	0.37	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
PCPG	cis	rs9595908	0.785	rs4942804	ENSG00000212293.1	SNORA16	4.83	3.34e-06	0.00202	0.45	0.37	Body mass index;	chr13:32684365	chr13:32420390~32420516:-
PCPG	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	4.83	3.35e-06	0.00202	0.46	0.37	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
PCPG	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	4.83	3.35e-06	0.00202	0.35	0.37	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
PCPG	cis	rs308097	1	rs308097	ENSG00000235944.6	ZNF815P	-4.83	3.35e-06	0.00202	-0.93	-0.37	IgG glycosylation;	chr7:5840746	chr7:5823160~5854435:+
PCPG	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	4.83	3.35e-06	0.00202	0.51	0.37	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
PCPG	cis	rs17772222	0.958	rs74074098	ENSG00000222990.1	RNU4-22P	4.83	3.35e-06	0.00203	0.49	0.37	Coronary artery calcification;	chr14:88484213	chr14:88513498~88513663:+
PCPG	cis	rs11671005	0.651	rs55716128	ENSG00000269600.1	AC016629.3	-4.83	3.36e-06	0.00203	-0.59	-0.37	Mean platelet volume;	chr19:58537387	chr19:58593896~58599355:-
PCPG	cis	rs9649213	0.593	rs6947340	ENSG00000272950.1	RP11-307C18.1	-4.83	3.37e-06	0.00203	-0.47	-0.37	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr7:98322853~98323430:+
PCPG	cis	rs1908814	0.51	rs57655799	ENSG00000255495.1	AC145124.2	4.83	3.37e-06	0.00203	0.37	0.37	Neuroticism;	chr8:11924908	chr8:12194467~12196280:+
PCPG	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-4.83	3.37e-06	0.00203	-0.49	-0.37	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-4.83	3.37e-06	0.00203	-0.49	-0.37	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-4.83	3.37e-06	0.00203	-0.49	-0.37	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-4.83	3.37e-06	0.00203	-0.49	-0.37	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-4.83	3.37e-06	0.00203	-0.49	-0.37	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
PCPG	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-4.83	3.37e-06	0.00203	-0.47	-0.37	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
PCPG	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	4.83	3.37e-06	0.00204	0.41	0.37	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
PCPG	cis	rs2734839	0.964	rs7131440	ENSG00000270179.1	RP11-159N11.4	4.83	3.37e-06	0.00204	0.38	0.37	Information processing speed;	chr11:113429188	chr11:113368478~113369117:+
PCPG	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	-4.83	3.38e-06	0.00204	-0.52	-0.37	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
PCPG	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	-4.83	3.38e-06	0.00204	-0.52	-0.37	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
PCPG	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	-4.83	3.38e-06	0.00204	-0.52	-0.37	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
PCPG	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-4.83	3.38e-06	0.00204	-0.43	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-4.83	3.38e-06	0.00204	-0.43	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
PCPG	cis	rs3806843	0.735	rs2563335	ENSG00000202515.1	VTRNA1-3	-4.83	3.38e-06	0.00204	-0.46	-0.37	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.801	rs2531358	ENSG00000202515.1	VTRNA1-3	4.83	3.38e-06	0.00204	0.46	0.37	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr5:140726158~140726246:+
PCPG	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-4.83	3.39e-06	0.00204	-0.58	-0.37	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
PCPG	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	4.83	3.39e-06	0.00204	0.34	0.37	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
PCPG	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-4.83	3.39e-06	0.00205	-0.5	-0.37	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-4.83	3.39e-06	0.00205	-0.5	-0.37	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-4.83	3.39e-06	0.00205	-0.5	-0.37	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
PCPG	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	4.83	3.39e-06	0.00205	0.49	0.37	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
PCPG	cis	rs9309473	0.558	rs11679042	ENSG00000163016.8	ALMS1P	4.83	3.4e-06	0.00205	0.57	0.37	Metabolite levels;	chr2:73680184	chr2:73644919~73685576:+
PCPG	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-4.83	3.4e-06	0.00205	-0.45	-0.37	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
PCPG	cis	rs7819412	0.642	rs11250117	ENSG00000255020.1	AF131216.5	-4.83	3.41e-06	0.00206	-0.49	-0.37	Triglycerides;	chr8:11115230	chr8:11345748~11347502:-
PCPG	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-4.83	3.41e-06	0.00206	-0.47	-0.37	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-4.83	3.41e-06	0.00206	-0.47	-0.37	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
PCPG	cis	rs2288884	0.515	rs9676397	ENSG00000275055.1	CTC-471J1.11	-4.83	3.41e-06	0.00206	-0.34	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:52049007~52049754:+
PCPG	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	4.82	3.41e-06	0.00206	0.45	0.37	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
PCPG	cis	rs73607972	0.935	rs16952396	ENSG00000275191.1	RP11-36I17.2	-4.82	3.41e-06	0.00206	-0.61	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53616751	chr16:53628256~53628816:-
PCPG	cis	rs9926296	0.585	rs8058009	ENSG00000260259.1	RP11-368I7.4	-4.82	3.41e-06	0.00206	-0.48	-0.37	Vitiligo;	chr16:89790031	chr16:89682620~89686569:-
PCPG	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	4.82	3.42e-06	0.00206	0.53	0.37	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
PCPG	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-4.82	3.42e-06	0.00206	-0.49	-0.37	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
PCPG	cis	rs5758511	0.68	rs58654759	ENSG00000205702.9	CYP2D7	4.82	3.42e-06	0.00206	0.5	0.37	Birth weight;	chr22:42246570	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.68	rs5758682	ENSG00000205702.9	CYP2D7	4.82	3.42e-06	0.00206	0.5	0.37	Birth weight;	chr22:42249196	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.68	rs34107327	ENSG00000205702.9	CYP2D7	4.82	3.42e-06	0.00206	0.5	0.37	Birth weight;	chr22:42252347	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.68	rs5758684	ENSG00000205702.9	CYP2D7	4.82	3.42e-06	0.00206	0.5	0.37	Birth weight;	chr22:42253503	chr22:42140203~42144577:-
PCPG	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-4.82	3.42e-06	0.00206	-0.44	-0.37	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
PCPG	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-4.82	3.42e-06	0.00206	-0.45	-0.37	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
PCPG	cis	rs2625529	0.586	rs11639282	ENSG00000260037.4	CTD-2524L6.3	4.82	3.42e-06	0.00206	0.47	0.37	Red blood cell count;	chr15:72142919	chr15:71818396~71823384:+
PCPG	cis	rs3806843	0.868	rs2563291	ENSG00000202515.1	VTRNA1-3	4.82	3.42e-06	0.00206	0.47	0.37	Depressive symptoms (multi-trait analysis);	chr5:140740014	chr5:140726158~140726246:+
PCPG	cis	rs1949733	0.958	rs2631731	ENSG00000205959.3	RP11-689P11.2	-4.82	3.43e-06	0.00206	-0.41	-0.37	Response to antineoplastic agents;	chr4:8428090	chr4:8482270~8512610:+
PCPG	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-4.82	3.43e-06	0.00207	-0.35	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
PCPG	cis	rs8098244	0.603	rs1711456	ENSG00000265752.2	RP11-403A21.1	4.82	3.43e-06	0.00207	0.44	0.37	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23697390	chr18:23957754~23982556:-
PCPG	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-4.82	3.43e-06	0.00207	-0.43	-0.37	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-4.82	3.43e-06	0.00207	-0.43	-0.37	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-4.82	3.43e-06	0.00207	-0.43	-0.37	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
PCPG	cis	rs9494145	0.667	rs1331309	ENSG00000232876.1	CTA-212D2.2	-4.82	3.43e-06	0.00207	-0.48	-0.37	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135085040	chr6:135055033~135060550:+
PCPG	cis	rs6762	0.748	rs7928935	ENSG00000279672.1	CMB9-55F22.1	4.82	3.44e-06	0.00207	0.4	0.37	Mean platelet volume;	chr11:839127	chr11:779617~780755:+
PCPG	cis	rs6762	0.692	rs7928925	ENSG00000279672.1	CMB9-55F22.1	4.82	3.44e-06	0.00207	0.4	0.37	Mean platelet volume;	chr11:839155	chr11:779617~780755:+
PCPG	cis	rs6762	0.719	rs7936806	ENSG00000279672.1	CMB9-55F22.1	4.82	3.44e-06	0.00207	0.4	0.37	Mean platelet volume;	chr11:839186	chr11:779617~780755:+
PCPG	cis	rs6762	0.748	rs28735718	ENSG00000279672.1	CMB9-55F22.1	4.82	3.44e-06	0.00207	0.4	0.37	Mean platelet volume;	chr11:839629	chr11:779617~780755:+
PCPG	cis	rs13108904	0.901	rs6826029	ENSG00000254094.1	AC078852.1	-4.82	3.44e-06	0.00207	-0.42	-0.37	Obesity-related traits;	chr4:1313901	chr4:1356581~1358075:+
PCPG	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	4.82	3.44e-06	0.00207	0.38	0.37	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
PCPG	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	4.82	3.45e-06	0.00208	0.37	0.37	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	4.82	3.45e-06	0.00208	0.37	0.37	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
PCPG	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	4.82	3.45e-06	0.00208	0.37	0.37	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
PCPG	cis	rs1949733	0.656	rs6845969	ENSG00000205959.3	RP11-689P11.2	-4.82	3.46e-06	0.00208	-0.41	-0.37	Response to antineoplastic agents;	chr4:8400738	chr4:8482270~8512610:+
PCPG	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-4.82	3.46e-06	0.00208	-0.35	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
PCPG	cis	rs11858159	0.627	rs7166584	ENSG00000259905.4	PWRN1	4.82	3.46e-06	0.00208	0.42	0.37	Platelet thrombus formation;	chr15:24555585	chr15:24493137~24652130:+
PCPG	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	4.82	3.47e-06	0.00209	0.39	0.37	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	4.82	3.47e-06	0.00209	0.37	0.37	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	4.82	3.47e-06	0.00209	0.37	0.37	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
PCPG	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-4.82	3.47e-06	0.00209	-0.36	-0.37	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
PCPG	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-4.82	3.48e-06	0.00209	-0.47	-0.37	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-4.82	3.48e-06	0.00209	-0.47	-0.37	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-4.82	3.48e-06	0.00209	-0.47	-0.37	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
PCPG	cis	rs575908	0.684	rs10913461	ENSG00000254154.7	RP4-798P15.3	4.82	3.48e-06	0.00209	0.36	0.37	Breast cancer;	chr1:177917982	chr1:177928788~178038007:-
PCPG	cis	rs4713118	0.662	rs9357060	ENSG00000216901.1	AL022393.7	4.82	3.48e-06	0.00209	0.51	0.37	Parkinson's disease;	chr6:28056708	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs9468271	ENSG00000216901.1	AL022393.7	4.82	3.48e-06	0.00209	0.51	0.37	Parkinson's disease;	chr6:28056792	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs9380045	ENSG00000216901.1	AL022393.7	4.82	3.48e-06	0.00209	0.51	0.37	Parkinson's disease;	chr6:28057501	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.616	rs9348789	ENSG00000216901.1	AL022393.7	4.82	3.48e-06	0.00209	0.51	0.37	Parkinson's disease;	chr6:28057708	chr6:28176188~28176674:+
PCPG	cis	rs7246657	0.943	rs8109038	ENSG00000226686.6	LINC01535	4.82	3.48e-06	0.00209	0.58	0.37	Coronary artery calcification;	chr19:37524807	chr19:37251912~37265535:+
PCPG	cis	rs1075265	0.722	rs13414216	ENSG00000233266.1	HMGB1P31	4.82	3.48e-06	0.00209	0.45	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53699166	chr2:54051334~54051760:+
PCPG	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	4.82	3.48e-06	0.00209	0.4	0.37	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
PCPG	cis	rs1609391	0.543	rs9881139	ENSG00000273486.1	RP11-731C17.2	4.82	3.48e-06	0.00209	0.38	0.37	Neuroticism;	chr3:136915198	chr3:136837338~136839021:-
PCPG	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-4.82	3.49e-06	0.0021	-0.41	-0.37	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
PCPG	cis	rs11148252	0.574	rs7139495	ENSG00000198384.8	TPTE2P3	-4.82	3.49e-06	0.0021	-0.47	-0.37	Lewy body disease;	chr13:52709183	chr13:52522632~52586906:+
PCPG	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-4.82	3.5e-06	0.0021	-0.45	-0.37	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
PCPG	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	4.82	3.5e-06	0.0021	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
PCPG	cis	rs5758511	0.689	rs56906457	ENSG00000205702.9	CYP2D7	4.82	3.5e-06	0.0021	0.52	0.37	Birth weight;	chr22:42232329	chr22:42140203~42144577:-
PCPG	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	4.82	3.5e-06	0.0021	0.55	0.37	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
PCPG	cis	rs4713118	0.662	rs149969	ENSG00000216901.1	AL022393.7	4.82	3.51e-06	0.00211	0.5	0.37	Parkinson's disease;	chr6:28009959	chr6:28176188~28176674:+
PCPG	cis	rs2734839	0.929	rs7131627	ENSG00000270179.1	RP11-159N11.4	-4.82	3.51e-06	0.00211	-0.38	-0.37	Information processing speed;	chr11:113429107	chr11:113368478~113369117:+
PCPG	cis	rs12908161	1	rs12908161	ENSG00000259295.5	CSPG4P12	4.82	3.51e-06	0.00211	0.55	0.37	Schizophrenia;	chr15:84664594	chr15:85191438~85213905:+
PCPG	cis	rs9513627	0.915	rs7327204	ENSG00000228501.2	RPL15P18	4.82	3.51e-06	0.00211	0.67	0.37	Obesity-related traits;	chr13:99474698	chr13:100150481~100151092:-
PCPG	cis	rs11858159	0.644	rs11636595	ENSG00000259905.4	PWRN1	4.82	3.52e-06	0.00211	0.39	0.37	Platelet thrombus formation;	chr15:24479874	chr15:24493137~24652130:+
PCPG	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	4.82	3.52e-06	0.00211	0.59	0.37	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
PCPG	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	4.82	3.52e-06	0.00211	0.64	0.37	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	4.82	3.52e-06	0.00211	0.64	0.37	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
PCPG	cis	rs10899021	0.915	rs11236198	ENSG00000279353.1	RP11-864N7.4	4.82	3.52e-06	0.00211	0.76	0.37	Response to metformin (IC50);	chr11:74661155	chr11:74698231~74699658:-
PCPG	cis	rs9595908	0.785	rs7331393	ENSG00000212293.1	SNORA16	-4.82	3.52e-06	0.00211	-0.43	-0.37	Body mass index;	chr13:32647065	chr13:32420390~32420516:-
PCPG	cis	rs7017914	0.905	rs2639958	ENSG00000254031.4	RP11-326E22.1	4.82	3.52e-06	0.00212	0.36	0.37	Bone mineral density;	chr8:71009915	chr8:71155457~71204223:+
PCPG	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	4.82	3.53e-06	0.00212	0.64	0.37	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
PCPG	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	4.82	3.53e-06	0.00212	0.47	0.37	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
PCPG	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	4.82	3.53e-06	0.00212	0.56	0.37	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
PCPG	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	4.82	3.54e-06	0.00212	0.47	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
PCPG	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	4.82	3.54e-06	0.00213	0.48	0.37	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
PCPG	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-4.82	3.54e-06	0.00213	-0.46	-0.37	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
PCPG	cis	rs9302635	0.55	rs35959677	ENSG00000260886.1	TAT-AS1	4.82	3.54e-06	0.00213	0.55	0.37	Blood protein levels;	chr16:72166902	chr16:71565789~71578187:+
PCPG	cis	rs720064	0.586	rs8083137	ENSG00000265752.2	RP11-403A21.1	4.82	3.55e-06	0.00213	0.41	0.37	Strep throat;	chr18:23962963	chr18:23957754~23982556:-
PCPG	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-4.82	3.55e-06	0.00213	-0.47	-0.37	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-4.82	3.55e-06	0.00213	-0.47	-0.37	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
PCPG	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	4.81	3.56e-06	0.00214	0.35	0.37	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
PCPG	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	4.81	3.56e-06	0.00214	0.35	0.37	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
PCPG	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	4.81	3.57e-06	0.00214	0.38	0.37	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
PCPG	cis	rs7017914	0.935	rs2732093	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71006844	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2639899	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71007227	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732094	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71007683	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732095	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71007711	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.87	rs2732096	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71007745	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.935	rs2732097	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71007778	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.875	rs2639897	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71008441	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2639896	ENSG00000254031.4	RP11-326E22.1	4.81	3.57e-06	0.00214	0.36	0.37	Bone mineral density;	chr8:71008548	chr8:71155457~71204223:+
PCPG	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-4.81	3.57e-06	0.00214	-0.33	-0.37	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
PCPG	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-4.81	3.57e-06	0.00214	-0.33	-0.37	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
PCPG	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	4.81	3.58e-06	0.00214	0.4	0.37	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
PCPG	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-4.81	3.58e-06	0.00214	-0.38	-0.37	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
PCPG	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	4.81	3.59e-06	0.00215	0.51	0.37	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
PCPG	cis	rs2235642	0.685	rs2667681	ENSG00000260989.1	LA16c-395F10.2	-4.81	3.59e-06	0.00215	-0.4	-0.37	Coronary artery disease;	chr16:1603205	chr16:1580527~1610328:+
PCPG	cis	rs2235642	0.653	rs7197288	ENSG00000260989.1	LA16c-395F10.2	-4.81	3.59e-06	0.00215	-0.4	-0.37	Coronary artery disease;	chr16:1604752	chr16:1580527~1610328:+
PCPG	cis	rs7402982	0.934	rs8027457	ENSG00000278022.1	RP11-35O15.2	-4.81	3.59e-06	0.00215	-0.37	-0.37	Birth weight;	chr15:98660872	chr15:98660210~98660668:+
PCPG	cis	rs7688540	0.8	rs61792060	ENSG00000275426.1	CH17-262A2.1	4.81	3.6e-06	0.00215	0.43	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:149738~150317:+
PCPG	cis	rs7403037	1	rs28380602	ENSG00000259905.4	PWRN1	4.81	3.6e-06	0.00215	0.41	0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24532999	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.871	rs28477593	ENSG00000259905.4	PWRN1	4.81	3.6e-06	0.00215	0.41	0.37	Platelet thrombus formation;	chr15:24533441	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs28394774	ENSG00000259905.4	PWRN1	4.81	3.6e-06	0.00215	0.41	0.37	Platelet thrombus formation;	chr15:24533451	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs28735204	ENSG00000259905.4	PWRN1	4.81	3.6e-06	0.00215	0.41	0.37	Platelet thrombus formation;	chr15:24533537	chr15:24493137~24652130:+
PCPG	cis	rs7017914	0.967	rs2100908	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70671075	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13271442	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70672934	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs34558600	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70673917	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs6472538	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70674736	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs7001162	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70675235	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs56112621	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70676159	chr8:71155457~71204223:+
PCPG	cis	rs7017914	1	rs7017914	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70678968	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13256250	ENSG00000254031.4	RP11-326E22.1	4.81	3.6e-06	0.00215	0.36	0.37	Bone mineral density;	chr8:70683958	chr8:71155457~71204223:+
PCPG	cis	rs2625529	0.652	rs2957750	ENSG00000260037.4	CTD-2524L6.3	4.81	3.6e-06	0.00215	0.48	0.37	Red blood cell count;	chr15:72039917	chr15:71818396~71823384:+
PCPG	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-4.81	3.6e-06	0.00215	-0.34	-0.37	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
PCPG	cis	rs2281558	0.517	rs16987966	ENSG00000125804.12	FAM182A	-4.81	3.6e-06	0.00215	-0.54	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25662778	chr20:26054655~26086917:+
PCPG	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-4.81	3.6e-06	0.00215	-0.48	-0.37	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
PCPG	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	4.81	3.6e-06	0.00215	0.42	0.37	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	4.81	3.6e-06	0.00215	0.42	0.37	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
PCPG	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-4.81	3.61e-06	0.00215	-0.54	-0.37	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
PCPG	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-4.81	3.61e-06	0.00216	-0.55	-0.37	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
PCPG	cis	rs12681963	0.688	rs12541087	ENSG00000248159.1	HSPA8P11	4.81	3.61e-06	0.00216	0.68	0.37	Migraine;	chr8:30172398	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs12544416	ENSG00000248159.1	HSPA8P11	4.81	3.61e-06	0.00216	0.68	0.37	Migraine;	chr8:30182057	chr8:30237382~30240997:+
PCPG	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-4.81	3.61e-06	0.00216	-0.35	-0.37	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
PCPG	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	4.81	3.61e-06	0.00216	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
PCPG	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-4.81	3.62e-06	0.00216	-0.44	-0.37	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
PCPG	cis	rs300890	0.513	rs72719179	ENSG00000250326.1	RP11-284M14.1	-4.81	3.62e-06	0.00216	-0.35	-0.37	Nasopharyngeal carcinoma;	chr4:143140280	chr4:142933195~143184861:-
PCPG	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-4.81	3.62e-06	0.00216	-0.47	-0.37	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
PCPG	cis	rs7246657	0.943	rs35540940	ENSG00000226686.6	LINC01535	-4.81	3.62e-06	0.00216	-0.59	-0.37	Coronary artery calcification;	chr19:37517333	chr19:37251912~37265535:+
PCPG	cis	rs7824557	0.547	rs2736287	ENSG00000255020.1	AF131216.5	-4.81	3.63e-06	0.00217	-0.48	-0.37	Retinal vascular caliber;	chr8:11370497	chr8:11345748~11347502:-
PCPG	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	4.81	3.63e-06	0.00217	0.56	0.37	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
PCPG	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-4.81	3.63e-06	0.00217	-0.47	-0.37	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-4.81	3.63e-06	0.00217	-0.47	-0.37	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs6948685	ENSG00000078319.8	PMS2P1	-4.81	3.63e-06	0.00217	-0.47	-0.37	Platelet count;	chr7:100372565	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-4.81	3.63e-06	0.00217	-0.47	-0.37	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-4.81	3.63e-06	0.00217	-0.47	-0.37	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-4.81	3.63e-06	0.00217	-0.47	-0.37	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
PCPG	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-4.81	3.63e-06	0.00217	-0.49	-0.37	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
PCPG	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-4.81	3.64e-06	0.00217	-0.43	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
PCPG	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-4.81	3.64e-06	0.00217	-0.43	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
PCPG	cis	rs13108904	0.65	rs3796618	ENSG00000253399.1	AC078852.2	-4.81	3.65e-06	0.00218	-0.39	-0.37	Obesity-related traits;	chr4:1355814	chr4:1358479~1359461:+
PCPG	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	4.81	3.65e-06	0.00218	0.57	0.37	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
PCPG	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	4.81	3.65e-06	0.00218	0.57	0.37	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
PCPG	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	4.81	3.65e-06	0.00218	0.44	0.37	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
PCPG	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-4.81	3.65e-06	0.00218	-0.41	-0.37	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
PCPG	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-4.81	3.65e-06	0.00218	-0.48	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
PCPG	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-4.81	3.65e-06	0.00218	-0.28	-0.37	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
PCPG	cis	rs11858159	0.934	rs61993130	ENSG00000259905.4	PWRN1	4.81	3.66e-06	0.00218	0.41	0.37	Platelet thrombus formation;	chr15:24541124	chr15:24493137~24652130:+
PCPG	cis	rs2921036	0.545	rs4840975	ENSG00000173295.6	FAM86B3P	4.81	3.66e-06	0.00218	0.45	0.37	Neuroticism;	chr8:8505748	chr8:8228595~8244865:+
PCPG	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-4.81	3.66e-06	0.00218	-0.56	-0.37	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
PCPG	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-4.81	3.66e-06	0.00218	-0.47	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
PCPG	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	4.81	3.66e-06	0.00218	0.52	0.37	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
PCPG	cis	rs300890	0.536	rs300924	ENSG00000250326.1	RP11-284M14.1	4.81	3.67e-06	0.00219	0.34	0.37	Nasopharyngeal carcinoma;	chr4:143261032	chr4:142933195~143184861:-
PCPG	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	4.81	3.67e-06	0.00219	0.45	0.37	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
PCPG	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	4.81	3.68e-06	0.00219	0.51	0.37	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	4.81	3.68e-06	0.00219	0.51	0.37	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	4.81	3.68e-06	0.00219	0.51	0.37	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	4.81	3.68e-06	0.00219	0.51	0.37	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	4.81	3.68e-06	0.00219	0.51	0.37	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
PCPG	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-4.81	3.68e-06	0.00219	-0.47	-0.37	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
PCPG	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	4.81	3.68e-06	0.00219	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
PCPG	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	4.81	3.68e-06	0.00219	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
PCPG	cis	rs1440410	0.83	rs12501994	ENSG00000250326.1	RP11-284M14.1	4.81	3.68e-06	0.00219	0.33	0.37	Ischemic stroke;	chr4:143259802	chr4:142933195~143184861:-
PCPG	cis	rs7759001	0.744	rs13217162	ENSG00000271755.1	RP1-153G14.4	4.81	3.68e-06	0.0022	0.52	0.37	Glomerular filtration rate (creatinine);	chr6:27509320	chr6:27404010~27406964:-
PCPG	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-4.81	3.69e-06	0.0022	-0.52	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
PCPG	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	4.81	3.69e-06	0.0022	0.47	0.37	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	4.81	3.69e-06	0.0022	0.47	0.37	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
PCPG	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	4.81	3.69e-06	0.0022	0.47	0.37	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
PCPG	cis	rs7208859	0.573	rs73267873	ENSG00000263603.1	CTD-2349P21.5	-4.81	3.69e-06	0.0022	-0.6	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.561	rs4085382	ENSG00000263603.1	CTD-2349P21.5	-4.81	3.69e-06	0.0022	-0.6	-0.37	Body mass index;	chr17:30744184	chr17:30729469~30731202:+
PCPG	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-4.81	3.69e-06	0.0022	-0.45	-0.37	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
PCPG	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-4.81	3.69e-06	0.0022	-0.47	-0.37	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
PCPG	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-4.81	3.7e-06	0.0022	-0.35	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
PCPG	cis	rs4713118	0.516	rs6931858	ENSG00000216901.1	AL022393.7	4.81	3.7e-06	0.0022	0.53	0.37	Parkinson's disease;	chr6:28110633	chr6:28176188~28176674:+
PCPG	cis	rs2115630	0.691	rs61322921	ENSG00000275120.1	RP11-182J1.17	-4.81	3.7e-06	0.0022	-0.37	-0.37	P wave terminal force;	chr15:84620407	chr15:84599434~84606463:-
PCPG	cis	rs7403037	0.527	rs12907622	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24547372	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs12324730	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24553608	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs7162379	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24554744	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.871	rs11853919	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24556624	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.702	rs28435380	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24557156	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.871	rs28538042	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24557324	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12914379	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24557477	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7179797	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24557909	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7495278	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24559003	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7495971	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24559094	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7496179	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24559417	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs7495882	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24559529	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs7496204	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24559549	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs7496984	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24559716	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.729	rs9788744	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24559825	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs12594408	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24560051	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs8032958	ENSG00000259905.4	PWRN1	4.81	3.7e-06	0.0022	0.41	0.37	Platelet thrombus formation;	chr15:24561604	chr15:24493137~24652130:+
PCPG	cis	rs3736858	0.935	rs9530471	ENSG00000261105.4	LMO7-AS1	-4.81	3.71e-06	0.00221	-0.71	-0.37	Interleukin-9 levels;	chr13:75845638	chr13:75604700~75635994:-
PCPG	cis	rs7811142	1	rs11771419	ENSG00000078319.8	PMS2P1	-4.81	3.71e-06	0.00221	-0.47	-0.37	Platelet count;	chr7:100390780	chr7:100320992~100341908:-
PCPG	cis	rs1048886	0.872	rs35159719	ENSG00000271967.1	RP11-134K13.4	-4.81	3.71e-06	0.00221	-0.48	-0.37	Type 2 diabetes;	chr6:70561987	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs75179941	ENSG00000271967.1	RP11-134K13.4	-4.81	3.71e-06	0.00221	-0.48	-0.37	Type 2 diabetes;	chr6:70563130	chr6:70596438~70596980:+
PCPG	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	4.81	3.71e-06	0.00221	0.46	0.37	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
PCPG	cis	rs6957923	0.934	rs7788661	ENSG00000230658.1	KLHL7-AS1	4.8	3.72e-06	0.00221	0.44	0.37	Height;	chr7:23451694	chr7:23101228~23105703:-
PCPG	cis	rs5758511	0.68	rs5758686	ENSG00000205702.9	CYP2D7	4.8	3.72e-06	0.00221	0.49	0.37	Birth weight;	chr22:42259371	chr22:42140203~42144577:-
PCPG	cis	rs10899021	0.79	rs12288525	ENSG00000279353.1	RP11-864N7.4	4.8	3.72e-06	0.00221	0.61	0.37	Response to metformin (IC50);	chr11:74621544	chr11:74698231~74699658:-
PCPG	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-4.8	3.72e-06	0.00221	-0.47	-0.37	Height;	chr6:109405874	chr6:109382795~109383666:+
PCPG	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-4.8	3.73e-06	0.00222	-0.59	-0.37	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
PCPG	cis	rs300890	0.585	rs1440412	ENSG00000250326.1	RP11-284M14.1	4.8	3.74e-06	0.00222	0.35	0.37	Nasopharyngeal carcinoma;	chr4:143237122	chr4:142933195~143184861:-
PCPG	cis	rs3736858	1	rs2296093	ENSG00000261105.4	LMO7-AS1	-4.8	3.74e-06	0.00222	-0.7	-0.37	Interleukin-9 levels;	chr13:75856325	chr13:75604700~75635994:-
PCPG	cis	rs73607972	0.935	rs4783818	ENSG00000275191.1	RP11-36I17.2	-4.8	3.75e-06	0.00223	-0.63	-0.37	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53704371	chr16:53628256~53628816:-
PCPG	cis	rs7208859	0.623	rs11657662	ENSG00000263603.1	CTD-2349P21.5	4.8	3.75e-06	0.00223	0.62	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30729469~30731202:+
PCPG	cis	rs804280	0.509	rs4841639	ENSG00000255495.1	AC145124.2	4.8	3.75e-06	0.00223	0.37	0.37	Myopia (pathological);	chr8:11938584	chr8:12194467~12196280:+
PCPG	cis	rs1949733	1	rs1357481	ENSG00000205959.3	RP11-689P11.2	-4.8	3.76e-06	0.00223	-0.41	-0.37	Response to antineoplastic agents;	chr4:8494494	chr4:8482270~8512610:+
PCPG	cis	rs7829975	0.572	rs28730413	ENSG00000173295.6	FAM86B3P	4.8	3.76e-06	0.00223	0.42	0.37	Mood instability;	chr8:8937937	chr8:8228595~8244865:+
PCPG	cis	rs17772222	0.958	rs60878614	ENSG00000222990.1	RNU4-22P	4.8	3.76e-06	0.00223	0.48	0.37	Coronary artery calcification;	chr14:88513871	chr14:88513498~88513663:+
PCPG	cis	rs11673344	0.523	rs7245453	ENSG00000226686.6	LINC01535	4.8	3.76e-06	0.00223	0.46	0.37	Obesity-related traits;	chr19:37043447	chr19:37251912~37265535:+
PCPG	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	4.8	3.76e-06	0.00224	0.46	0.37	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
PCPG	cis	rs13113518	0.678	rs7663650	ENSG00000272969.1	RP11-528I4.2	-4.8	3.76e-06	0.00224	-0.43	-0.37	Height;	chr4:55364952	chr4:55547112~55547889:+
PCPG	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	4.8	3.77e-06	0.00224	0.49	0.36	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
PCPG	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-4.8	3.78e-06	0.00224	-0.43	-0.36	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
PCPG	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	4.8	3.78e-06	0.00224	0.44	0.36	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
PCPG	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	4.8	3.78e-06	0.00224	0.37	0.36	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
PCPG	cis	rs11858159	0.533	rs12592979	ENSG00000259905.4	PWRN1	4.8	3.78e-06	0.00224	0.39	0.36	Platelet thrombus formation;	chr15:24507362	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.708	rs11856249	ENSG00000259905.4	PWRN1	4.8	3.78e-06	0.00224	0.39	0.36	Platelet thrombus formation;	chr15:24511276	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.845	rs11632311	ENSG00000259905.4	PWRN1	4.8	3.78e-06	0.00224	0.39	0.36	Platelet thrombus formation;	chr15:24512946	chr15:24493137~24652130:+
PCPG	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	4.8	3.78e-06	0.00224	0.48	0.36	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
PCPG	cis	rs7017914	0.905	rs2639898	ENSG00000254031.4	RP11-326E22.1	4.8	3.78e-06	0.00224	0.36	0.36	Bone mineral density;	chr8:71008075	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.84	rs2732099	ENSG00000254031.4	RP11-326E22.1	4.8	3.78e-06	0.00224	0.36	0.36	Bone mineral density;	chr8:71008815	chr8:71155457~71204223:+
PCPG	cis	rs3806843	0.735	rs778597	ENSG00000202515.1	VTRNA1-3	-4.8	3.78e-06	0.00224	-0.46	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr5:140726158~140726246:+
PCPG	cis	rs7208859	0.623	rs8082537	ENSG00000263603.1	CTD-2349P21.5	-4.8	3.79e-06	0.00225	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.561	rs11655876	ENSG00000263603.1	CTD-2349P21.5	-4.8	3.79e-06	0.00225	-0.6	-0.36	Body mass index;	chr17:30690132	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9907197	ENSG00000263603.1	CTD-2349P21.5	-4.8	3.79e-06	0.00225	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9915963	ENSG00000263603.1	CTD-2349P21.5	-4.8	3.79e-06	0.00225	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30729469~30731202:+
PCPG	cis	rs300890	0.513	rs4270544	ENSG00000250326.1	RP11-284M14.1	-4.8	3.79e-06	0.00225	-0.34	-0.36	Nasopharyngeal carcinoma;	chr4:143123185	chr4:142933195~143184861:-
PCPG	cis	rs7811142	1	rs11771241	ENSG00000078319.8	PMS2P1	-4.8	3.79e-06	0.00225	-0.48	-0.36	Platelet count;	chr7:100397162	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.943	rs10241492	ENSG00000078319.8	PMS2P1	-4.8	3.79e-06	0.00225	-0.48	-0.36	Platelet count;	chr7:100397190	chr7:100320992~100341908:-
PCPG	cis	rs7759001	0.681	rs13212050	ENSG00000271755.1	RP1-153G14.4	4.8	3.79e-06	0.00225	0.52	0.36	Glomerular filtration rate (creatinine);	chr6:27511830	chr6:27404010~27406964:-
PCPG	cis	rs11858159	1	rs7172889	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24546910	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs7173110	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24547023	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs7170832	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24547103	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs12907301	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24547168	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs7173287	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24547307	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs12908585	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24547584	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs13379866	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24548683	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.841	rs13379975	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24549067	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7162797	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24549292	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7164247	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24550048	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs6576336	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24550072	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs9920337	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24551206	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs3903029	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24551388	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs4076153	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24551944	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12324712	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24553127	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7497040	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24553206	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12324769	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24553522	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12324394	ENSG00000259905.4	PWRN1	4.8	3.8e-06	0.00225	0.41	0.36	Platelet thrombus formation;	chr15:24553528	chr15:24493137~24652130:+
PCPG	cis	rs2736345	1	rs922483	ENSG00000255020.1	AF131216.5	4.8	3.8e-06	0.00225	0.49	0.36	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494403	chr8:11345748~11347502:-
PCPG	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	4.8	3.8e-06	0.00225	0.55	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
PCPG	cis	rs3808502	0.516	rs6983727	ENSG00000255020.1	AF131216.5	4.8	3.8e-06	0.00225	0.47	0.36	Neuroticism;	chr8:11558303	chr8:11345748~11347502:-
PCPG	cis	rs3806843	0.838	rs2337514	ENSG00000202515.1	VTRNA1-3	4.8	3.8e-06	0.00225	0.46	0.36	Depressive symptoms (multi-trait analysis);	chr5:140753147	chr5:140726158~140726246:+
PCPG	cis	rs10760158	0.832	rs878691	ENSG00000226752.6	PSMD5-AS1	-4.8	3.8e-06	0.00225	-0.47	-0.36	Pulse pressure;	chr9:121275329	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs880823	ENSG00000226752.6	PSMD5-AS1	-4.8	3.8e-06	0.00225	-0.47	-0.36	Pulse pressure;	chr9:121276189	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs4837827	ENSG00000226752.6	PSMD5-AS1	-4.8	3.8e-06	0.00225	-0.47	-0.36	Pulse pressure;	chr9:121277593	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs13292100	ENSG00000226752.6	PSMD5-AS1	-4.8	3.8e-06	0.00225	-0.47	-0.36	Pulse pressure;	chr9:121278719	chr9:120824828~120854385:+
PCPG	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-4.8	3.8e-06	0.00226	-0.52	-0.36	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
PCPG	cis	rs4266144	1	rs4266144	ENSG00000241770.1	RP11-555M1.3	-4.8	3.81e-06	0.00226	-0.44	-0.36	Coronary artery disease;	chr3:157134803	chr3:157163452~157169133:+
PCPG	cis	rs2898290	0.617	rs13278965	ENSG00000255020.1	AF131216.5	4.8	3.81e-06	0.00226	0.5	0.36	Systolic blood pressure;	chr8:11609236	chr8:11345748~11347502:-
PCPG	cis	rs4713118	0.662	rs175954	ENSG00000216901.1	AL022393.7	4.8	3.81e-06	0.00226	0.51	0.36	Parkinson's disease;	chr6:28043807	chr6:28176188~28176674:+
PCPG	cis	rs10435719	0.647	rs10092605	ENSG00000255495.1	AC145124.2	4.8	3.82e-06	0.00226	0.37	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11929886	chr8:12194467~12196280:+
PCPG	cis	rs7246657	0.943	rs8106839	ENSG00000226686.6	LINC01535	-4.8	3.82e-06	0.00226	-0.6	-0.36	Coronary artery calcification;	chr19:37467573	chr19:37251912~37265535:+
PCPG	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-4.8	3.82e-06	0.00226	-0.44	-0.36	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
PCPG	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	4.8	3.83e-06	0.00227	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
PCPG	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	4.8	3.83e-06	0.00227	0.48	0.36	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	4.8	3.83e-06	0.00227	0.48	0.36	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
PCPG	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	4.8	3.83e-06	0.00227	0.4	0.36	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
PCPG	cis	rs7017914	0.967	rs6991329	ENSG00000254031.4	RP11-326E22.1	4.8	3.83e-06	0.00227	0.36	0.36	Bone mineral density;	chr8:70681190	chr8:71155457~71204223:+
PCPG	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-4.8	3.83e-06	0.00227	-0.74	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
PCPG	cis	rs7587476	0.906	rs62201985	ENSG00000229267.2	AC072062.1	-4.8	3.84e-06	0.00227	-0.5	-0.36	Neuroblastoma;	chr2:214793914	chr2:214810229~214963274:+
PCPG	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	4.8	3.84e-06	0.00227	0.66	0.36	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
PCPG	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	4.8	3.84e-06	0.00227	0.41	0.36	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
PCPG	cis	rs3736858	1	rs3825439	ENSG00000261105.4	LMO7-AS1	-4.8	3.84e-06	0.00227	-0.71	-0.36	Interleukin-9 levels;	chr13:75832713	chr13:75604700~75635994:-
PCPG	cis	rs3736858	0.866	rs9544051	ENSG00000261105.4	LMO7-AS1	-4.8	3.84e-06	0.00227	-0.71	-0.36	Interleukin-9 levels;	chr13:75832845	chr13:75604700~75635994:-
PCPG	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	4.8	3.85e-06	0.00228	0.46	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
PCPG	cis	rs2625529	0.938	rs4238447	ENSG00000260037.4	CTD-2524L6.3	-4.8	3.85e-06	0.00228	-0.59	-0.36	Red blood cell count;	chr15:71839539	chr15:71818396~71823384:+
PCPG	cis	rs3806843	1	rs10072015	ENSG00000202515.1	VTRNA1-3	4.8	3.85e-06	0.00228	0.46	0.36	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr5:140726158~140726246:+
PCPG	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	4.8	3.85e-06	0.00228	0.37	0.36	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
PCPG	cis	rs1609391	0.561	rs9289523	ENSG00000273486.1	RP11-731C17.2	4.8	3.86e-06	0.00228	0.38	0.36	Neuroticism;	chr3:136916747	chr3:136837338~136839021:-
PCPG	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	4.8	3.86e-06	0.00228	0.41	0.36	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
PCPG	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-4.8	3.86e-06	0.00228	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
PCPG	cis	rs10435719	0.764	rs10103485	ENSG00000255495.1	AC145124.2	4.8	3.86e-06	0.00228	0.37	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930054	chr8:12194467~12196280:+
PCPG	cis	rs853679	0.607	rs67998226	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28270281	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34878803	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28282402	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34396849	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28283178	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13211507	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28289600	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34691223	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28290431	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34950484	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28310911	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34661125	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28314117	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13190888	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28318208	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs67340775	ENSG00000219392.1	RP1-265C24.5	-4.8	3.86e-06	0.00228	-0.77	-0.36	Depression;	chr6:28336607	chr6:28115628~28116551:+
PCPG	cis	rs1075265	0.572	rs2193682	ENSG00000233266.1	HMGB1P31	4.8	3.86e-06	0.00228	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54051334~54051760:+
PCPG	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-4.8	3.86e-06	0.00228	-0.48	-0.36	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
PCPG	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-4.8	3.86e-06	0.00228	-0.31	-0.36	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
PCPG	cis	rs2625529	0.761	rs16956444	ENSG00000260037.4	CTD-2524L6.3	-4.8	3.87e-06	0.00229	-0.58	-0.36	Red blood cell count;	chr15:71978894	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.816	rs8025504	ENSG00000260037.4	CTD-2524L6.3	-4.8	3.87e-06	0.00229	-0.58	-0.36	Red blood cell count;	chr15:72002416	chr15:71818396~71823384:+
PCPG	cis	rs7759001	0.711	rs13217248	ENSG00000271755.1	RP1-153G14.4	4.8	3.87e-06	0.00229	0.52	0.36	Glomerular filtration rate (creatinine);	chr6:27509170	chr6:27404010~27406964:-
PCPG	cis	rs3806843	0.9	rs2262576	ENSG00000202515.1	VTRNA1-3	4.8	3.87e-06	0.00229	0.46	0.36	Depressive symptoms (multi-trait analysis);	chr5:140755951	chr5:140726158~140726246:+
PCPG	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	4.8	3.88e-06	0.00229	0.54	0.36	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
PCPG	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	4.8	3.88e-06	0.00229	0.48	0.36	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
PCPG	cis	rs5743030	0.826	rs73044269	ENSG00000253559.1	OSGEPL1-AS1	-4.8	3.88e-06	0.00229	-0.64	-0.36	Subcutaneous adipose tissue;	chr2:189925667	chr2:189762704~189765556:+
PCPG	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	4.8	3.88e-06	0.00229	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
PCPG	cis	rs720064	0.615	rs8095395	ENSG00000265752.2	RP11-403A21.1	4.8	3.88e-06	0.00229	0.41	0.36	Strep throat;	chr18:23962644	chr18:23957754~23982556:-
PCPG	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-4.79	3.88e-06	0.0023	-0.37	-0.36	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
PCPG	cis	rs11148252	0.716	rs3803262	ENSG00000278238.1	RP11-245D16.4	-4.79	3.89e-06	0.0023	-0.33	-0.36	Lewy body disease;	chr13:52462263	chr13:52454775~52455331:-
PCPG	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-4.79	3.89e-06	0.0023	-0.5	-0.36	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
PCPG	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	4.79	3.89e-06	0.0023	0.44	0.36	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
PCPG	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	4.79	3.89e-06	0.0023	0.4	0.36	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
PCPG	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	4.79	3.9e-06	0.0023	0.5	0.36	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	4.79	3.9e-06	0.0023	0.5	0.36	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	4.79	3.9e-06	0.0023	0.5	0.36	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	4.79	3.9e-06	0.0023	0.5	0.36	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-4.79	3.9e-06	0.0023	-0.5	-0.36	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
PCPG	cis	rs11148252	0.846	rs7333451	ENSG00000278238.1	RP11-245D16.4	-4.79	3.9e-06	0.0023	-0.33	-0.36	Lewy body disease;	chr13:52473574	chr13:52454775~52455331:-
PCPG	cis	rs11148252	0.846	rs9379	ENSG00000278238.1	RP11-245D16.4	-4.79	3.9e-06	0.0023	-0.33	-0.36	Lewy body disease;	chr13:52476344	chr13:52454775~52455331:-
PCPG	cis	rs916888	0.647	rs199524	ENSG00000262500.1	RP11-259G18.2	-4.79	3.9e-06	0.0023	-0.53	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.647	rs199523	ENSG00000262500.1	RP11-259G18.2	-4.79	3.9e-06	0.0023	-0.53	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46243606~46245044:+
PCPG	cis	rs10504130	0.569	rs4626585	ENSG00000272024.1	RP11-546K22.3	4.79	3.9e-06	0.0023	0.46	0.36	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51950284~51950690:+
PCPG	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	4.79	3.9e-06	0.00231	0.49	0.36	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
PCPG	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	4.79	3.91e-06	0.00231	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
PCPG	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	4.79	3.91e-06	0.00231	0.45	0.36	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
PCPG	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	4.79	3.91e-06	0.00231	0.45	0.36	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
PCPG	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-4.79	3.91e-06	0.00231	-0.33	-0.36	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
PCPG	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-4.79	3.91e-06	0.00231	-0.37	-0.36	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
PCPG	cis	rs11858159	1	rs8036695	ENSG00000259905.4	PWRN1	4.79	3.92e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24574711	chr15:24493137~24652130:+
PCPG	cis	rs7403037	0.509	rs7495212	ENSG00000259905.4	PWRN1	4.79	3.92e-06	0.00231	0.41	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24575084	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs12901453	ENSG00000259905.4	PWRN1	4.79	3.92e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24576065	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs12901154	ENSG00000259905.4	PWRN1	4.79	3.92e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24576608	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs12902959	ENSG00000259905.4	PWRN1	4.79	3.92e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24577027	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.783	rs12907560	ENSG00000259905.4	PWRN1	4.79	3.92e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24577092	chr15:24493137~24652130:+
PCPG	cis	rs7403037	1	rs12906032	ENSG00000259905.4	PWRN1	4.79	3.92e-06	0.00231	0.41	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24577241	chr15:24493137~24652130:+
PCPG	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-4.79	3.92e-06	0.00231	-0.34	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
PCPG	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	4.79	3.92e-06	0.00231	0.6	0.36	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
PCPG	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	4.79	3.92e-06	0.00231	0.44	0.36	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
PCPG	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	4.79	3.92e-06	0.00231	0.33	0.36	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
PCPG	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-4.79	3.92e-06	0.00231	-0.36	-0.36	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
PCPG	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-4.79	3.93e-06	0.00231	-0.45	-0.36	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
PCPG	cis	rs11858159	1	rs8026062	ENSG00000259905.4	PWRN1	4.79	3.93e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24537878	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs6576318	ENSG00000259905.4	PWRN1	4.79	3.93e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24538008	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs6576319	ENSG00000259905.4	PWRN1	4.79	3.93e-06	0.00231	0.41	0.36	Platelet thrombus formation;	chr15:24538014	chr15:24493137~24652130:+
PCPG	cis	rs8014204	0.604	rs11625594	ENSG00000279594.1	RP11-950C14.10	4.79	3.93e-06	0.00231	0.5	0.36	Caffeine consumption;	chr14:74923130	chr14:75011269~75012851:-
PCPG	cis	rs12130219	0.543	rs11204988	ENSG00000237975.5	FLG-AS1	4.79	3.93e-06	0.00232	0.63	0.36	Inflammatory skin disease;	chr1:152371417	chr1:152168125~152445456:+
PCPG	cis	rs3736858	0.825	rs9544047	ENSG00000261105.4	LMO7-AS1	-4.79	3.94e-06	0.00232	-0.7	-0.36	Interleukin-9 levels;	chr13:75812019	chr13:75604700~75635994:-
PCPG	cis	rs7208859	0.623	rs216434	ENSG00000263603.1	CTD-2349P21.5	-4.79	3.94e-06	0.00232	-0.61	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30729469~30731202:+
PCPG	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	4.79	3.95e-06	0.00233	0.5	0.36	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
PCPG	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	4.79	3.95e-06	0.00233	0.47	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	4.79	3.95e-06	0.00233	0.47	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	4.79	3.95e-06	0.00233	0.47	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	4.79	3.95e-06	0.00233	0.47	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
PCPG	cis	rs308097	1	rs308096	ENSG00000235944.6	ZNF815P	-4.79	3.95e-06	0.00233	-0.92	-0.36	IgG glycosylation;	chr7:5842117	chr7:5823160~5854435:+
PCPG	cis	rs5742933	0.857	rs12471217	ENSG00000273240.1	RP11-455J20.3	4.79	3.96e-06	0.00233	0.39	0.36	Ferritin levels;	chr2:189707337	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.762	rs12992061	ENSG00000273240.1	RP11-455J20.3	4.79	3.96e-06	0.00233	0.39	0.36	Ferritin levels;	chr2:189736026	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.744	rs13002216	ENSG00000273240.1	RP11-455J20.3	4.79	3.96e-06	0.00233	0.39	0.36	Ferritin levels;	chr2:189746358	chr2:189763859~189764456:-
PCPG	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	4.79	3.96e-06	0.00233	0.51	0.36	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
PCPG	cis	rs1949733	1	rs2631740	ENSG00000205959.3	RP11-689P11.2	4.79	3.96e-06	0.00233	0.41	0.36	Response to antineoplastic agents;	chr4:8482379	chr4:8482270~8512610:+
PCPG	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	4.79	3.96e-06	0.00233	0.53	0.36	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	4.79	3.96e-06	0.00233	0.53	0.36	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
PCPG	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	-4.79	3.97e-06	0.00234	-0.42	-0.36	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
PCPG	cis	rs2911132	1	rs2911140	ENSG00000248734.2	CTD-2260A17.1	4.79	3.98e-06	0.00234	0.38	0.36	Urate levels (BMI interaction);	chr5:96844240	chr5:96784777~96785999:+
PCPG	cis	rs73607972	0.935	rs4617860	ENSG00000275191.1	RP11-36I17.2	-4.79	3.98e-06	0.00234	-0.61	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53690608	chr16:53628256~53628816:-
PCPG	cis	rs73607972	0.935	rs35089292	ENSG00000275191.1	RP11-36I17.2	-4.79	3.98e-06	0.00234	-0.61	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53692910	chr16:53628256~53628816:-
PCPG	cis	rs73607972	0.935	rs73609954	ENSG00000275191.1	RP11-36I17.2	-4.79	3.98e-06	0.00234	-0.61	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53693937	chr16:53628256~53628816:-
PCPG	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-4.79	3.98e-06	0.00234	-0.46	-0.36	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
PCPG	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-4.79	3.98e-06	0.00234	-0.46	-0.36	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
PCPG	cis	rs7017914	0.87	rs1353057	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71009862	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2639960	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71009904	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs1908036	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71010089	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs1908035	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71010173	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs1908034	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71010319	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs1389206	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71012627	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2639955	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71013107	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.869	rs2639954	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71013340	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.837	rs2639952	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71013495	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732108	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71013864	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732109	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71013988	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs1493203	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71014272	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732110	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71014576	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2639951	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71014990	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732112	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71015606	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.811	rs1389204	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71016063	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732113	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71016314	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732114	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71016477	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732116	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71017092	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2956610	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71017298	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3098868	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71017457	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3098870	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71017700	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110240	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71017869	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.875	rs3098871	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71018180	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3098873	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71020351	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110241	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71020729	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110242	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71020732	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110243	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71020834	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.87	rs3098874	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71022103	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110247	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71022652	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110248	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71022700	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110249	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71023310	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3098876	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71024009	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.87	rs3098877	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71024211	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.875	rs3110251	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71024739	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110252	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71024985	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110253	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71025318	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110254	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71025627	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.87	rs3110256	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71025901	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110257	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71025916	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3098879	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71026225	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.935	rs3110258	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71026297	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.87	rs3098880	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71026686	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3098881	ENSG00000254031.4	RP11-326E22.1	4.79	3.99e-06	0.00234	0.35	0.36	Bone mineral density;	chr8:71027455	chr8:71155457~71204223:+
PCPG	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-4.79	3.99e-06	0.00235	-0.6	-0.36	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
PCPG	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-4.79	3.99e-06	0.00235	-0.41	-0.36	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-4.79	3.99e-06	0.00235	-0.41	-0.36	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
PCPG	cis	rs62246343	0.654	rs7631372	ENSG00000254485.4	RP11-380O24.1	4.79	4e-06	0.00235	0.56	0.36	Fibrinogen levels;	chr3:9451631	chr3:9292588~9363303:-
PCPG	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	4.79	4.01e-06	0.00235	0.33	0.36	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
PCPG	cis	rs7759001	0.744	rs12213598	ENSG00000271755.1	RP1-153G14.4	4.79	4.01e-06	0.00236	0.51	0.36	Glomerular filtration rate (creatinine);	chr6:27468466	chr6:27404010~27406964:-
PCPG	cis	rs4713118	0.629	rs203888	ENSG00000216901.1	AL022393.7	4.79	4.02e-06	0.00236	0.5	0.36	Parkinson's disease;	chr6:28053811	chr6:28176188~28176674:+
PCPG	cis	rs916888	0.61	rs199454	ENSG00000232300.1	FAM215B	-4.79	4.02e-06	0.00236	-0.47	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46558830~46562795:-
PCPG	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-4.79	4.02e-06	0.00236	-0.46	-0.36	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
PCPG	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	4.79	4.03e-06	0.00236	0.45	0.36	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
PCPG	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-4.79	4.03e-06	0.00236	-0.46	-0.36	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
PCPG	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-4.79	4.03e-06	0.00236	-0.46	-0.36	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
PCPG	cis	rs11858159	1	rs6576323	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24539732	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs6576324	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24539767	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs6576326	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24540053	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12908893	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24540869	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12907711	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24540888	chr15:24493137~24652130:+
PCPG	cis	rs7403037	0.527	rs58815588	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24541029	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs11161105	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24542005	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12903884	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24543447	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs12906416	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24543834	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs6576327	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24544777	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12915525	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24545723	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.871	rs12917281	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24545726	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12916887	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24545849	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12902323	ENSG00000259905.4	PWRN1	4.79	4.03e-06	0.00236	0.41	0.36	Platelet thrombus formation;	chr15:24545969	chr15:24493137~24652130:+
PCPG	cis	rs4835473	0.637	rs13110964	ENSG00000250345.2	RP11-780M14.1	-4.79	4.03e-06	0.00236	-0.41	-0.36	Immature fraction of reticulocytes;	chr4:143765119	chr4:143760399~143762093:-
PCPG	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-4.79	4.03e-06	0.00237	-0.39	-0.36	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
PCPG	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	4.79	4.03e-06	0.00237	0.61	0.36	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
PCPG	cis	rs12681963	0.688	rs4733444	ENSG00000248159.1	HSPA8P11	4.79	4.04e-06	0.00237	0.69	0.36	Migraine;	chr8:30218739	chr8:30237382~30240997:+
PCPG	cis	rs7811142	1	rs60478351	ENSG00000078319.8	PMS2P1	-4.79	4.05e-06	0.00237	-0.47	-0.36	Platelet count;	chr7:100491394	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs7787620	ENSG00000078319.8	PMS2P1	-4.79	4.05e-06	0.00237	-0.47	-0.36	Platelet count;	chr7:100491611	chr7:100320992~100341908:-
PCPG	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-4.79	4.05e-06	0.00237	-0.33	-0.36	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
PCPG	cis	rs12681963	0.688	rs1566738	ENSG00000248159.1	HSPA8P11	4.79	4.05e-06	0.00237	0.69	0.36	Migraine;	chr8:30221355	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs4733447	ENSG00000248159.1	HSPA8P11	4.79	4.05e-06	0.00237	0.69	0.36	Migraine;	chr8:30221526	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs4733451	ENSG00000248159.1	HSPA8P11	4.79	4.05e-06	0.00237	0.69	0.36	Migraine;	chr8:30221825	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.545	rs11994172	ENSG00000248159.1	HSPA8P11	4.79	4.05e-06	0.00237	0.69	0.36	Migraine;	chr8:30222043	chr8:30237382~30240997:+
PCPG	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-4.79	4.05e-06	0.00238	-0.5	-0.36	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
PCPG	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-4.79	4.05e-06	0.00238	-0.49	-0.36	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-4.79	4.05e-06	0.00238	-0.49	-0.36	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
PCPG	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	4.78	4.06e-06	0.00238	0.39	0.36	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
PCPG	cis	rs2929282	1	rs2929282	ENSG00000205771.5	CATSPER2P1	-4.78	4.07e-06	0.00238	-0.62	-0.36	Triglycerides;Triglyceride levels;	chr15:43953733	chr15:43726918~43747094:-
PCPG	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	4.78	4.07e-06	0.00238	0.45	0.36	Height;	chr6:109424139	chr6:109382795~109383666:+
PCPG	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-4.78	4.07e-06	0.00239	-0.37	-0.36	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
PCPG	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-4.78	4.07e-06	0.00239	-0.37	-0.36	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
PCPG	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	4.78	4.07e-06	0.00239	0.4	0.36	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
PCPG	cis	rs13113518	1	rs4864993	ENSG00000272969.1	RP11-528I4.2	4.78	4.08e-06	0.00239	0.4	0.36	Height;	chr4:55450662	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11133381	ENSG00000272969.1	RP11-528I4.2	4.78	4.08e-06	0.00239	0.4	0.36	Height;	chr4:55450812	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4864995	ENSG00000272969.1	RP11-528I4.2	4.78	4.08e-06	0.00239	0.4	0.36	Height;	chr4:55452853	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs12651640	ENSG00000272969.1	RP11-528I4.2	4.78	4.08e-06	0.00239	0.4	0.36	Height;	chr4:55454154	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs1554483	ENSG00000272969.1	RP11-528I4.2	4.78	4.08e-06	0.00239	0.4	0.36	Height;	chr4:55455650	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs10517346	ENSG00000272969.1	RP11-528I4.2	4.78	4.08e-06	0.00239	0.4	0.36	Height;	chr4:55457027	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs11133384	ENSG00000272969.1	RP11-528I4.2	4.78	4.08e-06	0.00239	0.4	0.36	Height;	chr4:55457086	chr4:55547112~55547889:+
PCPG	cis	rs6991838	0.702	rs7007987	ENSG00000272010.1	CTD-3025N20.3	4.78	4.08e-06	0.00239	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65700754	chr8:65591850~65592472:-
PCPG	cis	rs10435719	0.867	rs62493601	ENSG00000255495.1	AC145124.2	4.78	4.08e-06	0.00239	0.37	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11930798	chr8:12194467~12196280:+
PCPG	cis	rs7017914	0.905	rs3110246	ENSG00000254031.4	RP11-326E22.1	4.78	4.08e-06	0.00239	0.35	0.36	Bone mineral density;	chr8:71022378	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs3110250	ENSG00000254031.4	RP11-326E22.1	4.78	4.08e-06	0.00239	0.35	0.36	Bone mineral density;	chr8:71024149	chr8:71155457~71204223:+
PCPG	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	4.78	4.09e-06	0.00239	0.44	0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
PCPG	cis	rs3736858	1	rs9544053	ENSG00000261105.4	LMO7-AS1	-4.78	4.09e-06	0.00239	-0.7	-0.36	Interleukin-9 levels;	chr13:75853716	chr13:75604700~75635994:-
PCPG	cis	rs11858159	1	rs7402589	ENSG00000259905.4	PWRN1	4.78	4.09e-06	0.00239	0.42	0.36	Platelet thrombus formation;	chr15:24574029	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs12902956	ENSG00000259905.4	PWRN1	4.78	4.09e-06	0.00239	0.42	0.36	Platelet thrombus formation;	chr15:24577019	chr15:24493137~24652130:+
PCPG	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-4.78	4.1e-06	0.0024	-0.43	-0.36	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
PCPG	cis	rs9299346	0.594	rs1924031	ENSG00000225376.4	TMEM246-AS1	4.78	4.1e-06	0.0024	0.44	0.36	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101667642	chr9:101468439~101481502:+
PCPG	cis	rs11673344	0.583	rs7254411	ENSG00000226686.6	LINC01535	4.78	4.1e-06	0.0024	0.46	0.36	Obesity-related traits;	chr19:37034969	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs2891766	ENSG00000226686.6	LINC01535	4.78	4.1e-06	0.0024	0.46	0.36	Obesity-related traits;	chr19:37037057	chr19:37251912~37265535:+
PCPG	cis	rs7824557	0.591	rs2043510	ENSG00000255020.1	AF131216.5	-4.78	4.1e-06	0.0024	-0.48	-0.36	Retinal vascular caliber;	chr8:11367659	chr8:11345748~11347502:-
PCPG	cis	rs7017914	0.934	rs1389202	ENSG00000254031.4	RP11-326E22.1	4.78	4.1e-06	0.0024	0.35	0.36	Bone mineral density;	chr8:70940050	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13255735	ENSG00000254031.4	RP11-326E22.1	4.78	4.1e-06	0.0024	0.35	0.36	Bone mineral density;	chr8:70947504	chr8:71155457~71204223:+
PCPG	cis	rs1440410	0.804	rs4131029	ENSG00000250326.1	RP11-284M14.1	4.78	4.11e-06	0.0024	0.33	0.36	Ischemic stroke;	chr4:143222425	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4407450	ENSG00000250326.1	RP11-284M14.1	4.78	4.11e-06	0.0024	0.33	0.36	Ischemic stroke;	chr4:143225854	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs6828369	ENSG00000250326.1	RP11-284M14.1	4.78	4.11e-06	0.0024	0.33	0.36	Ischemic stroke;	chr4:143226331	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs13116414	ENSG00000250326.1	RP11-284M14.1	4.78	4.11e-06	0.0024	0.33	0.36	Ischemic stroke;	chr4:143226473	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs11100782	ENSG00000250326.1	RP11-284M14.1	4.78	4.11e-06	0.0024	0.33	0.36	Ischemic stroke;	chr4:143231744	chr4:142933195~143184861:-
PCPG	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-4.78	4.11e-06	0.00241	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-4.78	4.11e-06	0.00241	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
PCPG	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-4.78	4.12e-06	0.00241	-0.44	-0.36	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
PCPG	cis	rs561341	1	rs498391	ENSG00000265798.5	RP11-271K11.5	4.78	4.12e-06	0.00241	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32001685	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs501312	ENSG00000265798.5	RP11-271K11.5	4.78	4.12e-06	0.00241	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32002047	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs554078	ENSG00000265798.5	RP11-271K11.5	4.78	4.12e-06	0.00241	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32003090	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.941	rs72825736	ENSG00000265798.5	RP11-271K11.5	4.78	4.12e-06	0.00241	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32003267	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.941	rs8081016	ENSG00000265798.5	RP11-271K11.5	4.78	4.12e-06	0.00241	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32004732	chr17:31038575~31059121:-
PCPG	cis	rs7017914	0.677	rs1973364	ENSG00000254031.4	RP11-326E22.1	-4.78	4.12e-06	0.00241	-0.34	-0.36	Bone mineral density;	chr8:70955007	chr8:71155457~71204223:+
PCPG	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	4.78	4.12e-06	0.00241	0.41	0.36	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
PCPG	cis	rs4835473	0.637	rs11932061	ENSG00000250345.2	RP11-780M14.1	-4.78	4.13e-06	0.00241	-0.41	-0.36	Immature fraction of reticulocytes;	chr4:143768124	chr4:143760399~143762093:-
PCPG	cis	rs2412819	0.571	rs4923965	ENSG00000249839.1	AC011330.5	4.78	4.13e-06	0.00241	0.47	0.36	Lung cancer;	chr15:43790232	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs4644832	ENSG00000249839.1	AC011330.5	4.78	4.13e-06	0.00241	0.47	0.36	Lung cancer;	chr15:43792507	chr15:43663654~43684339:-
PCPG	cis	rs7759001	0.744	rs10946932	ENSG00000271755.1	RP1-153G14.4	4.78	4.13e-06	0.00241	0.51	0.36	Glomerular filtration rate (creatinine);	chr6:27502334	chr6:27404010~27406964:-
PCPG	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-4.78	4.13e-06	0.00241	-0.46	-0.36	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-4.78	4.13e-06	0.00241	-0.46	-0.36	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-4.78	4.13e-06	0.00241	-0.46	-0.36	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
PCPG	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-4.78	4.13e-06	0.00241	-0.46	-0.36	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
PCPG	cis	rs7208859	0.524	rs11653605	ENSG00000263603.1	CTD-2349P21.5	-4.78	4.14e-06	0.00242	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30729469~30731202:+
PCPG	cis	rs4713118	0.662	rs156744	ENSG00000216901.1	AL022393.7	4.78	4.14e-06	0.00242	0.5	0.36	Parkinson's disease;	chr6:27999496	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs149947	ENSG00000216901.1	AL022393.7	4.78	4.14e-06	0.00242	0.5	0.36	Parkinson's disease;	chr6:28004655	chr6:28176188~28176674:+
PCPG	cis	rs4143844	1	rs12917339	ENSG00000259251.2	RP11-643M14.1	4.78	4.14e-06	0.00242	0.72	0.36	Bipolar disorder and schizophrenia;	chr15:62054591	chr15:62060503~62062434:+
PCPG	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-4.78	4.15e-06	0.00242	-0.37	-0.36	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
PCPG	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-4.78	4.15e-06	0.00243	-0.38	-0.36	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
PCPG	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-4.78	4.16e-06	0.00243	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
PCPG	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	4.78	4.16e-06	0.00243	0.74	0.36	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	4.78	4.16e-06	0.00243	0.74	0.36	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	4.78	4.16e-06	0.00243	0.74	0.36	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	4.78	4.16e-06	0.00243	0.74	0.36	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	4.78	4.16e-06	0.00243	0.74	0.36	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	4.78	4.16e-06	0.00243	0.74	0.36	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
PCPG	cis	rs748404	0.666	rs12906481	ENSG00000249839.1	AC011330.5	-4.78	4.16e-06	0.00243	-0.49	-0.36	Lung cancer;	chr15:43467356	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs35958032	ENSG00000249839.1	AC011330.5	-4.78	4.16e-06	0.00243	-0.49	-0.36	Lung cancer;	chr15:43494397	chr15:43663654~43684339:-
PCPG	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	4.78	4.17e-06	0.00243	0.45	0.36	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	4.78	4.17e-06	0.00243	0.45	0.36	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	4.78	4.17e-06	0.00243	0.45	0.36	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
PCPG	cis	rs964611	0.882	rs12909148	ENSG00000259488.2	RP11-154J22.1	4.78	4.17e-06	0.00243	0.37	0.36	Metabolite levels (Pyroglutamine);	chr15:48356800	chr15:48312353~48331856:-
PCPG	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-4.78	4.17e-06	0.00243	-0.39	-0.36	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
PCPG	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-4.78	4.17e-06	0.00243	-0.39	-0.36	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
PCPG	cis	rs73607972	0.935	rs4591140	ENSG00000275191.1	RP11-36I17.2	-4.78	4.17e-06	0.00244	-0.62	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53699775	chr16:53628256~53628816:-
PCPG	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-4.78	4.18e-06	0.00244	-0.57	-0.36	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
PCPG	cis	rs13113518	1	rs4865007	ENSG00000272969.1	RP11-528I4.2	-4.78	4.18e-06	0.00244	-0.4	-0.36	Height;	chr4:55537550	chr4:55547112~55547889:+
PCPG	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-4.78	4.19e-06	0.00245	-0.45	-0.36	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
PCPG	cis	rs7688540	0.8	rs11723492	ENSG00000275426.1	CH17-262A2.1	4.78	4.19e-06	0.00245	0.43	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:149738~150317:+
PCPG	cis	rs7819412	0.749	rs2001433	ENSG00000255020.1	AF131216.5	-4.78	4.2e-06	0.00245	-0.53	-0.36	Triglycerides;	chr8:11045965	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.9	rs7167211	ENSG00000260760.1	PWRN3	4.78	4.21e-06	0.00245	0.39	0.36	Platelet thrombus formation;	chr15:24555227	chr15:24441127~24447967:+
PCPG	cis	rs5758511	0.508	rs28715885	ENSG00000205702.9	CYP2D7	4.78	4.21e-06	0.00245	0.48	0.36	Birth weight;	chr22:42045087	chr22:42140203~42144577:-
PCPG	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	4.78	4.21e-06	0.00246	0.39	0.36	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
PCPG	cis	rs12908161	1	rs35630683	ENSG00000259295.5	CSPG4P12	4.78	4.21e-06	0.00246	0.54	0.36	Schizophrenia;	chr15:84806000	chr15:85191438~85213905:+
PCPG	cis	rs35828350	1	rs35828350	ENSG00000259295.5	CSPG4P12	4.78	4.21e-06	0.00246	0.54	0.36	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:85191438~85213905:+
PCPG	cis	rs12908161	1	rs56864281	ENSG00000259295.5	CSPG4P12	4.78	4.21e-06	0.00246	0.54	0.36	Schizophrenia;	chr15:84814418	chr15:85191438~85213905:+
PCPG	cis	rs11858159	1	rs12905994	ENSG00000259905.4	PWRN1	4.78	4.22e-06	0.00246	0.41	0.36	Platelet thrombus formation;	chr15:24577169	chr15:24493137~24652130:+
PCPG	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	4.78	4.22e-06	0.00246	0.51	0.36	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
PCPG	cis	rs7688540	0.8	rs1578898	ENSG00000275426.1	CH17-262A2.1	4.78	4.23e-06	0.00247	0.43	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:149738~150317:+
PCPG	cis	rs7688540	0.76	rs7687833	ENSG00000275426.1	CH17-262A2.1	4.78	4.23e-06	0.00247	0.43	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:149738~150317:+
PCPG	cis	rs12681963	1	rs12675542	ENSG00000248159.1	HSPA8P11	-4.77	4.24e-06	0.00247	-0.57	-0.36	Migraine;	chr8:30128938	chr8:30237382~30240997:+
PCPG	cis	rs5769765	0.908	rs4074304	ENSG00000278869.1	CITF22-49E9.3	4.77	4.24e-06	0.00247	0.52	0.36	Schizophrenia;	chr22:49915798	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs9616376	ENSG00000278869.1	CITF22-49E9.3	4.77	4.24e-06	0.00247	0.52	0.36	Schizophrenia;	chr22:49917181	chr22:49933198~49934074:-
PCPG	cis	rs7017914	0.967	rs59992214	ENSG00000254031.4	RP11-326E22.1	4.77	4.24e-06	0.00247	0.36	0.36	Bone mineral density;	chr8:70687310	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.935	rs35564237	ENSG00000254031.4	RP11-326E22.1	4.77	4.24e-06	0.00247	0.36	0.36	Bone mineral density;	chr8:70688239	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs62530772	ENSG00000254031.4	RP11-326E22.1	4.77	4.24e-06	0.00247	0.36	0.36	Bone mineral density;	chr8:70689306	chr8:71155457~71204223:+
PCPG	cis	rs11148252	0.595	rs9526968	ENSG00000198384.8	TPTE2P3	-4.77	4.24e-06	0.00247	-0.46	-0.36	Lewy body disease;	chr13:52666048	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.553	rs7999849	ENSG00000198384.8	TPTE2P3	-4.77	4.24e-06	0.00247	-0.46	-0.36	Lewy body disease;	chr13:52675279	chr13:52522632~52586906:+
PCPG	cis	rs10760158	0.832	rs3810942	ENSG00000226752.6	PSMD5-AS1	-4.77	4.24e-06	0.00247	-0.47	-0.36	Pulse pressure;	chr9:121282717	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs3827678	ENSG00000226752.6	PSMD5-AS1	-4.77	4.24e-06	0.00247	-0.47	-0.36	Pulse pressure;	chr9:121284444	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs4836845	ENSG00000226752.6	PSMD5-AS1	-4.77	4.24e-06	0.00247	-0.47	-0.36	Pulse pressure;	chr9:121287678	chr9:120824828~120854385:+
PCPG	cis	rs3808502	0.527	rs4410870	ENSG00000255020.1	AF131216.5	-4.77	4.24e-06	0.00247	-0.47	-0.36	Neuroticism;	chr8:11298611	chr8:11345748~11347502:-
PCPG	cis	rs10899021	1	rs61900635	ENSG00000279353.1	RP11-864N7.4	4.77	4.25e-06	0.00247	0.67	0.36	Response to metformin (IC50);	chr11:74647965	chr11:74698231~74699658:-
PCPG	cis	rs10899021	1	rs61900636	ENSG00000279353.1	RP11-864N7.4	4.77	4.25e-06	0.00247	0.67	0.36	Response to metformin (IC50);	chr11:74648546	chr11:74698231~74699658:-
PCPG	cis	rs748404	0.666	rs7180812	ENSG00000249839.1	AC011330.5	-4.77	4.25e-06	0.00248	-0.49	-0.36	Lung cancer;	chr15:43403033	chr15:43663654~43684339:-
PCPG	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-4.77	4.25e-06	0.00248	-0.59	-0.36	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
PCPG	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-4.77	4.26e-06	0.00248	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
PCPG	cis	rs73607972	0.935	rs73605911	ENSG00000275191.1	RP11-36I17.2	-4.77	4.27e-06	0.00248	-0.62	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53597184	chr16:53628256~53628816:-
PCPG	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	4.77	4.27e-06	0.00248	0.44	0.36	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	4.77	4.27e-06	0.00248	0.44	0.36	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	4.77	4.27e-06	0.00248	0.44	0.36	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
PCPG	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-4.77	4.27e-06	0.00248	-0.45	-0.36	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
PCPG	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-4.77	4.27e-06	0.00248	-0.44	-0.36	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
PCPG	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-4.77	4.27e-06	0.00248	-0.6	-0.36	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
PCPG	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	4.77	4.27e-06	0.00249	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
PCPG	cis	rs8098244	0.603	rs1788787	ENSG00000265752.2	RP11-403A21.1	4.77	4.27e-06	0.00249	0.44	0.36	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23694775	chr18:23957754~23982556:-
PCPG	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	4.77	4.28e-06	0.00249	0.47	0.36	Height;	chr6:109415411	chr6:109382795~109383666:+
PCPG	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-4.77	4.28e-06	0.00249	-0.5	-0.36	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
PCPG	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	4.77	4.28e-06	0.00249	0.39	0.36	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
PCPG	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-4.77	4.28e-06	0.00249	-0.57	-0.36	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
PCPG	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	4.77	4.28e-06	0.00249	0.46	0.36	Height;	chr6:109352730	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	4.77	4.28e-06	0.00249	0.46	0.36	Height;	chr6:109353355	chr6:109382795~109383666:+
PCPG	cis	rs4763879	0.593	rs2080206	ENSG00000278635.1	CTD-2318O12.1	4.77	4.29e-06	0.00249	0.43	0.36	Type 1 diabetes;	chr12:9715370	chr12:9415641~9416718:+
PCPG	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	4.77	4.29e-06	0.00249	0.4	0.36	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	4.77	4.29e-06	0.00249	0.4	0.36	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	4.77	4.29e-06	0.00249	0.4	0.36	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
PCPG	cis	rs11858159	0.903	rs8026878	ENSG00000259905.4	PWRN1	4.77	4.29e-06	0.0025	0.39	0.36	Platelet thrombus formation;	chr15:24517878	chr15:24493137~24652130:+
PCPG	cis	rs17507216	0.628	rs8028130	ENSG00000228141.5	AC105339.1	-4.77	4.3e-06	0.0025	-0.56	-0.36	Excessive daytime sleepiness;	chr15:82734974	chr15:82710471~82714026:-
PCPG	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-4.77	4.3e-06	0.0025	-0.33	-0.36	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
PCPG	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-4.77	4.3e-06	0.0025	-0.57	-0.36	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
PCPG	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	4.77	4.31e-06	0.00251	0.45	0.36	Height;	chr6:109471826	chr6:109382795~109383666:+
PCPG	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-4.77	4.31e-06	0.00251	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
PCPG	cis	rs7017914	0.967	rs7814648	ENSG00000254031.4	RP11-326E22.1	4.77	4.32e-06	0.00251	0.36	0.36	Bone mineral density;	chr8:70691749	chr8:71155457~71204223:+
PCPG	cis	rs8014204	0.604	rs11159109	ENSG00000279594.1	RP11-950C14.10	4.77	4.33e-06	0.00251	0.5	0.36	Caffeine consumption;	chr14:74922371	chr14:75011269~75012851:-
PCPG	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-4.77	4.33e-06	0.00251	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
PCPG	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-4.77	4.33e-06	0.00252	-0.33	-0.36	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
PCPG	cis	rs300890	0.56	rs300929	ENSG00000250326.1	RP11-284M14.1	4.77	4.33e-06	0.00252	0.34	0.36	Nasopharyngeal carcinoma;	chr4:143272388	chr4:142933195~143184861:-
PCPG	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	4.77	4.33e-06	0.00252	0.52	0.36	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
PCPG	cis	rs561341	1	rs535151	ENSG00000265798.5	RP11-271K11.5	4.77	4.33e-06	0.00252	0.61	0.36	Hip circumference adjusted for BMI;	chr17:31990386	chr17:31038575~31059121:-
PCPG	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-4.77	4.34e-06	0.00252	-0.5	-0.36	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-4.77	4.34e-06	0.00252	-0.5	-0.36	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	4.77	4.34e-06	0.00252	0.3	0.36	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	4.77	4.34e-06	0.00252	0.3	0.36	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
PCPG	cis	rs657075	0.643	rs4646298	ENSG00000233006.5	AC034220.3	-4.77	4.34e-06	0.00252	-0.51	-0.36	Rheumatoid arthritis;	chr5:132369527	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.527	rs13180169	ENSG00000233006.5	AC034220.3	-4.77	4.34e-06	0.00252	-0.51	-0.36	Rheumatoid arthritis;	chr5:132369834	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3788987	ENSG00000233006.5	AC034220.3	-4.77	4.34e-06	0.00252	-0.51	-0.36	Rheumatoid arthritis;	chr5:132370597	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs13185655	ENSG00000233006.5	AC034220.3	-4.77	4.34e-06	0.00252	-0.51	-0.36	Rheumatoid arthritis;	chr5:132371055	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs13163451	ENSG00000233006.5	AC034220.3	-4.77	4.34e-06	0.00252	-0.51	-0.36	Rheumatoid arthritis;	chr5:132373907	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs34590412	ENSG00000233006.5	AC034220.3	-4.77	4.34e-06	0.00252	-0.51	-0.36	Rheumatoid arthritis;	chr5:132374335	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs4646302	ENSG00000233006.5	AC034220.3	-4.77	4.34e-06	0.00252	-0.51	-0.36	Rheumatoid arthritis;	chr5:132376790	chr5:132311285~132369916:-
PCPG	cis	rs7208859	0.623	rs383436	ENSG00000263603.1	CTD-2349P21.5	-4.77	4.34e-06	0.00252	-0.63	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.714	rs11650821	ENSG00000263603.1	CTD-2349P21.5	-4.77	4.34e-06	0.00252	-0.63	-0.36	Body mass index;	chr17:30641132	chr17:30729469~30731202:+
PCPG	cis	rs867371	0.656	rs2665103	ENSG00000228141.5	AC105339.1	4.77	4.35e-06	0.00252	0.45	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82710471~82714026:-
PCPG	cis	rs7811142	1	rs11769700	ENSG00000078319.8	PMS2P1	-4.77	4.35e-06	0.00252	-0.47	-0.36	Platelet count;	chr7:100492426	chr7:100320992~100341908:-
PCPG	cis	rs13108904	0.935	rs1732100	ENSG00000254094.1	AC078852.1	4.77	4.36e-06	0.00253	0.41	0.36	Obesity-related traits;	chr4:1287973	chr4:1356581~1358075:+
PCPG	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	4.77	4.36e-06	0.00253	0.47	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
PCPG	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	4.77	4.36e-06	0.00253	0.47	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
PCPG	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	4.77	4.37e-06	0.00253	0.39	0.36	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
PCPG	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	4.77	4.37e-06	0.00254	0.5	0.36	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
PCPG	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-4.77	4.38e-06	0.00254	-0.51	-0.36	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
PCPG	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-4.77	4.38e-06	0.00254	-0.51	-0.36	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
PCPG	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-4.77	4.38e-06	0.00254	-0.51	-0.36	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
PCPG	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-4.77	4.38e-06	0.00254	-0.37	-0.36	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
PCPG	cis	rs7402982	0.934	rs8028620	ENSG00000278022.1	RP11-35O15.2	-4.77	4.39e-06	0.00254	-0.37	-0.36	Birth weight;	chr15:98659646	chr15:98660210~98660668:+
PCPG	cis	rs7829975	0.511	rs2980426	ENSG00000173295.6	FAM86B3P	-4.77	4.39e-06	0.00254	-0.42	-0.36	Mood instability;	chr8:8288087	chr8:8228595~8244865:+
PCPG	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	4.77	4.39e-06	0.00254	0.45	0.36	Height;	chr6:109429207	chr6:109382795~109383666:+
PCPG	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-4.77	4.39e-06	0.00255	-0.39	-0.36	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
PCPG	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-4.77	4.4e-06	0.00255	-0.56	-0.36	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
PCPG	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	4.77	4.41e-06	0.00255	0.39	0.36	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
PCPG	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	4.77	4.41e-06	0.00255	0.63	0.36	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
PCPG	cis	rs7017914	0.967	rs12675271	ENSG00000254031.4	RP11-326E22.1	4.77	4.41e-06	0.00256	0.36	0.36	Bone mineral density;	chr8:70689774	chr8:71155457~71204223:+
PCPG	cis	rs964611	0.748	rs61248772	ENSG00000259488.2	RP11-154J22.1	-4.77	4.42e-06	0.00256	-0.4	-0.36	Metabolite levels (Pyroglutamine);	chr15:48306529	chr15:48312353~48331856:-
PCPG	cis	rs964611	1	rs7168752	ENSG00000259488.2	RP11-154J22.1	-4.77	4.42e-06	0.00256	-0.4	-0.36	Metabolite levels (Pyroglutamine);	chr15:48308583	chr15:48312353~48331856:-
PCPG	cis	rs964611	1	rs79040993	ENSG00000259488.2	RP11-154J22.1	-4.77	4.42e-06	0.00256	-0.4	-0.36	Metabolite levels (Pyroglutamine);	chr15:48309949	chr15:48312353~48331856:-
PCPG	cis	rs4143844	1	rs62007454	ENSG00000259251.2	RP11-643M14.1	4.76	4.42e-06	0.00256	0.72	0.36	Bipolar disorder and schizophrenia;	chr15:62062496	chr15:62060503~62062434:+
PCPG	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	4.76	4.43e-06	0.00256	0.39	0.36	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
PCPG	cis	rs7246657	0.943	rs10415024	ENSG00000226686.6	LINC01535	-4.76	4.44e-06	0.00257	-0.6	-0.36	Coronary artery calcification;	chr19:37323822	chr19:37251912~37265535:+
PCPG	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	4.76	4.44e-06	0.00257	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
PCPG	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	4.76	4.44e-06	0.00257	0.41	0.36	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	4.76	4.44e-06	0.00257	0.41	0.36	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	4.76	4.44e-06	0.00257	0.41	0.36	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	4.76	4.44e-06	0.00257	0.41	0.36	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	4.76	4.44e-06	0.00257	0.41	0.36	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	4.76	4.44e-06	0.00257	0.41	0.36	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
PCPG	cis	rs12681963	0.688	rs1566741	ENSG00000248159.1	HSPA8P11	4.76	4.44e-06	0.00257	0.69	0.36	Migraine;	chr8:30220913	chr8:30237382~30240997:+
PCPG	cis	rs11673344	0.523	rs2082010	ENSG00000226686.6	LINC01535	4.76	4.44e-06	0.00257	0.46	0.36	Obesity-related traits;	chr19:37039874	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs7256380	ENSG00000226686.6	LINC01535	4.76	4.44e-06	0.00257	0.46	0.36	Obesity-related traits;	chr19:37041178	chr19:37251912~37265535:+
PCPG	cis	rs13113518	0.557	rs13142096	ENSG00000272969.1	RP11-528I4.2	4.76	4.44e-06	0.00257	0.41	0.36	Height;	chr4:55566291	chr4:55547112~55547889:+
PCPG	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-4.76	4.44e-06	0.00257	-0.54	-0.36	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
PCPG	cis	rs6957923	1	rs4304239	ENSG00000230658.1	KLHL7-AS1	4.76	4.45e-06	0.00257	0.43	0.36	Height;	chr7:23456342	chr7:23101228~23105703:-
PCPG	cis	rs964611	1	rs16960758	ENSG00000259488.2	RP11-154J22.1	-4.76	4.45e-06	0.00257	-0.37	-0.36	Metabolite levels (Pyroglutamine);	chr15:48314955	chr15:48312353~48331856:-
PCPG	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-4.76	4.46e-06	0.00258	-0.46	-0.36	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
PCPG	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	4.76	4.48e-06	0.00259	0.41	0.36	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
PCPG	cis	rs9595908	0.709	rs55797910	ENSG00000212293.1	SNORA16	4.76	4.49e-06	0.00259	0.44	0.36	Body mass index;	chr13:32787154	chr13:32420390~32420516:-
PCPG	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	4.76	4.49e-06	0.00259	0.44	0.36	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
PCPG	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	-4.76	4.49e-06	0.00259	-0.42	-0.36	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
PCPG	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	4.76	4.49e-06	0.0026	0.57	0.36	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
PCPG	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-4.76	4.5e-06	0.0026	-0.5	-0.36	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-4.76	4.5e-06	0.0026	-0.5	-0.36	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
PCPG	cis	rs8044188	1	rs6497627	ENSG00000261090.1	RP11-20G6.2	4.76	4.5e-06	0.0026	0.57	0.36	Multiple system atrophy;	chr16:23025084	chr16:23020337~23023611:+
PCPG	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-4.76	4.5e-06	0.0026	-0.4	-0.36	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-4.76	4.5e-06	0.0026	-0.4	-0.36	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-4.76	4.5e-06	0.0026	-0.4	-0.36	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
PCPG	cis	rs7829975	0.774	rs57312668	ENSG00000173295.6	FAM86B3P	-4.76	4.51e-06	0.0026	-0.44	-0.36	Mood instability;	chr8:8822967	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.744	rs2409092	ENSG00000173295.6	FAM86B3P	-4.76	4.51e-06	0.0026	-0.44	-0.36	Mood instability;	chr8:8824682	chr8:8228595~8244865:+
PCPG	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	4.76	4.52e-06	0.00261	0.47	0.36	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
PCPG	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-4.76	4.52e-06	0.00261	-0.3	-0.36	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
PCPG	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	4.76	4.52e-06	0.00261	0.51	0.36	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
PCPG	cis	rs7824557	1	rs7824557	ENSG00000255020.1	AF131216.5	-4.76	4.52e-06	0.00261	-0.47	-0.36	Retinal vascular caliber;	chr8:11246602	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.549	rs28887839	ENSG00000255020.1	AF131216.5	-4.76	4.52e-06	0.00261	-0.52	-0.36	Triglycerides;	chr8:11142903	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.966	rs11852561	ENSG00000259905.4	PWRN1	4.76	4.52e-06	0.00261	0.41	0.36	Platelet thrombus formation;	chr15:24560231	chr15:24493137~24652130:+
PCPG	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	4.76	4.52e-06	0.00261	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
PCPG	cis	rs13113518	1	rs4864994	ENSG00000272969.1	RP11-528I4.2	4.76	4.53e-06	0.00261	0.4	0.36	Height;	chr4:55451955	chr4:55547112~55547889:+
PCPG	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	4.76	4.53e-06	0.00261	0.48	0.36	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
PCPG	cis	rs2911132	0.564	rs731827	ENSG00000248734.2	CTD-2260A17.1	4.76	4.53e-06	0.00262	0.39	0.36	Urate levels (BMI interaction);	chr5:96751311	chr5:96784777~96785999:+
PCPG	cis	rs28386778	0.769	rs6504179	ENSG00000240280.5	TCAM1P	-4.76	4.53e-06	0.00262	-0.5	-0.36	Prudent dietary pattern;	chr17:63735635	chr17:63849292~63864379:+
PCPG	cis	rs7759001	0.744	rs7771590	ENSG00000271755.1	RP1-153G14.4	4.76	4.53e-06	0.00262	0.52	0.36	Glomerular filtration rate (creatinine);	chr6:27500117	chr6:27404010~27406964:-
PCPG	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-4.76	4.55e-06	0.00262	-0.43	-0.36	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
PCPG	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-4.76	4.55e-06	0.00262	-0.32	-0.36	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-4.76	4.55e-06	0.00262	-0.32	-0.36	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-4.76	4.55e-06	0.00262	-0.32	-0.36	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-4.76	4.55e-06	0.00262	-0.32	-0.36	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-4.76	4.55e-06	0.00262	-0.32	-0.36	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
PCPG	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	4.76	4.55e-06	0.00263	0.55	0.36	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
PCPG	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	4.76	4.56e-06	0.00263	0.56	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
PCPG	cis	rs7017914	0.967	rs6987007	ENSG00000254031.4	RP11-326E22.1	4.76	4.56e-06	0.00263	0.36	0.36	Bone mineral density;	chr8:70688707	chr8:71155457~71204223:+
PCPG	cis	rs6762	0.719	rs1130698	ENSG00000279672.1	CMB9-55F22.1	4.76	4.56e-06	0.00263	0.41	0.36	Mean platelet volume;	chr11:838542	chr11:779617~780755:+
PCPG	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	4.76	4.56e-06	0.00263	0.45	0.36	Height;	chr6:109340338	chr6:109382795~109383666:+
PCPG	cis	rs7208859	0.524	rs60114476	ENSG00000263603.1	CTD-2349P21.5	-4.76	4.57e-06	0.00263	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30729469~30731202:+
PCPG	cis	rs7849270	0.918	rs746873	ENSG00000268707.1	RP11-247A12.7	4.76	4.57e-06	0.00263	0.4	0.36	Blood metabolite ratios;	chr9:129102671	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs746872	ENSG00000268707.1	RP11-247A12.7	4.76	4.57e-06	0.00263	0.4	0.36	Blood metabolite ratios;	chr9:129102748	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs3124498	ENSG00000268707.1	RP11-247A12.7	4.76	4.57e-06	0.00263	0.4	0.36	Blood metabolite ratios;	chr9:129103214	chr9:129170434~129170940:+
PCPG	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	4.76	4.57e-06	0.00263	0.58	0.36	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
PCPG	cis	rs11671005	0.569	rs73068335	ENSG00000269600.1	AC016629.3	-4.76	4.57e-06	0.00264	-0.58	-0.36	Mean platelet volume;	chr19:58577941	chr19:58593896~58599355:-
PCPG	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-4.76	4.57e-06	0.00264	-0.54	-0.36	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
PCPG	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-4.76	4.57e-06	0.00264	-0.36	-0.36	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
PCPG	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	4.76	4.58e-06	0.00264	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	4.76	4.58e-06	0.00264	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
PCPG	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-4.76	4.58e-06	0.00264	-0.44	-0.36	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-4.76	4.58e-06	0.00264	-0.44	-0.36	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-4.76	4.58e-06	0.00264	-0.44	-0.36	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-4.76	4.58e-06	0.00264	-0.44	-0.36	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
PCPG	cis	rs2736345	1	rs2736345	ENSG00000255020.1	AF131216.5	4.76	4.58e-06	0.00264	0.48	0.36	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494976	chr8:11345748~11347502:-
PCPG	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-4.76	4.59e-06	0.00264	-0.49	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
PCPG	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	4.76	4.59e-06	0.00265	0.57	0.36	Depression;	chr6:28253486	chr6:28115628~28116551:+
PCPG	cis	rs853679	1	rs1679709	ENSG00000219392.1	RP1-265C24.5	4.76	4.59e-06	0.00265	0.57	0.36	Depression;	chr6:28260564	chr6:28115628~28116551:+
PCPG	cis	rs853679	1	rs1778511	ENSG00000219392.1	RP1-265C24.5	4.76	4.59e-06	0.00265	0.57	0.36	Depression;	chr6:28261633	chr6:28115628~28116551:+
PCPG	cis	rs853679	1	rs1778508	ENSG00000219392.1	RP1-265C24.5	4.76	4.59e-06	0.00265	0.57	0.36	Depression;	chr6:28262103	chr6:28115628~28116551:+
PCPG	cis	rs853679	1	rs2799077	ENSG00000219392.1	RP1-265C24.5	-4.76	4.59e-06	0.00265	-0.57	-0.36	Depression;	chr6:28266819	chr6:28115628~28116551:+
PCPG	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-4.76	4.6e-06	0.00265	-0.36	-0.36	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
PCPG	cis	rs10760158	0.832	rs4837820	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121247816	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs4837821	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121248241	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10760164	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121248884	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.8	rs4837823	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121249733	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10818519	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121250657	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs4837825	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121253136	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10985192	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121254162	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.8	rs10818520	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121256395	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10818522	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121256732	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10513365	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121258647	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.768	rs2149805	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121259221	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs4837826	ENSG00000226752.6	PSMD5-AS1	-4.76	4.6e-06	0.00265	-0.47	-0.36	Pulse pressure;	chr9:121261851	chr9:120824828~120854385:+
PCPG	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	4.76	4.6e-06	0.00265	0.39	0.36	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
PCPG	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	4.76	4.6e-06	0.00265	0.45	0.36	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
PCPG	cis	rs3808502	0.527	rs2736389	ENSG00000255020.1	AF131216.5	4.76	4.61e-06	0.00266	0.5	0.36	Neuroticism;	chr8:11303801	chr8:11345748~11347502:-
PCPG	cis	rs748404	0.626	rs57938858	ENSG00000205771.5	CATSPER2P1	-4.75	4.62e-06	0.00266	-0.46	-0.36	Lung cancer;	chr15:43520259	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.589	rs3862138	ENSG00000205771.5	CATSPER2P1	-4.75	4.62e-06	0.00266	-0.46	-0.36	Lung cancer;	chr15:43523801	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.589	rs62020612	ENSG00000205771.5	CATSPER2P1	-4.75	4.62e-06	0.00266	-0.46	-0.36	Lung cancer;	chr15:43525881	chr15:43726918~43747094:-
PCPG	cis	rs3764021	0.87	rs10743819	ENSG00000278635.1	CTD-2318O12.1	-4.75	4.63e-06	0.00266	-0.43	-0.36	Type 1 diabetes;	chr12:9724172	chr12:9415641~9416718:+
PCPG	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	4.75	4.63e-06	0.00266	0.51	0.36	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
PCPG	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	4.75	4.63e-06	0.00266	0.5	0.36	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
PCPG	cis	rs7829975	1	rs7829975	ENSG00000173295.6	FAM86B3P	4.75	4.63e-06	0.00266	0.43	0.36	Mood instability;	chr8:8690607	chr8:8228595~8244865:+
PCPG	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	4.75	4.63e-06	0.00266	0.55	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
PCPG	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-4.75	4.63e-06	0.00267	-0.46	-0.36	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
PCPG	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	4.75	4.63e-06	0.00267	0.5	0.36	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	4.75	4.63e-06	0.00267	0.5	0.36	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	4.75	4.63e-06	0.00267	0.5	0.36	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	4.75	4.63e-06	0.00267	0.5	0.36	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	4.75	4.63e-06	0.00267	0.5	0.36	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
PCPG	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	4.75	4.64e-06	0.00267	0.48	0.36	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
PCPG	cis	rs7208859	0.623	rs28556733	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.5	rs28452421	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Body mass index;	chr17:30756962	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs28433704	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs28779471	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11658022	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.5	rs61685770	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Body mass index;	chr17:30758695	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs57486336	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs55764512	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Body mass index;	chr17:30758740	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.524	rs73988172	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs12103440	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs12103508	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11657777	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7217984	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73269916	ENSG00000263603.1	CTD-2349P21.5	-4.75	4.64e-06	0.00267	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30729469~30731202:+
PCPG	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-4.75	4.64e-06	0.00267	-0.5	-0.36	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
PCPG	cis	rs752864	0.934	rs8028033	ENSG00000259438.1	CTD-2650P22.1	4.75	4.65e-06	0.00267	0.44	0.36	Number of common colds;	chr15:52356919	chr15:52010999~52019095:-
PCPG	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-4.75	4.65e-06	0.00267	-0.49	-0.36	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
PCPG	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	4.75	4.65e-06	0.00267	0.47	0.36	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	4.75	4.65e-06	0.00267	0.47	0.36	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
PCPG	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-4.75	4.66e-06	0.00268	-0.52	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
PCPG	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-4.75	4.66e-06	0.00268	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-4.75	4.66e-06	0.00268	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
PCPG	cis	rs17507216	0.628	rs17158396	ENSG00000228141.5	AC105339.1	-4.75	4.67e-06	0.00268	-0.54	-0.36	Excessive daytime sleepiness;	chr15:82615688	chr15:82710471~82714026:-
PCPG	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	4.75	4.69e-06	0.00269	0.33	0.36	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
PCPG	cis	rs17507216	0.588	rs28864981	ENSG00000228141.5	AC105339.1	-4.75	4.7e-06	0.0027	-0.55	-0.36	Excessive daytime sleepiness;	chr15:82695420	chr15:82710471~82714026:-
PCPG	cis	rs17507216	0.628	rs8032321	ENSG00000228141.5	AC105339.1	-4.75	4.7e-06	0.0027	-0.55	-0.36	Excessive daytime sleepiness;	chr15:82698956	chr15:82710471~82714026:-
PCPG	cis	rs17507216	0.628	rs8040488	ENSG00000228141.5	AC105339.1	-4.75	4.7e-06	0.0027	-0.55	-0.36	Excessive daytime sleepiness;	chr15:82699081	chr15:82710471~82714026:-
PCPG	cis	rs17507216	0.628	rs4627310	ENSG00000228141.5	AC105339.1	-4.75	4.7e-06	0.0027	-0.55	-0.36	Excessive daytime sleepiness;	chr15:82708330	chr15:82710471~82714026:-
PCPG	cis	rs17507216	0.628	rs4513065	ENSG00000228141.5	AC105339.1	-4.75	4.7e-06	0.0027	-0.55	-0.36	Excessive daytime sleepiness;	chr15:82712096	chr15:82710471~82714026:-
PCPG	cis	rs17507216	0.628	rs28371837	ENSG00000228141.5	AC105339.1	-4.75	4.7e-06	0.0027	-0.55	-0.36	Excessive daytime sleepiness;	chr15:82714435	chr15:82710471~82714026:-
PCPG	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-4.75	4.7e-06	0.0027	-0.54	-0.36	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-4.75	4.7e-06	0.0027	-0.54	-0.36	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-4.75	4.7e-06	0.0027	-0.54	-0.36	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
PCPG	cis	rs7182621	0.546	rs11632596	ENSG00000182397.13	DNM1P46	4.75	4.7e-06	0.0027	0.53	0.36	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99790156~99806927:-
PCPG	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	4.75	4.71e-06	0.0027	0.46	0.36	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
PCPG	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-4.75	4.71e-06	0.0027	-0.36	-0.36	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
PCPG	cis	rs7824557	0.592	rs2572371	ENSG00000255020.1	AF131216.5	4.75	4.71e-06	0.0027	0.48	0.36	Retinal vascular caliber;	chr8:11366284	chr8:11345748~11347502:-
PCPG	cis	rs7017914	0.667	rs2639925	ENSG00000254031.4	RP11-326E22.1	4.75	4.72e-06	0.00271	0.35	0.36	Bone mineral density;	chr8:70991937	chr8:71155457~71204223:+
PCPG	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	4.75	4.73e-06	0.00271	0.44	0.36	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	4.75	4.73e-06	0.00271	0.44	0.36	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	4.75	4.73e-06	0.00271	0.44	0.36	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	4.75	4.73e-06	0.00271	0.44	0.36	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
PCPG	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	4.75	4.73e-06	0.00271	0.44	0.36	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
PCPG	cis	rs2625529	0.761	rs972028	ENSG00000260037.4	CTD-2524L6.3	-4.75	4.74e-06	0.00272	-0.55	-0.36	Red blood cell count;	chr15:71880751	chr15:71818396~71823384:+
PCPG	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	4.75	4.75e-06	0.00272	0.42	0.36	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
PCPG	cis	rs9911578	0.967	rs8082544	ENSG00000267416.1	CTD-2319I12.2	-4.75	4.75e-06	0.00272	-0.38	-0.36	Intelligence (multi-trait analysis);	chr17:59108446	chr17:60079309~60088695:+
PCPG	cis	rs7819412	0.875	rs11250121	ENSG00000255020.1	AF131216.5	-4.75	4.76e-06	0.00272	-0.49	-0.36	Triglycerides;	chr8:11202802	chr8:11345748~11347502:-
PCPG	cis	rs7403037	0.509	rs7164560	ENSG00000259905.4	PWRN1	4.75	4.76e-06	0.00272	0.41	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24566509	chr15:24493137~24652130:+
PCPG	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	4.75	4.76e-06	0.00273	0.42	0.36	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
PCPG	cis	rs73607972	0.866	rs16952362	ENSG00000275191.1	RP11-36I17.2	-4.75	4.76e-06	0.00273	-0.64	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53603976	chr16:53628256~53628816:-
PCPG	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	4.75	4.76e-06	0.00273	0.46	0.36	Height;	chr6:109613205	chr6:109382795~109383666:+
PCPG	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	4.75	4.76e-06	0.00273	0.47	0.36	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
PCPG	cis	rs12130219	0.588	rs2282302	ENSG00000237975.5	FLG-AS1	4.75	4.78e-06	0.00273	0.62	0.36	Inflammatory skin disease;	chr1:152356893	chr1:152168125~152445456:+
PCPG	cis	rs2836974	0.583	rs8132993	ENSG00000255568.3	BRWD1-AS2	4.75	4.78e-06	0.00274	0.37	0.36	Cognitive function;	chr21:39344484	chr21:39313935~39314962:+
PCPG	cis	rs6991838	0.806	rs11781358	ENSG00000200714.1	Y_RNA	4.75	4.78e-06	0.00274	0.48	0.36	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65592731~65592820:+
PCPG	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-4.75	4.78e-06	0.00274	-0.44	-0.36	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
PCPG	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-4.75	4.79e-06	0.00274	-0.46	-0.36	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
PCPG	cis	rs9299346	0.594	rs10114009	ENSG00000225376.4	TMEM246-AS1	4.75	4.79e-06	0.00274	0.44	0.36	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101661672	chr9:101468439~101481502:+
PCPG	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	4.75	4.8e-06	0.00275	0.37	0.36	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
PCPG	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	4.75	4.81e-06	0.00275	0.43	0.36	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
PCPG	cis	rs11168351	1	rs11168351	ENSG00000240399.1	RP1-228P16.1	4.75	4.81e-06	0.00275	0.37	0.36	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48054813~48055591:-
PCPG	cis	rs11640439	0.892	rs12932277	ENSG00000260038.1	RP11-407G23.4	-4.75	4.81e-06	0.00275	-0.7	-0.36	Sleep duration;	chr16:57264753	chr16:57247350~57248492:+
PCPG	cis	rs7017914	0.905	rs2732115	ENSG00000254031.4	RP11-326E22.1	4.75	4.81e-06	0.00275	0.35	0.36	Bone mineral density;	chr8:71016619	chr8:71155457~71204223:+
PCPG	cis	rs11673344	0.523	rs7245520	ENSG00000226686.6	LINC01535	4.74	4.82e-06	0.00276	0.46	0.36	Obesity-related traits;	chr19:37036416	chr19:37251912~37265535:+
PCPG	cis	rs748404	0.666	rs7183708	ENSG00000249839.1	AC011330.5	-4.74	4.82e-06	0.00276	-0.46	-0.36	Lung cancer;	chr15:43355226	chr15:43663654~43684339:-
PCPG	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	4.74	4.83e-06	0.00276	0.51	0.36	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
PCPG	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.83e-06	0.00276	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
PCPG	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	4.74	4.83e-06	0.00276	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
PCPG	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	4.74	4.85e-06	0.00277	0.5	0.36	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
PCPG	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	4.74	4.85e-06	0.00277	0.5	0.36	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
PCPG	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-4.74	4.85e-06	0.00277	-0.58	-0.36	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
PCPG	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	4.74	4.85e-06	0.00277	0.58	0.36	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
PCPG	cis	rs7824557	0.806	rs7007394	ENSG00000255020.1	AF131216.5	-4.74	4.86e-06	0.00277	-0.48	-0.36	Retinal vascular caliber;	chr8:11237057	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.806	rs6601573	ENSG00000255020.1	AF131216.5	-4.74	4.86e-06	0.00277	-0.48	-0.36	Retinal vascular caliber;	chr8:11237242	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.806	rs6601574	ENSG00000255020.1	AF131216.5	-4.74	4.86e-06	0.00277	-0.48	-0.36	Retinal vascular caliber;	chr8:11237376	chr8:11345748~11347502:-
PCPG	cis	rs2734839	0.964	rs12808482	ENSG00000270179.1	RP11-159N11.4	-4.74	4.86e-06	0.00278	-0.38	-0.36	Information processing speed;	chr11:113424276	chr11:113368478~113369117:+
PCPG	cis	rs2734839	0.964	rs1076563	ENSG00000270179.1	RP11-159N11.4	-4.74	4.86e-06	0.00278	-0.38	-0.36	Information processing speed;	chr11:113425187	chr11:113368478~113369117:+
PCPG	cis	rs2734839	0.964	rs1116313	ENSG00000270179.1	RP11-159N11.4	-4.74	4.86e-06	0.00278	-0.38	-0.36	Information processing speed;	chr11:113425385	chr11:113368478~113369117:+
PCPG	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	4.74	4.86e-06	0.00278	0.5	0.36	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
PCPG	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	4.74	4.86e-06	0.00278	0.6	0.36	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
PCPG	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	4.74	4.86e-06	0.00278	0.33	0.36	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
PCPG	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	-4.74	4.86e-06	0.00278	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
PCPG	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-4.74	4.87e-06	0.00278	-0.48	-0.36	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
PCPG	cis	rs657075	0.697	rs34689843	ENSG00000233006.5	AC034220.3	-4.74	4.87e-06	0.00278	-0.51	-0.36	Rheumatoid arthritis;	chr5:132349563	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583477	ENSG00000233006.5	AC034220.3	-4.74	4.87e-06	0.00278	-0.51	-0.36	Rheumatoid arthritis;	chr5:132350347	chr5:132311285~132369916:-
PCPG	cis	rs308097	0.609	rs10951965	ENSG00000235944.6	ZNF815P	4.74	4.87e-06	0.00278	0.78	0.36	IgG glycosylation;	chr7:5805738	chr7:5823160~5854435:+
PCPG	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	4.74	4.88e-06	0.00279	0.5	0.36	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	4.74	4.88e-06	0.00279	0.5	0.36	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
PCPG	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	4.74	4.88e-06	0.00279	0.5	0.36	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
PCPG	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	4.74	4.9e-06	0.00279	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
PCPG	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-4.74	4.9e-06	0.00279	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
PCPG	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	4.74	4.9e-06	0.0028	0.44	0.36	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
PCPG	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-4.74	4.91e-06	0.0028	-0.43	-0.36	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-4.74	4.91e-06	0.0028	-0.43	-0.36	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-4.74	4.91e-06	0.0028	-0.43	-0.36	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
PCPG	cis	rs1048886	0.808	rs113870111	ENSG00000271967.1	RP11-134K13.4	-4.74	4.91e-06	0.0028	-0.44	-0.36	Type 2 diabetes;	chr6:70445856	chr6:70596438~70596980:+
PCPG	cis	rs9649213	0.593	rs7812180	ENSG00000272950.1	RP11-307C18.1	-4.74	4.92e-06	0.0028	-0.46	-0.36	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr7:98322853~98323430:+
PCPG	cis	rs2898290	0.622	rs1382567	ENSG00000269954.1	RP11-148O21.6	-4.74	4.92e-06	0.0028	-0.4	-0.36	Systolic blood pressure;	chr8:11493390	chr8:11552488~11552991:-
PCPG	cis	rs9650657	0.53	rs6982381	ENSG00000255020.1	AF131216.5	-4.74	4.92e-06	0.00281	-0.51	-0.36	Neuroticism;	chr8:11094990	chr8:11345748~11347502:-
PCPG	cis	rs7246657	0.943	rs6508732	ENSG00000226686.6	LINC01535	-4.74	4.92e-06	0.00281	-0.54	-0.36	Coronary artery calcification;	chr19:37509566	chr19:37251912~37265535:+
PCPG	cis	rs11858159	1	rs3901472	ENSG00000259905.4	PWRN1	4.74	4.93e-06	0.00281	0.41	0.36	Platelet thrombus formation;	chr15:24569435	chr15:24493137~24652130:+
PCPG	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	4.74	4.93e-06	0.00281	0.45	0.36	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
PCPG	cis	rs17772222	0.958	rs2297128	ENSG00000222990.1	RNU4-22P	4.74	4.93e-06	0.00281	0.48	0.36	Coronary artery calcification;	chr14:88469910	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.837	rs1864748	ENSG00000222990.1	RNU4-22P	4.74	4.93e-06	0.00281	0.48	0.36	Coronary artery calcification;	chr14:88488847	chr14:88513498~88513663:+
PCPG	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	4.74	4.93e-06	0.00281	0.54	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
PCPG	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	4.74	4.93e-06	0.00281	0.54	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
PCPG	cis	rs2625529	0.938	rs2625530	ENSG00000260037.4	CTD-2524L6.3	-4.74	4.94e-06	0.00281	-0.58	-0.36	Red blood cell count;	chr15:71833693	chr15:71818396~71823384:+
PCPG	cis	rs2898290	0.694	rs2248909	ENSG00000255020.1	AF131216.5	-4.74	4.94e-06	0.00281	-0.46	-0.36	Systolic blood pressure;	chr8:11534584	chr8:11345748~11347502:-
PCPG	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
PCPG	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-4.74	4.94e-06	0.00281	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
PCPG	cis	rs1440410	0.795	rs9308169	ENSG00000250326.1	RP11-284M14.1	-4.74	4.94e-06	0.00281	-0.33	-0.36	Ischemic stroke;	chr4:143263590	chr4:142933195~143184861:-
PCPG	cis	rs7250849	0.688	rs78019331	ENSG00000273837.1	LLNLR-470E3.1	-4.74	4.94e-06	0.00281	-0.56	-0.36	Blood protein levels;	chr19:51658484	chr19:51639478~51639931:-
PCPG	cis	rs28386778	0.897	rs2665832	ENSG00000240280.5	TCAM1P	-4.74	4.95e-06	0.00282	-0.49	-0.36	Prudent dietary pattern;	chr17:63834901	chr17:63849292~63864379:+
PCPG	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	4.74	4.95e-06	0.00282	0.37	0.36	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
PCPG	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	4.74	4.96e-06	0.00282	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
PCPG	cis	rs561341	1	rs55736640	ENSG00000265798.5	RP11-271K11.5	4.74	4.97e-06	0.00283	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32006829	chr17:31038575~31059121:-
PCPG	cis	rs13108904	0.935	rs1680072	ENSG00000254094.1	AC078852.1	4.74	4.97e-06	0.00283	0.41	0.36	Obesity-related traits;	chr4:1287907	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.935	rs922698	ENSG00000254094.1	AC078852.1	4.74	4.97e-06	0.00283	0.41	0.36	Obesity-related traits;	chr4:1288934	chr4:1356581~1358075:+
PCPG	cis	rs7714584	1	rs59043558	ENSG00000271795.1	CTC-251D13.1	-4.74	4.97e-06	0.00283	-0.73	-0.36	Crohn's disease;	chr5:150955100	chr5:151509453~151512769:+
PCPG	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	4.74	4.97e-06	0.00283	0.5	0.36	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
PCPG	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	4.74	4.98e-06	0.00283	0.46	0.36	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
PCPG	cis	rs10760158	0.769	rs7870797	ENSG00000226752.6	PSMD5-AS1	-4.74	4.99e-06	0.00283	-0.46	-0.36	Pulse pressure;	chr9:121298144	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10760172	ENSG00000226752.6	PSMD5-AS1	-4.74	4.99e-06	0.00283	-0.46	-0.36	Pulse pressure;	chr9:121299624	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs4836848	ENSG00000226752.6	PSMD5-AS1	-4.74	4.99e-06	0.00283	-0.46	-0.36	Pulse pressure;	chr9:121301074	chr9:120824828~120854385:+
PCPG	cis	rs28386778	0.863	rs6919	ENSG00000240280.5	TCAM1P	4.74	4.99e-06	0.00284	0.48	0.36	Prudent dietary pattern;	chr17:63832125	chr17:63849292~63864379:+
PCPG	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	4.74	5e-06	0.00284	0.44	0.36	Height;	chr6:109332622	chr6:109382795~109383666:+
PCPG	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	4.74	5e-06	0.00284	0.44	0.36	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
PCPG	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	4.74	5e-06	0.00284	0.5	0.36	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
PCPG	cis	rs9494145	0.59	rs9376090	ENSG00000232876.1	CTA-212D2.2	-4.74	5.01e-06	0.00285	-0.47	-0.36	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135090090	chr6:135055033~135060550:+
PCPG	cis	rs561341	0.882	rs563539	ENSG00000265798.5	RP11-271K11.5	4.74	5.01e-06	0.00285	0.63	0.36	Hip circumference adjusted for BMI;	chr17:31980939	chr17:31038575~31059121:-
PCPG	cis	rs11673344	0.503	rs10414520	ENSG00000226686.6	LINC01535	4.74	5.02e-06	0.00285	0.46	0.36	Obesity-related traits;	chr19:37057279	chr19:37251912~37265535:+
PCPG	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	4.74	5.02e-06	0.00285	0.3	0.36	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
PCPG	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	4.74	5.03e-06	0.00285	0.34	0.36	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
PCPG	cis	rs301901	0.861	rs217797	ENSG00000250155.1	CTD-2353F22.1	-4.74	5.03e-06	0.00286	-0.43	-0.36	Height;	chr5:37318193	chr5:36666214~36725195:-
PCPG	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-4.74	5.03e-06	0.00286	-0.37	-0.36	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
PCPG	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	4.73	5.03e-06	0.00286	0.48	0.36	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
PCPG	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	4.73	5.03e-06	0.00286	0.33	0.36	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	4.73	5.03e-06	0.00286	0.33	0.36	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	4.73	5.03e-06	0.00286	0.33	0.36	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	4.73	5.03e-06	0.00286	0.33	0.36	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	4.73	5.03e-06	0.00286	0.33	0.36	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	4.73	5.03e-06	0.00286	0.33	0.36	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	4.73	5.03e-06	0.00286	0.33	0.36	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
PCPG	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	4.73	5.03e-06	0.00286	0.41	0.36	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
PCPG	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-4.73	5.03e-06	0.00286	-0.51	-0.36	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
PCPG	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	4.73	5.03e-06	0.00286	0.5	0.36	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
PCPG	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	4.73	5.05e-06	0.00286	0.56	0.36	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	4.73	5.05e-06	0.00286	0.56	0.36	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	4.73	5.05e-06	0.00286	0.56	0.36	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
PCPG	cis	rs5742933	0.744	rs12693557	ENSG00000273240.1	RP11-455J20.3	4.73	5.05e-06	0.00286	0.38	0.36	Ferritin levels;	chr2:189726211	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.817	rs13035966	ENSG00000273240.1	RP11-455J20.3	4.73	5.05e-06	0.00286	0.38	0.36	Ferritin levels;	chr2:189726507	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.762	rs2033746	ENSG00000273240.1	RP11-455J20.3	4.73	5.05e-06	0.00286	0.38	0.36	Ferritin levels;	chr2:189734726	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.857	rs11685425	ENSG00000273240.1	RP11-455J20.3	4.73	5.05e-06	0.00286	0.38	0.36	Ferritin levels;	chr2:189747977	chr2:189763859~189764456:-
PCPG	cis	rs11858159	0.871	rs11858315	ENSG00000259905.4	PWRN1	4.73	5.05e-06	0.00287	0.41	0.36	Platelet thrombus formation;	chr15:24556575	chr15:24493137~24652130:+
PCPG	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-4.73	5.06e-06	0.00287	-0.47	-0.36	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
PCPG	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	4.73	5.06e-06	0.00287	0.42	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
PCPG	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	4.73	5.06e-06	0.00287	0.48	0.36	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
PCPG	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	4.73	5.06e-06	0.00287	0.59	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
PCPG	cis	rs11992162	0.613	rs56094399	ENSG00000255020.1	AF131216.5	-4.73	5.06e-06	0.00287	-0.51	-0.36	Monocyte count;	chr8:11939961	chr8:11345748~11347502:-
PCPG	cis	rs1949733	1	rs2631745	ENSG00000205959.3	RP11-689P11.2	4.73	5.07e-06	0.00287	0.4	0.36	Response to antineoplastic agents;	chr4:8488803	chr4:8482270~8512610:+
PCPG	cis	rs1949733	1	rs2688233	ENSG00000205959.3	RP11-689P11.2	-4.73	5.07e-06	0.00287	-0.4	-0.36	Response to antineoplastic agents;	chr4:8490158	chr4:8482270~8512610:+
PCPG	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	4.73	5.07e-06	0.00287	0.36	0.36	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	4.73	5.07e-06	0.00287	0.36	0.36	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
PCPG	cis	rs561341	1	rs72825740	ENSG00000265798.5	RP11-271K11.5	4.73	5.07e-06	0.00287	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32011337	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.941	rs17780080	ENSG00000265798.5	RP11-271K11.5	4.73	5.07e-06	0.00287	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32016127	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.941	rs17780086	ENSG00000265798.5	RP11-271K11.5	4.73	5.07e-06	0.00287	0.64	0.36	Hip circumference adjusted for BMI;	chr17:32016263	chr17:31038575~31059121:-
PCPG	cis	rs1075232	0.522	rs57924788	ENSG00000270055.1	CTD-3092A11.2	-4.73	5.07e-06	0.00287	-0.69	-0.36	Survival in colorectal cancer (non-distant metastatic);	chr15:31457519	chr15:30487963~30490313:+
PCPG	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-4.73	5.07e-06	0.00287	-0.45	-0.36	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
PCPG	cis	rs964611	0.935	rs76749119	ENSG00000259488.2	RP11-154J22.1	-4.73	5.08e-06	0.00288	-0.4	-0.36	Metabolite levels (Pyroglutamine);	chr15:48312868	chr15:48312353~48331856:-
PCPG	cis	rs964611	1	rs74012001	ENSG00000259488.2	RP11-154J22.1	-4.73	5.08e-06	0.00288	-0.4	-0.36	Metabolite levels (Pyroglutamine);	chr15:48313011	chr15:48312353~48331856:-
PCPG	cis	rs7017914	0.846	rs6472561	ENSG00000254031.4	RP11-326E22.1	-4.73	5.08e-06	0.00288	-0.35	-0.36	Bone mineral density;	chr8:71042948	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs4074909	ENSG00000254031.4	RP11-326E22.1	-4.73	5.08e-06	0.00288	-0.35	-0.36	Bone mineral density;	chr8:71043592	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs4078067	ENSG00000254031.4	RP11-326E22.1	-4.73	5.08e-06	0.00288	-0.35	-0.36	Bone mineral density;	chr8:71044236	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs4504667	ENSG00000254031.4	RP11-326E22.1	-4.73	5.08e-06	0.00288	-0.35	-0.36	Bone mineral density;	chr8:71044557	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs4571761	ENSG00000254031.4	RP11-326E22.1	-4.73	5.08e-06	0.00288	-0.35	-0.36	Bone mineral density;	chr8:71044938	chr8:71155457~71204223:+
PCPG	cis	rs3002142	0.57	rs3008633	ENSG00000272750.1	RP11-378J18.8	-4.73	5.08e-06	0.00288	-0.54	-0.36	LDL peak particle diameter (total fat intake interaction);	chr1:222671498	chr1:222658867~222661512:-
PCPG	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	4.73	5.09e-06	0.00289	0.48	0.36	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
PCPG	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	4.73	5.09e-06	0.00289	0.45	0.36	Height;	chr5:37481330	chr5:36666214~36725195:-
PCPG	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	4.73	5.1e-06	0.00289	0.41	0.36	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
PCPG	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-4.73	5.1e-06	0.00289	-0.46	-0.36	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
PCPG	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-4.73	5.12e-06	0.0029	-0.37	-0.36	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
PCPG	cis	rs950169	0.656	rs748455	ENSG00000259295.5	CSPG4P12	4.73	5.12e-06	0.0029	0.53	0.36	Schizophrenia;	chr15:84606344	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.544	rs12913702	ENSG00000259295.5	CSPG4P12	4.73	5.12e-06	0.0029	0.53	0.36	Schizophrenia;	chr15:84609953	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.509	rs71395455	ENSG00000259295.5	CSPG4P12	4.73	5.12e-06	0.0029	0.53	0.36	Schizophrenia;	chr15:84610573	chr15:85191438~85213905:+
PCPG	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	4.73	5.12e-06	0.0029	0.4	0.36	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
PCPG	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	4.73	5.12e-06	0.0029	0.44	0.36	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
PCPG	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-4.73	5.13e-06	0.0029	-0.39	-0.36	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
PCPG	cis	rs1440410	0.795	rs3967098	ENSG00000250326.1	RP11-284M14.1	4.73	5.13e-06	0.0029	0.32	0.36	Ischemic stroke;	chr4:143274628	chr4:142933195~143184861:-
PCPG	cis	rs6957923	0.935	rs13226524	ENSG00000230658.1	KLHL7-AS1	4.73	5.13e-06	0.0029	0.43	0.36	Height;	chr7:23442258	chr7:23101228~23105703:-
PCPG	cis	rs5742933	0.817	rs11679767	ENSG00000273240.1	RP11-455J20.3	4.73	5.14e-06	0.00291	0.38	0.36	Ferritin levels;	chr2:189681574	chr2:189763859~189764456:-
PCPG	cis	rs7824557	0.628	rs7820301	ENSG00000255020.1	AF131216.5	4.73	5.14e-06	0.00291	0.48	0.36	Retinal vascular caliber;	chr8:11371163	chr8:11345748~11347502:-
PCPG	cis	rs34421088	0.702	rs7838131	ENSG00000255020.1	AF131216.5	-4.73	5.14e-06	0.00291	-0.49	-0.36	Neuroticism;	chr8:11738654	chr8:11345748~11347502:-
PCPG	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-4.73	5.14e-06	0.00291	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
PCPG	cis	rs17482078	0.885	rs10045403	ENSG00000248734.2	CTD-2260A17.1	4.73	5.14e-06	0.00291	0.4	0.36	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96784777~96785999:+
PCPG	cis	rs7824557	0.583	rs2263511	ENSG00000255020.1	AF131216.5	-4.73	5.14e-06	0.00291	-0.47	-0.36	Retinal vascular caliber;	chr8:11375809	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.583	rs2263512	ENSG00000255020.1	AF131216.5	-4.73	5.14e-06	0.00291	-0.47	-0.36	Retinal vascular caliber;	chr8:11375910	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.583	rs6601585	ENSG00000255020.1	AF131216.5	-4.73	5.14e-06	0.00291	-0.47	-0.36	Retinal vascular caliber;	chr8:11376150	chr8:11345748~11347502:-
PCPG	cis	rs1440410	0.795	rs11100785	ENSG00000250326.1	RP11-284M14.1	4.73	5.15e-06	0.00291	0.32	0.36	Ischemic stroke;	chr4:143274404	chr4:142933195~143184861:-
PCPG	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-4.73	5.15e-06	0.00291	-0.48	-0.36	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
PCPG	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	4.73	5.15e-06	0.00291	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
PCPG	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-4.73	5.15e-06	0.00291	-0.49	-0.36	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
PCPG	cis	rs11858159	0.966	rs9920573	ENSG00000259905.4	PWRN1	4.73	5.16e-06	0.00292	0.4	0.36	Platelet thrombus formation;	chr15:24543194	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.783	rs7177757	ENSG00000259905.4	PWRN1	4.73	5.16e-06	0.00292	0.41	0.36	Platelet thrombus formation;	chr15:24547144	chr15:24493137~24652130:+
PCPG	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-4.73	5.17e-06	0.00292	-0.49	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
PCPG	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	4.73	5.17e-06	0.00292	0.32	0.36	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
PCPG	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-4.73	5.18e-06	0.00293	-0.58	-0.36	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
PCPG	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-4.73	5.18e-06	0.00293	-0.45	-0.36	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
PCPG	cis	rs7208859	0.623	rs170051	ENSG00000263603.1	CTD-2349P21.5	-4.73	5.18e-06	0.00293	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30729469~30731202:+
PCPG	cis	rs4295623	0.531	rs2898295	ENSG00000255020.1	AF131216.5	-4.73	5.19e-06	0.00293	-0.48	-0.36	Morning vs. evening chronotype;	chr8:11738460	chr8:11345748~11347502:-
PCPG	cis	rs1048886	0.872	rs12201029	ENSG00000271967.1	RP11-134K13.4	-4.73	5.19e-06	0.00293	-0.44	-0.36	Type 2 diabetes;	chr6:70599019	chr6:70596438~70596980:+
PCPG	cis	rs10899021	0.92	rs7112384	ENSG00000279353.1	RP11-864N7.4	4.73	5.2e-06	0.00294	0.63	0.36	Response to metformin (IC50);	chr11:74637160	chr11:74698231~74699658:-
PCPG	cis	rs1440410	0.835	rs34342939	ENSG00000250326.1	RP11-284M14.1	4.73	5.2e-06	0.00294	0.33	0.36	Ischemic stroke;	chr4:143240517	chr4:142933195~143184861:-
PCPG	cis	rs7208859	0.623	rs73269913	ENSG00000263603.1	CTD-2349P21.5	-4.73	5.2e-06	0.00294	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30729469~30731202:+
PCPG	cis	rs3806843	0.931	rs13168670	ENSG00000202515.1	VTRNA1-3	-4.73	5.2e-06	0.00294	-0.47	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr5:140726158~140726246:+
PCPG	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-4.73	5.21e-06	0.00294	-0.39	-0.36	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
PCPG	cis	rs7246657	0.943	rs4802766	ENSG00000226686.6	LINC01535	-4.73	5.21e-06	0.00294	-0.58	-0.36	Coronary artery calcification;	chr19:37491031	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs2291004	ENSG00000226686.6	LINC01535	-4.73	5.21e-06	0.00294	-0.58	-0.36	Coronary artery calcification;	chr19:37507050	chr19:37251912~37265535:+
PCPG	cis	rs300890	0.56	rs6812850	ENSG00000250326.1	RP11-284M14.1	4.73	5.21e-06	0.00294	0.33	0.36	Nasopharyngeal carcinoma;	chr4:143264929	chr4:142933195~143184861:-
PCPG	cis	rs7759001	0.681	rs7756377	ENSG00000271755.1	RP1-153G14.4	4.73	5.22e-06	0.00295	0.51	0.36	Glomerular filtration rate (creatinine);	chr6:27513882	chr6:27404010~27406964:-
PCPG	cis	rs17772222	0.958	rs2274737	ENSG00000222990.1	RNU4-22P	4.73	5.22e-06	0.00295	0.48	0.36	Coronary artery calcification;	chr14:88469307	chr14:88513498~88513663:+
PCPG	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-4.73	5.22e-06	0.00295	-0.39	-0.36	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-4.73	5.22e-06	0.00295	-0.39	-0.36	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-4.73	5.22e-06	0.00295	-0.39	-0.36	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
PCPG	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	4.73	5.22e-06	0.00295	0.72	0.36	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	4.73	5.22e-06	0.00295	0.72	0.36	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
PCPG	cis	rs73607972	0.877	rs1477199	ENSG00000275191.1	RP11-36I17.2	-4.73	5.22e-06	0.00295	-0.64	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53678223	chr16:53628256~53628816:-
PCPG	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	4.73	5.23e-06	0.00295	0.45	0.36	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
PCPG	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	4.73	5.23e-06	0.00295	0.48	0.36	Height;	chr6:109339681	chr6:109382795~109383666:+
PCPG	cis	rs964611	0.882	rs7182177	ENSG00000259488.2	RP11-154J22.1	-4.73	5.24e-06	0.00296	-0.36	-0.36	Metabolite levels (Pyroglutamine);	chr15:48354357	chr15:48312353~48331856:-
PCPG	cis	rs11858159	0.627	rs8032288	ENSG00000259905.4	PWRN1	4.73	5.25e-06	0.00296	0.41	0.36	Platelet thrombus formation;	chr15:24540281	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.812	rs8033597	ENSG00000259905.4	PWRN1	4.73	5.25e-06	0.00296	0.41	0.36	Platelet thrombus formation;	chr15:24540282	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.603	rs8033605	ENSG00000259905.4	PWRN1	4.73	5.25e-06	0.00296	0.41	0.36	Platelet thrombus formation;	chr15:24540294	chr15:24493137~24652130:+
PCPG	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	4.73	5.25e-06	0.00296	0.42	0.36	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-4.73	5.25e-06	0.00296	-0.42	-0.36	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
PCPG	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	4.73	5.25e-06	0.00296	0.39	0.36	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
PCPG	cis	rs2625529	0.816	rs4777467	ENSG00000260037.4	CTD-2524L6.3	-4.72	5.25e-06	0.00296	-0.58	-0.36	Red blood cell count;	chr15:71846137	chr15:71818396~71823384:+
PCPG	cis	rs9788721	0.775	rs8040868	ENSG00000279421.1	RP11-335K5.3	4.72	5.25e-06	0.00296	0.4	0.36	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78618839	chr15:78599892~78600013:-
PCPG	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	4.72	5.25e-06	0.00296	0.5	0.36	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
PCPG	cis	rs7017914	0.905	rs1908033	ENSG00000254031.4	RP11-326E22.1	4.72	5.25e-06	0.00296	0.35	0.36	Bone mineral density;	chr8:71010564	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.905	rs2732103	ENSG00000254031.4	RP11-326E22.1	4.72	5.25e-06	0.00296	0.35	0.36	Bone mineral density;	chr8:71011261	chr8:71155457~71204223:+
PCPG	cis	rs11858159	1	rs6576331	ENSG00000259905.4	PWRN1	4.72	5.26e-06	0.00296	0.41	0.36	Platelet thrombus formation;	chr15:24545022	chr15:24493137~24652130:+
PCPG	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	4.72	5.26e-06	0.00297	0.45	0.36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
PCPG	cis	rs2625529	0.878	rs16956302	ENSG00000260037.4	CTD-2524L6.3	-4.72	5.27e-06	0.00297	-0.58	-0.36	Red blood cell count;	chr15:71843902	chr15:71818396~71823384:+
PCPG	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-4.72	5.27e-06	0.00297	-0.38	-0.36	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
PCPG	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-4.72	5.27e-06	0.00297	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
PCPG	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	4.72	5.27e-06	0.00297	0.56	0.36	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
PCPG	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	4.72	5.27e-06	0.00297	0.46	0.36	Height;	chr6:109581800	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	4.72	5.27e-06	0.00297	0.46	0.36	Height;	chr6:109582583	chr6:109382795~109383666:+
PCPG	cis	rs5769765	0.913	rs4824111	ENSG00000278869.1	CITF22-49E9.3	-4.72	5.27e-06	0.00297	-0.47	-0.36	Schizophrenia;	chr22:49890657	chr22:49933198~49934074:-
PCPG	cis	rs73607972	1	rs73607972	ENSG00000275191.1	RP11-36I17.2	-4.72	5.28e-06	0.00297	-0.64	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53634741	chr16:53628256~53628816:-
PCPG	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	4.72	5.28e-06	0.00298	0.5	0.36	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	4.72	5.28e-06	0.00298	0.5	0.36	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
PCPG	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-4.72	5.28e-06	0.00298	-0.4	-0.36	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
PCPG	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-4.72	5.29e-06	0.00298	-0.42	-0.36	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
PCPG	cis	rs7017914	0.905	rs4434651	ENSG00000254031.4	RP11-326E22.1	4.72	5.29e-06	0.00298	0.35	0.36	Bone mineral density;	chr8:71034952	chr8:71155457~71204223:+
PCPG	cis	rs8098244	0.603	rs1711455	ENSG00000265752.2	RP11-403A21.1	4.72	5.29e-06	0.00298	0.42	0.36	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23695207	chr18:23957754~23982556:-
PCPG	cis	rs1908814	0.516	rs10113042	ENSG00000255495.1	AC145124.2	4.72	5.29e-06	0.00298	0.36	0.36	Neuroticism;	chr8:11935669	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs10113062	ENSG00000255495.1	AC145124.2	4.72	5.29e-06	0.00298	0.36	0.36	Neuroticism;	chr8:11935740	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs10113145	ENSG00000255495.1	AC145124.2	4.72	5.29e-06	0.00298	0.36	0.36	Neuroticism;	chr8:11935786	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs7812563	ENSG00000255495.1	AC145124.2	4.72	5.29e-06	0.00298	0.36	0.36	Neuroticism;	chr8:11936979	chr8:12194467~12196280:+
PCPG	cis	rs3806843	0.868	rs2531342	ENSG00000202515.1	VTRNA1-3	4.72	5.3e-06	0.00298	0.46	0.36	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.9	rs2563279	ENSG00000202515.1	VTRNA1-3	4.72	5.3e-06	0.00298	0.46	0.36	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr5:140726158~140726246:+
PCPG	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-4.72	5.3e-06	0.00299	-0.48	-0.36	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
PCPG	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	4.72	5.3e-06	0.00299	0.48	0.36	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
PCPG	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-4.72	5.3e-06	0.00299	-0.47	-0.36	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-4.72	5.3e-06	0.00299	-0.47	-0.36	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
PCPG	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	4.72	5.31e-06	0.00299	0.49	0.36	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	4.72	5.31e-06	0.00299	0.49	0.36	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
PCPG	cis	rs11673344	0.504	rs11666786	ENSG00000226686.6	LINC01535	4.72	5.31e-06	0.00299	0.46	0.36	Obesity-related traits;	chr19:37133947	chr19:37251912~37265535:+
PCPG	cis	rs13108904	0.875	rs1732099	ENSG00000254094.1	AC078852.1	4.72	5.31e-06	0.00299	0.41	0.36	Obesity-related traits;	chr4:1288908	chr4:1356581~1358075:+
PCPG	cis	rs720064	0.555	rs9956312	ENSG00000265752.2	RP11-403A21.1	4.72	5.32e-06	0.00299	0.4	0.36	Strep throat;	chr18:23969713	chr18:23957754~23982556:-
PCPG	cis	rs5742933	0.817	rs2033870	ENSG00000273240.1	RP11-455J20.3	-4.72	5.32e-06	0.00299	-0.38	-0.36	Ferritin levels;	chr2:189739104	chr2:189763859~189764456:-
PCPG	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-4.72	5.33e-06	0.003	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-4.72	5.33e-06	0.003	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
PCPG	cis	rs7587476	0.765	rs2121284	ENSG00000229267.2	AC072062.1	4.72	5.33e-06	0.003	0.43	0.36	Neuroblastoma;	chr2:214791536	chr2:214810229~214963274:+
PCPG	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-4.72	5.33e-06	0.003	-0.41	-0.36	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
PCPG	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-4.72	5.33e-06	0.003	-0.61	-0.36	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
PCPG	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-4.72	5.34e-06	0.003	-0.45	-0.36	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
PCPG	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	4.72	5.34e-06	0.003	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
PCPG	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-4.72	5.34e-06	0.003	-0.83	-0.36	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-4.72	5.34e-06	0.003	-0.83	-0.36	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
PCPG	cis	rs6121246	0.542	rs2376990	ENSG00000230613.1	HM13-AS1	4.72	5.34e-06	0.00301	0.53	0.36	Mean corpuscular hemoglobin;	chr20:31650941	chr20:31567707~31573263:-
PCPG	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-4.72	5.36e-06	0.00301	-0.41	-0.36	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-4.72	5.36e-06	0.00301	-0.41	-0.36	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
PCPG	cis	rs657075	0.64	rs13180186	ENSG00000233006.5	AC034220.3	-4.72	5.36e-06	0.00301	-0.51	-0.36	Rheumatoid arthritis;	chr5:132369866	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs13180295	ENSG00000233006.5	AC034220.3	-4.72	5.36e-06	0.00301	-0.51	-0.36	Rheumatoid arthritis;	chr5:132369896	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583478	ENSG00000233006.5	AC034220.3	-4.72	5.36e-06	0.00301	-0.53	-0.36	Rheumatoid arthritis;	chr5:132353131	chr5:132311285~132369916:-
PCPG	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	4.72	5.36e-06	0.00301	0.48	0.36	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
PCPG	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-4.72	5.37e-06	0.00302	-0.43	-0.36	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-4.72	5.37e-06	0.00302	-0.43	-0.36	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
PCPG	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	4.72	5.37e-06	0.00302	0.41	0.36	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
PCPG	cis	rs7208859	0.51	rs216402	ENSG00000263603.1	CTD-2349P21.5	-4.72	5.37e-06	0.00302	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30729469~30731202:+
PCPG	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-4.72	5.37e-06	0.00302	-0.47	-0.36	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
PCPG	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-4.72	5.38e-06	0.00302	-0.38	-0.36	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
PCPG	cis	rs60695258	0.55	rs388401	ENSG00000251411.1	RP11-397E7.4	4.72	5.39e-06	0.00303	0.33	0.36	Hematocrit;	chr4:87053263	chr4:86913266~86914817:-
PCPG	cis	rs7849782	0.875	rs1323424	ENSG00000225376.4	TMEM246-AS1	4.72	5.39e-06	0.00303	0.42	0.36	Coronary artery aneurysm in Kawasaki disease;	chr9:101653306	chr9:101468439~101481502:+
PCPG	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	4.72	5.39e-06	0.00303	0.36	0.36	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
PCPG	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-4.72	5.4e-06	0.00303	-0.43	-0.36	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
PCPG	cis	rs3806843	0.966	rs6891559	ENSG00000202515.1	VTRNA1-3	-4.72	5.41e-06	0.00304	-0.47	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs11741994	ENSG00000202515.1	VTRNA1-3	-4.72	5.41e-06	0.00304	-0.47	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs2563261	ENSG00000202515.1	VTRNA1-3	4.72	5.41e-06	0.00304	0.47	0.36	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr5:140726158~140726246:+
PCPG	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-4.72	5.41e-06	0.00304	-0.46	-0.36	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	4.72	5.41e-06	0.00304	0.46	0.36	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
PCPG	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	4.72	5.42e-06	0.00304	0.44	0.36	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	4.72	5.42e-06	0.00304	0.44	0.36	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	4.72	5.42e-06	0.00304	0.44	0.36	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
PCPG	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	4.72	5.42e-06	0.00304	0.49	0.36	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
PCPG	cis	rs11992162	0.636	rs4841645	ENSG00000255020.1	AF131216.5	-4.72	5.43e-06	0.00305	-0.49	-0.36	Monocyte count;	chr8:11941175	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.902	rs61995200	ENSG00000259905.4	PWRN1	4.72	5.44e-06	0.00305	0.41	0.36	Platelet thrombus formation;	chr15:24570034	chr15:24493137~24652130:+
PCPG	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-4.72	5.45e-06	0.00305	-0.5	-0.36	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
PCPG	cis	rs11673344	0.523	rs7258438	ENSG00000226686.6	LINC01535	4.72	5.45e-06	0.00305	0.46	0.36	Obesity-related traits;	chr19:37032534	chr19:37251912~37265535:+
PCPG	cis	rs3806843	0.966	rs2337516	ENSG00000202515.1	VTRNA1-3	4.72	5.45e-06	0.00305	0.47	0.36	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr5:140726158~140726246:+
PCPG	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	4.72	5.45e-06	0.00306	0.5	0.36	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	4.72	5.45e-06	0.00306	0.5	0.36	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
PCPG	cis	rs1949733	1	rs2631758	ENSG00000205959.3	RP11-689P11.2	4.72	5.45e-06	0.00306	0.4	0.36	Response to antineoplastic agents;	chr4:8493577	chr4:8482270~8512610:+
PCPG	cis	rs9303029	0.611	rs9909476	ENSG00000279744.1	RP13-20L14.10	4.72	5.46e-06	0.00306	0.52	0.36	Protein quantitative trait loci;	chr17:82481857	chr17:82462601~82464255:+
PCPG	cis	rs3806843	0.966	rs10060640	ENSG00000202515.1	VTRNA1-3	-4.72	5.46e-06	0.00306	-0.48	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr5:140726158~140726246:+
PCPG	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	4.72	5.46e-06	0.00306	0.3	0.36	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	4.72	5.46e-06	0.00306	0.3	0.36	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	4.72	5.46e-06	0.00306	0.3	0.36	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
PCPG	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	4.72	5.47e-06	0.00307	0.5	0.36	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
PCPG	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	4.71	5.49e-06	0.00307	0.4	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
PCPG	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-4.71	5.49e-06	0.00308	-0.48	-0.36	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
PCPG	cis	rs35934224	0.771	rs34820460	ENSG00000232926.1	AC000078.5	4.71	5.51e-06	0.00309	0.41	0.36	Glaucoma (primary open-angle);	chr22:19881687	chr22:19887289~19887970:+
PCPG	cis	rs13108904	0.875	rs10024013	ENSG00000254094.1	AC078852.1	4.71	5.51e-06	0.00309	0.41	0.36	Obesity-related traits;	chr4:1287004	chr4:1356581~1358075:+
PCPG	cis	rs3806843	0.966	rs2563260	ENSG00000202515.1	VTRNA1-3	4.71	5.51e-06	0.00309	0.46	0.36	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr5:140726158~140726246:+
PCPG	cis	rs748404	0.666	rs7177146	ENSG00000249839.1	AC011330.5	-4.71	5.52e-06	0.00309	-0.48	-0.36	Lung cancer;	chr15:43506110	chr15:43663654~43684339:-
PCPG	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	4.71	5.52e-06	0.00309	0.46	0.36	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
PCPG	cis	rs28386778	0.897	rs7212196	ENSG00000240280.5	TCAM1P	-4.71	5.52e-06	0.00309	-0.48	-0.36	Prudent dietary pattern;	chr17:63757621	chr17:63849292~63864379:+
PCPG	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	4.71	5.53e-06	0.00309	0.49	0.36	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
PCPG	cis	rs11858159	1	rs11854549	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24562616	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs11854816	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24562681	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs12898677	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24562887	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs8043434	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24563781	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs8025086	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24563897	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7496699	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24564716	chr15:24493137~24652130:+
PCPG	cis	rs7403037	0.565	rs12909476	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24564823	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.871	rs12909793	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24565230	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs12910163	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24565407	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12908881	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24565731	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12915177	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24565882	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.841	rs12913964	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24566377	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs12915797	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24566455	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs11852693	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24567871	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs11857090	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24568104	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs7178027	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24568910	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7172700	ENSG00000259905.4	PWRN1	4.71	5.53e-06	0.00309	0.41	0.36	Platelet thrombus formation;	chr15:24569014	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.966	rs11854681	ENSG00000259905.4	PWRN1	-4.71	5.53e-06	0.00309	-0.41	-0.36	Platelet thrombus formation;	chr15:24563004	chr15:24493137~24652130:+
PCPG	cis	rs4713118	0.662	rs149900	ENSG00000216901.1	AL022393.7	4.71	5.53e-06	0.00309	0.5	0.36	Parkinson's disease;	chr6:28046819	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.662	rs149961	ENSG00000216901.1	AL022393.7	4.71	5.53e-06	0.00309	0.5	0.36	Parkinson's disease;	chr6:28047791	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.629	rs149899	ENSG00000216901.1	AL022393.7	4.71	5.53e-06	0.00309	0.5	0.36	Parkinson's disease;	chr6:28052201	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.629	rs172165	ENSG00000216901.1	AL022393.7	4.71	5.53e-06	0.00309	0.5	0.36	Parkinson's disease;	chr6:28053036	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.597	rs172166	ENSG00000216901.1	AL022393.7	4.71	5.53e-06	0.00309	0.5	0.36	Parkinson's disease;	chr6:28053042	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.629	rs203889	ENSG00000216901.1	AL022393.7	4.71	5.53e-06	0.00309	0.5	0.36	Parkinson's disease;	chr6:28053997	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.629	rs203890	ENSG00000216901.1	AL022393.7	4.71	5.53e-06	0.00309	0.5	0.36	Parkinson's disease;	chr6:28054470	chr6:28176188~28176674:+
PCPG	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-4.71	5.54e-06	0.0031	-0.36	-0.36	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
PCPG	cis	rs11148252	0.777	rs9535889	ENSG00000235660.1	LINC00345	-4.71	5.54e-06	0.0031	-0.46	-0.36	Lewy body disease;	chr13:52159499	chr13:52484161~52484680:-
PCPG	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	4.71	5.54e-06	0.0031	0.34	0.36	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
PCPG	cis	rs11858159	0.676	rs13380324	ENSG00000259905.4	PWRN1	4.71	5.54e-06	0.0031	0.41	0.36	Platelet thrombus formation;	chr15:24548874	chr15:24493137~24652130:+
PCPG	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-4.71	5.55e-06	0.0031	-0.39	-0.36	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
PCPG	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	4.71	5.55e-06	0.0031	0.4	0.36	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
PCPG	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	4.71	5.55e-06	0.0031	0.4	0.36	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
PCPG	cis	rs2625529	0.701	rs12911154	ENSG00000260037.4	CTD-2524L6.3	-4.71	5.57e-06	0.00311	-0.58	-0.36	Red blood cell count;	chr15:71920312	chr15:71818396~71823384:+
PCPG	cis	rs1440410	0.795	rs12506120	ENSG00000250326.1	RP11-284M14.1	4.71	5.57e-06	0.00311	0.33	0.36	Ischemic stroke;	chr4:143269295	chr4:142933195~143184861:-
PCPG	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-4.71	5.57e-06	0.00311	-0.39	-0.36	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-4.71	5.57e-06	0.00311	-0.39	-0.36	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-4.71	5.57e-06	0.00311	-0.39	-0.36	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
PCPG	cis	rs804280	0.509	rs13268030	ENSG00000255495.1	AC145124.2	4.71	5.57e-06	0.00311	0.36	0.36	Myopia (pathological);	chr8:11925564	chr8:12194467~12196280:+
PCPG	cis	rs2625529	0.73	rs12912771	ENSG00000260037.4	CTD-2524L6.3	-4.71	5.57e-06	0.00311	-0.47	-0.36	Red blood cell count;	chr15:71870587	chr15:71818396~71823384:+
PCPG	cis	rs1048886	0.938	rs55778329	ENSG00000271967.1	RP11-134K13.4	-4.71	5.58e-06	0.00311	-0.47	-0.36	Type 2 diabetes;	chr6:70491271	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs77937573	ENSG00000271967.1	RP11-134K13.4	-4.71	5.58e-06	0.00311	-0.47	-0.36	Type 2 diabetes;	chr6:70491930	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs80232745	ENSG00000271967.1	RP11-134K13.4	-4.71	5.58e-06	0.00311	-0.47	-0.36	Type 2 diabetes;	chr6:70492385	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs76920724	ENSG00000271967.1	RP11-134K13.4	-4.71	5.58e-06	0.00311	-0.47	-0.36	Type 2 diabetes;	chr6:70494450	chr6:70596438~70596980:+
PCPG	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	4.71	5.58e-06	0.00311	0.55	0.36	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
PCPG	cis	rs748404	0.666	rs12908460	ENSG00000249839.1	AC011330.5	-4.71	5.58e-06	0.00312	-0.48	-0.36	Lung cancer;	chr15:43413472	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs2230451	ENSG00000249839.1	AC011330.5	-4.71	5.58e-06	0.00312	-0.48	-0.36	Lung cancer;	chr15:43415610	chr15:43663654~43684339:-
PCPG	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	4.71	5.58e-06	0.00312	0.42	0.36	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
PCPG	cis	rs657075	0.697	rs34786243	ENSG00000233006.5	AC034220.3	-4.71	5.59e-06	0.00312	-0.51	-0.36	Rheumatoid arthritis;	chr5:132369028	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3788988	ENSG00000233006.5	AC034220.3	-4.71	5.59e-06	0.00312	-0.51	-0.36	Rheumatoid arthritis;	chr5:132370679	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.64	rs13167994	ENSG00000233006.5	AC034220.3	-4.71	5.59e-06	0.00312	-0.51	-0.36	Rheumatoid arthritis;	chr5:132371131	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs4646301	ENSG00000233006.5	AC034220.3	-4.71	5.59e-06	0.00312	-0.51	-0.36	Rheumatoid arthritis;	chr5:132375408	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs34452667	ENSG00000233006.5	AC034220.3	-4.71	5.59e-06	0.00312	-0.51	-0.36	Rheumatoid arthritis;	chr5:132377863	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs4646304	ENSG00000233006.5	AC034220.3	-4.71	5.59e-06	0.00312	-0.51	-0.36	Rheumatoid arthritis;	chr5:132379086	chr5:132311285~132369916:-
PCPG	cis	rs9299346	0.594	rs11793339	ENSG00000225376.4	TMEM246-AS1	4.71	5.6e-06	0.00312	0.45	0.36	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101673198	chr9:101468439~101481502:+
PCPG	cis	rs2235642	0.75	rs2859310	ENSG00000260989.1	LA16c-395F10.2	4.71	5.6e-06	0.00312	0.38	0.36	Coronary artery disease;	chr16:1606764	chr16:1580527~1610328:+
PCPG	cis	rs2235642	0.75	rs1894649	ENSG00000260989.1	LA16c-395F10.2	-4.71	5.6e-06	0.00312	-0.38	-0.36	Coronary artery disease;	chr16:1607283	chr16:1580527~1610328:+
PCPG	cis	rs950169	0.519	rs7237	ENSG00000259295.5	CSPG4P12	4.71	5.61e-06	0.00313	0.54	0.36	Schizophrenia;	chr15:84643346	chr15:85191438~85213905:+
PCPG	cis	rs748404	0.666	rs34591748	ENSG00000249839.1	AC011330.5	-4.71	5.61e-06	0.00313	-0.48	-0.36	Lung cancer;	chr15:43334917	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs35326382	ENSG00000249839.1	AC011330.5	-4.71	5.61e-06	0.00313	-0.48	-0.36	Lung cancer;	chr15:43338686	chr15:43663654~43684339:-
PCPG	cis	rs6802315	0.575	rs1864508	ENSG00000271778.1	RP11-379F4.8	4.71	5.61e-06	0.00313	0.33	0.36	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158782547~158783124:+
PCPG	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-4.71	5.62e-06	0.00313	-0.46	-0.36	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
PCPG	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-4.71	5.62e-06	0.00313	-0.44	-0.36	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
PCPG	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-4.71	5.63e-06	0.00314	-0.5	-0.36	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
PCPG	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-4.71	5.63e-06	0.00314	-0.44	-0.36	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
PCPG	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-4.71	5.64e-06	0.00314	-0.46	-0.36	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
PCPG	cis	rs7824557	1	rs2736371	ENSG00000255020.1	AF131216.5	-4.71	5.64e-06	0.00314	-0.46	-0.36	Retinal vascular caliber;	chr8:11248020	chr8:11345748~11347502:-
PCPG	cis	rs7208859	0.524	rs8065744	ENSG00000263603.1	CTD-2349P21.5	-4.71	5.65e-06	0.00315	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs8071236	ENSG00000263603.1	CTD-2349P21.5	-4.71	5.65e-06	0.00315	-0.59	-0.36	Body mass index;	chr17:30772984	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.636	rs2449770	ENSG00000263603.1	CTD-2349P21.5	-4.71	5.65e-06	0.00315	-0.59	-0.36	Body mass index;	chr17:30774046	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.524	rs59913838	ENSG00000263603.1	CTD-2349P21.5	-4.71	5.65e-06	0.00315	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30729469~30731202:+
PCPG	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	4.71	5.65e-06	0.00315	0.46	0.36	Height;	chr6:109617741	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	4.71	5.65e-06	0.00315	0.46	0.36	Height;	chr6:109619295	chr6:109382795~109383666:+
PCPG	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-4.71	5.65e-06	0.00315	-0.29	-0.36	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
PCPG	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	4.71	5.65e-06	0.00315	0.44	0.36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	4.71	5.65e-06	0.00315	0.44	0.36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	4.71	5.65e-06	0.00315	0.44	0.36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-4.71	5.65e-06	0.00315	-0.44	-0.36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
PCPG	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-4.71	5.66e-06	0.00315	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
PCPG	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	4.71	5.66e-06	0.00315	0.54	0.36	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
PCPG	cis	rs3808502	0.563	rs12549144	ENSG00000255020.1	AF131216.5	4.71	5.66e-06	0.00315	0.44	0.36	Neuroticism;	chr8:11565352	chr8:11345748~11347502:-
PCPG	cis	rs6802315	0.575	rs57932243	ENSG00000271778.1	RP11-379F4.8	4.71	5.66e-06	0.00315	0.33	0.36	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158782547~158783124:+
PCPG	cis	rs6802315	0.604	rs2364927	ENSG00000271778.1	RP11-379F4.8	4.71	5.66e-06	0.00315	0.33	0.36	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158782547~158783124:+
PCPG	cis	rs6802315	0.604	rs9881462	ENSG00000271778.1	RP11-379F4.8	4.71	5.66e-06	0.00315	0.33	0.36	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158782547~158783124:+
PCPG	cis	rs73607972	0.935	rs7186069	ENSG00000275191.1	RP11-36I17.2	-4.71	5.67e-06	0.00316	-0.6	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563693	chr16:53628256~53628816:-
PCPG	cis	rs73607972	0.935	rs7193194	ENSG00000275191.1	RP11-36I17.2	-4.71	5.67e-06	0.00316	-0.6	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563802	chr16:53628256~53628816:-
PCPG	cis	rs10172965	1	rs10172965	ENSG00000203435.2	E2F3P2	4.71	5.68e-06	0.00316	0.48	0.36	Neuroticism;Temperament;	chr2:195007095	chr2:195994259~195995680:-
PCPG	cis	rs3736858	0.8	rs9544059	ENSG00000261105.4	LMO7-AS1	-4.71	5.69e-06	0.00317	-0.71	-0.36	Interleukin-9 levels;	chr13:75873062	chr13:75604700~75635994:-
PCPG	cis	rs3736858	0.8	rs2165774	ENSG00000261105.4	LMO7-AS1	-4.71	5.69e-06	0.00317	-0.71	-0.36	Interleukin-9 levels;	chr13:75873096	chr13:75604700~75635994:-
PCPG	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	4.71	5.69e-06	0.00317	0.45	0.36	Height;	chr6:109347085	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	4.71	5.69e-06	0.00317	0.45	0.36	Height;	chr6:109347277	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	4.71	5.69e-06	0.00317	0.45	0.36	Height;	chr6:109352852	chr6:109382795~109383666:+
PCPG	cis	rs4819052	0.679	rs4819053	ENSG00000215447.6	BX322557.10	4.71	5.7e-06	0.00317	0.33	0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45288052~45291738:+
PCPG	cis	rs2625529	0.701	rs62025574	ENSG00000260037.4	CTD-2524L6.3	-4.71	5.7e-06	0.00317	-0.58	-0.36	Red blood cell count;	chr15:71943734	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.878	rs71395051	ENSG00000260037.4	CTD-2524L6.3	-4.71	5.7e-06	0.00317	-0.58	-0.36	Red blood cell count;	chr15:71947448	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs11072339	ENSG00000260037.4	CTD-2524L6.3	-4.71	5.7e-06	0.00317	-0.58	-0.36	Red blood cell count;	chr15:71954849	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs1074330	ENSG00000260037.4	CTD-2524L6.3	-4.71	5.7e-06	0.00317	-0.58	-0.36	Red blood cell count;	chr15:71958400	chr15:71818396~71823384:+
PCPG	cis	rs453301	0.658	rs9329175	ENSG00000173295.6	FAM86B3P	4.71	5.71e-06	0.00318	0.43	0.36	Joint mobility (Beighton score);	chr8:9009151	chr8:8228595~8244865:+
PCPG	cis	rs6519955	0.897	rs4073601	ENSG00000231711.2	LINC00899	4.71	5.71e-06	0.00318	0.34	0.36	Dupuytren's disease;	chr22:46038806	chr22:46039907~46044853:-
PCPG	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-4.71	5.71e-06	0.00318	-0.47	-0.36	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
PCPG	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-4.7	5.72e-06	0.00318	-0.62	-0.36	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
PCPG	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	4.7	5.72e-06	0.00318	0.54	0.36	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
PCPG	cis	rs748404	0.666	rs16957715	ENSG00000249839.1	AC011330.5	-4.7	5.72e-06	0.00318	-0.48	-0.36	Lung cancer;	chr15:43416539	chr15:43663654~43684339:-
PCPG	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	4.7	5.73e-06	0.00319	0.46	0.36	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
PCPG	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	4.7	5.73e-06	0.00319	0.42	0.36	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
PCPG	cis	rs4763879	0.593	rs7960328	ENSG00000278635.1	CTD-2318O12.1	4.7	5.74e-06	0.00319	0.42	0.36	Type 1 diabetes;	chr12:9699584	chr12:9415641~9416718:+
PCPG	cis	rs4763879	0.634	rs61915472	ENSG00000278635.1	CTD-2318O12.1	4.7	5.74e-06	0.00319	0.42	0.36	Type 1 diabetes;	chr12:9700995	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.868	rs7306304	ENSG00000278635.1	CTD-2318O12.1	-4.7	5.74e-06	0.00319	-0.43	-0.36	Type 1 diabetes;	chr12:9724600	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.837	rs7306557	ENSG00000278635.1	CTD-2318O12.1	-4.7	5.74e-06	0.00319	-0.43	-0.36	Type 1 diabetes;	chr12:9724760	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.87	rs7307111	ENSG00000278635.1	CTD-2318O12.1	-4.7	5.74e-06	0.00319	-0.43	-0.36	Type 1 diabetes;	chr12:9725227	chr12:9415641~9416718:+
PCPG	cis	rs7017914	0.902	rs7831792	ENSG00000254031.4	RP11-326E22.1	4.7	5.75e-06	0.00319	0.35	0.36	Bone mineral density;	chr8:70653121	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.902	rs34882924	ENSG00000254031.4	RP11-326E22.1	4.7	5.75e-06	0.00319	0.35	0.36	Bone mineral density;	chr8:70654073	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs6987313	ENSG00000254031.4	RP11-326E22.1	4.7	5.75e-06	0.00319	0.35	0.36	Bone mineral density;	chr8:70658754	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.902	rs35580034	ENSG00000254031.4	RP11-326E22.1	4.7	5.75e-06	0.00319	0.35	0.36	Bone mineral density;	chr8:70659838	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs17760050	ENSG00000254031.4	RP11-326E22.1	4.7	5.75e-06	0.00319	0.35	0.36	Bone mineral density;	chr8:70662016	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs35214141	ENSG00000254031.4	RP11-326E22.1	4.7	5.75e-06	0.00319	0.35	0.36	Bone mineral density;	chr8:70662329	chr8:71155457~71204223:+
PCPG	cis	rs11858159	0.934	rs7172595	ENSG00000259905.4	PWRN1	4.7	5.75e-06	0.00319	0.41	0.36	Platelet thrombus formation;	chr15:24555197	chr15:24493137~24652130:+
PCPG	cis	rs2060793	0.741	rs10734227	ENSG00000251991.1	RNU7-49P	4.7	5.75e-06	0.0032	0.4	0.36	Vitamin D levels;	chr11:14767471	chr11:14478892~14478953:+
PCPG	cis	rs6762	0.692	rs5030778	ENSG00000279672.1	CMB9-55F22.1	4.7	5.76e-06	0.0032	0.4	0.36	Mean platelet volume;	chr11:836008	chr11:779617~780755:+
PCPG	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-4.7	5.76e-06	0.0032	-0.37	-0.36	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
PCPG	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-4.7	5.76e-06	0.0032	-0.44	-0.36	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
PCPG	cis	rs11672691	0.871	rs2191139	ENSG00000267107.5	PCAT19	4.7	5.77e-06	0.00321	0.32	0.36	Prostate cancer;	chr19:41495302	chr19:41454169~41500649:-
PCPG	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	4.7	5.77e-06	0.00321	0.5	0.36	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
PCPG	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-4.7	5.78e-06	0.00321	-0.34	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
PCPG	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-4.7	5.78e-06	0.00321	-0.43	-0.36	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
PCPG	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	4.7	5.79e-06	0.00321	0.37	0.36	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
PCPG	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.7	5.79e-06	0.00321	-0.43	-0.36	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-4.7	5.79e-06	0.00321	-0.43	-0.36	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
PCPG	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	4.7	5.79e-06	0.00321	0.47	0.36	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
PCPG	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	4.7	5.79e-06	0.00321	0.49	0.36	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
PCPG	cis	rs11836164	0.58	rs12303723	ENSG00000278095.1	RP11-283G6.6	4.7	5.79e-06	0.00322	0.55	0.36	Mammographic density (dense area);	chr12:26327825	chr12:26273329~26273900:-
PCPG	cis	rs11836164	0.58	rs35245553	ENSG00000278095.1	RP11-283G6.6	4.7	5.79e-06	0.00322	0.55	0.36	Mammographic density (dense area);	chr12:26328282	chr12:26273329~26273900:-
PCPG	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	4.7	5.8e-06	0.00322	0.37	0.36	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
PCPG	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-4.7	5.8e-06	0.00322	-0.33	-0.36	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
PCPG	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-4.7	5.8e-06	0.00322	-0.33	-0.36	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-4.7	5.8e-06	0.00322	-0.33	-0.36	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
PCPG	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	4.7	5.8e-06	0.00322	0.33	0.36	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
PCPG	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	4.7	5.8e-06	0.00322	0.56	0.36	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
PCPG	cis	rs12681963	0.688	rs6997926	ENSG00000248159.1	HSPA8P11	4.7	5.8e-06	0.00322	0.78	0.36	Migraine;	chr8:30197384	chr8:30237382~30240997:+
PCPG	cis	rs1440410	0.795	rs34282097	ENSG00000250326.1	RP11-284M14.1	4.7	5.8e-06	0.00322	0.32	0.36	Ischemic stroke;	chr4:143270817	chr4:142933195~143184861:-
PCPG	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-4.7	5.8e-06	0.00322	-0.47	-0.36	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
PCPG	cis	rs2235642	0.75	rs763152	ENSG00000260989.1	LA16c-395F10.2	-4.7	5.81e-06	0.00322	-0.38	-0.36	Coronary artery disease;	chr16:1608055	chr16:1580527~1610328:+
PCPG	cis	rs2235642	0.717	rs9937922	ENSG00000260989.1	LA16c-395F10.2	-4.7	5.81e-06	0.00322	-0.38	-0.36	Coronary artery disease;	chr16:1608153	chr16:1580527~1610328:+
PCPG	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-4.7	5.82e-06	0.00323	-0.46	-0.36	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
PCPG	cis	rs60695258	0.517	rs867196	ENSG00000251411.1	RP11-397E7.4	-4.7	5.82e-06	0.00323	-0.33	-0.36	Hematocrit;	chr4:87050448	chr4:86913266~86914817:-
PCPG	cis	rs196889	0.572	rs196814	ENSG00000253535.4	RP11-624C23.1	4.7	5.82e-06	0.00323	0.35	0.36	Seasonality;	chr8:24859081	chr8:24295814~24912073:-
PCPG	cis	rs196889	0.706	rs2979675	ENSG00000253535.4	RP11-624C23.1	4.7	5.82e-06	0.00323	0.35	0.36	Seasonality;	chr8:24861440	chr8:24295814~24912073:-
PCPG	cis	rs196889	0.706	rs2975190	ENSG00000253535.4	RP11-624C23.1	4.7	5.82e-06	0.00323	0.35	0.36	Seasonality;	chr8:24861456	chr8:24295814~24912073:-
PCPG	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	4.7	5.82e-06	0.00323	0.44	0.36	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
PCPG	cis	rs7824557	0.591	rs2736283	ENSG00000255020.1	AF131216.5	-4.7	5.82e-06	0.00323	-0.46	-0.36	Retinal vascular caliber;	chr8:11368401	chr8:11345748~11347502:-
PCPG	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	4.7	5.83e-06	0.00323	0.46	0.36	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	4.7	5.83e-06	0.00323	0.46	0.36	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	4.7	5.83e-06	0.00323	0.46	0.36	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
PCPG	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	4.7	5.83e-06	0.00323	0.44	0.36	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
PCPG	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-4.7	5.83e-06	0.00323	-0.43	-0.36	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
PCPG	cis	rs7826238	0.594	rs2948285	ENSG00000173295.6	FAM86B3P	-4.7	5.84e-06	0.00324	-0.42	-0.36	Systolic blood pressure;	chr8:8273016	chr8:8228595~8244865:+
PCPG	cis	rs7267979	1	rs2474777	ENSG00000125804.12	FAM182A	-4.7	5.84e-06	0.00324	-0.4	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:26054655~26086917:+
PCPG	cis	rs7824557	0.544	rs1865521	ENSG00000255020.1	AF131216.5	4.7	5.84e-06	0.00324	0.49	0.36	Retinal vascular caliber;	chr8:11373740	chr8:11345748~11347502:-
PCPG	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-4.7	5.84e-06	0.00324	-0.37	-0.36	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
PCPG	cis	rs1440410	0.795	rs13119330	ENSG00000250326.1	RP11-284M14.1	4.7	5.84e-06	0.00324	0.32	0.36	Ischemic stroke;	chr4:143264416	chr4:142933195~143184861:-
PCPG	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-4.7	5.84e-06	0.00324	-0.47	-0.36	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
PCPG	cis	rs1440410	0.804	rs28470858	ENSG00000250326.1	RP11-284M14.1	4.7	5.85e-06	0.00324	0.32	0.36	Ischemic stroke;	chr4:143187008	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4574353	ENSG00000250326.1	RP11-284M14.1	4.7	5.85e-06	0.00324	0.32	0.36	Ischemic stroke;	chr4:143187488	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4690777	ENSG00000250326.1	RP11-284M14.1	4.7	5.85e-06	0.00324	0.32	0.36	Ischemic stroke;	chr4:143188382	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs6818149	ENSG00000250326.1	RP11-284M14.1	4.7	5.85e-06	0.00324	0.32	0.36	Ischemic stroke;	chr4:143203932	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4234887	ENSG00000250326.1	RP11-284M14.1	4.7	5.85e-06	0.00324	0.32	0.36	Ischemic stroke;	chr4:143213124	chr4:142933195~143184861:-
PCPG	cis	rs34421088	0.56	rs11780851	ENSG00000255020.1	AF131216.5	-4.7	5.85e-06	0.00324	-0.47	-0.36	Neuroticism;	chr8:11543607	chr8:11345748~11347502:-
PCPG	cis	rs13108904	0.905	rs1680074	ENSG00000254094.1	AC078852.1	4.7	5.85e-06	0.00324	0.41	0.36	Obesity-related traits;	chr4:1285833	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.901	rs1680073	ENSG00000254094.1	AC078852.1	4.7	5.85e-06	0.00324	0.41	0.36	Obesity-related traits;	chr4:1286549	chr4:1356581~1358075:+
PCPG	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	4.7	5.86e-06	0.00325	0.49	0.36	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	4.7	5.86e-06	0.00325	0.49	0.36	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	4.7	5.86e-06	0.00325	0.49	0.36	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	4.7	5.86e-06	0.00325	0.49	0.36	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	4.7	5.86e-06	0.00325	0.49	0.36	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	4.7	5.86e-06	0.00325	0.49	0.36	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
PCPG	cis	rs11148252	0.712	rs61957257	ENSG00000198384.8	TPTE2P3	-4.7	5.86e-06	0.00325	-0.42	-0.36	Lewy body disease;	chr13:52195567	chr13:52522632~52586906:+
PCPG	cis	rs561341	1	rs7214017	ENSG00000265798.5	RP11-271K11.5	4.7	5.86e-06	0.00325	0.62	0.36	Hip circumference adjusted for BMI;	chr17:32005201	chr17:31038575~31059121:-
PCPG	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-4.7	5.86e-06	0.00325	-0.44	-0.36	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
PCPG	cis	rs3736858	1	rs61959583	ENSG00000261105.4	LMO7-AS1	-4.7	5.87e-06	0.00325	-0.69	-0.36	Interleukin-9 levels;	chr13:75854458	chr13:75604700~75635994:-
PCPG	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	4.7	5.87e-06	0.00325	0.37	0.36	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
PCPG	cis	rs3806843	1	rs10066278	ENSG00000202515.1	VTRNA1-3	-4.7	5.87e-06	0.00325	-0.46	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr5:140726158~140726246:+
PCPG	cis	rs748404	0.666	rs62021180	ENSG00000205771.5	CATSPER2P1	-4.7	5.88e-06	0.00325	-0.47	-0.36	Lung cancer;	chr15:43420139	chr15:43726918~43747094:-
PCPG	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-4.7	5.88e-06	0.00326	-0.56	-0.36	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
PCPG	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-4.7	5.88e-06	0.00326	-0.48	-0.36	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
PCPG	cis	rs4972806	0.775	rs2857534	ENSG00000226363.3	HAGLROS	-4.7	5.88e-06	0.00326	-0.36	-0.36	IgG glycosylation;	chr2:176170948	chr2:176177717~176179008:+
PCPG	cis	rs7017914	0.967	rs7825446	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70751939	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs6472543	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70752173	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs7819332	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70756030	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs7012404	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70756463	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs7018381	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70757882	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13258584	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70759344	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs7009297	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70760131	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs7014012	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70760508	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs1471114	ENSG00000254031.4	RP11-326E22.1	4.7	5.88e-06	0.00326	0.35	0.36	Bone mineral density;	chr8:70763312	chr8:71155457~71204223:+
PCPG	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-4.7	5.88e-06	0.00326	-0.47	-0.36	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
PCPG	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-4.7	5.88e-06	0.00326	-0.5	-0.36	Temperament;	chr17:14018109	chr17:14024514~14025488:+
PCPG	cis	rs11858159	1	rs12900285	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Platelet thrombus formation;	chr15:24572506	chr15:24493137~24652130:+
PCPG	cis	rs7403037	0.509	rs7402599	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24572787	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7402269	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Platelet thrombus formation;	chr15:24573014	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7402480	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Platelet thrombus formation;	chr15:24573269	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7402588	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Platelet thrombus formation;	chr15:24573298	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs7174282	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Platelet thrombus formation;	chr15:24577902	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs8038395	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Platelet thrombus formation;	chr15:24578879	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs11858159	ENSG00000259905.4	PWRN1	4.7	5.89e-06	0.00326	0.4	0.36	Platelet thrombus formation;	chr15:24579041	chr15:24493137~24652130:+
PCPG	cis	rs60695258	0.572	rs375795	ENSG00000251411.1	RP11-397E7.4	-4.7	5.89e-06	0.00326	-0.33	-0.36	Hematocrit;	chr4:87051313	chr4:86913266~86914817:-
PCPG	cis	rs60695258	0.55	rs2007132	ENSG00000251411.1	RP11-397E7.4	-4.7	5.89e-06	0.00326	-0.33	-0.36	Hematocrit;	chr4:87051433	chr4:86913266~86914817:-
PCPG	cis	rs60695258	0.55	rs6531948	ENSG00000251411.1	RP11-397E7.4	-4.7	5.89e-06	0.00326	-0.33	-0.36	Hematocrit;	chr4:87051816	chr4:86913266~86914817:-
PCPG	cis	rs1949733	1	rs1880023	ENSG00000205959.3	RP11-689P11.2	4.7	5.89e-06	0.00326	0.4	0.36	Response to antineoplastic agents;	chr4:8479104	chr4:8482270~8512610:+
PCPG	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-4.7	5.9e-06	0.00326	-0.39	-0.36	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
PCPG	cis	rs2028414	0.512	rs2251389	ENSG00000258701.1	LINC00638	4.7	5.9e-06	0.00326	0.46	0.36	IgG glycosylation;	chr14:104885918	chr14:104821201~104823718:+
PCPG	cis	rs7824557	0.843	rs2572418	ENSG00000255020.1	AF131216.5	-4.7	5.9e-06	0.00327	-0.47	-0.36	Retinal vascular caliber;	chr8:11255580	chr8:11345748~11347502:-
PCPG	cis	rs11673344	0.523	rs10420330	ENSG00000226686.6	LINC01535	4.7	5.91e-06	0.00327	0.46	0.36	Obesity-related traits;	chr19:37111269	chr19:37251912~37265535:+
PCPG	cis	rs2625529	0.667	rs16956381	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71900896	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.775	rs12913042	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71909968	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs4777470	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71915177	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.761	rs4776582	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71915179	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs4777471	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71915463	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12906711	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71922724	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs7170754	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71926253	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs7170461	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71926258	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12917428	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71929657	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.701	rs2306490	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71935496	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.762	rs1384007	ENSG00000260037.4	CTD-2524L6.3	-4.7	5.91e-06	0.00327	-0.58	-0.36	Red blood cell count;	chr15:71937193	chr15:71818396~71823384:+
PCPG	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	4.7	5.91e-06	0.00327	0.38	0.36	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	4.7	5.91e-06	0.00327	0.38	0.36	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
PCPG	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	4.7	5.93e-06	0.00328	0.51	0.36	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
PCPG	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-4.7	5.93e-06	0.00328	-0.55	-0.36	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	4.7	5.93e-06	0.00328	0.55	0.36	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	4.7	5.93e-06	0.00328	0.55	0.36	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
PCPG	cis	rs3806843	0.966	rs10053945	ENSG00000202515.1	VTRNA1-3	-4.7	5.93e-06	0.00328	-0.46	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140780542	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs1548700	ENSG00000202515.1	VTRNA1-3	-4.7	5.93e-06	0.00328	-0.46	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140785304	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs1548699	ENSG00000202515.1	VTRNA1-3	-4.7	5.93e-06	0.00328	-0.46	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140785333	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs6898939	ENSG00000202515.1	VTRNA1-3	-4.7	5.93e-06	0.00328	-0.46	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140789770	chr5:140726158~140726246:+
PCPG	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	4.7	5.93e-06	0.00328	0.46	0.36	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
PCPG	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	4.7	5.94e-06	0.00328	0.48	0.36	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
PCPG	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	4.7	5.95e-06	0.00329	0.47	0.36	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
PCPG	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	4.7	5.95e-06	0.00329	0.61	0.36	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
PCPG	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	4.7	5.95e-06	0.00329	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
PCPG	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	4.7	5.95e-06	0.00329	0.46	0.36	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
PCPG	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-4.7	5.95e-06	0.00329	-0.47	-0.36	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
PCPG	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-4.7	5.96e-06	0.00329	-0.38	-0.36	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
PCPG	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	4.7	5.96e-06	0.00329	0.47	0.36	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
PCPG	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	4.7	5.96e-06	0.00329	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
PCPG	cis	rs11858159	1	rs7496600	ENSG00000259905.4	PWRN1	4.7	5.96e-06	0.00329	0.4	0.36	Platelet thrombus formation;	chr15:24570865	chr15:24493137~24652130:+
PCPG	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-4.7	5.96e-06	0.00329	-0.44	-0.36	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
PCPG	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	4.7	5.96e-06	0.00329	0.39	0.36	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
PCPG	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-4.69	5.97e-06	0.0033	-0.43	-0.36	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-4.69	5.97e-06	0.0033	-0.43	-0.36	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
PCPG	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-4.69	5.97e-06	0.0033	-0.41	-0.36	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
PCPG	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	4.69	5.97e-06	0.0033	0.49	0.36	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
PCPG	cis	rs9890032	0.532	rs1808257	ENSG00000263603.1	CTD-2349P21.5	-4.69	5.98e-06	0.0033	-0.39	-0.36	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30729469~30731202:+
PCPG	cis	rs3806843	0.868	rs2531349	ENSG00000202515.1	VTRNA1-3	4.69	5.98e-06	0.0033	0.45	0.36	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr5:140726158~140726246:+
PCPG	cis	rs11858159	1	rs12903200	ENSG00000259905.4	PWRN1	4.69	5.98e-06	0.0033	0.4	0.36	Platelet thrombus formation;	chr15:24546747	chr15:24493137~24652130:+
PCPG	cis	rs13113518	0.966	rs11133387	ENSG00000272969.1	RP11-528I4.2	4.69	5.98e-06	0.0033	0.39	0.36	Height;	chr4:55475130	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs9312661	ENSG00000272969.1	RP11-528I4.2	4.69	5.98e-06	0.0033	0.39	0.36	Height;	chr4:55476159	chr4:55547112~55547889:+
PCPG	cis	rs3806843	1	rs12055222	ENSG00000202515.1	VTRNA1-3	-4.69	5.98e-06	0.0033	-0.46	-0.36	Depressive symptoms (multi-trait analysis);	chr5:140785983	chr5:140726158~140726246:+
PCPG	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-4.69	5.99e-06	0.0033	-0.38	-0.36	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
PCPG	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	4.69	5.99e-06	0.0033	0.48	0.36	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
PCPG	cis	rs1488515	0.547	rs7785652	ENSG00000279067.1	GS1-25M2.1	-4.69	5.99e-06	0.0033	-0.53	-0.36	Obesity-related traits;	chr7:96039739	chr7:96118647~96119995:+
PCPG	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	4.69	5.99e-06	0.00331	0.44	0.36	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
PCPG	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	4.69	6e-06	0.00331	0.41	0.36	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	4.69	6e-06	0.00331	0.41	0.36	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	4.69	6e-06	0.00331	0.41	0.36	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
PCPG	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-4.69	6e-06	0.00331	-0.41	-0.36	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-4.69	6e-06	0.00331	-0.41	-0.36	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-4.69	6e-06	0.00331	-0.41	-0.36	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-4.69	6e-06	0.00331	-0.41	-0.36	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
PCPG	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-4.69	6e-06	0.00331	-0.41	-0.36	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
PCPG	cis	rs7017914	0.837	rs2732105	ENSG00000254031.4	RP11-326E22.1	4.69	6.01e-06	0.00332	0.34	0.36	Bone mineral density;	chr8:71011410	chr8:71155457~71204223:+
PCPG	cis	rs300890	0.56	rs300925	ENSG00000250326.1	RP11-284M14.1	4.69	6.01e-06	0.00332	0.33	0.36	Nasopharyngeal carcinoma;	chr4:143263040	chr4:142933195~143184861:-
PCPG	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-4.69	6.01e-06	0.00332	-0.49	-0.36	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
PCPG	cis	rs5743030	0.702	rs2168057	ENSG00000253559.1	OSGEPL1-AS1	4.69	6.02e-06	0.00332	0.54	0.36	Subcutaneous adipose tissue;	chr2:189912978	chr2:189762704~189765556:+
PCPG	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-4.69	6.03e-06	0.00332	-0.43	-0.36	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
PCPG	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	4.69	6.04e-06	0.00333	0.44	0.36	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
PCPG	cis	rs17507216	0.671	rs4779035	ENSG00000228141.5	AC105339.1	-4.69	6.04e-06	0.00333	-0.55	-0.36	Excessive daytime sleepiness;	chr15:82591686	chr15:82710471~82714026:-
PCPG	cis	rs10435719	0.753	rs9694940	ENSG00000255495.1	AC145124.2	4.69	6.04e-06	0.00333	0.36	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932349	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.78	rs9692662	ENSG00000255495.1	AC145124.2	4.69	6.04e-06	0.00333	0.36	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932354	chr8:12194467~12196280:+
PCPG	cis	rs10435719	0.899	rs9693925	ENSG00000255495.1	AC145124.2	4.69	6.04e-06	0.00333	0.36	0.36	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11932454	chr8:12194467~12196280:+
PCPG	cis	rs748404	0.666	rs72709879	ENSG00000249839.1	AC011330.5	-4.69	6.05e-06	0.00333	-0.48	-0.36	Lung cancer;	chr15:43507777	chr15:43663654~43684339:-
PCPG	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	4.69	6.05e-06	0.00333	0.55	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
PCPG	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	4.69	6.06e-06	0.00334	0.42	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
PCPG	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-4.69	6.06e-06	0.00334	-0.43	-0.36	Height;	chr2:231551270	chr2:231508426~231514339:-
PCPG	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	4.69	6.09e-06	0.00335	0.49	0.36	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
PCPG	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-4.69	6.09e-06	0.00335	-0.5	-0.36	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
PCPG	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	4.69	6.09e-06	0.00335	0.5	0.36	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
PCPG	cis	rs11673344	0.504	rs8099987	ENSG00000226686.6	LINC01535	4.69	6.09e-06	0.00335	0.46	0.36	Obesity-related traits;	chr19:37132570	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs8110796	ENSG00000226686.6	LINC01535	4.69	6.09e-06	0.00335	0.46	0.36	Obesity-related traits;	chr19:37132682	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs8111285	ENSG00000226686.6	LINC01535	4.69	6.09e-06	0.00335	0.46	0.36	Obesity-related traits;	chr19:37132747	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs6510591	ENSG00000226686.6	LINC01535	4.69	6.09e-06	0.00335	0.46	0.36	Obesity-related traits;	chr19:37133186	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs6510592	ENSG00000226686.6	LINC01535	4.69	6.09e-06	0.00335	0.46	0.36	Obesity-related traits;	chr19:37133430	chr19:37251912~37265535:+
PCPG	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-4.69	6.1e-06	0.00335	-0.37	-0.36	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
PCPG	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-4.69	6.1e-06	0.00335	-0.31	-0.36	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
PCPG	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-4.69	6.1e-06	0.00335	-0.39	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
PCPG	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-4.69	6.1e-06	0.00336	-0.38	-0.36	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-4.69	6.1e-06	0.00336	-0.38	-0.36	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-4.69	6.1e-06	0.00336	-0.38	-0.36	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-4.69	6.1e-06	0.00336	-0.38	-0.36	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
PCPG	cis	rs7824557	0.778	rs6601572	ENSG00000255020.1	AF131216.5	-4.69	6.12e-06	0.00337	-0.47	-0.36	Retinal vascular caliber;	chr8:11235828	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	4.69	6.13e-06	0.00337	0.44	0.36	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
PCPG	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-4.69	6.13e-06	0.00337	-0.37	-0.36	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
PCPG	cis	rs10760158	0.768	rs10985187	ENSG00000226752.6	PSMD5-AS1	-4.69	6.14e-06	0.00337	-0.46	-0.36	Pulse pressure;	chr9:121232398	chr9:120824828~120854385:+
PCPG	cis	rs2408955	0.521	rs1476607	ENSG00000240399.1	RP1-228P16.1	-4.69	6.14e-06	0.00337	-0.38	-0.36	Glycated hemoglobin levels;	chr12:48131021	chr12:48054813~48055591:-
PCPG	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	4.69	6.14e-06	0.00338	0.3	0.36	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
PCPG	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	4.69	6.14e-06	0.00338	0.36	0.36	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
PCPG	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-4.69	6.14e-06	0.00338	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
PCPG	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-4.69	6.15e-06	0.00338	-0.43	-0.36	Height;	chr2:231553603	chr2:231508426~231514339:-
PCPG	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-4.69	6.15e-06	0.00338	-0.46	-0.36	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
PCPG	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-4.69	6.15e-06	0.00338	-0.46	-0.36	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
PCPG	cis	rs34421088	0.56	rs2245357	ENSG00000255020.1	AF131216.5	-4.69	6.15e-06	0.00338	-0.47	-0.36	Neuroticism;	chr8:11541975	chr8:11345748~11347502:-
PCPG	cis	rs1440410	0.835	rs13133090	ENSG00000250326.1	RP11-284M14.1	4.69	6.16e-06	0.00339	0.33	0.36	Ischemic stroke;	chr4:143155916	chr4:142933195~143184861:-
PCPG	cis	rs2625529	0.556	rs11630611	ENSG00000260037.4	CTD-2524L6.3	4.69	6.17e-06	0.00339	0.45	0.36	Red blood cell count;	chr15:72173971	chr15:71818396~71823384:+
PCPG	cis	rs11168351	0.889	rs12817104	ENSG00000240399.1	RP1-228P16.1	4.69	6.17e-06	0.00339	0.37	0.36	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48054813~48055591:-
PCPG	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-4.69	6.18e-06	0.00339	-0.38	-0.36	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-4.69	6.18e-06	0.00339	-0.38	-0.36	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
PCPG	cis	rs6540731	0.521	rs10779572	ENSG00000226251.4	RP11-15I11.3	4.69	6.18e-06	0.0034	0.44	0.36	Intelligence (childhood);	chr1:212181070	chr1:212225278~212238977:-
PCPG	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	4.69	6.18e-06	0.0034	0.56	0.36	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
PCPG	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	4.69	6.19e-06	0.0034	0.49	0.36	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
PCPG	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	4.69	6.19e-06	0.0034	0.49	0.36	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
PCPG	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	4.69	6.19e-06	0.0034	0.4	0.36	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
PCPG	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-4.69	6.19e-06	0.0034	-0.44	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
PCPG	cis	rs5758511	0.68	rs5758688	ENSG00000205702.9	CYP2D7	4.69	6.22e-06	0.00341	0.48	0.36	Birth weight;	chr22:42266495	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.633	rs5758689	ENSG00000205702.9	CYP2D7	4.69	6.22e-06	0.00341	0.48	0.36	Birth weight;	chr22:42268966	chr22:42140203~42144577:-
PCPG	cis	rs2625529	0.824	rs16956328	ENSG00000260037.4	CTD-2524L6.3	-4.69	6.22e-06	0.00341	-0.57	-0.36	Red blood cell count;	chr15:71851514	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.775	rs62023342	ENSG00000260037.4	CTD-2524L6.3	-4.69	6.22e-06	0.00341	-0.57	-0.36	Red blood cell count;	chr15:71868964	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.713	rs12903980	ENSG00000260037.4	CTD-2524L6.3	-4.69	6.22e-06	0.00341	-0.57	-0.36	Red blood cell count;	chr15:71873208	chr15:71818396~71823384:+
PCPG	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	4.69	6.22e-06	0.00341	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	4.69	6.22e-06	0.00341	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	4.69	6.22e-06	0.00341	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	4.69	6.22e-06	0.00341	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	4.69	6.22e-06	0.00341	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
PCPG	cis	rs10899021	0.92	rs7112664	ENSG00000279353.1	RP11-864N7.4	4.69	6.22e-06	0.00341	0.65	0.36	Response to metformin (IC50);	chr11:74637381	chr11:74698231~74699658:-
PCPG	cis	rs17772222	0.958	rs1123421	ENSG00000222990.1	RNU4-22P	4.69	6.23e-06	0.00342	0.46	0.36	Coronary artery calcification;	chr14:88524651	chr14:88513498~88513663:+
PCPG	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-4.68	6.23e-06	0.00342	-0.47	-0.36	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
PCPG	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	4.68	6.23e-06	0.00342	0.51	0.36	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
PCPG	cis	rs7824557	0.583	rs4448232	ENSG00000255020.1	AF131216.5	4.68	6.23e-06	0.00342	0.49	0.36	Retinal vascular caliber;	chr8:11373845	chr8:11345748~11347502:-
PCPG	cis	rs7208859	0.623	rs56163556	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8067035	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8067338	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs4055105	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73269923	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.562	rs8078897	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8075163	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs8075107	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Body mass index;	chr17:30779631	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7223209	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs7223404	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9916725	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9916727	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9914499	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73269945	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9897728	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs1054400	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs1054397	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9890558	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9912283	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs12006	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs3752021	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs3752020	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9890855	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9893422	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs9891166	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs73269974	ENSG00000263603.1	CTD-2349P21.5	-4.68	6.23e-06	0.00342	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30729469~30731202:+
PCPG	cis	rs11148252	0.595	rs9526974	ENSG00000198384.8	TPTE2P3	-4.68	6.23e-06	0.00342	-0.46	-0.36	Lewy body disease;	chr13:52676905	chr13:52522632~52586906:+
PCPG	cis	rs11148252	0.669	rs61958050	ENSG00000278238.1	RP11-245D16.4	-4.68	6.24e-06	0.00342	-0.34	-0.36	Lewy body disease;	chr13:52420292	chr13:52454775~52455331:-
PCPG	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	4.68	6.24e-06	0.00342	0.43	0.36	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
PCPG	cis	rs10461617	0.541	rs860581	ENSG00000271828.1	CTD-2310F14.1	4.68	6.24e-06	0.00342	0.78	0.36	Type 2 diabetes;	chr5:56854710	chr5:56927874~56929573:+
PCPG	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-4.68	6.24e-06	0.00342	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
PCPG	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-4.68	6.25e-06	0.00342	-0.42	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
PCPG	cis	rs11858159	1	rs11161106	ENSG00000259905.4	PWRN1	4.68	6.25e-06	0.00342	0.41	0.36	Platelet thrombus formation;	chr15:24542034	chr15:24493137~24652130:+
PCPG	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	4.68	6.26e-06	0.00343	0.34	0.36	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	4.68	6.26e-06	0.00343	0.34	0.36	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
PCPG	cis	rs561341	1	rs508192	ENSG00000265798.5	RP11-271K11.5	-4.68	6.26e-06	0.00343	-0.62	-0.36	Hip circumference adjusted for BMI;	chr17:31988128	chr17:31038575~31059121:-
PCPG	cis	rs5769765	0.862	rs56377703	ENSG00000278869.1	CITF22-49E9.3	4.68	6.26e-06	0.00343	0.49	0.36	Schizophrenia;	chr22:49913292	chr22:49933198~49934074:-
PCPG	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-4.68	6.26e-06	0.00343	-0.51	-0.36	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
PCPG	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	4.68	6.27e-06	0.00344	0.38	0.36	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
PCPG	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-4.68	6.28e-06	0.00344	-0.42	-0.36	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
PCPG	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	4.68	6.29e-06	0.00344	0.45	0.36	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	4.68	6.29e-06	0.00344	0.45	0.36	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	4.68	6.29e-06	0.00344	0.45	0.36	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	4.68	6.29e-06	0.00344	0.45	0.36	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
PCPG	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	4.68	6.29e-06	0.00344	0.4	0.36	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
PCPG	cis	rs17507216	0.628	rs28737193	ENSG00000228141.5	AC105339.1	-4.68	6.3e-06	0.00345	-0.54	-0.36	Excessive daytime sleepiness;	chr15:82701318	chr15:82710471~82714026:-
PCPG	cis	rs2279440	0.585	rs7651326	ENSG00000254485.4	RP11-380O24.1	4.68	6.3e-06	0.00345	0.58	0.36	Glucose homeostasis traits;	chr3:9459629	chr3:9292588~9363303:-
PCPG	cis	rs2836974	0.604	rs914156	ENSG00000255568.3	BRWD1-AS2	4.68	6.31e-06	0.00345	0.36	0.36	Cognitive function;	chr21:39345552	chr21:39313935~39314962:+
PCPG	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-4.68	6.31e-06	0.00345	-0.47	-0.36	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-4.68	6.31e-06	0.00345	-0.47	-0.36	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
PCPG	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	4.68	6.31e-06	0.00345	0.51	0.36	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
PCPG	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	4.68	6.32e-06	0.00346	0.43	0.36	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
PCPG	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-4.68	6.32e-06	0.00346	-0.44	-0.36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
PCPG	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-4.68	6.32e-06	0.00346	-0.44	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
PCPG	cis	rs7017914	0.69	rs2732127	ENSG00000254031.4	RP11-326E22.1	4.68	6.33e-06	0.00347	0.33	0.36	Bone mineral density;	chr8:70984584	chr8:71155457~71204223:+
PCPG	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	4.68	6.33e-06	0.00347	0.42	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
PCPG	cis	rs2625529	0.824	rs2415130	ENSG00000260037.4	CTD-2524L6.3	-4.68	6.34e-06	0.00347	-0.58	-0.36	Red blood cell count;	chr15:71950213	chr15:71818396~71823384:+
PCPG	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	4.68	6.35e-06	0.00347	0.42	0.36	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
PCPG	cis	rs950169	0.96	rs35159785	ENSG00000235370.6	DNM1P51	4.68	6.35e-06	0.00347	0.39	0.36	Schizophrenia;	chr15:84135262	chr15:84398316~84411701:-
PCPG	cis	rs66486766	1	rs66486766	ENSG00000235370.6	DNM1P51	4.68	6.35e-06	0.00347	0.39	0.36	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84398316~84411701:-
PCPG	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-4.68	6.35e-06	0.00347	-0.33	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
PCPG	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	4.68	6.35e-06	0.00348	0.47	0.36	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
PCPG	cis	rs1440410	0.835	rs4594668	ENSG00000250326.1	RP11-284M14.1	-4.68	6.35e-06	0.00348	-0.33	-0.36	Ischemic stroke;	chr4:143129293	chr4:142933195~143184861:-
PCPG	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-4.68	6.36e-06	0.00348	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-4.68	6.36e-06	0.00348	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-4.68	6.36e-06	0.00348	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-4.68	6.36e-06	0.00348	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-4.68	6.36e-06	0.00348	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-4.68	6.36e-06	0.00348	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
PCPG	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	4.68	6.36e-06	0.00348	0.41	0.36	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	4.68	6.36e-06	0.00348	0.41	0.36	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	4.68	6.36e-06	0.00348	0.41	0.36	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
PCPG	cis	rs1048886	0.872	rs55761717	ENSG00000271967.1	RP11-134K13.4	-4.68	6.37e-06	0.00348	-0.46	-0.36	Type 2 diabetes;	chr6:70489778	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs78892979	ENSG00000271967.1	RP11-134K13.4	-4.68	6.37e-06	0.00348	-0.46	-0.36	Type 2 diabetes;	chr6:70495559	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs77092253	ENSG00000271967.1	RP11-134K13.4	-4.68	6.37e-06	0.00348	-0.46	-0.36	Type 2 diabetes;	chr6:70505156	chr6:70596438~70596980:+
PCPG	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-4.68	6.37e-06	0.00348	-0.37	-0.36	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
PCPG	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-4.68	6.38e-06	0.00349	-0.37	-0.36	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
PCPG	cis	rs300890	0.513	rs4269133	ENSG00000250326.1	RP11-284M14.1	4.68	6.39e-06	0.00349	0.34	0.36	Nasopharyngeal carcinoma;	chr4:143125692	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.52	rs4629391	ENSG00000250326.1	RP11-284M14.1	4.68	6.39e-06	0.00349	0.34	0.36	Ischemic stroke;	chr4:143125721	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs4286475	ENSG00000250326.1	RP11-284M14.1	4.68	6.39e-06	0.00349	0.34	0.36	Nasopharyngeal carcinoma;	chr4:143125758	chr4:142933195~143184861:-
PCPG	cis	rs748404	0.666	rs16957715	ENSG00000205771.5	CATSPER2P1	-4.68	6.39e-06	0.00349	-0.46	-0.36	Lung cancer;	chr15:43416539	chr15:43726918~43747094:-
PCPG	cis	rs11858159	0.934	rs12912509	ENSG00000259905.4	PWRN1	4.68	6.39e-06	0.00349	0.41	0.36	Platelet thrombus formation;	chr15:24571513	chr15:24493137~24652130:+
PCPG	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	4.68	6.4e-06	0.00349	0.56	0.36	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	4.68	6.4e-06	0.00349	0.56	0.36	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
PCPG	cis	rs2625529	0.526	rs1035744	ENSG00000260037.4	CTD-2524L6.3	4.68	6.4e-06	0.0035	0.45	0.36	Red blood cell count;	chr15:72274274	chr15:71818396~71823384:+
PCPG	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	4.68	6.4e-06	0.0035	0.48	0.36	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
PCPG	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-4.68	6.4e-06	0.0035	-0.68	-0.36	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
PCPG	cis	rs2115630	0.846	rs8024538	ENSG00000275120.1	RP11-182J1.17	-4.68	6.4e-06	0.0035	-0.36	-0.36	P wave terminal force;	chr15:84825188	chr15:84599434~84606463:-
PCPG	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-4.68	6.41e-06	0.0035	-0.42	-0.36	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
PCPG	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	4.68	6.42e-06	0.00351	0.53	0.36	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
PCPG	cis	rs2412819	0.545	rs654276	ENSG00000249839.1	AC011330.5	4.68	6.42e-06	0.00351	0.48	0.36	Lung cancer;	chr15:43798656	chr15:43663654~43684339:-
PCPG	cis	rs2625529	0.617	rs7175792	ENSG00000260037.4	CTD-2524L6.3	-4.68	6.43e-06	0.00351	-0.47	-0.36	Red blood cell count;	chr15:72139542	chr15:71818396~71823384:+
PCPG	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	4.68	6.43e-06	0.00351	0.44	0.36	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
PCPG	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-4.68	6.44e-06	0.00352	-0.6	-0.36	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
PCPG	cis	rs591584	0.704	rs12574292	ENSG00000255893.1	RP11-685N10.1	-4.68	6.44e-06	0.00352	-0.43	-0.36	Macrophage Migration Inhibitory Factor levels;	chr11:94586652	chr11:94472908~94473570:-
PCPG	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-4.68	6.44e-06	0.00352	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
PCPG	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	4.68	6.44e-06	0.00352	0.33	0.36	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
PCPG	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	4.68	6.44e-06	0.00352	0.59	0.36	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
PCPG	cis	rs11250097	0.507	rs2409779	ENSG00000255020.1	AF131216.5	-4.68	6.45e-06	0.00352	-0.54	-0.36	Neuroticism;	chr8:11453831	chr8:11345748~11347502:-
PCPG	cis	rs9392556	0.626	rs626080	ENSG00000230648.1	RP3-406P24.3	-4.68	6.45e-06	0.00352	-0.42	-0.36	Blood metabolite levels;	chr6:4101333	chr6:4018843~4021215:-
PCPG	cis	rs2060793	0.659	rs1839834	ENSG00000251991.1	RNU7-49P	4.68	6.45e-06	0.00352	0.4	0.36	Vitamin D levels;	chr11:14807914	chr11:14478892~14478953:+
PCPG	cis	rs1488515	0.501	rs73232542	ENSG00000279067.1	GS1-25M2.1	-4.68	6.46e-06	0.00352	-0.52	-0.36	Obesity-related traits;	chr7:96042653	chr7:96118647~96119995:+
PCPG	cis	rs12681963	0.614	rs4507726	ENSG00000248159.1	HSPA8P11	4.68	6.48e-06	0.00353	0.67	0.36	Migraine;	chr8:30214491	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs4454242	ENSG00000248159.1	HSPA8P11	4.68	6.48e-06	0.00353	0.67	0.36	Migraine;	chr8:30214804	chr8:30237382~30240997:+
PCPG	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	4.68	6.49e-06	0.00354	0.4	0.36	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
PCPG	cis	rs11673344	0.543	rs8108429	ENSG00000226686.6	LINC01535	4.68	6.5e-06	0.00354	0.46	0.36	Obesity-related traits;	chr19:37145874	chr19:37251912~37265535:+
PCPG	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	4.68	6.5e-06	0.00354	0.48	0.36	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
PCPG	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	4.67	6.5e-06	0.00355	0.39	0.36	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
PCPG	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	4.67	6.5e-06	0.00355	0.45	0.36	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	4.67	6.5e-06	0.00355	0.45	0.36	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	4.67	6.5e-06	0.00355	0.45	0.36	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	4.67	6.5e-06	0.00355	0.45	0.36	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
PCPG	cis	rs5743030	0.702	rs9917356	ENSG00000253559.1	OSGEPL1-AS1	-4.67	6.51e-06	0.00355	-0.54	-0.36	Subcutaneous adipose tissue;	chr2:189925268	chr2:189762704~189765556:+
PCPG	cis	rs7945705	0.875	rs10769955	ENSG00000254860.4	TMEM9B-AS1	-4.67	6.51e-06	0.00355	-0.37	-0.36	Hemoglobin concentration;	chr11:8763100	chr11:8964675~8977527:+
PCPG	cis	rs7819412	0.74	rs11250119	ENSG00000255020.1	AF131216.5	-4.67	6.51e-06	0.00355	-0.45	-0.36	Triglycerides;	chr8:11179525	chr8:11345748~11347502:-
PCPG	cis	rs9959145	0.543	rs11664013	ENSG00000267108.1	RP11-861E21.1	-4.67	6.53e-06	0.00356	-0.47	-0.36	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12432897~12437635:+
PCPG	cis	rs9302635	0.678	rs8054585	ENSG00000260886.1	TAT-AS1	4.67	6.53e-06	0.00356	0.5	0.36	Blood protein levels;	chr16:72191415	chr16:71565789~71578187:+
PCPG	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-4.67	6.53e-06	0.00356	-0.38	-0.36	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-4.67	6.53e-06	0.00356	-0.38	-0.36	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-4.67	6.53e-06	0.00356	-0.38	-0.36	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-4.67	6.53e-06	0.00356	-0.38	-0.36	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-4.67	6.53e-06	0.00356	-0.38	-0.36	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-4.67	6.53e-06	0.00356	-0.38	-0.36	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
PCPG	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-4.67	6.54e-06	0.00356	-0.38	-0.36	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
PCPG	cis	rs7772486	0.654	rs9376958	ENSG00000270638.1	RP3-466P17.1	-4.67	6.54e-06	0.00356	-0.38	-0.36	Lobe attachment (rater-scored or self-reported);	chr6:145701904	chr6:145735570~145737218:+
PCPG	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-4.67	6.54e-06	0.00356	-0.46	-0.36	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
PCPG	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	4.67	6.56e-06	0.00357	0.39	0.36	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
PCPG	cis	rs17772222	1	rs3814855	ENSG00000222990.1	RNU4-22P	4.67	6.56e-06	0.00357	0.49	0.36	Coronary artery calcification;	chr14:88467016	chr14:88513498~88513663:+
PCPG	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-4.67	6.56e-06	0.00357	-0.49	-0.36	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
PCPG	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-4.67	6.57e-06	0.00358	-0.34	-0.36	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
PCPG	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-4.67	6.58e-06	0.00358	-0.42	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
PCPG	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-4.67	6.59e-06	0.00359	-0.46	-0.36	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
PCPG	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-4.67	6.59e-06	0.00359	-0.46	-0.36	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-4.67	6.59e-06	0.00359	-0.46	-0.36	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-4.67	6.59e-06	0.00359	-0.46	-0.36	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-4.67	6.59e-06	0.00359	-0.46	-0.36	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-4.67	6.59e-06	0.00359	-0.46	-0.36	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-4.67	6.59e-06	0.00359	-0.46	-0.36	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
PCPG	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-4.67	6.59e-06	0.00359	-0.38	-0.36	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
PCPG	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-4.67	6.59e-06	0.00359	-0.44	-0.36	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
PCPG	cis	rs10419113	0.668	rs2360530	ENSG00000268545.1	VN1R107P	4.67	6.59e-06	0.00359	0.38	0.36	Pediatric bone mineral density (spine);	chr19:57669785	chr19:57459912~57460120:+
PCPG	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-4.67	6.6e-06	0.00359	-0.33	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
PCPG	cis	rs5742933	0.857	rs10931430	ENSG00000273240.1	RP11-455J20.3	4.67	6.6e-06	0.00359	0.38	0.36	Ferritin levels;	chr2:189677460	chr2:189763859~189764456:-
PCPG	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	4.67	6.6e-06	0.00359	0.44	0.36	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
PCPG	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	4.67	6.61e-06	0.0036	0.54	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
PCPG	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	4.67	6.62e-06	0.0036	0.5	0.36	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
PCPG	cis	rs748404	0.666	rs60018990	ENSG00000249839.1	AC011330.5	-4.67	6.62e-06	0.0036	-0.48	-0.36	Lung cancer;	chr15:43504606	chr15:43663654~43684339:-
PCPG	cis	rs1048886	0.808	rs75589353	ENSG00000271967.1	RP11-134K13.4	-4.67	6.62e-06	0.0036	-0.46	-0.36	Type 2 diabetes;	chr6:70540228	chr6:70596438~70596980:+
PCPG	cis	rs10419113	0.701	rs10403317	ENSG00000268545.1	VN1R107P	4.67	6.63e-06	0.00361	0.37	0.36	Pediatric bone mineral density (spine);	chr19:57680115	chr19:57459912~57460120:+
PCPG	cis	rs561341	0.882	rs16967101	ENSG00000265798.5	RP11-271K11.5	4.67	6.63e-06	0.00361	0.6	0.36	Hip circumference adjusted for BMI;	chr17:32050143	chr17:31038575~31059121:-
PCPG	cis	rs7587476	0.861	rs17488049	ENSG00000229267.2	AC072062.1	-4.67	6.63e-06	0.00361	-0.49	-0.36	Neuroblastoma;	chr2:214787026	chr2:214810229~214963274:+
PCPG	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	4.67	6.63e-06	0.00361	0.44	0.36	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
PCPG	cis	rs3764021	0.87	rs11052710	ENSG00000278635.1	CTD-2318O12.1	-4.67	6.63e-06	0.00361	-0.43	-0.36	Type 1 diabetes;	chr12:9723754	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.87	rs10772085	ENSG00000278635.1	CTD-2318O12.1	-4.67	6.63e-06	0.00361	-0.43	-0.36	Type 1 diabetes;	chr12:9724281	chr12:9415641~9416718:+
PCPG	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	4.67	6.63e-06	0.00361	0.47	0.36	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
PCPG	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-4.67	6.64e-06	0.00361	-0.37	-0.36	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-4.67	6.64e-06	0.00361	-0.37	-0.36	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
PCPG	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-4.67	6.64e-06	0.00361	-0.46	-0.36	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
PCPG	cis	rs10760158	0.832	rs12238702	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121237547	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10985188	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121237747	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs4837818	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121240041	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10760160	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121241048	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.769	rs10760161	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121241790	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.769	rs10818517	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121242321	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.769	rs10760162	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121242905	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.739	rs4837819	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121246156	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.739	rs10760163	ENSG00000226752.6	PSMD5-AS1	-4.67	6.64e-06	0.00361	-0.46	-0.36	Pulse pressure;	chr9:121246174	chr9:120824828~120854385:+
PCPG	cis	rs591584	0.73	rs7342170	ENSG00000255893.1	RP11-685N10.1	-4.67	6.65e-06	0.00361	-0.42	-0.36	Macrophage Migration Inhibitory Factor levels;	chr11:94581311	chr11:94472908~94473570:-
PCPG	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	4.67	6.66e-06	0.00362	0.49	0.36	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
PCPG	cis	rs7017914	0.934	rs1993862	ENSG00000254031.4	RP11-326E22.1	4.67	6.66e-06	0.00362	0.35	0.36	Bone mineral density;	chr8:70667127	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.87	rs34282253	ENSG00000254031.4	RP11-326E22.1	4.67	6.66e-06	0.00362	0.35	0.36	Bone mineral density;	chr8:70670131	chr8:71155457~71204223:+
PCPG	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	4.67	6.66e-06	0.00362	0.44	0.36	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
PCPG	cis	rs7017914	0.934	rs10504479	ENSG00000254031.4	RP11-326E22.1	4.67	6.67e-06	0.00362	0.35	0.36	Bone mineral density;	chr8:70665280	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs35109143	ENSG00000254031.4	RP11-326E22.1	4.67	6.67e-06	0.00362	0.35	0.36	Bone mineral density;	chr8:70665665	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.902	rs13269513	ENSG00000254031.4	RP11-326E22.1	4.67	6.67e-06	0.00362	0.35	0.36	Bone mineral density;	chr8:70665844	chr8:71155457~71204223:+
PCPG	cis	rs13113518	0.812	rs12500601	ENSG00000272969.1	RP11-528I4.2	4.67	6.67e-06	0.00363	0.38	0.36	Height;	chr4:55451489	chr4:55547112~55547889:+
PCPG	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	4.67	6.68e-06	0.00363	0.59	0.36	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
PCPG	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	4.67	6.68e-06	0.00363	0.49	0.36	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	4.67	6.68e-06	0.00363	0.49	0.36	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
PCPG	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-4.67	6.68e-06	0.00363	-0.49	-0.36	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
PCPG	cis	rs11858159	0.903	rs12324726	ENSG00000259905.4	PWRN1	4.67	6.68e-06	0.00363	0.38	0.36	Platelet thrombus formation;	chr15:24553517	chr15:24493137~24652130:+
PCPG	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-4.67	6.69e-06	0.00363	-0.4	-0.36	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-4.67	6.69e-06	0.00363	-0.4	-0.36	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
PCPG	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	4.67	6.69e-06	0.00363	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
PCPG	cis	rs12646107	0.882	rs112842531	ENSG00000261672.1	RP11-475B2.1	-4.67	6.69e-06	0.00363	-0.57	-0.36	Response to amphetamines;	chr4:173616821	chr4:173593672~173594556:+
PCPG	cis	rs12646107	0.766	rs76980454	ENSG00000261672.1	RP11-475B2.1	-4.67	6.69e-06	0.00363	-0.57	-0.36	Response to amphetamines;	chr4:173629792	chr4:173593672~173594556:+
PCPG	cis	rs12646107	0.882	rs111266996	ENSG00000261672.1	RP11-475B2.1	-4.67	6.69e-06	0.00363	-0.57	-0.36	Response to amphetamines;	chr4:173633651	chr4:173593672~173594556:+
PCPG	cis	rs7017914	0.967	rs6472539	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70717575	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs3954897	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70723720	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.811	rs4272413	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70723952	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.935	rs6981435	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70724913	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs6999739	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70724977	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs7013657	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70725324	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs7006615	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70727572	chr8:71155457~71204223:+
PCPG	cis	rs7017914	1	rs7007450	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70728034	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs11989553	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70728664	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13272523	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70729237	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs62530826	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70729408	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs35295900	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70729826	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs35115527	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70730774	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.902	rs11991273	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70733625	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.869	rs11987511	ENSG00000254031.4	RP11-326E22.1	4.67	6.69e-06	0.00363	0.35	0.36	Bone mineral density;	chr8:70733636	chr8:71155457~71204223:+
PCPG	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	4.67	6.69e-06	0.00363	0.58	0.36	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
PCPG	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	4.67	6.7e-06	0.00364	0.4	0.36	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	4.67	6.7e-06	0.00364	0.4	0.36	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
PCPG	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-4.67	6.71e-06	0.00364	-0.41	-0.36	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
PCPG	cis	rs896854	0.625	rs4735336	ENSG00000253528.2	RP11-347C18.4	-4.67	6.72e-06	0.00365	-0.39	-0.36	Type 2 diabetes;	chr8:94961182	chr8:94974573~94974853:-
PCPG	cis	rs561341	1	rs546748	ENSG00000265798.5	RP11-271K11.5	4.67	6.73e-06	0.00365	0.6	0.36	Hip circumference adjusted for BMI;	chr17:31997274	chr17:31038575~31059121:-
PCPG	cis	rs13113518	1	rs13133579	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55459921	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.902	rs11133386	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55461320	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.967	rs4340844	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55462689	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs1522112	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55463606	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs4864997	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55466010	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs960152	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55467308	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.967	rs12644948	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55470266	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs3805151	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55470874	chr4:55547112~55547889:+
PCPG	cis	rs13113518	1	rs13118237	ENSG00000272969.1	RP11-528I4.2	4.67	6.73e-06	0.00365	0.39	0.36	Height;	chr4:55474259	chr4:55547112~55547889:+
PCPG	cis	rs964611	1	rs1820492	ENSG00000259488.2	RP11-154J22.1	4.67	6.74e-06	0.00365	0.34	0.36	Metabolite levels (Pyroglutamine);	chr15:48311230	chr15:48312353~48331856:-
PCPG	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-4.67	6.75e-06	0.00366	-0.41	-0.36	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-4.67	6.75e-06	0.00366	-0.41	-0.36	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
PCPG	cis	rs9393777	0.777	rs35984974	ENSG00000219392.1	RP1-265C24.5	-4.67	6.75e-06	0.00366	-0.71	-0.36	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28115628~28116551:+
PCPG	cis	rs1949733	0.675	rs2688219	ENSG00000205959.3	RP11-689P11.2	-4.67	6.75e-06	0.00366	-0.4	-0.36	Response to antineoplastic agents;	chr4:8442904	chr4:8482270~8512610:+
PCPG	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-4.67	6.75e-06	0.00366	-0.46	-0.36	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
PCPG	cis	rs2625529	0.824	rs4776581	ENSG00000260037.4	CTD-2524L6.3	-4.67	6.75e-06	0.00366	-0.57	-0.36	Red blood cell count;	chr15:71914730	chr15:71818396~71823384:+
PCPG	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	4.67	6.75e-06	0.00366	0.47	0.36	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	4.67	6.75e-06	0.00366	0.47	0.36	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
PCPG	cis	rs11673344	0.504	rs10402907	ENSG00000226686.6	LINC01535	4.67	6.77e-06	0.00367	0.46	0.36	Obesity-related traits;	chr19:37112874	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.563	rs4805199	ENSG00000226686.6	LINC01535	4.67	6.77e-06	0.00367	0.46	0.36	Obesity-related traits;	chr19:37115527	chr19:37251912~37265535:+
PCPG	cis	rs3764021	0.87	rs10466829	ENSG00000278635.1	CTD-2318O12.1	-4.67	6.78e-06	0.00367	-0.43	-0.36	Type 1 diabetes;	chr12:9723495	chr12:9415641~9416718:+
PCPG	cis	rs10760158	0.832	rs10760159	ENSG00000226752.6	PSMD5-AS1	-4.66	6.79e-06	0.00368	-0.45	-0.36	Pulse pressure;	chr9:121236064	chr9:120824828~120854385:+
PCPG	cis	rs394563	0.625	rs394526	ENSG00000231760.4	RP11-350J20.5	4.66	6.79e-06	0.00368	0.44	0.36	Dupuytren's disease;	chr6:149475839	chr6:149796151~149826294:-
PCPG	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	4.66	6.79e-06	0.00368	0.4	0.36	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	4.66	6.79e-06	0.00368	0.39	0.36	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
PCPG	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-4.66	6.8e-06	0.00368	-0.34	-0.36	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
PCPG	cis	rs5742933	0.652	rs10210345	ENSG00000273240.1	RP11-455J20.3	4.66	6.8e-06	0.00368	0.38	0.36	Ferritin levels;	chr2:189754760	chr2:189763859~189764456:-
PCPG	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	4.66	6.8e-06	0.00369	0.58	0.36	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
PCPG	cis	rs7017914	0.967	rs1477944	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70703365	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs17760497	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70704810	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs34677078	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70705480	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs62530792	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70706532	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.902	rs35893260	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70707838	chr8:71155457~71204223:+
PCPG	cis	rs7017914	1	rs13253842	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70713268	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13254908	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70713863	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13264669	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70714537	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs34508469	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70716228	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs56043721	ENSG00000254031.4	RP11-326E22.1	4.66	6.81e-06	0.00369	0.35	0.36	Bone mineral density;	chr8:70718192	chr8:71155457~71204223:+
PCPG	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	4.66	6.81e-06	0.00369	0.4	0.36	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
PCPG	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	4.66	6.82e-06	0.00369	0.73	0.36	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
PCPG	cis	rs9649213	0.574	rs7802560	ENSG00000272950.1	RP11-307C18.1	-4.66	6.82e-06	0.00369	-0.45	-0.36	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr7:98322853~98323430:+
PCPG	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-4.66	6.82e-06	0.00369	-0.43	-0.36	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
PCPG	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-4.66	6.82e-06	0.00369	-0.43	-0.36	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
PCPG	cis	rs17684571	0.751	rs7758867	ENSG00000231441.1	RP11-472M19.2	4.66	6.82e-06	0.0037	0.57	0.36	Schizophrenia;	chr6:56836000	chr6:56844002~56864078:+
PCPG	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	4.66	6.83e-06	0.0037	0.36	0.36	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
PCPG	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-4.66	6.85e-06	0.00371	-0.45	-0.36	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
PCPG	cis	rs916888	0.61	rs199453	ENSG00000232300.1	FAM215B	4.66	6.85e-06	0.00371	0.46	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46558830~46562795:-
PCPG	cis	rs8064024	1	rs8064024	ENSG00000267077.1	RP11-127I20.5	-4.66	6.86e-06	0.00371	-0.42	-0.36	Cancer;	chr16:4805278	chr16:4795265~4796532:-
PCPG	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	4.66	6.86e-06	0.00371	0.42	0.36	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
PCPG	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	4.66	6.86e-06	0.00371	0.57	0.36	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
PCPG	cis	rs5742933	0.857	rs893784	ENSG00000273240.1	RP11-455J20.3	-4.66	6.86e-06	0.00372	-0.38	-0.36	Ferritin levels;	chr2:189671557	chr2:189763859~189764456:-
PCPG	cis	rs13113518	0.683	rs9761521	ENSG00000272969.1	RP11-528I4.2	4.66	6.86e-06	0.00372	0.43	0.36	Height;	chr4:55363436	chr4:55547112~55547889:+
PCPG	cis	rs10419113	0.645	rs12162230	ENSG00000268545.1	VN1R107P	4.66	6.88e-06	0.00372	0.38	0.36	Pediatric bone mineral density (spine);	chr19:57683020	chr19:57459912~57460120:+
PCPG	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	4.66	6.88e-06	0.00372	0.54	0.36	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
PCPG	cis	rs7811142	1	rs2406253	ENSG00000078319.8	PMS2P1	-4.66	6.89e-06	0.00373	-0.45	-0.36	Platelet count;	chr7:100479650	chr7:100320992~100341908:-
PCPG	cis	rs11148252	0.514	rs3783242	ENSG00000235660.1	LINC00345	-4.66	6.89e-06	0.00373	-0.44	-0.36	Lewy body disease;	chr13:52143814	chr13:52484161~52484680:-
PCPG	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	-4.66	6.9e-06	0.00373	-0.4	-0.36	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
PCPG	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	4.66	6.9e-06	0.00373	0.44	0.36	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	4.66	6.9e-06	0.00373	0.44	0.36	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
PCPG	cis	rs12908161	0.959	rs61074241	ENSG00000259728.4	LINC00933	4.66	6.91e-06	0.00374	0.5	0.36	Schizophrenia;	chr15:84790165	chr15:84570649~84580175:+
PCPG	cis	rs11250097	0.549	rs11778177	ENSG00000255020.1	AF131216.5	-4.66	6.94e-06	0.00375	-0.53	-0.36	Neuroticism;	chr8:11452853	chr8:11345748~11347502:-
PCPG	cis	rs11250097	0.549	rs11784897	ENSG00000255020.1	AF131216.5	-4.66	6.94e-06	0.00375	-0.53	-0.36	Neuroticism;	chr8:11452933	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.606	rs7819827	ENSG00000173295.6	FAM86B3P	4.66	6.94e-06	0.00375	0.43	0.36	Mood instability;	chr8:8939545	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	4.66	6.94e-06	0.00375	0.43	0.36	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.573	rs7842359	ENSG00000173295.6	FAM86B3P	4.66	6.94e-06	0.00375	0.43	0.36	Mood instability;	chr8:8939568	chr8:8228595~8244865:+
PCPG	cis	rs8030379	1	rs11259936	ENSG00000230373.7	GOLGA6L5P	4.66	6.94e-06	0.00375	0.35	0.36	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84507885~84516814:-
PCPG	cis	rs6121246	0.697	rs6120970	ENSG00000230613.1	HM13-AS1	4.66	6.95e-06	0.00376	0.52	0.36	Mean corpuscular hemoglobin;	chr20:31644649	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.697	rs7269866	ENSG00000230613.1	HM13-AS1	4.66	6.95e-06	0.00376	0.52	0.36	Mean corpuscular hemoglobin;	chr20:31644701	chr20:31567707~31573263:-
PCPG	cis	rs196889	0.611	rs405378	ENSG00000253535.4	RP11-624C23.1	4.66	6.95e-06	0.00376	0.35	0.36	Seasonality;	chr8:24863083	chr8:24295814~24912073:-
PCPG	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-4.66	6.96e-06	0.00376	-0.41	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
PCPG	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-4.66	6.97e-06	0.00376	-0.47	-0.36	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
PCPG	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-4.66	6.97e-06	0.00376	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-4.66	6.97e-06	0.00376	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-4.66	6.97e-06	0.00376	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
PCPG	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-4.66	6.97e-06	0.00376	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-4.66	6.97e-06	0.00376	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-4.66	6.97e-06	0.00376	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
PCPG	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	4.66	6.98e-06	0.00377	0.38	0.36	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
PCPG	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	4.66	6.98e-06	0.00377	0.34	0.36	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
PCPG	cis	rs11858159	1	rs12595260	ENSG00000259905.4	PWRN1	4.66	6.99e-06	0.00377	0.41	0.36	Platelet thrombus formation;	chr15:24541711	chr15:24493137~24652130:+
PCPG	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	4.66	6.99e-06	0.00378	0.39	0.36	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	4.66	6.99e-06	0.00378	0.39	0.36	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	4.66	6.99e-06	0.00378	0.39	0.36	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
PCPG	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-4.66	6.99e-06	0.00378	-0.36	-0.36	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
PCPG	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-4.66	7e-06	0.00378	-0.55	-0.36	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
PCPG	cis	rs8098244	0.683	rs1941524	ENSG00000265752.2	RP11-403A21.1	-4.66	7.01e-06	0.00378	-0.42	-0.36	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23865299	chr18:23957754~23982556:-
PCPG	cis	rs748404	0.666	rs34515241	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43342011	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.626	rs35992154	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43345669	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs17780417	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43347264	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs7181634	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43351703	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.626	rs72707530	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43353622	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs55748552	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43359428	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs10518812	ENSG00000249839.1	AC011330.5	4.66	7.01e-06	0.00378	0.48	0.36	Lung cancer;	chr15:43360739	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.63	rs35278805	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43361124	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs35160541	ENSG00000249839.1	AC011330.5	-4.66	7.01e-06	0.00378	-0.48	-0.36	Lung cancer;	chr15:43365601	chr15:43663654~43684339:-
PCPG	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-4.66	7.01e-06	0.00378	-0.39	-0.36	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
PCPG	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	-4.66	7.01e-06	0.00378	-0.41	-0.36	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
PCPG	cis	rs11148252	0.5	rs342768	ENSG00000198384.8	TPTE2P3	-4.66	7.01e-06	0.00379	-0.45	-0.36	Lewy body disease;	chr13:52634747	chr13:52522632~52586906:+
PCPG	cis	rs2830585	0.677	rs229048	ENSG00000197934.7	CYYR1-AS1	4.66	7.02e-06	0.00379	0.47	0.36	Blood protein levels;	chr21:26941711	chr21:26393635~26569252:+
PCPG	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	4.66	7.02e-06	0.00379	0.42	0.36	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
PCPG	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	4.66	7.03e-06	0.00379	0.43	0.36	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
PCPG	cis	rs7759001	0.744	rs10946933	ENSG00000271755.1	RP1-153G14.4	4.66	7.03e-06	0.00379	0.51	0.36	Glomerular filtration rate (creatinine);	chr6:27503319	chr6:27404010~27406964:-
PCPG	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	4.66	7.03e-06	0.00379	0.48	0.36	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
PCPG	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-4.66	7.04e-06	0.00379	-0.39	-0.36	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-4.66	7.04e-06	0.00379	-0.39	-0.36	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-4.66	7.04e-06	0.00379	-0.39	-0.36	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-4.66	7.04e-06	0.00379	-0.39	-0.36	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
PCPG	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-4.66	7.04e-06	0.0038	-0.46	-0.36	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
PCPG	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	4.66	7.04e-06	0.0038	0.43	0.36	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
PCPG	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	4.66	7.04e-06	0.0038	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	4.66	7.04e-06	0.0038	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	4.66	7.04e-06	0.0038	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
PCPG	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	4.66	7.04e-06	0.0038	0.4	0.36	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	4.66	7.04e-06	0.0038	0.4	0.36	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
PCPG	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	4.66	7.05e-06	0.0038	0.47	0.36	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
PCPG	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	4.66	7.06e-06	0.0038	0.37	0.36	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
PCPG	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	4.66	7.06e-06	0.0038	0.45	0.36	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
PCPG	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	4.66	7.06e-06	0.0038	0.45	0.36	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
PCPG	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	4.66	7.06e-06	0.0038	0.45	0.36	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
PCPG	cis	rs1440410	0.795	rs724517	ENSG00000250326.1	RP11-284M14.1	4.66	7.06e-06	0.00381	0.33	0.36	Ischemic stroke;	chr4:143275383	chr4:142933195~143184861:-
PCPG	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	4.66	7.06e-06	0.00381	0.4	0.36	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	4.66	7.06e-06	0.00381	0.4	0.36	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
PCPG	cis	rs748404	0.666	rs60018990	ENSG00000205771.5	CATSPER2P1	-4.66	7.06e-06	0.00381	-0.46	-0.36	Lung cancer;	chr15:43504606	chr15:43726918~43747094:-
PCPG	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	4.66	7.07e-06	0.00381	0.38	0.36	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
PCPG	cis	rs2235642	0.75	rs2755185	ENSG00000260989.1	LA16c-395F10.2	-4.65	7.08e-06	0.00381	-0.38	-0.36	Coronary artery disease;	chr16:1595826	chr16:1580527~1610328:+
PCPG	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	4.65	7.08e-06	0.00381	0.4	0.36	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
PCPG	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-4.65	7.08e-06	0.00381	-0.47	-0.36	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
PCPG	cis	rs7824557	0.547	rs4512344	ENSG00000255020.1	AF131216.5	-4.65	7.08e-06	0.00381	-0.5	-0.36	Retinal vascular caliber;	chr8:11221272	chr8:11345748~11347502:-
PCPG	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	4.65	7.09e-06	0.00382	0.4	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
PCPG	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-4.65	7.1e-06	0.00382	-0.45	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
PCPG	cis	rs7819412	0.669	rs28630509	ENSG00000255020.1	AF131216.5	-4.65	7.1e-06	0.00382	-0.5	-0.36	Triglycerides;	chr8:11139529	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.669	rs7823349	ENSG00000255020.1	AF131216.5	-4.65	7.1e-06	0.00382	-0.5	-0.36	Triglycerides;	chr8:11141120	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.669	rs4840549	ENSG00000255020.1	AF131216.5	-4.65	7.1e-06	0.00382	-0.5	-0.36	Triglycerides;	chr8:11141445	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.643	rs7829396	ENSG00000255020.1	AF131216.5	-4.65	7.1e-06	0.00382	-0.5	-0.36	Triglycerides;	chr8:11142073	chr8:11345748~11347502:-
PCPG	cis	rs10419113	0.668	rs2360533	ENSG00000268545.1	VN1R107P	4.65	7.11e-06	0.00383	0.38	0.36	Pediatric bone mineral density (spine);	chr19:57668907	chr19:57459912~57460120:+
PCPG	cis	rs10419113	0.628	rs12608585	ENSG00000268545.1	VN1R107P	4.65	7.11e-06	0.00383	0.38	0.36	Pediatric bone mineral density (spine);	chr19:57689260	chr19:57459912~57460120:+
PCPG	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	4.65	7.12e-06	0.00383	0.46	0.36	Height;	chr6:109530435	chr6:109382795~109383666:+
PCPG	cis	rs2281603	0.951	rs1982440	ENSG00000259116.1	RP11-973N13.4	-4.65	7.14e-06	0.00384	-0.34	-0.36	Lymphocyte counts;	chr14:64494049	chr14:64514154~64540368:-
PCPG	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	4.65	7.14e-06	0.00384	0.49	0.36	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
PCPG	cis	rs11858159	1	rs73356079	ENSG00000259905.4	PWRN1	4.65	7.14e-06	0.00384	0.4	0.36	Platelet thrombus formation;	chr15:24552683	chr15:24493137~24652130:+
PCPG	cis	rs7849270	0.84	rs3118639	ENSG00000268707.1	RP11-247A12.7	4.65	7.14e-06	0.00385	0.4	0.36	Blood metabolite ratios;	chr9:129093324	chr9:129170434~129170940:+
PCPG	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	4.65	7.14e-06	0.00385	0.3	0.36	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
PCPG	cis	rs2898290	0.622	rs1600250	ENSG00000269954.1	RP11-148O21.6	-4.65	7.14e-06	0.00385	-0.41	-0.36	Systolic blood pressure;	chr8:11487916	chr8:11552488~11552991:-
PCPG	cis	rs2898290	0.593	rs1600252	ENSG00000269954.1	RP11-148O21.6	-4.65	7.14e-06	0.00385	-0.41	-0.36	Systolic blood pressure;	chr8:11488135	chr8:11552488~11552991:-
PCPG	cis	rs9392556	0.533	rs619439	ENSG00000230648.1	RP3-406P24.3	4.65	7.16e-06	0.00385	0.43	0.36	Blood metabolite levels;	chr6:4113695	chr6:4018843~4021215:-
PCPG	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	4.65	7.16e-06	0.00385	0.47	0.36	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
PCPG	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	4.65	7.17e-06	0.00386	0.53	0.36	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	4.65	7.17e-06	0.00386	0.53	0.36	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	4.65	7.17e-06	0.00386	0.53	0.36	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
PCPG	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-4.65	7.17e-06	0.00386	-0.56	-0.36	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
PCPG	cis	rs28386778	0.897	rs2665831	ENSG00000240280.5	TCAM1P	-4.65	7.18e-06	0.00386	-0.48	-0.36	Prudent dietary pattern;	chr17:63835032	chr17:63849292~63864379:+
PCPG	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	4.65	7.19e-06	0.00387	0.49	0.36	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
PCPG	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	4.65	7.19e-06	0.00387	0.42	0.36	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
PCPG	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-4.65	7.19e-06	0.00387	-0.45	-0.36	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-4.65	7.19e-06	0.00387	-0.45	-0.36	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-4.65	7.19e-06	0.00387	-0.45	-0.36	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
PCPG	cis	rs5743030	0.702	rs256550	ENSG00000253559.1	OSGEPL1-AS1	4.65	7.19e-06	0.00387	0.53	0.36	Subcutaneous adipose tissue;	chr2:189880012	chr2:189762704~189765556:+
PCPG	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-4.65	7.19e-06	0.00387	-0.55	-0.36	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	4.65	7.19e-06	0.00387	0.55	0.36	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	4.65	7.19e-06	0.00387	0.55	0.36	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	4.65	7.19e-06	0.00387	0.55	0.36	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	4.65	7.19e-06	0.00387	0.55	0.36	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	4.65	7.19e-06	0.00387	0.55	0.36	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
PCPG	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	4.65	7.19e-06	0.00387	0.55	0.36	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
PCPG	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-4.65	7.19e-06	0.00387	-0.33	-0.36	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-4.65	7.19e-06	0.00387	-0.33	-0.36	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
PCPG	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-4.65	7.19e-06	0.00387	-0.33	-0.36	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
PCPG	cis	rs7208859	0.673	rs216411	ENSG00000263531.1	RP13-753N3.1	-4.65	7.2e-06	0.00387	-0.52	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30863921~30864940:-
PCPG	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	4.65	7.2e-06	0.00387	0.43	0.35	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
PCPG	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	4.65	7.21e-06	0.00387	0.61	0.35	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	4.65	7.21e-06	0.00387	0.61	0.35	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
PCPG	cis	rs804280	1	rs804280	ENSG00000255020.1	AF131216.5	4.65	7.21e-06	0.00388	0.49	0.35	Myopia (pathological);	chr8:11755189	chr8:11345748~11347502:-
PCPG	cis	rs6802315	0.604	rs9863103	ENSG00000271778.1	RP11-379F4.8	-4.65	7.22e-06	0.00388	-0.32	-0.35	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158782547~158783124:+
PCPG	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	4.65	7.22e-06	0.00388	0.45	0.35	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
PCPG	cis	rs2625529	0.824	rs2279283	ENSG00000260037.4	CTD-2524L6.3	-4.65	7.23e-06	0.00388	-0.57	-0.35	Red blood cell count;	chr15:71951325	chr15:71818396~71823384:+
PCPG	cis	rs4763879	0.634	rs7974396	ENSG00000278635.1	CTD-2318O12.1	4.65	7.23e-06	0.00389	0.43	0.35	Type 1 diabetes;	chr12:9708101	chr12:9415641~9416718:+
PCPG	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	4.65	7.24e-06	0.00389	0.44	0.35	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
PCPG	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-4.65	7.25e-06	0.00389	-0.44	-0.35	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
PCPG	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-4.65	7.25e-06	0.00389	-0.36	-0.35	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
PCPG	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	4.65	7.26e-06	0.0039	0.39	0.35	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
PCPG	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-4.65	7.26e-06	0.0039	-0.46	-0.35	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
PCPG	cis	rs657075	0.697	rs13161860	ENSG00000233006.5	AC034220.3	-4.65	7.27e-06	0.0039	-0.52	-0.35	Rheumatoid arthritis;	chr5:132386168	chr5:132311285~132369916:-
PCPG	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	4.65	7.28e-06	0.00391	0.36	0.35	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
PCPG	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	4.65	7.3e-06	0.00391	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
PCPG	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	4.65	7.3e-06	0.00391	0.44	0.35	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
PCPG	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	4.65	7.31e-06	0.00392	0.55	0.35	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
PCPG	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	4.65	7.31e-06	0.00392	0.55	0.35	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
PCPG	cis	rs7182621	0.639	rs35248328	ENSG00000182397.13	DNM1P46	4.65	7.31e-06	0.00392	0.55	0.35	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99790156~99806927:-
PCPG	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	4.65	7.31e-06	0.00392	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
PCPG	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	4.65	7.31e-06	0.00392	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
PCPG	cis	rs7017914	0.87	rs2639953	ENSG00000254031.4	RP11-326E22.1	4.65	7.32e-06	0.00392	0.35	0.35	Bone mineral density;	chr8:71013425	chr8:71155457~71204223:+
PCPG	cis	rs8044188	1	rs8044188	ENSG00000261090.1	RP11-20G6.2	4.65	7.34e-06	0.00393	0.56	0.35	Multiple system atrophy;	chr16:23019939	chr16:23020337~23023611:+
PCPG	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	4.65	7.35e-06	0.00394	0.39	0.35	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
PCPG	cis	rs12681963	0.536	rs7814629	ENSG00000248159.1	HSPA8P11	4.65	7.35e-06	0.00394	0.62	0.35	Migraine;	chr8:30257784	chr8:30237382~30240997:+
PCPG	cis	rs7247513	1	rs2042947	ENSG00000213290.4	PGK1P2	-4.65	7.35e-06	0.00394	-0.48	-0.35	Bipolar disorder;	chr19:12582289	chr19:12559571~12561105:+
PCPG	cis	rs7017914	0.967	rs17689955	ENSG00000254031.4	RP11-326E22.1	4.65	7.36e-06	0.00394	0.35	0.35	Bone mineral density;	chr8:70936629	chr8:71155457~71204223:+
PCPG	cis	rs4266144	0.562	rs2086667	ENSG00000244515.1	KRT18P34	-4.65	7.36e-06	0.00394	-0.42	-0.35	Coronary artery disease;	chr3:157118728	chr3:157162663~157163932:-
PCPG	cis	rs1949733	1	rs6447875	ENSG00000205959.3	RP11-689P11.2	-4.65	7.36e-06	0.00394	-0.41	-0.35	Response to antineoplastic agents;	chr4:8501479	chr4:8482270~8512610:+
PCPG	cis	rs7017914	0.967	rs2732090	ENSG00000254031.4	RP11-326E22.1	-4.65	7.38e-06	0.00395	-0.34	-0.35	Bone mineral density;	chr8:71006022	chr8:71155457~71204223:+
PCPG	cis	rs2212361	0.529	rs11020821	ENSG00000255893.1	RP11-685N10.1	-4.64	7.38e-06	0.00395	-0.44	-0.35	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94538497	chr11:94472908~94473570:-
PCPG	cis	rs7824557	0.628	rs58283816	ENSG00000255020.1	AF131216.5	4.64	7.39e-06	0.00396	0.46	0.35	Retinal vascular caliber;	chr8:11335042	chr8:11345748~11347502:-
PCPG	cis	rs6504622	0.902	rs1052586	ENSG00000262879.4	RP11-156P1.3	-4.64	7.4e-06	0.00396	-0.38	-0.35	Orofacial clefts;	chr17:46941097	chr17:46984045~47100323:-
PCPG	cis	rs8049040	0.586	rs13333985	ENSG00000260886.1	TAT-AS1	4.64	7.4e-06	0.00396	0.53	0.35	Blood protein levels;	chr16:71516950	chr16:71565789~71578187:+
PCPG	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-4.64	7.4e-06	0.00396	-0.45	-0.35	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
PCPG	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	4.64	7.4e-06	0.00396	0.38	0.35	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
PCPG	cis	rs1440410	0.835	rs10016850	ENSG00000250326.1	RP11-284M14.1	4.64	7.41e-06	0.00396	0.32	0.35	Ischemic stroke;	chr4:143135694	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs13121583	ENSG00000250326.1	RP11-284M14.1	4.64	7.41e-06	0.00396	0.32	0.35	Ischemic stroke;	chr4:143149432	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.795	rs11728962	ENSG00000250326.1	RP11-284M14.1	4.64	7.41e-06	0.00396	0.32	0.35	Ischemic stroke;	chr4:143158718	chr4:142933195~143184861:-
PCPG	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-4.64	7.41e-06	0.00396	-0.44	-0.35	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
PCPG	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-4.64	7.41e-06	0.00396	-0.45	-0.35	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
PCPG	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	4.64	7.41e-06	0.00397	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
PCPG	cis	rs591584	0.73	rs2155098	ENSG00000255893.1	RP11-685N10.1	-4.64	7.42e-06	0.00397	-0.43	-0.35	Macrophage Migration Inhibitory Factor levels;	chr11:94588886	chr11:94472908~94473570:-
PCPG	cis	rs591584	0.693	rs11020845	ENSG00000255893.1	RP11-685N10.1	-4.64	7.42e-06	0.00397	-0.43	-0.35	Macrophage Migration Inhibitory Factor levels;	chr11:94589186	chr11:94472908~94473570:-
PCPG	cis	rs591584	0.693	rs11020846	ENSG00000255893.1	RP11-685N10.1	-4.64	7.42e-06	0.00397	-0.43	-0.35	Macrophage Migration Inhibitory Factor levels;	chr11:94589187	chr11:94472908~94473570:-
PCPG	cis	rs7824557	0.593	rs11774673	ENSG00000255020.1	AF131216.5	4.64	7.42e-06	0.00397	0.46	0.35	Retinal vascular caliber;	chr8:11334028	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.628	rs7831346	ENSG00000255020.1	AF131216.5	4.64	7.42e-06	0.00397	0.46	0.35	Retinal vascular caliber;	chr8:11336021	chr8:11345748~11347502:-
PCPG	cis	rs5743030	0.702	rs12997257	ENSG00000253559.1	OSGEPL1-AS1	4.64	7.42e-06	0.00397	0.54	0.35	Subcutaneous adipose tissue;	chr2:189897328	chr2:189762704~189765556:+
PCPG	cis	rs2830585	0.628	rs233598	ENSG00000223563.1	AP001601.2	-4.64	7.43e-06	0.00397	-0.48	-0.35	Blood protein levels;	chr21:26958519	chr21:26889376~26939742:+
PCPG	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	4.64	7.43e-06	0.00397	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	4.64	7.43e-06	0.00397	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
PCPG	cis	rs7824557	0.628	rs6601580	ENSG00000255020.1	AF131216.5	4.64	7.44e-06	0.00398	0.46	0.35	Retinal vascular caliber;	chr8:11336227	chr8:11345748~11347502:-
PCPG	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-4.64	7.44e-06	0.00398	-0.43	-0.35	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
PCPG	cis	rs1075232	1	rs66581165	ENSG00000215302.7	CTD-3092A11.1	-4.64	7.46e-06	0.00398	-0.94	-0.35	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30470779~30507623:+
PCPG	cis	rs7247513	0.897	rs12972944	ENSG00000213290.4	PGK1P2	-4.64	7.47e-06	0.00399	-0.48	-0.35	Bipolar disorder;	chr19:12602994	chr19:12559571~12561105:+
PCPG	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	4.64	7.47e-06	0.00399	0.49	0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
PCPG	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-4.64	7.47e-06	0.00399	-0.45	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
PCPG	cis	rs7017914	0.905	rs2732106	ENSG00000254031.4	RP11-326E22.1	4.64	7.47e-06	0.00399	0.34	0.35	Bone mineral density;	chr8:71011604	chr8:71155457~71204223:+
PCPG	cis	rs7208859	0.524	rs8069400	ENSG00000263603.1	CTD-2349P21.5	-4.64	7.47e-06	0.00399	-0.63	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30729469~30731202:+
PCPG	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-4.64	7.47e-06	0.00399	-0.5	-0.35	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-4.64	7.47e-06	0.00399	-0.5	-0.35	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-4.64	7.47e-06	0.00399	-0.5	-0.35	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-4.64	7.47e-06	0.00399	-0.5	-0.35	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
PCPG	cis	rs12899811	0.512	rs7164916	ENSG00000214432.8	AC068831.10	-4.64	7.48e-06	0.004	-0.4	-0.35	Type 2 diabetes;	chr15:91018216	chr15:91022619~91036611:+
PCPG	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	4.64	7.5e-06	0.004	0.44	0.35	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
PCPG	cis	rs3736858	1	rs3736858	ENSG00000261105.4	LMO7-AS1	4.64	7.5e-06	0.00401	0.69	0.35	Interleukin-9 levels;	chr13:75841243	chr13:75604700~75635994:-
PCPG	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	4.64	7.52e-06	0.00401	0.51	0.35	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
PCPG	cis	rs9911578	0.967	rs7502208	ENSG00000267416.1	CTD-2319I12.2	4.64	7.52e-06	0.00401	0.38	0.35	Intelligence (multi-trait analysis);	chr17:59087736	chr17:60079309~60088695:+
PCPG	cis	rs6991838	0.806	rs35284121	ENSG00000200714.1	Y_RNA	4.64	7.52e-06	0.00402	0.45	0.35	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.751	rs35553155	ENSG00000200714.1	Y_RNA	4.64	7.52e-06	0.00402	0.45	0.35	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.806	rs35024820	ENSG00000200714.1	Y_RNA	4.64	7.52e-06	0.00402	0.45	0.35	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65592731~65592820:+
PCPG	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-4.64	7.53e-06	0.00402	-0.46	-0.35	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
PCPG	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-4.64	7.53e-06	0.00402	-0.42	-0.35	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-4.64	7.53e-06	0.00402	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-4.64	7.53e-06	0.00402	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-4.64	7.53e-06	0.00402	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
PCPG	cis	rs1048886	0.872	rs10214805	ENSG00000271967.1	RP11-134K13.4	-4.64	7.54e-06	0.00402	-0.46	-0.35	Type 2 diabetes;	chr6:70535423	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs9455150	ENSG00000271967.1	RP11-134K13.4	-4.64	7.54e-06	0.00402	-0.46	-0.35	Type 2 diabetes;	chr6:70535805	chr6:70596438~70596980:+
PCPG	cis	rs10899021	1	rs7102084	ENSG00000279353.1	RP11-864N7.4	4.64	7.55e-06	0.00403	0.65	0.35	Response to metformin (IC50);	chr11:74647087	chr11:74698231~74699658:-
PCPG	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-4.64	7.55e-06	0.00403	-0.39	-0.35	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
PCPG	cis	rs13108904	0.901	rs12509700	ENSG00000253399.1	AC078852.2	-4.64	7.55e-06	0.00403	-0.36	-0.35	Obesity-related traits;	chr4:1302533	chr4:1358479~1359461:+
PCPG	cis	rs2625529	0.73	rs3759900	ENSG00000260037.4	CTD-2524L6.3	4.64	7.56e-06	0.00403	0.45	0.35	Red blood cell count;	chr15:72159486	chr15:71818396~71823384:+
PCPG	cis	rs2164273	0.523	rs1435279	ENSG00000255020.1	AF131216.5	4.64	7.56e-06	0.00403	0.44	0.35	Extraversion;	chr8:11300878	chr8:11345748~11347502:-
PCPG	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	4.64	7.57e-06	0.00403	0.44	0.35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
PCPG	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	4.64	7.57e-06	0.00403	0.38	0.35	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	4.64	7.57e-06	0.00403	0.38	0.35	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	4.64	7.57e-06	0.00403	0.38	0.35	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	4.64	7.57e-06	0.00403	0.38	0.35	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	4.64	7.57e-06	0.00403	0.38	0.35	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	4.64	7.57e-06	0.00403	0.38	0.35	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	4.64	7.57e-06	0.00403	0.38	0.35	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
PCPG	cis	rs9392556	0.734	rs648900	ENSG00000230648.1	RP3-406P24.3	4.64	7.57e-06	0.00404	0.43	0.35	Blood metabolite levels;	chr6:4109188	chr6:4018843~4021215:-
PCPG	cis	rs6840258	0.76	rs58633957	ENSG00000251411.1	RP11-397E7.4	-4.64	7.58e-06	0.00404	-0.36	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047827	chr4:86913266~86914817:-
PCPG	cis	rs964611	0.882	rs16960809	ENSG00000259488.2	RP11-154J22.1	4.64	7.59e-06	0.00405	0.36	0.35	Metabolite levels (Pyroglutamine);	chr15:48354318	chr15:48312353~48331856:-
PCPG	cis	rs5742933	0.857	rs7571089	ENSG00000273240.1	RP11-455J20.3	4.64	7.59e-06	0.00405	0.38	0.35	Ferritin levels;	chr2:189697067	chr2:189763859~189764456:-
PCPG	cis	rs7824557	0.547	rs2409749	ENSG00000255020.1	AF131216.5	-4.64	7.6e-06	0.00405	-0.49	-0.35	Retinal vascular caliber;	chr8:11221440	chr8:11345748~11347502:-
PCPG	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-4.64	7.6e-06	0.00405	-0.47	-0.35	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
PCPG	cis	rs5742933	0.817	rs1233297	ENSG00000273240.1	RP11-455J20.3	-4.64	7.6e-06	0.00405	-0.37	-0.35	Ferritin levels;	chr2:189829449	chr2:189763859~189764456:-
PCPG	cis	rs458017	0.661	rs33965856	ENSG00000255389.1	C6orf3	-4.64	7.6e-06	0.00405	-0.78	-0.35	Psoriasis;	chr6:111172750	chr6:111599875~111602295:+
PCPG	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	4.64	7.61e-06	0.00405	0.3	0.35	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
PCPG	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-4.64	7.61e-06	0.00405	-0.43	-0.35	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
PCPG	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	4.64	7.61e-06	0.00405	0.44	0.35	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	4.64	7.61e-06	0.00405	0.44	0.35	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	4.64	7.61e-06	0.00405	0.44	0.35	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
PCPG	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	4.64	7.61e-06	0.00406	0.73	0.35	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	4.64	7.61e-06	0.00406	0.73	0.35	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	4.64	7.61e-06	0.00406	0.73	0.35	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	4.64	7.61e-06	0.00406	0.73	0.35	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	4.64	7.61e-06	0.00406	0.73	0.35	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	4.64	7.61e-06	0.00406	0.73	0.35	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
PCPG	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	4.64	7.62e-06	0.00406	0.54	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
PCPG	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-4.64	7.63e-06	0.00406	-0.59	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
PCPG	cis	rs2732480	0.5	rs2450989	ENSG00000240399.1	RP1-228P16.1	-4.64	7.63e-06	0.00406	-0.37	-0.35	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48054813~48055591:-
PCPG	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-4.64	7.64e-06	0.00407	-0.49	-0.35	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
PCPG	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	4.64	7.64e-06	0.00407	0.49	0.35	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
PCPG	cis	rs9303542	0.512	rs67412921	ENSG00000279036.1	RP11-81K2.2	-4.64	7.65e-06	0.00407	-0.6	-0.35	Epithelial ovarian cancer;Ovarian cancer;	chr17:48559263	chr17:49494223~49497800:-
PCPG	cis	rs6504340	0.739	rs1062037	ENSG00000279036.1	RP11-81K2.2	-4.64	7.65e-06	0.00407	-0.6	-0.35	Primary tooth development (number of teeth);	chr17:48560792	chr17:49494223~49497800:-
PCPG	cis	rs2830585	0.651	rs229054	ENSG00000197934.7	CYYR1-AS1	4.64	7.65e-06	0.00408	0.46	0.35	Blood protein levels;	chr21:26944497	chr21:26393635~26569252:+
PCPG	cis	rs300890	0.513	rs4277733	ENSG00000250326.1	RP11-284M14.1	-4.64	7.66e-06	0.00408	-0.33	-0.35	Nasopharyngeal carcinoma;	chr4:143126893	chr4:142933195~143184861:-
PCPG	cis	rs7587476	0.861	rs3768716	ENSG00000229267.2	AC072062.1	-4.64	7.68e-06	0.00409	-0.49	-0.35	Neuroblastoma;	chr2:214771070	chr2:214810229~214963274:+
PCPG	cis	rs7017914	0.69	rs10090230	ENSG00000254031.4	RP11-326E22.1	4.64	7.68e-06	0.00409	0.34	0.35	Bone mineral density;	chr8:70884778	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs10090471	ENSG00000254031.4	RP11-326E22.1	4.64	7.68e-06	0.00409	0.34	0.35	Bone mineral density;	chr8:70885034	chr8:71155457~71204223:+
PCPG	cis	rs748404	0.666	rs7183708	ENSG00000205771.5	CATSPER2P1	-4.64	7.69e-06	0.00409	-0.44	-0.35	Lung cancer;	chr15:43355226	chr15:43726918~43747094:-
PCPG	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	4.64	7.7e-06	0.00409	0.41	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	4.64	7.7e-06	0.00409	0.41	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	4.64	7.7e-06	0.00409	0.41	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	4.64	7.7e-06	0.00409	0.41	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	4.64	7.7e-06	0.00409	0.41	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
PCPG	cis	rs453301	0.506	rs686189	ENSG00000173295.6	FAM86B3P	4.63	7.7e-06	0.0041	0.41	0.35	Joint mobility (Beighton score);	chr8:8766127	chr8:8228595~8244865:+
PCPG	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-4.63	7.7e-06	0.0041	-0.37	-0.35	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
PCPG	cis	rs2564921	0.765	rs35333155	ENSG00000243224.1	RP5-1157M23.2	4.63	7.7e-06	0.0041	0.35	0.35	Height;	chr3:53073764	chr3:52239258~52241097:+
PCPG	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-4.63	7.7e-06	0.0041	-0.52	-0.35	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
PCPG	cis	rs2179367	0.959	rs4895788	ENSG00000231760.4	RP11-350J20.5	4.63	7.71e-06	0.0041	0.46	0.35	Dupuytren's disease;	chr6:149426955	chr6:149796151~149826294:-
PCPG	cis	rs300890	0.513	rs10005340	ENSG00000250326.1	RP11-284M14.1	4.63	7.72e-06	0.00411	0.33	0.35	Nasopharyngeal carcinoma;	chr4:143122478	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.513	rs10007896	ENSG00000250326.1	RP11-284M14.1	4.63	7.72e-06	0.00411	0.33	0.35	Nasopharyngeal carcinoma;	chr4:143122808	chr4:142933195~143184861:-
PCPG	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	4.63	7.74e-06	0.00412	0.44	0.35	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
PCPG	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	4.63	7.76e-06	0.00412	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	4.63	7.76e-06	0.00412	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
PCPG	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	4.63	7.76e-06	0.00413	0.38	0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
PCPG	cis	rs7017914	0.905	rs1353058	ENSG00000254031.4	RP11-326E22.1	4.63	7.77e-06	0.00413	0.34	0.35	Bone mineral density;	chr8:71009783	chr8:71155457~71204223:+
PCPG	cis	rs10760158	0.62	rs10739596	ENSG00000226752.6	PSMD5-AS1	-4.63	7.78e-06	0.00414	-0.48	-0.35	Pulse pressure;	chr9:121327845	chr9:120824828~120854385:+
PCPG	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	4.63	7.79e-06	0.00414	0.47	0.35	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
PCPG	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-4.63	7.79e-06	0.00414	-0.46	-0.35	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
PCPG	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	4.63	7.8e-06	0.00414	0.59	0.35	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
PCPG	cis	rs7811142	0.72	rs112622797	ENSG00000078319.8	PMS2P1	-4.63	7.8e-06	0.00415	-0.49	-0.35	Platelet count;	chr7:100319793	chr7:100320992~100341908:-
PCPG	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	4.63	7.81e-06	0.00415	0.54	0.35	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
PCPG	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-4.63	7.81e-06	0.00415	-0.47	-0.35	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
PCPG	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	4.63	7.81e-06	0.00415	0.45	0.35	Height;	chr6:109501402	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	4.63	7.81e-06	0.00415	0.45	0.35	Height;	chr6:109501429	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	4.63	7.81e-06	0.00415	0.45	0.35	Height;	chr6:109503623	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	4.63	7.81e-06	0.00415	0.45	0.35	Height;	chr6:109507271	chr6:109382795~109383666:+
PCPG	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-4.63	7.82e-06	0.00415	-0.59	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-4.63	7.82e-06	0.00415	-0.59	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-4.63	7.82e-06	0.00415	-0.59	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-4.63	7.82e-06	0.00415	-0.59	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-4.63	7.82e-06	0.00415	-0.59	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
PCPG	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-4.63	7.82e-06	0.00416	-0.82	-0.35	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
PCPG	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-4.63	7.82e-06	0.00416	-0.42	-0.35	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
PCPG	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	4.63	7.83e-06	0.00416	0.54	0.35	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	4.63	7.83e-06	0.00416	0.54	0.35	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
PCPG	cis	rs13108904	0.967	rs1732107	ENSG00000254094.1	AC078852.1	4.63	7.83e-06	0.00416	0.4	0.35	Obesity-related traits;	chr4:1282970	chr4:1356581~1358075:+
PCPG	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-4.63	7.84e-06	0.00416	-0.43	-0.35	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
PCPG	cis	rs11673344	0.543	rs1818748	ENSG00000226686.6	LINC01535	4.63	7.85e-06	0.00417	0.45	0.35	Obesity-related traits;	chr19:37065416	chr19:37251912~37265535:+
PCPG	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-4.63	7.85e-06	0.00417	-0.53	-0.35	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
PCPG	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-4.63	7.85e-06	0.00417	-0.38	-0.35	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
PCPG	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-4.63	7.86e-06	0.00417	-0.37	-0.35	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
PCPG	cis	rs301901	0.895	rs292172	ENSG00000250155.1	CTD-2353F22.1	-4.63	7.87e-06	0.00418	-0.41	-0.35	Height;	chr5:36817237	chr5:36666214~36725195:-
PCPG	cis	rs1048886	0.808	rs76755006	ENSG00000271967.1	RP11-134K13.4	-4.63	7.89e-06	0.00419	-0.46	-0.35	Type 2 diabetes;	chr6:70545733	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs77057748	ENSG00000271967.1	RP11-134K13.4	-4.63	7.89e-06	0.00419	-0.46	-0.35	Type 2 diabetes;	chr6:70549286	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs12530057	ENSG00000271967.1	RP11-134K13.4	-4.63	7.89e-06	0.00419	-0.46	-0.35	Type 2 diabetes;	chr6:70551446	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs12529309	ENSG00000271967.1	RP11-134K13.4	-4.63	7.89e-06	0.00419	-0.46	-0.35	Type 2 diabetes;	chr6:70553931	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs56143128	ENSG00000271967.1	RP11-134K13.4	-4.63	7.89e-06	0.00419	-0.46	-0.35	Type 2 diabetes;	chr6:70557963	chr6:70596438~70596980:+
PCPG	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-4.63	7.89e-06	0.00419	-0.38	-0.35	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
PCPG	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	4.63	7.89e-06	0.00419	0.48	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
PCPG	cis	rs5769765	1	rs4824112	ENSG00000278869.1	CITF22-49E9.3	4.63	7.9e-06	0.00419	0.47	0.35	Schizophrenia;	chr22:49890697	chr22:49933198~49934074:-
PCPG	cis	rs11858159	0.934	rs7182190	ENSG00000259905.4	PWRN1	4.63	7.9e-06	0.00419	0.4	0.35	Platelet thrombus formation;	chr15:24554442	chr15:24493137~24652130:+
PCPG	cis	rs657075	0.697	rs13179841	ENSG00000233006.5	AC034220.3	-4.63	7.9e-06	0.00419	-0.52	-0.35	Rheumatoid arthritis;	chr5:132407128	chr5:132311285~132369916:-
PCPG	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	4.63	7.9e-06	0.00419	0.43	0.35	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	4.63	7.9e-06	0.00419	0.43	0.35	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	4.63	7.9e-06	0.00419	0.43	0.35	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
PCPG	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-4.63	7.91e-06	0.00419	-0.33	-0.35	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
PCPG	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-4.63	7.91e-06	0.00419	-0.38	-0.35	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
PCPG	cis	rs7819412	0.635	rs4841501	ENSG00000255020.1	AF131216.5	-4.63	7.91e-06	0.0042	-0.5	-0.35	Triglycerides;	chr8:11143466	chr8:11345748~11347502:-
PCPG	cis	rs804280	0.509	rs13276433	ENSG00000255495.1	AC145124.2	4.63	7.92e-06	0.0042	0.35	0.35	Myopia (pathological);	chr8:11925527	chr8:12194467~12196280:+
PCPG	cis	rs13108904	0.875	rs73069950	ENSG00000254094.1	AC078852.1	4.63	7.92e-06	0.0042	0.39	0.35	Obesity-related traits;	chr4:1282257	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.967	rs12502916	ENSG00000254094.1	AC078852.1	4.63	7.92e-06	0.0042	0.39	0.35	Obesity-related traits;	chr4:1282561	chr4:1356581~1358075:+
PCPG	cis	rs71403859	0.541	rs73588051	ENSG00000260886.1	TAT-AS1	4.63	7.93e-06	0.0042	0.76	0.35	Post bronchodilator FEV1;	chr16:71354724	chr16:71565789~71578187:+
PCPG	cis	rs2898290	0.622	rs1478890	ENSG00000269954.1	RP11-148O21.6	-4.63	7.93e-06	0.0042	-0.39	-0.35	Systolic blood pressure;	chr8:11498093	chr8:11552488~11552991:-
PCPG	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-4.63	7.95e-06	0.00421	-0.42	-0.35	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
PCPG	cis	rs7017914	0.84	rs1481804	ENSG00000254031.4	RP11-326E22.1	4.63	7.95e-06	0.00421	0.34	0.35	Bone mineral density;	chr8:71057195	chr8:71155457~71204223:+
PCPG	cis	rs7849270	1	rs2768630	ENSG00000268707.1	RP11-247A12.7	4.63	7.95e-06	0.00421	0.4	0.35	Blood metabolite ratios;	chr9:129104109	chr9:129170434~129170940:+
PCPG	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	4.63	7.96e-06	0.00422	0.58	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
PCPG	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-4.63	7.97e-06	0.00422	-0.38	-0.35	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
PCPG	cis	rs7824557	0.547	rs6601570	ENSG00000255020.1	AF131216.5	-4.63	7.97e-06	0.00422	-0.49	-0.35	Retinal vascular caliber;	chr8:11221858	chr8:11345748~11347502:-
PCPG	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	4.63	7.97e-06	0.00422	0.34	0.35	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	4.63	7.98e-06	0.00422	0.35	0.35	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	4.63	7.98e-06	0.00422	0.35	0.35	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	4.63	7.98e-06	0.00422	0.35	0.35	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	4.63	7.98e-06	0.00422	0.35	0.35	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
PCPG	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-4.63	7.98e-06	0.00422	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
PCPG	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-4.63	7.99e-06	0.00423	-0.48	-0.35	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-4.63	7.99e-06	0.00423	-0.48	-0.35	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
PCPG	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-4.63	8e-06	0.00423	-0.38	-0.35	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-4.63	8e-06	0.00423	-0.38	-0.35	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
PCPG	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	4.63	8e-06	0.00423	0.4	0.35	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
PCPG	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	4.63	8e-06	0.00424	0.45	0.35	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
PCPG	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	4.63	8.01e-06	0.00424	0.43	0.35	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
PCPG	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-4.63	8.01e-06	0.00424	-0.38	-0.35	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
PCPG	cis	rs7017914	0.967	rs13257800	ENSG00000254031.4	RP11-326E22.1	4.63	8.01e-06	0.00424	0.35	0.35	Bone mineral density;	chr8:70801898	chr8:71155457~71204223:+
PCPG	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	4.63	8.02e-06	0.00424	0.43	0.35	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
PCPG	cis	rs11858159	0.967	rs7172047	ENSG00000259905.4	PWRN1	4.63	8.02e-06	0.00424	0.4	0.35	Platelet thrombus formation;	chr15:24538589	chr15:24493137~24652130:+
PCPG	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-4.63	8.03e-06	0.00425	-0.39	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
PCPG	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	4.62	8.04e-06	0.00425	0.33	0.35	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
PCPG	cis	rs11858159	0.966	rs7172621	ENSG00000260760.1	PWRN3	4.62	8.04e-06	0.00426	0.39	0.35	Platelet thrombus formation;	chr15:24555234	chr15:24441127~24447967:+
PCPG	cis	rs11168351	0.927	rs10875716	ENSG00000240399.1	RP1-228P16.1	4.62	8.04e-06	0.00426	0.36	0.35	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48054813~48055591:-
PCPG	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-4.62	8.05e-06	0.00426	-0.51	-0.35	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
PCPG	cis	rs6957923	0.934	rs9969137	ENSG00000230658.1	KLHL7-AS1	4.62	8.05e-06	0.00426	0.41	0.35	Height;	chr7:23438669	chr7:23101228~23105703:-
PCPG	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	4.62	8.05e-06	0.00426	0.55	0.35	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
PCPG	cis	rs6957923	1	rs6956228	ENSG00000230658.1	KLHL7-AS1	4.62	8.06e-06	0.00426	0.43	0.35	Height;	chr7:23448096	chr7:23101228~23105703:-
PCPG	cis	rs748404	0.736	rs542036	ENSG00000205771.5	CATSPER2P1	4.62	8.07e-06	0.00427	0.39	0.35	Lung cancer;	chr15:43248941	chr15:43726918~43747094:-
PCPG	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	4.62	8.07e-06	0.00427	0.51	0.35	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	4.62	8.07e-06	0.00427	0.51	0.35	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	4.62	8.07e-06	0.00427	0.51	0.35	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	4.62	8.07e-06	0.00427	0.51	0.35	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-4.62	8.07e-06	0.00427	-0.51	-0.35	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-4.62	8.07e-06	0.00427	-0.51	-0.35	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-4.62	8.07e-06	0.00427	-0.51	-0.35	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-4.62	8.07e-06	0.00427	-0.51	-0.35	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-4.62	8.07e-06	0.00427	-0.51	-0.35	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-4.62	8.07e-06	0.00427	-0.51	-0.35	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-4.62	8.07e-06	0.00427	-0.51	-0.35	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
PCPG	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-4.62	8.08e-06	0.00427	-0.42	-0.35	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
PCPG	cis	rs2361718	0.5	rs12451697	ENSG00000275479.1	RP11-334C17.6	4.62	8.08e-06	0.00427	0.29	0.35	Yeast infection;	chr17:80126891	chr17:80149627~80149798:+
PCPG	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	4.62	8.08e-06	0.00427	0.39	0.35	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
PCPG	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-4.62	8.09e-06	0.00427	-0.36	-0.35	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
PCPG	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-4.62	8.09e-06	0.00427	-0.5	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
PCPG	cis	rs591584	0.666	rs1939139	ENSG00000255893.1	RP11-685N10.1	-4.62	8.09e-06	0.00428	-0.41	-0.35	Macrophage Migration Inhibitory Factor levels;	chr11:94573836	chr11:94472908~94473570:-
PCPG	cis	rs2179367	0.568	rs9498358	ENSG00000231760.4	RP11-350J20.5	4.62	8.1e-06	0.00428	0.5	0.35	Dupuytren's disease;	chr6:149458529	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.6	rs58747890	ENSG00000231760.4	RP11-350J20.5	4.62	8.1e-06	0.00428	0.5	0.35	Dupuytren's disease;	chr6:149459369	chr6:149796151~149826294:-
PCPG	cis	rs964611	0.882	rs73406442	ENSG00000259488.2	RP11-154J22.1	-4.62	8.11e-06	0.00428	-0.36	-0.35	Metabolite levels (Pyroglutamine);	chr15:48354146	chr15:48312353~48331856:-
PCPG	cis	rs13113518	0.729	rs12641881	ENSG00000272969.1	RP11-528I4.2	4.62	8.11e-06	0.00429	0.41	0.35	Height;	chr4:55401306	chr4:55547112~55547889:+
PCPG	cis	rs9828933	0.577	rs832193	ENSG00000280620.1	SCAANT1	-4.62	8.11e-06	0.00429	-0.49	-0.35	Type 2 diabetes;	chr3:63868769	chr3:63911518~63911772:-
PCPG	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	4.62	8.11e-06	0.00429	0.44	0.35	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
PCPG	cis	rs11673344	0.504	rs4254428	ENSG00000226686.6	LINC01535	4.62	8.12e-06	0.00429	0.46	0.35	Obesity-related traits;	chr19:37093748	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs11084874	ENSG00000226686.6	LINC01535	4.62	8.12e-06	0.00429	0.46	0.35	Obesity-related traits;	chr19:37096667	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs4806409	ENSG00000226686.6	LINC01535	4.62	8.12e-06	0.00429	0.46	0.35	Obesity-related traits;	chr19:37097923	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs8109501	ENSG00000226686.6	LINC01535	4.62	8.12e-06	0.00429	0.46	0.35	Obesity-related traits;	chr19:37102194	chr19:37251912~37265535:+
PCPG	cis	rs7819412	1	rs7819412	ENSG00000255020.1	AF131216.5	4.62	8.14e-06	0.0043	0.48	0.35	Triglycerides;	chr8:11187652	chr8:11345748~11347502:-
PCPG	cis	rs2836974	0.545	rs3167757	ENSG00000255568.3	BRWD1-AS2	4.62	8.15e-06	0.0043	0.35	0.35	Cognitive function;	chr21:39342552	chr21:39313935~39314962:+
PCPG	cis	rs7017914	0.905	rs3110244	ENSG00000254031.4	RP11-326E22.1	-4.62	8.16e-06	0.00431	-0.34	-0.35	Bone mineral density;	chr8:71020962	chr8:71155457~71204223:+
PCPG	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	4.62	8.17e-06	0.00431	0.44	0.35	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
PCPG	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	4.62	8.17e-06	0.00431	0.61	0.35	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	4.62	8.17e-06	0.00431	0.61	0.35	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	4.62	8.17e-06	0.00431	0.61	0.35	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
PCPG	cis	rs916888	0.61	rs142167	ENSG00000232300.1	FAM215B	-4.62	8.17e-06	0.00431	-0.46	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46558830~46562795:-
PCPG	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-4.62	8.17e-06	0.00431	-0.46	-0.35	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
PCPG	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-4.62	8.17e-06	0.00431	-0.46	-0.35	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
PCPG	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
PCPG	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	4.62	8.19e-06	0.00432	0.33	0.35	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
PCPG	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	4.62	8.19e-06	0.00432	0.54	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
PCPG	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	4.62	8.2e-06	0.00433	0.5	0.35	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
PCPG	cis	rs11858159	1	rs12899764	ENSG00000259905.4	PWRN1	4.62	8.21e-06	0.00433	0.4	0.35	Platelet thrombus formation;	chr15:24572167	chr15:24493137~24652130:+
PCPG	cis	rs11148252	0.595	rs4885325	ENSG00000273784.3	RP11-78J21.7	-4.62	8.21e-06	0.00433	-0.34	-0.35	Lewy body disease;	chr13:52597182	chr13:52600042~52642542:+
PCPG	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-4.62	8.22e-06	0.00434	-0.47	-0.35	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
PCPG	cis	rs300890	0.513	rs7684017	ENSG00000250326.1	RP11-284M14.1	4.62	8.22e-06	0.00434	0.33	0.35	Nasopharyngeal carcinoma;	chr4:143124212	chr4:142933195~143184861:-
PCPG	cis	rs7811142	1	rs6972167	ENSG00000078319.8	PMS2P1	-4.62	8.23e-06	0.00434	-0.45	-0.35	Platelet count;	chr7:100482390	chr7:100320992~100341908:-
PCPG	cis	rs3808502	0.563	rs12541800	ENSG00000255020.1	AF131216.5	4.62	8.23e-06	0.00434	0.44	0.35	Neuroticism;	chr8:11565563	chr8:11345748~11347502:-
PCPG	cis	rs13113518	0.812	rs12500686	ENSG00000272969.1	RP11-528I4.2	4.62	8.23e-06	0.00434	0.4	0.35	Height;	chr4:55457922	chr4:55547112~55547889:+
PCPG	cis	rs964611	1	rs74011998	ENSG00000259488.2	RP11-154J22.1	-4.62	8.24e-06	0.00434	-0.39	-0.35	Metabolite levels (Pyroglutamine);	chr15:48304516	chr15:48312353~48331856:-
PCPG	cis	rs964611	1	rs964611	ENSG00000259488.2	RP11-154J22.1	-4.62	8.24e-06	0.00434	-0.39	-0.35	Metabolite levels (Pyroglutamine);	chr15:48305317	chr15:48312353~48331856:-
PCPG	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	4.62	8.25e-06	0.00435	0.4	0.35	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
PCPG	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	4.62	8.25e-06	0.00435	0.55	0.35	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
PCPG	cis	rs7182621	0.639	rs12906068	ENSG00000182397.13	DNM1P46	4.62	8.25e-06	0.00435	0.55	0.35	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99790156~99806927:-
PCPG	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-4.62	8.25e-06	0.00435	-0.41	-0.35	Height;	chr5:36963703	chr5:36666214~36725195:-
PCPG	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-4.62	8.25e-06	0.00435	-0.37	-0.35	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
PCPG	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-4.62	8.26e-06	0.00435	-0.49	-0.35	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
PCPG	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-4.62	8.26e-06	0.00435	-0.5	-0.35	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
PCPG	cis	rs804280	0.509	rs10109241	ENSG00000255495.1	AC145124.2	4.62	8.28e-06	0.00436	0.35	0.35	Myopia (pathological);	chr8:11927476	chr8:12194467~12196280:+
PCPG	cis	rs28386778	0.897	rs2044125	ENSG00000240280.5	TCAM1P	4.62	8.28e-06	0.00436	0.47	0.35	Prudent dietary pattern;	chr17:63785824	chr17:63849292~63864379:+
PCPG	cis	rs748404	0.666	rs16957680	ENSG00000249839.1	AC011330.5	-4.62	8.3e-06	0.00437	-0.48	-0.35	Lung cancer;	chr15:43396207	chr15:43663654~43684339:-
PCPG	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	4.62	8.31e-06	0.00438	0.48	0.35	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	4.62	8.31e-06	0.00438	0.48	0.35	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
PCPG	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	4.62	8.32e-06	0.00438	0.47	0.35	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
PCPG	cis	rs2281558	0.583	rs7260957	ENSG00000125804.12	FAM182A	-4.62	8.34e-06	0.00439	-0.52	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:26054655~26086917:+
PCPG	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	4.62	8.35e-06	0.0044	0.5	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
PCPG	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	4.62	8.35e-06	0.0044	0.5	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
PCPG	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	4.62	8.35e-06	0.0044	0.5	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
PCPG	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	4.62	8.35e-06	0.0044	0.5	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
PCPG	cis	rs9299346	0.594	rs10125732	ENSG00000225376.4	TMEM246-AS1	4.62	8.36e-06	0.0044	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101673839	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10125758	ENSG00000225376.4	TMEM246-AS1	4.62	8.36e-06	0.0044	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101673897	chr9:101468439~101481502:+
PCPG	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-4.62	8.36e-06	0.0044	-0.5	-0.35	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
PCPG	cis	rs5758511	0.633	rs5751258	ENSG00000205702.9	CYP2D7	4.62	8.36e-06	0.0044	0.48	0.35	Birth weight;	chr22:42267865	chr22:42140203~42144577:-
PCPG	cis	rs2898290	0.622	rs13272061	ENSG00000269954.1	RP11-148O21.6	-4.62	8.37e-06	0.0044	-0.39	-0.35	Systolic blood pressure;	chr8:11494752	chr8:11552488~11552991:-
PCPG	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-4.62	8.37e-06	0.0044	-0.5	-0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
PCPG	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-4.61	8.38e-06	0.00441	-0.45	-0.35	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
PCPG	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	4.61	8.38e-06	0.00441	0.43	0.35	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
PCPG	cis	rs11673344	0.542	rs826331	ENSG00000226686.6	LINC01535	4.61	8.39e-06	0.00441	0.45	0.35	Obesity-related traits;	chr19:37007360	chr19:37251912~37265535:+
PCPG	cis	rs2235642	0.785	rs1057983	ENSG00000260989.1	LA16c-395F10.2	-4.61	8.39e-06	0.00441	-0.38	-0.35	Coronary artery disease;	chr16:1610273	chr16:1580527~1610328:+
PCPG	cis	rs7017914	0.69	rs6984056	ENSG00000254031.4	RP11-326E22.1	4.61	8.39e-06	0.00441	0.34	0.35	Bone mineral density;	chr8:70858886	chr8:71155457~71204223:+
PCPG	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	4.61	8.39e-06	0.00442	0.48	0.35	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
PCPG	cis	rs6840258	0.76	rs10032244	ENSG00000251411.1	RP11-397E7.4	-4.61	8.41e-06	0.00442	-0.36	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86996779	chr4:86913266~86914817:-
PCPG	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-4.61	8.41e-06	0.00442	-0.35	-0.35	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
PCPG	cis	rs950169	0.922	rs8037078	ENSG00000235370.6	DNM1P51	-4.61	8.42e-06	0.00443	-0.36	-0.35	Schizophrenia;	chr15:84150119	chr15:84398316~84411701:-
PCPG	cis	rs4835473	0.637	rs2323201	ENSG00000250345.2	RP11-780M14.1	-4.61	8.43e-06	0.00443	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143765629	chr4:143760399~143762093:-
PCPG	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-4.61	8.43e-06	0.00443	-0.49	-0.35	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
PCPG	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-4.61	8.43e-06	0.00443	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-4.61	8.43e-06	0.00443	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
PCPG	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-4.61	8.44e-06	0.00443	-0.39	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
PCPG	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	4.61	8.44e-06	0.00444	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	4.61	8.44e-06	0.00444	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	4.61	8.44e-06	0.00444	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	4.61	8.44e-06	0.00444	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	4.61	8.44e-06	0.00444	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	4.61	8.44e-06	0.00444	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
PCPG	cis	rs853679	0.769	rs17720293	ENSG00000219392.1	RP1-265C24.5	-4.61	8.45e-06	0.00444	-0.69	-0.35	Depression;	chr6:28246920	chr6:28115628~28116551:+
PCPG	cis	rs916888	0.647	rs199449	ENSG00000232300.1	FAM215B	4.61	8.45e-06	0.00444	0.46	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.61	rs199444	ENSG00000232300.1	FAM215B	4.61	8.45e-06	0.00444	0.46	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.61	rs199442	ENSG00000232300.1	FAM215B	4.61	8.45e-06	0.00444	0.46	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46558830~46562795:-
PCPG	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	4.61	8.45e-06	0.00444	0.4	0.35	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
PCPG	cis	rs28386778	0.863	rs3760252	ENSG00000240280.5	TCAM1P	-4.61	8.45e-06	0.00444	-0.46	-0.35	Prudent dietary pattern;	chr17:63774826	chr17:63849292~63864379:+
PCPG	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	4.61	8.45e-06	0.00444	0.37	0.35	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
PCPG	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	4.61	8.45e-06	0.00444	0.44	0.35	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
PCPG	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	4.61	8.46e-06	0.00444	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
PCPG	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	4.61	8.46e-06	0.00444	0.48	0.35	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
PCPG	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	4.61	8.46e-06	0.00444	0.57	0.35	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	4.61	8.46e-06	0.00444	0.57	0.35	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	4.61	8.46e-06	0.00444	0.57	0.35	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
PCPG	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	4.61	8.47e-06	0.00445	0.46	0.35	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
PCPG	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	4.61	8.48e-06	0.00445	0.43	0.35	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
PCPG	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	4.61	8.48e-06	0.00445	0.49	0.35	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	4.61	8.48e-06	0.00445	0.49	0.35	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
PCPG	cis	rs5743030	0.609	rs11688123	ENSG00000253559.1	OSGEPL1-AS1	4.61	8.49e-06	0.00445	0.53	0.35	Subcutaneous adipose tissue;	chr2:189910273	chr2:189762704~189765556:+
PCPG	cis	rs7208859	0.673	rs1347360	ENSG00000263603.1	CTD-2349P21.5	-4.61	8.49e-06	0.00446	-0.58	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30729469~30731202:+
PCPG	cis	rs8044188	1	rs6497630	ENSG00000261090.1	RP11-20G6.2	4.61	8.5e-06	0.00446	0.56	0.35	Multiple system atrophy;	chr16:23033939	chr16:23020337~23023611:+
PCPG	cis	rs12681963	0.688	rs73236825	ENSG00000248159.1	HSPA8P11	4.61	8.5e-06	0.00446	0.69	0.35	Migraine;	chr8:30229590	chr8:30237382~30240997:+
PCPG	cis	rs4819052	0.851	rs1006779	ENSG00000215447.6	BX322557.10	-4.61	8.5e-06	0.00446	-0.33	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45288052~45291738:+
PCPG	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-4.61	8.51e-06	0.00446	-0.43	-0.35	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
PCPG	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-4.61	8.52e-06	0.00447	-0.4	-0.35	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
PCPG	cis	rs73607972	0.518	rs7193898	ENSG00000275191.1	RP11-36I17.2	4.61	8.52e-06	0.00447	0.48	0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53551009	chr16:53628256~53628816:-
PCPG	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-4.61	8.52e-06	0.00447	-0.39	-0.35	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
PCPG	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	4.61	8.52e-06	0.00447	0.53	0.35	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
PCPG	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	4.61	8.53e-06	0.00447	0.34	0.35	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
PCPG	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	4.61	8.54e-06	0.00448	0.45	0.35	Height;	chr6:109640682	chr6:109382795~109383666:+
PCPG	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-4.61	8.54e-06	0.00448	-0.5	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-4.61	8.54e-06	0.00448	-0.5	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
PCPG	cis	rs75686122	0.892	rs17806104	ENSG00000271830.1	RP11-1C8.7	4.61	8.55e-06	0.00448	0.55	0.35	Cocaine dependence;	chr8:103523283	chr8:103481266~103481619:-
PCPG	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	4.61	8.55e-06	0.00448	0.54	0.35	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
PCPG	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-4.61	8.56e-06	0.00448	-0.4	-0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
PCPG	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-4.61	8.57e-06	0.00449	-0.47	-0.35	Temperament;	chr17:14015466	chr17:14024514~14025488:+
PCPG	cis	rs5758511	0.68	rs5758698	ENSG00000205702.9	CYP2D7	4.61	8.57e-06	0.00449	0.47	0.35	Birth weight;	chr22:42288812	chr22:42140203~42144577:-
PCPG	cis	rs763121	1	rs138464	ENSG00000273076.1	RP3-508I15.22	-4.61	8.58e-06	0.00449	-0.35	-0.35	Menopause (age at onset);	chr22:38510427	chr22:38743495~38743910:+
PCPG	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-4.61	8.58e-06	0.00449	-0.46	-0.35	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
PCPG	cis	rs9299346	0.594	rs12352582	ENSG00000225376.4	TMEM246-AS1	4.61	8.59e-06	0.00449	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101660848	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10117029	ENSG00000225376.4	TMEM246-AS1	4.61	8.59e-06	0.00449	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101661430	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10819975	ENSG00000225376.4	TMEM246-AS1	4.61	8.59e-06	0.00449	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101662334	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1323418	ENSG00000225376.4	TMEM246-AS1	4.61	8.59e-06	0.00449	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101662957	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1323417	ENSG00000225376.4	TMEM246-AS1	4.61	8.59e-06	0.00449	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101663170	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1323416	ENSG00000225376.4	TMEM246-AS1	4.61	8.59e-06	0.00449	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101663337	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10760800	ENSG00000225376.4	TMEM246-AS1	4.61	8.59e-06	0.00449	0.43	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101663631	chr9:101468439~101481502:+
PCPG	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-4.61	8.59e-06	0.00449	-0.46	-0.35	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-4.61	8.59e-06	0.00449	-0.46	-0.35	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-4.61	8.59e-06	0.00449	-0.46	-0.35	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
PCPG	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-4.61	8.59e-06	0.00449	-0.5	-0.35	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-4.61	8.59e-06	0.00449	-0.5	-0.35	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
PCPG	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	4.61	8.59e-06	0.00449	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
PCPG	cis	rs28386778	0.897	rs2665823	ENSG00000240280.5	TCAM1P	-4.61	8.6e-06	0.0045	-0.47	-0.35	Prudent dietary pattern;	chr17:63808557	chr17:63849292~63864379:+
PCPG	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	4.61	8.62e-06	0.00451	0.38	0.35	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
PCPG	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	4.61	8.63e-06	0.00451	0.51	0.35	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
PCPG	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-4.61	8.64e-06	0.00452	-0.41	-0.35	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
PCPG	cis	rs11673344	0.523	rs36096221	ENSG00000226686.6	LINC01535	4.61	8.64e-06	0.00452	0.45	0.35	Obesity-related traits;	chr19:37060838	chr19:37251912~37265535:+
PCPG	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	4.61	8.65e-06	0.00452	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
PCPG	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-4.61	8.65e-06	0.00452	-0.43	-0.35	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
PCPG	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	4.61	8.65e-06	0.00452	0.58	0.35	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
PCPG	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	4.61	8.66e-06	0.00452	0.52	0.35	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
PCPG	cis	rs34421088	0.548	rs2618443	ENSG00000255020.1	AF131216.5	-4.61	8.67e-06	0.00453	-0.45	-0.35	Neuroticism;	chr8:11527047	chr8:11345748~11347502:-
PCPG	cis	rs34421088	0.506	rs4841518	ENSG00000255020.1	AF131216.5	4.61	8.67e-06	0.00453	0.44	0.35	Neuroticism;	chr8:11288454	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.527	rs2409756	ENSG00000255020.1	AF131216.5	-4.61	8.68e-06	0.00453	-0.46	-0.35	Retinal vascular caliber;	chr8:11384516	chr8:11345748~11347502:-
PCPG	cis	rs2564921	0.765	rs2581799	ENSG00000243224.1	RP5-1157M23.2	-4.61	8.68e-06	0.00454	-0.34	-0.35	Height;	chr3:53074760	chr3:52239258~52241097:+
PCPG	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-4.61	8.69e-06	0.00454	-0.53	-0.35	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
PCPG	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	4.61	8.7e-06	0.00454	0.48	0.35	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	4.61	8.7e-06	0.00454	0.48	0.35	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	4.61	8.7e-06	0.00454	0.48	0.35	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	4.61	8.7e-06	0.00454	0.48	0.35	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
PCPG	cis	rs11148252	0.532	rs9536262	ENSG00000198384.8	TPTE2P3	4.61	8.7e-06	0.00454	0.45	0.35	Lewy body disease;	chr13:52728939	chr13:52522632~52586906:+
PCPG	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	4.61	8.71e-06	0.00455	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	4.61	8.71e-06	0.00455	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
PCPG	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-4.61	8.72e-06	0.00455	-0.35	-0.35	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
PCPG	cis	rs13113518	0.934	rs10866425	ENSG00000272969.1	RP11-528I4.2	4.61	8.72e-06	0.00455	0.4	0.35	Height;	chr4:55582068	chr4:55547112~55547889:+
PCPG	cis	rs6957923	1	rs10807815	ENSG00000230658.1	KLHL7-AS1	4.61	8.72e-06	0.00455	0.43	0.35	Height;	chr7:23453199	chr7:23101228~23105703:-
PCPG	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	4.61	8.73e-06	0.00455	0.6	0.35	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
PCPG	cis	rs28386778	0.83	rs67905415	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63763876	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs3744293	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63764428	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs6504184	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63765048	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs8081454	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63765286	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs58269663	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63765770	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs8067102	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63771419	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs6504185	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63771432	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs8077013	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63773032	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.797	rs4968664	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63774006	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs9913323	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63774125	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs9906247	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63779954	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs7221573	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63782030	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs7221853	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63782476	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs7207005	ENSG00000240280.5	TCAM1P	-4.61	8.73e-06	0.00455	-0.46	-0.35	Prudent dietary pattern;	chr17:63782995	chr17:63849292~63864379:+
PCPG	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-4.61	8.73e-06	0.00455	-0.71	-0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
PCPG	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	4.6	8.75e-06	0.00456	0.45	0.35	Height;	chr6:109655182	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	4.6	8.75e-06	0.00456	0.45	0.35	Height;	chr6:109656105	chr6:109382795~109383666:+
PCPG	cis	rs10760158	0.587	rs10985212	ENSG00000226752.6	PSMD5-AS1	-4.6	8.75e-06	0.00456	-0.48	-0.35	Pulse pressure;	chr9:121338550	chr9:120824828~120854385:+
PCPG	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	4.6	8.76e-06	0.00457	0.45	0.35	Height;	chr6:109496073	chr6:109382795~109383666:+
PCPG	cis	rs13392177	0.672	rs1877715	ENSG00000273466.1	RP11-548H3.1	4.6	8.77e-06	0.00457	0.19	0.35	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218633256~218634014:-
PCPG	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	4.6	8.77e-06	0.00457	0.45	0.35	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
PCPG	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	4.6	8.78e-06	0.00458	0.35	0.35	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
PCPG	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-4.6	8.79e-06	0.00458	-0.44	-0.35	Height;	chr6:109380015	chr6:109382795~109383666:+
PCPG	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-4.6	8.79e-06	0.00458	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-4.6	8.79e-06	0.00458	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
PCPG	cis	rs5743030	0.702	rs12479375	ENSG00000253559.1	OSGEPL1-AS1	4.6	8.8e-06	0.00459	0.53	0.35	Subcutaneous adipose tissue;	chr2:189920760	chr2:189762704~189765556:+
PCPG	cis	rs34779708	0.832	rs12764283	ENSG00000230534.5	RP11-297A16.2	4.6	8.81e-06	0.00459	0.48	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35098006~35127020:-
PCPG	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-4.6	8.82e-06	0.00459	-0.44	-0.35	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
PCPG	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-4.6	8.82e-06	0.00459	-0.44	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
PCPG	cis	rs11858159	0.845	rs6576352	ENSG00000259905.4	PWRN1	-4.6	8.83e-06	0.0046	-0.37	-0.35	Platelet thrombus formation;	chr15:24593312	chr15:24493137~24652130:+
PCPG	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-4.6	8.83e-06	0.0046	-0.39	-0.35	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
PCPG	cis	rs7824557	0.591	rs2736282	ENSG00000255020.1	AF131216.5	4.6	8.83e-06	0.0046	0.46	0.35	Retinal vascular caliber;	chr8:11367971	chr8:11345748~11347502:-
PCPG	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-4.6	8.84e-06	0.00461	-0.46	-0.35	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
PCPG	cis	rs3758911	0.861	rs11212112	ENSG00000255353.1	RP11-382M14.1	-4.6	8.84e-06	0.00461	-0.48	-0.35	Coronary artery disease;	chr11:107272667	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs11212113	ENSG00000255353.1	RP11-382M14.1	-4.6	8.84e-06	0.00461	-0.48	-0.35	Coronary artery disease;	chr11:107272776	chr11:107176286~107177530:+
PCPG	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	4.6	8.84e-06	0.00461	0.46	0.35	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
PCPG	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	4.6	8.85e-06	0.00461	0.43	0.35	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	4.6	8.85e-06	0.00461	0.43	0.35	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	4.6	8.85e-06	0.00461	0.43	0.35	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	4.6	8.85e-06	0.00461	0.43	0.35	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	4.6	8.85e-06	0.00461	0.43	0.35	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
PCPG	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-4.6	8.85e-06	0.00461	-0.39	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
PCPG	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	4.6	8.86e-06	0.00461	0.53	0.35	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
PCPG	cis	rs13113518	0.841	rs11133400	ENSG00000272969.1	RP11-528I4.2	4.6	8.86e-06	0.00461	0.39	0.35	Height;	chr4:55578787	chr4:55547112~55547889:+
PCPG	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-4.6	8.87e-06	0.00462	-0.46	-0.35	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
PCPG	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-4.6	8.87e-06	0.00462	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
PCPG	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	4.6	8.87e-06	0.00462	0.51	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
PCPG	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	4.6	8.88e-06	0.00462	0.49	0.35	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	4.6	8.88e-06	0.00462	0.49	0.35	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	4.6	8.88e-06	0.00462	0.49	0.35	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	4.6	8.88e-06	0.00462	0.49	0.35	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	4.6	8.88e-06	0.00462	0.49	0.35	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	4.6	8.88e-06	0.00462	0.49	0.35	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	4.6	8.88e-06	0.00462	0.49	0.35	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
PCPG	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	4.6	8.88e-06	0.00462	0.44	0.35	Height;	chr6:109423238	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	4.6	8.88e-06	0.00462	0.44	0.35	Height;	chr6:109428824	chr6:109382795~109383666:+
PCPG	cis	rs7688540	0.8	rs28531997	ENSG00000275426.1	CH17-262A2.1	4.6	8.88e-06	0.00462	0.42	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:149738~150317:+
PCPG	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	4.6	8.89e-06	0.00462	0.53	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
PCPG	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	4.6	8.89e-06	0.00462	0.35	0.35	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	4.6	8.89e-06	0.00462	0.35	0.35	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
PCPG	cis	rs7829975	0.714	rs7823757	ENSG00000173295.6	FAM86B3P	-4.6	8.89e-06	0.00462	-0.41	-0.35	Mood instability;	chr8:8812667	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	-4.6	8.89e-06	0.00462	-0.41	-0.35	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
PCPG	cis	rs11858159	0.741	rs28373415	ENSG00000259905.4	PWRN1	4.6	8.9e-06	0.00463	0.38	0.35	Platelet thrombus formation;	chr15:24533790	chr15:24493137~24652130:+
PCPG	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	4.6	8.9e-06	0.00463	0.41	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
PCPG	cis	rs6121246	0.697	rs6087716	ENSG00000230613.1	HM13-AS1	4.6	8.9e-06	0.00463	0.51	0.35	Mean corpuscular hemoglobin;	chr20:31641237	chr20:31567707~31573263:-
PCPG	cis	rs28386778	0.897	rs896064	ENSG00000240280.5	TCAM1P	-4.6	8.91e-06	0.00463	-0.46	-0.35	Prudent dietary pattern;	chr17:63783572	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.83	rs2665841	ENSG00000240280.5	TCAM1P	-4.6	8.91e-06	0.00463	-0.46	-0.35	Prudent dietary pattern;	chr17:63783859	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584640	ENSG00000240280.5	TCAM1P	-4.6	8.91e-06	0.00463	-0.46	-0.35	Prudent dietary pattern;	chr17:63786128	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584639	ENSG00000240280.5	TCAM1P	-4.6	8.91e-06	0.00463	-0.46	-0.35	Prudent dietary pattern;	chr17:63786372	chr17:63849292~63864379:+
PCPG	cis	rs8042680	0.522	rs10775251	ENSG00000214432.8	AC068831.10	-4.6	8.92e-06	0.00463	-0.4	-0.35	Type 2 diabetes;	chr15:91011195	chr15:91022619~91036611:+
PCPG	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-4.6	8.92e-06	0.00463	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
PCPG	cis	rs28386778	0.897	rs2665795	ENSG00000240280.5	TCAM1P	4.6	8.92e-06	0.00464	0.46	0.35	Prudent dietary pattern;	chr17:63847912	chr17:63849292~63864379:+
PCPG	cis	rs10899021	0.92	rs7122710	ENSG00000279353.1	RP11-864N7.4	4.6	8.92e-06	0.00464	0.61	0.35	Response to metformin (IC50);	chr11:74612130	chr11:74698231~74699658:-
PCPG	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	4.6	8.92e-06	0.00464	0.47	0.35	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
PCPG	cis	rs12681963	0.688	rs7004466	ENSG00000248159.1	HSPA8P11	4.6	8.92e-06	0.00464	0.7	0.35	Migraine;	chr8:30196778	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs7004806	ENSG00000248159.1	HSPA8P11	4.6	8.92e-06	0.00464	0.7	0.35	Migraine;	chr8:30197002	chr8:30237382~30240997:+
PCPG	cis	rs12681963	0.688	rs73242331	ENSG00000248159.1	HSPA8P11	4.6	8.92e-06	0.00464	0.7	0.35	Migraine;	chr8:30198328	chr8:30237382~30240997:+
PCPG	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-4.6	8.92e-06	0.00464	-0.36	-0.35	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
PCPG	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	4.6	8.94e-06	0.00465	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	4.6	8.94e-06	0.00465	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	4.6	8.94e-06	0.00465	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
PCPG	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-4.6	8.95e-06	0.00465	-0.42	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
PCPG	cis	rs657075	0.697	rs2073645	ENSG00000233006.5	AC034220.3	-4.6	8.96e-06	0.00465	-0.51	-0.35	Rheumatoid arthritis;	chr5:132389122	chr5:132311285~132369916:-
PCPG	cis	rs7759001	0.681	rs6918131	ENSG00000271755.1	RP1-153G14.4	4.6	8.96e-06	0.00465	0.51	0.35	Glomerular filtration rate (creatinine);	chr6:27513138	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.681	rs7776338	ENSG00000271755.1	RP1-153G14.4	4.6	8.96e-06	0.00465	0.51	0.35	Glomerular filtration rate (creatinine);	chr6:27513892	chr6:27404010~27406964:-
PCPG	cis	rs11858159	0.967	rs12914308	ENSG00000259905.4	PWRN1	4.6	8.98e-06	0.00466	0.4	0.35	Platelet thrombus formation;	chr15:24566565	chr15:24493137~24652130:+
PCPG	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-4.6	8.98e-06	0.00466	-0.46	-0.35	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
PCPG	cis	rs6957923	0.967	rs34677598	ENSG00000230658.1	KLHL7-AS1	4.6	8.98e-06	0.00467	0.41	0.35	Height;	chr7:23460008	chr7:23101228~23105703:-
PCPG	cis	rs1440410	0.83	rs300939	ENSG00000250326.1	RP11-284M14.1	4.6	8.99e-06	0.00467	0.33	0.35	Ischemic stroke;	chr4:143252059	chr4:142933195~143184861:-
PCPG	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	4.6	8.99e-06	0.00467	0.38	0.35	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
PCPG	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	4.6	9.01e-06	0.00468	0.52	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
PCPG	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-4.6	9.01e-06	0.00468	-0.42	-0.35	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
PCPG	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-4.6	9.02e-06	0.00468	-0.31	-0.35	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
PCPG	cis	rs5743030	0.702	rs256549	ENSG00000253559.1	OSGEPL1-AS1	-4.6	9.02e-06	0.00468	-0.53	-0.35	Subcutaneous adipose tissue;	chr2:189881381	chr2:189762704~189765556:+
PCPG	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	4.6	9.03e-06	0.00468	0.63	0.35	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
PCPG	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	4.6	9.03e-06	0.00469	0.52	0.35	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
PCPG	cis	rs11858159	0.902	rs12900858	ENSG00000259905.4	PWRN1	4.6	9.04e-06	0.00469	0.4	0.35	Platelet thrombus formation;	chr15:24572913	chr15:24493137~24652130:+
PCPG	cis	rs5758511	0.68	rs739147	ENSG00000205702.9	CYP2D7	4.6	9.05e-06	0.00469	0.47	0.35	Birth weight;	chr22:42275060	chr22:42140203~42144577:-
PCPG	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	4.6	9.06e-06	0.0047	0.45	0.35	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	4.6	9.06e-06	0.0047	0.46	0.35	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
PCPG	cis	rs9595908	0.606	rs4942925	ENSG00000212293.1	SNORA16	4.6	9.06e-06	0.0047	0.43	0.35	Body mass index;	chr13:32807106	chr13:32420390~32420516:-
PCPG	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	4.6	9.06e-06	0.0047	0.48	0.35	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
PCPG	cis	rs2243480	1	rs313813	ENSG00000230189.5	GS1-124K5.2	4.6	9.07e-06	0.00471	0.51	0.35	Diabetic kidney disease;	chr7:66038513	chr7:66409143~66490059:-
PCPG	cis	rs1949733	1	rs2140337	ENSG00000205959.3	RP11-689P11.2	-4.6	9.07e-06	0.00471	-0.41	-0.35	Response to antineoplastic agents;	chr4:8500385	chr4:8482270~8512610:+
PCPG	cis	rs1949733	1	rs6837429	ENSG00000205959.3	RP11-689P11.2	-4.6	9.07e-06	0.00471	-0.41	-0.35	Response to antineoplastic agents;	chr4:8500647	chr4:8482270~8512610:+
PCPG	cis	rs7696431	0.653	rs13129779	ENSG00000279384.1	RP11-635L1.2	4.6	9.08e-06	0.00471	0.37	0.35	Coronary artery disease;	chr4:168804876	chr4:168843988~168844735:+
PCPG	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-4.6	9.09e-06	0.00472	-0.33	-0.35	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
PCPG	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-4.6	9.09e-06	0.00472	-0.47	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
PCPG	cis	rs11858159	0.874	rs9920852	ENSG00000259905.4	PWRN1	4.6	9.1e-06	0.00472	0.38	0.35	Platelet thrombus formation;	chr15:24551018	chr15:24493137~24652130:+
PCPG	cis	rs9911578	0.967	rs8072712	ENSG00000267416.1	CTD-2319I12.2	4.6	9.11e-06	0.00472	0.37	0.35	Intelligence (multi-trait analysis);	chr17:59085103	chr17:60079309~60088695:+
PCPG	cis	rs9911578	0.933	rs11868348	ENSG00000267416.1	CTD-2319I12.2	4.6	9.11e-06	0.00472	0.37	0.35	Intelligence (multi-trait analysis);	chr17:59101877	chr17:60079309~60088695:+
PCPG	cis	rs9911578	0.9	rs8067264	ENSG00000267416.1	CTD-2319I12.2	4.6	9.11e-06	0.00472	0.37	0.35	Intelligence (multi-trait analysis);	chr17:59105432	chr17:60079309~60088695:+
PCPG	cis	rs9911578	0.967	rs7503190	ENSG00000267416.1	CTD-2319I12.2	4.6	9.11e-06	0.00472	0.37	0.35	Intelligence (multi-trait analysis);	chr17:59106801	chr17:60079309~60088695:+
PCPG	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	4.59	9.11e-06	0.00472	0.43	0.35	Height;	chr5:37454091	chr5:36666214~36725195:-
PCPG	cis	rs12681963	0.688	rs962420	ENSG00000248159.1	HSPA8P11	4.59	9.12e-06	0.00473	0.65	0.35	Migraine;	chr8:30233419	chr8:30237382~30240997:+
PCPG	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	4.59	9.12e-06	0.00473	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
PCPG	cis	rs11858159	0.899	rs12914305	ENSG00000259905.4	PWRN1	4.59	9.13e-06	0.00473	0.4	0.35	Platelet thrombus formation;	chr15:24566555	chr15:24493137~24652130:+
PCPG	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	4.59	9.13e-06	0.00473	0.41	0.35	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-4.59	9.14e-06	0.00474	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
PCPG	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	4.59	9.14e-06	0.00474	0.59	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	4.59	9.14e-06	0.00474	0.59	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
PCPG	cis	rs35851103	0.627	rs6601644	ENSG00000255020.1	AF131216.5	4.59	9.15e-06	0.00474	0.46	0.35	Neuroticism;	chr8:11989569	chr8:11345748~11347502:-
PCPG	cis	rs1048886	0.872	rs12191321	ENSG00000271967.1	RP11-134K13.4	-4.59	9.16e-06	0.00474	-0.43	-0.35	Type 2 diabetes;	chr6:70593484	chr6:70596438~70596980:+
PCPG	cis	rs60695258	0.512	rs2053769	ENSG00000251411.1	RP11-397E7.4	4.59	9.16e-06	0.00474	0.33	0.35	Hematocrit;	chr4:86986855	chr4:86913266~86914817:-
PCPG	cis	rs60695258	0.512	rs2053770	ENSG00000251411.1	RP11-397E7.4	4.59	9.16e-06	0.00474	0.33	0.35	Hematocrit;	chr4:86986933	chr4:86913266~86914817:-
PCPG	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	4.59	9.16e-06	0.00474	0.45	0.35	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
PCPG	cis	rs73607972	0.932	rs111886096	ENSG00000275191.1	RP11-36I17.2	-4.59	9.19e-06	0.00475	-0.63	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53564398	chr16:53628256~53628816:-
PCPG	cis	rs17772222	0.958	rs59136503	ENSG00000222990.1	RNU4-22P	4.59	9.19e-06	0.00476	0.48	0.35	Coronary artery calcification;	chr14:88501921	chr14:88513498~88513663:+
PCPG	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	4.59	9.19e-06	0.00476	0.46	0.35	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
PCPG	cis	rs7824557	0.628	rs7005469	ENSG00000255020.1	AF131216.5	4.59	9.19e-06	0.00476	0.45	0.35	Retinal vascular caliber;	chr8:11336948	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.628	rs6988922	ENSG00000255020.1	AF131216.5	4.59	9.19e-06	0.00476	0.45	0.35	Retinal vascular caliber;	chr8:11337402	chr8:11345748~11347502:-
PCPG	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	4.59	9.2e-06	0.00476	0.47	0.35	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
PCPG	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	4.59	9.2e-06	0.00476	0.45	0.35	Height;	chr6:109494237	chr6:109382795~109383666:+
PCPG	cis	rs13108904	0.901	rs6851528	ENSG00000253399.1	AC078852.2	-4.59	9.2e-06	0.00476	-0.36	-0.35	Obesity-related traits;	chr4:1302221	chr4:1358479~1359461:+
PCPG	cis	rs13108904	0.901	rs7695691	ENSG00000253399.1	AC078852.2	-4.59	9.2e-06	0.00476	-0.36	-0.35	Obesity-related traits;	chr4:1310844	chr4:1358479~1359461:+
PCPG	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	4.59	9.2e-06	0.00476	0.47	0.35	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
PCPG	cis	rs7824557	0.579	rs10098322	ENSG00000255020.1	AF131216.5	4.59	9.21e-06	0.00476	0.43	0.35	Retinal vascular caliber;	chr8:11338786	chr8:11345748~11347502:-
PCPG	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
PCPG	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-4.59	9.21e-06	0.00476	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
PCPG	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-4.59	9.22e-06	0.00477	-0.34	-0.35	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
PCPG	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-4.59	9.23e-06	0.00477	-0.32	-0.35	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
PCPG	cis	rs10899021	0.92	rs61901540	ENSG00000279353.1	RP11-864N7.4	4.59	9.23e-06	0.00477	0.61	0.35	Response to metformin (IC50);	chr11:74603820	chr11:74698231~74699658:-
PCPG	cis	rs7017914	0.935	rs6472551	ENSG00000254031.4	RP11-326E22.1	4.59	9.26e-06	0.00479	0.34	0.35	Bone mineral density;	chr8:70869614	chr8:71155457~71204223:+
PCPG	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	4.59	9.27e-06	0.00479	0.48	0.35	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
PCPG	cis	rs561341	1	rs72821952	ENSG00000265798.5	RP11-271K11.5	4.59	9.27e-06	0.00479	0.64	0.35	Hip circumference adjusted for BMI;	chr17:31921114	chr17:31038575~31059121:-
PCPG	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	4.59	9.27e-06	0.00479	0.58	0.35	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
PCPG	cis	rs5758511	0.689	rs5758691	ENSG00000205702.9	CYP2D7	4.59	9.29e-06	0.0048	0.47	0.35	Birth weight;	chr22:42272498	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.68	rs5758692	ENSG00000205702.9	CYP2D7	4.59	9.29e-06	0.0048	0.47	0.35	Birth weight;	chr22:42273023	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.634	rs1001587	ENSG00000205702.9	CYP2D7	4.59	9.29e-06	0.0048	0.47	0.35	Birth weight;	chr22:42274105	chr22:42140203~42144577:-
PCPG	cis	rs5758511	0.68	rs1001586	ENSG00000205702.9	CYP2D7	4.59	9.29e-06	0.0048	0.47	0.35	Birth weight;	chr22:42274287	chr22:42140203~42144577:-
PCPG	cis	rs1048886	0.872	rs12200777	ENSG00000271967.1	RP11-134K13.4	-4.59	9.31e-06	0.00481	-0.43	-0.35	Type 2 diabetes;	chr6:70577251	chr6:70596438~70596980:+
PCPG	cis	rs11858159	0.535	rs7497405	ENSG00000259905.4	PWRN1	4.59	9.31e-06	0.00481	0.4	0.35	Platelet thrombus formation;	chr15:24571284	chr15:24493137~24652130:+
PCPG	cis	rs7017914	0.559	rs12056347	ENSG00000254031.4	RP11-326E22.1	4.59	9.32e-06	0.00481	0.34	0.35	Bone mineral density;	chr8:71072374	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.667	rs1481801	ENSG00000254031.4	RP11-326E22.1	4.59	9.32e-06	0.00481	0.34	0.35	Bone mineral density;	chr8:71077484	chr8:71155457~71204223:+
PCPG	cis	rs6991838	0.806	rs13262793	ENSG00000200714.1	Y_RNA	4.59	9.32e-06	0.00481	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.778	rs13261559	ENSG00000200714.1	Y_RNA	4.59	9.32e-06	0.00481	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.778	rs7843697	ENSG00000200714.1	Y_RNA	4.59	9.32e-06	0.00481	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.778	rs7843724	ENSG00000200714.1	Y_RNA	4.59	9.32e-06	0.00481	0.44	0.35	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65592731~65592820:+
PCPG	cis	rs300890	0.536	rs10033104	ENSG00000250326.1	RP11-284M14.1	4.59	9.33e-06	0.00482	0.33	0.35	Nasopharyngeal carcinoma;	chr4:143252330	chr4:142933195~143184861:-
PCPG	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	4.59	9.33e-06	0.00482	0.4	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
PCPG	cis	rs7759001	0.857	rs2015648	ENSG00000271755.1	RP1-153G14.4	4.59	9.33e-06	0.00482	0.52	0.35	Glomerular filtration rate (creatinine);	chr6:27397946	chr6:27404010~27406964:-
PCPG	cis	rs7819412	0.749	rs11991118	ENSG00000255020.1	AF131216.5	4.59	9.33e-06	0.00482	0.52	0.35	Triglycerides;	chr8:11081763	chr8:11345748~11347502:-
PCPG	cis	rs2625529	0.557	rs1000281	ENSG00000260037.4	CTD-2524L6.3	4.59	9.34e-06	0.00482	0.44	0.35	Red blood cell count;	chr15:72261081	chr15:71818396~71823384:+
PCPG	cis	rs950169	0.922	rs4842940	ENSG00000235370.6	DNM1P51	-4.59	9.35e-06	0.00483	-0.36	-0.35	Schizophrenia;	chr15:84162473	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs4842941	ENSG00000235370.6	DNM1P51	-4.59	9.35e-06	0.00483	-0.36	-0.35	Schizophrenia;	chr15:84162560	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs12911223	ENSG00000235370.6	DNM1P51	-4.59	9.35e-06	0.00483	-0.36	-0.35	Schizophrenia;	chr15:84162919	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.845	rs4106951	ENSG00000235370.6	DNM1P51	4.59	9.35e-06	0.00483	0.36	0.35	Schizophrenia;	chr15:84164642	chr15:84398316~84411701:-
PCPG	cis	rs11858159	1	rs11858845	ENSG00000259905.4	PWRN1	4.59	9.35e-06	0.00483	0.41	0.35	Platelet thrombus formation;	chr15:24562065	chr15:24493137~24652130:+
PCPG	cis	rs1048886	0.808	rs77554252	ENSG00000271967.1	RP11-134K13.4	-4.59	9.36e-06	0.00483	-0.46	-0.35	Type 2 diabetes;	chr6:70540257	chr6:70596438~70596980:+
PCPG	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	4.59	9.37e-06	0.00483	0.44	0.35	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
PCPG	cis	rs2836974	0.544	rs2776312	ENSG00000255568.3	BRWD1-AS2	4.59	9.37e-06	0.00484	0.36	0.35	Cognitive function;	chr21:39346592	chr21:39313935~39314962:+
PCPG	cis	rs561341	0.941	rs2428341	ENSG00000265798.5	RP11-271K11.5	4.59	9.37e-06	0.00484	0.59	0.35	Hip circumference adjusted for BMI;	chr17:31990276	chr17:31038575~31059121:-
PCPG	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-4.59	9.37e-06	0.00484	-0.49	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
PCPG	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	4.59	9.38e-06	0.00484	0.48	0.35	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
PCPG	cis	rs3806843	1	rs2098058	ENSG00000202515.1	VTRNA1-3	4.59	9.39e-06	0.00484	0.45	0.35	Depressive symptoms (multi-trait analysis);	chr5:140777842	chr5:140726158~140726246:+
PCPG	cis	rs8030379	0.967	rs8036748	ENSG00000230373.7	GOLGA6L5P	-4.59	9.39e-06	0.00485	-0.35	-0.35	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903084	chr15:84507885~84516814:-
PCPG	cis	rs7246657	0.891	rs7253114	ENSG00000226686.6	LINC01535	-4.59	9.39e-06	0.00485	-0.54	-0.35	Coronary artery calcification;	chr19:37497823	chr19:37251912~37265535:+
PCPG	cis	rs7759001	0.857	rs4713094	ENSG00000271755.1	RP1-153G14.4	4.59	9.39e-06	0.00485	0.52	0.35	Glomerular filtration rate (creatinine);	chr6:27405299	chr6:27404010~27406964:-
PCPG	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	4.59	9.41e-06	0.00485	0.53	0.35	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
PCPG	cis	rs1949733	0.701	rs940136	ENSG00000205959.3	RP11-689P11.2	-4.59	9.41e-06	0.00485	-0.39	-0.35	Response to antineoplastic agents;	chr4:8447265	chr4:8482270~8512610:+
PCPG	cis	rs12908161	0.959	rs11637728	ENSG00000259295.5	CSPG4P12	4.59	9.42e-06	0.00486	0.52	0.35	Schizophrenia;	chr15:84660161	chr15:85191438~85213905:+
PCPG	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	4.59	9.43e-06	0.00486	0.37	0.35	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
PCPG	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-4.59	9.44e-06	0.00487	-0.4	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
PCPG	cis	rs17772222	0.958	rs60213984	ENSG00000222990.1	RNU4-22P	4.59	9.44e-06	0.00487	0.48	0.35	Coronary artery calcification;	chr14:88401473	chr14:88513498~88513663:+
PCPG	cis	rs17772222	1	rs55722539	ENSG00000222990.1	RNU4-22P	4.59	9.44e-06	0.00487	0.48	0.35	Coronary artery calcification;	chr14:88411691	chr14:88513498~88513663:+
PCPG	cis	rs17772222	1	rs11159856	ENSG00000222990.1	RNU4-22P	4.59	9.44e-06	0.00487	0.48	0.35	Coronary artery calcification;	chr14:88417585	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs17124652	ENSG00000222990.1	RNU4-22P	4.59	9.44e-06	0.00487	0.48	0.35	Coronary artery calcification;	chr14:88424384	chr14:88513498~88513663:+
PCPG	cis	rs17772222	1	rs2295135	ENSG00000222990.1	RNU4-22P	4.59	9.44e-06	0.00487	0.48	0.35	Coronary artery calcification;	chr14:88427866	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.674	rs112788894	ENSG00000222990.1	RNU4-22P	4.59	9.44e-06	0.00487	0.48	0.35	Coronary artery calcification;	chr14:88442850	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.876	rs4375590	ENSG00000222990.1	RNU4-22P	4.59	9.44e-06	0.00487	0.48	0.35	Coronary artery calcification;	chr14:88451334	chr14:88513498~88513663:+
PCPG	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	4.59	9.44e-06	0.00487	0.46	0.35	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
PCPG	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-4.59	9.45e-06	0.00487	-0.46	-0.35	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
PCPG	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	4.59	9.47e-06	0.00488	0.42	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
PCPG	cis	rs7824557	0.872	rs1347410	ENSG00000255020.1	AF131216.5	-4.59	9.47e-06	0.00488	-0.45	-0.35	Retinal vascular caliber;	chr8:11253733	chr8:11345748~11347502:-
PCPG	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-4.59	9.47e-06	0.00488	-0.37	-0.35	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
PCPG	cis	rs5769707	0.521	rs739244	ENSG00000235111.1	RP1-29C18.8	-4.59	9.47e-06	0.00488	-0.4	-0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49612657~49615716:-
PCPG	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	4.59	9.48e-06	0.00488	0.6	0.35	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	4.59	9.48e-06	0.00488	0.6	0.35	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	4.59	9.48e-06	0.00488	0.6	0.35	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
PCPG	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	4.59	9.48e-06	0.00488	0.47	0.35	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
PCPG	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-4.59	9.49e-06	0.00489	-0.36	-0.35	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
PCPG	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-4.59	9.49e-06	0.00489	-0.36	-0.35	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
PCPG	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	-4.59	9.5e-06	0.00489	-0.41	-0.35	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
PCPG	cis	rs73607972	0.501	rs4784317	ENSG00000275191.1	RP11-36I17.2	-4.58	9.5e-06	0.00489	-0.55	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53552273	chr16:53628256~53628816:-
PCPG	cis	rs964611	0.882	rs4775746	ENSG00000259488.2	RP11-154J22.1	4.58	9.51e-06	0.0049	0.35	0.35	Metabolite levels (Pyroglutamine);	chr15:48346050	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs4775748	ENSG00000259488.2	RP11-154J22.1	4.58	9.51e-06	0.0049	0.35	0.35	Metabolite levels (Pyroglutamine);	chr15:48346598	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs12917438	ENSG00000259488.2	RP11-154J22.1	4.58	9.51e-06	0.0049	0.35	0.35	Metabolite levels (Pyroglutamine);	chr15:48347540	chr15:48312353~48331856:-
PCPG	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-4.58	9.51e-06	0.0049	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
PCPG	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	4.58	9.52e-06	0.0049	0.47	0.35	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
PCPG	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	4.58	9.55e-06	0.00491	0.45	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
PCPG	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	4.58	9.55e-06	0.00491	0.45	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
PCPG	cis	rs2736345	0.672	rs2618473	ENSG00000255020.1	AF131216.5	4.58	9.56e-06	0.00492	0.47	0.35	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486618	chr8:11345748~11347502:-
PCPG	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	4.58	9.57e-06	0.00492	0.39	0.35	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
PCPG	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	4.58	9.57e-06	0.00492	0.43	0.35	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	4.58	9.57e-06	0.00492	0.43	0.35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	4.58	9.57e-06	0.00492	0.43	0.35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-4.58	9.57e-06	0.00492	-0.43	-0.35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
PCPG	cis	rs11673344	0.542	rs1667380	ENSG00000226686.6	LINC01535	4.58	9.58e-06	0.00493	0.44	0.35	Obesity-related traits;	chr19:37001848	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.542	rs826325	ENSG00000226686.6	LINC01535	4.58	9.58e-06	0.00493	0.44	0.35	Obesity-related traits;	chr19:37003580	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.598	rs826326	ENSG00000226686.6	LINC01535	4.58	9.58e-06	0.00493	0.44	0.35	Obesity-related traits;	chr19:37003863	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.542	rs826328	ENSG00000226686.6	LINC01535	4.58	9.58e-06	0.00493	0.44	0.35	Obesity-related traits;	chr19:37004479	chr19:37251912~37265535:+
PCPG	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	4.58	9.58e-06	0.00493	0.78	0.35	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
PCPG	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	4.58	9.59e-06	0.00493	0.43	0.35	Height;	chr5:37454360	chr5:36666214~36725195:-
PCPG	cis	rs11148252	0.514	rs2296347	ENSG00000235660.1	LINC00345	4.58	9.59e-06	0.00493	0.43	0.35	Lewy body disease;	chr13:52154288	chr13:52484161~52484680:-
PCPG	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-4.58	9.59e-06	0.00493	-0.54	-0.35	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
PCPG	cis	rs11858159	1	rs3924639	ENSG00000260760.1	PWRN3	4.58	9.6e-06	0.00493	0.37	0.35	Platelet thrombus formation;	chr15:24570220	chr15:24441127~24447967:+
PCPG	cis	rs7945705	0.967	rs2568090	ENSG00000254860.4	TMEM9B-AS1	-4.58	9.6e-06	0.00493	-0.34	-0.35	Hemoglobin concentration;	chr11:8827948	chr11:8964675~8977527:+
PCPG	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	4.58	9.6e-06	0.00493	0.45	0.35	Height;	chr6:109499759	chr6:109382795~109383666:+
PCPG	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	4.58	9.61e-06	0.00494	0.43	0.35	Height;	chr5:37468413	chr5:36666214~36725195:-
PCPG	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	4.58	9.61e-06	0.00494	0.49	0.35	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
PCPG	cis	rs5758511	0.68	rs5758687	ENSG00000205702.9	CYP2D7	4.58	9.62e-06	0.00494	0.47	0.35	Birth weight;	chr22:42260582	chr22:42140203~42144577:-
PCPG	cis	rs2836974	0.545	rs2776311	ENSG00000255568.3	BRWD1-AS2	4.58	9.63e-06	0.00495	0.36	0.35	Cognitive function;	chr21:39344959	chr21:39313935~39314962:+
PCPG	cis	rs2836974	0.583	rs741795	ENSG00000255568.3	BRWD1-AS2	4.58	9.63e-06	0.00495	0.36	0.35	Cognitive function;	chr21:39346514	chr21:39313935~39314962:+
PCPG	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	4.58	9.63e-06	0.00495	0.5	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-4.58	9.64e-06	0.00495	-0.5	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
PCPG	cis	rs964611	0.882	rs971952	ENSG00000259488.2	RP11-154J22.1	4.58	9.64e-06	0.00495	0.35	0.35	Metabolite levels (Pyroglutamine);	chr15:48363743	chr15:48312353~48331856:-
PCPG	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	4.58	9.66e-06	0.00496	0.44	0.35	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
PCPG	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	4.58	9.66e-06	0.00496	0.44	0.35	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
PCPG	cis	rs11858159	0.656	rs12913957	ENSG00000259905.4	PWRN1	4.58	9.66e-06	0.00496	0.37	0.35	Platelet thrombus formation;	chr15:24566369	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.903	rs12913246	ENSG00000259905.4	PWRN1	4.58	9.66e-06	0.00496	0.37	0.35	Platelet thrombus formation;	chr15:24570686	chr15:24493137~24652130:+
PCPG	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-4.58	9.67e-06	0.00496	-0.55	-0.35	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
PCPG	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-4.58	9.68e-06	0.00497	-0.35	-0.35	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	4.58	9.68e-06	0.00497	0.35	0.35	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
PCPG	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-4.58	9.69e-06	0.00497	-0.47	-0.35	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
PCPG	cis	rs11640439	1	rs11640439	ENSG00000260038.1	RP11-407G23.4	-4.58	9.69e-06	0.00498	-0.67	-0.35	Sleep duration;	chr16:57269282	chr16:57247350~57248492:+
PCPG	cis	rs748404	0.666	rs12900259	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43427369	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs34921640	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43429187	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs62020574	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43429380	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs16957730	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43438288	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs12913977	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43438913	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs12914122	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43438956	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs34697113	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43442041	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs12907870	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43453971	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs72709850	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43462486	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs12905220	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43465641	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs36078097	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43466209	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs7181783	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43469723	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs35903301	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43472332	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs34002293	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43472401	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs34181131	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43478527	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs7173383	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43480838	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs55801120	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43495042	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs12911740	ENSG00000249839.1	AC011330.5	-4.58	9.7e-06	0.00498	-0.47	-0.35	Lung cancer;	chr15:43498254	chr15:43663654~43684339:-
PCPG	cis	rs1153858	0.562	rs8025019	ENSG00000259520.4	CTD-2651B20.3	-4.58	9.71e-06	0.00498	-0.75	-0.35	Homoarginine levels;	chr15:45443667	chr15:45251580~45279251:-
PCPG	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-4.58	9.71e-06	0.00498	-0.42	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
PCPG	cis	rs964611	0.882	rs1905612	ENSG00000259488.2	RP11-154J22.1	4.58	9.71e-06	0.00498	0.36	0.35	Metabolite levels (Pyroglutamine);	chr15:48363720	chr15:48312353~48331856:-
PCPG	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	4.58	9.71e-06	0.00498	0.53	0.35	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	4.58	9.71e-06	0.00498	0.53	0.35	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
PCPG	cis	rs1949733	0.656	rs2631762	ENSG00000205959.3	RP11-689P11.2	-4.58	9.72e-06	0.00498	-0.39	-0.35	Response to antineoplastic agents;	chr4:8421395	chr4:8482270~8512610:+
PCPG	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-4.58	9.73e-06	0.00499	-0.42	-0.35	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-4.58	9.73e-06	0.00499	-0.42	-0.35	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
PCPG	cis	rs35851103	0.6	rs4841662	ENSG00000255020.1	AF131216.5	-4.58	9.73e-06	0.00499	-0.46	-0.35	Neuroticism;	chr8:11986249	chr8:11345748~11347502:-
PCPG	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	4.58	9.73e-06	0.00499	0.55	0.35	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	4.58	9.73e-06	0.00499	0.55	0.35	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
PCPG	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	4.58	9.75e-06	0.005	0.29	0.35	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
PCPG	cis	rs12928939	0.859	rs11670	ENSG00000260886.1	TAT-AS1	4.58	9.75e-06	0.005	0.45	0.35	Post bronchodilator FEV1;	chr16:71645124	chr16:71565789~71578187:+
PCPG	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	4.58	9.75e-06	0.005	0.34	0.35	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	4.58	9.75e-06	0.005	0.34	0.35	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	4.58	9.75e-06	0.005	0.34	0.35	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	4.58	9.75e-06	0.005	0.34	0.35	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	4.58	9.75e-06	0.005	0.34	0.35	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	4.58	9.75e-06	0.005	0.34	0.35	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	4.58	9.75e-06	0.005	0.34	0.35	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
PCPG	cis	rs13108904	0.935	rs2293633	ENSG00000254094.1	AC078852.1	-4.58	9.76e-06	0.005	-0.4	-0.35	Obesity-related traits;	chr4:1297852	chr4:1356581~1358075:+
PCPG	cis	rs17772222	1	rs74071851	ENSG00000222990.1	RNU4-22P	4.58	9.76e-06	0.005	0.49	0.35	Coronary artery calcification;	chr14:88415858	chr14:88513498~88513663:+
PCPG	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	4.58	9.77e-06	0.005	0.48	0.35	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
PCPG	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	4.58	9.77e-06	0.005	0.45	0.35	Height;	chr6:109498586	chr6:109382795~109383666:+
PCPG	cis	rs34421088	0.506	rs2409755	ENSG00000255020.1	AF131216.5	4.58	9.78e-06	0.00501	0.43	0.35	Neuroticism;	chr8:11312474	chr8:11345748~11347502:-
PCPG	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	4.58	9.78e-06	0.00501	0.45	0.35	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
PCPG	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-4.58	9.79e-06	0.00501	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
PCPG	cis	rs11858159	1	rs11858320	ENSG00000260760.1	PWRN3	4.58	9.79e-06	0.00501	0.38	0.35	Platelet thrombus formation;	chr15:24536215	chr15:24441127~24447967:+
PCPG	cis	rs7403037	0.56	rs11161102	ENSG00000260760.1	PWRN3	4.58	9.79e-06	0.00501	0.38	0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24536668	chr15:24441127~24447967:+
PCPG	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	4.58	9.79e-06	0.00501	0.48	0.35	Height;	chr6:109333018	chr6:109382795~109383666:+
PCPG	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	4.58	9.79e-06	0.00501	0.45	0.35	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
PCPG	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-4.58	9.81e-06	0.00502	-0.47	-0.35	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
PCPG	cis	rs1440410	0.56	rs4299537	ENSG00000250326.1	RP11-284M14.1	4.58	9.82e-06	0.00503	0.33	0.35	Ischemic stroke;	chr4:143127155	chr4:142933195~143184861:-
PCPG	cis	rs13438712	0.573	rs4727635	ENSG00000280439.1	RP4-568B10.1	4.58	9.82e-06	0.00503	0.4	0.35	Obesity-related traits;	chr7:105904286	chr7:106035798~106036431:+
PCPG	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-4.58	9.82e-06	0.00503	-0.49	-0.35	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
PCPG	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-4.58	9.82e-06	0.00503	-0.49	-0.35	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
PCPG	cis	rs11673344	0.504	rs2595555	ENSG00000226686.6	LINC01535	4.58	9.82e-06	0.00503	0.45	0.35	Obesity-related traits;	chr19:37000219	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs1667377	ENSG00000226686.6	LINC01535	4.58	9.82e-06	0.00503	0.45	0.35	Obesity-related traits;	chr19:37000966	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs1667379	ENSG00000226686.6	LINC01535	4.58	9.82e-06	0.00503	0.45	0.35	Obesity-related traits;	chr19:37001192	chr19:37251912~37265535:+
PCPG	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-4.58	9.83e-06	0.00503	-0.42	-0.35	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
PCPG	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	4.58	9.84e-06	0.00504	0.44	0.35	Height;	chr6:109676091	chr6:109382795~109383666:+
PCPG	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-4.58	9.84e-06	0.00504	-0.3	-0.35	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
PCPG	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	4.58	9.85e-06	0.00504	0.46	0.35	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
PCPG	cis	rs7208859	0.673	rs999798	ENSG00000263603.1	CTD-2349P21.5	-4.58	9.85e-06	0.00504	-0.56	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30729469~30731202:+
PCPG	cis	rs591584	0.73	rs72963846	ENSG00000255893.1	RP11-685N10.1	-4.58	9.86e-06	0.00504	-0.41	-0.35	Macrophage Migration Inhibitory Factor levels;	chr11:94574596	chr11:94472908~94473570:-
PCPG	cis	rs2274273	0.743	rs7161656	ENSG00000258413.1	RP11-665C16.6	-4.58	9.88e-06	0.00505	-0.42	-0.35	Protein biomarker;	chr14:55057812	chr14:55262767~55272075:-
PCPG	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	4.58	9.88e-06	0.00505	0.62	0.35	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
PCPG	cis	rs3850699	0.926	rs2002916	ENSG00000269609.4	RPARP-AS1	-4.58	9.88e-06	0.00505	-0.29	-0.35	Prostate cancer;	chr10:102672296	chr10:102449817~102461106:+
PCPG	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	4.58	9.89e-06	0.00506	0.62	0.35	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	4.58	9.89e-06	0.00506	0.62	0.35	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	4.58	9.89e-06	0.00506	0.62	0.35	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	4.58	9.89e-06	0.00506	0.62	0.35	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	4.58	9.89e-06	0.00506	0.62	0.35	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
PCPG	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-4.58	9.9e-06	0.00506	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
PCPG	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	4.58	9.91e-06	0.00506	0.37	0.35	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
PCPG	cis	rs301901	0.796	rs3941788	ENSG00000250155.1	CTD-2353F22.1	4.58	9.91e-06	0.00506	0.43	0.35	Height;	chr5:37498809	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	4.58	9.91e-06	0.00506	0.43	0.35	Height;	chr5:37504063	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	4.58	9.91e-06	0.00506	0.43	0.35	Height;	chr5:37505544	chr5:36666214~36725195:-
PCPG	cis	rs5742933	0.817	rs4667297	ENSG00000273240.1	RP11-455J20.3	4.57	9.92e-06	0.00507	0.37	0.35	Ferritin levels;	chr2:189664270	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.711	rs12693551	ENSG00000273240.1	RP11-455J20.3	4.57	9.92e-06	0.00507	0.37	0.35	Ferritin levels;	chr2:189664505	chr2:189763859~189764456:-
PCPG	cis	rs12681963	0.688	rs10503864	ENSG00000248159.1	HSPA8P11	-4.57	9.93e-06	0.00507	-0.69	-0.35	Migraine;	chr8:30193697	chr8:30237382~30240997:+
PCPG	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	4.57	9.94e-06	0.00508	0.35	0.35	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
PCPG	cis	rs2274273	0.623	rs1187877	ENSG00000258413.1	RP11-665C16.6	4.57	9.94e-06	0.00508	0.43	0.35	Protein biomarker;	chr14:55028443	chr14:55262767~55272075:-
PCPG	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-4.57	9.95e-06	0.00508	-0.42	-0.35	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
PCPG	cis	rs7017914	0.934	rs7015035	ENSG00000254031.4	RP11-326E22.1	4.57	9.96e-06	0.00509	0.34	0.35	Bone mineral density;	chr8:70741366	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs6982406	ENSG00000254031.4	RP11-326E22.1	4.57	9.96e-06	0.00509	0.34	0.35	Bone mineral density;	chr8:70742373	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs1902614	ENSG00000254031.4	RP11-326E22.1	4.57	9.96e-06	0.00509	0.34	0.35	Bone mineral density;	chr8:70743932	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs34905858	ENSG00000254031.4	RP11-326E22.1	4.57	9.96e-06	0.00509	0.34	0.35	Bone mineral density;	chr8:70747215	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs6998024	ENSG00000254031.4	RP11-326E22.1	4.57	9.96e-06	0.00509	0.34	0.35	Bone mineral density;	chr8:70748605	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs35960437	ENSG00000254031.4	RP11-326E22.1	4.57	9.96e-06	0.00509	0.34	0.35	Bone mineral density;	chr8:70749725	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs34409123	ENSG00000254031.4	RP11-326E22.1	4.57	9.96e-06	0.00509	0.34	0.35	Bone mineral density;	chr8:70749881	chr8:71155457~71204223:+
PCPG	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-4.57	9.96e-06	0.00509	-0.45	-0.35	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
PCPG	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	4.57	9.99e-06	0.0051	0.43	0.35	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
PCPG	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	4.57	9.99e-06	0.0051	0.46	0.35	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
PCPG	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	4.57	1e-05	0.0051	0.43	0.35	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
PCPG	cis	rs9595908	0.606	rs4942922	ENSG00000212293.1	SNORA16	4.57	1e-05	0.0051	0.43	0.35	Body mass index;	chr13:32806832	chr13:32420390~32420516:-
PCPG	cis	rs7824557	0.564	rs34964435	ENSG00000255020.1	AF131216.5	-4.57	1e-05	0.0051	-0.47	-0.35	Retinal vascular caliber;	chr8:11372697	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.564	rs55758514	ENSG00000255020.1	AF131216.5	-4.57	1e-05	0.0051	-0.47	-0.35	Retinal vascular caliber;	chr8:11372750	chr8:11345748~11347502:-
PCPG	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	4.57	1e-05	0.00511	0.47	0.35	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
PCPG	cis	rs301901	0.828	rs10941337	ENSG00000250155.1	CTD-2353F22.1	4.57	1e-05	0.00511	0.43	0.35	Height;	chr5:37474023	chr5:36666214~36725195:-
PCPG	cis	rs11673344	0.504	rs2385374	ENSG00000226686.6	LINC01535	4.57	1e-05	0.00511	0.45	0.35	Obesity-related traits;	chr19:37092115	chr19:37251912~37265535:+
PCPG	cis	rs3764021	0.87	rs10844597	ENSG00000278635.1	CTD-2318O12.1	-4.57	1e-05	0.00511	-0.43	-0.35	Type 1 diabetes;	chr12:9722303	chr12:9415641~9416718:+
PCPG	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-4.57	1e-05	0.00511	-0.46	-0.35	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
PCPG	cis	rs5758511	0.68	rs5758681	ENSG00000205702.9	CYP2D7	4.57	1e-05	0.00511	0.48	0.35	Birth weight;	chr22:42249085	chr22:42140203~42144577:-
PCPG	cis	rs3736858	0.736	rs9544056	ENSG00000261105.4	LMO7-AS1	-4.57	1e-05	0.00511	-0.69	-0.35	Interleukin-9 levels;	chr13:75869711	chr13:75604700~75635994:-
PCPG	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	4.57	1e-05	0.00512	0.39	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
PCPG	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	4.57	1.01e-05	0.00512	0.59	0.35	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	4.57	1.01e-05	0.00512	0.59	0.35	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	4.57	1.01e-05	0.00512	0.59	0.35	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
PCPG	cis	rs748404	0.666	rs66629206	ENSG00000249839.1	AC011330.5	-4.57	1.01e-05	0.00512	-0.47	-0.35	Lung cancer;	chr15:43458804	chr15:43663654~43684339:-
PCPG	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-4.57	1.01e-05	0.00513	-0.42	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
PCPG	cis	rs13113518	0.934	rs11935823	ENSG00000272969.1	RP11-528I4.2	4.57	1.01e-05	0.00513	0.39	0.35	Height;	chr4:55589624	chr4:55547112~55547889:+
PCPG	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	4.57	1.01e-05	0.00513	0.48	0.35	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
PCPG	cis	rs8098244	0.706	rs6508004	ENSG00000265752.2	RP11-403A21.1	4.57	1.01e-05	0.00513	0.43	0.35	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23884153	chr18:23957754~23982556:-
PCPG	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	4.57	1.01e-05	0.00513	0.36	0.35	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
PCPG	cis	rs17684571	0.7	rs16888171	ENSG00000231441.1	RP11-472M19.2	4.57	1.01e-05	0.00514	0.54	0.35	Schizophrenia;	chr6:56810369	chr6:56844002~56864078:+
PCPG	cis	rs2625529	0.824	rs12902006	ENSG00000260037.4	CTD-2524L6.3	-4.57	1.01e-05	0.00514	-0.54	-0.35	Red blood cell count;	chr15:71960655	chr15:71818396~71823384:+
PCPG	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-4.57	1.01e-05	0.00514	-0.48	-0.35	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
PCPG	cis	rs7824557	0.628	rs11782706	ENSG00000255020.1	AF131216.5	4.57	1.01e-05	0.00514	0.45	0.35	Retinal vascular caliber;	chr8:11328706	chr8:11345748~11347502:-
PCPG	cis	rs4671400	0.571	rs62152270	ENSG00000270820.4	RP11-355B11.2	-4.57	1.01e-05	0.00514	-0.49	-0.35	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267125	chr2:61471188~61484130:+
PCPG	cis	rs8044188	1	rs6497629	ENSG00000261090.1	RP11-20G6.2	4.57	1.01e-05	0.00515	0.55	0.35	Multiple system atrophy;	chr16:23033554	chr16:23020337~23023611:+
PCPG	cis	rs7819412	1	rs2409722	ENSG00000255020.1	AF131216.5	-4.57	1.01e-05	0.00515	-0.47	-0.35	Triglycerides;	chr8:11182307	chr8:11345748~11347502:-
PCPG	cis	rs9650657	0.504	rs2409724	ENSG00000255020.1	AF131216.5	-4.57	1.01e-05	0.00515	-0.47	-0.35	Neuroticism;	chr8:11184133	chr8:11345748~11347502:-
PCPG	cis	rs1949733	1	rs3103099	ENSG00000205959.3	RP11-689P11.2	4.57	1.01e-05	0.00515	0.4	0.35	Response to antineoplastic agents;	chr4:8509840	chr4:8482270~8512610:+
PCPG	cis	rs2974238	1	rs2974238	ENSG00000269656.1	CTD-2571L23.6	4.57	1.01e-05	0.00515	0.45	0.35	Parental longevity (mother's age at death);	chr19:47613804	chr19:47757036~47768840:-
PCPG	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	4.57	1.01e-05	0.00515	0.45	0.35	Height;	chr6:109449796	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	4.57	1.01e-05	0.00515	0.45	0.35	Height;	chr6:109452743	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	4.57	1.01e-05	0.00515	0.45	0.35	Height;	chr6:109454855	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	4.57	1.01e-05	0.00515	0.45	0.35	Height;	chr6:109465229	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	4.57	1.01e-05	0.00515	0.45	0.35	Height;	chr6:109469907	chr6:109382795~109383666:+
PCPG	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	4.57	1.01e-05	0.00516	0.38	0.35	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
PCPG	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-4.57	1.01e-05	0.00516	-0.52	-0.35	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
PCPG	cis	rs1048886	0.808	rs2207425	ENSG00000271967.1	RP11-134K13.4	-4.57	1.01e-05	0.00516	-0.45	-0.35	Type 2 diabetes;	chr6:70509867	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs17713547	ENSG00000271967.1	RP11-134K13.4	-4.57	1.01e-05	0.00516	-0.45	-0.35	Type 2 diabetes;	chr6:70516848	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.808	rs17635510	ENSG00000271967.1	RP11-134K13.4	-4.57	1.01e-05	0.00516	-0.45	-0.35	Type 2 diabetes;	chr6:70516932	chr6:70596438~70596980:+
PCPG	cis	rs9469578	0.579	rs73743401	ENSG00000224796.1	RPL32P1	-4.57	1.01e-05	0.00516	-0.96	-0.35	Phosphorus levels;	chr6:33749168	chr6:33079451~33079860:+
PCPG	cis	rs17772222	0.958	rs17798341	ENSG00000222990.1	RNU4-22P	4.57	1.02e-05	0.00517	0.46	0.35	Coronary artery calcification;	chr14:88548201	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs61984683	ENSG00000222990.1	RNU4-22P	4.57	1.02e-05	0.00517	0.46	0.35	Coronary artery calcification;	chr14:88553162	chr14:88513498~88513663:+
PCPG	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	4.57	1.02e-05	0.00517	0.48	0.35	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
PCPG	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	4.57	1.02e-05	0.00517	0.48	0.35	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
PCPG	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	4.57	1.02e-05	0.00517	0.48	0.35	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
PCPG	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-4.57	1.02e-05	0.00517	-0.39	-0.35	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
PCPG	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-4.57	1.02e-05	0.00517	-0.77	-0.35	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-4.57	1.02e-05	0.00517	-0.77	-0.35	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
PCPG	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-4.57	1.02e-05	0.00517	-0.44	-0.35	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
PCPG	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	4.57	1.02e-05	0.00517	0.79	0.35	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
PCPG	cis	rs189798	0.807	rs330912	ENSG00000253893.2	FAM85B	-4.57	1.02e-05	0.00518	-0.5	-0.35	Myopia (pathological);	chr8:9138784	chr8:8167819~8226614:-
PCPG	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	4.57	1.02e-05	0.00518	0.56	0.35	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	4.57	1.02e-05	0.00518	0.56	0.35	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	4.57	1.02e-05	0.00518	0.56	0.35	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	4.57	1.02e-05	0.00518	0.56	0.35	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
PCPG	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	4.57	1.02e-05	0.00518	0.56	0.35	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
PCPG	cis	rs916888	0.61	rs199446	ENSG00000232300.1	FAM215B	-4.57	1.02e-05	0.00518	-0.45	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.61	rs199536	ENSG00000232300.1	FAM215B	-4.57	1.02e-05	0.00518	-0.45	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46558830~46562795:-
PCPG	cis	rs561341	0.883	rs6505274	ENSG00000265798.5	RP11-271K11.5	4.57	1.02e-05	0.00518	0.62	0.35	Hip circumference adjusted for BMI;	chr17:32017562	chr17:31038575~31059121:-
PCPG	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-4.57	1.02e-05	0.00518	-0.43	-0.35	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
PCPG	cis	rs17507216	0.628	rs28607761	ENSG00000228141.5	AC105339.1	-4.57	1.02e-05	0.00518	-0.52	-0.35	Excessive daytime sleepiness;	chr15:82715317	chr15:82710471~82714026:-
PCPG	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	4.57	1.02e-05	0.00519	0.44	0.35	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
PCPG	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-4.57	1.02e-05	0.00519	-0.38	-0.35	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
PCPG	cis	rs7829975	0.593	rs2921061	ENSG00000173295.6	FAM86B3P	-4.57	1.02e-05	0.00519	-0.4	-0.35	Mood instability;	chr8:8460105	chr8:8228595~8244865:+
PCPG	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	4.57	1.02e-05	0.00519	0.46	0.35	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	4.57	1.02e-05	0.00519	0.46	0.35	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	4.57	1.02e-05	0.00519	0.46	0.35	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
PCPG	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	4.57	1.02e-05	0.00519	0.27	0.35	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
PCPG	cis	rs4819052	0.704	rs2297283	ENSG00000223768.1	LINC00205	-4.57	1.02e-05	0.0052	-0.42	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45293285~45297354:+
PCPG	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-4.57	1.02e-05	0.0052	-0.52	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
PCPG	cis	rs7017914	0.967	rs1348535	ENSG00000254031.4	RP11-326E22.1	4.57	1.02e-05	0.0052	0.34	0.35	Bone mineral density;	chr8:70750506	chr8:71155457~71204223:+
PCPG	cis	rs11148252	0.669	rs4884320	ENSG00000278238.1	RP11-245D16.4	-4.57	1.02e-05	0.0052	-0.33	-0.35	Lewy body disease;	chr13:52432779	chr13:52454775~52455331:-
PCPG	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	4.57	1.02e-05	0.0052	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
PCPG	cis	rs944797	0.643	rs10757270	ENSG00000266446.1	RP11-149I2.4	4.57	1.03e-05	0.0052	0.42	0.35	Coronary heart disease;	chr9:22072720	chr9:21995482~21996013:+
PCPG	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	4.57	1.03e-05	0.00521	0.43	0.35	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
PCPG	cis	rs7818382	0.967	rs7812465	ENSG00000272509.1	RP11-347C18.5	-4.57	1.03e-05	0.00521	-0.35	-0.35	Alzheimer's disease (late onset);	chr8:95038329	chr8:94884609~94885070:+
PCPG	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	4.57	1.03e-05	0.00522	0.35	0.35	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
PCPG	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-4.57	1.03e-05	0.00522	-0.58	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
PCPG	cis	rs7208859	0.673	rs56846352	ENSG00000263603.1	CTD-2349P21.5	-4.57	1.03e-05	0.00522	-0.56	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs7211776	ENSG00000263603.1	CTD-2349P21.5	-4.57	1.03e-05	0.00522	-0.56	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9912122	ENSG00000263603.1	CTD-2349P21.5	-4.57	1.03e-05	0.00522	-0.56	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30729469~30731202:+
PCPG	cis	rs1949733	0.675	rs2010758	ENSG00000205959.3	RP11-689P11.2	-4.57	1.03e-05	0.00522	-0.37	-0.35	Response to antineoplastic agents;	chr4:8473896	chr4:8482270~8512610:+
PCPG	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-4.57	1.03e-05	0.00522	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-4.57	1.03e-05	0.00522	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-4.57	1.03e-05	0.00522	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
PCPG	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-4.57	1.03e-05	0.00523	-0.48	-0.35	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
PCPG	cis	rs728616	0.867	rs7893241	ENSG00000242600.5	MBL1P	4.57	1.03e-05	0.00524	0.77	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194582	chr10:79904898~79950336:+
PCPG	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	4.57	1.03e-05	0.00524	0.33	0.35	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
PCPG	cis	rs7824557	0.628	rs7815802	ENSG00000255020.1	AF131216.5	4.57	1.03e-05	0.00524	0.45	0.35	Retinal vascular caliber;	chr8:11333138	chr8:11345748~11347502:-
PCPG	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-4.57	1.03e-05	0.00524	-0.46	-0.35	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
PCPG	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-4.57	1.03e-05	0.00524	-0.32	-0.35	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
PCPG	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-4.56	1.03e-05	0.00524	-0.36	-0.35	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
PCPG	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-4.56	1.03e-05	0.00525	-0.58	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-4.56	1.03e-05	0.00525	-0.58	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
PCPG	cis	rs453301	0.562	rs1038248	ENSG00000253893.2	FAM85B	4.56	1.03e-05	0.00525	0.4	0.35	Joint mobility (Beighton score);	chr8:9183348	chr8:8167819~8226614:-
PCPG	cis	rs16949788	0.826	rs74245473	ENSG00000261351.2	CTD-3185P2.1	-4.56	1.03e-05	0.00525	-0.48	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66416437	chr15:66488658~66492109:-
PCPG	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	4.56	1.03e-05	0.00525	0.37	0.35	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
PCPG	cis	rs7759001	0.857	rs6915934	ENSG00000271755.1	RP1-153G14.4	4.56	1.04e-05	0.00525	0.52	0.35	Glomerular filtration rate (creatinine);	chr6:27400108	chr6:27404010~27406964:-
PCPG	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	4.56	1.04e-05	0.00526	0.39	0.35	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
PCPG	cis	rs11672691	0.829	rs8112363	ENSG00000267107.5	PCAT19	4.56	1.04e-05	0.00526	0.31	0.35	Prostate cancer;	chr19:41483803	chr19:41454169~41500649:-
PCPG	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	4.56	1.04e-05	0.00526	0.43	0.35	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	4.56	1.04e-05	0.00526	0.43	0.35	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	4.56	1.04e-05	0.00526	0.43	0.35	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
PCPG	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	4.56	1.04e-05	0.00527	0.77	0.35	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	4.56	1.04e-05	0.00527	0.77	0.35	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	4.56	1.04e-05	0.00527	0.77	0.35	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	4.56	1.04e-05	0.00527	0.77	0.35	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	4.56	1.04e-05	0.00527	0.77	0.35	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-4.56	1.04e-05	0.00527	-0.77	-0.35	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
PCPG	cis	rs748404	0.666	rs72709879	ENSG00000205771.5	CATSPER2P1	-4.56	1.04e-05	0.00527	-0.46	-0.35	Lung cancer;	chr15:43507777	chr15:43726918~43747094:-
PCPG	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-4.56	1.04e-05	0.00527	-0.46	-0.35	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
PCPG	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-4.56	1.04e-05	0.00527	-0.46	-0.35	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
PCPG	cis	rs11858159	0.874	rs6576321	ENSG00000259905.4	PWRN1	4.56	1.04e-05	0.00527	0.37	0.35	Platelet thrombus formation;	chr15:24538188	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.812	rs11633507	ENSG00000259905.4	PWRN1	4.56	1.04e-05	0.00527	0.37	0.35	Platelet thrombus formation;	chr15:24540945	chr15:24493137~24652130:+
PCPG	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	4.56	1.04e-05	0.00528	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
PCPG	cis	rs2736345	0.89	rs4840565	ENSG00000254774.1	RP11-148O21.3	4.56	1.04e-05	0.00528	0.41	0.35	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:11553224~11554207:-
PCPG	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-4.56	1.04e-05	0.00528	-0.43	-0.35	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
PCPG	cis	rs2439831	0.85	rs2439832	ENSG00000205771.5	CATSPER2P1	-4.56	1.04e-05	0.00528	-0.49	-0.35	Lung cancer in ever smokers;	chr15:43487488	chr15:43726918~43747094:-
PCPG	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	4.56	1.04e-05	0.00529	0.39	0.35	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
PCPG	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-4.56	1.04e-05	0.00529	-0.4	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-4.56	1.04e-05	0.00529	-0.4	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
PCPG	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-4.56	1.04e-05	0.00529	-0.49	-0.35	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
PCPG	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-4.56	1.04e-05	0.00529	-0.45	-0.35	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
PCPG	cis	rs13113518	0.934	rs11133397	ENSG00000272969.1	RP11-528I4.2	4.56	1.04e-05	0.00529	0.39	0.35	Height;	chr4:55534166	chr4:55547112~55547889:+
PCPG	cis	rs13113518	0.934	rs11133398	ENSG00000272969.1	RP11-528I4.2	4.56	1.04e-05	0.00529	0.39	0.35	Height;	chr4:55534180	chr4:55547112~55547889:+
PCPG	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	4.56	1.05e-05	0.0053	0.43	0.35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
PCPG	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	4.56	1.05e-05	0.0053	0.43	0.35	Height;	chr5:37490184	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	4.56	1.05e-05	0.0053	0.43	0.35	Height;	chr5:37499677	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	4.56	1.05e-05	0.0053	0.43	0.35	Height;	chr5:37533964	chr5:36666214~36725195:-
PCPG	cis	rs11673344	0.523	rs6510585	ENSG00000226686.6	LINC01535	4.56	1.05e-05	0.0053	0.45	0.35	Obesity-related traits;	chr19:37063081	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.503	rs1829603	ENSG00000226686.6	LINC01535	4.56	1.05e-05	0.0053	0.45	0.35	Obesity-related traits;	chr19:37065396	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs17206540	ENSG00000226686.6	LINC01535	4.56	1.05e-05	0.0053	0.45	0.35	Obesity-related traits;	chr19:37069009	chr19:37251912~37265535:+
PCPG	cis	rs7017914	0.967	rs12680166	ENSG00000254031.4	RP11-326E22.1	4.56	1.05e-05	0.0053	0.34	0.35	Bone mineral density;	chr8:70766403	chr8:71155457~71204223:+
PCPG	cis	rs7246657	0.943	rs13343471	ENSG00000226686.6	LINC01535	-4.56	1.05e-05	0.0053	-0.61	-0.35	Coronary artery calcification;	chr19:37441228	chr19:37251912~37265535:+
PCPG	cis	rs7017914	0.935	rs56289931	ENSG00000254031.4	RP11-326E22.1	4.56	1.05e-05	0.0053	0.34	0.35	Bone mineral density;	chr8:70925519	chr8:71155457~71204223:+
PCPG	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	4.56	1.05e-05	0.00531	0.46	0.35	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
PCPG	cis	rs2235642	0.691	rs2281235	ENSG00000260989.1	LA16c-395F10.2	-4.56	1.05e-05	0.00531	-0.37	-0.35	Coronary artery disease;	chr16:1553534	chr16:1580527~1610328:+
PCPG	cis	rs2235642	0.821	rs2281236	ENSG00000260989.1	LA16c-395F10.2	-4.56	1.05e-05	0.00531	-0.37	-0.35	Coronary artery disease;	chr16:1553575	chr16:1580527~1610328:+
PCPG	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	4.56	1.05e-05	0.00532	0.41	0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
PCPG	cis	rs2898290	0.622	rs7822109	ENSG00000269954.1	RP11-148O21.6	-4.56	1.05e-05	0.00532	-0.39	-0.35	Systolic blood pressure;	chr8:11491638	chr8:11552488~11552991:-
PCPG	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	4.56	1.05e-05	0.00532	0.5	0.35	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
PCPG	cis	rs10101158	0.638	rs1542195	ENSG00000253595.4	LINC01300	4.56	1.05e-05	0.00532	0.35	0.35	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);	chr8:141854266	chr8:141340549~141344621:+
PCPG	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	4.56	1.05e-05	0.00532	0.43	0.35	Height;	chr5:37474739	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	4.56	1.05e-05	0.00532	0.43	0.35	Height;	chr5:37475788	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	4.56	1.05e-05	0.00532	0.43	0.35	Height;	chr5:37475789	chr5:36666214~36725195:-
PCPG	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-4.56	1.05e-05	0.00532	-0.48	-0.35	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
PCPG	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	4.56	1.05e-05	0.00532	0.44	0.35	Height;	chr6:109438349	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	4.56	1.05e-05	0.00532	0.44	0.35	Height;	chr6:109441033	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	4.56	1.05e-05	0.00532	0.44	0.35	Height;	chr6:109446728	chr6:109382795~109383666:+
PCPG	cis	rs7403037	0.509	rs7180190	ENSG00000260760.1	PWRN3	4.56	1.05e-05	0.00532	0.37	0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24571846	chr15:24441127~24447967:+
PCPG	cis	rs748404	0.666	rs7177146	ENSG00000205771.5	CATSPER2P1	-4.56	1.05e-05	0.00533	-0.46	-0.35	Lung cancer;	chr15:43506110	chr15:43726918~43747094:-
PCPG	cis	rs7208859	0.673	rs216424	ENSG00000266490.1	CTD-2349P21.9	4.56	1.05e-05	0.00533	0.44	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30792372~30792833:+
PCPG	cis	rs7824557	0.806	rs34171564	ENSG00000255020.1	AF131216.5	-4.56	1.05e-05	0.00533	-0.47	-0.35	Retinal vascular caliber;	chr8:11237837	chr8:11345748~11347502:-
PCPG	cis	rs9299346	0.594	rs1407870	ENSG00000225376.4	TMEM246-AS1	4.56	1.05e-05	0.00533	0.42	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101658566	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10115431	ENSG00000225376.4	TMEM246-AS1	4.56	1.05e-05	0.00533	0.42	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101659822	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs12338799	ENSG00000225376.4	TMEM246-AS1	4.56	1.05e-05	0.00533	0.42	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101660066	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10989587	ENSG00000225376.4	TMEM246-AS1	4.56	1.05e-05	0.00533	0.42	0.35	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101660544	chr9:101468439~101481502:+
PCPG	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-4.56	1.05e-05	0.00533	-0.48	-0.35	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-4.56	1.05e-05	0.00533	-0.48	-0.35	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
PCPG	cis	rs7208859	0.573	rs8078182	ENSG00000263603.1	CTD-2349P21.5	-4.56	1.05e-05	0.00533	-0.55	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30729469~30731202:+
PCPG	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-4.56	1.05e-05	0.00534	-0.47	-0.35	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
PCPG	cis	rs300890	0.513	rs4605600	ENSG00000250326.1	RP11-284M14.1	4.56	1.06e-05	0.00534	0.32	0.35	Nasopharyngeal carcinoma;	chr4:143124552	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.536	rs4279157	ENSG00000250326.1	RP11-284M14.1	4.56	1.06e-05	0.00534	0.32	0.35	Nasopharyngeal carcinoma;	chr4:143124849	chr4:142933195~143184861:-
PCPG	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-4.56	1.06e-05	0.00534	-0.39	-0.35	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
PCPG	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	4.56	1.06e-05	0.00534	0.77	0.35	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	4.56	1.06e-05	0.00534	0.77	0.35	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	4.56	1.06e-05	0.00534	0.77	0.35	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	4.56	1.06e-05	0.00534	0.77	0.35	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
PCPG	cis	rs916888	0.531	rs183211	ENSG00000232300.1	FAM215B	4.56	1.06e-05	0.00535	0.46	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46558830~46562795:-
PCPG	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-4.56	1.06e-05	0.00535	-0.5	-0.35	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
PCPG	cis	rs9911578	0.839	rs7208505	ENSG00000267416.1	CTD-2319I12.2	4.56	1.06e-05	0.00535	0.37	0.35	Intelligence (multi-trait analysis);	chr17:59110368	chr17:60079309~60088695:+
PCPG	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	4.56	1.06e-05	0.00536	0.48	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
PCPG	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	4.56	1.06e-05	0.00536	0.48	0.35	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
PCPG	cis	rs2836974	0.931	rs13047663	ENSG00000252915.1	Y_RNA	-4.56	1.06e-05	0.00536	-0.38	-0.35	Cognitive function;	chr21:39336892	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs13047678	ENSG00000252915.1	Y_RNA	-4.56	1.06e-05	0.00536	-0.38	-0.35	Cognitive function;	chr21:39336927	chr21:39344537~39344628:+
PCPG	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-4.56	1.06e-05	0.00536	-0.43	-0.35	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
PCPG	cis	rs16949788	0.793	rs78198355	ENSG00000261351.2	CTD-3185P2.1	-4.56	1.06e-05	0.00537	-0.47	-0.35	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66393470	chr15:66488658~66492109:-
PCPG	cis	rs2281603	0.951	rs73267743	ENSG00000259116.1	RP11-973N13.4	-4.56	1.06e-05	0.00537	-0.33	-0.35	Lymphocyte counts;	chr14:64511424	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs61985707	ENSG00000259116.1	RP11-973N13.4	-4.56	1.06e-05	0.00537	-0.33	-0.35	Lymphocyte counts;	chr14:64512846	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs12589947	ENSG00000259116.1	RP11-973N13.4	-4.56	1.06e-05	0.00537	-0.33	-0.35	Lymphocyte counts;	chr14:64515453	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs10142835	ENSG00000259116.1	RP11-973N13.4	-4.56	1.06e-05	0.00537	-0.33	-0.35	Lymphocyte counts;	chr14:64526733	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs12588886	ENSG00000259116.1	RP11-973N13.4	-4.56	1.06e-05	0.00537	-0.33	-0.35	Lymphocyte counts;	chr14:64530226	chr14:64514154~64540368:-
PCPG	cis	rs8098244	0.603	rs2337186	ENSG00000265752.2	RP11-403A21.1	4.56	1.06e-05	0.00537	0.42	0.35	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732088	chr18:23957754~23982556:-
PCPG	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-4.56	1.06e-05	0.00537	-0.35	-0.35	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
PCPG	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	4.56	1.06e-05	0.00537	0.45	0.35	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
PCPG	cis	rs357618	0.897	rs165362	ENSG00000260581.1	CTB-113P19.4	4.56	1.07e-05	0.00537	0.41	0.35	Basophil percentage of white cells;	chr5:151483526	chr5:151652275~151655449:+
PCPG	cis	rs10760158	0.832	rs4837834	ENSG00000226752.6	PSMD5-AS1	-4.56	1.07e-05	0.00538	-0.45	-0.35	Pulse pressure;	chr9:121296899	chr9:120824828~120854385:+
PCPG	cis	rs7819412	0.936	rs7814499	ENSG00000255020.1	AF131216.5	-4.56	1.07e-05	0.00538	-0.47	-0.35	Triglycerides;	chr8:11183138	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.774	rs11775523	ENSG00000173295.6	FAM86B3P	-4.56	1.07e-05	0.00538	-0.42	-0.35	Mood instability;	chr8:8821666	chr8:8228595~8244865:+
PCPG	cis	rs12681963	0.688	rs67240919	ENSG00000248159.1	HSPA8P11	4.56	1.07e-05	0.00538	0.63	0.35	Migraine;	chr8:30171039	chr8:30237382~30240997:+
PCPG	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	4.56	1.07e-05	0.00538	0.56	0.35	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
PCPG	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-4.56	1.07e-05	0.00539	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-4.56	1.07e-05	0.00539	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-4.56	1.07e-05	0.00539	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-4.56	1.07e-05	0.00539	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
PCPG	cis	rs5743030	0.702	rs256552	ENSG00000253559.1	OSGEPL1-AS1	-4.56	1.07e-05	0.00539	-0.53	-0.35	Subcutaneous adipose tissue;	chr2:189877648	chr2:189762704~189765556:+
PCPG	cis	rs964611	0.882	rs75094472	ENSG00000259488.2	RP11-154J22.1	-4.56	1.07e-05	0.0054	-0.35	-0.35	Metabolite levels (Pyroglutamine);	chr15:48351917	chr15:48312353~48331856:-
PCPG	cis	rs2531992	0.858	rs2230742	ENSG00000262185.1	RP11-462G12.1	4.56	1.07e-05	0.0054	0.56	0.35	Waist circumference;	chr16:3966675	chr16:3947609~3950444:-
PCPG	cis	rs7702057	0.53	rs3946989	ENSG00000271918.1	CTD-2287O16.5	4.56	1.07e-05	0.0054	0.5	0.35	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116083807~116085416:-
PCPG	cis	rs7702057	0.53	rs1567331	ENSG00000271918.1	CTD-2287O16.5	4.56	1.07e-05	0.0054	0.5	0.35	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116083807~116085416:-
PCPG	cis	rs7702057	0.53	rs1567332	ENSG00000271918.1	CTD-2287O16.5	4.56	1.07e-05	0.0054	0.5	0.35	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116083807~116085416:-
PCPG	cis	rs7702057	0.53	rs6890263	ENSG00000271918.1	CTD-2287O16.5	4.56	1.07e-05	0.0054	0.5	0.35	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116083807~116085416:-
PCPG	cis	rs12194062	0.524	rs270041	ENSG00000220694.2	RP3-403A15.1	4.56	1.07e-05	0.0054	0.4	0.35	QRS duration;	chr6:127863593	chr6:127435636~127436189:+
PCPG	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-4.56	1.07e-05	0.0054	-0.37	-0.35	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
PCPG	cis	rs28386778	0.897	rs2665797	ENSG00000240280.5	TCAM1P	4.56	1.07e-05	0.0054	0.47	0.35	Prudent dietary pattern;	chr17:63845125	chr17:63849292~63864379:+
PCPG	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-4.56	1.07e-05	0.0054	-0.42	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
PCPG	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	-4.56	1.07e-05	0.00541	-0.39	-0.35	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
PCPG	cis	rs2836441	0.731	rs2836464	ENSG00000232837.1	AF064858.7	-4.56	1.07e-05	0.00541	-0.54	-0.35	Plateletcrit;Platelet count;	chr21:38524668	chr21:38974429~38977774:-
PCPG	cis	rs1048886	0.872	rs78721430	ENSG00000271967.1	RP11-134K13.4	-4.56	1.07e-05	0.00541	-0.45	-0.35	Type 2 diabetes;	chr6:70520228	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs75170426	ENSG00000271967.1	RP11-134K13.4	-4.56	1.07e-05	0.00541	-0.45	-0.35	Type 2 diabetes;	chr6:70521415	chr6:70596438~70596980:+
PCPG	cis	rs7017914	0.967	rs34042354	ENSG00000254031.4	RP11-326E22.1	4.56	1.07e-05	0.00541	0.34	0.35	Bone mineral density;	chr8:70818726	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13261712	ENSG00000254031.4	RP11-326E22.1	4.56	1.07e-05	0.00541	0.34	0.35	Bone mineral density;	chr8:70820029	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs13274062	ENSG00000254031.4	RP11-326E22.1	4.56	1.07e-05	0.00541	0.34	0.35	Bone mineral density;	chr8:70824852	chr8:71155457~71204223:+
PCPG	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-4.56	1.08e-05	0.00542	-0.4	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
PCPG	cis	rs4671400	0.543	rs62152274	ENSG00000270820.4	RP11-355B11.2	-4.55	1.08e-05	0.00543	-0.5	-0.35	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61272453	chr2:61471188~61484130:+
PCPG	cis	rs4671400	0.571	rs62152275	ENSG00000270820.4	RP11-355B11.2	-4.55	1.08e-05	0.00543	-0.5	-0.35	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61275103	chr2:61471188~61484130:+
PCPG	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-4.55	1.08e-05	0.00543	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
PCPG	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	4.55	1.08e-05	0.00543	0.36	0.35	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
PCPG	cis	rs916888	0.61	rs199438	ENSG00000232300.1	FAM215B	4.55	1.08e-05	0.00543	0.46	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46558830~46562795:-
PCPG	cis	rs950169	0.922	rs6603022	ENSG00000235370.6	DNM1P51	-4.55	1.08e-05	0.00543	-0.36	-0.35	Schizophrenia;	chr15:84161418	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs11639244	ENSG00000235370.6	DNM1P51	4.55	1.08e-05	0.00543	0.36	0.35	Schizophrenia;	chr15:84163898	chr15:84398316~84411701:-
PCPG	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	4.55	1.08e-05	0.00544	0.56	0.35	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
PCPG	cis	rs6957923	0.714	rs11766660	ENSG00000230658.1	KLHL7-AS1	4.55	1.08e-05	0.00544	0.41	0.35	Height;	chr7:23484606	chr7:23101228~23105703:-
PCPG	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	4.55	1.08e-05	0.00544	0.37	0.35	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
PCPG	cis	rs9494145	0.838	rs9483788	ENSG00000232876.1	CTA-212D2.2	-4.55	1.08e-05	0.00544	-0.48	-0.35	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135114363	chr6:135055033~135060550:+
PCPG	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-4.55	1.08e-05	0.00544	-0.51	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
PCPG	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-4.55	1.08e-05	0.00545	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
PCPG	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	4.55	1.08e-05	0.00545	0.53	0.35	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
PCPG	cis	rs433852	0.75	rs386243	ENSG00000232871.7	SEC1P	-4.55	1.08e-05	0.00546	-0.45	-0.35	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48624233	chr19:48638071~48682245:+
PCPG	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-4.55	1.09e-05	0.00547	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
PCPG	cis	rs1044573	0.526	rs6050422	ENSG00000276952.1	RP5-965G21.6	4.55	1.09e-05	0.00547	0.38	0.35	Allergic rhinitis;	chr20:25197284	chr20:25284915~25285588:-
PCPG	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	4.55	1.09e-05	0.00548	0.42	0.35	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
PCPG	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	4.55	1.09e-05	0.00548	0.42	0.35	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
PCPG	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-4.55	1.09e-05	0.00549	-0.58	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-4.55	1.09e-05	0.00549	-0.58	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
PCPG	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	4.55	1.09e-05	0.00549	0.42	0.35	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
PCPG	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-4.55	1.09e-05	0.00549	-0.42	-0.35	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
PCPG	cis	rs7017914	0.902	rs1373480	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70774732	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs10448014	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70775930	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs7000647	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70776173	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs13254801	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70776749	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.783	rs13252584	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70776796	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.84	rs13254851	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70776799	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs62508771	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70780453	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs6998786	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70782395	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs12680988	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70783655	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs1596566	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70786341	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs6993115	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70786948	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs6992879	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70787048	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.967	rs1838393	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70790356	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.935	rs7826483	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.00549	0.34	0.35	Bone mineral density;	chr8:70790658	chr8:71155457~71204223:+
PCPG	cis	rs28386778	0.897	rs2727326	ENSG00000240280.5	TCAM1P	-4.55	1.09e-05	0.0055	-0.47	-0.35	Prudent dietary pattern;	chr17:63845656	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2727327	ENSG00000240280.5	TCAM1P	-4.55	1.09e-05	0.0055	-0.47	-0.35	Prudent dietary pattern;	chr17:63846062	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2727328	ENSG00000240280.5	TCAM1P	-4.55	1.09e-05	0.0055	-0.47	-0.35	Prudent dietary pattern;	chr17:63846204	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.831	rs2584618	ENSG00000240280.5	TCAM1P	-4.55	1.09e-05	0.0055	-0.47	-0.35	Prudent dietary pattern;	chr17:63846251	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2665796	ENSG00000240280.5	TCAM1P	-4.55	1.09e-05	0.0055	-0.47	-0.35	Prudent dietary pattern;	chr17:63846356	chr17:63849292~63864379:+
PCPG	cis	rs7017914	0.967	rs35207116	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.0055	0.34	0.35	Bone mineral density;	chr8:70796736	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.934	rs17689585	ENSG00000254031.4	RP11-326E22.1	4.55	1.09e-05	0.0055	0.34	0.35	Bone mineral density;	chr8:70906566	chr8:71155457~71204223:+
PCPG	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	4.55	1.09e-05	0.0055	0.72	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
PCPG	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-4.55	1.1e-05	0.0055	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
PCPG	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-4.55	1.1e-05	0.0055	-0.5	-0.35	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
PCPG	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-4.55	1.1e-05	0.00551	-0.32	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
PCPG	cis	rs950169	0.922	rs4586394	ENSG00000235370.6	DNM1P51	-4.55	1.1e-05	0.00551	-0.36	-0.35	Schizophrenia;	chr15:84153633	chr15:84398316~84411701:-
PCPG	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-4.55	1.1e-05	0.00551	-0.41	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
PCPG	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	4.55	1.1e-05	0.00551	0.35	0.35	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	4.55	1.1e-05	0.00551	0.35	0.35	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	4.55	1.1e-05	0.00551	0.35	0.35	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	4.55	1.1e-05	0.00551	0.35	0.35	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	4.55	1.1e-05	0.00551	0.35	0.35	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
PCPG	cis	rs7246657	1	rs34544865	ENSG00000226686.6	LINC01535	-4.55	1.1e-05	0.00551	-0.63	-0.35	Coronary artery calcification;	chr19:37310340	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-4.55	1.1e-05	0.00551	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
PCPG	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	4.55	1.1e-05	0.00551	0.48	0.35	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	4.55	1.1e-05	0.00551	0.48	0.35	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	4.55	1.1e-05	0.00551	0.48	0.35	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	4.55	1.1e-05	0.00551	0.48	0.35	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	4.55	1.1e-05	0.00551	0.48	0.35	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	4.55	1.1e-05	0.00551	0.48	0.35	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	4.55	1.1e-05	0.00551	0.48	0.35	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-4.55	1.1e-05	0.00551	-0.48	-0.35	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
PCPG	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-4.55	1.1e-05	0.00552	-0.43	-0.35	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
PCPG	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-4.55	1.1e-05	0.00552	-0.46	-0.35	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
PCPG	cis	rs1159787	0.517	rs7045301	ENSG00000233569.1	RP11-500B12.1	-4.55	1.1e-05	0.00552	-0.51	-0.35	Blood protein levels;	chr9:117640955	chr9:117648606~117657027:+
PCPG	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-4.55	1.1e-05	0.00552	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
PCPG	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	4.55	1.1e-05	0.00552	0.45	0.35	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	4.55	1.1e-05	0.00552	0.45	0.35	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
PCPG	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	4.55	1.1e-05	0.00552	0.46	0.35	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
PCPG	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	4.55	1.1e-05	0.00552	0.39	0.35	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
PCPG	cis	rs10200850	0.772	rs10209343	ENSG00000265215.1	MIR4269	4.55	1.1e-05	0.00552	0.61	0.35	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239342525	chr2:239305462~239305545:+
PCPG	cis	rs4713118	0.869	rs7776351	ENSG00000216901.1	AL022393.7	-4.55	1.1e-05	0.00552	-0.46	-0.35	Parkinson's disease;	chr6:27758952	chr6:28176188~28176674:+
PCPG	cis	rs7017914	0.967	rs62508819	ENSG00000254031.4	RP11-326E22.1	4.55	1.1e-05	0.00553	0.34	0.35	Bone mineral density;	chr8:70805871	chr8:71155457~71204223:+
PCPG	cis	rs7017914	1	rs13252719	ENSG00000254031.4	RP11-326E22.1	4.55	1.1e-05	0.00553	0.34	0.35	Bone mineral density;	chr8:70822334	chr8:71155457~71204223:+
PCPG	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	4.55	1.1e-05	0.00553	0.49	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
PCPG	cis	rs7824557	0.806	rs10503418	ENSG00000255020.1	AF131216.5	-4.55	1.1e-05	0.00553	-0.44	-0.35	Retinal vascular caliber;	chr8:11261474	chr8:11345748~11347502:-
PCPG	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	4.55	1.1e-05	0.00553	0.53	0.35	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	4.55	1.1e-05	0.00553	0.53	0.35	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
PCPG	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-4.55	1.1e-05	0.00554	-0.5	-0.35	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
PCPG	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-4.55	1.1e-05	0.00554	-0.45	-0.35	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
PCPG	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-4.55	1.11e-05	0.00554	-0.45	-0.35	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	4.55	1.11e-05	0.00554	0.46	0.35	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
PCPG	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	4.55	1.11e-05	0.00554	0.5	0.35	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
PCPG	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	4.55	1.11e-05	0.00554	0.38	0.35	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
PCPG	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	4.55	1.11e-05	0.00555	0.41	0.35	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
PCPG	cis	rs7824557	0.592	rs920044	ENSG00000255020.1	AF131216.5	4.55	1.11e-05	0.00555	0.44	0.35	Retinal vascular caliber;	chr8:11366804	chr8:11345748~11347502:-
PCPG	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-4.55	1.11e-05	0.00555	-0.41	-0.35	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
PCPG	cis	rs3736858	0.8	rs12427729	ENSG00000261105.4	LMO7-AS1	-4.55	1.11e-05	0.00555	-0.69	-0.35	Interleukin-9 levels;	chr13:75870254	chr13:75604700~75635994:-
PCPG	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-4.55	1.11e-05	0.00555	-0.32	-0.35	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
PCPG	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	4.55	1.11e-05	0.00556	0.41	0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
PCPG	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	4.55	1.11e-05	0.00557	0.47	0.35	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	4.55	1.11e-05	0.00557	0.47	0.35	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	4.55	1.11e-05	0.00557	0.47	0.35	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
PCPG	cis	rs9926296	0.509	rs2159113	ENSG00000260259.1	RP11-368I7.4	-4.55	1.11e-05	0.00557	-0.45	-0.35	Vitiligo;	chr16:89765675	chr16:89682620~89686569:-
PCPG	cis	rs34421088	0.56	rs2245250	ENSG00000255020.1	AF131216.5	-4.55	1.11e-05	0.00557	-0.46	-0.35	Neuroticism;	chr8:11543171	chr8:11345748~11347502:-
PCPG	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	4.55	1.12e-05	0.00558	0.38	0.35	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
PCPG	cis	rs12681420	0.665	rs67705199	ENSG00000254031.4	RP11-326E22.1	4.55	1.12e-05	0.00559	0.33	0.35	Erythrocyte cadmium concentration in never smokers;	chr8:70695170	chr8:71155457~71204223:+
PCPG	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-4.55	1.12e-05	0.00559	-0.42	-0.35	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
PCPG	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	4.55	1.12e-05	0.00559	0.44	0.35	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	4.55	1.12e-05	0.00559	0.44	0.35	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	4.55	1.12e-05	0.00559	0.44	0.35	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
PCPG	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	4.55	1.12e-05	0.00559	0.39	0.35	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
PCPG	cis	rs853679	0.513	rs13437444	ENSG00000216901.1	AL022393.7	4.55	1.12e-05	0.00559	0.55	0.35	Depression;	chr6:28103220	chr6:28176188~28176674:+
PCPG	cis	rs11250097	0.528	rs36043848	ENSG00000255020.1	AF131216.5	-4.55	1.12e-05	0.00559	-0.52	-0.35	Neuroticism;	chr8:11452024	chr8:11345748~11347502:-
PCPG	cis	rs7017914	0.967	rs17688313	ENSG00000254031.4	RP11-326E22.1	-4.55	1.12e-05	0.0056	-0.34	-0.35	Bone mineral density;	chr8:70771629	chr8:71155457~71204223:+
PCPG	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-4.55	1.12e-05	0.0056	-0.43	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
PCPG	cis	rs748404	0.666	rs34178146	ENSG00000249839.1	AC011330.5	-4.55	1.12e-05	0.0056	-0.47	-0.35	Lung cancer;	chr15:43384406	chr15:43663654~43684339:-
PCPG	cis	rs7017914	0.902	rs10504481	ENSG00000254031.4	RP11-326E22.1	4.55	1.12e-05	0.0056	0.34	0.35	Bone mineral density;	chr8:70787282	chr8:71155457~71204223:+
PCPG	cis	rs7759001	0.857	rs4455661	ENSG00000271755.1	RP1-153G14.4	-4.55	1.12e-05	0.00561	-0.51	-0.35	Glomerular filtration rate (creatinine);	chr6:27405351	chr6:27404010~27406964:-
PCPG	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-4.55	1.12e-05	0.00561	-0.43	-0.35	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
PCPG	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-4.54	1.12e-05	0.00562	-0.5	-0.35	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
PCPG	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	4.54	1.12e-05	0.00562	0.38	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
PCPG	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	4.54	1.13e-05	0.00563	0.49	0.35	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
PCPG	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-4.54	1.13e-05	0.00563	-0.36	-0.35	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
PCPG	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-4.54	1.13e-05	0.00563	-0.36	-0.35	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
PCPG	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	4.54	1.13e-05	0.00563	0.36	0.35	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
PCPG	cis	rs2735413	0.599	rs112375862	ENSG00000276007.1	RP11-358L22.3	4.54	1.13e-05	0.00563	0.38	0.35	Systolic blood pressure (alcohol consumption interaction);	chr16:78045340	chr16:78123243~78124332:+
PCPG	cis	rs10435719	0.902	rs7459545	ENSG00000255495.1	AC145124.2	4.54	1.13e-05	0.00564	0.36	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11946880	chr8:12194467~12196280:+
PCPG	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	4.54	1.13e-05	0.00564	0.52	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
PCPG	cis	rs4986172	0.726	rs12946454	ENSG00000267288.2	RP13-890H12.2	-4.54	1.13e-05	0.00564	-0.48	-0.35	Height;	chr17:45130754	chr17:45168800~45171584:-
PCPG	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	4.54	1.13e-05	0.00564	0.37	0.35	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
PCPG	cis	rs748404	0.589	rs62020616	ENSG00000205771.5	CATSPER2P1	-4.54	1.13e-05	0.00565	-0.45	-0.35	Lung cancer;	chr15:43558554	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.626	rs60367691	ENSG00000205771.5	CATSPER2P1	-4.54	1.13e-05	0.00565	-0.45	-0.35	Lung cancer;	chr15:43559201	chr15:43726918~43747094:-
PCPG	cis	rs1159787	0.517	rs7038974	ENSG00000233569.1	RP11-500B12.1	-4.54	1.13e-05	0.00565	-0.5	-0.35	Blood protein levels;	chr9:117635375	chr9:117648606~117657027:+
PCPG	cis	rs2733201	1	rs2623019	ENSG00000205771.5	CATSPER2P1	4.54	1.13e-05	0.00567	0.59	0.35	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44107430	chr15:43726918~43747094:-
PCPG	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-4.54	1.13e-05	0.00567	-0.74	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
PCPG	cis	rs3806843	0.966	rs2563265	ENSG00000202515.1	VTRNA1-3	4.54	1.13e-05	0.00567	0.45	0.35	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs3756340	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140800866	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs3756338	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140800976	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs7701755	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140802516	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs2240693	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140803740	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs2240692	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140804000	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs6579987	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140804074	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs1030163	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140805547	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs1030164	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140805687	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs1030165	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140805863	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs1030166	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140805888	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs4151680	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140807072	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs3822346	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140807737	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.933	rs2337987	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140808798	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.933	rs2879087	ENSG00000202515.1	VTRNA1-3	-4.54	1.13e-05	0.00567	-0.45	-0.35	Depressive symptoms (multi-trait analysis);	chr5:140808990	chr5:140726158~140726246:+
PCPG	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-4.54	1.13e-05	0.00567	-0.37	-0.35	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
PCPG	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	4.54	1.14e-05	0.00567	0.46	0.35	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	4.54	1.14e-05	0.00567	0.46	0.35	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
PCPG	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	4.54	1.14e-05	0.00567	0.44	0.35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
PCPG	cis	rs7829975	0.742	rs882462	ENSG00000173295.6	FAM86B3P	-4.54	1.14e-05	0.00567	-0.42	-0.35	Mood instability;	chr8:8821020	chr8:8228595~8244865:+
PCPG	cis	rs591584	0.73	rs72963868	ENSG00000255893.1	RP11-685N10.1	-4.54	1.14e-05	0.00568	-0.42	-0.35	Macrophage Migration Inhibitory Factor levels;	chr11:94584543	chr11:94472908~94473570:-
PCPG	cis	rs1048886	0.872	rs74586626	ENSG00000271967.1	RP11-134K13.4	-4.54	1.14e-05	0.00568	-0.45	-0.35	Type 2 diabetes;	chr6:70514387	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs17635446	ENSG00000271967.1	RP11-134K13.4	-4.54	1.14e-05	0.00568	-0.45	-0.35	Type 2 diabetes;	chr6:70516453	chr6:70596438~70596980:+
PCPG	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	4.54	1.14e-05	0.00568	0.43	0.35	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
PCPG	cis	rs1949733	1	rs3103072	ENSG00000205959.3	RP11-689P11.2	4.54	1.14e-05	0.00568	0.4	0.35	Response to antineoplastic agents;	chr4:8506704	chr4:8482270~8512610:+
PCPG	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	4.54	1.14e-05	0.00568	0.49	0.35	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
PCPG	cis	rs7208859	0.614	rs216412	ENSG00000263603.1	CTD-2349P21.5	4.54	1.14e-05	0.00569	0.48	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30729469~30731202:+
PCPG	cis	rs2836974	0.604	rs2854727	ENSG00000255568.3	BRWD1-AS2	4.54	1.14e-05	0.0057	0.34	0.35	Cognitive function;	chr21:39341861	chr21:39313935~39314962:+
PCPG	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-4.54	1.14e-05	0.0057	-0.45	-0.35	Height;	chr6:109432968	chr6:109382795~109383666:+
PCPG	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-4.54	1.14e-05	0.0057	-0.45	-0.35	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-4.54	1.14e-05	0.0057	-0.45	-0.35	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
PCPG	cis	rs17772222	0.958	rs1816372	ENSG00000222990.1	RNU4-22P	4.54	1.14e-05	0.0057	0.46	0.35	Coronary artery calcification;	chr14:88507033	chr14:88513498~88513663:+
PCPG	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-4.54	1.15e-05	0.00572	-0.47	-0.35	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
PCPG	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-4.54	1.15e-05	0.00572	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-4.54	1.15e-05	0.00572	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
PCPG	cis	rs9309711	0.961	rs6739269	ENSG00000225234.1	TRAPPC12-AS1	-4.54	1.15e-05	0.00572	-0.38	-0.35	Neurofibrillary tangles;	chr2:3467224	chr2:3481242~3482409:-
PCPG	cis	rs10504130	0.569	rs2069119	ENSG00000272024.1	RP11-546K22.3	-4.54	1.15e-05	0.00572	-0.45	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:51773876	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs35603537	ENSG00000272024.1	RP11-546K22.3	-4.54	1.15e-05	0.00572	-0.45	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:51773899	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.502	rs71513552	ENSG00000272024.1	RP11-546K22.3	-4.54	1.15e-05	0.00572	-0.45	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs34073804	ENSG00000272024.1	RP11-546K22.3	-4.54	1.15e-05	0.00572	-0.45	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs34319820	ENSG00000272024.1	RP11-546K22.3	-4.54	1.15e-05	0.00572	-0.45	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51950284~51950690:+
PCPG	cis	rs1949733	1	rs3103071	ENSG00000205959.3	RP11-689P11.2	4.54	1.15e-05	0.00573	0.4	0.35	Response to antineoplastic agents;	chr4:8506852	chr4:8482270~8512610:+
PCPG	cis	rs1949733	0.958	rs3103069	ENSG00000205959.3	RP11-689P11.2	4.54	1.15e-05	0.00573	0.4	0.35	Response to antineoplastic agents;	chr4:8507724	chr4:8482270~8512610:+
PCPG	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-4.54	1.15e-05	0.00573	-0.41	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
PCPG	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-4.54	1.15e-05	0.00573	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.618	rs12499907	ENSG00000251600.4	RP11-673E1.1	-4.54	1.15e-05	0.00574	-0.41	-0.35	Immature fraction of reticulocytes;	chr4:143999748	chr4:143912331~143982454:+
PCPG	cis	rs4143844	0.609	rs62007453	ENSG00000259251.2	RP11-643M14.1	4.54	1.15e-05	0.00574	0.69	0.35	Bipolar disorder and schizophrenia;	chr15:62062061	chr15:62060503~62062434:+
PCPG	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	4.54	1.15e-05	0.00574	0.54	0.35	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
PCPG	cis	rs4819052	0.851	rs7279011	ENSG00000215447.6	BX322557.10	-4.54	1.15e-05	0.00574	-0.34	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.765	rs2838827	ENSG00000215447.6	BX322557.10	-4.54	1.15e-05	0.00574	-0.34	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45288052~45291738:+
PCPG	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	4.54	1.15e-05	0.00575	0.44	0.35	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
PCPG	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	4.54	1.15e-05	0.00575	0.6	0.35	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
PCPG	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-4.54	1.16e-05	0.00576	-0.44	-0.35	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-4.54	1.16e-05	0.00576	-0.44	-0.35	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-4.54	1.16e-05	0.00576	-0.44	-0.35	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
PCPG	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-4.54	1.16e-05	0.00576	-0.36	-0.35	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
PCPG	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-4.54	1.16e-05	0.00576	-0.49	-0.35	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-4.54	1.16e-05	0.00576	-0.49	-0.35	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-4.54	1.16e-05	0.00576	-0.49	-0.35	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
PCPG	cis	rs9911578	0.839	rs1871751	ENSG00000267416.1	CTD-2319I12.2	4.54	1.16e-05	0.00576	0.37	0.35	Intelligence (multi-trait analysis);	chr17:59113007	chr17:60079309~60088695:+
PCPG	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-4.54	1.16e-05	0.00576	-0.58	-0.35	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
PCPG	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	4.54	1.16e-05	0.00577	0.48	0.35	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
PCPG	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-4.54	1.16e-05	0.00577	-0.37	-0.35	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
PCPG	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	4.54	1.16e-05	0.00578	0.43	0.35	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	4.54	1.16e-05	0.00578	0.43	0.35	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
PCPG	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	4.54	1.16e-05	0.00578	0.29	0.35	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
PCPG	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-4.54	1.16e-05	0.00578	-0.41	-0.35	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
PCPG	cis	rs748404	0.666	rs34633582	ENSG00000205771.5	CATSPER2P1	-4.54	1.16e-05	0.00579	-0.45	-0.35	Lung cancer;	chr15:43462683	chr15:43726918~43747094:-
PCPG	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-4.54	1.16e-05	0.00579	-0.46	-0.35	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-4.54	1.16e-05	0.00579	-0.46	-0.35	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-4.54	1.16e-05	0.00579	-0.46	-0.35	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
PCPG	cis	rs7759001	0.857	rs2206251	ENSG00000271755.1	RP1-153G14.4	4.54	1.16e-05	0.00579	0.51	0.35	Glomerular filtration rate (creatinine);	chr6:27390613	chr6:27404010~27406964:-
PCPG	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-4.54	1.16e-05	0.00579	-0.34	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
PCPG	cis	rs964611	0.882	rs12441867	ENSG00000259488.2	RP11-154J22.1	4.54	1.16e-05	0.00579	0.34	0.35	Metabolite levels (Pyroglutamine);	chr15:48343856	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs11629725	ENSG00000259488.2	RP11-154J22.1	4.54	1.16e-05	0.00579	0.34	0.35	Metabolite levels (Pyroglutamine);	chr15:48347986	chr15:48312353~48331856:-
PCPG	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	4.54	1.16e-05	0.0058	0.38	0.35	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
PCPG	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	4.54	1.17e-05	0.0058	0.4	0.35	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
PCPG	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	4.54	1.17e-05	0.0058	0.5	0.35	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
PCPG	cis	rs28386778	0.897	rs4968598	ENSG00000240280.5	TCAM1P	-4.54	1.17e-05	0.0058	-0.45	-0.35	Prudent dietary pattern;	chr17:63758219	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs4968663	ENSG00000240280.5	TCAM1P	-4.54	1.17e-05	0.0058	-0.45	-0.35	Prudent dietary pattern;	chr17:63758243	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs4968599	ENSG00000240280.5	TCAM1P	-4.54	1.17e-05	0.0058	-0.45	-0.35	Prudent dietary pattern;	chr17:63758632	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs7222189	ENSG00000240280.5	TCAM1P	-4.54	1.17e-05	0.0058	-0.45	-0.35	Prudent dietary pattern;	chr17:63759012	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs11654841	ENSG00000240280.5	TCAM1P	-4.54	1.17e-05	0.0058	-0.45	-0.35	Prudent dietary pattern;	chr17:63760899	chr17:63849292~63864379:+
PCPG	cis	rs6957923	0.967	rs11770192	ENSG00000230658.1	KLHL7-AS1	4.54	1.17e-05	0.0058	0.43	0.35	Height;	chr7:23458739	chr7:23101228~23105703:-
PCPG	cis	rs7529073	0.545	rs1431985	ENSG00000274895.1	RP11-478J18.2	-4.54	1.17e-05	0.0058	-0.36	-0.35	Schizophrenia;	chr1:213974903	chr1:213983793~213986419:-
PCPG	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-4.54	1.17e-05	0.0058	-0.5	-0.35	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-4.54	1.17e-05	0.0058	-0.5	-0.35	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-4.54	1.17e-05	0.0058	-0.5	-0.35	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-4.54	1.17e-05	0.0058	-0.5	-0.35	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
PCPG	cis	rs6121246	0.908	rs6089094	ENSG00000230613.1	HM13-AS1	4.54	1.17e-05	0.00581	0.5	0.35	Mean corpuscular hemoglobin;	chr20:31843968	chr20:31567707~31573263:-
PCPG	cis	rs4671400	0.543	rs10178135	ENSG00000270820.4	RP11-355B11.2	-4.54	1.17e-05	0.00581	-0.49	-0.35	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258132	chr2:61471188~61484130:+
PCPG	cis	rs4671400	0.571	rs2421116	ENSG00000270820.4	RP11-355B11.2	-4.54	1.17e-05	0.00581	-0.49	-0.35	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61261276	chr2:61471188~61484130:+
PCPG	cis	rs1488515	0.687	rs739512	ENSG00000279067.1	GS1-25M2.1	-4.54	1.17e-05	0.00581	-0.55	-0.35	Obesity-related traits;	chr7:96006677	chr7:96118647~96119995:+
PCPG	cis	rs7829975	0.774	rs1039915	ENSG00000173295.6	FAM86B3P	-4.54	1.17e-05	0.00581	-0.42	-0.35	Mood instability;	chr8:8822104	chr8:8228595~8244865:+
PCPG	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	4.54	1.17e-05	0.00581	0.62	0.35	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
PCPG	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	4.54	1.17e-05	0.00582	0.71	0.35	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
PCPG	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	4.54	1.17e-05	0.00582	0.36	0.35	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
PCPG	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	4.54	1.17e-05	0.00582	0.45	0.35	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	4.54	1.17e-05	0.00582	0.45	0.35	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
PCPG	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	4.54	1.17e-05	0.00582	0.45	0.35	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
PCPG	cis	rs2253762	0.507	rs4752630	ENSG00000276742.1	RP11-500G22.4	4.53	1.17e-05	0.00582	0.52	0.35	Breast cancer;	chr10:121991440	chr10:121956782~121957098:+
PCPG	cis	rs2733954	0.747	rs410817	ENSG00000179219.5	LINC00311	-4.53	1.17e-05	0.00582	-0.43	-0.35	Leprosy;	chr16:85768392	chr16:85282958~85285963:+
PCPG	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	4.53	1.17e-05	0.00583	0.56	0.35	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
PCPG	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-4.53	1.17e-05	0.00583	-0.49	-0.35	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
PCPG	cis	rs5742933	0.779	rs1899025	ENSG00000273240.1	RP11-455J20.3	4.53	1.17e-05	0.00583	0.37	0.35	Ferritin levels;	chr2:189784856	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.817	rs5742938	ENSG00000273240.1	RP11-455J20.3	4.53	1.17e-05	0.00583	0.37	0.35	Ferritin levels;	chr2:189785232	chr2:189763859~189764456:-
PCPG	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	4.53	1.17e-05	0.00583	0.48	0.35	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
PCPG	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	4.53	1.17e-05	0.00583	0.52	0.35	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
PCPG	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-4.53	1.17e-05	0.00583	-0.57	-0.35	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
PCPG	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	4.53	1.18e-05	0.00584	0.48	0.35	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	4.53	1.18e-05	0.00584	0.48	0.35	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
PCPG	cis	rs28386778	0.83	rs7209321	ENSG00000240280.5	TCAM1P	-4.53	1.18e-05	0.00584	-0.46	-0.35	Prudent dietary pattern;	chr17:63778308	chr17:63849292~63864379:+
PCPG	cis	rs9928842	0.882	rs11641896	ENSG00000280152.1	RP11-331F4.5	4.53	1.18e-05	0.00584	0.59	0.35	Alcoholic chronic pancreatitis;	chr16:75266281	chr16:75245994~75250077:-
PCPG	cis	rs9928842	0.823	rs11149811	ENSG00000280152.1	RP11-331F4.5	4.53	1.18e-05	0.00584	0.59	0.35	Alcoholic chronic pancreatitis;	chr16:75266810	chr16:75245994~75250077:-
PCPG	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	4.53	1.18e-05	0.00584	0.37	0.35	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
PCPG	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	4.53	1.18e-05	0.00585	0.42	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
PCPG	cis	rs34375054	0.525	rs7398636	ENSG00000279233.1	RP11-158L12.4	4.53	1.18e-05	0.00585	0.37	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125114058	chr12:125138245~125141711:+
PCPG	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-4.53	1.18e-05	0.00585	-0.42	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
PCPG	cis	rs3806843	0.735	rs778595	ENSG00000202515.1	VTRNA1-3	4.53	1.18e-05	0.00586	0.43	0.35	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr5:140726158~140726246:+
PCPG	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	4.53	1.18e-05	0.00586	0.47	0.35	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
PCPG	cis	rs11673344	0.523	rs2562609	ENSG00000226686.6	LINC01535	4.53	1.18e-05	0.00586	0.44	0.35	Obesity-related traits;	chr19:37036255	chr19:37251912~37265535:+
PCPG	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	4.53	1.18e-05	0.00586	0.42	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	4.53	1.18e-05	0.00586	0.42	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	4.53	1.18e-05	0.00586	0.42	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	4.53	1.18e-05	0.00586	0.42	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
PCPG	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-4.53	1.18e-05	0.00587	-0.46	-0.35	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
PCPG	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-4.53	1.18e-05	0.00587	-0.46	-0.35	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-4.53	1.18e-05	0.00587	-0.46	-0.35	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
PCPG	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-4.53	1.18e-05	0.00587	-0.46	-0.35	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
PCPG	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-4.53	1.18e-05	0.00587	-0.46	-0.35	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
PCPG	cis	rs964611	0.882	rs11630744	ENSG00000259488.2	RP11-154J22.1	4.53	1.18e-05	0.00587	0.35	0.35	Metabolite levels (Pyroglutamine);	chr15:48355310	chr15:48312353~48331856:-
PCPG	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-4.53	1.18e-05	0.00588	-0.56	-0.35	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
PCPG	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	4.53	1.19e-05	0.00588	0.6	0.35	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	4.53	1.19e-05	0.00588	0.6	0.35	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
PCPG	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	4.53	1.19e-05	0.00588	0.36	0.35	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
PCPG	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-4.53	1.19e-05	0.00588	-0.43	-0.35	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
PCPG	cis	rs9890032	0.52	rs2321926	ENSG00000263603.1	CTD-2349P21.5	-4.53	1.19e-05	0.00588	-0.38	-0.35	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30729469~30731202:+
PCPG	cis	rs75686122	0.892	rs12676448	ENSG00000271830.1	RP11-1C8.7	-4.53	1.19e-05	0.00589	-0.57	-0.35	Cocaine dependence;	chr8:103466989	chr8:103481266~103481619:-
PCPG	cis	rs2288884	0.559	rs6509611	ENSG00000275055.1	CTC-471J1.11	-4.53	1.19e-05	0.00589	-0.33	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:52049007~52049754:+
PCPG	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	4.53	1.19e-05	0.00589	0.47	0.35	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	4.53	1.19e-05	0.00589	0.47	0.35	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	4.53	1.19e-05	0.00589	0.47	0.35	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
PCPG	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-4.53	1.19e-05	0.00589	-0.37	-0.35	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
PCPG	cis	rs7759001	0.857	rs766092	ENSG00000271755.1	RP1-153G14.4	4.53	1.19e-05	0.0059	0.52	0.35	Glomerular filtration rate (creatinine);	chr6:27400252	chr6:27404010~27406964:-
PCPG	cis	rs1048886	0.745	rs12524814	ENSG00000271967.1	RP11-134K13.4	-4.53	1.19e-05	0.00591	-0.45	-0.35	Type 2 diabetes;	chr6:70519449	chr6:70596438~70596980:+
PCPG	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-4.53	1.19e-05	0.00591	-0.5	-0.35	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
PCPG	cis	rs7172677	0.732	rs1867147	ENSG00000261543.1	RP11-665J16.1	4.53	1.19e-05	0.00591	0.44	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75071016	chr15:74152800~74179226:-
PCPG	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	4.53	1.19e-05	0.00591	0.36	0.35	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	4.53	1.19e-05	0.00591	0.36	0.35	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
PCPG	cis	rs3806843	0.735	rs2530242	ENSG00000202515.1	VTRNA1-3	4.53	1.19e-05	0.00591	0.43	0.35	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs2530241	ENSG00000202515.1	VTRNA1-3	4.53	1.19e-05	0.00591	0.43	0.35	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.735	rs2530235	ENSG00000202515.1	VTRNA1-3	4.53	1.19e-05	0.00591	0.43	0.35	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr5:140726158~140726246:+
PCPG	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-4.53	1.19e-05	0.00592	-0.45	-0.35	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-4.53	1.19e-05	0.00592	-0.45	-0.35	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-4.53	1.19e-05	0.00592	-0.45	-0.35	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
PCPG	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	4.53	1.19e-05	0.00592	0.48	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
PCPG	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-4.53	1.2e-05	0.00593	-0.43	-0.35	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
PCPG	cis	rs11858159	0.967	rs7495965	ENSG00000260760.1	PWRN3	4.53	1.2e-05	0.00593	0.36	0.35	Platelet thrombus formation;	chr15:24594791	chr15:24441127~24447967:+
PCPG	cis	rs10899021	0.92	rs10899014	ENSG00000279353.1	RP11-864N7.4	4.53	1.2e-05	0.00593	0.6	0.35	Response to metformin (IC50);	chr11:74614064	chr11:74698231~74699658:-
PCPG	cis	rs10899021	0.92	rs11236172	ENSG00000279353.1	RP11-864N7.4	4.53	1.2e-05	0.00593	0.6	0.35	Response to metformin (IC50);	chr11:74619843	chr11:74698231~74699658:-
PCPG	cis	rs10899021	0.92	rs12287097	ENSG00000279353.1	RP11-864N7.4	4.53	1.2e-05	0.00593	0.6	0.35	Response to metformin (IC50);	chr11:74621619	chr11:74698231~74699658:-
PCPG	cis	rs10899021	0.92	rs11236174	ENSG00000279353.1	RP11-864N7.4	4.53	1.2e-05	0.00593	0.6	0.35	Response to metformin (IC50);	chr11:74623156	chr11:74698231~74699658:-
PCPG	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-4.53	1.2e-05	0.00594	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
PCPG	cis	rs73607972	0.501	rs73614583	ENSG00000275191.1	RP11-36I17.2	-4.53	1.2e-05	0.00594	-0.54	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554597	chr16:53628256~53628816:-
PCPG	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	4.53	1.2e-05	0.00594	0.42	0.35	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
PCPG	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-4.53	1.2e-05	0.00595	-0.47	-0.35	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
PCPG	cis	rs7824557	0.843	rs2736375	ENSG00000255020.1	AF131216.5	-4.53	1.2e-05	0.00595	-0.45	-0.35	Retinal vascular caliber;	chr8:11258240	chr8:11345748~11347502:-
PCPG	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	4.53	1.2e-05	0.00595	0.47	0.35	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
PCPG	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	4.53	1.2e-05	0.00596	0.49	0.35	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	4.53	1.2e-05	0.00596	0.49	0.35	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	4.53	1.2e-05	0.00596	0.46	0.35	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
PCPG	cis	rs11148252	0.774	rs6561666	ENSG00000235660.1	LINC00345	-4.53	1.21e-05	0.00596	-0.41	-0.35	Lewy body disease;	chr13:52355910	chr13:52484161~52484680:-
PCPG	cis	rs7017914	0.934	rs7814274	ENSG00000254031.4	RP11-326E22.1	-4.53	1.21e-05	0.00596	-0.33	-0.35	Bone mineral density;	chr8:70658176	chr8:71155457~71204223:+
PCPG	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-4.53	1.21e-05	0.00596	-0.45	-0.35	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
PCPG	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	-4.53	1.21e-05	0.00597	-0.41	-0.35	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
PCPG	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-4.53	1.21e-05	0.00597	-0.41	-0.35	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
PCPG	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	4.53	1.21e-05	0.00597	0.41	0.35	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
PCPG	cis	rs11673344	0.542	rs2562598	ENSG00000226686.6	LINC01535	4.53	1.21e-05	0.00598	0.44	0.35	Obesity-related traits;	chr19:37025318	chr19:37251912~37265535:+
PCPG	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	4.53	1.21e-05	0.00598	0.46	0.35	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	4.53	1.21e-05	0.00598	0.46	0.35	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
PCPG	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-4.53	1.21e-05	0.00598	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-4.53	1.21e-05	0.00598	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
PCPG	cis	rs17772222	0.958	rs10134008	ENSG00000222990.1	RNU4-22P	4.53	1.21e-05	0.00598	0.45	0.35	Coronary artery calcification;	chr14:88549183	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.958	rs891750	ENSG00000222990.1	RNU4-22P	4.53	1.21e-05	0.00598	0.45	0.35	Coronary artery calcification;	chr14:88550856	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.958	rs891749	ENSG00000222990.1	RNU4-22P	4.53	1.21e-05	0.00598	0.45	0.35	Coronary artery calcification;	chr14:88550893	chr14:88513498~88513663:+
PCPG	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-4.53	1.21e-05	0.00599	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
PCPG	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	4.53	1.21e-05	0.00599	0.76	0.35	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	4.53	1.21e-05	0.00599	0.76	0.35	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	4.53	1.21e-05	0.00599	0.76	0.35	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	4.53	1.21e-05	0.00599	0.76	0.35	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	4.53	1.21e-05	0.00599	0.76	0.35	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-4.53	1.21e-05	0.00599	-0.76	-0.35	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	4.53	1.21e-05	0.006	0.4	0.35	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
PCPG	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	4.53	1.21e-05	0.006	0.5	0.35	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
PCPG	cis	rs4819052	0.851	rs7279182	ENSG00000215447.6	BX322557.10	-4.53	1.21e-05	0.006	-0.34	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45288052~45291738:+
PCPG	cis	rs11662586	0.574	rs55645353	ENSG00000267251.2	AC139100.3	4.53	1.21e-05	0.006	0.52	0.35	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79995474	chr18:80183680~80202992:+
PCPG	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-4.53	1.22e-05	0.006	-0.44	-0.35	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
PCPG	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	4.53	1.22e-05	0.00601	0.52	0.35	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	4.53	1.22e-05	0.00601	0.52	0.35	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	4.53	1.22e-05	0.00601	0.52	0.35	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	4.53	1.22e-05	0.00601	0.52	0.35	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	4.53	1.22e-05	0.00601	0.52	0.35	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	4.53	1.22e-05	0.00601	0.52	0.35	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	4.53	1.22e-05	0.00601	0.52	0.35	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
PCPG	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	4.53	1.22e-05	0.00602	0.46	0.35	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
PCPG	cis	rs10751667	0.666	rs7124480	ENSG00000255142.1	AP006621.6	4.53	1.22e-05	0.00602	0.34	0.35	Alzheimer's disease (late onset);	chr11:971601	chr11:781645~782105:+
PCPG	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	4.52	1.22e-05	0.00602	0.45	0.35	Height;	chr6:109462738	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	4.52	1.22e-05	0.00602	0.45	0.35	Height;	chr6:109464011	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	4.52	1.22e-05	0.00602	0.45	0.35	Height;	chr6:109465777	chr6:109382795~109383666:+
PCPG	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	4.52	1.22e-05	0.00603	0.45	0.35	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
PCPG	cis	rs8098244	0.683	rs10853591	ENSG00000265752.2	RP11-403A21.1	4.52	1.22e-05	0.00604	0.42	0.35	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23845888	chr18:23957754~23982556:-
PCPG	cis	rs916888	0.61	rs199452	ENSG00000232300.1	FAM215B	4.52	1.22e-05	0.00604	0.44	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46558830~46562795:-
PCPG	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-4.52	1.22e-05	0.00604	-0.46	-0.35	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
PCPG	cis	rs5758511	0.508	rs58099562	ENSG00000226450.2	CYP2D8P	4.52	1.23e-05	0.00604	0.46	0.35	Birth weight;	chr22:42057768	chr22:42149886~42155001:-
PCPG	cis	rs5758511	0.508	rs2413667	ENSG00000226450.2	CYP2D8P	4.52	1.23e-05	0.00604	0.46	0.35	Birth weight;	chr22:42076233	chr22:42149886~42155001:-
PCPG	cis	rs5769765	0.817	rs11912619	ENSG00000278869.1	CITF22-49E9.3	4.52	1.23e-05	0.00604	0.47	0.35	Schizophrenia;	chr22:49923753	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.73	rs62233964	ENSG00000278869.1	CITF22-49E9.3	4.52	1.23e-05	0.00604	0.47	0.35	Schizophrenia;	chr22:49923762	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs9616211	ENSG00000278869.1	CITF22-49E9.3	4.52	1.23e-05	0.00604	0.47	0.35	Schizophrenia;	chr22:49924028	chr22:49933198~49934074:-
PCPG	cis	rs1949733	0.701	rs2631754	ENSG00000205959.3	RP11-689P11.2	-4.52	1.23e-05	0.00606	-0.39	-0.35	Response to antineoplastic agents;	chr4:8447506	chr4:8482270~8512610:+
PCPG	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	4.52	1.23e-05	0.00606	0.44	0.35	Height;	chr6:109440234	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	4.52	1.23e-05	0.00606	0.44	0.35	Height;	chr6:109443332	chr6:109382795~109383666:+
PCPG	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	4.52	1.23e-05	0.00606	0.4	0.35	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
PCPG	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	4.52	1.23e-05	0.00606	0.48	0.35	Height;	chr6:109331033	chr6:109382795~109383666:+
PCPG	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-4.52	1.23e-05	0.00606	-0.43	-0.35	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
PCPG	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	4.52	1.23e-05	0.00606	0.54	0.35	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
PCPG	cis	rs7688540	0.8	rs61794998	ENSG00000275426.1	CH17-262A2.1	4.52	1.23e-05	0.00607	0.41	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:149738~150317:+
PCPG	cis	rs7688540	0.76	rs28460123	ENSG00000275426.1	CH17-262A2.1	4.52	1.23e-05	0.00607	0.41	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:149738~150317:+
PCPG	cis	rs17507216	0.681	rs28877110	ENSG00000228141.5	AC105339.1	-4.52	1.23e-05	0.00607	-0.53	-0.35	Excessive daytime sleepiness;	chr15:82672111	chr15:82710471~82714026:-
PCPG	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	4.52	1.23e-05	0.00607	0.35	0.35	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
PCPG	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	4.52	1.23e-05	0.00608	0.38	0.35	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
PCPG	cis	rs8030379	1	rs1480823	ENSG00000230373.7	GOLGA6L5P	-4.52	1.23e-05	0.00608	-0.34	-0.35	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84507885~84516814:-
PCPG	cis	rs12908161	0.92	rs12904605	ENSG00000259295.5	CSPG4P12	4.52	1.24e-05	0.00609	0.51	0.35	Schizophrenia;	chr15:84658188	chr15:85191438~85213905:+
PCPG	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	4.52	1.24e-05	0.00609	0.44	0.35	Height;	chr6:109454233	chr6:109382795~109383666:+
PCPG	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	4.52	1.24e-05	0.00609	0.45	0.35	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	4.52	1.24e-05	0.00609	0.45	0.35	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
PCPG	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	4.52	1.24e-05	0.00609	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
PCPG	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-4.52	1.24e-05	0.0061	-0.41	-0.35	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
PCPG	cis	rs9494145	0.531	rs9399136	ENSG00000232876.1	CTA-212D2.2	-4.52	1.24e-05	0.0061	-0.46	-0.35	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135081201	chr6:135055033~135060550:+
PCPG	cis	rs5758511	0.68	rs1107553	ENSG00000205702.9	CYP2D7	4.52	1.24e-05	0.0061	0.47	0.35	Birth weight;	chr22:42271467	chr22:42140203~42144577:-
PCPG	cis	rs916888	0.821	rs199499	ENSG00000262500.1	RP11-259G18.2	4.52	1.24e-05	0.0061	0.62	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46243606~46245044:+
PCPG	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	4.52	1.24e-05	0.0061	0.43	0.35	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
PCPG	cis	rs7819412	0.807	rs9657519	ENSG00000255020.1	AF131216.5	-4.52	1.24e-05	0.0061	-0.49	-0.35	Triglycerides;	chr8:11087929	chr8:11345748~11347502:-
PCPG	cis	rs62229266	0.839	rs11088335	ENSG00000230212.5	AP000688.14	-4.52	1.24e-05	0.00611	-0.39	-0.35	Mitral valve prolapse;	chr21:36098037	chr21:36069642~36126640:-
PCPG	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	4.52	1.24e-05	0.00611	0.58	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
PCPG	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	4.52	1.24e-05	0.00611	0.37	0.35	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
PCPG	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	4.52	1.24e-05	0.00611	0.38	0.35	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
PCPG	cis	rs7017914	0.967	rs2933853	ENSG00000254031.4	RP11-326E22.1	4.52	1.24e-05	0.00612	0.34	0.35	Bone mineral density;	chr8:70996987	chr8:71155457~71204223:+
PCPG	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-4.52	1.24e-05	0.00612	-0.49	-0.35	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
PCPG	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	4.52	1.24e-05	0.00612	0.43	0.35	Height;	chr6:109690255	chr6:109382795~109383666:+
PCPG	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	4.52	1.24e-05	0.00612	0.34	0.35	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
PCPG	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-4.52	1.24e-05	0.00612	-0.46	-0.35	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-4.52	1.24e-05	0.00612	-0.46	-0.35	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
PCPG	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-4.52	1.25e-05	0.00612	-0.44	-0.35	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-4.52	1.25e-05	0.00612	-0.44	-0.35	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-4.52	1.25e-05	0.00612	-0.44	-0.35	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-4.52	1.25e-05	0.00612	-0.44	-0.35	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-4.52	1.25e-05	0.00612	-0.44	-0.35	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-4.52	1.25e-05	0.00612	-0.44	-0.35	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
PCPG	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-4.52	1.25e-05	0.00612	-0.44	-0.35	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
PCPG	cis	rs10510102	0.507	rs12244092	ENSG00000276742.1	RP11-500G22.4	4.52	1.25e-05	0.00613	0.55	0.35	Breast cancer;	chr10:122005769	chr10:121956782~121957098:+
PCPG	cis	rs7246657	0.943	rs7248733	ENSG00000226686.6	LINC01535	-4.52	1.25e-05	0.00613	-0.53	-0.35	Coronary artery calcification;	chr19:37505459	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.943	rs6508733	ENSG00000226686.6	LINC01535	-4.52	1.25e-05	0.00613	-0.53	-0.35	Coronary artery calcification;	chr19:37509646	chr19:37251912~37265535:+
PCPG	cis	rs10504130	0.502	rs10087958	ENSG00000272024.1	RP11-546K22.3	-4.52	1.25e-05	0.00613	-0.43	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:51954109	chr8:51950284~51950690:+
PCPG	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-4.52	1.25e-05	0.00614	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
PCPG	cis	rs4143844	0.867	rs17271312	ENSG00000259251.2	RP11-643M14.1	4.52	1.25e-05	0.00614	0.68	0.35	Bipolar disorder and schizophrenia;	chr15:62044080	chr15:62060503~62062434:+
PCPG	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	4.52	1.25e-05	0.00614	0.65	0.35	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
PCPG	cis	rs28386778	0.897	rs2028567	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63837966	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs894413	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63838987	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs894414	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63839024	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs6504187	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63839739	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2859619	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63840326	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs8076760	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63843137	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.83	rs2665798	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63844037	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.799	rs2727322	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63844346	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2727323	ENSG00000240280.5	TCAM1P	-4.52	1.25e-05	0.00614	-0.47	-0.35	Prudent dietary pattern;	chr17:63844639	chr17:63849292~63864379:+
PCPG	cis	rs657075	0.697	rs56996855	ENSG00000233006.5	AC034220.3	-4.52	1.25e-05	0.00615	-0.49	-0.35	Rheumatoid arthritis;	chr5:132353945	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs34034297	ENSG00000233006.5	AC034220.3	-4.52	1.25e-05	0.00615	-0.49	-0.35	Rheumatoid arthritis;	chr5:132355483	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs35834048	ENSG00000233006.5	AC034220.3	-4.52	1.25e-05	0.00615	-0.49	-0.35	Rheumatoid arthritis;	chr5:132359643	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583481	ENSG00000233006.5	AC034220.3	-4.52	1.25e-05	0.00615	-0.49	-0.35	Rheumatoid arthritis;	chr5:132360859	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583482	ENSG00000233006.5	AC034220.3	-4.52	1.25e-05	0.00615	-0.49	-0.35	Rheumatoid arthritis;	chr5:132362249	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583483	ENSG00000233006.5	AC034220.3	-4.52	1.25e-05	0.00615	-0.49	-0.35	Rheumatoid arthritis;	chr5:132362327	chr5:132311285~132369916:-
PCPG	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-4.52	1.25e-05	0.00615	-0.45	-0.35	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
PCPG	cis	rs2060793	0.741	rs1542291	ENSG00000251991.1	RNU7-49P	4.52	1.25e-05	0.00615	0.39	0.35	Vitamin D levels;	chr11:14784720	chr11:14478892~14478953:+
PCPG	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-4.52	1.25e-05	0.00615	-0.43	-0.35	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
PCPG	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-4.52	1.25e-05	0.00615	-0.43	-0.35	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
PCPG	cis	rs300890	0.651	rs300917	ENSG00000250326.1	RP11-284M14.1	-4.52	1.25e-05	0.00615	-0.31	-0.35	Nasopharyngeal carcinoma;	chr4:143348696	chr4:142933195~143184861:-
PCPG	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-4.52	1.25e-05	0.00616	-0.43	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
PCPG	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	4.52	1.25e-05	0.00616	0.49	0.35	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
PCPG	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-4.52	1.26e-05	0.00616	-0.32	-0.35	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
PCPG	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	4.52	1.26e-05	0.00616	0.45	0.35	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
PCPG	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-4.52	1.26e-05	0.00616	-0.4	-0.35	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
PCPG	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	4.52	1.26e-05	0.00617	0.39	0.35	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	4.52	1.26e-05	0.00617	0.39	0.35	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
PCPG	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-4.52	1.26e-05	0.00617	-0.5	-0.35	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-4.52	1.26e-05	0.00617	-0.5	-0.35	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-4.52	1.26e-05	0.00617	-0.5	-0.35	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
PCPG	cis	rs2898290	0.622	rs4840567	ENSG00000269954.1	RP11-148O21.6	-4.52	1.26e-05	0.00617	-0.38	-0.35	Systolic blood pressure;	chr8:11490116	chr8:11552488~11552991:-
PCPG	cis	rs394563	0.601	rs439495	ENSG00000231760.4	RP11-350J20.5	-4.52	1.26e-05	0.00618	-0.43	-0.35	Dupuytren's disease;	chr6:149472088	chr6:149796151~149826294:-
PCPG	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	4.52	1.26e-05	0.00618	0.43	0.35	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	4.52	1.26e-05	0.00618	0.43	0.35	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	4.52	1.26e-05	0.00618	0.43	0.35	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
PCPG	cis	rs7789940	0.904	rs7459185	ENSG00000186704.9	DTX2P1	-4.52	1.26e-05	0.00618	-0.43	-0.35	Multiple sclerosis;	chr7:76305323	chr7:76978617~77004308:+
PCPG	cis	rs6957923	0.835	rs4445126	ENSG00000230658.1	KLHL7-AS1	4.52	1.26e-05	0.00618	0.43	0.35	Height;	chr7:23457476	chr7:23101228~23105703:-
PCPG	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	4.52	1.26e-05	0.00618	0.45	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
PCPG	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	4.52	1.26e-05	0.00618	0.45	0.35	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-4.52	1.26e-05	0.00619	-0.47	-0.35	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
PCPG	cis	rs56804039	0.524	rs7001071	ENSG00000253893.2	FAM85B	4.52	1.26e-05	0.00619	0.62	0.35	Cervical cancer;	chr8:8509011	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs55669645	ENSG00000253893.2	FAM85B	4.52	1.26e-05	0.00619	0.62	0.35	Cervical cancer;	chr8:8509849	chr8:8167819~8226614:-
PCPG	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	4.52	1.27e-05	0.00619	0.39	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
PCPG	cis	rs7017914	0.967	rs7842851	ENSG00000254031.4	RP11-326E22.1	4.52	1.27e-05	0.0062	0.33	0.35	Bone mineral density;	chr8:70751570	chr8:71155457~71204223:+
PCPG	cis	rs17684571	0.7	rs35886823	ENSG00000231441.1	RP11-472M19.2	4.52	1.27e-05	0.0062	0.55	0.35	Schizophrenia;	chr6:56816682	chr6:56844002~56864078:+
PCPG	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-4.52	1.27e-05	0.0062	-0.5	-0.35	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
PCPG	cis	rs10435719	0.902	rs12681142	ENSG00000255495.1	AC145124.2	4.52	1.27e-05	0.0062	0.35	0.35	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11945092	chr8:12194467~12196280:+
PCPG	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.0062	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.0062	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
PCPG	cis	rs2554380	0.527	rs7164782	ENSG00000230373.7	GOLGA6L5P	-4.52	1.27e-05	0.00621	-0.41	-0.35	Height;	chr15:83833447	chr15:84507885~84516814:-
PCPG	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	4.52	1.27e-05	0.00621	0.49	0.35	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
PCPG	cis	rs11858159	0.803	rs7179453	ENSG00000259905.4	PWRN1	4.52	1.27e-05	0.00621	0.37	0.35	Platelet thrombus formation;	chr15:24557746	chr15:24493137~24652130:+
PCPG	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	4.52	1.27e-05	0.00621	0.36	0.35	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
PCPG	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-4.52	1.27e-05	0.00622	-0.44	-0.35	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
PCPG	cis	rs4819052	0.808	rs2838825	ENSG00000215447.6	BX322557.10	-4.52	1.27e-05	0.00622	-0.34	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45288052~45291738:+
PCPG	cis	rs11858159	0.834	rs12593399	ENSG00000259905.4	PWRN1	4.52	1.27e-05	0.00622	0.37	0.35	Platelet thrombus formation;	chr15:24563513	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.809	rs6576348	ENSG00000259905.4	PWRN1	4.52	1.27e-05	0.00622	0.37	0.35	Platelet thrombus formation;	chr15:24578191	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.874	rs6576349	ENSG00000259905.4	PWRN1	4.52	1.27e-05	0.00622	0.37	0.35	Platelet thrombus formation;	chr15:24578254	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.845	rs6576350	ENSG00000259905.4	PWRN1	4.52	1.27e-05	0.00622	0.37	0.35	Platelet thrombus formation;	chr15:24578391	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.874	rs12903376	ENSG00000259905.4	PWRN1	4.52	1.27e-05	0.00622	0.37	0.35	Platelet thrombus formation;	chr15:24579166	chr15:24493137~24652130:+
PCPG	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-4.52	1.27e-05	0.00622	-0.39	-0.35	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
PCPG	cis	rs7911712	0.872	rs2793299	ENSG00000228462.1	RP11-445N18.3	4.51	1.27e-05	0.00622	0.49	0.35	Emphysema-related traits;	chr10:44783144	chr10:45073146~45073541:-
PCPG	cis	rs1949733	1	rs1916326	ENSG00000205959.3	RP11-689P11.2	4.51	1.27e-05	0.00623	0.4	0.35	Response to antineoplastic agents;	chr4:8498296	chr4:8482270~8512610:+
PCPG	cis	rs1949733	1	rs868105	ENSG00000205959.3	RP11-689P11.2	4.51	1.27e-05	0.00623	0.4	0.35	Response to antineoplastic agents;	chr4:8499303	chr4:8482270~8512610:+
PCPG	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	4.51	1.28e-05	0.00623	0.6	0.35	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
PCPG	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	4.51	1.28e-05	0.00624	0.47	0.35	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
PCPG	cis	rs748404	0.666	rs12908460	ENSG00000205771.5	CATSPER2P1	-4.51	1.28e-05	0.00624	-0.45	-0.35	Lung cancer;	chr15:43413472	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs2230451	ENSG00000205771.5	CATSPER2P1	-4.51	1.28e-05	0.00624	-0.45	-0.35	Lung cancer;	chr15:43415610	chr15:43726918~43747094:-
PCPG	cis	rs1155848	0.571	rs17511364	ENSG00000227354.5	RBM26-AS1	4.51	1.28e-05	0.00624	0.65	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79678460	chr13:79406309~79424328:+
PCPG	cis	rs7306456	0.623	rs10902513	ENSG00000256312.1	RP13-977J11.8	-4.51	1.28e-05	0.00624	-0.4	-0.35	Anti-saccade response;	chr12:132208942	chr12:132190213~132190997:+
PCPG	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-4.51	1.28e-05	0.00625	-0.49	-0.35	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-4.51	1.28e-05	0.00625	-0.49	-0.35	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-4.51	1.28e-05	0.00625	-0.49	-0.35	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-4.51	1.28e-05	0.00625	-0.49	-0.35	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-4.51	1.28e-05	0.00625	-0.49	-0.35	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-4.51	1.28e-05	0.00625	-0.49	-0.35	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-4.51	1.28e-05	0.00625	-0.49	-0.35	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
PCPG	cis	rs11673344	0.504	rs7245882	ENSG00000226686.6	LINC01535	-4.51	1.28e-05	0.00626	-0.45	-0.35	Obesity-related traits;	chr19:37089513	chr19:37251912~37265535:+
PCPG	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	4.51	1.28e-05	0.00626	0.42	0.35	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
PCPG	cis	rs28386778	0.591	rs2584619	ENSG00000240280.5	TCAM1P	-4.51	1.28e-05	0.00626	-0.46	-0.35	Prudent dietary pattern;	chr17:63835855	chr17:63849292~63864379:+
PCPG	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	4.51	1.28e-05	0.00626	0.38	0.35	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
PCPG	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	4.51	1.28e-05	0.00626	0.4	0.35	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
PCPG	cis	rs7017914	0.905	rs4738105	ENSG00000254031.4	RP11-326E22.1	-4.51	1.28e-05	0.00626	-0.34	-0.35	Bone mineral density;	chr8:71046683	chr8:71155457~71204223:+
PCPG	cis	rs2733954	0.747	rs367052	ENSG00000179219.5	LINC00311	4.51	1.28e-05	0.00626	0.43	0.35	Leprosy;	chr16:85768292	chr16:85282958~85285963:+
PCPG	cis	rs10760158	0.832	rs963003	ENSG00000226752.6	PSMD5-AS1	-4.51	1.29e-05	0.00627	-0.45	-0.35	Pulse pressure;	chr9:121272531	chr9:120824828~120854385:+
PCPG	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-4.51	1.29e-05	0.00627	-0.43	-0.35	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
PCPG	cis	rs11673344	0.562	rs6510580	ENSG00000226686.6	LINC01535	4.51	1.29e-05	0.00627	0.45	0.35	Obesity-related traits;	chr19:37038452	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs2082009	ENSG00000226686.6	LINC01535	4.51	1.29e-05	0.00627	0.45	0.35	Obesity-related traits;	chr19:37039834	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs7246739	ENSG00000226686.6	LINC01535	4.51	1.29e-05	0.00627	0.45	0.35	Obesity-related traits;	chr19:37040829	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs6510584	ENSG00000226686.6	LINC01535	4.51	1.29e-05	0.00627	0.45	0.35	Obesity-related traits;	chr19:37058699	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs7260488	ENSG00000226686.6	LINC01535	4.51	1.29e-05	0.00627	0.45	0.35	Obesity-related traits;	chr19:37058883	chr19:37251912~37265535:+
PCPG	cis	rs6957923	0.967	rs35133514	ENSG00000230658.1	KLHL7-AS1	4.51	1.29e-05	0.00628	0.4	0.35	Height;	chr7:23462189	chr7:23101228~23105703:-
PCPG	cis	rs2898290	0.622	rs978803	ENSG00000269954.1	RP11-148O21.6	4.51	1.29e-05	0.00628	0.38	0.35	Systolic blood pressure;	chr8:11485966	chr8:11552488~11552991:-
PCPG	cis	rs28386778	0.897	rs8066754	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63739230	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs3826341	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63741862	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs1877318	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63742600	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs11079510	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63743542	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs3760256	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63743801	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs8069969	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63744863	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs9207	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63746539	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs8079818	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63747307	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs4638645	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63750989	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.805	rs9911714	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63751592	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs3785572	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63752629	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs4968662	ENSG00000240280.5	TCAM1P	-4.51	1.29e-05	0.00629	-0.45	-0.35	Prudent dietary pattern;	chr17:63757177	chr17:63849292~63864379:+
PCPG	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-4.51	1.29e-05	0.00629	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
PCPG	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-4.51	1.29e-05	0.00629	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
PCPG	cis	rs3850699	0.926	rs12262998	ENSG00000269609.4	RPARP-AS1	-4.51	1.29e-05	0.00629	-0.29	-0.35	Prostate cancer;	chr10:102668959	chr10:102449817~102461106:+
PCPG	cis	rs2439831	0.85	rs524417	ENSG00000205771.5	CATSPER2P1	-4.51	1.29e-05	0.0063	-0.48	-0.35	Lung cancer in ever smokers;	chr15:43480176	chr15:43726918~43747094:-
PCPG	cis	rs7017914	0.934	rs7830550	ENSG00000254031.4	RP11-326E22.1	4.51	1.29e-05	0.0063	0.34	0.35	Bone mineral density;	chr8:70658196	chr8:71155457~71204223:+
PCPG	cis	rs9828933	0.701	rs7621544	ENSG00000280620.1	SCAANT1	4.51	1.29e-05	0.0063	0.45	0.35	Type 2 diabetes;	chr3:63943005	chr3:63911518~63911772:-
PCPG	cis	rs9650657	0.504	rs7813802	ENSG00000255020.1	AF131216.5	4.51	1.3e-05	0.00631	0.46	0.35	Neuroticism;	chr8:11176467	chr8:11345748~11347502:-
PCPG	cis	rs5769765	0.908	rs7410318	ENSG00000278869.1	CITF22-49E9.3	4.51	1.3e-05	0.00631	0.47	0.35	Schizophrenia;	chr22:49923401	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.862	rs7410537	ENSG00000278869.1	CITF22-49E9.3	4.51	1.3e-05	0.00631	0.47	0.35	Schizophrenia;	chr22:49923682	chr22:49933198~49934074:-
PCPG	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	4.51	1.3e-05	0.00631	0.4	0.35	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
PCPG	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-4.51	1.3e-05	0.00631	-0.45	-0.35	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
PCPG	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	4.51	1.3e-05	0.00632	0.39	0.35	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	4.51	1.3e-05	0.00632	0.39	0.35	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
PCPG	cis	rs5769765	0.908	rs7410601	ENSG00000278869.1	CITF22-49E9.3	4.51	1.3e-05	0.00632	0.46	0.35	Schizophrenia;	chr22:49923539	chr22:49933198~49934074:-
PCPG	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-4.51	1.3e-05	0.00632	-0.43	-0.35	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
PCPG	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	4.51	1.3e-05	0.00632	0.44	0.35	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
PCPG	cis	rs6121246	0.954	rs6121245	ENSG00000230613.1	HM13-AS1	4.51	1.3e-05	0.00633	0.49	0.35	Mean corpuscular hemoglobin;	chr20:31844257	chr20:31567707~31573263:-
PCPG	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-4.51	1.3e-05	0.00633	-0.46	-0.35	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
PCPG	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	4.51	1.3e-05	0.00633	0.46	0.35	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
PCPG	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	4.51	1.3e-05	0.00633	0.46	0.35	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
PCPG	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	4.51	1.3e-05	0.00633	0.41	0.35	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
PCPG	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	4.51	1.3e-05	0.00634	0.34	0.35	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
PCPG	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-4.51	1.3e-05	0.00634	-0.37	-0.35	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
PCPG	cis	rs7208859	0.623	rs9898084	ENSG00000263603.1	CTD-2349P21.5	-4.51	1.31e-05	0.00635	-0.56	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30729469~30731202:+
PCPG	cis	rs13113518	0.812	rs12648271	ENSG00000272969.1	RP11-528I4.2	4.51	1.31e-05	0.00635	0.4	0.35	Height;	chr4:55501955	chr4:55547112~55547889:+
PCPG	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	4.51	1.31e-05	0.00635	0.35	0.35	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
PCPG	cis	rs7017914	0.902	rs6472562	ENSG00000254031.4	RP11-326E22.1	4.51	1.31e-05	0.00636	0.34	0.35	Bone mineral density;	chr8:71057643	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.902	rs6472563	ENSG00000254031.4	RP11-326E22.1	4.51	1.31e-05	0.00636	0.34	0.35	Bone mineral density;	chr8:71057672	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.902	rs34856835	ENSG00000254031.4	RP11-326E22.1	4.51	1.31e-05	0.00636	0.34	0.35	Bone mineral density;	chr8:71058376	chr8:71155457~71204223:+
PCPG	cis	rs964611	0.882	rs56308793	ENSG00000259488.2	RP11-154J22.1	-4.51	1.31e-05	0.00636	-0.34	-0.35	Metabolite levels (Pyroglutamine);	chr15:48350611	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs4775749	ENSG00000259488.2	RP11-154J22.1	4.51	1.31e-05	0.00636	0.34	0.35	Metabolite levels (Pyroglutamine);	chr15:48350064	chr15:48312353~48331856:-
PCPG	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	4.51	1.31e-05	0.00636	0.42	0.35	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
PCPG	cis	rs9926296	0.568	rs417323	ENSG00000260259.1	RP11-368I7.4	4.51	1.31e-05	0.00636	0.44	0.35	Vitiligo;	chr16:89679869	chr16:89682620~89686569:-
PCPG	cis	rs763121	0.853	rs6001173	ENSG00000273076.1	RP3-508I15.22	4.51	1.31e-05	0.00637	0.39	0.35	Menopause (age at onset);	chr22:38619297	chr22:38743495~38743910:+
PCPG	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-4.51	1.31e-05	0.00637	-0.49	-0.35	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
PCPG	cis	rs6840258	0.689	rs6811587	ENSG00000251411.1	RP11-397E7.4	4.51	1.31e-05	0.00637	0.35	0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000653	chr4:86913266~86914817:-
PCPG	cis	rs1150668	0.83	rs2859365	ENSG00000219392.1	RP1-265C24.5	4.51	1.31e-05	0.00638	0.41	0.35	Pubertal anthropometrics;	chr6:28423688	chr6:28115628~28116551:+
PCPG	cis	rs1150668	0.796	rs2247002	ENSG00000219392.1	RP1-265C24.5	-4.51	1.31e-05	0.00638	-0.41	-0.35	Pubertal anthropometrics;	chr6:28430174	chr6:28115628~28116551:+
PCPG	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	4.51	1.31e-05	0.00638	0.52	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
PCPG	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	4.51	1.31e-05	0.00638	0.39	0.35	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
PCPG	cis	rs11673344	0.542	rs826324	ENSG00000226686.6	LINC01535	4.51	1.32e-05	0.00639	0.45	0.35	Obesity-related traits;	chr19:37014343	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs2562594	ENSG00000226686.6	LINC01535	4.51	1.32e-05	0.00639	0.45	0.35	Obesity-related traits;	chr19:37023783	chr19:37251912~37265535:+
PCPG	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	4.51	1.32e-05	0.00639	0.45	0.35	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
PCPG	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-4.51	1.32e-05	0.0064	-0.45	-0.35	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-4.51	1.32e-05	0.0064	-0.45	-0.35	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-4.51	1.32e-05	0.0064	-0.45	-0.35	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
PCPG	cis	rs7017914	0.622	rs10957534	ENSG00000254031.4	RP11-326E22.1	4.51	1.32e-05	0.0064	0.35	0.35	Bone mineral density;	chr8:71096068	chr8:71155457~71204223:+
PCPG	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-4.51	1.32e-05	0.00641	-0.43	-0.35	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
PCPG	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-4.51	1.32e-05	0.00641	-0.44	-0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
PCPG	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	4.51	1.32e-05	0.00641	0.51	0.35	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
PCPG	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	4.51	1.32e-05	0.00642	0.37	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
PCPG	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-4.51	1.32e-05	0.00642	-0.5	-0.35	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
PCPG	cis	rs916888	0.61	rs199436	ENSG00000232300.1	FAM215B	-4.51	1.32e-05	0.00643	-0.45	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46558830~46562795:-
PCPG	cis	rs2412819	0.571	rs678084	ENSG00000249839.1	AC011330.5	4.51	1.33e-05	0.00643	0.44	0.35	Lung cancer;	chr15:43828361	chr15:43663654~43684339:-
PCPG	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-4.51	1.33e-05	0.00643	-0.44	-0.35	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
PCPG	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	4.51	1.33e-05	0.00643	0.42	0.35	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
PCPG	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	4.5	1.33e-05	0.00643	0.53	0.35	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
PCPG	cis	rs11858159	0.845	rs12903675	ENSG00000259905.4	PWRN1	4.5	1.33e-05	0.00644	0.37	0.35	Platelet thrombus formation;	chr15:24514364	chr15:24493137~24652130:+
PCPG	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	-4.5	1.33e-05	0.00644	-0.49	-0.35	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
PCPG	cis	rs6957923	0.967	rs10950947	ENSG00000230658.1	KLHL7-AS1	-4.5	1.33e-05	0.00645	-0.4	-0.35	Height;	chr7:23464135	chr7:23101228~23105703:-
PCPG	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	4.5	1.33e-05	0.00645	0.47	0.35	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs61984684	ENSG00000222990.1	RNU4-22P	4.5	1.33e-05	0.00645	0.46	0.35	Coronary artery calcification;	chr14:88559104	chr14:88513498~88513663:+
PCPG	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-4.5	1.33e-05	0.00645	-0.32	-0.35	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
PCPG	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-4.5	1.33e-05	0.00645	-0.32	-0.35	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
PCPG	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-4.5	1.33e-05	0.00645	-0.32	-0.35	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
PCPG	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-4.5	1.33e-05	0.00645	-0.32	-0.35	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
PCPG	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-4.5	1.33e-05	0.00645	-0.32	-0.35	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
PCPG	cis	rs853679	0.538	rs13199081	ENSG00000219392.1	RP1-265C24.5	-4.5	1.33e-05	0.00646	-0.47	-0.35	Depression;	chr6:28364057	chr6:28115628~28116551:+
PCPG	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-4.5	1.33e-05	0.00646	-0.46	-0.35	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
PCPG	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-4.5	1.33e-05	0.00646	-0.49	-0.35	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-4.5	1.33e-05	0.00646	-0.49	-0.35	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-4.5	1.33e-05	0.00646	-0.49	-0.35	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-4.5	1.33e-05	0.00646	-0.49	-0.35	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-4.5	1.33e-05	0.00646	-0.49	-0.35	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
PCPG	cis	rs11220082	0.666	rs12224788	ENSG00000254671.2	STT3A-AS1	-4.5	1.33e-05	0.00646	-0.35	-0.35	Schizophrenia;	chr11:125459165	chr11:125570284~125592568:-
PCPG	cis	rs4980659	0.742	rs12365305	ENSG00000260679.1	RP11-643C9.2	4.5	1.33e-05	0.00646	0.34	0.35	Total body bone mineral density;	chr11:69492676	chr11:69921638~69926813:-
PCPG	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	4.5	1.33e-05	0.00647	0.3	0.35	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
PCPG	cis	rs17507216	0.718	rs7161977	ENSG00000228141.5	AC105339.1	-4.5	1.33e-05	0.00647	-0.53	-0.35	Excessive daytime sleepiness;	chr15:82646782	chr15:82710471~82714026:-
PCPG	cis	rs4713118	0.662	rs9393881	ENSG00000216901.1	AL022393.7	4.5	1.34e-05	0.00648	0.47	0.35	Parkinson's disease;	chr6:28055973	chr6:28176188~28176674:+
PCPG	cis	rs561341	0.825	rs2008368	ENSG00000265798.5	RP11-271K11.5	4.5	1.34e-05	0.00648	0.62	0.35	Hip circumference adjusted for BMI;	chr17:32020378	chr17:31038575~31059121:-
PCPG	cis	rs7017914	0.69	rs7845516	ENSG00000254031.4	RP11-326E22.1	-4.5	1.34e-05	0.00648	-0.33	-0.35	Bone mineral density;	chr8:70773587	chr8:71155457~71204223:+
PCPG	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	4.5	1.34e-05	0.00648	0.56	0.35	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
PCPG	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-4.5	1.34e-05	0.00649	-0.44	-0.35	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
PCPG	cis	rs591584	0.59	rs7107559	ENSG00000255893.1	RP11-685N10.1	4.5	1.34e-05	0.00649	0.39	0.35	Macrophage Migration Inhibitory Factor levels;	chr11:94590508	chr11:94472908~94473570:-
PCPG	cis	rs11858159	1	rs7402670	ENSG00000260760.1	PWRN3	4.5	1.34e-05	0.0065	0.37	0.35	Platelet thrombus formation;	chr15:24561224	chr15:24441127~24447967:+
PCPG	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-4.5	1.34e-05	0.0065	-0.48	-0.35	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
PCPG	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	4.5	1.34e-05	0.00651	0.47	0.35	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
PCPG	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-4.5	1.34e-05	0.00651	-0.76	-0.35	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-4.5	1.34e-05	0.00651	-0.76	-0.35	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
PCPG	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-4.5	1.35e-05	0.00652	-0.46	-0.34	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
PCPG	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	4.5	1.35e-05	0.00652	0.32	0.34	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
PCPG	cis	rs4835473	0.897	rs4054616	ENSG00000251600.4	RP11-673E1.1	4.5	1.35e-05	0.00652	0.41	0.34	Immature fraction of reticulocytes;	chr4:143837472	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs2323325	ENSG00000251600.4	RP11-673E1.1	4.5	1.35e-05	0.00652	0.41	0.34	Immature fraction of reticulocytes;	chr4:143837561	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.8	rs4835330	ENSG00000251600.4	RP11-673E1.1	4.5	1.35e-05	0.00652	0.41	0.34	Immature fraction of reticulocytes;	chr4:143846303	chr4:143912331~143982454:+
PCPG	cis	rs720064	0.537	rs2676106	ENSG00000265752.2	RP11-403A21.1	4.5	1.35e-05	0.00652	0.41	0.34	Strep throat;	chr18:23685075	chr18:23957754~23982556:-
PCPG	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-4.5	1.35e-05	0.00652	-0.37	-0.34	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
PCPG	cis	rs7811142	1	rs11763511	ENSG00000078319.8	PMS2P1	-4.5	1.35e-05	0.00653	-0.44	-0.34	Platelet count;	chr7:100484321	chr7:100320992~100341908:-
PCPG	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	4.5	1.35e-05	0.00653	0.43	0.34	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
PCPG	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	4.5	1.35e-05	0.00653	0.37	0.34	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
PCPG	cis	rs1876905	0.597	rs1150076	ENSG00000255389.1	C6orf3	4.5	1.35e-05	0.00654	0.46	0.34	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111599875~111602295:+
PCPG	cis	rs964611	0.938	rs7163887	ENSG00000259488.2	RP11-154J22.1	4.5	1.35e-05	0.00654	0.34	0.34	Metabolite levels (Pyroglutamine);	chr15:48367357	chr15:48312353~48331856:-
PCPG	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-4.5	1.35e-05	0.00654	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
PCPG	cis	rs11836164	0.58	rs36120270	ENSG00000278095.1	RP11-283G6.6	4.5	1.35e-05	0.00654	0.54	0.34	Mammographic density (dense area);	chr12:26325518	chr12:26273329~26273900:-
PCPG	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	4.5	1.35e-05	0.00654	0.44	0.34	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
PCPG	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-4.5	1.36e-05	0.00654	-0.4	-0.34	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
PCPG	cis	rs763121	1	rs86796	ENSG00000273076.1	RP3-508I15.22	-4.5	1.36e-05	0.00655	-0.34	-0.34	Menopause (age at onset);	chr22:38485449	chr22:38743495~38743910:+
PCPG	cis	rs10751667	0.666	rs6597962	ENSG00000255142.1	AP006621.6	4.5	1.36e-05	0.00655	0.34	0.34	Alzheimer's disease (late onset);	chr11:976351	chr11:781645~782105:+
PCPG	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-4.5	1.36e-05	0.00655	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-4.5	1.36e-05	0.00655	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
PCPG	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-4.5	1.36e-05	0.00655	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
PCPG	cis	rs10899021	0.92	rs11236171	ENSG00000279353.1	RP11-864N7.4	4.5	1.36e-05	0.00655	0.62	0.34	Response to metformin (IC50);	chr11:74606473	chr11:74698231~74699658:-
PCPG	cis	rs10899021	0.92	rs61901541	ENSG00000279353.1	RP11-864N7.4	4.5	1.36e-05	0.00655	0.62	0.34	Response to metformin (IC50);	chr11:74606940	chr11:74698231~74699658:-
PCPG	cis	rs10504130	0.569	rs13275967	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs13274159	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs4436115	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs4573262	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs11785467	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs34004633	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs12679983	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs12680128	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.53	rs4292674	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs4292675	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs76746661	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs71513549	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.502	rs4321994	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.66	rs79691523	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs12676345	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.569	rs34213209	ENSG00000272024.1	RP11-546K22.3	-4.5	1.36e-05	0.00656	-0.45	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51950284~51950690:+
PCPG	cis	rs7819412	0.875	rs6981523	ENSG00000255020.1	AF131216.5	-4.5	1.36e-05	0.00656	-0.47	-0.34	Triglycerides;	chr8:11204283	chr8:11345748~11347502:-
PCPG	cis	rs6957923	0.934	rs7808836	ENSG00000230658.1	KLHL7-AS1	4.5	1.36e-05	0.00656	0.45	0.34	Height;	chr7:23434706	chr7:23101228~23105703:-
PCPG	cis	rs2531992	1	rs710893	ENSG00000262185.1	RP11-462G12.1	-4.5	1.36e-05	0.00656	-0.56	-0.34	Waist circumference;	chr16:3964963	chr16:3947609~3950444:-
PCPG	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	4.5	1.36e-05	0.00656	0.43	0.34	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
PCPG	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	4.5	1.36e-05	0.00657	0.47	0.34	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
PCPG	cis	rs4376189	0.51	rs13119888	ENSG00000207497.1	Y_RNA	4.5	1.36e-05	0.00657	0.45	0.34	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185721494	chr4:185709873~185709967:-
PCPG	cis	rs2898290	0.622	rs7829381	ENSG00000269954.1	RP11-148O21.6	-4.5	1.36e-05	0.00657	-0.39	-0.34	Systolic blood pressure;	chr8:11487064	chr8:11552488~11552991:-
PCPG	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-4.5	1.36e-05	0.00657	-0.33	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-4.5	1.36e-05	0.00657	-0.33	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
PCPG	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-4.5	1.36e-05	0.00657	-0.49	-0.34	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.901	rs313808	ENSG00000230189.5	GS1-124K5.2	4.5	1.36e-05	0.00658	0.52	0.34	Diabetic kidney disease;	chr7:66034886	chr7:66409143~66490059:-
PCPG	cis	rs298555	1	rs298555	ENSG00000240785.1	RPL36AP21	4.5	1.36e-05	0.00658	0.38	0.34	Subjective well-being;	chr5:17330299	chr5:18049550~18049872:+
PCPG	cis	rs657075	0.697	rs4646200	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132335443	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3805678	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132339514	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.639	rs2306772	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132340288	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs4646204	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132344302	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs4646305	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132382847	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583484	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132383438	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583485	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132383690	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583486	ENSG00000233006.5	AC034220.3	-4.5	1.36e-05	0.00658	-0.47	-0.34	Rheumatoid arthritis;	chr5:132383997	chr5:132311285~132369916:-
PCPG	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	4.5	1.36e-05	0.00658	0.37	0.34	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
PCPG	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-4.5	1.37e-05	0.00658	-0.39	-0.34	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
PCPG	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-4.5	1.37e-05	0.00658	-0.39	-0.34	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
PCPG	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-4.5	1.37e-05	0.00658	-0.39	-0.34	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
PCPG	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-4.5	1.37e-05	0.00658	-0.39	-0.34	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
PCPG	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-4.5	1.37e-05	0.00658	-0.39	-0.34	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
PCPG	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-4.5	1.37e-05	0.00659	-0.3	-0.34	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-4.5	1.37e-05	0.00659	-0.3	-0.34	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
PCPG	cis	rs6674176	0.66	rs12726706	ENSG00000237950.1	RP11-7O11.3	4.5	1.37e-05	0.00659	0.39	0.34	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934270	chr1:43944370~43946551:-
PCPG	cis	rs7824557	0.507	rs7010590	ENSG00000255020.1	AF131216.5	4.5	1.37e-05	0.0066	0.47	0.34	Retinal vascular caliber;	chr8:11205373	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	4.5	1.37e-05	0.0066	0.43	0.34	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
PCPG	cis	rs12681963	0.614	rs2958740	ENSG00000248159.1	HSPA8P11	-4.5	1.37e-05	0.0066	-0.68	-0.34	Migraine;	chr8:30235218	chr8:30237382~30240997:+
PCPG	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	4.5	1.37e-05	0.0066	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
PCPG	cis	rs12899811	0.53	rs11073967	ENSG00000214432.8	AC068831.10	-4.5	1.37e-05	0.0066	-0.38	-0.34	Type 2 diabetes;	chr15:91022574	chr15:91022619~91036611:+
PCPG	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	4.5	1.37e-05	0.0066	0.45	0.34	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
PCPG	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	4.5	1.37e-05	0.0066	0.43	0.34	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	4.5	1.37e-05	0.0066	0.43	0.34	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	4.5	1.37e-05	0.0066	0.43	0.34	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
PCPG	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	4.5	1.37e-05	0.0066	0.43	0.34	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
PCPG	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-4.5	1.37e-05	0.00661	-0.5	-0.34	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
PCPG	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	4.5	1.37e-05	0.00661	0.53	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
PCPG	cis	rs11673344	0.523	rs2562605	ENSG00000226686.6	LINC01535	4.5	1.37e-05	0.00662	0.45	0.34	Obesity-related traits;	chr19:37029302	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs2562607	ENSG00000226686.6	LINC01535	4.5	1.37e-05	0.00662	0.45	0.34	Obesity-related traits;	chr19:37031358	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs2385415	ENSG00000226686.6	LINC01535	4.5	1.37e-05	0.00662	0.45	0.34	Obesity-related traits;	chr19:37035291	chr19:37251912~37265535:+
PCPG	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	4.5	1.37e-05	0.00662	0.39	0.34	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
PCPG	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	4.5	1.37e-05	0.00662	0.62	0.34	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	4.5	1.37e-05	0.00662	0.62	0.34	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	4.5	1.37e-05	0.00662	0.62	0.34	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
PCPG	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	4.5	1.37e-05	0.00662	0.62	0.34	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
PCPG	cis	rs3758911	0.861	rs1388171	ENSG00000255353.1	RP11-382M14.1	-4.5	1.38e-05	0.00663	-0.48	-0.34	Coronary artery disease;	chr11:107272411	chr11:107176286~107177530:+
PCPG	cis	rs5758511	0.68	rs5758667	ENSG00000227370.1	RP4-669P10.19	4.5	1.38e-05	0.00664	0.53	0.34	Birth weight;	chr22:42237198	chr22:42132543~42132998:+
PCPG	cis	rs7789940	0.81	rs12533978	ENSG00000186704.9	DTX2P1	4.5	1.38e-05	0.00664	0.43	0.34	Multiple sclerosis;	chr7:76314035	chr7:76978617~77004308:+
PCPG	cis	rs7789940	0.904	rs6953281	ENSG00000186704.9	DTX2P1	4.5	1.38e-05	0.00664	0.43	0.34	Multiple sclerosis;	chr7:76317626	chr7:76978617~77004308:+
PCPG	cis	rs7789940	0.951	rs7787526	ENSG00000186704.9	DTX2P1	4.5	1.38e-05	0.00664	0.43	0.34	Multiple sclerosis;	chr7:76318236	chr7:76978617~77004308:+
PCPG	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	4.5	1.38e-05	0.00664	0.53	0.34	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
PCPG	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-4.5	1.38e-05	0.00665	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
PCPG	cis	rs7759001	0.857	rs7754411	ENSG00000271755.1	RP1-153G14.4	-4.5	1.38e-05	0.00665	-0.5	-0.34	Glomerular filtration rate (creatinine);	chr6:27391805	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6936539	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27391138	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs9461378	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27392466	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs9461379	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27392587	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4711148	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27392911	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs980963	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27393158	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs980962	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27393229	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs980961	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27393240	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6923108	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27394330	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6903254	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27394580	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6923539	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27394704	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10807022	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27394819	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10080555	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27395087	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs10080814	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27395095	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10080558	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27395119	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10080567	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27395279	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10080569	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27395297	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs9461380	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27395778	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs9468115	ENSG00000271755.1	RP1-153G14.4	4.5	1.38e-05	0.00665	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27395808	chr6:27404010~27406964:-
PCPG	cis	rs11858159	1	rs7402794	ENSG00000260760.1	PWRN3	4.49	1.38e-05	0.00665	0.37	0.34	Platelet thrombus formation;	chr15:24561199	chr15:24441127~24447967:+
PCPG	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-4.49	1.38e-05	0.00665	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
PCPG	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-4.49	1.38e-05	0.00665	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
PCPG	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	4.49	1.38e-05	0.00666	0.4	0.34	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
PCPG	cis	rs591584	0.73	rs112062277	ENSG00000255893.1	RP11-685N10.1	-4.49	1.38e-05	0.00666	-0.41	-0.34	Macrophage Migration Inhibitory Factor levels;	chr11:94581107	chr11:94472908~94473570:-
PCPG	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	4.49	1.38e-05	0.00666	0.7	0.34	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	4.49	1.38e-05	0.00666	0.7	0.34	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	4.49	1.38e-05	0.00666	0.7	0.34	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
PCPG	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	4.49	1.39e-05	0.00666	0.46	0.34	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
PCPG	cis	rs10899021	0.79	rs12296094	ENSG00000279353.1	RP11-864N7.4	4.49	1.39e-05	0.00666	0.6	0.34	Response to metformin (IC50);	chr11:74610655	chr11:74698231~74699658:-
PCPG	cis	rs657075	0.697	rs35948329	ENSG00000233006.5	AC034220.3	-4.49	1.39e-05	0.00667	-0.49	-0.34	Rheumatoid arthritis;	chr5:132350759	chr5:132311285~132369916:-
PCPG	cis	rs11673344	0.542	rs826327	ENSG00000226686.6	LINC01535	4.49	1.39e-05	0.00667	0.45	0.34	Obesity-related traits;	chr19:37004397	chr19:37251912~37265535:+
PCPG	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	4.49	1.39e-05	0.00667	0.45	0.34	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
PCPG	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	4.49	1.39e-05	0.00667	0.38	0.34	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
PCPG	cis	rs6991838	0.778	rs11782837	ENSG00000200714.1	Y_RNA	4.49	1.39e-05	0.00667	0.44	0.34	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65592731~65592820:+
PCPG	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-4.49	1.39e-05	0.00668	-0.32	-0.34	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
PCPG	cis	rs2797160	0.714	rs1777220	ENSG00000237742.5	RP11-624M8.1	4.49	1.39e-05	0.00668	0.35	0.34	Endometrial cancer;	chr6:125701456	chr6:125578558~125749190:-
PCPG	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	4.49	1.39e-05	0.00668	0.42	0.34	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
PCPG	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-4.49	1.39e-05	0.00669	-0.49	-0.34	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
PCPG	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-4.49	1.39e-05	0.00669	-0.49	-0.34	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
PCPG	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	4.49	1.39e-05	0.00669	0.45	0.34	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
PCPG	cis	rs3764021	0.87	rs10844622	ENSG00000278635.1	CTD-2318O12.1	-4.49	1.39e-05	0.00669	-0.42	-0.34	Type 1 diabetes;	chr12:9732486	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.84	rs12304510	ENSG00000278635.1	CTD-2318O12.1	-4.49	1.39e-05	0.00669	-0.42	-0.34	Type 1 diabetes;	chr12:9732930	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.933	rs10492165	ENSG00000278635.1	CTD-2318O12.1	-4.49	1.39e-05	0.00669	-0.42	-0.34	Type 1 diabetes;	chr12:9733365	chr12:9415641~9416718:+
PCPG	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-4.49	1.39e-05	0.00669	-0.44	-0.34	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
PCPG	cis	rs11671005	0.568	rs55987239	ENSG00000269600.1	AC016629.3	-4.49	1.39e-05	0.0067	-0.57	-0.34	Mean platelet volume;	chr19:58573678	chr19:58593896~58599355:-
PCPG	cis	rs16949788	1	rs12323975	ENSG00000261351.2	CTD-3185P2.1	-4.49	1.39e-05	0.0067	-0.47	-0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66382296	chr15:66488658~66492109:-
PCPG	cis	rs16949788	1	rs16949849	ENSG00000261351.2	CTD-3185P2.1	-4.49	1.39e-05	0.0067	-0.47	-0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66390371	chr15:66488658~66492109:-
PCPG	cis	rs16949788	1	rs80298548	ENSG00000261351.2	CTD-3185P2.1	-4.49	1.39e-05	0.0067	-0.47	-0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66398110	chr15:66488658~66492109:-
PCPG	cis	rs12439619	0.693	rs7165536	ENSG00000228141.5	AC105339.1	-4.49	1.39e-05	0.0067	-0.51	-0.34	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82710471~82714026:-
PCPG	cis	rs1488515	0.512	rs7782220	ENSG00000279067.1	GS1-25M2.1	-4.49	1.4e-05	0.0067	-0.5	-0.34	Obesity-related traits;	chr7:96028979	chr7:96118647~96119995:+
PCPG	cis	rs3850699	0.926	rs7094325	ENSG00000269609.4	RPARP-AS1	-4.49	1.4e-05	0.0067	-0.28	-0.34	Prostate cancer;	chr10:102669989	chr10:102449817~102461106:+
PCPG	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-4.49	1.4e-05	0.00671	-0.4	-0.34	Height;	chr5:36995103	chr5:36666214~36725195:-
PCPG	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-4.49	1.4e-05	0.00671	-0.4	-0.34	Height;	chr5:36997725	chr5:36666214~36725195:-
PCPG	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	4.49	1.4e-05	0.00671	0.37	0.34	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
PCPG	cis	rs3764021	1	rs3764021	ENSG00000278635.1	CTD-2318O12.1	-4.49	1.4e-05	0.00671	-0.41	-0.34	Type 1 diabetes;	chr12:9681032	chr12:9415641~9416718:+
PCPG	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	4.49	1.4e-05	0.00671	0.54	0.34	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
PCPG	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	4.49	1.4e-05	0.00672	0.43	0.34	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
PCPG	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	4.49	1.4e-05	0.00673	0.47	0.34	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
PCPG	cis	rs11673344	0.542	rs2562585	ENSG00000226686.6	LINC01535	4.49	1.4e-05	0.00673	0.45	0.34	Obesity-related traits;	chr19:37018321	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs8101392	ENSG00000226686.6	LINC01535	4.49	1.4e-05	0.00673	0.45	0.34	Obesity-related traits;	chr19:37024416	chr19:37251912~37265535:+
PCPG	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	4.49	1.4e-05	0.00673	0.48	0.34	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
PCPG	cis	rs964611	0.882	rs7162774	ENSG00000259488.2	RP11-154J22.1	4.49	1.4e-05	0.00673	0.34	0.34	Metabolite levels (Pyroglutamine);	chr15:48367336	chr15:48312353~48331856:-
PCPG	cis	rs5769765	0.908	rs9616370	ENSG00000278869.1	CITF22-49E9.3	-4.49	1.41e-05	0.00675	-0.46	-0.34	Schizophrenia;	chr22:49912668	chr22:49933198~49934074:-
PCPG	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	4.49	1.41e-05	0.00675	0.45	0.34	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	4.49	1.41e-05	0.00675	0.43	0.34	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	4.49	1.41e-05	0.00675	0.43	0.34	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	4.49	1.41e-05	0.00675	0.43	0.34	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
PCPG	cis	rs13108904	0.557	rs1250086	ENSG00000254094.1	AC078852.1	4.49	1.41e-05	0.00675	0.42	0.34	Obesity-related traits;	chr4:1254263	chr4:1356581~1358075:+
PCPG	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	4.49	1.41e-05	0.00675	0.41	0.34	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
PCPG	cis	rs7017914	0.967	rs13274381	ENSG00000254031.4	RP11-326E22.1	4.49	1.41e-05	0.00676	0.34	0.34	Bone mineral density;	chr8:70852859	chr8:71155457~71204223:+
PCPG	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-4.49	1.41e-05	0.00676	-0.69	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
PCPG	cis	rs13118159	0.505	rs1250128	ENSG00000254094.1	AC078852.1	4.49	1.41e-05	0.00677	0.46	0.34	Longevity;	chr4:1263523	chr4:1356581~1358075:+
PCPG	cis	rs13118159	0.527	rs1250119	ENSG00000254094.1	AC078852.1	4.49	1.41e-05	0.00677	0.46	0.34	Longevity;	chr4:1267548	chr4:1356581~1358075:+
PCPG	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-4.49	1.41e-05	0.00677	-0.44	-0.34	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
PCPG	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-4.49	1.41e-05	0.00677	-0.41	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
PCPG	cis	rs4763879	0.634	rs2012643	ENSG00000278635.1	CTD-2318O12.1	4.49	1.41e-05	0.00677	0.41	0.34	Type 1 diabetes;	chr12:9707128	chr12:9415641~9416718:+
PCPG	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	4.49	1.41e-05	0.00677	0.49	0.34	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
PCPG	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-4.49	1.41e-05	0.00677	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
PCPG	cis	rs5758511	0.68	rs5758686	ENSG00000227370.1	RP4-669P10.19	4.49	1.41e-05	0.00678	0.53	0.34	Birth weight;	chr22:42259371	chr22:42132543~42132998:+
PCPG	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	4.49	1.41e-05	0.00678	0.42	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
PCPG	cis	rs1949733	0.959	rs2688242	ENSG00000205959.3	RP11-689P11.2	-4.49	1.41e-05	0.00678	-0.39	-0.34	Response to antineoplastic agents;	chr4:8428216	chr4:8482270~8512610:+
PCPG	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-4.49	1.42e-05	0.00678	-0.37	-0.34	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
PCPG	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-4.49	1.42e-05	0.00678	-0.43	-0.34	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
PCPG	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	4.49	1.42e-05	0.00679	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
PCPG	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	4.49	1.42e-05	0.00679	0.47	0.34	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
PCPG	cis	rs9326248	0.681	rs641620	ENSG00000280143.1	AP000892.6	-4.49	1.42e-05	0.00679	-0.49	-0.34	Blood protein levels;	chr11:117203513	chr11:117204967~117210292:+
PCPG	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	4.49	1.42e-05	0.00679	0.36	0.34	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
PCPG	cis	rs2235642	0.893	rs2076442	ENSG00000260989.1	LA16c-395F10.2	-4.49	1.42e-05	0.0068	-0.35	-0.34	Coronary artery disease;	chr16:1541111	chr16:1580527~1610328:+
PCPG	cis	rs17772222	1	rs17772222	ENSG00000222990.1	RNU4-22P	-4.49	1.42e-05	0.0068	-0.46	-0.34	Coronary artery calcification;	chr14:88360138	chr14:88513498~88513663:+
PCPG	cis	rs11858159	1	rs67804163	ENSG00000259905.4	PWRN1	4.49	1.42e-05	0.0068	0.39	0.34	Platelet thrombus formation;	chr15:24552896	chr15:24493137~24652130:+
PCPG	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	4.49	1.42e-05	0.0068	0.56	0.34	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
PCPG	cis	rs4143844	1	rs34311301	ENSG00000259251.2	RP11-643M14.1	4.49	1.42e-05	0.0068	0.67	0.34	Bipolar disorder and schizophrenia;	chr15:62050356	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs12148573	ENSG00000259251.2	RP11-643M14.1	4.49	1.42e-05	0.0068	0.67	0.34	Bipolar disorder and schizophrenia;	chr15:62051994	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs75520981	ENSG00000259251.2	RP11-643M14.1	4.49	1.42e-05	0.0068	0.67	0.34	Bipolar disorder and schizophrenia;	chr15:62052478	chr15:62060503~62062434:+
PCPG	cis	rs561341	0.941	rs8066156	ENSG00000265798.5	RP11-271K11.5	4.49	1.42e-05	0.0068	0.59	0.34	Hip circumference adjusted for BMI;	chr17:32034610	chr17:31038575~31059121:-
PCPG	cis	rs11673344	0.504	rs1667378	ENSG00000226686.6	LINC01535	4.49	1.42e-05	0.0068	0.45	0.34	Obesity-related traits;	chr19:37001171	chr19:37251912~37265535:+
PCPG	cis	rs17772222	0.92	rs61975260	ENSG00000222990.1	RNU4-22P	4.49	1.42e-05	0.00681	0.47	0.34	Coronary artery calcification;	chr14:88429597	chr14:88513498~88513663:+
PCPG	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	4.49	1.42e-05	0.00681	0.39	0.34	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
PCPG	cis	rs394563	0.601	rs431978	ENSG00000231760.4	RP11-350J20.5	-4.49	1.42e-05	0.00681	-0.41	-0.34	Dupuytren's disease;	chr6:149471864	chr6:149796151~149826294:-
PCPG	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	4.49	1.42e-05	0.00681	0.4	0.34	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
PCPG	cis	rs60695258	0.55	rs4693798	ENSG00000251411.1	RP11-397E7.4	4.49	1.42e-05	0.00681	0.32	0.34	Hematocrit;	chr4:86993136	chr4:86913266~86914817:-
PCPG	cis	rs60695258	0.55	rs4693800	ENSG00000251411.1	RP11-397E7.4	4.49	1.42e-05	0.00681	0.32	0.34	Hematocrit;	chr4:86994468	chr4:86913266~86914817:-
PCPG	cis	rs1003719	0.715	rs2251952	ENSG00000228677.1	TTC3-AS1	-4.49	1.42e-05	0.00682	-0.44	-0.34	Eye color traits;	chr21:37187410	chr21:37187666~37193926:-
PCPG	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	4.49	1.43e-05	0.00682	0.47	0.34	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	4.49	1.43e-05	0.00682	0.47	0.34	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	4.49	1.43e-05	0.00682	0.47	0.34	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	4.49	1.43e-05	0.00682	0.47	0.34	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
PCPG	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-4.49	1.43e-05	0.00683	-0.4	-0.34	Height;	chr5:37053881	chr5:36666214~36725195:-
PCPG	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-4.49	1.43e-05	0.00683	-0.46	-0.34	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
PCPG	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-4.49	1.43e-05	0.00683	-0.39	-0.34	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
PCPG	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-4.49	1.43e-05	0.00683	-0.39	-0.34	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
PCPG	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	4.49	1.43e-05	0.00684	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
PCPG	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-4.49	1.43e-05	0.00684	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
PCPG	cis	rs2911132	1	rs2549803	ENSG00000248734.2	CTD-2260A17.1	4.49	1.43e-05	0.00685	0.36	0.34	Urate levels (BMI interaction);	chr5:96839226	chr5:96784777~96785999:+
PCPG	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	4.49	1.43e-05	0.00685	0.36	0.34	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
PCPG	cis	rs7017914	0.818	rs13252808	ENSG00000254031.4	RP11-326E22.1	4.49	1.43e-05	0.00685	0.33	0.34	Bone mineral density;	chr8:70704420	chr8:71155457~71204223:+
PCPG	cis	rs853679	0.882	rs9468300	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.00685	0.66	0.34	Depression;	chr6:28159062	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.825	rs8180562	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.00685	0.66	0.34	Depression;	chr6:28173682	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.882	rs9380064	ENSG00000216901.1	AL022393.7	4.49	1.43e-05	0.00685	0.66	0.34	Depression;	chr6:28175340	chr6:28176188~28176674:+
PCPG	cis	rs12681963	0.61	rs75739606	ENSG00000248159.1	HSPA8P11	4.49	1.43e-05	0.00686	0.65	0.34	Migraine;	chr8:30178768	chr8:30237382~30240997:+
PCPG	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-4.49	1.43e-05	0.00686	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
PCPG	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	4.49	1.43e-05	0.00686	0.35	0.34	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
PCPG	cis	rs964611	0.706	rs11070638	ENSG00000259488.2	RP11-154J22.1	4.49	1.44e-05	0.00686	0.33	0.34	Metabolite levels (Pyroglutamine);	chr15:48371906	chr15:48312353~48331856:-
PCPG	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-4.49	1.44e-05	0.00686	-0.33	-0.34	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
PCPG	cis	rs7789940	0.904	rs56919252	ENSG00000186704.9	DTX2P1	4.49	1.44e-05	0.00687	0.43	0.34	Multiple sclerosis;	chr7:76308203	chr7:76978617~77004308:+
PCPG	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	4.49	1.44e-05	0.00688	0.38	0.34	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
PCPG	cis	rs7746199	0.736	rs58616630	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13212093	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs34038546	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28115628~28116551:+
PCPG	cis	rs141342723	1	rs141342723	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs34543938	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs56405707	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13210634	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13215275	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs17749927	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13192965	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28115628~28116551:+
PCPG	cis	rs45509595	0.556	rs34409918	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Breast cancer;	chr6:27717569	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13212318	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13202291	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs17750424	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13193542	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13193480	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.673	rs72847313	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.611	rs17750747	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28115628~28116551:+
PCPG	cis	rs45509595	0.841	rs17751184	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Breast cancer;	chr6:27807250	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs67101035	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27831109	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.556	rs34706883	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27837477	chr6:28115628~28116551:+
PCPG	cis	rs67340775	0.748	rs13212651	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Lung cancer in ever smokers;	chr6:27839207	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs35819751	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27842791	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13194781	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27847861	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs36116761	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27850704	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs34194357	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27850757	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13199772	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27866307	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13199906	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27866361	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs17763089	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27867440	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs17695758	ENSG00000219392.1	RP1-265C24.5	-4.49	1.44e-05	0.00688	-0.75	-0.34	Depression;	chr6:27869405	chr6:28115628~28116551:+
PCPG	cis	rs7017914	0.582	rs7012796	ENSG00000254031.4	RP11-326E22.1	4.49	1.44e-05	0.00688	0.32	0.34	Bone mineral density;	chr8:70763958	chr8:71155457~71204223:+
PCPG	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-4.49	1.44e-05	0.00688	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-4.49	1.44e-05	0.00688	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
PCPG	cis	rs17507216	0.609	rs1431716	ENSG00000228141.5	AC105339.1	-4.49	1.44e-05	0.00689	-0.53	-0.34	Excessive daytime sleepiness;	chr15:82676180	chr15:82710471~82714026:-
PCPG	cis	rs1440410	0.835	rs7693583	ENSG00000250326.1	RP11-284M14.1	4.48	1.44e-05	0.00689	0.32	0.34	Ischemic stroke;	chr4:143130189	chr4:142933195~143184861:-
PCPG	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-4.48	1.44e-05	0.00689	-0.46	-0.34	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-4.48	1.44e-05	0.00689	-0.46	-0.34	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
PCPG	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-4.48	1.44e-05	0.00689	-0.41	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
PCPG	cis	rs7819412	0.806	rs2409689	ENSG00000255020.1	AF131216.5	-4.48	1.44e-05	0.00689	-0.51	-0.34	Triglycerides;	chr8:11075358	chr8:11345748~11347502:-
PCPG	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	4.48	1.44e-05	0.0069	0.51	0.34	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
PCPG	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	4.48	1.44e-05	0.0069	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
PCPG	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-4.48	1.44e-05	0.0069	-0.42	-0.34	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
PCPG	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	4.48	1.44e-05	0.0069	0.41	0.34	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
PCPG	cis	rs1150668	0.83	rs2531831	ENSG00000219392.1	RP1-265C24.5	-4.48	1.44e-05	0.0069	-0.41	-0.34	Pubertal anthropometrics;	chr6:28420988	chr6:28115628~28116551:+
PCPG	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	4.48	1.45e-05	0.0069	0.43	0.34	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
PCPG	cis	rs2898290	0.592	rs2736342	ENSG00000254774.1	RP11-148O21.3	-4.48	1.45e-05	0.0069	-0.39	-0.34	Systolic blood pressure;	chr8:11489780	chr8:11553224~11554207:-
PCPG	cis	rs4671400	0.571	rs6738482	ENSG00000270820.4	RP11-355B11.2	-4.48	1.45e-05	0.00691	-0.49	-0.34	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267766	chr2:61471188~61484130:+
PCPG	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	4.48	1.45e-05	0.00691	0.45	0.34	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
PCPG	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	4.48	1.45e-05	0.00691	0.39	0.34	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	4.48	1.45e-05	0.00691	0.39	0.34	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-4.48	1.45e-05	0.00691	-0.39	-0.34	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
PCPG	cis	rs180358	0.509	rs1263057	ENSG00000280143.1	AP000892.6	4.48	1.45e-05	0.00692	0.36	0.34	Multiple sclerosis (severity);	chr11:116705038	chr11:117204967~117210292:+
PCPG	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	4.48	1.45e-05	0.00692	0.63	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
PCPG	cis	rs6840258	0.628	rs9715807	ENSG00000251411.1	RP11-397E7.4	4.48	1.45e-05	0.00693	0.34	0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86991479	chr4:86913266~86914817:-
PCPG	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-4.48	1.45e-05	0.00693	-0.45	-0.34	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
PCPG	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-4.48	1.45e-05	0.00693	-0.45	-0.34	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
PCPG	cis	rs73607972	0.518	rs35618081	ENSG00000275191.1	RP11-36I17.2	-4.48	1.45e-05	0.00693	-0.49	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53536855	chr16:53628256~53628816:-
PCPG	cis	rs11858159	0.871	rs12905055	ENSG00000259905.4	PWRN1	4.48	1.45e-05	0.00693	0.39	0.34	Platelet thrombus formation;	chr15:24568183	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.871	rs11853495	ENSG00000259905.4	PWRN1	4.48	1.45e-05	0.00693	0.39	0.34	Platelet thrombus formation;	chr15:24568187	chr15:24493137~24652130:+
PCPG	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-4.48	1.45e-05	0.00693	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-4.48	1.45e-05	0.00693	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-4.48	1.45e-05	0.00693	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-4.48	1.45e-05	0.00693	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
PCPG	cis	rs16949788	0.59	rs75625666	ENSG00000261351.2	CTD-3185P2.1	-4.48	1.45e-05	0.00693	-0.71	-0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66561001	chr15:66488658~66492109:-
PCPG	cis	rs2243480	1	rs34815098	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65827267	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs7456042	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65834791	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35735127	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65835436	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34703416	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65835655	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs35256305	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65841418	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs73142121	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65846219	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs34004500	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65847191	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35825738	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65853040	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34702770	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65879836	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs35480979	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65892097	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34637256	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65895144	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35391607	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65895842	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs13220979	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65898217	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34974928	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65899019	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs67728539	ENSG00000230189.5	GS1-124K5.2	4.48	1.45e-05	0.00693	0.53	0.34	Diabetic kidney disease;	chr7:65913137	chr7:66409143~66490059:-
PCPG	cis	rs7402241	0.764	rs73371733	ENSG00000207063.1	SNORD116-1	4.48	1.46e-05	0.00694	0.66	0.34	Residual cognition;	chr15:25537900	chr15:25051477~25051571:+
PCPG	cis	rs7402241	0.764	rs112107083	ENSG00000207063.1	SNORD116-1	4.48	1.46e-05	0.00694	0.66	0.34	Residual cognition;	chr15:25539132	chr15:25051477~25051571:+
PCPG	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-4.48	1.46e-05	0.00695	-0.44	-0.34	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
PCPG	cis	rs7759001	0.857	rs2206252	ENSG00000271755.1	RP1-153G14.4	4.48	1.46e-05	0.00695	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27390683	chr6:27404010~27406964:-
PCPG	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-4.48	1.46e-05	0.00695	-0.46	-0.34	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-4.48	1.46e-05	0.00695	-0.46	-0.34	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
PCPG	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-4.48	1.46e-05	0.00695	-0.49	-0.34	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
PCPG	cis	rs5760092	0.618	rs4461358	ENSG00000231271.1	AP000350.8	-4.48	1.46e-05	0.00695	-0.46	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23949918~23954042:+
PCPG	cis	rs2440129	0.591	rs312466	ENSG00000262089.1	RP11-589P10.5	-4.48	1.46e-05	0.00695	-0.25	-0.34	Tonsillectomy;	chr17:6995902	chr17:6994642~6995189:-
PCPG	cis	rs340630	0.967	rs13126334	ENSG00000251411.1	RP11-397E7.4	4.48	1.46e-05	0.00696	0.32	0.34	Systemic lupus erythematosus;	chr4:86988738	chr4:86913266~86914817:-
PCPG	cis	rs748404	0.626	rs62021176	ENSG00000249839.1	AC011330.5	-4.48	1.46e-05	0.00696	-0.46	-0.34	Lung cancer;	chr15:43388014	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs35158584	ENSG00000249839.1	AC011330.5	-4.48	1.46e-05	0.00696	-0.46	-0.34	Lung cancer;	chr15:43392876	chr15:43663654~43684339:-
PCPG	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-4.48	1.46e-05	0.00696	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
PCPG	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	4.48	1.46e-05	0.00696	0.52	0.34	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
PCPG	cis	rs7824557	0.713	rs9286062	ENSG00000255020.1	AF131216.5	-4.48	1.46e-05	0.00696	-0.44	-0.34	Retinal vascular caliber;	chr8:11261018	chr8:11345748~11347502:-
PCPG	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-4.48	1.46e-05	0.00697	-0.41	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
PCPG	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	4.48	1.46e-05	0.00697	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	4.48	1.46e-05	0.00697	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	4.48	1.46e-05	0.00697	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
PCPG	cis	rs2921036	0.505	rs35190619	ENSG00000173295.6	FAM86B3P	4.48	1.46e-05	0.00697	0.43	0.34	Neuroticism;	chr8:8504313	chr8:8228595~8244865:+
PCPG	cis	rs4671400	0.516	rs62152277	ENSG00000270820.4	RP11-355B11.2	-4.48	1.47e-05	0.00699	-0.49	-0.34	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61276269	chr2:61471188~61484130:+
PCPG	cis	rs75804782	0.572	rs111233411	ENSG00000227107.1	AC096574.5	-4.48	1.47e-05	0.00699	-0.62	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238380400	chr2:237612977~237626525:+
PCPG	cis	rs7182621	0.509	rs12917012	ENSG00000259363.4	CTD-2054N24.2	-4.48	1.47e-05	0.007	-0.42	-0.34	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99807023~99877148:+
PCPG	cis	rs7017914	0.69	rs6991708	ENSG00000254031.4	RP11-326E22.1	4.48	1.47e-05	0.007	0.32	0.34	Bone mineral density;	chr8:70756293	chr8:71155457~71204223:+
PCPG	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	4.48	1.47e-05	0.00701	0.57	0.34	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	4.48	1.47e-05	0.00701	0.57	0.34	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
PCPG	cis	rs1159787	0.606	rs7026576	ENSG00000233569.1	RP11-500B12.1	-4.48	1.47e-05	0.00701	-0.5	-0.34	Blood protein levels;	chr9:117636142	chr9:117648606~117657027:+
PCPG	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-4.48	1.47e-05	0.00701	-0.48	-0.34	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
PCPG	cis	rs4432245	0.793	rs711906	ENSG00000248508.5	SRP14-AS1	-4.48	1.48e-05	0.00702	-0.56	-0.34	Body mass index;	chr15:40033490	chr15:40039311~40067290:+
PCPG	cis	rs3736858	0.825	rs3759445	ENSG00000261105.4	LMO7-AS1	-4.48	1.48e-05	0.00702	-0.61	-0.34	Interleukin-9 levels;	chr13:75816090	chr13:75604700~75635994:-
PCPG	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	4.48	1.48e-05	0.00702	0.36	0.34	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
PCPG	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-4.48	1.48e-05	0.00703	-0.59	-0.34	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
PCPG	cis	rs10435719	0.899	rs11250177	ENSG00000255495.1	AC145124.2	4.48	1.48e-05	0.00703	0.35	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:12194467~12196280:+
PCPG	cis	rs17684571	0.7	rs35642890	ENSG00000231441.1	RP11-472M19.2	4.48	1.48e-05	0.00703	0.54	0.34	Schizophrenia;	chr6:56809919	chr6:56844002~56864078:+
PCPG	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-4.48	1.48e-05	0.00703	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
PCPG	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	4.48	1.48e-05	0.00703	0.6	0.34	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	4.48	1.48e-05	0.00703	0.6	0.34	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
PCPG	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-4.48	1.48e-05	0.00704	-0.44	-0.34	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
PCPG	cis	rs7746199	0.736	rs34064842	ENSG00000219392.1	RP1-265C24.5	-4.48	1.48e-05	0.00704	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.673	rs35501037	ENSG00000219392.1	RP1-265C24.5	-4.48	1.48e-05	0.00704	-0.75	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28115628~28116551:+
PCPG	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	4.48	1.48e-05	0.00705	0.45	0.34	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
PCPG	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	4.48	1.48e-05	0.00705	0.41	0.34	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
PCPG	cis	rs1949733	1	rs1949733	ENSG00000205959.3	RP11-689P11.2	4.48	1.49e-05	0.00706	0.4	0.34	Response to antineoplastic agents;	chr4:8501632	chr4:8482270~8512610:+
PCPG	cis	rs899997	1	rs7182993	ENSG00000261143.1	ADAMTS7P3	4.48	1.49e-05	0.00707	0.41	0.34	Coronary artery disease or large artery stroke;	chr15:78752672	chr15:77976042~77993057:+
PCPG	cis	rs899997	1	rs7182694	ENSG00000261143.1	ADAMTS7P3	4.48	1.49e-05	0.00707	0.41	0.34	Coronary artery disease or large artery stroke;	chr15:78752688	chr15:77976042~77993057:+
PCPG	cis	rs5743030	0.51	rs256542	ENSG00000253559.1	OSGEPL1-AS1	-4.48	1.49e-05	0.00707	-0.53	-0.34	Subcutaneous adipose tissue;	chr2:189892233	chr2:189762704~189765556:+
PCPG	cis	rs5743030	0.702	rs256541	ENSG00000253559.1	OSGEPL1-AS1	-4.48	1.49e-05	0.00707	-0.53	-0.34	Subcutaneous adipose tissue;	chr2:189893216	chr2:189762704~189765556:+
PCPG	cis	rs5743030	0.826	rs256540	ENSG00000253559.1	OSGEPL1-AS1	-4.48	1.49e-05	0.00707	-0.53	-0.34	Subcutaneous adipose tissue;	chr2:189893496	chr2:189762704~189765556:+
PCPG	cis	rs5743030	0.702	rs256539	ENSG00000253559.1	OSGEPL1-AS1	-4.48	1.49e-05	0.00707	-0.53	-0.34	Subcutaneous adipose tissue;	chr2:189894094	chr2:189762704~189765556:+
PCPG	cis	rs916888	0.647	rs199524	ENSG00000232300.1	FAM215B	-4.48	1.49e-05	0.00707	-0.45	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46558830~46562795:-
PCPG	cis	rs916888	0.647	rs199523	ENSG00000232300.1	FAM215B	-4.48	1.49e-05	0.00707	-0.45	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46558830~46562795:-
PCPG	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-4.48	1.49e-05	0.00708	-0.76	-0.34	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	4.48	1.49e-05	0.00708	0.76	0.34	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	4.48	1.49e-05	0.00708	0.76	0.34	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	4.48	1.49e-05	0.00708	0.76	0.34	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	4.48	1.49e-05	0.00708	0.76	0.34	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
PCPG	cis	rs17772222	0.917	rs61984708	ENSG00000222990.1	RNU4-22P	4.48	1.49e-05	0.00708	0.44	0.34	Coronary artery calcification;	chr14:88565523	chr14:88513498~88513663:+
PCPG	cis	rs1440410	0.835	rs11940580	ENSG00000250326.1	RP11-284M14.1	4.48	1.49e-05	0.00708	0.32	0.34	Ischemic stroke;	chr4:143240372	chr4:142933195~143184861:-
PCPG	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-4.48	1.49e-05	0.00709	-0.48	-0.34	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
PCPG	cis	rs748404	0.666	rs12900259	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43427369	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs34921640	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43429187	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs62020574	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43429380	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs16957730	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43438288	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs12913977	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43438913	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs12914122	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43438956	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs34697113	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43442041	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs12907870	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43453971	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs72709850	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43462486	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs12905220	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43465641	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs36078097	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43466209	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs7181783	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43469723	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs35903301	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43472332	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs34002293	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43472401	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs34181131	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43478527	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs7173383	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43480838	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs55801120	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43495042	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs12911740	ENSG00000205771.5	CATSPER2P1	-4.48	1.5e-05	0.00709	-0.44	-0.34	Lung cancer;	chr15:43498254	chr15:43726918~43747094:-
PCPG	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	4.48	1.5e-05	0.0071	0.44	0.34	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
PCPG	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-4.48	1.5e-05	0.0071	-0.42	-0.34	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
PCPG	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-4.48	1.5e-05	0.00711	-0.44	-0.34	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
PCPG	cis	rs7208859	0.623	rs7220289	ENSG00000263603.1	CTD-2349P21.5	-4.48	1.5e-05	0.00711	-0.56	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs55811708	ENSG00000263603.1	CTD-2349P21.5	-4.48	1.5e-05	0.00711	-0.56	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30729469~30731202:+
PCPG	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	4.48	1.5e-05	0.00712	0.39	0.34	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
PCPG	cis	rs964611	0.882	rs4630496	ENSG00000259488.2	RP11-154J22.1	-4.48	1.5e-05	0.00712	-0.34	-0.34	Metabolite levels (Pyroglutamine);	chr15:48366466	chr15:48312353~48331856:-
PCPG	cis	rs2974238	1	rs2913996	ENSG00000269656.1	CTD-2571L23.6	4.48	1.5e-05	0.00712	0.45	0.34	Parental longevity (mother's age at death);	chr19:47613437	chr19:47757036~47768840:-
PCPG	cis	rs2974238	1	rs2913995	ENSG00000269656.1	CTD-2571L23.6	4.48	1.5e-05	0.00712	0.45	0.34	Parental longevity (mother's age at death);	chr19:47613771	chr19:47757036~47768840:-
PCPG	cis	rs8098244	0.706	rs1154227	ENSG00000265752.2	RP11-403A21.1	-4.48	1.5e-05	0.00712	-0.41	-0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23901376	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.756	rs1154229	ENSG00000265752.2	RP11-403A21.1	-4.48	1.5e-05	0.00712	-0.41	-0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23902252	chr18:23957754~23982556:-
PCPG	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-4.47	1.5e-05	0.00712	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-4.47	1.5e-05	0.00712	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
PCPG	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	4.47	1.5e-05	0.00713	0.36	0.34	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
PCPG	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	4.47	1.51e-05	0.00714	0.34	0.34	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-4.47	1.51e-05	0.00714	-0.34	-0.34	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
PCPG	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-4.47	1.51e-05	0.00714	-0.4	-0.34	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
PCPG	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-4.47	1.51e-05	0.00714	-0.49	-0.34	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
PCPG	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-4.47	1.51e-05	0.00714	-0.49	-0.34	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
PCPG	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-4.47	1.51e-05	0.00714	-0.49	-0.34	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
PCPG	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	4.47	1.51e-05	0.00715	0.48	0.34	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
PCPG	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	4.47	1.51e-05	0.00715	0.37	0.34	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
PCPG	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-4.47	1.51e-05	0.00715	-0.68	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
PCPG	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	4.47	1.51e-05	0.00715	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
PCPG	cis	rs17772222	0.917	rs1998670	ENSG00000222990.1	RNU4-22P	4.47	1.51e-05	0.00715	0.47	0.34	Coronary artery calcification;	chr14:88504581	chr14:88513498~88513663:+
PCPG	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	4.47	1.51e-05	0.00715	0.47	0.34	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
PCPG	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	4.47	1.51e-05	0.00715	0.47	0.34	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
PCPG	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	4.47	1.51e-05	0.00715	0.47	0.34	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
PCPG	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	4.47	1.51e-05	0.00715	0.35	0.34	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
PCPG	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	4.47	1.51e-05	0.00715	0.46	0.34	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	4.47	1.51e-05	0.00715	0.46	0.34	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	4.47	1.51e-05	0.00715	0.46	0.34	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	4.47	1.51e-05	0.00715	0.46	0.34	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	4.47	1.51e-05	0.00715	0.46	0.34	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	4.47	1.51e-05	0.00715	0.46	0.34	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
PCPG	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-4.47	1.51e-05	0.00716	-0.44	-0.34	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
PCPG	cis	rs4671400	0.571	rs4672428	ENSG00000270820.4	RP11-355B11.2	-4.47	1.51e-05	0.00717	-0.49	-0.34	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61251362	chr2:61471188~61484130:+
PCPG	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-4.47	1.51e-05	0.00717	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
PCPG	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	4.47	1.51e-05	0.00717	0.38	0.34	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
PCPG	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	4.47	1.51e-05	0.00717	0.69	0.34	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	4.47	1.51e-05	0.00717	0.69	0.34	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
PCPG	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-4.47	1.52e-05	0.00717	-0.45	-0.34	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	4.47	1.52e-05	0.00717	0.45	0.34	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
PCPG	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	4.47	1.52e-05	0.00718	0.54	0.34	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
PCPG	cis	rs4671400	0.571	rs12615222	ENSG00000270820.4	RP11-355B11.2	-4.47	1.52e-05	0.00718	-0.49	-0.34	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267760	chr2:61471188~61484130:+
PCPG	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	4.47	1.52e-05	0.00718	0.45	0.34	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
PCPG	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	4.47	1.52e-05	0.00719	0.44	0.34	Height;	chr6:109470427	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	4.47	1.52e-05	0.00719	0.44	0.34	Height;	chr6:109470900	chr6:109382795~109383666:+
PCPG	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	4.47	1.52e-05	0.00719	0.52	0.34	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
PCPG	cis	rs7819412	0.807	rs4840542	ENSG00000255020.1	AF131216.5	-4.47	1.52e-05	0.00719	-0.49	-0.34	Triglycerides;	chr8:11087299	chr8:11345748~11347502:-
PCPG	cis	rs763014	0.932	rs2384974	ENSG00000262528.2	LA16c-349E10.1	4.47	1.52e-05	0.0072	0.41	0.34	Height;	chr16:601279	chr16:654611~656194:-
PCPG	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	4.47	1.52e-05	0.0072	0.46	0.34	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
PCPG	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	4.47	1.52e-05	0.0072	0.46	0.34	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
PCPG	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	4.47	1.52e-05	0.0072	0.38	0.34	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
PCPG	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	4.47	1.52e-05	0.0072	0.48	0.34	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
PCPG	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-4.47	1.52e-05	0.0072	-0.37	-0.34	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
PCPG	cis	rs2898290	0.622	rs978804	ENSG00000269954.1	RP11-148O21.6	-4.47	1.52e-05	0.00721	-0.38	-0.34	Systolic blood pressure;	chr8:11486164	chr8:11552488~11552991:-
PCPG	cis	rs9393777	0.844	rs28360634	ENSG00000219392.1	RP1-265C24.5	-4.47	1.52e-05	0.00721	-0.74	-0.34	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28115628~28116551:+
PCPG	cis	rs11148252	0.595	rs4884522	ENSG00000273784.3	RP11-78J21.7	-4.47	1.53e-05	0.00723	-0.33	-0.34	Lewy body disease;	chr13:52479633	chr13:52600042~52642542:+
PCPG	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-4.47	1.53e-05	0.00723	-0.51	-0.34	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
PCPG	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-4.47	1.53e-05	0.00723	-0.38	-0.34	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
PCPG	cis	rs2243480	1	rs313807	ENSG00000230189.5	GS1-124K5.2	4.47	1.53e-05	0.00723	0.52	0.34	Diabetic kidney disease;	chr7:66034494	chr7:66409143~66490059:-
PCPG	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	4.47	1.53e-05	0.00724	0.5	0.34	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
PCPG	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	4.47	1.53e-05	0.00724	0.69	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
PCPG	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	4.47	1.53e-05	0.00724	0.69	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
PCPG	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	4.47	1.53e-05	0.00724	0.69	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
PCPG	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	4.47	1.53e-05	0.00724	0.69	0.34	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
PCPG	cis	rs7017914	0.69	rs11989644	ENSG00000254031.4	RP11-326E22.1	4.47	1.53e-05	0.00724	0.32	0.34	Bone mineral density;	chr8:70728961	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.568	rs13272884	ENSG00000254031.4	RP11-326E22.1	4.47	1.53e-05	0.00724	0.32	0.34	Bone mineral density;	chr8:70729413	chr8:71155457~71204223:+
PCPG	cis	rs1908814	0.516	rs11996277	ENSG00000255495.1	AC145124.2	4.47	1.53e-05	0.00724	0.35	0.34	Neuroticism;	chr8:11942522	chr8:12194467~12196280:+
PCPG	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	4.47	1.53e-05	0.00724	0.45	0.34	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
PCPG	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	4.47	1.53e-05	0.00724	0.52	0.34	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
PCPG	cis	rs2235642	0.717	rs2236269	ENSG00000260989.1	LA16c-395F10.2	-4.47	1.53e-05	0.00725	-0.36	-0.34	Coronary artery disease;	chr16:1602613	chr16:1580527~1610328:+
PCPG	cis	rs10899021	0.92	rs11236181	ENSG00000279353.1	RP11-864N7.4	4.47	1.54e-05	0.00726	0.61	0.34	Response to metformin (IC50);	chr11:74634778	chr11:74698231~74699658:-
PCPG	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-4.47	1.54e-05	0.00726	-0.47	-0.34	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
PCPG	cis	rs964611	0.882	rs8027003	ENSG00000259488.2	RP11-154J22.1	-4.47	1.54e-05	0.00726	-0.35	-0.34	Metabolite levels (Pyroglutamine);	chr15:48355229	chr15:48312353~48331856:-
PCPG	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-4.47	1.54e-05	0.00726	-0.4	-0.34	Height;	chr5:37022673	chr5:36666214~36725195:-
PCPG	cis	rs12079745	0.623	rs12091844	ENSG00000234604.2	RP1-206D15.5	4.47	1.54e-05	0.00728	0.68	0.34	QT interval;	chr1:169464035	chr1:169474060~169474159:-
PCPG	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	4.47	1.54e-05	0.00728	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
PCPG	cis	rs10435719	0.902	rs11250179	ENSG00000255495.1	AC145124.2	4.47	1.54e-05	0.00728	0.35	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:12194467~12196280:+
PCPG	cis	rs9393777	0.92	rs35120058	ENSG00000219392.1	RP1-265C24.5	-4.47	1.54e-05	0.00729	-0.73	-0.34	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28115628~28116551:+
PCPG	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-4.47	1.54e-05	0.00729	-0.39	-0.34	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
PCPG	cis	rs899997	0.862	rs8032552	ENSG00000261143.1	ADAMTS7P3	-4.47	1.54e-05	0.00729	-0.42	-0.34	Coronary artery disease or large artery stroke;	chr15:78678794	chr15:77976042~77993057:+
PCPG	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	4.47	1.55e-05	0.00731	0.43	0.34	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
PCPG	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	4.47	1.55e-05	0.00732	0.39	0.34	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
PCPG	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-4.47	1.55e-05	0.00732	-0.44	-0.34	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-4.47	1.55e-05	0.00732	-0.44	-0.34	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
PCPG	cis	rs8098244	0.516	rs1711451	ENSG00000265752.2	RP11-403A21.1	4.47	1.55e-05	0.00732	0.41	0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690470	chr18:23957754~23982556:-
PCPG	cis	rs6121246	0.58	rs6121016	ENSG00000230613.1	HM13-AS1	4.47	1.55e-05	0.00733	0.5	0.34	Mean corpuscular hemoglobin;	chr20:31657436	chr20:31567707~31573263:-
PCPG	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	4.47	1.55e-05	0.00733	0.47	0.34	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
PCPG	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	4.47	1.55e-05	0.00734	0.53	0.34	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
PCPG	cis	rs891378	0.785	rs1346720	ENSG00000274245.1	RP11-357P18.2	4.47	1.55e-05	0.00734	0.43	0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207214421	chr1:207372559~207373252:+
PCPG	cis	rs7208859	0.623	rs8082537	ENSG00000266490.1	CTD-2349P21.9	4.47	1.55e-05	0.00734	0.45	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.561	rs11655876	ENSG00000266490.1	CTD-2349P21.9	4.47	1.55e-05	0.00734	0.45	0.34	Body mass index;	chr17:30690132	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs9907197	ENSG00000266490.1	CTD-2349P21.9	4.47	1.55e-05	0.00734	0.45	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs9915963	ENSG00000266490.1	CTD-2349P21.9	4.47	1.55e-05	0.00734	0.45	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30792372~30792833:+
PCPG	cis	rs10760158	0.832	rs10760166	ENSG00000226752.6	PSMD5-AS1	-4.47	1.56e-05	0.00734	-0.45	-0.34	Pulse pressure;	chr9:121264336	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10985194	ENSG00000226752.6	PSMD5-AS1	-4.47	1.56e-05	0.00734	-0.45	-0.34	Pulse pressure;	chr9:121265434	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10818523	ENSG00000226752.6	PSMD5-AS1	-4.47	1.56e-05	0.00734	-0.45	-0.34	Pulse pressure;	chr9:121265809	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs10818524	ENSG00000226752.6	PSMD5-AS1	-4.47	1.56e-05	0.00734	-0.45	-0.34	Pulse pressure;	chr9:121267901	chr9:120824828~120854385:+
PCPG	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	4.47	1.56e-05	0.00734	0.43	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
PCPG	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-4.47	1.56e-05	0.00735	-0.45	-0.34	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
PCPG	cis	rs11858159	0.967	rs80040713	ENSG00000259905.4	PWRN1	4.47	1.56e-05	0.00737	0.4	0.34	Platelet thrombus formation;	chr15:24554036	chr15:24493137~24652130:+
PCPG	cis	rs2836974	0.799	rs13047550	ENSG00000252915.1	Y_RNA	-4.47	1.56e-05	0.00737	-0.38	-0.34	Cognitive function;	chr21:39143569	chr21:39344537~39344628:+
PCPG	cis	rs453301	0.506	rs476845	ENSG00000173295.6	FAM86B3P	4.46	1.57e-05	0.00738	0.39	0.34	Joint mobility (Beighton score);	chr8:8765367	chr8:8228595~8244865:+
PCPG	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	4.46	1.57e-05	0.00738	0.5	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
PCPG	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-4.46	1.57e-05	0.00739	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-4.46	1.57e-05	0.00739	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-4.46	1.57e-05	0.00739	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
PCPG	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	4.46	1.57e-05	0.00739	0.37	0.34	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
PCPG	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	4.46	1.57e-05	0.0074	0.49	0.34	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	4.46	1.57e-05	0.0074	0.49	0.34	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	4.46	1.57e-05	0.0074	0.49	0.34	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
PCPG	cis	rs300890	1	rs300904	ENSG00000250326.1	RP11-284M14.1	-4.46	1.57e-05	0.0074	-0.31	-0.34	Nasopharyngeal carcinoma;	chr4:143318672	chr4:142933195~143184861:-
PCPG	cis	rs561341	1	rs1557731	ENSG00000265798.5	RP11-271K11.5	4.46	1.57e-05	0.0074	0.6	0.34	Hip circumference adjusted for BMI;	chr17:31994548	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs537166	ENSG00000265798.5	RP11-271K11.5	4.46	1.57e-05	0.0074	0.6	0.34	Hip circumference adjusted for BMI;	chr17:31999808	chr17:31038575~31059121:-
PCPG	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-4.46	1.57e-05	0.0074	-0.45	-0.34	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
PCPG	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	4.46	1.57e-05	0.00742	0.36	0.34	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
PCPG	cis	rs2228479	0.85	rs11640336	ENSG00000268218.1	AC137932.4	-4.46	1.57e-05	0.00742	-0.47	-0.34	Skin colour saturation;	chr16:89874745	chr16:89268104~89273044:+
PCPG	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	4.46	1.58e-05	0.00744	0.42	0.34	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	4.46	1.58e-05	0.00745	0.42	0.34	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
PCPG	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	4.46	1.58e-05	0.00745	0.47	0.34	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
PCPG	cis	rs7759001	0.857	rs1022515	ENSG00000271755.1	RP1-153G14.4	4.46	1.58e-05	0.00745	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27398028	chr6:27404010~27406964:-
PCPG	cis	rs498136	0.55	rs672488	ENSG00000254495.1	AP000487.4	4.46	1.58e-05	0.00745	0.38	0.34	Cutaneous malignant melanoma;Melanoma;	chr11:69591232	chr11:70358198~70358677:-
PCPG	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	4.46	1.58e-05	0.00746	0.46	0.34	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
PCPG	cis	rs758324	0.58	rs35566767	ENSG00000233006.5	AC034220.3	-4.46	1.58e-05	0.00746	-0.5	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132270356	chr5:132311285~132369916:-
PCPG	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	4.46	1.58e-05	0.00746	0.46	0.34	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	4.46	1.58e-05	0.00746	0.46	0.34	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	4.46	1.58e-05	0.00746	0.46	0.34	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
PCPG	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-4.46	1.59e-05	0.00747	-0.52	-0.34	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
PCPG	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-4.46	1.59e-05	0.00748	-0.48	-0.34	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
PCPG	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-4.46	1.59e-05	0.00748	-0.48	-0.34	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
PCPG	cis	rs2625529	0.526	rs8031386	ENSG00000260037.4	CTD-2524L6.3	-4.46	1.59e-05	0.00748	-0.44	-0.34	Red blood cell count;	chr15:72216458	chr15:71818396~71823384:+
PCPG	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	4.46	1.59e-05	0.00748	0.52	0.34	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
PCPG	cis	rs34421088	0.56	rs2248699	ENSG00000269954.1	RP11-148O21.6	-4.46	1.59e-05	0.00748	-0.39	-0.34	Neuroticism;	chr8:11536255	chr8:11552488~11552991:-
PCPG	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	4.46	1.59e-05	0.00748	0.44	0.34	Height;	chr4:57019797	chr4:56960927~56961373:-
PCPG	cis	rs28386778	0.897	rs6504177	ENSG00000240280.5	TCAM1P	-4.46	1.59e-05	0.00749	-0.45	-0.34	Prudent dietary pattern;	chr17:63735295	chr17:63849292~63864379:+
PCPG	cis	rs2281603	0.762	rs61987034	ENSG00000259116.1	RP11-973N13.4	-4.46	1.59e-05	0.00749	-0.32	-0.34	Lymphocyte counts;	chr14:64567405	chr14:64514154~64540368:-
PCPG	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	4.46	1.59e-05	0.0075	0.35	0.34	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
PCPG	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	4.46	1.59e-05	0.0075	0.49	0.34	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
PCPG	cis	rs12439619	0.693	rs4778989	ENSG00000228141.5	AC105339.1	-4.46	1.59e-05	0.0075	-0.5	-0.34	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82710471~82714026:-
PCPG	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	4.46	1.6e-05	0.00751	0.44	0.34	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	4.46	1.6e-05	0.00751	0.44	0.34	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
PCPG	cis	rs7894051	1	rs7074435	ENSG00000214279.11	SCART1	-4.46	1.6e-05	0.00751	-0.63	-0.34	Lifespan;	chr10:133377066	chr10:133453928~133523558:+
PCPG	cis	rs1692580	0.682	rs12045693	ENSG00000271806.1	RP5-892K4.1	-4.46	1.6e-05	0.00751	-0.37	-0.34	Coronary artery disease;	chr1:2274142	chr1:2141084~2145279:-
PCPG	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-4.46	1.6e-05	0.00751	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-4.46	1.6e-05	0.00751	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-4.46	1.6e-05	0.00751	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
PCPG	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-4.46	1.6e-05	0.00752	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-4.46	1.6e-05	0.00752	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
PCPG	cis	rs2836974	0.583	rs2776306	ENSG00000255568.3	BRWD1-AS2	4.46	1.6e-05	0.00753	0.34	0.34	Cognitive function;	chr21:39341828	chr21:39313935~39314962:+
PCPG	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.6e-05	0.00754	-0.44	-0.34	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.6e-05	0.00754	-0.44	-0.34	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
PCPG	cis	rs6579956	0.639	rs35963184	ENSG00000270978.1	RP11-54C4.2	-4.46	1.61e-05	0.00755	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152729563	chr5:151848886~151850791:+
PCPG	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	4.46	1.61e-05	0.00755	0.46	0.34	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	4.46	1.61e-05	0.00755	0.46	0.34	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	4.46	1.61e-05	0.00755	0.46	0.34	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
PCPG	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.61e-05	0.00755	-0.4	-0.34	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.61e-05	0.00755	-0.4	-0.34	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.61e-05	0.00755	-0.4	-0.34	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.61e-05	0.00755	-0.4	-0.34	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.61e-05	0.00755	-0.4	-0.34	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.61e-05	0.00755	-0.4	-0.34	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
PCPG	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	4.46	1.61e-05	0.00755	0.39	0.34	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
PCPG	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-4.46	1.61e-05	0.00756	-0.49	-0.34	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
PCPG	cis	rs5742933	0.817	rs3816196	ENSG00000273240.1	RP11-455J20.3	4.46	1.61e-05	0.00756	0.37	0.34	Ferritin levels;	chr2:189775749	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.817	rs6738042	ENSG00000273240.1	RP11-455J20.3	4.46	1.61e-05	0.00756	0.37	0.34	Ferritin levels;	chr2:189776958	chr2:189763859~189764456:-
PCPG	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	4.46	1.61e-05	0.00756	0.6	0.34	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
PCPG	cis	rs7789940	1	rs76024966	ENSG00000186704.9	DTX2P1	4.46	1.61e-05	0.00756	0.42	0.34	Multiple sclerosis;	chr7:76365704	chr7:76978617~77004308:+
PCPG	cis	rs5742933	0.744	rs13009889	ENSG00000273240.1	RP11-455J20.3	4.46	1.61e-05	0.00756	0.37	0.34	Ferritin levels;	chr2:189763842	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.75	rs10197331	ENSG00000273240.1	RP11-455J20.3	4.46	1.61e-05	0.00756	0.37	0.34	Ferritin levels;	chr2:189768112	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.817	rs1055091	ENSG00000273240.1	RP11-455J20.3	4.46	1.61e-05	0.00756	0.37	0.34	Ferritin levels;	chr2:189770417	chr2:189763859~189764456:-
PCPG	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-4.46	1.61e-05	0.00756	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
PCPG	cis	rs3947	0.951	rs1692819	ENSG00000227203.3	SUB1P1	-4.46	1.61e-05	0.00757	-0.53	-0.34	Blood protein levels;	chr8:11847939	chr8:11790005~11790386:+
PCPG	cis	rs10504130	0.569	rs60153173	ENSG00000272024.1	RP11-546K22.3	-4.46	1.61e-05	0.00757	-0.44	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51950284~51950690:+
PCPG	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	4.46	1.61e-05	0.00758	0.5	0.34	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
PCPG	cis	rs7945705	0.967	rs7943377	ENSG00000254860.4	TMEM9B-AS1	-4.46	1.61e-05	0.00758	-0.34	-0.34	Hemoglobin concentration;	chr11:8827153	chr11:8964675~8977527:+
PCPG	cis	rs7849782	0.702	rs10819990	ENSG00000225376.4	TMEM246-AS1	4.46	1.61e-05	0.00758	0.38	0.34	Coronary artery aneurysm in Kawasaki disease;	chr9:101772843	chr9:101468439~101481502:+
PCPG	cis	rs2274273	0.745	rs56262555	ENSG00000258413.1	RP11-665C16.6	-4.46	1.61e-05	0.00758	-0.43	-0.34	Protein biomarker;	chr14:55095244	chr14:55262767~55272075:-
PCPG	cis	rs2625529	0.556	rs8038007	ENSG00000260037.4	CTD-2524L6.3	4.46	1.62e-05	0.00758	0.43	0.34	Red blood cell count;	chr15:72275702	chr15:71818396~71823384:+
PCPG	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	4.46	1.62e-05	0.00758	0.39	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
PCPG	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-4.46	1.62e-05	0.00758	-0.45	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
PCPG	cis	rs2408955	0.522	rs3997	ENSG00000240399.1	RP1-228P16.1	-4.46	1.62e-05	0.00758	-0.36	-0.34	Glycated hemoglobin levels;	chr12:48087804	chr12:48054813~48055591:-
PCPG	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	4.46	1.62e-05	0.00759	0.44	0.34	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
PCPG	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-4.46	1.62e-05	0.00759	-0.47	-0.34	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
PCPG	cis	rs7017914	0.644	rs13251367	ENSG00000254031.4	RP11-326E22.1	4.46	1.62e-05	0.0076	0.34	0.34	Bone mineral density;	chr8:71089696	chr8:71155457~71204223:+
PCPG	cis	rs9303029	0.866	rs72857495	ENSG00000279744.1	RP13-20L14.10	-4.46	1.62e-05	0.00761	-0.44	-0.34	Protein quantitative trait loci;	chr17:82454991	chr17:82462601~82464255:+
PCPG	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-4.46	1.62e-05	0.00761	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
PCPG	cis	rs13108904	0.935	rs1620928	ENSG00000253399.1	AC078852.2	4.46	1.62e-05	0.00761	0.36	0.34	Obesity-related traits;	chr4:1285336	chr4:1358479~1359461:+
PCPG	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	4.46	1.62e-05	0.00761	0.51	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
PCPG	cis	rs2281603	0.517	rs10134770	ENSG00000259116.1	RP11-973N13.4	-4.46	1.62e-05	0.00761	-0.31	-0.34	Lymphocyte counts;	chr14:64596597	chr14:64514154~64540368:-
PCPG	cis	rs651907	0.557	rs13077925	ENSG00000244119.1	PDCL3P4	4.46	1.62e-05	0.00761	0.28	0.34	Colorectal cancer;	chr3:101769337	chr3:101712472~101713191:+
PCPG	cis	rs2440129	0.963	rs12325805	ENSG00000262089.1	RP11-589P10.5	-4.46	1.63e-05	0.00762	-0.27	-0.34	Tonsillectomy;	chr17:7008900	chr17:6994642~6995189:-
PCPG	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-4.46	1.63e-05	0.00763	-0.45	-0.34	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
PCPG	cis	rs6840258	0.689	rs340639	ENSG00000251411.1	RP11-397E7.4	4.46	1.63e-05	0.00764	0.33	0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87003827	chr4:86913266~86914817:-
PCPG	cis	rs7819412	0.668	rs2409721	ENSG00000255020.1	AF131216.5	-4.46	1.63e-05	0.00764	-0.44	-0.34	Triglycerides;	chr8:11180735	chr8:11345748~11347502:-
PCPG	cis	rs2625529	0.818	rs16956241	ENSG00000260037.4	CTD-2524L6.3	-4.46	1.63e-05	0.00764	-0.55	-0.34	Red blood cell count;	chr15:71819347	chr15:71818396~71823384:+
PCPG	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	4.46	1.63e-05	0.00764	0.42	0.34	Height;	chr6:109586733	chr6:109382795~109383666:+
PCPG	cis	rs9299346	0.594	rs10819971	ENSG00000225376.4	TMEM246-AS1	4.46	1.63e-05	0.00764	0.41	0.34	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101657314	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10819972	ENSG00000225376.4	TMEM246-AS1	4.46	1.63e-05	0.00764	0.41	0.34	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101657574	chr9:101468439~101481502:+
PCPG	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-4.46	1.63e-05	0.00764	-0.4	-0.34	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
PCPG	cis	rs853679	0.607	rs34243448	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28225324	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13204012	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28233753	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13205211	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28235278	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13208096	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28257533	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13207345	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28297795	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs72854513	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28298177	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs56189111	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28304196	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs35072899	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28313764	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs56075693	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28322551	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34218844	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28322870	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs35030260	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28337731	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13217619	ENSG00000219392.1	RP1-265C24.5	-4.45	1.63e-05	0.00764	-0.74	-0.34	Depression;	chr6:28338894	chr6:28115628~28116551:+
PCPG	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	4.45	1.63e-05	0.00765	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	4.45	1.63e-05	0.00765	0.48	0.34	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
PCPG	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	4.45	1.63e-05	0.00765	0.47	0.34	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
PCPG	cis	rs6957923	0.839	rs58201821	ENSG00000230658.1	KLHL7-AS1	4.45	1.64e-05	0.00766	0.4	0.34	Height;	chr7:23471241	chr7:23101228~23105703:-
PCPG	cis	rs6957923	0.818	rs10950949	ENSG00000230658.1	KLHL7-AS1	4.45	1.64e-05	0.00766	0.4	0.34	Height;	chr7:23479641	chr7:23101228~23105703:-
PCPG	cis	rs6957923	0.81	rs7779665	ENSG00000230658.1	KLHL7-AS1	4.45	1.64e-05	0.00766	0.4	0.34	Height;	chr7:23481344	chr7:23101228~23105703:-
PCPG	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-4.45	1.64e-05	0.00766	-0.42	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
PCPG	cis	rs657075	0.697	rs34754328	ENSG00000233006.5	AC034220.3	-4.45	1.64e-05	0.00766	-0.49	-0.34	Rheumatoid arthritis;	chr5:132352381	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.584	rs71583479	ENSG00000233006.5	AC034220.3	-4.45	1.64e-05	0.00766	-0.49	-0.34	Rheumatoid arthritis;	chr5:132356459	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs35809179	ENSG00000233006.5	AC034220.3	-4.45	1.64e-05	0.00766	-0.49	-0.34	Rheumatoid arthritis;	chr5:132359713	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583480	ENSG00000233006.5	AC034220.3	-4.45	1.64e-05	0.00766	-0.49	-0.34	Rheumatoid arthritis;	chr5:132360559	chr5:132311285~132369916:-
PCPG	cis	rs35934224	0.891	rs73148965	ENSG00000232926.1	AC000078.5	4.45	1.64e-05	0.00766	0.44	0.34	Glaucoma (primary open-angle);	chr22:19885412	chr22:19887289~19887970:+
PCPG	cis	rs17826219	0.636	rs12946563	ENSG00000263603.1	CTD-2349P21.5	-4.45	1.64e-05	0.00767	-0.56	-0.34	Body mass index;	chr17:30776148	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8081299	ENSG00000263603.1	CTD-2349P21.5	-4.45	1.64e-05	0.00767	-0.56	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs8068645	ENSG00000263603.1	CTD-2349P21.5	-4.45	1.64e-05	0.00767	-0.56	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30729469~30731202:+
PCPG	cis	rs17826219	0.706	rs2322197	ENSG00000263603.1	CTD-2349P21.5	-4.45	1.64e-05	0.00767	-0.56	-0.34	Body mass index;	chr17:30778787	chr17:30729469~30731202:+
PCPG	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	4.45	1.64e-05	0.00767	0.38	0.34	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
PCPG	cis	rs7824557	0.547	rs2409745	ENSG00000255020.1	AF131216.5	4.45	1.64e-05	0.00767	0.46	0.34	Retinal vascular caliber;	chr8:11219126	chr8:11345748~11347502:-
PCPG	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	4.45	1.64e-05	0.00767	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
PCPG	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-4.45	1.64e-05	0.00768	-0.47	-0.34	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-4.45	1.64e-05	0.00768	-0.47	-0.34	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-4.45	1.64e-05	0.00768	-0.47	-0.34	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
PCPG	cis	rs7017914	0.967	rs6993170	ENSG00000254031.4	RP11-326E22.1	4.45	1.64e-05	0.00768	0.33	0.34	Bone mineral density;	chr8:70781284	chr8:71155457~71204223:+
PCPG	cis	rs1048886	0.872	rs79339185	ENSG00000271967.1	RP11-134K13.4	-4.45	1.64e-05	0.00768	-0.44	-0.34	Type 2 diabetes;	chr6:70572379	chr6:70596438~70596980:+
PCPG	cis	rs1003719	0.715	rs8128387	ENSG00000228677.1	TTC3-AS1	-4.45	1.64e-05	0.00768	-0.42	-0.34	Eye color traits;	chr21:37184485	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.612	rs2835652	ENSG00000228677.1	TTC3-AS1	-4.45	1.64e-05	0.00768	-0.42	-0.34	Eye color traits;	chr21:37185106	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs2835653	ENSG00000228677.1	TTC3-AS1	-4.45	1.64e-05	0.00768	-0.42	-0.34	Eye color traits;	chr21:37186335	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs9980353	ENSG00000228677.1	TTC3-AS1	-4.45	1.64e-05	0.00768	-0.42	-0.34	Eye color traits;	chr21:37186511	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs6517405	ENSG00000228677.1	TTC3-AS1	-4.45	1.64e-05	0.00768	-0.42	-0.34	Eye color traits;	chr21:37188033	chr21:37187666~37193926:-
PCPG	cis	rs8098244	0.516	rs7236486	ENSG00000265752.2	RP11-403A21.1	4.45	1.64e-05	0.00768	0.41	0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23685001	chr18:23957754~23982556:-
PCPG	cis	rs7759001	0.817	rs10080571	ENSG00000271755.1	RP1-153G14.4	4.45	1.64e-05	0.00769	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27395371	chr6:27404010~27406964:-
PCPG	cis	rs3947	0.906	rs709822	ENSG00000255556.2	RP11-351I21.6	-4.45	1.64e-05	0.00769	-0.39	-0.34	Blood protein levels;	chr8:11844804	chr8:12378679~12380265:-
PCPG	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-4.45	1.65e-05	0.0077	-0.35	-0.34	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
PCPG	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	4.45	1.65e-05	0.0077	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	4.45	1.65e-05	0.0077	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	4.45	1.65e-05	0.0077	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
PCPG	cis	rs17684571	0.751	rs6934714	ENSG00000231441.1	RP11-472M19.2	4.45	1.65e-05	0.00771	0.55	0.34	Schizophrenia;	chr6:56821811	chr6:56844002~56864078:+
PCPG	cis	rs2836974	0.583	rs2735307	ENSG00000255568.3	BRWD1-AS2	4.45	1.65e-05	0.00771	0.34	0.34	Cognitive function;	chr21:39341432	chr21:39313935~39314962:+
PCPG	cis	rs2625529	0.824	rs12899485	ENSG00000260037.4	CTD-2524L6.3	4.45	1.65e-05	0.00771	0.51	0.34	Red blood cell count;	chr15:71850874	chr15:71818396~71823384:+
PCPG	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	4.45	1.65e-05	0.00772	0.44	0.34	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
PCPG	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	4.45	1.65e-05	0.00773	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
PCPG	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-4.45	1.65e-05	0.00773	-0.78	-0.34	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-4.45	1.65e-05	0.00773	-0.78	-0.34	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-4.45	1.65e-05	0.00773	-0.78	-0.34	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
PCPG	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	4.45	1.65e-05	0.00773	0.45	0.34	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
PCPG	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-4.45	1.65e-05	0.00773	-0.45	-0.34	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
PCPG	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	4.45	1.66e-05	0.00773	0.48	0.34	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
PCPG	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	4.45	1.66e-05	0.00774	0.44	0.34	Height;	chr6:109477209	chr6:109382795~109383666:+
PCPG	cis	rs412050	0.744	rs238781	ENSG00000224086.5	LL22NC03-86G7.1	-4.45	1.66e-05	0.00774	-0.5	-0.34	Attention deficit hyperactivity disorder;	chr22:21987474	chr22:21938293~21977632:+
PCPG	cis	rs412050	0.793	rs238782	ENSG00000224086.5	LL22NC03-86G7.1	-4.45	1.66e-05	0.00774	-0.5	-0.34	Attention deficit hyperactivity disorder;	chr22:21987595	chr22:21938293~21977632:+
PCPG	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-4.45	1.66e-05	0.00774	-0.53	-0.34	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-4.45	1.66e-05	0.00774	-0.53	-0.34	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-4.45	1.66e-05	0.00774	-0.53	-0.34	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-4.45	1.66e-05	0.00774	-0.53	-0.34	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-4.45	1.66e-05	0.00774	-0.53	-0.34	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
PCPG	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	4.45	1.66e-05	0.00775	0.46	0.34	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	4.45	1.66e-05	0.00775	0.46	0.34	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	4.45	1.66e-05	0.00775	0.46	0.34	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
PCPG	cis	rs4489787	0.764	rs2705162	ENSG00000240399.1	RP1-228P16.1	4.45	1.66e-05	0.00775	0.45	0.34	Prostate cancer (SNP x SNP interaction);	chr12:48504734	chr12:48054813~48055591:-
PCPG	cis	rs357618	1	rs441652	ENSG00000260581.1	CTB-113P19.4	4.45	1.66e-05	0.00775	0.4	0.34	Basophil percentage of white cells;	chr5:151467944	chr5:151652275~151655449:+
PCPG	cis	rs8030379	1	rs4842924	ENSG00000230373.7	GOLGA6L5P	4.45	1.66e-05	0.00776	0.34	0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84507885~84516814:-
PCPG	cis	rs12908161	0.96	rs11633450	ENSG00000259295.5	CSPG4P12	4.45	1.66e-05	0.00776	0.53	0.34	Schizophrenia;	chr15:84764056	chr15:85191438~85213905:+
PCPG	cis	rs6674176	0.66	rs2108202	ENSG00000237950.1	RP11-7O11.3	-4.45	1.66e-05	0.00776	-0.39	-0.34	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930114	chr1:43944370~43946551:-
PCPG	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-4.45	1.66e-05	0.00777	-0.41	-0.34	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
PCPG	cis	rs8024893	0.764	rs7178760	ENSG00000270055.1	CTD-3092A11.2	4.45	1.67e-05	0.00778	0.65	0.34	Red cell distribution width;	chr15:31239170	chr15:30487963~30490313:+
PCPG	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-4.45	1.67e-05	0.00778	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
PCPG	cis	rs8030379	0.811	rs7162542	ENSG00000230373.7	GOLGA6L5P	-4.45	1.67e-05	0.00778	-0.34	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84507885~84516814:-
PCPG	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	4.45	1.67e-05	0.00778	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	4.45	1.67e-05	0.00778	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	4.45	1.67e-05	0.00778	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	4.45	1.67e-05	0.00778	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
PCPG	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	4.45	1.67e-05	0.00778	0.58	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
PCPG	cis	rs5742933	0.725	rs1132360	ENSG00000273240.1	RP11-455J20.3	4.45	1.67e-05	0.00778	0.36	0.34	Ferritin levels;	chr2:189661498	chr2:189763859~189764456:-
PCPG	cis	rs7759001	0.857	rs6904883	ENSG00000271755.1	RP1-153G14.4	4.45	1.67e-05	0.00778	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27389529	chr6:27404010~27406964:-
PCPG	cis	rs2302464	1	rs6828144	ENSG00000214846.4	RP11-115L11.1	4.45	1.67e-05	0.00778	0.88	0.34	Cerebrospinal fluid biomarker levels;	chr4:15725766	chr4:15730962~15731627:-
PCPG	cis	rs7017914	0.667	rs6990397	ENSG00000254031.4	RP11-326E22.1	4.45	1.67e-05	0.00778	0.35	0.34	Bone mineral density;	chr8:71099537	chr8:71155457~71204223:+
PCPG	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	4.45	1.67e-05	0.00779	0.39	0.34	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
PCPG	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	4.45	1.67e-05	0.00779	0.47	0.34	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	4.45	1.67e-05	0.00779	0.47	0.34	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
PCPG	cis	rs748404	0.666	rs34633582	ENSG00000249839.1	AC011330.5	-4.45	1.67e-05	0.00779	-0.46	-0.34	Lung cancer;	chr15:43462683	chr15:43663654~43684339:-
PCPG	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	4.45	1.67e-05	0.0078	0.61	0.34	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	4.45	1.67e-05	0.0078	0.61	0.34	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
PCPG	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.67e-05	0.0078	-0.4	-0.34	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
PCPG	cis	rs2235642	0.893	rs2076445	ENSG00000260989.1	LA16c-395F10.2	-4.45	1.67e-05	0.0078	-0.35	-0.34	Coronary artery disease;	chr16:1542265	chr16:1580527~1610328:+
PCPG	cis	rs11858159	1	rs7172329	ENSG00000260760.1	PWRN3	4.45	1.67e-05	0.00781	0.37	0.34	Platelet thrombus formation;	chr15:24538386	chr15:24441127~24447967:+
PCPG	cis	rs1159787	0.558	rs6478311	ENSG00000233569.1	RP11-500B12.1	-4.45	1.67e-05	0.00781	-0.49	-0.34	Blood protein levels;	chr9:117618968	chr9:117648606~117657027:+
PCPG	cis	rs2625529	0.641	rs11852789	ENSG00000260037.4	CTD-2524L6.3	-4.45	1.67e-05	0.00781	-0.54	-0.34	Red blood cell count;	chr15:71973153	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12595228	ENSG00000260037.4	CTD-2524L6.3	-4.45	1.67e-05	0.00781	-0.54	-0.34	Red blood cell count;	chr15:71974874	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.775	rs4777477	ENSG00000260037.4	CTD-2524L6.3	-4.45	1.67e-05	0.00781	-0.54	-0.34	Red blood cell count;	chr15:71977271	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12592364	ENSG00000260037.4	CTD-2524L6.3	-4.45	1.67e-05	0.00781	-0.54	-0.34	Red blood cell count;	chr15:71992306	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.641	rs2035379	ENSG00000260037.4	CTD-2524L6.3	-4.45	1.67e-05	0.00781	-0.54	-0.34	Red blood cell count;	chr15:72000861	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12595464	ENSG00000260037.4	CTD-2524L6.3	-4.45	1.67e-05	0.00781	-0.54	-0.34	Red blood cell count;	chr15:72002057	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12916694	ENSG00000260037.4	CTD-2524L6.3	-4.45	1.67e-05	0.00781	-0.54	-0.34	Red blood cell count;	chr15:72005799	chr15:71818396~71823384:+
PCPG	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-4.45	1.68e-05	0.00782	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
PCPG	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-4.45	1.68e-05	0.00783	-0.37	-0.34	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
PCPG	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-4.45	1.68e-05	0.00783	-0.5	-0.34	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
PCPG	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	4.45	1.68e-05	0.00783	0.38	0.34	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
PCPG	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	4.45	1.68e-05	0.00783	0.47	0.34	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
PCPG	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	4.45	1.68e-05	0.00783	0.43	0.34	Height;	chr6:109350642	chr6:109382795~109383666:+
PCPG	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-4.45	1.68e-05	0.00784	-0.49	-0.34	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
PCPG	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-4.45	1.68e-05	0.00784	-0.44	-0.34	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
PCPG	cis	rs3806843	0.932	rs2563269	ENSG00000202515.1	VTRNA1-3	4.45	1.68e-05	0.00784	0.43	0.34	Depressive symptoms (multi-trait analysis);	chr5:140756883	chr5:140726158~140726246:+
PCPG	cis	rs899997	0.954	rs4887091	ENSG00000261143.1	ADAMTS7P3	4.45	1.68e-05	0.00784	0.41	0.34	Coronary artery disease or large artery stroke;	chr15:78751238	chr15:77976042~77993057:+
PCPG	cis	rs899997	1	rs11632672	ENSG00000261143.1	ADAMTS7P3	4.45	1.68e-05	0.00784	0.41	0.34	Coronary artery disease or large artery stroke;	chr15:78751988	chr15:77976042~77993057:+
PCPG	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-4.45	1.68e-05	0.00784	-0.58	-0.34	Depression;	chr6:28129415	chr6:28115628~28116551:+
PCPG	cis	rs2412819	0.597	rs2412821	ENSG00000249839.1	AC011330.5	-4.45	1.68e-05	0.00785	-0.44	-0.34	Lung cancer;	chr15:43864966	chr15:43663654~43684339:-
PCPG	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	4.45	1.68e-05	0.00785	0.76	0.34	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
PCPG	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-4.45	1.68e-05	0.00785	-0.51	-0.34	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
PCPG	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	4.45	1.69e-05	0.00786	0.36	0.34	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
PCPG	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-4.45	1.69e-05	0.00786	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
PCPG	cis	rs9393777	0.668	rs16897515	ENSG00000216901.1	AL022393.7	-4.45	1.69e-05	0.00786	-0.54	-0.34	Intelligence (multi-trait analysis);	chr6:27310241	chr6:28176188~28176674:+
PCPG	cis	rs5742933	0.857	rs2289226	ENSG00000273240.1	RP11-455J20.3	-4.45	1.69e-05	0.00786	-0.36	-0.34	Ferritin levels;	chr2:189661479	chr2:189763859~189764456:-
PCPG	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	4.45	1.69e-05	0.00786	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
PCPG	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	4.45	1.69e-05	0.00786	0.41	0.34	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
PCPG	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	4.45	1.69e-05	0.00787	0.42	0.34	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
PCPG	cis	rs2830585	0.602	rs233895	ENSG00000197934.7	CYYR1-AS1	4.45	1.69e-05	0.00787	0.48	0.34	Blood protein levels;	chr21:26952992	chr21:26393635~26569252:+
PCPG	cis	rs17507216	0.718	rs72751675	ENSG00000228141.5	AC105339.1	-4.45	1.69e-05	0.00788	-0.52	-0.34	Excessive daytime sleepiness;	chr15:82630452	chr15:82710471~82714026:-
PCPG	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	4.45	1.69e-05	0.00788	0.44	0.34	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
PCPG	cis	rs172166	0.561	rs149976	ENSG00000219392.1	RP1-265C24.5	4.45	1.69e-05	0.00788	0.37	0.34	Cardiac Troponin-T levels;	chr6:28019998	chr6:28115628~28116551:+
PCPG	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-4.45	1.69e-05	0.00788	-0.39	-0.34	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
PCPG	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	4.45	1.69e-05	0.00788	0.43	0.34	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
PCPG	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.69e-05	0.00788	-0.4	-0.34	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.69e-05	0.00788	-0.4	-0.34	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.69e-05	0.00788	-0.4	-0.34	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.69e-05	0.00788	-0.4	-0.34	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.69e-05	0.00788	-0.4	-0.34	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.69e-05	0.00788	-0.4	-0.34	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-4.45	1.69e-05	0.00788	-0.4	-0.34	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
PCPG	cis	rs2898290	0.622	rs1478890	ENSG00000270154.1	RP11-419I17.1	-4.45	1.69e-05	0.00788	-0.39	-0.34	Systolic blood pressure;	chr8:11498093	chr8:12476462~12477122:+
PCPG	cis	rs748404	0.55	rs12912505	ENSG00000205771.5	CATSPER2P1	-4.45	1.7e-05	0.00789	-0.43	-0.34	Lung cancer;	chr15:43525206	chr15:43726918~43747094:-
PCPG	cis	rs1003719	0.715	rs2835657	ENSG00000228677.1	TTC3-AS1	-4.45	1.7e-05	0.00789	-0.42	-0.34	Eye color traits;	chr21:37192763	chr21:37187666~37193926:-
PCPG	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	4.45	1.7e-05	0.0079	0.5	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
PCPG	cis	rs5743030	0.702	rs6757196	ENSG00000253559.1	OSGEPL1-AS1	4.44	1.7e-05	0.0079	0.52	0.34	Subcutaneous adipose tissue;	chr2:189903101	chr2:189762704~189765556:+
PCPG	cis	rs4713118	0.869	rs9295743	ENSG00000216901.1	AL022393.7	4.44	1.7e-05	0.00791	0.45	0.34	Parkinson's disease;	chr6:27747323	chr6:28176188~28176674:+
PCPG	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-4.44	1.7e-05	0.00791	-0.38	-0.34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
PCPG	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-4.44	1.7e-05	0.00792	-0.45	-0.34	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
PCPG	cis	rs6121246	0.697	rs6060446	ENSG00000230613.1	HM13-AS1	4.44	1.71e-05	0.00792	0.49	0.34	Mean corpuscular hemoglobin;	chr20:31643834	chr20:31567707~31573263:-
PCPG	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-4.44	1.71e-05	0.00793	-0.31	-0.34	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
PCPG	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	4.44	1.71e-05	0.00793	0.48	0.34	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
PCPG	cis	rs1003719	0.68	rs8130069	ENSG00000228677.1	TTC3-AS1	-4.44	1.71e-05	0.00795	-0.42	-0.34	Eye color traits;	chr21:37179814	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs2835658	ENSG00000228677.1	TTC3-AS1	-4.44	1.71e-05	0.00795	-0.42	-0.34	Eye color traits;	chr21:37192900	chr21:37187666~37193926:-
PCPG	cis	rs10899021	1	rs10899025	ENSG00000279353.1	RP11-864N7.4	4.44	1.71e-05	0.00795	0.62	0.34	Response to metformin (IC50);	chr11:74655995	chr11:74698231~74699658:-
PCPG	cis	rs7759001	0.857	rs6936356	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27391074	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4713092	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27396119	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs1022518	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27397107	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs1022517	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27397230	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs4711149	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27398066	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6456777	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27398215	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs9468117	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27399083	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10946913	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27402094	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10946914	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27402113	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6456778	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27402267	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs6456779	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27402694	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs3734575	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27403232	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs3734574	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27403414	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs4339442	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27404348	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4504471	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27404463	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4305708	ENSG00000271755.1	RP1-153G14.4	4.44	1.71e-05	0.00795	0.51	0.34	Glomerular filtration rate (creatinine);	chr6:27404524	chr6:27404010~27406964:-
PCPG	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	4.44	1.71e-05	0.00795	0.51	0.34	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
PCPG	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	4.44	1.71e-05	0.00795	0.46	0.34	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
PCPG	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-4.44	1.72e-05	0.00796	-0.46	-0.34	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
PCPG	cis	rs4489787	0.892	rs2705133	ENSG00000240399.1	RP1-228P16.1	4.44	1.72e-05	0.00797	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr12:48495454	chr12:48054813~48055591:-
PCPG	cis	rs5758511	0.508	rs28715885	ENSG00000226450.2	CYP2D8P	4.44	1.72e-05	0.00797	0.44	0.34	Birth weight;	chr22:42045087	chr22:42149886~42155001:-
PCPG	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-4.44	1.72e-05	0.00798	-0.34	-0.34	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
PCPG	cis	rs10971721	0.643	rs10971699	ENSG00000260947.1	RP11-384P7.7	4.44	1.72e-05	0.00798	0.55	0.34	Body mass index;	chr9:33777186	chr9:33697459~33700986:+
PCPG	cis	rs6579956	0.639	rs13178231	ENSG00000270978.1	RP11-54C4.2	-4.44	1.72e-05	0.00798	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152740110	chr5:151848886~151850791:+
PCPG	cis	rs6579956	0.554	rs62398722	ENSG00000270978.1	RP11-54C4.2	-4.44	1.72e-05	0.00798	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152740944	chr5:151848886~151850791:+
PCPG	cis	rs6579956	0.63	rs56125403	ENSG00000270978.1	RP11-54C4.2	-4.44	1.72e-05	0.00798	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152749980	chr5:151848886~151850791:+
PCPG	cis	rs6579956	0.546	rs4958578	ENSG00000270978.1	RP11-54C4.2	-4.44	1.72e-05	0.00798	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152758873	chr5:151848886~151850791:+
PCPG	cis	rs6579956	0.614	rs35835162	ENSG00000270978.1	RP11-54C4.2	-4.44	1.72e-05	0.00798	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152759294	chr5:151848886~151850791:+
PCPG	cis	rs6579956	0.643	rs62400564	ENSG00000270978.1	RP11-54C4.2	-4.44	1.72e-05	0.00798	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152772675	chr5:151848886~151850791:+
PCPG	cis	rs6579956	0.675	rs35663252	ENSG00000270978.1	RP11-54C4.2	-4.44	1.72e-05	0.00798	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152775577	chr5:151848886~151850791:+
PCPG	cis	rs7819412	0.715	rs2409727	ENSG00000255020.1	AF131216.5	-4.44	1.72e-05	0.00798	-0.44	-0.34	Triglycerides;	chr8:11185727	chr8:11345748~11347502:-
PCPG	cis	rs7819412	0.715	rs35223712	ENSG00000255020.1	AF131216.5	-4.44	1.72e-05	0.00798	-0.44	-0.34	Triglycerides;	chr8:11186417	chr8:11345748~11347502:-
PCPG	cis	rs11858159	1	rs8032894	ENSG00000260760.1	PWRN3	4.44	1.72e-05	0.00799	0.37	0.34	Platelet thrombus formation;	chr15:24540625	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs9920583	ENSG00000260760.1	PWRN3	4.44	1.72e-05	0.00799	0.37	0.34	Platelet thrombus formation;	chr15:24544540	chr15:24441127~24447967:+
PCPG	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	4.44	1.72e-05	0.00799	0.44	0.34	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	4.44	1.72e-05	0.00799	0.44	0.34	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
PCPG	cis	rs2625529	0.938	rs8747	ENSG00000260037.4	CTD-2524L6.3	-4.44	1.72e-05	0.00799	-0.54	-0.34	Red blood cell count;	chr15:71823200	chr15:71818396~71823384:+
PCPG	cis	rs2243480	1	rs34136756	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65916269	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs78803505	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65917585	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34933526	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65918212	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34577383	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65920739	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs6949812	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65922114	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs55895244	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65922691	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs6970243	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65923503	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs7794661	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65924743	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs7795242	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65925107	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.708	rs35310401	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65925372	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35058610	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65925938	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs2177703	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65926730	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35432774	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65928032	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs56985706	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65929575	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs60683927	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65929781	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs58062456	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65929865	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34529418	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65938222	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs35087093	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65940221	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35046236	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65943626	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs36068983	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65944004	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs68189316	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65944182	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs34804747	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65947955	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs59794892	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65950886	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs57126451	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65951319	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs36004293	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65951525	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs35268390	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65951549	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs11538349	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65956884	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs937108	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65963465	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35542501	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65966228	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.711	rs1626926	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65970805	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.708	rs781141	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65973566	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1039664	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65984729	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1964692	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65989196	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs2456483	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65996588	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs2949697	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:65999249	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1701750	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66002158	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1701758	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66005214	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs1701759	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66005945	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1723267	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66008327	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs781157	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66013324	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs781156	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66014154	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs781149	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66016297	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs451396	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66019087	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs58207111	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66021736	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1167613	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66022452	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1715235	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66023407	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs313799	ENSG00000230189.5	GS1-124K5.2	4.44	1.72e-05	0.00799	0.51	0.34	Diabetic kidney disease;	chr7:66029343	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.831	rs7806717	ENSG00000230189.5	GS1-124K5.2	-4.44	1.72e-05	0.00799	-0.51	-0.34	Diabetic kidney disease;	chr7:65928187	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs2462569	ENSG00000230189.5	GS1-124K5.2	-4.44	1.72e-05	0.00799	-0.51	-0.34	Diabetic kidney disease;	chr7:66009859	chr7:66409143~66490059:-
PCPG	cis	rs2404602	0.532	rs206205	ENSG00000259514.1	RP11-685G9.2	-4.44	1.73e-05	0.008	-0.34	-0.34	Blood metabolite levels;	chr15:76443750	chr15:76339609~76342063:-
PCPG	cis	rs78623212	1	rs79142932	ENSG00000234715.1	CTB-107G13.1	-4.44	1.73e-05	0.008	-0.94	-0.34	Interleukin-18 levels;	chr7:103688500	chr7:103445207~103514007:+
PCPG	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	4.44	1.73e-05	0.008	0.34	0.34	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
PCPG	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	4.44	1.73e-05	0.008	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
PCPG	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	4.44	1.73e-05	0.00801	0.34	0.34	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
PCPG	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-4.44	1.73e-05	0.00801	-0.43	-0.34	Height;	chr6:109485060	chr6:109382795~109383666:+
PCPG	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-4.44	1.73e-05	0.00801	-0.46	-0.34	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
PCPG	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	4.44	1.73e-05	0.00801	0.46	0.34	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	4.44	1.73e-05	0.00801	0.46	0.34	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	4.44	1.73e-05	0.00801	0.46	0.34	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
PCPG	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-4.44	1.73e-05	0.00802	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-4.44	1.73e-05	0.00802	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-4.44	1.73e-05	0.00802	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-4.44	1.73e-05	0.00802	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-4.44	1.73e-05	0.00802	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-4.44	1.73e-05	0.00802	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-4.44	1.73e-05	0.00802	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
PCPG	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-4.44	1.73e-05	0.00802	-0.47	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
PCPG	cis	rs300890	1	rs300905	ENSG00000250326.1	RP11-284M14.1	-4.44	1.73e-05	0.00802	-0.31	-0.34	Nasopharyngeal carcinoma;	chr4:143319320	chr4:142933195~143184861:-
PCPG	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	4.44	1.73e-05	0.00802	0.34	0.34	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
PCPG	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-4.44	1.73e-05	0.00802	-0.45	-0.34	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-4.44	1.73e-05	0.00802	-0.45	-0.34	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
PCPG	cis	rs1440410	0.61	rs12640330	ENSG00000250326.1	RP11-284M14.1	4.44	1.73e-05	0.00802	0.3	0.34	Ischemic stroke;	chr4:143121871	chr4:142933195~143184861:-
PCPG	cis	rs728616	0.764	rs12413678	ENSG00000242600.5	MBL1P	4.44	1.74e-05	0.00804	0.79	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927343	chr10:79904898~79950336:+
PCPG	cis	rs950169	0.58	rs35516100	ENSG00000259295.5	CSPG4P12	4.44	1.74e-05	0.00805	0.5	0.34	Schizophrenia;	chr15:84652199	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs62021208	ENSG00000259295.5	CSPG4P12	4.44	1.74e-05	0.00805	0.5	0.34	Schizophrenia;	chr15:84653013	chr15:85191438~85213905:+
PCPG	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-4.44	1.74e-05	0.00805	-0.4	-0.34	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
PCPG	cis	rs12906542	0.516	rs894301	ENSG00000259792.1	RP11-114H24.6	-4.44	1.74e-05	0.00806	-0.44	-0.34	Breast cancer;	chr15:78005183	chr15:77993405~77995289:+
PCPG	cis	rs12906542	0.516	rs4886989	ENSG00000259792.1	RP11-114H24.6	-4.44	1.74e-05	0.00806	-0.44	-0.34	Breast cancer;	chr15:78011406	chr15:77993405~77995289:+
PCPG	cis	rs12906542	0.516	rs56357772	ENSG00000259792.1	RP11-114H24.6	-4.44	1.74e-05	0.00806	-0.44	-0.34	Breast cancer;	chr15:78020699	chr15:77993405~77995289:+
PCPG	cis	rs12906542	0.516	rs4886992	ENSG00000259792.1	RP11-114H24.6	-4.44	1.74e-05	0.00806	-0.44	-0.34	Breast cancer;	chr15:78032887	chr15:77993405~77995289:+
PCPG	cis	rs12906542	0.516	rs16969422	ENSG00000259792.1	RP11-114H24.6	-4.44	1.74e-05	0.00806	-0.44	-0.34	Breast cancer;	chr15:78033857	chr15:77993405~77995289:+
PCPG	cis	rs5758511	0.68	rs56111723	ENSG00000205702.9	CYP2D7	4.44	1.74e-05	0.00807	0.46	0.34	Birth weight;	chr22:42268877	chr22:42140203~42144577:-
PCPG	cis	rs7017914	0.69	rs13280922	ENSG00000254031.4	RP11-326E22.1	4.44	1.75e-05	0.00807	0.32	0.34	Bone mineral density;	chr8:70713163	chr8:71155457~71204223:+
PCPG	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
PCPG	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	4.44	1.75e-05	0.00808	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
PCPG	cis	rs9326248	0.689	rs236916	ENSG00000280143.1	AP000892.6	-4.44	1.75e-05	0.00808	-0.54	-0.34	Blood protein levels;	chr11:117218912	chr11:117204967~117210292:+
PCPG	cis	rs3806843	0.9	rs3756334	ENSG00000202515.1	VTRNA1-3	-4.44	1.75e-05	0.00808	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140834211	chr5:140726158~140726246:+
PCPG	cis	rs2736345	0.516	rs9657551	ENSG00000255020.1	AF131216.5	4.44	1.75e-05	0.00809	0.45	0.34	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11540674	chr8:11345748~11347502:-
PCPG	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-4.44	1.75e-05	0.00809	-0.39	-0.34	Height;	chr5:36954710	chr5:36666214~36725195:-
PCPG	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-4.44	1.75e-05	0.00809	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
PCPG	cis	rs1440410	0.835	rs11722027	ENSG00000250326.1	RP11-284M14.1	4.44	1.75e-05	0.0081	0.32	0.34	Ischemic stroke;	chr4:143128864	chr4:142933195~143184861:-
PCPG	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-4.44	1.75e-05	0.0081	-0.44	-0.34	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
PCPG	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	4.44	1.75e-05	0.0081	0.49	0.34	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
PCPG	cis	rs561341	0.941	rs72825746	ENSG00000265798.5	RP11-271K11.5	4.44	1.75e-05	0.0081	0.61	0.34	Hip circumference adjusted for BMI;	chr17:32037591	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.882	rs72825748	ENSG00000265798.5	RP11-271K11.5	4.44	1.75e-05	0.0081	0.61	0.34	Hip circumference adjusted for BMI;	chr17:32040377	chr17:31038575~31059121:-
PCPG	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	4.44	1.75e-05	0.0081	0.42	0.34	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
PCPG	cis	rs8098244	0.683	rs4334381	ENSG00000265752.2	RP11-403A21.1	4.44	1.75e-05	0.00811	0.42	0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852485	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.683	rs4488534	ENSG00000265752.2	RP11-403A21.1	4.44	1.75e-05	0.00811	0.42	0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852486	chr18:23957754~23982556:-
PCPG	cis	rs10504130	0.569	rs35509250	ENSG00000272024.1	RP11-546K22.3	-4.44	1.75e-05	0.00811	-0.44	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:51774993	chr8:51950284~51950690:+
PCPG	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-4.44	1.76e-05	0.00811	-0.43	-0.34	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
PCPG	cis	rs657075	0.697	rs35497612	ENSG00000233006.5	AC034220.3	-4.44	1.76e-05	0.00811	-0.48	-0.34	Rheumatoid arthritis;	chr5:132337413	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs13184379	ENSG00000233006.5	AC034220.3	-4.44	1.76e-05	0.00811	-0.48	-0.34	Rheumatoid arthritis;	chr5:132342452	chr5:132311285~132369916:-
PCPG	cis	rs196889	0.611	rs442641	ENSG00000253535.4	RP11-624C23.1	4.44	1.76e-05	0.00811	0.34	0.34	Seasonality;	chr8:24863370	chr8:24295814~24912073:-
PCPG	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-4.44	1.76e-05	0.00811	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
PCPG	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-4.44	1.76e-05	0.00811	-0.45	-0.34	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
PCPG	cis	rs7017914	0.967	rs4628281	ENSG00000254031.4	RP11-326E22.1	4.44	1.76e-05	0.00812	0.34	0.34	Bone mineral density;	chr8:70926929	chr8:71155457~71204223:+
PCPG	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	4.44	1.76e-05	0.00813	0.39	0.34	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
PCPG	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	4.44	1.76e-05	0.00814	0.44	0.34	Height;	chr6:109482392	chr6:109382795~109383666:+
PCPG	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-4.44	1.76e-05	0.00814	-0.44	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
PCPG	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-4.44	1.76e-05	0.00814	-0.45	-0.34	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
PCPG	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-4.44	1.76e-05	0.00814	-0.4	-0.34	Height;	chr5:36982949	chr5:36666214~36725195:-
PCPG	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-4.44	1.76e-05	0.00814	-0.4	-0.34	Height;	chr5:36990381	chr5:36666214~36725195:-
PCPG	cis	rs11858159	1	rs12915206	ENSG00000259905.4	PWRN1	4.44	1.76e-05	0.00814	0.39	0.34	Platelet thrombus formation;	chr15:24545525	chr15:24493137~24652130:+
PCPG	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	4.44	1.77e-05	0.00815	0.49	0.34	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
PCPG	cis	rs1478897	0.804	rs9329246	ENSG00000255020.1	AF131216.5	4.44	1.77e-05	0.00815	0.45	0.34	Systemic lupus erythematosus;	chr8:11535371	chr8:11345748~11347502:-
PCPG	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	4.44	1.77e-05	0.00816	0.37	0.34	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	4.44	1.77e-05	0.00816	0.37	0.34	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
PCPG	cis	rs2625529	0.938	rs9120	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.77e-05	0.00817	-0.54	-0.34	Red blood cell count;	chr15:71823422	chr15:71818396~71823384:+
PCPG	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-4.43	1.77e-05	0.00818	-0.49	-0.34	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
PCPG	cis	rs7017914	0.967	rs2732091	ENSG00000254031.4	RP11-326E22.1	-4.43	1.77e-05	0.00818	-0.33	-0.34	Bone mineral density;	chr8:71006188	chr8:71155457~71204223:+
PCPG	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	4.43	1.77e-05	0.00818	0.35	0.34	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
PCPG	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	4.43	1.78e-05	0.0082	0.54	0.34	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
PCPG	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	4.43	1.78e-05	0.0082	0.37	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
PCPG	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	-4.43	1.78e-05	0.0082	-0.41	-0.34	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
PCPG	cis	rs11133665	0.683	rs7719875	ENSG00000249201.2	CTD-3080P12.3	4.43	1.78e-05	0.0082	0.41	0.34	Urinary metabolites;	chr5:1189973	chr5:1173141~1178605:-
PCPG	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	4.43	1.78e-05	0.00821	0.35	0.34	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
PCPG	cis	rs8049040	0.609	rs16972805	ENSG00000260886.1	TAT-AS1	-4.43	1.78e-05	0.00821	-0.49	-0.34	Blood protein levels;	chr16:71444346	chr16:71565789~71578187:+
PCPG	cis	rs8049040	0.609	rs11866859	ENSG00000260886.1	TAT-AS1	4.43	1.78e-05	0.00821	0.49	0.34	Blood protein levels;	chr16:71444985	chr16:71565789~71578187:+
PCPG	cis	rs34421088	0.531	rs2245232	ENSG00000255020.1	AF131216.5	-4.43	1.78e-05	0.00822	-0.45	-0.34	Neuroticism;	chr8:11543435	chr8:11345748~11347502:-
PCPG	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-4.43	1.78e-05	0.00822	-0.75	-0.34	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
PCPG	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-4.43	1.78e-05	0.00822	-0.4	-0.34	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
PCPG	cis	rs2625529	0.761	rs8028532	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.79e-05	0.00823	-0.54	-0.34	Red blood cell count;	chr15:72055713	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs4445848	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.79e-05	0.00823	-0.54	-0.34	Red blood cell count;	chr15:72062257	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs4131630	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.79e-05	0.00823	-0.54	-0.34	Red blood cell count;	chr15:72063057	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs7172309	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.79e-05	0.00823	-0.54	-0.34	Red blood cell count;	chr15:72092142	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.775	rs35673773	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.79e-05	0.00823	-0.54	-0.34	Red blood cell count;	chr15:72107545	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs11072346	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.79e-05	0.00823	-0.54	-0.34	Red blood cell count;	chr15:72108093	chr15:71818396~71823384:+
PCPG	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-4.43	1.79e-05	0.00823	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
PCPG	cis	rs896854	0.818	rs896855	ENSG00000253528.2	RP11-347C18.4	4.43	1.79e-05	0.00824	0.37	0.34	Type 2 diabetes;	chr8:94947580	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.936	rs10108430	ENSG00000253528.2	RP11-347C18.4	4.43	1.79e-05	0.00824	0.37	0.34	Type 2 diabetes;	chr8:94949566	chr8:94974573~94974853:-
PCPG	cis	rs10484885	0.757	rs72912535	ENSG00000232532.1	RP11-63K6.7	4.43	1.79e-05	0.00824	0.63	0.34	QRS interval (sulfonylurea treatment interaction);	chr6:89450043	chr6:89920196~89921760:+
PCPG	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	4.43	1.79e-05	0.00824	0.38	0.34	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
PCPG	cis	rs1440410	0.798	rs7663553	ENSG00000250326.1	RP11-284M14.1	4.43	1.79e-05	0.00825	0.32	0.34	Ischemic stroke;	chr4:143127883	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs7663762	ENSG00000250326.1	RP11-284M14.1	4.43	1.79e-05	0.00825	0.32	0.34	Ischemic stroke;	chr4:143128019	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs7670624	ENSG00000250326.1	RP11-284M14.1	4.43	1.79e-05	0.00825	0.32	0.34	Ischemic stroke;	chr4:143129092	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs7665674	ENSG00000250326.1	RP11-284M14.1	4.43	1.79e-05	0.00825	0.32	0.34	Ischemic stroke;	chr4:143129181	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs7682068	ENSG00000250326.1	RP11-284M14.1	4.43	1.79e-05	0.00825	0.32	0.34	Ischemic stroke;	chr4:143129226	chr4:142933195~143184861:-
PCPG	cis	rs10899021	0.79	rs7932194	ENSG00000279353.1	RP11-864N7.4	4.43	1.79e-05	0.00825	0.58	0.34	Response to metformin (IC50);	chr11:74616333	chr11:74698231~74699658:-
PCPG	cis	rs7911712	0.808	rs2793298	ENSG00000228462.1	RP11-445N18.3	4.43	1.79e-05	0.00825	0.49	0.34	Emphysema-related traits;	chr10:44783175	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.81	rs2611373	ENSG00000228462.1	RP11-445N18.3	4.43	1.79e-05	0.00825	0.49	0.34	Emphysema-related traits;	chr10:44783676	chr10:45073146~45073541:-
PCPG	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-4.43	1.79e-05	0.00825	-0.49	-0.34	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-4.43	1.79e-05	0.00825	-0.49	-0.34	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-4.43	1.79e-05	0.00825	-0.49	-0.34	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-4.43	1.79e-05	0.00825	-0.49	-0.34	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-4.43	1.79e-05	0.00825	-0.49	-0.34	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.736	rs6851661	ENSG00000251600.4	RP11-673E1.1	4.43	1.79e-05	0.00826	0.4	0.34	Immature fraction of reticulocytes;	chr4:143850587	chr4:143912331~143982454:+
PCPG	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	4.43	1.79e-05	0.00826	0.42	0.34	Height;	chr6:109672088	chr6:109382795~109383666:+
PCPG	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-4.43	1.79e-05	0.00826	-0.49	-0.34	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
PCPG	cis	rs2625529	1	rs2625529	ENSG00000260037.4	CTD-2524L6.3	4.43	1.8e-05	0.00827	0.49	0.34	Red blood cell count;	chr15:71826436	chr15:71818396~71823384:+
PCPG	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-4.43	1.8e-05	0.00827	-0.31	-0.34	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
PCPG	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	4.43	1.8e-05	0.00827	0.42	0.34	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
PCPG	cis	rs3806843	0.9	rs2261651	ENSG00000202515.1	VTRNA1-3	4.43	1.8e-05	0.00827	0.43	0.34	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.9	rs2337983	ENSG00000202515.1	VTRNA1-3	4.43	1.8e-05	0.00827	0.43	0.34	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr5:140726158~140726246:+
PCPG	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-4.43	1.8e-05	0.00827	-0.45	-0.34	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
PCPG	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-4.43	1.8e-05	0.00827	-0.45	-0.34	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
PCPG	cis	rs3806843	0.9	rs2337984	ENSG00000202515.1	VTRNA1-3	4.43	1.8e-05	0.00827	0.44	0.34	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr5:140726158~140726246:+
PCPG	cis	rs9393777	0.72	rs56401801	ENSG00000219392.1	RP1-265C24.5	-4.43	1.8e-05	0.00828	-0.73	-0.34	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28115628~28116551:+
PCPG	cis	rs71537559	1	rs71537559	ENSG00000219392.1	RP1-265C24.5	-4.43	1.8e-05	0.00828	-0.73	-0.34	Squamous cell lung carcinoma;	chr6:27342000	chr6:28115628~28116551:+
PCPG	cis	rs2404602	0.967	rs7167613	ENSG00000259422.1	RP11-593F23.1	4.43	1.8e-05	0.00828	0.41	0.34	Blood metabolite levels;	chr15:76748851	chr15:76174891~76181486:-
PCPG	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	4.43	1.8e-05	0.00828	0.37	0.34	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	4.43	1.8e-05	0.00828	0.37	0.34	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
PCPG	cis	rs657075	0.697	rs36108085	ENSG00000233006.5	AC034220.3	-4.43	1.8e-05	0.00829	-0.49	-0.34	Rheumatoid arthritis;	chr5:132350786	chr5:132311285~132369916:-
PCPG	cis	rs7017914	0.69	rs4446768	ENSG00000254031.4	RP11-326E22.1	4.43	1.8e-05	0.00829	0.32	0.34	Bone mineral density;	chr8:70865354	chr8:71155457~71204223:+
PCPG	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	4.43	1.8e-05	0.00829	0.47	0.34	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
PCPG	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	4.43	1.8e-05	0.00829	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
PCPG	cis	rs11671005	0.693	rs11668821	ENSG00000252334.1	RNU6-1337P	4.43	1.8e-05	0.00829	0.5	0.34	Mean platelet volume;	chr19:58444446	chr19:58483749~58483843:-
PCPG	cis	rs11671005	0.616	rs12980907	ENSG00000252334.1	RNU6-1337P	4.43	1.8e-05	0.00829	0.5	0.34	Mean platelet volume;	chr19:58444959	chr19:58483749~58483843:-
PCPG	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	4.43	1.81e-05	0.00829	0.42	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
PCPG	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-4.43	1.81e-05	0.00829	-0.47	-0.34	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-4.43	1.81e-05	0.00829	-0.47	-0.34	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-4.43	1.81e-05	0.00829	-0.47	-0.34	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
PCPG	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-4.43	1.81e-05	0.00829	-0.47	-0.34	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
PCPG	cis	rs11673344	0.563	rs55825113	ENSG00000226686.6	LINC01535	4.43	1.81e-05	0.0083	0.44	0.34	Obesity-related traits;	chr19:37191523	chr19:37251912~37265535:+
PCPG	cis	rs13113518	0.513	rs13147861	ENSG00000272969.1	RP11-528I4.2	4.43	1.81e-05	0.00832	0.4	0.34	Height;	chr4:55611014	chr4:55547112~55547889:+
PCPG	cis	rs964611	0.882	rs59324936	ENSG00000259488.2	RP11-154J22.1	-4.43	1.81e-05	0.00832	-0.35	-0.34	Metabolite levels (Pyroglutamine);	chr15:48354061	chr15:48312353~48331856:-
PCPG	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-4.43	1.81e-05	0.00832	-0.41	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
PCPG	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-4.43	1.81e-05	0.00832	-0.4	-0.34	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
PCPG	cis	rs896854	0.53	rs10956934	ENSG00000272509.1	RP11-347C18.5	4.43	1.81e-05	0.00833	0.34	0.34	Type 2 diabetes;	chr8:94980245	chr8:94884609~94885070:+
PCPG	cis	rs591584	0.73	rs11020840	ENSG00000255893.1	RP11-685N10.1	-4.43	1.82e-05	0.00833	-0.4	-0.34	Macrophage Migration Inhibitory Factor levels;	chr11:94580348	chr11:94472908~94473570:-
PCPG	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	4.43	1.82e-05	0.00834	0.39	0.34	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	4.43	1.82e-05	0.00834	0.39	0.34	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
PCPG	cis	rs2732480	0.5	rs7297824	ENSG00000240399.1	RP1-228P16.1	4.43	1.82e-05	0.00835	0.38	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.5	rs7315820	ENSG00000240399.1	RP1-228P16.1	4.43	1.82e-05	0.00835	0.38	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.5	rs11168464	ENSG00000240399.1	RP1-228P16.1	4.43	1.82e-05	0.00835	0.38	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48054813~48055591:-
PCPG	cis	rs1387259	0.899	rs7307566	ENSG00000240399.1	RP1-228P16.1	4.43	1.82e-05	0.00835	0.38	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48054813~48055591:-
PCPG	cis	rs465969	0.793	rs34288099	ENSG00000255389.1	C6orf3	-4.43	1.82e-05	0.00835	-0.64	-0.34	Psoriasis;	chr6:111424034	chr6:111599875~111602295:+
PCPG	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-4.43	1.82e-05	0.00835	-0.34	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
PCPG	cis	rs7208859	0.623	rs58908911	ENSG00000263603.1	CTD-2349P21.5	-4.43	1.82e-05	0.00836	-0.67	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs28588622	ENSG00000263603.1	CTD-2349P21.5	-4.43	1.82e-05	0.00836	-0.67	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30729469~30731202:+
PCPG	cis	rs2239557	0.539	rs2302117	ENSG00000279026.1	RP3-414A15.12	4.43	1.82e-05	0.00836	0.51	0.34	Common traits (Other);	chr14:73988110	chr14:73580694~73582918:+
PCPG	cis	rs2239557	0.539	rs62005063	ENSG00000279026.1	RP3-414A15.12	4.43	1.82e-05	0.00836	0.51	0.34	Common traits (Other);	chr14:73989276	chr14:73580694~73582918:+
PCPG	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-4.43	1.82e-05	0.00836	-0.38	-0.34	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	4.43	1.82e-05	0.00836	0.38	0.34	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	4.43	1.82e-05	0.00836	0.38	0.34	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
PCPG	cis	rs7017914	0.667	rs13277069	ENSG00000254031.4	RP11-326E22.1	4.43	1.83e-05	0.00837	0.34	0.34	Bone mineral density;	chr8:71097296	chr8:71155457~71204223:+
PCPG	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	4.43	1.83e-05	0.00837	0.35	0.34	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	4.43	1.83e-05	0.00837	0.35	0.34	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
PCPG	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	4.43	1.83e-05	0.00837	0.33	0.34	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
PCPG	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	4.43	1.83e-05	0.00837	0.43	0.34	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
PCPG	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-4.43	1.83e-05	0.00838	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
PCPG	cis	rs73201462	1	rs2955083	ENSG00000242551.2	POU5F1P6	-4.43	1.83e-05	0.00838	-0.69	-0.34	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128242335	chr3:128674735~128677005:-
PCPG	cis	rs7746199	0.736	rs34573979	ENSG00000219392.1	RP1-265C24.5	-4.43	1.83e-05	0.00838	-0.74	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13195636	ENSG00000219392.1	RP1-265C24.5	-4.43	1.83e-05	0.00838	-0.74	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs13209332	ENSG00000219392.1	RP1-265C24.5	-4.43	1.83e-05	0.00838	-0.74	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs34105070	ENSG00000219392.1	RP1-265C24.5	-4.43	1.83e-05	0.00838	-0.74	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.673	rs72845046	ENSG00000219392.1	RP1-265C24.5	-4.43	1.83e-05	0.00838	-0.74	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28115628~28116551:+
PCPG	cis	rs7746199	0.736	rs67652222	ENSG00000219392.1	RP1-265C24.5	-4.43	1.83e-05	0.00838	-0.74	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28115628~28116551:+
PCPG	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-4.43	1.83e-05	0.00839	-0.41	-0.34	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
PCPG	cis	rs7017914	0.652	rs441890	ENSG00000254031.4	RP11-326E22.1	4.43	1.83e-05	0.00839	0.34	0.34	Bone mineral density;	chr8:70652432	chr8:71155457~71204223:+
PCPG	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	4.43	1.83e-05	0.00839	0.35	0.34	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
PCPG	cis	rs657075	0.595	rs57750646	ENSG00000233006.5	AC034220.3	-4.43	1.83e-05	0.0084	-0.46	-0.34	Rheumatoid arthritis;	chr5:132344571	chr5:132311285~132369916:-
PCPG	cis	rs7017914	0.905	rs2639956	ENSG00000254031.4	RP11-326E22.1	4.43	1.84e-05	0.0084	0.32	0.34	Bone mineral density;	chr8:71011856	chr8:71155457~71204223:+
PCPG	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-4.43	1.84e-05	0.00841	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
PCPG	cis	rs12048904	1	rs12048904	ENSG00000235795.1	RP11-421L21.2	4.43	1.84e-05	0.00841	0.4	0.34	Multiple sclerosis;	chr1:100865980	chr1:100995473~100996260:+
PCPG	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-4.43	1.84e-05	0.00842	-0.43	-0.34	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
PCPG	cis	rs9302635	0.625	rs34417180	ENSG00000260886.1	TAT-AS1	4.43	1.84e-05	0.00842	0.62	0.34	Blood protein levels;	chr16:72185857	chr16:71565789~71578187:+
PCPG	cis	rs7246657	0.678	rs2927740	ENSG00000226686.6	LINC01535	4.43	1.84e-05	0.00842	0.5	0.34	Coronary artery calcification;	chr19:37650065	chr19:37251912~37265535:+
PCPG	cis	rs13113518	1	rs13132420	ENSG00000272969.1	RP11-528I4.2	-4.43	1.84e-05	0.00843	-0.36	-0.34	Height;	chr4:55526646	chr4:55547112~55547889:+
PCPG	cis	rs60695258	0.55	rs340636	ENSG00000251411.1	RP11-397E7.4	4.43	1.84e-05	0.00843	0.31	0.34	Hematocrit;	chr4:87009608	chr4:86913266~86914817:-
PCPG	cis	rs60695258	0.55	rs340648	ENSG00000251411.1	RP11-397E7.4	4.43	1.84e-05	0.00843	0.31	0.34	Hematocrit;	chr4:87019788	chr4:86913266~86914817:-
PCPG	cis	rs2235642	0.893	rs2143285	ENSG00000260989.1	LA16c-395F10.2	-4.43	1.84e-05	0.00844	-0.34	-0.34	Coronary artery disease;	chr16:1543170	chr16:1580527~1610328:+
PCPG	cis	rs1048886	0.872	rs12525538	ENSG00000271967.1	RP11-134K13.4	-4.42	1.85e-05	0.00845	-0.43	-0.34	Type 2 diabetes;	chr6:70575198	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs34246525	ENSG00000271967.1	RP11-134K13.4	-4.42	1.85e-05	0.00845	-0.43	-0.34	Type 2 diabetes;	chr6:70575239	chr6:70596438~70596980:+
PCPG	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-4.42	1.85e-05	0.00845	-0.47	-0.34	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
PCPG	cis	rs1048886	0.872	rs55639214	ENSG00000271967.1	RP11-134K13.4	-4.42	1.85e-05	0.00845	-0.42	-0.34	Type 2 diabetes;	chr6:70577494	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs56114703	ENSG00000271967.1	RP11-134K13.4	-4.42	1.85e-05	0.00845	-0.42	-0.34	Type 2 diabetes;	chr6:70577594	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs12203089	ENSG00000271967.1	RP11-134K13.4	-4.42	1.85e-05	0.00845	-0.42	-0.34	Type 2 diabetes;	chr6:70578956	chr6:70596438~70596980:+
PCPG	cis	rs964611	0.882	rs3784619	ENSG00000259488.2	RP11-154J22.1	4.42	1.85e-05	0.00845	0.35	0.34	Metabolite levels (Pyroglutamine);	chr15:48333741	chr15:48312353~48331856:-
PCPG	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	4.42	1.85e-05	0.00846	0.46	0.34	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	4.42	1.85e-05	0.00846	0.46	0.34	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
PCPG	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	4.42	1.85e-05	0.00847	0.44	0.34	Height;	chr6:109478720	chr6:109382795~109383666:+
PCPG	cis	rs763014	0.931	rs7191939	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:580089	chr16:654611~656194:-
PCPG	cis	rs763014	0.865	rs2018789	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:582051	chr16:654611~656194:-
PCPG	cis	rs763014	0.898	rs916414	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:582073	chr16:654611~656194:-
PCPG	cis	rs763014	0.833	rs916415	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:582115	chr16:654611~656194:-
PCPG	cis	rs763014	0.898	rs4984897	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:582180	chr16:654611~656194:-
PCPG	cis	rs763014	0.898	rs916416	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:582198	chr16:654611~656194:-
PCPG	cis	rs763014	0.833	rs3743902	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:582728	chr16:654611~656194:-
PCPG	cis	rs763014	0.898	rs1045277	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:583125	chr16:654611~656194:-
PCPG	cis	rs763014	0.865	rs710924	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:583353	chr16:654611~656194:-
PCPG	cis	rs763014	0.931	rs710925	ENSG00000262528.2	LA16c-349E10.1	4.42	1.85e-05	0.00847	0.41	0.34	Height;	chr16:583354	chr16:654611~656194:-
PCPG	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	4.42	1.85e-05	0.00847	0.46	0.34	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
PCPG	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	4.42	1.85e-05	0.00848	0.39	0.34	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
PCPG	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	-4.42	1.85e-05	0.00848	-0.39	-0.34	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
PCPG	cis	rs3806843	0.966	rs2563263	ENSG00000202515.1	VTRNA1-3	-4.42	1.85e-05	0.00848	-0.45	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr5:140726158~140726246:+
PCPG	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	4.42	1.85e-05	0.00848	0.43	0.34	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
PCPG	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-4.42	1.86e-05	0.00848	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-4.42	1.86e-05	0.00848	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-4.42	1.86e-05	0.00848	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
PCPG	cis	rs7911712	0.872	rs2764351	ENSG00000228462.1	RP11-445N18.3	4.42	1.86e-05	0.00848	0.48	0.34	Emphysema-related traits;	chr10:44784055	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs2793297	ENSG00000228462.1	RP11-445N18.3	4.42	1.86e-05	0.00848	0.48	0.34	Emphysema-related traits;	chr10:44784204	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs2764350	ENSG00000228462.1	RP11-445N18.3	4.42	1.86e-05	0.00848	0.48	0.34	Emphysema-related traits;	chr10:44784738	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs2793296	ENSG00000228462.1	RP11-445N18.3	4.42	1.86e-05	0.00848	0.48	0.34	Emphysema-related traits;	chr10:44785129	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs2611374	ENSG00000228462.1	RP11-445N18.3	4.42	1.86e-05	0.00848	0.48	0.34	Emphysema-related traits;	chr10:44785216	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs2793295	ENSG00000228462.1	RP11-445N18.3	4.42	1.86e-05	0.00848	0.48	0.34	Emphysema-related traits;	chr10:44785824	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs1325160	ENSG00000228462.1	RP11-445N18.3	4.42	1.86e-05	0.00848	0.48	0.34	Emphysema-related traits;	chr10:44786183	chr10:45073146~45073541:-
PCPG	cis	rs7017914	0.69	rs7844508	ENSG00000254031.4	RP11-326E22.1	4.42	1.86e-05	0.00849	0.32	0.34	Bone mineral density;	chr8:70690760	chr8:71155457~71204223:+
PCPG	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-4.42	1.86e-05	0.00849	-0.36	-0.34	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
PCPG	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-4.42	1.86e-05	0.00849	-0.56	-0.34	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
PCPG	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	4.42	1.86e-05	0.0085	0.45	0.34	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
PCPG	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	4.42	1.86e-05	0.0085	0.49	0.34	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
PCPG	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-4.42	1.86e-05	0.0085	-0.33	-0.34	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
PCPG	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	4.42	1.86e-05	0.00851	0.48	0.34	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	4.42	1.86e-05	0.00851	0.48	0.34	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
PCPG	cis	rs2288884	0.559	rs12461141	ENSG00000275055.1	CTC-471J1.11	-4.42	1.86e-05	0.00852	-0.32	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.559	rs12459079	ENSG00000275055.1	CTC-471J1.11	-4.42	1.86e-05	0.00852	-0.32	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.559	rs12461226	ENSG00000275055.1	CTC-471J1.11	-4.42	1.86e-05	0.00852	-0.32	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.559	rs12461230	ENSG00000275055.1	CTC-471J1.11	-4.42	1.86e-05	0.00852	-0.32	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:52049007~52049754:+
PCPG	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-4.42	1.87e-05	0.00853	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-4.42	1.87e-05	0.00853	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
PCPG	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-4.42	1.87e-05	0.00855	-0.37	-0.34	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
PCPG	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	4.42	1.87e-05	0.00855	0.34	0.34	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-4.42	1.87e-05	0.00855	-0.36	-0.34	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-4.42	1.87e-05	0.00855	-0.36	-0.34	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
PCPG	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-4.42	1.87e-05	0.00856	-0.42	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
PCPG	cis	rs11858159	1	rs12913638	ENSG00000260760.1	PWRN3	4.42	1.87e-05	0.00856	0.37	0.34	Platelet thrombus formation;	chr15:24566200	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.783	rs12915660	ENSG00000260760.1	PWRN3	4.42	1.87e-05	0.00856	0.37	0.34	Platelet thrombus formation;	chr15:24566371	chr15:24441127~24447967:+
PCPG	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	4.42	1.88e-05	0.00857	0.5	0.34	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
PCPG	cis	rs7824557	0.603	rs2250028	ENSG00000255020.1	AF131216.5	4.42	1.88e-05	0.00857	0.47	0.34	Retinal vascular caliber;	chr8:11356080	chr8:11345748~11347502:-
PCPG	cis	rs763121	0.815	rs9306328	ENSG00000273076.1	RP3-508I15.22	4.42	1.88e-05	0.00857	0.34	0.34	Menopause (age at onset);	chr22:38632908	chr22:38743495~38743910:+
PCPG	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	4.42	1.88e-05	0.00857	0.47	0.34	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
PCPG	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	4.42	1.88e-05	0.00858	0.57	0.34	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
PCPG	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-4.42	1.88e-05	0.00858	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
PCPG	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	4.42	1.88e-05	0.00858	0.45	0.34	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
PCPG	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-4.42	1.89e-05	0.0086	-0.49	-0.34	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
PCPG	cis	rs4376189	0.614	rs11132339	ENSG00000207497.1	Y_RNA	4.42	1.89e-05	0.0086	0.48	0.34	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185717434	chr4:185709873~185709967:-
PCPG	cis	rs7746199	0.736	rs34965299	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0086	-0.74	-0.34	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28115628~28116551:+
PCPG	cis	rs35491132	1	rs35491132	ENSG00000219392.1	RP1-265C24.5	-4.42	1.89e-05	0.0086	-0.74	-0.34	Urinary tract infection frequency;	chr6:27559449	chr6:28115628~28116551:+
PCPG	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-4.42	1.89e-05	0.00861	-0.34	-0.34	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
PCPG	cis	rs1440410	0.965	rs57168887	ENSG00000250326.1	RP11-284M14.1	4.42	1.89e-05	0.00862	0.3	0.34	Ischemic stroke;	chr4:143193042	chr4:142933195~143184861:-
PCPG	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	4.42	1.89e-05	0.00862	0.39	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
PCPG	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	4.42	1.89e-05	0.00862	0.46	0.34	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
PCPG	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	4.42	1.89e-05	0.00863	0.41	0.34	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
PCPG	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-4.42	1.89e-05	0.00863	-0.49	-0.34	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
PCPG	cis	rs2736345	0.89	rs4840565	ENSG00000255518.1	RP11-148O21.4	4.42	1.9e-05	0.00864	0.41	0.34	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:11556251~11558022:-
PCPG	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	4.42	1.9e-05	0.00865	0.56	0.34	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
PCPG	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-4.42	1.9e-05	0.00865	-0.39	-0.34	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-4.42	1.9e-05	0.00865	-0.39	-0.34	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
PCPG	cis	rs9840812	0.623	rs1145106	ENSG00000273486.1	RP11-731C17.2	4.42	1.9e-05	0.00865	0.41	0.34	Fibrinogen levels;	chr3:136393075	chr3:136837338~136839021:-
PCPG	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	4.42	1.9e-05	0.00865	0.39	0.34	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
PCPG	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	4.42	1.9e-05	0.00866	0.46	0.34	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
PCPG	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-4.42	1.9e-05	0.00866	-0.3	-0.34	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
PCPG	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	4.42	1.9e-05	0.00866	0.51	0.34	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
PCPG	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	4.42	1.9e-05	0.00866	0.73	0.34	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
PCPG	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	4.42	1.9e-05	0.00867	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	4.42	1.9e-05	0.00867	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	4.42	1.9e-05	0.00867	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	4.42	1.9e-05	0.00867	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
PCPG	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-4.42	1.9e-05	0.00867	-0.41	-0.34	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
PCPG	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	4.42	1.9e-05	0.00867	0.52	0.34	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
PCPG	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-4.42	1.9e-05	0.00867	-0.3	-0.34	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
PCPG	cis	rs2572431	0.543	rs2256016	ENSG00000255020.1	AF131216.5	4.42	1.91e-05	0.00868	0.42	0.34	Neuroticism;	chr8:11305093	chr8:11345748~11347502:-
PCPG	cis	rs5742933	0.557	rs1233276	ENSG00000273240.1	RP11-455J20.3	-4.42	1.91e-05	0.00868	-0.4	-0.34	Ferritin levels;	chr2:189820056	chr2:189763859~189764456:-
PCPG	cis	rs1048886	0.872	rs112809632	ENSG00000271967.1	RP11-134K13.4	-4.42	1.91e-05	0.00868	-0.43	-0.34	Type 2 diabetes;	chr6:70413963	chr6:70596438~70596980:+
PCPG	cis	rs2732480	0.5	rs2450991	ENSG00000240399.1	RP1-228P16.1	4.42	1.91e-05	0.00869	0.36	0.34	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48054813~48055591:-
PCPG	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-4.42	1.91e-05	0.00869	-0.46	-0.34	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
PCPG	cis	rs5742933	0.857	rs1233282	ENSG00000273240.1	RP11-455J20.3	-4.42	1.91e-05	0.0087	-0.35	-0.34	Ferritin levels;	chr2:189823518	chr2:189763859~189764456:-
PCPG	cis	rs575908	0.708	rs6663622	ENSG00000254154.7	RP4-798P15.3	4.42	1.91e-05	0.0087	0.33	0.34	Breast cancer;	chr1:177898473	chr1:177928788~178038007:-
PCPG	cis	rs4489787	0.892	rs2705159	ENSG00000240399.1	RP1-228P16.1	4.42	1.91e-05	0.0087	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr12:48508409	chr12:48054813~48055591:-
PCPG	cis	rs4489787	0.803	rs2705158	ENSG00000240399.1	RP1-228P16.1	4.42	1.91e-05	0.0087	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr12:48511092	chr12:48054813~48055591:-
PCPG	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	4.42	1.91e-05	0.0087	0.52	0.34	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	4.42	1.91e-05	0.0087	0.52	0.34	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	4.42	1.91e-05	0.0087	0.52	0.34	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
PCPG	cis	rs2531992	0.925	rs2531993	ENSG00000262185.1	RP11-462G12.1	-4.42	1.91e-05	0.0087	-0.55	-0.34	Waist circumference;	chr16:3964244	chr16:3947609~3950444:-
PCPG	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	4.42	1.91e-05	0.00871	0.38	0.34	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
PCPG	cis	rs7208859	0.623	rs426434	ENSG00000263603.1	CTD-2349P21.5	-4.42	1.92e-05	0.00872	-0.57	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30729469~30731202:+
PCPG	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-4.42	1.92e-05	0.00872	-0.41	-0.34	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
PCPG	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	4.42	1.92e-05	0.00873	0.34	0.34	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
PCPG	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-4.42	1.92e-05	0.00873	-0.48	-0.34	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
PCPG	cis	rs11214589	0.651	rs12360992	ENSG00000256757.1	RP11-159N11.3	4.41	1.92e-05	0.00874	0.35	0.34	Neuroticism;	chr11:113392178	chr11:113405321~113412117:+
PCPG	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-4.41	1.93e-05	0.00875	-0.49	-0.34	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
PCPG	cis	rs1150668	0.796	rs2531825	ENSG00000219392.1	RP1-265C24.5	-4.41	1.93e-05	0.00877	-0.41	-0.34	Pubertal anthropometrics;	chr6:28381487	chr6:28115628~28116551:+
PCPG	cis	rs5758511	0.633	rs5758690	ENSG00000227370.1	RP4-669P10.19	4.41	1.93e-05	0.00877	0.51	0.34	Birth weight;	chr22:42272289	chr22:42132543~42132998:+
PCPG	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-4.41	1.93e-05	0.00877	-0.51	-0.34	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-4.41	1.93e-05	0.00877	-0.51	-0.34	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
PCPG	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-4.41	1.93e-05	0.00878	-0.44	-0.34	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
PCPG	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-4.41	1.93e-05	0.00878	-0.35	-0.34	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
PCPG	cis	rs2625529	0.59	rs7183196	ENSG00000260037.4	CTD-2524L6.3	-4.41	1.93e-05	0.00878	-0.48	-0.34	Red blood cell count;	chr15:72252060	chr15:71818396~71823384:+
PCPG	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	4.41	1.93e-05	0.00878	0.34	0.34	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
PCPG	cis	rs9595908	0.832	rs2032495	ENSG00000212293.1	SNORA16	4.41	1.93e-05	0.00879	0.42	0.34	Body mass index;	chr13:32630605	chr13:32420390~32420516:-
PCPG	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	4.41	1.93e-05	0.00879	0.49	0.34	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	4.41	1.93e-05	0.00879	0.49	0.34	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
PCPG	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	4.41	1.94e-05	0.00879	0.42	0.34	Height;	chr5:37535278	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.761	rs1533521	ENSG00000250155.1	CTD-2353F22.1	4.41	1.94e-05	0.00879	0.42	0.34	Height;	chr5:37540355	chr5:36666214~36725195:-
PCPG	cis	rs5758511	0.68	rs58654759	ENSG00000227370.1	RP4-669P10.19	4.41	1.94e-05	0.0088	0.52	0.34	Birth weight;	chr22:42246570	chr22:42132543~42132998:+
PCPG	cis	rs5758511	0.68	rs5758682	ENSG00000227370.1	RP4-669P10.19	4.41	1.94e-05	0.0088	0.52	0.34	Birth weight;	chr22:42249196	chr22:42132543~42132998:+
PCPG	cis	rs5758511	0.68	rs34107327	ENSG00000227370.1	RP4-669P10.19	4.41	1.94e-05	0.0088	0.52	0.34	Birth weight;	chr22:42252347	chr22:42132543~42132998:+
PCPG	cis	rs5758511	0.68	rs5758684	ENSG00000227370.1	RP4-669P10.19	4.41	1.94e-05	0.0088	0.52	0.34	Birth weight;	chr22:42253503	chr22:42132543~42132998:+
PCPG	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-4.41	1.94e-05	0.0088	-0.44	-0.34	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-4.41	1.94e-05	0.0088	-0.44	-0.34	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-4.41	1.94e-05	0.0088	-0.44	-0.34	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-4.41	1.94e-05	0.0088	-0.44	-0.34	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-4.41	1.94e-05	0.0088	-0.44	-0.34	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
PCPG	cis	rs7911712	0.872	rs2793308	ENSG00000228462.1	RP11-445N18.3	4.41	1.94e-05	0.0088	0.48	0.34	Emphysema-related traits;	chr10:44775763	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs2793305	ENSG00000228462.1	RP11-445N18.3	4.41	1.94e-05	0.0088	0.48	0.34	Emphysema-related traits;	chr10:44776850	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs1590559	ENSG00000228462.1	RP11-445N18.3	4.41	1.94e-05	0.0088	0.48	0.34	Emphysema-related traits;	chr10:44781810	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs2793301	ENSG00000228462.1	RP11-445N18.3	4.41	1.94e-05	0.0088	0.48	0.34	Emphysema-related traits;	chr10:44782385	chr10:45073146~45073541:-
PCPG	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-4.41	1.94e-05	0.0088	-0.55	-0.34	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
PCPG	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-4.41	1.94e-05	0.0088	-0.55	-0.34	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
PCPG	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-4.41	1.94e-05	0.0088	-0.55	-0.34	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
PCPG	cis	rs7849270	0.76	rs882616	ENSG00000268707.1	RP11-247A12.7	4.41	1.94e-05	0.0088	0.38	0.34	Blood metabolite ratios;	chr9:129178586	chr9:129170434~129170940:+
PCPG	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	4.41	1.94e-05	0.0088	0.49	0.34	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
PCPG	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	4.41	1.94e-05	0.0088	0.39	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
PCPG	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-4.41	1.94e-05	0.0088	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-4.41	1.94e-05	0.0088	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
PCPG	cis	rs11858159	0.845	rs12908249	ENSG00000259905.4	PWRN1	4.41	1.94e-05	0.00881	0.36	0.34	Platelet thrombus formation;	chr15:24587002	chr15:24493137~24652130:+
PCPG	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-4.41	1.94e-05	0.00882	-0.5	-0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
PCPG	cis	rs2531992	0.62	rs2041248	ENSG00000262185.1	RP11-462G12.1	-4.41	1.94e-05	0.00882	-0.56	-0.34	Waist circumference;	chr16:3982488	chr16:3947609~3950444:-
PCPG	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-4.41	1.94e-05	0.00882	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
PCPG	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-4.41	1.94e-05	0.00882	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
PCPG	cis	rs7208859	0.673	rs11657270	ENSG00000263603.1	CTD-2349P21.5	-4.41	1.94e-05	0.00882	-0.66	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30729469~30731202:+
PCPG	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-4.41	1.94e-05	0.00883	-0.48	-0.34	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
PCPG	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-4.41	1.94e-05	0.00883	-0.48	-0.34	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
PCPG	cis	rs7017914	0.677	rs7010889	ENSG00000254031.4	RP11-326E22.1	4.41	1.95e-05	0.00883	0.32	0.34	Bone mineral density;	chr8:70741136	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs7016334	ENSG00000254031.4	RP11-326E22.1	4.41	1.95e-05	0.00883	0.32	0.34	Bone mineral density;	chr8:70742171	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.714	rs28376252	ENSG00000254031.4	RP11-326E22.1	4.41	1.95e-05	0.00883	0.32	0.34	Bone mineral density;	chr8:70747652	chr8:71155457~71204223:+
PCPG	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	4.41	1.95e-05	0.00883	0.36	0.34	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	4.41	1.95e-05	0.00883	0.36	0.34	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	4.41	1.95e-05	0.00883	0.36	0.34	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
PCPG	cis	rs9650657	0.537	rs7016385	ENSG00000255020.1	AF131216.5	4.41	1.95e-05	0.00884	0.47	0.34	Neuroticism;	chr8:10921962	chr8:11345748~11347502:-
PCPG	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	4.41	1.95e-05	0.00885	0.5	0.34	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
PCPG	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	4.41	1.95e-05	0.00885	0.45	0.34	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
PCPG	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	4.41	1.95e-05	0.00885	0.45	0.34	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
PCPG	cis	rs28386778	0.897	rs2727330	ENSG00000240280.5	TCAM1P	4.41	1.95e-05	0.00886	0.44	0.34	Prudent dietary pattern;	chr17:63848138	chr17:63849292~63864379:+
PCPG	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-4.41	1.95e-05	0.00886	-0.35	-0.34	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
PCPG	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-4.41	1.95e-05	0.00886	-0.35	-0.34	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
PCPG	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-4.41	1.95e-05	0.00886	-0.41	-0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
PCPG	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	4.41	1.95e-05	0.00886	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	4.41	1.95e-05	0.00886	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	4.41	1.95e-05	0.00886	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	4.41	1.95e-05	0.00886	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	4.41	1.95e-05	0.00886	0.49	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
PCPG	cis	rs10208649	0.611	rs3929001	ENSG00000272156.1	RP11-477N3.1	-4.41	1.95e-05	0.00887	-0.54	-0.34	Body mass index;	chr2:54055750	chr2:54082554~54085066:+
PCPG	cis	rs4835473	0.932	rs11730929	ENSG00000251600.4	RP11-673E1.1	-4.41	1.95e-05	0.00887	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143834795	chr4:143912331~143982454:+
PCPG	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	4.41	1.96e-05	0.00887	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
PCPG	cis	rs752864	0.58	rs17613475	ENSG00000259438.1	CTD-2650P22.1	-4.41	1.96e-05	0.00887	-0.43	-0.34	Number of common colds;	chr15:52315065	chr15:52010999~52019095:-
PCPG	cis	rs12439619	0.705	rs4778665	ENSG00000228141.5	AC105339.1	-4.41	1.96e-05	0.00888	-0.52	-0.34	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82710471~82714026:-
PCPG	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-4.41	1.96e-05	0.00888	-0.45	-0.34	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
PCPG	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-4.41	1.96e-05	0.00888	-0.42	-0.34	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
PCPG	cis	rs2281603	0.598	rs10151656	ENSG00000259116.1	RP11-973N13.4	-4.41	1.96e-05	0.00888	-0.3	-0.34	Lymphocyte counts;	chr14:64594970	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs12385918	ENSG00000259116.1	RP11-973N13.4	-4.41	1.96e-05	0.00889	-0.32	-0.34	Lymphocyte counts;	chr14:64533227	chr14:64514154~64540368:-
PCPG	cis	rs13108904	0.87	rs3733338	ENSG00000254094.1	AC078852.1	-4.41	1.97e-05	0.00891	-0.39	-0.34	Obesity-related traits;	chr4:1247684	chr4:1356581~1358075:+
PCPG	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	4.41	1.97e-05	0.00891	0.47	0.34	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
PCPG	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-4.41	1.97e-05	0.00891	-0.3	-0.34	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
PCPG	cis	rs2060793	0.741	rs2060794	ENSG00000251991.1	RNU7-49P	4.41	1.97e-05	0.00892	0.39	0.34	Vitamin D levels;	chr11:14791437	chr11:14478892~14478953:+
PCPG	cis	rs2060793	0.741	rs3740823	ENSG00000251991.1	RNU7-49P	4.41	1.97e-05	0.00892	0.39	0.34	Vitamin D levels;	chr11:14804158	chr11:14478892~14478953:+
PCPG	cis	rs11148252	0.683	rs9536006	ENSG00000235660.1	LINC00345	-4.41	1.97e-05	0.00892	-0.41	-0.34	Lewy body disease;	chr13:52313572	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.711	rs61957304	ENSG00000235660.1	LINC00345	-4.41	1.97e-05	0.00893	-0.4	-0.34	Lewy body disease;	chr13:52224288	chr13:52484161~52484680:-
PCPG	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-4.41	1.97e-05	0.00893	-0.57	-0.34	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-4.41	1.97e-05	0.00893	-0.57	-0.34	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
PCPG	cis	rs6940638	0.637	rs13217239	ENSG00000216901.1	AL022393.7	4.41	1.97e-05	0.00893	0.46	0.34	Intelligence (multi-trait analysis);	chr6:27287188	chr6:28176188~28176674:+
PCPG	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-4.41	1.97e-05	0.00894	-0.45	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
PCPG	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	4.41	1.97e-05	0.00894	0.56	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
PCPG	cis	rs7759001	0.857	rs4713086	ENSG00000271755.1	RP1-153G14.4	4.41	1.98e-05	0.00895	0.5	0.34	Glomerular filtration rate (creatinine);	chr6:27382667	chr6:27404010~27406964:-
PCPG	cis	rs5758511	0.68	rs56111723	ENSG00000227370.1	RP4-669P10.19	4.41	1.98e-05	0.00895	0.52	0.34	Birth weight;	chr22:42268877	chr22:42132543~42132998:+
PCPG	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-4.41	1.98e-05	0.00895	-0.35	-0.34	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
PCPG	cis	rs11858159	0.871	rs7181390	ENSG00000260760.1	PWRN3	4.41	1.98e-05	0.00895	0.37	0.34	Platelet thrombus formation;	chr15:24566498	chr15:24441127~24447967:+
PCPG	cis	rs75804782	0.572	rs56330821	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238365308	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs56108200	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238368247	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs113725999	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238379010	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs55708222	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238379052	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.515	rs75251934	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238379746	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.515	rs79557340	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238389311	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.572	rs112551758	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238391129	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.572	rs74979875	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238393927	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.572	rs77008212	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238398472	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs11895642	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238399639	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs13024052	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238399815	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs57435966	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238402728	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs80271258	ENSG00000227107.1	AC096574.5	-4.41	1.98e-05	0.00896	-0.59	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:238402864	chr2:237612977~237626525:+
PCPG	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-4.41	1.98e-05	0.00896	-0.34	-0.34	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
PCPG	cis	rs539514	0.516	rs9318377	ENSG00000261105.4	LMO7-AS1	-4.41	1.98e-05	0.00896	-0.46	-0.34	Type 1 diabetes;	chr13:75835882	chr13:75604700~75635994:-
PCPG	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-4.41	1.98e-05	0.00896	-0.42	-0.34	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
PCPG	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-4.41	1.98e-05	0.00897	-0.69	-0.34	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
PCPG	cis	rs7911712	0.872	rs2764361	ENSG00000228462.1	RP11-445N18.3	4.41	1.98e-05	0.00897	0.48	0.34	Emphysema-related traits;	chr10:44777040	chr10:45073146~45073541:-
PCPG	cis	rs3806843	0.966	rs2563267	ENSG00000202515.1	VTRNA1-3	4.41	1.98e-05	0.00898	0.43	0.34	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.966	rs2563266	ENSG00000202515.1	VTRNA1-3	4.41	1.98e-05	0.00898	0.43	0.34	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr5:140726158~140726246:+
PCPG	cis	rs9393777	0.841	rs34332556	ENSG00000219392.1	RP1-265C24.5	-4.41	1.98e-05	0.00898	-0.72	-0.34	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28115628~28116551:+
PCPG	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	4.41	1.98e-05	0.00898	0.56	0.34	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
PCPG	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	4.41	1.99e-05	0.00899	0.46	0.34	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
PCPG	cis	rs7829975	0.714	rs11777085	ENSG00000173295.6	FAM86B3P	-4.41	1.99e-05	0.00899	-0.4	-0.34	Mood instability;	chr8:8814919	chr8:8228595~8244865:+
PCPG	cis	rs2898290	0.622	rs11250140	ENSG00000269954.1	RP11-148O21.6	-4.41	1.99e-05	0.009	-0.38	-0.34	Systolic blood pressure;	chr8:11489083	chr8:11552488~11552991:-
PCPG	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	4.41	1.99e-05	0.009	0.47	0.34	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
PCPG	cis	rs1949733	0.701	rs4696828	ENSG00000205959.3	RP11-689P11.2	4.41	1.99e-05	0.00901	0.38	0.34	Response to antineoplastic agents;	chr4:8453877	chr4:8482270~8512610:+
PCPG	cis	rs1949733	0.701	rs1880024	ENSG00000205959.3	RP11-689P11.2	-4.41	1.99e-05	0.00901	-0.38	-0.34	Response to antineoplastic agents;	chr4:8452912	chr4:8482270~8512610:+
PCPG	cis	rs1949733	0.701	rs940134	ENSG00000205959.3	RP11-689P11.2	-4.41	1.99e-05	0.00901	-0.38	-0.34	Response to antineoplastic agents;	chr4:8453143	chr4:8482270~8512610:+
PCPG	cis	rs1949733	0.701	rs871768	ENSG00000205959.3	RP11-689P11.2	-4.41	1.99e-05	0.00901	-0.38	-0.34	Response to antineoplastic agents;	chr4:8453211	chr4:8482270~8512610:+
PCPG	cis	rs5742933	0.948	rs7592066	ENSG00000273240.1	RP11-455J20.3	4.41	1.99e-05	0.00902	0.36	0.34	Ferritin levels;	chr2:189778792	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.779	rs7595020	ENSG00000273240.1	RP11-455J20.3	4.41	1.99e-05	0.00902	0.36	0.34	Ferritin levels;	chr2:189778950	chr2:189763859~189764456:-
PCPG	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-4.41	1.99e-05	0.00902	-0.49	-0.34	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
PCPG	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	4.41	2e-05	0.00903	0.45	0.34	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
PCPG	cis	rs11673344	0.503	rs703531	ENSG00000226686.6	LINC01535	4.41	2e-05	0.00903	0.43	0.34	Obesity-related traits;	chr19:37010050	chr19:37251912~37265535:+
PCPG	cis	rs9494145	0.68	rs9376092	ENSG00000232876.1	CTA-212D2.2	4.41	2e-05	0.00903	0.42	0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135055033~135060550:+
PCPG	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	4.41	2e-05	0.00904	0.42	0.34	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
PCPG	cis	rs4718428	1	rs4718421	ENSG00000273142.1	RP11-458F8.4	-4.41	2e-05	0.00904	-0.32	-0.34	Corneal structure;	chr7:66885313	chr7:66902857~66906297:+
PCPG	cis	rs2625529	0.652	rs2034879	ENSG00000260037.4	CTD-2524L6.3	-4.41	2e-05	0.00904	-0.43	-0.34	Red blood cell count;	chr15:72137648	chr15:71818396~71823384:+
PCPG	cis	rs875971	0.597	rs11771318	ENSG00000273142.1	RP11-458F8.4	4.41	2e-05	0.00904	0.32	0.34	Aortic root size;	chr7:66597493	chr7:66902857~66906297:+
PCPG	cis	rs9309711	0.813	rs11690865	ENSG00000225234.1	TRAPPC12-AS1	-4.41	2e-05	0.00905	-0.36	-0.34	Neurofibrillary tangles;	chr2:3468179	chr2:3481242~3482409:-
PCPG	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-4.4	2e-05	0.00905	-0.44	-0.34	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
PCPG	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	4.4	2e-05	0.00906	0.35	0.34	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
PCPG	cis	rs6957923	1	rs34287907	ENSG00000230658.1	KLHL7-AS1	4.4	2e-05	0.00906	0.42	0.34	Height;	chr7:23451065	chr7:23101228~23105703:-
PCPG	cis	rs6957923	0.967	rs10950944	ENSG00000230658.1	KLHL7-AS1	4.4	2e-05	0.00906	0.42	0.34	Height;	chr7:23451447	chr7:23101228~23105703:-
PCPG	cis	rs13113518	0.729	rs13120134	ENSG00000272969.1	RP11-528I4.2	4.4	2.01e-05	0.00907	0.39	0.34	Height;	chr4:55415153	chr4:55547112~55547889:+
PCPG	cis	rs9302635	0.513	rs8050238	ENSG00000260886.1	TAT-AS1	4.4	2.01e-05	0.00907	0.49	0.34	Blood protein levels;	chr16:72120288	chr16:71565789~71578187:+
PCPG	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	4.4	2.01e-05	0.00907	0.38	0.34	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
PCPG	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-4.4	2.01e-05	0.00907	-0.38	-0.34	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
PCPG	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-4.4	2.01e-05	0.00907	-0.36	-0.34	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
PCPG	cis	rs7824557	0.603	rs7016671	ENSG00000255020.1	AF131216.5	4.4	2.01e-05	0.00908	0.43	0.34	Retinal vascular caliber;	chr8:11324946	chr8:11345748~11347502:-
PCPG	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.00909	-0.49	-0.34	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.00909	-0.49	-0.34	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.00909	-0.49	-0.34	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.00909	-0.49	-0.34	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.00909	-0.49	-0.34	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.00909	-0.49	-0.34	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.00909	-0.49	-0.34	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
PCPG	cis	rs11673344	0.504	rs4806408	ENSG00000226686.6	LINC01535	4.4	2.01e-05	0.00909	0.45	0.34	Obesity-related traits;	chr19:37097875	chr19:37251912~37265535:+
PCPG	cis	rs7824557	0.628	rs34237267	ENSG00000255020.1	AF131216.5	4.4	2.01e-05	0.0091	0.43	0.34	Retinal vascular caliber;	chr8:11339792	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.628	rs7008205	ENSG00000255020.1	AF131216.5	4.4	2.01e-05	0.0091	0.43	0.34	Retinal vascular caliber;	chr8:11339814	chr8:11345748~11347502:-
PCPG	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.0091	-0.49	-0.34	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-4.4	2.01e-05	0.0091	-0.49	-0.34	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
PCPG	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-4.4	2.01e-05	0.0091	-0.32	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
PCPG	cis	rs11148252	0.514	rs3818422	ENSG00000235660.1	LINC00345	4.4	2.02e-05	0.0091	0.41	0.34	Lewy body disease;	chr13:52145079	chr13:52484161~52484680:-
PCPG	cis	rs4266144	1	rs4561781	ENSG00000241770.1	RP11-555M1.3	4.4	2.02e-05	0.00911	0.41	0.34	Coronary artery disease;	chr3:157135154	chr3:157163452~157169133:+
PCPG	cis	rs301901	0.796	rs4869520	ENSG00000250155.1	CTD-2353F22.1	4.4	2.02e-05	0.00911	0.4	0.34	Height;	chr5:37508981	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.796	rs1517789	ENSG00000250155.1	CTD-2353F22.1	4.4	2.02e-05	0.00911	0.4	0.34	Height;	chr5:37510578	chr5:36666214~36725195:-
PCPG	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-4.4	2.02e-05	0.00912	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-4.4	2.02e-05	0.00912	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-4.4	2.02e-05	0.00912	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
PCPG	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-4.4	2.02e-05	0.00912	-0.69	-0.34	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
PCPG	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-4.4	2.02e-05	0.00912	-0.69	-0.34	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
PCPG	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-4.4	2.02e-05	0.00913	-0.45	-0.34	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
PCPG	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-4.4	2.02e-05	0.00913	-0.45	-0.34	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
PCPG	cis	rs4819052	0.851	rs2838839	ENSG00000215447.6	BX322557.10	4.4	2.02e-05	0.00913	0.32	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45288052~45291738:+
PCPG	cis	rs10484885	0.757	rs12201016	ENSG00000232532.1	RP11-63K6.7	-4.4	2.02e-05	0.00913	-0.61	-0.34	QRS interval (sulfonylurea treatment interaction);	chr6:89439556	chr6:89920196~89921760:+
PCPG	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	4.4	2.02e-05	0.00913	0.43	0.34	Height;	chr6:109490935	chr6:109382795~109383666:+
PCPG	cis	rs1908814	0.516	rs60176945	ENSG00000255495.1	AC145124.2	4.4	2.03e-05	0.00914	0.35	0.34	Neuroticism;	chr8:11939165	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs56102998	ENSG00000255495.1	AC145124.2	4.4	2.03e-05	0.00914	0.35	0.34	Neuroticism;	chr8:11939166	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs35391955	ENSG00000255495.1	AC145124.2	4.4	2.03e-05	0.00914	0.35	0.34	Neuroticism;	chr8:11939219	chr8:12194467~12196280:+
PCPG	cis	rs1908814	0.516	rs58869268	ENSG00000255495.1	AC145124.2	4.4	2.03e-05	0.00914	0.35	0.34	Neuroticism;	chr8:11939586	chr8:12194467~12196280:+
PCPG	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	4.4	2.03e-05	0.00914	0.44	0.34	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
PCPG	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	4.4	2.03e-05	0.00915	0.45	0.34	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
PCPG	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-4.4	2.03e-05	0.00915	-0.44	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
PCPG	cis	rs58688157	0.96	rs60870990	ENSG00000251661.3	RP11-326C3.11	4.4	2.03e-05	0.00916	0.7	0.34	Systemic lupus erythematosus;	chr11:613742	chr11:318640~325631:+
PCPG	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-4.4	2.03e-05	0.00916	-0.42	-0.34	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-4.4	2.03e-05	0.00916	-0.42	-0.34	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
PCPG	cis	rs2235642	0.787	rs2235646	ENSG00000260989.1	LA16c-395F10.2	-4.4	2.03e-05	0.00916	-0.35	-0.34	Coronary artery disease;	chr16:1551286	chr16:1580527~1610328:+
PCPG	cis	rs2235642	0.821	rs8051895	ENSG00000260989.1	LA16c-395F10.2	-4.4	2.03e-05	0.00916	-0.35	-0.34	Coronary artery disease;	chr16:1552810	chr16:1580527~1610328:+
PCPG	cis	rs2235642	0.821	rs2281234	ENSG00000260989.1	LA16c-395F10.2	-4.4	2.03e-05	0.00916	-0.35	-0.34	Coronary artery disease;	chr16:1552937	chr16:1580527~1610328:+
PCPG	cis	rs2235642	0.75	rs2974845	ENSG00000260989.1	LA16c-395F10.2	-4.4	2.03e-05	0.00916	-0.36	-0.34	Coronary artery disease;	chr16:1598161	chr16:1580527~1610328:+
PCPG	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	4.4	2.03e-05	0.00916	0.43	0.34	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	4.4	2.03e-05	0.00917	0.44	0.34	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	4.4	2.03e-05	0.00917	0.44	0.34	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
PCPG	cis	rs13108904	0.901	rs66987549	ENSG00000254094.1	AC078852.1	-4.4	2.03e-05	0.00917	-0.39	-0.34	Obesity-related traits;	chr4:1278829	chr4:1356581~1358075:+
PCPG	cis	rs1048886	0.938	rs56397968	ENSG00000271967.1	RP11-134K13.4	-4.4	2.03e-05	0.00918	-0.43	-0.34	Type 2 diabetes;	chr6:70419103	chr6:70596438~70596980:+
PCPG	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	4.4	2.04e-05	0.00918	0.39	0.34	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
PCPG	cis	rs801193	0.613	rs2016325	ENSG00000273142.1	RP11-458F8.4	4.4	2.04e-05	0.00919	0.31	0.34	Aortic root size;	chr7:66858513	chr7:66902857~66906297:+
PCPG	cis	rs6579956	0.614	rs62398720	ENSG00000270978.1	RP11-54C4.2	-4.4	2.04e-05	0.00919	-0.41	-0.34	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152731576	chr5:151848886~151850791:+
PCPG	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-4.4	2.04e-05	0.00919	-0.43	-0.34	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
PCPG	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-4.4	2.04e-05	0.00919	-0.44	-0.34	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
PCPG	cis	rs6840258	0.723	rs443459	ENSG00000251411.1	RP11-397E7.4	-4.4	2.04e-05	0.0092	-0.33	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87054903	chr4:86913266~86914817:-
PCPG	cis	rs950169	0.922	rs4842939	ENSG00000235370.6	DNM1P51	-4.4	2.04e-05	0.0092	-0.31	-0.34	Schizophrenia;	chr15:84159214	chr15:84398316~84411701:-
PCPG	cis	rs13108904	0.935	rs4974575	ENSG00000254094.1	AC078852.1	-4.4	2.04e-05	0.0092	-0.38	-0.34	Obesity-related traits;	chr4:1258240	chr4:1356581~1358075:+
PCPG	cis	rs11673344	0.523	rs8108509	ENSG00000226686.6	LINC01535	4.4	2.04e-05	0.00921	0.43	0.34	Obesity-related traits;	chr19:37060370	chr19:37251912~37265535:+
PCPG	cis	rs11148252	0.774	rs7334583	ENSG00000235660.1	LINC00345	4.4	2.05e-05	0.00922	0.4	0.34	Lewy body disease;	chr13:52356217	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.774	rs9596649	ENSG00000235660.1	LINC00345	4.4	2.05e-05	0.00922	0.4	0.34	Lewy body disease;	chr13:52360475	chr13:52484161~52484680:-
PCPG	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-4.4	2.05e-05	0.00922	-0.45	-0.34	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
PCPG	cis	rs4819052	0.851	rs2330011	ENSG00000215447.6	BX322557.10	-4.4	2.05e-05	0.00923	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45288052~45291738:+
PCPG	cis	rs561341	0.882	rs28649357	ENSG00000265798.5	RP11-271K11.5	4.4	2.05e-05	0.00923	0.58	0.34	Hip circumference adjusted for BMI;	chr17:32040171	chr17:31038575~31059121:-
PCPG	cis	rs950169	0.881	rs150965	ENSG00000235370.6	DNM1P51	4.4	2.05e-05	0.00924	0.36	0.34	Schizophrenia;	chr15:84537296	chr15:84398316~84411701:-
PCPG	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-4.4	2.05e-05	0.00925	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
PCPG	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-4.4	2.05e-05	0.00926	-0.73	-0.34	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
PCPG	cis	rs2439831	1	rs689826	ENSG00000205771.5	CATSPER2P1	-4.4	2.06e-05	0.00927	-0.47	-0.34	Lung cancer in ever smokers;	chr15:43457718	chr15:43726918~43747094:-
PCPG	cis	rs2281603	0.951	rs73267744	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64511461	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs12586212	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64513329	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs60908674	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64514181	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.904	rs59440409	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64514249	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs61615397	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64514346	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs10133243	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64514807	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs3783724	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64516759	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs3783723	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64516821	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs12587136	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64518570	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs58893738	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64519093	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs28626711	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64521561	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs10133411	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64522206	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs17101896	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64526205	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs59512674	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64526295	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs61985711	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64526540	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs10143170	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64527045	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs10138256	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64528494	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs10149286	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64528518	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs1453009	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64528976	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.951	rs11158544	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64529769	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.857	rs3783722	ENSG00000259116.1	RP11-973N13.4	-4.4	2.06e-05	0.00927	-0.32	-0.34	Lymphocyte counts;	chr14:64531248	chr14:64514154~64540368:-
PCPG	cis	rs899997	0.862	rs11072787	ENSG00000261143.1	ADAMTS7P3	-4.4	2.06e-05	0.00927	-0.42	-0.34	Coronary artery disease or large artery stroke;	chr15:78680635	chr15:77976042~77993057:+
PCPG	cis	rs2736345	0.788	rs2618476	ENSG00000254774.1	RP11-148O21.3	4.4	2.06e-05	0.00927	0.39	0.34	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11553224~11554207:-
PCPG	cis	rs12989701	0.778	rs7584040	ENSG00000260163.1	RP11-521O16.2	-4.4	2.06e-05	0.00928	-0.38	-0.34	Alzheimer's disease (late onset);	chr2:127105648	chr2:127025211~127029686:+
PCPG	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-4.4	2.06e-05	0.00929	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
PCPG	cis	rs4835473	0.831	rs1579816	ENSG00000251600.4	RP11-673E1.1	4.4	2.07e-05	0.00929	0.4	0.34	Immature fraction of reticulocytes;	chr4:143866772	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4240334	ENSG00000251600.4	RP11-673E1.1	4.4	2.07e-05	0.00929	0.4	0.34	Immature fraction of reticulocytes;	chr4:143871352	chr4:143912331~143982454:+
PCPG	cis	rs2098713	0.549	rs62359033	ENSG00000250155.1	CTD-2353F22.1	4.4	2.07e-05	0.00929	0.41	0.34	Telomere length;	chr5:37549741	chr5:36666214~36725195:-
PCPG	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	4.4	2.07e-05	0.0093	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	4.4	2.07e-05	0.0093	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	4.4	2.07e-05	0.0093	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	4.4	2.07e-05	0.0093	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
PCPG	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-4.4	2.07e-05	0.0093	-0.37	-0.34	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
PCPG	cis	rs394563	0.726	rs366905	ENSG00000231760.4	RP11-350J20.5	4.4	2.07e-05	0.00931	0.43	0.34	Dupuytren's disease;	chr6:149413961	chr6:149796151~149826294:-
PCPG	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	4.4	2.07e-05	0.00932	0.32	0.34	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
PCPG	cis	rs5742933	0.681	rs4525728	ENSG00000273240.1	RP11-455J20.3	4.4	2.07e-05	0.00932	0.36	0.34	Ferritin levels;	chr2:189780324	chr2:189763859~189764456:-
PCPG	cis	rs1478897	0.898	rs2248700	ENSG00000255020.1	AF131216.5	-4.4	2.07e-05	0.00932	-0.44	-0.34	Systemic lupus erythematosus;	chr8:11536236	chr8:11345748~11347502:-
PCPG	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	4.4	2.07e-05	0.00932	0.34	0.34	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	4.4	2.07e-05	0.00932	0.34	0.34	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	4.4	2.07e-05	0.00932	0.34	0.34	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	4.4	2.07e-05	0.00932	0.34	0.34	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	4.4	2.07e-05	0.00932	0.34	0.34	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
PCPG	cis	rs7911712	0.872	rs2611375	ENSG00000228462.1	RP11-445N18.3	4.4	2.07e-05	0.00932	0.49	0.34	Emphysema-related traits;	chr10:44769132	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs1771990	ENSG00000228462.1	RP11-445N18.3	4.4	2.07e-05	0.00932	0.49	0.34	Emphysema-related traits;	chr10:44773677	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs1749331	ENSG00000228462.1	RP11-445N18.3	4.4	2.07e-05	0.00932	0.49	0.34	Emphysema-related traits;	chr10:44774267	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs1771985	ENSG00000228462.1	RP11-445N18.3	4.4	2.07e-05	0.00932	0.49	0.34	Emphysema-related traits;	chr10:44774598	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs1749333	ENSG00000228462.1	RP11-445N18.3	4.4	2.07e-05	0.00932	0.49	0.34	Emphysema-related traits;	chr10:44774725	chr10:45073146~45073541:-
PCPG	cis	rs657075	0.697	rs34362950	ENSG00000233006.5	AC034220.3	-4.4	2.07e-05	0.00932	-0.47	-0.34	Rheumatoid arthritis;	chr5:132430811	chr5:132311285~132369916:-
PCPG	cis	rs10865541	0.806	rs10187625	ENSG00000225234.1	TRAPPC12-AS1	-4.4	2.07e-05	0.00933	-0.33	-0.34	Obesity-related traits;	chr2:3417397	chr2:3481242~3482409:-
PCPG	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	4.4	2.08e-05	0.00933	0.69	0.34	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
PCPG	cis	rs889122	0.55	rs8108431	ENSG00000267289.1	CTD-2623N2.11	4.4	2.08e-05	0.00934	0.43	0.34	Menarche (age at onset);	chr19:9886011	chr19:9834079~9835013:-
PCPG	cis	rs7824557	0.614	rs2293860	ENSG00000255020.1	AF131216.5	4.4	2.08e-05	0.00934	0.44	0.34	Retinal vascular caliber;	chr8:11361877	chr8:11345748~11347502:-
PCPG	cis	rs11220082	0.666	rs12789687	ENSG00000254671.2	STT3A-AS1	-4.4	2.08e-05	0.00934	-0.34	-0.34	Schizophrenia;	chr11:125461254	chr11:125570284~125592568:-
PCPG	cis	rs11220082	0.666	rs12223186	ENSG00000254671.2	STT3A-AS1	-4.4	2.08e-05	0.00934	-0.34	-0.34	Schizophrenia;	chr11:125461743	chr11:125570284~125592568:-
PCPG	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	4.4	2.08e-05	0.00935	0.32	0.34	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
PCPG	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	4.4	2.08e-05	0.00935	0.38	0.34	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	4.4	2.08e-05	0.00935	0.38	0.34	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	4.4	2.08e-05	0.00935	0.38	0.34	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	4.4	2.08e-05	0.00935	0.38	0.34	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
PCPG	cis	rs2060793	0.712	rs6486202	ENSG00000251991.1	RNU7-49P	4.4	2.08e-05	0.00935	0.37	0.34	Vitamin D levels;	chr11:14777260	chr11:14478892~14478953:+
PCPG	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-4.4	2.08e-05	0.00935	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
PCPG	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-4.4	2.08e-05	0.00935	-0.4	-0.34	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
PCPG	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	4.4	2.08e-05	0.00935	0.43	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
PCPG	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	4.4	2.08e-05	0.00935	0.51	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
PCPG	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	4.4	2.08e-05	0.00935	0.51	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
PCPG	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	4.4	2.08e-05	0.00936	0.44	0.34	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
PCPG	cis	rs8098244	0.603	rs1711457	ENSG00000265752.2	RP11-403A21.1	4.39	2.09e-05	0.00936	0.41	0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699494	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.603	rs1788813	ENSG00000265752.2	RP11-403A21.1	4.39	2.09e-05	0.00936	0.41	0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701204	chr18:23957754~23982556:-
PCPG	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	4.39	2.09e-05	0.00937	0.55	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
PCPG	cis	rs748404	1	rs66651343	ENSG00000249839.1	AC011330.5	-4.39	2.09e-05	0.00937	-0.43	-0.34	Lung cancer;	chr15:43265806	chr15:43663654~43684339:-
PCPG	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-4.39	2.09e-05	0.00937	-0.48	-0.34	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	4.39	2.09e-05	0.00937	0.5	0.34	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
PCPG	cis	rs853679	0.882	rs9468287	ENSG00000216901.1	AL022393.7	4.39	2.09e-05	0.00937	0.65	0.34	Depression;	chr6:28111963	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.766	rs9368561	ENSG00000216901.1	AL022393.7	4.39	2.09e-05	0.00937	0.65	0.34	Depression;	chr6:28200565	chr6:28176188~28176674:+
PCPG	cis	rs1440410	0.798	rs11727441	ENSG00000250326.1	RP11-284M14.1	4.39	2.09e-05	0.00938	0.31	0.34	Ischemic stroke;	chr4:143242602	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs10010367	ENSG00000250326.1	RP11-284M14.1	4.39	2.09e-05	0.00938	0.31	0.34	Ischemic stroke;	chr4:143243669	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs1605581	ENSG00000250326.1	RP11-284M14.1	4.39	2.09e-05	0.00938	0.31	0.34	Ischemic stroke;	chr4:143245634	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs1039763	ENSG00000250326.1	RP11-284M14.1	4.39	2.09e-05	0.00938	0.31	0.34	Ischemic stroke;	chr4:143246860	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.763	rs1039762	ENSG00000250326.1	RP11-284M14.1	4.39	2.09e-05	0.00938	0.31	0.34	Ischemic stroke;	chr4:143246893	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs10002867	ENSG00000250326.1	RP11-284M14.1	4.39	2.09e-05	0.00938	0.31	0.34	Ischemic stroke;	chr4:143248497	chr4:142933195~143184861:-
PCPG	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-4.39	2.09e-05	0.00938	-0.49	-0.34	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-4.39	2.09e-05	0.00938	-0.49	-0.34	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-4.39	2.09e-05	0.00938	-0.49	-0.34	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-4.39	2.09e-05	0.00938	-0.49	-0.34	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
PCPG	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	4.39	2.09e-05	0.00939	0.38	0.34	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs138709	ENSG00000273076.1	RP3-508I15.22	4.39	2.09e-05	0.00939	0.38	0.34	Menopause (age at onset);	chr22:38743211	chr22:38743495~38743910:+
PCPG	cis	rs10200850	0.892	rs68080737	ENSG00000265215.1	MIR4269	4.39	2.09e-05	0.00939	0.56	0.34	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239329596	chr2:239305462~239305545:+
PCPG	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	4.39	2.09e-05	0.0094	0.44	0.34	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
PCPG	cis	rs12908161	0.959	rs2175567	ENSG00000259295.5	CSPG4P12	4.39	2.1e-05	0.00941	0.49	0.34	Schizophrenia;	chr15:84657715	chr15:85191438~85213905:+
PCPG	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	4.39	2.1e-05	0.00941	0.47	0.34	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
PCPG	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-4.39	2.1e-05	0.00941	-0.72	-0.34	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
PCPG	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-4.39	2.1e-05	0.00942	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-4.39	2.1e-05	0.00942	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
PCPG	cis	rs8030379	1	rs7183263	ENSG00000230373.7	GOLGA6L5P	-4.39	2.1e-05	0.00943	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904289	chr15:84507885~84516814:-
PCPG	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-4.39	2.11e-05	0.00945	-0.52	-0.34	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-4.39	2.11e-05	0.00945	-0.52	-0.34	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
PCPG	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-4.39	2.11e-05	0.00945	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-4.39	2.11e-05	0.00945	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-4.39	2.11e-05	0.00945	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-4.39	2.11e-05	0.00945	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
PCPG	cis	rs1600249	0.562	rs17153419	ENSG00000270154.1	RP11-419I17.1	-4.39	2.11e-05	0.00945	-0.42	-0.34	Rheumatoid arthritis;	chr8:11536724	chr8:12476462~12477122:+
PCPG	cis	rs10484885	0.757	rs12215741	ENSG00000232532.1	RP11-63K6.7	4.39	2.11e-05	0.00945	0.62	0.34	QRS interval (sulfonylurea treatment interaction);	chr6:89445126	chr6:89920196~89921760:+
PCPG	cis	rs34779708	0.766	rs16935949	ENSG00000230534.5	RP11-297A16.2	4.39	2.11e-05	0.00945	0.45	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35262887	chr10:35098006~35127020:-
PCPG	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-4.39	2.11e-05	0.00946	-0.3	-0.34	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
PCPG	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-4.39	2.11e-05	0.00946	-0.48	-0.34	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
PCPG	cis	rs8030379	1	rs7162129	ENSG00000230373.7	GOLGA6L5P	-4.39	2.11e-05	0.00946	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897692	chr15:84507885~84516814:-
PCPG	cis	rs916888	0.61	rs199530	ENSG00000232300.1	FAM215B	-4.39	2.11e-05	0.00946	-0.44	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46558830~46562795:-
PCPG	cis	rs657075	0.595	rs17693348	ENSG00000233006.5	AC034220.3	-4.39	2.11e-05	0.00948	-0.46	-0.34	Rheumatoid arthritis;	chr5:132280515	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.595	rs6864922	ENSG00000233006.5	AC034220.3	-4.39	2.11e-05	0.00948	-0.46	-0.34	Rheumatoid arthritis;	chr5:132280597	chr5:132311285~132369916:-
PCPG	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	4.39	2.12e-05	0.00948	0.36	0.34	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
PCPG	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	4.39	2.12e-05	0.00948	0.43	0.34	Height;	chr6:109518783	chr6:109382795~109383666:+
PCPG	cis	rs6456042	0.893	rs3099283	ENSG00000231297.3	RP11-459F1.2	4.39	2.12e-05	0.00948	0.38	0.34	Asthma;	chr6:166140682	chr6:166099665~166113273:+
PCPG	cis	rs13108904	0.935	rs13148614	ENSG00000254094.1	AC078852.1	-4.39	2.12e-05	0.00949	-0.38	-0.34	Obesity-related traits;	chr4:1254569	chr4:1356581~1358075:+
PCPG	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	4.39	2.12e-05	0.0095	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-4.39	2.12e-05	0.0095	-0.44	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
PCPG	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	-4.39	2.12e-05	0.0095	-0.41	-0.34	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
PCPG	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	4.39	2.12e-05	0.0095	0.41	0.34	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
PCPG	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-4.39	2.12e-05	0.00951	-0.56	-0.34	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-4.39	2.12e-05	0.00951	-0.56	-0.34	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
PCPG	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	4.39	2.12e-05	0.00951	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
PCPG	cis	rs2733954	0.689	rs8054972	ENSG00000179219.5	LINC00311	4.39	2.12e-05	0.00951	0.42	0.34	Leprosy;	chr16:85767759	chr16:85282958~85285963:+
PCPG	cis	rs13108904	0.521	rs4974609	ENSG00000253399.1	AC078852.2	4.39	2.13e-05	0.00953	0.35	0.34	Obesity-related traits;	chr4:1363136	chr4:1358479~1359461:+
PCPG	cis	rs7688540	0.8	rs6857106	ENSG00000275426.1	CH17-262A2.1	-4.39	2.13e-05	0.00953	-0.39	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:149738~150317:+
PCPG	cis	rs198389	0.589	rs198401	ENSG00000242349.4	NPPA-AS1	-4.39	2.13e-05	0.00953	-0.31	-0.34	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11828327	chr1:11841017~11848079:+
PCPG	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-4.39	2.13e-05	0.00953	-0.46	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
PCPG	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-4.39	2.13e-05	0.00953	-0.46	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
PCPG	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	4.39	2.13e-05	0.00954	0.43	0.34	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
PCPG	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-4.39	2.13e-05	0.00954	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
PCPG	cis	rs34421088	0.56	rs1478898	ENSG00000269954.1	RP11-148O21.6	-4.39	2.13e-05	0.00954	-0.38	-0.34	Neuroticism;	chr8:11537570	chr8:11552488~11552991:-
PCPG	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-4.39	2.13e-05	0.00954	-0.44	-0.34	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
PCPG	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	4.39	2.13e-05	0.00954	0.48	0.34	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	4.39	2.13e-05	0.00954	0.48	0.34	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	4.39	2.13e-05	0.00954	0.48	0.34	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
PCPG	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-4.39	2.13e-05	0.00955	-0.49	-0.34	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-4.39	2.13e-05	0.00955	-0.49	-0.34	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-4.39	2.13e-05	0.00955	-0.49	-0.34	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
PCPG	cis	rs7160336	0.641	rs17782448	ENSG00000259065.1	RP5-1021I20.1	-4.39	2.14e-05	0.00955	-0.43	-0.34	Blood protein levels;	chr14:74215998	chr14:73787360~73803270:+
PCPG	cis	rs867371	0.929	rs7173852	ENSG00000278603.1	RP13-608F4.5	4.39	2.14e-05	0.00955	0.42	0.34	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472203~82472426:+
PCPG	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	4.39	2.14e-05	0.00956	0.39	0.34	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
PCPG	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-4.39	2.14e-05	0.00957	-0.44	-0.34	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-4.39	2.14e-05	0.00957	-0.44	-0.34	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
PCPG	cis	rs4713118	0.738	rs200465	ENSG00000216901.1	AL022393.7	4.39	2.14e-05	0.00957	0.45	0.34	Parkinson's disease;	chr6:27789875	chr6:28176188~28176674:+
PCPG	cis	rs899997	0.773	rs62010525	ENSG00000261143.1	ADAMTS7P3	-4.39	2.14e-05	0.00958	-0.5	-0.34	Coronary artery disease or large artery stroke;	chr15:78675968	chr15:77976042~77993057:+
PCPG	cis	rs899997	0.773	rs12595461	ENSG00000261143.1	ADAMTS7P3	-4.39	2.14e-05	0.00958	-0.5	-0.34	Coronary artery disease or large artery stroke;	chr15:78676830	chr15:77976042~77993057:+
PCPG	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	-4.39	2.14e-05	0.00958	-0.41	-0.34	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
PCPG	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	4.39	2.14e-05	0.00958	0.56	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
PCPG	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-4.39	2.14e-05	0.00959	-0.39	-0.34	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-4.39	2.14e-05	0.00959	-0.39	-0.34	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-4.39	2.14e-05	0.00959	-0.39	-0.34	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-4.39	2.14e-05	0.00959	-0.39	-0.34	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
PCPG	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	4.39	2.15e-05	0.00959	0.47	0.34	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	4.39	2.15e-05	0.00959	0.47	0.34	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	4.39	2.15e-05	0.0096	0.46	0.34	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
PCPG	cis	rs6957923	0.935	rs67128962	ENSG00000230658.1	KLHL7-AS1	4.39	2.15e-05	0.0096	0.42	0.34	Height;	chr7:23447928	chr7:23101228~23105703:-
PCPG	cis	rs1048886	0.872	rs17634491	ENSG00000271967.1	RP11-134K13.4	-4.39	2.15e-05	0.0096	-0.43	-0.34	Type 2 diabetes;	chr6:70456784	chr6:70596438~70596980:+
PCPG	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-4.39	2.15e-05	0.0096	-0.76	-0.34	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
PCPG	cis	rs11673344	0.504	rs6510588	ENSG00000226686.6	LINC01535	-4.39	2.15e-05	0.0096	-0.44	-0.34	Obesity-related traits;	chr19:37106493	chr19:37251912~37265535:+
PCPG	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-4.39	2.15e-05	0.00961	-0.34	-0.34	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
PCPG	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	4.39	2.15e-05	0.00961	0.42	0.34	Height;	chr6:109332929	chr6:109382795~109383666:+
PCPG	cis	rs1048886	0.938	rs17706833	ENSG00000271967.1	RP11-134K13.4	-4.39	2.15e-05	0.00962	-0.43	-0.34	Type 2 diabetes;	chr6:70435844	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs79128960	ENSG00000271967.1	RP11-134K13.4	-4.39	2.15e-05	0.00963	-0.43	-0.34	Type 2 diabetes;	chr6:70425140	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.938	rs77408282	ENSG00000271967.1	RP11-134K13.4	-4.39	2.15e-05	0.00963	-0.43	-0.34	Type 2 diabetes;	chr6:70433388	chr6:70596438~70596980:+
PCPG	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-4.39	2.16e-05	0.00963	-0.34	-0.34	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
PCPG	cis	rs17826219	0.706	rs609472	ENSG00000266490.1	CTD-2349P21.9	4.39	2.16e-05	0.00963	0.41	0.34	Body mass index;	chr17:30624409	chr17:30792372~30792833:+
PCPG	cis	rs5742933	0.817	rs1233299	ENSG00000273240.1	RP11-455J20.3	-4.39	2.16e-05	0.00965	-0.35	-0.34	Ferritin levels;	chr2:189799912	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.803	rs1233302	ENSG00000273240.1	RP11-455J20.3	-4.39	2.16e-05	0.00965	-0.35	-0.34	Ferritin levels;	chr2:189804154	chr2:189763859~189764456:-
PCPG	cis	rs875971	0.862	rs778720	ENSG00000235475.1	LINC01372	-4.39	2.16e-05	0.00966	-0.34	-0.34	Aortic root size;	chr7:66381288	chr7:67335976~67340024:+
PCPG	cis	rs28386778	0.724	rs35092235	ENSG00000240280.5	TCAM1P	-4.39	2.16e-05	0.00966	-0.45	-0.34	Prudent dietary pattern;	chr17:63867261	chr17:63849292~63864379:+
PCPG	cis	rs748404	1	rs17779494	ENSG00000249839.1	AC011330.5	4.39	2.16e-05	0.00966	0.43	0.34	Lung cancer;	chr15:43287025	chr15:43663654~43684339:-
PCPG	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-4.39	2.16e-05	0.00966	-0.58	-0.34	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
PCPG	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	4.39	2.16e-05	0.00966	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
PCPG	cis	rs950169	0.922	rs2033284	ENSG00000235370.6	DNM1P51	4.39	2.17e-05	0.00967	0.36	0.34	Schizophrenia;	chr15:84391575	chr15:84398316~84411701:-
PCPG	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	4.39	2.17e-05	0.00967	0.45	0.34	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	4.39	2.17e-05	0.00967	0.45	0.34	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
PCPG	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-4.39	2.17e-05	0.00967	-0.44	-0.34	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
PCPG	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	4.39	2.17e-05	0.00968	0.36	0.34	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
PCPG	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	4.39	2.17e-05	0.00968	0.48	0.34	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	4.39	2.17e-05	0.00968	0.48	0.34	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
PCPG	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	4.39	2.17e-05	0.00968	0.48	0.34	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
PCPG	cis	rs8030379	0.967	rs11857009	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83898661	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2046120	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899010	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs11259928	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899343	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs922664	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900803	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1471553	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83902286	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1564475	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903477	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs62027761	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903845	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs117031571	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903902	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs7178962	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904496	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs899926	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904739	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs8029387	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906523	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs8028359	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906593	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs940934	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906776	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.935	rs1815172	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907080	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1810049	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907300	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs11853052	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907407	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2401172	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908205	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2401173	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908218	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2401174	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908240	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs11259929	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908450	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs11259930	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908598	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1480827	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909040	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2401176	ENSG00000230373.7	GOLGA6L5P	-4.39	2.17e-05	0.00968	-0.33	-0.34	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909612	chr15:84507885~84516814:-
PCPG	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	4.39	2.17e-05	0.00968	0.47	0.34	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
PCPG	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-4.39	2.17e-05	0.00968	-0.49	-0.34	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
PCPG	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	4.38	2.17e-05	0.00969	0.42	0.34	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
PCPG	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	4.38	2.17e-05	0.00969	0.55	0.34	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
PCPG	cis	rs7017914	0.69	rs7838421	ENSG00000254031.4	RP11-326E22.1	4.38	2.17e-05	0.0097	0.31	0.34	Bone mineral density;	chr8:70760088	chr8:71155457~71204223:+
PCPG	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-4.38	2.18e-05	0.0097	-0.49	-0.34	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
PCPG	cis	rs3809060	0.92	rs7120686	ENSG00000213713.3	PIGCP1	4.38	2.18e-05	0.0097	0.18	0.34	Inguinal hernia;	chr11:32438681	chr11:33075566~33076460:-
PCPG	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	4.38	2.18e-05	0.0097	0.46	0.34	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
PCPG	cis	rs7789940	0.904	rs12531348	ENSG00000186704.9	DTX2P1	4.38	2.18e-05	0.00971	0.43	0.34	Multiple sclerosis;	chr7:76307874	chr7:76978617~77004308:+
PCPG	cis	rs7789940	0.904	rs61294900	ENSG00000186704.9	DTX2P1	4.38	2.18e-05	0.00971	0.43	0.34	Multiple sclerosis;	chr7:76307895	chr7:76978617~77004308:+
PCPG	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-4.38	2.18e-05	0.00972	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
PCPG	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	4.38	2.18e-05	0.00973	0.48	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
PCPG	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-4.38	2.18e-05	0.00973	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-4.38	2.18e-05	0.00973	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
PCPG	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	4.38	2.18e-05	0.00973	0.38	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
PCPG	cis	rs9400467	0.528	rs17539197	ENSG00000271789.1	RP5-1112D6.7	-4.38	2.19e-05	0.00975	-0.33	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111297126~111298510:+
PCPG	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-4.38	2.19e-05	0.00975	-0.38	-0.34	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
PCPG	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-4.38	2.19e-05	0.00976	-0.5	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
PCPG	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-4.38	2.19e-05	0.00976	-0.34	-0.34	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
PCPG	cis	rs9650657	0.537	rs4841457	ENSG00000255020.1	AF131216.5	-4.38	2.19e-05	0.00976	-0.46	-0.34	Neuroticism;	chr8:10916001	chr8:11345748~11347502:-
PCPG	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	4.38	2.19e-05	0.00977	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
PCPG	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	4.38	2.19e-05	0.00977	0.47	0.34	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
PCPG	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	4.38	2.2e-05	0.00978	0.43	0.34	Height;	chr6:109526846	chr6:109382795~109383666:+
PCPG	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-4.38	2.2e-05	0.00978	-0.44	-0.34	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
PCPG	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	4.38	2.2e-05	0.00979	0.75	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
PCPG	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-4.38	2.2e-05	0.00979	-0.44	-0.34	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
PCPG	cis	rs2243480	1	rs427044	ENSG00000230189.5	GS1-124K5.2	4.38	2.2e-05	0.00979	0.52	0.34	Diabetic kidney disease;	chr7:66043558	chr7:66409143~66490059:-
PCPG	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	4.38	2.2e-05	0.00979	0.39	0.34	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
PCPG	cis	rs196889	0.611	rs396626	ENSG00000253535.4	RP11-624C23.1	-4.38	2.2e-05	0.0098	-0.34	-0.34	Seasonality;	chr8:24862556	chr8:24295814~24912073:-
PCPG	cis	rs1949733	0.655	rs2631736	ENSG00000205959.3	RP11-689P11.2	4.38	2.2e-05	0.0098	0.38	0.34	Response to antineoplastic agents;	chr4:8476694	chr4:8482270~8512610:+
PCPG	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	4.38	2.21e-05	0.00982	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
PCPG	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	-4.38	2.21e-05	0.00983	-0.38	-0.34	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	-4.38	2.21e-05	0.00983	-0.38	-0.34	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
PCPG	cis	rs853679	0.882	rs9380069	ENSG00000219392.1	RP1-265C24.5	-4.38	2.21e-05	0.00983	-0.54	-0.34	Depression;	chr6:28235522	chr6:28115628~28116551:+
PCPG	cis	rs1874124	0.577	rs2807880	ENSG00000272823.1	RP11-295M18.6	4.38	2.21e-05	0.00983	0.47	0.34	Cholesterol, total;	chr1:220869661	chr1:220828676~220829211:-
PCPG	cis	rs6121246	0.697	rs45557936	ENSG00000230613.1	HM13-AS1	4.38	2.21e-05	0.00984	0.49	0.34	Mean corpuscular hemoglobin;	chr20:31638887	chr20:31567707~31573263:-
PCPG	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-4.38	2.22e-05	0.00986	-0.49	-0.34	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
PCPG	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-4.38	2.22e-05	0.00987	-0.44	-0.34	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
PCPG	cis	rs1003719	0.715	rs2835659	ENSG00000228677.1	TTC3-AS1	-4.38	2.22e-05	0.00987	-0.41	-0.34	Eye color traits;	chr21:37195601	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs7280251	ENSG00000228677.1	TTC3-AS1	-4.38	2.22e-05	0.00987	-0.41	-0.34	Eye color traits;	chr21:37195610	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs6579	ENSG00000228677.1	TTC3-AS1	-4.38	2.22e-05	0.00987	-0.41	-0.34	Eye color traits;	chr21:37196007	chr21:37187666~37193926:-
PCPG	cis	rs2625529	0.526	rs8040828	ENSG00000260037.4	CTD-2524L6.3	4.38	2.22e-05	0.00988	0.44	0.34	Red blood cell count;	chr15:72200438	chr15:71818396~71823384:+
PCPG	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	4.38	2.22e-05	0.00988	0.36	0.34	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
PCPG	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	4.38	2.22e-05	0.00989	0.5	0.34	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
PCPG	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-4.38	2.23e-05	0.00991	-0.55	-0.34	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
PCPG	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-4.38	2.23e-05	0.00991	-0.55	-0.34	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
PCPG	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-4.38	2.23e-05	0.00992	-0.45	-0.34	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
PCPG	cis	rs3758911	0.861	rs1388170	ENSG00000255353.1	RP11-382M14.1	-4.38	2.23e-05	0.00992	-0.46	-0.34	Coronary artery disease;	chr11:107272130	chr11:107176286~107177530:+
PCPG	cis	rs5769765	0.817	rs9616212	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49924039	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs9616213	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49924203	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.773	rs7290751	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49924664	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.779	rs12170530	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49924774	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs9616216	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49925279	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs9616217	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49925298	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs9627800	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49925703	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.865	rs10854860	ENSG00000278869.1	CITF22-49E9.3	4.38	2.23e-05	0.00992	0.45	0.34	Schizophrenia;	chr22:49926381	chr22:49933198~49934074:-
PCPG	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-4.38	2.23e-05	0.00992	-0.39	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
PCPG	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-4.38	2.23e-05	0.00992	-0.64	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
PCPG	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	4.38	2.24e-05	0.00993	0.43	0.34	Height;	chr6:109533040	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	4.38	2.24e-05	0.00993	0.43	0.34	Height;	chr6:109534269	chr6:109382795~109383666:+
PCPG	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	4.38	2.24e-05	0.00993	0.45	0.34	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
PCPG	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-4.38	2.24e-05	0.00993	-0.4	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
PCPG	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-4.38	2.24e-05	0.00993	-0.47	-0.34	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
PCPG	cis	rs9299346	0.594	rs10819967	ENSG00000225376.4	TMEM246-AS1	4.38	2.24e-05	0.00994	0.41	0.34	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101656637	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10819968	ENSG00000225376.4	TMEM246-AS1	4.38	2.24e-05	0.00994	0.41	0.34	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101656792	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10819969	ENSG00000225376.4	TMEM246-AS1	4.38	2.24e-05	0.00994	0.41	0.34	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101656991	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10819970	ENSG00000225376.4	TMEM246-AS1	4.38	2.24e-05	0.00994	0.41	0.34	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101657023	chr9:101468439~101481502:+
PCPG	cis	rs6957923	0.967	rs11762106	ENSG00000230658.1	KLHL7-AS1	4.38	2.24e-05	0.00994	0.41	0.34	Height;	chr7:23454841	chr7:23101228~23105703:-
PCPG	cis	rs6957923	1	rs11772260	ENSG00000230658.1	KLHL7-AS1	4.38	2.24e-05	0.00994	0.41	0.34	Height;	chr7:23454881	chr7:23101228~23105703:-
PCPG	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-4.38	2.24e-05	0.00995	-0.55	-0.34	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
PCPG	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-4.38	2.24e-05	0.00995	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-4.38	2.25e-05	0.00997	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-4.38	2.25e-05	0.00997	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
PCPG	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	4.38	2.25e-05	0.00998	0.49	0.34	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
PCPG	cis	rs1440410	0.835	rs11100771	ENSG00000250326.1	RP11-284M14.1	-4.38	2.25e-05	0.00998	-0.31	-0.34	Ischemic stroke;	chr4:143132728	chr4:142933195~143184861:-
PCPG	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-4.38	2.25e-05	0.00999	-0.37	-0.34	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
PCPG	cis	rs2733954	0.83	rs301164	ENSG00000179219.5	LINC00311	-4.38	2.25e-05	0.00999	-0.44	-0.34	Leprosy;	chr16:85780274	chr16:85282958~85285963:+
PCPG	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	4.38	2.25e-05	0.00999	0.45	0.34	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
PCPG	cis	rs11976180	0.517	rs6949375	ENSG00000228960.5	OR2A9P	-4.38	2.25e-05	0.00999	-0.59	-0.34	Obesity-related traits;	chr7:144076758	chr7:144294480~144300934:+
PCPG	cis	rs8098244	0.565	rs11664777	ENSG00000265752.2	RP11-403A21.1	4.38	2.25e-05	0.01	0.39	0.34	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23731793	chr18:23957754~23982556:-
PCPG	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-4.38	2.25e-05	0.01	-0.45	-0.34	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
PCPG	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-4.38	2.25e-05	0.01	-0.34	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
PCPG	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	4.38	2.26e-05	0.01	0.38	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	4.38	2.26e-05	0.01	0.38	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
PCPG	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	4.38	2.26e-05	0.01	0.39	0.34	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
PCPG	cis	rs964611	1	rs74012002	ENSG00000259488.2	RP11-154J22.1	-4.38	2.26e-05	0.01	-0.37	-0.34	Metabolite levels (Pyroglutamine);	chr15:48313250	chr15:48312353~48331856:-
PCPG	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	4.37	2.26e-05	0.01	0.49	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
PCPG	cis	rs7017914	0.667	rs13281864	ENSG00000254031.4	RP11-326E22.1	4.37	2.26e-05	0.01	0.32	0.34	Bone mineral density;	chr8:70730338	chr8:71155457~71204223:+
PCPG	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	4.37	2.27e-05	0.01	0.35	0.34	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
PCPG	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-4.37	2.27e-05	0.01	-0.45	-0.34	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
PCPG	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-4.37	2.27e-05	0.01	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-4.37	2.27e-05	0.01	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-4.37	2.27e-05	0.01	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
PCPG	cis	rs748404	0.736	rs542036	ENSG00000249839.1	AC011330.5	4.37	2.27e-05	0.0101	0.38	0.34	Lung cancer;	chr15:43248941	chr15:43663654~43684339:-
PCPG	cis	rs5769765	0.908	rs9616396	ENSG00000278869.1	CITF22-49E9.3	4.37	2.27e-05	0.0101	0.45	0.34	Schizophrenia;	chr22:49924177	chr22:49933198~49934074:-
PCPG	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-4.37	2.27e-05	0.0101	-0.49	-0.34	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-4.37	2.27e-05	0.0101	-0.49	-0.34	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-4.37	2.27e-05	0.0101	-0.49	-0.34	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-4.37	2.27e-05	0.0101	-0.49	-0.34	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-4.37	2.27e-05	0.0101	-0.49	-0.34	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-4.37	2.27e-05	0.0101	-0.49	-0.34	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
PCPG	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	4.37	2.27e-05	0.0101	0.38	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
PCPG	cis	rs6456042	0.964	rs3127418	ENSG00000231297.3	RP11-459F1.2	4.37	2.27e-05	0.0101	0.37	0.34	Asthma;	chr6:166124688	chr6:166099665~166113273:+
PCPG	cis	rs6456042	0.829	rs3127419	ENSG00000231297.3	RP11-459F1.2	4.37	2.27e-05	0.0101	0.37	0.34	Asthma;	chr6:166125039	chr6:166099665~166113273:+
PCPG	cis	rs10435719	0.902	rs7006538	ENSG00000255495.1	AC145124.2	4.37	2.28e-05	0.0101	0.34	0.34	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947473	chr8:12194467~12196280:+
PCPG	cis	rs3806843	1	rs11167600	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140795280	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs3806845	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140801152	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs3733707	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140802307	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs2879089	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140812308	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs11167609	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140820841	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs6885319	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140821026	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs4151682	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140821679	chr5:140726158~140726246:+
PCPG	cis	rs3806843	1	rs7710794	ENSG00000202515.1	VTRNA1-3	-4.37	2.28e-05	0.0101	-0.44	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140829882	chr5:140726158~140726246:+
PCPG	cis	rs1003719	0.715	rs2835649	ENSG00000228677.1	TTC3-AS1	4.37	2.28e-05	0.0101	0.41	0.34	Eye color traits;	chr21:37179928	chr21:37187666~37193926:-
PCPG	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-4.37	2.28e-05	0.0101	-0.5	-0.34	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
PCPG	cis	rs5742933	0.857	rs1233291	ENSG00000273240.1	RP11-455J20.3	-4.37	2.28e-05	0.0101	-0.35	-0.34	Ferritin levels;	chr2:189826225	chr2:189763859~189764456:-
PCPG	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-4.37	2.28e-05	0.0101	-0.34	-0.34	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
PCPG	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-4.37	2.28e-05	0.0101	-0.43	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
PCPG	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-4.37	2.28e-05	0.0101	-0.43	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-4.37	2.28e-05	0.0101	-0.43	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
PCPG	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	4.37	2.28e-05	0.0101	0.56	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
PCPG	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	4.37	2.28e-05	0.0101	0.74	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
PCPG	cis	rs2404602	0.503	rs284909	ENSG00000259514.1	RP11-685G9.2	-4.37	2.28e-05	0.0101	-0.34	-0.34	Blood metabolite levels;	chr15:76444287	chr15:76339609~76342063:-
PCPG	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-4.37	2.28e-05	0.0101	-0.36	-0.34	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
PCPG	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-4.37	2.28e-05	0.0101	-0.38	-0.34	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-4.37	2.28e-05	0.0101	-0.38	-0.34	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-4.37	2.28e-05	0.0101	-0.38	-0.34	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-4.37	2.28e-05	0.0101	-0.38	-0.34	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-4.37	2.28e-05	0.0101	-0.38	-0.34	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-4.37	2.28e-05	0.0101	-0.38	-0.34	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
PCPG	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-4.37	2.28e-05	0.0101	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
PCPG	cis	rs7403037	0.545	rs2354086	ENSG00000259905.4	PWRN1	4.37	2.28e-05	0.0101	0.39	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24552158	chr15:24493137~24652130:+
PCPG	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	4.37	2.28e-05	0.0101	0.53	0.34	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
PCPG	cis	rs1440410	1	rs1440410	ENSG00000250326.1	RP11-284M14.1	4.37	2.29e-05	0.0101	0.31	0.34	Ischemic stroke;	chr4:143237156	chr4:142933195~143184861:-
PCPG	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	4.37	2.29e-05	0.0101	0.3	0.34	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
PCPG	cis	rs12681963	0.688	rs4504591	ENSG00000248159.1	HSPA8P11	-4.37	2.29e-05	0.0101	-0.63	-0.34	Migraine;	chr8:30214868	chr8:30237382~30240997:+
PCPG	cis	rs853679	0.567	rs1005126	ENSG00000219392.1	RP1-265C24.5	-4.37	2.29e-05	0.0101	-0.45	-0.34	Depression;	chr6:28399846	chr6:28115628~28116551:+
PCPG	cis	rs8044188	0.866	rs2214022	ENSG00000261090.1	RP11-20G6.2	4.37	2.29e-05	0.0101	0.54	0.34	Multiple system atrophy;	chr16:23035077	chr16:23020337~23023611:+
PCPG	cis	rs9299346	0.594	rs10989586	ENSG00000225376.4	TMEM246-AS1	4.37	2.29e-05	0.0101	0.41	0.34	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101660420	chr9:101468439~101481502:+
PCPG	cis	rs847649	1	rs28856331	ENSG00000252643.1	RNU6-1136P	-4.37	2.3e-05	0.0101	-0.4	-0.34	Morning vs. evening chronotype;	chr7:102903316	chr7:102834605~102834708:+
PCPG	cis	rs847649	1	rs1100046	ENSG00000252643.1	RNU6-1136P	-4.37	2.3e-05	0.0101	-0.4	-0.34	Morning vs. evening chronotype;	chr7:102908848	chr7:102834605~102834708:+
PCPG	cis	rs7789940	1	rs2072435	ENSG00000186704.9	DTX2P1	4.37	2.3e-05	0.0101	0.41	0.34	Multiple sclerosis;	chr7:76329871	chr7:76978617~77004308:+
PCPG	cis	rs7789940	0.904	rs6948661	ENSG00000186704.9	DTX2P1	4.37	2.3e-05	0.0101	0.41	0.34	Multiple sclerosis;	chr7:76332330	chr7:76978617~77004308:+
PCPG	cis	rs7789940	0.951	rs7779014	ENSG00000186704.9	DTX2P1	4.37	2.3e-05	0.0101	0.41	0.34	Multiple sclerosis;	chr7:76346269	chr7:76978617~77004308:+
PCPG	cis	rs7789940	0.951	rs73140055	ENSG00000186704.9	DTX2P1	4.37	2.3e-05	0.0101	0.41	0.34	Multiple sclerosis;	chr7:76346460	chr7:76978617~77004308:+
PCPG	cis	rs7789940	1	rs17149161	ENSG00000186704.9	DTX2P1	4.37	2.3e-05	0.0101	0.41	0.34	Multiple sclerosis;	chr7:76348912	chr7:76978617~77004308:+
PCPG	cis	rs7789940	1	rs11765693	ENSG00000186704.9	DTX2P1	4.37	2.3e-05	0.0101	0.41	0.34	Multiple sclerosis;	chr7:76356056	chr7:76978617~77004308:+
PCPG	cis	rs7789940	1	rs73140069	ENSG00000186704.9	DTX2P1	4.37	2.3e-05	0.0101	0.41	0.34	Multiple sclerosis;	chr7:76357473	chr7:76978617~77004308:+
PCPG	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-4.37	2.3e-05	0.0102	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-4.37	2.3e-05	0.0102	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-4.37	2.3e-05	0.0102	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-4.37	2.3e-05	0.0102	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-4.37	2.3e-05	0.0102	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
PCPG	cis	rs12681963	0.541	rs12334730	ENSG00000248159.1	HSPA8P11	-4.37	2.3e-05	0.0102	-0.73	-0.34	Migraine;	chr8:30142830	chr8:30237382~30240997:+
PCPG	cis	rs7829975	0.714	rs4840362	ENSG00000173295.6	FAM86B3P	4.37	2.3e-05	0.0102	0.39	0.34	Mood instability;	chr8:8812572	chr8:8228595~8244865:+
PCPG	cis	rs10971721	0.643	rs7040130	ENSG00000281128.1	PTENP1-AS	4.37	2.3e-05	0.0102	0.57	0.34	Body mass index;	chr9:33785075	chr9:33677268~33688011:+
PCPG	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-4.37	2.3e-05	0.0102	-0.49	-0.34	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
PCPG	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	4.37	2.3e-05	0.0102	0.49	0.34	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
PCPG	cis	rs2625529	0.824	rs12903484	ENSG00000260037.4	CTD-2524L6.3	-4.37	2.3e-05	0.0102	-0.52	-0.34	Red blood cell count;	chr15:72007140	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs4777480	ENSG00000260037.4	CTD-2524L6.3	-4.37	2.3e-05	0.0102	-0.52	-0.34	Red blood cell count;	chr15:72036656	chr15:71818396~71823384:+
PCPG	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-4.37	2.3e-05	0.0102	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-4.37	2.3e-05	0.0102	-0.41	-0.34	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
PCPG	cis	rs748404	0.666	rs7180812	ENSG00000205771.5	CATSPER2P1	-4.37	2.3e-05	0.0102	-0.44	-0.34	Lung cancer;	chr15:43403033	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-4.37	2.31e-05	0.0102	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-4.37	2.31e-05	0.0102	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-4.37	2.31e-05	0.0102	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-4.37	2.31e-05	0.0102	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
PCPG	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-4.37	2.31e-05	0.0102	-0.76	-0.34	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
PCPG	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-4.37	2.31e-05	0.0102	-0.38	-0.34	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
PCPG	cis	rs9813712	0.78	rs7625942	ENSG00000228252.7	COL6A4P2	4.37	2.31e-05	0.0102	0.41	0.34	Response to amphetamines;	chr3:130232611	chr3:130212823~130273806:+
PCPG	cis	rs5742933	0.817	rs1233265	ENSG00000273240.1	RP11-455J20.3	-4.37	2.31e-05	0.0102	-0.35	-0.34	Ferritin levels;	chr2:189796390	chr2:189763859~189764456:-
PCPG	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	4.37	2.31e-05	0.0102	0.48	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
PCPG	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-4.37	2.32e-05	0.0102	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
PCPG	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	4.37	2.32e-05	0.0102	0.41	0.34	Height;	chr6:109360263	chr6:109382795~109383666:+
PCPG	cis	rs1048886	0.938	rs76784072	ENSG00000271967.1	RP11-134K13.4	-4.37	2.32e-05	0.0102	-0.42	-0.34	Type 2 diabetes;	chr6:70417191	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs74818996	ENSG00000271967.1	RP11-134K13.4	-4.37	2.32e-05	0.0102	-0.42	-0.34	Type 2 diabetes;	chr6:70419970	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.938	rs114047845	ENSG00000271967.1	RP11-134K13.4	-4.37	2.32e-05	0.0102	-0.42	-0.34	Type 2 diabetes;	chr6:70421021	chr6:70596438~70596980:+
PCPG	cis	rs1048886	1	rs74552954	ENSG00000271967.1	RP11-134K13.4	-4.37	2.32e-05	0.0102	-0.42	-0.34	Type 2 diabetes;	chr6:70422914	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs41265349	ENSG00000271967.1	RP11-134K13.4	-4.37	2.32e-05	0.0102	-0.42	-0.34	Type 2 diabetes;	chr6:70428289	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.808	rs17706748	ENSG00000271967.1	RP11-134K13.4	-4.37	2.32e-05	0.0102	-0.42	-0.34	Type 2 diabetes;	chr6:70430664	chr6:70596438~70596980:+
PCPG	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	4.37	2.32e-05	0.0102	0.44	0.34	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	4.37	2.32e-05	0.0102	0.44	0.34	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
PCPG	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-4.37	2.32e-05	0.0102	-0.54	-0.34	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-4.37	2.32e-05	0.0102	-0.54	-0.34	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-4.37	2.32e-05	0.0102	-0.54	-0.34	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-4.37	2.32e-05	0.0102	-0.54	-0.34	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-4.37	2.32e-05	0.0102	-0.54	-0.34	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-4.37	2.32e-05	0.0102	-0.54	-0.34	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
PCPG	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-4.37	2.32e-05	0.0102	-0.44	-0.34	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
PCPG	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-4.37	2.32e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-4.37	2.32e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
PCPG	cis	rs7824557	0.603	rs6995404	ENSG00000255020.1	AF131216.5	4.37	2.32e-05	0.0103	0.43	0.34	Retinal vascular caliber;	chr8:11324639	chr8:11345748~11347502:-
PCPG	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	4.37	2.32e-05	0.0103	0.49	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
PCPG	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	4.37	2.32e-05	0.0103	0.49	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
PCPG	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	4.37	2.32e-05	0.0103	0.49	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
PCPG	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	4.37	2.32e-05	0.0103	0.49	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
PCPG	cis	rs1912483	0.505	rs3760372	ENSG00000228782.6	CTD-2026D20.3	4.37	2.32e-05	0.0103	0.43	0.34	Coronary artery disease;	chr17:47302636	chr17:47450568~47492492:-
PCPG	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-4.37	2.32e-05	0.0103	-0.43	-0.34	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
PCPG	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	4.37	2.33e-05	0.0103	0.51	0.34	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
PCPG	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	4.37	2.33e-05	0.0103	0.37	0.34	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
PCPG	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-4.37	2.33e-05	0.0103	-0.38	-0.34	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
PCPG	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-4.37	2.33e-05	0.0103	-0.43	-0.34	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
PCPG	cis	rs28386778	0.83	rs6504180	ENSG00000240280.5	TCAM1P	-4.37	2.33e-05	0.0103	-0.44	-0.34	Prudent dietary pattern;	chr17:63735809	chr17:63849292~63864379:+
PCPG	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	-4.37	2.33e-05	0.0103	-0.41	-0.34	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
PCPG	cis	rs5758511	0.633	rs5758690	ENSG00000205702.9	CYP2D7	4.37	2.33e-05	0.0103	0.45	0.34	Birth weight;	chr22:42272289	chr22:42140203~42144577:-
PCPG	cis	rs2736345	0.89	rs4840565	ENSG00000184608.7	FAM167A-AS1	4.37	2.33e-05	0.0103	0.49	0.34	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:11368402~11438658:+
PCPG	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-4.37	2.34e-05	0.0103	-0.45	-0.34	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
PCPG	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	4.37	2.34e-05	0.0103	0.42	0.34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
PCPG	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-4.37	2.34e-05	0.0103	-0.44	-0.34	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
PCPG	cis	rs1387259	0.931	rs1107654	ENSG00000240399.1	RP1-228P16.1	4.37	2.34e-05	0.0103	0.37	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48054813~48055591:-
PCPG	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	4.37	2.34e-05	0.0103	0.35	0.34	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
PCPG	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	4.37	2.34e-05	0.0103	0.37	0.34	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
PCPG	cis	rs7824557	0.767	rs17797443	ENSG00000184608.7	FAM167A-AS1	4.37	2.34e-05	0.0103	0.48	0.34	Retinal vascular caliber;	chr8:11306503	chr8:11368402~11438658:+
PCPG	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	4.37	2.34e-05	0.0103	0.37	0.34	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
PCPG	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	4.37	2.34e-05	0.0103	0.37	0.34	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
PCPG	cis	rs1048886	0.872	rs55990831	ENSG00000271967.1	RP11-134K13.4	-4.37	2.35e-05	0.0103	-0.43	-0.34	Type 2 diabetes;	chr6:70457679	chr6:70596438~70596980:+
PCPG	cis	rs75686122	1	rs79392847	ENSG00000271830.1	RP11-1C8.7	4.37	2.35e-05	0.0103	0.59	0.34	Cocaine dependence;	chr8:103461421	chr8:103481266~103481619:-
PCPG	cis	rs964611	0.882	rs4775754	ENSG00000259488.2	RP11-154J22.1	4.37	2.35e-05	0.0103	0.32	0.34	Metabolite levels (Pyroglutamine);	chr15:48369146	chr15:48312353~48331856:-
PCPG	cis	rs11672691	0.792	rs7248215	ENSG00000267107.5	PCAT19	4.37	2.35e-05	0.0103	0.29	0.34	Prostate cancer;	chr19:41493212	chr19:41454169~41500649:-
PCPG	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-4.37	2.35e-05	0.0104	-0.34	-0.34	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
PCPG	cis	rs2243480	1	rs4548056	ENSG00000230189.5	GS1-124K5.2	4.36	2.36e-05	0.0104	0.51	0.34	Diabetic kidney disease;	chr7:65833886	chr7:66409143~66490059:-
PCPG	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-4.36	2.36e-05	0.0104	-0.48	-0.34	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-4.36	2.36e-05	0.0104	-0.48	-0.34	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-4.36	2.36e-05	0.0104	-0.48	-0.34	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
PCPG	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	4.36	2.36e-05	0.0104	0.43	0.34	Height;	chr6:109447092	chr6:109382795~109383666:+
PCPG	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	4.36	2.36e-05	0.0104	0.48	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
PCPG	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-4.36	2.36e-05	0.0104	-0.76	-0.34	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
PCPG	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-4.36	2.36e-05	0.0104	-0.38	-0.34	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
PCPG	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-4.36	2.36e-05	0.0104	-0.48	-0.34	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
PCPG	cis	rs6929812	0.665	rs10946920	ENSG00000271755.1	RP1-153G14.4	-4.36	2.37e-05	0.0104	-0.44	-0.34	Neuroticism (multi-trait analysis);	chr6:27461212	chr6:27404010~27406964:-
PCPG	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-4.36	2.37e-05	0.0104	-0.41	-0.34	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
PCPG	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	4.36	2.37e-05	0.0104	0.46	0.34	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
PCPG	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-4.36	2.37e-05	0.0104	-0.43	-0.34	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
PCPG	cis	rs2281558	0.754	rs73597824	ENSG00000125804.12	FAM182A	-4.36	2.37e-05	0.0104	-0.45	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610841	chr20:26054655~26086917:+
PCPG	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-4.36	2.38e-05	0.0105	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
PCPG	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-4.36	2.38e-05	0.0105	-0.39	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
PCPG	cis	rs657075	0.697	rs4646194	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132313369	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3792883	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132315488	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3828673	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132315872	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.639	rs3792885	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132316555	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs34757387	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132316984	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs34604423	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132317818	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs57600888	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132318360	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.643	rs71583471	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132318474	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3761659	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132322091	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3805672	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132323281	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs71583474	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132326117	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs77975982	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132326300	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.64	rs71583475	ENSG00000233006.5	AC034220.3	-4.36	2.38e-05	0.0105	-0.48	-0.34	Rheumatoid arthritis;	chr5:132326814	chr5:132311285~132369916:-
PCPG	cis	rs9393777	0.92	rs41269265	ENSG00000219392.1	RP1-265C24.5	-4.36	2.38e-05	0.0105	-0.72	-0.34	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28115628~28116551:+
PCPG	cis	rs11148252	0.668	rs6561658	ENSG00000235660.1	LINC00345	-4.36	2.38e-05	0.0105	-0.42	-0.34	Lewy body disease;	chr13:52160016	chr13:52484161~52484680:-
PCPG	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-4.36	2.38e-05	0.0105	-0.44	-0.34	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
PCPG	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-4.36	2.38e-05	0.0105	-0.38	-0.34	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
PCPG	cis	rs2281558	0.876	rs12625157	ENSG00000125804.12	FAM182A	-4.36	2.38e-05	0.0105	-0.47	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:26054655~26086917:+
PCPG	cis	rs2281558	0.837	rs67676850	ENSG00000125804.12	FAM182A	-4.36	2.38e-05	0.0105	-0.47	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:26054655~26086917:+
PCPG	cis	rs1440410	0.835	rs4626148	ENSG00000250326.1	RP11-284M14.1	4.36	2.39e-05	0.0105	0.31	0.34	Ischemic stroke;	chr4:143131307	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs10034769	ENSG00000250326.1	RP11-284M14.1	4.36	2.39e-05	0.0105	0.31	0.34	Ischemic stroke;	chr4:143131740	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs6829621	ENSG00000250326.1	RP11-284M14.1	4.36	2.39e-05	0.0105	0.31	0.34	Ischemic stroke;	chr4:143131818	chr4:142933195~143184861:-
PCPG	cis	rs12681963	0.688	rs7817838	ENSG00000248159.1	HSPA8P11	4.36	2.39e-05	0.0105	0.7	0.34	Migraine;	chr8:30205298	chr8:30237382~30240997:+
PCPG	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-4.36	2.39e-05	0.0105	-0.43	-0.34	Height;	chr6:109497253	chr6:109382795~109383666:+
PCPG	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	4.36	2.39e-05	0.0105	0.34	0.34	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
PCPG	cis	rs748404	0.666	rs12906017	ENSG00000205771.5	CATSPER2P1	-4.36	2.39e-05	0.0105	-0.44	-0.34	Lung cancer;	chr15:43504710	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	4.36	2.39e-05	0.0105	0.38	0.34	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
PCPG	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	4.36	2.39e-05	0.0105	0.53	0.34	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	4.36	2.39e-05	0.0105	0.53	0.34	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	4.36	2.39e-05	0.0105	0.53	0.34	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	4.36	2.39e-05	0.0105	0.53	0.34	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	4.36	2.39e-05	0.0105	0.53	0.34	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
PCPG	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-4.36	2.39e-05	0.0105	-0.54	-0.34	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
PCPG	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-4.36	2.39e-05	0.0105	-0.42	-0.34	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
PCPG	cis	rs13113518	0.783	rs12504300	ENSG00000272969.1	RP11-528I4.2	4.36	2.4e-05	0.0105	0.38	0.34	Height;	chr4:55482360	chr4:55547112~55547889:+
PCPG	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-4.36	2.4e-05	0.0105	-0.29	-0.34	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
PCPG	cis	rs11148252	0.512	rs9526950	ENSG00000273784.3	RP11-78J21.7	-4.36	2.4e-05	0.0105	-0.32	-0.34	Lewy body disease;	chr13:52600328	chr13:52600042~52642542:+
PCPG	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	4.36	2.4e-05	0.0105	0.39	0.34	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
PCPG	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-4.36	2.4e-05	0.0105	-0.34	-0.34	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
PCPG	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-4.36	2.4e-05	0.0105	-0.34	-0.34	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
PCPG	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	4.36	2.4e-05	0.0105	0.35	0.34	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
PCPG	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	4.36	2.4e-05	0.0105	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
PCPG	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-4.36	2.41e-05	0.0106	-0.42	-0.34	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
PCPG	cis	rs4763879	0.634	rs11052582	ENSG00000278635.1	CTD-2318O12.1	4.36	2.41e-05	0.0106	0.4	0.34	Type 1 diabetes;	chr12:9706714	chr12:9415641~9416718:+
PCPG	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-4.36	2.41e-05	0.0106	-0.49	-0.34	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-4.36	2.41e-05	0.0106	-0.49	-0.34	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
PCPG	cis	rs28386778	1	rs3020613	ENSG00000240280.5	TCAM1P	-4.36	2.41e-05	0.0106	-0.44	-0.34	Prudent dietary pattern;	chr17:63878623	chr17:63849292~63864379:+
PCPG	cis	rs28386778	1	rs2665851	ENSG00000240280.5	TCAM1P	-4.36	2.41e-05	0.0106	-0.44	-0.34	Prudent dietary pattern;	chr17:63879663	chr17:63849292~63864379:+
PCPG	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-4.36	2.41e-05	0.0106	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
PCPG	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-4.36	2.41e-05	0.0106	-0.39	-0.34	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
PCPG	cis	rs7937890	0.559	rs6486193	ENSG00000251991.1	RNU7-49P	4.36	2.41e-05	0.0106	0.39	0.34	Mitochondrial DNA levels;	chr11:14416061	chr11:14478892~14478953:+
PCPG	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	4.36	2.41e-05	0.0106	0.47	0.34	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
PCPG	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	4.36	2.41e-05	0.0106	0.44	0.34	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
PCPG	cis	rs748404	1	rs12909095	ENSG00000249839.1	AC011330.5	-4.36	2.41e-05	0.0106	-0.42	-0.34	Lung cancer;	chr15:43265944	chr15:43663654~43684339:-
PCPG	cis	rs748404	1	rs12911132	ENSG00000249839.1	AC011330.5	-4.36	2.41e-05	0.0106	-0.42	-0.34	Lung cancer;	chr15:43268238	chr15:43663654~43684339:-
PCPG	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-4.36	2.42e-05	0.0106	-0.34	-0.34	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
PCPG	cis	rs4835473	0.797	rs34585546	ENSG00000251600.4	RP11-673E1.1	-4.36	2.42e-05	0.0106	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143680693	chr4:143912331~143982454:+
PCPG	cis	rs3809566	0.526	rs35829897	ENSG00000259498.1	RP11-244F12.3	4.36	2.42e-05	0.0106	0.51	0.34	Platelet count;	chr15:63042489	chr15:63046034~63049387:-
PCPG	cis	rs5742933	0.857	rs1233284	ENSG00000273240.1	RP11-455J20.3	-4.36	2.42e-05	0.0106	-0.35	-0.34	Ferritin levels;	chr2:189825045	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.817	rs1233288	ENSG00000273240.1	RP11-455J20.3	-4.36	2.42e-05	0.0106	-0.35	-0.34	Ferritin levels;	chr2:189825999	chr2:189763859~189764456:-
PCPG	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-4.36	2.42e-05	0.0106	-0.44	-0.34	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
PCPG	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	4.36	2.42e-05	0.0106	0.48	0.34	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
PCPG	cis	rs2705520	1	rs2705520	ENSG00000240057.4	RP11-572M11.4	4.36	2.42e-05	0.0106	0.37	0.34	Asthma (childhood onset);	chr3:112550440	chr3:113019532~113183301:+
PCPG	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-4.36	2.42e-05	0.0106	-0.4	-0.34	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
PCPG	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-4.36	2.42e-05	0.0106	-0.44	-0.34	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
PCPG	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-4.36	2.42e-05	0.0106	-0.44	-0.34	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
PCPG	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-4.36	2.42e-05	0.0106	-0.56	-0.34	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-4.36	2.42e-05	0.0106	-0.56	-0.34	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
PCPG	cis	rs300890	1	rs624189	ENSG00000250326.1	RP11-284M14.1	4.36	2.42e-05	0.0106	0.3	0.34	Nasopharyngeal carcinoma;	chr4:143324210	chr4:142933195~143184861:-
PCPG	cis	rs2361701	0.929	rs1467979	ENSG00000279259.1	RP11-334C17.3	-4.36	2.42e-05	0.0106	-0.36	-0.34	IgG glycosylation;	chr17:80086944	chr17:80147250~80148596:+
PCPG	cis	rs7017914	0.905	rs2732102	ENSG00000254031.4	RP11-326E22.1	-4.36	2.43e-05	0.0106	-0.32	-0.34	Bone mineral density;	chr8:71010637	chr8:71155457~71204223:+
PCPG	cis	rs11673344	0.503	rs7246720	ENSG00000226686.6	LINC01535	4.36	2.43e-05	0.0106	0.44	0.34	Obesity-related traits;	chr19:37073726	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.562	rs7257320	ENSG00000226686.6	LINC01535	4.36	2.43e-05	0.0106	0.44	0.34	Obesity-related traits;	chr19:37080933	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs10403975	ENSG00000226686.6	LINC01535	4.36	2.43e-05	0.0106	0.44	0.34	Obesity-related traits;	chr19:37082172	chr19:37251912~37265535:+
PCPG	cis	rs66887589	0.592	rs11731571	ENSG00000249244.1	RP11-548H18.2	4.36	2.43e-05	0.0107	0.31	0.34	Diastolic blood pressure;	chr4:119300030	chr4:119391831~119395335:-
PCPG	cis	rs950169	1	rs1818950	ENSG00000235370.6	DNM1P51	4.36	2.43e-05	0.0107	0.33	0.34	Schizophrenia;	chr15:84053769	chr15:84398316~84411701:-
PCPG	cis	rs12050794	0.636	rs4506844	ENSG00000260037.4	CTD-2524L6.3	4.36	2.43e-05	0.0107	0.43	0.34	Metabolite levels (HVA/MHPG ratio);	chr15:72216797	chr15:71818396~71823384:+
PCPG	cis	rs1387259	0.79	rs2732445	ENSG00000240399.1	RP1-228P16.1	4.36	2.43e-05	0.0107	0.36	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48054813~48055591:-
PCPG	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-4.36	2.43e-05	0.0107	-0.43	-0.34	Temperament;	chr17:13999319	chr17:14024514~14025488:+
PCPG	cis	rs2898290	0.622	rs978802	ENSG00000269954.1	RP11-148O21.6	-4.36	2.43e-05	0.0107	-0.37	-0.34	Systolic blood pressure;	chr8:11485769	chr8:11552488~11552991:-
PCPG	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-4.36	2.44e-05	0.0107	-0.52	-0.34	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
PCPG	cis	rs1635	0.655	rs9380024	ENSG00000271755.1	RP1-153G14.4	-4.36	2.44e-05	0.0107	-0.89	-0.34	Schizophrenia;	chr6:27862576	chr6:27404010~27406964:-
PCPG	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	4.36	2.44e-05	0.0107	0.34	0.34	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
PCPG	cis	rs172166	0.516	rs1225710	ENSG00000219392.1	RP1-265C24.5	4.36	2.44e-05	0.0107	0.37	0.34	Cardiac Troponin-T levels;	chr6:28132862	chr6:28115628~28116551:+
PCPG	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-4.36	2.44e-05	0.0107	-0.49	-0.34	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-4.36	2.44e-05	0.0107	-0.49	-0.34	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
PCPG	cis	rs1159787	0.558	rs576691	ENSG00000233569.1	RP11-500B12.1	-4.36	2.44e-05	0.0107	-0.48	-0.34	Blood protein levels;	chr9:117600196	chr9:117648606~117657027:+
PCPG	cis	rs1159787	0.558	rs9408899	ENSG00000233569.1	RP11-500B12.1	-4.36	2.44e-05	0.0107	-0.48	-0.34	Blood protein levels;	chr9:117601525	chr9:117648606~117657027:+
PCPG	cis	rs1159787	0.517	rs2416598	ENSG00000233569.1	RP11-500B12.1	-4.36	2.44e-05	0.0107	-0.48	-0.34	Blood protein levels;	chr9:117601962	chr9:117648606~117657027:+
PCPG	cis	rs1159787	0.512	rs4837402	ENSG00000233569.1	RP11-500B12.1	-4.36	2.44e-05	0.0107	-0.48	-0.34	Blood protein levels;	chr9:117606597	chr9:117648606~117657027:+
PCPG	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-4.36	2.44e-05	0.0107	-0.47	-0.34	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
PCPG	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-4.36	2.45e-05	0.0107	-0.44	-0.34	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
PCPG	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	4.36	2.45e-05	0.0107	0.39	0.34	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-4.36	2.45e-05	0.0107	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-4.36	2.45e-05	0.0107	-0.39	-0.34	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
PCPG	cis	rs4713118	0.824	rs9366702	ENSG00000216901.1	AL022393.7	4.36	2.45e-05	0.0107	0.45	0.34	Parkinson's disease;	chr6:27766691	chr6:28176188~28176674:+
PCPG	cis	rs28386778	0.897	rs2854208	ENSG00000240280.5	TCAM1P	-4.36	2.45e-05	0.0107	-0.44	-0.34	Prudent dietary pattern;	chr17:63869525	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.966	rs2854206	ENSG00000240280.5	TCAM1P	-4.36	2.45e-05	0.0107	-0.44	-0.34	Prudent dietary pattern;	chr17:63869843	chr17:63849292~63864379:+
PCPG	cis	rs12050794	0.671	rs8192362	ENSG00000260037.4	CTD-2524L6.3	4.36	2.45e-05	0.0107	0.43	0.34	Metabolite levels (HVA/MHPG ratio);	chr15:72227517	chr15:71818396~71823384:+
PCPG	cis	rs12050794	0.671	rs2052713	ENSG00000260037.4	CTD-2524L6.3	4.36	2.45e-05	0.0107	0.43	0.34	Metabolite levels (HVA/MHPG ratio);	chr15:72228051	chr15:71818396~71823384:+
PCPG	cis	rs12050794	0.636	rs3759902	ENSG00000260037.4	CTD-2524L6.3	4.36	2.45e-05	0.0107	0.43	0.34	Metabolite levels (HVA/MHPG ratio);	chr15:72232933	chr15:71818396~71823384:+
PCPG	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	4.36	2.45e-05	0.0107	0.31	0.34	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
PCPG	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-4.36	2.45e-05	0.0107	-0.43	-0.34	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
PCPG	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	4.36	2.45e-05	0.0107	0.28	0.34	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
PCPG	cis	rs9650657	0.617	rs7814795	ENSG00000255020.1	AF131216.5	-4.36	2.45e-05	0.0107	-0.45	-0.34	Neuroticism;	chr8:10661775	chr8:11345748~11347502:-
PCPG	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-4.35	2.45e-05	0.0107	-0.43	-0.34	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
PCPG	cis	rs6479901	0.639	rs10995448	ENSG00000232075.1	MRPL35P2	-4.35	2.46e-05	0.0107	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:63127299	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.639	rs7082200	ENSG00000232075.1	MRPL35P2	-4.35	2.46e-05	0.0107	-0.42	-0.34	Intelligence (multi-trait analysis);	chr10:63128561	chr10:63634317~63634827:-
PCPG	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-4.35	2.46e-05	0.0107	-0.49	-0.34	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-4.35	2.46e-05	0.0107	-0.49	-0.34	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-4.35	2.46e-05	0.0107	-0.49	-0.34	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
PCPG	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-4.35	2.46e-05	0.0108	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
PCPG	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	4.35	2.46e-05	0.0108	0.45	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
PCPG	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	4.35	2.46e-05	0.0108	0.45	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
PCPG	cis	rs17507216	1	rs17356118	ENSG00000228141.5	AC105339.1	-4.35	2.46e-05	0.0108	-0.47	-0.33	Excessive daytime sleepiness;	chr15:82569149	chr15:82710471~82714026:-
PCPG	cis	rs11148252	0.87	rs11148246	ENSG00000235660.1	LINC00345	-4.35	2.46e-05	0.0108	-0.4	-0.33	Lewy body disease;	chr13:52223402	chr13:52484161~52484680:-
PCPG	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	4.35	2.46e-05	0.0108	0.46	0.33	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
PCPG	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	4.35	2.46e-05	0.0108	0.44	0.33	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
PCPG	cis	rs2625529	0.824	rs12439900	ENSG00000260037.4	CTD-2524L6.3	-4.35	2.46e-05	0.0108	-0.52	-0.33	Red blood cell count;	chr15:72081299	chr15:71818396~71823384:+
PCPG	cis	rs300890	1	rs300895	ENSG00000250326.1	RP11-284M14.1	4.35	2.46e-05	0.0108	0.31	0.33	Nasopharyngeal carcinoma;	chr4:143334685	chr4:142933195~143184861:-
PCPG	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	4.35	2.46e-05	0.0108	0.36	0.33	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
PCPG	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	4.35	2.47e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	4.35	2.47e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
PCPG	cis	rs11858159	0.651	rs7168626	ENSG00000260760.1	PWRN3	4.35	2.47e-05	0.0108	0.36	0.33	Platelet thrombus formation;	chr15:24555586	chr15:24441127~24447967:+
PCPG	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	4.35	2.47e-05	0.0108	0.54	0.33	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
PCPG	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	4.35	2.47e-05	0.0108	0.36	0.33	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	4.35	2.47e-05	0.0108	0.36	0.33	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
PCPG	cis	rs7759001	0.857	rs9468116	ENSG00000271755.1	RP1-153G14.4	4.35	2.47e-05	0.0108	0.5	0.33	Glomerular filtration rate (creatinine);	chr6:27399033	chr6:27404010~27406964:-
PCPG	cis	rs6991838	0.806	rs4285523	ENSG00000200714.1	Y_RNA	4.35	2.47e-05	0.0108	0.43	0.33	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65592731~65592820:+
PCPG	cis	rs1440410	0.835	rs11100770	ENSG00000250326.1	RP11-284M14.1	4.35	2.47e-05	0.0108	0.31	0.33	Ischemic stroke;	chr4:143132629	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs11100772	ENSG00000250326.1	RP11-284M14.1	4.35	2.47e-05	0.0108	0.31	0.33	Ischemic stroke;	chr4:143132935	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs11100773	ENSG00000250326.1	RP11-284M14.1	4.35	2.47e-05	0.0108	0.31	0.33	Ischemic stroke;	chr4:143133075	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs7684430	ENSG00000250326.1	RP11-284M14.1	4.35	2.47e-05	0.0108	0.31	0.33	Ischemic stroke;	chr4:143133191	chr4:142933195~143184861:-
PCPG	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	4.35	2.48e-05	0.0108	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
PCPG	cis	rs66887589	0.592	rs11731571	ENSG00000250412.1	KLHL2P1	4.35	2.48e-05	0.0108	0.34	0.33	Diastolic blood pressure;	chr4:119300030	chr4:119334329~119378233:+
PCPG	cis	rs2732480	0.577	rs2732457	ENSG00000240399.1	RP1-228P16.1	-4.35	2.48e-05	0.0108	-0.34	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48054813~48055591:-
PCPG	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	4.35	2.48e-05	0.0108	0.37	0.33	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
PCPG	cis	rs9650657	0.59	rs10096777	ENSG00000255020.1	AF131216.5	-4.35	2.48e-05	0.0108	-0.44	-0.33	Neuroticism;	chr8:10660990	chr8:11345748~11347502:-
PCPG	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-4.35	2.48e-05	0.0108	-0.35	-0.33	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
PCPG	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-4.35	2.48e-05	0.0108	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-4.35	2.48e-05	0.0108	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
PCPG	cis	rs11673344	0.504	rs2385375	ENSG00000226686.6	LINC01535	4.35	2.48e-05	0.0108	0.44	0.33	Obesity-related traits;	chr19:37087620	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs35162188	ENSG00000226686.6	LINC01535	4.35	2.48e-05	0.0108	0.44	0.33	Obesity-related traits;	chr19:37088908	chr19:37251912~37265535:+
PCPG	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-4.35	2.48e-05	0.0109	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
PCPG	cis	rs7824557	0.505	rs2736313	ENSG00000255020.1	AF131216.5	4.35	2.49e-05	0.0109	0.47	0.33	Retinal vascular caliber;	chr8:11229433	chr8:11345748~11347502:-
PCPG	cis	rs28386778	1	rs28386778	ENSG00000240280.5	TCAM1P	-4.35	2.49e-05	0.0109	-0.44	-0.33	Prudent dietary pattern;	chr17:63887455	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.901	rs2665855	ENSG00000240280.5	TCAM1P	-4.35	2.49e-05	0.0109	-0.44	-0.33	Prudent dietary pattern;	chr17:63887783	chr17:63849292~63864379:+
PCPG	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	4.35	2.49e-05	0.0109	0.44	0.33	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
PCPG	cis	rs62392365	0.536	rs303020	ENSG00000219682.4	RP3-425P12.4	-4.35	2.49e-05	0.0109	-0.81	-0.33	Intelligence (multi-trait analysis);Schizophrenia;	chr6:25137288	chr6:25140003~25141403:+
PCPG	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	4.35	2.49e-05	0.0109	0.34	0.33	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
PCPG	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	4.35	2.49e-05	0.0109	0.48	0.33	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
PCPG	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-4.35	2.49e-05	0.0109	-0.38	-0.33	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
PCPG	cis	rs7247513	0.964	rs35235213	ENSG00000213290.4	PGK1P2	-4.35	2.5e-05	0.0109	-0.46	-0.33	Bipolar disorder;	chr19:12602342	chr19:12559571~12561105:+
PCPG	cis	rs3806843	1	rs10038174	ENSG00000202515.1	VTRNA1-3	-4.35	2.5e-05	0.0109	-0.43	-0.33	Depressive symptoms (multi-trait analysis);	chr5:140831031	chr5:140726158~140726246:+
PCPG	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	4.35	2.5e-05	0.0109	0.38	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
PCPG	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-4.35	2.5e-05	0.0109	-0.45	-0.33	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
PCPG	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	4.35	2.5e-05	0.0109	0.54	0.33	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
PCPG	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	4.35	2.5e-05	0.0109	0.54	0.33	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
PCPG	cis	rs10208649	0.611	rs75340524	ENSG00000272156.1	RP11-477N3.1	4.35	2.5e-05	0.0109	0.58	0.33	Body mass index;	chr2:54068793	chr2:54082554~54085066:+
PCPG	cis	rs867371	0.929	rs1045508	ENSG00000278603.1	RP13-608F4.5	-4.35	2.5e-05	0.0109	-0.41	-0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472203~82472426:+
PCPG	cis	rs7826238	0.517	rs35144760	ENSG00000253893.2	FAM85B	4.35	2.5e-05	0.0109	0.45	0.33	Systolic blood pressure;	chr8:8504213	chr8:8167819~8226614:-
PCPG	cis	rs6929812	0.665	rs7744110	ENSG00000271755.1	RP1-153G14.4	4.35	2.5e-05	0.0109	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27453525	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs2235252	ENSG00000271755.1	RP1-153G14.4	4.35	2.5e-05	0.0109	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27454714	chr6:27404010~27406964:-
PCPG	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-4.35	2.5e-05	0.0109	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-4.35	2.5e-05	0.0109	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
PCPG	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	4.35	2.51e-05	0.0109	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	4.35	2.51e-05	0.0109	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	4.35	2.51e-05	0.0109	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	4.35	2.51e-05	0.0109	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	4.35	2.51e-05	0.0109	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
PCPG	cis	rs3806843	0.676	rs2245643	ENSG00000202515.1	VTRNA1-3	4.35	2.51e-05	0.0109	0.42	0.33	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.676	rs2245640	ENSG00000202515.1	VTRNA1-3	4.35	2.51e-05	0.0109	0.42	0.33	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr5:140726158~140726246:+
PCPG	cis	rs1371867	0.846	rs1660345	ENSG00000212994.5	RPS26P6	4.35	2.51e-05	0.0109	0.4	0.33	Atrioventricular conduction;	chr8:100310534	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1660344	ENSG00000212994.5	RPS26P6	4.35	2.51e-05	0.0109	0.4	0.33	Atrioventricular conduction;	chr8:100312431	chr8:100895771~100896118:+
PCPG	cis	rs6929812	0.665	rs6456786	ENSG00000271755.1	RP1-153G14.4	4.35	2.51e-05	0.0109	0.45	0.33	Neuroticism (multi-trait analysis);	chr6:27448052	chr6:27404010~27406964:-
PCPG	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	4.35	2.51e-05	0.0109	0.33	0.33	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
PCPG	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-4.35	2.51e-05	0.0109	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
PCPG	cis	rs916888	0.61	rs199436	ENSG00000262500.1	RP11-259G18.2	-4.35	2.51e-05	0.011	-0.48	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46243606~46245044:+
PCPG	cis	rs28386778	0.787	rs2665827	ENSG00000240280.5	TCAM1P	-4.35	2.51e-05	0.011	-0.45	-0.33	Prudent dietary pattern;	chr17:63883990	chr17:63849292~63864379:+
PCPG	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	-4.35	2.51e-05	0.011	-0.41	-0.33	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
PCPG	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	4.35	2.51e-05	0.011	0.42	0.33	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
PCPG	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	4.35	2.52e-05	0.011	0.43	0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
PCPG	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	4.35	2.52e-05	0.011	0.43	0.33	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	4.35	2.52e-05	0.011	0.43	0.33	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	4.35	2.52e-05	0.011	0.43	0.33	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	4.35	2.52e-05	0.011	0.45	0.33	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
PCPG	cis	rs8098244	0.516	rs60464408	ENSG00000265752.2	RP11-403A21.1	4.35	2.52e-05	0.011	0.39	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692874	chr18:23957754~23982556:-
PCPG	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	4.35	2.52e-05	0.011	0.42	0.33	Height;	chr6:109375548	chr6:109382795~109383666:+
PCPG	cis	rs3850699	0.886	rs12773833	ENSG00000269609.4	RPARP-AS1	-4.35	2.53e-05	0.011	-0.27	-0.33	Prostate cancer;	chr10:102658593	chr10:102449817~102461106:+
PCPG	cis	rs3850699	0.926	rs12570611	ENSG00000269609.4	RPARP-AS1	-4.35	2.53e-05	0.011	-0.27	-0.33	Prostate cancer;	chr10:102661922	chr10:102449817~102461106:+
PCPG	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	4.35	2.53e-05	0.011	0.56	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
PCPG	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	4.35	2.53e-05	0.011	0.43	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
PCPG	cis	rs9302635	0.513	rs7184169	ENSG00000260886.1	TAT-AS1	4.35	2.53e-05	0.011	0.49	0.33	Blood protein levels;	chr16:72119034	chr16:71565789~71578187:+
PCPG	cis	rs12908161	0.959	rs1051168	ENSG00000259295.5	CSPG4P12	4.35	2.53e-05	0.011	0.5	0.33	Schizophrenia;	chr15:84657289	chr15:85191438~85213905:+
PCPG	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	-4.35	2.53e-05	0.011	-0.39	-0.33	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
PCPG	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-4.35	2.54e-05	0.011	-0.4	-0.33	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
PCPG	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	4.35	2.54e-05	0.011	0.28	0.33	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	4.35	2.54e-05	0.011	0.28	0.33	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	4.35	2.54e-05	0.011	0.28	0.33	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
PCPG	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-4.35	2.54e-05	0.0111	-0.45	-0.33	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
PCPG	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-4.35	2.54e-05	0.0111	-0.48	-0.33	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-4.35	2.54e-05	0.0111	-0.48	-0.33	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-4.35	2.54e-05	0.0111	-0.48	-0.33	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-4.35	2.54e-05	0.0111	-0.48	-0.33	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-4.35	2.54e-05	0.0111	-0.48	-0.33	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-4.35	2.54e-05	0.0111	-0.48	-0.33	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-4.35	2.54e-05	0.0111	-0.48	-0.33	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
PCPG	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	4.35	2.54e-05	0.0111	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	4.35	2.54e-05	0.0111	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	4.35	2.54e-05	0.0111	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	4.35	2.54e-05	0.0111	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	4.35	2.54e-05	0.0111	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	4.35	2.54e-05	0.0111	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	4.35	2.54e-05	0.0111	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
PCPG	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	4.35	2.54e-05	0.0111	0.48	0.33	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
PCPG	cis	rs591584	0.73	rs10765688	ENSG00000255893.1	RP11-685N10.1	-4.35	2.54e-05	0.0111	-0.4	-0.33	Macrophage Migration Inhibitory Factor levels;	chr11:94576693	chr11:94472908~94473570:-
PCPG	cis	rs591584	0.73	rs72963850	ENSG00000255893.1	RP11-685N10.1	-4.35	2.54e-05	0.0111	-0.4	-0.33	Macrophage Migration Inhibitory Factor levels;	chr11:94577566	chr11:94472908~94473570:-
PCPG	cis	rs591584	0.704	rs2186624	ENSG00000255893.1	RP11-685N10.1	-4.35	2.54e-05	0.0111	-0.4	-0.33	Macrophage Migration Inhibitory Factor levels;	chr11:94578152	chr11:94472908~94473570:-
PCPG	cis	rs591584	0.73	rs2212361	ENSG00000255893.1	RP11-685N10.1	-4.35	2.54e-05	0.0111	-0.4	-0.33	Macrophage Migration Inhibitory Factor levels;	chr11:94579157	chr11:94472908~94473570:-
PCPG	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	4.35	2.54e-05	0.0111	0.43	0.33	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
PCPG	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-4.35	2.55e-05	0.0111	-0.44	-0.33	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
PCPG	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-4.35	2.55e-05	0.0111	-0.49	-0.33	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
PCPG	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-4.35	2.55e-05	0.0111	-0.51	-0.33	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
PCPG	cis	rs4763879	0.634	rs12424826	ENSG00000278635.1	CTD-2318O12.1	4.35	2.55e-05	0.0111	0.39	0.33	Type 1 diabetes;	chr12:9701981	chr12:9415641~9416718:+
PCPG	cis	rs6051080	1	rs6051080	ENSG00000125804.12	FAM182A	-4.35	2.55e-05	0.0111	-0.38	-0.33	Colorectal or endometrial cancer;	chr20:25995038	chr20:26054655~26086917:+
PCPG	cis	rs9302635	0.513	rs12928732	ENSG00000260886.1	TAT-AS1	4.35	2.55e-05	0.0111	0.5	0.33	Blood protein levels;	chr16:72154784	chr16:71565789~71578187:+
PCPG	cis	rs964611	0.58	rs75570984	ENSG00000259488.2	RP11-154J22.1	4.34	2.56e-05	0.0111	0.32	0.33	Metabolite levels (Pyroglutamine);	chr15:48361246	chr15:48312353~48331856:-
PCPG	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-4.34	2.56e-05	0.0111	-0.38	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
PCPG	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	4.34	2.56e-05	0.0111	0.34	0.33	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
PCPG	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	4.34	2.56e-05	0.0111	0.36	0.33	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	4.34	2.56e-05	0.0111	0.36	0.33	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	4.34	2.56e-05	0.0111	0.36	0.33	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
PCPG	cis	rs17826219	0.561	rs562840	ENSG00000266490.1	CTD-2349P21.9	4.34	2.56e-05	0.0111	0.39	0.33	Body mass index;	chr17:30622372	chr17:30792372~30792833:+
PCPG	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	4.34	2.56e-05	0.0111	0.39	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
PCPG	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	4.34	2.56e-05	0.0111	0.39	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
PCPG	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	4.34	2.56e-05	0.0111	0.34	0.33	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
PCPG	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	4.34	2.56e-05	0.0111	0.34	0.33	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
PCPG	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-4.34	2.56e-05	0.0111	-0.51	-0.33	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
PCPG	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	4.34	2.56e-05	0.0111	0.43	0.33	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
PCPG	cis	rs11858159	1	rs11858845	ENSG00000260760.1	PWRN3	4.34	2.57e-05	0.0111	0.36	0.33	Platelet thrombus formation;	chr15:24562065	chr15:24441127~24447967:+
PCPG	cis	rs748404	0.666	rs8027748	ENSG00000249839.1	AC011330.5	-4.34	2.57e-05	0.0112	-0.46	-0.33	Lung cancer;	chr15:43447622	chr15:43663654~43684339:-
PCPG	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	4.34	2.57e-05	0.0112	0.42	0.33	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
PCPG	cis	rs964611	0.938	rs1820494	ENSG00000259488.2	RP11-154J22.1	4.34	2.57e-05	0.0112	0.32	0.33	Metabolite levels (Pyroglutamine);	chr15:48310977	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs1820491	ENSG00000259488.2	RP11-154J22.1	4.34	2.57e-05	0.0112	0.32	0.33	Metabolite levels (Pyroglutamine);	chr15:48311245	chr15:48312353~48331856:-
PCPG	cis	rs13108904	0.935	rs3755920	ENSG00000254094.1	AC078852.1	-4.34	2.57e-05	0.0112	-0.38	-0.33	Obesity-related traits;	chr4:1249829	chr4:1356581~1358075:+
PCPG	cis	rs28386778	0.897	rs2727295	ENSG00000240280.5	TCAM1P	-4.34	2.58e-05	0.0112	-0.44	-0.33	Prudent dietary pattern;	chr17:63810333	chr17:63849292~63864379:+
PCPG	cis	rs9302635	0.513	rs8044555	ENSG00000260886.1	TAT-AS1	4.34	2.58e-05	0.0112	0.49	0.33	Blood protein levels;	chr16:72118856	chr16:71565789~71578187:+
PCPG	cis	rs1949733	0.675	rs2688235	ENSG00000205959.3	RP11-689P11.2	-4.34	2.58e-05	0.0112	-0.38	-0.33	Response to antineoplastic agents;	chr4:8448819	chr4:8482270~8512610:+
PCPG	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-4.34	2.58e-05	0.0112	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
PCPG	cis	rs11858159	0.934	rs68126063	ENSG00000260760.1	PWRN3	4.34	2.58e-05	0.0112	0.36	0.33	Platelet thrombus formation;	chr15:24541113	chr15:24441127~24447967:+
PCPG	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-4.34	2.58e-05	0.0112	-0.49	-0.33	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
PCPG	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	4.34	2.58e-05	0.0112	0.36	0.33	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
PCPG	cis	rs2625529	0.586	rs59975112	ENSG00000260037.4	CTD-2524L6.3	4.34	2.58e-05	0.0112	0.44	0.33	Red blood cell count;	chr15:72131369	chr15:71818396~71823384:+
PCPG	cis	rs4713118	0.869	rs7773070	ENSG00000216901.1	AL022393.7	4.34	2.58e-05	0.0112	0.45	0.33	Parkinson's disease;	chr6:27761048	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-4.34	2.58e-05	0.0112	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
PCPG	cis	rs6929812	0.665	rs2235254	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27455015	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs12199110	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27455789	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs2092121	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27456405	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs2092122	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27456532	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs764460	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27456595	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.594	rs764461	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27456664	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.629	rs10484398	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27457181	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs1883216	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27457406	chr6:27404010~27406964:-
PCPG	cis	rs2064219	0.662	rs7761989	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Depressive symptoms;Depressive symptoms (multi-trait analysis);	chr6:27458055	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.639	rs6456789	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27458719	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.629	rs7743443	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27458880	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs7743465	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27458938	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs7748366	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27459763	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.691	rs10807024	ENSG00000271755.1	RP1-153G14.4	4.34	2.58e-05	0.0112	0.44	0.33	Neuroticism (multi-trait analysis);	chr6:27460926	chr6:27404010~27406964:-
PCPG	cis	rs853679	0.76	rs9393909	ENSG00000216901.1	AL022393.7	-4.34	2.59e-05	0.0112	-0.55	-0.33	Depression;	chr6:28239422	chr6:28176188~28176674:+
PCPG	cis	rs7746199	0.736	rs13202295	ENSG00000219392.1	RP1-265C24.5	-4.34	2.59e-05	0.0112	-0.74	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28115628~28116551:+
PCPG	cis	rs10899021	0.704	rs11236177	ENSG00000279353.1	RP11-864N7.4	4.34	2.59e-05	0.0112	0.58	0.33	Response to metformin (IC50);	chr11:74628022	chr11:74698231~74699658:-
PCPG	cis	rs10899021	0.79	rs10899022	ENSG00000279353.1	RP11-864N7.4	4.34	2.59e-05	0.0112	0.58	0.33	Response to metformin (IC50);	chr11:74628341	chr11:74698231~74699658:-
PCPG	cis	rs10899021	0.79	rs11236180	ENSG00000279353.1	RP11-864N7.4	4.34	2.59e-05	0.0112	0.58	0.33	Response to metformin (IC50);	chr11:74631883	chr11:74698231~74699658:-
PCPG	cis	rs11673344	0.523	rs8110158	ENSG00000226686.6	LINC01535	4.34	2.59e-05	0.0112	0.44	0.33	Obesity-related traits;	chr19:37063491	chr19:37251912~37265535:+
PCPG	cis	rs7017914	0.69	rs1838392	ENSG00000254031.4	RP11-326E22.1	4.34	2.59e-05	0.0112	0.31	0.33	Bone mineral density;	chr8:70770348	chr8:71155457~71204223:+
PCPG	cis	rs11148252	0.595	rs4885117	ENSG00000273784.3	RP11-78J21.7	-4.34	2.59e-05	0.0112	-0.32	-0.33	Lewy body disease;	chr13:52578892	chr13:52600042~52642542:+
PCPG	cis	rs5758511	0.633	rs5751258	ENSG00000227370.1	RP4-669P10.19	4.34	2.59e-05	0.0112	0.51	0.33	Birth weight;	chr22:42267865	chr22:42132543~42132998:+
PCPG	cis	rs28386778	0.897	rs2854221	ENSG00000240280.5	TCAM1P	-4.34	2.59e-05	0.0112	-0.44	-0.33	Prudent dietary pattern;	chr17:63864085	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584642	ENSG00000240280.5	TCAM1P	-4.34	2.59e-05	0.0112	-0.44	-0.33	Prudent dietary pattern;	chr17:63865067	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs2584637	ENSG00000240280.5	TCAM1P	-4.34	2.59e-05	0.0112	-0.44	-0.33	Prudent dietary pattern;	chr17:63865592	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2854214	ENSG00000240280.5	TCAM1P	4.34	2.59e-05	0.0112	0.44	0.33	Prudent dietary pattern;	chr17:63868089	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2854213	ENSG00000240280.5	TCAM1P	-4.34	2.59e-05	0.0112	-0.44	-0.33	Prudent dietary pattern;	chr17:63868271	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.966	rs2008053	ENSG00000240280.5	TCAM1P	-4.34	2.59e-05	0.0112	-0.44	-0.33	Prudent dietary pattern;	chr17:63877558	chr17:63849292~63864379:+
PCPG	cis	rs116248771	0.739	rs4680448	ENSG00000272087.1	RP11-379F4.7	4.34	2.59e-05	0.0112	0.5	0.33	diarrhoeal disease at age 2;	chr3:158632189	chr3:158693120~158693768:-
PCPG	cis	rs440932	1	rs378974	ENSG00000173295.6	FAM86B3P	-4.34	2.59e-05	0.0112	-0.42	-0.33	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:8228595~8244865:+
PCPG	cis	rs7849782	0.875	rs1323421	ENSG00000225376.4	TMEM246-AS1	4.34	2.59e-05	0.0112	0.39	0.33	Coronary artery aneurysm in Kawasaki disease;	chr9:101655272	chr9:101468439~101481502:+
PCPG	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	4.34	2.6e-05	0.0113	0.58	0.33	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	4.34	2.6e-05	0.0113	0.58	0.33	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	4.34	2.6e-05	0.0113	0.58	0.33	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
PCPG	cis	rs2836974	0.965	rs9941894	ENSG00000252915.1	Y_RNA	-4.34	2.6e-05	0.0113	-0.36	-0.33	Cognitive function;	chr21:39262132	chr21:39344537~39344628:+
PCPG	cis	rs2531992	0.686	rs2041247	ENSG00000262888.1	RP11-462G12.2	-4.34	2.6e-05	0.0113	-0.54	-0.33	Waist circumference;	chr16:3982580	chr16:3931217~3946305:-
PCPG	cis	rs11148252	0.574	rs61958118	ENSG00000273784.3	RP11-78J21.7	-4.34	2.6e-05	0.0113	-0.32	-0.33	Lewy body disease;	chr13:52596091	chr13:52600042~52642542:+
PCPG	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	4.34	2.6e-05	0.0113	0.42	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
PCPG	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-4.34	2.6e-05	0.0113	-0.39	-0.33	Height;	chr5:37007527	chr5:36666214~36725195:-
PCPG	cis	rs657075	0.697	rs35373795	ENSG00000233006.5	AC034220.3	-4.34	2.6e-05	0.0113	-0.5	-0.33	Rheumatoid arthritis;	chr5:132418132	chr5:132311285~132369916:-
PCPG	cis	rs4713118	0.824	rs7759217	ENSG00000216901.1	AL022393.7	4.34	2.6e-05	0.0113	0.45	0.33	Parkinson's disease;	chr6:27762684	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.784	rs9468219	ENSG00000216901.1	AL022393.7	4.34	2.6e-05	0.0113	0.45	0.33	Parkinson's disease;	chr6:27763976	chr6:28176188~28176674:+
PCPG	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-4.34	2.6e-05	0.0113	-0.43	-0.33	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
PCPG	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	4.34	2.6e-05	0.0113	0.45	0.33	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
PCPG	cis	rs3947	0.789	rs9009	ENSG00000255556.2	RP11-351I21.6	4.34	2.61e-05	0.0113	0.37	0.33	Blood protein levels;	chr8:11844497	chr8:12378679~12380265:-
PCPG	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	4.34	2.61e-05	0.0113	0.33	0.33	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
PCPG	cis	rs539514	0.501	rs8000656	ENSG00000261105.4	LMO7-AS1	-4.34	2.61e-05	0.0113	-0.45	-0.33	Type 1 diabetes;	chr13:75826504	chr13:75604700~75635994:-
PCPG	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	4.34	2.61e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
PCPG	cis	rs5758511	0.68	rs1107553	ENSG00000227370.1	RP4-669P10.19	4.34	2.61e-05	0.0113	0.51	0.33	Birth weight;	chr22:42271467	chr22:42132543~42132998:+
PCPG	cis	rs34421088	0.532	rs3808515	ENSG00000255020.1	AF131216.5	4.34	2.61e-05	0.0113	0.41	0.33	Neuroticism;	chr8:11298532	chr8:11345748~11347502:-
PCPG	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	4.34	2.61e-05	0.0113	0.41	0.33	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
PCPG	cis	rs950169	0.8	rs4842847	ENSG00000235370.6	DNM1P51	4.34	2.61e-05	0.0113	0.36	0.33	Schizophrenia;	chr15:84262447	chr15:84398316~84411701:-
PCPG	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	4.34	2.61e-05	0.0113	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
PCPG	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	4.34	2.61e-05	0.0113	0.42	0.33	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
PCPG	cis	rs6044112	0.606	rs6075076	ENSG00000273998.1	RP4-777L9.2	4.34	2.61e-05	0.0113	0.64	0.33	Response to taxane treatment (docetaxel);	chr20:16579700	chr20:16576068~16579615:+
PCPG	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	4.34	2.62e-05	0.0113	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
PCPG	cis	rs10760158	0.769	rs10760170	ENSG00000226752.6	PSMD5-AS1	-4.34	2.62e-05	0.0113	-0.43	-0.33	Pulse pressure;	chr9:121295935	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.832	rs1865542	ENSG00000226752.6	PSMD5-AS1	-4.34	2.62e-05	0.0113	-0.43	-0.33	Pulse pressure;	chr9:121296521	chr9:120824828~120854385:+
PCPG	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-4.34	2.62e-05	0.0113	-0.33	-0.33	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
PCPG	cis	rs8030379	1	rs11259931	ENSG00000230373.7	GOLGA6L5P	4.34	2.62e-05	0.0113	0.31	0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911270	chr15:84507885~84516814:-
PCPG	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-4.34	2.62e-05	0.0113	-0.35	-0.33	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
PCPG	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	4.34	2.62e-05	0.0113	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	4.34	2.62e-05	0.0113	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	4.34	2.62e-05	0.0113	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
PCPG	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	4.34	2.62e-05	0.0113	0.42	0.33	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
PCPG	cis	rs6929812	0.664	rs3918438	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27430354	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.628	rs2206254	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27431852	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs1569566	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27432252	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs979352	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27433417	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs6908086	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27434244	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs6914585	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27435566	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs12197858	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27436992	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs10484397	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27437904	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs12200018	ENSG00000271755.1	RP1-153G14.4	4.34	2.62e-05	0.0113	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27438377	chr6:27404010~27406964:-
PCPG	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	4.34	2.62e-05	0.0114	0.34	0.33	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
PCPG	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	4.34	2.62e-05	0.0114	0.51	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
PCPG	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-4.34	2.62e-05	0.0114	-0.33	-0.33	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
PCPG	cis	rs1440410	0.835	rs4690771	ENSG00000250326.1	RP11-284M14.1	4.34	2.63e-05	0.0114	0.32	0.33	Ischemic stroke;	chr4:143129944	chr4:142933195~143184861:-
PCPG	cis	rs17772222	1	rs17124700	ENSG00000222990.1	RNU4-22P	4.34	2.63e-05	0.0114	0.46	0.33	Coronary artery calcification;	chr14:88439285	chr14:88513498~88513663:+
PCPG	cis	rs853679	0.556	rs13197633	ENSG00000219392.1	RP1-265C24.5	-4.34	2.63e-05	0.0114	-0.73	-0.33	Depression;	chr6:28206979	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs35001169	ENSG00000219392.1	RP1-265C24.5	-4.34	2.63e-05	0.0114	-0.73	-0.33	Depression;	chr6:28219854	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs35656932	ENSG00000219392.1	RP1-265C24.5	-4.34	2.63e-05	0.0114	-0.73	-0.33	Depression;	chr6:28223510	chr6:28115628~28116551:+
PCPG	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-4.34	2.63e-05	0.0114	-0.33	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
PCPG	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-4.34	2.63e-05	0.0114	-0.33	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
PCPG	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	4.34	2.63e-05	0.0114	0.36	0.33	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
PCPG	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.49	-0.33	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.48	-0.33	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.48	-0.33	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.48	-0.33	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.48	-0.33	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.48	-0.33	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
PCPG	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-4.34	2.63e-05	0.0114	-0.35	-0.33	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
PCPG	cis	rs2404602	0.532	rs744336	ENSG00000259514.1	RP11-685G9.2	-4.34	2.63e-05	0.0114	-0.34	-0.33	Blood metabolite levels;	chr15:76382283	chr15:76339609~76342063:-
PCPG	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.49	-0.33	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.49	-0.33	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.49	-0.33	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.49	-0.33	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-4.34	2.63e-05	0.0114	-0.49	-0.33	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
PCPG	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	-4.34	2.63e-05	0.0114	-0.38	-0.33	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
PCPG	cis	rs6456042	0.893	rs3127441	ENSG00000231297.3	RP11-459F1.2	4.34	2.64e-05	0.0114	0.37	0.33	Asthma;	chr6:166149366	chr6:166099665~166113273:+
PCPG	cis	rs5742933	0.817	rs6942	ENSG00000273240.1	RP11-455J20.3	4.34	2.64e-05	0.0114	0.36	0.33	Ferritin levels;	chr2:189771685	chr2:189763859~189764456:-
PCPG	cis	rs13108904	0.905	rs1732108	ENSG00000254094.1	AC078852.1	4.34	2.64e-05	0.0114	0.38	0.33	Obesity-related traits;	chr4:1282762	chr4:1356581~1358075:+
PCPG	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	4.34	2.64e-05	0.0114	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
PCPG	cis	rs1440410	0.83	rs1470130	ENSG00000250326.1	RP11-284M14.1	4.34	2.64e-05	0.0114	0.31	0.33	Ischemic stroke;	chr4:143257749	chr4:142933195~143184861:-
PCPG	cis	rs9303542	0.559	rs2229302	ENSG00000279036.1	RP11-81K2.2	-4.34	2.65e-05	0.0114	-0.54	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48543040	chr17:49494223~49497800:-
PCPG	cis	rs728616	1	rs728616	ENSG00000242600.5	MBL1P	4.34	2.65e-05	0.0114	0.65	0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:79904898~79950336:+
PCPG	cis	rs657075	0.586	rs28532117	ENSG00000233006.5	AC034220.3	-4.34	2.65e-05	0.0114	-0.48	-0.33	Rheumatoid arthritis;	chr5:132287998	chr5:132311285~132369916:-
PCPG	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	4.34	2.65e-05	0.0114	0.33	0.33	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
PCPG	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	4.34	2.65e-05	0.0115	0.44	0.33	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
PCPG	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-4.34	2.65e-05	0.0115	-0.49	-0.33	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
PCPG	cis	rs916888	0.531	rs183211	ENSG00000262500.1	RP11-259G18.2	4.34	2.66e-05	0.0115	0.49	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46243606~46245044:+
PCPG	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-4.34	2.66e-05	0.0115	-0.43	-0.33	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
PCPG	cis	rs17684571	0.938	rs4073960	ENSG00000231441.1	RP11-472M19.2	4.34	2.66e-05	0.0115	0.5	0.33	Schizophrenia;	chr6:56683561	chr6:56844002~56864078:+
PCPG	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	4.34	2.66e-05	0.0115	0.33	0.33	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	4.34	2.66e-05	0.0115	0.33	0.33	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
PCPG	cis	rs11673344	0.504	rs10403728	ENSG00000226686.6	LINC01535	4.34	2.66e-05	0.0115	0.44	0.33	Obesity-related traits;	chr19:37091569	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.562	rs7250507	ENSG00000226686.6	LINC01535	4.34	2.66e-05	0.0115	0.44	0.33	Obesity-related traits;	chr19:37095772	chr19:37251912~37265535:+
PCPG	cis	rs775326	0.599	rs346429	ENSG00000217416.4	ISCA1P1	-4.34	2.66e-05	0.0115	-0.34	-0.33	Educational attainment (years of education);	chr5:63297969	chr5:62776877~62777263:-
PCPG	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	4.34	2.66e-05	0.0115	0.33	0.33	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
PCPG	cis	rs9928842	0.882	rs9319481	ENSG00000280152.1	RP11-331F4.5	4.34	2.66e-05	0.0115	0.54	0.33	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75245994~75250077:-
PCPG	cis	rs4143844	0.737	rs11633932	ENSG00000259251.2	RP11-643M14.1	4.34	2.66e-05	0.0115	0.78	0.33	Bipolar disorder and schizophrenia;	chr15:62080954	chr15:62060503~62062434:+
PCPG	cis	rs7243821	0.543	rs8092980	ENSG00000267112.1	RP11-839G9.1	4.33	2.66e-05	0.0115	0.43	0.33	Chin dimples;	chr18:54896710	chr18:54885866~54898083:-
PCPG	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	4.33	2.66e-05	0.0115	0.45	0.33	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	4.33	2.66e-05	0.0115	0.45	0.33	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
PCPG	cis	rs11858159	0.741	rs28373415	ENSG00000260760.1	PWRN3	4.33	2.66e-05	0.0115	0.34	0.33	Platelet thrombus formation;	chr15:24533790	chr15:24441127~24447967:+
PCPG	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	4.33	2.66e-05	0.0115	0.33	0.33	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
PCPG	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-4.33	2.66e-05	0.0115	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-4.33	2.66e-05	0.0115	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
PCPG	cis	rs748404	0.706	rs35975365	ENSG00000205771.5	CATSPER2P1	-4.33	2.67e-05	0.0115	-0.46	-0.33	Lung cancer;	chr15:43379347	chr15:43726918~43747094:-
PCPG	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-4.33	2.67e-05	0.0115	-0.35	-0.33	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
PCPG	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	4.33	2.67e-05	0.0115	0.38	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	4.33	2.67e-05	0.0115	0.38	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
PCPG	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-4.33	2.67e-05	0.0115	-0.5	-0.33	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
PCPG	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-4.33	2.67e-05	0.0115	-0.48	-0.33	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
PCPG	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-4.33	2.67e-05	0.0115	-0.45	-0.33	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
PCPG	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	4.33	2.67e-05	0.0115	0.4	0.33	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
PCPG	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	4.33	2.67e-05	0.0115	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
PCPG	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-4.33	2.68e-05	0.0115	-0.44	-0.33	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-4.33	2.68e-05	0.0115	-0.44	-0.33	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
PCPG	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	4.33	2.68e-05	0.0115	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	4.33	2.68e-05	0.0115	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
PCPG	cis	rs8099594	0.565	rs1942999	ENSG00000278983.1	RP11-426J5.3	4.33	2.68e-05	0.0115	0.36	0.33	Height;	chr18:49186458	chr18:48564795~48568342:+
PCPG	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-4.33	2.68e-05	0.0115	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
PCPG	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-4.33	2.68e-05	0.0115	-0.43	-0.33	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-4.33	2.68e-05	0.0115	-0.43	-0.33	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-4.33	2.68e-05	0.0115	-0.43	-0.33	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
PCPG	cis	rs2625529	0.59	rs713048	ENSG00000260037.4	CTD-2524L6.3	-4.33	2.68e-05	0.0115	-0.49	-0.33	Red blood cell count;	chr15:72250743	chr15:71818396~71823384:+
PCPG	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-4.33	2.68e-05	0.0115	-0.48	-0.33	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
PCPG	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	4.33	2.68e-05	0.0116	0.36	0.33	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
PCPG	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-4.33	2.69e-05	0.0116	-0.41	-0.33	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
PCPG	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	4.33	2.69e-05	0.0116	0.44	0.33	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
PCPG	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-4.33	2.69e-05	0.0116	-0.42	-0.33	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-4.33	2.69e-05	0.0116	-0.42	-0.33	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
PCPG	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-4.33	2.69e-05	0.0116	-0.43	-0.33	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-4.33	2.69e-05	0.0116	-0.43	-0.33	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
PCPG	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-4.33	2.69e-05	0.0116	-0.43	-0.33	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
PCPG	cis	rs748404	0.626	rs17780920	ENSG00000249839.1	AC011330.5	-4.33	2.69e-05	0.0116	-0.44	-0.33	Lung cancer;	chr15:43370164	chr15:43663654~43684339:-
PCPG	cis	rs4713118	0.621	rs9295755	ENSG00000216901.1	AL022393.7	-4.33	2.69e-05	0.0116	-0.47	-0.33	Parkinson's disease;	chr6:28065396	chr6:28176188~28176674:+
PCPG	cis	rs62246343	0.605	rs17050395	ENSG00000254485.4	RP11-380O24.1	4.33	2.69e-05	0.0116	0.44	0.33	Fibrinogen levels;	chr3:9492290	chr3:9292588~9363303:-
PCPG	cis	rs453301	0.598	rs10104303	ENSG00000173295.6	FAM86B3P	-4.33	2.7e-05	0.0116	-0.39	-0.33	Joint mobility (Beighton score);	chr8:8977018	chr8:8228595~8244865:+
PCPG	cis	rs73198271	0.7	rs10103282	ENSG00000253893.2	FAM85B	4.33	2.7e-05	0.0116	0.45	0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.74	rs11781430	ENSG00000253893.2	FAM85B	4.33	2.7e-05	0.0116	0.45	0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.7	rs10090152	ENSG00000253893.2	FAM85B	4.33	2.7e-05	0.0116	0.45	0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8167819~8226614:-
PCPG	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	4.33	2.7e-05	0.0116	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	4.33	2.7e-05	0.0116	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	4.33	2.7e-05	0.0116	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	4.33	2.7e-05	0.0116	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
PCPG	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	4.33	2.7e-05	0.0116	0.39	0.33	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
PCPG	cis	rs6579956	0.565	rs13167390	ENSG00000270978.1	RP11-54C4.2	4.33	2.7e-05	0.0116	0.41	0.33	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152803008	chr5:151848886~151850791:+
PCPG	cis	rs17264034	0.861	rs55713652	ENSG00000250786.1	SNHG18	4.33	2.7e-05	0.0116	0.5	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557010	chr5:9546200~9550609:+
PCPG	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
PCPG	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	4.33	2.7e-05	0.0116	0.33	0.33	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
PCPG	cis	rs72615157	0.628	rs7801070	ENSG00000078319.8	PMS2P1	-4.33	2.71e-05	0.0116	-0.41	-0.33	Lung function (FEV1/FVC);	chr7:100249524	chr7:100320992~100341908:-
PCPG	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	4.33	2.71e-05	0.0116	0.41	0.33	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
PCPG	cis	rs7759001	0.857	rs4579353	ENSG00000271755.1	RP1-153G14.4	4.33	2.71e-05	0.0117	0.49	0.33	Glomerular filtration rate (creatinine);	chr6:27404711	chr6:27404010~27406964:-
PCPG	cis	rs3758911	0.861	rs10890689	ENSG00000255353.1	RP11-382M14.1	-4.33	2.71e-05	0.0117	-0.45	-0.33	Coronary artery disease;	chr11:107275626	chr11:107176286~107177530:+
PCPG	cis	rs4295623	0.585	rs34421088	ENSG00000255020.1	AF131216.5	-4.33	2.71e-05	0.0117	-0.46	-0.33	Morning vs. evening chronotype;	chr8:11731533	chr8:11345748~11347502:-
PCPG	cis	rs803923	0.545	rs1441747	ENSG00000230734.1	RPL10P3	4.33	2.72e-05	0.0117	0.32	0.33	Lung function (FEV1/FVC);	chr9:116725532	chr9:117180628~117181095:-
PCPG	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	4.33	2.72e-05	0.0117	0.37	0.33	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
PCPG	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-4.33	2.72e-05	0.0117	-0.75	-0.33	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
PCPG	cis	rs181553	0.504	rs28889615	ENSG00000278983.1	RP11-426J5.3	-4.33	2.72e-05	0.0117	-0.38	-0.33	Hip circumference adjusted for BMI;	chr18:49449084	chr18:48564795~48568342:+
PCPG	cis	rs561341	1	rs68140514	ENSG00000265798.5	RP11-271K11.5	4.33	2.72e-05	0.0117	0.58	0.33	Hip circumference adjusted for BMI;	chr17:32008762	chr17:31038575~31059121:-
PCPG	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-4.33	2.72e-05	0.0117	-0.26	-0.33	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
PCPG	cis	rs2439831	1	rs2467743	ENSG00000205771.5	CATSPER2P1	-4.33	2.72e-05	0.0117	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43458148	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2245176	ENSG00000205771.5	CATSPER2P1	-4.33	2.72e-05	0.0117	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43458564	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2245054	ENSG00000205771.5	CATSPER2P1	-4.33	2.72e-05	0.0117	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43459711	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2444032	ENSG00000205771.5	CATSPER2P1	-4.33	2.72e-05	0.0117	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43463148	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2264876	ENSG00000205771.5	CATSPER2P1	-4.33	2.72e-05	0.0117	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43465221	chr15:43726918~43747094:-
PCPG	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-4.33	2.73e-05	0.0117	-0.56	-0.33	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
PCPG	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-4.33	2.73e-05	0.0117	-0.27	-0.33	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-4.33	2.73e-05	0.0117	-0.27	-0.33	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
PCPG	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	4.33	2.73e-05	0.0117	0.33	0.33	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
PCPG	cis	rs11910494	0.553	rs2833567	ENSG00000273091.1	AP000255.6	4.33	2.73e-05	0.0117	0.4	0.33	IgG glycosylation;	chr21:31943221	chr21:31735732~31736407:+
PCPG	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-4.33	2.73e-05	0.0117	-0.27	-0.33	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-4.33	2.73e-05	0.0117	-0.27	-0.33	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-4.33	2.73e-05	0.0117	-0.27	-0.33	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-4.33	2.73e-05	0.0117	-0.27	-0.33	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-4.33	2.73e-05	0.0117	-0.27	-0.33	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
PCPG	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	4.33	2.73e-05	0.0117	0.45	0.33	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	4.33	2.73e-05	0.0117	0.45	0.33	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	4.33	2.73e-05	0.0117	0.45	0.33	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
PCPG	cis	rs4489787	0.892	rs2731101	ENSG00000240399.1	RP1-228P16.1	4.33	2.73e-05	0.0117	0.44	0.33	Prostate cancer (SNP x SNP interaction);	chr12:48510456	chr12:48054813~48055591:-
PCPG	cis	rs9393777	0.668	rs7746199	ENSG00000216901.1	AL022393.7	-4.33	2.73e-05	0.0117	-0.5	-0.33	Intelligence (multi-trait analysis);	chr6:27293545	chr6:28176188~28176674:+
PCPG	cis	rs12681963	1	rs4733384	ENSG00000248159.1	HSPA8P11	4.33	2.73e-05	0.0117	0.54	0.33	Migraine;	chr8:30127865	chr8:30237382~30240997:+
PCPG	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-4.33	2.73e-05	0.0117	-0.39	-0.33	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
PCPG	cis	rs7042889	1	rs7042889	ENSG00000281892.1	Metazoa_SRP	4.33	2.74e-05	0.0117	0.56	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129033082	chr9:128314614~128314876:-
PCPG	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	4.33	2.74e-05	0.0117	0.51	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
PCPG	cis	rs2440129	0.611	rs1126667	ENSG00000262089.1	RP11-589P10.5	-4.33	2.74e-05	0.0117	-0.23	-0.33	Tonsillectomy;	chr17:6999441	chr17:6994642~6995189:-
PCPG	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	4.33	2.74e-05	0.0117	0.53	0.33	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	4.33	2.74e-05	0.0117	0.53	0.33	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
PCPG	cis	rs6121246	0.697	rs6088864	ENSG00000230613.1	HM13-AS1	4.33	2.74e-05	0.0118	0.5	0.33	Mean corpuscular hemoglobin;	chr20:31640354	chr20:31567707~31573263:-
PCPG	cis	rs8042680	0.522	rs12595616	ENSG00000214432.8	AC068831.10	4.33	2.74e-05	0.0118	0.37	0.33	Type 2 diabetes;	chr15:91020283	chr15:91022619~91036611:+
PCPG	cis	rs9469578	0.579	rs77528762	ENSG00000224796.1	RPL32P1	-4.33	2.75e-05	0.0118	-0.84	-0.33	Phosphorus levels;	chr6:33715291	chr6:33079451~33079860:+
PCPG	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-4.33	2.75e-05	0.0118	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
PCPG	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-4.33	2.75e-05	0.0118	-0.37	-0.33	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-4.33	2.75e-05	0.0118	-0.37	-0.33	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
PCPG	cis	rs412050	0.793	rs17821866	ENSG00000224086.5	LL22NC03-86G7.1	-4.33	2.75e-05	0.0118	-0.5	-0.33	Attention deficit hyperactivity disorder;	chr22:21988067	chr22:21938293~21977632:+
PCPG	cis	rs4143844	0.609	rs35577653	ENSG00000259251.2	RP11-643M14.1	4.33	2.75e-05	0.0118	0.78	0.33	Bipolar disorder and schizophrenia;	chr15:62079948	chr15:62060503~62062434:+
PCPG	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	4.33	2.75e-05	0.0118	0.38	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
PCPG	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	4.33	2.75e-05	0.0118	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	4.33	2.75e-05	0.0118	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	4.33	2.75e-05	0.0118	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	4.33	2.75e-05	0.0118	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	4.33	2.75e-05	0.0118	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	4.33	2.75e-05	0.0118	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	4.33	2.75e-05	0.0118	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
PCPG	cis	rs6901152	1	rs9376745	ENSG00000217648.1	RP1-95L4.4	-4.33	2.75e-05	0.0118	-0.39	-0.33	Acute lymphoblastic leukemia (childhood);	chr6:143336155	chr6:143342246~143343383:+
PCPG	cis	rs6700559	0.74	rs6663322	ENSG00000260088.1	RP11-92G12.3	4.33	2.75e-05	0.0118	0.39	0.33	Coronary artery disease;	chr1:200680741	chr1:200669507~200694250:+
PCPG	cis	rs8030379	1	rs11259932	ENSG00000230373.7	GOLGA6L5P	-4.33	2.75e-05	0.0118	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911305	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs11259934	ENSG00000230373.7	GOLGA6L5P	-4.33	2.75e-05	0.0118	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911419	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs11259935	ENSG00000230373.7	GOLGA6L5P	-4.33	2.75e-05	0.0118	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911675	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs12914857	ENSG00000230373.7	GOLGA6L5P	-4.33	2.75e-05	0.0118	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912414	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2055712	ENSG00000230373.7	GOLGA6L5P	-4.33	2.75e-05	0.0118	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912853	chr15:84507885~84516814:-
PCPG	cis	rs964611	0.938	rs12592155	ENSG00000259488.2	RP11-154J22.1	-4.33	2.75e-05	0.0118	-0.34	-0.33	Metabolite levels (Pyroglutamine);	chr15:48331303	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.938	rs12592157	ENSG00000259488.2	RP11-154J22.1	-4.33	2.75e-05	0.0118	-0.34	-0.33	Metabolite levels (Pyroglutamine);	chr15:48331327	chr15:48312353~48331856:-
PCPG	cis	rs28386778	0.83	rs2854210	ENSG00000240280.5	TCAM1P	-4.33	2.75e-05	0.0118	-0.45	-0.33	Prudent dietary pattern;	chr17:63868978	chr17:63849292~63864379:+
PCPG	cis	rs9303542	0.559	rs12603976	ENSG00000279036.1	RP11-81K2.2	-4.33	2.75e-05	0.0118	-0.54	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48539801	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs12602539	ENSG00000279036.1	RP11-81K2.2	-4.33	2.75e-05	0.0118	-0.54	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48540097	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs62066693	ENSG00000279036.1	RP11-81K2.2	-4.33	2.75e-05	0.0118	-0.54	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48540168	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs1042822	ENSG00000279036.1	RP11-81K2.2	-4.33	2.75e-05	0.0118	-0.54	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48542733	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs1042818	ENSG00000279036.1	RP11-81K2.2	-4.33	2.75e-05	0.0118	-0.54	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48542749	chr17:49494223~49497800:-
PCPG	cis	rs6504340	0.793	rs56128659	ENSG00000279036.1	RP11-81K2.2	-4.33	2.76e-05	0.0118	-0.55	-0.33	Primary tooth development (number of teeth);	chr17:48544466	chr17:49494223~49497800:-
PCPG	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-4.33	2.76e-05	0.0118	-0.46	-0.33	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
PCPG	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	4.33	2.76e-05	0.0118	0.33	0.33	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
PCPG	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	-4.33	2.76e-05	0.0118	-0.41	-0.33	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
PCPG	cis	rs5742933	0.857	rs1233272	ENSG00000273240.1	RP11-455J20.3	-4.33	2.76e-05	0.0118	-0.35	-0.33	Ferritin levels;	chr2:189814968	chr2:189763859~189764456:-
PCPG	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-4.33	2.76e-05	0.0118	-0.48	-0.33	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
PCPG	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-4.33	2.76e-05	0.0118	-0.52	-0.33	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
PCPG	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	4.33	2.76e-05	0.0118	0.33	0.33	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
PCPG	cis	rs394563	0.967	rs447025	ENSG00000268592.3	RAET1E-AS1	4.33	2.77e-05	0.0118	0.42	0.33	Dupuytren's disease;	chr6:149477992	chr6:149863494~149919507:+
PCPG	cis	rs5758511	0.68	rs5758662	ENSG00000227370.1	RP4-669P10.19	4.33	2.77e-05	0.0118	0.51	0.33	Birth weight;	chr22:42232082	chr22:42132543~42132998:+
PCPG	cis	rs8030379	1	rs6603004	ENSG00000230373.7	GOLGA6L5P	4.33	2.77e-05	0.0118	0.33	0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899752	chr15:84507885~84516814:-
PCPG	cis	rs17684571	0.7	rs35609883	ENSG00000231441.1	RP11-472M19.2	4.33	2.77e-05	0.0119	0.52	0.33	Schizophrenia;	chr6:56807034	chr6:56844002~56864078:+
PCPG	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	4.32	2.77e-05	0.0119	0.32	0.33	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
PCPG	cis	rs1387259	0.929	rs2956703	ENSG00000240399.1	RP1-228P16.1	4.32	2.77e-05	0.0119	0.37	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48054813~48055591:-
PCPG	cis	rs657075	0.697	rs3792880	ENSG00000233006.5	AC034220.3	4.32	2.77e-05	0.0119	0.43	0.33	Rheumatoid arthritis;	chr5:132309272	chr5:132311285~132369916:-
PCPG	cis	rs2404602	0.692	rs3110382	ENSG00000259514.1	RP11-685G9.2	4.32	2.77e-05	0.0119	0.33	0.33	Blood metabolite levels;	chr15:76856347	chr15:76339609~76342063:-
PCPG	cis	rs17684571	0.7	rs61601344	ENSG00000231441.1	RP11-472M19.2	4.32	2.77e-05	0.0119	0.52	0.33	Schizophrenia;	chr6:56797356	chr6:56844002~56864078:+
PCPG	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-4.32	2.77e-05	0.0119	-0.56	-0.33	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
PCPG	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-4.32	2.77e-05	0.0119	-0.56	-0.33	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
PCPG	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-4.32	2.77e-05	0.0119	-0.56	-0.33	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
PCPG	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-4.32	2.77e-05	0.0119	-0.56	-0.33	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
PCPG	cis	rs950169	0.959	rs12911210	ENSG00000235370.6	DNM1P51	4.32	2.78e-05	0.0119	0.33	0.33	Schizophrenia;	chr15:84123331	chr15:84398316~84411701:-
PCPG	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	4.32	2.78e-05	0.0119	0.33	0.33	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	4.32	2.78e-05	0.0119	0.33	0.33	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
PCPG	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	4.32	2.78e-05	0.0119	0.34	0.33	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
PCPG	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	4.32	2.78e-05	0.0119	0.38	0.33	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
PCPG	cis	rs2439831	0.702	rs495175	ENSG00000205771.5	CATSPER2P1	-4.32	2.78e-05	0.0119	-0.47	-0.33	Lung cancer in ever smokers;	chr15:43506486	chr15:43726918~43747094:-
PCPG	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	4.32	2.78e-05	0.0119	0.38	0.33	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
PCPG	cis	rs8030379	1	rs8041056	ENSG00000230373.7	GOLGA6L5P	-4.32	2.78e-05	0.0119	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896065	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs6603001	ENSG00000230373.7	GOLGA6L5P	-4.32	2.78e-05	0.0119	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896516	chr15:84507885~84516814:-
PCPG	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	4.32	2.78e-05	0.0119	0.7	0.33	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
PCPG	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-4.32	2.79e-05	0.0119	-0.47	-0.33	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
PCPG	cis	rs1387259	0.929	rs2634666	ENSG00000240399.1	RP1-228P16.1	4.32	2.79e-05	0.0119	0.37	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48054813~48055591:-
PCPG	cis	rs2281558	0.876	rs2281562	ENSG00000125804.12	FAM182A	-4.32	2.79e-05	0.0119	-0.47	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25292726	chr20:26054655~26086917:+
PCPG	cis	rs2281558	0.876	rs6115135	ENSG00000125804.12	FAM182A	-4.32	2.79e-05	0.0119	-0.47	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299242	chr20:26054655~26086917:+
PCPG	cis	rs2281558	0.876	rs6107025	ENSG00000125804.12	FAM182A	-4.32	2.79e-05	0.0119	-0.47	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299244	chr20:26054655~26086917:+
PCPG	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-4.32	2.79e-05	0.0119	-0.44	-0.33	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
PCPG	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-4.32	2.79e-05	0.0119	-0.42	-0.33	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
PCPG	cis	rs5769765	0.773	rs9616395	ENSG00000278869.1	CITF22-49E9.3	4.32	2.79e-05	0.0119	0.45	0.33	Schizophrenia;	chr22:49924155	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.773	rs11090920	ENSG00000278869.1	CITF22-49E9.3	4.32	2.79e-05	0.0119	0.45	0.33	Schizophrenia;	chr22:49926457	chr22:49933198~49934074:-
PCPG	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	4.32	2.79e-05	0.0119	0.54	0.33	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
PCPG	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	4.32	2.79e-05	0.0119	0.54	0.33	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
PCPG	cis	rs7042889	1	rs77357573	ENSG00000281892.1	Metazoa_SRP	4.32	2.79e-05	0.0119	0.57	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129031782	chr9:128314614~128314876:-
PCPG	cis	rs7042889	0.826	rs7873667	ENSG00000281892.1	Metazoa_SRP	4.32	2.79e-05	0.0119	0.57	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129033676	chr9:128314614~128314876:-
PCPG	cis	rs11858159	0.934	rs7172595	ENSG00000260760.1	PWRN3	4.32	2.79e-05	0.0119	0.36	0.33	Platelet thrombus formation;	chr15:24555197	chr15:24441127~24447967:+
PCPG	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	4.32	2.79e-05	0.0119	0.34	0.33	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
PCPG	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	4.32	2.79e-05	0.0119	0.6	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
PCPG	cis	rs10899021	0.79	rs59958321	ENSG00000279353.1	RP11-864N7.4	4.32	2.79e-05	0.0119	0.6	0.33	Response to metformin (IC50);	chr11:74643569	chr11:74698231~74699658:-
PCPG	cis	rs4803480	0.554	rs12462194	ENSG00000267107.5	PCAT19	4.32	2.79e-05	0.0119	0.27	0.33	Schizophrenia;	chr19:41565931	chr19:41454169~41500649:-
PCPG	cis	rs2625529	0.668	rs34189331	ENSG00000260037.4	CTD-2524L6.3	-4.32	2.8e-05	0.012	-0.52	-0.33	Red blood cell count;	chr15:72112232	chr15:71818396~71823384:+
PCPG	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	4.32	2.8e-05	0.012	0.44	0.33	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
PCPG	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	4.32	2.8e-05	0.012	0.38	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
PCPG	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-4.32	2.8e-05	0.012	-0.26	-0.33	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-4.32	2.8e-05	0.012	-0.26	-0.33	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
PCPG	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	4.32	2.8e-05	0.012	0.37	0.33	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
PCPG	cis	rs7403037	1	rs28380602	ENSG00000260760.1	PWRN3	4.32	2.8e-05	0.012	0.36	0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24532999	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.871	rs28477593	ENSG00000260760.1	PWRN3	4.32	2.8e-05	0.012	0.36	0.33	Platelet thrombus formation;	chr15:24533441	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs28394774	ENSG00000260760.1	PWRN3	4.32	2.8e-05	0.012	0.36	0.33	Platelet thrombus formation;	chr15:24533451	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs28735204	ENSG00000260760.1	PWRN3	4.32	2.8e-05	0.012	0.36	0.33	Platelet thrombus formation;	chr15:24533537	chr15:24441127~24447967:+
PCPG	cis	rs2732480	0.5	rs2450986	ENSG00000240399.1	RP1-228P16.1	4.32	2.8e-05	0.012	0.36	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48054813~48055591:-
PCPG	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	4.32	2.8e-05	0.012	0.51	0.33	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
PCPG	cis	rs1440410	0.582	rs62330278	ENSG00000250326.1	RP11-284M14.1	4.32	2.8e-05	0.012	0.31	0.33	Ischemic stroke;	chr4:143184856	chr4:142933195~143184861:-
PCPG	cis	rs9303029	0.932	rs12450192	ENSG00000279744.1	RP13-20L14.10	-4.32	2.8e-05	0.012	-0.42	-0.33	Protein quantitative trait loci;	chr17:82450102	chr17:82462601~82464255:+
PCPG	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-4.32	2.8e-05	0.012	-0.42	-0.33	Height;	chr6:109531713	chr6:109382795~109383666:+
PCPG	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-4.32	2.81e-05	0.012	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-4.32	2.81e-05	0.012	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-4.32	2.81e-05	0.012	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-4.32	2.81e-05	0.012	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-4.32	2.81e-05	0.012	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
PCPG	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	4.32	2.81e-05	0.012	0.44	0.33	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
PCPG	cis	rs394563	0.591	rs11155641	ENSG00000231760.4	RP11-350J20.5	-4.32	2.81e-05	0.012	-0.41	-0.33	Dupuytren's disease;	chr6:149327459	chr6:149796151~149826294:-
PCPG	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	4.32	2.81e-05	0.012	0.39	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
PCPG	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-4.32	2.81e-05	0.012	-0.43	-0.33	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
PCPG	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	4.32	2.81e-05	0.012	0.42	0.33	Height;	chr6:109392096	chr6:109382795~109383666:+
PCPG	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-4.32	2.82e-05	0.012	-0.48	-0.33	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-4.32	2.82e-05	0.012	-0.48	-0.33	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
PCPG	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-4.32	2.82e-05	0.012	-0.41	-0.33	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
PCPG	cis	rs6479901	0.588	rs10740105	ENSG00000232075.1	MRPL35P2	-4.32	2.82e-05	0.012	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63634317~63634827:-
PCPG	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	4.32	2.82e-05	0.012	0.31	0.33	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
PCPG	cis	rs8098244	0.516	rs2960586	ENSG00000265752.2	RP11-403A21.1	4.32	2.82e-05	0.012	0.4	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690207	chr18:23957754~23982556:-
PCPG	cis	rs11858159	0.966	rs11852561	ENSG00000260760.1	PWRN3	4.32	2.82e-05	0.012	0.36	0.33	Platelet thrombus formation;	chr15:24560231	chr15:24441127~24447967:+
PCPG	cis	rs728616	0.764	rs56196124	ENSG00000242600.5	MBL1P	4.32	2.82e-05	0.012	0.68	0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142899	chr10:79904898~79950336:+
PCPG	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	4.32	2.82e-05	0.012	0.33	0.33	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
PCPG	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-4.32	2.82e-05	0.012	-0.48	-0.33	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-4.32	2.82e-05	0.012	-0.48	-0.33	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-4.32	2.83e-05	0.012	-0.48	-0.33	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
PCPG	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-4.32	2.83e-05	0.012	-0.37	-0.33	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
PCPG	cis	rs9303029	0.611	rs8008	ENSG00000279744.1	RP13-20L14.10	4.32	2.83e-05	0.0121	0.46	0.33	Protein quantitative trait loci;	chr17:82442879	chr17:82462601~82464255:+
PCPG	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-4.32	2.83e-05	0.0121	-0.41	-0.33	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
PCPG	cis	rs35934224	0.783	rs7288061	ENSG00000232926.1	AC000078.5	4.32	2.84e-05	0.0121	0.4	0.33	Glaucoma (primary open-angle);	chr22:19876716	chr22:19887289~19887970:+
PCPG	cis	rs35934224	0.783	rs7287073	ENSG00000232926.1	AC000078.5	4.32	2.84e-05	0.0121	0.4	0.33	Glaucoma (primary open-angle);	chr22:19876812	chr22:19887289~19887970:+
PCPG	cis	rs11858159	0.756	rs71404356	ENSG00000259905.4	PWRN1	4.32	2.84e-05	0.0121	0.38	0.33	Platelet thrombus formation;	chr15:24552756	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.603	rs76802982	ENSG00000259905.4	PWRN1	4.32	2.84e-05	0.0121	0.38	0.33	Platelet thrombus formation;	chr15:24552801	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.58	rs77327676	ENSG00000259905.4	PWRN1	4.32	2.84e-05	0.0121	0.38	0.33	Platelet thrombus formation;	chr15:24552802	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.934	rs71404358	ENSG00000259905.4	PWRN1	4.32	2.84e-05	0.0121	0.38	0.33	Platelet thrombus formation;	chr15:24552810	chr15:24493137~24652130:+
PCPG	cis	rs1908814	0.516	rs11250178	ENSG00000255495.1	AC145124.2	4.32	2.84e-05	0.0121	0.34	0.33	Neuroticism;	chr8:11942725	chr8:12194467~12196280:+
PCPG	cis	rs13108904	0.901	rs12641735	ENSG00000253399.1	AC078852.2	-4.32	2.84e-05	0.0121	-0.34	-0.33	Obesity-related traits;	chr4:1310646	chr4:1358479~1359461:+
PCPG	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-4.32	2.84e-05	0.0121	-0.53	-0.33	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
PCPG	cis	rs11148252	0.595	rs9526968	ENSG00000273784.3	RP11-78J21.7	-4.32	2.85e-05	0.0121	-0.32	-0.33	Lewy body disease;	chr13:52666048	chr13:52600042~52642542:+
PCPG	cis	rs11148252	0.553	rs7999849	ENSG00000273784.3	RP11-78J21.7	-4.32	2.85e-05	0.0121	-0.32	-0.33	Lewy body disease;	chr13:52675279	chr13:52600042~52642542:+
PCPG	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-4.32	2.85e-05	0.0121	-0.44	-0.33	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
PCPG	cis	rs11673344	0.504	rs12984458	ENSG00000226686.6	LINC01535	-4.32	2.85e-05	0.0121	-0.43	-0.33	Obesity-related traits;	chr19:37138189	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs4239587	ENSG00000226686.6	LINC01535	4.32	2.85e-05	0.0121	0.43	0.33	Obesity-related traits;	chr19:37136211	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs4805202	ENSG00000226686.6	LINC01535	4.32	2.85e-05	0.0121	0.43	0.33	Obesity-related traits;	chr19:37136499	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs4805203	ENSG00000226686.6	LINC01535	4.32	2.85e-05	0.0121	0.43	0.33	Obesity-related traits;	chr19:37136586	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs7252940	ENSG00000226686.6	LINC01535	4.32	2.85e-05	0.0121	0.43	0.33	Obesity-related traits;	chr19:37138589	chr19:37251912~37265535:+
PCPG	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	4.32	2.85e-05	0.0121	0.69	0.33	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
PCPG	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-4.32	2.85e-05	0.0121	-0.33	-0.33	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
PCPG	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-4.32	2.85e-05	0.0121	-0.48	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
PCPG	cis	rs728616	0.867	rs57257258	ENSG00000242600.5	MBL1P	4.32	2.85e-05	0.0121	0.64	0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80084264	chr10:79904898~79950336:+
PCPG	cis	rs728616	1	rs728615	ENSG00000242600.5	MBL1P	4.32	2.85e-05	0.0121	0.64	0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:79904898~79950336:+
PCPG	cis	rs34421088	0.56	rs2248325	ENSG00000269954.1	RP11-148O21.6	-4.32	2.85e-05	0.0121	-0.38	-0.33	Neuroticism;	chr8:11539365	chr8:11552488~11552991:-
PCPG	cis	rs34421088	0.56	rs2248316	ENSG00000269954.1	RP11-148O21.6	-4.32	2.85e-05	0.0121	-0.38	-0.33	Neuroticism;	chr8:11539564	chr8:11552488~11552991:-
PCPG	cis	rs34421088	0.56	rs2248315	ENSG00000269954.1	RP11-148O21.6	-4.32	2.85e-05	0.0121	-0.38	-0.33	Neuroticism;	chr8:11539577	chr8:11552488~11552991:-
PCPG	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	4.32	2.86e-05	0.0121	0.44	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
PCPG	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	4.32	2.86e-05	0.0121	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
PCPG	cis	rs28386778	0.863	rs3760254	ENSG00000240280.5	TCAM1P	-4.32	2.86e-05	0.0121	-0.44	-0.33	Prudent dietary pattern;	chr17:63774391	chr17:63849292~63864379:+
PCPG	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	4.32	2.86e-05	0.0121	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
PCPG	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	4.32	2.86e-05	0.0121	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
PCPG	cis	rs8030379	1	rs2401179	ENSG00000230373.7	GOLGA6L5P	-4.32	2.86e-05	0.0122	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910196	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2401180	ENSG00000230373.7	GOLGA6L5P	-4.32	2.86e-05	0.0122	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910434	chr15:84507885~84516814:-
PCPG	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	4.32	2.86e-05	0.0122	0.28	0.33	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
PCPG	cis	rs7017914	0.714	rs1481796	ENSG00000254031.4	RP11-326E22.1	-4.32	2.86e-05	0.0122	-0.32	-0.33	Bone mineral density;	chr8:71082115	chr8:71155457~71204223:+
PCPG	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-4.32	2.87e-05	0.0122	-0.44	-0.33	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
PCPG	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	-4.32	2.87e-05	0.0122	-0.38	-0.33	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	4.32	2.87e-05	0.0122	0.41	0.33	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
PCPG	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-4.32	2.87e-05	0.0122	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
PCPG	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-4.32	2.87e-05	0.0122	-0.4	-0.33	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
PCPG	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	4.32	2.87e-05	0.0122	0.36	0.33	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
PCPG	cis	rs896854	0.875	rs4735333	ENSG00000253528.2	RP11-347C18.4	4.32	2.87e-05	0.0122	0.36	0.33	Type 2 diabetes;	chr8:94942846	chr8:94974573~94974853:-
PCPG	cis	rs1048886	0.938	rs74520771	ENSG00000271967.1	RP11-134K13.4	-4.32	2.87e-05	0.0122	-0.42	-0.33	Type 2 diabetes;	chr6:70444760	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs74716033	ENSG00000271967.1	RP11-134K13.4	-4.32	2.87e-05	0.0122	-0.42	-0.33	Type 2 diabetes;	chr6:70445021	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs75175495	ENSG00000271967.1	RP11-134K13.4	-4.32	2.87e-05	0.0122	-0.42	-0.33	Type 2 diabetes;	chr6:70451869	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs74751032	ENSG00000271967.1	RP11-134K13.4	-4.32	2.87e-05	0.0122	-0.42	-0.33	Type 2 diabetes;	chr6:70458728	chr6:70596438~70596980:+
PCPG	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	4.32	2.88e-05	0.0122	0.42	0.33	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
PCPG	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-4.32	2.88e-05	0.0122	-0.48	-0.33	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
PCPG	cis	rs11858159	0.535	rs7497405	ENSG00000260760.1	PWRN3	4.32	2.88e-05	0.0122	0.35	0.33	Platelet thrombus formation;	chr15:24571284	chr15:24441127~24447967:+
PCPG	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	4.31	2.89e-05	0.0122	0.3	0.33	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
PCPG	cis	rs425277	1	rs385039	ENSG00000271806.1	RP5-892K4.1	-4.31	2.89e-05	0.0123	-0.39	-0.33	Height;	chr1:2145970	chr1:2141084~2145279:-
PCPG	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	4.31	2.89e-05	0.0123	0.45	0.33	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	4.31	2.89e-05	0.0123	0.45	0.33	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
PCPG	cis	rs12681963	0.688	rs2938229	ENSG00000248159.1	HSPA8P11	4.31	2.89e-05	0.0123	0.67	0.33	Migraine;	chr8:30237431	chr8:30237382~30240997:+
PCPG	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	4.31	2.89e-05	0.0123	0.32	0.33	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
PCPG	cis	rs9393777	0.844	rs72839477	ENSG00000219392.1	RP1-265C24.5	-4.31	2.89e-05	0.0123	-0.73	-0.33	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28115628~28116551:+
PCPG	cis	rs9393777	0.92	rs67859638	ENSG00000219392.1	RP1-265C24.5	-4.31	2.89e-05	0.0123	-0.73	-0.33	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28115628~28116551:+
PCPG	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	4.31	2.89e-05	0.0123	0.28	0.33	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	4.31	2.89e-05	0.0123	0.28	0.33	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
PCPG	cis	rs7017914	0.69	rs62508859	ENSG00000254031.4	RP11-326E22.1	4.31	2.89e-05	0.0123	0.31	0.33	Bone mineral density;	chr8:70828699	chr8:71155457~71204223:+
PCPG	cis	rs896854	0.684	rs2340534	ENSG00000253528.2	RP11-347C18.4	4.31	2.9e-05	0.0123	0.36	0.33	Type 2 diabetes;	chr8:94980102	chr8:94974573~94974853:-
PCPG	cis	rs6569038	0.631	rs2357030	ENSG00000253194.1	RP11-351A11.1	4.31	2.9e-05	0.0123	0.44	0.33	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065138	chr6:118934785~119031541:+
PCPG	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-4.31	2.9e-05	0.0123	-0.38	-0.33	Height;	chr5:36968438	chr5:36666214~36725195:-
PCPG	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	4.31	2.9e-05	0.0123	0.58	0.33	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	4.31	2.9e-05	0.0123	0.58	0.33	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
PCPG	cis	rs60695258	0.594	rs6531946	ENSG00000251411.1	RP11-397E7.4	-4.31	2.9e-05	0.0123	-0.31	-0.33	Hematocrit;	chr4:87044239	chr4:86913266~86914817:-
PCPG	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	4.31	2.9e-05	0.0123	0.52	0.33	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	4.31	2.9e-05	0.0123	0.52	0.33	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
PCPG	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	4.31	2.9e-05	0.0123	0.52	0.33	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
PCPG	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-4.31	2.91e-05	0.0123	-0.52	-0.33	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
PCPG	cis	rs1371867	0.846	rs1788194	ENSG00000212994.5	RPS26P6	4.31	2.91e-05	0.0123	0.38	0.33	Atrioventricular conduction;	chr8:100265688	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660323	ENSG00000212994.5	RPS26P6	4.31	2.91e-05	0.0123	0.38	0.33	Atrioventricular conduction;	chr8:100266496	chr8:100895771~100896118:+
PCPG	cis	rs9299346	0.594	rs10819965	ENSG00000225376.4	TMEM246-AS1	4.31	2.91e-05	0.0123	0.4	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101656443	chr9:101468439~101481502:+
PCPG	cis	rs5743030	0.702	rs256564	ENSG00000253559.1	OSGEPL1-AS1	-4.31	2.91e-05	0.0123	-0.5	-0.33	Subcutaneous adipose tissue;	chr2:189865323	chr2:189762704~189765556:+
PCPG	cis	rs17826219	0.706	rs609472	ENSG00000263603.1	CTD-2349P21.5	-4.31	2.91e-05	0.0123	-0.5	-0.33	Body mass index;	chr17:30624409	chr17:30729469~30731202:+
PCPG	cis	rs2732480	0.577	rs1489109	ENSG00000240399.1	RP1-228P16.1	4.31	2.92e-05	0.0124	0.36	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.577	rs1489108	ENSG00000240399.1	RP1-228P16.1	4.31	2.92e-05	0.0124	0.36	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48054813~48055591:-
PCPG	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	4.31	2.92e-05	0.0124	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
PCPG	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	4.31	2.92e-05	0.0124	0.33	0.33	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
PCPG	cis	rs9393777	0.92	rs13207689	ENSG00000219392.1	RP1-265C24.5	-4.31	2.92e-05	0.0124	-0.73	-0.33	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28115628~28116551:+
PCPG	cis	rs1371867	0.764	rs1020171	ENSG00000212994.5	RPS26P6	4.31	2.92e-05	0.0124	0.39	0.33	Atrioventricular conduction;	chr8:100276382	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660326	ENSG00000212994.5	RPS26P6	4.31	2.92e-05	0.0124	0.39	0.33	Atrioventricular conduction;	chr8:100278219	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660327	ENSG00000212994.5	RPS26P6	4.31	2.92e-05	0.0124	0.39	0.33	Atrioventricular conduction;	chr8:100279978	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs959022	ENSG00000212994.5	RPS26P6	4.31	2.92e-05	0.0124	0.39	0.33	Atrioventricular conduction;	chr8:100283764	chr8:100895771~100896118:+
PCPG	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	4.31	2.92e-05	0.0124	0.43	0.33	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
PCPG	cis	rs5743030	0.702	rs256562	ENSG00000253559.1	OSGEPL1-AS1	-4.31	2.93e-05	0.0124	-0.51	-0.33	Subcutaneous adipose tissue;	chr2:189869642	chr2:189762704~189765556:+
PCPG	cis	rs6929812	0.664	rs4711151	ENSG00000271755.1	RP1-153G14.4	4.31	2.93e-05	0.0124	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27412322	chr6:27404010~27406964:-
PCPG	cis	rs1150668	0.796	rs728122	ENSG00000219392.1	RP1-265C24.5	-4.31	2.93e-05	0.0124	-0.4	-0.33	Pubertal anthropometrics;	chr6:28431347	chr6:28115628~28116551:+
PCPG	cis	rs2732480	0.5	rs12828309	ENSG00000240399.1	RP1-228P16.1	4.31	2.93e-05	0.0124	0.36	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.5	rs1552550	ENSG00000240399.1	RP1-228P16.1	4.31	2.93e-05	0.0124	0.36	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48054813~48055591:-
PCPG	cis	rs13438712	0.512	rs10279381	ENSG00000280439.1	RP4-568B10.1	4.31	2.94e-05	0.0124	0.37	0.33	Obesity-related traits;	chr7:105911202	chr7:106035798~106036431:+
PCPG	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	4.31	2.94e-05	0.0124	0.42	0.33	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
PCPG	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	4.31	2.94e-05	0.0124	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
PCPG	cis	rs8030379	1	rs10906982	ENSG00000230373.7	GOLGA6L5P	-4.31	2.94e-05	0.0124	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84507885~84516814:-
PCPG	cis	rs2235642	0.826	rs8053605	ENSG00000260989.1	LA16c-395F10.2	-4.31	2.94e-05	0.0124	-0.34	-0.33	Coronary artery disease;	chr16:1544157	chr16:1580527~1610328:+
PCPG	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-4.31	2.94e-05	0.0124	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
PCPG	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.31	2.94e-05	0.0124	0.42	0.33	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
PCPG	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	4.31	2.94e-05	0.0124	0.4	0.33	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
PCPG	cis	rs1048886	0.872	rs7450771	ENSG00000271967.1	RP11-134K13.4	-4.31	2.94e-05	0.0124	-0.42	-0.33	Type 2 diabetes;	chr6:70565926	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs77665410	ENSG00000271967.1	RP11-134K13.4	-4.31	2.94e-05	0.0124	-0.42	-0.33	Type 2 diabetes;	chr6:70569676	chr6:70596438~70596980:+
PCPG	cis	rs11148252	0.532	rs9536185	ENSG00000273784.3	RP11-78J21.7	-4.31	2.94e-05	0.0125	-0.32	-0.33	Lewy body disease;	chr13:52605666	chr13:52600042~52642542:+
PCPG	cis	rs11148252	0.532	rs9536190	ENSG00000273784.3	RP11-78J21.7	-4.31	2.94e-05	0.0125	-0.32	-0.33	Lewy body disease;	chr13:52606909	chr13:52600042~52642542:+
PCPG	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-4.31	2.95e-05	0.0125	-0.34	-0.33	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-4.31	2.95e-05	0.0125	-0.34	-0.33	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-4.31	2.95e-05	0.0125	-0.34	-0.33	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
PCPG	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-4.31	2.95e-05	0.0125	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-4.31	2.95e-05	0.0125	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-4.31	2.95e-05	0.0125	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-4.31	2.95e-05	0.0125	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
PCPG	cis	rs7819412	0.659	rs4073948	ENSG00000255020.1	AF131216.5	-4.31	2.95e-05	0.0125	-0.46	-0.33	Triglycerides;	chr8:10915134	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.736	rs35392635	ENSG00000184608.7	FAM167A-AS1	4.31	2.95e-05	0.0125	0.47	0.33	Retinal vascular caliber;	chr8:11306840	chr8:11368402~11438658:+
PCPG	cis	rs7824557	0.767	rs11775635	ENSG00000184608.7	FAM167A-AS1	4.31	2.95e-05	0.0125	0.47	0.33	Retinal vascular caliber;	chr8:11307356	chr8:11368402~11438658:+
PCPG	cis	rs4919687	0.55	rs11191371	ENSG00000269609.4	RPARP-AS1	-4.31	2.95e-05	0.0125	-0.28	-0.33	Colorectal cancer;	chr10:102700140	chr10:102449817~102461106:+
PCPG	cis	rs9393777	0.668	rs3800318	ENSG00000216901.1	AL022393.7	4.31	2.95e-05	0.0125	0.54	0.33	Intelligence (multi-trait analysis);	chr6:27295862	chr6:28176188~28176674:+
PCPG	cis	rs9393777	0.623	rs13211166	ENSG00000216901.1	AL022393.7	4.31	2.95e-05	0.0125	0.54	0.33	Intelligence (multi-trait analysis);	chr6:27298161	chr6:28176188~28176674:+
PCPG	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	4.31	2.95e-05	0.0125	0.46	0.33	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	4.31	2.95e-05	0.0125	0.46	0.33	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
PCPG	cis	rs2665103	0.715	rs11639440	ENSG00000228141.5	AC105339.1	-4.31	2.95e-05	0.0125	-0.41	-0.33	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82710471~82714026:-
PCPG	cis	rs8031341	0.586	rs59284434	ENSG00000278514.1	AC068831.16	4.31	2.96e-05	0.0125	0.53	0.33	Delta-5 desaturase activity;	chr15:90827473	chr15:91022766~91023200:+
PCPG	cis	rs8031341	0.586	rs61321686	ENSG00000278514.1	AC068831.16	4.31	2.96e-05	0.0125	0.53	0.33	Delta-5 desaturase activity;	chr15:90827477	chr15:91022766~91023200:+
PCPG	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	4.31	2.96e-05	0.0125	0.33	0.33	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
PCPG	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	4.31	2.96e-05	0.0125	0.41	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
PCPG	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	4.31	2.96e-05	0.0125	0.48	0.33	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
PCPG	cis	rs394563	0.967	rs447025	ENSG00000216906.2	RP11-350J20.9	4.31	2.96e-05	0.0125	0.32	0.33	Dupuytren's disease;	chr6:149477992	chr6:149904243~149906418:+
PCPG	cis	rs2665103	0.715	rs7403041	ENSG00000228141.5	AC105339.1	4.31	2.97e-05	0.0125	0.4	0.33	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82710471~82714026:-
PCPG	cis	rs4842666	0.915	rs73437358	ENSG00000258302.2	RP11-981P6.1	4.31	2.97e-05	0.0125	0.49	0.33	Blood pressure;	chr12:89678299	chr12:89561129~89594878:+
PCPG	cis	rs11148252	0.553	rs9536219	ENSG00000273784.3	RP11-78J21.7	-4.31	2.97e-05	0.0125	-0.32	-0.33	Lewy body disease;	chr13:52653166	chr13:52600042~52642542:+
PCPG	cis	rs1023500	0.573	rs133380	ENSG00000226450.2	CYP2D8P	4.31	2.97e-05	0.0125	0.33	0.33	Schizophrenia;	chr22:42072906	chr22:42149886~42155001:-
PCPG	cis	rs911119	1	rs6515375	ENSG00000270001.1	RP11-218C14.8	-4.31	2.97e-05	0.0125	-0.54	-0.33	Chronic kidney disease;	chr20:23630204	chr20:23631826~23632316:-
PCPG	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-4.31	2.97e-05	0.0125	-0.31	-0.33	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
PCPG	cis	rs2098713	0.599	rs12652658	ENSG00000250155.1	CTD-2353F22.1	4.31	2.97e-05	0.0125	0.41	0.33	Telomere length;	chr5:37555461	chr5:36666214~36725195:-
PCPG	cis	rs4763879	0.634	rs917913	ENSG00000278635.1	CTD-2318O12.1	4.31	2.97e-05	0.0125	0.4	0.33	Type 1 diabetes;	chr12:9707040	chr12:9415641~9416718:+
PCPG	cis	rs4763879	0.634	rs2098298	ENSG00000278635.1	CTD-2318O12.1	4.31	2.97e-05	0.0125	0.4	0.33	Type 1 diabetes;	chr12:9707473	chr12:9415641~9416718:+
PCPG	cis	rs4763879	0.594	rs12427310	ENSG00000278635.1	CTD-2318O12.1	4.31	2.97e-05	0.0125	0.4	0.33	Type 1 diabetes;	chr12:9707539	chr12:9415641~9416718:+
PCPG	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-4.31	2.97e-05	0.0126	-0.42	-0.33	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
PCPG	cis	rs3809060	0.959	rs4140413	ENSG00000213713.3	PIGCP1	4.31	2.97e-05	0.0126	0.18	0.33	Inguinal hernia;	chr11:32437682	chr11:33075566~33076460:-
PCPG	cis	rs748404	1	rs748404	ENSG00000249839.1	AC011330.5	-4.31	2.97e-05	0.0126	-0.42	-0.33	Lung cancer;	chr15:43267033	chr15:43663654~43684339:-
PCPG	cis	rs6921919	0.945	rs61289879	ENSG00000219392.1	RP1-265C24.5	-4.31	2.97e-05	0.0126	-0.54	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28115628~28116551:+
PCPG	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-4.31	2.98e-05	0.0126	-0.46	-0.33	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
PCPG	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-4.31	2.98e-05	0.0126	-0.49	-0.33	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-4.31	2.98e-05	0.0126	-0.49	-0.33	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
PCPG	cis	rs28386778	0.897	rs2584617	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63847938	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584615	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63850414	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.865	rs2727276	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63852349	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs2727355	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63854430	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.799	rs2584612	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63854844	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2584610	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63857423	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2156903	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63859819	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2236737	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63860740	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2236736	ENSG00000240280.5	TCAM1P	-4.31	2.98e-05	0.0126	-0.44	-0.33	Prudent dietary pattern;	chr17:63860888	chr17:63849292~63864379:+
PCPG	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	4.31	2.98e-05	0.0126	0.36	0.33	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	4.31	2.98e-05	0.0126	0.36	0.33	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
PCPG	cis	rs853679	0.607	rs67662114	ENSG00000219392.1	RP1-265C24.5	-4.31	2.98e-05	0.0126	-0.73	-0.33	Depression;	chr6:27964523	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13216117	ENSG00000219392.1	RP1-265C24.5	-4.31	2.98e-05	0.0126	-0.73	-0.33	Depression;	chr6:27970706	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs36101351	ENSG00000219392.1	RP1-265C24.5	-4.31	2.98e-05	0.0126	-0.73	-0.33	Depression;	chr6:27975591	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs28360499	ENSG00000219392.1	RP1-265C24.5	-4.31	2.98e-05	0.0126	-0.73	-0.33	Depression;	chr6:27977618	chr6:28115628~28116551:+
PCPG	cis	rs2243480	1	rs437889	ENSG00000230189.5	GS1-124K5.2	4.31	2.98e-05	0.0126	0.51	0.33	Diabetic kidney disease;	chr7:66044247	chr7:66409143~66490059:-
PCPG	cis	rs2408955	0.522	rs11168408	ENSG00000240399.1	RP1-228P16.1	-4.31	2.98e-05	0.0126	-0.35	-0.33	Glycated hemoglobin levels;	chr12:48104544	chr12:48054813~48055591:-
PCPG	cis	rs4143844	0.737	rs11634818	ENSG00000259251.2	RP11-643M14.1	4.31	2.98e-05	0.0126	0.7	0.33	Bipolar disorder and schizophrenia;	chr15:62064187	chr15:62060503~62062434:+
PCPG	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-4.31	2.98e-05	0.0126	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
PCPG	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	4.31	2.98e-05	0.0126	0.43	0.33	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
PCPG	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-4.31	2.98e-05	0.0126	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
PCPG	cis	rs7746199	0.736	rs35037868	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.556	rs45509595	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:27873148	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs66868086	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:27898124	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs71537572	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28002937	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.556	rs13200214	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28049472	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs71559070	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28071151	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs35902873	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28091171	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13197574	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28092461	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34166054	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28098023	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34662244	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28106103	chr6:28115628~28116551:+
PCPG	cis	rs35952432	1	rs35952432	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Lung cancer;	chr6:28107123	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13203816	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28111820	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.556	rs34588114	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28112850	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs68188794	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28112999	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs34371502	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28113980	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs66886492	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28121953	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs35345226	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28123802	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs35749575	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28147040	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs72846780	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28151277	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13205911	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28156336	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13197176	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28161454	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13201308	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28162311	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34765154	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28162672	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34505829	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28165461	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs35098436	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28166443	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs72846794	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28169721	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs13217984	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28171932	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.556	rs67297533	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28173475	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.505	rs35781323	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28177054	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs13195291	ENSG00000219392.1	RP1-265C24.5	-4.31	2.99e-05	0.0126	-0.73	-0.33	Depression;	chr6:28201463	chr6:28115628~28116551:+
PCPG	cis	rs2836974	0.544	rs8128919	ENSG00000255568.3	BRWD1-AS2	4.31	2.99e-05	0.0126	0.33	0.33	Cognitive function;	chr21:39339936	chr21:39313935~39314962:+
PCPG	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	4.31	2.99e-05	0.0126	0.39	0.33	Height;	chr5:37041491	chr5:36666214~36725195:-
PCPG	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-4.31	2.99e-05	0.0126	-0.39	-0.33	Height;	chr5:37053874	chr5:36666214~36725195:-
PCPG	cis	rs9303542	0.559	rs12951076	ENSG00000279036.1	RP11-81K2.2	-4.31	2.99e-05	0.0126	-0.55	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48547747	chr17:49494223~49497800:-
PCPG	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	4.31	2.99e-05	0.0126	0.4	0.33	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
PCPG	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	4.31	2.99e-05	0.0126	0.43	0.33	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
PCPG	cis	rs748404	0.666	rs514438	ENSG00000205771.5	CATSPER2P1	-4.31	2.99e-05	0.0126	-0.43	-0.33	Lung cancer;	chr15:43328245	chr15:43726918~43747094:-
PCPG	cis	rs6121246	0.909	rs1994251	ENSG00000230613.1	HM13-AS1	4.31	2.99e-05	0.0126	0.48	0.33	Mean corpuscular hemoglobin;	chr20:31699525	chr20:31567707~31573263:-
PCPG	cis	rs1150668	0.745	rs213238	ENSG00000219392.1	RP1-265C24.5	-4.31	3e-05	0.0126	-0.37	-0.33	Pubertal anthropometrics;	chr6:28354216	chr6:28115628~28116551:+
PCPG	cis	rs4919687	0.55	rs10748828	ENSG00000269609.4	RPARP-AS1	4.31	3e-05	0.0126	0.28	0.33	Colorectal cancer;	chr10:102697037	chr10:102449817~102461106:+
PCPG	cis	rs6957923	1	rs6957923	ENSG00000230658.1	KLHL7-AS1	4.31	3e-05	0.0126	0.4	0.33	Height;	chr7:23443066	chr7:23101228~23105703:-
PCPG	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	4.31	3e-05	0.0126	0.54	0.33	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
PCPG	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	4.31	3e-05	0.0126	0.54	0.33	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
PCPG	cis	rs1440410	0.798	rs4690779	ENSG00000250326.1	RP11-284M14.1	4.3	3e-05	0.0126	0.31	0.33	Ischemic stroke;	chr4:143198780	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4234886	ENSG00000250326.1	RP11-284M14.1	4.3	3e-05	0.0126	0.31	0.33	Ischemic stroke;	chr4:143203339	chr4:142933195~143184861:-
PCPG	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-4.3	3e-05	0.0127	-0.36	-0.33	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
PCPG	cis	rs2243480	1	rs781142	ENSG00000230189.5	GS1-124K5.2	4.3	3e-05	0.0127	0.51	0.33	Diabetic kidney disease;	chr7:65973791	chr7:66409143~66490059:-
PCPG	cis	rs2281558	0.793	rs6115227	ENSG00000125804.12	FAM182A	-4.3	3.01e-05	0.0127	-0.46	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610741	chr20:26054655~26086917:+
PCPG	cis	rs950169	0.84	rs72748702	ENSG00000235370.6	DNM1P51	4.3	3.01e-05	0.0127	0.35	0.33	Schizophrenia;	chr15:84246494	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs4338765	ENSG00000235370.6	DNM1P51	4.3	3.01e-05	0.0127	0.35	0.33	Schizophrenia;	chr15:84248084	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs62028133	ENSG00000235370.6	DNM1P51	4.3	3.01e-05	0.0127	0.35	0.33	Schizophrenia;	chr15:84250623	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.723	rs17589320	ENSG00000235370.6	DNM1P51	4.3	3.01e-05	0.0127	0.35	0.33	Schizophrenia;	chr15:84251244	chr15:84398316~84411701:-
PCPG	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-4.3	3.01e-05	0.0127	-0.45	-0.33	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
PCPG	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-4.3	3.01e-05	0.0127	-0.38	-0.33	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
PCPG	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	4.3	3.01e-05	0.0127	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
PCPG	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-4.3	3.01e-05	0.0127	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
PCPG	cis	rs9650657	0.644	rs4395858	ENSG00000255020.1	AF131216.5	4.3	3.01e-05	0.0127	0.43	0.33	Neuroticism;	chr8:10663511	chr8:11345748~11347502:-
PCPG	cis	rs4819052	0.679	rs28623526	ENSG00000215447.6	BX322557.10	-4.3	3.01e-05	0.0127	-0.31	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45288052~45291738:+
PCPG	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-4.3	3.01e-05	0.0127	-0.44	-0.33	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
PCPG	cis	rs13118159	0.556	rs4974615	ENSG00000254094.1	AC078852.1	4.3	3.02e-05	0.0127	0.4	0.33	Longevity;	chr4:1379763	chr4:1356581~1358075:+
PCPG	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-4.3	3.02e-05	0.0127	-0.39	-0.33	Height;	chr5:36880769	chr5:36666214~36725195:-
PCPG	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-4.3	3.02e-05	0.0127	-0.39	-0.33	Height;	chr5:36882917	chr5:36666214~36725195:-
PCPG	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-4.3	3.02e-05	0.0127	-0.48	-0.33	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
PCPG	cis	rs28386778	0.742	rs3020617	ENSG00000240280.5	TCAM1P	-4.3	3.02e-05	0.0127	-0.45	-0.33	Prudent dietary pattern;	chr17:63869943	chr17:63849292~63864379:+
PCPG	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-4.3	3.02e-05	0.0127	-0.33	-0.33	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
PCPG	cis	rs6456042	0.929	rs3127421	ENSG00000231297.3	RP11-459F1.2	4.3	3.02e-05	0.0127	0.37	0.33	Asthma;	chr6:166125571	chr6:166099665~166113273:+
PCPG	cis	rs6456042	0.893	rs3127422	ENSG00000231297.3	RP11-459F1.2	4.3	3.02e-05	0.0127	0.37	0.33	Asthma;	chr6:166125582	chr6:166099665~166113273:+
PCPG	cis	rs6456042	0.824	rs3127423	ENSG00000231297.3	RP11-459F1.2	4.3	3.02e-05	0.0127	0.37	0.33	Asthma;	chr6:166125600	chr6:166099665~166113273:+
PCPG	cis	rs6456042	0.893	rs3127424	ENSG00000231297.3	RP11-459F1.2	4.3	3.02e-05	0.0127	0.37	0.33	Asthma;	chr6:166125602	chr6:166099665~166113273:+
PCPG	cis	rs2531992	0.8	rs2601782	ENSG00000262185.1	RP11-462G12.1	-4.3	3.02e-05	0.0127	-0.54	-0.33	Waist circumference;	chr16:3971050	chr16:3947609~3950444:-
PCPG	cis	rs4143844	0.867	rs11637599	ENSG00000259251.2	RP11-643M14.1	4.3	3.03e-05	0.0127	0.66	0.33	Bipolar disorder and schizophrenia;	chr15:62058866	chr15:62060503~62062434:+
PCPG	cis	rs11148252	0.538	rs2408611	ENSG00000235660.1	LINC00345	-4.3	3.03e-05	0.0127	-0.4	-0.33	Lewy body disease;	chr13:52135606	chr13:52484161~52484680:-
PCPG	cis	rs13126694	0.778	rs6814979	ENSG00000248429.4	RP11-597D13.9	-4.3	3.03e-05	0.0127	-0.34	-0.33	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158170752~158202877:+
PCPG	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-4.3	3.03e-05	0.0127	-0.41	-0.33	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
PCPG	cis	rs11673344	0.504	rs4806407	ENSG00000226686.6	LINC01535	-4.3	3.03e-05	0.0128	-0.42	-0.33	Obesity-related traits;	chr19:37097849	chr19:37251912~37265535:+
PCPG	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-4.3	3.04e-05	0.0128	-0.27	-0.33	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
PCPG	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-4.3	3.04e-05	0.0128	-0.43	-0.33	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-4.3	3.04e-05	0.0128	-0.43	-0.33	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-4.3	3.04e-05	0.0128	-0.43	-0.33	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
PCPG	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-4.3	3.04e-05	0.0128	-0.39	-0.33	Height;	chr5:36865567	chr5:36666214~36725195:-
PCPG	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-4.3	3.04e-05	0.0128	-0.39	-0.33	Height;	chr5:36878678	chr5:36666214~36725195:-
PCPG	cis	rs75686122	0.892	rs78033999	ENSG00000271830.1	RP11-1C8.7	4.3	3.04e-05	0.0128	0.57	0.33	Cocaine dependence;	chr8:103465575	chr8:103481266~103481619:-
PCPG	cis	rs11858159	0.738	rs7402143	ENSG00000260760.1	PWRN3	4.3	3.04e-05	0.0128	0.34	0.33	Platelet thrombus formation;	chr15:24508163	chr15:24441127~24447967:+
PCPG	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	4.3	3.04e-05	0.0128	0.32	0.33	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
PCPG	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	4.3	3.04e-05	0.0128	0.32	0.33	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
PCPG	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	4.3	3.05e-05	0.0128	0.42	0.33	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
PCPG	cis	rs453301	0.631	rs28572014	ENSG00000173295.6	FAM86B3P	4.3	3.05e-05	0.0128	0.38	0.33	Joint mobility (Beighton score);	chr8:8936097	chr8:8228595~8244865:+
PCPG	cis	rs5758511	0.689	rs55906806	ENSG00000205702.9	CYP2D7	4.3	3.05e-05	0.0128	0.49	0.33	Birth weight;	chr22:42248465	chr22:42140203~42144577:-
PCPG	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	4.3	3.05e-05	0.0128	0.33	0.33	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
PCPG	cis	rs748404	0.666	rs16957680	ENSG00000205771.5	CATSPER2P1	-4.3	3.05e-05	0.0128	-0.43	-0.33	Lung cancer;	chr15:43396207	chr15:43726918~43747094:-
PCPG	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	4.3	3.05e-05	0.0128	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
PCPG	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-4.3	3.05e-05	0.0128	-0.27	-0.33	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
PCPG	cis	rs7017914	0.653	rs6983845	ENSG00000254031.4	RP11-326E22.1	4.3	3.05e-05	0.0128	0.31	0.33	Bone mineral density;	chr8:70834245	chr8:71155457~71204223:+
PCPG	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	4.3	3.06e-05	0.0128	0.44	0.33	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
PCPG	cis	rs804280	0.509	rs12719915	ENSG00000255495.1	AC145124.2	-4.3	3.06e-05	0.0128	-0.33	-0.33	Myopia (pathological);	chr8:11928746	chr8:12194467~12196280:+
PCPG	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-4.3	3.06e-05	0.0129	-0.49	-0.33	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-4.3	3.06e-05	0.0129	-0.49	-0.33	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
PCPG	cis	rs1371867	0.846	rs1660324	ENSG00000212994.5	RPS26P6	4.3	3.06e-05	0.0129	0.39	0.33	Atrioventricular conduction;	chr8:100269043	chr8:100895771~100896118:+
PCPG	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28230678	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28231053	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28231986	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28232159	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28237724	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28240414	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28240780	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28241324	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28241753	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28242515	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-4.3	3.06e-05	0.0129	-0.49	-0.33	Depression;	chr6:28242910	chr6:28115628~28116551:+
PCPG	cis	rs2830585	0.602	rs233895	ENSG00000223563.1	AP001601.2	4.3	3.07e-05	0.0129	0.47	0.33	Blood protein levels;	chr21:26952992	chr21:26889376~26939742:+
PCPG	cis	rs1440410	0.798	rs11100783	ENSG00000250326.1	RP11-284M14.1	4.3	3.07e-05	0.0129	0.31	0.33	Ischemic stroke;	chr4:143241047	chr4:142933195~143184861:-
PCPG	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	4.3	3.07e-05	0.0129	0.35	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
PCPG	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	4.3	3.07e-05	0.0129	0.35	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
PCPG	cis	rs7208859	0.673	rs450585	ENSG00000266490.1	CTD-2349P21.9	4.3	3.08e-05	0.0129	0.39	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30792372~30792833:+
PCPG	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	4.3	3.08e-05	0.0129	0.35	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
PCPG	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-4.3	3.08e-05	0.0129	-0.49	-0.33	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
PCPG	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-4.3	3.08e-05	0.0129	-0.32	-0.33	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
PCPG	cis	rs300890	0.76	rs1532981	ENSG00000250326.1	RP11-284M14.1	4.3	3.08e-05	0.0129	0.31	0.33	Nasopharyngeal carcinoma;	chr4:143294193	chr4:142933195~143184861:-
PCPG	cis	rs6579956	0.565	rs62400576	ENSG00000254226.4	CTB-12O2.1	-4.3	3.08e-05	0.0129	-0.44	-0.33	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152806398	chr5:151949571~152270448:+
PCPG	cis	rs657075	0.697	rs2304081	ENSG00000233006.5	AC034220.3	4.3	3.08e-05	0.0129	0.48	0.33	Rheumatoid arthritis;	chr5:132331855	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.757	rs3805665	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132309025	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3792879	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132309142	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3792882	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132309418	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs34695718	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132309839	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3805667	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132310823	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3805668	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132310895	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3805669	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132311069	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.64	rs2073838	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132313529	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs2073839	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132314552	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.697	rs3805673	ENSG00000233006.5	AC034220.3	-4.3	3.08e-05	0.0129	-0.48	-0.33	Rheumatoid arthritis;	chr5:132323410	chr5:132311285~132369916:-
PCPG	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-4.3	3.08e-05	0.0129	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-4.3	3.08e-05	0.0129	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-4.3	3.08e-05	0.0129	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
PCPG	cis	rs2279440	0.759	rs7642020	ENSG00000254485.4	RP11-380O24.1	-4.3	3.08e-05	0.0129	-0.48	-0.33	Glucose homeostasis traits;	chr3:9480796	chr3:9292588~9363303:-
PCPG	cis	rs394563	0.934	rs384334	ENSG00000216906.2	RP11-350J20.9	4.3	3.09e-05	0.0129	0.32	0.33	Dupuytren's disease;	chr6:149475036	chr6:149904243~149906418:+
PCPG	cis	rs853679	0.824	rs34712084	ENSG00000216901.1	AL022393.7	4.3	3.09e-05	0.013	0.64	0.33	Depression;	chr6:28076050	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.824	rs1321505	ENSG00000216901.1	AL022393.7	4.3	3.09e-05	0.013	0.64	0.33	Depression;	chr6:28085045	chr6:28176188~28176674:+
PCPG	cis	rs7824557	0.767	rs2060463	ENSG00000184608.7	FAM167A-AS1	4.3	3.09e-05	0.013	0.47	0.33	Retinal vascular caliber;	chr8:11304101	chr8:11368402~11438658:+
PCPG	cis	rs7824557	0.767	rs2164272	ENSG00000184608.7	FAM167A-AS1	4.3	3.09e-05	0.013	0.47	0.33	Retinal vascular caliber;	chr8:11304987	chr8:11368402~11438658:+
PCPG	cis	rs7824557	0.701	rs2060465	ENSG00000184608.7	FAM167A-AS1	4.3	3.09e-05	0.013	0.47	0.33	Retinal vascular caliber;	chr8:11305100	chr8:11368402~11438658:+
PCPG	cis	rs7824557	0.767	rs3808509	ENSG00000184608.7	FAM167A-AS1	4.3	3.09e-05	0.013	0.47	0.33	Retinal vascular caliber;	chr8:11305747	chr8:11368402~11438658:+
PCPG	cis	rs11148252	0.875	rs4885953	ENSG00000235660.1	LINC00345	-4.3	3.09e-05	0.013	-0.41	-0.33	Lewy body disease;	chr13:52402356	chr13:52484161~52484680:-
PCPG	cis	rs4713118	0.696	rs2394002	ENSG00000216901.1	AL022393.7	4.3	3.09e-05	0.013	0.44	0.33	Parkinson's disease;	chr6:27780236	chr6:28176188~28176674:+
PCPG	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	4.3	3.09e-05	0.013	0.43	0.33	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
PCPG	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	4.3	3.09e-05	0.013	0.36	0.33	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	4.3	3.09e-05	0.013	0.36	0.33	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
PCPG	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	4.3	3.09e-05	0.013	0.36	0.33	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
PCPG	cis	rs11858159	0.656	rs12913957	ENSG00000260760.1	PWRN3	4.3	3.09e-05	0.013	0.33	0.33	Platelet thrombus formation;	chr15:24566369	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.903	rs12913246	ENSG00000260760.1	PWRN3	4.3	3.09e-05	0.013	0.33	0.33	Platelet thrombus formation;	chr15:24570686	chr15:24441127~24447967:+
PCPG	cis	rs10865541	1	rs11692425	ENSG00000225234.1	TRAPPC12-AS1	-4.3	3.09e-05	0.013	-0.32	-0.33	Obesity-related traits;	chr2:3391612	chr2:3481242~3482409:-
PCPG	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	4.3	3.09e-05	0.013	0.41	0.33	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
PCPG	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	4.3	3.1e-05	0.013	0.33	0.33	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
PCPG	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	4.3	3.1e-05	0.013	0.33	0.33	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
PCPG	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	4.3	3.1e-05	0.013	0.33	0.33	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	4.3	3.1e-05	0.013	0.33	0.33	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
PCPG	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	4.3	3.1e-05	0.013	0.33	0.33	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
PCPG	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	4.3	3.1e-05	0.013	0.33	0.33	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
PCPG	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	4.3	3.1e-05	0.013	0.43	0.33	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
PCPG	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-4.3	3.1e-05	0.013	-0.44	-0.33	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-4.3	3.1e-05	0.013	-0.44	-0.33	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-4.3	3.1e-05	0.013	-0.44	-0.33	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
PCPG	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-4.3	3.1e-05	0.013	-0.42	-0.33	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
PCPG	cis	rs950169	0.845	rs4502182	ENSG00000235370.6	DNM1P51	4.3	3.1e-05	0.013	0.35	0.33	Schizophrenia;	chr15:84254768	chr15:84398316~84411701:-
PCPG	cis	rs13108904	0.557	rs1250098	ENSG00000254094.1	AC078852.1	4.3	3.1e-05	0.013	0.41	0.33	Obesity-related traits;	chr4:1244468	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.557	rs1250097	ENSG00000254094.1	AC078852.1	4.3	3.1e-05	0.013	0.41	0.33	Obesity-related traits;	chr4:1244550	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.557	rs1680041	ENSG00000254094.1	AC078852.1	4.3	3.1e-05	0.013	0.41	0.33	Obesity-related traits;	chr4:1244733	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.557	rs1250095	ENSG00000254094.1	AC078852.1	4.3	3.1e-05	0.013	0.41	0.33	Obesity-related traits;	chr4:1245524	chr4:1356581~1358075:+
PCPG	cis	rs4432245	0.793	rs2898985	ENSG00000259584.1	RP11-521C20.2	-4.3	3.11e-05	0.013	-0.62	-0.33	Body mass index;	chr15:40035100	chr15:40075204~40078704:-
PCPG	cis	rs11836164	0.58	rs7300380	ENSG00000278095.1	RP11-283G6.6	-4.3	3.11e-05	0.013	-0.5	-0.33	Mammographic density (dense area);	chr12:26322620	chr12:26273329~26273900:-
PCPG	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-4.3	3.11e-05	0.013	-0.41	-0.33	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
PCPG	cis	rs4841097	0.806	rs6992247	ENSG00000253893.2	FAM85B	-4.3	3.11e-05	0.013	-0.41	-0.33	Platelet distribution width;	chr8:9090959	chr8:8167819~8226614:-
PCPG	cis	rs950169	0.881	rs4842852	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84387263	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.84	rs4842853	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84387606	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs4842946	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84387633	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.84	rs4842854	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84387641	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.84	rs2896002	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84390423	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.887	rs3860265	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84390487	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.724	rs11632668	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84393989	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.881	rs34591918	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84396135	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.887	rs12903946	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84399732	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.887	rs62029593	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84400482	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.81	rs62029594	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84400554	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.84	rs62029595	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84400603	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.881	rs62029596	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84400736	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.881	rs4081123	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84401537	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.881	rs62029599	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84401867	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.8	rs4099846	ENSG00000235370.6	DNM1P51	4.3	3.11e-05	0.013	0.36	0.33	Schizophrenia;	chr15:84402196	chr15:84398316~84411701:-
PCPG	cis	rs1048886	1	rs12526787	ENSG00000271967.1	RP11-134K13.4	-4.3	3.11e-05	0.013	-0.42	-0.33	Type 2 diabetes;	chr6:70478110	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.938	rs75668908	ENSG00000271967.1	RP11-134K13.4	-4.3	3.11e-05	0.013	-0.42	-0.33	Type 2 diabetes;	chr6:70483846	chr6:70596438~70596980:+
PCPG	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-4.3	3.11e-05	0.013	-0.45	-0.33	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-4.3	3.11e-05	0.013	-0.45	-0.33	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-4.3	3.11e-05	0.013	-0.45	-0.33	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
PCPG	cis	rs2732480	0.5	rs2932093	ENSG00000240399.1	RP1-228P16.1	4.3	3.11e-05	0.013	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48054813~48055591:-
PCPG	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-4.3	3.11e-05	0.013	-0.33	-0.33	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
PCPG	cis	rs561341	1	rs7216102	ENSG00000265798.5	RP11-271K11.5	4.3	3.12e-05	0.013	0.54	0.33	Hip circumference adjusted for BMI;	chr17:31932431	chr17:31038575~31059121:-
PCPG	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-4.3	3.12e-05	0.013	-0.36	-0.33	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
PCPG	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-4.3	3.12e-05	0.013	-0.34	-0.33	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
PCPG	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-4.3	3.12e-05	0.013	-0.34	-0.33	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
PCPG	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	4.3	3.12e-05	0.013	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	4.3	3.12e-05	0.013	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	4.3	3.12e-05	0.013	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	4.3	3.12e-05	0.013	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
PCPG	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	4.3	3.12e-05	0.013	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	4.3	3.12e-05	0.013	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
PCPG	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	4.3	3.12e-05	0.013	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
PCPG	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-4.3	3.12e-05	0.013	-0.43	-0.33	Temperament;	chr17:14007198	chr17:14024514~14025488:+
PCPG	cis	rs1440410	0.835	rs6827229	ENSG00000250326.1	RP11-284M14.1	4.3	3.12e-05	0.013	0.31	0.33	Ischemic stroke;	chr4:143219223	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs34168479	ENSG00000250326.1	RP11-284M14.1	4.3	3.12e-05	0.013	0.31	0.33	Ischemic stroke;	chr4:143219439	chr4:142933195~143184861:-
PCPG	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-4.3	3.12e-05	0.013	-0.42	-0.33	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
PCPG	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	4.3	3.12e-05	0.013	0.44	0.33	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	4.3	3.12e-05	0.013	0.44	0.33	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	4.3	3.12e-05	0.013	0.44	0.33	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	4.3	3.12e-05	0.013	0.44	0.33	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	4.3	3.12e-05	0.013	0.44	0.33	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
PCPG	cis	rs6519955	0.86	rs8136098	ENSG00000231711.2	LINC00899	4.3	3.12e-05	0.013	0.31	0.33	Dupuytren's disease;	chr22:46029766	chr22:46039907~46044853:-
PCPG	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	4.3	3.12e-05	0.0131	0.41	0.33	Height;	chr6:109382188	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	4.3	3.12e-05	0.0131	0.41	0.33	Height;	chr6:109383239	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	4.3	3.12e-05	0.0131	0.41	0.33	Height;	chr6:109383248	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	4.3	3.12e-05	0.0131	0.41	0.33	Height;	chr6:109383848	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	4.3	3.12e-05	0.0131	0.41	0.33	Height;	chr6:109384807	chr6:109382795~109383666:+
PCPG	cis	rs2236231	0.55	rs2038490	ENSG00000259502.1	RP11-643G16.3	-4.3	3.12e-05	0.0131	-0.44	-0.33	Plasma kynurenine levels in major depressive disorder;	chr14:67593658	chr14:67610986~67613864:+
PCPG	cis	rs2236231	0.55	rs61990080	ENSG00000259502.1	RP11-643G16.3	-4.3	3.12e-05	0.0131	-0.44	-0.33	Plasma kynurenine levels in major depressive disorder;	chr14:67595207	chr14:67610986~67613864:+
PCPG	cis	rs2236231	0.55	rs61990081	ENSG00000259502.1	RP11-643G16.3	-4.3	3.12e-05	0.0131	-0.44	-0.33	Plasma kynurenine levels in major depressive disorder;	chr14:67595222	chr14:67610986~67613864:+
PCPG	cis	rs6657613	0.68	rs10887994	ENSG00000186715.9	MST1L	4.29	3.13e-05	0.0131	0.33	0.33	Hip circumference adjusted for BMI;	chr1:17045260	chr1:16754910~16770237:-
PCPG	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-4.29	3.13e-05	0.0131	-0.43	-0.33	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-4.29	3.13e-05	0.0131	-0.43	-0.33	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-4.29	3.13e-05	0.0131	-0.43	-0.33	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
PCPG	cis	rs4819052	0.851	rs1999334	ENSG00000215447.6	BX322557.10	-4.29	3.13e-05	0.0131	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45288052~45291738:+
PCPG	cis	rs4803480	0.507	rs10420992	ENSG00000267107.5	PCAT19	4.29	3.13e-05	0.0131	0.27	0.33	Schizophrenia;	chr19:41558092	chr19:41454169~41500649:-
PCPG	cis	rs1048886	0.872	rs17634272	ENSG00000271967.1	RP11-134K13.4	-4.29	3.13e-05	0.0131	-0.42	-0.33	Type 2 diabetes;	chr6:70436792	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs76730904	ENSG00000271967.1	RP11-134K13.4	-4.29	3.13e-05	0.0131	-0.42	-0.33	Type 2 diabetes;	chr6:70440983	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs76917369	ENSG00000271967.1	RP11-134K13.4	-4.29	3.13e-05	0.0131	-0.42	-0.33	Type 2 diabetes;	chr6:70443516	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.938	rs12528385	ENSG00000271967.1	RP11-134K13.4	-4.29	3.13e-05	0.0131	-0.42	-0.33	Type 2 diabetes;	chr6:70448582	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.808	rs76320501	ENSG00000271967.1	RP11-134K13.4	-4.29	3.13e-05	0.0131	-0.42	-0.33	Type 2 diabetes;	chr6:70449586	chr6:70596438~70596980:+
PCPG	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-4.29	3.13e-05	0.0131	-0.72	-0.33	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
PCPG	cis	rs16964211	0.702	rs12439794	ENSG00000259438.1	CTD-2650P22.1	-4.29	3.13e-05	0.0131	-0.66	-0.33	Height;	chr15:51284441	chr15:52010999~52019095:-
PCPG	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-4.29	3.13e-05	0.0131	-0.56	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
PCPG	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	4.29	3.13e-05	0.0131	0.44	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
PCPG	cis	rs763014	0.966	rs4144003	ENSG00000262528.2	LA16c-349E10.1	4.29	3.14e-05	0.0131	0.4	0.33	Height;	chr16:595968	chr16:654611~656194:-
PCPG	cis	rs11673344	0.504	rs35579954	ENSG00000226686.6	LINC01535	4.29	3.14e-05	0.0131	0.43	0.33	Obesity-related traits;	chr19:37139308	chr19:37251912~37265535:+
PCPG	cis	rs1048886	0.938	rs12525408	ENSG00000271967.1	RP11-134K13.4	-4.29	3.14e-05	0.0131	-0.5	-0.33	Type 2 diabetes;	chr6:70580420	chr6:70596438~70596980:+
PCPG	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	4.29	3.14e-05	0.0131	0.42	0.33	Height;	chr6:109588639	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	4.29	3.14e-05	0.0131	0.42	0.33	Height;	chr6:109589051	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	4.29	3.14e-05	0.0131	0.42	0.33	Height;	chr6:109592105	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	4.29	3.14e-05	0.0131	0.42	0.33	Height;	chr6:109608105	chr6:109382795~109383666:+
PCPG	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-4.29	3.14e-05	0.0131	-0.34	-0.33	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
PCPG	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-4.29	3.14e-05	0.0131	-0.44	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
PCPG	cis	rs6500637	0.86	rs11644917	ENSG00000267077.1	RP11-127I20.5	-4.29	3.14e-05	0.0131	-0.41	-0.33	Cancer;	chr16:4890386	chr16:4795265~4796532:-
PCPG	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	4.29	3.14e-05	0.0131	0.38	0.33	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
PCPG	cis	rs4489787	0.772	rs6580673	ENSG00000240399.1	RP1-228P16.1	4.29	3.15e-05	0.0131	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr12:48464882	chr12:48054813~48055591:-
PCPG	cis	rs9299346	0.594	rs2181560	ENSG00000225376.4	TMEM246-AS1	4.29	3.15e-05	0.0131	0.4	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665101	chr9:101468439~101481502:+
PCPG	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	4.29	3.16e-05	0.0132	0.38	0.33	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
PCPG	cis	rs657075	0.697	rs3805666	ENSG00000233006.5	AC034220.3	-4.29	3.16e-05	0.0132	-0.48	-0.33	Rheumatoid arthritis;	chr5:132310782	chr5:132311285~132369916:-
PCPG	cis	rs4835473	0.864	rs4835343	ENSG00000251600.4	RP11-673E1.1	4.29	3.16e-05	0.0132	0.39	0.33	Immature fraction of reticulocytes;	chr4:143866038	chr4:143912331~143982454:+
PCPG	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-4.29	3.16e-05	0.0132	-0.48	-0.33	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
PCPG	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-4.29	3.16e-05	0.0132	-0.4	-0.33	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
PCPG	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-4.29	3.16e-05	0.0132	-0.42	-0.33	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-4.29	3.16e-05	0.0132	-0.42	-0.33	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-4.29	3.16e-05	0.0132	-0.42	-0.33	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
PCPG	cis	rs8099594	0.565	rs7238371	ENSG00000278983.1	RP11-426J5.3	4.29	3.16e-05	0.0132	0.36	0.33	Height;	chr18:49185269	chr18:48564795~48568342:+
PCPG	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-4.29	3.16e-05	0.0132	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-4.29	3.16e-05	0.0132	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-4.29	3.16e-05	0.0132	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-4.29	3.16e-05	0.0132	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4092718	ENSG00000251600.4	RP11-673E1.1	-4.29	3.16e-05	0.0132	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143799637	chr4:143912331~143982454:+
PCPG	cis	rs3758911	0.861	rs10890688	ENSG00000255353.1	RP11-382M14.1	-4.29	3.16e-05	0.0132	-0.45	-0.33	Coronary artery disease;	chr11:107272020	chr11:107176286~107177530:+
PCPG	cis	rs301901	1	rs300049	ENSG00000250155.1	CTD-2353F22.1	-4.29	3.16e-05	0.0132	-0.38	-0.33	Height;	chr5:37083971	chr5:36666214~36725195:-
PCPG	cis	rs950169	0.922	rs12906983	ENSG00000235370.6	DNM1P51	4.29	3.16e-05	0.0132	0.36	0.33	Schizophrenia;	chr15:84262270	chr15:84398316~84411701:-
PCPG	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-4.29	3.16e-05	0.0132	-0.4	-0.33	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
PCPG	cis	rs300890	1	rs300893	ENSG00000250326.1	RP11-284M14.1	4.29	3.16e-05	0.0132	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143335963	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.931	rs300892	ENSG00000250326.1	RP11-284M14.1	4.29	3.16e-05	0.0132	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143335998	chr4:142933195~143184861:-
PCPG	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	4.29	3.17e-05	0.0132	0.86	0.33	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	4.29	3.17e-05	0.0132	0.86	0.33	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	4.29	3.17e-05	0.0132	0.86	0.33	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
PCPG	cis	rs11250098	0.574	rs7015168	ENSG00000255020.1	AF131216.5	-4.29	3.17e-05	0.0132	-0.43	-0.33	Morning vs. evening chronotype;	chr8:10914700	chr8:11345748~11347502:-
PCPG	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-4.29	3.17e-05	0.0132	-0.41	-0.33	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
PCPG	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-4.29	3.17e-05	0.0132	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-4.29	3.17e-05	0.0132	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-4.29	3.17e-05	0.0132	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-4.29	3.17e-05	0.0132	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-4.29	3.17e-05	0.0132	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-4.29	3.17e-05	0.0132	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-4.29	3.17e-05	0.0132	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
PCPG	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	4.29	3.18e-05	0.0132	0.57	0.33	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
PCPG	cis	rs56379725	1	rs56379725	ENSG00000214783.8	POLR2J4	4.29	3.18e-05	0.0132	0.38	0.33	Peak insulin response;	chr7:43819816	chr7:43940895~44019175:-
PCPG	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-4.29	3.18e-05	0.0132	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
PCPG	cis	rs1387259	0.929	rs11168460	ENSG00000240399.1	RP1-228P16.1	4.29	3.18e-05	0.0132	0.37	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48054813~48055591:-
PCPG	cis	rs7172677	0.96	rs8026273	ENSG00000261543.1	RP11-665J16.1	-4.29	3.18e-05	0.0132	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75121425	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs4886658	ENSG00000261543.1	RP11-665J16.1	-4.29	3.18e-05	0.0132	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75122195	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs4886659	ENSG00000261543.1	RP11-665J16.1	-4.29	3.18e-05	0.0132	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75122419	chr15:74152800~74179226:-
PCPG	cis	rs10899021	0.79	rs12280434	ENSG00000279353.1	RP11-864N7.4	4.29	3.19e-05	0.0133	0.57	0.33	Response to metformin (IC50);	chr11:74621782	chr11:74698231~74699658:-
PCPG	cis	rs10899021	0.79	rs10899019	ENSG00000279353.1	RP11-864N7.4	4.29	3.19e-05	0.0133	0.57	0.33	Response to metformin (IC50);	chr11:74624117	chr11:74698231~74699658:-
PCPG	cis	rs7042889	1	rs7863575	ENSG00000281892.1	Metazoa_SRP	4.29	3.19e-05	0.0133	0.56	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129036282	chr9:128314614~128314876:-
PCPG	cis	rs7042889	1	rs10513506	ENSG00000281892.1	Metazoa_SRP	4.29	3.19e-05	0.0133	0.56	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129036860	chr9:128314614~128314876:-
PCPG	cis	rs7042889	1	rs11564101	ENSG00000281892.1	Metazoa_SRP	4.29	3.19e-05	0.0133	0.56	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129036982	chr9:128314614~128314876:-
PCPG	cis	rs7042889	1	rs7867379	ENSG00000281892.1	Metazoa_SRP	4.29	3.19e-05	0.0133	0.56	0.33	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129041051	chr9:128314614~128314876:-
PCPG	cis	rs7772486	0.686	rs9403741	ENSG00000270638.1	RP3-466P17.1	-4.29	3.19e-05	0.0133	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9485019	ENSG00000270638.1	RP3-466P17.1	-4.29	3.19e-05	0.0133	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145735570~145737218:+
PCPG	cis	rs6121246	0.738	rs2376996	ENSG00000230613.1	HM13-AS1	4.29	3.19e-05	0.0133	0.48	0.33	Mean corpuscular hemoglobin;	chr20:31728864	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.821	rs7265413	ENSG00000230613.1	HM13-AS1	4.29	3.19e-05	0.0133	0.48	0.33	Mean corpuscular hemoglobin;	chr20:31730120	chr20:31567707~31573263:-
PCPG	cis	rs6569038	0.669	rs17513308	ENSG00000253194.1	RP11-351A11.1	4.29	3.19e-05	0.0133	0.44	0.33	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119061186	chr6:118934785~119031541:+
PCPG	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	4.29	3.19e-05	0.0133	0.37	0.33	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	4.29	3.19e-05	0.0133	0.37	0.33	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
PCPG	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-4.29	3.19e-05	0.0133	-0.41	-0.33	Temperament;	chr17:14007232	chr17:14024514~14025488:+
PCPG	cis	rs9828933	0.577	rs832194	ENSG00000280620.1	SCAANT1	-4.29	3.19e-05	0.0133	-0.47	-0.33	Type 2 diabetes;	chr3:63871395	chr3:63911518~63911772:-
PCPG	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	4.29	3.2e-05	0.0133	0.41	0.33	Height;	chr6:109390116	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	4.29	3.2e-05	0.0133	0.41	0.33	Height;	chr6:109390638	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	4.29	3.2e-05	0.0133	0.41	0.33	Height;	chr6:109391534	chr6:109382795~109383666:+
PCPG	cis	rs6003958	1	rs6003958	ENSG00000218537.1	MIF-AS1	-4.29	3.2e-05	0.0133	-0.48	-0.33	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23894426~23898930:-
PCPG	cis	rs5760092	0.755	rs6003959	ENSG00000218537.1	MIF-AS1	-4.29	3.2e-05	0.0133	-0.48	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23894426~23898930:-
PCPG	cis	rs7172677	1	rs4479194	ENSG00000261543.1	RP11-665J16.1	-4.29	3.2e-05	0.0133	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75129790	chr15:74152800~74179226:-
PCPG	cis	rs5743030	1	rs256572	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.2e-05	0.0133	-0.5	-0.33	Subcutaneous adipose tissue;	chr2:189853141	chr2:189762704~189765556:+
PCPG	cis	rs5743030	0.702	rs735559	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.2e-05	0.0133	-0.5	-0.33	Subcutaneous adipose tissue;	chr2:189857617	chr2:189762704~189765556:+
PCPG	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	4.29	3.2e-05	0.0133	0.43	0.33	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
PCPG	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-4.29	3.2e-05	0.0133	-0.35	-0.33	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
PCPG	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-4.29	3.2e-05	0.0133	-0.47	-0.33	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
PCPG	cis	rs1371867	0.875	rs1371868	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100318039	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1660311	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100318351	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1788178	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100320290	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.839	rs1660313	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100320484	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.817	rs1660314	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100320725	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.817	rs1660315	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100320728	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660316	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100320821	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660317	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100321024	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.817	rs1788179	ENSG00000212994.5	RPS26P6	4.29	3.2e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100321117	chr8:100895771~100896118:+
PCPG	cis	rs11148252	0.74	rs9596643	ENSG00000278238.1	RP11-245D16.4	4.29	3.21e-05	0.0133	0.3	0.33	Lewy body disease;	chr13:52338245	chr13:52454775~52455331:-
PCPG	cis	rs720064	0.586	rs9950879	ENSG00000265752.2	RP11-403A21.1	4.29	3.21e-05	0.0133	0.38	0.33	Strep throat;	chr18:23965115	chr18:23957754~23982556:-
PCPG	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-4.29	3.21e-05	0.0133	-0.44	-0.33	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
PCPG	cis	rs1371867	0.846	rs1788203	ENSG00000212994.5	RPS26P6	4.29	3.21e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100291493	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1788204	ENSG00000212994.5	RPS26P6	4.29	3.21e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100291708	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660329	ENSG00000212994.5	RPS26P6	4.29	3.21e-05	0.0133	0.39	0.33	Atrioventricular conduction;	chr8:100291820	chr8:100895771~100896118:+
PCPG	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-4.29	3.21e-05	0.0133	-0.37	-0.33	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-4.29	3.21e-05	0.0133	-0.37	-0.33	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-4.29	3.21e-05	0.0133	-0.37	-0.33	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
PCPG	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	4.29	3.21e-05	0.0133	0.49	0.33	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
PCPG	cis	rs5743030	0.702	rs256556	ENSG00000253559.1	OSGEPL1-AS1	-4.29	3.21e-05	0.0133	-0.51	-0.33	Subcutaneous adipose tissue;	chr2:189872118	chr2:189762704~189765556:+
PCPG	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	4.29	3.21e-05	0.0133	0.67	0.33	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
PCPG	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-4.29	3.21e-05	0.0133	-0.35	-0.33	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
PCPG	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-4.29	3.21e-05	0.0133	-0.4	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
PCPG	cis	rs6840258	0.723	rs340642	ENSG00000251411.1	RP11-397E7.4	4.29	3.22e-05	0.0134	0.34	0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87028261	chr4:86913266~86914817:-
PCPG	cis	rs11858159	0.903	rs12324726	ENSG00000260760.1	PWRN3	4.29	3.22e-05	0.0134	0.33	0.33	Platelet thrombus formation;	chr15:24553517	chr15:24441127~24447967:+
PCPG	cis	rs7945705	0.791	rs12421789	ENSG00000254860.4	TMEM9B-AS1	4.29	3.22e-05	0.0134	0.32	0.33	Hemoglobin concentration;	chr11:8792409	chr11:8964675~8977527:+
PCPG	cis	rs13108904	0.967	rs62293658	ENSG00000253399.1	AC078852.2	4.29	3.22e-05	0.0134	0.34	0.33	Obesity-related traits;	chr4:1282628	chr4:1358479~1359461:+
PCPG	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-4.29	3.22e-05	0.0134	-0.56	-0.33	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-4.29	3.22e-05	0.0134	-0.56	-0.33	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-4.29	3.22e-05	0.0134	-0.56	-0.33	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
PCPG	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	4.29	3.22e-05	0.0134	0.42	0.33	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	4.29	3.22e-05	0.0134	0.42	0.33	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	4.29	3.22e-05	0.0134	0.42	0.33	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	4.29	3.22e-05	0.0134	0.42	0.33	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	4.29	3.22e-05	0.0134	0.42	0.33	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	4.29	3.22e-05	0.0134	0.42	0.33	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
PCPG	cis	rs8064024	0.538	rs11076854	ENSG00000267077.1	RP11-127I20.5	-4.29	3.22e-05	0.0134	-0.39	-0.33	Cancer;	chr16:4879268	chr16:4795265~4796532:-
PCPG	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	4.29	3.22e-05	0.0134	0.37	0.33	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
PCPG	cis	rs867371	0.929	rs1045508	ENSG00000228141.5	AC105339.1	4.29	3.22e-05	0.0134	0.39	0.33	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82710471~82714026:-
PCPG	cis	rs2439831	1	rs2584726	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43423184	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs565007	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43424443	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs550239	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43427999	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.85	rs558656	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43431316	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs690002	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43437151	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs537115	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43437750	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2245908	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43439256	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2444029	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43445286	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs690316	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43445682	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2467739	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43447998	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs28666488	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43448892	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2245790	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43452259	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2467740	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43454594	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	4.29	3.22e-05	0.0134	0.46	0.33	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs561863	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43469154	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs689596	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43469519	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs689616	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43469703	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs689647	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43469998	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2251538	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43475011	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2439850	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43492656	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2467736	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43492719	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2444250	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43492853	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs101094	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43495124	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs689781	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43499899	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2584725	ENSG00000205771.5	CATSPER2P1	-4.29	3.22e-05	0.0134	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43500937	chr15:43726918~43747094:-
PCPG	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-4.29	3.22e-05	0.0134	-0.42	-0.33	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
PCPG	cis	rs9717605	1	rs12178180	ENSG00000226445.1	XXyac-YX65C7_A.2	4.29	3.23e-05	0.0134	0.41	0.33	Left atrial antero-posterior diameter;	chr6:169248672	chr6:169213254~169239565:+
PCPG	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-4.29	3.23e-05	0.0134	-0.42	-0.33	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-4.29	3.23e-05	0.0134	-0.42	-0.33	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-4.29	3.23e-05	0.0134	-0.42	-0.33	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-4.29	3.23e-05	0.0134	-0.42	-0.33	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
PCPG	cis	rs2836974	0.899	rs114399588	ENSG00000252915.1	Y_RNA	-4.29	3.23e-05	0.0134	-0.36	-0.33	Cognitive function;	chr21:39282032	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.965	rs8131126	ENSG00000252915.1	Y_RNA	-4.29	3.23e-05	0.0134	-0.36	-0.33	Cognitive function;	chr21:39283828	chr21:39344537~39344628:+
PCPG	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	4.29	3.23e-05	0.0134	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
PCPG	cis	rs2736345	1	rs922483	ENSG00000154316.13	TDH	4.29	3.24e-05	0.0134	0.42	0.33	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494403	chr8:11339637~11368452:+
PCPG	cis	rs73198271	0.71	rs3827808	ENSG00000253893.2	FAM85B	4.29	3.24e-05	0.0134	0.43	0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8167819~8226614:-
PCPG	cis	rs7819412	0.811	rs2409691	ENSG00000269918.1	AF131215.9	-4.29	3.24e-05	0.0134	-0.37	-0.33	Triglycerides;	chr8:11085766	chr8:11104691~11106704:-
PCPG	cis	rs9650657	0.513	rs4841459	ENSG00000255020.1	AF131216.5	-4.29	3.24e-05	0.0134	-0.45	-0.33	Neuroticism;	chr8:10924932	chr8:11345748~11347502:-
PCPG	cis	rs7746199	0.736	rs35848276	ENSG00000219392.1	RP1-265C24.5	-4.29	3.24e-05	0.0134	-0.73	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28115628~28116551:+
PCPG	cis	rs8098244	0.557	rs11660632	ENSG00000265752.2	RP11-403A21.1	4.29	3.24e-05	0.0134	0.38	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696084	chr18:23957754~23982556:-
PCPG	cis	rs75804782	0.63	rs55762325	ENSG00000227107.1	AC096574.5	-4.29	3.24e-05	0.0135	-0.57	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238342082	chr2:237612977~237626525:+
PCPG	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	4.29	3.25e-05	0.0135	0.49	0.33	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
PCPG	cis	rs7017914	0.69	rs13269690	ENSG00000254031.4	RP11-326E22.1	4.29	3.25e-05	0.0135	0.31	0.33	Bone mineral density;	chr8:70732572	chr8:71155457~71204223:+
PCPG	cis	rs1371867	0.726	rs1660333	ENSG00000212994.5	RPS26P6	4.29	3.25e-05	0.0135	0.39	0.33	Atrioventricular conduction;	chr8:100297761	chr8:100895771~100896118:+
PCPG	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	4.29	3.25e-05	0.0135	0.56	0.33	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
PCPG	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	4.29	3.25e-05	0.0135	0.36	0.33	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
PCPG	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-4.28	3.26e-05	0.0135	-0.48	-0.33	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
PCPG	cis	rs10899021	1	rs10899021	ENSG00000279353.1	RP11-864N7.4	-4.28	3.26e-05	0.0135	-0.56	-0.33	Response to metformin (IC50);	chr11:74627009	chr11:74698231~74699658:-
PCPG	cis	rs1150668	0.764	rs9368565	ENSG00000219392.1	RP1-265C24.5	4.28	3.26e-05	0.0135	0.39	0.33	Pubertal anthropometrics;	chr6:28377433	chr6:28115628~28116551:+
PCPG	cis	rs1150668	0.796	rs1052215	ENSG00000219392.1	RP1-265C24.5	4.28	3.26e-05	0.0135	0.39	0.33	Pubertal anthropometrics;	chr6:28380381	chr6:28115628~28116551:+
PCPG	cis	rs11673344	0.504	rs7258360	ENSG00000226686.6	LINC01535	4.28	3.26e-05	0.0135	0.42	0.33	Obesity-related traits;	chr19:37115015	chr19:37251912~37265535:+
PCPG	cis	rs6569038	0.557	rs9387629	ENSG00000253194.1	RP11-351A11.1	4.28	3.26e-05	0.0135	0.43	0.33	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035036	chr6:118934785~119031541:+
PCPG	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	4.28	3.26e-05	0.0135	0.36	0.33	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
PCPG	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	-4.28	3.26e-05	0.0135	-0.38	-0.33	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
PCPG	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	4.28	3.26e-05	0.0135	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
PCPG	cis	rs950169	0.887	rs35986397	ENSG00000235370.6	DNM1P51	4.28	3.26e-05	0.0135	0.36	0.33	Schizophrenia;	chr15:84400409	chr15:84398316~84411701:-
PCPG	cis	rs7911712	0.935	rs1771999	ENSG00000228462.1	RP11-445N18.3	4.28	3.26e-05	0.0135	0.47	0.33	Emphysema-related traits;	chr10:44796534	chr10:45073146~45073541:-
PCPG	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-4.28	3.27e-05	0.0135	-0.42	-0.33	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
PCPG	cis	rs11099942	0.826	rs10517588	ENSG00000249309.1	RP11-153M7.5	4.28	3.27e-05	0.0135	0.63	0.33	Type 2 diabetes (age of onset);	chr4:154190587	chr4:153720327~153727722:+
PCPG	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	4.28	3.27e-05	0.0135	0.69	0.33	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
PCPG	cis	rs879620	0.929	rs2238435	ENSG00000262185.1	RP11-462G12.1	-4.28	3.27e-05	0.0135	-0.44	-0.33	Hip circumference;Body mass index;	chr16:3964281	chr16:3947609~3950444:-
PCPG	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	4.28	3.27e-05	0.0135	0.44	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
PCPG	cis	rs7849270	0.837	rs10819463	ENSG00000268707.1	RP11-247A12.7	-4.28	3.27e-05	0.0135	-0.35	-0.33	Blood metabolite ratios;	chr9:129100958	chr9:129170434~129170940:+
PCPG	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-4.28	3.27e-05	0.0135	-0.39	-0.33	Height;	chr5:37023796	chr5:36666214~36725195:-
PCPG	cis	rs8099594	0.565	rs1893526	ENSG00000278983.1	RP11-426J5.3	4.28	3.27e-05	0.0135	0.35	0.33	Height;	chr18:49185406	chr18:48564795~48568342:+
PCPG	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	-4.28	3.27e-05	0.0135	-0.48	-0.33	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
PCPG	cis	rs10865541	1	rs11684337	ENSG00000225234.1	TRAPPC12-AS1	4.28	3.27e-05	0.0136	0.33	0.33	Obesity-related traits;	chr2:3391516	chr2:3481242~3482409:-
PCPG	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	4.28	3.28e-05	0.0136	0.37	0.33	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
PCPG	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-4.28	3.28e-05	0.0136	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
PCPG	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-4.28	3.28e-05	0.0136	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-4.28	3.28e-05	0.0136	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
PCPG	cis	rs5742933	0.597	rs7568449	ENSG00000273240.1	RP11-455J20.3	4.28	3.28e-05	0.0136	0.36	0.33	Ferritin levels;	chr2:189656328	chr2:189763859~189764456:-
PCPG	cis	rs7247513	0.964	rs4804202	ENSG00000213290.4	PGK1P2	-4.28	3.28e-05	0.0136	-0.45	-0.33	Bipolar disorder;	chr19:12607805	chr19:12559571~12561105:+
PCPG	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	4.28	3.28e-05	0.0136	0.42	0.33	Height;	chr6:109584789	chr6:109382795~109383666:+
PCPG	cis	rs9311474	0.659	rs7638808	ENSG00000275956.1	RP5-966M1.7	4.28	3.28e-05	0.0136	0.38	0.33	Electroencephalogram traits;	chr3:52538040	chr3:52732547~52733867:+
PCPG	cis	rs4713118	0.513	rs149878	ENSG00000219392.1	RP1-265C24.5	-4.28	3.28e-05	0.0136	-0.4	-0.33	Parkinson's disease;	chr6:27910960	chr6:28115628~28116551:+
PCPG	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-4.28	3.28e-05	0.0136	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
PCPG	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-4.28	3.29e-05	0.0136	-0.43	-0.33	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
PCPG	cis	rs2732480	0.577	rs2634680	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.577	rs2634678	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.577	rs2732479	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.537	rs1061986	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.577	rs2732481	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.557	rs2732484	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.577	rs2732486	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.517	rs2634676	ENSG00000240399.1	RP1-228P16.1	4.28	3.29e-05	0.0136	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48054813~48055591:-
PCPG	cis	rs10504130	0.696	rs17212214	ENSG00000272024.1	RP11-546K22.3	4.28	3.29e-05	0.0136	0.4	0.33	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51950284~51950690:+
PCPG	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	4.28	3.29e-05	0.0136	0.26	0.33	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
PCPG	cis	rs6121246	0.821	rs6121209	ENSG00000230613.1	HM13-AS1	4.28	3.29e-05	0.0136	0.48	0.33	Mean corpuscular hemoglobin;	chr20:31723455	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs57726761	ENSG00000230613.1	HM13-AS1	4.28	3.29e-05	0.0136	0.48	0.33	Mean corpuscular hemoglobin;	chr20:31726243	chr20:31567707~31573263:-
PCPG	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	4.28	3.29e-05	0.0136	0.43	0.33	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	4.28	3.29e-05	0.0136	0.43	0.33	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
PCPG	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	4.28	3.29e-05	0.0136	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	4.28	3.29e-05	0.0136	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
PCPG	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-4.28	3.3e-05	0.0136	-0.51	-0.33	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
PCPG	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	4.28	3.3e-05	0.0136	0.34	0.33	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
PCPG	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-4.28	3.3e-05	0.0136	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
PCPG	cis	rs7172677	0.793	rs8029712	ENSG00000261543.1	RP11-665J16.1	-4.28	3.3e-05	0.0136	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75125829	chr15:74152800~74179226:-
PCPG	cis	rs172166	0.585	rs149963	ENSG00000219392.1	RP1-265C24.5	-4.28	3.3e-05	0.0137	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28049354	chr6:28115628~28116551:+
PCPG	cis	rs2361718	0.5	rs12451697	ENSG00000279259.1	RP11-334C17.3	4.28	3.3e-05	0.0137	0.3	0.33	Yeast infection;	chr17:80126891	chr17:80147250~80148596:+
PCPG	cis	rs17711722	0.583	rs11768292	ENSG00000273142.1	RP11-458F8.4	4.28	3.31e-05	0.0137	0.31	0.33	Calcium levels;	chr7:66009814	chr7:66902857~66906297:+
PCPG	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-4.28	3.31e-05	0.0137	-0.4	-0.33	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
PCPG	cis	rs10995505	0.578	rs1533068	ENSG00000232075.1	MRPL35P2	-4.28	3.31e-05	0.0137	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63132407	chr10:63634317~63634827:-
PCPG	cis	rs2836974	0.931	rs2735306	ENSG00000252915.1	Y_RNA	4.28	3.31e-05	0.0137	0.36	0.33	Cognitive function;	chr21:39341208	chr21:39344537~39344628:+
PCPG	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-4.28	3.31e-05	0.0137	-0.34	-0.33	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
PCPG	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	4.28	3.31e-05	0.0137	0.38	0.33	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
PCPG	cis	rs853679	0.567	rs13196606	ENSG00000219392.1	RP1-265C24.5	-4.28	3.31e-05	0.0137	-0.44	-0.33	Depression;	chr6:28402301	chr6:28115628~28116551:+
PCPG	cis	rs10101158	0.733	rs11777156	ENSG00000253595.4	LINC01300	4.28	3.31e-05	0.0137	0.33	0.33	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);	chr8:141852092	chr8:141340549~141344621:+
PCPG	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-4.28	3.32e-05	0.0137	-0.37	-0.33	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
PCPG	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-4.28	3.32e-05	0.0137	-0.42	-0.33	Height;	chr6:109636120	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	4.28	3.32e-05	0.0137	0.4	0.33	Height;	chr6:109361200	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	4.28	3.32e-05	0.0137	0.4	0.33	Height;	chr6:109367335	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	4.28	3.32e-05	0.0137	0.4	0.33	Height;	chr6:109368228	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	4.28	3.32e-05	0.0137	0.4	0.33	Height;	chr6:109370741	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	4.28	3.32e-05	0.0137	0.4	0.33	Height;	chr6:109371524	chr6:109382795~109383666:+
PCPG	cis	rs9303542	0.559	rs2326012	ENSG00000279036.1	RP11-81K2.2	-4.28	3.32e-05	0.0137	-0.53	-0.33	Epithelial ovarian cancer;Ovarian cancer;	chr17:48541219	chr17:49494223~49497800:-
PCPG	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	4.28	3.32e-05	0.0137	0.42	0.33	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
PCPG	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	4.28	3.32e-05	0.0137	0.36	0.33	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	4.28	3.32e-05	0.0137	0.37	0.33	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	4.28	3.32e-05	0.0137	0.37	0.33	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
PCPG	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-4.28	3.32e-05	0.0137	-0.42	-0.33	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
PCPG	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-4.28	3.32e-05	0.0137	-0.42	-0.33	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
PCPG	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-4.28	3.33e-05	0.0137	-0.42	-0.33	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
PCPG	cis	rs12439619	0.846	rs62012059	ENSG00000228141.5	AC105339.1	-4.28	3.33e-05	0.0137	-0.5	-0.33	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82710471~82714026:-
PCPG	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-4.28	3.33e-05	0.0137	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
PCPG	cis	rs2243480	1	rs313814	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66038306	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs402418	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66044482	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs423187	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66044512	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs431318	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66046610	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs313803	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66049744	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs313802	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66051386	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs403089	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66052736	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs458291	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66055492	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs466983	ENSG00000230189.5	GS1-124K5.2	4.28	3.33e-05	0.0137	0.51	0.33	Diabetic kidney disease;	chr7:66055509	chr7:66409143~66490059:-
PCPG	cis	rs75804782	0.63	rs74404946	ENSG00000227107.1	AC096574.5	-4.28	3.33e-05	0.0137	-0.56	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238392131	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.572	rs76084375	ENSG00000227107.1	AC096574.5	-4.28	3.33e-05	0.0137	-0.56	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238392552	chr2:237612977~237626525:+
PCPG	cis	rs61332075	0.503	rs113377546	ENSG00000227107.1	AC096574.5	-4.28	3.33e-05	0.0137	-0.56	-0.33	Lung function (FEV1/FVC);	chr2:238395229	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs3739070	ENSG00000227107.1	AC096574.5	-4.28	3.33e-05	0.0137	-0.56	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238397627	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.572	rs11900963	ENSG00000227107.1	AC096574.5	-4.28	3.33e-05	0.0137	-0.56	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238399408	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs11900807	ENSG00000227107.1	AC096574.5	-4.28	3.33e-05	0.0137	-0.56	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238401348	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.515	rs11897824	ENSG00000227107.1	AC096574.5	-4.28	3.33e-05	0.0137	-0.56	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238402804	chr2:237612977~237626525:+
PCPG	cis	rs181553	1	rs181553	ENSG00000278983.1	RP11-426J5.3	4.28	3.33e-05	0.0138	0.36	0.33	Hip circumference adjusted for BMI;	chr18:49035660	chr18:48564795~48568342:+
PCPG	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	4.28	3.34e-05	0.0138	0.32	0.33	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	4.28	3.34e-05	0.0138	0.32	0.33	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
PCPG	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.28	3.34e-05	0.0138	0.42	0.33	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
PCPG	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	-4.28	3.34e-05	0.0138	-0.38	-0.33	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
PCPG	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-4.28	3.34e-05	0.0138	-0.38	-0.33	Height;	chr5:37072722	chr5:36666214~36725195:-
PCPG	cis	rs394563	0.591	rs237019	ENSG00000231760.4	RP11-350J20.5	4.28	3.34e-05	0.0138	0.42	0.33	Dupuytren's disease;	chr6:149405928	chr6:149796151~149826294:-
PCPG	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	4.28	3.34e-05	0.0138	0.35	0.33	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
PCPG	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	4.28	3.34e-05	0.0138	0.37	0.33	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
PCPG	cis	rs1440410	0.798	rs10026015	ENSG00000250326.1	RP11-284M14.1	4.28	3.35e-05	0.0138	0.31	0.33	Ischemic stroke;	chr4:143248486	chr4:142933195~143184861:-
PCPG	cis	rs896854	0.684	rs10098778	ENSG00000253528.2	RP11-347C18.4	4.28	3.35e-05	0.0138	0.35	0.33	Type 2 diabetes;	chr8:94979792	chr8:94974573~94974853:-
PCPG	cis	rs10208649	0.706	rs75833613	ENSG00000272156.1	RP11-477N3.1	4.28	3.35e-05	0.0138	0.58	0.33	Body mass index;	chr2:54065224	chr2:54082554~54085066:+
PCPG	cis	rs11858159	0.902	rs13379971	ENSG00000259905.4	PWRN1	4.28	3.35e-05	0.0138	0.38	0.33	Platelet thrombus formation;	chr15:24548833	chr15:24493137~24652130:+
PCPG	cis	rs11858159	1	rs3901472	ENSG00000260760.1	PWRN3	4.28	3.35e-05	0.0138	0.35	0.33	Platelet thrombus formation;	chr15:24569435	chr15:24441127~24447967:+
PCPG	cis	rs9299346	0.594	rs1323415	ENSG00000225376.4	TMEM246-AS1	4.28	3.35e-05	0.0138	0.39	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101664176	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1323414	ENSG00000225376.4	TMEM246-AS1	4.28	3.35e-05	0.0138	0.39	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101664355	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1885978	ENSG00000225376.4	TMEM246-AS1	4.28	3.35e-05	0.0138	0.39	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101664587	chr9:101468439~101481502:+
PCPG	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-4.28	3.35e-05	0.0138	-0.4	-0.33	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
PCPG	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	4.28	3.35e-05	0.0138	0.34	0.33	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
PCPG	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-4.28	3.35e-05	0.0138	-0.48	-0.33	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-4.28	3.35e-05	0.0138	-0.48	-0.33	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-4.28	3.35e-05	0.0138	-0.48	-0.33	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-4.28	3.35e-05	0.0138	-0.48	-0.33	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
PCPG	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	4.28	3.35e-05	0.0138	0.36	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
PCPG	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-4.28	3.36e-05	0.0138	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
PCPG	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	4.28	3.36e-05	0.0138	0.44	0.33	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
PCPG	cis	rs12744310	0.887	rs12024263	ENSG00000227527.2	RP11-223A3.1	-4.28	3.36e-05	0.0138	-0.38	-0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41355277	chr1:42335386~42338376:-
PCPG	cis	rs4489787	1	rs4760708	ENSG00000240399.1	RP1-228P16.1	4.28	3.36e-05	0.0138	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr12:48470055	chr12:48054813~48055591:-
PCPG	cis	rs7186908	0.711	rs9923344	ENSG00000260886.1	TAT-AS1	4.28	3.36e-05	0.0138	0.49	0.33	Liver enzyme levels (alkaline phosphatase);	chr16:72156754	chr16:71565789~71578187:+
PCPG	cis	rs2404602	0.655	rs10444809	ENSG00000259514.1	RP11-685G9.2	4.28	3.36e-05	0.0138	0.33	0.33	Blood metabolite levels;	chr15:76832195	chr15:76339609~76342063:-
PCPG	cis	rs11250098	0.51	rs4840525	ENSG00000255020.1	AF131216.5	-4.28	3.36e-05	0.0138	-0.43	-0.33	Morning vs. evening chronotype;	chr8:10908125	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.902	rs7180843	ENSG00000259905.4	PWRN1	4.28	3.36e-05	0.0138	0.38	0.33	Platelet thrombus formation;	chr15:24566914	chr15:24493137~24652130:+
PCPG	cis	rs2797160	0.904	rs2326292	ENSG00000237742.5	RP11-624M8.1	-4.28	3.36e-05	0.0138	-0.34	-0.33	Endometrial cancer;	chr6:125678528	chr6:125578558~125749190:-
PCPG	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	4.28	3.36e-05	0.0138	0.35	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
PCPG	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-4.28	3.37e-05	0.0138	-0.48	-0.33	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
PCPG	cis	rs7824557	0.606	rs1435277	ENSG00000255020.1	AF131216.5	4.28	3.37e-05	0.0139	0.44	0.33	Retinal vascular caliber;	chr8:11339461	chr8:11345748~11347502:-
PCPG	cis	rs73198271	0.653	rs10087633	ENSG00000253893.2	FAM85B	4.28	3.37e-05	0.0139	0.43	0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.653	rs10087742	ENSG00000253893.2	FAM85B	4.28	3.37e-05	0.0139	0.43	0.33	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8167819~8226614:-
PCPG	cis	rs916888	0.61	rs199438	ENSG00000262500.1	RP11-259G18.2	4.28	3.37e-05	0.0139	0.49	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46243606~46245044:+
PCPG	cis	rs2228479	0.717	rs1007932	ENSG00000268218.1	AC137932.4	-4.28	3.37e-05	0.0139	-0.45	-0.33	Skin colour saturation;	chr16:89772133	chr16:89268104~89273044:+
PCPG	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	4.28	3.37e-05	0.0139	0.43	0.33	Height;	chr6:109494760	chr6:109382795~109383666:+
PCPG	cis	rs1440410	0.835	rs9790396	ENSG00000250326.1	RP11-284M14.1	4.28	3.37e-05	0.0139	0.31	0.33	Ischemic stroke;	chr4:143130366	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs7693817	ENSG00000250326.1	RP11-284M14.1	4.28	3.37e-05	0.0139	0.31	0.33	Ischemic stroke;	chr4:143130372	chr4:142933195~143184861:-
PCPG	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	4.28	3.37e-05	0.0139	0.46	0.33	Temperament;	chr17:13996939	chr17:14024514~14025488:+
PCPG	cis	rs1150668	0.796	rs1005125	ENSG00000219392.1	RP1-265C24.5	-4.28	3.38e-05	0.0139	-0.4	-0.33	Pubertal anthropometrics;	chr6:28399578	chr6:28115628~28116551:+
PCPG	cis	rs7772486	0.686	rs6933161	ENSG00000270638.1	RP3-466P17.1	-4.28	3.38e-05	0.0139	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9399565	ENSG00000270638.1	RP3-466P17.1	-4.28	3.38e-05	0.0139	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145735570~145737218:+
PCPG	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	4.28	3.38e-05	0.0139	0.36	0.33	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	4.28	3.38e-05	0.0139	0.36	0.33	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
PCPG	cis	rs6012953	1	rs3787334	ENSG00000231742.4	LINC01273	4.28	3.38e-05	0.0139	0.35	0.33	Vitiligo;	chr20:50511483	chr20:50172550~50176671:+
PCPG	cis	rs6012953	1	rs932420	ENSG00000231742.4	LINC01273	4.28	3.38e-05	0.0139	0.35	0.33	Vitiligo;	chr20:50516532	chr20:50172550~50176671:+
PCPG	cis	rs6012953	1	rs6091173	ENSG00000231742.4	LINC01273	4.28	3.38e-05	0.0139	0.35	0.33	Vitiligo;	chr20:50517562	chr20:50172550~50176671:+
PCPG	cis	rs9595908	0.645	rs56399737	ENSG00000212293.1	SNORA16	4.27	3.39e-05	0.0139	0.41	0.33	Body mass index;	chr13:32807583	chr13:32420390~32420516:-
PCPG	cis	rs1048886	0.938	rs79421004	ENSG00000271967.1	RP11-134K13.4	-4.27	3.39e-05	0.0139	-0.41	-0.33	Type 2 diabetes;	chr6:70478869	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs17713105	ENSG00000271967.1	RP11-134K13.4	-4.27	3.39e-05	0.0139	-0.41	-0.33	Type 2 diabetes;	chr6:70484097	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.938	rs17713212	ENSG00000271967.1	RP11-134K13.4	-4.27	3.39e-05	0.0139	-0.41	-0.33	Type 2 diabetes;	chr6:70489129	chr6:70596438~70596980:+
PCPG	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	4.27	3.39e-05	0.0139	0.42	0.33	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
PCPG	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	4.27	3.39e-05	0.0139	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
PCPG	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	4.27	3.39e-05	0.0139	0.48	0.33	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	4.27	3.39e-05	0.0139	0.48	0.33	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-4.27	3.39e-05	0.0139	-0.48	-0.33	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-4.27	3.39e-05	0.0139	-0.48	-0.33	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-4.27	3.39e-05	0.0139	-0.48	-0.33	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-4.27	3.39e-05	0.0139	-0.48	-0.33	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-4.27	3.39e-05	0.0139	-0.48	-0.33	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-4.27	3.39e-05	0.0139	-0.48	-0.33	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
PCPG	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-4.27	3.39e-05	0.0139	-0.43	-0.33	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
PCPG	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-4.27	3.39e-05	0.0139	-0.43	-0.33	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
PCPG	cis	rs6445975	0.715	rs3773006	ENSG00000272360.1	RP11-359I18.5	-4.27	3.39e-05	0.0139	-0.4	-0.33	Systemic lupus erythematosus;	chr3:58283812	chr3:58490830~58491291:-
PCPG	cis	rs6504340	0.741	rs34822124	ENSG00000279036.1	RP11-81K2.2	-4.27	3.39e-05	0.0139	-0.57	-0.33	Primary tooth development (number of teeth);	chr17:48571317	chr17:49494223~49497800:-
PCPG	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	4.27	3.39e-05	0.0139	0.33	0.33	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
PCPG	cis	rs2404602	0.532	rs12591100	ENSG00000259514.1	RP11-685G9.2	4.27	3.39e-05	0.0139	0.33	0.33	Blood metabolite levels;	chr15:76408460	chr15:76339609~76342063:-
PCPG	cis	rs6121246	0.909	rs6060793	ENSG00000230613.1	HM13-AS1	4.27	3.39e-05	0.0139	0.48	0.33	Mean corpuscular hemoglobin;	chr20:31701027	chr20:31567707~31573263:-
PCPG	cis	rs5758511	0.68	rs739146	ENSG00000227370.1	RP4-669P10.19	4.27	3.39e-05	0.0139	0.49	0.33	Birth weight;	chr22:42264408	chr22:42132543~42132998:+
PCPG	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	4.27	3.4e-05	0.014	0.38	0.33	Height;	chr5:36887793	chr5:36666214~36725195:-
PCPG	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	4.27	3.4e-05	0.014	0.43	0.33	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
PCPG	cis	rs1440410	0.798	rs1440416	ENSG00000250326.1	RP11-284M14.1	4.27	3.4e-05	0.014	0.3	0.33	Ischemic stroke;	chr4:143233882	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.666	rs2165302	ENSG00000250326.1	RP11-284M14.1	4.27	3.4e-05	0.014	0.3	0.33	Ischemic stroke;	chr4:143234744	chr4:142933195~143184861:-
PCPG	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-4.27	3.4e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	4.27	3.4e-05	0.014	0.48	0.33	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
PCPG	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	4.27	3.4e-05	0.014	0.48	0.33	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs11630887	ENSG00000259295.5	CSPG4P12	4.27	3.4e-05	0.014	0.48	0.33	Schizophrenia;	chr15:84649784	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs11636189	ENSG00000259295.5	CSPG4P12	4.27	3.4e-05	0.014	0.48	0.33	Schizophrenia;	chr15:84650323	chr15:85191438~85213905:+
PCPG	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-4.27	3.4e-05	0.014	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
PCPG	cis	rs13113518	0.729	rs11133377	ENSG00000272969.1	RP11-528I4.2	4.27	3.4e-05	0.014	0.38	0.33	Height;	chr4:55413708	chr4:55547112~55547889:+
PCPG	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	4.27	3.4e-05	0.014	0.44	0.33	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	4.27	3.4e-05	0.014	0.44	0.33	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
PCPG	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-4.27	3.41e-05	0.014	-0.51	-0.33	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-4.27	3.41e-05	0.014	-0.51	-0.33	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-4.27	3.41e-05	0.014	-0.51	-0.33	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
PCPG	cis	rs2625529	0.556	rs55679065	ENSG00000260037.4	CTD-2524L6.3	4.27	3.41e-05	0.014	0.43	0.33	Red blood cell count;	chr15:72141054	chr15:71818396~71823384:+
PCPG	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	4.27	3.41e-05	0.014	0.36	0.33	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
PCPG	cis	rs300890	0.76	rs13118846	ENSG00000250326.1	RP11-284M14.1	-4.27	3.42e-05	0.014	-0.3	-0.33	Nasopharyngeal carcinoma;	chr4:143289009	chr4:142933195~143184861:-
PCPG	cis	rs6974235	0.901	rs450	ENSG00000279067.1	GS1-25M2.1	4.27	3.42e-05	0.014	0.38	0.33	Total body bone mineral density;	chr7:96092922	chr7:96118647~96119995:+
PCPG	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-4.27	3.42e-05	0.014	-0.48	-0.33	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
PCPG	cis	rs6479901	0.639	rs871690	ENSG00000232075.1	MRPL35P2	-4.27	3.42e-05	0.014	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63634317~63634827:-
PCPG	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	4.27	3.42e-05	0.014	0.46	0.33	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
PCPG	cis	rs11214589	0.774	rs877137	ENSG00000256757.1	RP11-159N11.3	4.27	3.42e-05	0.014	0.35	0.33	Neuroticism;	chr11:113385608	chr11:113405321~113412117:+
PCPG	cis	rs4803480	0.529	rs4803481	ENSG00000267107.5	PCAT19	4.27	3.42e-05	0.014	0.27	0.33	Schizophrenia;	chr19:41560186	chr19:41454169~41500649:-
PCPG	cis	rs4803480	0.507	rs11083627	ENSG00000267107.5	PCAT19	4.27	3.42e-05	0.014	0.27	0.33	Schizophrenia;	chr19:41563530	chr19:41454169~41500649:-
PCPG	cis	rs4803480	0.554	rs12150975	ENSG00000267107.5	PCAT19	4.27	3.42e-05	0.014	0.27	0.33	Schizophrenia;	chr19:41563990	chr19:41454169~41500649:-
PCPG	cis	rs4803480	0.554	rs12983999	ENSG00000267107.5	PCAT19	4.27	3.42e-05	0.014	0.27	0.33	Schizophrenia;	chr19:41564158	chr19:41454169~41500649:-
PCPG	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-4.27	3.42e-05	0.014	-0.49	-0.33	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
PCPG	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-4.27	3.42e-05	0.014	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
PCPG	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	4.27	3.42e-05	0.014	0.41	0.33	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
PCPG	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-4.27	3.42e-05	0.014	-0.44	-0.33	Temperament;	chr17:14042870	chr17:14024514~14025488:+
PCPG	cis	rs1440410	0.93	rs4618266	ENSG00000250326.1	RP11-284M14.1	4.27	3.43e-05	0.0141	0.3	0.33	Ischemic stroke;	chr4:143114974	chr4:142933195~143184861:-
PCPG	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	4.27	3.43e-05	0.0141	0.39	0.33	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
PCPG	cis	rs3758911	0.929	rs10749895	ENSG00000255353.1	RP11-382M14.1	-4.27	3.43e-05	0.0141	-0.42	-0.33	Coronary artery disease;	chr11:107310855	chr11:107176286~107177530:+
PCPG	cis	rs1150668	0.796	rs2531832	ENSG00000219392.1	RP1-265C24.5	-4.27	3.44e-05	0.0141	-0.39	-0.33	Pubertal anthropometrics;	chr6:28421445	chr6:28115628~28116551:+
PCPG	cis	rs1150668	0.83	rs2023493	ENSG00000219392.1	RP1-265C24.5	-4.27	3.44e-05	0.0141	-0.39	-0.33	Pubertal anthropometrics;	chr6:28432385	chr6:28115628~28116551:+
PCPG	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	4.27	3.44e-05	0.0141	0.42	0.33	Height;	chr6:109618620	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	4.27	3.44e-05	0.0141	0.42	0.33	Height;	chr6:109620772	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	4.27	3.44e-05	0.0141	0.42	0.33	Height;	chr6:109634150	chr6:109382795~109383666:+
PCPG	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-4.27	3.44e-05	0.0141	-0.48	-0.33	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-4.27	3.44e-05	0.0141	-0.48	-0.33	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-4.27	3.44e-05	0.0141	-0.48	-0.33	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-4.27	3.44e-05	0.0141	-0.48	-0.33	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-4.27	3.44e-05	0.0141	-0.48	-0.33	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-4.27	3.44e-05	0.0141	-0.48	-0.33	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
PCPG	cis	rs748404	0.666	rs8027748	ENSG00000205771.5	CATSPER2P1	-4.27	3.44e-05	0.0141	-0.43	-0.33	Lung cancer;	chr15:43447622	chr15:43726918~43747094:-
PCPG	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	4.27	3.45e-05	0.0141	0.42	0.33	Height;	chr6:109546439	chr6:109382795~109383666:+
PCPG	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	4.27	3.45e-05	0.0141	0.42	0.33	Height;	chr6:109551060	chr6:109382795~109383666:+
PCPG	cis	rs1371867	0.846	rs1660346	ENSG00000212994.5	RPS26P6	4.27	3.45e-05	0.0141	0.39	0.33	Atrioventricular conduction;	chr8:100300269	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.817	rs1788208	ENSG00000212994.5	RPS26P6	4.27	3.45e-05	0.0141	0.39	0.33	Atrioventricular conduction;	chr8:100300287	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660347	ENSG00000212994.5	RPS26P6	4.27	3.45e-05	0.0141	0.39	0.33	Atrioventricular conduction;	chr8:100302752	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660349	ENSG00000212994.5	RPS26P6	4.27	3.45e-05	0.0141	0.39	0.33	Atrioventricular conduction;	chr8:100307098	chr8:100895771~100896118:+
PCPG	cis	rs7824557	0.606	rs2736270	ENSG00000255020.1	AF131216.5	4.27	3.45e-05	0.0141	0.44	0.33	Retinal vascular caliber;	chr8:11335084	chr8:11345748~11347502:-
PCPG	cis	rs4713118	0.629	rs203887	ENSG00000216901.1	AL022393.7	4.27	3.45e-05	0.0141	0.53	0.33	Parkinson's disease;	chr6:28053491	chr6:28176188~28176674:+
PCPG	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	4.27	3.45e-05	0.0141	0.53	0.33	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
PCPG	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	4.27	3.45e-05	0.0141	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
PCPG	cis	rs3758911	0.964	rs10749896	ENSG00000255353.1	RP11-382M14.1	-4.27	3.46e-05	0.0141	-0.42	-0.33	Coronary artery disease;	chr11:107314102	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs10789607	ENSG00000255353.1	RP11-382M14.1	-4.27	3.46e-05	0.0141	-0.42	-0.33	Coronary artery disease;	chr11:107314128	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs10789608	ENSG00000255353.1	RP11-382M14.1	-4.27	3.46e-05	0.0141	-0.42	-0.33	Coronary artery disease;	chr11:107314132	chr11:107176286~107177530:+
PCPG	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	4.27	3.46e-05	0.0141	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
PCPG	cis	rs12681963	0.688	rs4262289	ENSG00000248159.1	HSPA8P11	4.27	3.46e-05	0.0142	0.69	0.33	Migraine;	chr8:30191588	chr8:30237382~30240997:+
PCPG	cis	rs853679	0.599	rs13193295	ENSG00000219392.1	RP1-265C24.5	-4.27	3.46e-05	0.0142	-0.72	-0.33	Depression;	chr6:28035450	chr6:28115628~28116551:+
PCPG	cis	rs8030379	1	rs11259933	ENSG00000230373.7	GOLGA6L5P	-4.27	3.46e-05	0.0142	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911404	chr15:84507885~84516814:-
PCPG	cis	rs6519955	0.866	rs9626920	ENSG00000231711.2	LINC00899	-4.27	3.47e-05	0.0142	-0.31	-0.33	Dupuytren's disease;	chr22:46033113	chr22:46039907~46044853:-
PCPG	cis	rs1371867	0.846	rs1660338	ENSG00000212994.5	RPS26P6	4.27	3.47e-05	0.0142	0.38	0.33	Atrioventricular conduction;	chr8:100230529	chr8:100895771~100896118:+
PCPG	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-4.27	3.47e-05	0.0142	-0.41	-0.33	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
PCPG	cis	rs2797160	0.837	rs1739364	ENSG00000237742.5	RP11-624M8.1	-4.27	3.47e-05	0.0142	-0.33	-0.33	Endometrial cancer;	chr6:125701237	chr6:125578558~125749190:-
PCPG	cis	rs937213	0.608	rs7177179	ENSG00000259584.1	RP11-521C20.2	4.27	3.47e-05	0.0142	0.4	0.33	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39995781	chr15:40075204~40078704:-
PCPG	cis	rs13118159	0.509	rs10023473	ENSG00000254094.1	AC078852.1	-4.27	3.47e-05	0.0142	-0.4	-0.33	Longevity;	chr4:1381497	chr4:1356581~1358075:+
PCPG	cis	rs11858159	1	rs67007380	ENSG00000259905.4	PWRN1	4.27	3.47e-05	0.0142	0.38	0.33	Platelet thrombus formation;	chr15:24553007	chr15:24493137~24652130:+
PCPG	cis	rs1440410	0.835	rs9790822	ENSG00000250326.1	RP11-284M14.1	4.27	3.47e-05	0.0142	0.31	0.33	Ischemic stroke;	chr4:143130748	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4323054	ENSG00000250326.1	RP11-284M14.1	4.27	3.47e-05	0.0142	0.31	0.33	Ischemic stroke;	chr4:143130970	chr4:142933195~143184861:-
PCPG	cis	rs6504340	0.741	rs35624684	ENSG00000279036.1	RP11-81K2.2	-4.27	3.47e-05	0.0142	-0.57	-0.33	Primary tooth development (number of teeth);	chr17:48581113	chr17:49494223~49497800:-
PCPG	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	4.27	3.47e-05	0.0142	0.47	0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
PCPG	cis	rs1440410	0.571	rs4690768	ENSG00000250326.1	RP11-284M14.1	-4.27	3.48e-05	0.0142	-0.3	-0.33	Ischemic stroke;	chr4:143118125	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs7675127	ENSG00000250326.1	RP11-284M14.1	-4.27	3.48e-05	0.0142	-0.3	-0.33	Ischemic stroke;	chr4:143119916	chr4:142933195~143184861:-
PCPG	cis	rs2836974	0.897	rs2836928	ENSG00000252915.1	Y_RNA	-4.27	3.48e-05	0.0142	-0.36	-0.33	Cognitive function;	chr21:39171394	chr21:39344537~39344628:+
PCPG	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	4.27	3.48e-05	0.0142	0.32	0.33	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	4.27	3.48e-05	0.0142	0.32	0.33	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
PCPG	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	4.27	3.48e-05	0.0142	0.55	0.33	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
PCPG	cis	rs10200850	0.881	rs10189520	ENSG00000265215.1	MIR4269	4.27	3.48e-05	0.0142	0.55	0.33	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239329222	chr2:239305462~239305545:+
PCPG	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	4.27	3.48e-05	0.0142	0.38	0.33	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
PCPG	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	4.27	3.49e-05	0.0143	0.44	0.33	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
PCPG	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	4.27	3.49e-05	0.0143	0.44	0.33	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
PCPG	cis	rs748404	0.666	rs66629206	ENSG00000205771.5	CATSPER2P1	-4.27	3.49e-05	0.0143	-0.43	-0.33	Lung cancer;	chr15:43458804	chr15:43726918~43747094:-
PCPG	cis	rs7017914	0.69	rs10453108	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70870705	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs7003794	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70876911	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.714	rs1982884	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70877318	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs13255749	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70889586	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs11985482	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70898343	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.583	rs7838671	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70899057	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs13248937	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70906514	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs6992048	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70911636	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs6984663	ENSG00000254031.4	RP11-326E22.1	4.27	3.49e-05	0.0143	0.31	0.33	Bone mineral density;	chr8:70915430	chr8:71155457~71204223:+
PCPG	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	4.27	3.49e-05	0.0143	0.37	0.33	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
PCPG	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-4.27	3.49e-05	0.0143	-0.48	-0.33	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
PCPG	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	4.27	3.49e-05	0.0143	0.45	0.33	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
PCPG	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	4.27	3.49e-05	0.0143	0.46	0.33	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
PCPG	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	4.27	3.5e-05	0.0143	0.37	0.33	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
PCPG	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	4.27	3.5e-05	0.0143	0.42	0.33	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	4.27	3.5e-05	0.0143	0.42	0.33	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
PCPG	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	4.27	3.5e-05	0.0143	0.27	0.33	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	4.27	3.5e-05	0.0143	0.27	0.33	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	4.27	3.5e-05	0.0143	0.27	0.33	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
PCPG	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	4.27	3.5e-05	0.0143	0.36	0.33	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
PCPG	cis	rs1048886	0.872	rs10945231	ENSG00000271967.1	RP11-134K13.4	-4.27	3.5e-05	0.0143	-0.39	-0.33	Type 2 diabetes;	chr6:70588060	chr6:70596438~70596980:+
PCPG	cis	rs8042680	0.522	rs8026678	ENSG00000214432.8	AC068831.10	-4.27	3.5e-05	0.0143	-0.37	-0.33	Type 2 diabetes;	chr15:91018775	chr15:91022619~91036611:+
PCPG	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	4.27	3.51e-05	0.0143	0.45	0.33	Height;	chr6:109375848	chr6:109382795~109383666:+
PCPG	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-4.27	3.51e-05	0.0143	-0.48	-0.33	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-4.27	3.51e-05	0.0143	-0.48	-0.33	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-4.27	3.51e-05	0.0143	-0.48	-0.33	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
PCPG	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	4.27	3.51e-05	0.0143	0.4	0.33	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
PCPG	cis	rs10200850	0.892	rs925737	ENSG00000265215.1	MIR4269	4.27	3.51e-05	0.0143	0.54	0.33	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239330556	chr2:239305462~239305545:+
PCPG	cis	rs10200850	0.892	rs13407112	ENSG00000265215.1	MIR4269	4.27	3.51e-05	0.0143	0.54	0.33	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239331167	chr2:239305462~239305545:+
PCPG	cis	rs10200850	0.892	rs72992666	ENSG00000265215.1	MIR4269	4.27	3.51e-05	0.0143	0.54	0.33	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239331932	chr2:239305462~239305545:+
PCPG	cis	rs10200850	0.892	rs4852048	ENSG00000265215.1	MIR4269	4.27	3.51e-05	0.0143	0.54	0.33	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239336906	chr2:239305462~239305545:+
PCPG	cis	rs9303029	1	rs9911854	ENSG00000279744.1	RP13-20L14.10	-4.27	3.51e-05	0.0143	-0.41	-0.33	Protein quantitative trait loci;	chr17:82450472	chr17:82462601~82464255:+
PCPG	cis	rs10411161	0.702	rs11879319	ENSG00000275055.1	CTC-471J1.11	-4.27	3.51e-05	0.0143	-0.35	-0.33	Breast cancer;	chr19:51886339	chr19:52049007~52049754:+
PCPG	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	4.27	3.51e-05	0.0143	0.35	0.33	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
PCPG	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	4.27	3.51e-05	0.0143	0.47	0.33	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	4.27	3.51e-05	0.0143	0.47	0.33	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
PCPG	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-4.27	3.52e-05	0.0143	-0.38	-0.33	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
PCPG	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	4.27	3.52e-05	0.0144	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	4.27	3.52e-05	0.0144	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
PCPG	cis	rs7247513	0.866	rs2861405	ENSG00000213290.4	PGK1P2	-4.27	3.52e-05	0.0144	-0.47	-0.33	Bipolar disorder;	chr19:12611518	chr19:12559571~12561105:+
PCPG	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-4.27	3.52e-05	0.0144	-0.4	-0.33	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
PCPG	cis	rs7819412	0.537	rs2127127	ENSG00000269954.1	RP11-148O21.6	-4.27	3.52e-05	0.0144	-0.38	-0.33	Triglycerides;	chr8:11577283	chr8:11552488~11552991:-
PCPG	cis	rs2243480	1	rs1404147	ENSG00000251451.1	GS1-124K5.6	4.26	3.52e-05	0.0144	0.59	0.33	Diabetic kidney disease;	chr7:65799537	chr7:66407288~66409239:-
PCPG	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-4.26	3.53e-05	0.0144	-0.44	-0.33	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
PCPG	cis	rs1048886	0.872	rs76513668	ENSG00000271967.1	RP11-134K13.4	-4.26	3.53e-05	0.0144	-0.41	-0.33	Type 2 diabetes;	chr6:70465172	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs79485742	ENSG00000271967.1	RP11-134K13.4	-4.26	3.53e-05	0.0144	-0.41	-0.33	Type 2 diabetes;	chr6:70465305	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs74749095	ENSG00000271967.1	RP11-134K13.4	-4.26	3.53e-05	0.0144	-0.41	-0.33	Type 2 diabetes;	chr6:70467165	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs76309923	ENSG00000271967.1	RP11-134K13.4	-4.26	3.53e-05	0.0144	-0.41	-0.33	Type 2 diabetes;	chr6:70471257	chr6:70596438~70596980:+
PCPG	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	4.26	3.53e-05	0.0144	0.33	0.33	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
PCPG	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-4.26	3.53e-05	0.0144	-0.48	-0.33	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-4.26	3.53e-05	0.0144	-0.48	-0.33	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-4.26	3.53e-05	0.0144	-0.48	-0.33	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-4.26	3.53e-05	0.0144	-0.48	-0.33	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-4.26	3.53e-05	0.0144	-0.48	-0.33	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-4.26	3.53e-05	0.0144	-0.48	-0.33	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
PCPG	cis	rs28386778	0.933	rs2665804	ENSG00000240280.5	TCAM1P	-4.26	3.53e-05	0.0144	-0.43	-0.33	Prudent dietary pattern;	chr17:63874476	chr17:63849292~63864379:+
PCPG	cis	rs12681963	0.688	rs2958746	ENSG00000248159.1	HSPA8P11	-4.26	3.53e-05	0.0144	-0.65	-0.33	Migraine;	chr8:30231554	chr8:30237382~30240997:+
PCPG	cis	rs3806843	0.966	rs11958868	ENSG00000202515.1	VTRNA1-3	-4.26	3.53e-05	0.0144	-0.43	-0.33	Depressive symptoms (multi-trait analysis);	chr5:140821835	chr5:140726158~140726246:+
PCPG	cis	rs11858159	0.627	rs7166584	ENSG00000260760.1	PWRN3	4.26	3.54e-05	0.0144	0.36	0.33	Platelet thrombus formation;	chr15:24555585	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs28688952	ENSG00000260760.1	PWRN3	4.26	3.54e-05	0.0144	0.36	0.33	Platelet thrombus formation;	chr15:24576460	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs12900960	ENSG00000260760.1	PWRN3	4.26	3.54e-05	0.0144	0.36	0.33	Platelet thrombus formation;	chr15:24576461	chr15:24441127~24447967:+
PCPG	cis	rs28386778	0.897	rs2584601	ENSG00000240280.5	TCAM1P	-4.26	3.54e-05	0.0144	-0.44	-0.33	Prudent dietary pattern;	chr17:63863617	chr17:63849292~63864379:+
PCPG	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	4.26	3.55e-05	0.0145	0.42	0.33	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
PCPG	cis	rs75804782	0.63	rs56304316	ENSG00000227107.1	AC096574.5	-4.26	3.55e-05	0.0145	-0.57	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238344625	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.572	rs55764347	ENSG00000227107.1	AC096574.5	-4.26	3.55e-05	0.0145	-0.57	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238344888	chr2:237612977~237626525:+
PCPG	cis	rs12906542	0.516	rs10444863	ENSG00000259792.1	RP11-114H24.6	-4.26	3.55e-05	0.0145	-0.42	-0.33	Breast cancer;	chr15:78066495	chr15:77993405~77995289:+
PCPG	cis	rs7772486	0.686	rs9376961	ENSG00000270638.1	RP3-466P17.1	4.26	3.55e-05	0.0145	0.34	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145735570~145737218:+
PCPG	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-4.26	3.55e-05	0.0145	-0.48	-0.33	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
PCPG	cis	rs3858704	0.517	rs7297186	ENSG00000257595.2	RP3-473L9.4	-4.26	3.55e-05	0.0145	-0.41	-0.33	Idiopathic osteonecrosis of the femoral head;	chr12:111340374	chr12:111369282~111403310:+
PCPG	cis	rs7208859	0.673	rs216440	ENSG00000266490.1	CTD-2349P21.9	4.26	3.55e-05	0.0145	0.38	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30792372~30792833:+
PCPG	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	4.26	3.55e-05	0.0145	0.36	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
PCPG	cis	rs1003719	0.715	rs9974494	ENSG00000228677.1	TTC3-AS1	-4.26	3.55e-05	0.0145	-0.41	-0.33	Eye color traits;	chr21:37194265	chr21:37187666~37193926:-
PCPG	cis	rs11148252	0.74	rs9596642	ENSG00000278238.1	RP11-245D16.4	4.26	3.56e-05	0.0145	0.3	0.33	Lewy body disease;	chr13:52326744	chr13:52454775~52455331:-
PCPG	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	4.26	3.56e-05	0.0145	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
PCPG	cis	rs8030379	0.967	rs7182563	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83879994	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs11629657	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880228	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs7181926	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880676	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs6603000	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883142	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs12916223	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883742	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.875	rs28801104	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884091	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs12900412	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884314	chr15:84507885~84516814:-
PCPG	cis	rs8030379	0.967	rs2401171	ENSG00000230373.7	GOLGA6L5P	-4.26	3.56e-05	0.0145	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83888924	chr15:84507885~84516814:-
PCPG	cis	rs66731853	0.769	rs530104	ENSG00000117242.7	PINK1-AS	4.26	3.56e-05	0.0145	0.39	0.33	Mean corpuscular volume;	chr1:20569228	chr1:20642657~20652193:-
PCPG	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-4.26	3.56e-05	0.0145	-0.4	-0.33	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
PCPG	cis	rs7017914	0.69	rs7013495	ENSG00000254031.4	RP11-326E22.1	4.26	3.56e-05	0.0145	0.31	0.33	Bone mineral density;	chr8:70781282	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs10429277	ENSG00000254031.4	RP11-326E22.1	4.26	3.56e-05	0.0145	0.31	0.33	Bone mineral density;	chr8:70789156	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs13255849	ENSG00000254031.4	RP11-326E22.1	4.26	3.56e-05	0.0145	0.31	0.33	Bone mineral density;	chr8:70840518	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.653	rs6472548	ENSG00000254031.4	RP11-326E22.1	4.26	3.56e-05	0.0145	0.31	0.33	Bone mineral density;	chr8:70842064	chr8:71155457~71204223:+
PCPG	cis	rs7017914	0.69	rs1156956	ENSG00000254031.4	RP11-326E22.1	4.26	3.56e-05	0.0145	0.31	0.33	Bone mineral density;	chr8:70842803	chr8:71155457~71204223:+
PCPG	cis	rs950169	0.544	rs2036949	ENSG00000259295.5	CSPG4P12	4.26	3.56e-05	0.0145	0.48	0.33	Schizophrenia;	chr15:84620374	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs11635597	ENSG00000259295.5	CSPG4P12	4.26	3.56e-05	0.0145	0.48	0.33	Schizophrenia;	chr15:84622468	chr15:85191438~85213905:+
PCPG	cis	rs4376189	0.51	rs6836237	ENSG00000207497.1	Y_RNA	4.26	3.56e-05	0.0145	0.48	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185718896	chr4:185709873~185709967:-
PCPG	cis	rs4376189	0.558	rs4862565	ENSG00000207497.1	Y_RNA	4.26	3.56e-05	0.0145	0.48	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185719435	chr4:185709873~185709967:-
PCPG	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	4.26	3.57e-05	0.0145	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
PCPG	cis	rs748404	0.626	rs62021176	ENSG00000205771.5	CATSPER2P1	-4.26	3.57e-05	0.0145	-0.43	-0.33	Lung cancer;	chr15:43388014	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs35158584	ENSG00000205771.5	CATSPER2P1	-4.26	3.57e-05	0.0145	-0.43	-0.33	Lung cancer;	chr15:43392876	chr15:43726918~43747094:-
PCPG	cis	rs17772222	0.958	rs61579615	ENSG00000222990.1	RNU4-22P	4.26	3.57e-05	0.0145	0.45	0.33	Coronary artery calcification;	chr14:88400054	chr14:88513498~88513663:+
PCPG	cis	rs17772222	1	rs12589480	ENSG00000222990.1	RNU4-22P	4.26	3.57e-05	0.0145	0.45	0.33	Coronary artery calcification;	chr14:88414926	chr14:88513498~88513663:+
PCPG	cis	rs17772222	1	rs61977058	ENSG00000222990.1	RNU4-22P	4.26	3.57e-05	0.0145	0.45	0.33	Coronary artery calcification;	chr14:88415571	chr14:88513498~88513663:+
PCPG	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-4.26	3.57e-05	0.0145	-0.47	-0.33	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
PCPG	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	4.26	3.57e-05	0.0145	0.32	0.33	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
PCPG	cis	rs8098244	0.58	rs1620152	ENSG00000265752.2	RP11-403A21.1	4.26	3.58e-05	0.0146	0.39	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23678335	chr18:23957754~23982556:-
PCPG	cis	rs6674176	0.66	rs6680421	ENSG00000237950.1	RP11-7O11.3	-4.26	3.58e-05	0.0146	-0.4	-0.33	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43943297	chr1:43944370~43946551:-
PCPG	cis	rs2243480	1	rs160655	ENSG00000230189.5	GS1-124K5.2	4.26	3.58e-05	0.0146	0.51	0.33	Diabetic kidney disease;	chr7:66068227	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.803	rs160649	ENSG00000230189.5	GS1-124K5.2	4.26	3.58e-05	0.0146	0.51	0.33	Diabetic kidney disease;	chr7:66078212	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs160648	ENSG00000230189.5	GS1-124K5.2	4.26	3.58e-05	0.0146	0.51	0.33	Diabetic kidney disease;	chr7:66078397	chr7:66409143~66490059:-
PCPG	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-4.26	3.59e-05	0.0146	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
PCPG	cis	rs2732480	0.577	rs2634681	ENSG00000240399.1	RP1-228P16.1	-4.26	3.59e-05	0.0146	-0.34	-0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48054813~48055591:-
PCPG	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	4.26	3.59e-05	0.0146	0.44	0.33	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
PCPG	cis	rs2836974	0.931	rs2989330	ENSG00000252915.1	Y_RNA	-4.26	3.59e-05	0.0146	-0.37	-0.33	Cognitive function;	chr21:39344283	chr21:39344537~39344628:+
PCPG	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-4.26	3.59e-05	0.0146	-0.48	-0.33	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
PCPG	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-4.26	3.59e-05	0.0146	-0.42	-0.33	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
PCPG	cis	rs2439831	1	rs2253708	ENSG00000205771.5	CATSPER2P1	-4.26	3.59e-05	0.0146	-0.46	-0.33	Lung cancer in ever smokers;	chr15:43505075	chr15:43726918~43747094:-
PCPG	cis	rs889122	0.531	rs8113425	ENSG00000267289.1	CTD-2623N2.11	-4.26	3.6e-05	0.0146	-0.39	-0.33	Menarche (age at onset);	chr19:9889630	chr19:9834079~9835013:-
PCPG	cis	rs3806843	0.648	rs702399	ENSG00000202515.1	VTRNA1-3	4.26	3.6e-05	0.0146	0.4	0.33	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr5:140726158~140726246:+
PCPG	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	4.26	3.6e-05	0.0146	0.49	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
PCPG	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-4.26	3.61e-05	0.0147	-0.29	-0.33	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
PCPG	cis	rs57502260	0.573	rs11228294	ENSG00000212093.1	AP000807.1	4.26	3.61e-05	0.0147	0.3	0.33	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:68506083~68506166:-
PCPG	cis	rs853679	0.567	rs3799499	ENSG00000219392.1	RP1-265C24.5	-4.26	3.61e-05	0.0147	-0.44	-0.33	Depression;	chr6:28386473	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.567	rs2232427	ENSG00000219392.1	RP1-265C24.5	-4.26	3.61e-05	0.0147	-0.44	-0.33	Depression;	chr6:28391932	chr6:28115628~28116551:+
PCPG	cis	rs11858159	0.756	rs12901793	ENSG00000259905.4	PWRN1	4.26	3.61e-05	0.0147	0.38	0.33	Platelet thrombus formation;	chr15:24546224	chr15:24493137~24652130:+
PCPG	cis	rs2060793	0.741	rs4344519	ENSG00000251991.1	RNU7-49P	4.26	3.61e-05	0.0147	0.36	0.33	Vitamin D levels;	chr11:14701347	chr11:14478892~14478953:+
PCPG	cis	rs2060793	0.712	rs11023310	ENSG00000251991.1	RNU7-49P	4.26	3.61e-05	0.0147	0.36	0.33	Vitamin D levels;	chr11:14703717	chr11:14478892~14478953:+
PCPG	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	4.26	3.61e-05	0.0147	0.35	0.33	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
PCPG	cis	rs4819052	0.851	rs1056101	ENSG00000223768.1	LINC00205	-4.26	3.61e-05	0.0147	-0.43	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45293285~45297354:+
PCPG	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	4.26	3.61e-05	0.0147	0.36	0.33	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
PCPG	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	4.26	3.61e-05	0.0147	0.38	0.33	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	4.26	3.61e-05	0.0147	0.38	0.33	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
PCPG	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	4.26	3.62e-05	0.0147	0.37	0.33	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
PCPG	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	4.26	3.62e-05	0.0147	0.44	0.33	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
PCPG	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	4.26	3.62e-05	0.0147	0.47	0.33	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
PCPG	cis	rs9388451	0.868	rs1268083	ENSG00000237742.5	RP11-624M8.1	4.26	3.63e-05	0.0147	0.35	0.33	Brugada syndrome;	chr6:125727894	chr6:125578558~125749190:-
PCPG	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	4.26	3.63e-05	0.0147	0.38	0.33	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
PCPG	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	4.26	3.63e-05	0.0147	0.4	0.33	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
PCPG	cis	rs8098244	0.537	rs7236794	ENSG00000265752.2	RP11-403A21.1	4.26	3.63e-05	0.0147	0.37	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23697706	chr18:23957754~23982556:-
PCPG	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-4.26	3.63e-05	0.0147	-0.39	-0.33	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
PCPG	cis	rs8049040	0.521	rs12935725	ENSG00000260886.1	TAT-AS1	4.26	3.63e-05	0.0147	0.51	0.33	Blood protein levels;	chr16:71535485	chr16:71565789~71578187:+
PCPG	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-4.26	3.64e-05	0.0148	-0.41	-0.33	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
PCPG	cis	rs7819412	0.539	rs11250131	ENSG00000255020.1	AF131216.5	-4.26	3.64e-05	0.0148	-0.41	-0.33	Triglycerides;	chr8:11393666	chr8:11345748~11347502:-
PCPG	cis	rs847649	0.961	rs10250490	ENSG00000252643.1	RNU6-1136P	-4.26	3.64e-05	0.0148	-0.4	-0.33	Morning vs. evening chronotype;	chr7:102896830	chr7:102834605~102834708:+
PCPG	cis	rs847649	1	rs12537977	ENSG00000252643.1	RNU6-1136P	-4.26	3.64e-05	0.0148	-0.4	-0.33	Morning vs. evening chronotype;	chr7:102898783	chr7:102834605~102834708:+
PCPG	cis	rs4819052	0.788	rs13049700	ENSG00000223768.1	LINC00205	-4.26	3.64e-05	0.0148	-0.4	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45293285~45297354:+
PCPG	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-4.26	3.64e-05	0.0148	-0.37	-0.33	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
PCPG	cis	rs6840258	0.76	rs340643	ENSG00000251411.1	RP11-397E7.4	-4.26	3.64e-05	0.0148	-0.34	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87026006	chr4:86913266~86914817:-
PCPG	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-4.26	3.65e-05	0.0148	-0.49	-0.33	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
PCPG	cis	rs748404	0.666	rs12899865	ENSG00000249839.1	AC011330.5	-4.26	3.65e-05	0.0148	-0.43	-0.33	Lung cancer;	chr15:43448819	chr15:43663654~43684339:-
PCPG	cis	rs7181230	0.885	rs3923235	ENSG00000259584.1	RP11-521C20.2	4.26	3.65e-05	0.0148	0.44	0.33	Dehydroepiandrosterone sulphate levels;	chr15:40078920	chr15:40075204~40078704:-
PCPG	cis	rs300890	1	rs300890	ENSG00000250326.1	RP11-284M14.1	4.26	3.66e-05	0.0148	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143328617	chr4:142933195~143184861:-
PCPG	cis	rs300890	1	rs300891	ENSG00000250326.1	RP11-284M14.1	4.26	3.66e-05	0.0148	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143329058	chr4:142933195~143184861:-
PCPG	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-4.26	3.66e-05	0.0148	-0.35	-0.33	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
PCPG	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-4.26	3.66e-05	0.0148	-0.48	-0.33	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-4.26	3.66e-05	0.0148	-0.48	-0.33	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
PCPG	cis	rs8064024	0.87	rs6500635	ENSG00000267077.1	RP11-127I20.5	4.26	3.67e-05	0.0149	0.4	0.33	Cancer;	chr16:4817564	chr16:4795265~4796532:-
PCPG	cis	rs73201462	1	rs2811528	ENSG00000242551.2	POU5F1P6	-4.25	3.67e-05	0.0149	-0.6	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275593	chr3:128674735~128677005:-
PCPG	cis	rs7208859	0.623	rs216436	ENSG00000263603.1	CTD-2349P21.5	-4.25	3.67e-05	0.0149	-0.57	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30729469~30731202:+
PCPG	cis	rs2733954	0.707	rs2072627	ENSG00000179219.5	LINC00311	-4.25	3.67e-05	0.0149	-0.48	-0.33	Leprosy;	chr16:85800131	chr16:85282958~85285963:+
PCPG	cis	rs4934494	0.813	rs34928397	ENSG00000240996.1	RP11-80H5.7	-4.25	3.67e-05	0.0149	-0.49	-0.33	Red blood cell count;	chr10:89766842	chr10:89694295~89697928:-
PCPG	cis	rs2625529	0.617	rs13858	ENSG00000260037.4	CTD-2524L6.3	-4.25	3.67e-05	0.0149	-0.43	-0.33	Red blood cell count;	chr15:72140803	chr15:71818396~71823384:+
PCPG	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	4.25	3.67e-05	0.0149	0.29	0.33	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
PCPG	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.67e-05	0.0149	-0.41	-0.33	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.67e-05	0.0149	-0.41	-0.33	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.67e-05	0.0149	-0.41	-0.33	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.67e-05	0.0149	-0.41	-0.33	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
PCPG	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.67e-05	0.0149	-0.41	-0.33	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.67e-05	0.0149	-0.41	-0.33	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.67e-05	0.0149	-0.41	-0.33	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
PCPG	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	4.25	3.68e-05	0.0149	0.41	0.33	Height;	chr6:109506513	chr6:109382795~109383666:+
PCPG	cis	rs8098244	0.708	rs1154244	ENSG00000265752.2	RP11-403A21.1	4.25	3.68e-05	0.0149	0.46	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964052	chr18:23957754~23982556:-
PCPG	cis	rs950169	0.58	rs1061737	ENSG00000259295.5	CSPG4P12	4.25	3.68e-05	0.0149	0.49	0.33	Schizophrenia;	chr15:84640559	chr15:85191438~85213905:+
PCPG	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	4.25	3.69e-05	0.0149	0.42	0.33	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	4.25	3.69e-05	0.0149	0.34	0.33	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
PCPG	cis	rs733592	0.504	rs2261608	ENSG00000258273.1	RP11-370I10.4	-4.25	3.69e-05	0.0149	-0.34	-0.33	Plateletcrit;	chr12:48327851	chr12:48333755~48333901:-
PCPG	cis	rs539514	0.516	rs2273996	ENSG00000261105.4	LMO7-AS1	-4.25	3.69e-05	0.0149	-0.45	-0.33	Type 1 diabetes;	chr13:75836589	chr13:75604700~75635994:-
PCPG	cis	rs9302635	0.626	rs34508528	ENSG00000260886.1	TAT-AS1	4.25	3.69e-05	0.0149	0.52	0.33	Blood protein levels;	chr16:72181216	chr16:71565789~71578187:+
PCPG	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-4.25	3.69e-05	0.0149	-0.39	-0.33	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
PCPG	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-4.25	3.69e-05	0.0149	-0.36	-0.33	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
PCPG	cis	rs6121246	0.909	rs6060679	ENSG00000230613.1	HM13-AS1	-4.25	3.7e-05	0.015	-0.47	-0.33	Mean corpuscular hemoglobin;	chr20:31682969	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.821	rs3181073	ENSG00000230613.1	HM13-AS1	-4.25	3.7e-05	0.015	-0.47	-0.33	Mean corpuscular hemoglobin;	chr20:31719396	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6060633	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31675514	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs2376992	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31675615	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6060644	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31677849	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs1994250	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31699691	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs1994249	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31699790	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6060812	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31705000	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.865	rs6058421	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31707210	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6060870	ENSG00000230613.1	HM13-AS1	4.25	3.7e-05	0.015	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31715496	chr20:31567707~31573263:-
PCPG	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-4.25	3.7e-05	0.015	-0.48	-0.33	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-4.25	3.7e-05	0.015	-0.48	-0.33	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-4.25	3.7e-05	0.015	-0.48	-0.33	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-4.25	3.7e-05	0.015	-0.48	-0.33	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
PCPG	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-4.25	3.7e-05	0.015	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-4.25	3.7e-05	0.015	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-4.25	3.7e-05	0.015	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-4.25	3.7e-05	0.015	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-4.25	3.7e-05	0.015	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
PCPG	cis	rs13118159	0.573	rs4974618	ENSG00000254094.1	AC078852.1	-4.25	3.7e-05	0.015	-0.4	-0.33	Longevity;	chr4:1379875	chr4:1356581~1358075:+
PCPG	cis	rs13118159	0.55	rs28614045	ENSG00000254094.1	AC078852.1	-4.25	3.7e-05	0.015	-0.4	-0.33	Longevity;	chr4:1380907	chr4:1356581~1358075:+
PCPG	cis	rs13118159	0.55	rs28522910	ENSG00000254094.1	AC078852.1	-4.25	3.7e-05	0.015	-0.4	-0.33	Longevity;	chr4:1380986	chr4:1356581~1358075:+
PCPG	cis	rs964611	0.882	rs8025164	ENSG00000259488.2	RP11-154J22.1	4.25	3.7e-05	0.015	0.32	0.33	Metabolite levels (Pyroglutamine);	chr15:48346517	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs79379792	ENSG00000259488.2	RP11-154J22.1	-4.25	3.7e-05	0.015	-0.32	-0.33	Metabolite levels (Pyroglutamine);	chr15:48351980	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs13380180	ENSG00000259488.2	RP11-154J22.1	-4.25	3.7e-05	0.015	-0.32	-0.33	Metabolite levels (Pyroglutamine);	chr15:48352572	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs13379705	ENSG00000259488.2	RP11-154J22.1	-4.25	3.7e-05	0.015	-0.32	-0.33	Metabolite levels (Pyroglutamine);	chr15:48352611	chr15:48312353~48331856:-
PCPG	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	4.25	3.7e-05	0.015	0.47	0.33	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
PCPG	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	4.25	3.71e-05	0.015	0.46	0.33	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	4.25	3.71e-05	0.015	0.46	0.33	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
PCPG	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	4.25	3.71e-05	0.015	0.46	0.33	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
PCPG	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-4.25	3.71e-05	0.015	-0.26	-0.33	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
PCPG	cis	rs2212361	0.558	rs7934178	ENSG00000255893.1	RP11-685N10.1	-4.25	3.71e-05	0.015	-0.41	-0.33	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531307	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs7934183	ENSG00000255893.1	RP11-685N10.1	-4.25	3.71e-05	0.015	-0.41	-0.33	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531321	chr11:94472908~94473570:-
PCPG	cis	rs3764021	0.84	rs10743823	ENSG00000278635.1	CTD-2318O12.1	-4.25	3.71e-05	0.015	-0.4	-0.33	Type 1 diabetes;	chr12:9728529	chr12:9415641~9416718:+
PCPG	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	4.25	3.72e-05	0.015	0.46	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
PCPG	cis	rs972540	0.64	rs35382888	ENSG00000279220.1	GPR1-AS	4.25	3.72e-05	0.015	0.4	0.33	Body mass index;	chr2:206325964	chr2:206203376~206266243:+
PCPG	cis	rs972540	0.64	rs34427052	ENSG00000279220.1	GPR1-AS	4.25	3.72e-05	0.015	0.4	0.33	Body mass index;	chr2:206326497	chr2:206203376~206266243:+
PCPG	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	4.25	3.72e-05	0.015	0.51	0.33	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
PCPG	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-4.25	3.72e-05	0.015	-0.43	-0.33	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
PCPG	cis	rs4819052	0.851	rs9977178	ENSG00000215447.6	BX322557.10	-4.25	3.72e-05	0.015	-0.31	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45288052~45291738:+
PCPG	cis	rs8098244	0.638	rs1941516	ENSG00000265752.2	RP11-403A21.1	4.25	3.72e-05	0.015	0.37	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23812603	chr18:23957754~23982556:-
PCPG	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	4.25	3.73e-05	0.0151	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
PCPG	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-4.25	3.73e-05	0.0151	-0.47	-0.33	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
PCPG	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-4.25	3.73e-05	0.0151	-0.42	-0.33	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
PCPG	cis	rs4919687	0.55	rs10437480	ENSG00000269609.4	RPARP-AS1	-4.25	3.73e-05	0.0151	-0.28	-0.33	Colorectal cancer;	chr10:102693267	chr10:102449817~102461106:+
PCPG	cis	rs4919687	0.55	rs4264100	ENSG00000269609.4	RPARP-AS1	-4.25	3.73e-05	0.0151	-0.28	-0.33	Colorectal cancer;	chr10:102694356	chr10:102449817~102461106:+
PCPG	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	4.25	3.73e-05	0.0151	0.33	0.33	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
PCPG	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-4.25	3.74e-05	0.0151	-0.52	-0.33	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
PCPG	cis	rs115344852	0.598	rs2191035	ENSG00000216901.1	AL022393.7	4.25	3.74e-05	0.0151	0.44	0.33	Epithelial ovarian cancer;	chr6:28467166	chr6:28176188~28176674:+
PCPG	cis	rs115344852	0.598	rs2531815	ENSG00000216901.1	AL022393.7	4.25	3.74e-05	0.0151	0.44	0.33	Epithelial ovarian cancer;	chr6:28468283	chr6:28176188~28176674:+
PCPG	cis	rs950169	0.959	rs12902070	ENSG00000235370.6	DNM1P51	4.25	3.74e-05	0.0151	0.34	0.33	Schizophrenia;	chr15:84124806	chr15:84398316~84411701:-
PCPG	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-4.25	3.74e-05	0.0151	-0.48	-0.33	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-4.25	3.74e-05	0.0151	-0.48	-0.33	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
PCPG	cis	rs10504130	0.569	rs11775611	ENSG00000272024.1	RP11-546K22.3	-4.25	3.74e-05	0.0151	-0.42	-0.33	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51950284~51950690:+
PCPG	cis	rs8098244	0.603	rs4800507	ENSG00000265752.2	RP11-403A21.1	4.25	3.74e-05	0.0151	0.39	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23726168	chr18:23957754~23982556:-
PCPG	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	4.25	3.74e-05	0.0151	0.46	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
PCPG	cis	rs4819052	0.851	rs2838831	ENSG00000215447.6	BX322557.10	-4.25	3.75e-05	0.0151	-0.31	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45288052~45291738:+
PCPG	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-4.25	3.75e-05	0.0151	-0.39	-0.33	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
PCPG	cis	rs9595908	0.645	rs4942924	ENSG00000212293.1	SNORA16	4.25	3.75e-05	0.0151	0.4	0.33	Body mass index;	chr13:32806987	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.568	rs4942926	ENSG00000212293.1	SNORA16	4.25	3.75e-05	0.0151	0.4	0.33	Body mass index;	chr13:32807204	chr13:32420390~32420516:-
PCPG	cis	rs9990333	0.562	rs12632706	ENSG00000235897.1	TM4SF19-AS1	4.25	3.75e-05	0.0151	0.37	0.33	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:196318330~196325570:+
PCPG	cis	rs8030379	1	rs1564473	ENSG00000230373.7	GOLGA6L5P	-4.25	3.75e-05	0.0151	-0.32	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901190	chr15:84507885~84516814:-
PCPG	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-4.25	3.75e-05	0.0151	-0.71	-0.33	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
PCPG	cis	rs116248771	0.739	rs12639329	ENSG00000272087.1	RP11-379F4.7	4.25	3.76e-05	0.0152	0.49	0.33	diarrhoeal disease at age 2;	chr3:158629356	chr3:158693120~158693768:-
PCPG	cis	rs7945705	0.791	rs4579928	ENSG00000254860.4	TMEM9B-AS1	-4.25	3.76e-05	0.0152	-0.33	-0.33	Hemoglobin concentration;	chr11:8794157	chr11:8964675~8977527:+
PCPG	cis	rs6479901	0.639	rs10995450	ENSG00000232075.1	MRPL35P2	4.25	3.76e-05	0.0152	0.4	0.33	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63634317~63634827:-
PCPG	cis	rs6929812	0.664	rs10484396	ENSG00000271755.1	RP1-153G14.4	4.25	3.76e-05	0.0152	0.42	0.33	Neuroticism (multi-trait analysis);	chr6:27429419	chr6:27404010~27406964:-
PCPG	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	4.25	3.76e-05	0.0152	0.34	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
PCPG	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	4.25	3.76e-05	0.0152	0.41	0.33	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	4.25	3.76e-05	0.0152	0.41	0.33	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-4.25	3.76e-05	0.0152	-0.41	-0.33	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-4.25	3.76e-05	0.0152	-0.41	-0.33	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
PCPG	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	4.25	3.76e-05	0.0152	0.49	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
PCPG	cis	rs1440410	0.798	rs13106497	ENSG00000250326.1	RP11-284M14.1	4.25	3.76e-05	0.0152	0.3	0.33	Ischemic stroke;	chr4:143199527	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4513514	ENSG00000250326.1	RP11-284M14.1	4.25	3.76e-05	0.0152	0.3	0.33	Ischemic stroke;	chr4:143218559	chr4:142933195~143184861:-
PCPG	cis	rs853679	0.567	rs7774981	ENSG00000219392.1	RP1-265C24.5	-4.25	3.77e-05	0.0152	-0.44	-0.33	Depression;	chr6:28379133	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.567	rs7754960	ENSG00000219392.1	RP1-265C24.5	-4.25	3.77e-05	0.0152	-0.44	-0.33	Depression;	chr6:28379168	chr6:28115628~28116551:+
PCPG	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-4.25	3.77e-05	0.0152	-0.51	-0.33	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
PCPG	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	4.25	3.77e-05	0.0152	0.69	0.33	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
PCPG	cis	rs7772486	0.686	rs1569540	ENSG00000270638.1	RP3-466P17.1	-4.25	3.77e-05	0.0152	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs2142983	ENSG00000270638.1	RP3-466P17.1	-4.25	3.77e-05	0.0152	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145735570~145737218:+
PCPG	cis	rs7824557	0.614	rs2293858	ENSG00000255020.1	AF131216.5	4.25	3.77e-05	0.0152	0.42	0.33	Retinal vascular caliber;	chr8:11356372	chr8:11345748~11347502:-
PCPG	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	4.25	3.77e-05	0.0152	0.39	0.33	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
PCPG	cis	rs4845570	0.831	rs11588258	ENSG00000183586.8	HMGN3P1	4.25	3.77e-05	0.0152	0.57	0.33	Coronary artery disease;	chr1:151808252	chr1:152399577~152399769:+
PCPG	cis	rs6003958	1	rs6003958	ENSG00000225282.1	AP000350.6	-4.25	3.77e-05	0.0152	-0.48	-0.33	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23926900~23929574:+
PCPG	cis	rs5760092	0.755	rs6003959	ENSG00000225282.1	AP000350.6	-4.25	3.77e-05	0.0152	-0.48	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23926900~23929574:+
PCPG	cis	rs2797160	0.904	rs1418637	ENSG00000237742.5	RP11-624M8.1	-4.25	3.78e-05	0.0152	-0.34	-0.33	Endometrial cancer;	chr6:125671407	chr6:125578558~125749190:-
PCPG	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	4.25	3.78e-05	0.0152	0.48	0.33	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	4.25	3.78e-05	0.0152	0.48	0.33	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	4.25	3.78e-05	0.0152	0.48	0.33	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs4603535	ENSG00000259295.5	CSPG4P12	4.25	3.78e-05	0.0152	0.48	0.33	Schizophrenia;	chr15:84630641	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs11634320	ENSG00000259295.5	CSPG4P12	-4.25	3.78e-05	0.0152	-0.48	-0.33	Schizophrenia;	chr15:84628952	chr15:85191438~85213905:+
PCPG	cis	rs763121	0.962	rs1980455	ENSG00000273076.1	RP3-508I15.22	4.25	3.78e-05	0.0152	0.34	0.33	Menopause (age at onset);	chr22:38529714	chr22:38743495~38743910:+
PCPG	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	4.25	3.78e-05	0.0152	0.32	0.33	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
PCPG	cis	rs879620	1	rs879620	ENSG00000262185.1	RP11-462G12.1	4.25	3.78e-05	0.0152	0.44	0.33	Hip circumference;Body mass index;	chr16:3965728	chr16:3947609~3950444:-
PCPG	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-4.25	3.78e-05	0.0152	-0.42	-0.33	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
PCPG	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	4.25	3.78e-05	0.0152	0.43	0.33	Height;	chr6:109458989	chr6:109382795~109383666:+
PCPG	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-4.25	3.78e-05	0.0152	-0.4	-0.33	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
PCPG	cis	rs34792	0.637	rs2450356	ENSG00000207425.1	Y_RNA	4.25	3.78e-05	0.0152	0.43	0.33	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:14915457~14915556:-
PCPG	cis	rs11858159	1	rs12902327	ENSG00000259905.4	PWRN1	4.25	3.78e-05	0.0152	0.38	0.33	Platelet thrombus formation;	chr15:24546172	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.756	rs12906581	ENSG00000259905.4	PWRN1	4.25	3.78e-05	0.0152	0.38	0.33	Platelet thrombus formation;	chr15:24546179	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.651	rs12900679	ENSG00000259905.4	PWRN1	4.25	3.78e-05	0.0152	0.38	0.33	Platelet thrombus formation;	chr15:24546219	chr15:24493137~24652130:+
PCPG	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	4.25	3.79e-05	0.0152	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
PCPG	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-4.25	3.79e-05	0.0153	-0.39	-0.33	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	4.25	3.79e-05	0.0153	0.39	0.33	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
PCPG	cis	rs9595908	0.645	rs7983065	ENSG00000212293.1	SNORA16	4.25	3.79e-05	0.0153	0.4	0.33	Body mass index;	chr13:32806648	chr13:32420390~32420516:-
PCPG	cis	rs9595908	0.622	rs7983267	ENSG00000212293.1	SNORA16	4.25	3.79e-05	0.0153	0.4	0.33	Body mass index;	chr13:32806767	chr13:32420390~32420516:-
PCPG	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	4.25	3.79e-05	0.0153	0.54	0.33	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	4.25	3.79e-05	0.0153	0.54	0.33	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
PCPG	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-4.25	3.79e-05	0.0153	-0.42	-0.33	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
PCPG	cis	rs1240773	0.508	rs1787708	ENSG00000280143.1	AP000892.6	4.25	3.79e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116690677	chr11:117204967~117210292:+
PCPG	cis	rs9302635	0.513	rs3812987	ENSG00000260886.1	TAT-AS1	4.25	3.79e-05	0.0153	0.48	0.33	Blood protein levels;	chr16:72125021	chr16:71565789~71578187:+
PCPG	cis	rs11214589	0.651	rs11214595	ENSG00000256757.1	RP11-159N11.3	4.25	3.79e-05	0.0153	0.34	0.33	Neuroticism;	chr11:113388936	chr11:113405321~113412117:+
PCPG	cis	rs2836974	0.897	rs2836973	ENSG00000252915.1	Y_RNA	-4.25	3.79e-05	0.0153	-0.34	-0.33	Cognitive function;	chr21:39283002	chr21:39344537~39344628:+
PCPG	cis	rs6840258	1	rs6840258	ENSG00000251411.1	RP11-397E7.4	-4.25	3.79e-05	0.0153	-0.36	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87052516	chr4:86913266~86914817:-
PCPG	cis	rs4791051	0.723	rs12948610	ENSG00000264491.1	RP11-349A8.3	-4.25	3.8e-05	0.0153	-0.34	-0.33	Heschl's gyrus morphology;	chr17:66453121	chr17:67019934~67021743:-
PCPG	cis	rs8099594	0.565	rs8090015	ENSG00000278983.1	RP11-426J5.3	4.25	3.8e-05	0.0153	0.35	0.33	Height;	chr18:49187716	chr18:48564795~48568342:+
PCPG	cis	rs12048904	0.964	rs3188491	ENSG00000235795.1	RP11-421L21.2	-4.25	3.8e-05	0.0153	-0.41	-0.33	Multiple sclerosis;	chr1:100872926	chr1:100995473~100996260:+
PCPG	cis	rs6840258	1	rs6819155	ENSG00000251411.1	RP11-397E7.4	-4.25	3.8e-05	0.0153	-0.36	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87055026	chr4:86913266~86914817:-
PCPG	cis	rs7849270	0.879	rs7046990	ENSG00000268707.1	RP11-247A12.7	-4.25	3.8e-05	0.0153	-0.35	-0.33	Blood metabolite ratios;	chr9:129093859	chr9:129170434~129170940:+
PCPG	cis	rs2736345	0.502	rs12680762	ENSG00000255020.1	AF131216.5	-4.25	3.81e-05	0.0153	-0.44	-0.33	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11474517	chr8:11345748~11347502:-
PCPG	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	4.25	3.81e-05	0.0153	0.67	0.33	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	4.25	3.81e-05	0.0153	0.67	0.33	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	4.25	3.81e-05	0.0153	0.67	0.33	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
PCPG	cis	rs7829975	0.714	rs11784052	ENSG00000254235.4	RP11-115J16.1	4.25	3.81e-05	0.0153	0.4	0.33	Mood instability;	chr8:8814452	chr8:9249417~9413714:+
PCPG	cis	rs7849782	0.702	rs2095682	ENSG00000225376.4	TMEM246-AS1	4.25	3.81e-05	0.0153	0.37	0.33	Coronary artery aneurysm in Kawasaki disease;	chr9:101775173	chr9:101468439~101481502:+
PCPG	cis	rs4720118	0.609	rs10257361	ENSG00000173862.3	RP11-89N17.1	-4.25	3.81e-05	0.0153	-0.39	-0.33	Leprosy;	chr7:33153702	chr7:33725981~33728456:+
PCPG	cis	rs4720118	0.66	rs4723265	ENSG00000173862.3	RP11-89N17.1	-4.25	3.81e-05	0.0153	-0.39	-0.33	Leprosy;	chr7:33159441	chr7:33725981~33728456:+
PCPG	cis	rs412050	0.895	rs2329886	ENSG00000224086.5	LL22NC03-86G7.1	-4.25	3.81e-05	0.0153	-0.47	-0.33	Attention deficit hyperactivity disorder;	chr22:21944102	chr22:21938293~21977632:+
PCPG	cis	rs657075	0.697	rs78003854	ENSG00000233006.5	AC034220.3	-4.25	3.81e-05	0.0153	-0.44	-0.33	Rheumatoid arthritis;	chr5:132424697	chr5:132311285~132369916:-
PCPG	cis	rs4819052	0.851	rs2838832	ENSG00000215447.6	BX322557.10	4.25	3.81e-05	0.0153	0.32	0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45288052~45291738:+
PCPG	cis	rs1240773	0.508	rs1787716	ENSG00000280143.1	AP000892.6	4.25	3.81e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116689458	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs3017232	ENSG00000280143.1	AP000892.6	4.25	3.81e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116690167	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs3017230	ENSG00000280143.1	AP000892.6	4.25	3.81e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116690245	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs3017228	ENSG00000280143.1	AP000892.6	4.25	3.81e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116690276	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs1787710	ENSG00000280143.1	AP000892.6	4.25	3.81e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116690486	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs1787709	ENSG00000280143.1	AP000892.6	4.25	3.81e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116690612	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs1784123	ENSG00000280143.1	AP000892.6	4.25	3.81e-05	0.0153	0.33	0.33	HIV-1 susceptibility;	chr11:116690665	chr11:117204967~117210292:+
PCPG	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	4.25	3.81e-05	0.0153	0.33	0.33	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	4.25	3.81e-05	0.0153	0.33	0.33	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	4.25	3.81e-05	0.0153	0.33	0.33	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
PCPG	cis	rs2253762	0.54	rs11200324	ENSG00000276742.1	RP11-500G22.4	-4.25	3.81e-05	0.0153	-0.52	-0.33	Breast cancer;	chr10:122009999	chr10:121956782~121957098:+
PCPG	cis	rs4713118	0.662	rs149970	ENSG00000216901.1	AL022393.7	4.25	3.81e-05	0.0153	0.44	0.33	Parkinson's disease;	chr6:28012442	chr6:28176188~28176674:+
PCPG	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-4.25	3.81e-05	0.0153	-0.48	-0.33	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
PCPG	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	4.24	3.82e-05	0.0153	0.4	0.33	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
PCPG	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	4.24	3.82e-05	0.0153	0.45	0.33	Height;	chr6:109372084	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	4.24	3.82e-05	0.0153	0.45	0.33	Height;	chr6:109373851	chr6:109382795~109383666:+
PCPG	cis	rs4489787	1	rs2468942	ENSG00000240399.1	RP1-228P16.1	-4.24	3.82e-05	0.0153	-0.41	-0.33	Prostate cancer (SNP x SNP interaction);	chr12:48446708	chr12:48054813~48055591:-
PCPG	cis	rs4489787	0.892	rs2468353	ENSG00000240399.1	RP1-228P16.1	4.24	3.82e-05	0.0153	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr12:48451803	chr12:48054813~48055591:-
PCPG	cis	rs4489787	1	rs2251773	ENSG00000240399.1	RP1-228P16.1	4.24	3.82e-05	0.0153	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr12:48458039	chr12:48054813~48055591:-
PCPG	cis	rs4489787	0.892	rs6580674	ENSG00000240399.1	RP1-228P16.1	4.24	3.82e-05	0.0153	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr12:48465353	chr12:48054813~48055591:-
PCPG	cis	rs4489787	1	rs10875818	ENSG00000240399.1	RP1-228P16.1	4.24	3.82e-05	0.0153	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr12:48471429	chr12:48054813~48055591:-
PCPG	cis	rs7824557	0.564	rs7839307	ENSG00000255020.1	AF131216.5	4.24	3.82e-05	0.0154	0.44	0.33	Retinal vascular caliber;	chr8:11341283	chr8:11345748~11347502:-
PCPG	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-4.24	3.82e-05	0.0154	-0.55	-0.33	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
PCPG	cis	rs911119	1	rs6048956	ENSG00000270001.1	RP11-218C14.8	-4.24	3.82e-05	0.0154	-0.54	-0.33	Chronic kidney disease;	chr20:23628664	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs34374560	ENSG00000270001.1	RP11-218C14.8	-4.24	3.82e-05	0.0154	-0.54	-0.33	Chronic kidney disease;	chr20:23628825	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs6036476	ENSG00000270001.1	RP11-218C14.8	-4.24	3.82e-05	0.0154	-0.54	-0.33	Chronic kidney disease;	chr20:23629671	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs6036478	ENSG00000270001.1	RP11-218C14.8	-4.24	3.82e-05	0.0154	-0.54	-0.33	Chronic kidney disease;	chr20:23630722	chr20:23631826~23632316:-
PCPG	cis	rs2439831	1	rs690263	ENSG00000205771.5	CATSPER2P1	-4.24	3.82e-05	0.0154	-0.45	-0.33	Lung cancer in ever smokers;	chr15:43412267	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2254321	ENSG00000205771.5	CATSPER2P1	-4.24	3.82e-05	0.0154	-0.45	-0.33	Lung cancer in ever smokers;	chr15:43415344	chr15:43726918~43747094:-
PCPG	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-4.24	3.83e-05	0.0154	-0.39	-0.33	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
PCPG	cis	rs2212361	0.527	rs12282965	ENSG00000255893.1	RP11-685N10.1	-4.24	3.83e-05	0.0154	-0.41	-0.33	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94528348	chr11:94472908~94473570:-
PCPG	cis	rs11020821	0.884	rs12286498	ENSG00000255893.1	RP11-685N10.1	-4.24	3.83e-05	0.0154	-0.41	-0.33	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94529857	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.527	rs7931179	ENSG00000255893.1	RP11-685N10.1	-4.24	3.83e-05	0.0154	-0.41	-0.33	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531037	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs7934286	ENSG00000255893.1	RP11-685N10.1	-4.24	3.83e-05	0.0154	-0.41	-0.33	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531347	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs12294732	ENSG00000255893.1	RP11-685N10.1	-4.24	3.83e-05	0.0154	-0.41	-0.33	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531716	chr11:94472908~94473570:-
PCPG	cis	rs1048886	0.872	rs113350471	ENSG00000271967.1	RP11-134K13.4	-4.24	3.83e-05	0.0154	-0.49	-0.33	Type 2 diabetes;	chr6:70433373	chr6:70596438~70596980:+
PCPG	cis	rs6929812	0.702	rs979353	ENSG00000271755.1	RP1-153G14.4	4.24	3.83e-05	0.0154	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27433159	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.664	rs6914542	ENSG00000271755.1	RP1-153G14.4	4.24	3.83e-05	0.0154	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27435446	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs4713101	ENSG00000271755.1	RP1-153G14.4	4.24	3.83e-05	0.0154	0.43	0.33	Neuroticism (multi-trait analysis);	chr6:27440019	chr6:27404010~27406964:-
PCPG	cis	rs6840258	0.76	rs340650	ENSG00000251411.1	RP11-397E7.4	4.24	3.83e-05	0.0154	0.34	0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87017533	chr4:86913266~86914817:-
PCPG	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	4.24	3.83e-05	0.0154	0.45	0.33	Height;	chr6:109359125	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	4.24	3.83e-05	0.0154	0.45	0.33	Height;	chr6:109360679	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	4.24	3.83e-05	0.0154	0.45	0.33	Height;	chr6:109365409	chr6:109382795~109383666:+
PCPG	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	4.24	3.84e-05	0.0154	0.36	0.33	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
PCPG	cis	rs4720118	0.66	rs2006387	ENSG00000173862.3	RP11-89N17.1	-4.24	3.84e-05	0.0154	-0.39	-0.33	Leprosy;	chr7:33174666	chr7:33725981~33728456:+
PCPG	cis	rs72843506	0.591	rs117720402	ENSG00000261033.1	RP11-209D14.2	4.24	3.84e-05	0.0154	0.65	0.33	Schizophrenia;	chr17:20444298	chr17:20008051~20009234:-
PCPG	cis	rs11858159	1	rs8026062	ENSG00000260760.1	PWRN3	4.24	3.84e-05	0.0154	0.35	0.33	Platelet thrombus formation;	chr15:24537878	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs6576318	ENSG00000260760.1	PWRN3	4.24	3.84e-05	0.0154	0.35	0.33	Platelet thrombus formation;	chr15:24538008	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs6576319	ENSG00000260760.1	PWRN3	4.24	3.84e-05	0.0154	0.35	0.33	Platelet thrombus formation;	chr15:24538014	chr15:24441127~24447967:+
PCPG	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-4.24	3.84e-05	0.0154	-0.48	-0.33	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
PCPG	cis	rs7208859	0.673	rs11652370	ENSG00000263603.1	CTD-2349P21.5	-4.24	3.84e-05	0.0154	-0.5	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30729469~30731202:+
PCPG	cis	rs4819052	0.851	rs2838855	ENSG00000215447.6	BX322557.10	4.24	3.84e-05	0.0154	0.31	0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45288052~45291738:+
PCPG	cis	rs113817606	1	rs113817606	ENSG00000250999.1	RP11-1379J22.5	-4.24	3.84e-05	0.0154	-0.85	-0.33	Daytime sleep phenotypes;	chr5:179629159	chr5:179657762~179664432:+
PCPG	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	4.24	3.85e-05	0.0154	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
PCPG	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	4.24	3.85e-05	0.0154	0.32	0.33	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	4.24	3.85e-05	0.0154	0.32	0.33	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
PCPG	cis	rs11858159	0.729	rs28620819	ENSG00000259905.4	PWRN1	4.24	3.85e-05	0.0155	0.38	0.33	Platelet thrombus formation;	chr15:24577077	chr15:24493137~24652130:+
PCPG	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-4.24	3.85e-05	0.0155	-0.48	-0.33	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-4.24	3.85e-05	0.0155	-0.48	-0.33	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-4.24	3.85e-05	0.0155	-0.48	-0.33	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
PCPG	cis	rs34421088	0.56	rs2248699	ENSG00000254774.1	RP11-148O21.3	-4.24	3.85e-05	0.0155	-0.37	-0.33	Neuroticism;	chr8:11536255	chr8:11553224~11554207:-
PCPG	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	4.24	3.85e-05	0.0155	0.39	0.33	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
PCPG	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	4.24	3.85e-05	0.0155	0.43	0.33	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
PCPG	cis	rs853679	1	rs10456362	ENSG00000219392.1	RP1-265C24.5	4.24	3.86e-05	0.0155	0.51	0.33	Depression;	chr6:28254038	chr6:28115628~28116551:+
PCPG	cis	rs17684571	0.751	rs7771085	ENSG00000231441.1	RP11-472M19.2	4.24	3.86e-05	0.0155	0.56	0.33	Schizophrenia;	chr6:56818631	chr6:56844002~56864078:+
PCPG	cis	rs7208859	0.673	rs56846352	ENSG00000266490.1	CTD-2349P21.9	4.24	3.86e-05	0.0155	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs7211776	ENSG00000266490.1	CTD-2349P21.9	4.24	3.86e-05	0.0155	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs9912122	ENSG00000266490.1	CTD-2349P21.9	4.24	3.86e-05	0.0155	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30792372~30792833:+
PCPG	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66692349	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66693028	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66693433	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66694214	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66701371	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66702658	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66706390	chr7:66654538~66669855:+
PCPG	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66710076	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66715944	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66721259	chr7:66654538~66669855:+
PCPG	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-4.24	3.86e-05	0.0155	-0.71	-0.33	Gout;	chr7:66732812	chr7:66654538~66669855:+
PCPG	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	4.24	3.86e-05	0.0155	0.71	0.33	Gout;	chr7:66682070	chr7:66654538~66669855:+
PCPG	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	4.24	3.86e-05	0.0155	0.71	0.33	Gout;	chr7:66682162	chr7:66654538~66669855:+
PCPG	cis	rs10751667	0.666	rs11246358	ENSG00000255142.1	AP006621.6	4.24	3.86e-05	0.0155	0.32	0.33	Alzheimer's disease (late onset);	chr11:967349	chr11:781645~782105:+
PCPG	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	4.24	3.86e-05	0.0155	0.38	0.33	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
PCPG	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	4.24	3.86e-05	0.0155	0.38	0.33	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	4.24	3.86e-05	0.0155	0.38	0.33	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	4.24	3.86e-05	0.0155	0.38	0.33	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
PCPG	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-4.24	3.86e-05	0.0155	-0.38	-0.33	Height;	chr5:36925633	chr5:36666214~36725195:-
PCPG	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-4.24	3.86e-05	0.0155	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-4.24	3.86e-05	0.0155	-0.44	-0.33	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
PCPG	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	4.24	3.87e-05	0.0155	0.45	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
PCPG	cis	rs189798	0.738	rs330911	ENSG00000253893.2	FAM85B	-4.24	3.87e-05	0.0155	-0.47	-0.33	Myopia (pathological);	chr8:9138763	chr8:8167819~8226614:-
PCPG	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	4.24	3.87e-05	0.0155	0.27	0.33	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	4.24	3.87e-05	0.0155	0.27	0.33	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	4.24	3.87e-05	0.0155	0.27	0.33	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	4.24	3.87e-05	0.0155	0.27	0.33	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	4.24	3.87e-05	0.0155	0.27	0.33	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
PCPG	cis	rs3758911	0.929	rs1843	ENSG00000255353.1	RP11-382M14.1	-4.24	3.87e-05	0.0155	-0.42	-0.33	Coronary artery disease;	chr11:107312219	chr11:107176286~107177530:+
PCPG	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-4.24	3.87e-05	0.0155	-0.39	-0.33	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-4.24	3.87e-05	0.0155	-0.39	-0.33	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-4.24	3.87e-05	0.0155	-0.39	-0.33	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
PCPG	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	4.24	3.87e-05	0.0155	0.71	0.33	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
PCPG	cis	rs1009077	0.514	rs13126170	ENSG00000245958.5	RP11-33B1.1	4.24	3.87e-05	0.0155	0.43	0.33	Endometriosis;	chr4:119402033	chr4:119454791~119552025:+
PCPG	cis	rs1009077	0.514	rs988146	ENSG00000245958.5	RP11-33B1.1	4.24	3.87e-05	0.0155	0.43	0.33	Endometriosis;	chr4:119478350	chr4:119454791~119552025:+
PCPG	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-4.24	3.87e-05	0.0155	-0.47	-0.33	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
PCPG	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	4.24	3.88e-05	0.0155	0.55	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
PCPG	cis	rs13118159	0.55	rs4974614	ENSG00000254094.1	AC078852.1	-4.24	3.88e-05	0.0155	-0.42	-0.33	Longevity;	chr4:1379701	chr4:1356581~1358075:+
PCPG	cis	rs2060793	0.712	rs10741654	ENSG00000251991.1	RNU7-49P	4.24	3.88e-05	0.0155	0.36	0.33	Vitamin D levels;	chr11:14726506	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.505	rs9971395	ENSG00000251991.1	RNU7-49P	4.24	3.88e-05	0.0155	0.36	0.33	Mitochondrial DNA levels;	chr11:14745580	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.506	rs10741655	ENSG00000251991.1	RNU7-49P	4.24	3.88e-05	0.0155	0.36	0.33	Mitochondrial DNA levels;	chr11:14746838	chr11:14478892~14478953:+
PCPG	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	4.24	3.88e-05	0.0155	0.38	0.33	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
PCPG	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	4.24	3.88e-05	0.0155	0.46	0.33	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
PCPG	cis	rs9928842	0.882	rs9927264	ENSG00000280152.1	RP11-331F4.5	4.24	3.88e-05	0.0156	0.53	0.33	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75245994~75250077:-
PCPG	cis	rs11858159	0.644	rs11636595	ENSG00000260760.1	PWRN3	4.24	3.88e-05	0.0156	0.33	0.33	Platelet thrombus formation;	chr15:24479874	chr15:24441127~24447967:+
PCPG	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-4.24	3.88e-05	0.0156	-0.37	-0.33	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
PCPG	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-4.24	3.89e-05	0.0156	-0.43	-0.33	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-4.24	3.89e-05	0.0156	-0.43	-0.33	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
PCPG	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	4.24	3.89e-05	0.0156	0.51	0.33	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
PCPG	cis	rs2281603	0.808	rs10132424	ENSG00000259116.1	RP11-973N13.4	-4.24	3.89e-05	0.0156	-0.32	-0.33	Lymphocyte counts;	chr14:64527157	chr14:64514154~64540368:-
PCPG	cis	rs6121246	0.697	rs6060912	ENSG00000230613.1	HM13-AS1	4.24	3.89e-05	0.0156	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31737952	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6089058	ENSG00000230613.1	HM13-AS1	4.24	3.89e-05	0.0156	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31738535	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.821	rs6119718	ENSG00000230613.1	HM13-AS1	4.24	3.89e-05	0.0156	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31743271	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.821	rs6058448	ENSG00000230613.1	HM13-AS1	4.24	3.89e-05	0.0156	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31744593	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs8126355	ENSG00000230613.1	HM13-AS1	4.24	3.89e-05	0.0156	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31744857	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6060923	ENSG00000230613.1	HM13-AS1	4.24	3.89e-05	0.0156	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31748852	chr20:31567707~31573263:-
PCPG	cis	rs4722748	1	rs4722748	ENSG00000254369.5	HOXA-AS3	4.24	3.89e-05	0.0156	0.38	0.33	Alcoholic chronic pancreatitis;	chr7:27963897	chr7:27129977~27155928:+
PCPG	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-4.24	3.89e-05	0.0156	-0.42	-0.33	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
PCPG	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	4.24	3.89e-05	0.0156	0.32	0.33	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
PCPG	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	4.24	3.89e-05	0.0156	0.64	0.33	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
PCPG	cis	rs8030379	1	rs8024628	ENSG00000230373.7	GOLGA6L5P	-4.24	3.89e-05	0.0156	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917711	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs8029016	ENSG00000230373.7	GOLGA6L5P	-4.24	3.89e-05	0.0156	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917712	chr15:84507885~84516814:-
PCPG	cis	rs5742933	0.803	rs1233262	ENSG00000273240.1	RP11-455J20.3	-4.24	3.89e-05	0.0156	-0.35	-0.33	Ferritin levels;	chr2:189793107	chr2:189763859~189764456:-
PCPG	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-4.24	3.89e-05	0.0156	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
PCPG	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	4.24	3.9e-05	0.0156	0.43	0.33	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
PCPG	cis	rs75804782	0.572	rs56400267	ENSG00000227107.1	AC096574.5	-4.24	3.9e-05	0.0156	-0.57	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:238338572	chr2:237612977~237626525:+
PCPG	cis	rs6121246	0.697	rs8118150	ENSG00000230613.1	HM13-AS1	4.24	3.9e-05	0.0156	0.49	0.33	Mean corpuscular hemoglobin;	chr20:31848285	chr20:31567707~31573263:-
PCPG	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-4.24	3.9e-05	0.0156	-0.41	-0.33	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-4.24	3.9e-05	0.0156	-0.41	-0.33	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
PCPG	cis	rs4143844	0.867	rs35168171	ENSG00000259251.2	RP11-643M14.1	4.24	3.9e-05	0.0156	0.67	0.33	Bipolar disorder and schizophrenia;	chr15:62060759	chr15:62060503~62062434:+
PCPG	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-4.24	3.91e-05	0.0156	-0.42	-0.33	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
PCPG	cis	rs8098244	0.628	rs8083184	ENSG00000265752.2	RP11-403A21.1	4.24	3.91e-05	0.0156	0.38	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23683708	chr18:23957754~23982556:-
PCPG	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	4.24	3.91e-05	0.0156	0.42	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
PCPG	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	4.24	3.91e-05	0.0156	0.36	0.33	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
PCPG	cis	rs1440410	0.798	rs11724872	ENSG00000250326.1	RP11-284M14.1	4.24	3.91e-05	0.0157	0.3	0.33	Ischemic stroke;	chr4:143219512	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs28649839	ENSG00000250326.1	RP11-284M14.1	4.24	3.91e-05	0.0157	0.3	0.33	Ischemic stroke;	chr4:143225047	chr4:142933195~143184861:-
PCPG	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	4.24	3.91e-05	0.0157	0.39	0.33	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
PCPG	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-4.24	3.91e-05	0.0157	-0.26	-0.33	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-4.24	3.91e-05	0.0157	-0.26	-0.33	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-4.24	3.91e-05	0.0157	-0.26	-0.33	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-4.24	3.91e-05	0.0157	-0.26	-0.33	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
PCPG	cis	rs9650657	0.538	rs11250093	ENSG00000255020.1	AF131216.5	4.24	3.92e-05	0.0157	0.46	0.33	Neuroticism;	chr8:10941318	chr8:11345748~11347502:-
PCPG	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	4.24	3.92e-05	0.0157	0.32	0.33	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
PCPG	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-4.24	3.92e-05	0.0157	-0.42	-0.33	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
PCPG	cis	rs1371867	0.846	rs1660312	ENSG00000212994.5	RPS26P6	4.24	3.92e-05	0.0157	0.38	0.33	Atrioventricular conduction;	chr8:100318406	chr8:100895771~100896118:+
PCPG	cis	rs875971	0.577	rs35072105	ENSG00000273142.1	RP11-458F8.4	4.24	3.92e-05	0.0157	0.3	0.33	Aortic root size;	chr7:66144830	chr7:66902857~66906297:+
PCPG	cis	rs17826219	0.706	rs9905827	ENSG00000263603.1	CTD-2349P21.5	-4.24	3.92e-05	0.0157	-0.64	-0.33	Body mass index;	chr17:30865150	chr17:30729469~30731202:+
PCPG	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-4.24	3.92e-05	0.0157	-0.43	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
PCPG	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	4.24	3.93e-05	0.0157	0.35	0.33	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	4.24	3.93e-05	0.0157	0.35	0.33	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
PCPG	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	4.24	3.93e-05	0.0157	0.32	0.33	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
PCPG	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	4.24	3.93e-05	0.0157	0.32	0.33	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	4.24	3.93e-05	0.0157	0.32	0.33	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
PCPG	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	4.24	3.93e-05	0.0157	0.32	0.33	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
PCPG	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	4.24	3.93e-05	0.0157	0.32	0.33	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
PCPG	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	4.24	3.93e-05	0.0157	0.29	0.33	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
PCPG	cis	rs425277	1	rs425277	ENSG00000271806.1	RP5-892K4.1	4.24	3.93e-05	0.0157	0.39	0.33	Height;	chr1:2137733	chr1:2141084~2145279:-
PCPG	cis	rs748404	0.601	rs502157	ENSG00000205771.5	CATSPER2P1	4.24	3.93e-05	0.0157	0.34	0.33	Lung cancer;	chr15:43236375	chr15:43726918~43747094:-
PCPG	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-4.24	3.93e-05	0.0157	-0.48	-0.33	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
PCPG	cis	rs1440410	0.835	rs9992189	ENSG00000250326.1	RP11-284M14.1	4.24	3.93e-05	0.0157	0.3	0.33	Ischemic stroke;	chr4:143139575	chr4:142933195~143184861:-
PCPG	cis	rs28386778	1	rs2955241	ENSG00000240280.5	TCAM1P	-4.24	3.93e-05	0.0157	-0.43	-0.33	Prudent dietary pattern;	chr17:63890753	chr17:63849292~63864379:+
PCPG	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-4.24	3.93e-05	0.0157	-0.52	-0.33	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
PCPG	cis	rs6957923	0.934	rs4265095	ENSG00000230658.1	KLHL7-AS1	4.24	3.93e-05	0.0157	0.4	0.33	Height;	chr7:23460605	chr7:23101228~23105703:-
PCPG	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-4.24	3.93e-05	0.0157	-0.25	-0.33	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
PCPG	cis	rs6121246	0.909	rs6060821	ENSG00000230613.1	HM13-AS1	4.24	3.93e-05	0.0157	0.46	0.33	Mean corpuscular hemoglobin;	chr20:31706231	chr20:31567707~31573263:-
PCPG	cis	rs7772486	0.654	rs702321	ENSG00000270638.1	RP3-466P17.1	-4.24	3.93e-05	0.0157	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145735570~145737218:+
PCPG	cis	rs13108904	0.901	rs7673398	ENSG00000253399.1	AC078852.2	-4.24	3.94e-05	0.0157	-0.34	-0.33	Obesity-related traits;	chr4:1306289	chr4:1358479~1359461:+
PCPG	cis	rs6504622	0.791	rs758392	ENSG00000262879.4	RP11-156P1.3	-4.24	3.94e-05	0.0157	-0.36	-0.33	Orofacial clefts;	chr17:46940493	chr17:46984045~47100323:-
PCPG	cis	rs73201462	1	rs6765233	ENSG00000242551.2	POU5F1P6	-4.24	3.94e-05	0.0157	-0.6	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128284007	chr3:128674735~128677005:-
PCPG	cis	rs35934224	0.831	rs1044732	ENSG00000232926.1	AC000078.5	4.24	3.94e-05	0.0157	0.39	0.33	Glaucoma (primary open-angle);	chr22:19875619	chr22:19887289~19887970:+
PCPG	cis	rs8030379	1	rs8024418	ENSG00000230373.7	GOLGA6L5P	-4.24	3.94e-05	0.0157	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917556	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs8042970	ENSG00000230373.7	GOLGA6L5P	-4.24	3.94e-05	0.0157	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917616	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs11259937	ENSG00000230373.7	GOLGA6L5P	-4.24	3.94e-05	0.0157	-0.33	-0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919081	chr15:84507885~84516814:-
PCPG	cis	rs2243480	1	rs709607	ENSG00000230189.5	GS1-124K5.2	-4.24	3.95e-05	0.0158	-0.45	-0.33	Diabetic kidney disease;	chr7:65984554	chr7:66409143~66490059:-
PCPG	cis	rs9302635	0.513	rs7198572	ENSG00000260886.1	TAT-AS1	4.24	3.95e-05	0.0158	0.48	0.33	Blood protein levels;	chr16:72149321	chr16:71565789~71578187:+
PCPG	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	4.24	3.95e-05	0.0158	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
PCPG	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	4.24	3.95e-05	0.0158	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
PCPG	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	4.24	3.95e-05	0.0158	0.67	0.33	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
PCPG	cis	rs7829975	0.582	rs448231	ENSG00000173295.6	FAM86B3P	4.24	3.96e-05	0.0158	0.38	0.33	Mood instability;	chr8:8932549	chr8:8228595~8244865:+
PCPG	cis	rs56114371	0.568	rs200468	ENSG00000216901.1	AL022393.7	4.24	3.96e-05	0.0158	0.47	0.33	Breast cancer;	chr6:27790076	chr6:28176188~28176674:+
PCPG	cis	rs964611	0.882	rs4775750	ENSG00000259488.2	RP11-154J22.1	4.24	3.96e-05	0.0158	0.31	0.33	Metabolite levels (Pyroglutamine);	chr15:48360567	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs4775751	ENSG00000259488.2	RP11-154J22.1	4.24	3.96e-05	0.0158	0.31	0.33	Metabolite levels (Pyroglutamine);	chr15:48360910	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs11631831	ENSG00000259488.2	RP11-154J22.1	4.24	3.96e-05	0.0158	0.31	0.33	Metabolite levels (Pyroglutamine);	chr15:48361563	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs11070636	ENSG00000259488.2	RP11-154J22.1	4.24	3.96e-05	0.0158	0.31	0.33	Metabolite levels (Pyroglutamine);	chr15:48364720	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs11070637	ENSG00000259488.2	RP11-154J22.1	4.24	3.96e-05	0.0158	0.31	0.33	Metabolite levels (Pyroglutamine);	chr15:48364881	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs12439526	ENSG00000259488.2	RP11-154J22.1	4.24	3.96e-05	0.0158	0.31	0.33	Metabolite levels (Pyroglutamine);	chr15:48366050	chr15:48312353~48331856:-
PCPG	cis	rs889398	0.56	rs8057620	ENSG00000196696.11	PDXDC2P	-4.24	3.96e-05	0.0158	-0.26	-0.33	Body mass index;	chr16:69850716	chr16:69976297~70065948:-
PCPG	cis	rs1371867	0.875	rs1788169	ENSG00000212994.5	RPS26P6	4.24	3.96e-05	0.0158	0.38	0.33	Atrioventricular conduction;	chr8:100314086	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1125706	ENSG00000212994.5	RPS26P6	4.24	3.96e-05	0.0158	0.38	0.33	Atrioventricular conduction;	chr8:100314511	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs28595052	ENSG00000212994.5	RPS26P6	4.24	3.96e-05	0.0158	0.38	0.33	Atrioventricular conduction;	chr8:100315325	chr8:100895771~100896118:+
PCPG	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	4.24	3.96e-05	0.0158	0.4	0.33	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
PCPG	cis	rs2243480	1	rs464895	ENSG00000230189.5	GS1-124K5.2	4.24	3.97e-05	0.0158	0.51	0.33	Diabetic kidney disease;	chr7:66062119	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs160633	ENSG00000230189.5	GS1-124K5.2	4.24	3.97e-05	0.0158	0.51	0.33	Diabetic kidney disease;	chr7:66063241	chr7:66409143~66490059:-
PCPG	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	4.24	3.97e-05	0.0158	0.39	0.33	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
PCPG	cis	rs7160336	0.568	rs10146294	ENSG00000259065.1	RP5-1021I20.1	-4.24	3.97e-05	0.0158	-0.42	-0.33	Blood protein levels;	chr14:74214679	chr14:73787360~73803270:+
PCPG	cis	rs7160336	0.641	rs10136002	ENSG00000259065.1	RP5-1021I20.1	-4.24	3.97e-05	0.0158	-0.42	-0.33	Blood protein levels;	chr14:74215072	chr14:73787360~73803270:+
PCPG	cis	rs7160336	0.604	rs10149539	ENSG00000259065.1	RP5-1021I20.1	-4.24	3.97e-05	0.0158	-0.42	-0.33	Blood protein levels;	chr14:74215524	chr14:73787360~73803270:+
PCPG	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	4.23	3.97e-05	0.0158	0.45	0.33	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
PCPG	cis	rs11220082	0.644	rs34435097	ENSG00000254671.2	STT3A-AS1	-4.23	3.98e-05	0.0159	-0.33	-0.33	Schizophrenia;	chr11:125469075	chr11:125570284~125592568:-
PCPG	cis	rs11220082	0.666	rs7103665	ENSG00000254671.2	STT3A-AS1	-4.23	3.98e-05	0.0159	-0.33	-0.33	Schizophrenia;	chr11:125472998	chr11:125570284~125592568:-
PCPG	cis	rs11220082	0.644	rs61917855	ENSG00000254671.2	STT3A-AS1	-4.23	3.98e-05	0.0159	-0.33	-0.33	Schizophrenia;	chr11:125473652	chr11:125570284~125592568:-
PCPG	cis	rs950169	0.922	rs12910334	ENSG00000235370.6	DNM1P51	4.23	3.98e-05	0.0159	0.35	0.33	Schizophrenia;	chr15:84403620	chr15:84398316~84411701:-
PCPG	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	4.23	3.98e-05	0.0159	0.75	0.33	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	4.23	3.98e-05	0.0159	0.75	0.33	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
PCPG	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-4.23	3.98e-05	0.0159	-0.42	-0.33	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
PCPG	cis	rs12681963	0.614	rs2341178	ENSG00000248159.1	HSPA8P11	4.23	3.98e-05	0.0159	0.66	0.33	Migraine;	chr8:30240679	chr8:30237382~30240997:+
PCPG	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-4.23	3.98e-05	0.0159	-0.36	-0.33	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
PCPG	cis	rs4143844	1	rs12909386	ENSG00000259251.2	RP11-643M14.1	4.23	3.98e-05	0.0159	0.65	0.33	Bipolar disorder and schizophrenia;	chr15:62040700	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs35119291	ENSG00000259251.2	RP11-643M14.1	4.23	3.98e-05	0.0159	0.65	0.33	Bipolar disorder and schizophrenia;	chr15:62042007	chr15:62060503~62062434:+
PCPG	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	4.23	3.99e-05	0.0159	0.47	0.33	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	4.23	3.99e-05	0.0159	0.47	0.33	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-4.23	3.99e-05	0.0159	-0.47	-0.33	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-4.23	3.99e-05	0.0159	-0.47	-0.33	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-4.23	3.99e-05	0.0159	-0.47	-0.33	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-4.23	3.99e-05	0.0159	-0.47	-0.33	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-4.23	3.99e-05	0.0159	-0.47	-0.33	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
PCPG	cis	rs8098244	0.617	rs34511347	ENSG00000265752.2	RP11-403A21.1	4.23	3.99e-05	0.0159	0.37	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23822920	chr18:23957754~23982556:-
PCPG	cis	rs9847710	0.967	rs4687694	ENSG00000242142.1	SERBP1P3	4.23	3.99e-05	0.0159	0.35	0.33	Ulcerative colitis;	chr3:53015031	chr3:53064283~53065091:-
PCPG	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	4.23	3.99e-05	0.0159	0.32	0.33	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
PCPG	cis	rs66887589	0.592	rs62320740	ENSG00000249244.1	RP11-548H18.2	4.23	3.99e-05	0.0159	0.32	0.33	Diastolic blood pressure;	chr4:119358331	chr4:119391831~119395335:-
PCPG	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	4.23	3.99e-05	0.0159	0.37	0.33	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
PCPG	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	4.23	3.99e-05	0.0159	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
PCPG	cis	rs1440410	0.835	rs10029243	ENSG00000250326.1	RP11-284M14.1	4.23	3.99e-05	0.0159	0.3	0.33	Ischemic stroke;	chr4:143139591	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs9992285	ENSG00000250326.1	RP11-284M14.1	4.23	3.99e-05	0.0159	0.3	0.33	Ischemic stroke;	chr4:143139670	chr4:142933195~143184861:-
PCPG	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-4.23	3.99e-05	0.0159	-0.42	-0.33	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
PCPG	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	4.23	4e-05	0.0159	0.48	0.33	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	4.23	4e-05	0.0159	0.48	0.33	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
PCPG	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	4.23	4e-05	0.0159	0.29	0.33	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
PCPG	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-4.23	4e-05	0.0159	-0.38	-0.33	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
PCPG	cis	rs2439831	0.867	rs2260160	ENSG00000205771.5	CATSPER2P1	-4.23	4e-05	0.0159	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43603445	chr15:43726918~43747094:-
PCPG	cis	rs11168936	1	rs11168936	ENSG00000258017.1	RP11-386G11.10	-4.23	4.01e-05	0.016	-0.43	-0.33	Cancer (pleiotropy);	chr12:49251457	chr12:49127782~49147869:+
PCPG	cis	rs6929812	0.702	rs57647048	ENSG00000271755.1	RP1-153G14.4	4.23	4.01e-05	0.016	0.42	0.33	Neuroticism (multi-trait analysis);	chr6:27441385	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs55705181	ENSG00000271755.1	RP1-153G14.4	4.23	4.01e-05	0.016	0.42	0.33	Neuroticism (multi-trait analysis);	chr6:27441508	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.665	rs7754678	ENSG00000271755.1	RP1-153G14.4	4.23	4.01e-05	0.016	0.42	0.33	Neuroticism (multi-trait analysis);	chr6:27444951	chr6:27404010~27406964:-
PCPG	cis	rs9847710	0.967	rs2581778	ENSG00000242142.1	SERBP1P3	4.23	4.01e-05	0.016	0.35	0.33	Ulcerative colitis;	chr3:53021295	chr3:53064283~53065091:-
PCPG	cis	rs9595908	0.606	rs7988462	ENSG00000212293.1	SNORA16	4.23	4.01e-05	0.016	0.39	0.33	Body mass index;	chr13:32806701	chr13:32420390~32420516:-
PCPG	cis	rs16964211	1	rs16964221	ENSG00000259438.1	CTD-2650P22.1	-4.23	4.01e-05	0.016	-0.67	-0.33	Height;	chr15:51252934	chr15:52010999~52019095:-
PCPG	cis	rs16964211	1	rs28757156	ENSG00000259438.1	CTD-2650P22.1	-4.23	4.01e-05	0.016	-0.67	-0.33	Height;	chr15:51253258	chr15:52010999~52019095:-
PCPG	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-4.23	4.01e-05	0.016	-0.33	-0.33	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
PCPG	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-4.23	4.01e-05	0.016	-0.31	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
PCPG	cis	rs9928842	0.77	rs4888364	ENSG00000280152.1	RP11-331F4.5	4.23	4.02e-05	0.016	0.5	0.33	Alcoholic chronic pancreatitis;	chr16:75245612	chr16:75245994~75250077:-
PCPG	cis	rs12291225	0.679	rs11238	ENSG00000251991.1	RNU7-49P	-4.23	4.02e-05	0.016	-0.37	-0.33	Sense of smell;	chr11:14266582	chr11:14478892~14478953:+
PCPG	cis	rs9595908	0.568	rs4942923	ENSG00000212293.1	SNORA16	4.23	4.02e-05	0.016	0.4	0.33	Body mass index;	chr13:32806887	chr13:32420390~32420516:-
PCPG	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-4.23	4.02e-05	0.016	-0.42	-0.33	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
PCPG	cis	rs35538253	0.522	rs12934297	ENSG00000260886.1	TAT-AS1	4.23	4.02e-05	0.016	0.68	0.33	Post bronchodilator FEV1;	chr16:71988922	chr16:71565789~71578187:+
PCPG	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-4.23	4.02e-05	0.016	-0.49	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
PCPG	cis	rs7208859	0.673	rs2470251	ENSG00000263603.1	CTD-2349P21.5	-4.23	4.02e-05	0.016	-0.5	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30729469~30731202:+
PCPG	cis	rs1371867	0.875	rs962451	ENSG00000212994.5	RPS26P6	4.23	4.02e-05	0.016	0.38	0.33	Atrioventricular conduction;	chr8:100318782	chr8:100895771~100896118:+
PCPG	cis	rs9650657	0.617	rs28680211	ENSG00000255020.1	AF131216.5	-4.23	4.02e-05	0.016	-0.43	-0.33	Neuroticism;	chr8:10661935	chr8:11345748~11347502:-
PCPG	cis	rs7172677	0.961	rs34511319	ENSG00000261543.1	RP11-665J16.1	-4.23	4.02e-05	0.016	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75137376	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs62027286	ENSG00000261543.1	RP11-665J16.1	-4.23	4.02e-05	0.016	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75137379	chr15:74152800~74179226:-
PCPG	cis	rs7172677	0.961	rs62027287	ENSG00000261543.1	RP11-665J16.1	-4.23	4.02e-05	0.016	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75137380	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs2415159	ENSG00000261543.1	RP11-665J16.1	-4.23	4.02e-05	0.016	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75138374	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs8032208	ENSG00000261543.1	RP11-665J16.1	-4.23	4.02e-05	0.016	-0.4	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75138904	chr15:74152800~74179226:-
PCPG	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-4.23	4.04e-05	0.0161	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-4.23	4.04e-05	0.0161	-0.39	-0.33	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
PCPG	cis	rs901683	1	rs33997730	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45572665	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35639934	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45575179	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34383275	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45577429	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs78661209	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45579491	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35968565	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45580748	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs75820736	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45580788	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71496621	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45580900	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12766764	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45584065	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12761573	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45584069	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35070150	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45584385	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs76469200	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45584585	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs79490183	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45584793	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34793991	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45585142	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35183191	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45585169	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34163035	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45585271	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12779637	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45585648	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12772102	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45585653	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35183751	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45585910	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71496622	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45586140	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34516867	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45586289	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35049879	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45586296	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs36102549	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45586595	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs36052429	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45586897	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs4442500	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45587050	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35916836	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45587068	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12763285	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45587421	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71499567	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45588508	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35506889	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45589189	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71496623	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45590418	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71496624	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45590501	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.867	rs34144887	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45590945	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.867	rs71496625	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45591201	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.867	rs35003524	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45591333	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs36100685	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45591406	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34574958	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45591592	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12779005	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45591926	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34539215	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45591930	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs78766622	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45592071	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34618850	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45592415	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35670420	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45592604	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs36053776	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45592697	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35713143	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45592711	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs35626777	ENSG00000230869.1	CTGLF10P	-4.23	4.04e-05	0.0161	-0.8	-0.33	Mean corpuscular volume;Red blood cell traits;	chr10:45592719	chr10:45678692~45700532:+
PCPG	cis	rs7172677	0.961	rs12102035	ENSG00000261543.1	RP11-665J16.1	-4.23	4.04e-05	0.0161	-0.39	-0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75126530	chr15:74152800~74179226:-
PCPG	cis	rs10971721	0.643	rs10971701	ENSG00000260947.1	RP11-384P7.7	4.23	4.04e-05	0.0161	0.52	0.33	Body mass index;	chr9:33781900	chr9:33697459~33700986:+
PCPG	cis	rs10971721	0.643	rs10971702	ENSG00000260947.1	RP11-384P7.7	4.23	4.04e-05	0.0161	0.52	0.33	Body mass index;	chr9:33784104	chr9:33697459~33700986:+
PCPG	cis	rs10971721	0.643	rs12375483	ENSG00000260947.1	RP11-384P7.7	4.23	4.04e-05	0.0161	0.52	0.33	Body mass index;	chr9:33784910	chr9:33697459~33700986:+
PCPG	cis	rs10971721	0.643	rs72711741	ENSG00000260947.1	RP11-384P7.7	4.23	4.04e-05	0.0161	0.52	0.33	Body mass index;	chr9:33785113	chr9:33697459~33700986:+
PCPG	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	4.23	4.04e-05	0.0161	0.52	0.33	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
PCPG	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	4.23	4.04e-05	0.0161	0.52	0.33	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
PCPG	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	4.23	4.04e-05	0.0161	0.52	0.33	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
PCPG	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	4.23	4.04e-05	0.0161	0.57	0.33	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
PCPG	cis	rs13118159	0.509	rs1882098	ENSG00000254094.1	AC078852.1	-4.23	4.04e-05	0.0161	-0.42	-0.33	Longevity;	chr4:1358643	chr4:1356581~1358075:+
PCPG	cis	rs2281558	0.876	rs2274890	ENSG00000125804.12	FAM182A	-4.23	4.04e-05	0.0161	-0.46	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:26054655~26086917:+
PCPG	cis	rs17826219	0.568	rs2014455	ENSG00000263531.1	RP13-753N3.1	-4.23	4.04e-05	0.0161	-0.85	-0.33	Body mass index;	chr17:30503472	chr17:30863921~30864940:-
PCPG	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-4.23	4.04e-05	0.0161	-0.26	-0.33	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
PCPG	cis	rs6479891	1	rs4746149	ENSG00000232075.1	MRPL35P2	-4.23	4.05e-05	0.0161	-0.48	-0.33	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63634317~63634827:-
PCPG	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	4.23	4.05e-05	0.0161	0.38	0.33	Height;	chr5:37025769	chr5:36666214~36725195:-
PCPG	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	4.23	4.05e-05	0.0161	0.3	0.33	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
PCPG	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-4.23	4.05e-05	0.0161	-0.33	-0.33	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
PCPG	cis	rs9302635	0.513	rs35460163	ENSG00000260886.1	TAT-AS1	4.23	4.05e-05	0.0161	0.48	0.33	Blood protein levels;	chr16:72143161	chr16:71565789~71578187:+
PCPG	cis	rs7186908	0.761	rs34714490	ENSG00000260886.1	TAT-AS1	4.23	4.05e-05	0.0161	0.48	0.33	Liver enzyme levels (alkaline phosphatase);	chr16:72143200	chr16:71565789~71578187:+
PCPG	cis	rs13108904	0.901	rs7668661	ENSG00000253399.1	AC078852.2	-4.23	4.05e-05	0.0161	-0.34	-0.33	Obesity-related traits;	chr4:1306384	chr4:1358479~1359461:+
PCPG	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	4.23	4.05e-05	0.0161	0.41	0.33	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
PCPG	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-4.23	4.05e-05	0.0161	-0.38	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
PCPG	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	4.23	4.05e-05	0.0161	0.36	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
PCPG	cis	rs11673344	0.504	rs2118208	ENSG00000226686.6	LINC01535	4.23	4.05e-05	0.0161	0.43	0.33	Obesity-related traits;	chr19:37135573	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs2118209	ENSG00000226686.6	LINC01535	4.23	4.05e-05	0.0161	0.43	0.33	Obesity-related traits;	chr19:37135618	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs4805204	ENSG00000226686.6	LINC01535	4.23	4.05e-05	0.0161	0.43	0.33	Obesity-related traits;	chr19:37136666	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs4805205	ENSG00000226686.6	LINC01535	4.23	4.05e-05	0.0161	0.43	0.33	Obesity-related traits;	chr19:37136693	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.504	rs8105065	ENSG00000226686.6	LINC01535	4.23	4.05e-05	0.0161	0.43	0.33	Obesity-related traits;	chr19:37141003	chr19:37251912~37265535:+
PCPG	cis	rs2412819	0.571	rs514255	ENSG00000249839.1	AC011330.5	-4.23	4.05e-05	0.0161	-0.41	-0.33	Lung cancer;	chr15:43893134	chr15:43663654~43684339:-
PCPG	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-4.23	4.05e-05	0.0161	-0.36	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
PCPG	cis	rs6479901	0.696	rs931972	ENSG00000232075.1	MRPL35P2	-4.23	4.05e-05	0.0161	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63150467	chr10:63634317~63634827:-
PCPG	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	4.23	4.06e-05	0.0161	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
PCPG	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	4.23	4.06e-05	0.0161	0.39	0.33	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
PCPG	cis	rs752864	0.812	rs1669867	ENSG00000259438.1	CTD-2650P22.1	4.23	4.06e-05	0.0161	0.39	0.33	Number of common colds;	chr15:52454664	chr15:52010999~52019095:-
PCPG	cis	rs6044834	0.583	rs6044776	ENSG00000212232.1	SNORD17	4.23	4.06e-05	0.0161	0.44	0.33	Obesity-related traits;	chr20:17386949	chr20:17962710~17962946:-
PCPG	cis	rs2361718	0.521	rs2361724	ENSG00000275479.1	RP11-334C17.6	4.23	4.06e-05	0.0161	0.27	0.33	Yeast infection;	chr17:80125315	chr17:80149627~80149798:+
PCPG	cis	rs1240773	0.508	rs3016360	ENSG00000280143.1	AP000892.6	4.23	4.06e-05	0.0161	0.33	0.33	HIV-1 susceptibility;	chr11:116689027	chr11:117204967~117210292:+
PCPG	cis	rs9299346	0.594	rs1323412	ENSG00000225376.4	TMEM246-AS1	-4.23	4.06e-05	0.0161	-0.39	-0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101664532	chr9:101468439~101481502:+
PCPG	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	4.23	4.06e-05	0.0161	0.33	0.33	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
PCPG	cis	rs7772486	0.714	rs1883365	ENSG00000270638.1	RP3-466P17.1	-4.23	4.06e-05	0.0161	-0.34	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145735570~145737218:+
PCPG	cis	rs1876905	0.68	rs354540	ENSG00000255389.1	C6orf3	4.23	4.06e-05	0.0161	0.43	0.33	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111599875~111602295:+
PCPG	cis	rs9928842	0.882	rs1107593	ENSG00000280152.1	RP11-331F4.5	4.23	4.07e-05	0.0161	0.55	0.33	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75245994~75250077:-
PCPG	cis	rs9928842	0.824	rs12924999	ENSG00000280152.1	RP11-331F4.5	4.23	4.07e-05	0.0161	0.55	0.33	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75245994~75250077:-
PCPG	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	4.23	4.07e-05	0.0161	0.36	0.33	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
PCPG	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	4.23	4.07e-05	0.0162	0.32	0.33	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
PCPG	cis	rs728616	0.867	rs17098720	ENSG00000242600.5	MBL1P	4.23	4.07e-05	0.0162	0.63	0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80080480	chr10:79904898~79950336:+
PCPG	cis	rs728616	0.717	rs12414332	ENSG00000242600.5	MBL1P	4.23	4.07e-05	0.0162	0.63	0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80081199	chr10:79904898~79950336:+
PCPG	cis	rs17453880	0.611	rs2964242	ENSG00000249035.5	CTB-113P19.1	-4.23	4.07e-05	0.0162	-0.35	-0.33	Subjective well-being;	chr5:152544420	chr5:151676945~151724782:+
PCPG	cis	rs17453880	0.591	rs2961762	ENSG00000249035.5	CTB-113P19.1	-4.23	4.07e-05	0.0162	-0.35	-0.33	Subjective well-being;	chr5:152544597	chr5:151676945~151724782:+
PCPG	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-4.23	4.07e-05	0.0162	-0.38	-0.33	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
PCPG	cis	rs4720118	0.634	rs10275544	ENSG00000173862.3	RP11-89N17.1	-4.23	4.08e-05	0.0162	-0.39	-0.33	Leprosy;	chr7:33147269	chr7:33725981~33728456:+
PCPG	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
PCPG	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.38	0.33	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
PCPG	cis	rs2735413	0.564	rs73580867	ENSG00000276007.1	RP11-358L22.3	4.23	4.08e-05	0.0162	0.33	0.33	Systolic blood pressure (alcohol consumption interaction);	chr16:78087056	chr16:78123243~78124332:+
PCPG	cis	rs8042680	0.522	rs1867225	ENSG00000214432.8	AC068831.10	-4.23	4.08e-05	0.0162	-0.37	-0.33	Type 2 diabetes;	chr15:91020599	chr15:91022619~91036611:+
PCPG	cis	rs35934224	0.891	rs33997573	ENSG00000232926.1	AC000078.5	4.23	4.08e-05	0.0162	0.38	0.33	Glaucoma (primary open-angle);	chr22:19881428	chr22:19887289~19887970:+
PCPG	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	4.23	4.08e-05	0.0162	0.39	0.33	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
PCPG	cis	rs2625529	0.938	rs2742323	ENSG00000260037.4	CTD-2524L6.3	4.23	4.08e-05	0.0162	0.51	0.33	Red blood cell count;	chr15:71824437	chr15:71818396~71823384:+
PCPG	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	4.23	4.08e-05	0.0162	0.42	0.33	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
PCPG	cis	rs11148252	0.574	rs2038826	ENSG00000273784.3	RP11-78J21.7	-4.23	4.08e-05	0.0162	-0.31	-0.33	Lewy body disease;	chr13:52705878	chr13:52600042~52642542:+
PCPG	cis	rs6940638	0.662	rs6915678	ENSG00000216901.1	AL022393.7	4.23	4.08e-05	0.0162	0.44	0.33	Intelligence (multi-trait analysis);	chr6:27268087	chr6:28176188~28176674:+
PCPG	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	4.23	4.08e-05	0.0162	0.5	0.33	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
PCPG	cis	rs60695258	0.529	rs340630	ENSG00000251411.1	RP11-397E7.4	4.23	4.09e-05	0.0162	0.3	0.33	Hematocrit;	chr4:87037243	chr4:86913266~86914817:-
PCPG	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	4.23	4.09e-05	0.0162	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	4.23	4.09e-05	0.0162	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
PCPG	cis	rs10200850	1	rs10183376	ENSG00000265215.1	MIR4269	4.23	4.09e-05	0.0162	0.62	0.33	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239308870	chr2:239305462~239305545:+
PCPG	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-4.23	4.09e-05	0.0162	-0.54	-0.33	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
PCPG	cis	rs13108904	0.901	rs66987549	ENSG00000253399.1	AC078852.2	-4.23	4.1e-05	0.0162	-0.34	-0.33	Obesity-related traits;	chr4:1278829	chr4:1358479~1359461:+
PCPG	cis	rs2732480	0.538	rs1387260	ENSG00000240399.1	RP1-228P16.1	4.23	4.1e-05	0.0162	0.36	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48054813~48055591:-
PCPG	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	4.23	4.1e-05	0.0162	0.4	0.33	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
PCPG	cis	rs853679	0.607	rs13199649	ENSG00000219392.1	RP1-265C24.5	-4.23	4.1e-05	0.0163	-0.71	-0.33	Depression;	chr6:27901014	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs34788973	ENSG00000219392.1	RP1-265C24.5	-4.23	4.1e-05	0.0163	-0.71	-0.33	Depression;	chr6:27911422	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs61742093	ENSG00000219392.1	RP1-265C24.5	-4.23	4.1e-05	0.0163	-0.71	-0.33	Depression;	chr6:27912204	chr6:28115628~28116551:+
PCPG	cis	rs67340775	0.834	rs13218875	ENSG00000219392.1	RP1-265C24.5	-4.23	4.1e-05	0.0163	-0.71	-0.33	Lung cancer in ever smokers;	chr6:27916234	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.607	rs67040724	ENSG00000219392.1	RP1-265C24.5	-4.23	4.1e-05	0.0163	-0.71	-0.33	Depression;	chr6:27937731	chr6:28115628~28116551:+
PCPG	cis	rs6121246	0.909	rs6058460	ENSG00000230613.1	HM13-AS1	4.23	4.11e-05	0.0163	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31775268	chr20:31567707~31573263:-
PCPG	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	4.23	4.11e-05	0.0163	0.37	0.33	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
PCPG	cis	rs9840812	0.623	rs1145106	ENSG00000239213.4	NCK1-AS1	4.23	4.11e-05	0.0163	0.4	0.33	Fibrinogen levels;	chr3:136393075	chr3:136841726~136862054:-
PCPG	cis	rs1023500	0.505	rs134874	ENSG00000226450.2	CYP2D8P	4.23	4.11e-05	0.0163	0.32	0.33	Schizophrenia;	chr22:42265138	chr22:42149886~42155001:-
PCPG	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	-4.23	4.11e-05	0.0163	-0.37	-0.33	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
PCPG	cis	rs73201462	1	rs2811530	ENSG00000242551.2	POU5F1P6	-4.23	4.11e-05	0.0163	-0.6	-0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274323	chr3:128674735~128677005:-
PCPG	cis	rs1949733	0.917	rs10461079	ENSG00000205959.3	RP11-689P11.2	4.23	4.11e-05	0.0163	0.38	0.33	Response to antineoplastic agents;	chr4:8390997	chr4:8482270~8512610:+
PCPG	cis	rs11858159	0.729	rs7183482	ENSG00000259905.4	PWRN1	4.23	4.12e-05	0.0163	0.38	0.33	Platelet thrombus formation;	chr15:24554391	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs71404365	ENSG00000259905.4	PWRN1	4.23	4.12e-05	0.0163	0.38	0.33	Platelet thrombus formation;	chr15:24554393	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.902	rs7182166	ENSG00000259905.4	PWRN1	4.23	4.12e-05	0.0163	0.38	0.33	Platelet thrombus formation;	chr15:24554398	chr15:24493137~24652130:+
PCPG	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-4.23	4.12e-05	0.0163	-0.31	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
PCPG	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	4.23	4.13e-05	0.0163	0.45	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	4.23	4.13e-05	0.0163	0.45	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
PCPG	cis	rs28386778	0.933	rs2665801	ENSG00000240280.5	TCAM1P	-4.23	4.13e-05	0.0163	-0.43	-0.33	Prudent dietary pattern;	chr17:63874740	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.901	rs2854194	ENSG00000240280.5	TCAM1P	-4.23	4.13e-05	0.0163	-0.43	-0.33	Prudent dietary pattern;	chr17:63874750	chr17:63849292~63864379:+
PCPG	cis	rs28386778	1	rs2665849	ENSG00000240280.5	TCAM1P	-4.23	4.13e-05	0.0163	-0.43	-0.33	Prudent dietary pattern;	chr17:63876310	chr17:63849292~63864379:+
PCPG	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-4.23	4.13e-05	0.0163	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
PCPG	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	4.23	4.13e-05	0.0163	0.35	0.33	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
PCPG	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	4.23	4.13e-05	0.0163	0.37	0.33	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
PCPG	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-4.22	4.13e-05	0.0163	-0.64	-0.33	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
PCPG	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	4.22	4.13e-05	0.0163	0.45	0.33	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
PCPG	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	4.22	4.13e-05	0.0163	0.32	0.33	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	4.22	4.13e-05	0.0163	0.32	0.33	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	4.22	4.13e-05	0.0163	0.32	0.33	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	4.22	4.13e-05	0.0163	0.32	0.33	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	4.22	4.13e-05	0.0163	0.32	0.33	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	4.22	4.13e-05	0.0163	0.32	0.33	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
PCPG	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	4.22	4.13e-05	0.0163	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
PCPG	cis	rs12048904	0.964	rs12027668	ENSG00000235795.1	RP11-421L21.2	-4.22	4.13e-05	0.0164	-0.4	-0.33	Multiple sclerosis;	chr1:100865428	chr1:100995473~100996260:+
PCPG	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	4.22	4.13e-05	0.0164	0.42	0.33	Height;	chr6:109694120	chr6:109382795~109383666:+
PCPG	cis	rs2064219	0.554	rs6914846	ENSG00000271755.1	RP1-153G14.4	4.22	4.13e-05	0.0164	0.43	0.33	Depressive symptoms;Depressive symptoms (multi-trait analysis);	chr6:27442900	chr6:27404010~27406964:-
PCPG	cis	rs7017914	0.667	rs13262350	ENSG00000254031.4	RP11-326E22.1	4.22	4.13e-05	0.0164	0.31	0.33	Bone mineral density;	chr8:71069371	chr8:71155457~71204223:+
PCPG	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	4.22	4.14e-05	0.0164	0.46	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
PCPG	cis	rs1440410	0.835	rs7684481	ENSG00000250326.1	RP11-284M14.1	4.22	4.14e-05	0.0164	0.3	0.33	Ischemic stroke;	chr4:143133252	chr4:142933195~143184861:-
PCPG	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-4.22	4.14e-05	0.0164	-0.39	-0.33	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
PCPG	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-4.22	4.14e-05	0.0164	-0.39	-0.33	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
PCPG	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-4.22	4.14e-05	0.0164	-0.39	-0.33	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
PCPG	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-4.22	4.14e-05	0.0164	-0.39	-0.33	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
PCPG	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-4.22	4.14e-05	0.0164	-0.39	-0.33	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
PCPG	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-4.22	4.14e-05	0.0164	-0.71	-0.33	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-4.22	4.14e-05	0.0164	-0.71	-0.33	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-4.22	4.14e-05	0.0164	-0.71	-0.33	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-4.22	4.14e-05	0.0164	-0.71	-0.33	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-4.22	4.14e-05	0.0164	-0.71	-0.33	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-4.22	4.14e-05	0.0164	-0.71	-0.33	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	4.22	4.14e-05	0.0164	0.71	0.33	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	4.22	4.14e-05	0.0164	0.71	0.33	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	4.22	4.14e-05	0.0164	0.71	0.33	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	4.22	4.14e-05	0.0164	0.71	0.33	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	4.22	4.14e-05	0.0164	0.71	0.33	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	4.22	4.14e-05	0.0164	0.71	0.33	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
PCPG	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	-4.22	4.14e-05	0.0164	-0.38	-0.33	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
PCPG	cis	rs950169	0.541	rs10795	ENSG00000259295.5	CSPG4P12	4.22	4.14e-05	0.0164	0.48	0.33	Schizophrenia;	chr15:84634066	chr15:85191438~85213905:+
PCPG	cis	rs950169	0.58	rs36126054	ENSG00000259295.5	CSPG4P12	4.22	4.14e-05	0.0164	0.48	0.33	Schizophrenia;	chr15:84634492	chr15:85191438~85213905:+
PCPG	cis	rs8098244	0.617	rs12965616	ENSG00000265752.2	RP11-403A21.1	4.22	4.14e-05	0.0164	0.37	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23831262	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.617	rs12969104	ENSG00000265752.2	RP11-403A21.1	4.22	4.14e-05	0.0164	0.37	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23832275	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.638	rs1109949	ENSG00000265752.2	RP11-403A21.1	4.22	4.14e-05	0.0164	0.37	0.33	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23834136	chr18:23957754~23982556:-
PCPG	cis	rs1387259	0.859	rs2054905	ENSG00000240399.1	RP1-228P16.1	4.22	4.15e-05	0.0164	0.36	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.5	rs2732461	ENSG00000240399.1	RP1-228P16.1	4.22	4.15e-05	0.0164	0.36	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48054813~48055591:-
PCPG	cis	rs937213	0.676	rs2412456	ENSG00000259584.1	RP11-521C20.2	4.22	4.15e-05	0.0164	0.39	0.33	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39997826	chr15:40075204~40078704:-
PCPG	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-4.22	4.15e-05	0.0164	-0.35	-0.33	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
PCPG	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-4.22	4.15e-05	0.0164	-0.35	-0.33	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
PCPG	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-4.22	4.15e-05	0.0164	-0.35	-0.33	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
PCPG	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-4.22	4.15e-05	0.0164	-0.35	-0.33	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
PCPG	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-4.22	4.15e-05	0.0164	-0.35	-0.33	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
PCPG	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-4.22	4.15e-05	0.0164	-0.35	-0.33	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
PCPG	cis	rs1371867	0.846	rs1788199	ENSG00000212994.5	RPS26P6	4.22	4.15e-05	0.0164	0.38	0.33	Atrioventricular conduction;	chr8:100280626	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1613453	ENSG00000212994.5	RPS26P6	-4.22	4.15e-05	0.0164	-0.38	-0.33	Atrioventricular conduction;	chr8:100231987	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.81	rs1692004	ENSG00000212994.5	RPS26P6	-4.22	4.15e-05	0.0164	-0.38	-0.33	Atrioventricular conduction;	chr8:100235092	chr8:100895771~100896118:+
PCPG	cis	rs6569038	0.669	rs7764418	ENSG00000253194.1	RP11-351A11.1	4.22	4.15e-05	0.0164	0.44	0.33	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119062817	chr6:118934785~119031541:+
PCPG	cis	rs9299346	0.505	rs10989584	ENSG00000225376.4	TMEM246-AS1	4.22	4.15e-05	0.0164	0.5	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101659359	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.536	rs10819974	ENSG00000225376.4	TMEM246-AS1	4.22	4.15e-05	0.0164	0.5	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101660062	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.504	rs12351398	ENSG00000225376.4	TMEM246-AS1	4.22	4.15e-05	0.0164	0.5	0.33	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101660076	chr9:101468439~101481502:+
PCPG	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	4.22	4.15e-05	0.0164	0.37	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
PCPG	cis	rs7707921	0.957	rs226205	ENSG00000249483.1	CTD-2249K22.1	4.22	4.15e-05	0.0164	0.45	0.33	Breast cancer;	chr5:82297835	chr5:81851601~81852201:+
PCPG	cis	rs2836974	0.965	rs2836967	ENSG00000252915.1	Y_RNA	-4.22	4.16e-05	0.0164	-0.34	-0.33	Cognitive function;	chr21:39267176	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.931	rs2836968	ENSG00000252915.1	Y_RNA	-4.22	4.16e-05	0.0164	-0.34	-0.33	Cognitive function;	chr21:39270460	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.931	rs7283569	ENSG00000252915.1	Y_RNA	-4.22	4.16e-05	0.0164	-0.34	-0.33	Cognitive function;	chr21:39272136	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.931	rs2836972	ENSG00000252915.1	Y_RNA	-4.22	4.16e-05	0.0164	-0.34	-0.33	Cognitive function;	chr21:39280216	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.965	rs7354783	ENSG00000252915.1	Y_RNA	-4.22	4.16e-05	0.0164	-0.34	-0.33	Cognitive function;	chr21:39281066	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.931	rs8132285	ENSG00000252915.1	Y_RNA	-4.22	4.16e-05	0.0164	-0.34	-0.33	Cognitive function;	chr21:39283826	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.965	rs6517538	ENSG00000252915.1	Y_RNA	-4.22	4.16e-05	0.0164	-0.34	-0.33	Cognitive function;	chr21:39284316	chr21:39344537~39344628:+
PCPG	cis	rs2898290	0.622	rs1478890	ENSG00000184608.7	FAM167A-AS1	-4.22	4.16e-05	0.0164	-0.44	-0.33	Systolic blood pressure;	chr8:11498093	chr8:11368402~11438658:+
PCPG	cis	rs7172677	1	rs55662404	ENSG00000261543.1	RP11-665J16.1	4.22	4.16e-05	0.0164	0.4	0.33	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75140000	chr15:74152800~74179226:-
PCPG	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	4.22	4.16e-05	0.0164	0.36	0.33	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
PCPG	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-4.22	4.17e-05	0.0165	-0.31	-0.33	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
PCPG	cis	rs17507216	1	rs3850610	ENSG00000228141.5	AC105339.1	4.22	4.17e-05	0.0165	0.46	0.33	Excessive daytime sleepiness;	chr15:82552642	chr15:82710471~82714026:-
PCPG	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-4.22	4.17e-05	0.0165	-0.45	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
PCPG	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-4.22	4.17e-05	0.0165	-0.34	-0.33	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
PCPG	cis	rs6714710	0.603	rs7421146	ENSG00000278766.2	AC159540.2	4.22	4.18e-05	0.0165	0.37	0.33	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935808	chr2:97421075~97434847:+
PCPG	cis	rs7824557	0.701	rs4568582	ENSG00000184608.7	FAM167A-AS1	4.22	4.18e-05	0.0165	0.46	0.33	Retinal vascular caliber;	chr8:11302986	chr8:11368402~11438658:+
PCPG	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	4.22	4.18e-05	0.0165	0.41	0.33	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	4.22	4.18e-05	0.0165	0.41	0.33	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	4.22	4.18e-05	0.0165	0.41	0.33	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
PCPG	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	4.22	4.18e-05	0.0165	0.41	0.33	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
PCPG	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-4.22	4.18e-05	0.0165	-0.39	-0.33	Height;	chr6:109360458	chr6:109382795~109383666:+
PCPG	cis	rs28386778	0.829	rs1877317	ENSG00000240280.5	TCAM1P	-4.22	4.18e-05	0.0165	-0.43	-0.33	Prudent dietary pattern;	chr17:63699119	chr17:63849292~63864379:+
PCPG	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	4.22	4.18e-05	0.0165	0.45	0.33	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
PCPG	cis	rs7610312	0.681	rs7626140	ENSG00000273493.1	RP11-80H18.4	-4.22	4.18e-05	0.0165	-0.38	-0.33	Red blood cell count;	chr3:58292517	chr3:58329965~58330118:+
PCPG	cis	rs7610312	0.612	rs2176083	ENSG00000273493.1	RP11-80H18.4	-4.22	4.18e-05	0.0165	-0.38	-0.33	Red blood cell count;	chr3:58294044	chr3:58329965~58330118:+
PCPG	cis	rs7610312	0.681	rs6924	ENSG00000273493.1	RP11-80H18.4	-4.22	4.18e-05	0.0165	-0.38	-0.33	Red blood cell count;	chr3:58294334	chr3:58329965~58330118:+
PCPG	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	4.22	4.19e-05	0.0165	0.57	0.33	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
PCPG	cis	rs7849782	0.875	rs12352862	ENSG00000225376.4	TMEM246-AS1	4.22	4.19e-05	0.0165	0.38	0.33	Coronary artery aneurysm in Kawasaki disease;	chr9:101656201	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.846	rs12351943	ENSG00000225376.4	TMEM246-AS1	4.22	4.19e-05	0.0165	0.38	0.33	Coronary artery aneurysm in Kawasaki disease;	chr9:101656254	chr9:101468439~101481502:+
PCPG	cis	rs9876781	0.624	rs12491849	ENSG00000229759.1	MRPS18AP1	4.22	4.19e-05	0.0165	0.4	0.33	Longevity;	chr3:48489975	chr3:48256350~48256938:-
PCPG	cis	rs875971	0.862	rs6460307	ENSG00000235475.1	LINC01372	4.22	4.19e-05	0.0165	0.33	0.33	Aortic root size;	chr7:66595884	chr7:67335976~67340024:+
PCPG	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-4.22	4.2e-05	0.0165	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-4.22	4.2e-05	0.0165	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-4.22	4.2e-05	0.0165	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-4.22	4.2e-05	0.0165	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
PCPG	cis	rs763014	0.898	rs2017567	ENSG00000262528.2	LA16c-349E10.1	4.22	4.2e-05	0.0166	0.39	0.33	Height;	chr16:587212	chr16:654611~656194:-
PCPG	cis	rs4713118	0.869	rs9461405	ENSG00000216901.1	AL022393.7	4.22	4.2e-05	0.0166	0.43	0.33	Parkinson's disease;	chr6:27751596	chr6:28176188~28176674:+
PCPG	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	4.22	4.2e-05	0.0166	0.35	0.33	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
PCPG	cis	rs7208859	0.614	rs73265646	ENSG00000263603.1	CTD-2349P21.5	-4.22	4.2e-05	0.0166	-0.63	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs216418	ENSG00000266490.1	CTD-2349P21.9	4.22	4.2e-05	0.0166	0.39	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30792372~30792833:+
PCPG	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	4.22	4.2e-05	0.0166	0.38	0.33	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
PCPG	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-4.22	4.2e-05	0.0166	-0.36	-0.33	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
PCPG	cis	rs1003719	0.679	rs2835674	ENSG00000228677.1	TTC3-AS1	-4.22	4.2e-05	0.0166	-0.4	-0.33	Eye color traits;	chr21:37209221	chr21:37187666~37193926:-
PCPG	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	4.22	4.2e-05	0.0166	0.44	0.33	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
PCPG	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	4.22	4.21e-05	0.0166	0.38	0.33	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
PCPG	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-4.22	4.21e-05	0.0166	-0.42	-0.33	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-4.22	4.21e-05	0.0166	-0.42	-0.33	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-4.22	4.21e-05	0.0166	-0.42	-0.33	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
PCPG	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-4.22	4.21e-05	0.0166	-0.47	-0.33	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
PCPG	cis	rs1023500	0.505	rs134886	ENSG00000226450.2	CYP2D8P	-4.22	4.21e-05	0.0166	-0.31	-0.33	Schizophrenia;	chr22:42277850	chr22:42149886~42155001:-
PCPG	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	4.22	4.21e-05	0.0166	0.32	0.33	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
PCPG	cis	rs7772486	0.686	rs1337839	ENSG00000270638.1	RP3-466P17.1	-4.22	4.21e-05	0.0166	-0.35	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9497395	ENSG00000270638.1	RP3-466P17.1	-4.22	4.21e-05	0.0166	-0.35	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145735570~145737218:+
PCPG	cis	rs6840258	0.6	rs1447994	ENSG00000251411.1	RP11-397E7.4	4.22	4.21e-05	0.0166	0.39	0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86966902	chr4:86913266~86914817:-
PCPG	cis	rs6840258	0.66	rs10015639	ENSG00000251411.1	RP11-397E7.4	4.22	4.21e-05	0.0166	0.39	0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970413	chr4:86913266~86914817:-
PCPG	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	4.22	4.22e-05	0.0166	0.36	0.33	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
PCPG	cis	rs7208859	0.623	rs216423	ENSG00000266490.1	CTD-2349P21.9	4.22	4.22e-05	0.0166	0.38	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30792372~30792833:+
PCPG	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-4.22	4.23e-05	0.0167	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
PCPG	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	4.22	4.23e-05	0.0167	0.48	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
PCPG	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	4.22	4.23e-05	0.0167	0.48	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
PCPG	cis	rs12439619	0.846	rs7496227	ENSG00000228141.5	AC105339.1	-4.22	4.23e-05	0.0167	-0.49	-0.33	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82710471~82714026:-
PCPG	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-4.22	4.23e-05	0.0167	-0.43	-0.33	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
PCPG	cis	rs10751667	0.643	rs7395592	ENSG00000255142.1	AP006621.6	4.22	4.23e-05	0.0167	0.33	0.33	Alzheimer's disease (late onset);	chr11:934094	chr11:781645~782105:+
PCPG	cis	rs72634258	0.554	rs12745962	ENSG00000270035.1	RP11-338N10.2	-4.22	4.23e-05	0.0167	-0.45	-0.33	Inflammatory bowel disease;	chr1:7859765	chr1:7698303~7698872:-
PCPG	cis	rs72634258	0.554	rs35307738	ENSG00000270035.1	RP11-338N10.2	-4.22	4.23e-05	0.0167	-0.45	-0.33	Inflammatory bowel disease;	chr1:7859779	chr1:7698303~7698872:-
PCPG	cis	rs2281603	1	rs2281603	ENSG00000259116.1	RP11-973N13.4	-4.22	4.24e-05	0.0167	-0.31	-0.33	Lymphocyte counts;	chr14:64459379	chr14:64514154~64540368:-
PCPG	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-4.22	4.25e-05	0.0167	-0.52	-0.33	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
PCPG	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-4.22	4.25e-05	0.0167	-0.26	-0.33	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
PCPG	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	4.22	4.25e-05	0.0167	0.38	0.33	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
PCPG	cis	rs2736345	0.788	rs2618476	ENSG00000255518.1	RP11-148O21.4	4.22	4.25e-05	0.0167	0.39	0.33	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11556251~11558022:-
PCPG	cis	rs13118159	0.55	rs2336081	ENSG00000254094.1	AC078852.1	4.22	4.26e-05	0.0168	0.42	0.33	Longevity;	chr4:1356534	chr4:1356581~1358075:+
PCPG	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	4.22	4.26e-05	0.0168	0.43	0.33	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
PCPG	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-4.22	4.26e-05	0.0168	-0.26	-0.33	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
PCPG	cis	rs2732480	0.577	rs2732466	ENSG00000240399.1	RP1-228P16.1	4.22	4.26e-05	0.0168	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.557	rs2634682	ENSG00000240399.1	RP1-228P16.1	4.22	4.26e-05	0.0168	0.35	0.33	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48054813~48055591:-
PCPG	cis	rs896854	0.54	rs2011567	ENSG00000272509.1	RP11-347C18.5	4.22	4.26e-05	0.0168	0.33	0.33	Type 2 diabetes;	chr8:94959692	chr8:94884609~94885070:+
PCPG	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	4.22	4.26e-05	0.0168	0.32	0.33	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
PCPG	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-4.22	4.26e-05	0.0168	-0.44	-0.33	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
PCPG	cis	rs13392177	0.672	rs4674270	ENSG00000273466.1	RP11-548H3.1	-4.22	4.27e-05	0.0168	-0.18	-0.33	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218633256~218634014:-
PCPG	cis	rs9840812	0.637	rs698270	ENSG00000273486.1	RP11-731C17.2	4.22	4.27e-05	0.0168	0.39	0.33	Fibrinogen levels;	chr3:136390670	chr3:136837338~136839021:-
PCPG	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	4.22	4.27e-05	0.0168	0.36	0.33	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
PCPG	cis	rs2278034	0.578	rs881753	ENSG00000207650.1	MIR570	-4.22	4.28e-05	0.0168	-0.32	-0.33	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195699401~195699497:+
PCPG	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	4.22	4.28e-05	0.0168	0.38	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
PCPG	cis	rs394563	0.775	rs412894	ENSG00000231760.4	RP11-350J20.5	4.22	4.28e-05	0.0168	0.4	0.33	Dupuytren's disease;	chr6:149460039	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.717	rs548848	ENSG00000231760.4	RP11-350J20.5	4.22	4.28e-05	0.0168	0.4	0.33	Dupuytren's disease;	chr6:149460873	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.775	rs399673	ENSG00000231760.4	RP11-350J20.5	4.22	4.28e-05	0.0168	0.4	0.33	Dupuytren's disease;	chr6:149462085	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.775	rs420430	ENSG00000231760.4	RP11-350J20.5	4.22	4.28e-05	0.0168	0.4	0.33	Dupuytren's disease;	chr6:149464403	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.775	rs448420	ENSG00000231760.4	RP11-350J20.5	4.22	4.28e-05	0.0168	0.4	0.33	Dupuytren's disease;	chr6:149464666	chr6:149796151~149826294:-
PCPG	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-4.22	4.29e-05	0.0168	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
PCPG	cis	rs4718428	0.96	rs6460317	ENSG00000273142.1	RP11-458F8.4	-4.22	4.29e-05	0.0168	-0.3	-0.33	Corneal structure;	chr7:66925268	chr7:66902857~66906297:+
PCPG	cis	rs2531992	1	rs2531992	ENSG00000262185.1	RP11-462G12.1	-4.22	4.29e-05	0.0168	-0.52	-0.33	Waist circumference;	chr16:3971733	chr16:3947609~3950444:-
PCPG	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	4.22	4.29e-05	0.0168	0.38	0.33	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	4.22	4.29e-05	0.0168	0.38	0.33	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	4.22	4.29e-05	0.0168	0.38	0.33	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
PCPG	cis	rs5743030	0.702	rs256563	ENSG00000253559.1	OSGEPL1-AS1	-4.22	4.29e-05	0.0168	-0.49	-0.33	Subcutaneous adipose tissue;	chr2:189867106	chr2:189762704~189765556:+
PCPG	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	4.22	4.29e-05	0.0169	0.68	0.33	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
PCPG	cis	rs4819052	0.704	rs2297283	ENSG00000215447.6	BX322557.10	-4.22	4.29e-05	0.0169	-0.29	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45288052~45291738:+
PCPG	cis	rs11858159	0.902	rs61995200	ENSG00000260760.1	PWRN3	4.22	4.3e-05	0.0169	0.35	0.33	Platelet thrombus formation;	chr15:24570034	chr15:24441127~24447967:+
PCPG	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	4.22	4.3e-05	0.0169	0.32	0.33	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	4.22	4.3e-05	0.0169	0.32	0.33	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
PCPG	cis	rs6787172	0.782	rs4431160	ENSG00000271778.1	RP11-379F4.8	4.22	4.3e-05	0.0169	0.29	0.33	Subjective well-being;	chr3:158491277	chr3:158782547~158783124:+
PCPG	cis	rs6579956	0.565	rs62400576	ENSG00000270978.1	RP11-54C4.2	-4.22	4.3e-05	0.0169	-0.4	-0.33	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152806398	chr5:151848886~151850791:+
PCPG	cis	rs4718428	0.924	rs6971897	ENSG00000273142.1	RP11-458F8.4	-4.21	4.3e-05	0.0169	-0.3	-0.33	Corneal structure;	chr7:66947787	chr7:66902857~66906297:+
PCPG	cis	rs12681963	0.748	rs12546409	ENSG00000248159.1	HSPA8P11	4.21	4.3e-05	0.0169	0.49	0.33	Migraine;	chr8:30045440	chr8:30237382~30240997:+
PCPG	cis	rs9393777	0.92	rs13196692	ENSG00000219392.1	RP1-265C24.5	-4.21	4.3e-05	0.0169	-0.71	-0.33	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28115628~28116551:+
PCPG	cis	rs9393777	0.92	rs34150729	ENSG00000219392.1	RP1-265C24.5	-4.21	4.3e-05	0.0169	-0.71	-0.33	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28115628~28116551:+
PCPG	cis	rs9393777	0.92	rs13191227	ENSG00000219392.1	RP1-265C24.5	-4.21	4.3e-05	0.0169	-0.71	-0.33	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28115628~28116551:+
PCPG	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-4.21	4.3e-05	0.0169	-0.41	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
PCPG	cis	rs2554380	0.55	rs12904106	ENSG00000230373.7	GOLGA6L5P	-4.21	4.3e-05	0.0169	-0.38	-0.33	Height;	chr15:83842571	chr15:84507885~84516814:-
PCPG	cis	rs2554380	0.55	rs11853949	ENSG00000230373.7	GOLGA6L5P	-4.21	4.3e-05	0.0169	-0.38	-0.33	Height;	chr15:83848152	chr15:84507885~84516814:-
PCPG	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	4.21	4.3e-05	0.0169	0.34	0.33	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
PCPG	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	4.21	4.3e-05	0.0169	0.34	0.33	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
PCPG	cis	rs394563	0.663	rs415434	ENSG00000231760.4	RP11-350J20.5	4.21	4.3e-05	0.0169	0.41	0.33	Dupuytren's disease;	chr6:149451509	chr6:149796151~149826294:-
PCPG	cis	rs7247513	0.964	rs12979795	ENSG00000213290.4	PGK1P2	4.21	4.31e-05	0.0169	0.44	0.33	Bipolar disorder;	chr19:12607033	chr19:12559571~12561105:+
PCPG	cis	rs440932	0.757	rs330943	ENSG00000173295.6	FAM86B3P	-4.21	4.31e-05	0.0169	-0.39	-0.33	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:8228595~8244865:+
PCPG	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	4.21	4.31e-05	0.0169	0.35	0.33	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
PCPG	cis	rs9614461	0.609	rs9614666	ENSG00000280383.1	CTA-941F9.10	4.21	4.32e-05	0.0169	0.37	0.33	Tonsillectomy;	chr22:45433680	chr22:45657019~45680130:+
PCPG	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	4.21	4.32e-05	0.0169	0.43	0.33	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
PCPG	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-4.21	4.32e-05	0.0169	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
PCPG	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	4.21	4.32e-05	0.0169	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
PCPG	cis	rs1440410	0.798	rs13128884	ENSG00000250326.1	RP11-284M14.1	4.21	4.32e-05	0.0169	0.3	0.33	Ischemic stroke;	chr4:143186669	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4582112	ENSG00000250326.1	RP11-284M14.1	4.21	4.32e-05	0.0169	0.3	0.33	Ischemic stroke;	chr4:143190579	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.866	rs13139457	ENSG00000250326.1	RP11-284M14.1	4.21	4.32e-05	0.0169	0.3	0.33	Ischemic stroke;	chr4:143192647	chr4:142933195~143184861:-
PCPG	cis	rs11148252	0.774	rs9536066	ENSG00000235660.1	LINC00345	-4.21	4.32e-05	0.0169	-0.39	-0.33	Lewy body disease;	chr13:52409846	chr13:52484161~52484680:-
PCPG	cis	rs6121246	0.909	rs6087778	ENSG00000230613.1	HM13-AS1	4.21	4.33e-05	0.017	0.47	0.33	Mean corpuscular hemoglobin;	chr20:31766339	chr20:31567707~31573263:-
PCPG	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-4.21	4.33e-05	0.017	-0.47	-0.33	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
PCPG	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	4.21	4.33e-05	0.017	0.4	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	4.21	4.33e-05	0.017	0.4	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	4.21	4.33e-05	0.017	0.4	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	4.21	4.33e-05	0.017	0.4	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	4.21	4.33e-05	0.017	0.4	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	4.21	4.33e-05	0.017	0.4	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
PCPG	cis	rs7772486	0.686	rs1337841	ENSG00000270638.1	RP3-466P17.1	-4.21	4.33e-05	0.017	-0.33	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145735570~145737218:+
PCPG	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-4.21	4.33e-05	0.017	-0.41	-0.33	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
PCPG	cis	rs300890	0.76	rs6537152	ENSG00000250326.1	RP11-284M14.1	4.21	4.34e-05	0.017	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143280891	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.76	rs12643013	ENSG00000250326.1	RP11-284M14.1	4.21	4.34e-05	0.017	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143285795	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.76	rs6823434	ENSG00000250326.1	RP11-284M14.1	4.21	4.34e-05	0.017	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143278700	chr4:142933195~143184861:-
PCPG	cis	rs7702057	0.53	rs3087831	ENSG00000271918.1	CTD-2287O16.5	4.21	4.34e-05	0.017	0.46	0.33	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116083807~116085416:-
PCPG	cis	rs300890	0.76	rs10028909	ENSG00000250326.1	RP11-284M14.1	4.21	4.34e-05	0.017	0.3	0.33	Nasopharyngeal carcinoma;	chr4:143279439	chr4:142933195~143184861:-
PCPG	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	4.21	4.34e-05	0.017	0.35	0.33	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
PCPG	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-4.21	4.34e-05	0.017	-0.49	-0.33	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
PCPG	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-4.21	4.35e-05	0.017	-0.48	-0.33	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
PCPG	cis	rs748404	0.915	rs35535692	ENSG00000249839.1	AC011330.5	-4.21	4.35e-05	0.017	-0.45	-0.33	Lung cancer;	chr15:43252037	chr15:43663654~43684339:-
PCPG	cis	rs561341	0.941	rs736678	ENSG00000265798.5	RP11-271K11.5	4.21	4.35e-05	0.017	0.58	0.33	Hip circumference adjusted for BMI;	chr17:32020404	chr17:31038575~31059121:-
PCPG	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	4.21	4.35e-05	0.017	0.43	0.33	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
PCPG	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	4.21	4.35e-05	0.017	0.43	0.33	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
PCPG	cis	rs7824557	0.603	rs2249804	ENSG00000255020.1	AF131216.5	4.21	4.36e-05	0.0171	0.44	0.33	Retinal vascular caliber;	chr8:11358108	chr8:11345748~11347502:-
PCPG	cis	rs3095748	1	rs3095748	ENSG00000226237.1	RP11-276H19.1	4.21	4.36e-05	0.0171	0.76	0.33	Immune reponse to smallpox (secreted IFN-alpha);	chr9:87594222	chr9:86948699~87002033:+
PCPG	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-4.21	4.36e-05	0.0171	-0.71	-0.33	Gout;	chr7:66679692	chr7:66654538~66669855:+
PCPG	cis	rs2911132	0.967	rs2042380	ENSG00000248734.2	CTD-2260A17.1	4.21	4.36e-05	0.0171	0.34	0.33	Urate levels (BMI interaction);	chr5:96851563	chr5:96784777~96785999:+
PCPG	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	4.21	4.36e-05	0.0171	0.42	0.33	Height;	chr6:109476101	chr6:109382795~109383666:+
PCPG	cis	rs13108904	0.875	rs10024013	ENSG00000253399.1	AC078852.2	4.21	4.37e-05	0.0171	0.34	0.33	Obesity-related traits;	chr4:1287004	chr4:1358479~1359461:+
PCPG	cis	rs7819412	0.522	rs4841497	ENSG00000255020.1	AF131216.5	-4.21	4.37e-05	0.0171	-0.45	-0.33	Triglycerides;	chr8:11127630	chr8:11345748~11347502:-
PCPG	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	4.21	4.37e-05	0.0171	0.49	0.33	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	4.21	4.37e-05	0.0171	0.49	0.33	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	4.21	4.37e-05	0.0171	0.49	0.33	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
PCPG	cis	rs3764021	0.87	rs7970116	ENSG00000278635.1	CTD-2318O12.1	4.21	4.37e-05	0.0171	0.4	0.33	Type 1 diabetes;	chr12:9727518	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.87	rs7976584	ENSG00000278635.1	CTD-2318O12.1	-4.21	4.37e-05	0.0171	-0.4	-0.33	Type 1 diabetes;	chr12:9726059	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.87	rs2192437	ENSG00000278635.1	CTD-2318O12.1	-4.21	4.37e-05	0.0171	-0.4	-0.33	Type 1 diabetes;	chr12:9726639	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.87	rs10844617	ENSG00000278635.1	CTD-2318O12.1	-4.21	4.37e-05	0.0171	-0.4	-0.33	Type 1 diabetes;	chr12:9726772	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.87	rs2401394	ENSG00000278635.1	CTD-2318O12.1	-4.21	4.37e-05	0.0171	-0.4	-0.33	Type 1 diabetes;	chr12:9726830	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.743	rs7973535	ENSG00000278635.1	CTD-2318O12.1	-4.21	4.37e-05	0.0171	-0.4	-0.33	Type 1 diabetes;	chr12:9727801	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.87	rs7973638	ENSG00000278635.1	CTD-2318O12.1	-4.21	4.37e-05	0.0171	-0.4	-0.33	Type 1 diabetes;	chr12:9727845	chr12:9415641~9416718:+
PCPG	cis	rs7824557	0.767	rs10104728	ENSG00000184608.7	FAM167A-AS1	4.21	4.37e-05	0.0171	0.46	0.33	Retinal vascular caliber;	chr8:11313791	chr8:11368402~11438658:+
PCPG	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	4.21	4.38e-05	0.0171	0.4	0.33	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
PCPG	cis	rs11148252	0.564	rs2296350	ENSG00000235660.1	LINC00345	-4.21	4.38e-05	0.0171	-0.39	-0.33	Lewy body disease;	chr13:52135908	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.538	rs2296348	ENSG00000235660.1	LINC00345	-4.21	4.38e-05	0.0171	-0.39	-0.33	Lewy body disease;	chr13:52136000	chr13:52484161~52484680:-
PCPG	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-4.21	4.38e-05	0.0171	-0.34	-0.33	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
PCPG	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-4.21	4.38e-05	0.0171	-0.41	-0.33	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-4.21	4.38e-05	0.0171	-0.41	-0.33	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-4.21	4.38e-05	0.0171	-0.41	-0.33	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
PCPG	cis	rs761746	0.739	rs5998072	ENSG00000128254.12	C22orf24	-4.21	4.39e-05	0.0171	-0.43	-0.33	Intelligence;	chr22:31652388	chr22:31933521~31945518:-
PCPG	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-4.21	4.39e-05	0.0171	-0.64	-0.33	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
PCPG	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	4.21	4.39e-05	0.0172	0.33	0.33	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	4.21	4.39e-05	0.0172	0.33	0.33	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-4.21	4.39e-05	0.0172	-0.33	-0.33	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-4.21	4.39e-05	0.0172	-0.33	-0.33	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
PCPG	cis	rs1240773	0.508	rs1784120	ENSG00000280143.1	AP000892.6	4.21	4.4e-05	0.0172	0.33	0.33	HIV-1 susceptibility;	chr11:116691143	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs1787703	ENSG00000280143.1	AP000892.6	4.21	4.4e-05	0.0172	0.33	0.33	HIV-1 susceptibility;	chr11:116691550	chr11:117204967~117210292:+
PCPG	cis	rs1240773	0.508	rs1787702	ENSG00000280143.1	AP000892.6	4.21	4.4e-05	0.0172	0.33	0.33	HIV-1 susceptibility;	chr11:116691572	chr11:117204967~117210292:+
PCPG	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	4.21	4.4e-05	0.0172	0.42	0.33	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
PCPG	cis	rs8030379	1	rs4842838	ENSG00000230373.7	GOLGA6L5P	4.21	4.4e-05	0.0172	0.33	0.33	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84507885~84516814:-
PCPG	cis	rs2439831	1	rs690436	ENSG00000205771.5	CATSPER2P1	-4.21	4.4e-05	0.0172	-0.44	-0.33	Lung cancer in ever smokers;	chr15:43469007	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2264239	ENSG00000205771.5	CATSPER2P1	-4.21	4.4e-05	0.0172	-0.44	-0.33	Lung cancer in ever smokers;	chr15:43473335	chr15:43726918~43747094:-
PCPG	cis	rs2439831	1	rs2439831	ENSG00000205771.5	CATSPER2P1	-4.21	4.4e-05	0.0172	-0.44	-0.33	Lung cancer in ever smokers;	chr15:43492277	chr15:43726918~43747094:-
PCPG	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-4.21	4.4e-05	0.0172	-0.44	-0.33	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
PCPG	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-4.21	4.4e-05	0.0172	-0.44	-0.33	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
PCPG	cis	rs17772222	0.917	rs12588535	ENSG00000222990.1	RNU4-22P	4.21	4.4e-05	0.0172	0.42	0.33	Coronary artery calcification;	chr14:88781900	chr14:88513498~88513663:+
PCPG	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	4.21	4.41e-05	0.0172	0.35	0.32	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
PCPG	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	4.21	4.41e-05	0.0172	0.42	0.32	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	4.21	4.41e-05	0.0172	0.42	0.32	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
PCPG	cis	rs853679	0.882	rs9461432	ENSG00000216901.1	AL022393.7	4.21	4.41e-05	0.0172	0.62	0.32	Depression;	chr6:28119105	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.882	rs4713139	ENSG00000216901.1	AL022393.7	4.21	4.41e-05	0.0172	0.62	0.32	Depression;	chr6:28124907	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.882	rs3757188	ENSG00000216901.1	AL022393.7	4.21	4.41e-05	0.0172	0.62	0.32	Depression;	chr6:28139579	chr6:28176188~28176674:+
PCPG	cis	rs1440410	0.835	rs6820538	ENSG00000250326.1	RP11-284M14.1	4.21	4.41e-05	0.0172	0.3	0.32	Ischemic stroke;	chr4:143207923	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.866	rs4637346	ENSG00000250326.1	RP11-284M14.1	4.21	4.41e-05	0.0172	0.3	0.32	Ischemic stroke;	chr4:143212890	chr4:142933195~143184861:-
PCPG	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	4.21	4.41e-05	0.0172	0.48	0.32	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
PCPG	cis	rs7444	0.941	rs73166622	ENSG00000211645.2	IGLV1-50	4.21	4.41e-05	0.0172	0.41	0.32	Systemic lupus erythematosus;	chr22:21584574	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs1034329	ENSG00000211645.2	IGLV1-50	4.21	4.41e-05	0.0172	0.41	0.32	Systemic lupus erythematosus;	chr22:21589649	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs2283789	ENSG00000211645.2	IGLV1-50	4.21	4.41e-05	0.0172	0.41	0.32	Systemic lupus erythematosus;	chr22:21590189	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs73166632	ENSG00000211645.2	IGLV1-50	4.21	4.41e-05	0.0172	0.41	0.32	Systemic lupus erythematosus;	chr22:21591884	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs5754295	ENSG00000211645.2	IGLV1-50	4.21	4.41e-05	0.0172	0.41	0.32	Systemic lupus erythematosus;	chr22:21597451	chr22:22327300~22327814:+
PCPG	cis	rs7160336	0.738	rs11849883	ENSG00000259065.1	RP5-1021I20.1	4.21	4.41e-05	0.0172	0.41	0.32	Blood protein levels;	chr14:74010633	chr14:73787360~73803270:+
PCPG	cis	rs4295623	0.556	rs10903343	ENSG00000255495.1	AC145124.2	4.21	4.42e-05	0.0172	0.31	0.32	Morning vs. evening chronotype;	chr8:11838363	chr8:12194467~12196280:+
PCPG	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-4.21	4.42e-05	0.0172	-0.46	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
PCPG	cis	rs7017914	0.677	rs6472566	ENSG00000254031.4	RP11-326E22.1	4.21	4.42e-05	0.0172	0.32	0.32	Bone mineral density;	chr8:71088249	chr8:71155457~71204223:+
PCPG	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-4.21	4.42e-05	0.0173	-0.42	-0.32	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
PCPG	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	4.21	4.43e-05	0.0173	0.43	0.32	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-4.21	4.43e-05	0.0173	-0.45	-0.32	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
PCPG	cis	rs13108904	0.87	rs4974541	ENSG00000254094.1	AC078852.1	-4.21	4.43e-05	0.0173	-0.38	-0.32	Obesity-related traits;	chr4:1250249	chr4:1356581~1358075:+
PCPG	cis	rs3764021	0.527	rs10844537	ENSG00000278635.1	CTD-2318O12.1	-4.21	4.43e-05	0.0173	-0.4	-0.32	Type 1 diabetes;	chr12:9709528	chr12:9415641~9416718:+
PCPG	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	4.21	4.43e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	4.21	4.43e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
PCPG	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	4.21	4.43e-05	0.0173	0.33	0.32	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
PCPG	cis	rs1003719	0.715	rs7277820	ENSG00000228677.1	TTC3-AS1	-4.21	4.44e-05	0.0173	-0.4	-0.32	Eye color traits;	chr21:37208008	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs2835675	ENSG00000228677.1	TTC3-AS1	-4.21	4.44e-05	0.0173	-0.4	-0.32	Eye color traits;	chr21:37210514	chr21:37187666~37193926:-
PCPG	cis	rs4980659	0.742	rs12365303	ENSG00000260679.1	RP11-643C9.2	4.21	4.44e-05	0.0173	0.33	0.32	Total body bone mineral density;	chr11:69492629	chr11:69921638~69926813:-
PCPG	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	4.21	4.44e-05	0.0173	0.4	0.32	Height;	chr6:109351795	chr6:109382795~109383666:+
PCPG	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	4.21	4.44e-05	0.0173	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
PCPG	cis	rs240993	0.812	rs118203	ENSG00000230177.1	RP5-1112D6.4	-4.21	4.45e-05	0.0173	-0.39	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111277932~111278742:+
PCPG	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-4.21	4.45e-05	0.0173	-0.34	-0.32	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
PCPG	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-4.21	4.45e-05	0.0173	-0.48	-0.32	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
PCPG	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
PCPG	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	4.21	4.45e-05	0.0173	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
PCPG	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
PCPG	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	4.21	4.45e-05	0.0173	0.42	0.32	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
PCPG	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	4.21	4.45e-05	0.0173	0.37	0.32	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
PCPG	cis	rs1003719	0.715	rs2835667	ENSG00000228677.1	TTC3-AS1	-4.21	4.46e-05	0.0174	-0.4	-0.32	Eye color traits;	chr21:37207613	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs2835668	ENSG00000228677.1	TTC3-AS1	-4.21	4.46e-05	0.0174	-0.4	-0.32	Eye color traits;	chr21:37207850	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs2835670	ENSG00000228677.1	TTC3-AS1	-4.21	4.46e-05	0.0174	-0.4	-0.32	Eye color traits;	chr21:37208813	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.646	rs2835671	ENSG00000228677.1	TTC3-AS1	-4.21	4.46e-05	0.0174	-0.4	-0.32	Eye color traits;	chr21:37208824	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.646	rs2835672	ENSG00000228677.1	TTC3-AS1	-4.21	4.46e-05	0.0174	-0.4	-0.32	Eye color traits;	chr21:37208933	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.707	rs9976360	ENSG00000228677.1	TTC3-AS1	-4.21	4.46e-05	0.0174	-0.4	-0.32	Eye color traits;	chr21:37215559	chr21:37187666~37193926:-
PCPG	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-4.21	4.46e-05	0.0174	-0.34	-0.32	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
PCPG	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-4.21	4.46e-05	0.0174	-0.36	-0.32	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
PCPG	cis	rs763014	0.931	rs2071981	ENSG00000262528.2	LA16c-349E10.1	4.21	4.46e-05	0.0174	0.38	0.32	Height;	chr16:580025	chr16:654611~656194:-
PCPG	cis	rs763014	0.931	rs7192508	ENSG00000262528.2	LA16c-349E10.1	4.21	4.46e-05	0.0174	0.38	0.32	Height;	chr16:580367	chr16:654611~656194:-
PCPG	cis	rs763014	0.931	rs2071982	ENSG00000262528.2	LA16c-349E10.1	4.21	4.46e-05	0.0174	0.38	0.32	Height;	chr16:580405	chr16:654611~656194:-
PCPG	cis	rs763014	0.931	rs1981483	ENSG00000262528.2	LA16c-349E10.1	4.21	4.46e-05	0.0174	0.38	0.32	Height;	chr16:580665	chr16:654611~656194:-
PCPG	cis	rs763014	0.898	rs1981484	ENSG00000262528.2	LA16c-349E10.1	4.21	4.46e-05	0.0174	0.38	0.32	Height;	chr16:580710	chr16:654611~656194:-
PCPG	cis	rs763014	0.898	rs4984892	ENSG00000262528.2	LA16c-349E10.1	4.21	4.47e-05	0.0174	0.39	0.32	Height;	chr16:572325	chr16:654611~656194:-
PCPG	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	4.21	4.47e-05	0.0174	0.3	0.32	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-4.21	4.47e-05	0.0174	-0.3	-0.32	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
PCPG	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	4.2	4.47e-05	0.0174	0.67	0.32	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	4.2	4.47e-05	0.0174	0.67	0.32	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
PCPG	cis	rs2554380	0.542	rs7164141	ENSG00000230373.7	GOLGA6L5P	4.2	4.47e-05	0.0174	0.38	0.32	Height;	chr15:83824253	chr15:84507885~84516814:-
PCPG	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-4.2	4.47e-05	0.0174	-0.52	-0.32	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
PCPG	cis	rs720064	0.586	rs9950106	ENSG00000265752.2	RP11-403A21.1	4.2	4.47e-05	0.0174	0.37	0.32	Strep throat;	chr18:23967901	chr18:23957754~23982556:-
PCPG	cis	rs720064	0.586	rs9961089	ENSG00000265752.2	RP11-403A21.1	4.2	4.47e-05	0.0174	0.37	0.32	Strep throat;	chr18:23967999	chr18:23957754~23982556:-
PCPG	cis	rs7824557	0.564	rs13260727	ENSG00000255495.1	AC145124.2	4.2	4.47e-05	0.0174	0.32	0.32	Retinal vascular caliber;	chr8:11375351	chr8:12194467~12196280:+
PCPG	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	4.2	4.48e-05	0.0174	0.32	0.32	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
PCPG	cis	rs6121246	0.909	rs3203770	ENSG00000230613.1	HM13-AS1	4.2	4.48e-05	0.0174	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31794512	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6058463	ENSG00000230613.1	HM13-AS1	4.2	4.48e-05	0.0174	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31797389	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6119725	ENSG00000230613.1	HM13-AS1	4.2	4.48e-05	0.0174	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31797754	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs1075698	ENSG00000230613.1	HM13-AS1	4.2	4.48e-05	0.0174	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31800189	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.738	rs6121242	ENSG00000230613.1	HM13-AS1	4.2	4.48e-05	0.0174	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31823074	chr20:31567707~31573263:-
PCPG	cis	rs6674176	0.597	rs2352990	ENSG00000237950.1	RP11-7O11.3	4.2	4.48e-05	0.0174	0.38	0.32	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927604	chr1:43944370~43946551:-
PCPG	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-4.2	4.48e-05	0.0174	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
PCPG	cis	rs357618	1	rs165351	ENSG00000260581.1	CTB-113P19.4	4.2	4.48e-05	0.0174	0.38	0.32	Basophil percentage of white cells;	chr5:151475320	chr5:151652275~151655449:+
PCPG	cis	rs7444	0.941	rs4821108	ENSG00000211645.2	IGLV1-50	4.2	4.48e-05	0.0174	0.41	0.32	Systemic lupus erythematosus;	chr22:21604749	chr22:22327300~22327814:+
PCPG	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	4.2	4.48e-05	0.0174	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
PCPG	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-4.2	4.49e-05	0.0175	-0.48	-0.32	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-4.2	4.49e-05	0.0175	-0.48	-0.32	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-4.2	4.49e-05	0.0175	-0.47	-0.32	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
PCPG	cis	rs6504340	0.741	rs34490194	ENSG00000279036.1	RP11-81K2.2	-4.2	4.49e-05	0.0175	-0.57	-0.32	Primary tooth development (number of teeth);	chr17:48571382	chr17:49494223~49497800:-
PCPG	cis	rs11992162	1	rs7460395	ENSG00000255020.1	AF131216.5	4.2	4.49e-05	0.0175	0.43	0.32	Monocyte count;	chr8:11977866	chr8:11345748~11347502:-
PCPG	cis	rs4713118	0.588	rs200994	ENSG00000216901.1	AL022393.7	-4.2	4.49e-05	0.0175	-0.47	-0.32	Parkinson's disease;	chr6:27846035	chr6:28176188~28176674:+
PCPG	cis	rs17684571	0.751	rs17684878	ENSG00000231441.1	RP11-472M19.2	4.2	4.5e-05	0.0175	0.55	0.32	Schizophrenia;	chr6:56838178	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.751	rs17684884	ENSG00000231441.1	RP11-472M19.2	4.2	4.5e-05	0.0175	0.55	0.32	Schizophrenia;	chr6:56838852	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.751	rs74777312	ENSG00000231441.1	RP11-472M19.2	4.2	4.5e-05	0.0175	0.55	0.32	Schizophrenia;	chr6:56845568	chr6:56844002~56864078:+
PCPG	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-4.2	4.5e-05	0.0175	-0.35	-0.32	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
PCPG	cis	rs394563	0.967	rs444784	ENSG00000268592.3	RAET1E-AS1	4.2	4.5e-05	0.0175	0.41	0.32	Dupuytren's disease;	chr6:149477230	chr6:149863494~149919507:+
PCPG	cis	rs394563	0.967	rs369643	ENSG00000268592.3	RAET1E-AS1	4.2	4.5e-05	0.0175	0.41	0.32	Dupuytren's disease;	chr6:149478662	chr6:149863494~149919507:+
PCPG	cis	rs7824557	0.606	rs1047950	ENSG00000255020.1	AF131216.5	4.2	4.5e-05	0.0175	0.43	0.32	Retinal vascular caliber;	chr8:11327587	chr8:11345748~11347502:-
PCPG	cis	rs7017914	0.714	rs13273979	ENSG00000254031.4	RP11-326E22.1	4.2	4.5e-05	0.0175	0.3	0.32	Bone mineral density;	chr8:70825087	chr8:71155457~71204223:+
PCPG	cis	rs5758511	0.68	rs5758688	ENSG00000227370.1	RP4-669P10.19	4.2	4.5e-05	0.0175	0.49	0.32	Birth weight;	chr22:42266495	chr22:42132543~42132998:+
PCPG	cis	rs5758511	0.633	rs5758689	ENSG00000227370.1	RP4-669P10.19	4.2	4.5e-05	0.0175	0.49	0.32	Birth weight;	chr22:42268966	chr22:42132543~42132998:+
PCPG	cis	rs3947	1	rs1736081	ENSG00000227203.3	SUB1P1	-4.2	4.5e-05	0.0175	-0.49	-0.32	Blood protein levels;	chr8:11845331	chr8:11790005~11790386:+
PCPG	cis	rs6802315	0.573	rs7635993	ENSG00000271778.1	RP11-379F4.8	4.2	4.5e-05	0.0175	0.29	0.32	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158782547~158783124:+
PCPG	cis	rs11858159	1	rs11854549	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24562616	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs11854816	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24562681	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs12898677	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24562887	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs8043434	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24563781	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs8025086	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24563897	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7496699	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24564716	chr15:24441127~24447967:+
PCPG	cis	rs7403037	0.565	rs12909476	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24564823	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.871	rs12909793	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24565230	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs12910163	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24565407	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12908881	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24565731	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12915177	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24565882	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.841	rs12913964	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24566377	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12915797	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24566455	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs11852693	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24567871	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs11857090	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24568104	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs7178027	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24568910	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7172700	ENSG00000260760.1	PWRN3	4.2	4.51e-05	0.0175	0.35	0.32	Platelet thrombus formation;	chr15:24569014	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs11854681	ENSG00000260760.1	PWRN3	-4.2	4.51e-05	0.0175	-0.35	-0.32	Platelet thrombus formation;	chr15:24563004	chr15:24441127~24447967:+
PCPG	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	4.2	4.51e-05	0.0175	0.42	0.32	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
PCPG	cis	rs17684571	0.7	rs6904535	ENSG00000231441.1	RP11-472M19.2	4.2	4.51e-05	0.0175	0.53	0.32	Schizophrenia;	chr6:56767178	chr6:56844002~56864078:+
PCPG	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-4.2	4.51e-05	0.0175	-0.43	-0.32	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
PCPG	cis	rs763014	0.865	rs62030874	ENSG00000262528.2	LA16c-349E10.1	4.2	4.51e-05	0.0175	0.39	0.32	Height;	chr16:582233	chr16:654611~656194:-
PCPG	cis	rs937213	0.643	rs11852600	ENSG00000259584.1	RP11-521C20.2	4.2	4.52e-05	0.0175	0.39	0.32	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39998280	chr15:40075204~40078704:-
PCPG	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-4.2	4.52e-05	0.0175	-0.41	-0.32	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
PCPG	cis	rs11858159	0.646	rs4778410	ENSG00000259905.4	PWRN1	4.2	4.52e-05	0.0175	0.37	0.32	Platelet thrombus formation;	chr15:24136058	chr15:24493137~24652130:+
PCPG	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	4.2	4.52e-05	0.0175	0.53	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
PCPG	cis	rs1048886	0.872	rs76830193	ENSG00000271967.1	RP11-134K13.4	-4.2	4.52e-05	0.0175	-0.41	-0.32	Type 2 diabetes;	chr6:70461113	chr6:70596438~70596980:+
PCPG	cis	rs1371867	0.817	rs1788185	ENSG00000212994.5	RPS26P6	4.2	4.52e-05	0.0175	0.37	0.32	Atrioventricular conduction;	chr8:100323301	chr8:100895771~100896118:+
PCPG	cis	rs5758511	0.689	rs5758691	ENSG00000227370.1	RP4-669P10.19	4.2	4.52e-05	0.0175	0.49	0.32	Birth weight;	chr22:42272498	chr22:42132543~42132998:+
PCPG	cis	rs5758511	0.68	rs5758692	ENSG00000227370.1	RP4-669P10.19	4.2	4.52e-05	0.0175	0.49	0.32	Birth weight;	chr22:42273023	chr22:42132543~42132998:+
PCPG	cis	rs5758511	0.634	rs1001587	ENSG00000227370.1	RP4-669P10.19	4.2	4.52e-05	0.0175	0.49	0.32	Birth weight;	chr22:42274105	chr22:42132543~42132998:+
PCPG	cis	rs5758511	0.68	rs1001586	ENSG00000227370.1	RP4-669P10.19	4.2	4.52e-05	0.0175	0.49	0.32	Birth weight;	chr22:42274287	chr22:42132543~42132998:+
PCPG	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	4.2	4.52e-05	0.0175	0.38	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
PCPG	cis	rs13118159	0.55	rs1137789	ENSG00000254094.1	AC078852.1	-4.2	4.52e-05	0.0175	-0.4	-0.32	Longevity;	chr4:1388010	chr4:1356581~1358075:+
PCPG	cis	rs748404	0.626	rs1814324	ENSG00000205771.5	CATSPER2P1	-4.2	4.52e-05	0.0175	-0.43	-0.32	Lung cancer;	chr15:43314951	chr15:43726918~43747094:-
PCPG	cis	rs12048904	0.964	rs17123467	ENSG00000235795.1	RP11-421L21.2	-4.2	4.52e-05	0.0175	-0.39	-0.32	Multiple sclerosis;	chr1:100866204	chr1:100995473~100996260:+
PCPG	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	4.2	4.52e-05	0.0175	0.45	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
PCPG	cis	rs7759001	0.857	rs980960	ENSG00000271755.1	RP1-153G14.4	4.2	4.52e-05	0.0176	0.5	0.32	Glomerular filtration rate (creatinine);	chr6:27393263	chr6:27404010~27406964:-
PCPG	cis	rs1240773	0.508	rs1784122	ENSG00000280143.1	AP000892.6	4.2	4.52e-05	0.0176	0.33	0.32	HIV-1 susceptibility;	chr11:116690985	chr11:117204967~117210292:+
PCPG	cis	rs9393813	0.566	rs12662076	ENSG00000271755.1	RP1-153G14.4	4.2	4.53e-05	0.0176	0.42	0.32	Bipolar disorder;	chr6:27395358	chr6:27404010~27406964:-
PCPG	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-4.2	4.53e-05	0.0176	-0.32	-0.32	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
PCPG	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	4.2	4.53e-05	0.0176	0.48	0.32	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
PCPG	cis	rs4143844	1	rs11071644	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61969565	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs17271291	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61982818	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs34556569	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61989619	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs34042779	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61990899	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs62007791	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61992487	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs35259011	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61993260	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs12905264	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61994464	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs34424197	ENSG00000259251.2	RP11-643M14.1	4.2	4.53e-05	0.0176	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:61996620	chr15:62060503~62062434:+
PCPG	cis	rs8030379	1	rs11637866	ENSG00000230373.7	GOLGA6L5P	-4.2	4.53e-05	0.0176	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919206	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2135880	ENSG00000230373.7	GOLGA6L5P	-4.2	4.53e-05	0.0176	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83920861	chr15:84507885~84516814:-
PCPG	cis	rs1023500	0.505	rs134885	ENSG00000226450.2	CYP2D8P	4.2	4.53e-05	0.0176	0.31	0.32	Schizophrenia;	chr22:42277805	chr22:42149886~42155001:-
PCPG	cis	rs11148252	0.634	rs66849828	ENSG00000235660.1	LINC00345	-4.2	4.53e-05	0.0176	-0.4	-0.32	Lewy body disease;	chr13:52140701	chr13:52484161~52484680:-
PCPG	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	4.2	4.54e-05	0.0176	0.42	0.32	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
PCPG	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	4.2	4.54e-05	0.0176	0.43	0.32	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
PCPG	cis	rs896854	0.654	rs13248607	ENSG00000253528.2	RP11-347C18.4	4.2	4.54e-05	0.0176	0.35	0.32	Type 2 diabetes;	chr8:94974409	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.684	rs10099059	ENSG00000253528.2	RP11-347C18.4	4.2	4.54e-05	0.0176	0.35	0.32	Type 2 diabetes;	chr8:94974744	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.684	rs10099941	ENSG00000253528.2	RP11-347C18.4	4.2	4.54e-05	0.0176	0.35	0.32	Type 2 diabetes;	chr8:94974780	chr8:94974573~94974853:-
PCPG	cis	rs11148252	0.875	rs4884452	ENSG00000235660.1	LINC00345	4.2	4.54e-05	0.0176	0.4	0.32	Lewy body disease;	chr13:52375649	chr13:52484161~52484680:-
PCPG	cis	rs2440129	0.611	rs434473	ENSG00000262089.1	RP11-589P10.5	-4.2	4.54e-05	0.0176	-0.23	-0.32	Tonsillectomy;	chr17:7001615	chr17:6994642~6995189:-
PCPG	cis	rs11264799	0.765	rs12136747	ENSG00000224520.2	KRT8P45	-4.2	4.55e-05	0.0176	-0.4	-0.32	IgA nephropathy;	chr1:157667140	chr1:157073257~157074703:+
PCPG	cis	rs11783469	0.522	rs13281304	ENSG00000253390.1	CTC-756D1.2	-4.2	4.55e-05	0.0176	-0.46	-0.32	Reticulocyte count;	chr8:23409409	chr8:23458601~23484971:+
PCPG	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	4.2	4.55e-05	0.0176	0.35	0.32	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
PCPG	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-4.2	4.55e-05	0.0176	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
PCPG	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-4.2	4.56e-05	0.0177	-0.45	-0.32	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
PCPG	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-4.2	4.56e-05	0.0177	-0.39	-0.32	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-4.2	4.56e-05	0.0177	-0.39	-0.32	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
PCPG	cis	rs7610312	0.614	rs4681842	ENSG00000273493.1	RP11-80H18.4	-4.2	4.56e-05	0.0177	-0.38	-0.32	Red blood cell count;	chr3:58306852	chr3:58329965~58330118:+
PCPG	cis	rs9311676	0.502	rs4681676	ENSG00000273493.1	RP11-80H18.4	-4.2	4.56e-05	0.0177	-0.38	-0.32	Systemic lupus erythematosus;	chr3:58314070	chr3:58329965~58330118:+
PCPG	cis	rs7610312	0.681	rs6445969	ENSG00000273493.1	RP11-80H18.4	-4.2	4.56e-05	0.0177	-0.38	-0.32	Red blood cell count;	chr3:58315609	chr3:58329965~58330118:+
PCPG	cis	rs7610312	0.681	rs4681677	ENSG00000273493.1	RP11-80H18.4	-4.2	4.56e-05	0.0177	-0.38	-0.32	Red blood cell count;	chr3:58316313	chr3:58329965~58330118:+
PCPG	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-4.2	4.57e-05	0.0177	-0.49	-0.32	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
PCPG	cis	rs9326248	0.53	rs11216316	ENSG00000280143.1	AP000892.6	-4.2	4.57e-05	0.0177	-0.57	-0.32	Blood protein levels;	chr11:117210784	chr11:117204967~117210292:+
PCPG	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-4.2	4.57e-05	0.0177	-0.46	-0.32	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
PCPG	cis	rs324126	0.752	rs10445584	ENSG00000277977.1	CTD-3018O17.5	4.2	4.57e-05	0.0177	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs10445585	ENSG00000277977.1	CTD-3018O17.5	4.2	4.57e-05	0.0177	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs10445586	ENSG00000277977.1	CTD-3018O17.5	4.2	4.57e-05	0.0177	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs62108317	ENSG00000277977.1	CTD-3018O17.5	4.2	4.57e-05	0.0177	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52392659~52392755:+
PCPG	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	4.2	4.57e-05	0.0177	0.41	0.32	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
PCPG	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	4.2	4.58e-05	0.0177	0.3	0.32	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
PCPG	cis	rs394563	0.591	rs805026	ENSG00000231760.4	RP11-350J20.5	4.2	4.58e-05	0.0177	0.41	0.32	Dupuytren's disease;	chr6:149407118	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.591	rs237012	ENSG00000231760.4	RP11-350J20.5	4.2	4.58e-05	0.0177	0.41	0.32	Dupuytren's disease;	chr6:149408062	chr6:149796151~149826294:-
PCPG	cis	rs13108904	0.557	rs1680033	ENSG00000254094.1	AC078852.1	4.2	4.58e-05	0.0177	0.4	0.32	Obesity-related traits;	chr4:1249616	chr4:1356581~1358075:+
PCPG	cis	rs801193	0.875	rs13227951	ENSG00000273142.1	RP11-458F8.4	4.2	4.58e-05	0.0177	0.32	0.32	Aortic root size;	chr7:66748121	chr7:66902857~66906297:+
PCPG	cis	rs1003719	0.688	rs2835660	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37196581	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.688	rs2835662	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37196666	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs1034357	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37199181	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs2835664	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37201128	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.553	rs1063948	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37202373	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.646	rs2032063	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37204356	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.646	rs7276711	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37205888	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs7276569	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37205906	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs2212742	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37206384	chr21:37187666~37193926:-
PCPG	cis	rs6714900	0.588	rs11675048	ENSG00000179818.12	PCBP1-AS1	-4.2	4.58e-05	0.0177	-0.36	-0.32	Blood protein levels;	chr2:71065534	chr2:69962263~70103220:-
PCPG	cis	rs1003719	0.523	rs1063949	ENSG00000228677.1	TTC3-AS1	-4.2	4.58e-05	0.0177	-0.4	-0.32	Eye color traits;	chr21:37202374	chr21:37187666~37193926:-
PCPG	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-4.2	4.58e-05	0.0177	-0.37	-0.32	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
PCPG	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	4.2	4.58e-05	0.0177	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
PCPG	cis	rs7824557	0.614	rs2736277	ENSG00000255020.1	AF131216.5	-4.2	4.59e-05	0.0178	-0.41	-0.32	Retinal vascular caliber;	chr8:11361384	chr8:11345748~11347502:-
PCPG	cis	rs2243480	1	rs4718269	ENSG00000251451.1	GS1-124K5.6	-4.2	4.59e-05	0.0178	-0.58	-0.32	Diabetic kidney disease;	chr7:65735810	chr7:66407288~66409239:-
PCPG	cis	rs7772486	0.686	rs9399564	ENSG00000270638.1	RP3-466P17.1	-4.2	4.59e-05	0.0178	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145735570~145737218:+
PCPG	cis	rs3947	0.906	rs1692821	ENSG00000255556.2	RP11-351I21.6	-4.2	4.59e-05	0.0178	-0.37	-0.32	Blood protein levels;	chr8:11842479	chr8:12378679~12380265:-
PCPG	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	4.2	4.59e-05	0.0178	0.37	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	4.2	4.59e-05	0.0178	0.37	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	4.2	4.59e-05	0.0178	0.37	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
PCPG	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	4.2	4.59e-05	0.0178	0.37	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
PCPG	cis	rs17826219	0.568	rs3110092	ENSG00000263531.1	RP13-753N3.1	4.2	4.6e-05	0.0178	0.88	0.32	Body mass index;	chr17:30335741	chr17:30863921~30864940:-
PCPG	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	4.2	4.6e-05	0.0178	0.38	0.32	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
PCPG	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-4.2	4.6e-05	0.0178	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
PCPG	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-4.2	4.6e-05	0.0178	-0.42	-0.32	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-4.2	4.6e-05	0.0178	-0.42	-0.32	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
PCPG	cis	rs4489787	1	rs11168576	ENSG00000240399.1	RP1-228P16.1	-4.2	4.6e-05	0.0178	-0.41	-0.32	Prostate cancer (SNP x SNP interaction);	chr12:48446635	chr12:48054813~48055591:-
PCPG	cis	rs4489787	1	rs2956716	ENSG00000240399.1	RP1-228P16.1	4.2	4.6e-05	0.0178	0.41	0.32	Prostate cancer (SNP x SNP interaction);	chr12:48462400	chr12:48054813~48055591:-
PCPG	cis	rs4489787	1	rs10783256	ENSG00000240399.1	RP1-228P16.1	4.2	4.6e-05	0.0178	0.41	0.32	Prostate cancer (SNP x SNP interaction);	chr12:48471843	chr12:48054813~48055591:-
PCPG	cis	rs1488515	0.598	rs2237591	ENSG00000279067.1	GS1-25M2.1	-4.2	4.6e-05	0.0178	-0.5	-0.32	Obesity-related traits;	chr7:96016198	chr7:96118647~96119995:+
PCPG	cis	rs4763879	0.634	rs61915473	ENSG00000278635.1	CTD-2318O12.1	4.2	4.6e-05	0.0178	0.38	0.32	Type 1 diabetes;	chr12:9705282	chr12:9415641~9416718:+
PCPG	cis	rs3809060	0.959	rs3930513	ENSG00000213713.3	PIGCP1	4.2	4.6e-05	0.0178	0.18	0.32	Inguinal hernia;	chr11:32433981	chr11:33075566~33076460:-
PCPG	cis	rs2060793	0.741	rs10741653	ENSG00000251991.1	RNU7-49P	4.2	4.6e-05	0.0178	0.36	0.32	Vitamin D levels;	chr11:14683294	chr11:14478892~14478953:+
PCPG	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	4.2	4.61e-05	0.0178	0.41	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	4.2	4.61e-05	0.0178	0.41	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	4.2	4.61e-05	0.0178	0.41	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	4.2	4.61e-05	0.0178	0.41	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	4.2	4.61e-05	0.0178	0.41	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
PCPG	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	4.2	4.61e-05	0.0178	0.41	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
PCPG	cis	rs181553	0.504	rs7237062	ENSG00000278983.1	RP11-426J5.3	4.2	4.61e-05	0.0178	0.37	0.32	Hip circumference adjusted for BMI;	chr18:49200883	chr18:48564795~48568342:+
PCPG	cis	rs7208859	0.673	rs423151	ENSG00000266490.1	CTD-2349P21.9	4.2	4.62e-05	0.0179	0.37	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30792372~30792833:+
PCPG	cis	rs9393777	0.547	rs2893910	ENSG00000216901.1	AL022393.7	4.2	4.62e-05	0.0179	0.52	0.32	Intelligence (multi-trait analysis);	chr6:27315475	chr6:28176188~28176674:+
PCPG	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-4.2	4.62e-05	0.0179	-0.42	-0.32	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
PCPG	cis	rs8099594	0.565	rs1943001	ENSG00000278983.1	RP11-426J5.3	4.2	4.62e-05	0.0179	0.36	0.32	Height;	chr18:49193057	chr18:48564795~48568342:+
PCPG	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	4.2	4.63e-05	0.0179	0.32	0.32	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	4.2	4.63e-05	0.0179	0.32	0.32	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
PCPG	cis	rs6012953	1	rs6020572	ENSG00000231742.4	LINC01273	4.2	4.63e-05	0.0179	0.34	0.32	Vitiligo;	chr20:50511703	chr20:50172550~50176671:+
PCPG	cis	rs62246343	0.605	rs4328788	ENSG00000254485.4	RP11-380O24.1	4.2	4.63e-05	0.0179	0.44	0.32	Fibrinogen levels;	chr3:9415577	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.605	rs4308263	ENSG00000254485.4	RP11-380O24.1	4.2	4.63e-05	0.0179	0.44	0.32	Fibrinogen levels;	chr3:9415674	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.605	rs34665459	ENSG00000254485.4	RP11-380O24.1	4.2	4.63e-05	0.0179	0.44	0.32	Fibrinogen levels;	chr3:9423041	chr3:9292588~9363303:-
PCPG	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-4.2	4.63e-05	0.0179	-0.42	-0.32	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
PCPG	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-4.2	4.63e-05	0.0179	-0.38	-0.32	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
PCPG	cis	rs9302635	0.513	rs9923575	ENSG00000260886.1	TAT-AS1	4.2	4.63e-05	0.0179	0.5	0.32	Blood protein levels;	chr16:72196213	chr16:71565789~71578187:+
PCPG	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	4.2	4.63e-05	0.0179	0.35	0.32	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
PCPG	cis	rs9828933	0.752	rs12633353	ENSG00000280620.1	SCAANT1	4.2	4.63e-05	0.0179	0.56	0.32	Type 2 diabetes;	chr3:63984604	chr3:63911518~63911772:-
PCPG	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-4.2	4.63e-05	0.0179	-0.39	-0.32	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
PCPG	cis	rs6714900	0.588	rs2287331	ENSG00000179818.12	PCBP1-AS1	-4.2	4.64e-05	0.0179	-0.37	-0.32	Blood protein levels;	chr2:71067422	chr2:69962263~70103220:-
PCPG	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	4.2	4.64e-05	0.0179	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
PCPG	cis	rs4671400	0.602	rs2694623	ENSG00000270820.4	RP11-355B11.2	-4.2	4.64e-05	0.0179	-0.46	-0.32	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61326331	chr2:61471188~61484130:+
PCPG	cis	rs394563	0.934	rs384334	ENSG00000268592.3	RAET1E-AS1	4.2	4.65e-05	0.0179	0.4	0.32	Dupuytren's disease;	chr6:149475036	chr6:149863494~149919507:+
PCPG	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-4.19	4.65e-05	0.018	-0.45	-0.32	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
PCPG	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	4.19	4.65e-05	0.018	0.69	0.32	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
PCPG	cis	rs7772486	0.686	rs9390349	ENSG00000270638.1	RP3-466P17.1	-4.19	4.66e-05	0.018	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs2072911	ENSG00000270638.1	RP3-466P17.1	-4.19	4.66e-05	0.018	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145735570~145737218:+
PCPG	cis	rs7829975	0.811	rs7011229	ENSG00000173295.6	FAM86B3P	4.19	4.66e-05	0.018	0.37	0.32	Mood instability;	chr8:8685814	chr8:8228595~8244865:+
PCPG	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-4.19	4.66e-05	0.018	-0.33	-0.32	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
PCPG	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	4.19	4.66e-05	0.018	0.42	0.32	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	4.19	4.66e-05	0.018	0.42	0.32	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	4.19	4.66e-05	0.018	0.42	0.32	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	4.19	4.66e-05	0.018	0.42	0.32	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
PCPG	cis	rs6012953	1	rs6012953	ENSG00000231742.4	LINC01273	4.19	4.66e-05	0.018	0.34	0.32	Vitiligo;	chr20:50506506	chr20:50172550~50176671:+
PCPG	cis	rs5498	0.869	rs2569702	ENSG00000267612.1	CTD-3116E22.7	4.19	4.66e-05	0.018	0.4	0.32	Soluble ICAM-1;Lymphocyte counts;Blood protein levels;	chr19:10293271	chr19:9730853~9731943:+
PCPG	cis	rs8030379	1	rs2061999	ENSG00000230373.7	GOLGA6L5P	-4.19	4.66e-05	0.018	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913988	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs3934135	ENSG00000230373.7	GOLGA6L5P	-4.19	4.66e-05	0.018	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915047	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2030838	ENSG00000230373.7	GOLGA6L5P	-4.19	4.66e-05	0.018	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915058	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2030839	ENSG00000230373.7	GOLGA6L5P	-4.19	4.66e-05	0.018	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915207	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs2030840	ENSG00000230373.7	GOLGA6L5P	-4.19	4.66e-05	0.018	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915382	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1880730	ENSG00000230373.7	GOLGA6L5P	-4.19	4.66e-05	0.018	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915432	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs7496814	ENSG00000230373.7	GOLGA6L5P	-4.19	4.66e-05	0.018	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916207	chr15:84507885~84516814:-
PCPG	cis	rs2439831	0.867	rs8039638	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43342207	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs28415933	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43343602	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs12324572	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43344002	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2412780	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43363596	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2899082	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43363845	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs4583210	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43368727	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs28461955	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43369261	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs3213991	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43378082	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.85	rs7163245	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43379096	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs28729853	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43381482	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.717	rs9806227	ENSG00000205771.5	CATSPER2P1	-4.19	4.66e-05	0.018	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43387917	chr15:43726918~43747094:-
PCPG	cis	rs12681963	0.702	rs10954851	ENSG00000248159.1	HSPA8P11	-4.19	4.66e-05	0.018	-0.48	-0.32	Migraine;	chr8:30089365	chr8:30237382~30240997:+
PCPG	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	4.19	4.67e-05	0.018	0.43	0.32	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
PCPG	cis	rs12906542	0.516	rs12593545	ENSG00000259792.1	RP11-114H24.6	-4.19	4.67e-05	0.018	-0.41	-0.32	Breast cancer;	chr15:78045597	chr15:77993405~77995289:+
PCPG	cis	rs3809060	0.568	rs11031791	ENSG00000213713.3	PIGCP1	-4.19	4.68e-05	0.018	-0.17	-0.32	Inguinal hernia;	chr11:32448183	chr11:33075566~33076460:-
PCPG	cis	rs172166	0.538	rs149956	ENSG00000219392.1	RP1-265C24.5	-4.19	4.68e-05	0.018	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28068473	chr6:28115628~28116551:+
PCPG	cis	rs875971	0.862	rs9791712	ENSG00000235475.1	LINC01372	-4.19	4.68e-05	0.018	-0.33	-0.32	Aortic root size;	chr7:66640176	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs9791713	ENSG00000235475.1	LINC01372	-4.19	4.68e-05	0.018	-0.33	-0.32	Aortic root size;	chr7:66640211	chr7:67335976~67340024:+
PCPG	cis	rs7829975	0.846	rs7005216	ENSG00000173295.6	FAM86B3P	4.19	4.68e-05	0.018	0.37	0.32	Mood instability;	chr8:8689600	chr8:8228595~8244865:+
PCPG	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	4.19	4.68e-05	0.018	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
PCPG	cis	rs11148252	0.538	rs9535880	ENSG00000235660.1	LINC00345	-4.19	4.68e-05	0.0181	-0.39	-0.32	Lewy body disease;	chr13:52132007	chr13:52484161~52484680:-
PCPG	cis	rs7403037	0.509	rs7164560	ENSG00000260760.1	PWRN3	4.19	4.68e-05	0.0181	0.34	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24566509	chr15:24441127~24447967:+
PCPG	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	4.19	4.68e-05	0.0181	0.4	0.32	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	4.19	4.68e-05	0.0181	0.4	0.32	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
PCPG	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	4.19	4.68e-05	0.0181	0.4	0.32	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
PCPG	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	4.19	4.68e-05	0.0181	0.53	0.32	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
PCPG	cis	rs1552244	1	rs113153120	ENSG00000180385.7	EMC3-AS1	4.19	4.68e-05	0.0181	0.41	0.32	Alzheimer's disease;	chr3:10114714	chr3:9986893~10006990:+
PCPG	cis	rs1552244	1	rs112509186	ENSG00000180385.7	EMC3-AS1	4.19	4.68e-05	0.0181	0.41	0.32	Alzheimer's disease;	chr3:10114849	chr3:9986893~10006990:+
PCPG	cis	rs1440410	0.835	rs28592151	ENSG00000250326.1	RP11-284M14.1	4.19	4.69e-05	0.0181	0.3	0.32	Ischemic stroke;	chr4:143172971	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs7656276	ENSG00000250326.1	RP11-284M14.1	4.19	4.69e-05	0.0181	0.3	0.32	Ischemic stroke;	chr4:143176396	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs10019249	ENSG00000250326.1	RP11-284M14.1	4.19	4.69e-05	0.0181	0.3	0.32	Ischemic stroke;	chr4:143181040	chr4:142933195~143184861:-
PCPG	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-4.19	4.69e-05	0.0181	-0.37	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
PCPG	cis	rs7772486	0.654	rs4896829	ENSG00000270638.1	RP3-466P17.1	4.19	4.69e-05	0.0181	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145735570~145737218:+
PCPG	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	4.19	4.69e-05	0.0181	0.63	0.32	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
PCPG	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	4.19	4.69e-05	0.0181	0.38	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
PCPG	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	4.19	4.69e-05	0.0181	0.42	0.32	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
PCPG	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	4.19	4.69e-05	0.0181	0.46	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
PCPG	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-4.19	4.69e-05	0.0181	-0.32	-0.32	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	4.19	4.7e-05	0.0181	0.41	0.32	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	4.19	4.7e-05	0.0181	0.41	0.32	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
PCPG	cis	rs11098499	1	rs1011054	ENSG00000249244.1	RP11-548H18.2	-4.19	4.7e-05	0.0181	-0.32	-0.32	Corneal astigmatism;	chr4:119281232	chr4:119391831~119395335:-
PCPG	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-4.19	4.7e-05	0.0181	-0.3	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
PCPG	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	4.19	4.7e-05	0.0181	0.26	0.32	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	4.19	4.7e-05	0.0181	0.26	0.32	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
PCPG	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-4.19	4.7e-05	0.0181	-0.26	-0.32	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
PCPG	cis	rs394563	0.81	rs480870	ENSG00000231760.4	RP11-350J20.5	4.19	4.7e-05	0.0181	0.4	0.32	Dupuytren's disease;	chr6:149463682	chr6:149796151~149826294:-
PCPG	cis	rs7772486	0.624	rs9485018	ENSG00000270638.1	RP3-466P17.1	-4.19	4.7e-05	0.0181	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs2092263	ENSG00000270638.1	RP3-466P17.1	-4.19	4.7e-05	0.0181	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs1004752	ENSG00000270638.1	RP3-466P17.1	-4.19	4.7e-05	0.0181	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9390347	ENSG00000270638.1	RP3-466P17.1	-4.19	4.7e-05	0.0181	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9390348	ENSG00000270638.1	RP3-466P17.1	-4.19	4.7e-05	0.0181	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.632	rs9386128	ENSG00000270638.1	RP3-466P17.1	-4.19	4.7e-05	0.0181	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145735570~145737218:+
PCPG	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-4.19	4.71e-05	0.0181	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
PCPG	cis	rs11148252	0.74	rs9536046	ENSG00000278238.1	RP11-245D16.4	-4.19	4.71e-05	0.0181	-0.3	-0.32	Lewy body disease;	chr13:52381764	chr13:52454775~52455331:-
PCPG	cis	rs10504130	0.569	rs34364864	ENSG00000272024.1	RP11-546K22.3	-4.19	4.71e-05	0.0181	-0.41	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51950284~51950690:+
PCPG	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	4.19	4.71e-05	0.0181	0.35	0.32	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
PCPG	cis	rs116248771	0.739	rs73156415	ENSG00000272087.1	RP11-379F4.7	4.19	4.72e-05	0.0181	0.48	0.32	diarrhoeal disease at age 2;	chr3:158624906	chr3:158693120~158693768:-
PCPG	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	4.19	4.72e-05	0.0182	0.36	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
PCPG	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-4.19	4.72e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
PCPG	cis	rs6840258	0.8	rs6839933	ENSG00000251411.1	RP11-397E7.4	-4.19	4.72e-05	0.0182	-0.33	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043211	chr4:86913266~86914817:-
PCPG	cis	rs7403037	0.527	rs12907622	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24547372	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs12324730	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24553608	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs7162379	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24554744	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.871	rs11853919	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24556624	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.702	rs28435380	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24557156	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.871	rs28538042	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24557324	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12914379	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24557477	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7179797	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24557909	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7495278	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24559003	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7495971	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24559094	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7496179	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24559417	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs7495882	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24559529	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs7496204	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24559549	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs7496984	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24559716	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.729	rs9788744	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24559825	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs12594408	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24560051	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs8032958	ENSG00000260760.1	PWRN3	4.19	4.73e-05	0.0182	0.35	0.32	Platelet thrombus formation;	chr15:24561604	chr15:24441127~24447967:+
PCPG	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-4.19	4.73e-05	0.0182	-0.31	-0.32	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
PCPG	cis	rs6940638	0.615	rs9393801	ENSG00000216901.1	AL022393.7	4.19	4.73e-05	0.0182	0.43	0.32	Intelligence (multi-trait analysis);	chr6:27274902	chr6:28176188~28176674:+
PCPG	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-4.19	4.73e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
PCPG	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-4.19	4.74e-05	0.0182	-0.38	-0.32	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
PCPG	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	4.19	4.74e-05	0.0182	0.38	0.32	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
PCPG	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	4.19	4.74e-05	0.0182	0.46	0.32	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
PCPG	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	4.19	4.74e-05	0.0182	0.41	0.32	Height;	chr6:109646187	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	4.19	4.74e-05	0.0182	0.41	0.32	Height;	chr6:109652694	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	4.19	4.74e-05	0.0182	0.41	0.32	Height;	chr6:109655791	chr6:109382795~109383666:+
PCPG	cis	rs6012953	1	rs6020559	ENSG00000231742.4	LINC01273	4.19	4.74e-05	0.0182	0.34	0.32	Vitiligo;	chr20:50502094	chr20:50172550~50176671:+
PCPG	cis	rs6012953	1	rs6020560	ENSG00000231742.4	LINC01273	4.19	4.74e-05	0.0182	0.34	0.32	Vitiligo;	chr20:50502882	chr20:50172550~50176671:+
PCPG	cis	rs6012953	1	rs6020563	ENSG00000231742.4	LINC01273	4.19	4.74e-05	0.0182	0.34	0.32	Vitiligo;	chr20:50503858	chr20:50172550~50176671:+
PCPG	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-4.19	4.74e-05	0.0182	-0.46	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
PCPG	cis	rs9303029	0.8	rs9896620	ENSG00000279744.1	RP13-20L14.10	-4.19	4.74e-05	0.0182	-0.41	-0.32	Protein quantitative trait loci;	chr17:82453331	chr17:82462601~82464255:+
PCPG	cis	rs116248771	0.739	rs73156423	ENSG00000272087.1	RP11-379F4.7	4.19	4.74e-05	0.0182	0.48	0.32	diarrhoeal disease at age 2;	chr3:158627839	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs76493374	ENSG00000272087.1	RP11-379F4.7	4.19	4.74e-05	0.0182	0.48	0.32	diarrhoeal disease at age 2;	chr3:158627850	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156425	ENSG00000272087.1	RP11-379F4.7	4.19	4.74e-05	0.0182	0.48	0.32	diarrhoeal disease at age 2;	chr3:158627888	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156426	ENSG00000272087.1	RP11-379F4.7	4.19	4.74e-05	0.0182	0.48	0.32	diarrhoeal disease at age 2;	chr3:158628500	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156428	ENSG00000272087.1	RP11-379F4.7	4.19	4.74e-05	0.0182	0.48	0.32	diarrhoeal disease at age 2;	chr3:158628682	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs12630515	ENSG00000272087.1	RP11-379F4.7	4.19	4.74e-05	0.0182	0.48	0.32	diarrhoeal disease at age 2;	chr3:158628826	chr3:158693120~158693768:-
PCPG	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	4.19	4.75e-05	0.0182	0.37	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
PCPG	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-4.19	4.75e-05	0.0182	-0.47	-0.32	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
PCPG	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	4.19	4.75e-05	0.0182	0.47	0.32	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
PCPG	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-4.19	4.75e-05	0.0182	-0.42	-0.32	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
PCPG	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-4.19	4.75e-05	0.0182	-0.52	-0.32	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
PCPG	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-4.19	4.75e-05	0.0182	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	4.19	4.75e-05	0.0182	0.38	0.32	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
PCPG	cis	rs78579285	0.589	rs113010486	ENSG00000260630.5	SNAI3-AS1	-4.19	4.75e-05	0.0182	-0.59	-0.32	Joint mobility (Beighton score);	chr16:88731990	chr16:88663298~88687186:+
PCPG	cis	rs10208649	0.611	rs61740458	ENSG00000272156.1	RP11-477N3.1	4.19	4.75e-05	0.0183	0.54	0.32	Body mass index;	chr2:54065503	chr2:54082554~54085066:+
PCPG	cis	rs11858159	1	rs73356079	ENSG00000260760.1	PWRN3	4.19	4.76e-05	0.0183	0.35	0.32	Platelet thrombus formation;	chr15:24552683	chr15:24441127~24447967:+
PCPG	cis	rs2404602	0.692	rs12911174	ENSG00000259514.1	RP11-685G9.2	-4.19	4.76e-05	0.0183	-0.33	-0.32	Blood metabolite levels;	chr15:76857602	chr15:76339609~76342063:-
PCPG	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-4.19	4.77e-05	0.0183	-0.37	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-4.19	4.77e-05	0.0183	-0.37	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-4.19	4.77e-05	0.0183	-0.37	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-4.19	4.77e-05	0.0183	-0.37	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
PCPG	cis	rs58365266	1	rs58365266	ENSG00000235897.1	TM4SF19-AS1	4.19	4.77e-05	0.0183	0.5	0.32	Red cell distribution width;	chr3:196086886	chr3:196318330~196325570:+
PCPG	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-4.19	4.77e-05	0.0183	-0.43	-0.32	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
PCPG	cis	rs1440410	0.835	rs7684847	ENSG00000250326.1	RP11-284M14.1	4.19	4.77e-05	0.0183	0.3	0.32	Ischemic stroke;	chr4:143133414	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs11725565	ENSG00000250326.1	RP11-284M14.1	-4.19	4.77e-05	0.0183	-0.3	-0.32	Ischemic stroke;	chr4:143216206	chr4:142933195~143184861:-
PCPG	cis	rs7247513	0.964	rs8105902	ENSG00000213290.4	PGK1P2	-4.19	4.77e-05	0.0183	-0.45	-0.32	Bipolar disorder;	chr19:12607537	chr19:12559571~12561105:+
PCPG	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-4.19	4.78e-05	0.0183	-0.38	-0.32	Height;	chr5:37045739	chr5:36666214~36725195:-
PCPG	cis	rs7819412	0.594	rs7460507	ENSG00000255020.1	AF131216.5	-4.19	4.78e-05	0.0183	-0.43	-0.32	Triglycerides;	chr8:11111565	chr8:11345748~11347502:-
PCPG	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-4.19	4.78e-05	0.0183	-0.38	-0.32	Height;	chr5:37061159	chr5:36666214~36725195:-
PCPG	cis	rs12439619	0.846	rs62013464	ENSG00000228141.5	AC105339.1	-4.19	4.78e-05	0.0183	-0.48	-0.32	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82710471~82714026:-
PCPG	cis	rs2408955	0.561	rs11168365	ENSG00000240399.1	RP1-228P16.1	-4.19	4.78e-05	0.0183	-0.33	-0.32	Glycated hemoglobin levels;	chr12:48027989	chr12:48054813~48055591:-
PCPG	cis	rs3002142	0.731	rs11485122	ENSG00000272750.1	RP11-378J18.8	4.19	4.78e-05	0.0183	0.53	0.32	LDL peak particle diameter (total fat intake interaction);	chr1:222660729	chr1:222658867~222661512:-
PCPG	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	4.19	4.78e-05	0.0183	0.35	0.32	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
PCPG	cis	rs1023500	0.551	rs2301521	ENSG00000226450.2	CYP2D8P	4.19	4.79e-05	0.0184	0.32	0.32	Schizophrenia;	chr22:42027106	chr22:42149886~42155001:-
PCPG	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-4.19	4.79e-05	0.0184	-0.45	-0.32	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
PCPG	cis	rs6012953	1	rs6020586	ENSG00000231742.4	LINC01273	4.19	4.79e-05	0.0184	0.33	0.32	Vitiligo;	chr20:50539126	chr20:50172550~50176671:+
PCPG	cis	rs6012953	0.934	rs2904269	ENSG00000231742.4	LINC01273	4.19	4.79e-05	0.0184	0.33	0.32	Vitiligo;	chr20:50539794	chr20:50172550~50176671:+
PCPG	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-4.19	4.79e-05	0.0184	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-4.19	4.79e-05	0.0184	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
PCPG	cis	rs7603514	0.585	rs6758395	ENSG00000279220.1	GPR1-AS	4.19	4.8e-05	0.0184	0.4	0.32	Obesity (extreme);	chr2:206213576	chr2:206203376~206266243:+
PCPG	cis	rs1440410	0.897	rs9999826	ENSG00000250326.1	RP11-284M14.1	4.19	4.8e-05	0.0184	0.3	0.32	Ischemic stroke;	chr4:143115304	chr4:142933195~143184861:-
PCPG	cis	rs12291225	0.679	rs7934671	ENSG00000251991.1	RNU7-49P	4.19	4.8e-05	0.0184	0.37	0.32	Sense of smell;	chr11:14283555	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.679	rs11023178	ENSG00000251991.1	RNU7-49P	4.19	4.8e-05	0.0184	0.37	0.32	Sense of smell;	chr11:14288736	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.679	rs34238445	ENSG00000251991.1	RNU7-49P	4.19	4.8e-05	0.0184	0.37	0.32	Sense of smell;	chr11:14294369	chr11:14478892~14478953:+
PCPG	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	4.19	4.81e-05	0.0184	0.79	0.32	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
PCPG	cis	rs11858159	1	rs12903200	ENSG00000260760.1	PWRN3	4.19	4.81e-05	0.0184	0.34	0.32	Platelet thrombus formation;	chr15:24546747	chr15:24441127~24447967:+
PCPG	cis	rs28386778	0.897	rs9912557	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63707603	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs7210443	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63708014	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs1043127	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63713850	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs2036911	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63717479	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs8073515	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63717968	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.863	rs11649912	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63720155	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.734	rs7210724	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63721838	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs1470697	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63722480	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs57108948	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63725018	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs7501614	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63725252	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs4968597	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63728387	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs10221279	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63728778	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.687	rs59596917	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63728904	chr17:63849292~63864379:+
PCPG	cis	rs28386778	0.897	rs6504176	ENSG00000240280.5	TCAM1P	-4.19	4.81e-05	0.0184	-0.42	-0.32	Prudent dietary pattern;	chr17:63734560	chr17:63849292~63864379:+
PCPG	cis	rs575908	0.708	rs10798579	ENSG00000254154.7	RP4-798P15.3	4.19	4.82e-05	0.0184	0.31	0.32	Breast cancer;	chr1:177891196	chr1:177928788~178038007:-
PCPG	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	4.19	4.82e-05	0.0184	0.42	0.32	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
PCPG	cis	rs2302464	1	rs73121382	ENSG00000214846.4	RP11-115L11.1	4.19	4.82e-05	0.0184	0.87	0.32	Cerebrospinal fluid biomarker levels;	chr4:15717816	chr4:15730962~15731627:-
PCPG	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-4.19	4.82e-05	0.0185	-0.54	-0.32	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
PCPG	cis	rs11673344	0.523	rs2562599	ENSG00000226686.6	LINC01535	-4.19	4.82e-05	0.0185	-0.41	-0.32	Obesity-related traits;	chr19:37025472	chr19:37251912~37265535:+
PCPG	cis	rs4819052	0.788	rs35323494	ENSG00000223768.1	LINC00205	-4.19	4.83e-05	0.0185	-0.39	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45293285~45297354:+
PCPG	cis	rs11148252	0.557	rs9536223	ENSG00000273784.3	RP11-78J21.7	-4.19	4.83e-05	0.0185	-0.31	-0.32	Lewy body disease;	chr13:52659059	chr13:52600042~52642542:+
PCPG	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-4.19	4.83e-05	0.0185	-0.47	-0.32	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-4.19	4.83e-05	0.0185	-0.47	-0.32	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
PCPG	cis	rs9299346	0.594	rs2417289	ENSG00000225376.4	TMEM246-AS1	4.19	4.83e-05	0.0185	0.39	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101666048	chr9:101468439~101481502:+
PCPG	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	4.19	4.83e-05	0.0185	0.42	0.32	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
PCPG	cis	rs7587476	1	rs2121285	ENSG00000229267.2	AC072062.1	4.19	4.83e-05	0.0185	0.42	0.32	Neuroblastoma;	chr2:214791444	chr2:214810229~214963274:+
PCPG	cis	rs7587476	1	rs1542173	ENSG00000229267.2	AC072062.1	4.19	4.83e-05	0.0185	0.42	0.32	Neuroblastoma;	chr2:214792836	chr2:214810229~214963274:+
PCPG	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-4.19	4.83e-05	0.0185	-0.36	-0.32	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-4.19	4.83e-05	0.0185	-0.36	-0.32	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-4.19	4.83e-05	0.0185	-0.36	-0.32	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
PCPG	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	4.19	4.83e-05	0.0185	0.36	0.32	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
PCPG	cis	rs1003719	0.715	rs8126941	ENSG00000228677.1	TTC3-AS1	-4.19	4.83e-05	0.0185	-0.41	-0.32	Eye color traits;	chr21:37179240	chr21:37187666~37193926:-
PCPG	cis	rs6579956	0.542	rs11740092	ENSG00000270978.1	RP11-54C4.2	-4.19	4.83e-05	0.0185	-0.41	-0.32	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152805871	chr5:151848886~151850791:+
PCPG	cis	rs6579956	0.565	rs34578343	ENSG00000270978.1	RP11-54C4.2	-4.19	4.83e-05	0.0185	-0.41	-0.32	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152806544	chr5:151848886~151850791:+
PCPG	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	4.19	4.84e-05	0.0185	0.36	0.32	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
PCPG	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-4.18	4.84e-05	0.0185	-0.47	-0.32	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
PCPG	cis	rs11858159	1	rs12900285	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Platelet thrombus formation;	chr15:24572506	chr15:24441127~24447967:+
PCPG	cis	rs7403037	0.509	rs7402599	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24572787	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7402269	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Platelet thrombus formation;	chr15:24573014	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7402480	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Platelet thrombus formation;	chr15:24573269	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7402588	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Platelet thrombus formation;	chr15:24573298	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7174282	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Platelet thrombus formation;	chr15:24577902	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs8038395	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Platelet thrombus formation;	chr15:24578879	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs11858159	ENSG00000260760.1	PWRN3	4.18	4.84e-05	0.0185	0.34	0.32	Platelet thrombus formation;	chr15:24579041	chr15:24441127~24447967:+
PCPG	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-4.18	4.84e-05	0.0185	-0.5	-0.32	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
PCPG	cis	rs1908814	0.516	rs4841641	ENSG00000255495.1	AC145124.2	4.18	4.84e-05	0.0185	0.33	0.32	Neuroticism;	chr8:11940718	chr8:12194467~12196280:+
PCPG	cis	rs9329221	1	rs9329221	ENSG00000255020.1	AF131216.5	4.18	4.85e-05	0.0185	0.42	0.32	Neuroticism;	chr8:10382692	chr8:11345748~11347502:-
PCPG	cis	rs6714710	0.603	rs34503448	ENSG00000278766.2	AC159540.2	4.18	4.85e-05	0.0185	0.37	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97970825	chr2:97421075~97434847:+
PCPG	cis	rs6714710	0.603	rs953320	ENSG00000278766.2	AC159540.2	4.18	4.85e-05	0.0185	0.37	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97990307	chr2:97421075~97434847:+
PCPG	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	4.18	4.85e-05	0.0185	0.32	0.32	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
PCPG	cis	rs7208859	0.673	rs11651802	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs17826219	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs61223749	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs3764420	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs3764421	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11651858	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs36056619	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9909497	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11080135	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9894876	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73277967	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs60020217	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.573	rs73277974	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73277978	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11657391	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs58089675	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73263755	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9899349	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11652358	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11656845	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9891179	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9891413	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73263776	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs11650271	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73263785	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs78799101	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs55904046	ENSG00000263603.1	CTD-2349P21.5	-4.18	4.86e-05	0.0186	-0.63	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30729469~30731202:+
PCPG	cis	rs11148252	0.74	rs9596648	ENSG00000278238.1	RP11-245D16.4	4.18	4.86e-05	0.0186	0.29	0.32	Lewy body disease;	chr13:52360434	chr13:52454775~52455331:-
PCPG	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-4.18	4.86e-05	0.0186	-0.41	-0.32	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
PCPG	cis	rs2980439	0.557	rs2976876	ENSG00000173295.6	FAM86B3P	-4.18	4.86e-05	0.0186	-0.37	-0.32	Neuroticism;	chr8:8461340	chr8:8228595~8244865:+
PCPG	cis	rs2980439	0.557	rs2921056	ENSG00000173295.6	FAM86B3P	-4.18	4.86e-05	0.0186	-0.37	-0.32	Neuroticism;	chr8:8461672	chr8:8228595~8244865:+
PCPG	cis	rs7826238	0.524	rs2921055	ENSG00000173295.6	FAM86B3P	-4.18	4.86e-05	0.0186	-0.37	-0.32	Systolic blood pressure;	chr8:8461832	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	-4.18	4.86e-05	0.0186	-0.39	-0.32	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
PCPG	cis	rs6974235	0.806	rs42079	ENSG00000279067.1	GS1-25M2.1	4.18	4.86e-05	0.0186	0.36	0.32	Total body bone mineral density;	chr7:96081989	chr7:96118647~96119995:+
PCPG	cis	rs7172677	1	rs72730601	ENSG00000261543.1	RP11-665J16.1	4.18	4.86e-05	0.0186	0.39	0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75129379	chr15:74152800~74179226:-
PCPG	cis	rs4295623	0.504	rs11250160	ENSG00000255020.1	AF131216.5	-4.18	4.86e-05	0.0186	-0.42	-0.32	Morning vs. evening chronotype;	chr8:11735208	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	-4.18	4.86e-05	0.0186	-0.37	-0.32	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
PCPG	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	4.18	4.86e-05	0.0186	0.67	0.32	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	4.18	4.86e-05	0.0186	0.67	0.32	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	4.18	4.86e-05	0.0186	0.67	0.32	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	4.18	4.86e-05	0.0186	0.67	0.32	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
PCPG	cis	rs10208649	0.656	rs74693460	ENSG00000272156.1	RP11-477N3.1	4.18	4.86e-05	0.0186	0.55	0.32	Body mass index;	chr2:54071471	chr2:54082554~54085066:+
PCPG	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	4.18	4.86e-05	0.0186	0.41	0.32	Height;	chr6:109747119	chr6:109382795~109383666:+
PCPG	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	4.18	4.86e-05	0.0186	0.41	0.32	Height;	chr6:109747411	chr6:109382795~109383666:+
PCPG	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	4.18	4.86e-05	0.0186	0.41	0.32	Height;	chr6:109748819	chr6:109382795~109383666:+
PCPG	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	4.18	4.86e-05	0.0186	0.41	0.32	Height;	chr6:109749564	chr6:109382795~109383666:+
PCPG	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	4.18	4.86e-05	0.0186	0.41	0.32	Height;	chr6:109763331	chr6:109382795~109383666:+
PCPG	cis	rs2836974	0.897	rs3945	ENSG00000252915.1	Y_RNA	-4.18	4.87e-05	0.0186	-0.35	-0.32	Cognitive function;	chr21:39194141	chr21:39344537~39344628:+
PCPG	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-4.18	4.87e-05	0.0186	-0.38	-0.32	Height;	chr5:36999896	chr5:36666214~36725195:-
PCPG	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-4.18	4.87e-05	0.0186	-0.38	-0.32	Height;	chr5:37005003	chr5:36666214~36725195:-
PCPG	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-4.18	4.87e-05	0.0186	-0.42	-0.32	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-4.18	4.87e-05	0.0186	-0.42	-0.32	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
PCPG	cis	rs11858159	0.934	rs7182190	ENSG00000260760.1	PWRN3	4.18	4.87e-05	0.0186	0.35	0.32	Platelet thrombus formation;	chr15:24554442	chr15:24441127~24447967:+
PCPG	cis	rs748404	0.666	rs12906481	ENSG00000205771.5	CATSPER2P1	-4.18	4.87e-05	0.0186	-0.42	-0.32	Lung cancer;	chr15:43467356	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs35958032	ENSG00000205771.5	CATSPER2P1	-4.18	4.87e-05	0.0186	-0.42	-0.32	Lung cancer;	chr15:43494397	chr15:43726918~43747094:-
PCPG	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	4.18	4.87e-05	0.0186	0.74	0.32	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
PCPG	cis	rs7118412	0.793	rs11225976	ENSG00000260966.1	RP11-690D19.3	-4.18	4.87e-05	0.0186	-0.35	-0.32	Disc degeneration (lumbar);	chr11:103693040	chr11:103050687~103055799:-
PCPG	cis	rs7118412	0.793	rs1014211	ENSG00000260966.1	RP11-690D19.3	-4.18	4.87e-05	0.0186	-0.35	-0.32	Disc degeneration (lumbar);	chr11:103694944	chr11:103050687~103055799:-
PCPG	cis	rs7118412	0.793	rs7924591	ENSG00000260966.1	RP11-690D19.3	-4.18	4.87e-05	0.0186	-0.35	-0.32	Disc degeneration (lumbar);	chr11:103695668	chr11:103050687~103055799:-
PCPG	cis	rs2531992	0.62	rs2041248	ENSG00000262888.1	RP11-462G12.2	-4.18	4.88e-05	0.0186	-0.55	-0.32	Waist circumference;	chr16:3982488	chr16:3931217~3946305:-
PCPG	cis	rs10760158	0.769	rs10985200	ENSG00000226752.6	PSMD5-AS1	-4.18	4.88e-05	0.0186	-0.41	-0.32	Pulse pressure;	chr9:121281589	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.8	rs4837829	ENSG00000226752.6	PSMD5-AS1	-4.18	4.88e-05	0.0186	-0.41	-0.32	Pulse pressure;	chr9:121283680	chr9:120824828~120854385:+
PCPG	cis	rs10760158	0.736	rs10760168	ENSG00000226752.6	PSMD5-AS1	-4.18	4.88e-05	0.0186	-0.41	-0.32	Pulse pressure;	chr9:121286449	chr9:120824828~120854385:+
PCPG	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	4.18	4.88e-05	0.0186	0.43	0.32	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
PCPG	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	4.18	4.88e-05	0.0186	0.34	0.32	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
PCPG	cis	rs7826238	0.653	rs2979202	ENSG00000173295.6	FAM86B3P	-4.18	4.88e-05	0.0186	-0.36	-0.32	Systolic blood pressure;	chr8:8486617	chr8:8228595~8244865:+
PCPG	cis	rs6901152	0.525	rs974754	ENSG00000217648.1	RP1-95L4.4	-4.18	4.89e-05	0.0186	-0.38	-0.32	Acute lymphoblastic leukemia (childhood);	chr6:143366384	chr6:143342246~143343383:+
PCPG	cis	rs748404	0.666	rs34178146	ENSG00000205771.5	CATSPER2P1	-4.18	4.89e-05	0.0187	-0.42	-0.32	Lung cancer;	chr15:43384406	chr15:43726918~43747094:-
PCPG	cis	rs964611	0.671	rs11070639	ENSG00000259488.2	RP11-154J22.1	4.18	4.89e-05	0.0187	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48371908	chr15:48312353~48331856:-
PCPG	cis	rs11673344	0.503	rs1667370	ENSG00000226686.6	LINC01535	4.18	4.89e-05	0.0187	0.41	0.32	Obesity-related traits;	chr19:36999318	chr19:37251912~37265535:+
PCPG	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-4.18	4.89e-05	0.0187	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
PCPG	cis	rs425277	1	rs809912	ENSG00000271806.1	RP5-892K4.1	4.18	4.9e-05	0.0187	0.38	0.32	Height;	chr1:2146946	chr1:2141084~2145279:-
PCPG	cis	rs425277	1	rs196128	ENSG00000271806.1	RP5-892K4.1	4.18	4.9e-05	0.0187	0.38	0.32	Height;	chr1:2147005	chr1:2141084~2145279:-
PCPG	cis	rs425277	1	rs262676	ENSG00000271806.1	RP5-892K4.1	4.18	4.9e-05	0.0187	0.38	0.32	Height;	chr1:2147043	chr1:2141084~2145279:-
PCPG	cis	rs425277	1	rs262672	ENSG00000271806.1	RP5-892K4.1	4.18	4.9e-05	0.0187	0.38	0.32	Height;	chr1:2149374	chr1:2141084~2145279:-
PCPG	cis	rs9788721	0.775	rs12914385	ENSG00000279421.1	RP11-335K5.3	-4.18	4.9e-05	0.0187	-0.38	-0.32	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78606381	chr15:78599892~78600013:-
PCPG	cis	rs8085804	0.556	rs7228411	ENSG00000267586.5	LINC00907	-4.18	4.9e-05	0.0187	-0.41	-0.32	Cognitive performance;	chr18:42625341	chr18:42159283~42691422:+
PCPG	cis	rs8085804	0.556	rs12454240	ENSG00000267586.5	LINC00907	-4.18	4.9e-05	0.0187	-0.41	-0.32	Cognitive performance;	chr18:42625391	chr18:42159283~42691422:+
PCPG	cis	rs75804782	0.63	rs56328549	ENSG00000227107.1	AC096574.5	-4.18	4.9e-05	0.0187	-0.62	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:238317912	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs57033609	ENSG00000227107.1	AC096574.5	-4.18	4.9e-05	0.0187	-0.62	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:238319871	chr2:237612977~237626525:+
PCPG	cis	rs8042680	0.955	rs1867220	ENSG00000214432.8	AC068831.10	-4.18	4.91e-05	0.0187	-0.36	-0.32	Type 2 diabetes;	chr15:90960522	chr15:91022619~91036611:+
PCPG	cis	rs9299346	0.594	rs2417286	ENSG00000225376.4	TMEM246-AS1	-4.18	4.91e-05	0.0187	-0.38	-0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665576	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2146800	ENSG00000225376.4	TMEM246-AS1	4.18	4.91e-05	0.0187	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665429	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2146799	ENSG00000225376.4	TMEM246-AS1	4.18	4.91e-05	0.0187	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665437	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.554	rs10819976	ENSG00000225376.4	TMEM246-AS1	4.18	4.91e-05	0.0187	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665642	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs766551	ENSG00000225376.4	TMEM246-AS1	4.18	4.91e-05	0.0187	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665774	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2417287	ENSG00000225376.4	TMEM246-AS1	4.18	4.91e-05	0.0187	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665902	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2417288	ENSG00000225376.4	TMEM246-AS1	4.18	4.91e-05	0.0187	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665969	chr9:101468439~101481502:+
PCPG	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	4.18	4.91e-05	0.0187	0.33	0.32	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
PCPG	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	4.18	4.91e-05	0.0187	0.42	0.32	Height;	chr6:109350188	chr6:109382795~109383666:+
PCPG	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-4.18	4.91e-05	0.0187	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
PCPG	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-4.18	4.91e-05	0.0187	-0.38	-0.32	Height;	chr5:37046524	chr5:36666214~36725195:-
PCPG	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	4.18	4.92e-05	0.0187	0.28	0.32	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
PCPG	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	4.18	4.92e-05	0.0187	0.28	0.32	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	4.18	4.92e-05	0.0187	0.28	0.32	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	4.18	4.92e-05	0.0187	0.28	0.32	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	4.18	4.92e-05	0.0187	0.28	0.32	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
PCPG	cis	rs17772222	0.917	rs61984736	ENSG00000222990.1	RNU4-22P	4.18	4.92e-05	0.0188	0.42	0.32	Coronary artery calcification;	chr14:88626359	chr14:88513498~88513663:+
PCPG	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-4.18	4.93e-05	0.0188	-0.47	-0.32	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-4.18	4.93e-05	0.0188	-0.47	-0.32	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
PCPG	cis	rs901683	1	rs71496620	ENSG00000230869.1	CTGLF10P	-4.18	4.93e-05	0.0188	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45578881	chr10:45678692~45700532:+
PCPG	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-4.18	4.93e-05	0.0188	-0.38	-0.32	Height;	chr5:37019252	chr5:36666214~36725195:-
PCPG	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	4.18	4.93e-05	0.0188	0.39	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
PCPG	cis	rs9311676	0.609	rs12634722	ENSG00000273493.1	RP11-80H18.4	-4.18	4.93e-05	0.0188	-0.32	-0.32	Systemic lupus erythematosus;	chr3:58362430	chr3:58329965~58330118:+
PCPG	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-4.18	4.94e-05	0.0188	-0.4	-0.32	Temperament;	chr17:14003617	chr17:14024514~14025488:+
PCPG	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	4.18	4.94e-05	0.0188	0.55	0.32	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
PCPG	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	4.18	4.94e-05	0.0188	0.3	0.32	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
PCPG	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	4.18	4.94e-05	0.0188	0.3	0.32	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
PCPG	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-4.18	4.94e-05	0.0188	-0.3	-0.32	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
PCPG	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	4.18	4.94e-05	0.0188	0.41	0.32	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
PCPG	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	4.18	4.94e-05	0.0188	0.41	0.32	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
PCPG	cis	rs11858159	0.646	rs12912365	ENSG00000259905.4	PWRN1	4.18	4.94e-05	0.0188	0.37	0.32	Platelet thrombus formation;	chr15:24135166	chr15:24493137~24652130:+
PCPG	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-4.18	4.95e-05	0.0188	-0.36	-0.32	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-4.18	4.95e-05	0.0188	-0.36	-0.32	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-4.18	4.95e-05	0.0188	-0.36	-0.32	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-4.18	4.95e-05	0.0188	-0.36	-0.32	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
PCPG	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-4.18	4.95e-05	0.0188	-0.36	-0.32	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
PCPG	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-4.18	4.95e-05	0.0188	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
PCPG	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	4.18	4.95e-05	0.0188	0.44	0.32	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
PCPG	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	4.18	4.95e-05	0.0188	0.36	0.32	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
PCPG	cis	rs763121	0.853	rs5750669	ENSG00000273076.1	RP3-508I15.22	4.18	4.95e-05	0.0188	0.4	0.32	Menopause (age at onset);	chr22:38684633	chr22:38743495~38743910:+
PCPG	cis	rs2404602	0.608	rs12439484	ENSG00000259422.1	RP11-593F23.1	4.18	4.96e-05	0.0189	0.36	0.32	Blood metabolite levels;	chr15:76310596	chr15:76174891~76181486:-
PCPG	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-4.18	4.96e-05	0.0189	-0.34	-0.32	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
PCPG	cis	rs75804782	0.566	rs77693902	ENSG00000227107.1	AC096574.5	-4.18	4.96e-05	0.0189	-0.56	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:238351836	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs75921156	ENSG00000227107.1	AC096574.5	-4.18	4.96e-05	0.0189	-0.56	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:238370992	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.566	rs56314406	ENSG00000227107.1	AC096574.5	-4.18	4.96e-05	0.0189	-0.56	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:238371736	chr2:237612977~237626525:+
PCPG	cis	rs75804782	0.63	rs79693451	ENSG00000227107.1	AC096574.5	-4.18	4.96e-05	0.0189	-0.56	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:238387832	chr2:237612977~237626525:+
PCPG	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	4.18	4.97e-05	0.0189	0.32	0.32	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
PCPG	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	4.18	4.97e-05	0.0189	0.32	0.32	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
PCPG	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-4.18	4.97e-05	0.0189	-0.43	-0.32	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
PCPG	cis	rs2281558	0.837	rs56238023	ENSG00000125804.12	FAM182A	-4.18	4.98e-05	0.0189	-0.45	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:26054655~26086917:+
PCPG	cis	rs17772222	0.917	rs10143767	ENSG00000222990.1	RNU4-22P	4.18	4.98e-05	0.0189	0.41	0.32	Coronary artery calcification;	chr14:88514867	chr14:88513498~88513663:+
PCPG	cis	rs1387259	0.931	rs11168474	ENSG00000240399.1	RP1-228P16.1	4.18	4.99e-05	0.019	0.36	0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48054813~48055591:-
PCPG	cis	rs2098713	0.535	rs11748123	ENSG00000250155.1	CTD-2353F22.1	4.18	4.99e-05	0.019	0.4	0.32	Telomere length;	chr5:37575317	chr5:36666214~36725195:-
PCPG	cis	rs2098713	0.599	rs62359042	ENSG00000250155.1	CTD-2353F22.1	4.18	4.99e-05	0.019	0.4	0.32	Telomere length;	chr5:37577604	chr5:36666214~36725195:-
PCPG	cis	rs2098713	0.535	rs56044522	ENSG00000250155.1	CTD-2353F22.1	4.18	4.99e-05	0.019	0.4	0.32	Telomere length;	chr5:37582698	chr5:36666214~36725195:-
PCPG	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	4.18	4.99e-05	0.019	0.37	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
PCPG	cis	rs728616	1	rs56317427	ENSG00000242600.5	MBL1P	4.18	4.99e-05	0.019	0.63	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80102178	chr10:79904898~79950336:+
PCPG	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	4.18	4.99e-05	0.019	0.31	0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
PCPG	cis	rs4845570	0.831	rs11588634	ENSG00000183586.8	HMGN3P1	4.18	5e-05	0.019	0.56	0.32	Coronary artery disease;	chr1:151808210	chr1:152399577~152399769:+
PCPG	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	4.18	5e-05	0.019	0.32	0.32	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	4.18	5e-05	0.019	0.32	0.32	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	4.18	5e-05	0.019	0.32	0.32	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	4.18	5e-05	0.019	0.32	0.32	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	4.18	5e-05	0.019	0.32	0.32	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	4.18	5e-05	0.019	0.32	0.32	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
PCPG	cis	rs2439831	0.867	rs2412779	ENSG00000205771.5	CATSPER2P1	-4.18	5e-05	0.019	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43363729	chr15:43726918~43747094:-
PCPG	cis	rs11858159	1	rs7172889	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24546910	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs7173110	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24547023	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs7170832	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24547103	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs12907301	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24547168	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs7173287	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24547307	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs12908585	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24547584	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.966	rs13379866	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24548683	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.841	rs13379975	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24549067	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7162797	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24549292	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7164247	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24550048	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs6576336	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24550072	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs9920337	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24551206	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs3903029	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24551388	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs4076153	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24551944	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12324712	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24553127	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7497040	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24553206	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12324769	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24553522	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12324394	ENSG00000260760.1	PWRN3	4.18	5e-05	0.019	0.34	0.32	Platelet thrombus formation;	chr15:24553528	chr15:24441127~24447967:+
PCPG	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	4.18	5e-05	0.019	0.41	0.32	Height;	chr6:109495102	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	4.18	5e-05	0.019	0.41	0.32	Height;	chr6:109496680	chr6:109382795~109383666:+
PCPG	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	4.18	5e-05	0.019	0.42	0.32	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	4.18	5e-05	0.019	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	4.18	5e-05	0.019	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	4.18	5e-05	0.019	0.42	0.32	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
PCPG	cis	rs4376189	0.558	rs6837079	ENSG00000207497.1	Y_RNA	4.18	5e-05	0.019	0.48	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185719315	chr4:185709873~185709967:-
PCPG	cis	rs4376189	0.51	rs10017672	ENSG00000207497.1	Y_RNA	4.18	5e-05	0.019	0.48	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185720386	chr4:185709873~185709967:-
PCPG	cis	rs4376189	0.558	rs2047499	ENSG00000207497.1	Y_RNA	4.18	5e-05	0.019	0.48	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185721052	chr4:185709873~185709967:-
PCPG	cis	rs6121246	0.909	rs6058450	ENSG00000230613.1	HM13-AS1	4.18	5.01e-05	0.019	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31756108	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6060929	ENSG00000230613.1	HM13-AS1	4.18	5.01e-05	0.019	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31758111	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.909	rs6119720	ENSG00000230613.1	HM13-AS1	4.18	5.01e-05	0.019	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31759765	chr20:31567707~31573263:-
PCPG	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	4.18	5.01e-05	0.019	0.33	0.32	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
PCPG	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-4.18	5.01e-05	0.019	-0.39	-0.32	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
PCPG	cis	rs2882667	0.627	rs1549203	ENSG00000222937.1	SNORD63	-4.18	5.01e-05	0.019	-0.29	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138558970~138559039:-
PCPG	cis	rs11858159	1	rs8036695	ENSG00000260760.1	PWRN3	4.18	5.01e-05	0.019	0.35	0.32	Platelet thrombus formation;	chr15:24574711	chr15:24441127~24447967:+
PCPG	cis	rs7403037	0.509	rs7495212	ENSG00000260760.1	PWRN3	4.18	5.01e-05	0.019	0.35	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24575084	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs12901453	ENSG00000260760.1	PWRN3	4.18	5.01e-05	0.019	0.35	0.32	Platelet thrombus formation;	chr15:24576065	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs12901154	ENSG00000260760.1	PWRN3	4.18	5.01e-05	0.019	0.35	0.32	Platelet thrombus formation;	chr15:24576608	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs12902959	ENSG00000260760.1	PWRN3	4.18	5.01e-05	0.019	0.35	0.32	Platelet thrombus formation;	chr15:24577027	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.783	rs12907560	ENSG00000260760.1	PWRN3	4.18	5.01e-05	0.019	0.35	0.32	Platelet thrombus formation;	chr15:24577092	chr15:24441127~24447967:+
PCPG	cis	rs7403037	1	rs12906032	ENSG00000260760.1	PWRN3	4.18	5.01e-05	0.019	0.35	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24577241	chr15:24441127~24447967:+
PCPG	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	4.18	5.02e-05	0.019	0.34	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
PCPG	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-4.18	5.02e-05	0.019	-0.41	-0.32	Height;	chr6:109731677	chr6:109382795~109383666:+
PCPG	cis	rs11220082	0.602	rs10893383	ENSG00000254671.2	STT3A-AS1	-4.18	5.02e-05	0.019	-0.33	-0.32	Schizophrenia;	chr11:125466237	chr11:125570284~125592568:-
PCPG	cis	rs131656	1	rs131656	ENSG00000211645.2	IGLV1-50	4.18	5.02e-05	0.019	0.41	0.32	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr22:21563161	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs5998599	ENSG00000211645.2	IGLV1-50	4.18	5.02e-05	0.019	0.41	0.32	Systemic lupus erythematosus;	chr22:21587692	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs5998619	ENSG00000211645.2	IGLV1-50	4.18	5.02e-05	0.019	0.41	0.32	Systemic lupus erythematosus;	chr22:21591562	chr22:22327300~22327814:+
PCPG	cis	rs112427907	1	rs112427907	ENSG00000199476.1	Y_RNA	4.18	5.02e-05	0.019	0.72	0.32	Stem cell growth factor beta levels;	chr3:47953780	chr3:48288587~48288694:+
PCPG	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	4.18	5.03e-05	0.0191	0.33	0.32	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
PCPG	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	4.18	5.03e-05	0.0191	0.32	0.32	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
PCPG	cis	rs2974238	0.957	rs8110285	ENSG00000269656.1	CTD-2571L23.6	4.17	5.03e-05	0.0191	0.43	0.32	Parental longevity (mother's age at death);	chr19:47613221	chr19:47757036~47768840:-
PCPG	cis	rs853679	0.567	rs9969098	ENSG00000219392.1	RP1-265C24.5	-4.17	5.04e-05	0.0191	-0.44	-0.32	Depression;	chr6:28430971	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.567	rs16894106	ENSG00000219392.1	RP1-265C24.5	-4.17	5.04e-05	0.0191	-0.44	-0.32	Depression;	chr6:28432562	chr6:28115628~28116551:+
PCPG	cis	rs896854	0.654	rs6982393	ENSG00000272509.1	RP11-347C18.5	4.17	5.04e-05	0.0191	0.32	0.32	Type 2 diabetes;	chr8:94968480	chr8:94884609~94885070:+
PCPG	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-4.17	5.04e-05	0.0191	-0.48	-0.32	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
PCPG	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	4.17	5.04e-05	0.0191	0.3	0.32	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
PCPG	cis	rs4489787	0.568	rs2705160	ENSG00000240399.1	RP1-228P16.1	4.17	5.04e-05	0.0191	0.36	0.32	Prostate cancer (SNP x SNP interaction);	chr12:48507373	chr12:48054813~48055591:-
PCPG	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	4.17	5.04e-05	0.0191	0.32	0.32	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	4.17	5.04e-05	0.0191	0.32	0.32	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
PCPG	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-4.17	5.04e-05	0.0191	-0.5	-0.32	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
PCPG	cis	rs10200850	0.881	rs116470355	ENSG00000265215.1	MIR4269	4.17	5.04e-05	0.0191	0.57	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239346515	chr2:239305462~239305545:+
PCPG	cis	rs10200850	0.57	rs72994544	ENSG00000265215.1	MIR4269	4.17	5.04e-05	0.0191	0.57	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239347118	chr2:239305462~239305545:+
PCPG	cis	rs10200850	0.655	rs4852050	ENSG00000265215.1	MIR4269	4.17	5.04e-05	0.0191	0.57	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239347766	chr2:239305462~239305545:+
PCPG	cis	rs10899021	0.512	rs10219168	ENSG00000279353.1	RP11-864N7.4	-4.17	5.05e-05	0.0191	-0.45	-0.32	Response to metformin (IC50);	chr11:74663408	chr11:74698231~74699658:-
PCPG	cis	rs7824557	0.628	rs3779891	ENSG00000255020.1	AF131216.5	4.17	5.05e-05	0.0191	0.42	0.32	Retinal vascular caliber;	chr8:11325996	chr8:11345748~11347502:-
PCPG	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	4.17	5.05e-05	0.0191	0.36	0.32	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
PCPG	cis	rs5758511	0.596	rs55644935	ENSG00000227370.1	RP4-669P10.19	4.17	5.05e-05	0.0192	0.48	0.32	Birth weight;	chr22:42270063	chr22:42132543~42132998:+
PCPG	cis	rs896854	0.846	rs7845219	ENSG00000253528.2	RP11-347C18.4	4.17	5.05e-05	0.0192	0.34	0.32	Type 2 diabetes;	chr8:94925274	chr8:94974573~94974853:-
PCPG	cis	rs9990333	0.562	rs12632706	ENSG00000242086.7	LINC00969	4.17	5.07e-05	0.0192	0.34	0.32	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195658062~195739964:+
PCPG	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-4.17	5.07e-05	0.0192	-0.38	-0.32	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
PCPG	cis	rs7772486	0.654	rs1011597	ENSG00000270638.1	RP3-466P17.1	-4.17	5.07e-05	0.0192	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145735570~145737218:+
PCPG	cis	rs13108904	0.557	rs1680030	ENSG00000254094.1	AC078852.1	4.17	5.07e-05	0.0192	0.4	0.32	Obesity-related traits;	chr4:1251712	chr4:1356581~1358075:+
PCPG	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	4.17	5.08e-05	0.0192	0.38	0.32	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
PCPG	cis	rs2281603	0.674	rs74883409	ENSG00000259116.1	RP11-973N13.4	-4.17	5.08e-05	0.0192	-0.32	-0.32	Lymphocyte counts;	chr14:64594361	chr14:64514154~64540368:-
PCPG	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	4.17	5.08e-05	0.0192	0.4	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
PCPG	cis	rs11858159	0.871	rs11858315	ENSG00000260760.1	PWRN3	4.17	5.08e-05	0.0192	0.35	0.32	Platelet thrombus formation;	chr15:24556575	chr15:24441127~24447967:+
PCPG	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	4.17	5.08e-05	0.0192	0.42	0.32	Height;	chr6:109479396	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	4.17	5.08e-05	0.0192	0.42	0.32	Height;	chr6:109480428	chr6:109382795~109383666:+
PCPG	cis	rs2315504	0.568	rs8078796	ENSG00000278954.1	RP13-415G19.2	-4.17	5.08e-05	0.0192	-0.38	-0.32	Height;	chr17:40807395	chr17:41665566~41668031:+
PCPG	cis	rs9813712	0.672	rs73210789	ENSG00000228252.7	COL6A4P2	4.17	5.08e-05	0.0192	0.41	0.32	Response to amphetamines;	chr3:130243418	chr3:130212823~130273806:+
PCPG	cis	rs9813712	1	rs57804141	ENSG00000228252.7	COL6A4P2	4.17	5.08e-05	0.0192	0.41	0.32	Response to amphetamines;	chr3:130243669	chr3:130212823~130273806:+
PCPG	cis	rs2060793	0.741	rs10741656	ENSG00000251991.1	RNU7-49P	4.17	5.08e-05	0.0192	0.37	0.32	Vitamin D levels;	chr11:14803699	chr11:14478892~14478953:+
PCPG	cis	rs73201462	1	rs2811381	ENSG00000242551.2	POU5F1P6	-4.17	5.09e-05	0.0193	-0.59	-0.32	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128279069	chr3:128674735~128677005:-
PCPG	cis	rs17772222	0.917	rs4635267	ENSG00000222990.1	RNU4-22P	4.17	5.09e-05	0.0193	0.41	0.32	Coronary artery calcification;	chr14:88621922	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.876	rs56144430	ENSG00000222990.1	RNU4-22P	4.17	5.09e-05	0.0193	0.41	0.32	Coronary artery calcification;	chr14:88622013	chr14:88513498~88513663:+
PCPG	cis	rs2652834	0.851	rs11071721	ENSG00000259498.1	RP11-244F12.3	-4.17	5.09e-05	0.0193	-0.53	-0.32	HDL cholesterol;	chr15:63058019	chr15:63046034~63049387:-
PCPG	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	4.17	5.09e-05	0.0193	0.41	0.32	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
PCPG	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	4.17	5.1e-05	0.0193	0.27	0.32	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs7651721	ENSG00000244119.1	PDCL3P4	4.17	5.1e-05	0.0193	0.27	0.32	Colorectal cancer;	chr3:101674739	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	4.17	5.1e-05	0.0193	0.27	0.32	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	4.17	5.1e-05	0.0193	0.27	0.32	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
PCPG	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	4.17	5.1e-05	0.0193	0.29	0.32	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	4.17	5.1e-05	0.0193	0.29	0.32	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	4.17	5.1e-05	0.0193	0.29	0.32	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
PCPG	cis	rs5742933	0.597	rs12471663	ENSG00000273240.1	RP11-455J20.3	4.17	5.1e-05	0.0193	0.36	0.32	Ferritin levels;	chr2:189642372	chr2:189763859~189764456:-
PCPG	cis	rs5742933	0.597	rs6761923	ENSG00000273240.1	RP11-455J20.3	4.17	5.1e-05	0.0193	0.36	0.32	Ferritin levels;	chr2:189642873	chr2:189763859~189764456:-
PCPG	cis	rs9302635	0.745	rs35549608	ENSG00000260886.1	TAT-AS1	4.17	5.1e-05	0.0193	0.58	0.32	Blood protein levels;	chr16:72193499	chr16:71565789~71578187:+
PCPG	cis	rs11098499	0.874	rs13123591	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119184835	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs9995277	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119187448	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs17839089	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119189914	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs6826823	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119190943	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	4.17	5.11e-05	0.0193	0.33	0.32	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
PCPG	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	4.17	5.11e-05	0.0193	0.41	0.32	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
PCPG	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	4.17	5.11e-05	0.0193	0.41	0.32	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
PCPG	cis	rs425277	0.958	rs262688	ENSG00000271806.1	RP5-892K4.1	4.17	5.11e-05	0.0193	0.4	0.32	Height;	chr1:2182126	chr1:2141084~2145279:-
PCPG	cis	rs11858159	0.783	rs7177757	ENSG00000260760.1	PWRN3	4.17	5.12e-05	0.0193	0.34	0.32	Platelet thrombus formation;	chr15:24547144	chr15:24441127~24447967:+
PCPG	cis	rs10853057	0.541	rs62065481	ENSG00000214174.7	AMZ2P1	4.17	5.12e-05	0.0193	0.63	0.32	White matter microstructure (global fractional anisotropy);	chr17:65008273	chr17:64966550~64975576:-
PCPG	cis	rs7208859	0.623	rs216423	ENSG00000263603.1	CTD-2349P21.5	-4.17	5.12e-05	0.0194	-0.47	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30729469~30731202:+
PCPG	cis	rs7702057	0.53	rs1567330	ENSG00000271918.1	CTD-2287O16.5	4.17	5.12e-05	0.0194	0.46	0.32	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116083807~116085416:-
PCPG	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	4.17	5.12e-05	0.0194	0.37	0.32	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	4.17	5.12e-05	0.0194	0.37	0.32	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
PCPG	cis	rs728616	0.867	rs17606361	ENSG00000242600.5	MBL1P	4.17	5.12e-05	0.0194	0.64	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:79904898~79950336:+
PCPG	cis	rs73198271	0.71	rs11779561	ENSG00000253893.2	FAM85B	4.17	5.13e-05	0.0194	0.43	0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8167819~8226614:-
PCPG	cis	rs6585424	1	rs35180576	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163215	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs35025775	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164529	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs34749786	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164634	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs61860024	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165607	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs61860025	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165798	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs12411386	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166475	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs2228427	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166962	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs34332933	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166994	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs61860035	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172697	chr10:79904898~79950336:+
PCPG	cis	rs6585424	0.85	rs75804987	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172753	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs12769115	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173745	chr10:79904898~79950336:+
PCPG	cis	rs6585424	0.85	rs61860036	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175103	chr10:79904898~79950336:+
PCPG	cis	rs728616	0.51	rs12411989	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178094	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs35483545	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179417	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs34386571	ENSG00000242600.5	MBL1P	4.17	5.13e-05	0.0194	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179676	chr10:79904898~79950336:+
PCPG	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	4.17	5.13e-05	0.0194	0.36	0.32	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
PCPG	cis	rs9303542	0.625	rs7225995	ENSG00000279036.1	RP11-81K2.2	-4.17	5.13e-05	0.0194	-0.52	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48518906	chr17:49494223~49497800:-
PCPG	cis	rs17772222	0.876	rs61983303	ENSG00000222990.1	RNU4-22P	4.17	5.13e-05	0.0194	0.41	0.32	Coronary artery calcification;	chr14:88764459	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs2224333	ENSG00000222990.1	RNU4-22P	4.17	5.13e-05	0.0194	0.41	0.32	Coronary artery calcification;	chr14:88768748	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs12590826	ENSG00000222990.1	RNU4-22P	4.17	5.13e-05	0.0194	0.41	0.32	Coronary artery calcification;	chr14:88769357	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs57889459	ENSG00000222990.1	RNU4-22P	4.17	5.13e-05	0.0194	0.41	0.32	Coronary artery calcification;	chr14:88770820	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs61982733	ENSG00000222990.1	RNU4-22P	4.17	5.13e-05	0.0194	0.41	0.32	Coronary artery calcification;	chr14:88776244	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs2145120	ENSG00000222990.1	RNU4-22P	4.17	5.13e-05	0.0194	0.41	0.32	Coronary artery calcification;	chr14:88777699	chr14:88513498~88513663:+
PCPG	cis	rs2732480	0.577	rs2634684	ENSG00000240399.1	RP1-228P16.1	-4.17	5.13e-05	0.0194	-0.35	-0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48054813~48055591:-
PCPG	cis	rs891378	0.675	rs7543002	ENSG00000274245.1	RP11-357P18.2	-4.17	5.13e-05	0.0194	-0.41	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205496	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.785	rs7554219	ENSG00000274245.1	RP11-357P18.2	-4.17	5.13e-05	0.0194	-0.41	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205712	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.785	rs6700846	ENSG00000274245.1	RP11-357P18.2	-4.17	5.13e-05	0.0194	-0.41	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228799	chr1:207372559~207373252:+
PCPG	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-4.17	5.13e-05	0.0194	-0.5	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
PCPG	cis	rs13126694	0.778	rs12503001	ENSG00000248429.4	RP11-597D13.9	4.17	5.14e-05	0.0194	0.33	0.32	Blood osmolality (transformed sodium);	chr4:158100822	chr4:158170752~158202877:+
PCPG	cis	rs9650657	0.506	rs7823296	ENSG00000255020.1	AF131216.5	-4.17	5.14e-05	0.0194	-0.44	-0.32	Neuroticism;	chr8:10921036	chr8:11345748~11347502:-
PCPG	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-4.17	5.14e-05	0.0194	-0.42	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
PCPG	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-4.17	5.14e-05	0.0194	-0.42	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
PCPG	cis	rs561341	1	rs4795667	ENSG00000265798.5	RP11-271K11.5	4.17	5.14e-05	0.0194	0.57	0.32	Hip circumference adjusted for BMI;	chr17:31917424	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs4795668	ENSG00000265798.5	RP11-271K11.5	4.17	5.14e-05	0.0194	0.57	0.32	Hip circumference adjusted for BMI;	chr17:31917535	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs4795669	ENSG00000265798.5	RP11-271K11.5	4.17	5.14e-05	0.0194	0.57	0.32	Hip circumference adjusted for BMI;	chr17:31917682	chr17:31038575~31059121:-
PCPG	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-4.17	5.15e-05	0.0194	-0.43	-0.32	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
PCPG	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	4.17	5.15e-05	0.0194	0.37	0.32	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
PCPG	cis	rs1478897	0.804	rs9329246	ENSG00000270154.1	RP11-419I17.1	4.17	5.15e-05	0.0194	0.38	0.32	Systemic lupus erythematosus;	chr8:11535371	chr8:12476462~12477122:+
PCPG	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	4.17	5.15e-05	0.0194	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
PCPG	cis	rs6570726	0.967	rs6903252	ENSG00000270638.1	RP3-466P17.1	4.17	5.15e-05	0.0195	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145735570~145737218:+
PCPG	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	4.17	5.15e-05	0.0195	0.31	0.32	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
PCPG	cis	rs853679	0.567	rs13209596	ENSG00000219392.1	RP1-265C24.5	-4.17	5.16e-05	0.0195	-0.45	-0.32	Depression;	chr6:28428413	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.567	rs7740429	ENSG00000219392.1	RP1-265C24.5	-4.17	5.16e-05	0.0195	-0.45	-0.32	Depression;	chr6:28431469	chr6:28115628~28116551:+
PCPG	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	4.17	5.16e-05	0.0195	0.37	0.32	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	4.17	5.16e-05	0.0195	0.37	0.32	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
PCPG	cis	rs6121246	0.909	rs6119651	ENSG00000230613.1	HM13-AS1	4.17	5.16e-05	0.0195	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31671443	chr20:31567707~31573263:-
PCPG	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	4.17	5.16e-05	0.0195	0.49	0.32	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
PCPG	cis	rs911119	1	rs13039536	ENSG00000270001.1	RP11-218C14.8	-4.17	5.16e-05	0.0195	-0.51	-0.32	Chronic kidney disease;	chr20:23631668	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs734801	ENSG00000270001.1	RP11-218C14.8	-4.17	5.16e-05	0.0195	-0.51	-0.32	Chronic kidney disease;	chr20:23632154	chr20:23631826~23632316:-
PCPG	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	4.17	5.17e-05	0.0195	0.41	0.32	Height;	chr6:109640141	chr6:109382795~109383666:+
PCPG	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	4.17	5.17e-05	0.0195	0.4	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
PCPG	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	4.17	5.17e-05	0.0195	0.44	0.32	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
PCPG	cis	rs4819052	0.851	rs4819041	ENSG00000215447.6	BX322557.10	-4.17	5.18e-05	0.0195	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45288052~45291738:+
PCPG	cis	rs2404602	0.716	rs4886813	ENSG00000259514.1	RP11-685G9.2	4.17	5.19e-05	0.0196	0.32	0.32	Blood metabolite levels;	chr15:76545880	chr15:76339609~76342063:-
PCPG	cis	rs10751667	0.643	rs10902237	ENSG00000255142.1	AP006621.6	4.17	5.19e-05	0.0196	0.32	0.32	Alzheimer's disease (late onset);	chr11:944801	chr11:781645~782105:+
PCPG	cis	rs394563	0.901	rs448874	ENSG00000268592.3	RAET1E-AS1	4.17	5.19e-05	0.0196	0.41	0.32	Dupuytren's disease;	chr6:149475831	chr6:149863494~149919507:+
PCPG	cis	rs394563	1	rs394563	ENSG00000268592.3	RAET1E-AS1	4.17	5.19e-05	0.0196	0.41	0.32	Dupuytren's disease;	chr6:149475878	chr6:149863494~149919507:+
PCPG	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	4.17	5.19e-05	0.0196	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
PCPG	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	4.17	5.19e-05	0.0196	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
PCPG	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	4.17	5.19e-05	0.0196	0.32	0.32	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	4.17	5.19e-05	0.0196	0.32	0.32	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
PCPG	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-4.17	5.2e-05	0.0196	-0.38	-0.32	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
PCPG	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	4.17	5.2e-05	0.0196	0.33	0.32	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
PCPG	cis	rs4489787	1	rs2705123	ENSG00000240399.1	RP1-228P16.1	4.17	5.2e-05	0.0196	0.4	0.32	Prostate cancer (SNP x SNP interaction);	chr12:48485009	chr12:48054813~48055591:-
PCPG	cis	rs2736345	1	rs2736345	ENSG00000154316.13	TDH	4.17	5.2e-05	0.0196	0.41	0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11494976	chr8:11339637~11368452:+
PCPG	cis	rs1874124	0.577	rs2807872	ENSG00000272823.1	RP11-295M18.6	-4.17	5.2e-05	0.0196	-0.45	-0.32	Cholesterol, total;	chr1:220866908	chr1:220828676~220829211:-
PCPG	cis	rs12906542	1	rs12906542	ENSG00000259792.1	RP11-114H24.6	-4.17	5.21e-05	0.0196	-0.4	-0.32	Breast cancer;	chr15:77977130	chr15:77993405~77995289:+
PCPG	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	4.17	5.21e-05	0.0196	0.41	0.32	Height;	chr6:109494148	chr6:109382795~109383666:+
PCPG	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	4.17	5.21e-05	0.0196	0.32	0.32	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
PCPG	cis	rs1003719	0.715	rs762139	ENSG00000228677.1	TTC3-AS1	4.17	5.21e-05	0.0196	0.4	0.32	Eye color traits;	chr21:37196174	chr21:37187666~37193926:-
PCPG	cis	rs17772222	0.917	rs61977053	ENSG00000222990.1	RNU4-22P	4.17	5.21e-05	0.0196	0.44	0.32	Coronary artery calcification;	chr14:88380876	chr14:88513498~88513663:+
PCPG	cis	rs16964211	0.826	rs28757122	ENSG00000259438.1	CTD-2650P22.1	-4.17	5.21e-05	0.0196	-0.65	-0.32	Height;	chr15:51289133	chr15:52010999~52019095:-
PCPG	cis	rs748404	0.666	rs34591748	ENSG00000205771.5	CATSPER2P1	-4.17	5.21e-05	0.0196	-0.42	-0.32	Lung cancer;	chr15:43334917	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs35326382	ENSG00000205771.5	CATSPER2P1	-4.17	5.21e-05	0.0196	-0.42	-0.32	Lung cancer;	chr15:43338686	chr15:43726918~43747094:-
PCPG	cis	rs7246657	0.524	rs28542490	ENSG00000226686.6	LINC01535	-4.17	5.21e-05	0.0196	-0.61	-0.32	Coronary artery calcification;	chr19:36965682	chr19:37251912~37265535:+
PCPG	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	4.17	5.21e-05	0.0196	0.32	0.32	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
PCPG	cis	rs6787172	0.811	rs1369562	ENSG00000271778.1	RP11-379F4.8	4.17	5.21e-05	0.0196	0.29	0.32	Subjective well-being;	chr3:158490771	chr3:158782547~158783124:+
PCPG	cis	rs2652834	0.851	rs4238372	ENSG00000259498.1	RP11-244F12.3	-4.17	5.21e-05	0.0196	-0.54	-0.32	HDL cholesterol;	chr15:63059289	chr15:63046034~63049387:-
PCPG	cis	rs2652834	0.808	rs4775614	ENSG00000259498.1	RP11-244F12.3	-4.17	5.21e-05	0.0196	-0.54	-0.32	HDL cholesterol;	chr15:63059488	chr15:63046034~63049387:-
PCPG	cis	rs2652834	0.808	rs11071723	ENSG00000259498.1	RP11-244F12.3	-4.17	5.21e-05	0.0196	-0.54	-0.32	HDL cholesterol;	chr15:63063076	chr15:63046034~63049387:-
PCPG	cis	rs2652834	0.851	rs16946416	ENSG00000259498.1	RP11-244F12.3	4.17	5.21e-05	0.0196	0.54	0.32	HDL cholesterol;	chr15:63064522	chr15:63046034~63049387:-
PCPG	cis	rs2282300	0.956	rs2685286	ENSG00000242353.1	RP4-710M3.1	-4.17	5.22e-05	0.0196	-0.42	-0.32	Morning vs. evening chronotype;	chr11:30360041	chr11:30368148~30368646:+
PCPG	cis	rs2282300	0.956	rs1717773	ENSG00000242353.1	RP4-710M3.1	-4.17	5.22e-05	0.0196	-0.42	-0.32	Morning vs. evening chronotype;	chr11:30361607	chr11:30368148~30368646:+
PCPG	cis	rs11220082	0.627	rs35102191	ENSG00000254671.2	STT3A-AS1	-4.17	5.22e-05	0.0196	-0.33	-0.32	Schizophrenia;	chr11:125455250	chr11:125570284~125592568:-
PCPG	cis	rs6456042	1	rs4343903	ENSG00000231297.3	RP11-459F1.2	4.17	5.22e-05	0.0196	0.35	0.32	Asthma;	chr6:166126106	chr6:166099665~166113273:+
PCPG	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
PCPG	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	4.17	5.22e-05	0.0197	0.78	0.32	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
PCPG	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	4.17	5.22e-05	0.0197	0.36	0.32	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
PCPG	cis	rs2736345	0.516	rs7844858	ENSG00000255020.1	AF131216.5	4.17	5.22e-05	0.0197	0.42	0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11535150	chr8:11345748~11347502:-
PCPG	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	4.17	5.22e-05	0.0197	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
PCPG	cis	rs9813712	0.953	rs9883455	ENSG00000228252.7	COL6A4P2	-4.17	5.23e-05	0.0197	-0.44	-0.32	Response to amphetamines;	chr3:130260088	chr3:130212823~130273806:+
PCPG	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	4.17	5.23e-05	0.0197	0.46	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
PCPG	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-4.17	5.23e-05	0.0197	-0.37	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
PCPG	cis	rs2736345	0.755	rs2736340	ENSG00000184608.7	FAM167A-AS1	4.17	5.23e-05	0.0197	0.49	0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:11368402~11438658:+
PCPG	cis	rs1023500	0.551	rs133355	ENSG00000226450.2	CYP2D8P	4.16	5.24e-05	0.0197	0.31	0.32	Schizophrenia;	chr22:42044281	chr22:42149886~42155001:-
PCPG	cis	rs2665103	0.687	rs11633000	ENSG00000228141.5	AC105339.1	-4.16	5.24e-05	0.0197	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82710471~82714026:-
PCPG	cis	rs1440410	0.835	rs7685075	ENSG00000250326.1	RP11-284M14.1	4.16	5.24e-05	0.0197	0.3	0.32	Ischemic stroke;	chr4:143133546	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs10155324	ENSG00000250326.1	RP11-284M14.1	4.16	5.24e-05	0.0197	0.3	0.32	Ischemic stroke;	chr4:143135820	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs6537150	ENSG00000250326.1	RP11-284M14.1	4.16	5.24e-05	0.0197	0.3	0.32	Ischemic stroke;	chr4:143146716	chr4:142933195~143184861:-
PCPG	cis	rs7208859	0.673	rs216435	ENSG00000266490.1	CTD-2349P21.9	4.16	5.24e-05	0.0197	0.39	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30792372~30792833:+
PCPG	cis	rs4934494	0.834	rs1359624	ENSG00000240996.1	RP11-80H5.7	-4.16	5.24e-05	0.0197	-0.38	-0.32	Red blood cell count;	chr10:89635671	chr10:89694295~89697928:-
PCPG	cis	rs875971	0.755	rs76288834	ENSG00000235475.1	LINC01372	-4.16	5.24e-05	0.0197	-0.33	-0.32	Aortic root size;	chr7:66604815	chr7:67335976~67340024:+
PCPG	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	4.16	5.25e-05	0.0197	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
PCPG	cis	rs13108904	0.935	rs2293633	ENSG00000253399.1	AC078852.2	-4.16	5.25e-05	0.0197	-0.33	-0.32	Obesity-related traits;	chr4:1297852	chr4:1358479~1359461:+
PCPG	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-4.16	5.25e-05	0.0197	-0.45	-0.32	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
PCPG	cis	rs7772486	0.686	rs1045820	ENSG00000270638.1	RP3-466P17.1	4.16	5.25e-05	0.0197	0.35	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.754	rs6570703	ENSG00000270638.1	RP3-466P17.1	4.16	5.25e-05	0.0197	0.35	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs6570705	ENSG00000270638.1	RP3-466P17.1	4.16	5.25e-05	0.0197	0.35	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs4896833	ENSG00000270638.1	RP3-466P17.1	4.16	5.25e-05	0.0197	0.35	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145735570~145737218:+
PCPG	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	4.16	5.25e-05	0.0197	0.47	0.32	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
PCPG	cis	rs7772486	0.686	rs9403746	ENSG00000270638.1	RP3-466P17.1	-4.16	5.25e-05	0.0197	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145735570~145737218:+
PCPG	cis	rs8024893	0.764	rs7182545	ENSG00000270055.1	CTD-3092A11.2	-4.16	5.25e-05	0.0198	-0.61	-0.32	Red cell distribution width;	chr15:31239638	chr15:30487963~30490313:+
PCPG	cis	rs7118412	0.762	rs2016826	ENSG00000260966.1	RP11-690D19.3	-4.16	5.25e-05	0.0198	-0.34	-0.32	Disc degeneration (lumbar);	chr11:103692259	chr11:103050687~103055799:-
PCPG	cis	rs34421088	0.56	rs2467520	ENSG00000269954.1	RP11-148O21.6	-4.16	5.25e-05	0.0198	-0.37	-0.32	Neuroticism;	chr8:11541444	chr8:11552488~11552991:-
PCPG	cis	rs3758911	0.861	rs11212197	ENSG00000255353.1	RP11-382M14.1	-4.16	5.25e-05	0.0198	-0.43	-0.32	Coronary artery disease;	chr11:107391784	chr11:107176286~107177530:+
PCPG	cis	rs1488515	0.598	rs73230266	ENSG00000279067.1	GS1-25M2.1	-4.16	5.26e-05	0.0198	-0.49	-0.32	Obesity-related traits;	chr7:96017142	chr7:96118647~96119995:+
PCPG	cis	rs748404	0.626	rs1814324	ENSG00000249839.1	AC011330.5	-4.16	5.26e-05	0.0198	-0.44	-0.32	Lung cancer;	chr15:43314951	chr15:43663654~43684339:-
PCPG	cis	rs9494145	0.68	rs11759553	ENSG00000232876.1	CTA-212D2.2	-4.16	5.27e-05	0.0198	-0.41	-0.32	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135101158	chr6:135055033~135060550:+
PCPG	cis	rs11858159	0.966	rs7163557	ENSG00000260760.1	PWRN3	4.16	5.27e-05	0.0198	0.35	0.32	Platelet thrombus formation;	chr15:24550313	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs7180453	ENSG00000260760.1	PWRN3	4.16	5.27e-05	0.0198	0.35	0.32	Platelet thrombus formation;	chr15:24550318	chr15:24441127~24447967:+
PCPG	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	4.16	5.27e-05	0.0198	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	4.16	5.27e-05	0.0198	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
PCPG	cis	rs901683	1	rs71494791	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45482883	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs34268168	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45493078	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12774690	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45494297	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71499566	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45500567	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71494799	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45507408	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12766550	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45515907	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71496611	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45526284	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12775527	ENSG00000230869.1	CTGLF10P	-4.16	5.28e-05	0.0198	-0.79	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45529542	chr10:45678692~45700532:+
PCPG	cis	rs4819052	0.851	rs7275468	ENSG00000215447.6	BX322557.10	-4.16	5.28e-05	0.0198	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45288052~45291738:+
PCPG	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	4.16	5.28e-05	0.0198	0.3	0.32	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
PCPG	cis	rs1440410	0.83	rs1440411	ENSG00000250326.1	RP11-284M14.1	4.16	5.28e-05	0.0198	0.31	0.32	Ischemic stroke;	chr4:143237132	chr4:142933195~143184861:-
PCPG	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	4.16	5.28e-05	0.0198	0.41	0.32	Height;	chr6:109642186	chr6:109382795~109383666:+
PCPG	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-4.16	5.29e-05	0.0199	-0.38	-0.32	Height;	chr5:36911514	chr5:36666214~36725195:-
PCPG	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-4.16	5.29e-05	0.0199	-0.42	-0.32	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
PCPG	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	4.16	5.29e-05	0.0199	0.43	0.32	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
PCPG	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	4.16	5.29e-05	0.0199	0.43	0.32	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
PCPG	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	4.16	5.3e-05	0.0199	0.32	0.32	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
PCPG	cis	rs11858159	0.934	rs61993130	ENSG00000260760.1	PWRN3	4.16	5.3e-05	0.0199	0.34	0.32	Platelet thrombus formation;	chr15:24541124	chr15:24441127~24447967:+
PCPG	cis	rs7819412	0.745	rs6601569	ENSG00000255020.1	AF131216.5	-4.16	5.3e-05	0.0199	-0.42	-0.32	Triglycerides;	chr8:11216069	chr8:11345748~11347502:-
PCPG	cis	rs7575217	0.588	rs7572457	ENSG00000272902.2	RP11-299H21.1	4.16	5.3e-05	0.0199	0.37	0.32	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;	chr2:101059346	chr2:101151660~101155412:+
PCPG	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	4.16	5.31e-05	0.0199	0.29	0.32	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
PCPG	cis	rs748404	0.666	rs12911569	ENSG00000205771.5	CATSPER2P1	-4.16	5.31e-05	0.0199	-0.45	-0.32	Lung cancer;	chr15:43305099	chr15:43726918~43747094:-
PCPG	cis	rs7172677	1	rs7177528	ENSG00000261543.1	RP11-665J16.1	-4.16	5.31e-05	0.0199	-0.39	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75117253	chr15:74152800~74179226:-
PCPG	cis	rs7829975	0.684	rs546603	ENSG00000253893.2	FAM85B	4.16	5.31e-05	0.0199	0.39	0.32	Mood instability;	chr8:8738328	chr8:8167819~8226614:-
PCPG	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-4.16	5.31e-05	0.0199	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
PCPG	cis	rs875971	0.825	rs7384021	ENSG00000235475.1	LINC01372	-4.16	5.31e-05	0.0199	-0.33	-0.32	Aortic root size;	chr7:66612917	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.825	rs66981195	ENSG00000235475.1	LINC01372	-4.16	5.31e-05	0.0199	-0.33	-0.32	Aortic root size;	chr7:66614048	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs3926380	ENSG00000235475.1	LINC01372	-4.16	5.31e-05	0.0199	-0.33	-0.32	Aortic root size;	chr7:66615658	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.825	rs28480509	ENSG00000235475.1	LINC01372	-4.16	5.31e-05	0.0199	-0.33	-0.32	Aortic root size;	chr7:66634237	chr7:67335976~67340024:+
PCPG	cis	rs1150668	0.796	rs213236	ENSG00000219392.1	RP1-265C24.5	-4.16	5.31e-05	0.0199	-0.38	-0.32	Pubertal anthropometrics;	chr6:28356620	chr6:28115628~28116551:+
PCPG	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	4.16	5.31e-05	0.0199	0.41	0.32	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	4.16	5.31e-05	0.0199	0.41	0.32	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	4.16	5.31e-05	0.0199	0.41	0.32	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
PCPG	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-4.16	5.31e-05	0.0199	-0.36	-0.32	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
PCPG	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	4.16	5.31e-05	0.0199	0.42	0.32	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	4.16	5.31e-05	0.0199	0.42	0.32	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
PCPG	cis	rs896854	0.714	rs6471503	ENSG00000253528.2	RP11-347C18.4	4.16	5.32e-05	0.0199	0.35	0.32	Type 2 diabetes;	chr8:94978055	chr8:94974573~94974853:-
PCPG	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	4.16	5.32e-05	0.0199	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
PCPG	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-4.16	5.32e-05	0.0199	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
PCPG	cis	rs6929812	0.702	rs2064220	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27420248	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs6456782	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27420960	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs7771598	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27421479	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs7754086	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27421711	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs62401131	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27422113	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.729	rs6456784	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27422242	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs6928314	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27423214	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs12212288	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27423464	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs12205189	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27423541	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs12525544	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27424262	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs13207099	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27424369	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs7747444	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27425930	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.702	rs2206253	ENSG00000271755.1	RP1-153G14.4	4.16	5.32e-05	0.0199	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27428287	chr6:27404010~27406964:-
PCPG	cis	rs6840258	1	rs17604480	ENSG00000251411.1	RP11-397E7.4	-4.16	5.32e-05	0.0199	-0.36	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87048975	chr4:86913266~86914817:-
PCPG	cis	rs7759001	0.857	rs1883404	ENSG00000271755.1	RP1-153G14.4	-4.16	5.33e-05	0.02	-0.49	-0.32	Glomerular filtration rate (creatinine);	chr6:27382602	chr6:27404010~27406964:-
PCPG	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	4.16	5.33e-05	0.02	0.39	0.32	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
PCPG	cis	rs7208859	0.623	rs216433	ENSG00000266490.1	CTD-2349P21.9	4.16	5.33e-05	0.02	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30792372~30792833:+
PCPG	cis	rs8098244	0.737	rs1154237	ENSG00000265752.2	RP11-403A21.1	-4.16	5.33e-05	0.02	-0.47	-0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23935225	chr18:23957754~23982556:-
PCPG	cis	rs301901	1	rs300051	ENSG00000250155.1	CTD-2353F22.1	-4.16	5.33e-05	0.02	-0.38	-0.32	Height;	chr5:37088525	chr5:36666214~36725195:-
PCPG	cis	rs8030379	1	rs1526080	ENSG00000230373.7	GOLGA6L5P	-4.16	5.33e-05	0.02	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921168	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1852264	ENSG00000230373.7	GOLGA6L5P	-4.16	5.33e-05	0.02	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921188	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1526081	ENSG00000230373.7	GOLGA6L5P	-4.16	5.33e-05	0.02	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921314	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs8030379	ENSG00000230373.7	GOLGA6L5P	-4.16	5.33e-05	0.02	-0.32	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922158	chr15:84507885~84516814:-
PCPG	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	4.16	5.33e-05	0.02	0.39	0.32	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
PCPG	cis	rs9813712	0.818	rs11718381	ENSG00000228252.7	COL6A4P2	4.16	5.33e-05	0.02	0.39	0.32	Response to amphetamines;	chr3:130222660	chr3:130212823~130273806:+
PCPG	cis	rs1048886	0.872	rs12529984	ENSG00000271967.1	RP11-134K13.4	-4.16	5.33e-05	0.02	-0.38	-0.32	Type 2 diabetes;	chr6:70394764	chr6:70596438~70596980:+
PCPG	cis	rs11858159	0.966	rs9920573	ENSG00000260760.1	PWRN3	4.16	5.33e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24543194	chr15:24441127~24447967:+
PCPG	cis	rs657075	0.595	rs35466090	ENSG00000233006.5	AC034220.3	-4.16	5.34e-05	0.02	-0.46	-0.32	Rheumatoid arthritis;	chr5:132287143	chr5:132311285~132369916:-
PCPG	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	4.16	5.34e-05	0.02	0.55	0.32	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
PCPG	cis	rs875971	0.862	rs6460290	ENSG00000235475.1	LINC01372	-4.16	5.34e-05	0.02	-0.33	-0.32	Aortic root size;	chr7:66344119	chr7:67335976~67340024:+
PCPG	cis	rs301901	0.581	rs292175	ENSG00000250155.1	CTD-2353F22.1	-4.16	5.34e-05	0.02	-0.39	-0.32	Height;	chr5:36832512	chr5:36666214~36725195:-
PCPG	cis	rs17037831	0.584	rs6442359	ENSG00000272263.1	RP11-767C1.2	4.16	5.34e-05	0.02	0.49	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr3:13216012	chr3:12832219~12832728:-
PCPG	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	4.16	5.34e-05	0.02	0.37	0.32	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
PCPG	cis	rs1876905	0.597	rs354551	ENSG00000255389.1	C6orf3	4.16	5.34e-05	0.02	0.46	0.32	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111599875~111602295:+
PCPG	cis	rs1371867	0.875	rs1788176	ENSG00000212994.5	RPS26P6	4.16	5.34e-05	0.02	0.37	0.32	Atrioventricular conduction;	chr8:100319884	chr8:100895771~100896118:+
PCPG	cis	rs11671005	0.735	rs11084544	ENSG00000269600.1	AC016629.3	-4.16	5.35e-05	0.02	-0.49	-0.32	Mean platelet volume;	chr19:58428760	chr19:58593896~58599355:-
PCPG	cis	rs9650657	0.645	rs11774552	ENSG00000255020.1	AF131216.5	-4.16	5.35e-05	0.02	-0.4	-0.32	Neuroticism;	chr8:10658169	chr8:11345748~11347502:-
PCPG	cis	rs11858159	1	rs6576323	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24539732	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs6576324	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24539767	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs6576326	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24540053	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12908893	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24540869	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12907711	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24540888	chr15:24441127~24447967:+
PCPG	cis	rs7403037	0.527	rs58815588	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24541029	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs11161105	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24542005	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12903884	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24543447	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.902	rs12906416	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24543834	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs6576327	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24544777	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12915525	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24545723	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.871	rs12917281	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24545726	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12916887	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24545849	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12902323	ENSG00000260760.1	PWRN3	4.16	5.35e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24545969	chr15:24441127~24447967:+
PCPG	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-4.16	5.35e-05	0.02	-0.4	-0.32	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
PCPG	cis	rs2288884	0.559	rs12459268	ENSG00000275055.1	CTC-471J1.11	-4.16	5.35e-05	0.02	-0.3	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52002719	chr19:52049007~52049754:+
PCPG	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	4.16	5.35e-05	0.02	0.4	0.32	Height;	chr6:109507364	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	4.16	5.35e-05	0.02	0.4	0.32	Height;	chr6:109507366	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-4.16	5.35e-05	0.02	-0.4	-0.32	Height;	chr6:109501793	chr6:109382795~109383666:+
PCPG	cis	rs9650657	0.645	rs4841407	ENSG00000255020.1	AF131216.5	-4.16	5.35e-05	0.02	-0.4	-0.32	Neuroticism;	chr8:10658675	chr8:11345748~11347502:-
PCPG	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	4.16	5.35e-05	0.02	0.41	0.32	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
PCPG	cis	rs11858159	0.934	rs10873590	ENSG00000259905.4	PWRN1	4.16	5.36e-05	0.02	0.34	0.32	Platelet thrombus formation;	chr15:24568470	chr15:24493137~24652130:+
PCPG	cis	rs6585424	1	rs12777867	ENSG00000242600.5	MBL1P	4.16	5.36e-05	0.02	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175774	chr10:79904898~79950336:+
PCPG	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-4.16	5.36e-05	0.02	-0.41	-0.32	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
PCPG	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-4.16	5.36e-05	0.02	-0.41	-0.32	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
PCPG	cis	rs7017914	0.714	rs13268251	ENSG00000254031.4	RP11-326E22.1	-4.16	5.36e-05	0.02	-0.3	-0.32	Bone mineral density;	chr8:71066579	chr8:71155457~71204223:+
PCPG	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	4.16	5.36e-05	0.02	0.45	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
PCPG	cis	rs9650657	0.585	rs4841401	ENSG00000255020.1	AF131216.5	-4.16	5.36e-05	0.02	-0.4	-0.32	Neuroticism;	chr8:10632082	chr8:11345748~11347502:-
PCPG	cis	rs16949788	1	rs10468036	ENSG00000261351.2	CTD-3185P2.1	-4.16	5.36e-05	0.02	-0.46	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66417938	chr15:66488658~66492109:-
PCPG	cis	rs17684571	0.751	rs6905603	ENSG00000231441.1	RP11-472M19.2	4.16	5.36e-05	0.02	0.54	0.32	Schizophrenia;	chr6:56848145	chr6:56844002~56864078:+
PCPG	cis	rs11148252	0.574	rs7139495	ENSG00000273784.3	RP11-78J21.7	-4.16	5.36e-05	0.0201	-0.31	-0.32	Lewy body disease;	chr13:52709183	chr13:52600042~52642542:+
PCPG	cis	rs17152411	1	rs41303609	ENSG00000278831.1	RP11-12J10.4	4.16	5.36e-05	0.0201	0.46	0.32	Height;	chr10:124982044	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs2241541	ENSG00000278831.1	RP11-12J10.4	4.16	5.36e-05	0.0201	0.46	0.32	Height;	chr10:124983104	chr10:124623353~124624079:+
PCPG	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-4.16	5.37e-05	0.0201	-0.32	-0.32	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
PCPG	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	4.16	5.37e-05	0.0201	0.68	0.32	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	4.16	5.37e-05	0.0201	0.68	0.32	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
PCPG	cis	rs11861812	1	rs11861812	ENSG00000260018.1	RP11-505K9.1	4.16	5.37e-05	0.0201	0.51	0.32	Gait speed in old age;	chr16:83439508	chr16:84117051~84117571:+
PCPG	cis	rs58785573	1	rs58785573	ENSG00000231160.8	KLF3-AS1	-4.16	5.37e-05	0.0201	-0.28	-0.32	Lymphocyte percentage of white cells;	chr4:38652152	chr4:38612701~38664883:-
PCPG	cis	rs3758911	0.788	rs10890704	ENSG00000255353.1	RP11-382M14.1	-4.16	5.37e-05	0.0201	-0.43	-0.32	Coronary artery disease;	chr11:107312779	chr11:107176286~107177530:+
PCPG	cis	rs1440410	0.835	rs7685461	ENSG00000250326.1	RP11-284M14.1	4.16	5.37e-05	0.0201	0.3	0.32	Ischemic stroke;	chr4:143133730	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs10857405	ENSG00000250326.1	RP11-284M14.1	4.16	5.37e-05	0.0201	0.3	0.32	Ischemic stroke;	chr4:143134361	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs7666785	ENSG00000250326.1	RP11-284M14.1	4.16	5.37e-05	0.0201	0.3	0.32	Ischemic stroke;	chr4:143139311	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs10004598	ENSG00000250326.1	RP11-284M14.1	4.16	5.37e-05	0.0201	0.3	0.32	Ischemic stroke;	chr4:143141264	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.763	rs9631769	ENSG00000250326.1	RP11-284M14.1	4.16	5.37e-05	0.0201	0.3	0.32	Ischemic stroke;	chr4:143144588	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs6537151	ENSG00000250326.1	RP11-284M14.1	4.16	5.37e-05	0.0201	0.3	0.32	Ischemic stroke;	chr4:143146753	chr4:142933195~143184861:-
PCPG	cis	rs7172677	1	rs2029520	ENSG00000261543.1	RP11-665J16.1	-4.16	5.37e-05	0.0201	-0.39	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75123427	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs2029519	ENSG00000261543.1	RP11-665J16.1	-4.16	5.37e-05	0.0201	-0.39	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75123621	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs1021382	ENSG00000261543.1	RP11-665J16.1	-4.16	5.37e-05	0.0201	-0.39	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75125057	chr15:74152800~74179226:-
PCPG	cis	rs7829975	0.66	rs10093926	ENSG00000173295.6	FAM86B3P	4.16	5.38e-05	0.0201	0.37	0.32	Mood instability;	chr8:8691510	chr8:8228595~8244865:+
PCPG	cis	rs4819052	0.851	rs1056100	ENSG00000223768.1	LINC00205	-4.16	5.38e-05	0.0201	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45293285~45297354:+
PCPG	cis	rs9303542	0.625	rs62065846	ENSG00000279036.1	RP11-81K2.2	-4.16	5.38e-05	0.0201	-0.52	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48515496	chr17:49494223~49497800:-
PCPG	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-4.16	5.39e-05	0.0201	-0.7	-0.32	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
PCPG	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-4.16	5.39e-05	0.0201	-0.41	-0.32	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
PCPG	cis	rs324126	0.78	rs11084153	ENSG00000277977.1	CTD-3018O17.5	4.16	5.39e-05	0.0201	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs11084154	ENSG00000277977.1	CTD-3018O17.5	4.16	5.39e-05	0.0201	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs11084155	ENSG00000277977.1	CTD-3018O17.5	4.16	5.39e-05	0.0201	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.752	rs11084156	ENSG00000277977.1	CTD-3018O17.5	4.16	5.39e-05	0.0201	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs11084157	ENSG00000277977.1	CTD-3018O17.5	4.16	5.39e-05	0.0201	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs8104808	ENSG00000277977.1	CTD-3018O17.5	4.16	5.39e-05	0.0201	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs8104812	ENSG00000277977.1	CTD-3018O17.5	4.16	5.39e-05	0.0201	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52392659~52392755:+
PCPG	cis	rs78579285	0.622	rs4782322	ENSG00000260630.5	SNAI3-AS1	-4.16	5.39e-05	0.0201	-0.58	-0.32	Joint mobility (Beighton score);	chr16:88731261	chr16:88663298~88687186:+
PCPG	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	4.16	5.39e-05	0.0201	0.37	0.32	Height;	chr5:36948260	chr5:36666214~36725195:-
PCPG	cis	rs453301	0.631	rs7843789	ENSG00000173295.6	FAM86B3P	4.16	5.39e-05	0.0201	0.38	0.32	Joint mobility (Beighton score);	chr8:8943051	chr8:8228595~8244865:+
PCPG	cis	rs453301	0.631	rs4840376	ENSG00000173295.6	FAM86B3P	4.16	5.39e-05	0.0201	0.38	0.32	Joint mobility (Beighton score);	chr8:8944591	chr8:8228595~8244865:+
PCPG	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	4.16	5.39e-05	0.0201	0.47	0.32	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
PCPG	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	4.16	5.39e-05	0.0202	0.34	0.32	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
PCPG	cis	rs3758785	0.737	rs12270338	ENSG00000255893.1	RP11-685N10.1	4.16	5.39e-05	0.0202	0.45	0.32	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94414298	chr11:94472908~94473570:-
PCPG	cis	rs8030379	1	rs2401175	ENSG00000230373.7	GOLGA6L5P	4.16	5.39e-05	0.0202	0.32	0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909465	chr15:84507885~84516814:-
PCPG	cis	rs2836974	0.831	rs34592564	ENSG00000252915.1	Y_RNA	-4.16	5.4e-05	0.0202	-0.35	-0.32	Cognitive function;	chr21:39144362	chr21:39344537~39344628:+
PCPG	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	4.16	5.4e-05	0.0202	0.31	0.32	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
PCPG	cis	rs1865760	0.516	rs9393684	ENSG00000272810.1	U91328.22	-4.16	5.4e-05	0.0202	-0.33	-0.32	Height;	chr6:26075303	chr6:26013241~26013757:+
PCPG	cis	rs7759001	0.857	rs2393927	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27380316	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4713084	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27382084	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4713085	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27382185	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs1883405	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27382645	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4713088	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27382847	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs4713090	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27383068	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs6920362	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27383460	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs2393928	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27384048	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs2393929	ENSG00000271755.1	RP1-153G14.4	4.16	5.41e-05	0.0202	0.49	0.32	Glomerular filtration rate (creatinine);	chr6:27384152	chr6:27404010~27406964:-
PCPG	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	4.16	5.41e-05	0.0202	0.48	0.32	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
PCPG	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	4.16	5.41e-05	0.0202	0.41	0.32	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
PCPG	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	4.16	5.42e-05	0.0202	0.33	0.32	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
PCPG	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	4.16	5.42e-05	0.0202	0.31	0.32	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
PCPG	cis	rs28673968	0.725	rs12644119	ENSG00000270720.1	RP11-84C13.2	4.16	5.42e-05	0.0202	0.4	0.32	Idiopathic pulmonary fibrosis;	chr4:89682268	chr4:89119284~89119871:+
PCPG	cis	rs10971721	0.643	rs7040130	ENSG00000231165.3	TRBV26OR9-2	4.16	5.42e-05	0.0202	0.41	0.32	Body mass index;	chr9:33785075	chr9:33695767~33696059:+
PCPG	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-4.16	5.42e-05	0.0202	-0.41	-0.32	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
PCPG	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-4.16	5.42e-05	0.0202	-0.41	-0.32	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
PCPG	cis	rs2898290	0.5	rs11998678	ENSG00000255020.1	AF131216.5	-4.16	5.42e-05	0.0202	-0.41	-0.32	Systolic blood pressure;	chr8:11972641	chr8:11345748~11347502:-
PCPG	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-4.16	5.43e-05	0.0203	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
PCPG	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-4.16	5.44e-05	0.0203	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-4.16	5.44e-05	0.0203	-0.38	-0.32	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
PCPG	cis	rs11098499	0.874	rs7661020	ENSG00000249244.1	RP11-548H18.2	4.16	5.44e-05	0.0203	0.33	0.32	Corneal astigmatism;	chr4:119185827	chr4:119391831~119395335:-
PCPG	cis	rs28386778	0.863	rs6504178	ENSG00000240280.5	TCAM1P	4.16	5.44e-05	0.0203	0.42	0.32	Prudent dietary pattern;	chr17:63735373	chr17:63849292~63864379:+
PCPG	cis	rs425277	1	rs427811	ENSG00000271806.1	RP5-892K4.1	4.15	5.44e-05	0.0203	0.38	0.32	Height;	chr1:2144121	chr1:2141084~2145279:-
PCPG	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-4.15	5.45e-05	0.0203	-0.45	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
PCPG	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	4.15	5.45e-05	0.0203	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
PCPG	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-4.15	5.45e-05	0.0203	-0.39	-0.32	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
PCPG	cis	rs9880211	0.846	rs73230043	ENSG00000273486.1	RP11-731C17.2	4.15	5.45e-05	0.0203	0.43	0.32	Height;Body mass index;	chr3:136688317	chr3:136837338~136839021:-
PCPG	cis	rs3758911	0.964	rs10890703	ENSG00000255353.1	RP11-382M14.1	-4.15	5.45e-05	0.0203	-0.42	-0.32	Coronary artery disease;	chr11:107310403	chr11:107176286~107177530:+
PCPG	cis	rs324126	0.78	rs3170100	ENSG00000277977.1	CTD-3018O17.5	4.15	5.46e-05	0.0203	0.39	0.32	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52392659~52392755:+
PCPG	cis	rs3764021	0.509	rs10772073	ENSG00000278635.1	CTD-2318O12.1	-4.15	5.46e-05	0.0203	-0.4	-0.32	Type 1 diabetes;	chr12:9717428	chr12:9415641~9416718:+
PCPG	cis	rs12439619	0.846	rs62010071	ENSG00000228141.5	AC105339.1	-4.15	5.46e-05	0.0203	-0.5	-0.32	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82710471~82714026:-
PCPG	cis	rs7587476	0.906	rs17487792	ENSG00000229267.2	AC072062.1	4.15	5.46e-05	0.0204	0.42	0.32	Neuroblastoma;	chr2:214778776	chr2:214810229~214963274:+
PCPG	cis	rs964611	0.882	rs11857977	ENSG00000259488.2	RP11-154J22.1	4.15	5.46e-05	0.0204	0.3	0.32	Metabolite levels (Pyroglutamine);	chr15:48353478	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs12903327	ENSG00000259488.2	RP11-154J22.1	4.15	5.46e-05	0.0204	0.3	0.32	Metabolite levels (Pyroglutamine);	chr15:48355466	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs12148383	ENSG00000259488.2	RP11-154J22.1	4.15	5.46e-05	0.0204	0.3	0.32	Metabolite levels (Pyroglutamine);	chr15:48368235	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs873661	ENSG00000259488.2	RP11-154J22.1	4.15	5.46e-05	0.0204	0.3	0.32	Metabolite levels (Pyroglutamine);	chr15:48368914	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.882	rs4775753	ENSG00000259488.2	RP11-154J22.1	4.15	5.46e-05	0.0204	0.3	0.32	Metabolite levels (Pyroglutamine);	chr15:48369022	chr15:48312353~48331856:-
PCPG	cis	rs17772222	0.917	rs58550317	ENSG00000222990.1	RNU4-22P	4.15	5.46e-05	0.0204	0.41	0.32	Coronary artery calcification;	chr14:88775243	chr14:88513498~88513663:+
PCPG	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	4.15	5.46e-05	0.0204	0.41	0.32	Height;	chr6:109498751	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	4.15	5.46e-05	0.0204	0.41	0.32	Height;	chr6:109500687	chr6:109382795~109383666:+
PCPG	cis	rs1440410	0.835	rs10029373	ENSG00000250326.1	RP11-284M14.1	4.15	5.46e-05	0.0204	0.29	0.32	Ischemic stroke;	chr4:143208965	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs11737209	ENSG00000250326.1	RP11-284M14.1	4.15	5.46e-05	0.0204	0.29	0.32	Ischemic stroke;	chr4:143211519	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs11933603	ENSG00000250326.1	RP11-284M14.1	4.15	5.46e-05	0.0204	0.29	0.32	Ischemic stroke;	chr4:143212704	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs10001113	ENSG00000250326.1	RP11-284M14.1	4.15	5.46e-05	0.0204	0.29	0.32	Ischemic stroke;	chr4:143215252	chr4:142933195~143184861:-
PCPG	cis	rs72615157	0.645	rs76281814	ENSG00000078319.8	PMS2P1	-4.15	5.47e-05	0.0204	-0.41	-0.32	Lung function (FEV1/FVC);	chr7:100248791	chr7:100320992~100341908:-
PCPG	cis	rs72615157	0.595	rs112241539	ENSG00000078319.8	PMS2P1	-4.15	5.47e-05	0.0204	-0.41	-0.32	Lung function (FEV1/FVC);	chr7:100249614	chr7:100320992~100341908:-
PCPG	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	4.15	5.47e-05	0.0204	0.77	0.32	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
PCPG	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	4.15	5.47e-05	0.0204	0.77	0.32	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
PCPG	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	4.15	5.47e-05	0.0204	0.77	0.32	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
PCPG	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	4.15	5.47e-05	0.0204	0.77	0.32	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
PCPG	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	4.15	5.47e-05	0.0204	0.77	0.32	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
PCPG	cis	rs7246657	0.722	rs2909105	ENSG00000226686.6	LINC01535	4.15	5.47e-05	0.0204	0.48	0.32	Coronary artery calcification;	chr19:37677005	chr19:37251912~37265535:+
PCPG	cis	rs11858159	0.903	rs8026878	ENSG00000260760.1	PWRN3	4.15	5.47e-05	0.0204	0.33	0.32	Platelet thrombus formation;	chr15:24517878	chr15:24441127~24447967:+
PCPG	cis	rs11858159	1	rs12905994	ENSG00000260760.1	PWRN3	4.15	5.47e-05	0.0204	0.35	0.32	Platelet thrombus formation;	chr15:24577169	chr15:24441127~24447967:+
PCPG	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-4.15	5.47e-05	0.0204	-0.3	-0.32	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
PCPG	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	4.15	5.48e-05	0.0204	0.41	0.32	Height;	chr6:109497088	chr6:109382795~109383666:+
PCPG	cis	rs6787172	0.811	rs1978781	ENSG00000271778.1	RP11-379F4.8	4.15	5.48e-05	0.0204	0.29	0.32	Subjective well-being;	chr3:158488994	chr3:158782547~158783124:+
PCPG	cis	rs7208859	0.673	rs450585	ENSG00000263603.1	CTD-2349P21.5	-4.15	5.48e-05	0.0204	-0.47	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30729469~30731202:+
PCPG	cis	rs7772486	0.623	rs9485021	ENSG00000270638.1	RP3-466P17.1	-4.15	5.48e-05	0.0204	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.654	rs6928007	ENSG00000270638.1	RP3-466P17.1	-4.15	5.48e-05	0.0204	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145735570~145737218:+
PCPG	cis	rs7444	0.825	rs131664	ENSG00000211645.2	IGLV1-50	4.15	5.48e-05	0.0204	0.41	0.32	Systemic lupus erythematosus;	chr22:21566114	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs131665	ENSG00000211645.2	IGLV1-50	4.15	5.48e-05	0.0204	0.41	0.32	Systemic lupus erythematosus;	chr22:21566614	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs140491	ENSG00000211645.2	IGLV1-50	4.15	5.48e-05	0.0204	0.41	0.32	Systemic lupus erythematosus;	chr22:21568075	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs140498	ENSG00000211645.2	IGLV1-50	4.15	5.48e-05	0.0204	0.41	0.32	Systemic lupus erythematosus;	chr22:21572775	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs140499	ENSG00000211645.2	IGLV1-50	4.15	5.48e-05	0.0204	0.41	0.32	Systemic lupus erythematosus;	chr22:21572942	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs181366	ENSG00000211645.2	IGLV1-50	4.15	5.48e-05	0.0204	0.41	0.32	Systemic lupus erythematosus;	chr22:21579491	chr22:22327300~22327814:+
PCPG	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	4.15	5.48e-05	0.0204	0.66	0.32	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	4.15	5.48e-05	0.0204	0.66	0.32	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	4.15	5.48e-05	0.0204	0.66	0.32	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
PCPG	cis	rs875971	0.861	rs801215	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66546951	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.756	rs2901210	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66552518	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs13536	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66554203	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs801209	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66554403	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs801206	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66556979	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs801204	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66557934	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs801203	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66558025	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.825	rs801202	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66558942	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs801195	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66561128	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs801194	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66563508	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs2024192	ENSG00000235475.1	LINC01372	-4.15	5.49e-05	0.0204	-0.33	-0.32	Aortic root size;	chr7:66576460	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.798	rs12698522	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66502354	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.83	rs28714531	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66503250	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs12698526	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66504118	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs13232191	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66521661	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs35378740	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66522725	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs10950043	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66523623	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs17747530	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66529742	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs13226170	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66534311	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs2420611	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66534333	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.767	rs61348003	ENSG00000235475.1	LINC01372	4.15	5.49e-05	0.0204	0.33	0.32	Aortic root size;	chr7:66540947	chr7:67335976~67340024:+
PCPG	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	4.15	5.49e-05	0.0204	0.4	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
PCPG	cis	rs2836974	0.899	rs68004583	ENSG00000252915.1	Y_RNA	-4.15	5.49e-05	0.0204	-0.34	-0.32	Cognitive function;	chr21:39287661	chr21:39344537~39344628:+
PCPG	cis	rs9302635	0.513	rs3902135	ENSG00000260886.1	TAT-AS1	4.15	5.49e-05	0.0204	0.47	0.32	Blood protein levels;	chr16:72141921	chr16:71565789~71578187:+
PCPG	cis	rs4819052	0.851	rs2838857	ENSG00000223768.1	LINC00205	-4.15	5.49e-05	0.0204	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45293285~45297354:+
PCPG	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-4.15	5.49e-05	0.0204	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
PCPG	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	4.15	5.49e-05	0.0204	0.37	0.32	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	4.15	5.49e-05	0.0204	0.37	0.32	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	4.15	5.49e-05	0.0204	0.37	0.32	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	4.15	5.49e-05	0.0204	0.37	0.32	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
PCPG	cis	rs73198271	0.71	rs7837843	ENSG00000253893.2	FAM85B	4.15	5.5e-05	0.0205	0.42	0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.64	rs7838012	ENSG00000253893.2	FAM85B	4.15	5.5e-05	0.0205	0.42	0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8167819~8226614:-
PCPG	cis	rs2836974	0.863	rs8128026	ENSG00000252915.1	Y_RNA	-4.15	5.5e-05	0.0205	-0.34	-0.32	Cognitive function;	chr21:39161776	chr21:39344537~39344628:+
PCPG	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	4.15	5.5e-05	0.0205	0.31	0.32	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	4.15	5.5e-05	0.0205	0.31	0.32	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	4.15	5.5e-05	0.0205	0.31	0.32	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	4.15	5.5e-05	0.0205	0.31	0.32	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
PCPG	cis	rs2836974	0.966	rs7283420	ENSG00000252915.1	Y_RNA	-4.15	5.5e-05	0.0205	-0.35	-0.32	Cognitive function;	chr21:39294939	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.965	rs34578707	ENSG00000252915.1	Y_RNA	-4.15	5.5e-05	0.0205	-0.35	-0.32	Cognitive function;	chr21:39303241	chr21:39344537~39344628:+
PCPG	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-4.15	5.5e-05	0.0205	-0.34	-0.32	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
PCPG	cis	rs9813712	0.78	rs55929137	ENSG00000228252.7	COL6A4P2	4.15	5.5e-05	0.0205	0.41	0.32	Response to amphetamines;	chr3:130236002	chr3:130212823~130273806:+
PCPG	cis	rs240993	0.672	rs6922226	ENSG00000230177.1	RP5-1112D6.4	-4.15	5.5e-05	0.0205	-0.4	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111277932~111278742:+
PCPG	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-4.15	5.5e-05	0.0205	-0.42	-0.32	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
PCPG	cis	rs35934224	0.891	rs13054713	ENSG00000232926.1	AC000078.5	4.15	5.51e-05	0.0205	0.38	0.32	Glaucoma (primary open-angle);	chr22:19880391	chr22:19887289~19887970:+
PCPG	cis	rs12765878	1	rs12765878	ENSG00000260461.1	RP11-541N10.3	-4.15	5.51e-05	0.0205	-0.36	-0.32	Coronary artery disease;	chr10:103909864	chr10:103877374~103879761:-
PCPG	cis	rs6598541	0.963	rs6598542	ENSG00000278022.1	RP11-35O15.2	4.15	5.51e-05	0.0205	0.3	0.32	Urate levels;	chr15:98749827	chr15:98660210~98660668:+
PCPG	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	4.15	5.51e-05	0.0205	0.54	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
PCPG	cis	rs17507216	0.718	rs7165690	ENSG00000228141.5	AC105339.1	-4.15	5.51e-05	0.0205	-0.47	-0.32	Excessive daytime sleepiness;	chr15:82654804	chr15:82710471~82714026:-
PCPG	cis	rs16949788	1	rs7183477	ENSG00000261351.2	CTD-3185P2.1	-4.15	5.51e-05	0.0205	-0.46	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66455874	chr15:66488658~66492109:-
PCPG	cis	rs16949788	1	rs7182169	ENSG00000261351.2	CTD-3185P2.1	-4.15	5.51e-05	0.0205	-0.46	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66455875	chr15:66488658~66492109:-
PCPG	cis	rs16949788	1	rs79097157	ENSG00000261351.2	CTD-3185P2.1	-4.15	5.51e-05	0.0205	-0.46	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66472476	chr15:66488658~66492109:-
PCPG	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	-4.15	5.52e-05	0.0205	-0.35	-0.32	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
PCPG	cis	rs7702057	0.53	rs17138848	ENSG00000271918.1	CTD-2287O16.5	4.15	5.52e-05	0.0205	0.46	0.32	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116083807~116085416:-
PCPG	cis	rs7702057	0.53	rs3087832	ENSG00000271918.1	CTD-2287O16.5	4.15	5.52e-05	0.0205	0.46	0.32	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116083807~116085416:-
PCPG	cis	rs7702057	0.53	rs74583480	ENSG00000271918.1	CTD-2287O16.5	4.15	5.52e-05	0.0205	0.46	0.32	Amyotrophic lateral sclerosis;	chr5:116085200	chr5:116083807~116085416:-
PCPG	cis	rs7702057	0.53	rs73780832	ENSG00000271918.1	CTD-2287O16.5	4.15	5.52e-05	0.0205	0.46	0.32	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116083807~116085416:-
PCPG	cis	rs7702057	0.53	rs17138850	ENSG00000271918.1	CTD-2287O16.5	4.15	5.52e-05	0.0205	0.46	0.32	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116083807~116085416:-
PCPG	cis	rs7945705	0.818	rs10769948	ENSG00000254860.4	TMEM9B-AS1	4.15	5.52e-05	0.0205	0.32	0.32	Hemoglobin concentration;	chr11:8740235	chr11:8964675~8977527:+
PCPG	cis	rs6579956	0.565	rs4460127	ENSG00000270978.1	RP11-54C4.2	-4.15	5.52e-05	0.0205	-0.4	-0.32	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152804188	chr5:151848886~151850791:+
PCPG	cis	rs7587476	0.501	rs11888027	ENSG00000229267.2	AC072062.1	4.15	5.53e-05	0.0205	0.37	0.32	Neuroblastoma;	chr2:214774888	chr2:214810229~214963274:+
PCPG	cis	rs9650657	0.529	rs10108618	ENSG00000255020.1	AF131216.5	-4.15	5.53e-05	0.0205	-0.45	-0.32	Neuroticism;	chr8:11095582	chr8:11345748~11347502:-
PCPG	cis	rs6445975	0.688	rs2271633	ENSG00000272360.1	RP11-359I18.5	-4.15	5.53e-05	0.0206	-0.4	-0.32	Systemic lupus erythematosus;	chr3:58274346	chr3:58490830~58491291:-
PCPG	cis	rs11858159	1	rs12899764	ENSG00000260760.1	PWRN3	4.15	5.53e-05	0.0206	0.35	0.32	Platelet thrombus formation;	chr15:24572167	chr15:24441127~24447967:+
PCPG	cis	rs2361718	0.5	rs8068856	ENSG00000275479.1	RP11-334C17.6	4.15	5.53e-05	0.0206	0.27	0.32	Yeast infection;	chr17:80126932	chr17:80149627~80149798:+
PCPG	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-4.15	5.53e-05	0.0206	-0.43	-0.32	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
PCPG	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	4.15	5.54e-05	0.0206	0.41	0.32	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
PCPG	cis	rs853679	0.882	rs9393908	ENSG00000216901.1	AL022393.7	4.15	5.54e-05	0.0206	0.62	0.32	Depression;	chr6:28223052	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.882	rs9366717	ENSG00000216901.1	AL022393.7	4.15	5.54e-05	0.0206	0.62	0.32	Depression;	chr6:28223279	chr6:28176188~28176674:+
PCPG	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	4.15	5.54e-05	0.0206	0.33	0.32	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
PCPG	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	4.15	5.54e-05	0.0206	0.33	0.32	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
PCPG	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-4.15	5.55e-05	0.0206	-0.37	-0.32	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
PCPG	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	4.15	5.55e-05	0.0206	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
PCPG	cis	rs6121246	0.779	rs6060763	ENSG00000230613.1	HM13-AS1	4.15	5.55e-05	0.0206	0.47	0.32	Mean corpuscular hemoglobin;	chr20:31694420	chr20:31567707~31573263:-
PCPG	cis	rs35934224	0.783	rs13056219	ENSG00000232926.1	AC000078.5	4.15	5.55e-05	0.0206	0.38	0.32	Glaucoma (primary open-angle);	chr22:19873323	chr22:19887289~19887970:+
PCPG	cis	rs35934224	0.783	rs7290770	ENSG00000232926.1	AC000078.5	4.15	5.55e-05	0.0206	0.38	0.32	Glaucoma (primary open-angle);	chr22:19873638	chr22:19887289~19887970:+
PCPG	cis	rs901683	1	rs17523413	ENSG00000230869.1	CTGLF10P	-4.15	5.56e-05	0.0206	-0.86	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45452727	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs76493570	ENSG00000230869.1	CTGLF10P	-4.15	5.56e-05	0.0206	-0.86	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45453806	chr10:45678692~45700532:+
PCPG	cis	rs2797160	0.651	rs6569437	ENSG00000237742.5	RP11-624M8.1	4.15	5.56e-05	0.0206	0.35	0.32	Endometrial cancer;	chr6:125713394	chr6:125578558~125749190:-
PCPG	cis	rs2243480	1	rs4718269	ENSG00000230189.5	GS1-124K5.2	-4.15	5.56e-05	0.0207	-0.47	-0.32	Diabetic kidney disease;	chr7:65735810	chr7:66409143~66490059:-
PCPG	cis	rs2830585	0.651	rs182774	ENSG00000223563.1	AP001601.2	4.15	5.56e-05	0.0207	0.42	0.32	Blood protein levels;	chr21:26942277	chr21:26889376~26939742:+
PCPG	cis	rs2921073	0.605	rs2976933	ENSG00000173295.6	FAM86B3P	-4.15	5.56e-05	0.0207	-0.4	-0.32	Parkinson's disease;	chr8:8397365	chr8:8228595~8244865:+
PCPG	cis	rs748404	0.666	rs7177892	ENSG00000249839.1	AC011330.5	-4.15	5.56e-05	0.0207	-0.46	-0.32	Lung cancer;	chr15:43321171	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs7181545	ENSG00000249839.1	AC011330.5	-4.15	5.56e-05	0.0207	-0.46	-0.32	Lung cancer;	chr15:43321363	chr15:43663654~43684339:-
PCPG	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-4.15	5.57e-05	0.0207	-0.37	-0.32	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-4.15	5.57e-05	0.0207	-0.37	-0.32	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-4.15	5.57e-05	0.0207	-0.37	-0.32	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
PCPG	cis	rs7172677	0.96	rs11072526	ENSG00000261543.1	RP11-665J16.1	-4.15	5.57e-05	0.0207	-0.39	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75140176	chr15:74152800~74179226:-
PCPG	cis	rs853679	0.546	rs13214023	ENSG00000220721.1	OR1F12	-4.15	5.57e-05	0.0207	-0.62	-0.32	Depression;	chr6:28364364	chr6:28073316~28074233:+
PCPG	cis	rs875971	0.558	rs4433015	ENSG00000273142.1	RP11-458F8.4	4.15	5.57e-05	0.0207	0.29	0.32	Aortic root size;	chr7:66174736	chr7:66902857~66906297:+
PCPG	cis	rs8098244	0.597	rs12958312	ENSG00000265752.2	RP11-403A21.1	-4.15	5.57e-05	0.0207	-0.37	-0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23784372	chr18:23957754~23982556:-
PCPG	cis	rs9393813	0.528	rs6899950	ENSG00000271755.1	RP1-153G14.4	4.15	5.58e-05	0.0207	0.41	0.32	Bipolar disorder;	chr6:27466216	chr6:27404010~27406964:-
PCPG	cis	rs6929812	0.639	rs7754724	ENSG00000271755.1	RP1-153G14.4	4.15	5.58e-05	0.0207	0.41	0.32	Neuroticism (multi-trait analysis);	chr6:27483018	chr6:27404010~27406964:-
PCPG	cis	rs9393813	0.528	rs4713108	ENSG00000271755.1	RP1-153G14.4	4.15	5.58e-05	0.0207	0.41	0.32	Bipolar disorder;	chr6:27490234	chr6:27404010~27406964:-
PCPG	cis	rs1949733	1	rs2688223	ENSG00000205959.3	RP11-689P11.2	-4.15	5.58e-05	0.0207	-0.36	-0.32	Response to antineoplastic agents;	chr4:8469671	chr4:8482270~8512610:+
PCPG	cis	rs1371867	0.846	rs1660353	ENSG00000212994.5	RPS26P6	-4.15	5.58e-05	0.0207	-0.36	-0.32	Atrioventricular conduction;	chr8:100238679	chr8:100895771~100896118:+
PCPG	cis	rs2797160	0.904	rs1739370	ENSG00000237742.5	RP11-624M8.1	4.15	5.58e-05	0.0207	0.33	0.32	Endometrial cancer;	chr6:125690085	chr6:125578558~125749190:-
PCPG	cis	rs7911712	0.872	rs10900116	ENSG00000228462.1	RP11-445N18.3	4.15	5.58e-05	0.0207	0.46	0.32	Emphysema-related traits;	chr10:44815598	chr10:45073146~45073541:-
PCPG	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-4.15	5.59e-05	0.0207	-0.39	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
PCPG	cis	rs11858159	0.874	rs6576321	ENSG00000260760.1	PWRN3	4.15	5.59e-05	0.0207	0.32	0.32	Platelet thrombus formation;	chr15:24538188	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.812	rs11633507	ENSG00000260760.1	PWRN3	4.15	5.59e-05	0.0207	0.32	0.32	Platelet thrombus formation;	chr15:24540945	chr15:24441127~24447967:+
PCPG	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-4.15	5.59e-05	0.0208	-0.44	-0.32	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
PCPG	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	4.15	5.59e-05	0.0208	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
PCPG	cis	rs34421088	0.532	rs1545073	ENSG00000255020.1	AF131216.5	4.15	5.59e-05	0.0208	0.41	0.32	Neuroticism;	chr8:11310191	chr8:11345748~11347502:-
PCPG	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	4.15	5.59e-05	0.0208	0.32	0.32	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
PCPG	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	4.15	5.6e-05	0.0208	0.49	0.32	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
PCPG	cis	rs2830585	0.651	rs229052	ENSG00000223563.1	AP001601.2	4.15	5.6e-05	0.0208	0.42	0.32	Blood protein levels;	chr21:26943889	chr21:26889376~26939742:+
PCPG	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	4.15	5.6e-05	0.0208	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
PCPG	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	4.15	5.6e-05	0.0208	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
PCPG	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-4.15	5.61e-05	0.0208	-0.37	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
PCPG	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	4.15	5.61e-05	0.0208	0.4	0.32	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
PCPG	cis	rs7523050	0.643	rs7519293	ENSG00000203897.3	SPATA42	-4.15	5.61e-05	0.0208	-0.52	-0.32	Fat distribution (HIV);	chr1:108856921	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs7522324	ENSG00000203897.3	SPATA42	-4.15	5.61e-05	0.0208	-0.52	-0.32	Fat distribution (HIV);	chr1:108857022	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs7551142	ENSG00000203897.3	SPATA42	-4.15	5.61e-05	0.0208	-0.52	-0.32	Fat distribution (HIV);	chr1:108857088	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs7551313	ENSG00000203897.3	SPATA42	-4.15	5.61e-05	0.0208	-0.52	-0.32	Fat distribution (HIV);	chr1:108857259	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs12736534	ENSG00000203897.3	SPATA42	-4.15	5.61e-05	0.0208	-0.52	-0.32	Fat distribution (HIV);	chr1:108857312	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs12741194	ENSG00000203897.3	SPATA42	-4.15	5.61e-05	0.0208	-0.52	-0.32	Fat distribution (HIV);	chr1:108857768	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs12741359	ENSG00000203897.3	SPATA42	-4.15	5.61e-05	0.0208	-0.52	-0.32	Fat distribution (HIV);	chr1:108857867	chr1:108857217~108858524:+
PCPG	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	4.15	5.61e-05	0.0208	0.42	0.32	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
PCPG	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	4.15	5.62e-05	0.0208	0.42	0.32	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	4.15	5.62e-05	0.0208	0.42	0.32	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
PCPG	cis	rs6981523	0.566	rs34162231	ENSG00000255020.1	AF131216.5	-4.15	5.62e-05	0.0208	-0.48	-0.32	Neuroticism;	chr8:11145578	chr8:11345748~11347502:-
PCPG	cis	rs657075	0.697	rs3805676	ENSG00000233006.5	AC034220.3	-4.15	5.62e-05	0.0208	-0.41	-0.32	Rheumatoid arthritis;	chr5:132332774	chr5:132311285~132369916:-
PCPG	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0208	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
PCPG	cis	rs8098244	0.597	rs12964391	ENSG00000265752.2	RP11-403A21.1	4.15	5.62e-05	0.0209	0.36	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23734541	chr18:23957754~23982556:-
PCPG	cis	rs6840258	0.941	rs6854749	ENSG00000251411.1	RP11-397E7.4	-4.15	5.62e-05	0.0209	-0.36	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047646	chr4:86913266~86914817:-
PCPG	cis	rs748404	0.666	rs10518812	ENSG00000205771.5	CATSPER2P1	4.15	5.62e-05	0.0209	0.42	0.32	Lung cancer;	chr15:43360739	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs34515241	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43342011	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.626	rs35992154	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43345669	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs17780417	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43347264	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs7181634	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43351703	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.626	rs72707530	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43353622	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs55748552	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43359428	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.63	rs35278805	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43361124	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs35160541	ENSG00000205771.5	CATSPER2P1	-4.15	5.62e-05	0.0209	-0.42	-0.32	Lung cancer;	chr15:43365601	chr15:43726918~43747094:-
PCPG	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	4.15	5.62e-05	0.0209	0.41	0.32	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	4.15	5.62e-05	0.0209	0.41	0.32	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
PCPG	cis	rs7031325	1	rs7031325	ENSG00000229611.1	RP11-390F4.10	-4.15	5.63e-05	0.0209	-0.35	-0.32	Systemic lupus erythematosus;	chr9:6655056	chr9:6704471~6707780:+
PCPG	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	4.15	5.63e-05	0.0209	0.43	0.32	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
PCPG	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-4.15	5.63e-05	0.0209	-0.38	-0.32	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
PCPG	cis	rs964611	0.882	rs11629805	ENSG00000259488.2	RP11-154J22.1	4.15	5.63e-05	0.0209	0.31	0.32	Metabolite levels (Pyroglutamine);	chr15:48363267	chr15:48312353~48331856:-
PCPG	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	4.15	5.63e-05	0.0209	0.37	0.32	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
PCPG	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	4.15	5.64e-05	0.0209	0.31	0.32	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	4.15	5.64e-05	0.0209	0.31	0.32	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	4.15	5.64e-05	0.0209	0.31	0.32	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
PCPG	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	4.15	5.65e-05	0.0209	0.54	0.32	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
PCPG	cis	rs75686122	0.892	rs17806104	ENSG00000253477.4	RP11-1C8.4	4.15	5.65e-05	0.0209	0.44	0.32	Cocaine dependence;	chr8:103523283	chr8:103483398~103501676:-
PCPG	cis	rs875971	0.862	rs778736	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66348861	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778734	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66349862	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.83	rs778711	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66386670	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs1083554	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66387354	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778707	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66392040	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778705	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66396128	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778697	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66405439	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.798	rs7789615	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66413674	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6978028	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66421313	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6947339	ENSG00000235475.1	LINC01372	4.15	5.65e-05	0.0209	0.33	0.32	Aortic root size;	chr7:66423483	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs10240949	ENSG00000235475.1	LINC01372	-4.15	5.65e-05	0.0209	-0.33	-0.32	Aortic root size;	chr7:66339430	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs7782704	ENSG00000235475.1	LINC01372	-4.15	5.65e-05	0.0209	-0.33	-0.32	Aortic root size;	chr7:66340379	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs2088653	ENSG00000235475.1	LINC01372	-4.15	5.65e-05	0.0209	-0.33	-0.32	Aortic root size;	chr7:66343621	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6460293	ENSG00000235475.1	LINC01372	-4.15	5.65e-05	0.0209	-0.33	-0.32	Aortic root size;	chr7:66345205	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6959268	ENSG00000235475.1	LINC01372	-4.15	5.65e-05	0.0209	-0.33	-0.32	Aortic root size;	chr7:66347979	chr7:67335976~67340024:+
PCPG	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	4.15	5.65e-05	0.0209	0.58	0.32	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
PCPG	cis	rs34421088	0.56	rs2618434	ENSG00000269954.1	RP11-148O21.6	-4.15	5.65e-05	0.0209	-0.37	-0.32	Neuroticism;	chr8:11541356	chr8:11552488~11552991:-
PCPG	cis	rs896854	0.596	rs7823059	ENSG00000272509.1	RP11-347C18.5	4.15	5.65e-05	0.0209	0.32	0.32	Type 2 diabetes;	chr8:94962733	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.653	rs13266313	ENSG00000272509.1	RP11-347C18.5	4.15	5.65e-05	0.0209	0.32	0.32	Type 2 diabetes;	chr8:94963074	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.654	rs4735340	ENSG00000272509.1	RP11-347C18.5	4.15	5.65e-05	0.0209	0.32	0.32	Type 2 diabetes;	chr8:94964023	chr8:94884609~94885070:+
PCPG	cis	rs2797160	0.904	rs1612274	ENSG00000237742.5	RP11-624M8.1	4.15	5.66e-05	0.0209	0.33	0.32	Endometrial cancer;	chr6:125693761	chr6:125578558~125749190:-
PCPG	cis	rs9303542	0.559	rs12947405	ENSG00000279036.1	RP11-81K2.2	-4.14	5.66e-05	0.021	-0.53	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48537393	chr17:49494223~49497800:-
PCPG	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	4.14	5.66e-05	0.021	0.37	0.32	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
PCPG	cis	rs394563	0.967	rs444784	ENSG00000216906.2	RP11-350J20.9	4.14	5.67e-05	0.021	0.31	0.32	Dupuytren's disease;	chr6:149477230	chr6:149904243~149906418:+
PCPG	cis	rs394563	0.967	rs369643	ENSG00000216906.2	RP11-350J20.9	4.14	5.67e-05	0.021	0.31	0.32	Dupuytren's disease;	chr6:149478662	chr6:149904243~149906418:+
PCPG	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	4.14	5.67e-05	0.021	0.42	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
PCPG	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-4.14	5.67e-05	0.021	-0.32	-0.32	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
PCPG	cis	rs7759001	0.817	rs6925606	ENSG00000271755.1	RP1-153G14.4	4.14	5.67e-05	0.021	0.42	0.32	Glomerular filtration rate (creatinine);	chr6:27389677	chr6:27404010~27406964:-
PCPG	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	4.14	5.67e-05	0.021	0.42	0.32	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
PCPG	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	4.14	5.67e-05	0.021	0.41	0.32	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
PCPG	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	4.14	5.67e-05	0.021	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
PCPG	cis	rs950169	0.922	rs11631096	ENSG00000235370.6	DNM1P51	4.14	5.67e-05	0.021	0.34	0.32	Schizophrenia;	chr15:84557698	chr15:84398316~84411701:-
PCPG	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-4.14	5.68e-05	0.021	-0.38	-0.32	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
PCPG	cis	rs13108904	0.905	rs1680074	ENSG00000253399.1	AC078852.2	4.14	5.68e-05	0.021	0.33	0.32	Obesity-related traits;	chr4:1285833	chr4:1358479~1359461:+
PCPG	cis	rs13108904	0.901	rs1680073	ENSG00000253399.1	AC078852.2	4.14	5.68e-05	0.021	0.33	0.32	Obesity-related traits;	chr4:1286549	chr4:1358479~1359461:+
PCPG	cis	rs7772486	0.686	rs702314	ENSG00000270638.1	RP3-466P17.1	-4.14	5.68e-05	0.021	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.659	rs9376957	ENSG00000270638.1	RP3-466P17.1	-4.14	5.68e-05	0.021	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9497396	ENSG00000270638.1	RP3-466P17.1	-4.14	5.68e-05	0.021	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145735570~145737218:+
PCPG	cis	rs7037266	0.727	rs10815496	ENSG00000206147.5	RP11-106A1.2	-4.14	5.69e-05	0.021	-0.36	-0.32	Menarche (age at onset);	chr9:6966486	chr9:6639139~6639604:+
PCPG	cis	rs12718244	0.508	rs13239674	ENSG00000228204.2	RP4-724E13.2	4.14	5.69e-05	0.021	0.35	0.32	Inflammatory bowel disease;Ulcerative colitis;Crohn's disease;	chr7:49999044	chr7:50866747~51022990:+
PCPG	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	4.14	5.69e-05	0.021	0.4	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
PCPG	cis	rs2212361	0.6	rs34185869	ENSG00000255893.1	RP11-685N10.1	-4.14	5.69e-05	0.021	-0.41	-0.32	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535430	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.593	rs34288874	ENSG00000255893.1	RP11-685N10.1	-4.14	5.69e-05	0.021	-0.41	-0.32	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535484	chr11:94472908~94473570:-
PCPG	cis	rs4819052	0.851	rs4819046	ENSG00000215447.6	BX322557.10	-4.14	5.69e-05	0.021	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45288052~45291738:+
PCPG	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	4.14	5.69e-05	0.021	0.57	0.32	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
PCPG	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-4.14	5.7e-05	0.0211	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
PCPG	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-4.14	5.7e-05	0.0211	-0.43	-0.32	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
PCPG	cis	rs6065	0.529	rs113183521	ENSG00000229782.1	AC118754.4	4.14	5.7e-05	0.0211	0.7	0.32	Platelet count;	chr17:5026820	chr17:4497394~4499674:-
PCPG	cis	rs964611	0.938	rs12592330	ENSG00000259488.2	RP11-154J22.1	4.14	5.7e-05	0.0211	0.32	0.32	Metabolite levels (Pyroglutamine);	chr15:48353083	chr15:48312353~48331856:-
PCPG	cis	rs17152411	1	rs17152411	ENSG00000278831.1	RP11-12J10.4	4.14	5.7e-05	0.0211	0.45	0.32	Height;	chr10:124960947	chr10:124623353~124624079:+
PCPG	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-4.14	5.7e-05	0.0211	-0.56	-0.32	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
PCPG	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	4.14	5.71e-05	0.0211	0.43	0.32	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
PCPG	cis	rs1440410	0.798	rs34664017	ENSG00000250326.1	RP11-284M14.1	4.14	5.71e-05	0.0211	0.29	0.32	Ischemic stroke;	chr4:143173191	chr4:142933195~143184861:-
PCPG	cis	rs62355901	0.505	rs62356568	ENSG00000271828.1	CTD-2310F14.1	4.14	5.71e-05	0.0211	0.85	0.32	Breast cancer;	chr5:56955617	chr5:56927874~56929573:+
PCPG	cis	rs896854	0.654	rs28716845	ENSG00000272509.1	RP11-347C18.5	4.14	5.71e-05	0.0211	0.32	0.32	Type 2 diabetes;	chr8:94962257	chr8:94884609~94885070:+
PCPG	cis	rs2236231	0.55	rs12897715	ENSG00000259502.1	RP11-643G16.3	-4.14	5.71e-05	0.0211	-0.41	-0.32	Plasma kynurenine levels in major depressive disorder;	chr14:67593117	chr14:67610986~67613864:+
PCPG	cis	rs7705042	0.581	rs11742584	ENSG00000280047.1	CTC-463A16.1	-4.14	5.71e-05	0.0211	-0.46	-0.32	Asthma;	chr5:142172745	chr5:142165767~142168387:+
PCPG	cis	rs6991838	0.702	rs10106749	ENSG00000200714.1	Y_RNA	4.14	5.71e-05	0.0211	0.4	0.32	Intelligence (multi-trait analysis);	chr8:65692355	chr8:65592731~65592820:+
PCPG	cis	rs7772486	0.686	rs2328708	ENSG00000270638.1	RP3-466P17.1	-4.14	5.71e-05	0.0211	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145735570~145737218:+
PCPG	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-4.14	5.72e-05	0.0211	-0.41	-0.32	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
PCPG	cis	rs1440410	0.571	rs62331619	ENSG00000250326.1	RP11-284M14.1	-4.14	5.72e-05	0.0211	-0.29	-0.32	Ischemic stroke;	chr4:143107299	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs72719141	ENSG00000250326.1	RP11-284M14.1	-4.14	5.72e-05	0.0211	-0.29	-0.32	Ischemic stroke;	chr4:143107415	chr4:142933195~143184861:-
PCPG	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-4.14	5.72e-05	0.0211	-0.25	-0.32	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
PCPG	cis	rs6840258	0.76	rs340626	ENSG00000251411.1	RP11-397E7.4	4.14	5.73e-05	0.0212	0.33	0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87035287	chr4:86913266~86914817:-
PCPG	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	4.14	5.73e-05	0.0212	0.66	0.32	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
PCPG	cis	rs748404	0.629	rs34657657	ENSG00000249839.1	AC011330.5	-4.14	5.73e-05	0.0212	-0.46	-0.32	Lung cancer;	chr15:43315763	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.626	rs62019432	ENSG00000249839.1	AC011330.5	-4.14	5.73e-05	0.0212	-0.46	-0.32	Lung cancer;	chr15:43316482	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs7176923	ENSG00000249839.1	AC011330.5	-4.14	5.73e-05	0.0212	-0.46	-0.32	Lung cancer;	chr15:43317679	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.666	rs17723479	ENSG00000249839.1	AC011330.5	-4.14	5.73e-05	0.0212	-0.46	-0.32	Lung cancer;	chr15:43322114	chr15:43663654~43684339:-
PCPG	cis	rs10056811	0.556	rs57441318	ENSG00000271815.1	CTD-2235C13.3	-4.14	5.73e-05	0.0212	-0.54	-0.32	Coronary artery disease;	chr5:75083850	chr5:75363760~75364242:+
PCPG	cis	rs6570726	0.846	rs7762536	ENSG00000270638.1	RP3-466P17.1	4.14	5.73e-05	0.0212	0.35	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145735570~145737218:+
PCPG	cis	rs6570726	0.791	rs952406	ENSG00000270638.1	RP3-466P17.1	4.14	5.73e-05	0.0212	0.35	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145735570~145737218:+
PCPG	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-4.14	5.73e-05	0.0212	-0.26	-0.32	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
PCPG	cis	rs657075	0.595	rs6865305	ENSG00000233006.5	AC034220.3	-4.14	5.73e-05	0.0212	-0.41	-0.32	Rheumatoid arthritis;	chr5:132280980	chr5:132311285~132369916:-
PCPG	cis	rs56804039	0.524	rs66989459	ENSG00000253893.2	FAM85B	4.14	5.73e-05	0.0212	0.58	0.32	Cervical cancer;	chr8:8510401	chr8:8167819~8226614:-
PCPG	cis	rs11250098	0.547	rs2409764	ENSG00000269954.1	RP11-148O21.6	4.14	5.74e-05	0.0212	0.37	0.32	Morning vs. evening chronotype;	chr8:11423764	chr8:11552488~11552991:-
PCPG	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	4.14	5.74e-05	0.0212	0.41	0.32	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	4.14	5.74e-05	0.0212	0.41	0.32	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	4.14	5.74e-05	0.0212	0.41	0.32	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
PCPG	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	4.14	5.74e-05	0.0212	0.37	0.32	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
PCPG	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	4.14	5.74e-05	0.0212	0.37	0.32	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
PCPG	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-4.14	5.74e-05	0.0212	-0.38	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
PCPG	cis	rs9322193	0.961	rs4870144	ENSG00000223701.3	RAET1E-AS1	4.14	5.74e-05	0.0212	0.42	0.32	Lung cancer;	chr6:149575540	chr6:149884431~149919508:+
PCPG	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-4.14	5.74e-05	0.0212	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
PCPG	cis	rs6840258	0.76	rs340638	ENSG00000251411.1	RP11-397E7.4	4.14	5.75e-05	0.0212	0.33	0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87007052	chr4:86913266~86914817:-
PCPG	cis	rs6929812	0.665	rs10946919	ENSG00000271755.1	RP1-153G14.4	4.14	5.75e-05	0.0212	0.42	0.32	Neuroticism (multi-trait analysis);	chr6:27445188	chr6:27404010~27406964:-
PCPG	cis	rs10844706	0.699	rs10844615	ENSG00000278635.1	CTD-2318O12.1	-4.14	5.75e-05	0.0212	-0.4	-0.32	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9415641~9416718:+
PCPG	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-4.14	5.75e-05	0.0212	-0.47	-0.32	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
PCPG	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	4.14	5.76e-05	0.0212	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
PCPG	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	4.14	5.76e-05	0.0212	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
PCPG	cis	rs16976116	0.901	rs16976177	ENSG00000279145.1	RP11-547D13.1	4.14	5.76e-05	0.0212	0.47	0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55217062	chr15:55171972~55178175:-
PCPG	cis	rs7772486	0.686	rs9403739	ENSG00000270638.1	RP3-466P17.1	-4.14	5.76e-05	0.0212	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145735570~145737218:+
PCPG	cis	rs9813712	1	rs9864582	ENSG00000228252.7	COL6A4P2	4.14	5.76e-05	0.0212	0.41	0.32	Response to amphetamines;	chr3:130251619	chr3:130212823~130273806:+
PCPG	cis	rs8042680	0.544	rs2034085	ENSG00000214432.8	AC068831.10	-4.14	5.76e-05	0.0212	-0.34	-0.32	Type 2 diabetes;	chr15:90963222	chr15:91022619~91036611:+
PCPG	cis	rs73072330	1	rs73072330	ENSG00000199476.1	Y_RNA	4.14	5.76e-05	0.0213	0.71	0.32	Stem cell growth factor beta levels;	chr3:48123599	chr3:48288587~48288694:+
PCPG	cis	rs34421088	0.532	rs4515509	ENSG00000255020.1	AF131216.5	4.14	5.76e-05	0.0213	0.41	0.32	Neuroticism;	chr8:11314614	chr8:11345748~11347502:-
PCPG	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-4.14	5.76e-05	0.0213	-0.42	-0.32	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
PCPG	cis	rs7911712	0.935	rs2793312	ENSG00000228462.1	RP11-445N18.3	4.14	5.76e-05	0.0213	0.46	0.32	Emphysema-related traits;	chr10:44802960	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.935	rs2793311	ENSG00000228462.1	RP11-445N18.3	4.14	5.76e-05	0.0213	0.46	0.32	Emphysema-related traits;	chr10:44803057	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs1771981	ENSG00000228462.1	RP11-445N18.3	4.14	5.76e-05	0.0213	0.46	0.32	Emphysema-related traits;	chr10:44806213	chr10:45073146~45073541:-
PCPG	cis	rs4713118	0.505	rs156740	ENSG00000219392.1	RP1-265C24.5	-4.14	5.77e-05	0.0213	-0.35	-0.32	Parkinson's disease;	chr6:27992657	chr6:28115628~28116551:+
PCPG	cis	rs2898290	0.592	rs2736342	ENSG00000255518.1	RP11-148O21.4	-4.14	5.77e-05	0.0213	-0.38	-0.32	Systolic blood pressure;	chr8:11489780	chr8:11556251~11558022:-
PCPG	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	4.14	5.77e-05	0.0213	0.44	0.32	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	4.14	5.77e-05	0.0213	0.44	0.32	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
PCPG	cis	rs7208859	0.673	rs216411	ENSG00000263603.1	CTD-2349P21.5	4.14	5.77e-05	0.0213	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30729469~30731202:+
PCPG	cis	rs2836974	0.965	rs8130984	ENSG00000252915.1	Y_RNA	-4.14	5.77e-05	0.0213	-0.34	-0.32	Cognitive function;	chr21:39268040	chr21:39344537~39344628:+
PCPG	cis	rs7657257	1	rs9942275	ENSG00000214846.4	RP11-115L11.1	4.14	5.78e-05	0.0213	0.84	0.32	Blood protein levels;	chr4:15721903	chr4:15730962~15731627:-
PCPG	cis	rs13118159	0.55	rs4974617	ENSG00000254094.1	AC078852.1	-4.14	5.78e-05	0.0213	-0.4	-0.32	Longevity;	chr4:1379870	chr4:1356581~1358075:+
PCPG	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	4.14	5.78e-05	0.0213	0.33	0.32	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	4.14	5.78e-05	0.0213	0.33	0.32	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
PCPG	cis	rs116248771	0.739	rs12488447	ENSG00000272087.1	RP11-379F4.7	4.14	5.78e-05	0.0213	0.49	0.32	diarrhoeal disease at age 2;	chr3:158704035	chr3:158693120~158693768:-
PCPG	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-4.14	5.78e-05	0.0213	-0.37	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
PCPG	cis	rs11148252	0.538	rs2408609	ENSG00000235660.1	LINC00345	-4.14	5.78e-05	0.0213	-0.39	-0.32	Lewy body disease;	chr13:52139907	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.538	rs2897976	ENSG00000235660.1	LINC00345	-4.14	5.78e-05	0.0213	-0.39	-0.32	Lewy body disease;	chr13:52141808	chr13:52484161~52484680:-
PCPG	cis	rs12906542	0.529	rs62008651	ENSG00000259792.1	RP11-114H24.6	-4.14	5.78e-05	0.0213	-0.37	-0.32	Breast cancer;	chr15:77984075	chr15:77993405~77995289:+
PCPG	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-4.14	5.78e-05	0.0213	-0.34	-0.32	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
PCPG	cis	rs9303542	0.625	rs8066613	ENSG00000279036.1	RP11-81K2.2	-4.14	5.79e-05	0.0213	-0.52	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48506158	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.592	rs34378400	ENSG00000279036.1	RP11-81K2.2	-4.14	5.79e-05	0.0213	-0.52	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48511903	chr17:49494223~49497800:-
PCPG	cis	rs7829975	0.502	rs7820738	ENSG00000173295.6	FAM86B3P	4.14	5.79e-05	0.0213	0.36	0.32	Mood instability;	chr8:8845097	chr8:8228595~8244865:+
PCPG	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	4.14	5.79e-05	0.0213	0.29	0.32	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
PCPG	cis	rs11858159	0.934	rs12912509	ENSG00000260760.1	PWRN3	4.14	5.79e-05	0.0213	0.35	0.32	Platelet thrombus formation;	chr15:24571513	chr15:24441127~24447967:+
PCPG	cis	rs6657613	0.68	rs11579925	ENSG00000186715.9	MST1L	-4.14	5.79e-05	0.0213	-0.34	-0.32	Hip circumference adjusted for BMI;	chr1:17036210	chr1:16754910~16770237:-
PCPG	cis	rs2836974	0.568	rs2836969	ENSG00000252915.1	Y_RNA	4.14	5.79e-05	0.0213	0.33	0.32	Cognitive function;	chr21:39276339	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.605	rs2836971	ENSG00000252915.1	Y_RNA	4.14	5.79e-05	0.0213	0.33	0.32	Cognitive function;	chr21:39280114	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.584	rs6517535	ENSG00000252915.1	Y_RNA	4.14	5.79e-05	0.0213	0.33	0.32	Cognitive function;	chr21:39281426	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.627	rs7278985	ENSG00000252915.1	Y_RNA	4.14	5.79e-05	0.0213	0.33	0.32	Cognitive function;	chr21:39281841	chr21:39344537~39344628:+
PCPG	cis	rs4143844	0.867	rs11634077	ENSG00000259251.2	RP11-643M14.1	4.14	5.79e-05	0.0213	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:62001376	chr15:62060503~62062434:+
PCPG	cis	rs6464929	0.956	rs4727005	ENSG00000281189.1	GHET1	4.14	5.79e-05	0.0213	0.41	0.32	Pediatric bone mineral content (hip);	chr7:149007777	chr7:148987527~148989432:+
PCPG	cis	rs6464929	0.956	rs10272564	ENSG00000281189.1	GHET1	4.14	5.79e-05	0.0213	0.41	0.32	Pediatric bone mineral content (hip);	chr7:149008398	chr7:148987527~148989432:+
PCPG	cis	rs6500637	0.591	rs2075466	ENSG00000267077.1	RP11-127I20.5	4.14	5.8e-05	0.0213	0.45	0.32	Cancer;	chr16:4822969	chr16:4795265~4796532:-
PCPG	cis	rs875971	0.862	rs1968126	ENSG00000235475.1	LINC01372	-4.14	5.8e-05	0.0214	-0.32	-0.32	Aortic root size;	chr7:66592017	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6460306	ENSG00000235475.1	LINC01372	-4.14	5.8e-05	0.0214	-0.32	-0.32	Aortic root size;	chr7:66595806	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6971059	ENSG00000235475.1	LINC01372	-4.14	5.8e-05	0.0214	-0.32	-0.32	Aortic root size;	chr7:66602045	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.789	rs7808013	ENSG00000235475.1	LINC01372	-4.14	5.8e-05	0.0214	-0.32	-0.32	Aortic root size;	chr7:66606209	chr7:67335976~67340024:+
PCPG	cis	rs761746	0.705	rs10154390	ENSG00000128254.12	C22orf24	-4.14	5.8e-05	0.0214	-0.43	-0.32	Intelligence;	chr22:31655103	chr22:31933521~31945518:-
PCPG	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-4.14	5.8e-05	0.0214	-0.49	-0.32	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
PCPG	cis	rs9400180	0.918	rs1123255	ENSG00000271734.1	RP1-111B22.3	-4.14	5.8e-05	0.0214	-0.37	-0.32	Major depressive disorder;	chr6:108076006	chr6:108030249~108030718:-
PCPG	cis	rs896854	0.654	rs28591375	ENSG00000272509.1	RP11-347C18.5	4.14	5.8e-05	0.0214	0.32	0.32	Type 2 diabetes;	chr8:94961409	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.654	rs4735339	ENSG00000272509.1	RP11-347C18.5	4.14	5.8e-05	0.0214	0.32	0.32	Type 2 diabetes;	chr8:94962145	chr8:94884609~94885070:+
PCPG	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	4.14	5.81e-05	0.0214	0.36	0.32	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
PCPG	cis	rs5760092	0.618	rs4461358	ENSG00000250470.1	AP000351.3	-4.14	5.81e-05	0.0214	-0.44	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23976904~23977585:-
PCPG	cis	rs11671005	0.736	rs11668201	ENSG00000269600.1	AC016629.3	-4.14	5.81e-05	0.0214	-0.48	-0.32	Mean platelet volume;	chr19:58492265	chr19:58593896~58599355:-
PCPG	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	4.14	5.81e-05	0.0214	0.36	0.32	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
PCPG	cis	rs1440410	0.835	rs4337690	ENSG00000250326.1	RP11-284M14.1	4.14	5.81e-05	0.0214	0.29	0.32	Ischemic stroke;	chr4:143148408	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs13139558	ENSG00000250326.1	RP11-284M14.1	4.14	5.81e-05	0.0214	0.29	0.32	Ischemic stroke;	chr4:143149410	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs7670439	ENSG00000250326.1	RP11-284M14.1	4.14	5.81e-05	0.0214	0.29	0.32	Ischemic stroke;	chr4:143159114	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs10011709	ENSG00000250326.1	RP11-284M14.1	4.14	5.81e-05	0.0214	0.29	0.32	Ischemic stroke;	chr4:143159347	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs10015190	ENSG00000250326.1	RP11-284M14.1	4.14	5.81e-05	0.0214	0.29	0.32	Ischemic stroke;	chr4:143160595	chr4:142933195~143184861:-
PCPG	cis	rs1009077	0.514	rs71614451	ENSG00000245958.5	RP11-33B1.1	4.14	5.81e-05	0.0214	0.41	0.32	Endometriosis;	chr4:119483305	chr4:119454791~119552025:+
PCPG	cis	rs1009077	0.514	rs62319578	ENSG00000245958.5	RP11-33B1.1	4.14	5.81e-05	0.0214	0.41	0.32	Endometriosis;	chr4:119487266	chr4:119454791~119552025:+
PCPG	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-4.14	5.81e-05	0.0214	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
PCPG	cis	rs10865541	1	rs10165099	ENSG00000225234.1	TRAPPC12-AS1	-4.14	5.82e-05	0.0214	-0.32	-0.32	Obesity-related traits;	chr2:3398820	chr2:3481242~3482409:-
PCPG	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	4.14	5.82e-05	0.0214	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	4.14	5.82e-05	0.0214	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
PCPG	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	4.14	5.82e-05	0.0214	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
PCPG	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	4.14	5.82e-05	0.0214	0.36	0.32	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
PCPG	cis	rs11673344	0.504	rs6510593	ENSG00000226686.6	LINC01535	4.14	5.82e-05	0.0214	0.42	0.32	Obesity-related traits;	chr19:37143153	chr19:37251912~37265535:+
PCPG	cis	rs958685	0.735	rs3771504	ENSG00000281195.1	ZNF638-IT1	-4.14	5.83e-05	0.0214	-0.29	-0.32	Hand grip strength;	chr2:70484873	chr2:71373938~71376320:+
PCPG	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-4.14	5.83e-05	0.0214	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
PCPG	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	4.14	5.83e-05	0.0214	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
PCPG	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-4.14	5.83e-05	0.0214	-0.46	-0.32	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
PCPG	cis	rs4934494	0.768	rs34993776	ENSG00000240996.1	RP11-80H5.7	-4.14	5.83e-05	0.0214	-0.48	-0.32	Red blood cell count;	chr10:89681932	chr10:89694295~89697928:-
PCPG	cis	rs875971	0.862	rs709596	ENSG00000235475.1	LINC01372	4.14	5.83e-05	0.0215	0.33	0.32	Aortic root size;	chr7:66360926	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778724	ENSG00000235475.1	LINC01372	4.14	5.83e-05	0.0215	0.33	0.32	Aortic root size;	chr7:66364304	chr7:67335976~67340024:+
PCPG	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-4.14	5.83e-05	0.0215	-0.37	-0.32	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
PCPG	cis	rs2412459	0.635	rs72729469	ENSG00000245849.5	RAD51-AS1	-4.14	5.83e-05	0.0215	-0.53	-0.32	Response to haloperidol in psychosis;	chr15:39958997	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs1436278	ENSG00000245849.5	RAD51-AS1	-4.14	5.83e-05	0.0215	-0.53	-0.32	Response to haloperidol in psychosis;	chr15:39961045	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs16970098	ENSG00000245849.5	RAD51-AS1	-4.14	5.83e-05	0.0215	-0.53	-0.32	Response to haloperidol in psychosis;	chr15:39969078	chr15:40686724~40695107:-
PCPG	cis	rs2836974	0.932	rs2150415	ENSG00000255568.3	BRWD1-AS2	4.14	5.84e-05	0.0215	0.35	0.32	Cognitive function;	chr21:39243441	chr21:39313935~39314962:+
PCPG	cis	rs4842666	0.915	rs11105368	ENSG00000258302.2	RP11-981P6.1	4.14	5.84e-05	0.0215	0.49	0.32	Blood pressure;	chr12:89680664	chr12:89561129~89594878:+
PCPG	cis	rs4842666	0.765	rs4842675	ENSG00000258302.2	RP11-981P6.1	4.14	5.84e-05	0.0215	0.49	0.32	Blood pressure;	chr12:89681466	chr12:89561129~89594878:+
PCPG	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	4.14	5.84e-05	0.0215	0.33	0.32	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
PCPG	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-4.14	5.85e-05	0.0215	-0.32	-0.32	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
PCPG	cis	rs763014	0.931	rs56048717	ENSG00000262528.2	LA16c-349E10.1	4.14	5.85e-05	0.0215	0.37	0.32	Height;	chr16:584867	chr16:654611~656194:-
PCPG	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	4.14	5.85e-05	0.0215	0.34	0.32	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
PCPG	cis	rs10461617	0.541	rs832575	ENSG00000271828.1	CTD-2310F14.1	4.14	5.85e-05	0.0215	0.67	0.32	Type 2 diabetes;	chr5:56865960	chr5:56927874~56929573:+
PCPG	cis	rs6121246	0.56	rs6088854	ENSG00000230613.1	HM13-AS1	4.14	5.85e-05	0.0215	0.5	0.32	Mean corpuscular hemoglobin;	chr20:31637554	chr20:31567707~31573263:-
PCPG	cis	rs9462027	0.517	rs2744973	ENSG00000217130.1	RP3-375P9.2	4.14	5.86e-05	0.0215	0.27	0.32	Systemic lupus erythematosus;	chr6:34612444	chr6:34744176~34744673:+
PCPG	cis	rs12999373	0.501	rs11127496	ENSG00000272342.1	RP13-539J13.1	4.14	5.86e-05	0.0216	0.42	0.32	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:739588~740164:-
PCPG	cis	rs1150668	0.745	rs213238	ENSG00000176933.5	TOB2P1	-4.14	5.86e-05	0.0216	-0.36	-0.32	Pubertal anthropometrics;	chr6:28354216	chr6:28217643~28218634:-
PCPG	cis	rs896854	0.654	rs4735337	ENSG00000272509.1	RP11-347C18.5	4.14	5.87e-05	0.0216	0.32	0.32	Type 2 diabetes;	chr8:94961237	chr8:94884609~94885070:+
PCPG	cis	rs324126	0.743	rs34221182	ENSG00000277977.1	CTD-3018O17.5	4.14	5.87e-05	0.0216	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52392659~52392755:+
PCPG	cis	rs7246657	0.765	rs10402455	ENSG00000226686.6	LINC01535	-4.14	5.87e-05	0.0216	-0.55	-0.32	Coronary artery calcification;	chr19:37237805	chr19:37251912~37265535:+
PCPG	cis	rs11148252	0.875	rs7987115	ENSG00000235660.1	LINC00345	-4.14	5.87e-05	0.0216	-0.4	-0.32	Lewy body disease;	chr13:52387962	chr13:52484161~52484680:-
PCPG	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	4.14	5.87e-05	0.0216	0.41	0.32	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
PCPG	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	4.14	5.87e-05	0.0216	0.33	0.32	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
PCPG	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	4.14	5.87e-05	0.0216	0.33	0.32	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
PCPG	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	4.14	5.87e-05	0.0216	0.33	0.32	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
PCPG	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	4.14	5.87e-05	0.0216	0.33	0.32	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
PCPG	cis	rs7696431	0.933	rs6823685	ENSG00000279384.1	RP11-635L1.2	-4.14	5.88e-05	0.0216	-0.34	-0.32	Coronary artery disease;	chr4:168769669	chr4:168843988~168844735:+
PCPG	cis	rs875971	0.767	rs12668005	ENSG00000235475.1	LINC01372	4.14	5.88e-05	0.0216	0.32	0.32	Aortic root size;	chr7:66444034	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs11765791	ENSG00000235475.1	LINC01372	4.14	5.88e-05	0.0216	0.32	0.32	Aortic root size;	chr7:66471587	chr7:67335976~67340024:+
PCPG	cis	rs1874124	0.836	rs17596947	ENSG00000272823.1	RP11-295M18.6	4.14	5.88e-05	0.0216	0.43	0.32	Cholesterol, total;	chr1:220820122	chr1:220828676~220829211:-
PCPG	cis	rs7896471	0.546	rs7091871	ENSG00000260475.1	RP11-85A1.3	4.14	5.88e-05	0.0216	0.41	0.32	Blood protein levels;	chr10:100050547	chr10:99621055~99621918:+
PCPG	cis	rs7208859	0.673	rs2470251	ENSG00000266490.1	CTD-2349P21.9	4.14	5.88e-05	0.0216	0.39	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30792372~30792833:+
PCPG	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-4.14	5.89e-05	0.0216	-0.52	-0.32	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
PCPG	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-4.14	5.89e-05	0.0216	-0.52	-0.32	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
PCPG	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-4.14	5.89e-05	0.0216	-0.45	-0.32	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
PCPG	cis	rs10853057	0.85	rs8076385	ENSG00000214174.7	AMZ2P1	4.14	5.89e-05	0.0216	0.64	0.32	White matter microstructure (global fractional anisotropy);	chr17:65002369	chr17:64966550~64975576:-
PCPG	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-4.13	5.89e-05	0.0216	-0.86	-0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
PCPG	cis	rs896854	0.608	rs6991067	ENSG00000253528.2	RP11-347C18.4	4.13	5.89e-05	0.0216	0.34	0.32	Type 2 diabetes;	chr8:94863448	chr8:94974573~94974853:-
PCPG	cis	rs2836974	0.674	rs1011413	ENSG00000252915.1	Y_RNA	4.13	5.89e-05	0.0216	0.33	0.32	Cognitive function;	chr21:39266315	chr21:39344537~39344628:+
PCPG	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	4.13	5.89e-05	0.0216	0.32	0.32	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
PCPG	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	4.13	5.89e-05	0.0216	0.28	0.32	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
PCPG	cis	rs11148252	0.538	rs2296349	ENSG00000235660.1	LINC00345	-4.13	5.89e-05	0.0216	-0.39	-0.32	Lewy body disease;	chr13:52135922	chr13:52484161~52484680:-
PCPG	cis	rs561341	0.883	rs1034626	ENSG00000265798.5	RP11-271K11.5	-4.13	5.89e-05	0.0216	-0.51	-0.32	Hip circumference adjusted for BMI;	chr17:31892481	chr17:31038575~31059121:-
PCPG	cis	rs2404602	0.679	rs12908421	ENSG00000259514.1	RP11-685G9.2	-4.13	5.9e-05	0.0217	-0.32	-0.32	Blood metabolite levels;	chr15:76589453	chr15:76339609~76342063:-
PCPG	cis	rs10200850	1	rs72992617	ENSG00000265215.1	MIR4269	4.13	5.9e-05	0.0217	0.53	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239298718	chr2:239305462~239305545:+
PCPG	cis	rs10200850	1	rs13405743	ENSG00000265215.1	MIR4269	4.13	5.9e-05	0.0217	0.53	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239309431	chr2:239305462~239305545:+
PCPG	cis	rs10200850	0.892	rs13391934	ENSG00000265215.1	MIR4269	4.13	5.9e-05	0.0217	0.53	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239314427	chr2:239305462~239305545:+
PCPG	cis	rs10200850	0.892	rs56327958	ENSG00000265215.1	MIR4269	4.13	5.9e-05	0.0217	0.53	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239340541	chr2:239305462~239305545:+
PCPG	cis	rs7911712	0.872	rs11239240	ENSG00000228462.1	RP11-445N18.3	4.13	5.9e-05	0.0217	0.46	0.32	Emphysema-related traits;	chr10:44769697	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs11239242	ENSG00000228462.1	RP11-445N18.3	4.13	5.9e-05	0.0217	0.46	0.32	Emphysema-related traits;	chr10:44776787	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.872	rs11239245	ENSG00000228462.1	RP11-445N18.3	4.13	5.9e-05	0.0217	0.46	0.32	Emphysema-related traits;	chr10:44786028	chr10:45073146~45073541:-
PCPG	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-4.13	5.9e-05	0.0217	-0.35	-0.32	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
PCPG	cis	rs6901152	1	rs4895609	ENSG00000217648.1	RP1-95L4.4	-4.13	5.9e-05	0.0217	-0.37	-0.32	Acute lymphoblastic leukemia (childhood);	chr6:143356998	chr6:143342246~143343383:+
PCPG	cis	rs1440410	0.835	rs13107465	ENSG00000250326.1	RP11-284M14.1	4.13	5.9e-05	0.0217	0.3	0.32	Ischemic stroke;	chr4:143147664	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs4511955	ENSG00000250326.1	RP11-284M14.1	4.13	5.9e-05	0.0217	0.3	0.32	Ischemic stroke;	chr4:143149081	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs13140643	ENSG00000250326.1	RP11-284M14.1	4.13	5.9e-05	0.0217	0.3	0.32	Ischemic stroke;	chr4:143149221	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs6817849	ENSG00000250326.1	RP11-284M14.1	4.13	5.9e-05	0.0217	0.3	0.32	Ischemic stroke;	chr4:143154848	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.798	rs10012434	ENSG00000250326.1	RP11-284M14.1	4.13	5.9e-05	0.0217	0.3	0.32	Ischemic stroke;	chr4:143156365	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs7687417	ENSG00000250326.1	RP11-284M14.1	4.13	5.9e-05	0.0217	0.3	0.32	Ischemic stroke;	chr4:143158848	chr4:142933195~143184861:-
PCPG	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	4.13	5.91e-05	0.0217	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
PCPG	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-4.13	5.91e-05	0.0217	-0.49	-0.32	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
PCPG	cis	rs66887589	0.616	rs10032299	ENSG00000249244.1	RP11-548H18.2	4.13	5.91e-05	0.0217	0.29	0.32	Diastolic blood pressure;	chr4:119285264	chr4:119391831~119395335:-
PCPG	cis	rs717344	0.629	rs12919205	ENSG00000279877.1	RP11-420N3.3	4.13	5.91e-05	0.0217	0.4	0.32	Cancer;	chr16:4999313	chr16:5239802~6776014:+
PCPG	cis	rs3020264	0.544	rs1834451	ENSG00000271743.1	CTD-2541M15.3	-4.13	5.91e-05	0.0217	-0.37	-0.32	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6633660	chr8:6615604~6617198:-
PCPG	cis	rs13108904	0.935	rs2199956	ENSG00000254094.1	AC078852.1	-4.13	5.91e-05	0.0217	-0.36	-0.32	Obesity-related traits;	chr4:1255131	chr4:1356581~1358075:+
PCPG	cis	rs2098713	0.562	rs55794983	ENSG00000250155.1	CTD-2353F22.1	4.13	5.91e-05	0.0217	0.4	0.32	Telomere length;	chr5:37549046	chr5:36666214~36725195:-
PCPG	cis	rs3095748	1	rs888331	ENSG00000226237.1	RP11-276H19.1	4.13	5.91e-05	0.0217	0.69	0.32	Immune reponse to smallpox (secreted IFN-alpha);	chr9:87598294	chr9:86948699~87002033:+
PCPG	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	4.13	5.92e-05	0.0217	0.56	0.32	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
PCPG	cis	rs11641231	0.571	rs1687626	ENSG00000261567.1	RP11-680G10.1	4.13	5.92e-05	0.0217	0.37	0.32	Response to statin therapy;	chr16:86348514	chr16:85357463~85359449:+
PCPG	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-4.13	5.92e-05	0.0217	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
PCPG	cis	rs2361718	0.5	rs8064429	ENSG00000279259.1	RP11-334C17.3	4.13	5.92e-05	0.0217	0.3	0.32	Yeast infection;	chr17:80122388	chr17:80147250~80148596:+
PCPG	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	4.13	5.92e-05	0.0217	0.53	0.32	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
PCPG	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-4.13	5.92e-05	0.0217	-0.42	-0.32	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
PCPG	cis	rs6683071	0.689	rs12063226	ENSG00000272750.1	RP11-378J18.8	-4.13	5.92e-05	0.0217	-0.58	-0.32	Cognitive performance;	chr1:222753913	chr1:222658867~222661512:-
PCPG	cis	rs7849270	0.692	rs4397510	ENSG00000268707.1	RP11-247A12.7	-4.13	5.92e-05	0.0217	-0.35	-0.32	Blood metabolite ratios;	chr9:129092671	chr9:129170434~129170940:+
PCPG	cis	rs7849270	0.879	rs10739741	ENSG00000268707.1	RP11-247A12.7	-4.13	5.92e-05	0.0217	-0.35	-0.32	Blood metabolite ratios;	chr9:129092881	chr9:129170434~129170940:+
PCPG	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-4.13	5.92e-05	0.0217	-0.3	-0.32	Breast cancer;	chr11:825777	chr11:777578~784297:+
PCPG	cis	rs1876905	0.597	rs191631	ENSG00000255389.1	C6orf3	4.13	5.92e-05	0.0217	0.45	0.32	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111599875~111602295:+
PCPG	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-4.13	5.93e-05	0.0217	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
PCPG	cis	rs2098713	0.599	rs1812818	ENSG00000250155.1	CTD-2353F22.1	4.13	5.93e-05	0.0217	0.38	0.32	Telomere length;	chr5:37546652	chr5:36666214~36725195:-
PCPG	cis	rs3947	1	rs1736082	ENSG00000227203.3	SUB1P1	-4.13	5.93e-05	0.0217	-0.49	-0.32	Blood protein levels;	chr8:11845911	chr8:11790005~11790386:+
PCPG	cis	rs3947	1	rs1736083	ENSG00000227203.3	SUB1P1	-4.13	5.93e-05	0.0217	-0.49	-0.32	Blood protein levels;	chr8:11845988	chr8:11790005~11790386:+
PCPG	cis	rs3947	1	rs1692812	ENSG00000227203.3	SUB1P1	-4.13	5.93e-05	0.0217	-0.49	-0.32	Blood protein levels;	chr8:11846014	chr8:11790005~11790386:+
PCPG	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-4.13	5.93e-05	0.0217	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
PCPG	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	4.13	5.93e-05	0.0217	0.36	0.32	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
PCPG	cis	rs13126694	0.75	rs2346782	ENSG00000248429.4	RP11-597D13.9	4.13	5.93e-05	0.0217	0.33	0.32	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158170752~158202877:+
PCPG	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	4.13	5.93e-05	0.0218	0.29	0.32	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	4.13	5.93e-05	0.0218	0.29	0.32	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
PCPG	cis	rs7181230	0.961	rs7183977	ENSG00000259584.1	RP11-521C20.2	-4.13	5.93e-05	0.0218	-0.43	-0.32	Dehydroepiandrosterone sulphate levels;	chr15:40084891	chr15:40075204~40078704:-
PCPG	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	4.13	5.94e-05	0.0218	0.36	0.32	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
PCPG	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	4.13	5.94e-05	0.0218	0.31	0.32	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
PCPG	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-4.13	5.95e-05	0.0218	-0.36	-0.32	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
PCPG	cis	rs17152411	0.895	rs3940439	ENSG00000278831.1	RP11-12J10.4	4.13	5.95e-05	0.0218	0.46	0.32	Height;	chr10:124895962	chr10:124623353~124624079:+
PCPG	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-4.13	5.95e-05	0.0218	-0.41	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
PCPG	cis	rs11673344	0.504	rs7259332	ENSG00000226686.6	LINC01535	4.13	5.95e-05	0.0218	0.42	0.32	Obesity-related traits;	chr19:37143389	chr19:37251912~37265535:+
PCPG	cis	rs1371867	0.875	rs1788174	ENSG00000212994.5	RPS26P6	-4.13	5.95e-05	0.0218	-0.37	-0.32	Atrioventricular conduction;	chr8:100318729	chr8:100895771~100896118:+
PCPG	cis	rs11214589	0.774	rs10891544	ENSG00000256757.1	RP11-159N11.3	-4.13	5.95e-05	0.0218	-0.34	-0.32	Neuroticism;	chr11:113385430	chr11:113405321~113412117:+
PCPG	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-4.13	5.95e-05	0.0218	-0.37	-0.32	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
PCPG	cis	rs2281558	0.833	rs55792313	ENSG00000125804.12	FAM182A	-4.13	5.95e-05	0.0218	-0.44	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25540619	chr20:26054655~26086917:+
PCPG	cis	rs2281558	0.833	rs12480853	ENSG00000125804.12	FAM182A	-4.13	5.95e-05	0.0218	-0.44	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25542323	chr20:26054655~26086917:+
PCPG	cis	rs853679	1	rs2799079	ENSG00000219392.1	RP1-265C24.5	-4.13	5.96e-05	0.0218	-0.49	-0.32	Depression;	chr6:28267398	chr6:28115628~28116551:+
PCPG	cis	rs10200850	0.536	rs13429023	ENSG00000265215.1	MIR4269	4.13	5.96e-05	0.0218	0.54	0.32	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239296497	chr2:239305462~239305545:+
PCPG	cis	rs8098244	0.638	rs9951784	ENSG00000265752.2	RP11-403A21.1	4.13	5.96e-05	0.0218	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23882709	chr18:23957754~23982556:-
PCPG	cis	rs2836974	0.644	rs7281853	ENSG00000255568.3	BRWD1-AS2	-4.13	5.96e-05	0.0218	-0.34	-0.32	Cognitive function;	chr21:39321564	chr21:39313935~39314962:+
PCPG	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	4.13	5.96e-05	0.0219	0.32	0.32	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	4.13	5.96e-05	0.0219	0.32	0.32	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
PCPG	cis	rs2625529	0.668	rs72733369	ENSG00000260037.4	CTD-2524L6.3	-4.13	5.97e-05	0.0219	-0.49	-0.32	Red blood cell count;	chr15:72274919	chr15:71818396~71823384:+
PCPG	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	4.13	5.97e-05	0.0219	0.49	0.32	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
PCPG	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	4.13	5.97e-05	0.0219	0.37	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
PCPG	cis	rs901683	1	rs3764990	ENSG00000230869.1	CTGLF10P	-4.13	5.97e-05	0.0219	-0.81	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45461380	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs71494788	ENSG00000230869.1	CTGLF10P	-4.13	5.97e-05	0.0219	-0.81	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45476877	chr10:45678692~45700532:+
PCPG	cis	rs3758911	0.828	rs10789598	ENSG00000255353.1	RP11-382M14.1	-4.13	5.97e-05	0.0219	-0.44	-0.32	Coronary artery disease;	chr11:107307878	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs11212143	ENSG00000255353.1	RP11-382M14.1	-4.13	5.97e-05	0.0219	-0.44	-0.32	Coronary artery disease;	chr11:107308554	chr11:107176286~107177530:+
PCPG	cis	rs56804039	0.524	rs6988990	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8510890	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs7011761	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8511045	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs7016788	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8511226	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs7012227	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8511280	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs6995198	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8512445	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs6985671	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8512494	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs6993658	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8512842	chr8:8167819~8226614:-
PCPG	cis	rs56804039	0.524	rs6998450	ENSG00000253893.2	FAM85B	4.13	5.97e-05	0.0219	0.58	0.32	Cervical cancer;	chr8:8512843	chr8:8167819~8226614:-
PCPG	cis	rs7523050	0.643	rs34367763	ENSG00000203897.3	SPATA42	-4.13	5.98e-05	0.0219	-0.52	-0.32	Fat distribution (HIV);	chr1:108858183	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs35662800	ENSG00000203897.3	SPATA42	-4.13	5.98e-05	0.0219	-0.52	-0.32	Fat distribution (HIV);	chr1:108858194	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs17621851	ENSG00000203897.3	SPATA42	-4.13	5.98e-05	0.0219	-0.52	-0.32	Fat distribution (HIV);	chr1:108858213	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs34920128	ENSG00000203897.3	SPATA42	-4.13	5.98e-05	0.0219	-0.52	-0.32	Fat distribution (HIV);	chr1:108858267	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs34096625	ENSG00000203897.3	SPATA42	-4.13	5.98e-05	0.0219	-0.52	-0.32	Fat distribution (HIV);	chr1:108858479	chr1:108857217~108858524:+
PCPG	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-4.13	5.98e-05	0.0219	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
PCPG	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-4.13	5.98e-05	0.0219	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
PCPG	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	4.13	5.98e-05	0.0219	0.42	0.32	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
PCPG	cis	rs116248771	0.69	rs16847125	ENSG00000272087.1	RP11-379F4.7	4.13	5.98e-05	0.0219	0.49	0.32	diarrhoeal disease at age 2;	chr3:158699910	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156495	ENSG00000272087.1	RP11-379F4.7	4.13	5.98e-05	0.0219	0.49	0.32	diarrhoeal disease at age 2;	chr3:158702758	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156496	ENSG00000272087.1	RP11-379F4.7	4.13	5.98e-05	0.0219	0.49	0.32	diarrhoeal disease at age 2;	chr3:158703373	chr3:158693120~158693768:-
PCPG	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	4.13	5.98e-05	0.0219	0.41	0.32	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
PCPG	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	4.13	5.98e-05	0.0219	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
PCPG	cis	rs394563	0.601	rs367133	ENSG00000231760.4	RP11-350J20.5	4.13	5.99e-05	0.0219	0.4	0.32	Dupuytren's disease;	chr6:149476584	chr6:149796151~149826294:-
PCPG	cis	rs853679	0.607	rs33932084	ENSG00000219392.1	RP1-265C24.5	-4.13	5.99e-05	0.0219	-0.66	-0.32	Depression;	chr6:28301047	chr6:28115628~28116551:+
PCPG	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-4.13	5.99e-05	0.0219	-0.35	-0.32	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
PCPG	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	4.13	5.99e-05	0.0219	0.29	0.32	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
PCPG	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	4.13	5.99e-05	0.0219	0.34	0.32	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	4.13	5.99e-05	0.0219	0.34	0.32	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
PCPG	cis	rs7017914	0.644	rs1159724	ENSG00000254031.4	RP11-326E22.1	4.13	5.99e-05	0.0219	0.31	0.32	Bone mineral density;	chr8:71087586	chr8:71155457~71204223:+
PCPG	cis	rs11148252	0.583	rs9536048	ENSG00000278238.1	RP11-245D16.4	-4.13	6e-05	0.022	-0.3	-0.32	Lewy body disease;	chr13:52384653	chr13:52454775~52455331:-
PCPG	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-4.13	6e-05	0.022	-0.47	-0.32	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
PCPG	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	4.13	6e-05	0.022	0.36	0.32	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
PCPG	cis	rs116248771	0.739	rs73156451	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158647660	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156455	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158649768	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs12633674	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158650428	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.793	rs73156465	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158656746	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs7648050	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158659681	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs4680454	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158660124	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs2291595	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158661058	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs4680455	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158667094	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs16829290	ENSG00000272087.1	RP11-379F4.7	4.13	6.01e-05	0.022	0.48	0.32	diarrhoeal disease at age 2;	chr3:158674489	chr3:158693120~158693768:-
PCPG	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-4.13	6.01e-05	0.022	-0.37	-0.32	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
PCPG	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	4.13	6.01e-05	0.022	0.33	0.32	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
PCPG	cis	rs4711336	0.712	rs942641	ENSG00000197251.3	LINC00336	-4.13	6.01e-05	0.022	-0.35	-0.32	Height;	chr6:33719230	chr6:33586106~33593338:-
PCPG	cis	rs2404602	0.692	rs12910734	ENSG00000259514.1	RP11-685G9.2	-4.13	6.01e-05	0.022	-0.32	-0.32	Blood metabolite levels;	chr15:76857590	chr15:76339609~76342063:-
PCPG	cis	rs7849782	0.875	rs7035242	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101652206	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.817	rs1407872	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101652414	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.846	rs1407871	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101652678	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.846	rs1951781	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101652780	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.875	rs10819964	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101653708	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.905	rs7027697	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101654088	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.846	rs7046942	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101654325	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.875	rs7031245	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101654414	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.875	rs7030623	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101654653	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.875	rs7031570	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101654673	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.817	rs7020043	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101654768	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.875	rs1323422	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101654946	chr9:101468439~101481502:+
PCPG	cis	rs7849782	0.875	rs1924032	ENSG00000225376.4	TMEM246-AS1	4.13	6.01e-05	0.022	0.37	0.32	Coronary artery aneurysm in Kawasaki disease;	chr9:101655530	chr9:101468439~101481502:+
PCPG	cis	rs12744310	0.887	rs12048805	ENSG00000227527.2	RP11-223A3.1	-4.13	6.01e-05	0.022	-0.36	-0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348604	chr1:42335386~42338376:-
PCPG	cis	rs12744310	0.887	rs12032040	ENSG00000227527.2	RP11-223A3.1	-4.13	6.01e-05	0.022	-0.36	-0.32	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41352635	chr1:42335386~42338376:-
PCPG	cis	rs9303542	0.559	rs56038617	ENSG00000279036.1	RP11-81K2.2	-4.13	6.01e-05	0.022	-0.53	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48535216	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs55859232	ENSG00000279036.1	RP11-81K2.2	-4.13	6.01e-05	0.022	-0.53	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48535283	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs12946931	ENSG00000279036.1	RP11-81K2.2	-4.13	6.01e-05	0.022	-0.53	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48536718	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs12938390	ENSG00000279036.1	RP11-81K2.2	-4.13	6.01e-05	0.022	-0.53	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48537360	chr17:49494223~49497800:-
PCPG	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	4.13	6.01e-05	0.022	0.4	0.32	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
PCPG	cis	rs1003719	0.708	rs8126491	ENSG00000228677.1	TTC3-AS1	-4.13	6.02e-05	0.022	-0.39	-0.32	Eye color traits;	chr21:37178917	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs8130643	ENSG00000228677.1	TTC3-AS1	-4.13	6.02e-05	0.022	-0.39	-0.32	Eye color traits;	chr21:37179413	chr21:37187666~37193926:-
PCPG	cis	rs9299346	0.594	rs4568659	ENSG00000225376.4	TMEM246-AS1	4.13	6.02e-05	0.022	0.39	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101672382	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs4582620	ENSG00000225376.4	TMEM246-AS1	4.13	6.02e-05	0.022	0.39	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101672501	chr9:101468439~101481502:+
PCPG	cis	rs11148252	0.875	rs9596651	ENSG00000235660.1	LINC00345	4.13	6.02e-05	0.022	0.39	0.32	Lewy body disease;	chr13:52364447	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.875	rs9568728	ENSG00000235660.1	LINC00345	-4.13	6.02e-05	0.022	-0.39	-0.32	Lewy body disease;	chr13:52372458	chr13:52484161~52484680:-
PCPG	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	4.13	6.02e-05	0.022	0.35	0.32	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
PCPG	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	4.13	6.02e-05	0.022	0.34	0.32	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
PCPG	cis	rs11250098	0.547	rs2409764	ENSG00000154316.13	TDH	4.13	6.03e-05	0.022	0.41	0.32	Morning vs. evening chronotype;	chr8:11423764	chr8:11339637~11368452:+
PCPG	cis	rs6445975	0.715	rs3773007	ENSG00000272360.1	RP11-359I18.5	-4.13	6.03e-05	0.022	-0.39	-0.32	Systemic lupus erythematosus;	chr3:58283839	chr3:58490830~58491291:-
PCPG	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	4.13	6.03e-05	0.022	0.44	0.32	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
PCPG	cis	rs11671005	0.695	rs12972898	ENSG00000252334.1	RNU6-1337P	4.13	6.04e-05	0.0221	0.47	0.32	Mean platelet volume;	chr19:58445521	chr19:58483749~58483843:-
PCPG	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-4.13	6.04e-05	0.0221	-0.33	-0.32	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
PCPG	cis	rs172166	0.56	rs203878	ENSG00000219392.1	RP1-265C24.5	-4.13	6.05e-05	0.0221	-0.35	-0.32	Cardiac Troponin-T levels;	chr6:28081218	chr6:28115628~28116551:+
PCPG	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	4.13	6.05e-05	0.0221	0.26	0.32	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	4.13	6.05e-05	0.0221	0.26	0.32	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
PCPG	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	4.13	6.05e-05	0.0221	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
PCPG	cis	rs6504622	0.818	rs9898527	ENSG00000262879.4	RP11-156P1.3	4.13	6.05e-05	0.0221	0.36	0.32	Orofacial clefts;	chr17:46958844	chr17:46984045~47100323:-
PCPG	cis	rs6504622	0.791	rs61671555	ENSG00000262879.4	RP11-156P1.3	4.13	6.05e-05	0.0221	0.36	0.32	Orofacial clefts;	chr17:46960491	chr17:46984045~47100323:-
PCPG	cis	rs7610312	0.681	rs7610449	ENSG00000273493.1	RP11-80H18.4	-4.13	6.06e-05	0.0221	-0.38	-0.32	Red blood cell count;	chr3:58334231	chr3:58329965~58330118:+
PCPG	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-4.13	6.06e-05	0.0221	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
PCPG	cis	rs8044188	0.743	rs2369533	ENSG00000261090.1	RP11-20G6.2	4.13	6.06e-05	0.0221	0.5	0.32	Multiple system atrophy;	chr16:23017725	chr16:23020337~23023611:+
PCPG	cis	rs911119	1	rs13038305	ENSG00000270001.1	RP11-218C14.8	-4.13	6.06e-05	0.0221	-0.51	-0.32	Chronic kidney disease;	chr20:23629625	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs6114206	ENSG00000270001.1	RP11-218C14.8	-4.13	6.06e-05	0.0221	-0.51	-0.32	Chronic kidney disease;	chr20:23631152	chr20:23631826~23632316:-
PCPG	cis	rs3947	1	rs1736084	ENSG00000255556.2	RP11-351I21.6	-4.13	6.06e-05	0.0221	-0.41	-0.32	Blood protein levels;	chr8:11846148	chr8:12378679~12380265:-
PCPG	cis	rs3947	1	rs1736085	ENSG00000255556.2	RP11-351I21.6	-4.13	6.06e-05	0.0221	-0.41	-0.32	Blood protein levels;	chr8:11846150	chr8:12378679~12380265:-
PCPG	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-4.13	6.06e-05	0.0221	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
PCPG	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-4.13	6.06e-05	0.0221	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
PCPG	cis	rs5769765	0.773	rs4075331	ENSG00000278869.1	CITF22-49E9.3	4.13	6.06e-05	0.0221	0.39	0.32	Schizophrenia;	chr22:49909202	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.865	rs9616369	ENSG00000278869.1	CITF22-49E9.3	4.13	6.06e-05	0.0221	0.39	0.32	Schizophrenia;	chr22:49910943	chr22:49933198~49934074:-
PCPG	cis	rs425277	1	rs421992	ENSG00000271806.1	RP5-892K4.1	4.13	6.06e-05	0.0222	0.38	0.32	Height;	chr1:2145821	chr1:2141084~2145279:-
PCPG	cis	rs2836974	0.568	rs4816620	ENSG00000255568.3	BRWD1-AS2	-4.13	6.07e-05	0.0222	-0.33	-0.32	Cognitive function;	chr21:39241860	chr21:39313935~39314962:+
PCPG	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-4.13	6.07e-05	0.0222	-0.36	-0.32	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
PCPG	cis	rs17772222	0.917	rs1950806	ENSG00000222990.1	RNU4-22P	4.13	6.07e-05	0.0222	0.42	0.32	Coronary artery calcification;	chr14:88774412	chr14:88513498~88513663:+
PCPG	cis	rs4819052	0.851	rs8134392	ENSG00000215447.6	BX322557.10	4.13	6.07e-05	0.0222	0.32	0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45288052~45291738:+
PCPG	cis	rs116248771	0.691	rs2363658	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158678077	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs4680456	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158680053	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156478	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158680927	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.69	rs4459938	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158688286	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156488	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158696153	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs73156489	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158696237	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs10276	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158697377	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs1051109	ENSG00000272087.1	RP11-379F4.7	4.13	6.07e-05	0.0222	0.49	0.32	diarrhoeal disease at age 2;	chr3:158697555	chr3:158693120~158693768:-
PCPG	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-4.13	6.07e-05	0.0222	-0.39	-0.32	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
PCPG	cis	rs6012953	0.967	rs6020585	ENSG00000231742.4	LINC01273	4.13	6.07e-05	0.0222	0.33	0.32	Vitiligo;	chr20:50530955	chr20:50172550~50176671:+
PCPG	cis	rs9388451	0.513	rs1268069	ENSG00000237742.5	RP11-624M8.1	-4.13	6.07e-05	0.0222	-0.34	-0.32	Brugada syndrome;	chr6:125718848	chr6:125578558~125749190:-
PCPG	cis	rs748404	0.666	rs514438	ENSG00000249839.1	AC011330.5	-4.13	6.07e-05	0.0222	-0.43	-0.32	Lung cancer;	chr15:43328245	chr15:43663654~43684339:-
PCPG	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-4.13	6.08e-05	0.0222	-0.41	-0.32	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
PCPG	cis	rs3758911	1	rs11212159	ENSG00000255353.1	RP11-382M14.1	-4.13	6.08e-05	0.0222	-0.41	-0.32	Coronary artery disease;	chr11:107326003	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs11212160	ENSG00000255353.1	RP11-382M14.1	-4.13	6.08e-05	0.0222	-0.41	-0.32	Coronary artery disease;	chr11:107326192	chr11:107176286~107177530:+
PCPG	cis	rs8098244	0.737	rs1154243	ENSG00000265752.2	RP11-403A21.1	-4.13	6.08e-05	0.0222	-0.48	-0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23963824	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.708	rs1154245	ENSG00000265752.2	RP11-403A21.1	-4.13	6.08e-05	0.0222	-0.48	-0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964250	chr18:23957754~23982556:-
PCPG	cis	rs7772486	0.754	rs702323	ENSG00000270638.1	RP3-466P17.1	-4.13	6.09e-05	0.0222	-0.34	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145735570~145737218:+
PCPG	cis	rs2736345	0.89	rs4840565	ENSG00000269954.1	RP11-148O21.6	4.13	6.09e-05	0.0222	0.38	0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11488036	chr8:11552488~11552991:-
PCPG	cis	rs12210905	0.925	rs858986	ENSG00000216901.1	AL022393.7	-4.13	6.09e-05	0.0222	-0.64	-0.32	Hip circumference adjusted for BMI;	chr6:27210744	chr6:28176188~28176674:+
PCPG	cis	rs8098244	0.638	rs9958787	ENSG00000265752.2	RP11-403A21.1	4.13	6.09e-05	0.0222	0.36	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23870461	chr18:23957754~23982556:-
PCPG	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	4.13	6.09e-05	0.0222	0.41	0.32	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	4.13	6.09e-05	0.0222	0.41	0.32	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	4.13	6.09e-05	0.0222	0.41	0.32	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
PCPG	cis	rs4713118	0.869	rs9366700	ENSG00000216901.1	AL022393.7	4.13	6.09e-05	0.0222	0.42	0.32	Parkinson's disease;	chr6:27729172	chr6:28176188~28176674:+
PCPG	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	4.13	6.1e-05	0.0222	0.31	0.32	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
PCPG	cis	rs7824557	0.767	rs28507159	ENSG00000184608.7	FAM167A-AS1	4.13	6.1e-05	0.0223	0.45	0.32	Retinal vascular caliber;	chr8:11308567	chr8:11368402~11438658:+
PCPG	cis	rs300890	0.841	rs6840603	ENSG00000250326.1	RP11-284M14.1	4.13	6.1e-05	0.0223	0.29	0.32	Nasopharyngeal carcinoma;	chr4:143306423	chr4:142933195~143184861:-
PCPG	cis	rs300890	0.901	rs6537153	ENSG00000250326.1	RP11-284M14.1	4.13	6.1e-05	0.0223	0.29	0.32	Nasopharyngeal carcinoma;	chr4:143309749	chr4:142933195~143184861:-
PCPG	cis	rs11214589	0.774	rs7116782	ENSG00000256757.1	RP11-159N11.3	4.13	6.1e-05	0.0223	0.34	0.32	Neuroticism;	chr11:113380216	chr11:113405321~113412117:+
PCPG	cis	rs2404602	0.532	rs284892	ENSG00000259514.1	RP11-685G9.2	-4.13	6.1e-05	0.0223	-0.32	-0.32	Blood metabolite levels;	chr15:76428696	chr15:76339609~76342063:-
PCPG	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	4.13	6.11e-05	0.0223	0.38	0.32	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
PCPG	cis	rs9813712	0.953	rs9871734	ENSG00000228252.7	COL6A4P2	4.13	6.11e-05	0.0223	0.4	0.32	Response to amphetamines;	chr3:130240756	chr3:130212823~130273806:+
PCPG	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-4.13	6.11e-05	0.0223	-0.41	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
PCPG	cis	rs8098244	0.557	rs7229859	ENSG00000265752.2	RP11-403A21.1	4.13	6.11e-05	0.0223	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716812	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.557	rs12957301	ENSG00000265752.2	RP11-403A21.1	4.13	6.11e-05	0.0223	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23717906	chr18:23957754~23982556:-
PCPG	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	-4.13	6.11e-05	0.0223	-0.38	-0.32	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
PCPG	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	4.13	6.11e-05	0.0223	0.39	0.32	Height;	chr6:109354092	chr6:109382795~109383666:+
PCPG	cis	rs4713118	0.699	rs573179	ENSG00000220721.1	OR1F12	4.13	6.11e-05	0.0223	0.42	0.32	Parkinson's disease;	chr6:27881898	chr6:28073316~28074233:+
PCPG	cis	rs4713118	0.699	rs200978	ENSG00000220721.1	OR1F12	4.13	6.11e-05	0.0223	0.42	0.32	Parkinson's disease;	chr6:27885390	chr6:28073316~28074233:+
PCPG	cis	rs4713118	0.699	rs200969	ENSG00000220721.1	OR1F12	4.13	6.11e-05	0.0223	0.42	0.32	Parkinson's disease;	chr6:27891675	chr6:28073316~28074233:+
PCPG	cis	rs2882667	0.518	rs10041986	ENSG00000222937.1	SNORD63	4.13	6.12e-05	0.0223	0.27	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138558970~138559039:-
PCPG	cis	rs6585424	1	rs34148644	ENSG00000242600.5	MBL1P	4.13	6.12e-05	0.0223	0.62	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163700	chr10:79904898~79950336:+
PCPG	cis	rs7208859	0.673	rs9911989	ENSG00000263603.1	CTD-2349P21.5	4.13	6.12e-05	0.0223	0.62	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30729469~30731202:+
PCPG	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-4.13	6.12e-05	0.0223	-0.41	-0.32	Temperament;	chr17:14007316	chr17:14024514~14025488:+
PCPG	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	4.13	6.12e-05	0.0223	0.42	0.32	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
PCPG	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	4.13	6.12e-05	0.0223	0.38	0.32	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
PCPG	cis	rs901683	1	rs12781506	ENSG00000230869.1	CTGLF10P	-4.13	6.12e-05	0.0223	-0.77	-0.32	Mean corpuscular volume;Red blood cell traits;	chr10:45543254	chr10:45678692~45700532:+
PCPG	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	4.13	6.12e-05	0.0223	0.43	0.32	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
PCPG	cis	rs7208859	0.673	rs216409	ENSG00000263603.1	CTD-2349P21.5	4.13	6.12e-05	0.0223	0.47	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30729469~30731202:+
PCPG	cis	rs896854	0.625	rs7823886	ENSG00000272509.1	RP11-347C18.5	4.12	6.12e-05	0.0223	0.32	0.32	Type 2 diabetes;	chr8:94974231	chr8:94884609~94885070:+
PCPG	cis	rs4919687	0.55	rs11191372	ENSG00000269609.4	RPARP-AS1	-4.12	6.12e-05	0.0223	-0.27	-0.32	Colorectal cancer;	chr10:102702430	chr10:102449817~102461106:+
PCPG	cis	rs4919687	0.55	rs12784517	ENSG00000269609.4	RPARP-AS1	-4.12	6.12e-05	0.0223	-0.27	-0.32	Colorectal cancer;	chr10:102705213	chr10:102449817~102461106:+
PCPG	cis	rs4919687	0.55	rs12761195	ENSG00000269609.4	RPARP-AS1	-4.12	6.12e-05	0.0223	-0.27	-0.32	Colorectal cancer;	chr10:102705617	chr10:102449817~102461106:+
PCPG	cis	rs4143844	1	rs34173668	ENSG00000259251.2	RP11-643M14.1	4.12	6.12e-05	0.0223	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:62013385	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs11629645	ENSG00000259251.2	RP11-643M14.1	4.12	6.12e-05	0.0223	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:62014275	chr15:62060503~62062434:+
PCPG	cis	rs9400467	0.568	rs4947121	ENSG00000255389.1	C6orf3	4.12	6.12e-05	0.0223	0.4	0.32	Amino acid levels;Blood metabolite levels;	chr6:111513751	chr6:111599875~111602295:+
PCPG	cis	rs7589728	0.858	rs1914734	ENSG00000243290.1	IGKV1-12	-4.12	6.13e-05	0.0223	-0.41	-0.32	Plasma clusterin levels;	chr2:88229990	chr2:89040224~89040745:-
PCPG	cis	rs301901	0.634	rs4869429	ENSG00000250155.1	CTD-2353F22.1	4.12	6.13e-05	0.0223	0.37	0.32	Height;	chr5:37407777	chr5:36666214~36725195:-
PCPG	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-4.12	6.13e-05	0.0224	-0.28	-0.32	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
PCPG	cis	rs8067354	0.789	rs1292068	ENSG00000259349.1	RP11-15E18.1	-4.12	6.14e-05	0.0224	-0.45	-0.32	Hemoglobin concentration;	chr17:59851958	chr17:60526293~60550798:+
PCPG	cis	rs7017914	0.69	rs7837005	ENSG00000254031.4	RP11-326E22.1	4.12	6.14e-05	0.0224	0.32	0.32	Bone mineral density;	chr8:71086797	chr8:71155457~71204223:+
PCPG	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	4.12	6.14e-05	0.0224	0.37	0.32	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
PCPG	cis	rs757282	0.679	rs2524319	ENSG00000258024.1	OR5BT1P	4.12	6.14e-05	0.0224	0.45	0.32	Optic nerve measurement (cup-to-disc ratio);	chr12:47682519	chr12:48385417~48386265:-
PCPG	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-4.12	6.15e-05	0.0224	-0.4	-0.32	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
PCPG	cis	rs7610312	0.681	rs6445972	ENSG00000273493.1	RP11-80H18.4	-4.12	6.15e-05	0.0224	-0.37	-0.32	Red blood cell count;	chr3:58335980	chr3:58329965~58330118:+
PCPG	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-4.12	6.15e-05	0.0224	-0.38	-0.32	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
PCPG	cis	rs747687	0.536	rs7215355	ENSG00000262133.1	RP11-676J12.6	4.12	6.16e-05	0.0224	0.59	0.32	Blood pressure;	chr17:866908	chr17:877902~880093:+
PCPG	cis	rs4819052	0.851	rs7276103	ENSG00000215447.6	BX322557.10	-4.12	6.17e-05	0.0225	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45288052~45291738:+
PCPG	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	4.12	6.17e-05	0.0225	0.31	0.32	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
PCPG	cis	rs728616	0.764	rs61859016	ENSG00000242600.5	MBL1P	4.12	6.17e-05	0.0225	0.63	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:79904898~79950336:+
PCPG	cis	rs875971	0.862	rs6955837	ENSG00000235475.1	LINC01372	-4.12	6.17e-05	0.0225	-0.33	-0.32	Aortic root size;	chr7:66578155	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.825	rs10281499	ENSG00000235475.1	LINC01372	-4.12	6.17e-05	0.0225	-0.33	-0.32	Aortic root size;	chr7:66583979	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs4718377	ENSG00000235475.1	LINC01372	-4.12	6.17e-05	0.0225	-0.33	-0.32	Aortic root size;	chr7:66584691	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs10278014	ENSG00000235475.1	LINC01372	-4.12	6.17e-05	0.0225	-0.33	-0.32	Aortic root size;	chr7:66586277	chr7:67335976~67340024:+
PCPG	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	4.12	6.17e-05	0.0225	0.45	0.32	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
PCPG	cis	rs875971	0.862	rs778686	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66370923	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.767	rs1643394	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66371107	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778684	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66371416	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778680	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66375427	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs11769079	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66377141	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs1695820	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66379576	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.83	rs778715	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66384222	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.83	rs809025	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66384832	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs778702	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66399848	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs1643375	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66407690	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6962717	ENSG00000235475.1	LINC01372	4.12	6.18e-05	0.0225	0.33	0.32	Aortic root size;	chr7:66418748	chr7:67335976~67340024:+
PCPG	cis	rs12882718	0.565	rs11626838	ENSG00000205562.2	RP11-497E19.1	4.12	6.18e-05	0.0225	0.37	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr14:86440027	chr14:85524432~85529988:-
PCPG	cis	rs896854	0.654	rs10429443	ENSG00000272509.1	RP11-347C18.5	4.12	6.18e-05	0.0225	0.32	0.32	Type 2 diabetes;	chr8:94958936	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.654	rs896846	ENSG00000272509.1	RP11-347C18.5	4.12	6.18e-05	0.0225	0.32	0.32	Type 2 diabetes;	chr8:94960225	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.654	rs896847	ENSG00000272509.1	RP11-347C18.5	4.12	6.18e-05	0.0225	0.32	0.32	Type 2 diabetes;	chr8:94960323	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.654	rs13281625	ENSG00000272509.1	RP11-347C18.5	4.12	6.18e-05	0.0225	0.32	0.32	Type 2 diabetes;	chr8:94960510	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.625	rs13281709	ENSG00000272509.1	RP11-347C18.5	4.12	6.18e-05	0.0225	0.32	0.32	Type 2 diabetes;	chr8:94960591	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.654	rs13278601	ENSG00000272509.1	RP11-347C18.5	4.12	6.18e-05	0.0225	0.32	0.32	Type 2 diabetes;	chr8:94960746	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.625	rs4735335	ENSG00000272509.1	RP11-347C18.5	4.12	6.18e-05	0.0225	0.32	0.32	Type 2 diabetes;	chr8:94961099	chr8:94884609~94885070:+
PCPG	cis	rs5742933	0.597	rs6756913	ENSG00000273240.1	RP11-455J20.3	4.12	6.19e-05	0.0225	0.35	0.32	Ferritin levels;	chr2:189641040	chr2:189763859~189764456:-
PCPG	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-4.12	6.19e-05	0.0225	-0.43	-0.32	Temperament;	chr17:14033087	chr17:14024514~14025488:+
PCPG	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	4.12	6.19e-05	0.0225	0.4	0.32	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
PCPG	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	4.12	6.19e-05	0.0225	0.38	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
PCPG	cis	rs17772222	0.917	rs61983300	ENSG00000222990.1	RNU4-22P	4.12	6.19e-05	0.0225	0.41	0.32	Coronary artery calcification;	chr14:88754047	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.876	rs78068036	ENSG00000222990.1	RNU4-22P	4.12	6.19e-05	0.0225	0.41	0.32	Coronary artery calcification;	chr14:88754817	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs11159868	ENSG00000222990.1	RNU4-22P	4.12	6.19e-05	0.0225	0.41	0.32	Coronary artery calcification;	chr14:88760528	chr14:88513498~88513663:+
PCPG	cis	rs72615157	0.634	rs11762932	ENSG00000242294.5	STAG3L5P	-4.12	6.19e-05	0.0225	-0.27	-0.32	Lung function (FEV1/FVC);	chr7:100195043	chr7:100336079~100351900:+
PCPG	cis	rs761746	0.739	rs5994420	ENSG00000128254.12	C22orf24	-4.12	6.19e-05	0.0225	-0.42	-0.32	Intelligence;	chr22:31674765	chr22:31933521~31945518:-
PCPG	cis	rs728616	0.867	rs61859022	ENSG00000242600.5	MBL1P	4.12	6.19e-05	0.0225	0.63	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79904898~79950336:+
PCPG	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-4.12	6.2e-05	0.0225	-0.25	-0.32	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
PCPG	cis	rs728616	0.867	rs7080405	ENSG00000242600.5	MBL1P	4.12	6.2e-05	0.0225	0.7	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:79904898~79950336:+
PCPG	cis	rs116248771	0.696	rs16847123	ENSG00000272087.1	RP11-379F4.7	4.12	6.2e-05	0.0226	0.49	0.32	diarrhoeal disease at age 2;	chr3:158698348	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.69	rs73156490	ENSG00000272087.1	RP11-379F4.7	4.12	6.2e-05	0.0226	0.49	0.32	diarrhoeal disease at age 2;	chr3:158698695	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.69	rs73156491	ENSG00000272087.1	RP11-379F4.7	4.12	6.2e-05	0.0226	0.49	0.32	diarrhoeal disease at age 2;	chr3:158698783	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.69	rs73156492	ENSG00000272087.1	RP11-379F4.7	4.12	6.2e-05	0.0226	0.49	0.32	diarrhoeal disease at age 2;	chr3:158699010	chr3:158693120~158693768:-
PCPG	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-4.12	6.2e-05	0.0226	-0.42	-0.32	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
PCPG	cis	rs62246343	0.572	rs62246311	ENSG00000254485.4	RP11-380O24.1	4.12	6.2e-05	0.0226	0.55	0.32	Fibrinogen levels;	chr3:9456459	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.572	rs111979419	ENSG00000254485.4	RP11-380O24.1	4.12	6.2e-05	0.0226	0.55	0.32	Fibrinogen levels;	chr3:9457372	chr3:9292588~9363303:-
PCPG	cis	rs3020736	0.5	rs11090076	ENSG00000226450.2	CYP2D8P	-4.12	6.2e-05	0.0226	-0.32	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42149886~42155001:-
PCPG	cis	rs763014	0.966	rs35642938	ENSG00000262528.2	LA16c-349E10.1	4.12	6.2e-05	0.0226	0.37	0.32	Height;	chr16:592249	chr16:654611~656194:-
PCPG	cis	rs3764021	0.509	rs10772070	ENSG00000278635.1	CTD-2318O12.1	-4.12	6.2e-05	0.0226	-0.4	-0.32	Type 1 diabetes;	chr12:9717320	chr12:9415641~9416718:+
PCPG	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-4.12	6.21e-05	0.0226	-0.43	-0.32	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
PCPG	cis	rs301901	0.581	rs10941343	ENSG00000250155.1	CTD-2353F22.1	4.12	6.21e-05	0.0226	0.38	0.32	Height;	chr5:37543239	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.573	rs12652433	ENSG00000250155.1	CTD-2353F22.1	4.12	6.21e-05	0.0226	0.38	0.32	Height;	chr5:37543358	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.581	rs6881383	ENSG00000250155.1	CTD-2353F22.1	4.12	6.21e-05	0.0226	0.38	0.32	Height;	chr5:37545897	chr5:36666214~36725195:-
PCPG	cis	rs853679	0.567	rs6905380	ENSG00000219392.1	RP1-265C24.5	-4.12	6.21e-05	0.0226	-0.44	-0.32	Depression;	chr6:28407125	chr6:28115628~28116551:+
PCPG	cis	rs1635	0.574	rs73400572	ENSG00000216901.1	AL022393.7	4.12	6.21e-05	0.0226	0.86	0.32	Schizophrenia;	chr6:28211745	chr6:28176188~28176674:+
PCPG	cis	rs11148252	0.553	rs2147692	ENSG00000273784.3	RP11-78J21.7	-4.12	6.22e-05	0.0226	-0.3	-0.32	Lewy body disease;	chr13:52712888	chr13:52600042~52642542:+
PCPG	cis	rs7444	0.941	rs140489	ENSG00000211645.2	IGLV1-50	4.12	6.22e-05	0.0226	0.37	0.32	Systemic lupus erythematosus;	chr22:21567005	chr22:22327300~22327814:+
PCPG	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	4.12	6.22e-05	0.0226	0.4	0.32	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
PCPG	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	4.12	6.22e-05	0.0226	0.39	0.32	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
PCPG	cis	rs9299346	0.62	rs2209064	ENSG00000225376.4	TMEM246-AS1	4.12	6.22e-05	0.0226	0.39	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101673152	chr9:101468439~101481502:+
PCPG	cis	rs7714584	1	rs11747270	ENSG00000271795.1	CTC-251D13.1	4.12	6.22e-05	0.0226	0.6	0.32	Crohn's disease;	chr5:150879305	chr5:151509453~151512769:+
PCPG	cis	rs425277	1	rs436045	ENSG00000271806.1	RP5-892K4.1	-4.12	6.23e-05	0.0226	-0.38	-0.32	Height;	chr1:2140117	chr1:2141084~2145279:-
PCPG	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-4.12	6.23e-05	0.0226	-0.47	-0.32	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
PCPG	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	4.12	6.23e-05	0.0226	0.75	0.32	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
PCPG	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-4.12	6.23e-05	0.0226	-0.37	-0.32	Height;	chr5:37068442	chr5:36666214~36725195:-
PCPG	cis	rs6598541	0.963	rs12898337	ENSG00000278022.1	RP11-35O15.2	4.12	6.23e-05	0.0227	0.3	0.32	Urate levels;	chr15:98751126	chr15:98660210~98660668:+
PCPG	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	4.12	6.24e-05	0.0227	0.33	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
PCPG	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	4.12	6.24e-05	0.0227	0.33	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
PCPG	cis	rs2733954	0.806	rs301160	ENSG00000179219.5	LINC00311	-4.12	6.24e-05	0.0227	-0.44	-0.32	Leprosy;	chr16:85776251	chr16:85282958~85285963:+
PCPG	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-4.12	6.24e-05	0.0227	-0.46	-0.32	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
PCPG	cis	rs1003719	0.715	rs13046581	ENSG00000228677.1	TTC3-AS1	-4.12	6.24e-05	0.0227	-0.39	-0.32	Eye color traits;	chr21:37179683	chr21:37187666~37193926:-
PCPG	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	4.12	6.24e-05	0.0227	0.32	0.32	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
PCPG	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	4.12	6.25e-05	0.0227	0.52	0.32	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
PCPG	cis	rs5743030	0.702	rs256567	ENSG00000253559.1	OSGEPL1-AS1	-4.12	6.25e-05	0.0227	-0.49	-0.32	Subcutaneous adipose tissue;	chr2:189862805	chr2:189762704~189765556:+
PCPG	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.12	6.26e-05	0.0227	0.4	0.32	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.12	6.26e-05	0.0227	0.4	0.32	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
PCPG	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.12	6.26e-05	0.0227	0.4	0.32	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
PCPG	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	4.12	6.26e-05	0.0227	0.55	0.32	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
PCPG	cis	rs1865760	0.566	rs2051544	ENSG00000272810.1	U91328.22	-4.12	6.26e-05	0.0227	-0.33	-0.32	Height;	chr6:26070865	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs9379825	ENSG00000272810.1	U91328.22	-4.12	6.26e-05	0.0227	-0.33	-0.32	Height;	chr6:26083643	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs9467672	ENSG00000272810.1	U91328.22	-4.12	6.26e-05	0.0227	-0.33	-0.32	Height;	chr6:26083676	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs9295688	ENSG00000272810.1	U91328.22	-4.12	6.26e-05	0.0227	-0.33	-0.32	Height;	chr6:26083989	chr6:26013241~26013757:+
PCPG	cis	rs324126	0.78	rs62108319	ENSG00000277977.1	CTD-3018O17.5	4.12	6.26e-05	0.0227	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.78	rs62108320	ENSG00000277977.1	CTD-3018O17.5	4.12	6.26e-05	0.0227	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52392659~52392755:+
PCPG	cis	rs324126	0.752	rs62108321	ENSG00000277977.1	CTD-3018O17.5	4.12	6.26e-05	0.0227	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52392659~52392755:+
PCPG	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	-4.12	6.26e-05	0.0227	-0.36	-0.32	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
PCPG	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	4.12	6.26e-05	0.0227	0.47	0.32	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
PCPG	cis	rs17270561	0.562	rs12199626	ENSG00000272810.1	U91328.22	-4.12	6.27e-05	0.0228	-0.41	-0.32	Iron status biomarkers;	chr6:26013376	chr6:26013241~26013757:+
PCPG	cis	rs11858159	0.627	rs8032288	ENSG00000260760.1	PWRN3	4.12	6.27e-05	0.0228	0.34	0.32	Platelet thrombus formation;	chr15:24540281	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.812	rs8033597	ENSG00000260760.1	PWRN3	4.12	6.27e-05	0.0228	0.34	0.32	Platelet thrombus formation;	chr15:24540282	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.603	rs8033605	ENSG00000260760.1	PWRN3	4.12	6.27e-05	0.0228	0.34	0.32	Platelet thrombus formation;	chr15:24540294	chr15:24441127~24447967:+
PCPG	cis	rs11148252	0.538	rs3368	ENSG00000235660.1	LINC00345	-4.12	6.27e-05	0.0228	-0.39	-0.32	Lewy body disease;	chr13:52133104	chr13:52484161~52484680:-
PCPG	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-4.12	6.27e-05	0.0228	-0.38	-0.32	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
PCPG	cis	rs8098244	0.557	rs12185288	ENSG00000265752.2	RP11-403A21.1	4.12	6.27e-05	0.0228	0.36	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732782	chr18:23957754~23982556:-
PCPG	cis	rs6137473	0.621	rs201576	ENSG00000227063.5	RPL41P1	-4.12	6.28e-05	0.0228	-0.35	-0.32	Adolescent idiopathic scoliosis;	chr20:22036558	chr20:21755270~21755350:+
PCPG	cis	rs6456042	0.893	rs3127440	ENSG00000231297.3	RP11-459F1.2	4.12	6.28e-05	0.0228	0.35	0.32	Asthma;	chr6:166145462	chr6:166099665~166113273:+
PCPG	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-4.12	6.28e-05	0.0228	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
PCPG	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-4.12	6.28e-05	0.0228	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
PCPG	cis	rs2732480	0.577	rs2732448	ENSG00000240399.1	RP1-228P16.1	4.12	6.28e-05	0.0228	0.34	0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48054813~48055591:-
PCPG	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-4.12	6.28e-05	0.0228	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
PCPG	cis	rs7208859	0.524	rs73263982	ENSG00000266490.1	CTD-2349P21.9	4.12	6.28e-05	0.0228	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30792372~30792833:+
PCPG	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	4.12	6.28e-05	0.0228	0.66	0.32	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
PCPG	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	4.12	6.28e-05	0.0228	0.53	0.32	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
PCPG	cis	rs60695258	0.55	rs340641	ENSG00000251411.1	RP11-397E7.4	4.12	6.28e-05	0.0228	0.29	0.32	Hematocrit;	chr4:87030241	chr4:86913266~86914817:-
PCPG	cis	rs9299346	0.521	rs10819982	ENSG00000225376.4	TMEM246-AS1	4.12	6.29e-05	0.0228	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101720847	chr9:101468439~101481502:+
PCPG	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
PCPG	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
PCPG	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	4.12	6.29e-05	0.0228	0.38	0.32	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
PCPG	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	4.12	6.29e-05	0.0228	0.25	0.32	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
PCPG	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-4.12	6.29e-05	0.0228	-0.36	-0.32	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
PCPG	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-4.12	6.29e-05	0.0228	-0.36	-0.32	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
PCPG	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	4.12	6.3e-05	0.0228	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-4.12	6.3e-05	0.0228	-0.42	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
PCPG	cis	rs11671324	1	rs11671324	ENSG00000268678.1	CTC-444N24.13	-4.12	6.3e-05	0.0228	-0.75	-0.32	Positive affect;	chr19:57004035	chr19:57350848~57352012:-
PCPG	cis	rs11858159	1	rs6576331	ENSG00000260760.1	PWRN3	4.12	6.3e-05	0.0228	0.34	0.32	Platelet thrombus formation;	chr15:24545022	chr15:24441127~24447967:+
PCPG	cis	rs6456042	0.965	rs3127425	ENSG00000231297.3	RP11-459F1.2	4.12	6.3e-05	0.0228	0.35	0.32	Asthma;	chr6:166125739	chr6:166099665~166113273:+
PCPG	cis	rs6456042	0.965	rs6927190	ENSG00000231297.3	RP11-459F1.2	4.12	6.3e-05	0.0228	0.35	0.32	Asthma;	chr6:166126051	chr6:166099665~166113273:+
PCPG	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-4.12	6.3e-05	0.0228	-0.48	-0.32	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
PCPG	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	4.12	6.3e-05	0.0228	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
PCPG	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-4.12	6.3e-05	0.0228	-0.52	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
PCPG	cis	rs10751667	0.643	rs10794350	ENSG00000255142.1	AP006621.6	4.12	6.31e-05	0.0229	0.31	0.32	Alzheimer's disease (late onset);	chr11:946070	chr11:781645~782105:+
PCPG	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-4.12	6.31e-05	0.0229	-0.47	-0.32	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
PCPG	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	4.12	6.31e-05	0.0229	0.41	0.32	Height;	chr6:109355573	chr6:109382795~109383666:+
PCPG	cis	rs9303029	1	rs9303029	ENSG00000279744.1	RP13-20L14.10	-4.12	6.31e-05	0.0229	-0.41	-0.32	Protein quantitative trait loci;	chr17:82450939	chr17:82462601~82464255:+
PCPG	cis	rs12079745	0.59	rs3766088	ENSG00000234604.2	RP1-206D15.5	-4.12	6.32e-05	0.0229	-0.65	-0.32	QT interval;	chr1:169299454	chr1:169474060~169474159:-
PCPG	cis	rs590820	0.72	rs584751	ENSG00000223635.1	RP4-613A2.1	4.12	6.32e-05	0.0229	0.38	0.32	Metabolite levels (lipoprotein measures);	chr1:230187001	chr1:229508501~229514272:+
PCPG	cis	rs9303542	0.559	rs12939811	ENSG00000279036.1	RP11-81K2.2	-4.12	6.32e-05	0.0229	-0.52	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48530596	chr17:49494223~49497800:-
PCPG	cis	rs8064024	0.604	rs1049212	ENSG00000267077.1	RP11-127I20.5	-4.12	6.32e-05	0.0229	-0.38	-0.32	Cancer;	chr16:4882928	chr16:4795265~4796532:-
PCPG	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-4.12	6.32e-05	0.0229	-0.37	-0.32	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
PCPG	cis	rs9302635	0.513	rs13334151	ENSG00000260886.1	TAT-AS1	4.12	6.33e-05	0.0229	0.46	0.32	Blood protein levels;	chr16:72155828	chr16:71565789~71578187:+
PCPG	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-4.12	6.33e-05	0.0229	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
PCPG	cis	rs4958581	0.932	rs35239101	ENSG00000254226.4	CTB-12O2.1	-4.12	6.33e-05	0.0229	-0.44	-0.32	Subjective well-being;	chr5:152814618	chr5:151949571~152270448:+
PCPG	cis	rs4958581	0.932	rs4077752	ENSG00000254226.4	CTB-12O2.1	-4.12	6.33e-05	0.0229	-0.44	-0.32	Subjective well-being;	chr5:152815317	chr5:151949571~152270448:+
PCPG	cis	rs4958581	0.932	rs4077753	ENSG00000254226.4	CTB-12O2.1	-4.12	6.33e-05	0.0229	-0.44	-0.32	Subjective well-being;	chr5:152815348	chr5:151949571~152270448:+
PCPG	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-4.12	6.33e-05	0.0229	-0.47	-0.32	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
PCPG	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-4.12	6.33e-05	0.0229	-0.25	-0.32	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
PCPG	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-4.12	6.33e-05	0.0229	-0.25	-0.32	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
PCPG	cis	rs2098713	0.536	rs2366419	ENSG00000250155.1	CTD-2353F22.1	4.12	6.33e-05	0.0229	0.38	0.32	Telomere length;	chr5:37529948	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.729	rs217781	ENSG00000250155.1	CTD-2353F22.1	-4.12	6.34e-05	0.0229	-0.37	-0.32	Height;	chr5:37344444	chr5:36666214~36725195:-
PCPG	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	4.12	6.34e-05	0.0229	0.42	0.32	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
PCPG	cis	rs875971	0.862	rs1860469	ENSG00000235475.1	LINC01372	-4.12	6.34e-05	0.0229	-0.34	-0.32	Aortic root size;	chr7:66641888	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs4718383	ENSG00000235475.1	LINC01372	-4.12	6.34e-05	0.0229	-0.34	-0.32	Aortic root size;	chr7:66643422	chr7:67335976~67340024:+
PCPG	cis	rs6657613	0.503	rs9435739	ENSG00000186715.9	MST1L	4.12	6.34e-05	0.023	0.37	0.32	Hip circumference adjusted for BMI;	chr1:17016429	chr1:16754910~16770237:-
PCPG	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-4.12	6.34e-05	0.023	-0.37	-0.32	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
PCPG	cis	rs12291225	0.753	rs1431374	ENSG00000251991.1	RNU7-49P	4.12	6.34e-05	0.023	0.37	0.32	Sense of smell;	chr11:14282429	chr11:14478892~14478953:+
PCPG	cis	rs240993	0.812	rs7764543	ENSG00000230177.1	RP5-1112D6.4	-4.12	6.34e-05	0.023	-0.39	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111277932~111278742:+
PCPG	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-4.12	6.35e-05	0.023	-0.47	-0.32	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
PCPG	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	4.12	6.35e-05	0.023	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	4.12	6.35e-05	0.023	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
PCPG	cis	rs1440410	0.835	rs11100780	ENSG00000250326.1	RP11-284M14.1	4.12	6.35e-05	0.023	0.29	0.32	Ischemic stroke;	chr4:143183753	chr4:142933195~143184861:-
PCPG	cis	rs11148252	0.84	rs4369550	ENSG00000198384.8	TPTE2P3	-4.12	6.35e-05	0.023	-0.39	-0.32	Lewy body disease;	chr13:52170775	chr13:52522632~52586906:+
PCPG	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	4.12	6.35e-05	0.023	0.33	0.32	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
PCPG	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	4.12	6.35e-05	0.023	0.41	0.32	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
PCPG	cis	rs2243480	1	rs464895	ENSG00000251451.1	GS1-124K5.6	4.12	6.35e-05	0.023	0.6	0.32	Diabetic kidney disease;	chr7:66062119	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs160633	ENSG00000251451.1	GS1-124K5.6	4.12	6.35e-05	0.023	0.6	0.32	Diabetic kidney disease;	chr7:66063241	chr7:66407288~66409239:-
PCPG	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-4.12	6.36e-05	0.023	-0.43	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
PCPG	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-4.12	6.36e-05	0.023	-0.37	-0.32	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
PCPG	cis	rs7911712	0.745	rs11239239	ENSG00000228462.1	RP11-445N18.3	4.12	6.36e-05	0.023	0.46	0.32	Emphysema-related traits;	chr10:44767033	chr10:45073146~45073541:-
PCPG	cis	rs6929812	0.702	rs4713096	ENSG00000271755.1	RP1-153G14.4	-4.12	6.36e-05	0.023	-0.41	-0.32	Neuroticism (multi-trait analysis);	chr6:27411630	chr6:27404010~27406964:-
PCPG	cis	rs853679	0.567	rs16894091	ENSG00000219392.1	RP1-265C24.5	4.12	6.36e-05	0.023	0.43	0.32	Depression;	chr6:28422360	chr6:28115628~28116551:+
PCPG	cis	rs17684571	0.751	rs7761729	ENSG00000231441.1	RP11-472M19.2	4.11	6.37e-05	0.023	0.51	0.32	Schizophrenia;	chr6:56846478	chr6:56844002~56864078:+
PCPG	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	4.11	6.37e-05	0.023	0.42	0.32	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
PCPG	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	4.11	6.37e-05	0.023	0.25	0.32	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
PCPG	cis	rs4934494	0.768	rs34663515	ENSG00000240996.1	RP11-80H5.7	-4.11	6.37e-05	0.023	-0.48	-0.32	Red blood cell count;	chr10:89632786	chr10:89694295~89697928:-
PCPG	cis	rs7246657	0.525	rs10401417	ENSG00000226686.6	LINC01535	-4.11	6.37e-05	0.0231	-0.62	-0.32	Coronary artery calcification;	chr19:36976638	chr19:37251912~37265535:+
PCPG	cis	rs4512344	0.509	rs2409784	ENSG00000270154.1	RP11-419I17.1	-4.11	6.38e-05	0.0231	-0.37	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12476462~12477122:+
PCPG	cis	rs2665103	0.715	rs16973457	ENSG00000228141.5	AC105339.1	-4.11	6.38e-05	0.0231	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82710471~82714026:-
PCPG	cis	rs6579956	0.565	rs4460127	ENSG00000254226.4	CTB-12O2.1	-4.11	6.38e-05	0.0231	-0.42	-0.32	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152804188	chr5:151949571~152270448:+
PCPG	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-4.11	6.38e-05	0.0231	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
PCPG	cis	rs950169	0.763	rs35372971	ENSG00000235370.6	DNM1P51	4.11	6.38e-05	0.0231	0.35	0.32	Schizophrenia;	chr15:84387097	chr15:84398316~84411701:-
PCPG	cis	rs11858159	1	rs7402589	ENSG00000260760.1	PWRN3	4.11	6.39e-05	0.0231	0.35	0.32	Platelet thrombus formation;	chr15:24574029	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs12902956	ENSG00000260760.1	PWRN3	4.11	6.39e-05	0.0231	0.35	0.32	Platelet thrombus formation;	chr15:24577019	chr15:24441127~24447967:+
PCPG	cis	rs11638352	1	rs2706473	ENSG00000205771.5	CATSPER2P1	4.11	6.4e-05	0.0231	0.58	0.32	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44125537	chr15:43726918~43747094:-
PCPG	cis	rs4819052	0.851	rs8133045	ENSG00000215447.6	BX322557.10	-4.11	6.41e-05	0.0232	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45288052~45291738:+
PCPG	cis	rs1370156	0.899	rs12439785	ENSG00000261559.1	FSCN1P1	-4.11	6.41e-05	0.0232	-0.3	-0.32	Myopia;	chr15:34706448	chr15:34494420~34495900:+
PCPG	cis	rs2836974	0.897	rs35386515	ENSG00000252915.1	Y_RNA	-4.11	6.41e-05	0.0232	-0.34	-0.32	Cognitive function;	chr21:39160121	chr21:39344537~39344628:+
PCPG	cis	rs7246657	0.943	rs2279148	ENSG00000226686.6	LINC01535	-4.11	6.42e-05	0.0232	-0.5	-0.32	Coronary artery calcification;	chr19:37533781	chr19:37251912~37265535:+
PCPG	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-4.11	6.43e-05	0.0232	-0.37	-0.32	Height;	chr5:36941456	chr5:36666214~36725195:-
PCPG	cis	rs6929812	0.702	rs10946918	ENSG00000271755.1	RP1-153G14.4	4.11	6.43e-05	0.0232	0.41	0.32	Neuroticism (multi-trait analysis);	chr6:27413214	chr6:27404010~27406964:-
PCPG	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-4.11	6.43e-05	0.0232	-0.37	-0.32	Height;	chr5:37081780	chr5:36666214~36725195:-
PCPG	cis	rs11220082	0.787	rs34632138	ENSG00000254671.2	STT3A-AS1	-4.11	6.43e-05	0.0232	-0.34	-0.32	Schizophrenia;	chr11:125428402	chr11:125570284~125592568:-
PCPG	cis	rs2243480	0.908	rs4718273	ENSG00000251451.1	GS1-124K5.6	-4.11	6.43e-05	0.0232	-0.6	-0.32	Diabetic kidney disease;	chr7:65751112	chr7:66407288~66409239:-
PCPG	cis	rs748404	0.666	rs12899865	ENSG00000205771.5	CATSPER2P1	-4.11	6.44e-05	0.0232	-0.4	-0.32	Lung cancer;	chr15:43448819	chr15:43726918~43747094:-
PCPG	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-4.11	6.44e-05	0.0232	-0.39	-0.32	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
PCPG	cis	rs394563	0.601	rs391875	ENSG00000231760.4	RP11-350J20.5	4.11	6.44e-05	0.0233	0.39	0.32	Dupuytren's disease;	chr6:149474000	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.601	rs376269	ENSG00000231760.4	RP11-350J20.5	4.11	6.44e-05	0.0233	0.39	0.32	Dupuytren's disease;	chr6:149474018	chr6:149796151~149826294:-
PCPG	cis	rs5743030	0.702	rs256554	ENSG00000253559.1	OSGEPL1-AS1	-4.11	6.44e-05	0.0233	-0.5	-0.32	Subcutaneous adipose tissue;	chr2:189874288	chr2:189762704~189765556:+
PCPG	cis	rs228614	0.509	rs223486	ENSG00000230069.3	LRRC37A15P	-4.11	6.44e-05	0.0233	-0.29	-0.32	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102727274~102730721:-
PCPG	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-4.11	6.44e-05	0.0233	-0.39	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
PCPG	cis	rs7945705	0.791	rs10769958	ENSG00000254860.4	TMEM9B-AS1	4.11	6.45e-05	0.0233	0.31	0.32	Hemoglobin concentration;	chr11:8793568	chr11:8964675~8977527:+
PCPG	cis	rs7945705	0.738	rs11042067	ENSG00000254860.4	TMEM9B-AS1	4.11	6.45e-05	0.0233	0.31	0.32	Hemoglobin concentration;	chr11:8793906	chr11:8964675~8977527:+
PCPG	cis	rs2882667	0.638	rs2351905	ENSG00000222937.1	SNORD63	4.11	6.45e-05	0.0233	0.28	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138558970~138559039:-
PCPG	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-4.11	6.45e-05	0.0233	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-4.11	6.45e-05	0.0233	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
PCPG	cis	rs4919687	0.514	rs3850699	ENSG00000269609.4	RPARP-AS1	-4.11	6.46e-05	0.0233	-0.27	-0.32	Colorectal cancer;	chr10:102654464	chr10:102449817~102461106:+
PCPG	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	4.11	6.46e-05	0.0233	0.3	0.32	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
PCPG	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-4.11	6.46e-05	0.0233	-0.54	-0.32	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
PCPG	cis	rs12928939	0.723	rs34053338	ENSG00000260886.1	TAT-AS1	4.11	6.46e-05	0.0233	0.42	0.32	Post bronchodilator FEV1;	chr16:71816071	chr16:71565789~71578187:+
PCPG	cis	rs12928939	0.768	rs11861296	ENSG00000260886.1	TAT-AS1	4.11	6.46e-05	0.0233	0.42	0.32	Post bronchodilator FEV1;	chr16:71816729	chr16:71565789~71578187:+
PCPG	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-4.11	6.46e-05	0.0233	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
PCPG	cis	rs1823874	0.584	rs9806196	ENSG00000182397.13	DNM1P46	-4.11	6.46e-05	0.0233	-0.44	-0.32	IgG glycosylation;	chr15:99842201	chr15:99790156~99806927:-
PCPG	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-4.11	6.46e-05	0.0233	-0.42	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
PCPG	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	4.11	6.47e-05	0.0233	0.36	0.32	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
PCPG	cis	rs7208859	0.673	rs999797	ENSG00000263603.1	CTD-2349P21.5	-4.11	6.47e-05	0.0234	-0.62	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30729469~30731202:+
PCPG	cis	rs7247513	0.964	rs1007352	ENSG00000213290.4	PGK1P2	-4.11	6.48e-05	0.0234	-0.45	-0.32	Bipolar disorder;	chr19:12611731	chr19:12559571~12561105:+
PCPG	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-4.11	6.48e-05	0.0234	-0.4	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
PCPG	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	4.11	6.48e-05	0.0234	0.42	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
PCPG	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-4.11	6.48e-05	0.0234	-0.45	-0.32	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
PCPG	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-4.11	6.48e-05	0.0234	-0.4	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
PCPG	cis	rs7772486	0.623	rs735535	ENSG00000270638.1	RP3-466P17.1	-4.11	6.49e-05	0.0234	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.566	rs735536	ENSG00000270638.1	RP3-466P17.1	-4.11	6.49e-05	0.0234	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145735570~145737218:+
PCPG	cis	rs13108904	0.87	rs1564508	ENSG00000254094.1	AC078852.1	-4.11	6.49e-05	0.0234	-0.38	-0.32	Obesity-related traits;	chr4:1251091	chr4:1356581~1358075:+
PCPG	cis	rs4237845	0.78	rs3751331	ENSG00000257698.1	RP11-620J15.3	-4.11	6.49e-05	0.0234	-0.29	-0.32	Intelligence (multi-trait analysis);	chr12:57896495	chr12:57931528~57936175:-
PCPG	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	4.11	6.49e-05	0.0234	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	4.11	6.49e-05	0.0234	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	4.11	6.49e-05	0.0234	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
PCPG	cis	rs847649	1	rs847649	ENSG00000252643.1	RNU6-1136P	-4.11	6.49e-05	0.0234	-0.38	-0.32	Morning vs. evening chronotype;	chr7:102915564	chr7:102834605~102834708:+
PCPG	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-4.11	6.5e-05	0.0234	-0.37	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
PCPG	cis	rs4376189	0.614	rs6826210	ENSG00000207497.1	Y_RNA	-4.11	6.5e-05	0.0234	-0.45	-0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185715777	chr4:185709873~185709967:-
PCPG	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-4.11	6.5e-05	0.0234	-0.29	-0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
PCPG	cis	rs6570726	0.818	rs952405	ENSG00000270638.1	RP3-466P17.1	4.11	6.5e-05	0.0234	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145735570~145737218:+
PCPG	cis	rs6570726	0.846	rs4896824	ENSG00000270638.1	RP3-466P17.1	4.11	6.5e-05	0.0234	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145735570~145737218:+
PCPG	cis	rs3198697	1	rs3198697	ENSG00000260872.1	RP11-680G24.5	4.11	6.5e-05	0.0234	0.35	0.32	Triglycerides;	chr16:15036083	chr16:15018106~15020488:-
PCPG	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-4.11	6.5e-05	0.0234	-0.31	-0.32	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
PCPG	cis	rs181553	0.545	rs35807361	ENSG00000278983.1	RP11-426J5.3	4.11	6.51e-05	0.0234	0.32	0.32	Hip circumference adjusted for BMI;	chr18:49045766	chr18:48564795~48568342:+
PCPG	cis	rs12194062	0.524	rs270037	ENSG00000220694.2	RP3-403A15.1	-4.11	6.51e-05	0.0235	-0.37	-0.32	QRS duration;	chr6:127860327	chr6:127435636~127436189:+
PCPG	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-4.11	6.51e-05	0.0235	-0.25	-0.32	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
PCPG	cis	rs6121246	0.657	rs74392247	ENSG00000230613.1	HM13-AS1	4.11	6.51e-05	0.0235	0.49	0.32	Mean corpuscular hemoglobin;	chr20:31653934	chr20:31567707~31573263:-
PCPG	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	4.11	6.51e-05	0.0235	0.45	0.32	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
PCPG	cis	rs2439831	0.867	rs12323999	ENSG00000205771.5	CATSPER2P1	-4.11	6.52e-05	0.0235	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43390917	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2584702	ENSG00000205771.5	CATSPER2P1	-4.11	6.52e-05	0.0235	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43392716	chr15:43726918~43747094:-
PCPG	cis	rs4819052	0.788	rs9978857	ENSG00000223768.1	LINC00205	-4.11	6.52e-05	0.0235	-0.38	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45293285~45297354:+
PCPG	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	4.11	6.52e-05	0.0235	0.36	0.32	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	4.11	6.52e-05	0.0235	0.36	0.32	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	4.11	6.52e-05	0.0235	0.36	0.32	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
PCPG	cis	rs4143844	1	rs62006969	ENSG00000259251.2	RP11-643M14.1	4.11	6.53e-05	0.0235	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:62001213	chr15:62060503~62062434:+
PCPG	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	4.11	6.53e-05	0.0235	0.36	0.32	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
PCPG	cis	rs2836974	0.897	rs2026267	ENSG00000252915.1	Y_RNA	-4.11	6.53e-05	0.0235	-0.35	-0.32	Cognitive function;	chr21:39339551	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs35123057	ENSG00000252915.1	Y_RNA	-4.11	6.53e-05	0.0235	-0.35	-0.32	Cognitive function;	chr21:39339763	chr21:39344537~39344628:+
PCPG	cis	rs1048886	0.808	rs1534049	ENSG00000271967.1	RP11-134K13.4	-4.11	6.54e-05	0.0235	-0.4	-0.32	Type 2 diabetes;	chr6:70603491	chr6:70596438~70596980:+
PCPG	cis	rs6929812	0.628	rs4713097	ENSG00000271755.1	RP1-153G14.4	4.11	6.54e-05	0.0235	0.41	0.32	Neuroticism (multi-trait analysis);	chr6:27411768	chr6:27404010~27406964:-
PCPG	cis	rs2836974	0.681	rs8128827	ENSG00000252915.1	Y_RNA	-4.11	6.54e-05	0.0236	-0.35	-0.32	Cognitive function;	chr21:39338621	chr21:39344537~39344628:+
PCPG	cis	rs394563	0.601	rs432582	ENSG00000231760.4	RP11-350J20.5	4.11	6.54e-05	0.0236	0.39	0.32	Dupuytren's disease;	chr6:149473007	chr6:149796151~149826294:-
PCPG	cis	rs34421088	0.56	rs2245357	ENSG00000269954.1	RP11-148O21.6	-4.11	6.55e-05	0.0236	-0.37	-0.32	Neuroticism;	chr8:11541975	chr8:11552488~11552991:-
PCPG	cis	rs8098244	0.617	rs11872810	ENSG00000265752.2	RP11-403A21.1	4.11	6.55e-05	0.0236	0.36	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23823416	chr18:23957754~23982556:-
PCPG	cis	rs17507216	0.958	rs28648832	ENSG00000228141.5	AC105339.1	-4.11	6.55e-05	0.0236	-0.44	-0.32	Excessive daytime sleepiness;	chr15:82567642	chr15:82710471~82714026:-
PCPG	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	4.11	6.55e-05	0.0236	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
PCPG	cis	rs8098244	0.638	rs867448	ENSG00000265752.2	RP11-403A21.1	4.11	6.55e-05	0.0236	0.36	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23857757	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.638	rs12965685	ENSG00000265752.2	RP11-403A21.1	4.11	6.55e-05	0.0236	0.36	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23861753	chr18:23957754~23982556:-
PCPG	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	4.11	6.56e-05	0.0236	0.4	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
PCPG	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	4.11	6.56e-05	0.0236	0.4	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
PCPG	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-4.11	6.56e-05	0.0236	-0.4	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
PCPG	cis	rs425277	1	rs1401138	ENSG00000271806.1	RP5-892K4.1	4.11	6.56e-05	0.0236	0.37	0.32	Height;	chr1:2131710	chr1:2141084~2145279:-
PCPG	cis	rs4819052	0.724	rs1304487	ENSG00000215447.6	BX322557.10	4.11	6.56e-05	0.0236	0.32	0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45288052~45291738:+
PCPG	cis	rs3758911	0.861	rs10789621	ENSG00000255353.1	RP11-382M14.1	4.11	6.57e-05	0.0236	0.4	0.32	Coronary artery disease;	chr11:107388345	chr11:107176286~107177530:+
PCPG	cis	rs324126	0.78	rs10445583	ENSG00000277977.1	CTD-3018O17.5	4.11	6.57e-05	0.0236	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52392659~52392755:+
PCPG	cis	rs847649	1	rs847648	ENSG00000252643.1	RNU6-1136P	-4.11	6.57e-05	0.0236	-0.38	-0.32	Morning vs. evening chronotype;	chr7:102913403	chr7:102834605~102834708:+
PCPG	cis	rs2625529	0.586	rs7170456	ENSG00000260037.4	CTD-2524L6.3	4.11	6.57e-05	0.0236	0.42	0.32	Red blood cell count;	chr15:72177605	chr15:71818396~71823384:+
PCPG	cis	rs13276960	0.794	rs7833563	ENSG00000254281.1	KB-1507C5.4	4.11	6.57e-05	0.0236	0.39	0.32	Schizophrenia;	chr8:102932406	chr8:102978785~103000184:+
PCPG	cis	rs6121246	0.909	rs6060960	ENSG00000230613.1	HM13-AS1	-4.11	6.58e-05	0.0236	-0.45	-0.32	Mean corpuscular hemoglobin;	chr20:31806714	chr20:31567707~31573263:-
PCPG	cis	rs1440410	0.835	rs13150694	ENSG00000250326.1	RP11-284M14.1	4.11	6.58e-05	0.0236	0.3	0.32	Ischemic stroke;	chr4:143155900	chr4:142933195~143184861:-
PCPG	cis	rs728616	0.867	rs56235549	ENSG00000242600.5	MBL1P	4.11	6.58e-05	0.0237	0.63	0.32	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:79904898~79950336:+
PCPG	cis	rs28386778	0.863	rs4968661	ENSG00000240280.5	TCAM1P	-4.11	6.58e-05	0.0237	-0.4	-0.32	Prudent dietary pattern;	chr17:63718946	chr17:63849292~63864379:+
PCPG	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-4.11	6.58e-05	0.0237	-0.46	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
PCPG	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	4.11	6.58e-05	0.0237	0.4	0.32	Height;	chr6:109393881	chr6:109382795~109383666:+
PCPG	cis	rs2836974	0.644	rs2836981	ENSG00000255568.3	BRWD1-AS2	-4.11	6.58e-05	0.0237	-0.32	-0.32	Cognitive function;	chr21:39316439	chr21:39313935~39314962:+
PCPG	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-4.11	6.6e-05	0.0237	-0.36	-0.32	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
PCPG	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	4.11	6.6e-05	0.0237	0.42	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
PCPG	cis	rs394563	0.726	rs6942381	ENSG00000231760.4	RP11-350J20.5	-4.11	6.6e-05	0.0237	-0.4	-0.32	Dupuytren's disease;	chr6:149341855	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.726	rs6906384	ENSG00000231760.4	RP11-350J20.5	-4.11	6.6e-05	0.0237	-0.4	-0.32	Dupuytren's disease;	chr6:149343404	chr6:149796151~149826294:-
PCPG	cis	rs11858159	0.902	rs12900858	ENSG00000260760.1	PWRN3	4.11	6.6e-05	0.0237	0.34	0.32	Platelet thrombus formation;	chr15:24572913	chr15:24441127~24447967:+
PCPG	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	4.11	6.61e-05	0.0237	0.54	0.32	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	4.11	6.61e-05	0.0237	0.54	0.32	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
PCPG	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	4.11	6.61e-05	0.0237	0.54	0.32	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
PCPG	cis	rs8003054	0.589	rs4465523	ENSG00000258515.1	RP11-203M5.7	4.11	6.61e-05	0.0238	0.25	0.32	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445364	chr14:20451305~20451918:+
PCPG	cis	rs8030379	1	rs4842923	ENSG00000230373.7	GOLGA6L5P	-4.11	6.61e-05	0.0238	-0.31	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913152	chr15:84507885~84516814:-
PCPG	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-4.11	6.61e-05	0.0238	-0.45	-0.32	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
PCPG	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	4.11	6.61e-05	0.0238	0.49	0.32	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
PCPG	cis	rs8064024	0.508	rs2037912	ENSG00000267077.1	RP11-127I20.5	-4.11	6.62e-05	0.0238	-0.38	-0.32	Cancer;	chr16:4883938	chr16:4795265~4796532:-
PCPG	cis	rs8064024	0.513	rs1049207	ENSG00000267077.1	RP11-127I20.5	-4.11	6.62e-05	0.0238	-0.38	-0.32	Cancer;	chr16:4884563	chr16:4795265~4796532:-
PCPG	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	4.1	6.62e-05	0.0238	0.4	0.32	Height;	chr6:109424122	chr6:109382795~109383666:+
PCPG	cis	rs3764021	0.527	rs12227655	ENSG00000278635.1	CTD-2318O12.1	-4.1	6.62e-05	0.0238	-0.4	-0.32	Type 1 diabetes;	chr12:9715652	chr12:9415641~9416718:+
PCPG	cis	rs3764021	0.506	rs12228641	ENSG00000278635.1	CTD-2318O12.1	-4.1	6.62e-05	0.0238	-0.4	-0.32	Type 1 diabetes;	chr12:9715680	chr12:9415641~9416718:+
PCPG	cis	rs3758911	0.964	rs10789602	ENSG00000255353.1	RP11-382M14.1	-4.1	6.62e-05	0.0238	-0.41	-0.32	Coronary artery disease;	chr11:107310729	chr11:107176286~107177530:+
PCPG	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-4.1	6.62e-05	0.0238	-0.46	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
PCPG	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	4.1	6.62e-05	0.0238	0.26	0.32	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	4.1	6.62e-05	0.0238	0.26	0.32	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
PCPG	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	4.1	6.62e-05	0.0238	0.26	0.32	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
PCPG	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-4.1	6.62e-05	0.0238	-0.36	-0.32	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
PCPG	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	4.1	6.63e-05	0.0238	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
PCPG	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	4.1	6.63e-05	0.0238	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
PCPG	cis	rs9636231	0.901	rs72879623	ENSG00000234645.3	YWHAEP5	-4.1	6.63e-05	0.0238	-0.34	-0.32	Alcohol dependence;	chr2:138878399	chr2:138288029~138288793:-
PCPG	cis	rs9494145	0.68	rs35959442	ENSG00000232876.1	CTA-212D2.2	-4.1	6.63e-05	0.0238	-0.4	-0.32	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135103041	chr6:135055033~135060550:+
PCPG	cis	rs6121246	0.909	rs6119729	ENSG00000230613.1	HM13-AS1	-4.1	6.63e-05	0.0238	-0.45	-0.32	Mean corpuscular hemoglobin;	chr20:31825360	chr20:31567707~31573263:-
PCPG	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-4.1	6.64e-05	0.0238	-0.38	-0.32	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
PCPG	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-4.1	6.64e-05	0.0238	-0.38	-0.32	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
PCPG	cis	rs67180937	0.542	rs61824282	ENSG00000225265.1	TAF1A-AS1	4.1	6.64e-05	0.0238	0.3	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222589825~222593032:+
PCPG	cis	rs2412459	0.635	rs503671	ENSG00000245849.5	RAD51-AS1	4.1	6.64e-05	0.0238	0.51	0.32	Response to haloperidol in psychosis;	chr15:39962745	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs7170569	ENSG00000245849.5	RAD51-AS1	4.1	6.64e-05	0.0238	0.51	0.32	Response to haloperidol in psychosis;	chr15:39964584	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.803	rs472027	ENSG00000245849.5	RAD51-AS1	4.1	6.64e-05	0.0238	0.51	0.32	Response to haloperidol in psychosis;	chr15:39965414	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs8029465	ENSG00000245849.5	RAD51-AS1	4.1	6.64e-05	0.0238	0.51	0.32	Response to haloperidol in psychosis;	chr15:39970074	chr15:40686724~40695107:-
PCPG	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	4.1	6.64e-05	0.0238	0.38	0.32	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	4.1	6.64e-05	0.0238	0.38	0.32	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	4.1	6.64e-05	0.0238	0.38	0.32	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	4.1	6.64e-05	0.0238	0.38	0.32	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
PCPG	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	4.1	6.65e-05	0.0238	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
PCPG	cis	rs2735413	0.563	rs72800910	ENSG00000276007.1	RP11-358L22.3	4.1	6.65e-05	0.0239	0.36	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78014005	chr16:78123243~78124332:+
PCPG	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	4.1	6.65e-05	0.0239	0.34	0.32	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
PCPG	cis	rs748404	0.666	rs12911569	ENSG00000249839.1	AC011330.5	-4.1	6.66e-05	0.0239	-0.45	-0.32	Lung cancer;	chr15:43305099	chr15:43663654~43684339:-
PCPG	cis	rs7829975	0.84	rs555617	ENSG00000173295.6	FAM86B3P	4.1	6.66e-05	0.0239	0.36	0.32	Mood instability;	chr8:8735335	chr8:8228595~8244865:+
PCPG	cis	rs7246657	0.891	rs2279149	ENSG00000226686.6	LINC01535	-4.1	6.66e-05	0.0239	-0.5	-0.32	Coronary artery calcification;	chr19:37533465	chr19:37251912~37265535:+
PCPG	cis	rs7227917	0.536	rs4603334	ENSG00000269365.2	RP11-380M21.4	4.1	6.66e-05	0.0239	0.62	0.32	Lung cancer in ever smokers;	chr18:47997496	chr18:47878295~47882444:+
PCPG	cis	rs10051787	0.954	rs10061683	ENSG00000223652.2	AC106786.1	4.1	6.67e-05	0.0239	0.44	0.32	Waist circumference;	chr5:123361188	chr5:123087248~123090299:-
PCPG	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	4.1	6.67e-05	0.0239	0.33	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
PCPG	cis	rs2060793	0.741	rs7119073	ENSG00000251991.1	RNU7-49P	4.1	6.68e-05	0.024	0.35	0.32	Vitamin D levels;	chr11:14669416	chr11:14478892~14478953:+
PCPG	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-4.1	6.68e-05	0.024	-0.52	-0.32	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
PCPG	cis	rs8064024	0.513	rs1049208	ENSG00000267077.1	RP11-127I20.5	-4.1	6.69e-05	0.024	-0.38	-0.32	Cancer;	chr16:4884548	chr16:4795265~4796532:-
PCPG	cis	rs4819052	0.807	rs1075788	ENSG00000215447.6	BX322557.10	-4.1	6.69e-05	0.024	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45288052~45291738:+
PCPG	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	4.1	6.69e-05	0.024	0.37	0.32	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
PCPG	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-4.1	6.69e-05	0.024	-0.46	-0.32	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
PCPG	cis	rs2274273	0.588	rs17128145	ENSG00000258413.1	RP11-665C16.6	4.1	6.69e-05	0.024	0.39	0.32	Protein biomarker;	chr14:55069688	chr14:55262767~55272075:-
PCPG	cis	rs4295623	0.553	rs34962960	ENSG00000255020.1	AF131216.5	-4.1	6.69e-05	0.024	-0.45	-0.32	Morning vs. evening chronotype;	chr8:11737088	chr8:11345748~11347502:-
PCPG	cis	rs12439619	0.846	rs62012056	ENSG00000228141.5	AC105339.1	-4.1	6.69e-05	0.024	-0.48	-0.32	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82710471~82714026:-
PCPG	cis	rs240993	0.672	rs6922226	ENSG00000271789.1	RP5-1112D6.7	-4.1	6.69e-05	0.024	-0.41	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111403281	chr6:111297126~111298510:+
PCPG	cis	rs2243480	0.706	rs34466769	ENSG00000251451.1	GS1-124K5.6	4.1	6.69e-05	0.024	0.5	0.32	Diabetic kidney disease;	chr7:65988305	chr7:66407288~66409239:-
PCPG	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	4.1	6.7e-05	0.024	0.49	0.32	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
PCPG	cis	rs720064	0.586	rs12957815	ENSG00000265752.2	RP11-403A21.1	4.1	6.71e-05	0.024	0.36	0.32	Strep throat;	chr18:23976626	chr18:23957754~23982556:-
PCPG	cis	rs7603514	0.626	rs6730407	ENSG00000279220.1	GPR1-AS	-4.1	6.71e-05	0.024	-0.39	-0.32	Obesity (extreme);	chr2:206213809	chr2:206203376~206266243:+
PCPG	cis	rs950169	0.92	rs12915390	ENSG00000235370.6	DNM1P51	4.1	6.72e-05	0.0241	0.32	0.32	Schizophrenia;	chr15:84123317	chr15:84398316~84411701:-
PCPG	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-4.1	6.72e-05	0.0241	-0.38	-0.32	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
PCPG	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	4.1	6.72e-05	0.0241	0.28	0.32	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
PCPG	cis	rs9356009	0.892	rs9347803	ENSG00000213078.3	RP5-933K21.2	-4.1	6.72e-05	0.0241	-0.61	-0.32	Lipoprotein (a) - cholesterol levels;	chr6:157950544	chr6:157365990~157366923:-
PCPG	cis	rs9356009	0.892	rs9347804	ENSG00000213078.3	RP5-933K21.2	-4.1	6.72e-05	0.0241	-0.61	-0.32	Lipoprotein (a) - cholesterol levels;	chr6:157950559	chr6:157365990~157366923:-
PCPG	cis	rs9356009	0.772	rs114534095	ENSG00000213078.3	RP5-933K21.2	-4.1	6.72e-05	0.0241	-0.61	-0.32	Lipoprotein (a) - cholesterol levels;	chr6:157950718	chr6:157365990~157366923:-
PCPG	cis	rs9356009	1	rs6938385	ENSG00000213078.3	RP5-933K21.2	-4.1	6.72e-05	0.0241	-0.61	-0.32	Lipoprotein (a) - cholesterol levels;	chr6:157950930	chr6:157365990~157366923:-
PCPG	cis	rs9356009	0.772	rs11962437	ENSG00000213078.3	RP5-933K21.2	-4.1	6.72e-05	0.0241	-0.61	-0.32	Lipoprotein (a) - cholesterol levels;	chr6:157951053	chr6:157365990~157366923:-
PCPG	cis	rs9788721	0.934	rs1317286	ENSG00000279421.1	RP11-335K5.3	-4.1	6.72e-05	0.0241	-0.38	-0.32	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78603787	chr15:78599892~78600013:-
PCPG	cis	rs1371867	0.875	rs2439456	ENSG00000212994.5	RPS26P6	4.1	6.72e-05	0.0241	0.36	0.32	Atrioventricular conduction;	chr8:100324646	chr8:100895771~100896118:+
PCPG	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	4.1	6.73e-05	0.0241	0.32	0.32	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	4.1	6.73e-05	0.0241	0.32	0.32	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	4.1	6.73e-05	0.0241	0.32	0.32	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
PCPG	cis	rs17507216	1	rs17158413	ENSG00000228141.5	AC105339.1	-4.1	6.73e-05	0.0241	-0.44	-0.32	Excessive daytime sleepiness;	chr15:82566658	chr15:82710471~82714026:-
PCPG	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-4.1	6.73e-05	0.0241	-0.49	-0.32	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
PCPG	cis	rs4950322	0.515	rs11239954	ENSG00000237188.3	RP11-337C18.8	4.1	6.73e-05	0.0241	0.37	0.32	Protein quantitative trait loci;	chr1:147246045	chr1:147172771~147211568:+
PCPG	cis	rs8098244	0.617	rs12957168	ENSG00000265752.2	RP11-403A21.1	-4.1	6.73e-05	0.0241	-0.36	-0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23821960	chr18:23957754~23982556:-
PCPG	cis	rs6728642	0.572	rs2872686	ENSG00000278766.2	AC159540.2	-4.1	6.73e-05	0.0241	-0.42	-0.32	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935287	chr2:97421075~97434847:+
PCPG	cis	rs13108904	0.87	rs2279281	ENSG00000254094.1	AC078852.1	-4.1	6.73e-05	0.0241	-0.38	-0.32	Obesity-related traits;	chr4:1251489	chr4:1356581~1358075:+
PCPG	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	4.1	6.74e-05	0.0241	0.31	0.32	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	4.1	6.74e-05	0.0241	0.31	0.32	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	4.1	6.74e-05	0.0241	0.31	0.32	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
PCPG	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	4.1	6.74e-05	0.0241	0.39	0.32	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
PCPG	cis	rs11858159	0.902	rs8033788	ENSG00000260760.1	PWRN3	4.1	6.74e-05	0.0241	0.34	0.32	Platelet thrombus formation;	chr15:24540436	chr15:24441127~24447967:+
PCPG	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	4.1	6.74e-05	0.0241	0.45	0.32	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	4.1	6.74e-05	0.0241	0.45	0.32	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
PCPG	cis	rs73198271	0.737	rs506960	ENSG00000253893.2	FAM85B	4.1	6.75e-05	0.0241	0.4	0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8167819~8226614:-
PCPG	cis	rs4791051	0.706	rs7225164	ENSG00000264491.1	RP11-349A8.3	4.1	6.75e-05	0.0241	0.37	0.32	Heschl's gyrus morphology;	chr17:66486033	chr17:67019934~67021743:-
PCPG	cis	rs2243480	1	rs6460260	ENSG00000251451.1	GS1-124K5.6	-4.1	6.75e-05	0.0241	-0.6	-0.32	Diabetic kidney disease;	chr7:65750468	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs6460261	ENSG00000251451.1	GS1-124K5.6	-4.1	6.75e-05	0.0241	-0.6	-0.32	Diabetic kidney disease;	chr7:65750593	chr7:66407288~66409239:-
PCPG	cis	rs8098244	0.536	rs7232217	ENSG00000265752.2	RP11-403A21.1	4.1	6.75e-05	0.0241	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699115	chr18:23957754~23982556:-
PCPG	cis	rs720064	0.655	rs12964862	ENSG00000265752.2	RP11-403A21.1	4.1	6.75e-05	0.0241	0.37	0.32	Strep throat;	chr18:23700711	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.536	rs12955616	ENSG00000265752.2	RP11-403A21.1	4.1	6.75e-05	0.0241	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701097	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.557	rs8089282	ENSG00000265752.2	RP11-403A21.1	4.1	6.75e-05	0.0241	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23708402	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.557	rs10853571	ENSG00000265752.2	RP11-403A21.1	4.1	6.75e-05	0.0241	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710723	chr18:23957754~23982556:-
PCPG	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	4.1	6.75e-05	0.0241	0.4	0.32	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
PCPG	cis	rs6696239	0.513	rs7528094	ENSG00000227711.2	RP11-275O4.5	-4.1	6.75e-05	0.0241	-0.37	-0.32	Height;	chr1:227548538	chr1:227509028~227520477:-
PCPG	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	4.1	6.75e-05	0.0242	0.35	0.32	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
PCPG	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	4.1	6.75e-05	0.0242	0.35	0.32	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
PCPG	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-4.1	6.75e-05	0.0242	-0.41	-0.32	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
PCPG	cis	rs7819412	0.74	rs28633434	ENSG00000255020.1	AF131216.5	-4.1	6.75e-05	0.0242	-0.43	-0.32	Triglycerides;	chr8:11196413	chr8:11345748~11347502:-
PCPG	cis	rs62246343	0.541	rs2596937	ENSG00000254485.4	RP11-380O24.1	4.1	6.76e-05	0.0242	0.42	0.32	Fibrinogen levels;	chr3:9439222	chr3:9292588~9363303:-
PCPG	cis	rs394563	0.967	rs420099	ENSG00000268592.3	RAET1E-AS1	4.1	6.76e-05	0.0242	0.4	0.32	Dupuytren's disease;	chr6:149473154	chr6:149863494~149919507:+
PCPG	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-4.1	6.76e-05	0.0242	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
PCPG	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-4.1	6.76e-05	0.0242	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
PCPG	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-4.1	6.76e-05	0.0242	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
PCPG	cis	rs2060793	0.712	rs10832290	ENSG00000251991.1	RNU7-49P	4.1	6.76e-05	0.0242	0.35	0.32	Vitamin D levels;	chr11:14650684	chr11:14478892~14478953:+
PCPG	cis	rs2060793	0.774	rs1403249	ENSG00000251991.1	RNU7-49P	4.1	6.76e-05	0.0242	0.35	0.32	Vitamin D levels;	chr11:14651438	chr11:14478892~14478953:+
PCPG	cis	rs7824557	0.628	rs3174048	ENSG00000255020.1	AF131216.5	4.1	6.76e-05	0.0242	0.41	0.32	Retinal vascular caliber;	chr8:11327428	chr8:11345748~11347502:-
PCPG	cis	rs8098244	0.603	rs2960580	ENSG00000265752.2	RP11-403A21.1	4.1	6.76e-05	0.0242	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23712058	chr18:23957754~23982556:-
PCPG	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	4.1	6.77e-05	0.0242	0.4	0.32	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
PCPG	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-4.1	6.77e-05	0.0242	-0.38	-0.32	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
PCPG	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-4.1	6.77e-05	0.0242	-0.38	-0.32	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
PCPG	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-4.1	6.77e-05	0.0242	-0.38	-0.32	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
PCPG	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-4.1	6.77e-05	0.0242	-0.38	-0.32	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
PCPG	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	4.1	6.78e-05	0.0242	0.37	0.32	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	4.1	6.78e-05	0.0242	0.37	0.32	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
PCPG	cis	rs7789940	1	rs758944	ENSG00000186704.9	DTX2P1	4.1	6.78e-05	0.0242	0.38	0.32	Multiple sclerosis;	chr7:76323980	chr7:76978617~77004308:+
PCPG	cis	rs7249142	0.527	rs12975096	ENSG00000279843.1	AC011477.2	4.1	6.78e-05	0.0242	0.34	0.32	IgG glycosylation;	chr19:19168600	chr19:19835158~19836016:+
PCPG	cis	rs7403037	0.526	rs28545658	ENSG00000260760.1	PWRN3	4.1	6.78e-05	0.0242	0.34	0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24553856	chr15:24441127~24447967:+
PCPG	cis	rs2221593	0.502	rs2501851	ENSG00000237980.1	RP11-338C15.3	4.1	6.78e-05	0.0242	0.42	0.32	Leprosy;	chr1:212674065	chr1:212653999~212665434:-
PCPG	cis	rs196889	1	rs395691	ENSG00000253535.4	RP11-624C23.1	4.1	6.79e-05	0.0243	0.4	0.32	Seasonality;	chr8:24863839	chr8:24295814~24912073:-
PCPG	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-4.1	6.79e-05	0.0243	-0.38	-0.32	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
PCPG	cis	rs2836974	0.831	rs2836921	ENSG00000252915.1	Y_RNA	-4.1	6.79e-05	0.0243	-0.35	-0.32	Cognitive function;	chr21:39144144	chr21:39344537~39344628:+
PCPG	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	4.1	6.8e-05	0.0243	0.41	0.32	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
PCPG	cis	rs11148252	0.538	rs9535879	ENSG00000235660.1	LINC00345	-4.1	6.8e-05	0.0243	-0.39	-0.32	Lewy body disease;	chr13:52130488	chr13:52484161~52484680:-
PCPG	cis	rs11638352	1	rs2706481	ENSG00000205771.5	CATSPER2P1	4.1	6.8e-05	0.0243	0.56	0.32	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44114119	chr15:43726918~43747094:-
PCPG	cis	rs11214589	0.806	rs4551806	ENSG00000256757.1	RP11-159N11.3	4.1	6.8e-05	0.0243	0.34	0.32	Neuroticism;	chr11:113379818	chr11:113405321~113412117:+
PCPG	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	4.1	6.81e-05	0.0243	0.27	0.32	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
PCPG	cis	rs896854	0.654	rs13274945	ENSG00000253528.2	RP11-347C18.4	4.1	6.81e-05	0.0243	0.34	0.32	Type 2 diabetes;	chr8:94974398	chr8:94974573~94974853:-
PCPG	cis	rs2404602	0.692	rs34478400	ENSG00000259514.1	RP11-685G9.2	-4.1	6.81e-05	0.0243	-0.32	-0.32	Blood metabolite levels;	chr15:76631169	chr15:76339609~76342063:-
PCPG	cis	rs9649213	0.593	rs6967576	ENSG00000272950.1	RP11-307C18.1	-4.1	6.81e-05	0.0243	-0.43	-0.32	Prostate cancer (SNP x SNP interaction);	chr7:98387061	chr7:98322853~98323430:+
PCPG	cis	rs34421088	0.56	rs2248325	ENSG00000254774.1	RP11-148O21.3	-4.1	6.82e-05	0.0243	-0.36	-0.32	Neuroticism;	chr8:11539365	chr8:11553224~11554207:-
PCPG	cis	rs34421088	0.56	rs2248316	ENSG00000254774.1	RP11-148O21.3	-4.1	6.82e-05	0.0243	-0.36	-0.32	Neuroticism;	chr8:11539564	chr8:11553224~11554207:-
PCPG	cis	rs34421088	0.56	rs2248315	ENSG00000254774.1	RP11-148O21.3	-4.1	6.82e-05	0.0243	-0.36	-0.32	Neuroticism;	chr8:11539577	chr8:11553224~11554207:-
PCPG	cis	rs425277	1	rs262670	ENSG00000271806.1	RP5-892K4.1	4.1	6.82e-05	0.0243	0.37	0.32	Height;	chr1:2151019	chr1:2141084~2145279:-
PCPG	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	4.1	6.82e-05	0.0243	0.26	0.32	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
PCPG	cis	rs11148252	0.87	rs11148246	ENSG00000198384.8	TPTE2P3	-4.1	6.82e-05	0.0243	-0.38	-0.32	Lewy body disease;	chr13:52223402	chr13:52522632~52586906:+
PCPG	cis	rs7267979	0.545	rs6050426	ENSG00000276952.1	RP5-965G21.6	4.1	6.82e-05	0.0243	0.34	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25197629	chr20:25284915~25285588:-
PCPG	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-4.1	6.82e-05	0.0243	-0.3	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
PCPG	cis	rs7829975	0.871	rs7829826	ENSG00000173295.6	FAM86B3P	4.1	6.82e-05	0.0243	0.36	0.32	Mood instability;	chr8:8720610	chr8:8228595~8244865:+
PCPG	cis	rs2652834	0.808	rs28583444	ENSG00000259498.1	RP11-244F12.3	-4.1	6.82e-05	0.0243	-0.53	-0.32	HDL cholesterol;	chr15:63065653	chr15:63046034~63049387:-
PCPG	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	4.1	6.82e-05	0.0243	0.41	0.32	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	4.1	6.82e-05	0.0243	0.41	0.32	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	4.1	6.82e-05	0.0243	0.41	0.32	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	4.1	6.82e-05	0.0243	0.41	0.32	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	4.1	6.82e-05	0.0243	0.41	0.32	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	4.1	6.82e-05	0.0243	0.41	0.32	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
PCPG	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	4.1	6.82e-05	0.0244	0.37	0.32	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
PCPG	cis	rs321358	0.731	rs516110	ENSG00000271584.1	RP11-89C3.4	4.1	6.83e-05	0.0244	0.44	0.32	Body mass index;	chr11:111166525	chr11:111091932~111097357:-
PCPG	cis	rs10851885	0.779	rs11634260	ENSG00000261813.2	RP11-151H2.3	-4.1	6.83e-05	0.0244	-0.41	-0.32	Glomerular filtration rate (creatinine);	chr15:75954268	chr15:74976240~74976573:-
PCPG	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-4.1	6.83e-05	0.0244	-0.32	-0.32	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
PCPG	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-4.1	6.83e-05	0.0244	-0.32	-0.32	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
PCPG	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-4.1	6.83e-05	0.0244	-0.32	-0.32	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
PCPG	cis	rs7824557	0.505	rs2572440	ENSG00000255020.1	AF131216.5	4.1	6.84e-05	0.0244	0.42	0.32	Retinal vascular caliber;	chr8:11391501	chr8:11345748~11347502:-
PCPG	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-4.1	6.84e-05	0.0244	-0.36	-0.32	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
PCPG	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-4.1	6.84e-05	0.0244	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
PCPG	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	4.1	6.84e-05	0.0244	0.48	0.32	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	4.1	6.84e-05	0.0244	0.48	0.32	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
PCPG	cis	rs293748	0.891	rs6861906	ENSG00000250155.1	CTD-2353F22.1	-4.1	6.85e-05	0.0244	-0.46	-0.32	Obesity-related traits;	chr5:37075834	chr5:36666214~36725195:-
PCPG	cis	rs181553	0.664	rs948789	ENSG00000278983.1	RP11-426J5.3	-4.1	6.85e-05	0.0244	-0.35	-0.32	Hip circumference adjusted for BMI;	chr18:49174326	chr18:48564795~48568342:+
PCPG	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-4.1	6.85e-05	0.0244	-0.45	-0.32	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
PCPG	cis	rs172166	0.61	rs156737	ENSG00000219392.1	RP1-265C24.5	-4.1	6.85e-05	0.0244	-0.34	-0.32	Cardiac Troponin-T levels;	chr6:27927435	chr6:28115628~28116551:+
PCPG	cis	rs6714710	0.603	rs1470483	ENSG00000278766.2	AC159540.2	4.1	6.86e-05	0.0245	0.36	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97777431	chr2:97421075~97434847:+
PCPG	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-4.1	6.86e-05	0.0245	-0.38	-0.32	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
PCPG	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-4.1	6.86e-05	0.0245	-0.38	-0.32	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
PCPG	cis	rs8099594	0.565	rs4939849	ENSG00000278983.1	RP11-426J5.3	-4.1	6.86e-05	0.0245	-0.35	-0.32	Height;	chr18:49201252	chr18:48564795~48568342:+
PCPG	cis	rs2212361	0.558	rs72980453	ENSG00000255893.1	RP11-685N10.1	-4.1	6.87e-05	0.0245	-0.42	-0.32	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94522923	chr11:94472908~94473570:-
PCPG	cis	rs5743030	0.59	rs256580	ENSG00000253559.1	OSGEPL1-AS1	-4.1	6.87e-05	0.0245	-0.49	-0.32	Subcutaneous adipose tissue;	chr2:189846159	chr2:189762704~189765556:+
PCPG	cis	rs2315504	0.626	rs57976804	ENSG00000278954.1	RP13-415G19.2	-4.1	6.87e-05	0.0245	-0.37	-0.32	Height;	chr17:40825993	chr17:41665566~41668031:+
PCPG	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-4.1	6.87e-05	0.0245	-0.4	-0.32	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
PCPG	cis	rs10411161	0.702	rs11879336	ENSG00000275055.1	CTC-471J1.11	-4.1	6.88e-05	0.0245	-0.37	-0.32	Breast cancer;	chr19:51886374	chr19:52049007~52049754:+
PCPG	cis	rs2212361	0.558	rs11020812	ENSG00000255893.1	RP11-685N10.1	4.1	6.88e-05	0.0245	0.38	0.32	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94533951	chr11:94472908~94473570:-
PCPG	cis	rs17826219	0.561	rs562840	ENSG00000263603.1	CTD-2349P21.5	-4.1	6.88e-05	0.0245	-0.46	-0.32	Body mass index;	chr17:30622372	chr17:30729469~30731202:+
PCPG	cis	rs17037831	0.568	rs9809112	ENSG00000272263.1	RP11-767C1.2	4.09	6.89e-05	0.0246	0.45	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr3:13222986	chr3:12832219~12832728:-
PCPG	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	4.09	6.89e-05	0.0246	0.38	0.32	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
PCPG	cis	rs3764021	0.509	rs10844569	ENSG00000278635.1	CTD-2318O12.1	-4.09	6.9e-05	0.0246	-0.4	-0.32	Type 1 diabetes;	chr12:9717756	chr12:9415641~9416718:+
PCPG	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	4.09	6.9e-05	0.0246	0.4	0.32	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
PCPG	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	4.09	6.9e-05	0.0246	0.42	0.32	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	4.09	6.9e-05	0.0246	0.42	0.32	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
PCPG	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	4.09	6.9e-05	0.0246	0.4	0.32	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
PCPG	cis	rs2836974	0.897	rs11911112	ENSG00000252915.1	Y_RNA	-4.09	6.91e-05	0.0246	-0.33	-0.32	Cognitive function;	chr21:39156420	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.831	rs11911149	ENSG00000252915.1	Y_RNA	-4.09	6.91e-05	0.0246	-0.33	-0.32	Cognitive function;	chr21:39156449	chr21:39344537~39344628:+
PCPG	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-4.09	6.91e-05	0.0246	-0.41	-0.32	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
PCPG	cis	rs11673344	0.543	rs12980849	ENSG00000226686.6	LINC01535	4.09	6.91e-05	0.0246	0.42	0.32	Obesity-related traits;	chr19:37160812	chr19:37251912~37265535:+
PCPG	cis	rs657075	0.757	rs3792876	ENSG00000233006.5	AC034220.3	-4.09	6.91e-05	0.0246	-0.47	-0.32	Rheumatoid arthritis;	chr5:132301616	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.757	rs13175394	ENSG00000233006.5	AC034220.3	-4.09	6.91e-05	0.0246	-0.47	-0.32	Rheumatoid arthritis;	chr5:132305513	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.757	rs71583470	ENSG00000233006.5	AC034220.3	-4.09	6.91e-05	0.0246	-0.47	-0.32	Rheumatoid arthritis;	chr5:132307623	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.757	rs35316456	ENSG00000233006.5	AC034220.3	-4.09	6.91e-05	0.0246	-0.47	-0.32	Rheumatoid arthritis;	chr5:132308131	chr5:132311285~132369916:-
PCPG	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	4.09	6.91e-05	0.0246	0.31	0.32	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
PCPG	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	4.09	6.91e-05	0.0246	0.37	0.32	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	4.09	6.91e-05	0.0246	0.37	0.32	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	4.09	6.91e-05	0.0246	0.37	0.32	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	4.09	6.91e-05	0.0246	0.37	0.32	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	4.09	6.91e-05	0.0246	0.37	0.32	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
PCPG	cis	rs3947	1	rs709821	ENSG00000227203.3	SUB1P1	-4.09	6.91e-05	0.0246	-0.48	-0.32	Blood protein levels;	chr8:11845085	chr8:11790005~11790386:+
PCPG	cis	rs16964211	0.793	rs16964220	ENSG00000259438.1	CTD-2650P22.1	-4.09	6.91e-05	0.0246	-0.65	-0.32	Height;	chr15:51251185	chr15:52010999~52019095:-
PCPG	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	4.09	6.93e-05	0.0247	0.32	0.32	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
PCPG	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	4.09	6.93e-05	0.0247	0.39	0.32	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
PCPG	cis	rs17684571	0.751	rs1903332	ENSG00000231441.1	RP11-472M19.2	-4.09	6.93e-05	0.0247	-0.5	-0.32	Schizophrenia;	chr6:56857437	chr6:56844002~56864078:+
PCPG	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	4.09	6.93e-05	0.0247	0.31	0.32	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
PCPG	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-4.09	6.93e-05	0.0247	-0.3	-0.32	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
PCPG	cis	rs899997	0.906	rs1994018	ENSG00000261143.1	ADAMTS7P3	-4.09	6.93e-05	0.0247	-0.47	-0.32	Coronary artery disease or large artery stroke;	chr15:78733242	chr15:77976042~77993057:+
PCPG	cis	rs899997	0.731	rs58717592	ENSG00000261143.1	ADAMTS7P3	-4.09	6.93e-05	0.0247	-0.47	-0.32	Coronary artery disease or large artery stroke;	chr15:78738075	chr15:77976042~77993057:+
PCPG	cis	rs13108904	0.935	rs1732100	ENSG00000253399.1	AC078852.2	4.09	6.93e-05	0.0247	0.33	0.32	Obesity-related traits;	chr4:1287973	chr4:1358479~1359461:+
PCPG	cis	rs801193	0.569	rs2659893	ENSG00000235475.1	LINC01372	4.09	6.94e-05	0.0247	0.33	0.32	Aortic root size;	chr7:66735006	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs2659892	ENSG00000235475.1	LINC01372	4.09	6.94e-05	0.0247	0.33	0.32	Aortic root size;	chr7:66735318	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.548	rs2659891	ENSG00000235475.1	LINC01372	4.09	6.94e-05	0.0247	0.33	0.32	Aortic root size;	chr7:66736127	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs2707847	ENSG00000235475.1	LINC01372	4.09	6.94e-05	0.0247	0.33	0.32	Aortic root size;	chr7:66737884	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.548	rs7805152	ENSG00000235475.1	LINC01372	4.09	6.94e-05	0.0247	0.33	0.32	Aortic root size;	chr7:66744266	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs11761542	ENSG00000235475.1	LINC01372	4.09	6.94e-05	0.0247	0.33	0.32	Aortic root size;	chr7:66753209	chr7:67335976~67340024:+
PCPG	cis	rs2736345	0.742	rs4840568	ENSG00000255020.1	AF131216.5	4.09	6.94e-05	0.0247	0.41	0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11493510	chr8:11345748~11347502:-
PCPG	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-4.09	6.95e-05	0.0247	-0.46	-0.32	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-4.09	6.95e-05	0.0247	-0.46	-0.32	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-4.09	6.95e-05	0.0247	-0.46	-0.32	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-4.09	6.95e-05	0.0247	-0.46	-0.32	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-4.09	6.95e-05	0.0247	-0.46	-0.32	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-4.09	6.95e-05	0.0247	-0.46	-0.32	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
PCPG	cis	rs7118412	0.793	rs7115005	ENSG00000260966.1	RP11-690D19.3	-4.09	6.95e-05	0.0247	-0.34	-0.32	Disc degeneration (lumbar);	chr11:103691118	chr11:103050687~103055799:-
PCPG	cis	rs7118412	0.793	rs7103497	ENSG00000260966.1	RP11-690D19.3	-4.09	6.95e-05	0.0247	-0.34	-0.32	Disc degeneration (lumbar);	chr11:103691225	chr11:103050687~103055799:-
PCPG	cis	rs2412459	0.635	rs16970033	ENSG00000245849.5	RAD51-AS1	4.09	6.95e-05	0.0247	0.52	0.32	Response to haloperidol in psychosis;	chr15:39953599	chr15:40686724~40695107:-
PCPG	cis	rs2625529	0.652	rs8023788	ENSG00000260037.4	CTD-2524L6.3	4.09	6.96e-05	0.0247	0.41	0.32	Red blood cell count;	chr15:72167506	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.617	rs8025939	ENSG00000260037.4	CTD-2524L6.3	4.09	6.96e-05	0.0247	0.41	0.32	Red blood cell count;	chr15:72167998	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.586	rs7175197	ENSG00000260037.4	CTD-2524L6.3	4.09	6.96e-05	0.0247	0.41	0.32	Red blood cell count;	chr15:72169307	chr15:71818396~71823384:+
PCPG	cis	rs3809060	0.844	rs7110547	ENSG00000213713.3	PIGCP1	4.09	6.96e-05	0.0248	0.17	0.32	Inguinal hernia;	chr11:32425801	chr11:33075566~33076460:-
PCPG	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-4.09	6.96e-05	0.0248	-0.46	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
PCPG	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	4.09	6.96e-05	0.0248	0.3	0.32	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
PCPG	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	4.09	6.97e-05	0.0248	0.32	0.32	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
PCPG	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-4.09	6.97e-05	0.0248	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-4.09	6.97e-05	0.0248	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-4.09	6.97e-05	0.0248	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
PCPG	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-4.09	6.97e-05	0.0248	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
PCPG	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-4.09	6.97e-05	0.0248	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
PCPG	cis	rs2735413	0.563	rs8046446	ENSG00000276007.1	RP11-358L22.3	4.09	6.97e-05	0.0248	0.36	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78015689	chr16:78123243~78124332:+
PCPG	cis	rs9302635	0.816	rs7202323	ENSG00000260886.1	TAT-AS1	4.09	6.98e-05	0.0248	0.49	0.32	Blood protein levels;	chr16:72183214	chr16:71565789~71578187:+
PCPG	cis	rs17684571	0.7	rs36022925	ENSG00000231441.1	RP11-472M19.2	4.09	6.98e-05	0.0248	0.53	0.32	Schizophrenia;	chr6:56818169	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs34520435	ENSG00000231441.1	RP11-472M19.2	4.09	6.98e-05	0.0248	0.53	0.32	Schizophrenia;	chr6:56818319	chr6:56844002~56864078:+
PCPG	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	4.09	6.99e-05	0.0248	0.34	0.32	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
PCPG	cis	rs427576	0.816	rs417278	ENSG00000261079.1	RP11-252A24.3	4.09	6.99e-05	0.0248	0.38	0.32	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr16:73796577	chr16:74367462~74369826:+
PCPG	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-4.09	6.99e-05	0.0248	-0.42	-0.32	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
PCPG	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	4.09	7e-05	0.0249	0.29	0.32	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
PCPG	cis	rs1023500	0.596	rs133350	ENSG00000226450.2	CYP2D8P	4.09	7.01e-05	0.0249	0.32	0.32	Schizophrenia;	chr22:42033045	chr22:42149886~42155001:-
PCPG	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	4.09	7.01e-05	0.0249	0.41	0.32	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
PCPG	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	4.09	7.01e-05	0.0249	0.38	0.32	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
PCPG	cis	rs12554020	0.786	rs3893381	ENSG00000227603.1	RP11-165J3.6	-4.09	7.01e-05	0.0249	-0.56	-0.32	Schizophrenia;	chr9:93519576	chr9:93435332~93437121:-
PCPG	cis	rs7824557	0.767	rs1897951	ENSG00000184608.7	FAM167A-AS1	4.09	7.02e-05	0.0249	0.44	0.32	Retinal vascular caliber;	chr8:11312345	chr8:11368402~11438658:+
PCPG	cis	rs7824557	0.767	rs11250127	ENSG00000184608.7	FAM167A-AS1	4.09	7.02e-05	0.0249	0.44	0.32	Retinal vascular caliber;	chr8:11312700	chr8:11368402~11438658:+
PCPG	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-4.09	7.02e-05	0.0249	-0.4	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
PCPG	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-4.09	7.02e-05	0.0249	-0.4	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
PCPG	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-4.09	7.02e-05	0.0249	-0.4	-0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
PCPG	cis	rs7208859	0.673	rs423151	ENSG00000263603.1	CTD-2349P21.5	-4.09	7.02e-05	0.0249	-0.46	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30729469~30731202:+
PCPG	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	4.09	7.03e-05	0.0249	0.27	0.32	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	4.09	7.03e-05	0.0249	0.27	0.32	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	4.09	7.03e-05	0.0249	0.27	0.32	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	4.09	7.03e-05	0.0249	0.27	0.32	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
PCPG	cis	rs7444	0.882	rs140492	ENSG00000211645.2	IGLV1-50	4.09	7.03e-05	0.0249	0.37	0.32	Systemic lupus erythematosus;	chr22:21568855	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs181362	ENSG00000211645.2	IGLV1-50	4.09	7.03e-05	0.0249	0.37	0.32	Systemic lupus erythematosus;	chr22:21577779	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs5749485	ENSG00000211645.2	IGLV1-50	4.09	7.03e-05	0.0249	0.37	0.32	Systemic lupus erythematosus;	chr22:21583935	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.882	rs5754217	ENSG00000211645.2	IGLV1-50	4.09	7.03e-05	0.0249	0.37	0.32	Systemic lupus erythematosus;	chr22:21585386	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs5749493	ENSG00000211645.2	IGLV1-50	4.09	7.03e-05	0.0249	0.37	0.32	Systemic lupus erythematosus;	chr22:21585398	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs2070512	ENSG00000211645.2	IGLV1-50	4.09	7.03e-05	0.0249	0.37	0.32	Systemic lupus erythematosus;	chr22:21595122	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs2266964	ENSG00000211645.2	IGLV1-50	4.09	7.03e-05	0.0249	0.37	0.32	Systemic lupus erythematosus;	chr22:21604015	chr22:22327300~22327814:+
PCPG	cis	rs7864133	0.737	rs10867761	ENSG00000225901.1	MTND2P9	-4.09	7.03e-05	0.0249	-0.52	-0.32	Post bronchodilator FEV1 in COPD;	chr9:81448175	chr9:80565032~80565962:-
PCPG	cis	rs13108904	0.901	rs6826029	ENSG00000253399.1	AC078852.2	-4.09	7.03e-05	0.025	-0.33	-0.32	Obesity-related traits;	chr4:1313901	chr4:1358479~1359461:+
PCPG	cis	rs950169	0.92	rs2135551	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84039099	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs12902672	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84048234	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs12903820	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84055068	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.919	rs12915589	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84065712	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.959	rs66801143	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84067905	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs35648189	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84071996	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.92	rs17300048	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84080725	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs1848093	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84086775	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs12915234	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84089549	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs34751999	ENSG00000235370.6	DNM1P51	4.09	7.03e-05	0.025	0.32	0.32	Schizophrenia;	chr15:84089667	chr15:84398316~84411701:-
PCPG	cis	rs2282300	0.91	rs528292	ENSG00000242353.1	RP4-710M3.1	4.09	7.04e-05	0.025	0.42	0.32	Morning vs. evening chronotype;	chr11:30368163	chr11:30368148~30368646:+
PCPG	cis	rs2282300	0.956	rs594937	ENSG00000242353.1	RP4-710M3.1	4.09	7.04e-05	0.025	0.42	0.32	Morning vs. evening chronotype;	chr11:30368585	chr11:30368148~30368646:+
PCPG	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-4.09	7.04e-05	0.025	-0.37	-0.32	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
PCPG	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-4.09	7.05e-05	0.025	-0.46	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
PCPG	cis	rs34421088	0.548	rs2618443	ENSG00000269954.1	RP11-148O21.6	-4.09	7.05e-05	0.025	-0.35	-0.32	Neuroticism;	chr8:11527047	chr8:11552488~11552991:-
PCPG	cis	rs11148252	0.634	rs4941727	ENSG00000235660.1	LINC00345	4.09	7.05e-05	0.025	0.39	0.32	Lewy body disease;	chr13:52146932	chr13:52484161~52484680:-
PCPG	cis	rs2836974	0.897	rs2836925	ENSG00000252915.1	Y_RNA	-4.09	7.05e-05	0.025	-0.33	-0.32	Cognitive function;	chr21:39160427	chr21:39344537~39344628:+
PCPG	cis	rs2439831	0.867	rs486301	ENSG00000205771.5	CATSPER2P1	-4.09	7.05e-05	0.025	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43544751	chr15:43726918~43747094:-
PCPG	cis	rs11673344	0.523	rs7255724	ENSG00000226686.6	LINC01535	4.09	7.05e-05	0.025	0.42	0.32	Obesity-related traits;	chr19:37158675	chr19:37251912~37265535:+
PCPG	cis	rs11673344	0.523	rs10406110	ENSG00000226686.6	LINC01535	4.09	7.05e-05	0.025	0.42	0.32	Obesity-related traits;	chr19:37160027	chr19:37251912~37265535:+
PCPG	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-4.09	7.06e-05	0.025	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-4.09	7.06e-05	0.025	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-4.09	7.06e-05	0.025	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
PCPG	cis	rs2732480	0.5	rs7966829	ENSG00000240399.1	RP1-228P16.1	4.09	7.06e-05	0.025	0.34	0.32	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48054813~48055591:-
PCPG	cis	rs3758911	0.964	rs11212158	ENSG00000255353.1	RP11-382M14.1	-4.09	7.06e-05	0.025	-0.4	-0.32	Coronary artery disease;	chr11:107325745	chr11:107176286~107177530:+
PCPG	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-4.09	7.06e-05	0.025	-0.36	-0.32	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
PCPG	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-4.09	7.06e-05	0.025	-0.49	-0.32	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
PCPG	cis	rs8042680	0.688	rs11073964	ENSG00000214432.8	AC068831.10	-4.09	7.06e-05	0.025	-0.37	-0.32	Type 2 diabetes;	chr15:91000531	chr15:91022619~91036611:+
PCPG	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-4.09	7.06e-05	0.025	-0.37	-0.32	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
PCPG	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	4.09	7.07e-05	0.0251	0.37	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
PCPG	cis	rs13108904	0.935	rs13148614	ENSG00000253399.1	AC078852.2	-4.09	7.07e-05	0.0251	-0.33	-0.32	Obesity-related traits;	chr4:1254569	chr4:1358479~1359461:+
PCPG	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	4.09	7.07e-05	0.0251	0.26	0.32	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	4.09	7.07e-05	0.0251	0.26	0.32	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	4.09	7.07e-05	0.0251	0.26	0.32	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	4.09	7.07e-05	0.0251	0.26	0.32	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
PCPG	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-4.09	7.07e-05	0.0251	-0.33	-0.32	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
PCPG	cis	rs6981992	1	rs6981992	ENSG00000272010.1	CTD-3025N20.3	4.09	7.08e-05	0.0251	0.32	0.32	Obesity-related traits;	chr8:65551243	chr8:65591850~65592472:-
PCPG	cis	rs7819412	0.538	rs4523214	ENSG00000269954.1	RP11-148O21.6	-4.09	7.08e-05	0.0251	-0.38	-0.32	Triglycerides;	chr8:11113263	chr8:11552488~11552991:-
PCPG	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-4.09	7.08e-05	0.0251	-0.4	-0.32	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
PCPG	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	4.09	7.08e-05	0.0251	0.48	0.32	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
PCPG	cis	rs6714710	0.627	rs11680883	ENSG00000278766.2	AC159540.2	4.09	7.09e-05	0.0251	0.36	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97856147	chr2:97421075~97434847:+
PCPG	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	4.09	7.09e-05	0.0251	0.45	0.32	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	4.09	7.09e-05	0.0251	0.45	0.32	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
PCPG	cis	rs11148252	0.84	rs3886077	ENSG00000198384.8	TPTE2P3	-4.09	7.09e-05	0.0251	-0.39	-0.32	Lewy body disease;	chr13:52374918	chr13:52522632~52586906:+
PCPG	cis	rs8059260	0.541	rs34361212	ENSG00000263179.1	HNRNPCP4	4.09	7.09e-05	0.0251	0.65	0.32	Alcohol consumption over the past year;	chr16:11145832	chr16:11242653~11243552:+
PCPG	cis	rs4919687	0.55	rs7904252	ENSG00000269609.4	RPARP-AS1	4.09	7.09e-05	0.0251	0.26	0.32	Colorectal cancer;	chr10:102696968	chr10:102449817~102461106:+
PCPG	cis	rs803923	0.545	rs756118	ENSG00000230734.1	RPL10P3	-4.09	7.09e-05	0.0251	-0.31	-0.32	Lung function (FEV1/FVC);	chr9:116725051	chr9:117180628~117181095:-
PCPG	cis	rs2243480	1	rs437889	ENSG00000251451.1	GS1-124K5.6	4.09	7.1e-05	0.0252	0.59	0.32	Diabetic kidney disease;	chr7:66044247	chr7:66407288~66409239:-
PCPG	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-4.09	7.1e-05	0.0252	-0.44	-0.32	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
PCPG	cis	rs7849270	0.837	rs4642748	ENSG00000268707.1	RP11-247A12.7	-4.09	7.11e-05	0.0252	-0.35	-0.32	Blood metabolite ratios;	chr9:129092668	chr9:129170434~129170940:+
PCPG	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-4.09	7.11e-05	0.0252	-0.26	-0.32	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
PCPG	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	4.09	7.11e-05	0.0252	0.34	0.32	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
PCPG	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-4.09	7.12e-05	0.0252	-0.37	-0.32	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
PCPG	cis	rs73201462	1	rs11710704	ENSG00000242551.2	POU5F1P6	4.09	7.12e-05	0.0252	0.64	0.32	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328393	chr3:128674735~128677005:-
PCPG	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-4.09	7.12e-05	0.0252	-0.31	-0.32	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
PCPG	cis	rs7772486	0.686	rs6570701	ENSG00000270638.1	RP3-466P17.1	4.09	7.12e-05	0.0252	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145735570~145737218:+
PCPG	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	4.09	7.12e-05	0.0252	0.32	0.32	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	4.09	7.12e-05	0.0252	0.32	0.32	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	4.09	7.12e-05	0.0252	0.32	0.32	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
PCPG	cis	rs6579956	0.542	rs11740092	ENSG00000254226.4	CTB-12O2.1	-4.09	7.13e-05	0.0252	-0.42	-0.32	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152805871	chr5:151949571~152270448:+
PCPG	cis	rs6579956	0.565	rs34578343	ENSG00000254226.4	CTB-12O2.1	-4.09	7.13e-05	0.0252	-0.42	-0.32	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152806544	chr5:151949571~152270448:+
PCPG	cis	rs9650657	0.504	rs10108347	ENSG00000255020.1	AF131216.5	-4.09	7.13e-05	0.0252	-0.42	-0.32	Neuroticism;	chr8:11176008	chr8:11345748~11347502:-
PCPG	cis	rs9650657	0.504	rs10109167	ENSG00000255020.1	AF131216.5	-4.09	7.13e-05	0.0252	-0.42	-0.32	Neuroticism;	chr8:11176016	chr8:11345748~11347502:-
PCPG	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-4.09	7.13e-05	0.0252	-0.4	-0.32	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
PCPG	cis	rs801193	0.901	rs4273746	ENSG00000273142.1	RP11-458F8.4	4.09	7.13e-05	0.0252	0.31	0.32	Aortic root size;	chr7:66836124	chr7:66902857~66906297:+
PCPG	cis	rs34977459	1	rs34977459	ENSG00000211645.2	IGLV1-50	4.09	7.14e-05	0.0253	0.4	0.32	Mean corpuscular hemoglobin;	chr22:21578365	chr22:22327300~22327814:+
PCPG	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-4.09	7.14e-05	0.0253	-0.51	-0.32	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
PCPG	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-4.09	7.14e-05	0.0253	-0.36	-0.32	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
PCPG	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-4.09	7.15e-05	0.0253	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
PCPG	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-4.09	7.15e-05	0.0253	-0.46	-0.32	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
PCPG	cis	rs1009077	0.536	rs35708340	ENSG00000245958.5	RP11-33B1.1	4.09	7.15e-05	0.0253	0.46	0.32	Endometriosis;	chr4:119442215	chr4:119454791~119552025:+
PCPG	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	4.09	7.15e-05	0.0253	0.41	0.32	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
PCPG	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	4.09	7.15e-05	0.0253	0.31	0.32	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
PCPG	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-4.08	7.15e-05	0.0253	-0.35	-0.32	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-4.08	7.15e-05	0.0253	-0.35	-0.32	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
PCPG	cis	rs875971	0.862	rs10274883	ENSG00000235475.1	LINC01372	-4.08	7.15e-05	0.0253	-0.33	-0.32	Aortic root size;	chr7:66651104	chr7:67335976~67340024:+
PCPG	cis	rs324126	0.78	rs2059817	ENSG00000277977.1	CTD-3018O17.5	4.08	7.15e-05	0.0253	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52392659~52392755:+
PCPG	cis	rs5758511	0.68	rs739147	ENSG00000227370.1	RP4-669P10.19	4.08	7.16e-05	0.0253	0.48	0.32	Birth weight;	chr22:42275060	chr22:42132543~42132998:+
PCPG	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-4.08	7.16e-05	0.0253	-0.4	-0.32	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-4.08	7.16e-05	0.0253	-0.4	-0.32	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
PCPG	cis	rs78487399	0.614	rs77981966	ENSG00000234936.1	AC010883.5	4.08	7.16e-05	0.0253	0.68	0.32	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43550825	chr2:43229573~43233394:+
PCPG	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-4.08	7.17e-05	0.0253	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
PCPG	cis	rs2439831	0.867	rs2255440	ENSG00000205771.5	CATSPER2P1	-4.08	7.17e-05	0.0254	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43538269	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-4.08	7.17e-05	0.0254	-0.46	-0.32	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
PCPG	cis	rs4791051	0.723	rs7221805	ENSG00000264491.1	RP11-349A8.3	4.08	7.17e-05	0.0254	0.34	0.32	Heschl's gyrus morphology;	chr17:66458842	chr17:67019934~67021743:-
PCPG	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	4.08	7.17e-05	0.0254	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
PCPG	cis	rs7760535	0.763	rs9487666	ENSG00000271789.1	RP5-1112D6.7	-4.08	7.18e-05	0.0254	-0.31	-0.32	Metabolic traits;	chr6:111547821	chr6:111297126~111298510:+
PCPG	cis	rs2404602	0.655	rs4886507	ENSG00000259514.1	RP11-685G9.2	-4.08	7.18e-05	0.0254	-0.32	-0.32	Blood metabolite levels;	chr15:76917353	chr15:76339609~76342063:-
PCPG	cis	rs6929812	0.664	rs12529840	ENSG00000271755.1	RP1-153G14.4	4.08	7.18e-05	0.0254	0.41	0.32	Neuroticism (multi-trait analysis);	chr6:27426105	chr6:27404010~27406964:-
PCPG	cis	rs6728642	0.908	rs10203833	ENSG00000230606.9	AC159540.1	4.08	7.18e-05	0.0254	0.42	0.32	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97356336	chr2:97416165~97433527:-
PCPG	cis	rs11783469	0.522	rs4872125	ENSG00000253390.1	CTC-756D1.2	-4.08	7.19e-05	0.0254	-0.47	-0.32	Reticulocyte count;	chr8:23410757	chr8:23458601~23484971:+
PCPG	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	4.08	7.19e-05	0.0254	0.33	0.32	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
PCPG	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-4.08	7.19e-05	0.0254	-0.41	-0.32	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
PCPG	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-4.08	7.19e-05	0.0254	-0.41	-0.32	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
PCPG	cis	rs425277	0.585	rs3107157	ENSG00000271806.1	RP5-892K4.1	-4.08	7.19e-05	0.0254	-0.32	-0.32	Height;	chr1:2130530	chr1:2141084~2145279:-
PCPG	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	-4.08	7.19e-05	0.0254	-0.38	-0.32	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
PCPG	cis	rs2302464	1	rs9942247	ENSG00000214846.4	RP11-115L11.1	4.08	7.19e-05	0.0254	0.83	0.32	Cerebrospinal fluid biomarker levels;	chr4:15722452	chr4:15730962~15731627:-
PCPG	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	4.08	7.19e-05	0.0254	0.44	0.32	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
PCPG	cis	rs11662586	0.517	rs7228070	ENSG00000261126.6	RP11-795F19.1	4.08	7.2e-05	0.0254	0.3	0.32	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79938967	chr18:80046900~80095482:+
PCPG	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	4.08	7.2e-05	0.0254	0.46	0.32	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
PCPG	cis	rs2736345	0.755	rs2736340	ENSG00000254774.1	RP11-148O21.3	4.08	7.2e-05	0.0254	0.38	0.32	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:11553224~11554207:-
PCPG	cis	rs8030379	1	rs10906983	ENSG00000230373.7	GOLGA6L5P	-4.08	7.2e-05	0.0254	-0.31	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900431	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1564474	ENSG00000230373.7	GOLGA6L5P	-4.08	7.2e-05	0.0254	-0.31	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901281	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs10152119	ENSG00000230373.7	GOLGA6L5P	-4.08	7.2e-05	0.0254	-0.31	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901629	chr15:84507885~84516814:-
PCPG	cis	rs8030379	1	rs1471552	ENSG00000230373.7	GOLGA6L5P	-4.08	7.2e-05	0.0254	-0.31	-0.32	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901982	chr15:84507885~84516814:-
PCPG	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	4.08	7.2e-05	0.0254	0.33	0.32	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
PCPG	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	4.08	7.21e-05	0.0255	0.56	0.32	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
PCPG	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-4.08	7.21e-05	0.0255	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
PCPG	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-4.08	7.21e-05	0.0255	-0.37	-0.32	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
PCPG	cis	rs7208859	0.673	rs216420	ENSG00000263603.1	CTD-2349P21.5	-4.08	7.21e-05	0.0255	-0.47	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30729469~30731202:+
PCPG	cis	rs4934494	0.768	rs58163515	ENSG00000240996.1	RP11-80H5.7	-4.08	7.21e-05	0.0255	-0.47	-0.32	Red blood cell count;	chr10:89637807	chr10:89694295~89697928:-
PCPG	cis	rs7772486	0.743	rs62433835	ENSG00000270638.1	RP3-466P17.1	-4.08	7.21e-05	0.0255	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.743	rs2092262	ENSG00000270638.1	RP3-466P17.1	-4.08	7.21e-05	0.0255	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.682	rs1337840	ENSG00000270638.1	RP3-466P17.1	-4.08	7.21e-05	0.0255	-0.32	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145735570~145737218:+
PCPG	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	4.08	7.22e-05	0.0255	0.46	0.32	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
PCPG	cis	rs394563	0.901	rs448874	ENSG00000216906.2	RP11-350J20.9	4.08	7.22e-05	0.0255	0.31	0.32	Dupuytren's disease;	chr6:149475831	chr6:149904243~149906418:+
PCPG	cis	rs394563	1	rs394563	ENSG00000216906.2	RP11-350J20.9	4.08	7.22e-05	0.0255	0.31	0.32	Dupuytren's disease;	chr6:149475878	chr6:149904243~149906418:+
PCPG	cis	rs7772486	0.743	rs9376955	ENSG00000270638.1	RP3-466P17.1	4.08	7.22e-05	0.0255	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.805	rs4896831	ENSG00000270638.1	RP3-466P17.1	4.08	7.22e-05	0.0255	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145735570~145737218:+
PCPG	cis	rs7523050	0.643	rs34801874	ENSG00000203897.3	SPATA42	-4.08	7.22e-05	0.0255	-0.48	-0.32	Fat distribution (HIV);	chr1:108861760	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs35860016	ENSG00000203897.3	SPATA42	-4.08	7.22e-05	0.0255	-0.48	-0.32	Fat distribution (HIV);	chr1:108862017	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs35050241	ENSG00000203897.3	SPATA42	-4.08	7.22e-05	0.0255	-0.48	-0.32	Fat distribution (HIV);	chr1:108862254	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs35526993	ENSG00000203897.3	SPATA42	-4.08	7.22e-05	0.0255	-0.48	-0.32	Fat distribution (HIV);	chr1:108862485	chr1:108857217~108858524:+
PCPG	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-4.08	7.23e-05	0.0255	-0.36	-0.32	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
PCPG	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	4.08	7.23e-05	0.0255	0.4	0.32	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
PCPG	cis	rs561341	0.769	rs12941700	ENSG00000265798.5	RP11-271K11.5	-4.08	7.23e-05	0.0255	-0.55	-0.32	Hip circumference adjusted for BMI;	chr17:31858003	chr17:31038575~31059121:-
PCPG	cis	rs950173	1	rs950173	ENSG00000235934.1	AC007405.8	4.08	7.23e-05	0.0255	0.59	0.32	Hippocampal volume;	chr2:171713909	chr2:170816293~170818037:-
PCPG	cis	rs950173	1	rs13000153	ENSG00000235934.1	AC007405.8	4.08	7.23e-05	0.0255	0.59	0.32	Hippocampal volume;	chr2:171729557	chr2:170816293~170818037:-
PCPG	cis	rs7772486	0.686	rs9373473	ENSG00000270638.1	RP3-466P17.1	4.08	7.23e-05	0.0255	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145735570~145737218:+
PCPG	cis	rs1874124	0.836	rs7549963	ENSG00000272823.1	RP11-295M18.6	-4.08	7.24e-05	0.0255	-0.44	-0.32	Cholesterol, total;	chr1:220814918	chr1:220828676~220829211:-
PCPG	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	4.08	7.24e-05	0.0255	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
PCPG	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-4.08	7.24e-05	0.0256	-0.37	-0.32	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
PCPG	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-4.08	7.24e-05	0.0256	-0.37	-0.32	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
PCPG	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	4.08	7.24e-05	0.0256	0.62	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
PCPG	cis	rs4713118	0.869	rs6901520	ENSG00000216901.1	AL022393.7	4.08	7.24e-05	0.0256	0.42	0.32	Parkinson's disease;	chr6:27746796	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9283880	ENSG00000216901.1	AL022393.7	4.08	7.24e-05	0.0256	0.42	0.32	Parkinson's disease;	chr6:27747464	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9283881	ENSG00000216901.1	AL022393.7	4.08	7.24e-05	0.0256	0.42	0.32	Parkinson's disease;	chr6:27747476	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9283882	ENSG00000216901.1	AL022393.7	4.08	7.24e-05	0.0256	0.42	0.32	Parkinson's disease;	chr6:27747479	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9283883	ENSG00000216901.1	AL022393.7	4.08	7.24e-05	0.0256	0.42	0.32	Parkinson's disease;	chr6:27747691	chr6:28176188~28176674:+
PCPG	cis	rs16949788	1	rs7169463	ENSG00000261351.2	CTD-3185P2.1	-4.08	7.24e-05	0.0256	-0.44	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66453591	chr15:66488658~66492109:-
PCPG	cis	rs6456042	0.965	rs1900056	ENSG00000231297.3	RP11-459F1.2	4.08	7.25e-05	0.0256	0.34	0.32	Asthma;	chr6:166132422	chr6:166099665~166113273:+
PCPG	cis	rs9299346	0.521	rs4615635	ENSG00000225376.4	TMEM246-AS1	-4.08	7.25e-05	0.0256	-0.38	-0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101719098	chr9:101468439~101481502:+
PCPG	cis	rs7829975	0.807	rs519019	ENSG00000173295.6	FAM86B3P	4.08	7.25e-05	0.0256	0.35	0.32	Mood instability;	chr8:8737594	chr8:8228595~8244865:+
PCPG	cis	rs9303542	0.559	rs35621842	ENSG00000279036.1	RP11-81K2.2	-4.08	7.25e-05	0.0256	-0.52	-0.32	Epithelial ovarian cancer;Ovarian cancer;	chr17:48528860	chr17:49494223~49497800:-
PCPG	cis	rs16949788	1	rs9672789	ENSG00000261351.2	CTD-3185P2.1	-4.08	7.27e-05	0.0256	-0.45	-0.32	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66421295	chr15:66488658~66492109:-
PCPG	cis	rs6570726	0.846	rs9376954	ENSG00000270638.1	RP3-466P17.1	4.08	7.27e-05	0.0256	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145735570~145737218:+
PCPG	cis	rs8098244	0.617	rs35943794	ENSG00000265752.2	RP11-403A21.1	4.08	7.27e-05	0.0256	0.37	0.32	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23826485	chr18:23957754~23982556:-
PCPG	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	4.08	7.27e-05	0.0256	0.33	0.32	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
PCPG	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-4.08	7.27e-05	0.0256	-0.37	-0.32	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
PCPG	cis	rs801193	0.967	rs2420827	ENSG00000273142.1	RP11-458F8.4	4.08	7.28e-05	0.0257	0.3	0.32	Aortic root size;	chr7:66682114	chr7:66902857~66906297:+
PCPG	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	4.08	7.28e-05	0.0257	0.36	0.32	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	4.08	7.28e-05	0.0257	0.36	0.32	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
PCPG	cis	rs2797160	1	rs2747725	ENSG00000237742.5	RP11-624M8.1	4.08	7.28e-05	0.0257	0.33	0.32	Endometrial cancer;	chr6:125691251	chr6:125578558~125749190:-
PCPG	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-4.08	7.28e-05	0.0257	-0.34	-0.32	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
PCPG	cis	rs4934494	0.727	rs12764076	ENSG00000240996.1	RP11-80H5.7	-4.08	7.28e-05	0.0257	-0.47	-0.32	Red blood cell count;	chr10:89630443	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.634	rs12762448	ENSG00000240996.1	RP11-80H5.7	-4.08	7.28e-05	0.0257	-0.47	-0.32	Red blood cell count;	chr10:89630483	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs12570813	ENSG00000240996.1	RP11-80H5.7	-4.08	7.28e-05	0.0257	-0.47	-0.32	Red blood cell count;	chr10:89630974	chr10:89694295~89697928:-
PCPG	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	4.08	7.28e-05	0.0257	0.44	0.32	Height;	chr6:109403951	chr6:109382795~109383666:+
PCPG	cis	rs763014	0.932	rs35067229	ENSG00000262528.2	LA16c-349E10.1	4.08	7.28e-05	0.0257	0.37	0.32	Height;	chr16:599638	chr16:654611~656194:-
PCPG	cis	rs950169	1	rs950169	ENSG00000235370.6	DNM1P51	4.08	7.29e-05	0.0257	0.32	0.32	Schizophrenia;	chr15:84037709	chr15:84398316~84411701:-
PCPG	cis	rs6696239	0.513	rs2492635	ENSG00000227711.2	RP11-275O4.5	-4.08	7.29e-05	0.0257	-0.37	-0.32	Height;	chr1:227517134	chr1:227509028~227520477:-
PCPG	cis	rs13108904	0.935	rs1680072	ENSG00000253399.1	AC078852.2	4.08	7.29e-05	0.0257	0.32	0.32	Obesity-related traits;	chr4:1287907	chr4:1358479~1359461:+
PCPG	cis	rs13108904	0.935	rs922698	ENSG00000253399.1	AC078852.2	4.08	7.29e-05	0.0257	0.32	0.32	Obesity-related traits;	chr4:1288934	chr4:1358479~1359461:+
PCPG	cis	rs3806843	0.676	rs753280	ENSG00000202515.1	VTRNA1-3	-4.08	7.3e-05	0.0257	-0.34	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140644457	chr5:140726158~140726246:+
PCPG	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	4.08	7.31e-05	0.0257	0.47	0.32	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
PCPG	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-4.08	7.31e-05	0.0258	-0.42	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
PCPG	cis	rs324126	0.78	rs1993531	ENSG00000277977.1	CTD-3018O17.5	4.08	7.31e-05	0.0258	0.37	0.32	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52392659~52392755:+
PCPG	cis	rs2735413	0.563	rs11647117	ENSG00000276007.1	RP11-358L22.3	4.08	7.31e-05	0.0258	0.34	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78024165	chr16:78123243~78124332:+
PCPG	cis	rs748404	0.666	rs7177892	ENSG00000205771.5	CATSPER2P1	-4.08	7.31e-05	0.0258	-0.44	-0.32	Lung cancer;	chr15:43321171	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs7181545	ENSG00000205771.5	CATSPER2P1	-4.08	7.31e-05	0.0258	-0.44	-0.32	Lung cancer;	chr15:43321363	chr15:43726918~43747094:-
PCPG	cis	rs4791051	0.706	rs7225699	ENSG00000264491.1	RP11-349A8.3	-4.08	7.31e-05	0.0258	-0.36	-0.32	Heschl's gyrus morphology;	chr17:66485891	chr17:67019934~67021743:-
PCPG	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	4.08	7.32e-05	0.0258	0.36	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	4.08	7.32e-05	0.0258	0.36	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	4.08	7.32e-05	0.0258	0.36	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
PCPG	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	4.08	7.32e-05	0.0258	0.36	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
PCPG	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
PCPG	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-4.08	7.32e-05	0.0258	-0.46	-0.32	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
PCPG	cis	rs752864	0.934	rs752866	ENSG00000259438.1	CTD-2650P22.1	4.08	7.32e-05	0.0258	0.38	0.32	Number of common colds;	chr15:52339596	chr15:52010999~52019095:-
PCPG	cis	rs56804039	0.524	rs11785096	ENSG00000253893.2	FAM85B	4.08	7.32e-05	0.0258	0.55	0.32	Cervical cancer;	chr8:8515304	chr8:8167819~8226614:-
PCPG	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	4.08	7.32e-05	0.0258	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
PCPG	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	4.08	7.32e-05	0.0258	0.42	0.32	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
PCPG	cis	rs11662586	0.517	rs7230837	ENSG00000261126.6	RP11-795F19.1	4.08	7.32e-05	0.0258	0.3	0.32	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79935384	chr18:80046900~80095482:+
PCPG	cis	rs4143844	1	rs34017665	ENSG00000259251.2	RP11-643M14.1	4.08	7.32e-05	0.0258	0.66	0.32	Bipolar disorder and schizophrenia;	chr15:62027008	chr15:62060503~62062434:+
PCPG	cis	rs911119	1	rs3088162	ENSG00000270001.1	RP11-218C14.8	-4.08	7.32e-05	0.0258	-0.5	-0.32	Chronic kidney disease;	chr20:23627115	chr20:23631826~23632316:-
PCPG	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	4.08	7.32e-05	0.0258	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
PCPG	cis	rs34421088	0.532	rs1369368	ENSG00000255020.1	AF131216.5	4.08	7.33e-05	0.0258	0.39	0.32	Neuroticism;	chr8:11292704	chr8:11345748~11347502:-
PCPG	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	4.08	7.33e-05	0.0258	0.34	0.32	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
PCPG	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	4.08	7.33e-05	0.0258	0.38	0.32	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
PCPG	cis	rs2281603	0.694	rs45618332	ENSG00000259116.1	RP11-973N13.4	-4.08	7.33e-05	0.0258	-0.28	-0.32	Lymphocyte counts;	chr14:64439258	chr14:64514154~64540368:-
PCPG	cis	rs7246657	0.524	rs10411251	ENSG00000226686.6	LINC01535	-4.08	7.34e-05	0.0258	-0.57	-0.32	Coronary artery calcification;	chr19:36937853	chr19:37251912~37265535:+
PCPG	cis	rs6464929	0.956	rs66691097	ENSG00000281189.1	GHET1	4.08	7.34e-05	0.0258	0.41	0.32	Pediatric bone mineral content (hip);	chr7:149008851	chr7:148987527~148989432:+
PCPG	cis	rs6464929	0.956	rs11980538	ENSG00000281189.1	GHET1	4.08	7.34e-05	0.0258	0.41	0.32	Pediatric bone mineral content (hip);	chr7:149009071	chr7:148987527~148989432:+
PCPG	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	4.08	7.35e-05	0.0258	0.42	0.32	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
PCPG	cis	rs2554380	0.55	rs6602997	ENSG00000230373.7	GOLGA6L5P	-4.08	7.35e-05	0.0259	-0.36	-0.32	Height;	chr15:83852646	chr15:84507885~84516814:-
PCPG	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	4.08	7.35e-05	0.0259	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
PCPG	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-4.08	7.35e-05	0.0259	-0.39	-0.32	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-4.08	7.35e-05	0.0259	-0.39	-0.32	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
PCPG	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	4.08	7.35e-05	0.0259	0.39	0.32	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
PCPG	cis	rs1440410	0.571	rs4410482	ENSG00000250326.1	RP11-284M14.1	4.08	7.36e-05	0.0259	0.28	0.32	Ischemic stroke;	chr4:143116498	chr4:142933195~143184861:-
PCPG	cis	rs4143844	1	rs11634312	ENSG00000259251.2	RP11-643M14.1	4.08	7.36e-05	0.0259	0.66	0.32	Bipolar disorder and schizophrenia;	chr15:62038868	chr15:62060503~62062434:+
PCPG	cis	rs7824557	0.767	rs7003241	ENSG00000184608.7	FAM167A-AS1	4.08	7.36e-05	0.0259	0.44	0.32	Retinal vascular caliber;	chr8:11311566	chr8:11368402~11438658:+
PCPG	cis	rs7824557	0.767	rs1897950	ENSG00000184608.7	FAM167A-AS1	4.08	7.36e-05	0.0259	0.44	0.32	Retinal vascular caliber;	chr8:11312042	chr8:11368402~11438658:+
PCPG	cis	rs10751667	0.643	rs10902245	ENSG00000255142.1	AP006621.6	-4.08	7.36e-05	0.0259	-0.3	-0.32	Alzheimer's disease (late onset);	chr11:953014	chr11:781645~782105:+
PCPG	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	4.08	7.36e-05	0.0259	0.41	0.32	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
PCPG	cis	rs1991651	0.578	rs13259086	ENSG00000255020.1	AF131216.5	4.08	7.36e-05	0.0259	0.4	0.32	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632708	chr8:11345748~11347502:-
PCPG	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	4.08	7.36e-05	0.0259	0.31	0.32	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
PCPG	cis	rs13108904	0.935	rs4974575	ENSG00000253399.1	AC078852.2	-4.08	7.36e-05	0.0259	-0.33	-0.32	Obesity-related traits;	chr4:1258240	chr4:1358479~1359461:+
PCPG	cis	rs357618	1	rs357618	ENSG00000260581.1	CTB-113P19.4	4.08	7.37e-05	0.0259	0.37	0.32	Basophil percentage of white cells;	chr5:151467051	chr5:151652275~151655449:+
PCPG	cis	rs2735413	0.563	rs11646833	ENSG00000276007.1	RP11-358L22.3	4.08	7.37e-05	0.0259	0.34	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78023482	chr16:78123243~78124332:+
PCPG	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	4.08	7.37e-05	0.0259	0.38	0.32	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
PCPG	cis	rs1499614	1	rs1267817	ENSG00000230189.5	GS1-124K5.2	4.08	7.37e-05	0.0259	0.46	0.32	Gout;	chr7:66645053	chr7:66409143~66490059:-
PCPG	cis	rs73198271	0.653	rs10099808	ENSG00000253893.2	FAM85B	-4.08	7.38e-05	0.0259	-0.41	-0.32	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8167819~8226614:-
PCPG	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	4.08	7.38e-05	0.026	0.48	0.32	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
PCPG	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	4.08	7.38e-05	0.026	0.48	0.32	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
PCPG	cis	rs56804039	0.524	rs6982112	ENSG00000253893.2	FAM85B	-4.08	7.38e-05	0.026	-0.56	-0.32	Cervical cancer;	chr8:8514866	chr8:8167819~8226614:-
PCPG	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	4.08	7.38e-05	0.026	0.42	0.32	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	4.08	7.38e-05	0.026	0.42	0.32	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
PCPG	cis	rs79407237	0.635	rs12631431	ENSG00000225733.4	FGD5-AS1	-4.08	7.39e-05	0.026	-0.43	-0.32	Sjögren's syndrome;	chr3:14713756	chr3:14920347~14948424:-
PCPG	cis	rs911186	0.812	rs3800316	ENSG00000216901.1	AL022393.7	4.08	7.39e-05	0.026	0.44	0.32	Autism spectrum disorder or schizophrenia;	chr6:27288323	chr6:28176188~28176674:+
PCPG	cis	rs6696239	0.531	rs2644140	ENSG00000227711.2	RP11-275O4.5	-4.08	7.39e-05	0.026	-0.38	-0.32	Height;	chr1:227509680	chr1:227509028~227520477:-
PCPG	cis	rs6696239	0.531	rs2018401	ENSG00000227711.2	RP11-275O4.5	-4.08	7.39e-05	0.026	-0.38	-0.32	Height;	chr1:227509952	chr1:227509028~227520477:-
PCPG	cis	rs6696239	0.531	rs2644150	ENSG00000227711.2	RP11-275O4.5	-4.08	7.39e-05	0.026	-0.38	-0.32	Height;	chr1:227514120	chr1:227509028~227520477:-
PCPG	cis	rs6696239	0.531	rs2644151	ENSG00000227711.2	RP11-275O4.5	-4.08	7.39e-05	0.026	-0.38	-0.32	Height;	chr1:227514993	chr1:227509028~227520477:-
PCPG	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-4.08	7.39e-05	0.026	-0.4	-0.32	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
PCPG	cis	rs2275565	0.872	rs72762130	ENSG00000230325.1	RP11-385F5.4	4.08	7.4e-05	0.026	0.51	0.32	Homocysteine levels;	chr1:236893410	chr1:236540094~236550280:-
PCPG	cis	rs9650657	0.645	rs4841409	ENSG00000255020.1	AF131216.5	4.08	7.4e-05	0.026	0.41	0.32	Neuroticism;	chr8:10658864	chr8:11345748~11347502:-
PCPG	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-4.08	7.4e-05	0.026	-0.33	-0.32	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
PCPG	cis	rs7172677	1	rs11072525	ENSG00000261543.1	RP11-665J16.1	-4.08	7.4e-05	0.026	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75126769	chr15:74152800~74179226:-
PCPG	cis	rs720064	0.586	rs9958904	ENSG00000265752.2	RP11-403A21.1	-4.08	7.41e-05	0.026	-0.36	-0.32	Strep throat;	chr18:23969940	chr18:23957754~23982556:-
PCPG	cis	rs4489787	1	rs2705155	ENSG00000240399.1	RP1-228P16.1	4.08	7.41e-05	0.026	0.37	0.32	Prostate cancer (SNP x SNP interaction);	chr12:48513307	chr12:48054813~48055591:-
PCPG	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-4.08	7.41e-05	0.026	-0.37	-0.32	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
PCPG	cis	rs7824557	0.628	rs7841394	ENSG00000255020.1	AF131216.5	4.08	7.41e-05	0.026	0.41	0.32	Retinal vascular caliber;	chr8:11328162	chr8:11345748~11347502:-
PCPG	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-4.08	7.42e-05	0.026	-0.38	-0.32	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
PCPG	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	4.08	7.42e-05	0.026	0.5	0.32	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
PCPG	cis	rs7208859	0.524	rs73263982	ENSG00000263603.1	CTD-2349P21.5	-4.08	7.42e-05	0.0261	-0.47	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30729469~30731202:+
PCPG	cis	rs7118412	0.793	rs6591043	ENSG00000260966.1	RP11-690D19.3	-4.08	7.42e-05	0.0261	-0.34	-0.32	Disc degeneration (lumbar);	chr11:103690461	chr11:103050687~103055799:-
PCPG	cis	rs7118412	0.793	rs6591044	ENSG00000260966.1	RP11-690D19.3	-4.08	7.42e-05	0.0261	-0.34	-0.32	Disc degeneration (lumbar);	chr11:103690525	chr11:103050687~103055799:-
PCPG	cis	rs13108904	0.935	rs1732102	ENSG00000253399.1	AC078852.2	4.08	7.43e-05	0.0261	0.32	0.32	Obesity-related traits;	chr4:1284136	chr4:1358479~1359461:+
PCPG	cis	rs6107516	0.763	rs13045348	ENSG00000225022.1	UBE2D3P1	-4.08	7.43e-05	0.0261	-0.35	-0.32	Creutzfeldt-Jakob disease (sporadic);Creutzfeldt-Jakob disease (variant);	chr20:4694943	chr20:5292388~5292831:-
PCPG	cis	rs853679	0.723	rs1736904	ENSG00000219392.1	RP1-265C24.5	-4.08	7.43e-05	0.0261	-0.4	-0.32	Depression;	chr6:28251492	chr6:28115628~28116551:+
PCPG	cis	rs11168351	0.75	rs11168366	ENSG00000240399.1	RP1-228P16.1	-4.08	7.43e-05	0.0261	-0.34	-0.32	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48054813~48055591:-
PCPG	cis	rs13113518	0.513	rs13132085	ENSG00000272969.1	RP11-528I4.2	-4.08	7.43e-05	0.0261	-0.38	-0.32	Height;	chr4:55593918	chr4:55547112~55547889:+
PCPG	cis	rs9303029	1	rs2291394	ENSG00000279744.1	RP13-20L14.10	-4.08	7.43e-05	0.0261	-0.42	-0.32	Protein quantitative trait loci;	chr17:82446018	chr17:82462601~82464255:+
PCPG	cis	rs3758911	1	rs1046095	ENSG00000255353.1	RP11-382M14.1	-4.08	7.43e-05	0.0261	-0.4	-0.32	Coronary artery disease;	chr11:107326509	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs3758911	ENSG00000255353.1	RP11-382M14.1	-4.08	7.43e-05	0.0261	-0.4	-0.32	Coronary artery disease;	chr11:107326914	chr11:107176286~107177530:+
PCPG	cis	rs9847710	0.967	rs2244552	ENSG00000242142.1	SERBP1P3	4.08	7.43e-05	0.0261	0.33	0.32	Ulcerative colitis;	chr3:53021506	chr3:53064283~53065091:-
PCPG	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	4.08	7.43e-05	0.0261	0.37	0.32	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	4.08	7.43e-05	0.0261	0.37	0.32	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	4.08	7.43e-05	0.0261	0.37	0.32	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	4.08	7.43e-05	0.0261	0.37	0.32	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
PCPG	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-4.07	7.43e-05	0.0261	-0.26	-0.32	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
PCPG	cis	rs57502260	0.573	rs11228295	ENSG00000212093.1	AP000807.1	4.07	7.43e-05	0.0261	0.28	0.32	Total body bone mineral density (age 45-60);	chr11:68621120	chr11:68506083~68506166:-
PCPG	cis	rs7937890	0.559	rs2597196	ENSG00000251991.1	RNU7-49P	-4.07	7.43e-05	0.0261	-0.36	-0.32	Mitochondrial DNA levels;	chr11:14470055	chr11:14478892~14478953:+
PCPG	cis	rs11250098	0.541	rs6997839	ENSG00000255020.1	AF131216.5	-4.07	7.44e-05	0.0261	-0.41	-0.32	Morning vs. evening chronotype;	chr8:10908518	chr8:11345748~11347502:-
PCPG	cis	rs11250098	0.541	rs6997997	ENSG00000255020.1	AF131216.5	-4.07	7.44e-05	0.0261	-0.41	-0.32	Morning vs. evening chronotype;	chr8:10908572	chr8:11345748~11347502:-
PCPG	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	4.07	7.44e-05	0.0261	0.34	0.32	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
PCPG	cis	rs11992162	1	rs11994417	ENSG00000255020.1	AF131216.5	4.07	7.45e-05	0.0261	0.41	0.32	Monocyte count;	chr8:11975753	chr8:11345748~11347502:-
PCPG	cis	rs4819052	0.851	rs10470245	ENSG00000215447.6	BX322557.10	-4.07	7.45e-05	0.0261	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45288052~45291738:+
PCPG	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-4.07	7.45e-05	0.0261	-0.41	-0.32	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
PCPG	cis	rs7444	0.941	rs878825	ENSG00000211645.2	IGLV1-50	4.07	7.45e-05	0.0262	0.36	0.32	Systemic lupus erythematosus;	chr22:21627960	chr22:22327300~22327814:+
PCPG	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	4.07	7.45e-05	0.0262	0.36	0.32	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
PCPG	cis	rs561341	1	rs4795670	ENSG00000265798.5	RP11-271K11.5	4.07	7.46e-05	0.0262	0.55	0.32	Hip circumference adjusted for BMI;	chr17:31917820	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs8073186	ENSG00000265798.5	RP11-271K11.5	4.07	7.46e-05	0.0262	0.55	0.32	Hip circumference adjusted for BMI;	chr17:31917937	chr17:31038575~31059121:-
PCPG	cis	rs6012953	0.845	rs968701	ENSG00000231742.4	LINC01273	-4.07	7.46e-05	0.0262	-0.33	-0.32	Vitiligo;	chr20:50578711	chr20:50172550~50176671:+
PCPG	cis	rs6012953	0.845	rs718053	ENSG00000231742.4	LINC01273	-4.07	7.46e-05	0.0262	-0.33	-0.32	Vitiligo;	chr20:50580065	chr20:50172550~50176671:+
PCPG	cis	rs9472414	0.66	rs16873364	ENSG00000229349.2	ACTG1P9	-4.07	7.46e-05	0.0262	-0.52	-0.32	Height;	chr6:45360420	chr6:46204729~46207386:+
PCPG	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-4.07	7.46e-05	0.0262	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-4.07	7.46e-05	0.0262	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-4.07	7.46e-05	0.0262	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-4.07	7.46e-05	0.0262	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
PCPG	cis	rs9859260	0.744	rs3933	ENSG00000207650.1	MIR570	-4.07	7.47e-05	0.0262	-0.33	-0.32	Mean corpuscular volume;	chr3:196058126	chr3:195699401~195699497:+
PCPG	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	4.07	7.47e-05	0.0262	0.41	0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
PCPG	cis	rs7746199	0.736	rs6904596	ENSG00000219392.1	RP1-265C24.5	-4.07	7.47e-05	0.0262	-0.61	-0.32	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28115628~28116551:+
PCPG	cis	rs7727544	0.618	rs2631367	ENSG00000233006.5	AC034220.3	-4.07	7.47e-05	0.0262	-0.23	-0.32	Blood metabolite levels;	chr5:132369766	chr5:132311285~132369916:-
PCPG	cis	rs853679	1	rs735765	ENSG00000219392.1	RP1-265C24.5	-4.07	7.47e-05	0.0262	-0.54	-0.32	Depression;	chr6:28202519	chr6:28115628~28116551:+
PCPG	cis	rs7586085	0.626	rs1076969	ENSG00000229195.1	AC009495.4	-4.07	7.48e-05	0.0262	-0.3	-0.32	Total body bone mineral density;	chr2:165784064	chr2:165794857~165846091:-
PCPG	cis	rs7586085	0.626	rs744158	ENSG00000229195.1	AC009495.4	-4.07	7.48e-05	0.0262	-0.3	-0.32	Total body bone mineral density;	chr2:165784065	chr2:165794857~165846091:-
PCPG	cis	rs2404602	0.692	rs2120108	ENSG00000259514.1	RP11-685G9.2	4.07	7.48e-05	0.0262	0.32	0.32	Blood metabolite levels;	chr15:76577588	chr15:76339609~76342063:-
PCPG	cis	rs9299346	0.582	rs1323411	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101666817	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10113872	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101667142	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1924030	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101667841	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2224766	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101667977	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2025335	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101668064	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2025334	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101668084	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs2025333	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101668232	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs12377563	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101668587	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs12376170	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101668805	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs13298935	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101668950	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10989588	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101669197	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1323436	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101669876	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1323435	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101669895	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1323434	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101670011	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs942142	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101670591	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs10512285	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101670752	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs1885980	ENSG00000225376.4	TMEM246-AS1	4.07	7.49e-05	0.0262	0.38	0.32	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101671154	chr9:101468439~101481502:+
PCPG	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-4.07	7.49e-05	0.0262	-0.36	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
PCPG	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	4.07	7.49e-05	0.0262	0.4	0.32	Height;	chr6:109738307	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	4.07	7.49e-05	0.0262	0.4	0.32	Height;	chr6:109738751	chr6:109382795~109383666:+
PCPG	cis	rs6714710	0.603	rs956039	ENSG00000278766.2	AC159540.2	4.07	7.49e-05	0.0263	0.36	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800385	chr2:97421075~97434847:+
PCPG	cis	rs6714710	0.603	rs717417	ENSG00000278766.2	AC159540.2	4.07	7.49e-05	0.0263	0.36	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800387	chr2:97421075~97434847:+
PCPG	cis	rs7192392	0.527	rs67382945	ENSG00000261472.1	RP11-467I17.1	4.07	7.49e-05	0.0263	0.38	0.32	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr16:78902175	chr16:79505603~79516293:+
PCPG	cis	rs7705042	0.581	rs17649451	ENSG00000280047.1	CTC-463A16.1	-4.07	7.5e-05	0.0263	-0.46	-0.32	Asthma;	chr5:142169971	chr5:142165767~142168387:+
PCPG	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	4.07	7.5e-05	0.0263	0.35	0.32	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
PCPG	cis	rs5742933	0.557	rs6756571	ENSG00000273240.1	RP11-455J20.3	4.07	7.5e-05	0.0263	0.35	0.32	Ferritin levels;	chr2:189640971	chr2:189763859~189764456:-
PCPG	cis	rs11671005	0.779	rs3752112	ENSG00000269600.1	AC016629.3	-4.07	7.5e-05	0.0263	-0.49	-0.32	Mean platelet volume;	chr19:58480853	chr19:58593896~58599355:-
PCPG	cis	rs7610312	0.583	rs2056119	ENSG00000273493.1	RP11-80H18.4	-4.07	7.5e-05	0.0263	-0.37	-0.32	Red blood cell count;	chr3:58323666	chr3:58329965~58330118:+
PCPG	cis	rs964611	0.748	rs55831142	ENSG00000259488.2	RP11-154J22.1	-4.07	7.5e-05	0.0263	-0.39	-0.32	Metabolite levels (Pyroglutamine);	chr15:48277319	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.935	rs7495591	ENSG00000259488.2	RP11-154J22.1	-4.07	7.5e-05	0.0263	-0.39	-0.32	Metabolite levels (Pyroglutamine);	chr15:48278571	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.935	rs74011994	ENSG00000259488.2	RP11-154J22.1	-4.07	7.5e-05	0.0263	-0.39	-0.32	Metabolite levels (Pyroglutamine);	chr15:48283226	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.935	rs8029972	ENSG00000259488.2	RP11-154J22.1	-4.07	7.5e-05	0.0263	-0.39	-0.32	Metabolite levels (Pyroglutamine);	chr15:48285970	chr15:48312353~48331856:-
PCPG	cis	rs3758911	0.861	rs2355840	ENSG00000255353.1	RP11-382M14.1	-4.07	7.51e-05	0.0263	-0.44	-0.32	Coronary artery disease;	chr11:107287251	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs11212132	ENSG00000255353.1	RP11-382M14.1	-4.07	7.51e-05	0.0263	-0.44	-0.32	Coronary artery disease;	chr11:107288576	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs10789594	ENSG00000255353.1	RP11-382M14.1	-4.07	7.51e-05	0.0263	-0.44	-0.32	Coronary artery disease;	chr11:107290391	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs7131522	ENSG00000255353.1	RP11-382M14.1	-4.07	7.51e-05	0.0263	-0.44	-0.32	Coronary artery disease;	chr11:107293773	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.828	rs11212138	ENSG00000255353.1	RP11-382M14.1	-4.07	7.51e-05	0.0263	-0.44	-0.32	Coronary artery disease;	chr11:107294553	chr11:107176286~107177530:+
PCPG	cis	rs911119	0.955	rs6036474	ENSG00000270001.1	RP11-218C14.8	-4.07	7.51e-05	0.0263	-0.51	-0.32	Chronic kidney disease;	chr20:23623777	chr20:23631826~23632316:-
PCPG	cis	rs6570726	0.846	rs1935616	ENSG00000270638.1	RP3-466P17.1	4.07	7.51e-05	0.0263	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145735570~145737218:+
PCPG	cis	rs6570726	0.846	rs9399559	ENSG00000270638.1	RP3-466P17.1	4.07	7.51e-05	0.0263	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9376956	ENSG00000270638.1	RP3-466P17.1	4.07	7.51e-05	0.0263	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs9497380	ENSG00000270638.1	RP3-466P17.1	4.07	7.51e-05	0.0263	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.658	rs6570706	ENSG00000270638.1	RP3-466P17.1	4.07	7.51e-05	0.0263	0.34	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145735570~145737218:+
PCPG	cis	rs116248771	0.739	rs73156437	ENSG00000272087.1	RP11-379F4.7	4.07	7.51e-05	0.0263	0.48	0.32	diarrhoeal disease at age 2;	chr3:158641495	chr3:158693120~158693768:-
PCPG	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-4.07	7.52e-05	0.0263	-0.41	-0.32	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
PCPG	cis	rs13118159	0.55	rs2878607	ENSG00000254094.1	AC078852.1	-4.07	7.52e-05	0.0263	-0.41	-0.32	Longevity;	chr4:1359522	chr4:1356581~1358075:+
PCPG	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	4.07	7.52e-05	0.0263	0.41	0.32	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
PCPG	cis	rs10844706	0.699	rs2401390	ENSG00000278635.1	CTD-2318O12.1	-4.07	7.52e-05	0.0263	-0.4	-0.32	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9415641~9416718:+
PCPG	cis	rs6840258	0.76	rs340637	ENSG00000251411.1	RP11-397E7.4	4.07	7.52e-05	0.0263	0.33	0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87008040	chr4:86913266~86914817:-
PCPG	cis	rs6840258	0.723	rs340633	ENSG00000251411.1	RP11-397E7.4	4.07	7.52e-05	0.0263	0.33	0.32	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87010746	chr4:86913266~86914817:-
PCPG	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	4.07	7.53e-05	0.0263	0.33	0.32	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
PCPG	cis	rs2281603	0.762	rs10144661	ENSG00000259116.1	RP11-973N13.4	-4.07	7.53e-05	0.0263	-0.3	-0.32	Lymphocyte counts;	chr14:64569651	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.762	rs61987035	ENSG00000259116.1	RP11-973N13.4	-4.07	7.53e-05	0.0263	-0.3	-0.32	Lymphocyte counts;	chr14:64571149	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.762	rs10150987	ENSG00000259116.1	RP11-973N13.4	-4.07	7.53e-05	0.0263	-0.3	-0.32	Lymphocyte counts;	chr14:64571472	chr14:64514154~64540368:-
PCPG	cis	rs9880211	0.904	rs9857833	ENSG00000273486.1	RP11-731C17.2	4.07	7.53e-05	0.0264	0.43	0.32	Height;Body mass index;	chr3:136685625	chr3:136837338~136839021:-
PCPG	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	4.07	7.53e-05	0.0264	0.41	0.32	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
PCPG	cis	rs698833	0.506	rs713448	ENSG00000236502.1	SIX3-AS1	4.07	7.53e-05	0.0264	0.42	0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44277738	chr2:44940154~44941873:-
PCPG	cis	rs2404602	0.692	rs1838048	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76639338	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs56193230	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76642131	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs35077207	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76642965	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs35195096	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76646106	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs34287706	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76650061	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.669	rs12438540	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76650872	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs36070630	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76656918	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs8037005	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76658768	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs35498563	ENSG00000259514.1	RP11-685G9.2	-4.07	7.53e-05	0.0264	-0.32	-0.32	Blood metabolite levels;	chr15:76666527	chr15:76339609~76342063:-
PCPG	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-4.07	7.54e-05	0.0264	-0.33	-0.32	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
PCPG	cis	rs3764021	0.87	rs2401393	ENSG00000278635.1	CTD-2318O12.1	-4.07	7.54e-05	0.0264	-0.38	-0.32	Type 1 diabetes;	chr12:9726488	chr12:9415641~9416718:+
PCPG	cis	rs11168249	0.819	rs2525051	ENSG00000276691.1	RP5-1057I20.5	4.07	7.54e-05	0.0264	0.35	0.32	Lymphocyte counts;Inflammatory bowel disease;Ulcerative colitis;	chr12:47802156	chr12:47788426~47788971:+
PCPG	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	4.07	7.55e-05	0.0264	0.43	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
PCPG	cis	rs801193	0.569	rs2659908	ENSG00000235475.1	LINC01372	4.07	7.55e-05	0.0264	0.33	0.32	Aortic root size;	chr7:66695835	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs2659907	ENSG00000235475.1	LINC01372	4.07	7.55e-05	0.0264	0.33	0.32	Aortic root size;	chr7:66699045	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs7782587	ENSG00000235475.1	LINC01372	4.07	7.55e-05	0.0264	0.33	0.32	Aortic root size;	chr7:66701485	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs4717315	ENSG00000235475.1	LINC01372	4.07	7.55e-05	0.0264	0.33	0.32	Aortic root size;	chr7:66713338	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.527	rs2707837	ENSG00000235475.1	LINC01372	4.07	7.55e-05	0.0264	0.33	0.32	Aortic root size;	chr7:66716086	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs2707824	ENSG00000235475.1	LINC01372	4.07	7.55e-05	0.0264	0.33	0.32	Aortic root size;	chr7:66724256	chr7:67335976~67340024:+
PCPG	cis	rs7824557	0.527	rs2572448	ENSG00000255556.2	RP11-351I21.6	-4.07	7.56e-05	0.0264	-0.34	-0.32	Retinal vascular caliber;	chr8:11381843	chr8:12378679~12380265:-
PCPG	cis	rs7824557	0.527	rs2572447	ENSG00000255556.2	RP11-351I21.6	-4.07	7.56e-05	0.0264	-0.34	-0.32	Retinal vascular caliber;	chr8:11382001	chr8:12378679~12380265:-
PCPG	cis	rs7824557	0.527	rs2572446	ENSG00000255556.2	RP11-351I21.6	-4.07	7.56e-05	0.0264	-0.34	-0.32	Retinal vascular caliber;	chr8:11382056	chr8:12378679~12380265:-
PCPG	cis	rs7824557	0.527	rs10109537	ENSG00000255556.2	RP11-351I21.6	-4.07	7.56e-05	0.0264	-0.34	-0.32	Retinal vascular caliber;	chr8:11382131	chr8:12378679~12380265:-
PCPG	cis	rs2228479	0.557	rs57071566	ENSG00000268218.1	AC137932.4	-4.07	7.56e-05	0.0264	-0.47	-0.32	Skin colour saturation;	chr16:89822919	chr16:89268104~89273044:+
PCPG	cis	rs2228479	0.85	rs62054224	ENSG00000268218.1	AC137932.4	-4.07	7.56e-05	0.0264	-0.47	-0.32	Skin colour saturation;	chr16:89825663	chr16:89268104~89273044:+
PCPG	cis	rs4713118	0.869	rs6902689	ENSG00000216901.1	AL022393.7	4.07	7.56e-05	0.0264	0.41	0.32	Parkinson's disease;	chr6:27741662	chr6:28176188~28176674:+
PCPG	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	4.07	7.56e-05	0.0264	0.4	0.32	Height;	chr6:109558247	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	4.07	7.56e-05	0.0264	0.4	0.32	Height;	chr6:109564443	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	4.07	7.56e-05	0.0264	0.4	0.32	Height;	chr6:109571489	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	4.07	7.56e-05	0.0264	0.4	0.32	Height;	chr6:109576414	chr6:109382795~109383666:+
PCPG	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-4.07	7.56e-05	0.0264	-0.37	-0.32	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
PCPG	cis	rs6957923	0.747	rs10950950	ENSG00000230658.1	KLHL7-AS1	4.07	7.56e-05	0.0264	0.38	0.32	Height;	chr7:23484124	chr7:23101228~23105703:-
PCPG	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	4.07	7.57e-05	0.0264	0.37	0.32	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	4.07	7.57e-05	0.0264	0.37	0.32	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	4.07	7.57e-05	0.0264	0.37	0.32	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	4.07	7.57e-05	0.0264	0.37	0.32	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	4.07	7.57e-05	0.0264	0.37	0.32	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	4.07	7.57e-05	0.0264	0.37	0.32	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
PCPG	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	4.07	7.57e-05	0.0264	0.33	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
PCPG	cis	rs2841233	0.692	rs2028416	ENSG00000258701.1	LINC00638	4.07	7.57e-05	0.0264	0.36	0.32	IgG glycosylation;	chr14:104882215	chr14:104821201~104823718:+
PCPG	cis	rs2440129	0.611	rs1042356	ENSG00000262089.1	RP11-589P10.5	4.07	7.57e-05	0.0264	0.22	0.32	Tonsillectomy;	chr17:6999424	chr17:6994642~6995189:-
PCPG	cis	rs2836974	1	rs28360661	ENSG00000252915.1	Y_RNA	-4.07	7.57e-05	0.0264	-0.35	-0.32	Cognitive function;	chr21:39310046	chr21:39344537~39344628:+
PCPG	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-4.07	7.58e-05	0.0264	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-4.07	7.58e-05	0.0264	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-4.07	7.58e-05	0.0264	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
PCPG	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-4.07	7.58e-05	0.0264	-0.32	-0.32	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
PCPG	cis	rs453301	0.657	rs36056437	ENSG00000173295.6	FAM86B3P	4.07	7.58e-05	0.0265	0.37	0.32	Joint mobility (Beighton score);	chr8:8935355	chr8:8228595~8244865:+
PCPG	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-4.07	7.58e-05	0.0265	-0.4	-0.32	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
PCPG	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	4.07	7.58e-05	0.0265	0.38	0.32	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
PCPG	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-4.07	7.59e-05	0.0265	-0.4	-0.32	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-4.07	7.59e-05	0.0265	-0.4	-0.32	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
PCPG	cis	rs2562456	0.833	rs516519	ENSG00000213976.4	CTD-2561J22.2	4.07	7.59e-05	0.0265	0.39	0.32	Pain;	chr19:21298730	chr19:21382865~21387177:+
PCPG	cis	rs2562456	0.833	rs552800	ENSG00000213976.4	CTD-2561J22.2	4.07	7.59e-05	0.0265	0.39	0.32	Pain;	chr19:21301840	chr19:21382865~21387177:+
PCPG	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-4.07	7.59e-05	0.0265	-0.42	-0.32	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
PCPG	cis	rs11638352	1	rs2733203	ENSG00000205771.5	CATSPER2P1	4.07	7.59e-05	0.0265	0.55	0.32	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44123404	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs2615288	ENSG00000205771.5	CATSPER2P1	4.07	7.59e-05	0.0265	0.55	0.32	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44123688	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs2615287	ENSG00000205771.5	CATSPER2P1	4.07	7.59e-05	0.0265	0.55	0.32	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44123795	chr15:43726918~43747094:-
PCPG	cis	rs4143844	1	rs4143844	ENSG00000259251.2	RP11-643M14.1	-4.07	7.59e-05	0.0265	-0.66	-0.32	Bipolar disorder and schizophrenia;	chr15:62020641	chr15:62060503~62062434:+
PCPG	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	4.07	7.6e-05	0.0265	0.38	0.32	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
PCPG	cis	rs13126694	0.75	rs6833295	ENSG00000248429.4	RP11-597D13.9	4.07	7.6e-05	0.0265	0.33	0.32	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158170752~158202877:+
PCPG	cis	rs2404602	0.692	rs55676827	ENSG00000259514.1	RP11-685G9.2	-4.07	7.6e-05	0.0265	-0.32	-0.32	Blood metabolite levels;	chr15:76669375	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs10444858	ENSG00000259514.1	RP11-685G9.2	-4.07	7.6e-05	0.0265	-0.32	-0.32	Blood metabolite levels;	chr15:76670163	chr15:76339609~76342063:-
PCPG	cis	rs763014	0.865	rs2071979	ENSG00000262528.2	LA16c-349E10.1	4.07	7.6e-05	0.0265	0.38	0.32	Height;	chr16:574114	chr16:654611~656194:-
PCPG	cis	rs763014	0.865	rs2384977	ENSG00000262528.2	LA16c-349E10.1	4.07	7.6e-05	0.0265	0.38	0.32	Height;	chr16:575388	chr16:654611~656194:-
PCPG	cis	rs763014	0.898	rs4984896	ENSG00000262528.2	LA16c-349E10.1	4.07	7.6e-05	0.0265	0.38	0.32	Height;	chr16:575493	chr16:654611~656194:-
PCPG	cis	rs763014	0.931	rs2071980	ENSG00000262528.2	LA16c-349E10.1	4.07	7.6e-05	0.0265	0.38	0.32	Height;	chr16:576346	chr16:654611~656194:-
PCPG	cis	rs763014	0.931	rs10903017	ENSG00000262528.2	LA16c-349E10.1	4.07	7.6e-05	0.0265	0.38	0.32	Height;	chr16:577920	chr16:654611~656194:-
PCPG	cis	rs763014	0.931	rs3752568	ENSG00000262528.2	LA16c-349E10.1	4.07	7.6e-05	0.0265	0.38	0.32	Height;	chr16:578302	chr16:654611~656194:-
PCPG	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-4.07	7.6e-05	0.0265	-0.37	-0.32	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
PCPG	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	4.07	7.6e-05	0.0265	0.4	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
PCPG	cis	rs2836974	0.644	rs2410123	ENSG00000255568.3	BRWD1-AS2	-4.07	7.6e-05	0.0265	-0.32	-0.32	Cognitive function;	chr21:39328167	chr21:39313935~39314962:+
PCPG	cis	rs9813712	0.547	rs6807290	ENSG00000228252.7	COL6A4P2	4.07	7.6e-05	0.0265	0.4	0.32	Response to amphetamines;	chr3:130297952	chr3:130212823~130273806:+
PCPG	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	4.07	7.61e-05	0.0265	0.62	0.32	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	4.07	7.61e-05	0.0265	0.62	0.32	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
PCPG	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-4.07	7.61e-05	0.0266	-0.34	-0.32	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
PCPG	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-4.07	7.61e-05	0.0266	-0.34	-0.32	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
PCPG	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-4.07	7.61e-05	0.0266	-0.34	-0.32	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
PCPG	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-4.07	7.61e-05	0.0266	-0.34	-0.32	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
PCPG	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-4.07	7.61e-05	0.0266	-0.34	-0.32	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
PCPG	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-4.07	7.61e-05	0.0266	-0.34	-0.32	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
PCPG	cis	rs763014	0.898	rs4984895	ENSG00000262528.2	LA16c-349E10.1	4.07	7.62e-05	0.0266	0.38	0.32	Height;	chr16:573238	chr16:654611~656194:-
PCPG	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	4.07	7.62e-05	0.0266	0.4	0.32	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
PCPG	cis	rs34421088	0.56	rs1478898	ENSG00000254774.1	RP11-148O21.3	-4.07	7.62e-05	0.0266	-0.35	-0.32	Neuroticism;	chr8:11537570	chr8:11553224~11554207:-
PCPG	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	4.07	7.62e-05	0.0266	0.45	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
PCPG	cis	rs10504130	0.597	rs4598243	ENSG00000272024.1	RP11-546K22.3	-4.07	7.62e-05	0.0266	-0.4	-0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51950284~51950690:+
PCPG	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-4.07	7.62e-05	0.0266	-0.37	-0.32	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
PCPG	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-4.07	7.62e-05	0.0266	-0.37	-0.32	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
PCPG	cis	rs1371867	0.846	rs1660351	ENSG00000212994.5	RPS26P6	4.07	7.62e-05	0.0266	0.36	0.32	Atrioventricular conduction;	chr8:100262806	chr8:100895771~100896118:+
PCPG	cis	rs3758911	0.796	rs112617433	ENSG00000255353.1	RP11-382M14.1	-4.07	7.63e-05	0.0266	-0.43	-0.32	Coronary artery disease;	chr11:107282855	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs7929343	ENSG00000255353.1	RP11-382M14.1	-4.07	7.63e-05	0.0266	-0.43	-0.32	Coronary artery disease;	chr11:107285183	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs7929345	ENSG00000255353.1	RP11-382M14.1	-4.07	7.63e-05	0.0266	-0.43	-0.32	Coronary artery disease;	chr11:107285185	chr11:107176286~107177530:+
PCPG	cis	rs6957923	0.846	rs12700443	ENSG00000230658.1	KLHL7-AS1	4.07	7.64e-05	0.0266	0.37	0.32	Height;	chr7:23475249	chr7:23101228~23105703:-
PCPG	cis	rs6957923	0.846	rs6967145	ENSG00000230658.1	KLHL7-AS1	4.07	7.64e-05	0.0266	0.37	0.32	Height;	chr7:23477849	chr7:23101228~23105703:-
PCPG	cis	rs6957923	0.755	rs34979424	ENSG00000230658.1	KLHL7-AS1	4.07	7.64e-05	0.0266	0.37	0.32	Height;	chr7:23480028	chr7:23101228~23105703:-
PCPG	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	4.07	7.64e-05	0.0266	0.41	0.32	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	4.07	7.64e-05	0.0266	0.41	0.32	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
PCPG	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	4.07	7.64e-05	0.0266	0.34	0.32	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
PCPG	cis	rs7523050	0.643	rs71655970	ENSG00000203897.3	SPATA42	-4.07	7.64e-05	0.0266	-0.49	-0.32	Fat distribution (HIV);	chr1:108861273	chr1:108857217~108858524:+
PCPG	cis	rs748404	0.629	rs35311230	ENSG00000249839.1	AC011330.5	-4.07	7.64e-05	0.0266	-0.4	-0.32	Lung cancer;	chr15:43341299	chr15:43663654~43684339:-
PCPG	cis	rs12681963	0.748	rs1511168	ENSG00000248159.1	HSPA8P11	-4.07	7.64e-05	0.0266	-0.48	-0.32	Migraine;	chr8:30036318	chr8:30237382~30240997:+
PCPG	cis	rs964611	0.786	rs5020564	ENSG00000259488.2	RP11-154J22.1	-4.07	7.65e-05	0.0266	-0.31	-0.32	Metabolite levels (Pyroglutamine);	chr15:48372356	chr15:48312353~48331856:-
PCPG	cis	rs8192282	0.793	rs10159236	ENSG00000236675.1	MTX1P1	4.07	7.65e-05	0.0266	0.37	0.32	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr1:154458929	chr1:155230975~155234325:+
PCPG	cis	rs2268365	0.571	rs2268372	ENSG00000227617.7	CERS6-AS1	-4.07	7.65e-05	0.0266	-0.34	-0.32	Blood pressure (smoking interaction);	chr2:169208074	chr2:168771953~168786961:-
PCPG	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	4.07	7.65e-05	0.0266	0.32	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
PCPG	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	4.07	7.65e-05	0.0267	0.36	0.32	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
PCPG	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-4.07	7.65e-05	0.0267	-0.41	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
PCPG	cis	rs964611	0.935	rs2291341	ENSG00000259488.2	RP11-154J22.1	-4.07	7.66e-05	0.0267	-0.35	-0.32	Metabolite levels (Pyroglutamine);	chr15:48291640	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.872	rs60820695	ENSG00000259488.2	RP11-154J22.1	-4.07	7.66e-05	0.0267	-0.35	-0.32	Metabolite levels (Pyroglutamine);	chr15:48292686	chr15:48312353~48331856:-
PCPG	cis	rs7017914	0.902	rs6472542	ENSG00000254031.4	RP11-326E22.1	-4.07	7.66e-05	0.0267	-0.3	-0.32	Bone mineral density;	chr8:70741852	chr8:71155457~71204223:+
PCPG	cis	rs1075232	1	rs67634762	ENSG00000269930.1	RP11-932O9.9	-4.07	7.67e-05	0.0267	-0.76	-0.32	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30616958~30617749:+
PCPG	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-4.07	7.67e-05	0.0267	-0.41	-0.32	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
PCPG	cis	rs1440410	0.798	rs4690775	ENSG00000250326.1	RP11-284M14.1	4.07	7.67e-05	0.0267	0.29	0.32	Ischemic stroke;	chr4:143164707	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.835	rs4132266	ENSG00000250326.1	RP11-284M14.1	4.07	7.67e-05	0.0267	0.29	0.32	Ischemic stroke;	chr4:143165092	chr4:142933195~143184861:-
PCPG	cis	rs13118159	0.527	rs6599308	ENSG00000254094.1	AC078852.1	-4.07	7.68e-05	0.0267	-0.4	-0.32	Longevity;	chr4:1393992	chr4:1356581~1358075:+
PCPG	cis	rs300890	0.733	rs300911	ENSG00000250326.1	RP11-284M14.1	4.07	7.68e-05	0.0267	0.27	0.32	Nasopharyngeal carcinoma;	chr4:143355602	chr4:142933195~143184861:-
PCPG	cis	rs2243480	1	rs4718270	ENSG00000251451.1	GS1-124K5.6	4.07	7.68e-05	0.0267	0.56	0.32	Diabetic kidney disease;	chr7:65737415	chr7:66407288~66409239:-
PCPG	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	4.07	7.68e-05	0.0267	0.33	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
PCPG	cis	rs6714710	0.603	rs34974566	ENSG00000278766.2	AC159540.2	4.07	7.68e-05	0.0267	0.35	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935836	chr2:97421075~97434847:+
PCPG	cis	rs6714710	0.603	rs35255677	ENSG00000278766.2	AC159540.2	4.07	7.68e-05	0.0267	0.35	0.32	Posterior cortical atrophy and Alzheimer's disease;	chr2:97951357	chr2:97421075~97434847:+
PCPG	cis	rs300890	0.642	rs300912	ENSG00000250326.1	RP11-284M14.1	-4.07	7.68e-05	0.0267	-0.27	-0.32	Nasopharyngeal carcinoma;	chr4:143355564	chr4:142933195~143184861:-
PCPG	cis	rs763014	0.932	rs2384975	ENSG00000262528.2	LA16c-349E10.1	4.07	7.69e-05	0.0268	0.37	0.32	Height;	chr16:601115	chr16:654611~656194:-
PCPG	cis	rs4819052	0.851	rs2236445	ENSG00000223768.1	LINC00205	-4.07	7.69e-05	0.0268	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45293285~45297354:+
PCPG	cis	rs7208859	0.673	rs216440	ENSG00000263603.1	CTD-2349P21.5	-4.07	7.69e-05	0.0268	-0.46	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30729469~30731202:+
PCPG	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	4.07	7.69e-05	0.0268	0.33	0.32	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	4.07	7.69e-05	0.0268	0.33	0.32	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
PCPG	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-4.07	7.69e-05	0.0268	-0.4	-0.32	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
PCPG	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	4.07	7.7e-05	0.0268	0.51	0.32	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
PCPG	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	4.07	7.7e-05	0.0268	0.29	0.32	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
PCPG	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-4.07	7.7e-05	0.0268	-0.56	-0.32	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
PCPG	cis	rs6728642	0.572	rs60621865	ENSG00000278766.2	AC159540.2	-4.07	7.7e-05	0.0268	-0.4	-0.32	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96932264	chr2:97421075~97434847:+
PCPG	cis	rs6728642	0.572	rs7574488	ENSG00000278766.2	AC159540.2	-4.07	7.7e-05	0.0268	-0.4	-0.32	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96933881	chr2:97421075~97434847:+
PCPG	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	4.07	7.7e-05	0.0268	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
PCPG	cis	rs3947	1	rs1736082	ENSG00000255556.2	RP11-351I21.6	-4.07	7.7e-05	0.0268	-0.41	-0.32	Blood protein levels;	chr8:11845911	chr8:12378679~12380265:-
PCPG	cis	rs3947	1	rs1736083	ENSG00000255556.2	RP11-351I21.6	-4.07	7.7e-05	0.0268	-0.41	-0.32	Blood protein levels;	chr8:11845988	chr8:12378679~12380265:-
PCPG	cis	rs3947	1	rs1692812	ENSG00000255556.2	RP11-351I21.6	-4.07	7.7e-05	0.0268	-0.41	-0.32	Blood protein levels;	chr8:11846014	chr8:12378679~12380265:-
PCPG	cis	rs7172677	0.538	rs1806795	ENSG00000261543.1	RP11-665J16.1	-4.07	7.7e-05	0.0268	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75130403	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs1806794	ENSG00000261543.1	RP11-665J16.1	-4.07	7.7e-05	0.0268	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75130599	chr15:74152800~74179226:-
PCPG	cis	rs11220082	0.666	rs35203305	ENSG00000254671.2	STT3A-AS1	-4.07	7.7e-05	0.0268	-0.32	-0.32	Schizophrenia;	chr11:125468987	chr11:125570284~125592568:-
PCPG	cis	rs1150668	0.796	rs1124132	ENSG00000219392.1	RP1-265C24.5	-4.07	7.7e-05	0.0268	-0.37	-0.32	Pubertal anthropometrics;	chr6:28412544	chr6:28115628~28116551:+
PCPG	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-4.07	7.71e-05	0.0268	-0.48	-0.32	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
PCPG	cis	rs7727544	0.606	rs17622208	ENSG00000233006.5	AC034220.3	4.07	7.71e-05	0.0268	0.22	0.32	Blood metabolite levels;	chr5:132381358	chr5:132311285~132369916:-
PCPG	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	4.07	7.72e-05	0.0268	0.31	0.32	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
PCPG	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	4.07	7.72e-05	0.0268	0.27	0.32	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
PCPG	cis	rs9437689	0.584	rs2766003	ENSG00000235501.4	RP4-639F20.1	4.07	7.72e-05	0.0268	0.29	0.32	Phospholipid levels (plasma);	chr1:94960809	chr1:94927566~94963270:+
PCPG	cis	rs7172677	1	rs4243032	ENSG00000261543.1	RP11-665J16.1	-4.07	7.72e-05	0.0268	-0.38	-0.32	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75134543	chr15:74152800~74179226:-
PCPG	cis	rs3758911	0.894	rs10890698	ENSG00000255353.1	RP11-382M14.1	-4.07	7.72e-05	0.0268	-0.4	-0.32	Coronary artery disease;	chr11:107308080	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.929	rs10890700	ENSG00000255353.1	RP11-382M14.1	-4.07	7.72e-05	0.0268	-0.4	-0.32	Coronary artery disease;	chr11:107308243	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs10789599	ENSG00000255353.1	RP11-382M14.1	-4.07	7.72e-05	0.0268	-0.4	-0.32	Coronary artery disease;	chr11:107309145	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.929	rs10749894	ENSG00000255353.1	RP11-382M14.1	-4.07	7.72e-05	0.0268	-0.4	-0.32	Coronary artery disease;	chr11:107309586	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.929	rs10789600	ENSG00000255353.1	RP11-382M14.1	-4.07	7.72e-05	0.0268	-0.4	-0.32	Coronary artery disease;	chr11:107310335	chr11:107176286~107177530:+
PCPG	cis	rs3806843	0.619	rs2569160	ENSG00000202515.1	VTRNA1-3	4.07	7.72e-05	0.0268	0.4	0.32	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr5:140726158~140726246:+
PCPG	cis	rs11148252	0.634	rs1571189	ENSG00000235660.1	LINC00345	-4.07	7.72e-05	0.0268	-0.39	-0.32	Lewy body disease;	chr13:52156869	chr13:52484161~52484680:-
PCPG	cis	rs6121246	0.954	rs6058470	ENSG00000230613.1	HM13-AS1	4.07	7.72e-05	0.0268	0.46	0.32	Mean corpuscular hemoglobin;	chr20:31829024	chr20:31567707~31573263:-
PCPG	cis	rs4143844	1	rs12911422	ENSG00000259251.2	RP11-643M14.1	4.07	7.72e-05	0.0269	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:62035935	chr15:62060503~62062434:+
PCPG	cis	rs4143844	1	rs62007448	ENSG00000259251.2	RP11-643M14.1	4.07	7.72e-05	0.0269	0.67	0.32	Bipolar disorder and schizophrenia;	chr15:62036971	chr15:62060503~62062434:+
PCPG	cis	rs2836974	0.777	rs34038277	ENSG00000252915.1	Y_RNA	-4.07	7.72e-05	0.0269	-0.33	-0.32	Cognitive function;	chr21:39327921	chr21:39344537~39344628:+
PCPG	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	4.06	7.73e-05	0.0269	0.35	0.32	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
PCPG	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-4.06	7.73e-05	0.0269	-0.38	-0.31	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
PCPG	cis	rs9928842	0.823	rs2870472	ENSG00000280152.1	RP11-331F4.5	4.06	7.74e-05	0.0269	0.47	0.31	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75245994~75250077:-
PCPG	cis	rs1600249	0.594	rs12674768	ENSG00000270154.1	RP11-419I17.1	4.06	7.74e-05	0.0269	0.4	0.31	Rheumatoid arthritis;	chr8:11514038	chr8:12476462~12477122:+
PCPG	cis	rs2733954	0.887	rs301163	ENSG00000179219.5	LINC00311	-4.06	7.75e-05	0.0269	-0.44	-0.31	Leprosy;	chr16:85779920	chr16:85282958~85285963:+
PCPG	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	4.06	7.75e-05	0.0269	0.4	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
PCPG	cis	rs4237845	0.788	rs6581157	ENSG00000257698.1	RP11-620J15.3	-4.06	7.75e-05	0.0269	-0.29	-0.31	Intelligence (multi-trait analysis);	chr12:57895010	chr12:57931528~57936175:-
PCPG	cis	rs7587476	0.906	rs2734674	ENSG00000229267.2	AC072062.1	4.06	7.75e-05	0.0269	0.41	0.31	Neuroblastoma;	chr2:214794171	chr2:214810229~214963274:+
PCPG	cis	rs12765878	1	rs1980653	ENSG00000260461.1	RP11-541N10.3	4.06	7.75e-05	0.0269	0.36	0.31	Coronary artery disease;	chr10:103894406	chr10:103877374~103879761:-
PCPG	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	4.06	7.75e-05	0.0269	0.55	0.31	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
PCPG	cis	rs7172677	1	rs7172205	ENSG00000261543.1	RP11-665J16.1	-4.06	7.75e-05	0.0269	-0.38	-0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75131994	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs7178784	ENSG00000261543.1	RP11-665J16.1	-4.06	7.75e-05	0.0269	-0.38	-0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75133103	chr15:74152800~74179226:-
PCPG	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	4.06	7.76e-05	0.0269	0.37	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
PCPG	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	4.06	7.76e-05	0.027	0.65	0.31	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
PCPG	cis	rs875971	0.798	rs6460304	ENSG00000235475.1	LINC01372	4.06	7.76e-05	0.027	0.32	0.31	Aortic root size;	chr7:66499741	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.862	rs6945775	ENSG00000235475.1	LINC01372	4.06	7.76e-05	0.027	0.32	0.31	Aortic root size;	chr7:66503987	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.798	rs57739047	ENSG00000235475.1	LINC01372	4.06	7.76e-05	0.027	0.32	0.31	Aortic root size;	chr7:66507579	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.83	rs6950137	ENSG00000235475.1	LINC01372	4.06	7.76e-05	0.027	0.32	0.31	Aortic root size;	chr7:66511623	chr7:67335976~67340024:+
PCPG	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	4.06	7.76e-05	0.027	0.43	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
PCPG	cis	rs7444	0.941	rs11089629	ENSG00000211645.2	IGLV1-50	4.06	7.77e-05	0.027	0.36	0.31	Systemic lupus erythematosus;	chr22:21604583	chr22:22327300~22327814:+
PCPG	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	4.06	7.77e-05	0.027	0.49	0.31	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
PCPG	cis	rs6929812	0.702	rs7753569	ENSG00000271755.1	RP1-153G14.4	4.06	7.77e-05	0.027	0.41	0.31	Neuroticism (multi-trait analysis);	chr6:27421371	chr6:27404010~27406964:-
PCPG	cis	rs575908	0.708	rs1336785	ENSG00000254154.7	RP4-798P15.3	4.06	7.78e-05	0.027	0.31	0.31	Breast cancer;	chr1:177890507	chr1:177928788~178038007:-
PCPG	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	4.06	7.78e-05	0.027	0.36	0.31	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
PCPG	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	4.06	7.78e-05	0.027	0.36	0.31	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
PCPG	cis	rs761746	0.739	rs5998086	ENSG00000128254.12	C22orf24	-4.06	7.78e-05	0.027	-0.42	-0.31	Intelligence;	chr22:31684258	chr22:31933521~31945518:-
PCPG	cis	rs7246657	0.722	rs2927739	ENSG00000226686.6	LINC01535	4.06	7.78e-05	0.027	0.47	0.31	Coronary artery calcification;	chr19:37658429	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs2909102	ENSG00000226686.6	LINC01535	4.06	7.78e-05	0.027	0.47	0.31	Coronary artery calcification;	chr19:37676463	chr19:37251912~37265535:+
PCPG	cis	rs7208859	0.673	rs11652370	ENSG00000266490.1	CTD-2349P21.9	4.06	7.78e-05	0.027	0.38	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30792372~30792833:+
PCPG	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-4.06	7.79e-05	0.027	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-4.06	7.79e-05	0.027	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
PCPG	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-4.06	7.79e-05	0.027	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
PCPG	cis	rs2836974	0.627	rs8127986	ENSG00000252915.1	Y_RNA	4.06	7.79e-05	0.027	0.33	0.31	Cognitive function;	chr21:39315285	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.563	rs997147	ENSG00000252915.1	Y_RNA	4.06	7.79e-05	0.027	0.33	0.31	Cognitive function;	chr21:39323399	chr21:39344537~39344628:+
PCPG	cis	rs8042680	0.614	rs7171333	ENSG00000214432.8	AC068831.10	-4.06	7.79e-05	0.027	-0.33	-0.31	Type 2 diabetes;	chr15:90963972	chr15:91022619~91036611:+
PCPG	cis	rs6728642	0.572	rs13387563	ENSG00000278766.2	AC159540.2	-4.06	7.79e-05	0.027	-0.4	-0.31	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935179	chr2:97421075~97434847:+
PCPG	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	4.06	7.79e-05	0.027	0.36	0.31	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	4.06	7.79e-05	0.027	0.36	0.31	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	4.06	7.79e-05	0.027	0.36	0.31	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	4.06	7.79e-05	0.027	0.36	0.31	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	4.06	7.79e-05	0.027	0.36	0.31	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	4.06	7.79e-05	0.027	0.36	0.31	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
PCPG	cis	rs1150668	0.796	rs9468372	ENSG00000219392.1	RP1-265C24.5	-4.06	7.79e-05	0.027	-0.37	-0.31	Pubertal anthropometrics;	chr6:28411584	chr6:28115628~28116551:+
PCPG	cis	rs1440410	0.571	rs4333135	ENSG00000250326.1	RP11-284M14.1	-4.06	7.79e-05	0.027	-0.28	-0.31	Ischemic stroke;	chr4:143118436	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.598	rs9308167	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143111081	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs10034934	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143112368	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs10471103	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143112503	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs11728569	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143115500	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs13116507	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143118285	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.535	rs4561881	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143118988	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.535	rs10015279	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143119872	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs4579067	ENSG00000250326.1	RP11-284M14.1	4.06	7.79e-05	0.027	0.28	0.31	Ischemic stroke;	chr4:143120675	chr4:142933195~143184861:-
PCPG	cis	rs11858159	0.617	rs12909071	ENSG00000259905.4	PWRN1	4.06	7.79e-05	0.027	0.35	0.31	Platelet thrombus formation;	chr15:24129619	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.646	rs12909139	ENSG00000259905.4	PWRN1	4.06	7.79e-05	0.027	0.35	0.31	Platelet thrombus formation;	chr15:24130956	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.616	rs34183064	ENSG00000259905.4	PWRN1	4.06	7.79e-05	0.027	0.35	0.31	Platelet thrombus formation;	chr15:24132140	chr15:24493137~24652130:+
PCPG	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-4.06	7.8e-05	0.0271	-0.38	-0.31	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
PCPG	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-4.06	7.8e-05	0.0271	-0.38	-0.31	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
PCPG	cis	rs11220082	0.627	rs34912904	ENSG00000254671.2	STT3A-AS1	-4.06	7.8e-05	0.0271	-0.32	-0.31	Schizophrenia;	chr11:125475460	chr11:125570284~125592568:-
PCPG	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	4.06	7.8e-05	0.0271	0.44	0.31	Height;	chr6:109387972	chr6:109382795~109383666:+
PCPG	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	4.06	7.8e-05	0.0271	0.34	0.31	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
PCPG	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	4.06	7.81e-05	0.0271	0.26	0.31	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
PCPG	cis	rs9847710	0.869	rs2564917	ENSG00000242142.1	SERBP1P3	4.06	7.81e-05	0.0271	0.33	0.31	Ulcerative colitis;	chr3:53003679	chr3:53064283~53065091:-
PCPG	cis	rs7772486	0.686	rs4896828	ENSG00000270638.1	RP3-466P17.1	4.06	7.81e-05	0.0271	0.34	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145735570~145737218:+
PCPG	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-4.06	7.81e-05	0.0271	-0.39	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
PCPG	cis	rs73201462	1	rs2955129	ENSG00000242551.2	POU5F1P6	-4.06	7.81e-05	0.0271	-0.61	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128210364	chr3:128674735~128677005:-
PCPG	cis	rs590820	0.777	rs681106	ENSG00000223635.1	RP4-613A2.1	4.06	7.81e-05	0.0271	0.37	0.31	Metabolite levels (lipoprotein measures);	chr1:230178781	chr1:229508501~229514272:+
PCPG	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	4.06	7.83e-05	0.0271	0.45	0.31	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
PCPG	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	4.06	7.83e-05	0.0271	0.28	0.31	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
PCPG	cis	rs6598266	1	rs12903750	ENSG00000259363.4	CTD-2054N24.2	-4.06	7.83e-05	0.0271	-0.55	-0.31	Major depressive disorder;	chr15:99760136	chr15:99807023~99877148:+
PCPG	cis	rs4237845	0.761	rs11172378	ENSG00000257698.1	RP11-620J15.3	-4.06	7.84e-05	0.0272	-0.27	-0.31	Intelligence (multi-trait analysis);	chr12:57904378	chr12:57931528~57936175:-
PCPG	cis	rs17807624	0.964	rs13249843	ENSG00000255020.1	AF131216.5	4.06	7.84e-05	0.0272	0.42	0.31	Systemic lupus erythematosus;	chr8:11601509	chr8:11345748~11347502:-
PCPG	cis	rs2898290	0.506	rs2736311	ENSG00000255020.1	AF131216.5	-4.06	7.84e-05	0.0272	-0.38	-0.31	Systolic blood pressure;	chr8:11394661	chr8:11345748~11347502:-
PCPG	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	4.06	7.84e-05	0.0272	0.41	0.31	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
PCPG	cis	rs78579285	0.583	rs1061238	ENSG00000260630.5	SNAI3-AS1	4.06	7.85e-05	0.0272	0.57	0.31	Joint mobility (Beighton score);	chr16:88715442	chr16:88663298~88687186:+
PCPG	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-4.06	7.85e-05	0.0272	-0.37	-0.31	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
PCPG	cis	rs4835473	0.897	rs28701142	ENSG00000251600.4	RP11-673E1.1	4.06	7.85e-05	0.0272	0.36	0.31	Immature fraction of reticulocytes;	chr4:143945730	chr4:143912331~143982454:+
PCPG	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	4.06	7.85e-05	0.0272	0.4	0.31	Height;	chr6:109403287	chr6:109382795~109383666:+
PCPG	cis	rs4713118	0.869	rs6914924	ENSG00000216901.1	AL022393.7	4.06	7.85e-05	0.0272	0.42	0.31	Parkinson's disease;	chr6:27743751	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs6930992	ENSG00000216901.1	AL022393.7	4.06	7.85e-05	0.0272	0.42	0.31	Parkinson's disease;	chr6:27744341	chr6:28176188~28176674:+
PCPG	cis	rs72634258	0.554	rs68024107	ENSG00000270035.1	RP11-338N10.2	-4.06	7.86e-05	0.0272	-0.43	-0.31	Inflammatory bowel disease;	chr1:7854006	chr1:7698303~7698872:-
PCPG	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	4.06	7.86e-05	0.0272	0.41	0.31	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
PCPG	cis	rs7702057	0.53	rs56953556	ENSG00000271918.1	CTD-2287O16.5	4.06	7.87e-05	0.0272	0.46	0.31	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116083807~116085416:-
PCPG	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-4.06	7.87e-05	0.0272	-0.41	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
PCPG	cis	rs899997	0.906	rs1809415	ENSG00000261143.1	ADAMTS7P3	-4.06	7.87e-05	0.0272	-0.45	-0.31	Coronary artery disease or large artery stroke;	chr15:78735859	chr15:77976042~77993057:+
PCPG	cis	rs801193	0.548	rs6975044	ENSG00000235475.1	LINC01372	4.06	7.87e-05	0.0273	0.34	0.31	Aortic root size;	chr7:66762495	chr7:67335976~67340024:+
PCPG	cis	rs763014	0.966	rs15564	ENSG00000262528.2	LA16c-349E10.1	4.06	7.87e-05	0.0273	0.36	0.31	Height;	chr16:627854	chr16:654611~656194:-
PCPG	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-4.06	7.88e-05	0.0273	-0.41	-0.31	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-4.06	7.88e-05	0.0273	-0.41	-0.31	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
PCPG	cis	rs6598541	0.963	rs4966024	ENSG00000278022.1	RP11-35O15.2	4.06	7.88e-05	0.0273	0.3	0.31	Urate levels;	chr15:98752341	chr15:98660210~98660668:+
PCPG	cis	rs4376189	0.614	rs10019263	ENSG00000207497.1	Y_RNA	4.06	7.88e-05	0.0273	0.45	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185716087	chr4:185709873~185709967:-
PCPG	cis	rs4489787	0.568	rs2705135	ENSG00000240399.1	RP1-228P16.1	4.06	7.88e-05	0.0273	0.35	0.31	Prostate cancer (SNP x SNP interaction);	chr12:48496773	chr12:48054813~48055591:-
PCPG	cis	rs10751667	0.666	rs7934963	ENSG00000255142.1	AP006621.6	4.06	7.88e-05	0.0273	0.31	0.31	Alzheimer's disease (late onset);	chr11:957220	chr11:781645~782105:+
PCPG	cis	rs747687	0.655	rs7218037	ENSG00000262133.1	RP11-676J12.6	4.06	7.89e-05	0.0273	0.56	0.31	Blood pressure;	chr17:866227	chr17:877902~880093:+
PCPG	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	4.06	7.89e-05	0.0273	0.65	0.31	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
PCPG	cis	rs7707921	0.757	rs226198	ENSG00000249483.1	CTD-2249K22.1	4.06	7.89e-05	0.0273	0.42	0.31	Breast cancer;	chr5:82278173	chr5:81851601~81852201:+
PCPG	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	4.06	7.89e-05	0.0273	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
PCPG	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-4.06	7.9e-05	0.0273	-0.3	-0.31	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
PCPG	cis	rs17152411	0.947	rs55674450	ENSG00000278831.1	RP11-12J10.4	4.06	7.9e-05	0.0273	0.46	0.31	Height;	chr10:124903584	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs12569940	ENSG00000278831.1	RP11-12J10.4	4.06	7.9e-05	0.0273	0.46	0.31	Height;	chr10:124904115	chr10:124623353~124624079:+
PCPG	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-4.06	7.91e-05	0.0273	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-4.06	7.91e-05	0.0273	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
PCPG	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	4.06	7.91e-05	0.0273	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
PCPG	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-4.06	7.91e-05	0.0273	-0.38	-0.31	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
PCPG	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	4.06	7.91e-05	0.0274	0.42	0.31	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
PCPG	cis	rs10411161	0.702	rs8110073	ENSG00000275055.1	CTC-471J1.11	-4.06	7.92e-05	0.0274	-0.34	-0.31	Breast cancer;	chr19:51879870	chr19:52049007~52049754:+
PCPG	cis	rs728616	0.867	rs2152548	ENSG00000242600.5	MBL1P	4.06	7.92e-05	0.0274	0.62	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79904898~79950336:+
PCPG	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-4.06	7.92e-05	0.0274	-0.4	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
PCPG	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-4.06	7.92e-05	0.0274	-0.4	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
PCPG	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	4.06	7.92e-05	0.0274	0.4	0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
PCPG	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	4.06	7.92e-05	0.0274	0.26	0.31	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	4.06	7.92e-05	0.0274	0.26	0.31	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	4.06	7.92e-05	0.0274	0.26	0.31	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	4.06	7.92e-05	0.0274	0.26	0.31	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
PCPG	cis	rs8098244	0.576	rs11082762	ENSG00000265752.2	RP11-403A21.1	4.06	7.92e-05	0.0274	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23785889	chr18:23957754~23982556:-
PCPG	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	4.06	7.93e-05	0.0274	0.41	0.31	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
PCPG	cis	rs939317	0.678	rs843372	ENSG00000272721.4	RP11-778D9.12	-4.06	7.93e-05	0.0274	-0.5	-0.31	Menarche (age at onset);	chr3:184278425	chr3:184134019~184135238:-
PCPG	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	4.06	7.93e-05	0.0274	0.39	0.31	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
PCPG	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	4.06	7.93e-05	0.0274	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
PCPG	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	4.06	7.93e-05	0.0274	0.36	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
PCPG	cis	rs12681963	0.702	rs13272074	ENSG00000248159.1	HSPA8P11	-4.06	7.93e-05	0.0274	-0.47	-0.31	Migraine;	chr8:30087471	chr8:30237382~30240997:+
PCPG	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	4.06	7.93e-05	0.0274	0.23	0.31	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	4.06	7.93e-05	0.0274	0.23	0.31	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
PCPG	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-4.06	7.94e-05	0.0274	-0.32	-0.31	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
PCPG	cis	rs8064024	0.676	rs9926458	ENSG00000267077.1	RP11-127I20.5	4.06	7.94e-05	0.0274	0.41	0.31	Cancer;	chr16:4822627	chr16:4795265~4796532:-
PCPG	cis	rs4934494	0.768	rs1409357	ENSG00000240996.1	RP11-80H5.7	-4.06	7.94e-05	0.0274	-0.47	-0.31	Red blood cell count;	chr10:89669719	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs17125834	ENSG00000240996.1	RP11-80H5.7	-4.06	7.94e-05	0.0274	-0.47	-0.31	Red blood cell count;	chr10:89673405	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs12571918	ENSG00000240996.1	RP11-80H5.7	-4.06	7.94e-05	0.0274	-0.47	-0.31	Red blood cell count;	chr10:89674920	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs12776306	ENSG00000240996.1	RP11-80H5.7	-4.06	7.94e-05	0.0274	-0.47	-0.31	Red blood cell count;	chr10:89676300	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs7078321	ENSG00000240996.1	RP11-80H5.7	-4.06	7.94e-05	0.0274	-0.47	-0.31	Red blood cell count;	chr10:89678341	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs34379399	ENSG00000240996.1	RP11-80H5.7	-4.06	7.94e-05	0.0274	-0.47	-0.31	Red blood cell count;	chr10:89683526	chr10:89694295~89697928:-
PCPG	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	4.06	7.94e-05	0.0274	0.37	0.31	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
PCPG	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	4.06	7.94e-05	0.0274	0.31	0.31	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
PCPG	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	4.06	7.94e-05	0.0274	0.29	0.31	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
PCPG	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-4.06	7.94e-05	0.0274	-0.38	-0.31	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
PCPG	cis	rs172166	0.694	rs2791332	ENSG00000220721.1	OR1F12	4.06	7.94e-05	0.0274	0.37	0.31	Cardiac Troponin-T levels;	chr6:28141010	chr6:28073316~28074233:+
PCPG	cis	rs6728642	0.572	rs1320147	ENSG00000278766.2	AC159540.2	4.06	7.95e-05	0.0274	0.39	0.31	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96934889	chr2:97421075~97434847:+
PCPG	cis	rs950169	0.686	rs12906474	ENSG00000235370.6	DNM1P51	4.06	7.95e-05	0.0274	0.33	0.31	Schizophrenia;	chr15:84566006	chr15:84398316~84411701:-
PCPG	cis	rs7246657	0.722	rs2927746	ENSG00000226686.6	LINC01535	4.06	7.95e-05	0.0274	0.47	0.31	Coronary artery calcification;	chr19:37665669	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs2927747	ENSG00000226686.6	LINC01535	4.06	7.95e-05	0.0274	0.47	0.31	Coronary artery calcification;	chr19:37668629	chr19:37251912~37265535:+
PCPG	cis	rs7824557	0.564	rs11781637	ENSG00000255020.1	AF131216.5	-4.06	7.95e-05	0.0275	-0.43	-0.31	Retinal vascular caliber;	chr8:11357463	chr8:11345748~11347502:-
PCPG	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-4.06	7.95e-05	0.0275	-0.4	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
PCPG	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	4.06	7.95e-05	0.0275	0.41	0.31	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
PCPG	cis	rs17684571	0.751	rs17752106	ENSG00000231441.1	RP11-472M19.2	4.06	7.96e-05	0.0275	0.54	0.31	Schizophrenia;	chr6:56837455	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.751	rs7761501	ENSG00000231441.1	RP11-472M19.2	4.06	7.96e-05	0.0275	0.54	0.31	Schizophrenia;	chr6:56839187	chr6:56844002~56864078:+
PCPG	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	4.06	7.96e-05	0.0275	0.38	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
PCPG	cis	rs11018904	0.861	rs4589254	ENSG00000280385.1	AP000648.5	4.06	7.96e-05	0.0275	0.38	0.31	Intelligence (multi-trait analysis);	chr11:90230187	chr11:90193614~90198120:+
PCPG	cis	rs301901	0.698	rs62360226	ENSG00000250155.1	CTD-2353F22.1	4.06	7.96e-05	0.0275	0.37	0.31	Height;	chr5:37428489	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.698	rs11948801	ENSG00000250155.1	CTD-2353F22.1	4.06	7.96e-05	0.0275	0.37	0.31	Height;	chr5:37430113	chr5:36666214~36725195:-
PCPG	cis	rs11148252	0.774	rs56033750	ENSG00000235660.1	LINC00345	-4.06	7.97e-05	0.0275	-0.37	-0.31	Lewy body disease;	chr13:52173143	chr13:52484161~52484680:-
PCPG	cis	rs11671005	0.779	rs3752112	ENSG00000252334.1	RNU6-1337P	4.06	7.97e-05	0.0275	0.46	0.31	Mean platelet volume;	chr19:58480853	chr19:58483749~58483843:-
PCPG	cis	rs7444	0.941	rs181359	ENSG00000211645.2	IGLV1-50	4.06	7.97e-05	0.0275	0.4	0.31	Systemic lupus erythematosus;	chr22:21574352	chr22:22327300~22327814:+
PCPG	cis	rs7772486	0.686	rs10872579	ENSG00000270638.1	RP3-466P17.1	4.06	7.98e-05	0.0275	0.35	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145735570~145737218:+
PCPG	cis	rs12439619	0.774	rs2867649	ENSG00000228141.5	AC105339.1	-4.06	7.98e-05	0.0275	-0.47	-0.31	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82710471~82714026:-
PCPG	cis	rs12439619	0.846	rs28697264	ENSG00000228141.5	AC105339.1	-4.06	7.98e-05	0.0275	-0.47	-0.31	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82710471~82714026:-
PCPG	cis	rs801193	0.569	rs35070132	ENSG00000235475.1	LINC01372	4.06	7.98e-05	0.0275	0.34	0.31	Aortic root size;	chr7:66773096	chr7:67335976~67340024:+
PCPG	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	4.06	7.99e-05	0.0276	0.32	0.31	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-4.06	7.99e-05	0.0276	-0.32	-0.31	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-4.06	7.99e-05	0.0276	-0.32	-0.31	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
PCPG	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-4.06	7.99e-05	0.0276	-0.35	-0.31	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
PCPG	cis	rs12765878	0.967	rs10883940	ENSG00000260461.1	RP11-541N10.3	4.06	7.99e-05	0.0276	0.36	0.31	Coronary artery disease;	chr10:103890840	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs11191847	ENSG00000260461.1	RP11-541N10.3	4.06	7.99e-05	0.0276	0.36	0.31	Coronary artery disease;	chr10:103890868	chr10:103877374~103879761:-
PCPG	cis	rs12765878	0.967	rs10883941	ENSG00000260461.1	RP11-541N10.3	4.06	7.99e-05	0.0276	0.36	0.31	Coronary artery disease;	chr10:103891024	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs11191848	ENSG00000260461.1	RP11-541N10.3	4.06	7.99e-05	0.0276	0.36	0.31	Coronary artery disease;	chr10:103891079	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs11191849	ENSG00000260461.1	RP11-541N10.3	4.06	7.99e-05	0.0276	0.36	0.31	Coronary artery disease;	chr10:103891122	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs10883942	ENSG00000260461.1	RP11-541N10.3	4.06	7.99e-05	0.0276	0.36	0.31	Coronary artery disease;	chr10:103891628	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs10883943	ENSG00000260461.1	RP11-541N10.3	4.06	7.99e-05	0.0276	0.36	0.31	Coronary artery disease;	chr10:103891658	chr10:103877374~103879761:-
PCPG	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-4.06	7.99e-05	0.0276	-0.42	-0.31	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
PCPG	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	4.06	7.99e-05	0.0276	0.34	0.31	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
PCPG	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	4.06	7.99e-05	0.0276	0.27	0.31	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
PCPG	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	4.06	7.99e-05	0.0276	0.27	0.31	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
PCPG	cis	rs116248771	0.739	rs116045655	ENSG00000272087.1	RP11-379F4.7	4.06	8e-05	0.0276	0.46	0.31	diarrhoeal disease at age 2;	chr3:158617579	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.69	rs116470672	ENSG00000272087.1	RP11-379F4.7	4.06	8e-05	0.0276	0.46	0.31	diarrhoeal disease at age 2;	chr3:158619973	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs114379619	ENSG00000272087.1	RP11-379F4.7	4.06	8e-05	0.0276	0.46	0.31	diarrhoeal disease at age 2;	chr3:158620992	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.793	rs12494750	ENSG00000272087.1	RP11-379F4.7	4.06	8e-05	0.0276	0.46	0.31	diarrhoeal disease at age 2;	chr3:158580622	chr3:158693120~158693768:-
PCPG	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-4.06	8e-05	0.0276	-0.4	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
PCPG	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	4.06	8e-05	0.0276	0.34	0.31	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
PCPG	cis	rs2060793	0.519	rs10832285	ENSG00000251991.1	RNU7-49P	4.06	8e-05	0.0276	0.35	0.31	Vitamin D levels;	chr11:14628031	chr11:14478892~14478953:+
PCPG	cis	rs7523050	0.643	rs36047249	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108858877	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs17563938	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108859032	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs34572569	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108859234	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs35885176	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108859246	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs67091034	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108859945	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs67567504	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108859958	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs35438081	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108860209	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs34114412	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108860244	chr1:108857217~108858524:+
PCPG	cis	rs7523050	0.643	rs36052234	ENSG00000203897.3	SPATA42	-4.06	8.01e-05	0.0276	-0.51	-0.31	Fat distribution (HIV);	chr1:108860321	chr1:108857217~108858524:+
PCPG	cis	rs11858159	1	rs12913328	ENSG00000259905.4	PWRN1	4.06	8.01e-05	0.0276	0.36	0.31	Platelet thrombus formation;	chr15:24571992	chr15:24493137~24652130:+
PCPG	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	4.06	8.02e-05	0.0276	0.34	0.31	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
PCPG	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	4.06	8.02e-05	0.0276	0.56	0.31	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
PCPG	cis	rs763014	0.931	rs3752567	ENSG00000262528.2	LA16c-349E10.1	4.06	8.03e-05	0.0277	0.38	0.31	Height;	chr16:578130	chr16:654611~656194:-
PCPG	cis	rs964611	0.808	rs2279369	ENSG00000259488.2	RP11-154J22.1	-4.06	8.03e-05	0.0277	-0.39	-0.31	Metabolite levels (Pyroglutamine);	chr15:48250133	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.745	rs74011991	ENSG00000259488.2	RP11-154J22.1	-4.06	8.03e-05	0.0277	-0.39	-0.31	Metabolite levels (Pyroglutamine);	chr15:48256154	chr15:48312353~48331856:-
PCPG	cis	rs8098244	0.603	rs1711460	ENSG00000265752.2	RP11-403A21.1	4.05	8.03e-05	0.0277	0.37	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23711441	chr18:23957754~23982556:-
PCPG	cis	rs561341	1	rs693116	ENSG00000265798.5	RP11-271K11.5	4.05	8.03e-05	0.0277	0.56	0.31	Hip circumference adjusted for BMI;	chr17:31919105	chr17:31038575~31059121:-
PCPG	cis	rs561341	0.714	rs55925849	ENSG00000265798.5	RP11-271K11.5	4.05	8.03e-05	0.0277	0.56	0.31	Hip circumference adjusted for BMI;	chr17:31926066	chr17:31038575~31059121:-
PCPG	cis	rs561341	1	rs55959993	ENSG00000265798.5	RP11-271K11.5	4.05	8.03e-05	0.0277	0.56	0.31	Hip circumference adjusted for BMI;	chr17:31927752	chr17:31038575~31059121:-
PCPG	cis	rs6452524	0.618	rs4266384	ENSG00000281327.1	LINC01338	4.05	8.04e-05	0.0277	0.35	0.31	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:82850864~82859836:-
PCPG	cis	rs4934494	0.768	rs17126269	ENSG00000240996.1	RP11-80H5.7	-4.05	8.04e-05	0.0277	-0.47	-0.31	Red blood cell count;	chr10:89694974	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs768805	ENSG00000240996.1	RP11-80H5.7	-4.05	8.04e-05	0.0277	-0.47	-0.31	Red blood cell count;	chr10:89695448	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs12571268	ENSG00000240996.1	RP11-80H5.7	-4.05	8.04e-05	0.0277	-0.47	-0.31	Red blood cell count;	chr10:89698830	chr10:89694295~89697928:-
PCPG	cis	rs2262909	1	rs431328	ENSG00000279377.1	AC003973.3	4.05	8.05e-05	0.0277	0.45	0.31	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22039434	chr19:21965708~21968529:-
PCPG	cis	rs6579956	0.59	rs11745807	ENSG00000270978.1	RP11-54C4.2	-4.05	8.05e-05	0.0277	-0.39	-0.31	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152798263	chr5:151848886~151850791:+
PCPG	cis	rs2404602	0.692	rs1116535	ENSG00000259514.1	RP11-685G9.2	4.05	8.05e-05	0.0277	0.32	0.31	Blood metabolite levels;	chr15:76717173	chr15:76339609~76342063:-
PCPG	cis	rs10200850	1	rs10200850	ENSG00000265215.1	MIR4269	4.05	8.05e-05	0.0277	0.52	0.31	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239313206	chr2:239305462~239305545:+
PCPG	cis	rs394563	0.69	rs237009	ENSG00000231760.4	RP11-350J20.5	4.05	8.06e-05	0.0277	0.39	0.31	Dupuytren's disease;	chr6:149438416	chr6:149796151~149826294:-
PCPG	cis	rs5769765	0.955	rs1321	ENSG00000278869.1	CITF22-49E9.3	4.05	8.06e-05	0.0277	0.39	0.31	Schizophrenia;	chr22:49903787	chr22:49933198~49934074:-
PCPG	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	4.05	8.06e-05	0.0277	0.45	0.31	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	4.05	8.06e-05	0.0277	0.45	0.31	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
PCPG	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-4.05	8.06e-05	0.0278	-0.48	-0.31	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
PCPG	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-4.05	8.06e-05	0.0278	-0.45	-0.31	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
PCPG	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-4.05	8.06e-05	0.0278	-0.27	-0.31	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
PCPG	cis	rs7824557	0.614	rs2060456	ENSG00000255020.1	AF131216.5	4.05	8.06e-05	0.0278	0.41	0.31	Retinal vascular caliber;	chr8:11355854	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.614	rs5029571	ENSG00000255020.1	AF131216.5	4.05	8.06e-05	0.0278	0.41	0.31	Retinal vascular caliber;	chr8:11355880	chr8:11345748~11347502:-
PCPG	cis	rs3758911	0.964	rs10890715	ENSG00000255353.1	RP11-382M14.1	-4.05	8.07e-05	0.0278	-0.4	-0.31	Coronary artery disease;	chr11:107322457	chr11:107176286~107177530:+
PCPG	cis	rs964611	0.872	rs17350938	ENSG00000259488.2	RP11-154J22.1	-4.05	8.07e-05	0.0278	-0.39	-0.31	Metabolite levels (Pyroglutamine);	chr15:48297784	chr15:48312353~48331856:-
PCPG	cis	rs4835473	0.932	rs10857415	ENSG00000251600.4	RP11-673E1.1	4.05	8.07e-05	0.0278	0.37	0.31	Immature fraction of reticulocytes;	chr4:143908753	chr4:143912331~143982454:+
PCPG	cis	rs896854	0.654	rs1453377	ENSG00000272509.1	RP11-347C18.5	4.05	8.07e-05	0.0278	0.31	0.31	Type 2 diabetes;	chr8:94957719	chr8:94884609~94885070:+
PCPG	cis	rs899997	0.773	rs8032156	ENSG00000261143.1	ADAMTS7P3	4.05	8.07e-05	0.0278	0.46	0.31	Coronary artery disease or large artery stroke;	chr15:78672156	chr15:77976042~77993057:+
PCPG	cis	rs899997	0.773	rs11072784	ENSG00000261143.1	ADAMTS7P3	4.05	8.07e-05	0.0278	0.46	0.31	Coronary artery disease or large artery stroke;	chr15:78673716	chr15:77976042~77993057:+
PCPG	cis	rs4720118	0.66	rs7793759	ENSG00000173862.3	RP11-89N17.1	-4.05	8.08e-05	0.0278	-0.37	-0.31	Leprosy;	chr7:33183371	chr7:33725981~33728456:+
PCPG	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	4.05	8.08e-05	0.0278	0.4	0.31	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
PCPG	cis	rs16976116	0.901	rs28478777	ENSG00000279145.1	RP11-547D13.1	4.05	8.09e-05	0.0278	0.43	0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr15:55220548	chr15:55171972~55178175:-
PCPG	cis	rs7696431	0.62	rs11726774	ENSG00000279384.1	RP11-635L1.2	-4.05	8.09e-05	0.0278	-0.31	-0.31	Coronary artery disease;	chr4:168805919	chr4:168843988~168844735:+
PCPG	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-4.05	8.09e-05	0.0279	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
PCPG	cis	rs78579285	0.583	rs77376965	ENSG00000260630.5	SNAI3-AS1	-4.05	8.1e-05	0.0279	-0.58	-0.31	Joint mobility (Beighton score);	chr16:88734069	chr16:88663298~88687186:+
PCPG	cis	rs698813	0.674	rs713447	ENSG00000236502.1	SIX3-AS1	4.05	8.1e-05	0.0279	0.43	0.31	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44278046	chr2:44940154~44941873:-
PCPG	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	4.05	8.1e-05	0.0279	0.42	0.31	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	4.05	8.1e-05	0.0279	0.42	0.31	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	4.05	8.1e-05	0.0279	0.42	0.31	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-4.05	8.1e-05	0.0279	-0.42	-0.31	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
PCPG	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-4.05	8.1e-05	0.0279	-0.4	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
PCPG	cis	rs75686122	1	rs79392847	ENSG00000253477.4	RP11-1C8.4	4.05	8.1e-05	0.0279	0.48	0.31	Cocaine dependence;	chr8:103461421	chr8:103483398~103501676:-
PCPG	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	4.05	8.11e-05	0.0279	0.34	0.31	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
PCPG	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	4.05	8.11e-05	0.0279	0.4	0.31	Height;	chr6:109397362	chr6:109382795~109383666:+
PCPG	cis	rs7772486	0.79	rs2254288	ENSG00000270638.1	RP3-466P17.1	4.05	8.11e-05	0.0279	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145735570~145737218:+
PCPG	cis	rs4819052	0.788	rs2236449	ENSG00000223768.1	LINC00205	-4.05	8.11e-05	0.0279	-0.39	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45293285~45297354:+
PCPG	cis	rs591584	0.59	rs10765689	ENSG00000255893.1	RP11-685N10.1	-4.05	8.11e-05	0.0279	-0.37	-0.31	Macrophage Migration Inhibitory Factor levels;	chr11:94589519	chr11:94472908~94473570:-
PCPG	cis	rs9356009	0.892	rs34426501	ENSG00000213078.3	RP5-933K21.2	-4.05	8.11e-05	0.0279	-0.6	-0.31	Lipoprotein (a) - cholesterol levels;	chr6:157951363	chr6:157365990~157366923:-
PCPG	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	4.05	8.12e-05	0.0279	0.5	0.31	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
PCPG	cis	rs7772486	0.686	rs1011596	ENSG00000270638.1	RP3-466P17.1	4.05	8.12e-05	0.0279	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145735570~145737218:+
PCPG	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-4.05	8.12e-05	0.0279	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
PCPG	cis	rs17227506	0.529	rs13258748	ENSG00000254491.1	RP11-145O15.2	4.05	8.13e-05	0.0279	0.37	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:13613400	chr8:13583889~13584533:-
PCPG	cis	rs11671005	0.656	rs55652736	ENSG00000269600.1	AC016629.3	-4.05	8.13e-05	0.0279	-0.55	-0.31	Mean platelet volume;	chr19:58496199	chr19:58593896~58599355:-
PCPG	cis	rs7911712	0.872	rs1253325	ENSG00000228462.1	RP11-445N18.3	4.05	8.13e-05	0.0279	0.44	0.31	Emphysema-related traits;	chr10:44789968	chr10:45073146~45073541:-
PCPG	cis	rs4295623	0.553	rs11250163	ENSG00000255020.1	AF131216.5	4.05	8.13e-05	0.028	0.44	0.31	Morning vs. evening chronotype;	chr8:11738928	chr8:11345748~11347502:-
PCPG	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	4.05	8.13e-05	0.028	0.7	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
PCPG	cis	rs752864	0.899	rs62015999	ENSG00000259438.1	CTD-2650P22.1	4.05	8.14e-05	0.028	0.38	0.31	Number of common colds;	chr15:52342012	chr15:52010999~52019095:-
PCPG	cis	rs12765878	1	rs2067832	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103883376	chr10:103877374~103879761:-
PCPG	cis	rs12765878	0.934	rs58543155	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103883486	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs34300861	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103883574	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs61277100	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103883594	chr10:103877374~103879761:-
PCPG	cis	rs12765878	0.967	rs34887477	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103883678	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs4918067	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103884878	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs4918068	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103884978	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs9325507	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103885864	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs3814220	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103887542	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs11191843	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103888893	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs2273698	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103889400	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs11191846	ENSG00000260461.1	RP11-541N10.3	4.05	8.14e-05	0.028	0.36	0.31	Coronary artery disease;	chr10:103890055	chr10:103877374~103879761:-
PCPG	cis	rs10844706	0.666	rs10844609	ENSG00000278635.1	CTD-2318O12.1	-4.05	8.14e-05	0.028	-0.39	-0.31	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9415641~9416718:+
PCPG	cis	rs853679	0.628	rs9368560	ENSG00000272009.1	RP1-313I6.12	-4.05	8.14e-05	0.028	-0.32	-0.31	Depression;	chr6:28192182	chr6:28078792~28081130:-
PCPG	cis	rs720064	0.586	rs9963697	ENSG00000265752.2	RP11-403A21.1	4.05	8.14e-05	0.028	0.35	0.31	Strep throat;	chr18:23944796	chr18:23957754~23982556:-
PCPG	cis	rs13263959	0.636	rs10103171	ENSG00000253307.1	RP11-10J21.4	-4.05	8.15e-05	0.028	-0.41	-0.31	Hair color;	chr8:141636434	chr8:141252286~141253292:-
PCPG	cis	rs896854	0.608	rs7004862	ENSG00000253528.2	RP11-347C18.4	4.05	8.15e-05	0.028	0.33	0.31	Type 2 diabetes;	chr8:94864735	chr8:94974573~94974853:-
PCPG	cis	rs2736345	0.788	rs2618476	ENSG00000269954.1	RP11-148O21.6	4.05	8.15e-05	0.028	0.37	0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11552488~11552991:-
PCPG	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	4.05	8.16e-05	0.028	0.4	0.31	Height;	chr6:109402736	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	4.05	8.16e-05	0.028	0.4	0.31	Height;	chr6:109403734	chr6:109382795~109383666:+
PCPG	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	4.05	8.16e-05	0.028	0.32	0.31	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	4.05	8.16e-05	0.028	0.32	0.31	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	4.05	8.16e-05	0.028	0.32	0.31	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
PCPG	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	4.05	8.16e-05	0.028	0.39	0.31	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
PCPG	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	4.05	8.17e-05	0.0281	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
PCPG	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	4.05	8.17e-05	0.0281	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
PCPG	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-4.05	8.17e-05	0.0281	-0.46	-0.31	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
PCPG	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	4.05	8.17e-05	0.0281	0.28	0.31	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
PCPG	cis	rs9847710	0.869	rs2581793	ENSG00000242142.1	SERBP1P3	4.05	8.17e-05	0.0281	0.33	0.31	Ulcerative colitis;	chr3:53001639	chr3:53064283~53065091:-
PCPG	cis	rs357618	1	rs357627	ENSG00000260581.1	CTB-113P19.4	4.05	8.17e-05	0.0281	0.37	0.31	Basophil percentage of white cells;	chr5:151470699	chr5:151652275~151655449:+
PCPG	cis	rs357618	1	rs357628	ENSG00000260581.1	CTB-113P19.4	4.05	8.17e-05	0.0281	0.37	0.31	Basophil percentage of white cells;	chr5:151470791	chr5:151652275~151655449:+
PCPG	cis	rs357618	1	rs357629	ENSG00000260581.1	CTB-113P19.4	-4.05	8.17e-05	0.0281	-0.37	-0.31	Basophil percentage of white cells;	chr5:151471385	chr5:151652275~151655449:+
PCPG	cis	rs4791051	0.723	rs11650754	ENSG00000264491.1	RP11-349A8.3	-4.05	8.18e-05	0.0281	-0.34	-0.31	Heschl's gyrus morphology;	chr17:66459149	chr17:67019934~67021743:-
PCPG	cis	rs2228479	0.85	rs1108063	ENSG00000268218.1	AC137932.4	-4.05	8.18e-05	0.0281	-0.46	-0.31	Skin colour saturation;	chr16:89827575	chr16:89268104~89273044:+
PCPG	cis	rs3109133	0.869	rs3115037	ENSG00000279512.1	RP11-575M22.1	-4.05	8.19e-05	0.0281	-0.38	-0.31	Calcium levels;	chr2:132538324	chr2:133117004~133119052:+
PCPG	cis	rs2836974	0.897	rs2776308	ENSG00000252915.1	Y_RNA	-4.05	8.19e-05	0.0281	-0.34	-0.31	Cognitive function;	chr21:39343249	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.83	rs2735309	ENSG00000252915.1	Y_RNA	-4.05	8.19e-05	0.0281	-0.34	-0.31	Cognitive function;	chr21:39343387	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.931	rs2776309	ENSG00000252915.1	Y_RNA	-4.05	8.19e-05	0.0281	-0.34	-0.31	Cognitive function;	chr21:39343865	chr21:39344537~39344628:+
PCPG	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-4.05	8.19e-05	0.0281	-0.44	-0.31	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
PCPG	cis	rs1023500	0.596	rs133352	ENSG00000226450.2	CYP2D8P	4.05	8.2e-05	0.0282	0.3	0.31	Schizophrenia;	chr22:42038018	chr22:42149886~42155001:-
PCPG	cis	rs1150668	0.835	rs203869	ENSG00000219392.1	RP1-265C24.5	-4.05	8.2e-05	0.0282	-0.34	-0.31	Pubertal anthropometrics;	chr6:28073041	chr6:28115628~28116551:+
PCPG	cis	rs2836974	0.897	rs14194	ENSG00000252915.1	Y_RNA	-4.05	8.2e-05	0.0282	-0.33	-0.31	Cognitive function;	chr21:39177540	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.831	rs6517521	ENSG00000252915.1	Y_RNA	-4.05	8.2e-05	0.0282	-0.33	-0.31	Cognitive function;	chr21:39179662	chr21:39344537~39344628:+
PCPG	cis	rs11148252	0.538	rs2274202	ENSG00000235660.1	LINC00345	-4.05	8.2e-05	0.0282	-0.38	-0.31	Lewy body disease;	chr13:52148663	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.538	rs9535885	ENSG00000235660.1	LINC00345	-4.05	8.2e-05	0.0282	-0.38	-0.31	Lewy body disease;	chr13:52152389	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.538	rs9526842	ENSG00000235660.1	LINC00345	-4.05	8.2e-05	0.0282	-0.38	-0.31	Lewy body disease;	chr13:52153588	chr13:52484161~52484680:-
PCPG	cis	rs11148252	0.538	rs9535887	ENSG00000235660.1	LINC00345	-4.05	8.2e-05	0.0282	-0.38	-0.31	Lewy body disease;	chr13:52156626	chr13:52484161~52484680:-
PCPG	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-4.05	8.21e-05	0.0282	-0.41	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
PCPG	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-4.05	8.21e-05	0.0282	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
PCPG	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-4.05	8.22e-05	0.0282	-0.53	-0.31	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
PCPG	cis	rs7267979	0.932	rs1985737	ENSG00000276952.1	RP5-965G21.6	4.05	8.22e-05	0.0282	0.35	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25284915~25285588:-
PCPG	cis	rs9650657	0.645	rs56057779	ENSG00000255020.1	AF131216.5	-4.05	8.22e-05	0.0282	-0.4	-0.31	Neuroticism;	chr8:10659370	chr8:11345748~11347502:-
PCPG	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	4.05	8.23e-05	0.0282	0.48	0.31	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
PCPG	cis	rs8064024	0.56	rs741769	ENSG00000267077.1	RP11-127I20.5	4.05	8.23e-05	0.0282	0.41	0.31	Cancer;	chr16:4886204	chr16:4795265~4796532:-
PCPG	cis	rs2288884	0.559	rs8109948	ENSG00000275055.1	CTC-471J1.11	-4.05	8.24e-05	0.0283	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004796	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.559	rs8109964	ENSG00000275055.1	CTC-471J1.11	-4.05	8.24e-05	0.0283	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004835	chr19:52049007~52049754:+
PCPG	cis	rs2288884	0.559	rs8109854	ENSG00000275055.1	CTC-471J1.11	-4.05	8.24e-05	0.0283	-0.3	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004866	chr19:52049007~52049754:+
PCPG	cis	rs9926296	0.632	rs72807526	ENSG00000260259.1	RP11-368I7.4	4.05	8.24e-05	0.0283	0.4	0.31	Vitiligo;	chr16:89709538	chr16:89682620~89686569:-
PCPG	cis	rs357618	0.581	rs165331	ENSG00000260581.1	CTB-113P19.4	-4.05	8.24e-05	0.0283	-0.41	-0.31	Basophil percentage of white cells;	chr5:151496406	chr5:151652275~151655449:+
PCPG	cis	rs13392177	0.684	rs6720449	ENSG00000273466.1	RP11-548H3.1	-4.05	8.24e-05	0.0283	-0.18	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218633256~218634014:-
PCPG	cis	rs116248771	0.739	rs4334688	ENSG00000272087.1	RP11-379F4.7	4.05	8.25e-05	0.0283	0.48	0.31	diarrhoeal disease at age 2;	chr3:158640877	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.69	rs73156439	ENSG00000272087.1	RP11-379F4.7	4.05	8.25e-05	0.0283	0.48	0.31	diarrhoeal disease at age 2;	chr3:158641673	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs2082159	ENSG00000272087.1	RP11-379F4.7	4.05	8.25e-05	0.0283	0.48	0.31	diarrhoeal disease at age 2;	chr3:158641878	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs2082158	ENSG00000272087.1	RP11-379F4.7	4.05	8.25e-05	0.0283	0.48	0.31	diarrhoeal disease at age 2;	chr3:158642002	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs12185969	ENSG00000272087.1	RP11-379F4.7	4.05	8.25e-05	0.0283	0.48	0.31	diarrhoeal disease at age 2;	chr3:158643091	chr3:158693120~158693768:-
PCPG	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	4.05	8.25e-05	0.0283	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
PCPG	cis	rs11148252	0.633	rs9535888	ENSG00000235660.1	LINC00345	-4.05	8.25e-05	0.0283	-0.38	-0.31	Lewy body disease;	chr13:52159071	chr13:52484161~52484680:-
PCPG	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-4.05	8.25e-05	0.0283	-0.36	-0.31	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
PCPG	cis	rs992157	0.56	rs7578940	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Colorectal cancer;	chr2:218218595	chr2:218633256~218634014:-
PCPG	cis	rs992157	0.56	rs1514132	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Colorectal cancer;	chr2:218219359	chr2:218633256~218634014:-
PCPG	cis	rs992157	0.56	rs10932763	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Colorectal cancer;	chr2:218221140	chr2:218633256~218634014:-
PCPG	cis	rs992157	0.56	rs12992937	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Colorectal cancer;	chr2:218222349	chr2:218633256~218634014:-
PCPG	cis	rs992157	0.56	rs4674274	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Colorectal cancer;	chr2:218224408	chr2:218633256~218634014:-
PCPG	cis	rs2382817	0.58	rs6756265	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218633256~218634014:-
PCPG	cis	rs992157	0.56	rs4674275	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Colorectal cancer;	chr2:218233015	chr2:218633256~218634014:-
PCPG	cis	rs992157	0.585	rs62182795	ENSG00000273466.1	RP11-548H3.1	-4.05	8.25e-05	0.0283	-0.17	-0.31	Colorectal cancer;	chr2:218235479	chr2:218633256~218634014:-
PCPG	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	4.05	8.26e-05	0.0283	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
PCPG	cis	rs11858159	1	rs7496600	ENSG00000260760.1	PWRN3	4.05	8.26e-05	0.0283	0.33	0.31	Platelet thrombus formation;	chr15:24570865	chr15:24441127~24447967:+
PCPG	cis	rs7819412	0.74	rs7844536	ENSG00000255020.1	AF131216.5	-4.05	8.27e-05	0.0283	-0.41	-0.31	Triglycerides;	chr8:11176519	chr8:11345748~11347502:-
PCPG	cis	rs2736345	0.747	rs1478901	ENSG00000184608.7	FAM167A-AS1	4.05	8.27e-05	0.0283	0.47	0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11490324	chr8:11368402~11438658:+
PCPG	cis	rs2736345	0.788	rs9693589	ENSG00000184608.7	FAM167A-AS1	4.05	8.27e-05	0.0283	0.47	0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491452	chr8:11368402~11438658:+
PCPG	cis	rs2736345	0.788	rs13277113	ENSG00000184608.7	FAM167A-AS1	4.05	8.27e-05	0.0283	0.47	0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491677	chr8:11368402~11438658:+
PCPG	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	4.05	8.27e-05	0.0284	0.4	0.31	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
PCPG	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	4.05	8.27e-05	0.0284	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
PCPG	cis	rs899997	0.773	rs11072783	ENSG00000261143.1	ADAMTS7P3	4.05	8.27e-05	0.0284	0.46	0.31	Coronary artery disease or large artery stroke;	chr15:78673624	chr15:77976042~77993057:+
PCPG	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-4.05	8.28e-05	0.0284	-0.4	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
PCPG	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	4.05	8.29e-05	0.0284	0.42	0.31	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
PCPG	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	4.05	8.3e-05	0.0284	0.34	0.31	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
PCPG	cis	rs1048886	0.872	rs16869371	ENSG00000271967.1	RP11-134K13.4	-4.05	8.3e-05	0.0284	-0.4	-0.31	Type 2 diabetes;	chr6:70559756	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.935	rs3193656	ENSG00000271967.1	RP11-134K13.4	-4.05	8.3e-05	0.0284	-0.4	-0.31	Type 2 diabetes;	chr6:70560840	chr6:70596438~70596980:+
PCPG	cis	rs7824557	0.767	rs6985146	ENSG00000184608.7	FAM167A-AS1	4.05	8.3e-05	0.0284	0.44	0.31	Retinal vascular caliber;	chr8:11313212	chr8:11368402~11438658:+
PCPG	cis	rs1371867	0.817	rs7846076	ENSG00000212994.5	RPS26P6	4.05	8.3e-05	0.0285	0.37	0.31	Atrioventricular conduction;	chr8:100315401	chr8:100895771~100896118:+
PCPG	cis	rs17152411	1	rs17152448	ENSG00000278831.1	RP11-12J10.4	4.05	8.31e-05	0.0285	0.45	0.31	Height;	chr10:124987076	chr10:124623353~124624079:+
PCPG	cis	rs6714710	0.58	rs11680018	ENSG00000278766.2	AC159540.2	4.05	8.31e-05	0.0285	0.35	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97863118	chr2:97421075~97434847:+
PCPG	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	4.05	8.31e-05	0.0285	0.38	0.31	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
PCPG	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	4.05	8.32e-05	0.0285	0.4	0.31	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
PCPG	cis	rs453301	0.597	rs7001187	ENSG00000173295.6	FAM86B3P	4.05	8.32e-05	0.0285	0.37	0.31	Joint mobility (Beighton score);	chr8:8935272	chr8:8228595~8244865:+
PCPG	cis	rs181553	0.629	rs12232591	ENSG00000278983.1	RP11-426J5.3	4.05	8.32e-05	0.0285	0.35	0.31	Hip circumference adjusted for BMI;	chr18:49164091	chr18:48564795~48568342:+
PCPG	cis	rs181553	0.699	rs12970381	ENSG00000278983.1	RP11-426J5.3	4.05	8.32e-05	0.0285	0.35	0.31	Hip circumference adjusted for BMI;	chr18:49167450	chr18:48564795~48568342:+
PCPG	cis	rs8099594	0.51	rs7233575	ENSG00000278983.1	RP11-426J5.3	4.05	8.32e-05	0.0285	0.35	0.31	Height;	chr18:49168712	chr18:48564795~48568342:+
PCPG	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	4.05	8.32e-05	0.0285	0.35	0.31	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
PCPG	cis	rs703842	1	rs10431505	ENSG00000270039.1	RP11-571M6.17	-4.05	8.33e-05	0.0285	-0.4	-0.31	Multiple sclerosis;	chr12:57784806	chr12:57803838~57804415:+
PCPG	cis	rs703842	1	rs11172344	ENSG00000270039.1	RP11-571M6.17	-4.05	8.33e-05	0.0285	-0.4	-0.31	Multiple sclerosis;	chr12:57799665	chr12:57803838~57804415:+
PCPG	cis	rs703842	1	rs10783847	ENSG00000270039.1	RP11-571M6.17	-4.05	8.33e-05	0.0285	-0.4	-0.31	Multiple sclerosis;	chr12:57802664	chr12:57803838~57804415:+
PCPG	cis	rs703842	1	rs10783848	ENSG00000270039.1	RP11-571M6.17	-4.05	8.33e-05	0.0285	-0.4	-0.31	Multiple sclerosis;	chr12:57802745	chr12:57803838~57804415:+
PCPG	cis	rs2404602	0.692	rs55729975	ENSG00000259514.1	RP11-685G9.2	-4.05	8.33e-05	0.0285	-0.32	-0.31	Blood metabolite levels;	chr15:76510885	chr15:76339609~76342063:-
PCPG	cis	rs7819412	0.66	rs7462931	ENSG00000255020.1	AF131216.5	-4.05	8.33e-05	0.0285	-0.42	-0.31	Triglycerides;	chr8:11052833	chr8:11345748~11347502:-
PCPG	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	4.05	8.33e-05	0.0285	0.41	0.31	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
PCPG	cis	rs75686122	0.892	rs76161982	ENSG00000253477.4	RP11-1C8.4	4.05	8.34e-05	0.0285	0.48	0.31	Cocaine dependence;	chr8:103647517	chr8:103483398~103501676:-
PCPG	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-4.05	8.34e-05	0.0285	-0.45	-0.31	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
PCPG	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	4.05	8.34e-05	0.0286	0.4	0.31	Height;	chr6:109409679	chr6:109382795~109383666:+
PCPG	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-4.05	8.34e-05	0.0286	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-4.05	8.34e-05	0.0286	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-4.05	8.34e-05	0.0286	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
PCPG	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-4.04	8.35e-05	0.0286	-0.39	-0.31	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-4.04	8.35e-05	0.0286	-0.39	-0.31	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-4.04	8.35e-05	0.0286	-0.39	-0.31	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
PCPG	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-4.04	8.35e-05	0.0286	-0.43	-0.31	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
PCPG	cis	rs6957923	0.818	rs7810773	ENSG00000230658.1	KLHL7-AS1	4.04	8.35e-05	0.0286	0.37	0.31	Height;	chr7:23480485	chr7:23101228~23105703:-
PCPG	cis	rs7037266	0.791	rs7865491	ENSG00000206147.5	RP11-106A1.2	-4.04	8.35e-05	0.0286	-0.34	-0.31	Menarche (age at onset);	chr9:6967846	chr9:6639139~6639604:+
PCPG	cis	rs7037266	0.791	rs1018586	ENSG00000206147.5	RP11-106A1.2	-4.04	8.35e-05	0.0286	-0.34	-0.31	Menarche (age at onset);	chr9:6969240	chr9:6639139~6639604:+
PCPG	cis	rs66887589	0.616	rs11098497	ENSG00000249244.1	RP11-548H18.2	4.04	8.36e-05	0.0286	0.29	0.31	Diastolic blood pressure;	chr4:119265913	chr4:119391831~119395335:-
PCPG	cis	rs66887589	0.616	rs11098498	ENSG00000249244.1	RP11-548H18.2	4.04	8.36e-05	0.0286	0.29	0.31	Diastolic blood pressure;	chr4:119265964	chr4:119391831~119395335:-
PCPG	cis	rs66887589	0.616	rs7659403	ENSG00000249244.1	RP11-548H18.2	4.04	8.36e-05	0.0286	0.29	0.31	Diastolic blood pressure;	chr4:119286099	chr4:119391831~119395335:-
PCPG	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	4.04	8.36e-05	0.0286	0.29	0.31	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
PCPG	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	4.04	8.36e-05	0.0286	0.29	0.31	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
PCPG	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	4.04	8.36e-05	0.0286	0.29	0.31	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
PCPG	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	4.04	8.36e-05	0.0286	0.44	0.31	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
PCPG	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-4.04	8.36e-05	0.0286	-0.46	-0.31	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
PCPG	cis	rs2734839	0.537	rs11214603	ENSG00000256757.1	RP11-159N11.3	4.04	8.37e-05	0.0286	0.34	0.31	Information processing speed;	chr11:113409200	chr11:113405321~113412117:+
PCPG	cis	rs875971	0.651	rs2420596	ENSG00000235475.1	LINC01372	4.04	8.37e-05	0.0286	0.32	0.31	Aortic root size;	chr7:66450996	chr7:67335976~67340024:+
PCPG	cis	rs875971	0.52	rs2420597	ENSG00000235475.1	LINC01372	4.04	8.37e-05	0.0286	0.32	0.31	Aortic root size;	chr7:66450999	chr7:67335976~67340024:+
PCPG	cis	rs7772486	0.625	rs9390355	ENSG00000270638.1	RP3-466P17.1	-4.04	8.37e-05	0.0286	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.658	rs4895683	ENSG00000270638.1	RP3-466P17.1	-4.04	8.37e-05	0.0286	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.625	rs2050027	ENSG00000270638.1	RP3-466P17.1	-4.04	8.37e-05	0.0286	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145735570~145737218:+
PCPG	cis	rs2836974	0.739	rs12482181	ENSG00000252915.1	Y_RNA	-4.04	8.37e-05	0.0287	-0.33	-0.31	Cognitive function;	chr21:39176926	chr21:39344537~39344628:+
PCPG	cis	rs9880211	1	rs9818056	ENSG00000273486.1	RP11-731C17.2	4.04	8.38e-05	0.0287	0.41	0.31	Height;Body mass index;	chr3:136491232	chr3:136837338~136839021:-
PCPG	cis	rs12765878	0.967	rs11598018	ENSG00000260461.1	RP11-541N10.3	4.04	8.38e-05	0.0287	0.36	0.31	Coronary artery disease;	chr10:103901557	chr10:103877374~103879761:-
PCPG	cis	rs1478897	0.898	rs2248932	ENSG00000255020.1	AF131216.5	-4.04	8.38e-05	0.0287	-0.4	-0.31	Systemic lupus erythematosus;	chr8:11534141	chr8:11345748~11347502:-
PCPG	cis	rs4791051	0.723	rs4082896	ENSG00000264491.1	RP11-349A8.3	-4.04	8.38e-05	0.0287	-0.32	-0.31	Heschl's gyrus morphology;	chr17:66452125	chr17:67019934~67021743:-
PCPG	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	4.04	8.39e-05	0.0287	0.35	0.31	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	4.04	8.39e-05	0.0287	0.35	0.31	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
PCPG	cis	rs5769765	1	rs910800	ENSG00000278869.1	CITF22-49E9.3	-4.04	8.39e-05	0.0287	-0.38	-0.31	Schizophrenia;	chr22:49884994	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.874	rs4624	ENSG00000278869.1	CITF22-49E9.3	-4.04	8.39e-05	0.0287	-0.38	-0.31	Schizophrenia;	chr22:49888269	chr22:49933198~49934074:-
PCPG	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-4.04	8.4e-05	0.0287	-0.45	-0.31	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
PCPG	cis	rs8098244	0.638	rs12953820	ENSG00000265752.2	RP11-403A21.1	4.04	8.4e-05	0.0287	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23878760	chr18:23957754~23982556:-
PCPG	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-4.04	8.4e-05	0.0287	-0.36	-0.31	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
PCPG	cis	rs12291225	0.679	rs10832240	ENSG00000251991.1	RNU7-49P	4.04	8.41e-05	0.0287	0.36	0.31	Sense of smell;	chr11:14283198	chr11:14478892~14478953:+
PCPG	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	4.04	8.41e-05	0.0287	0.34	0.31	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
PCPG	cis	rs6456042	0.893	rs3099312	ENSG00000231297.3	RP11-459F1.2	4.04	8.41e-05	0.0288	0.34	0.31	Asthma;	chr6:166143851	chr6:166099665~166113273:+
PCPG	cis	rs2732480	0.5	rs11168468	ENSG00000240399.1	RP1-228P16.1	4.04	8.41e-05	0.0288	0.34	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.5	rs12829841	ENSG00000240399.1	RP1-228P16.1	4.04	8.41e-05	0.0288	0.34	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.523	rs34286639	ENSG00000240399.1	RP1-228P16.1	4.04	8.41e-05	0.0288	0.34	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48054813~48055591:-
PCPG	cis	rs1387259	0.929	rs11168484	ENSG00000240399.1	RP1-228P16.1	4.04	8.41e-05	0.0288	0.34	0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.5	rs1387257	ENSG00000240399.1	RP1-228P16.1	4.04	8.41e-05	0.0288	0.34	0.31	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48054813~48055591:-
PCPG	cis	rs10411161	0.752	rs4584941	ENSG00000275055.1	CTC-471J1.11	-4.04	8.41e-05	0.0288	-0.37	-0.31	Breast cancer;	chr19:51888888	chr19:52049007~52049754:+
PCPG	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-4.04	8.42e-05	0.0288	-0.43	-0.31	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-4.04	8.42e-05	0.0288	-0.43	-0.31	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
PCPG	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-4.04	8.42e-05	0.0288	-0.43	-0.31	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
PCPG	cis	rs11671005	0.611	rs56026876	ENSG00000269600.1	AC016629.3	-4.04	8.42e-05	0.0288	-0.5	-0.31	Mean platelet volume;	chr19:58494790	chr19:58593896~58599355:-
PCPG	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	4.04	8.42e-05	0.0288	0.38	0.31	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
PCPG	cis	rs4713118	0.869	rs6456802	ENSG00000216901.1	AL022393.7	4.04	8.42e-05	0.0288	0.41	0.31	Parkinson's disease;	chr6:27730576	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9393851	ENSG00000216901.1	AL022393.7	4.04	8.42e-05	0.0288	0.41	0.31	Parkinson's disease;	chr6:27731802	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9461400	ENSG00000216901.1	AL022393.7	4.04	8.42e-05	0.0288	0.41	0.31	Parkinson's disease;	chr6:27732780	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs10214440	ENSG00000216901.1	AL022393.7	4.04	8.42e-05	0.0288	0.41	0.31	Parkinson's disease;	chr6:27734661	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9295742	ENSG00000216901.1	AL022393.7	4.04	8.42e-05	0.0288	0.41	0.31	Parkinson's disease;	chr6:27735053	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9461401	ENSG00000216901.1	AL022393.7	4.04	8.42e-05	0.0288	0.41	0.31	Parkinson's disease;	chr6:27735512	chr6:28176188~28176674:+
PCPG	cis	rs12291225	0.679	rs4756786	ENSG00000251991.1	RNU7-49P	4.04	8.43e-05	0.0288	0.36	0.31	Sense of smell;	chr11:14264354	chr11:14478892~14478953:+
PCPG	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	4.04	8.43e-05	0.0288	0.32	0.31	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
PCPG	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	4.04	8.43e-05	0.0288	0.36	0.31	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
PCPG	cis	rs7208859	0.623	rs122898	ENSG00000264538.5	SUZ12P1	4.04	8.44e-05	0.0288	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30709299~30790908:+
PCPG	cis	rs1150668	0.799	rs1736891	ENSG00000176933.5	TOB2P1	-4.04	8.44e-05	0.0288	-0.35	-0.31	Pubertal anthropometrics;	chr6:28219323	chr6:28217643~28218634:-
PCPG	cis	rs4842666	0.915	rs11105376	ENSG00000258302.2	RP11-981P6.1	4.04	8.44e-05	0.0288	0.51	0.31	Blood pressure;	chr12:89694991	chr12:89561129~89594878:+
PCPG	cis	rs763014	0.931	rs59476302	ENSG00000262528.2	LA16c-349E10.1	4.04	8.44e-05	0.0288	0.37	0.31	Height;	chr16:579006	chr16:654611~656194:-
PCPG	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	4.04	8.44e-05	0.0288	0.41	0.31	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
PCPG	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-4.04	8.45e-05	0.0288	-0.45	-0.31	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
PCPG	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	4.04	8.45e-05	0.0288	0.36	0.31	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
PCPG	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-4.04	8.45e-05	0.0288	-0.43	-0.31	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
PCPG	cis	rs2898290	0.622	rs1600250	ENSG00000254774.1	RP11-148O21.3	-4.04	8.45e-05	0.0289	-0.35	-0.31	Systolic blood pressure;	chr8:11487916	chr8:11553224~11554207:-
PCPG	cis	rs2898290	0.593	rs1600252	ENSG00000254774.1	RP11-148O21.3	-4.04	8.45e-05	0.0289	-0.35	-0.31	Systolic blood pressure;	chr8:11488135	chr8:11553224~11554207:-
PCPG	cis	rs561341	1	rs757009	ENSG00000265798.5	RP11-271K11.5	4.04	8.46e-05	0.0289	0.55	0.31	Hip circumference adjusted for BMI;	chr17:31916918	chr17:31038575~31059121:-
PCPG	cis	rs10842750	0.636	rs11048579	ENSG00000255968.1	RP11-513G19.1	-4.04	8.46e-05	0.0289	-0.42	-0.31	Kashin-Beck disease;	chr12:26564534	chr12:26318953~26421462:+
PCPG	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	4.04	8.46e-05	0.0289	0.34	0.31	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
PCPG	cis	rs12765878	1	rs35223321	ENSG00000260461.1	RP11-541N10.3	4.04	8.46e-05	0.0289	0.36	0.31	Coronary artery disease;	chr10:103886637	chr10:103877374~103879761:-
PCPG	cis	rs357618	0.931	rs394736	ENSG00000260581.1	CTB-113P19.4	4.04	8.46e-05	0.0289	0.37	0.31	Basophil percentage of white cells;	chr5:151467948	chr5:151652275~151655449:+
PCPG	cis	rs357618	0.965	rs357621	ENSG00000260581.1	CTB-113P19.4	4.04	8.46e-05	0.0289	0.37	0.31	Basophil percentage of white cells;	chr5:151467993	chr5:151652275~151655449:+
PCPG	cis	rs357618	1	rs193299	ENSG00000260581.1	CTB-113P19.4	4.04	8.46e-05	0.0289	0.37	0.31	Basophil percentage of white cells;	chr5:151468094	chr5:151652275~151655449:+
PCPG	cis	rs357618	0.965	rs187180	ENSG00000260581.1	CTB-113P19.4	4.04	8.46e-05	0.0289	0.37	0.31	Basophil percentage of white cells;	chr5:151468434	chr5:151652275~151655449:+
PCPG	cis	rs357618	1	rs357622	ENSG00000260581.1	CTB-113P19.4	4.04	8.46e-05	0.0289	0.37	0.31	Basophil percentage of white cells;	chr5:151468844	chr5:151652275~151655449:+
PCPG	cis	rs357618	1	rs357623	ENSG00000260581.1	CTB-113P19.4	4.04	8.46e-05	0.0289	0.37	0.31	Basophil percentage of white cells;	chr5:151468939	chr5:151652275~151655449:+
PCPG	cis	rs357618	1	rs357624	ENSG00000260581.1	CTB-113P19.4	4.04	8.46e-05	0.0289	0.37	0.31	Basophil percentage of white cells;	chr5:151469140	chr5:151652275~151655449:+
PCPG	cis	rs11613189	0.513	rs10846621	ENSG00000275389.1	RP11-214K3.24	4.04	8.47e-05	0.0289	0.37	0.31	Optic cup area;	chr12:124183041	chr12:124085761~124088598:+
PCPG	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	4.04	8.47e-05	0.0289	0.36	0.31	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
PCPG	cis	rs7759001	0.948	rs6456781	ENSG00000271755.1	RP1-153G14.4	4.04	8.48e-05	0.0289	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27418278	chr6:27404010~27406964:-
PCPG	cis	rs9813712	0.595	rs1901787	ENSG00000228252.7	COL6A4P2	4.04	8.48e-05	0.0289	0.39	0.31	Response to amphetamines;	chr3:130288678	chr3:130212823~130273806:+
PCPG	cis	rs7789940	1	rs7789940	ENSG00000186704.9	DTX2P1	4.04	8.48e-05	0.0289	0.39	0.31	Multiple sclerosis;	chr7:76321913	chr7:76978617~77004308:+
PCPG	cis	rs9650657	0.645	rs4841408	ENSG00000255020.1	AF131216.5	-4.04	8.48e-05	0.0289	-0.39	-0.31	Neuroticism;	chr8:10658826	chr8:11345748~11347502:-
PCPG	cis	rs7727544	0.836	rs10463892	ENSG00000233006.5	AC034220.3	4.04	8.49e-05	0.029	0.23	0.31	Blood metabolite levels;	chr5:132263012	chr5:132311285~132369916:-
PCPG	cis	rs7727544	0.901	rs55633655	ENSG00000233006.5	AC034220.3	4.04	8.49e-05	0.029	0.23	0.31	Blood metabolite levels;	chr5:132263063	chr5:132311285~132369916:-
PCPG	cis	rs1874124	0.577	rs2807853	ENSG00000272823.1	RP11-295M18.6	4.04	8.49e-05	0.029	0.44	0.31	Cholesterol, total;	chr1:220851011	chr1:220828676~220829211:-
PCPG	cis	rs1874124	0.504	rs2491257	ENSG00000272823.1	RP11-295M18.6	4.04	8.49e-05	0.029	0.44	0.31	Cholesterol, total;	chr1:220855900	chr1:220828676~220829211:-
PCPG	cis	rs75804782	0.63	rs56354063	ENSG00000227107.1	AC096574.5	-4.04	8.49e-05	0.029	-0.55	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:238345278	chr2:237612977~237626525:+
PCPG	cis	rs3109133	0.835	rs3115033	ENSG00000279512.1	RP11-575M22.1	-4.04	8.5e-05	0.029	-0.38	-0.31	Calcium levels;	chr2:132539524	chr2:133117004~133119052:+
PCPG	cis	rs2243480	0.908	rs4718273	ENSG00000230189.5	GS1-124K5.2	-4.04	8.5e-05	0.029	-0.49	-0.31	Diabetic kidney disease;	chr7:65751112	chr7:66409143~66490059:-
PCPG	cis	rs875971	0.862	rs11763189	ENSG00000235475.1	LINC01372	4.04	8.5e-05	0.029	0.32	0.31	Aortic root size;	chr7:66518542	chr7:67335976~67340024:+
PCPG	cis	rs897984	0.644	rs73524556	ENSG00000275263.1	RP11-1072A3.4	-4.04	8.5e-05	0.029	-0.32	-0.31	Dementia with Lewy bodies;	chr16:30811841	chr16:30956872~30957199:-
PCPG	cis	rs9923283	0.673	rs3759987	ENSG00000261067.5	RP11-264B17.3	-4.04	8.5e-05	0.029	-0.35	-0.31	Plateletcrit;	chr16:29662582	chr16:28974804~28990783:+
PCPG	cis	rs9923283	0.673	rs11574550	ENSG00000261067.5	RP11-264B17.3	-4.04	8.5e-05	0.029	-0.35	-0.31	Plateletcrit;	chr16:29662649	chr16:28974804~28990783:+
PCPG	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	4.04	8.51e-05	0.029	0.39	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
PCPG	cis	rs324126	0.78	rs60935857	ENSG00000277977.1	CTD-3018O17.5	4.04	8.51e-05	0.029	0.37	0.31	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52392659~52392755:+
PCPG	cis	rs2404602	0.692	rs57178708	ENSG00000259514.1	RP11-685G9.2	-4.04	8.51e-05	0.029	-0.32	-0.31	Blood metabolite levels;	chr15:76611728	chr15:76339609~76342063:-
PCPG	cis	rs2735413	0.599	rs76440854	ENSG00000276007.1	RP11-358L22.3	4.04	8.52e-05	0.029	0.34	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78046986	chr16:78123243~78124332:+
PCPG	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	4.04	8.53e-05	0.0291	0.41	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
PCPG	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	4.04	8.53e-05	0.0291	0.41	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
PCPG	cis	rs6893300	0.542	rs3797774	ENSG00000245317.2	CTC-241N9.1	4.04	8.53e-05	0.0291	0.28	0.31	Resting heart rate;	chr5:179766969	chr5:179859013~179861283:+
PCPG	cis	rs6893300	0.542	rs7736300	ENSG00000245317.2	CTC-241N9.1	4.04	8.53e-05	0.0291	0.28	0.31	Resting heart rate;	chr5:179769897	chr5:179859013~179861283:+
PCPG	cis	rs17177078	0.681	rs113695741	ENSG00000275494.1	RP11-266L9.8	-4.04	8.53e-05	0.0291	-0.48	-0.31	Type 2 diabetes (dietary heme iron intake interaction);	chr16:24857080	chr16:25106569~25107102:-
PCPG	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-4.04	8.53e-05	0.0291	-0.46	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
PCPG	cis	rs4376189	0.614	rs2030143	ENSG00000207497.1	Y_RNA	4.04	8.53e-05	0.0291	0.45	0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185716242	chr4:185709873~185709967:-
PCPG	cis	rs2625529	0.824	rs10518979	ENSG00000260037.4	CTD-2524L6.3	-4.04	8.53e-05	0.0291	-0.49	-0.31	Red blood cell count;	chr15:71976645	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.878	rs4777478	ENSG00000260037.4	CTD-2524L6.3	-4.04	8.53e-05	0.0291	-0.49	-0.31	Red blood cell count;	chr15:71986744	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs16956452	ENSG00000260037.4	CTD-2524L6.3	-4.04	8.53e-05	0.0291	-0.49	-0.31	Red blood cell count;	chr15:71991751	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs2306488	ENSG00000260037.4	CTD-2524L6.3	-4.04	8.53e-05	0.0291	-0.49	-0.31	Red blood cell count;	chr15:71999774	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.642	rs2200056	ENSG00000260037.4	CTD-2524L6.3	-4.04	8.53e-05	0.0291	-0.49	-0.31	Red blood cell count;	chr15:72010326	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12593134	ENSG00000260037.4	CTD-2524L6.3	-4.04	8.53e-05	0.0291	-0.49	-0.31	Red blood cell count;	chr15:72010666	chr15:71818396~71823384:+
PCPG	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	4.04	8.53e-05	0.0291	0.44	0.31	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
PCPG	cis	rs7211079	0.912	rs4889831	ENSG00000279259.1	RP11-334C17.3	4.04	8.54e-05	0.0291	0.29	0.31	Myocardial infarction;	chr17:80140854	chr17:80147250~80148596:+
PCPG	cis	rs7211079	0.957	rs935117	ENSG00000279259.1	RP11-334C17.3	4.04	8.54e-05	0.0291	0.29	0.31	Myocardial infarction;	chr17:80141685	chr17:80147250~80148596:+
PCPG	cis	rs7211079	0.957	rs58120535	ENSG00000279259.1	RP11-334C17.3	4.04	8.54e-05	0.0291	0.29	0.31	Myocardial infarction;	chr17:80142225	chr17:80147250~80148596:+
PCPG	cis	rs7211079	0.917	rs8067991	ENSG00000279259.1	RP11-334C17.3	4.04	8.54e-05	0.0291	0.29	0.31	Myocardial infarction;	chr17:80145503	chr17:80147250~80148596:+
PCPG	cis	rs2836974	1	rs2836974	ENSG00000252915.1	Y_RNA	4.04	8.54e-05	0.0291	0.33	0.31	Cognitive function;	chr21:39291255	chr21:39344537~39344628:+
PCPG	cis	rs2281558	0.833	rs6115202	ENSG00000125804.12	FAM182A	4.04	8.54e-05	0.0291	0.43	0.31	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:26054655~26086917:+
PCPG	cis	rs2836974	0.897	rs7280375	ENSG00000252915.1	Y_RNA	4.04	8.54e-05	0.0291	0.32	0.31	Cognitive function;	chr21:39180482	chr21:39344537~39344628:+
PCPG	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	4.04	8.55e-05	0.0291	0.36	0.31	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
PCPG	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-4.04	8.56e-05	0.0291	-0.39	-0.31	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
PCPG	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	4.04	8.56e-05	0.0291	0.31	0.31	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	4.04	8.56e-05	0.0291	0.31	0.31	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
PCPG	cis	rs6456042	0.893	rs2277093	ENSG00000231297.3	RP11-459F1.2	4.04	8.56e-05	0.0291	0.35	0.31	Asthma;	chr6:166157278	chr6:166099665~166113273:+
PCPG	cis	rs6456042	0.893	rs1134482	ENSG00000231297.3	RP11-459F1.2	4.04	8.56e-05	0.0291	0.35	0.31	Asthma;	chr6:166157669	chr6:166099665~166113273:+
PCPG	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	4.04	8.56e-05	0.0291	0.39	0.31	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
PCPG	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-4.04	8.56e-05	0.0291	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
PCPG	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-4.04	8.56e-05	0.0291	-0.43	-0.31	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-4.04	8.56e-05	0.0291	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-4.04	8.56e-05	0.0291	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-4.04	8.56e-05	0.0291	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-4.04	8.56e-05	0.0291	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
PCPG	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-4.04	8.56e-05	0.0291	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
PCPG	cis	rs425277	1	rs262665	ENSG00000271806.1	RP5-892K4.1	4.04	8.56e-05	0.0291	0.37	0.31	Height;	chr1:2151734	chr1:2141084~2145279:-
PCPG	cis	rs16879308	0.581	rs79450313	ENSG00000248898.1	CTD-2288O8.1	4.04	8.56e-05	0.0292	0.81	0.31	Migraine without aura;	chr5:52107218	chr5:52675193~52788026:-
PCPG	cis	rs1003719	0.68	rs2154537	ENSG00000228677.1	TTC3-AS1	-4.04	8.57e-05	0.0292	-0.38	-0.31	Eye color traits;	chr21:37129712	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs4261789	ENSG00000228677.1	TTC3-AS1	-4.04	8.57e-05	0.0292	-0.38	-0.31	Eye color traits;	chr21:37131462	chr21:37187666~37193926:-
PCPG	cis	rs1371867	0.81	rs2860518	ENSG00000212994.5	RPS26P6	-4.04	8.57e-05	0.0292	-0.37	-0.31	Atrioventricular conduction;	chr8:100225892	chr8:100895771~100896118:+
PCPG	cis	rs5758511	0.596	rs55644935	ENSG00000205702.9	CYP2D7	4.04	8.57e-05	0.0292	0.41	0.31	Birth weight;	chr22:42270063	chr22:42140203~42144577:-
PCPG	cis	rs6714710	0.603	rs2044459	ENSG00000278766.2	AC159540.2	4.04	8.57e-05	0.0292	0.35	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97830541	chr2:97421075~97434847:+
PCPG	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	4.04	8.57e-05	0.0292	0.39	0.31	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
PCPG	cis	rs79349575	0.87	rs12941262	ENSG00000270781.1	RP11-501C14.9	-4.04	8.57e-05	0.0292	-0.38	-0.31	Type 2 diabetes;	chr17:48889675	chr17:48899131~48899748:+
PCPG	cis	rs6452524	0.648	rs27364	ENSG00000281327.1	LINC01338	4.04	8.58e-05	0.0292	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:82850864~82859836:-
PCPG	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	4.04	8.58e-05	0.0292	0.37	0.31	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
PCPG	cis	rs4720118	0.66	rs4723272	ENSG00000173862.3	RP11-89N17.1	-4.04	8.58e-05	0.0292	-0.37	-0.31	Leprosy;	chr7:33181254	chr7:33725981~33728456:+
PCPG	cis	rs1949733	0.816	rs2631746	ENSG00000205959.3	RP11-689P11.2	4.04	8.58e-05	0.0292	0.32	0.31	Response to antineoplastic agents;	chr4:8489207	chr4:8482270~8512610:+
PCPG	cis	rs2404602	0.692	rs1867197	ENSG00000259514.1	RP11-685G9.2	4.04	8.59e-05	0.0292	0.34	0.31	Blood metabolite levels;	chr15:76617690	chr15:76339609~76342063:-
PCPG	cis	rs2836974	0.897	rs1571709	ENSG00000252915.1	Y_RNA	-4.04	8.59e-05	0.0292	-0.33	-0.31	Cognitive function;	chr21:39182054	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs13052882	ENSG00000252915.1	Y_RNA	-4.04	8.59e-05	0.0292	-0.33	-0.31	Cognitive function;	chr21:39183425	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs35064900	ENSG00000252915.1	Y_RNA	-4.04	8.59e-05	0.0292	-0.33	-0.31	Cognitive function;	chr21:39183566	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs36113648	ENSG00000252915.1	Y_RNA	-4.04	8.59e-05	0.0292	-0.33	-0.31	Cognitive function;	chr21:39183571	chr21:39344537~39344628:+
PCPG	cis	rs1440410	0.571	rs7673171	ENSG00000250326.1	RP11-284M14.1	4.04	8.59e-05	0.0292	0.28	0.31	Ischemic stroke;	chr4:143109945	chr4:142933195~143184861:-
PCPG	cis	rs1440410	0.571	rs10471101	ENSG00000250326.1	RP11-284M14.1	4.04	8.59e-05	0.0292	0.28	0.31	Ischemic stroke;	chr4:143110775	chr4:142933195~143184861:-
PCPG	cis	rs797680	0.856	rs6541404	ENSG00000223745.6	RP4-717I23.3	-4.04	8.59e-05	0.0292	-0.3	-0.31	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93277877	chr1:93262186~93346025:-
PCPG	cis	rs240993	0.812	rs9387013	ENSG00000271789.1	RP5-1112D6.7	4.04	8.59e-05	0.0292	0.41	0.31	Inflammatory skin disease;Psoriasis;	chr6:111512517	chr6:111297126~111298510:+
PCPG	cis	rs453301	0.631	rs13250781	ENSG00000173295.6	FAM86B3P	4.04	8.59e-05	0.0292	0.37	0.31	Joint mobility (Beighton score);	chr8:8935833	chr8:8228595~8244865:+
PCPG	cis	rs3758911	1	rs11212164	ENSG00000255353.1	RP11-382M14.1	-4.04	8.59e-05	0.0292	-0.4	-0.31	Coronary artery disease;	chr11:107328113	chr11:107176286~107177530:+
PCPG	cis	rs16879308	0.581	rs79104746	ENSG00000248898.1	CTD-2288O8.1	4.04	8.6e-05	0.0292	0.81	0.31	Migraine without aura;	chr5:52110428	chr5:52675193~52788026:-
PCPG	cis	rs16879308	0.581	rs79232761	ENSG00000248898.1	CTD-2288O8.1	4.04	8.6e-05	0.0292	0.81	0.31	Migraine without aura;	chr5:52111313	chr5:52675193~52788026:-
PCPG	cis	rs16879308	0.581	rs76564130	ENSG00000248898.1	CTD-2288O8.1	4.04	8.6e-05	0.0292	0.81	0.31	Migraine without aura;	chr5:52113836	chr5:52675193~52788026:-
PCPG	cis	rs16879308	0.581	rs75896961	ENSG00000248898.1	CTD-2288O8.1	4.04	8.6e-05	0.0292	0.81	0.31	Migraine without aura;	chr5:52113867	chr5:52675193~52788026:-
PCPG	cis	rs3758911	0.964	rs10789601	ENSG00000255353.1	RP11-382M14.1	-4.04	8.6e-05	0.0293	-0.39	-0.31	Coronary artery disease;	chr11:107310693	chr11:107176286~107177530:+
PCPG	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-4.04	8.61e-05	0.0293	-0.34	-0.31	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
PCPG	cis	rs2262909	0.962	rs7255049	ENSG00000279377.1	AC003973.3	4.04	8.61e-05	0.0293	0.44	0.31	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22030309	chr19:21965708~21968529:-
PCPG	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	4.04	8.61e-05	0.0293	0.32	0.31	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
PCPG	cis	rs6479901	0.501	rs7084396	ENSG00000232075.1	MRPL35P2	-4.04	8.61e-05	0.0293	-0.4	-0.31	Intelligence (multi-trait analysis);	chr10:63116965	chr10:63634317~63634827:-
PCPG	cis	rs720064	0.586	rs12956330	ENSG00000265752.2	RP11-403A21.1	4.04	8.61e-05	0.0293	0.36	0.31	Strep throat;	chr18:23981536	chr18:23957754~23982556:-
PCPG	cis	rs13118159	0.509	rs9683830	ENSG00000254094.1	AC078852.1	-4.04	8.61e-05	0.0293	-0.4	-0.31	Longevity;	chr4:1384085	chr4:1356581~1358075:+
PCPG	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-4.04	8.62e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
PCPG	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	4.04	8.62e-05	0.0293	0.37	0.31	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	4.04	8.62e-05	0.0293	0.37	0.31	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
PCPG	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	4.04	8.62e-05	0.0293	0.3	0.31	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
PCPG	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	4.04	8.62e-05	0.0293	0.42	0.31	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	4.04	8.62e-05	0.0293	0.42	0.31	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
PCPG	cis	rs2243480	1	rs3885839	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65825416	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs3813708	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65840645	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs73142122	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65846311	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs73142137	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65878455	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs13247184	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65893941	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35283677	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65894246	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35421653	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65898442	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs73142162	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65909309	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs73142166	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65910845	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.908	rs55876148	ENSG00000230189.5	GS1-124K5.2	4.04	8.62e-05	0.0293	0.48	0.31	Diabetic kidney disease;	chr7:65914813	chr7:66409143~66490059:-
PCPG	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	4.04	8.63e-05	0.0293	0.32	0.31	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
PCPG	cis	rs13392177	0.684	rs11682371	ENSG00000273466.1	RP11-548H3.1	-4.04	8.63e-05	0.0293	-0.18	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218633256~218634014:-
PCPG	cis	rs13392177	0.684	rs6720105	ENSG00000273466.1	RP11-548H3.1	-4.04	8.63e-05	0.0293	-0.18	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218633256~218634014:-
PCPG	cis	rs12765878	0.967	rs10883948	ENSG00000260461.1	RP11-541N10.3	4.04	8.64e-05	0.0293	0.35	0.31	Coronary artery disease;	chr10:103907794	chr10:103877374~103879761:-
PCPG	cis	rs12765878	0.967	rs7920217	ENSG00000260461.1	RP11-541N10.3	4.04	8.64e-05	0.0293	0.35	0.31	Coronary artery disease;	chr10:103908414	chr10:103877374~103879761:-
PCPG	cis	rs12765878	1	rs11191865	ENSG00000260461.1	RP11-541N10.3	4.04	8.64e-05	0.0293	0.35	0.31	Coronary artery disease;	chr10:103913084	chr10:103877374~103879761:-
PCPG	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	4.04	8.64e-05	0.0293	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
PCPG	cis	rs4819052	0.851	rs2877018	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2330012	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2877019	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2877020	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs10470258	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs4819038	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs4819039	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs4818768	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs4819042	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.8	rs4819045	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs13048789	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs13047598	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.724	rs9753962	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.724	rs9753987	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs9753963	ENSG00000215447.6	BX322557.10	-4.04	8.64e-05	0.0293	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45288052~45291738:+
PCPG	cis	rs748404	0.629	rs34657657	ENSG00000205771.5	CATSPER2P1	-4.04	8.64e-05	0.0293	-0.43	-0.31	Lung cancer;	chr15:43315763	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.626	rs62019432	ENSG00000205771.5	CATSPER2P1	-4.04	8.64e-05	0.0293	-0.43	-0.31	Lung cancer;	chr15:43316482	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs7176923	ENSG00000205771.5	CATSPER2P1	-4.04	8.64e-05	0.0293	-0.43	-0.31	Lung cancer;	chr15:43317679	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.666	rs17723479	ENSG00000205771.5	CATSPER2P1	-4.04	8.64e-05	0.0293	-0.43	-0.31	Lung cancer;	chr15:43322114	chr15:43726918~43747094:-
PCPG	cis	rs2281603	0.762	rs12588437	ENSG00000259116.1	RP11-973N13.4	-4.04	8.64e-05	0.0294	-0.3	-0.31	Lymphocyte counts;	chr14:64580366	chr14:64514154~64540368:-
PCPG	cis	rs2281603	0.762	rs11850291	ENSG00000259116.1	RP11-973N13.4	-4.04	8.64e-05	0.0294	-0.3	-0.31	Lymphocyte counts;	chr14:64582676	chr14:64514154~64540368:-
PCPG	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-4.04	8.64e-05	0.0294	-0.46	-0.31	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
PCPG	cis	rs3947	1	rs1736084	ENSG00000227203.3	SUB1P1	-4.04	8.65e-05	0.0294	-0.48	-0.31	Blood protein levels;	chr8:11846148	chr8:11790005~11790386:+
PCPG	cis	rs3947	1	rs1736085	ENSG00000227203.3	SUB1P1	-4.04	8.65e-05	0.0294	-0.48	-0.31	Blood protein levels;	chr8:11846150	chr8:11790005~11790386:+
PCPG	cis	rs2404602	0.716	rs4886817	ENSG00000259514.1	RP11-685G9.2	-4.04	8.65e-05	0.0294	-0.32	-0.31	Blood metabolite levels;	chr15:76585361	chr15:76339609~76342063:-
PCPG	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-4.04	8.65e-05	0.0294	-0.34	-0.31	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
PCPG	cis	rs2652834	0.904	rs2937859	ENSG00000259498.1	RP11-244F12.3	-4.04	8.65e-05	0.0294	-0.5	-0.31	HDL cholesterol;	chr15:63074083	chr15:63046034~63049387:-
PCPG	cis	rs2652834	0.904	rs7175602	ENSG00000259498.1	RP11-244F12.3	4.04	8.65e-05	0.0294	0.5	0.31	HDL cholesterol;	chr15:63074833	chr15:63046034~63049387:-
PCPG	cis	rs801193	1	rs17566701	ENSG00000273142.1	RP11-458F8.4	-4.04	8.65e-05	0.0294	-0.3	-0.31	Aortic root size;	chr7:66728196	chr7:66902857~66906297:+
PCPG	cis	rs12681963	0.748	rs12546330	ENSG00000248159.1	HSPA8P11	-4.04	8.65e-05	0.0294	-0.48	-0.31	Migraine;	chr8:30044958	chr8:30237382~30240997:+
PCPG	cis	rs1635	0.655	rs9368532	ENSG00000271755.1	RP1-153G14.4	-4.04	8.65e-05	0.0294	-0.86	-0.31	Schizophrenia;	chr6:27814232	chr6:27404010~27406964:-
PCPG	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-4.04	8.65e-05	0.0294	-0.25	-0.31	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
PCPG	cis	rs453301	0.631	rs11780774	ENSG00000173295.6	FAM86B3P	4.04	8.66e-05	0.0294	0.37	0.31	Joint mobility (Beighton score);	chr8:8941601	chr8:8228595~8244865:+
PCPG	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-4.04	8.66e-05	0.0294	-0.25	-0.31	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
PCPG	cis	rs9388451	0.807	rs1268070	ENSG00000237742.5	RP11-624M8.1	-4.04	8.66e-05	0.0294	-0.34	-0.31	Brugada syndrome;	chr6:125720018	chr6:125578558~125749190:-
PCPG	cis	rs2797160	0.651	rs6939969	ENSG00000237742.5	RP11-624M8.1	4.04	8.67e-05	0.0294	0.33	0.31	Endometrial cancer;	chr6:125713417	chr6:125578558~125749190:-
PCPG	cis	rs2797160	0.651	rs1268067	ENSG00000237742.5	RP11-624M8.1	4.04	8.67e-05	0.0294	0.33	0.31	Endometrial cancer;	chr6:125715475	chr6:125578558~125749190:-
PCPG	cis	rs2836974	0.644	rs11088471	ENSG00000252915.1	Y_RNA	4.04	8.67e-05	0.0294	0.32	0.31	Cognitive function;	chr21:39327387	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.644	rs11088472	ENSG00000252915.1	Y_RNA	4.04	8.67e-05	0.0294	0.32	0.31	Cognitive function;	chr21:39327450	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.602	rs2037925	ENSG00000252915.1	Y_RNA	4.04	8.67e-05	0.0294	0.32	0.31	Cognitive function;	chr21:39328005	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.623	rs7280326	ENSG00000252915.1	Y_RNA	4.04	8.67e-05	0.0294	0.32	0.31	Cognitive function;	chr21:39328482	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.644	rs2836986	ENSG00000252915.1	Y_RNA	4.04	8.67e-05	0.0294	0.32	0.31	Cognitive function;	chr21:39330210	chr21:39344537~39344628:+
PCPG	cis	rs591584	0.73	rs11020836	ENSG00000255893.1	RP11-685N10.1	-4.04	8.67e-05	0.0294	-0.37	-0.31	Macrophage Migration Inhibitory Factor levels;	chr11:94575726	chr11:94472908~94473570:-
PCPG	cis	rs240993	0.812	rs7764543	ENSG00000271789.1	RP5-1112D6.7	-4.04	8.67e-05	0.0294	-0.4	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111297126~111298510:+
PCPG	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-4.03	8.67e-05	0.0294	-0.36	-0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
PCPG	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	4.03	8.68e-05	0.0294	0.45	0.31	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
PCPG	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	4.03	8.68e-05	0.0294	0.45	0.31	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
PCPG	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-4.03	8.68e-05	0.0294	-0.32	-0.31	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
PCPG	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	4.03	8.68e-05	0.0294	0.36	0.31	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
PCPG	cis	rs4720118	0.66	rs1420148	ENSG00000173862.3	RP11-89N17.1	-4.03	8.69e-05	0.0295	-0.37	-0.31	Leprosy;	chr7:33178053	chr7:33725981~33728456:+
PCPG	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	4.03	8.69e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
PCPG	cis	rs10760158	0.8	rs3747850	ENSG00000226752.6	PSMD5-AS1	-4.03	8.69e-05	0.0295	-0.42	-0.31	Pulse pressure;	chr9:121302650	chr9:120824828~120854385:+
PCPG	cis	rs11098499	1	rs10029750	ENSG00000250412.1	KLHL2P1	4.03	8.69e-05	0.0295	0.33	0.31	Corneal astigmatism;	chr4:119251388	chr4:119334329~119378233:+
PCPG	cis	rs2404602	0.692	rs34181263	ENSG00000259514.1	RP11-685G9.2	-4.03	8.7e-05	0.0295	-0.32	-0.31	Blood metabolite levels;	chr15:76773047	chr15:76339609~76342063:-
PCPG	cis	rs2980439	0.525	rs2980508	ENSG00000173295.6	FAM86B3P	-4.03	8.7e-05	0.0295	-0.34	-0.31	Neuroticism;	chr8:8314210	chr8:8228595~8244865:+
PCPG	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	4.03	8.7e-05	0.0295	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
PCPG	cis	rs300890	0.699	rs300918	ENSG00000250326.1	RP11-284M14.1	4.03	8.71e-05	0.0295	0.27	0.31	Nasopharyngeal carcinoma;	chr4:143345826	chr4:142933195~143184861:-
PCPG	cis	rs17158807	0.565	rs75666428	ENSG00000259728.4	LINC00933	-4.03	8.71e-05	0.0295	-0.77	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr15:84012650	chr15:84570649~84580175:+
PCPG	cis	rs9303029	1	rs12450191	ENSG00000279744.1	RP13-20L14.10	-4.03	8.71e-05	0.0295	-0.41	-0.31	Protein quantitative trait loci;	chr17:82450072	chr17:82462601~82464255:+
PCPG	cis	rs75686122	0.892	rs76082564	ENSG00000253477.4	RP11-1C8.4	4.03	8.71e-05	0.0295	0.48	0.31	Cocaine dependence;	chr8:103524421	chr8:103483398~103501676:-
PCPG	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	4.03	8.71e-05	0.0295	0.39	0.31	Height;	chr6:109424305	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	4.03	8.71e-05	0.0295	0.39	0.31	Height;	chr6:109425054	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	4.03	8.71e-05	0.0295	0.39	0.31	Height;	chr6:109426518	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	4.03	8.71e-05	0.0295	0.39	0.31	Height;	chr6:109427644	chr6:109382795~109383666:+
PCPG	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	4.03	8.71e-05	0.0295	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
PCPG	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	4.03	8.71e-05	0.0295	0.56	0.31	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
PCPG	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	4.03	8.71e-05	0.0295	0.4	0.31	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
PCPG	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	4.03	8.71e-05	0.0295	0.4	0.31	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
PCPG	cis	rs896854	0.715	rs12548874	ENSG00000253528.2	RP11-347C18.4	-4.03	8.71e-05	0.0295	-0.32	-0.31	Type 2 diabetes;	chr8:94922936	chr8:94974573~94974853:-
PCPG	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	4.03	8.72e-05	0.0295	0.35	0.31	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
PCPG	cis	rs13392177	0.66	rs62185964	ENSG00000273466.1	RP11-548H3.1	-4.03	8.72e-05	0.0295	-0.18	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218633256~218634014:-
PCPG	cis	rs13392177	0.684	rs62185965	ENSG00000273466.1	RP11-548H3.1	-4.03	8.72e-05	0.0295	-0.18	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218633256~218634014:-
PCPG	cis	rs13392177	0.66	rs10932762	ENSG00000273466.1	RP11-548H3.1	-4.03	8.72e-05	0.0295	-0.18	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218633256~218634014:-
PCPG	cis	rs2404602	0.716	rs67920045	ENSG00000259514.1	RP11-685G9.2	-4.03	8.72e-05	0.0296	-0.32	-0.31	Blood metabolite levels;	chr15:76507743	chr15:76339609~76342063:-
PCPG	cis	rs6901152	0.895	rs9376743	ENSG00000217648.1	RP1-95L4.4	-4.03	8.72e-05	0.0296	-0.37	-0.31	Acute lymphoblastic leukemia (childhood);	chr6:143325797	chr6:143342246~143343383:+
PCPG	cis	rs7707921	1	rs2407064	ENSG00000249483.1	CTD-2249K22.1	4.03	8.73e-05	0.0296	0.43	0.31	Breast cancer;	chr5:82161539	chr5:81851601~81852201:+
PCPG	cis	rs657075	0.595	rs4877	ENSG00000233006.5	AC034220.3	-4.03	8.73e-05	0.0296	-0.43	-0.31	Rheumatoid arthritis;	chr5:132271895	chr5:132311285~132369916:-
PCPG	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	4.03	8.73e-05	0.0296	0.4	0.31	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
PCPG	cis	rs17507216	0.958	rs72751643	ENSG00000228141.5	AC105339.1	-4.03	8.73e-05	0.0296	-0.44	-0.31	Excessive daytime sleepiness;	chr15:82559444	chr15:82710471~82714026:-
PCPG	cis	rs9911578	0.9	rs7214335	ENSG00000267416.1	CTD-2319I12.2	4.03	8.73e-05	0.0296	0.34	0.31	Intelligence (multi-trait analysis);	chr17:59081479	chr17:60079309~60088695:+
PCPG	cis	rs2404602	0.669	rs17464903	ENSG00000259514.1	RP11-685G9.2	-4.03	8.73e-05	0.0296	-0.31	-0.31	Blood metabolite levels;	chr15:76903145	chr15:76339609~76342063:-
PCPG	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	4.03	8.73e-05	0.0296	0.38	0.31	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
PCPG	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-4.03	8.73e-05	0.0296	-0.36	-0.31	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
PCPG	cis	rs7824557	0.62	rs6996368	ENSG00000255020.1	AF131216.5	4.03	8.74e-05	0.0296	0.41	0.31	Retinal vascular caliber;	chr8:11325195	chr8:11345748~11347502:-
PCPG	cis	rs425277	0.958	rs262660	ENSG00000271806.1	RP5-892K4.1	4.03	8.75e-05	0.0296	0.37	0.31	Height;	chr1:2155318	chr1:2141084~2145279:-
PCPG	cis	rs425277	1	rs262657	ENSG00000271806.1	RP5-892K4.1	4.03	8.75e-05	0.0296	0.37	0.31	Height;	chr1:2157138	chr1:2141084~2145279:-
PCPG	cis	rs425277	0.917	rs262656	ENSG00000271806.1	RP5-892K4.1	4.03	8.75e-05	0.0296	0.37	0.31	Height;	chr1:2157315	chr1:2141084~2145279:-
PCPG	cis	rs425277	0.958	rs262652	ENSG00000271806.1	RP5-892K4.1	4.03	8.75e-05	0.0296	0.37	0.31	Height;	chr1:2159377	chr1:2141084~2145279:-
PCPG	cis	rs425277	1	rs262651	ENSG00000271806.1	RP5-892K4.1	4.03	8.75e-05	0.0296	0.37	0.31	Height;	chr1:2159958	chr1:2141084~2145279:-
PCPG	cis	rs2836974	0.931	rs12151994	ENSG00000252915.1	Y_RNA	-4.03	8.75e-05	0.0296	-0.33	-0.31	Cognitive function;	chr21:39318471	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.966	rs7283516	ENSG00000252915.1	Y_RNA	-4.03	8.75e-05	0.0296	-0.33	-0.31	Cognitive function;	chr21:39318611	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.796	rs77153312	ENSG00000252915.1	Y_RNA	-4.03	8.75e-05	0.0296	-0.33	-0.31	Cognitive function;	chr21:39323573	chr21:39344537~39344628:+
PCPG	cis	rs7444	0.941	rs181363	ENSG00000211645.2	IGLV1-50	4.03	8.75e-05	0.0296	0.36	0.31	Systemic lupus erythematosus;	chr22:21577975	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.825	rs5994638	ENSG00000211645.2	IGLV1-50	4.03	8.75e-05	0.0296	0.36	0.31	Systemic lupus erythematosus;	chr22:21598987	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.882	rs5998644	ENSG00000211645.2	IGLV1-50	4.03	8.75e-05	0.0296	0.36	0.31	Systemic lupus erythematosus;	chr22:21598999	chr22:22327300~22327814:+
PCPG	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	-4.03	8.75e-05	0.0296	-0.36	-0.31	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
PCPG	cis	rs12681963	0.688	rs12548744	ENSG00000272375.1	RP11-51J9.6	4.03	8.75e-05	0.0296	0.45	0.31	Migraine;	chr8:30184400	chr8:30197404~30198048:+
PCPG	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	4.03	8.76e-05	0.0297	0.4	0.31	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	4.03	8.76e-05	0.0297	0.4	0.31	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
PCPG	cis	rs2243480	1	rs313814	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66038306	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs402418	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66044482	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.803	rs423187	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66044512	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs431318	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66046610	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs313803	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66049744	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs313802	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66051386	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.803	rs403089	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66052736	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs458291	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66055492	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs466983	ENSG00000251451.1	GS1-124K5.6	4.03	8.76e-05	0.0297	0.58	0.31	Diabetic kidney disease;	chr7:66055509	chr7:66407288~66409239:-
PCPG	cis	rs911119	1	rs1010117	ENSG00000270001.1	RP11-218C14.8	-4.03	8.78e-05	0.0297	-0.5	-0.31	Chronic kidney disease;	chr20:23627784	chr20:23631826~23632316:-
PCPG	cis	rs7247513	0.964	rs8100964	ENSG00000213290.4	PGK1P2	-4.03	8.78e-05	0.0297	-0.44	-0.31	Bipolar disorder;	chr19:12609817	chr19:12559571~12561105:+
PCPG	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	4.03	8.78e-05	0.0297	0.37	0.31	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
PCPG	cis	rs7172677	0.96	rs1602360	ENSG00000261543.1	RP11-665J16.1	-4.03	8.79e-05	0.0298	-0.37	-0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75128420	chr15:74152800~74179226:-
PCPG	cis	rs7172677	1	rs8032261	ENSG00000261543.1	RP11-665J16.1	-4.03	8.79e-05	0.0298	-0.37	-0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75131671	chr15:74152800~74179226:-
PCPG	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	4.03	8.8e-05	0.0298	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
PCPG	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-4.03	8.8e-05	0.0298	-0.44	-0.31	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
PCPG	cis	rs1876905	0.68	rs373526	ENSG00000255389.1	C6orf3	-4.03	8.81e-05	0.0298	-0.41	-0.31	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111599875~111602295:+
PCPG	cis	rs1876905	0.68	rs1150082	ENSG00000255389.1	C6orf3	4.03	8.81e-05	0.0298	0.41	0.31	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111599875~111602295:+
PCPG	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	4.03	8.81e-05	0.0298	0.36	0.31	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	4.03	8.81e-05	0.0298	0.36	0.31	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	4.03	8.81e-05	0.0298	0.36	0.31	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	4.03	8.81e-05	0.0298	0.36	0.31	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	4.03	8.81e-05	0.0298	0.36	0.31	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
PCPG	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-4.03	8.82e-05	0.0298	-0.39	-0.31	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
PCPG	cis	rs728616	0.85	rs3889823	ENSG00000242600.5	MBL1P	4.03	8.82e-05	0.0298	0.72	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79904898~79950336:+
PCPG	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	4.03	8.82e-05	0.0298	0.4	0.31	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
PCPG	cis	rs9880211	1	rs9823373	ENSG00000273486.1	RP11-731C17.2	4.03	8.82e-05	0.0298	0.42	0.31	Height;Body mass index;	chr3:136448185	chr3:136837338~136839021:-
PCPG	cis	rs12681963	0.688	rs16876622	ENSG00000248159.1	HSPA8P11	4.03	8.82e-05	0.0298	0.63	0.31	Migraine;	chr8:30178120	chr8:30237382~30240997:+
PCPG	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-4.03	8.82e-05	0.0298	-0.4	-0.31	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-4.03	8.82e-05	0.0298	-0.4	-0.31	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-4.03	8.82e-05	0.0298	-0.4	-0.31	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
PCPG	cis	rs7487075	0.6	rs35396015	ENSG00000274723.1	RP11-618L22.1	4.03	8.82e-05	0.0298	0.38	0.31	Itch intensity from mosquito bite;	chr12:46299723	chr12:46970504~46972155:+
PCPG	cis	rs2243480	0.901	rs2900904	ENSG00000230189.5	GS1-124K5.2	4.03	8.83e-05	0.0298	0.48	0.31	Diabetic kidney disease;	chr7:65739282	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs313809	ENSG00000230189.5	GS1-124K5.2	4.03	8.83e-05	0.0298	0.48	0.31	Diabetic kidney disease;	chr7:66034996	chr7:66409143~66490059:-
PCPG	cis	rs2404602	0.716	rs2404737	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76579876	chr15:76339609~76342063:-
PCPG	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	4.03	8.83e-05	0.0299	0.37	0.31	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
PCPG	cis	rs12765878	1	rs2902639	ENSG00000260461.1	RP11-541N10.3	4.03	8.83e-05	0.0299	0.36	0.31	Coronary artery disease;	chr10:103898830	chr10:103877374~103879761:-
PCPG	cis	rs7246657	0.722	rs3095726	ENSG00000276846.1	CTD-3220F14.3	-4.03	8.83e-05	0.0299	-0.46	-0.31	Coronary artery calcification;	chr19:37738923	chr19:37314868~37315620:-
PCPG	cis	rs896854	0.624	rs9297949	ENSG00000272509.1	RP11-347C18.5	4.03	8.83e-05	0.0299	0.31	0.31	Type 2 diabetes;	chr8:94957217	chr8:94884609~94885070:+
PCPG	cis	rs2404602	0.692	rs12904198	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76854637	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs2137307	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76856679	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.669	rs17367297	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76865685	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs12594556	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76873022	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs12913810	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76874334	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs12595586	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76879869	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs58889902	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76880729	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs4360890	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76880954	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.669	rs12916324	ENSG00000259514.1	RP11-685G9.2	-4.03	8.83e-05	0.0299	-0.32	-0.31	Blood metabolite levels;	chr15:76887262	chr15:76339609~76342063:-
PCPG	cis	rs79349575	0.778	rs12950328	ENSG00000270781.1	RP11-501C14.9	-4.03	8.84e-05	0.0299	-0.38	-0.31	Type 2 diabetes;	chr17:48889699	chr17:48899131~48899748:+
PCPG	cis	rs79349575	0.594	rs1985785	ENSG00000270781.1	RP11-501C14.9	-4.03	8.84e-05	0.0299	-0.38	-0.31	Type 2 diabetes;	chr17:48890426	chr17:48899131~48899748:+
PCPG	cis	rs79349575	0.685	rs1124829	ENSG00000270781.1	RP11-501C14.9	-4.03	8.84e-05	0.0299	-0.38	-0.31	Type 2 diabetes;	chr17:48890435	chr17:48899131~48899748:+
PCPG	cis	rs79349575	0.721	rs1008834	ENSG00000270781.1	RP11-501C14.9	-4.03	8.84e-05	0.0299	-0.38	-0.31	Type 2 diabetes;	chr17:48890646	chr17:48899131~48899748:+
PCPG	cis	rs79349575	0.721	rs9904645	ENSG00000270781.1	RP11-501C14.9	-4.03	8.84e-05	0.0299	-0.38	-0.31	Type 2 diabetes;	chr17:48892303	chr17:48899131~48899748:+
PCPG	cis	rs7487075	0.6	rs35396015	ENSG00000257261.4	RP11-96H19.1	4.03	8.84e-05	0.0299	0.41	0.31	Itch intensity from mosquito bite;	chr12:46299723	chr12:46383679~46876159:+
PCPG	cis	rs11671005	0.779	rs3794971	ENSG00000252334.1	RNU6-1337P	4.03	8.84e-05	0.0299	0.45	0.31	Mean platelet volume;	chr19:58474499	chr19:58483749~58483843:-
PCPG	cis	rs357618	1	rs165352	ENSG00000260581.1	CTB-113P19.4	4.03	8.84e-05	0.0299	0.37	0.31	Basophil percentage of white cells;	chr5:151476546	chr5:151652275~151655449:+
PCPG	cis	rs357618	1	rs165353	ENSG00000260581.1	CTB-113P19.4	4.03	8.84e-05	0.0299	0.37	0.31	Basophil percentage of white cells;	chr5:151477196	chr5:151652275~151655449:+
PCPG	cis	rs9388451	0.626	rs3799712	ENSG00000237742.5	RP11-624M8.1	-4.03	8.84e-05	0.0299	-0.35	-0.31	Brugada syndrome;	chr6:125753957	chr6:125578558~125749190:-
PCPG	cis	rs4835473	0.838	rs12507468	ENSG00000251600.4	RP11-673E1.1	-4.03	8.85e-05	0.0299	-0.37	-0.31	Immature fraction of reticulocytes;	chr4:143908061	chr4:143912331~143982454:+
PCPG	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-4.03	8.85e-05	0.0299	-0.44	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
PCPG	cis	rs79349575	0.716	rs595767	ENSG00000270781.1	RP11-501C14.9	-4.03	8.85e-05	0.0299	-0.38	-0.31	Type 2 diabetes;	chr17:48880625	chr17:48899131~48899748:+
PCPG	cis	rs11220082	0.644	rs36143594	ENSG00000254671.2	STT3A-AS1	-4.03	8.85e-05	0.0299	-0.32	-0.31	Schizophrenia;	chr11:125457076	chr11:125570284~125592568:-
PCPG	cis	rs4835473	0.932	rs1973608	ENSG00000251600.4	RP11-673E1.1	4.03	8.86e-05	0.0299	0.37	0.31	Immature fraction of reticulocytes;	chr4:143913057	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	4.03	8.86e-05	0.0299	0.37	0.31	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
PCPG	cis	rs12439619	0.846	rs28470877	ENSG00000228141.5	AC105339.1	-4.03	8.86e-05	0.0299	-0.47	-0.31	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82710471~82714026:-
PCPG	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	4.03	8.86e-05	0.0299	0.43	0.31	Height;	chr6:109415050	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	4.03	8.86e-05	0.0299	0.43	0.31	Height;	chr6:109416945	chr6:109382795~109383666:+
PCPG	cis	rs10411161	0.702	rs8110531	ENSG00000275055.1	CTC-471J1.11	-4.03	8.87e-05	0.03	-0.33	-0.31	Breast cancer;	chr19:51880257	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs8110546	ENSG00000275055.1	CTC-471J1.11	-4.03	8.87e-05	0.03	-0.33	-0.31	Breast cancer;	chr19:51880303	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs8110461	ENSG00000275055.1	CTC-471J1.11	-4.03	8.87e-05	0.03	-0.33	-0.31	Breast cancer;	chr19:51880316	chr19:52049007~52049754:+
PCPG	cis	rs2836974	0.59	rs11911822	ENSG00000255568.3	BRWD1-AS2	-4.03	8.87e-05	0.03	-0.32	-0.31	Cognitive function;	chr21:39235917	chr21:39313935~39314962:+
PCPG	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	4.03	8.87e-05	0.03	0.3	0.31	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	4.03	8.87e-05	0.03	0.3	0.31	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	4.03	8.87e-05	0.03	0.3	0.31	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	4.03	8.87e-05	0.03	0.3	0.31	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	4.03	8.87e-05	0.03	0.3	0.31	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	4.03	8.87e-05	0.03	0.3	0.31	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
PCPG	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-4.03	8.87e-05	0.03	-0.4	-0.31	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
PCPG	cis	rs12928939	0.769	rs1056303	ENSG00000260886.1	TAT-AS1	4.03	8.88e-05	0.03	0.4	0.31	Post bronchodilator FEV1;	chr16:71636163	chr16:71565789~71578187:+
PCPG	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	4.03	8.88e-05	0.03	0.37	0.31	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
PCPG	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	4.03	8.88e-05	0.03	0.35	0.31	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
PCPG	cis	rs6445975	0.667	rs3773004	ENSG00000272360.1	RP11-359I18.5	-4.03	8.88e-05	0.03	-0.39	-0.31	Systemic lupus erythematosus;	chr3:58283724	chr3:58490830~58491291:-
PCPG	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	4.03	8.88e-05	0.03	0.32	0.31	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
PCPG	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	4.03	8.88e-05	0.03	0.39	0.31	Height;	chr6:109732518	chr6:109382795~109383666:+
PCPG	cis	rs7772486	0.686	rs9386131	ENSG00000270638.1	RP3-466P17.1	4.03	8.89e-05	0.03	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs7739735	ENSG00000270638.1	RP3-466P17.1	4.03	8.89e-05	0.03	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs7744014	ENSG00000270638.1	RP3-466P17.1	4.03	8.89e-05	0.03	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs4895684	ENSG00000270638.1	RP3-466P17.1	-4.03	8.89e-05	0.03	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145735570~145737218:+
PCPG	cis	rs2836974	0.966	rs2836977	ENSG00000252915.1	Y_RNA	-4.03	8.89e-05	0.03	-0.34	-0.31	Cognitive function;	chr21:39294140	chr21:39344537~39344628:+
PCPG	cis	rs8098244	0.557	rs11082724	ENSG00000265752.2	RP11-403A21.1	4.03	8.89e-05	0.03	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732544	chr18:23957754~23982556:-
PCPG	cis	rs2404602	0.692	rs7169663	ENSG00000259514.1	RP11-685G9.2	-4.03	8.89e-05	0.03	-0.31	-0.31	Blood metabolite levels;	chr15:76900502	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs35999717	ENSG00000259514.1	RP11-685G9.2	-4.03	8.89e-05	0.03	-0.31	-0.31	Blood metabolite levels;	chr15:76901026	chr15:76339609~76342063:-
PCPG	cis	rs17264034	1	rs17264034	ENSG00000250786.1	SNHG18	-4.03	8.89e-05	0.03	-0.48	-0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557490	chr5:9546200~9550609:+
PCPG	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	4.03	8.9e-05	0.03	0.34	0.31	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	4.03	8.9e-05	0.03	0.34	0.31	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	4.03	8.9e-05	0.03	0.34	0.31	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	4.03	8.9e-05	0.03	0.34	0.31	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	4.03	8.9e-05	0.03	0.34	0.31	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
PCPG	cis	rs6504340	0.739	rs1123630	ENSG00000279036.1	RP11-81K2.2	-4.03	8.9e-05	0.03	-0.51	-0.31	Primary tooth development (number of teeth);	chr17:48594454	chr17:49494223~49497800:-
PCPG	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	4.03	8.9e-05	0.03	0.48	0.31	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
PCPG	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-4.03	8.9e-05	0.03	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
PCPG	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	4.03	8.9e-05	0.03	0.41	0.31	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
PCPG	cis	rs3824435	0.763	rs3758240	ENSG00000272866.1	RP11-12D24.10	-4.03	8.9e-05	0.03	-0.33	-0.31	Risky sexual behaviors in alcohol dependence;	chr9:5340129	chr9:5351796~5352410:-
PCPG	cis	rs11858159	0.967	rs7172047	ENSG00000260760.1	PWRN3	4.03	8.91e-05	0.0301	0.34	0.31	Platelet thrombus formation;	chr15:24538589	chr15:24441127~24447967:+
PCPG	cis	rs2361718	0.521	rs2361724	ENSG00000279259.1	RP11-334C17.3	4.03	8.91e-05	0.0301	0.29	0.31	Yeast infection;	chr17:80125315	chr17:80147250~80148596:+
PCPG	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	4.03	8.91e-05	0.0301	0.36	0.31	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	4.03	8.91e-05	0.0301	0.36	0.31	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	4.03	8.91e-05	0.0301	0.36	0.31	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
PCPG	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	4.03	8.91e-05	0.0301	0.4	0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
PCPG	cis	rs5769765	0.955	rs61136468	ENSG00000278869.1	CITF22-49E9.3	4.03	8.91e-05	0.0301	0.38	0.31	Schizophrenia;	chr22:49919031	chr22:49933198~49934074:-
PCPG	cis	rs4819052	0.851	rs1999333	ENSG00000215447.6	BX322557.10	-4.03	8.92e-05	0.0301	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45288052~45291738:+
PCPG	cis	rs11672691	0.519	rs12973063	ENSG00000267107.5	PCAT19	4.03	8.92e-05	0.0301	0.26	0.31	Prostate cancer;	chr19:41503757	chr19:41454169~41500649:-
PCPG	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	4.03	8.92e-05	0.0301	0.38	0.31	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-4.03	8.92e-05	0.0301	-0.38	-0.31	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-4.03	8.92e-05	0.0301	-0.38	-0.31	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-4.03	8.92e-05	0.0301	-0.38	-0.31	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
PCPG	cis	rs17037831	0.749	rs9851071	ENSG00000272263.1	RP11-767C1.2	4.03	8.92e-05	0.0301	0.44	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr3:13223623	chr3:12832219~12832728:-
PCPG	cis	rs17037831	0.584	rs9813558	ENSG00000272263.1	RP11-767C1.2	4.03	8.92e-05	0.0301	0.44	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr3:13223649	chr3:12832219~12832728:-
PCPG	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-4.03	8.92e-05	0.0301	-0.4	-0.31	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
PCPG	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	4.03	8.92e-05	0.0301	0.39	0.31	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
PCPG	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	4.03	8.92e-05	0.0301	0.39	0.31	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
PCPG	cis	rs10751667	0.666	rs7105477	ENSG00000255142.1	AP006621.6	4.03	8.92e-05	0.0301	0.3	0.31	Alzheimer's disease (late onset);	chr11:964271	chr11:781645~782105:+
PCPG	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-4.03	8.93e-05	0.0301	-0.25	-0.31	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
PCPG	cis	rs2404602	0.716	rs2404736	ENSG00000259514.1	RP11-685G9.2	-4.03	8.93e-05	0.0301	-0.32	-0.31	Blood metabolite levels;	chr15:76583602	chr15:76339609~76342063:-
PCPG	cis	rs8064024	0.538	rs12446456	ENSG00000267077.1	RP11-127I20.5	4.03	8.93e-05	0.0301	0.37	0.31	Cancer;	chr16:4872200	chr16:4795265~4796532:-
PCPG	cis	rs4237845	0.844	rs4630335	ENSG00000257698.1	RP11-620J15.3	-4.03	8.93e-05	0.0301	-0.28	-0.31	Intelligence (multi-trait analysis);	chr12:57908475	chr12:57931528~57936175:-
PCPG	cis	rs13108904	0.87	rs4974577	ENSG00000254094.1	AC078852.1	-4.03	8.94e-05	0.0301	-0.36	-0.31	Obesity-related traits;	chr4:1272258	chr4:1356581~1358075:+
PCPG	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	4.03	8.94e-05	0.0301	0.35	0.31	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
PCPG	cis	rs4720118	0.66	rs6960483	ENSG00000173862.3	RP11-89N17.1	-4.03	8.94e-05	0.0301	-0.38	-0.31	Leprosy;	chr7:33125535	chr7:33725981~33728456:+
PCPG	cis	rs4720118	0.634	rs7776834	ENSG00000173862.3	RP11-89N17.1	-4.03	8.94e-05	0.0301	-0.38	-0.31	Leprosy;	chr7:33134770	chr7:33725981~33728456:+
PCPG	cis	rs7707921	1	rs6888977	ENSG00000249483.1	CTD-2249K22.1	4.03	8.94e-05	0.0302	0.42	0.31	Breast cancer;	chr5:82237916	chr5:81851601~81852201:+
PCPG	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-4.03	8.95e-05	0.0302	-0.42	-0.31	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
PCPG	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-4.03	8.95e-05	0.0302	-0.28	-0.31	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
PCPG	cis	rs6728642	0.831	rs10496325	ENSG00000230606.9	AC159540.1	-4.03	8.95e-05	0.0302	-0.39	-0.31	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97017592	chr2:97416165~97433527:-
PCPG	cis	rs6585424	1	rs11202031	ENSG00000242600.5	MBL1P	4.03	8.95e-05	0.0302	0.61	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184287	chr10:79904898~79950336:+
PCPG	cis	rs11148252	0.624	rs6561682	ENSG00000278238.1	RP11-245D16.4	4.03	8.95e-05	0.0302	0.31	0.31	Lewy body disease;	chr13:52692162	chr13:52454775~52455331:-
PCPG	cis	rs17684571	0.751	rs10498813	ENSG00000231441.1	RP11-472M19.2	4.03	8.95e-05	0.0302	0.54	0.31	Schizophrenia;	chr6:56819921	chr6:56844002~56864078:+
PCPG	cis	rs10865541	0.902	rs10206964	ENSG00000225234.1	TRAPPC12-AS1	-4.03	8.95e-05	0.0302	-0.31	-0.31	Obesity-related traits;	chr2:3422177	chr2:3481242~3482409:-
PCPG	cis	rs11214589	0.62	rs34601878	ENSG00000256757.1	RP11-159N11.3	4.03	8.96e-05	0.0302	0.33	0.31	Neuroticism;	chr11:113390176	chr11:113405321~113412117:+
PCPG	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-4.03	8.96e-05	0.0302	-0.38	-0.31	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
PCPG	cis	rs79349575	0.721	rs4794004	ENSG00000270781.1	RP11-501C14.9	-4.03	8.96e-05	0.0302	-0.37	-0.31	Type 2 diabetes;	chr17:48961109	chr17:48899131~48899748:+
PCPG	cis	rs28386778	0.897	rs1982400	ENSG00000240280.5	TCAM1P	-4.03	8.96e-05	0.0302	-0.41	-0.31	Prudent dietary pattern;	chr17:63716458	chr17:63849292~63864379:+
PCPG	cis	rs875971	0.83	rs6976714	ENSG00000235475.1	LINC01372	4.03	8.96e-05	0.0302	0.32	0.31	Aortic root size;	chr7:66426474	chr7:67335976~67340024:+
PCPG	cis	rs2625529	0.668	rs12914070	ENSG00000260037.4	CTD-2524L6.3	-4.03	8.97e-05	0.0302	-0.48	-0.31	Red blood cell count;	chr15:72041938	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.775	rs4777484	ENSG00000260037.4	CTD-2524L6.3	-4.03	8.97e-05	0.0302	-0.48	-0.31	Red blood cell count;	chr15:72084202	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs7183749	ENSG00000260037.4	CTD-2524L6.3	-4.03	8.97e-05	0.0302	-0.48	-0.31	Red blood cell count;	chr15:72084937	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs35167572	ENSG00000260037.4	CTD-2524L6.3	-4.03	8.97e-05	0.0302	-0.48	-0.31	Red blood cell count;	chr15:72086619	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs12901886	ENSG00000260037.4	CTD-2524L6.3	-4.03	8.97e-05	0.0302	-0.48	-0.31	Red blood cell count;	chr15:72115728	chr15:71818396~71823384:+
PCPG	cis	rs2404602	0.716	rs1125932	ENSG00000259514.1	RP11-685G9.2	-4.03	8.97e-05	0.0302	-0.31	-0.31	Blood metabolite levels;	chr15:76528199	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.716	rs66754747	ENSG00000259514.1	RP11-685G9.2	-4.03	8.97e-05	0.0302	-0.31	-0.31	Blood metabolite levels;	chr15:76536227	chr15:76339609~76342063:-
PCPG	cis	rs590820	0.777	rs611229	ENSG00000223635.1	RP4-613A2.1	-4.03	8.98e-05	0.0302	-0.36	-0.31	Metabolite levels (lipoprotein measures);	chr1:230188321	chr1:229508501~229514272:+
PCPG	cis	rs6802315	0.604	rs9861938	ENSG00000271778.1	RP11-379F4.8	4.03	8.98e-05	0.0302	0.29	0.31	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158782547~158783124:+
PCPG	cis	rs2239557	0.539	rs35864336	ENSG00000279026.1	RP3-414A15.12	4.03	8.98e-05	0.0302	0.47	0.31	Common traits (Other);	chr14:73987492	chr14:73580694~73582918:+
PCPG	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	4.03	8.98e-05	0.0302	0.43	0.31	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
PCPG	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	4.03	8.98e-05	0.0302	0.43	0.31	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
PCPG	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	4.03	8.98e-05	0.0302	0.28	0.31	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
PCPG	cis	rs7772486	0.624	rs6930154	ENSG00000270638.1	RP3-466P17.1	-4.03	8.98e-05	0.0303	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145735570~145737218:+
PCPG	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	4.03	8.99e-05	0.0303	0.44	0.31	Height;	chr6:109381443	chr6:109382795~109383666:+
PCPG	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	4.03	8.99e-05	0.0303	0.44	0.31	Height;	chr6:109382480	chr6:109382795~109383666:+
PCPG	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	4.03	8.99e-05	0.0303	0.31	0.31	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	4.03	8.99e-05	0.0303	0.31	0.31	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
PCPG	cis	rs6696239	0.513	rs903684	ENSG00000227711.2	RP11-275O4.5	-4.03	8.99e-05	0.0303	-0.37	-0.31	Height;	chr1:227509398	chr1:227509028~227520477:-
PCPG	cis	rs4835473	0.897	rs13145976	ENSG00000251600.4	RP11-673E1.1	-4.03	8.99e-05	0.0303	-0.35	-0.31	Immature fraction of reticulocytes;	chr4:143735710	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs13114071	ENSG00000251600.4	RP11-673E1.1	-4.03	8.99e-05	0.0303	-0.35	-0.31	Immature fraction of reticulocytes;	chr4:143735728	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs13140654	ENSG00000251600.4	RP11-673E1.1	-4.03	8.99e-05	0.0303	-0.35	-0.31	Immature fraction of reticulocytes;	chr4:143735733	chr4:143912331~143982454:+
PCPG	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	4.03	8.99e-05	0.0303	0.41	0.31	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
PCPG	cis	rs3758911	1	rs12146472	ENSG00000255353.1	RP11-382M14.1	-4.03	9e-05	0.0303	-0.39	-0.31	Coronary artery disease;	chr11:107323450	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs12146473	ENSG00000255353.1	RP11-382M14.1	-4.03	9e-05	0.0303	-0.39	-0.31	Coronary artery disease;	chr11:107323540	chr11:107176286~107177530:+
PCPG	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	4.02	9.01e-05	0.0303	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
PCPG	cis	rs575908	0.708	rs10798576	ENSG00000254154.7	RP4-798P15.3	4.02	9.01e-05	0.0303	0.3	0.31	Breast cancer;	chr1:177883908	chr1:177928788~178038007:-
PCPG	cis	rs992157	0.56	rs12987130	ENSG00000273466.1	RP11-548H3.1	-4.02	9.01e-05	0.0303	-0.17	-0.31	Colorectal cancer;	chr2:218240267	chr2:218633256~218634014:-
PCPG	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	4.02	9.02e-05	0.0303	0.39	0.31	Height;	chr6:109430292	chr6:109382795~109383666:+
PCPG	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	4.02	9.02e-05	0.0303	0.47	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
PCPG	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	4.02	9.02e-05	0.0303	0.47	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
PCPG	cis	rs2404602	0.716	rs1946650	ENSG00000259514.1	RP11-685G9.2	-4.02	9.02e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76556122	chr15:76339609~76342063:-
PCPG	cis	rs7037266	0.791	rs10815495	ENSG00000206147.5	RP11-106A1.2	-4.02	9.02e-05	0.0304	-0.34	-0.31	Menarche (age at onset);	chr9:6966001	chr9:6639139~6639604:+
PCPG	cis	rs4919687	0.55	rs7907503	ENSG00000269609.4	RPARP-AS1	-4.02	9.02e-05	0.0304	-0.26	-0.31	Colorectal cancer;	chr10:102680293	chr10:102449817~102461106:+
PCPG	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	4.02	9.03e-05	0.0304	0.33	0.31	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	4.02	9.03e-05	0.0304	0.33	0.31	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	4.02	9.03e-05	0.0304	0.33	0.31	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	4.02	9.03e-05	0.0304	0.33	0.31	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
PCPG	cis	rs8064024	0.68	rs8056320	ENSG00000267077.1	RP11-127I20.5	4.02	9.03e-05	0.0304	0.37	0.31	Cancer;	chr16:4868016	chr16:4795265~4796532:-
PCPG	cis	rs10172965	0.913	rs891518	ENSG00000203435.2	E2F3P2	4.02	9.03e-05	0.0304	0.41	0.31	Neuroticism;Temperament;	chr2:195003762	chr2:195994259~195995680:-
PCPG	cis	rs7824557	0.534	rs10092549	ENSG00000255020.1	AF131216.5	-4.02	9.03e-05	0.0304	-0.41	-0.31	Retinal vascular caliber;	chr8:11231570	chr8:11345748~11347502:-
PCPG	cis	rs11858159	0.646	rs4778402	ENSG00000259905.4	PWRN1	4.02	9.03e-05	0.0304	0.35	0.31	Platelet thrombus formation;	chr15:24125248	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.589	rs4238499	ENSG00000259905.4	PWRN1	4.02	9.03e-05	0.0304	0.35	0.31	Platelet thrombus formation;	chr15:24125285	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.646	rs4778404	ENSG00000259905.4	PWRN1	4.02	9.03e-05	0.0304	0.35	0.31	Platelet thrombus formation;	chr15:24125403	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.646	rs12901477	ENSG00000259905.4	PWRN1	4.02	9.03e-05	0.0304	0.35	0.31	Platelet thrombus formation;	chr15:24127550	chr15:24493137~24652130:+
PCPG	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	4.02	9.03e-05	0.0304	0.37	0.31	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	4.02	9.03e-05	0.0304	0.37	0.31	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	4.02	9.03e-05	0.0304	0.37	0.31	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	4.02	9.03e-05	0.0304	0.37	0.31	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	4.02	9.03e-05	0.0304	0.37	0.31	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
PCPG	cis	rs2688482	0.557	rs2550236	ENSG00000229178.1	AC069513.4	-4.02	9.03e-05	0.0304	-0.44	-0.31	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195655565~195657927:-
PCPG	cis	rs2404602	0.716	rs67204011	ENSG00000259514.1	RP11-685G9.2	-4.02	9.03e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76554214	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs59088060	ENSG00000259514.1	RP11-685G9.2	-4.02	9.03e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76567633	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.716	rs12902174	ENSG00000259514.1	RP11-685G9.2	-4.02	9.03e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76571199	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.716	rs12438077	ENSG00000259514.1	RP11-685G9.2	-4.02	9.03e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76571260	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.716	rs12441550	ENSG00000259514.1	RP11-685G9.2	-4.02	9.03e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76571341	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.716	rs1874944	ENSG00000259514.1	RP11-685G9.2	-4.02	9.03e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76571587	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.669	rs9788684	ENSG00000259514.1	RP11-685G9.2	-4.02	9.03e-05	0.0304	-0.31	-0.31	Blood metabolite levels;	chr15:76902497	chr15:76339609~76342063:-
PCPG	cis	rs5758511	0.68	rs1107554	ENSG00000205702.9	CYP2D7	4.02	9.03e-05	0.0304	0.42	0.31	Birth weight;	chr22:42271588	chr22:42140203~42144577:-
PCPG	cis	rs9840812	0.567	rs2655008	ENSG00000273486.1	RP11-731C17.2	4.02	9.04e-05	0.0304	0.38	0.31	Fibrinogen levels;	chr3:136404933	chr3:136837338~136839021:-
PCPG	cis	rs75686122	0.892	rs78033999	ENSG00000253477.4	RP11-1C8.4	4.02	9.04e-05	0.0304	0.47	0.31	Cocaine dependence;	chr8:103465575	chr8:103483398~103501676:-
PCPG	cis	rs720475	0.732	rs62483107	ENSG00000170356.8	OR2A20P	4.02	9.05e-05	0.0304	0.46	0.31	Breast cancer;	chr7:144442144	chr7:144250045~144252957:-
PCPG	cis	rs720475	0.695	rs62483108	ENSG00000170356.8	OR2A20P	4.02	9.05e-05	0.0304	0.46	0.31	Breast cancer;	chr7:144442326	chr7:144250045~144252957:-
PCPG	cis	rs6121246	0.909	rs7272062	ENSG00000230613.1	HM13-AS1	4.02	9.05e-05	0.0304	0.45	0.31	Mean corpuscular hemoglobin;	chr20:31671342	chr20:31567707~31573263:-
PCPG	cis	rs2235642	0.891	rs2281231	ENSG00000260989.1	LA16c-395F10.2	-4.02	9.05e-05	0.0304	-0.32	-0.31	Coronary artery disease;	chr16:1551878	chr16:1580527~1610328:+
PCPG	cis	rs9525927	0.625	rs4942301	ENSG00000227258.4	SMIM2-AS1	4.02	9.06e-05	0.0305	0.48	0.31	Dupuytren's disease;	chr13:44237111	chr13:44110451~44240517:+
PCPG	cis	rs1371867	0.846	rs1788167	ENSG00000212994.5	RPS26P6	4.02	9.06e-05	0.0305	0.36	0.31	Atrioventricular conduction;	chr8:100307768	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1788168	ENSG00000212994.5	RPS26P6	4.02	9.06e-05	0.0305	0.36	0.31	Atrioventricular conduction;	chr8:100312732	chr8:100895771~100896118:+
PCPG	cis	rs324126	0.78	rs1993530	ENSG00000277977.1	CTD-3018O17.5	-4.02	9.06e-05	0.0305	-0.37	-0.31	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52392659~52392755:+
PCPG	cis	rs9876781	1	rs9812647	ENSG00000229759.1	MRPS18AP1	-4.02	9.07e-05	0.0305	-0.37	-0.31	Longevity;	chr3:48407507	chr3:48256350~48256938:-
PCPG	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	4.02	9.07e-05	0.0305	0.4	0.31	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
PCPG	cis	rs7610312	0.646	rs4681673	ENSG00000273493.1	RP11-80H18.4	-4.02	9.07e-05	0.0305	-0.37	-0.31	Red blood cell count;	chr3:58288016	chr3:58329965~58330118:+
PCPG	cis	rs7610312	0.681	rs4681674	ENSG00000273493.1	RP11-80H18.4	-4.02	9.07e-05	0.0305	-0.37	-0.31	Red blood cell count;	chr3:58288088	chr3:58329965~58330118:+
PCPG	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	4.02	9.07e-05	0.0305	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
PCPG	cis	rs8030379	1	rs6603003	ENSG00000230373.7	GOLGA6L5P	-4.02	9.07e-05	0.0305	-0.31	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896850	chr15:84507885~84516814:-
PCPG	cis	rs2404602	0.536	rs11072599	ENSG00000270036.1	RP11-685G9.4	-4.02	9.07e-05	0.0305	-0.3	-0.31	Blood metabolite levels;	chr15:76482167	chr15:76343642~76344365:+
PCPG	cis	rs10208649	0.908	rs76073574	ENSG00000272156.1	RP11-477N3.1	4.02	9.07e-05	0.0305	0.72	0.31	Body mass index;	chr2:53980525	chr2:54082554~54085066:+
PCPG	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	4.02	9.08e-05	0.0305	0.41	0.31	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
PCPG	cis	rs6585424	0.929	rs12256429	ENSG00000242600.5	MBL1P	4.02	9.08e-05	0.0305	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178876	chr10:79904898~79950336:+
PCPG	cis	rs3809060	0.959	rs3809061	ENSG00000213713.3	PIGCP1	4.02	9.08e-05	0.0305	0.17	0.31	Inguinal hernia;	chr11:32437519	chr11:33075566~33076460:-
PCPG	cis	rs3809060	0.959	rs3809062	ENSG00000213713.3	PIGCP1	4.02	9.08e-05	0.0305	0.17	0.31	Inguinal hernia;	chr11:32437536	chr11:33075566~33076460:-
PCPG	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	4.02	9.08e-05	0.0305	0.36	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
PCPG	cis	rs6504622	0.967	rs11869840	ENSG00000262879.4	RP11-156P1.3	-4.02	9.09e-05	0.0305	-0.33	-0.31	Orofacial clefts;	chr17:46918734	chr17:46984045~47100323:-
PCPG	cis	rs425277	1	rs262654	ENSG00000271806.1	RP5-892K4.1	4.02	9.09e-05	0.0305	0.37	0.31	Height;	chr1:2158087	chr1:2141084~2145279:-
PCPG	cis	rs6700559	0.643	rs1540682	ENSG00000260088.1	RP11-92G12.3	4.02	9.09e-05	0.0305	0.37	0.31	Coronary artery disease;	chr1:200693231	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.643	rs4556395	ENSG00000260088.1	RP11-92G12.3	4.02	9.09e-05	0.0305	0.37	0.31	Coronary artery disease;	chr1:200693813	chr1:200669507~200694250:+
PCPG	cis	rs2243480	0.901	rs2900904	ENSG00000251451.1	GS1-124K5.6	4.02	9.09e-05	0.0305	0.58	0.31	Diabetic kidney disease;	chr7:65739282	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs313809	ENSG00000251451.1	GS1-124K5.6	4.02	9.09e-05	0.0305	0.58	0.31	Diabetic kidney disease;	chr7:66034996	chr7:66407288~66409239:-
PCPG	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	4.02	9.09e-05	0.0305	0.4	0.31	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	4.02	9.09e-05	0.0305	0.4	0.31	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	4.02	9.09e-05	0.0305	0.4	0.31	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
PCPG	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	4.02	9.1e-05	0.0306	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
PCPG	cis	rs17152411	1	rs10901843	ENSG00000278831.1	RP11-12J10.4	4.02	9.1e-05	0.0306	0.44	0.31	Height;	chr10:124949451	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs7092008	ENSG00000278831.1	RP11-12J10.4	4.02	9.1e-05	0.0306	0.44	0.31	Height;	chr10:124949657	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs12355869	ENSG00000278831.1	RP11-12J10.4	4.02	9.1e-05	0.0306	0.44	0.31	Height;	chr10:124956662	chr10:124623353~124624079:+
PCPG	cis	rs9368481	0.569	rs6907403	ENSG00000261584.1	RP11-457M11.5	4.02	9.1e-05	0.0306	0.35	0.31	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26686241~26687964:+
PCPG	cis	rs9368481	0.502	rs3933232	ENSG00000261584.1	RP11-457M11.5	4.02	9.1e-05	0.0306	0.35	0.31	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26686241~26687964:+
PCPG	cis	rs9368481	0.546	rs12664610	ENSG00000261584.1	RP11-457M11.5	4.02	9.1e-05	0.0306	0.35	0.31	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26686241~26687964:+
PCPG	cis	rs9368481	0.524	rs9393768	ENSG00000261584.1	RP11-457M11.5	4.02	9.1e-05	0.0306	0.35	0.31	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26686241~26687964:+
PCPG	cis	rs9368481	0.569	rs10946868	ENSG00000261584.1	RP11-457M11.5	4.02	9.1e-05	0.0306	0.35	0.31	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26686241~26687964:+
PCPG	cis	rs181553	1	rs833521	ENSG00000278983.1	RP11-426J5.3	4.02	9.11e-05	0.0306	0.35	0.31	Hip circumference adjusted for BMI;	chr18:49041382	chr18:48564795~48568342:+
PCPG	cis	rs2243480	1	rs313832	ENSG00000230189.5	GS1-124K5.2	4.02	9.11e-05	0.0306	0.47	0.31	Diabetic kidney disease;	chr7:66085904	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs313831	ENSG00000230189.5	GS1-124K5.2	4.02	9.11e-05	0.0306	0.47	0.31	Diabetic kidney disease;	chr7:66086239	chr7:66409143~66490059:-
PCPG	cis	rs425277	0.958	rs626479	ENSG00000271806.1	RP5-892K4.1	-4.02	9.11e-05	0.0306	-0.39	-0.31	Height;	chr1:2178821	chr1:2141084~2145279:-
PCPG	cis	rs7819412	0.765	rs7000132	ENSG00000255020.1	AF131216.5	-4.02	9.11e-05	0.0306	-0.43	-0.31	Triglycerides;	chr8:11173426	chr8:11345748~11347502:-
PCPG	cis	rs7246657	0.722	rs2972437	ENSG00000226686.6	LINC01535	-4.02	9.11e-05	0.0306	-0.47	-0.31	Coronary artery calcification;	chr19:37719610	chr19:37251912~37265535:+
PCPG	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-4.02	9.11e-05	0.0306	-0.25	-0.31	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
PCPG	cis	rs17152411	0.843	rs7904691	ENSG00000278831.1	RP11-12J10.4	4.02	9.11e-05	0.0306	0.45	0.31	Height;	chr10:124894358	chr10:124623353~124624079:+
PCPG	cis	rs7523050	0.643	rs12752417	ENSG00000203897.3	SPATA42	4.02	9.12e-05	0.0306	0.61	0.31	Fat distribution (HIV);	chr1:108858017	chr1:108857217~108858524:+
PCPG	cis	rs41311933	0.71	rs1930777	ENSG00000226752.6	PSMD5-AS1	-4.02	9.12e-05	0.0306	-0.58	-0.31	Coronary artery disease;	chr9:120878890	chr9:120824828~120854385:+
PCPG	cis	rs62246343	0.63	rs60771966	ENSG00000254485.4	RP11-380O24.1	4.02	9.12e-05	0.0306	0.55	0.31	Fibrinogen levels;	chr3:9465573	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.63	rs59302296	ENSG00000254485.4	RP11-380O24.1	4.02	9.12e-05	0.0306	0.55	0.31	Fibrinogen levels;	chr3:9465630	chr3:9292588~9363303:-
PCPG	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	4.02	9.12e-05	0.0306	0.33	0.31	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
PCPG	cis	rs12549025	0.685	rs36104352	ENSG00000253390.1	CTC-756D1.2	-4.02	9.12e-05	0.0306	-0.57	-0.31	Reticulocyte fraction of red cells;	chr8:23520091	chr8:23458601~23484971:+
PCPG	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	4.02	9.12e-05	0.0306	0.75	0.31	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
PCPG	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	4.02	9.13e-05	0.0306	0.36	0.31	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	4.02	9.13e-05	0.0306	0.36	0.31	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
PCPG	cis	rs6657613	0.68	rs10887990	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17032891	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.68	rs10788650	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17036364	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.649	rs2179793	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17039238	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.68	rs7517920	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17042820	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.68	rs11203284	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17043457	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.649	rs11203285	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17043625	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.68	rs10887992	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17043718	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.68	rs10887993	ENSG00000186715.9	MST1L	-4.02	9.13e-05	0.0306	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17043746	chr1:16754910~16770237:-
PCPG	cis	rs6121246	0.909	rs6089071	ENSG00000230613.1	HM13-AS1	4.02	9.13e-05	0.0306	0.44	0.31	Mean corpuscular hemoglobin;	chr20:31790581	chr20:31567707~31573263:-
PCPG	cis	rs17684571	0.751	rs6918949	ENSG00000231441.1	RP11-472M19.2	-4.02	9.13e-05	0.0306	-0.51	-0.31	Schizophrenia;	chr6:56845183	chr6:56844002~56864078:+
PCPG	cis	rs13118159	0.55	rs28733902	ENSG00000254094.1	AC078852.1	-4.02	9.13e-05	0.0306	-0.39	-0.31	Longevity;	chr4:1381001	chr4:1356581~1358075:+
PCPG	cis	rs6701037	0.566	rs13373754	ENSG00000230777.1	RP11-318C24.1	-4.02	9.14e-05	0.0306	-0.29	-0.31	Alcohol dependence;	chr1:175170139	chr1:175921975~175922145:+
PCPG	cis	rs1823874	0.542	rs1962946	ENSG00000182397.13	DNM1P46	-4.02	9.14e-05	0.0307	-0.43	-0.31	IgG glycosylation;	chr15:99834410	chr15:99790156~99806927:-
PCPG	cis	rs425277	1	rs12401379	ENSG00000271806.1	RP5-892K4.1	4.02	9.15e-05	0.0307	0.37	0.31	Height;	chr1:2127141	chr1:2141084~2145279:-
PCPG	cis	rs425277	1	rs55826501	ENSG00000271806.1	RP5-892K4.1	4.02	9.15e-05	0.0307	0.37	0.31	Height;	chr1:2127704	chr1:2141084~2145279:-
PCPG	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-4.02	9.15e-05	0.0307	-0.37	-0.31	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
PCPG	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	4.02	9.15e-05	0.0307	0.33	0.31	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	4.02	9.15e-05	0.0307	0.33	0.31	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
PCPG	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	4.02	9.16e-05	0.0307	0.33	0.31	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
PCPG	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	4.02	9.16e-05	0.0307	0.4	0.31	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
PCPG	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	4.02	9.16e-05	0.0307	0.4	0.31	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
PCPG	cis	rs71403859	0.73	rs12927768	ENSG00000279412.1	RP11-394B2.5	4.02	9.16e-05	0.0307	0.57	0.31	Post bronchodilator FEV1;	chr16:71611360	chr16:70713987~70716890:+
PCPG	cis	rs394563	0.726	rs366905	ENSG00000216906.2	RP11-350J20.9	4.02	9.16e-05	0.0307	0.3	0.31	Dupuytren's disease;	chr6:149413961	chr6:149904243~149906418:+
PCPG	cis	rs575908	0.708	rs6692651	ENSG00000254154.7	RP4-798P15.3	4.02	9.17e-05	0.0307	0.29	0.31	Breast cancer;	chr1:177885264	chr1:177928788~178038007:-
PCPG	cis	rs5758511	0.68	rs739146	ENSG00000205702.9	CYP2D7	4.02	9.17e-05	0.0307	0.41	0.31	Birth weight;	chr22:42264408	chr22:42140203~42144577:-
PCPG	cis	rs1048886	0.808	rs9455151	ENSG00000271967.1	RP11-134K13.4	-4.02	9.17e-05	0.0307	-0.4	-0.31	Type 2 diabetes;	chr6:70537737	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.745	rs78525529	ENSG00000271967.1	RP11-134K13.4	-4.02	9.17e-05	0.0307	-0.4	-0.31	Type 2 diabetes;	chr6:70538160	chr6:70596438~70596980:+
PCPG	cis	rs3806843	0.676	rs778593	ENSG00000202515.1	VTRNA1-3	4.02	9.18e-05	0.0308	0.4	0.31	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr5:140726158~140726246:+
PCPG	cis	rs3806843	0.676	rs778594	ENSG00000202515.1	VTRNA1-3	4.02	9.18e-05	0.0308	0.4	0.31	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr5:140726158~140726246:+
PCPG	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-4.02	9.18e-05	0.0308	-0.4	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
PCPG	cis	rs6700559	0.643	rs4915451	ENSG00000260088.1	RP11-92G12.3	4.02	9.19e-05	0.0308	0.36	0.31	Coronary artery disease;	chr1:200690726	chr1:200669507~200694250:+
PCPG	cis	rs6700559	0.643	rs6427844	ENSG00000260088.1	RP11-92G12.3	4.02	9.19e-05	0.0308	0.36	0.31	Coronary artery disease;	chr1:200692216	chr1:200669507~200694250:+
PCPG	cis	rs8098244	0.737	rs1258137	ENSG00000265752.2	RP11-403A21.1	-4.02	9.19e-05	0.0308	-0.47	-0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23980147	chr18:23957754~23982556:-
PCPG	cis	rs1552244	1	rs67852463	ENSG00000180385.7	EMC3-AS1	4.02	9.19e-05	0.0308	0.4	0.31	Alzheimer's disease;	chr3:10115521	chr3:9986893~10006990:+
PCPG	cis	rs6570726	0.846	rs6570698	ENSG00000270638.1	RP3-466P17.1	4.02	9.19e-05	0.0308	0.34	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145735570~145737218:+
PCPG	cis	rs6570726	0.846	rs6914304	ENSG00000270638.1	RP3-466P17.1	4.02	9.19e-05	0.0308	0.34	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145735570~145737218:+
PCPG	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	4.02	9.2e-05	0.0308	0.36	0.31	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
PCPG	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-4.02	9.2e-05	0.0308	-0.42	-0.31	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
PCPG	cis	rs2243480	1	rs427044	ENSG00000251451.1	GS1-124K5.6	4.02	9.2e-05	0.0308	0.58	0.31	Diabetic kidney disease;	chr7:66043558	chr7:66407288~66409239:-
PCPG	cis	rs9299346	0.594	rs2146801	ENSG00000225376.4	TMEM246-AS1	-4.02	9.21e-05	0.0308	-0.37	-0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101665300	chr9:101468439~101481502:+
PCPG	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-4.02	9.21e-05	0.0308	-0.38	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
PCPG	cis	rs8062405	0.756	rs151301	ENSG00000251417.2	RP11-1348G14.4	-4.02	9.21e-05	0.0308	-0.38	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28802743~28817828:+
PCPG	cis	rs3758911	1	rs6588965	ENSG00000255353.1	RP11-382M14.1	-4.02	9.21e-05	0.0308	-0.4	-0.31	Coronary artery disease;	chr11:107330963	chr11:107176286~107177530:+
PCPG	cis	rs13108904	0.935	rs6853002	ENSG00000253399.1	AC078852.2	-4.02	9.21e-05	0.0308	-0.32	-0.31	Obesity-related traits;	chr4:1302203	chr4:1358479~1359461:+
PCPG	cis	rs172166	0.61	rs276369	ENSG00000219392.1	RP1-265C24.5	-4.02	9.22e-05	0.0309	-0.34	-0.31	Cardiac Troponin-T levels;	chr6:27951465	chr6:28115628~28116551:+
PCPG	cis	rs13108904	0.901	rs4974594	ENSG00000253399.1	AC078852.2	4.02	9.22e-05	0.0309	0.32	0.31	Obesity-related traits;	chr4:1306692	chr4:1358479~1359461:+
PCPG	cis	rs2404602	0.716	rs7174953	ENSG00000259514.1	RP11-685G9.2	-4.02	9.22e-05	0.0309	-0.31	-0.31	Blood metabolite levels;	chr15:76614506	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.679	rs12900494	ENSG00000259514.1	RP11-685G9.2	-4.02	9.22e-05	0.0309	-0.31	-0.31	Blood metabolite levels;	chr15:76620163	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.716	rs7169394	ENSG00000259514.1	RP11-685G9.2	-4.02	9.22e-05	0.0309	-0.31	-0.31	Blood metabolite levels;	chr15:76620933	chr15:76339609~76342063:-
PCPG	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	4.02	9.22e-05	0.0309	0.43	0.31	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	4.02	9.22e-05	0.0309	0.43	0.31	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
PCPG	cis	rs1949733	0.701	rs2631735	ENSG00000205959.3	RP11-689P11.2	-4.02	9.22e-05	0.0309	-0.35	-0.31	Response to antineoplastic agents;	chr4:8474391	chr4:8482270~8512610:+
PCPG	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-4.02	9.23e-05	0.0309	-0.42	-0.31	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
PCPG	cis	rs6121246	0.954	rs73241710	ENSG00000230613.1	HM13-AS1	4.02	9.23e-05	0.0309	0.45	0.31	Mean corpuscular hemoglobin;	chr20:31837153	chr20:31567707~31573263:-
PCPG	cis	rs6060987	1	rs6060987	ENSG00000230613.1	HM13-AS1	4.02	9.23e-05	0.0309	0.45	0.31	Mean corpuscular volume;	chr20:31839274	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.908	rs17093657	ENSG00000230613.1	HM13-AS1	4.02	9.23e-05	0.0309	0.45	0.31	Mean corpuscular hemoglobin;	chr20:31841091	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.954	rs6060989	ENSG00000230613.1	HM13-AS1	4.02	9.23e-05	0.0309	0.45	0.31	Mean corpuscular hemoglobin;	chr20:31841960	chr20:31567707~31573263:-
PCPG	cis	rs6121246	0.954	rs6060992	ENSG00000230613.1	HM13-AS1	4.02	9.23e-05	0.0309	0.45	0.31	Mean corpuscular hemoglobin;	chr20:31843452	chr20:31567707~31573263:-
PCPG	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	4.02	9.23e-05	0.0309	0.69	0.31	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
PCPG	cis	rs7267979	0.509	rs6115218	ENSG00000274973.1	RP13-401N8.7	-4.02	9.23e-05	0.0309	-0.37	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25845497~25845862:+
PCPG	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-4.02	9.23e-05	0.0309	-0.39	-0.31	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
PCPG	cis	rs2836974	0.899	rs34176878	ENSG00000252915.1	Y_RNA	-4.02	9.24e-05	0.0309	-0.33	-0.31	Cognitive function;	chr21:39176929	chr21:39344537~39344628:+
PCPG	cis	rs6957923	0.967	rs4496867	ENSG00000230658.1	KLHL7-AS1	4.02	9.24e-05	0.0309	0.39	0.31	Height;	chr7:23467900	chr7:23101228~23105703:-
PCPG	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-4.02	9.25e-05	0.0309	-0.34	-0.31	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
PCPG	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-4.02	9.25e-05	0.0309	-0.34	-0.31	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
PCPG	cis	rs1371867	0.846	rs1788189	ENSG00000212994.5	RPS26P6	-4.02	9.25e-05	0.0309	-0.35	-0.31	Atrioventricular conduction;	chr8:100237534	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.775	rs6511	ENSG00000212994.5	RPS26P6	-4.02	9.25e-05	0.0309	-0.35	-0.31	Atrioventricular conduction;	chr8:100240452	chr8:100895771~100896118:+
PCPG	cis	rs11858159	1	rs11161106	ENSG00000260760.1	PWRN3	4.02	9.25e-05	0.031	0.34	0.31	Platelet thrombus formation;	chr15:24542034	chr15:24441127~24447967:+
PCPG	cis	rs75804782	0.63	rs75651012	ENSG00000227107.1	AC096574.5	-4.02	9.26e-05	0.031	-0.54	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:238325755	chr2:237612977~237626525:+
PCPG	cis	rs733592	0.599	rs12819124	ENSG00000240399.1	RP1-228P16.1	4.02	9.26e-05	0.031	0.28	0.31	Plateletcrit;	chr12:48015271	chr12:48054813~48055591:-
PCPG	cis	rs2243480	0.706	rs6460257	ENSG00000251451.1	GS1-124K5.6	4.02	9.26e-05	0.031	0.46	0.31	Diabetic kidney disease;	chr7:65731813	chr7:66407288~66409239:-
PCPG	cis	rs55882075	0.723	rs56227602	ENSG00000245317.2	CTC-241N9.1	4.02	9.27e-05	0.031	0.28	0.31	Monocyte percentage of white cells;	chr5:179752471	chr5:179859013~179861283:+
PCPG	cis	rs9303542	0.527	rs62066689	ENSG00000279036.1	RP11-81K2.2	-4.02	9.27e-05	0.031	-0.52	-0.31	Epithelial ovarian cancer;Ovarian cancer;	chr17:48531730	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.559	rs8079617	ENSG00000279036.1	RP11-81K2.2	-4.02	9.27e-05	0.031	-0.52	-0.31	Epithelial ovarian cancer;Ovarian cancer;	chr17:48532666	chr17:49494223~49497800:-
PCPG	cis	rs9303542	0.527	rs8074125	ENSG00000279036.1	RP11-81K2.2	-4.02	9.27e-05	0.031	-0.52	-0.31	Epithelial ovarian cancer;Ovarian cancer;	chr17:48532698	chr17:49494223~49497800:-
PCPG	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-4.02	9.27e-05	0.031	-0.35	-0.31	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
PCPG	cis	rs3809060	0.568	rs4980793	ENSG00000213713.3	PIGCP1	4.02	9.28e-05	0.031	0.17	0.31	Inguinal hernia;	chr11:32443139	chr11:33075566~33076460:-
PCPG	cis	rs9880211	0.898	rs35304385	ENSG00000273486.1	RP11-731C17.2	4.02	9.28e-05	0.031	0.42	0.31	Height;Body mass index;	chr3:136667411	chr3:136837338~136839021:-
PCPG	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	4.02	9.29e-05	0.0311	0.34	0.31	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
PCPG	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	4.02	9.29e-05	0.0311	0.34	0.31	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
PCPG	cis	rs7444	0.941	rs4821112	ENSG00000211645.2	IGLV1-50	4.02	9.29e-05	0.0311	0.39	0.31	Systemic lupus erythematosus;	chr22:21610472	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs5754352	ENSG00000211645.2	IGLV1-50	4.02	9.29e-05	0.0311	0.39	0.31	Systemic lupus erythematosus;	chr22:21610662	chr22:22327300~22327814:+
PCPG	cis	rs7849270	0.879	rs7042928	ENSG00000268707.1	RP11-247A12.7	4.02	9.3e-05	0.0311	0.35	0.31	Blood metabolite ratios;	chr9:129092996	chr9:129170434~129170940:+
PCPG	cis	rs7227917	0.536	rs72916011	ENSG00000269365.2	RP11-380M21.4	4.02	9.3e-05	0.0311	0.63	0.31	Lung cancer in ever smokers;	chr18:47984286	chr18:47878295~47882444:+
PCPG	cis	rs7227917	0.536	rs72916012	ENSG00000269365.2	RP11-380M21.4	4.02	9.3e-05	0.0311	0.63	0.31	Lung cancer in ever smokers;	chr18:47984539	chr18:47878295~47882444:+
PCPG	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	4.02	9.3e-05	0.0311	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
PCPG	cis	rs4819052	0.807	rs4819047	ENSG00000215447.6	BX322557.10	-4.02	9.3e-05	0.0311	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45288052~45291738:+
PCPG	cis	rs8003054	0.616	rs12050102	ENSG00000258515.1	RP11-203M5.7	4.02	9.31e-05	0.0311	0.24	0.31	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20442073	chr14:20451305~20451918:+
PCPG	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	4.02	9.31e-05	0.0311	0.41	0.31	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
PCPG	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	4.02	9.31e-05	0.0311	0.33	0.31	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
PCPG	cis	rs11018874	0.597	rs4268468	ENSG00000254916.1	RP11-529A4.12	-4.02	9.32e-05	0.0311	-0.38	-0.31	White blood cell types;	chr11:90153116	chr11:90051837~90053736:-
PCPG	cis	rs7824557	0.527	rs4634600	ENSG00000255556.2	RP11-351I21.6	-4.02	9.32e-05	0.0311	-0.33	-0.31	Retinal vascular caliber;	chr8:11381508	chr8:12378679~12380265:-
PCPG	cis	rs7824557	0.527	rs4631425	ENSG00000255556.2	RP11-351I21.6	-4.02	9.32e-05	0.0311	-0.33	-0.31	Retinal vascular caliber;	chr8:11381545	chr8:12378679~12380265:-
PCPG	cis	rs3808502	0.585	rs4549730	ENSG00000255556.2	RP11-351I21.6	-4.02	9.32e-05	0.0311	-0.33	-0.31	Neuroticism;	chr8:11381569	chr8:12378679~12380265:-
PCPG	cis	rs3758911	0.822	rs10749903	ENSG00000255353.1	RP11-382M14.1	-4.02	9.32e-05	0.0311	-0.4	-0.31	Coronary artery disease;	chr11:107336840	chr11:107176286~107177530:+
PCPG	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	4.02	9.32e-05	0.0311	0.33	0.31	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
PCPG	cis	rs181553	0.504	rs66622242	ENSG00000278983.1	RP11-426J5.3	-4.02	9.32e-05	0.0311	-0.36	-0.31	Hip circumference adjusted for BMI;	chr18:49457225	chr18:48564795~48568342:+
PCPG	cis	rs7864204	0.671	rs4271029	ENSG00000234506.4	LINC01506	-4.02	9.32e-05	0.0311	-0.36	-0.31	Body mass index (recreational physical activity interaction);	chr9:68607514	chr9:68543541~68546589:-
PCPG	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	4.02	9.33e-05	0.0312	0.37	0.31	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
PCPG	cis	rs73198271	0.599	rs10103169	ENSG00000253893.2	FAM85B	4.02	9.33e-05	0.0312	0.42	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.641	rs34473848	ENSG00000253893.2	FAM85B	4.02	9.33e-05	0.0312	0.43	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.601	rs11997731	ENSG00000253893.2	FAM85B	4.02	9.33e-05	0.0312	0.43	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8167819~8226614:-
PCPG	cis	rs7610312	0.681	rs6445971	ENSG00000273493.1	RP11-80H18.4	-4.02	9.33e-05	0.0312	-0.38	-0.31	Red blood cell count;	chr3:58328597	chr3:58329965~58330118:+
PCPG	cis	rs1876905	0.569	rs354542	ENSG00000255389.1	C6orf3	4.02	9.33e-05	0.0312	0.41	0.31	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111599875~111602295:+
PCPG	cis	rs1876905	0.68	rs1216020	ENSG00000255389.1	C6orf3	4.02	9.33e-05	0.0312	0.41	0.31	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111599875~111602295:+
PCPG	cis	rs1876905	0.569	rs354541	ENSG00000255389.1	C6orf3	4.02	9.33e-05	0.0312	0.41	0.31	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111599875~111602295:+
PCPG	cis	rs1876905	0.68	rs354537	ENSG00000255389.1	C6orf3	4.02	9.33e-05	0.0312	0.41	0.31	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111599875~111602295:+
PCPG	cis	rs1876905	0.68	rs354536	ENSG00000255389.1	C6orf3	4.02	9.33e-05	0.0312	0.41	0.31	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111599875~111602295:+
PCPG	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	4.02	9.33e-05	0.0312	0.64	0.31	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	4.02	9.33e-05	0.0312	0.64	0.31	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
PCPG	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	4.02	9.34e-05	0.0312	0.78	0.31	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	4.02	9.34e-05	0.0312	0.78	0.31	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
PCPG	cis	rs4720118	0.551	rs1548880	ENSG00000173862.3	RP11-89N17.1	-4.02	9.34e-05	0.0312	-0.37	-0.31	Leprosy;	chr7:33131046	chr7:33725981~33728456:+
PCPG	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	4.02	9.34e-05	0.0312	0.37	0.31	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-4.02	9.34e-05	0.0312	-0.27	-0.31	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
PCPG	cis	rs7707921	0.881	rs324914	ENSG00000249483.1	CTD-2249K22.1	4.02	9.35e-05	0.0312	0.42	0.31	Breast cancer;	chr5:82094131	chr5:81851601~81852201:+
PCPG	cis	rs875971	0.577	rs34888281	ENSG00000273142.1	RP11-458F8.4	4.02	9.35e-05	0.0312	0.29	0.31	Aortic root size;	chr7:66120784	chr7:66902857~66906297:+
PCPG	cis	rs13392177	0.647	rs6718220	ENSG00000273466.1	RP11-548H3.1	-4.02	9.35e-05	0.0312	-0.17	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218633256~218634014:-
PCPG	cis	rs2882667	0.652	rs6596463	ENSG00000222937.1	SNORD63	4.02	9.35e-05	0.0312	0.28	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138558970~138559039:-
PCPG	cis	rs4489787	0.892	rs2731071	ENSG00000240399.1	RP1-228P16.1	4.02	9.35e-05	0.0312	0.38	0.31	Prostate cancer (SNP x SNP interaction);	chr12:48523224	chr12:48054813~48055591:-
PCPG	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	4.02	9.36e-05	0.0312	0.39	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
PCPG	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	4.02	9.36e-05	0.0312	0.39	0.31	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
PCPG	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	4.02	9.36e-05	0.0312	0.39	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
PCPG	cis	rs6585424	1	rs12268619	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80160904	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs35497678	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80161322	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs2304410	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162054	chr10:79904898~79950336:+
PCPG	cis	rs6585424	0.778	rs12257082	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162365	chr10:79904898~79950336:+
PCPG	cis	rs6585424	0.925	rs11201964	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80171611	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs11201966	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172024	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs11201972	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172924	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs6585424	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173992	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs56190825	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80174980	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs3851055	ENSG00000242600.5	MBL1P	4.02	9.36e-05	0.0312	0.6	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178340	chr10:79904898~79950336:+
PCPG	cis	rs3809060	0.568	rs7103000	ENSG00000213713.3	PIGCP1	4.01	9.36e-05	0.0312	0.17	0.31	Inguinal hernia;	chr11:32441559	chr11:33075566~33076460:-
PCPG	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	4.01	9.37e-05	0.0313	0.36	0.31	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
PCPG	cis	rs10411161	0.702	rs11878580	ENSG00000275055.1	CTC-471J1.11	-4.01	9.37e-05	0.0313	-0.34	-0.31	Breast cancer;	chr19:51885232	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs11878586	ENSG00000275055.1	CTC-471J1.11	-4.01	9.37e-05	0.0313	-0.34	-0.31	Breast cancer;	chr19:51885323	chr19:52049007~52049754:+
PCPG	cis	rs2735413	0.564	rs7191314	ENSG00000276007.1	RP11-358L22.3	4.01	9.37e-05	0.0313	0.34	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78050339	chr16:78123243~78124332:+
PCPG	cis	rs7714584	1	rs11167518	ENSG00000271795.1	CTC-251D13.1	-4.01	9.37e-05	0.0313	-0.59	-0.31	Crohn's disease;	chr5:150879358	chr5:151509453~151512769:+
PCPG	cis	rs7707921	0.958	rs4703870	ENSG00000249483.1	CTD-2249K22.1	4.01	9.37e-05	0.0313	0.42	0.31	Breast cancer;	chr5:82196824	chr5:81851601~81852201:+
PCPG	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	4.01	9.38e-05	0.0313	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
PCPG	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	4.01	9.38e-05	0.0313	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
PCPG	cis	rs10865541	0.934	rs4627605	ENSG00000225234.1	TRAPPC12-AS1	-4.01	9.38e-05	0.0313	-0.31	-0.31	Obesity-related traits;	chr2:3408152	chr2:3481242~3482409:-
PCPG	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	4.01	9.38e-05	0.0313	0.36	0.31	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
PCPG	cis	rs62229266	0.835	rs998384	ENSG00000230212.5	AP000688.14	-4.01	9.39e-05	0.0313	-0.36	-0.31	Mitral valve prolapse;	chr21:36073228	chr21:36069642~36126640:-
PCPG	cis	rs66731853	0.769	rs476582	ENSG00000117242.7	PINK1-AS	4.01	9.39e-05	0.0313	0.28	0.31	Mean corpuscular volume;	chr1:20567957	chr1:20642657~20652193:-
PCPG	cis	rs5758511	0.689	rs17478227	ENSG00000226450.2	CYP2D8P	-4.01	9.39e-05	0.0313	-0.44	-0.31	Birth weight;	chr22:42258321	chr22:42149886~42155001:-
PCPG	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-4.01	9.39e-05	0.0313	-0.46	-0.31	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-4.01	9.39e-05	0.0313	-0.46	-0.31	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
PCPG	cis	rs6921919	0.945	rs16901847	ENSG00000219392.1	RP1-265C24.5	-4.01	9.39e-05	0.0313	-0.49	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28115628~28116551:+
PCPG	cis	rs6921919	0.945	rs7765989	ENSG00000219392.1	RP1-265C24.5	-4.01	9.39e-05	0.0313	-0.49	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28115628~28116551:+
PCPG	cis	rs6921919	0.887	rs16894116	ENSG00000219392.1	RP1-265C24.5	-4.01	9.39e-05	0.0313	-0.49	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28115628~28116551:+
PCPG	cis	rs9636231	0.951	rs10432381	ENSG00000234645.3	YWHAEP5	-4.01	9.4e-05	0.0313	-0.33	-0.31	Alcohol dependence;	chr2:138887994	chr2:138288029~138288793:-
PCPG	cis	rs7772486	0.727	rs10447449	ENSG00000270638.1	RP3-466P17.1	4.01	9.41e-05	0.0314	0.33	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145735570~145737218:+
PCPG	cis	rs7824557	0.527	rs2572449	ENSG00000255556.2	RP11-351I21.6	4.01	9.41e-05	0.0314	0.33	0.31	Retinal vascular caliber;	chr8:11381628	chr8:12378679~12380265:-
PCPG	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-4.01	9.42e-05	0.0314	-0.45	-0.31	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
PCPG	cis	rs728616	0.867	rs4633405	ENSG00000242600.5	MBL1P	4.01	9.42e-05	0.0314	0.75	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79904898~79950336:+
PCPG	cis	rs728616	0.867	rs61860034	ENSG00000242600.5	MBL1P	4.01	9.42e-05	0.0314	0.75	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79904898~79950336:+
PCPG	cis	rs728616	0.867	rs61860039	ENSG00000242600.5	MBL1P	4.01	9.42e-05	0.0314	0.75	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79904898~79950336:+
PCPG	cis	rs3758785	0.679	rs11819857	ENSG00000255893.1	RP11-685N10.1	-4.01	9.43e-05	0.0314	-0.46	-0.31	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94495070	chr11:94472908~94473570:-
PCPG	cis	rs3808502	0.527	rs2736374	ENSG00000255020.1	AF131216.5	-4.01	9.43e-05	0.0314	-0.41	-0.31	Neuroticism;	chr8:11256319	chr8:11345748~11347502:-
PCPG	cis	rs2736345	0.788	rs2618476	ENSG00000154316.13	TDH	4.01	9.43e-05	0.0314	0.4	0.31	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11339637~11368452:+
PCPG	cis	rs897984	0.683	rs72799316	ENSG00000275263.1	RP11-1072A3.4	-4.01	9.44e-05	0.0314	-0.32	-0.31	Dementia with Lewy bodies;	chr16:30815884	chr16:30956872~30957199:-
PCPG	cis	rs6504340	0.739	rs4793938	ENSG00000279036.1	RP11-81K2.2	-4.01	9.44e-05	0.0315	-0.54	-0.31	Primary tooth development (number of teeth);	chr17:48587867	chr17:49494223~49497800:-
PCPG	cis	rs6504340	0.739	rs4793939	ENSG00000279036.1	RP11-81K2.2	-4.01	9.44e-05	0.0315	-0.54	-0.31	Primary tooth development (number of teeth);	chr17:48587873	chr17:49494223~49497800:-
PCPG	cis	rs6504340	0.739	rs4793943	ENSG00000279036.1	RP11-81K2.2	-4.01	9.44e-05	0.0315	-0.54	-0.31	Primary tooth development (number of teeth);	chr17:48589575	chr17:49494223~49497800:-
PCPG	cis	rs6504340	0.739	rs4793589	ENSG00000279036.1	RP11-81K2.2	-4.01	9.44e-05	0.0315	-0.54	-0.31	Primary tooth development (number of teeth);	chr17:48590501	chr17:49494223~49497800:-
PCPG	cis	rs7172677	0.768	rs72730583	ENSG00000261543.1	RP11-665J16.1	4.01	9.45e-05	0.0315	0.37	0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75059289	chr15:74152800~74179226:-
PCPG	cis	rs7172677	0.768	rs72730585	ENSG00000261543.1	RP11-665J16.1	4.01	9.45e-05	0.0315	0.37	0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75061565	chr15:74152800~74179226:-
PCPG	cis	rs2404602	0.536	rs11072599	ENSG00000259514.1	RP11-685G9.2	-4.01	9.45e-05	0.0315	-0.32	-0.31	Blood metabolite levels;	chr15:76482167	chr15:76339609~76342063:-
PCPG	cis	rs8085804	0.529	rs72895369	ENSG00000267586.5	LINC00907	-4.01	9.45e-05	0.0315	-0.4	-0.31	Cognitive performance;	chr18:42623198	chr18:42159283~42691422:+
PCPG	cis	rs2404602	0.74	rs34924128	ENSG00000259514.1	RP11-685G9.2	-4.01	9.45e-05	0.0315	-0.31	-0.31	Blood metabolite levels;	chr15:76672828	chr15:76339609~76342063:-
PCPG	cis	rs425277	1	rs262647	ENSG00000271806.1	RP5-892K4.1	4.01	9.46e-05	0.0315	0.37	0.31	Height;	chr1:2164260	chr1:2141084~2145279:-
PCPG	cis	rs425277	0.916	rs414777	ENSG00000271806.1	RP5-892K4.1	4.01	9.46e-05	0.0315	0.37	0.31	Height;	chr1:2170248	chr1:2141084~2145279:-
PCPG	cis	rs2836974	0.831	rs34294410	ENSG00000252915.1	Y_RNA	-4.01	9.46e-05	0.0315	-0.33	-0.31	Cognitive function;	chr21:39183234	chr21:39344537~39344628:+
PCPG	cis	rs752864	0.934	rs7182150	ENSG00000259438.1	CTD-2650P22.1	4.01	9.46e-05	0.0315	0.38	0.31	Number of common colds;	chr15:52346232	chr15:52010999~52019095:-
PCPG	cis	rs752864	0.934	rs4776037	ENSG00000259438.1	CTD-2650P22.1	4.01	9.46e-05	0.0315	0.38	0.31	Number of common colds;	chr15:52348453	chr15:52010999~52019095:-
PCPG	cis	rs5758511	0.68	rs5758698	ENSG00000227370.1	RP4-669P10.19	4.01	9.47e-05	0.0315	0.48	0.31	Birth weight;	chr22:42288812	chr22:42132543~42132998:+
PCPG	cis	rs6452524	0.618	rs10051445	ENSG00000281327.1	LINC01338	4.01	9.47e-05	0.0315	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:82850864~82859836:-
PCPG	cis	rs6452524	0.618	rs6867727	ENSG00000281327.1	LINC01338	4.01	9.47e-05	0.0315	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:82850864~82859836:-
PCPG	cis	rs6452524	0.618	rs7723639	ENSG00000281327.1	LINC01338	4.01	9.47e-05	0.0315	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:82850864~82859836:-
PCPG	cis	rs6452524	0.589	rs6882386	ENSG00000281327.1	LINC01338	4.01	9.47e-05	0.0315	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:82850864~82859836:-
PCPG	cis	rs6452524	0.618	rs6860752	ENSG00000281327.1	LINC01338	4.01	9.47e-05	0.0315	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:82850864~82859836:-
PCPG	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
PCPG	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	4.01	9.47e-05	0.0315	0.44	0.31	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
PCPG	cis	rs4713118	0.869	rs4713121	ENSG00000216901.1	AL022393.7	4.01	9.47e-05	0.0315	0.42	0.31	Parkinson's disease;	chr6:27754285	chr6:28176188~28176674:+
PCPG	cis	rs11858159	0.532	rs12898466	ENSG00000259905.4	PWRN1	4.01	9.47e-05	0.0315	0.36	0.31	Platelet thrombus formation;	chr15:24179687	chr15:24493137~24652130:+
PCPG	cis	rs6657613	0.649	rs11203286	ENSG00000186715.9	MST1L	-4.01	9.47e-05	0.0315	-0.32	-0.31	Hip circumference adjusted for BMI;	chr1:17044302	chr1:16754910~16770237:-
PCPG	cis	rs1823874	0.72	rs1993296	ENSG00000254744.3	CTD-3076O17.1	-4.01	9.47e-05	0.0316	-0.41	-0.31	IgG glycosylation;	chr15:99823383	chr15:99970215~99974010:+
PCPG	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	4.01	9.48e-05	0.0316	0.34	0.31	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
PCPG	cis	rs6750795	0.641	rs10933375	ENSG00000181798.2	LINC00471	4.01	9.48e-05	0.0316	0.38	0.31	Height;	chr2:231502585	chr2:231508426~231514339:-
PCPG	cis	rs2652834	0.851	rs4468558	ENSG00000259498.1	RP11-244F12.3	-4.01	9.48e-05	0.0316	-0.51	-0.31	HDL cholesterol;	chr15:63054482	chr15:63046034~63049387:-
PCPG	cis	rs6452524	0.618	rs1871203	ENSG00000281327.1	LINC01338	4.01	9.48e-05	0.0316	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:82850864~82859836:-
PCPG	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-4.01	9.49e-05	0.0316	-0.38	-0.31	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
PCPG	cis	rs2836974	0.932	rs11910151	ENSG00000252915.1	Y_RNA	-4.01	9.49e-05	0.0316	-0.33	-0.31	Cognitive function;	chr21:39188336	chr21:39344537~39344628:+
PCPG	cis	rs12188164	0.582	rs80273890	ENSG00000188242.4	PP7080	4.01	9.49e-05	0.0316	0.32	0.31	Cystic fibrosis severity;	chr5:482942	chr5:466124~473098:-
PCPG	cis	rs8098244	0.557	rs10445487	ENSG00000265752.2	RP11-403A21.1	4.01	9.49e-05	0.0316	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23723728	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.536	rs10445488	ENSG00000265752.2	RP11-403A21.1	4.01	9.49e-05	0.0316	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23725402	chr18:23957754~23982556:-
PCPG	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	4.01	9.49e-05	0.0316	0.4	0.31	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
PCPG	cis	rs6032067	0.636	rs6032092	ENSG00000232880.1	RP3-453C12.8	-4.01	9.49e-05	0.0316	-0.38	-0.31	Blood protein levels;	chr20:45283246	chr20:45388347~45388705:-
PCPG	cis	rs9813712	0.855	rs10934930	ENSG00000228252.7	COL6A4P2	4.01	9.5e-05	0.0316	0.42	0.31	Response to amphetamines;	chr3:130259564	chr3:130212823~130273806:+
PCPG	cis	rs11858159	0.902	rs7180843	ENSG00000260760.1	PWRN3	4.01	9.5e-05	0.0316	0.34	0.31	Platelet thrombus formation;	chr15:24566914	chr15:24441127~24447967:+
PCPG	cis	rs6579956	0.529	rs4629584	ENSG00000270978.1	RP11-54C4.2	-4.01	9.5e-05	0.0316	-0.38	-0.31	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152802525	chr5:151848886~151850791:+
PCPG	cis	rs13108904	0.875	rs1732099	ENSG00000253399.1	AC078852.2	4.01	9.5e-05	0.0316	0.32	0.31	Obesity-related traits;	chr4:1288908	chr4:1358479~1359461:+
PCPG	cis	rs7247513	0.93	rs35275129	ENSG00000213290.4	PGK1P2	-4.01	9.51e-05	0.0316	-0.42	-0.31	Bipolar disorder;	chr19:12605679	chr19:12559571~12561105:+
PCPG	cis	rs7247513	0.897	rs12979146	ENSG00000213290.4	PGK1P2	-4.01	9.51e-05	0.0316	-0.42	-0.31	Bipolar disorder;	chr19:12607090	chr19:12559571~12561105:+
PCPG	cis	rs3758911	1	rs11212153	ENSG00000255353.1	RP11-382M14.1	-4.01	9.51e-05	0.0316	-0.39	-0.31	Coronary artery disease;	chr11:107319234	chr11:107176286~107177530:+
PCPG	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-4.01	9.51e-05	0.0316	-0.39	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
PCPG	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-4.01	9.51e-05	0.0316	-0.39	-0.31	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
PCPG	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	4.01	9.51e-05	0.0316	0.4	0.31	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
PCPG	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-4.01	9.51e-05	0.0317	-0.37	-0.31	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	4.01	9.51e-05	0.0317	0.37	0.31	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
PCPG	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	4.01	9.52e-05	0.0317	0.42	0.31	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
PCPG	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	4.01	9.52e-05	0.0317	0.44	0.31	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
PCPG	cis	rs853679	0.55	rs9295762	ENSG00000272009.1	RP1-313I6.12	4.01	9.53e-05	0.0317	0.31	0.31	Depression;	chr6:28187640	chr6:28078792~28081130:-
PCPG	cis	rs181553	0.664	rs1838962	ENSG00000278983.1	RP11-426J5.3	4.01	9.53e-05	0.0317	0.35	0.31	Hip circumference adjusted for BMI;	chr18:49153529	chr18:48564795~48568342:+
PCPG	cis	rs964611	0.882	rs7170447	ENSG00000259488.2	RP11-154J22.1	4.01	9.53e-05	0.0317	0.29	0.31	Metabolite levels (Pyroglutamine);	chr15:48361245	chr15:48312353~48331856:-
PCPG	cis	rs2404602	0.692	rs12437733	ENSG00000259514.1	RP11-685G9.2	-4.01	9.53e-05	0.0317	-0.31	-0.31	Blood metabolite levels;	chr15:76863221	chr15:76339609~76342063:-
PCPG	cis	rs9880211	0.848	rs71336069	ENSG00000273486.1	RP11-731C17.2	4.01	9.54e-05	0.0317	0.42	0.31	Height;Body mass index;	chr3:136633024	chr3:136837338~136839021:-
PCPG	cis	rs9880211	1	rs28750366	ENSG00000273486.1	RP11-731C17.2	4.01	9.54e-05	0.0317	0.42	0.31	Height;Body mass index;	chr3:136642213	chr3:136837338~136839021:-
PCPG	cis	rs2652834	0.851	rs7170462	ENSG00000259498.1	RP11-244F12.3	-4.01	9.54e-05	0.0317	-0.52	-0.31	HDL cholesterol;	chr15:63053423	chr15:63046034~63049387:-
PCPG	cis	rs1023500	0.505	rs134889	ENSG00000226450.2	CYP2D8P	4.01	9.54e-05	0.0317	0.3	0.31	Schizophrenia;	chr22:42278344	chr22:42149886~42155001:-
PCPG	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	4.01	9.54e-05	0.0317	0.27	0.31	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
PCPG	cis	rs763014	1	rs7205409	ENSG00000262528.2	LA16c-349E10.1	4.01	9.55e-05	0.0317	0.35	0.31	Height;	chr16:592610	chr16:654611~656194:-
PCPG	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-4.01	9.55e-05	0.0317	-0.48	-0.31	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
PCPG	cis	rs7444	0.941	rs5754422	ENSG00000211645.2	IGLV1-50	4.01	9.55e-05	0.0318	0.38	0.31	Systemic lupus erythematosus;	chr22:21625968	chr22:22327300~22327814:+
PCPG	cis	rs34421088	0.506	rs4841519	ENSG00000255020.1	AF131216.5	4.01	9.55e-05	0.0318	0.38	0.31	Neuroticism;	chr8:11288719	chr8:11345748~11347502:-
PCPG	cis	rs4791051	0.706	rs6504434	ENSG00000264491.1	RP11-349A8.3	-4.01	9.55e-05	0.0318	-0.33	-0.31	Heschl's gyrus morphology;	chr17:66475339	chr17:67019934~67021743:-
PCPG	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	4.01	9.55e-05	0.0318	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
PCPG	cis	rs73201462	0.908	rs4593050	ENSG00000242551.2	POU5F1P6	-4.01	9.56e-05	0.0318	-0.57	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128285688	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs6439124	ENSG00000242551.2	POU5F1P6	-4.01	9.56e-05	0.0318	-0.57	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128288623	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs7373998	ENSG00000242551.2	POU5F1P6	-4.01	9.56e-05	0.0318	-0.57	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128289380	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs2955101	ENSG00000242551.2	POU5F1P6	-4.01	9.56e-05	0.0318	-0.57	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128290769	chr3:128674735~128677005:-
PCPG	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-4.01	9.57e-05	0.0318	-0.39	-0.31	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
PCPG	cis	rs7824557	0.527	rs2572369	ENSG00000255556.2	RP11-351I21.6	-4.01	9.57e-05	0.0318	-0.33	-0.31	Retinal vascular caliber;	chr8:11381088	chr8:12378679~12380265:-
PCPG	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	4.01	9.57e-05	0.0318	0.32	0.31	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
PCPG	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-4.01	9.57e-05	0.0318	-0.33	-0.31	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
PCPG	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-4.01	9.57e-05	0.0318	-0.35	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
PCPG	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	4.01	9.58e-05	0.0318	0.37	0.31	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
PCPG	cis	rs11910494	0.531	rs35951611	ENSG00000273091.1	AP000255.6	-4.01	9.58e-05	0.0318	-0.38	-0.31	IgG glycosylation;	chr21:31944298	chr21:31735732~31736407:+
PCPG	cis	rs2243480	1	rs35820085	ENSG00000230189.5	GS1-124K5.2	4.01	9.58e-05	0.0318	0.47	0.31	Diabetic kidney disease;	chr7:65977771	chr7:66409143~66490059:-
PCPG	cis	rs17772222	0.917	rs61986664	ENSG00000222990.1	RNU4-22P	4.01	9.58e-05	0.0318	0.41	0.31	Coronary artery calcification;	chr14:88711251	chr14:88513498~88513663:+
PCPG	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	4.01	9.6e-05	0.0319	0.31	0.31	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
PCPG	cis	rs2243480	1	rs73150014	ENSG00000230189.5	GS1-124K5.2	4.01	9.6e-05	0.0319	0.47	0.31	Diabetic kidney disease;	chr7:65985932	chr7:66409143~66490059:-
PCPG	cis	rs5769765	0.773	rs138834	ENSG00000278869.1	CITF22-49E9.3	4.01	9.61e-05	0.0319	0.44	0.31	Schizophrenia;	chr22:49786849	chr22:49933198~49934074:-
PCPG	cis	rs2735413	0.563	rs117731654	ENSG00000276007.1	RP11-358L22.3	4.01	9.61e-05	0.0319	0.35	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78013450	chr16:78123243~78124332:+
PCPG	cis	rs2735413	0.563	rs72800909	ENSG00000276007.1	RP11-358L22.3	4.01	9.61e-05	0.0319	0.35	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78013605	chr16:78123243~78124332:+
PCPG	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-4.01	9.61e-05	0.0319	-0.41	-0.31	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
PCPG	cis	rs2337406	1	rs79452530	ENSG00000274576.2	IGHV2-70	-4.01	9.61e-05	0.0319	-0.4	-0.31	Alzheimer's disease (late onset);	chr14:106699992	chr14:106770577~106771020:-
PCPG	cis	rs16949788	1	rs41306345	ENSG00000261351.2	CTD-3185P2.1	-4.01	9.62e-05	0.0319	-0.44	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66489710	chr15:66488658~66492109:-
PCPG	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	4.01	9.62e-05	0.032	0.47	0.31	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
PCPG	cis	rs853679	0.546	rs35017208	ENSG00000219392.1	RP1-265C24.5	-4.01	9.63e-05	0.032	-0.69	-0.31	Depression;	chr6:28377505	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs36092177	ENSG00000219392.1	RP1-265C24.5	-4.01	9.63e-05	0.032	-0.69	-0.31	Depression;	chr6:28390030	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs2232429	ENSG00000219392.1	RP1-265C24.5	-4.01	9.63e-05	0.032	-0.69	-0.31	Depression;	chr6:28391855	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs2232426	ENSG00000219392.1	RP1-265C24.5	-4.01	9.63e-05	0.032	-0.69	-0.31	Depression;	chr6:28392882	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs2232423	ENSG00000219392.1	RP1-265C24.5	-4.01	9.63e-05	0.032	-0.69	-0.31	Depression;	chr6:28398374	chr6:28115628~28116551:+
PCPG	cis	rs10844706	0.699	rs741199	ENSG00000278635.1	CTD-2318O12.1	-4.01	9.63e-05	0.032	-0.39	-0.31	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9415641~9416718:+
PCPG	cis	rs4143844	0.867	rs11629851	ENSG00000259251.2	RP11-643M14.1	4.01	9.64e-05	0.032	0.7	0.31	Bipolar disorder and schizophrenia;	chr15:61862888	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs12915283	ENSG00000259251.2	RP11-643M14.1	4.01	9.64e-05	0.032	0.7	0.31	Bipolar disorder and schizophrenia;	chr15:61865380	chr15:62060503~62062434:+
PCPG	cis	rs9494145	0.68	rs4895440	ENSG00000232876.1	CTA-212D2.2	-4.01	9.64e-05	0.032	-0.39	-0.31	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105420	chr6:135055033~135060550:+
PCPG	cis	rs11858159	0.676	rs13380324	ENSG00000260760.1	PWRN3	4.01	9.65e-05	0.032	0.34	0.31	Platelet thrombus formation;	chr15:24548874	chr15:24441127~24447967:+
PCPG	cis	rs6728642	0.572	rs2872686	ENSG00000230606.9	AC159540.1	4.01	9.65e-05	0.032	0.35	0.31	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935287	chr2:97416165~97433527:-
PCPG	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-4.01	9.65e-05	0.032	-0.59	-0.31	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
PCPG	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	4.01	9.66e-05	0.032	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
PCPG	cis	rs7267979	0.586	rs6037057	ENSG00000276952.1	RP5-965G21.6	4.01	9.66e-05	0.032	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25284915~25285588:-
PCPG	cis	rs7267979	0.586	rs6050429	ENSG00000276952.1	RP5-965G21.6	4.01	9.66e-05	0.032	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25284915~25285588:-
PCPG	cis	rs10751667	0.6	rs10751672	ENSG00000255142.1	AP006621.6	4.01	9.66e-05	0.0321	0.3	0.31	Alzheimer's disease (late onset);	chr11:948712	chr11:781645~782105:+
PCPG	cis	rs10751667	0.621	rs10794353	ENSG00000255142.1	AP006621.6	4.01	9.66e-05	0.0321	0.3	0.31	Alzheimer's disease (late onset);	chr11:948740	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs10902244	ENSG00000255142.1	AP006621.6	4.01	9.66e-05	0.0321	0.3	0.31	Alzheimer's disease (late onset);	chr11:949981	chr11:781645~782105:+
PCPG	cis	rs10751667	0.666	rs6597967	ENSG00000255142.1	AP006621.6	4.01	9.66e-05	0.0321	0.3	0.31	Alzheimer's disease (late onset);	chr11:950583	chr11:781645~782105:+
PCPG	cis	rs2836974	0.666	rs12626405	ENSG00000252915.1	Y_RNA	4.01	9.66e-05	0.0321	0.32	0.31	Cognitive function;	chr21:39291195	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.666	rs2836975	ENSG00000252915.1	Y_RNA	4.01	9.66e-05	0.0321	0.32	0.31	Cognitive function;	chr21:39291694	chr21:39344537~39344628:+
PCPG	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	4.01	9.66e-05	0.0321	0.36	0.31	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	4.01	9.66e-05	0.0321	0.36	0.31	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
PCPG	cis	rs2404602	0.608	rs12911035	ENSG00000259422.1	RP11-593F23.1	4.01	9.67e-05	0.0321	0.35	0.31	Blood metabolite levels;	chr15:76314250	chr15:76174891~76181486:-
PCPG	cis	rs11214589	0.651	rs11214594	ENSG00000256757.1	RP11-159N11.3	4.01	9.67e-05	0.0321	0.33	0.31	Neuroticism;	chr11:113388610	chr11:113405321~113412117:+
PCPG	cis	rs9303029	1	rs3751913	ENSG00000279744.1	RP13-20L14.10	-4.01	9.67e-05	0.0321	-0.4	-0.31	Protein quantitative trait loci;	chr17:82447676	chr17:82462601~82464255:+
PCPG	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	4.01	9.67e-05	0.0321	0.36	0.31	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
PCPG	cis	rs9928842	0.679	rs4888361	ENSG00000280152.1	RP11-331F4.5	4.01	9.67e-05	0.0321	0.48	0.31	Alcoholic chronic pancreatitis;	chr16:75233778	chr16:75245994~75250077:-
PCPG	cis	rs10208649	0.611	rs1974771	ENSG00000272156.1	RP11-477N3.1	4.01	9.67e-05	0.0321	0.55	0.31	Body mass index;	chr2:54051406	chr2:54082554~54085066:+
PCPG	cis	rs75686122	0.892	rs75775215	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103526656	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs12676333	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103530144	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs17806378	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103532274	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs57252025	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103535530	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.772	rs78303485	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103540688	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs75861389	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103652765	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs12681640	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103657181	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs74869978	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103666225	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs77472944	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103685249	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs75784460	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103698500	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs117473860	ENSG00000253477.4	RP11-1C8.4	4.01	9.68e-05	0.0321	0.48	0.31	Cocaine dependence;	chr8:103698588	chr8:103483398~103501676:-
PCPG	cis	rs3764021	0.87	rs2401395	ENSG00000278635.1	CTD-2318O12.1	-4.01	9.68e-05	0.0321	-0.38	-0.31	Type 1 diabetes;	chr12:9726944	chr12:9415641~9416718:+
PCPG	cis	rs13276960	0.794	rs35644318	ENSG00000254281.1	KB-1507C5.4	4.01	9.68e-05	0.0321	0.39	0.31	Schizophrenia;	chr8:102942649	chr8:102978785~103000184:+
PCPG	cis	rs13118159	0.573	rs7664763	ENSG00000254094.1	AC078852.1	-4.01	9.68e-05	0.0321	-0.4	-0.31	Longevity;	chr4:1358517	chr4:1356581~1358075:+
PCPG	cis	rs6991838	0.702	rs7007987	ENSG00000200714.1	Y_RNA	4.01	9.69e-05	0.0321	0.4	0.31	Intelligence (multi-trait analysis);	chr8:65700754	chr8:65592731~65592820:+
PCPG	cis	rs11148252	0.84	rs4369550	ENSG00000235660.1	LINC00345	-4.01	9.69e-05	0.0321	-0.37	-0.31	Lewy body disease;	chr13:52170775	chr13:52484161~52484680:-
PCPG	cis	rs703842	0.963	rs2291617	ENSG00000270039.1	RP11-571M6.17	-4.01	9.69e-05	0.0321	-0.39	-0.31	Multiple sclerosis;	chr12:57772620	chr12:57803838~57804415:+
PCPG	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	4.01	9.69e-05	0.0321	0.44	0.31	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
PCPG	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-4.01	9.7e-05	0.0321	-0.36	-0.31	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
PCPG	cis	rs9299346	0.594	rs11793342	ENSG00000225376.4	TMEM246-AS1	4.01	9.7e-05	0.0321	0.38	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101673224	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.594	rs13285879	ENSG00000225376.4	TMEM246-AS1	4.01	9.7e-05	0.0321	0.38	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101673269	chr9:101468439~101481502:+
PCPG	cis	rs17772222	0.561	rs8020376	ENSG00000258983.2	RP11-507K2.2	4.01	9.7e-05	0.0322	0.4	0.31	Coronary artery calcification;	chr14:88349823	chr14:88499334~88515502:+
PCPG	cis	rs2404602	0.692	rs67010831	ENSG00000259514.1	RP11-685G9.2	-4.01	9.71e-05	0.0322	-0.31	-0.31	Blood metabolite levels;	chr15:76672967	chr15:76339609~76342063:-
PCPG	cis	rs13108904	0.934	rs13149952	ENSG00000254094.1	AC078852.1	-4.01	9.71e-05	0.0322	-0.35	-0.31	Obesity-related traits;	chr4:1314649	chr4:1356581~1358075:+
PCPG	cis	rs16879308	0.581	rs116710909	ENSG00000248898.1	CTD-2288O8.1	4.01	9.71e-05	0.0322	0.78	0.31	Migraine without aura;	chr5:52111287	chr5:52675193~52788026:-
PCPG	cis	rs16879308	0.581	rs78697002	ENSG00000248898.1	CTD-2288O8.1	4.01	9.71e-05	0.0322	0.78	0.31	Migraine without aura;	chr5:52113947	chr5:52675193~52788026:-
PCPG	cis	rs9689649	0.883	rs4708920	ENSG00000272841.1	RP3-428L16.2	4.01	9.71e-05	0.0322	0.37	0.31	Squamous cell carcinoma;	chr6:161674423	chr6:160990318~160992342:-
PCPG	cis	rs2243480	1	rs6460260	ENSG00000230189.5	GS1-124K5.2	-4.01	9.72e-05	0.0322	-0.48	-0.31	Diabetic kidney disease;	chr7:65750468	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs6460261	ENSG00000230189.5	GS1-124K5.2	-4.01	9.72e-05	0.0322	-0.48	-0.31	Diabetic kidney disease;	chr7:65750593	chr7:66409143~66490059:-
PCPG	cis	rs3947	1	rs3947	ENSG00000227203.3	SUB1P1	-4.01	9.72e-05	0.0322	-0.47	-0.31	Blood protein levels;	chr8:11844866	chr8:11790005~11790386:+
PCPG	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-4.01	9.72e-05	0.0322	-0.39	-0.31	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
PCPG	cis	rs7772486	0.686	rs702305	ENSG00000270638.1	RP3-466P17.1	-4.01	9.72e-05	0.0322	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.622	rs1292333	ENSG00000270638.1	RP3-466P17.1	-4.01	9.72e-05	0.0322	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145735570~145737218:+
PCPG	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	4	9.73e-05	0.0322	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
PCPG	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-4	9.73e-05	0.0322	-0.32	-0.31	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
PCPG	cis	rs1003719	0.715	rs2835613	ENSG00000228677.1	TTC3-AS1	-4	9.73e-05	0.0322	-0.38	-0.31	Eye color traits;	chr21:37124583	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.743	rs2835615	ENSG00000228677.1	TTC3-AS1	-4	9.73e-05	0.0322	-0.38	-0.31	Eye color traits;	chr21:37125003	chr21:37187666~37193926:-
PCPG	cis	rs4237845	0.844	rs4628718	ENSG00000257698.1	RP11-620J15.3	-4	9.74e-05	0.0322	-0.28	-0.31	Intelligence (multi-trait analysis);	chr12:57907817	chr12:57931528~57936175:-
PCPG	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-4	9.74e-05	0.0322	-0.35	-0.31	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
PCPG	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-4	9.74e-05	0.0322	-0.34	-0.31	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
PCPG	cis	rs9368481	0.524	rs12530345	ENSG00000261584.1	RP11-457M11.5	4	9.74e-05	0.0322	0.35	0.31	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26686241~26687964:+
PCPG	cis	rs2404602	0.536	rs17364330	ENSG00000259514.1	RP11-685G9.2	-4	9.74e-05	0.0322	-0.32	-0.31	Blood metabolite levels;	chr15:76473044	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.563	rs12914005	ENSG00000259514.1	RP11-685G9.2	-4	9.74e-05	0.0322	-0.32	-0.31	Blood metabolite levels;	chr15:76473326	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.536	rs7163946	ENSG00000259514.1	RP11-685G9.2	-4	9.74e-05	0.0322	-0.32	-0.31	Blood metabolite levels;	chr15:76473708	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.536	rs7165025	ENSG00000259514.1	RP11-685G9.2	-4	9.74e-05	0.0322	-0.32	-0.31	Blood metabolite levels;	chr15:76474093	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.536	rs1587381	ENSG00000259514.1	RP11-685G9.2	-4	9.74e-05	0.0322	-0.32	-0.31	Blood metabolite levels;	chr15:76477279	chr15:76339609~76342063:-
PCPG	cis	rs4819052	0.851	rs9754134	ENSG00000215447.6	BX322557.10	-4	9.74e-05	0.0323	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45288052~45291738:+
PCPG	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	-4	9.75e-05	0.0323	-0.35	-0.31	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	-4	9.75e-05	0.0323	-0.35	-0.31	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
PCPG	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	4	9.75e-05	0.0323	0.32	0.31	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
PCPG	cis	rs34421088	0.532	rs11782742	ENSG00000269954.1	RP11-148O21.6	4	9.75e-05	0.0323	0.34	0.31	Neuroticism;	chr8:11307500	chr8:11552488~11552991:-
PCPG	cis	rs7208859	0.573	rs73267873	ENSG00000266490.1	CTD-2349P21.9	4	9.75e-05	0.0323	0.4	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.561	rs4085382	ENSG00000266490.1	CTD-2349P21.9	4	9.75e-05	0.0323	0.4	0.31	Body mass index;	chr17:30744184	chr17:30792372~30792833:+
PCPG	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	4	9.75e-05	0.0323	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
PCPG	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	4	9.76e-05	0.0323	0.32	0.31	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
PCPG	cis	rs763121	0.889	rs9610971	ENSG00000273076.1	RP3-508I15.22	4	9.77e-05	0.0323	0.37	0.31	Menopause (age at onset);	chr22:38514805	chr22:38743495~38743910:+
PCPG	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	4	9.78e-05	0.0323	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
PCPG	cis	rs301901	0.729	rs125682	ENSG00000250155.1	CTD-2353F22.1	-4	9.78e-05	0.0323	-0.36	-0.31	Height;	chr5:37337045	chr5:36666214~36725195:-
PCPG	cis	rs172166	0.561	rs149971	ENSG00000219392.1	RP1-265C24.5	-4	9.78e-05	0.0323	-0.34	-0.31	Cardiac Troponin-T levels;	chr6:28014374	chr6:28115628~28116551:+
PCPG	cis	rs752864	0.934	rs12324100	ENSG00000259438.1	CTD-2650P22.1	4	9.78e-05	0.0323	0.38	0.31	Number of common colds;	chr15:52349491	chr15:52010999~52019095:-
PCPG	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-4	9.78e-05	0.0323	-0.67	-0.31	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-4	9.78e-05	0.0323	-0.67	-0.31	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-4	9.78e-05	0.0323	-0.67	-0.31	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
PCPG	cis	rs2733954	0.836	rs96603	ENSG00000179219.5	LINC00311	-4	9.78e-05	0.0323	-0.43	-0.31	Leprosy;	chr16:85781491	chr16:85282958~85285963:+
PCPG	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-4	9.79e-05	0.0324	-0.43	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
PCPG	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	4	9.8e-05	0.0324	0.45	0.31	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
PCPG	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	4	9.8e-05	0.0324	0.55	0.31	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
PCPG	cis	rs7759001	0.948	rs11966173	ENSG00000271755.1	RP1-153G14.4	4	9.8e-05	0.0324	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27424083	chr6:27404010~27406964:-
PCPG	cis	rs7772486	0.686	rs1292336	ENSG00000270638.1	RP3-466P17.1	-4	9.8e-05	0.0324	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145735570~145737218:+
PCPG	cis	rs73198271	0.74	rs10103163	ENSG00000253893.2	FAM85B	4	9.81e-05	0.0324	0.42	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8167819~8226614:-
PCPG	cis	rs6929812	0.613	rs9468140	ENSG00000271755.1	RP1-153G14.4	4	9.81e-05	0.0324	0.39	0.31	Neuroticism (multi-trait analysis);	chr6:27503736	chr6:27404010~27406964:-
PCPG	cis	rs4934494	0.689	rs17127588	ENSG00000240996.1	RP11-80H5.7	-4	9.81e-05	0.0324	-0.44	-0.31	Red blood cell count;	chr10:89815887	chr10:89694295~89697928:-
PCPG	cis	rs73198271	0.737	rs535094	ENSG00000253893.2	FAM85B	4	9.81e-05	0.0324	0.42	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.765	rs534103	ENSG00000253893.2	FAM85B	4	9.81e-05	0.0324	0.42	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.514	rs2945873	ENSG00000173295.6	FAM86B3P	-4	9.81e-05	0.0324	-0.36	-0.31	Mood instability;	chr8:8402935	chr8:8228595~8244865:+
PCPG	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	-4	9.81e-05	0.0324	-0.36	-0.31	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
PCPG	cis	rs4143844	1	rs35932993	ENSG00000259251.2	RP11-643M14.1	4	9.81e-05	0.0324	0.67	0.31	Bipolar disorder and schizophrenia;	chr15:62069557	chr15:62060503~62062434:+
PCPG	cis	rs9923283	0.673	rs3764275	ENSG00000261067.5	RP11-264B17.3	-4	9.82e-05	0.0324	-0.35	-0.31	Plateletcrit;	chr16:29661661	chr16:28974804~28990783:+
PCPG	cis	rs2243480	1	rs56016656	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65918494	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs56291018	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65925352	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs36033484	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65925571	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34193460	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65928123	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34560516	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65939105	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs57057549	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65940751	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.808	rs12698508	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65946971	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs2961102	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65959671	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs34970380	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65966506	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs73148097	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65966800	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs906134	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:65979301	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1723270	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:66004843	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1723269	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:66007799	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs781150	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:66015986	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs313798	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:66028044	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs35396113	ENSG00000230189.5	GS1-124K5.2	4	9.82e-05	0.0324	0.47	0.31	Diabetic kidney disease;	chr7:66030474	chr7:66409143~66490059:-
PCPG	cis	rs13392177	0.66	rs12988046	ENSG00000273466.1	RP11-548H3.1	-4	9.83e-05	0.0324	-0.17	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218633256~218634014:-
PCPG	cis	rs2998286	0.723	rs1034087	ENSG00000254635.4	WAC-AS1	-4	9.83e-05	0.0324	-0.37	-0.31	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28643143	chr10:28522652~28532743:-
PCPG	cis	rs2998286	0.597	rs1272396	ENSG00000254635.4	WAC-AS1	-4	9.83e-05	0.0324	-0.37	-0.31	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28643416	chr10:28522652~28532743:-
PCPG	cis	rs2998286	0.636	rs2772436	ENSG00000254635.4	WAC-AS1	-4	9.83e-05	0.0324	-0.37	-0.31	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28644655	chr10:28522652~28532743:-
PCPG	cis	rs1075232	1	rs67634762	ENSG00000215302.7	CTD-3092A11.1	-4	9.83e-05	0.0324	-0.82	-0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30470779~30507623:+
PCPG	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	4	9.83e-05	0.0324	0.36	0.31	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	4	9.83e-05	0.0324	0.36	0.31	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	4	9.83e-05	0.0324	0.36	0.31	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
PCPG	cis	rs34421088	0.56	rs2245250	ENSG00000269954.1	RP11-148O21.6	-4	9.84e-05	0.0325	-0.36	-0.31	Neuroticism;	chr8:11543171	chr8:11552488~11552991:-
PCPG	cis	rs875971	0.825	rs1860472	ENSG00000235475.1	LINC01372	-4	9.84e-05	0.0325	-0.31	-0.31	Aortic root size;	chr7:66617736	chr7:67335976~67340024:+
PCPG	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-4	9.84e-05	0.0325	-0.33	-0.31	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
PCPG	cis	rs2735413	0.564	rs78375430	ENSG00000276007.1	RP11-358L22.3	4	9.85e-05	0.0325	0.33	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78050916	chr16:78123243~78124332:+
PCPG	cis	rs9813712	0.595	rs1453238	ENSG00000228252.7	COL6A4P2	4	9.85e-05	0.0325	0.39	0.31	Response to amphetamines;	chr3:130290494	chr3:130212823~130273806:+
PCPG	cis	rs698813	0.674	rs3738985	ENSG00000236502.1	SIX3-AS1	4	9.85e-05	0.0325	0.41	0.31	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44275649	chr2:44940154~44941873:-
PCPG	cis	rs17152411	0.895	rs61872118	ENSG00000278831.1	RP11-12J10.4	4	9.86e-05	0.0325	0.44	0.31	Height;	chr10:124894881	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs61872119	ENSG00000278831.1	RP11-12J10.4	4	9.86e-05	0.0325	0.44	0.31	Height;	chr10:124894965	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs61872120	ENSG00000278831.1	RP11-12J10.4	4	9.86e-05	0.0325	0.44	0.31	Height;	chr10:124895019	chr10:124623353~124624079:+
PCPG	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-4	9.86e-05	0.0325	-0.39	-0.31	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
PCPG	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-4	9.86e-05	0.0325	-0.39	-0.31	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
PCPG	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	4	9.86e-05	0.0325	0.39	0.31	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
PCPG	cis	rs9902453	0.817	rs4294865	ENSG00000265845.2	RP11-20B24.5	4	9.86e-05	0.0325	0.37	0.31	Coffee consumption (cups per day);	chr17:29878718	chr17:28926275~28944749:+
PCPG	cis	rs9948	1	rs1320149	ENSG00000230606.9	AC159540.1	4	9.86e-05	0.0325	0.38	0.31	Erectile dysfunction and prostate cancer treatment;	chr2:96828140	chr2:97416165~97433527:-
PCPG	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	4	9.87e-05	0.0325	0.44	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
PCPG	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	4	9.87e-05	0.0325	0.46	0.31	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
PCPG	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	4	9.87e-05	0.0325	0.34	0.31	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
PCPG	cis	rs803923	0.545	rs12376144	ENSG00000230734.1	RPL10P3	4	9.88e-05	0.0326	0.3	0.31	Lung function (FEV1/FVC);	chr9:116726362	chr9:117180628~117181095:-
PCPG	cis	rs17684571	0.7	rs62411376	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56794436	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs34228698	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56795962	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.637	rs34359353	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56800963	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs13198204	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56804057	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs13201639	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56804329	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.637	rs17751966	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56804850	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs71564861	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56806793	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs35251663	ENSG00000231441.1	RP11-472M19.2	4	9.88e-05	0.0326	0.52	0.31	Schizophrenia;	chr6:56806940	chr6:56844002~56864078:+
PCPG	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	4	9.89e-05	0.0326	0.45	0.31	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
PCPG	cis	rs9299346	0.594	rs11790837	ENSG00000225376.4	TMEM246-AS1	4	9.89e-05	0.0326	0.38	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101673188	chr9:101468439~101481502:+
PCPG	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	4	9.89e-05	0.0326	0.33	0.31	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
PCPG	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-4	9.89e-05	0.0326	-0.28	-0.31	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
PCPG	cis	rs7208859	0.673	rs1347359	ENSG00000263603.1	CTD-2349P21.5	-4	9.89e-05	0.0326	-0.47	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30729469~30731202:+
PCPG	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-4	9.9e-05	0.0326	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
PCPG	cis	rs7267979	0.586	rs6050431	ENSG00000276952.1	RP5-965G21.6	4	9.9e-05	0.0326	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25284915~25285588:-
PCPG	cis	rs7267979	0.586	rs6050432	ENSG00000276952.1	RP5-965G21.6	4	9.9e-05	0.0326	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25284915~25285588:-
PCPG	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-4	9.9e-05	0.0326	-0.36	-0.31	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
PCPG	cis	rs116248771	0.739	rs7617983	ENSG00000272087.1	RP11-379F4.7	4	9.9e-05	0.0326	0.46	0.31	diarrhoeal disease at age 2;	chr3:158605927	chr3:158693120~158693768:-
PCPG	cis	rs4664293	0.764	rs1425044	ENSG00000226266.5	AC009961.3	-4	9.9e-05	0.0326	-0.34	-0.31	Monocyte percentage of white cells;	chr2:159618426	chr2:159670708~159712435:-
PCPG	cis	rs7829975	0.742	rs1533059	ENSG00000254235.4	RP11-115J16.1	-4	9.9e-05	0.0326	-0.39	-0.31	Mood instability;	chr8:8827443	chr8:9249417~9413714:+
PCPG	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-4	9.9e-05	0.0326	-0.36	-0.31	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
PCPG	cis	rs11148252	0.553	rs9536236	ENSG00000273784.3	RP11-78J21.7	-4	9.9e-05	0.0326	-0.3	-0.31	Lewy body disease;	chr13:52680877	chr13:52600042~52642542:+
PCPG	cis	rs6672530	0.5	rs2313219	ENSG00000227711.2	RP11-275O4.5	4	9.91e-05	0.0326	0.37	0.31	Hip circumference adjusted for BMI;	chr1:227508223	chr1:227509028~227520477:-
PCPG	cis	rs10799445	0.55	rs2313218	ENSG00000227711.2	RP11-275O4.5	4	9.91e-05	0.0326	0.37	0.31	Height;	chr1:227508224	chr1:227509028~227520477:-
PCPG	cis	rs7772486	0.686	rs1292337	ENSG00000270638.1	RP3-466P17.1	-4	9.91e-05	0.0326	-0.33	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs857879	ENSG00000270638.1	RP3-466P17.1	-4	9.91e-05	0.0326	-0.33	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.686	rs2179323	ENSG00000270638.1	RP3-466P17.1	-4	9.91e-05	0.0326	-0.33	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145735570~145737218:+
PCPG	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	4	9.91e-05	0.0326	0.32	0.31	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	4	9.91e-05	0.0326	0.32	0.31	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
PCPG	cis	rs4934494	0.727	rs36019294	ENSG00000240996.1	RP11-80H5.7	-4	9.91e-05	0.0327	-0.46	-0.31	Red blood cell count;	chr10:89777822	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.636	rs34408087	ENSG00000240996.1	RP11-80H5.7	-4	9.91e-05	0.0327	-0.46	-0.31	Red blood cell count;	chr10:89783794	chr10:89694295~89697928:-
PCPG	cis	rs7702057	0.53	rs7728055	ENSG00000271918.1	CTD-2287O16.5	4	9.92e-05	0.0327	0.45	0.31	Amyotrophic lateral sclerosis;	chr5:116078170	chr5:116083807~116085416:-
PCPG	cis	rs181553	0.664	rs11874831	ENSG00000278983.1	RP11-426J5.3	4	9.92e-05	0.0327	0.34	0.31	Hip circumference adjusted for BMI;	chr18:49176221	chr18:48564795~48568342:+
PCPG	cis	rs7911712	0.935	rs11239246	ENSG00000228462.1	RP11-445N18.3	4	9.92e-05	0.0327	0.45	0.31	Emphysema-related traits;	chr10:44812828	chr10:45073146~45073541:-
PCPG	cis	rs3758911	0.828	rs11212141	ENSG00000255353.1	RP11-382M14.1	-4	9.92e-05	0.0327	-0.43	-0.31	Coronary artery disease;	chr11:107298200	chr11:107176286~107177530:+
PCPG	cis	rs4919687	0.55	rs17784294	ENSG00000269609.4	RPARP-AS1	-4	9.92e-05	0.0327	-0.26	-0.31	Colorectal cancer;	chr10:102719628	chr10:102449817~102461106:+
PCPG	cis	rs4489787	0.568	rs2731066	ENSG00000240399.1	RP1-228P16.1	4	9.92e-05	0.0327	0.34	0.31	Prostate cancer (SNP x SNP interaction);	chr12:48504780	chr12:48054813~48055591:-
PCPG	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	4	9.93e-05	0.0327	0.43	0.31	Height;	chr6:109351533	chr6:109382795~109383666:+
PCPG	cis	rs950169	0.887	rs220333	ENSG00000235370.6	DNM1P51	4	9.94e-05	0.0327	0.32	0.31	Schizophrenia;	chr15:84547902	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs11630507	ENSG00000235370.6	DNM1P51	4	9.94e-05	0.0327	0.32	0.31	Schizophrenia;	chr15:84552494	chr15:84398316~84411701:-
PCPG	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	4	9.94e-05	0.0327	0.39	0.31	Height;	chr6:109739615	chr6:109382795~109383666:+
PCPG	cis	rs75686122	0.772	rs79360484	ENSG00000271830.1	RP11-1C8.7	4	9.94e-05	0.0327	0.55	0.31	Cocaine dependence;	chr8:103479421	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.892	rs12679095	ENSG00000271830.1	RP11-1C8.7	4	9.94e-05	0.0327	0.55	0.31	Cocaine dependence;	chr8:103487366	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.892	rs12677819	ENSG00000271830.1	RP11-1C8.7	4	9.94e-05	0.0327	0.55	0.31	Cocaine dependence;	chr8:103490492	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.892	rs77737965	ENSG00000271830.1	RP11-1C8.7	4	9.94e-05	0.0327	0.55	0.31	Cocaine dependence;	chr8:103494228	chr8:103481266~103481619:-
PCPG	cis	rs2404602	0.692	rs35557205	ENSG00000259514.1	RP11-685G9.2	-4	9.94e-05	0.0327	-0.32	-0.31	Blood metabolite levels;	chr15:76838370	chr15:76339609~76342063:-
PCPG	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	4	9.95e-05	0.0327	0.3	0.31	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	4	9.95e-05	0.0327	0.3	0.31	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	4	9.95e-05	0.0327	0.3	0.31	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
PCPG	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-4	9.95e-05	0.0327	-0.39	-0.31	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
PCPG	cis	rs2735413	0.564	rs11863954	ENSG00000276007.1	RP11-358L22.3	-4	9.95e-05	0.0327	-0.34	-0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78093252	chr16:78123243~78124332:+
PCPG	cis	rs561341	0.769	rs9899093	ENSG00000265798.5	RP11-271K11.5	4	9.95e-05	0.0327	0.51	0.31	Hip circumference adjusted for BMI;	chr17:31864935	chr17:31038575~31059121:-
PCPG	cis	rs7707921	0.881	rs73134747	ENSG00000249483.1	CTD-2249K22.1	-4	9.96e-05	0.0327	-0.42	-0.31	Breast cancer;	chr5:82082475	chr5:81851601~81852201:+
PCPG	cis	rs3758911	0.894	rs999985	ENSG00000255353.1	RP11-382M14.1	-4	9.96e-05	0.0328	-0.42	-0.31	Coronary artery disease;	chr11:107321531	chr11:107176286~107177530:+
PCPG	cis	rs950169	0.922	rs62029585	ENSG00000235370.6	DNM1P51	4	9.97e-05	0.0328	0.33	0.31	Schizophrenia;	chr15:84397176	chr15:84398316~84411701:-
PCPG	cis	rs2898290	0.592	rs2736342	ENSG00000270154.1	RP11-419I17.1	-4	9.97e-05	0.0328	-0.37	-0.31	Systolic blood pressure;	chr8:11489780	chr8:12476462~12477122:+
PCPG	cis	rs5769765	0.913	rs8135071	ENSG00000278869.1	CITF22-49E9.3	4	9.98e-05	0.0328	0.38	0.31	Schizophrenia;	chr22:49905939	chr22:49933198~49934074:-
PCPG	cis	rs7444	0.941	rs878825	ENSG00000273342.1	KB-1440D3.14	-4	9.98e-05	0.0328	-0.34	-0.31	Systemic lupus erythematosus;	chr22:21627960	chr22:21640844~21641284:+
PCPG	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	4	9.99e-05	0.0328	0.28	0.31	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
PCPG	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	4	9.99e-05	0.0328	0.28	0.31	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
PCPG	cis	rs17684571	0.938	rs16888118	ENSG00000231441.1	RP11-472M19.2	4	9.99e-05	0.0329	0.45	0.31	Schizophrenia;	chr6:56687838	chr6:56844002~56864078:+
PCPG	cis	rs116248771	0.69	rs10936149	ENSG00000272087.1	RP11-379F4.7	4	1e-04	0.0329	0.45	0.31	diarrhoeal disease at age 2;	chr3:158576104	chr3:158693120~158693768:-
PCPG	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	4	1e-04	0.0329	0.36	0.31	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	4	1e-04	0.0329	0.36	0.31	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
PCPG	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-4	1e-04	0.0329	-0.49	-0.31	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
PCPG	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-4	1e-04	0.0329	-0.49	-0.31	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
PCPG	cis	rs17453880	0.7	rs12655008	ENSG00000249035.5	CTB-113P19.1	4	1e-04	0.0329	0.33	0.31	Subjective well-being;	chr5:152619469	chr5:151676945~151724782:+
PCPG	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-4	1e-04	0.0329	-0.43	-0.31	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
PCPG	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	4	1e-04	0.0329	0.43	0.31	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
PCPG	cis	rs9394169	0.613	rs7774682	ENSG00000197251.3	LINC00336	-4	1e-04	0.0329	-0.36	-0.31	Essential tremor;	chr6:33754867	chr6:33586106~33593338:-
PCPG	cis	rs6452524	0.618	rs10462394	ENSG00000281327.1	LINC01338	4	1e-04	0.0329	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:82850864~82859836:-
PCPG	cis	rs2243480	1	rs4718270	ENSG00000230189.5	GS1-124K5.2	4	1e-04	0.0329	0.45	0.31	Diabetic kidney disease;	chr7:65737415	chr7:66409143~66490059:-
PCPG	cis	rs10435719	0.902	rs4840599	ENSG00000255495.1	AC145124.2	-4	1e-04	0.0329	-0.31	-0.31	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12194467~12196280:+
PCPG	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	4	1e-04	0.0329	0.37	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
PCPG	cis	rs172166	0.637	rs1233708	ENSG00000220721.1	OR1F12	4	1e-04	0.0329	0.35	0.31	Cardiac Troponin-T levels;	chr6:28205441	chr6:28073316~28074233:+
PCPG	cis	rs1865760	0.534	rs2032444	ENSG00000272810.1	U91328.22	-4	1e-04	0.0329	-0.33	-0.31	Height;	chr6:26046516	chr6:26013241~26013757:+
PCPG	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	4	1e-04	0.033	0.32	0.31	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	4	1e-04	0.033	0.32	0.31	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	4	1e-04	0.033	0.32	0.31	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
PCPG	cis	rs2836974	0.863	rs6517519	ENSG00000252915.1	Y_RNA	-4	1e-04	0.033	-0.33	-0.31	Cognitive function;	chr21:39168319	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.867	rs77959119	ENSG00000252915.1	Y_RNA	-4	1e-04	0.033	-0.33	-0.31	Cognitive function;	chr21:39170842	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs2836927	ENSG00000252915.1	Y_RNA	-4	1e-04	0.033	-0.33	-0.31	Cognitive function;	chr21:39171290	chr21:39344537~39344628:+
PCPG	cis	rs13118159	0.509	rs4974554	ENSG00000254094.1	AC078852.1	-4	1e-04	0.033	-0.4	-0.31	Longevity;	chr4:1363179	chr4:1356581~1358075:+
PCPG	cis	rs13118159	0.509	rs4974556	ENSG00000254094.1	AC078852.1	-4	1e-04	0.033	-0.4	-0.31	Longevity;	chr4:1364353	chr4:1356581~1358075:+
PCPG	cis	rs13118159	0.55	rs4974611	ENSG00000254094.1	AC078852.1	-4	1e-04	0.033	-0.4	-0.31	Longevity;	chr4:1364661	chr4:1356581~1358075:+
PCPG	cis	rs13118159	0.509	rs7688922	ENSG00000254094.1	AC078852.1	-4	1e-04	0.033	-0.4	-0.31	Longevity;	chr4:1367223	chr4:1356581~1358075:+
PCPG	cis	rs16949788	1	rs76623374	ENSG00000261351.2	CTD-3185P2.1	-4	1e-04	0.033	-0.44	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66475530	chr15:66488658~66492109:-
PCPG	cis	rs16949788	0.793	rs78483581	ENSG00000261351.2	CTD-3185P2.1	-4	1e-04	0.033	-0.44	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477027	chr15:66488658~66492109:-
PCPG	cis	rs16949788	1	rs76847935	ENSG00000261351.2	CTD-3185P2.1	-4	1e-04	0.033	-0.44	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477275	chr15:66488658~66492109:-
PCPG	cis	rs9650657	0.571	rs4240673	ENSG00000255020.1	AF131216.5	-4	1e-04	0.033	-0.42	-0.31	Neuroticism;	chr8:10930102	chr8:11345748~11347502:-
PCPG	cis	rs6728642	0.572	rs13403225	ENSG00000278766.2	AC159540.2	-4	1e-04	0.033	-0.39	-0.31	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935090	chr2:97421075~97434847:+
PCPG	cis	rs11018874	0.597	rs4393275	ENSG00000254916.1	RP11-529A4.12	-4	1e-04	0.033	-0.37	-0.31	White blood cell types;	chr11:90153229	chr11:90051837~90053736:-
PCPG	cis	rs3741151	0.773	rs17244602	ENSG00000254837.2	AP001372.2	4	0.000101	0.033	0.39	0.31	GIP levels in response to oral glucose tolerance test (120 minutes);	chr11:73508862	chr11:74493366~74498533:+
PCPG	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-4	0.000101	0.033	-0.41	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
PCPG	cis	rs761746	0.739	rs9621317	ENSG00000128254.12	C22orf24	-4	0.000101	0.033	-0.43	-0.31	Intelligence;	chr22:31698060	chr22:31933521~31945518:-
PCPG	cis	rs4489787	1	rs2705154	ENSG00000240399.1	RP1-228P16.1	4	0.000101	0.033	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr12:48514010	chr12:48054813~48055591:-
PCPG	cis	rs2404602	0.692	rs3110382	ENSG00000270036.1	RP11-685G9.4	4	0.000101	0.033	0.28	0.31	Blood metabolite levels;	chr15:76856347	chr15:76343642~76344365:+
PCPG	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-4	0.000101	0.0331	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-4	0.000101	0.0331	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
PCPG	cis	rs412050	0.696	rs56226933	ENSG00000224086.5	LL22NC03-86G7.1	-4	0.000101	0.0331	-0.48	-0.31	Attention deficit hyperactivity disorder;	chr22:21985504	chr22:21938293~21977632:+
PCPG	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-4	0.000101	0.0331	-0.41	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
PCPG	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-4	0.000101	0.0331	-0.34	-0.31	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
PCPG	cis	rs6585424	1	rs6585454	ENSG00000242600.5	MBL1P	-4	0.000101	0.0331	-0.57	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180945	chr10:79904898~79950336:+
PCPG	cis	rs75686122	0.892	rs4734715	ENSG00000271830.1	RP11-1C8.7	4	0.000101	0.0331	0.55	0.31	Cocaine dependence;	chr8:103495785	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.772	rs79344235	ENSG00000271830.1	RP11-1C8.7	4	0.000101	0.0331	0.55	0.31	Cocaine dependence;	chr8:103497770	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.892	rs79580171	ENSG00000271830.1	RP11-1C8.7	4	0.000101	0.0331	0.55	0.31	Cocaine dependence;	chr8:103502071	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.892	rs2028083	ENSG00000271830.1	RP11-1C8.7	4	0.000101	0.0331	0.55	0.31	Cocaine dependence;	chr8:103503566	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.772	rs76370225	ENSG00000271830.1	RP11-1C8.7	4	0.000101	0.0331	0.55	0.31	Cocaine dependence;	chr8:103507799	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.892	rs80327507	ENSG00000271830.1	RP11-1C8.7	4	0.000101	0.0331	0.55	0.31	Cocaine dependence;	chr8:103520826	chr8:103481266~103481619:-
PCPG	cis	rs75686122	0.892	rs17805990	ENSG00000271830.1	RP11-1C8.7	4	0.000101	0.0331	0.55	0.31	Cocaine dependence;	chr8:103521797	chr8:103481266~103481619:-
PCPG	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	3.99	0.000101	0.0332	0.36	0.31	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	3.99	0.000101	0.0332	0.36	0.31	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	3.99	0.000101	0.0332	0.36	0.31	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	3.99	0.000101	0.0332	0.36	0.31	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
PCPG	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	3.99	0.000101	0.0332	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
PCPG	cis	rs4432245	0.793	rs2898985	ENSG00000248508.5	SRP14-AS1	-3.99	0.000101	0.0332	-0.48	-0.31	Body mass index;	chr15:40035100	chr15:40039311~40067290:+
PCPG	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	3.99	0.000101	0.0332	0.32	0.31	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
PCPG	cis	rs7267979	0.586	rs6083776	ENSG00000276952.1	RP5-965G21.6	3.99	0.000101	0.0332	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25284915~25285588:-
PCPG	cis	rs7267979	0.586	rs1473695	ENSG00000276952.1	RP5-965G21.6	3.99	0.000101	0.0332	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25284915~25285588:-
PCPG	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000101	0.0332	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
PCPG	cis	rs7819412	0.765	rs17783634	ENSG00000255020.1	AF131216.5	-3.99	0.000101	0.0332	-0.42	-0.31	Triglycerides;	chr8:11196588	chr8:11345748~11347502:-
PCPG	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	3.99	0.000101	0.0332	0.42	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
PCPG	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	3.99	0.000101	0.0332	0.44	0.31	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
PCPG	cis	rs4713118	0.824	rs742046	ENSG00000216901.1	AL022393.7	3.99	0.000101	0.0332	0.42	0.31	Parkinson's disease;	chr6:27771475	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.824	rs2179095	ENSG00000216901.1	AL022393.7	-3.99	0.000101	0.0332	-0.42	-0.31	Parkinson's disease;	chr6:27783079	chr6:28176188~28176674:+
PCPG	cis	rs2652834	0.861	rs4774472	ENSG00000259498.1	RP11-244F12.3	-3.99	0.000102	0.0333	-0.51	-0.31	HDL cholesterol;	chr15:63061561	chr15:63046034~63049387:-
PCPG	cis	rs7829975	0.51	rs332037	ENSG00000173295.6	FAM86B3P	-3.99	0.000102	0.0333	-0.39	-0.31	Mood instability;	chr8:8865165	chr8:8228595~8244865:+
PCPG	cis	rs3758911	1	rs10749901	ENSG00000255353.1	RP11-382M14.1	-3.99	0.000102	0.0333	-0.39	-0.31	Coronary artery disease;	chr11:107324776	chr11:107176286~107177530:+
PCPG	cis	rs301161	0.541	rs301154	ENSG00000179219.5	LINC00311	-3.99	0.000102	0.0333	-0.42	-0.31	Eosinophil counts;Sum eosinophil basophil counts;	chr16:85773744	chr16:85282958~85285963:+
PCPG	cis	rs394563	0.625	rs384306	ENSG00000231760.4	RP11-350J20.5	3.99	0.000102	0.0333	0.38	0.31	Dupuytren's disease;	chr6:149475004	chr6:149796151~149826294:-
PCPG	cis	rs425277	1	rs262667	ENSG00000271806.1	RP5-892K4.1	3.99	0.000102	0.0333	0.37	0.31	Height;	chr1:2151283	chr1:2141084~2145279:-
PCPG	cis	rs12744310	0.887	rs12022655	ENSG00000227527.2	RP11-223A3.1	-3.99	0.000102	0.0333	-0.35	-0.31	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41350647	chr1:42335386~42338376:-
PCPG	cis	rs34421088	0.506	rs2572428	ENSG00000255020.1	AF131216.5	3.99	0.000102	0.0333	0.38	0.31	Neuroticism;	chr8:11289163	chr8:11345748~11347502:-
PCPG	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-3.99	0.000102	0.0333	-0.43	-0.31	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
PCPG	cis	rs3758911	0.828	rs10890701	ENSG00000255353.1	RP11-382M14.1	-3.99	0.000102	0.0333	-0.43	-0.31	Coronary artery disease;	chr11:107309216	chr11:107176286~107177530:+
PCPG	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-3.99	0.000102	0.0333	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
PCPG	cis	rs3809060	0.568	rs4275604	ENSG00000213713.3	PIGCP1	-3.99	0.000102	0.0333	-0.16	-0.31	Inguinal hernia;	chr11:32441030	chr11:33075566~33076460:-
PCPG	cis	rs9650657	0.547	rs11250099	ENSG00000269918.1	AF131215.9	3.99	0.000102	0.0333	0.34	0.31	Neuroticism;	chr8:10961147	chr8:11104691~11106704:-
PCPG	cis	rs10443196	1	rs10443196	ENSG00000228084.1	RP5-884G6.2	-3.99	0.000102	0.0334	-0.33	-0.31	Obesity-related traits;	chr1:98987731	chr1:99968383~99969864:-
PCPG	cis	rs4835473	0.618	rs12499429	ENSG00000251600.4	RP11-673E1.1	-3.99	0.000102	0.0334	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143889914	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.801	rs28715976	ENSG00000251600.4	RP11-673E1.1	-3.99	0.000102	0.0334	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143891603	chr4:143912331~143982454:+
PCPG	cis	rs7208859	0.623	rs216433	ENSG00000263603.1	CTD-2349P21.5	-3.99	0.000102	0.0334	-0.46	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30729469~30731202:+
PCPG	cis	rs73129298	0.551	rs6020179	ENSG00000222365.1	SNORD12B	3.99	0.000102	0.0334	0.48	0.31	Inflammatory skin disease;	chr20:49987739	chr20:49280319~49280409:+
PCPG	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	3.99	0.000102	0.0334	0.38	0.31	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
PCPG	cis	rs9500256	0.967	rs4928431	ENSG00000215190.7	LINC00680	3.99	0.000102	0.0334	0.35	0.31	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57946074~57961501:-
PCPG	cis	rs11858159	0.729	rs28620819	ENSG00000260760.1	PWRN3	3.99	0.000102	0.0335	0.34	0.31	Platelet thrombus formation;	chr15:24577077	chr15:24441127~24447967:+
PCPG	cis	rs9393813	0.506	rs4713105	ENSG00000271755.1	RP1-153G14.4	3.99	0.000102	0.0335	0.39	0.31	Bipolar disorder;	chr6:27467141	chr6:27404010~27406964:-
PCPG	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	3.99	0.000102	0.0335	0.38	0.31	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
PCPG	cis	rs10760158	0.832	rs4240466	ENSG00000226752.6	PSMD5-AS1	-3.99	0.000102	0.0335	-0.4	-0.31	Pulse pressure;	chr9:121277456	chr9:120824828~120854385:+
PCPG	cis	rs964611	0.935	rs3784618	ENSG00000259488.2	RP11-154J22.1	-3.99	0.000102	0.0335	-0.38	-0.31	Metabolite levels (Pyroglutamine);	chr15:48284184	chr15:48312353~48331856:-
PCPG	cis	rs9788721	0.934	rs55676755	ENSG00000279421.1	RP11-335K5.3	-3.99	0.000102	0.0335	-0.38	-0.31	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78606590	chr15:78599892~78600013:-
PCPG	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-3.99	0.000102	0.0335	-0.39	-0.31	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
PCPG	cis	rs8098244	0.737	rs1258131	ENSG00000265752.2	RP11-403A21.1	-3.99	0.000102	0.0335	-0.47	-0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959755	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.737	rs948432	ENSG00000265752.2	RP11-403A21.1	-3.99	0.000102	0.0335	-0.47	-0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959998	chr18:23957754~23982556:-
PCPG	cis	rs34421088	0.56	rs11780851	ENSG00000269954.1	RP11-148O21.6	-3.99	0.000102	0.0335	-0.35	-0.31	Neuroticism;	chr8:11543607	chr8:11552488~11552991:-
PCPG	cis	rs11858159	0.871	rs12905055	ENSG00000260760.1	PWRN3	3.99	0.000103	0.0336	0.33	0.31	Platelet thrombus formation;	chr15:24568183	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.871	rs11853495	ENSG00000260760.1	PWRN3	3.99	0.000103	0.0336	0.33	0.31	Platelet thrombus formation;	chr15:24568187	chr15:24441127~24447967:+
PCPG	cis	rs240993	0.761	rs6920014	ENSG00000271789.1	RP5-1112D6.7	-3.99	0.000103	0.0336	-0.4	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111385198	chr6:111297126~111298510:+
PCPG	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-3.99	0.000103	0.0336	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
PCPG	cis	rs10208649	1	rs75213010	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0336	0.7	0.31	Body mass index;	chr2:53709320	chr2:54082554~54085066:+
PCPG	cis	rs11858159	1	rs67007380	ENSG00000260760.1	PWRN3	3.99	0.000103	0.0336	0.34	0.31	Platelet thrombus formation;	chr15:24553007	chr15:24441127~24447967:+
PCPG	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	3.99	0.000103	0.0336	0.32	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
PCPG	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	3.99	0.000103	0.0336	0.49	0.31	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
PCPG	cis	rs453301	0.605	rs7843024	ENSG00000173295.6	FAM86B3P	3.99	0.000103	0.0336	0.36	0.31	Joint mobility (Beighton score);	chr8:8942466	chr8:8228595~8244865:+
PCPG	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	3.99	0.000103	0.0336	0.4	0.31	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
PCPG	cis	rs17684571	0.7	rs13220618	ENSG00000231441.1	RP11-472M19.2	3.99	0.000103	0.0337	0.53	0.31	Schizophrenia;	chr6:56819388	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.751	rs35081015	ENSG00000231441.1	RP11-472M19.2	3.99	0.000103	0.0337	0.53	0.31	Schizophrenia;	chr6:56819757	chr6:56844002~56864078:+
PCPG	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-3.99	0.000103	0.0337	-0.39	-0.31	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
PCPG	cis	rs7824557	0.544	rs1865521	ENSG00000255495.1	AC145124.2	3.99	0.000103	0.0337	0.32	0.31	Retinal vascular caliber;	chr8:11373740	chr8:12194467~12196280:+
PCPG	cis	rs10208649	1	rs74627832	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0337	0.71	0.31	Body mass index;	chr2:53933972	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.908	rs114837028	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0337	0.71	0.31	Body mass index;	chr2:53983416	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.908	rs74930210	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0337	0.71	0.31	Body mass index;	chr2:53995287	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.808	rs115322634	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0337	0.71	0.31	Body mass index;	chr2:53997572	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.908	rs78688150	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0337	0.71	0.31	Body mass index;	chr2:53997658	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.908	rs114242964	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0337	0.71	0.31	Body mass index;	chr2:54013985	chr2:54082554~54085066:+
PCPG	cis	rs62103177	0.683	rs62101232	ENSG00000261126.6	RP11-795F19.1	3.99	0.000103	0.0337	0.47	0.31	Opioid sensitivity;	chr18:79962454	chr18:80046900~80095482:+
PCPG	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-3.99	0.000103	0.0337	-0.43	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
PCPG	cis	rs1371867	0.81	rs1618528	ENSG00000212994.5	RPS26P6	-3.99	0.000103	0.0337	-0.36	-0.31	Atrioventricular conduction;	chr8:100246906	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1788191	ENSG00000212994.5	RPS26P6	-3.99	0.000103	0.0337	-0.36	-0.31	Atrioventricular conduction;	chr8:100248616	chr8:100895771~100896118:+
PCPG	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-3.99	0.000103	0.0337	-0.37	-0.31	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
PCPG	cis	rs7227917	0.536	rs72916016	ENSG00000269365.2	RP11-380M21.4	3.99	0.000103	0.0337	0.62	0.31	Lung cancer in ever smokers;	chr18:47984939	chr18:47878295~47882444:+
PCPG	cis	rs7227917	0.536	rs72916029	ENSG00000269365.2	RP11-380M21.4	3.99	0.000103	0.0337	0.62	0.31	Lung cancer in ever smokers;	chr18:47987089	chr18:47878295~47882444:+
PCPG	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-3.99	0.000103	0.0337	-0.4	-0.31	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
PCPG	cis	rs17152411	0.895	rs7914206	ENSG00000278831.1	RP11-12J10.4	3.99	0.000103	0.0337	0.47	0.31	Height;	chr10:124896828	chr10:124623353~124624079:+
PCPG	cis	rs35123781	0.518	rs13160670	ENSG00000253404.1	AC034243.1	3.99	0.000103	0.0337	0.44	0.31	Schizophrenia;	chr5:139589594	chr5:138744434~138753309:-
PCPG	cis	rs10208649	0.908	rs78244745	ENSG00000272156.1	RP11-477N3.1	3.99	0.000103	0.0337	0.72	0.31	Body mass index;	chr2:54056137	chr2:54082554~54085066:+
PCPG	cis	rs3850699	0.666	rs7905481	ENSG00000269609.4	RPARP-AS1	-3.99	0.000103	0.0337	-0.26	-0.31	Prostate cancer;	chr10:102716535	chr10:102449817~102461106:+
PCPG	cis	rs62246343	0.605	rs9832810	ENSG00000254485.4	RP11-380O24.1	3.99	0.000103	0.0337	0.39	0.31	Fibrinogen levels;	chr3:9424095	chr3:9292588~9363303:-
PCPG	cis	rs17112190	0.568	rs10786311	ENSG00000235677.1	NPM1P26	-3.99	0.000103	0.0337	-0.38	-0.31	Multiple myeloma (IgH translocation);	chr10:96801469	chr10:96560185~96560922:+
PCPG	cis	rs763014	0.898	rs4984894	ENSG00000262528.2	LA16c-349E10.1	3.99	0.000103	0.0337	0.37	0.31	Height;	chr16:573103	chr16:654611~656194:-
PCPG	cis	rs6921919	0.562	rs13198809	ENSG00000219392.1	RP1-265C24.5	-3.99	0.000103	0.0337	-0.69	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28115628~28116551:+
PCPG	cis	rs9813712	0.953	rs6439222	ENSG00000228252.7	COL6A4P2	3.99	0.000103	0.0337	0.41	0.31	Response to amphetamines;	chr3:130256298	chr3:130212823~130273806:+
PCPG	cis	rs13118159	0.509	rs7681872	ENSG00000254094.1	AC078852.1	-3.99	0.000103	0.0337	-0.37	-0.31	Longevity;	chr4:1382947	chr4:1356581~1358075:+
PCPG	cis	rs2404602	0.716	rs7174953	ENSG00000259422.1	RP11-593F23.1	3.99	0.000103	0.0338	0.37	0.31	Blood metabolite levels;	chr15:76614506	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.679	rs12900494	ENSG00000259422.1	RP11-593F23.1	3.99	0.000103	0.0338	0.37	0.31	Blood metabolite levels;	chr15:76620163	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.716	rs7169394	ENSG00000259422.1	RP11-593F23.1	3.99	0.000103	0.0338	0.37	0.31	Blood metabolite levels;	chr15:76620933	chr15:76174891~76181486:-
PCPG	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	3.99	0.000103	0.0338	0.3	0.31	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	3.99	0.000103	0.0338	0.3	0.31	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	3.99	0.000103	0.0338	0.3	0.31	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
PCPG	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-3.99	0.000103	0.0338	-0.35	-0.31	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
PCPG	cis	rs901683	0.85	rs113588255	ENSG00000230869.1	CTGLF10P	-3.99	0.000103	0.0338	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45571885	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs112392416	ENSG00000230869.1	CTGLF10P	-3.99	0.000103	0.0338	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45575018	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs79319916	ENSG00000230869.1	CTGLF10P	-3.99	0.000103	0.0338	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45578532	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs78999882	ENSG00000230869.1	CTGLF10P	-3.99	0.000103	0.0338	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45581365	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs76849715	ENSG00000230869.1	CTGLF10P	-3.99	0.000103	0.0338	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45584985	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.702	rs75758972	ENSG00000230869.1	CTGLF10P	-3.99	0.000103	0.0338	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45586150	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs76395348	ENSG00000230869.1	CTGLF10P	-3.99	0.000103	0.0338	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45586616	chr10:45678692~45700532:+
PCPG	cis	rs425277	1	rs381664	ENSG00000271806.1	RP5-892K4.1	3.99	0.000104	0.0338	0.37	0.31	Height;	chr1:2156665	chr1:2141084~2145279:-
PCPG	cis	rs4763879	0.502	rs11052552	ENSG00000278635.1	CTD-2318O12.1	-3.99	0.000104	0.0338	-0.37	-0.31	Type 1 diabetes;	chr12:9703362	chr12:9415641~9416718:+
PCPG	cis	rs7160336	0.628	rs12893501	ENSG00000258586.1	RP5-1021I20.2	3.99	0.000104	0.0338	0.36	0.31	Blood protein levels;	chr14:73990459	chr14:73822559~73830135:-
PCPG	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-3.99	0.000104	0.0338	-0.39	-0.31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
PCPG	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	3.99	0.000104	0.0338	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
PCPG	cis	rs11858159	1	rs12595260	ENSG00000260760.1	PWRN3	3.99	0.000104	0.0338	0.33	0.31	Platelet thrombus formation;	chr15:24541711	chr15:24441127~24447967:+
PCPG	cis	rs6762	0.692	rs5030778	ENSG00000255108.1	AP006621.8	3.99	0.000104	0.0338	0.4	0.31	Mean platelet volume;	chr11:836008	chr11:823634~832883:-
PCPG	cis	rs4295623	0.556	rs10903343	ENSG00000255556.2	RP11-351I21.6	3.99	0.000104	0.0338	0.33	0.31	Morning vs. evening chronotype;	chr8:11838363	chr8:12378679~12380265:-
PCPG	cis	rs7819412	0.595	rs2409712	ENSG00000255020.1	AF131216.5	-3.99	0.000104	0.0338	-0.42	-0.31	Triglycerides;	chr8:11129327	chr8:11345748~11347502:-
PCPG	cis	rs8099594	0.51	rs1893528	ENSG00000278983.1	RP11-426J5.3	3.99	0.000104	0.0339	0.35	0.31	Height;	chr18:49169720	chr18:48564795~48568342:+
PCPG	cis	rs6452524	0.618	rs6452501	ENSG00000281327.1	LINC01338	3.99	0.000104	0.0339	0.32	0.31	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:82850864~82859836:-
PCPG	cis	rs4143844	0.867	rs11635880	ENSG00000259251.2	RP11-643M14.1	3.99	0.000104	0.0339	0.68	0.31	Bipolar disorder and schizophrenia;	chr15:61863843	chr15:62060503~62062434:+
PCPG	cis	rs17152411	1	rs10901837	ENSG00000278831.1	RP11-12J10.4	3.99	0.000104	0.0339	0.45	0.31	Height;	chr10:124926049	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs61873277	ENSG00000278831.1	RP11-12J10.4	3.99	0.000104	0.0339	0.45	0.31	Height;	chr10:124930762	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs7906592	ENSG00000278831.1	RP11-12J10.4	3.99	0.000104	0.0339	0.45	0.31	Height;	chr10:124939292	chr10:124623353~124624079:+
PCPG	cis	rs11148252	0.84	rs3886077	ENSG00000235660.1	LINC00345	-3.99	0.000104	0.0339	-0.38	-0.31	Lewy body disease;	chr13:52374918	chr13:52484161~52484680:-
PCPG	cis	rs34421088	0.532	rs2736258	ENSG00000255020.1	AF131216.5	3.99	0.000104	0.0339	0.38	0.31	Neuroticism;	chr8:11312940	chr8:11345748~11347502:-
PCPG	cis	rs1876905	0.539	rs190246	ENSG00000255389.1	C6orf3	-3.99	0.000104	0.0339	-0.45	-0.31	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111599875~111602295:+
PCPG	cis	rs1692580	0.87	rs262680	ENSG00000271806.1	RP5-892K4.1	3.99	0.000104	0.0339	0.35	0.31	Coronary artery disease;	chr1:2235710	chr1:2141084~2145279:-
PCPG	cis	rs6452524	0.56	rs6895174	ENSG00000281327.1	LINC01338	3.99	0.000104	0.0339	0.32	0.31	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:82850864~82859836:-
PCPG	cis	rs6452524	0.618	rs6452502	ENSG00000281327.1	LINC01338	3.99	0.000104	0.0339	0.32	0.31	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:82850864~82859836:-
PCPG	cis	rs6452524	0.618	rs6452503	ENSG00000281327.1	LINC01338	3.99	0.000104	0.0339	0.32	0.31	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:82850864~82859836:-
PCPG	cis	rs6452524	0.618	rs6452504	ENSG00000281327.1	LINC01338	3.99	0.000104	0.0339	0.32	0.31	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:82850864~82859836:-
PCPG	cis	rs8098244	0.557	rs11662031	ENSG00000265752.2	RP11-403A21.1	3.99	0.000104	0.0339	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707799	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.557	rs2226835	ENSG00000265752.2	RP11-403A21.1	3.99	0.000104	0.0339	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23715912	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.515	rs4387667	ENSG00000265752.2	RP11-403A21.1	3.99	0.000104	0.0339	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716161	chr18:23957754~23982556:-
PCPG	cis	rs11250098	0.6	rs4240671	ENSG00000255020.1	AF131216.5	3.99	0.000104	0.0339	0.4	0.31	Morning vs. evening chronotype;	chr8:10910238	chr8:11345748~11347502:-
PCPG	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-3.99	0.000104	0.0339	-0.32	-0.31	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
PCPG	cis	rs2998286	0.678	rs1755205	ENSG00000254635.4	WAC-AS1	-3.99	0.000104	0.0339	-0.37	-0.31	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28644828	chr10:28522652~28532743:-
PCPG	cis	rs10899021	1	rs11236186	ENSG00000279353.1	RP11-864N7.4	3.99	0.000104	0.0339	0.6	0.31	Response to metformin (IC50);	chr11:74651820	chr11:74698231~74699658:-
PCPG	cis	rs10899021	1	rs7935426	ENSG00000279353.1	RP11-864N7.4	3.99	0.000104	0.0339	0.6	0.31	Response to metformin (IC50);	chr11:74652845	chr11:74698231~74699658:-
PCPG	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	3.99	0.000104	0.034	0.4	0.31	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	3.99	0.000104	0.034	0.4	0.31	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
PCPG	cis	rs2404602	0.692	rs2120108	ENSG00000259422.1	RP11-593F23.1	-3.99	0.000104	0.034	-0.37	-0.31	Blood metabolite levels;	chr15:76577588	chr15:76174891~76181486:-
PCPG	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-3.99	0.000104	0.034	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
PCPG	cis	rs4713118	0.869	rs9468214	ENSG00000216901.1	AL022393.7	3.99	0.000104	0.034	0.41	0.31	Parkinson's disease;	chr6:27745520	chr6:28176188~28176674:+
PCPG	cis	rs17152411	0.947	rs17152408	ENSG00000278831.1	RP11-12J10.4	3.99	0.000104	0.034	0.43	0.31	Height;	chr10:124960438	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs7077936	ENSG00000278831.1	RP11-12J10.4	3.99	0.000104	0.034	0.43	0.31	Height;	chr10:124961496	chr10:124623353~124624079:+
PCPG	cis	rs539096	0.54	rs3011217	ENSG00000237950.1	RP11-7O11.3	-3.99	0.000104	0.034	-0.32	-0.31	Intelligence (multi-trait analysis);	chr1:43837594	chr1:43944370~43946551:-
PCPG	cis	rs2098713	0.569	rs7715951	ENSG00000250155.1	CTD-2353F22.1	3.99	0.000104	0.034	0.38	0.31	Telomere length;	chr5:37492108	chr5:36666214~36725195:-
PCPG	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	3.99	0.000104	0.034	0.3	0.31	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	3.99	0.000104	0.034	0.3	0.31	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
PCPG	cis	rs8098244	0.617	rs7244406	ENSG00000265752.2	RP11-403A21.1	3.99	0.000104	0.034	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23820041	chr18:23957754~23982556:-
PCPG	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	3.99	0.000104	0.034	0.42	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
PCPG	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	3.99	0.000105	0.034	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
PCPG	cis	rs9595908	0.537	rs7993153	ENSG00000212293.1	SNORA16	3.99	0.000105	0.034	0.37	0.31	Body mass index;	chr13:32804647	chr13:32420390~32420516:-
PCPG	cis	rs13118159	0.527	rs9328733	ENSG00000254094.1	AC078852.1	-3.99	0.000105	0.034	-0.39	-0.31	Longevity;	chr4:1394795	chr4:1356581~1358075:+
PCPG	cis	rs2075466	0.588	rs17832589	ENSG00000267077.1	RP11-127I20.5	-3.99	0.000105	0.034	-0.61	-0.31	Colonoscopy-negative controls vs population controls;	chr16:4828587	chr16:4795265~4796532:-
PCPG	cis	rs763121	0.819	rs6001205	ENSG00000273076.1	RP3-508I15.22	3.99	0.000105	0.0341	0.38	0.31	Menopause (age at onset);	chr22:38704259	chr22:38743495~38743910:+
PCPG	cis	rs12928939	0.637	rs8046629	ENSG00000260886.1	TAT-AS1	3.99	0.000105	0.0341	0.43	0.31	Post bronchodilator FEV1;	chr16:71609213	chr16:71565789~71578187:+
PCPG	cis	rs5758511	0.689	rs56906457	ENSG00000226450.2	CYP2D8P	3.99	0.000105	0.0341	0.43	0.31	Birth weight;	chr22:42232329	chr22:42149886~42155001:-
PCPG	cis	rs2243480	1	rs73150014	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65985932	chr7:66407288~66409239:-
PCPG	cis	rs7772486	0.686	rs857875	ENSG00000270638.1	RP3-466P17.1	-3.99	0.000105	0.0341	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145735570~145737218:+
PCPG	cis	rs7227917	0.536	rs72916034	ENSG00000269365.2	RP11-380M21.4	3.99	0.000105	0.0341	0.62	0.31	Lung cancer in ever smokers;	chr18:47988279	chr18:47878295~47882444:+
PCPG	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	3.99	0.000105	0.0341	0.4	0.31	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	3.99	0.000105	0.0341	0.4	0.31	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
PCPG	cis	rs2836974	0.932	rs73221193	ENSG00000252915.1	Y_RNA	-3.99	0.000105	0.0341	-0.32	-0.31	Cognitive function;	chr21:39182767	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.932	rs6517523	ENSG00000252915.1	Y_RNA	-3.99	0.000105	0.0341	-0.32	-0.31	Cognitive function;	chr21:39185406	chr21:39344537~39344628:+
PCPG	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	3.99	0.000105	0.0341	0.37	0.31	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
PCPG	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-3.99	0.000105	0.0341	-0.48	-0.31	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
PCPG	cis	rs17684571	0.654	rs4348308	ENSG00000231441.1	RP11-472M19.2	3.99	0.000105	0.0341	0.52	0.31	Schizophrenia;	chr6:56815545	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs34640766	ENSG00000231441.1	RP11-472M19.2	3.99	0.000105	0.0341	0.52	0.31	Schizophrenia;	chr6:56815876	chr6:56844002~56864078:+
PCPG	cis	rs9771228	0.585	rs10269368	ENSG00000205763.12	RP9P	3.99	0.000105	0.0341	0.37	0.31	Cognitive ability;Verbal-numerical reasoning;	chr7:32231902	chr7:32916815~32943176:-
PCPG	cis	rs9771228	0.585	rs11764155	ENSG00000205763.12	RP9P	3.99	0.000105	0.0341	0.37	0.31	Cognitive ability;Verbal-numerical reasoning;	chr7:32232500	chr7:32916815~32943176:-
PCPG	cis	rs2243480	1	rs56016656	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65918494	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs56291018	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65925352	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs36033484	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65925571	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs34193460	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65928123	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs34560516	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65939105	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs57057549	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65940751	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.808	rs12698508	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65946971	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs2961102	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65959671	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs34970380	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65966506	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.901	rs73148097	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65966800	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs906134	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:65979301	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1723270	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:66004843	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1723269	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:66007799	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs781150	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:66015986	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs313798	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:66028044	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs35396113	ENSG00000251451.1	GS1-124K5.6	3.99	0.000105	0.0341	0.57	0.31	Diabetic kidney disease;	chr7:66030474	chr7:66407288~66409239:-
PCPG	cis	rs240993	0.812	rs459809	ENSG00000271789.1	RP5-1112D6.7	-3.99	0.000105	0.0341	-0.39	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111297126~111298510:+
PCPG	cis	rs1876905	0.68	rs395564	ENSG00000255389.1	C6orf3	3.99	0.000105	0.0341	0.43	0.31	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111599875~111602295:+
PCPG	cis	rs875971	0.66	rs10229345	ENSG00000237310.1	GS1-124K5.4	3.99	0.000105	0.0341	0.27	0.31	Aortic root size;	chr7:66517181	chr7:66493706~66495474:+
PCPG	cis	rs4919687	0.55	rs12780827	ENSG00000269609.4	RPARP-AS1	-3.99	0.000105	0.0341	-0.26	-0.31	Colorectal cancer;	chr10:102708197	chr10:102449817~102461106:+
PCPG	cis	rs1865760	0.532	rs1061482	ENSG00000272810.1	U91328.22	-3.98	0.000105	0.0342	-0.32	-0.31	Height;	chr6:26086471	chr6:26013241~26013757:+
PCPG	cis	rs412050	0.744	rs735244	ENSG00000224086.5	LL22NC03-86G7.1	-3.98	0.000105	0.0342	-0.45	-0.31	Attention deficit hyperactivity disorder;	chr22:21937727	chr22:21938293~21977632:+
PCPG	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	3.98	0.000105	0.0342	0.4	0.31	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
PCPG	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-3.98	0.000105	0.0342	-0.26	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
PCPG	cis	rs3758911	1	rs2046903	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107315208	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10890705	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107315308	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs4387327	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107315334	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs12286342	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107315568	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs12273125	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107315602	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10789611	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107316810	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10789612	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107316931	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10890707	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107317153	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10890708	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107317315	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs10890709	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107317378	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs10890711	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107317424	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs12290112	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107317487	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs12270655	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107317507	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs10890712	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107317583	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs10789614	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107318047	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10789615	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107318088	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10789616	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107318365	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10789617	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000105	0.0342	-0.39	-0.31	Coronary artery disease;	chr11:107318968	chr11:107176286~107177530:+
PCPG	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	3.98	0.000105	0.0342	0.35	0.31	Height;	chr5:36941665	chr5:36666214~36725195:-
PCPG	cis	rs2836974	0.59	rs9974757	ENSG00000255568.3	BRWD1-AS2	-3.98	0.000105	0.0342	-0.32	-0.31	Cognitive function;	chr21:39245318	chr21:39313935~39314962:+
PCPG	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000105	0.0342	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000105	0.0342	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000105	0.0342	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
PCPG	cis	rs8030379	1	rs11633301	ENSG00000230373.7	GOLGA6L5P	3.98	0.000105	0.0342	0.31	0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916286	chr15:84507885~84516814:-
PCPG	cis	rs7037266	0.857	rs10758813	ENSG00000206147.5	RP11-106A1.2	-3.98	0.000105	0.0342	-0.3	-0.31	Menarche (age at onset);	chr9:6964820	chr9:6639139~6639604:+
PCPG	cis	rs9299346	0.504	rs4266702	ENSG00000225376.4	TMEM246-AS1	3.98	0.000105	0.0342	0.47	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101672394	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.505	rs4442195	ENSG00000225376.4	TMEM246-AS1	3.98	0.000105	0.0342	0.47	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101672612	chr9:101468439~101481502:+
PCPG	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	3.98	0.000105	0.0342	0.57	0.31	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
PCPG	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	3.98	0.000105	0.0342	0.49	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
PCPG	cis	rs3806843	0.762	rs3756337	ENSG00000202515.1	VTRNA1-3	-3.98	0.000105	0.0342	-0.4	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140806853	chr5:140726158~140726246:+
PCPG	cis	rs2275565	0.81	rs4659735	ENSG00000230325.1	RP11-385F5.4	3.98	0.000105	0.0342	0.49	0.31	Homocysteine levels;	chr1:236869625	chr1:236540094~236550280:-
PCPG	cis	rs7208859	0.623	rs426434	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000105	0.0342	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30792372~30792833:+
PCPG	cis	rs4512344	0.509	rs2409784	ENSG00000254866.2	DEFB109P3	3.98	0.000105	0.0342	0.41	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12150895~12151134:-
PCPG	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	3.98	0.000105	0.0342	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
PCPG	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	3.98	0.000105	0.0342	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
PCPG	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	3.98	0.000105	0.0343	0.28	0.31	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
PCPG	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	3.98	0.000105	0.0343	0.41	0.31	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
PCPG	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	3.98	0.000105	0.0343	0.48	0.31	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
PCPG	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	3.98	0.000105	0.0343	0.52	0.31	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
PCPG	cis	rs17684571	0.7	rs17684784	ENSG00000231441.1	RP11-472M19.2	-3.98	0.000106	0.0343	-0.51	-0.31	Schizophrenia;	chr6:56813644	chr6:56844002~56864078:+
PCPG	cis	rs56804039	0.524	rs7016459	ENSG00000253893.2	FAM85B	3.98	0.000106	0.0343	0.57	0.31	Cervical cancer;	chr8:8509006	chr8:8167819~8226614:-
PCPG	cis	rs7819412	0.623	rs7833435	ENSG00000255020.1	AF131216.5	-3.98	0.000106	0.0343	-0.42	-0.31	Triglycerides;	chr8:10943627	chr8:11345748~11347502:-
PCPG	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	3.98	0.000106	0.0343	0.28	0.31	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	3.98	0.000106	0.0343	0.28	0.31	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	3.98	0.000106	0.0343	0.28	0.31	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	3.98	0.000106	0.0343	0.28	0.31	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	3.98	0.000106	0.0343	0.28	0.31	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	3.98	0.000106	0.0343	0.28	0.31	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
PCPG	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-3.98	0.000106	0.0343	-0.55	-0.31	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
PCPG	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-3.98	0.000106	0.0343	-0.33	-0.31	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
PCPG	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-3.98	0.000106	0.0343	-0.33	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
PCPG	cis	rs300890	0.786	rs300910	ENSG00000250326.1	RP11-284M14.1	3.98	0.000106	0.0343	0.28	0.31	Nasopharyngeal carcinoma;	chr4:143355846	chr4:142933195~143184861:-
PCPG	cis	rs444881	0.777	rs449555	ENSG00000260018.1	RP11-505K9.1	3.98	0.000106	0.0343	0.25	0.31	IgG glycosylation;	chr16:83729267	chr16:84117051~84117571:+
PCPG	cis	rs11148252	0.875	rs9526913	ENSG00000235660.1	LINC00345	-3.98	0.000106	0.0343	-0.38	-0.31	Lewy body disease;	chr13:52401702	chr13:52484161~52484680:-
PCPG	cis	rs9876781	0.874	rs56298324	ENSG00000229759.1	MRPS18AP1	-3.98	0.000106	0.0343	-0.37	-0.31	Longevity;	chr3:48393626	chr3:48256350~48256938:-
PCPG	cis	rs2735413	0.564	rs4324138	ENSG00000276007.1	RP11-358L22.3	3.98	0.000106	0.0343	0.31	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78067475	chr16:78123243~78124332:+
PCPG	cis	rs7246657	0.722	rs8100646	ENSG00000226686.6	LINC01535	-3.98	0.000106	0.0343	-0.47	-0.31	Coronary artery calcification;	chr19:37617042	chr19:37251912~37265535:+
PCPG	cis	rs9472414	0.599	rs16873379	ENSG00000229349.2	ACTG1P9	-3.98	0.000106	0.0343	-0.51	-0.31	Height;	chr6:45372114	chr6:46204729~46207386:+
PCPG	cis	rs9472414	0.599	rs2295295	ENSG00000229349.2	ACTG1P9	-3.98	0.000106	0.0343	-0.51	-0.31	Height;	chr6:45377994	chr6:46204729~46207386:+
PCPG	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	3.98	0.000106	0.0343	0.45	0.31	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
PCPG	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-3.98	0.000106	0.0343	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
PCPG	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	3.98	0.000106	0.0344	0.4	0.31	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
PCPG	cis	rs240993	0.812	rs118203	ENSG00000271789.1	RP5-1112D6.7	-3.98	0.000106	0.0344	-0.39	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111297126~111298510:+
PCPG	cis	rs889398	0.741	rs6499270	ENSG00000196696.11	PDXDC2P	3.98	0.000106	0.0344	0.24	0.31	Body mass index;	chr16:69883837	chr16:69976297~70065948:-
PCPG	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-3.98	0.000106	0.0344	-0.37	-0.31	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
PCPG	cis	rs6696239	0.531	rs951083	ENSG00000227711.2	RP11-275O4.5	-3.98	0.000106	0.0344	-0.36	-0.31	Height;	chr1:227512770	chr1:227509028~227520477:-
PCPG	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	3.98	0.000106	0.0344	0.36	0.31	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
PCPG	cis	rs4819052	0.851	rs2838864	ENSG00000215447.6	BX322557.10	3.98	0.000106	0.0344	0.3	0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45288052~45291738:+
PCPG	cis	rs4835473	0.897	rs35140014	ENSG00000251600.4	RP11-673E1.1	3.98	0.000106	0.0344	0.36	0.31	Immature fraction of reticulocytes;	chr4:143964292	chr4:143912331~143982454:+
PCPG	cis	rs9299346	0.536	rs10989596	ENSG00000225376.4	TMEM246-AS1	3.98	0.000106	0.0344	0.5	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101701522	chr9:101468439~101481502:+
PCPG	cis	rs6044834	0.614	rs2284911	ENSG00000212232.1	SNORD17	-3.98	0.000106	0.0344	-0.43	-0.31	Obesity-related traits;	chr20:17457395	chr20:17962710~17962946:-
PCPG	cis	rs11148252	0.811	rs9536030	ENSG00000235660.1	LINC00345	3.98	0.000106	0.0344	0.38	0.31	Lewy body disease;	chr13:52364156	chr13:52484161~52484680:-
PCPG	cis	rs12705054	0.529	rs11761427	ENSG00000242687.2	AC004893.11	-3.98	0.000106	0.0345	-0.55	-0.31	Facial emotion recognition (sad faces);	chr7:99249853	chr7:99013165~99048240:+
PCPG	cis	rs12705054	0.529	rs13438315	ENSG00000242687.2	AC004893.11	-3.98	0.000106	0.0345	-0.55	-0.31	Facial emotion recognition (sad faces);	chr7:99250776	chr7:99013165~99048240:+
PCPG	cis	rs2404602	0.669	rs12441484	ENSG00000259514.1	RP11-685G9.2	-3.98	0.000106	0.0345	-0.31	-0.31	Blood metabolite levels;	chr15:76817534	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs4886503	ENSG00000259514.1	RP11-685G9.2	3.98	0.000106	0.0345	0.31	0.31	Blood metabolite levels;	chr15:76816533	chr15:76339609~76342063:-
PCPG	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	3.98	0.000106	0.0345	0.32	0.31	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
PCPG	cis	rs703842	1	rs703842	ENSG00000270039.1	RP11-571M6.17	3.98	0.000106	0.0345	0.38	0.31	Multiple sclerosis;	chr12:57768956	chr12:57803838~57804415:+
PCPG	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-3.98	0.000106	0.0345	-0.35	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
PCPG	cis	rs2115630	0.846	rs8024538	ENSG00000259295.5	CSPG4P12	-3.98	0.000106	0.0345	-0.38	-0.31	P wave terminal force;	chr15:84825188	chr15:85191438~85213905:+
PCPG	cis	rs8067354	0.83	rs2453913	ENSG00000259349.1	RP11-15E18.1	-3.98	0.000107	0.0345	-0.44	-0.31	Hemoglobin concentration;	chr17:59782789	chr17:60526293~60550798:+
PCPG	cis	rs17772222	0.917	rs17188046	ENSG00000222990.1	RNU4-22P	3.98	0.000107	0.0345	0.39	0.31	Coronary artery calcification;	chr14:88624417	chr14:88513498~88513663:+
PCPG	cis	rs3758911	0.861	rs10890690	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000107	0.0345	-0.41	-0.31	Coronary artery disease;	chr11:107276174	chr11:107176286~107177530:+
PCPG	cis	rs4713118	0.506	rs9366697	ENSG00000216901.1	AL022393.7	3.98	0.000107	0.0345	0.4	0.31	Parkinson's disease;	chr6:27665239	chr6:28176188~28176674:+
PCPG	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	3.98	0.000107	0.0345	0.34	0.31	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
PCPG	cis	rs6137473	0.65	rs201559	ENSG00000227063.5	RPL41P1	3.98	0.000107	0.0346	0.33	0.31	Adolescent idiopathic scoliosis;	chr20:22016477	chr20:21755270~21755350:+
PCPG	cis	rs1371867	0.875	rs962452	ENSG00000212994.5	RPS26P6	3.98	0.000107	0.0346	0.35	0.31	Atrioventricular conduction;	chr8:100319141	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1788180	ENSG00000212994.5	RPS26P6	3.98	0.000107	0.0346	0.35	0.31	Atrioventricular conduction;	chr8:100321140	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1788181	ENSG00000212994.5	RPS26P6	3.98	0.000107	0.0346	0.35	0.31	Atrioventricular conduction;	chr8:100321840	chr8:100895771~100896118:+
PCPG	cis	rs9867325	0.895	rs9879531	ENSG00000273486.1	RP11-731C17.2	3.98	0.000107	0.0346	0.42	0.31	Body mass index;	chr3:136920133	chr3:136837338~136839021:-
PCPG	cis	rs17772222	0.917	rs17188228	ENSG00000222990.1	RNU4-22P	3.98	0.000107	0.0346	0.41	0.31	Coronary artery calcification;	chr14:88738921	chr14:88513498~88513663:+
PCPG	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-3.98	0.000107	0.0346	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-3.98	0.000107	0.0346	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
PCPG	cis	rs1048886	0.938	rs58085250	ENSG00000271967.1	RP11-134K13.4	-3.98	0.000107	0.0346	-0.39	-0.31	Type 2 diabetes;	chr6:70508878	chr6:70596438~70596980:+
PCPG	cis	rs950169	0.919	rs17300292	ENSG00000235370.6	DNM1P51	3.98	0.000107	0.0346	0.31	0.31	Schizophrenia;	chr15:84093816	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs12916348	ENSG00000235370.6	DNM1P51	3.98	0.000107	0.0346	0.31	0.31	Schizophrenia;	chr15:84096775	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs35297609	ENSG00000235370.6	DNM1P51	3.98	0.000107	0.0346	0.31	0.31	Schizophrenia;	chr15:84104144	chr15:84398316~84411701:-
PCPG	cis	rs6452524	0.618	rs3899556	ENSG00000281327.1	LINC01338	3.98	0.000107	0.0346	0.32	0.31	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:82850864~82859836:-
PCPG	cis	rs7772486	0.686	rs4896827	ENSG00000270638.1	RP3-466P17.1	3.98	0.000107	0.0346	0.33	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145735570~145737218:+
PCPG	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-3.98	0.000107	0.0346	-0.35	-0.31	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-3.98	0.000107	0.0346	-0.35	-0.31	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
PCPG	cis	rs6787172	0.811	rs6780896	ENSG00000271778.1	RP11-379F4.8	3.98	0.000107	0.0346	0.28	0.31	Subjective well-being;	chr3:158477606	chr3:158782547~158783124:+
PCPG	cis	rs6787172	0.728	rs6783284	ENSG00000271778.1	RP11-379F4.8	3.98	0.000107	0.0346	0.28	0.31	Subjective well-being;	chr3:158477761	chr3:158782547~158783124:+
PCPG	cis	rs875971	0.54	rs35510581	ENSG00000273142.1	RP11-458F8.4	3.98	0.000107	0.0346	0.28	0.31	Aortic root size;	chr7:66113790	chr7:66902857~66906297:+
PCPG	cis	rs5769765	0.954	rs6009900	ENSG00000278869.1	CITF22-49E9.3	3.98	0.000107	0.0347	0.38	0.31	Schizophrenia;	chr22:49842962	chr22:49933198~49934074:-
PCPG	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	3.98	0.000107	0.0347	0.28	0.31	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
PCPG	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	3.98	0.000107	0.0347	0.3	0.31	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
PCPG	cis	rs6479901	0.841	rs10761720	ENSG00000232075.1	MRPL35P2	-3.98	0.000107	0.0347	-0.37	-0.31	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63634317~63634827:-
PCPG	cis	rs75686122	0.892	rs4734715	ENSG00000253477.4	RP11-1C8.4	3.98	0.000107	0.0347	0.48	0.31	Cocaine dependence;	chr8:103495785	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.772	rs79344235	ENSG00000253477.4	RP11-1C8.4	3.98	0.000107	0.0347	0.48	0.31	Cocaine dependence;	chr8:103497770	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs79580171	ENSG00000253477.4	RP11-1C8.4	3.98	0.000107	0.0347	0.48	0.31	Cocaine dependence;	chr8:103502071	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs2028083	ENSG00000253477.4	RP11-1C8.4	3.98	0.000107	0.0347	0.48	0.31	Cocaine dependence;	chr8:103503566	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.772	rs76370225	ENSG00000253477.4	RP11-1C8.4	3.98	0.000107	0.0347	0.48	0.31	Cocaine dependence;	chr8:103507799	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs80327507	ENSG00000253477.4	RP11-1C8.4	3.98	0.000107	0.0347	0.48	0.31	Cocaine dependence;	chr8:103520826	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs17805990	ENSG00000253477.4	RP11-1C8.4	3.98	0.000107	0.0347	0.48	0.31	Cocaine dependence;	chr8:103521797	chr8:103483398~103501676:-
PCPG	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-3.98	0.000107	0.0348	-0.34	-0.31	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
PCPG	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-3.98	0.000107	0.0348	-0.41	-0.31	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
PCPG	cis	rs896854	0.738	rs527234	ENSG00000272509.1	RP11-347C18.5	-3.98	0.000107	0.0348	-0.29	-0.31	Type 2 diabetes;	chr8:94951570	chr8:94884609~94885070:+
PCPG	cis	rs3758911	0.828	rs10789605	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000107	0.0348	-0.41	-0.31	Coronary artery disease;	chr11:107313859	chr11:107176286~107177530:+
PCPG	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	3.98	0.000107	0.0348	0.54	0.31	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
PCPG	cis	rs7172677	0.768	rs34180494	ENSG00000261543.1	RP11-665J16.1	3.98	0.000107	0.0348	0.38	0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75077671	chr15:74152800~74179226:-
PCPG	cis	rs2243480	0.706	rs6460257	ENSG00000230189.5	GS1-124K5.2	3.98	0.000107	0.0348	0.38	0.31	Diabetic kidney disease;	chr7:65731813	chr7:66409143~66490059:-
PCPG	cis	rs6901152	0.965	rs4896645	ENSG00000217648.1	RP1-95L4.4	-3.98	0.000107	0.0348	-0.37	-0.31	Acute lymphoblastic leukemia (childhood);	chr6:143349242	chr6:143342246~143343383:+
PCPG	cis	rs9840812	0.623	rs4678433	ENSG00000273486.1	RP11-731C17.2	3.98	0.000108	0.0348	0.35	0.31	Fibrinogen levels;	chr3:136546840	chr3:136837338~136839021:-
PCPG	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-3.98	0.000108	0.0348	-0.46	-0.31	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
PCPG	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-3.98	0.000108	0.0348	-0.33	-0.31	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
PCPG	cis	rs8098244	0.565	rs2850205	ENSG00000265752.2	RP11-403A21.1	3.98	0.000108	0.0348	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677531	chr18:23957754~23982556:-
PCPG	cis	rs2625529	0.818	rs2246225	ENSG00000260037.4	CTD-2524L6.3	3.98	0.000108	0.0349	0.44	0.31	Red blood cell count;	chr15:71822889	chr15:71818396~71823384:+
PCPG	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	3.98	0.000108	0.0349	0.41	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
PCPG	cis	rs2275565	0.81	rs17599657	ENSG00000230325.1	RP11-385F5.4	3.98	0.000108	0.0349	0.48	0.31	Homocysteine levels;	chr1:236853776	chr1:236540094~236550280:-
PCPG	cis	rs7824557	0.583	rs4448232	ENSG00000255495.1	AC145124.2	3.98	0.000108	0.0349	0.32	0.31	Retinal vascular caliber;	chr8:11373845	chr8:12194467~12196280:+
PCPG	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	3.98	0.000108	0.0349	0.3	0.31	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
PCPG	cis	rs1488515	0.598	rs7807222	ENSG00000279067.1	GS1-25M2.1	-3.98	0.000108	0.0349	-0.44	-0.31	Obesity-related traits;	chr7:96024666	chr7:96118647~96119995:+
PCPG	cis	rs5769765	0.825	rs7511620	ENSG00000278869.1	CITF22-49E9.3	3.98	0.000108	0.0349	0.43	0.31	Schizophrenia;	chr22:49914284	chr22:49933198~49934074:-
PCPG	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-3.98	0.000108	0.0349	-0.35	-0.31	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
PCPG	cis	rs5769765	1	rs5770728	ENSG00000278869.1	CITF22-49E9.3	-3.98	0.000108	0.0349	-0.38	-0.31	Schizophrenia;	chr22:49866336	chr22:49933198~49934074:-
PCPG	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	3.98	0.000108	0.0349	0.36	0.31	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
PCPG	cis	rs6600671	0.899	rs2319971	ENSG00000227082.1	CH17-437K3.1	-3.98	0.000108	0.0349	-0.38	-0.31	Hip geometry;	chr1:121485184	chr1:121396754~121463129:+
PCPG	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000108	0.0349	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000108	0.0349	0.41	0.31	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000108	0.0349	0.41	0.31	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000108	0.0349	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	3.98	0.000108	0.0349	0.43	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
PCPG	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	3.98	0.000108	0.035	0.41	0.31	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
PCPG	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	3.98	0.000108	0.035	0.41	0.31	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
PCPG	cis	rs4720118	0.66	rs1009355	ENSG00000173862.3	RP11-89N17.1	3.98	0.000108	0.035	0.36	0.31	Leprosy;	chr7:33179151	chr7:33725981~33728456:+
PCPG	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	3.98	0.000108	0.035	0.35	0.31	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
PCPG	cis	rs301161	0.541	rs301158	ENSG00000179219.5	LINC00311	-3.98	0.000108	0.035	-0.43	-0.31	Eosinophil counts;Sum eosinophil basophil counts;	chr16:85775973	chr16:85282958~85285963:+
PCPG	cis	rs3758911	0.929	rs55837508	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000108	0.035	-0.39	-0.31	Coronary artery disease;	chr11:107323756	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10890716	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000108	0.035	-0.39	-0.31	Coronary artery disease;	chr11:107324310	chr11:107176286~107177530:+
PCPG	cis	rs3758911	1	rs10789619	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000108	0.035	-0.39	-0.31	Coronary artery disease;	chr11:107324570	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.964	rs11212157	ENSG00000255353.1	RP11-382M14.1	-3.98	0.000108	0.035	-0.39	-0.31	Coronary artery disease;	chr11:107324572	chr11:107176286~107177530:+
PCPG	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	3.98	0.000108	0.035	0.39	0.31	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
PCPG	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	3.98	0.000108	0.035	0.39	0.31	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
PCPG	cis	rs9614461	0.609	rs9614666	ENSG00000226328.5	NUP50-AS1	3.98	0.000108	0.035	0.46	0.31	Tonsillectomy;	chr22:45433680	chr22:45133020~45163781:-
PCPG	cis	rs10751667	0.58	rs10751664	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:927077	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs7396951	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:927355	chr11:781645~782105:+
PCPG	cis	rs10751667	0.621	rs7394862	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:927500	chr11:781645~782105:+
PCPG	cis	rs10751667	0.666	rs7395182	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:927553	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs6597969	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:928843	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs7479473	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:929111	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs7396407	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:929374	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs11246344	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:933783	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs7394524	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:933865	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs7395613	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:933873	chr11:781645~782105:+
PCPG	cis	rs10751667	0.621	rs11246345	ENSG00000255142.1	AP006621.6	3.98	0.000108	0.035	0.31	0.31	Alzheimer's disease (late onset);	chr11:934924	chr11:781645~782105:+
PCPG	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	3.98	0.000108	0.035	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
PCPG	cis	rs2404602	0.692	rs66866130	ENSG00000259514.1	RP11-685G9.2	-3.98	0.000108	0.035	-0.31	-0.31	Blood metabolite levels;	chr15:76836233	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs35170561	ENSG00000259514.1	RP11-685G9.2	-3.98	0.000108	0.035	-0.31	-0.31	Blood metabolite levels;	chr15:76838354	chr15:76339609~76342063:-
PCPG	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	3.98	0.000108	0.035	0.5	0.31	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
PCPG	cis	rs7707921	1	rs1019806	ENSG00000249483.1	CTD-2249K22.1	3.98	0.000108	0.035	0.41	0.31	Breast cancer;	chr5:82255840	chr5:81851601~81852201:+
PCPG	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	3.98	0.000108	0.035	0.37	0.31	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
PCPG	cis	rs4819052	0.851	rs1006779	ENSG00000223768.1	LINC00205	-3.98	0.000108	0.035	-0.39	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45293285~45297354:+
PCPG	cis	rs2243480	1	rs316322	ENSG00000230189.5	GS1-124K5.2	3.98	0.000108	0.035	0.46	0.31	Diabetic kidney disease;	chr7:66146246	chr7:66409143~66490059:-
PCPG	cis	rs2652834	0.904	rs2729826	ENSG00000259498.1	RP11-244F12.3	3.98	0.000108	0.035	0.46	0.31	HDL cholesterol;	chr15:63068247	chr15:63046034~63049387:-
PCPG	cis	rs17772222	0.917	rs61986671	ENSG00000222990.1	RNU4-22P	3.98	0.000109	0.0351	0.4	0.31	Coronary artery calcification;	chr14:88732917	chr14:88513498~88513663:+
PCPG	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-3.98	0.000109	0.0351	-0.69	-0.31	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-3.98	0.000109	0.0351	-0.69	-0.31	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
PCPG	cis	rs964611	0.938	rs8032357	ENSG00000259488.2	RP11-154J22.1	-3.98	0.000109	0.0351	-0.32	-0.31	Metabolite levels (Pyroglutamine);	chr15:48326622	chr15:48312353~48331856:-
PCPG	cis	rs7208859	0.562	rs216408	ENSG00000263603.1	CTD-2349P21.5	3.98	0.000109	0.0351	0.46	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30729469~30731202:+
PCPG	cis	rs301161	0.573	rs301157	ENSG00000179219.5	LINC00311	-3.98	0.000109	0.0351	-0.42	-0.31	Eosinophil counts;Sum eosinophil basophil counts;	chr16:85774716	chr16:85282958~85285963:+
PCPG	cis	rs6137473	0.65	rs201588	ENSG00000227063.5	RPL41P1	-3.98	0.000109	0.0351	-0.34	-0.31	Adolescent idiopathic scoliosis;	chr20:22050518	chr20:21755270~21755350:+
PCPG	cis	rs9299346	0.536	rs1323427	ENSG00000225376.4	TMEM246-AS1	3.98	0.000109	0.0351	0.47	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101649154	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.536	rs13296742	ENSG00000225376.4	TMEM246-AS1	3.98	0.000109	0.0351	0.47	0.31	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101650752	chr9:101468439~101481502:+
PCPG	cis	rs6714710	0.603	rs34373359	ENSG00000278766.2	AC159540.2	3.98	0.000109	0.0351	0.35	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97825739	chr2:97421075~97434847:+
PCPG	cis	rs6714710	0.557	rs17490429	ENSG00000278766.2	AC159540.2	3.98	0.000109	0.0351	0.35	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97832561	chr2:97421075~97434847:+
PCPG	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	3.98	0.000109	0.0351	0.49	0.31	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	3.98	0.000109	0.0351	0.49	0.31	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
PCPG	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	3.98	0.000109	0.0351	0.49	0.31	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
PCPG	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-3.98	0.000109	0.0352	-0.41	-0.31	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
PCPG	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	3.98	0.000109	0.0352	0.37	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
PCPG	cis	rs6657613	0.815	rs9435672	ENSG00000186715.9	MST1L	-3.98	0.000109	0.0352	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17016164	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.815	rs9435741	ENSG00000186715.9	MST1L	-3.98	0.000109	0.0352	-0.33	-0.31	Hip circumference adjusted for BMI;	chr1:17017409	chr1:16754910~16770237:-
PCPG	cis	rs2002030	0.658	rs11774655	ENSG00000255518.1	RP11-148O21.4	-3.98	0.000109	0.0352	-0.64	-0.31	Cognitive performance;	chr8:11413917	chr8:11556251~11558022:-
PCPG	cis	rs13118159	0.527	rs6599309	ENSG00000254094.1	AC078852.1	-3.98	0.000109	0.0352	-0.39	-0.31	Longevity;	chr4:1394327	chr4:1356581~1358075:+
PCPG	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	3.98	0.000109	0.0352	0.33	0.31	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
PCPG	cis	rs7707921	1	rs79616997	ENSG00000249483.1	CTD-2249K22.1	-3.98	0.000109	0.0352	-0.42	-0.31	Breast cancer;	chr5:82208781	chr5:81851601~81852201:+
PCPG	cis	rs146817970	1	rs146817970	ENSG00000249483.1	CTD-2249K22.1	-3.98	0.000109	0.0352	-0.42	-0.31	Breast cancer;	chr5:82217129	chr5:81851601~81852201:+
PCPG	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	3.98	0.000109	0.0352	0.39	0.31	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
PCPG	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-3.97	0.000109	0.0352	-0.38	-0.31	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
PCPG	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-3.97	0.000109	0.0352	-0.38	-0.31	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
PCPG	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-3.97	0.000109	0.0352	-0.38	-0.31	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
PCPG	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-3.97	0.000109	0.0352	-0.38	-0.31	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
PCPG	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-3.97	0.000109	0.0352	-0.38	-0.31	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
PCPG	cis	rs7118412	1	rs7118412	ENSG00000260966.1	RP11-690D19.3	3.97	0.000109	0.0352	0.32	0.31	Disc degeneration (lumbar);	chr11:103655026	chr11:103050687~103055799:-
PCPG	cis	rs180358	0.509	rs882398	ENSG00000280143.1	AP000892.6	3.97	0.000109	0.0352	0.33	0.31	Multiple sclerosis (severity);	chr11:116703122	chr11:117204967~117210292:+
PCPG	cis	rs2836974	0.932	rs35571600	ENSG00000255568.3	BRWD1-AS2	3.97	0.000109	0.0352	0.32	0.31	Cognitive function;	chr21:39218698	chr21:39313935~39314962:+
PCPG	cis	rs2836974	0.932	rs8129416	ENSG00000255568.3	BRWD1-AS2	3.97	0.000109	0.0352	0.32	0.31	Cognitive function;	chr21:39245219	chr21:39313935~39314962:+
PCPG	cis	rs2836974	0.932	rs2836953	ENSG00000255568.3	BRWD1-AS2	3.97	0.000109	0.0352	0.32	0.31	Cognitive function;	chr21:39245557	chr21:39313935~39314962:+
PCPG	cis	rs2836974	0.899	rs34433511	ENSG00000255568.3	BRWD1-AS2	3.97	0.000109	0.0352	0.32	0.31	Cognitive function;	chr21:39246957	chr21:39313935~39314962:+
PCPG	cis	rs1552244	0.766	rs34232505	ENSG00000180385.7	EMC3-AS1	3.97	0.000109	0.0352	0.4	0.31	Alzheimer's disease;	chr3:10144532	chr3:9986893~10006990:+
PCPG	cis	rs2898290	0.592	rs2736342	ENSG00000154316.13	TDH	-3.97	0.000109	0.0352	-0.39	-0.31	Systolic blood pressure;	chr8:11489780	chr8:11339637~11368452:+
PCPG	cis	rs7937890	0.531	rs2575828	ENSG00000251991.1	RNU7-49P	3.97	0.000109	0.0352	0.36	0.31	Mitochondrial DNA levels;	chr11:14462646	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.559	rs2575829	ENSG00000251991.1	RNU7-49P	3.97	0.000109	0.0352	0.36	0.31	Mitochondrial DNA levels;	chr11:14463475	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.559	rs2597200	ENSG00000251991.1	RNU7-49P	3.97	0.000109	0.0352	0.36	0.31	Mitochondrial DNA levels;	chr11:14464054	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.559	rs2575830	ENSG00000251991.1	RNU7-49P	3.97	0.000109	0.0352	0.36	0.31	Mitochondrial DNA levels;	chr11:14464056	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.559	rs2575831	ENSG00000251991.1	RNU7-49P	3.97	0.000109	0.0352	0.36	0.31	Mitochondrial DNA levels;	chr11:14464648	chr11:14478892~14478953:+
PCPG	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	3.97	0.000109	0.0353	0.43	0.31	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
PCPG	cis	rs12906542	0.58	rs16973688	ENSG00000259792.1	RP11-114H24.6	-3.97	0.000109	0.0353	-0.39	-0.31	Breast cancer;	chr15:77981136	chr15:77993405~77995289:+
PCPG	cis	rs6137473	0.65	rs201590	ENSG00000227063.5	RPL41P1	-3.97	0.000109	0.0353	-0.34	-0.31	Adolescent idiopathic scoliosis;	chr20:22050892	chr20:21755270~21755350:+
PCPG	cis	rs6137473	0.65	rs201593	ENSG00000227063.5	RPL41P1	-3.97	0.000109	0.0353	-0.34	-0.31	Adolescent idiopathic scoliosis;	chr20:22053181	chr20:21755270~21755350:+
PCPG	cis	rs2243480	1	rs160652	ENSG00000251451.1	GS1-124K5.6	3.97	0.000109	0.0353	0.59	0.31	Diabetic kidney disease;	chr7:66073444	chr7:66407288~66409239:-
PCPG	cis	rs227425	1	rs227425	ENSG00000242071.3	RPL7AP6	-3.97	0.000109	0.0353	-0.21	-0.31	Bone mineral density;	chr14:69989982	chr14:69885340~69886140:-
PCPG	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	3.97	0.000109	0.0353	0.42	0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
PCPG	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	3.97	0.000109	0.0353	0.56	0.31	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
PCPG	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	3.97	0.000109	0.0353	0.56	0.31	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
PCPG	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	3.97	0.000109	0.0353	0.29	0.31	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
PCPG	cis	rs916888	0.61	rs199529	ENSG00000262500.1	RP11-259G18.2	3.97	0.000109	0.0353	0.48	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46243606~46245044:+
PCPG	cis	rs11601239	0.621	rs1542162	ENSG00000263371.2	AP000673.1	3.97	0.000109	0.0353	0.35	0.31	Refractive error;	chr11:105645467	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.621	rs7115043	ENSG00000263371.2	AP000673.1	3.97	0.000109	0.0353	0.35	0.31	Refractive error;	chr11:105646737	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.651	rs7129054	ENSG00000263371.2	AP000673.1	3.97	0.000109	0.0353	0.35	0.31	Refractive error;	chr11:105647002	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.621	rs7130156	ENSG00000263371.2	AP000673.1	3.97	0.000109	0.0353	0.35	0.31	Refractive error;	chr11:105647198	chr11:105933951~105934034:+
PCPG	cis	rs2836974	0.829	rs34227163	ENSG00000252915.1	Y_RNA	-3.97	0.000109	0.0353	-0.32	-0.31	Cognitive function;	chr21:39180017	chr21:39344537~39344628:+
PCPG	cis	rs7707921	0.881	rs74906189	ENSG00000249483.1	CTD-2249K22.1	-3.97	0.000109	0.0353	-0.44	-0.31	Breast cancer;	chr5:81966104	chr5:81851601~81852201:+
PCPG	cis	rs2404602	0.655	rs4886507	ENSG00000259422.1	RP11-593F23.1	3.97	0.000109	0.0353	0.37	0.31	Blood metabolite levels;	chr15:76917353	chr15:76174891~76181486:-
PCPG	cis	rs8030379	1	rs1564472	ENSG00000230373.7	GOLGA6L5P	-3.97	0.000109	0.0353	-0.31	-0.31	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901041	chr15:84507885~84516814:-
PCPG	cis	rs11601239	0.621	rs1445599	ENSG00000263371.2	AP000673.1	3.97	0.00011	0.0353	0.35	0.31	Refractive error;	chr11:105644575	chr11:105933951~105934034:+
PCPG	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	3.97	0.00011	0.0353	0.38	0.31	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
PCPG	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	3.97	0.00011	0.0353	0.34	0.31	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
PCPG	cis	rs4824093	0.61	rs28473584	ENSG00000278869.1	CITF22-49E9.3	3.97	0.00011	0.0353	0.73	0.31	Amyotrophic lateral sclerosis (sporadic);	chr22:49921765	chr22:49933198~49934074:-
PCPG	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-3.97	0.00011	0.0353	-0.39	-0.31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
PCPG	cis	rs833911	0.712	rs35485509	ENSG00000268756.1	AC104534.2	-3.97	0.00011	0.0353	-0.3	-0.31	Subjective well-being;	chr19:38034899	chr19:38820166~38823223:+
PCPG	cis	rs8031341	0.639	rs2079769	ENSG00000278514.1	AC068831.16	3.97	0.00011	0.0353	0.49	0.31	Delta-5 desaturase activity;	chr15:90826475	chr15:91022766~91023200:+
PCPG	cis	rs11858159	0.934	rs10873590	ENSG00000260760.1	PWRN3	3.97	0.00011	0.0353	0.31	0.31	Platelet thrombus formation;	chr15:24568470	chr15:24441127~24447967:+
PCPG	cis	rs3758911	0.861	rs11212114	ENSG00000255353.1	RP11-382M14.1	3.97	0.00011	0.0354	0.42	0.31	Coronary artery disease;	chr11:107274940	chr11:107176286~107177530:+
PCPG	cis	rs11098499	0.874	rs13139045	ENSG00000249244.1	RP11-548H18.2	3.97	0.00011	0.0354	0.3	0.31	Corneal astigmatism;	chr4:119247433	chr4:119391831~119395335:-
PCPG	cis	rs559555	0.612	rs585890	ENSG00000272716.1	RP11-563N4.1	3.97	0.00011	0.0354	0.31	0.31	Blood metabolite ratios;Blood metabolite levels;	chr2:31594361	chr2:32165046~32165757:-
PCPG	cis	rs2275565	0.872	rs72762132	ENSG00000230325.1	RP11-385F5.4	3.97	0.00011	0.0354	0.51	0.31	Homocysteine levels;	chr1:236893413	chr1:236540094~236550280:-
PCPG	cis	rs181553	0.961	rs1288812	ENSG00000278983.1	RP11-426J5.3	3.97	0.00011	0.0354	0.35	0.31	Hip circumference adjusted for BMI;	chr18:49041111	chr18:48564795~48568342:+
PCPG	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-3.97	0.00011	0.0354	-0.36	-0.31	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
PCPG	cis	rs240993	0.812	rs9487626	ENSG00000271789.1	RP5-1112D6.7	-3.97	0.00011	0.0354	-0.39	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111297126~111298510:+
PCPG	cis	rs240993	0.715	rs9487627	ENSG00000271789.1	RP5-1112D6.7	-3.97	0.00011	0.0354	-0.39	-0.31	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111297126~111298510:+
PCPG	cis	rs11601239	0.621	rs12575513	ENSG00000263371.2	AP000673.1	3.97	0.00011	0.0354	0.35	0.31	Refractive error;	chr11:105648876	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.621	rs12575516	ENSG00000263371.2	AP000673.1	3.97	0.00011	0.0354	0.35	0.31	Refractive error;	chr11:105648889	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.621	rs12576615	ENSG00000263371.2	AP000673.1	3.97	0.00011	0.0354	0.35	0.31	Refractive error;	chr11:105648952	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.621	rs1942979	ENSG00000263371.2	AP000673.1	3.97	0.00011	0.0354	0.35	0.31	Refractive error;	chr11:105649234	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.621	rs1942978	ENSG00000263371.2	AP000673.1	3.97	0.00011	0.0354	0.35	0.31	Refractive error;	chr11:105649332	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.621	rs1822982	ENSG00000263371.2	AP000673.1	3.97	0.00011	0.0354	0.35	0.31	Refractive error;	chr11:105649414	chr11:105933951~105934034:+
PCPG	cis	rs75686122	1	rs2114249	ENSG00000253477.4	RP11-1C8.4	3.97	0.00011	0.0354	0.47	0.31	Cocaine dependence;	chr8:103707291	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.881	rs116856209	ENSG00000253477.4	RP11-1C8.4	3.97	0.00011	0.0354	0.47	0.31	Cocaine dependence;	chr8:103707733	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs17234965	ENSG00000253477.4	RP11-1C8.4	3.97	0.00011	0.0354	0.47	0.31	Cocaine dependence;	chr8:103716911	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs17234986	ENSG00000253477.4	RP11-1C8.4	3.97	0.00011	0.0354	0.47	0.31	Cocaine dependence;	chr8:103717073	chr8:103483398~103501676:-
PCPG	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-3.97	0.00011	0.0354	-0.34	-0.31	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
PCPG	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-3.97	0.00011	0.0354	-0.34	-0.31	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
PCPG	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	3.97	0.00011	0.0354	0.72	0.31	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
PCPG	cis	rs1003719	1	rs2835607	ENSG00000228677.1	TTC3-AS1	3.97	0.00011	0.0354	0.38	0.31	Eye color traits;	chr21:37119673	chr21:37187666~37193926:-
PCPG	cis	rs9876781	1	rs6784322	ENSG00000229759.1	MRPS18AP1	3.97	0.00011	0.0355	0.38	0.31	Longevity;	chr3:48380745	chr3:48256350~48256938:-
PCPG	cis	rs8098244	0.537	rs11877880	ENSG00000265752.2	RP11-403A21.1	3.97	0.00011	0.0355	0.36	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716401	chr18:23957754~23982556:-
PCPG	cis	rs6137473	0.65	rs201587	ENSG00000227063.5	RPL41P1	-3.97	0.00011	0.0355	-0.34	-0.31	Adolescent idiopathic scoliosis;	chr20:22047036	chr20:21755270~21755350:+
PCPG	cis	rs12681963	0.614	rs7813902	ENSG00000248159.1	HSPA8P11	-3.97	0.00011	0.0355	-0.87	-0.31	Migraine;	chr8:30138740	chr8:30237382~30240997:+
PCPG	cis	rs763121	1	rs138457	ENSG00000273076.1	RP3-508I15.22	-3.97	0.00011	0.0355	-0.31	-0.31	Menopause (age at onset);	chr22:38502046	chr22:38743495~38743910:+
PCPG	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-3.97	0.00011	0.0355	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-3.97	0.00011	0.0355	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
PCPG	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	-3.97	0.00011	0.0355	-0.36	-0.31	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
PCPG	cis	rs875971	0.862	rs11773628	ENSG00000235475.1	LINC01372	-3.97	0.00011	0.0355	-0.32	-0.31	Aortic root size;	chr7:66517644	chr7:67335976~67340024:+
PCPG	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	3.97	0.00011	0.0355	0.35	0.31	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
PCPG	cis	rs300890	0.664	rs7690761	ENSG00000250326.1	RP11-284M14.1	3.97	0.00011	0.0355	0.28	0.31	Nasopharyngeal carcinoma;	chr4:143287609	chr4:142933195~143184861:-
PCPG	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-3.97	0.00011	0.0355	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-3.97	0.00011	0.0355	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-3.97	0.00011	0.0355	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
PCPG	cis	rs34421088	0.532	rs2736388	ENSG00000255020.1	AF131216.5	3.97	0.00011	0.0355	0.4	0.31	Neuroticism;	chr8:11302079	chr8:11345748~11347502:-
PCPG	cis	rs301901	0.772	rs7715883	ENSG00000250155.1	CTD-2353F22.1	-3.97	0.00011	0.0355	-0.36	-0.31	Height;	chr5:37238160	chr5:36666214~36725195:-
PCPG	cis	rs9771228	0.56	rs9639646	ENSG00000205763.12	RP9P	3.97	0.00011	0.0355	0.37	0.31	Cognitive ability;Verbal-numerical reasoning;	chr7:32240631	chr7:32916815~32943176:-
PCPG	cis	rs9771228	0.585	rs73306623	ENSG00000205763.12	RP9P	3.97	0.00011	0.0355	0.37	0.31	Cognitive ability;Verbal-numerical reasoning;	chr7:32241203	chr7:32916815~32943176:-
PCPG	cis	rs9771228	0.56	rs9639648	ENSG00000205763.12	RP9P	3.97	0.00011	0.0355	0.37	0.31	Cognitive ability;Verbal-numerical reasoning;	chr7:32242530	chr7:32916815~32943176:-
PCPG	cis	rs9771228	0.585	rs10263673	ENSG00000205763.12	RP9P	3.97	0.00011	0.0355	0.37	0.31	Cognitive ability;Verbal-numerical reasoning;	chr7:32242907	chr7:32916815~32943176:-
PCPG	cis	rs763014	0.932	rs34498660	ENSG00000262528.2	LA16c-349E10.1	3.97	0.00011	0.0355	0.36	0.31	Height;	chr16:616149	chr16:654611~656194:-
PCPG	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-3.97	0.00011	0.0355	-0.38	-0.31	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
PCPG	cis	rs4819052	0.851	rs2838834	ENSG00000215447.6	BX322557.10	-3.97	0.00011	0.0355	-0.29	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45288052~45291738:+
PCPG	cis	rs1371867	0.846	rs1788182	ENSG00000212994.5	RPS26P6	3.97	0.000111	0.0356	0.35	0.31	Atrioventricular conduction;	chr8:100322392	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1788184	ENSG00000212994.5	RPS26P6	3.97	0.000111	0.0356	0.35	0.31	Atrioventricular conduction;	chr8:100322878	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.839	rs1788186	ENSG00000212994.5	RPS26P6	3.97	0.000111	0.0356	0.35	0.31	Atrioventricular conduction;	chr8:100323458	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1788187	ENSG00000212994.5	RPS26P6	3.97	0.000111	0.0356	0.35	0.31	Atrioventricular conduction;	chr8:100323871	chr8:100895771~100896118:+
PCPG	cis	rs4819052	0.851	rs34101026	ENSG00000215447.6	BX322557.10	-3.97	0.000111	0.0356	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs13052312	ENSG00000215447.6	BX322557.10	-3.97	0.000111	0.0356	-0.31	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45288052~45291738:+
PCPG	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-3.97	0.000111	0.0356	-0.46	-0.31	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
PCPG	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	3.97	0.000111	0.0356	0.33	0.31	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
PCPG	cis	rs75686122	0.772	rs1079944	ENSG00000253477.4	RP11-1C8.4	3.97	0.000111	0.0356	0.47	0.31	Cocaine dependence;	chr8:103542959	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs117436056	ENSG00000253477.4	RP11-1C8.4	3.97	0.000111	0.0356	0.47	0.31	Cocaine dependence;	chr8:103552148	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.772	rs76135007	ENSG00000253477.4	RP11-1C8.4	3.97	0.000111	0.0356	0.47	0.31	Cocaine dependence;	chr8:103558058	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs17806929	ENSG00000253477.4	RP11-1C8.4	3.97	0.000111	0.0356	0.47	0.31	Cocaine dependence;	chr8:103559380	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs79477585	ENSG00000253477.4	RP11-1C8.4	3.97	0.000111	0.0356	0.47	0.31	Cocaine dependence;	chr8:103559505	chr8:103483398~103501676:-
PCPG	cis	rs75686122	1	rs75686122	ENSG00000253477.4	RP11-1C8.4	3.97	0.000111	0.0356	0.47	0.31	Cocaine dependence;	chr8:103561561	chr8:103483398~103501676:-
PCPG	cis	rs939317	0.635	rs843371	ENSG00000272721.4	RP11-778D9.12	-3.97	0.000111	0.0356	-0.47	-0.31	Menarche (age at onset);	chr3:184276748	chr3:184134019~184135238:-
PCPG	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-3.97	0.000111	0.0356	-0.44	-0.31	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
PCPG	cis	rs5769765	0.908	rs9627788	ENSG00000278869.1	CITF22-49E9.3	3.97	0.000111	0.0356	0.37	0.31	Schizophrenia;	chr22:49906790	chr22:49933198~49934074:-
PCPG	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	3.97	0.000111	0.0356	0.45	0.31	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
PCPG	cis	rs12882718	0.874	rs35227986	ENSG00000205562.2	RP11-497E19.1	3.97	0.000111	0.0356	0.37	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr14:86434591	chr14:85524432~85529988:-
PCPG	cis	rs12882718	0.838	rs12891810	ENSG00000205562.2	RP11-497E19.1	3.97	0.000111	0.0356	0.37	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr14:86441064	chr14:85524432~85529988:-
PCPG	cis	rs6137473	0.65	rs28592	ENSG00000227063.5	RPL41P1	-3.97	0.000111	0.0356	-0.34	-0.31	Adolescent idiopathic scoliosis;	chr20:22028003	chr20:21755270~21755350:+
PCPG	cis	rs62246343	0.63	rs3774063	ENSG00000254485.4	RP11-380O24.1	3.97	0.000111	0.0356	0.54	0.31	Fibrinogen levels;	chr3:9470052	chr3:9292588~9363303:-
PCPG	cis	rs62246343	0.63	rs62246320	ENSG00000254485.4	RP11-380O24.1	3.97	0.000111	0.0356	0.54	0.31	Fibrinogen levels;	chr3:9470291	chr3:9292588~9363303:-
PCPG	cis	rs9636231	0.951	rs72879694	ENSG00000234645.3	YWHAEP5	-3.97	0.000111	0.0356	-0.32	-0.31	Alcohol dependence;	chr2:138895009	chr2:138288029~138288793:-
PCPG	cis	rs7911712	0.935	rs1749325	ENSG00000228462.1	RP11-445N18.3	3.97	0.000111	0.0356	0.44	0.31	Emphysema-related traits;	chr10:44805680	chr10:45073146~45073541:-
PCPG	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-3.97	0.000111	0.0356	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
PCPG	cis	rs9472414	0.599	rs2024786	ENSG00000229349.2	ACTG1P9	-3.97	0.000111	0.0356	-0.5	-0.31	Height;	chr6:45350984	chr6:46204729~46207386:+
PCPG	cis	rs7267979	0.966	rs454723	ENSG00000276952.1	RP5-965G21.6	3.97	0.000111	0.0356	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25284915~25285588:-
PCPG	cis	rs7017914	0.644	rs13258800	ENSG00000254031.4	RP11-326E22.1	3.97	0.000111	0.0356	0.29	0.31	Bone mineral density;	chr8:70819867	chr8:71155457~71204223:+
PCPG	cis	rs891378	1	rs2564978	ENSG00000274245.1	RP11-357P18.2	-3.97	0.000111	0.0356	-0.41	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207321071	chr1:207372559~207373252:+
PCPG	cis	rs2836974	0.653	rs8130556	ENSG00000252915.1	Y_RNA	-3.97	0.000111	0.0357	-0.34	-0.31	Cognitive function;	chr21:39144946	chr21:39344537~39344628:+
PCPG	cis	rs3758911	0.861	rs12287772	ENSG00000255353.1	RP11-382M14.1	-3.97	0.000111	0.0357	-0.4	-0.31	Coronary artery disease;	chr11:107271121	chr11:107176286~107177530:+
PCPG	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	3.97	0.000111	0.0357	0.27	0.31	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
PCPG	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	3.97	0.000111	0.0357	0.27	0.31	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	3.97	0.000111	0.0357	0.27	0.31	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
PCPG	cis	rs17684571	0.751	rs13203681	ENSG00000231441.1	RP11-472M19.2	3.97	0.000111	0.0357	0.52	0.31	Schizophrenia;	chr6:56841361	chr6:56844002~56864078:+
PCPG	cis	rs2052670	0.822	rs10200999	ENSG00000232613.5	AC007386.4	3.97	0.000111	0.0357	0.43	0.31	Waist circumference adjusted for body mass index;	chr2:66029047	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.927	rs2699781	ENSG00000232613.5	AC007386.4	3.97	0.000111	0.0357	0.43	0.31	Waist circumference adjusted for body mass index;	chr2:66029162	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.964	rs2627850	ENSG00000232613.5	AC007386.4	3.97	0.000111	0.0357	0.43	0.31	Waist circumference adjusted for body mass index;	chr2:66029585	chr2:65030727~65053017:+
PCPG	cis	rs7864133	0.649	rs11139264	ENSG00000225901.1	MTND2P9	-3.97	0.000111	0.0357	-0.53	-0.31	Post bronchodilator FEV1 in COPD;	chr9:81456305	chr9:80565032~80565962:-
PCPG	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	3.97	0.000111	0.0357	0.36	0.31	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
PCPG	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	3.97	0.000111	0.0357	0.33	0.31	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
PCPG	cis	rs7707921	0.846	rs4293895	ENSG00000249483.1	CTD-2249K22.1	-3.97	0.000111	0.0357	-0.42	-0.31	Breast cancer;	chr5:82129773	chr5:81851601~81852201:+
PCPG	cis	rs28475163	0.958	rs7395116	ENSG00000251661.3	RP11-326C3.11	-3.97	0.000111	0.0357	-0.36	-0.31	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:318640~325631:+
PCPG	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-3.97	0.000111	0.0357	-0.44	-0.31	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
PCPG	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	3.97	0.000111	0.0357	0.3	0.31	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	3.97	0.000111	0.0357	0.3	0.31	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
PCPG	cis	rs2898290	0.622	rs1382567	ENSG00000254774.1	RP11-148O21.3	-3.97	0.000111	0.0357	-0.34	-0.31	Systolic blood pressure;	chr8:11493390	chr8:11553224~11554207:-
PCPG	cis	rs9928842	0.771	rs2870471	ENSG00000280152.1	RP11-331F4.5	-3.97	0.000111	0.0357	-0.46	-0.31	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75245994~75250077:-
PCPG	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	3.97	0.000111	0.0357	0.43	0.31	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
PCPG	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	3.97	0.000111	0.0357	0.43	0.31	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
PCPG	cis	rs2243480	1	rs35820085	ENSG00000251451.1	GS1-124K5.6	3.97	0.000111	0.0358	0.57	0.31	Diabetic kidney disease;	chr7:65977771	chr7:66407288~66409239:-
PCPG	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-3.97	0.000111	0.0358	-0.39	-0.31	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
PCPG	cis	rs5769765	0.955	rs7511159	ENSG00000278869.1	CITF22-49E9.3	3.97	0.000111	0.0358	0.37	0.31	Schizophrenia;	chr22:49914248	chr22:49933198~49934074:-
PCPG	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	3.97	0.000111	0.0358	0.44	0.31	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
PCPG	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	3.97	0.000111	0.0358	0.44	0.31	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
PCPG	cis	rs7172677	0.768	rs72730586	ENSG00000261543.1	RP11-665J16.1	3.97	0.000111	0.0358	0.36	0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75061824	chr15:74152800~74179226:-
PCPG	cis	rs71403859	0.73	rs17355804	ENSG00000279412.1	RP11-394B2.5	3.97	0.000111	0.0358	0.54	0.31	Post bronchodilator FEV1;	chr16:71683311	chr16:70713987~70716890:+
PCPG	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	3.97	0.000111	0.0358	0.44	0.31	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
PCPG	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-3.97	0.000112	0.0358	-0.37	-0.31	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
PCPG	cis	rs8085804	0.571	rs11082290	ENSG00000267586.5	LINC00907	-3.97	0.000112	0.0358	-0.36	-0.31	Cognitive performance;	chr18:42680527	chr18:42159283~42691422:+
PCPG	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	3.97	0.000112	0.0358	0.48	0.31	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
PCPG	cis	rs875971	0.862	rs2909688	ENSG00000235475.1	LINC01372	3.97	0.000112	0.0358	0.32	0.31	Aortic root size;	chr7:66376625	chr7:67335976~67340024:+
PCPG	cis	rs1009077	0.536	rs13116789	ENSG00000245958.5	RP11-33B1.1	3.97	0.000112	0.0358	0.44	0.31	Endometriosis;	chr4:119494057	chr4:119454791~119552025:+
PCPG	cis	rs1009077	0.536	rs13124532	ENSG00000245958.5	RP11-33B1.1	3.97	0.000112	0.0358	0.44	0.31	Endometriosis;	chr4:119495290	chr4:119454791~119552025:+
PCPG	cis	rs6714710	0.603	rs13034929	ENSG00000278766.2	AC159540.2	3.97	0.000112	0.0359	0.35	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786309	chr2:97421075~97434847:+
PCPG	cis	rs896854	0.738	rs1713669	ENSG00000272509.1	RP11-347C18.5	3.97	0.000112	0.0359	0.3	0.31	Type 2 diabetes;	chr8:94946409	chr8:94884609~94885070:+
PCPG	cis	rs801193	0.569	rs881285	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66654433	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs3846973	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66655048	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs2013908	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66656082	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs13242290	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66656898	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.548	rs2109297	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66657397	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs6978178	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66658097	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.591	rs721717	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66665305	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs6951302	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66667525	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.591	rs4506088	ENSG00000235475.1	LINC01372	-3.97	0.000112	0.0359	-0.32	-0.31	Aortic root size;	chr7:66670470	chr7:67335976~67340024:+
PCPG	cis	rs1371867	0.846	rs1788197	ENSG00000212994.5	RPS26P6	3.97	0.000112	0.0359	0.35	0.31	Atrioventricular conduction;	chr8:100278700	chr8:100895771~100896118:+
PCPG	cis	rs8064024	0.676	rs2075467	ENSG00000267077.1	RP11-127I20.5	-3.97	0.000112	0.0359	-0.39	-0.31	Cancer;	chr16:4823241	chr16:4795265~4796532:-
PCPG	cis	rs7707921	0.881	rs324910	ENSG00000249483.1	CTD-2249K22.1	-3.97	0.000112	0.0359	-0.42	-0.31	Breast cancer;	chr5:82104445	chr5:81851601~81852201:+
PCPG	cis	rs7707921	0.881	rs1428940	ENSG00000249483.1	CTD-2249K22.1	-3.97	0.000112	0.0359	-0.42	-0.31	Breast cancer;	chr5:82152176	chr5:81851601~81852201:+
PCPG	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	3.97	0.000112	0.0359	0.36	0.31	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	3.97	0.000112	0.0359	0.36	0.31	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	3.97	0.000112	0.0359	0.36	0.31	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	3.97	0.000112	0.0359	0.36	0.31	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	3.97	0.000112	0.0359	0.36	0.31	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	3.97	0.000112	0.0359	0.36	0.31	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	3.97	0.000112	0.0359	0.36	0.31	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
PCPG	cis	rs9368481	0.547	rs2093303	ENSG00000261584.1	RP11-457M11.5	3.97	0.000112	0.0359	0.34	0.31	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26686241~26687964:+
PCPG	cis	rs901683	1	rs34011467	ENSG00000230869.1	CTGLF10P	-3.97	0.000112	0.0359	-0.74	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45564310	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs12778143	ENSG00000230869.1	CTGLF10P	-3.97	0.000112	0.0359	-0.74	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45568092	chr10:45678692~45700532:+
PCPG	cis	rs901683	1	rs12776336	ENSG00000230869.1	CTGLF10P	-3.97	0.000112	0.0359	-0.74	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45568463	chr10:45678692~45700532:+
PCPG	cis	rs2274273	0.623	rs1187881	ENSG00000258413.1	RP11-665C16.6	3.97	0.000112	0.0359	0.38	0.31	Protein biomarker;	chr14:55022479	chr14:55262767~55272075:-
PCPG	cis	rs3947	0.95	rs1692811	ENSG00000255556.2	RP11-351I21.6	-3.97	0.000112	0.0359	-0.4	-0.31	Blood protein levels;	chr8:11845539	chr8:12378679~12380265:-
PCPG	cis	rs6714710	0.603	rs11679828	ENSG00000278766.2	AC159540.2	3.97	0.000112	0.0359	0.34	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97901163	chr2:97421075~97434847:+
PCPG	cis	rs6714710	0.58	rs11692470	ENSG00000278766.2	AC159540.2	3.97	0.000112	0.0359	0.34	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97904101	chr2:97421075~97434847:+
PCPG	cis	rs6445967	0.53	rs12634132	ENSG00000273493.1	RP11-80H18.4	-3.97	0.000112	0.0359	-0.34	-0.31	Platelet count;	chr3:58423355	chr3:58329965~58330118:+
PCPG	cis	rs6445967	0.53	rs12486031	ENSG00000273493.1	RP11-80H18.4	-3.97	0.000112	0.0359	-0.34	-0.31	Platelet count;	chr3:58423952	chr3:58329965~58330118:+
PCPG	cis	rs6445967	0.53	rs12492472	ENSG00000273493.1	RP11-80H18.4	-3.97	0.000112	0.0359	-0.34	-0.31	Platelet count;	chr3:58424245	chr3:58329965~58330118:+
PCPG	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-3.97	0.000112	0.0359	-0.41	-0.31	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
PCPG	cis	rs7819412	0.545	rs11781155	ENSG00000255020.1	AF131216.5	-3.97	0.000112	0.036	-0.41	-0.31	Triglycerides;	chr8:11060050	chr8:11345748~11347502:-
PCPG	cis	rs7246657	0.654	rs10407568	ENSG00000226686.6	LINC01535	-3.97	0.000112	0.036	-0.46	-0.31	Coronary artery calcification;	chr19:37632108	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs10409605	ENSG00000226686.6	LINC01535	-3.97	0.000112	0.036	-0.46	-0.31	Coronary artery calcification;	chr19:37632236	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs16958861	ENSG00000226686.6	LINC01535	-3.97	0.000112	0.036	-0.46	-0.31	Coronary artery calcification;	chr19:37633278	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs16958863	ENSG00000226686.6	LINC01535	-3.97	0.000112	0.036	-0.46	-0.31	Coronary artery calcification;	chr19:37633334	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs2972447	ENSG00000226686.6	LINC01535	3.97	0.000112	0.036	0.46	0.31	Coronary artery calcification;	chr19:37638835	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.678	rs2972446	ENSG00000226686.6	LINC01535	3.97	0.000112	0.036	0.46	0.31	Coronary artery calcification;	chr19:37638992	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs2972458	ENSG00000226686.6	LINC01535	3.97	0.000112	0.036	0.46	0.31	Coronary artery calcification;	chr19:37644502	chr19:37251912~37265535:+
PCPG	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	3.97	0.000112	0.036	0.38	0.31	Height;	chr6:109358227	chr6:109382795~109383666:+
PCPG	cis	rs6585424	1	rs34100029	ENSG00000242600.5	MBL1P	3.97	0.000112	0.036	0.59	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163842	chr10:79904898~79950336:+
PCPG	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	3.97	0.000112	0.036	0.31	0.31	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	3.97	0.000112	0.036	0.31	0.31	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	3.97	0.000112	0.036	0.31	0.31	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
PCPG	cis	rs888194	0.738	rs1075467	ENSG00000278993.1	RP3-424M6.4	-3.97	0.000112	0.036	-0.31	-0.31	Neuroticism;	chr12:109549130	chr12:110501614~110503441:+
PCPG	cis	rs888194	0.69	rs11067231	ENSG00000278993.1	RP3-424M6.4	-3.97	0.000112	0.036	-0.31	-0.31	Neuroticism;	chr12:109555798	chr12:110501614~110503441:+
PCPG	cis	rs888194	0.69	rs9593	ENSG00000278993.1	RP3-424M6.4	-3.97	0.000112	0.036	-0.31	-0.31	Neuroticism;	chr12:109557065	chr12:110501614~110503441:+
PCPG	cis	rs888194	0.69	rs888192	ENSG00000278993.1	RP3-424M6.4	3.97	0.000112	0.036	0.31	0.31	Neuroticism;	chr12:109557292	chr12:110501614~110503441:+
PCPG	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-3.97	0.000112	0.036	-0.36	-0.31	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
PCPG	cis	rs2734839	0.537	rs10891549	ENSG00000256757.1	RP11-159N11.3	3.97	0.000112	0.036	0.32	0.31	Information processing speed;	chr11:113407725	chr11:113405321~113412117:+
PCPG	cis	rs1371867	0.846	rs1660330	ENSG00000212994.5	RPS26P6	3.97	0.000112	0.036	0.36	0.31	Atrioventricular conduction;	chr8:100292787	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1788205	ENSG00000212994.5	RPS26P6	3.97	0.000112	0.036	0.36	0.31	Atrioventricular conduction;	chr8:100294318	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1788206	ENSG00000212994.5	RPS26P6	3.97	0.000112	0.036	0.36	0.31	Atrioventricular conduction;	chr8:100294738	chr8:100895771~100896118:+
PCPG	cis	rs6003958	1	rs6003958	ENSG00000231271.1	AP000350.8	-3.97	0.000112	0.036	-0.43	-0.31	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23949918~23954042:+
PCPG	cis	rs5760092	0.755	rs6003959	ENSG00000231271.1	AP000350.8	-3.97	0.000112	0.036	-0.43	-0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23949918~23954042:+
PCPG	cis	rs7759001	0.857	rs9468101	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27385159	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs2393931	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27385335	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs2393932	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27385418	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs2143061	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27385926	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs1534936	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27386416	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs1534937	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27386556	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6912091	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27387073	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6934933	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27387083	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs6934985	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27387164	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6935116	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27387170	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs6935118	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27387179	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs9468111	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27387304	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs6913122	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27387513	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.817	rs2206250	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27388063	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs2223463	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27388414	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs2223464	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27388437	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs12195788	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27388627	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10807020	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27389123	chr6:27404010~27406964:-
PCPG	cis	rs7759001	0.857	rs10807021	ENSG00000271755.1	RP1-153G14.4	3.97	0.000113	0.0361	0.47	0.31	Glomerular filtration rate (creatinine);	chr6:27389146	chr6:27404010~27406964:-
PCPG	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-3.97	0.000113	0.0361	-0.37	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
PCPG	cis	rs10200159	0.744	rs7586124	ENSG00000272606.1	RP11-554J4.1	3.97	0.000113	0.0361	0.57	0.31	Vitiligo;	chr2:55558165	chr2:55617909~55618373:+
PCPG	cis	rs9876781	1	rs2242150	ENSG00000229759.1	MRPS18AP1	-3.97	0.000113	0.0361	-0.36	-0.31	Longevity;	chr3:48464565	chr3:48256350~48256938:-
PCPG	cis	rs301901	0.698	rs4869505	ENSG00000250155.1	CTD-2353F22.1	3.97	0.000113	0.0361	0.35	0.31	Height;	chr5:37425888	chr5:36666214~36725195:-
PCPG	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	3.97	0.000113	0.0361	0.49	0.31	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
PCPG	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-3.97	0.000113	0.0361	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
PCPG	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	-3.97	0.000113	0.0361	-0.35	-0.31	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
PCPG	cis	rs6981523	0.517	rs13251510	ENSG00000255020.1	AF131216.5	-3.97	0.000113	0.0361	-0.4	-0.31	Neuroticism;	chr8:11059464	chr8:11345748~11347502:-
PCPG	cis	rs12188164	0.762	rs11745923	ENSG00000221990.4	EXOC3-AS1	3.97	0.000113	0.0361	0.27	0.31	Cystic fibrosis severity;	chr5:475293	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	3.97	0.000113	0.0361	0.27	0.31	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
PCPG	cis	rs17684571	0.7	rs4299824	ENSG00000231441.1	RP11-472M19.2	3.97	0.000113	0.0361	0.51	0.31	Schizophrenia;	chr6:56815697	chr6:56844002~56864078:+
PCPG	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	3.97	0.000113	0.0361	0.41	0.31	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
PCPG	cis	rs7246657	0.722	rs3101746	ENSG00000226686.6	LINC01535	3.97	0.000113	0.0361	0.46	0.31	Coronary artery calcification;	chr19:37655499	chr19:37251912~37265535:+
PCPG	cis	rs13276960	0.868	rs7015831	ENSG00000254281.1	KB-1507C5.4	3.97	0.000113	0.0361	0.39	0.31	Schizophrenia;	chr8:102922054	chr8:102978785~103000184:+
PCPG	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	3.97	0.000113	0.0361	0.38	0.31	Height;	chr6:109370985	chr6:109382795~109383666:+
PCPG	cis	rs1150668	0.799	rs2142730	ENSG00000176933.5	TOB2P1	-3.97	0.000113	0.0361	-0.34	-0.31	Pubertal anthropometrics;	chr6:28298372	chr6:28217643~28218634:-
PCPG	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	3.97	0.000113	0.0361	0.72	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
PCPG	cis	rs6464929	0.91	rs12534095	ENSG00000281189.1	GHET1	3.97	0.000113	0.0361	0.39	0.31	Pediatric bone mineral content (hip);	chr7:149023613	chr7:148987527~148989432:+
PCPG	cis	rs10865541	0.869	rs6711292	ENSG00000225234.1	TRAPPC12-AS1	-3.97	0.000113	0.0361	-0.3	-0.31	Obesity-related traits;	chr2:3418399	chr2:3481242~3482409:-
PCPG	cis	rs12444795	0.855	rs12445265	ENSG00000267077.1	RP11-127I20.5	3.97	0.000113	0.0362	0.61	0.31	Cancer;	chr16:4874159	chr16:4795265~4796532:-
PCPG	cis	rs2052670	0.964	rs1026955	ENSG00000232613.5	AC007386.4	-3.97	0.000113	0.0362	-0.43	-0.31	Waist circumference adjusted for body mass index;	chr2:66020426	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.964	rs2627853	ENSG00000232613.5	AC007386.4	3.97	0.000113	0.0362	0.43	0.31	Waist circumference adjusted for body mass index;	chr2:66023475	chr2:65030727~65053017:+
PCPG	cis	rs12188164	0.62	rs56070387	ENSG00000188242.4	PP7080	3.97	0.000113	0.0362	0.31	0.31	Cystic fibrosis severity;	chr5:482416	chr5:466124~473098:-
PCPG	cis	rs2554380	0.6	rs6602986	ENSG00000230373.7	GOLGA6L5P	-3.97	0.000113	0.0362	-0.35	-0.31	Height;	chr15:83778347	chr15:84507885~84516814:-
PCPG	cis	rs7824557	0.524	rs7835318	ENSG00000269954.1	RP11-148O21.6	-3.96	0.000113	0.0363	-0.39	-0.31	Retinal vascular caliber;	chr8:11096364	chr8:11552488~11552991:-
PCPG	cis	rs1371867	0.641	rs1788209	ENSG00000212994.5	RPS26P6	3.96	0.000113	0.0363	0.35	0.31	Atrioventricular conduction;	chr8:100324828	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1660319	ENSG00000212994.5	RPS26P6	3.96	0.000113	0.0363	0.35	0.31	Atrioventricular conduction;	chr8:100325302	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1660320	ENSG00000212994.5	RPS26P6	3.96	0.000113	0.0363	0.35	0.31	Atrioventricular conduction;	chr8:100325351	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs1612773	ENSG00000212994.5	RPS26P6	3.96	0.000113	0.0363	0.35	0.31	Atrioventricular conduction;	chr8:100325590	chr8:100895771~100896118:+
PCPG	cis	rs7772486	0.713	rs2328704	ENSG00000270638.1	RP3-466P17.1	-3.96	0.000113	0.0363	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145735570~145737218:+
PCPG	cis	rs1440410	0.597	rs4690766	ENSG00000250326.1	RP11-284M14.1	3.96	0.000113	0.0363	0.27	0.31	Ischemic stroke;	chr4:143108887	chr4:142933195~143184861:-
PCPG	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
PCPG	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
PCPG	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	3.96	0.000113	0.0363	0.42	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
PCPG	cis	rs16856186	0.52	rs34439790	ENSG00000271580.1	RP11-536L3.4	-3.96	0.000113	0.0363	-0.52	-0.31	Pulmonary function decline;	chr1:205849051	chr1:205091163~205091946:+
PCPG	cis	rs5769765	1	rs5769760	ENSG00000278869.1	CITF22-49E9.3	-3.96	0.000114	0.0363	-0.37	-0.31	Schizophrenia;	chr22:49866048	chr22:49933198~49934074:-
PCPG	cis	rs9311676	0.693	rs11714515	ENSG00000273493.1	RP11-80H18.4	3.96	0.000114	0.0363	0.33	0.31	Systemic lupus erythematosus;	chr3:58424704	chr3:58329965~58330118:+
PCPG	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	3.96	0.000114	0.0363	0.4	0.31	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
PCPG	cis	rs698813	0.637	rs4952706	ENSG00000236502.1	SIX3-AS1	3.96	0.000114	0.0363	0.4	0.31	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44273397	chr2:44940154~44941873:-
PCPG	cis	rs698813	0.674	rs4953080	ENSG00000236502.1	SIX3-AS1	3.96	0.000114	0.0363	0.4	0.31	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44273710	chr2:44940154~44941873:-
PCPG	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	3.96	0.000114	0.0363	0.4	0.31	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
PCPG	cis	rs12191082	0.878	rs2021916	ENSG00000270761.1	RP11-385F7.1	3.96	0.000114	0.0364	0.42	0.31	Mean platelet volume;	chr6:46946784	chr6:47477243~47477572:-
PCPG	cis	rs901683	0.572	rs17157859	ENSG00000230869.1	CTGLF10P	-3.96	0.000114	0.0364	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45493961	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs17157861	ENSG00000230869.1	CTGLF10P	-3.96	0.000114	0.0364	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45495477	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs77364880	ENSG00000230869.1	CTGLF10P	-3.96	0.000114	0.0364	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45500652	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs80222863	ENSG00000230869.1	CTGLF10P	-3.96	0.000114	0.0364	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45521527	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs17157890	ENSG00000230869.1	CTGLF10P	-3.96	0.000114	0.0364	-0.84	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45525204	chr10:45678692~45700532:+
PCPG	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	3.96	0.000114	0.0364	0.4	0.31	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
PCPG	cis	rs801193	0.967	rs3800823	ENSG00000273142.1	RP11-458F8.4	3.96	0.000114	0.0364	0.29	0.31	Aortic root size;	chr7:66682123	chr7:66902857~66906297:+
PCPG	cis	rs4835473	0.932	rs1849135	ENSG00000251600.4	RP11-673E1.1	-3.96	0.000114	0.0364	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143912279	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs1849136	ENSG00000251600.4	RP11-673E1.1	-3.96	0.000114	0.0364	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143912380	chr4:143912331~143982454:+
PCPG	cis	rs8024893	0.764	rs7182721	ENSG00000270055.1	CTD-3092A11.2	3.96	0.000114	0.0364	0.58	0.31	Red cell distribution width;	chr15:31239730	chr15:30487963~30490313:+
PCPG	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-3.96	0.000114	0.0364	-0.34	-0.31	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
PCPG	cis	rs9311676	0.609	rs6767498	ENSG00000273493.1	RP11-80H18.4	3.96	0.000114	0.0364	0.32	0.31	Systemic lupus erythematosus;	chr3:58423399	chr3:58329965~58330118:+
PCPG	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	3.96	0.000114	0.0364	0.37	0.31	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
PCPG	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	3.96	0.000114	0.0364	0.49	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
PCPG	cis	rs16949788	1	rs11071894	ENSG00000261351.2	CTD-3185P2.1	3.96	0.000114	0.0364	0.44	0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66481395	chr15:66488658~66492109:-
PCPG	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-3.96	0.000114	0.0364	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
PCPG	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-3.96	0.000114	0.0364	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
PCPG	cis	rs6570726	0.846	rs870491	ENSG00000270638.1	RP3-466P17.1	3.96	0.000114	0.0364	0.33	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145735570~145737218:+
PCPG	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	3.96	0.000114	0.0364	0.36	0.31	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
PCPG	cis	rs7546	0.501	rs12102426	ENSG00000267077.1	RP11-127I20.5	3.96	0.000114	0.0364	0.37	0.31	Cancer;	chr16:4872449	chr16:4795265~4796532:-
PCPG	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	3.96	0.000114	0.0364	0.32	0.31	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
PCPG	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	3.96	0.000114	0.0364	0.4	0.31	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	3.96	0.000114	0.0364	0.4	0.31	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
PCPG	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	3.96	0.000114	0.0364	0.4	0.31	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
PCPG	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-3.96	0.000114	0.0365	-0.35	-0.31	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
PCPG	cis	rs7246657	0.722	rs10402671	ENSG00000226686.6	LINC01535	-3.96	0.000114	0.0365	-0.46	-0.31	Coronary artery calcification;	chr19:37626185	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs10417576	ENSG00000226686.6	LINC01535	-3.96	0.000114	0.0365	-0.46	-0.31	Coronary artery calcification;	chr19:37628311	chr19:37251912~37265535:+
PCPG	cis	rs12681963	0.623	rs2340418	ENSG00000248159.1	HSPA8P11	-3.96	0.000114	0.0365	-0.5	-0.31	Migraine;	chr8:30040190	chr8:30237382~30240997:+
PCPG	cis	rs10865541	0.902	rs7558487	ENSG00000225234.1	TRAPPC12-AS1	-3.96	0.000114	0.0365	-0.3	-0.31	Obesity-related traits;	chr2:3421743	chr2:3481242~3482409:-
PCPG	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-3.96	0.000114	0.0365	-0.38	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
PCPG	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000114	0.0365	-0.41	-0.31	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
PCPG	cis	rs6579956	0.565	rs13167390	ENSG00000254226.4	CTB-12O2.1	3.96	0.000114	0.0365	0.4	0.31	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152803008	chr5:151949571~152270448:+
PCPG	cis	rs4295623	0.585	rs13259242	ENSG00000255020.1	AF131216.5	-3.96	0.000114	0.0365	-0.43	-0.31	Morning vs. evening chronotype;	chr8:11735524	chr8:11345748~11347502:-
PCPG	cis	rs2404602	0.692	rs7163397	ENSG00000259514.1	RP11-685G9.2	-3.96	0.000115	0.0365	-0.31	-0.31	Blood metabolite levels;	chr15:76647974	chr15:76339609~76342063:-
PCPG	cis	rs950169	0.922	rs11635505	ENSG00000235370.6	DNM1P51	-3.96	0.000115	0.0365	-0.31	-0.31	Schizophrenia;	chr15:84553803	chr15:84398316~84411701:-
PCPG	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-3.96	0.000115	0.0366	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
PCPG	cis	rs2243480	1	rs465359	ENSG00000230189.5	GS1-124K5.2	3.96	0.000115	0.0366	0.45	0.31	Diabetic kidney disease;	chr7:66093177	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs462853	ENSG00000230189.5	GS1-124K5.2	3.96	0.000115	0.0366	0.45	0.31	Diabetic kidney disease;	chr7:66093180	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs160644	ENSG00000230189.5	GS1-124K5.2	3.96	0.000115	0.0366	0.45	0.31	Diabetic kidney disease;	chr7:66093199	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs160642	ENSG00000230189.5	GS1-124K5.2	3.96	0.000115	0.0366	0.45	0.31	Diabetic kidney disease;	chr7:66093386	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.614	rs34032527	ENSG00000230189.5	GS1-124K5.2	3.96	0.000115	0.0366	0.45	0.31	Diabetic kidney disease;	chr7:66100154	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1499614	ENSG00000230189.5	GS1-124K5.2	3.96	0.000115	0.0366	0.45	0.31	Diabetic kidney disease;	chr7:66265811	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1392104	ENSG00000230189.5	GS1-124K5.2	-3.96	0.000115	0.0366	-0.45	-0.31	Diabetic kidney disease;	chr7:66294120	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs4718333	ENSG00000230189.5	GS1-124K5.2	-3.96	0.000115	0.0366	-0.45	-0.31	Diabetic kidney disease;	chr7:66307771	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs7792391	ENSG00000230189.5	GS1-124K5.2	-3.96	0.000115	0.0366	-0.45	-0.31	Diabetic kidney disease;	chr7:66308442	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs10247526	ENSG00000230189.5	GS1-124K5.2	-3.96	0.000115	0.0366	-0.45	-0.31	Diabetic kidney disease;	chr7:66315709	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs4718334	ENSG00000230189.5	GS1-124K5.2	-3.96	0.000115	0.0366	-0.45	-0.31	Diabetic kidney disease;	chr7:66324467	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.908	rs1532573	ENSG00000230189.5	GS1-124K5.2	-3.96	0.000115	0.0366	-0.45	-0.31	Diabetic kidney disease;	chr7:66333815	chr7:66409143~66490059:-
PCPG	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	3.96	0.000115	0.0366	0.31	0.31	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	3.96	0.000115	0.0366	0.31	0.31	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
PCPG	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	3.96	0.000115	0.0366	0.37	0.31	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	3.96	0.000115	0.0366	0.37	0.31	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	3.96	0.000115	0.0366	0.37	0.31	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	3.96	0.000115	0.0366	0.37	0.31	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
PCPG	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	3.96	0.000115	0.0366	0.41	0.31	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	3.96	0.000115	0.0366	0.41	0.31	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	3.96	0.000115	0.0366	0.41	0.31	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	3.96	0.000115	0.0366	0.41	0.31	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
PCPG	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	3.96	0.000115	0.0366	0.37	0.31	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
PCPG	cis	rs1862618	0.853	rs1423620	ENSG00000271828.1	CTD-2310F14.1	3.96	0.000115	0.0366	0.49	0.31	Initial pursuit acceleration;	chr5:56805169	chr5:56927874~56929573:+
PCPG	cis	rs9393813	0.528	rs6903282	ENSG00000271755.1	RP1-153G14.4	3.96	0.000115	0.0366	0.39	0.31	Bipolar disorder;	chr6:27498933	chr6:27404010~27406964:-
PCPG	cis	rs7772486	0.754	rs9399567	ENSG00000270638.1	RP3-466P17.1	3.96	0.000115	0.0366	0.33	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145735570~145737218:+
PCPG	cis	rs6464929	0.956	rs28463009	ENSG00000281189.1	GHET1	3.96	0.000115	0.0366	0.41	0.31	Pediatric bone mineral content (hip);	chr7:149011111	chr7:148987527~148989432:+
PCPG	cis	rs9880211	1	rs9869630	ENSG00000273486.1	RP11-731C17.2	3.96	0.000115	0.0366	0.4	0.31	Height;Body mass index;	chr3:136529177	chr3:136837338~136839021:-
PCPG	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	3.96	0.000115	0.0366	0.6	0.31	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
PCPG	cis	rs4845875	0.514	rs198393	ENSG00000242349.4	NPPA-AS1	-3.96	0.000115	0.0366	-0.28	-0.31	Midregional pro atrial natriuretic peptide levels;	chr1:11819628	chr1:11841017~11848079:+
PCPG	cis	rs7227917	0.536	rs72916027	ENSG00000269365.2	RP11-380M21.4	3.96	0.000115	0.0366	0.62	0.31	Lung cancer in ever smokers;	chr18:47987082	chr18:47878295~47882444:+
PCPG	cis	rs8098244	0.557	rs11662720	ENSG00000265752.2	RP11-403A21.1	-3.96	0.000115	0.0366	-0.35	-0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722127	chr18:23957754~23982556:-
PCPG	cis	rs2733954	0.887	rs8587	ENSG00000179219.5	LINC00311	-3.96	0.000115	0.0366	-0.42	-0.31	Leprosy;	chr16:85779625	chr16:85282958~85285963:+
PCPG	cis	rs2404602	0.669	rs12148877	ENSG00000259514.1	RP11-685G9.2	-3.96	0.000115	0.0366	-0.31	-0.31	Blood metabolite levels;	chr15:76627618	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs12902452	ENSG00000259514.1	RP11-685G9.2	-3.96	0.000115	0.0366	-0.31	-0.31	Blood metabolite levels;	chr15:76629124	chr15:76339609~76342063:-
PCPG	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	3.96	0.000115	0.0366	0.41	0.31	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	3.96	0.000115	0.0367	0.3	0.31	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
PCPG	cis	rs12906542	0.58	rs62008650	ENSG00000259792.1	RP11-114H24.6	-3.96	0.000115	0.0367	-0.39	-0.31	Breast cancer;	chr15:77981947	chr15:77993405~77995289:+
PCPG	cis	rs9472414	0.66	rs10948230	ENSG00000229349.2	ACTG1P9	-3.96	0.000115	0.0367	-0.5	-0.31	Height;	chr6:45340709	chr6:46204729~46207386:+
PCPG	cis	rs3947	0.687	rs1736065	ENSG00000227888.4	FAM66A	-3.96	0.000115	0.0367	-0.38	-0.31	Blood protein levels;	chr8:11827944	chr8:12362019~12388296:+
PCPG	cis	rs17772222	0.876	rs61986665	ENSG00000222990.1	RNU4-22P	3.96	0.000115	0.0367	0.4	0.31	Coronary artery calcification;	chr14:88711354	chr14:88513498~88513663:+
PCPG	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000115	0.0367	0.31	0.31	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
PCPG	cis	rs2898290	0.622	rs978803	ENSG00000254774.1	RP11-148O21.3	3.96	0.000115	0.0367	0.33	0.31	Systolic blood pressure;	chr8:11485966	chr8:11553224~11554207:-
PCPG	cis	rs3758911	0.861	rs11212116	ENSG00000255353.1	RP11-382M14.1	-3.96	0.000115	0.0367	-0.4	-0.31	Coronary artery disease;	chr11:107276621	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs10890692	ENSG00000255353.1	RP11-382M14.1	-3.96	0.000115	0.0367	-0.4	-0.31	Coronary artery disease;	chr11:107277053	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs10749890	ENSG00000255353.1	RP11-382M14.1	-3.96	0.000115	0.0367	-0.4	-0.31	Coronary artery disease;	chr11:107278357	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs10454489	ENSG00000255353.1	RP11-382M14.1	-3.96	0.000115	0.0367	-0.4	-0.31	Coronary artery disease;	chr11:107279206	chr11:107176286~107177530:+
PCPG	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	3.96	0.000115	0.0367	0.3	0.31	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
PCPG	cis	rs9472414	0.654	rs1852985	ENSG00000229349.2	ACTG1P9	-3.96	0.000115	0.0367	-0.5	-0.31	Height;	chr6:45361919	chr6:46204729~46207386:+
PCPG	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-3.96	0.000115	0.0367	-0.48	-0.31	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
PCPG	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-3.96	0.000115	0.0367	-0.48	-0.31	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
PCPG	cis	rs2735413	0.599	rs77209133	ENSG00000276007.1	RP11-358L22.3	3.96	0.000115	0.0367	0.32	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78042827	chr16:78123243~78124332:+
PCPG	cis	rs2735413	0.599	rs79414963	ENSG00000276007.1	RP11-358L22.3	3.96	0.000115	0.0367	0.32	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78043132	chr16:78123243~78124332:+
PCPG	cis	rs7819412	0.505	rs67849263	ENSG00000255020.1	AF131216.5	-3.96	0.000115	0.0367	-0.44	-0.31	Triglycerides;	chr8:11150034	chr8:11345748~11347502:-
PCPG	cis	rs16949788	1	rs74521803	ENSG00000261351.2	CTD-3185P2.1	-3.96	0.000115	0.0367	-0.44	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66539923	chr15:66488658~66492109:-
PCPG	cis	rs16949788	1	rs75532475	ENSG00000261351.2	CTD-3185P2.1	-3.96	0.000115	0.0367	-0.44	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66540128	chr15:66488658~66492109:-
PCPG	cis	rs75686122	0.772	rs79360484	ENSG00000253477.4	RP11-1C8.4	3.96	0.000115	0.0367	0.47	0.31	Cocaine dependence;	chr8:103479421	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs12679095	ENSG00000253477.4	RP11-1C8.4	3.96	0.000115	0.0367	0.47	0.31	Cocaine dependence;	chr8:103487366	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs12677819	ENSG00000253477.4	RP11-1C8.4	3.96	0.000115	0.0367	0.47	0.31	Cocaine dependence;	chr8:103490492	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs77737965	ENSG00000253477.4	RP11-1C8.4	3.96	0.000115	0.0367	0.47	0.31	Cocaine dependence;	chr8:103494228	chr8:103483398~103501676:-
PCPG	cis	rs2436845	0.651	rs2513911	ENSG00000253320.4	KB-1507C5.2	-3.96	0.000115	0.0367	-0.42	-0.31	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102805637	chr8:102864300~102977876:+
PCPG	cis	rs6854137	0.553	rs7654189	ENSG00000279384.1	RP11-635L1.2	3.96	0.000115	0.0367	0.32	0.31	Vein graft stenosis in coronary artery bypass grafting;	chr4:168805262	chr4:168843988~168844735:+
PCPG	cis	rs42648	0.935	rs2188232	ENSG00000225498.1	AC002064.5	3.96	0.000115	0.0368	0.36	0.31	Homocysteine levels;	chr7:90329000	chr7:90312496~90322592:+
PCPG	cis	rs42648	0.935	rs2188233	ENSG00000225498.1	AC002064.5	3.96	0.000115	0.0368	0.36	0.31	Homocysteine levels;	chr7:90329001	chr7:90312496~90322592:+
PCPG	cis	rs2075277	1	rs2075279	ENSG00000206145.7	P2RX6P	3.96	0.000115	0.0368	0.54	0.31	Eosinophilic esophagitis;	chr22:21029023	chr22:21035243~21045017:-
PCPG	cis	rs7829975	0.591	rs12677543	ENSG00000173295.6	FAM86B3P	-3.96	0.000115	0.0368	-0.36	-0.31	Mood instability;	chr8:8786764	chr8:8228595~8244865:+
PCPG	cis	rs6456042	1	rs3127416	ENSG00000231297.3	RP11-459F1.2	3.96	0.000115	0.0368	0.34	0.31	Asthma;	chr6:166123924	chr6:166099665~166113273:+
PCPG	cis	rs2404602	0.669	rs8036703	ENSG00000259514.1	RP11-685G9.2	-3.96	0.000115	0.0368	-0.31	-0.31	Blood metabolite levels;	chr15:76658699	chr15:76339609~76342063:-
PCPG	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	3.96	0.000115	0.0368	0.44	0.31	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	3.96	0.000115	0.0368	0.44	0.31	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
PCPG	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	3.96	0.000115	0.0368	0.44	0.31	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
PCPG	cis	rs12681963	0.688	rs55810013	ENSG00000272375.1	RP11-51J9.6	3.96	0.000115	0.0368	0.41	0.31	Migraine;	chr8:30181507	chr8:30197404~30198048:+
PCPG	cis	rs4143844	0.867	rs978141	ENSG00000259251.2	RP11-643M14.1	3.96	0.000115	0.0368	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61974584	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs34646089	ENSG00000259251.2	RP11-643M14.1	3.96	0.000115	0.0368	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61978298	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs11631273	ENSG00000259251.2	RP11-643M14.1	3.96	0.000115	0.0368	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61985871	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs34257602	ENSG00000259251.2	RP11-643M14.1	3.96	0.000115	0.0368	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61993548	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs62006964	ENSG00000259251.2	RP11-643M14.1	3.96	0.000115	0.0368	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61995424	chr15:62060503~62062434:+
PCPG	cis	rs11148252	0.683	rs9536006	ENSG00000198384.8	TPTE2P3	-3.96	0.000115	0.0368	-0.37	-0.31	Lewy body disease;	chr13:52313572	chr13:52522632~52586906:+
PCPG	cis	rs720475	0.732	rs17195725	ENSG00000170356.8	OR2A20P	-3.96	0.000115	0.0368	-0.45	-0.31	Breast cancer;	chr7:144440044	chr7:144250045~144252957:-
PCPG	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000115	0.0368	-0.39	-0.31	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000115	0.0368	-0.39	-0.31	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000115	0.0368	-0.39	-0.31	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000115	0.0368	-0.39	-0.31	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000115	0.0368	-0.39	-0.31	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000115	0.0368	-0.39	-0.31	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
PCPG	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000115	0.0368	-0.39	-0.31	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
PCPG	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	3.96	0.000116	0.0368	0.39	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
PCPG	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	3.96	0.000116	0.0368	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
PCPG	cis	rs7707921	0.958	rs6452447	ENSG00000249483.1	CTD-2249K22.1	3.96	0.000116	0.0368	0.42	0.31	Breast cancer;	chr5:82186703	chr5:81851601~81852201:+
PCPG	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	3.96	0.000116	0.0368	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
PCPG	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	3.96	0.000116	0.0368	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
PCPG	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	3.96	0.000116	0.0368	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
PCPG	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	3.96	0.000116	0.0368	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
PCPG	cis	rs11601239	0.621	rs7114305	ENSG00000263371.2	AP000673.1	3.96	0.000116	0.0368	0.34	0.31	Refractive error;	chr11:105653507	chr11:105933951~105934034:+
PCPG	cis	rs73607972	0.735	rs73603962	ENSG00000275191.1	RP11-36I17.2	-3.96	0.000116	0.0368	-0.5	-0.31	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53562292	chr16:53628256~53628816:-
PCPG	cis	rs10208649	0.831	rs76039968	ENSG00000272156.1	RP11-477N3.1	3.96	0.000116	0.0368	0.7	0.31	Body mass index;	chr2:53694900	chr2:54082554~54085066:+
PCPG	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	3.96	0.000116	0.0369	0.36	0.31	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
PCPG	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-3.96	0.000116	0.0369	-0.4	-0.31	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
PCPG	cis	rs575908	0.708	rs12749133	ENSG00000254154.7	RP4-798P15.3	3.96	0.000116	0.0369	0.3	0.31	Breast cancer;	chr1:177888167	chr1:177928788~178038007:-
PCPG	cis	rs711830	1	rs711830	ENSG00000226363.3	HAGLROS	3.96	0.000116	0.0369	0.32	0.31	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172583	chr2:176177717~176179008:+
PCPG	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	3.96	0.000116	0.0369	0.31	0.31	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
PCPG	cis	rs4791051	0.706	rs8074294	ENSG00000264491.1	RP11-349A8.3	-3.96	0.000116	0.0369	-0.32	-0.31	Heschl's gyrus morphology;	chr17:66475557	chr17:67019934~67021743:-
PCPG	cis	rs6456042	1	rs3127413	ENSG00000231297.3	RP11-459F1.2	3.96	0.000116	0.0369	0.33	0.31	Asthma;	chr6:166122240	chr6:166099665~166113273:+
PCPG	cis	rs6456042	1	rs3127415	ENSG00000231297.3	RP11-459F1.2	3.96	0.000116	0.0369	0.33	0.31	Asthma;	chr6:166123600	chr6:166099665~166113273:+
PCPG	cis	rs6456042	1	rs3127417	ENSG00000231297.3	RP11-459F1.2	3.96	0.000116	0.0369	0.33	0.31	Asthma;	chr6:166124246	chr6:166099665~166113273:+
PCPG	cis	rs6456042	1	rs3127420	ENSG00000231297.3	RP11-459F1.2	3.96	0.000116	0.0369	0.33	0.31	Asthma;	chr6:166125060	chr6:166099665~166113273:+
PCPG	cis	rs10751667	0.666	rs11246357	ENSG00000255142.1	AP006621.6	3.96	0.000116	0.0369	0.29	0.31	Alzheimer's disease (late onset);	chr11:963980	chr11:781645~782105:+
PCPG	cis	rs1003719	1	rs1003719	ENSG00000228677.1	TTC3-AS1	3.96	0.000116	0.0369	0.38	0.31	Eye color traits;	chr21:37118795	chr21:37187666~37193926:-
PCPG	cis	rs12882718	0.803	rs12431721	ENSG00000205562.2	RP11-497E19.1	3.96	0.000116	0.037	0.37	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr14:86421420	chr14:85524432~85529988:-
PCPG	cis	rs17684571	0.751	rs13190854	ENSG00000231441.1	RP11-472M19.2	3.96	0.000116	0.037	0.53	0.31	Schizophrenia;	chr6:56827020	chr6:56844002~56864078:+
PCPG	cis	rs1003719	0.679	rs1133001	ENSG00000228677.1	TTC3-AS1	-3.96	0.000116	0.037	-0.37	-0.31	Eye color traits;	chr21:37140656	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.654	rs764175	ENSG00000228677.1	TTC3-AS1	-3.96	0.000116	0.037	-0.37	-0.31	Eye color traits;	chr21:37144758	chr21:37187666~37193926:-
PCPG	cis	rs703842	0.963	rs923829	ENSG00000270039.1	RP11-571M6.17	-3.96	0.000116	0.037	-0.38	-0.31	Multiple sclerosis;	chr12:57780523	chr12:57803838~57804415:+
PCPG	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	3.96	0.000116	0.037	0.4	0.31	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
PCPG	cis	rs7937890	0.559	rs2597197	ENSG00000251991.1	RNU7-49P	3.96	0.000116	0.037	0.36	0.31	Mitochondrial DNA levels;	chr11:14468286	chr11:14478892~14478953:+
PCPG	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	3.96	0.000116	0.037	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
PCPG	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-3.96	0.000116	0.037	-0.36	-0.31	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
PCPG	cis	rs1552244	0.832	rs61056817	ENSG00000180385.7	EMC3-AS1	3.96	0.000117	0.0371	0.39	0.31	Alzheimer's disease;	chr3:9985957	chr3:9986893~10006990:+
PCPG	cis	rs11858159	0.834	rs12593399	ENSG00000260760.1	PWRN3	3.96	0.000117	0.0371	0.31	0.31	Platelet thrombus formation;	chr15:24563513	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.809	rs6576348	ENSG00000260760.1	PWRN3	3.96	0.000117	0.0371	0.31	0.31	Platelet thrombus formation;	chr15:24578191	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.874	rs6576349	ENSG00000260760.1	PWRN3	3.96	0.000117	0.0371	0.31	0.31	Platelet thrombus formation;	chr15:24578254	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.845	rs6576350	ENSG00000260760.1	PWRN3	3.96	0.000117	0.0371	0.31	0.31	Platelet thrombus formation;	chr15:24578391	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.874	rs12903376	ENSG00000260760.1	PWRN3	3.96	0.000117	0.0371	0.31	0.31	Platelet thrombus formation;	chr15:24579166	chr15:24441127~24447967:+
PCPG	cis	rs181553	0.664	rs7241593	ENSG00000278983.1	RP11-426J5.3	3.96	0.000117	0.0371	0.33	0.31	Hip circumference adjusted for BMI;	chr18:49173711	chr18:48564795~48568342:+
PCPG	cis	rs1371867	0.555	rs2861348	ENSG00000212994.5	RPS26P6	3.96	0.000117	0.0371	0.35	0.31	Atrioventricular conduction;	chr8:100272846	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1788196	ENSG00000212994.5	RPS26P6	3.96	0.000117	0.0371	0.35	0.31	Atrioventricular conduction;	chr8:100277860	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs2439458	ENSG00000212994.5	RPS26P6	3.96	0.000117	0.0371	0.35	0.31	Atrioventricular conduction;	chr8:100285756	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660328	ENSG00000212994.5	RPS26P6	3.96	0.000117	0.0371	0.35	0.31	Atrioventricular conduction;	chr8:100291222	chr8:100895771~100896118:+
PCPG	cis	rs12291225	0.679	rs11605531	ENSG00000251991.1	RNU7-49P	3.96	0.000117	0.0371	0.35	0.31	Sense of smell;	chr11:14270048	chr11:14478892~14478953:+
PCPG	cis	rs728616	0.867	rs61858980	ENSG00000242600.5	MBL1P	3.96	0.000117	0.0371	0.58	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:79904898~79950336:+
PCPG	cis	rs728616	0.867	rs2152550	ENSG00000242600.5	MBL1P	3.96	0.000117	0.0371	0.58	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:79904898~79950336:+
PCPG	cis	rs911119	1	rs71334202	ENSG00000270001.1	RP11-218C14.8	-3.96	0.000117	0.0371	-0.48	-0.31	Chronic kidney disease;	chr20:23638015	chr20:23631826~23632316:-
PCPG	cis	rs1275468	0.731	rs3912214	ENSG00000257497.2	RP11-585P4.5	-3.96	0.000117	0.0371	-0.48	-0.31	Polycystic ovary syndrome;	chr12:75550245	chr12:75483454~75489820:-
PCPG	cis	rs8098244	0.557	rs11082712	ENSG00000265752.2	RP11-403A21.1	3.96	0.000117	0.0371	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23718286	chr18:23957754~23982556:-
PCPG	cis	rs3002142	0.643	rs76147757	ENSG00000272750.1	RP11-378J18.8	3.96	0.000117	0.0371	0.51	0.31	LDL peak particle diameter (total fat intake interaction);	chr1:222633789	chr1:222658867~222661512:-
PCPG	cis	rs3758911	0.964	rs7358296	ENSG00000255353.1	RP11-382M14.1	-3.96	0.000117	0.0371	-0.39	-0.31	Coronary artery disease;	chr11:107403212	chr11:107176286~107177530:+
PCPG	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-3.96	0.000117	0.0371	-0.44	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-3.96	0.000117	0.0371	-0.44	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-3.96	0.000117	0.0371	-0.44	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
PCPG	cis	rs12928939	0.769	rs34680964	ENSG00000260886.1	TAT-AS1	3.96	0.000117	0.0371	0.39	0.31	Post bronchodilator FEV1;	chr16:71624691	chr16:71565789~71578187:+
PCPG	cis	rs4143844	0.867	rs12901036	ENSG00000259251.2	RP11-643M14.1	3.96	0.000117	0.0372	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61977797	chr15:62060503~62062434:+
PCPG	cis	rs13385025	0.935	rs17515892	ENSG00000228541.1	AC093159.1	3.96	0.000117	0.0372	0.59	0.31	Rheumatoid arthritis;	chr2:62216315	chr2:62463127~62464070:+
PCPG	cis	rs7575217	0.552	rs13032971	ENSG00000272902.2	RP11-299H21.1	3.96	0.000117	0.0372	0.36	0.31	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;	chr2:101073264	chr2:101151660~101155412:+
PCPG	cis	rs6696239	0.513	rs2492634	ENSG00000227711.2	RP11-275O4.5	3.96	0.000117	0.0372	0.36	0.31	Height;	chr1:227517157	chr1:227509028~227520477:-
PCPG	cis	rs7560272	0.669	rs13008860	ENSG00000163016.8	ALMS1P	3.96	0.000117	0.0372	0.36	0.31	Schizophrenia;	chr2:73546892	chr2:73644919~73685576:+
PCPG	cis	rs2243480	1	rs2707844	ENSG00000230189.5	GS1-124K5.2	3.96	0.000117	0.0372	0.45	0.31	Diabetic kidney disease;	chr7:66594522	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1796220	ENSG00000230189.5	GS1-124K5.2	3.96	0.000117	0.0372	0.45	0.31	Diabetic kidney disease;	chr7:66597113	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs2707831	ENSG00000230189.5	GS1-124K5.2	3.96	0.000117	0.0372	0.45	0.31	Diabetic kidney disease;	chr7:66597524	chr7:66409143~66490059:-
PCPG	cis	rs8085804	0.825	rs9952041	ENSG00000267586.5	LINC00907	-3.96	0.000117	0.0372	-0.36	-0.31	Cognitive performance;	chr18:42627405	chr18:42159283~42691422:+
PCPG	cis	rs804280	0.564	rs4639	ENSG00000255020.1	AF131216.5	3.96	0.000117	0.0372	0.42	0.31	Myopia (pathological);	chr8:11787242	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.503	rs2061830	ENSG00000269954.1	RP11-148O21.6	3.96	0.000117	0.0372	0.35	0.31	Neuroticism;	chr8:11539948	chr8:11552488~11552991:-
PCPG	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	3.96	0.000117	0.0372	0.32	0.31	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
PCPG	cis	rs1048886	0.872	rs9455181	ENSG00000271967.1	RP11-134K13.4	-3.96	0.000117	0.0372	-0.35	-0.31	Type 2 diabetes;	chr6:70593014	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs10945235	ENSG00000271967.1	RP11-134K13.4	-3.96	0.000117	0.0372	-0.35	-0.31	Type 2 diabetes;	chr6:70595342	chr6:70596438~70596980:+
PCPG	cis	rs72829446	0.556	rs12936464	ENSG00000214999.3	AC129492.6	3.96	0.000117	0.0373	0.36	0.31	Androgen levels;	chr17:7500623	chr17:8079482~8081565:+
PCPG	cis	rs6570726	0.791	rs4332001	ENSG00000270638.1	RP3-466P17.1	3.96	0.000117	0.0373	0.33	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145735570~145737218:+
PCPG	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	3.96	0.000117	0.0373	0.31	0.31	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-3.96	0.000117	0.0373	-0.31	-0.31	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
PCPG	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-3.96	0.000118	0.0373	-0.55	-0.31	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
PCPG	cis	rs1865760	0.516	rs9358903	ENSG00000272810.1	U91328.22	-3.96	0.000118	0.0373	-0.31	-0.31	Height;	chr6:26061721	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.516	rs9393683	ENSG00000272810.1	U91328.22	-3.96	0.000118	0.0373	-0.31	-0.31	Height;	chr6:26065970	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.516	rs9295684	ENSG00000272810.1	U91328.22	-3.96	0.000118	0.0373	-0.31	-0.31	Height;	chr6:26069441	chr6:26013241~26013757:+
PCPG	cis	rs12216125	0.549	rs9358905	ENSG00000272810.1	U91328.22	-3.96	0.000118	0.0373	-0.31	-0.31	Iron status biomarkers;	chr6:26077611	chr6:26013241~26013757:+
PCPG	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	3.96	0.000118	0.0373	0.32	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
PCPG	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	3.96	0.000118	0.0373	0.4	0.31	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
PCPG	cis	rs2279440	0.759	rs17050392	ENSG00000254485.4	RP11-380O24.1	3.96	0.000118	0.0373	0.44	0.31	Glucose homeostasis traits;	chr3:9481610	chr3:9292588~9363303:-
PCPG	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-3.96	0.000118	0.0373	-0.46	-0.31	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
PCPG	cis	rs1003719	0.68	rs2835621	ENSG00000228677.1	TTC3-AS1	-3.96	0.000118	0.0373	-0.37	-0.31	Eye color traits;	chr21:37138316	chr21:37187666~37193926:-
PCPG	cis	rs7487075	0.78	rs12307969	ENSG00000257261.4	RP11-96H19.1	3.96	0.000118	0.0373	0.4	0.31	Itch intensity from mosquito bite;	chr12:46365274	chr12:46383679~46876159:+
PCPG	cis	rs10435719	0.902	rs7459983	ENSG00000255495.1	AC145124.2	3.95	0.000118	0.0373	0.31	0.31	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:12194467~12196280:+
PCPG	cis	rs13126694	1	rs13126694	ENSG00000248429.4	RP11-597D13.9	-3.95	0.000118	0.0374	-0.32	-0.31	Blood osmolality (transformed sodium);	chr4:158177632	chr4:158170752~158202877:+
PCPG	cis	rs1023500	0.596	rs5751204	ENSG00000226450.2	CYP2D8P	3.95	0.000118	0.0374	0.31	0.31	Schizophrenia;	chr22:42037797	chr22:42149886~42155001:-
PCPG	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	3.95	0.000118	0.0374	0.29	0.31	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	3.95	0.000118	0.0374	0.29	0.31	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	3.95	0.000118	0.0374	0.29	0.31	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
PCPG	cis	rs9650657	0.645	rs4841411	ENSG00000255020.1	AF131216.5	3.95	0.000118	0.0374	0.41	0.31	Neuroticism;	chr8:10664380	chr8:11345748~11347502:-
PCPG	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-3.95	0.000118	0.0374	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-3.95	0.000118	0.0374	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-3.95	0.000118	0.0374	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-3.95	0.000118	0.0374	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
PCPG	cis	rs4143844	0.867	rs12907534	ENSG00000259251.2	RP11-643M14.1	3.95	0.000118	0.0374	0.65	0.31	Bipolar disorder and schizophrenia;	chr15:61908396	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs35607089	ENSG00000259251.2	RP11-643M14.1	3.95	0.000118	0.0374	0.65	0.31	Bipolar disorder and schizophrenia;	chr15:61909573	chr15:62060503~62062434:+
PCPG	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-3.95	0.000118	0.0374	-0.32	-0.31	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
PCPG	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	-3.95	0.000118	0.0374	-0.35	-0.31	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
PCPG	cis	rs7037266	0.759	rs1890918	ENSG00000206147.5	RP11-106A1.2	-3.95	0.000118	0.0374	-0.33	-0.31	Menarche (age at onset);	chr9:6965451	chr9:6639139~6639604:+
PCPG	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	3.95	0.000118	0.0374	0.3	0.31	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	3.95	0.000118	0.0374	0.3	0.31	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
PCPG	cis	rs8042680	0.868	rs1867219	ENSG00000214432.8	AC068831.10	-3.95	0.000118	0.0375	-0.34	-0.31	Type 2 diabetes;	chr15:90960641	chr15:91022619~91036611:+
PCPG	cis	rs12188164	0.9	rs72717425	ENSG00000221990.4	EXOC3-AS1	3.95	0.000118	0.0375	0.26	0.31	Cystic fibrosis severity;	chr5:438694	chr5:441498~443160:-
PCPG	cis	rs17684571	0.751	rs4415160	ENSG00000231441.1	RP11-472M19.2	-3.95	0.000118	0.0375	-0.52	-0.31	Schizophrenia;	chr6:56821424	chr6:56844002~56864078:+
PCPG	cis	rs13392177	0.647	rs10932761	ENSG00000273466.1	RP11-548H3.1	-3.95	0.000118	0.0375	-0.17	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218633256~218634014:-
PCPG	cis	rs7172677	1	rs7172677	ENSG00000261543.1	RP11-665J16.1	3.95	0.000118	0.0375	0.37	0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75132252	chr15:74152800~74179226:-
PCPG	cis	rs459482	0.501	rs148214	ENSG00000227698.1	AP001619.2	-3.95	0.000118	0.0375	-0.32	-0.31	IgG glycosylation;	chr21:41442291	chr21:41874756~41877613:-
PCPG	cis	rs4713118	0.866	rs2179094	ENSG00000216901.1	AL022393.7	3.95	0.000118	0.0375	0.42	0.31	Parkinson's disease;	chr6:27774046	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.824	rs9468225	ENSG00000216901.1	AL022393.7	3.95	0.000118	0.0375	0.42	0.31	Parkinson's disease;	chr6:27777940	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.739	rs2893931	ENSG00000216901.1	AL022393.7	3.95	0.000118	0.0375	0.42	0.31	Parkinson's disease;	chr6:27780231	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.824	rs2092075	ENSG00000216901.1	AL022393.7	3.95	0.000118	0.0375	0.42	0.31	Parkinson's disease;	chr6:27781551	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.824	rs13211701	ENSG00000216901.1	AL022393.7	3.95	0.000118	0.0375	0.42	0.31	Parkinson's disease;	chr6:27782300	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.824	rs9468229	ENSG00000216901.1	AL022393.7	3.95	0.000118	0.0375	0.42	0.31	Parkinson's disease;	chr6:27782307	chr6:28176188~28176674:+
PCPG	cis	rs853679	0.713	rs200991	ENSG00000220721.1	OR1F12	-3.95	0.000118	0.0375	-0.46	-0.31	Depression;	chr6:27847716	chr6:28073316~28074233:+
PCPG	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-3.95	0.000118	0.0375	-0.62	-0.31	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
PCPG	cis	rs6464929	1	rs6464929	ENSG00000281189.1	GHET1	3.95	0.000118	0.0375	0.4	0.31	Pediatric bone mineral content (hip);	chr7:149020375	chr7:148987527~148989432:+
PCPG	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	3.95	0.000118	0.0375	0.26	0.31	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	3.95	0.000118	0.0375	0.26	0.31	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	3.95	0.000118	0.0375	0.26	0.31	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
PCPG	cis	rs7246657	0.722	rs11083432	ENSG00000226686.6	LINC01535	3.95	0.000119	0.0375	0.45	0.31	Coronary artery calcification;	chr19:37691732	chr19:37251912~37265535:+
PCPG	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	3.95	0.000119	0.0375	0.38	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
PCPG	cis	rs8042680	0.614	rs12910825	ENSG00000214432.8	AC068831.10	3.95	0.000119	0.0376	0.32	0.31	Type 2 diabetes;	chr15:90968030	chr15:91022619~91036611:+
PCPG	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	3.95	0.000119	0.0376	0.4	0.31	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
PCPG	cis	rs73129298	0.551	rs6020177	ENSG00000222365.1	SNORD12B	3.95	0.000119	0.0376	0.44	0.31	Inflammatory skin disease;	chr20:49986787	chr20:49280319~49280409:+
PCPG	cis	rs6479901	0.793	rs4450077	ENSG00000232075.1	MRPL35P2	-3.95	0.000119	0.0376	-0.37	-0.31	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63634317~63634827:-
PCPG	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-3.95	0.000119	0.0376	-0.37	-0.31	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
PCPG	cis	rs595244	1	rs16960886	ENSG00000259705.1	RP11-227D13.1	3.95	0.000119	0.0376	0.67	0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48407289	chr15:48645951~48652016:+
PCPG	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	3.95	0.000119	0.0376	0.27	0.31	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
PCPG	cis	rs13276960	0.794	rs6468849	ENSG00000254281.1	KB-1507C5.4	3.95	0.000119	0.0376	0.38	0.31	Schizophrenia;	chr8:102937425	chr8:102978785~103000184:+
PCPG	cis	rs11858159	0.967	rs12914308	ENSG00000260760.1	PWRN3	3.95	0.000119	0.0376	0.33	0.31	Platelet thrombus formation;	chr15:24566565	chr15:24441127~24447967:+
PCPG	cis	rs5498	0.809	rs62130684	ENSG00000267612.1	CTD-3116E22.7	3.95	0.000119	0.0376	0.39	0.31	Soluble ICAM-1;Lymphocyte counts;Blood protein levels;	chr19:10297751	chr19:9730853~9731943:+
PCPG	cis	rs5770917	0.522	rs5770916	ENSG00000273272.1	CTA-384D8.34	-3.95	0.000119	0.0376	-0.44	-0.31	Narcolepsy;	chr22:50577669	chr22:50542650~50543011:+
PCPG	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	3.95	0.000119	0.0377	0.34	0.31	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
PCPG	cis	rs2098713	0.599	rs12152831	ENSG00000250155.1	CTD-2353F22.1	3.95	0.000119	0.0377	0.37	0.31	Telomere length;	chr5:37555215	chr5:36666214~36725195:-
PCPG	cis	rs11671005	0.693	rs11084542	ENSG00000269600.1	AC016629.3	-3.95	0.000119	0.0377	-0.47	-0.31	Mean platelet volume;	chr19:58420732	chr19:58593896~58599355:-
PCPG	cis	rs7911712	0.873	rs11812151	ENSG00000228462.1	RP11-445N18.3	3.95	0.000119	0.0377	0.43	0.31	Emphysema-related traits;	chr10:44819558	chr10:45073146~45073541:-
PCPG	cis	rs7911712	0.873	rs17157056	ENSG00000228462.1	RP11-445N18.3	3.95	0.000119	0.0377	0.43	0.31	Emphysema-related traits;	chr10:44819969	chr10:45073146~45073541:-
PCPG	cis	rs394563	0.967	rs420099	ENSG00000216906.2	RP11-350J20.9	3.95	0.000119	0.0377	0.3	0.31	Dupuytren's disease;	chr6:149473154	chr6:149904243~149906418:+
PCPG	cis	rs867371	0.896	rs8033831	ENSG00000278603.1	RP13-608F4.5	3.95	0.000119	0.0377	0.37	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472203~82472426:+
PCPG	cis	rs7696431	0.933	rs6854026	ENSG00000279384.1	RP11-635L1.2	-3.95	0.000119	0.0378	-0.33	-0.31	Coronary artery disease;	chr4:168769663	chr4:168843988~168844735:+
PCPG	cis	rs7829975	0.774	rs35039922	ENSG00000173295.6	FAM86B3P	-3.95	0.000119	0.0378	-0.36	-0.31	Mood instability;	chr8:8817815	chr8:8228595~8244865:+
PCPG	cis	rs7705042	0.581	rs10074925	ENSG00000280047.1	CTC-463A16.1	-3.95	0.000119	0.0378	-0.44	-0.31	Asthma;	chr5:142168825	chr5:142165767~142168387:+
PCPG	cis	rs7705042	0.581	rs3764	ENSG00000280047.1	CTC-463A16.1	-3.95	0.000119	0.0378	-0.44	-0.31	Asthma;	chr5:142171563	chr5:142165767~142168387:+
PCPG	cis	rs7705042	0.581	rs3899510	ENSG00000280047.1	CTC-463A16.1	-3.95	0.000119	0.0378	-0.44	-0.31	Asthma;	chr5:142171888	chr5:142165767~142168387:+
PCPG	cis	rs7705042	0.581	rs11745706	ENSG00000280047.1	CTC-463A16.1	-3.95	0.000119	0.0378	-0.44	-0.31	Asthma;	chr5:142173180	chr5:142165767~142168387:+
PCPG	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	3.95	0.000119	0.0378	0.42	0.31	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
PCPG	cis	rs394563	0.591	rs6570964	ENSG00000231760.4	RP11-350J20.5	-3.95	0.00012	0.0378	-0.39	-0.31	Dupuytren's disease;	chr6:149370723	chr6:149796151~149826294:-
PCPG	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	3.95	0.00012	0.0378	0.28	0.31	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
PCPG	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
PCPG	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	3.95	0.00012	0.0378	0.4	0.31	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
PCPG	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	3.95	0.00012	0.0378	0.43	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
PCPG	cis	rs2408955	0.715	rs1793957	ENSG00000240399.1	RP1-228P16.1	3.95	0.00012	0.0378	0.29	0.31	Glycated hemoglobin levels;	chr12:47999041	chr12:48054813~48055591:-
PCPG	cis	rs875971	0.54	rs781152	ENSG00000273142.1	RP11-458F8.4	-3.95	0.00012	0.0379	-0.28	-0.31	Aortic root size;	chr7:66014585	chr7:66902857~66906297:+
PCPG	cis	rs17711722	0.727	rs781151	ENSG00000273142.1	RP11-458F8.4	-3.95	0.00012	0.0379	-0.28	-0.31	Calcium levels;	chr7:66014891	chr7:66902857~66906297:+
PCPG	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-3.95	0.00012	0.0379	-0.47	-0.31	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
PCPG	cis	rs950169	0.579	rs11633088	ENSG00000259728.4	LINC00933	-3.95	0.00012	0.0379	-0.43	-0.31	Schizophrenia;	chr15:84003429	chr15:84570649~84580175:+
PCPG	cis	rs11858159	0.533	rs12592979	ENSG00000260760.1	PWRN3	3.95	0.00012	0.0379	0.31	0.31	Platelet thrombus formation;	chr15:24507362	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.708	rs11856249	ENSG00000260760.1	PWRN3	3.95	0.00012	0.0379	0.31	0.31	Platelet thrombus formation;	chr15:24511276	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.845	rs11632311	ENSG00000260760.1	PWRN3	3.95	0.00012	0.0379	0.31	0.31	Platelet thrombus formation;	chr15:24512946	chr15:24441127~24447967:+
PCPG	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	3.95	0.00012	0.0379	0.41	0.31	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
PCPG	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	3.95	0.00012	0.0379	0.27	0.31	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
PCPG	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-3.95	0.00012	0.0379	-0.35	-0.31	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
PCPG	cis	rs10208649	0.831	rs77308271	ENSG00000272156.1	RP11-477N3.1	3.95	0.00012	0.0379	0.71	0.31	Body mass index;	chr2:54075827	chr2:54082554~54085066:+
PCPG	cis	rs10208649	0.831	rs75447473	ENSG00000272156.1	RP11-477N3.1	3.95	0.00012	0.0379	0.71	0.31	Body mass index;	chr2:54077507	chr2:54082554~54085066:+
PCPG	cis	rs17019682	0.614	rs67582918	ENSG00000277851.1	RP11-756G20.1	-3.95	0.00012	0.0379	-0.64	-0.31	Heart failure;	chr12:91916851	chr12:92247756~92363832:-
PCPG	cis	rs17019682	0.614	rs4482064	ENSG00000277851.1	RP11-756G20.1	-3.95	0.00012	0.0379	-0.64	-0.31	Heart failure;	chr12:91918951	chr12:92247756~92363832:-
PCPG	cis	rs897984	0.646	rs9938088	ENSG00000275263.1	RP11-1072A3.4	-3.95	0.00012	0.0379	-0.32	-0.31	Dementia with Lewy bodies;	chr16:30818683	chr16:30956872~30957199:-
PCPG	cis	rs4791051	0.723	rs3859214	ENSG00000264491.1	RP11-349A8.3	-3.95	0.00012	0.0379	-0.32	-0.31	Heschl's gyrus morphology;	chr17:66464690	chr17:67019934~67021743:-
PCPG	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	3.95	0.00012	0.0379	0.4	0.31	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
PCPG	cis	rs10172965	0.955	rs1346856	ENSG00000203435.2	E2F3P2	3.95	0.00012	0.0379	0.43	0.31	Neuroticism;Temperament;	chr2:195001642	chr2:195994259~195995680:-
PCPG	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	3.95	0.00012	0.0379	0.37	0.31	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
PCPG	cis	rs453301	0.631	rs28572014	ENSG00000253893.2	FAM85B	3.95	0.00012	0.0379	0.38	0.31	Joint mobility (Beighton score);	chr8:8936097	chr8:8167819~8226614:-
PCPG	cis	rs9513627	0.915	rs9582298	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99466453	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs9585070	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99466589	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7338537	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99467327	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7317330	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99467622	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs73556165	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99468063	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7334274	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99468547	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7334844	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99468793	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.92	rs7335315	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469054	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs73556170	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469358	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs73556172	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469430	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs73556173	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469512	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs80270035	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469530	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs73556174	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469543	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs73556177	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469586	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs73556178	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469693	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs73556179	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469755	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs73556181	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469838	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs73556182	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99469853	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs4324006	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99470291	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.915	rs4539436	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99470548	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.833	rs112671387	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.0379	0.61	0.31	Obesity-related traits;	chr13:99470819	chr13:100150481~100151092:-
PCPG	cis	rs2836974	0.932	rs56306759	ENSG00000255568.3	BRWD1-AS2	3.95	0.00012	0.0379	0.32	0.31	Cognitive function;	chr21:39236180	chr21:39313935~39314962:+
PCPG	cis	rs17826219	0.5	rs117560728	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.00012	0.0379	-0.63	-0.31	Body mass index;	chr17:30743920	chr17:30729469~30731202:+
PCPG	cis	rs12928939	0.815	rs61753635	ENSG00000260886.1	TAT-AS1	3.95	0.00012	0.0379	0.39	0.31	Post bronchodilator FEV1;	chr16:71626501	chr16:71565789~71578187:+
PCPG	cis	rs6579956	0.518	rs11738913	ENSG00000254226.4	CTB-12O2.1	3.95	0.00012	0.0379	0.43	0.31	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152818932	chr5:151949571~152270448:+
PCPG	cis	rs8064024	0.65	rs3813749	ENSG00000267077.1	RP11-127I20.5	3.95	0.00012	0.0379	0.36	0.31	Cancer;	chr16:4869126	chr16:4795265~4796532:-
PCPG	cis	rs17772222	0.917	rs8006652	ENSG00000222990.1	RNU4-22P	3.95	0.00012	0.0379	0.39	0.31	Coronary artery calcification;	chr14:88631290	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs12587200	ENSG00000222990.1	RNU4-22P	3.95	0.00012	0.0379	0.39	0.31	Coronary artery calcification;	chr14:88632060	chr14:88513498~88513663:+
PCPG	cis	rs207145	0.562	rs17414449	ENSG00000233203.5	RP11-67L3.4	-3.95	0.00012	0.038	-0.45	-0.31	Age-related cataracts (age at onset);	chr1:55284917	chr1:54887563~54888850:+
PCPG	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-3.95	0.00012	0.038	-0.34	-0.31	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
PCPG	cis	rs888194	0.601	rs2058806	ENSG00000278993.1	RP3-424M6.4	-3.95	0.00012	0.038	-0.31	-0.31	Neuroticism;	chr12:109558538	chr12:110501614~110503441:+
PCPG	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	3.95	0.00012	0.038	0.31	0.31	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
PCPG	cis	rs687432	0.851	rs12804093	ENSG00000254602.1	AP000662.4	3.95	0.00012	0.038	0.36	0.31	Parkinson's disease;	chr11:57966616	chr11:57638024~57652790:+
PCPG	cis	rs12050794	0.671	rs7179427	ENSG00000260037.4	CTD-2524L6.3	3.95	0.00012	0.038	0.39	0.31	Metabolite levels (HVA/MHPG ratio);	chr15:72224480	chr15:71818396~71823384:+
PCPG	cis	rs9513627	1	rs7338335	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99473042	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.831	rs7319727	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99473287	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.831	rs9582301	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99473560	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs9582302	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99473731	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7321381	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99473902	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7321269	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99474017	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7327068	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99474711	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs7996624	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99475287	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.834	rs73556197	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99476225	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.588	rs9585073	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99476262	chr13:100150481~100151092:-
PCPG	cis	rs9513627	1	rs9585075	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99476380	chr13:100150481~100151092:-
PCPG	cis	rs9513627	0.92	rs73556201	ENSG00000228501.2	RPL15P18	3.95	0.00012	0.038	0.61	0.31	Obesity-related traits;	chr13:99476499	chr13:100150481~100151092:-
PCPG	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	3.95	0.00012	0.038	0.31	0.31	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
PCPG	cis	rs3758911	0.828	rs10789606	ENSG00000255353.1	RP11-382M14.1	-3.95	0.00012	0.038	-0.41	-0.31	Coronary artery disease;	chr11:107313862	chr11:107176286~107177530:+
PCPG	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-3.95	0.00012	0.038	-0.39	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-3.95	0.00012	0.038	-0.39	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-3.95	0.00012	0.038	-0.39	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-3.95	0.00012	0.038	-0.39	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-3.95	0.00012	0.038	-0.39	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-3.95	0.00012	0.038	-0.39	-0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
PCPG	cis	rs3758911	0.861	rs10890721	ENSG00000255353.1	RP11-382M14.1	-3.95	0.00012	0.038	-0.42	-0.31	Coronary artery disease;	chr11:107336876	chr11:107176286~107177530:+
PCPG	cis	rs1371867	0.846	rs2439460	ENSG00000212994.5	RPS26P6	3.95	0.00012	0.038	0.35	0.31	Atrioventricular conduction;	chr8:100300437	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.846	rs1660348	ENSG00000212994.5	RPS26P6	3.95	0.00012	0.038	0.35	0.31	Atrioventricular conduction;	chr8:100303020	chr8:100895771~100896118:+
PCPG	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	3.95	0.000121	0.038	0.35	0.31	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
PCPG	cis	rs7042889	1	rs75451763	ENSG00000281892.1	Metazoa_SRP	3.95	0.000121	0.038	0.52	0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129033176	chr9:128314614~128314876:-
PCPG	cis	rs7042889	0.85	rs76503180	ENSG00000281892.1	Metazoa_SRP	3.95	0.000121	0.038	0.52	0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129033235	chr9:128314614~128314876:-
PCPG	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	3.95	0.000121	0.038	0.47	0.31	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
PCPG	cis	rs7246657	0.722	rs35863684	ENSG00000226686.6	LINC01535	-3.95	0.000121	0.0381	-0.46	-0.31	Coronary artery calcification;	chr19:37618876	chr19:37251912~37265535:+
PCPG	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	3.95	0.000121	0.0381	0.4	0.31	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
PCPG	cis	rs6012953	0.874	rs1885177	ENSG00000231742.4	LINC01273	-3.95	0.000121	0.0381	-0.32	-0.31	Vitiligo;	chr20:50574691	chr20:50172550~50176671:+
PCPG	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	3.95	0.000121	0.0381	0.31	0.31	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
PCPG	cis	rs901683	0.85	rs77876088	ENSG00000230869.1	CTGLF10P	-3.95	0.000121	0.0381	-0.83	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45598673	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs76040096	ENSG00000230869.1	CTGLF10P	-3.95	0.000121	0.0381	-0.83	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45599178	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs74914325	ENSG00000230869.1	CTGLF10P	-3.95	0.000121	0.0381	-0.83	-0.31	Mean corpuscular volume;Red blood cell traits;	chr10:45602200	chr10:45678692~45700532:+
PCPG	cis	rs34421088	0.532	rs11782742	ENSG00000255518.1	RP11-148O21.4	3.95	0.000121	0.0381	0.34	0.31	Neuroticism;	chr8:11307500	chr8:11556251~11558022:-
PCPG	cis	rs7267979	0.816	rs1044573	ENSG00000276952.1	RP5-965G21.6	3.95	0.000121	0.0381	0.34	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25284915~25285588:-
PCPG	cis	rs79349575	0.783	rs62075838	ENSG00000270781.1	RP11-501C14.9	-3.95	0.000121	0.0381	-0.37	-0.31	Type 2 diabetes;	chr17:48919070	chr17:48899131~48899748:+
PCPG	cis	rs79349575	0.783	rs62075839	ENSG00000270781.1	RP11-501C14.9	-3.95	0.000121	0.0381	-0.37	-0.31	Type 2 diabetes;	chr17:48919072	chr17:48899131~48899748:+
PCPG	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	3.95	0.000121	0.0381	0.39	0.31	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
PCPG	cis	rs7444	0.941	rs2298429	ENSG00000211645.2	IGLV1-50	3.95	0.000121	0.0381	0.36	0.31	Systemic lupus erythematosus;	chr22:21628971	chr22:22327300~22327814:+
PCPG	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	3.95	0.000121	0.0381	0.44	0.31	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
PCPG	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	3.95	0.000121	0.0381	0.4	0.31	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
PCPG	cis	rs748404	0.666	rs72709871	ENSG00000205771.5	CATSPER2P1	-3.95	0.000121	0.0381	-0.41	-0.31	Lung cancer;	chr15:43499025	chr15:43726918~43747094:-
PCPG	cis	rs4281086	0.541	rs10094938	ENSG00000269918.1	AF131215.9	3.95	0.000121	0.0382	0.31	0.31	Obesity-related traits;	chr8:10537816	chr8:11104691~11106704:-
PCPG	cis	rs9388451	0.772	rs1268064	ENSG00000237742.5	RP11-624M8.1	3.95	0.000121	0.0382	0.34	0.31	Brugada syndrome;	chr6:125721432	chr6:125578558~125749190:-
PCPG	cis	rs9388451	0.807	rs1268065	ENSG00000237742.5	RP11-624M8.1	3.95	0.000121	0.0382	0.34	0.31	Brugada syndrome;	chr6:125721637	chr6:125578558~125749190:-
PCPG	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	3.95	0.000121	0.0382	0.26	0.31	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
PCPG	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-3.95	0.000121	0.0382	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
PCPG	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-3.95	0.000121	0.0382	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
PCPG	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	3.95	0.000121	0.0382	0.35	0.31	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
PCPG	cis	rs2898290	0.617	rs13278965	ENSG00000270154.1	RP11-419I17.1	3.95	0.000121	0.0382	0.38	0.31	Systolic blood pressure;	chr8:11609236	chr8:12476462~12477122:+
PCPG	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	3.95	0.000121	0.0382	0.33	0.31	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
PCPG	cis	rs9876781	1	rs922075	ENSG00000229759.1	MRPS18AP1	-3.95	0.000121	0.0382	-0.36	-0.31	Longevity;	chr3:48447994	chr3:48256350~48256938:-
PCPG	cis	rs9876781	1	rs2045554	ENSG00000229759.1	MRPS18AP1	-3.95	0.000121	0.0382	-0.36	-0.31	Longevity;	chr3:48453142	chr3:48256350~48256938:-
PCPG	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-3.95	0.000121	0.0383	-0.32	-0.31	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
PCPG	cis	rs2404602	0.536	rs12915248	ENSG00000270036.1	RP11-685G9.4	-3.95	0.000122	0.0383	-0.28	-0.31	Blood metabolite levels;	chr15:76473274	chr15:76343642~76344365:+
PCPG	cis	rs11671005	0.656	rs11672609	ENSG00000269600.1	AC016629.3	-3.95	0.000122	0.0383	-0.54	-0.31	Mean platelet volume;	chr19:58495557	chr19:58593896~58599355:-
PCPG	cis	rs720064	0.618	rs4800171	ENSG00000265752.2	RP11-403A21.1	3.95	0.000122	0.0383	0.37	0.31	Strep throat;	chr18:23952495	chr18:23957754~23982556:-
PCPG	cis	rs7707921	0.914	rs4081859	ENSG00000249483.1	CTD-2249K22.1	3.95	0.000122	0.0383	0.41	0.31	Breast cancer;	chr5:82170850	chr5:81851601~81852201:+
PCPG	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	3.95	0.000122	0.0383	0.37	0.31	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
PCPG	cis	rs7208859	0.673	rs9889968	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs61348930	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.614	rs28758251	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9899943	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11080138	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73265612	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs2433	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11658435	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73265624	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs2269915	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs2269916	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11649765	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs12103759	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.623	rs59029591	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs73265633	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9913782	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs79541516	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs9895684	ENSG00000263603.1	CTD-2349P21.5	-3.95	0.000122	0.0383	-0.59	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30729469~30731202:+
PCPG	cis	rs9813712	0.953	rs6782280	ENSG00000228252.7	COL6A4P2	3.95	0.000122	0.0384	0.38	0.31	Response to amphetamines;	chr3:130245370	chr3:130212823~130273806:+
PCPG	cis	rs8098244	0.557	rs12954712	ENSG00000265752.2	RP11-403A21.1	3.95	0.000122	0.0384	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707144	chr18:23957754~23982556:-
PCPG	cis	rs7610312	0.681	rs1554125	ENSG00000273493.1	RP11-80H18.4	3.95	0.000122	0.0384	0.37	0.31	Red blood cell count;	chr3:58291774	chr3:58329965~58330118:+
PCPG	cis	rs73201462	1	rs2811527	ENSG00000242551.2	POU5F1P6	-3.95	0.000122	0.0384	-0.56	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275761	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs2811526	ENSG00000242551.2	POU5F1P6	-3.95	0.000122	0.0384	-0.56	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128276875	chr3:128674735~128677005:-
PCPG	cis	rs73201462	0.908	rs2811373	ENSG00000242551.2	POU5F1P6	-3.95	0.000122	0.0384	-0.56	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128278586	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs2811525	ENSG00000242551.2	POU5F1P6	-3.95	0.000122	0.0384	-0.56	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128280587	chr3:128674735~128677005:-
PCPG	cis	rs73201462	0.831	rs2811524	ENSG00000242551.2	POU5F1P6	-3.95	0.000122	0.0384	-0.56	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281112	chr3:128674735~128677005:-
PCPG	cis	rs73201462	0.908	rs2811386	ENSG00000242551.2	POU5F1P6	-3.95	0.000122	0.0384	-0.56	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281172	chr3:128674735~128677005:-
PCPG	cis	rs2625529	0.824	rs4238449	ENSG00000260037.4	CTD-2524L6.3	-3.95	0.000122	0.0384	-0.48	-0.31	Red blood cell count;	chr15:72129262	chr15:71818396~71823384:+
PCPG	cis	rs2625529	0.824	rs4411469	ENSG00000260037.4	CTD-2524L6.3	-3.95	0.000122	0.0384	-0.48	-0.31	Red blood cell count;	chr15:72129348	chr15:71818396~71823384:+
PCPG	cis	rs9393777	0.92	rs34953377	ENSG00000219392.1	RP1-265C24.5	-3.95	0.000122	0.0384	-0.65	-0.31	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28115628~28116551:+
PCPG	cis	rs427941	0.732	rs378011	ENSG00000239480.1	RP11-514P8.2	-3.95	0.000122	0.0384	-0.35	-0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102206116	chr7:102426818~102434780:-
PCPG	cis	rs7208859	0.673	rs9915139	ENSG00000264538.5	SUZ12P1	-3.95	0.000122	0.0384	-0.45	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30709299~30790908:+
PCPG	cis	rs10200159	1	rs9309267	ENSG00000272606.1	RP11-554J4.1	-3.95	0.000122	0.0384	-0.57	-0.31	Vitiligo;	chr2:55623198	chr2:55617909~55618373:+
PCPG	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-3.95	0.000122	0.0384	-0.35	-0.31	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-3.95	0.000122	0.0384	-0.35	-0.31	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
PCPG	cis	rs7824557	0.767	rs2164273	ENSG00000184608.7	FAM167A-AS1	3.95	0.000122	0.0384	0.43	0.31	Retinal vascular caliber;	chr8:11310990	chr8:11368402~11438658:+
PCPG	cis	rs357618	0.897	rs357630	ENSG00000260581.1	CTB-113P19.4	3.95	0.000122	0.0384	0.37	0.31	Basophil percentage of white cells;	chr5:151471697	chr5:151652275~151655449:+
PCPG	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	3.95	0.000122	0.0384	0.43	0.31	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
PCPG	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	3.95	0.000122	0.0384	0.43	0.31	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
PCPG	cis	rs6714710	0.603	rs6738389	ENSG00000278766.2	AC159540.2	3.94	0.000122	0.0385	0.35	0.31	Posterior cortical atrophy and Alzheimer's disease;	chr2:97770268	chr2:97421075~97434847:+
PCPG	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	3.94	0.000122	0.0385	0.47	0.31	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
PCPG	cis	rs728616	0.717	rs61860016	ENSG00000242600.5	MBL1P	3.94	0.000122	0.0385	0.7	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:79904898~79950336:+
PCPG	cis	rs34421088	0.532	rs2736385	ENSG00000255020.1	AF131216.5	3.94	0.000122	0.0385	0.37	0.31	Neuroticism;	chr8:11291104	chr8:11345748~11347502:-
PCPG	cis	rs2733954	0.779	rs301170	ENSG00000179219.5	LINC00311	-3.94	0.000122	0.0385	-0.42	-0.31	Leprosy;	chr16:85783365	chr16:85282958~85285963:+
PCPG	cis	rs2179367	0.959	rs9377212	ENSG00000268592.3	RAET1E-AS1	3.94	0.000122	0.0385	0.39	0.31	Dupuytren's disease;	chr6:149383765	chr6:149863494~149919507:+
PCPG	cis	rs9388451	0.626	rs3734637	ENSG00000237742.5	RP11-624M8.1	-3.94	0.000123	0.0385	-0.34	-0.31	Brugada syndrome;	chr6:125760173	chr6:125578558~125749190:-
PCPG	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-3.94	0.000123	0.0385	-0.4	-0.31	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
PCPG	cis	rs6479901	0.501	rs4414112	ENSG00000232075.1	MRPL35P2	-3.94	0.000123	0.0385	-0.39	-0.31	Intelligence (multi-trait analysis);	chr10:63115786	chr10:63634317~63634827:-
PCPG	cis	rs9650657	0.513	rs7005884	ENSG00000255020.1	AF131216.5	-3.94	0.000123	0.0385	-0.43	-0.31	Neuroticism;	chr8:10938962	chr8:11345748~11347502:-
PCPG	cis	rs847649	0.699	rs10241865	ENSG00000252643.1	RNU6-1136P	-3.94	0.000123	0.0386	-0.37	-0.31	Morning vs. evening chronotype;	chr7:102887070	chr7:102834605~102834708:+
PCPG	cis	rs847649	0.699	rs10271157	ENSG00000252643.1	RNU6-1136P	-3.94	0.000123	0.0386	-0.37	-0.31	Morning vs. evening chronotype;	chr7:102887144	chr7:102834605~102834708:+
PCPG	cis	rs720064	0.586	rs2241643	ENSG00000265752.2	RP11-403A21.1	3.94	0.000123	0.0386	0.35	0.31	Strep throat;	chr18:23949758	chr18:23957754~23982556:-
PCPG	cis	rs2836974	0.897	rs2836933	ENSG00000252915.1	Y_RNA	-3.94	0.000123	0.0386	-0.32	-0.31	Cognitive function;	chr21:39192276	chr21:39344537~39344628:+
PCPG	cis	rs394563	0.589	rs1900300	ENSG00000231760.4	RP11-350J20.5	-3.94	0.000123	0.0386	-0.39	-0.31	Dupuytren's disease;	chr6:149320491	chr6:149796151~149826294:-
PCPG	cis	rs7772486	0.79	rs7742333	ENSG00000270638.1	RP3-466P17.1	-3.94	0.000123	0.0386	-0.33	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145735570~145737218:+
PCPG	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-3.94	0.000123	0.0386	-0.44	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
PCPG	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	3.94	0.000123	0.0386	0.3	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
PCPG	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	3.94	0.000123	0.0386	0.31	0.31	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
PCPG	cis	rs27434	0.583	rs151953	ENSG00000248734.2	CTD-2260A17.1	3.94	0.000123	0.0387	0.31	0.31	Ankylosing spondylitis;	chr5:96821945	chr5:96784777~96785999:+
PCPG	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-3.94	0.000123	0.0387	-0.31	-0.31	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
PCPG	cis	rs7849782	0.875	rs1323425	ENSG00000225376.4	TMEM246-AS1	3.94	0.000123	0.0387	0.36	0.31	Coronary artery aneurysm in Kawasaki disease;	chr9:101653039	chr9:101468439~101481502:+
PCPG	cis	rs11671005	0.735	rs11670871	ENSG00000269600.1	AC016629.3	3.94	0.000123	0.0387	0.45	0.31	Mean platelet volume;	chr19:58429147	chr19:58593896~58599355:-
PCPG	cis	rs12194062	0.524	rs270045	ENSG00000220694.2	RP3-403A15.1	-3.94	0.000123	0.0387	-0.35	-0.31	QRS duration;	chr6:127866437	chr6:127435636~127436189:+
PCPG	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-3.94	0.000123	0.0387	-0.36	-0.31	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
PCPG	cis	rs896854	1	rs13255935	ENSG00000253528.2	RP11-347C18.4	3.94	0.000123	0.0387	0.34	0.31	Type 2 diabetes;	chr8:94953457	chr8:94974573~94974853:-
PCPG	cis	rs28386778	0.863	rs9897229	ENSG00000240280.5	TCAM1P	-3.94	0.000123	0.0387	-0.41	-0.31	Prudent dietary pattern;	chr17:63704965	chr17:63849292~63864379:+
PCPG	cis	rs17684571	0.751	rs7775182	ENSG00000231441.1	RP11-472M19.2	3.94	0.000123	0.0387	0.52	0.31	Schizophrenia;	chr6:56831848	chr6:56844002~56864078:+
PCPG	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	3.94	0.000123	0.0387	0.39	0.31	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
PCPG	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	3.94	0.000123	0.0387	0.39	0.31	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
PCPG	cis	rs7772486	0.806	rs2253648	ENSG00000270638.1	RP3-466P17.1	3.94	0.000123	0.0388	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145735570~145737218:+
PCPG	cis	rs1387259	0.64	rs10783243	ENSG00000240399.1	RP1-228P16.1	-3.94	0.000123	0.0388	-0.32	-0.31	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48054813~48055591:-
PCPG	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-3.94	0.000123	0.0388	-0.49	-0.31	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
PCPG	cis	rs12928939	0.815	rs7185575	ENSG00000260886.1	TAT-AS1	3.94	0.000123	0.0388	0.39	0.31	Post bronchodilator FEV1;	chr16:71638666	chr16:71565789~71578187:+
PCPG	cis	rs11858159	0.967	rs80040713	ENSG00000260760.1	PWRN3	3.94	0.000123	0.0388	0.33	0.31	Platelet thrombus formation;	chr15:24554036	chr15:24441127~24447967:+
PCPG	cis	rs13276960	0.794	rs11988501	ENSG00000254281.1	KB-1507C5.4	3.94	0.000124	0.0388	0.38	0.31	Schizophrenia;	chr8:102941571	chr8:102978785~103000184:+
PCPG	cis	rs7819412	0.654	rs6987059	ENSG00000255020.1	AF131216.5	-3.94	0.000124	0.0388	-0.43	-0.31	Triglycerides;	chr8:11213548	chr8:11345748~11347502:-
PCPG	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-3.94	0.000124	0.0388	-0.47	-0.31	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
PCPG	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-3.94	0.000124	0.0388	-0.46	-0.31	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
PCPG	cis	rs6981523	0.5	rs4412337	ENSG00000255020.1	AF131216.5	3.94	0.000124	0.0388	0.44	0.31	Neuroticism;	chr8:11214511	chr8:11345748~11347502:-
PCPG	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-3.94	0.000124	0.0388	-0.38	-0.31	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
PCPG	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-3.94	0.000124	0.0388	-0.4	-0.31	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
PCPG	cis	rs71403859	0.73	rs12447672	ENSG00000279412.1	RP11-394B2.5	3.94	0.000124	0.0388	0.58	0.31	Post bronchodilator FEV1;	chr16:71681228	chr16:70713987~70716890:+
PCPG	cis	rs71403859	0.73	rs17356316	ENSG00000279412.1	RP11-394B2.5	3.94	0.000124	0.0388	0.58	0.31	Post bronchodilator FEV1;	chr16:71713018	chr16:70713987~70716890:+
PCPG	cis	rs748404	0.601	rs489964	ENSG00000205771.5	CATSPER2P1	3.94	0.000124	0.0389	0.32	0.31	Lung cancer;	chr15:43225356	chr15:43726918~43747094:-
PCPG	cis	rs10200159	1	rs1045920	ENSG00000272606.1	RP11-554J4.1	3.94	0.000124	0.0389	0.59	0.31	Vitiligo;	chr2:55544033	chr2:55617909~55618373:+
PCPG	cis	rs10411161	0.702	rs8113584	ENSG00000275055.1	CTC-471J1.11	-3.94	0.000124	0.0389	-0.33	-0.31	Breast cancer;	chr19:51880621	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs8113768	ENSG00000275055.1	CTC-471J1.11	-3.94	0.000124	0.0389	-0.33	-0.31	Breast cancer;	chr19:51880685	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs8100716	ENSG00000275055.1	CTC-471J1.11	-3.94	0.000124	0.0389	-0.33	-0.31	Breast cancer;	chr19:51880808	chr19:52049007~52049754:+
PCPG	cis	rs17005891	0.73	rs6535363	ENSG00000214988.4	RPL7AP26	-3.94	0.000124	0.0389	-0.38	-0.31	Eosinophil counts;Sum eosinophil basophil counts;	chr4:82641416	chr4:82490823~82491635:-
PCPG	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	3.94	0.000124	0.0389	0.35	0.31	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
PCPG	cis	rs3218092	0.872	rs11968166	ENSG00000269387.1	RP11-298J23.8	3.94	0.000124	0.0389	0.32	0.31	Red cell distribution width;	chr6:41957566	chr6:41764292~41764460:-
PCPG	cis	rs10411161	0.702	rs11878583	ENSG00000275055.1	CTC-471J1.11	3.94	0.000124	0.0389	0.33	0.31	Breast cancer;	chr19:51885293	chr19:52049007~52049754:+
PCPG	cis	rs6856616	0.558	rs55843528	ENSG00000249863.2	RP11-177C12.1	3.94	0.000124	0.0389	0.45	0.31	Crohn's disease;Inflammatory bowel disease;	chr4:38359795	chr4:37868292~37869978:+
PCPG	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	3.94	0.000124	0.0389	0.3	0.31	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
PCPG	cis	rs17019682	0.614	rs7973111	ENSG00000277851.1	RP11-756G20.1	-3.94	0.000124	0.0389	-0.64	-0.31	Heart failure;	chr12:91918651	chr12:92247756~92363832:-
PCPG	cis	rs1501138	0.688	rs1121630	ENSG00000249506.3	ZEB2P1	3.94	0.000124	0.0389	0.56	0.31	Systemic juvenile idiopathic arthritis;	chr4:16285117	chr4:16360686~16397323:-
PCPG	cis	rs2268365	0.602	rs10188487	ENSG00000227617.7	CERS6-AS1	-3.94	0.000124	0.0389	-0.34	-0.31	Blood pressure (smoking interaction);	chr2:169208748	chr2:168771953~168786961:-
PCPG	cis	rs2243480	1	rs316315	ENSG00000230189.5	GS1-124K5.2	-3.94	0.000124	0.0389	-0.37	-0.31	Diabetic kidney disease;	chr7:66126218	chr7:66409143~66490059:-
PCPG	cis	rs2733954	0.779	rs100812	ENSG00000179219.5	LINC00311	-3.94	0.000124	0.0389	-0.42	-0.31	Leprosy;	chr16:85782598	chr16:85282958~85285963:+
PCPG	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	3.94	0.000124	0.0389	0.4	0.31	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	3.94	0.000124	0.0389	0.4	0.31	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
PCPG	cis	rs752864	0.805	rs1464963	ENSG00000259438.1	CTD-2650P22.1	3.94	0.000124	0.039	0.36	0.31	Number of common colds;	chr15:52417737	chr15:52010999~52019095:-
PCPG	cis	rs7324557	0.717	rs7330646	ENSG00000205861.10	C1QTNF9B-AS1	3.94	0.000124	0.039	0.4	0.31	Visceral adipose tissue adjusted for BMI;	chr13:23828025	chr13:23888889~23897263:+
PCPG	cis	rs896854	0.818	rs13262110	ENSG00000253528.2	RP11-347C18.4	3.94	0.000124	0.039	0.32	0.31	Type 2 diabetes;	chr8:94914662	chr8:94974573~94974853:-
PCPG	cis	rs7937890	0.532	rs2575827	ENSG00000251991.1	RNU7-49P	3.94	0.000124	0.039	0.35	0.31	Mitochondrial DNA levels;	chr11:14453969	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.532	rs2256884	ENSG00000251991.1	RNU7-49P	3.94	0.000124	0.039	0.35	0.31	Mitochondrial DNA levels;	chr11:14454856	chr11:14478892~14478953:+
PCPG	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-3.94	0.000124	0.039	-0.36	-0.31	Height;	chr5:36904297	chr5:36666214~36725195:-
PCPG	cis	rs301901	0.734	rs216387	ENSG00000250155.1	CTD-2353F22.1	-3.94	0.000124	0.039	-0.35	-0.31	Height;	chr5:37276657	chr5:36666214~36725195:-
PCPG	cis	rs783540	0.681	rs1259178	ENSG00000278603.1	RP13-608F4.5	-3.94	0.000124	0.039	-0.42	-0.31	Schizophrenia;	chr15:82603127	chr15:82472203~82472426:+
PCPG	cis	rs964611	0.872	rs11855410	ENSG00000259488.2	RP11-154J22.1	-3.94	0.000124	0.039	-0.31	-0.31	Metabolite levels (Pyroglutamine);	chr15:48301657	chr15:48312353~48331856:-
PCPG	cis	rs7160336	0.738	rs35579176	ENSG00000259065.1	RP5-1021I20.1	3.94	0.000124	0.039	0.38	0.31	Blood protein levels;	chr14:74013601	chr14:73787360~73803270:+
PCPG	cis	rs7160336	0.738	rs7145427	ENSG00000259065.1	RP5-1021I20.1	3.94	0.000124	0.039	0.38	0.31	Blood protein levels;	chr14:74016745	chr14:73787360~73803270:+
PCPG	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-3.94	0.000125	0.039	-0.37	-0.31	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
PCPG	cis	rs34421088	0.506	rs2572426	ENSG00000255020.1	AF131216.5	3.94	0.000125	0.039	0.37	0.31	Neuroticism;	chr8:11289614	chr8:11345748~11347502:-
PCPG	cis	rs7829975	0.582	rs11783950	ENSG00000173295.6	FAM86B3P	3.94	0.000125	0.039	0.36	0.31	Mood instability;	chr8:8740321	chr8:8228595~8244865:+
PCPG	cis	rs728616	0.681	rs34816332	ENSG00000242600.5	MBL1P	3.94	0.000125	0.039	0.64	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148211	chr10:79904898~79950336:+
PCPG	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	3.94	0.000125	0.0391	0.32	0.31	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
PCPG	cis	rs11148252	0.712	rs61957257	ENSG00000235660.1	LINC00345	-3.94	0.000125	0.0391	-0.36	-0.31	Lewy body disease;	chr13:52195567	chr13:52484161~52484680:-
PCPG	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-3.94	0.000125	0.0391	-0.4	-0.31	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
PCPG	cis	rs3808502	0.503	rs2061830	ENSG00000184608.7	FAM167A-AS1	3.94	0.000125	0.0391	0.43	0.31	Neuroticism;	chr8:11539948	chr8:11368402~11438658:+
PCPG	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-3.94	0.000125	0.0391	-0.5	-0.31	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
PCPG	cis	rs4819052	0.885	rs9980676	ENSG00000215447.6	BX322557.10	-3.94	0.000125	0.0391	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2838836	ENSG00000215447.6	BX322557.10	-3.94	0.000125	0.0391	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2838837	ENSG00000215447.6	BX322557.10	-3.94	0.000125	0.0391	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45288052~45291738:+
PCPG	cis	rs2898290	0.54	rs35005793	ENSG00000255020.1	AF131216.5	3.94	0.000125	0.0391	0.41	0.31	Systolic blood pressure;	chr8:11592963	chr8:11345748~11347502:-
PCPG	cis	rs4713118	0.869	rs2056925	ENSG00000216901.1	AL022393.7	3.94	0.000125	0.0391	0.4	0.31	Parkinson's disease;	chr6:27723126	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs6922574	ENSG00000216901.1	AL022393.7	3.94	0.000125	0.0391	0.4	0.31	Parkinson's disease;	chr6:27725224	chr6:28176188~28176674:+
PCPG	cis	rs4713118	0.869	rs9348775	ENSG00000216901.1	AL022393.7	3.94	0.000125	0.0391	0.4	0.31	Parkinson's disease;	chr6:27727550	chr6:28176188~28176674:+
PCPG	cis	rs7172677	0.768	rs2304901	ENSG00000261543.1	RP11-665J16.1	3.94	0.000125	0.0391	0.36	0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75048381	chr15:74152800~74179226:-
PCPG	cis	rs6504622	0.755	rs34038545	ENSG00000263142.4	LRRC37A17P	-3.94	0.000125	0.0391	-0.24	-0.31	Orofacial clefts;	chr17:47067541	chr17:46978481~47054569:+
PCPG	cis	rs875971	0.628	rs6974355	ENSG00000273142.1	RP11-458F8.4	-3.94	0.000125	0.0391	-0.28	-0.31	Aortic root size;	chr7:66376994	chr7:66902857~66906297:+
PCPG	cis	rs11601239	0.621	rs10502059	ENSG00000263371.2	AP000673.1	-3.94	0.000125	0.0391	-0.33	-0.31	Refractive error;	chr11:105653654	chr11:105933951~105934034:+
PCPG	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-3.94	0.000125	0.0391	-0.33	-0.31	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
PCPG	cis	rs16856186	0.52	rs2282429	ENSG00000271580.1	RP11-536L3.4	3.94	0.000125	0.0391	0.47	0.31	Pulmonary function decline;	chr1:205912696	chr1:205091163~205091946:+
PCPG	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	3.94	0.000125	0.0391	0.41	0.31	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
PCPG	cis	rs2236231	0.55	rs4902496	ENSG00000259502.1	RP11-643G16.3	-3.94	0.000125	0.0391	-0.41	-0.31	Plasma kynurenine levels in major depressive disorder;	chr14:67588896	chr14:67610986~67613864:+
PCPG	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	3.94	0.000125	0.0391	0.4	0.31	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	3.94	0.000125	0.0391	0.4	0.31	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
PCPG	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	3.94	0.000125	0.0391	0.35	0.31	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
PCPG	cis	rs2404602	0.655	rs4886824	ENSG00000259514.1	RP11-685G9.2	-3.94	0.000125	0.0392	-0.31	-0.31	Blood metabolite levels;	chr15:76676915	chr15:76339609~76342063:-
PCPG	cis	rs1371867	0.875	rs1962901	ENSG00000212994.5	RPS26P6	3.94	0.000125	0.0392	0.35	0.31	Atrioventricular conduction;	chr8:100314200	chr8:100895771~100896118:+
PCPG	cis	rs1371867	0.875	rs7830342	ENSG00000212994.5	RPS26P6	3.94	0.000125	0.0392	0.35	0.31	Atrioventricular conduction;	chr8:100315510	chr8:100895771~100896118:+
PCPG	cis	rs7103004	1	rs7103004	ENSG00000260966.1	RP11-690D19.3	3.94	0.000125	0.0392	0.32	0.31	Disc degeneration (lumbar);	chr11:103655296	chr11:103050687~103055799:-
PCPG	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-3.94	0.000125	0.0392	-0.32	-0.31	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
PCPG	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-3.94	0.000125	0.0392	-0.36	-0.31	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
PCPG	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-3.94	0.000125	0.0392	-0.36	-0.31	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
PCPG	cis	rs6832769	1	rs9684708	ENSG00000272969.1	RP11-528I4.2	-3.94	0.000125	0.0392	-0.33	-0.31	Personality dimensions;	chr4:55564214	chr4:55547112~55547889:+
PCPG	cis	rs6832769	0.961	rs28445925	ENSG00000272969.1	RP11-528I4.2	-3.94	0.000125	0.0392	-0.33	-0.31	Personality dimensions;	chr4:55569682	chr4:55547112~55547889:+
PCPG	cis	rs6832769	0.961	rs10009593	ENSG00000272969.1	RP11-528I4.2	-3.94	0.000125	0.0392	-0.33	-0.31	Personality dimensions;	chr4:55570514	chr4:55547112~55547889:+
PCPG	cis	rs8014204	1	rs10483863	ENSG00000279594.1	RP11-950C14.10	-3.94	0.000125	0.0392	-0.37	-0.31	Caffeine consumption;	chr14:74855624	chr14:75011269~75012851:-
PCPG	cis	rs3809060	0.569	rs4304749	ENSG00000213713.3	PIGCP1	3.94	0.000125	0.0392	0.16	0.31	Inguinal hernia;	chr11:32444758	chr11:33075566~33076460:-
PCPG	cis	rs6456042	1	rs3099301	ENSG00000231297.3	RP11-459F1.2	-3.94	0.000125	0.0392	-0.33	-0.31	Asthma;	chr6:166110929	chr6:166099665~166113273:+
PCPG	cis	rs2052670	0.964	rs1406743	ENSG00000232613.5	AC007386.4	3.94	0.000125	0.0392	0.42	0.31	Waist circumference adjusted for body mass index;	chr2:66022698	chr2:65030727~65053017:+
PCPG	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	3.94	0.000125	0.0392	0.3	0.31	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	3.94	0.000125	0.0392	0.3	0.31	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
PCPG	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	3.94	0.000125	0.0392	0.39	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
PCPG	cis	rs1865760	0.566	rs9366634	ENSG00000272810.1	U91328.22	-3.94	0.000125	0.0392	-0.31	-0.31	Height;	chr6:26072168	chr6:26013241~26013757:+
PCPG	cis	rs5769765	0.874	rs11703411	ENSG00000278869.1	CITF22-49E9.3	-3.94	0.000125	0.0393	-0.37	-0.31	Schizophrenia;	chr22:49865103	chr22:49933198~49934074:-
PCPG	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-3.94	0.000125	0.0393	-0.35	-0.31	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
PCPG	cis	rs11858159	0.874	rs9920852	ENSG00000260760.1	PWRN3	3.94	0.000125	0.0393	0.31	0.31	Platelet thrombus formation;	chr15:24551018	chr15:24441127~24447967:+
PCPG	cis	rs5769765	0.773	rs7410291	ENSG00000278869.1	CITF22-49E9.3	3.94	0.000125	0.0393	0.37	0.31	Schizophrenia;	chr22:49906430	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.955	rs9616366	ENSG00000278869.1	CITF22-49E9.3	3.94	0.000125	0.0393	0.37	0.31	Schizophrenia;	chr22:49907530	chr22:49933198~49934074:-
PCPG	cis	rs7819412	0.645	rs4841508	ENSG00000255020.1	AF131216.5	-3.94	0.000125	0.0393	-0.41	-0.31	Triglycerides;	chr8:11207494	chr8:11345748~11347502:-
PCPG	cis	rs11214589	0.651	rs11214596	ENSG00000256757.1	RP11-159N11.3	3.94	0.000125	0.0393	0.32	0.31	Neuroticism;	chr11:113393789	chr11:113405321~113412117:+
PCPG	cis	rs11858159	0.618	rs12593131	ENSG00000259905.4	PWRN1	3.94	0.000126	0.0393	0.35	0.31	Platelet thrombus formation;	chr15:24140667	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.618	rs12593133	ENSG00000259905.4	PWRN1	3.94	0.000126	0.0393	0.35	0.31	Platelet thrombus formation;	chr15:24140676	chr15:24493137~24652130:+
PCPG	cis	rs11858159	0.618	rs4778411	ENSG00000259905.4	PWRN1	3.94	0.000126	0.0393	0.35	0.31	Platelet thrombus formation;	chr15:24140980	chr15:24493137~24652130:+
PCPG	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-3.94	0.000126	0.0393	-0.26	-0.31	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
PCPG	cis	rs57933945	1	rs77897311	ENSG00000260034.1	LCMT1-AS2	3.94	0.000126	0.0393	0.64	0.31	Cleft palate;	chr16:25189643	chr16:25140577~25149032:-
PCPG	cis	rs4789693	0.938	rs4789694	ENSG00000279744.1	RP13-20L14.10	3.94	0.000126	0.0393	0.28	0.31	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82462601~82464255:+
PCPG	cis	rs11148252	0.574	rs73186430	ENSG00000273784.3	RP11-78J21.7	-3.94	0.000126	0.0393	-0.29	-0.31	Lewy body disease;	chr13:52658756	chr13:52600042~52642542:+
PCPG	cis	rs9393777	0.841	rs13191474	ENSG00000219392.1	RP1-265C24.5	-3.94	0.000126	0.0393	-0.65	-0.31	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28115628~28116551:+
PCPG	cis	rs6456042	1	rs6456042	ENSG00000231297.3	RP11-459F1.2	-3.94	0.000126	0.0393	-0.33	-0.31	Asthma;	chr6:166121254	chr6:166099665~166113273:+
PCPG	cis	rs7772486	0.806	rs7740785	ENSG00000270638.1	RP3-466P17.1	3.94	0.000126	0.0393	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145735570~145737218:+
PCPG	cis	rs7819412	0.539	rs11250131	ENSG00000255556.2	RP11-351I21.6	-3.94	0.000126	0.0393	-0.32	-0.31	Triglycerides;	chr8:11393666	chr8:12378679~12380265:-
PCPG	cis	rs2836974	0.568	rs2183573	ENSG00000255568.3	BRWD1-AS2	-3.94	0.000126	0.0393	-0.31	-0.31	Cognitive function;	chr21:39202379	chr21:39313935~39314962:+
PCPG	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	3.94	0.000126	0.0393	0.31	0.31	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
PCPG	cis	rs992157	0.71	rs6752254	ENSG00000273466.1	RP11-548H3.1	3.94	0.000126	0.0393	0.17	0.31	Colorectal cancer;	chr2:218194020	chr2:218633256~218634014:-
PCPG	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	3.94	0.000126	0.0394	0.39	0.31	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
PCPG	cis	rs896854	1	rs896854	ENSG00000253528.2	RP11-347C18.4	3.94	0.000126	0.0394	0.34	0.31	Type 2 diabetes;	chr8:94948283	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.967	rs1320164	ENSG00000253528.2	RP11-347C18.4	3.94	0.000126	0.0394	0.34	0.31	Type 2 diabetes;	chr8:94948539	chr8:94974573~94974853:-
PCPG	cis	rs896854	0.902	rs896852	ENSG00000253528.2	RP11-347C18.4	3.94	0.000126	0.0394	0.34	0.31	Type 2 diabetes;	chr8:94948658	chr8:94974573~94974853:-
PCPG	cis	rs896854	1	rs7003387	ENSG00000253528.2	RP11-347C18.4	3.94	0.000126	0.0394	0.34	0.31	Type 2 diabetes;	chr8:94949751	chr8:94974573~94974853:-
PCPG	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-3.94	0.000126	0.0394	-0.31	-0.31	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
PCPG	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	3.94	0.000126	0.0394	0.34	0.31	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
PCPG	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	3.94	0.000126	0.0394	0.34	0.31	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
PCPG	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	3.94	0.000126	0.0394	0.3	0.31	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	3.94	0.000126	0.0394	0.3	0.31	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
PCPG	cis	rs7707921	0.881	rs112355050	ENSG00000249483.1	CTD-2249K22.1	-3.94	0.000126	0.0394	-0.42	-0.31	Breast cancer;	chr5:82090216	chr5:81851601~81852201:+
PCPG	cis	rs7824557	0.767	rs6985460	ENSG00000184608.7	FAM167A-AS1	3.94	0.000126	0.0394	0.43	0.31	Retinal vascular caliber;	chr8:11313578	chr8:11368402~11438658:+
PCPG	cis	rs964611	0.882	rs4775747	ENSG00000259488.2	RP11-154J22.1	-3.94	0.000126	0.0394	-0.29	-0.31	Metabolite levels (Pyroglutamine);	chr15:48346146	chr15:48312353~48331856:-
PCPG	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	3.94	0.000126	0.0394	0.39	0.31	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
PCPG	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-3.94	0.000126	0.0394	-0.34	-0.31	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
PCPG	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-3.94	0.000126	0.0395	-0.39	-0.31	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
PCPG	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-3.94	0.000126	0.0395	-0.37	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
PCPG	cis	rs72753537	0.872	rs10983892	ENSG00000159712.10	ANKRD18CP	3.94	0.000126	0.0395	0.63	0.31	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97833868	chr9:97156570~97221235:-
PCPG	cis	rs72753537	0.81	rs10983896	ENSG00000159712.10	ANKRD18CP	3.94	0.000126	0.0395	0.63	0.31	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97834046	chr9:97156570~97221235:-
PCPG	cis	rs4835473	0.932	rs12503900	ENSG00000251600.4	RP11-673E1.1	-3.94	0.000126	0.0395	-0.36	-0.31	Immature fraction of reticulocytes;	chr4:143812459	chr4:143912331~143982454:+
PCPG	cis	rs6121246	0.954	rs7266148	ENSG00000230613.1	HM13-AS1	3.94	0.000126	0.0395	0.44	0.31	Mean corpuscular hemoglobin;	chr20:31843267	chr20:31567707~31573263:-
PCPG	cis	rs763121	0.853	rs1569492	ENSG00000273076.1	RP3-508I15.22	-3.94	0.000126	0.0395	-0.31	-0.31	Menopause (age at onset);	chr22:38579506	chr22:38743495~38743910:+
PCPG	cis	rs12928939	0.815	rs10500560	ENSG00000260886.1	TAT-AS1	3.94	0.000126	0.0395	0.39	0.31	Post bronchodilator FEV1;	chr16:71647250	chr16:71565789~71578187:+
PCPG	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	3.94	0.000126	0.0395	0.38	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
PCPG	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	3.94	0.000126	0.0395	0.4	0.31	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
PCPG	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	3.94	0.000126	0.0395	0.5	0.31	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
PCPG	cis	rs4237845	0.816	rs61935769	ENSG00000257698.1	RP11-620J15.3	-3.94	0.000126	0.0395	-0.28	-0.31	Intelligence (multi-trait analysis);	chr12:57900561	chr12:57931528~57936175:-
PCPG	cis	rs7829975	0.681	rs2271342	ENSG00000173295.6	FAM86B3P	-3.94	0.000126	0.0395	-0.37	-0.31	Mood instability;	chr8:8786428	chr8:8228595~8244865:+
PCPG	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-3.94	0.000126	0.0395	-0.37	-0.31	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
PCPG	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	3.94	0.000126	0.0395	0.4	0.31	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
PCPG	cis	rs12765878	1	rs3850671	ENSG00000260461.1	RP11-541N10.3	3.94	0.000127	0.0395	0.35	0.31	Coronary artery disease;	chr10:103899629	chr10:103877374~103879761:-
PCPG	cis	rs17684571	0.7	rs17752002	ENSG00000231441.1	RP11-472M19.2	3.94	0.000127	0.0395	0.51	0.31	Schizophrenia;	chr6:56812209	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.872	rs4640889	ENSG00000231441.1	RP11-472M19.2	-3.94	0.000127	0.0395	-0.49	-0.31	Schizophrenia;	chr6:56740534	chr6:56844002~56864078:+
PCPG	cis	rs11220082	0.787	rs11220064	ENSG00000254671.2	STT3A-AS1	-3.94	0.000127	0.0396	-0.32	-0.31	Schizophrenia;	chr11:125424186	chr11:125570284~125592568:-
PCPG	cis	rs2404602	0.692	rs12911902	ENSG00000259514.1	RP11-685G9.2	-3.94	0.000127	0.0396	-0.31	-0.31	Blood metabolite levels;	chr15:76761234	chr15:76339609~76342063:-
PCPG	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	3.94	0.000127	0.0396	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
PCPG	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	3.94	0.000127	0.0396	0.43	0.31	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
PCPG	cis	rs801193	1	rs2055682	ENSG00000273142.1	RP11-458F8.4	-3.94	0.000127	0.0396	-0.29	-0.31	Aortic root size;	chr7:66795302	chr7:66902857~66906297:+
PCPG	cis	rs703842	1	rs10747783	ENSG00000270039.1	RP11-571M6.17	-3.94	0.000127	0.0396	-0.38	-0.31	Multiple sclerosis;	chr12:57782831	chr12:57803838~57804415:+
PCPG	cis	rs703842	0.964	rs10431552	ENSG00000270039.1	RP11-571M6.17	-3.94	0.000127	0.0396	-0.38	-0.31	Multiple sclerosis;	chr12:57784365	chr12:57803838~57804415:+
PCPG	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	3.94	0.000127	0.0396	0.38	0.31	Height;	chr4:55387515	chr4:55363971~55395847:-
PCPG	cis	rs4791051	0.706	rs55931613	ENSG00000264491.1	RP11-349A8.3	-3.94	0.000127	0.0396	-0.32	-0.31	Heschl's gyrus morphology;	chr17:66479323	chr17:67019934~67021743:-
PCPG	cis	rs4791051	0.706	rs6504435	ENSG00000264491.1	RP11-349A8.3	-3.94	0.000127	0.0396	-0.32	-0.31	Heschl's gyrus morphology;	chr17:66483443	chr17:67019934~67021743:-
PCPG	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	3.94	0.000127	0.0396	0.31	0.31	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
PCPG	cis	rs8098244	0.638	rs9962076	ENSG00000265752.2	RP11-403A21.1	3.94	0.000127	0.0396	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23850198	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.638	rs2001437	ENSG00000265752.2	RP11-403A21.1	3.94	0.000127	0.0396	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23854811	chr18:23957754~23982556:-
PCPG	cis	rs2735413	0.563	rs11640933	ENSG00000276007.1	RP11-358L22.3	3.94	0.000127	0.0396	0.34	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78031710	chr16:78123243~78124332:+
PCPG	cis	rs17152411	0.817	rs4478950	ENSG00000278831.1	RP11-12J10.4	3.93	0.000127	0.0396	0.42	0.31	Height;	chr10:124907856	chr10:124623353~124624079:+
PCPG	cis	rs394563	0.619	rs4895787	ENSG00000231760.4	RP11-350J20.5	-3.93	0.000127	0.0396	-0.38	-0.31	Dupuytren's disease;	chr6:149325364	chr6:149796151~149826294:-
PCPG	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	3.93	0.000127	0.0396	0.4	0.31	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	3.93	0.000127	0.0396	0.4	0.31	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
PCPG	cis	rs8064024	0.65	rs8056889	ENSG00000267077.1	RP11-127I20.5	3.93	0.000127	0.0397	0.36	0.31	Cancer;	chr16:4853242	chr16:4795265~4796532:-
PCPG	cis	rs591584	0.59	rs7126782	ENSG00000255893.1	RP11-685N10.1	-3.93	0.000127	0.0397	-0.37	-0.31	Macrophage Migration Inhibitory Factor levels;	chr11:94590674	chr11:94472908~94473570:-
PCPG	cis	rs5769765	0.955	rs2295406	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000127	0.0397	-0.37	-0.31	Schizophrenia;	chr22:49866521	chr22:49933198~49934074:-
PCPG	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-3.93	0.000127	0.0397	-0.34	-0.31	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
PCPG	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	3.93	0.000128	0.0398	0.36	0.31	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
PCPG	cis	rs131777	0.545	rs131759	ENSG00000205559.3	CHKB-AS1	-3.93	0.000128	0.0398	-0.34	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50577052	chr22:50583026~50583877:+
PCPG	cis	rs9311676	0.632	rs11714870	ENSG00000273493.1	RP11-80H18.4	3.93	0.000128	0.0398	0.32	0.31	Systemic lupus erythematosus;	chr3:58442670	chr3:58329965~58330118:+
PCPG	cis	rs67539049	0.891	rs73209223	ENSG00000255020.1	AF131216.5	-3.93	0.000128	0.0398	-0.56	-0.31	Itch intensity from mosquito bite;	chr8:11447435	chr8:11345748~11347502:-
PCPG	cis	rs440932	0.887	rs398801	ENSG00000173295.6	FAM86B3P	3.93	0.000128	0.0398	0.35	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:8228595~8244865:+
PCPG	cis	rs4713118	0.588	rs200994	ENSG00000220721.1	OR1F12	-3.93	0.000128	0.0398	-0.4	-0.31	Parkinson's disease;	chr6:27846035	chr6:28073316~28074233:+
PCPG	cis	rs2243480	1	rs313807	ENSG00000251451.1	GS1-124K5.6	3.93	0.000128	0.0398	0.56	0.31	Diabetic kidney disease;	chr7:66034494	chr7:66407288~66409239:-
PCPG	cis	rs5769765	0.955	rs8139758	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49867475	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.913	rs2319462	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49869722	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.955	rs5769761	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49869993	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.954	rs5769762	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49870394	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs34774661	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49873860	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs4824106	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49874174	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.954	rs5770739	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49874366	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs5770741	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49876567	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs5770742	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49876661	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs4597652	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49876922	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs5769764	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49877136	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs5769765	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49877528	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.908	rs4824109	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49877812	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.837	rs4824110	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49877983	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.74	rs2103932	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49878867	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs8184990	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49879526	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.955	rs5770750	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49883180	chr22:49933198~49934074:-
PCPG	cis	rs5769765	0.955	rs5769767	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49883261	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs2092982	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49888556	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs738711	ENSG00000278869.1	CITF22-49E9.3	-3.93	0.000128	0.0398	-0.37	-0.31	Schizophrenia;	chr22:49888955	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs764813	ENSG00000278869.1	CITF22-49E9.3	3.93	0.000128	0.0398	0.37	0.31	Schizophrenia;	chr22:49892524	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs768618	ENSG00000278869.1	CITF22-49E9.3	3.93	0.000128	0.0398	0.37	0.31	Schizophrenia;	chr22:49893179	chr22:49933198~49934074:-
PCPG	cis	rs5769765	1	rs768619	ENSG00000278869.1	CITF22-49E9.3	3.93	0.000128	0.0398	0.37	0.31	Schizophrenia;	chr22:49893618	chr22:49933198~49934074:-
PCPG	cis	rs7172677	0.768	rs72730587	ENSG00000261543.1	RP11-665J16.1	3.93	0.000128	0.0398	0.38	0.31	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75065712	chr15:74152800~74179226:-
PCPG	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0398	0.39	0.31	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
PCPG	cis	rs6452524	0.618	rs6452506	ENSG00000281327.1	LINC01338	3.93	0.000128	0.0398	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:82850864~82859836:-
PCPG	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	3.93	0.000128	0.0399	0.3	0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
PCPG	cis	rs58785573	0.57	rs1824652	ENSG00000231160.8	KLF3-AS1	-3.93	0.000128	0.0399	-0.27	-0.31	Lymphocyte percentage of white cells;	chr4:38642976	chr4:38612701~38664883:-
PCPG	cis	rs11723261	0.513	rs2353623	ENSG00000250892.1	RP11-1365D11.1	3.93	0.000128	0.0399	0.43	0.31	Immune response to smallpox vaccine (IL-6);	chr4:95673	chr4:201409~205009:-
PCPG	cis	rs394563	0.591	rs237018	ENSG00000268592.3	RAET1E-AS1	3.93	0.000128	0.0399	0.37	0.31	Dupuytren's disease;	chr6:149422794	chr6:149863494~149919507:+
PCPG	cis	rs8042680	0.688	rs4244883	ENSG00000214432.8	AC068831.10	-3.93	0.000128	0.0399	-0.35	-0.31	Type 2 diabetes;	chr15:91003267	chr15:91022619~91036611:+
PCPG	cis	rs6517329	0.538	rs4816521	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36138440	chr21:36131767~36175815:-
PCPG	cis	rs6517329	0.538	rs8126939	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36140649	chr21:36131767~36175815:-
PCPG	cis	rs6517329	0.538	rs4817781	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36141298	chr21:36131767~36175815:-
PCPG	cis	rs6517329	0.538	rs4817782	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36141449	chr21:36131767~36175815:-
PCPG	cis	rs6517329	0.538	rs1056892	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36146408	chr21:36131767~36175815:-
PCPG	cis	rs6517329	0.538	rs4510305	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36148374	chr21:36131767~36175815:-
PCPG	cis	rs6517329	0.513	rs62229302	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36156202	chr21:36131767~36175815:-
PCPG	cis	rs6517329	0.513	rs61232790	ENSG00000236830.5	CBR3-AS1	-3.93	0.000128	0.0399	-0.26	-0.31	Schizophrenia;	chr21:36156559	chr21:36131767~36175815:-
PCPG	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	3.93	0.000128	0.0399	0.55	0.31	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
PCPG	cis	rs2952156	0.92	rs2247862	ENSG00000279199.1	RP11-749I16.3	3.93	0.000128	0.0399	0.3	0.31	Asthma;	chr17:39672876	chr17:40113215~40115442:-
PCPG	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-3.93	0.000128	0.0399	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-3.93	0.000128	0.0399	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
PCPG	cis	rs4143844	0.867	rs12901055	ENSG00000259251.2	RP11-643M14.1	3.93	0.000128	0.0399	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61880708	chr15:62060503~62062434:+
PCPG	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	3.93	0.000128	0.0399	0.38	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
PCPG	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	3.93	0.000128	0.0399	0.39	0.31	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
PCPG	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	3.93	0.000128	0.0399	0.39	0.31	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
PCPG	cis	rs921665	1	rs7581068	ENSG00000237370.1	AC010907.2	3.93	0.000128	0.04	0.52	0.31	World class endurance athleticism;	chr2:3175060	chr2:3603397~3604242:-
PCPG	cis	rs12079745	0.793	rs3766064	ENSG00000234604.2	RP1-206D15.5	-3.93	0.000128	0.04	-0.58	-0.31	QT interval;	chr1:169188681	chr1:169474060~169474159:-
PCPG	cis	rs34421088	0.531	rs2245232	ENSG00000269954.1	RP11-148O21.6	-3.93	0.000128	0.04	-0.35	-0.31	Neuroticism;	chr8:11543435	chr8:11552488~11552991:-
PCPG	cis	rs853679	0.546	rs13213152	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Depression;	chr6:28381921	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs13213986	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Depression;	chr6:28390232	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs34546986	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Depression;	chr6:28394532	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs34871267	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Depression;	chr6:28396455	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs35883476	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Depression;	chr6:28400731	chr6:28115628~28116551:+
PCPG	cis	rs6921919	0.673	rs13201681	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28115628~28116551:+
PCPG	cis	rs6921919	0.778	rs67381177	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28115628~28116551:+
PCPG	cis	rs138024639	1	rs138024639	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Breast cancer;	chr6:28468244	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs55690788	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Depression;	chr6:28468368	chr6:28115628~28116551:+
PCPG	cis	rs13191038	1	rs13191038	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000129	0.04	-0.69	-0.31	Urinary tract infection frequency;	chr6:28515140	chr6:28115628~28116551:+
PCPG	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	3.93	0.000129	0.04	0.64	0.31	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
PCPG	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	3.93	0.000129	0.04	0.64	0.31	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
PCPG	cis	rs6012953	1	rs6063533	ENSG00000231742.4	LINC01273	-3.93	0.000129	0.04	-0.31	-0.31	Vitiligo;	chr20:50542862	chr20:50172550~50176671:+
PCPG	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-3.93	0.000129	0.04	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
PCPG	cis	rs34421088	0.56	rs2467520	ENSG00000254774.1	RP11-148O21.3	-3.93	0.000129	0.04	-0.35	-0.31	Neuroticism;	chr8:11541444	chr8:11553224~11554207:-
PCPG	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	3.93	0.000129	0.04	0.27	0.31	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
PCPG	cis	rs7707921	0.881	rs73136782	ENSG00000249483.1	CTD-2249K22.1	-3.93	0.000129	0.04	-0.42	-0.31	Breast cancer;	chr5:82147701	chr5:81851601~81852201:+
PCPG	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	3.93	0.000129	0.0401	0.26	0.31	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
PCPG	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	3.93	0.000129	0.0401	0.4	0.31	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
PCPG	cis	rs1062177	1	rs62377945	ENSG00000249035.5	CTB-113P19.1	-3.93	0.000129	0.0401	-0.38	-0.31	Preschool internalizing problems;	chr5:151828443	chr5:151676945~151724782:+
PCPG	cis	rs8064024	0.68	rs2063101	ENSG00000267077.1	RP11-127I20.5	3.93	0.000129	0.0401	0.36	0.31	Cancer;	chr16:4866347	chr16:4795265~4796532:-
PCPG	cis	rs6901152	0.869	rs7454731	ENSG00000217648.1	RP1-95L4.4	-3.93	0.000129	0.0401	-0.36	-0.31	Acute lymphoblastic leukemia (childhood);	chr6:143340963	chr6:143342246~143343383:+
PCPG	cis	rs2733954	0.707	rs9931892	ENSG00000179219.5	LINC00311	-3.93	0.000129	0.0401	-0.41	-0.31	Leprosy;	chr16:85791923	chr16:85282958~85285963:+
PCPG	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	3.93	0.000129	0.0401	0.41	0.31	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
PCPG	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	3.93	0.000129	0.0401	0.25	0.31	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
PCPG	cis	rs875971	0.666	rs13242072	ENSG00000273142.1	RP11-458F8.4	3.93	0.000129	0.0401	0.28	0.31	Aortic root size;	chr7:66301001	chr7:66902857~66906297:+
PCPG	cis	rs78579285	0.545	rs79311053	ENSG00000260630.5	SNAI3-AS1	-3.93	0.000129	0.0401	-0.56	-0.31	Joint mobility (Beighton score);	chr16:88718798	chr16:88663298~88687186:+
PCPG	cis	rs78579285	0.545	rs113385327	ENSG00000260630.5	SNAI3-AS1	-3.93	0.000129	0.0401	-0.56	-0.31	Joint mobility (Beighton score);	chr16:88718834	chr16:88663298~88687186:+
PCPG	cis	rs6012953	0.967	rs4496379	ENSG00000231742.4	LINC01273	-3.93	0.000129	0.0401	-0.31	-0.31	Vitiligo;	chr20:50543407	chr20:50172550~50176671:+
PCPG	cis	rs2243480	1	rs316307	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66105184	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.908	rs313822	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66108952	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs313820	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66109479	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs431076	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66135333	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.764	rs2460423	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66136229	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs2460422	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66136518	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316334	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66137139	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs410128	ENSG00000230189.5	GS1-124K5.2	3.93	0.000129	0.0401	0.46	0.31	Diabetic kidney disease;	chr7:66138186	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1499613	ENSG00000230189.5	GS1-124K5.2	-3.93	0.000129	0.0401	-0.46	-0.31	Diabetic kidney disease;	chr7:66265873	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1553174	ENSG00000230189.5	GS1-124K5.2	-3.93	0.000129	0.0401	-0.46	-0.31	Diabetic kidney disease;	chr7:66266207	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs10950032	ENSG00000230189.5	GS1-124K5.2	-3.93	0.000129	0.0401	-0.46	-0.31	Diabetic kidney disease;	chr7:66273604	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs6958420	ENSG00000230189.5	GS1-124K5.2	-3.93	0.000129	0.0401	-0.46	-0.31	Diabetic kidney disease;	chr7:66286184	chr7:66409143~66490059:-
PCPG	cis	rs13263959	0.636	rs7830635	ENSG00000253307.1	RP11-10J21.4	-3.93	0.000129	0.0402	-0.39	-0.31	Hair color;	chr8:141629361	chr8:141252286~141253292:-
PCPG	cis	rs2404602	0.692	rs60658665	ENSG00000259514.1	RP11-685G9.2	-3.93	0.000129	0.0402	-0.31	-0.31	Blood metabolite levels;	chr15:76750167	chr15:76339609~76342063:-
PCPG	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	3.93	0.000129	0.0402	0.4	0.31	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
PCPG	cis	rs302972	0.826	rs303010	ENSG00000168405.13	CMAHP	-3.93	0.000129	0.0402	-0.5	-0.31	Creatinine levels in ischemic stroke;	chr6:25081877	chr6:25081068~25166555:-
PCPG	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	3.93	0.000129	0.0402	0.39	0.31	Height;	chr6:109416903	chr6:109382795~109383666:+
PCPG	cis	rs6456042	1	rs6940243	ENSG00000231297.3	RP11-459F1.2	-3.93	0.000129	0.0402	-0.33	-0.31	Asthma;	chr6:166121170	chr6:166099665~166113273:+
PCPG	cis	rs711830	1	rs1318778	ENSG00000226363.3	HAGLROS	-3.93	0.000129	0.0402	-0.33	-0.31	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176173103	chr2:176177717~176179008:+
PCPG	cis	rs950169	1	rs62026530	ENSG00000235370.6	DNM1P51	3.93	0.000129	0.0402	0.31	0.31	Schizophrenia;	chr15:84107088	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs35658069	ENSG00000235370.6	DNM1P51	3.93	0.000129	0.0402	0.31	0.31	Schizophrenia;	chr15:84111394	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs11638297	ENSG00000235370.6	DNM1P51	3.93	0.000129	0.0402	0.31	0.31	Schizophrenia;	chr15:84113665	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs79318564	ENSG00000235370.6	DNM1P51	3.93	0.000129	0.0402	0.31	0.31	Schizophrenia;	chr15:84117398	chr15:84398316~84411701:-
PCPG	cis	rs950169	1	rs1911155	ENSG00000235370.6	DNM1P51	3.93	0.000129	0.0402	0.31	0.31	Schizophrenia;	chr15:84118883	chr15:84398316~84411701:-
PCPG	cis	rs2797160	0.651	rs1269176	ENSG00000237742.5	RP11-624M8.1	-3.93	0.000129	0.0402	-0.32	-0.31	Endometrial cancer;	chr6:125708536	chr6:125578558~125749190:-
PCPG	cis	rs2625529	0.823	rs11072332	ENSG00000260037.4	CTD-2524L6.3	-3.93	0.00013	0.0402	-0.51	-0.31	Red blood cell count;	chr15:71815966	chr15:71818396~71823384:+
PCPG	cis	rs2974238	1	rs2974238	ENSG00000269814.1	CTC-273B12.10	3.93	0.00013	0.0402	0.35	0.31	Parental longevity (mother's age at death);	chr19:47613804	chr19:48513207~48513660:-
PCPG	cis	rs11020821	0.886	rs16912567	ENSG00000255893.1	RP11-685N10.1	-3.93	0.00013	0.0402	-0.41	-0.31	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94536839	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs12576083	ENSG00000255893.1	RP11-685N10.1	-3.93	0.00013	0.0402	-0.41	-0.31	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94537839	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs113242956	ENSG00000255893.1	RP11-685N10.1	-3.93	0.00013	0.0402	-0.41	-0.31	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94539300	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs72963816	ENSG00000255893.1	RP11-685N10.1	-3.93	0.00013	0.0402	-0.41	-0.31	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94539634	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs72963821	ENSG00000255893.1	RP11-685N10.1	-3.93	0.00013	0.0402	-0.41	-0.31	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94540820	chr11:94472908~94473570:-
PCPG	cis	rs2212361	0.558	rs72963823	ENSG00000255893.1	RP11-685N10.1	-3.93	0.00013	0.0402	-0.41	-0.31	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94540874	chr11:94472908~94473570:-
PCPG	cis	rs17772222	0.917	rs61986670	ENSG00000222990.1	RNU4-22P	3.93	0.00013	0.0402	0.4	0.31	Coronary artery calcification;	chr14:88730875	chr14:88513498~88513663:+
PCPG	cis	rs7181230	1	rs28620926	ENSG00000259584.1	RP11-521C20.2	3.93	0.00013	0.0402	0.39	0.31	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:40075204~40078704:-
PCPG	cis	rs2404602	0.631	rs9646213	ENSG00000259514.1	RP11-685G9.2	-3.93	0.00013	0.0402	-0.31	-0.31	Blood metabolite levels;	chr15:76515331	chr15:76339609~76342063:-
PCPG	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	3.93	0.00013	0.0403	0.3	0.31	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
PCPG	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	3.93	0.00013	0.0403	0.43	0.31	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
PCPG	cis	rs7610312	0.646	rs6764635	ENSG00000273493.1	RP11-80H18.4	-3.93	0.00013	0.0403	-0.37	-0.31	Red blood cell count;	chr3:58291802	chr3:58329965~58330118:+
PCPG	cis	rs7610312	0.681	rs1554127	ENSG00000273493.1	RP11-80H18.4	-3.93	0.00013	0.0403	-0.37	-0.31	Red blood cell count;	chr3:58291819	chr3:58329965~58330118:+
PCPG	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	3.93	0.00013	0.0403	0.43	0.31	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
PCPG	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	3.93	0.00013	0.0403	0.44	0.31	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
PCPG	cis	rs8098244	0.557	rs4347707	ENSG00000265752.2	RP11-403A21.1	3.93	0.00013	0.0403	0.35	0.31	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710362	chr18:23957754~23982556:-
PCPG	cis	rs7937890	0.505	rs1403248	ENSG00000251991.1	RNU7-49P	3.93	0.00013	0.0403	0.33	0.31	Mitochondrial DNA levels;	chr11:14657471	chr11:14478892~14478953:+
PCPG	cis	rs1003719	0.68	rs2835629	ENSG00000228677.1	TTC3-AS1	-3.93	0.00013	0.0403	-0.37	-0.31	Eye color traits;	chr21:37149360	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs767998	ENSG00000228677.1	TTC3-AS1	-3.93	0.00013	0.0403	-0.37	-0.31	Eye color traits;	chr21:37153352	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.582	rs2835634	ENSG00000228677.1	TTC3-AS1	-3.93	0.00013	0.0403	-0.37	-0.31	Eye color traits;	chr21:37155969	chr21:37187666~37193926:-
PCPG	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	3.93	0.00013	0.0403	0.28	0.31	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
PCPG	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	3.93	0.00013	0.0403	0.39	0.31	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	3.93	0.00013	0.0403	0.39	0.31	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
PCPG	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	3.93	0.00013	0.0403	0.39	0.31	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
PCPG	cis	rs10411161	0.657	rs67462252	ENSG00000275055.1	CTC-471J1.11	-3.93	0.00013	0.0403	-0.33	-0.31	Breast cancer;	chr19:51879598	chr19:52049007~52049754:+
PCPG	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	3.93	0.00013	0.0403	0.35	0.31	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
PCPG	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	3.93	0.00013	0.0404	0.35	0.31	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
PCPG	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-3.93	0.00013	0.0404	-0.27	-0.31	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
PCPG	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	3.93	0.00013	0.0404	0.35	0.31	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
PCPG	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	3.93	0.00013	0.0404	0.36	0.31	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
PCPG	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	3.93	0.00013	0.0404	0.36	0.31	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
PCPG	cis	rs62229266	0.771	rs7280136	ENSG00000230212.5	AP000688.14	3.93	0.00013	0.0404	0.35	0.31	Mitral valve prolapse;	chr21:36060612	chr21:36069642~36126640:-
PCPG	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-3.93	0.00013	0.0404	-0.25	-0.31	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
PCPG	cis	rs2243480	0.666	rs1880311	ENSG00000230189.5	GS1-124K5.2	-3.93	0.00013	0.0404	-0.49	-0.31	Diabetic kidney disease;	chr7:65811765	chr7:66409143~66490059:-
PCPG	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	3.93	0.00013	0.0404	0.3	0.31	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	3.93	0.00013	0.0404	0.3	0.31	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	3.93	0.00013	0.0404	0.3	0.31	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
PCPG	cis	rs6832769	1	rs35767091	ENSG00000272969.1	RP11-528I4.2	3.93	0.00013	0.0404	0.33	0.31	Personality dimensions;	chr4:55480556	chr4:55547112~55547889:+
PCPG	cis	rs6832769	0.961	rs11735267	ENSG00000272969.1	RP11-528I4.2	3.93	0.00013	0.0404	0.33	0.31	Personality dimensions;	chr4:55481120	chr4:55547112~55547889:+
PCPG	cis	rs6832769	1	rs3805154	ENSG00000272969.1	RP11-528I4.2	3.93	0.00013	0.0404	0.33	0.31	Personality dimensions;	chr4:55497760	chr4:55547112~55547889:+
PCPG	cis	rs6832769	1	rs7670225	ENSG00000272969.1	RP11-528I4.2	3.93	0.00013	0.0404	0.33	0.31	Personality dimensions;	chr4:55501851	chr4:55547112~55547889:+
PCPG	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	3.93	0.00013	0.0404	0.32	0.31	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
PCPG	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	3.93	0.00013	0.0404	0.32	0.31	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
PCPG	cis	rs9636231	0.906	rs10928678	ENSG00000234645.3	YWHAEP5	-3.93	0.00013	0.0404	-0.32	-0.31	Alcohol dependence;	chr2:138892326	chr2:138288029~138288793:-
PCPG	cis	rs9636231	0.951	rs59923335	ENSG00000234645.3	YWHAEP5	-3.93	0.00013	0.0404	-0.32	-0.31	Alcohol dependence;	chr2:138893595	chr2:138288029~138288793:-
PCPG	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	3.93	0.00013	0.0404	0.32	0.31	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
PCPG	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-3.93	0.00013	0.0404	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
PCPG	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	3.93	0.00013	0.0404	0.51	0.31	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
PCPG	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	3.93	0.000131	0.0405	0.48	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
PCPG	cis	rs763121	0.853	rs2413546	ENSG00000273076.1	RP3-508I15.22	3.93	0.000131	0.0405	0.38	0.31	Menopause (age at onset);	chr22:38710996	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs2413547	ENSG00000273076.1	RP3-508I15.22	3.93	0.000131	0.0405	0.38	0.31	Menopause (age at onset);	chr22:38711333	chr22:38743495~38743910:+
PCPG	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	3.93	0.000131	0.0405	0.36	0.31	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
PCPG	cis	rs12681963	0.688	rs12541087	ENSG00000272375.1	RP11-51J9.6	3.93	0.000131	0.0405	0.43	0.31	Migraine;	chr8:30172398	chr8:30197404~30198048:+
PCPG	cis	rs12681963	0.688	rs12544416	ENSG00000272375.1	RP11-51J9.6	3.93	0.000131	0.0405	0.43	0.31	Migraine;	chr8:30182057	chr8:30197404~30198048:+
PCPG	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	3.93	0.000131	0.0405	0.4	0.31	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
PCPG	cis	rs12681963	0.702	rs2136958	ENSG00000248159.1	HSPA8P11	3.93	0.000131	0.0405	0.46	0.31	Migraine;	chr8:30054156	chr8:30237382~30240997:+
PCPG	cis	rs7772486	0.806	rs4075695	ENSG00000270638.1	RP3-466P17.1	-3.93	0.000131	0.0405	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145735570~145737218:+
PCPG	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	3.93	0.000131	0.0405	0.36	0.31	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	3.93	0.000131	0.0405	0.36	0.31	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	3.93	0.000131	0.0405	0.36	0.31	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	3.93	0.000131	0.0405	0.36	0.31	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
PCPG	cis	rs775326	0.54	rs434365	ENSG00000217416.4	ISCA1P1	-3.93	0.000131	0.0405	-0.31	-0.31	Educational attainment (years of education);	chr5:63297106	chr5:62776877~62777263:-
PCPG	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	3.93	0.000131	0.0405	0.41	0.31	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
PCPG	cis	rs3758785	0.737	rs79512686	ENSG00000255893.1	RP11-685N10.1	-3.93	0.000131	0.0405	-0.46	-0.31	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94398331	chr11:94472908~94473570:-
PCPG	cis	rs1003719	0.715	rs2051398	ENSG00000228677.1	TTC3-AS1	3.93	0.000131	0.0405	0.37	0.31	Eye color traits;	chr21:37177956	chr21:37187666~37193926:-
PCPG	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-3.93	0.000131	0.0405	-0.35	-0.31	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
PCPG	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	3.93	0.000131	0.0405	0.35	0.31	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
PCPG	cis	rs4934494	0.813	rs12775783	ENSG00000240996.1	RP11-80H5.7	-3.93	0.000131	0.0406	-0.45	-0.31	Red blood cell count;	chr10:89646494	chr10:89694295~89697928:-
PCPG	cis	rs28386778	0.863	rs1376110	ENSG00000240280.5	TCAM1P	-3.93	0.000131	0.0406	-0.41	-0.31	Prudent dietary pattern;	chr17:63702567	chr17:63849292~63864379:+
PCPG	cis	rs2412459	0.635	rs2307107	ENSG00000245849.5	RAD51-AS1	-3.93	0.000131	0.0406	-0.52	-0.31	Response to haloperidol in psychosis;	chr15:39973109	chr15:40686724~40695107:-
PCPG	cis	rs7267979	0.932	rs6115215	ENSG00000276952.1	RP5-965G21.6	3.93	0.000131	0.0406	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25284915~25285588:-
PCPG	cis	rs7267979	0.866	rs6138609	ENSG00000276952.1	RP5-965G21.6	3.93	0.000131	0.0406	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25284915~25285588:-
PCPG	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	3.93	0.000131	0.0406	0.4	0.31	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
PCPG	cis	rs4803480	0.63	rs16975338	ENSG00000269374.1	CTB-50E14.5	-3.93	0.000131	0.0406	-0.46	-0.31	Schizophrenia;	chr19:41551655	chr19:42485076~42485714:-
PCPG	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	3.93	0.000131	0.0406	0.39	0.31	Height;	chr6:109415123	chr6:109382795~109383666:+
PCPG	cis	rs2069757	0.632	rs2243300	ENSG00000235253.1	AC010240.2	-3.93	0.000131	0.0406	-0.66	-0.31	Hodgkin's lymphoma;	chr5:132668394	chr5:132942932~132945050:+
PCPG	cis	rs4143844	0.867	rs17303915	ENSG00000259251.2	RP11-643M14.1	3.93	0.000131	0.0406	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61882695	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs12902859	ENSG00000259251.2	RP11-643M14.1	3.93	0.000131	0.0406	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61884966	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs12185103	ENSG00000259251.2	RP11-643M14.1	3.93	0.000131	0.0406	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61889092	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs35559361	ENSG00000259251.2	RP11-643M14.1	3.93	0.000131	0.0406	0.64	0.31	Bipolar disorder and schizophrenia;	chr15:61891318	chr15:62060503~62062434:+
PCPG	cis	rs9880211	1	rs4038586	ENSG00000273486.1	RP11-731C17.2	3.93	0.000131	0.0406	0.41	0.31	Height;Body mass index;	chr3:136644449	chr3:136837338~136839021:-
PCPG	cis	rs9880211	1	rs6767889	ENSG00000273486.1	RP11-731C17.2	3.93	0.000131	0.0406	0.41	0.31	Height;Body mass index;	chr3:136646613	chr3:136837338~136839021:-
PCPG	cis	rs6445967	0.554	rs10866018	ENSG00000273493.1	RP11-80H18.4	-3.93	0.000131	0.0406	-0.34	-0.31	Platelet count;	chr3:58460273	chr3:58329965~58330118:+
PCPG	cis	rs6452524	0.618	rs7722924	ENSG00000281327.1	LINC01338	3.93	0.000131	0.0406	0.33	0.31	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:82850864~82859836:-
PCPG	cis	rs9650657	0.645	rs9969657	ENSG00000255020.1	AF131216.5	3.93	0.000131	0.0406	0.38	0.31	Neuroticism;	chr8:10657768	chr8:11345748~11347502:-
PCPG	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	3.93	0.000131	0.0406	0.44	0.31	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
PCPG	cis	rs1003719	0.68	rs2835630	ENSG00000228677.1	TTC3-AS1	-3.93	0.000131	0.0406	-0.37	-0.31	Eye color traits;	chr21:37149542	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs2257091	ENSG00000228677.1	TTC3-AS1	-3.93	0.000131	0.0406	-0.37	-0.31	Eye color traits;	chr21:37150318	chr21:37187666~37193926:-
PCPG	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	3.93	0.000131	0.0406	0.36	0.31	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
PCPG	cis	rs763121	0.853	rs4820345	ENSG00000273076.1	RP3-508I15.22	3.93	0.000131	0.0406	0.39	0.31	Menopause (age at onset);	chr22:38695146	chr22:38743495~38743910:+
PCPG	cis	rs7575217	0.588	rs11675221	ENSG00000272902.2	RP11-299H21.1	3.93	0.000131	0.0406	0.36	0.31	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;	chr2:101054475	chr2:101151660~101155412:+
PCPG	cis	rs7575217	0.588	rs11675224	ENSG00000272902.2	RP11-299H21.1	3.93	0.000131	0.0406	0.36	0.31	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;	chr2:101054493	chr2:101151660~101155412:+
PCPG	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	3.93	0.000131	0.0406	0.36	0.31	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.536	rs17364330	ENSG00000270036.1	RP11-685G9.4	-3.93	0.000131	0.0406	-0.29	-0.31	Blood metabolite levels;	chr15:76473044	chr15:76343642~76344365:+
PCPG	cis	rs2404602	0.563	rs12914005	ENSG00000270036.1	RP11-685G9.4	-3.93	0.000131	0.0406	-0.29	-0.31	Blood metabolite levels;	chr15:76473326	chr15:76343642~76344365:+
PCPG	cis	rs2404602	0.536	rs7163946	ENSG00000270036.1	RP11-685G9.4	-3.93	0.000131	0.0406	-0.29	-0.31	Blood metabolite levels;	chr15:76473708	chr15:76343642~76344365:+
PCPG	cis	rs2404602	0.536	rs7165025	ENSG00000270036.1	RP11-685G9.4	-3.93	0.000131	0.0406	-0.29	-0.31	Blood metabolite levels;	chr15:76474093	chr15:76343642~76344365:+
PCPG	cis	rs2404602	0.536	rs1587381	ENSG00000270036.1	RP11-685G9.4	-3.93	0.000131	0.0406	-0.29	-0.31	Blood metabolite levels;	chr15:76477279	chr15:76343642~76344365:+
PCPG	cis	rs324126	0.78	rs55748277	ENSG00000277977.1	CTD-3018O17.5	3.93	0.000131	0.0406	0.37	0.31	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52392659~52392755:+
PCPG	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	3.93	0.000131	0.0406	0.39	0.31	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
PCPG	cis	rs7714584	1	rs7736554	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150878746	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs7736873	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150878920	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs7716903	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150879012	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs10041072	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150880080	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs1428552	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150880269	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs10463310	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150881343	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs60134818	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150881481	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs73284126	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150881745	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs7732643	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150881874	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs7732945	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150882039	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs1820682	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150882580	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs2344181	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150883012	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs11746108	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150885060	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs11739619	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150885100	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs11167519	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150885845	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs11167520	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150886077	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs73284141	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150886524	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs3906527	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150886830	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs2345001	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150886956	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs3906528	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150887156	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs2344180	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150887795	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs2880791	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150887814	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs3857422	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150889047	chr5:151509453~151512769:+
PCPG	cis	rs7714584	0.59	rs4352593	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150889770	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs7709464	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150889879	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs10053750	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150890489	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs7714415	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150890730	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs7714584	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150890858	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs6579806	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150891522	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs4958848	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150891560	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs1863998	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150892191	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs11167521	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150892223	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs10057988	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150892500	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs10052606	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150892655	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs57001853	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150892890	chr5:151509453~151512769:+
PCPG	cis	rs7714584	1	rs2217266	ENSG00000271795.1	CTC-251D13.1	-3.93	0.000131	0.0406	-0.57	-0.31	Crohn's disease;	chr5:150893059	chr5:151509453~151512769:+
PCPG	cis	rs1908814	0.51	rs57655799	ENSG00000255518.1	RP11-148O21.4	3.93	0.000131	0.0406	0.36	0.31	Neuroticism;	chr8:11924908	chr8:11556251~11558022:-
PCPG	cis	rs4489787	0.527	rs2731085	ENSG00000240399.1	RP1-228P16.1	3.93	0.000132	0.0407	0.34	0.31	Prostate cancer (SNP x SNP interaction);	chr12:48507516	chr12:48054813~48055591:-
PCPG	cis	rs3758911	0.788	rs10890676	ENSG00000255353.1	RP11-382M14.1	-3.93	0.000132	0.0407	-0.4	-0.31	Coronary artery disease;	chr11:107254631	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.788	rs10890680	ENSG00000255353.1	RP11-382M14.1	-3.93	0.000132	0.0407	-0.4	-0.31	Coronary artery disease;	chr11:107255139	chr11:107176286~107177530:+
PCPG	cis	rs6974235	0.806	rs42065	ENSG00000279067.1	GS1-25M2.1	3.93	0.000132	0.0407	0.35	0.31	Total body bone mineral density;	chr7:96089267	chr7:96118647~96119995:+
PCPG	cis	rs1003719	0.641	rs13046844	ENSG00000228677.1	TTC3-AS1	-3.93	0.000132	0.0407	-0.37	-0.31	Eye color traits;	chr21:37145303	chr21:37187666~37193926:-
PCPG	cis	rs7601713	0.539	rs13020545	ENSG00000226383.4	AC093375.1	-3.93	0.000132	0.0407	-0.45	-0.31	QT interval;	chr2:156658668	chr2:156011617~156024613:-
PCPG	cis	rs10751667	0.643	rs7396767	ENSG00000255142.1	AP006621.6	3.93	0.000132	0.0407	0.3	0.31	Alzheimer's disease (late onset);	chr11:938808	chr11:781645~782105:+
PCPG	cis	rs10751667	0.643	rs11246348	ENSG00000255142.1	AP006621.6	3.93	0.000132	0.0407	0.3	0.31	Alzheimer's disease (late onset);	chr11:939476	chr11:781645~782105:+
PCPG	cis	rs10751667	0.621	rs10794348	ENSG00000255142.1	AP006621.6	3.93	0.000132	0.0407	0.3	0.31	Alzheimer's disease (late onset);	chr11:939941	chr11:781645~782105:+
PCPG	cis	rs10751667	0.6	rs10751665	ENSG00000255142.1	AP006621.6	3.93	0.000132	0.0407	0.3	0.31	Alzheimer's disease (late onset);	chr11:941300	chr11:781645~782105:+
PCPG	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	3.93	0.000132	0.0407	0.4	0.31	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
PCPG	cis	rs17177078	0.717	rs72768664	ENSG00000275494.1	RP11-266L9.8	-3.93	0.000132	0.0407	-0.53	-0.31	Type 2 diabetes (dietary heme iron intake interaction);	chr16:24725197	chr16:25106569~25107102:-
PCPG	cis	rs12291225	0.645	rs3763950	ENSG00000251991.1	RNU7-49P	3.93	0.000132	0.0407	0.34	0.31	Sense of smell;	chr11:14256503	chr11:14478892~14478953:+
PCPG	cis	rs2404602	0.716	rs12441247	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000132	0.0407	-0.31	-0.31	Blood metabolite levels;	chr15:76519975	chr15:76339609~76342063:-
PCPG	cis	rs10751667	0.643	rs10902238	ENSG00000255142.1	AP006621.6	3.92	0.000132	0.0407	0.3	0.31	Alzheimer's disease (late onset);	chr11:944810	chr11:781645~782105:+
PCPG	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-3.92	0.000132	0.0407	-0.49	-0.31	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
PCPG	cis	rs2404602	0.692	rs12910382	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000132	0.0407	-0.31	-0.31	Blood metabolite levels;	chr15:76761101	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs4383105	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000132	0.0407	-0.31	-0.31	Blood metabolite levels;	chr15:76763169	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs7174673	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000132	0.0407	-0.31	-0.31	Blood metabolite levels;	chr15:76779657	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs4641709	ENSG00000259514.1	RP11-685G9.2	3.92	0.000132	0.0407	0.31	0.31	Blood metabolite levels;	chr15:76755395	chr15:76339609~76342063:-
PCPG	cis	rs11148252	0.774	rs7993748	ENSG00000235660.1	LINC00345	-3.92	0.000132	0.0407	-0.37	-0.31	Lewy body disease;	chr13:52367496	chr13:52484161~52484680:-
PCPG	cis	rs5769765	0.913	rs28670284	ENSG00000278869.1	CITF22-49E9.3	3.92	0.000132	0.0407	0.42	0.31	Schizophrenia;	chr22:49828325	chr22:49933198~49934074:-
PCPG	cis	rs2439831	0.867	rs2243434	ENSG00000205771.5	CATSPER2P1	-3.92	0.000132	0.0407	-0.42	-0.31	Lung cancer in ever smokers;	chr15:43397669	chr15:43726918~43747094:-
PCPG	cis	rs2212361	0.558	rs11020815	ENSG00000255893.1	RP11-685N10.1	-3.92	0.000132	0.0408	-0.39	-0.31	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535890	chr11:94472908~94473570:-
PCPG	cis	rs2836441	0.52	rs2212599	ENSG00000232837.1	AF064858.7	3.92	0.000132	0.0408	0.49	0.31	Plateletcrit;Platelet count;	chr21:38525975	chr21:38974429~38977774:-
PCPG	cis	rs1876905	0.68	rs354547	ENSG00000255389.1	C6orf3	-3.92	0.000132	0.0408	-0.4	-0.31	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111599875~111602295:+
PCPG	cis	rs6585424	1	rs34162901	ENSG00000242600.5	MBL1P	3.92	0.000132	0.0408	0.59	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187100	chr10:79904898~79950336:+
PCPG	cis	rs6585424	1	rs61860045	ENSG00000242600.5	MBL1P	3.92	0.000132	0.0408	0.59	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187641	chr10:79904898~79950336:+
PCPG	cis	rs7267979	0.932	rs6132848	ENSG00000276952.1	RP5-965G21.6	3.92	0.000132	0.0408	0.36	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25284915~25285588:-
PCPG	cis	rs4934494	0.768	rs2094214	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000132	0.0408	-0.45	-0.31	Red blood cell count;	chr10:89649624	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.635	rs12572869	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000132	0.0408	-0.45	-0.31	Red blood cell count;	chr10:89653611	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs67111731	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000132	0.0408	-0.45	-0.31	Red blood cell count;	chr10:89659528	chr10:89694295~89697928:-
PCPG	cis	rs1150668	0.799	rs853684	ENSG00000219392.1	RP1-265C24.5	-3.92	0.000132	0.0408	-0.33	-0.31	Pubertal anthropometrics;	chr6:28326773	chr6:28115628~28116551:+
PCPG	cis	rs2735413	0.563	rs72800906	ENSG00000276007.1	RP11-358L22.3	3.92	0.000132	0.0408	0.34	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78012430	chr16:78123243~78124332:+
PCPG	cis	rs2735413	0.563	rs72800907	ENSG00000276007.1	RP11-358L22.3	3.92	0.000132	0.0408	0.34	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78012475	chr16:78123243~78124332:+
PCPG	cis	rs2735413	0.563	rs72800908	ENSG00000276007.1	RP11-358L22.3	3.92	0.000132	0.0408	0.34	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78012621	chr16:78123243~78124332:+
PCPG	cis	rs7178375	0.654	rs2525008	ENSG00000270055.1	CTD-3092A11.2	-3.92	0.000132	0.0408	-0.36	-0.31	Hypertriglyceridemia;	chr15:30817581	chr15:30487963~30490313:+
PCPG	cis	rs7178375	0.544	rs2525009	ENSG00000270055.1	CTD-3092A11.2	-3.92	0.000132	0.0408	-0.36	-0.31	Hypertriglyceridemia;	chr15:30817582	chr15:30487963~30490313:+
PCPG	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	3.92	0.000132	0.0408	0.4	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
PCPG	cis	rs2404602	0.716	rs12437627	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000132	0.0408	-0.31	-0.31	Blood metabolite levels;	chr15:76552709	chr15:76339609~76342063:-
PCPG	cis	rs73198271	0.681	rs35457364	ENSG00000253893.2	FAM85B	3.92	0.000132	0.0408	0.42	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.74	rs10100066	ENSG00000253893.2	FAM85B	3.92	0.000132	0.0408	0.42	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8167819~8226614:-
PCPG	cis	rs73198271	0.74	rs10110711	ENSG00000253893.2	FAM85B	3.92	0.000132	0.0408	0.42	0.31	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8167819~8226614:-
PCPG	cis	rs2735413	0.563	rs72800915	ENSG00000276007.1	RP11-358L22.3	3.92	0.000132	0.0408	0.35	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78021880	chr16:78123243~78124332:+
PCPG	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	3.92	0.000132	0.0409	0.42	0.31	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	3.92	0.000132	0.0409	0.42	0.31	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	3.92	0.000132	0.0409	0.42	0.31	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	3.92	0.000132	0.0409	0.42	0.31	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
PCPG	cis	rs2404602	0.735	rs4886800	ENSG00000259422.1	RP11-593F23.1	-3.92	0.000132	0.0409	-0.4	-0.31	Blood metabolite levels;	chr15:76386351	chr15:76174891~76181486:-
PCPG	cis	rs2282300	0.956	rs1222212	ENSG00000242353.1	RP4-710M3.1	-3.92	0.000133	0.0409	-0.41	-0.31	Morning vs. evening chronotype;	chr11:30353096	chr11:30368148~30368646:+
PCPG	cis	rs10842750	0.543	rs1875580	ENSG00000255968.1	RP11-513G19.1	-3.92	0.000133	0.0409	-0.41	-0.31	Kashin-Beck disease;	chr12:26496501	chr12:26318953~26421462:+
PCPG	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	3.92	0.000133	0.0409	0.78	0.31	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
PCPG	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	3.92	0.000133	0.0409	0.78	0.31	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
PCPG	cis	rs6728642	0.519	rs7589232	ENSG00000230606.9	AC159540.1	3.92	0.000133	0.0409	0.4	0.31	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900411	chr2:97416165~97433527:-
PCPG	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	3.92	0.000133	0.0409	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
PCPG	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	3.92	0.000133	0.0409	0.38	0.31	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
PCPG	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	3.92	0.000133	0.0409	0.34	0.31	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
PCPG	cis	rs13392177	0.543	rs12623716	ENSG00000273466.1	RP11-548H3.1	-3.92	0.000133	0.0409	-0.17	-0.31	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218633256~218634014:-
PCPG	cis	rs2440129	0.611	rs11571335	ENSG00000262089.1	RP11-589P10.5	3.92	0.000133	0.0409	0.22	0.31	Tonsillectomy;	chr17:7000944	chr17:6994642~6995189:-
PCPG	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-3.92	0.000133	0.0409	-0.46	-0.31	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
PCPG	cis	rs8064024	0.681	rs1395602	ENSG00000267077.1	RP11-127I20.5	3.92	0.000133	0.0409	0.37	0.31	Cancer;	chr16:4861238	chr16:4795265~4796532:-
PCPG	cis	rs2836974	0.526	rs1888488	ENSG00000252915.1	Y_RNA	3.92	0.000133	0.041	0.32	0.31	Cognitive function;	chr21:39314595	chr21:39344537~39344628:+
PCPG	cis	rs897984	0.683	rs8046001	ENSG00000275263.1	RP11-1072A3.4	-3.92	0.000133	0.041	-0.32	-0.31	Dementia with Lewy bodies;	chr16:30822000	chr16:30956872~30957199:-
PCPG	cis	rs2281603	0.762	rs10130241	ENSG00000259116.1	RP11-973N13.4	-3.92	0.000133	0.041	-0.3	-0.31	Lymphocyte counts;	chr14:64577402	chr14:64514154~64540368:-
PCPG	cis	rs3758911	0.964	rs10890702	ENSG00000255353.1	RP11-382M14.1	3.92	0.000133	0.041	0.38	0.31	Coronary artery disease;	chr11:107310159	chr11:107176286~107177530:+
PCPG	cis	rs42648	0.935	rs42621	ENSG00000225498.1	AC002064.5	3.92	0.000133	0.041	0.35	0.31	Homocysteine levels;	chr7:90327170	chr7:90312496~90322592:+
PCPG	cis	rs42648	0.905	rs42622	ENSG00000225498.1	AC002064.5	3.92	0.000133	0.041	0.35	0.31	Homocysteine levels;	chr7:90327510	chr7:90312496~90322592:+
PCPG	cis	rs42648	0.935	rs42624	ENSG00000225498.1	AC002064.5	3.92	0.000133	0.041	0.35	0.31	Homocysteine levels;	chr7:90328227	chr7:90312496~90322592:+
PCPG	cis	rs11133665	1	rs11133665	ENSG00000249201.2	CTD-3080P12.3	3.92	0.000133	0.041	0.38	0.31	Urinary metabolites;	chr5:1188170	chr5:1173141~1178605:-
PCPG	cis	rs4143844	1	rs34391931	ENSG00000259251.2	RP11-643M14.1	3.92	0.000133	0.041	0.68	0.31	Bipolar disorder and schizophrenia;	chr15:62065419	chr15:62060503~62062434:+
PCPG	cis	rs1062177	1	rs72802204	ENSG00000249035.5	CTB-113P19.1	-3.92	0.000133	0.041	-0.38	-0.31	Preschool internalizing problems;	chr5:151803622	chr5:151676945~151724782:+
PCPG	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	3.92	0.000133	0.041	0.39	0.31	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
PCPG	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-3.92	0.000133	0.041	-0.38	-0.31	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	3.92	0.000133	0.041	0.36	0.31	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
PCPG	cis	rs10916248	0.559	rs56023673	ENSG00000232628.4	RP11-365O16.3	3.92	0.000133	0.041	0.53	0.3	QT interval (drug interaction);	chr1:224180821	chr1:224208747~224213279:-
PCPG	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	3.92	0.000133	0.041	0.38	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
PCPG	cis	rs172166	0.516	rs2622322	ENSG00000219392.1	RP1-265C24.5	-3.92	0.000133	0.041	-0.33	-0.3	Cardiac Troponin-T levels;	chr6:28149665	chr6:28115628~28116551:+
PCPG	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	3.92	0.000133	0.0411	0.35	0.3	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
PCPG	cis	rs11098499	0.955	rs6815725	ENSG00000250412.1	KLHL2P1	3.92	0.000133	0.0411	0.32	0.3	Corneal astigmatism;	chr4:119237255	chr4:119334329~119378233:+
PCPG	cis	rs11098499	0.955	rs1551	ENSG00000250412.1	KLHL2P1	3.92	0.000133	0.0411	0.32	0.3	Corneal astigmatism;	chr4:119237345	chr4:119334329~119378233:+
PCPG	cis	rs11098499	1	rs28374891	ENSG00000250412.1	KLHL2P1	3.92	0.000133	0.0411	0.32	0.3	Corneal astigmatism;	chr4:119262395	chr4:119334329~119378233:+
PCPG	cis	rs11098499	1	rs12506395	ENSG00000250412.1	KLHL2P1	3.92	0.000133	0.0411	0.32	0.3	Corneal astigmatism;	chr4:119263939	chr4:119334329~119378233:+
PCPG	cis	rs992157	0.56	rs7605980	ENSG00000273466.1	RP11-548H3.1	3.92	0.000133	0.0411	0.17	0.3	Colorectal cancer;	chr2:218236146	chr2:218633256~218634014:-
PCPG	cis	rs7937890	0.559	rs2597208	ENSG00000251991.1	RNU7-49P	3.92	0.000133	0.0411	0.35	0.3	Mitochondrial DNA levels;	chr11:14450783	chr11:14478892~14478953:+
PCPG	cis	rs657075	0.595	rs6878253	ENSG00000233006.5	AC034220.3	-3.92	0.000133	0.0411	-0.41	-0.3	Rheumatoid arthritis;	chr5:132277600	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.595	rs6878192	ENSG00000233006.5	AC034220.3	-3.92	0.000133	0.0411	-0.41	-0.3	Rheumatoid arthritis;	chr5:132277850	chr5:132311285~132369916:-
PCPG	cis	rs657075	0.595	rs11954518	ENSG00000233006.5	AC034220.3	-3.92	0.000133	0.0411	-0.41	-0.3	Rheumatoid arthritis;	chr5:132278406	chr5:132311285~132369916:-
PCPG	cis	rs687432	1	rs687432	ENSG00000254602.1	AP000662.4	3.92	0.000133	0.0411	0.35	0.3	Parkinson's disease;	chr11:57926788	chr11:57638024~57652790:+
PCPG	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-3.92	0.000133	0.0411	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
PCPG	cis	rs720064	0.586	rs2288592	ENSG00000265752.2	RP11-403A21.1	3.92	0.000133	0.0411	0.34	0.3	Strep throat;	chr18:23946123	chr18:23957754~23982556:-
PCPG	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	3.92	0.000133	0.0411	0.4	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
PCPG	cis	rs2282300	1	rs12799529	ENSG00000242353.1	RP4-710M3.1	-3.92	0.000133	0.0411	-0.41	-0.3	Morning vs. evening chronotype;	chr11:30387005	chr11:30368148~30368646:+
PCPG	cis	rs4934494	0.681	rs1129777	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89709168	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs3824607	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89711258	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.681	rs3740035	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89716708	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.681	rs34591435	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89721691	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs12783845	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89722872	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs12572012	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89727892	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs3758388	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89729222	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs12783582	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89735210	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs67827533	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89745626	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.768	rs1926139	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89753395	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs55823491	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89757598	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.727	rs12570750	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89761273	chr10:89694295~89697928:-
PCPG	cis	rs4934494	0.723	rs17127001	ENSG00000240996.1	RP11-80H5.7	-3.92	0.000133	0.0411	-0.45	-0.3	Red blood cell count;	chr10:89762932	chr10:89694295~89697928:-
PCPG	cis	rs448720	0.84	rs399755	ENSG00000260657.2	RP11-315D16.4	3.92	0.000133	0.0411	0.38	0.3	Cognitive performance;	chr15:67869249	chr15:68267792~68277994:-
PCPG	cis	rs73201462	0.803	rs2955084	ENSG00000242551.2	POU5F1P6	-3.92	0.000134	0.0411	-0.7	-0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128242462	chr3:128674735~128677005:-
PCPG	cis	rs62229266	0.804	rs998383	ENSG00000230212.5	AP000688.14	-3.92	0.000134	0.0411	-0.35	-0.3	Mitral valve prolapse;	chr21:36073441	chr21:36069642~36126640:-
PCPG	cis	rs3809060	0.547	rs10835911	ENSG00000213713.3	PIGCP1	-3.92	0.000134	0.0411	-0.16	-0.3	Inguinal hernia;	chr11:32446001	chr11:33075566~33076460:-
PCPG	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000134	0.0411	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000134	0.0411	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000134	0.0411	-0.36	-0.3	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
PCPG	cis	rs2243480	0.901	rs313808	ENSG00000251451.1	GS1-124K5.6	3.92	0.000134	0.0412	0.56	0.3	Diabetic kidney disease;	chr7:66034886	chr7:66407288~66409239:-
PCPG	cis	rs8064024	0.625	rs960006	ENSG00000267077.1	RP11-127I20.5	3.92	0.000134	0.0412	0.37	0.3	Cancer;	chr16:4861194	chr16:4795265~4796532:-
PCPG	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	3.92	0.000134	0.0412	0.39	0.3	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	3.92	0.000134	0.0412	0.39	0.3	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	3.92	0.000134	0.0412	0.39	0.3	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
PCPG	cis	rs2736345	0.747	rs1478901	ENSG00000154316.13	TDH	3.92	0.000134	0.0412	0.41	0.3	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11490324	chr8:11339637~11368452:+
PCPG	cis	rs2736345	0.788	rs9693589	ENSG00000154316.13	TDH	3.92	0.000134	0.0412	0.41	0.3	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491452	chr8:11339637~11368452:+
PCPG	cis	rs2736345	0.788	rs13277113	ENSG00000154316.13	TDH	3.92	0.000134	0.0412	0.41	0.3	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491677	chr8:11339637~11368452:+
PCPG	cis	rs4713118	0.505	rs276371	ENSG00000219392.1	RP1-265C24.5	-3.92	0.000134	0.0412	-0.34	-0.3	Parkinson's disease;	chr6:27942930	chr6:28115628~28116551:+
PCPG	cis	rs7523050	0.643	rs12725689	ENSG00000203897.3	SPATA42	-3.92	0.000134	0.0412	-0.49	-0.3	Fat distribution (HIV);	chr1:108862529	chr1:108857217~108858524:+
PCPG	cis	rs9847710	0.967	rs2581824	ENSG00000242142.1	SERBP1P3	-3.92	0.000134	0.0412	-0.33	-0.3	Ulcerative colitis;	chr3:52988392	chr3:53064283~53065091:-
PCPG	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	3.92	0.000134	0.0412	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
PCPG	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-3.92	0.000134	0.0412	-0.34	-0.3	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
PCPG	cis	rs1499614	1	rs1882655	ENSG00000230189.5	GS1-124K5.2	-3.92	0.000134	0.0412	-0.45	-0.3	Gout;	chr7:66682070	chr7:66409143~66490059:-
PCPG	cis	rs1499614	0.831	rs3800822	ENSG00000230189.5	GS1-124K5.2	-3.92	0.000134	0.0412	-0.45	-0.3	Gout;	chr7:66682162	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2659913	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66692349	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2707840	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66693028	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2659911	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66693433	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2707838	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66694214	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs60326618	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66701371	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2707830	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66702658	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2707828	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66706390	chr7:66409143~66490059:-
PCPG	cis	rs1499614	0.803	rs1922723	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66710076	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2659903	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66715944	chr7:66409143~66490059:-
PCPG	cis	rs1499614	1	rs2141924	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66721259	chr7:66409143~66490059:-
PCPG	cis	rs1499614	0.901	rs2178742	ENSG00000230189.5	GS1-124K5.2	3.92	0.000134	0.0412	0.45	0.3	Gout;	chr7:66732812	chr7:66409143~66490059:-
PCPG	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	3.92	0.000134	0.0412	0.44	0.3	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
PCPG	cis	rs3806843	1	rs991918	ENSG00000202515.1	VTRNA1-3	-3.92	0.000134	0.0412	-0.4	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140815273	chr5:140726158~140726246:+
PCPG	cis	rs9376098	0.825	rs7764187	ENSG00000232876.1	CTA-212D2.2	-3.92	0.000134	0.0412	-0.39	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135162604	chr6:135055033~135060550:+
PCPG	cis	rs2302464	1	rs6835705	ENSG00000214846.4	RP11-115L11.1	-3.92	0.000134	0.0413	-0.77	-0.3	Cerebrospinal fluid biomarker levels;	chr4:15736747	chr4:15730962~15731627:-
PCPG	cis	rs9525927	0.625	rs9533803	ENSG00000227258.4	SMIM2-AS1	3.92	0.000134	0.0413	0.46	0.3	Dupuytren's disease;	chr13:44246472	chr13:44110451~44240517:+
PCPG	cis	rs765751	0.544	rs11118308	ENSG00000225920.2	RIMKLBP2	3.92	0.000134	0.0413	0.26	0.3	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;	chr1:219460527	chr1:219199914~219200567:-
PCPG	cis	rs763121	0.853	rs4821812	ENSG00000273076.1	RP3-508I15.22	3.92	0.000134	0.0413	0.38	0.3	Menopause (age at onset);	chr22:38679230	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs3827357	ENSG00000273076.1	RP3-508I15.22	3.92	0.000134	0.0413	0.38	0.3	Menopause (age at onset);	chr22:38683408	chr22:38743495~38743910:+
PCPG	cis	rs763121	0.853	rs5750668	ENSG00000273076.1	RP3-508I15.22	3.92	0.000134	0.0413	0.38	0.3	Menopause (age at onset);	chr22:38683959	chr22:38743495~38743910:+
PCPG	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	3.92	0.000134	0.0413	0.41	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
PCPG	cis	rs7759001	0.901	rs4713106	ENSG00000271755.1	RP1-153G14.4	3.92	0.000134	0.0413	0.47	0.3	Glomerular filtration rate (creatinine);	chr6:27476935	chr6:27404010~27406964:-
PCPG	cis	rs71403859	0.73	rs17356206	ENSG00000279412.1	RP11-394B2.5	3.92	0.000134	0.0413	0.56	0.3	Post bronchodilator FEV1;	chr16:71702456	chr16:70713987~70716890:+
PCPG	cis	rs71403859	0.73	rs35390364	ENSG00000279412.1	RP11-394B2.5	3.92	0.000134	0.0413	0.56	0.3	Post bronchodilator FEV1;	chr16:71706146	chr16:70713987~70716890:+
PCPG	cis	rs2898290	0.622	rs13272061	ENSG00000254774.1	RP11-148O21.3	-3.92	0.000134	0.0413	-0.33	-0.3	Systolic blood pressure;	chr8:11494752	chr8:11553224~11554207:-
PCPG	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	3.92	0.000134	0.0413	0.3	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
PCPG	cis	rs189798	0.807	rs330905	ENSG00000253893.2	FAM85B	-3.92	0.000134	0.0413	-0.42	-0.3	Myopia (pathological);	chr8:9136041	chr8:8167819~8226614:-
PCPG	cis	rs6689335	0.549	rs12119837	ENSG00000225920.2	RIMKLBP2	-3.92	0.000134	0.0413	-0.28	-0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI;	chr1:219425552	chr1:219199914~219200567:-
PCPG	cis	rs4713118	0.55	rs9368527	ENSG00000216901.1	AL022393.7	3.92	0.000134	0.0413	0.39	0.3	Parkinson's disease;	chr6:27711666	chr6:28176188~28176674:+
PCPG	cis	rs2404602	0.692	rs34272342	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000134	0.0413	-0.31	-0.3	Blood metabolite levels;	chr15:76719935	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs67570291	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000134	0.0413	-0.31	-0.3	Blood metabolite levels;	chr15:76728161	chr15:76339609~76342063:-
PCPG	cis	rs2404602	0.692	rs1471780	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000134	0.0413	-0.31	-0.3	Blood metabolite levels;	chr15:76734185	chr15:76339609~76342063:-
PCPG	cis	rs3947	0.906	rs1692821	ENSG00000249889.1	ALG1L11P	-3.92	0.000134	0.0413	-0.31	-0.3	Blood protein levels;	chr8:11842479	chr8:12178697~12182719:+
PCPG	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-3.92	0.000134	0.0413	-0.35	-0.3	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
PCPG	cis	rs964611	0.938	rs8026751	ENSG00000259488.2	RP11-154J22.1	-3.92	0.000135	0.0414	-0.3	-0.3	Metabolite levels (Pyroglutamine);	chr15:48290648	chr15:48312353~48331856:-
PCPG	cis	rs964611	0.872	rs72623972	ENSG00000259488.2	RP11-154J22.1	-3.92	0.000135	0.0414	-0.3	-0.3	Metabolite levels (Pyroglutamine);	chr15:48294797	chr15:48312353~48331856:-
PCPG	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	3.92	0.000135	0.0414	0.32	0.3	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
PCPG	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	3.92	0.000135	0.0414	0.39	0.3	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs2275045	ENSG00000223701.3	RAET1E-AS1	3.92	0.000135	0.0414	0.39	0.3	Lung cancer;	chr6:149842775	chr6:149884431~149919508:+
PCPG	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	3.92	0.000135	0.0414	0.48	0.3	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
PCPG	cis	rs11148252	0.967	rs11620062	ENSG00000198384.8	TPTE2P3	-3.92	0.000135	0.0414	-0.39	-0.3	Lewy body disease;	chr13:52419891	chr13:52522632~52586906:+
PCPG	cis	rs804280	0.509	rs4841639	ENSG00000255556.2	RP11-351I21.6	3.92	0.000135	0.0414	0.34	0.3	Myopia (pathological);	chr8:11938584	chr8:12378679~12380265:-
PCPG	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-3.92	0.000135	0.0414	-0.34	-0.3	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
PCPG	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	3.92	0.000135	0.0415	0.33	0.3	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
PCPG	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	3.92	0.000135	0.0415	0.35	0.3	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	3.92	0.000135	0.0415	0.35	0.3	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
PCPG	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-3.92	0.000135	0.0415	-0.36	-0.3	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
PCPG	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-3.92	0.000135	0.0415	-0.44	-0.3	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
PCPG	cis	rs357618	0.581	rs165365	ENSG00000260581.1	CTB-113P19.4	-3.92	0.000135	0.0415	-0.41	-0.3	Basophil percentage of white cells;	chr5:151486884	chr5:151652275~151655449:+
PCPG	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-3.92	0.000135	0.0415	-0.28	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
PCPG	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-3.92	0.000135	0.0415	-0.28	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
PCPG	cis	rs228614	0.536	rs223478	ENSG00000230069.3	LRRC37A15P	-3.92	0.000135	0.0415	-0.28	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102727274~102730721:-
PCPG	cis	rs228614	0.536	rs150898	ENSG00000230069.3	LRRC37A15P	-3.92	0.000135	0.0415	-0.28	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102727274~102730721:-
PCPG	cis	rs7267979	0.899	rs6115213	ENSG00000276952.1	RP5-965G21.6	3.92	0.000135	0.0415	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25284915~25285588:-
PCPG	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	3.92	0.000135	0.0415	0.29	0.3	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
PCPG	cis	rs17807624	1	rs17807624	ENSG00000255020.1	AF131216.5	-3.92	0.000135	0.0415	-0.4	-0.3	Systemic lupus erythematosus;	chr8:11605506	chr8:11345748~11347502:-
PCPG	cis	rs11671005	0.779	rs35631681	ENSG00000269600.1	AC016629.3	-3.92	0.000135	0.0415	-0.48	-0.3	Mean platelet volume;	chr19:58488473	chr19:58593896~58599355:-
PCPG	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-3.92	0.000135	0.0415	-0.34	-0.3	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
PCPG	cis	rs1371867	0.846	rs1692006	ENSG00000212994.5	RPS26P6	-3.92	0.000135	0.0415	-0.34	-0.3	Atrioventricular conduction;	chr8:100240234	chr8:100895771~100896118:+
PCPG	cis	rs2052670	0.964	rs1026954	ENSG00000232613.5	AC007386.4	-3.92	0.000135	0.0415	-0.43	-0.3	Waist circumference adjusted for body mass index;	chr2:66020642	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.964	rs1406744	ENSG00000232613.5	AC007386.4	3.92	0.000135	0.0415	0.43	0.3	Waist circumference adjusted for body mass index;	chr2:66022608	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.964	rs1385169	ENSG00000232613.5	AC007386.4	3.92	0.000135	0.0415	0.43	0.3	Waist circumference adjusted for body mass index;	chr2:66023648	chr2:65030727~65053017:+
PCPG	cis	rs12928939	0.815	rs1345868	ENSG00000260886.1	TAT-AS1	3.92	0.000135	0.0416	0.38	0.3	Post bronchodilator FEV1;	chr16:71635721	chr16:71565789~71578187:+
PCPG	cis	rs7707921	0.881	rs7733122	ENSG00000249483.1	CTD-2249K22.1	-3.92	0.000135	0.0416	-0.41	-0.3	Breast cancer;	chr5:82055624	chr5:81851601~81852201:+
PCPG	cis	rs4143844	0.867	rs11638455	ENSG00000259251.2	RP11-643M14.1	3.92	0.000135	0.0416	0.64	0.3	Bipolar disorder and schizophrenia;	chr15:61870969	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs11629559	ENSG00000259251.2	RP11-643M14.1	3.92	0.000135	0.0416	0.64	0.3	Bipolar disorder and schizophrenia;	chr15:61871348	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs17303887	ENSG00000259251.2	RP11-643M14.1	3.92	0.000135	0.0416	0.64	0.3	Bipolar disorder and schizophrenia;	chr15:61873354	chr15:62060503~62062434:+
PCPG	cis	rs7160336	0.738	rs66941731	ENSG00000259065.1	RP5-1021I20.1	3.92	0.000136	0.0416	0.38	0.3	Blood protein levels;	chr14:74026538	chr14:73787360~73803270:+
PCPG	cis	rs17152411	1	rs12573033	ENSG00000278831.1	RP11-12J10.4	3.92	0.000136	0.0416	0.44	0.3	Height;	chr10:124919234	chr10:124623353~124624079:+
PCPG	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	3.92	0.000136	0.0416	0.4	0.3	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
PCPG	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-3.92	0.000136	0.0416	-0.4	-0.3	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
PCPG	cis	rs17684571	0.751	rs36094082	ENSG00000231441.1	RP11-472M19.2	3.92	0.000136	0.0416	0.51	0.3	Schizophrenia;	chr6:56842153	chr6:56844002~56864078:+
PCPG	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	3.92	0.000136	0.0416	0.39	0.3	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
PCPG	cis	rs2075466	0.588	rs111581085	ENSG00000267077.1	RP11-127I20.5	3.92	0.000136	0.0416	0.61	0.3	Colonoscopy-negative controls vs population controls;	chr16:4818292	chr16:4795265~4796532:-
PCPG	cis	rs11148252	0.967	rs4286007	ENSG00000198384.8	TPTE2P3	-3.92	0.000136	0.0416	-0.39	-0.3	Lewy body disease;	chr13:52448383	chr13:52522632~52586906:+
PCPG	cis	rs12906542	0.507	rs4395040	ENSG00000259792.1	RP11-114H24.6	-3.92	0.000136	0.0416	-0.36	-0.3	Breast cancer;	chr15:77990191	chr15:77993405~77995289:+
PCPG	cis	rs2404602	0.655	rs8028294	ENSG00000259514.1	RP11-685G9.2	-3.92	0.000136	0.0417	-0.31	-0.3	Blood metabolite levels;	chr15:76792536	chr15:76339609~76342063:-
PCPG	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	3.92	0.000136	0.0417	0.39	0.3	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
PCPG	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	3.92	0.000136	0.0417	0.7	0.3	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
PCPG	cis	rs698813	0.674	rs4952707	ENSG00000236502.1	SIX3-AS1	3.92	0.000136	0.0417	0.4	0.3	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44273544	chr2:44940154~44941873:-
PCPG	cis	rs916888	0.61	rs142167	ENSG00000262500.1	RP11-259G18.2	-3.92	0.000136	0.0417	-0.44	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46243606~46245044:+
PCPG	cis	rs7176527	1	rs3762168	ENSG00000188388.10	GOLGA6L3	3.92	0.000136	0.0417	0.45	0.3	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85240472~85247170:+
PCPG	cis	rs7211079	0.879	rs66693363	ENSG00000275479.1	RP11-334C17.6	3.92	0.000136	0.0417	0.25	0.3	Myocardial infarction;	chr17:80155136	chr17:80149627~80149798:+
PCPG	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	3.92	0.000136	0.0417	0.36	0.3	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
PCPG	cis	rs1150668	0.835	rs1233696	ENSG00000176933.5	TOB2P1	-3.92	0.000136	0.0417	-0.34	-0.3	Pubertal anthropometrics;	chr6:28175232	chr6:28217643~28218634:-
PCPG	cis	rs1550584	0.967	rs1667519	ENSG00000205562.2	RP11-497E19.1	3.92	0.000136	0.0418	0.32	0.3	IgG glycosylation;	chr14:85218647	chr14:85524432~85529988:-
PCPG	cis	rs11671005	0.735	rs45617039	ENSG00000269600.1	AC016629.3	-3.92	0.000136	0.0418	-0.47	-0.3	Mean platelet volume;	chr19:58439729	chr19:58593896~58599355:-
PCPG	cis	rs12681963	0.541	rs13271667	ENSG00000248159.1	HSPA8P11	-3.92	0.000136	0.0418	-0.84	-0.3	Migraine;	chr8:30138935	chr8:30237382~30240997:+
PCPG	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-3.92	0.000136	0.0418	-0.68	-0.3	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
PCPG	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	3.92	0.000136	0.0418	0.41	0.3	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
PCPG	cis	rs9472414	0.599	rs6926638	ENSG00000229349.2	ACTG1P9	-3.92	0.000136	0.0418	-0.51	-0.3	Height;	chr6:45354276	chr6:46204729~46207386:+
PCPG	cis	rs7172677	0.731	rs1108059	ENSG00000261543.1	RP11-665J16.1	3.92	0.000136	0.0418	0.36	0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75046549	chr15:74152800~74179226:-
PCPG	cis	rs1048886	0.872	rs16869373	ENSG00000271967.1	RP11-134K13.4	-3.92	0.000136	0.0418	-0.38	-0.3	Type 2 diabetes;	chr6:70559929	chr6:70596438~70596980:+
PCPG	cis	rs7714584	1	rs7715981	ENSG00000271795.1	CTC-251D13.1	-3.92	0.000136	0.0418	-0.55	-0.3	Crohn's disease;	chr5:150878545	chr5:151509453~151512769:+
PCPG	cis	rs2948294	0.566	rs13261997	ENSG00000254340.1	RP11-10A14.3	3.92	0.000136	0.0418	0.34	0.3	Red cell distribution width;	chr8:8254773	chr8:9141424~9145435:+
PCPG	cis	rs3947	1	rs1736081	ENSG00000255556.2	RP11-351I21.6	-3.92	0.000137	0.0419	-0.39	-0.3	Blood protein levels;	chr8:11845331	chr8:12378679~12380265:-
PCPG	cis	rs11638352	1	rs1808509	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44117341	chr15:43726918~43747094:-
PCPG	cis	rs2733201	1	rs1160066	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44118739	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs2615295	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44120400	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs2615292	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44122178	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs2059628	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44123073	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs2733204	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44124814	chr15:43726918~43747094:-
PCPG	cis	rs2733201	1	rs2615285	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44125178	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs7166715	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44125408	chr15:43726918~43747094:-
PCPG	cis	rs11638352	1	rs2555385	ENSG00000205771.5	CATSPER2P1	3.92	0.000137	0.0419	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44127261	chr15:43726918~43747094:-
PCPG	cis	rs243505	1	rs243511	ENSG00000133624.12	ZNF767P	3.92	0.000137	0.0419	0.26	0.3	Inflammatory bowel disease;Crohn's disease;	chr7:148733056	chr7:149547154~149624752:-
PCPG	cis	rs12928939	0.815	rs12446005	ENSG00000260886.1	TAT-AS1	3.92	0.000137	0.0419	0.39	0.3	Post bronchodilator FEV1;	chr16:71621132	chr16:71565789~71578187:+
PCPG	cis	rs728616	0.681	rs35420115	ENSG00000242600.5	MBL1P	3.92	0.000137	0.0419	0.63	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148432	chr10:79904898~79950336:+
PCPG	cis	rs728616	0.681	rs3862518	ENSG00000242600.5	MBL1P	3.92	0.000137	0.0419	0.63	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158201	chr10:79904898~79950336:+
PCPG	cis	rs728616	0.867	rs12781912	ENSG00000242600.5	MBL1P	3.92	0.000137	0.0419	0.63	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158372	chr10:79904898~79950336:+
PCPG	cis	rs3109133	0.869	rs6430366	ENSG00000279512.1	RP11-575M22.1	-3.92	0.000137	0.0419	-0.37	-0.3	Calcium levels;	chr2:132535424	chr2:133117004~133119052:+
PCPG	cis	rs1499614	1	rs1267818	ENSG00000230189.5	GS1-124K5.2	3.92	0.000137	0.0419	0.44	0.3	Gout;	chr7:66642037	chr7:66409143~66490059:-
PCPG	cis	rs889398	0.742	rs12446197	ENSG00000196696.11	PDXDC2P	3.92	0.000137	0.0419	0.24	0.3	Body mass index;	chr16:69820966	chr16:69976297~70065948:-
PCPG	cis	rs889398	0.802	rs12921407	ENSG00000196696.11	PDXDC2P	3.92	0.000137	0.0419	0.24	0.3	Body mass index;	chr16:69827030	chr16:69976297~70065948:-
PCPG	cis	rs889398	0.802	rs2937121	ENSG00000196696.11	PDXDC2P	3.92	0.000137	0.0419	0.24	0.3	Body mass index;	chr16:69836506	chr16:69976297~70065948:-
PCPG	cis	rs2836974	0.865	rs34778912	ENSG00000252915.1	Y_RNA	-3.92	0.000137	0.0419	-0.32	-0.3	Cognitive function;	chr21:39295111	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.931	rs13625	ENSG00000252915.1	Y_RNA	-3.92	0.000137	0.0419	-0.32	-0.3	Cognitive function;	chr21:39297157	chr21:39344537~39344628:+
PCPG	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	3.92	0.000137	0.0419	0.36	0.3	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
PCPG	cis	rs7208859	0.673	rs216424	ENSG00000263603.1	CTD-2349P21.5	-3.92	0.000137	0.0419	-0.48	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30729469~30731202:+
PCPG	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-3.92	0.000137	0.0419	-0.34	-0.3	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
PCPG	cis	rs17329882	0.687	rs62328674	ENSG00000280551.1	RP11-358D17.2	3.92	0.000137	0.0419	0.44	0.3	Epithelial ovarian cancer;Invasive epithelial ovarian cancer;	chr4:119044600	chr4:119042024~119043937:+
PCPG	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-3.92	0.000137	0.0419	-0.6	-0.3	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
PCPG	cis	rs8064024	0.65	rs12926178	ENSG00000267077.1	RP11-127I20.5	-3.91	0.000137	0.0419	-0.36	-0.3	Cancer;	chr16:4855914	chr16:4795265~4796532:-
PCPG	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-3.91	0.000137	0.0419	-0.35	-0.3	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-3.91	0.000137	0.0419	-0.35	-0.3	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
PCPG	cis	rs2531992	0.686	rs933392	ENSG00000262888.1	RP11-462G12.2	-3.91	0.000137	0.0419	-0.53	-0.3	Waist circumference;	chr16:3982715	chr16:3931217~3946305:-
PCPG	cis	rs75686122	0.892	rs12676448	ENSG00000253477.4	RP11-1C8.4	-3.91	0.000137	0.0419	-0.44	-0.3	Cocaine dependence;	chr8:103466989	chr8:103483398~103501676:-
PCPG	cis	rs2282300	0.956	rs1717779	ENSG00000242353.1	RP4-710M3.1	-3.91	0.000137	0.0419	-0.41	-0.3	Morning vs. evening chronotype;	chr11:30355151	chr11:30368148~30368646:+
PCPG	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-3.91	0.000137	0.042	-0.31	-0.3	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
PCPG	cis	rs7104745	0.517	rs636865	ENSG00000255027.2	RP11-680F20.9	3.91	0.000137	0.042	0.31	0.3	Breast size;	chr11:125999507	chr11:125903247~125938916:-
PCPG	cis	rs1129187	0.755	rs9462856	ENSG00000272223.1	RP1-20C7.6	3.91	0.000137	0.042	0.3	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42958286	chr6:43033897~43034405:-
PCPG	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	3.91	0.000137	0.042	0.7	0.3	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
PCPG	cis	rs17684571	0.7	rs13200166	ENSG00000231441.1	RP11-472M19.2	3.91	0.000137	0.042	0.51	0.3	Schizophrenia;	chr6:56816414	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs17752046	ENSG00000231441.1	RP11-472M19.2	3.91	0.000137	0.042	0.51	0.3	Schizophrenia;	chr6:56816550	chr6:56844002~56864078:+
PCPG	cis	rs3809060	0.568	rs3930317	ENSG00000213713.3	PIGCP1	3.91	0.000137	0.042	0.17	0.3	Inguinal hernia;	chr11:32452782	chr11:33075566~33076460:-
PCPG	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	3.91	0.000137	0.042	0.31	0.3	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	3.91	0.000137	0.042	0.31	0.3	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	3.91	0.000137	0.042	0.31	0.3	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
PCPG	cis	rs172166	0.637	rs1233691	ENSG00000220721.1	OR1F12	3.91	0.000137	0.042	0.34	0.3	Cardiac Troponin-T levels;	chr6:28186119	chr6:28073316~28074233:+
PCPG	cis	rs847649	0.924	rs6960428	ENSG00000252643.1	RNU6-1136P	3.91	0.000137	0.042	0.37	0.3	Morning vs. evening chronotype;	chr7:102949259	chr7:102834605~102834708:+
PCPG	cis	rs992157	0.56	rs6436048	ENSG00000273466.1	RP11-548H3.1	3.91	0.000137	0.042	0.17	0.3	Colorectal cancer;	chr2:218244310	chr2:218633256~218634014:-
PCPG	cis	rs7249142	0.562	rs10854009	ENSG00000279843.1	AC011477.2	3.91	0.000137	0.042	0.33	0.3	IgG glycosylation;	chr19:19173896	chr19:19835158~19836016:+
PCPG	cis	rs7249142	0.562	rs2314035	ENSG00000279843.1	AC011477.2	3.91	0.000137	0.042	0.33	0.3	IgG glycosylation;	chr19:19174111	chr19:19835158~19836016:+
PCPG	cis	rs172166	0.516	rs2791333	ENSG00000219392.1	RP1-265C24.5	-3.91	0.000137	0.042	-0.33	-0.3	Cardiac Troponin-T levels;	chr6:28143336	chr6:28115628~28116551:+
PCPG	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	3.91	0.000137	0.042	0.35	0.3	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	3.91	0.000137	0.042	0.35	0.3	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	3.91	0.000137	0.042	0.35	0.3	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
PCPG	cis	rs7743045	0.548	rs2357023	ENSG00000253194.1	RP11-351A11.1	-3.91	0.000137	0.0421	-0.37	-0.3	Mean platelet volume;	chr6:119023364	chr6:118934785~119031541:+
PCPG	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	3.91	0.000137	0.0421	0.35	0.3	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
PCPG	cis	rs6517329	0.538	rs1028997	ENSG00000236830.5	CBR3-AS1	-3.91	0.000138	0.0421	-0.26	-0.3	Schizophrenia;	chr21:36159924	chr21:36131767~36175815:-
PCPG	cis	rs2032366	0.63	rs6567226	ENSG00000267279.1	RP11-879F14.2	-3.91	0.000138	0.0421	-0.32	-0.3	Obesity-related traits;	chr18:61635689	chr18:61585746~61606916:-
PCPG	cis	rs2625529	0.53	rs2959930	ENSG00000260037.4	CTD-2524L6.3	-3.91	0.000138	0.0421	-0.47	-0.3	Red blood cell count;	chr15:72306273	chr15:71818396~71823384:+
PCPG	cis	rs7707921	0.881	rs60733727	ENSG00000249483.1	CTD-2249K22.1	-3.91	0.000138	0.0421	-0.42	-0.3	Breast cancer;	chr5:82152464	chr5:81851601~81852201:+
PCPG	cis	rs2898290	0.617	rs13273172	ENSG00000269954.1	RP11-148O21.6	-3.91	0.000138	0.0421	-0.36	-0.3	Systolic blood pressure;	chr8:11603602	chr8:11552488~11552991:-
PCPG	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	3.91	0.000138	0.0421	0.33	0.3	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
PCPG	cis	rs13118159	0.55	rs11941200	ENSG00000254094.1	AC078852.1	-3.91	0.000138	0.0421	-0.4	-0.3	Longevity;	chr4:1375305	chr4:1356581~1358075:+
PCPG	cis	rs13118159	0.55	rs11946956	ENSG00000254094.1	AC078852.1	-3.91	0.000138	0.0421	-0.4	-0.3	Longevity;	chr4:1375306	chr4:1356581~1358075:+
PCPG	cis	rs1552244	0.882	rs56125067	ENSG00000180385.7	EMC3-AS1	3.91	0.000138	0.0421	0.39	0.3	Alzheimer's disease;	chr3:9942446	chr3:9986893~10006990:+
PCPG	cis	rs17270561	0.562	rs74293932	ENSG00000272810.1	U91328.22	-3.91	0.000138	0.0422	-0.38	-0.3	Iron status biomarkers;	chr6:26014583	chr6:26013241~26013757:+
PCPG	cis	rs4143844	0.867	rs71411468	ENSG00000259251.2	RP11-643M14.1	3.91	0.000138	0.0422	0.64	0.3	Bipolar disorder and schizophrenia;	chr15:61894514	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs36056548	ENSG00000259251.2	RP11-643M14.1	3.91	0.000138	0.0422	0.64	0.3	Bipolar disorder and schizophrenia;	chr15:61904187	chr15:62060503~62062434:+
PCPG	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000138	0.0422	-0.38	-0.3	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
PCPG	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000138	0.0422	-0.38	-0.3	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
PCPG	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	3.91	0.000138	0.0422	0.23	0.3	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
PCPG	cis	rs2836974	0.897	rs12481860	ENSG00000252915.1	Y_RNA	-3.91	0.000138	0.0422	-0.32	-0.3	Cognitive function;	chr21:39165910	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.899	rs8127087	ENSG00000252915.1	Y_RNA	-3.91	0.000138	0.0422	-0.32	-0.3	Cognitive function;	chr21:39172576	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs2836932	ENSG00000252915.1	Y_RNA	-3.91	0.000138	0.0422	-0.32	-0.3	Cognitive function;	chr21:39174791	chr21:39344537~39344628:+
PCPG	cis	rs3758785	0.679	rs13447595	ENSG00000255893.1	RP11-685N10.1	-3.91	0.000138	0.0422	-0.44	-0.3	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94489524	chr11:94472908~94473570:-
PCPG	cis	rs228614	0.509	rs223476	ENSG00000230069.3	LRRC37A15P	-3.91	0.000138	0.0422	-0.28	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102727274~102730721:-
PCPG	cis	rs228614	0.509	rs150896	ENSG00000230069.3	LRRC37A15P	-3.91	0.000138	0.0422	-0.28	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102727274~102730721:-
PCPG	cis	rs9299346	0.702	rs72745349	ENSG00000225376.4	TMEM246-AS1	3.91	0.000138	0.0422	0.42	0.3	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101616606	chr9:101468439~101481502:+
PCPG	cis	rs16949788	1	rs41315964	ENSG00000261351.2	CTD-3185P2.1	-3.91	0.000138	0.0422	-0.43	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66487360	chr15:66488658~66492109:-
PCPG	cis	rs2412459	0.572	rs536503	ENSG00000245849.5	RAD51-AS1	3.91	0.000138	0.0422	0.44	0.3	Response to haloperidol in psychosis;	chr15:39961473	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs548091	ENSG00000245849.5	RAD51-AS1	3.91	0.000138	0.0422	0.44	0.3	Response to haloperidol in psychosis;	chr15:39961522	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs1436276	ENSG00000245849.5	RAD51-AS1	3.91	0.000138	0.0422	0.44	0.3	Response to haloperidol in psychosis;	chr15:39961542	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs509200	ENSG00000245849.5	RAD51-AS1	3.91	0.000138	0.0422	0.44	0.3	Response to haloperidol in psychosis;	chr15:39962131	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs518802	ENSG00000245849.5	RAD51-AS1	3.91	0.000138	0.0422	0.44	0.3	Response to haloperidol in psychosis;	chr15:39962412	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.732	rs479500	ENSG00000245849.5	RAD51-AS1	3.91	0.000138	0.0422	0.44	0.3	Response to haloperidol in psychosis;	chr15:39963061	chr15:40686724~40695107:-
PCPG	cis	rs2412459	0.635	rs2640645	ENSG00000245849.5	RAD51-AS1	3.91	0.000138	0.0422	0.44	0.3	Response to haloperidol in psychosis;	chr15:39963199	chr15:40686724~40695107:-
PCPG	cis	rs7707921	0.881	rs57621982	ENSG00000249483.1	CTD-2249K22.1	-3.91	0.000138	0.0422	-0.41	-0.3	Breast cancer;	chr5:82110951	chr5:81851601~81852201:+
PCPG	cis	rs12188164	0.62	rs1043356	ENSG00000188242.4	PP7080	-3.91	0.000138	0.0422	-0.3	-0.3	Cystic fibrosis severity;	chr5:480833	chr5:466124~473098:-
PCPG	cis	rs11858159	1	rs67804163	ENSG00000260760.1	PWRN3	3.91	0.000138	0.0423	0.33	0.3	Platelet thrombus formation;	chr15:24552896	chr15:24441127~24447967:+
PCPG	cis	rs6445975	0.715	rs17059125	ENSG00000272360.1	RP11-359I18.5	-3.91	0.000138	0.0423	-0.37	-0.3	Systemic lupus erythematosus;	chr3:58283023	chr3:58490830~58491291:-
PCPG	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-3.91	0.000138	0.0423	-0.4	-0.3	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
PCPG	cis	rs1865760	0.622	rs9968910	ENSG00000272810.1	U91328.22	-3.91	0.000138	0.0423	-0.32	-0.3	Height;	chr6:26071867	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.622	rs10946807	ENSG00000272810.1	U91328.22	-3.91	0.000138	0.0423	-0.32	-0.3	Height;	chr6:26079410	chr6:26013241~26013757:+
PCPG	cis	rs4143844	0.867	rs17303894	ENSG00000259251.2	RP11-643M14.1	3.91	0.000138	0.0423	0.63	0.3	Bipolar disorder and schizophrenia;	chr15:61873378	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.867	rs34589937	ENSG00000259251.2	RP11-643M14.1	3.91	0.000138	0.0423	0.63	0.3	Bipolar disorder and schizophrenia;	chr15:61876196	chr15:62060503~62062434:+
PCPG	cis	rs7772486	0.743	rs9390344	ENSG00000270638.1	RP3-466P17.1	-3.91	0.000138	0.0423	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145735570~145737218:+
PCPG	cis	rs7707921	1	rs1543911	ENSG00000249483.1	CTD-2249K22.1	3.91	0.000138	0.0423	0.41	0.3	Breast cancer;	chr5:82209022	chr5:81851601~81852201:+
PCPG	cis	rs7707921	0.957	rs2059891	ENSG00000249483.1	CTD-2249K22.1	3.91	0.000138	0.0423	0.41	0.3	Breast cancer;	chr5:82212973	chr5:81851601~81852201:+
PCPG	cis	rs10895140	0.709	rs2513192	ENSG00000255337.1	RP11-315O6.1	3.91	0.000138	0.0423	0.34	0.3	Menarche (age at onset);	chr11:101606173	chr11:102452919~102462008:+
PCPG	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-3.91	0.000139	0.0423	-0.4	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
PCPG	cis	rs2612778	0.737	rs1795961	ENSG00000267737.1	AC061992.2	3.91	0.000139	0.0423	0.3	0.3	Mononucleosis;	chr17:79154698	chr17:78315729~78347798:+
PCPG	cis	rs7772486	0.754	rs9373476	ENSG00000270638.1	RP3-466P17.1	3.91	0.000139	0.0423	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145735570~145737218:+
PCPG	cis	rs7772486	0.727	rs11155442	ENSG00000270638.1	RP3-466P17.1	3.91	0.000139	0.0423	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145735570~145737218:+
PCPG	cis	rs8085804	0.597	rs8084832	ENSG00000267586.5	LINC00907	-3.91	0.000139	0.0423	-0.35	-0.3	Cognitive performance;	chr18:42669061	chr18:42159283~42691422:+
PCPG	cis	rs8085804	0.624	rs891567	ENSG00000267586.5	LINC00907	-3.91	0.000139	0.0423	-0.35	-0.3	Cognitive performance;	chr18:42674998	chr18:42159283~42691422:+
PCPG	cis	rs10465746	0.905	rs1324484	ENSG00000271576.1	RP11-486G15.2	-3.91	0.000139	0.0423	-0.27	-0.3	Obesity-related traits;	chr1:83917161	chr1:84076331~84077931:-
PCPG	cis	rs6957923	0.967	rs11773741	ENSG00000230658.1	KLHL7-AS1	3.91	0.000139	0.0423	0.36	0.3	Height;	chr7:23444613	chr7:23101228~23105703:-
PCPG	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	3.91	0.000139	0.0423	0.75	0.3	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	3.91	0.000139	0.0423	0.75	0.3	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
PCPG	cis	rs73201462	1	rs2811392	ENSG00000242551.2	POU5F1P6	-3.91	0.000139	0.0423	-0.62	-0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305133	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs56287882	ENSG00000242551.2	POU5F1P6	3.91	0.000139	0.0423	0.62	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311500	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs73197383	ENSG00000242551.2	POU5F1P6	3.91	0.000139	0.0423	0.62	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311631	chr3:128674735~128677005:-
PCPG	cis	rs9847710	0.967	rs2564934	ENSG00000242142.1	SERBP1P3	3.91	0.000139	0.0423	0.33	0.3	Ulcerative colitis;	chr3:52990564	chr3:53064283~53065091:-
PCPG	cis	rs9847710	0.901	rs2564937	ENSG00000242142.1	SERBP1P3	3.91	0.000139	0.0423	0.33	0.3	Ulcerative colitis;	chr3:52991843	chr3:53064283~53065091:-
PCPG	cis	rs9847710	0.967	rs2564938	ENSG00000242142.1	SERBP1P3	3.91	0.000139	0.0423	0.33	0.3	Ulcerative colitis;	chr3:52992368	chr3:53064283~53065091:-
PCPG	cis	rs9469578	0.579	rs9469584	ENSG00000224796.1	RPL32P1	-3.91	0.000139	0.0423	-0.8	-0.3	Phosphorus levels;	chr6:33752714	chr6:33079451~33079860:+
PCPG	cis	rs7118412	0.929	rs7947314	ENSG00000260966.1	RP11-690D19.3	3.91	0.000139	0.0423	0.32	0.3	Disc degeneration (lumbar);	chr11:103658470	chr11:103050687~103055799:-
PCPG	cis	rs2002030	0.915	rs56069917	ENSG00000255518.1	RP11-148O21.4	-3.91	0.000139	0.0423	-0.62	-0.3	Cognitive performance;	chr8:11414670	chr8:11556251~11558022:-
PCPG	cis	rs2002030	0.915	rs56255555	ENSG00000255518.1	RP11-148O21.4	-3.91	0.000139	0.0423	-0.62	-0.3	Cognitive performance;	chr8:11414775	chr8:11556251~11558022:-
PCPG	cis	rs2002030	0.731	rs56125952	ENSG00000255518.1	RP11-148O21.4	-3.91	0.000139	0.0423	-0.62	-0.3	Cognitive performance;	chr8:11414803	chr8:11556251~11558022:-
PCPG	cis	rs2002030	0.915	rs55888399	ENSG00000255518.1	RP11-148O21.4	-3.91	0.000139	0.0423	-0.62	-0.3	Cognitive performance;	chr8:11415652	chr8:11556251~11558022:-
PCPG	cis	rs7824557	0.569	rs10106207	ENSG00000254866.2	DEFB109P3	3.91	0.000139	0.0424	0.44	0.3	Retinal vascular caliber;	chr8:11157828	chr8:12150895~12151134:-
PCPG	cis	rs10040610	0.524	rs271422	ENSG00000248677.1	CTD-2044J15.1	-3.91	0.000139	0.0424	-0.35	-0.3	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6355594	chr5:6686325~6707711:-
PCPG	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	3.91	0.000139	0.0424	0.28	0.3	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
PCPG	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	3.91	0.000139	0.0424	0.28	0.3	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
PCPG	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	3.91	0.000139	0.0424	0.3	0.3	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	3.91	0.000139	0.0424	0.3	0.3	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	3.91	0.000139	0.0424	0.3	0.3	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
PCPG	cis	rs4819052	0.851	rs2838829	ENSG00000215447.6	BX322557.10	-3.91	0.000139	0.0424	-0.3	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45288052~45291738:+
PCPG	cis	rs6657613	0.621	rs11578903	ENSG00000186715.9	MST1L	-3.91	0.000139	0.0424	-0.32	-0.3	Hip circumference adjusted for BMI;	chr1:17051461	chr1:16754910~16770237:-
PCPG	cis	rs10200159	0.744	rs75365186	ENSG00000272606.1	RP11-554J4.1	3.91	0.000139	0.0424	0.58	0.3	Vitiligo;	chr2:55575834	chr2:55617909~55618373:+
PCPG	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	3.91	0.000139	0.0424	0.35	0.3	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	3.91	0.000139	0.0424	0.35	0.3	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
PCPG	cis	rs1129187	0.755	rs28868299	ENSG00000272223.1	RP1-20C7.6	3.91	0.000139	0.0424	0.3	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42953483	chr6:43033897~43034405:-
PCPG	cis	rs1129187	0.686	rs6458313	ENSG00000272223.1	RP1-20C7.6	3.91	0.000139	0.0424	0.3	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42954280	chr6:43033897~43034405:-
PCPG	cis	rs9472414	0.599	rs6458433	ENSG00000229349.2	ACTG1P9	3.91	0.000139	0.0424	0.5	0.3	Height;	chr6:45241546	chr6:46204729~46207386:+
PCPG	cis	rs3947	0.789	rs8005	ENSG00000255556.2	RP11-351I21.6	3.91	0.000139	0.0424	0.34	0.3	Blood protein levels;	chr8:11843587	chr8:12378679~12380265:-
PCPG	cis	rs7824557	0.675	rs2736265	ENSG00000255020.1	AF131216.5	3.91	0.000139	0.0424	0.41	0.3	Retinal vascular caliber;	chr8:11329165	chr8:11345748~11347502:-
PCPG	cis	rs5769765	1	rs2319458	ENSG00000278869.1	CITF22-49E9.3	3.91	0.000139	0.0425	0.38	0.3	Schizophrenia;	chr22:49842658	chr22:49933198~49934074:-
PCPG	cis	rs6456042	1	rs3099293	ENSG00000231297.3	RP11-459F1.2	3.91	0.000139	0.0425	0.32	0.3	Asthma;	chr6:166117170	chr6:166099665~166113273:+
PCPG	cis	rs6456042	1	rs3127408	ENSG00000231297.3	RP11-459F1.2	3.91	0.000139	0.0425	0.32	0.3	Asthma;	chr6:166117171	chr6:166099665~166113273:+
PCPG	cis	rs6456042	0.965	rs3099294	ENSG00000231297.3	RP11-459F1.2	3.91	0.000139	0.0425	0.32	0.3	Asthma;	chr6:166117504	chr6:166099665~166113273:+
PCPG	cis	rs11250098	0.574	rs4554431	ENSG00000255020.1	AF131216.5	-3.91	0.000139	0.0425	-0.39	-0.3	Morning vs. evening chronotype;	chr8:10914128	chr8:11345748~11347502:-
PCPG	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-3.91	0.000139	0.0425	-0.32	-0.3	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
PCPG	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	3.91	0.000139	0.0425	0.3	0.3	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	3.91	0.000139	0.0425	0.3	0.3	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	3.91	0.000139	0.0425	0.3	0.3	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
PCPG	cis	rs1729407	0.586	rs1729408	ENSG00000250699.1	AP000892.4	-3.91	0.000139	0.0425	-0.34	-0.3	Apolipoprotein A-IV levels;	chr11:116804102	chr11:117316362~117328038:-
PCPG	cis	rs67539049	1	rs67684445	ENSG00000255020.1	AF131216.5	-3.91	0.000139	0.0425	-0.56	-0.3	Itch intensity from mosquito bite;	chr8:11439818	chr8:11345748~11347502:-
PCPG	cis	rs67539049	1	rs60320871	ENSG00000255020.1	AF131216.5	-3.91	0.000139	0.0425	-0.56	-0.3	Itch intensity from mosquito bite;	chr8:11440040	chr8:11345748~11347502:-
PCPG	cis	rs10769025	0.674	rs4755802	ENSG00000252355.1	RN7SKP287	-3.91	0.000139	0.0425	-0.3	-0.3	Gout;	chr11:44268753	chr11:43435132~43435397:-
PCPG	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	3.91	0.00014	0.0425	0.26	0.3	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	3.91	0.00014	0.0425	0.26	0.3	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	3.91	0.00014	0.0425	0.26	0.3	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	3.91	0.00014	0.0425	0.26	0.3	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	3.91	0.00014	0.0425	0.26	0.3	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
PCPG	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	3.91	0.00014	0.0425	0.26	0.3	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
PCPG	cis	rs11148252	0.574	rs3742297	ENSG00000273784.3	RP11-78J21.7	-3.91	0.00014	0.0425	-0.29	-0.3	Lewy body disease;	chr13:52703932	chr13:52600042~52642542:+
PCPG	cis	rs11148252	0.574	rs9536247	ENSG00000273784.3	RP11-78J21.7	-3.91	0.00014	0.0425	-0.29	-0.3	Lewy body disease;	chr13:52705407	chr13:52600042~52642542:+
PCPG	cis	rs2797160	1	rs1935774	ENSG00000237742.5	RP11-624M8.1	3.91	0.00014	0.0425	0.31	0.3	Endometrial cancer;	chr6:125675515	chr6:125578558~125749190:-
PCPG	cis	rs897984	0.683	rs13337900	ENSG00000275263.1	RP11-1072A3.4	-3.91	0.00014	0.0426	-0.31	-0.3	Dementia with Lewy bodies;	chr16:30811088	chr16:30956872~30957199:-
PCPG	cis	rs17152411	1	rs7089014	ENSG00000278831.1	RP11-12J10.4	3.91	0.00014	0.0426	0.44	0.3	Height;	chr10:124901773	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs7083298	ENSG00000278831.1	RP11-12J10.4	3.91	0.00014	0.0426	0.44	0.3	Height;	chr10:124902122	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs7083336	ENSG00000278831.1	RP11-12J10.4	3.91	0.00014	0.0426	0.44	0.3	Height;	chr10:124902202	chr10:124623353~124624079:+
PCPG	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-3.91	0.00014	0.0426	-0.28	-0.3	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
PCPG	cis	rs2179367	0.959	rs544947	ENSG00000268592.3	RAET1E-AS1	3.91	0.00014	0.0426	0.39	0.3	Dupuytren's disease;	chr6:149402412	chr6:149863494~149919507:+
PCPG	cis	rs4489787	1	rs10459230	ENSG00000240399.1	RP1-228P16.1	-3.91	0.00014	0.0426	-0.4	-0.3	Prostate cancer (SNP x SNP interaction);	chr12:48457213	chr12:48054813~48055591:-
PCPG	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	3.91	0.00014	0.0426	0.37	0.3	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
PCPG	cis	rs11250098	0.503	rs7821826	ENSG00000255020.1	AF131216.5	-3.91	0.00014	0.0426	-0.39	-0.3	Morning vs. evening chronotype;	chr8:10911929	chr8:11345748~11347502:-
PCPG	cis	rs11250097	0.535	rs11250086	ENSG00000255020.1	AF131216.5	-3.91	0.00014	0.0426	-0.39	-0.3	Neuroticism;	chr8:10912273	chr8:11345748~11347502:-
PCPG	cis	rs301901	0.772	rs301874	ENSG00000250155.1	CTD-2353F22.1	-3.91	0.00014	0.0426	-0.36	-0.3	Height;	chr5:37094189	chr5:36666214~36725195:-
PCPG	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	3.91	0.00014	0.0426	0.35	0.3	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
PCPG	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-3.91	0.00014	0.0426	-0.43	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
PCPG	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	3.91	0.00014	0.0426	0.31	0.3	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
PCPG	cis	rs7714584	1	rs4560537	ENSG00000271795.1	CTC-251D13.1	-3.91	0.00014	0.0426	-0.57	-0.3	Crohn's disease;	chr5:150883024	chr5:151509453~151512769:+
PCPG	cis	rs1707322	0.821	rs11211182	ENSG00000234329.1	RP11-767N6.2	3.91	0.00014	0.0427	0.36	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45651039~45651826:-
PCPG	cis	rs2732480	0.538	rs2732462	ENSG00000240399.1	RP1-228P16.1	3.91	0.00014	0.0427	0.33	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48054813~48055591:-
PCPG	cis	rs1876905	1	rs1876905	ENSG00000255389.1	C6orf3	3.91	0.00014	0.0427	0.43	0.3	Mean corpuscular hemoglobin;	chr6:111096756	chr6:111599875~111602295:+
PCPG	cis	rs720475	0.732	rs62483106	ENSG00000170356.8	OR2A20P	3.91	0.00014	0.0427	0.44	0.3	Breast cancer;	chr7:144439533	chr7:144250045~144252957:-
PCPG	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	3.91	0.00014	0.0427	0.5	0.3	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
PCPG	cis	rs17508449	0.732	rs74610368	ENSG00000232450.1	RP4-730K3.3	-3.91	0.00014	0.0427	-0.47	-0.3	Leprosy;	chr1:113742681	chr1:113698884~113699631:-
PCPG	cis	rs2836974	0.932	rs13048178	ENSG00000252915.1	Y_RNA	-3.91	0.00014	0.0427	-0.32	-0.3	Cognitive function;	chr21:39189086	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs13049280	ENSG00000252915.1	Y_RNA	-3.91	0.00014	0.0427	-0.33	-0.3	Cognitive function;	chr21:39222730	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs13339986	ENSG00000252915.1	Y_RNA	-3.91	0.00014	0.0427	-0.33	-0.3	Cognitive function;	chr21:39234056	chr21:39344537~39344628:+
PCPG	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	3.91	0.00014	0.0427	0.33	0.3	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
PCPG	cis	rs889398	0.56	rs4985445	ENSG00000196696.11	PDXDC2P	-3.91	0.00014	0.0427	-0.24	-0.3	Body mass index;	chr16:69833932	chr16:69976297~70065948:-
PCPG	cis	rs7759001	0.857	rs6934748	ENSG00000271755.1	RP1-153G14.4	3.91	0.00014	0.0427	0.46	0.3	Glomerular filtration rate (creatinine);	chr6:27387002	chr6:27404010~27406964:-
PCPG	cis	rs2554380	0.891	rs1426164	ENSG00000259442.1	RP11-752G15.8	-3.91	0.00014	0.0427	-0.39	-0.3	Height;	chr15:83633084	chr15:82744223~82750289:+
PCPG	cis	rs2554380	0.891	rs2562781	ENSG00000259442.1	RP11-752G15.8	-3.91	0.00014	0.0427	-0.39	-0.3	Height;	chr15:83643816	chr15:82744223~82750289:+
PCPG	cis	rs17772222	0.917	rs17260408	ENSG00000222990.1	RNU4-22P	3.91	0.00014	0.0427	0.4	0.3	Coronary artery calcification;	chr14:88715464	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs8021690	ENSG00000222990.1	RNU4-22P	3.91	0.00014	0.0427	0.4	0.3	Coronary artery calcification;	chr14:88717806	chr14:88513498~88513663:+
PCPG	cis	rs10411161	0.702	rs16983200	ENSG00000275055.1	CTC-471J1.11	-3.91	0.000141	0.0428	-0.33	-0.3	Breast cancer;	chr19:51883470	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs10423835	ENSG00000275055.1	CTC-471J1.11	-3.91	0.000141	0.0428	-0.33	-0.3	Breast cancer;	chr19:51884069	chr19:52049007~52049754:+
PCPG	cis	rs7824557	0.569	rs2409718	ENSG00000254866.2	DEFB109P3	3.91	0.000141	0.0428	0.43	0.3	Retinal vascular caliber;	chr8:11155467	chr8:12150895~12151134:-
PCPG	cis	rs7598759	0.604	rs4973407	ENSG00000181798.2	LINC00471	-3.91	0.000141	0.0428	-0.39	-0.3	Noise-induced hearing loss;	chr2:231446928	chr2:231508426~231514339:-
PCPG	cis	rs4432245	1	rs4432245	ENSG00000248508.5	SRP14-AS1	3.91	0.000141	0.0428	0.53	0.3	Body mass index;	chr15:40032280	chr15:40039311~40067290:+
PCPG	cis	rs4432245	0.793	rs75266116	ENSG00000248508.5	SRP14-AS1	-3.91	0.000141	0.0428	-0.53	-0.3	Body mass index;	chr15:40031197	chr15:40039311~40067290:+
PCPG	cis	rs4432245	0.793	rs2291622	ENSG00000248508.5	SRP14-AS1	-3.91	0.000141	0.0428	-0.53	-0.3	Body mass index;	chr15:40032528	chr15:40039311~40067290:+
PCPG	cis	rs1865760	0.566	rs3752420	ENSG00000272810.1	U91328.22	-3.91	0.000141	0.0428	-0.31	-0.3	Height;	chr6:26026907	chr6:26013241~26013757:+
PCPG	cis	rs1129187	0.719	rs3805953	ENSG00000272223.1	RP1-20C7.6	3.91	0.000141	0.0428	0.3	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42969162	chr6:43033897~43034405:-
PCPG	cis	rs2554380	0.628	rs919069	ENSG00000230373.7	GOLGA6L5P	-3.91	0.000141	0.0428	-0.34	-0.3	Height;	chr15:83775776	chr15:84507885~84516814:-
PCPG	cis	rs2830585	0.677	rs229048	ENSG00000223563.1	AP001601.2	3.91	0.000141	0.0428	0.4	0.3	Blood protein levels;	chr21:26941711	chr21:26889376~26939742:+
PCPG	cis	rs425277	0.958	rs262687	ENSG00000271806.1	RP5-892K4.1	3.91	0.000141	0.0429	0.38	0.3	Height;	chr1:2185716	chr1:2141084~2145279:-
PCPG	cis	rs240993	0.809	rs11153277	ENSG00000255389.1	C6orf3	3.91	0.000141	0.0429	0.34	0.3	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111599875~111602295:+
PCPG	cis	rs7172677	0.696	rs56262544	ENSG00000261543.1	RP11-665J16.1	3.91	0.000141	0.0429	0.37	0.3	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75087130	chr15:74152800~74179226:-
PCPG	cis	rs1865760	0.516	rs10807007	ENSG00000272810.1	U91328.22	-3.91	0.000141	0.0429	-0.3	-0.3	Height;	chr6:26048703	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.516	rs9379819	ENSG00000272810.1	U91328.22	-3.91	0.000141	0.0429	-0.3	-0.3	Height;	chr6:26049591	chr6:26013241~26013757:+
PCPG	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	3.91	0.000141	0.0429	0.64	0.3	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
PCPG	cis	rs7523050	0.643	rs35924015	ENSG00000203897.3	SPATA42	-3.91	0.000141	0.0429	-0.45	-0.3	Fat distribution (HIV);	chr1:108862004	chr1:108857217~108858524:+
PCPG	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	3.91	0.000141	0.0429	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
PCPG	cis	rs911119	1	rs6114209	ENSG00000270001.1	RP11-218C14.8	-3.91	0.000141	0.0429	-0.5	-0.3	Chronic kidney disease;	chr20:23641629	chr20:23631826~23632316:-
PCPG	cis	rs301901	0.772	rs7711452	ENSG00000250155.1	CTD-2353F22.1	-3.91	0.000141	0.0429	-0.36	-0.3	Height;	chr5:37216735	chr5:36666214~36725195:-
PCPG	cis	rs1159787	0.558	rs532742	ENSG00000233569.1	RP11-500B12.1	3.91	0.000141	0.0429	0.42	0.3	Blood protein levels;	chr9:117598033	chr9:117648606~117657027:+
PCPG	cis	rs72753537	0.935	rs72753506	ENSG00000159712.10	ANKRD18CP	3.91	0.000141	0.0429	0.65	0.3	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97851407	chr9:97156570~97221235:-
PCPG	cis	rs72753537	0.935	rs10984009	ENSG00000159712.10	ANKRD18CP	3.91	0.000141	0.0429	0.65	0.3	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97856378	chr9:97156570~97221235:-
PCPG	cis	rs2179367	0.959	rs9390677	ENSG00000268592.3	RAET1E-AS1	3.91	0.000141	0.0429	0.39	0.3	Dupuytren's disease;	chr6:149389361	chr6:149863494~149919507:+
PCPG	cis	rs2179367	0.959	rs237034	ENSG00000268592.3	RAET1E-AS1	3.91	0.000141	0.0429	0.39	0.3	Dupuytren's disease;	chr6:149390726	chr6:149863494~149919507:+
PCPG	cis	rs2179367	0.959	rs628488	ENSG00000268592.3	RAET1E-AS1	3.91	0.000141	0.0429	0.39	0.3	Dupuytren's disease;	chr6:149398264	chr6:149863494~149919507:+
PCPG	cis	rs9311474	0.632	rs6445528	ENSG00000275956.1	RP5-966M1.7	3.91	0.000141	0.0429	0.34	0.3	Electroencephalogram traits;	chr3:52538431	chr3:52732547~52733867:+
PCPG	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	3.91	0.000141	0.0429	0.35	0.3	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	3.91	0.000141	0.0429	0.35	0.3	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
PCPG	cis	rs889398	0.802	rs12919094	ENSG00000196696.11	PDXDC2P	3.91	0.000141	0.0429	0.24	0.3	Body mass index;	chr16:69809454	chr16:69976297~70065948:-
PCPG	cis	rs4143844	0.655	rs35633657	ENSG00000259251.2	RP11-643M14.1	3.91	0.000141	0.0429	0.64	0.3	Bipolar disorder and schizophrenia;	chr15:61977739	chr15:62060503~62062434:+
PCPG	cis	rs1552244	1	rs35993975	ENSG00000180385.7	EMC3-AS1	3.91	0.000141	0.0429	0.39	0.3	Alzheimer's disease;	chr3:10026110	chr3:9986893~10006990:+
PCPG	cis	rs394563	0.591	rs237016	ENSG00000231760.4	RP11-350J20.5	3.91	0.000141	0.0429	0.39	0.3	Dupuytren's disease;	chr6:149423723	chr6:149796151~149826294:-
PCPG	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	3.91	0.000141	0.043	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
PCPG	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	3.91	0.000141	0.043	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
PCPG	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	3.91	0.000141	0.043	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
PCPG	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	3.91	0.000141	0.043	0.35	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
PCPG	cis	rs2243480	1	rs316330	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66140385	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316329	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66143429	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316326	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66144466	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316325	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66144531	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316321	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66146626	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316318	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66147917	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316317	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66148650	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316304	ENSG00000230189.5	GS1-124K5.2	3.91	0.000141	0.043	0.46	0.3	Diabetic kidney disease;	chr7:66151907	chr7:66409143~66490059:-
PCPG	cis	rs2243480	0.901	rs12530490	ENSG00000230189.5	GS1-124K5.2	-3.91	0.000141	0.043	-0.46	-0.3	Diabetic kidney disease;	chr7:66226660	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs7778911	ENSG00000230189.5	GS1-124K5.2	-3.91	0.000141	0.043	-0.46	-0.3	Diabetic kidney disease;	chr7:66229519	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs1979823	ENSG00000230189.5	GS1-124K5.2	-3.91	0.000141	0.043	-0.46	-0.3	Diabetic kidney disease;	chr7:66239626	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs6964245	ENSG00000230189.5	GS1-124K5.2	-3.91	0.000141	0.043	-0.46	-0.3	Diabetic kidney disease;	chr7:66253730	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs10807701	ENSG00000230189.5	GS1-124K5.2	-3.91	0.000141	0.043	-0.46	-0.3	Diabetic kidney disease;	chr7:66259699	chr7:66409143~66490059:-
PCPG	cis	rs3020264	0.962	rs1974946	ENSG00000271743.1	CTD-2541M15.3	-3.91	0.000141	0.043	-0.38	-0.3	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631266	chr8:6615604~6617198:-
PCPG	cis	rs73201462	1	rs2999089	ENSG00000242551.2	POU5F1P6	-3.91	0.000141	0.043	-0.6	-0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128216316	chr3:128674735~128677005:-
PCPG	cis	rs240993	0.812	rs9487632	ENSG00000271789.1	RP5-1112D6.7	-3.91	0.000141	0.043	-0.38	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111297126~111298510:+
PCPG	cis	rs240993	0.812	rs11153295	ENSG00000271789.1	RP5-1112D6.7	-3.91	0.000141	0.043	-0.38	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111297126~111298510:+
PCPG	cis	rs240993	0.812	rs6915753	ENSG00000271789.1	RP5-1112D6.7	-3.91	0.000141	0.043	-0.38	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111297126~111298510:+
PCPG	cis	rs240993	0.812	rs4620159	ENSG00000271789.1	RP5-1112D6.7	-3.91	0.000141	0.043	-0.38	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111297126~111298510:+
PCPG	cis	rs240993	0.812	rs10214442	ENSG00000271789.1	RP5-1112D6.7	-3.91	0.000141	0.043	-0.38	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111297126~111298510:+
PCPG	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-3.91	0.000141	0.043	-0.3	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
PCPG	cis	rs13108904	0.87	rs3755927	ENSG00000254094.1	AC078852.1	-3.91	0.000142	0.043	-0.36	-0.3	Obesity-related traits;	chr4:1244458	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.87	rs3755924	ENSG00000254094.1	AC078852.1	-3.91	0.000142	0.043	-0.36	-0.3	Obesity-related traits;	chr4:1244575	chr4:1356581~1358075:+
PCPG	cis	rs13108904	0.87	rs3775094	ENSG00000254094.1	AC078852.1	-3.91	0.000142	0.043	-0.36	-0.3	Obesity-related traits;	chr4:1245071	chr4:1356581~1358075:+
PCPG	cis	rs16879308	0.581	rs4635893	ENSG00000248898.1	CTD-2288O8.1	3.91	0.000142	0.043	0.8	0.3	Migraine without aura;	chr5:52093356	chr5:52675193~52788026:-
PCPG	cis	rs16879308	0.581	rs78916041	ENSG00000248898.1	CTD-2288O8.1	3.91	0.000142	0.043	0.8	0.3	Migraine without aura;	chr5:52097283	chr5:52675193~52788026:-
PCPG	cis	rs9513627	0.833	rs73556129	ENSG00000228501.2	RPL15P18	3.91	0.000142	0.043	0.55	0.3	Obesity-related traits;	chr13:99460913	chr13:100150481~100151092:-
PCPG	cis	rs2898290	0.592	rs2736342	ENSG00000184608.7	FAM167A-AS1	-3.91	0.000142	0.043	-0.43	-0.3	Systolic blood pressure;	chr8:11489780	chr8:11368402~11438658:+
PCPG	cis	rs6504340	0.739	rs66459980	ENSG00000279036.1	RP11-81K2.2	-3.91	0.000142	0.043	-0.51	-0.3	Primary tooth development (number of teeth);	chr17:48595354	chr17:49494223~49497800:-
PCPG	cis	rs17177078	1	rs17177078	ENSG00000275494.1	RP11-266L9.8	3.91	0.000142	0.043	0.51	0.3	Type 2 diabetes (dietary heme iron intake interaction);	chr16:24799360	chr16:25106569~25107102:-
PCPG	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-3.91	0.000142	0.043	-0.44	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
PCPG	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-3.91	0.000142	0.043	-0.44	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
PCPG	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-3.91	0.000142	0.043	-0.35	-0.3	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
PCPG	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-3.91	0.000142	0.043	-0.43	-0.3	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
PCPG	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	3.91	0.000142	0.0431	0.3	0.3	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
PCPG	cis	rs181553	0.961	rs10853575	ENSG00000278983.1	RP11-426J5.3	-3.91	0.000142	0.0431	-0.33	-0.3	Hip circumference adjusted for BMI;	chr18:49033349	chr18:48564795~48568342:+
PCPG	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	3.91	0.000142	0.0431	0.31	0.3	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.913	rs56122576	ENSG00000249244.1	RP11-548H18.2	3.91	0.000142	0.0431	0.31	0.3	Corneal astigmatism;	chr4:119208181	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	3.91	0.000142	0.0431	0.31	0.3	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	3.91	0.000142	0.0431	0.31	0.3	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
PCPG	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	3.91	0.000142	0.0431	0.32	0.3	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
PCPG	cis	rs2439831	0.717	rs690170	ENSG00000205771.5	CATSPER2P1	-3.91	0.000142	0.0431	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43518224	chr15:43726918~43747094:-
PCPG	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	3.91	0.000142	0.0431	0.7	0.3	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
PCPG	cis	rs17772222	0.917	rs8018755	ENSG00000222990.1	RNU4-22P	3.91	0.000142	0.0431	0.4	0.3	Coronary artery calcification;	chr14:88714249	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs8018630	ENSG00000222990.1	RNU4-22P	3.91	0.000142	0.0431	0.4	0.3	Coronary artery calcification;	chr14:88714250	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs8020072	ENSG00000222990.1	RNU4-22P	3.91	0.000142	0.0431	0.4	0.3	Coronary artery calcification;	chr14:88714332	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs12589982	ENSG00000222990.1	RNU4-22P	3.91	0.000142	0.0431	0.4	0.3	Coronary artery calcification;	chr14:88716861	chr14:88513498~88513663:+
PCPG	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000142	0.0431	-0.33	-0.3	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
PCPG	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000142	0.0431	-0.33	-0.3	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
PCPG	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000142	0.0431	-0.33	-0.3	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
PCPG	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-3.91	0.000142	0.0431	-0.33	-0.3	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
PCPG	cis	rs6728642	0.901	rs10179966	ENSG00000230606.9	AC159540.1	3.91	0.000142	0.0431	0.4	0.3	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97179363	chr2:97416165~97433527:-
PCPG	cis	rs8098244	0.638	rs3745027	ENSG00000265752.2	RP11-403A21.1	3.9	0.000142	0.0432	0.35	0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23893999	chr18:23957754~23982556:-
PCPG	cis	rs9788721	0.934	rs16969968	ENSG00000279421.1	RP11-335K5.3	-3.9	0.000142	0.0432	-0.37	-0.3	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78590583	chr15:78599892~78600013:-
PCPG	cis	rs8192482	1	rs8192482	ENSG00000279421.1	RP11-335K5.3	-3.9	0.000142	0.0432	-0.37	-0.3	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78593856	chr15:78599892~78600013:-
PCPG	cis	rs4887067	1	rs4887067	ENSG00000279421.1	RP11-335K5.3	-3.9	0.000142	0.0432	-0.37	-0.3	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78594605	chr15:78599892~78600013:-
PCPG	cis	rs11638352	1	rs2957581	ENSG00000205771.5	CATSPER2P1	3.9	0.000142	0.0432	0.53	0.3	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44117884	chr15:43726918~43747094:-
PCPG	cis	rs131777	0.545	rs140514	ENSG00000205559.3	CHKB-AS1	-3.9	0.000142	0.0432	-0.34	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50583026~50583877:+
PCPG	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-3.9	0.000142	0.0432	-0.47	-0.3	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
PCPG	cis	rs7819412	0.654	rs34741518	ENSG00000255020.1	AF131216.5	-3.9	0.000142	0.0432	-0.41	-0.3	Triglycerides;	chr8:10919350	chr8:11345748~11347502:-
PCPG	cis	rs2921073	0.604	rs2979140	ENSG00000173295.6	FAM86B3P	-3.9	0.000142	0.0432	-0.35	-0.3	Parkinson's disease;	chr8:8409692	chr8:8228595~8244865:+
PCPG	cis	rs2882667	0.537	rs6887866	ENSG00000222937.1	SNORD63	3.9	0.000142	0.0432	0.27	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138558970~138559039:-
PCPG	cis	rs9923283	0.673	rs4788172	ENSG00000261067.5	RP11-264B17.3	-3.9	0.000142	0.0432	-0.37	-0.3	Plateletcrit;	chr16:29656932	chr16:28974804~28990783:+
PCPG	cis	rs11671005	0.571	rs56243535	ENSG00000269600.1	AC016629.3	-3.9	0.000142	0.0432	-0.51	-0.3	Mean platelet volume;	chr19:58494783	chr19:58593896~58599355:-
PCPG	cis	rs10865541	0.967	rs6755448	ENSG00000225234.1	TRAPPC12-AS1	-3.9	0.000142	0.0432	-0.3	-0.3	Obesity-related traits;	chr2:3393588	chr2:3481242~3482409:-
PCPG	cis	rs10865541	0.967	rs6751808	ENSG00000225234.1	TRAPPC12-AS1	-3.9	0.000142	0.0432	-0.3	-0.3	Obesity-related traits;	chr2:3393606	chr2:3481242~3482409:-
PCPG	cis	rs172166	0.538	rs1150686	ENSG00000176933.5	TOB2P1	-3.9	0.000142	0.0432	-0.34	-0.3	Cardiac Troponin-T levels;	chr6:28193493	chr6:28217643~28218634:-
PCPG	cis	rs1150688	1	rs1150688	ENSG00000176933.5	TOB2P1	-3.9	0.000142	0.0432	-0.34	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28217643~28218634:-
PCPG	cis	rs2999052	1	rs9879865	ENSG00000242551.2	POU5F1P6	-3.9	0.000142	0.0432	-0.4	-0.3	Hypospadias;	chr3:128217684	chr3:128674735~128677005:-
PCPG	cis	rs2999052	1	rs9879866	ENSG00000242551.2	POU5F1P6	-3.9	0.000142	0.0432	-0.4	-0.3	Hypospadias;	chr3:128217689	chr3:128674735~128677005:-
PCPG	cis	rs2999052	1	rs9847576	ENSG00000242551.2	POU5F1P6	-3.9	0.000142	0.0432	-0.4	-0.3	Hypospadias;	chr3:128218802	chr3:128674735~128677005:-
PCPG	cis	rs2999052	0.951	rs9814834	ENSG00000242551.2	POU5F1P6	-3.9	0.000142	0.0432	-0.4	-0.3	Hypospadias;	chr3:128219294	chr3:128674735~128677005:-
PCPG	cis	rs2999052	1	rs9857235	ENSG00000242551.2	POU5F1P6	-3.9	0.000142	0.0432	-0.4	-0.3	Hypospadias;	chr3:128220191	chr3:128674735~128677005:-
PCPG	cis	rs2999052	0.951	rs4323023	ENSG00000242551.2	POU5F1P6	-3.9	0.000142	0.0432	-0.4	-0.3	Hypospadias;	chr3:128220514	chr3:128674735~128677005:-
PCPG	cis	rs12194062	0.524	rs270044	ENSG00000220694.2	RP3-403A15.1	3.9	0.000142	0.0432	0.35	0.3	QRS duration;	chr6:127865338	chr6:127435636~127436189:+
PCPG	cis	rs950169	0.8	rs34302901	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84567712	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs12915832	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84568226	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs11630760	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84570106	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.887	rs71395453	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84570259	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs11633075	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84570741	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.84	rs12905223	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84571037	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs12912934	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84571216	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs62021167	ENSG00000235370.6	DNM1P51	3.9	0.000143	0.0432	0.32	0.3	Schizophrenia;	chr15:84574820	chr15:84398316~84411701:-
PCPG	cis	rs7937890	0.559	rs1116739	ENSG00000251991.1	RNU7-49P	3.9	0.000143	0.0432	0.35	0.3	Mitochondrial DNA levels;	chr11:14467636	chr11:14478892~14478953:+
PCPG	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-3.9	0.000143	0.0432	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
PCPG	cis	rs2361701	0.929	rs1561810	ENSG00000279259.1	RP11-334C17.3	3.9	0.000143	0.0433	0.32	0.3	IgG glycosylation;	chr17:80095525	chr17:80147250~80148596:+
PCPG	cis	rs7824557	0.527	rs2572448	ENSG00000269954.1	RP11-148O21.6	-3.9	0.000143	0.0433	-0.35	-0.3	Retinal vascular caliber;	chr8:11381843	chr8:11552488~11552991:-
PCPG	cis	rs7824557	0.527	rs2572447	ENSG00000269954.1	RP11-148O21.6	-3.9	0.000143	0.0433	-0.35	-0.3	Retinal vascular caliber;	chr8:11382001	chr8:11552488~11552991:-
PCPG	cis	rs7824557	0.527	rs2572446	ENSG00000269954.1	RP11-148O21.6	-3.9	0.000143	0.0433	-0.35	-0.3	Retinal vascular caliber;	chr8:11382056	chr8:11552488~11552991:-
PCPG	cis	rs7824557	0.527	rs10109537	ENSG00000269954.1	RP11-148O21.6	-3.9	0.000143	0.0433	-0.35	-0.3	Retinal vascular caliber;	chr8:11382131	chr8:11552488~11552991:-
PCPG	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	3.9	0.000143	0.0433	0.34	0.3	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
PCPG	cis	rs17772222	0.582	rs11625009	ENSG00000258983.2	RP11-507K2.2	-3.9	0.000143	0.0433	-0.38	-0.3	Coronary artery calcification;	chr14:88521018	chr14:88499334~88515502:+
PCPG	cis	rs763014	0.966	rs7185390	ENSG00000266124.1	MIR5587	-3.9	0.000143	0.0433	-0.31	-0.3	Height;	chr16:616382	chr16:535316~535368:+
PCPG	cis	rs763014	0.966	rs4984675	ENSG00000266124.1	MIR5587	-3.9	0.000143	0.0433	-0.31	-0.3	Height;	chr16:620117	chr16:535316~535368:+
PCPG	cis	rs4143844	0.737	rs11636682	ENSG00000259251.2	RP11-643M14.1	3.9	0.000143	0.0433	0.75	0.3	Bipolar disorder and schizophrenia;	chr15:62083234	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.737	rs10519155	ENSG00000259251.2	RP11-643M14.1	3.9	0.000143	0.0433	0.75	0.3	Bipolar disorder and schizophrenia;	chr15:62083254	chr15:62060503~62062434:+
PCPG	cis	rs4143844	0.737	rs10519156	ENSG00000259251.2	RP11-643M14.1	3.9	0.000143	0.0433	0.75	0.3	Bipolar disorder and schizophrenia;	chr15:62083599	chr15:62060503~62062434:+
PCPG	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-3.9	0.000143	0.0433	-0.39	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
PCPG	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-3.9	0.000143	0.0433	-0.39	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
PCPG	cis	rs116248771	0.739	rs4679831	ENSG00000272087.1	RP11-379F4.7	3.9	0.000143	0.0433	0.45	0.3	diarrhoeal disease at age 2;	chr3:158603199	chr3:158693120~158693768:-
PCPG	cis	rs116248771	0.739	rs12629635	ENSG00000272087.1	RP11-379F4.7	3.9	0.000143	0.0433	0.45	0.3	diarrhoeal disease at age 2;	chr3:158604280	chr3:158693120~158693768:-
PCPG	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	3.9	0.000143	0.0433	0.26	0.3	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
PCPG	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	3.9	0.000143	0.0433	0.26	0.3	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
PCPG	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	3.9	0.000143	0.0433	0.35	0.3	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
PCPG	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	3.9	0.000143	0.0433	0.35	0.3	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
PCPG	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	3.9	0.000143	0.0433	0.35	0.3	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
PCPG	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	3.9	0.000143	0.0433	0.35	0.3	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
PCPG	cis	rs7824557	0.815	rs2736372	ENSG00000255020.1	AF131216.5	-3.9	0.000143	0.0433	-0.4	-0.3	Retinal vascular caliber;	chr8:11248532	chr8:11345748~11347502:-
PCPG	cis	rs17684571	0.872	rs3002011	ENSG00000231441.1	RP11-472M19.2	3.9	0.000143	0.0433	0.5	0.3	Schizophrenia;	chr6:56760325	chr6:56844002~56864078:+
PCPG	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-3.9	0.000143	0.0433	-0.28	-0.3	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
PCPG	cis	rs1552244	0.882	rs34706481	ENSG00000180385.7	EMC3-AS1	3.9	0.000143	0.0434	0.39	0.3	Alzheimer's disease;	chr3:9962439	chr3:9986893~10006990:+
PCPG	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	3.9	0.000143	0.0434	0.52	0.3	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
PCPG	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	3.9	0.000143	0.0434	0.52	0.3	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
PCPG	cis	rs9513627	1	rs7338761	ENSG00000228501.2	RPL15P18	3.9	0.000143	0.0434	0.61	0.3	Obesity-related traits;	chr13:99467477	chr13:100150481~100151092:-
PCPG	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-3.9	0.000143	0.0434	-0.51	-0.3	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
PCPG	cis	rs698833	0.506	rs4952705	ENSG00000236502.1	SIX3-AS1	3.9	0.000143	0.0434	0.4	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44272728	chr2:44940154~44941873:-
PCPG	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	3.9	0.000143	0.0434	0.28	0.3	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
PCPG	cis	rs9393777	0.92	rs34071253	ENSG00000219392.1	RP1-265C24.5	-3.9	0.000143	0.0434	-0.62	-0.3	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28115628~28116551:+
PCPG	cis	rs2243480	1	rs160646	ENSG00000230189.5	GS1-124K5.2	3.9	0.000143	0.0434	0.45	0.3	Diabetic kidney disease;	chr7:66091293	chr7:66409143~66490059:-
PCPG	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-3.9	0.000143	0.0434	-0.35	-0.3	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
PCPG	cis	rs72753537	0.935	rs10983904	ENSG00000159712.10	ANKRD18CP	3.9	0.000143	0.0434	0.62	0.3	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97835250	chr9:97156570~97221235:-
PCPG	cis	rs6657613	0.68	rs2295059	ENSG00000186715.9	MST1L	-3.9	0.000143	0.0434	-0.32	-0.3	Hip circumference adjusted for BMI;	chr1:17050914	chr1:16754910~16770237:-
PCPG	cis	rs6657613	0.651	rs2295057	ENSG00000186715.9	MST1L	-3.9	0.000143	0.0434	-0.32	-0.3	Hip circumference adjusted for BMI;	chr1:17051061	chr1:16754910~16770237:-
PCPG	cis	rs172166	0.637	rs1071893	ENSG00000220721.1	OR1F12	3.9	0.000143	0.0434	0.35	0.3	Cardiac Troponin-T levels;	chr6:28199857	chr6:28073316~28074233:+
PCPG	cis	rs13008603	0.571	rs281472	ENSG00000239332.4	LINC01119	3.9	0.000143	0.0434	0.65	0.3	High light scatter reticulocyte count;Hemoglobin levels;Red blood cell traits;	chr2:46176698	chr2:46816697~46859007:+
PCPG	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	3.9	0.000143	0.0434	0.36	0.3	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
PCPG	cis	rs4938303	0.756	rs4938301	ENSG00000280143.1	AP000892.6	-3.9	0.000143	0.0434	-0.37	-0.3	Triglycerides;	chr11:116704757	chr11:117204967~117210292:+
PCPG	cis	rs34421088	0.56	rs2618434	ENSG00000254774.1	RP11-148O21.3	-3.9	0.000143	0.0434	-0.34	-0.3	Neuroticism;	chr8:11541356	chr8:11553224~11554207:-
PCPG	cis	rs1048886	0.872	rs75782125	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000144	0.0434	-0.38	-0.3	Type 2 diabetes;	chr6:70550554	chr6:70596438~70596980:+
PCPG	cis	rs1048886	0.872	rs12529284	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000144	0.0434	-0.38	-0.3	Type 2 diabetes;	chr6:70553813	chr6:70596438~70596980:+
PCPG	cis	rs17684571	0.751	rs28360570	ENSG00000231441.1	RP11-472M19.2	3.9	0.000144	0.0434	0.53	0.3	Schizophrenia;	chr6:56852832	chr6:56844002~56864078:+
PCPG	cis	rs9299346	0.536	rs2417291	ENSG00000225376.4	TMEM246-AS1	3.9	0.000144	0.0434	0.5	0.3	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101704782	chr9:101468439~101481502:+
PCPG	cis	rs763121	0.853	rs4821816	ENSG00000273076.1	RP3-508I15.22	3.9	0.000144	0.0434	0.33	0.3	Menopause (age at onset);	chr22:38717129	chr22:38743495~38743910:+
PCPG	cis	rs799165	0.818	rs34958196	ENSG00000174353.16	STAG3L3	-3.9	0.000144	0.0435	-0.4	-0.3	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr7:73628771	chr7:72969696~73005922:-
PCPG	cis	rs3809060	0.959	rs2234580	ENSG00000213713.3	PIGCP1	3.9	0.000144	0.0435	0.17	0.3	Inguinal hernia;	chr11:32435592	chr11:33075566~33076460:-
PCPG	cis	rs3809060	0.959	rs2301254	ENSG00000213713.3	PIGCP1	3.9	0.000144	0.0435	0.17	0.3	Inguinal hernia;	chr11:32436129	chr11:33075566~33076460:-
PCPG	cis	rs3809060	0.959	rs2301253	ENSG00000213713.3	PIGCP1	3.9	0.000144	0.0435	0.17	0.3	Inguinal hernia;	chr11:32436228	chr11:33075566~33076460:-
PCPG	cis	rs3809060	0.959	rs2301252	ENSG00000213713.3	PIGCP1	3.9	0.000144	0.0435	0.17	0.3	Inguinal hernia;	chr11:32436381	chr11:33075566~33076460:-
PCPG	cis	rs116248771	0.739	rs4679833	ENSG00000272087.1	RP11-379F4.7	3.9	0.000144	0.0435	0.45	0.3	diarrhoeal disease at age 2;	chr3:158622046	chr3:158693120~158693768:-
PCPG	cis	rs720064	0.589	rs10502441	ENSG00000265752.2	RP11-403A21.1	3.9	0.000144	0.0435	0.34	0.3	Strep throat;	chr18:23923207	chr18:23957754~23982556:-
PCPG	cis	rs703842	1	rs10877014	ENSG00000270039.1	RP11-571M6.17	-3.9	0.000144	0.0435	-0.37	-0.3	Multiple sclerosis;	chr12:57773878	chr12:57803838~57804415:+
PCPG	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	3.9	0.000144	0.0435	0.35	0.3	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
PCPG	cis	rs172166	0.516	rs1150670	ENSG00000176933.5	TOB2P1	-3.9	0.000144	0.0435	-0.34	-0.3	Cardiac Troponin-T levels;	chr6:28162781	chr6:28217643~28218634:-
PCPG	cis	rs172166	0.516	rs2021826	ENSG00000176933.5	TOB2P1	-3.9	0.000144	0.0435	-0.34	-0.3	Cardiac Troponin-T levels;	chr6:28164978	chr6:28217643~28218634:-
PCPG	cis	rs2836974	0.583	rs9636957	ENSG00000255568.3	BRWD1-AS2	-3.9	0.000144	0.0435	-0.32	-0.3	Cognitive function;	chr21:39333921	chr21:39313935~39314962:+
PCPG	cis	rs2836974	0.602	rs2836987	ENSG00000255568.3	BRWD1-AS2	-3.9	0.000144	0.0435	-0.32	-0.3	Cognitive function;	chr21:39334668	chr21:39313935~39314962:+
PCPG	cis	rs2836974	0.897	rs1541102	ENSG00000252915.1	Y_RNA	-3.9	0.000144	0.0435	-0.31	-0.3	Cognitive function;	chr21:39256839	chr21:39344537~39344628:+
PCPG	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	3.9	0.000144	0.0435	0.39	0.3	Height;	chr6:109420812	chr6:109382795~109383666:+
PCPG	cis	rs2836974	0.831	rs4375956	ENSG00000252915.1	Y_RNA	-3.9	0.000144	0.0435	-0.33	-0.3	Cognitive function;	chr21:39149862	chr21:39344537~39344628:+
PCPG	cis	rs12444795	0.755	rs741692	ENSG00000267077.1	RP11-127I20.5	3.9	0.000144	0.0435	0.54	0.3	Cancer;	chr16:4812424	chr16:4795265~4796532:-
PCPG	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-3.9	0.000144	0.0435	-0.35	-0.3	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
PCPG	cis	rs4791051	0.644	rs7210816	ENSG00000264491.1	RP11-349A8.3	-3.9	0.000144	0.0435	-0.32	-0.3	Heschl's gyrus morphology;	chr17:66486228	chr17:67019934~67021743:-
PCPG	cis	rs2404602	0.716	rs67920045	ENSG00000259422.1	RP11-593F23.1	3.9	0.000144	0.0435	0.36	0.3	Blood metabolite levels;	chr15:76507743	chr15:76174891~76181486:-
PCPG	cis	rs8098244	0.52	rs12955456	ENSG00000265752.2	RP11-403A21.1	3.9	0.000144	0.0436	0.34	0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677624	chr18:23957754~23982556:-
PCPG	cis	rs6137473	0.516	rs6113492	ENSG00000227063.5	RPL41P1	3.9	0.000144	0.0436	0.34	0.3	Adolescent idiopathic scoliosis;	chr20:22077868	chr20:21755270~21755350:+
PCPG	cis	rs847649	1	rs9718453	ENSG00000252643.1	RNU6-1136P	3.9	0.000144	0.0436	0.37	0.3	Morning vs. evening chronotype;	chr7:102954529	chr7:102834605~102834708:+
PCPG	cis	rs847649	0.961	rs7456502	ENSG00000252643.1	RNU6-1136P	3.9	0.000144	0.0436	0.37	0.3	Morning vs. evening chronotype;	chr7:102955575	chr7:102834605~102834708:+
PCPG	cis	rs12291225	0.637	rs8570	ENSG00000251991.1	RNU7-49P	3.9	0.000144	0.0436	0.34	0.3	Sense of smell;	chr11:14279213	chr11:14478892~14478953:+
PCPG	cis	rs6706693	0.88	rs7587945	ENSG00000228509.4	AC006460.2	-3.9	0.000144	0.0436	-0.39	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil);	chr2:191601231	chr2:190676944~190708716:-
PCPG	cis	rs6706693	0.919	rs7562037	ENSG00000228509.4	AC006460.2	-3.9	0.000144	0.0436	-0.39	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil);	chr2:191601474	chr2:190676944~190708716:-
PCPG	cis	rs16879308	0.748	rs7722279	ENSG00000248898.1	CTD-2288O8.1	3.9	0.000144	0.0436	0.73	0.3	Migraine without aura;	chr5:52268436	chr5:52675193~52788026:-
PCPG	cis	rs17152411	1	rs17152377	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124904283	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs17152381	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124904334	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs7082846	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124904741	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs7097282	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124904923	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs7086447	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124904984	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs1807099	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124905205	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs733402	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124905583	chr10:124623353~124624079:+
PCPG	cis	rs17152411	1	rs733401	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124905589	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.947	rs733400	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124905771	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.947	rs61873270	ENSG00000278831.1	RP11-12J10.4	3.9	0.000144	0.0436	0.43	0.3	Height;	chr10:124907354	chr10:124623353~124624079:+
PCPG	cis	rs698813	0.674	rs11680456	ENSG00000236502.1	SIX3-AS1	3.9	0.000145	0.0436	0.4	0.3	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44270405	chr2:44940154~44941873:-
PCPG	cis	rs11858159	0.899	rs12914305	ENSG00000260760.1	PWRN3	3.9	0.000145	0.0436	0.33	0.3	Platelet thrombus formation;	chr15:24566555	chr15:24441127~24447967:+
PCPG	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-3.9	0.000145	0.0436	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
PCPG	cis	rs2898290	0.622	rs7822109	ENSG00000254774.1	RP11-148O21.3	-3.9	0.000145	0.0437	-0.33	-0.3	Systolic blood pressure;	chr8:11491638	chr8:11553224~11554207:-
PCPG	cis	rs7707921	0.881	rs112413913	ENSG00000249483.1	CTD-2249K22.1	-3.9	0.000145	0.0437	-0.41	-0.3	Breast cancer;	chr5:82063890	chr5:81851601~81852201:+
PCPG	cis	rs7707921	0.881	rs73134739	ENSG00000249483.1	CTD-2249K22.1	-3.9	0.000145	0.0437	-0.41	-0.3	Breast cancer;	chr5:82074941	chr5:81851601~81852201:+
PCPG	cis	rs2625529	0.59	rs12904652	ENSG00000260037.4	CTD-2524L6.3	-3.9	0.000145	0.0437	-0.4	-0.3	Red blood cell count;	chr15:72256424	chr15:71818396~71823384:+
PCPG	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	3.9	0.000145	0.0437	0.35	0.3	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
PCPG	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	3.9	0.000145	0.0437	0.35	0.3	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
PCPG	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	3.9	0.000145	0.0437	0.35	0.3	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
PCPG	cis	rs13108904	0.935	rs2199956	ENSG00000253399.1	AC078852.2	-3.9	0.000145	0.0437	-0.31	-0.3	Obesity-related traits;	chr4:1255131	chr4:1358479~1359461:+
PCPG	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	3.9	0.000145	0.0437	0.29	0.3	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	3.9	0.000145	0.0437	0.29	0.3	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
PCPG	cis	rs12214131	0.931	rs10457134	ENSG00000231628.1	RP3-355L5.4	-3.9	0.000145	0.0437	-0.26	-0.3	Male-pattern baldness;	chr6:105786320	chr6:105279016~105281755:+
PCPG	cis	rs2404602	0.692	rs12904198	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76854637	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs2137307	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76856679	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.669	rs17367297	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76865685	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs12594556	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76873022	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs12913810	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76874334	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs12595586	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76879869	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs58889902	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76880729	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs4360890	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76880954	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.669	rs12916324	ENSG00000259422.1	RP11-593F23.1	3.9	0.000145	0.0437	0.36	0.3	Blood metabolite levels;	chr15:76887262	chr15:76174891~76181486:-
PCPG	cis	rs9902453	0.838	rs9646436	ENSG00000265845.2	RP11-20B24.5	3.9	0.000145	0.0437	0.36	0.3	Coffee consumption (cups per day);	chr17:29882041	chr17:28926275~28944749:+
PCPG	cis	rs9902453	0.838	rs9646437	ENSG00000265845.2	RP11-20B24.5	3.9	0.000145	0.0437	0.36	0.3	Coffee consumption (cups per day);	chr17:29882047	chr17:28926275~28944749:+
PCPG	cis	rs9902453	0.838	rs9646438	ENSG00000265845.2	RP11-20B24.5	3.9	0.000145	0.0437	0.36	0.3	Coffee consumption (cups per day);	chr17:29882073	chr17:28926275~28944749:+
PCPG	cis	rs9902453	0.808	rs56216220	ENSG00000265845.2	RP11-20B24.5	3.9	0.000145	0.0437	0.36	0.3	Coffee consumption (cups per day);	chr17:29882164	chr17:28926275~28944749:+
PCPG	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	3.9	0.000145	0.0437	0.6	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
PCPG	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	3.9	0.000145	0.0437	0.6	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
PCPG	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	3.9	0.000145	0.0437	0.6	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
PCPG	cis	rs889398	0.802	rs12598642	ENSG00000196696.11	PDXDC2P	3.9	0.000145	0.0437	0.24	0.3	Body mass index;	chr16:69814869	chr16:69976297~70065948:-
PCPG	cis	rs6714710	0.603	rs17489984	ENSG00000278766.2	AC159540.2	3.9	0.000145	0.0437	0.34	0.3	Posterior cortical atrophy and Alzheimer's disease;	chr2:97804901	chr2:97421075~97434847:+
PCPG	cis	rs11250098	0.567	rs4326350	ENSG00000255020.1	AF131216.5	3.9	0.000145	0.0437	0.41	0.3	Morning vs. evening chronotype;	chr8:10906145	chr8:11345748~11347502:-
PCPG	cis	rs12289510	0.539	rs3808995	ENSG00000250073.2	RP11-677M14.3	3.9	0.000145	0.0437	0.36	0.3	Platelet-derived growth factor BB levels;	chr11:125086081	chr11:124759129~124765936:+
PCPG	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-3.9	0.000145	0.0437	-0.37	-0.3	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
PCPG	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-3.9	0.000145	0.0437	-0.37	-0.3	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
PCPG	cis	rs7911712	0.873	rs10900114	ENSG00000228462.1	RP11-445N18.3	3.9	0.000145	0.0437	0.41	0.3	Emphysema-related traits;	chr10:44811757	chr10:45073146~45073541:-
PCPG	cis	rs657075	0.697	rs2073642	ENSG00000233006.5	AC034220.3	3.9	0.000145	0.0437	0.4	0.3	Rheumatoid arthritis;	chr5:132378082	chr5:132311285~132369916:-
PCPG	cis	rs5769765	0.778	rs4574208	ENSG00000278869.1	CITF22-49E9.3	-3.9	0.000145	0.0437	-0.37	-0.3	Schizophrenia;	chr22:49863090	chr22:49933198~49934074:-
PCPG	cis	rs853679	0.769	rs7752448	ENSG00000216901.1	AL022393.7	3.9	0.000145	0.0438	0.53	0.3	Depression;	chr6:28333322	chr6:28176188~28176674:+
PCPG	cis	rs7246657	0.722	rs2927742	ENSG00000226686.6	LINC01535	3.9	0.000145	0.0438	0.46	0.3	Coronary artery calcification;	chr19:37642717	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs2972430	ENSG00000226686.6	LINC01535	3.9	0.000145	0.0438	0.46	0.3	Coronary artery calcification;	chr19:37691210	chr19:37251912~37265535:+
PCPG	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	3.9	0.000145	0.0438	0.39	0.3	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
PCPG	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-3.9	0.000145	0.0438	-0.3	-0.3	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
PCPG	cis	rs4791051	0.723	rs2319527	ENSG00000264491.1	RP11-349A8.3	-3.9	0.000145	0.0438	-0.31	-0.3	Heschl's gyrus morphology;	chr17:66461074	chr17:67019934~67021743:-
PCPG	cis	rs12291225	0.679	rs11369	ENSG00000251991.1	RNU7-49P	3.9	0.000145	0.0438	0.34	0.3	Sense of smell;	chr11:14266550	chr11:14478892~14478953:+
PCPG	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-3.9	0.000145	0.0438	-0.3	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-3.9	0.000145	0.0438	-0.3	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
PCPG	cis	rs13178541	0.745	rs9986164	ENSG00000249119.1	MTND6P4	-3.9	0.000145	0.0438	-0.4	-0.3	IgG glycosylation;	chr5:135827074	chr5:134924123~134924644:+
PCPG	cis	rs13178541	0.81	rs9986268	ENSG00000249119.1	MTND6P4	-3.9	0.000145	0.0438	-0.4	-0.3	IgG glycosylation;	chr5:135827124	chr5:134924123~134924644:+
PCPG	cis	rs8042680	1	rs4544218	ENSG00000214432.8	AC068831.10	-3.9	0.000145	0.0438	-0.32	-0.3	Type 2 diabetes;	chr15:90977143	chr15:91022619~91036611:+
PCPG	cis	rs12188164	0.965	rs1056465	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:442323	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs56146525	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:442456	chr5:441498~443160:-
PCPG	cis	rs12188164	0.931	rs115554641	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:443121	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
PCPG	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
PCPG	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	3.9	0.000145	0.0438	0.27	0.3	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
PCPG	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-3.9	0.000145	0.0438	-0.36	-0.3	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
PCPG	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	3.9	0.000145	0.0438	0.35	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
PCPG	cis	rs12681963	0.688	rs61621868	ENSG00000272375.1	RP11-51J9.6	3.9	0.000145	0.0438	0.4	0.3	Migraine;	chr8:30182621	chr8:30197404~30198048:+
PCPG	cis	rs12681963	0.541	rs56302321	ENSG00000272375.1	RP11-51J9.6	3.9	0.000145	0.0438	0.4	0.3	Migraine;	chr8:30183018	chr8:30197404~30198048:+
PCPG	cis	rs7707921	1	rs7707921	ENSG00000249483.1	CTD-2249K22.1	3.9	0.000146	0.0439	0.41	0.3	Breast cancer;	chr5:82242227	chr5:81851601~81852201:+
PCPG	cis	rs17152411	0.895	rs7900929	ENSG00000278831.1	RP11-12J10.4	3.9	0.000146	0.0439	0.42	0.3	Height;	chr10:124896430	chr10:124623353~124624079:+
PCPG	cis	rs1023500	0.551	rs133379	ENSG00000226450.2	CYP2D8P	3.9	0.000146	0.0439	0.31	0.3	Schizophrenia;	chr22:42072531	chr22:42149886~42155001:-
PCPG	cis	rs1023500	0.573	rs13057094	ENSG00000226450.2	CYP2D8P	3.9	0.000146	0.0439	0.31	0.3	Schizophrenia;	chr22:42074313	chr22:42149886~42155001:-
PCPG	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	3.9	0.000146	0.0439	0.28	0.3	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
PCPG	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	3.9	0.000146	0.0439	0.67	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
PCPG	cis	rs4720118	0.634	rs4723273	ENSG00000173862.3	RP11-89N17.1	-3.9	0.000146	0.0439	-0.35	-0.3	Leprosy;	chr7:33184409	chr7:33725981~33728456:+
PCPG	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	3.9	0.000146	0.0439	0.39	0.3	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	3.9	0.000146	0.0439	0.39	0.3	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
PCPG	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-3.9	0.000146	0.0439	-0.37	-0.3	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
PCPG	cis	rs2275565	0.872	rs4659734	ENSG00000230325.1	RP11-385F5.4	3.9	0.000146	0.0439	0.48	0.3	Homocysteine levels;	chr1:236867488	chr1:236540094~236550280:-
PCPG	cis	rs763014	0.966	rs12935215	ENSG00000262528.2	LA16c-349E10.1	3.9	0.000146	0.0439	0.35	0.3	Height;	chr16:620605	chr16:654611~656194:-
PCPG	cis	rs763014	0.966	rs4984677	ENSG00000262528.2	LA16c-349E10.1	3.9	0.000146	0.0439	0.35	0.3	Height;	chr16:621682	chr16:654611~656194:-
PCPG	cis	rs7267979	0.586	rs6050445	ENSG00000276952.1	RP5-965G21.6	3.9	0.000146	0.044	0.33	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25284915~25285588:-
PCPG	cis	rs10172965	0.738	rs10174127	ENSG00000203435.2	E2F3P2	-3.9	0.000146	0.044	-0.42	-0.3	Neuroticism;Temperament;	chr2:195002308	chr2:195994259~195995680:-
PCPG	cis	rs1876905	0.68	rs7767302	ENSG00000255389.1	C6orf3	-3.9	0.000146	0.044	-0.42	-0.3	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111599875~111602295:+
PCPG	cis	rs2404602	0.692	rs7169663	ENSG00000259422.1	RP11-593F23.1	3.9	0.000146	0.044	0.36	0.3	Blood metabolite levels;	chr15:76900502	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs35999717	ENSG00000259422.1	RP11-593F23.1	3.9	0.000146	0.044	0.36	0.3	Blood metabolite levels;	chr15:76901026	chr15:76174891~76181486:-
PCPG	cis	rs10101158	0.733	rs6985498	ENSG00000253595.4	LINC01300	3.9	0.000146	0.044	0.31	0.3	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);	chr8:141850923	chr8:141340549~141344621:+
PCPG	cis	rs7246657	0.525	rs997516	ENSG00000226686.6	LINC01535	-3.9	0.000146	0.044	-0.58	-0.3	Coronary artery calcification;	chr19:36983362	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.525	rs10410594	ENSG00000226686.6	LINC01535	-3.9	0.000146	0.044	-0.58	-0.3	Coronary artery calcification;	chr19:36986856	chr19:37251912~37265535:+
PCPG	cis	rs3758911	0.828	rs11212173	ENSG00000255353.1	RP11-382M14.1	-3.9	0.000146	0.0441	-0.41	-0.3	Coronary artery disease;	chr11:107343881	chr11:107176286~107177530:+
PCPG	cis	rs13315649	0.614	rs7609765	ENSG00000242551.2	POU5F1P6	-3.9	0.000146	0.0441	-0.42	-0.3	Sum eosinophil basophil counts;	chr3:128688295	chr3:128674735~128677005:-
PCPG	cis	rs13315649	0.639	rs7612926	ENSG00000242551.2	POU5F1P6	-3.9	0.000146	0.0441	-0.42	-0.3	Sum eosinophil basophil counts;	chr3:128689221	chr3:128674735~128677005:-
PCPG	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	3.9	0.000147	0.0441	0.38	0.3	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
PCPG	cis	rs752864	0.934	rs7176639	ENSG00000259438.1	CTD-2650P22.1	3.9	0.000147	0.0441	0.37	0.3	Number of common colds;	chr15:52368489	chr15:52010999~52019095:-
PCPG	cis	rs17684571	0.872	rs6901176	ENSG00000231441.1	RP11-472M19.2	3.9	0.000147	0.0441	0.44	0.3	Schizophrenia;	chr6:56696759	chr6:56844002~56864078:+
PCPG	cis	rs5769765	0.862	rs138870	ENSG00000278869.1	CITF22-49E9.3	3.9	0.000147	0.0441	0.37	0.3	Schizophrenia;	chr22:49816089	chr22:49933198~49934074:-
PCPG	cis	rs2239557	0.508	rs56120998	ENSG00000279026.1	RP3-414A15.12	3.9	0.000147	0.0441	0.47	0.3	Common traits (Other);	chr14:73844011	chr14:73580694~73582918:+
PCPG	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	3.9	0.000147	0.0441	0.35	0.3	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
PCPG	cis	rs9923283	0.673	rs11574551	ENSG00000261067.5	RP11-264B17.3	-3.9	0.000147	0.0441	-0.34	-0.3	Plateletcrit;	chr16:29662674	chr16:28974804~28990783:+
PCPG	cis	rs4713118	0.824	rs9468223	ENSG00000216901.1	AL022393.7	3.9	0.000147	0.0441	0.41	0.3	Parkinson's disease;	chr6:27772887	chr6:28176188~28176674:+
PCPG	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	3.9	0.000147	0.0441	0.66	0.3	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
PCPG	cis	rs7267979	0.586	rs1007707	ENSG00000276952.1	RP5-965G21.6	3.9	0.000147	0.0441	0.33	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25284915~25285588:-
PCPG	cis	rs7267979	0.586	rs1007708	ENSG00000276952.1	RP5-965G21.6	3.9	0.000147	0.0441	0.33	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25284915~25285588:-
PCPG	cis	rs7267979	0.586	rs6050439	ENSG00000276952.1	RP5-965G21.6	3.9	0.000147	0.0441	0.33	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25284915~25285588:-
PCPG	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000147	0.0441	-0.4	-0.3	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
PCPG	cis	rs9322193	0.886	rs4039600	ENSG00000223701.3	RAET1E-AS1	3.9	0.000147	0.0441	0.39	0.3	Lung cancer;	chr6:149576319	chr6:149884431~149919508:+
PCPG	cis	rs4489787	1	rs2731073	ENSG00000240399.1	RP1-228P16.1	3.9	0.000147	0.0441	0.4	0.3	Prostate cancer (SNP x SNP interaction);	chr12:48525773	chr12:48054813~48055591:-
PCPG	cis	rs2243480	1	rs34136756	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65916269	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs78803505	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65917585	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs34933526	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65918212	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs34577383	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65920739	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs6949812	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65922114	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs55895244	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65922691	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs6970243	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65923503	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs7794661	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65924743	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs7795242	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65925107	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.708	rs35310401	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65925372	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs35058610	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65925938	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs2177703	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65926730	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs35432774	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65928032	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs56985706	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65929575	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs60683927	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65929781	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs58062456	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65929865	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs34529418	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65938222	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.901	rs35087093	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65940221	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs35046236	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65943626	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs36068983	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65944004	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs68189316	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65944182	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.803	rs34804747	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65947955	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs59794892	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65950886	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.901	rs57126451	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65951319	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.803	rs36004293	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65951525	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.803	rs35268390	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65951549	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs11538349	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65956884	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs937108	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65963465	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs35542501	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65966228	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.711	rs1626926	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65970805	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.708	rs781141	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65973566	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1039664	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65984729	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1964692	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65989196	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.901	rs2456483	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65996588	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.901	rs2949697	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65999249	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1701750	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66002158	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1701758	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66005214	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.901	rs1701759	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66005945	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1723267	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66008327	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs781157	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66013324	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs781156	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66014154	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs781149	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66016297	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs451396	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66019087	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.901	rs58207111	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66021736	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1167613	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66022452	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs1715235	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66023407	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs313799	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:66029343	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.831	rs7806717	ENSG00000251451.1	GS1-124K5.6	-3.9	0.000147	0.0441	-0.56	-0.3	Diabetic kidney disease;	chr7:65928187	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs2462569	ENSG00000251451.1	GS1-124K5.6	-3.9	0.000147	0.0441	-0.56	-0.3	Diabetic kidney disease;	chr7:66009859	chr7:66407288~66409239:-
PCPG	cis	rs394563	0.601	rs382720	ENSG00000231760.4	RP11-350J20.5	-3.9	0.000147	0.0441	-0.37	-0.3	Dupuytren's disease;	chr6:149474125	chr6:149796151~149826294:-
PCPG	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	3.9	0.000147	0.0441	0.33	0.3	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
PCPG	cis	rs10411161	0.702	rs8113685	ENSG00000275055.1	CTC-471J1.11	-3.9	0.000147	0.0441	-0.32	-0.3	Breast cancer;	chr19:51880637	chr19:52049007~52049754:+
PCPG	cis	rs2243480	0.803	rs55700941	ENSG00000251451.1	GS1-124K5.6	3.9	0.000147	0.0441	0.56	0.3	Diabetic kidney disease;	chr7:65924813	chr7:66407288~66409239:-
PCPG	cis	rs4703129	0.506	rs723206	ENSG00000251102.1	CTBP2P4	3.9	0.000147	0.0441	0.33	0.3	Asperger disorder;	chr5:98453609	chr5:98576341~98577260:+
PCPG	cis	rs425277	0.917	rs12410859	ENSG00000271806.1	RP5-892K4.1	3.9	0.000147	0.0442	0.37	0.3	Height;	chr1:2107293	chr1:2141084~2145279:-
PCPG	cis	rs2243480	1	rs4548056	ENSG00000179406.6	LINC00174	3.9	0.000147	0.0442	0.5	0.3	Diabetic kidney disease;	chr7:65833886	chr7:66376044~66401338:-
PCPG	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	3.9	0.000147	0.0442	0.26	0.3	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
PCPG	cis	rs595244	1	rs1678982	ENSG00000259705.1	RP11-227D13.1	-3.9	0.000147	0.0442	-0.63	-0.3	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48609223	chr15:48645951~48652016:+
PCPG	cis	rs394563	0.591	rs11964335	ENSG00000231760.4	RP11-350J20.5	-3.9	0.000147	0.0442	-0.38	-0.3	Dupuytren's disease;	chr6:149336965	chr6:149796151~149826294:-
PCPG	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-3.9	0.000147	0.0442	-0.43	-0.3	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
PCPG	cis	rs2736345	0.755	rs2736340	ENSG00000154316.13	TDH	3.9	0.000147	0.0442	0.41	0.3	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:11339637~11368452:+
PCPG	cis	rs1383484	0.506	rs899927	ENSG00000230373.7	GOLGA6L5P	-3.9	0.000147	0.0442	-0.34	-0.3	Height;	chr15:83893127	chr15:84507885~84516814:-
PCPG	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-3.9	0.000147	0.0442	-0.42	-0.3	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
PCPG	cis	rs75686122	0.892	rs1895898	ENSG00000253477.4	RP11-1C8.4	3.9	0.000147	0.0442	0.49	0.3	Cocaine dependence;	chr8:103689173	chr8:103483398~103501676:-
PCPG	cis	rs2288884	0.649	rs11667001	ENSG00000275055.1	CTC-471J1.11	-3.9	0.000147	0.0442	-0.39	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049416	chr19:52049007~52049754:+
PCPG	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	3.9	0.000147	0.0442	0.31	0.3	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	3.9	0.000147	0.0442	0.31	0.3	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	3.9	0.000147	0.0442	0.31	0.3	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	3.9	0.000147	0.0442	0.31	0.3	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
PCPG	cis	rs198389	0.589	rs198399	ENSG00000242349.4	NPPA-AS1	-3.9	0.000147	0.0442	-0.28	-0.3	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11823572	chr1:11841017~11848079:+
PCPG	cis	rs73198271	0.737	rs565203	ENSG00000253893.2	FAM85B	3.9	0.000147	0.0442	0.41	0.3	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:8167819~8226614:-
PCPG	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-3.9	0.000147	0.0442	-0.26	-0.3	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
PCPG	cis	rs6728642	0.708	rs56807297	ENSG00000230606.9	AC159540.1	3.9	0.000147	0.0442	0.4	0.3	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97195603	chr2:97416165~97433527:-
PCPG	cis	rs7674212	0.833	rs61075040	ENSG00000251288.2	RP11-10L12.2	-3.9	0.000147	0.0443	-0.37	-0.3	Type 2 diabetes;	chr4:103052804	chr4:102751401~102752641:+
PCPG	cis	rs17684571	0.872	rs3002009	ENSG00000231441.1	RP11-472M19.2	3.9	0.000147	0.0443	0.5	0.3	Schizophrenia;	chr6:56757983	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.872	rs3002010	ENSG00000231441.1	RP11-472M19.2	3.9	0.000147	0.0443	0.5	0.3	Schizophrenia;	chr6:56760050	chr6:56844002~56864078:+
PCPG	cis	rs8098244	0.597	rs12960583	ENSG00000265752.2	RP11-403A21.1	3.9	0.000147	0.0443	0.36	0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23772629	chr18:23957754~23982556:-
PCPG	cis	rs11601239	0.563	rs7951215	ENSG00000263371.2	AP000673.1	3.9	0.000147	0.0443	0.34	0.3	Refractive error;	chr11:105654409	chr11:105933951~105934034:+
PCPG	cis	rs11601239	0.593	rs10895851	ENSG00000263371.2	AP000673.1	3.9	0.000147	0.0443	0.34	0.3	Refractive error;	chr11:105654716	chr11:105933951~105934034:+
PCPG	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	3.89	0.000147	0.0443	0.35	0.3	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
PCPG	cis	rs8049040	0.609	rs9940485	ENSG00000260886.1	TAT-AS1	3.89	0.000148	0.0443	0.43	0.3	Blood protein levels;	chr16:71452202	chr16:71565789~71578187:+
PCPG	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	3.89	0.000148	0.0443	0.35	0.3	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
PCPG	cis	rs412050	1	rs239916	ENSG00000224086.5	LL22NC03-86G7.1	-3.89	0.000148	0.0443	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr22:21961900	chr22:21938293~21977632:+
PCPG	cis	rs412050	0.947	rs239915	ENSG00000224086.5	LL22NC03-86G7.1	-3.89	0.000148	0.0443	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr22:21962259	chr22:21938293~21977632:+
PCPG	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	3.89	0.000148	0.0443	0.32	0.3	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
PCPG	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-3.89	0.000148	0.0443	-0.41	-0.3	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
PCPG	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000148	0.0443	-0.67	-0.3	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
PCPG	cis	rs763014	1	rs763014	ENSG00000262528.2	LA16c-349E10.1	3.89	0.000148	0.0443	0.35	0.3	Height;	chr16:625680	chr16:654611~656194:-
PCPG	cis	rs459482	0.504	rs469483	ENSG00000227698.1	AP001619.2	-3.89	0.000148	0.0444	-0.32	-0.3	IgG glycosylation;	chr21:41446588	chr21:41874756~41877613:-
PCPG	cis	rs34421088	0.532	rs2409754	ENSG00000255020.1	AF131216.5	3.89	0.000148	0.0444	0.38	0.3	Neuroticism;	chr8:11298104	chr8:11345748~11347502:-
PCPG	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	3.89	0.000148	0.0444	0.25	0.3	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
PCPG	cis	rs172166	0.516	rs1225618	ENSG00000176933.5	TOB2P1	-3.89	0.000148	0.0444	-0.33	-0.3	Cardiac Troponin-T levels;	chr6:28161935	chr6:28217643~28218634:-
PCPG	cis	rs2736340	0.539	rs9644687	ENSG00000184608.7	FAM167A-AS1	-3.89	0.000148	0.0444	-0.44	-0.3	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465516	chr8:11368402~11438658:+
PCPG	cis	rs4824093	0.61	rs7410773	ENSG00000278869.1	CITF22-49E9.3	3.89	0.000148	0.0444	0.7	0.3	Amyotrophic lateral sclerosis (sporadic);	chr22:49920079	chr22:49933198~49934074:-
PCPG	cis	rs4824093	0.61	rs74371371	ENSG00000278869.1	CITF22-49E9.3	3.89	0.000148	0.0444	0.7	0.3	Amyotrophic lateral sclerosis (sporadic);	chr22:49920426	chr22:49933198~49934074:-
PCPG	cis	rs4824093	0.61	rs73443974	ENSG00000278869.1	CITF22-49E9.3	3.89	0.000148	0.0444	0.7	0.3	Amyotrophic lateral sclerosis (sporadic);	chr22:49920668	chr22:49933198~49934074:-
PCPG	cis	rs1865760	0.566	rs9379821	ENSG00000272810.1	U91328.22	-3.89	0.000148	0.0444	-0.31	-0.3	Height;	chr6:26054040	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs9358902	ENSG00000272810.1	U91328.22	-3.89	0.000148	0.0444	-0.31	-0.3	Height;	chr6:26058342	chr6:26013241~26013757:+
PCPG	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	3.89	0.000148	0.0444	0.55	0.3	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
PCPG	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	3.89	0.000148	0.0444	0.55	0.3	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
PCPG	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000148	0.0444	-0.38	-0.3	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
PCPG	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000148	0.0444	-0.38	-0.3	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
PCPG	cis	rs6452524	0.618	rs2306336	ENSG00000281327.1	LINC01338	3.89	0.000148	0.0444	0.32	0.3	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:82850864~82859836:-
PCPG	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-3.89	0.000148	0.0445	-0.39	-0.3	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
PCPG	cis	rs7864204	0.524	rs11143179	ENSG00000234506.4	LINC01506	-3.89	0.000148	0.0445	-0.37	-0.3	Body mass index (recreational physical activity interaction);	chr9:68621078	chr9:68543541~68546589:-
PCPG	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-3.89	0.000148	0.0445	-0.31	-0.3	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
PCPG	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	3.89	0.000148	0.0445	0.27	0.3	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
PCPG	cis	rs7760535	0.826	rs10872068	ENSG00000271789.1	RP5-1112D6.7	3.89	0.000148	0.0445	0.29	0.3	Metabolic traits;	chr6:111528657	chr6:111297126~111298510:+
PCPG	cis	rs2404602	0.716	rs1125932	ENSG00000259422.1	RP11-593F23.1	3.89	0.000148	0.0445	0.36	0.3	Blood metabolite levels;	chr15:76528199	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.716	rs66754747	ENSG00000259422.1	RP11-593F23.1	3.89	0.000148	0.0445	0.36	0.3	Blood metabolite levels;	chr15:76536227	chr15:76174891~76181486:-
PCPG	cis	rs7402241	0.764	rs113398290	ENSG00000207063.1	SNORD116-1	3.89	0.000148	0.0445	0.65	0.3	Residual cognition;	chr15:25533778	chr15:25051477~25051571:+
PCPG	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-3.89	0.000148	0.0445	-0.4	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-3.89	0.000148	0.0445	-0.4	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
PCPG	cis	rs1456297	0.758	rs35859241	ENSG00000259378.1	DCAF13P3	3.89	0.000148	0.0445	0.42	0.3	Intelligence (multi-trait analysis);	chr15:51444463	chr15:50944663~50945996:+
PCPG	cis	rs889398	0.802	rs9940315	ENSG00000196696.11	PDXDC2P	-3.89	0.000148	0.0445	-0.24	-0.3	Body mass index;	chr16:69842261	chr16:69976297~70065948:-
PCPG	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000148	0.0445	-0.38	-0.3	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
PCPG	cis	rs3758911	0.796	rs11212206	ENSG00000255353.1	RP11-382M14.1	-3.89	0.000148	0.0445	-0.41	-0.3	Coronary artery disease;	chr11:107404525	chr11:107176286~107177530:+
PCPG	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	3.89	0.000149	0.0445	0.43	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
PCPG	cis	rs7208859	0.725	rs9897673	ENSG00000263603.1	CTD-2349P21.5	-3.89	0.000149	0.0446	-0.54	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30729469~30731202:+
PCPG	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	3.89	0.000149	0.0446	0.36	0.3	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
PCPG	cis	rs75686122	0.892	rs76082564	ENSG00000271830.1	RP11-1C8.7	3.89	0.000149	0.0446	0.53	0.3	Cocaine dependence;	chr8:103524421	chr8:103481266~103481619:-
PCPG	cis	rs4853012	0.887	rs7570950	ENSG00000257800.1	FNBP1P1	3.89	0.000149	0.0446	0.33	0.3	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74120680~74123218:+
PCPG	cis	rs5498	0.839	rs62130686	ENSG00000267612.1	CTD-3116E22.7	3.89	0.000149	0.0446	0.39	0.3	Soluble ICAM-1;Lymphocyte counts;Blood protein levels;	chr19:10298066	chr19:9730853~9731943:+
PCPG	cis	rs5498	0.839	rs62130688	ENSG00000267612.1	CTD-3116E22.7	3.89	0.000149	0.0446	0.39	0.3	Soluble ICAM-1;Lymphocyte counts;Blood protein levels;	chr19:10298331	chr19:9730853~9731943:+
PCPG	cis	rs7829975	0.846	rs11779061	ENSG00000173295.6	FAM86B3P	3.89	0.000149	0.0446	0.35	0.3	Mood instability;	chr8:8691922	chr8:8228595~8244865:+
PCPG	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
PCPG	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
PCPG	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-3.89	0.000149	0.0446	-0.68	-0.3	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
PCPG	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-3.89	0.000149	0.0446	-0.45	-0.3	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
PCPG	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-3.89	0.000149	0.0446	-0.39	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
PCPG	cis	rs8098244	0.706	rs720064	ENSG00000265752.2	RP11-403A21.1	3.89	0.000149	0.0446	0.36	0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23890360	chr18:23957754~23982556:-
PCPG	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	3.89	0.000149	0.0446	0.39	0.3	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
PCPG	cis	rs590820	0.785	rs606587	ENSG00000223635.1	RP4-613A2.1	3.89	0.000149	0.0446	0.36	0.3	Metabolite levels (lipoprotein measures);	chr1:230180443	chr1:229508501~229514272:+
PCPG	cis	rs1129187	0.755	rs3293	ENSG00000272223.1	RP1-20C7.6	3.89	0.000149	0.0446	0.3	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42970639	chr6:43033897~43034405:-
PCPG	cis	rs1129187	0.755	rs9471985	ENSG00000272223.1	RP1-20C7.6	3.89	0.000149	0.0446	0.3	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42973586	chr6:43033897~43034405:-
PCPG	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	3.89	0.000149	0.0446	0.29	0.3	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
PCPG	cis	rs9356009	0.892	rs12175884	ENSG00000213078.3	RP5-933K21.2	-3.89	0.000149	0.0446	-0.57	-0.3	Lipoprotein (a) - cholesterol levels;	chr6:157948813	chr6:157365990~157366923:-
PCPG	cis	rs9356009	0.892	rs9347800	ENSG00000213078.3	RP5-933K21.2	-3.89	0.000149	0.0446	-0.57	-0.3	Lipoprotein (a) - cholesterol levels;	chr6:157950052	chr6:157365990~157366923:-
PCPG	cis	rs9356009	0.892	rs9347801	ENSG00000213078.3	RP5-933K21.2	-3.89	0.000149	0.0446	-0.57	-0.3	Lipoprotein (a) - cholesterol levels;	chr6:157950323	chr6:157365990~157366923:-
PCPG	cis	rs9356009	0.892	rs9356162	ENSG00000213078.3	RP5-933K21.2	-3.89	0.000149	0.0446	-0.57	-0.3	Lipoprotein (a) - cholesterol levels;	chr6:157950348	chr6:157365990~157366923:-
PCPG	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	3.89	0.000149	0.0446	0.38	0.3	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
PCPG	cis	rs11250098	0.547	rs2409764	ENSG00000254774.1	RP11-148O21.3	3.89	0.000149	0.0447	0.35	0.3	Morning vs. evening chronotype;	chr8:11423764	chr8:11553224~11554207:-
PCPG	cis	rs11836164	0.731	rs35245953	ENSG00000278095.1	RP11-283G6.6	3.89	0.000149	0.0447	0.39	0.3	Mammographic density (dense area);	chr12:26297937	chr12:26273329~26273900:-
PCPG	cis	rs7707921	1	rs891159	ENSG00000249483.1	CTD-2249K22.1	-3.89	0.000149	0.0447	-0.41	-0.3	Breast cancer;	chr5:82195268	chr5:81851601~81852201:+
PCPG	cis	rs2243480	1	rs313813	ENSG00000251451.1	GS1-124K5.6	3.89	0.000149	0.0447	0.54	0.3	Diabetic kidney disease;	chr7:66038513	chr7:66407288~66409239:-
PCPG	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	3.89	0.000149	0.0447	0.31	0.3	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
PCPG	cis	rs9813712	0.595	rs1453240	ENSG00000228252.7	COL6A4P2	-3.89	0.000149	0.0447	-0.36	-0.3	Response to amphetamines;	chr3:130282849	chr3:130212823~130273806:+
PCPG	cis	rs7267979	1	rs2474777	ENSG00000276952.1	RP5-965G21.6	3.89	0.000149	0.0447	0.33	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25284915~25285588:-
PCPG	cis	rs2412459	0.803	rs510949	ENSG00000245849.5	RAD51-AS1	3.89	0.000149	0.0447	0.44	0.3	Response to haloperidol in psychosis;	chr15:39961954	chr15:40686724~40695107:-
PCPG	cis	rs10486158	0.744	rs1294627	ENSG00000234718.6	AC007161.5	3.89	0.000149	0.0447	0.37	0.3	Bipolar disorder and schizophrenia;	chr7:7381679	chr7:7738524~7742574:-
PCPG	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-3.89	0.000149	0.0447	-0.37	-0.3	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
PCPG	cis	rs2337406	0.789	rs9324095	ENSG00000211937.3	IGHV2-5	-3.89	0.000149	0.0447	-0.41	-0.3	Alzheimer's disease (late onset);	chr14:106795885	chr14:106037902~106038365:-
PCPG	cis	rs2337406	0.866	rs58154560	ENSG00000211937.3	IGHV2-5	-3.89	0.000149	0.0447	-0.41	-0.3	Alzheimer's disease (late onset);	chr14:106799601	chr14:106037902~106038365:-
PCPG	cis	rs10411161	0.721	rs10401778	ENSG00000275055.1	CTC-471J1.11	-3.89	0.000149	0.0447	-0.32	-0.3	Breast cancer;	chr19:51881062	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs10402630	ENSG00000275055.1	CTC-471J1.11	-3.89	0.000149	0.0447	-0.32	-0.3	Breast cancer;	chr19:51881317	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.752	rs10402107	ENSG00000275055.1	CTC-471J1.11	-3.89	0.000149	0.0447	-0.32	-0.3	Breast cancer;	chr19:51881347	chr19:52049007~52049754:+
PCPG	cis	rs10411161	0.702	rs16983196	ENSG00000275055.1	CTC-471J1.11	-3.89	0.000149	0.0447	-0.32	-0.3	Breast cancer;	chr19:51881526	chr19:52049007~52049754:+
PCPG	cis	rs12188164	0.965	rs11742144	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:422063	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs56182240	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:423054	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs56346498	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:423480	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs55948934	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:423556	chr5:441498~443160:-
PCPG	cis	rs12188164	0.897	rs55932239	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:423791	chr5:441498~443160:-
PCPG	cis	rs12188164	0.931	rs72717407	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:424538	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs12188678	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:428116	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs12188164	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:428121	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs72717410	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:428670	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs72717411	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:429009	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs72717412	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:429266	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs72717414	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:429703	chr5:441498~443160:-
PCPG	cis	rs12188164	0.965	rs72717415	ENSG00000221990.4	EXOC3-AS1	3.89	0.000149	0.0447	0.27	0.3	Cystic fibrosis severity;	chr5:429944	chr5:441498~443160:-
PCPG	cis	rs11836164	0.689	rs11048449	ENSG00000278095.1	RP11-283G6.6	3.89	0.000149	0.0447	0.39	0.3	Mammographic density (dense area);	chr12:26291934	chr12:26273329~26273900:-
PCPG	cis	rs10865541	0.967	rs6755327	ENSG00000225234.1	TRAPPC12-AS1	-3.89	0.000149	0.0447	-0.3	-0.3	Obesity-related traits;	chr2:3393510	chr2:3481242~3482409:-
PCPG	cis	rs11250098	0.574	rs4240672	ENSG00000255020.1	AF131216.5	-3.89	0.000149	0.0447	-0.39	-0.3	Morning vs. evening chronotype;	chr8:10910407	chr8:11345748~11347502:-
PCPG	cis	rs11250098	0.503	rs13270870	ENSG00000255020.1	AF131216.5	-3.89	0.000149	0.0447	-0.39	-0.3	Morning vs. evening chronotype;	chr8:10913272	chr8:11345748~11347502:-
PCPG	cis	rs75686122	0.892	rs76423444	ENSG00000253477.4	RP11-1C8.4	3.89	0.000149	0.0447	0.47	0.3	Cocaine dependence;	chr8:103701800	chr8:103483398~103501676:-
PCPG	cis	rs75686122	0.892	rs12156411	ENSG00000253477.4	RP11-1C8.4	3.89	0.000149	0.0447	0.47	0.3	Cocaine dependence;	chr8:103704249	chr8:103483398~103501676:-
PCPG	cis	rs300890	0.76	rs7655782	ENSG00000250326.1	RP11-284M14.1	3.89	0.00015	0.0448	0.28	0.3	Nasopharyngeal carcinoma;	chr4:143285095	chr4:142933195~143184861:-
PCPG	cis	rs6696239	0.513	rs12040302	ENSG00000227711.2	RP11-275O4.5	3.89	0.00015	0.0448	0.36	0.3	Height;	chr1:227509464	chr1:227509028~227520477:-
PCPG	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	3.89	0.00015	0.0448	0.47	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
PCPG	cis	rs2404602	0.716	rs67204011	ENSG00000259422.1	RP11-593F23.1	3.89	0.00015	0.0448	0.36	0.3	Blood metabolite levels;	chr15:76554214	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.692	rs59088060	ENSG00000259422.1	RP11-593F23.1	3.89	0.00015	0.0448	0.36	0.3	Blood metabolite levels;	chr15:76567633	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.716	rs12902174	ENSG00000259422.1	RP11-593F23.1	3.89	0.00015	0.0448	0.36	0.3	Blood metabolite levels;	chr15:76571199	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.716	rs12438077	ENSG00000259422.1	RP11-593F23.1	3.89	0.00015	0.0448	0.36	0.3	Blood metabolite levels;	chr15:76571260	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.716	rs12441550	ENSG00000259422.1	RP11-593F23.1	3.89	0.00015	0.0448	0.36	0.3	Blood metabolite levels;	chr15:76571341	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.716	rs1874944	ENSG00000259422.1	RP11-593F23.1	3.89	0.00015	0.0448	0.36	0.3	Blood metabolite levels;	chr15:76571587	chr15:76174891~76181486:-
PCPG	cis	rs2404602	0.669	rs9788684	ENSG00000259422.1	RP11-593F23.1	3.89	0.00015	0.0448	0.36	0.3	Blood metabolite levels;	chr15:76902497	chr15:76174891~76181486:-
PCPG	cis	rs748404	0.533	rs2139651	ENSG00000205771.5	CATSPER2P1	3.89	0.00015	0.0448	0.31	0.3	Lung cancer;	chr15:43126560	chr15:43726918~43747094:-
PCPG	cis	rs748404	0.533	rs7165861	ENSG00000205771.5	CATSPER2P1	3.89	0.00015	0.0448	0.31	0.3	Lung cancer;	chr15:43131129	chr15:43726918~43747094:-
PCPG	cis	rs2243480	0.803	rs55700941	ENSG00000230189.5	GS1-124K5.2	3.89	0.00015	0.0448	0.46	0.3	Diabetic kidney disease;	chr7:65924813	chr7:66409143~66490059:-
PCPG	cis	rs10070219	1	rs10069333	ENSG00000249167.1	CTB-118N6.2	-3.89	0.00015	0.0448	-0.69	-0.3	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117364288	chr5:116574482~116591398:+
PCPG	cis	rs8042680	0.688	rs2386584	ENSG00000214432.8	AC068831.10	-3.89	0.00015	0.0448	-0.35	-0.3	Type 2 diabetes;	chr15:90996342	chr15:91022619~91036611:+
PCPG	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-3.89	0.00015	0.0449	-0.38	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
PCPG	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-3.89	0.00015	0.0449	-0.38	-0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
PCPG	cis	rs7942368	1	rs1440980	ENSG00000254985.1	RSF1-IT2	3.89	0.00015	0.0449	0.42	0.3	Endometriosis;	chr11:76784032	chr11:77717712~77718411:-
PCPG	cis	rs7772486	0.681	rs9390343	ENSG00000270638.1	RP3-466P17.1	-3.89	0.00015	0.0449	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145735570~145737218:+
PCPG	cis	rs412050	0.842	rs1530229	ENSG00000224086.5	LL22NC03-86G7.1	-3.89	0.00015	0.0449	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr22:21946306	chr22:21938293~21977632:+
PCPG	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	3.89	0.00015	0.0449	0.28	0.3	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
PCPG	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	3.89	0.00015	0.0449	0.28	0.3	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
PCPG	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	3.89	0.00015	0.0449	0.28	0.3	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
PCPG	cis	rs9303029	0.932	rs9905527	ENSG00000279744.1	RP13-20L14.10	-3.89	0.00015	0.0449	-0.36	-0.3	Protein quantitative trait loci;	chr17:82482049	chr17:82462601~82464255:+
PCPG	cis	rs5498	0.809	rs1056538	ENSG00000267612.1	CTD-3116E22.7	3.89	0.00015	0.0449	0.38	0.3	Soluble ICAM-1;Lymphocyte counts;Blood protein levels;	chr19:10292262	chr19:9730853~9731943:+
PCPG	cis	rs5498	0.809	rs2228615	ENSG00000267612.1	CTD-3116E22.7	3.89	0.00015	0.0449	0.38	0.3	Soluble ICAM-1;Lymphocyte counts;Blood protein levels;	chr19:10292692	chr19:9730853~9731943:+
PCPG	cis	rs896854	0.654	rs2011566	ENSG00000272509.1	RP11-347C18.5	3.89	0.00015	0.0449	0.31	0.3	Type 2 diabetes;	chr8:94959693	chr8:94884609~94885070:+
PCPG	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	3.89	0.00015	0.0449	0.35	0.3	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
PCPG	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	3.89	0.00015	0.0449	0.33	0.3	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
PCPG	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-3.89	0.00015	0.045	-0.53	-0.3	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
PCPG	cis	rs17076896	0.867	rs36214443	ENSG00000237672.1	KRR1P1	-3.89	0.00015	0.045	-0.55	-0.3	Coronary artery aneurysm in Kawasaki disease;	chr13:19181247	chr13:20070250~20072136:-
PCPG	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	3.89	0.00015	0.045	0.44	0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
PCPG	cis	rs7246657	0.722	rs2972438	ENSG00000226686.6	LINC01535	-3.89	0.00015	0.045	-0.45	-0.3	Coronary artery calcification;	chr19:37719946	chr19:37251912~37265535:+
PCPG	cis	rs4958581	0.895	rs13168888	ENSG00000254226.4	CTB-12O2.1	-3.89	0.000151	0.045	-0.42	-0.3	Subjective well-being;	chr5:152811874	chr5:151949571~152270448:+
PCPG	cis	rs2836974	0.583	rs2410124	ENSG00000255568.3	BRWD1-AS2	-3.89	0.000151	0.045	-0.32	-0.3	Cognitive function;	chr21:39332834	chr21:39313935~39314962:+
PCPG	cis	rs9717605	1	rs73046034	ENSG00000226445.1	XXyac-YX65C7_A.2	3.89	0.000151	0.045	0.39	0.3	Left atrial antero-posterior diameter;	chr6:169252164	chr6:169213254~169239565:+
PCPG	cis	rs9717605	1	rs9717605	ENSG00000226445.1	XXyac-YX65C7_A.2	3.89	0.000151	0.045	0.39	0.3	Left atrial antero-posterior diameter;	chr6:169252297	chr6:169213254~169239565:+
PCPG	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	3.89	0.000151	0.045	0.22	0.3	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
PCPG	cis	rs10949834	0.877	rs34325097	ENSG00000225969.1	ABHD11-AS1	3.89	0.000151	0.045	0.64	0.3	Verbal memory performance (residualized delayed recall change);	chr7:74078660	chr7:73735038~73736054:+
PCPG	cis	rs10949834	0.878	rs36010170	ENSG00000225969.1	ABHD11-AS1	3.89	0.000151	0.045	0.64	0.3	Verbal memory performance (residualized delayed recall change);	chr7:74085168	chr7:73735038~73736054:+
PCPG	cis	rs2836974	0.897	rs68090597	ENSG00000252915.1	Y_RNA	-3.89	0.000151	0.045	-0.32	-0.3	Cognitive function;	chr21:39163707	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.863	rs12483216	ENSG00000252915.1	Y_RNA	-3.89	0.000151	0.045	-0.32	-0.3	Cognitive function;	chr21:39167688	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.897	rs2836929	ENSG00000252915.1	Y_RNA	-3.89	0.000151	0.045	-0.32	-0.3	Cognitive function;	chr21:39171885	chr21:39344537~39344628:+
PCPG	cis	rs853679	0.76	rs9393909	ENSG00000219392.1	RP1-265C24.5	3.89	0.000151	0.0451	0.46	0.3	Depression;	chr6:28239422	chr6:28115628~28116551:+
PCPG	cis	rs2404602	0.716	rs2404737	ENSG00000259422.1	RP11-593F23.1	3.89	0.000151	0.0451	0.36	0.3	Blood metabolite levels;	chr15:76579876	chr15:76174891~76181486:-
PCPG	cis	rs6570726	0.967	rs7772286	ENSG00000270638.1	RP3-466P17.1	-3.89	0.000151	0.0451	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145735570~145737218:+
PCPG	cis	rs698813	0.674	rs7590224	ENSG00000236502.1	SIX3-AS1	3.89	0.000151	0.0451	0.4	0.3	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44274070	chr2:44940154~44941873:-
PCPG	cis	rs698813	0.674	rs6544753	ENSG00000236502.1	SIX3-AS1	3.89	0.000151	0.0451	0.4	0.3	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44274756	chr2:44940154~44941873:-
PCPG	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	3.89	0.000151	0.0451	0.38	0.3	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
PCPG	cis	rs1383484	0.506	rs4414460	ENSG00000230373.7	GOLGA6L5P	-3.89	0.000151	0.0451	-0.34	-0.3	Height;	chr15:83893988	chr15:84507885~84516814:-
PCPG	cis	rs10411161	0.752	rs10404812	ENSG00000275055.1	CTC-471J1.11	-3.89	0.000151	0.0451	-0.34	-0.3	Breast cancer;	chr19:51897438	chr19:52049007~52049754:+
PCPG	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	3.89	0.000151	0.0451	0.39	0.3	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
PCPG	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-3.89	0.000151	0.0451	-0.39	-0.3	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
PCPG	cis	rs2404602	0.692	rs57178708	ENSG00000259422.1	RP11-593F23.1	3.89	0.000151	0.0451	0.36	0.3	Blood metabolite levels;	chr15:76611728	chr15:76174891~76181486:-
PCPG	cis	rs2625529	0.668	rs35206011	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000151	0.0451	-0.44	-0.3	Red blood cell count;	chr15:72247153	chr15:71818396~71823384:+
PCPG	cis	rs899997	0.862	rs12912524	ENSG00000261143.1	ADAMTS7P3	3.89	0.000151	0.0451	0.36	0.3	Coronary artery disease or large artery stroke;	chr15:78660414	chr15:77976042~77993057:+
PCPG	cis	rs2733954	0.83	rs301153	ENSG00000179219.5	LINC00311	-3.89	0.000151	0.0452	-0.42	-0.3	Leprosy;	chr16:85773333	chr16:85282958~85285963:+
PCPG	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	3.89	0.000151	0.0452	0.39	0.3	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
PCPG	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	3.89	0.000151	0.0452	0.62	0.3	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
PCPG	cis	rs1150668	0.796	rs213237	ENSG00000219392.1	RP1-265C24.5	-3.89	0.000151	0.0452	-0.35	-0.3	Pubertal anthropometrics;	chr6:28356161	chr6:28115628~28116551:+
PCPG	cis	rs2412459	0.635	rs514152	ENSG00000245849.5	RAD51-AS1	3.89	0.000151	0.0452	0.44	0.3	Response to haloperidol in psychosis;	chr15:39962955	chr15:40686724~40695107:-
PCPG	cis	rs6445975	0.715	rs6809809	ENSG00000272360.1	RP11-359I18.5	-3.89	0.000151	0.0452	-0.37	-0.3	Systemic lupus erythematosus;	chr3:58282223	chr3:58490830~58491291:-
PCPG	cis	rs6445975	0.715	rs13320332	ENSG00000272360.1	RP11-359I18.5	-3.89	0.000151	0.0452	-0.37	-0.3	Systemic lupus erythematosus;	chr3:58282617	chr3:58490830~58491291:-
PCPG	cis	rs4791051	0.723	rs3848425	ENSG00000264491.1	RP11-349A8.3	-3.89	0.000152	0.0452	-0.31	-0.3	Heschl's gyrus morphology;	chr17:66467803	chr17:67019934~67021743:-
PCPG	cis	rs7826238	0.517	rs35144760	ENSG00000173295.6	FAM86B3P	3.89	0.000152	0.0452	0.38	0.3	Systolic blood pressure;	chr8:8504213	chr8:8228595~8244865:+
PCPG	cis	rs950169	0.881	rs34117475	ENSG00000235370.6	DNM1P51	3.89	0.000152	0.0452	0.32	0.3	Schizophrenia;	chr15:84565212	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.81	rs2879976	ENSG00000235370.6	DNM1P51	3.89	0.000152	0.0452	0.32	0.3	Schizophrenia;	chr15:84566347	chr15:84398316~84411701:-
PCPG	cis	rs12681963	0.688	rs67240919	ENSG00000272375.1	RP11-51J9.6	3.89	0.000152	0.0453	0.42	0.3	Migraine;	chr8:30171039	chr8:30197404~30198048:+
PCPG	cis	rs3809060	0.959	rs2301251	ENSG00000213713.3	PIGCP1	3.89	0.000152	0.0453	0.17	0.3	Inguinal hernia;	chr11:32436439	chr11:33075566~33076460:-
PCPG	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	3.89	0.000152	0.0453	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
PCPG	cis	rs6832769	1	rs9312662	ENSG00000272969.1	RP11-528I4.2	-3.89	0.000152	0.0453	-0.33	-0.3	Personality dimensions;	chr4:55520204	chr4:55547112~55547889:+
PCPG	cis	rs847649	1	rs4620204	ENSG00000252643.1	RNU6-1136P	3.89	0.000152	0.0453	0.36	0.3	Morning vs. evening chronotype;	chr7:102953770	chr7:102834605~102834708:+
PCPG	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	3.89	0.000152	0.0453	0.64	0.3	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
PCPG	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-3.89	0.000152	0.0453	-0.52	-0.3	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
PCPG	cis	rs2529218	1	rs2529218	ENSG00000271745.1	AC093668.2	3.89	0.000152	0.0453	0.49	0.3	Lobe attachment (rater-scored or self-reported);	chr7:101789738	chr7:102480080~102480165:+
PCPG	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-3.89	0.000152	0.0453	-0.31	-0.3	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
PCPG	cis	rs172166	0.637	rs1225597	ENSG00000220721.1	OR1F12	3.89	0.000152	0.0453	0.35	0.3	Cardiac Troponin-T levels;	chr6:28194309	chr6:28073316~28074233:+
PCPG	cis	rs6570726	0.846	rs6570700	ENSG00000270638.1	RP3-466P17.1	3.89	0.000152	0.0453	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145735570~145737218:+
PCPG	cis	rs4819052	0.724	rs1304487	ENSG00000223768.1	LINC00205	3.89	0.000152	0.0453	0.4	0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45293285~45297354:+
PCPG	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	3.89	0.000152	0.0453	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
PCPG	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	3.89	0.000152	0.0453	0.41	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
PCPG	cis	rs7246657	0.606	rs2972439	ENSG00000226686.6	LINC01535	3.89	0.000152	0.0453	0.46	0.3	Coronary artery calcification;	chr19:37721680	chr19:37251912~37265535:+
PCPG	cis	rs7246657	0.722	rs2909100	ENSG00000226686.6	LINC01535	3.89	0.000152	0.0453	0.46	0.3	Coronary artery calcification;	chr19:37721779	chr19:37251912~37265535:+
PCPG	cis	rs4478147	0.506	rs17409478	ENSG00000251411.1	RP11-397E7.4	-3.89	0.000152	0.0454	-0.31	-0.3	Migraine - clinic-based;	chr4:86323681	chr4:86913266~86914817:-
PCPG	cis	rs7707921	1	rs6884232	ENSG00000249483.1	CTD-2249K22.1	3.89	0.000152	0.0454	0.41	0.3	Breast cancer;	chr5:82254224	chr5:81851601~81852201:+
PCPG	cis	rs7707921	0.881	rs2407153	ENSG00000249483.1	CTD-2249K22.1	3.89	0.000152	0.0454	0.41	0.3	Breast cancer;	chr5:82259509	chr5:81851601~81852201:+
PCPG	cis	rs7707921	1	rs749402	ENSG00000249483.1	CTD-2249K22.1	-3.89	0.000152	0.0454	-0.41	-0.3	Breast cancer;	chr5:82265506	chr5:81851601~81852201:+
PCPG	cis	rs7707921	1	rs749401	ENSG00000249483.1	CTD-2249K22.1	-3.89	0.000152	0.0454	-0.41	-0.3	Breast cancer;	chr5:82265550	chr5:81851601~81852201:+
PCPG	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-3.89	0.000152	0.0454	-0.32	-0.3	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
PCPG	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	3.89	0.000152	0.0454	0.74	0.3	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	3.89	0.000152	0.0454	0.74	0.3	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	3.89	0.000152	0.0454	0.74	0.3	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
PCPG	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	3.89	0.000152	0.0454	0.74	0.3	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
PCPG	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	3.89	0.000152	0.0454	0.29	0.3	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
PCPG	cis	rs12188164	0.965	rs77101200	ENSG00000221990.4	EXOC3-AS1	3.89	0.000152	0.0454	0.27	0.3	Cystic fibrosis severity;	chr5:442944	chr5:441498~443160:-
PCPG	cis	rs12681963	0.614	rs7013787	ENSG00000272375.1	RP11-51J9.6	3.89	0.000152	0.0454	0.44	0.3	Migraine;	chr8:30203272	chr8:30197404~30198048:+
PCPG	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-3.89	0.000152	0.0454	-0.33	-0.3	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
PCPG	cis	rs2348418	0.715	rs1355471	ENSG00000247934.4	RP11-967K21.1	-3.89	0.000152	0.0454	-0.34	-0.3	Lung function (FEV1);Lung function (FVC);	chr12:28568792	chr12:28163298~28190738:-
PCPG	cis	rs6517329	0.932	rs4817775	ENSG00000236830.5	CBR3-AS1	-3.89	0.000152	0.0454	-0.25	-0.3	Schizophrenia;	chr21:36112764	chr21:36131767~36175815:-
PCPG	cis	rs1003719	0.591	rs1053984	ENSG00000228677.1	TTC3-AS1	-3.89	0.000153	0.0454	-0.38	-0.3	Eye color traits;	chr21:37201717	chr21:37187666~37193926:-
PCPG	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	3.89	0.000153	0.0454	0.26	0.3	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
PCPG	cis	rs7819412	0.561	rs2001328	ENSG00000255020.1	AF131216.5	-3.89	0.000153	0.0454	-0.42	-0.3	Triglycerides;	chr8:11129689	chr8:11345748~11347502:-
PCPG	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	3.89	0.000153	0.0455	0.39	0.3	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
PCPG	cis	rs10155981	0.655	rs2069835	ENSG00000230042.1	AK3P3	3.89	0.000153	0.0455	0.74	0.3	Bilirubin levels;	chr7:22728252	chr7:23129178~23129841:+
PCPG	cis	rs7249142	0.597	rs759999	ENSG00000279843.1	AC011477.2	3.89	0.000153	0.0455	0.33	0.3	IgG glycosylation;	chr19:19170398	chr19:19835158~19836016:+
PCPG	cis	rs7142002	0.568	rs746781	ENSG00000272444.1	RP11-1017G21.6	-3.89	0.000153	0.0455	-0.39	-0.3	Autism;	chr14:101922138	chr14:101952416~101953063:+
PCPG	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-3.89	0.000153	0.0455	-0.39	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
PCPG	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	3.89	0.000153	0.0455	0.36	0.3	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
PCPG	cis	rs763121	0.925	rs9835	ENSG00000273076.1	RP3-508I15.22	3.89	0.000153	0.0455	0.32	0.3	Menopause (age at onset);	chr22:38734966	chr22:38743495~38743910:+
PCPG	cis	rs3758911	0.724	rs2216998	ENSG00000255353.1	RP11-382M14.1	-3.89	0.000153	0.0455	-0.39	-0.3	Coronary artery disease;	chr11:107246965	chr11:107176286~107177530:+
PCPG	cis	rs8042680	0.955	rs2034084	ENSG00000214432.8	AC068831.10	-3.89	0.000153	0.0455	-0.33	-0.3	Type 2 diabetes;	chr15:90963509	chr15:91022619~91036611:+
PCPG	cis	rs1550584	0.903	rs1623642	ENSG00000205562.2	RP11-497E19.1	3.89	0.000153	0.0455	0.31	0.3	IgG glycosylation;	chr14:85221927	chr14:85524432~85529988:-
PCPG	cis	rs901683	1	rs35047800	ENSG00000230869.1	CTGLF10P	-3.89	0.000153	0.0455	-0.74	-0.3	Mean corpuscular volume;Red blood cell traits;	chr10:45593599	chr10:45678692~45700532:+
PCPG	cis	rs6957923	0.655	rs10232644	ENSG00000230658.1	KLHL7-AS1	3.89	0.000153	0.0455	0.34	0.3	Height;	chr7:23552301	chr7:23101228~23105703:-
PCPG	cis	rs2735413	0.564	rs11863846	ENSG00000276007.1	RP11-358L22.3	3.89	0.000153	0.0455	0.31	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78085660	chr16:78123243~78124332:+
PCPG	cis	rs2735413	0.564	rs7192226	ENSG00000276007.1	RP11-358L22.3	3.89	0.000153	0.0455	0.31	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78086363	chr16:78123243~78124332:+
PCPG	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-3.89	0.000153	0.0456	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
PCPG	cis	rs17152411	0.895	rs7080330	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124897104	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs7084646	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124897169	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs7080475	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124897198	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs7094381	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124897279	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs11245418	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124897750	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs11245419	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124897823	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs11245420	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124897900	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs61872121	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124898226	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.895	rs66531168	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124898339	chr10:124623353~124624079:+
PCPG	cis	rs17152411	0.793	rs7085829	ENSG00000278831.1	RP11-12J10.4	3.89	0.000153	0.0456	0.43	0.3	Height;	chr10:124898573	chr10:124623353~124624079:+
PCPG	cis	rs698813	0.674	rs6759891	ENSG00000236502.1	SIX3-AS1	3.88	0.000153	0.0456	0.4	0.3	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);	chr2:44268866	chr2:44940154~44941873:-
PCPG	cis	rs6700559	0.643	rs1540683	ENSG00000260088.1	RP11-92G12.3	3.88	0.000153	0.0456	0.34	0.3	Coronary artery disease;	chr1:200693050	chr1:200669507~200694250:+
PCPG	cis	rs6832720	1	rs6832720	ENSG00000269921.1	RP11-646I6.5	3.88	0.000153	0.0456	0.64	0.3	Cotinine glucuronidation;	chr4:57282220	chr4:56387625~56388153:+
PCPG	cis	rs13118159	0.55	rs10016557	ENSG00000254094.1	AC078852.1	3.88	0.000153	0.0456	0.39	0.3	Longevity;	chr4:1369840	chr4:1356581~1358075:+
PCPG	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-3.88	0.000153	0.0456	-0.38	-0.3	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
PCPG	cis	rs301161	0.573	rs301155	ENSG00000179219.5	LINC00311	-3.88	0.000153	0.0456	-0.41	-0.3	Eosinophil counts;Sum eosinophil basophil counts;	chr16:85774057	chr16:85282958~85285963:+
PCPG	cis	rs301901	0.772	rs6451313	ENSG00000250155.1	CTD-2353F22.1	-3.88	0.000153	0.0456	-0.35	-0.3	Height;	chr5:37182208	chr5:36666214~36725195:-
PCPG	cis	rs7227917	0.536	rs72916032	ENSG00000269365.2	RP11-380M21.4	3.88	0.000153	0.0456	0.6	0.3	Lung cancer in ever smokers;	chr18:47988258	chr18:47878295~47882444:+
PCPG	cis	rs113716316	0.541	rs72884695	ENSG00000237429.1	RP1-159A19.4	3.88	0.000153	0.0456	0.62	0.3	Coronary artery disease;	chr1:27555761	chr1:27525805~27530561:+
PCPG	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
PCPG	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000153	0.0456	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
PCPG	cis	rs6832769	1	rs3736544	ENSG00000272969.1	RP11-528I4.2	3.88	0.000154	0.0457	0.33	0.3	Personality dimensions;	chr4:55443825	chr4:55547112~55547889:+
PCPG	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	3.88	0.000154	0.0457	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
PCPG	cis	rs9307551	0.857	rs2196978	ENSG00000250334.4	LINC00989	3.88	0.000154	0.0457	0.31	0.3	Refractive error;	chr4:79614815	chr4:79492416~79576460:+
PCPG	cis	rs888194	0.738	rs6606732	ENSG00000278993.1	RP3-424M6.4	-3.88	0.000154	0.0457	-0.31	-0.3	Neuroticism;	chr12:109546756	chr12:110501614~110503441:+
PCPG	cis	rs888194	0.738	rs4766611	ENSG00000278993.1	RP3-424M6.4	-3.88	0.000154	0.0457	-0.31	-0.3	Neuroticism;	chr12:109550033	chr12:110501614~110503441:+
PCPG	cis	rs888194	0.699	rs7304862	ENSG00000278993.1	RP3-424M6.4	-3.88	0.000154	0.0457	-0.31	-0.3	Neuroticism;	chr12:109551086	chr12:110501614~110503441:+
PCPG	cis	rs888194	0.738	rs10850358	ENSG00000278993.1	RP3-424M6.4	-3.88	0.000154	0.0457	-0.31	-0.3	Neuroticism;	chr12:109553245	chr12:110501614~110503441:+
PCPG	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-3.88	0.000154	0.0457	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
PCPG	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-3.88	0.000154	0.0457	-0.23	-0.3	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
PCPG	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-3.88	0.000154	0.0457	-0.38	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
PCPG	cis	rs4380275	0.782	rs4854276	ENSG00000223751.1	AC116609.2	3.88	0.000154	0.0457	0.35	0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:742488~747767:+
PCPG	cis	rs3808502	0.534	rs1529858	ENSG00000255020.1	AF131216.5	3.88	0.000154	0.0458	0.37	0.3	Neuroticism;	chr8:11288153	chr8:11345748~11347502:-
PCPG	cis	rs7824557	0.619	rs7012218	ENSG00000255020.1	AF131216.5	3.88	0.000154	0.0458	0.37	0.3	Retinal vascular caliber;	chr8:11288167	chr8:11345748~11347502:-
PCPG	cis	rs3808502	0.501	rs7012219	ENSG00000255020.1	AF131216.5	3.88	0.000154	0.0458	0.37	0.3	Neuroticism;	chr8:11288170	chr8:11345748~11347502:-
PCPG	cis	rs11836164	0.731	rs61914546	ENSG00000278095.1	RP11-283G6.6	3.88	0.000154	0.0458	0.4	0.3	Mammographic density (dense area);	chr12:26305574	chr12:26273329~26273900:-
PCPG	cis	rs9813712	0.595	rs6439226	ENSG00000228252.7	COL6A4P2	3.88	0.000154	0.0459	0.37	0.3	Response to amphetamines;	chr3:130283686	chr3:130212823~130273806:+
PCPG	cis	rs1550584	1	rs1449419	ENSG00000205562.2	RP11-497E19.1	3.88	0.000154	0.0459	0.31	0.3	IgG glycosylation;	chr14:85221069	chr14:85524432~85529988:-
PCPG	cis	rs1550584	1	rs1449418	ENSG00000205562.2	RP11-497E19.1	3.88	0.000154	0.0459	0.31	0.3	IgG glycosylation;	chr14:85221246	chr14:85524432~85529988:-
PCPG	cis	rs801193	0.569	rs11772819	ENSG00000235475.1	LINC01372	3.88	0.000154	0.0459	0.31	0.3	Aortic root size;	chr7:66752983	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs7800620	ENSG00000235475.1	LINC01372	3.88	0.000154	0.0459	0.31	0.3	Aortic root size;	chr7:66758701	chr7:67335976~67340024:+
PCPG	cis	rs801193	0.569	rs13226966	ENSG00000235475.1	LINC01372	3.88	0.000154	0.0459	0.31	0.3	Aortic root size;	chr7:66768636	chr7:67335976~67340024:+
PCPG	cis	rs7208859	0.673	rs1347360	ENSG00000266490.1	CTD-2349P21.9	3.88	0.000154	0.0459	0.39	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30792372~30792833:+
PCPG	cis	rs6012953	0.874	rs6063534	ENSG00000231742.4	LINC01273	3.88	0.000154	0.0459	0.32	0.3	Vitiligo;	chr20:50572631	chr20:50172550~50176671:+
PCPG	cis	rs4237845	0.591	rs4760344	ENSG00000257698.1	RP11-620J15.3	-3.88	0.000155	0.0459	-0.28	-0.3	Intelligence (multi-trait analysis);	chr12:57927000	chr12:57931528~57936175:-
PCPG	cis	rs11220082	0.661	rs2321158	ENSG00000254671.2	STT3A-AS1	3.88	0.000155	0.0459	0.31	0.3	Schizophrenia;	chr11:125414990	chr11:125570284~125592568:-
PCPG	cis	rs10844706	0.699	rs11052717	ENSG00000278635.1	CTD-2318O12.1	-3.88	0.000155	0.0459	-0.37	-0.3	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9415641~9416718:+
PCPG	cis	rs10865541	0.934	rs6738333	ENSG00000225234.1	TRAPPC12-AS1	-3.88	0.000155	0.0459	-0.3	-0.3	Obesity-related traits;	chr2:3399633	chr2:3481242~3482409:-
PCPG	cis	rs911119	1	rs13041070	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23633624	chr20:23631826~23632316:-
PCPG	cis	rs911119	0.955	rs35610040	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23635832	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs3787498	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23636144	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs3787499	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23636170	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs3827142	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23636370	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs1064039	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23637790	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs73318135	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23637934	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs5030707	ENSG00000270001.1	RP11-218C14.8	-3.88	0.000155	0.0459	-0.51	-0.3	Chronic kidney disease;	chr20:23638019	chr20:23631826~23632316:-
PCPG	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-3.88	0.000155	0.046	-0.37	-0.3	Temperament;	chr17:14046511	chr17:14024514~14025488:+
PCPG	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-3.88	0.000155	0.046	-0.37	-0.3	Temperament;	chr17:14048649	chr17:14024514~14025488:+
PCPG	cis	rs13315649	0.724	rs28787069	ENSG00000242551.2	POU5F1P6	-3.88	0.000155	0.046	-0.41	-0.3	Sum eosinophil basophil counts;	chr3:128695613	chr3:128674735~128677005:-
PCPG	cis	rs9500256	0.934	rs1343391	ENSG00000215190.7	LINC00680	-3.88	0.000155	0.046	-0.35	-0.3	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57946074~57961501:-
PCPG	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000155	0.046	-0.32	-0.3	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
PCPG	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000155	0.046	-0.32	-0.3	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
PCPG	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000155	0.046	-0.32	-0.3	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
PCPG	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-3.88	0.000155	0.046	-0.32	-0.3	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
PCPG	cis	rs13178541	0.745	rs6596262	ENSG00000249119.1	MTND6P4	-3.88	0.000155	0.046	-0.4	-0.3	IgG glycosylation;	chr5:135723983	chr5:134924123~134924644:+
PCPG	cis	rs9307551	0.711	rs11098774	ENSG00000250334.4	LINC00989	3.88	0.000155	0.046	0.32	0.3	Refractive error;	chr4:79615697	chr4:79492416~79576460:+
PCPG	cis	rs2836974	0.644	rs2836982	ENSG00000252915.1	Y_RNA	3.88	0.000155	0.046	0.32	0.3	Cognitive function;	chr21:39317245	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.644	rs4818017	ENSG00000252915.1	Y_RNA	3.88	0.000155	0.046	0.32	0.3	Cognitive function;	chr21:39318635	chr21:39344537~39344628:+
PCPG	cis	rs2836974	0.644	rs1882779	ENSG00000252915.1	Y_RNA	3.88	0.000155	0.046	0.32	0.3	Cognitive function;	chr21:39319012	chr21:39344537~39344628:+
PCPG	cis	rs2404602	0.716	rs4886817	ENSG00000259422.1	RP11-593F23.1	3.88	0.000155	0.046	0.36	0.3	Blood metabolite levels;	chr15:76585361	chr15:76174891~76181486:-
PCPG	cis	rs34864796	0.547	rs200476	ENSG00000216901.1	AL022393.7	3.88	0.000155	0.046	0.43	0.3	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28176188~28176674:+
PCPG	cis	rs56114371	0.53	rs169262	ENSG00000216901.1	AL022393.7	3.88	0.000155	0.046	0.43	0.3	Breast cancer;	chr6:27803112	chr6:28176188~28176674:+
PCPG	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	3.88	0.000155	0.0461	0.26	0.3	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
PCPG	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-3.88	0.000155	0.0461	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
PCPG	cis	rs757282	0.555	rs62640116	ENSG00000258024.1	OR5BT1P	3.88	0.000155	0.0461	0.42	0.3	Optic nerve measurement (cup-to-disc ratio);	chr12:47634251	chr12:48385417~48386265:-
PCPG	cis	rs2732480	0.577	rs2634693	ENSG00000240399.1	RP1-228P16.1	3.88	0.000155	0.0461	0.32	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.577	rs2634691	ENSG00000240399.1	RP1-228P16.1	3.88	0.000155	0.0461	0.32	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48054813~48055591:-
PCPG	cis	rs2732480	0.557	rs2732441	ENSG00000240399.1	RP1-228P16.1	3.88	0.000155	0.0461	0.32	0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48054813~48055591:-
PCPG	cis	rs2239547	0.563	rs4687699	ENSG00000242142.1	SERBP1P3	3.88	0.000155	0.0461	0.35	0.3	Schizophrenia;	chr3:53067208	chr3:53064283~53065091:-
PCPG	cis	rs2228479	0.702	rs78331410	ENSG00000268218.1	AC137932.4	-3.88	0.000155	0.0461	-0.46	-0.3	Skin colour saturation;	chr16:89851367	chr16:89268104~89273044:+
PCPG	cis	rs2228479	0.85	rs117675822	ENSG00000268218.1	AC137932.4	-3.88	0.000155	0.0461	-0.46	-0.3	Skin colour saturation;	chr16:89852673	chr16:89268104~89273044:+
PCPG	cis	rs2228479	0.702	rs62056087	ENSG00000268218.1	AC137932.4	-3.88	0.000155	0.0461	-0.46	-0.3	Skin colour saturation;	chr16:89853975	chr16:89268104~89273044:+
PCPG	cis	rs2228479	0.85	rs34033205	ENSG00000268218.1	AC137932.4	-3.88	0.000155	0.0461	-0.46	-0.3	Skin colour saturation;	chr16:89856551	chr16:89268104~89273044:+
PCPG	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-3.88	0.000155	0.0461	-0.36	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
PCPG	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-3.88	0.000155	0.0461	-0.42	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
PCPG	cis	rs3764021	0.527	rs10772062	ENSG00000278635.1	CTD-2318O12.1	-3.88	0.000155	0.0461	-0.37	-0.3	Type 1 diabetes;	chr12:9712561	chr12:9415641~9416718:+
PCPG	cis	rs6585424	1	rs10466228	ENSG00000242600.5	MBL1P	3.88	0.000156	0.0461	0.57	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164617	chr10:79904898~79950336:+
PCPG	cis	rs73201462	1	rs11715394	ENSG00000242551.2	POU5F1P6	3.88	0.000156	0.0461	0.63	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128174721	chr3:128674735~128677005:-
PCPG	cis	rs2404602	0.692	rs34181263	ENSG00000259422.1	RP11-593F23.1	3.88	0.000156	0.0461	0.36	0.3	Blood metabolite levels;	chr15:76773047	chr15:76174891~76181486:-
PCPG	cis	rs1129187	0.755	rs9471988	ENSG00000272223.1	RP1-20C7.6	3.88	0.000156	0.0461	0.3	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42977035	chr6:43033897~43034405:-
PCPG	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	3.88	0.000156	0.0462	0.55	0.3	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
PCPG	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-3.88	0.000156	0.0462	-0.68	-0.3	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
PCPG	cis	rs10040610	0.524	rs271414	ENSG00000248677.1	CTD-2044J15.1	-3.88	0.000156	0.0462	-0.34	-0.3	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6349022	chr5:6686325~6707711:-
PCPG	cis	rs2361701	1	rs2361701	ENSG00000279259.1	RP11-334C17.3	3.88	0.000156	0.0462	0.32	0.3	IgG glycosylation;	chr17:80092818	chr17:80147250~80148596:+
PCPG	cis	rs1550584	0.967	rs1767402	ENSG00000205562.2	RP11-497E19.1	3.88	0.000156	0.0462	0.31	0.3	IgG glycosylation;	chr14:85220791	chr14:85524432~85529988:-
PCPG	cis	rs17684571	0.637	rs35566812	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56792077	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs62411375	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56794361	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs13220851	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56796753	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs59432342	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56797506	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs34171958	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56800000	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs35440822	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56801006	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.575	rs71564855	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56801117	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs13218913	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56801247	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs71564856	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56803447	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs13201733	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56804226	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs17684730	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56804425	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs4371846	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56805767	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs17684748	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56809419	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs17751977	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56809820	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs17684772	ENSG00000231441.1	RP11-472M19.2	3.88	0.000156	0.0462	0.5	0.3	Schizophrenia;	chr6:56810415	chr6:56844002~56864078:+
PCPG	cis	rs3758911	0.828	rs17106875	ENSG00000255353.1	RP11-382M14.1	-3.88	0.000156	0.0462	-0.41	-0.3	Coronary artery disease;	chr11:107407957	chr11:107176286~107177530:+
PCPG	cis	rs950169	0.84	rs62019457	ENSG00000235370.6	DNM1P51	3.88	0.000156	0.0462	0.31	0.3	Schizophrenia;	chr15:84558911	chr15:84398316~84411701:-
PCPG	cis	rs950169	0.922	rs67804993	ENSG00000235370.6	DNM1P51	3.88	0.000156	0.0462	0.31	0.3	Schizophrenia;	chr15:84560799	chr15:84398316~84411701:-
PCPG	cis	rs6504622	0.755	rs4074249	ENSG00000263142.4	LRRC37A17P	-3.88	0.000156	0.0462	-0.24	-0.3	Orofacial clefts;	chr17:47072043	chr17:46978481~47054569:+
PCPG	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-3.88	0.000156	0.0463	-0.38	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
PCPG	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	3.88	0.000156	0.0463	0.3	0.3	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
PCPG	cis	rs1865760	0.534	rs72834629	ENSG00000272810.1	U91328.22	-3.88	0.000156	0.0463	-0.32	-0.3	Height;	chr6:26022804	chr6:26013241~26013757:+
PCPG	cis	rs7618915	0.501	rs3733045	ENSG00000275956.1	RP5-966M1.7	-3.88	0.000156	0.0463	-0.35	-0.3	Bipolar disorder;	chr3:52609291	chr3:52732547~52733867:+
PCPG	cis	rs4819052	0.851	rs2838832	ENSG00000223768.1	LINC00205	3.88	0.000156	0.0463	0.39	0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45293285~45297354:+
PCPG	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	3.88	0.000156	0.0463	0.38	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
PCPG	cis	rs28386778	0.799	rs2955234	ENSG00000240280.5	TCAM1P	3.88	0.000156	0.0463	0.39	0.3	Prudent dietary pattern;	chr17:63906241	chr17:63849292~63864379:+
PCPG	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-3.88	0.000156	0.0463	-0.48	-0.3	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
PCPG	cis	rs11098499	1	rs13435802	ENSG00000250412.1	KLHL2P1	-3.88	0.000156	0.0463	-0.32	-0.3	Corneal astigmatism;	chr4:119256805	chr4:119334329~119378233:+
PCPG	cis	rs2243480	1	rs313824	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66116220	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs186378	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66117071	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs160637	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66119331	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs422164	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66121618	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316313	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66128561	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs316312	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66131504	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs419603	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66132354	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs387676	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66133233	chr7:66409143~66490059:-
PCPG	cis	rs2243480	1	rs13310597	ENSG00000230189.5	GS1-124K5.2	3.88	0.000156	0.0463	0.43	0.3	Diabetic kidney disease;	chr7:66133553	chr7:66409143~66490059:-
PCPG	cis	rs7118412	1	rs6591040	ENSG00000260966.1	RP11-690D19.3	3.88	0.000156	0.0463	0.31	0.3	Disc degeneration (lumbar);	chr11:103657841	chr11:103050687~103055799:-
PCPG	cis	rs7118412	0.965	rs12805875	ENSG00000260966.1	RP11-690D19.3	3.88	0.000156	0.0463	0.31	0.3	Disc degeneration (lumbar);	chr11:103658904	chr11:103050687~103055799:-
PCPG	cis	rs7118412	0.824	rs7126823	ENSG00000260966.1	RP11-690D19.3	3.88	0.000156	0.0463	0.31	0.3	Disc degeneration (lumbar);	chr11:103659143	chr11:103050687~103055799:-
PCPG	cis	rs7118412	0.965	rs4554859	ENSG00000260966.1	RP11-690D19.3	3.88	0.000156	0.0463	0.31	0.3	Disc degeneration (lumbar);	chr11:103659638	chr11:103050687~103055799:-
PCPG	cis	rs703842	1	rs6581155	ENSG00000270039.1	RP11-571M6.17	-3.88	0.000157	0.0463	-0.37	-0.3	Multiple sclerosis;	chr12:57784379	chr12:57803838~57804415:+
PCPG	cis	rs728616	0.867	rs56271768	ENSG00000242600.5	MBL1P	3.88	0.000157	0.0464	0.58	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:79904898~79950336:+
PCPG	cis	rs7937890	0.559	rs2597201	ENSG00000251991.1	RNU7-49P	3.88	0.000157	0.0464	0.35	0.3	Mitochondrial DNA levels;	chr11:14463858	chr11:14478892~14478953:+
PCPG	cis	rs2404602	0.716	rs17362383	ENSG00000259514.1	RP11-685G9.2	-3.88	0.000157	0.0464	-0.3	-0.3	Blood metabolite levels;	chr15:76358361	chr15:76339609~76342063:-
PCPG	cis	rs2052670	0.964	rs1471762	ENSG00000232613.5	AC007386.4	-3.88	0.000157	0.0464	-0.42	-0.3	Waist circumference adjusted for body mass index;	chr2:66022426	chr2:65030727~65053017:+
PCPG	cis	rs1048886	0.872	rs9455182	ENSG00000271967.1	RP11-134K13.4	-3.88	0.000157	0.0464	-0.35	-0.3	Type 2 diabetes;	chr6:70593212	chr6:70596438~70596980:+
PCPG	cis	rs6728642	0.908	rs10203833	ENSG00000278766.2	AC159540.2	-3.88	0.000157	0.0464	-0.46	-0.3	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97356336	chr2:97421075~97434847:+
PCPG	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	3.88	0.000157	0.0464	0.41	0.3	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
PCPG	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	3.88	0.000157	0.0464	0.41	0.3	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
PCPG	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	3.88	0.000157	0.0464	0.41	0.3	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
PCPG	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	3.88	0.000157	0.0464	0.41	0.3	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
PCPG	cis	rs888194	0.738	rs731178	ENSG00000278993.1	RP3-424M6.4	-3.88	0.000157	0.0464	-0.31	-0.3	Neuroticism;	chr12:109543873	chr12:110501614~110503441:+
PCPG	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	3.88	0.000157	0.0464	0.4	0.3	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
PCPG	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-3.88	0.000157	0.0465	-0.44	-0.3	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
PCPG	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-3.88	0.000157	0.0465	-0.35	-0.3	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
PCPG	cis	rs853679	0.546	rs35016036	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000157	0.0465	-0.66	-0.3	Depression;	chr6:28347103	chr6:28115628~28116551:+
PCPG	cis	rs853679	0.546	rs35744819	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000157	0.0465	-0.66	-0.3	Depression;	chr6:28350554	chr6:28115628~28116551:+
PCPG	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-3.88	0.000157	0.0465	-0.27	-0.3	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
PCPG	cis	rs3809060	0.717	rs10835917	ENSG00000213713.3	PIGCP1	3.88	0.000157	0.0465	0.16	0.3	Inguinal hernia;	chr11:32462719	chr11:33075566~33076460:-
PCPG	cis	rs6832769	1	rs4865008	ENSG00000272969.1	RP11-528I4.2	-3.88	0.000157	0.0465	-0.33	-0.3	Personality dimensions;	chr4:55544688	chr4:55547112~55547889:+
PCPG	cis	rs6832769	1	rs28448438	ENSG00000272969.1	RP11-528I4.2	-3.88	0.000157	0.0465	-0.33	-0.3	Personality dimensions;	chr4:55550498	chr4:55547112~55547889:+
PCPG	cis	rs6832769	1	rs28572116	ENSG00000272969.1	RP11-528I4.2	-3.88	0.000157	0.0465	-0.33	-0.3	Personality dimensions;	chr4:55558177	chr4:55547112~55547889:+
PCPG	cis	rs6832769	0.961	rs2412647	ENSG00000272969.1	RP11-528I4.2	3.88	0.000157	0.0465	0.33	0.3	Personality dimensions;	chr4:55452938	chr4:55547112~55547889:+
PCPG	cis	rs2836974	0.965	rs8134733	ENSG00000252915.1	Y_RNA	-3.88	0.000157	0.0465	-0.32	-0.3	Cognitive function;	chr21:39311533	chr21:39344537~39344628:+
PCPG	cis	rs896854	0.738	rs509594	ENSG00000272509.1	RP11-347C18.5	-3.88	0.000157	0.0465	-0.29	-0.3	Type 2 diabetes;	chr8:94954928	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.738	rs481887	ENSG00000272509.1	RP11-347C18.5	-3.88	0.000157	0.0465	-0.29	-0.3	Type 2 diabetes;	chr8:94955610	chr8:94884609~94885070:+
PCPG	cis	rs6832769	1	rs6834676	ENSG00000272969.1	RP11-528I4.2	3.88	0.000157	0.0465	0.32	0.3	Personality dimensions;	chr4:55432247	chr4:55547112~55547889:+
PCPG	cis	rs6832769	0.961	rs3805147	ENSG00000272969.1	RP11-528I4.2	3.88	0.000157	0.0465	0.32	0.3	Personality dimensions;	chr4:55440563	chr4:55547112~55547889:+
PCPG	cis	rs6832769	1	rs4580704	ENSG00000272969.1	RP11-528I4.2	-3.88	0.000157	0.0465	-0.32	-0.3	Personality dimensions;	chr4:55460540	chr4:55547112~55547889:+
PCPG	cis	rs12291225	0.639	rs61883858	ENSG00000251991.1	RNU7-49P	3.88	0.000157	0.0465	0.34	0.3	Sense of smell;	chr11:14273162	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.679	rs11023170	ENSG00000251991.1	RNU7-49P	3.88	0.000157	0.0465	0.34	0.3	Sense of smell;	chr11:14273363	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.679	rs11023172	ENSG00000251991.1	RNU7-49P	3.88	0.000157	0.0465	0.34	0.3	Sense of smell;	chr11:14273821	chr11:14478892~14478953:+
PCPG	cis	rs12291225	0.679	rs4757245	ENSG00000251991.1	RNU7-49P	3.88	0.000157	0.0465	0.34	0.3	Sense of smell;	chr11:14276326	chr11:14478892~14478953:+
PCPG	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-3.88	0.000157	0.0465	-0.39	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
PCPG	cis	rs72615157	0.561	rs113401658	ENSG00000078319.8	PMS2P1	-3.88	0.000157	0.0465	-0.38	-0.3	Lung function (FEV1/FVC);	chr7:100260882	chr7:100320992~100341908:-
PCPG	cis	rs72615157	0.561	rs113844570	ENSG00000078319.8	PMS2P1	-3.88	0.000157	0.0465	-0.38	-0.3	Lung function (FEV1/FVC);	chr7:100276155	chr7:100320992~100341908:-
PCPG	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-3.88	0.000157	0.0465	-0.42	-0.3	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
PCPG	cis	rs2164273	0.528	rs3824212	ENSG00000255020.1	AF131216.5	3.88	0.000157	0.0465	0.38	0.3	Extraversion;	chr8:11285409	chr8:11345748~11347502:-
PCPG	cis	rs6137473	0.516	rs6113507	ENSG00000227063.5	RPL41P1	3.88	0.000157	0.0465	0.34	0.3	Adolescent idiopathic scoliosis;	chr20:22095004	chr20:21755270~21755350:+
PCPG	cis	rs7772486	0.727	rs10223508	ENSG00000270638.1	RP3-466P17.1	-3.88	0.000157	0.0465	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145735570~145737218:+
PCPG	cis	rs888194	0.651	rs6606734	ENSG00000278993.1	RP3-424M6.4	-3.88	0.000157	0.0465	-0.31	-0.3	Neuroticism;	chr12:109575834	chr12:110501614~110503441:+
PCPG	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	3.88	0.000157	0.0466	0.38	0.3	Height;	chr6:109740895	chr6:109382795~109383666:+
PCPG	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	3.88	0.000157	0.0466	0.31	0.3	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
PCPG	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	3.88	0.000157	0.0466	0.35	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
PCPG	cis	rs728616	0.867	rs12414877	ENSG00000242600.5	MBL1P	3.88	0.000157	0.0466	0.69	0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80020952	chr10:79904898~79950336:+
PCPG	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.35	-0.3	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.35	-0.3	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
PCPG	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-3.88	0.000158	0.0466	-0.36	-0.3	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
PCPG	cis	rs7017914	0.714	rs12155783	ENSG00000254031.4	RP11-326E22.1	-3.88	0.000158	0.0466	-0.29	-0.3	Bone mineral density;	chr8:71086891	chr8:71155457~71204223:+
PCPG	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-3.88	0.000158	0.0466	-0.31	-0.3	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
PCPG	cis	rs4280164	0.56	rs11626191	ENSG00000259321.1	RP11-468E2.5	3.88	0.000158	0.0466	0.38	0.3	Parent of origin effect on language impairment (paternal);	chr14:24267368	chr14:24139445~24140444:+
PCPG	cis	rs4280164	0.613	rs11621353	ENSG00000259321.1	RP11-468E2.5	3.88	0.000158	0.0466	0.38	0.3	Parent of origin effect on language impairment (paternal);	chr14:24267463	chr14:24139445~24140444:+
PCPG	cis	rs4280164	0.562	rs78807053	ENSG00000259321.1	RP11-468E2.5	3.88	0.000158	0.0466	0.38	0.3	Parent of origin effect on language impairment (paternal);	chr14:24271066	chr14:24139445~24140444:+
PCPG	cis	rs867371	0.929	rs1501371	ENSG00000278603.1	RP13-608F4.5	3.88	0.000158	0.0466	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472203~82472426:+
PCPG	cis	rs10801727	0.641	rs10801741	ENSG00000231999.5	FLJ27354	3.88	0.000158	0.0466	0.36	0.3	Parental extreme longevity (95 years and older);	chr1:89456016	chr1:89583241~89632894:-
PCPG	cis	rs28735056	0.592	rs10853392	ENSG00000261126.6	RP11-795F19.1	-3.88	0.000158	0.0466	-0.29	-0.3	Schizophrenia;	chr18:79948781	chr18:80046900~80095482:+
PCPG	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	3.88	0.000158	0.0467	0.39	0.3	Height;	chr6:109417941	chr6:109382795~109383666:+
PCPG	cis	rs2404602	0.692	rs12910734	ENSG00000259422.1	RP11-593F23.1	3.88	0.000158	0.0467	0.36	0.3	Blood metabolite levels;	chr15:76857590	chr15:76174891~76181486:-
PCPG	cis	rs7156960	0.54	rs4903393	ENSG00000258454.1	RP11-361H10.3	3.88	0.000158	0.0467	0.38	0.3	Acute lymphoblastic leukemia (childhood);	chr14:76267845	chr14:76235817~76263474:+
PCPG	cis	rs761746	0.739	rs140078	ENSG00000128254.12	C22orf24	3.88	0.000158	0.0467	0.4	0.3	Intelligence;	chr22:31714177	chr22:31933521~31945518:-
PCPG	cis	rs889398	0.771	rs1566453	ENSG00000196696.11	PDXDC2P	-3.88	0.000158	0.0467	-0.24	-0.3	Body mass index;	chr16:69865884	chr16:69976297~70065948:-
PCPG	cis	rs7601713	0.539	rs2352106	ENSG00000226383.4	AC093375.1	-3.88	0.000158	0.0467	-0.44	-0.3	QT interval;	chr2:156646004	chr2:156011617~156024613:-
PCPG	cis	rs7601713	0.539	rs34909690	ENSG00000226383.4	AC093375.1	-3.88	0.000158	0.0467	-0.44	-0.3	QT interval;	chr2:156648059	chr2:156011617~156024613:-
PCPG	cis	rs7601713	0.539	rs62178499	ENSG00000226383.4	AC093375.1	-3.88	0.000158	0.0467	-0.44	-0.3	QT interval;	chr2:156654783	chr2:156011617~156024613:-
PCPG	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	3.88	0.000158	0.0467	0.38	0.3	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
PCPG	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	3.88	0.000158	0.0467	0.44	0.3	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
PCPG	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	3.88	0.000158	0.0467	0.44	0.3	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
PCPG	cis	rs13118159	0.55	rs4974612	ENSG00000254094.1	AC078852.1	-3.88	0.000158	0.0467	-0.4	-0.3	Longevity;	chr4:1370755	chr4:1356581~1358075:+
PCPG	cis	rs9393777	0.92	rs35716472	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000158	0.0467	-0.62	-0.3	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28115628~28116551:+
PCPG	cis	rs11771526	1	rs17351142	ENSG00000281332.1	LINC00997	3.88	0.000158	0.0467	0.56	0.3	Body mass index;	chr7:32300231	chr7:32760279~32762924:+
PCPG	cis	rs11771526	1	rs11770367	ENSG00000281332.1	LINC00997	3.88	0.000158	0.0467	0.56	0.3	Body mass index;	chr7:32314707	chr7:32760279~32762924:+
PCPG	cis	rs11771526	1	rs62457533	ENSG00000281332.1	LINC00997	3.88	0.000158	0.0467	0.56	0.3	Body mass index;	chr7:32315722	chr7:32760279~32762924:+
PCPG	cis	rs11771526	0.892	rs62457534	ENSG00000281332.1	LINC00997	3.88	0.000158	0.0467	0.56	0.3	Body mass index;	chr7:32318040	chr7:32760279~32762924:+
PCPG	cis	rs11771526	0.681	rs62457535	ENSG00000281332.1	LINC00997	3.88	0.000158	0.0467	0.56	0.3	Body mass index;	chr7:32319098	chr7:32760279~32762924:+
PCPG	cis	rs748404	0.556	rs7166467	ENSG00000205771.5	CATSPER2P1	3.88	0.000158	0.0467	0.32	0.3	Lung cancer;	chr15:43148324	chr15:43726918~43747094:-
PCPG	cis	rs8031584	0.651	rs28664821	ENSG00000270015.1	RP11-540B6.6	3.88	0.000158	0.0467	0.28	0.3	Huntington's disease progression;	chr15:30880120	chr15:30926514~30928407:+
PCPG	cis	rs3758911	0.894	rs11212154	ENSG00000255353.1	RP11-382M14.1	-3.88	0.000158	0.0467	-0.41	-0.3	Coronary artery disease;	chr11:107319238	chr11:107176286~107177530:+
PCPG	cis	rs2115630	0.967	rs10438428	ENSG00000259295.5	CSPG4P12	-3.88	0.000158	0.0467	-0.36	-0.3	P wave terminal force;	chr15:84787514	chr15:85191438~85213905:+
PCPG	cis	rs11671005	0.735	rs12977592	ENSG00000252334.1	RNU6-1337P	3.88	0.000158	0.0468	0.4	0.3	Mean platelet volume;	chr19:58449689	chr19:58483749~58483843:-
PCPG	cis	rs10200850	0.892	rs13389628	ENSG00000265215.1	MIR4269	3.88	0.000158	0.0468	0.44	0.3	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239300173	chr2:239305462~239305545:+
PCPG	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-3.88	0.000158	0.0468	-0.39	-0.3	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
PCPG	cis	rs181553	0.961	rs357909	ENSG00000278983.1	RP11-426J5.3	3.88	0.000158	0.0468	0.33	0.3	Hip circumference adjusted for BMI;	chr18:49033509	chr18:48564795~48568342:+
PCPG	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-3.88	0.000158	0.0468	-0.31	-0.3	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
PCPG	cis	rs16879308	0.581	rs12109588	ENSG00000248898.1	CTD-2288O8.1	3.88	0.000158	0.0468	0.77	0.3	Migraine without aura;	chr5:52086269	chr5:52675193~52788026:-
PCPG	cis	rs8056446	0.53	rs9929762	ENSG00000276007.1	RP11-358L22.3	-3.88	0.000158	0.0468	-0.22	-0.3	Pulmonary function (smoking interaction);	chr16:78135778	chr16:78123243~78124332:+
PCPG	cis	rs78579285	0.51	rs78759106	ENSG00000260630.5	SNAI3-AS1	-3.88	0.000159	0.0468	-0.55	-0.3	Joint mobility (Beighton score);	chr16:88722127	chr16:88663298~88687186:+
PCPG	cis	rs2836974	0.666	rs4624474	ENSG00000252915.1	Y_RNA	3.88	0.000159	0.0468	0.32	0.3	Cognitive function;	chr21:39314401	chr21:39344537~39344628:+
PCPG	cis	rs1075232	1	rs66581165	ENSG00000269930.1	RP11-932O9.9	-3.88	0.000159	0.0468	-0.73	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30616958~30617749:+
PCPG	cis	rs7707921	0.881	rs73136777	ENSG00000249483.1	CTD-2249K22.1	-3.88	0.000159	0.0468	-0.41	-0.3	Breast cancer;	chr5:82138660	chr5:81851601~81852201:+
PCPG	cis	rs7819412	0.749	rs2001433	ENSG00000269954.1	RP11-148O21.6	-3.88	0.000159	0.0468	-0.38	-0.3	Triglycerides;	chr8:11045965	chr8:11552488~11552991:-
PCPG	cis	rs10200159	1	rs13428486	ENSG00000272606.1	RP11-554J4.1	3.88	0.000159	0.0468	0.57	0.3	Vitiligo;	chr2:55569451	chr2:55617909~55618373:+
PCPG	cis	rs10200159	1	rs6545507	ENSG00000272606.1	RP11-554J4.1	3.88	0.000159	0.0468	0.57	0.3	Vitiligo;	chr2:55588756	chr2:55617909~55618373:+
PCPG	cis	rs10200159	1	rs17047119	ENSG00000272606.1	RP11-554J4.1	3.88	0.000159	0.0468	0.57	0.3	Vitiligo;	chr2:55599979	chr2:55617909~55618373:+
PCPG	cis	rs10936632	0.728	rs10804840	ENSG00000242578.1	RP11-469J4.3	-3.88	0.000159	0.0468	-0.31	-0.3	Prostate cancer;	chr3:170354019	chr3:170410512~170418615:+
PCPG	cis	rs2361718	0.5	rs8068856	ENSG00000279259.1	RP11-334C17.3	3.88	0.000159	0.0468	0.28	0.3	Yeast infection;	chr17:80126932	chr17:80147250~80148596:+
PCPG	cis	rs2797160	0.651	rs1268092	ENSG00000237742.5	RP11-624M8.1	-3.88	0.000159	0.0468	-0.32	-0.3	Endometrial cancer;	chr6:125707897	chr6:125578558~125749190:-
PCPG	cis	rs2797160	0.651	rs6569436	ENSG00000237742.5	RP11-624M8.1	3.88	0.000159	0.0468	0.32	0.3	Endometrial cancer;	chr6:125710958	chr6:125578558~125749190:-
PCPG	cis	rs867371	0.896	rs8033831	ENSG00000228141.5	AC105339.1	-3.88	0.000159	0.0468	-0.35	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82710471~82714026:-
PCPG	cis	rs8098244	0.66	rs12970745	ENSG00000265752.2	RP11-403A21.1	3.88	0.000159	0.0468	0.35	0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23908142	chr18:23957754~23982556:-
PCPG	cis	rs13392177	0.684	rs11695527	ENSG00000273466.1	RP11-548H3.1	3.88	0.000159	0.0468	0.17	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218633256~218634014:-
PCPG	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	3.88	0.000159	0.0469	0.31	0.3	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
PCPG	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-3.88	0.000159	0.0469	-0.34	-0.3	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
PCPG	cis	rs17684571	0.687	rs35461301	ENSG00000231441.1	RP11-472M19.2	3.88	0.000159	0.0469	0.52	0.3	Schizophrenia;	chr6:56832577	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.687	rs35851452	ENSG00000231441.1	RP11-472M19.2	3.88	0.000159	0.0469	0.52	0.3	Schizophrenia;	chr6:56832602	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.751	rs35073881	ENSG00000231441.1	RP11-472M19.2	3.88	0.000159	0.0469	0.52	0.3	Schizophrenia;	chr6:56842410	chr6:56844002~56864078:+
PCPG	cis	rs17684571	0.7	rs1610156	ENSG00000231441.1	RP11-472M19.2	3.88	0.000159	0.0469	0.52	0.3	Schizophrenia;	chr6:56844274	chr6:56844002~56864078:+
PCPG	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	3.88	0.000159	0.0469	0.42	0.3	Height;	chr6:109427303	chr6:109382795~109383666:+
PCPG	cis	rs6445975	0.667	rs6772264	ENSG00000272360.1	RP11-359I18.5	-3.88	0.000159	0.0469	-0.39	-0.3	Systemic lupus erythematosus;	chr3:58247214	chr3:58490830~58491291:-
PCPG	cis	rs440932	0.798	rs330942	ENSG00000173295.6	FAM86B3P	-3.87	0.000159	0.0469	-0.35	-0.3	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8228595~8244865:+
PCPG	cis	rs2836974	0.899	rs35774464	ENSG00000252915.1	Y_RNA	-3.87	0.000159	0.0469	-0.32	-0.3	Cognitive function;	chr21:39208243	chr21:39344537~39344628:+
PCPG	cis	rs9880211	1	rs6774964	ENSG00000273486.1	RP11-731C17.2	3.87	0.000159	0.047	0.4	0.3	Height;Body mass index;	chr3:136556740	chr3:136837338~136839021:-
PCPG	cis	rs9880211	1	rs6775314	ENSG00000273486.1	RP11-731C17.2	3.87	0.000159	0.047	0.4	0.3	Height;Body mass index;	chr3:136557106	chr3:136837338~136839021:-
PCPG	cis	rs1894633	0.574	rs10489286	ENSG00000229785.1	SLC25A38P1	3.87	0.000159	0.047	0.41	0.3	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:172343779	chr1:172748560~172749502:+
PCPG	cis	rs448720	0.806	rs4306451	ENSG00000260657.2	RP11-315D16.4	-3.87	0.000159	0.047	-0.37	-0.3	Cognitive performance;	chr15:67865543	chr15:68267792~68277994:-
PCPG	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	3.87	0.000159	0.047	0.34	0.3	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	3.87	0.000159	0.047	0.34	0.3	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	3.87	0.000159	0.047	0.34	0.3	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	3.87	0.000159	0.047	0.34	0.3	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
PCPG	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	3.87	0.000159	0.047	0.34	0.3	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
PCPG	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-3.87	0.000159	0.047	-0.34	-0.3	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
PCPG	cis	rs6504340	0.739	rs872760	ENSG00000279036.1	RP11-81K2.2	-3.87	0.000159	0.047	-0.51	-0.3	Primary tooth development (number of teeth);	chr17:48591589	chr17:49494223~49497800:-
PCPG	cis	rs4835473	0.708	rs7655939	ENSG00000251600.4	RP11-673E1.1	3.87	0.000159	0.047	0.35	0.3	Immature fraction of reticulocytes;	chr4:143956889	chr4:143912331~143982454:+
PCPG	cis	rs10751667	0.58	rs11246363	ENSG00000255142.1	AP006621.6	3.87	0.000159	0.047	0.29	0.3	Alzheimer's disease (late onset);	chr11:971667	chr11:781645~782105:+
PCPG	cis	rs17826219	0.5	rs117560728	ENSG00000266490.1	CTD-2349P21.9	3.87	0.000159	0.047	0.49	0.3	Body mass index;	chr17:30743920	chr17:30792372~30792833:+
PCPG	cis	rs7615952	0.932	rs6438948	ENSG00000250012.1	RP11-124N2.1	3.87	0.00016	0.047	0.36	0.3	Blood pressure (smoking interaction);	chr3:125931202	chr3:126084220~126095349:+
PCPG	cis	rs9299346	0.536	rs12380816	ENSG00000225376.4	TMEM246-AS1	3.87	0.00016	0.047	0.46	0.3	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101651388	chr9:101468439~101481502:+
PCPG	cis	rs1062177	1	rs12653926	ENSG00000249035.5	CTB-113P19.1	-3.87	0.00016	0.047	-0.38	-0.3	Preschool internalizing problems;	chr5:151870687	chr5:151676945~151724782:+
PCPG	cis	rs228614	0.51	rs223378	ENSG00000230069.3	LRRC37A15P	-3.87	0.00016	0.0471	-0.29	-0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102727274~102730721:-
PCPG	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	3.87	0.00016	0.0471	0.31	0.3	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
PCPG	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	3.87	0.00016	0.0471	0.31	0.3	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
PCPG	cis	rs2243480	1	rs12698509	ENSG00000251451.1	GS1-124K5.6	3.87	0.00016	0.0471	0.55	0.3	Diabetic kidney disease;	chr7:65953889	chr7:66407288~66409239:-
PCPG	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-3.87	0.00016	0.0471	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
PCPG	cis	rs7829975	0.714	rs11777085	ENSG00000254235.4	RP11-115J16.1	3.87	0.00016	0.0471	0.37	0.3	Mood instability;	chr8:8814919	chr8:9249417~9413714:+
PCPG	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	3.87	0.00016	0.0471	0.4	0.3	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
PCPG	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	3.87	0.00016	0.0471	0.36	0.3	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
PCPG	cis	rs13392177	0.637	rs61041183	ENSG00000273466.1	RP11-548H3.1	3.87	0.00016	0.0471	0.17	0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218633256~218634014:-
PCPG	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-3.87	0.00016	0.0471	-0.34	-0.3	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
PCPG	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-3.87	0.00016	0.0471	-0.36	-0.3	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
PCPG	cis	rs12681963	0.688	rs73242337	ENSG00000272375.1	RP11-51J9.6	3.87	0.00016	0.0472	0.46	0.3	Migraine;	chr8:30200526	chr8:30197404~30198048:+
PCPG	cis	rs12681963	0.688	rs73242338	ENSG00000272375.1	RP11-51J9.6	3.87	0.00016	0.0472	0.46	0.3	Migraine;	chr8:30200574	chr8:30197404~30198048:+
PCPG	cis	rs6456042	1	rs3099300	ENSG00000231297.3	RP11-459F1.2	3.87	0.00016	0.0472	0.33	0.3	Asthma;	chr6:166113011	chr6:166099665~166113273:+
PCPG	cis	rs2221593	0.502	rs2456812	ENSG00000237980.1	RP11-338C15.3	3.87	0.00016	0.0472	0.4	0.3	Leprosy;	chr1:212678671	chr1:212653999~212665434:-
PCPG	cis	rs7772486	0.79	rs2814879	ENSG00000270638.1	RP3-466P17.1	3.87	0.00016	0.0472	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145735570~145737218:+
PCPG	cis	rs1823874	0.584	rs1823872	ENSG00000182397.13	DNM1P46	-3.87	0.00016	0.0472	-0.4	-0.3	IgG glycosylation;	chr15:99839246	chr15:99790156~99806927:-
PCPG	cis	rs804280	0.509	rs9886639	ENSG00000184608.7	FAM167A-AS1	3.87	0.00016	0.0472	0.43	0.3	Myopia (pathological);	chr8:11927020	chr8:11368402~11438658:+
PCPG	cis	rs1003719	0.751	rs55740803	ENSG00000228677.1	TTC3-AS1	-3.87	0.00016	0.0472	-0.37	-0.3	Eye color traits;	chr21:37170459	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.751	rs56268364	ENSG00000228677.1	TTC3-AS1	-3.87	0.00016	0.0472	-0.37	-0.3	Eye color traits;	chr21:37170463	chr21:37187666~37193926:-
PCPG	cis	rs11148252	0.716	rs2760772	ENSG00000278238.1	RP11-245D16.4	-3.87	0.00016	0.0472	-0.27	-0.3	Lewy body disease;	chr13:52206238	chr13:52454775~52455331:-
PCPG	cis	rs7444	0.941	rs9619386	ENSG00000211645.2	IGLV1-50	3.87	0.00016	0.0472	0.37	0.3	Systemic lupus erythematosus;	chr22:21625649	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs5754426	ENSG00000211645.2	IGLV1-50	3.87	0.00016	0.0472	0.37	0.3	Systemic lupus erythematosus;	chr22:21626349	chr22:22327300~22327814:+
PCPG	cis	rs7444	0.941	rs4821130	ENSG00000211645.2	IGLV1-50	3.87	0.00016	0.0472	0.37	0.3	Systemic lupus erythematosus;	chr22:21626605	chr22:22327300~22327814:+
PCPG	cis	rs964611	0.872	rs2279366	ENSG00000259488.2	RP11-154J22.1	-3.87	0.00016	0.0472	-0.29	-0.3	Metabolite levels (Pyroglutamine);	chr15:48249830	chr15:48312353~48331856:-
PCPG	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	3.87	0.00016	0.0472	0.38	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
PCPG	cis	rs6121246	0.909	rs4518038	ENSG00000230613.1	HM13-AS1	3.87	0.00016	0.0472	0.46	0.3	Mean corpuscular hemoglobin;	chr20:31831248	chr20:31567707~31573263:-
PCPG	cis	rs240993	0.812	rs2025269	ENSG00000271789.1	RP5-1112D6.7	-3.87	0.00016	0.0472	-0.39	-0.3	Inflammatory skin disease;Psoriasis;	chr6:111489237	chr6:111297126~111298510:+
PCPG	cis	rs17772222	0.876	rs58655091	ENSG00000222990.1	RNU4-22P	3.87	0.000161	0.0472	0.4	0.3	Coronary artery calcification;	chr14:88748567	chr14:88513498~88513663:+
PCPG	cis	rs17772222	0.917	rs1956406	ENSG00000222990.1	RNU4-22P	3.87	0.000161	0.0472	0.4	0.3	Coronary artery calcification;	chr14:88749711	chr14:88513498~88513663:+
PCPG	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000161	0.0473	-0.33	-0.3	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
PCPG	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000161	0.0473	-0.33	-0.3	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
PCPG	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000161	0.0473	-0.33	-0.3	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
PCPG	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000161	0.0473	-0.33	-0.3	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
PCPG	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000161	0.0473	-0.33	-0.3	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
PCPG	cis	rs7772486	0.806	rs2265477	ENSG00000270638.1	RP3-466P17.1	3.87	0.000161	0.0473	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145735570~145737218:+
PCPG	cis	rs17039212	0.85	rs1914787	ENSG00000234253.1	RPL7P13	3.87	0.000161	0.0473	0.43	0.3	Systemic lupus erythematosus;	chr2:49697024	chr2:49878623~49879363:+
PCPG	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-3.87	0.000161	0.0473	-0.44	-0.3	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
PCPG	cis	rs763014	0.966	rs4247097	ENSG00000262528.2	LA16c-349E10.1	3.87	0.000161	0.0473	0.36	0.3	Height;	chr16:604224	chr16:654611~656194:-
PCPG	cis	rs6456042	1	rs6456040	ENSG00000231297.3	RP11-459F1.2	3.87	0.000161	0.0473	0.33	0.3	Asthma;	chr6:166121148	chr6:166099665~166113273:+
PCPG	cis	rs13315649	0.639	rs73196928	ENSG00000242551.2	POU5F1P6	-3.87	0.000161	0.0473	-0.41	-0.3	Sum eosinophil basophil counts;	chr3:128670583	chr3:128674735~128677005:-
PCPG	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-3.87	0.000161	0.0473	-0.33	-0.3	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
PCPG	cis	rs795484	0.856	rs1699160	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000161	0.0473	-0.35	-0.3	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118318531	chr12:118430147~118430699:+
PCPG	cis	rs1023500	0.551	rs2854837	ENSG00000226450.2	CYP2D8P	3.87	0.000161	0.0473	0.31	0.3	Schizophrenia;	chr22:42062477	chr22:42149886~42155001:-
PCPG	cis	rs7714584	1	rs1428555	ENSG00000271795.1	CTC-251D13.1	3.87	0.000161	0.0473	0.53	0.3	Crohn's disease;	chr5:150877829	chr5:151509453~151512769:+
PCPG	cis	rs9393813	0.506	rs13201985	ENSG00000271755.1	RP1-153G14.4	3.87	0.000161	0.0473	0.38	0.3	Bipolar disorder;	chr6:27465854	chr6:27404010~27406964:-
PCPG	cis	rs9393813	0.528	rs13207497	ENSG00000271755.1	RP1-153G14.4	3.87	0.000161	0.0473	0.38	0.3	Bipolar disorder;	chr6:27489601	chr6:27404010~27406964:-
PCPG	cis	rs2251666	0.514	rs12444761	ENSG00000267077.1	RP11-127I20.5	3.87	0.000161	0.0473	0.62	0.3	Cancer;	chr16:4877284	chr16:4795265~4796532:-
PCPG	cis	rs901683	0.85	rs74500471	ENSG00000230869.1	CTGLF10P	-3.87	0.000161	0.0473	-0.8	-0.3	Mean corpuscular volume;Red blood cell traits;	chr10:45536287	chr10:45678692~45700532:+
PCPG	cis	rs901683	0.85	rs80021398	ENSG00000230869.1	CTGLF10P	-3.87	0.000161	0.0473	-0.8	-0.3	Mean corpuscular volume;Red blood cell traits;	chr10:45543935	chr10:45678692~45700532:+
PCPG	cis	rs1823874	0.72	rs2003037	ENSG00000254744.3	CTD-3076O17.1	-3.87	0.000161	0.0473	-0.39	-0.3	IgG glycosylation;	chr15:99821757	chr15:99970215~99974010:+
PCPG	cis	rs1865760	0.516	rs9379818	ENSG00000272810.1	U91328.22	-3.87	0.000161	0.0473	-0.3	-0.3	Height;	chr6:26022978	chr6:26013241~26013757:+
PCPG	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	3.87	0.000161	0.0473	0.38	0.3	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
PCPG	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-3.87	0.000161	0.0473	-0.38	-0.3	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
PCPG	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	3.87	0.000161	0.0473	0.36	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
PCPG	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	3.87	0.000161	0.0473	0.42	0.3	Height;	chr6:109436760	chr6:109382795~109383666:+
PCPG	cis	rs1552244	0.882	rs28366039	ENSG00000180385.7	EMC3-AS1	3.87	0.000161	0.0473	0.38	0.3	Alzheimer's disease;	chr3:9987304	chr3:9986893~10006990:+
PCPG	cis	rs7819412	0.522	rs4841497	ENSG00000269954.1	RP11-148O21.6	-3.87	0.000161	0.0474	-0.36	-0.3	Triglycerides;	chr8:11127630	chr8:11552488~11552991:-
PCPG	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	3.87	0.000161	0.0474	0.36	0.3	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
PCPG	cis	rs7402982	0.525	rs11247361	ENSG00000278022.1	RP11-35O15.2	3.87	0.000161	0.0474	0.31	0.3	Birth weight;	chr15:98664163	chr15:98660210~98660668:+
PCPG	cis	rs1129187	0.755	rs3818554	ENSG00000272223.1	RP1-20C7.6	3.87	0.000161	0.0474	0.31	0.3	Alzheimer's disease in APOE e4+ carriers;	chr6:42966882	chr6:43033897~43034405:-
PCPG	cis	rs75686122	0.892	rs76161982	ENSG00000271830.1	RP11-1C8.7	3.87	0.000161	0.0474	0.53	0.3	Cocaine dependence;	chr8:103647517	chr8:103481266~103481619:-
PCPG	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	3.87	0.000161	0.0474	0.44	0.3	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
PCPG	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	3.87	0.000161	0.0474	0.63	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
PCPG	cis	rs9717605	1	rs73046018	ENSG00000226445.1	XXyac-YX65C7_A.2	3.87	0.000161	0.0474	0.4	0.3	Left atrial antero-posterior diameter;	chr6:169247495	chr6:169213254~169239565:+
PCPG	cis	rs9717605	1	rs73046021	ENSG00000226445.1	XXyac-YX65C7_A.2	3.87	0.000161	0.0474	0.4	0.3	Left atrial antero-posterior diameter;	chr6:169247514	chr6:169213254~169239565:+
PCPG	cis	rs875971	0.706	rs1643374	ENSG00000273142.1	RP11-458F8.4	-3.87	0.000161	0.0474	-0.28	-0.3	Aortic root size;	chr7:66407695	chr7:66902857~66906297:+
PCPG	cis	rs2733954	1	rs2733955	ENSG00000179219.5	LINC00311	-3.87	0.000161	0.0474	-0.42	-0.3	Leprosy;	chr16:85802685	chr16:85282958~85285963:+
PCPG	cis	rs9322193	0.923	rs2184370	ENSG00000223701.3	RAET1E-AS1	3.87	0.000161	0.0474	0.39	0.3	Lung cancer;	chr6:149843242	chr6:149884431~149919508:+
PCPG	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	3.87	0.000161	0.0474	0.33	0.3	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
PCPG	cis	rs896854	0.654	rs13274945	ENSG00000272509.1	RP11-347C18.5	3.87	0.000161	0.0474	0.3	0.3	Type 2 diabetes;	chr8:94974398	chr8:94884609~94885070:+
PCPG	cis	rs9840812	0.645	rs13068119	ENSG00000239213.4	NCK1-AS1	-3.87	0.000161	0.0474	-0.36	-0.3	Fibrinogen levels;	chr3:136487527	chr3:136841726~136862054:-
PCPG	cis	rs6121246	0.821	rs115585940	ENSG00000230613.1	HM13-AS1	3.87	0.000161	0.0474	0.45	0.3	Mean corpuscular hemoglobin;	chr20:31730099	chr20:31567707~31573263:-
PCPG	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-3.87	0.000162	0.0475	-0.43	-0.3	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
PCPG	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	3.87	0.000162	0.0475	0.44	0.3	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
PCPG	cis	rs11018874	0.597	rs10765243	ENSG00000254916.1	RP11-529A4.12	-3.87	0.000162	0.0475	-0.37	-0.3	White blood cell types;	chr11:90121950	chr11:90051837~90053736:-
PCPG	cis	rs1150668	0.799	rs7206	ENSG00000176933.5	TOB2P1	-3.87	0.000162	0.0475	-0.33	-0.3	Pubertal anthropometrics;	chr6:28233360	chr6:28217643~28218634:-
PCPG	cis	rs896854	0.738	rs2515226	ENSG00000272509.1	RP11-347C18.5	-3.87	0.000162	0.0475	-0.29	-0.3	Type 2 diabetes;	chr8:94953515	chr8:94884609~94885070:+
PCPG	cis	rs896854	0.714	rs572547	ENSG00000272509.1	RP11-347C18.5	-3.87	0.000162	0.0475	-0.29	-0.3	Type 2 diabetes;	chr8:94954058	chr8:94884609~94885070:+
PCPG	cis	rs2735413	0.563	rs7192814	ENSG00000276007.1	RP11-358L22.3	3.87	0.000162	0.0475	0.29	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78007475	chr16:78123243~78124332:+
PCPG	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	3.87	0.000162	0.0475	0.37	0.3	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
PCPG	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	3.87	0.000162	0.0475	0.38	0.3	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
PCPG	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	3.87	0.000162	0.0475	0.38	0.3	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
PCPG	cis	rs10200850	0.881	rs950225	ENSG00000265215.1	MIR4269	3.87	0.000162	0.0475	0.51	0.3	Perioperative myocardial infarction in coronary artery bypass surgery;	chr2:239336549	chr2:239305462~239305545:+
PCPG	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-3.87	0.000162	0.0475	-0.37	-0.3	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
PCPG	cis	rs720475	0.732	rs7784282	ENSG00000170356.8	OR2A20P	3.87	0.000162	0.0475	0.43	0.3	Breast cancer;	chr7:144431561	chr7:144250045~144252957:-
PCPG	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	3.87	0.000162	0.0476	0.32	0.3	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
PCPG	cis	rs2380220	0.51	rs9387562	ENSG00000261366.1	MANEA-AS1	-3.87	0.000162	0.0476	-0.35	-0.3	Behavioural disinhibition (generation interaction);	chr6:95609130	chr6:95575183~95577450:-
PCPG	cis	rs17152411	0.793	rs12569669	ENSG00000278831.1	RP11-12J10.4	3.87	0.000162	0.0476	0.44	0.3	Height;	chr10:124904102	chr10:124623353~124624079:+
PCPG	cis	rs2921073	0.51	rs2976944	ENSG00000173295.6	FAM86B3P	-3.87	0.000162	0.0476	-0.35	-0.3	Parkinson's disease;	chr8:8413404	chr8:8228595~8244865:+
PCPG	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	3.87	0.000162	0.0476	0.32	0.3	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
PCPG	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	3.87	0.000162	0.0476	0.37	0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
PCPG	cis	rs7402241	0.764	rs74710671	ENSG00000207063.1	SNORD116-1	3.87	0.000162	0.0476	0.65	0.3	Residual cognition;	chr15:25535232	chr15:25051477~25051571:+
PCPG	cis	rs7402241	0.764	rs78005005	ENSG00000207063.1	SNORD116-1	3.87	0.000162	0.0476	0.65	0.3	Residual cognition;	chr15:25536284	chr15:25051477~25051571:+
PCPG	cis	rs7402241	0.764	rs76452525	ENSG00000207063.1	SNORD116-1	3.87	0.000162	0.0476	0.65	0.3	Residual cognition;	chr15:25542539	chr15:25051477~25051571:+
PCPG	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	3.87	0.000162	0.0476	0.7	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
PCPG	cis	rs2243480	1	rs1404147	ENSG00000230189.5	GS1-124K5.2	3.87	0.000162	0.0476	0.45	0.3	Diabetic kidney disease;	chr7:65799537	chr7:66409143~66490059:-
PCPG	cis	rs11148252	0.875	rs9526913	ENSG00000198384.8	TPTE2P3	-3.87	0.000162	0.0476	-0.37	-0.3	Lewy body disease;	chr13:52401702	chr13:52522632~52586906:+
PCPG	cis	rs4376189	0.558	rs6820044	ENSG00000207497.1	Y_RNA	3.87	0.000162	0.0476	0.44	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185715174	chr4:185709873~185709967:-
PCPG	cis	rs4376189	0.614	rs6825114	ENSG00000207497.1	Y_RNA	3.87	0.000162	0.0476	0.44	0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185715410	chr4:185709873~185709967:-
PCPG	cis	rs4376189	0.614	rs6825669	ENSG00000207497.1	Y_RNA	-3.87	0.000162	0.0476	-0.44	-0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185715651	chr4:185709873~185709967:-
PCPG	cis	rs1865760	0.566	rs9348706	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26065253	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.622	rs9295685	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26071497	chr6:26013241~26013757:+
PCPG	cis	rs12216125	0.554	rs6942196	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Iron status biomarkers;	chr6:26072576	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs1539183	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26074823	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs9295686	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26081755	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.532	rs9295687	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26082482	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs4529296	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26082907	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs1971509	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26085549	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.532	rs2006736	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26085789	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs1800702	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26086235	chr6:26013241~26013757:+
PCPG	cis	rs1865760	0.566	rs2794720	ENSG00000272810.1	U91328.22	-3.87	0.000162	0.0476	-0.3	-0.3	Height;	chr6:26086974	chr6:26013241~26013757:+
PCPG	cis	rs7246657	0.722	rs12974225	ENSG00000276846.1	CTD-3220F14.3	-3.87	0.000162	0.0476	-0.43	-0.3	Coronary artery calcification;	chr19:37749458	chr19:37314868~37315620:-
PCPG	cis	rs10865541	0.87	rs6548161	ENSG00000225234.1	TRAPPC12-AS1	-3.87	0.000162	0.0477	-0.3	-0.3	Obesity-related traits;	chr2:3420579	chr2:3481242~3482409:-
PCPG	cis	rs867371	0.502	rs3759800	ENSG00000228141.5	AC105339.1	3.87	0.000163	0.0477	0.37	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82710471~82714026:-
PCPG	cis	rs756699	1	rs168649	ENSG00000271737.1	CTB-113I20.2	-3.87	0.000163	0.0477	-0.31	-0.3	Multiple sclerosis;	chr5:134109229	chr5:134005147~134005562:+
PCPG	cis	rs756699	1	rs244948	ENSG00000271737.1	CTB-113I20.2	-3.87	0.000163	0.0477	-0.31	-0.3	Multiple sclerosis;	chr5:134109370	chr5:134005147~134005562:+
PCPG	cis	rs756699	1	rs244950	ENSG00000271737.1	CTB-113I20.2	-3.87	0.000163	0.0477	-0.31	-0.3	Multiple sclerosis;	chr5:134109937	chr5:134005147~134005562:+
PCPG	cis	rs756699	0.915	rs244951	ENSG00000271737.1	CTB-113I20.2	-3.87	0.000163	0.0477	-0.31	-0.3	Multiple sclerosis;	chr5:134110017	chr5:134005147~134005562:+
PCPG	cis	rs11671005	0.779	rs11670125	ENSG00000269600.1	AC016629.3	-3.87	0.000163	0.0477	-0.48	-0.3	Mean platelet volume;	chr19:58476023	chr19:58593896~58599355:-
PCPG	cis	rs17214007	0.597	rs4781677	ENSG00000263335.1	AF001548.5	-3.87	0.000163	0.0477	-0.4	-0.3	Cognitive function;	chr16:15636388	chr16:15726674~15732993:+
PCPG	cis	rs763014	0.932	rs2384972	ENSG00000262528.2	LA16c-349E10.1	3.87	0.000163	0.0477	0.35	0.3	Height;	chr16:624424	chr16:654611~656194:-
PCPG	cis	rs7824557	0.527	rs2572369	ENSG00000255495.1	AC145124.2	-3.87	0.000163	0.0477	-0.29	-0.3	Retinal vascular caliber;	chr8:11381088	chr8:12194467~12196280:+
PCPG	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-3.87	0.000163	0.0478	-0.37	-0.3	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
PCPG	cis	rs1048886	0.938	rs55968813	ENSG00000271967.1	RP11-134K13.4	-3.87	0.000163	0.0478	-0.38	-0.3	Type 2 diabetes;	chr6:70514521	chr6:70596438~70596980:+
PCPG	cis	rs6121246	1	rs6121246	ENSG00000230613.1	HM13-AS1	3.87	0.000163	0.0478	0.43	0.3	Mean corpuscular hemoglobin;	chr20:31845549	chr20:31567707~31573263:-
PCPG	cis	rs11671005	0.779	rs731259	ENSG00000269600.1	AC016629.3	-3.87	0.000163	0.0478	-0.48	-0.3	Mean platelet volume;	chr19:58478057	chr19:58593896~58599355:-
PCPG	cis	rs17152411	1	rs1065301	ENSG00000278831.1	RP11-12J10.4	3.87	0.000163	0.0478	0.44	0.3	Height;	chr10:124927469	chr10:124623353~124624079:+
PCPG	cis	rs2998286	0.678	rs332114	ENSG00000254635.4	WAC-AS1	3.87	0.000163	0.0478	0.35	0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28636772	chr10:28522652~28532743:-
PCPG	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	3.87	0.000163	0.0478	0.36	0.3	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
PCPG	cis	rs9393777	0.778	rs66841633	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000163	0.0478	-0.63	-0.3	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28115628~28116551:+
PCPG	cis	rs13315649	0.562	rs6439137	ENSG00000242551.2	POU5F1P6	-3.87	0.000163	0.0479	-0.42	-0.3	Sum eosinophil basophil counts;	chr3:128668107	chr3:128674735~128677005:-
PCPG	cis	rs394563	0.559	rs13219868	ENSG00000231760.4	RP11-350J20.5	-3.87	0.000163	0.0479	-0.38	-0.3	Dupuytren's disease;	chr6:149365382	chr6:149796151~149826294:-
PCPG	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-3.87	0.000163	0.0479	-0.38	-0.3	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
PCPG	cis	rs34779708	0.733	rs60616028	ENSG00000230534.5	RP11-297A16.2	3.87	0.000163	0.0479	0.41	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35254874	chr10:35098006~35127020:-
PCPG	cis	rs17152411	0.901	rs7098050	ENSG00000278831.1	RP11-12J10.4	3.87	0.000163	0.0479	0.43	0.3	Height;	chr10:124968446	chr10:124623353~124624079:+
PCPG	cis	rs2898290	0.622	rs1478890	ENSG00000254774.1	RP11-148O21.3	-3.87	0.000163	0.0479	-0.32	-0.3	Systolic blood pressure;	chr8:11498093	chr8:11553224~11554207:-
PCPG	cis	rs889398	0.802	rs2291959	ENSG00000196696.11	PDXDC2P	-3.87	0.000163	0.0479	-0.24	-0.3	Body mass index;	chr16:69840089	chr16:69976297~70065948:-
PCPG	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	3.87	0.000163	0.0479	0.43	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
PCPG	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	3.87	0.000163	0.0479	0.43	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
PCPG	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	3.87	0.000163	0.0479	0.43	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
PCPG	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	3.87	0.000163	0.0479	0.43	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
PCPG	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-3.87	0.000164	0.0479	-0.25	-0.3	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
PCPG	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-3.87	0.000164	0.0479	-0.25	-0.3	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
PCPG	cis	rs6504622	0.755	rs11079750	ENSG00000263142.4	LRRC37A17P	-3.87	0.000164	0.0479	-0.24	-0.3	Orofacial clefts;	chr17:47072149	chr17:46978481~47054569:+
PCPG	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	3.87	0.000164	0.0479	0.44	0.3	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
PCPG	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-3.87	0.000164	0.0479	-0.38	-0.3	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
PCPG	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-3.87	0.000164	0.0479	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-3.87	0.000164	0.0479	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-3.87	0.000164	0.0479	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
PCPG	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-3.87	0.000164	0.0479	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
PCPG	cis	rs459482	0.504	rs467773	ENSG00000227698.1	AP001619.2	-3.87	0.000164	0.0479	-0.32	-0.3	IgG glycosylation;	chr21:41446179	chr21:41874756~41877613:-
PCPG	cis	rs459482	0.504	rs363882	ENSG00000227698.1	AP001619.2	-3.87	0.000164	0.0479	-0.32	-0.3	IgG glycosylation;	chr21:41446346	chr21:41874756~41877613:-
PCPG	cis	rs7032482	1	rs7032482	ENSG00000225901.1	MTND2P9	-3.87	0.000164	0.048	-0.42	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr9:81419260	chr9:80565032~80565962:-
PCPG	cis	rs58785573	0.624	rs337605	ENSG00000231160.8	KLF3-AS1	-3.87	0.000164	0.048	-0.25	-0.3	Lymphocyte percentage of white cells;	chr4:38646132	chr4:38612701~38664883:-
PCPG	cis	rs720064	0.555	rs11873358	ENSG00000265752.2	RP11-403A21.1	3.87	0.000164	0.048	0.34	0.3	Strep throat;	chr18:23951942	chr18:23957754~23982556:-
PCPG	cis	rs9303029	1	rs72859125	ENSG00000279744.1	RP13-20L14.10	-3.87	0.000164	0.0481	-0.39	-0.3	Protein quantitative trait loci;	chr17:82470099	chr17:82462601~82464255:+
PCPG	cis	rs8098244	0.638	rs9948008	ENSG00000265752.2	RP11-403A21.1	3.87	0.000164	0.0481	0.35	0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23906049	chr18:23957754~23982556:-
PCPG	cis	rs8098244	0.617	rs12969388	ENSG00000265752.2	RP11-403A21.1	3.87	0.000164	0.0481	0.35	0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23907089	chr18:23957754~23982556:-
PCPG	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	3.87	0.000164	0.0481	0.3	0.3	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	3.87	0.000164	0.0481	0.3	0.3	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
PCPG	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	3.87	0.000164	0.0481	0.3	0.3	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
PCPG	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	3.87	0.000164	0.0481	0.43	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
PCPG	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	3.87	0.000164	0.0481	0.35	0.3	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
PCPG	cis	rs3738814	0.529	rs761422	ENSG00000186715.9	MST1L	-3.87	0.000164	0.0481	-0.32	-0.3	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Height;	chr1:16975285	chr1:16754910~16770237:-
PCPG	cis	rs6981523	0.553	rs11783890	ENSG00000255020.1	AF131216.5	-3.87	0.000165	0.0481	-0.43	-0.3	Neuroticism;	chr8:11198879	chr8:11345748~11347502:-
PCPG	cis	rs6921919	1	rs35875412	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000165	0.0481	-0.48	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28115628~28116551:+
PCPG	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	3.87	0.000165	0.0481	0.31	0.3	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
PCPG	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	3.87	0.000165	0.0481	0.31	0.3	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
PCPG	cis	rs875971	0.862	rs6460302	ENSG00000235475.1	LINC01372	3.87	0.000165	0.0482	0.3	0.3	Aortic root size;	chr7:66495270	chr7:67335976~67340024:+
PCPG	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	3.87	0.000165	0.0482	0.36	0.3	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
PCPG	cis	rs394563	0.591	rs237019	ENSG00000216906.2	RP11-350J20.9	3.87	0.000165	0.0482	0.29	0.3	Dupuytren's disease;	chr6:149405928	chr6:149904243~149906418:+
PCPG	cis	rs9299346	0.536	rs10989597	ENSG00000225376.4	TMEM246-AS1	3.87	0.000165	0.0482	0.48	0.3	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101703341	chr9:101468439~101481502:+
PCPG	cis	rs9299346	0.536	rs10989598	ENSG00000225376.4	TMEM246-AS1	3.87	0.000165	0.0482	0.48	0.3	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;	chr9:101703632	chr9:101468439~101481502:+
PCPG	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	3.87	0.000165	0.0482	0.37	0.3	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
PCPG	cis	rs243505	1	rs243510	ENSG00000133624.12	ZNF767P	3.87	0.000165	0.0482	0.26	0.3	Inflammatory bowel disease;Crohn's disease;	chr7:148735442	chr7:149547154~149624752:-
PCPG	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	3.87	0.000165	0.0482	0.38	0.3	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
PCPG	cis	rs2811415	0.627	rs4602340	ENSG00000242551.2	POU5F1P6	3.87	0.000165	0.0482	0.45	0.3	Lung function (FEV1/FVC);	chr3:128014099	chr3:128674735~128677005:-
PCPG	cis	rs7824557	0.527	rs2572449	ENSG00000255495.1	AC145124.2	3.86	0.000165	0.0482	0.29	0.3	Retinal vascular caliber;	chr8:11381628	chr8:12194467~12196280:+
PCPG	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	3.86	0.000165	0.0482	0.43	0.3	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
PCPG	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	3.86	0.000165	0.0483	0.37	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
PCPG	cis	rs12681963	0.748	rs10088714	ENSG00000248159.1	HSPA8P11	-3.86	0.000165	0.0483	-0.46	-0.3	Migraine;	chr8:30034635	chr8:30237382~30240997:+
PCPG	cis	rs62184315	0.575	rs256546	ENSG00000253559.1	OSGEPL1-AS1	-3.86	0.000165	0.0483	-0.33	-0.3	Alcohol dependence (age at onset);	chr2:189886437	chr2:189762704~189765556:+
PCPG	cis	rs7176527	0.848	rs3748374	ENSG00000229212.6	RP11-561C5.4	3.86	0.000165	0.0483	0.46	0.3	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85205440~85234795:-
PCPG	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-3.86	0.000165	0.0483	-0.34	-0.3	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
PCPG	cis	rs2052670	0.892	rs1351858	ENSG00000232613.5	AC007386.4	3.86	0.000165	0.0483	0.42	0.3	Waist circumference adjusted for body mass index;	chr2:66025841	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.964	rs1569278	ENSG00000232613.5	AC007386.4	3.86	0.000165	0.0483	0.42	0.3	Waist circumference adjusted for body mass index;	chr2:66026089	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.964	rs2627851	ENSG00000232613.5	AC007386.4	3.86	0.000165	0.0483	0.42	0.3	Waist circumference adjusted for body mass index;	chr2:66026993	chr2:65030727~65053017:+
PCPG	cis	rs2052670	0.964	rs12623197	ENSG00000232613.5	AC007386.4	3.86	0.000165	0.0483	0.42	0.3	Waist circumference adjusted for body mass index;	chr2:66027706	chr2:65030727~65053017:+
PCPG	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	3.86	0.000166	0.0484	0.4	0.3	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
PCPG	cis	rs6901152	0.93	rs4896644	ENSG00000217648.1	RP1-95L4.4	-3.86	0.000166	0.0484	-0.36	-0.3	Acute lymphoblastic leukemia (childhood);	chr6:143348901	chr6:143342246~143343383:+
PCPG	cis	rs896854	0.654	rs10104909	ENSG00000272509.1	RP11-347C18.5	3.86	0.000166	0.0484	0.3	0.3	Type 2 diabetes;	chr8:94965745	chr8:94884609~94885070:+
PCPG	cis	rs6445967	0.554	rs4364180	ENSG00000273493.1	RP11-80H18.4	-3.86	0.000166	0.0484	-0.33	-0.3	Platelet count;	chr3:58466912	chr3:58329965~58330118:+
PCPG	cis	rs6445967	0.53	rs4273385	ENSG00000273493.1	RP11-80H18.4	-3.86	0.000166	0.0484	-0.33	-0.3	Platelet count;	chr3:58467140	chr3:58329965~58330118:+
PCPG	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-3.86	0.000166	0.0484	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
PCPG	cis	rs3758911	0.828	rs10890697	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000166	0.0484	-0.41	-0.3	Coronary artery disease;	chr11:107307915	chr11:107176286~107177530:+
PCPG	cis	rs711830	1	rs2113559	ENSG00000226363.3	HAGLROS	-3.86	0.000166	0.0484	-0.34	-0.3	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166371	chr2:176177717~176179008:+
PCPG	cis	rs711830	0.931	rs717852	ENSG00000226363.3	HAGLROS	-3.86	0.000166	0.0484	-0.34	-0.3	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166895	chr2:176177717~176179008:+
PCPG	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	3.86	0.000166	0.0484	0.36	0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
PCPG	cis	rs1003719	0.751	rs55992706	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0484	-0.37	-0.3	Eye color traits;	chr21:37170447	chr21:37187666~37193926:-
PCPG	cis	rs2243480	1	rs1638734	ENSG00000230189.5	GS1-124K5.2	3.86	0.000166	0.0485	0.44	0.3	Diabetic kidney disease;	chr7:66632552	chr7:66409143~66490059:-
PCPG	cis	rs3758911	0.861	rs11212117	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000166	0.0485	-0.4	-0.3	Coronary artery disease;	chr11:107276757	chr11:107176286~107177530:+
PCPG	cis	rs17684571	0.872	rs3002008	ENSG00000231441.1	RP11-472M19.2	3.86	0.000166	0.0485	0.49	0.3	Schizophrenia;	chr6:56757527	chr6:56844002~56864078:+
PCPG	cis	rs1003719	0.715	rs9981715	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37127310	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.646	rs9985082	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37128721	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.742	rs8129231	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37128734	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.708	rs3787788	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37130504	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.708	rs2000417	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37130568	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs2835619	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37133080	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs2835620	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37133281	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs7275984	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37133396	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.68	rs3992	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37133669	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs2252893	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37135272	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs7282195	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37136319	chr21:37187666~37193926:-
PCPG	cis	rs1003719	0.715	rs35199609	ENSG00000228677.1	TTC3-AS1	-3.86	0.000166	0.0485	-0.36	-0.3	Eye color traits;	chr21:37137962	chr21:37187666~37193926:-
PCPG	cis	rs972540	0.64	rs12989476	ENSG00000279220.1	GPR1-AS	3.86	0.000166	0.0485	0.37	0.3	Body mass index;	chr2:206332431	chr2:206203376~206266243:+
PCPG	cis	rs6445975	0.715	rs4681836	ENSG00000272360.1	RP11-359I18.5	-3.86	0.000166	0.0485	-0.37	-0.3	Systemic lupus erythematosus;	chr3:58281560	chr3:58490830~58491291:-
PCPG	cis	rs575908	0.708	rs1415084	ENSG00000254154.7	RP4-798P15.3	3.86	0.000166	0.0485	0.28	0.3	Breast cancer;	chr1:177901122	chr1:177928788~178038007:-
PCPG	cis	rs575908	0.708	rs10157480	ENSG00000254154.7	RP4-798P15.3	3.86	0.000166	0.0485	0.28	0.3	Breast cancer;	chr1:177904198	chr1:177928788~178038007:-
PCPG	cis	rs7707921	0.881	rs6875409	ENSG00000249483.1	CTD-2249K22.1	-3.86	0.000166	0.0485	-0.41	-0.3	Breast cancer;	chr5:82001258	chr5:81851601~81852201:+
PCPG	cis	rs7937890	0.532	rs2575832	ENSG00000251991.1	RNU7-49P	3.86	0.000166	0.0485	0.35	0.3	Mitochondrial DNA levels;	chr11:14467264	chr11:14478892~14478953:+
PCPG	cis	rs7937890	0.532	rs2575833	ENSG00000251991.1	RNU7-49P	3.86	0.000166	0.0485	0.35	0.3	Mitochondrial DNA levels;	chr11:14470959	chr11:14478892~14478953:+
PCPG	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	3.86	0.000166	0.0485	0.26	0.3	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	3.86	0.000166	0.0485	0.26	0.3	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
PCPG	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	3.86	0.000166	0.0485	0.26	0.3	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
PCPG	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	3.86	0.000166	0.0485	0.26	0.3	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
PCPG	cis	rs9821348	0.929	rs9288843	ENSG00000273125.1	RP11-115H18.1	3.86	0.000166	0.0485	0.46	0.3	Perceived unattractiveness to mosquitoes;	chr3:107088774	chr3:107430930~107463912:+
PCPG	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-3.86	0.000166	0.0485	-0.37	-0.3	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
PCPG	cis	rs7942368	1	rs1440979	ENSG00000254985.1	RSF1-IT2	3.86	0.000166	0.0485	0.41	0.3	Endometriosis;	chr11:76784085	chr11:77717712~77718411:-
PCPG	cis	rs274567	0.711	rs404771	ENSG00000233006.5	AC034220.3	3.86	0.000166	0.0485	0.26	0.3	Blood metabolite levels;	chr5:132299399	chr5:132311285~132369916:-
PCPG	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	3.86	0.000166	0.0485	0.39	0.3	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	3.86	0.000166	0.0485	0.39	0.3	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	3.86	0.000166	0.0485	0.39	0.3	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	3.86	0.000166	0.0485	0.39	0.3	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
PCPG	cis	rs4819052	0.851	rs12626188	ENSG00000215447.6	BX322557.10	-3.86	0.000166	0.0485	-0.3	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45288052~45291738:+
PCPG	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-3.86	0.000166	0.0485	-0.3	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
PCPG	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	3.86	0.000167	0.0486	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
PCPG	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	3.86	0.000167	0.0486	0.34	0.3	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
PCPG	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	3.86	0.000167	0.0486	0.34	0.3	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
PCPG	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-3.86	0.000167	0.0486	-0.45	-0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
PCPG	cis	rs17275866	0.862	rs41436546	ENSG00000248174.4	RP11-148L24.1	3.86	0.000167	0.0486	0.35	0.3	Chin dimples;	chr4:174139123	chr4:174094660~174220398:-
PCPG	cis	rs3758911	0.828	rs10890695	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000167	0.0486	-0.41	-0.3	Coronary artery disease;	chr11:107294923	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs11212142	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000167	0.0486	-0.41	-0.3	Coronary artery disease;	chr11:107302994	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs10789597	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000167	0.0486	-0.41	-0.3	Coronary artery disease;	chr11:107304314	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs12285607	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000167	0.0486	-0.41	-0.3	Coronary artery disease;	chr11:107304608	chr11:107176286~107177530:+
PCPG	cis	rs3758911	0.861	rs10890696	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000167	0.0486	-0.41	-0.3	Coronary artery disease;	chr11:107306487	chr11:107176286~107177530:+
PCPG	cis	rs7227917	0.536	rs76932461	ENSG00000269365.2	RP11-380M21.4	3.86	0.000167	0.0486	0.59	0.3	Lung cancer in ever smokers;	chr18:47985796	chr18:47878295~47882444:+
PCPG	cis	rs4819052	0.851	rs2330011	ENSG00000223768.1	LINC00205	-3.86	0.000167	0.0486	-0.4	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45293285~45297354:+
PCPG	cis	rs2841233	0.558	rs10145270	ENSG00000258701.1	LINC00638	3.86	0.000167	0.0486	0.36	0.3	IgG glycosylation;	chr14:104883554	chr14:104821201~104823718:+
PCPG	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	3.86	0.000167	0.0486	0.47	0.3	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
PCPG	cis	rs172166	0.637	rs1225592	ENSG00000220721.1	OR1F12	3.86	0.000167	0.0486	0.34	0.3	Cardiac Troponin-T levels;	chr6:28182464	chr6:28073316~28074233:+
PCPG	cis	rs172166	0.637	rs1225595	ENSG00000220721.1	OR1F12	3.86	0.000167	0.0486	0.34	0.3	Cardiac Troponin-T levels;	chr6:28183562	chr6:28073316~28074233:+
PCPG	cis	rs7160336	0.713	rs7161293	ENSG00000259065.1	RP5-1021I20.1	3.86	0.000167	0.0487	0.36	0.3	Blood protein levels;	chr14:74031655	chr14:73787360~73803270:+
PCPG	cis	rs394563	0.591	rs6570963	ENSG00000231760.4	RP11-350J20.5	-3.86	0.000167	0.0487	-0.38	-0.3	Dupuytren's disease;	chr6:149370219	chr6:149796151~149826294:-
PCPG	cis	rs6600671	0.899	rs2319971	ENSG00000272583.1	RP11-344P13.6	-3.86	0.000167	0.0487	-0.32	-0.3	Hip geometry;	chr1:121485184	chr1:121518366~121518829:-
PCPG	cis	rs2658782	0.507	rs4457713	ENSG00000279684.1	RP11-755E23.2	-3.86	0.000167	0.0487	-0.43	-0.3	Pulmonary function decline;	chr11:93304264	chr11:93286629~93288903:-
PCPG	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-3.86	0.000167	0.0487	-0.43	-0.3	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
PCPG	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-3.86	0.000167	0.0487	-0.43	-0.3	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
PCPG	cis	rs897984	0.537	rs8045637	ENSG00000275263.1	RP11-1072A3.4	-3.86	0.000167	0.0487	-0.31	-0.3	Dementia with Lewy bodies;	chr16:30807341	chr16:30956872~30957199:-
PCPG	cis	rs2733954	0.732	rs8052508	ENSG00000179219.5	LINC00311	-3.86	0.000167	0.0487	-0.42	-0.3	Leprosy;	chr16:85809645	chr16:85282958~85285963:+
PCPG	cis	rs7560272	0.549	rs2421554	ENSG00000163016.8	ALMS1P	3.86	0.000167	0.0487	0.35	0.3	Schizophrenia;	chr2:73579075	chr2:73644919~73685576:+
PCPG	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-3.86	0.000167	0.0487	-0.35	-0.3	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
PCPG	cis	rs4927850	0.501	rs9881504	ENSG00000207650.1	MIR570	3.86	0.000167	0.0487	0.33	0.3	Pancreatic cancer;	chr3:195929743	chr3:195699401~195699497:+
PCPG	cis	rs6579956	0.738	rs13172785	ENSG00000270978.1	RP11-54C4.2	-3.86	0.000167	0.0487	-0.36	-0.3	Subjective well-being (multi-trait analysis);Subjective well-being;	chr5:152709100	chr5:151848886~151850791:+
PCPG	cis	rs7819412	0.703	rs2409713	ENSG00000255020.1	AF131216.5	-3.86	0.000167	0.0487	-0.42	-0.3	Triglycerides;	chr8:11152287	chr8:11345748~11347502:-
PCPG	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-3.86	0.000167	0.0488	-0.34	-0.3	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
PCPG	cis	rs11858159	0.756	rs71404356	ENSG00000260760.1	PWRN3	3.86	0.000167	0.0488	0.33	0.3	Platelet thrombus formation;	chr15:24552756	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.603	rs76802982	ENSG00000260760.1	PWRN3	3.86	0.000167	0.0488	0.33	0.3	Platelet thrombus formation;	chr15:24552801	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.58	rs77327676	ENSG00000260760.1	PWRN3	3.86	0.000167	0.0488	0.33	0.3	Platelet thrombus formation;	chr15:24552802	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.934	rs71404358	ENSG00000260760.1	PWRN3	3.86	0.000167	0.0488	0.33	0.3	Platelet thrombus formation;	chr15:24552810	chr15:24441127~24447967:+
PCPG	cis	rs12681963	0.614	rs59483213	ENSG00000272375.1	RP11-51J9.6	3.86	0.000168	0.0488	0.46	0.3	Migraine;	chr8:30200085	chr8:30197404~30198048:+
PCPG	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	3.86	0.000168	0.0488	0.4	0.3	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
PCPG	cis	rs1062177	1	rs973529	ENSG00000249035.5	CTB-113P19.1	-3.86	0.000168	0.0488	-0.38	-0.3	Preschool internalizing problems;	chr5:151808597	chr5:151676945~151724782:+
PCPG	cis	rs775326	0.513	rs346431	ENSG00000217416.4	ISCA1P1	-3.86	0.000168	0.0488	-0.31	-0.3	Educational attainment (years of education);	chr5:63288688	chr5:62776877~62777263:-
PCPG	cis	rs896854	0.548	rs574183	ENSG00000272509.1	RP11-347C18.5	-3.86	0.000168	0.0488	-0.3	-0.3	Type 2 diabetes;	chr8:94961588	chr8:94884609~94885070:+
PCPG	cis	rs2052670	0.964	rs2627852	ENSG00000232613.5	AC007386.4	-3.86	0.000168	0.0488	-0.41	-0.3	Waist circumference adjusted for body mass index;	chr2:66026631	chr2:65030727~65053017:+
PCPG	cis	rs2948294	0.524	rs13270062	ENSG00000254340.1	RP11-10A14.3	3.86	0.000168	0.0488	0.34	0.3	Red cell distribution width;	chr8:8255128	chr8:9141424~9145435:+
PCPG	cis	rs28386778	0.897	rs2137144	ENSG00000240280.5	TCAM1P	-3.86	0.000168	0.0488	-0.39	-0.3	Prudent dietary pattern;	chr17:63728247	chr17:63849292~63864379:+
PCPG	cis	rs4489787	1	rs2705126	ENSG00000240399.1	RP1-228P16.1	3.86	0.000168	0.0488	0.37	0.3	Prostate cancer (SNP x SNP interaction);	chr12:48488779	chr12:48054813~48055591:-
PCPG	cis	rs1003719	0.788	rs2835593	ENSG00000228677.1	TTC3-AS1	3.86	0.000168	0.0488	0.38	0.3	Eye color traits;	chr21:37093573	chr21:37187666~37193926:-
PCPG	cis	rs6012953	0.874	rs734589	ENSG00000231742.4	LINC01273	-3.86	0.000168	0.0489	-0.32	-0.3	Vitiligo;	chr20:50562384	chr20:50172550~50176671:+
PCPG	cis	rs3808502	0.527	rs2736389	ENSG00000254774.1	RP11-148O21.3	3.86	0.000168	0.0489	0.35	0.3	Neuroticism;	chr8:11303801	chr8:11553224~11554207:-
PCPG	cis	rs2404602	0.679	rs12908421	ENSG00000259422.1	RP11-593F23.1	3.86	0.000168	0.0489	0.36	0.3	Blood metabolite levels;	chr15:76589453	chr15:76174891~76181486:-
PCPG	cis	rs1023500	0.596	rs5758562	ENSG00000226450.2	CYP2D8P	3.86	0.000168	0.0489	0.3	0.3	Schizophrenia;	chr22:42052234	chr22:42149886~42155001:-
PCPG	cis	rs1023500	0.596	rs5751209	ENSG00000226450.2	CYP2D8P	3.86	0.000168	0.0489	0.3	0.3	Schizophrenia;	chr22:42055599	chr22:42149886~42155001:-
PCPG	cis	rs6832769	1	rs10016506	ENSG00000272969.1	RP11-528I4.2	-3.86	0.000168	0.0489	-0.33	-0.3	Personality dimensions;	chr4:55530507	chr4:55547112~55547889:+
PCPG	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-3.86	0.000168	0.0489	-0.35	-0.3	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
PCPG	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-3.86	0.000168	0.0489	-0.35	-0.3	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
PCPG	cis	rs6764363	0.545	rs331858	ENSG00000224239.1	AC090044.2	3.86	0.000168	0.0489	0.36	0.3	Sudden cardiac arrest;	chr3:274867	chr3:857124~858091:+
PCPG	cis	rs72753537	0.872	rs72753508	ENSG00000159712.10	ANKRD18CP	3.86	0.000168	0.0489	0.62	0.3	Papillary thyroid cancer;Differentiated thyroid cancer;	chr9:97851603	chr9:97156570~97221235:-
PCPG	cis	rs412050	1	rs239919	ENSG00000224086.5	LL22NC03-86G7.1	-3.86	0.000168	0.0489	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr22:21958756	chr22:21938293~21977632:+
PCPG	cis	rs11858159	0.756	rs12901793	ENSG00000260760.1	PWRN3	3.86	0.000168	0.0489	0.33	0.3	Platelet thrombus formation;	chr15:24546224	chr15:24441127~24447967:+
PCPG	cis	rs561341	0.709	rs11542477	ENSG00000265798.5	RP11-271K11.5	-3.86	0.000168	0.049	-0.52	-0.3	Hip circumference adjusted for BMI;	chr17:31858873	chr17:31038575~31059121:-
PCPG	cis	rs10040610	0.524	rs271419	ENSG00000248677.1	CTD-2044J15.1	-3.86	0.000168	0.049	-0.34	-0.3	Survival in microsatellite instability low/stable colorectal cancer;	chr5:6353897	chr5:6686325~6707711:-
PCPG	cis	rs2625529	0.824	rs12592044	ENSG00000260037.4	CTD-2524L6.3	-3.86	0.000168	0.049	-0.47	-0.3	Red blood cell count;	chr15:72126774	chr15:71818396~71823384:+
PCPG	cis	rs453301	0.682	rs2929451	ENSG00000254235.4	RP11-115J16.1	3.86	0.000168	0.049	0.36	0.3	Joint mobility (Beighton score);	chr8:9227785	chr8:9249417~9413714:+
PCPG	cis	rs10208649	0.731	rs724387	ENSG00000272156.1	RP11-477N3.1	3.86	0.000168	0.049	0.69	0.3	Body mass index;	chr2:53672707	chr2:54082554~54085066:+
PCPG	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	3.86	0.000168	0.049	0.24	0.3	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
PCPG	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-3.86	0.000168	0.049	-0.28	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
PCPG	cis	rs73201462	1	rs56328893	ENSG00000242551.2	POU5F1P6	3.86	0.000169	0.049	0.61	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128322987	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs55925538	ENSG00000242551.2	POU5F1P6	3.86	0.000169	0.049	0.61	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324034	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs73197388	ENSG00000242551.2	POU5F1P6	3.86	0.000169	0.049	0.61	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128325077	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs11710627	ENSG00000242551.2	POU5F1P6	3.86	0.000169	0.049	0.61	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328166	chr3:128674735~128677005:-
PCPG	cis	rs73201462	1	rs11706304	ENSG00000242551.2	POU5F1P6	3.86	0.000169	0.049	0.61	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128331771	chr3:128674735~128677005:-
PCPG	cis	rs3758911	0.765	rs10789592	ENSG00000255353.1	RP11-382M14.1	-3.86	0.000169	0.049	-0.4	-0.3	Coronary artery disease;	chr11:107283589	chr11:107176286~107177530:+
PCPG	cis	rs1387259	0.619	rs2130095	ENSG00000240399.1	RP1-228P16.1	-3.86	0.000169	0.049	-0.31	-0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48054813~48055591:-
PCPG	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-3.86	0.000169	0.049	-0.4	-0.3	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
PCPG	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	3.86	0.000169	0.049	0.28	0.3	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
PCPG	cis	rs720064	0.555	rs7244601	ENSG00000265752.2	RP11-403A21.1	3.86	0.000169	0.049	0.34	0.3	Strep throat;	chr18:23929704	chr18:23957754~23982556:-
PCPG	cis	rs11051970	0.513	rs4931013	ENSG00000274964.1	RP11-817I4.1	-3.86	0.000169	0.049	-0.43	-0.3	Response to tocilizumab in rheumatoid arthritis;	chr12:32407788	chr12:32339368~32340724:+
PCPG	cis	rs11051970	0.546	rs11051989	ENSG00000274964.1	RP11-817I4.1	-3.86	0.000169	0.049	-0.43	-0.3	Response to tocilizumab in rheumatoid arthritis;	chr12:32407956	chr12:32339368~32340724:+
PCPG	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	3.86	0.000169	0.0491	0.38	0.3	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
PCPG	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	3.86	0.000169	0.0491	0.69	0.3	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
PCPG	cis	rs2243480	1	rs160655	ENSG00000251451.1	GS1-124K5.6	3.86	0.000169	0.0491	0.56	0.3	Diabetic kidney disease;	chr7:66068227	chr7:66407288~66409239:-
PCPG	cis	rs2243480	0.803	rs160649	ENSG00000251451.1	GS1-124K5.6	3.86	0.000169	0.0491	0.56	0.3	Diabetic kidney disease;	chr7:66078212	chr7:66407288~66409239:-
PCPG	cis	rs2243480	1	rs160648	ENSG00000251451.1	GS1-124K5.6	3.86	0.000169	0.0491	0.56	0.3	Diabetic kidney disease;	chr7:66078397	chr7:66407288~66409239:-
PCPG	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	3.86	0.000169	0.0491	0.38	0.3	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	3.86	0.000169	0.0491	0.38	0.3	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
PCPG	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	3.86	0.000169	0.0491	0.38	0.3	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
PCPG	cis	rs8098244	0.557	rs11659490	ENSG00000265752.2	RP11-403A21.1	-3.86	0.000169	0.0492	-0.34	-0.3	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722343	chr18:23957754~23982556:-
PCPG	cis	rs889398	0.771	rs3790080	ENSG00000196696.11	PDXDC2P	-3.86	0.000169	0.0492	-0.24	-0.3	Body mass index;	chr16:69868236	chr16:69976297~70065948:-
PCPG	cis	rs847058	0.633	rs847073	ENSG00000184617.10	ZNF840P	-3.86	0.000169	0.0492	-0.3	-0.3	Gout;	chr20:46626966	chr20:46484461~46492640:+
PCPG	cis	rs847058	0.608	rs847072	ENSG00000184617.10	ZNF840P	-3.86	0.000169	0.0492	-0.3	-0.3	Gout;	chr20:46627105	chr20:46484461~46492640:+
PCPG	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-3.86	0.000169	0.0492	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
PCPG	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	3.86	0.000169	0.0492	0.39	0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
PCPG	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-3.86	0.000169	0.0492	-0.34	-0.3	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
PCPG	cis	rs9717605	1	rs12181068	ENSG00000226445.1	XXyac-YX65C7_A.2	3.86	0.000169	0.0492	0.4	0.3	Left atrial antero-posterior diameter;	chr6:169248281	chr6:169213254~169239565:+
PCPG	cis	rs7824557	0.564	rs12547100	ENSG00000255556.2	RP11-351I21.6	-3.86	0.000169	0.0492	-0.33	-0.3	Retinal vascular caliber;	chr8:11385123	chr8:12378679~12380265:-
PCPG	cis	rs10208649	0.731	rs6760038	ENSG00000272156.1	RP11-477N3.1	3.86	0.00017	0.0493	0.7	0.3	Body mass index;	chr2:53661017	chr2:54082554~54085066:+
PCPG	cis	rs1552244	0.882	rs17050672	ENSG00000180385.7	EMC3-AS1	3.86	0.00017	0.0493	0.38	0.3	Alzheimer's disease;	chr3:9983779	chr3:9986893~10006990:+
PCPG	cis	rs1552244	0.882	rs3755783	ENSG00000180385.7	EMC3-AS1	3.86	0.00017	0.0493	0.38	0.3	Alzheimer's disease;	chr3:9987605	chr3:9986893~10006990:+
PCPG	cis	rs9650657	0.537	rs11250092	ENSG00000255020.1	AF131216.5	3.86	0.00017	0.0493	0.41	0.3	Neuroticism;	chr8:10929033	chr8:11345748~11347502:-
PCPG	cis	rs6787172	0.622	rs67761009	ENSG00000271778.1	RP11-379F4.8	3.86	0.00017	0.0493	0.27	0.3	Subjective well-being;	chr3:158350472	chr3:158782547~158783124:+
PCPG	cis	rs1823874	0.886	rs2123933	ENSG00000182397.13	DNM1P46	-3.86	0.00017	0.0493	-0.4	-0.3	IgG glycosylation;	chr15:99824131	chr15:99790156~99806927:-
PCPG	cis	rs12188164	1	rs56104584	ENSG00000221990.4	EXOC3-AS1	3.86	0.00017	0.0493	0.26	0.3	Cystic fibrosis severity;	chr5:437427	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs55842567	ENSG00000221990.4	EXOC3-AS1	3.86	0.00017	0.0493	0.26	0.3	Cystic fibrosis severity;	chr5:437471	chr5:441498~443160:-
PCPG	cis	rs12188164	1	rs56042615	ENSG00000221990.4	EXOC3-AS1	3.86	0.00017	0.0493	0.26	0.3	Cystic fibrosis severity;	chr5:437552	chr5:441498~443160:-
PCPG	cis	rs911119	0.909	rs111360484	ENSG00000270001.1	RP11-218C14.8	-3.86	0.00017	0.0493	-0.5	-0.3	Chronic kidney disease;	chr20:23638347	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs67567111	ENSG00000270001.1	RP11-218C14.8	-3.86	0.00017	0.0493	-0.5	-0.3	Chronic kidney disease;	chr20:23638438	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs3827143	ENSG00000270001.1	RP11-218C14.8	-3.86	0.00017	0.0493	-0.5	-0.3	Chronic kidney disease;	chr20:23638980	chr20:23631826~23632316:-
PCPG	cis	rs911119	0.909	rs3761279	ENSG00000270001.1	RP11-218C14.8	-3.86	0.00017	0.0493	-0.5	-0.3	Chronic kidney disease;	chr20:23639438	chr20:23631826~23632316:-
PCPG	cis	rs911119	0.779	rs3761280	ENSG00000270001.1	RP11-218C14.8	-3.86	0.00017	0.0493	-0.5	-0.3	Chronic kidney disease;	chr20:23639439	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs34897231	ENSG00000270001.1	RP11-218C14.8	-3.86	0.00017	0.0493	-0.5	-0.3	Chronic kidney disease;	chr20:23639631	chr20:23631826~23632316:-
PCPG	cis	rs911119	1	rs35488434	ENSG00000270001.1	RP11-218C14.8	-3.86	0.00017	0.0493	-0.5	-0.3	Chronic kidney disease;	chr20:23639764	chr20:23631826~23632316:-
PCPG	cis	rs4791051	0.696	rs4082895	ENSG00000264491.1	RP11-349A8.3	-3.86	0.00017	0.0493	-0.31	-0.3	Heschl's gyrus morphology;	chr17:66452153	chr17:67019934~67021743:-
PCPG	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	3.86	0.00017	0.0493	0.48	0.3	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
PCPG	cis	rs16949788	1	rs9806600	ENSG00000261351.2	CTD-3185P2.1	-3.86	0.00017	0.0493	-0.42	-0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66302109	chr15:66488658~66492109:-
PCPG	cis	rs7707921	0.667	rs111549985	ENSG00000249483.1	CTD-2249K22.1	-3.86	0.00017	0.0493	-0.41	-0.3	Breast cancer;	chr5:81972251	chr5:81851601~81852201:+
PCPG	cis	rs4143844	0.609	rs11632560	ENSG00000259251.2	RP11-643M14.1	3.86	0.00017	0.0494	0.64	0.3	Bipolar disorder and schizophrenia;	chr15:62009299	chr15:62060503~62062434:+
PCPG	cis	rs7227917	0.536	rs56055402	ENSG00000269365.2	RP11-380M21.4	3.86	0.00017	0.0494	0.59	0.3	Lung cancer in ever smokers;	chr18:47985553	chr18:47878295~47882444:+
PCPG	cis	rs1048886	0.938	rs2295200	ENSG00000271967.1	RP11-134K13.4	-3.86	0.00017	0.0494	-0.38	-0.3	Type 2 diabetes;	chr6:70523848	chr6:70596438~70596980:+
PCPG	cis	rs7208859	0.673	rs11656462	ENSG00000263603.1	CTD-2349P21.5	-3.86	0.00017	0.0494	-0.56	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11655623	ENSG00000263603.1	CTD-2349P21.5	-3.86	0.00017	0.0494	-0.56	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30729469~30731202:+
PCPG	cis	rs7208859	0.673	rs11654331	ENSG00000263603.1	CTD-2349P21.5	-3.86	0.00017	0.0494	-0.56	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30729469~30731202:+
PCPG	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	3.86	0.00017	0.0494	0.35	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
PCPG	cis	rs13092825	1	rs71319373	ENSG00000240751.1	RP11-553D4.2	-3.86	0.00017	0.0494	-0.4	-0.3	Dental caries;	chr3:113587894	chr3:113360267~113361319:+
PCPG	cis	rs13092825	1	rs17259475	ENSG00000240751.1	RP11-553D4.2	-3.86	0.00017	0.0494	-0.4	-0.3	Dental caries;	chr3:113589298	chr3:113360267~113361319:+
PCPG	cis	rs7211079	0.843	rs73438138	ENSG00000275479.1	RP11-334C17.6	3.86	0.00017	0.0494	0.25	0.3	Myocardial infarction;	chr17:80148608	chr17:80149627~80149798:+
PCPG	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	3.86	0.00017	0.0494	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
PCPG	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	3.86	0.00017	0.0494	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
PCPG	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	3.86	0.00017	0.0494	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
PCPG	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	3.86	0.00017	0.0495	0.27	0.3	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
PCPG	cis	rs6475606	0.532	rs10738604	ENSG00000266446.1	RP11-149I2.4	3.86	0.00017	0.0495	0.37	0.3	Intracranial aneurysm;	chr9:22025494	chr9:21995482~21996013:+
PCPG	cis	rs12500234	0.582	rs2381392	ENSG00000249348.1	UGDH-AS1	-3.86	0.000171	0.0495	-0.27	-0.3	Colorectal cancer;	chr4:39585225	chr4:39528019~39594707:+
PCPG	cis	rs1150668	0.699	rs2394049	ENSG00000219392.1	RP1-265C24.5	-3.86	0.000171	0.0495	-0.34	-0.3	Pubertal anthropometrics;	chr6:28271903	chr6:28115628~28116551:+
PCPG	cis	rs7444	0.941	rs4821116	ENSG00000273342.1	KB-1440D3.14	3.86	0.000171	0.0495	0.38	0.3	Systemic lupus erythematosus;	chr22:21619030	chr22:21640844~21641284:+
PCPG	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	3.86	0.000171	0.0495	0.31	0.3	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
PCPG	cis	rs7267979	1	rs6076339	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000171	0.0495	-0.34	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25284915~25285588:-
PCPG	cis	rs7267979	1	rs6107033	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000171	0.0495	-0.34	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25284915~25285588:-
PCPG	cis	rs2836974	0.863	rs1065242	ENSG00000252915.1	Y_RNA	-3.86	0.000171	0.0495	-0.32	-0.3	Cognitive function;	chr21:39195790	chr21:39344537~39344628:+
PCPG	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-3.86	0.000171	0.0496	-0.4	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
PCPG	cis	rs2281603	0.951	rs1453004	ENSG00000259116.1	RP11-973N13.4	-3.86	0.000171	0.0496	-0.27	-0.3	Lymphocyte counts;	chr14:64530237	chr14:64514154~64540368:-
PCPG	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	3.86	0.000171	0.0496	0.32	0.3	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
PCPG	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	3.86	0.000171	0.0496	0.32	0.3	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
PCPG	cis	rs9876781	1	rs7636782	ENSG00000229759.1	MRPS18AP1	3.86	0.000171	0.0496	0.35	0.3	Longevity;	chr3:48379897	chr3:48256350~48256938:-
PCPG	cis	rs5769765	0.632	rs13056783	ENSG00000278869.1	CITF22-49E9.3	-3.86	0.000171	0.0496	-0.37	-0.3	Schizophrenia;	chr22:49865504	chr22:49933198~49934074:-
PCPG	cis	rs2732480	0.538	rs1387259	ENSG00000240399.1	RP1-228P16.1	-3.85	0.000171	0.0497	-0.32	-0.3	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48054813~48055591:-
PCPG	cis	rs720475	0.732	rs17172978	ENSG00000170356.8	OR2A20P	3.85	0.000171	0.0497	0.44	0.3	Breast cancer;	chr7:144429551	chr7:144250045~144252957:-
PCPG	cis	rs73129298	0.551	rs6020164	ENSG00000222365.1	SNORD12B	3.85	0.000171	0.0497	0.49	0.3	Inflammatory skin disease;	chr20:49977653	chr20:49280319~49280409:+
PCPG	cis	rs11148252	0.811	rs9535895	ENSG00000235660.1	LINC00345	-3.85	0.000171	0.0497	-0.36	-0.3	Lewy body disease;	chr13:52191712	chr13:52484161~52484680:-
PCPG	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-3.85	0.000171	0.0497	-0.28	-0.3	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
PCPG	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	3.85	0.000172	0.0497	0.28	0.3	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
PCPG	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	3.85	0.000172	0.0497	0.28	0.3	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
PCPG	cis	rs964611	0.882	rs11070635	ENSG00000259488.2	RP11-154J22.1	3.85	0.000172	0.0497	0.28	0.3	Metabolite levels (Pyroglutamine);	chr15:48361928	chr15:48312353~48331856:-
PCPG	cis	rs10949834	1	rs34346732	ENSG00000225969.1	ABHD11-AS1	3.85	0.000172	0.0497	0.63	0.3	Verbal memory performance (residualized delayed recall change);	chr7:74071483	chr7:73735038~73736054:+
PCPG	cis	rs763014	0.932	rs2269560	ENSG00000262528.2	LA16c-349E10.1	3.85	0.000172	0.0498	0.35	0.3	Height;	chr16:632442	chr16:654611~656194:-
PCPG	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	3.85	0.000172	0.0498	0.31	0.3	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
PCPG	cis	rs8003054	0.589	rs999692	ENSG00000258515.1	RP11-203M5.7	-3.85	0.000172	0.0498	-0.21	-0.3	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20449506	chr14:20451305~20451918:+
PCPG	cis	rs427941	0.706	rs7788596	ENSG00000239480.1	RP11-514P8.2	3.85	0.000172	0.0498	0.34	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102196206	chr7:102426818~102434780:-
PCPG	cis	rs427941	0.732	rs11760331	ENSG00000239480.1	RP11-514P8.2	3.85	0.000172	0.0498	0.34	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102197623	chr7:102426818~102434780:-
PCPG	cis	rs6012953	0.817	rs16995294	ENSG00000231742.4	LINC01273	-3.85	0.000172	0.0498	-0.31	-0.3	Vitiligo;	chr20:50564808	chr20:50172550~50176671:+
PCPG	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-3.85	0.000172	0.0498	-0.38	-0.3	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
PCPG	cis	rs67366981	1	rs56357623	ENSG00000258454.1	RP11-361H10.3	3.85	0.000172	0.0498	0.57	0.3	Obsessive-compulsive symptoms;	chr14:77231050	chr14:76235817~76263474:+
PCPG	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	3.85	0.000172	0.0498	0.34	0.3	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
PCPG	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	3.85	0.000172	0.0498	0.34	0.3	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
PCPG	cis	rs11858159	1	rs12902327	ENSG00000260760.1	PWRN3	3.85	0.000172	0.0499	0.33	0.3	Platelet thrombus formation;	chr15:24546172	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.756	rs12906581	ENSG00000260760.1	PWRN3	3.85	0.000172	0.0499	0.33	0.3	Platelet thrombus formation;	chr15:24546179	chr15:24441127~24447967:+
PCPG	cis	rs11858159	0.651	rs12900679	ENSG00000260760.1	PWRN3	3.85	0.000172	0.0499	0.33	0.3	Platelet thrombus formation;	chr15:24546219	chr15:24441127~24447967:+
PCPG	cis	rs66887589	0.616	rs13113885	ENSG00000250412.1	KLHL2P1	3.85	0.000172	0.0499	0.31	0.3	Diastolic blood pressure;	chr4:119300021	chr4:119334329~119378233:+
PCPG	cis	rs10504130	0.569	rs13265006	ENSG00000272024.1	RP11-546K22.3	-3.85	0.000172	0.0499	-0.39	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51950284~51950690:+
PCPG	cis	rs10504130	0.597	rs34058697	ENSG00000272024.1	RP11-546K22.3	-3.85	0.000172	0.0499	-0.39	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51950284~51950690:+
PCPG	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	3.85	0.000172	0.0499	0.28	0.3	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
PCPG	cis	rs2349775	0.92	rs985210	ENSG00000234141.1	AC009473.1	-3.85	0.000172	0.0499	-0.41	-0.3	Neuroticism;	chr7:8628407	chr7:7949853~7950709:-
PCPG	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	3.85	0.000173	0.05	0.32	0.3	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
PCPG	cis	rs12744310	0.836	rs12048808	ENSG00000227527.2	RP11-223A3.1	-3.85	0.000173	0.05	-0.35	-0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348636	chr1:42335386~42338376:-
PCPG	cis	rs804280	0.509	rs13276433	ENSG00000255556.2	RP11-351I21.6	3.85	0.000173	0.05	0.33	0.3	Myopia (pathological);	chr8:11925527	chr8:12378679~12380265:-
PCPG	cis	rs2836974	0.666	rs1888487	ENSG00000252915.1	Y_RNA	3.85	0.000173	0.05	0.32	0.3	Cognitive function;	chr21:39311333	chr21:39344537~39344628:+
PCPG	cis	rs1048886	0.872	rs6933150	ENSG00000271967.1	RP11-134K13.4	-3.85	0.000173	0.05	-0.38	-0.3	Type 2 diabetes;	chr6:70519176	chr6:70596438~70596980:+
PCPG	cis	rs12908161	0.853	rs11633788	ENSG00000259295.5	CSPG4P12	3.85	0.000173	0.05	0.38	0.3	Schizophrenia;	chr15:84761911	chr15:85191438~85213905:+
PCPG	cis	rs34421088	0.56	rs2245357	ENSG00000254774.1	RP11-148O21.3	-3.85	0.000173	0.05	-0.34	-0.3	Neuroticism;	chr8:11541975	chr8:11553224~11554207:-
PCPG	cis	rs633715	0.55	rs10798578	ENSG00000254154.7	RP4-798P15.3	-3.85	0.000173	0.05	-0.3	-0.3	Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;	chr1:177887790	chr1:177928788~178038007:-
PCPG	cis	rs11771526	0.892	rs62457504	ENSG00000281332.1	LINC00997	3.85	0.000173	0.05	0.55	0.3	Body mass index;	chr7:32296485	chr7:32760279~32762924:+
PCPG	cis	rs11771526	1	rs11764617	ENSG00000281332.1	LINC00997	3.85	0.000173	0.05	0.55	0.3	Body mass index;	chr7:32299490	chr7:32760279~32762924:+
PCPG	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	26.3	4.84e-58	2.73e-47	1.1	0.91	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	25.32	5.03e-56	4.67e-46	1.08	0.9	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	25.32	5.03e-56	4.67e-46	1.08	0.9	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	25.24	7.46e-56	4.67e-46	1.08	0.9	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	25.24	7.46e-56	4.67e-46	1.08	0.9	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	24.98	2.62e-55	1.34e-45	1.09	0.9	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	24.98	2.62e-55	1.34e-45	1.09	0.9	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	24.96	2.89e-55	1.36e-45	1.09	0.9	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	24.15	1.47e-53	6.37e-44	1.09	0.89	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
PCPG	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	23.29	1.12e-51	4.19e-42	1.14	0.89	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
PCPG	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-23.06	3.64e-51	1.28e-41	-1.05	-0.88	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
PCPG	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	22.37	1.21e-49	2.72e-40	1.13	0.88	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	22.18	3.22e-49	6.41e-40	1.1	0.88	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
PCPG	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	22.1	5.03e-49	9.15e-40	1.28	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
PCPG	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	21.87	1.62e-48	2.77e-39	1.11	0.87	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
PCPG	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	21.53	9.8e-48	1.53e-38	1.27	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	21.53	9.8e-48	1.53e-38	1.27	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
PCPG	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-19.81	1.01e-43	1.27e-34	-1.05	-0.85	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
PCPG	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	19.78	1.2e-43	1.47e-34	1.27	0.85	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-19.68	2.05e-43	2.46e-34	-1.26	-0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
PCPG	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	19.64	2.63e-43	3.09e-34	1.11	0.85	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
PCPG	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	19.6	3.36e-43	3.87e-34	1.1	0.85	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
PCPG	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	19.57	3.83e-43	4.32e-34	1.27	0.85	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
PCPG	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	19.52	5.05e-43	5.58e-34	1.12	0.85	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
PCPG	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	19.47	6.9e-43	7.35e-34	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	19.44	7.83e-43	7.35e-34	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	19.44	7.83e-43	7.35e-34	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	19.44	7.83e-43	7.35e-34	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	19.44	7.83e-43	7.35e-34	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	19.44	7.83e-43	7.35e-34	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	19.44	7.83e-43	7.35e-34	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	19.44	7.83e-43	7.35e-34	1.26	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
PCPG	trans	rs2657294	0.603	rs11543	ENSG00000172974.11	AC007318.5	19.42	8.81e-43	8.13e-34	0.92	0.85	Pneumonia;	chr10:75210855	chr2:65205108~65205988:+
PCPG	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	19.37	1.15e-42	9.69e-34	1.27	0.85	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	19.37	1.15e-42	9.69e-34	1.27	0.85	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	19.35	1.32e-42	9.69e-34	1.26	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	19.35	1.32e-42	9.69e-34	1.26	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	19.35	1.32e-42	9.69e-34	1.26	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	19.35	1.32e-42	9.69e-34	1.26	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	19.35	1.32e-42	9.69e-34	1.26	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	19.35	1.32e-42	9.69e-34	1.26	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
PCPG	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	19.28	1.96e-42	1.38e-33	1.17	0.84	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	19.25	2.28e-42	1.56e-33	1.15	0.84	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
PCPG	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	19.16	3.71e-42	2.26e-33	1.26	0.84	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	19.16	3.71e-42	2.26e-33	1.26	0.84	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	19.16	3.71e-42	2.26e-33	1.26	0.84	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	19.16	3.71e-42	2.26e-33	1.26	0.84	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	19.16	3.71e-42	2.26e-33	1.26	0.84	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	18.9	1.6e-41	9.46e-33	1.27	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	18.9	1.6e-41	9.46e-33	1.27	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
PCPG	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	18.89	1.66e-41	9.75e-33	1.12	0.84	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-18.88	1.77e-41	1.03e-32	-1.12	-0.84	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	18.75	3.75e-41	2.16e-32	1.18	0.84	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	18.73	4.18e-41	2.38e-32	1.13	0.84	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
PCPG	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	18.68	5.47e-41	3.08e-32	1.25	0.84	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
PCPG	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	18.66	6.03e-41	3.36e-32	1.17	0.84	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	18.66	6.11e-41	3.37e-32	1.11	0.84	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
PCPG	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	18.61	8.16e-41	4.47e-32	1.25	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
PCPG	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	18.56	1.07e-40	5.58e-32	1.27	0.83	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	18.56	1.07e-40	5.58e-32	1.27	0.83	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	18.56	1.07e-40	5.58e-32	1.27	0.83	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	18.35	3.58e-40	1.82e-31	1.25	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
PCPG	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	17.97	3.06e-39	1.26e-30	1.06	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	17.85	6.34e-39	2.08e-30	1.23	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	17.85	6.34e-39	2.08e-30	1.23	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
PCPG	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	17.83	7.05e-39	2.28e-30	1.15	0.82	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
PCPG	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-17.81	7.69e-39	2.39e-30	-1.26	-0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
PCPG	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	17.8	8.31e-39	2.54e-30	1.12	0.82	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	17.8	8.31e-39	2.54e-30	1.12	0.82	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	17.8	8.31e-39	2.54e-30	1.12	0.82	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
PCPG	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	17.76	1.05e-38	3.18e-30	1.2	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
PCPG	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-17.69	1.51e-38	3.91e-30	-1.07	-0.82	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	17.69	1.51e-38	3.91e-30	1.07	0.82	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
PCPG	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	17.66	1.81e-38	4.68e-30	1.06	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	17.52	4.21e-38	1.04e-29	1.05	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
PCPG	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	17.51	4.47e-38	1.1e-29	1.21	0.82	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
PCPG	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	17.5	4.59e-38	1.12e-29	1.05	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	17.48	5.16e-38	1.25e-29	1.04	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	17.48	5.16e-38	1.25e-29	1.04	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	17.48	5.24e-38	1.25e-29	1.04	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	17.46	5.83e-38	1.35e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	17.46	5.83e-38	1.35e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	17.46	5.83e-38	1.35e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	17.46	5.83e-38	1.35e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	17.46	5.83e-38	1.35e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	17.46	5.83e-38	1.35e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	17.46	5.83e-38	1.35e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
PCPG	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	17.35	1.11e-37	2.22e-29	1.22	0.82	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
PCPG	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	17.35	1.12e-37	2.23e-29	1.04	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	17.31	1.35e-37	2.6e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	17.31	1.35e-37	2.6e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	17.31	1.35e-37	2.6e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	17.31	1.35e-37	2.6e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	17.31	1.35e-37	2.6e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	17.31	1.35e-37	2.6e-29	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
PCPG	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	17.31	1.36e-37	2.61e-29	1.22	0.82	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
PCPG	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	17.19	2.71e-37	5.09e-29	1.04	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	17.19	2.71e-37	5.09e-29	1.04	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	17.19	2.71e-37	5.09e-29	1.04	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	17.16	3.23e-37	6.03e-29	1.03	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	17.13	4.02e-37	7.44e-29	1.21	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
PCPG	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	17.13	4.03e-37	7.44e-29	1.22	0.81	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	17.13	4.03e-37	7.44e-29	1.22	0.81	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	17.12	4.11e-37	7.57e-29	1.22	0.81	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
PCPG	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	17.08	5.33e-37	9.75e-29	1.04	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	17.04	6.64e-37	1.2e-28	1.21	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	17.04	6.64e-37	1.2e-28	1.21	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
PCPG	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	17.02	7.61e-37	1.37e-28	1.03	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	16.97	1.03e-36	1.85e-28	1.05	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
PCPG	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	16.95	1.12e-36	2e-28	1.22	0.81	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
PCPG	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	16.95	1.15e-36	2.05e-28	1.05	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	16.94	1.17e-36	2.07e-28	1.03	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
PCPG	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	16.9	1.52e-36	2.66e-28	1.2	0.81	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	16.86	1.87e-36	3.27e-28	1.22	0.81	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	16.72	4.32e-36	7.52e-28	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
PCPG	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	16.62	7.84e-36	1.33e-27	1.04	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-16.6	8.47e-36	1.43e-27	-1.21	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	16.59	9.05e-36	1.51e-27	1.24	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
PCPG	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-16.52	1.41e-35	2.24e-27	-0.96	-0.8	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	16.52	1.41e-35	2.24e-27	0.96	0.8	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	16.5	1.59e-35	2.52e-27	1.25	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
PCPG	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	16.45	2.07e-35	3.17e-27	0.96	0.8	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	16.45	2.07e-35	3.17e-27	0.96	0.8	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	16.45	2.07e-35	3.17e-27	0.96	0.8	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	16.45	2.07e-35	3.17e-27	0.96	0.8	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	16.45	2.07e-35	3.17e-27	0.96	0.8	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	16.45	2.07e-35	3.17e-27	0.96	0.8	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	16.45	2.07e-35	3.17e-27	0.96	0.8	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
PCPG	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	16.45	2.12e-35	3.24e-27	1.17	0.8	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
PCPG	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	16.43	2.4e-35	3.58e-27	0.96	0.8	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	16.43	2.4e-35	3.58e-27	0.96	0.8	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	16.43	2.4e-35	3.58e-27	0.96	0.8	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	16.43	2.4e-35	3.58e-27	0.96	0.8	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	16.43	2.4e-35	3.58e-27	0.96	0.8	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	16.43	2.4e-35	3.58e-27	0.96	0.8	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
PCPG	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	16.38	3.21e-35	4.72e-27	1.02	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
PCPG	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	16.33	4.3e-35	6.24e-27	1.04	0.8	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
PCPG	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	16.29	5.53e-35	7.99e-27	0.96	0.8	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	16.25	6.66e-35	9.39e-27	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	16.25	6.66e-35	9.39e-27	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	16.25	6.66e-35	9.39e-27	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	16.25	6.66e-35	9.39e-27	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	16.25	6.66e-35	9.39e-27	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	16.25	6.66e-35	9.39e-27	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	16.25	6.66e-35	9.39e-27	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	16.24	7.37e-35	1.01e-26	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	16.24	7.37e-35	1.01e-26	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	16.24	7.37e-35	1.01e-26	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	16.24	7.37e-35	1.01e-26	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	16.24	7.37e-35	1.01e-26	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	16.24	7.37e-35	1.01e-26	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
PCPG	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	16.2	9e-35	1.2e-26	0.96	0.8	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	16.2	9e-35	1.2e-26	0.96	0.8	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	16.2	9e-35	1.2e-26	0.96	0.8	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	16.2	9e-35	1.2e-26	0.96	0.8	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	16.2	9e-35	1.2e-26	0.96	0.8	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	16.2	9e-35	1.2e-26	0.96	0.8	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	16.2	9e-35	1.2e-26	0.96	0.8	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
PCPG	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-16.19	9.71e-35	1.28e-26	-1.07	-0.8	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-16.19	9.71e-35	1.28e-26	-1.07	-0.8	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-16.19	9.71e-35	1.28e-26	-1.07	-0.8	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
PCPG	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	16.07	2e-34	2.6e-26	1.03	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
PCPG	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	16.04	2.4e-34	3.1e-26	0.95	0.79	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	15.98	3.47e-34	4.47e-26	1.15	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
PCPG	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-15.95	4.15e-34	5.29e-26	-1.07	-0.79	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-15.95	4.15e-34	5.29e-26	-1.07	-0.79	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
PCPG	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	15.87	6.59e-34	8.32e-26	0.96	0.79	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	15.86	6.97e-34	8.78e-26	0.97	0.79	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	15.83	8.31e-34	1.05e-25	0.96	0.79	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	15.8	9.99e-34	1.24e-25	1.1	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
PCPG	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	15.8	1.01e-33	1.25e-25	1.25	0.79	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	15.78	1.12e-33	1.38e-25	1.11	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	15.78	1.12e-33	1.38e-25	1.11	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	15.77	1.16e-33	1.43e-25	1.11	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
PCPG	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	15.76	1.23e-33	1.52e-25	0.96	0.79	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	15.75	1.34e-33	1.64e-25	0.97	0.79	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	15.73	1.47e-33	1.78e-25	1.22	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	15.73	1.47e-33	1.78e-25	1.22	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	15.72	1.55e-33	1.87e-25	1.14	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	15.72	1.55e-33	1.87e-25	1.14	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	15.67	2.09e-33	2.52e-25	1.18	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
PCPG	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	15.65	2.47e-33	2.93e-25	1.25	0.79	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
PCPG	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	15.63	2.75e-33	3.25e-25	1.25	0.79	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	15.63	2.76e-33	3.26e-25	1.14	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
PCPG	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	15.59	3.52e-33	4.11e-25	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
PCPG	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	15.59	3.52e-33	4.11e-25	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
PCPG	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	15.54	4.71e-33	5.45e-25	1.18	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	15.53	4.86e-33	5.61e-25	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	15.49	6.36e-33	7.33e-25	1.1	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	15.45	7.86e-33	8.95e-25	1.1	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	15.45	7.86e-33	8.95e-25	1.1	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	15.35	1.44e-32	1.62e-24	1.19	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
PCPG	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-15.31	1.82e-32	2.04e-24	-0.99	-0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
PCPG	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	15.27	2.33e-32	2.59e-24	1.24	0.78	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	15.22	3.12e-32	3.45e-24	1.13	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
PCPG	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	15.21	3.29e-32	3.63e-24	0.99	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	15.09	6.88e-32	7.37e-24	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	15.09	6.88e-32	7.37e-24	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	15.03	1e-31	1.05e-23	1.21	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	14.89	2.39e-31	2.45e-23	1.12	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	14.89	2.39e-31	2.45e-23	1.12	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
PCPG	trans	rs13253073	0.525	rs35509895	ENSG00000260318.1	COX6CP1	14.86	2.73e-31	2.79e-23	1.19	0.77	Glucose homeostasis traits;	chr8:99872093	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	14.8	4.05e-31	4.08e-23	1.17	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
PCPG	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	14.75	5.37e-31	5.36e-23	0.97	0.77	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	14.75	5.37e-31	5.36e-23	0.97	0.77	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
PCPG	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	14.67	9.01e-31	8.89e-23	1.09	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
PCPG	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	14.66	9.22e-31	8.9e-23	0.97	0.77	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	14.66	9.22e-31	8.9e-23	0.97	0.77	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	14.66	9.22e-31	8.9e-23	0.97	0.77	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	14.66	9.22e-31	8.9e-23	0.97	0.77	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	14.66	9.22e-31	8.9e-23	0.97	0.77	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	14.66	9.22e-31	8.9e-23	0.97	0.77	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	14.66	9.22e-31	8.9e-23	0.97	0.77	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
PCPG	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	14.62	1.17e-30	1.13e-22	1.13	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
PCPG	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	14.6	1.37e-30	1.31e-22	1.17	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
PCPG	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	14.6	1.37e-30	1.31e-22	1.17	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
PCPG	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	14.59	1.41e-30	1.35e-22	0.93	0.77	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
PCPG	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	14.59	1.44e-30	1.38e-22	1.17	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
PCPG	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	14.53	2.02e-30	1.92e-22	0.92	0.76	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	14.52	2.18e-30	2.05e-22	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	14.52	2.18e-30	2.05e-22	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
PCPG	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	14.51	2.32e-30	2.17e-22	0.92	0.76	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	14.51	2.32e-30	2.17e-22	0.92	0.76	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	14.48	2.85e-30	2.65e-22	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
PCPG	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	14.41	4.16e-30	3.81e-22	0.92	0.76	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	14.39	4.74e-30	4.34e-22	0.97	0.76	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-14.35	5.93e-30	5.38e-22	-0.96	-0.76	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	14.35	6e-30	5.42e-22	0.91	0.76	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	14.35	6.05e-30	5.44e-22	0.91	0.76	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	14.33	6.79e-30	6.08e-22	0.96	0.76	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	14.33	7.06e-30	6.27e-22	0.98	0.76	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	14.33	7.06e-30	6.27e-22	0.98	0.76	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	14.33	7.06e-30	6.27e-22	0.98	0.76	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	14.33	7.06e-30	6.27e-22	0.98	0.76	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	14.3	8.04e-30	7.11e-22	0.97	0.76	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	14.28	9.34e-30	8.2e-22	0.9	0.76	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	14.28	9.34e-30	8.2e-22	0.9	0.76	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	14.25	1.15e-29	9.99e-22	0.96	0.76	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
PCPG	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	14.21	1.46e-29	1.26e-21	1.16	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
PCPG	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	14.19	1.61e-29	1.39e-21	0.97	0.76	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	14.17	1.84e-29	1.59e-21	0.96	0.76	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	14.17	1.86e-29	1.6e-21	0.89	0.76	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	14.17	1.87e-29	1.6e-21	0.96	0.76	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	14.17	1.87e-29	1.6e-21	0.96	0.76	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	14.09	2.9e-29	2.46e-21	0.97	0.75	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
PCPG	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	14.09	2.91e-29	2.46e-21	1.07	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
PCPG	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	14.08	3.16e-29	2.65e-21	0.96	0.75	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
PCPG	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	14.08	3.16e-29	2.65e-21	0.96	0.75	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
PCPG	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	14.06	3.58e-29	2.97e-21	1.18	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
PCPG	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	14.06	3.58e-29	2.97e-21	1.18	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
PCPG	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	14.06	3.58e-29	2.97e-21	0.91	0.75	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
PCPG	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	14.06	3.58e-29	2.97e-21	0.91	0.75	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	14.02	4.44e-29	3.66e-21	0.96	0.75	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	14.02	4.56e-29	3.73e-21	0.91	0.75	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	14.01	4.97e-29	4.06e-21	0.89	0.75	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	13.99	5.45e-29	4.41e-21	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
PCPG	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	13.99	5.55e-29	4.48e-21	0.9	0.75	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
PCPG	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	13.98	5.8e-29	4.67e-21	1.23	0.75	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
PCPG	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	13.98	5.95e-29	4.79e-21	1.17	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
PCPG	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	13.97	6.26e-29	5.02e-21	0.91	0.75	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	13.96	6.5e-29	5.18e-21	0.96	0.75	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	13.96	6.5e-29	5.18e-21	0.96	0.75	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
PCPG	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	13.95	6.86e-29	5.44e-21	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
PCPG	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	13.95	6.98e-29	5.53e-21	0.89	0.75	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
PCPG	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-13.94	7.25e-29	5.72e-21	-0.9	-0.75	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	13.91	8.68e-29	6.76e-21	0.95	0.75	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	13.91	8.68e-29	6.76e-21	0.95	0.75	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	13.91	8.68e-29	6.76e-21	0.95	0.75	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	13.91	8.68e-29	6.76e-21	0.95	0.75	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	13.91	8.68e-29	6.76e-21	0.95	0.75	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	13.91	8.68e-29	6.76e-21	0.95	0.75	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	13.91	8.68e-29	6.76e-21	0.95	0.75	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
PCPG	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	13.9	9.27e-29	7.18e-21	1.07	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	13.9	9.27e-29	7.18e-21	1.07	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
PCPG	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	13.87	1.14e-28	8.8e-21	0.91	0.75	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
PCPG	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-13.85	1.27e-28	9.76e-21	-1.21	-0.75	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
PCPG	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	13.85	1.28e-28	9.78e-21	1.2	0.75	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
PCPG	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	13.85	1.3e-28	9.9e-21	0.91	0.75	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
PCPG	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	13.85	1.3e-28	9.9e-21	0.91	0.75	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	13.84	1.39e-28	1.05e-20	1.02	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
PCPG	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	13.81	1.63e-28	1.23e-20	0.94	0.75	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
PCPG	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	13.8	1.76e-28	1.32e-20	0.81	0.75	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
PCPG	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	13.79	1.84e-28	1.38e-20	0.94	0.75	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
PCPG	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	13.78	1.97e-28	1.47e-20	0.81	0.75	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
PCPG	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-13.75	2.36e-28	1.76e-20	-0.95	-0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
PCPG	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-13.75	2.36e-28	1.76e-20	-0.95	-0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
PCPG	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	13.75	2.42e-28	1.8e-20	0.93	0.75	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
PCPG	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	13.71	2.95e-28	2.19e-20	0.95	0.75	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
PCPG	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	13.69	3.35e-28	2.44e-20	0.96	0.75	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	13.69	3.35e-28	2.44e-20	0.96	0.75	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	13.69	3.35e-28	2.44e-20	0.96	0.75	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
PCPG	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	13.69	3.35e-28	2.44e-20	0.96	0.75	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
PCPG	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	13.69	3.35e-28	2.44e-20	0.96	0.75	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
PCPG	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	13.69	3.35e-28	2.44e-20	0.96	0.75	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
PCPG	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	13.66	4.15e-28	3.01e-20	1.15	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
PCPG	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	13.62	5.21e-28	3.75e-20	0.94	0.74	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
PCPG	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	13.62	5.21e-28	3.75e-20	0.94	0.74	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
PCPG	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	13.61	5.52e-28	3.94e-20	0.95	0.74	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	13.6	5.92e-28	4.18e-20	0.88	0.74	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	13.6	5.92e-28	4.18e-20	0.88	0.74	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	13.6	5.92e-28	4.18e-20	0.88	0.74	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	13.6	5.92e-28	4.18e-20	0.88	0.74	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	13.6	5.92e-28	4.18e-20	0.88	0.74	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
PCPG	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	13.57	7.2e-28	5.03e-20	0.95	0.74	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	13.57	7.2e-28	5.03e-20	0.95	0.74	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	13.57	7.2e-28	5.03e-20	0.95	0.74	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	13.57	7.2e-28	5.03e-20	0.95	0.74	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	13.57	7.2e-28	5.03e-20	0.95	0.74	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
PCPG	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	13.55	8.11e-28	5.65e-20	0.88	0.74	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	13.55	8.11e-28	5.65e-20	0.88	0.74	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	13.55	8.11e-28	5.65e-20	0.88	0.74	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
PCPG	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-13.54	8.54e-28	5.91e-20	-0.79	-0.74	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
PCPG	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	13.53	9.02e-28	6.16e-20	0.88	0.74	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
PCPG	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-13.5	1.12e-27	7.63e-20	-1.21	-0.74	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-13.48	1.2e-27	8.1e-20	-1.19	-0.74	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-13.48	1.2e-27	8.1e-20	-1.19	-0.74	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-13.48	1.2e-27	8.1e-20	-1.19	-0.74	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
PCPG	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	13.47	1.32e-27	8.87e-20	0.92	0.74	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
PCPG	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	13.47	1.32e-27	8.87e-20	0.92	0.74	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
PCPG	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	13.45	1.46e-27	9.74e-20	0.87	0.74	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	13.45	1.46e-27	9.74e-20	0.94	0.74	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
PCPG	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	13.44	1.61e-27	1.07e-19	1.2	0.74	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-13.43	1.65e-27	1.1e-19	-1.2	-0.74	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
PCPG	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	13.38	2.27e-27	1.48e-19	1.2	0.74	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
PCPG	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	13.34	2.86e-27	1.86e-19	0.93	0.74	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
PCPG	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-13.32	3.24e-27	2.09e-19	-1.18	-0.74	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
PCPG	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	13.3	3.71e-27	2.38e-19	0.97	0.74	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
PCPG	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	13.3	3.79e-27	2.42e-19	0.89	0.74	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
PCPG	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	13.29	3.95e-27	2.51e-19	0.93	0.74	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	13.22	5.97e-27	3.75e-19	0.88	0.73	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	13.21	6.6e-27	4.08e-19	0.88	0.73	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	13.2	7e-27	4.3e-19	0.88	0.73	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	13.2	7e-27	4.3e-19	0.88	0.73	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	13.2	7e-27	4.3e-19	0.88	0.73	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	13.19	7.23e-27	4.43e-19	0.88	0.73	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	13.18	7.59e-27	4.63e-19	1.15	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
PCPG	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-13.17	8.2e-27	4.92e-19	-1.17	-0.73	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	13.17	8.2e-27	4.92e-19	1.17	0.73	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	13.15	9.4e-27	5.6e-19	0.88	0.73	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
PCPG	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-13.15	9.55e-27	5.67e-19	-1.18	-0.73	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-13.15	9.55e-27	5.67e-19	-1.18	-0.73	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	13.13	1.06e-26	6.23e-19	1.2	0.73	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	13.13	1.06e-26	6.27e-19	0.88	0.73	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	13.12	1.11e-26	6.55e-19	0.88	0.73	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
PCPG	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	13.11	1.23e-26	7.2e-19	1.22	0.73	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-13.1	1.3e-26	7.63e-19	-0.87	-0.73	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
PCPG	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-13.07	1.54e-26	8.97e-19	-0.91	-0.73	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
PCPG	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-13.07	1.57e-26	9.16e-19	-0.92	-0.73	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	13.03	1.9e-26	1.09e-18	0.87	0.73	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	13.03	1.95e-26	1.11e-18	0.87	0.73	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
PCPG	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	13.02	2.08e-26	1.19e-18	0.99	0.73	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
PCPG	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-13.01	2.15e-26	1.21e-18	-0.91	-0.73	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
PCPG	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	13.01	2.17e-26	1.22e-18	1.17	0.73	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-13.01	2.28e-26	1.27e-18	-0.89	-0.73	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
PCPG	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-13	2.41e-26	1.34e-18	-0.94	-0.73	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	12.99	2.54e-26	1.4e-18	0.86	0.73	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	12.99	2.54e-26	1.4e-18	0.86	0.73	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
PCPG	trans	rs13177918	0.871	rs11745133	ENSG00000224114.1	RP11-343H5.4	12.97	2.77e-26	1.52e-18	1.04	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.871	rs11745194	ENSG00000224114.1	RP11-343H5.4	12.97	2.77e-26	1.52e-18	1.04	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	12.97	2.82e-26	1.55e-18	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	12.96	3e-26	1.65e-18	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
PCPG	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	12.95	3.15e-26	1.72e-18	0.98	0.73	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
PCPG	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-12.95	3.24e-26	1.77e-18	-1.19	-0.73	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
PCPG	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	12.94	3.3e-26	1.8e-18	0.76	0.73	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
PCPG	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	12.94	3.43e-26	1.86e-18	0.87	0.73	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
PCPG	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	12.92	3.9e-26	2.1e-18	0.78	0.73	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
PCPG	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-12.9	4.37e-26	2.35e-18	-0.94	-0.73	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
PCPG	trans	rs13177918	0.834	rs13163277	ENSG00000224114.1	RP11-343H5.4	12.88	4.82e-26	2.58e-18	1.04	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr1:206695837~206696269:-
PCPG	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	12.86	5.49e-26	2.89e-18	0.77	0.72	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
PCPG	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-12.86	5.56e-26	2.91e-18	-1.17	-0.72	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-12.86	5.56e-26	2.91e-18	-1.17	-0.72	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-12.86	5.56e-26	2.91e-18	-1.17	-0.72	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-12.86	5.56e-26	2.91e-18	-1.17	-0.72	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
PCPG	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	12.86	5.68e-26	2.98e-18	0.87	0.72	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
PCPG	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	12.85	5.85e-26	3.06e-18	0.91	0.72	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
PCPG	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	12.83	6.49e-26	3.38e-18	1.06	0.72	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
PCPG	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	12.83	6.75e-26	3.5e-18	0.88	0.72	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	12.83	6.75e-26	3.5e-18	0.88	0.72	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
PCPG	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-12.82	7.05e-26	3.65e-18	-1.16	-0.72	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	12.82	7.12e-26	3.68e-18	0.87	0.72	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
PCPG	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	12.81	7.34e-26	3.79e-18	0.91	0.72	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
PCPG	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	12.78	8.85e-26	4.53e-18	1.18	0.72	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	12.78	9.06e-26	4.61e-18	0.87	0.72	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	12.78	9.06e-26	4.61e-18	0.87	0.72	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	12.78	9.06e-26	4.61e-18	0.87	0.72	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	12.78	9.06e-26	4.61e-18	0.87	0.72	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
PCPG	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	12.77	9.77e-26	4.93e-18	0.98	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
PCPG	trans	rs13177918	0.798	rs12516161	ENSG00000224114.1	RP11-343H5.4	12.77	9.96e-26	5.02e-18	1.03	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	12.76	1e-25	5.05e-18	1.01	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
PCPG	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	12.74	1.15e-25	5.77e-18	0.76	0.72	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
PCPG	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	12.73	1.21e-25	6.07e-18	0.88	0.72	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
PCPG	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	12.73	1.24e-25	6.2e-18	0.97	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
PCPG	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	12.7	1.51e-25	7.53e-18	1.16	0.72	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	12.7	1.51e-25	7.53e-18	1.16	0.72	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	12.66	1.86e-25	9.17e-18	0.88	0.72	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	12.66	1.86e-25	9.17e-18	0.88	0.72	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	12.66	1.95e-25	9.64e-18	0.86	0.72	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
PCPG	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	12.64	2.11e-25	1.04e-17	0.88	0.72	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
PCPG	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-12.63	2.35e-25	1.15e-17	-1.16	-0.72	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-12.63	2.35e-25	1.15e-17	-1.16	-0.72	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
PCPG	trans	rs916888	0.773	rs199535	ENSG00000263503.1	RP11-707O23.5	12.62	2.45e-25	1.19e-17	1.24	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.697	rs199516	ENSG00000263503.1	RP11-707O23.5	-12.61	2.59e-25	1.25e-17	-1.23	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.821	rs199514	ENSG00000263503.1	RP11-707O23.5	-12.61	2.59e-25	1.25e-17	-1.23	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.821	rs199512	ENSG00000263503.1	RP11-707O23.5	-12.61	2.59e-25	1.25e-17	-1.23	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.821	rs199509	ENSG00000263503.1	RP11-707O23.5	-12.61	2.59e-25	1.25e-17	-1.23	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.821	rs199507	ENSG00000263503.1	RP11-707O23.5	-12.61	2.59e-25	1.25e-17	-1.23	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45600869~45602340:-
PCPG	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	12.61	2.61e-25	1.26e-17	0.87	0.72	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
PCPG	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-12.6	2.83e-25	1.36e-17	-0.95	-0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
PCPG	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	12.59	2.87e-25	1.38e-17	0.85	0.72	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
PCPG	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-12.57	3.31e-25	1.58e-17	-1.17	-0.72	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
PCPG	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	12.55	3.82e-25	1.81e-17	0.86	0.72	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
PCPG	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	12.51	4.84e-25	2.27e-17	1.15	0.71	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-12.51	4.84e-25	2.27e-17	-1.14	-0.71	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-12.5	5.2e-25	2.44e-17	-1.16	-0.71	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
PCPG	trans	rs13177918	0.822	rs62382255	ENSG00000224114.1	RP11-343H5.4	12.48	5.63e-25	2.63e-17	1.03	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459154	chr1:206695837~206696269:-
PCPG	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	12.48	5.83e-25	2.71e-17	0.82	0.71	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
PCPG	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	12.46	6.54e-25	3.03e-17	1.15	0.71	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
PCPG	trans	rs916888	0.773	rs199447	ENSG00000263503.1	RP11-707O23.5	12.44	7.18e-25	3.3e-17	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs199445	ENSG00000263503.1	RP11-707O23.5	12.44	7.18e-25	3.3e-17	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs199443	ENSG00000263503.1	RP11-707O23.5	12.44	7.18e-25	3.3e-17	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs199534	ENSG00000263503.1	RP11-707O23.5	12.44	7.18e-25	3.3e-17	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs199533	ENSG00000263503.1	RP11-707O23.5	12.44	7.18e-25	3.3e-17	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45600869~45602340:-
PCPG	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	12.44	7.34e-25	3.37e-17	1.08	0.71	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
PCPG	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	12.41	8.8e-25	4.01e-17	0.97	0.71	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
PCPG	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	12.41	8.84e-25	4.03e-17	1.15	0.71	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
PCPG	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	12.41	9e-25	4.1e-17	0.99	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
PCPG	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	12.38	1.09e-24	4.95e-17	0.91	0.71	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
PCPG	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	12.37	1.11e-24	5.02e-17	0.99	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
PCPG	trans	rs916888	0.779	rs199528	ENSG00000263503.1	RP11-707O23.5	12.35	1.27e-24	5.74e-17	1.23	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.821	rs199525	ENSG00000263503.1	RP11-707O23.5	12.35	1.27e-24	5.74e-17	1.23	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45600869~45602340:-
PCPG	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	12.29	1.86e-24	8.22e-17	1.15	0.71	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
PCPG	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-12.28	2.03e-24	8.92e-17	-0.92	-0.71	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-12.28	2.03e-24	8.92e-17	-0.92	-0.71	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
PCPG	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-12.27	2.12e-24	9.29e-17	-1.07	-0.71	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
PCPG	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	12.25	2.37e-24	1.03e-16	1.12	0.71	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	12.25	2.37e-24	1.03e-16	1.12	0.71	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	12.25	2.37e-24	1.03e-16	1.12	0.71	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	12.25	2.45e-24	1.05e-16	1.14	0.71	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	12.25	2.45e-24	1.05e-16	1.14	0.71	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	12.25	2.45e-24	1.05e-16	1.14	0.71	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	12.25	2.45e-24	1.05e-16	1.14	0.71	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	12.25	2.45e-24	1.05e-16	1.14	0.71	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-12.21	3.09e-24	1.31e-16	-1.15	-0.71	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
PCPG	trans	rs916888	0.821	rs415430	ENSG00000263503.1	RP11-707O23.5	-12.21	3.1e-24	1.31e-16	-1.22	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.779	rs430685	ENSG00000263503.1	RP11-707O23.5	-12.21	3.1e-24	1.31e-16	-1.22	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs199451	ENSG00000263503.1	RP11-707O23.5	12.2	3.21e-24	1.36e-16	1.2	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45600869~45602340:-
PCPG	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-12.15	4.34e-24	1.82e-16	-0.91	-0.7	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
PCPG	trans	rs916888	0.687	rs199456	ENSG00000263503.1	RP11-707O23.5	12.15	4.38e-24	1.84e-16	1.21	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45600869~45602340:-
PCPG	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	12.15	4.39e-24	1.84e-16	1.15	0.7	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
PCPG	trans	rs916888	0.773	rs199448	ENSG00000263503.1	RP11-707O23.5	12.14	4.83e-24	2.02e-16	1.19	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45600869~45602340:-
PCPG	trans	rs13253073	0.545	rs35769167	ENSG00000260318.1	COX6CP1	12.13	4.96e-24	2.07e-16	1.17	0.7	Glucose homeostasis traits;	chr8:99872095	chr16:11903923~11904137:-
PCPG	trans	rs916888	0.821	rs199504	ENSG00000263503.1	RP11-707O23.5	-12.13	5e-24	2.08e-16	-1.2	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45600869~45602340:-
PCPG	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	12.09	6.55e-24	2.7e-16	0.97	0.7	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
PCPG	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	12.07	7.21e-24	2.96e-16	1.12	0.7	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	12.07	7.21e-24	2.96e-16	1.12	0.7	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	12.07	7.22e-24	2.96e-16	1.13	0.7	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
PCPG	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	12.07	7.37e-24	3.02e-16	0.86	0.7	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	12.05	8.12e-24	3.32e-16	0.85	0.7	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
PCPG	trans	rs916888	0.773	rs199457	ENSG00000263503.1	RP11-707O23.5	12.04	8.61e-24	3.51e-16	1.2	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45600869~45602340:-
PCPG	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	12.04	8.9e-24	3.62e-16	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	12.04	8.9e-24	3.62e-16	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-12.02	9.85e-24	4.01e-16	-0.88	-0.7	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
PCPG	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	12.02	9.93e-24	4.04e-16	0.97	0.7	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
PCPG	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	12.01	1.02e-23	4.13e-16	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	12.01	1.02e-23	4.13e-16	0.87	0.7	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
PCPG	trans	rs916888	0.773	rs9896243	ENSG00000263503.1	RP11-707O23.5	12	1.1e-23	4.44e-16	1.2	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45600869~45602340:-
PCPG	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	12	1.12e-23	4.51e-16	1.12	0.7	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	12	1.12e-23	4.51e-16	1.12	0.7	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
PCPG	trans	rs916888	0.821	rs199513	ENSG00000263503.1	RP11-707O23.5	-11.99	1.19e-23	4.78e-16	-1.2	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45600869~45602340:-
PCPG	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	11.95	1.48e-23	5.94e-16	0.96	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
PCPG	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	11.95	1.49e-23	5.98e-16	1.16	0.7	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
PCPG	trans	rs916888	0.821	rs70600	ENSG00000263503.1	RP11-707O23.5	11.92	1.87e-23	7.42e-16	1.21	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45600869~45602340:-
PCPG	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	11.91	1.88e-23	7.46e-16	0.95	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
PCPG	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	11.91	1.89e-23	7.46e-16	0.97	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
PCPG	trans	rs916888	0.821	rs199505	ENSG00000263503.1	RP11-707O23.5	-11.9	2.11e-23	8.33e-16	-1.2	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.821	rs70602	ENSG00000263503.1	RP11-707O23.5	-11.9	2.11e-23	8.33e-16	-1.2	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45600869~45602340:-
PCPG	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	11.89	2.13e-23	8.37e-16	0.85	0.7	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	11.83	3.21e-23	1.26e-15	0.85	0.69	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
PCPG	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	11.83	3.24e-23	1.27e-15	0.97	0.69	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
PCPG	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	11.82	3.39e-23	1.31e-15	0.87	0.69	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
PCPG	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	11.79	4.07e-23	1.57e-15	1.31	0.69	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
PCPG	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	11.79	4.11e-23	1.59e-15	1.1	0.69	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	11.79	4.11e-23	1.59e-15	1.1	0.69	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	11.79	4.11e-23	1.59e-15	1.1	0.69	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
PCPG	trans	rs916888	0.773	rs199439	ENSG00000263503.1	RP11-707O23.5	11.75	5.05e-23	1.93e-15	1.19	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs1378358	ENSG00000263503.1	RP11-707O23.5	11.68	7.89e-23	2.95e-15	1.2	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs538628	ENSG00000263503.1	RP11-707O23.5	11.68	7.89e-23	2.95e-15	1.2	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.773	rs169201	ENSG00000263503.1	RP11-707O23.5	11.68	7.89e-23	2.95e-15	1.2	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45600869~45602340:-
PCPG	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	11.65	9.67e-23	3.6e-15	0.9	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
PCPG	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	11.64	1.04e-22	3.8e-15	0.79	0.69	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
PCPG	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-11.64	1.04e-22	3.8e-15	-0.79	-0.69	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
PCPG	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	11.63	1.06e-22	3.87e-15	1.2	0.69	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-11.63	1.07e-22	3.88e-15	-1.09	-0.69	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
PCPG	trans	rs13177918	0.871	rs11745133	ENSG00000239528.1	RPS14P8	11.61	1.23e-22	4.44e-15	1	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr5:116562562~116562930:+
PCPG	trans	rs13177918	0.871	rs11745194	ENSG00000239528.1	RPS14P8	11.61	1.23e-22	4.44e-15	1	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr5:116562562~116562930:+
PCPG	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-11.59	1.42e-22	5.12e-15	-0.86	-0.69	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
PCPG	trans	rs916888	0.738	rs199515	ENSG00000263503.1	RP11-707O23.5	-11.58	1.48e-22	5.33e-15	-1.16	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45600869~45602340:-
PCPG	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	11.58	1.5e-22	5.38e-15	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	11.57	1.59e-22	5.7e-15	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	11.57	1.59e-22	5.7e-15	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	11.57	1.59e-22	5.7e-15	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	11.56	1.64e-22	5.79e-15	0.85	0.69	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
PCPG	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	11.54	1.84e-22	6.45e-15	0.85	0.69	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	11.54	1.84e-22	6.45e-15	0.85	0.69	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
PCPG	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	11.54	1.88e-22	6.58e-15	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	11.54	1.88e-22	6.58e-15	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	11.54	1.93e-22	6.75e-15	0.86	0.69	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
PCPG	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	11.52	2.09e-22	7.3e-15	0.91	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
PCPG	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-11.52	2.11e-22	7.34e-15	-0.82	-0.69	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
PCPG	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	11.51	2.21e-22	7.71e-15	1.29	0.68	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
PCPG	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-11.51	2.26e-22	7.86e-15	-0.7	-0.68	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	11.51	2.26e-22	7.86e-15	0.7	0.68	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	11.51	2.27e-22	7.89e-15	0.7	0.68	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	11.51	2.27e-22	7.89e-15	0.7	0.68	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
PCPG	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	11.51	2.34e-22	8.11e-15	0.86	0.68	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
PCPG	trans	rs916888	0.821	rs199506	ENSG00000263503.1	RP11-707O23.5	-11.5	2.44e-22	8.43e-15	-1.2	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45600869~45602340:-
PCPG	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	11.5	2.47e-22	8.54e-15	0.84	0.68	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
PCPG	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	11.49	2.6e-22	8.92e-15	0.84	0.68	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
PCPG	trans	rs13177918	0.834	rs13163277	ENSG00000239528.1	RPS14P8	11.49	2.64e-22	9.06e-15	1	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr5:116562562~116562930:+
PCPG	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-11.48	2.67e-22	9.14e-15	-0.79	-0.68	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-11.48	2.67e-22	9.14e-15	-0.79	-0.68	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
PCPG	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	11.47	2.93e-22	9.99e-15	0.91	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
PCPG	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	11.45	3.36e-22	1.13e-14	1.09	0.68	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	11.45	3.36e-22	1.13e-14	1.09	0.68	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	11.45	3.36e-22	1.13e-14	1.09	0.68	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	11.45	3.36e-22	1.13e-14	1.09	0.68	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	11.45	3.36e-22	1.13e-14	1.09	0.68	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	11.45	3.36e-22	1.13e-14	1.09	0.68	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
PCPG	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	11.45	3.38e-22	1.14e-14	0.93	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
PCPG	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	11.43	3.77e-22	1.27e-14	1.12	0.68	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
PCPG	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	11.41	4.23e-22	1.41e-14	1.28	0.68	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
PCPG	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	11.41	4.23e-22	1.41e-14	1.28	0.68	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
PCPG	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-11.38	5.09e-22	1.68e-14	-0.8	-0.68	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
PCPG	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	11.34	6.3e-22	2.07e-14	1.24	0.68	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
PCPG	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	11.34	6.5e-22	2.14e-14	0.84	0.68	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
PCPG	trans	rs13177918	0.798	rs12516161	ENSG00000239528.1	RPS14P8	11.33	6.93e-22	2.27e-14	0.99	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr5:116562562~116562930:+
PCPG	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	11.33	7.07e-22	2.32e-14	0.68	0.68	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
PCPG	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	11.31	7.6e-22	2.49e-14	0.84	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
PCPG	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	11.29	8.61e-22	2.81e-14	0.84	0.68	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
PCPG	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	11.28	9.33e-22	3.03e-14	1.28	0.68	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
PCPG	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-11.28	9.39e-22	3.05e-14	-0.68	-0.68	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
PCPG	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	11.28	9.46e-22	3.06e-14	1.23	0.68	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
PCPG	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-11.26	1.05e-21	3.36e-14	-1.26	-0.68	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
PCPG	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-11.26	1.07e-21	3.42e-14	-0.8	-0.68	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
PCPG	trans	rs116095464	0.51	rs10057501	ENSG00000185986.11	SDHAP3	11.23	1.27e-21	4.03e-14	0.86	0.68	Breast cancer;	chr5:239430	chr5:1572222~1594620:-
PCPG	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	11.23	1.3e-21	4.1e-14	0.93	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.822	rs62382255	ENSG00000239528.1	RPS14P8	11.21	1.47e-21	4.59e-14	0.99	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459154	chr5:116562562~116562930:+
PCPG	trans	rs116095464	0.542	rs28650039	ENSG00000185986.11	SDHAP3	11.2	1.5e-21	4.62e-14	0.85	0.67	Breast cancer;	chr5:273839	chr5:1572222~1594620:-
PCPG	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	11.19	1.59e-21	4.85e-14	0.69	0.67	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.73	rs1259508	ENSG00000172974.11	AC007318.5	11.19	1.64e-21	5.01e-14	0.7	0.67	Pneumonia;	chr10:75238334	chr2:65205108~65205988:+
PCPG	trans	rs116095464	0.558	rs6555055	ENSG00000185986.11	SDHAP3	11.18	1.71e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:226045	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7725227	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:233402	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7710005	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:233457	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7708182	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:234673	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10058428	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:235493	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10036253	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:238404	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10075018	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:239060	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10076655	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:239349	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10057492	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:239388	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs28418643	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:240744	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.614	rs62344339	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:252880	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs9687898	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:253837	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs9688045	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:253920	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs112343653	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:257059	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs73024831	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:257077	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs62344345	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:257305	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6869925	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:263921	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6875291	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:264077	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6866776	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:264380	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6874745	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:264412	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7715108	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:264546	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7730700	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:264598	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10057674	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:266698	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs1812843	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:267543	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs12173244	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:269409	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs56127718	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:270158	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs55664502	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:270370	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.51	rs7723883	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:270683	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.614	rs10061564	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:271214	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs55776650	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:273711	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs28635197	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:278956	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs59113266	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:279850	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs11959126	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:283765	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7356696	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:284136	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7356561	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:284266	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs59284383	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:284410	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs28558836	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:285633	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7731089	ENSG00000185986.11	SDHAP3	11.17	1.79e-21	5.12e-14	0.85	0.67	Breast cancer;	chr5:290307	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.614	rs28736753	ENSG00000185986.11	SDHAP3	11.16	1.99e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:273966	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6555056	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:226107	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10043002	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:226638	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs62347678	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:227381	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs73031482	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:227479	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs2162870	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:228014	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs28729548	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:228910	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs9688136	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:229233	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.51	rs55750776	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:230352	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.764	rs10069197	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:230707	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.867	rs10074958	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:230713	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs2288459	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:231028	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs2288458	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:231145	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs2288457	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:231155	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7736600	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:231222	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.51	rs7714944	ENSG00000185986.11	SDHAP3	11.16	2e-21	5.59e-14	0.85	0.67	Breast cancer;	chr5:231650	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs1541822	ENSG00000185986.11	SDHAP3	-11.16	2e-21	5.59e-14	-0.85	-0.67	Breast cancer;	chr5:269119	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7703803	ENSG00000185986.11	SDHAP3	11.15	2.11e-21	5.9e-14	0.85	0.67	Breast cancer;	chr5:292196	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs62347683	ENSG00000185986.11	SDHAP3	11.14	2.17e-21	6.03e-14	0.85	0.67	Breast cancer;	chr5:230216	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs1971229	ENSG00000185986.11	SDHAP3	11.14	2.27e-21	6.29e-14	0.85	0.67	Breast cancer;	chr5:268072	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.614	rs4371799	ENSG00000185986.11	SDHAP3	11.14	2.27e-21	6.29e-14	0.85	0.67	Breast cancer;	chr5:268077	chr5:1572222~1594620:-
PCPG	trans	rs2657294	0.73	rs1259505	ENSG00000172974.11	AC007318.5	11.13	2.39e-21	6.62e-14	0.69	0.67	Pneumonia;	chr10:75237183	chr2:65205108~65205988:+
PCPG	trans	rs13253073	0.883	rs2305290	ENSG00000260318.1	COX6CP1	11.12	2.51e-21	6.93e-14	1.27	0.67	Glucose homeostasis traits;	chr8:99819066	chr16:11903923~11904137:-
PCPG	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	11.12	2.51e-21	6.94e-14	0.68	0.67	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
PCPG	trans	rs116095464	0.558	rs7708515	ENSG00000185986.11	SDHAP3	11.11	2.68e-21	7.41e-14	0.77	0.67	Breast cancer;	chr5:234874	chr5:1572222~1594620:-
PCPG	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	11.1	2.76e-21	7.59e-14	1.26	0.67	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
PCPG	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	11.1	2.76e-21	7.59e-14	1.26	0.67	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
PCPG	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	11.1	2.82e-21	7.74e-14	1.27	0.67	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
PCPG	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	11.1	2.89e-21	7.93e-14	0.82	0.67	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
PCPG	trans	rs116095464	0.51	rs73016876	ENSG00000185986.11	SDHAP3	11.09	3.04e-21	8.26e-14	0.89	0.67	Breast cancer;	chr5:244360	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6882584	ENSG00000185986.11	SDHAP3	11.08	3.29e-21	8.85e-14	0.85	0.67	Breast cancer;	chr5:223296	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs3213838	ENSG00000185986.11	SDHAP3	11.08	3.29e-21	8.85e-14	0.85	0.67	Breast cancer;	chr5:223775	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6555052	ENSG00000185986.11	SDHAP3	11.08	3.29e-21	8.85e-14	0.85	0.67	Breast cancer;	chr5:224153	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs61689490	ENSG00000185986.11	SDHAP3	11.08	3.29e-21	8.85e-14	0.85	0.67	Breast cancer;	chr5:224789	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs61492827	ENSG00000185986.11	SDHAP3	11.08	3.29e-21	8.85e-14	0.85	0.67	Breast cancer;	chr5:225659	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs56342538	ENSG00000185986.11	SDHAP3	11.08	3.29e-21	8.85e-14	0.85	0.67	Breast cancer;	chr5:225681	chr5:1572222~1594620:-
PCPG	trans	rs13177918	0.871	rs11745133	ENSG00000213058.3	RP4-765C7.2	11.07	3.42e-21	9.19e-14	1	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150457826	chr1:178411616~178411972:+
PCPG	trans	rs13177918	0.871	rs11745194	ENSG00000213058.3	RP4-765C7.2	11.07	3.42e-21	9.19e-14	1	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150458065	chr1:178411616~178411972:+
PCPG	trans	rs116095464	0.558	rs9654452	ENSG00000185986.11	SDHAP3	11.07	3.5e-21	9.37e-14	0.85	0.67	Breast cancer;	chr5:299446	chr5:1572222~1594620:-
PCPG	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	11.06	3.58e-21	9.58e-14	0.88	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
PCPG	trans	rs116095464	0.558	rs6872854	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:208923	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.867	rs7726582	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:215234	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.619	rs2303741	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:218241	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.614	rs10067482	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:219213	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.614	rs56299325	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:220479	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs62346526	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:220499	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs56043030	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:220802	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10067021	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:221375	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs9312977	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:221801	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6881920	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:222296	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6878061	ENSG00000185986.11	SDHAP3	11.05	3.82e-21	1.01e-13	0.85	0.67	Breast cancer;	chr5:222957	chr5:1572222~1594620:-
PCPG	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	11.05	3.87e-21	1.02e-13	0.81	0.67	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	11.04	4.09e-21	1.07e-13	0.74	0.67	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
PCPG	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	11.03	4.31e-21	1.13e-13	1.25	0.67	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
PCPG	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	11.02	4.6e-21	1.2e-13	0.68	0.67	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
PCPG	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	11	5.37e-21	1.38e-13	0.77	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
PCPG	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-10.99	5.74e-21	1.48e-13	-0.93	-0.67	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
PCPG	trans	rs116095464	0.681	rs10060016	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:240985	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10057299	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:242020	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs13357299	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:242096	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs13354585	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:242148	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs13356367	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:242280	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.85	rs10055295	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:243634	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10055354	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:243679	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs60251075	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:245177	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs62344300	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:246221	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10462754	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:246554	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10462755	ENSG00000185986.11	SDHAP3	10.97	6.34e-21	1.6e-13	0.85	0.67	Breast cancer;	chr5:246633	chr5:1572222~1594620:-
PCPG	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	10.95	7.08e-21	1.78e-13	0.95	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
PCPG	trans	rs13177918	0.834	rs13163277	ENSG00000213058.3	RP4-765C7.2	10.95	7.17e-21	1.8e-13	0.99	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459359	chr1:178411616~178411972:+
PCPG	trans	rs116095464	0.681	rs9687745	ENSG00000185986.11	SDHAP3	10.94	7.4e-21	1.85e-13	0.84	0.67	Breast cancer;	chr5:229194	chr5:1572222~1594620:-
PCPG	trans	rs13177918	0.798	rs12516161	ENSG00000213058.3	RP4-765C7.2	10.9	9.91e-21	2.44e-13	0.99	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150461098	chr1:178411616~178411972:+
PCPG	trans	rs6959887	0.609	rs2191883	ENSG00000255583.2	RP11-415I12.2	10.88	1.1e-20	2.7e-13	0.7	0.66	Birth weight;	chr7:35233679	chr12:63682523~63724935:-
PCPG	trans	rs116095464	0.558	rs10079760	ENSG00000185986.11	SDHAP3	10.87	1.2e-20	2.93e-13	0.84	0.66	Breast cancer;	chr5:230663	chr5:1572222~1594620:-
PCPG	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-10.85	1.29e-20	3.16e-13	-0.83	-0.66	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
PCPG	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	10.84	1.36e-20	3.3e-13	1.02	0.66	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
PCPG	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	10.84	1.43e-20	3.48e-13	1.26	0.66	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-10.83	1.53e-20	3.7e-13	-0.74	-0.66	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-10.83	1.53e-20	3.7e-13	-0.74	-0.66	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
PCPG	trans	rs6959887	0.609	rs4723398	ENSG00000255583.2	RP11-415I12.2	10.82	1.58e-20	3.82e-13	0.69	0.66	Birth weight;	chr7:35233311	chr12:63682523~63724935:-
PCPG	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-10.81	1.65e-20	3.96e-13	-0.77	-0.66	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
PCPG	trans	rs116095464	0.558	rs7713524	ENSG00000185986.11	SDHAP3	-10.8	1.76e-20	4.21e-13	-0.84	-0.66	Breast cancer;	chr5:276085	chr5:1572222~1594620:-
PCPG	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	10.8	1.79e-20	4.28e-13	0.79	0.66	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	10.8	1.79e-20	4.28e-13	0.79	0.66	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
PCPG	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	10.79	1.9e-20	4.51e-13	0.81	0.66	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
PCPG	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-10.77	2.14e-20	5.08e-13	-0.78	-0.66	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
PCPG	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	10.74	2.65e-20	6.12e-13	0.75	0.66	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	10.74	2.65e-20	6.12e-13	0.75	0.66	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	10.74	2.65e-20	6.12e-13	0.75	0.66	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	10.74	2.65e-20	6.12e-13	0.75	0.66	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
PCPG	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-10.73	2.79e-20	6.43e-13	-0.82	-0.66	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-10.72	2.87e-20	6.6e-13	-0.73	-0.66	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
PCPG	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-10.7	3.28e-20	7.38e-13	-0.76	-0.66	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-10.7	3.28e-20	7.38e-13	-0.76	-0.66	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-10.7	3.28e-20	7.38e-13	-0.76	-0.66	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-10.7	3.28e-20	7.38e-13	-0.76	-0.66	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-10.7	3.28e-20	7.38e-13	-0.76	-0.66	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
PCPG	trans	rs116095464	0.558	rs113796397	ENSG00000185986.11	SDHAP3	10.68	3.74e-20	8.01e-13	0.85	0.66	Breast cancer;	chr5:246388	chr5:1572222~1594620:-
PCPG	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	10.67	3.98e-20	8.5e-13	0.75	0.66	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
PCPG	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-10.67	3.99e-20	8.51e-13	-0.76	-0.66	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
PCPG	trans	rs916888	0.821	rs199499	ENSG00000263503.1	RP11-707O23.5	10.67	4.06e-20	8.66e-13	1.22	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:45600869~45602340:-
PCPG	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	10.66	4.17e-20	8.88e-13	0.71	0.66	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	10.66	4.17e-20	8.88e-13	0.71	0.66	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
PCPG	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	10.65	4.49e-20	9.53e-13	0.88	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
PCPG	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	10.65	4.52e-20	9.58e-13	0.8	0.66	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	10.65	4.52e-20	9.58e-13	0.8	0.66	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
PCPG	trans	rs116095464	0.614	rs62344292	ENSG00000185986.11	SDHAP3	10.61	5.55e-20	1.16e-12	0.84	0.65	Breast cancer;	chr5:244515	chr5:1572222~1594620:-
PCPG	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	10.58	6.78e-20	1.41e-12	0.75	0.65	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
PCPG	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-10.56	7.6e-20	1.57e-12	-0.75	-0.65	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-10.56	7.6e-20	1.57e-12	-0.75	-0.65	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-10.56	7.6e-20	1.57e-12	-0.75	-0.65	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
PCPG	trans	rs116095464	0.558	rs62347677	ENSG00000185986.11	SDHAP3	10.56	7.79e-20	1.59e-12	0.83	0.65	Breast cancer;	chr5:227338	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10052012	ENSG00000185986.11	SDHAP3	10.56	7.79e-20	1.59e-12	0.83	0.65	Breast cancer;	chr5:231793	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10077076	ENSG00000185986.11	SDHAP3	10.56	7.79e-20	1.59e-12	0.83	0.65	Breast cancer;	chr5:231825	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10080225	ENSG00000185986.11	SDHAP3	10.56	7.79e-20	1.59e-12	0.83	0.65	Breast cancer;	chr5:232060	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10475136	ENSG00000185986.11	SDHAP3	10.56	7.79e-20	1.59e-12	0.83	0.65	Breast cancer;	chr5:232681	chr5:1572222~1594620:-
PCPG	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	10.56	7.93e-20	1.62e-12	0.8	0.65	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	10.56	7.93e-20	1.62e-12	0.8	0.65	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	10.55	8.14e-20	1.66e-12	0.82	0.65	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
PCPG	trans	rs116095464	0.558	rs57335027	ENSG00000185986.11	SDHAP3	10.55	8.37e-20	1.71e-12	0.82	0.65	Breast cancer;	chr5:262792	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs6878087	ENSG00000185986.11	SDHAP3	-10.55	8.44e-20	1.72e-12	-0.8	-0.65	Breast cancer;	chr5:223002	chr5:1572222~1594620:-
PCPG	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	10.51	1.03e-19	2.07e-12	1.23	0.65	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
PCPG	trans	rs13177918	0.822	rs62382255	ENSG00000213058.3	RP4-765C7.2	10.51	1.08e-19	2.17e-12	0.97	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150459154	chr1:178411616~178411972:+
PCPG	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	10.48	1.28e-19	2.55e-12	0.75	0.65	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
PCPG	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	10.47	1.32e-19	2.63e-12	0.81	0.65	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
PCPG	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	10.47	1.35e-19	2.68e-12	0.75	0.65	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
PCPG	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	10.43	1.7e-19	3.36e-12	0.83	0.65	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
PCPG	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	10.42	1.78e-19	3.51e-12	0.75	0.65	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
PCPG	trans	rs116095464	0.558	rs6866632	ENSG00000185986.11	SDHAP3	10.42	1.83e-19	3.59e-12	0.83	0.65	Breast cancer;	chr5:264314	chr5:1572222~1594620:-
PCPG	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	10.41	1.9e-19	3.73e-12	0.79	0.65	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
PCPG	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	10.41	1.99e-19	3.89e-12	0.71	0.65	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
PCPG	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	10.4	2.11e-19	4.12e-12	0.76	0.65	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	10.4	2.11e-19	4.12e-12	0.76	0.65	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	10.4	2.11e-19	4.12e-12	0.76	0.65	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
PCPG	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	10.37	2.46e-19	4.77e-12	0.85	0.65	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
PCPG	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	10.35	2.75e-19	5.32e-12	0.75	0.65	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
PCPG	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-10.33	3.08e-19	5.93e-12	-0.77	-0.64	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	10.33	3.1e-19	5.96e-12	0.82	0.64	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
PCPG	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	10.33	3.19e-19	6.13e-12	0.86	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
PCPG	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-10.3	3.75e-19	7.15e-12	-1.22	-0.64	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
PCPG	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	10.3	3.8e-19	7.25e-12	0.79	0.64	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
PCPG	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-10.3	3.84e-19	7.32e-12	-0.74	-0.64	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
PCPG	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	10.27	4.64e-19	8.8e-12	0.85	0.64	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-10.26	4.82e-19	9.13e-12	-0.85	-0.64	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-10.26	4.82e-19	9.13e-12	-0.85	-0.64	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-10.26	4.82e-19	9.13e-12	-0.85	-0.64	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	10.23	5.63e-19	1.05e-11	0.85	0.64	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	10.23	5.63e-19	1.05e-11	0.85	0.64	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
PCPG	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	10.23	5.78e-19	1.08e-11	0.76	0.64	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	10.21	6.64e-19	1.23e-11	0.84	0.64	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	10.21	6.64e-19	1.23e-11	0.84	0.64	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	10.21	6.64e-19	1.23e-11	0.84	0.64	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	10.21	6.64e-19	1.23e-11	0.84	0.64	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	10.21	6.64e-19	1.23e-11	0.84	0.64	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	10.21	6.64e-19	1.23e-11	0.84	0.64	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-10.21	6.68e-19	1.23e-11	-0.9	-0.64	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-10.19	7.26e-19	1.34e-11	-0.85	-0.64	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	10.18	7.63e-19	1.4e-11	0.86	0.64	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
PCPG	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-10.18	8.03e-19	1.47e-11	-0.77	-0.64	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	10.15	9.33e-19	1.69e-11	0.76	0.64	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
PCPG	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	10.15	9.36e-19	1.69e-11	0.75	0.64	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
PCPG	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-10.15	9.6e-19	1.73e-11	-0.85	-0.64	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-10.14	9.98e-19	1.8e-11	-0.84	-0.64	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-10.14	1.01e-18	1.82e-11	-0.85	-0.64	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-10.14	1.01e-18	1.82e-11	-0.85	-0.64	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	10.13	1.03e-18	1.86e-11	0.8	0.64	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-10.13	1.05e-18	1.87e-11	-0.72	-0.64	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
PCPG	trans	rs116095464	0.558	rs6555058	ENSG00000185986.11	SDHAP3	-10.12	1.14e-18	2.02e-11	-0.81	-0.64	Breast cancer;	chr5:226261	chr5:1572222~1594620:-
PCPG	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	10.12	1.15e-18	2.04e-11	0.82	0.64	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
PCPG	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-10.12	1.15e-18	2.05e-11	-0.8	-0.64	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
PCPG	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	10.11	1.19e-18	2.12e-11	0.74	0.64	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	10.1	1.25e-18	2.21e-11	0.74	0.64	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-10.1	1.25e-18	2.22e-11	-0.79	-0.64	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-10.09	1.35e-18	2.38e-11	-0.83	-0.64	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-10.09	1.35e-18	2.38e-11	-0.83	-0.64	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
PCPG	trans	rs116095464	0.558	rs6879656	ENSG00000185986.11	SDHAP3	10.07	1.53e-18	2.67e-11	0.87	0.64	Breast cancer;	chr5:264313	chr5:1572222~1594620:-
PCPG	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	10.07	1.56e-18	2.71e-11	0.84	0.63	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-10.06	1.65e-18	2.86e-11	-0.81	-0.63	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
PCPG	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	10.06	1.67e-18	2.89e-11	0.82	0.63	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
PCPG	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	10.05	1.68e-18	2.92e-11	0.81	0.63	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
PCPG	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	10.05	1.78e-18	3.08e-11	1.19	0.63	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
PCPG	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	10.03	1.95e-18	3.36e-11	0.8	0.63	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
PCPG	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	10.03	1.98e-18	3.41e-11	0.79	0.63	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
PCPG	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	10.03	2e-18	3.44e-11	0.84	0.63	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	10.03	2e-18	3.44e-11	0.84	0.63	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	10.03	2e-18	3.44e-11	0.84	0.63	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	10.02	2.12e-18	3.62e-11	0.8	0.63	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	10	2.39e-18	4.07e-11	0.8	0.63	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	10	2.39e-18	4.07e-11	0.8	0.63	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
PCPG	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-9.98	2.61e-18	4.44e-11	-0.83	-0.63	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
PCPG	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-9.97	2.79e-18	4.73e-11	-0.72	-0.63	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
PCPG	trans	rs12291225	0.546	rs11023199	ENSG00000236360.2	RP11-334A14.2	9.96	2.93e-18	4.95e-11	0.74	0.63	Sense of smell;	chr11:14372712	chr1:52993201~52993702:-
PCPG	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	9.95	3.14e-18	5.26e-11	0.92	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
PCPG	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-9.95	3.26e-18	5.46e-11	-0.77	-0.63	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
PCPG	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	9.94	3.3e-18	5.51e-11	0.79	0.63	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	9.94	3.3e-18	5.51e-11	0.79	0.63	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	9.94	3.3e-18	5.51e-11	0.79	0.63	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
PCPG	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	9.94	3.36e-18	5.61e-11	0.82	0.63	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
PCPG	trans	rs13253073	0.883	rs12545602	ENSG00000260318.1	COX6CP1	9.94	3.43e-18	5.73e-11	1.2	0.63	Glucose homeostasis traits;	chr8:99834612	chr16:11903923~11904137:-
PCPG	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	9.93	3.57e-18	5.94e-11	0.8	0.63	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
PCPG	trans	rs13253073	0.765	rs35615286	ENSG00000260318.1	COX6CP1	9.91	4.01e-18	6.66e-11	1.2	0.63	Glucose homeostasis traits;	chr8:99834866	chr16:11903923~11904137:-
PCPG	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	9.9	4.19e-18	6.97e-11	0.77	0.63	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
PCPG	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	9.9	4.26e-18	7.07e-11	0.85	0.63	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	9.9	4.26e-18	7.07e-11	0.85	0.63	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	9.9	4.26e-18	7.07e-11	0.85	0.63	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	9.88	4.98e-18	8.19e-11	0.8	0.63	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	9.88	4.98e-18	8.19e-11	0.8	0.63	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
PCPG	trans	rs116095464	0.558	rs7714335	ENSG00000185986.11	SDHAP3	9.87	5.2e-18	8.54e-11	0.84	0.63	Breast cancer;	chr5:263398	chr5:1572222~1594620:-
PCPG	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	9.86	5.55e-18	9.11e-11	0.77	0.63	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
PCPG	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	9.85	5.83e-18	9.55e-11	0.78	0.63	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	9.85	5.83e-18	9.55e-11	0.78	0.63	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
PCPG	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	9.83	6.42e-18	1.05e-10	0.83	0.63	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
PCPG	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	9.83	6.53e-18	1.06e-10	0.75	0.63	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	9.81	7.26e-18	1.18e-10	0.78	0.63	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
PCPG	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	9.79	8.35e-18	1.35e-10	0.81	0.62	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	9.79	8.35e-18	1.35e-10	0.81	0.62	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
PCPG	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	9.78	8.72e-18	1.41e-10	0.84	0.62	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
PCPG	trans	rs6959887	0.609	rs4720169	ENSG00000255583.2	RP11-415I12.2	9.78	8.82e-18	1.42e-10	0.67	0.62	Birth weight;	chr7:35247689	chr12:63682523~63724935:-
PCPG	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-9.78	8.95e-18	1.44e-10	-0.79	-0.62	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
PCPG	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	9.77	9.55e-18	1.54e-10	0.77	0.62	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
PCPG	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	9.77	9.56e-18	1.54e-10	0.84	0.62	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
PCPG	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	9.76	1e-17	1.61e-10	0.77	0.62	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
PCPG	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-9.75	1.06e-17	1.7e-10	-0.79	-0.62	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
PCPG	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	9.75	1.06e-17	1.7e-10	1.45	0.62	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
PCPG	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-9.75	1.09e-17	1.74e-10	-0.77	-0.62	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
PCPG	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	9.72	1.24e-17	1.97e-10	0.78	0.62	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
PCPG	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	9.72	1.24e-17	1.98e-10	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	9.72	1.24e-17	1.98e-10	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	9.72	1.24e-17	1.98e-10	0.83	0.62	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	9.72	1.24e-17	1.98e-10	0.83	0.62	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	9.72	1.24e-17	1.98e-10	0.83	0.62	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
PCPG	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	9.71	1.31e-17	2.09e-10	0.76	0.62	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
PCPG	trans	rs916888	0.779	rs199526	ENSG00000263503.1	RP11-707O23.5	-9.71	1.32e-17	2.1e-10	-0.98	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45600869~45602340:-
PCPG	trans	rs61990749	0.571	rs2364841	ENSG00000235400.1	RP4-641G12.4	9.71	1.33e-17	2.11e-10	1.09	0.62	Fibroblast growth factor basic levels;	chr14:77817693	chr1:78749073~78750659:+
PCPG	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	9.71	1.35e-17	2.14e-10	0.78	0.62	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
PCPG	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	9.71	1.36e-17	2.16e-10	0.82	0.62	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
PCPG	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-9.7	1.4e-17	2.22e-10	-0.77	-0.62	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
PCPG	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	9.7	1.43e-17	2.26e-10	0.82	0.62	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
PCPG	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	9.7	1.46e-17	2.31e-10	0.76	0.62	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-9.68	1.61e-17	2.53e-10	-0.78	-0.62	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
PCPG	trans	rs116095464	0.614	rs78905930	ENSG00000185986.11	SDHAP3	9.68	1.66e-17	2.61e-10	0.81	0.62	Breast cancer;	chr5:246445	chr5:1572222~1594620:-
PCPG	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	9.68	1.67e-17	2.61e-10	0.89	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
PCPG	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	9.67	1.69e-17	2.65e-10	1.08	0.62	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
PCPG	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	9.67	1.75e-17	2.74e-10	0.76	0.62	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
PCPG	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	9.66	1.81e-17	2.83e-10	0.68	0.62	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
PCPG	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	9.66	1.82e-17	2.85e-10	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
PCPG	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	9.65	1.91e-17	2.98e-10	0.76	0.62	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
PCPG	trans	rs6959887	0.548	rs1861095	ENSG00000255583.2	RP11-415I12.2	-9.64	2.01e-17	3.13e-10	-0.64	-0.62	Birth weight;	chr7:35265713	chr12:63682523~63724935:-
PCPG	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	9.64	2.09e-17	3.26e-10	0.7	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
PCPG	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	9.63	2.15e-17	3.34e-10	1.08	0.62	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
PCPG	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-9.63	2.17e-17	3.37e-10	-0.81	-0.62	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-9.63	2.17e-17	3.37e-10	-0.81	-0.62	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-9.63	2.17e-17	3.37e-10	-0.81	-0.62	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	9.62	2.3e-17	3.55e-10	0.8	0.62	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	9.62	2.3e-17	3.55e-10	0.8	0.62	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
PCPG	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	9.61	2.44e-17	3.76e-10	0.74	0.62	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	9.61	2.44e-17	3.76e-10	0.74	0.62	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	9.61	2.44e-17	3.76e-10	0.74	0.62	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
PCPG	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	9.61	2.5e-17	3.85e-10	0.83	0.62	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	9.61	2.5e-17	3.85e-10	0.83	0.62	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
PCPG	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	9.6	2.54e-17	3.91e-10	0.74	0.62	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	9.59	2.71e-17	4.17e-10	0.73	0.62	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
PCPG	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	9.59	2.8e-17	4.3e-10	0.75	0.62	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	9.59	2.8e-17	4.3e-10	0.75	0.62	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
PCPG	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	9.59	2.8e-17	4.3e-10	0.75	0.62	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
PCPG	trans	rs6959887	0.548	rs33916666	ENSG00000255583.2	RP11-415I12.2	-9.58	2.91e-17	4.46e-10	-0.65	-0.62	Birth weight;	chr7:35267107	chr12:63682523~63724935:-
PCPG	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	9.58	2.96e-17	4.53e-10	0.78	0.62	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	9.58	2.96e-17	4.53e-10	0.78	0.62	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
PCPG	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	9.58	2.96e-17	4.53e-10	0.77	0.62	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
PCPG	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	9.57	3.06e-17	4.68e-10	0.76	0.62	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	9.57	3.06e-17	4.68e-10	0.76	0.62	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
PCPG	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	9.57	3.15e-17	4.8e-10	0.77	0.62	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
PCPG	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	9.57	3.18e-17	4.84e-10	0.77	0.62	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
PCPG	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	9.57	3.18e-17	4.84e-10	0.77	0.62	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
PCPG	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-9.56	3.33e-17	5.05e-10	-0.85	-0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
PCPG	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	9.56	3.37e-17	5.12e-10	0.74	0.62	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
PCPG	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	9.56	3.38e-17	5.12e-10	0.83	0.62	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
PCPG	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	9.55	3.44e-17	5.21e-10	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	9.55	3.44e-17	5.21e-10	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
PCPG	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	9.55	3.47e-17	5.25e-10	0.81	0.62	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
PCPG	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	9.55	3.61e-17	5.46e-10	1.34	0.61	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	9.55	3.61e-17	5.46e-10	1.34	0.61	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	9.55	3.61e-17	5.46e-10	1.34	0.61	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	9.55	3.61e-17	5.46e-10	1.34	0.61	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
PCPG	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	9.55	3.62e-17	5.46e-10	0.77	0.61	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
PCPG	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	9.54	3.68e-17	5.55e-10	0.76	0.61	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
PCPG	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	9.54	3.68e-17	5.55e-10	0.76	0.61	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
PCPG	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	9.54	3.72e-17	5.61e-10	0.79	0.61	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	9.54	3.82e-17	5.76e-10	0.79	0.61	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	9.54	3.82e-17	5.76e-10	0.79	0.61	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	9.54	3.82e-17	5.76e-10	0.79	0.61	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	9.54	3.82e-17	5.76e-10	0.79	0.61	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	9.54	3.82e-17	5.76e-10	0.79	0.61	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
PCPG	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	9.54	3.86e-17	5.81e-10	1.06	0.61	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
PCPG	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	9.53	3.91e-17	5.88e-10	0.79	0.61	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	9.53	3.94e-17	5.92e-10	0.74	0.61	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	9.53	3.94e-17	5.92e-10	0.74	0.61	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	9.53	3.94e-17	5.92e-10	0.74	0.61	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
PCPG	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	9.52	4.2e-17	6.29e-10	0.81	0.61	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
PCPG	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	9.51	4.47e-17	6.66e-10	1.29	0.61	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	9.51	4.47e-17	6.66e-10	1.29	0.61	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	9.51	4.47e-17	6.66e-10	1.29	0.61	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	9.51	4.47e-17	6.66e-10	1.29	0.61	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	9.51	4.47e-17	6.66e-10	1.29	0.61	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	9.51	4.47e-17	6.66e-10	1.29	0.61	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	9.51	4.47e-17	6.66e-10	1.29	0.61	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
PCPG	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-9.51	4.54e-17	6.75e-10	-0.78	-0.61	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
PCPG	trans	rs959695	0.864	rs7844422	ENSG00000260318.1	COX6CP1	9.5	4.86e-17	7.21e-10	0.78	0.61	Hippocampal atrophy;	chr8:99837782	chr16:11903923~11904137:-
PCPG	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-9.49	4.92e-17	7.28e-10	-0.84	-0.61	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-9.49	4.92e-17	7.28e-10	-0.84	-0.61	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-9.49	4.92e-17	7.28e-10	-0.84	-0.61	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	9.49	5.05e-17	7.45e-10	0.78	0.61	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
PCPG	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	9.48	5.32e-17	7.84e-10	1.29	0.61	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
PCPG	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	9.48	5.41e-17	7.98e-10	0.84	0.61	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
PCPG	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	9.48	5.42e-17	7.98e-10	0.71	0.61	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
PCPG	trans	rs10242455	0.702	rs74416635	ENSG00000228834.1	RP11-249L21.4	9.47	5.64e-17	8.3e-10	1.34	0.61	Blood metabolite levels;	chr7:99582946	chr6:108907615~108907873:-
PCPG	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	9.47	5.76e-17	8.44e-10	0.72	0.61	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	9.47	5.76e-17	8.44e-10	0.72	0.61	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	9.47	5.76e-17	8.44e-10	0.72	0.61	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
PCPG	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	9.46	5.95e-17	8.71e-10	0.79	0.61	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
PCPG	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	9.46	6.13e-17	8.95e-10	0.75	0.61	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
PCPG	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	9.46	6.23e-17	9.08e-10	0.78	0.61	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	9.46	6.23e-17	9.08e-10	0.78	0.61	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	9.46	6.23e-17	9.08e-10	0.78	0.61	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
PCPG	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	9.45	6.45e-17	9.39e-10	0.76	0.61	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
PCPG	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	9.44	6.66e-17	9.69e-10	0.67	0.61	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
PCPG	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	9.44	6.81e-17	9.91e-10	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	9.44	6.83e-17	9.92e-10	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	9.44	6.83e-17	9.92e-10	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	9.44	6.83e-17	9.92e-10	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	9.44	6.83e-17	9.92e-10	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	9.44	6.83e-17	9.92e-10	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
PCPG	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	9.43	7.12e-17	1.03e-09	0.74	0.61	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	9.43	7.12e-17	1.03e-09	0.74	0.61	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
PCPG	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	9.43	7.25e-17	1.05e-09	0.76	0.61	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
PCPG	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	9.43	7.29e-17	1.05e-09	0.74	0.61	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	9.43	7.29e-17	1.05e-09	0.74	0.61	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
PCPG	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	9.42	7.68e-17	1.11e-09	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-9.42	7.68e-17	1.11e-09	-0.8	-0.61	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
PCPG	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	9.42	7.83e-17	1.13e-09	0.83	0.61	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
PCPG	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	9.41	8.39e-17	1.21e-09	0.79	0.61	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	9.41	8.39e-17	1.21e-09	0.79	0.61	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	9.41	8.39e-17	1.21e-09	0.79	0.61	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-9.4	8.82e-17	1.26e-09	-0.92	-0.61	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
PCPG	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	9.4	8.87e-17	1.27e-09	1.28	0.61	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
PCPG	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-9.39	8.95e-17	1.28e-09	-0.74	-0.61	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
PCPG	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	9.39	9.04e-17	1.29e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
PCPG	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-9.39	9.23e-17	1.31e-09	-0.74	-0.61	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-9.39	9.23e-17	1.31e-09	-0.74	-0.61	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-9.39	9.23e-17	1.31e-09	-0.74	-0.61	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
PCPG	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	9.39	9.28e-17	1.31e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-9.39	9.28e-17	1.31e-09	-0.75	-0.61	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-9.39	9.28e-17	1.31e-09	-0.75	-0.61	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
PCPG	trans	rs10242455	0.702	rs58348977	ENSG00000228834.1	RP11-249L21.4	9.38	9.66e-17	1.36e-09	1.31	0.61	Blood metabolite levels;	chr7:99590391	chr6:108907615~108907873:-
PCPG	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	9.38	9.69e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	9.38	9.71e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	9.38	9.71e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	9.38	9.71e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	9.38	9.71e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	9.38	9.71e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	9.38	9.71e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	9.38	9.74e-17	1.37e-09	0.75	0.61	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-9.37	1.03e-16	1.44e-09	-0.81	-0.61	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
PCPG	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-9.37	1.05e-16	1.47e-09	-0.76	-0.61	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	9.36	1.08e-16	1.52e-09	0.74	0.61	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	9.36	1.08e-16	1.52e-09	0.74	0.61	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	9.36	1.1e-16	1.54e-09	0.79	0.61	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
PCPG	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	9.35	1.18e-16	1.65e-09	0.76	0.61	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
PCPG	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	9.34	1.22e-16	1.7e-09	0.78	0.61	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	9.34	1.22e-16	1.7e-09	0.78	0.61	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
PCPG	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	9.34	1.23e-16	1.72e-09	1.03	0.61	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	9.34	1.23e-16	1.72e-09	1.03	0.61	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
PCPG	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	9.34	1.23e-16	1.72e-09	1.03	0.61	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
PCPG	trans	rs1816752	0.704	rs7995968	ENSG00000237917.1	PARP4P1	-9.34	1.25e-16	1.75e-09	-0.75	-0.61	Obesity-related traits;	chr13:24392754	chrY:26594851~26634652:-
PCPG	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	9.32	1.36e-16	1.89e-09	0.77	0.61	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
PCPG	trans	rs2657294	1	rs2657294	ENSG00000172974.11	AC007318.5	9.32	1.4e-16	1.94e-09	0.62	0.61	Pneumonia;	chr10:75193267	chr2:65205108~65205988:+
PCPG	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-9.31	1.48e-16	2.05e-09	-0.75	-0.61	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
PCPG	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-9.31	1.51e-16	2.09e-09	-0.72	-0.61	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
PCPG	trans	rs916888	0.61	rs199529	ENSG00000263503.1	RP11-707O23.5	9.31	1.52e-16	2.11e-09	0.97	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45600869~45602340:-
PCPG	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	9.3	1.54e-16	2.13e-09	0.73	0.6	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	9.3	1.54e-16	2.13e-09	0.73	0.6	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	9.3	1.54e-16	2.13e-09	0.73	0.6	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
PCPG	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	9.3	1.55e-16	2.14e-09	0.8	0.6	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
PCPG	trans	rs9899728	0.572	rs4365317	ENSG00000234925.2	ATP5HP4	9.3	1.61e-16	2.23e-09	0.79	0.6	Alzheimer's disease or small vessel stroke;	chr17:75063725	chr12:68642519~68642993:-
PCPG	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	9.3	1.61e-16	2.23e-09	0.76	0.6	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	9.3	1.62e-16	2.24e-09	0.75	0.6	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	9.29	1.63e-16	2.25e-09	0.78	0.6	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
PCPG	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-9.29	1.71e-16	2.36e-09	-0.75	-0.6	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
PCPG	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	9.28	1.73e-16	2.39e-09	0.77	0.6	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
PCPG	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-9.28	1.76e-16	2.43e-09	-0.74	-0.6	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
PCPG	trans	rs9899728	0.572	rs9915968	ENSG00000234925.2	ATP5HP4	9.28	1.79e-16	2.46e-09	0.79	0.6	Alzheimer's disease or small vessel stroke;	chr17:75063521	chr12:68642519~68642993:-
PCPG	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	9.28	1.82e-16	2.5e-09	0.77	0.6	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	9.28	1.82e-16	2.5e-09	0.77	0.6	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	9.28	1.82e-16	2.5e-09	0.77	0.6	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	9.28	1.82e-16	2.5e-09	0.77	0.6	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	9.28	1.82e-16	2.5e-09	0.77	0.6	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	9.28	1.82e-16	2.5e-09	0.77	0.6	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
PCPG	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	9.26	1.96e-16	2.67e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	9.26	1.96e-16	2.67e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	9.26	1.96e-16	2.67e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-9.26	2e-16	2.73e-09	-0.73	-0.6	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.571	rs7805661	ENSG00000228834.1	RP11-249L21.4	9.26	2.01e-16	2.75e-09	1.28	0.6	Blood metabolite levels;	chr7:99573899	chr6:108907615~108907873:-
PCPG	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	9.26	2.02e-16	2.75e-09	0.75	0.6	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
PCPG	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
PCPG	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	9.25	2.07e-16	2.81e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
PCPG	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	9.25	2.16e-16	2.93e-09	1.35	0.6	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	9.25	2.16e-16	2.93e-09	1.35	0.6	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	9.25	2.16e-16	2.93e-09	1.35	0.6	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	9.25	2.16e-16	2.93e-09	1.35	0.6	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	9.25	2.16e-16	2.93e-09	1.35	0.6	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
PCPG	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	9.25	2.17e-16	2.94e-09	0.74	0.6	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
PCPG	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	9.25	2.18e-16	2.95e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	9.25	2.18e-16	2.95e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
PCPG	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	9.25	2.18e-16	2.95e-09	0.75	0.6	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
PCPG	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	9.22	2.54e-16	3.43e-09	0.76	0.6	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
PCPG	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	9.21	2.64e-16	3.55e-09	0.82	0.6	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	9.21	2.64e-16	3.55e-09	0.82	0.6	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	9.21	2.64e-16	3.55e-09	0.82	0.6	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
PCPG	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-9.21	2.67e-16	3.58e-09	-0.81	-0.6	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-9.21	2.67e-16	3.58e-09	-0.81	-0.6	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
PCPG	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	9.2	2.8e-16	3.76e-09	0.78	0.6	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-9.2	2.85e-16	3.83e-09	-0.77	-0.6	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
PCPG	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	9.2	2.88e-16	3.86e-09	1.28	0.6	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	9.2	2.88e-16	3.86e-09	1.28	0.6	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	9.2	2.88e-16	3.86e-09	1.28	0.6	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	9.2	2.88e-16	3.86e-09	1.28	0.6	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
PCPG	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	9.2	2.92e-16	3.91e-09	0.74	0.6	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
PCPG	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	9.19	2.99e-16	3.97e-09	0.73	0.6	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
PCPG	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-9.18	3.13e-16	4.14e-09	-0.8	-0.6	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-9.18	3.13e-16	4.14e-09	-0.8	-0.6	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
PCPG	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-9.18	3.17e-16	4.2e-09	-0.74	-0.6	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
PCPG	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-9.18	3.26e-16	4.31e-09	-0.8	-0.6	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
PCPG	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	9.18	3.31e-16	4.37e-09	0.82	0.6	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
PCPG	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	9.17	3.34e-16	4.41e-09	0.79	0.6	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
PCPG	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	9.17	3.37e-16	4.45e-09	0.74	0.6	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	9.17	3.47e-16	4.57e-09	0.73	0.6	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	9.17	3.47e-16	4.57e-09	0.73	0.6	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
PCPG	trans	rs1816752	0.679	rs7999480	ENSG00000237917.1	PARP4P1	-9.16	3.64e-16	4.78e-09	-0.73	-0.6	Obesity-related traits;	chr13:24397865	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	9.15	3.93e-16	5.16e-09	0.76	0.6	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	9.15	3.93e-16	5.16e-09	0.76	0.6	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-9.14	4.05e-16	5.3e-09	-0.8	-0.6	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
PCPG	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-9.14	4.13e-16	5.41e-09	-0.93	-0.6	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
PCPG	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-9.13	4.41e-16	5.75e-09	-0.81	-0.6	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-9.13	4.41e-16	5.75e-09	-0.81	-0.6	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
PCPG	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	9.13	4.41e-16	5.75e-09	1.28	0.6	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
PCPG	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-9.12	4.5e-16	5.86e-09	-0.65	-0.6	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
PCPG	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-9.12	4.72e-16	6.15e-09	-0.71	-0.6	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	9.11	4.9e-16	6.37e-09	0.72	0.6	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
PCPG	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	9.11	4.91e-16	6.39e-09	0.82	0.6	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
PCPG	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	9.11	4.91e-16	6.39e-09	0.82	0.6	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
PCPG	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-9.1	5.07e-16	6.58e-09	-0.76	-0.6	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-9.1	5.09e-16	6.6e-09	-0.76	-0.6	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
PCPG	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-9.1	5.3e-16	6.88e-09	-0.82	-0.6	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
PCPG	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	9.09	5.53e-16	7.16e-09	0.74	0.6	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-9.09	5.55e-16	7.19e-09	-0.8	-0.6	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-9.09	5.58e-16	7.23e-09	-0.76	-0.6	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.571	rs56167514	ENSG00000228834.1	RP11-249L21.4	9.09	5.62e-16	7.27e-09	1.36	0.6	Blood metabolite levels;	chr7:99563724	chr6:108907615~108907873:-
PCPG	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	9.09	5.65e-16	7.31e-09	1.28	0.6	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	9.06	6.62e-16	8.45e-09	1.26	0.59	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	9.06	6.62e-16	8.45e-09	1.26	0.59	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	9.06	6.62e-16	8.45e-09	1.26	0.59	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	9.06	6.62e-16	8.45e-09	1.26	0.59	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	9.06	6.62e-16	8.45e-09	1.26	0.59	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	9.06	6.62e-16	8.45e-09	1.26	0.59	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	9.06	6.62e-16	8.45e-09	1.26	0.59	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
PCPG	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-9.06	6.64e-16	8.48e-09	-0.77	-0.59	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-9.06	6.65e-16	8.49e-09	-0.78	-0.59	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-9.05	6.96e-16	8.87e-09	-0.74	-0.59	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
PCPG	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	9.05	7.14e-16	9.1e-09	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
PCPG	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-9.05	7.16e-16	9.11e-09	-0.73	-0.59	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
PCPG	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	9.04	7.42e-16	9.44e-09	1.31	0.59	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
PCPG	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	9.03	7.68e-16	9.75e-09	0.81	0.59	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
PCPG	trans	rs2657294	0.965	rs10824286	ENSG00000172974.11	AC007318.5	9.03	8.05e-16	1.02e-08	0.6	0.59	Pneumonia;	chr10:75172251	chr2:65205108~65205988:+
PCPG	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	9.02	8.46e-16	1.07e-08	0.71	0.59	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
PCPG	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	9.02	8.56e-16	1.08e-08	0.81	0.59	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
PCPG	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	9	9.18e-16	1.16e-08	0.74	0.59	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
PCPG	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-9	9.63e-16	1.21e-08	-0.81	-0.59	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.592	rs1888861	ENSG00000227183.3	HDGFP1	-9	9.63e-16	1.21e-08	-0.81	-0.59	Platelet count;	chr1:156828169	chrX:131646639~131646890:+
PCPG	trans	rs928391	0.592	rs7516856	ENSG00000227183.3	HDGFP1	-9	9.63e-16	1.21e-08	-0.81	-0.59	Platelet count;	chr1:156828324	chrX:131646639~131646890:+
PCPG	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-8.99	9.66e-16	1.22e-08	-0.78	-0.59	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-8.99	9.93e-16	1.25e-08	-0.79	-0.59	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	8.99	1.01e-15	1.27e-08	1.35	0.59	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
PCPG	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-8.98	1.02e-15	1.29e-08	-0.73	-0.59	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
PCPG	trans	rs916888	0.779	rs199498	ENSG00000263503.1	RP11-707O23.5	8.98	1.03e-15	1.29e-08	1.04	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45600869~45602340:-
PCPG	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-8.98	1.04e-15	1.31e-08	-0.76	-0.59	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-8.98	1.07e-15	1.34e-08	-0.8	-0.59	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-8.98	1.07e-15	1.34e-08	-0.8	-0.59	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-8.98	1.07e-15	1.34e-08	-0.8	-0.59	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-8.98	1.08e-15	1.36e-08	-0.88	-0.59	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
PCPG	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	8.97	1.09e-15	1.36e-08	1.27	0.59	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	8.97	1.09e-15	1.36e-08	1.27	0.59	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
PCPG	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	8.97	1.09e-15	1.36e-08	1.27	0.59	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
PCPG	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	8.97	1.09e-15	1.36e-08	1.27	0.59	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
PCPG	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	8.97	1.09e-15	1.36e-08	1.27	0.59	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
PCPG	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	8.97	1.1e-15	1.37e-08	0.73	0.59	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	8.97	1.1e-15	1.37e-08	0.73	0.59	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-8.97	1.11e-15	1.39e-08	-0.77	-0.59	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
PCPG	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-8.96	1.21e-15	1.5e-08	-0.82	-0.59	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
PCPG	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-8.93	1.4e-15	1.74e-08	-0.81	-0.59	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
PCPG	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	8.93	1.41e-15	1.74e-08	0.72	0.59	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	8.93	1.41e-15	1.74e-08	0.72	0.59	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
PCPG	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	8.93	1.44e-15	1.78e-08	0.78	0.59	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
PCPG	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-8.93	1.46e-15	1.8e-08	-0.76	-0.59	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-8.93	1.46e-15	1.8e-08	-0.76	-0.59	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-8.93	1.46e-15	1.8e-08	-0.76	-0.59	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-8.93	1.46e-15	1.8e-08	-0.76	-0.59	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-8.93	1.46e-15	1.8e-08	-0.76	-0.59	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-8.93	1.46e-15	1.8e-08	-0.76	-0.59	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
PCPG	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	8.92	1.47e-15	1.82e-08	0.68	0.59	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
PCPG	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	8.92	1.48e-15	1.82e-08	1.34	0.59	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	8.92	1.48e-15	1.82e-08	1.34	0.59	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	8.92	1.48e-15	1.82e-08	1.34	0.59	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	8.92	1.48e-15	1.82e-08	1.34	0.59	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	8.92	1.48e-15	1.82e-08	1.34	0.59	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
PCPG	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-8.9	1.69e-15	2.07e-08	-0.72	-0.59	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
PCPG	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	8.9	1.7e-15	2.08e-08	0.78	0.59	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
PCPG	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	8.88	1.92e-15	2.35e-08	0.72	0.59	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
PCPG	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	8.88	1.96e-15	2.39e-08	0.72	0.59	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	8.87	2.01e-15	2.45e-08	0.72	0.59	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
PCPG	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	8.87	2.04e-15	2.49e-08	0.79	0.59	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
PCPG	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	8.86	2.13e-15	2.59e-08	0.79	0.59	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
PCPG	trans	rs2657294	0.931	rs2804522	ENSG00000172974.11	AC007318.5	8.85	2.32e-15	2.81e-08	0.6	0.59	Pneumonia;	chr10:75159132	chr2:65205108~65205988:+
PCPG	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-8.84	2.38e-15	2.89e-08	-0.73	-0.59	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
PCPG	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-8.84	2.38e-15	2.89e-08	-0.73	-0.59	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
PCPG	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	8.83	2.49e-15	3.01e-08	0.99	0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
PCPG	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-8.83	2.5e-15	3.03e-08	-0.82	-0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
PCPG	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	8.83	2.52e-15	3.05e-08	0.83	0.58	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
PCPG	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	8.83	2.59e-15	3.13e-08	0.72	0.58	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-8.82	2.64e-15	3.19e-08	-0.74	-0.58	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
PCPG	trans	rs2657294	0.965	rs2047951	ENSG00000172974.11	AC007318.5	8.82	2.65e-15	3.2e-08	0.6	0.58	Pneumonia;	chr10:75161310	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs2804523	ENSG00000172974.11	AC007318.5	8.82	2.65e-15	3.2e-08	0.6	0.58	Pneumonia;	chr10:75161584	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs2657285	ENSG00000172974.11	AC007318.5	8.82	2.65e-15	3.2e-08	0.6	0.58	Pneumonia;	chr10:75164166	chr2:65205108~65205988:+
PCPG	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	8.82	2.77e-15	3.33e-08	0.79	0.58	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
PCPG	trans	rs2657294	0.929	rs6480771	ENSG00000172974.11	AC007318.5	8.82	2.78e-15	3.34e-08	0.6	0.58	Pneumonia;	chr10:75101922	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs7899946	ENSG00000172974.11	AC007318.5	8.82	2.78e-15	3.34e-08	0.6	0.58	Pneumonia;	chr10:75166013	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs2657291	ENSG00000172974.11	AC007318.5	8.82	2.78e-15	3.34e-08	0.6	0.58	Pneumonia;	chr10:75166945	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs4746270	ENSG00000172974.11	AC007318.5	8.82	2.78e-15	3.34e-08	0.6	0.58	Pneumonia;	chr10:75185189	chr2:65205108~65205988:+
PCPG	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-8.81	2.81e-15	3.37e-08	-0.76	-0.58	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	8.79	3.24e-15	3.87e-08	0.72	0.58	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
PCPG	trans	rs9899728	0.539	rs12938889	ENSG00000234925.2	ATP5HP4	-8.79	3.31e-15	3.96e-08	-0.96	-0.58	Alzheimer's disease or small vessel stroke;	chr17:75043834	chr12:68642519~68642993:-
PCPG	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-8.78	3.35e-15	4e-08	-0.8	-0.58	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
PCPG	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	8.77	3.66e-15	4.36e-08	0.72	0.58	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	8.77	3.66e-15	4.36e-08	0.72	0.58	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
PCPG	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-8.75	4.2e-15	4.97e-08	-0.72	-0.58	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
PCPG	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-8.74	4.43e-15	5.23e-08	-0.83	-0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
PCPG	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-8.73	4.57e-15	5.4e-08	-0.72	-0.58	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
PCPG	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	8.72	4.87e-15	5.73e-08	0.76	0.58	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
PCPG	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-8.71	5.07e-15	5.96e-08	-0.78	-0.58	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
PCPG	trans	rs10242455	0.571	rs11972210	ENSG00000228834.1	RP11-249L21.4	8.7	5.55e-15	6.52e-08	1.24	0.58	Blood metabolite levels;	chr7:99609320	chr6:108907615~108907873:-
PCPG	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	8.7	5.61e-15	6.59e-08	0.79	0.58	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
PCPG	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-8.68	6.12e-15	7.16e-08	-0.73	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
PCPG	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	8.68	6.3e-15	7.36e-08	0.78	0.58	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
PCPG	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	8.67	6.51e-15	7.59e-08	0.71	0.58	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
PCPG	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	8.67	6.67e-15	7.77e-08	0.8	0.58	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
PCPG	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	8.66	6.73e-15	7.83e-08	0.78	0.58	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
PCPG	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	8.66	6.8e-15	7.91e-08	0.81	0.58	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
PCPG	trans	rs916888	0.61	rs199436	ENSG00000263503.1	RP11-707O23.5	-8.66	6.87e-15	7.99e-08	-0.86	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45600869~45602340:-
PCPG	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	8.66	6.95e-15	8.08e-08	0.81	0.58	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
PCPG	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	8.66	7.08e-15	8.22e-08	0.72	0.58	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	8.65	7.27e-15	8.43e-08	0.7	0.58	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
PCPG	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	8.65	7.27e-15	8.43e-08	0.79	0.58	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
PCPG	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	8.65	7.44e-15	8.63e-08	0.81	0.58	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
PCPG	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	8.64	7.6e-15	8.79e-08	0.82	0.58	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
PCPG	trans	rs959695	1	rs2442756	ENSG00000260318.1	COX6CP1	8.64	7.91e-15	9.15e-08	0.73	0.58	Hippocampal atrophy;	chr8:99816910	chr16:11903923~11904137:-
PCPG	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	8.63	8.01e-15	9.25e-08	0.75	0.58	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
PCPG	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	8.63	8.29e-15	9.55e-08	1.33	0.58	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	8.63	8.29e-15	9.55e-08	1.33	0.58	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	8.63	8.29e-15	9.55e-08	1.33	0.58	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	8.63	8.29e-15	9.55e-08	1.33	0.58	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs6974831	ENSG00000228834.1	RP11-249L21.4	8.63	8.29e-15	9.55e-08	1.33	0.58	Blood metabolite levels;	chr7:99533982	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	8.63	8.29e-15	9.55e-08	1.33	0.58	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
PCPG	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	8.63	8.48e-15	9.76e-08	0.77	0.58	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
PCPG	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	8.62	8.64e-15	9.94e-08	0.72	0.58	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	8.62	8.64e-15	9.94e-08	0.72	0.58	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
PCPG	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	8.62	8.72e-15	1e-07	0.77	0.58	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
PCPG	trans	rs916888	0.61	rs199452	ENSG00000263503.1	RP11-707O23.5	8.62	8.72e-15	1e-07	0.84	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45600869~45602340:-
PCPG	trans	rs2657294	0.965	rs4746264	ENSG00000172974.11	AC007318.5	8.6	9.73e-15	1.11e-07	0.58	0.57	Pneumonia;	chr10:75114194	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs9299525	ENSG00000172974.11	AC007318.5	8.6	9.73e-15	1.11e-07	0.58	0.57	Pneumonia;	chr10:75118267	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs10762658	ENSG00000172974.11	AC007318.5	8.6	9.73e-15	1.11e-07	0.58	0.57	Pneumonia;	chr10:75119804	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs2395140	ENSG00000172974.11	AC007318.5	8.6	9.73e-15	1.11e-07	0.58	0.57	Pneumonia;	chr10:75139253	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs2997754	ENSG00000172974.11	AC007318.5	8.6	9.73e-15	1.11e-07	0.58	0.57	Pneumonia;	chr10:75144379	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs10824285	ENSG00000172974.11	AC007318.5	8.6	9.73e-15	1.11e-07	0.58	0.57	Pneumonia;	chr10:75153271	chr2:65205108~65205988:+
PCPG	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-8.6	1.01e-14	1.15e-07	-0.73	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
PCPG	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	8.59	1.04e-14	1.19e-07	0.69	0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
PCPG	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-8.58	1.1e-14	1.25e-07	-0.73	-0.57	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-8.58	1.12e-14	1.27e-07	-0.77	-0.57	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
PCPG	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	8.57	1.16e-14	1.32e-07	0.74	0.57	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
PCPG	trans	rs9876781	1	rs9838618	ENSG00000225528.1	RP3-370M22.8	-8.57	1.17e-14	1.33e-07	-0.68	-0.57	Longevity;	chr3:48445949	chr22:39960397~39964683:+
PCPG	trans	rs9899728	0.52	rs12936866	ENSG00000234925.2	ATP5HP4	8.57	1.18e-14	1.34e-07	0.96	0.57	Alzheimer's disease or small vessel stroke;	chr17:75055955	chr12:68642519~68642993:-
PCPG	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	8.55	1.35e-14	1.52e-07	1	0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
PCPG	trans	rs9899728	0.539	rs56267297	ENSG00000234925.2	ATP5HP4	8.53	1.47e-14	1.65e-07	0.95	0.57	Alzheimer's disease or small vessel stroke;	chr17:75050901	chr12:68642519~68642993:-
PCPG	trans	rs9899728	0.539	rs113775187	ENSG00000234925.2	ATP5HP4	8.53	1.47e-14	1.65e-07	0.95	0.57	Alzheimer's disease or small vessel stroke;	chr17:75051195	chr12:68642519~68642993:-
PCPG	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-8.52	1.56e-14	1.76e-07	-0.86	-0.57	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-8.52	1.56e-14	1.76e-07	-0.86	-0.57	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-8.52	1.59e-14	1.79e-07	-0.73	-0.57	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-8.52	1.59e-14	1.79e-07	-0.73	-0.57	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
PCPG	trans	rs2657294	0.895	rs2395137	ENSG00000172974.11	AC007318.5	8.51	1.67e-14	1.87e-07	0.59	0.57	Pneumonia;	chr10:75088235	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.796	rs7082123	ENSG00000172974.11	AC007318.5	8.51	1.67e-14	1.87e-07	0.59	0.57	Pneumonia;	chr10:75091101	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.861	rs6480769	ENSG00000172974.11	AC007318.5	8.51	1.67e-14	1.87e-07	0.59	0.57	Pneumonia;	chr10:75091745	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.895	rs3088142	ENSG00000172974.11	AC007318.5	8.51	1.67e-14	1.87e-07	0.59	0.57	Pneumonia;	chr10:75094806	chr2:65205108~65205988:+
PCPG	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-8.5	1.72e-14	1.92e-07	-0.73	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
PCPG	trans	rs9876781	1	rs1109227	ENSG00000225528.1	RP3-370M22.8	-8.5	1.74e-14	1.95e-07	-0.67	-0.57	Longevity;	chr3:48437797	chr22:39960397~39964683:+
PCPG	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-8.5	1.74e-14	1.95e-07	-0.8	-0.57	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
PCPG	trans	rs916888	0.647	rs199524	ENSG00000263503.1	RP11-707O23.5	-8.49	1.83e-14	2.05e-07	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.647	rs199523	ENSG00000263503.1	RP11-707O23.5	-8.49	1.83e-14	2.05e-07	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45600869~45602340:-
PCPG	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-8.49	1.87e-14	2.09e-07	-0.79	-0.57	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
PCPG	trans	rs2657294	0.895	rs4746262	ENSG00000172974.11	AC007318.5	8.48	1.92e-14	2.15e-07	0.59	0.57	Pneumonia;	chr10:75093631	chr2:65205108~65205988:+
PCPG	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	8.48	2e-14	2.22e-07	0.71	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	8.48	2e-14	2.22e-07	0.71	0.57	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	8.47	2.06e-14	2.3e-07	0.72	0.57	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
PCPG	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-8.47	2.1e-14	2.34e-07	-0.71	-0.57	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
PCPG	trans	rs10242455	0.702	rs73711293	ENSG00000228834.1	RP11-249L21.4	8.47	2.15e-14	2.39e-07	1.5	0.57	Blood metabolite levels;	chr7:99483972	chr6:108907615~108907873:-
PCPG	trans	rs9876781	1	rs13069724	ENSG00000225528.1	RP3-370M22.8	-8.46	2.16e-14	2.4e-07	-0.67	-0.57	Longevity;	chr3:48436629	chr22:39960397~39964683:+
PCPG	trans	rs9899728	0.539	rs11077772	ENSG00000234925.2	ATP5HP4	8.46	2.16e-14	2.41e-07	0.95	0.57	Alzheimer's disease or small vessel stroke;	chr17:75039603	chr12:68642519~68642993:-
PCPG	trans	rs12709013	0.536	rs1646260	ENSG00000233719.3	GOT2P3	8.46	2.18e-14	2.42e-07	0.65	0.57	Blood metabolite ratios;	chr16:58734951	chr12:9641802~9643007:+
PCPG	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	8.46	2.24e-14	2.49e-07	0.72	0.57	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	8.46	2.27e-14	2.52e-07	0.68	0.57	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
PCPG	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-8.45	2.34e-14	2.6e-07	-0.79	-0.57	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	8.43	2.57e-14	2.83e-07	1.29	0.57	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
PCPG	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	8.43	2.57e-14	2.83e-07	0.75	0.57	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
PCPG	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	8.43	2.57e-14	2.83e-07	0.75	0.57	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
PCPG	trans	rs10242455	0.702	rs57832867	ENSG00000228834.1	RP11-249L21.4	8.43	2.58e-14	2.85e-07	1.56	0.57	Blood metabolite levels;	chr7:99368773	chr6:108907615~108907873:-
PCPG	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	8.43	2.62e-14	2.89e-07	0.68	0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
PCPG	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	8.43	2.67e-14	2.94e-07	0.77	0.57	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
PCPG	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-8.42	2.87e-14	3.16e-07	-1.01	-0.57	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
PCPG	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	8.41	2.89e-14	3.18e-07	0.77	0.57	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
PCPG	trans	rs2657294	0.965	rs7079694	ENSG00000172974.11	AC007318.5	8.41	2.94e-14	3.23e-07	0.57	0.57	Pneumonia;	chr10:75136804	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.965	rs7088974	ENSG00000172974.11	AC007318.5	8.41	2.99e-14	3.28e-07	0.58	0.57	Pneumonia;	chr10:75131338	chr2:65205108~65205988:+
PCPG	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	8.4	3.16e-14	3.46e-07	0.77	0.57	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
PCPG	trans	rs916888	0.61	rs199530	ENSG00000263503.1	RP11-707O23.5	-8.39	3.29e-14	3.6e-07	-0.84	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45600869~45602340:-
PCPG	trans	rs9899728	0.539	rs57813751	ENSG00000234925.2	ATP5HP4	8.38	3.47e-14	3.78e-07	0.94	0.56	Alzheimer's disease or small vessel stroke;	chr17:75057417	chr12:68642519~68642993:-
PCPG	trans	rs9899728	0.539	rs12940199	ENSG00000234925.2	ATP5HP4	8.38	3.47e-14	3.78e-07	0.94	0.56	Alzheimer's disease or small vessel stroke;	chr17:75058664	chr12:68642519~68642993:-
PCPG	trans	rs10242455	0.702	rs73403286	ENSG00000228834.1	RP11-249L21.4	8.38	3.47e-14	3.79e-07	1.41	0.56	Blood metabolite levels;	chr7:99557242	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs73405247	ENSG00000228834.1	RP11-249L21.4	8.38	3.47e-14	3.79e-07	1.41	0.56	Blood metabolite levels;	chr7:99561551	chr6:108907615~108907873:-
PCPG	trans	rs116095464	0.558	rs9312957	ENSG00000185986.11	SDHAP3	8.38	3.48e-14	3.79e-07	0.78	0.56	Breast cancer;	chr5:202079	chr5:1572222~1594620:-
PCPG	trans	rs9876781	1	rs9883759	ENSG00000225528.1	RP3-370M22.8	-8.38	3.57e-14	3.89e-07	-0.66	-0.56	Longevity;	chr3:48422209	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs6442120	ENSG00000225528.1	RP3-370M22.8	-8.38	3.57e-14	3.89e-07	-0.66	-0.56	Longevity;	chr3:48423094	chr22:39960397~39964683:+
PCPG	trans	rs9876781	0.9	rs1037773	ENSG00000225528.1	RP3-370M22.8	-8.38	3.57e-14	3.89e-07	-0.66	-0.56	Longevity;	chr3:48426493	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs2279077	ENSG00000225528.1	RP3-370M22.8	-8.38	3.57e-14	3.89e-07	-0.66	-0.56	Longevity;	chr3:48432839	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs3774808	ENSG00000225528.1	RP3-370M22.8	-8.38	3.57e-14	3.89e-07	-0.66	-0.56	Longevity;	chr3:48440237	chr22:39960397~39964683:+
PCPG	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	8.37	3.71e-14	4.03e-07	0.73	0.56	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
PCPG	trans	rs116095464	0.614	rs10059220	ENSG00000185986.11	SDHAP3	8.37	3.8e-14	4.13e-07	0.8	0.56	Breast cancer;	chr5:242698	chr5:1572222~1594620:-
PCPG	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-8.37	3.82e-14	4.15e-07	-0.72	-0.56	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
PCPG	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	8.36	3.92e-14	4.25e-07	0.75	0.56	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
PCPG	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	8.36	3.94e-14	4.27e-07	0.99	0.56	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
PCPG	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-8.36	3.97e-14	4.3e-07	-0.72	-0.56	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
PCPG	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	8.36	4e-14	4.33e-07	0.71	0.56	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
PCPG	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	8.35	4.11e-14	4.44e-07	1.26	0.56	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
PCPG	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-8.35	4.13e-14	4.47e-07	-0.72	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
PCPG	trans	rs12709013	0.613	rs1657178	ENSG00000233719.3	GOT2P3	8.35	4.22e-14	4.56e-07	0.63	0.56	Blood metabolite ratios;	chr16:58735300	chr12:9641802~9643007:+
PCPG	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	8.35	4.23e-14	4.57e-07	0.7	0.56	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
PCPG	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	8.35	4.25e-14	4.58e-07	0.77	0.56	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
PCPG	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-8.34	4.35e-14	4.7e-07	-0.69	-0.56	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	8.33	4.65e-14	5e-07	0.72	0.56	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
PCPG	trans	rs12709013	0.613	rs4238801	ENSG00000233719.3	GOT2P3	8.33	4.71e-14	5.06e-07	0.63	0.56	Blood metabolite ratios;	chr16:58738275	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs4575523	ENSG00000233719.3	GOT2P3	8.33	4.71e-14	5.06e-07	0.63	0.56	Blood metabolite ratios;	chr16:58738559	chr12:9641802~9643007:+
PCPG	trans	rs9876781	0.967	rs9876891	ENSG00000225528.1	RP3-370M22.8	-8.32	4.95e-14	5.31e-07	-0.66	-0.56	Longevity;	chr3:48440024	chr22:39960397~39964683:+
PCPG	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	8.31	5.29e-14	5.65e-07	0.69	0.56	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
PCPG	trans	rs9876781	1	rs9881491	ENSG00000225528.1	RP3-370M22.8	-8.3	5.47e-14	5.84e-07	-0.66	-0.56	Longevity;	chr3:48446507	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs13091785	ENSG00000225528.1	RP3-370M22.8	-8.3	5.47e-14	5.84e-07	-0.66	-0.56	Longevity;	chr3:48452692	chr22:39960397~39964683:+
PCPG	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	8.3	5.53e-14	5.9e-07	0.76	0.56	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
PCPG	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-8.3	5.56e-14	5.93e-07	-0.7	-0.56	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-8.3	5.73e-14	6.1e-07	-0.82	-0.56	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
PCPG	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-8.29	6.1e-14	6.49e-07	-0.71	-0.56	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
PCPG	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-8.28	6.33e-14	6.73e-07	-0.82	-0.56	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
PCPG	trans	rs916888	0.61	rs199453	ENSG00000263503.1	RP11-707O23.5	8.27	6.7e-14	7.1e-07	0.82	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45600869~45602340:-
PCPG	trans	rs116095464	1	rs55847527	ENSG00000185986.11	SDHAP3	8.27	6.75e-14	7.15e-07	0.86	0.56	Breast cancer;	chr5:317405	chr5:1572222~1594620:-
PCPG	trans	rs10242455	0.702	rs76840929	ENSG00000228834.1	RP11-249L21.4	8.26	6.98e-14	7.38e-07	1.35	0.56	Blood metabolite levels;	chr7:99348235	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs116671616	ENSG00000228834.1	RP11-249L21.4	8.26	6.98e-14	7.38e-07	1.35	0.56	Blood metabolite levels;	chr7:99356935	chr6:108907615~108907873:-
PCPG	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	8.26	7.12e-14	7.52e-07	1	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
PCPG	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-8.26	7.15e-14	7.54e-07	-0.74	-0.56	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
PCPG	trans	rs116095464	1	rs908116	ENSG00000185986.11	SDHAP3	8.25	7.43e-14	7.82e-07	0.83	0.56	Breast cancer;	chr5:317004	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.85	rs73023433	ENSG00000185986.11	SDHAP3	8.25	7.43e-14	7.82e-07	0.83	0.56	Breast cancer;	chr5:317555	chr5:1572222~1594620:-
PCPG	trans	rs12709013	0.636	rs9937713	ENSG00000233719.3	GOT2P3	8.25	7.55e-14	7.95e-07	0.62	0.56	Blood metabolite ratios;	chr16:58771921	chr12:9641802~9643007:+
PCPG	trans	rs916888	0.647	rs199449	ENSG00000263503.1	RP11-707O23.5	8.25	7.56e-14	7.96e-07	0.83	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.61	rs199444	ENSG00000263503.1	RP11-707O23.5	8.25	7.56e-14	7.96e-07	0.83	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.61	rs199442	ENSG00000263503.1	RP11-707O23.5	8.25	7.56e-14	7.96e-07	0.83	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45600869~45602340:-
PCPG	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	8.24	7.97e-14	8.39e-07	0.74	0.56	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	8.24	7.97e-14	8.39e-07	0.74	0.56	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
PCPG	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	8.24	8.01e-14	8.42e-07	0.78	0.56	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
PCPG	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	8.24	8.01e-14	8.42e-07	0.78	0.56	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-8.24	8.04e-14	8.45e-07	-0.68	-0.56	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-8.24	8.04e-14	8.45e-07	-0.68	-0.56	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
PCPG	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	8.23	8.2e-14	8.61e-07	0.71	0.56	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.585	rs7188608	ENSG00000233719.3	GOT2P3	8.23	8.61e-14	9.01e-07	0.62	0.56	Blood metabolite ratios;	chr16:58736236	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1657176	ENSG00000233719.3	GOT2P3	8.23	8.61e-14	9.01e-07	0.62	0.56	Blood metabolite ratios;	chr16:58736833	chr12:9641802~9643007:+
PCPG	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	8.22	9.03e-14	9.44e-07	0.81	0.56	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
PCPG	trans	rs116095464	0.558	rs10068203	ENSG00000185986.11	SDHAP3	8.21	9.17e-14	9.57e-07	0.78	0.56	Breast cancer;	chr5:206503	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs73029475	ENSG00000185986.11	SDHAP3	8.21	9.17e-14	9.57e-07	0.78	0.56	Breast cancer;	chr5:206854	chr5:1572222~1594620:-
PCPG	trans	rs116095464	1	rs28416084	ENSG00000185986.11	SDHAP3	8.21	9.17e-14	9.57e-07	0.78	0.56	Breast cancer;	chr5:217525	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs9312978	ENSG00000185986.11	SDHAP3	8.21	9.17e-14	9.57e-07	0.78	0.56	Breast cancer;	chr5:221815	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs9312979	ENSG00000185986.11	SDHAP3	8.21	9.17e-14	9.57e-07	0.78	0.56	Breast cancer;	chr5:221942	chr5:1572222~1594620:-
PCPG	trans	rs116095464	1	rs1567956	ENSG00000185986.11	SDHAP3	8.21	9.44e-14	9.85e-07	0.82	0.56	Breast cancer;	chr5:315501	chr5:1572222~1594620:-
PCPG	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-8.21	9.46e-14	9.87e-07	-0.61	-0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
PCPG	trans	rs959695	1	rs959695	ENSG00000260318.1	COX6CP1	8.21	9.55e-14	9.96e-07	0.72	0.56	Hippocampal atrophy;	chr8:99822954	chr16:11903923~11904137:-
PCPG	trans	rs116095464	0.558	rs56081398	ENSG00000185986.11	SDHAP3	8.2	9.97e-14	1.03e-06	0.79	0.56	Breast cancer;	chr5:247203	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10065584	ENSG00000185986.11	SDHAP3	8.2	9.97e-14	1.03e-06	0.79	0.56	Breast cancer;	chr5:253882	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10065239	ENSG00000185986.11	SDHAP3	8.2	9.97e-14	1.03e-06	0.79	0.56	Breast cancer;	chr5:275173	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10056628	ENSG00000185986.11	SDHAP3	8.2	9.97e-14	1.03e-06	0.79	0.56	Breast cancer;	chr5:279397	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs56298907	ENSG00000185986.11	SDHAP3	8.2	9.97e-14	1.03e-06	0.79	0.56	Breast cancer;	chr5:283165	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs7356535	ENSG00000185986.11	SDHAP3	8.2	9.97e-14	1.03e-06	0.79	0.56	Breast cancer;	chr5:284002	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs55833259	ENSG00000185986.11	SDHAP3	8.2	9.97e-14	1.03e-06	0.79	0.56	Breast cancer;	chr5:286613	chr5:1572222~1594620:-
PCPG	trans	rs10242455	0.571	rs117370443	ENSG00000228834.1	RP11-249L21.4	8.2	1.01e-13	1.05e-06	1.41	0.56	Blood metabolite levels;	chr7:99377635	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs17161700	ENSG00000228834.1	RP11-249L21.4	8.2	1.01e-13	1.05e-06	1.41	0.56	Blood metabolite levels;	chr7:99379444	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.85	rs57367781	ENSG00000228834.1	RP11-249L21.4	8.19	1.03e-13	1.06e-06	1.31	0.56	Blood metabolite levels;	chr7:99519196	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.571	rs13438288	ENSG00000228834.1	RP11-249L21.4	8.19	1.04e-13	1.08e-06	1.31	0.56	Blood metabolite levels;	chr7:99318791	chr6:108907615~108907873:-
PCPG	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	8.19	1.05e-13	1.08e-06	0.68	0.56	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
PCPG	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	8.19	1.05e-13	1.09e-06	0.71	0.56	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
PCPG	trans	rs12709013	0.597	rs8051078	ENSG00000233719.3	GOT2P3	8.19	1.05e-13	1.09e-06	0.62	0.56	Blood metabolite ratios;	chr16:58774200	chr12:9641802~9643007:+
PCPG	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	8.19	1.08e-13	1.12e-06	0.74	0.56	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
PCPG	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	8.18	1.1e-13	1.13e-06	0.7	0.56	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
PCPG	trans	rs116095464	0.558	rs9687621	ENSG00000185986.11	SDHAP3	8.18	1.12e-13	1.16e-06	0.78	0.56	Breast cancer;	chr5:229079	chr5:1572222~1594620:-
PCPG	trans	rs116095464	1	rs6555159	ENSG00000185986.11	SDHAP3	8.18	1.13e-13	1.16e-06	0.81	0.56	Breast cancer;	chr5:311447	chr5:1572222~1594620:-
PCPG	trans	rs116095464	1	rs56235400	ENSG00000185986.11	SDHAP3	8.18	1.13e-13	1.16e-06	0.81	0.56	Breast cancer;	chr5:312510	chr5:1572222~1594620:-
PCPG	trans	rs116095464	1	rs6555160	ENSG00000185986.11	SDHAP3	-8.18	1.15e-13	1.18e-06	-0.78	-0.56	Breast cancer;	chr5:311554	chr5:1572222~1594620:-
PCPG	trans	rs2657294	0.965	rs2657286	ENSG00000172974.11	AC007318.5	-8.17	1.15e-13	1.19e-06	-0.56	-0.56	Pneumonia;	chr10:75145940	chr2:65205108~65205988:+
PCPG	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	8.17	1.17e-13	1.21e-06	0.79	0.55	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	8.17	1.17e-13	1.21e-06	0.79	0.55	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
PCPG	trans	rs916888	0.61	rs199446	ENSG00000263503.1	RP11-707O23.5	-8.17	1.19e-13	1.23e-06	-0.81	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45600869~45602340:-
PCPG	trans	rs916888	0.61	rs199536	ENSG00000263503.1	RP11-707O23.5	-8.17	1.19e-13	1.23e-06	-0.81	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45600869~45602340:-
PCPG	trans	rs12709013	0.636	rs1657161	ENSG00000233719.3	GOT2P3	8.17	1.21e-13	1.24e-06	0.61	0.55	Blood metabolite ratios;	chr16:58743234	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1646268	ENSG00000233719.3	GOT2P3	8.17	1.21e-13	1.24e-06	0.61	0.55	Blood metabolite ratios;	chr16:58743292	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1646269	ENSG00000233719.3	GOT2P3	8.17	1.21e-13	1.24e-06	0.61	0.55	Blood metabolite ratios;	chr16:58743412	chr12:9641802~9643007:+
PCPG	trans	rs10242455	0.702	rs75156180	ENSG00000228834.1	RP11-249L21.4	8.16	1.22e-13	1.25e-06	1.3	0.55	Blood metabolite levels;	chr7:99366477	chr6:108907615~108907873:-
PCPG	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	8.16	1.23e-13	1.26e-06	0.71	0.55	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
PCPG	trans	rs116095464	1	rs7721278	ENSG00000185986.11	SDHAP3	8.16	1.27e-13	1.3e-06	0.81	0.55	Breast cancer;	chr5:310415	chr5:1572222~1594620:-
PCPG	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	8.16	1.27e-13	1.3e-06	0.71	0.55	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
PCPG	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	8.16	1.27e-13	1.3e-06	0.75	0.55	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.636	rs4538000	ENSG00000233719.3	GOT2P3	8.16	1.28e-13	1.31e-06	0.61	0.55	Blood metabolite ratios;	chr16:58744506	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1646272	ENSG00000233719.3	GOT2P3	8.16	1.28e-13	1.31e-06	0.61	0.55	Blood metabolite ratios;	chr16:58746508	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.66	rs1657163	ENSG00000233719.3	GOT2P3	8.16	1.28e-13	1.31e-06	0.61	0.55	Blood metabolite ratios;	chr16:58746688	chr12:9641802~9643007:+
PCPG	trans	rs116095464	1	rs6873902	ENSG00000185986.11	SDHAP3	8.15	1.29e-13	1.32e-06	0.82	0.55	Breast cancer;	chr5:313222	chr5:1572222~1594620:-
PCPG	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	8.14	1.37e-13	1.4e-06	0.79	0.55	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
PCPG	trans	rs9876781	0.967	rs7618883	ENSG00000225528.1	RP3-370M22.8	-8.14	1.42e-13	1.45e-06	-0.65	-0.55	Longevity;	chr3:48457056	chr22:39960397~39964683:+
PCPG	trans	rs116095464	0.85	rs6896163	ENSG00000185986.11	SDHAP3	8.14	1.44e-13	1.47e-06	0.81	0.55	Breast cancer;	chr5:303571	chr5:1572222~1594620:-
PCPG	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	8.13	1.45e-13	1.47e-06	0.73	0.55	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	8.13	1.45e-13	1.47e-06	0.73	0.55	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
PCPG	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	8.13	1.47e-13	1.5e-06	0.81	0.55	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
PCPG	trans	rs9876781	1	rs6776700	ENSG00000225528.1	RP3-370M22.8	-8.13	1.51e-13	1.53e-06	-0.65	-0.55	Longevity;	chr3:48455358	chr22:39960397~39964683:+
PCPG	trans	rs10242455	0.702	rs6977165	ENSG00000228834.1	RP11-249L21.4	8.13	1.52e-13	1.54e-06	1.53	0.55	Blood metabolite levels;	chr7:99671774	chr6:108907615~108907873:-
PCPG	trans	rs916888	0.61	rs199454	ENSG00000263503.1	RP11-707O23.5	-8.13	1.52e-13	1.55e-06	-0.82	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45600869~45602340:-
PCPG	trans	rs116095464	0.558	rs62346506	ENSG00000185986.11	SDHAP3	8.12	1.55e-13	1.56e-06	0.78	0.55	Breast cancer;	chr5:201479	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs9312956	ENSG00000185986.11	SDHAP3	8.12	1.55e-13	1.56e-06	0.78	0.55	Breast cancer;	chr5:201697	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs62346508	ENSG00000185986.11	SDHAP3	8.12	1.55e-13	1.56e-06	0.78	0.55	Breast cancer;	chr5:203553	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10059907	ENSG00000185986.11	SDHAP3	8.12	1.55e-13	1.56e-06	0.78	0.55	Breast cancer;	chr5:205245	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.558	rs10060089	ENSG00000185986.11	SDHAP3	8.12	1.55e-13	1.56e-06	0.78	0.55	Breast cancer;	chr5:205450	chr5:1572222~1594620:-
PCPG	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	8.12	1.57e-13	1.58e-06	0.7	0.55	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
PCPG	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	8.12	1.57e-13	1.59e-06	0.75	0.55	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
PCPG	trans	rs12709013	0.636	rs1646282	ENSG00000233719.3	GOT2P3	8.12	1.58e-13	1.6e-06	0.61	0.55	Blood metabolite ratios;	chr16:58741296	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs4784977	ENSG00000233719.3	GOT2P3	8.12	1.58e-13	1.6e-06	0.61	0.55	Blood metabolite ratios;	chr16:58742120	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs10852565	ENSG00000233719.3	GOT2P3	8.12	1.61e-13	1.63e-06	0.61	0.55	Blood metabolite ratios;	chr16:58771277	chr12:9641802~9643007:+
PCPG	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	8.11	1.67e-13	1.68e-06	0.98	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
PCPG	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	8.1	1.73e-13	1.74e-06	0.7	0.55	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-8.1	1.77e-13	1.78e-06	-0.7	-0.55	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	8.09	1.84e-13	1.84e-06	0.7	0.55	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
PCPG	trans	rs10242455	0.571	rs45532337	ENSG00000228834.1	RP11-249L21.4	8.09	1.85e-13	1.84e-06	1.3	0.55	Blood metabolite levels;	chr7:99712696	chr6:108907615~108907873:-
PCPG	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-8.09	1.86e-13	1.86e-06	-0.71	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-8.09	1.86e-13	1.86e-06	-0.71	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-8.09	1.86e-13	1.86e-06	-0.71	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-8.09	1.86e-13	1.86e-06	-0.71	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-8.09	1.86e-13	1.86e-06	-0.71	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
PCPG	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	8.08	1.95e-13	1.94e-06	0.74	0.55	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
PCPG	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-8.08	1.97e-13	1.96e-06	-0.7	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
PCPG	trans	rs116095464	1	rs7736	ENSG00000185986.11	SDHAP3	8.08	1.99e-13	1.97e-06	0.81	0.55	Breast cancer;	chr5:314820	chr5:1572222~1594620:-
PCPG	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	8.07	2.06e-13	2.03e-06	0.7	0.55	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	8.07	2.06e-13	2.03e-06	0.7	0.55	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	8.07	2.06e-13	2.03e-06	0.7	0.55	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	8.07	2.06e-13	2.03e-06	0.7	0.55	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	8.07	2.06e-13	2.03e-06	0.7	0.55	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	8.07	2.06e-13	2.03e-06	0.7	0.55	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
PCPG	trans	rs916888	0.61	rs199438	ENSG00000263503.1	RP11-707O23.5	8.07	2.15e-13	2.11e-06	0.84	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45600869~45602340:-
PCPG	trans	rs116095464	0.558	rs9654453	ENSG00000185986.11	SDHAP3	8.06	2.17e-13	2.13e-06	0.82	0.55	Breast cancer;	chr5:299506	chr5:1572222~1594620:-
PCPG	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-8.06	2.23e-13	2.19e-06	-0.71	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-8.06	2.23e-13	2.19e-06	-0.71	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
PCPG	trans	rs12709013	0.646	rs8046154	ENSG00000233719.3	GOT2P3	-8.06	2.28e-13	2.23e-06	-0.63	-0.55	Blood metabolite ratios;	chr16:58773978	chr12:9641802~9643007:+
PCPG	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-8.05	2.29e-13	2.25e-06	-0.64	-0.55	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
PCPG	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	8.05	2.34e-13	2.29e-06	1.37	0.55	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-8.05	2.34e-13	2.29e-06	-0.66	-0.55	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
PCPG	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	8.05	2.4e-13	2.35e-06	0.7	0.55	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
PCPG	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-8.04	2.49e-13	2.43e-06	-0.69	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
PCPG	trans	rs12709013	0.636	rs4499224	ENSG00000233719.3	GOT2P3	8.04	2.52e-13	2.46e-06	0.6	0.55	Blood metabolite ratios;	chr16:58770364	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1595180	ENSG00000233719.3	GOT2P3	8.04	2.52e-13	2.46e-06	0.6	0.55	Blood metabolite ratios;	chr16:58770545	chr12:9641802~9643007:+
PCPG	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	8.04	2.53e-13	2.47e-06	0.73	0.55	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
PCPG	trans	rs10242455	0.717	rs2741872	ENSG00000228834.1	RP11-249L21.4	-8.04	2.54e-13	2.48e-06	-1.18	-0.55	Blood metabolite levels;	chr7:99742153	chr6:108907615~108907873:-
PCPG	trans	rs959695	1	rs35845479	ENSG00000260318.1	COX6CP1	8.03	2.62e-13	2.55e-06	0.7	0.55	Hippocampal atrophy;	chr8:99834273	chr16:11903923~11904137:-
PCPG	trans	rs3206736	0.663	rs329571	ENSG00000255583.2	RP11-415I12.2	8.03	2.63e-13	2.56e-06	0.57	0.55	Diastolic blood pressure;	chr7:35056175	chr12:63682523~63724935:-
PCPG	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	8.03	2.64e-13	2.57e-06	0.72	0.55	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
PCPG	trans	rs3206736	0.634	rs329546	ENSG00000255583.2	RP11-415I12.2	8.03	2.65e-13	2.58e-06	0.57	0.55	Diastolic blood pressure;	chr7:35071746	chr12:63682523~63724935:-
PCPG	trans	rs12709013	0.591	rs30842	ENSG00000233719.3	GOT2P3	-8.03	2.65e-13	2.58e-06	-0.63	-0.55	Blood metabolite ratios;	chr16:58709550	chr12:9641802~9643007:+
PCPG	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	8.02	2.72e-13	2.64e-06	0.74	0.55	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
PCPG	trans	rs12709013	0.574	rs35321124	ENSG00000233719.3	GOT2P3	8.02	2.77e-13	2.68e-06	0.63	0.55	Blood metabolite ratios;	chr16:58786561	chr12:9641802~9643007:+
PCPG	trans	rs3206736	0.729	rs1052355	ENSG00000255583.2	RP11-415I12.2	8.02	2.79e-13	2.7e-06	0.57	0.55	Diastolic blood pressure;	chr7:35080164	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.728	rs17800067	ENSG00000255583.2	RP11-415I12.2	8.02	2.79e-13	2.7e-06	0.57	0.55	Diastolic blood pressure;	chr7:35080740	chr12:63682523~63724935:-
PCPG	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-8.02	2.82e-13	2.72e-06	-0.73	-0.55	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
PCPG	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	8.02	2.82e-13	2.72e-06	0.7	0.55	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	8.02	2.82e-13	2.72e-06	0.7	0.55	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	8.02	2.82e-13	2.72e-06	0.7	0.55	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
PCPG	trans	rs916888	0.531	rs183211	ENSG00000263503.1	RP11-707O23.5	8.01	2.87e-13	2.77e-06	0.83	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45600869~45602340:-
PCPG	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	8.01	2.9e-13	2.8e-06	0.96	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
PCPG	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	8.01	2.96e-13	2.85e-06	0.73	0.55	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	8.01	2.96e-13	2.85e-06	0.73	0.55	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	8.01	2.96e-13	2.85e-06	0.73	0.55	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	8.01	2.96e-13	2.85e-06	0.73	0.55	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	8.01	2.96e-13	2.85e-06	0.73	0.55	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	8.01	2.96e-13	2.85e-06	0.73	0.55	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	8.01	2.96e-13	2.85e-06	0.73	0.55	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
PCPG	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-8.01	2.99e-13	2.87e-06	-0.77	-0.55	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-8.01	2.99e-13	2.87e-06	-0.77	-0.55	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
PCPG	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	8.01	3.01e-13	2.89e-06	0.74	0.55	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	8.01	3.01e-13	2.89e-06	0.74	0.55	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	8.01	3.01e-13	2.89e-06	0.74	0.55	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
PCPG	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	8.01	3.01e-13	2.89e-06	0.74	0.55	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
PCPG	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	8	3.05e-13	2.93e-06	0.75	0.55	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-8	3.06e-13	2.93e-06	-0.81	-0.55	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.702	rs73397481	ENSG00000228834.1	RP11-249L21.4	8	3.08e-13	2.95e-06	1.26	0.55	Blood metabolite levels;	chr7:99432485	chr6:108907615~108907873:-
PCPG	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-8	3.08e-13	2.95e-06	-0.63	-0.55	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.636	rs6499976	ENSG00000233719.3	GOT2P3	8	3.11e-13	2.98e-06	0.59	0.55	Blood metabolite ratios;	chr16:58770330	chr12:9641802~9643007:+
PCPG	trans	rs7121616	0.576	rs9665920	ENSG00000234176.1	HSPA8P1	8	3.12e-13	2.98e-06	0.7	0.55	Breast cancer;	chr11:123041700	chrX:121203182~121205014:-
PCPG	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-7.99	3.25e-13	3.11e-06	-0.8	-0.55	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	7.99	3.29e-13	3.14e-06	0.75	0.55	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	7.99	3.29e-13	3.14e-06	0.75	0.55	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	7.99	3.29e-13	3.14e-06	0.75	0.55	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	7.99	3.29e-13	3.14e-06	0.75	0.55	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	7.99	3.29e-13	3.14e-06	0.75	0.55	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	7.99	3.33e-13	3.18e-06	0.62	0.55	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
PCPG	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	7.99	3.36e-13	3.2e-06	0.72	0.55	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
PCPG	trans	rs10242455	0.702	rs74347626	ENSG00000228834.1	RP11-249L21.4	7.98	3.41e-13	3.25e-06	1.33	0.55	Blood metabolite levels;	chr7:99608398	chr6:108907615~108907873:-
PCPG	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	7.98	3.42e-13	3.25e-06	0.72	0.55	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
PCPG	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-7.98	3.53e-13	3.35e-06	-0.63	-0.55	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
PCPG	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	7.98	3.53e-13	3.36e-06	0.71	0.55	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
PCPG	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	7.98	3.55e-13	3.37e-06	0.64	0.55	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
PCPG	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-7.97	3.61e-13	3.43e-06	-0.65	-0.55	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.535	rs9924136	ENSG00000233719.3	GOT2P3	7.97	3.61e-13	3.43e-06	0.63	0.55	Blood metabolite ratios;	chr16:58779573	chr12:9641802~9643007:+
PCPG	trans	rs116095464	0.558	rs34629844	ENSG00000185986.11	SDHAP3	7.97	3.63e-13	3.44e-06	0.77	0.55	Breast cancer;	chr5:200714	chr5:1572222~1594620:-
PCPG	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	7.97	3.65e-13	3.46e-06	0.67	0.55	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
PCPG	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	7.96	3.84e-13	3.62e-06	0.86	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
PCPG	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	7.95	4.06e-13	3.82e-06	0.73	0.54	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	7.95	4.06e-13	3.82e-06	0.73	0.54	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	7.95	4.07e-13	3.83e-06	0.76	0.54	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
PCPG	trans	rs116095464	1	rs2015774	ENSG00000185986.11	SDHAP3	7.95	4.11e-13	3.87e-06	0.77	0.54	Breast cancer;	chr5:312843	chr5:1572222~1594620:-
PCPG	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	7.95	4.14e-13	3.89e-06	0.73	0.54	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
PCPG	trans	rs12709013	0.514	rs8062639	ENSG00000233719.3	GOT2P3	7.95	4.14e-13	3.89e-06	0.63	0.54	Blood metabolite ratios;	chr16:58800264	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.536	rs9930758	ENSG00000233719.3	GOT2P3	7.95	4.14e-13	3.89e-06	0.63	0.54	Blood metabolite ratios;	chr16:58803167	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.591	rs9932967	ENSG00000233719.3	GOT2P3	7.95	4.14e-13	3.89e-06	0.63	0.54	Blood metabolite ratios;	chr16:58805583	chr12:9641802~9643007:+
PCPG	trans	rs336284	0.502	rs336290	ENSG00000255583.2	RP11-415I12.2	7.95	4.17e-13	3.91e-06	0.63	0.54	Suicide behavior;Suicide;	chr7:35276128	chr12:63682523~63724935:-
PCPG	trans	rs959695	1	rs60891426	ENSG00000260318.1	COX6CP1	7.95	4.18e-13	3.91e-06	0.7	0.54	Hippocampal atrophy;	chr8:99831798	chr16:11903923~11904137:-
PCPG	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-7.95	4.24e-13	3.97e-06	-0.67	-0.54	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
PCPG	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	7.94	4.4e-13	4.09e-06	0.73	0.54	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
PCPG	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-7.94	4.41e-13	4.1e-06	-0.64	-0.54	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-7.94	4.41e-13	4.1e-06	-0.64	-0.54	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
PCPG	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-7.94	4.46e-13	4.14e-06	-0.69	-0.54	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
PCPG	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	7.94	4.47e-13	4.15e-06	0.73	0.54	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	7.94	4.47e-13	4.15e-06	0.73	0.54	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	7.94	4.47e-13	4.15e-06	0.73	0.54	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
PCPG	trans	rs3206736	0.636	rs6950920	ENSG00000255583.2	RP11-415I12.2	7.93	4.56e-13	4.22e-06	0.57	0.54	Diastolic blood pressure;	chr7:35181441	chr12:63682523~63724935:-
PCPG	trans	rs116095464	1	rs62330021	ENSG00000185986.11	SDHAP3	7.93	4.61e-13	4.26e-06	0.92	0.54	Breast cancer;	chr5:311787	chr5:1572222~1594620:-
PCPG	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-7.93	4.62e-13	4.28e-06	-0.63	-0.54	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.591	rs30834	ENSG00000233719.3	GOT2P3	7.93	4.65e-13	4.29e-06	0.63	0.54	Blood metabolite ratios;	chr16:58715394	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.569	rs30837	ENSG00000233719.3	GOT2P3	7.93	4.67e-13	4.31e-06	0.63	0.54	Blood metabolite ratios;	chr16:58711942	chr12:9641802~9643007:+
PCPG	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	7.93	4.69e-13	4.31e-06	0.72	0.54	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
PCPG	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-7.93	4.75e-13	4.36e-06	-0.64	-0.54	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	7.92	4.91e-13	4.49e-06	0.78	0.54	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
PCPG	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	7.92	4.91e-13	4.49e-06	0.78	0.54	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	7.92	4.91e-13	4.49e-06	0.78	0.54	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.702	rs3823813	ENSG00000228834.1	RP11-249L21.4	7.92	4.94e-13	4.51e-06	1.36	0.54	Blood metabolite levels;	chr7:99451766	chr6:108907615~108907873:-
PCPG	trans	rs336284	0.502	rs6976419	ENSG00000255583.2	RP11-415I12.2	7.92	4.95e-13	4.52e-06	0.61	0.54	Suicide behavior;Suicide;	chr7:35286407	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.606	rs6953221	ENSG00000255583.2	RP11-415I12.2	7.92	4.96e-13	4.53e-06	0.57	0.54	Diastolic blood pressure;	chr7:35176792	chr12:63682523~63724935:-
PCPG	trans	rs12709013	0.636	rs72792430	ENSG00000233719.3	GOT2P3	-7.92	4.96e-13	4.53e-06	-0.6	-0.54	Blood metabolite ratios;	chr16:58746990	chr12:9641802~9643007:+
PCPG	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	7.92	4.98e-13	4.55e-06	0.71	0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
PCPG	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	7.9	5.4e-13	4.92e-06	0.73	0.54	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs725310	ENSG00000225528.1	RP3-370M22.8	7.9	5.42e-13	4.94e-06	0.64	0.54	Longevity;	chr3:48377081	chr22:39960397~39964683:+
PCPG	trans	rs3206736	0.632	rs10252277	ENSG00000255583.2	RP11-415I12.2	7.9	5.58e-13	5.07e-06	0.56	0.54	Diastolic blood pressure;	chr7:35113247	chr12:63682523~63724935:-
PCPG	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-7.9	5.6e-13	5.09e-06	-0.64	-0.54	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	7.9	5.65e-13	5.13e-06	0.76	0.54	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	7.9	5.65e-13	5.13e-06	0.76	0.54	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
PCPG	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	7.89	5.67e-13	5.15e-06	0.68	0.54	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
PCPG	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	7.89	5.82e-13	5.28e-06	0.76	0.54	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
PCPG	trans	rs3206736	0.729	rs6972730	ENSG00000255583.2	RP11-415I12.2	7.89	5.87e-13	5.32e-06	0.56	0.54	Diastolic blood pressure;	chr7:35150797	chr12:63682523~63724935:-
PCPG	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	7.89	5.87e-13	5.32e-06	0.65	0.54	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
PCPG	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-7.88	6.02e-13	5.43e-06	-0.7	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-7.88	6.02e-13	5.43e-06	-0.7	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-7.88	6.02e-13	5.43e-06	-0.7	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
PCPG	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	7.88	6.12e-13	5.52e-06	0.71	0.54	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	7.88	6.22e-13	5.6e-06	0.71	0.54	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
PCPG	trans	rs12709013	0.597	rs1616072	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58747194	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs2575374	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58747494	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1657164	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58747949	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.537	rs1657167	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58748955	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs8054414	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58749772	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.597	rs11076259	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58749860	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs12325516	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58749899	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs11076260	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58749942	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1646278	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58750084	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1646279	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58750235	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1646280	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58750420	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.597	rs1646286	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58752651	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1624301	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58753491	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1626006	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58753691	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.684	rs1646287	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58753774	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.671	rs1369933	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58753927	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1369934	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58754124	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.561	rs1657174	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58755139	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.613	rs1646288	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58755576	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.561	rs727484	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58756568	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs257628	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58758924	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs257627	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58758956	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs191783	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58759994	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs257624	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58760994	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.559	rs8060721	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58765581	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs8044542	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58765620	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1865836	ENSG00000233719.3	GOT2P3	7.88	6.31e-13	5.65e-06	0.6	0.54	Blood metabolite ratios;	chr16:58768143	chr12:9641802~9643007:+
PCPG	trans	rs6688567	1	rs6688567	ENSG00000213331.4	RP11-713C19.2	7.88	6.31e-13	5.65e-06	0.7	0.54	Mosquito bite size;	chr1:173614275	chr4:187970273~187971284:+
PCPG	trans	rs3206736	0.664	rs3909150	ENSG00000255583.2	RP11-415I12.2	7.87	6.4e-13	5.72e-06	0.55	0.54	Diastolic blood pressure;	chr7:35078124	chr12:63682523~63724935:-
PCPG	trans	rs2657294	0.796	rs6480770	ENSG00000172974.11	AC007318.5	7.87	6.57e-13	5.87e-06	0.54	0.54	Pneumonia;	chr10:75098799	chr2:65205108~65205988:+
PCPG	trans	rs3206736	0.761	rs6462594	ENSG00000255583.2	RP11-415I12.2	7.87	6.58e-13	5.88e-06	0.54	0.54	Diastolic blood pressure;	chr7:35150472	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.604	rs10224131	ENSG00000255583.2	RP11-415I12.2	7.87	6.58e-13	5.88e-06	0.54	0.54	Diastolic blood pressure;	chr7:35161192	chr12:63682523~63724935:-
PCPG	trans	rs12709013	0.636	rs967852	ENSG00000233719.3	GOT2P3	7.87	6.61e-13	5.9e-06	0.63	0.54	Blood metabolite ratios;	chr16:58807313	chr12:9641802~9643007:+
PCPG	trans	rs116095464	0.867	rs10061296	ENSG00000185986.11	SDHAP3	7.87	6.62e-13	5.9e-06	0.8	0.54	Breast cancer;	chr5:312138	chr5:1572222~1594620:-
PCPG	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	7.86	6.78e-13	6.04e-06	0.95	0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
PCPG	trans	rs3206736	0.732	rs329557	ENSG00000255583.2	RP11-415I12.2	7.86	6.78e-13	6.04e-06	0.55	0.54	Diastolic blood pressure;	chr7:35063857	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.53	rs329553	ENSG00000255583.2	RP11-415I12.2	7.86	6.78e-13	6.04e-06	0.55	0.54	Diastolic blood pressure;	chr7:35065450	chr12:63682523~63724935:-
PCPG	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	7.86	6.89e-13	6.14e-06	0.71	0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
PCPG	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-7.86	7.1e-13	6.3e-06	-0.84	-0.54	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
PCPG	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	7.85	7.25e-13	6.43e-06	0.65	0.54	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
PCPG	trans	rs12709013	0.636	rs1646281	ENSG00000233719.3	GOT2P3	7.85	7.45e-13	6.59e-06	0.61	0.54	Blood metabolite ratios;	chr16:58750512	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.613	rs8049462	ENSG00000233719.3	GOT2P3	7.85	7.45e-13	6.59e-06	0.61	0.54	Blood metabolite ratios;	chr16:58757654	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.66	rs257629	ENSG00000233719.3	GOT2P3	7.85	7.45e-13	6.59e-06	0.61	0.54	Blood metabolite ratios;	chr16:58758044	chr12:9641802~9643007:+
PCPG	trans	rs1816752	0.564	rs9511223	ENSG00000237917.1	PARP4P1	-7.84	7.77e-13	6.86e-06	-0.64	-0.54	Obesity-related traits;	chr13:24380142	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.597	rs1657171	ENSG00000233719.3	GOT2P3	7.84	7.79e-13	6.88e-06	0.6	0.54	Blood metabolite ratios;	chr16:58752083	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs1646285	ENSG00000233719.3	GOT2P3	7.84	7.79e-13	6.88e-06	0.6	0.54	Blood metabolite ratios;	chr16:58752102	chr12:9641802~9643007:+
PCPG	trans	rs7121616	0.5	rs12574868	ENSG00000234176.1	HSPA8P1	7.84	7.89e-13	6.96e-06	0.69	0.54	Breast cancer;	chr11:123040824	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.531	rs12573932	ENSG00000234176.1	HSPA8P1	7.84	7.89e-13	6.96e-06	0.69	0.54	Breast cancer;	chr11:123040995	chrX:121203182~121205014:-
PCPG	trans	rs7121616	0.531	rs11826861	ENSG00000234176.1	HSPA8P1	7.84	7.89e-13	6.96e-06	0.69	0.54	Breast cancer;	chr11:123041207	chrX:121203182~121205014:-
PCPG	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	7.83	8.02e-13	7.07e-06	0.72	0.54	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
PCPG	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	7.83	8.03e-13	7.08e-06	0.65	0.54	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
PCPG	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	7.83	8.12e-13	7.14e-06	0.64	0.54	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
PCPG	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	7.83	8.14e-13	7.15e-06	0.77	0.54	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	7.83	8.14e-13	7.15e-06	0.77	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	7.83	8.14e-13	7.15e-06	0.77	0.54	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	7.83	8.14e-13	7.15e-06	0.77	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	7.83	8.14e-13	7.15e-06	0.77	0.54	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	7.83	8.14e-13	7.15e-06	0.77	0.54	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
PCPG	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-7.83	8.33e-13	7.3e-06	-0.69	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
PCPG	trans	rs2288327	0.557	rs7588593	ENSG00000269800.1	PLEKHA3P1	7.83	8.35e-13	7.32e-06	0.94	0.54	Atrial fibrillation;	chr2:178487723	chr19:41521043~41521989:-
PCPG	trans	rs2288327	0.557	rs7577862	ENSG00000269800.1	PLEKHA3P1	7.83	8.35e-13	7.32e-06	0.94	0.54	Atrial fibrillation;	chr2:178488130	chr19:41521043~41521989:-
PCPG	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-7.83	8.39e-13	7.35e-06	-0.83	-0.54	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.571	rs73713594	ENSG00000228834.1	RP11-249L21.4	7.83	8.41e-13	7.36e-06	1.33	0.54	Blood metabolite levels;	chr7:99728875	chr6:108907615~108907873:-
PCPG	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	7.82	8.54e-13	7.46e-06	0.75	0.54	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	7.82	8.54e-13	7.46e-06	0.75	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	7.82	8.54e-13	7.46e-06	0.75	0.54	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
PCPG	trans	rs3206736	0.548	rs6959047	ENSG00000255583.2	RP11-415I12.2	7.82	8.81e-13	7.7e-06	0.54	0.54	Diastolic blood pressure;	chr7:35170599	chr12:63682523~63724935:-
PCPG	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	7.81	8.94e-13	7.81e-06	0.79	0.54	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.636	rs1646284	ENSG00000233719.3	GOT2P3	7.81	9.13e-13	7.95e-06	0.61	0.54	Blood metabolite ratios;	chr16:58752093	chr12:9641802~9643007:+
PCPG	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-7.81	9.18e-13	7.99e-06	-0.72	-0.54	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-7.81	9.32e-13	8.09e-06	-0.78	-0.54	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-7.81	9.32e-13	8.09e-06	-0.78	-0.54	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	7.8	9.53e-13	8.26e-06	0.78	0.54	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.591	rs7184377	ENSG00000233719.3	GOT2P3	7.8	9.57e-13	8.26e-06	0.63	0.54	Blood metabolite ratios;	chr16:58808765	chr12:9641802~9643007:+
PCPG	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	7.8	9.75e-13	8.37e-06	0.68	0.54	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	7.8	9.75e-13	8.37e-06	0.68	0.54	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	7.8	9.75e-13	8.37e-06	0.68	0.54	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
PCPG	trans	rs2288327	0.557	rs60488846	ENSG00000269800.1	PLEKHA3P1	7.8	9.91e-13	8.49e-06	0.94	0.54	Atrial fibrillation;	chr2:178493115	chr19:41521043~41521989:-
PCPG	trans	rs12709013	0.591	rs6499980	ENSG00000233719.3	GOT2P3	7.79	1.01e-12	8.67e-06	0.63	0.54	Blood metabolite ratios;	chr16:58787972	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.591	rs899375	ENSG00000233719.3	GOT2P3	7.79	1.01e-12	8.67e-06	0.63	0.54	Blood metabolite ratios;	chr16:58792325	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.591	rs4410065	ENSG00000233719.3	GOT2P3	7.79	1.01e-12	8.67e-06	0.63	0.54	Blood metabolite ratios;	chr16:58800968	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.591	rs2406234	ENSG00000233719.3	GOT2P3	7.79	1.01e-12	8.67e-06	0.63	0.54	Blood metabolite ratios;	chr16:58801840	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.591	rs2086206	ENSG00000233719.3	GOT2P3	7.79	1.01e-12	8.67e-06	0.63	0.54	Blood metabolite ratios;	chr16:58802094	chr12:9641802~9643007:+
PCPG	trans	rs10242455	0.571	rs73713595	ENSG00000228834.1	RP11-249L21.4	7.79	1.02e-12	8.7e-06	1.33	0.54	Blood metabolite levels;	chr7:99729036	chr6:108907615~108907873:-
PCPG	trans	rs7399018	0.739	rs7399073	ENSG00000223825.5	DAZAP2P1	7.79	1.04e-12	8.86e-06	0.64	0.54	Cisplatin-induced ototoxicity;	chr12:51220266	chr2:202201384~202201886:-
PCPG	trans	rs12709013	0.591	rs30838	ENSG00000233719.3	GOT2P3	7.79	1.04e-12	8.86e-06	0.62	0.54	Blood metabolite ratios;	chr16:58711513	chr12:9641802~9643007:+
PCPG	trans	rs10242455	0.702	rs6956305	ENSG00000228834.1	RP11-249L21.4	7.78	1.06e-12	9.03e-06	1.36	0.54	Blood metabolite levels;	chr7:99643687	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs73713580	ENSG00000228834.1	RP11-249L21.4	7.78	1.06e-12	9.03e-06	1.36	0.54	Blood metabolite levels;	chr7:99643987	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs6976017	ENSG00000228834.1	RP11-249L21.4	7.78	1.06e-12	9.03e-06	1.36	0.54	Blood metabolite levels;	chr7:99652376	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.702	rs73713521	ENSG00000228834.1	RP11-249L21.4	7.78	1.11e-12	9.43e-06	1.29	0.54	Blood metabolite levels;	chr7:99591026	chr6:108907615~108907873:-
PCPG	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	7.78	1.11e-12	9.48e-06	0.68	0.54	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
PCPG	trans	rs6732160	0.624	rs10865397	ENSG00000236165.1	PRADC1P1	7.78	1.11e-12	9.5e-06	0.7	0.54	Intelligence (multi-trait analysis);	chr2:73131164	chr3:36976316~36976840:+
PCPG	trans	rs10242455	0.717	rs2687134	ENSG00000228834.1	RP11-249L21.4	-7.77	1.12e-12	9.57e-06	-1.15	-0.54	Blood metabolite levels;	chr7:99733419	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.717	rs2687133	ENSG00000228834.1	RP11-249L21.4	-7.77	1.12e-12	9.57e-06	-1.15	-0.54	Blood metabolite levels;	chr7:99734460	chr6:108907615~108907873:-
PCPG	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	7.77	1.14e-12	9.66e-06	0.78	0.54	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.574	rs839418	ENSG00000233719.3	GOT2P3	7.77	1.14e-12	9.73e-06	0.61	0.54	Blood metabolite ratios;	chr16:58705426	chr12:9641802~9643007:+
PCPG	trans	rs10242455	0.702	rs59574285	ENSG00000228834.1	RP11-249L21.4	7.76	1.19e-12	1.01e-05	1.36	0.54	Blood metabolite levels;	chr7:99638528	chr6:108907615~108907873:-
PCPG	trans	rs9876781	1	rs13314659	ENSG00000225528.1	RP3-370M22.8	7.75	1.26e-12	1.07e-05	0.62	0.53	Longevity;	chr3:48407742	chr22:39960397~39964683:+
PCPG	trans	rs4276421	0.774	rs6884716	ENSG00000231752.4	EMBP1	7.75	1.28e-12	1.08e-05	0.72	0.53	P wave duration;	chr5:46115267	chr1:121519112~121571892:+
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-7.75	1.28e-12	1.08e-05	-0.66	-0.53	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
PCPG	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	7.75	1.32e-12	1.11e-05	0.76	0.53	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
PCPG	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	7.74	1.33e-12	1.12e-05	0.77	0.53	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	7.74	1.33e-12	1.12e-05	0.77	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	7.74	1.33e-12	1.12e-05	0.77	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	7.74	1.33e-12	1.12e-05	0.77	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	7.74	1.33e-12	1.12e-05	0.77	0.53	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	7.74	1.33e-12	1.12e-05	0.77	0.53	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
PCPG	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	7.74	1.34e-12	1.13e-05	0.75	0.53	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
PCPG	trans	rs12709013	0.601	rs2432621	ENSG00000233719.3	GOT2P3	7.74	1.39e-12	1.17e-05	0.59	0.53	Blood metabolite ratios;	chr16:58749676	chr12:9641802~9643007:+
PCPG	trans	rs10242455	0.702	rs41385645	ENSG00000228834.1	RP11-249L21.4	7.73	1.41e-12	1.18e-05	1.33	0.53	Blood metabolite levels;	chr7:99376415	chr6:108907615~108907873:-
PCPG	trans	rs3206736	0.803	rs329580	ENSG00000255583.2	RP11-415I12.2	-7.73	1.41e-12	1.18e-05	-0.53	-0.53	Diastolic blood pressure;	chr7:35052263	chr12:63682523~63724935:-
PCPG	trans	rs12709013	0.591	rs30841	ENSG00000233719.3	GOT2P3	7.73	1.47e-12	1.23e-05	0.61	0.53	Blood metabolite ratios;	chr16:58709819	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.591	rs30840	ENSG00000233719.3	GOT2P3	7.73	1.47e-12	1.23e-05	0.61	0.53	Blood metabolite ratios;	chr16:58710165	chr12:9641802~9643007:+
PCPG	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-7.72	1.5e-12	1.26e-05	-0.64	-0.53	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
PCPG	trans	rs7399018	0.739	rs7953955	ENSG00000223825.5	DAZAP2P1	7.72	1.54e-12	1.29e-05	0.64	0.53	Cisplatin-induced ototoxicity;	chr12:51214683	chr2:202201384~202201886:-
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	7.71	1.58e-12	1.32e-05	0.62	0.53	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
PCPG	trans	rs9876781	1	rs11130171	ENSG00000225528.1	RP3-370M22.8	-7.71	1.64e-12	1.37e-05	-0.6	-0.53	Longevity;	chr3:48421052	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs9883927	ENSG00000225528.1	RP3-370M22.8	-7.71	1.64e-12	1.37e-05	-0.6	-0.53	Longevity;	chr3:48422302	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs9817615	ENSG00000225528.1	RP3-370M22.8	-7.71	1.64e-12	1.37e-05	-0.6	-0.53	Longevity;	chr3:48429347	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs2290822	ENSG00000225528.1	RP3-370M22.8	-7.71	1.64e-12	1.37e-05	-0.6	-0.53	Longevity;	chr3:48431794	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs13076076	ENSG00000225528.1	RP3-370M22.8	-7.71	1.64e-12	1.37e-05	-0.6	-0.53	Longevity;	chr3:48437629	chr22:39960397~39964683:+
PCPG	trans	rs12709013	0.613	rs6499984	ENSG00000233719.3	GOT2P3	7.71	1.65e-12	1.37e-05	0.62	0.53	Blood metabolite ratios;	chr16:58810209	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.574	rs9302706	ENSG00000233719.3	GOT2P3	7.71	1.65e-12	1.37e-05	0.62	0.53	Blood metabolite ratios;	chr16:58812060	chr12:9641802~9643007:+
PCPG	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-7.71	1.65e-12	1.37e-05	-0.63	-0.53	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.576	rs2432622	ENSG00000233719.3	GOT2P3	7.7	1.66e-12	1.38e-05	0.61	0.53	Blood metabolite ratios;	chr16:58749681	chr12:9641802~9643007:+
PCPG	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	7.7	1.66e-12	1.38e-05	0.63	0.53	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
PCPG	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	7.7	1.67e-12	1.39e-05	0.74	0.53	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
PCPG	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-7.7	1.68e-12	1.39e-05	-0.63	-0.53	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-7.7	1.68e-12	1.39e-05	-0.63	-0.53	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-7.7	1.68e-12	1.39e-05	-0.63	-0.53	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-7.7	1.68e-12	1.39e-05	-0.63	-0.53	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-7.7	1.68e-12	1.39e-05	-0.63	-0.53	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-7.7	1.68e-12	1.39e-05	-0.63	-0.53	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-7.7	1.68e-12	1.39e-05	-0.63	-0.53	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
PCPG	trans	rs9876781	0.967	rs1870444	ENSG00000225528.1	RP3-370M22.8	-7.7	1.7e-12	1.41e-05	-0.6	-0.53	Longevity;	chr3:48445369	chr22:39960397~39964683:+
PCPG	trans	rs13190036	0.786	rs10068127	ENSG00000217325.2	PRELID1P1	-7.7	1.71e-12	1.42e-05	-0.95	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177204786	chr6:126643488~126644390:+
PCPG	trans	rs9876781	1	rs11130170	ENSG00000225528.1	RP3-370M22.8	-7.69	1.75e-12	1.45e-05	-0.62	-0.53	Longevity;	chr3:48408490	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs10470686	ENSG00000225528.1	RP3-370M22.8	-7.69	1.75e-12	1.45e-05	-0.62	-0.53	Longevity;	chr3:48408549	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs3214041	ENSG00000225528.1	RP3-370M22.8	-7.69	1.75e-12	1.45e-05	-0.62	-0.53	Longevity;	chr3:48413059	chr22:39960397~39964683:+
PCPG	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-7.69	1.75e-12	1.45e-05	-0.61	-0.53	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
PCPG	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-7.69	1.79e-12	1.48e-05	-0.66	-0.53	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
PCPG	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	7.68	1.88e-12	1.56e-05	0.76	0.53	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	7.68	1.93e-12	1.59e-05	0.73	0.53	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	7.68	1.93e-12	1.59e-05	0.73	0.53	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	7.68	1.93e-12	1.59e-05	0.73	0.53	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
PCPG	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-7.68	1.94e-12	1.59e-05	-0.61	-0.53	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
PCPG	trans	rs12709013	0.613	rs1618602	ENSG00000233719.3	GOT2P3	7.67	1.98e-12	1.63e-05	0.61	0.53	Blood metabolite ratios;	chr16:58756080	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.636	rs8045466	ENSG00000233719.3	GOT2P3	7.67	1.98e-12	1.63e-05	0.61	0.53	Blood metabolite ratios;	chr16:58765113	chr12:9641802~9643007:+
PCPG	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-7.67	2.03e-12	1.67e-05	-0.76	-0.53	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-7.67	2.03e-12	1.67e-05	-0.76	-0.53	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
PCPG	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-7.67	2.07e-12	1.7e-05	-0.72	-0.53	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	7.66	2.07e-12	1.7e-05	0.77	0.53	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	7.66	2.07e-12	1.7e-05	0.77	0.53	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
PCPG	trans	rs9876781	1	rs9849509	ENSG00000225528.1	RP3-370M22.8	-7.66	2.1e-12	1.72e-05	-0.6	-0.53	Longevity;	chr3:48442021	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs60512868	ENSG00000225528.1	RP3-370M22.8	-7.66	2.1e-12	1.72e-05	-0.6	-0.53	Longevity;	chr3:48442035	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs7636044	ENSG00000225528.1	RP3-370M22.8	-7.66	2.1e-12	1.72e-05	-0.6	-0.53	Longevity;	chr3:48443151	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs4490383	ENSG00000225528.1	RP3-370M22.8	-7.66	2.1e-12	1.72e-05	-0.6	-0.53	Longevity;	chr3:48443275	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs9876781	ENSG00000225528.1	RP3-370M22.8	-7.66	2.1e-12	1.72e-05	-0.6	-0.53	Longevity;	chr3:48445934	chr22:39960397~39964683:+
PCPG	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-7.65	2.3e-12	1.88e-05	-1.03	-0.53	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
PCPG	trans	rs10242455	0.702	rs78218664	ENSG00000228834.1	RP11-249L21.4	7.64	2.34e-12	1.91e-05	1.35	0.53	Blood metabolite levels;	chr7:99556758	chr6:108907615~108907873:-
PCPG	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	7.64	2.36e-12	1.92e-05	0.64	0.53	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
PCPG	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-7.64	2.37e-12	1.94e-05	-0.7	-0.53	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-7.64	2.37e-12	1.94e-05	-0.7	-0.53	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
PCPG	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-7.64	2.4e-12	1.96e-05	-0.63	-0.53	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-7.64	2.42e-12	1.97e-05	-0.63	-0.53	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
PCPG	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-7.63	2.49e-12	2.02e-05	-0.7	-0.53	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
PCPG	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-7.63	2.57e-12	2.09e-05	-0.62	-0.53	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
PCPG	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	7.62	2.6e-12	2.11e-05	0.64	0.53	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
PCPG	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-7.62	2.67e-12	2.16e-05	-0.7	-0.53	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-7.62	2.69e-12	2.18e-05	-0.71	-0.53	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
PCPG	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	7.62	2.7e-12	2.18e-05	0.68	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
PCPG	trans	rs13190036	1	rs351862	ENSG00000217325.2	PRELID1P1	-7.62	2.7e-12	2.19e-05	-0.93	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177114369	chr6:126643488~126644390:+
PCPG	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-7.62	2.72e-12	2.2e-05	-0.7	-0.53	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-7.62	2.72e-12	2.2e-05	-0.7	-0.53	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-7.62	2.72e-12	2.2e-05	-0.7	-0.53	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-7.61	2.77e-12	2.24e-05	-0.7	-0.53	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-7.61	2.78e-12	2.25e-05	-0.7	-0.53	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-7.61	2.78e-12	2.25e-05	-0.7	-0.53	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
PCPG	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-7.61	2.78e-12	2.25e-05	-0.62	-0.53	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
PCPG	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	7.61	2.79e-12	2.26e-05	0.74	0.53	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
PCPG	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-7.61	2.82e-12	2.27e-05	-0.67	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
PCPG	trans	rs10242455	0.702	rs73713507	ENSG00000228834.1	RP11-249L21.4	7.61	2.84e-12	2.29e-05	1.35	0.53	Blood metabolite levels;	chr7:99540980	chr6:108907615~108907873:-
PCPG	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	7.6	2.99e-12	2.41e-05	0.7	0.53	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	7.6	2.99e-12	2.41e-05	0.7	0.53	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	7.6	2.99e-12	2.41e-05	0.7	0.53	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
PCPG	trans	rs12709013	0.636	rs8060717	ENSG00000233719.3	GOT2P3	7.6	3e-12	2.42e-05	0.58	0.53	Blood metabolite ratios;	chr16:58765574	chr12:9641802~9643007:+
PCPG	trans	rs12709013	0.621	rs6499974	ENSG00000233719.3	GOT2P3	7.6	3e-12	2.42e-05	0.58	0.53	Blood metabolite ratios;	chr16:58769642	chr12:9641802~9643007:+
PCPG	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	7.6	3.04e-12	2.44e-05	0.72	0.53	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
PCPG	trans	rs7819412	0.749	rs2001433	ENSG00000253893.2	FAM85B	7.59	3.09e-12	2.48e-05	0.73	0.53	Triglycerides;	chr8:11045965	chr8:8167819~8226614:-
PCPG	trans	rs9467773	0.933	rs35355150	ENSG00000242375.1	RP11-498P14.3	7.59	3.1e-12	2.5e-05	0.68	0.53	Intelligence (multi-trait analysis);	chr6:26525811	chr9:97195351~97197687:-
PCPG	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	7.59	3.11e-12	2.5e-05	0.69	0.53	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
PCPG	trans	rs9876781	1	rs2362450	ENSG00000225528.1	RP3-370M22.8	-7.59	3.12e-12	2.51e-05	-0.6	-0.53	Longevity;	chr3:48419904	chr22:39960397~39964683:+
PCPG	trans	rs9876781	0.967	rs1459249	ENSG00000225528.1	RP3-370M22.8	-7.59	3.12e-12	2.51e-05	-0.6	-0.53	Longevity;	chr3:48438208	chr22:39960397~39964683:+
PCPG	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	7.59	3.16e-12	2.54e-05	0.85	0.53	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
PCPG	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	7.59	3.22e-12	2.58e-05	0.69	0.53	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
PCPG	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	7.58	3.25e-12	2.61e-05	0.82	0.53	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
PCPG	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	7.58	3.27e-12	2.62e-05	0.71	0.53	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
PCPG	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-7.58	3.28e-12	2.62e-05	-0.78	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
PCPG	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-7.57	3.48e-12	2.78e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-7.57	3.48e-12	2.78e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	7.57	3.57e-12	2.83e-05	0.74	0.53	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
PCPG	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-7.57	3.57e-12	2.83e-05	-0.62	-0.53	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
PCPG	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-7.57	3.6e-12	2.85e-05	-0.7	-0.53	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
PCPG	trans	rs7819412	0.775	rs4840551	ENSG00000253893.2	FAM85B	7.57	3.61e-12	2.86e-05	0.68	0.53	Triglycerides;	chr8:11171530	chr8:8167819~8226614:-
PCPG	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-7.57	3.61e-12	2.86e-05	-0.61	-0.53	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-7.57	3.61e-12	2.86e-05	-0.61	-0.53	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-7.57	3.61e-12	2.86e-05	-0.61	-0.53	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
PCPG	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	7.56	3.62e-12	2.87e-05	0.66	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
PCPG	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-7.56	3.65e-12	2.89e-05	-0.92	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
PCPG	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-7.56	3.65e-12	2.89e-05	-0.92	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
PCPG	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-7.56	3.66e-12	2.9e-05	-0.62	-0.53	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-7.56	3.68e-12	2.91e-05	-0.61	-0.53	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-7.56	3.68e-12	2.91e-05	-0.61	-0.53	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-7.56	3.68e-12	2.91e-05	-0.61	-0.53	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
PCPG	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-7.56	3.69e-12	2.92e-05	-0.7	-0.53	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	7.56	3.74e-12	2.95e-05	0.71	0.53	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
PCPG	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	7.56	3.78e-12	2.98e-05	0.7	0.53	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
PCPG	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-7.54	4.12e-12	3.24e-05	-0.61	-0.52	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.586	rs9580991	ENSG00000237917.1	PARP4P1	7.54	4.2e-12	3.29e-05	0.62	0.52	Obesity-related traits;	chr13:24378278	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.586	rs6490906	ENSG00000237917.1	PARP4P1	7.54	4.2e-12	3.29e-05	0.62	0.52	Obesity-related traits;	chr13:24379013	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.586	rs6490907	ENSG00000237917.1	PARP4P1	7.54	4.2e-12	3.29e-05	0.62	0.52	Obesity-related traits;	chr13:24379136	chrY:26594851~26634652:-
PCPG	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-7.53	4.29e-12	3.36e-05	-0.7	-0.52	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-7.53	4.36e-12	3.41e-05	-0.7	-0.52	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
PCPG	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-7.53	4.38e-12	3.42e-05	-0.64	-0.52	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
PCPG	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-7.53	4.38e-12	3.42e-05	-0.64	-0.52	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
PCPG	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	7.52	4.53e-12	3.53e-05	0.62	0.52	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
PCPG	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-7.52	4.62e-12	3.59e-05	-0.69	-0.52	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-7.52	4.62e-12	3.59e-05	-0.69	-0.52	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	7.52	4.63e-12	3.6e-05	0.65	0.52	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
PCPG	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	7.52	4.7e-12	3.65e-05	0.69	0.52	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.774	rs4428422	ENSG00000231752.4	EMBP1	7.52	4.74e-12	3.68e-05	0.71	0.52	P wave duration;	chr5:46017216	chr1:121519112~121571892:+
PCPG	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	7.51	4.78e-12	3.71e-05	1.11	0.52	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
PCPG	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-7.51	4.94e-12	3.83e-05	-0.61	-0.52	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
PCPG	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	7.51	4.97e-12	3.85e-05	0.67	0.52	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	7.51	4.97e-12	3.85e-05	0.67	0.52	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	7.51	5.03e-12	3.9e-05	0.66	0.52	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
PCPG	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-7.51	5.05e-12	3.91e-05	-0.62	-0.52	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
PCPG	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	7.51	5.05e-12	3.91e-05	0.69	0.52	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	7.51	5.05e-12	3.91e-05	0.69	0.52	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-7.5	5.05e-12	3.91e-05	-0.71	-0.52	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-7.5	5.05e-12	3.91e-05	-0.71	-0.52	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
PCPG	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-7.5	5.08e-12	3.93e-05	-0.61	-0.52	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
PCPG	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	7.5	5.09e-12	3.93e-05	0.71	0.52	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
PCPG	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	7.5	5.1e-12	3.94e-05	0.68	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
PCPG	trans	rs10242455	0.702	rs76702117	ENSG00000228834.1	RP11-249L21.4	7.5	5.16e-12	3.99e-05	1.3	0.52	Blood metabolite levels;	chr7:99319156	chr6:108907615~108907873:-
PCPG	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	7.49	5.41e-12	4.17e-05	0.85	0.52	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	7.49	5.41e-12	4.17e-05	0.85	0.52	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	7.49	5.41e-12	4.17e-05	0.85	0.52	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
PCPG	trans	rs10242455	0.557	rs57830676	ENSG00000228834.1	RP11-249L21.4	7.49	5.46e-12	4.21e-05	1.36	0.52	Blood metabolite levels;	chr7:99683740	chr6:108907615~108907873:-
PCPG	trans	rs12709013	0.591	rs4784986	ENSG00000233719.3	GOT2P3	7.49	5.64e-12	4.34e-05	0.57	0.52	Blood metabolite ratios;	chr16:58803007	chr12:9641802~9643007:+
PCPG	trans	rs4276421	0.904	rs57299032	ENSG00000231752.4	EMBP1	7.48	5.73e-12	4.41e-05	0.68	0.52	P wave duration;	chr5:45998162	chr1:121519112~121571892:+
PCPG	trans	rs116095464	0.558	rs10055993	ENSG00000185986.11	SDHAP3	7.48	5.79e-12	4.45e-05	0.75	0.52	Breast cancer;	chr5:264181	chr5:1572222~1594620:-
PCPG	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	7.48	5.79e-12	4.45e-05	0.64	0.52	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
PCPG	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	7.48	5.88e-12	4.51e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	7.48	5.88e-12	4.51e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	7.48	5.88e-12	4.51e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	7.48	5.88e-12	4.51e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	7.48	5.88e-12	4.51e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-7.48	5.91e-12	4.53e-05	-0.64	-0.52	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
PCPG	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	7.46	6.32e-12	4.83e-05	0.7	0.52	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	7.46	6.44e-12	4.91e-05	0.67	0.52	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	7.46	6.47e-12	4.93e-05	0.7	0.52	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
PCPG	trans	rs12200782	0.53	rs9379892	ENSG00000242375.1	RP11-498P14.3	7.46	6.56e-12	4.99e-05	0.89	0.52	Small cell lung carcinoma;	chr6:26582186	chr9:97195351~97197687:-
PCPG	trans	rs10242455	0.571	rs55830753	ENSG00000228834.1	RP11-249L21.4	7.45	6.66e-12	5.07e-05	1.35	0.52	Blood metabolite levels;	chr7:99694599	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.571	rs45593341	ENSG00000228834.1	RP11-249L21.4	7.45	6.66e-12	5.07e-05	1.35	0.52	Blood metabolite levels;	chr7:99707288	chr6:108907615~108907873:-
PCPG	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-7.45	6.69e-12	5.08e-05	-0.72	-0.52	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
PCPG	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	7.45	6.9e-12	5.24e-05	0.81	0.52	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
PCPG	trans	rs9876781	1	rs9812647	ENSG00000225528.1	RP3-370M22.8	7.45	6.94e-12	5.27e-05	0.61	0.52	Longevity;	chr3:48407507	chr22:39960397~39964683:+
PCPG	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	7.44	7.06e-12	5.36e-05	0.67	0.52	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.845	rs62372987	ENSG00000231752.4	EMBP1	7.44	7.06e-12	5.36e-05	0.67	0.52	P wave duration;	chr5:45979889	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-7.44	7.11e-12	5.39e-05	-0.77	-0.52	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-7.44	7.21e-12	5.46e-05	-0.61	-0.52	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
PCPG	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	7.44	7.27e-12	5.5e-05	0.64	0.52	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
PCPG	trans	rs4276421	0.904	rs4569880	ENSG00000231752.4	EMBP1	7.44	7.41e-12	5.6e-05	0.68	0.52	P wave duration;	chr5:46011373	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.874	rs4569881	ENSG00000231752.4	EMBP1	7.44	7.41e-12	5.6e-05	0.68	0.52	P wave duration;	chr5:46011667	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.638	rs4551075	ENSG00000231752.4	EMBP1	7.44	7.41e-12	5.6e-05	0.68	0.52	P wave duration;	chr5:46011710	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.816	rs13362078	ENSG00000231752.4	EMBP1	7.44	7.41e-12	5.6e-05	0.68	0.52	P wave duration;	chr5:46013351	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.904	rs4489075	ENSG00000231752.4	EMBP1	7.44	7.41e-12	5.6e-05	0.68	0.52	P wave duration;	chr5:46018903	chr1:121519112~121571892:+
PCPG	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-7.43	7.47e-12	5.64e-05	-0.62	-0.52	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
PCPG	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-7.43	7.53e-12	5.68e-05	-0.6	-0.52	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-7.43	7.53e-12	5.68e-05	-0.6	-0.52	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-7.43	7.63e-12	5.75e-05	-0.6	-0.52	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
PCPG	trans	rs9876781	1	rs9826195	ENSG00000225528.1	RP3-370M22.8	-7.42	7.99e-12	6e-05	-0.61	-0.52	Longevity;	chr3:48392157	chr22:39960397~39964683:+
PCPG	trans	rs9876781	0.967	rs9864815	ENSG00000225528.1	RP3-370M22.8	-7.42	7.99e-12	6e-05	-0.61	-0.52	Longevity;	chr3:48392588	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs9809843	ENSG00000225528.1	RP3-370M22.8	-7.42	7.99e-12	6e-05	-0.61	-0.52	Longevity;	chr3:48392923	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs11712561	ENSG00000225528.1	RP3-370M22.8	-7.42	7.99e-12	6e-05	-0.61	-0.52	Longevity;	chr3:48393807	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs1563736	ENSG00000225528.1	RP3-370M22.8	-7.42	7.99e-12	6e-05	-0.61	-0.52	Longevity;	chr3:48395329	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs13071337	ENSG00000225528.1	RP3-370M22.8	-7.42	7.99e-12	6e-05	-0.61	-0.52	Longevity;	chr3:48396724	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs6442118	ENSG00000225528.1	RP3-370M22.8	-7.42	7.99e-12	6e-05	-0.61	-0.52	Longevity;	chr3:48398582	chr22:39960397~39964683:+
PCPG	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	7.42	8.02e-12	6.02e-05	0.76	0.52	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	7.42	8.02e-12	6.02e-05	0.76	0.52	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
PCPG	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	7.42	8.05e-12	6.04e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	7.42	8.05e-12	6.04e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
PCPG	trans	rs9876781	1	rs6442123	ENSG00000225528.1	RP3-370M22.8	-7.42	8.28e-12	6.2e-05	-0.59	-0.52	Longevity;	chr3:48458887	chr22:39960397~39964683:+
PCPG	trans	rs13190036	1	rs7714695	ENSG00000217325.2	PRELID1P1	-7.42	8.3e-12	6.21e-05	-0.96	-0.52	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177130444	chr6:126643488~126644390:+
PCPG	trans	rs2288327	0.643	rs16866334	ENSG00000269800.1	PLEKHA3P1	7.41	8.37e-12	6.27e-05	0.86	0.52	Atrial fibrillation;	chr2:178471945	chr19:41521043~41521989:-
PCPG	trans	rs2288327	0.643	rs1559908	ENSG00000269800.1	PLEKHA3P1	-7.41	8.37e-12	6.27e-05	-0.86	-0.52	Atrial fibrillation;	chr2:178471620	chr19:41521043~41521989:-
PCPG	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-7.41	8.52e-12	6.36e-05	-0.6	-0.52	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
PCPG	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-7.41	8.52e-12	6.36e-05	-0.6	-0.52	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
PCPG	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	7.41	8.53e-12	6.37e-05	0.83	0.52	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-7.4	8.78e-12	6.55e-05	-0.64	-0.52	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-7.4	8.78e-12	6.55e-05	-0.64	-0.52	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
PCPG	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	7.4	8.85e-12	6.59e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	7.4	8.85e-12	6.59e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
PCPG	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	7.4	8.89e-12	6.61e-05	0.66	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
PCPG	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	7.4	9.02e-12	6.71e-05	0.67	0.52	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
PCPG	trans	rs4276421	0.744	rs4541667	ENSG00000231752.4	EMBP1	7.4	9.07e-12	6.75e-05	0.69	0.52	P wave duration;	chr5:46060767	chr1:121519112~121571892:+
PCPG	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	7.4	9.17e-12	6.82e-05	0.8	0.52	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	7.4	9.17e-12	6.82e-05	0.8	0.52	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
PCPG	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	7.4	9.19e-12	6.82e-05	0.7	0.52	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
PCPG	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	7.4	9.23e-12	6.85e-05	0.69	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
PCPG	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	7.4	9.24e-12	6.86e-05	0.67	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
PCPG	trans	rs4276421	0.774	rs7720482	ENSG00000231752.4	EMBP1	-7.39	9.33e-12	6.93e-05	-0.7	-0.52	P wave duration;	chr5:46106061	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	7.39	9.43e-12	6.99e-05	0.75	0.52	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
PCPG	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	7.39	9.46e-12	7.01e-05	0.81	0.52	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	7.39	9.46e-12	7.01e-05	0.81	0.52	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	7.39	9.46e-12	7.01e-05	0.81	0.52	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
PCPG	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	7.38	1e-11	7.39e-05	0.65	0.52	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
PCPG	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	7.38	1e-11	7.39e-05	0.65	0.52	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
PCPG	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	7.38	1e-11	7.39e-05	0.65	0.52	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
PCPG	trans	rs10242455	0.571	rs45527841	ENSG00000228834.1	RP11-249L21.4	7.38	1.01e-11	7.44e-05	1.26	0.52	Blood metabolite levels;	chr7:99713342	chr6:108907615~108907873:-
PCPG	trans	rs336284	0.502	rs4723408	ENSG00000255583.2	RP11-415I12.2	7.38	1.01e-11	7.46e-05	0.58	0.52	Suicide behavior;Suicide;	chr7:35285838	chr12:63682523~63724935:-
PCPG	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-7.38	1.02e-11	7.48e-05	-0.76	-0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	7.37	1.04e-11	7.64e-05	0.7	0.52	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
PCPG	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	7.37	1.04e-11	7.67e-05	0.72	0.52	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	7.37	1.06e-11	7.75e-05	0.7	0.52	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	7.37	1.06e-11	7.75e-05	0.7	0.52	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	7.37	1.06e-11	7.75e-05	0.7	0.52	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
PCPG	trans	rs9876781	1	rs6442119	ENSG00000225528.1	RP3-370M22.8	-7.37	1.06e-11	7.8e-05	-0.6	-0.52	Longevity;	chr3:48398713	chr22:39960397~39964683:+
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-7.37	1.07e-11	7.86e-05	-0.59	-0.52	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-7.37	1.07e-11	7.86e-05	-0.59	-0.52	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
PCPG	trans	rs12200782	0.505	rs9295696	ENSG00000242375.1	RP11-498P14.3	7.36	1.1e-11	8.07e-05	0.91	0.52	Small cell lung carcinoma;	chr6:26550060	chr9:97195351~97197687:-
PCPG	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	7.36	1.12e-11	8.16e-05	0.7	0.52	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	7.36	1.12e-11	8.16e-05	0.7	0.52	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	7.36	1.12e-11	8.16e-05	0.7	0.52	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
PCPG	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-7.36	1.12e-11	8.2e-05	-0.66	-0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
PCPG	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	7.36	1.12e-11	8.21e-05	1.35	0.52	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
PCPG	trans	rs5877	0.568	rs1951627	ENSG00000213331.4	RP11-713C19.2	7.36	1.15e-11	8.41e-05	0.62	0.51	Subjective well-being (multi-trait analysis);	chr1:173922679	chr4:187970273~187971284:+
PCPG	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	7.36	1.15e-11	8.42e-05	0.69	0.51	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs7651407	ENSG00000225528.1	RP3-370M22.8	-7.35	1.16e-11	8.44e-05	-0.6	-0.51	Longevity;	chr3:48402409	chr22:39960397~39964683:+
PCPG	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	7.35	1.19e-11	8.66e-05	0.81	0.51	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
PCPG	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-7.35	1.2e-11	8.73e-05	-0.6	-0.51	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
PCPG	trans	rs9876781	1	rs9815103	ENSG00000225528.1	RP3-370M22.8	-7.34	1.26e-11	9.1e-05	-0.61	-0.51	Longevity;	chr3:48372725	chr22:39960397~39964683:+
PCPG	trans	rs10242455	0.702	rs73397447	ENSG00000228834.1	RP11-249L21.4	7.34	1.26e-11	9.1e-05	1.35	0.51	Blood metabolite levels;	chr7:99413326	chr6:108907615~108907873:-
PCPG	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-7.34	1.26e-11	9.14e-05	-0.65	-0.51	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
PCPG	trans	rs336284	0.543	rs2532184	ENSG00000255583.2	RP11-415I12.2	7.34	1.26e-11	9.15e-05	0.59	0.51	Suicide behavior;Suicide;	chr7:35272823	chr12:63682523~63724935:-
PCPG	trans	rs10242455	0.702	rs73713531	ENSG00000228834.1	RP11-249L21.4	7.34	1.27e-11	9.16e-05	1.28	0.51	Blood metabolite levels;	chr7:99624756	chr6:108907615~108907873:-
PCPG	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	7.34	1.27e-11	9.18e-05	0.69	0.51	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
PCPG	trans	rs453301	0.682	rs2929451	ENSG00000253893.2	FAM85B	-7.34	1.27e-11	9.18e-05	-0.64	-0.51	Joint mobility (Beighton score);	chr8:9227785	chr8:8167819~8226614:-
PCPG	trans	rs9876781	1	rs922075	ENSG00000225528.1	RP3-370M22.8	7.34	1.28e-11	9.27e-05	0.59	0.51	Longevity;	chr3:48447994	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs2045554	ENSG00000225528.1	RP3-370M22.8	7.34	1.28e-11	9.27e-05	0.59	0.51	Longevity;	chr3:48453142	chr22:39960397~39964683:+
PCPG	trans	rs336284	0.564	rs336285	ENSG00000255583.2	RP11-415I12.2	7.33	1.29e-11	9.35e-05	0.58	0.51	Suicide behavior;Suicide;	chr7:35258953	chr12:63682523~63724935:-
PCPG	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-7.33	1.33e-11	9.58e-05	-0.78	-0.51	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
PCPG	trans	rs3206736	0.803	rs329578	ENSG00000255583.2	RP11-415I12.2	7.33	1.34e-11	9.66e-05	0.52	0.51	Diastolic blood pressure;	chr7:35054582	chr12:63682523~63724935:-
PCPG	trans	rs1816752	0.586	rs6490903	ENSG00000237917.1	PARP4P1	7.33	1.35e-11	9.68e-05	0.6	0.51	Obesity-related traits;	chr13:24378442	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	7.33	1.35e-11	9.72e-05	0.72	0.51	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
PCPG	trans	rs116095464	0.558	rs28636067	ENSG00000185986.11	SDHAP3	7.33	1.35e-11	9.72e-05	0.77	0.51	Breast cancer;	chr5:199300	chr5:1572222~1594620:-
PCPG	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-7.33	1.36e-11	9.76e-05	-0.68	-0.51	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
PCPG	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	7.33	1.36e-11	9.8e-05	0.62	0.51	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
PCPG	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-7.32	1.38e-11	9.94e-05	-0.59	-0.51	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
PCPG	trans	rs13190036	1	rs351864	ENSG00000217325.2	PRELID1P1	-7.32	1.39e-11	9.95e-05	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177112285	chr6:126643488~126644390:+
PCPG	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-7.32	1.41e-11	0.000101	-0.68	-0.51	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-7.32	1.41e-11	0.000101	-0.68	-0.51	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-7.32	1.43e-11	0.000102	-0.68	-0.51	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	7.32	1.44e-11	0.000103	0.67	0.51	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
PCPG	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-7.31	1.45e-11	0.000104	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-7.31	1.46e-11	0.000104	-0.58	-0.51	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
PCPG	trans	rs13190036	0.901	rs55741473	ENSG00000217325.2	PRELID1P1	-7.31	1.46e-11	0.000104	-0.94	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147218	chr6:126643488~126644390:+
PCPG	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	7.31	1.46e-11	0.000104	0.81	0.51	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	7.31	1.48e-11	0.000105	0.62	0.51	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
PCPG	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	7.31	1.48e-11	0.000106	0.67	0.51	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.926	rs4723399	ENSG00000255583.2	RP11-415I12.2	-7.31	1.5e-11	0.000107	-0.55	-0.51	Birth weight;	chr7:35233504	chr12:63682523~63724935:-
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-7.3	1.52e-11	0.000109	-0.63	-0.51	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
PCPG	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-7.3	1.53e-11	0.000109	-0.67	-0.51	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-7.3	1.53e-11	0.000109	-0.67	-0.51	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.736	rs8188290	ENSG00000231752.4	EMBP1	7.3	1.54e-11	0.000109	0.68	0.51	P wave duration;	chr5:46047215	chr1:121519112~121571892:+
PCPG	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	7.3	1.57e-11	0.000111	0.6	0.51	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
PCPG	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-7.3	1.61e-11	0.000113	-0.64	-0.51	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-7.29	1.64e-11	0.000115	-0.64	-0.51	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-7.29	1.64e-11	0.000115	-0.64	-0.51	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.565	rs7720870	ENSG00000231752.4	EMBP1	7.29	1.66e-11	0.000117	0.68	0.51	P wave duration;	chr5:46139574	chr1:121519112~121571892:+
PCPG	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	7.29	1.69e-11	0.000119	0.69	0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
PCPG	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	7.28	1.7e-11	0.000119	0.6	0.51	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
PCPG	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-7.28	1.71e-11	0.00012	-0.48	-0.51	Longevity;	chr3:48445949	chr1:27649419~27649610:+
PCPG	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-7.28	1.71e-11	0.00012	-0.64	-0.51	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	7.28	1.71e-11	0.00012	0.64	0.51	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	7.28	1.71e-11	0.00012	0.64	0.51	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	7.28	1.71e-11	0.00012	0.64	0.51	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	7.28	1.71e-11	0.00012	0.64	0.51	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	7.28	1.71e-11	0.00012	0.64	0.51	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
PCPG	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-7.28	1.71e-11	0.00012	-0.68	-0.51	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
PCPG	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	7.28	1.71e-11	0.00012	0.7	0.51	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
PCPG	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-7.28	1.74e-11	0.000121	-0.64	-0.51	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-7.28	1.74e-11	0.000121	-0.64	-0.51	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-7.28	1.74e-11	0.000121	-0.64	-0.51	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
PCPG	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-7.28	1.74e-11	0.000122	-0.61	-0.51	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
PCPG	trans	rs9876781	0.967	rs2885509	ENSG00000225528.1	RP3-370M22.8	7.28	1.77e-11	0.000124	0.62	0.51	Longevity;	chr3:48376729	chr22:39960397~39964683:+
PCPG	trans	rs10242455	0.557	rs34943973	ENSG00000228834.1	RP11-249L21.4	7.28	1.78e-11	0.000124	1.33	0.51	Blood metabolite levels;	chr7:99434894	chr6:108907615~108907873:-
PCPG	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-7.28	1.79e-11	0.000125	-0.59	-0.51	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
PCPG	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-7.28	1.79e-11	0.000125	-0.73	-0.51	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
PCPG	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	7.27	1.83e-11	0.000128	0.69	0.51	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs10940359	ENSG00000231752.4	EMBP1	-7.27	1.84e-11	0.000128	-0.63	-0.51	Schizophrenia;	chr5:50538645	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs7704686	ENSG00000231752.4	EMBP1	-7.27	1.89e-11	0.000132	-0.64	-0.51	Schizophrenia;	chr5:50548995	chr1:121519112~121571892:+
PCPG	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	7.26	1.92e-11	0.000133	0.6	0.51	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	7.26	1.92e-11	0.000133	0.6	0.51	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	7.26	1.93e-11	0.000134	0.6	0.51	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	7.26	1.93e-11	0.000134	0.6	0.51	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
PCPG	trans	rs10940346	1	rs12520874	ENSG00000231752.4	EMBP1	-7.26	1.95e-11	0.000136	-0.64	-0.51	Schizophrenia;	chr5:50523857	chr1:121519112~121571892:+
PCPG	trans	rs959695	0.834	rs6468693	ENSG00000260318.1	COX6CP1	-7.26	1.96e-11	0.000136	-0.63	-0.51	Hippocampal atrophy;	chr8:99839040	chr16:11903923~11904137:-
PCPG	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	7.26	1.99e-11	0.000138	0.82	0.51	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	7.26	1.99e-11	0.000138	0.82	0.51	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
PCPG	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-7.25	2e-11	0.000138	-0.59	-0.51	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
PCPG	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	7.25	2.03e-11	0.00014	0.69	0.51	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
PCPG	trans	rs12200782	0.505	rs1535275	ENSG00000242375.1	RP11-498P14.3	7.25	2.08e-11	0.000143	0.9	0.51	Small cell lung carcinoma;	chr6:26520539	chr9:97195351~97197687:-
PCPG	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	7.25	2.09e-11	0.000144	0.66	0.51	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	7.25	2.09e-11	0.000144	0.66	0.51	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	7.25	2.09e-11	0.000144	0.66	0.51	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
PCPG	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	7.25	2.11e-11	0.000145	0.7	0.51	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
PCPG	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	7.24	2.12e-11	0.000146	0.47	0.51	Longevity;	chr3:48377081	chr1:27649419~27649610:+
PCPG	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	7.24	2.14e-11	0.000147	0.6	0.51	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	7.24	2.15e-11	0.000148	0.68	0.51	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	7.24	2.18e-11	0.000149	0.66	0.51	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-7.24	2.18e-11	0.000149	-0.66	-0.51	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
PCPG	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	7.24	2.19e-11	0.00015	0.6	0.51	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	7.24	2.19e-11	0.00015	0.6	0.51	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	7.24	2.2e-11	0.000151	0.68	0.51	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs28824259	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48384185	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs12487542	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48384586	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs9864371	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48385276	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs73074358	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48385757	chr22:39960397~39964683:+
PCPG	trans	rs9876781	0.967	rs34761139	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48386489	chr22:39960397~39964683:+
PCPG	trans	rs9876781	0.868	rs9875280	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48387420	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs6796491	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48388977	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs6804774	ENSG00000225528.1	RP3-370M22.8	-7.24	2.21e-11	0.000151	-0.6	-0.51	Longevity;	chr3:48389129	chr22:39960397~39964683:+
PCPG	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	7.24	2.23e-11	0.000152	0.66	0.51	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	7.24	2.23e-11	0.000152	0.66	0.51	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	7.24	2.23e-11	0.000152	0.66	0.51	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	7.24	2.23e-11	0.000152	0.66	0.51	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	7.24	2.23e-11	0.000152	0.66	0.51	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-7.23	2.25e-11	0.000153	-0.67	-0.51	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-7.23	2.25e-11	0.000153	-0.67	-0.51	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-7.23	2.25e-11	0.000153	-0.67	-0.51	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-7.23	2.26e-11	0.000154	-0.66	-0.51	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-7.23	2.27e-11	0.000155	-0.66	-0.51	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-7.23	2.27e-11	0.000155	-0.66	-0.51	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-7.23	2.27e-11	0.000155	-0.66	-0.51	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
PCPG	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	7.23	2.28e-11	0.000155	0.72	0.51	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	7.23	2.28e-11	0.000155	0.72	0.51	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
PCPG	trans	rs9467773	0.935	rs11752946	ENSG00000242375.1	RP11-498P14.3	7.23	2.3e-11	0.000156	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26560136	chr9:97195351~97197687:-
PCPG	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	7.23	2.32e-11	0.000158	0.66	0.51	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
PCPG	trans	rs336284	0.502	rs741202	ENSG00000255583.2	RP11-415I12.2	7.23	2.32e-11	0.000158	0.58	0.51	Suicide behavior;Suicide;	chr7:35280303	chr12:63682523~63724935:-
PCPG	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	7.23	2.32e-11	0.000158	0.68	0.51	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
PCPG	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	7.23	2.33e-11	0.000158	0.68	0.51	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
PCPG	trans	rs916888	0.61	rs142167	ENSG00000263503.1	RP11-707O23.5	-7.22	2.39e-11	0.000162	-0.76	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45600869~45602340:-
PCPG	trans	rs9876781	1	rs898225	ENSG00000225528.1	RP3-370M22.8	7.22	2.39e-11	0.000162	0.61	0.51	Longevity;	chr3:48371689	chr22:39960397~39964683:+
PCPG	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	7.22	2.39e-11	0.000162	0.68	0.51	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	7.22	2.39e-11	0.000162	0.68	0.51	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
PCPG	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-7.22	2.41e-11	0.000163	-0.67	-0.51	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
PCPG	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	7.22	2.46e-11	0.000166	0.82	0.51	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-7.22	2.48e-11	0.000168	-0.61	-0.51	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
PCPG	trans	rs7121616	1	rs75228513	ENSG00000234176.1	HSPA8P1	7.21	2.5e-11	0.000169	0.57	0.51	Breast cancer;	chr11:123096160	chrX:121203182~121205014:-
PCPG	trans	rs7121616	1	rs79401687	ENSG00000234176.1	HSPA8P1	7.21	2.5e-11	0.000169	0.57	0.51	Breast cancer;	chr11:123096264	chrX:121203182~121205014:-
PCPG	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	7.21	2.54e-11	0.000172	0.64	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
PCPG	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	7.21	2.58e-11	0.000174	0.6	0.51	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	7.21	2.58e-11	0.000174	0.6	0.51	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-7.21	2.59e-11	0.000175	-0.67	-0.51	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	7.21	2.61e-11	0.000175	0.68	0.51	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	7.2	2.66e-11	0.000177	0.67	0.51	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
PCPG	trans	rs7824557	0.569	rs10106207	ENSG00000253893.2	FAM85B	7.2	2.66e-11	0.000177	0.67	0.51	Retinal vascular caliber;	chr8:11157828	chr8:8167819~8226614:-
PCPG	trans	rs9876781	1	rs725309	ENSG00000225528.1	RP3-370M22.8	7.2	2.67e-11	0.000177	0.6	0.51	Longevity;	chr3:48377218	chr22:39960397~39964683:+
PCPG	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	7.2	2.67e-11	0.000177	0.68	0.51	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	7.2	2.67e-11	0.000177	0.68	0.51	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
PCPG	trans	rs6959887	0.925	rs7797315	ENSG00000255583.2	RP11-415I12.2	7.2	2.68e-11	0.000178	0.56	0.51	Birth weight;	chr7:35256265	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	7.2	2.68e-11	0.000178	0.67	0.51	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
PCPG	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	7.2	2.68e-11	0.000178	0.58	0.51	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
PCPG	trans	rs7824557	0.569	rs2409718	ENSG00000253893.2	FAM85B	7.2	2.7e-11	0.000179	0.67	0.51	Retinal vascular caliber;	chr8:11155467	chr8:8167819~8226614:-
PCPG	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-7.2	2.71e-11	0.00018	-0.73	-0.51	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-7.2	2.71e-11	0.00018	-0.73	-0.51	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
PCPG	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	7.19	2.82e-11	0.000186	0.61	0.51	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	7.19	2.82e-11	0.000186	0.61	0.51	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
PCPG	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	7.19	2.85e-11	0.000188	0.63	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
PCPG	trans	rs9876781	1	rs6794875	ENSG00000225528.1	RP3-370M22.8	-7.19	2.86e-11	0.000189	-0.58	-0.51	Longevity;	chr3:48414217	chr22:39960397~39964683:+
PCPG	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-7.19	2.89e-11	0.000191	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
PCPG	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-7.19	2.89e-11	0.000191	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
PCPG	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-7.19	2.89e-11	0.000191	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
PCPG	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-7.19	2.89e-11	0.000191	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
PCPG	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-7.19	2.89e-11	0.000191	-0.91	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
PCPG	trans	rs3779195	0.697	rs13232861	ENSG00000225169.1	BRI3P1	7.19	2.92e-11	0.000193	0.81	0.51	Sex hormone-binding globulin levels;	chr7:98299769	chr1:100213293~100213670:+
PCPG	trans	rs9876781	1	rs1459242	ENSG00000225528.1	RP3-370M22.8	7.18	2.96e-11	0.000195	0.61	0.51	Longevity;	chr3:48372047	chr22:39960397~39964683:+
PCPG	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	7.18	3.01e-11	0.000198	0.8	0.51	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
PCPG	trans	rs10242455	0.702	rs73711294	ENSG00000228834.1	RP11-249L21.4	7.18	3.01e-11	0.000198	1.31	0.51	Blood metabolite levels;	chr7:99491091	chr6:108907615~108907873:-
PCPG	trans	rs9876781	1	rs9311423	ENSG00000225528.1	RP3-370M22.8	-7.18	3.09e-11	0.000203	-0.6	-0.51	Longevity;	chr3:48378818	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs7634377	ENSG00000225528.1	RP3-370M22.8	-7.18	3.09e-11	0.000203	-0.6	-0.51	Longevity;	chr3:48379768	chr22:39960397~39964683:+
PCPG	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	7.18	3.1e-11	0.000203	0.76	0.51	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	7.18	3.1e-11	0.000203	0.76	0.51	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
PCPG	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	7.17	3.13e-11	0.000205	0.67	0.51	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	7.17	3.13e-11	0.000205	0.67	0.51	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-7.16	3.34e-11	0.000219	-0.63	-0.5	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	7.16	3.35e-11	0.000219	0.67	0.5	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.845	rs4492122	ENSG00000231752.4	EMBP1	7.16	3.37e-11	0.00022	0.66	0.5	P wave duration;	chr5:45982952	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	7.16	3.39e-11	0.000222	0.68	0.5	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	7.16	3.41e-11	0.000222	0.61	0.5	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
PCPG	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	7.16	3.41e-11	0.000223	0.61	0.5	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
PCPG	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	7.16	3.43e-11	0.000224	0.66	0.5	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	7.15	3.5e-11	0.000229	0.69	0.5	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
PCPG	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-7.15	3.52e-11	0.00023	-0.57	-0.5	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
PCPG	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	7.15	3.53e-11	0.00023	0.84	0.5	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
PCPG	trans	rs7121616	0.96	rs12361252	ENSG00000234176.1	HSPA8P1	7.15	3.61e-11	0.000235	0.57	0.5	Breast cancer;	chr11:123091564	chrX:121203182~121205014:-
PCPG	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-7.14	3.67e-11	0.000238	-0.66	-0.5	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-7.14	3.67e-11	0.000238	-0.66	-0.5	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-7.14	3.74e-11	0.000243	-0.66	-0.5	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.845	rs4371763	ENSG00000231752.4	EMBP1	7.14	3.78e-11	0.000245	0.66	0.5	P wave duration;	chr5:45983120	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-7.14	3.8e-11	0.000246	-0.66	-0.5	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs7293424	ENSG00000231752.4	EMBP1	7.14	3.81e-11	0.000247	0.65	0.5	P wave duration;	chr5:46184874	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs2885510	ENSG00000225528.1	RP3-370M22.8	7.14	3.84e-11	0.000248	0.61	0.5	Longevity;	chr3:48376736	chr22:39960397~39964683:+
PCPG	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-7.13	3.87e-11	0.000251	-0.66	-0.5	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-7.13	3.87e-11	0.000251	-0.66	-0.5	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-7.13	3.87e-11	0.000251	-0.66	-0.5	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	7.13	3.89e-11	0.000251	0.66	0.5	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-7.13	3.89e-11	0.000251	-0.66	-0.5	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs6784322	ENSG00000225528.1	RP3-370M22.8	-7.13	3.95e-11	0.000255	-0.6	-0.5	Longevity;	chr3:48380745	chr22:39960397~39964683:+
PCPG	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-7.13	3.98e-11	0.000257	-0.66	-0.5	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-7.13	4.01e-11	0.000258	-0.61	-0.5	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-7.13	4.01e-11	0.000258	-0.61	-0.5	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
PCPG	trans	rs7258465	1	rs8103622	ENSG00000267533.1	RP11-815J4.7	7.13	4.05e-11	0.000261	0.61	0.5	Breast cancer;	chr19:18462024	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	7.12	4.09e-11	0.000263	0.66	0.5	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	7.12	4.09e-11	0.000263	0.66	0.5	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	7.12	4.09e-11	0.000263	0.66	0.5	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	7.12	4.09e-11	0.000263	0.66	0.5	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	7.12	4.09e-11	0.000263	0.66	0.5	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	7.12	4.09e-11	0.000263	0.66	0.5	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	7.12	4.17e-11	0.000268	0.68	0.5	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	7.12	4.17e-11	0.000268	0.68	0.5	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	7.12	4.17e-11	0.000268	0.68	0.5	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	7.12	4.17e-11	0.000268	0.68	0.5	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	7.12	4.19e-11	0.000269	0.66	0.5	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	7.12	4.19e-11	0.000269	0.66	0.5	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
PCPG	trans	rs62344088	0.744	rs39788	ENSG00000185986.11	SDHAP3	-7.12	4.19e-11	0.000269	-0.88	-0.5	Asthma (childhood onset);	chr5:187187	chr5:1572222~1594620:-
PCPG	trans	rs4276421	0.845	rs10434580	ENSG00000231752.4	EMBP1	7.12	4.2e-11	0.00027	0.66	0.5	P wave duration;	chr5:46010910	chr1:121519112~121571892:+
PCPG	trans	rs116095464	1	rs7723693	ENSG00000185986.11	SDHAP3	7.11	4.32e-11	0.000277	0.77	0.5	Breast cancer;	chr5:305917	chr5:1572222~1594620:-
PCPG	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	7.11	4.49e-11	0.000288	0.66	0.5	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	7.11	4.49e-11	0.000288	0.66	0.5	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	7.11	4.49e-11	0.000288	0.66	0.5	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	7.11	4.49e-11	0.000288	0.66	0.5	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	7.11	4.49e-11	0.000288	0.66	0.5	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	7.11	4.49e-11	0.000288	0.66	0.5	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	7.11	4.49e-11	0.000288	0.66	0.5	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
PCPG	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-7.1	4.56e-11	0.000292	-0.63	-0.5	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
PCPG	trans	rs7258465	0.897	rs1043327	ENSG00000267533.1	RP11-815J4.7	7.1	4.56e-11	0.000292	0.62	0.5	Breast cancer;	chr19:18444162	chr18:12067173~12068417:-
PCPG	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	7.1	4.75e-11	0.000303	0.62	0.5	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	7.1	4.76e-11	0.000304	0.66	0.5	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-7.09	4.85e-11	0.000309	-0.63	-0.5	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	7.09	4.86e-11	0.00031	0.66	0.5	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
PCPG	trans	rs7258465	0.931	rs11673604	ENSG00000267533.1	RP11-815J4.7	7.09	4.89e-11	0.000312	0.61	0.5	Breast cancer;	chr19:18430178	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.656	rs13180509	ENSG00000231752.4	EMBP1	7.09	4.91e-11	0.000313	0.66	0.5	P wave duration;	chr5:46239147	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs8188149	ENSG00000231752.4	EMBP1	7.09	4.91e-11	0.000313	0.66	0.5	P wave duration;	chr5:46242641	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs13436334	ENSG00000231752.4	EMBP1	7.09	4.91e-11	0.000313	0.66	0.5	P wave duration;	chr5:46243759	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs4975961	ENSG00000231752.4	EMBP1	7.09	4.91e-11	0.000313	0.66	0.5	P wave duration;	chr5:46247615	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs7630741	ENSG00000225528.1	RP3-370M22.8	-7.09	4.91e-11	0.000313	-0.59	-0.5	Longevity;	chr3:48378233	chr22:39960397~39964683:+
PCPG	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	7.09	4.92e-11	0.000313	0.66	0.5	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
PCPG	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-7.09	4.92e-11	0.000313	-0.63	-0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
PCPG	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-7.09	4.93e-11	0.000314	-0.57	-0.5	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
PCPG	trans	rs4276421	0.656	rs10473416	ENSG00000231752.4	EMBP1	7.09	4.94e-11	0.000314	0.66	0.5	P wave duration;	chr5:46246868	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs8185100	ENSG00000231752.4	EMBP1	7.09	4.97e-11	0.000316	0.66	0.5	P wave duration;	chr5:46250619	chr1:121519112~121571892:+
PCPG	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	7.09	4.98e-11	0.000316	0.61	0.5	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.594	rs7293434	ENSG00000231752.4	EMBP1	7.08	5.1e-11	0.000323	0.66	0.5	P wave duration;	chr5:46257587	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-7.08	5.13e-11	0.000325	-0.78	-0.5	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
PCPG	trans	rs6732160	0.809	rs4299358	ENSG00000236165.1	PRADC1P1	7.08	5.16e-11	0.000326	0.68	0.5	Intelligence (multi-trait analysis);	chr2:73132213	chr3:36976316~36976840:+
PCPG	trans	rs9467773	0.935	rs1056668	ENSG00000242375.1	RP11-498P14.3	7.08	5.16e-11	0.000327	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26510377	chr9:97195351~97197687:-
PCPG	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	7.08	5.21e-11	0.00033	0.67	0.5	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
PCPG	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	7.08	5.26e-11	0.000333	0.61	0.5	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	7.08	5.26e-11	0.000333	0.61	0.5	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	7.08	5.26e-11	0.000333	0.61	0.5	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	7.08	5.26e-11	0.000333	0.61	0.5	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
PCPG	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	7.08	5.28e-11	0.000334	0.67	0.5	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
PCPG	trans	rs6959887	0.926	rs11976145	ENSG00000255583.2	RP11-415I12.2	7.08	5.32e-11	0.000336	0.54	0.5	Birth weight;	chr7:35242072	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10486660	ENSG00000255583.2	RP11-415I12.2	7.08	5.32e-11	0.000336	0.54	0.5	Birth weight;	chr7:35243319	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	7.07	5.34e-11	0.000337	0.66	0.5	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	7.07	5.34e-11	0.000337	0.66	0.5	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	7.07	5.34e-11	0.000337	0.66	0.5	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
PCPG	trans	rs1816752	0.669	rs4770699	ENSG00000237917.1	PARP4P1	-7.07	5.35e-11	0.000337	-0.59	-0.5	Obesity-related traits;	chr13:24488234	chrY:26594851~26634652:-
PCPG	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	7.07	5.35e-11	0.000338	0.64	0.5	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
PCPG	trans	rs9467773	0.935	rs1884947	ENSG00000242375.1	RP11-498P14.3	7.07	5.37e-11	0.000339	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26553045	chr9:97195351~97197687:-
PCPG	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-7.07	5.4e-11	0.000341	-0.63	-0.5	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.926	rs77553582	ENSG00000255583.2	RP11-415I12.2	7.07	5.45e-11	0.000343	0.55	0.5	Birth weight;	chr7:35260046	chr12:63682523~63724935:-
PCPG	trans	rs7258465	1	rs34746918	ENSG00000267533.1	RP11-815J4.7	7.07	5.46e-11	0.000344	0.6	0.5	Breast cancer;	chr19:18428934	chr18:12067173~12068417:-
PCPG	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	7.07	5.49e-11	0.000346	0.63	0.5	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	7.07	5.52e-11	0.000346	0.66	0.5	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
PCPG	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	7.06	5.64e-11	0.000353	0.61	0.5	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	7.06	5.64e-11	0.000353	0.61	0.5	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
PCPG	trans	rs9876781	1	rs2242150	ENSG00000225528.1	RP3-370M22.8	7.06	5.7e-11	0.000357	0.58	0.5	Longevity;	chr3:48464565	chr22:39960397~39964683:+
PCPG	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	7.06	5.71e-11	0.000357	0.61	0.5	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
PCPG	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	7.06	5.77e-11	0.00036	0.67	0.5	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	7.06	5.77e-11	0.00036	0.67	0.5	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	7.06	5.77e-11	0.00036	0.67	0.5	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	7.06	5.77e-11	0.00036	0.67	0.5	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	7.06	5.77e-11	0.00036	0.67	0.5	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	7.06	5.77e-11	0.00036	0.67	0.5	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
PCPG	trans	rs7258465	1	rs3810429	ENSG00000267533.1	RP11-815J4.7	7.06	5.79e-11	0.000361	0.61	0.5	Breast cancer;	chr19:18432460	chr18:12067173~12068417:-
PCPG	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	7.06	5.84e-11	0.000364	0.46	0.5	Longevity;	chr3:48407742	chr1:27649419~27649610:+
PCPG	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	7.06	5.86e-11	0.000365	0.65	0.5	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.926	rs6462599	ENSG00000255583.2	RP11-415I12.2	7.06	5.88e-11	0.000366	0.55	0.5	Birth weight;	chr7:35252809	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs6959887	ENSG00000255583.2	RP11-415I12.2	7.06	5.88e-11	0.000366	0.55	0.5	Birth weight;	chr7:35255754	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs6946632	ENSG00000255583.2	RP11-415I12.2	7.06	5.88e-11	0.000366	0.55	0.5	Birth weight;	chr7:35256209	chr12:63682523~63724935:-
PCPG	trans	rs62344088	0.59	rs62345236	ENSG00000185986.11	SDHAP3	7.06	5.9e-11	0.000367	0.88	0.5	Asthma (childhood onset);	chr5:283404	chr5:1572222~1594620:-
PCPG	trans	rs116095464	1	rs55671190	ENSG00000185986.11	SDHAP3	7.06	5.9e-11	0.000367	0.88	0.5	Breast cancer;	chr5:287307	chr5:1572222~1594620:-
PCPG	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	7.06	5.91e-11	0.000368	0.66	0.5	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	7.05	6.07e-11	0.000377	0.67	0.5	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
PCPG	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-7.05	6.08e-11	0.000378	-0.62	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
PCPG	trans	rs7258465	0.965	rs10408290	ENSG00000267533.1	RP11-815J4.7	7.05	6.14e-11	0.000382	0.61	0.5	Breast cancer;	chr19:18431891	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs10409003	ENSG00000267533.1	RP11-815J4.7	7.05	6.14e-11	0.000382	0.61	0.5	Breast cancer;	chr19:18432244	chr18:12067173~12068417:-
PCPG	trans	rs6959887	0.962	rs1362207	ENSG00000255583.2	RP11-415I12.2	7.05	6.24e-11	0.000387	0.54	0.5	Birth weight;	chr7:35242823	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs7795344	ENSG00000255583.2	RP11-415I12.2	7.05	6.24e-11	0.000387	0.54	0.5	Birth weight;	chr7:35243841	chr12:63682523~63724935:-
PCPG	trans	rs9876781	1	rs6442117	ENSG00000225528.1	RP3-370M22.8	7.04	6.28e-11	0.000389	0.6	0.5	Longevity;	chr3:48378407	chr22:39960397~39964683:+
PCPG	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	7.04	6.3e-11	0.00039	0.66	0.5	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	7.04	6.3e-11	0.00039	0.66	0.5	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
PCPG	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-7.04	6.35e-11	0.000392	-0.89	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
PCPG	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-7.04	6.35e-11	0.000392	-0.89	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
PCPG	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-7.04	6.35e-11	0.000392	-0.89	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
PCPG	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-7.04	6.35e-11	0.000392	-0.89	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
PCPG	trans	rs6959887	0.926	rs73099202	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35256695	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10280159	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35257027	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10264435	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35257052	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10264933	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35257408	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs2024346	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35257504	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs2024345	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35257629	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs2024344	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35257954	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs2024343	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35258009	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs12538541	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35258321	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs7790713	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35260230	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs7790968	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35260285	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.89	rs7790990	ENSG00000255583.2	RP11-415I12.2	7.04	6.37e-11	0.000394	0.54	0.5	Birth weight;	chr7:35260313	chr12:63682523~63724935:-
PCPG	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	7.04	6.39e-11	0.000395	0.78	0.5	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-7.04	6.39e-11	0.000395	-0.78	-0.5	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
PCPG	trans	rs941207	0.526	rs2242497	ENSG00000121089.4	NACA3P	-7.04	6.42e-11	0.000396	-0.61	-0.5	Platelet count;	chr12:56598846	chr4:164943290~164943937:+
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	7.04	6.42e-11	0.000396	0.63	0.5	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
PCPG	trans	rs6959887	0.962	rs17674947	ENSG00000255583.2	RP11-415I12.2	-7.04	6.48e-11	0.000399	-0.54	-0.5	Birth weight;	chr7:35242031	chr12:63682523~63724935:-
PCPG	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-7.04	6.48e-11	0.000399	-1.2	-0.5	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
PCPG	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	7.04	6.52e-11	0.000401	0.61	0.5	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	7.04	6.52e-11	0.000401	0.61	0.5	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	7.04	6.52e-11	0.000401	0.61	0.5	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	7.04	6.52e-11	0.000401	0.61	0.5	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	7.04	6.52e-11	0.000401	0.61	0.5	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.904	rs7293482	ENSG00000231752.4	EMBP1	7.04	6.58e-11	0.000405	0.65	0.5	P wave duration;	chr5:46003984	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	7.04	6.61e-11	0.000407	0.65	0.5	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-7.03	6.64e-11	0.000408	-0.62	-0.5	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-7.03	6.64e-11	0.000408	-0.62	-0.5	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
PCPG	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	7.03	6.73e-11	0.000413	0.76	0.5	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
PCPG	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	7.03	6.77e-11	0.000415	0.62	0.5	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	7.03	6.77e-11	0.000415	0.62	0.5	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	7.03	6.77e-11	0.000415	0.62	0.5	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-7.03	6.77e-11	0.000416	-0.46	-0.5	Longevity;	chr3:48446507	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-7.03	6.77e-11	0.000416	-0.46	-0.5	Longevity;	chr3:48452692	chr1:27649419~27649610:+
PCPG	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	7.03	6.8e-11	0.000417	0.61	0.5	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	7.03	6.8e-11	0.000417	0.61	0.5	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
PCPG	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	7.03	6.8e-11	0.000417	0.61	0.5	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	7.03	6.8e-11	0.000417	0.61	0.5	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	7.03	6.8e-11	0.000417	0.61	0.5	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
PCPG	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	7.03	6.86e-11	0.00042	0.62	0.5	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-7.03	6.86e-11	0.00042	-0.62	-0.5	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	7.03	6.86e-11	0.00042	0.66	0.5	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	7.03	6.86e-11	0.00042	0.66	0.5	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	7.03	6.86e-11	0.00042	0.66	0.5	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
PCPG	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	7.03	6.87e-11	0.00042	0.63	0.5	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	7.03	6.93e-11	0.000422	0.63	0.5	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
PCPG	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	7.03	6.94e-11	0.000422	0.67	0.5	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
PCPG	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	7.02	7.06e-11	0.000429	0.67	0.5	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
PCPG	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	7.02	7.27e-11	0.000441	0.6	0.5	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
PCPG	trans	rs12200782	0.53	rs6929908	ENSG00000242375.1	RP11-498P14.3	7.01	7.48e-11	0.000453	0.87	0.5	Small cell lung carcinoma;	chr6:26555061	chr9:97195351~97197687:-
PCPG	trans	rs7258465	0.931	rs76195	ENSG00000267533.1	RP11-815J4.7	7.01	7.49e-11	0.000454	0.57	0.5	Breast cancer;	chr19:18519020	chr18:12067173~12068417:-
PCPG	trans	rs6959887	0.821	rs4723403	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35238854	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.821	rs4723404	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35238939	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs1833127	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35240184	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs2072434	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35241081	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs2240994	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35241335	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs17606602	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35241963	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs73099148	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35242007	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs715112	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35242731	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs17606656	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35243437	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10280486	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35243666	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10224889	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35243917	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs17606698	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35244144	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10255047	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35244298	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs1346021	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35244549	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs6972725	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35245792	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs6976630	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35245950	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs6976783	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35246030	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs6977095	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35246142	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs6959445	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35246209	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs10263165	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35246245	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs4723405	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35246365	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs4720170	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35247872	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs4723407	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35248061	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs17675142	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35248521	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs17606844	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35248601	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs17675148	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35248664	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs714956	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35250589	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs714958	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35250613	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs73099185	ENSG00000255583.2	RP11-415I12.2	7.01	7.58e-11	0.000458	0.54	0.5	Birth weight;	chr7:35251702	chr12:63682523~63724935:-
PCPG	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	7.01	7.6e-11	0.000458	0.65	0.5	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.967	rs35648163	ENSG00000231752.4	EMBP1	7.01	7.6e-11	0.000458	0.65	0.5	P wave duration;	chr5:45945778	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.904	rs6451843	ENSG00000231752.4	EMBP1	7.01	7.6e-11	0.000458	0.65	0.5	P wave duration;	chr5:45946683	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	7.01	7.6e-11	0.000458	0.65	0.5	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
PCPG	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	7.01	7.6e-11	0.000458	0.6	0.5	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	7.01	7.6e-11	0.000458	0.6	0.5	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
PCPG	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	7.01	7.61e-11	0.000458	0.6	0.5	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
PCPG	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	7.01	7.62e-11	0.000458	0.67	0.5	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
PCPG	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-7.01	7.62e-11	0.000458	-0.62	-0.5	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-7.01	7.75e-11	0.000466	-0.67	-0.5	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
PCPG	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-7	7.78e-11	0.000468	-0.72	-0.5	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-7	7.78e-11	0.000468	-0.72	-0.5	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
PCPG	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	7	7.79e-11	0.000468	0.65	0.5	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.839	rs7719401	ENSG00000231752.4	EMBP1	7	7.79e-11	0.000468	0.65	0.5	P wave duration;	chr5:45938713	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-7	7.85e-11	0.000471	-0.46	-0.5	Longevity;	chr3:48422209	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-7	7.85e-11	0.000471	-0.46	-0.5	Longevity;	chr3:48423094	chr1:27649419~27649610:+
PCPG	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-7	7.85e-11	0.000471	-0.46	-0.5	Longevity;	chr3:48426493	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-7	7.85e-11	0.000471	-0.46	-0.5	Longevity;	chr3:48432839	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-7	7.85e-11	0.000471	-0.46	-0.5	Longevity;	chr3:48440237	chr1:27649419~27649610:+
PCPG	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	7	7.9e-11	0.000474	0.66	0.5	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
PCPG	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	7	7.95e-11	0.000477	0.65	0.5	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
PCPG	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	7	7.95e-11	0.000477	0.65	0.5	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
PCPG	trans	rs9876781	1	rs7653691	ENSG00000225528.1	RP3-370M22.8	7	7.96e-11	0.000477	0.59	0.5	Longevity;	chr3:48378199	chr22:39960397~39964683:+
PCPG	trans	rs6959887	0.962	rs73099187	ENSG00000255583.2	RP11-415I12.2	7	7.97e-11	0.000478	0.54	0.5	Birth weight;	chr7:35251880	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs28628585	ENSG00000255583.2	RP11-415I12.2	7	7.97e-11	0.000478	0.54	0.5	Birth weight;	chr7:35252029	chr12:63682523~63724935:-
PCPG	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	7	7.98e-11	0.000479	0.61	0.5	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
PCPG	trans	rs10940346	1	rs7380858	ENSG00000231752.4	EMBP1	-7	7.99e-11	0.000479	-0.62	-0.5	Schizophrenia;	chr5:50537022	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.962	rs10254475	ENSG00000255583.2	RP11-415I12.2	7	7.99e-11	0.000479	0.53	0.5	Birth weight;	chr7:35243972	chr12:63682523~63724935:-
PCPG	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-6.99	8.23e-11	0.000492	-0.61	-0.5	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-6.99	8.23e-11	0.000492	-0.61	-0.5	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-6.99	8.23e-11	0.000492	-0.61	-0.5	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	6.99	8.23e-11	0.000492	0.61	0.5	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	6.99	8.23e-11	0.000492	0.61	0.5	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	6.99	8.23e-11	0.000492	0.61	0.5	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	6.99	8.23e-11	0.000492	0.61	0.5	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	6.99	8.23e-11	0.000492	0.61	0.5	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs7708897	ENSG00000231752.4	EMBP1	-6.99	8.34e-11	0.000498	-0.62	-0.5	Schizophrenia;	chr5:50528209	chr1:121519112~121571892:+
PCPG	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-6.99	8.35e-11	0.000498	-0.46	-0.5	Longevity;	chr3:48440024	chr1:27649419~27649610:+
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-6.99	8.35e-11	0.000498	-0.58	-0.5	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
PCPG	trans	rs6959887	1	rs10249005	ENSG00000255583.2	RP11-415I12.2	6.99	8.45e-11	0.000504	0.54	0.5	Birth weight;	chr7:35255243	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs6959920	ENSG00000255583.2	RP11-415I12.2	6.99	8.45e-11	0.000504	0.54	0.5	Birth weight;	chr7:35255483	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs6959846	ENSG00000255583.2	RP11-415I12.2	6.99	8.45e-11	0.000504	0.54	0.5	Birth weight;	chr7:35255623	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs6963934	ENSG00000255583.2	RP11-415I12.2	6.99	8.45e-11	0.000504	0.54	0.5	Birth weight;	chr7:35255892	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs28561590	ENSG00000255583.2	RP11-415I12.2	6.99	8.45e-11	0.000504	0.54	0.5	Birth weight;	chr7:35256169	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs7797172	ENSG00000255583.2	RP11-415I12.2	6.99	8.45e-11	0.000504	0.54	0.5	Birth weight;	chr7:35256220	chr12:63682523~63724935:-
PCPG	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-6.99	8.49e-11	0.000505	-0.62	-0.5	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-6.99	8.49e-11	0.000505	-0.62	-0.5	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-6.99	8.49e-11	0.000505	-0.62	-0.5	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-6.99	8.49e-11	0.000505	-0.62	-0.5	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-6.99	8.49e-11	0.000505	-0.62	-0.5	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-6.99	8.49e-11	0.000505	-0.62	-0.5	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-6.99	8.49e-11	0.000505	-0.62	-0.5	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
PCPG	trans	rs7647973	0.961	rs7638750	ENSG00000197582.5	GPX1P1	-6.99	8.52e-11	0.000507	-0.72	-0.5	Menarche (age at onset);	chr3:49415524	chrX:13378735~13379340:-
PCPG	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-6.99	8.53e-11	0.000508	-0.62	-0.5	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-6.99	8.64e-11	0.000512	-0.62	-0.5	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-6.99	8.64e-11	0.000512	-0.62	-0.5	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	6.98	8.66e-11	0.000514	0.67	0.5	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
PCPG	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-6.98	8.73e-11	0.000518	-0.59	-0.5	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
PCPG	trans	rs7258465	0.965	rs2385088	ENSG00000267533.1	RP11-815J4.7	6.98	8.92e-11	0.000528	0.61	0.5	Breast cancer;	chr19:18434730	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs10442	ENSG00000267533.1	RP11-815J4.7	6.98	8.92e-11	0.000528	0.61	0.5	Breast cancer;	chr19:18434531	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.845	rs34040576	ENSG00000231752.4	EMBP1	6.98	8.93e-11	0.000529	0.65	0.5	P wave duration;	chr5:46005596	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.904	rs13360955	ENSG00000231752.4	EMBP1	6.98	8.93e-11	0.000529	0.65	0.5	P wave duration;	chr5:46005842	chr1:121519112~121571892:+
PCPG	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	6.98	8.97e-11	0.000531	0.65	0.5	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	6.98	8.97e-11	0.000531	0.65	0.5	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	6.98	8.97e-11	0.000531	0.65	0.5	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	6.98	8.97e-11	0.000531	0.65	0.5	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	6.98	8.97e-11	0.000531	0.65	0.5	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
PCPG	trans	rs6446601	1	rs6446601	ENSG00000262902.1	RP11-750B16.1	6.98	9.07e-11	0.000536	1.07	0.49	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr4:4298683	chr17:53105734~53106358:+
PCPG	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-6.98	9.07e-11	0.000536	-0.62	-0.49	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-6.98	9.07e-11	0.000536	-0.62	-0.49	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-6.98	9.07e-11	0.000536	-0.62	-0.49	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-6.98	9.07e-11	0.000536	-0.62	-0.49	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.962	rs1120204	ENSG00000255583.2	RP11-415I12.2	6.97	9.16e-11	0.00054	0.54	0.49	Birth weight;	chr7:35260765	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	6.97	9.3e-11	0.000548	0.65	0.49	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	6.97	9.3e-11	0.000548	0.65	0.49	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	6.97	9.3e-11	0.000548	0.65	0.49	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
PCPG	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-6.97	9.37e-11	0.000552	-0.46	-0.49	Longevity;	chr3:48437797	chr1:27649419~27649610:+
PCPG	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-6.97	9.4e-11	0.000553	-0.71	-0.49	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
PCPG	trans	rs116095464	1	rs6863730	ENSG00000185986.11	SDHAP3	6.97	9.54e-11	0.000562	0.78	0.49	Breast cancer;	chr5:324888	chr5:1572222~1594620:-
PCPG	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	6.96	9.72e-11	0.000572	0.67	0.49	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
PCPG	trans	rs4646450	0.636	rs2003499	ENSG00000228834.1	RP11-249L21.4	6.96	9.76e-11	0.000574	0.77	0.49	Blood metabolite levels;	chr7:99417361	chr6:108907615~108907873:-
PCPG	trans	rs7258465	1	rs28572537	ENSG00000267533.1	RP11-815J4.7	6.96	9.85e-11	0.000579	0.61	0.49	Breast cancer;	chr19:18441398	chr18:12067173~12068417:-
PCPG	trans	rs9467773	0.935	rs4573	ENSG00000242375.1	RP11-498P14.3	6.96	9.9e-11	0.000582	0.65	0.49	Intelligence (multi-trait analysis);	chr6:26546580	chr9:97195351~97197687:-
PCPG	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	6.95	1.02e-10	6e-04	0.64	0.49	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-6.95	1.03e-10	0.000601	-0.46	-0.49	Longevity;	chr3:48408490	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-6.95	1.03e-10	0.000601	-0.46	-0.49	Longevity;	chr3:48408549	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-6.95	1.03e-10	0.000601	-0.46	-0.49	Longevity;	chr3:48413059	chr1:27649419~27649610:+
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-6.95	1.03e-10	0.000602	-0.57	-0.49	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
PCPG	trans	rs3779195	0.627	rs6950023	ENSG00000225169.1	BRI3P1	6.95	1.03e-10	0.000604	0.79	0.49	Sex hormone-binding globulin levels;	chr7:98286323	chr1:100213293~100213670:+
PCPG	trans	rs3779195	0.627	rs6967728	ENSG00000225169.1	BRI3P1	6.95	1.03e-10	0.000604	0.79	0.49	Sex hormone-binding globulin levels;	chr7:98286325	chr1:100213293~100213670:+
PCPG	trans	rs740160	0.558	rs73395508	ENSG00000228834.1	RP11-249L21.4	6.95	1.04e-10	0.000606	0.96	0.49	Dehydroepiandrosterone sulphate levels;	chr7:99304271	chr6:108907615~108907873:-
PCPG	trans	rs740160	0.558	rs68164591	ENSG00000228834.1	RP11-249L21.4	6.95	1.04e-10	0.000606	0.96	0.49	Dehydroepiandrosterone sulphate levels;	chr7:99306817	chr6:108907615~108907873:-
PCPG	trans	rs740160	0.558	rs17161669	ENSG00000228834.1	RP11-249L21.4	6.95	1.04e-10	0.000606	0.96	0.49	Dehydroepiandrosterone sulphate levels;	chr7:99311040	chr6:108907615~108907873:-
PCPG	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	6.95	1.05e-10	0.000614	0.78	0.49	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	6.95	1.05e-10	0.000614	0.78	0.49	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
PCPG	trans	rs61990749	1	rs6574411	ENSG00000235400.1	RP4-641G12.4	-6.95	1.06e-10	0.000617	-0.93	-0.49	Fibroblast growth factor basic levels;	chr14:77907984	chr1:78749073~78750659:+
PCPG	trans	rs7258465	1	rs2303697	ENSG00000267533.1	RP11-815J4.7	6.95	1.07e-10	0.000622	0.61	0.49	Breast cancer;	chr19:18435868	chr18:12067173~12068417:-
PCPG	trans	rs7258465	1	rs4595905	ENSG00000267533.1	RP11-815J4.7	6.95	1.07e-10	0.000622	0.61	0.49	Breast cancer;	chr19:18436495	chr18:12067173~12068417:-
PCPG	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	6.95	1.07e-10	0.000622	0.6	0.49	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	6.95	1.07e-10	0.000622	0.6	0.49	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	6.95	1.07e-10	0.000622	0.6	0.49	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	6.95	1.07e-10	0.000622	0.6	0.49	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
PCPG	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	6.94	1.09e-10	0.000632	0.59	0.49	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
PCPG	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	6.94	1.1e-10	0.000639	0.65	0.49	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	6.94	1.1e-10	0.000641	0.64	0.49	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	6.94	1.1e-10	0.000641	0.64	0.49	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	6.94	1.1e-10	0.000641	0.64	0.49	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	6.94	1.1e-10	0.000641	0.64	0.49	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	6.94	1.1e-10	0.000641	0.64	0.49	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	6.94	1.1e-10	0.000641	0.64	0.49	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
PCPG	trans	rs12200782	0.505	rs7765920	ENSG00000242375.1	RP11-498P14.3	6.94	1.11e-10	0.000643	0.87	0.49	Small cell lung carcinoma;	chr6:26514543	chr9:97195351~97197687:-
PCPG	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	6.94	1.12e-10	0.000653	0.67	0.49	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-6.94	1.13e-10	0.000655	-0.58	-0.49	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-6.94	1.13e-10	0.000655	-0.58	-0.49	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
PCPG	trans	rs7140958	1	rs7140958	ENSG00000262902.1	RP11-750B16.1	6.93	1.14e-10	0.000661	0.96	0.49	Bilirubin levels;	chr14:45560484	chr17:53105734~53106358:+
PCPG	trans	rs7258465	1	rs10427083	ENSG00000267533.1	RP11-815J4.7	6.93	1.15e-10	0.000665	0.6	0.49	Breast cancer;	chr19:18439466	chr18:12067173~12068417:-
PCPG	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-6.93	1.15e-10	0.000665	-0.74	-0.49	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	6.93	1.16e-10	0.000674	0.66	0.49	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	6.93	1.16e-10	0.000674	0.66	0.49	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
PCPG	trans	rs3206736	0.549	rs10257774	ENSG00000255583.2	RP11-415I12.2	6.93	1.18e-10	0.000684	0.54	0.49	Diastolic blood pressure;	chr7:35189996	chr12:63682523~63724935:-
PCPG	trans	rs950169	0.922	rs8037078	ENSG00000259295.5	CSPG4P12	-6.92	1.2e-10	0.000696	-0.73	-0.49	Schizophrenia;	chr15:84150119	chr15:85191438~85213905:+
PCPG	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	6.92	1.21e-10	0.000699	0.66	0.49	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	6.92	1.21e-10	0.000699	0.66	0.49	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
PCPG	trans	rs336284	0.502	rs6977549	ENSG00000255583.2	RP11-415I12.2	6.92	1.23e-10	0.000713	0.54	0.49	Suicide behavior;Suicide;	chr7:35294972	chr12:63682523~63724935:-
PCPG	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	6.92	1.25e-10	0.00072	0.62	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
PCPG	trans	rs13190036	1	rs59737888	ENSG00000217325.2	PRELID1P1	-6.92	1.25e-10	0.000723	-0.9	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177160374	chr6:126643488~126644390:+
PCPG	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	6.91	1.27e-10	0.000727	0.66	0.49	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	6.91	1.27e-10	0.000727	0.66	0.49	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	6.91	1.27e-10	0.000727	0.66	0.49	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	6.91	1.27e-10	0.000727	0.66	0.49	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	6.91	1.27e-10	0.000727	0.66	0.49	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	6.91	1.27e-10	0.000727	0.66	0.49	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	6.91	1.27e-10	0.000727	0.66	0.49	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
PCPG	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	6.91	1.27e-10	0.000729	0.6	0.49	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
PCPG	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	6.91	1.31e-10	0.000753	0.56	0.49	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
PCPG	trans	rs6959887	0.788	rs57639115	ENSG00000255583.2	RP11-415I12.2	6.91	1.32e-10	0.00076	0.54	0.49	Birth weight;	chr7:35236309	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	6.9	1.33e-10	0.000766	0.67	0.49	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	6.9	1.38e-10	0.000788	0.65	0.49	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	6.9	1.38e-10	0.000792	0.61	0.49	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	6.9	1.39e-10	0.000795	0.64	0.49	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
PCPG	trans	rs9467773	0.838	rs3734540	ENSG00000242375.1	RP11-498P14.3	6.9	1.39e-10	0.000798	0.63	0.49	Intelligence (multi-trait analysis);	chr6:26463093	chr9:97195351~97197687:-
PCPG	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	6.9	1.4e-10	8e-04	0.65	0.49	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
PCPG	trans	rs950169	0.922	rs4842940	ENSG00000259295.5	CSPG4P12	-6.89	1.41e-10	0.000805	-0.72	-0.49	Schizophrenia;	chr15:84162473	chr15:85191438~85213905:+
PCPG	trans	rs950169	0.922	rs4842941	ENSG00000259295.5	CSPG4P12	-6.89	1.41e-10	0.000805	-0.72	-0.49	Schizophrenia;	chr15:84162560	chr15:85191438~85213905:+
PCPG	trans	rs950169	0.922	rs12911223	ENSG00000259295.5	CSPG4P12	-6.89	1.41e-10	0.000805	-0.72	-0.49	Schizophrenia;	chr15:84162919	chr15:85191438~85213905:+
PCPG	trans	rs950169	0.845	rs4106951	ENSG00000259295.5	CSPG4P12	6.89	1.41e-10	0.000805	0.72	0.49	Schizophrenia;	chr15:84164642	chr15:85191438~85213905:+
PCPG	trans	rs9876781	1	rs6770470	ENSG00000225528.1	RP3-370M22.8	-6.89	1.42e-10	0.000812	-0.56	-0.49	Longevity;	chr3:48393659	chr22:39960397~39964683:+
PCPG	trans	rs9467773	0.869	rs9295689	ENSG00000242375.1	RP11-498P14.3	6.89	1.42e-10	0.000813	0.63	0.49	Intelligence (multi-trait analysis);	chr6:26455583	chr9:97195351~97197687:-
PCPG	trans	rs7258465	0.896	rs8103660	ENSG00000267533.1	RP11-815J4.7	6.89	1.43e-10	0.000816	0.6	0.49	Breast cancer;	chr19:18455585	chr18:12067173~12068417:-
PCPG	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	6.89	1.44e-10	0.000822	0.64	0.49	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	6.89	1.44e-10	0.000822	0.64	0.49	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	6.89	1.44e-10	0.000822	0.64	0.49	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
PCPG	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-6.89	1.46e-10	0.00083	-0.71	-0.49	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
PCPG	trans	rs10242455	0.571	rs41258334	ENSG00000228834.1	RP11-249L21.4	6.89	1.48e-10	0.00084	1.34	0.49	Blood metabolite levels;	chr7:99674185	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.571	rs28365067	ENSG00000228834.1	RP11-249L21.4	6.89	1.48e-10	0.00084	1.34	0.49	Blood metabolite levels;	chr7:99674687	chr6:108907615~108907873:-
PCPG	trans	rs2657294	0.646	rs10762656	ENSG00000172974.11	AC007318.5	6.88	1.49e-10	0.000849	0.52	0.49	Pneumonia;	chr10:75085706	chr2:65205108~65205988:+
PCPG	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	6.88	1.49e-10	0.00085	0.6	0.49	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-6.88	1.51e-10	0.00086	-0.57	-0.49	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-6.88	1.51e-10	0.00086	-0.57	-0.49	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
PCPG	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-6.88	1.54e-10	0.000872	-0.62	-0.49	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
PCPG	trans	rs6959887	0.962	rs2270223	ENSG00000255583.2	RP11-415I12.2	6.87	1.57e-10	0.000888	0.53	0.49	Birth weight;	chr7:35241599	chr12:63682523~63724935:-
PCPG	trans	rs62344088	0.59	rs7700533	ENSG00000185986.11	SDHAP3	6.87	1.57e-10	0.000888	0.94	0.49	Asthma (childhood onset);	chr5:180531	chr5:1572222~1594620:-
PCPG	trans	rs6959887	0.855	rs78661208	ENSG00000255583.2	RP11-415I12.2	6.87	1.57e-10	0.000888	0.54	0.49	Birth weight;	chr7:35259405	chr12:63682523~63724935:-
PCPG	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-6.87	1.57e-10	0.000889	-0.59	-0.49	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
PCPG	trans	rs6959887	0.926	rs4723402	ENSG00000255583.2	RP11-415I12.2	6.87	1.57e-10	0.000892	0.53	0.49	Birth weight;	chr7:35238812	chr12:63682523~63724935:-
PCPG	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-6.87	1.57e-10	0.000893	-0.46	-0.49	Longevity;	chr3:48457056	chr1:27649419~27649610:+
PCPG	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-6.87	1.59e-10	0.000898	-0.71	-0.49	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
PCPG	trans	rs9467773	0.869	rs1796520	ENSG00000242375.1	RP11-498P14.3	-6.87	1.59e-10	0.000901	-0.64	-0.49	Intelligence (multi-trait analysis);	chr6:26410572	chr9:97195351~97197687:-
PCPG	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	6.87	1.63e-10	0.000919	0.64	0.49	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.845	rs4426926	ENSG00000231752.4	EMBP1	6.86	1.67e-10	0.000945	0.65	0.49	P wave duration;	chr5:45994241	chr1:121519112~121571892:+
PCPG	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	6.86	1.69e-10	0.000955	0.77	0.49	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	6.86	1.69e-10	0.000955	0.77	0.49	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	6.86	1.69e-10	0.000955	0.77	0.49	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	6.86	1.69e-10	0.000955	0.77	0.49	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	6.86	1.69e-10	0.000955	0.77	0.49	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	6.86	1.69e-10	0.000955	0.77	0.49	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
PCPG	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	6.86	1.71e-10	0.000965	0.58	0.49	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
PCPG	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	6.86	1.71e-10	0.000966	0.79	0.49	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
PCPG	trans	rs950169	0.922	rs6603022	ENSG00000259295.5	CSPG4P12	-6.85	1.75e-10	0.000983	-0.72	-0.49	Schizophrenia;	chr15:84161418	chr15:85191438~85213905:+
PCPG	trans	rs950169	0.922	rs11639244	ENSG00000259295.5	CSPG4P12	6.85	1.75e-10	0.000983	0.72	0.49	Schizophrenia;	chr15:84163898	chr15:85191438~85213905:+
PCPG	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	6.85	1.78e-10	0.000999	0.64	0.49	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	6.85	1.78e-10	0.000999	0.64	0.49	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
PCPG	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	6.85	1.82e-10	0.00102	0.59	0.49	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
PCPG	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-6.85	1.82e-10	0.00102	-0.46	-0.49	Longevity;	chr3:48455358	chr1:27649419~27649610:+
PCPG	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	6.84	1.84e-10	0.00103	0.68	0.49	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	6.84	1.85e-10	0.00104	0.64	0.49	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
PCPG	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	6.84	1.87e-10	0.00105	0.59	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
PCPG	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	6.84	1.87e-10	0.00105	0.64	0.49	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
PCPG	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	6.84	1.87e-10	0.00105	0.64	0.49	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
PCPG	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	6.84	1.9e-10	0.00106	0.67	0.49	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
PCPG	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	6.84	1.93e-10	0.00108	0.66	0.49	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
PCPG	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	6.83	1.93e-10	0.00108	0.82	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
PCPG	trans	rs3779195	0.52	rs17169479	ENSG00000225169.1	BRI3P1	6.83	1.93e-10	0.00108	0.74	0.49	Sex hormone-binding globulin levels;	chr7:98238721	chr1:100213293~100213670:+
PCPG	trans	rs950169	0.922	rs4586394	ENSG00000259295.5	CSPG4P12	-6.83	1.94e-10	0.00108	-0.72	-0.49	Schizophrenia;	chr15:84153633	chr15:85191438~85213905:+
PCPG	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	6.83	1.98e-10	0.00111	0.79	0.49	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
PCPG	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-6.83	1.99e-10	0.00111	-0.58	-0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
PCPG	trans	rs61990749	1	rs17106604	ENSG00000235400.1	RP4-641G12.4	6.83	2.01e-10	0.00112	0.96	0.49	Fibroblast growth factor basic levels;	chr14:77912813	chr1:78749073~78750659:+
PCPG	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-6.83	2.02e-10	0.00113	-0.57	-0.49	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
PCPG	trans	rs10242455	0.717	rs58649180	ENSG00000228834.1	RP11-249L21.4	6.82	2.06e-10	0.00114	1.14	0.49	Blood metabolite levels;	chr7:99738422	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.717	rs72494455	ENSG00000228834.1	RP11-249L21.4	6.82	2.06e-10	0.00114	1.14	0.49	Blood metabolite levels;	chr7:99739154	chr6:108907615~108907873:-
PCPG	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	6.82	2.09e-10	0.00116	0.69	0.49	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
PCPG	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	6.82	2.13e-10	0.00118	0.76	0.49	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
PCPG	trans	rs4276421	0.869	rs6892627	ENSG00000231752.4	EMBP1	6.82	2.14e-10	0.00119	0.67	0.49	P wave duration;	chr5:45722892	chr1:121519112~121571892:+
PCPG	trans	rs916888	0.821	rs199499	ENSG00000214425.5	LRRC37A4P	-6.81	2.17e-10	0.0012	-0.67	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:45506741~45550335:-
PCPG	trans	rs9467773	0.649	rs2145318	ENSG00000242375.1	RP11-498P14.3	6.81	2.18e-10	0.0012	0.62	0.49	Intelligence (multi-trait analysis);	chr6:26496375	chr9:97195351~97197687:-
PCPG	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	6.81	2.22e-10	0.00123	0.61	0.49	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.967	rs4866979	ENSG00000231752.4	EMBP1	-6.81	2.24e-10	0.00124	-0.62	-0.49	P wave duration;	chr5:45804745	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	6.81	2.24e-10	0.00124	0.64	0.49	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
PCPG	trans	rs9467773	0.901	rs1407045	ENSG00000242375.1	RP11-498P14.3	6.81	2.25e-10	0.00124	0.62	0.49	Intelligence (multi-trait analysis);	chr6:26475927	chr9:97195351~97197687:-
PCPG	trans	rs13190036	1	rs625882	ENSG00000217325.2	PRELID1P1	-6.81	2.25e-10	0.00124	-0.84	-0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177108030	chr6:126643488~126644390:+
PCPG	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	6.81	2.25e-10	0.00125	0.59	0.49	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
PCPG	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	6.81	2.26e-10	0.00125	0.65	0.49	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	6.81	2.26e-10	0.00125	0.65	0.49	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
PCPG	trans	rs7258465	1	rs4808804	ENSG00000267533.1	RP11-815J4.7	6.8	2.26e-10	0.00125	0.57	0.49	Breast cancer;	chr19:18474515	chr18:12067173~12068417:-
PCPG	trans	rs740160	0.558	rs12538893	ENSG00000228834.1	RP11-249L21.4	6.8	2.26e-10	0.00125	0.91	0.49	Dehydroepiandrosterone sulphate levels;	chr7:99310874	chr6:108907615~108907873:-
PCPG	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-6.8	2.3e-10	0.00127	-0.62	-0.49	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
PCPG	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-6.8	2.3e-10	0.00127	-0.62	-0.49	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-6.8	2.3e-10	0.00127	-0.62	-0.49	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
PCPG	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-6.8	2.3e-10	0.00127	-0.62	-0.49	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
PCPG	trans	rs7647973	1	rs62259944	ENSG00000197582.5	GPX1P1	-6.8	2.33e-10	0.00128	-0.7	-0.49	Menarche (age at onset);	chr3:49393450	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	6.8	2.34e-10	0.00129	0.67	0.49	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
PCPG	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-6.79	2.39e-10	0.00131	-0.61	-0.49	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
PCPG	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	6.79	2.4e-10	0.00132	0.61	0.49	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
PCPG	trans	rs116095464	0.681	rs1574220	ENSG00000185986.11	SDHAP3	6.79	2.44e-10	0.00134	0.72	0.48	Breast cancer;	chr5:314403	chr5:1572222~1594620:-
PCPG	trans	rs4276421	0.806	rs6451804	ENSG00000231752.4	EMBP1	6.78	2.53e-10	0.00139	0.64	0.48	P wave duration;	chr5:45492103	chr1:121519112~121571892:+
PCPG	trans	rs7647973	0.925	rs6808036	ENSG00000197582.5	GPX1P1	6.78	2.55e-10	0.00139	0.69	0.48	Menarche (age at onset);	chr3:49199006	chrX:13378735~13379340:-
PCPG	trans	rs13190036	0.901	rs28684504	ENSG00000228305.2	AC016734.2	6.78	2.55e-10	0.00139	0.79	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr2:63622178~63622831:-
PCPG	trans	rs10242455	1	rs73395557	ENSG00000228834.1	RP11-249L21.4	6.78	2.64e-10	0.00144	1	0.48	Blood metabolite levels;	chr7:99336801	chr6:108907615~108907873:-
PCPG	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	6.77	2.67e-10	0.00145	0.64	0.48	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	6.77	2.67e-10	0.00145	0.64	0.48	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	6.77	2.67e-10	0.00145	0.64	0.48	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	6.77	2.67e-10	0.00145	0.64	0.48	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	6.77	2.67e-10	0.00145	0.64	0.48	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
PCPG	trans	rs4276421	0.806	rs7732970	ENSG00000231752.4	EMBP1	6.77	2.67e-10	0.00145	0.64	0.48	P wave duration;	chr5:45452044	chr1:121519112~121571892:+
PCPG	trans	rs10242455	1	rs6948775	ENSG00000228834.1	RP11-249L21.4	6.77	2.68e-10	0.00145	0.99	0.48	Blood metabolite levels;	chr7:99347857	chr6:108907615~108907873:-
PCPG	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	6.77	2.69e-10	0.00146	0.58	0.48	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
PCPG	trans	rs3206736	0.549	rs57221424	ENSG00000255583.2	RP11-415I12.2	6.77	2.7e-10	0.00146	0.54	0.48	Diastolic blood pressure;	chr7:35176058	chr12:63682523~63724935:-
PCPG	trans	rs7647973	0.925	rs6446257	ENSG00000197582.5	GPX1P1	-6.77	2.7e-10	0.00146	-0.67	-0.48	Menarche (age at onset);	chr3:49216059	chrX:13378735~13379340:-
PCPG	trans	rs6959887	0.962	rs988270	ENSG00000255583.2	RP11-415I12.2	-6.77	2.71e-10	0.00147	-0.53	-0.48	Birth weight;	chr7:35260950	chr12:63682523~63724935:-
PCPG	trans	rs4276421	0.806	rs2337412	ENSG00000231752.4	EMBP1	6.77	2.72e-10	0.00147	0.64	0.48	P wave duration;	chr5:45483410	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.776	rs7717787	ENSG00000231752.4	EMBP1	6.77	2.74e-10	0.00149	0.64	0.48	P wave duration;	chr5:45466514	chr1:121519112~121571892:+
PCPG	trans	rs10242455	1	rs2301889	ENSG00000228834.1	RP11-249L21.4	6.77	2.78e-10	0.0015	0.98	0.48	Blood metabolite levels;	chr7:99333482	chr6:108907615~108907873:-
PCPG	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	6.77	2.78e-10	0.00151	0.56	0.48	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
PCPG	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-6.76	2.82e-10	0.00153	-0.6	-0.48	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
PCPG	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-6.76	2.83e-10	0.00153	-0.56	-0.48	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
PCPG	trans	rs4276421	0.901	rs35381866	ENSG00000231752.4	EMBP1	6.76	2.87e-10	0.00155	0.65	0.48	P wave duration;	chr5:45690085	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.837	rs10078625	ENSG00000231752.4	EMBP1	6.76	2.87e-10	0.00155	0.65	0.48	P wave duration;	chr5:45707015	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs7705696	ENSG00000231752.4	EMBP1	6.76	2.87e-10	0.00155	0.65	0.48	P wave duration;	chr5:45712387	chr1:121519112~121571892:+
PCPG	trans	rs3779195	0.929	rs2906184	ENSG00000225169.1	BRI3P1	-6.76	2.89e-10	0.00156	-0.77	-0.48	Sex hormone-binding globulin levels;	chr7:98310675	chr1:100213293~100213670:+
PCPG	trans	rs116095464	1	rs3936676	ENSG00000185986.11	SDHAP3	6.76	2.89e-10	0.00156	0.89	0.48	Breast cancer;	chr5:353562	chr5:1572222~1594620:-
PCPG	trans	rs4276421	0.87	rs7706116	ENSG00000231752.4	EMBP1	6.75	3e-10	0.00161	0.65	0.48	P wave duration;	chr5:45742522	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.87	rs4257782	ENSG00000231752.4	EMBP1	6.75	3e-10	0.00161	0.65	0.48	P wave duration;	chr5:45750292	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.901	rs9687260	ENSG00000231752.4	EMBP1	6.75	3e-10	0.00161	0.65	0.48	P wave duration;	chr5:45759774	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.839	rs28885449	ENSG00000231752.4	EMBP1	6.75	3.02e-10	0.00162	0.63	0.48	P wave duration;	chr5:45994103	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs6810060	ENSG00000225528.1	RP3-370M22.8	-6.75	3.08e-10	0.00165	-0.55	-0.48	Longevity;	chr3:48393284	chr22:39960397~39964683:+
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-6.74	3.11e-10	0.00167	-0.56	-0.48	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
PCPG	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-6.74	3.13e-10	0.00168	-0.6	-0.48	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
PCPG	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	6.74	3.14e-10	0.00168	0.64	0.48	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
PCPG	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	6.74	3.15e-10	0.00169	0.75	0.48	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
PCPG	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-6.74	3.16e-10	0.00169	-0.6	-0.48	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-6.74	3.16e-10	0.00169	-0.6	-0.48	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-6.74	3.16e-10	0.00169	-0.6	-0.48	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.962	rs2270222	ENSG00000255583.2	RP11-415I12.2	-6.74	3.16e-10	0.00169	-0.52	-0.48	Birth weight;	chr7:35241543	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.521	rs6948899	ENSG00000255583.2	RP11-415I12.2	6.74	3.17e-10	0.00169	0.53	0.48	Diastolic blood pressure;	chr7:35193190	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.576	rs28844277	ENSG00000255583.2	RP11-415I12.2	6.74	3.17e-10	0.00169	0.53	0.48	Diastolic blood pressure;	chr7:35193977	chr12:63682523~63724935:-
PCPG	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-6.74	3.18e-10	0.0017	-0.6	-0.48	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	6.74	3.18e-10	0.0017	0.6	0.48	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	6.74	3.18e-10	0.0017	0.6	0.48	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
PCPG	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-6.74	3.18e-10	0.0017	-0.55	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
PCPG	trans	rs10242455	0.571	rs79694709	ENSG00000228834.1	RP11-249L21.4	6.74	3.23e-10	0.00172	1.22	0.48	Blood metabolite levels;	chr7:99617088	chr6:108907615~108907873:-
PCPG	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	6.74	3.24e-10	0.00173	0.66	0.48	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	6.74	3.24e-10	0.00173	0.66	0.48	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.904	rs10070596	ENSG00000231752.4	EMBP1	6.73	3.34e-10	0.00177	0.64	0.48	P wave duration;	chr5:46004129	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.926	rs2109090	ENSG00000255583.2	RP11-415I12.2	6.73	3.34e-10	0.00177	0.53	0.48	Birth weight;	chr7:35231376	chr12:63682523~63724935:-
PCPG	trans	rs7647973	0.925	rs9834003	ENSG00000197582.5	GPX1P1	6.73	3.36e-10	0.00178	0.7	0.48	Menarche (age at onset);	chr3:49179039	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.925	rs4955421	ENSG00000197582.5	GPX1P1	6.73	3.36e-10	0.00178	0.7	0.48	Menarche (age at onset);	chr3:49181455	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.925	rs4955423	ENSG00000197582.5	GPX1P1	6.73	3.36e-10	0.00178	0.7	0.48	Menarche (age at onset);	chr3:49183015	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.925	rs11130183	ENSG00000197582.5	GPX1P1	6.73	3.36e-10	0.00178	0.7	0.48	Menarche (age at onset);	chr3:49191513	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	6.73	3.4e-10	0.0018	0.7	0.48	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	6.73	3.4e-10	0.0018	0.7	0.48	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	6.73	3.4e-10	0.0018	0.7	0.48	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-6.73	3.4e-10	0.0018	-0.7	-0.48	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-6.73	3.4e-10	0.0018	-0.7	-0.48	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-6.73	3.4e-10	0.0018	-0.7	-0.48	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-6.73	3.4e-10	0.0018	-0.7	-0.48	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-6.73	3.4e-10	0.0018	-0.7	-0.48	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-6.73	3.4e-10	0.0018	-0.7	-0.48	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-6.73	3.4e-10	0.0018	-0.7	-0.48	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
PCPG	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-6.73	3.42e-10	0.00181	-0.6	-0.48	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
PCPG	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	6.73	3.42e-10	0.00181	0.63	0.48	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
PCPG	trans	rs5022636	0.79	rs10399679	ENSG00000180764.13	PIPSL	6.73	3.42e-10	0.00181	0.57	0.48	Gut microbiota (functional units);	chr1:151278361	chr10:93958191~93961540:-
PCPG	trans	rs2657294	0.674	rs10824268	ENSG00000172974.11	AC007318.5	6.73	3.43e-10	0.00181	0.5	0.48	Pneumonia;	chr10:75085937	chr2:65205108~65205988:+
PCPG	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	6.72	3.47e-10	0.00183	0.67	0.48	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	6.72	3.47e-10	0.00183	0.67	0.48	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
PCPG	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-6.72	3.52e-10	0.00186	-0.61	-0.48	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
PCPG	trans	rs3206736	0.548	rs328891	ENSG00000255583.2	RP11-415I12.2	6.72	3.52e-10	0.00186	0.55	0.48	Diastolic blood pressure;	chr7:34973905	chr12:63682523~63724935:-
PCPG	trans	rs9650657	0.53	rs6982381	ENSG00000253893.2	FAM85B	6.72	3.52e-10	0.00186	0.65	0.48	Neuroticism;	chr8:11094990	chr8:8167819~8226614:-
PCPG	trans	rs7647973	0.925	rs6446256	ENSG00000197582.5	GPX1P1	6.72	3.52e-10	0.00186	0.7	0.48	Menarche (age at onset);	chr3:49186777	chrX:13378735~13379340:-
PCPG	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-6.72	3.56e-10	0.00188	-0.67	-0.48	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
PCPG	trans	rs9616064	0.704	rs41346347	ENSG00000269091.4	CTD-2126E3.3	-6.72	3.58e-10	0.00189	-0.59	-0.48	Urate levels in obese individuals;	chr22:46562610	chr19:50043196~50051062:-
PCPG	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	6.72	3.58e-10	0.00189	0.63	0.48	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
PCPG	trans	rs13190036	0.579	rs13159114	ENSG00000217325.2	PRELID1P1	6.72	3.6e-10	0.0019	0.92	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177234807	chr6:126643488~126644390:+
PCPG	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-6.72	3.61e-10	0.0019	-0.58	-0.48	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	6.72	3.61e-10	0.0019	0.56	0.48	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
PCPG	trans	rs7258465	1	rs271624	ENSG00000267533.1	RP11-815J4.7	6.72	3.64e-10	0.00192	0.55	0.48	Breast cancer;	chr19:18517143	chr18:12067173~12068417:-
PCPG	trans	rs336284	0.582	rs336288	ENSG00000255583.2	RP11-415I12.2	6.71	3.66e-10	0.00193	0.56	0.48	Suicide behavior;Suicide;	chr7:35263751	chr12:63682523~63724935:-
PCPG	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	6.71	3.67e-10	0.00193	0.56	0.48	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	6.71	3.67e-10	0.00193	0.63	0.48	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
PCPG	trans	rs7824557	0.524	rs7835318	ENSG00000253893.2	FAM85B	6.71	3.69e-10	0.00194	0.66	0.48	Retinal vascular caliber;	chr8:11096364	chr8:8167819~8226614:-
PCPG	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	6.71	3.69e-10	0.00194	0.65	0.48	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
PCPG	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	6.71	3.71e-10	0.00195	0.62	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
PCPG	trans	rs10242455	1	rs73395547	ENSG00000228834.1	RP11-249L21.4	6.71	3.74e-10	0.00196	0.99	0.48	Blood metabolite levels;	chr7:99325123	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.571	rs80045298	ENSG00000228834.1	RP11-249L21.4	6.71	3.75e-10	0.00197	1.21	0.48	Blood metabolite levels;	chr7:99709830	chr6:108907615~108907873:-
PCPG	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	6.71	3.76e-10	0.00197	0.57	0.48	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
PCPG	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	6.71	3.77e-10	0.00198	0.63	0.48	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-6.71	3.81e-10	0.002	-0.57	-0.48	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
PCPG	trans	rs5022636	1	rs5022636	ENSG00000180764.13	PIPSL	6.71	3.82e-10	0.002	0.55	0.48	Gut microbiota (functional units);	chr1:151322585	chr10:93958191~93961540:-
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-6.71	3.82e-10	0.002	-0.57	-0.48	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
PCPG	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	6.7	3.88e-10	0.00203	0.55	0.48	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.571	rs41279866	ENSG00000228834.1	RP11-249L21.4	6.7	3.9e-10	0.00204	1.21	0.48	Blood metabolite levels;	chr7:99717653	chr6:108907615~108907873:-
PCPG	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	6.7	3.95e-10	0.00207	0.67	0.48	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.837	rs7706140	ENSG00000231752.4	EMBP1	6.7	3.96e-10	0.00207	0.63	0.48	P wave duration;	chr5:45474712	chr1:121519112~121571892:+
PCPG	trans	rs9425766	0.639	rs10798295	ENSG00000213331.4	RP11-713C19.2	6.7	3.98e-10	0.00208	0.57	0.48	Life satisfaction;	chr1:173714815	chr4:187970273~187971284:+
PCPG	trans	rs4276421	0.81	rs13190242	ENSG00000231752.4	EMBP1	6.7	4.03e-10	0.00211	0.62	0.48	P wave duration;	chr5:46054443	chr1:121519112~121571892:+
PCPG	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	6.7	4.04e-10	0.00211	0.56	0.48	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
PCPG	trans	rs4276421	0.736	rs7445572	ENSG00000231752.4	EMBP1	6.7	4.04e-10	0.00211	0.62	0.48	P wave duration;	chr5:45920315	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.776	rs10473392	ENSG00000231752.4	EMBP1	6.69	4.08e-10	0.00213	0.64	0.48	P wave duration;	chr5:45709959	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs7736561	ENSG00000231752.4	EMBP1	6.69	4.08e-10	0.00213	0.64	0.48	P wave duration;	chr5:45716294	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs2337951	ENSG00000231752.4	EMBP1	6.69	4.08e-10	0.00213	0.64	0.48	P wave duration;	chr5:45717834	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs2337952	ENSG00000231752.4	EMBP1	6.69	4.08e-10	0.00213	0.64	0.48	P wave duration;	chr5:45722022	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs7718785	ENSG00000231752.4	EMBP1	6.69	4.08e-10	0.00213	0.64	0.48	P wave duration;	chr5:45725495	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	6.69	4.09e-10	0.00213	0.61	0.48	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.901	rs12110137	ENSG00000231752.4	EMBP1	6.69	4.1e-10	0.00214	0.64	0.48	P wave duration;	chr5:45727764	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs56387400	ENSG00000231752.4	EMBP1	-6.69	4.11e-10	0.00214	-0.6	-0.48	Schizophrenia;	chr5:50517577	chr1:121519112~121571892:+
PCPG	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	6.69	4.16e-10	0.00217	0.69	0.48	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
PCPG	trans	rs10940346	1	rs1423645	ENSG00000231752.4	EMBP1	-6.69	4.17e-10	0.00217	-0.59	-0.48	Schizophrenia;	chr5:50540881	chr1:121519112~121571892:+
PCPG	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-6.69	4.2e-10	0.00219	-0.7	-0.48	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
PCPG	trans	rs7258465	0.965	rs748609	ENSG00000267533.1	RP11-815J4.7	6.68	4.28e-10	0.00222	0.57	0.48	Breast cancer;	chr19:18449472	chr18:12067173~12068417:-
PCPG	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	6.68	4.28e-10	0.00222	0.66	0.48	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
PCPG	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	6.68	4.29e-10	0.00222	0.69	0.48	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
PCPG	trans	rs4276421	0.901	rs4455566	ENSG00000231752.4	EMBP1	6.68	4.29e-10	0.00223	0.64	0.48	P wave duration;	chr5:45752760	chr1:121519112~121571892:+
PCPG	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-6.68	4.32e-10	0.00224	-0.54	-0.48	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
PCPG	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	6.68	4.38e-10	0.00227	0.61	0.48	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	6.68	4.38e-10	0.00227	0.61	0.48	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	6.68	4.38e-10	0.00227	0.61	0.48	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	6.68	4.38e-10	0.00227	0.61	0.48	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	6.68	4.4e-10	0.00228	0.61	0.48	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	6.68	4.4e-10	0.00228	0.61	0.48	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	6.68	4.4e-10	0.00228	0.61	0.48	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
PCPG	trans	rs7312770	1	rs7312770	ENSG00000234354.3	RPS26P47	-6.68	4.41e-10	0.00228	-0.57	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr13:100539901~100540248:-
PCPG	trans	rs12709013	0.755	rs1424245	ENSG00000233719.3	GOT2P3	6.68	4.42e-10	0.00228	0.55	0.48	Blood metabolite ratios;	chr16:58729926	chr12:9641802~9643007:+
PCPG	trans	rs10940346	0.691	rs7706248	ENSG00000231752.4	EMBP1	-6.68	4.45e-10	0.00229	-0.64	-0.48	Schizophrenia;	chr5:50537190	chr1:121519112~121571892:+
PCPG	trans	rs4276421	1	rs4331911	ENSG00000231752.4	EMBP1	6.68	4.48e-10	0.00231	0.62	0.48	P wave duration;	chr5:45859273	chr1:121519112~121571892:+
PCPG	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	6.68	4.48e-10	0.00231	0.62	0.48	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
PCPG	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	6.68	4.48e-10	0.00231	0.62	0.48	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	6.68	4.48e-10	0.00231	0.62	0.48	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	6.68	4.49e-10	0.00231	0.61	0.48	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	6.68	4.49e-10	0.00231	0.61	0.48	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	6.68	4.49e-10	0.00231	0.61	0.48	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	6.68	4.49e-10	0.00231	0.61	0.48	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.904	rs34462057	ENSG00000231752.4	EMBP1	6.68	4.49e-10	0.00231	0.61	0.48	P wave duration;	chr5:45900215	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	6.68	4.49e-10	0.00231	0.61	0.48	P wave duration;	chr5:45904860	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	6.67	4.51e-10	0.00232	0.64	0.48	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	6.67	4.51e-10	0.00232	0.64	0.48	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	6.67	4.51e-10	0.00232	0.64	0.48	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	6.67	4.51e-10	0.00232	0.64	0.48	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.869	rs6451812	ENSG00000231752.4	EMBP1	6.67	4.53e-10	0.00233	0.65	0.48	P wave duration;	chr5:45692206	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-6.67	4.54e-10	0.00234	-0.61	-0.48	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
PCPG	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	6.67	4.57e-10	0.00235	0.62	0.48	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.967	rs4541666	ENSG00000231752.4	EMBP1	6.67	4.57e-10	0.00235	0.62	0.48	P wave duration;	chr5:45857027	chr1:121519112~121571892:+
PCPG	trans	rs6499129	0.571	rs9940665	ENSG00000262902.1	RP11-750B16.1	6.67	4.62e-10	0.00237	0.73	0.48	Waist-to-hip ratio adjusted for body mass index;	chr16:67255938	chr17:53105734~53106358:+
PCPG	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-6.67	4.71e-10	0.00242	-0.64	-0.48	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.805	rs13354798	ENSG00000231752.4	EMBP1	6.67	4.72e-10	0.00242	0.61	0.48	P wave duration;	chr5:45456975	chr1:121519112~121571892:+
PCPG	trans	rs7647973	1	rs9862534	ENSG00000197582.5	GPX1P1	6.67	4.73e-10	0.00243	0.7	0.48	Menarche (age at onset);	chr3:49560631	chrX:13378735~13379340:-
PCPG	trans	rs4276421	0.55	rs34812524	ENSG00000231752.4	EMBP1	6.66	4.74e-10	0.00243	0.61	0.48	P wave duration;	chr5:46054030	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	6.66	4.81e-10	0.00247	0.67	0.48	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
PCPG	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-6.66	4.86e-10	0.00249	-0.54	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
PCPG	trans	rs10940346	0.668	rs11746545	ENSG00000231752.4	EMBP1	-6.66	4.89e-10	0.00251	-0.64	-0.48	Schizophrenia;	chr5:50531238	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	6.66	4.91e-10	0.00252	0.66	0.48	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	6.66	4.91e-10	0.00252	0.66	0.48	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	6.66	4.91e-10	0.00252	0.66	0.48	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	6.66	4.91e-10	0.00252	0.66	0.48	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	6.66	4.93e-10	0.00253	0.66	0.48	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
PCPG	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	6.66	4.98e-10	0.00255	0.75	0.48	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	6.66	4.98e-10	0.00255	0.75	0.48	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	6.66	4.98e-10	0.00255	0.75	0.48	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	6.66	4.98e-10	0.00255	0.75	0.48	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	6.66	4.98e-10	0.00255	0.75	0.48	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
PCPG	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	6.65	5.03e-10	0.00257	0.63	0.48	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
PCPG	trans	rs10921288	0.661	rs111555630	ENSG00000232573.1	RPL3P4	6.65	5.09e-10	0.0026	0.88	0.48	Body fat percentage;	chr1:192849743	chr14:98972879~98973301:-
PCPG	trans	rs12709013	0.716	rs4784987	ENSG00000230849.2	GOT2P2	6.65	5.15e-10	0.00262	0.6	0.48	Blood metabolite ratios;	chr16:58824135	chr1:173141100~173142350:-
PCPG	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	6.65	5.16e-10	0.00263	0.62	0.48	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	6.65	5.16e-10	0.00263	0.62	0.48	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
PCPG	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	6.65	5.18e-10	0.00264	0.62	0.48	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
PCPG	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-6.65	5.2e-10	0.00264	-0.62	-0.48	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	6.65	5.24e-10	0.00266	0.66	0.48	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	6.65	5.24e-10	0.00266	0.66	0.48	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	6.65	5.24e-10	0.00266	0.66	0.48	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	6.65	5.24e-10	0.00266	0.66	0.48	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
PCPG	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-6.65	5.25e-10	0.00267	-0.44	-0.48	Longevity;	chr3:48398713	chr1:27649419~27649610:+
PCPG	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	6.65	5.25e-10	0.00267	0.61	0.48	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
PCPG	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	6.65	5.25e-10	0.00267	0.61	0.48	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	6.65	5.25e-10	0.00267	0.61	0.48	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	6.65	5.25e-10	0.00267	0.61	0.48	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-6.64	5.26e-10	0.00267	-0.62	-0.48	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	6.64	5.26e-10	0.00267	0.62	0.48	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
PCPG	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-6.64	5.26e-10	0.00267	-0.6	-0.48	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
PCPG	trans	rs6732160	1	rs6732160	ENSG00000236165.1	PRADC1P1	6.64	5.28e-10	0.00268	0.6	0.48	Intelligence (multi-trait analysis);	chr2:73160100	chr3:36976316~36976840:+
PCPG	trans	rs9611565	1	rs5758314	ENSG00000268568.1	AC007228.9	-6.64	5.29e-10	0.00268	-0.55	-0.48	Vitiligo;	chr22:41366519	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	6.64	5.29e-10	0.00268	0.66	0.48	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	6.64	5.29e-10	0.00268	0.66	0.48	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	6.64	5.29e-10	0.00268	0.66	0.48	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
PCPG	trans	rs10921288	0.661	rs6660343	ENSG00000232573.1	RPL3P4	6.64	5.42e-10	0.00274	0.87	0.48	Body fat percentage;	chr1:192846731	chr14:98972879~98973301:-
PCPG	trans	rs13190036	0.681	rs28461408	ENSG00000217325.2	PRELID1P1	6.64	5.43e-10	0.00275	0.88	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177235292	chr6:126643488~126644390:+
PCPG	trans	rs336284	0.502	rs1017132	ENSG00000255583.2	RP11-415I12.2	6.64	5.45e-10	0.00276	0.53	0.48	Suicide behavior;Suicide;	chr7:35307508	chr12:63682523~63724935:-
PCPG	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-6.64	5.47e-10	0.00277	-0.6	-0.48	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	6.63	5.55e-10	0.0028	0.66	0.48	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	6.63	5.55e-10	0.0028	0.66	0.48	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
PCPG	trans	rs9467773	0.933	rs2024970	ENSG00000242375.1	RP11-498P14.3	6.63	5.59e-10	0.00282	0.61	0.48	Intelligence (multi-trait analysis);	chr6:26497292	chr9:97195351~97197687:-
PCPG	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-6.63	5.69e-10	0.00287	-0.57	-0.48	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
PCPG	trans	rs10940346	1	rs11739291	ENSG00000231752.4	EMBP1	-6.63	5.77e-10	0.00291	-0.59	-0.48	Schizophrenia;	chr5:50550394	chr1:121519112~121571892:+
PCPG	trans	rs7647973	1	rs974495	ENSG00000197582.5	GPX1P1	6.63	5.78e-10	0.00291	0.69	0.48	Menarche (age at onset);	chr3:49363049	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs11719762	ENSG00000197582.5	GPX1P1	6.63	5.78e-10	0.00291	0.69	0.48	Menarche (age at onset);	chr3:49371569	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs10155014	ENSG00000197582.5	GPX1P1	6.63	5.78e-10	0.00291	0.69	0.48	Menarche (age at onset);	chr3:49394888	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	6.63	5.78e-10	0.00291	0.69	0.48	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-6.63	5.79e-10	0.00291	-0.61	-0.48	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	6.63	5.79e-10	0.00291	0.61	0.48	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
PCPG	trans	rs3206736	0.593	rs328923	ENSG00000255583.2	RP11-415I12.2	6.63	5.79e-10	0.00292	0.54	0.48	Diastolic blood pressure;	chr7:34996083	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.556	rs328924	ENSG00000255583.2	RP11-415I12.2	6.63	5.79e-10	0.00292	0.54	0.48	Diastolic blood pressure;	chr7:34996092	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328925	ENSG00000255583.2	RP11-415I12.2	6.63	5.79e-10	0.00292	0.54	0.48	Diastolic blood pressure;	chr7:34997715	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	6.63	5.83e-10	0.00294	0.61	0.48	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	6.63	5.83e-10	0.00294	0.61	0.48	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
PCPG	trans	rs4276421	1	rs13340341	ENSG00000231752.4	EMBP1	6.63	5.84e-10	0.00294	0.6	0.48	P wave duration;	chr5:45860834	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.806	rs6892290	ENSG00000231752.4	EMBP1	6.62	5.92e-10	0.00298	0.62	0.48	P wave duration;	chr5:45427035	chr1:121519112~121571892:+
PCPG	trans	rs12709013	0.636	rs30835	ENSG00000230849.2	GOT2P2	6.62	5.98e-10	0.003	0.53	0.48	Blood metabolite ratios;	chr16:58714117	chr1:173141100~173142350:-
PCPG	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-6.62	5.98e-10	0.003	-0.59	-0.48	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.926	rs12538515	ENSG00000255583.2	RP11-415I12.2	6.62	6.02e-10	0.00302	0.52	0.48	Birth weight;	chr7:35258347	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs7790964	ENSG00000255583.2	RP11-415I12.2	6.62	6.02e-10	0.00302	0.52	0.48	Birth weight;	chr7:35260273	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs988271	ENSG00000255583.2	RP11-415I12.2	6.62	6.02e-10	0.00302	0.52	0.48	Birth weight;	chr7:35260766	chr12:63682523~63724935:-
PCPG	trans	rs4276421	0.901	rs10044479	ENSG00000231752.4	EMBP1	6.62	6.02e-10	0.00302	0.64	0.48	P wave duration;	chr5:45751434	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.776	rs7723380	ENSG00000231752.4	EMBP1	6.62	6.02e-10	0.00302	0.62	0.48	P wave duration;	chr5:45428433	chr1:121519112~121571892:+
PCPG	trans	rs3779195	0.524	rs80195155	ENSG00000225169.1	BRI3P1	-6.62	6.06e-10	0.00304	-0.74	-0.48	Sex hormone-binding globulin levels;	chr7:98248841	chr1:100213293~100213670:+
PCPG	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	6.62	6.09e-10	0.00305	0.6	0.48	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
PCPG	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	6.62	6.14e-10	0.00307	0.6	0.48	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
PCPG	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-6.61	6.19e-10	0.0031	-0.52	-0.48	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-6.61	6.27e-10	0.00313	-0.66	-0.48	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	6.61	6.27e-10	0.00313	0.66	0.48	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
PCPG	trans	rs7647973	0.925	rs6769821	ENSG00000197582.5	GPX1P1	6.61	6.27e-10	0.00313	0.69	0.48	Menarche (age at onset);	chr3:49207224	chrX:13378735~13379340:-
PCPG	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-6.61	6.29e-10	0.00314	-0.62	-0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
PCPG	trans	rs73108077	0.736	rs6061028	ENSG00000279352.1	RP11-411B10.7	6.61	6.29e-10	0.00314	0.86	0.47	Red blood cell density in sickle cell anemia;	chr20:31285774	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs6058492	ENSG00000279352.1	RP11-411B10.7	6.61	6.29e-10	0.00314	0.86	0.47	Red blood cell density in sickle cell anemia;	chr20:31286965	chr18:14010054~14010917:+
PCPG	trans	rs4276421	0.869	rs6451814	ENSG00000231752.4	EMBP1	6.61	6.33e-10	0.00315	0.64	0.47	P wave duration;	chr5:45734981	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.837	rs6451807	ENSG00000231752.4	EMBP1	6.61	6.38e-10	0.00318	0.62	0.47	P wave duration;	chr5:45534321	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-6.61	6.42e-10	0.0032	-0.55	-0.47	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
PCPG	trans	rs336284	0.542	rs12538450	ENSG00000255583.2	RP11-415I12.2	6.61	6.48e-10	0.00323	0.54	0.47	Suicide behavior;Suicide;	chr7:35289860	chr12:63682523~63724935:-
PCPG	trans	rs5022636	0.74	rs11204795	ENSG00000180764.13	PIPSL	6.6	6.49e-10	0.00323	0.55	0.47	Gut microbiota (functional units);	chr1:151275522	chr10:93958191~93961540:-
PCPG	trans	rs6477998	0.647	rs10981704	ENSG00000238072.1	RP11-305M3.2	-6.6	6.5e-10	0.00323	-0.62	-0.47	Hematology traits;	chr9:113253989	chr7:129410113~129410370:-
PCPG	trans	rs4276421	0.806	rs12520124	ENSG00000231752.4	EMBP1	6.6	6.6e-10	0.00328	0.61	0.47	P wave duration;	chr5:45434917	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.806	rs34666220	ENSG00000231752.4	EMBP1	6.6	6.6e-10	0.00328	0.61	0.47	P wave duration;	chr5:45435884	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.806	rs6451801	ENSG00000231752.4	EMBP1	6.6	6.6e-10	0.00328	0.61	0.47	P wave duration;	chr5:45439331	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.806	rs6860200	ENSG00000231752.4	EMBP1	6.6	6.6e-10	0.00328	0.61	0.47	P wave duration;	chr5:45440241	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.806	rs13169726	ENSG00000231752.4	EMBP1	6.6	6.6e-10	0.00328	0.61	0.47	P wave duration;	chr5:45444967	chr1:121519112~121571892:+
PCPG	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-6.6	6.66e-10	0.00331	-0.6	-0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
PCPG	trans	rs10940346	0.728	rs12655271	ENSG00000231752.4	EMBP1	-6.6	6.71e-10	0.00333	-0.6	-0.47	Schizophrenia;	chr5:50212921	chr1:121519112~121571892:+
PCPG	trans	rs7140958	1	rs7140958	ENSG00000225972.1	MTND1P23	6.6	6.74e-10	0.00334	0.98	0.47	Bilirubin levels;	chr14:45560484	chr1:629062~629433:+
PCPG	trans	rs7647973	1	rs11928090	ENSG00000197582.5	GPX1P1	6.6	6.74e-10	0.00335	0.68	0.47	Menarche (age at onset);	chr3:49567471	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	6.6	6.81e-10	0.00337	0.63	0.47	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
PCPG	trans	rs9876781	1	rs4858817	ENSG00000225528.1	RP3-370M22.8	6.59	6.94e-10	0.00343	0.55	0.47	Longevity;	chr3:48375266	chr22:39960397~39964683:+
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-6.59	6.96e-10	0.00344	-0.6	-0.47	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
PCPG	trans	rs7647973	0.925	rs7429661	ENSG00000197582.5	GPX1P1	6.59	6.98e-10	0.00345	0.68	0.47	Menarche (age at onset);	chr3:49191367	chrX:13378735~13379340:-
PCPG	trans	rs2589161	1	rs2589161	ENSG00000231752.4	EMBP1	6.59	7.17e-10	0.00354	0.64	0.47	Breast cancer;	chr5:45653810	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs1405918	ENSG00000231752.4	EMBP1	6.59	7.17e-10	0.00354	0.64	0.47	P wave duration;	chr5:45654968	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	6.59	7.18e-10	0.00354	0.59	0.47	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
PCPG	trans	rs73108077	0.736	rs732860	ENSG00000279352.1	RP11-411B10.7	6.59	7.19e-10	0.00355	0.86	0.47	Red blood cell density in sickle cell anemia;	chr20:31269641	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs6121224	ENSG00000279352.1	RP11-411B10.7	6.59	7.19e-10	0.00355	0.86	0.47	Red blood cell density in sickle cell anemia;	chr20:31272881	chr18:14010054~14010917:+
PCPG	trans	rs6959887	0.926	rs4723406	ENSG00000255583.2	RP11-415I12.2	6.58	7.22e-10	0.00356	0.52	0.47	Birth weight;	chr7:35246859	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.962	rs17675131	ENSG00000255583.2	RP11-415I12.2	6.58	7.22e-10	0.00356	0.52	0.47	Birth weight;	chr7:35248456	chr12:63682523~63724935:-
PCPG	trans	rs116095464	1	rs56075848	ENSG00000185986.11	SDHAP3	6.58	7.25e-10	0.00357	0.77	0.47	Breast cancer;	chr5:308237	chr5:1572222~1594620:-
PCPG	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-6.58	7.25e-10	0.00357	-0.56	-0.47	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
PCPG	trans	rs4276421	0.806	rs6892594	ENSG00000231752.4	EMBP1	6.58	7.32e-10	0.0036	0.61	0.47	P wave duration;	chr5:45427071	chr1:121519112~121571892:+
PCPG	trans	rs6959887	0.821	rs17674869	ENSG00000255583.2	RP11-415I12.2	6.58	7.34e-10	0.00361	0.52	0.47	Birth weight;	chr7:35236095	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	6.58	7.36e-10	0.00362	0.64	0.47	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-6.58	7.51e-10	0.00369	-0.54	-0.47	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
PCPG	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	6.58	7.58e-10	0.00372	0.73	0.47	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	6.58	7.58e-10	0.00372	0.73	0.47	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
PCPG	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-6.57	7.62e-10	0.00374	-0.65	-0.47	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
PCPG	trans	rs7647973	1	rs11130189	ENSG00000197582.5	GPX1P1	6.57	7.72e-10	0.00378	0.68	0.47	Menarche (age at onset);	chr3:49309924	chrX:13378735~13379340:-
PCPG	trans	rs3206736	0.556	rs1649235	ENSG00000255583.2	RP11-415I12.2	6.57	7.77e-10	0.0038	0.54	0.47	Diastolic blood pressure;	chr7:34964270	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.514	rs1649236	ENSG00000255583.2	RP11-415I12.2	6.57	7.77e-10	0.0038	0.54	0.47	Diastolic blood pressure;	chr7:34964522	chr12:63682523~63724935:-
PCPG	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-6.57	7.78e-10	0.00381	-0.59	-0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
PCPG	trans	rs3206736	0.548	rs328929	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35000426	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs167893	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35003121	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.52	rs328934	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35004114	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328936	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35007967	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328937	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35009519	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328939	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35010615	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328940	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35010752	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328942	ENSG00000255583.2	RP11-415I12.2	6.57	7.85e-10	0.00383	0.54	0.47	Diastolic blood pressure;	chr7:35012203	chr12:63682523~63724935:-
PCPG	trans	rs7819412	0.806	rs6980856	ENSG00000253893.2	FAM85B	-6.57	7.85e-10	0.00383	-0.64	-0.47	Triglycerides;	chr8:11080750	chr8:8167819~8226614:-
PCPG	trans	rs2657294	0.704	rs10824266	ENSG00000172974.11	AC007318.5	6.57	7.97e-10	0.00388	0.51	0.47	Pneumonia;	chr10:75083476	chr2:65205108~65205988:+
PCPG	trans	rs3779195	0.585	rs58699591	ENSG00000225169.1	BRI3P1	-6.56	7.99e-10	0.00389	-0.73	-0.47	Sex hormone-binding globulin levels;	chr7:98247392	chr1:100213293~100213670:+
PCPG	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	6.56	8e-10	0.00389	0.64	0.47	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
PCPG	trans	rs6959887	0.926	rs73099190	ENSG00000255583.2	RP11-415I12.2	6.56	8e-10	0.00389	0.52	0.47	Birth weight;	chr7:35253806	chr12:63682523~63724935:-
PCPG	trans	rs6959887	1	rs10235849	ENSG00000255583.2	RP11-415I12.2	6.56	8e-10	0.00389	0.52	0.47	Birth weight;	chr7:35255752	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	6.56	8.03e-10	0.00391	0.66	0.47	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.901	rs7447717	ENSG00000231752.4	EMBP1	-6.56	8.05e-10	0.00391	-0.64	-0.47	P wave duration;	chr5:45770150	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs13187565	ENSG00000231752.4	EMBP1	6.56	8.05e-10	0.00391	0.64	0.47	P wave duration;	chr5:45707436	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	6.56	8.08e-10	0.00392	0.59	0.47	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	6.56	8.08e-10	0.00392	0.59	0.47	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-6.56	8.08e-10	0.00392	-0.59	-0.47	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
PCPG	trans	rs9876781	1	rs2362452	ENSG00000225528.1	RP3-370M22.8	6.56	8.14e-10	0.00395	0.55	0.47	Longevity;	chr3:48376724	chr22:39960397~39964683:+
PCPG	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-6.56	8.14e-10	0.00395	-0.66	-0.47	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-6.56	8.2e-10	0.00398	-0.62	-0.47	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
PCPG	trans	rs9425766	0.511	rs10912676	ENSG00000213331.4	RP11-713C19.2	6.56	8.27e-10	0.00401	0.56	0.47	Life satisfaction;	chr1:173740477	chr4:187970273~187971284:+
PCPG	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	6.55	8.45e-10	0.00409	0.6	0.47	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.934	rs6451840	ENSG00000231752.4	EMBP1	6.55	8.5e-10	0.00411	0.62	0.47	P wave duration;	chr5:45935584	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.87	rs6451842	ENSG00000231752.4	EMBP1	6.55	8.5e-10	0.00411	0.62	0.47	P wave duration;	chr5:45936431	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.901	rs10056175	ENSG00000231752.4	EMBP1	6.55	8.53e-10	0.00412	0.62	0.47	P wave duration;	chr5:45934503	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs7636782	ENSG00000225528.1	RP3-370M22.8	-6.55	8.7e-10	0.00419	-0.54	-0.47	Longevity;	chr3:48379897	chr22:39960397~39964683:+
PCPG	trans	rs7819412	0.875	rs11250121	ENSG00000253893.2	FAM85B	6.55	8.85e-10	0.00426	0.61	0.47	Triglycerides;	chr8:11202802	chr8:8167819~8226614:-
PCPG	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	6.54	8.88e-10	0.00427	0.54	0.47	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
PCPG	trans	rs4276421	0.869	rs2580258	ENSG00000231752.4	EMBP1	6.54	8.92e-10	0.00429	0.63	0.47	P wave duration;	chr5:45586815	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	6.54	8.95e-10	0.0043	0.65	0.47	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
PCPG	trans	rs4276421	0.837	rs7727890	ENSG00000231752.4	EMBP1	6.54	8.98e-10	0.00431	0.63	0.47	P wave duration;	chr5:45478669	chr1:121519112~121571892:+
PCPG	trans	rs4276421	1	rs4276421	ENSG00000231752.4	EMBP1	-6.54	8.99e-10	0.00432	-0.61	-0.47	P wave duration;	chr5:45801977	chr1:121519112~121571892:+
PCPG	trans	rs616147	0.816	rs1768190	ENSG00000183298.5	RP11-556K13.1	6.54	9.01e-10	0.00432	0.64	0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr1:101786340~101787219:-
PCPG	trans	rs6959887	0.926	rs56834372	ENSG00000255583.2	RP11-415I12.2	6.54	9.03e-10	0.00433	0.52	0.47	Birth weight;	chr7:35236622	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs17674881	ENSG00000255583.2	RP11-415I12.2	6.54	9.03e-10	0.00433	0.52	0.47	Birth weight;	chr7:35236650	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.926	rs17606554	ENSG00000255583.2	RP11-415I12.2	6.54	9.03e-10	0.00433	0.52	0.47	Birth weight;	chr7:35236724	chr12:63682523~63724935:-
PCPG	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	6.54	9.03e-10	0.00433	0.73	0.47	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	6.54	9.03e-10	0.00433	0.73	0.47	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	6.54	9.03e-10	0.00433	0.73	0.47	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
PCPG	trans	rs4276421	0.967	rs6865429	ENSG00000231752.4	EMBP1	-6.54	9.04e-10	0.00433	-0.6	-0.47	P wave duration;	chr5:45830406	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	6.54	9.25e-10	0.00443	0.63	0.47	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	6.54	9.25e-10	0.00443	0.63	0.47	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	6.54	9.25e-10	0.00443	0.63	0.47	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-6.54	9.25e-10	0.00443	-0.58	-0.47	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
PCPG	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	6.54	9.29e-10	0.00444	0.73	0.47	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
PCPG	trans	rs7819412	0.634	rs6987767	ENSG00000253893.2	FAM85B	-6.54	9.33e-10	0.00446	-0.61	-0.47	Triglycerides;	chr8:11052556	chr8:8167819~8226614:-
PCPG	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	6.53	9.42e-10	0.00449	0.61	0.47	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
PCPG	trans	rs7647973	0.925	rs4955439	ENSG00000197582.5	GPX1P1	-6.53	9.45e-10	0.0045	-0.64	-0.47	Menarche (age at onset);	chr3:49208212	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-6.53	9.45e-10	0.0045	-0.65	-0.47	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	6.53	9.45e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	6.53	9.45e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	6.53	9.45e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	6.53	9.45e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	6.53	9.45e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	6.53	9.45e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	6.53	9.45e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-6.53	9.48e-10	0.0045	-0.65	-0.47	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	6.53	9.48e-10	0.0045	0.65	0.47	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
PCPG	trans	rs6959887	0.926	rs2429420	ENSG00000255583.2	RP11-415I12.2	6.53	9.48e-10	0.0045	0.52	0.47	Birth weight;	chr7:35237384	chr12:63682523~63724935:-
PCPG	trans	rs6477998	0.603	rs12338803	ENSG00000238072.1	RP11-305M3.2	6.53	9.56e-10	0.00453	0.75	0.47	Hematology traits;	chr9:113263148	chr7:129410113~129410370:-
PCPG	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-6.53	9.64e-10	0.00457	-0.56	-0.47	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	6.53	9.7e-10	0.0046	0.56	0.47	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
PCPG	trans	rs3206736	0.548	rs1637673	ENSG00000255583.2	RP11-415I12.2	6.53	9.8e-10	0.00463	0.54	0.47	Diastolic blood pressure;	chr7:34958238	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.52	rs1637674	ENSG00000255583.2	RP11-415I12.2	6.53	9.8e-10	0.00463	0.54	0.47	Diastolic blood pressure;	chr7:34958475	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.583	rs1649233	ENSG00000255583.2	RP11-415I12.2	6.53	9.8e-10	0.00463	0.54	0.47	Diastolic blood pressure;	chr7:34960847	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs1637675	ENSG00000255583.2	RP11-415I12.2	6.53	9.8e-10	0.00463	0.54	0.47	Diastolic blood pressure;	chr7:34960880	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs1637676	ENSG00000255583.2	RP11-415I12.2	6.53	9.8e-10	0.00463	0.54	0.47	Diastolic blood pressure;	chr7:34960947	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.514	rs1637679	ENSG00000255583.2	RP11-415I12.2	6.53	9.8e-10	0.00463	0.54	0.47	Diastolic blood pressure;	chr7:34961410	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328895	ENSG00000255583.2	RP11-415I12.2	6.53	9.8e-10	0.00463	0.54	0.47	Diastolic blood pressure;	chr7:34976775	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	6.53	9.8e-10	0.00463	0.59	0.47	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
PCPG	trans	rs10242455	1	rs17161692	ENSG00000228834.1	RP11-249L21.4	-6.52	9.89e-10	0.00467	-0.94	-0.47	Blood metabolite levels;	chr7:99356240	chr6:108907615~108907873:-
PCPG	trans	rs10242455	0.571	rs6955162	ENSG00000228834.1	RP11-249L21.4	6.52	9.97e-10	0.00471	1.19	0.47	Blood metabolite levels;	chr7:99586777	chr6:108907615~108907873:-
PCPG	trans	rs9650657	0.515	rs6601560	ENSG00000253893.2	FAM85B	6.52	1.02e-09	0.0048	0.64	0.47	Neuroticism;	chr8:11093356	chr8:8167819~8226614:-
PCPG	trans	rs116095464	1	rs2721025	ENSG00000185986.11	SDHAP3	6.52	1.03e-09	0.00485	0.87	0.47	Breast cancer;	chr5:347329	chr5:1572222~1594620:-
PCPG	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-6.51	1.06e-09	0.00496	-0.59	-0.47	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
PCPG	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-6.51	1.06e-09	0.00496	-0.75	-0.47	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
PCPG	trans	rs10940346	0.519	rs7293422	ENSG00000231752.4	EMBP1	-6.51	1.06e-09	0.00499	-0.61	-0.47	Schizophrenia;	chr5:50146010	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.869	rs10036065	ENSG00000231752.4	EMBP1	-6.51	1.07e-09	0.00502	-0.64	-0.47	P wave duration;	chr5:45701926	chr1:121519112~121571892:+
PCPG	trans	rs62344088	0.59	rs60845955	ENSG00000185986.11	SDHAP3	6.51	1.07e-09	0.00504	0.76	0.47	Asthma (childhood onset);	chr5:184979	chr5:1572222~1594620:-
PCPG	trans	rs3206736	0.576	rs17205723	ENSG00000255583.2	RP11-415I12.2	-6.51	1.08e-09	0.00506	-0.54	-0.47	Diastolic blood pressure;	chr7:35076824	chr12:63682523~63724935:-
PCPG	trans	rs62344088	1	rs6898413	ENSG00000185986.11	SDHAP3	6.51	1.08e-09	0.00506	0.93	0.47	Asthma (childhood onset);	chr5:173812	chr5:1572222~1594620:-
PCPG	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-6.51	1.09e-09	0.00511	-0.65	-0.47	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
PCPG	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-6.5	1.09e-09	0.00511	-0.53	-0.47	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
PCPG	trans	rs3809095	0.821	rs55730604	ENSG00000229694.5	RP11-305L7.6	6.5	1.1e-09	0.00516	0.56	0.47	Total body bone mineral density;	chr11:16508962	chr9:91119062~91182762:+
PCPG	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	6.5	1.1e-09	0.00517	0.65	0.47	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
PCPG	trans	rs4660306	1	rs882803	ENSG00000235823.1	OLMALINC	-6.5	1.13e-09	0.0053	-0.51	-0.47	Homocysteine levels;	chr1:45510475	chr10:100373615~100383368:+
PCPG	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-6.5	1.14e-09	0.00531	-0.57	-0.47	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
PCPG	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	6.5	1.14e-09	0.00531	0.52	0.47	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
PCPG	trans	rs6959887	0.603	rs2392359	ENSG00000255583.2	RP11-415I12.2	6.5	1.14e-09	0.00532	0.52	0.47	Birth weight;	chr7:35237604	chr12:63682523~63724935:-
PCPG	trans	rs9876781	1	rs4858793	ENSG00000225528.1	RP3-370M22.8	6.5	1.14e-09	0.00532	0.53	0.47	Longevity;	chr3:48373517	chr22:39960397~39964683:+
PCPG	trans	rs10109025	0.67	rs7825690	ENSG00000253893.2	FAM85B	6.5	1.14e-09	0.00533	0.62	0.47	Joint mobility (Beighton score);	chr8:11000747	chr8:8167819~8226614:-
PCPG	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-6.5	1.14e-09	0.00533	-0.44	-0.47	Longevity;	chr3:48392157	chr1:27649419~27649610:+
PCPG	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-6.5	1.14e-09	0.00533	-0.44	-0.47	Longevity;	chr3:48392588	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-6.5	1.14e-09	0.00533	-0.44	-0.47	Longevity;	chr3:48392923	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-6.5	1.14e-09	0.00533	-0.44	-0.47	Longevity;	chr3:48393807	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-6.5	1.14e-09	0.00533	-0.44	-0.47	Longevity;	chr3:48395329	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-6.5	1.14e-09	0.00533	-0.44	-0.47	Longevity;	chr3:48396724	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-6.5	1.14e-09	0.00533	-0.44	-0.47	Longevity;	chr3:48398582	chr1:27649419~27649610:+
PCPG	trans	rs7937890	0.9	rs7118682	ENSG00000236360.2	RP11-334A14.2	-6.5	1.15e-09	0.00535	-0.5	-0.47	Mitochondrial DNA levels;	chr11:14253004	chr1:52993201~52993702:-
PCPG	trans	rs76329678	1	rs76329678	ENSG00000231752.4	EMBP1	-6.49	1.15e-09	0.00535	-0.58	-0.47	Schizophrenia;	chr5:50534452	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	6.49	1.16e-09	0.00538	0.65	0.47	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
PCPG	trans	rs12709013	0.636	rs1646256	ENSG00000233719.3	GOT2P3	6.49	1.17e-09	0.00543	0.52	0.47	Blood metabolite ratios;	chr16:58712114	chr12:9641802~9643007:+
PCPG	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-6.49	1.17e-09	0.00543	-0.58	-0.47	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.776	rs13175193	ENSG00000231752.4	EMBP1	6.49	1.17e-09	0.00544	0.61	0.47	P wave duration;	chr5:45408894	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	6.49	1.17e-09	0.00544	0.61	0.47	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	6.49	1.18e-09	0.00546	0.61	0.47	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
PCPG	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-6.49	1.18e-09	0.0055	-0.69	-0.47	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	6.49	1.19e-09	0.0055	0.65	0.47	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	6.49	1.19e-09	0.0055	0.65	0.47	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
PCPG	trans	rs62344088	0.59	rs6882234	ENSG00000185986.11	SDHAP3	6.49	1.19e-09	0.00551	0.77	0.47	Asthma (childhood onset);	chr5:177274	chr5:1572222~1594620:-
PCPG	trans	rs62344088	0.59	rs58563514	ENSG00000185986.11	SDHAP3	6.49	1.19e-09	0.00551	0.77	0.47	Asthma (childhood onset);	chr5:177722	chr5:1572222~1594620:-
PCPG	trans	rs116095464	1	rs62331560	ENSG00000185986.11	SDHAP3	6.49	1.19e-09	0.00554	0.9	0.47	Breast cancer;	chr5:346670	chr5:1572222~1594620:-
PCPG	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-6.49	1.2e-09	0.00557	-0.75	-0.47	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
PCPG	trans	rs9650657	0.504	rs10093053	ENSG00000253893.2	FAM85B	6.49	1.2e-09	0.00558	0.59	0.47	Neuroticism;	chr8:11179678	chr8:8167819~8226614:-
PCPG	trans	rs740160	0.558	rs17161662	ENSG00000228834.1	RP11-249L21.4	6.48	1.21e-09	0.00561	0.89	0.47	Dehydroepiandrosterone sulphate levels;	chr7:99309773	chr6:108907615~108907873:-
PCPG	trans	rs7047415	1	rs7047415	ENSG00000225972.1	MTND1P23	6.48	1.21e-09	0.00561	0.65	0.47	Alzheimer disease and age of onset;	chr9:95778950	chr1:629062~629433:+
PCPG	trans	rs10917477	0.594	rs2792043	ENSG00000224237.1	MINOS1P3	6.48	1.21e-09	0.00562	0.57	0.47	Thyroid function;	chr1:19598168	chr3:27214816~27215018:-
PCPG	trans	rs9611565	0.765	rs727563	ENSG00000268568.1	AC007228.9	6.48	1.22e-09	0.00565	0.54	0.47	Vitiligo;	chr22:41471373	chr19:56672574~56673901:-
PCPG	trans	rs4276421	0.806	rs6414906	ENSG00000231752.4	EMBP1	6.48	1.23e-09	0.00568	0.61	0.47	P wave duration;	chr5:45406219	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.776	rs4133429	ENSG00000231752.4	EMBP1	6.48	1.23e-09	0.00568	0.61	0.47	P wave duration;	chr5:45403633	chr1:121519112~121571892:+
PCPG	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-6.48	1.24e-09	0.00573	-0.53	-0.47	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
PCPG	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	6.48	1.24e-09	0.00573	0.61	0.47	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
PCPG	trans	rs3206736	0.548	rs1649238	ENSG00000255583.2	RP11-415I12.2	-6.48	1.25e-09	0.00574	-0.52	-0.47	Diastolic blood pressure;	chr7:34964905	chr12:63682523~63724935:-
PCPG	trans	rs2657294	0.734	rs10740449	ENSG00000172974.11	AC007318.5	6.48	1.25e-09	0.00576	0.5	0.47	Pneumonia;	chr10:75086620	chr2:65205108~65205988:+
PCPG	trans	rs2657294	0.734	rs2894244	ENSG00000172974.11	AC007318.5	6.48	1.25e-09	0.00576	0.5	0.47	Pneumonia;	chr10:75087112	chr2:65205108~65205988:+
PCPG	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	6.48	1.25e-09	0.00576	0.55	0.47	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	6.48	1.25e-09	0.00576	0.55	0.47	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
PCPG	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	6.48	1.25e-09	0.00577	0.65	0.47	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.821	rs56155624	ENSG00000275858.1	RP11-291L22.8	6.48	1.26e-09	0.00578	0.63	0.47	Corneal astigmatism;	chr4:119369871	chr10:38450738~38451069:-
PCPG	trans	rs7824557	0.547	rs2409745	ENSG00000253893.2	FAM85B	-6.48	1.26e-09	0.00579	-0.6	-0.47	Retinal vascular caliber;	chr8:11219126	chr8:8167819~8226614:-
PCPG	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-6.48	1.26e-09	0.00581	-0.7	-0.47	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
PCPG	trans	rs13358908	0.506	rs7293471	ENSG00000231752.4	EMBP1	-6.48	1.27e-09	0.00583	-0.64	-0.47	Schizophrenia;	chr5:46404446	chr1:121519112~121571892:+
PCPG	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	6.48	1.27e-09	0.00584	0.66	0.47	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
PCPG	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-6.48	1.27e-09	0.00586	-0.58	-0.47	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
PCPG	trans	rs3809095	0.753	rs12146438	ENSG00000229694.5	RP11-305L7.6	6.47	1.28e-09	0.00587	0.56	0.47	Total body bone mineral density;	chr11:16481214	chr9:91119062~91182762:+
PCPG	trans	rs4276421	0.869	rs1527831	ENSG00000231752.4	EMBP1	6.47	1.28e-09	0.00589	0.62	0.47	P wave duration;	chr5:45656821	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	6.47	1.29e-09	0.00594	0.6	0.47	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
PCPG	trans	rs3206736	0.548	rs329242	ENSG00000255583.2	RP11-415I12.2	6.47	1.31e-09	0.006	0.53	0.47	Diastolic blood pressure;	chr7:35020055	chr12:63682523~63724935:-
PCPG	trans	rs4276421	0.869	rs2589162	ENSG00000231752.4	EMBP1	-6.47	1.31e-09	0.00601	-0.61	-0.47	P wave duration;	chr5:45655791	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.806	rs13162651	ENSG00000231752.4	EMBP1	6.47	1.31e-09	0.00601	0.6	0.47	P wave duration;	chr5:45409798	chr1:121519112~121571892:+
PCPG	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-6.47	1.32e-09	0.00605	-0.67	-0.47	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-6.47	1.32e-09	0.00605	-0.67	-0.47	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-6.47	1.32e-09	0.00606	-0.66	-0.47	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
PCPG	trans	rs13190036	0.901	rs4631	ENSG00000228305.2	AC016734.2	6.47	1.32e-09	0.00606	0.78	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr2:63622178~63622831:-
PCPG	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-6.47	1.33e-09	0.00609	-0.69	-0.47	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-6.47	1.33e-09	0.00609	-0.69	-0.47	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-6.47	1.33e-09	0.00609	-0.69	-0.47	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
PCPG	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	6.46	1.35e-09	0.00616	0.73	0.47	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
PCPG	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	6.46	1.35e-09	0.00616	0.66	0.47	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	6.46	1.35e-09	0.00616	0.66	0.47	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	6.46	1.35e-09	0.00616	0.67	0.47	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.925	rs9881860	ENSG00000197582.5	GPX1P1	6.46	1.35e-09	0.00616	0.67	0.47	Menarche (age at onset);	chr3:49315089	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	6.46	1.36e-09	0.00619	0.61	0.47	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	6.46	1.38e-09	0.00627	0.56	0.47	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
PCPG	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	6.46	1.38e-09	0.00627	0.56	0.47	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
PCPG	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	6.46	1.38e-09	0.00627	0.56	0.47	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
PCPG	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	6.46	1.38e-09	0.00627	0.56	0.47	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
PCPG	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	6.46	1.38e-09	0.00627	0.56	0.47	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
PCPG	trans	rs7824557	0.547	rs6601570	ENSG00000253893.2	FAM85B	6.46	1.38e-09	0.00628	0.62	0.47	Retinal vascular caliber;	chr8:11221858	chr8:8167819~8226614:-
PCPG	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	6.46	1.38e-09	0.00629	0.72	0.47	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	6.46	1.38e-09	0.00629	0.72	0.47	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	6.46	1.38e-09	0.00629	0.72	0.47	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	6.46	1.38e-09	0.00629	0.72	0.47	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
PCPG	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-6.46	1.38e-09	0.0063	-0.59	-0.47	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
PCPG	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	6.46	1.39e-09	0.00632	0.73	0.47	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	6.46	1.39e-09	0.00632	0.73	0.47	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
PCPG	trans	rs3206736	0.548	rs328896	ENSG00000255583.2	RP11-415I12.2	6.46	1.4e-09	0.00635	0.53	0.47	Diastolic blood pressure;	chr7:34977610	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs2021177	ENSG00000255583.2	RP11-415I12.2	6.46	1.4e-09	0.00635	0.53	0.47	Diastolic blood pressure;	chr7:34980576	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328900	ENSG00000255583.2	RP11-415I12.2	6.46	1.4e-09	0.00635	0.53	0.47	Diastolic blood pressure;	chr7:34980668	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328901	ENSG00000255583.2	RP11-415I12.2	6.46	1.4e-09	0.00635	0.53	0.47	Diastolic blood pressure;	chr7:34980839	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328904	ENSG00000255583.2	RP11-415I12.2	6.46	1.4e-09	0.00635	0.53	0.47	Diastolic blood pressure;	chr7:34981564	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs328908	ENSG00000255583.2	RP11-415I12.2	6.46	1.4e-09	0.00635	0.53	0.47	Diastolic blood pressure;	chr7:34986396	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-6.46	1.4e-09	0.00637	-0.61	-0.47	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
PCPG	trans	rs3206736	0.548	rs328902	ENSG00000255583.2	RP11-415I12.2	6.46	1.4e-09	0.00638	0.53	0.47	Diastolic blood pressure;	chr7:34981231	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	6.46	1.4e-09	0.00638	0.6	0.47	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	6.46	1.4e-09	0.00638	0.6	0.47	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	6.46	1.4e-09	0.00638	0.6	0.47	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
PCPG	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	6.46	1.4e-09	0.00638	0.6	0.47	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
PCPG	trans	rs10940346	0.537	rs7293378	ENSG00000231752.4	EMBP1	-6.46	1.41e-09	0.00639	-0.6	-0.47	Schizophrenia;	chr5:50192402	chr1:121519112~121571892:+
PCPG	trans	rs4349753	0.595	rs17613806	ENSG00000250325.1	IGBP1P4	6.46	1.41e-09	0.00639	0.7	0.47	Photic sneeze reflex;	chr5:144950384	chr4:82401578~82402456:-
PCPG	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-6.45	1.44e-09	0.00652	-0.53	-0.47	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	6.45	1.44e-09	0.00653	0.64	0.47	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
PCPG	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	6.45	1.44e-09	0.00653	0.61	0.47	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
PCPG	trans	rs13358908	0.507	rs12521357	ENSG00000231752.4	EMBP1	-6.45	1.45e-09	0.00658	-0.6	-0.47	Schizophrenia;	chr5:46403146	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	6.45	1.46e-09	0.00661	0.6	0.47	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	6.45	1.46e-09	0.00661	0.6	0.47	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
PCPG	trans	rs6790105	1	rs6790105	ENSG00000197582.5	GPX1P1	6.45	1.47e-09	0.00666	0.69	0.47	Childhood ear infection;	chr3:49355976	chrX:13378735~13379340:-
PCPG	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-6.45	1.47e-09	0.00666	-0.55	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
PCPG	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-6.45	1.47e-09	0.00667	-0.61	-0.47	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-6.45	1.47e-09	0.00667	-0.61	-0.47	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
PCPG	trans	rs3206736	0.548	rs329229	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35014417	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.521	rs329232	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35015339	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs329233	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35016219	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs329234	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35016268	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs329235	ENSG00000255583.2	RP11-415I12.2	-6.45	1.49e-09	0.00671	-0.53	-0.47	Diastolic blood pressure;	chr7:35016554	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs329236	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35016654	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs6963995	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35018737	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs329240	ENSG00000255583.2	RP11-415I12.2	-6.45	1.49e-09	0.00671	-0.53	-0.47	Diastolic blood pressure;	chr7:35018828	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs329243	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35020104	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs10265125	ENSG00000255583.2	RP11-415I12.2	6.45	1.49e-09	0.00671	0.53	0.47	Diastolic blood pressure;	chr7:35021524	chr12:63682523~63724935:-
PCPG	trans	rs3779195	0.591	rs77968419	ENSG00000225169.1	BRI3P1	-6.45	1.49e-09	0.00672	-0.73	-0.47	Sex hormone-binding globulin levels;	chr7:98237168	chr1:100213293~100213670:+
PCPG	trans	rs6477998	0.58	rs10817467	ENSG00000238072.1	RP11-305M3.2	6.44	1.49e-09	0.00674	0.74	0.47	Hematology traits;	chr9:113246803	chr7:129410113~129410370:-
PCPG	trans	rs5022636	0.891	rs4971027	ENSG00000180764.13	PIPSL	6.44	1.49e-09	0.00674	0.54	0.47	Gut microbiota (functional units);	chr1:151277945	chr10:93958191~93961540:-
PCPG	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	6.44	1.5e-09	0.00676	0.61	0.47	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	6.44	1.5e-09	0.00676	0.61	0.47	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	6.44	1.5e-09	0.00676	0.61	0.47	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
PCPG	trans	rs13190036	1	rs6889220	ENSG00000228305.2	AC016734.2	6.44	1.5e-09	0.00676	0.79	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr2:63622178~63622831:-
PCPG	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-6.44	1.51e-09	0.00678	-0.62	-0.47	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
PCPG	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-6.44	1.51e-09	0.00678	-0.79	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
PCPG	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	6.44	1.51e-09	0.00679	0.53	0.47	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
PCPG	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	6.44	1.52e-09	0.00684	0.51	0.47	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
PCPG	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	6.44	1.52e-09	0.00686	0.66	0.47	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
PCPG	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-6.44	1.53e-09	0.00687	-0.42	-0.47	Longevity;	chr3:48445369	chr1:27649419~27649610:+
PCPG	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	6.43	1.58e-09	0.00706	0.73	0.47	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
PCPG	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	6.43	1.58e-09	0.00708	0.64	0.47	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	6.43	1.58e-09	0.00708	0.64	0.47	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	6.43	1.58e-09	0.00708	0.64	0.47	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	6.43	1.58e-09	0.00708	0.64	0.47	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
PCPG	trans	rs336284	0.502	rs9692057	ENSG00000255583.2	RP11-415I12.2	6.43	1.59e-09	0.00712	0.51	0.46	Suicide behavior;Suicide;	chr7:35306101	chr12:63682523~63724935:-
PCPG	trans	rs1045902	0.537	rs1018342	ENSG00000236165.1	PRADC1P1	6.43	1.6e-09	0.00713	0.63	0.46	Intelligence (multi-trait analysis);	chr2:73244525	chr3:36976316~36976840:+
PCPG	trans	rs4276421	0.776	rs56908114	ENSG00000231752.4	EMBP1	6.43	1.6e-09	0.00713	0.6	0.46	P wave duration;	chr5:45416692	chr1:121519112~121571892:+
PCPG	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-6.43	1.62e-09	0.00723	-0.55	-0.46	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
PCPG	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-6.43	1.63e-09	0.00727	-0.53	-0.46	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
PCPG	trans	rs3206736	0.549	rs10282424	ENSG00000255583.2	RP11-415I12.2	-6.43	1.63e-09	0.00728	-0.54	-0.46	Diastolic blood pressure;	chr7:35171523	chr12:63682523~63724935:-
PCPG	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	6.43	1.63e-09	0.00729	0.58	0.46	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
PCPG	trans	rs6477998	0.58	rs7851623	ENSG00000238072.1	RP11-305M3.2	6.43	1.63e-09	0.00729	0.74	0.46	Hematology traits;	chr9:113240285	chr7:129410113~129410370:-
PCPG	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-6.43	1.65e-09	0.00734	-0.6	-0.46	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	6.42	1.65e-09	0.00737	0.55	0.46	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
PCPG	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	6.42	1.66e-09	0.00739	0.66	0.46	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
PCPG	trans	rs13190036	0.901	rs28563911	ENSG00000228305.2	AC016734.2	6.42	1.66e-09	0.00741	0.8	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr2:63622178~63622831:-
PCPG	trans	rs7819412	0.838	rs3021494	ENSG00000253893.2	FAM85B	6.42	1.69e-09	0.00751	0.61	0.46	Triglycerides;	chr8:11126024	chr8:8167819~8226614:-
PCPG	trans	rs9876781	0.874	rs56298324	ENSG00000225528.1	RP3-370M22.8	6.42	1.69e-09	0.00755	0.54	0.46	Longevity;	chr3:48393626	chr22:39960397~39964683:+
PCPG	trans	rs9876781	1	rs7635522	ENSG00000225528.1	RP3-370M22.8	-6.42	1.7e-09	0.00756	-0.53	-0.46	Longevity;	chr3:48382166	chr22:39960397~39964683:+
PCPG	trans	rs7047415	1	rs7047415	ENSG00000262902.1	RP11-750B16.1	6.42	1.7e-09	0.00757	0.6	0.46	Alzheimer disease and age of onset;	chr9:95778950	chr17:53105734~53106358:+
PCPG	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	6.42	1.7e-09	0.00758	0.71	0.46	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
PCPG	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	6.42	1.71e-09	0.00759	0.55	0.46	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
PCPG	trans	rs1958078	1	rs1958078	ENSG00000266538.1	RP11-385D13.3	-6.41	1.74e-09	0.00773	-0.64	-0.46	Red cell distribution width;Mean corpuscular hemoglobin;	chr14:69888141	chr17:15530773~15531089:-
PCPG	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-6.41	1.76e-09	0.00783	-0.68	-0.46	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
PCPG	trans	rs10820904	1	rs12336034	ENSG00000249780.1	RP11-352E6.2	6.41	1.77e-09	0.00787	1.08	0.46	Body mass index;	chr9:91805553	chr4:12640298~12640637:-
PCPG	trans	rs7647973	0.961	rs11130186	ENSG00000197582.5	GPX1P1	6.41	1.78e-09	0.00789	0.67	0.46	Menarche (age at onset);	chr3:49238395	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.961	rs10154992	ENSG00000197582.5	GPX1P1	6.41	1.78e-09	0.00789	0.67	0.46	Menarche (age at onset);	chr3:49238644	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.961	rs4955443	ENSG00000197582.5	GPX1P1	6.41	1.78e-09	0.00789	0.67	0.46	Menarche (age at onset);	chr3:49249185	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.925	rs4384984	ENSG00000197582.5	GPX1P1	6.41	1.78e-09	0.00789	0.67	0.46	Menarche (age at onset);	chr3:49252445	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.961	rs4955417	ENSG00000197582.5	GPX1P1	6.41	1.78e-09	0.00789	0.67	0.46	Menarche (age at onset);	chr3:49260772	chrX:13378735~13379340:-
PCPG	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	6.41	1.79e-09	0.00793	0.72	0.46	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
PCPG	trans	rs4276421	0.805	rs6451810	ENSG00000231752.4	EMBP1	6.41	1.8e-09	0.00797	0.62	0.46	P wave duration;	chr5:45633898	chr1:121519112~121571892:+
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	6.41	1.8e-09	0.00799	0.57	0.46	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
PCPG	trans	rs4276421	0.837	rs2580260	ENSG00000231752.4	EMBP1	6.41	1.82e-09	0.00804	0.62	0.46	P wave duration;	chr5:45638527	chr1:121519112~121571892:+
PCPG	trans	rs4606360	1	rs4606360	ENSG00000213331.4	RP11-713C19.2	6.41	1.82e-09	0.00805	0.55	0.46	Subjective well-being;	chr1:173729868	chr4:187970273~187971284:+
PCPG	trans	rs11099942	0.826	rs10517588	ENSG00000232573.1	RPL3P4	-6.41	1.82e-09	0.00807	-0.71	-0.46	Type 2 diabetes (age of onset);	chr4:154190587	chr14:98972879~98973301:-
PCPG	trans	rs38864	1	rs153016	ENSG00000262902.1	RP11-750B16.1	6.4	1.85e-09	0.00816	0.76	0.46	Colonoscopy-negative controls vs population controls;	chr7:117175457	chr17:53105734~53106358:+
PCPG	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	6.4	1.85e-09	0.00816	0.65	0.46	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	6.4	1.85e-09	0.00816	0.65	0.46	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
PCPG	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-6.4	1.86e-09	0.00821	-0.42	-0.46	Longevity;	chr3:48442021	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-6.4	1.86e-09	0.00821	-0.42	-0.46	Longevity;	chr3:48442035	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-6.4	1.86e-09	0.00821	-0.42	-0.46	Longevity;	chr3:48443151	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-6.4	1.86e-09	0.00821	-0.42	-0.46	Longevity;	chr3:48443275	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-6.4	1.86e-09	0.00821	-0.42	-0.46	Longevity;	chr3:48445934	chr1:27649419~27649610:+
PCPG	trans	rs10940346	0.601	rs13175165	ENSG00000231752.4	EMBP1	-6.4	1.87e-09	0.00823	-0.6	-0.46	Schizophrenia;	chr5:50151463	chr1:121519112~121571892:+
PCPG	trans	rs7647973	0.961	rs11130187	ENSG00000197582.5	GPX1P1	6.4	1.87e-09	0.00825	0.67	0.46	Menarche (age at onset);	chr3:49270439	chrX:13378735~13379340:-
PCPG	trans	rs3206736	0.548	rs1649221	ENSG00000255583.2	RP11-415I12.2	6.4	1.88e-09	0.00829	0.53	0.46	Diastolic blood pressure;	chr7:34948146	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs1649224	ENSG00000255583.2	RP11-415I12.2	6.4	1.88e-09	0.00829	0.53	0.46	Diastolic blood pressure;	chr7:34951384	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.529	rs1649225	ENSG00000255583.2	RP11-415I12.2	6.4	1.88e-09	0.00829	0.53	0.46	Diastolic blood pressure;	chr7:34952064	chr12:63682523~63724935:-
PCPG	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-6.4	1.89e-09	0.00834	-0.54	-0.46	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-6.4	1.89e-09	0.00834	-0.54	-0.46	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-6.4	1.89e-09	0.00834	-0.54	-0.46	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
PCPG	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-6.4	1.9e-09	0.00836	-0.55	-0.46	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
PCPG	trans	rs80208956	1	rs11263527	ENSG00000262902.1	RP11-750B16.1	6.4	1.9e-09	0.00837	0.74	0.46	Major depressive disorder;	chr11:69665423	chr17:53105734~53106358:+
PCPG	trans	rs7121616	0.733	rs10790554	ENSG00000234176.1	HSPA8P1	6.4	1.91e-09	0.00838	0.5	0.46	Breast cancer;	chr11:123130376	chrX:121203182~121205014:-
PCPG	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-6.4	1.91e-09	0.0084	-0.43	-0.46	Longevity;	chr3:48402409	chr1:27649419~27649610:+
PCPG	trans	rs12709013	0.716	rs6416775	ENSG00000230849.2	GOT2P2	6.4	1.92e-09	0.00843	0.57	0.46	Blood metabolite ratios;	chr16:58830410	chr1:173141100~173142350:-
PCPG	trans	rs73108077	0.736	rs6119276	ENSG00000279352.1	RP11-411B10.7	6.39	1.93e-09	0.00849	0.82	0.46	Red blood cell density in sickle cell anemia;	chr20:31363733	chr18:14010054~14010917:+
PCPG	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-6.39	1.95e-09	0.00857	-0.55	-0.46	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
PCPG	trans	rs4276421	0.837	rs6893773	ENSG00000231752.4	EMBP1	6.39	1.97e-09	0.00862	0.62	0.46	P wave duration;	chr5:45622394	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-6.39	1.97e-09	0.00862	-0.62	-0.46	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
PCPG	trans	rs7819412	0.807	rs4840542	ENSG00000253893.2	FAM85B	6.39	1.97e-09	0.00863	0.63	0.46	Triglycerides;	chr8:11087299	chr8:8167819~8226614:-
PCPG	trans	rs713587	1	rs713587	ENSG00000274010.1	RP5-935K16.2	-6.39	1.97e-09	0.00863	-0.57	-0.46	Body mass index in non-asthmatics;	chr2:24935412	chr2:127840606~127841763:-
PCPG	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-6.39	2.01e-09	0.00877	-0.55	-0.46	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-6.39	2.01e-09	0.00877	-0.55	-0.46	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
PCPG	trans	rs6732160	0.967	rs6760964	ENSG00000236165.1	PRADC1P1	6.39	2.03e-09	0.00886	0.57	0.46	Intelligence (multi-trait analysis);	chr2:73160258	chr3:36976316~36976840:+
PCPG	trans	rs9467773	0.836	rs1624440	ENSG00000242375.1	RP11-498P14.3	-6.39	2.03e-09	0.00886	-0.6	-0.46	Intelligence (multi-trait analysis);	chr6:26433101	chr9:97195351~97197687:-
PCPG	trans	rs4276421	0.869	rs2879074	ENSG00000231752.4	EMBP1	6.38	2.03e-09	0.00887	0.63	0.46	P wave duration;	chr5:45716107	chr1:121519112~121571892:+
PCPG	trans	rs3206736	0.548	rs7779894	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35021897	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs10243141	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35022954	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs57315957	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35023207	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs10278195	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35024847	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs17793874	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35025946	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs59505449	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35026240	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs73110554	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35026919	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs73110557	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35028445	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs17793929	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35029368	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs73110562	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35030311	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs10254796	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35031323	chr12:63682523~63724935:-
PCPG	trans	rs3206736	0.548	rs1559959	ENSG00000255583.2	RP11-415I12.2	6.38	2.03e-09	0.00887	0.53	0.46	Diastolic blood pressure;	chr7:35034755	chr12:63682523~63724935:-
PCPG	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-6.38	2.04e-09	0.00891	-0.41	-0.46	Longevity;	chr3:48421052	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-6.38	2.04e-09	0.00891	-0.41	-0.46	Longevity;	chr3:48422302	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-6.38	2.04e-09	0.00891	-0.41	-0.46	Longevity;	chr3:48429347	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-6.38	2.04e-09	0.00891	-0.41	-0.46	Longevity;	chr3:48431794	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-6.38	2.04e-09	0.00891	-0.41	-0.46	Longevity;	chr3:48437629	chr1:27649419~27649610:+
PCPG	trans	rs9650657	0.529	rs10108618	ENSG00000253893.2	FAM85B	6.38	2.05e-09	0.00892	0.62	0.46	Neuroticism;	chr8:11095582	chr8:8167819~8226614:-
PCPG	trans	rs9329221	0.617	rs483916	ENSG00000253893.2	FAM85B	6.38	2.05e-09	0.00894	0.57	0.46	Neuroticism;	chr8:9936091	chr8:8167819~8226614:-
PCPG	trans	rs10820904	1	rs3802380	ENSG00000249780.1	RP11-352E6.2	6.38	2.07e-09	0.009	1.05	0.46	Body mass index;	chr9:91804610	chr4:12640298~12640637:-
PCPG	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	6.38	2.09e-09	0.0091	0.69	0.46	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
PCPG	trans	rs3779195	0.929	rs4268041	ENSG00000225169.1	BRI3P1	-6.38	2.1e-09	0.00913	-0.69	-0.46	Sex hormone-binding globulin levels;	chr7:98376226	chr1:100213293~100213670:+
PCPG	trans	rs11098499	0.691	rs10028773	ENSG00000275858.1	RP11-291L22.8	-6.38	2.1e-09	0.00914	-0.59	-0.46	Corneal astigmatism;	chr4:119344104	chr10:38450738~38451069:-
PCPG	trans	rs79740699	1	rs971556	ENSG00000239830.1	RPS4XP22	6.38	2.12e-09	0.00923	1.17	0.46	Loneliness (multivariate analysis);	chr4:27325479	chr19:9683294~9684073:-
PCPG	trans	rs7811142	1	rs7803454	ENSG00000228546.2	CTA-313A17.3	6.38	2.13e-09	0.00926	0.75	0.46	Platelet count;	chr7:100393925	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.943	rs11769886	ENSG00000228546.2	CTA-313A17.3	6.38	2.13e-09	0.00926	0.75	0.46	Platelet count;	chr7:100400984	chr7:102337316~102339115:+
PCPG	trans	rs7647973	1	rs1464569	ENSG00000197582.5	GPX1P1	6.38	2.13e-09	0.00927	0.66	0.46	Menarche (age at onset);	chr3:49422917	chrX:13378735~13379340:-
PCPG	trans	rs7811142	1	rs6972167	ENSG00000228546.2	CTA-313A17.3	6.38	2.13e-09	0.00928	0.71	0.46	Platelet count;	chr7:100482390	chr7:102337316~102339115:+
PCPG	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-6.37	2.16e-09	0.00937	-0.68	-0.46	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-6.37	2.16e-09	0.00937	-0.68	-0.46	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-6.37	2.16e-09	0.00937	-0.68	-0.46	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-6.37	2.16e-09	0.00937	-0.68	-0.46	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-6.37	2.16e-09	0.00937	-0.68	-0.46	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
PCPG	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	6.37	2.17e-09	0.00941	0.72	0.46	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
PCPG	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-6.37	2.18e-09	0.00944	-0.58	-0.46	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
PCPG	trans	rs9611565	1	rs1109151	ENSG00000268568.1	AC007228.9	-6.37	2.18e-09	0.00946	-0.53	-0.46	Vitiligo;	chr22:41356940	chr19:56672574~56673901:-
PCPG	trans	rs7811142	1	rs7783159	ENSG00000228546.2	CTA-313A17.3	6.37	2.19e-09	0.0095	0.8	0.46	Platelet count;	chr7:100419831	chr7:102337316~102339115:+
PCPG	trans	rs3779195	0.585	rs7777991	ENSG00000225169.1	BRI3P1	-6.37	2.22e-09	0.0096	-0.72	-0.46	Sex hormone-binding globulin levels;	chr7:98236445	chr1:100213293~100213670:+
PCPG	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	6.37	2.23e-09	0.00963	0.72	0.46	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	6.37	2.23e-09	0.00963	0.72	0.46	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
PCPG	trans	rs3206736	0.548	rs2108690	ENSG00000255583.2	RP11-415I12.2	6.37	2.23e-09	0.00965	0.54	0.46	Diastolic blood pressure;	chr7:35043197	chr12:63682523~63724935:-
PCPG	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	6.37	2.24e-09	0.00966	0.78	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
PCPG	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	6.37	2.24e-09	0.00968	0.67	0.46	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.826	rs9834535	ENSG00000197582.5	GPX1P1	6.37	2.24e-09	0.00968	0.67	0.46	Menarche (age at onset);	chr3:49341364	chrX:13378735~13379340:-
PCPG	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	6.37	2.25e-09	0.0097	0.74	0.46	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
PCPG	trans	rs950169	0.96	rs35159785	ENSG00000259295.5	CSPG4P12	6.37	2.25e-09	0.00971	0.73	0.46	Schizophrenia;	chr15:84135262	chr15:85191438~85213905:+
PCPG	trans	rs66486766	1	rs66486766	ENSG00000259295.5	CSPG4P12	6.37	2.25e-09	0.00971	0.73	0.46	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:85191438~85213905:+
PCPG	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	6.36	2.25e-09	0.00972	0.63	0.46	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	6.36	2.26e-09	0.00974	0.57	0.46	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
PCPG	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	6.36	2.26e-09	0.00975	0.43	0.46	Longevity;	chr3:48407507	chr1:27649419~27649610:+
PCPG	trans	rs9650657	0.504	rs10108347	ENSG00000253893.2	FAM85B	6.36	2.27e-09	0.00979	0.58	0.46	Neuroticism;	chr8:11176008	chr8:8167819~8226614:-
PCPG	trans	rs9650657	0.504	rs10109167	ENSG00000253893.2	FAM85B	6.36	2.27e-09	0.00979	0.58	0.46	Neuroticism;	chr8:11176016	chr8:8167819~8226614:-
PCPG	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	6.36	2.27e-09	0.0098	0.6	0.46	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	6.36	2.27e-09	0.0098	0.6	0.46	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	6.36	2.27e-09	0.0098	0.6	0.46	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	6.36	2.27e-09	0.0098	0.6	0.46	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	6.36	2.27e-09	0.0098	0.6	0.46	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	6.36	2.3e-09	0.00988	0.61	0.46	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
PCPG	trans	rs656319	0.629	rs10111315	ENSG00000253893.2	FAM85B	6.36	2.31e-09	0.00994	0.59	0.46	Myopia (pathological);	chr8:10008078	chr8:8167819~8226614:-
PCPG	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-6.36	2.31e-09	0.00995	-0.59	-0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
PCPG	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	6.36	2.31e-09	0.00996	0.54	0.46	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
PCPG	trans	rs7809615	0.515	rs3843540	ENSG00000225972.1	MTND1P23	6.36	2.33e-09	0.01	0.57	0.46	Blood metabolite ratios;	chr7:99529017	chr1:629062~629433:+
PCPG	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	6.36	2.33e-09	0.01	0.54	0.46	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
PCPG	trans	rs7811142	1	rs73161762	ENSG00000228546.2	CTA-313A17.3	6.36	2.34e-09	0.0101	0.79	0.46	Platelet count;	chr7:100417223	chr7:102337316~102339115:+
PCPG	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	6.36	2.34e-09	0.0101	0.59	0.46	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	6.36	2.35e-09	0.0101	0.63	0.46	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
PCPG	trans	rs9467773	0.869	rs742090	ENSG00000242375.1	RP11-498P14.3	-6.35	2.37e-09	0.0102	-0.6	-0.46	Intelligence (multi-trait analysis);	chr6:26415409	chr9:97195351~97197687:-
PCPG	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	6.35	2.37e-09	0.0102	0.62	0.46	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	6.35	2.38e-09	0.0102	0.63	0.46	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	6.35	2.38e-09	0.0102	0.63	0.46	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	6.35	2.38e-09	0.0102	0.63	0.46	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
PCPG	trans	rs7824557	0.547	rs2409749	ENSG00000253893.2	FAM85B	6.35	2.38e-09	0.0102	0.61	0.46	Retinal vascular caliber;	chr8:11221440	chr8:8167819~8226614:-
PCPG	trans	rs7258465	1	rs34010330	ENSG00000267533.1	RP11-815J4.7	6.35	2.39e-09	0.0102	0.57	0.46	Breast cancer;	chr19:18448847	chr18:12067173~12068417:-
PCPG	trans	rs61990749	1	rs61990749	ENSG00000235400.1	RP4-641G12.4	-6.35	2.39e-09	0.0103	-0.94	-0.46	Fibroblast growth factor basic levels;	chr14:77906158	chr1:78749073~78750659:+
PCPG	trans	rs7047415	1	rs7873723	ENSG00000225972.1	MTND1P23	6.35	2.41e-09	0.0103	0.63	0.46	Alzheimer disease and age of onset;	chr9:95781475	chr1:629062~629433:+
PCPG	trans	rs10940346	0.807	rs6898102	ENSG00000231752.4	EMBP1	-6.35	2.42e-09	0.0104	-0.62	-0.46	Schizophrenia;	chr5:50578496	chr1:121519112~121571892:+
PCPG	trans	rs7809615	0.551	rs952319	ENSG00000228834.1	RP11-249L21.4	6.35	2.48e-09	0.0106	0.69	0.46	Blood metabolite ratios;	chr7:99573826	chr6:108907615~108907873:-
PCPG	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-6.35	2.48e-09	0.0106	-0.42	-0.46	Longevity;	chr3:48414217	chr1:27649419~27649610:+
PCPG	trans	rs10940346	0.54	rs12521033	ENSG00000231752.4	EMBP1	-6.35	2.49e-09	0.0106	-0.6	-0.46	Schizophrenia;	chr5:50145974	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs12188257	ENSG00000231752.4	EMBP1	-6.35	2.49e-09	0.0106	-0.6	-0.46	Schizophrenia;	chr5:50147242	chr1:121519112~121571892:+
PCPG	trans	rs4349753	0.553	rs11741991	ENSG00000250325.1	IGBP1P4	6.34	2.51e-09	0.0107	0.69	0.46	Photic sneeze reflex;	chr5:144956360	chr4:82401578~82402456:-
PCPG	trans	rs4349753	0.574	rs11739803	ENSG00000250325.1	IGBP1P4	6.34	2.51e-09	0.0107	0.69	0.46	Photic sneeze reflex;	chr5:144956428	chr4:82401578~82402456:-
PCPG	trans	rs4349753	0.574	rs11739807	ENSG00000250325.1	IGBP1P4	6.34	2.51e-09	0.0107	0.69	0.46	Photic sneeze reflex;	chr5:144956443	chr4:82401578~82402456:-
PCPG	trans	rs4512344	0.509	rs2409784	ENSG00000253893.2	FAM85B	6.34	2.54e-09	0.0108	0.56	0.46	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:8167819~8226614:-
PCPG	trans	rs6732160	0.932	rs768851	ENSG00000236165.1	PRADC1P1	6.34	2.55e-09	0.0109	0.58	0.46	Intelligence (multi-trait analysis);	chr2:73151113	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.934	rs2421390	ENSG00000236165.1	PRADC1P1	6.34	2.55e-09	0.0109	0.58	0.46	Intelligence (multi-trait analysis);	chr2:73151975	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.932	rs6546802	ENSG00000236165.1	PRADC1P1	6.34	2.55e-09	0.0109	0.58	0.46	Intelligence (multi-trait analysis);	chr2:73152436	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.932	rs13417029	ENSG00000236165.1	PRADC1P1	6.34	2.55e-09	0.0109	0.58	0.46	Intelligence (multi-trait analysis);	chr2:73153295	chr3:36976316~36976840:+
PCPG	trans	rs6732160	0.932	rs6546803	ENSG00000236165.1	PRADC1P1	6.34	2.55e-09	0.0109	0.58	0.46	Intelligence (multi-trait analysis);	chr2:73154187	chr3:36976316~36976840:+
PCPG	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	6.34	2.55e-09	0.0109	0.63	0.46	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
PCPG	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	6.34	2.57e-09	0.0109	0.52	0.46	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.874	rs13123591	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119184835	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs9995277	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119187448	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs17839089	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119189914	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs6826823	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119190943	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs12509054	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119193920	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs10022508	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119194073	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs12502503	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119195100	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs6851169	ENSG00000275858.1	RP11-291L22.8	6.34	2.58e-09	0.011	0.62	0.46	Corneal astigmatism;	chr4:119196355	chr10:38450738~38451069:-
PCPG	trans	rs9467773	0.869	rs1796521	ENSG00000242375.1	RP11-498P14.3	-6.34	2.6e-09	0.0111	-0.61	-0.46	Intelligence (multi-trait analysis);	chr6:26421164	chr9:97195351~97197687:-
PCPG	trans	rs10028773	0.632	rs34481394	ENSG00000275858.1	RP11-291L22.8	6.34	2.61e-09	0.0111	0.6	0.46	Educational attainment;	chr4:119327219	chr10:38450738~38451069:-
PCPG	trans	rs10028773	0.666	rs35231872	ENSG00000275858.1	RP11-291L22.8	6.34	2.61e-09	0.0111	0.6	0.46	Educational attainment;	chr4:119327221	chr10:38450738~38451069:-
PCPG	trans	rs10028773	0.7	rs35653026	ENSG00000275858.1	RP11-291L22.8	6.34	2.61e-09	0.0111	0.6	0.46	Educational attainment;	chr4:119327223	chr10:38450738~38451069:-
PCPG	trans	rs12497850	0.931	rs1134591	ENSG00000197582.5	GPX1P1	6.34	2.61e-09	0.0111	0.61	0.46	Parkinson's disease;	chr3:48935459	chrX:13378735~13379340:-
PCPG	trans	rs3206736	0.548	rs1186721	ENSG00000255583.2	RP11-415I12.2	6.33	2.66e-09	0.0113	0.51	0.46	Diastolic blood pressure;	chr7:34934990	chr12:63682523~63724935:-
PCPG	trans	rs291096	0.709	rs12121499	ENSG00000236811.1	GAPDHP2	-6.33	2.68e-09	0.0114	-0.52	-0.46	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206907220	chr20:13392677~13393674:+
PCPG	trans	rs291096	0.647	rs12124035	ENSG00000236811.1	GAPDHP2	-6.33	2.68e-09	0.0114	-0.52	-0.46	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206907283	chr20:13392677~13393674:+
PCPG	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	6.33	2.69e-09	0.0114	0.61	0.46	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
PCPG	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	6.33	2.69e-09	0.0114	0.57	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
PCPG	trans	rs7819412	0.749	rs11991118	ENSG00000253893.2	FAM85B	-6.33	2.7e-09	0.0114	-0.65	-0.46	Triglycerides;	chr8:11081763	chr8:8167819~8226614:-
PCPG	trans	rs7647973	1	rs6774724	ENSG00000197582.5	GPX1P1	6.33	2.7e-09	0.0114	0.67	0.46	Menarche (age at onset);	chr3:49344478	chrX:13378735~13379340:-
PCPG	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48384185	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48384586	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48385276	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48385757	chr1:27649419~27649610:+
PCPG	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48386489	chr1:27649419~27649610:+
PCPG	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48387420	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48388977	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-6.33	2.7e-09	0.0115	-0.43	-0.46	Longevity;	chr3:48389129	chr1:27649419~27649610:+
PCPG	trans	rs4660306	1	rs2356561	ENSG00000235823.1	OLMALINC	-6.33	2.71e-09	0.0115	-0.51	-0.46	Homocysteine levels;	chr1:45515190	chr10:100373615~100383368:+
PCPG	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	6.33	2.72e-09	0.0115	0.72	0.46	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
PCPG	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	6.33	2.72e-09	0.0115	0.72	0.46	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
PCPG	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	6.33	2.72e-09	0.0115	0.72	0.46	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
PCPG	trans	rs4660306	1	rs10736426	ENSG00000235823.1	OLMALINC	6.33	2.72e-09	0.0115	0.5	0.46	Homocysteine levels;	chr1:45518681	chr10:100373615~100383368:+
PCPG	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	6.33	2.72e-09	0.0115	0.58	0.46	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
PCPG	trans	rs7047415	1	rs7029315	ENSG00000225972.1	MTND1P23	-6.33	2.74e-09	0.0116	-0.64	-0.46	Alzheimer disease and age of onset;	chr9:95782630	chr1:629062~629433:+
PCPG	trans	rs11098499	0.874	rs7661020	ENSG00000275858.1	RP11-291L22.8	6.33	2.74e-09	0.0116	0.62	0.46	Corneal astigmatism;	chr4:119185827	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	6.33	2.75e-09	0.0116	0.59	0.46	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
PCPG	trans	rs1187256	0.63	rs1187258	ENSG00000280060.1	RP11-5G9.6	-6.33	2.75e-09	0.0116	-1.06	-0.46	Neuroticism;	chr18:37707127	chr13:43894725~43895182:-
PCPG	trans	rs7258465	1	rs8111708	ENSG00000267533.1	RP11-815J4.7	6.32	2.77e-09	0.0117	0.57	0.46	Breast cancer;	chr19:18448066	chr18:12067173~12068417:-
PCPG	trans	rs11098499	0.874	rs6832670	ENSG00000275858.1	RP11-291L22.8	6.32	2.78e-09	0.0117	0.62	0.46	Corneal astigmatism;	chr4:119197637	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.874	rs6822498	ENSG00000275858.1	RP11-291L22.8	6.32	2.78e-09	0.0117	0.62	0.46	Corneal astigmatism;	chr4:119199028	chr10:38450738~38451069:-
PCPG	trans	rs6732160	0.834	rs57456443	ENSG00000236165.1	PRADC1P1	6.32	2.79e-09	0.0118	0.58	0.46	Intelligence (multi-trait analysis);	chr2:73139313	chr3:36976316~36976840:+
PCPG	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-6.32	2.79e-09	0.0118	-0.61	-0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
PCPG	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	6.32	2.79e-09	0.0118	0.6	0.46	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
PCPG	trans	rs12497850	0.931	rs4974085	ENSG00000197582.5	GPX1P1	6.32	2.8e-09	0.0118	0.64	0.46	Parkinson's disease;	chr3:48887467	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs28642807	ENSG00000197582.5	GPX1P1	6.32	2.8e-09	0.0118	0.64	0.46	Parkinson's disease;	chr3:48889383	chrX:13378735~13379340:-
PCPG	trans	rs7047415	1	rs7873723	ENSG00000262902.1	RP11-750B16.1	6.32	2.81e-09	0.0118	0.6	0.46	Alzheimer disease and age of onset;	chr9:95781475	chr17:53105734~53106358:+
PCPG	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-6.32	2.82e-09	0.0119	-0.66	-0.46	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
PCPG	trans	rs291096	0.709	rs167082	ENSG00000236811.1	GAPDHP2	-6.32	2.86e-09	0.012	-0.52	-0.46	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206914090	chr20:13392677~13393674:+
PCPG	trans	rs291096	0.709	rs291083	ENSG00000236811.1	GAPDHP2	6.32	2.86e-09	0.012	0.52	0.46	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206913624	chr20:13392677~13393674:+
PCPG	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	6.32	2.87e-09	0.0121	0.64	0.46	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
PCPG	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	6.32	2.88e-09	0.0121	0.55	0.46	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
PCPG	trans	rs12497850	0.931	rs9311433	ENSG00000197582.5	GPX1P1	6.32	2.89e-09	0.0121	0.64	0.46	Parkinson's disease;	chr3:48826402	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs11924597	ENSG00000197582.5	GPX1P1	6.32	2.9e-09	0.0122	0.64	0.46	Parkinson's disease;	chr3:48900357	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs13064911	ENSG00000197582.5	GPX1P1	6.32	2.9e-09	0.0122	0.64	0.46	Parkinson's disease;	chr3:48914952	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.897	rs9884022	ENSG00000197582.5	GPX1P1	6.32	2.9e-09	0.0122	0.64	0.46	Parkinson's disease;	chr3:48919429	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.897	rs9850134	ENSG00000197582.5	GPX1P1	6.32	2.9e-09	0.0122	0.64	0.46	Parkinson's disease;	chr3:48919714	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs9867373	ENSG00000197582.5	GPX1P1	6.32	2.9e-09	0.0122	0.64	0.46	Parkinson's disease;	chr3:48923505	chrX:13378735~13379340:-
PCPG	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-6.31	2.92e-09	0.0122	-0.43	-0.46	Longevity;	chr3:48436629	chr1:27649419~27649610:+
PCPG	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	6.31	2.92e-09	0.0122	0.6	0.46	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
PCPG	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-6.31	2.94e-09	0.0123	-0.98	-0.46	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
PCPG	trans	rs3809095	0.753	rs56311489	ENSG00000229694.5	RP11-305L7.6	6.31	2.95e-09	0.0123	0.54	0.46	Total body bone mineral density;	chr11:16477588	chr9:91119062~91182762:+
PCPG	trans	rs4660306	1	rs1044717	ENSG00000235823.1	OLMALINC	-6.31	2.97e-09	0.0124	-0.5	-0.46	Homocysteine levels;	chr1:45510915	chr10:100373615~100383368:+
PCPG	trans	rs12497850	0.897	rs6781790	ENSG00000197582.5	GPX1P1	6.31	2.97e-09	0.0124	0.64	0.46	Parkinson's disease;	chr3:49007334	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs13316620	ENSG00000197582.5	GPX1P1	6.31	2.97e-09	0.0124	0.64	0.46	Parkinson's disease;	chr3:49007922	chrX:13378735~13379340:-
PCPG	trans	rs73108077	0.736	rs6058546	ENSG00000279352.1	RP11-411B10.7	6.31	2.99e-09	0.0125	0.83	0.46	Red blood cell density in sickle cell anemia;	chr20:31314582	chr18:14010054~14010917:+
PCPG	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	6.31	3.02e-09	0.0126	0.64	0.46	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
PCPG	trans	rs10940346	0.601	rs1033109	ENSG00000231752.4	EMBP1	6.31	3.02e-09	0.0126	0.59	0.46	Schizophrenia;	chr5:50327705	chr1:121519112~121571892:+
PCPG	trans	rs7811142	0.943	rs3900792	ENSG00000228546.2	CTA-313A17.3	6.31	3.03e-09	0.0127	0.72	0.46	Platelet count;	chr7:100406954	chr7:102337316~102339115:+
PCPG	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	6.31	3.04e-09	0.0127	0.52	0.46	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
PCPG	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	6.31	3.04e-09	0.0127	0.52	0.46	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
PCPG	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	6.31	3.04e-09	0.0127	0.52	0.46	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
PCPG	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	6.31	3.04e-09	0.0127	0.52	0.46	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
PCPG	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-6.31	3.04e-09	0.0127	-0.57	-0.46	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs13174293	ENSG00000231752.4	EMBP1	6.3	3.07e-09	0.0128	0.6	0.46	Schizophrenia;	chr5:50352191	chr1:121519112~121571892:+
PCPG	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-6.3	3.11e-09	0.0129	-0.8	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
PCPG	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
PCPG	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	6.3	3.12e-09	0.0129	0.51	0.46	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
PCPG	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	6.3	3.12e-09	0.0129	0.64	0.46	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
PCPG	trans	rs13190036	1	rs28580074	ENSG00000228305.2	AC016734.2	6.3	3.12e-09	0.0129	0.77	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr2:63622178~63622831:-
PCPG	trans	rs12497850	0.931	rs9311432	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48813010	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs9682444	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48815206	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs9835307	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48820372	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs9755490	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48834231	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.897	rs9681717	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48835565	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs7430501	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48852686	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs10780033	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48853842	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs9840684	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48856347	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.864	rs7431857	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48862914	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs4974079	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48869036	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.897	rs6446252	ENSG00000197582.5	GPX1P1	6.3	3.13e-09	0.0129	0.64	0.46	Parkinson's disease;	chr3:48873692	chrX:13378735~13379340:-
PCPG	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	6.3	3.16e-09	0.013	0.52	0.46	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
PCPG	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-6.3	3.18e-09	0.0131	-0.6	-0.46	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
PCPG	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	6.3	3.2e-09	0.0132	0.67	0.46	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
PCPG	trans	rs10940346	0.519	rs10940514	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50146166	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs10940533	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50146552	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs9688065	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50147444	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs4379243	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50149933	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.541	rs4865914	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50173322	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.54	rs2199089	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50199332	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.52	rs7293339	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50207465	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.607	rs8188210	ENSG00000231752.4	EMBP1	-6.29	3.22e-09	0.0132	-0.59	-0.46	Schizophrenia;	chr5:50211664	chr1:121519112~121571892:+
PCPG	trans	rs10141207	0.531	rs1547213	ENSG00000270933.1	CTD-2227E11.1	-6.29	3.23e-09	0.0132	-0.48	-0.46	Asthma;	chr14:32209440	chr7:25948657~25949403:-
PCPG	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
PCPG	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	6.29	3.23e-09	0.0132	0.51	0.46	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
PCPG	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	6.29	3.25e-09	0.0133	0.68	0.46	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
PCPG	trans	rs4276421	0.904	rs7444405	ENSG00000231752.4	EMBP1	6.29	3.31e-09	0.0135	0.6	0.46	P wave duration;	chr5:45915373	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	6.29	3.33e-09	0.0135	0.6	0.46	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
PCPG	trans	rs72627509	0.523	rs9637714	ENSG00000211716.2	TRBV9	-6.29	3.34e-09	0.0136	-0.62	-0.46	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56865280	chr7:142391891~142392412:+
PCPG	trans	rs7819412	0.875	rs6981523	ENSG00000253893.2	FAM85B	6.29	3.35e-09	0.0136	0.59	0.46	Triglycerides;	chr8:11204283	chr8:8167819~8226614:-
PCPG	trans	rs10940346	0.562	rs559096	ENSG00000231752.4	EMBP1	-6.29	3.36e-09	0.0136	-0.58	-0.46	Schizophrenia;	chr5:50226512	chr1:121519112~121571892:+
PCPG	trans	rs877636	0.702	rs773108	ENSG00000243403.1	RP11-330L19.1	6.28	3.41e-09	0.0138	0.55	0.46	Cognitive function;	chr12:55976127	chr15:64592979~64593326:+
PCPG	trans	rs7662987	0.793	rs12697	ENSG00000233859.2	ADH5P4	-6.28	3.43e-09	0.0139	-0.76	-0.46	Smoking initiation;	chr4:99072225	chr6:65836930~65838039:-
PCPG	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	6.28	3.44e-09	0.0139	0.67	0.46	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	6.28	3.44e-09	0.0139	0.67	0.46	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs1009051	ENSG00000197582.5	GPX1P1	6.28	3.44e-09	0.0139	0.67	0.46	Menarche (age at onset);	chr3:49484116	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs3870339	ENSG00000197582.5	GPX1P1	6.28	3.44e-09	0.0139	0.67	0.46	Menarche (age at onset);	chr3:49499430	chrX:13378735~13379340:-
PCPG	trans	rs7647973	1	rs3905330	ENSG00000197582.5	GPX1P1	6.28	3.44e-09	0.0139	0.67	0.46	Menarche (age at onset);	chr3:49513341	chrX:13378735~13379340:-
PCPG	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	6.28	3.46e-09	0.014	0.51	0.46	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	6.28	3.46e-09	0.014	0.51	0.46	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	6.28	3.46e-09	0.014	0.51	0.46	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	6.28	3.46e-09	0.014	0.51	0.46	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
PCPG	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	6.28	3.46e-09	0.014	0.51	0.46	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	6.28	3.46e-09	0.014	0.51	0.46	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
PCPG	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.64	0.46	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.58	0.46	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.58	0.46	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.58	0.46	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.58	0.46	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.58	0.46	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.58	0.46	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	6.28	3.47e-09	0.014	0.58	0.46	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
PCPG	trans	rs7819412	0.745	rs2898260	ENSG00000253893.2	FAM85B	6.28	3.48e-09	0.014	0.64	0.46	Triglycerides;	chr8:11081980	chr8:8167819~8226614:-
PCPG	trans	rs4660306	0.961	rs11211138	ENSG00000235823.1	OLMALINC	-6.28	3.48e-09	0.014	-0.49	-0.46	Homocysteine levels;	chr1:45549485	chr10:100373615~100383368:+
PCPG	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	6.28	3.52e-09	0.0142	0.58	0.46	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	6.28	3.52e-09	0.0142	0.58	0.46	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	6.28	3.52e-09	0.0142	0.58	0.46	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	6.28	3.52e-09	0.0142	0.58	0.46	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
PCPG	trans	rs596169	0.655	rs676386	ENSG00000232573.1	RPL3P4	-6.28	3.53e-09	0.0142	-0.65	-0.46	Intraocular pressure;	chr1:218938416	chr14:98972879~98973301:-
PCPG	trans	rs5022636	0.821	rs4246525	ENSG00000180764.13	PIPSL	6.28	3.55e-09	0.0142	0.51	0.46	Gut microbiota (functional units);	chr1:151285263	chr10:93958191~93961540:-
PCPG	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	6.28	3.55e-09	0.0143	0.58	0.46	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	6.27	3.6e-09	0.0144	0.58	0.46	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
PCPG	trans	rs10940346	0.601	rs5011669	ENSG00000231752.4	EMBP1	-6.27	3.61e-09	0.0145	-0.6	-0.46	Schizophrenia;	chr5:50311788	chr1:121519112~121571892:+
PCPG	trans	rs10820904	1	rs35357880	ENSG00000249780.1	RP11-352E6.2	6.27	3.62e-09	0.0145	1.08	0.46	Body mass index;	chr9:91806166	chr4:12640298~12640637:-
PCPG	trans	rs4276421	0.904	rs4388219	ENSG00000231752.4	EMBP1	6.27	3.63e-09	0.0145	0.63	0.46	P wave duration;	chr5:45780648	chr1:121519112~121571892:+
PCPG	trans	rs3206736	0.548	rs73110545	ENSG00000255583.2	RP11-415I12.2	6.27	3.66e-09	0.0147	0.52	0.46	Diastolic blood pressure;	chr7:35024182	chr12:63682523~63724935:-
PCPG	trans	rs344364	0.511	rs12599337	ENSG00000212961.4	HNRNPA1P40	-6.27	3.67e-09	0.0147	-0.67	-0.46	Glomerular filtration rate in chronic kidney disease;	chr16:1896750	chr11:74354443~74355720:+
PCPG	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-6.27	3.69e-09	0.0148	-0.58	-0.46	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
PCPG	trans	rs291096	0.617	rs12123998	ENSG00000236811.1	GAPDHP2	-6.27	3.7e-09	0.0148	-0.51	-0.46	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206907169	chr20:13392677~13393674:+
PCPG	trans	rs7702057	0.619	rs17139591	ENSG00000232573.1	RPL3P4	6.27	3.73e-09	0.0149	0.81	0.46	Amyotrophic lateral sclerosis;	chr5:116366604	chr14:98972879~98973301:-
PCPG	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-6.27	3.74e-09	0.015	-0.56	-0.46	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
PCPG	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	6.26	3.75e-09	0.015	0.51	0.46	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	6.26	3.75e-09	0.015	0.51	0.46	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
PCPG	trans	rs12497850	0.931	rs13315711	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48948966	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs7430198	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48951327	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs7636057	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48955149	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs7643368	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48955422	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.866	rs6791234	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48958704	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs6446196	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48967290	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.805	rs6446198	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48970205	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs7621015	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48978623	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs4072859	ENSG00000197582.5	GPX1P1	6.26	3.75e-09	0.015	0.63	0.46	Parkinson's disease;	chr3:48994772	chrX:13378735~13379340:-
PCPG	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-6.26	3.76e-09	0.015	-0.57	-0.46	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
PCPG	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-6.26	3.76e-09	0.015	-0.57	-0.46	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
PCPG	trans	rs12497850	0.931	rs9840050	ENSG00000197582.5	GPX1P1	6.26	3.78e-09	0.0151	0.62	0.46	Parkinson's disease;	chr3:49095877	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs62262517	ENSG00000197582.5	GPX1P1	6.26	3.78e-09	0.0151	0.62	0.46	Parkinson's disease;	chr3:49097481	chrX:13378735~13379340:-
PCPG	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	6.26	3.79e-09	0.0151	0.51	0.46	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	6.26	3.79e-09	0.0151	0.51	0.46	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	6.26	3.79e-09	0.0151	0.51	0.46	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
PCPG	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	6.26	3.79e-09	0.0151	0.51	0.46	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
PCPG	trans	rs4276421	0.837	rs7446182	ENSG00000231752.4	EMBP1	-6.26	3.8e-09	0.0151	-0.58	-0.46	P wave duration;	chr5:45401715	chr1:121519112~121571892:+
PCPG	trans	rs10242455	1	rs10242455	ENSG00000228834.1	RP11-249L21.4	-6.26	3.85e-09	0.0153	-0.77	-0.46	Blood metabolite levels;	chr7:99642556	chr6:108907615~108907873:-
PCPG	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-6.26	3.86e-09	0.0154	-0.59	-0.46	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
PCPG	trans	rs13253073	1	rs12550092	ENSG00000260318.1	COX6CP1	6.26	3.88e-09	0.0154	1.24	0.46	Glucose homeostasis traits;	chr8:99886954	chr16:11903923~11904137:-
PCPG	trans	rs7647973	0.922	rs6809851	ENSG00000197582.5	GPX1P1	6.26	3.89e-09	0.0154	0.65	0.45	Menarche (age at onset);	chr3:49272354	chrX:13378735~13379340:-
PCPG	trans	rs10028773	0.6	rs4001390	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Educational attainment;	chr4:119344628	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs2136911	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119344704	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.779	rs6815934	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119346155	chr10:38450738~38451069:-
PCPG	trans	rs10028773	0.568	rs6838457	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Educational attainment;	chr4:119346212	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.661	rs10015965	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119347082	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.535	rs10005542	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119347147	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	6.26	3.89e-09	0.0154	0.58	0.45	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
PCPG	trans	rs6473252	0.546	rs7816651	ENSG00000267092.2	CTB-25B13.9	-6.26	3.91e-09	0.0155	-0.57	-0.45	Breast cancer;	chr8:80910474	chr19:1508375~1508963:+
PCPG	trans	rs10940346	0.542	rs2219452	ENSG00000231752.4	EMBP1	-6.26	3.91e-09	0.0155	-0.58	-0.45	Schizophrenia;	chr5:50209813	chr1:121519112~121571892:+
PCPG	trans	rs7042889	1	rs75451763	ENSG00000225972.1	MTND1P23	6.26	3.92e-09	0.0155	0.71	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129033176	chr1:629062~629433:+
PCPG	trans	rs7042889	0.85	rs76503180	ENSG00000225972.1	MTND1P23	6.26	3.92e-09	0.0155	0.71	0.45	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr9:129033235	chr1:629062~629433:+
PCPG	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	6.26	3.93e-09	0.0155	0.53	0.45	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
PCPG	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	6.26	3.93e-09	0.0155	0.58	0.45	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	6.26	3.93e-09	0.0155	0.58	0.45	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
PCPG	trans	rs7647973	0.961	rs7619016	ENSG00000197582.5	GPX1P1	6.25	3.96e-09	0.0157	0.65	0.45	Menarche (age at onset);	chr3:49235156	chrX:13378735~13379340:-
PCPG	trans	rs7647973	0.961	rs7626076	ENSG00000197582.5	GPX1P1	6.25	3.96e-09	0.0157	0.65	0.45	Menarche (age at onset);	chr3:49260706	chrX:13378735~13379340:-
PCPG	trans	rs1542829	0.634	rs4688764	ENSG00000262902.1	RP11-750B16.1	6.25	3.97e-09	0.0157	0.58	0.45	Body mass index;	chr3:130441593	chr17:53105734~53106358:+
PCPG	trans	rs7702057	0.619	rs73263082	ENSG00000232573.1	RPL3P4	6.25	3.99e-09	0.0158	0.84	0.45	Amyotrophic lateral sclerosis;	chr5:116328329	chr14:98972879~98973301:-
PCPG	trans	rs7702057	0.619	rs79096984	ENSG00000232573.1	RPL3P4	6.25	3.99e-09	0.0158	0.84	0.45	Amyotrophic lateral sclerosis;	chr5:116328357	chr14:98972879~98973301:-
PCPG	trans	rs10940346	0.56	rs7293410	ENSG00000231752.4	EMBP1	-6.25	4e-09	0.0158	-0.58	-0.45	Schizophrenia;	chr5:50163036	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs4865801	ENSG00000231752.4	EMBP1	-6.25	4e-09	0.0158	-0.58	-0.45	Schizophrenia;	chr5:50163364	chr1:121519112~121571892:+
PCPG	trans	rs10242455	1	rs28468623	ENSG00000228834.1	RP11-249L21.4	6.25	4.03e-09	0.0159	0.95	0.45	Blood metabolite levels;	chr7:99325189	chr6:108907615~108907873:-
PCPG	trans	rs12497850	0.931	rs7626445	ENSG00000197582.5	GPX1P1	6.25	4.03e-09	0.0159	0.62	0.45	Parkinson's disease;	chr3:49077111	chrX:13378735~13379340:-
PCPG	trans	rs4276421	0.837	rs1483303	ENSG00000231752.4	EMBP1	6.25	4.04e-09	0.0159	0.6	0.45	P wave duration;	chr5:45571997	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.837	rs2696013	ENSG00000231752.4	EMBP1	6.25	4.04e-09	0.0159	0.6	0.45	P wave duration;	chr5:45603104	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.837	rs2337483	ENSG00000231752.4	EMBP1	6.25	4.04e-09	0.0159	0.6	0.45	P wave duration;	chr5:45608220	chr1:121519112~121571892:+
PCPG	trans	rs4276421	0.837	rs1384732	ENSG00000231752.4	EMBP1	6.25	4.06e-09	0.016	0.6	0.45	P wave duration;	chr5:45553285	chr1:121519112~121571892:+
PCPG	trans	rs74405815	0.681	rs4679285	ENSG00000248540.2	RP11-247C2.2	6.25	4.08e-09	0.0161	0.67	0.45	Response to paliperidone in schizophrenia (positive Marder score);	chr3:126719063	chr15:74125915~74129278:-
PCPG	trans	rs73099903	0.611	rs7957445	ENSG00000229939.1	RP11-111F16.2	6.25	4.1e-09	0.0161	0.5	0.45	Systolic blood pressure;	chr12:53014796	chrX:111618808~111619094:+
PCPG	trans	rs3809095	0.821	rs67150549	ENSG00000229694.5	RP11-305L7.6	6.25	4.13e-09	0.0162	0.53	0.45	Total body bone mineral density;	chr11:16507555	chr9:91119062~91182762:+
PCPG	trans	rs12497850	1	rs4858798	ENSG00000197582.5	GPX1P1	6.25	4.13e-09	0.0162	0.57	0.45	Parkinson's disease;	chr3:48689679	chrX:13378735~13379340:-
PCPG	trans	rs2826340	1	rs2826340	ENSG00000256948.1	RP11-598F7.3	-6.25	4.14e-09	0.0162	-0.54	-0.45	Attention deficit hyperactivity disorder and conduct disorder;	chr21:20512990	chr12:106524~111850:-
PCPG	trans	rs16984718	1	rs10153868	ENSG00000227155.6	RP11-165F24.3	-6.25	4.14e-09	0.0162	-0.94	-0.45	Urate levels in obese individuals;	chr2:18303387	chr9:452492~492248:-
PCPG	trans	rs616147	1	rs1768208	ENSG00000183298.5	RP11-556K13.1	-6.24	4.16e-09	0.0163	-0.64	-0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr1:101786340~101787219:-
PCPG	trans	rs7662987	0.793	rs12106	ENSG00000233859.2	ADH5P4	6.24	4.16e-09	0.0163	0.76	0.45	Smoking initiation;	chr4:99072199	chr6:65836930~65838039:-
PCPG	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	6.24	4.17e-09	0.0163	0.51	0.45	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
PCPG	trans	rs11098499	0.554	rs2175381	ENSG00000275858.1	RP11-291L22.8	6.24	4.21e-09	0.0165	0.58	0.45	Corneal astigmatism;	chr4:119344812	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.599	rs3864142	ENSG00000275858.1	RP11-291L22.8	6.24	4.21e-09	0.0165	0.58	0.45	Corneal astigmatism;	chr4:119345036	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	6.24	4.21e-09	0.0165	0.58	0.45	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
PCPG	trans	rs73108077	0.736	rs2376545	ENSG00000279352.1	RP11-411B10.7	6.24	4.29e-09	0.0168	0.83	0.45	Red blood cell density in sickle cell anemia;	chr20:31293314	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs13433373	ENSG00000279352.1	RP11-411B10.7	6.24	4.29e-09	0.0168	0.83	0.45	Red blood cell density in sickle cell anemia;	chr20:31296736	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.688	rs6061150	ENSG00000279352.1	RP11-411B10.7	6.24	4.29e-09	0.0168	0.83	0.45	Red blood cell density in sickle cell anemia;	chr20:31301527	chr18:14010054~14010917:+
PCPG	trans	rs10940346	0.601	rs6860503	ENSG00000231752.4	EMBP1	6.24	4.31e-09	0.0168	0.6	0.45	Schizophrenia;	chr5:50446340	chr1:121519112~121571892:+
PCPG	trans	rs10908521	0.685	rs1998977	ENSG00000227183.3	HDGFP1	-6.23	4.4e-09	0.0171	-0.54	-0.45	Uric acid clearance;	chr1:156834329	chrX:131646639~131646890:+
PCPG	trans	rs1045902	0.574	rs1053329	ENSG00000236165.1	PRADC1P1	6.23	4.42e-09	0.0172	0.62	0.45	Intelligence (multi-trait analysis);	chr2:73234355	chr3:36976316~36976840:+
PCPG	trans	rs10940346	0.601	rs13172932	ENSG00000231752.4	EMBP1	6.23	4.42e-09	0.0172	0.6	0.45	Schizophrenia;	chr5:50345364	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs12651834	ENSG00000231752.4	EMBP1	6.23	4.42e-09	0.0172	0.6	0.45	Schizophrenia;	chr5:50351199	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.668	rs6884426	ENSG00000231752.4	EMBP1	-6.23	4.42e-09	0.0172	-0.59	-0.45	Schizophrenia;	chr5:50492782	chr1:121519112~121571892:+
PCPG	trans	rs12497850	0.897	rs7373778	ENSG00000197582.5	GPX1P1	6.23	4.44e-09	0.0173	0.63	0.45	Parkinson's disease;	chr3:48798959	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs9876848	ENSG00000197582.5	GPX1P1	6.23	4.44e-09	0.0173	0.63	0.45	Parkinson's disease;	chr3:48806626	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.805	rs11130176	ENSG00000197582.5	GPX1P1	6.23	4.44e-09	0.0173	0.63	0.45	Parkinson's disease;	chr3:48806644	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs9311430	ENSG00000197582.5	GPX1P1	6.23	4.44e-09	0.0173	0.63	0.45	Parkinson's disease;	chr3:48807818	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	6.23	4.45e-09	0.0173	0.6	0.45	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
PCPG	trans	rs7662987	0.793	rs7669660	ENSG00000233859.2	ADH5P4	6.23	4.45e-09	0.0173	0.75	0.45	Smoking initiation;	chr4:99071451	chr6:65836930~65838039:-
PCPG	trans	rs4276421	0.869	rs1351720	ENSG00000231752.4	EMBP1	6.23	4.46e-09	0.0173	0.61	0.45	P wave duration;	chr5:45561801	chr1:121519112~121571892:+
PCPG	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-6.23	4.46e-09	0.0173	-0.57	-0.45	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
PCPG	trans	rs9876781	1	rs2362450	ENSG00000235912.1	RP1-159A19.3	-6.23	4.47e-09	0.0173	-0.41	-0.45	Longevity;	chr3:48419904	chr1:27649419~27649610:+
PCPG	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-6.23	4.47e-09	0.0173	-0.41	-0.45	Longevity;	chr3:48438208	chr1:27649419~27649610:+
PCPG	trans	rs7824557	0.507	rs7010590	ENSG00000253893.2	FAM85B	-6.23	4.49e-09	0.0174	-0.59	-0.45	Retinal vascular caliber;	chr8:11205373	chr8:8167819~8226614:-
PCPG	trans	rs336284	0.529	rs336283	ENSG00000255583.2	RP11-415I12.2	6.23	4.51e-09	0.0175	0.53	0.45	Suicide behavior;Suicide;	chr7:35253582	chr12:63682523~63724935:-
PCPG	trans	rs10940346	0.562	rs7380318	ENSG00000231752.4	EMBP1	-6.23	4.56e-09	0.0177	-0.58	-0.45	Schizophrenia;	chr5:50510557	chr1:121519112~121571892:+
PCPG	trans	rs1045902	0.532	rs2288631	ENSG00000236165.1	PRADC1P1	6.23	4.58e-09	0.0177	0.61	0.45	Intelligence (multi-trait analysis);	chr2:73228619	chr3:36976316~36976840:+
PCPG	trans	rs10940346	0.777	rs11744698	ENSG00000231752.4	EMBP1	-6.23	4.58e-09	0.0177	-0.61	-0.45	Schizophrenia;	chr5:50586024	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10940075	ENSG00000231752.4	EMBP1	-6.22	4.61e-09	0.0178	-0.57	-0.45	Schizophrenia;	chr5:50304547	chr1:121519112~121571892:+
PCPG	trans	rs8175379	0.506	rs10035927	ENSG00000231752.4	EMBP1	-6.22	4.69e-09	0.0181	-0.58	-0.45	Interleukin-7 levels;	chr5:46404107	chr1:121519112~121571892:+
PCPG	trans	rs596169	1	rs596169	ENSG00000232573.1	RPL3P4	-6.22	4.69e-09	0.0181	-0.65	-0.45	Intraocular pressure;	chr1:218974077	chr14:98972879~98973301:-
PCPG	trans	rs7662987	0.793	rs28730602	ENSG00000233859.2	ADH5P4	6.22	4.69e-09	0.0181	0.79	0.45	Smoking initiation;	chr4:99080531	chr6:65836930~65838039:-
PCPG	trans	rs10940346	0.601	rs57300567	ENSG00000231752.4	EMBP1	6.22	4.7e-09	0.0181	0.58	0.45	Schizophrenia;	chr5:50467359	chr1:121519112~121571892:+
PCPG	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	6.22	4.74e-09	0.0183	0.59	0.45	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
PCPG	trans	rs10940346	0.601	rs62365901	ENSG00000231752.4	EMBP1	6.22	4.76e-09	0.0183	0.58	0.45	Schizophrenia;	chr5:50434497	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs62365902	ENSG00000231752.4	EMBP1	6.22	4.76e-09	0.0183	0.58	0.45	Schizophrenia;	chr5:50434594	chr1:121519112~121571892:+
PCPG	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	6.22	4.81e-09	0.0185	0.62	0.45	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
PCPG	trans	rs7937890	0.904	rs67623158	ENSG00000236360.2	RP11-334A14.2	-6.22	4.81e-09	0.0185	-0.48	-0.45	Mitochondrial DNA levels;	chr11:14273650	chr1:52993201~52993702:-
PCPG	trans	rs12497850	1	rs6788650	ENSG00000197582.5	GPX1P1	6.21	4.86e-09	0.0187	0.58	0.45	Parkinson's disease;	chr3:48712110	chrX:13378735~13379340:-
PCPG	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-6.21	4.87e-09	0.0187	-0.54	-0.45	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-6.21	4.87e-09	0.0187	-0.54	-0.45	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-6.21	4.87e-09	0.0187	-0.54	-0.45	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
PCPG	trans	rs56281245	0.793	rs972351	ENSG00000276550.3	HERC2P2	6.21	4.89e-09	0.0188	0.76	0.45	Hepcidin levels;	chr5:145700777	chr15:22495570~22590815:+
PCPG	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	6.21	4.9e-09	0.0188	0.6	0.45	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	6.21	4.9e-09	0.0188	0.6	0.45	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
PCPG	trans	rs4660306	0.961	rs12145526	ENSG00000235823.1	OLMALINC	-6.21	4.9e-09	0.0188	-0.49	-0.45	Homocysteine levels;	chr1:45503364	chr10:100373615~100383368:+
PCPG	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-6.21	4.92e-09	0.0189	-0.54	-0.45	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
PCPG	trans	rs10242455	0.717	rs4646461	ENSG00000228834.1	RP11-249L21.4	6.21	4.93e-09	0.0189	1	0.45	Blood metabolite levels;	chr7:99733850	chr6:108907615~108907873:-
PCPG	trans	rs7937890	0.904	rs11023169	ENSG00000236360.2	RP11-334A14.2	-6.21	4.95e-09	0.019	-0.48	-0.45	Mitochondrial DNA levels;	chr11:14269439	chr1:52993201~52993702:-
PCPG	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	6.21	4.95e-09	0.019	0.59	0.45	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	6.21	4.95e-09	0.019	0.59	0.45	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
PCPG	trans	rs74781061	0.858	rs4887162	ENSG00000227288.3	RP5-837I24.1	6.21	4.97e-09	0.0191	0.61	0.45	Endometriosis;	chr15:74580159	chr1:81501794~81503468:+
PCPG	trans	rs74781061	0.929	rs4887163	ENSG00000227288.3	RP5-837I24.1	6.21	4.97e-09	0.0191	0.61	0.45	Endometriosis;	chr15:74580405	chr1:81501794~81503468:+
PCPG	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	6.21	4.98e-09	0.0191	0.62	0.45	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.897	rs7432989	ENSG00000197582.5	GPX1P1	6.21	4.98e-09	0.0191	0.62	0.45	Parkinson's disease;	chr3:49067703	chrX:13378735~13379340:-
PCPG	trans	rs10940346	0.601	rs4145844	ENSG00000231752.4	EMBP1	-6.21	5e-09	0.0191	-0.58	-0.45	Schizophrenia;	chr5:50478019	chr1:121519112~121571892:+
PCPG	trans	rs10908521	0.685	rs12746582	ENSG00000227183.3	HDGFP1	-6.21	5.02e-09	0.0192	-0.53	-0.45	Uric acid clearance;	chr1:156836231	chrX:131646639~131646890:+
PCPG	trans	rs3206736	0.548	rs1186716	ENSG00000255583.2	RP11-415I12.2	6.21	5.03e-09	0.0192	0.5	0.45	Diastolic blood pressure;	chr7:34931073	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.89	rs2075125	ENSG00000255583.2	RP11-415I12.2	6.21	5.04e-09	0.0193	0.5	0.45	Birth weight;	chr7:35261931	chr12:63682523~63724935:-
PCPG	trans	rs6959887	0.821	rs12536299	ENSG00000255583.2	RP11-415I12.2	6.21	5.04e-09	0.0193	0.5	0.45	Birth weight;	chr7:35262867	chr12:63682523~63724935:-
PCPG	trans	rs4669226	1	rs67079049	ENSG00000232031.1	RP5-991C6.4	-6.21	5.05e-09	0.0193	-1.07	-0.45	Multiple sclerosis;	chr2:7905163	chr6:81724722~81736353:-
PCPG	trans	rs80033912	0.64	rs6785832	ENSG00000197582.5	GPX1P1	6.21	5.07e-09	0.0194	0.67	0.45	Intelligence (multi-trait analysis);	chr3:49186883	chrX:13378735~13379340:-
PCPG	trans	rs5022636	0.929	rs7552906	ENSG00000180764.13	PIPSL	6.21	5.08e-09	0.0194	0.5	0.45	Gut microbiota (functional units);	chr1:151341298	chr10:93958191~93961540:-
PCPG	trans	rs74781061	0.929	rs4886601	ENSG00000227288.3	RP5-837I24.1	6.2	5.12e-09	0.0195	0.62	0.45	Endometriosis;	chr15:74591510	chr1:81501794~81503468:+
PCPG	trans	rs291096	0.678	rs1150253	ENSG00000236811.1	GAPDHP2	-6.2	5.13e-09	0.0196	-0.5	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206898250	chr20:13392677~13393674:+
PCPG	trans	rs291096	0.678	rs1150255	ENSG00000236811.1	GAPDHP2	-6.2	5.13e-09	0.0196	-0.5	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206899614	chr20:13392677~13393674:+
PCPG	trans	rs291096	0.678	rs1150256	ENSG00000236811.1	GAPDHP2	-6.2	5.13e-09	0.0196	-0.5	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206899788	chr20:13392677~13393674:+
PCPG	trans	rs1929412	1	rs1446252	ENSG00000262902.1	RP11-750B16.1	-6.2	5.13e-09	0.0196	-1.05	-0.45	Amyotrophic lateral sclerosis (sporadic);	chr9:12032774	chr17:53105734~53106358:+
PCPG	trans	rs9329221	0.62	rs6601427	ENSG00000253893.2	FAM85B	6.2	5.18e-09	0.0197	0.56	0.45	Neuroticism;	chr8:10298515	chr8:8167819~8226614:-
PCPG	trans	rs10940346	0.584	rs7293449	ENSG00000231752.4	EMBP1	-6.2	5.24e-09	0.0199	-0.58	-0.45	Schizophrenia;	chr5:50259959	chr1:121519112~121571892:+
PCPG	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	6.2	5.27e-09	0.02	0.62	0.45	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
PCPG	trans	rs55665837	0.54	rs3206554	ENSG00000236360.2	RP11-334A14.2	6.2	5.32e-09	0.0202	0.51	0.45	Vitamin D levels;	chr11:14776399	chr1:52993201~52993702:-
PCPG	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-6.2	5.32e-09	0.0202	-0.6	-0.45	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
PCPG	trans	rs12497850	0.931	rs7627404	ENSG00000197582.5	GPX1P1	6.19	5.37e-09	0.0204	0.63	0.45	Parkinson's disease;	chr3:48782235	chrX:13378735~13379340:-
PCPG	trans	rs5022636	0.927	rs10788803	ENSG00000180764.13	PIPSL	6.19	5.37e-09	0.0204	0.51	0.45	Gut microbiota (functional units);	chr1:151291306	chr10:93958191~93961540:-
PCPG	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-6.19	5.4e-09	0.0204	-0.63	-0.45	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
PCPG	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	6.19	5.41e-09	0.0205	0.69	0.45	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
PCPG	trans	rs55665837	0.54	rs10766192	ENSG00000236360.2	RP11-334A14.2	6.19	5.41e-09	0.0205	0.51	0.45	Vitamin D levels;	chr11:14790140	chr1:52993201~52993702:-
PCPG	trans	rs7824557	0.547	rs4512344	ENSG00000253893.2	FAM85B	6.19	5.42e-09	0.0205	0.6	0.45	Retinal vascular caliber;	chr8:11221272	chr8:8167819~8226614:-
PCPG	trans	rs2038227	1	rs2038227	ENSG00000260896.4	RP11-314O13.1	6.19	5.42e-09	0.0205	0.62	0.45	Venous thromboembolism (SNP x SNP interaction);	chr16:489140	chr16:80828735~80892595:-
PCPG	trans	rs4660306	1	rs2993259	ENSG00000235823.1	OLMALINC	-6.19	5.5e-09	0.0208	-0.5	-0.45	Homocysteine levels;	chr1:45535878	chr10:100373615~100383368:+
PCPG	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-6.19	5.53e-09	0.0209	-0.63	-0.45	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
PCPG	trans	rs73108077	0.736	rs6060993	ENSG00000279352.1	RP11-411B10.7	6.19	5.53e-09	0.0209	0.83	0.45	Red blood cell density in sickle cell anemia;	chr20:31278917	chr18:14010054~14010917:+
PCPG	trans	rs1045902	0.532	rs10185579	ENSG00000236165.1	PRADC1P1	6.19	5.58e-09	0.021	0.61	0.45	Intelligence (multi-trait analysis);	chr2:73229214	chr3:36976316~36976840:+
PCPG	trans	rs72681920	0.881	rs72679893	ENSG00000262902.1	RP11-750B16.1	6.19	5.58e-09	0.021	0.65	0.45	Alcohol dependence;	chr4:99294430	chr17:53105734~53106358:+
PCPG	trans	rs72681920	0.881	rs56948765	ENSG00000262902.1	RP11-750B16.1	6.19	5.58e-09	0.021	0.65	0.45	Alcohol dependence;	chr4:99304179	chr17:53105734~53106358:+
PCPG	trans	rs4646450	0.891	rs2240384	ENSG00000225972.1	MTND1P23	-6.19	5.59e-09	0.0211	-0.53	-0.45	Blood metabolite levels;	chr7:99429421	chr1:629062~629433:+
PCPG	trans	rs10940346	0.601	rs4029989	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50474501	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.584	rs10061339	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50475952	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs1016620	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50490763	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs2353961	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50491604	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7379514	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50492052	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10755228	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50493498	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs34371354	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50494203	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs55843201	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50494254	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs56251178	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50494837	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.645	rs6450162	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50498547	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7706105	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50501745	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs11948302	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50502317	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10940335	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50502595	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs1833900	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50504668	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs10940336	ENSG00000231752.4	EMBP1	-6.18	5.65e-09	0.0212	-0.58	-0.45	Schizophrenia;	chr5:50505020	chr1:121519112~121571892:+
PCPG	trans	rs12497850	0.865	rs7649458	ENSG00000197582.5	GPX1P1	6.18	5.66e-09	0.0213	0.63	0.45	Parkinson's disease;	chr3:48882694	chrX:13378735~13379340:-
PCPG	trans	rs5022636	0.865	rs12069445	ENSG00000180764.13	PIPSL	6.18	5.68e-09	0.0213	0.52	0.45	Gut microbiota (functional units);	chr1:151362964	chr10:93958191~93961540:-
PCPG	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	6.18	5.69e-09	0.0213	0.51	0.45	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
PCPG	trans	rs9425766	0.962	rs9425430	ENSG00000213331.4	RP11-713C19.2	6.18	5.71e-09	0.0214	0.54	0.45	Life satisfaction;	chr1:173888145	chr4:187970273~187971284:+
PCPG	trans	rs9650657	0.645	rs4841409	ENSG00000253893.2	FAM85B	-6.18	5.71e-09	0.0214	-0.55	-0.45	Neuroticism;	chr8:10658864	chr8:8167819~8226614:-
PCPG	trans	rs7702057	0.619	rs73263087	ENSG00000232573.1	RPL3P4	6.18	5.74e-09	0.0215	0.82	0.45	Amyotrophic lateral sclerosis;	chr5:116329061	chr14:98972879~98973301:-
PCPG	trans	rs61990749	1	rs4533193	ENSG00000235400.1	RP4-641G12.4	-6.18	5.75e-09	0.0215	-0.87	-0.45	Fibroblast growth factor basic levels;	chr14:77913825	chr1:78749073~78750659:+
PCPG	trans	rs848490	0.651	rs12113119	ENSG00000231747.1	AC079922.2	6.18	5.76e-09	0.0216	0.38	0.45	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr2:112621809~112622167:-
PCPG	trans	rs12709013	0.59	rs982848	ENSG00000230849.2	GOT2P2	6.18	5.77e-09	0.0216	0.52	0.45	Blood metabolite ratios;	chr16:58704294	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-6.18	5.77e-09	0.0216	-0.52	-0.45	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
PCPG	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-6.18	5.77e-09	0.0216	-0.52	-0.45	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
PCPG	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	6.18	5.82e-09	0.0218	0.59	0.45	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	6.18	5.82e-09	0.0218	0.59	0.45	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
PCPG	trans	rs73108077	0.736	rs6060596	ENSG00000279352.1	RP11-411B10.7	6.18	5.82e-09	0.0218	0.83	0.45	Red blood cell density in sickle cell anemia;	chr20:31261457	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs6060617	ENSG00000279352.1	RP11-411B10.7	6.18	5.82e-09	0.0218	0.83	0.45	Red blood cell density in sickle cell anemia;	chr20:31261849	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs77855283	ENSG00000279352.1	RP11-411B10.7	6.18	5.82e-09	0.0218	0.83	0.45	Red blood cell density in sickle cell anemia;	chr20:31262576	chr18:14010054~14010917:+
PCPG	trans	rs10940346	0.562	rs34950042	ENSG00000231752.4	EMBP1	-6.18	5.87e-09	0.0219	-0.58	-0.45	Schizophrenia;	chr5:50479299	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs3845167	ENSG00000231752.4	EMBP1	-6.18	5.87e-09	0.0219	-0.58	-0.45	Schizophrenia;	chr5:50480297	chr1:121519112~121571892:+
PCPG	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	6.17	5.93e-09	0.0221	0.58	0.45	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
PCPG	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	6.17	5.97e-09	0.0223	0.71	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
PCPG	trans	rs4646450	0.838	rs10229569	ENSG00000225972.1	MTND1P23	6.17	5.98e-09	0.0223	0.54	0.45	Blood metabolite levels;	chr7:99586081	chr1:629062~629433:+
PCPG	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-6.17	5.99e-09	0.0223	-0.58	-0.45	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
PCPG	trans	rs10251504	1	rs10224786	ENSG00000215548.2	RP11-764K9.4	-6.17	6.02e-09	0.0224	-0.65	-0.45	Airway wall thickness;	chr7:78058256	chr9:63832127~63859641:-
PCPG	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	6.17	6.02e-09	0.0224	0.52	0.45	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
PCPG	trans	rs291096	0.678	rs1150258	ENSG00000236811.1	GAPDHP2	6.17	6.02e-09	0.0224	0.5	0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206901560	chr20:13392677~13393674:+
PCPG	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	6.17	6.04e-09	0.0225	0.57	0.45	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
PCPG	trans	rs12497850	0.644	rs11928552	ENSG00000197582.5	GPX1P1	6.17	6.05e-09	0.0225	0.59	0.45	Parkinson's disease;	chr3:48702450	chrX:13378735~13379340:-
PCPG	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-6.17	6.08e-09	0.0226	-0.58	-0.45	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
PCPG	trans	rs7937890	1	rs6486190	ENSG00000236360.2	RP11-334A14.2	6.17	6.1e-09	0.0227	0.51	0.45	Mitochondrial DNA levels;	chr11:14379670	chr1:52993201~52993702:-
PCPG	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	6.17	6.15e-09	0.0228	0.67	0.45	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	6.17	6.17e-09	0.0229	0.64	0.45	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	6.17	6.17e-09	0.0229	0.64	0.45	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
PCPG	trans	rs10940346	0.505	rs2219453	ENSG00000231752.4	EMBP1	-6.16	6.22e-09	0.0231	-0.58	-0.45	Schizophrenia;	chr5:50212774	chr1:121519112~121571892:+
PCPG	trans	rs7192380	0.767	rs8061725	ENSG00000257513.6	NPIPB1P	6.16	6.23e-09	0.0231	0.51	0.45	Sjögren's syndrome;	chr16:69547174	chr18:11619509~11639699:-
PCPG	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	6.16	6.24e-09	0.0231	0.58	0.45	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
PCPG	trans	rs10251504	0.928	rs10234923	ENSG00000215548.2	RP11-764K9.4	-6.16	6.24e-09	0.0231	-0.65	-0.45	Airway wall thickness;	chr7:78056667	chr9:63832127~63859641:-
PCPG	trans	rs7192380	0.767	rs11641686	ENSG00000257513.6	NPIPB1P	6.16	6.24e-09	0.0231	0.52	0.45	Sjögren's syndrome;	chr16:69546496	chr18:11619509~11639699:-
PCPG	trans	rs7192380	0.737	rs11641722	ENSG00000257513.6	NPIPB1P	6.16	6.24e-09	0.0231	0.52	0.45	Sjögren's syndrome;	chr16:69546499	chr18:11619509~11639699:-
PCPG	trans	rs7192380	0.737	rs9783756	ENSG00000257513.6	NPIPB1P	6.16	6.24e-09	0.0231	0.52	0.45	Sjögren's syndrome;	chr16:69546529	chr18:11619509~11639699:-
PCPG	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	6.16	6.25e-09	0.0231	0.57	0.45	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	6.16	6.25e-09	0.0231	0.57	0.45	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
PCPG	trans	rs1045902	0.516	rs7851	ENSG00000236165.1	PRADC1P1	6.16	6.28e-09	0.0233	0.61	0.45	Intelligence (multi-trait analysis);	chr2:73251333	chr3:36976316~36976840:+
PCPG	trans	rs344364	0.511	rs2982447	ENSG00000212961.4	HNRNPA1P40	-6.16	6.3e-09	0.0233	-0.66	-0.45	Glomerular filtration rate in chronic kidney disease;	chr16:1897412	chr11:74354443~74355720:+
PCPG	trans	rs12497850	0.931	rs12493289	ENSG00000197582.5	GPX1P1	6.16	6.3e-09	0.0233	0.63	0.45	Parkinson's disease;	chr3:48867728	chrX:13378735~13379340:-
PCPG	trans	rs12497850	1	rs1352420	ENSG00000197582.5	GPX1P1	6.16	6.31e-09	0.0233	0.59	0.45	Parkinson's disease;	chr3:48719858	chrX:13378735~13379340:-
PCPG	trans	rs3206736	0.521	rs2057819	ENSG00000255583.2	RP11-415I12.2	6.16	6.31e-09	0.0233	0.51	0.45	Diastolic blood pressure;	chr7:34905259	chr12:63682523~63724935:-
PCPG	trans	rs10940346	0.601	rs7378969	ENSG00000231752.4	EMBP1	-6.16	6.32e-09	0.0234	-0.58	-0.45	Schizophrenia;	chr5:50471925	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs7736775	ENSG00000231752.4	EMBP1	-6.16	6.32e-09	0.0234	-0.58	-0.45	Schizophrenia;	chr5:50472463	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.525	rs7728419	ENSG00000231752.4	EMBP1	-6.16	6.32e-09	0.0234	-0.58	-0.45	Schizophrenia;	chr5:50474238	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.541	rs10041893	ENSG00000231752.4	EMBP1	6.16	6.32e-09	0.0234	0.58	0.45	Schizophrenia;	chr5:50460740	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs10044979	ENSG00000231752.4	EMBP1	6.16	6.32e-09	0.0234	0.58	0.45	Schizophrenia;	chr5:50464074	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10045034	ENSG00000231752.4	EMBP1	6.16	6.32e-09	0.0234	0.58	0.45	Schizophrenia;	chr5:50464323	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.54	rs59940663	ENSG00000231752.4	EMBP1	6.16	6.32e-09	0.0234	0.58	0.45	Schizophrenia;	chr5:50467345	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs34586987	ENSG00000231752.4	EMBP1	6.16	6.32e-09	0.0234	0.58	0.45	Schizophrenia;	chr5:50467574	chr1:121519112~121571892:+
PCPG	trans	rs12497850	0.931	rs4974087	ENSG00000197582.5	GPX1P1	6.16	6.33e-09	0.0234	0.63	0.45	Parkinson's disease;	chr3:48881799	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-6.16	6.38e-09	0.0235	-0.59	-0.45	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
PCPG	trans	rs12497850	0.865	rs13072911	ENSG00000197582.5	GPX1P1	6.16	6.4e-09	0.0236	0.62	0.45	Parkinson's disease;	chr3:48924695	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs13064784	ENSG00000197582.5	GPX1P1	6.16	6.4e-09	0.0236	0.61	0.45	Parkinson's disease;	chr3:49098528	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	6.16	6.4e-09	0.0236	0.59	0.45	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	6.16	6.4e-09	0.0236	0.59	0.45	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
PCPG	trans	rs10940346	0.601	rs6450098	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50420076	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs62365896	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50422243	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.56	rs6450107	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50430069	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs58756661	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50436837	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs28528780	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50441293	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs28500170	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50441594	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.56	rs16879094	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50442603	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs13157992	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50444074	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7720960	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50450489	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs6863108	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50451450	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.56	rs13180267	ENSG00000231752.4	EMBP1	6.16	6.41e-09	0.0236	0.58	0.45	Schizophrenia;	chr5:50452300	chr1:121519112~121571892:+
PCPG	trans	rs10466239	0.892	rs11238514	ENSG00000226871.1	AC135178.7	-6.16	6.41e-09	0.0236	-0.78	-0.45	Telomere length;	chr10:43331011	chr17:8318088~8318712:-
PCPG	trans	rs10466239	0.892	rs7909500	ENSG00000226871.1	AC135178.7	-6.16	6.41e-09	0.0236	-0.78	-0.45	Telomere length;	chr10:43332205	chr17:8318088~8318712:-
PCPG	trans	rs12497850	0.931	rs7431710	ENSG00000197582.5	GPX1P1	6.16	6.42e-09	0.0236	0.59	0.45	Parkinson's disease;	chr3:48898150	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	6.16	6.43e-09	0.0237	0.64	0.45	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	6.16	6.43e-09	0.0237	0.64	0.45	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	6.16	6.43e-09	0.0237	0.64	0.45	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	6.16	6.43e-09	0.0237	0.64	0.45	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
PCPG	trans	rs12497850	0.931	rs11920534	ENSG00000197582.5	GPX1P1	6.16	6.43e-09	0.0237	0.59	0.45	Parkinson's disease;	chr3:48900328	chrX:13378735~13379340:-
PCPG	trans	rs73108077	0.736	rs1997741	ENSG00000279352.1	RP11-411B10.7	6.16	6.45e-09	0.0237	0.82	0.45	Red blood cell density in sickle cell anemia;	chr20:31323198	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs6058637	ENSG00000279352.1	RP11-411B10.7	6.16	6.45e-09	0.0237	0.82	0.45	Red blood cell density in sickle cell anemia;	chr20:31325430	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs6057561	ENSG00000279352.1	RP11-411B10.7	6.16	6.45e-09	0.0237	0.82	0.45	Red blood cell density in sickle cell anemia;	chr20:31327238	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs6119830	ENSG00000279352.1	RP11-411B10.7	6.16	6.45e-09	0.0237	0.82	0.45	Red blood cell density in sickle cell anemia;	chr20:31327636	chr18:14010054~14010917:+
PCPG	trans	rs73108077	0.736	rs6119831	ENSG00000279352.1	RP11-411B10.7	6.16	6.45e-09	0.0237	0.82	0.45	Red blood cell density in sickle cell anemia;	chr20:31328473	chr18:14010054~14010917:+
PCPG	trans	rs4660306	1	rs6429569	ENSG00000235823.1	OLMALINC	-6.16	6.46e-09	0.0237	-0.49	-0.45	Homocysteine levels;	chr1:45535658	chr10:100373615~100383368:+
PCPG	trans	rs7819412	0.765	rs17783634	ENSG00000253893.2	FAM85B	6.16	6.47e-09	0.0238	0.58	0.45	Triglycerides;	chr8:11196588	chr8:8167819~8226614:-
PCPG	trans	rs2306786	1	rs12591296	ENSG00000198106.8	SNX29P2	-6.15	6.56e-09	0.0241	-0.95	-0.45	Metabolite levels;	chr15:59194441	chr16:29291220~29372110:+
PCPG	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-6.15	6.56e-09	0.0241	-0.52	-0.45	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
PCPG	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-6.15	6.56e-09	0.0241	-0.52	-0.45	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
PCPG	trans	rs7811142	1	rs2897358	ENSG00000228546.2	CTA-313A17.3	6.15	6.56e-09	0.0241	0.69	0.45	Platelet count;	chr7:100491017	chr7:102337316~102339115:+
PCPG	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-6.15	6.57e-09	0.0241	-0.6	-0.45	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
PCPG	trans	rs12497850	0.931	rs6446205	ENSG00000197582.5	GPX1P1	6.15	6.58e-09	0.0241	0.64	0.45	Parkinson's disease;	chr3:48997778	chrX:13378735~13379340:-
PCPG	trans	rs7809615	0.515	rs10257273	ENSG00000225972.1	MTND1P23	6.15	6.6e-09	0.0242	0.55	0.45	Blood metabolite ratios;	chr7:99590966	chr1:629062~629433:+
PCPG	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-6.15	6.63e-09	0.0243	-0.67	-0.45	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
PCPG	trans	rs11099942	0.826	rs72721345	ENSG00000232573.1	RPL3P4	6.15	6.64e-09	0.0243	0.68	0.45	Type 2 diabetes (age of onset);	chr4:154188529	chr14:98972879~98973301:-
PCPG	trans	rs11099942	0.826	rs80198976	ENSG00000232573.1	RPL3P4	6.15	6.64e-09	0.0243	0.68	0.45	Type 2 diabetes (age of onset);	chr4:154189104	chr14:98972879~98973301:-
PCPG	trans	rs10940346	0.51	rs10038023	ENSG00000231752.4	EMBP1	-6.15	6.64e-09	0.0243	-0.57	-0.45	Schizophrenia;	chr5:50280387	chr1:121519112~121571892:+
PCPG	trans	rs7809615	0.515	rs6961634	ENSG00000225972.1	MTND1P23	6.15	6.68e-09	0.0244	0.55	0.45	Blood metabolite ratios;	chr7:99584216	chr1:629062~629433:+
PCPG	trans	rs1614887	1	rs1614887	ENSG00000242375.1	RP11-498P14.3	6.15	6.68e-09	0.0245	0.61	0.45	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr9:97195351~97197687:-
PCPG	trans	rs7811142	1	rs2406255	ENSG00000228546.2	CTA-313A17.3	6.15	6.69e-09	0.0245	0.76	0.45	Platelet count;	chr7:100456067	chr7:102337316~102339115:+
PCPG	trans	rs10940346	0.601	rs34616519	ENSG00000231752.4	EMBP1	6.15	6.73e-09	0.0246	0.6	0.45	Schizophrenia;	chr5:50353638	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.54	rs12109228	ENSG00000231752.4	EMBP1	6.15	6.73e-09	0.0246	0.6	0.45	Schizophrenia;	chr5:50383135	chr1:121519112~121571892:+
PCPG	trans	rs116095464	1	rs28587785	ENSG00000185986.11	SDHAP3	6.15	6.77e-09	0.0247	0.82	0.45	Breast cancer;	chr5:375385	chr5:1572222~1594620:-
PCPG	trans	rs7811142	1	rs11761725	ENSG00000228546.2	CTA-313A17.3	6.15	6.78e-09	0.0247	0.76	0.45	Platelet count;	chr7:100442192	chr7:102337316~102339115:+
PCPG	trans	rs12497850	0.863	rs4858799	ENSG00000197582.5	GPX1P1	6.15	6.8e-09	0.0248	0.57	0.45	Parkinson's disease;	chr3:48690771	chrX:13378735~13379340:-
PCPG	trans	rs291096	0.647	rs188334	ENSG00000236811.1	GAPDHP2	-6.15	6.85e-09	0.025	-0.51	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206906270	chr20:13392677~13393674:+
PCPG	trans	rs291096	0.647	rs189752	ENSG00000236811.1	GAPDHP2	-6.15	6.85e-09	0.025	-0.51	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206906437	chr20:13392677~13393674:+
PCPG	trans	rs291096	0.678	rs291106	ENSG00000236811.1	GAPDHP2	-6.15	6.85e-09	0.025	-0.51	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206906620	chr20:13392677~13393674:+
PCPG	trans	rs291096	0.617	rs291105	ENSG00000236811.1	GAPDHP2	-6.15	6.85e-09	0.025	-0.51	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206906696	chr20:13392677~13393674:+
PCPG	trans	rs116095464	1	rs6879758	ENSG00000185986.11	SDHAP3	6.14	6.88e-09	0.0251	0.83	0.45	Breast cancer;	chr5:350162	chr5:1572222~1594620:-
PCPG	trans	rs116095464	0.718	rs62331563	ENSG00000185986.11	SDHAP3	6.14	6.88e-09	0.0251	0.83	0.45	Breast cancer;	chr5:355171	chr5:1572222~1594620:-
PCPG	trans	rs12497850	0.931	rs6414613	ENSG00000197582.5	GPX1P1	6.14	6.88e-09	0.0251	0.62	0.45	Parkinson's disease;	chr3:48998452	chrX:13378735~13379340:-
PCPG	trans	rs73108077	0.736	rs6060436	ENSG00000279352.1	RP11-411B10.7	6.14	6.91e-09	0.0252	0.8	0.45	Red blood cell density in sickle cell anemia;	chr20:31258500	chr18:14010054~14010917:+
PCPG	trans	rs10251504	1	rs6978319	ENSG00000215548.2	RP11-764K9.4	-6.14	6.97e-09	0.0254	-0.65	-0.45	Airway wall thickness;	chr7:78057097	chr9:63832127~63859641:-
PCPG	trans	rs4669226	1	rs67087834	ENSG00000232031.1	RP5-991C6.4	-6.14	6.99e-09	0.0255	-1.1	-0.45	Multiple sclerosis;	chr2:7900088	chr6:81724722~81736353:-
PCPG	trans	rs1892094	0.55	rs36115308	ENSG00000264937.1	AC100830.5	6.14	7.03e-09	0.0256	0.5	0.45	Coronary artery disease;	chr1:169126074	chr15:64696622~64696861:+
PCPG	trans	rs1892094	0.53	rs80135751	ENSG00000264937.1	AC100830.5	6.14	7.03e-09	0.0256	0.5	0.45	Coronary artery disease;	chr1:169126076	chr15:64696622~64696861:+
PCPG	trans	rs1892094	0.53	rs75255502	ENSG00000264937.1	AC100830.5	6.14	7.03e-09	0.0256	0.5	0.45	Coronary artery disease;	chr1:169126077	chr15:64696622~64696861:+
PCPG	trans	rs1892094	0.53	rs35152438	ENSG00000264937.1	AC100830.5	6.14	7.03e-09	0.0256	0.5	0.45	Coronary artery disease;	chr1:169126079	chr15:64696622~64696861:+
PCPG	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	6.14	7.07e-09	0.0257	0.89	0.45	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
PCPG	trans	rs10940346	0.601	rs1841104	ENSG00000231752.4	EMBP1	-6.14	7.09e-09	0.0258	-0.58	-0.45	Schizophrenia;	chr5:50263930	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-6.14	7.09e-09	0.0258	-0.58	-0.45	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs2036902	ENSG00000231752.4	EMBP1	6.14	7.13e-09	0.0259	0.58	0.45	Schizophrenia;	chr5:50401098	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7717982	ENSG00000231752.4	EMBP1	6.14	7.13e-09	0.0259	0.58	0.45	Schizophrenia;	chr5:50401488	chr1:121519112~121571892:+
PCPG	trans	rs3809095	0.821	rs11023973	ENSG00000229694.5	RP11-305L7.6	6.14	7.14e-09	0.0259	0.53	0.45	Total body bone mineral density;	chr11:16518145	chr9:91119062~91182762:+
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-6.14	7.18e-09	0.026	-0.56	-0.45	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
PCPG	trans	rs74781061	0.929	rs9635320	ENSG00000227288.3	RP5-837I24.1	6.14	7.2e-09	0.0261	0.62	0.45	Endometriosis;	chr15:74592750	chr1:81501794~81503468:+
PCPG	trans	rs74781061	0.929	rs11072494	ENSG00000227288.3	RP5-837I24.1	6.14	7.2e-09	0.0261	0.62	0.45	Endometriosis;	chr15:74596822	chr1:81501794~81503468:+
PCPG	trans	rs74781061	0.929	rs11072495	ENSG00000227288.3	RP5-837I24.1	6.14	7.2e-09	0.0261	0.62	0.45	Endometriosis;	chr15:74598790	chr1:81501794~81503468:+
PCPG	trans	rs713587	0.967	rs713586	ENSG00000274010.1	RP5-935K16.2	-6.13	7.28e-09	0.0264	-0.54	-0.45	Body mass index in non-asthmatics;	chr2:24935139	chr2:127840606~127841763:-
PCPG	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-6.13	7.29e-09	0.0264	-0.42	-0.45	Longevity;	chr3:48378233	chr1:27649419~27649610:+
PCPG	trans	rs7819412	0.806	rs2409689	ENSG00000253893.2	FAM85B	6.13	7.31e-09	0.0265	0.63	0.45	Triglycerides;	chr8:11075358	chr8:8167819~8226614:-
PCPG	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	6.13	7.34e-09	0.0266	0.58	0.45	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	6.13	7.34e-09	0.0266	0.58	0.45	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	6.13	7.37e-09	0.0267	0.58	0.45	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
PCPG	trans	rs10921288	0.661	rs7514204	ENSG00000232573.1	RPL3P4	-6.13	7.37e-09	0.0267	-0.76	-0.45	Body fat percentage;	chr1:192837785	chr14:98972879~98973301:-
PCPG	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-6.13	7.41e-09	0.0268	-0.55	-0.45	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
PCPG	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	6.13	7.42e-09	0.0269	0.58	0.45	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
PCPG	trans	rs74781061	0.929	rs7176095	ENSG00000227288.3	RP5-837I24.1	6.13	7.48e-09	0.027	0.62	0.45	Endometriosis;	chr15:74594070	chr1:81501794~81503468:+
PCPG	trans	rs12497850	0.966	rs6792510	ENSG00000197582.5	GPX1P1	6.13	7.5e-09	0.0271	0.58	0.45	Parkinson's disease;	chr3:48685869	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.874	rs28452522	ENSG00000275858.1	RP11-291L22.8	6.13	7.53e-09	0.0272	0.6	0.45	Corneal astigmatism;	chr4:119189629	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	6.13	7.53e-09	0.0272	0.6	0.45	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
PCPG	trans	rs4276421	0.967	rs4541665	ENSG00000231752.4	EMBP1	-6.13	7.56e-09	0.0273	-0.58	-0.45	P wave duration;	chr5:45796444	chr1:121519112~121571892:+
PCPG	trans	rs7819412	1	rs2409722	ENSG00000253893.2	FAM85B	6.13	7.58e-09	0.0274	0.57	0.45	Triglycerides;	chr8:11182307	chr8:8167819~8226614:-
PCPG	trans	rs9650657	0.504	rs2409724	ENSG00000253893.2	FAM85B	6.13	7.58e-09	0.0274	0.57	0.45	Neuroticism;	chr8:11184133	chr8:8167819~8226614:-
PCPG	trans	rs9650657	0.515	rs7820860	ENSG00000253893.2	FAM85B	6.13	7.59e-09	0.0274	0.62	0.45	Neuroticism;	chr8:11092886	chr8:8167819~8226614:-
PCPG	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	6.13	7.6e-09	0.0274	0.56	0.45	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	6.13	7.6e-09	0.0274	0.56	0.45	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	6.13	7.6e-09	0.0274	0.56	0.45	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
PCPG	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	6.13	7.6e-09	0.0274	0.56	0.45	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	6.13	7.6e-09	0.0274	0.56	0.45	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	6.13	7.6e-09	0.0274	0.56	0.45	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	6.13	7.6e-09	0.0274	0.56	0.45	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-6.13	7.6e-09	0.0274	-0.56	-0.45	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
PCPG	trans	rs10940346	0.58	rs13357429	ENSG00000231752.4	EMBP1	6.12	7.63e-09	0.0275	0.57	0.45	Schizophrenia;	chr5:50413616	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4495185	ENSG00000231752.4	EMBP1	6.12	7.63e-09	0.0275	0.57	0.45	Schizophrenia;	chr5:50415453	chr1:121519112~121571892:+
PCPG	trans	rs12497850	1	rs12497850	ENSG00000197582.5	GPX1P1	6.12	7.63e-09	0.0275	0.57	0.45	Parkinson's disease;	chr3:48711556	chrX:13378735~13379340:-
PCPG	trans	rs2484992	1	rs7098232	ENSG00000232573.1	RPL3P4	6.12	7.67e-09	0.0276	0.75	0.45	Disc degeneration (lumbar);	chr10:31196224	chr14:98972879~98973301:-
PCPG	trans	rs10908521	0.685	rs11264568	ENSG00000227183.3	HDGFP1	-6.12	7.69e-09	0.0277	-0.51	-0.45	Uric acid clearance;	chr1:156836077	chrX:131646639~131646890:+
PCPG	trans	rs10908521	0.685	rs11264569	ENSG00000227183.3	HDGFP1	-6.12	7.69e-09	0.0277	-0.51	-0.45	Uric acid clearance;	chr1:156836098	chrX:131646639~131646890:+
PCPG	trans	rs10908521	0.626	rs11264570	ENSG00000227183.3	HDGFP1	-6.12	7.69e-09	0.0277	-0.51	-0.45	Uric acid clearance;	chr1:156836167	chrX:131646639~131646890:+
PCPG	trans	rs10908521	0.717	rs11264572	ENSG00000227183.3	HDGFP1	-6.12	7.69e-09	0.0277	-0.51	-0.45	Uric acid clearance;	chr1:156836245	chrX:131646639~131646890:+
PCPG	trans	rs7192380	0.651	rs34769743	ENSG00000257513.6	NPIPB1P	6.12	7.73e-09	0.0278	0.52	0.45	Sjögren's syndrome;	chr16:69546587	chr18:11619509~11639699:-
PCPG	trans	rs12497850	0.931	rs7647813	ENSG00000197582.5	GPX1P1	6.12	7.75e-09	0.0279	0.62	0.45	Parkinson's disease;	chr3:48795915	chrX:13378735~13379340:-
PCPG	trans	rs55665837	0.54	rs7938266	ENSG00000236360.2	RP11-334A14.2	6.12	7.8e-09	0.028	0.49	0.45	Vitamin D levels;	chr11:14687778	chr1:52993201~52993702:-
PCPG	trans	rs7811142	1	rs11559117	ENSG00000228546.2	CTA-313A17.3	6.12	7.81e-09	0.0281	0.7	0.45	Platelet count;	chr7:100478991	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs4463351	ENSG00000228546.2	CTA-313A17.3	6.12	7.81e-09	0.0281	0.7	0.45	Platelet count;	chr7:100480603	chr7:102337316~102339115:+
PCPG	trans	rs291096	0.647	rs1713231	ENSG00000236811.1	GAPDHP2	-6.12	7.88e-09	0.0283	-0.5	-0.45	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206908309	chr20:13392677~13393674:+
PCPG	trans	rs12497850	0.931	rs9311434	ENSG00000197582.5	GPX1P1	6.12	7.9e-09	0.0283	0.59	0.45	Parkinson's disease;	chr3:48846714	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs7623023	ENSG00000197582.5	GPX1P1	6.12	7.9e-09	0.0283	0.59	0.45	Parkinson's disease;	chr3:48876805	chrX:13378735~13379340:-
PCPG	trans	rs12497850	0.931	rs4974080	ENSG00000197582.5	GPX1P1	6.12	7.92e-09	0.0284	0.62	0.45	Parkinson's disease;	chr3:48993395	chrX:13378735~13379340:-
PCPG	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	6.12	7.98e-09	0.0286	0.7	0.45	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	6.12	7.98e-09	0.0286	0.7	0.45	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
PCPG	trans	rs12497850	0.931	rs7628719	ENSG00000197582.5	GPX1P1	6.12	7.98e-09	0.0286	0.58	0.45	Parkinson's disease;	chr3:48958054	chrX:13378735~13379340:-
PCPG	trans	rs10251504	0.963	rs6944647	ENSG00000215548.2	RP11-764K9.4	-6.12	7.99e-09	0.0286	-0.64	-0.45	Airway wall thickness;	chr7:78057496	chr9:63832127~63859641:-
PCPG	trans	rs10251504	1	rs6958035	ENSG00000215548.2	RP11-764K9.4	-6.12	7.99e-09	0.0286	-0.64	-0.45	Airway wall thickness;	chr7:78057544	chr9:63832127~63859641:-
PCPG	trans	rs6473252	0.546	rs7834840	ENSG00000267092.2	CTB-25B13.9	-6.12	7.99e-09	0.0286	-0.56	-0.45	Breast cancer;	chr8:80910284	chr19:1508375~1508963:+
PCPG	trans	rs7811142	1	rs11769700	ENSG00000228546.2	CTA-313A17.3	6.11	8e-09	0.0286	0.7	0.45	Platelet count;	chr7:100492426	chr7:102337316~102339115:+
PCPG	trans	rs72681920	0.881	rs28914770	ENSG00000262902.1	RP11-750B16.1	6.11	8.04e-09	0.0288	0.64	0.45	Alcohol dependence;	chr4:99312735	chr17:53105734~53106358:+
PCPG	trans	rs2306786	1	rs74506535	ENSG00000198106.8	SNX29P2	-6.11	8.05e-09	0.0288	-1.02	-0.45	Metabolite levels;	chr15:59197644	chr16:29291220~29372110:+
PCPG	trans	rs7937890	1	rs7937890	ENSG00000236360.2	RP11-334A14.2	6.11	8.07e-09	0.0289	0.51	0.45	Mitochondrial DNA levels;	chr11:14374939	chr1:52993201~52993702:-
PCPG	trans	rs7811142	1	rs60478351	ENSG00000228546.2	CTA-313A17.3	6.11	8.12e-09	0.029	0.7	0.45	Platelet count;	chr7:100491394	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs7787620	ENSG00000228546.2	CTA-313A17.3	6.11	8.12e-09	0.029	0.7	0.45	Platelet count;	chr7:100491611	chr7:102337316~102339115:+
PCPG	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	6.11	8.13e-09	0.029	0.6	0.45	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
PCPG	trans	rs282587	0.597	rs408247	ENSG00000236527.1	ARF4P2	6.11	8.16e-09	0.0291	0.68	0.45	Glycated hemoglobin levels;	chr13:112751424	chr20:62872250~62873076:-
PCPG	trans	rs4646450	0.735	rs10255399	ENSG00000225972.1	MTND1P23	6.11	8.18e-09	0.0292	0.57	0.45	Blood metabolite levels;	chr7:99372501	chr1:629062~629433:+
PCPG	trans	rs4646450	0.735	rs10270917	ENSG00000225972.1	MTND1P23	6.11	8.18e-09	0.0292	0.57	0.45	Blood metabolite levels;	chr7:99372591	chr1:629062~629433:+
PCPG	trans	rs7819412	0.936	rs7814499	ENSG00000253893.2	FAM85B	6.11	8.18e-09	0.0292	0.57	0.45	Triglycerides;	chr8:11183138	chr8:8167819~8226614:-
PCPG	trans	rs310008	0.623	rs2927300	ENSG00000256940.1	RP11-783K16.5	-6.11	8.23e-09	0.0293	-0.8	-0.45	Menarche (age at onset);	chr16:81469614	chr11:64245964~64248217:+
PCPG	trans	rs11098499	0.739	rs6534130	ENSG00000275858.1	RP11-291L22.8	-6.11	8.29e-09	0.0295	-0.57	-0.45	Corneal astigmatism;	chr4:119210184	chr10:38450738~38451069:-
PCPG	trans	rs950169	0.959	rs12902070	ENSG00000259295.5	CSPG4P12	6.11	8.35e-09	0.0297	0.66	0.45	Schizophrenia;	chr15:84124806	chr15:85191438~85213905:+
PCPG	trans	rs2745959	0.527	rs2745960	ENSG00000231369.1	RP1-40G4P.1	-6.11	8.4e-09	0.0299	-0.46	-0.45	Resting heart rate;	chr1:207922356	chr22:26886909~26887548:-
PCPG	trans	rs2936519	0.929	rs3115995	ENSG00000262902.1	RP11-750B16.1	6.1	8.41e-09	0.0299	0.51	0.45	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr8:6781003	chr17:53105734~53106358:+
PCPG	trans	rs2936519	1	rs2928606	ENSG00000262902.1	RP11-750B16.1	6.1	8.41e-09	0.0299	0.51	0.45	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr8:6781036	chr17:53105734~53106358:+
PCPG	trans	rs2936519	0.858	rs2912024	ENSG00000262902.1	RP11-750B16.1	6.1	8.41e-09	0.0299	0.51	0.45	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr8:6781378	chr17:53105734~53106358:+
PCPG	trans	rs10940346	0.601	rs1039798	ENSG00000231752.4	EMBP1	6.1	8.42e-09	0.0299	0.6	0.45	Schizophrenia;	chr5:50355909	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10072182	ENSG00000231752.4	EMBP1	6.1	8.42e-09	0.0299	0.6	0.45	Schizophrenia;	chr5:50356818	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7442762	ENSG00000231752.4	EMBP1	6.1	8.42e-09	0.0299	0.6	0.45	Schizophrenia;	chr5:50358137	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.56	rs10073530	ENSG00000231752.4	EMBP1	6.1	8.42e-09	0.0299	0.6	0.45	Schizophrenia;	chr5:50358823	chr1:121519112~121571892:+
PCPG	trans	rs3779195	0.524	rs76976120	ENSG00000225169.1	BRI3P1	-6.1	8.45e-09	0.0301	-0.7	-0.45	Sex hormone-binding globulin levels;	chr7:98264860	chr1:100213293~100213670:+
PCPG	trans	rs3779195	0.585	rs73709460	ENSG00000225169.1	BRI3P1	-6.1	8.45e-09	0.0301	-0.7	-0.45	Sex hormone-binding globulin levels;	chr7:98265942	chr1:100213293~100213670:+
PCPG	trans	rs3779195	0.585	rs56694862	ENSG00000225169.1	BRI3P1	-6.1	8.45e-09	0.0301	-0.7	-0.45	Sex hormone-binding globulin levels;	chr7:98267808	chr1:100213293~100213670:+
PCPG	trans	rs4660306	1	rs6667191	ENSG00000235823.1	OLMALINC	-6.1	8.47e-09	0.0301	-0.49	-0.45	Homocysteine levels;	chr1:45517172	chr10:100373615~100383368:+
PCPG	trans	rs62344088	0.59	rs6889904	ENSG00000185986.11	SDHAP3	6.1	8.47e-09	0.0301	0.71	0.45	Asthma (childhood onset);	chr5:177149	chr5:1572222~1594620:-
PCPG	trans	rs596169	0.764	rs659302	ENSG00000232573.1	RPL3P4	-6.1	8.5e-09	0.0302	-0.62	-0.45	Intraocular pressure;	chr1:218938993	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.685	rs659478	ENSG00000232573.1	RPL3P4	-6.1	8.5e-09	0.0302	-0.62	-0.45	Intraocular pressure;	chr1:218939885	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.764	rs642053	ENSG00000232573.1	RPL3P4	-6.1	8.51e-09	0.0302	-0.62	-0.45	Intraocular pressure;	chr1:218933864	chr14:98972879~98973301:-
PCPG	trans	rs3809095	0.821	rs11023974	ENSG00000229694.5	RP11-305L7.6	6.1	8.52e-09	0.0303	0.53	0.45	Total body bone mineral density;	chr11:16519744	chr9:91119062~91182762:+
PCPG	trans	rs10251504	0.929	rs10224805	ENSG00000215548.2	RP11-764K9.4	-6.1	8.54e-09	0.0303	-0.64	-0.45	Airway wall thickness;	chr7:78058299	chr9:63832127~63859641:-
PCPG	trans	rs7259376	0.645	rs7245650	ENSG00000256576.2	RP13-977J11.2	-6.1	8.6e-09	0.0305	-0.49	-0.45	Menopause (age at onset);	chr19:22300893	chr12:132186735~132189695:-
PCPG	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	6.1	8.66e-09	0.0307	0.41	0.45	Longevity;	chr3:48447994	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	6.1	8.66e-09	0.0307	0.41	0.45	Longevity;	chr3:48453142	chr1:27649419~27649610:+
PCPG	trans	rs10940346	0.601	rs11960276	ENSG00000231752.4	EMBP1	-6.1	8.68e-09	0.0308	-0.57	-0.45	Schizophrenia;	chr5:50265194	chr1:121519112~121571892:+
PCPG	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	6.1	8.69e-09	0.0308	0.51	0.45	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
PCPG	trans	rs80208956	1	rs11263527	ENSG00000225972.1	MTND1P23	6.1	8.74e-09	0.031	0.76	0.45	Major depressive disorder;	chr11:69665423	chr1:629062~629433:+
PCPG	trans	rs10940346	0.562	rs10051529	ENSG00000231752.4	EMBP1	-6.1	8.75e-09	0.031	-0.58	-0.45	Schizophrenia;	chr5:50303103	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10042601	ENSG00000231752.4	EMBP1	-6.1	8.75e-09	0.031	-0.58	-0.45	Schizophrenia;	chr5:50315248	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.54	rs34645496	ENSG00000231752.4	EMBP1	6.1	8.75e-09	0.031	0.58	0.45	Schizophrenia;	chr5:50322419	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs35330444	ENSG00000231752.4	EMBP1	6.1	8.75e-09	0.031	0.58	0.45	Schizophrenia;	chr5:50322606	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs6875734	ENSG00000231752.4	EMBP1	6.1	8.75e-09	0.031	0.58	0.45	Schizophrenia;	chr5:50323203	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs6868380	ENSG00000231752.4	EMBP1	6.1	8.75e-09	0.031	0.58	0.45	Schizophrenia;	chr5:50328473	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs34185098	ENSG00000231752.4	EMBP1	6.1	8.75e-09	0.031	0.58	0.45	Schizophrenia;	chr5:50330100	chr1:121519112~121571892:+
PCPG	trans	rs55665837	0.54	rs11023302	ENSG00000236360.2	RP11-334A14.2	6.1	8.8e-09	0.0311	0.48	0.45	Vitamin D levels;	chr11:14672389	chr1:52993201~52993702:-
PCPG	trans	rs150992	0.751	rs172874	ENSG00000278709.1	RP5-1059L7.1	-6.1	8.8e-09	0.0311	-0.54	-0.45	Body mass index;	chr5:98969402	chr20:57710183~57712780:+
PCPG	trans	rs6718203	1	rs918054	ENSG00000259295.5	CSPG4P12	6.1	8.81e-09	0.0312	0.86	0.45	Intelligence (multi-trait analysis);	chr2:60402748	chr15:85191438~85213905:+
PCPG	trans	rs6718203	1	rs918053	ENSG00000259295.5	CSPG4P12	6.1	8.81e-09	0.0312	0.86	0.45	Intelligence (multi-trait analysis);	chr2:60402881	chr15:85191438~85213905:+
PCPG	trans	rs6718203	1	rs56202165	ENSG00000259295.5	CSPG4P12	6.1	8.81e-09	0.0312	0.86	0.45	Intelligence (multi-trait analysis);	chr2:60403500	chr15:85191438~85213905:+
PCPG	trans	rs6718203	1	rs56404075	ENSG00000259295.5	CSPG4P12	6.1	8.81e-09	0.0312	0.86	0.45	Intelligence (multi-trait analysis);	chr2:60404230	chr15:85191438~85213905:+
PCPG	trans	rs12497850	1	rs12493578	ENSG00000197582.5	GPX1P1	-6.1	8.82e-09	0.0312	-0.59	-0.45	Parkinson's disease;	chr3:48692683	chrX:13378735~13379340:-
PCPG	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	6.1	8.82e-09	0.0312	0.57	0.45	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
PCPG	trans	rs62344088	0.59	rs2115276	ENSG00000185986.11	SDHAP3	6.09	8.85e-09	0.0313	0.84	0.45	Asthma (childhood onset);	chr5:169714	chr5:1572222~1594620:-
PCPG	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	6.09	8.9e-09	0.0313	0.91	0.45	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
PCPG	trans	rs282587	0.569	rs409896	ENSG00000236527.1	ARF4P2	6.09	8.91e-09	0.0313	0.67	0.45	Glycated hemoglobin levels;	chr13:112746024	chr20:62872250~62873076:-
PCPG	trans	rs5022636	0.964	rs7545392	ENSG00000180764.13	PIPSL	6.09	8.91e-09	0.0313	0.51	0.45	Gut microbiota (functional units);	chr1:151337779	chr10:93958191~93961540:-
PCPG	trans	rs10940346	0.562	rs549751	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50262114	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs1841103	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50263913	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs504773	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50264656	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.524	rs1458763	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50265531	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs1458765	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50266141	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs1458766	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50266457	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs514195	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50267123	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs552892	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50269093	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs1674514	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50269291	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs496230	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50275179	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs526329	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50276141	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs524184	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50276256	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs6868713	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50276741	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs555704	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50277066	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs563750	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50278004	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4865675	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50279300	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs507761	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50279558	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs506919	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50279635	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs494540	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50280228	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs471455	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50280427	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs13360551	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50287350	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs1858343	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50290180	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs1858344	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50290345	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4865685	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50290682	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs6449779	ENSG00000231752.4	EMBP1	-6.09	8.91e-09	0.0313	-0.57	-0.45	Schizophrenia;	chr5:50290876	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4865676	ENSG00000231752.4	EMBP1	6.09	8.91e-09	0.0313	0.57	0.45	Schizophrenia;	chr5:50279343	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs16879414	ENSG00000231752.4	EMBP1	6.09	8.99e-09	0.0316	0.58	0.45	Schizophrenia;	chr5:50337969	chr1:121519112~121571892:+
PCPG	trans	rs76228276	0.737	rs73271394	ENSG00000260318.1	COX6CP1	6.09	9e-09	0.0316	1.08	0.45	Childhood ear infection;	chr8:99841632	chr16:11903923~11904137:-
PCPG	trans	rs55665837	0.54	rs4757261	ENSG00000236360.2	RP11-334A14.2	6.09	9.01e-09	0.0316	0.49	0.45	Vitamin D levels;	chr11:14648256	chr1:52993201~52993702:-
PCPG	trans	rs10940346	0.601	rs6861461	ENSG00000231752.4	EMBP1	6.09	9.04e-09	0.0317	0.57	0.45	Schizophrenia;	chr5:50348493	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs12332500	ENSG00000231752.4	EMBP1	6.09	9.04e-09	0.0317	0.57	0.45	Schizophrenia;	chr5:50349021	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7710841	ENSG00000231752.4	EMBP1	6.09	9.04e-09	0.0317	0.57	0.45	Schizophrenia;	chr5:50349986	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7723480	ENSG00000231752.4	EMBP1	6.09	9.04e-09	0.0317	0.57	0.45	Schizophrenia;	chr5:50350324	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7722623	ENSG00000231752.4	EMBP1	6.09	9.04e-09	0.0317	0.57	0.45	Schizophrenia;	chr5:50350496	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs35815956	ENSG00000231752.4	EMBP1	6.09	9.04e-09	0.0317	0.57	0.45	Schizophrenia;	chr5:50350905	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10940242	ENSG00000231752.4	EMBP1	6.09	9.04e-09	0.0317	0.57	0.45	Schizophrenia;	chr5:50351018	chr1:121519112~121571892:+
PCPG	trans	rs6723226	0.766	rs398290	ENSG00000259032.2	ENSAP2	-6.09	9.04e-09	0.0317	-0.49	-0.45	Intelligence (multi-trait analysis);	chr2:32278457	chr14:82692704~82693055:-
PCPG	trans	rs10510628	0.903	rs13084337	ENSG00000196668.3	LINC00173	6.09	9.07e-09	0.0318	0.51	0.45	Bone mineral density;	chr3:29834262	chr12:116533422~116536518:+
PCPG	trans	rs10510628	0.817	rs13084217	ENSG00000196668.3	LINC00173	6.09	9.07e-09	0.0318	0.51	0.45	Bone mineral density;	chr3:29834285	chr12:116533422~116536518:+
PCPG	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	6.09	9.09e-09	0.0318	0.57	0.45	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
PCPG	trans	rs2936519	0.929	rs9694930	ENSG00000262902.1	RP11-750B16.1	6.09	9.13e-09	0.0319	0.52	0.45	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr8:6781932	chr17:53105734~53106358:+
PCPG	trans	rs2936519	0.929	rs9693912	ENSG00000262902.1	RP11-750B16.1	6.09	9.13e-09	0.0319	0.52	0.45	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);	chr8:6781941	chr17:53105734~53106358:+
PCPG	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-6.09	9.17e-09	0.032	-0.54	-0.45	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
PCPG	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-6.09	9.17e-09	0.032	-0.56	-0.45	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
PCPG	trans	rs17133858	0.737	rs41298121	ENSG00000262902.1	RP11-750B16.1	6.09	9.19e-09	0.0321	0.8	0.45	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr11:75205802	chr17:53105734~53106358:+
PCPG	trans	rs2797369	0.882	rs2797368	ENSG00000268568.1	AC007228.9	6.09	9.2e-09	0.0321	0.62	0.45	Renal function-related traits (eGRFcrea);	chr6:101224933	chr19:56672574~56673901:-
PCPG	trans	rs55665837	0.502	rs4757269	ENSG00000236360.2	RP11-334A14.2	6.09	9.23e-09	0.0322	0.5	0.45	Vitamin D levels;	chr11:14814646	chr1:52993201~52993702:-
PCPG	trans	rs10940346	0.524	rs35601537	ENSG00000231752.4	EMBP1	-6.09	9.27e-09	0.0323	-0.57	-0.44	Schizophrenia;	chr5:50509460	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.623	rs4865519	ENSG00000231752.4	EMBP1	-6.08	9.31e-09	0.0324	-0.57	-0.44	Schizophrenia;	chr5:50293002	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.562	rs13182357	ENSG00000231752.4	EMBP1	6.08	9.32e-09	0.0324	0.6	0.44	Schizophrenia;	chr5:50404060	chr1:121519112~121571892:+
PCPG	trans	rs7702057	0.619	rs56947773	ENSG00000232573.1	RPL3P4	6.08	9.33e-09	0.0325	0.8	0.44	Amyotrophic lateral sclerosis;	chr5:116367880	chr14:98972879~98973301:-
PCPG	trans	rs11250714	1	rs11250714	ENSG00000249532.3	RP11-148B6.1	-6.08	9.37e-09	0.0326	-0.6	-0.44	Gut microbiome composition (summer);	chr10:1660387	chr4:112646476~112650051:-
PCPG	trans	rs7672749	0.73	rs17013280	ENSG00000275286.1	RP11-499A10.3	-6.08	9.39e-09	0.0326	-0.8	-0.44	TB-LM or TBLH-BMD (pleiotropy);	chr4:87841144	chr12:44498616~44499158:-
PCPG	trans	rs10940346	0.601	rs2005573	ENSG00000231752.4	EMBP1	-6.08	9.47e-09	0.0329	-0.56	-0.44	Schizophrenia;	chr5:50301614	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs2011540	ENSG00000231752.4	EMBP1	-6.08	9.47e-09	0.0329	-0.56	-0.44	Schizophrenia;	chr5:50301634	chr1:121519112~121571892:+
PCPG	trans	rs9425766	0.679	rs7552939	ENSG00000213331.4	RP11-713C19.2	6.08	9.61e-09	0.0333	0.53	0.44	Life satisfaction;	chr1:173798305	chr4:187970273~187971284:+
PCPG	trans	rs596169	0.541	rs7540811	ENSG00000232573.1	RPL3P4	-6.08	9.65e-09	0.0334	-0.62	-0.44	Intraocular pressure;	chr1:218932974	chr14:98972879~98973301:-
PCPG	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-6.08	9.7e-09	0.0336	-0.56	-0.44	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
PCPG	trans	rs10940346	0.601	rs2353221	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50299085	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs6449802	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50299390	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7724645	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50299846	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.623	rs7736990	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50300008	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10079897	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50300032	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs2137129	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50300962	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs12513730	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50302800	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4865698	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50303332	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4865699	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50303347	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4865700	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50303862	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs13178993	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50305256	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs7447926	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50310902	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs1511737	ENSG00000231752.4	EMBP1	-6.08	9.7e-09	0.0336	-0.56	-0.44	Schizophrenia;	chr5:50312308	chr1:121519112~121571892:+
PCPG	trans	rs7829975	1	rs7829975	ENSG00000255020.1	AF131216.5	-6.08	9.71e-09	0.0336	-0.59	-0.44	Mood instability;	chr8:8690607	chr8:11345748~11347502:-
PCPG	trans	rs2306786	1	rs75007523	ENSG00000198106.8	SNX29P2	-6.08	9.72e-09	0.0336	-0.97	-0.44	Metabolite levels;	chr15:59197961	chr16:29291220~29372110:+
PCPG	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	6.08	9.72e-09	0.0336	0.51	0.44	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
PCPG	trans	rs7739264	1	rs9358270	ENSG00000267131.1	RP11-332H18.5	6.08	9.73e-09	0.0336	0.58	0.44	Endometriosis;	chr6:19780353	chr17:61361668~61400243:-
PCPG	trans	rs877636	1	rs877636	ENSG00000234354.3	RPS26P47	-6.07	9.79e-09	0.0338	-0.55	-0.44	Cognitive function;	chr12:56086799	chr13:100539901~100540248:-
PCPG	trans	rs596169	0.655	rs12068857	ENSG00000232573.1	RPL3P4	6.07	9.8e-09	0.0338	0.62	0.44	Intraocular pressure;	chr1:218980828	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.649	rs11118187	ENSG00000232573.1	RPL3P4	6.07	9.8e-09	0.0338	0.62	0.44	Intraocular pressure;	chr1:218982668	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.764	rs6693640	ENSG00000232573.1	RPL3P4	6.07	9.8e-09	0.0338	0.62	0.44	Intraocular pressure;	chr1:218987259	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.655	rs6702023	ENSG00000232573.1	RPL3P4	6.07	9.8e-09	0.0338	0.62	0.44	Intraocular pressure;	chr1:218994410	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.655	rs6696616	ENSG00000232573.1	RPL3P4	6.07	9.8e-09	0.0338	0.62	0.44	Intraocular pressure;	chr1:218996084	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.655	rs28438493	ENSG00000232573.1	RPL3P4	6.07	9.8e-09	0.0338	0.62	0.44	Intraocular pressure;	chr1:219000146	chr14:98972879~98973301:-
PCPG	trans	rs596169	0.655	rs12061363	ENSG00000232573.1	RPL3P4	6.07	9.8e-09	0.0338	0.62	0.44	Intraocular pressure;	chr1:219000691	chr14:98972879~98973301:-
PCPG	trans	rs282587	0.569	rs378491	ENSG00000236527.1	ARF4P2	6.07	9.84e-09	0.034	0.66	0.44	Glycated hemoglobin levels;	chr13:112744094	chr20:62872250~62873076:-
PCPG	trans	rs282587	0.502	rs416703	ENSG00000236527.1	ARF4P2	6.07	9.84e-09	0.034	0.66	0.44	Glycated hemoglobin levels;	chr13:112744905	chr20:62872250~62873076:-
PCPG	trans	rs282587	0.569	rs432522	ENSG00000236527.1	ARF4P2	6.07	9.84e-09	0.034	0.66	0.44	Glycated hemoglobin levels;	chr13:112745701	chr20:62872250~62873076:-
PCPG	trans	rs282587	0.502	rs408476	ENSG00000236527.1	ARF4P2	6.07	9.84e-09	0.034	0.66	0.44	Glycated hemoglobin levels;	chr13:112745742	chr20:62872250~62873076:-
PCPG	trans	rs74781061	0.929	rs8028430	ENSG00000227288.3	RP5-837I24.1	6.07	9.85e-09	0.034	0.59	0.44	Endometriosis;	chr15:74553404	chr1:81501794~81503468:+
PCPG	trans	rs7811142	0.83	rs118119933	ENSG00000228546.2	CTA-313A17.3	6.07	9.9e-09	0.0341	0.73	0.44	Platelet count;	chr7:100341427	chr7:102337316~102339115:+
PCPG	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	6.07	9.91e-09	0.0341	0.55	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
PCPG	trans	rs74781061	0.86	rs1456432	ENSG00000227288.3	RP5-837I24.1	6.07	9.97e-09	0.0343	0.58	0.44	Endometriosis;	chr15:74710710	chr1:81501794~81503468:+
PCPG	trans	rs74781061	0.932	rs6495121	ENSG00000227288.3	RP5-837I24.1	6.07	9.97e-09	0.0343	0.58	0.44	Endometriosis;	chr15:74711167	chr1:81501794~81503468:+
PCPG	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-6.07	1e-08	0.0344	-0.42	-0.44	Longevity;	chr3:48372725	chr1:27649419~27649610:+
PCPG	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	6.07	1e-08	0.0344	0.57	0.44	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	6.07	1e-08	0.0344	0.57	0.44	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	6.07	1e-08	0.0344	0.57	0.44	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
PCPG	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	6.07	1e-08	0.0345	0.54	0.44	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
PCPG	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	6.07	1e-08	0.0345	0.59	0.44	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	6.07	1.01e-08	0.0347	0.64	0.44	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-6.07	1.01e-08	0.0348	-0.57	-0.44	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
PCPG	trans	rs6718203	1	rs79659409	ENSG00000259295.5	CSPG4P12	6.07	1.02e-08	0.0348	0.85	0.44	Intelligence (multi-trait analysis);	chr2:60380501	chr15:85191438~85213905:+
PCPG	trans	rs7662987	0.793	rs7684735	ENSG00000233859.2	ADH5P4	6.07	1.02e-08	0.0349	0.73	0.44	Smoking initiation;	chr4:99070355	chr6:65836930~65838039:-
PCPG	trans	rs877636	1	rs705696	ENSG00000234354.3	RPS26P47	6.06	1.03e-08	0.0354	0.55	0.44	Cognitive function;	chr12:56086864	chr13:100539901~100540248:-
PCPG	trans	rs282587	0.569	rs377748	ENSG00000236527.1	ARF4P2	6.06	1.04e-08	0.0356	0.65	0.44	Glycated hemoglobin levels;	chr13:112751168	chr20:62872250~62873076:-
PCPG	trans	rs4660306	0.961	rs7546268	ENSG00000235823.1	OLMALINC	-6.06	1.05e-08	0.036	-0.48	-0.44	Homocysteine levels;	chr1:45499668	chr10:100373615~100383368:+
PCPG	trans	rs4660306	0.961	rs3748643	ENSG00000235823.1	OLMALINC	-6.06	1.05e-08	0.036	-0.48	-0.44	Homocysteine levels;	chr1:45500031	chr10:100373615~100383368:+
PCPG	trans	rs7811142	0.887	rs35111986	ENSG00000228546.2	CTA-313A17.3	6.06	1.06e-08	0.0362	0.75	0.44	Platelet count;	chr7:100402651	chr7:102337316~102339115:+
PCPG	trans	rs9371601	0.819	rs214946	ENSG00000271011.1	RP11-171I2.5	6.06	1.06e-08	0.0362	0.51	0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152392677	chr2:178577103~178577622:+
PCPG	trans	rs9371601	0.742	rs214947	ENSG00000271011.1	RP11-171I2.5	6.06	1.06e-08	0.0362	0.51	0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152392712	chr2:178577103~178577622:+
PCPG	trans	rs12709013	0.66	rs30839	ENSG00000233719.3	GOT2P3	6.06	1.06e-08	0.0362	0.46	0.44	Blood metabolite ratios;	chr16:58711437	chr12:9641802~9643007:+
PCPG	trans	rs74405815	0.867	rs9832163	ENSG00000248540.2	RP11-247C2.2	6.06	1.06e-08	0.0363	0.66	0.44	Response to paliperidone in schizophrenia (positive Marder score);	chr3:126687123	chr15:74125915~74129278:-
PCPG	trans	rs74405815	0.764	rs73199857	ENSG00000248540.2	RP11-247C2.2	6.06	1.06e-08	0.0363	0.66	0.44	Response to paliperidone in schizophrenia (positive Marder score);	chr3:126692191	chr15:74125915~74129278:-
PCPG	trans	rs74405815	0.681	rs9878106	ENSG00000248540.2	RP11-247C2.2	6.06	1.06e-08	0.0363	0.66	0.44	Response to paliperidone in schizophrenia (positive Marder score);	chr3:126697892	chr15:74125915~74129278:-
PCPG	trans	rs74405815	0.614	rs9814583	ENSG00000248540.2	RP11-247C2.2	6.06	1.06e-08	0.0363	0.66	0.44	Response to paliperidone in schizophrenia (positive Marder score);	chr3:126703519	chr15:74125915~74129278:-
PCPG	trans	rs78681719	1	rs7556918	ENSG00000262902.1	RP11-750B16.1	6.06	1.07e-08	0.0364	1.07	0.44	Ankle injury;	chr2:236320226	chr17:53105734~53106358:+
PCPG	trans	rs4660306	0.884	rs7543076	ENSG00000235823.1	OLMALINC	-6.06	1.07e-08	0.0365	-0.48	-0.44	Homocysteine levels;	chr1:45498566	chr10:100373615~100383368:+
PCPG	trans	rs9329221	0.617	rs615632	ENSG00000253893.2	FAM85B	6.06	1.07e-08	0.0365	0.55	0.44	Neuroticism;	chr8:9938811	chr8:8167819~8226614:-
PCPG	trans	rs12497850	0.931	rs11705888	ENSG00000197582.5	GPX1P1	6.06	1.07e-08	0.0365	0.61	0.44	Parkinson's disease;	chr3:48779856	chrX:13378735~13379340:-
PCPG	trans	rs6822297	0.745	rs7666651	ENSG00000266017.1	MIR4477B	6.05	1.08e-08	0.0368	0.45	0.44	Obesity-related traits;	chr4:26904814	chr9:63819574~63819654:+
PCPG	trans	rs55665837	0.523	rs10832301	ENSG00000236360.2	RP11-334A14.2	6.05	1.08e-08	0.0368	0.5	0.44	Vitamin D levels;	chr11:14767418	chr1:52993201~52993702:-
PCPG	trans	rs7028939	1	rs12377746	ENSG00000270001.1	RP11-218C14.8	6.05	1.08e-08	0.0369	0.91	0.44	Preeclampsia;	chr9:100158091	chr20:23631826~23632316:-
PCPG	trans	rs7028939	1	rs7860268	ENSG00000270001.1	RP11-218C14.8	6.05	1.08e-08	0.0369	0.91	0.44	Preeclampsia;	chr9:100178109	chr20:23631826~23632316:-
PCPG	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-6.05	1.09e-08	0.0371	-0.56	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
PCPG	trans	rs9371601	0.859	rs1203233	ENSG00000271011.1	RP11-171I2.5	-6.05	1.09e-08	0.0372	-0.51	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152393471	chr2:178577103~178577622:+
PCPG	trans	rs55665837	0.54	rs10128681	ENSG00000236360.2	RP11-334A14.2	6.05	1.1e-08	0.0373	0.48	0.44	Vitamin D levels;	chr11:14680030	chr1:52993201~52993702:-
PCPG	trans	rs7837649	0.824	rs11787532	ENSG00000236581.7	STARD13-AS	-6.05	1.1e-08	0.0374	-0.61	-0.44	Monobrow;	chr8:76717551	chr13:33180401~33281584:+
PCPG	trans	rs13358908	0.556	rs55638678	ENSG00000231752.4	EMBP1	-6.05	1.11e-08	0.0376	-0.59	-0.44	Schizophrenia;	chr5:46332618	chr1:121519112~121571892:+
PCPG	trans	rs55665837	0.54	rs12416696	ENSG00000236360.2	RP11-334A14.2	6.05	1.11e-08	0.0376	0.5	0.44	Vitamin D levels;	chr11:14769343	chr1:52993201~52993702:-
PCPG	trans	rs4646450	0.838	rs1589739	ENSG00000225972.1	MTND1P23	6.05	1.11e-08	0.0376	0.53	0.44	Blood metabolite levels;	chr7:99588124	chr1:629062~629433:+
PCPG	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	6.05	1.11e-08	0.0377	0.53	0.44	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
PCPG	trans	rs291096	0.678	rs1150254	ENSG00000236811.1	GAPDHP2	-6.05	1.11e-08	0.0378	-0.49	-0.44	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr1:206899170	chr20:13392677~13393674:+
PCPG	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	6.05	1.12e-08	0.0378	0.52	0.44	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
PCPG	trans	rs17133858	0.737	rs17133841	ENSG00000262902.1	RP11-750B16.1	6.05	1.12e-08	0.0379	0.76	0.44	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr11:75216430	chr17:53105734~53106358:+
PCPG	trans	rs10940346	0.56	rs10039233	ENSG00000231752.4	EMBP1	6.05	1.13e-08	0.0381	0.57	0.44	Schizophrenia;	chr5:50351630	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.51	rs4975991	ENSG00000231752.4	EMBP1	-6.05	1.13e-08	0.0383	-0.58	-0.44	Schizophrenia;	chr5:46328545	chr1:121519112~121571892:+
PCPG	trans	rs7662987	0.793	rs28730632	ENSG00000233859.2	ADH5P4	6.05	1.13e-08	0.0383	0.77	0.44	Smoking initiation;	chr4:99074552	chr6:65836930~65838039:-
PCPG	trans	rs7662987	0.793	rs4699700	ENSG00000233859.2	ADH5P4	6.05	1.13e-08	0.0383	0.77	0.44	Smoking initiation;	chr4:99077184	chr6:65836930~65838039:-
PCPG	trans	rs7811142	1	rs11771241	ENSG00000228546.2	CTA-313A17.3	6.04	1.14e-08	0.0384	0.7	0.44	Platelet count;	chr7:100397162	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.943	rs10241492	ENSG00000228546.2	CTA-313A17.3	6.04	1.14e-08	0.0384	0.7	0.44	Platelet count;	chr7:100397190	chr7:102337316~102339115:+
PCPG	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-6.04	1.14e-08	0.0385	-0.57	-0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
PCPG	trans	rs4646450	0.636	rs10279308	ENSG00000228834.1	RP11-249L21.4	6.04	1.14e-08	0.0386	0.71	0.44	Blood metabolite levels;	chr7:99407883	chr6:108907615~108907873:-
PCPG	trans	rs9371601	0.798	rs214941	ENSG00000271011.1	RP11-171I2.5	6.04	1.15e-08	0.0387	0.51	0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152389729	chr2:178577103~178577622:+
PCPG	trans	rs73108077	0.736	rs1997742	ENSG00000279352.1	RP11-411B10.7	6.04	1.15e-08	0.0388	0.7	0.44	Red blood cell density in sickle cell anemia;	chr20:31347432	chr18:14010054~14010917:+
PCPG	trans	rs74781061	0.929	rs12441932	ENSG00000227288.3	RP5-837I24.1	6.04	1.16e-08	0.039	0.62	0.44	Endometriosis;	chr15:74617658	chr1:81501794~81503468:+
PCPG	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	6.04	1.16e-08	0.039	0.5	0.44	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
PCPG	trans	rs7047415	1	rs7029315	ENSG00000262902.1	RP11-750B16.1	-6.04	1.16e-08	0.0392	-0.59	-0.44	Alzheimer disease and age of onset;	chr9:95782630	chr17:53105734~53106358:+
PCPG	trans	rs1186300	0.592	rs10219454	ENSG00000225423.1	TNPO1P1	6.04	1.17e-08	0.0393	0.62	0.44	QRS duration in Tripanosoma cruzi seropositivity;	chr12:17548725	chr10:84390908~84392045:+
PCPG	trans	rs73108077	0.736	rs6058479	ENSG00000279352.1	RP11-411B10.7	6.04	1.17e-08	0.0394	0.8	0.44	Red blood cell density in sickle cell anemia;	chr20:31282419	chr18:14010054~14010917:+
PCPG	trans	rs7819412	0.775	rs11773990	ENSG00000253893.2	FAM85B	6.04	1.17e-08	0.0395	0.61	0.44	Triglycerides;	chr8:11077572	chr8:8167819~8226614:-
PCPG	trans	rs7819412	0.775	rs4545055	ENSG00000253893.2	FAM85B	6.04	1.17e-08	0.0395	0.61	0.44	Triglycerides;	chr8:11077856	chr8:8167819~8226614:-
PCPG	trans	rs7819412	0.775	rs2898257	ENSG00000253893.2	FAM85B	6.04	1.17e-08	0.0395	0.61	0.44	Triglycerides;	chr8:11077858	chr8:8167819~8226614:-
PCPG	trans	rs7819412	0.775	rs34094119	ENSG00000253893.2	FAM85B	6.04	1.17e-08	0.0395	0.61	0.44	Triglycerides;	chr8:11078388	chr8:8167819~8226614:-
PCPG	trans	rs7819412	0.775	rs4841489	ENSG00000253893.2	FAM85B	6.04	1.17e-08	0.0395	0.61	0.44	Triglycerides;	chr8:11079301	chr8:8167819~8226614:-
PCPG	trans	rs7819412	0.775	rs4841490	ENSG00000253893.2	FAM85B	6.04	1.17e-08	0.0395	0.61	0.44	Triglycerides;	chr8:11079381	chr8:8167819~8226614:-
PCPG	trans	rs12497850	0.829	rs8926	ENSG00000197582.5	GPX1P1	6.04	1.17e-08	0.0395	0.62	0.44	Parkinson's disease;	chr3:49015352	chrX:13378735~13379340:-
PCPG	trans	rs848490	0.651	rs7810273	ENSG00000231747.1	AC079922.2	6.04	1.18e-08	0.0396	0.37	0.44	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr2:112621809~112622167:-
PCPG	trans	rs848490	0.651	rs11489586	ENSG00000231747.1	AC079922.2	6.04	1.18e-08	0.0396	0.37	0.44	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr2:112621809~112622167:-
PCPG	trans	rs7811142	1	rs11764818	ENSG00000228546.2	CTA-313A17.3	6.04	1.18e-08	0.0397	0.7	0.44	Platelet count;	chr7:100445432	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	6.04	1.18e-08	0.0397	0.7	0.44	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
PCPG	trans	rs13358908	0.511	rs34101830	ENSG00000231752.4	EMBP1	-6.04	1.18e-08	0.0397	-0.58	-0.44	Schizophrenia;	chr5:46349001	chr1:121519112~121571892:+
PCPG	trans	rs13358908	0.503	rs10073687	ENSG00000231752.4	EMBP1	-6.04	1.18e-08	0.0397	-0.58	-0.44	Schizophrenia;	chr5:46352187	chr1:121519112~121571892:+
PCPG	trans	rs9425766	0.924	rs5877	ENSG00000213331.4	RP11-713C19.2	6.04	1.18e-08	0.0397	0.54	0.44	Life satisfaction;	chr1:173909724	chr4:187970273~187971284:+
PCPG	trans	rs596169	0.764	rs618205	ENSG00000232573.1	RPL3P4	-6.04	1.19e-08	0.0398	-0.63	-0.44	Intraocular pressure;	chr1:218949051	chr14:98972879~98973301:-
PCPG	trans	rs4349753	0.557	rs2895625	ENSG00000250325.1	IGBP1P4	6.04	1.19e-08	0.0398	0.67	0.44	Photic sneeze reflex;	chr5:144946102	chr4:82401578~82402456:-
PCPG	trans	rs4349753	0.574	rs10476865	ENSG00000250325.1	IGBP1P4	6.04	1.19e-08	0.0398	0.67	0.44	Photic sneeze reflex;	chr5:144946164	chr4:82401578~82402456:-
PCPG	trans	rs4349753	0.595	rs13436836	ENSG00000250325.1	IGBP1P4	6.04	1.19e-08	0.0398	0.67	0.44	Photic sneeze reflex;	chr5:144947283	chr4:82401578~82402456:-
PCPG	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-6.03	1.2e-08	0.0401	-0.51	-0.44	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
PCPG	trans	rs616147	0.962	rs545397	ENSG00000183298.5	RP11-556K13.1	6.03	1.2e-08	0.0403	0.57	0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr1:101786340~101787219:-
PCPG	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	6.03	1.2e-08	0.0403	0.57	0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
PCPG	trans	rs10242455	0.867	rs2687136	ENSG00000228834.1	RP11-249L21.4	-6.03	1.21e-08	0.0404	-0.86	-0.44	Blood metabolite levels;	chr7:99728259	chr6:108907615~108907873:-
PCPG	trans	rs282587	0.569	rs385656	ENSG00000236527.1	ARF4P2	6.03	1.21e-08	0.0404	0.64	0.44	Glycated hemoglobin levels;	chr13:112758920	chr20:62872250~62873076:-
PCPG	trans	rs7811142	1	rs76913697	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100405149	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs67471932	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100412362	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs73161759	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100412371	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs67315960	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100417501	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs11763414	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100419221	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs67163493	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100426215	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs6975729	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100430564	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs1073	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100433989	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.887	rs4074838	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100435042	chr7:102337316~102339115:+
PCPG	trans	rs7811142	0.945	rs6955362	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100458543	chr7:102337316~102339115:+
PCPG	trans	rs7811142	1	rs6975514	ENSG00000228546.2	CTA-313A17.3	6.03	1.21e-08	0.0404	0.69	0.44	Platelet count;	chr7:100458597	chr7:102337316~102339115:+
PCPG	trans	rs282587	0.569	rs426765	ENSG00000236527.1	ARF4P2	6.03	1.21e-08	0.0404	0.63	0.44	Glycated hemoglobin levels;	chr13:112760484	chr20:62872250~62873076:-
PCPG	trans	rs282587	0.569	rs390657	ENSG00000236527.1	ARF4P2	6.03	1.21e-08	0.0404	0.63	0.44	Glycated hemoglobin levels;	chr13:112760771	chr20:62872250~62873076:-
PCPG	trans	rs282587	0.569	rs419334	ENSG00000236527.1	ARF4P2	6.03	1.21e-08	0.0404	0.63	0.44	Glycated hemoglobin levels;	chr13:112761032	chr20:62872250~62873076:-
PCPG	trans	rs282587	0.569	rs395246	ENSG00000236527.1	ARF4P2	6.03	1.21e-08	0.0404	0.63	0.44	Glycated hemoglobin levels;	chr13:112761078	chr20:62872250~62873076:-
PCPG	trans	rs1153996	0.559	rs1153989	ENSG00000214362.2	RP11-7D5.2	6.03	1.21e-08	0.0404	0.55	0.44	Exhaled nitric oxide output;	chr5:104903815	chr10:95594598~95595372:+
PCPG	trans	rs9371601	0.798	rs214952	ENSG00000271011.1	RP11-171I2.5	6.03	1.21e-08	0.0404	0.51	0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152401580	chr2:178577103~178577622:+
PCPG	trans	rs7809615	0.515	rs11772470	ENSG00000225972.1	MTND1P23	6.03	1.21e-08	0.0404	0.54	0.44	Blood metabolite ratios;	chr7:99583473	chr1:629062~629433:+
PCPG	trans	rs9371601	0.859	rs20585	ENSG00000271011.1	RP11-171I2.5	6.03	1.22e-08	0.0406	0.51	0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152393311	chr2:178577103~178577622:+
PCPG	trans	rs7811142	1	rs2406253	ENSG00000228546.2	CTA-313A17.3	6.03	1.22e-08	0.0407	0.69	0.44	Platelet count;	chr7:100479650	chr7:102337316~102339115:+
PCPG	trans	rs12643440	0.511	rs10489115	ENSG00000260468.1	LINC01290	-6.03	1.23e-08	0.041	-0.61	-0.44	Metabolite levels (Pyroglutamine);	chr4:17125704	chr16:10514842~10528202:-
PCPG	trans	rs344364	0.511	rs2982433	ENSG00000212961.4	HNRNPA1P40	6.03	1.24e-08	0.041	0.66	0.44	Glomerular filtration rate in chronic kidney disease;	chr16:1904507	chr11:74354443~74355720:+
PCPG	trans	rs6959887	0.821	rs7811472	ENSG00000255583.2	RP11-415I12.2	6.03	1.24e-08	0.041	0.49	0.44	Birth weight;	chr7:35264553	chr12:63682523~63724935:-
PCPG	trans	rs56339712	0.69	rs4078338	ENSG00000233025.1	CRYZP1	6.03	1.24e-08	0.0412	0.41	0.44	Reticulocyte count;Reticulocyte fraction of red cells;	chr9:89432518	chr7:103088664~103089610:-
PCPG	trans	rs4276421	0.571	rs59968174	ENSG00000231752.4	EMBP1	6.03	1.25e-08	0.0413	0.59	0.44	P wave duration;	chr5:46027939	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	6.03	1.25e-08	0.0415	0.42	0.44	Longevity;	chr3:48377218	chr1:27649419~27649610:+
PCPG	trans	rs10180496	0.685	rs6740818	ENSG00000275092.1	LA16c-329F2.2	-6.02	1.26e-08	0.0416	-0.74	-0.44	Dental caries;	chr2:12758221	chr16:1707252~1707973:+
PCPG	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	6.02	1.26e-08	0.0418	0.55	0.44	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
PCPG	trans	rs7047415	0.649	rs78943708	ENSG00000262902.1	RP11-750B16.1	6.02	1.26e-08	0.0418	0.91	0.44	Alzheimer disease and age of onset;	chr9:95773473	chr17:53105734~53106358:+
PCPG	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	6.02	1.27e-08	0.042	0.57	0.44	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
PCPG	trans	rs877636	0.736	rs773107	ENSG00000243403.1	RP11-330L19.1	6.02	1.27e-08	0.042	0.53	0.44	Cognitive function;	chr12:55975722	chr15:64592979~64593326:+
PCPG	trans	rs1153996	0.559	rs1217467	ENSG00000214362.2	RP11-7D5.2	-6.02	1.28e-08	0.0424	-0.56	-0.44	Exhaled nitric oxide output;	chr5:104895910	chr10:95594598~95595372:+
PCPG	trans	rs1153996	0.559	rs1153990	ENSG00000214362.2	RP11-7D5.2	-6.02	1.28e-08	0.0424	-0.56	-0.44	Exhaled nitric oxide output;	chr5:104897760	chr10:95594598~95595372:+
PCPG	trans	rs74781061	0.932	rs2198843	ENSG00000227288.3	RP5-837I24.1	6.02	1.29e-08	0.0425	0.57	0.44	Endometriosis;	chr15:74708889	chr1:81501794~81503468:+
PCPG	trans	rs606458	0.92	rs680273	ENSG00000262902.1	RP11-750B16.1	6.02	1.29e-08	0.0425	0.56	0.44	Urate levels;	chr11:64772163	chr17:53105734~53106358:+
PCPG	trans	rs7819412	0.74	rs28633434	ENSG00000253893.2	FAM85B	6.02	1.29e-08	0.0427	0.57	0.44	Triglycerides;	chr8:11196413	chr8:8167819~8226614:-
PCPG	trans	rs1892094	0.662	rs61803315	ENSG00000264937.1	AC100830.5	6.02	1.31e-08	0.0431	0.48	0.44	Coronary artery disease;	chr1:169132985	chr15:64696622~64696861:+
PCPG	trans	rs1892094	0.624	rs61803316	ENSG00000264937.1	AC100830.5	6.02	1.31e-08	0.0431	0.48	0.44	Coronary artery disease;	chr1:169133075	chr15:64696622~64696861:+
PCPG	trans	rs5752326	0.51	rs3747134	ENSG00000237485.4	SGOL1-AS1	6.01	1.32e-08	0.0433	0.77	0.44	Ischemic stroke;	chr22:26482015	chr3:20174244~20186427:+
PCPG	trans	rs4646450	0.735	rs10243678	ENSG00000225972.1	MTND1P23	6.01	1.33e-08	0.0435	0.55	0.44	Blood metabolite levels;	chr7:99394321	chr1:629062~629433:+
PCPG	trans	rs62445005	1	rs62445005	ENSG00000251034.1	RP11-582J16.4	6.01	1.33e-08	0.0435	0.64	0.44	Shingles;	chr7:38346957	chr8:22540845~22545405:-
PCPG	trans	rs8175379	0.575	rs8185283	ENSG00000231752.4	EMBP1	-6.01	1.33e-08	0.0435	-0.58	-0.44	Interleukin-7 levels;	chr5:46337706	chr1:121519112~121571892:+
PCPG	trans	rs8175379	0.515	rs8185067	ENSG00000231752.4	EMBP1	-6.01	1.33e-08	0.0435	-0.58	-0.44	Interleukin-7 levels;	chr5:46337722	chr1:121519112~121571892:+
PCPG	trans	rs713587	1	rs2384054	ENSG00000274010.1	RP5-935K16.2	-6.01	1.33e-08	0.0435	-0.55	-0.44	Body mass index in non-asthmatics;	chr2:24933904	chr2:127840606~127841763:-
PCPG	trans	rs1186300	0.559	rs1912886	ENSG00000225423.1	TNPO1P1	6.01	1.33e-08	0.0436	0.61	0.44	QRS duration in Tripanosoma cruzi seropositivity;	chr12:17551778	chr10:84390908~84392045:+
PCPG	trans	rs1186300	0.559	rs7309154	ENSG00000225423.1	TNPO1P1	6.01	1.33e-08	0.0436	0.61	0.44	QRS duration in Tripanosoma cruzi seropositivity;	chr12:17552859	chr10:84390908~84392045:+
PCPG	trans	rs12497850	1	rs4858828	ENSG00000197582.5	GPX1P1	6.01	1.33e-08	0.0436	0.56	0.44	Parkinson's disease;	chr3:48687378	chrX:13378735~13379340:-
PCPG	trans	rs55665837	1	rs10832276	ENSG00000236360.2	RP11-334A14.2	6.01	1.34e-08	0.0438	0.49	0.44	Vitamin D levels;	chr11:14461728	chr1:52993201~52993702:-
PCPG	trans	rs10940346	0.601	rs7712849	ENSG00000231752.4	EMBP1	6.01	1.35e-08	0.0441	0.57	0.44	Schizophrenia;	chr5:50407774	chr1:121519112~121571892:+
PCPG	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	6.01	1.35e-08	0.0441	0.52	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
PCPG	trans	rs4276421	0.967	rs10941703	ENSG00000231752.4	EMBP1	-6.01	1.35e-08	0.0441	-0.56	-0.44	P wave duration;	chr5:45781770	chr1:121519112~121571892:+
PCPG	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-6.01	1.35e-08	0.0442	-0.42	-0.44	Longevity;	chr3:48378818	chr1:27649419~27649610:+
PCPG	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-6.01	1.35e-08	0.0442	-0.42	-0.44	Longevity;	chr3:48379768	chr1:27649419~27649610:+
PCPG	trans	rs4660306	0.961	rs4660867	ENSG00000235823.1	OLMALINC	-6.01	1.36e-08	0.0444	-0.5	-0.44	Homocysteine levels;	chr1:45520812	chr10:100373615~100383368:+
PCPG	trans	rs4660306	0.961	rs4660868	ENSG00000235823.1	OLMALINC	-6.01	1.36e-08	0.0444	-0.5	-0.44	Homocysteine levels;	chr1:45520825	chr10:100373615~100383368:+
PCPG	trans	rs4660306	1	rs2077808	ENSG00000235823.1	OLMALINC	-6.01	1.36e-08	0.0444	-0.5	-0.44	Homocysteine levels;	chr1:45522443	chr10:100373615~100383368:+
PCPG	trans	rs4660306	1	rs7534467	ENSG00000235823.1	OLMALINC	-6.01	1.36e-08	0.0444	-0.5	-0.44	Homocysteine levels;	chr1:45523019	chr10:100373615~100383368:+
PCPG	trans	rs4660306	1	rs10157597	ENSG00000235823.1	OLMALINC	-6.01	1.36e-08	0.0444	-0.5	-0.44	Homocysteine levels;	chr1:45524606	chr10:100373615~100383368:+
PCPG	trans	rs4660306	1	rs11211132	ENSG00000235823.1	OLMALINC	-6.01	1.36e-08	0.0444	-0.5	-0.44	Homocysteine levels;	chr1:45524844	chr10:100373615~100383368:+
PCPG	trans	rs5022636	0.896	rs7531495	ENSG00000180764.13	PIPSL	6.01	1.37e-08	0.0446	0.5	0.44	Gut microbiota (functional units);	chr1:151352996	chr10:93958191~93961540:-
PCPG	trans	rs708224	0.713	rs326638	ENSG00000185275.6	CD24P4	-6.01	1.38e-08	0.0449	-0.46	-0.44	Pancreatic cancer;	chr12:32243846	chrY:18992467~18992709:-
PCPG	trans	rs3808502	0.527	rs2736374	ENSG00000253893.2	FAM85B	6.01	1.38e-08	0.045	0.55	0.44	Neuroticism;	chr8:11256319	chr8:8167819~8226614:-
PCPG	trans	rs719150	0.614	rs11970361	ENSG00000233247.3	GS1-257G1.1	-6.01	1.38e-08	0.045	-0.9	-0.44	Cancer;	chr6:137857999	chrX:14244382~14244928:+
PCPG	trans	rs5022636	0.927	rs4522000	ENSG00000180764.13	PIPSL	6.01	1.38e-08	0.045	0.51	0.44	Gut microbiota (functional units);	chr1:151283612	chr10:93958191~93961540:-
PCPG	trans	rs7647973	0.961	rs6778080	ENSG00000197582.5	GPX1P1	-6.01	1.38e-08	0.045	-0.61	-0.44	Menarche (age at onset);	chr3:49279905	chrX:13378735~13379340:-
PCPG	trans	rs55665837	0.54	rs12290926	ENSG00000236360.2	RP11-334A14.2	6	1.39e-08	0.0451	0.48	0.44	Vitamin D levels;	chr11:14673500	chr1:52993201~52993702:-
PCPG	trans	rs73108077	0.688	rs6058752	ENSG00000279352.1	RP11-411B10.7	6	1.39e-08	0.0451	0.71	0.44	Red blood cell density in sickle cell anemia;	chr20:31353900	chr18:14010054~14010917:+
PCPG	trans	rs10940346	0.58	rs9292005	ENSG00000231752.4	EMBP1	6	1.39e-08	0.0452	0.57	0.44	Schizophrenia;	chr5:50430521	chr1:121519112~121571892:+
PCPG	trans	rs336284	0.502	rs1425142	ENSG00000255583.2	RP11-415I12.2	6	1.39e-08	0.0452	0.48	0.44	Suicide behavior;Suicide;	chr7:35297133	chr12:63682523~63724935:-
PCPG	trans	rs7312770	1	rs7312770	ENSG00000227887.1	RPS26P13	-6	1.41e-08	0.0458	-0.54	-0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:208697369~208697698:-
PCPG	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	6	1.41e-08	0.0458	0.53	0.44	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
PCPG	trans	rs10940346	0.601	rs11959569	ENSG00000231752.4	EMBP1	6	1.42e-08	0.0462	0.57	0.44	Schizophrenia;	chr5:50369429	chr1:121519112~121571892:+
PCPG	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	6	1.43e-08	0.0463	0.53	0.44	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
PCPG	trans	rs9329221	0.868	rs7831557	ENSG00000253893.2	FAM85B	6	1.44e-08	0.0466	0.57	0.44	Neuroticism;	chr8:10422718	chr8:8167819~8226614:-
PCPG	trans	rs1892094	0.624	rs7552323	ENSG00000264937.1	AC100830.5	6	1.45e-08	0.0468	0.47	0.44	Coronary artery disease;	chr1:169134085	chr15:64696622~64696861:+
PCPG	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	6	1.45e-08	0.0469	0.56	0.44	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
PCPG	trans	rs4646450	0.838	rs10257758	ENSG00000225972.1	MTND1P23	5.99	1.46e-08	0.0472	0.53	0.44	Blood metabolite levels;	chr7:99591365	chr1:629062~629433:+
PCPG	trans	rs6822297	0.875	rs10939144	ENSG00000266017.1	MIR4477B	-5.99	1.46e-08	0.0473	-0.44	-0.44	Obesity-related traits;	chr4:26965284	chr9:63819574~63819654:+
PCPG	trans	rs11098499	0.739	rs9884728	ENSG00000275858.1	RP11-291L22.8	-5.99	1.47e-08	0.0473	-0.56	-0.44	Corneal astigmatism;	chr4:119205924	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.739	rs2203039	ENSG00000275858.1	RP11-291L22.8	-5.99	1.47e-08	0.0473	-0.56	-0.44	Corneal astigmatism;	chr4:119211192	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.739	rs7441137	ENSG00000275858.1	RP11-291L22.8	-5.99	1.47e-08	0.0473	-0.56	-0.44	Corneal astigmatism;	chr4:119212066	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.71	rs6851130	ENSG00000275858.1	RP11-291L22.8	-5.99	1.47e-08	0.0473	-0.56	-0.44	Corneal astigmatism;	chr4:119212557	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.739	rs4833612	ENSG00000275858.1	RP11-291L22.8	-5.99	1.47e-08	0.0473	-0.56	-0.44	Corneal astigmatism;	chr4:119226441	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.739	rs10013032	ENSG00000275858.1	RP11-291L22.8	-5.99	1.47e-08	0.0473	-0.56	-0.44	Corneal astigmatism;	chr4:119228264	chr10:38450738~38451069:-
PCPG	trans	rs11098499	0.739	rs951570	ENSG00000275858.1	RP11-291L22.8	-5.99	1.47e-08	0.0473	-0.56	-0.44	Corneal astigmatism;	chr4:119229312	chr10:38450738~38451069:-
PCPG	trans	rs596169	0.655	rs596820	ENSG00000232573.1	RPL3P4	-5.99	1.47e-08	0.0474	-0.63	-0.44	Intraocular pressure;	chr1:218970464	chr14:98972879~98973301:-
PCPG	trans	rs10510628	0.845	rs4408838	ENSG00000196668.3	LINC00173	5.99	1.47e-08	0.0474	0.5	0.44	Bone mineral density;	chr3:29828402	chr12:116533422~116536518:+
PCPG	trans	rs4646450	0.735	rs2404323	ENSG00000225972.1	MTND1P23	5.99	1.49e-08	0.0478	0.57	0.44	Blood metabolite levels;	chr7:99387773	chr1:629062~629433:+
PCPG	trans	rs2301573	0.749	rs4688772	ENSG00000260455.1	NBAT1	5.99	1.49e-08	0.0478	0.77	0.44	Hip circumference;	chr3:129713504	chr6:22134957~22147193:-
PCPG	trans	rs7028939	1	rs10988948	ENSG00000270001.1	RP11-218C14.8	5.99	1.52e-08	0.0487	0.93	0.44	Preeclampsia;	chr9:100028397	chr20:23631826~23632316:-
PCPG	trans	rs7028939	1	rs10988957	ENSG00000270001.1	RP11-218C14.8	5.99	1.52e-08	0.0487	0.93	0.44	Preeclampsia;	chr9:100053173	chr20:23631826~23632316:-
PCPG	trans	rs2484992	1	rs10826926	ENSG00000232573.1	RPL3P4	5.99	1.52e-08	0.0488	0.74	0.44	Disc degeneration (lumbar);	chr10:31245428	chr14:98972879~98973301:-
PCPG	trans	rs9371601	0.859	rs214944	ENSG00000271011.1	RP11-171I2.5	-5.98	1.53e-08	0.0491	-0.51	-0.44	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152391617	chr2:178577103~178577622:+
PCPG	trans	rs4660306	0.961	rs2152077	ENSG00000235823.1	OLMALINC	-5.98	1.53e-08	0.0491	-0.49	-0.44	Homocysteine levels;	chr1:45520998	chr10:100373615~100383368:+
PCPG	trans	rs10820904	1	rs7849482	ENSG00000249780.1	RP11-352E6.2	5.98	1.53e-08	0.0492	0.91	0.44	Body mass index;	chr9:91807521	chr4:12640298~12640637:-
PCPG	trans	rs7028939	1	rs7031081	ENSG00000270001.1	RP11-218C14.8	5.98	1.54e-08	0.0492	0.92	0.44	Preeclampsia;	chr9:100116540	chr20:23631826~23632316:-
PCPG	trans	rs10940346	0.56	rs6892613	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50353678	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.56	rs2137134	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50354188	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs6450056	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50356692	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4637546	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50358359	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10073591	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50359010	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.521	rs7730857	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50361516	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.58	rs10071725	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50361986	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs7732000	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50364779	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.54	rs57137858	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50369737	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs10042504	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50386329	chr1:121519112~121571892:+
PCPG	trans	rs10940346	0.601	rs4398636	ENSG00000231752.4	EMBP1	5.98	1.54e-08	0.0492	0.57	0.44	Schizophrenia;	chr5:50391957	chr1:121519112~121571892:+
PCPG	trans	rs10180496	0.685	rs60901280	ENSG00000275092.1	LA16c-329F2.2	-5.98	1.54e-08	0.0493	-0.75	-0.44	Dental caries;	chr2:12758761	chr16:1707252~1707973:+
PCPG	trans	rs7028939	1	rs10988964	ENSG00000270001.1	RP11-218C14.8	5.98	1.55e-08	0.0495	0.87	0.44	Preeclampsia;	chr9:100082784	chr20:23631826~23632316:-
PCPG	trans	rs6959887	0.89	rs2215614	ENSG00000255583.2	RP11-415I12.2	5.98	1.55e-08	0.0495	0.49	0.44	Birth weight;	chr7:35237481	chr12:63682523~63724935:-
PCPG	trans	rs8175379	0.521	rs8175430	ENSG00000231752.4	EMBP1	-5.98	1.55e-08	0.0495	-0.59	-0.44	Interleukin-7 levels;	chr5:46305095	chr1:121519112~121571892:+
PCPG	trans	rs7829975	0.533	rs1039917	ENSG00000239559.2	RPL37P2	-5.98	1.55e-08	0.0496	-0.39	-0.44	Mood instability;	chr8:8861340	chr11:67682772~67683058:-
PCPG	trans	rs10940346	0.601	rs6450063	ENSG00000231752.4	EMBP1	5.98	1.55e-08	0.0496	0.57	0.44	Schizophrenia;	chr5:50374147	chr1:121519112~121571892:+
PCPG	trans	rs62344088	0.59	rs61710713	ENSG00000185986.11	SDHAP3	5.98	1.56e-08	0.0498	0.98	0.44	Asthma (childhood onset);	chr5:181384	chr5:1572222~1594620:-
PCPG	trans	rs473651	0.74	rs502349	ENSG00000219451.3	AC005251.3	-5.98	1.56e-08	0.0499	-0.31	-0.44	Multiple system atrophy;	chr2:238409748	chr7:20827326~20827753:+
PCPG	trans	rs10820904	1	rs10761131	ENSG00000249780.1	RP11-352E6.2	5.98	1.57e-08	0.05	0.92	0.44	Body mass index;	chr9:91806969	chr4:12640298~12640637:-
PCPG	trans	rs10251504	1	rs3823800	ENSG00000215548.2	RP11-764K9.4	-5.98	1.57e-08	0.05	-0.62	-0.44	Airway wall thickness;	chr7:78060083	chr9:63832127~63859641:-